article_title,journal_title,journal_abbre,article_date,abstract,article_type,pub_days,citation,abstract_clean,Breast Cancer,Lung Cancer,Leukemia,Prostate Cancer,Colorectal Cancer,Lymphoma,Bone Cancer,Melanoma,Liver Cancer,Kidney Cancer,Ovarian Cancer,Pancreatic Cancer,Brain Tumor,Head and Neck Cancer,Acute Myeloid Leukemia (AML),Multiple Myeloma,Sarcoma,Bladder Cancer,Skin Cancer,Gastric Cancer,Gastrointestinal Tumor,Endometrial Cancer,Acute Lymphoblastic Leukemia (ALL),Chronic Lymphocytic Leukemia (CLL),Cardiac Tumors,Cervical Cancer,Esophageal Cancer,Thyroid Cancer,Rectal Cancer,text_clean_seq,text_length,pmid,w2v_similarity_rank_acute_lymphoblastic_leukemia_(all)
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia.,Nature genetics,Nat. Genet.,2001-12-03,"Acute lymphoblastic leukemias carrying a chromosomal translocation involving the mixed-lineage leukemia gene (MLL, ALL1, HRX) have a particularly poor prognosis. Here we show that they have a characteristic, highly distinct gene expression profile that is consistent with an early hematopoietic progenitor expressing select multilineage markers and individual HOX genes. Clustering algorithms reveal that lymphoblastic leukemias with MLL translocations can clearly be separated from conventional acute lymphoblastic and acute myelogenous leukemias. We propose that they constitute a distinct disease, denoted here as MLL, and show that the differences in gene expression are robust enough to classify leukemias correctly as MLL, acute lymphoblastic leukemia or acute myelogenous leukemia. Establishing that MLL is a unique entity is critical, as it mandates the examination of selectively expressed genes for urgently needed molecular targets.",Comparative Study,6623.0,1410.0,Acute lymphoblastic leukemias carrying a chromosomal translocation involving the mixed-lineage gene MLL ALL1 HRX have a particularly poor prognosis Here we show that they have a characteristic highly distinct gene expression profile that is consistent with an early hematopoietic progenitor expressing select multilineage markers and individual HOX genes Clustering algorithms reveal that lymphoblastic leukemias with MLL translocations can clearly be separated from conventional acute lymphoblastic and acute myelogenous leukemias We propose that they constitute a distinct disease denoted here as MLL and show that the differences in gene expression are robust enough to classify leukemias correctly as MLL acute lymphoblastic or acute myelogenous Establishing that MLL is a unique entity is critical as it mandates the examination of selectively expressed genes for urgently needed molecular targets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 2792, 2934, 8, 1860, 2006, 1267, 3, 1739, 2542, 145, 3049, 30178, 52667, 47, 8, 823, 334, 356, 467, 21, 514, 17, 491, 47, 8, 2037, 561, 834, 145, 55, 800, 17, 16, 925, 5, 35, 191, 1007, 2520, 1046, 1717, 12471, 525, 2, 797, 14722, 214, 3147, 3529, 2396, 17, 1275, 2792, 5, 3049, 3262, 122, 2536, 40, 4910, 29, 809, 286, 1275, 2, 286, 2194, 2792, 21, 2548, 17, 491, 4999, 8, 834, 34, 16175, 467, 22, 3049, 2, 514, 17, 3, 362, 4, 145, 55, 32, 1922, 5151, 6, 4896, 2792, 4911, 22, 3049, 286, 1275, 15, 286, 2194, 4431, 17, 3049, 16, 8, 991, 2983, 16, 740, 22, 192, 16176, 3, 1385, 1, 2382, 570, 214, 9, 5354, 575, 219, 637]",902.0,11731795,261
HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.,Clinical chemistry,Clin. Chem.,2002-01-01,"Mercaptopurine is a prodrug requiring intracellular activation to thiopurine nucleotides to exert antileukemic effect. We developed a reversed-phase liquid chromatographic assay for the quantification of mercaptopurine, thioguanine, and methylmercaptopurine nucleoside and nucleotide concentrations in the target tissue, the leukemic lymphoblast. Leukemic blasts were isolated from peripheral blood and bone marrow by a standard Ficoll-hypaque procedure. Proteins were removed by ultrafiltration in the presence of dithiothreitol. Thiopurine ribonucleotides were converted into their respective ribonucleosides by treatment of ultrafiltrate with acid phosphatase. Thiopurine nucleosides and bases were measured by direct injection of ultrafiltrate into the chromatographic system. Thiopurine nucleotide concentrations were calculated by subtracting the thiopurine nucleoside concentrations measured after treatment with acid phosphatase from those measured after direct injection of ultrafiltrate in the chromatographic system. Analytes were separated on a C18 Supelco column with ammonium phosphate-methanol eluent coupled with ultraviolet detection. CVs for intra- and interday precision were 1.1-14% (median, 4.9%), and recovery of added analyte was 89-126% (median, 105%) at low and high concentrations of analytes, except for mercaptopurine riboside. The median signal for each of the five metabolites in lymphoblast samples was 98% (range, 80-106%) of that in water. Detection limits for thiopurine bases and nucleosides ranged from 0.5 to 4.5 pmol/5 x 10(6) cells. This method is suitable for measurement of thiopurine metabolite concentrations in lymphoblasts in children with acute lymphoblastic leukemia following a single dose of intravenous mercaptopurine.",Journal Article,6594.0,38.0,Mercaptopurine is a prodrug requiring intracellular activation to thiopurine nucleotides to exert antileukemic effect We developed a reversed-phase liquid chromatographic assay for the quantification of mercaptopurine thioguanine and methylmercaptopurine nucleoside and nucleotide concentrations in the target tissue the leukemic lymphoblast Leukemic blasts were isolated from peripheral blood and marrow by a standard Ficoll-hypaque procedure Proteins were removed by ultrafiltration in the presence of dithiothreitol Thiopurine ribonucleotides were converted into their respective ribonucleosides by treatment of ultrafiltrate with acid phosphatase Thiopurine nucleosides and bases were measured by direct injection of ultrafiltrate into the chromatographic system Thiopurine nucleotide concentrations were calculated by subtracting the thiopurine nucleoside concentrations measured after treatment with acid phosphatase from those measured after direct injection of ultrafiltrate in the chromatographic system Analytes were separated on a C18 Supelco column with ammonium phosphate-methanol eluent coupled with ultraviolet detection CVs for intra- and interday precision were 1.1-14 median 4.9 and recovery of added analyte was 89-126 median 105 at low and high concentrations of analytes except for mercaptopurine riboside The median signal for each of the five metabolites in lymphoblast samples was 98 range 80-106 of that in water Detection limits for thiopurine bases and nucleosides ranged from 0.5 to 4.5 pmol/5 x 10 6 cells This method is suitable for measurement of thiopurine metabolite concentrations in lymphoblasts in children with acute lymphoblastic following a single dose of intravenous mercaptopurine,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9223, 16, 8, 5227, 1888, 2087, 363, 6, 14062, 11381, 6, 5448, 4512, 254, 21, 276, 8, 3682, 124, 3165, 23063, 719, 9, 3, 4752, 1, 9223, 17598, 2, 52669, 4032, 2, 1579, 1003, 4, 3, 283, 246, 3, 2015, 19414, 2015, 2438, 11, 1355, 29, 672, 315, 2, 581, 20, 8, 260, 42798, 52670, 1299, 652, 11, 2264, 20, 42799, 4, 3, 463, 1, 30180, 14062, 42800, 11, 4764, 237, 136, 3847, 52671, 20, 24, 1, 24400, 5, 971, 2577, 14062, 24401, 2, 9412, 11, 644, 20, 1196, 1754, 1, 24400, 237, 3, 23063, 398, 14062, 1579, 1003, 11, 981, 20, 30181, 3, 14062, 4032, 1003, 644, 50, 24, 5, 971, 2577, 29, 135, 644, 50, 1196, 1754, 1, 24400, 4, 3, 23063, 398, 10942, 11, 4910, 23, 8, 24402, 52672, 9004, 5, 24403, 4849, 30182, 52673, 3332, 5, 9224, 638, 14723, 9, 2392, 2, 52674, 2720, 11, 14, 14, 213, 52, 39, 83, 2, 1602, 1, 1953, 23064, 10, 887, 3927, 52, 3263, 28, 154, 2, 64, 1003, 1, 10942, 2187, 9, 9223, 33157, 3, 52, 1235, 9, 296, 1, 3, 365, 3406, 4, 19414, 347, 10, 1096, 184, 493, 3251, 1, 17, 4, 4388, 638, 3526, 9, 14062, 9412, 2, 24401, 1869, 29, 13, 33, 6, 39, 33, 9835, 33, 1006, 79, 49, 37, 26, 596, 16, 2884, 9, 2204, 1, 14062, 3379, 1003, 4, 10521, 4, 541, 5, 286, 1275, 366, 8, 226, 61, 1, 1262, 9223]",1721.0,11751539,790
Treatment of childhood acute lymphoblastic leukemia: results of Dana-Farber ALL Consortium Protocol 87-01.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-01-01,"To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic leukemia. Patients from all risk groups, including infants and those with T-cell disease, were treated between 1987 and 1991. Standard-risk (SR) patients did not receive cranial irradiation, whereas high-risk (HR) and very high-risk (VHR) patients participated in a randomized comparison of 18 Gy of cranial irradiation conventionally fractionated versus two fractions per day (hyperfractionated). At a median follow-up of 9.2 years, the 9-year event-free survival (EFS +/- SE) was 75% +/- 2% for all 369 patients, 77% +/- 4% for the 142 SR patients, and 73% +/- 3% for the 227 HR/VHR patients (P =.37 comparing SR and HR/VHR). The CNS, with or without concomitant bone marrow involvement, was the first site of relapse in 19 (13%) of the 142 SR patients: 16 (20%) of 79 SR boys and three (5%) of 63 SR girls. This high incidence of relapses necessitated a recall of SR boys for additional therapy. CNS relapse occurred in only two (1%) of 227 HR and VHR patients. There were no outcome differences found among randomized treatment groups. Nine-year overall survival was 84% +/- 2% for the entire population, 93% +/- 2% for SR children, and 79% +/- 3% for HR and VHR children (P <.01 comparing SR and HR/VHR). A high overall survival outcome was obtained for SR patients despite the high risk of CNS relapse for SR boys, which was presumed to be associated with eliminating cranial radiation without intensifying systemic or intrathecal chemotherapy. For HR/VHR patients, inability to salvage after relapse (nearly all of which were in the bone marrow) remains a significant clinical problem.",Clinical Trial,6594.0,42.0,To improve efficacy and reduce toxicity of treatment for children with acute lymphoblastic Patients from all risk groups including infants and those with T-cell disease were treated between 1987 and 1991 Standard-risk SR patients did not receive cranial irradiation whereas high-risk HR and very high-risk VHR patients participated in a randomized comparison of 18 Gy of cranial irradiation conventionally fractionated versus two fractions per day hyperfractionated At a median follow-up of 9.2 years the 9-year event-free survival EFS +/- SE was 75 +/- 2 for all 369 patients 77 +/- 4 for the 142 SR patients and 73 +/- 3 for the 227 HR/VHR patients P =.37 comparing SR and HR/VHR The CNS with or without concomitant marrow involvement was the first site of relapse in 19 13 of the 142 SR patients 16 20 of 79 SR boys and three 5 of 63 SR girls This high incidence of relapses necessitated a recall of SR boys for additional therapy CNS relapse occurred in only two 1 of 227 HR and VHR patients There were no outcome differences found among randomized treatment groups Nine-year overall survival was 84 +/- 2 for the entire population 93 +/- 2 for SR children and 79 +/- 3 for HR and VHR children P .01 comparing SR and HR/VHR A high overall survival outcome was obtained for SR patients despite the high risk of CNS relapse for SR boys which was presumed to be associated with eliminating cranial radiation without intensifying systemic or intrathecal chemotherapy For HR/VHR patients inability to salvage after relapse nearly all of which were in the marrow remains a significant clinical problem,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 401, 209, 2, 969, 155, 1, 24, 9, 541, 5, 286, 1275, 7, 29, 62, 43, 271, 141, 5585, 2, 135, 5, 102, 31, 34, 11, 73, 59, 5450, 2, 3372, 260, 43, 7460, 7, 205, 44, 560, 2565, 1104, 547, 64, 43, 168, 2, 923, 64, 43, 12957, 7, 3025, 4, 8, 384, 1155, 1, 203, 381, 1, 2565, 1104, 6846, 3950, 185, 100, 1550, 379, 218, 6201, 28, 8, 52, 166, 126, 1, 83, 18, 60, 3, 83, 111, 774, 115, 25, 1683, 3428, 10, 481, 18, 9, 62, 8718, 7, 849, 39, 9, 3, 4785, 7460, 7, 2, 803, 27, 9, 3, 7132, 168, 12957, 7, 19, 567, 1430, 7460, 2, 168, 12957, 3, 1025, 5, 15, 187, 1781, 581, 799, 10, 3, 157, 606, 1, 429, 4, 326, 233, 1, 3, 4785, 7460, 7, 245, 179, 1, 842, 7460, 12958, 2, 169, 33, 1, 676, 7460, 5989, 26, 64, 287, 1, 3713, 14727, 8, 6169, 1, 7460, 12958, 9, 402, 36, 1025, 429, 489, 4, 158, 100, 14, 1, 7132, 168, 2, 12957, 7, 125, 11, 77, 228, 362, 204, 107, 384, 24, 271, 762, 111, 63, 25, 10, 874, 18, 9, 3, 1797, 266, 966, 18, 9, 7460, 541, 2, 842, 27, 9, 168, 2, 12957, 541, 19, 355, 1430, 7460, 2, 168, 12957, 8, 64, 63, 25, 228, 10, 683, 9, 7460, 7, 550, 3, 64, 43, 1, 1025, 429, 9, 7460, 12958, 92, 10, 5472, 6, 40, 41, 5, 6923, 2565, 121, 187, 20150, 403, 15, 5126, 56, 9, 168, 12957, 7, 4985, 6, 992, 50, 429, 1857, 62, 1, 92, 11, 4, 3, 581, 469, 8, 93, 38, 2497]",1599.0,11773175,812
Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling.,Blood,Blood,2002-03-01,"In haploidentical transplantation, the mismatched haplotype of the donor can originate from either of the parents. We refer to such mismatched haplotypes as noninherited maternal antigens (NIMA haplotype) or noninherited paternal antigens (NIPA haplotype). To determine whether exposure to maternal HLA antigens benefits patients undergoing bone marrow transplantation, we analyzed graft failure and graft-versus-host disease (GVHD) after transplantations from parental or haploidentical sibling donors. We studied 269 patients receiving 1 or 2 HLA-A, -B, -DR antigen-mismatched sibling or parental non-T-cell-depleted bone marrow transplants for acute myelogenous leukemia, acute lymphoblastic leukemia, or chronic myelogenous leukemia between 1985 and 1997 that were reported to the International Bone Marrow Transplant Registry. Included were 121 (45%) NIMA-mismatched and 148 (55%) NIPA-mismatched transplantations. Sixty-three (52%) of the NIMA-mismatched transplants and 69 (47%) of the NIPA-mismatched transplants were from haploidentical sibling donors. Sibling transplantations mismatched for NIMA had similar rates of graft failure but lower rates of acute GVHD (P <.02) than NIPA-mismatched sibling transplantations. In the first 4 months after transplantation, mother-to-child transplantations involved significantly less chronic GVHD than father-to-child transplantations (P <.02). Treatment-related mortality (TRM) was significantly higher after parental transplantations (P =.009 for mother; P =.03 for father) than after haploidentical sibling transplantations mismatched for the NIMA. Non-T-cell-depleted bone marrow transplants donated by haploidentical siblings to recipients mismatched for NIPA and transplants donated by parents caused more acute and chronic GVHD and TRM than transplants donated by haploidentical siblings mismatched for NIMA.",Comparative Study,6535.0,217.0,In haploidentical transplantation the mismatched haplotype of the donor can originate from either of the parents We refer to such mismatched haplotypes as noninherited maternal antigens NIMA haplotype or noninherited paternal antigens NIPA haplotype To determine whether exposure to maternal HLA antigens benefits patients undergoing marrow transplantation we analyzed graft failure and graft-versus-host disease GVHD after transplantations from parental or haploidentical sibling donors We studied 269 patients receiving 1 or 2 HLA-A -B -DR antigen-mismatched sibling or parental non-T-cell-depleted marrow transplants for acute myelogenous acute lymphoblastic or chronic myelogenous between 1985 and 1997 that were reported to the International Marrow Transplant Registry Included were 121 45 NIMA-mismatched and 148 55 NIPA-mismatched transplantations Sixty-three 52 of the NIMA-mismatched transplants and 69 47 of the NIPA-mismatched transplants were from haploidentical sibling donors Sibling transplantations mismatched for NIMA had similar rates of graft failure but lower rates of acute GVHD P .02 than NIPA-mismatched sibling transplantations In the first 4 months after transplantation mother-to-child transplantations involved significantly less chronic GVHD than father-to-child transplantations P .02 Treatment-related mortality TRM was significantly higher after parental transplantations P =.009 for mother P =.03 for father than after haploidentical sibling transplantations mismatched for the NIMA Non-T-cell-depleted marrow transplants donated by haploidentical siblings to recipients mismatched for NIPA and transplants donated by parents caused more acute and chronic GVHD and TRM than transplants donated by haploidentical siblings mismatched for NIMA,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 5802, 497, 3, 5095, 4179, 1, 3, 1488, 122, 8838, 29, 361, 1, 3, 2418, 21, 7851, 6, 225, 5095, 5940, 22, 30205, 6039, 1575, 16624, 4179, 15, 30205, 10649, 1575, 30206, 4179, 6, 223, 317, 645, 6, 6039, 1160, 1575, 1141, 7, 479, 581, 497, 21, 311, 1599, 496, 2, 1599, 185, 1204, 34, 1562, 50, 6779, 29, 3418, 15, 5802, 3684, 2344, 21, 656, 8639, 7, 357, 14, 15, 18, 1160, 8, 132, 3436, 448, 5095, 3684, 15, 3418, 220, 102, 31, 4358, 581, 4016, 9, 286, 2194, 286, 1275, 15, 442, 2194, 59, 4675, 2, 2341, 17, 11, 210, 6, 3, 944, 581, 941, 1608, 159, 11, 4141, 512, 16624, 5095, 2, 4647, 614, 30206, 5095, 6779, 1746, 169, 653, 1, 3, 16624, 5095, 4016, 2, 790, 662, 1, 3, 30206, 5095, 4016, 11, 29, 5802, 3684, 2344, 3684, 6779, 5095, 9, 16624, 42, 288, 151, 1, 1599, 496, 84, 280, 151, 1, 286, 1562, 19, 588, 76, 30206, 5095, 3684, 6779, 4, 3, 157, 39, 53, 50, 497, 9733, 6, 2566, 6779, 646, 97, 299, 442, 1562, 76, 17610, 6, 2566, 6779, 19, 588, 24, 139, 282, 5064, 10, 97, 142, 50, 3418, 6779, 19, 2376, 9, 9733, 19, 680, 9, 17610, 76, 50, 5802, 3684, 6779, 5095, 9, 3, 16624, 220, 102, 31, 4358, 581, 4016, 25982, 20, 5802, 2758, 6, 2190, 5095, 9, 30206, 2, 4016, 25982, 20, 2418, 1546, 80, 286, 2, 442, 1562, 2, 5064, 76, 4016, 25982, 20, 5802, 2758, 5095, 9, 16624]",1772.0,11861270,158
Diagnostic X-rays and ultrasound exposure and risk of childhood acute lymphoblastic leukemia by immunophenotype.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2002-02-01,"The objective of this study was to evaluate the association between in utero diagnostic X-rays and childhood acute lymphoblastic leukemia (ALL) and the less well-studied relationship of this malignancy to preconception and postnatal diagnostic X-rays or fetal ultrasound exposures. The Children's Cancer Group conducted a case-control study including interviews with parents of 1842 ALL cases diagnosed under the age of 15 years and 1986 individually matched controls. Associations of self-reported parental preconception, in utero, and postnatal X-ray exposure with risk of childhood ALL were examined using odds ratios (ORs) and corresponding 95% confidence intervals (CIs) obtained from logistic regression models among the overall group of ALL cases as well as immunophenotypic and age-specific subgroups. Overall, in utero pelvimetric diagnostic X-rays were not associated with the risk of pediatric ALL (OR, 1.2; 95% CI, 0.8-1.7). Childhood ALL, all types combined (OR, 1.1; 95% CI, 0.9-1.2) and specific types were also not linked with postnatal diagnostic X-ray exposures. Neither maternal (OR, 0.9; 95% CI, 0.8-1.2) nor paternal (OR, 1.1; 95% CI, 0.8-1.4) lower abdominal preconception diagnostic X-rays were associated with risk of childhood ALL. Among the multiple comparisons for age-, sex-, and subtype-specific subgroups, we observed an elevated risk of total ALL among children ages 11-14 at diagnosis (OR, 2.4; 95% CI, 1.1-5.0) in relation to in utero pelvimetric diagnostic X-ray exposures and a small increase in pre-B ALL for all ages combined (OR, 1.7; 95% CI, 1.1-2.7) in relation to postnatal diagnostic X-rays. In utero diagnostic ultrasound tests were not linked with risk of childhood ALL. We found little consistent evidence that in utero diagnostic ultrasound tests or X-rays were linked with an increased risk of childhood ALL. Small increases in total or pre-B ALL risks for children in selected age groups to very low ionizing radiation exposures from postnatal or preconception diagnostic X-ray exposures may represent chance findings or biases. Future studies of diagnostic X-rays and childhood leukemia in the United States will require extensive additional efforts and resources to quantify risk because of declining in utero exposures in the general population (thus necessitating large numbers of subjects, particularly cases) and the difficulty in validating reported exposures.",Journal Article,6563.0,92.0,The objective of this study was to evaluate the association between in utero diagnostic X-rays and childhood acute lymphoblastic ALL and the less well-studied relationship of this malignancy to preconception and postnatal diagnostic X-rays or fetal ultrasound exposures The Children 's Cancer Group conducted a case-control study including interviews with parents of 1842 ALL cases diagnosed under the age of 15 years and 1986 individually matched controls Associations of self-reported parental preconception in utero and postnatal X-ray exposure with risk of childhood ALL were examined using odds ratios ORs and corresponding 95 confidence intervals CIs obtained from logistic regression models among the overall group of ALL cases as well as immunophenotypic and age-specific subgroups Overall in utero pelvimetric diagnostic X-rays were not associated with the risk of pediatric ALL OR 1.2 95 CI 0.8-1.7 Childhood ALL all types combined OR 1.1 95 CI 0.9-1.2 and specific types were also not linked with postnatal diagnostic X-ray exposures Neither maternal OR 0.9 95 CI 0.8-1.2 nor paternal OR 1.1 95 CI 0.8-1.4 lower abdominal preconception diagnostic X-rays were associated with risk of childhood ALL Among the multiple comparisons for age- sex- and subtype-specific subgroups we observed an elevated risk of total ALL among children ages 11-14 at diagnosis OR 2.4 95 CI 1.1-5.0 in relation to in utero pelvimetric diagnostic X-ray exposures and a small increase in pre-B ALL for all ages combined OR 1.7 95 CI 1.1-2.7 in relation to postnatal diagnostic X-rays In utero diagnostic ultrasound tests were not linked with risk of childhood ALL We found little consistent evidence that in utero diagnostic ultrasound tests or X-rays were linked with an increased risk of childhood ALL Small increases in total or pre-B ALL risks for children in selected age groups to very low ionizing radiation exposures from postnatal or preconception diagnostic X-ray exposures may represent chance findings or biases Future studies of diagnostic X-rays and childhood in the United States will require extensive additional efforts and resources to quantify risk because of declining in utero exposures in the general population thus necessitating large numbers of subjects particularly cases and the difficulty in validating reported exposures,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 376, 3, 248, 59, 4, 13767, 752, 1006, 8558, 2, 864, 286, 1275, 62, 2, 3, 299, 149, 656, 858, 1, 26, 710, 6, 25985, 2, 15472, 752, 1006, 8558, 15, 6698, 1945, 3401, 3, 541, 292, 12, 87, 426, 8, 473, 182, 45, 141, 4053, 5, 2418, 1, 25986, 62, 140, 265, 669, 3, 89, 1, 167, 60, 2, 3751, 4257, 655, 535, 685, 1, 1074, 210, 3418, 25985, 4, 13767, 2, 15472, 1006, 5520, 645, 5, 43, 1, 864, 62, 11, 409, 75, 610, 1137, 3694, 2, 1734, 48, 307, 1582, 1927, 683, 29, 812, 320, 274, 107, 3, 63, 87, 1, 62, 140, 22, 149, 22, 6599, 2, 89, 112, 1453, 63, 4, 13767, 37101, 752, 1006, 8558, 11, 44, 41, 5, 3, 43, 1, 815, 62, 15, 14, 18, 48, 58, 13, 66, 14, 67, 864, 62, 62, 630, 397, 15, 14, 14, 48, 58, 13, 83, 14, 18, 2, 112, 630, 11, 120, 44, 1199, 5, 15472, 752, 1006, 5520, 3401, 2174, 6039, 15, 13, 83, 48, 58, 13, 66, 14, 18, 2110, 10649, 15, 14, 14, 48, 58, 13, 66, 14, 39, 280, 1467, 25985, 752, 1006, 8558, 11, 41, 5, 43, 1, 864, 62, 107, 3, 232, 2213, 9, 89, 1035, 2, 875, 112, 1453, 21, 164, 35, 804, 43, 1, 181, 62, 107, 541, 2165, 175, 213, 28, 147, 15, 18, 39, 48, 58, 14, 14, 33, 13, 4, 2191, 6, 4, 13767, 37101, 752, 1006, 5520, 3401, 2, 8, 302, 344, 4, 671, 132, 62, 9, 62, 2165, 397, 15, 14, 67, 48, 58, 14, 14, 18, 67, 4, 2191, 6, 15472, 752, 1006, 8558, 4, 13767, 752, 1945, 895, 11, 44, 1199, 5, 43, 1, 864, 62, 21, 204, 1215, 925, 241, 17, 4, 13767, 752, 1945, 895, 15, 1006, 8558, 11, 1199, 5, 35, 101, 43, 1, 864, 62, 302, 1106, 4, 181, 15, 671, 132, 62, 1098, 9, 541, 4, 715, 89, 271, 6, 923, 154, 4341, 121, 3401, 29, 15472, 15, 25985, 752, 1006, 5520, 3401, 68, 1231, 3477, 272, 15, 8232, 508, 94, 1, 752, 1006, 8558, 2, 864, 4, 3, 1088, 907, 303, 1353, 1344, 402, 1413, 2, 2892, 6, 3091, 43, 408, 1, 6896, 4, 13767, 3401, 4, 3, 1083, 266, 631, 8365, 375, 1870, 1, 976, 823, 140, 2, 3, 4035, 4, 6897, 210, 3401]",2334.0,11867505,191
Genomic DNA breakpoints in AML1/RUNX1 and ETO cluster with topoisomerase II DNA cleavage and DNase I hypersensitive sites in t(8;21) leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2002-02-26,"The translocation t(8;21)(q22;q22) is one of the most frequent chromosome translocations in acute myeloid leukemia (AML). AML1/RUNX1 at 21q22 is involved in t(8;21), t(3;21), and t(16;21) in de novo and therapy-related AML and myelodysplastic syndrome as well as in t(12;21) in childhood B cell acute lymphoblastic leukemia. Although DNA breakpoints in AML1 and ETO (at 8q22) cluster in a few introns, the mechanisms of DNA recombination resulting in t(8;21) are unknown. The correlation of specific chromatin structural elements, i.e., topoisomerase II (topo II) DNA cleavage sites, DNase I hypersensitive sites, and scaffold-associated regions, which have been implicated in chromosome recombination with genomic DNA breakpoints in AML1 and ETO in t(8;21) is unknown. The breakpoints in AML1 and ETO were clustered in the Kasumi 1 cell line and in 31 leukemia patients with t(8;21); all except one had de novo AML. Sequencing of the breakpoint junctions revealed no common DNA motif; however, deletions, duplications, microhomologies, and nontemplate DNA were found. Ten in vivo topo II DNA cleavage sites were mapped in AML1, including three in intron 5 and seven in intron 7a, and two were in intron 1b of ETO. All strong topo II sites colocalized with DNase I hypersensitive sites and thus represent open chromatin regions. These sites correlated with genomic DNA breakpoints in both AML1 and ETO, thus implicating them in the de novo 8;21 translocation.",Journal Article,6538.0,86.0,The translocation t 8 21 q22 q22 is one of the most frequent chromosome translocations in acute myeloid AML AML1/RUNX1 at 21q22 is involved in t 8 21 t 3 21 and t 16 21 in de novo and therapy-related AML and syndrome as well as in t 12 21 in childhood B cell acute lymphoblastic Although DNA breakpoints in AML1 and ETO at 8q22 cluster in a few introns the mechanisms of DNA recombination resulting in t 8 21 are unknown The correlation of specific chromatin structural elements i.e. topoisomerase II topo II DNA cleavage sites DNase I hypersensitive sites and scaffold-associated regions which have been implicated in chromosome recombination with genomic DNA breakpoints in AML1 and ETO in t 8 21 is unknown The breakpoints in AML1 and ETO were clustered in the Kasumi 1 cell line and in 31 patients with t 8 21 all except one had de novo AML Sequencing of the breakpoint junctions revealed no common DNA motif however deletions duplications microhomologies and nontemplate DNA were found Ten in vivo topo II DNA cleavage sites were mapped in AML1 including three in intron 5 and seven in intron 7a and two were in intron 1b of ETO All strong topo II sites colocalized with DNase I hypersensitive sites and thus represent open chromatin regions These sites correlated with genomic DNA breakpoints in both AML1 and ETO thus implicating them in the de novo 8 21 translocation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2006, 102, 66, 239, 8026, 8026, 16, 104, 1, 3, 96, 908, 1170, 3262, 4, 286, 533, 329, 6535, 6092, 28, 14402, 16, 646, 4, 102, 66, 239, 102, 27, 239, 2, 102, 245, 239, 4, 1566, 2018, 2, 36, 139, 329, 2, 681, 22, 149, 22, 4, 102, 133, 239, 4, 864, 132, 31, 286, 1275, 242, 261, 7843, 4, 6535, 2, 8566, 28, 42858, 3132, 4, 8, 1021, 12491, 3, 483, 1, 261, 4017, 1113, 4, 102, 66, 239, 32, 860, 3, 816, 1, 112, 2287, 3281, 2531, 70, 563, 3999, 215, 7852, 215, 261, 3155, 633, 21951, 70, 14077, 633, 2, 11547, 41, 1374, 92, 47, 85, 1771, 4, 1170, 4017, 5, 572, 261, 7843, 4, 6535, 2, 8566, 4, 102, 66, 239, 16, 860, 3, 7843, 4, 6535, 2, 8566, 11, 6464, 4, 3, 18159, 14, 31, 328, 2, 4, 456, 7, 5, 102, 66, 239, 62, 2187, 104, 42, 1566, 2018, 329, 615, 1, 3, 8567, 10262, 553, 77, 186, 261, 5298, 137, 2439, 8910, 52765, 2, 52766, 261, 11, 204, 1618, 4, 386, 7852, 215, 261, 3155, 633, 11, 6224, 4, 6535, 141, 169, 4, 6259, 33, 2, 648, 4, 6259, 8730, 2, 100, 11, 4, 6259, 4693, 1, 8566, 62, 1082, 7852, 215, 633, 16625, 5, 21951, 70, 14077, 633, 2, 631, 1231, 1020, 2287, 1374, 46, 633, 438, 5, 572, 261, 7843, 4, 110, 6535, 2, 8566, 631, 7912, 1370, 4, 3, 1566, 2018, 66, 239, 2006]",1375.0,11867721,432
Magnetic resonance imaging findings in a case of cytarabine-induced myelopathy.,Military medicine,Mil Med,2002-02-01,"A 44-year-old white male with an isolated central nervous system relapse of acute lymphoblastic leukemia was treated with intrathecal cytarabine. He developed Staphylococcus epidermidis meningitis, which was treated successfully with intrathecal vancomycin. Four weeks after the initiation of intrathecal cytarabine, the patient developed progressive ascending paralysis to the upper cervical level. Initial magnetic resonance imaging of the brain and spine were normal, and cerebrospinal fluid evaluation showed no evidence of ongoing infection and clearance of lymphoblasts. Three weeks later, magnetic resonance imaging demonstrated marked edema and peripheral enhancement of the spinal cord, consistent with cytarabine toxicity.",Case Reports,6563.0,11.0,A 44-year-old white male with an isolated central nervous system relapse of acute lymphoblastic was treated with intrathecal cytarabine He developed Staphylococcus epidermidis meningitis which was treated successfully with intrathecal vancomycin Four weeks after the initiation of intrathecal cytarabine the patient developed progressive ascending paralysis to the upper level Initial magnetic resonance imaging of the brain and spine were normal and cerebrospinal fluid evaluation showed no evidence of ongoing infection and clearance of lymphoblasts Three weeks later magnetic resonance imaging demonstrated marked edema and peripheral enhancement of the spinal cord consistent with cytarabine toxicity,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,"[8, 584, 111, 1095, 886, 1045, 5, 35, 1355, 854, 1880, 398, 429, 1, 286, 1275, 10, 73, 5, 5126, 1855, 3174, 276, 14739, 42859, 10792, 92, 10, 73, 1878, 5, 5126, 9013, 294, 244, 50, 3, 1118, 1, 5126, 1855, 3, 69, 276, 1014, 14404, 11737, 6, 3, 1726, 301, 388, 1484, 1535, 270, 1, 3, 342, 2, 2342, 11, 295, 2, 5156, 2357, 451, 224, 77, 241, 1, 942, 930, 2, 1960, 1, 10521, 169, 244, 1559, 1484, 1535, 270, 264, 2003, 3306, 2, 672, 2461, 1, 3, 1499, 1885, 925, 5, 1855, 155]",704.0,11873541,558
Protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-03-01,"To determine dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD) of a protracted, intermittent schedule of daily 30-minute infusions of topotecan (TPT) for up to 12 consecutive days, every 3 weeks, in children with refractory leukemia. Forty-nine children were enrolled onto this phase I trial (24 with acute nonlymphoblastic leukemia [ANLL] and 25 with acute lymphoblastic leukemia [ALL]). TPT dosage was escalated from 2.0 to 5.2 mg/m(2)/d for 5 days and 2.4 mg/m(2)/d from 7 days to the same dose for 9 and 12 days in cohorts of three to six patients when no DLT was identified. TPT pharmacokinetics were studied in 33 children once or twice (first and last doses in patients who received TPT for > 7 days). Seventy assessable courses of TPT were administered to 49 children who had refractory leukemia. DLTs were typhlitis, diarrhea, and mucositis, and the MTD was 2.4 mg/m(2)/d for 9 days in this group of heavily pretreated children. In 33 patients, the median TPT lactone clearance after the first dose was 19.2 L/h/m(2) (range, 9.4 to 45.9 L/h/m(2)) and did not change during the course. There were significant responses (one complete response [CR] and four partial responses [PR] in patients with ANLL and one CR and two PRs in patients with ALL), and all but one were at dosages of TPT given for at least 9 days. The MTD was 2.4 mg/m(2)/d for 9 days. Further testing is warranted of TPT's schedule dependence in children with leukemia.",Clinical Trial,6535.0,34.0,To determine dose-limiting toxicity DLT and maximum-tolerated dose MTD of a protracted intermittent schedule of daily 30-minute infusions of topotecan TPT for up to 12 consecutive days every 3 weeks in children with refractory Forty-nine children were enrolled onto this phase I trial 24 with acute nonlymphoblastic ANLL and 25 with acute lymphoblastic ALL TPT dosage was escalated from 2.0 to 5.2 mg/m 2 /d for 5 days and 2.4 mg/m 2 /d from 7 days to the same dose for 9 and 12 days in cohorts of three to six patients when no DLT was identified TPT pharmacokinetics were studied in 33 children once or twice first and last doses in patients who received TPT for 7 days Seventy assessable courses of TPT were administered to 49 children who had refractory DLTs were typhlitis diarrhea and mucositis and the MTD was 2.4 mg/m 2 /d for 9 days in this group of heavily pretreated children In 33 patients the median TPT lactone clearance after the first dose was 19.2 L/h/m 2 range 9.4 to 45.9 L/h/m 2 and did not change during the course There were significant responses one complete response CR and four partial responses PR in patients with ANLL and one CR and two PRs in patients with ALL and all but one were at dosages of TPT given for at least 9 days The MTD was 2.4 mg/m 2 /d for 9 days Further testing is warranted of TPT 's schedule dependence in children with,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 61, 817, 155, 2059, 2, 689, 421, 61, 961, 1, 8, 7053, 4102, 1055, 1, 391, 201, 3949, 3435, 1, 2129, 12262, 9, 126, 6, 133, 935, 162, 454, 27, 244, 4, 541, 5, 430, 1213, 762, 541, 11, 346, 3301, 26, 124, 70, 160, 259, 5, 286, 52781, 27864, 2, 243, 5, 286, 1275, 62, 12262, 3323, 10, 2842, 29, 18, 13, 6, 33, 18, 81, 188, 18, 427, 9, 33, 162, 2, 18, 39, 81, 188, 18, 427, 29, 67, 162, 6, 3, 827, 61, 9, 83, 2, 133, 162, 4, 736, 1, 169, 6, 437, 7, 198, 77, 2059, 10, 108, 12262, 1159, 11, 656, 4, 466, 541, 1059, 15, 936, 157, 2, 1060, 415, 4, 7, 54, 103, 12262, 9, 67, 162, 2073, 3120, 1993, 1, 12262, 11, 468, 6, 739, 541, 54, 42, 430, 2506, 11, 12710, 1172, 2, 2606, 2, 3, 961, 10, 18, 39, 81, 188, 18, 427, 9, 83, 162, 4, 26, 87, 1, 2447, 2193, 541, 4, 466, 7, 3, 52, 12262, 8643, 1960, 50, 3, 157, 61, 10, 326, 18, 805, 555, 188, 18, 184, 83, 39, 6, 512, 83, 805, 555, 188, 18, 2, 205, 44, 707, 190, 3, 906, 125, 11, 93, 253, 104, 236, 51, 684, 2, 294, 450, 253, 998, 4, 7, 5, 27864, 2, 104, 684, 2, 100, 4018, 4, 7, 5, 62, 2, 62, 84, 104, 11, 28, 7352, 1, 12262, 447, 9, 28, 506, 83, 162, 3, 961, 10, 18, 39, 81, 188, 18, 427, 9, 83, 162, 195, 471, 16, 1197, 1, 12262, 292, 1055, 3721, 4, 541, 5]",1366.0,11896112,42
Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-03-01,"Acute doxorubicin-induced cardiotoxicity can be prevented in adults by continuous infusion of the drug, but mechanisms of cardiotoxicity are different in children. We compared cardiac outcomes in children receiving bolus or continuous infusion of doxorubicin. In a randomized study, children with high-risk acute lymphoblastic leukemia received doxorubicin 360 mg/m(2) in 30-mg/m(2) doses every 3 weeks either by bolus (within 1 hour, n = 57) or by continuous infusion (over 48 hours, n = 64). Echocardiograms obtained before doxorubicin and at longest follow-up times were centrally remeasured, and z scores of cardiac measurements were calculated based on a healthy population. The groups were similar in age, sex distribution, doxorubicin dose, and duration of follow-up. Before treatment, measures of left ventricular (LV) structure and function did not reveal dilated cardiomyopathy and were not statistically different between bolus and continuous-infusion groups. The follow-up echocardiograms demonstrated no significant difference between the two groups for any cardiac characteristic, but both groups showed significant abnormalities of LV structure and function compared with normal and with baseline. For example, the mean LV fractional shortening fell by approximately two SD in both groups between the two echocardiograms. LV contractility was depressed in both groups (for bolus patients, median z score = -0.70 SD, P =.006; for continuous-infusion patients, median z score = -0.765, P =.005). Dilated cardiomyopathy and inadequate LV hypertrophy were noted in both groups. Clinical cardiac manifestations and event-free survival did not differ. Continuous doxorubicin infusion over 48 hours for childhood leukemia did not offer a cardioprotective advantage over bolus infusion. Both regimens were associated with progressive subclinical cardiotoxicity. Other cardioprotective strategies should be explored.",Clinical Trial,6535.0,160.0,Acute doxorubicin-induced cardiotoxicity can be prevented in adults by continuous infusion of the drug but mechanisms of cardiotoxicity are different in children We compared outcomes in children receiving bolus or continuous infusion of doxorubicin In a randomized study children with high-risk acute lymphoblastic received doxorubicin 360 mg/m 2 in 30-mg/m 2 doses every 3 weeks either by bolus within 1 hour n 57 or by continuous infusion over 48 hours n 64 Echocardiograms obtained before doxorubicin and at longest follow-up times were centrally remeasured and z scores of measurements were calculated based on a healthy population The groups were similar in age sex distribution doxorubicin dose and duration of follow-up Before treatment measures of left ventricular LV structure and function did not reveal dilated cardiomyopathy and were not statistically different between bolus and continuous-infusion groups The follow-up echocardiograms demonstrated no significant difference between the two groups for any characteristic but both groups showed significant abnormalities of LV structure and function compared with normal and with baseline For example the mean LV fractional shortening fell by approximately two SD in both groups between the two echocardiograms LV contractility was depressed in both groups for bolus patients median z score -0.70 SD P =.006 for continuous-infusion patients median z score -0.765 P =.005 Dilated cardiomyopathy and inadequate LV hypertrophy were noted in both groups Clinical manifestations and event-free survival did not differ Continuous doxorubicin infusion over 48 hours for childhood did not offer a cardioprotective advantage over bolus infusion Both regimens were associated with progressive subclinical cardiotoxicity Other cardioprotective strategies should be explored,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[286, 856, 277, 4404, 122, 40, 3902, 4, 857, 20, 1314, 904, 1, 3, 234, 84, 483, 1, 4404, 32, 338, 4, 541, 21, 72, 123, 4, 541, 357, 3604, 15, 1314, 904, 1, 856, 4, 8, 384, 45, 541, 5, 64, 43, 286, 1275, 103, 856, 6739, 81, 188, 18, 4, 201, 81, 188, 18, 415, 454, 27, 244, 361, 20, 3604, 262, 14, 2583, 78, 696, 15, 20, 1314, 904, 252, 576, 1459, 78, 660, 15097, 683, 348, 856, 2, 28, 5683, 166, 126, 1072, 11, 4604, 42870, 2, 3905, 703, 1, 1685, 11, 981, 90, 23, 8, 1331, 266, 3, 271, 11, 288, 4, 89, 1035, 1395, 856, 61, 2, 654, 1, 166, 126, 348, 24, 1018, 1, 1712, 4028, 4072, 2772, 2, 343, 205, 44, 2396, 11536, 6460, 2, 11, 44, 712, 338, 59, 3604, 2, 1314, 904, 271, 3, 166, 126, 15097, 264, 77, 93, 523, 59, 3, 100, 271, 9, 500, 2037, 84, 110, 271, 224, 93, 1171, 1, 4072, 2772, 2, 343, 72, 5, 295, 2, 5, 330, 9, 2685, 3, 313, 4072, 7528, 9245, 7689, 20, 705, 100, 1270, 4, 110, 271, 59, 3, 100, 15097, 4072, 24430, 10, 9233, 4, 110, 271, 9, 3604, 7, 52, 3905, 368, 13, 431, 1270, 19, 1861, 9, 1314, 904, 7, 52, 3905, 368, 13, 12263, 19, 1614, 11536, 6460, 2, 3358, 4072, 9544, 11, 1051, 4, 110, 271, 38, 4282, 2, 774, 115, 25, 205, 44, 1505, 1314, 856, 904, 252, 576, 1459, 9, 864, 205, 44, 1918, 8, 17618, 1874, 252, 3604, 904, 110, 472, 11, 41, 5, 1014, 7403, 4404, 127, 17618, 422, 257, 40, 1443]",1824.0,11896119,312
"Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States).",Cancer causes & control : CCC,Cancer Causes Control,2002-02-01,"To investigate the associations of birth characteristics and maternal reproductive factors with risk of childhood acute lymphoblastic leukemia (ALL) by immunophenotypic subtypes. Data collected from a case-control study including 1842 ALL cases (age < 15 years) and 1986 individually matched controls were analyzed. Exposure information was obtained through telephone interviews of parents. Factors associated with risk of ALL from all subgroups combined included high birth weight (OR = 1.4, 95% CI = 1.1-1.8), high birth order (OR = 2.0, 95% CI = 1.3-3.0 for fourth-born child compared to first-born child). young maternal age (<20 compared to 25-29, OR = 1.4, 95% CI = 1.1-1.9), advanced paternal age (>39 compared to 25-29, OR = 1.4, 95% CI = 1.0-1.9), induced abortion prior to the index pregnancy (OR = 1.2, 95% CI = 1.0-1.4), and oral contraceptive use during the index pregnancy (OR = 1.5, 95% CI = 1.0-2.2) with children under the age of 2 (OR = 5.1, 95% CI = 1.0-24.7) being the predominantly affected group. Risk of early pre-B-cell ALL increased with advanced paternal age (OR = 1.7, 95% CI = 1.1-2.7) and high birth order (OR = 2.0, 95% CI = 1.1-3.6), while risk of pre-B-cell ALL increased with both younger (OR = 3.4, 95% CI = 1.4-8.4) and advanced maternal age (OR = 2.6, 95% CI = 1.1-5.9). T-cell ALL was associated with high birth weight (OR = 2.4, 95% CI = 1.1-5.5) and history of induced abortion (OR = 2.4, 95% CI = 1.3-4.5). This study suggests that the association of ALL with birth characteristics and maternal reproductive factors varies with the immunophenotype of the ALL. Future studies are needed to better understand the effect of maternal hormone in the development of subtype of childhood ALL.",Comparative Study,6563.0,58.0,To investigate the associations of birth characteristics and maternal reproductive factors with risk of childhood acute lymphoblastic ALL by immunophenotypic subtypes Data collected from a case-control study including 1842 ALL cases age 15 years and 1986 individually matched controls were analyzed Exposure information was obtained through telephone interviews of parents Factors associated with risk of ALL from all subgroups combined included high birth weight OR 1.4 95 CI 1.1-1.8 high birth order OR 2.0 95 CI 1.3-3.0 for fourth-born child compared to first-born child young maternal age 20 compared to 25-29 OR 1.4 95 CI 1.1-1.9 advanced paternal age 39 compared to 25-29 OR 1.4 95 CI 1.0-1.9 induced abortion prior to the index pregnancy OR 1.2 95 CI 1.0-1.4 and oral contraceptive use during the index pregnancy OR 1.5 95 CI 1.0-2.2 with children under the age of 2 OR 5.1 95 CI 1.0-24.7 being the predominantly affected group Risk of early pre-B-cell ALL increased with advanced paternal age OR 1.7 95 CI 1.1-2.7 and high birth order OR 2.0 95 CI 1.1-3.6 while risk of pre-B-cell ALL increased with both younger OR 3.4 95 CI 1.4-8.4 and advanced maternal age OR 2.6 95 CI 1.1-5.9 T-cell ALL was associated with high birth weight OR 2.4 95 CI 1.1-5.5 and history of induced abortion OR 2.4 95 CI 1.3-4.5 This study suggests that the association of ALL with birth characteristics and maternal reproductive factors varies with the immunophenotype of the ALL Future studies are needed to better understand the effect of maternal hormone in the development of subtype of childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 963, 3, 685, 1, 3809, 374, 2, 6039, 3705, 130, 5, 43, 1, 864, 286, 1275, 62, 20, 6599, 814, 74, 786, 29, 8, 473, 182, 45, 141, 25986, 62, 140, 89, 167, 60, 2, 3751, 4257, 655, 535, 11, 311, 645, 487, 10, 683, 298, 4258, 4053, 1, 2418, 130, 41, 5, 43, 1, 62, 29, 62, 1453, 397, 159, 64, 3809, 924, 15, 14, 39, 48, 58, 14, 14, 14, 66, 64, 3809, 1732, 15, 18, 13, 48, 58, 14, 27, 27, 13, 9, 3608, 8234, 2566, 72, 6, 157, 8234, 2566, 1169, 6039, 89, 179, 72, 6, 243, 462, 15, 14, 39, 48, 58, 14, 14, 14, 83, 131, 10649, 89, 587, 72, 6, 243, 462, 15, 14, 39, 48, 58, 14, 13, 14, 83, 277, 21938, 324, 6, 3, 558, 2290, 15, 14, 18, 48, 58, 14, 13, 14, 39, 2, 518, 6780, 119, 190, 3, 558, 2290, 15, 14, 33, 48, 58, 14, 13, 18, 18, 5, 541, 669, 3, 89, 1, 18, 15, 33, 14, 48, 58, 14, 13, 259, 67, 486, 3, 2117, 1424, 87, 43, 1, 191, 671, 132, 31, 62, 101, 5, 131, 10649, 89, 15, 14, 67, 48, 58, 14, 14, 18, 67, 2, 64, 3809, 1732, 15, 18, 13, 48, 58, 14, 14, 27, 49, 369, 43, 1, 671, 132, 31, 62, 101, 5, 110, 773, 15, 27, 39, 48, 58, 14, 39, 66, 39, 2, 131, 6039, 89, 15, 18, 49, 48, 58, 14, 14, 33, 83, 102, 31, 62, 10, 41, 5, 64, 3809, 924, 15, 18, 39, 48, 58, 14, 14, 33, 33, 2, 532, 1, 277, 21938, 15, 18, 39, 48, 58, 14, 27, 39, 33, 26, 45, 844, 17, 3, 248, 1, 62, 5, 3809, 374, 2, 6039, 3705, 130, 4037, 5, 3, 5496, 1, 3, 62, 508, 94, 32, 575, 6, 380, 1640, 3, 254, 1, 6039, 785, 4, 3, 193, 1, 875, 1, 864, 62]",1588.0,11899114,384
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.,Leukemia research,Leuk. Res.,2002-07-01,"We examined the pre-treatment bone marrow samples from 200 consecutive adult patients with acute lymphoblastic leukemia (ALL) treated on various protocols at the University of Texas, M.D. Anderson Cancer Center between 1986 and 1998. Standard MFC techniques were used to determine CD56 expression on the leukemia blasts cells. The expression of CD56 was correlated with clinical characteristics at diagnosis, response to therapy, survival and disease-free survival. Blast expression of CD56 (> or = 20% of leukemic blasts) was seen in 16 (8%) of patients, with a median expression of 67% (range 20-99%). CD56 expression was associated with a higher incidence of central nervous system (CNS) disease at diagnosis (19% versus 4%; P=0.016). Incidence of CNS disease at any time was higher in patients with CD56+ disease (31% versus 14%; P=0.057). Among the 109 patients uniformly treated with the hyperCVAD regimen, CD56 expression was associated with a statistically significant higher incidence of CNS disease (33% versus 9%; P=0.026). CD56 expression in ALL is uncommon but may predict a higher risk for CNS disease. If these results are confirmed, CD56 expression could be used in combination with other high-risk features (e.g. lactate dehydrogenase (LDH), S-phase fraction, mature B-cell phenotype) to design a risk-oriented approach to CNS prophylaxis.",Journal Article,6413.0,37.0,We examined the pre-treatment marrow samples from 200 consecutive adult patients with acute lymphoblastic ALL treated on various protocols at the University of Texas M.D Anderson Cancer Center between 1986 and 1998 Standard MFC techniques were used to determine CD56 expression on the blasts cells The expression of CD56 was correlated with clinical characteristics at diagnosis response to therapy survival and disease-free survival Blast expression of CD56 or 20 of leukemic blasts was seen in 16 8 of patients with a median expression of 67 range 20-99 CD56 expression was associated with a higher incidence of central nervous system CNS disease at diagnosis 19 versus 4 P=0.016 Incidence of CNS disease at any time was higher in patients with CD56+ disease 31 versus 14 P=0.057 Among the 109 patients uniformly treated with the hyperCVAD regimen CD56 expression was associated with a statistically significant higher incidence of CNS disease 33 versus 9 P=0.026 CD56 expression in ALL is uncommon but may predict a higher risk for CNS disease If these results are confirmed CD56 expression could be used in combination with other high-risk features e.g lactate dehydrogenase LDH S-phase fraction mature B-cell phenotype to design a risk-oriented approach to CNS prophylaxis,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 409, 3, 671, 24, 581, 347, 29, 1250, 935, 780, 7, 5, 286, 1275, 62, 73, 23, 747, 2189, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 59, 3751, 2, 1850, 260, 9439, 1092, 11, 95, 6, 223, 5803, 55, 23, 3, 2438, 37, 3, 55, 1, 5803, 10, 438, 5, 38, 374, 28, 147, 51, 6, 36, 25, 2, 34, 115, 25, 3112, 55, 1, 5803, 15, 179, 1, 2015, 2438, 10, 527, 4, 245, 66, 1, 7, 5, 8, 52, 55, 1, 598, 184, 179, 1058, 5803, 55, 10, 41, 5, 8, 142, 287, 1, 854, 1880, 398, 1025, 34, 28, 147, 326, 185, 39, 19, 13, 3820, 287, 1, 1025, 34, 28, 500, 98, 10, 142, 4, 7, 5, 5803, 34, 456, 185, 213, 19, 13, 10807, 107, 3, 3486, 7, 4254, 73, 5, 3, 13792, 477, 5803, 55, 10, 41, 5, 8, 712, 93, 142, 287, 1, 1025, 34, 466, 185, 83, 19, 13, 4554, 5803, 55, 4, 62, 16, 2052, 84, 68, 678, 8, 142, 43, 9, 1025, 34, 492, 46, 99, 32, 557, 5803, 55, 359, 40, 95, 4, 150, 5, 127, 64, 43, 404, 563, 499, 3330, 2374, 4592, 695, 124, 1509, 2908, 132, 31, 1005, 6, 771, 8, 43, 8095, 353, 6, 1025, 2049]",1277.0,12008081,297
Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2002-01-01,"For patients with high-risk or relapsed acute lymphoblastic leukemia (ALL) lacking a related histocompatible donor, autologous (Auto) and unrelated donor (URD) transplantation are available options. We compared outcomes and toxicities in 712 patients with ALL (517 URD, 195 Auto) in first complete remission (CR1) or second complete remission (CR2) who underwent transplantation. All patients were <50 years old, although URD patientswere younger (median age, 14 versus 18 years, P < .002). The proportion of patients in CR1 versus CR2 was similar (36% versus 38%, P = .57), but more URD recipients than Auto recipients had high-risk karyotypes (25% versus 13%, P = .003) and white blood cell (WBC) counts > or =50 x 10(9)/L (33% versus 14%, P < .001). Engraftment was similar in URD and Auto recipients. Ex vivo purging delayed but did not prevent engraftment after Auto transplantation. Transplantation-related mortality was higher after URD transplantation (42%+/-8%) than after Auto transplantation (20%+/-12%) in CR1 (P = .004) and also in CR2. Conversely, relapse was more frequent after Auto transplantation in CR1 (Auto, 49%+/-12% versus URD, 14%+/-5%) and CR2 (64%+/-8% versus 25%+/-5%) (P < .0001). These findings showed net similar outcomes for these 2 transplantation choices. Transplantation in CR1 yielded similar 3-year survival rates for URD (51%+/-7%) and Auto (44%+/-12%), as did transplantation in CR2 (40%+/-6% versus 32%+/-9%, respectively). Multivariate regression analysis identified significantly better disease-free survival after the first 6 months in matched URD versus Auto in younger patients, in those in CR2 with CR1 >1year, WBC <50 x 10(9)/L, performance status > or =90%, and in those who have undergone transplantation since 1995. These comparative data suggest that both matched URD and Auto transplantation can yield extended survival. Although URD transplantation offers substantially better protection against leukemic relapse, improvements in allotransplantation safety and refinements in patient selection are required to better aid treatment decision making for the best overall survival.",Comparative Study,6594.0,46.0,For patients with high-risk or relapsed acute lymphoblastic ALL lacking a related histocompatible donor autologous Auto and unrelated donor URD transplantation are available options We compared outcomes and toxicities in 712 patients with ALL 517 URD 195 Auto in first complete remission CR1 or second complete remission CR2 who underwent transplantation All patients were 50 years old although URD patientswere younger median age 14 versus 18 years P .002 The proportion of patients in CR1 versus CR2 was similar 36 versus 38 P .57 but more URD recipients than Auto recipients had high-risk karyotypes 25 versus 13 P .003 and white blood cell WBC counts or =50 x 10 9 /L 33 versus 14 P .001 Engraftment was similar in URD and Auto recipients Ex vivo purging delayed but did not prevent engraftment after Auto transplantation Transplantation-related mortality was higher after URD transplantation 42 +/-8 than after Auto transplantation 20 +/-12 in CR1 P .004 and also in CR2 Conversely relapse was more frequent after Auto transplantation in CR1 Auto 49 +/-12 versus URD 14 +/-5 and CR2 64 +/-8 versus 25 +/-5 P .0001 These findings showed net similar outcomes for these 2 transplantation choices Transplantation in CR1 yielded similar 3-year survival rates for URD 51 +/-7 and Auto 44 +/-12 as did transplantation in CR2 40 +/-6 versus 32 +/-9 respectively Multivariate regression analysis identified significantly better disease-free survival after the first 6 months in matched URD versus Auto in younger patients in those in CR2 with CR1 1year WBC 50 x 10 9 /L performance status or =90 and in those who have undergone transplantation since 1995 These comparative data suggest that both matched URD and Auto transplantation can yield extended survival Although URD transplantation offers substantially better protection against leukemic relapse improvements in allotransplantation safety and refinements in patient selection are required to better aid treatment decision making for the best overall survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 7, 5, 64, 43, 15, 591, 286, 1275, 62, 1941, 8, 139, 30254, 1488, 1028, 3005, 2, 2092, 1488, 5847, 497, 32, 390, 838, 21, 72, 123, 2, 385, 4, 13251, 7, 5, 62, 11100, 5847, 5786, 3005, 4, 157, 236, 734, 4516, 15, 419, 236, 734, 7865, 54, 208, 497, 62, 7, 11, 212, 60, 1095, 242, 5847, 52909, 773, 52, 89, 213, 185, 203, 60, 19, 1111, 3, 920, 1, 7, 4, 4516, 185, 7865, 10, 288, 511, 185, 519, 19, 696, 84, 80, 5847, 2190, 76, 3005, 2190, 42, 64, 43, 6809, 243, 185, 233, 19, 1421, 2, 886, 315, 31, 4685, 1911, 15, 212, 1006, 79, 83, 805, 466, 185, 213, 19, 144, 2881, 10, 288, 4, 5847, 2, 3005, 2190, 2581, 386, 9441, 1612, 84, 205, 44, 1682, 2881, 50, 3005, 497, 497, 139, 282, 10, 142, 50, 5847, 497, 595, 66, 76, 50, 3005, 497, 179, 133, 4, 4516, 19, 1520, 2, 120, 4, 7865, 3154, 429, 10, 80, 908, 50, 3005, 497, 4, 4516, 3005, 739, 133, 185, 5847, 213, 33, 2, 7865, 660, 66, 185, 243, 33, 19, 488, 46, 272, 224, 2587, 288, 123, 9, 46, 18, 497, 5218, 497, 4, 4516, 2178, 288, 27, 111, 25, 151, 9, 5847, 725, 67, 2, 3005, 584, 133, 22, 205, 497, 4, 7865, 327, 49, 185, 531, 83, 106, 331, 320, 65, 108, 97, 380, 34, 115, 25, 50, 3, 157, 49, 53, 4, 655, 5847, 185, 3005, 4, 773, 7, 4, 135, 4, 7865, 5, 4516, 27896, 4685, 212, 1006, 79, 83, 805, 528, 156, 15, 424, 2, 4, 135, 54, 47, 1989, 497, 1192, 2323, 46, 2352, 74, 309, 17, 110, 655, 5847, 2, 3005, 497, 122, 2309, 1747, 25, 242, 5847, 497, 2339, 2109, 380, 3525, 480, 2015, 429, 1474, 4, 37175, 367, 2, 10518, 4, 69, 881, 32, 616, 6, 380, 2427, 24, 948, 1079, 9, 3, 824, 63, 25]",2012.0,12014810,227
Radiation myelitis in a 5-year-old girl.,Journal of child neurology,J. Child Neurol.,2002-03-01,"Myelopathy is an uncommon complication of radiotherapy, particularly in the pediatric age group. A 5-year-old girl with acute lymphoblastic leukemia developed a severe but transient radiculopathy after intrathecal administration of methotrexate and cytarabine for an isolated central nervous system relapse. Chemotherapy was then given through an intraventricular catheter. Owing to a second central nervous system recurrence, she was treated with craniospinal radiation. The whole brain down to the level of C2 received a dose of 2400 cGy. Two months after completion of radiation, the child developed a progressive tetraparesis, and magnetic resonance imaging revealed an enhancing lesion involving the medulla and upper cervical cord. A biopsy was consistent with a treatment-related necrotizing leukoencephalopathy. This case suggests that patients who develop neurologic dysfunction when treated with methotrexate can also be particularly susceptible to radiation-related injury.",Case Reports,6535.0,8.0,Myelopathy is an uncommon complication of radiotherapy particularly in the pediatric age group A 5-year-old girl with acute lymphoblastic developed a severe but transient radiculopathy after intrathecal administration of methotrexate and cytarabine for an isolated central nervous system relapse Chemotherapy was then given through an intraventricular catheter Owing to a second central nervous system recurrence she was treated with craniospinal radiation The whole brain down to the level of C2 received a dose of 2400 cGy Two months after completion of radiation the child developed a progressive tetraparesis and magnetic resonance imaging revealed an enhancing lesion involving the medulla and upper cord A biopsy was consistent with a treatment-related necrotizing leukoencephalopathy This case suggests that patients who develop neurologic dysfunction when treated with methotrexate can also be particularly susceptible to radiation-related injury,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,"[10415, 16, 35, 2052, 1447, 1, 310, 823, 4, 3, 815, 89, 87, 8, 33, 111, 1095, 12079, 5, 286, 1275, 276, 8, 905, 84, 2473, 16642, 50, 5126, 634, 1, 2116, 2, 1855, 9, 35, 1355, 854, 1880, 398, 429, 56, 10, 818, 447, 298, 35, 7199, 3925, 3421, 6, 8, 419, 854, 1880, 398, 146, 3109, 10, 73, 5, 5748, 121, 3, 902, 342, 1328, 6, 3, 301, 1, 6706, 103, 8, 61, 1, 12518, 3071, 100, 53, 50, 1438, 1, 121, 3, 2566, 276, 8, 1014, 52917, 2, 1484, 1535, 270, 553, 35, 2430, 1180, 1267, 3, 20187, 2, 1726, 1885, 8, 411, 10, 925, 5, 8, 24, 139, 21974, 8744, 26, 473, 844, 17, 7, 54, 690, 2543, 1527, 198, 73, 5, 2116, 122, 120, 40, 823, 4012, 6, 121, 139, 2730]",954.0,12026238,745
Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983.,Blood,Blood,2002-06-01,"Second malignant neoplasms are a serious complication after successful treatment of childhood acute lymphoblastic leukemia (ALL). With improvement in survival, it is important to assess the impact of contemporary risk-based therapies on second neoplasms in ALL survivors. A cohort of 8831 children diagnosed with ALL and enrolled on Children's Cancer Group therapeutic protocols between 1983 and 1995 were observed to determine the incidence of second neoplasms and associated risk factors. The median age at diagnosis of ALL was 4.7 years. The cohort had accrued 54 883 person-years of follow-up. Sixty-three patients developed second neoplasms, including solid, nonhematopoietic tumors (n = 39: brain tumors n = 19, other solid tumors n = 20), myeloid leukemia or myelodysplasia (n = 16), and lymphoma (n = 8). The cumulative incidence of any second neoplasm was 1.18% at 10 years (95% confidence interval, 0.8%-1.5%), representing a 7.2-fold increased risk compared with the general population. The risk was increased significantly for acute myeloid leukemia (standardized incidence ratio [SIR] 52.3), non-Hodgkin lymphoma (SIR 8.3), parotid gland tumors (SIR 33.4), thyroid cancer (SIR 13.3), brain tumors (SIR 10.1), and soft tissue sarcoma (SIR 9.1). Multivariate analysis revealed female sex (relative risk [RR] 1.8), radiation to the craniospinal axis (RR 1.6), and relapse of primary disease (RR 3.5) to be independently associated with increased risk of all second neoplasms. Risk of second neoplasms increased with radiation dose (1800 cGy RR 1.5; 2400 cGy RR 3.9). Actuarial survival at 10 years from diagnosis of second neoplasms was 39%. Follow-up of this large cohort that was treated with contemporary risk-based therapy showed that the incidence of second neoplasms remains low after diagnosis of childhood ALL.",Clinical Trial,6443.0,159.0,Second malignant neoplasms are a serious complication after successful treatment of childhood acute lymphoblastic ALL With improvement in survival it is important to assess the impact of contemporary risk-based therapies on second neoplasms in ALL survivors A cohort of 8831 children diagnosed with ALL and enrolled on Children 's Cancer Group therapeutic protocols between 1983 and 1995 were observed to determine the incidence of second neoplasms and associated risk factors The median age at diagnosis of ALL was 4.7 years The cohort had accrued 54 883 person-years of follow-up Sixty-three patients developed second neoplasms including solid nonhematopoietic tumors n 39 brain tumors n 19 other solid tumors n 20 myeloid or myelodysplasia n 16 and n 8 The cumulative incidence of any second neoplasm was 1.18 at 10 years 95 confidence interval 0.8 -1.5 representing a 7.2-fold increased risk compared with the general population The risk was increased significantly for acute myeloid standardized incidence ratio SIR 52.3 SIR 8.3 parotid gland tumors SIR 33.4 cancer SIR 13.3 brain tumors SIR 10.1 and soft tissue SIR 9.1 Multivariate analysis revealed female sex relative risk RR 1.8 radiation to the craniospinal axis RR 1.6 and relapse of primary disease RR 3.5 to be independently associated with increased risk of all second neoplasms Risk of second neoplasms increased with radiation dose 1800 cGy RR 1.5 2400 cGy RR 3.9 Actuarial survival at 10 years from diagnosis of second neoplasms was 39 Follow-up of this large cohort that was treated with contemporary risk-based therapy showed that the incidence of second neoplasms remains low after diagnosis of childhood ALL,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,1,0,"[419, 393, 1179, 32, 8, 1762, 1447, 50, 1401, 24, 1, 864, 286, 1275, 62, 5, 767, 4, 25, 192, 16, 305, 6, 423, 3, 345, 1, 2667, 43, 90, 235, 23, 419, 1179, 4, 62, 332, 8, 180, 1, 52933, 541, 265, 5, 62, 2, 346, 23, 541, 292, 12, 87, 189, 2189, 59, 6656, 2, 2323, 11, 164, 6, 223, 3, 287, 1, 419, 1179, 2, 41, 43, 130, 3, 52, 89, 28, 147, 1, 62, 10, 39, 67, 60, 3, 180, 42, 3198, 667, 14748, 2719, 60, 1, 166, 126, 1746, 169, 7, 276, 419, 1179, 141, 537, 19463, 57, 78, 587, 342, 57, 78, 326, 127, 537, 57, 78, 179, 533, 15, 6128, 78, 245, 2, 78, 66, 3, 967, 287, 1, 500, 419, 2131, 10, 14, 203, 28, 79, 60, 48, 307, 268, 13, 66, 14, 33, 2861, 8, 67, 18, 1116, 101, 43, 72, 5, 3, 1083, 266, 3, 43, 10, 101, 97, 9, 286, 533, 1670, 287, 197, 3636, 653, 27, 3636, 66, 27, 5838, 2326, 57, 3636, 466, 39, 12, 3636, 233, 27, 342, 57, 3636, 79, 14, 2, 1214, 246, 3636, 83, 14, 331, 65, 553, 1061, 1035, 580, 43, 861, 14, 66, 121, 6, 3, 5748, 2310, 861, 14, 49, 2, 429, 1, 86, 34, 861, 27, 33, 6, 40, 1042, 41, 5, 101, 43, 1, 62, 419, 1179, 43, 1, 419, 1179, 101, 5, 121, 61, 13507, 3071, 861, 14, 33, 12518, 3071, 861, 27, 83, 2361, 25, 28, 79, 60, 29, 147, 1, 419, 1179, 10, 587, 166, 126, 1, 26, 375, 180, 17, 10, 73, 5, 2667, 43, 90, 36, 224, 17, 3, 287, 1, 419, 1179, 469, 154, 50, 147, 1, 864, 62]",1679.0,12036851,223
TEL/AML1-positive pediatric leukemia: prognostic significance and therapeutic approaches.,Current opinion in hematology,Curr. Opin. Hematol.,2002-07-01,"This article presents the most recent insights into the biology, prognostic significance, and therapeutic approaches to TEL/AML1-positive leukemia. The TEL/AML1 fusion gene, also known as ETV6 /CBFA2, is the most commonly occurring gene rearrangement in pediatric acute lymphoblastic leukemia (ALL). Considerable controversy exists over its prognostic significance with currently available therapies. Differences in outcome may be explained by the differing intensities of various chemotherapy regimens, individual host responses to chemotherapy, or the hypothesis that relapsed TEL/AML1-positive leukemia represents an outgrowth of a secondary leukemia that shares a common initiating event with the first. Incorporating knowledge of this gene rearrangement into treatment decisions serves as a paradigm for translating molecular discoveries into clinically meaningful data to direct patient care and improve outcome.",Journal Article,6413.0,53.0,This article presents the most recent insights into the biology prognostic significance and therapeutic approaches to TEL/AML1-positive The TEL/AML1 fusion gene also known as ETV6 /CBFA2 is the most commonly occurring gene rearrangement in pediatric acute lymphoblastic ALL Considerable controversy exists over its prognostic significance with currently available therapies Differences in outcome may be explained by the differing intensities of various chemotherapy regimens individual host responses to chemotherapy or the hypothesis that relapsed TEL/AML1-positive represents an outgrowth of a secondary that shares a common initiating event with the first Incorporating knowledge of this gene rearrangement into treatment decisions serves as a paradigm for translating molecular discoveries into clinically meaningful data to direct patient care and improve outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26, 946, 2740, 3, 96, 435, 1957, 237, 3, 891, 177, 724, 2, 189, 611, 6, 8573, 6535, 109, 3, 8573, 6535, 1212, 145, 120, 440, 22, 7306, 33205, 16, 3, 96, 841, 1821, 145, 2675, 4, 815, 286, 1275, 62, 2658, 4089, 2481, 252, 211, 177, 724, 5, 694, 390, 235, 362, 4, 228, 68, 40, 3672, 20, 3, 5276, 11565, 1, 747, 56, 472, 797, 1204, 253, 6, 56, 15, 3, 1492, 17, 591, 8573, 6535, 109, 1449, 35, 7201, 1, 8, 568, 17, 10641, 8, 186, 2637, 774, 5, 3, 157, 2570, 922, 1, 26, 145, 2675, 237, 24, 1526, 4711, 22, 8, 2431, 9, 8446, 219, 5012, 237, 505, 2538, 74, 6, 1196, 69, 165, 2, 401, 228]",869.0,12042710,96
Persistence of lymphoblasts in bone marrow on day 15 and days 22 to 25 of remission induction predicts a dismal treatment outcome in children with acute lymphoblastic leukemia.,Blood,Blood,2002-07-01,"We determined the prognostic importance of morphologically identifiable persistent disease at day 15 and days 22 to 25 of remission induction in childhood acute lymphoblastic leukemia (ALL). Among 546 patients entered on 2 consecutive protocols, 397 patients had evaluable bone marrow (BM) examinations on day 15 (+/- 1 day) and 218 on days 22 to 25 (+/- 1 day). Fifty-seven patients (14%) had persistent lymphoblasts (> or = 1%) in the BM on day 15 and 27 patients (5.5%) had persistent lymphoblasts on days 22 to 25. The 5-year event-free survival (EFS) was significantly worse for patients with lymphoblasts on day 15 (40% +/- 6%) or on days 22 to 25 (4% +/- 3%) as compared to those without lymphoblasts on these dates (78% +/- 2% and 76% +/- 2%, respectively, P <.001 for both comparisons). A worse prognosis was observed even for patients with a low percentage of lymphoblasts (ie, 1%-4%) at either day 15 (5-year EFS = 56% +/- 8%) or days 22 to 25 (5-year EFS = 0%) compared to those without morphologically identifiable persistent lymphoblasts at these times (P <.001 for both comparisons). The prognostic impact of persistent lymphoblasts on both dates remained significant after adjusting for other known risk factors, including treatment protocol, age, white blood cell count, DNA index, cell lineage, and central nervous system status, and National Cancer Institute/Rome criteria simultaneously. Hence, persistence of lymphoblasts (even 1%-4%) on day 15 of remission induction was associated with a poor prognosis and on days 22 to 25 signified a particularly dismal outcome; these very high-risk patients require novel or more intensive therapy to improve outcome.",Journal Article,6413.0,36.0,We determined the prognostic importance of morphologically identifiable persistent disease at day 15 and days 22 to 25 of remission induction in childhood acute lymphoblastic ALL Among 546 patients entered on 2 consecutive protocols 397 patients had evaluable marrow BM examinations on day 15 +/- 1 day and 218 on days 22 to 25 +/- 1 day Fifty-seven patients 14 had persistent lymphoblasts or 1 in the BM on day 15 and 27 patients 5.5 had persistent lymphoblasts on days 22 to 25 The 5-year event-free survival EFS was significantly worse for patients with lymphoblasts on day 15 40 +/- 6 or on days 22 to 25 4 +/- 3 as compared to those without lymphoblasts on these dates 78 +/- 2 and 76 +/- 2 respectively P .001 for both comparisons A worse prognosis was observed even for patients with a low percentage of lymphoblasts ie 1 -4 at either day 15 5-year EFS 56 +/- 8 or days 22 to 25 5-year EFS 0 compared to those without morphologically identifiable persistent lymphoblasts at these times P .001 for both comparisons The prognostic impact of persistent lymphoblasts on both dates remained significant after adjusting for other known risk factors including treatment protocol age white blood cell count DNA index cell lineage and central nervous system status and National Cancer Institute/Rome criteria simultaneously Hence persistence of lymphoblasts even 1 -4 on day 15 of remission induction was associated with a poor prognosis and on days 22 to 25 signified a particularly dismal outcome these very high-risk patients require novel or more intensive therapy to improve outcome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 509, 3, 177, 1187, 1, 6204, 6237, 1882, 34, 28, 218, 167, 2, 162, 350, 6, 243, 1, 734, 504, 4, 864, 286, 1275, 62, 107, 11912, 7, 2836, 23, 18, 935, 2189, 9156, 7, 42, 859, 581, 1246, 4209, 23, 218, 167, 14, 218, 2, 6070, 23, 162, 350, 6, 243, 14, 218, 1461, 648, 7, 213, 42, 1882, 10521, 15, 14, 4, 3, 1246, 23, 218, 167, 2, 428, 7, 33, 33, 42, 1882, 10521, 23, 162, 350, 6, 243, 3, 33, 111, 774, 115, 25, 1683, 10, 97, 639, 9, 7, 5, 10521, 23, 218, 167, 327, 49, 15, 23, 162, 350, 6, 243, 39, 27, 22, 72, 6, 135, 187, 10521, 23, 46, 9561, 833, 18, 2, 846, 18, 106, 19, 144, 9, 110, 2213, 8, 639, 356, 10, 164, 871, 9, 7, 5, 8, 154, 1150, 1, 10521, 2523, 14, 39, 28, 361, 218, 167, 33, 111, 1683, 664, 66, 15, 162, 350, 6, 243, 33, 111, 1683, 13, 72, 6, 135, 187, 6204, 6237, 1882, 10521, 28, 46, 1072, 19, 144, 9, 110, 2213, 3, 177, 345, 1, 1882, 10521, 23, 110, 9561, 958, 93, 50, 1358, 9, 127, 440, 43, 130, 141, 24, 1182, 89, 886, 315, 31, 1276, 261, 558, 31, 2542, 2, 854, 1880, 398, 156, 2, 657, 12, 1377, 21042, 371, 3074, 3665, 4108, 1, 10521, 871, 14, 39, 23, 218, 167, 1, 734, 504, 10, 41, 5, 8, 334, 356, 2, 23, 162, 350, 6, 243, 27914, 8, 823, 3929, 228, 46, 923, 64, 43, 7, 1353, 229, 15, 80, 1686, 36, 6, 401, 228]",1585.0,12070006,358
Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia.,Blood,Blood,2002-07-01,"Early clearance of leukemic cells is a favorable prognostic indicator in childhood acute lymphoblastic leukemia (ALL). However, identification of residual leukemic cells by their morphologic features is subjective and lacks sensitivity. To improve estimates of leukemia clearance, we applied flow cytometric techniques capable of detecting 1 leukemic cell in 10,000 or more normal cells and prospectively measured residual leukemia in bone marrow samples collected on day 19 of remission-induction chemotherapy from 248 children with newly diagnosed ALL. In 134 samples (54.0%), we identified at least 0.01% leukemic cells (0.01%-< 0.1% in 51 samples [20.6%], 0.1%-< 1% in 36 [14.5%], and > or = 1% in 47 [19.0%]). Among 110 children treated within a single chemotherapy program, the 5-year mean +/- SE cumulative incidence of relapse or failure to achieve remission was 32.2% +/- 6.5% for the 59 patients with 0.01% residual leukemic cells or greater on day 19 and 6.0% +/- 3.4% for the 51 patients with less than 0.01% leukemic cells (P <.001). The prognostic value of day-19 bone marrow status defined by flow cytometry was superior to that defined by morphologic studies and remained significant after adjustment for other clinical and biologic variables. Lack of detectable leukemic cells on day 19 was more closely associated with relapse-free survival than was lack of detectable residual disease at the end of remission induction (day 46). Thus, approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy, and these patients have an excellent treatment outcome.",Journal Article,6413.0,197.0,"Early clearance of leukemic cells is a favorable prognostic indicator in childhood acute lymphoblastic ALL However identification of residual leukemic cells by their morphologic features is subjective and lacks sensitivity To improve estimates of clearance we applied flow cytometric techniques capable of detecting 1 leukemic cell in 10,000 or more normal cells and prospectively measured residual in marrow samples collected on day 19 of remission-induction chemotherapy from 248 children with newly diagnosed ALL In 134 samples 54.0 we identified at least 0.01 leukemic cells 0.01 0.1 in 51 samples 20.6 0.1 1 in 36 14.5 and or 1 in 47 19.0 Among 110 children treated within a single chemotherapy program the 5-year mean +/- SE cumulative incidence of relapse or failure to achieve remission was 32.2 +/- 6.5 for the 59 patients with 0.01 residual leukemic cells or greater on day 19 and 6.0 +/- 3.4 for the 51 patients with less than 0.01 leukemic cells P .001 The prognostic value of day-19 marrow status defined by flow cytometry was superior to that defined by morphologic studies and remained significant after adjustment for other clinical and biologic variables Lack of detectable leukemic cells on day 19 was more closely associated with relapse-free survival than was lack of detectable residual disease at the end of remission induction day 46 Thus approximately half of the children with ALL achieve profound clearance of leukemic cells after 2 to 3 weeks of remission-induction chemotherapy and these patients have an excellent treatment outcome",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[191, 1960, 1, 2015, 37, 16, 8, 913, 177, 3287, 4, 864, 286, 1275, 62, 137, 911, 1, 753, 2015, 37, 20, 136, 2815, 404, 16, 5571, 2, 6856, 485, 6, 401, 1423, 1, 1960, 21, 1498, 1412, 6226, 1092, 2787, 1, 2502, 14, 2015, 31, 4, 79, 984, 15, 80, 295, 37, 2, 1143, 644, 753, 4, 581, 347, 786, 23, 218, 326, 1, 734, 504, 56, 29, 7100, 541, 5, 732, 265, 62, 4, 4842, 347, 667, 13, 21, 108, 28, 506, 13, 355, 2015, 37, 13, 355, 13, 14, 4, 725, 347, 179, 49, 13, 14, 14, 4, 511, 213, 33, 2, 15, 14, 4, 662, 326, 13, 107, 3129, 541, 73, 262, 8, 226, 56, 1243, 3, 33, 111, 313, 3428, 967, 287, 1, 429, 15, 496, 6, 1359, 734, 10, 531, 18, 49, 33, 9, 3, 728, 7, 5, 13, 355, 753, 2015, 37, 15, 378, 23, 218, 326, 2, 49, 13, 27, 39, 9, 3, 725, 7, 5, 299, 76, 13, 355, 2015, 37, 19, 144, 3, 177, 549, 1, 218, 326, 581, 156, 395, 20, 1412, 1914, 10, 1123, 6, 17, 395, 20, 2815, 94, 2, 958, 93, 50, 1852, 9, 127, 38, 2, 1283, 682, 926, 1, 2083, 2015, 37, 23, 218, 326, 10, 80, 3210, 41, 5, 429, 115, 25, 76, 10, 926, 1, 2083, 753, 34, 28, 3, 396, 1, 734, 504, 218, 641, 631, 705, 1303, 1, 3, 541, 5, 62, 1359, 4399, 1960, 1, 2015, 37, 50, 18, 6, 27, 244, 1, 734, 504, 56, 2, 46, 7, 47, 35, 1503, 24, 228]",1560.0,12070008,355
"Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia.",Blood,Blood,2002-07-01,"The glutathione S-transferase (GST) genes are involved in the metabolism of environmental carcinogens and of some classes of chemotherapy drugs. GSTM1 and GSTT1 genotypes are polymorphic in humans, and the phenotypic absence of enzyme activity is caused by a homozygous inherited deletion of the gene. Previous, smaller studies of childhood acute lymphoblastic leukemia (ALL) provided contrasting data on the role of the GST genotype in susceptibility and treatment outcomes. We analyzed GST genotypes in 710 children with ALL treated by the Children's Cancer Group. Frequencies were compared with those of normal controls, and outcomes were analyzed according to genotype. Comparisons of gene frequencies in ALL case and control patients showed similar frequencies (54% vs 53% GSTM1 null in whites, P =.9; 40% versus 32% in blacks, P =.45; 16% versus 15% GSTT1 null in whites, P =.8; 17% versus 28% in blacks, P =.3). ALL was not associated with the GSTM1-null genotype or the double-null genotype in blacks or whites, in contrast to previous reports. Stratification of cases by age at diagnosis, sex, white blood cell count at diagnosis, B or T lineage, or cytogenetics revealed no differences in genotype frequencies. Analysis of treatment outcomes showed no differences in outcome according to GST genotype; in particular, there were no differences in frequencies of relapse at any site. These data, representing a larger series than any reported previously, suggest that GST genotype does not affect etiology or outcome of childhood ALL.",Journal Article,6413.0,94.0,The glutathione S-transferase GST genes are involved in the metabolism of environmental carcinogens and of some classes of chemotherapy drugs GSTM1 and GSTT1 genotypes are polymorphic in humans and the phenotypic absence of enzyme activity is caused by a homozygous inherited deletion of the gene Previous smaller studies of childhood acute lymphoblastic ALL provided contrasting data on the role of the GST genotype in susceptibility and treatment outcomes We analyzed GST genotypes in 710 children with ALL treated by the Children 's Cancer Group Frequencies were compared with those of normal controls and outcomes were analyzed according to genotype Comparisons of gene frequencies in ALL case and control patients showed similar frequencies 54 vs 53 GSTM1 null in whites P =.9 40 versus 32 in blacks P =.45 16 versus 15 GSTT1 null in whites P =.8 17 versus 28 in blacks P =.3 ALL was not associated with the GSTM1-null genotype or the double-null genotype in blacks or whites in contrast to previous reports Stratification of cases by age at diagnosis sex white blood cell count at diagnosis B or T lineage or cytogenetics revealed no differences in genotype frequencies Analysis of treatment outcomes showed no differences in outcome according to GST genotype in particular there were no differences in frequencies of relapse at any site These data representing a larger series than any reported previously suggest that GST genotype does not affect etiology or outcome of childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 4571, 695, 4402, 5645, 214, 32, 646, 4, 3, 1600, 1, 3766, 8850, 2, 1, 476, 3211, 1, 56, 600, 9410, 2, 10790, 2071, 32, 7087, 4, 3218, 2, 3, 3290, 1127, 1, 1644, 128, 16, 1546, 20, 8, 3189, 2986, 1528, 1, 3, 145, 698, 2170, 94, 1, 864, 286, 1275, 62, 1052, 14116, 74, 23, 3, 200, 1, 3, 5645, 1183, 4, 1432, 2, 24, 123, 21, 311, 5645, 2071, 4, 9232, 541, 5, 62, 73, 20, 3, 541, 292, 12, 87, 2722, 11, 72, 5, 135, 1, 295, 535, 2, 123, 11, 311, 768, 6, 1183, 2213, 1, 145, 2722, 4, 62, 473, 2, 182, 7, 224, 288, 2722, 667, 105, 699, 9410, 3505, 4, 2556, 19, 83, 327, 185, 531, 4, 3544, 19, 512, 245, 185, 167, 10790, 3505, 4, 2556, 19, 66, 269, 185, 339, 4, 3544, 19, 27, 62, 10, 44, 41, 5, 3, 9410, 3505, 1183, 15, 3, 1627, 3505, 1183, 4, 3544, 15, 2556, 4, 748, 6, 698, 1198, 1541, 1, 140, 20, 89, 28, 147, 1035, 886, 315, 31, 1276, 28, 147, 132, 15, 102, 2542, 15, 2510, 553, 77, 362, 4, 1183, 2722, 65, 1, 24, 123, 224, 77, 362, 4, 228, 768, 6, 5645, 1183, 4, 1454, 125, 11, 77, 362, 4, 2722, 1, 429, 28, 500, 606, 46, 74, 2861, 8, 1077, 988, 76, 500, 210, 373, 309, 17, 5645, 1183, 1097, 44, 1158, 2855, 15, 228, 1, 864, 62]",1491.0,12070010,280
"Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.",Cancer cell,Cancer Cell,2002-03-01,"Treatment of pediatric acute lymphoblastic leukemia (ALL) is based on the concept of tailoring the intensity of therapy to a patient's risk of relapse. To determine whether gene expression profiling could enhance risk assignment, we used oligonucleotide microarrays to analyze the pattern of genes expressed in leukemic blasts from 360 pediatric ALL patients. Distinct expression profiles identified each of the prognostically important leukemia subtypes, including T-ALL, E2A-PBX1, BCR-ABL, TEL-AML1, MLL rearrangement, and hyperdiploid >50 chromosomes. In addition, another ALL subgroup was identified based on its unique expression profile. Examination of the genes comprising the expression signatures provided important insights into the biology of these leukemia subgroups. Further, within some genetic subgroups, expression profiles identified those patients that would eventually fail therapy. Thus, the single platform of expression profiling should enhance the accurate risk stratification of pediatric ALL patients.",Journal Article,6535.0,1488.0,Treatment of pediatric acute lymphoblastic ALL is based on the concept of tailoring the intensity of therapy to a patient 's risk of relapse To determine whether gene expression profiling could enhance risk assignment we used oligonucleotide microarrays to analyze the pattern of genes expressed in leukemic blasts from 360 pediatric ALL patients Distinct expression profiles identified each of the prognostically important subtypes including T-ALL E2A-PBX1 BCR-ABL TEL-AML1 MLL rearrangement and hyperdiploid 50 chromosomes In addition another ALL subgroup was identified based on its unique expression profile Examination of the genes comprising the expression signatures provided important insights into the biology of these subgroups Further within some genetic subgroups expression profiles identified those patients that would eventually fail therapy Thus the single platform of expression profiling should enhance the accurate risk stratification of pediatric ALL patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 815, 286, 1275, 62, 16, 90, 23, 3, 2545, 1, 7101, 3, 837, 1, 36, 6, 8, 69, 292, 43, 1, 429, 6, 223, 317, 145, 55, 1080, 359, 1304, 43, 4392, 21, 95, 4727, 2774, 6, 1992, 3, 1177, 1, 214, 570, 4, 2015, 2438, 29, 6739, 815, 62, 7, 834, 55, 1241, 108, 296, 1, 3, 7848, 305, 814, 141, 102, 62, 15127, 14434, 1062, 1425, 8573, 6535, 3049, 2675, 2, 8847, 212, 3560, 4, 352, 1809, 62, 1363, 10, 108, 90, 23, 211, 991, 55, 800, 1385, 1, 3, 214, 3538, 3, 55, 2210, 1052, 305, 1957, 237, 3, 891, 1, 46, 1453, 195, 262, 476, 336, 1453, 55, 1241, 108, 135, 7, 17, 688, 3124, 4373, 36, 631, 3, 226, 2243, 1, 55, 1080, 257, 1304, 3, 1481, 43, 1541, 1, 815, 62, 7]",979.0,12086872,776
Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2002-07-01,"Little is known about the long-term efficacy or adverse effects of growth hormone (GH) replacement therapy in survivors of childhood acute lymphoblastic leukemia (ALL) who have GH deficiency. We investigated the adult height of patients who had received GH and estimated their risk of leukemia relapse or development of a second malignancy. Of 910 patients treated for ALL at a single institution, 47 had received GH replacement therapy. The linear growth of these 47 patients was retrospectively evaluated. Their risk of leukemia relapse or second malignancy was compared with that of survivors who did not undergo GH therapy. The median height SD score at the start of GH therapy had decreased by 1.0 since the time of diagnosis of ALL. After a median duration of 4.5 years of GH therapy, adult height SD scores improved and approached height SD scores at the time of diagnosis of ALL. The median adult height for male patients was 173.2 cm (range, 157 to 191.9 cm), and for female patients, it was 158.1 cm (range, 141 to 168 cm). None of the patients developed adverse effects requiring discontinuation of GH treatment. At the 7-year and 11-year landmarks in continuous hematologic remission, there was no statistical evidence that GH therapy was associated with leukemia relapse or development of a second malignancy. This study suggests that GH replacement therapy is safe and efficacious for the correction of GH deficiency in survivors of childhood ALL.",Journal Article,6413.0,69.0,Little is known about the long-term efficacy or adverse effects of growth hormone GH replacement therapy in survivors of childhood acute lymphoblastic ALL who have GH deficiency We investigated the adult height of patients who had received GH and estimated their risk of relapse or development of a second malignancy Of 910 patients treated for ALL at a single institution 47 had received GH replacement therapy The linear growth of these 47 patients was retrospectively evaluated Their risk of relapse or second malignancy was compared with that of survivors who did not undergo GH therapy The median height SD score at the start of GH therapy had decreased by 1.0 since the time of diagnosis of ALL After a median duration of 4.5 years of GH therapy adult height SD scores improved and approached height SD scores at the time of diagnosis of ALL The median adult height for male patients was 173.2 cm range 157 to 191.9 cm and for female patients it was 158.1 cm range 141 to 168 cm None of the patients developed adverse effects requiring discontinuation of GH treatment At the 7-year and 11-year landmarks in continuous hematologic remission there was no statistical evidence that GH therapy was associated with relapse or development of a second malignancy This study suggests that GH replacement therapy is safe and efficacious for the correction of GH deficiency in survivors of childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1215, 16, 440, 545, 3, 319, 337, 209, 15, 290, 176, 1, 129, 785, 4579, 3892, 36, 4, 332, 1, 864, 286, 1275, 62, 54, 47, 4579, 2299, 21, 565, 3, 780, 4594, 1, 7, 54, 42, 103, 4579, 2, 661, 136, 43, 1, 429, 15, 193, 1, 8, 419, 710, 1, 15500, 7, 73, 9, 62, 28, 8, 226, 731, 662, 42, 103, 4579, 3892, 36, 3, 1646, 129, 1, 46, 662, 7, 10, 894, 194, 136, 43, 1, 429, 15, 419, 710, 10, 72, 5, 17, 1, 332, 54, 205, 44, 1251, 4579, 36, 3, 52, 4594, 1270, 368, 28, 3, 2435, 1, 4579, 36, 42, 340, 20, 14, 13, 1192, 3, 98, 1, 147, 1, 62, 50, 8, 52, 654, 1, 39, 33, 60, 1, 4579, 36, 780, 4594, 1270, 703, 231, 2, 5738, 4594, 1270, 703, 28, 3, 98, 1, 147, 1, 62, 3, 52, 780, 4594, 9, 1045, 7, 10, 5785, 18, 494, 184, 5311, 6, 6130, 83, 494, 2, 9, 1061, 7, 192, 10, 5162, 14, 494, 184, 4379, 6, 5359, 494, 1292, 1, 3, 7, 276, 290, 176, 1888, 2007, 1, 4579, 24, 28, 3, 67, 111, 2, 175, 111, 12092, 4, 1314, 813, 734, 125, 10, 77, 1050, 241, 17, 4579, 36, 10, 41, 5, 429, 15, 193, 1, 8, 419, 710, 26, 45, 844, 17, 4579, 3892, 36, 16, 1165, 2, 3289, 9, 3, 5360, 1, 4579, 2299, 4, 332, 1, 864, 62]",1399.0,12089225,179
Targeting CB2 cannabinoid receptors as a novel therapy to treat malignant lymphoblastic disease.,Blood,Blood,2002-07-01,"In the current study, we examined whether ligation of CB2 receptors would lead to induction of apoptosis in tumors of immune origin and whether CB2 agonist could be used to treat such cancers. Exposure of murine tumors EL-4, LSA, and P815 to delta-9-tetrahydrocannabinol (THC) in vitro led to a significant reduction in cell viability and an increase in apoptosis. Exposure of EL-4 tumor cells to the synthetic cannabinoid HU-210 and the endogenous cannabinoid anandamide led to significant induction of apoptosis, whereas exposure to WIN55212 was not effective. Treatment of EL-4 tumor-bearing mice with THC in vivo led to a significant reduction in tumor load, increase in tumor-cell apoptosis, and increase in survival of tumor-bearing mice. Examination of a number of human leukemia and lymphoma cell lines, including Jurkat, Molt-4, and Sup-T1, revealed that they expressed CB2 receptors but not CB1. These human tumor cells were also susceptible to apoptosis induced by THC, HU-210, anandamide, and the CB2-selective agonist JWH-015. This effect was mediated at least in part through the CB2 receptors because pretreatment with the CB2 antagonist SR144528 partially reversed the THC-induced apoptosis. Culture of primary acute lymphoblastic leukemia cells with THC in vitro reduced cell viability and induced apoptosis. Together, the current data demonstrate that CB2 cannabinoid receptors expressed on malignancies of the immune system may serve as potential targets for the induction of apoptosis. Also, because CB2 agonists lack psychotropic effects, they may serve as novel anticancer agents to selectively target and kill tumors of immune origin.",Journal Article,6413.0,210.0,In the current study we examined whether ligation of CB2 receptors would lead to induction of apoptosis in tumors of immune origin and whether CB2 agonist could be used to treat such cancers Exposure of murine tumors EL-4 LSA and P815 to delta-9-tetrahydrocannabinol THC in vitro led to a significant reduction in cell viability and an increase in apoptosis Exposure of EL-4 tumor cells to the synthetic cannabinoid HU-210 and the endogenous cannabinoid anandamide led to significant induction of apoptosis whereas exposure to WIN55212 was not effective Treatment of EL-4 tumor-bearing mice with THC in vivo led to a significant reduction in tumor load increase in tumor-cell apoptosis and increase in survival of tumor-bearing mice Examination of a number of human and cell lines including Jurkat Molt-4 and Sup-T1 revealed that they expressed CB2 receptors but not CB1 These human tumor cells were also susceptible to apoptosis induced by THC HU-210 anandamide and the CB2-selective agonist JWH-015 This effect was mediated at least in part through the CB2 receptors because pretreatment with the CB2 antagonist SR144528 partially reversed the THC-induced apoptosis Culture of primary acute lymphoblastic cells with THC in vitro reduced cell viability and induced apoptosis Together the current data demonstrate that CB2 cannabinoid receptors expressed on malignancies of the immune system may serve as potential targets for the induction of apoptosis Also because CB2 agonists lack psychotropic effects they may serve as novel anticancer agents to selectively target and kill tumors of immune origin,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 3, 291, 45, 21, 409, 317, 5307, 1, 24469, 1186, 688, 1122, 6, 504, 1, 351, 4, 57, 1, 250, 1938, 2, 317, 24469, 3821, 359, 40, 95, 6, 943, 225, 163, 645, 1, 1471, 57, 8852, 39, 52981, 2, 37212, 6, 4305, 83, 42970, 14771, 4, 439, 836, 6, 8, 93, 628, 4, 31, 2120, 2, 35, 344, 4, 351, 645, 1, 8852, 39, 30, 37, 6, 3, 3273, 27923, 5948, 5376, 2, 3, 2682, 27923, 42971, 836, 6, 93, 504, 1, 351, 547, 645, 6, 52982, 10, 44, 323, 24, 1, 8852, 39, 30, 1894, 399, 5, 14771, 4, 386, 836, 6, 8, 93, 628, 4, 30, 3800, 344, 4, 30, 31, 351, 2, 344, 4, 25, 1, 30, 1894, 399, 1385, 1, 8, 207, 1, 171, 2, 31, 285, 141, 8433, 30270, 39, 2, 172, 1534, 553, 17, 491, 570, 24469, 1186, 84, 44, 23099, 46, 171, 30, 37, 11, 120, 4012, 6, 351, 277, 20, 14771, 5948, 5376, 42971, 2, 3, 24469, 1094, 3821, 52983, 3433, 26, 254, 10, 517, 28, 506, 4, 760, 298, 3, 24469, 1186, 408, 1194, 5, 3, 24469, 3137, 52984, 2995, 3682, 3, 14771, 277, 351, 2099, 1, 86, 286, 1275, 37, 5, 14771, 4, 439, 405, 31, 2120, 2, 277, 351, 1162, 3, 291, 74, 608, 17, 24469, 27923, 1186, 570, 23, 441, 1, 3, 250, 398, 68, 1833, 22, 174, 637, 9, 3, 504, 1, 351, 120, 408, 24469, 4774, 926, 24470, 176, 491, 68, 1833, 22, 229, 1475, 183, 6, 2382, 283, 2, 5097, 57, 1, 250, 1938]",1602.0,12091357,166
Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2002-07-01,"Methotrexate (MTX) is an antifolate that is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL) and a number of other malignant and nonmalignant diseases. Within cells, MTX is metabolized to more active methotrexate polyglutamates (MTXPG), and these polyglutamates are subsequently cleaved in lysosomes by gamma-glutamyl hydrolase (GGH). GGH is reported to act as either an endopeptidase or an exopeptidase, exhibiting species differences in these functions. To better define the in vivo functions of GGH in human leukemia cells, we characterized GGH activity with different MTXPG substrates (MTX with three to five glutamates) in human T- and B-lineage leukemia cell lines, and in primary leukemia cells from newly diagnosed patients with ALL. Parameters estimated from fitting a series of hypothetical mathematical models to the data revealed that the experimental data were best fit by a model where GGH simultaneously cleaved multiple glutamyl residues, with highest activity at cleaving the outermost or two outermost residues from a polyglutamate chain. The model also revealed that GGH has a higher affinity for longer chain polyglutamates. Together, these findings provide new insights to the intracellular disposition of MTX in human ALL cells, and provides a mechanism-based model for characterizing differences among patients and genetic subtypes of ALL.",Comparative Study,6413.0,54.0,Methotrexate MTX is an antifolate that is widely used for the treatment of childhood acute lymphoblastic ALL and a number of other malignant and nonmalignant diseases Within cells MTX is metabolized to more active methotrexate polyglutamates MTXPG and these polyglutamates are subsequently cleaved in lysosomes by gamma-glutamyl hydrolase GGH GGH is reported to act as either an endopeptidase or an exopeptidase exhibiting species differences in these functions To better define the in vivo functions of GGH in human cells we characterized GGH activity with different MTXPG substrates MTX with three to five glutamates in human T- and B-lineage cell lines and in primary cells from newly diagnosed patients with ALL Parameters estimated from fitting a series of hypothetical mathematical models to the data revealed that the experimental data were best fit by a model where GGH simultaneously cleaved multiple glutamyl residues with highest activity at cleaving the outermost or two outermost residues from a polyglutamate chain The model also revealed that GGH has a higher affinity for longer chain polyglutamates Together these findings provide new insights to the intracellular disposition of MTX in human ALL cells and provides a mechanism-based model for characterizing differences among patients and genetic subtypes of ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 3453, 16, 35, 12278, 17, 16, 1792, 95, 9, 3, 24, 1, 864, 286, 1275, 62, 2, 8, 207, 1, 127, 393, 2, 5967, 1342, 262, 37, 3453, 16, 10523, 6, 80, 544, 2116, 16243, 11572, 2, 46, 16243, 32, 1611, 5885, 4, 22005, 20, 1705, 15867, 18796, 10820, 10820, 16, 210, 6, 2559, 22, 361, 35, 26033, 15, 35, 37225, 4801, 2915, 362, 4, 46, 1681, 6, 380, 1107, 3, 4, 386, 1681, 1, 10820, 4, 171, 37, 21, 765, 10820, 128, 5, 338, 11572, 6063, 3453, 5, 169, 6, 365, 42987, 4, 171, 102, 2, 132, 2542, 31, 285, 2, 4, 86, 37, 29, 732, 265, 7, 5, 62, 1038, 661, 29, 9748, 8, 988, 1, 7045, 7419, 274, 6, 3, 74, 553, 17, 3, 1560, 74, 11, 824, 2975, 20, 8, 202, 1257, 10820, 3074, 5885, 232, 15867, 6418, 5, 1076, 128, 28, 24481, 3, 30265, 15, 100, 30265, 6418, 29, 8, 22006, 1260, 3, 202, 120, 553, 17, 10820, 71, 8, 142, 3601, 9, 589, 1260, 16243, 1162, 46, 272, 377, 217, 1957, 6, 3, 2087, 5814, 1, 3453, 4, 171, 62, 37, 2, 777, 8, 670, 90, 202, 9, 5723, 362, 107, 7, 2, 336, 814, 1, 62]",1330.0,12114448,9
De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo.,Blood,Blood,2002-08-01,"Methotrexate (MTX) and mercaptopurine (MP) are widely used antileukemic agents that inhibit de novo purine synthesis (DNPS) as a mechanism of their antileukemic effects. To elucidate pharmacodynamic differences among children with acute lymphoblastic leukemia (ALL), DNPS was measured in leukemic blasts from newly diagnosed patients before and after therapy with these agents. Patients were randomized to receive low-dose MTX (LDMTX: 6 oral doses of 30 mg/m(2)) or high-dose MTX (HDMTX: intravenous 1 g/m(2)) followed by intravenous MP; or intravenous MP alone (1 g/m(2)), as initial therapy. At diagnosis, the rate of DNPS in bone marrow leukemia cells was 3-fold higher in patients with T-lineage ALL compared with those with B-lineage ALL (769 +/- 189 vs 250 +/- 38 fmol/nmol/h; P =.001). DNPS was not consistently inhibited following MP alone but was markedly inhibited following MTX plus MP (median decrease 3% vs 94%; P <.001). LDMTX plus MP and HDMTX plus MP produced greater antileukemic effects (percentage decrease in circulating leukocyte counts) compared with MP alone (-50% +/- 4%, -56% +/- 3%, and - 20% +/- 4%, respectively; P <.0001). Full DNPS inhibition was associated with greater antileukemic effects compared with partial or no inhibition (-63% +/- 4% vs -37% +/- 4%; P <.0001) in patients with nonhyperdiploid B-lineage and T-lineage ALL. HDMTX plus MP yielded 2-fold higher MTX polyglutamate concentrations than LDMTX plus MP (2148 +/- 298 vs 1075 +/- 114 pmol/10(9) cells; P <.01) and a higher percentage of patients with full DNPS inhibition (78% vs 53%; P <.001). Thus, the extent of DNPS inhibition was related to in vivo antileukemic effects, and a single dose of intravenous MP produced minimal DNPS inhibition and antileukemic effects, whereas MTX plus MP produced greater antileukemic effects and DNPS inhibition, with full inhibition more frequent after HDMTX.",Clinical Trial,6382.0,77.0,Methotrexate MTX and mercaptopurine MP are widely used antileukemic agents that inhibit de novo purine synthesis DNPS as a mechanism of their antileukemic effects To elucidate pharmacodynamic differences among children with acute lymphoblastic ALL DNPS was measured in leukemic blasts from newly diagnosed patients before and after therapy with these agents Patients were randomized to receive low-dose MTX LDMTX 6 oral doses of 30 mg/m 2 or high-dose MTX HDMTX intravenous 1 g/m 2 followed by intravenous MP or intravenous MP alone 1 g/m 2 as initial therapy At diagnosis the rate of DNPS in marrow cells was 3-fold higher in patients with T-lineage ALL compared with those with B-lineage ALL 769 +/- 189 vs 250 +/- 38 fmol/nmol/h P =.001 DNPS was not consistently inhibited following MP alone but was markedly inhibited following MTX plus MP median decrease 3 vs 94 P .001 LDMTX plus MP and HDMTX plus MP produced greater antileukemic effects percentage decrease in circulating leukocyte counts compared with MP alone -50 +/- 4 -56 +/- 3 and 20 +/- 4 respectively P .0001 Full DNPS inhibition was associated with greater antileukemic effects compared with partial or no inhibition -63 +/- 4 vs -37 +/- 4 P .0001 in patients with nonhyperdiploid B-lineage and T-lineage ALL HDMTX plus MP yielded 2-fold higher MTX polyglutamate concentrations than LDMTX plus MP 2148 +/- 298 vs 1075 +/- 114 pmol/10 9 cells P .01 and a higher percentage of patients with full DNPS inhibition 78 vs 53 P .001 Thus the extent of DNPS inhibition was related to in vivo antileukemic effects and a single dose of intravenous MP produced minimal DNPS inhibition and antileukemic effects whereas MTX plus MP produced greater antileukemic effects and DNPS inhibition with full inhibition more frequent after HDMTX,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 3453, 2, 9223, 4545, 32, 1792, 95, 4512, 183, 17, 1433, 1566, 2018, 5006, 2525, 18803, 22, 8, 670, 1, 136, 4512, 176, 6, 3061, 2424, 362, 107, 541, 5, 286, 1275, 62, 18803, 10, 644, 4, 2015, 2438, 29, 732, 265, 7, 348, 2, 50, 36, 5, 46, 183, 7, 11, 384, 6, 560, 154, 61, 3453, 37239, 49, 518, 415, 1, 201, 81, 188, 18, 15, 64, 61, 3453, 10061, 1262, 14, 499, 188, 18, 370, 20, 1262, 4545, 15, 1262, 4545, 279, 14, 499, 188, 18, 22, 388, 36, 28, 147, 3, 116, 1, 18803, 4, 581, 37, 10, 27, 1116, 142, 4, 7, 5, 102, 2542, 62, 72, 5, 135, 5, 132, 2542, 62, 17658, 5899, 105, 2039, 519, 18804, 4694, 555, 19, 144, 18803, 10, 44, 2433, 879, 366, 4545, 279, 84, 10, 2195, 879, 366, 3453, 349, 4545, 52, 775, 27, 105, 960, 19, 144, 37239, 349, 4545, 2, 10061, 349, 4545, 1687, 378, 4512, 176, 1150, 775, 4, 1033, 3627, 1911, 72, 5, 4545, 279, 212, 39, 664, 27, 2, 179, 39, 106, 19, 488, 1647, 18803, 297, 10, 41, 5, 378, 4512, 176, 72, 5, 450, 15, 77, 297, 676, 39, 105, 567, 39, 19, 488, 4, 7, 5, 26040, 132, 2542, 2, 102, 2542, 62, 10061, 349, 4545, 2178, 18, 1116, 142, 3453, 22006, 1003, 76, 37239, 349, 4545, 37240, 8651, 105, 26041, 3803, 9835, 79, 83, 37, 19, 355, 2, 8, 142, 1150, 1, 7, 5, 1647, 18803, 297, 833, 105, 699, 19, 144, 631, 3, 1039, 1, 18803, 297, 10, 139, 6, 4, 386, 4512, 176, 2, 8, 226, 61, 1, 1262, 4545, 1687, 1048, 18803, 297, 2, 4512, 176, 547, 3453, 349, 4545, 1687, 378, 4512, 176, 2, 18803, 297, 5, 1647, 297, 80, 908, 50, 10061]",1789.0,12149204,644
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives.,Reviews in clinical and experimental hematology,Rev Clin Exp Hematol,2002-06-01,"Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) is diagnosed rarely in children, but constitutes the most frequent cytogenetic abnormality in adults with ALL. In contrast to chronic myeloid leukemia (CML), patients with Ph-positive ALL usually demonstrate expression of a truncated version of the BCR-ABL protein called p190bcr-abl. Irrespective of age and breakpoint location, Ph-positive ALL carries a poor prognosis. Although remission rates are identical to those of Ph-negative ALL, relapse is almost universal and long-term survival remains rare. Given the poor outcome with current chemotherapy consolidation programs, stem cell transplantation is usually recommended for these patients in first remission or as soon as feasible. Even with transplantation the impact on outcome is limited and new therapeutic concepts are urgently needed. One of the most promising developments in recent years has been the introduction of the tyrosine kinase inhibitors such as STI571. An overview of current treatment modalities in Ph-positive ALL will be provided and the rationale for new therapies will be discussed.",Journal Article,6443.0,41.0,Philadelphia chromosome Ph -positive acute lymphoblastic ALL is diagnosed rarely in children but constitutes the most frequent cytogenetic abnormality in adults with ALL In contrast to chronic myeloid CML patients with Ph-positive ALL usually demonstrate expression of a truncated version of the BCR-ABL protein called p190bcr-abl Irrespective of age and breakpoint location Ph-positive ALL carries a poor prognosis Although remission rates are identical to those of Ph-negative ALL relapse is almost universal and long-term survival remains rare Given the poor outcome with current chemotherapy consolidation programs stem cell transplantation is usually recommended for these patients in first remission or as soon as feasible Even with transplantation the impact on outcome is limited and new therapeutic concepts are urgently needed One of the most promising developments in recent years has been the introduction of the tyrosine kinase inhibitors such as STI571 An overview of current treatment modalities in Ph-positive ALL will be provided and the rationale for new therapies will be discussed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 2058, 109, 286, 1275, 62, 16, 265, 2416, 4, 541, 84, 6788, 3, 96, 908, 1266, 3698, 4, 857, 5, 62, 4, 748, 6, 442, 533, 903, 7, 5, 2058, 109, 62, 2082, 608, 55, 1, 8, 6502, 2256, 1, 3, 1062, 1425, 178, 3472, 43024, 1425, 3500, 1, 89, 2, 8567, 1147, 2058, 109, 62, 4942, 8, 334, 356, 242, 734, 151, 32, 3038, 6, 135, 1, 2058, 199, 62, 429, 16, 2214, 4967, 2, 319, 337, 25, 469, 622, 447, 3, 334, 228, 5, 291, 56, 2173, 2251, 452, 31, 497, 16, 2082, 793, 9, 46, 7, 4, 157, 734, 15, 22, 6176, 22, 1313, 871, 5, 497, 3, 345, 23, 228, 16, 383, 2, 217, 189, 5101, 32, 5354, 575, 104, 1, 3, 96, 721, 3703, 4, 435, 60, 71, 85, 3, 2456, 1, 3, 564, 216, 222, 225, 22, 5735, 35, 2901, 1, 291, 24, 1558, 4, 2058, 109, 62, 303, 40, 1052, 2, 3, 1728, 9, 217, 235, 303, 40, 1588]",1100.0,12196213,206
Childhood acute lymphoblastic leukemia.,Reviews in clinical and experimental hematology,Rev Clin Exp Hematol,2002-06-01,"As cure rates in childhood acute lymphoblastic leukemia reach 80%, emphasis is increasingly placed on the accurate identification of drug-resistant cases, the elucidation of the mechanisms involved in drug resistance and the development of new therapeutic strategies targeted toward the pivotal molecular lesions. Pharmacodynamic and pharmacogenomic studies have provided rational criteria for individualizing therapy to enhance efficacy and reduce acute toxicity and late sequelae. Currently, assessment of the early response to treatment by measurement of minimal residual disease (MRD) is the most powerful independent prognostic indicator. MRD is affected by both the drug sensitivity of leukemic cells and the pharmacodynamic and pharmacogenetic properties of the host cells. Rapid advances in biotechnology and bioinformatics should ultimately facilitate the development of molecular diagnostic assays that can be used to optimize antileukemic therapy and elucidate the mechanisms of leukemogenesis. In the interim, prospective clinical trials have provided valuable clues that are further increasing the cure rate of childhood acute lymphoblastic leukemia.",Journal Article,6443.0,36.0,As cure rates in childhood acute lymphoblastic reach 80 emphasis is increasingly placed on the accurate identification of drug-resistant cases the elucidation of the mechanisms involved in drug resistance and the development of new therapeutic strategies targeted toward the pivotal molecular lesions Pharmacodynamic and pharmacogenomic studies have provided rational criteria for individualizing therapy to enhance efficacy and reduce acute toxicity and late sequelae Currently assessment of the early response to treatment by measurement of minimal residual disease MRD is the most powerful independent prognostic indicator MRD is affected by both the drug sensitivity of leukemic cells and the pharmacodynamic and pharmacogenetic properties of the host cells Rapid advances in biotechnology and bioinformatics should ultimately facilitate the development of molecular diagnostic assays that can be used to optimize antileukemic therapy and elucidate the mechanisms of leukemogenesis In the interim prospective clinical trials have provided valuable clues that are further increasing the cure rate of childhood acute lymphoblastic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[22, 1722, 151, 4, 864, 286, 1275, 3690, 493, 3136, 16, 1635, 3295, 23, 3, 1481, 911, 1, 234, 436, 140, 3, 7481, 1, 3, 483, 646, 4, 234, 251, 2, 3, 193, 1, 217, 189, 422, 238, 1317, 3, 3754, 219, 406, 2424, 2, 6971, 94, 47, 1052, 2696, 371, 9, 12747, 36, 6, 1304, 209, 2, 969, 286, 155, 2, 807, 4156, 694, 455, 1, 3, 191, 51, 6, 24, 20, 2204, 1, 1048, 753, 34, 2029, 16, 3, 96, 3757, 306, 177, 3287, 2029, 16, 1424, 20, 110, 3, 234, 485, 1, 2015, 37, 2, 3, 2424, 2, 6578, 1571, 1, 3, 1204, 37, 1321, 954, 4, 11767, 2, 6579, 257, 2050, 1876, 3, 193, 1, 219, 752, 1013, 17, 122, 40, 95, 6, 2465, 4512, 36, 2, 3061, 3, 483, 1, 5661, 4, 3, 2914, 482, 38, 143, 47, 1052, 2926, 10045, 17, 32, 195, 602, 3, 1722, 116, 1, 864, 286, 1275]",1132.0,12196214,502
Racial and ethnic differences in survival of children with acute lymphoblastic leukemia.,Blood,Blood,2002-09-01,"Black children with acute lymphoblastic leukemia (ALL) have poor outcomes, but limited information is available for children from other racial and ethnic backgrounds, such as Hispanic and Asian. We undertook a retrospective cohort study of children with ALL treated on Children's Cancer Group therapeutic protocols to determine outcomes by racial and ethnic backgrounds of patients treated with contemporary risk-based therapy. In total, 8447 children (white, n = 6703; Hispanic, n = 1071; black, n = 506; and Asian, n = 167) with newly diagnosed ALL between 1983 and 1995 were observed for a median of 6.5 years. Analysis of disease outcome was measured as overall survival (OS) and event-free survival (EFS) and was adjusted for known predictors of outcome including clinical features, disease biology, socioeconomic status, and treatment era (1983-1989 vs 1989-1995). There was a statistically significant difference in survival by ethnicity (P <.001). Five-year EFS rates were: Asian, 75.1% +/- 3.5%; white, 72.8% +/- 0.6%; Hispanic, 65.9% +/- 1.5%; and black, 61.5% +/- 2.2%. Multivariate analysis revealed that when compared with white children, black and Hispanic children had worse outcomes and Asian children had better outcomes after adjusting for known risk factors. The poorer outcomes among black children were most apparent among patients with standard-risk features (relative risk [RR], 2.0; 95% confidence interval [CI], 1.6-2.5), whereas poorer outcomes in Hispanic children (RR, 1.4; 95% CI, 1.2-1.6) were most evident among patients with high-risk features. Asian children had better outcomes than all racial and ethnic groups among high-risk patients, particularly in the recent era (5-year EFS, 90.9% +/- 6.1%). Racial and ethnic differences in OS and EFS persist among children with ALL who receive contemporary risk-based therapy. Future studies should focus on reasons-perhaps compliance or pharmacogenetics-for those differences.",Journal Article,6351.0,160.0,Black children with acute lymphoblastic ALL have poor outcomes but limited information is available for children from other racial and ethnic backgrounds such as Hispanic and Asian We undertook a retrospective cohort study of children with ALL treated on Children 's Cancer Group therapeutic protocols to determine outcomes by racial and ethnic backgrounds of patients treated with contemporary risk-based therapy In total 8447 children white n 6703 Hispanic n 1071 black n 506 and Asian n 167 with newly diagnosed ALL between 1983 and 1995 were observed for a median of 6.5 years Analysis of disease outcome was measured as overall survival OS and event-free survival EFS and was adjusted for known predictors of outcome including clinical features disease biology socioeconomic status and treatment era 1983-1989 vs 1989-1995 There was a statistically significant difference in survival by ethnicity P .001 Five-year EFS rates were Asian 75.1 +/- 3.5 white 72.8 +/- 0.6 Hispanic 65.9 +/- 1.5 and black 61.5 +/- 2.2 Multivariate analysis revealed that when compared with white children black and Hispanic children had worse outcomes and Asian children had better outcomes after adjusting for known risk factors The poorer outcomes among black children were most apparent among patients with standard-risk features relative risk RR 2.0 95 confidence interval CI 1.6-2.5 whereas poorer outcomes in Hispanic children RR 1.4 95 CI 1.2-1.6 were most evident among patients with high-risk features Asian children had better outcomes than all racial and ethnic groups among high-risk patients particularly in the recent era 5-year EFS 90.9 +/- 6.1 Racial and ethnic differences in OS and EFS persist among children with ALL who receive contemporary risk-based therapy Future studies should focus on reasons-perhaps compliance or pharmacogenetics-for those differences,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1445, 541, 5, 286, 1275, 62, 47, 334, 123, 84, 383, 487, 16, 390, 9, 541, 29, 127, 2257, 2, 2871, 10681, 225, 22, 1776, 2, 2399, 21, 5418, 8, 459, 180, 45, 1, 541, 5, 62, 73, 23, 541, 292, 12, 87, 189, 2189, 6, 223, 123, 20, 2257, 2, 2871, 10681, 1, 7, 73, 5, 2667, 43, 90, 36, 4, 181, 43025, 541, 886, 78, 53099, 1776, 78, 30302, 1445, 78, 9454, 2, 2399, 78, 5431, 5, 732, 265, 62, 59, 6656, 2, 2323, 11, 164, 9, 8, 52, 1, 49, 33, 60, 65, 1, 34, 228, 10, 644, 22, 63, 25, 118, 2, 774, 115, 25, 1683, 2, 10, 586, 9, 440, 674, 1, 228, 141, 38, 404, 34, 891, 3331, 156, 2, 24, 1713, 6656, 3965, 105, 3965, 2323, 125, 10, 8, 712, 93, 523, 4, 25, 20, 2091, 19, 144, 365, 111, 1683, 151, 11, 2399, 481, 14, 27, 33, 886, 720, 66, 13, 49, 1776, 556, 83, 14, 33, 2, 1445, 713, 33, 18, 18, 331, 65, 553, 17, 198, 72, 5, 886, 541, 1445, 2, 1776, 541, 42, 639, 123, 2, 2399, 541, 42, 380, 123, 50, 1358, 9, 440, 43, 130, 3, 1769, 123, 107, 1445, 541, 11, 96, 2235, 107, 7, 5, 260, 43, 404, 580, 43, 861, 18, 13, 48, 307, 268, 58, 14, 49, 18, 33, 547, 1769, 123, 4, 1776, 541, 861, 14, 39, 48, 58, 14, 18, 14, 49, 11, 96, 2853, 107, 7, 5, 64, 43, 404, 2399, 541, 42, 380, 123, 76, 62, 2257, 2, 2871, 271, 107, 64, 43, 7, 823, 4, 3, 435, 1713, 33, 111, 1683, 424, 83, 49, 14, 2257, 2, 2871, 362, 4, 118, 2, 1683, 5589, 107, 541, 5, 62, 54, 560, 2667, 43, 90, 36, 508, 94, 257, 1222, 23, 2325, 4434, 3336, 15, 8759, 9, 135, 362]",1861.0,12200352,322
A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias.,Blood,Blood,2002-09-01,"The translocation (9;22) gives rise to the p190(Bcr-Abl) and p210(Bcr-Abl) tyrosine kinase proteins, considered sufficient for leukemic transformation. Philadelphia-positive (Ph(+)) acute leukemia patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options. Imatinib is an orally administered, potent inhibitor of the Bcr-Abl tyrosine kinase. We conducted a clinical trial in 56 patients with relapsed or refractory Ph(+) acute lymphoblastic leukemia (ALL; 48 patients) or chronic myelogenous leukemia in lymphoid blast crisis (LyBC; 8 patients). Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses (CHRs) and complete marrow responses (marrow-CRs) in 29% of ALL patients (CHR, 19%; marrow-CR, 10%), which were sustained for at least 4 weeks in 6% of patients. Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months, respectively. CHRs were reported for 3 (38%) of the patients with LyBC (one sustained CHR). Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9% of patients; none of the patients discontinued therapy because of nonhematologic adverse reactions. Grade 4 neutropenia and thrombocytopenia occurred in 54% and 27% of patients, respectively. Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph(+) acute lymphoid leukemia patients, but development of resistance and subsequent disease progression were rapid. Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib.",Clinical Trial,6351.0,463.0,The translocation 9 22 gives rise to the p190 Bcr-Abl and p210 Bcr-Abl tyrosine kinase proteins considered sufficient for leukemic transformation Philadelphia-positive Ph acute patients failing to respond to initial induction therapy have a poor prognosis with few effective treatment options Imatinib is an orally administered potent inhibitor of the Bcr-Abl tyrosine kinase We conducted a clinical trial in 56 patients with relapsed or refractory Ph acute lymphoblastic ALL 48 patients or chronic myelogenous in lymphoid blast crisis LyBC 8 patients Imatinib was given once daily at 400 mg or 600 mg. Imatinib induced complete hematologic responses CHRs and complete marrow responses marrow-CRs in 29 of ALL patients CHR 19 marrow-CR 10 which were sustained for at least 4 weeks in 6 of patients Median estimated time to progression and overall survival for ALL patients were 2.2 and 4.9 months respectively CHRs were reported for 3 38 of the patients with LyBC one sustained CHR Grade 3 or 4 treatment-related nonhematologic toxicity was reported for 9 of patients none of the patients discontinued therapy because of nonhematologic adverse reactions Grade 4 neutropenia and thrombocytopenia occurred in 54 and 27 of patients respectively Imatinib therapy resulted in a clinically relevant hematologic response rate in relapsed or refractory Ph acute lymphoid patients but development of resistance and subsequent disease progression were rapid Further studies are warranted to test the effects of imatinib in combination with other agents and to define the mechanisms of resistance to imatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2006, 83, 350, 7989, 3693, 6, 3, 18813, 1062, 1425, 2, 11538, 1062, 1425, 564, 216, 652, 515, 1952, 9, 2015, 1392, 3006, 109, 2058, 286, 7, 7928, 6, 1892, 6, 388, 504, 36, 47, 8, 334, 356, 5, 1021, 323, 24, 838, 577, 16, 35, 1428, 468, 1157, 230, 1, 3, 1062, 1425, 564, 216, 21, 426, 8, 38, 160, 4, 664, 7, 5, 591, 15, 430, 2058, 286, 1275, 62, 576, 7, 15, 442, 2194, 4, 2303, 3112, 6540, 43026, 66, 7, 577, 10, 447, 1059, 391, 28, 1524, 81, 15, 2383, 81, 577, 277, 236, 813, 253, 37211, 2, 236, 581, 253, 581, 3115, 4, 462, 1, 62, 7, 8158, 326, 581, 684, 79, 92, 11, 2275, 9, 28, 506, 39, 244, 4, 49, 1, 7, 52, 661, 98, 6, 91, 2, 63, 25, 9, 62, 7, 11, 18, 18, 2, 39, 83, 53, 106, 37211, 11, 210, 9, 27, 519, 1, 3, 7, 5, 43026, 104, 2275, 8158, 88, 27, 15, 39, 24, 139, 3534, 155, 10, 210, 9, 83, 1, 7, 1292, 1, 3, 7, 2402, 36, 408, 1, 3534, 290, 2428, 88, 39, 778, 2, 1340, 489, 4, 667, 2, 428, 1, 7, 106, 577, 36, 627, 4, 8, 505, 867, 813, 51, 116, 4, 591, 15, 430, 2058, 286, 2303, 7, 84, 193, 1, 251, 2, 706, 34, 91, 11, 1321, 195, 94, 32, 1197, 6, 412, 3, 176, 1, 577, 4, 150, 5, 127, 183, 2, 6, 1107, 3, 483, 1, 251, 6, 577]",1597.0,12200353,143
"A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.",Cancer,Cancer,2002-08-01,"The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy. One option for patients with recurrent/refractory disease is to administer a reinduction regimen that employs a dose-intense combination of anthracycline and cytarabine. These salvage regimens are relatively distinct from the traditional vincristine/prednisone-based programs that are used typically as primary induction therapy. The authors studied a regimen that contained high-dose cytarabine and a single high dose of idarubicin as salvage induction therapy for patients with recurrent or refractory lymphoblastic disease. Twenty-nine previously treated adult patients with recurrent or refractory acute lymphoblastic leukemia were treated with a new intensive regimen. Eight patients had primary refractory disease. Twenty-one patients had recurrent disease, and 16 of these patients developed recurrent disease while they were still receiving their primary therapy. The treatment regimen consisted of cytarabine 3.0 g/m(2) by 3-hour infusion daily for 5 days and idarubicin 40 mg/m(2) given as a single dose on Day 3. Filgrastim (granulocyte-colony stimulating factor) 5 microg/kg administered subcutaneously every 12 hours was started on Day 7 and was continued until the absolute neutrophil count was > 5000/microL. Response was assessed using standard criteria. There were 11 complete responses (38%; 95% confidence interval, 20-56%). Four patients subsequently underwent allogeneic bone marrow transplantation. Moderate but acceptable toxicity was observed given the severely myelosuppressive nature of the regimen. There was only one treatment-related death (3%). Two patients, both with significant prior exposure to anthracyclines, suffered reductions in left ventricular function to the 20-30% range during episodes of severe systemic infection. After recovery from infection, the ejection fraction in one patient improved to 50%. The authors conclude that this regimen has moderate activity and a relatively low incidence of mortality for this high-risk group of patients. This regimen may be most suitable for patients who can undergo potentially curative allogeneic bone marrow transplantation if they achieve a complete response.",Clinical Trial,6382.0,22.0,The majority of adult patients who are treated for lymphoblastic disease will either develop recurrent disease or will be refractory to their initial therapy One option for patients with recurrent/refractory disease is to administer a reinduction regimen that employs a dose-intense combination of anthracycline and cytarabine These salvage regimens are relatively distinct from the traditional vincristine/prednisone-based programs that are used typically as primary induction therapy The authors studied a regimen that contained high-dose cytarabine and a single high dose of idarubicin as salvage induction therapy for patients with recurrent or refractory lymphoblastic disease Twenty-nine previously treated adult patients with recurrent or refractory acute lymphoblastic were treated with a new intensive regimen Eight patients had primary refractory disease Twenty-one patients had recurrent disease and 16 of these patients developed recurrent disease while they were still receiving their primary therapy The treatment regimen consisted of cytarabine 3.0 g/m 2 by 3-hour infusion daily for 5 days and idarubicin 40 mg/m 2 given as a single dose on Day 3 Filgrastim granulocyte-colony stimulating factor 5 microg/kg administered subcutaneously every 12 hours was started on Day 7 and was continued until the absolute neutrophil count was 5000/microL Response was assessed using standard criteria There were 11 complete responses 38 95 confidence interval 20-56 Four patients subsequently underwent allogeneic marrow transplantation Moderate but acceptable toxicity was observed given the severely myelosuppressive nature of the regimen There was only one treatment-related death 3 Two patients both with significant prior exposure to anthracyclines suffered reductions in left ventricular function to the 20-30 range during episodes of severe systemic infection After recovery from infection the ejection fraction in one patient improved to 50 The authors conclude that this regimen has moderate activity and a relatively low incidence of mortality for this high-risk group of patients This regimen may be most suitable for patients who can undergo potentially curative allogeneic marrow transplantation if they achieve a complete response,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 686, 1, 780, 7, 54, 32, 73, 9, 1275, 34, 303, 361, 690, 387, 34, 15, 303, 40, 430, 6, 136, 388, 36, 104, 1501, 9, 7, 5, 387, 430, 34, 16, 6, 6888, 8, 10177, 477, 17, 15151, 8, 61, 3933, 150, 1, 2044, 2, 1855, 46, 992, 472, 32, 1352, 834, 29, 3, 1847, 2132, 1979, 90, 2251, 17, 32, 95, 1969, 22, 86, 504, 36, 3, 738, 656, 8, 477, 17, 3070, 64, 61, 1855, 2, 8, 226, 64, 61, 1, 5684, 22, 992, 504, 36, 9, 7, 5, 387, 15, 430, 1275, 34, 737, 762, 373, 73, 780, 7, 5, 387, 15, 430, 286, 1275, 11, 73, 5, 8, 217, 1686, 477, 659, 7, 42, 86, 430, 34, 737, 104, 7, 42, 387, 34, 2, 245, 1, 46, 7, 276, 387, 34, 369, 491, 11, 1234, 357, 136, 86, 36, 3, 24, 477, 1695, 1, 1855, 27, 13, 499, 188, 18, 20, 27, 2583, 904, 391, 9, 33, 162, 2, 5684, 327, 81, 188, 18, 447, 22, 8, 226, 61, 23, 218, 27, 5552, 2764, 1975, 2122, 161, 33, 2440, 503, 468, 3928, 454, 133, 1459, 10, 3461, 23, 218, 67, 2, 10, 1351, 1100, 3, 1766, 2595, 1276, 10, 10410, 5128, 51, 10, 275, 75, 260, 371, 125, 11, 175, 236, 253, 519, 48, 307, 268, 179, 664, 294, 7, 1611, 208, 1063, 581, 497, 1163, 84, 1595, 155, 10, 164, 447, 3, 7207, 11109, 2202, 1, 3, 477, 125, 10, 158, 104, 24, 139, 273, 27, 100, 7, 110, 5, 93, 324, 645, 6, 3597, 6388, 2153, 4, 1712, 4028, 343, 6, 3, 179, 201, 184, 190, 3750, 1, 905, 403, 930, 50, 1602, 29, 930, 3, 5420, 1509, 4, 104, 69, 231, 6, 212, 3, 738, 2060, 17, 26, 477, 71, 1163, 128, 2, 8, 1352, 154, 287, 1, 282, 9, 26, 64, 43, 87, 1, 7, 26, 477, 68, 40, 96, 2884, 9, 7, 54, 122, 1251, 751, 1075, 1063, 581, 497, 492, 491, 1359, 8, 236, 51]",2247.0,12209751,440
Induction of a transient graft vs. leukemia effect following unrelated cord blood transplantation.,Pediatric transplantation,Pediatr Transplant,2002-08-01,"Umbilical cord blood (UCB) has become a frequent source of allogeneic hematopoietic stem cells for transplantation. Of theoretical concern is a potential decrease in the graft vs. leukemia (GvL) effect, given the lesser degree of graft vs. host disease (GvHD) with this donor source. We report a case of recurrent acute non-lymphoblastic leukemia (ANLL) following stem cell transplantation with unrelated mismatched UCB, which responded to the induction of GvHD. The response was documented both morphologically and by evaluation of chimeric engraftment by molecular DNA techniques. In addition, WT-1, a purported marker of minimal residual disease in acute leukemia, correlated with remission status in this patient. In summary, the GvL effect is seen with allogeneic UCB transplantation and has the potential to be induced along with GvHD.",Case Reports,6382.0,6.0,Umbilical cord blood UCB has become a frequent source of allogeneic hematopoietic stem cells for transplantation Of theoretical concern is a potential decrease in the graft vs. GvL effect given the lesser degree of graft vs. host disease GvHD with this donor source We report a case of recurrent acute non-lymphoblastic ANLL following stem cell transplantation with unrelated mismatched UCB which responded to the induction of GvHD The response was documented both morphologically and by evaluation of chimeric engraftment by molecular DNA techniques In addition WT-1 a purported marker of minimal residual disease in acute correlated with remission status in this patient In summary the GvL effect is seen with allogeneic UCB transplantation and has the potential to be induced along with GvHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5998, 1885, 315, 4056, 71, 1417, 8, 908, 2353, 1, 1063, 1007, 452, 37, 9, 497, 1, 7060, 2893, 16, 8, 174, 775, 4, 3, 1599, 105, 8149, 254, 447, 3, 5191, 1444, 1, 1599, 105, 1204, 34, 1562, 5, 26, 1488, 2353, 21, 414, 8, 473, 1, 387, 286, 220, 1275, 27864, 366, 452, 31, 497, 5, 2092, 5095, 4056, 92, 2211, 6, 3, 504, 1, 1562, 3, 51, 10, 1405, 110, 6204, 2, 20, 451, 1, 2897, 2881, 20, 219, 261, 1092, 4, 352, 1820, 14, 8, 17125, 952, 1, 1048, 753, 34, 4, 286, 438, 5, 734, 156, 4, 26, 69, 4, 1962, 3, 8149, 254, 16, 527, 5, 1063, 4056, 497, 2, 71, 3, 174, 6, 40, 277, 1510, 5, 1562]",794.0,12234279,181
Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia.,Blood,Blood,2002-10-01,"In children with acute lymphoblastic leukemia (ALL), response to treatment is assessed by bone marrow aspiration. We investigated whether minimal residual disease (MRD) can be effectively monitored in peripheral blood. We used flow cytometric techniques capable of detecting 1 leukemic cell among 10 000 or more normal cells to compare MRD measurements in 718 pairs of bone marrow and peripheral blood samples collected from 226 children during treatment for newly diagnosed ALL. MRD was detected in marrow and blood in 72 pairs and in marrow but not in blood in 67 pairs; it was undetectable in the remaining 579 pairs. Remarkably, findings in marrow and blood were completely concordant in the 150 paired samples from patients with T-lineage ALL: for each of the 35 positive marrow samples, the corresponding blood sample was positive. In B-lineage ALL, however, only 37 of 104 positive marrow samples had a corresponding positive blood sample. Notably, peripheral blood MRD in these patients was associated with a very high risk for disease recurrence. The 4-year cumulative incidence of relapse in patients with B-lineage ALL was 80.0% +/- 24.9% for those who had peripheral blood MRD at the end of remission induction therapy but only 13.3% +/- 9.1% for those with MRD confined to the marrow (P =.007). These results indicate that peripheral blood may be used to monitor MRD in patients with T-lineage ALL and that peripheral blood MRD may provide strong prognostic information in patients with B-lineage ALL.",Comparative Study,6321.0,135.0,In children with acute lymphoblastic ALL response to treatment is assessed by marrow aspiration We investigated whether minimal residual disease MRD can be effectively monitored in peripheral blood We used flow cytometric techniques capable of detecting 1 leukemic cell among 10 000 or more normal cells to compare MRD measurements in 718 pairs of marrow and peripheral blood samples collected from 226 children during treatment for newly diagnosed ALL MRD was detected in marrow and blood in 72 pairs and in marrow but not in blood in 67 pairs it was undetectable in the remaining 579 pairs Remarkably findings in marrow and blood were completely concordant in the 150 paired samples from patients with T-lineage ALL for each of the 35 positive marrow samples the corresponding blood sample was positive In B-lineage ALL however only 37 of 104 positive marrow samples had a corresponding positive blood sample Notably peripheral blood MRD in these patients was associated with a very high risk for disease recurrence The 4-year cumulative incidence of relapse in patients with B-lineage ALL was 80.0 +/- 24.9 for those who had peripheral blood MRD at the end of remission induction therapy but only 13.3 +/- 9.1 for those with MRD confined to the marrow P =.007 These results indicate that peripheral blood may be used to monitor MRD in patients with T-lineage ALL and that peripheral blood MRD may provide strong prognostic information in patients with B-lineage ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 541, 5, 286, 1275, 62, 51, 6, 24, 16, 275, 20, 581, 3256, 21, 565, 317, 1048, 753, 34, 2029, 122, 40, 1856, 2909, 4, 672, 315, 21, 95, 1412, 6226, 1092, 2787, 1, 2502, 14, 2015, 31, 107, 79, 984, 15, 80, 295, 37, 6, 932, 2029, 1685, 4, 15156, 2773, 1, 581, 2, 672, 315, 347, 786, 29, 7400, 541, 190, 24, 9, 732, 265, 62, 2029, 10, 530, 4, 581, 2, 315, 4, 720, 2773, 2, 4, 581, 84, 44, 4, 315, 4, 598, 2773, 192, 10, 3920, 4, 3, 1844, 11414, 2773, 4856, 272, 4, 581, 2, 315, 11, 2500, 3610, 4, 3, 1577, 2355, 347, 29, 7, 5, 102, 2542, 62, 9, 296, 1, 3, 465, 109, 581, 347, 3, 1734, 315, 1000, 10, 109, 4, 132, 2542, 62, 137, 158, 567, 1, 3407, 109, 581, 347, 42, 8, 1734, 109, 315, 1000, 2552, 672, 315, 2029, 4, 46, 7, 10, 41, 5, 8, 923, 64, 43, 9, 34, 146, 3, 39, 111, 967, 287, 1, 429, 4, 7, 5, 132, 2542, 62, 10, 493, 13, 259, 83, 9, 135, 54, 42, 672, 315, 2029, 28, 3, 396, 1, 734, 504, 36, 84, 158, 233, 27, 83, 14, 9, 135, 5, 2029, 2902, 6, 3, 581, 19, 1999, 46, 99, 1008, 17, 672, 315, 68, 40, 95, 6, 3334, 2029, 4, 7, 5, 102, 2542, 62, 2, 17, 672, 315, 2029, 68, 377, 1082, 177, 487, 4, 7, 5, 132, 2542, 62]",1468.0,12239148,139
Simultaneous occurrence of polycythemia vera and Waldenstrom macroglobulinemia: a case report and review of the literature.,Haematologia,Haematologia (Budap),2002-01-01,"Polycythemia vera and lymphoproliferative disorders can occur simultaneously. Lymphoproliferative disorders reported to occur simultaneously with polycythemia vera include chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), and acute lymphoblastic leukemia (ALL). Different theories have attempted to explain this occurrence. Some implicate a common cell of origin to the two disorders, others include chance alone, yet others implicate an underlying humoral or immune mechanism caused by the first disorder leading to a second clonal expansion. We report the first case of polycythemia vera with a simultaneous diagnosis of Waldenstrom macroglobulinemia, and we review the literature trying to explain this unusual occurrence.",Case Reports,6594.0,4.0,Polycythemia vera and lymphoproliferative disorders can occur simultaneously Lymphoproliferative disorders reported to occur simultaneously with polycythemia vera include chronic lymphocytic CLL 's NHL and acute lymphoblastic ALL Different theories have attempted to explain this occurrence Some implicate a common cell of origin to the two disorders others include chance alone yet others implicate an underlying humoral or immune mechanism caused by the first disorder leading to a second clonal expansion We report the first case of polycythemia vera with a simultaneous diagnosis of Waldenstrom macroglobulinemia and we review the literature trying to explain this unusual occurrence,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[5755, 5756, 2, 4192, 1997, 122, 1271, 3074, 4192, 1997, 210, 6, 1271, 3074, 5, 5755, 5756, 643, 442, 1193, 552, 292, 1176, 2, 286, 1275, 62, 338, 18219, 47, 4098, 6, 2943, 26, 2291, 476, 5545, 8, 186, 31, 1, 1938, 6, 3, 100, 1997, 1749, 643, 3477, 279, 1145, 1749, 5545, 35, 1181, 5498, 15, 250, 670, 1546, 20, 3, 157, 2645, 1049, 6, 8, 419, 1946, 1422, 21, 414, 3, 157, 473, 1, 5755, 5756, 5, 8, 2824, 147, 1, 7933, 3389, 2, 21, 206, 3, 789, 14453, 6, 2943, 26, 4015, 2291]",687.0,12243551,556
Endocrine complications in pediatric patients with acute lymphoblastic leukemia.,Blood reviews,Blood Rev.,2002-12-01,"Endocrine complications of therapy for acute lymphoblastic leukemia (ALL) are common and are potentially debilitating both during and after therapy. Growth velocity slows during therapy for ALL, especially during the first year; however, children who do not receive cranial irradiation usually reach normal adult height. While growth hormone deficiency generally occurs in patients who have received 24Gy of cranial irradiation, it may also develop in those treated with lower doses (18Gy) of cranial radiation or with only high-dose methotrexate. Obesity commonly occurs during therapy and persists after completion of therapy. Osteopenia can occur early during therapy for ALL and can persist for many years. Adrenal insufficiency should be suspected in any child who has recently received glucocorticoid therapy, and stress doses of steroid should be administered in the event of metabolic stress. Screening of urine is useful for early detection of hyperglycemia during therapy with glucocorticoids and L-asparaginase. The syndrome of inappropriate secretion of anti-diuretic hormone is usually associated with vincristine therapy and may be aggravated by concurrent use of azole antifungals. Finally, patients who have received 18 or 24Gy of cranial irradiation may have clinical or subclinical deficiencies of thyroid hormones.",Journal Article,6260.0,59.0,Endocrine complications of therapy for acute lymphoblastic ALL are common and are potentially debilitating both during and after therapy Growth velocity slows during therapy for ALL especially during the first year however children who do not receive cranial irradiation usually reach normal adult height While growth hormone deficiency generally occurs in patients who have received 24Gy of cranial irradiation it may also develop in those treated with lower doses 18Gy of cranial radiation or with only high-dose methotrexate Obesity commonly occurs during therapy and persists after completion of therapy Osteopenia can occur early during therapy for ALL and can persist for many years Adrenal insufficiency should be suspected in any child who has recently received glucocorticoid therapy and stress doses of steroid should be administered in the event of metabolic stress Screening of urine is useful for early detection of hyperglycemia during therapy with glucocorticoids and L-asparaginase The syndrome of inappropriate secretion of anti-diuretic hormone is usually associated with vincristine therapy and may be aggravated by concurrent use of azole antifungals Finally patients who have received 18 or 24Gy of cranial irradiation may have clinical or subclinical deficiencies of hormones,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,"[1293, 521, 1, 36, 9, 286, 1275, 62, 32, 186, 2, 32, 751, 8099, 110, 190, 2, 50, 36, 129, 6025, 21073, 190, 36, 9, 62, 1093, 190, 3, 157, 111, 137, 541, 54, 1022, 44, 560, 2565, 1104, 2082, 3690, 295, 780, 4594, 369, 129, 785, 2299, 1228, 1780, 4, 7, 54, 47, 103, 43046, 1, 2565, 1104, 192, 68, 120, 690, 4, 135, 73, 5, 280, 415, 53138, 1, 2565, 121, 15, 5, 158, 64, 61, 2116, 1661, 841, 1780, 190, 36, 2, 8936, 50, 1438, 1, 36, 10434, 122, 1271, 191, 190, 36, 9, 62, 2, 122, 5589, 9, 445, 60, 2987, 4360, 257, 40, 2768, 4, 500, 2566, 54, 71, 761, 103, 5399, 36, 2, 1531, 415, 1, 3853, 257, 40, 468, 4, 3, 774, 1, 1436, 1531, 453, 1, 2646, 16, 999, 9, 191, 638, 1, 3992, 190, 36, 5, 7307, 2, 805, 3709, 3, 681, 1, 5148, 2935, 1, 312, 27962, 785, 16, 2082, 41, 5, 2132, 36, 2, 68, 40, 30316, 20, 750, 119, 1, 27963, 24512, 1368, 7, 54, 47, 103, 203, 15, 43046, 1, 2565, 1104, 68, 47, 38, 15, 7403, 7159, 1, 4927]",1297.0,12350366,466
Limited and optimal sampling strategies for etoposide and etoposide catechol in children with leukemia.,Journal of pharmacokinetics and pharmacodynamics,J Pharmacokinet Pharmacodyn,2002-04-01,"Etoposide is used to treat childhood malignancies, and its plasma pharmacokinetics have been related to pharmacodynamic endpoints. Limiting the number of samples should facilitate the assessment of etoposide pharmacokinetics in children. We compared limited sampling strategies using multiple linear regression of plasma concentrations and clearance with Bayesian methods of estimating clearance using compartmental pharmacokinetic models. Optimal sampling times were estimated in the multiple linear regression method by determining the combination of two samples which maximized the correlation coefficient, and in the Bayesian estimation approach by minimizing the variance in estimates of clearance. Clearance estimates were compared to the actual clearances from Monte Carlo-simulated data and predicted clearances estimated using all available plasma concentrations in clinical data from children with acute lymphoblastic leukemia. Multiple linear regression poorly predicted clearance (mean bias 8.3%, precision 17.5%), but improved if plasma concentrations were logarithmically transformed (mean bias 1.4%, precision 12.5%). Bayesian estimation methods with optimal samples gave the best overall prediction (mean bias 2.5%, precision 6.8%) and also performed better than regression methods for abnormally high or low clearances. We conclude that Bayesian estimation with limited sampling gives the best estimates of etoposide clearance.",Comparative Study,6504.0,23.0,Etoposide is used to treat childhood malignancies and its plasma pharmacokinetics have been related to pharmacodynamic endpoints Limiting the number of samples should facilitate the assessment of etoposide pharmacokinetics in children We compared limited sampling strategies using multiple linear regression of plasma concentrations and clearance with Bayesian methods of estimating clearance using compartmental pharmacokinetic models Optimal sampling times were estimated in the multiple linear regression method by determining the combination of two samples which maximized the correlation coefficient and in the Bayesian estimation approach by minimizing the variance in estimates of clearance Clearance estimates were compared to the actual clearances from Monte Carlo-simulated data and predicted clearances estimated using all available plasma concentrations in clinical data from children with acute lymphoblastic Multiple linear regression poorly predicted clearance mean bias 8.3 precision 17.5 but improved if plasma concentrations were logarithmically transformed mean bias 1.4 precision 12.5 Bayesian estimation methods with optimal samples gave the best overall prediction mean bias 2.5 precision 6.8 and also performed better than regression methods for abnormally high or low clearances We conclude that Bayesian estimation with limited sampling gives the best estimates of etoposide clearance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1934, 16, 95, 6, 943, 864, 441, 2, 211, 554, 1159, 47, 85, 139, 6, 2424, 1387, 817, 3, 207, 1, 347, 257, 1876, 3, 455, 1, 1934, 1159, 4, 541, 21, 72, 383, 2874, 422, 75, 232, 1646, 320, 1, 554, 1003, 2, 1960, 5, 5032, 636, 1, 4563, 1960, 75, 13522, 1456, 274, 665, 2874, 1072, 11, 661, 4, 3, 232, 1646, 320, 596, 20, 2196, 3, 150, 1, 100, 347, 92, 14440, 3, 816, 3200, 2, 4, 3, 5032, 4470, 353, 20, 4501, 3, 4446, 4, 1423, 1, 1960, 1960, 1423, 11, 72, 6, 3, 3480, 20228, 29, 7990, 7991, 5872, 74, 2, 783, 20228, 661, 75, 62, 390, 554, 1003, 4, 38, 74, 29, 541, 5, 286, 1275, 232, 1646, 320, 1240, 783, 1960, 313, 2947, 66, 27, 2720, 269, 33, 84, 231, 492, 554, 1003, 11, 37280, 2423, 313, 2947, 14, 39, 2720, 133, 33, 5032, 4470, 636, 5, 665, 347, 6421, 3, 824, 63, 1590, 313, 2947, 18, 33, 2720, 49, 66, 2, 120, 173, 380, 76, 320, 636, 9, 11749, 64, 15, 154, 20228, 21, 2060, 17, 5032, 4470, 5, 383, 2874, 7989, 3, 824, 1423, 1, 1934, 1960]",1409.0,12361242,21
Parental medication use and risk of childhood acute lymphoblastic leukemia.,Cancer,Cancer,2002-10-01,"Few studies have examined the risk of childhood acute lymphoblastic leukemia (ALL) associated with parental medication use. As part of a large case-control study conducted by the Children's Cancer Group, we evaluated the association between maternal and paternal medication use and the risk of ALL in offspring. Information on selected medication use in the year before and during the index pregnancy was obtained by telephone interview. Participants included 1842 children of 14 years or younger with newly diagnosed and immunophenotypically defined ALL and 1986 individually matched controls. Data were analyzed using logistic regression models and stratified by immunophenotypes of ALL and age at diagnosis of cases. After adjusting for potential confounders and other medication use, we found that maternal use of vitamins (odds ratio [OR] = 0.7, 99% confidence interval [CI]: 0.5-1.0) and iron supplements (OR = 0.8, 99% CI: 0.7-1.0) only during the index pregnancy was associated with a decreased risk of ALL. Parental use of amphetamines or diet pills and mind-altering drugs before and during the index pregnancy was related to an increased risk of childhood ALL, particularly among children where both parents reported using these drugs (OR = 2.8, 99% CI: 0.5-15.6 for amphetamines or diet pills, OR = 1.8, 99% CI: 1.1-3.0 for mind-altering drugs). Stratified analyses showed that maternal use of antihistamines or allergic remedies and parental use of mind-altering drugs were strongly associated with infant ALL, whereas patterns of association between childhood ALL and parental medication use did not influence markedly the immunophenotypic subgroup of ALL. The findings of this study suggest that certain parental medication use immediately before and during the index pregnancy may influence risk of ALL in offspring.",Journal Article,6321.0,64.0,Few studies have examined the risk of childhood acute lymphoblastic ALL associated with parental medication use As part of a large case-control study conducted by the Children 's Cancer Group we evaluated the association between maternal and paternal medication use and the risk of ALL in offspring Information on selected medication use in the year before and during the index pregnancy was obtained by telephone interview Participants included 1842 children of 14 years or younger with newly diagnosed and immunophenotypically defined ALL and 1986 individually matched controls Data were analyzed using logistic regression models and stratified by immunophenotypes of ALL and age at diagnosis of cases After adjusting for potential confounders and other medication use we found that maternal use of vitamins odds ratio OR 0.7 99 confidence interval CI 0.5-1.0 and iron supplements OR 0.8 99 CI 0.7-1.0 only during the index pregnancy was associated with a decreased risk of ALL Parental use of amphetamines or diet pills and mind-altering drugs before and during the index pregnancy was related to an increased risk of childhood ALL particularly among children where both parents reported using these drugs OR 2.8 99 CI 0.5-15.6 for amphetamines or diet pills OR 1.8 99 CI 1.1-3.0 for mind-altering drugs Stratified analyses showed that maternal use of antihistamines or allergic remedies and parental use of mind-altering drugs were strongly associated with infant ALL whereas patterns of association between childhood ALL and parental medication use did not influence markedly the immunophenotypic subgroup of ALL The findings of this study suggest that certain parental medication use immediately before and during the index pregnancy may influence risk of ALL in offspring,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1021, 94, 47, 409, 3, 43, 1, 864, 286, 1275, 62, 41, 5, 3418, 3012, 119, 22, 760, 1, 8, 375, 473, 182, 45, 426, 20, 3, 541, 292, 12, 87, 21, 194, 3, 248, 59, 6039, 2, 10649, 3012, 119, 2, 3, 43, 1, 62, 4, 8304, 487, 23, 715, 3012, 119, 4, 3, 111, 348, 2, 190, 3, 558, 2290, 10, 683, 20, 4258, 4313, 776, 159, 25986, 541, 1, 213, 60, 15, 773, 5, 732, 265, 2, 24516, 395, 62, 2, 3751, 4257, 655, 535, 74, 11, 311, 75, 812, 320, 274, 2, 1173, 20, 16679, 1, 62, 2, 89, 28, 147, 1, 140, 50, 1358, 9, 174, 4423, 2, 127, 3012, 119, 21, 204, 17, 6039, 119, 1, 9447, 610, 197, 15, 13, 67, 1058, 307, 268, 58, 13, 33, 14, 13, 2, 4231, 6600, 15, 13, 66, 1058, 58, 13, 67, 14, 13, 158, 190, 3, 558, 2290, 10, 41, 5, 8, 340, 43, 1, 62, 3418, 119, 1, 37281, 15, 2453, 17655, 2, 8090, 4831, 600, 348, 2, 190, 3, 558, 2290, 10, 139, 6, 35, 101, 43, 1, 864, 62, 823, 107, 541, 1257, 110, 2418, 210, 75, 46, 600, 15, 18, 66, 1058, 58, 13, 33, 167, 49, 9, 37281, 15, 2453, 17655, 15, 14, 66, 1058, 58, 14, 14, 27, 13, 9, 8090, 4831, 600, 1173, 318, 224, 17, 6039, 119, 1, 27966, 15, 7465, 25973, 2, 3418, 119, 1, 8090, 4831, 600, 11, 1327, 41, 5, 8027, 62, 547, 764, 1, 248, 59, 864, 62, 2, 3418, 3012, 119, 205, 44, 1054, 2195, 3, 6599, 1363, 1, 62, 3, 272, 1, 26, 45, 309, 17, 1840, 3418, 3012, 119, 3467, 348, 2, 190, 3, 558, 2290, 68, 1054, 43, 1, 62, 4, 8304]",1778.0,12365028,26
Risk factors for traumatic and bloody lumbar puncture in children with acute lymphoblastic leukemia.,JAMA,JAMA,,"Traumatic or bloody lumbar puncture (LP) reduces the diagnostic value of the procedure and may worsen the outcome of patients with acute lymphoblastic leukemia (ALL). Little is known about the risk factors for traumatic and bloody LP. To determine the risk factors for traumatic and bloody LP. Retrospective cohort study of 956 consecutive patients with newly diagnosed childhood ALL who were treated at a pediatric cancer center between February 1984 and July 1998. All patients underwent a diagnostic LP followed by a median of 4 LPs to instill intrathecal chemotherapy. Traumatic LP was defined as an LP in which cerebrospinal fluid contained at least 10 red blood cells (RBCs) per microliter and bloody LP as one in which the cerebrospinal fluid contained at least 500 RBCs per microliter. Of the 5609 LPs evaluated, 1643 (29%) were traumatic and 581 (10%) were bloody. The estimated odds ratios (ORs) and 95% confidence intervals (CIs) for traumatic LP were 1.5 (95% CI, 1.2-1.8) for black vs white race, 2.3 (95% CI, 1.7-3.0) for age younger than 1 year vs 1 year or older, 1.4 (95% CI, 1.2-1.7) for early vs recent (dedicated procedure area and general anesthesia) treatment era, 1.5 (95% CI, 1.2-1.8) for platelet count of 100 x 10(3)/ microL or more vs less than 100 x 10(3 )/ microL, 10.8 (95% CI, 7.7-15.2) for short (1 day) vs longer (>15 days) interval since the previous LP, and 1.4 (95% CI, 1.1-1.8) for the least vs the most experienced practitioners. Analyses for bloody LP yielded similar results. The unmodifiable risk factors for traumatic and bloody LP include black race, age younger than 1 year, a traumatic or bloody previous LP performed within the past 2 weeks, and a previous LP performed when the platelet count was 50 x 10(3)/ microL or less. Modifiable risk factors include procedural factors reflected in treatment era, platelet count of 100 x 10(3)/ microL or less, an interval of 15 days or less between LPs, and a less experienced practitioner.",Journal Article,,,Traumatic or bloody lumbar puncture LP reduces the diagnostic value of the procedure and may worsen the outcome of patients with acute lymphoblastic ALL Little is known about the risk factors for traumatic and bloody LP To determine the risk factors for traumatic and bloody LP Retrospective cohort study of 956 consecutive patients with newly diagnosed childhood ALL who were treated at a pediatric cancer center between February 1984 and July 1998 All patients underwent a diagnostic LP followed by a median of 4 LPs to instill intrathecal chemotherapy Traumatic LP was defined as an LP in which cerebrospinal fluid contained at least 10 red blood cells RBCs per microliter and bloody LP as one in which the cerebrospinal fluid contained at least 500 RBCs per microliter Of the 5609 LPs evaluated 1643 29 were traumatic and 581 10 were bloody The estimated odds ratios ORs and 95 confidence intervals CIs for traumatic LP were 1.5 95 CI 1.2-1.8 for black vs white race 2.3 95 CI 1.7-3.0 for age younger than 1 year vs 1 year or older 1.4 95 CI 1.2-1.7 for early vs recent dedicated procedure area and general anesthesia treatment era 1.5 95 CI 1.2-1.8 for platelet count of 100 x 10 3 microL or more vs less than 100 x 10 3 microL 10.8 95 CI 7.7-15.2 for short 1 day vs longer 15 days interval since the previous LP and 1.4 95 CI 1.1-1.8 for the least vs the most experienced practitioners Analyses for bloody LP yielded similar results The unmodifiable risk factors for traumatic and bloody LP include black race age younger than 1 year a traumatic or bloody previous LP performed within the past 2 weeks and a previous LP performed when the platelet count was 50 x 10 3 microL or less Modifiable risk factors include procedural factors reflected in treatment era platelet count of 100 x 10 3 microL or less an interval of 15 days or less between LPs and a less experienced practitioner,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[11272, 15, 18830, 6187, 12104, 6427, 2389, 3, 752, 549, 1, 3, 1299, 2, 68, 12500, 3, 228, 1, 7, 5, 286, 1275, 62, 1215, 16, 440, 545, 3, 43, 130, 9, 11272, 2, 18830, 6427, 6, 223, 3, 43, 130, 9, 11272, 2, 18830, 6427, 459, 180, 45, 1, 14137, 935, 7, 5, 732, 265, 864, 62, 54, 11, 73, 28, 8, 815, 12, 574, 59, 3010, 6036, 2, 2066, 1850, 62, 7, 208, 8, 752, 6427, 370, 20, 8, 52, 1, 39, 6310, 6, 53163, 5126, 56, 11272, 6427, 10, 395, 22, 35, 6427, 4, 92, 5156, 2357, 3070, 28, 506, 79, 3422, 315, 37, 15859, 379, 23159, 2, 18830, 6427, 22, 104, 4, 92, 3, 5156, 2357, 3070, 28, 506, 1666, 15859, 379, 23159, 1, 3, 53164, 6310, 194, 37294, 462, 11, 11272, 2, 12482, 79, 11, 18830, 3, 661, 610, 1137, 3694, 2, 48, 307, 1582, 1927, 9, 11272, 6427, 11, 14, 33, 48, 58, 14, 18, 14, 66, 9, 1445, 105, 886, 1047, 18, 27, 48, 58, 14, 67, 27, 13, 9, 89, 773, 76, 14, 111, 105, 14, 111, 15, 434, 14, 39, 48, 58, 14, 18, 14, 67, 9, 191, 105, 435, 4827, 1299, 965, 2, 1083, 6433, 24, 1713, 14, 33, 48, 58, 14, 18, 14, 66, 9, 1596, 1276, 1, 394, 1006, 79, 27, 5128, 15, 80, 105, 299, 76, 394, 1006, 79, 27, 5128, 79, 66, 48, 58, 67, 67, 167, 18, 9, 978, 14, 218, 105, 589, 167, 162, 268, 1192, 3, 698, 6427, 2, 14, 39, 48, 58, 14, 14, 14, 66, 9, 3, 506, 105, 3, 96, 592, 6323, 318, 9, 18830, 6427, 2178, 288, 99, 3, 53165, 43, 130, 9, 11272, 2, 18830, 6427, 643, 1445, 1047, 89, 773, 76, 14, 111, 8, 11272, 15, 18830, 698, 6427, 173, 262, 3, 1219, 18, 244, 2, 8, 698, 6427, 173, 198, 3, 1596, 1276, 10, 212, 1006, 79, 27, 5128, 15, 299, 5222, 43, 130, 643, 8492, 130, 4686, 4, 24, 1713, 1596, 1276, 1, 394, 1006, 79, 27, 5128, 15, 299, 35, 268, 1, 167, 162, 15, 299, 59, 6310, 2, 8, 299, 592, 11929]",1889.0,12387652,453
T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.,Blood,Blood,2002-10-10,"Relapse of B-lineage acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (HSCT) commonly results from the failure of a graft-versus-leukemia (GVL) effect to eradicate minimal residual disease. Augmenting the GVL effect by the adoptive transfer of donor-derived B-ALL-specific T-cell clones is a conceptually attractive strategy to decrease relapse rates without exacerbating graft-versus-host disease (GVHD). Toward this end, we investigated whether a genetic engineering approach could render CD8(+) cytotoxic T lymphocytes (CTLs) specific for tumor cells that express the B-cell lineage cell surface molecule CD19. This was accomplished by the genetic modification of CTLs to express a chimeric immunoreceptor composed of a CD19-specific single-chain immunoglobulin extracellular targeting domain fused to a CD3-zeta intracellular signaling domain. CD19-redirected CTL clones display potent CD19-specific lytic activity and chimeric immunoreceptor-regulated cytokine production and proliferation. Because B-ALL cells can evade T-cell/natural killer- cell recognition by down-regulation of cell surface accessory molecules that participate in the formation of a functional immunologic synapse, we compared the CD19-specific effector function of genetically modified CD8(+) CTLs toward CD19(+) cells with disparate levels of intercellular adhesion molecule 1 (ICAM-1), leukocyte function-associated antigen 1 (LFA-1), and LFA-3. We observed that recognition of B-lineage tumor lines by CD19-specific CTLs was not impaired by low levels of ICAM-1, LFA-1, and LFA-3 cell surface expression, a functional attribute that is likely a consequence of our high-affinity CD19-specific chimeric immunoreceptor. Furthermore, the CD19-specific CTLs could lyse primary B-ALL blasts. These preclinical observations form the basis for implementing clinical trials using donor-derived CD19-specific T-cell clones to treat or prevent relapse of B-ALL after allogeneic HSCT.",Journal Article,6312.0,201.0,Relapse of B-lineage acute lymphoblastic B-ALL after allogeneic hematopoietic stem cell transplantation HSCT commonly results from the failure of a graft-versus-leukemia GVL effect to eradicate minimal residual disease Augmenting the GVL effect by the adoptive transfer of donor-derived B-ALL-specific T-cell clones is a conceptually attractive strategy to decrease relapse rates without exacerbating graft-versus-host disease GVHD Toward this end we investigated whether a genetic engineering approach could render CD8 cytotoxic T lymphocytes CTLs specific for tumor cells that express the B-cell lineage cell surface molecule CD19 This was accomplished by the genetic modification of CTLs to express a chimeric immunoreceptor composed of a CD19-specific single-chain immunoglobulin extracellular targeting domain fused to a CD3-zeta intracellular signaling domain CD19-redirected CTL clones display potent CD19-specific lytic activity and chimeric immunoreceptor-regulated cytokine production and proliferation Because B-ALL cells can evade T-cell/natural killer- cell recognition by down-regulation of cell surface accessory molecules that participate in the formation of a functional immunologic synapse we compared the CD19-specific effector function of genetically modified CD8 CTLs toward CD19 cells with disparate levels of intercellular adhesion molecule 1 ICAM-1 leukocyte function-associated antigen 1 LFA-1 and LFA-3 We observed that recognition of B-lineage tumor lines by CD19-specific CTLs was not impaired by low levels of ICAM-1 LFA-1 and LFA-3 cell surface expression a functional attribute that is likely a consequence of our high-affinity CD19-specific chimeric immunoreceptor Furthermore the CD19-specific CTLs could lyse primary B-ALL blasts These preclinical observations form the basis for implementing clinical trials using donor-derived CD19-specific T-cell clones to treat or prevent relapse of B-ALL after allogeneic HSCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[429, 1, 132, 2542, 286, 1275, 132, 62, 50, 1063, 1007, 452, 31, 497, 1703, 841, 99, 29, 3, 496, 1, 8, 1599, 185, 2647, 8149, 254, 6, 5650, 1048, 753, 34, 9015, 3, 8149, 254, 20, 3, 3159, 2602, 1, 1488, 526, 132, 62, 112, 102, 31, 2749, 16, 8, 13825, 3059, 692, 6, 775, 429, 151, 187, 21082, 1599, 185, 1204, 34, 1562, 1317, 26, 396, 21, 565, 317, 8, 336, 6717, 353, 359, 7873, 968, 759, 102, 1594, 5416, 112, 9, 30, 37, 17, 1669, 3, 132, 31, 2542, 31, 1255, 1354, 3158, 26, 10, 5741, 20, 3, 336, 2437, 1, 5416, 6, 1669, 8, 2897, 20236, 3317, 1, 8, 3158, 112, 226, 1260, 2593, 1976, 529, 1398, 6263, 6, 8, 3117, 12105, 2087, 314, 1398, 3158, 13278, 3872, 2749, 3640, 1157, 3158, 112, 6148, 128, 2, 2897, 20236, 1065, 1675, 1529, 2, 457, 408, 132, 62, 37, 122, 6636, 102, 31, 1504, 3458, 31, 2335, 20, 1328, 863, 1, 31, 1255, 12082, 1598, 17, 3506, 4, 3, 1264, 1, 8, 583, 3042, 15533, 21, 72, 3, 3158, 112, 2070, 343, 1, 2301, 1230, 968, 5416, 1317, 3158, 37, 5, 7985, 148, 1, 10417, 2128, 1354, 14, 9644, 14, 3627, 343, 41, 448, 14, 22038, 14, 2, 22038, 27, 21, 164, 17, 2335, 1, 132, 2542, 30, 285, 20, 3158, 112, 5416, 10, 44, 2364, 20, 154, 148, 1, 9644, 14, 22038, 14, 2, 22038, 27, 31, 1255, 55, 8, 583, 13530, 17, 16, 322, 8, 4177, 1, 114, 64, 3601, 3158, 112, 2897, 20236, 798, 3, 3158, 112, 5416, 359, 11436, 86, 132, 62, 2438, 46, 693, 2172, 1297, 3, 877, 9, 6436, 38, 143, 75, 1488, 526, 3158, 112, 102, 31, 2749, 6, 943, 15, 1682, 429, 1, 132, 62, 50, 1063, 1703]",1949.0,12393484,549
"Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia.",Blood,Blood,2002-08-22,"Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute leukemia and has been associated with unfavorable clinical outcome. We hypothesized that down-regulation of Bcl-2 would restore chemosensitivity in leukemic cells. To test this hypothesis, we performed a phase 1 study of G3139 (Genasense, Genta, Berkeley Heights, NJ), an 18-mer phosphorothioate Bcl-2 antisense, with fludarabine (FL), cytarabine (ARA-C), and granulocyte colony-stimulating factor (G-CSF) (FLAG) salvage chemotherapy in patients with refractory or relapsed acute leukemia. Twenty patients with refractory or relapsed acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) were enrolled. G3139 was delivered by continuous infusion on days 1 to 10. FLAG chemotherapy was administered on days 5 to 10. Common side effects of this combination included fever, nausea, emesis, electrolyte imbalance, and fluid retention that were not dose limiting. Plasma pharmacokinetics of G3139 demonstrated steady-state concentration (Css) within 24 hours. Of the 20 patients, 9 (45%) had disease response, 6 (5 AML, 1 ALL) with complete remission (CR) and 3 (2 AML and 1 ALL) with no evidence of disease but failure to recover normal neutrophil and/or platelet counts or to remain in remission for at least 30 days (incomplete remission). Bcl-2 mRNA levels were down-regulated in 9 of the 12 (75%) evaluable patients. This study demonstrates that G3139 can be administered safely with FLAG chemotherapy and down-regulate its target, Bcl-2. The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML (ie, age at least 60 years).",Clinical Trial,6361.0,186.0,Overexpression of Bcl-2 is a potential mechanism for chemoresistance in acute and has been associated with unfavorable clinical outcome We hypothesized that down-regulation of Bcl-2 would restore chemosensitivity in leukemic cells To test this hypothesis we performed a phase 1 study of G3139 Genasense Genta Berkeley Heights NJ an 18-mer phosphorothioate Bcl-2 antisense with fludarabine FL cytarabine ARA-C and granulocyte colony-stimulating factor G-CSF FLAG salvage chemotherapy in patients with refractory or relapsed acute Twenty patients with refractory or relapsed acute myeloid AML or acute lymphoblastic ALL were enrolled G3139 was delivered by continuous infusion on days 1 to 10 FLAG chemotherapy was administered on days 5 to 10 Common side effects of this combination included fever nausea emesis electrolyte imbalance and fluid retention that were not dose limiting Plasma pharmacokinetics of G3139 demonstrated steady-state concentration Css within 24 hours Of the 20 patients 9 45 had disease response 6 5 AML 1 ALL with complete remission CR and 3 2 AML and 1 ALL with no evidence of disease but failure to recover normal neutrophil and/or platelet counts or to remain in remission for at least 30 days incomplete remission Bcl-2 mRNA levels were down-regulated in 9 of the 12 75 evaluable patients This study demonstrates that G3139 can be administered safely with FLAG chemotherapy and down-regulate its target Bcl-2 The encouraging clinical and laboratory results justify the current plans for a phase 3 study in previously untreated high-risk AML ie age at least 60 years,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[851, 1, 1044, 18, 16, 8, 174, 670, 9, 3782, 4, 286, 2, 71, 85, 41, 5, 2483, 38, 228, 21, 1237, 17, 1328, 863, 1, 1044, 18, 688, 6075, 5522, 4, 2015, 37, 6, 412, 26, 1492, 21, 173, 8, 124, 14, 45, 1, 8252, 30327, 53176, 43057, 23162, 12754, 35, 203, 10068, 26074, 1044, 18, 4645, 5, 2027, 2633, 1855, 3899, 256, 2, 2764, 1975, 2122, 161, 499, 1211, 12546, 992, 56, 4, 7, 5, 430, 15, 591, 286, 737, 7, 5, 430, 15, 591, 286, 533, 329, 15, 286, 1275, 62, 11, 346, 8252, 10, 1623, 20, 1314, 904, 23, 162, 14, 6, 79, 12546, 56, 10, 468, 23, 162, 33, 6, 79, 186, 1152, 176, 1, 26, 150, 159, 2775, 1218, 6899, 10834, 6088, 2, 2357, 3947, 17, 11, 44, 61, 817, 554, 1159, 1, 8252, 264, 4152, 1309, 1227, 2687, 262, 259, 1459, 1, 3, 179, 7, 83, 512, 42, 34, 51, 49, 33, 329, 14, 62, 5, 236, 734, 684, 2, 27, 18, 329, 2, 14, 62, 5, 77, 241, 1, 34, 84, 496, 6, 9966, 295, 2595, 2, 15, 1596, 1911, 15, 6, 918, 4, 734, 9, 28, 506, 201, 162, 2610, 734, 1044, 18, 956, 148, 11, 1328, 1065, 4, 83, 1, 3, 133, 481, 859, 7, 26, 45, 1902, 17, 8252, 122, 40, 468, 2268, 5, 12546, 56, 2, 1328, 2288, 211, 283, 1044, 18, 3, 2269, 38, 2, 1624, 99, 6665, 3, 291, 1853, 9, 8, 124, 27, 45, 4, 373, 1278, 64, 43, 329, 2523, 89, 28, 506, 335, 60]",1593.0,12393493,153
"Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies.",Pharmacogenetics,Pharmacogenetics,2002-11-01,"Therapy-related acute myeloid leukemia and myelodysplastic syndrome (t-ML) are serious complications that affect some patients after acute lymphoblastic leukemia (ALL) treatment. Genetic polymorphisms in the promoter of CYP3A4 (CYP3A4*1B) and in NAD(P)H:quinone oxidoreductase (NQO1609C-->T substitution) have been associated with the risk of t-ML. A polymorphism in CYP3A5 (CYP3A5*3) affects CYP3A activity and the wild-type allele (CYP3A5*1) is in partial linkage with the CYP3A4*1B allele. We compared the genotype frequencies for the CYP3A5*3, the CYP3A4*1B and the NQO1609C-->T substitution in 224 children with ALL who did not develop t-ML (controls) and in 53 children with ALL who did develop the complication. The allele frequencies differed significantly among whites, blacks and Hispanics (P < 0.001 for CYP3A5*3, P < 0.001 for CYP3A4*1B and P = 0.004 for NQO1609), thus we performed the comparisons between ALL controls and t-ML patients after accounting for race. We found no differences in the CYP3A4*1B allele distribution between ALL controls and t-ML patients in whites (P = 0.339, 6.6% vs. 9.8%), blacks (P = 0.498, 93.8% vs. 87.5%) or Hispanics (P = 0.523, 39.1% vs. 25.0%). The frequencies for the NQO1609C-->T allele did not differ between control and t-ML groups in whites (P = 0.191, 35.0% vs. 44.9%), blacks (P = 0.664, 37.5% vs. 37.5%) or Hispanics (P = 0.447, 65.2% vs. 50.0%). We found no differences between the control and t-ML group in the incidence of homozygous CYP3A5*3 genotypes: 82.0% vs. 85.4% in whites (P = 0.403), 6.5% vs. 12.5% in blacks (P = 0.508), and 69.6% vs. 75.0% in Hispanics (P= 0.663). Our data do not support an association between common CYP3A4, NQO1 or CYP3A5 polymorphisms and the risk of t-ML in children treated for ALL.",Journal Article,6290.0,94.0,Therapy-related acute myeloid and syndrome t-ML are serious complications that affect some patients after acute lymphoblastic ALL treatment Genetic polymorphisms in the promoter of CYP3A4 CYP3A4*1B and in NAD P H quinone oxidoreductase NQO1609C -- T substitution have been associated with the risk of t-ML A polymorphism in CYP3A5 CYP3A5*3 affects CYP3A activity and the wild-type allele CYP3A5*1 is in partial linkage with the CYP3A4*1B allele We compared the genotype frequencies for the CYP3A5*3 the CYP3A4*1B and the NQO1609C -- T substitution in 224 children with ALL who did not develop t-ML controls and in 53 children with ALL who did develop the complication The allele frequencies differed significantly among whites blacks and Hispanics P 0.001 for CYP3A5*3 P 0.001 for CYP3A4*1B and P 0.004 for NQO1609 thus we performed the comparisons between ALL controls and t-ML patients after accounting for race We found no differences in the CYP3A4*1B allele distribution between ALL controls and t-ML patients in whites P 0.339 6.6 vs. 9.8 blacks P 0.498 93.8 vs. 87.5 or Hispanics P 0.523 39.1 vs. 25.0 The frequencies for the NQO1609C -- T allele did not differ between control and t-ML groups in whites P 0.191 35.0 vs. 44.9 blacks P 0.664 37.5 vs. 37.5 or Hispanics P 0.447 65.2 vs. 50.0 We found no differences between the control and t-ML group in the incidence of homozygous CYP3A5*3 genotypes 82.0 vs. 85.4 in whites P 0.403 6.5 vs. 12.5 in blacks P 0.508 and 69.6 vs. 75.0 in Hispanics P= 0.663 Our data do not support an association between common CYP3A4 NQO1 or CYP3A5 polymorphisms and the risk of t-ML in children treated for ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[36, 139, 286, 533, 2, 681, 102, 542, 32, 1762, 521, 17, 1158, 476, 7, 50, 286, 1275, 62, 24, 336, 1203, 4, 3, 973, 1, 6208, 6208, 4693, 2, 4, 11597, 19, 555, 19517, 18836, 37322, 102, 5029, 47, 85, 41, 5, 3, 43, 1, 102, 542, 8, 1907, 4, 10071, 10071, 27, 2561, 12768, 128, 2, 3, 955, 267, 1254, 10071, 14, 16, 4, 450, 4820, 5, 3, 6208, 4693, 1254, 21, 72, 3, 1183, 2722, 9, 3, 10071, 27, 3, 6208, 4693, 2, 3, 37322, 102, 5029, 4, 5908, 541, 5, 62, 54, 205, 44, 690, 102, 542, 535, 2, 4, 699, 541, 5, 62, 54, 205, 690, 3, 1447, 3, 1254, 2722, 2512, 97, 107, 2556, 3544, 2, 3850, 19, 13, 144, 9, 10071, 27, 19, 13, 144, 9, 6208, 4693, 2, 19, 13, 1520, 9, 53231, 631, 21, 173, 3, 2213, 59, 62, 535, 2, 102, 542, 7, 50, 3116, 9, 1047, 21, 204, 77, 362, 4, 3, 6208, 4693, 1254, 1395, 59, 62, 535, 2, 102, 542, 7, 4, 2556, 19, 13, 7881, 49, 49, 105, 83, 66, 3544, 19, 13, 8928, 966, 66, 105, 912, 33, 15, 3850, 19, 13, 10674, 587, 14, 105, 243, 13, 3, 2722, 9, 3, 37322, 102, 1254, 205, 44, 1505, 59, 182, 2, 102, 542, 271, 4, 2556, 19, 13, 6130, 465, 13, 105, 584, 83, 3544, 19, 13, 13025, 567, 33, 105, 567, 33, 15, 3850, 19, 13, 9472, 556, 18, 105, 212, 13, 21, 204, 77, 362, 59, 3, 182, 2, 102, 542, 87, 4, 3, 287, 1, 3189, 10071, 27, 2071, 878, 13, 105, 772, 39, 4, 2556, 19, 13, 10836, 49, 33, 105, 133, 33, 4, 3544, 19, 13, 11598, 2, 790, 49, 105, 481, 13, 4, 3850, 19, 13, 10693, 114, 74, 1022, 44, 538, 35, 248, 59, 186, 6208, 10187, 15, 10071, 1203, 2, 3, 43, 1, 102, 542, 4, 541, 73, 9, 62]",1646.0,12439220,13
A mathematical model of in vivo methotrexate accumulation in acute lymphoblastic leukemia.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2002-09-24,"Methotrexate (MTX) is one of the most widely used drugs for the treatment of childhood acute lymphoblastic leukemia (ALL). Interindividual differences in lymphoblast accumulation of MTX and its active metabolites, methotrexate polyglutamates (MTXPG), may contribute to the effectiveness of treatment among ALL subtypes. To better understand these differences in MTXPG accumulation, we developed a model to characterize the cellular influx and efflux of MTX, formation of MTXPG by the addition of glutamyl residues catalyzed by FPGS (folylpolyglutamate synthetase), and cleavage of glutamyl residues from MTXPG by GGH (gamma-glutamyl hydrolase). The model was fitted to in vivo intracellular MTXPG concentrations measured serially in leukemic blasts from 20 newly diagnosed patients with ALL treated with 24-h intravenous infusions of MTX. The observed median concentrations of total MTXPG at 44 h was higher in B-lineage than in T-cell ALL (1706 vs 518 pmol/10(9) cells, P<0.025), consistent with the higher estimated Vmax for FPGS activity in B-lineage vs T-lineage blasts (414 vs 93 pmol/10(9) cells/h, P<0.008). Simulations based on the model-estimated parameters indicated greater accumulation of MTX, MTXPGs (MTXPG(2-7)) and total MTX (MTXPG(1-7)) with longer MTX infusions and with higher MTX doses, with the highest concentrations in hyperdiploid B-lineage, intermediate in non-hyperdiploid B-lineage, and lowest in T-cell ALL. These differences provide mechanistic and treatment insights for lineage and ploidy differences in MTXPG accumulation in human leukemia cells in vivo.",Clinical Trial,6328.0,34.0,Methotrexate MTX is one of the most widely used drugs for the treatment of childhood acute lymphoblastic ALL Interindividual differences in lymphoblast accumulation of MTX and its active metabolites methotrexate polyglutamates MTXPG may contribute to the effectiveness of treatment among ALL subtypes To better understand these differences in MTXPG accumulation we developed a model to characterize the cellular influx and efflux of MTX formation of MTXPG by the addition of glutamyl residues catalyzed by FPGS folylpolyglutamate synthetase and cleavage of glutamyl residues from MTXPG by GGH gamma-glutamyl hydrolase The model was fitted to in vivo intracellular MTXPG concentrations measured serially in leukemic blasts from 20 newly diagnosed patients with ALL treated with 24-h intravenous infusions of MTX The observed median concentrations of total MTXPG at 44 h was higher in B-lineage than in T-cell ALL 1706 vs 518 pmol/10 9 cells P 0.025 consistent with the higher estimated Vmax for FPGS activity in B-lineage vs T-lineage blasts 414 vs 93 pmol/10 9 cells/h P 0.008 Simulations based on the model-estimated parameters indicated greater accumulation of MTX MTXPGs MTXPG 2-7 and total MTX MTXPG 1-7 with longer MTX infusions and with higher MTX doses with the highest concentrations in hyperdiploid B-lineage intermediate in non-hyperdiploid B-lineage and lowest in T-cell ALL These differences provide mechanistic and treatment insights for lineage and ploidy differences in MTXPG accumulation in human cells in vivo,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 3453, 16, 104, 1, 3, 96, 1792, 95, 600, 9, 3, 24, 1, 864, 286, 1275, 62, 7882, 362, 4, 19414, 1835, 1, 3453, 2, 211, 544, 3406, 2116, 16243, 11572, 68, 1248, 6, 3, 1236, 1, 24, 107, 62, 814, 6, 380, 1640, 46, 362, 4, 11572, 1835, 21, 276, 8, 202, 6, 1507, 3, 763, 11560, 2, 7043, 1, 3453, 1264, 1, 11572, 20, 3, 352, 1, 15867, 6418, 12724, 20, 14140, 30336, 12692, 2, 3155, 1, 15867, 6418, 29, 11572, 20, 10820, 1705, 15867, 18796, 3, 202, 10, 7315, 6, 4, 386, 2087, 11572, 1003, 644, 6754, 4, 2015, 2438, 29, 179, 732, 265, 7, 5, 62, 73, 5, 259, 555, 1262, 3435, 1, 3453, 3, 164, 52, 1003, 1, 181, 11572, 28, 584, 555, 10, 142, 4, 132, 2542, 76, 4, 102, 31, 62, 53232, 105, 10978, 9835, 79, 83, 37, 19, 13, 4067, 925, 5, 3, 142, 661, 33327, 9, 14140, 128, 4, 132, 2542, 105, 102, 2542, 2438, 9469, 105, 966, 9835, 79, 83, 37, 555, 19, 13, 2155, 7490, 90, 23, 3, 202, 661, 1038, 1103, 378, 1835, 1, 3453, 26082, 11572, 18, 67, 2, 181, 3453, 11572, 14, 67, 5, 589, 3453, 3435, 2, 5, 142, 3453, 415, 5, 3, 1076, 1003, 4, 8847, 132, 2542, 919, 4, 220, 8847, 132, 2542, 2, 2101, 4, 102, 31, 62, 46, 362, 377, 2716, 2, 24, 1957, 9, 2542, 2, 9032, 362, 4, 11572, 1835, 4, 171, 37, 4, 386]",1526.0,12439601,222
Acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2002-01-01,"This is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic leukemia (ALL). Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches, prognostic factors, risk stratification, and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies. Furthermore the role of minimal residual disease (MRD) for individual treatment decisions in prospective clinical studies in adult ALL is reviewed. Drs. Ching-Hon Pui and Mary Relling discuss late treatment sequelae in childhood ALL. The relation between the risk of second cancer and treatment schedule, pharmacogenetics, and gene expression profile studies is described. Also pathogenesis, risk factors, and management of other complications such as endocrinopathy, bone demineralization, obesity, and avascular necrosis of bone is reviewed. Dr. Fred Appelbaum addresses long-term results, late sequelae and quality of life in ALL patients after stem cell transplantation. New options for reduction of relapse risk, e.g., by intensified conditioning regimens or donor lymphocyte infusions, for reduction of mortality and new approaches such as nonmyeloablative transplantation in ALL are discussed. Drs. Jacques van Dongen and Tomasz Szczepanski demonstrate the prognostic value of MRD detection via flow cytometry or PCR analysis in childhood ALL. They discuss the relation between MRD results and type of treatment protocol, timing of the follow-up samples, and the applied technique and underline the importance of standardization and quality control. They also review MRD-based risk group definition and clinical consequences.",Journal Article,6594.0,117.0,This is a comprehensive overview on the most recent developments in diagnosis and treatment of acute lymphoblastic ALL Dr. Dieter Hoelzer and colleagues give an overview of current chemotherapy approaches prognostic factors risk stratification and new treatment options such as tyrosine kinase inhibitors and monoclonal antibodies Furthermore the role of minimal residual disease MRD for individual treatment decisions in prospective clinical studies in adult ALL is reviewed Drs Ching-Hon Pui and Mary Relling discuss late treatment sequelae in childhood ALL The relation between the risk of second cancer and treatment schedule pharmacogenetics and gene expression profile studies is described Also pathogenesis risk factors and management of other complications such as endocrinopathy demineralization obesity and avascular necrosis of is reviewed Dr. Fred Appelbaum addresses long-term results late sequelae and quality of life in ALL patients after stem cell transplantation New options for reduction of relapse risk e.g. by intensified conditioning regimens or donor lymphocyte infusions for reduction of mortality and new approaches such as nonmyeloablative transplantation in ALL are discussed Drs Jacques van Dongen and Tomasz Szczepanski demonstrate the prognostic value of MRD detection via flow cytometry or PCR analysis in childhood ALL They discuss the relation between MRD results and type of treatment protocol timing of the follow-up samples and the applied technique and underline the importance of standardization and quality control They also review MRD-based risk group definition and clinical consequences,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26, 16, 8, 949, 2901, 23, 3, 96, 435, 3703, 4, 147, 2, 24, 1, 286, 1275, 62, 3436, 53242, 53243, 2, 6367, 4978, 35, 2901, 1, 291, 56, 611, 177, 130, 43, 1541, 2, 217, 24, 838, 225, 22, 564, 216, 222, 2, 848, 890, 798, 3, 200, 1, 1048, 753, 34, 2029, 9, 797, 24, 1526, 4, 482, 38, 94, 4, 780, 62, 16, 446, 9227, 37328, 43083, 43084, 2, 37329, 43085, 1139, 807, 24, 4156, 4, 864, 62, 3, 2191, 59, 3, 43, 1, 419, 12, 2, 24, 1055, 8759, 2, 145, 55, 800, 94, 16, 1027, 120, 1384, 43, 130, 2, 284, 1, 127, 521, 225, 22, 13011, 43086, 1661, 2, 19455, 1523, 1, 16, 446, 3436, 24542, 53244, 5437, 319, 337, 99, 807, 4156, 2, 372, 1, 358, 4, 62, 7, 50, 452, 31, 497, 217, 838, 9, 628, 1, 429, 43, 563, 499, 20, 7311, 1933, 472, 15, 1488, 1448, 3435, 9, 628, 1, 282, 2, 217, 611, 225, 22, 6094, 497, 4, 62, 32, 1588, 9227, 53245, 19521, 53246, 2, 43087, 53247, 608, 3, 177, 549, 1, 2029, 638, 847, 1412, 1914, 15, 604, 65, 4, 864, 62, 491, 1139, 3, 2191, 59, 2029, 99, 2, 267, 1, 24, 1182, 1972, 1, 3, 166, 126, 347, 2, 3, 1498, 1312, 2, 22051, 3, 1187, 1, 6213, 2, 372, 182, 491, 120, 206, 2029, 90, 43, 87, 2470, 2, 38, 3255]",1627.0,12446423,382
Central nervous system lymphoma.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2002-01-01,"Central nervous system involvement with malignant lymphoma whether primary or secondary is an uncommon but not rare complication observed in the management of patients with hematological malignancy. Its importance lies in the considerable morbidity and mortality with which it is associated and the inadequacy of therapy. In Section I, Dr. Lauren Abrey addresses the totality of the problem of primary central nervous system lymphoma, with emphasis on strategies increasingly dependent on systemic chemotherapy. In Section II, Dr. John Sandlund reviews the success of sequential clinical trials of overall therapy for acute lymphoblastic leukemia in childhood, identifying those patients at high risk of central nervous system leukemia and the development of a rational therapeutic strategy for prevention. In Section III, Dr. Andrew Lister discusses the issue of secondary central nervous system involvement with lymphoma and the indications for prophylaxis.",Journal Article,6594.0,52.0,Central nervous system involvement with malignant whether primary or secondary is an uncommon but not rare complication observed in the management of patients with hematological malignancy Its importance lies in the considerable morbidity and mortality with which it is associated and the inadequacy of therapy In Section I Dr. Lauren Abrey addresses the totality of the problem of primary central nervous system with emphasis on strategies increasingly dependent on systemic chemotherapy In Section II Dr. John Sandlund reviews the success of sequential clinical trials of overall therapy for acute lymphoblastic in childhood identifying those patients at high risk of central nervous system and the development of a rational therapeutic strategy for prevention In Section III Dr. Andrew Lister discusses the issue of secondary central nervous system involvement with and the indications for prophylaxis,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[854, 1880, 398, 799, 5, 393, 317, 86, 15, 568, 16, 35, 2052, 84, 44, 622, 1447, 164, 4, 3, 284, 1, 7, 5, 2890, 710, 211, 1187, 9247, 4, 3, 2658, 787, 2, 282, 5, 92, 192, 16, 41, 2, 3, 24543, 1, 36, 4, 2917, 70, 3436, 16695, 53254, 5437, 3, 26085, 1, 3, 2497, 1, 86, 854, 1880, 398, 5, 3136, 23, 422, 1635, 470, 23, 403, 56, 4, 2917, 215, 3436, 9968, 53255, 2004, 3, 1825, 1, 1787, 38, 143, 1, 63, 36, 9, 286, 1275, 4, 864, 1386, 135, 7, 28, 64, 43, 1, 854, 1880, 398, 2, 3, 193, 1, 8, 2696, 189, 692, 9, 1070, 4, 2917, 316, 3436, 37332, 53256, 2759, 3, 2537, 1, 568, 854, 1880, 398, 799, 5, 2, 3, 2406, 9, 2049]",904.0,12446428,275
Advancing the treatment of hematologic malignancies through the development of targeted interventions.,Seminars in hematology,Semin. Hematol.,2002-10-01,"Significant advances have been made in the development of targeted interventions for hematologic malignancies. Progress has been made in defining the molecular pathogenesis of human leukemias. Data indicate that nonrandom, somatically acquired translocations, inversions, and other abnormalities occur in many acute leukemias. In the treatment of acute promyelocytic leukemia (APL), targeted therapy with all-trans retinoic acid (ATRA) and anthracycline-based chemotherapy leads to dramatic improvements in disease-free survival. Imatinib mesylate, a signal transduction inhibitor that inhibits tyrosine kinase activity, the protein product of the ABL proto-oncogene, has remarkable activity in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL). Farnesyltransferase inhibitors (FTIs), a promising class of agents that target multiple pathways including Ras proteins, are potential anticancer therapy for a wide range of malignancies, including leukemias and myelodysplastic syndromes (MDS). There also is evidence that recombinant human erythropoietin therapy (r-HuEPO) can benefit patients with chronic lymphocytic leukemia (CLL), multiple myeloma, and lymphomas. This supplement will discuss advances in our understanding of human leukemias, including the use of unconjugated monoclonal antibodies such as Campath-1H (Wellcome, Beckenham, UK, and Ilex Oncology, San Antonio, TX) and rituximab and immunoconjugates such as gemtuzumab ozogamicin and BL-22. Although these novel therapies are beginning to fulfill their promise, continued research efforts are needed to determine the optimal role of targeted therapy in acute and chronic leukemias.",Journal Article,6321.0,8.0,Significant advances have been made in the development of targeted interventions for hematologic malignancies Progress has been made in defining the molecular pathogenesis of human leukemias Data indicate that nonrandom somatically acquired translocations inversions and other abnormalities occur in many acute leukemias In the treatment of acute promyelocytic APL targeted therapy with all-trans retinoic acid ATRA and anthracycline-based chemotherapy leads to dramatic improvements in disease-free survival Imatinib mesylate a signal transduction inhibitor that inhibits tyrosine kinase activity the protein product of the ABL proto-oncogene has remarkable activity in patients with chronic myeloid CML and Philadelphia chromosome-positive Ph acute lymphoblastic ALL Farnesyltransferase inhibitors FTIs a promising class of agents that target multiple pathways including Ras proteins are potential anticancer therapy for a wide range of malignancies including leukemias and syndromes MDS There also is evidence that recombinant human erythropoietin therapy r-HuEPO can benefit patients with chronic lymphocytic CLL multiple and lymphomas This supplement will discuss advances in our understanding of human leukemias including the use of unconjugated monoclonal antibodies such as Campath-1H Wellcome Beckenham UK and Ilex Oncology San Antonio TX and rituximab and immunoconjugates such as gemtuzumab ozogamicin and BL-22 Although these novel therapies are beginning to fulfill their promise continued research efforts are needed to determine the optimal role of targeted therapy in acute and chronic leukemias,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[93, 954, 47, 85, 1229, 4, 3, 193, 1, 238, 1151, 9, 813, 441, 1466, 71, 85, 1229, 4, 2847, 3, 219, 1384, 1, 171, 2792, 74, 1008, 17, 12480, 12293, 1294, 3262, 24544, 2, 127, 1171, 1271, 4, 445, 286, 2792, 4, 3, 24, 1, 286, 4300, 2578, 238, 36, 5, 62, 3437, 3887, 971, 2822, 2, 2044, 90, 56, 1940, 6, 3079, 1474, 4, 34, 115, 25, 577, 2347, 8, 1235, 2761, 230, 17, 1576, 564, 216, 128, 3, 178, 2821, 1, 3, 1425, 4976, 1836, 71, 3813, 128, 4, 7, 5, 442, 533, 903, 2, 3006, 1170, 109, 2058, 286, 1275, 62, 7480, 222, 8576, 8, 721, 1040, 1, 183, 17, 283, 232, 460, 141, 1102, 652, 32, 174, 1475, 36, 9, 8, 1019, 184, 1, 441, 141, 2792, 2, 2040, 1223, 125, 120, 16, 241, 17, 2835, 171, 6266, 36, 668, 21090, 122, 247, 7, 5, 442, 1193, 552, 232, 2, 1557, 26, 5836, 303, 1139, 954, 4, 114, 612, 1, 171, 2792, 141, 3, 119, 1, 11116, 848, 890, 225, 22, 16622, 10147, 37335, 43091, 6975, 2, 43092, 413, 6889, 20244, 6614, 2, 855, 2, 15109, 225, 22, 7918, 5566, 2, 6331, 350, 242, 46, 229, 235, 32, 2948, 6, 11246, 136, 1783, 1351, 389, 1413, 32, 575, 6, 223, 3, 665, 200, 1, 238, 36, 4, 286, 2, 442, 2792]",1611.0,12447845,649
A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma.,Blood,Blood,2002-11-27,"Lymphoblastic lymphoma (LBL) is a rare, clinically aggressive neoplasm of the young that frequently involves the bone marrow (BM) and/or central nervous system. Because LBL is similar to acute lymphoblastic leukemia, some centers prefer allogeneic hematopoietic stem cell (SC) transplantation to autologous SC transplantation. We retrospectively analyzed outcomes for patients who underwent autologous (auto, n = 128) or HLA-identical sibling (allo, n = 76) SC transplantations from 1989 to 1998 and were reported to International Bone Marrow Transplant Registry (IBMTR) or Autologous Blood and Marrow Transplant Registry (ABMTR). Allo stem cell transplant (SCT) recipients had higher treatment-related mortality (TRM) at 6 months (18% versus 3%, P =.002), and this disadvantage persisted at 1 and 5 years. Early relapse rates after alloSC transplantation and autoSC transplantation were similar, but significantly lower relapse rates were observed in alloSCT recipients at 1 and 5 years (32% versus 46%, P =.05; and 34% versus 56%, P =.004, respectively). No differences were noted in lymphoma-free survival rates between alloSC transplantations and autoSC transplantations (5-year rates 36% versus 39%, P =.82). AutoSCT recipients had higher overall survival at 6 months (75% versus 59%, P =.01), but survival did not significantly differ between the 2 groups at 1 and 5 years (60% versus 49%, P =.09; 44% versus 39%, P =.47, respectively). Multivariate analyses to account for confounding factors confirmed these results. Independent of SCT type, BM involvement at the time of transplantation and disease status more advanced than first complete remission were associated with inferior outcomes. In summary, alloSC transplantation for LBL is associated with fewer relapses than with autoSC transplantation, but higher TRM offsets any potential survival benefit.",Comparative Study,6264.0,111.0,Lymphoblastic LBL is a rare clinically aggressive neoplasm of the young that frequently involves the marrow BM and/or central nervous system Because LBL is similar to acute lymphoblastic some centers prefer allogeneic hematopoietic stem cell SC transplantation to autologous SC transplantation We retrospectively analyzed outcomes for patients who underwent autologous auto n 128 or HLA-identical sibling allo n 76 SC transplantations from 1989 to 1998 and were reported to International Marrow Transplant Registry IBMTR or Autologous Blood and Marrow Transplant Registry ABMTR Allo stem cell transplant SCT recipients had higher treatment-related mortality TRM at 6 months 18 versus 3 P =.002 and this disadvantage persisted at 1 and 5 years Early relapse rates after alloSC transplantation and autoSC transplantation were similar but significantly lower relapse rates were observed in alloSCT recipients at 1 and 5 years 32 versus 46 P =.05 and 34 versus 56 P =.004 respectively No differences were noted in lymphoma-free survival rates between alloSC transplantations and autoSC transplantations 5-year rates 36 versus 39 P =.82 AutoSCT recipients had higher overall survival at 6 months 75 versus 59 P =.01 but survival did not significantly differ between the 2 groups at 1 and 5 years 60 versus 49 P =.09 44 versus 39 P =.47 respectively Multivariate analyses to account for confounding factors confirmed these results Independent of SCT type BM involvement at the time of transplantation and disease status more advanced than first complete remission were associated with inferior outcomes In summary alloSC transplantation for LBL is associated with fewer relapses than with autoSC transplantation but higher TRM offsets any potential survival benefit,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1275, 8315, 16, 8, 622, 505, 571, 2131, 1, 3, 1169, 17, 746, 2921, 3, 581, 1246, 2, 15, 854, 1880, 398, 408, 8315, 16, 288, 6, 286, 1275, 476, 1168, 11279, 1063, 1007, 452, 31, 2969, 497, 6, 1028, 2969, 497, 21, 894, 311, 123, 9, 7, 54, 208, 1028, 3005, 78, 3990, 15, 1160, 3038, 3684, 2564, 78, 846, 2969, 6779, 29, 3965, 6, 1850, 2, 11, 210, 6, 944, 581, 941, 1608, 30269, 15, 1028, 315, 2, 581, 941, 1608, 53266, 2564, 452, 31, 941, 1988, 2190, 42, 142, 24, 139, 282, 5064, 28, 49, 53, 203, 185, 27, 19, 1111, 2, 26, 14144, 3760, 28, 14, 2, 33, 60, 191, 429, 151, 50, 37336, 497, 2, 37337, 497, 11, 288, 84, 97, 280, 429, 151, 11, 164, 4, 7253, 2190, 28, 14, 2, 33, 60, 531, 185, 641, 19, 474, 2, 562, 185, 664, 19, 1520, 106, 77, 362, 11, 1051, 4, 4763, 115, 25, 151, 59, 37336, 6779, 2, 37337, 6779, 33, 111, 151, 511, 185, 587, 19, 878, 15890, 2190, 42, 142, 63, 25, 28, 49, 53, 481, 185, 728, 19, 355, 84, 25, 205, 44, 97, 1505, 59, 3, 18, 271, 28, 14, 2, 33, 60, 335, 185, 739, 19, 1730, 584, 185, 587, 19, 662, 106, 331, 318, 6, 1967, 9, 4339, 130, 557, 46, 99, 306, 1, 1988, 267, 1246, 799, 28, 3, 98, 1, 497, 2, 34, 156, 80, 131, 76, 157, 236, 734, 11, 41, 5, 1663, 123, 4, 1962, 37336, 497, 9, 8315, 16, 41, 5, 1497, 3713, 76, 5, 37337, 497, 84, 142, 5064, 22055, 500, 174, 25, 247]",1759.0,12456505,770
The cyclin-dependent kinase inhibitor flavopiridol disrupts sodium butyrate-induced p21WAF1/CIP1 expression and maturation while reciprocally potentiating apoptosis in human leukemia cells.,Molecular cancer therapeutics,Mol. Cancer Ther.,2002-02-01,"Interactions between the cyclin-dependent kinase inhibitor flavopiridol (FP) and the histone deacetylase inhibitor sodium butyrate (SB) have been examined in human leukemia cells (U937) in relation to differentiation and apoptosis. Whereas 1 mM of SB or 100 nM of FP minimally induced apoptosis (4% and 10%, respectively) at 24 h, simultaneous exposure of U937 cells to these agents dramatically increased cell death (e.g., approximately 60%), reflected by both morphological and Annexin/propidium iodide-staining features, procaspase 3 activation, and poly(ADP-ribose) polymerase cleavage. Similar interactions were observed in human promyelocytic (HL-60), B-lymphoblastic (Raji), and T-lymphoblastic (Jurkat) leukemia cells. Coadministration of FP opposed SB-mediated accumulation of cells in G0G1 and differentiation, reflected by reduced CD11b expression, but instead dramatically increased procaspase-3, procaspase-8, Bid, and poly(ADP-ribose) polymerase cleavage, as well as mitochondrial damage (e.g., loss of mitochondrial membrane potential and cytochrome c release). FP also blocked SB-related p21WAF1-CIP1 induction through a caspase-independent mechanism and triggered the caspase-mediated cleavage of p27KIP1 and retinoblastoma protein. The latter event was accompanied by a marked reduction in retinoblastoma protein/E2F1 complex formation. However, FP did not modify the extent of SB-associated acetylation of histones H3 and H4. Treatment of cells with FP/SB also resulted in the caspase-mediated cleavage of Bcl-2 and caspase-independent down-regulation of Mcl-1. Levels of cyclins A, D1, and E, and X-linked inhibitor of apoptosis also declined in SB/FP-treated cells. Finally, FP/SB coexposure potently induced apoptosis in two primary acute myelogenous leukemia samples. Together, these findings demonstrate that FP, when combined with SB, induces multiple perturbations in cell cycle and apoptosis regulatory proteins, which oppose leukemic cell differentiation but instead promote mitochondrial damage and apoptosis.",Journal Article,6563.0,68.0,Interactions between the cyclin-dependent kinase inhibitor flavopiridol FP and the histone deacetylase inhibitor sodium butyrate SB have been examined in human cells U937 in relation to differentiation and apoptosis Whereas 1 mM of SB or 100 nM of FP minimally induced apoptosis 4 and 10 respectively at 24 h simultaneous exposure of U937 cells to these agents dramatically increased cell death e.g. approximately 60 reflected by both morphological and Annexin/propidium iodide-staining features procaspase 3 activation and poly ADP-ribose polymerase cleavage Similar interactions were observed in human promyelocytic HL-60 B-lymphoblastic Raji and T-lymphoblastic Jurkat cells Coadministration of FP opposed SB-mediated accumulation of cells in G0G1 and differentiation reflected by reduced CD11b expression but instead dramatically increased procaspase-3 procaspase-8 Bid and poly ADP-ribose polymerase cleavage as well as mitochondrial damage e.g. loss of mitochondrial membrane potential and cytochrome c release FP also blocked SB-related p21WAF1-CIP1 induction through a caspase-independent mechanism and triggered the caspase-mediated cleavage of p27KIP1 and protein The latter event was accompanied by a marked reduction in protein/E2F1 complex formation However FP did not modify the extent of SB-associated acetylation of histones H3 and H4 Treatment of cells with FP/SB also resulted in the caspase-mediated cleavage of Bcl-2 and caspase-independent down-regulation of Mcl-1 Levels of cyclins A D1 and E and X-linked inhibitor of apoptosis also declined in SB/FP-treated cells Finally FP/SB coexposure potently induced apoptosis in two primary acute myelogenous samples Together these findings demonstrate that FP when combined with SB induces multiple perturbations in cell cycle and apoptosis regulatory proteins which oppose leukemic cell differentiation but instead promote mitochondrial damage and apoptosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1286, 59, 3, 1226, 470, 216, 230, 3030, 6434, 2, 3, 1508, 2732, 230, 4682, 12285, 5343, 47, 85, 409, 4, 171, 37, 7000, 4, 2191, 6, 910, 2, 351, 547, 14, 321, 1, 5343, 15, 394, 2878, 1, 6434, 2144, 277, 351, 39, 2, 79, 106, 28, 259, 555, 2824, 645, 1, 7000, 37, 6, 46, 183, 2729, 101, 31, 273, 563, 499, 705, 335, 4686, 20, 110, 4268, 2, 4850, 10839, 8456, 1029, 404, 10153, 27, 363, 2, 2699, 3638, 3507, 1451, 3155, 288, 1286, 11, 164, 4, 171, 4300, 1718, 335, 132, 1275, 9868, 2, 102, 1275, 8433, 37, 5777, 1, 6434, 6101, 5343, 517, 1835, 1, 37, 4, 53278, 2, 910, 4686, 20, 405, 6861, 55, 84, 3496, 2729, 101, 10153, 27, 10153, 66, 2793, 2, 2699, 3638, 3507, 1451, 3155, 22, 149, 22, 2019, 1350, 563, 499, 407, 1, 2019, 1905, 174, 2, 4155, 256, 2008, 6434, 120, 2582, 5343, 139, 18838, 6927, 504, 298, 8, 1469, 306, 670, 2, 4173, 3, 1469, 517, 3155, 1, 11581, 2, 178, 3, 3286, 774, 10, 2756, 20, 8, 2003, 628, 4, 178, 6112, 840, 1264, 137, 6434, 205, 44, 4289, 3, 1039, 1, 5343, 41, 4145, 1, 8457, 3739, 2, 7812, 24, 1, 37, 5, 6434, 5343, 120, 627, 4, 3, 1469, 517, 3155, 1, 1044, 18, 2, 1469, 306, 1328, 863, 1, 1308, 14, 148, 1, 10149, 8, 2146, 2, 563, 2, 1006, 1199, 230, 1, 351, 120, 3054, 4, 5343, 6434, 73, 37, 1368, 6434, 5343, 21094, 4684, 277, 351, 4, 100, 86, 286, 2194, 347, 1162, 46, 272, 608, 17, 6434, 198, 397, 5, 5343, 1516, 232, 7013, 4, 31, 417, 2, 351, 1253, 652, 92, 26089, 2015, 31, 910, 84, 3496, 1617, 2019, 1350, 2, 351]",1923.0,12467221,5
Acute leukemia: a pediatric perspective.,Cancer cell,Cancer Cell,2002-12-01,"The spectrum of hematological malignancies differs markedly between children and adults. Moreover, diseases such as acute lymphoblastic leukemia, acute myeloid leukemia, and myelodysplastic syndrome also demonstrate distinct biologic features and responses to treatment between these populations. In this review, we summarize our current understanding of the molecular pathology of acute leukemia and myelodysplastic syndrome, emphasizing areas in which studies in pediatric patients are providing unique insights into the hematopoietic malignancies of adults.",Comparative Study,6260.0,56.0,The spectrum of hematological malignancies differs markedly between children and adults Moreover diseases such as acute lymphoblastic acute myeloid and syndrome also demonstrate distinct biologic features and responses to treatment between these populations In this review we summarize our current understanding of the molecular pathology of acute and syndrome emphasizing areas in which studies in pediatric patients are providing unique insights into the hematopoietic malignancies of adults,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1873, 1, 2890, 441, 4990, 2195, 59, 541, 2, 857, 1393, 1342, 225, 22, 286, 1275, 286, 533, 2, 681, 120, 608, 834, 1283, 404, 2, 253, 6, 24, 59, 46, 1184, 4, 26, 206, 21, 2479, 114, 291, 612, 1, 3, 219, 1117, 1, 286, 2, 681, 6826, 1361, 4, 92, 94, 4, 815, 7, 32, 1736, 991, 1957, 237, 3, 1007, 441, 1, 857]",493.0,12498712,856
Simple rules underlying gene expression profiles of more than six subtypes of acute lymphoblastic leukemia (ALL) patients.,"Bioinformatics (Oxford, England)",Bioinformatics,2003-01-01,"For classifying gene expression profiles or other types of medical data, simple rules are preferable to non-linear distance or kernel functions. This is because rules may help us understand more about the application in addition to performing an accurate classification. In this paper, we discover novel rules that describe the gene expression profiles of more than six subtypes of acute lymphoblastic leukemia (ALL) patients. We also introduce a new classifier, named PCL, to make effective use of the rules. PCL is accurate and can handle multiple parallel classifications. We evaluate this method by classifying 327 heterogeneous ALL samples. Our test error rate is competitive to that of support vector machines, and it is 71% better than C4.5, 50% better than Naive Bayes, and 43% better than k-nearest neighbour. Experimental results on another independent data sets are also presented to show the strength of our method. Under http://sdmc.lit.org.sg/GEDatasets/, click on Supplementary Information.",Comparative Study,6229.0,88.0,For classifying gene expression profiles or other types of medical data simple rules are preferable to non-linear distance or kernel functions This is because rules may help us understand more about the application in addition to performing an accurate classification In this paper we discover novel rules that describe the gene expression profiles of more than six subtypes of acute lymphoblastic ALL patients We also introduce a new classifier named PCL to make effective use of the rules PCL is accurate and can handle multiple parallel classifications We evaluate this method by classifying 327 heterogeneous ALL samples Our test error rate is competitive to that of support vector machines and it is 71 better than C4.5 50 better than Naive Bayes and 43 better than k-nearest neighbour Experimental results on another independent data sets are also presented to show the strength of our method Under http //sdmc.lit.org.sg/GEDatasets/ click on Supplementary Information,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 8681, 145, 55, 1241, 15, 127, 630, 1, 484, 74, 2763, 8679, 32, 7474, 6, 220, 1646, 3019, 15, 33352, 1681, 26, 16, 408, 8679, 68, 987, 843, 1640, 80, 545, 3, 1581, 4, 352, 6, 3620, 35, 1481, 947, 4, 26, 2817, 21, 6134, 229, 8679, 17, 897, 3, 145, 55, 1241, 1, 80, 76, 437, 814, 1, 286, 1275, 62, 7, 21, 120, 7630, 8, 217, 4951, 8373, 9442, 6, 2378, 323, 119, 1, 3, 8679, 9442, 16, 1481, 2, 122, 17174, 232, 2755, 5787, 21, 376, 26, 596, 20, 8681, 7749, 1564, 62, 347, 114, 412, 3444, 116, 16, 6487, 6, 17, 1, 538, 3374, 18846, 2, 192, 16, 792, 380, 76, 7752, 33, 212, 380, 76, 2462, 16703, 2, 601, 380, 76, 1634, 11252, 43128, 1560, 99, 23, 1809, 306, 74, 2270, 32, 120, 917, 6, 514, 3, 3671, 1, 114, 596, 669, 5196, 53314, 53315, 5598, 7995, 53316, 43129, 23, 14150, 487]",974.0,12499295,140
Granulocyte colony-stimulating factor and the risk of secondary myeloid malignancy after etoposide treatment.,Blood,Blood,2003-01-16,"Event-free survival for children with acute lymphoblastic leukemia (ALL) now exceeds 80% in the most effective trials. Failures are due to relapse, toxicity, and second cancers such as therapy-related myeloid leukemia or myelodysplasia (t-ML). Topoisomerase II inhibitors and alkylators can induce t-ML; additional risk factors for t-ML remain poorly defined. The occurrence of t-ML among children who had received granulocyte colony-stimulating factor (G-CSF) following ALL remission induction therapy prompted us to examine this and other putative risk factors for t-ML in 412 children treated on 2 consecutive ALL protocols from 1991 to 1998. All children received etoposide and anthracyclines, 99 of whom received G-CSF; 284 also received cyclophosphamide, 58 of whom also received cranial irradiation. There were 20 children who developed t-ML at a median of 2.3 years (range, 1.0-6.0 years), including 16 cases of acute myeloid leukemia, 3 myelodysplasia, and 1 chronic myeloid leukemia. Stratifying by protocol, the cumulative incidence functions differed (P =.017) according to the use of G-CSF and irradiation: 6-year cumulative incidence (standard error) of t-ML of 12.3% (5.3%) among the 44 children who received irradiation without G-CSF, 11.0% (3.5%) among the 85 children who received G-CSF but no irradiation, 7.1% (7.2%) among the 14 children who received irradiation plus G-CSF, and 2.7% (1.3%) among the 269 children who received neither irradiation nor G-CSF. Even when children receiving irradiation were excluded, the incidence was still higher in those receiving G-CSF (P =.019). In the setting of intensive antileukemic therapy, short-term use of G-CSF may increase the risk of t-ML.",Clinical Trial,6214.0,122.0,Event-free survival for children with acute lymphoblastic ALL now exceeds 80 in the most effective trials Failures are due to relapse toxicity and second cancers such as therapy-related myeloid or myelodysplasia t-ML Topoisomerase II inhibitors and alkylators can induce t-ML additional risk factors for t-ML remain poorly defined The occurrence of t-ML among children who had received granulocyte colony-stimulating factor G-CSF following ALL remission induction therapy prompted us to examine this and other putative risk factors for t-ML in 412 children treated on 2 consecutive ALL protocols from 1991 to 1998 All children received etoposide and anthracyclines 99 of whom received G-CSF 284 also received cyclophosphamide 58 of whom also received cranial irradiation There were 20 children who developed t-ML at a median of 2.3 years range 1.0-6.0 years including 16 cases of acute myeloid 3 myelodysplasia and 1 chronic myeloid Stratifying by protocol the cumulative incidence functions differed P =.017 according to the use of G-CSF and irradiation 6-year cumulative incidence standard error of t-ML of 12.3 5.3 among the 44 children who received irradiation without G-CSF 11.0 3.5 among the 85 children who received G-CSF but no irradiation 7.1 7.2 among the 14 children who received irradiation plus G-CSF and 2.7 1.3 among the 269 children who received neither irradiation nor G-CSF Even when children receiving irradiation were excluded the incidence was still higher in those receiving G-CSF P =.019 In the setting of intensive antileukemic therapy short-term use of G-CSF may increase the risk of t-ML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[774, 115, 25, 9, 541, 5, 286, 1275, 62, 1134, 9956, 493, 4, 3, 96, 323, 143, 3368, 32, 520, 6, 429, 155, 2, 419, 163, 225, 22, 36, 139, 533, 15, 6128, 102, 542, 3999, 215, 222, 2, 12777, 122, 1290, 102, 542, 402, 43, 130, 9, 102, 542, 918, 1240, 395, 3, 2291, 1, 102, 542, 107, 541, 54, 42, 103, 2764, 1975, 2122, 161, 499, 1211, 366, 62, 734, 504, 36, 4140, 843, 6, 1004, 26, 2, 127, 2743, 43, 130, 9, 102, 542, 4, 9963, 541, 73, 23, 18, 935, 62, 2189, 29, 3372, 6, 1850, 62, 541, 103, 1934, 2, 3597, 1058, 1, 953, 103, 499, 1211, 8843, 120, 103, 1112, 717, 1, 953, 120, 103, 2565, 1104, 125, 11, 179, 541, 54, 276, 102, 542, 28, 8, 52, 1, 18, 27, 60, 184, 14, 13, 49, 13, 60, 141, 245, 140, 1, 286, 533, 27, 6128, 2, 14, 442, 533, 5035, 20, 1182, 3, 967, 287, 1681, 2512, 19, 3825, 768, 6, 3, 119, 1, 499, 1211, 2, 1104, 49, 111, 967, 287, 260, 3444, 1, 102, 542, 1, 133, 27, 33, 27, 107, 3, 584, 541, 54, 103, 1104, 187, 499, 1211, 175, 13, 27, 33, 107, 3, 772, 541, 54, 103, 499, 1211, 84, 77, 1104, 67, 14, 67, 18, 107, 3, 213, 541, 54, 103, 1104, 349, 499, 1211, 2, 18, 67, 14, 27, 107, 3, 8639, 541, 54, 103, 2174, 1104, 2110, 499, 1211, 871, 198, 541, 357, 1104, 11, 1800, 3, 287, 10, 1234, 142, 4, 135, 357, 499, 1211, 19, 4049, 4, 3, 546, 1, 1686, 4512, 36, 978, 337, 119, 1, 499, 1211, 68, 344, 3, 43, 1, 102, 542]",1613.0,12531808,714
"N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).",Leukemia research,Leuk. Res.,2003-03-01,"Retinoids have been shown to regulate vital cellular processes including cell proliferation, differentiation and apoptosis. N-(4-Hydroxyphenyl)-all-trans-retinamide (fenretinide, 4-HPR) is a synthetic ATRA derivative with chemopreventive and cytotoxic activity against various cancer cell lines including myeloid leukemia. Although several modes of action have been postulated, its mechanism of action in hematologic malignancies remains unclear. Furthermore, only limited information exists as to its activity in lymphoid malignancies. To test whether 4-HPR has activity in acute lymphoblastic leukemia (ALL), we first analyzed its antiproliferative effect in five ALL (Z-33, Z-138, Z-119, Z-181, and Jurkat) cell lines. We found that 4-HPR inhibited the proliferation of all cell lines in a dose-dependent manner at concentrations ranging from 1 to 10 microM. We further demonstrated by cell cycle analysis that 5 microM of 4-HPR blocked Z-119 cells in S phase thus preventing their progression through the cycle. Next we tested whether 4-HPR activated the caspase pathway and induced apoptotic cell death. We found that 4-HPR induced apoptosis in Z-119 cells through the activation of caspase-3 and subsequent cleavage of its substrate poly(ADP-ribose) polymerase (PARP). We then asked whether 4-HPR could affect fresh ALL progenitor cells. Therefore, we obtained bone marrow and peripheral blood cells from five patients with newly diagnosed ALL and tested the effect of 4-HPR using the ALL blast colony culture assay. To supplement our results, we also performed the ALL blast assay on one ALL cell line (ALL-1). We found that 4-HPR significantly inhibited ALL colony-forming cell proliferation in a dose-dependent manner. Our data show that 4-HPR is a potent inhibitor of ALL cell proliferation and that it induces in vitro apoptotic cell death in ALL blasts. Further studies are warranted to establish the in vivo effect of 4-HPR particularly in patients with ALL.",Journal Article,6170.0,26.0,Retinoids have been shown to regulate vital cellular processes including cell proliferation differentiation and apoptosis N- 4-Hydroxyphenyl -all-trans-retinamide fenretinide 4-HPR is a synthetic ATRA derivative with chemopreventive and cytotoxic activity against various cancer cell lines including myeloid Although several modes of action have been postulated its mechanism of action in hematologic malignancies remains unclear Furthermore only limited information exists as to its activity in lymphoid malignancies To test whether 4-HPR has activity in acute lymphoblastic ALL we first analyzed its antiproliferative effect in five ALL Z-33 Z-138 Z-119 Z-181 and Jurkat cell lines We found that 4-HPR inhibited the proliferation of all cell lines in a dose-dependent manner at concentrations ranging from 1 to 10 microM We further demonstrated by cell cycle analysis that 5 microM of 4-HPR blocked Z-119 cells in S phase thus preventing their progression through the cycle Next we tested whether 4-HPR activated the caspase pathway and induced apoptotic cell death We found that 4-HPR induced apoptosis in Z-119 cells through the activation of caspase-3 and subsequent cleavage of its substrate poly ADP-ribose polymerase PARP We then asked whether 4-HPR could affect fresh ALL progenitor cells Therefore we obtained marrow and peripheral blood cells from five patients with newly diagnosed ALL and tested the effect of 4-HPR using the ALL blast colony culture assay To supplement our results we also performed the ALL blast assay on one ALL cell line ALL-1 We found that 4-HPR significantly inhibited ALL colony-forming cell proliferation in a dose-dependent manner Our data show that 4-HPR is a potent inhibitor of ALL cell proliferation and that it induces in vitro apoptotic cell death in ALL blasts Further studies are warranted to establish the in vivo effect of 4-HPR particularly in patients with ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7358, 47, 85, 443, 6, 2288, 3511, 763, 1849, 141, 31, 457, 910, 2, 351, 78, 39, 26107, 62, 3437, 28004, 10062, 39, 14154, 16, 8, 3273, 2822, 4819, 5, 4401, 2, 759, 128, 480, 747, 12, 31, 285, 141, 533, 242, 392, 8256, 1, 1578, 47, 85, 6507, 211, 670, 1, 1578, 4, 813, 441, 469, 1200, 798, 158, 383, 487, 2481, 22, 6, 211, 128, 4, 2303, 441, 6, 412, 317, 39, 14154, 71, 128, 4, 286, 1275, 62, 21, 157, 311, 211, 3669, 254, 4, 365, 62, 3905, 466, 3905, 4478, 3905, 4299, 3905, 5540, 2, 8433, 31, 285, 21, 204, 17, 39, 14154, 879, 3, 457, 1, 62, 31, 285, 4, 8, 61, 470, 1708, 28, 1003, 2223, 29, 14, 6, 79, 3550, 21, 195, 264, 20, 31, 417, 65, 17, 33, 3550, 1, 39, 14154, 2582, 3905, 4299, 37, 4, 695, 124, 631, 3017, 136, 91, 298, 3, 417, 1305, 21, 650, 317, 39, 14154, 735, 3, 1469, 308, 2, 277, 1631, 31, 273, 21, 204, 17, 39, 14154, 277, 351, 4, 3905, 4299, 37, 298, 3, 363, 1, 1469, 27, 2, 706, 3155, 1, 211, 4235, 2699, 3638, 3507, 1451, 2041, 21, 818, 3732, 317, 39, 14154, 359, 1158, 4329, 62, 2520, 37, 673, 21, 683, 581, 2, 672, 315, 37, 29, 365, 7, 5, 732, 265, 62, 2, 650, 3, 254, 1, 39, 14154, 75, 3, 62, 3112, 1975, 2099, 719, 6, 5836, 114, 99, 21, 120, 173, 3, 62, 3112, 719, 23, 104, 62, 31, 328, 62, 14, 21, 204, 17, 39, 14154, 97, 879, 62, 1975, 4525, 31, 457, 4, 8, 61, 470, 1708, 114, 74, 514, 17, 39, 14154, 16, 8, 1157, 230, 1, 62, 31, 457, 2, 17, 192, 1516, 4, 439, 1631, 31, 273, 4, 62, 2438, 195, 94, 32, 1197, 6, 1811, 3, 4, 386, 254, 1, 39, 14154, 823, 4, 7, 5, 62]",1911.0,12537979,571
Specific homeodomain-DNA interactions are required for HOX11-mediated transformation.,Blood,Blood,2003-02-13,"HOX11 encodes a homeodomain protein that is aberrantly expressed in T-cell acute lymphoblastic leukemia as a consequence of the t(10;14) and t(7;10) chromosomal translocations. We previously reported that HOX11 immortalizes murine hematopoietic progenitors and induces pre-T-cell tumors in mice after long latency. It has been demonstrated in a number of studies that HOX11, similar to other homeodomain proteins, binds DNA and transactivates transcription. These findings suggest that translocation-activated HOX11 functions as an oncogenic transcription factor. Here we report that HOX11 represses transcription through both TATA-containing and TATA-less promoters. Interestingly, transcriptional repression by HOX11 is independent of its DNA binding capability. Moreover, a systematic mutational analysis indicated that repressor activity was separable from immortalizing function, which requires certain residues within the HOX11 homeodomain that make base-specific or phosphate-backbone contacts with DNA. We further showed that the pathologic action of HOX11 involves DNA binding-dependent transcriptional pathways that are distinct from those controlling expression of a chromosomal target gene (Aldh-1). We conclude that dysregulated expression of a particular set of downstream target genes by DNA binding via the homeodomain is of central importance for leukemia initiation mediated by HOX11.",Journal Article,6186.0,26.0,HOX11 encodes a homeodomain protein that is aberrantly expressed in T-cell acute lymphoblastic as a consequence of the t 10 14 and t 7 10 chromosomal translocations We previously reported that HOX11 immortalizes murine hematopoietic progenitors and induces pre-T-cell tumors in mice after long latency It has been demonstrated in a number of studies that HOX11 similar to other homeodomain proteins binds DNA and transactivates transcription These findings suggest that translocation-activated HOX11 functions as an oncogenic transcription factor Here we report that HOX11 represses transcription through both TATA-containing and TATA-less promoters Interestingly transcriptional repression by HOX11 is independent of its DNA binding capability Moreover a systematic mutational analysis indicated that repressor activity was separable from immortalizing function which requires certain residues within the HOX11 homeodomain that make base-specific or phosphate-backbone contacts with DNA We further showed that the pathologic action of HOX11 involves DNA binding-dependent transcriptional pathways that are distinct from those controlling expression of a chromosomal target gene Aldh-1 We conclude that dysregulated expression of a particular set of downstream target genes by DNA binding via the homeodomain is of central importance for initiation mediated by HOX11,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[18191, 4322, 8, 18140, 178, 17, 16, 5619, 570, 4, 102, 31, 286, 1275, 22, 8, 4177, 1, 3, 102, 79, 213, 2, 102, 67, 79, 1860, 3262, 21, 373, 210, 17, 18191, 53378, 1471, 1007, 4321, 2, 1516, 671, 102, 31, 57, 4, 399, 50, 319, 5301, 192, 71, 85, 264, 4, 8, 207, 1, 94, 17, 18191, 288, 6, 127, 18140, 652, 3333, 261, 2, 20148, 866, 46, 272, 309, 17, 2006, 735, 18191, 1681, 22, 35, 1302, 866, 161, 467, 21, 414, 17, 18191, 10946, 866, 298, 110, 23096, 1101, 2, 23096, 299, 4347, 2873, 1431, 5255, 20, 18191, 16, 306, 1, 211, 261, 791, 6188, 1393, 8, 1556, 1619, 65, 1103, 17, 7434, 128, 10, 26095, 29, 53379, 343, 92, 1706, 1840, 6418, 262, 3, 18191, 18140, 17, 2378, 1782, 112, 15, 4849, 7066, 13291, 5, 261, 21, 195, 224, 17, 3, 510, 1578, 1, 18191, 2921, 261, 791, 470, 1431, 460, 17, 32, 834, 29, 135, 1893, 55, 1, 8, 1860, 283, 145, 6409, 14, 21, 2060, 17, 4288, 55, 1, 8, 1454, 916, 1, 1489, 283, 214, 20, 261, 791, 847, 3, 18140, 16, 1, 854, 1187, 9, 1118, 517, 20, 18191]",1366.0,12586625,75
Characterization of the MLL partner gene AF15q14 involved in t(11;15)(q23;q14).,Oncogene,Oncogene,2003-03-01,"Translocations interrupting the mixed lineage leukemia gene (MLL) occur in 7-10% of acute lymphoblastic leukemia (ALL) and 5-6% of acute myeloid leukemia (AML) cases. One of these translocations, t(11;15)(q23;q14), occurs rarely in both ALL and AML. The gene on chromosome 15, AF15q14, was cloned recently in a patient with AML-M4. We have identified the same gene in a de novo T-ALL patient. However, both the MLL and AF15q14 breakpoints in these patients differed: in the previously reported AML-M4, both gene breaks were within exons, while in our ALL case the MLL break is intronic and the AF15q14 break is exonic. The MLL-AF15q14 fusion described previously shares no AF15q14 residues in common with the chimera reported here. The fusion proteins also differ with respect to MLL--the previously described fusion contains 55 extra amino acids as its MLL break is in exon 11, while the chimera we report breaks in intron 9. Contrary to the originally described normal AF15q14 (5925-bp cDNA encoding a 1833-aa protein), we identify a 7542-bp cDNA and a 2342-aa AF15q14 protein. AF15q14 appears identical to an mRNA previously found to be expressed in melanoma rendered nontumorigenic by microcell-mediated introduction of normal chromosome 6, suggesting the gene may function normally to suppress cell growth and/or enhance maturation.",Comparative Study,6170.0,18.0,Translocations interrupting the mixed lineage gene MLL occur in 7-10 of acute lymphoblastic ALL and 5-6 of acute myeloid AML cases One of these translocations t 11 15 q23 q14 occurs rarely in both ALL and AML The gene on chromosome 15 AF15q14 was cloned recently in a patient with AML-M4 We have identified the same gene in a de novo T-ALL patient However both the MLL and AF15q14 breakpoints in these patients differed in the previously reported AML-M4 both gene breaks were within exons while in our ALL case the MLL break is intronic and the AF15q14 break is exonic The MLL-AF15q14 fusion described previously shares no AF15q14 residues in common with the chimera reported here The fusion proteins also differ with respect to MLL -- the previously described fusion contains 55 extra amino acids as its MLL break is in exon 11 while the chimera we report breaks in intron 9 Contrary to the originally described normal AF15q14 5925-bp cDNA encoding a 1833-aa protein we identify a 7542-bp cDNA and a 2342-aa AF15q14 protein AF15q14 appears identical to an mRNA previously found to be expressed in rendered nontumorigenic by microcell-mediated introduction of normal chromosome 6 suggesting the gene may function normally to suppress cell growth and/or enhance maturation,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3262, 17164, 3, 1739, 2542, 145, 3049, 1271, 4, 67, 79, 1, 286, 1275, 62, 2, 33, 49, 1, 286, 533, 329, 140, 104, 1, 46, 3262, 102, 175, 167, 11423, 18847, 1780, 2416, 4, 110, 62, 2, 329, 3, 145, 23, 1170, 167, 24585, 10, 8560, 761, 4, 8, 69, 5, 329, 11452, 21, 47, 108, 3, 827, 145, 4, 8, 1566, 2018, 102, 62, 69, 137, 110, 3, 3049, 2, 24585, 7843, 4, 46, 7, 2512, 4, 3, 373, 210, 329, 11452, 110, 145, 4492, 11, 262, 3885, 369, 4, 114, 62, 473, 3, 3049, 4338, 16, 7998, 2, 3, 24585, 4338, 16, 13791, 3, 3049, 24585, 1212, 1027, 373, 10641, 77, 24585, 6418, 4, 186, 5, 3, 25992, 210, 467, 3, 1212, 652, 120, 1505, 5, 2184, 6, 3049, 3, 373, 1027, 1212, 4862, 614, 3420, 3078, 4562, 22, 211, 3049, 4338, 16, 4, 1725, 175, 369, 3, 25992, 21, 414, 4492, 4, 6259, 83, 7194, 6, 3, 5045, 1027, 295, 24585, 53398, 3044, 4212, 2362, 8, 33382, 1519, 178, 21, 255, 8, 43174, 3044, 4212, 2, 8, 53399, 1519, 24585, 178, 24585, 1233, 3038, 6, 35, 956, 373, 204, 6, 40, 570, 4, 6021, 17707, 20, 37406, 517, 2456, 1, 295, 1170, 49, 802, 3, 145, 68, 343, 6150, 6, 3134, 31, 129, 2, 15, 1304, 4537]",1271.0,12618768,827
Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification.,Cancer cell,Cancer Cell,2003-02-01,"We recently found that MLL-rearranged acute lymphoblastic leukemias (MLL) have a unique gene expression profile including high level expression of the receptor tyrosine kinase FLT3. We hypothesized that FLT3 might be a therapeutic target in MLL and found that 5 of 30 MLLs contain mutations in the activation loop of FLT3 that result in constitutive activation. Three are a newly described deletion of I836 and the others are D835 mutations. The recently described FLT3 inhibitor PKC412 proved cytotoxic to Ba/F3 cells dependent upon activated FLT3 containing either mutation. PKC412 is also differentially cytotoxic to leukemia cells with MLL translocations and FLT3 that is activated by either overexpression of the wild-type receptor or mutation. Finally, we developed a mouse model of MLL and used bioluminescent imaging to determine that PKC412 is active against MLL in vivo.",Comparative Study,6198.0,314.0,We recently found that MLL-rearranged acute lymphoblastic leukemias MLL have a unique gene expression profile including high level expression of the receptor tyrosine kinase FLT3 We hypothesized that FLT3 might be a therapeutic target in MLL and found that 5 of 30 MLLs contain mutations in the activation loop of FLT3 that result in constitutive activation Three are a newly described deletion of I836 and the others are D835 mutations The recently described FLT3 inhibitor PKC412 proved cytotoxic to Ba/F3 cells dependent upon activated FLT3 containing either mutation PKC412 is also differentially cytotoxic to cells with MLL translocations and FLT3 that is activated by either overexpression of the wild-type receptor or mutation Finally we developed a mouse model of MLL and used bioluminescent imaging to determine that PKC412 is active against MLL in vivo,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 761, 204, 17, 3049, 3201, 286, 1275, 2792, 3049, 47, 8, 991, 145, 55, 800, 141, 64, 301, 55, 1, 3, 153, 564, 216, 1224, 21, 1237, 17, 1224, 822, 40, 8, 189, 283, 4, 3049, 2, 204, 17, 33, 1, 201, 28020, 3725, 138, 4, 3, 363, 4432, 1, 1224, 17, 757, 4, 3178, 363, 169, 32, 8, 732, 1027, 1528, 1, 24587, 2, 3, 1749, 32, 16229, 138, 3, 761, 1027, 1224, 230, 7154, 4328, 759, 6, 6669, 6904, 37, 470, 1548, 735, 1224, 1101, 361, 258, 7154, 16, 120, 2478, 759, 6, 37, 5, 3049, 3262, 2, 1224, 17, 16, 735, 20, 361, 851, 1, 3, 955, 267, 153, 15, 258, 1368, 21, 276, 8, 830, 202, 1, 3049, 2, 95, 12571, 270, 6, 223, 17, 7154, 16, 544, 480, 3049, 4, 386]",862.0,12620411,592
Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine: Cancer and Leukemia Group B Study 9311.,Cancer,Cancer,2003-03-01,"Anti-B4-blocked ricin is an immunotoxin comprised of an anti-CD19 murine monoclonal antibody (B4) conjugated to blocked ricin, which has cytotoxic activity in patients with lymphoid malignancies. Adults with untreated acute lymphoblastic leukemia (ALL) were treated with a previously developed and tested chemotherapeutic regimen. Patients with CD19 positive ALL were given anti-B4-blocked ricin as 2 7-day continuous infusions 1 week apart. Patients with CD19 negative ALL received high-dose cytarabine. Serial polymerase chain reaction (PCR) assays of BCR-ABL, immunoglobulin heavy chain (IGH), and T-cell receptor (TCR) genes were used to measure the impact of lineage specific intensification treatment on minimal residual disease. Eighty-two adults were enrolled, and 78 were eligible. The median age was 34 years (range, 17-81 years). Sixty-six patients (85%) achieved complete remission. Forty-six patients received the anti-B4-blocked ricin, which generally was well tolerated; 80% were able to receive both courses. The most common toxicity was asymptomatic transient elevation of liver function tests in 72% of patients. Lymphopenia occurred in 46% of patients. Two patients developed antibodies to the anti-B4-blocked ricin. Molecular monitoring before and after the experimental course of intensification did not show a consistent change in the number of leukemia cells remaining, and the immediate posttreatment PCR studies did not correlate with remission duration. Intensification therapy with anti-B4-blocked ricin is feasible for patients with CD19 positive ALL, although there is little evidence of an additional clinical benefit from the anti-B4-blocked ricin. Cancer 2003;97:1471-80.",Clinical Trial,6170.0,43.0,Anti-B4-blocked ricin is an immunotoxin comprised of an anti-CD19 murine monoclonal antibody B4 conjugated to blocked ricin which has cytotoxic activity in patients with lymphoid malignancies Adults with untreated acute lymphoblastic ALL were treated with a previously developed and tested chemotherapeutic regimen Patients with CD19 positive ALL were given anti-B4-blocked ricin as 2 7-day continuous infusions 1 week apart Patients with CD19 negative ALL received high-dose cytarabine Serial polymerase chain reaction PCR assays of BCR-ABL immunoglobulin heavy chain IGH and T-cell receptor TCR genes were used to measure the impact of lineage specific intensification treatment on minimal residual disease Eighty-two adults were enrolled and 78 were eligible The median age was 34 years range 17-81 years Sixty-six patients 85 achieved complete remission Forty-six patients received the anti-B4-blocked ricin which generally was well tolerated 80 were able to receive both courses The most common toxicity was asymptomatic transient elevation of function tests in 72 of patients Lymphopenia occurred in 46 of patients Two patients developed antibodies to the anti-B4-blocked ricin Molecular monitoring before and after the experimental course of intensification did not show a consistent change in the number of cells remaining and the immediate posttreatment PCR studies did not correlate with remission duration Intensification therapy with anti-B4-blocked ricin is feasible for patients with CD19 positive ALL although there is little evidence of an additional clinical benefit from the anti-B4-blocked ricin Cancer 2003 97:1471-80,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[312, 14476, 2582, 18255, 16, 35, 14464, 2603, 1, 35, 312, 3158, 1471, 848, 548, 14476, 3868, 6, 2582, 18255, 92, 71, 759, 128, 4, 7, 5, 2303, 441, 857, 5, 1278, 286, 1275, 62, 11, 73, 5, 8, 373, 276, 2, 650, 1573, 477, 7, 5, 3158, 109, 62, 11, 447, 312, 14476, 2582, 18255, 22, 18, 67, 218, 1314, 3435, 14, 647, 5461, 7, 5, 3158, 199, 62, 103, 64, 61, 1855, 2108, 1451, 1260, 1329, 604, 1013, 1, 1062, 1425, 2593, 4013, 1260, 5221, 2, 102, 31, 153, 4134, 214, 11, 95, 6, 1463, 3, 345, 1, 2542, 112, 5091, 24, 23, 1048, 753, 34, 2207, 100, 857, 11, 346, 2, 833, 11, 625, 3, 52, 89, 10, 562, 60, 184, 269, 865, 60, 1746, 437, 7, 772, 513, 236, 734, 1213, 437, 7, 103, 3, 312, 14476, 2582, 18255, 92, 1228, 10, 149, 421, 493, 11, 1665, 6, 560, 110, 1993, 3, 96, 186, 155, 10, 2100, 2473, 3292, 1, 343, 895, 4, 720, 1, 7, 3655, 489, 4, 641, 1, 7, 100, 7, 276, 890, 6, 3, 312, 14476, 2582, 18255, 219, 1315, 348, 2, 50, 3, 1560, 906, 1, 5091, 205, 44, 514, 8, 925, 707, 4, 3, 207, 1, 37, 1844, 2, 3, 2181, 3149, 604, 94, 205, 44, 1513, 5, 734, 654, 5091, 36, 5, 312, 14476, 2582, 18255, 16, 1313, 9, 7, 5, 3158, 109, 62, 242, 125, 16, 1215, 241, 1, 35, 402, 38, 247, 29, 3, 312, 14476, 2582, 18255, 12, 1522, 1015, 43184, 493]",1637.0,12627512,442
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation.,Blood,Blood,2003-03-13,"Rearrangements of the MLL locus, located on human chromosome 11q23, are frequent in both infant and therapy-related leukemias. Gene expression analysis of MLL-rearranged B-precursor acute lymphoblastic leukemias (MLL B-ALLs) has identified these cases as a unique subtype of leukemia, characterized by the expression of genes associated with both lymphoid and myeloid hematopoietic lineages. Here we show that MLL fusions also generate a distinct genetic subtype of T-lineage ALL (MLL T-ALL), in which leukemic cells are characterized by an early arrest in thymocyte differentiation, with suggestive evidence of commitment to the gammadelta lineage. Interestingly, multiple genes linked to cell proliferation (eg, PCNA, MYC, CDK2, and POLA) were down-regulated in MLL-fusion samples, relative to those transformed by other T-ALL oncogenes (P <.000 001, Fisher exact test). Overall, MLL T-ALL cases consistently demonstrated increased levels of expression of a subset of major HOX genes--HOXA9, HOXA10, and HOXC6--and the MEIS1 HOX coregulator (P <.008, one-sided Wilcoxon test), a pattern of gene expression that was reiterated in MLL B-ALLs. However, expression of myeloid lineage genes, previously reported in MLL B-ALLs, was not identified in T-lineage cases with this abnormality, suggesting that myeloid gene dysregulation is dispensable in leukemic transformation mediated by MLL fusion proteins. Our findings implicate dysregulation of HOX gene family members as a dominant mechanism of leukemic transformation induced by chimeric MLL oncogenes.",Journal Article,6158.0,235.0,Rearrangements of the MLL locus located on human chromosome 11q23 are frequent in both infant and therapy-related leukemias Gene expression analysis of MLL-rearranged B-precursor acute lymphoblastic leukemias MLL B-ALLs has identified these cases as a unique subtype of characterized by the expression of genes associated with both lymphoid and myeloid hematopoietic lineages Here we show that MLL fusions also generate a distinct genetic subtype of T-lineage ALL MLL T-ALL in which leukemic cells are characterized by an early arrest in thymocyte differentiation with suggestive evidence of commitment to the gammadelta lineage Interestingly multiple genes linked to cell proliferation eg PCNA MYC CDK2 and POLA were down-regulated in MLL-fusion samples relative to those transformed by other T-ALL oncogenes P .000 001 Fisher exact test Overall MLL T-ALL cases consistently demonstrated increased levels of expression of a subset of major HOX genes -- HOXA9 HOXA10 and HOXC6 -- and the MEIS1 HOX coregulator P .008 one-sided Wilcoxon test a pattern of gene expression that was reiterated in MLL B-ALLs However expression of myeloid lineage genes previously reported in MLL B-ALLs was not identified in T-lineage cases with this abnormality suggesting that myeloid gene dysregulation is dispensable in leukemic transformation mediated by MLL fusion proteins Our findings implicate dysregulation of HOX gene family members as a dominant mechanism of leukemic transformation induced by chimeric MLL oncogenes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2072, 1, 3, 3049, 2474, 2308, 23, 171, 1170, 7975, 32, 908, 4, 110, 8027, 2, 36, 139, 2792, 145, 55, 65, 1, 3049, 3201, 132, 2765, 286, 1275, 2792, 3049, 132, 10706, 71, 108, 46, 140, 22, 8, 991, 875, 1, 765, 20, 3, 55, 1, 214, 41, 5, 110, 2303, 2, 533, 1007, 7234, 467, 21, 514, 17, 3049, 2530, 120, 2562, 8, 834, 336, 875, 1, 102, 2542, 62, 3049, 102, 62, 4, 92, 2015, 37, 32, 765, 20, 35, 191, 1854, 4, 16236, 910, 5, 3832, 241, 1, 11082, 6, 3, 43192, 2542, 2873, 232, 214, 1199, 6, 31, 457, 2887, 8220, 1371, 4547, 2, 53426, 11, 1328, 1065, 4, 3049, 1212, 347, 580, 6, 135, 2423, 20, 127, 102, 62, 3326, 19, 984, 144, 3135, 2472, 412, 63, 3049, 102, 62, 140, 2433, 264, 101, 148, 1, 55, 1, 8, 697, 1, 458, 14722, 214, 11453, 19553, 2, 37413, 2, 3, 18256, 14722, 30380, 19, 2155, 104, 1689, 3896, 412, 8, 1177, 1, 145, 55, 17, 10, 30381, 4, 3049, 132, 10706, 137, 55, 1, 533, 2542, 214, 373, 210, 4, 3049, 132, 10706, 10, 44, 108, 4, 102, 2542, 140, 5, 26, 3698, 802, 17, 533, 145, 3935, 16, 15142, 4, 2015, 1392, 517, 20, 3049, 1212, 652, 114, 272, 5545, 3935, 1, 14722, 145, 607, 1684, 22, 8, 2156, 670, 1, 2015, 1392, 277, 20, 2897, 3049, 3326]",1507.0,12637319,36
Biphenotypic acute leukemia with coexpression of CD79a and markers of myeloid lineage.,Archives of pathology & laboratory medicine,Arch. Pathol. Lab. Med.,2003-03-01,"Acute leukemias demonstrating immunophenotypic features of more than 1 cell lineage are referred to as acute leukemias of ambiguous lineage in the new World Health Organization classification system. A subtype of leukemia of ambiguous lineage is biphenotypic acute leukemia in which the malignant cell population expresses markers of 2 different lineages, most commonly myeloid and either B- or T-lymphoid lineages. This entity has been defined by a scoring system proposed by the European Group for the Immunological Characterization of Acute Leukemias (EGIL), with various markers assigned a score of 2, 1, or 0.5 depending on their specificity for myeloid or lymphoid lineage. Those cases having a score greater than 2 for the myeloid and either the B- or T-lymphoid lineages are biphenotypic acute leukemia in this system. One marker, CD79a, has been so clearly associated with acute lymphoblastic leukemia (ALL) by some researchers that its expression in the presence of blast markers is considered indicative of B-ALL. We describe an unusual case of acute leukemia meeting the criteria for biphenotypic acute leukemia in which CD79a expression was observed in the blast population.",Case Reports,6170.0,13.0,Acute leukemias demonstrating immunophenotypic features of more than 1 cell lineage are referred to as acute leukemias of ambiguous lineage in the new World Health Organization classification system A subtype of of ambiguous lineage is biphenotypic acute in which the malignant cell population expresses markers of 2 different lineages most commonly myeloid and either B- or T-lymphoid lineages This entity has been defined by a scoring system proposed by the European Group for the Immunological Characterization of Acute Leukemias EGIL with various markers assigned a score of 2 1 or 0.5 depending on their specificity for myeloid or lymphoid lineage Those cases having a score greater than 2 for the myeloid and either the B- or T-lymphoid lineages are biphenotypic acute in this system One marker CD79a has been so clearly associated with acute lymphoblastic ALL by some researchers that its expression in the presence of blast markers is considered indicative of B-ALL We describe an unusual case of acute meeting the criteria for biphenotypic acute in which CD79a expression was observed in the blast population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 2792, 2219, 6599, 404, 1, 80, 76, 14, 31, 2542, 32, 1995, 6, 22, 286, 2792, 1, 11286, 2542, 4, 3, 217, 1956, 341, 2533, 947, 398, 8, 875, 1, 1, 11286, 2542, 16, 20205, 286, 4, 92, 3, 393, 31, 266, 8293, 525, 1, 18, 338, 7234, 96, 841, 533, 2, 361, 132, 15, 102, 2303, 7234, 26, 2983, 71, 85, 395, 20, 8, 2504, 398, 1587, 20, 3, 1865, 87, 9, 3, 5073, 2136, 1, 286, 2792, 26135, 5, 747, 525, 896, 8, 368, 1, 18, 14, 15, 13, 33, 3221, 23, 136, 1121, 9, 533, 15, 2303, 2542, 135, 140, 1041, 8, 368, 378, 76, 18, 9, 3, 533, 2, 361, 3, 132, 15, 102, 2303, 7234, 32, 20205, 286, 4, 26, 398, 104, 952, 26047, 71, 85, 1743, 2536, 41, 5, 286, 1275, 62, 20, 476, 4211, 17, 211, 55, 4, 3, 463, 1, 3112, 525, 16, 515, 5572, 1, 132, 62, 21, 897, 35, 4015, 473, 1, 286, 2238, 3, 371, 9, 20205, 286, 4, 92, 26047, 55, 10, 164, 4, 3, 3112, 266]",1117.0,12653584,13
Pharmacokinetics and pharmacodynamics of oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-04-01,"To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic leukemia (ALL). Fifty-eight patients were randomly assigned to etoposide at 50 mg/m(2)/d with once- versus twice-daily doses for 22 days. On day 8, vincristine, asparaginase, and dexamethasone were started. Etoposide pharmacokinetics and pharmacodynamics were studied for 47, 28, and 26 patients on day 1, 8, and 22, respectively, of remission reinduction therapy. Of 48 patients with pharmacokinetic data, 42 (87.5%) achieved complete remission, three (6.3%) failed to achieve remission, and three (6.3%) died during induction. Median etoposide day 8 area under concentration-time curve (AUC) and cumulative AUC tended to be greater (P =.06 and P =.07, respectively) in patients (n = 23) who achieved complete remission (24 and 522 micro mol/L x h, respectively) than in patients (n = 3) who did not (14 and 303 micro mol/L x h, respectively). Three of eight patients with plasma concentrations exceeding 1.7 micro M (1 micro g/mL) for more than 8 hours daily, compared with one of 20 patients with concentrations exceeding 1.7 micro M for <or= 8 hours daily, were unable to receive all 22 days of etoposide because of toxicity. There was no difference in the AUC at day 1 or day 8 with once- versus twice-daily doses (P =.55 and P =.86, respectively). A pharmacodynamic relationship exists between systemic etoposide exposure and response to therapy when oral etoposide is used as part of remission induction regimens for relapsed or refractory childhood ALL.",Clinical Trial,6139.0,26.0,To study the pharmacokinetics and pharmacodynamics of once- versus twice-daily oral etoposide in children with relapsed or refractory acute lymphoblastic ALL Fifty-eight patients were randomly assigned to etoposide at 50 mg/m 2 /d with once- versus twice-daily doses for 22 days On day 8 vincristine asparaginase and dexamethasone were started Etoposide pharmacokinetics and pharmacodynamics were studied for 47 28 and 26 patients on day 1 8 and 22 respectively of remission reinduction therapy Of 48 patients with pharmacokinetic data 42 87.5 achieved complete remission three 6.3 failed to achieve remission and three 6.3 died during induction Median etoposide day 8 area under concentration-time curve AUC and cumulative AUC tended to be greater P =.06 and P =.07 respectively in patients n 23 who achieved complete remission 24 and 522 micro mol/L x h respectively than in patients n 3 who did not 14 and 303 micro mol/L x h respectively Three of eight patients with plasma concentrations exceeding 1.7 micro M 1 micro g/mL for more than 8 hours daily compared with one of 20 patients with concentrations exceeding 1.7 micro M for or= 8 hours daily were unable to receive all 22 days of etoposide because of toxicity There was no difference in the AUC at day 1 or day 8 with once- versus twice-daily doses P =.55 and P =.86 respectively A pharmacodynamic relationship exists between systemic etoposide exposure and response to therapy when oral etoposide is used as part of remission induction regimens for relapsed or refractory childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 45, 3, 1159, 2, 3587, 1, 1059, 185, 936, 391, 518, 1934, 4, 541, 5, 591, 15, 430, 286, 1275, 62, 1461, 659, 7, 11, 1108, 896, 6, 1934, 28, 212, 81, 188, 18, 427, 5, 1059, 185, 936, 391, 415, 9, 350, 162, 23, 218, 66, 2132, 3709, 2, 1217, 11, 3461, 1934, 1159, 2, 3587, 11, 656, 9, 662, 339, 2, 432, 7, 23, 218, 14, 66, 2, 350, 106, 1, 734, 10177, 36, 1, 576, 7, 5, 1456, 74, 595, 912, 33, 513, 236, 734, 169, 49, 27, 1551, 6, 1359, 734, 2, 169, 49, 27, 1016, 190, 504, 52, 1934, 218, 66, 965, 669, 1227, 98, 1496, 1376, 2, 967, 1376, 3886, 6, 40, 378, 19, 1460, 2, 19, 1615, 106, 4, 7, 78, 382, 54, 513, 236, 734, 259, 2, 9741, 4659, 5824, 805, 1006, 555, 106, 76, 4, 7, 78, 27, 54, 205, 44, 213, 2, 9044, 4659, 5824, 805, 1006, 555, 106, 169, 1, 659, 7, 5, 554, 1003, 5178, 14, 67, 4659, 188, 14, 4659, 499, 542, 9, 80, 76, 66, 1459, 391, 72, 5, 104, 1, 179, 7, 5, 1003, 5178, 14, 67, 4659, 188, 9, 15, 66, 1459, 391, 11, 4253, 6, 560, 62, 350, 162, 1, 1934, 408, 1, 155, 125, 10, 77, 523, 4, 3, 1376, 28, 218, 14, 15, 218, 66, 5, 1059, 185, 936, 391, 415, 19, 614, 2, 19, 868, 106, 8, 2424, 858, 2481, 59, 403, 1934, 645, 2, 51, 6, 36, 198, 518, 1934, 16, 95, 22, 760, 1, 734, 504, 472, 9, 591, 15, 430, 864, 62]",1547.0,12663724,353
Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-04-01,"To determine whether adult survivors (>or= 18 years of age) of childhood acute lymphoblastic leukemia (ALL) are at increased risk for obesity and to assess patient and treatment variables that influence risk. A retrospective cohort of participants of the Childhood Cancer Survivor Study was used to compare 1,765 adult survivors of childhood ALL to 2,565 adult siblings of childhood cancer survivors. Body-mass index (BMI; kilograms per square meter), calculated from self-reported heights and weights, was used to determine the prevalence of being overweight (BMI, 25-29.9) or obese (BMI >or= 30.0). Polytomous logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for being overweight or obese among ALL survivors relative to the sibling control group. The age- and race-adjusted OR for being obese in survivors treated with cranial radiation doses >or= 20 Gy in comparison with siblings was 2.59 for females (95% CI, 1.88 to 3.55; P <.001) and 1.86 for males (95% CI, 1.33 to 2.57; P <.001). The OR for obesity was greatest among females diagnosed at 0 to 4 years of age and treated with radiation doses >or= 20 Gy (OR, 3.81; 95% CI, 2.34 to 5.99; P <.001). Obesity was not associated with treatment consisting of chemotherapy only or with cranial radiation doses of 10 to 19 Gy. Cranial radiotherapy >or= 20 Gy is associated with an increased prevalence of obesity, especially in females treated at a young age. It is imperative that healthcare professionals recognize this risk and develop strategies to enhance weight control and encourage longitudinal follow-up.",Journal Article,6139.0,321.0,"To determine whether adult survivors or= 18 years of age of childhood acute lymphoblastic ALL are at increased risk for obesity and to assess patient and treatment variables that influence risk A retrospective cohort of participants of the Childhood Cancer Survivor Study was used to compare 1,765 adult survivors of childhood ALL to 2,565 adult siblings of childhood cancer survivors Body-mass index BMI kilograms per square meter calculated from self-reported heights and weights was used to determine the prevalence of being overweight BMI 25-29.9 or obese BMI or= 30.0 Polytomous logistic regression was used to estimate odds ratios ORs and 95 confidence intervals CIs for being overweight or obese among ALL survivors relative to the sibling control group The age- and race-adjusted OR for being obese in survivors treated with cranial radiation doses or= 20 Gy in comparison with siblings was 2.59 for females 95 CI 1.88 to 3.55 P .001 and 1.86 for males 95 CI 1.33 to 2.57 P .001 The OR for obesity was greatest among females diagnosed at 0 to 4 years of age and treated with radiation doses or= 20 Gy OR 3.81 95 CI 2.34 to 5.99 P .001 Obesity was not associated with treatment consisting of chemotherapy only or with cranial radiation doses of 10 to 19 Gy Cranial radiotherapy or= 20 Gy is associated with an increased prevalence of obesity especially in females treated at a young age It is imperative that healthcare professionals recognize this risk and develop strategies to enhance weight control and encourage longitudinal follow-up",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 317, 780, 332, 15, 203, 60, 1, 89, 1, 864, 286, 1275, 62, 32, 28, 101, 43, 9, 1661, 2, 6, 423, 69, 2, 24, 682, 17, 1054, 43, 8, 459, 180, 1, 776, 1, 3, 864, 12, 2628, 45, 10, 95, 6, 932, 14, 12263, 780, 332, 1, 864, 62, 6, 18, 10852, 780, 2758, 1, 864, 12, 332, 642, 782, 558, 1140, 18871, 379, 3219, 8591, 981, 29, 1074, 210, 23162, 2, 7966, 10, 95, 6, 223, 3, 1078, 1, 486, 3566, 1140, 243, 462, 83, 15, 2209, 1140, 15, 201, 13, 13540, 812, 320, 10, 95, 6, 1191, 610, 1137, 3694, 2, 48, 307, 1582, 1927, 9, 486, 3566, 15, 2209, 107, 62, 332, 580, 6, 3, 3684, 182, 87, 3, 89, 2, 1047, 586, 15, 9, 486, 2209, 4, 332, 73, 5, 2565, 121, 415, 15, 179, 381, 4, 1155, 5, 2758, 10, 18, 728, 9, 2451, 48, 58, 14, 889, 6, 27, 614, 19, 144, 2, 14, 868, 9, 2296, 48, 58, 14, 466, 6, 18, 696, 19, 144, 3, 15, 9, 1661, 10, 2199, 107, 2451, 265, 28, 13, 6, 39, 60, 1, 89, 2, 73, 5, 121, 415, 15, 179, 381, 15, 27, 865, 48, 58, 18, 562, 6, 33, 1058, 19, 144, 1661, 10, 44, 41, 5, 24, 2273, 1, 56, 158, 15, 5, 2565, 121, 415, 1, 79, 6, 326, 381, 2565, 310, 15, 179, 381, 16, 41, 5, 35, 101, 1078, 1, 1661, 1093, 4, 2451, 73, 28, 8, 1169, 89, 192, 16, 6305, 17, 2819, 3409, 4237, 26, 43, 2, 690, 422, 6, 1304, 924, 182, 2, 7113, 2380, 166, 126]",1546.0,12663727,150
Recombinant urate oxidase for prevention of hyperuricemia and tumor lysis syndrome in lymphoid malignancies.,Clinical lymphoma,Clin Lymphoma,2003-03-01,"Hyperuricemia is a common manifestation of lymphoid malignancies at diagnosis or after the start of chemotherapy. When accompanied by other metabolic abnormalities and/or organ failure, hyperuricemia may be a manifestation of tumor lysis syndrome (TLS). Patients at particularly high risk of such complications include those with acute lymphoblastic leukemia and advanced stage non-Hodgkin's lymphoma. Conventional measures to prevent hyperuricemia and TLS are comprised of hydration, alkalinization of body fluids, and administration of allopurinol. Although these measures are usually effective in preventing or managing hyperuricemia, approximately 20% of patients at high risk of TLS require dialysis, and many cannot receive chemotherapy as planned. Rasburicase, a recombinant form of the enzyme urate oxidase, has recently become available and may further reduce the morbidity of hyperuricemia and TLS. In this review, we provide an overview of hyperuricemia and TLS and discuss the impact of rasburicase in the overall management of these complications.",Journal Article,6170.0,30.0,Hyperuricemia is a common manifestation of lymphoid malignancies at diagnosis or after the start of chemotherapy When accompanied by other metabolic abnormalities and/or organ failure hyperuricemia may be a manifestation of tumor lysis syndrome TLS Patients at particularly high risk of such complications include those with acute lymphoblastic and advanced stage 's Conventional measures to prevent hyperuricemia and TLS are comprised of hydration alkalinization of body fluids and administration of allopurinol Although these measures are usually effective in preventing or managing hyperuricemia approximately 20 of patients at high risk of TLS require dialysis and many can not receive chemotherapy as planned Rasburicase a recombinant form of the enzyme urate oxidase has recently become available and may further reduce the morbidity of hyperuricemia and TLS In this review we provide an overview of hyperuricemia and TLS and discuss the impact of rasburicase in the overall management of these complications,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[14780, 16, 8, 186, 6746, 1, 2303, 441, 28, 147, 15, 50, 3, 2435, 1, 56, 198, 2756, 20, 127, 1436, 1171, 2, 15, 1259, 496, 14780, 68, 40, 8, 6746, 1, 30, 4783, 681, 8778, 7, 28, 823, 64, 43, 1, 225, 521, 643, 135, 5, 286, 1275, 2, 131, 82, 292, 809, 1018, 6, 1682, 14780, 2, 8778, 32, 2603, 1, 8517, 43215, 1, 642, 9332, 2, 634, 1, 22090, 242, 46, 1018, 32, 2082, 323, 4, 3017, 15, 3969, 14780, 705, 179, 1, 7, 28, 64, 43, 1, 8778, 1353, 7988, 2, 445, 122, 44, 560, 56, 22, 1465, 14480, 8, 2835, 1297, 1, 3, 1644, 20281, 10447, 71, 761, 1417, 390, 2, 68, 195, 969, 3, 787, 1, 14780, 2, 8778, 4, 26, 206, 21, 377, 35, 2901, 1, 14780, 2, 8778, 2, 1139, 3, 345, 1, 14480, 4, 3, 63, 284, 1, 46, 521]",1014.0,12672271,39
Vincristine-induced neuropathy as the initial presentation of charcot-marie-tooth disease in acute lymphoblastic leukemia: a Pediatric Oncology Group study.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2003-04-01,"After profound peripheral neurotoxicity during induction chemotherapy for acute lymphoblastic leukemia (ALL) in the index patient with Charcot-Marie-Tooth hereditary neuropathy (CMT), study coordinators of the Pediatric Oncology Group (POG) front-line ALL protocols reviewed patient registrations to identify any other patients with possible CMT. The goal was to provide preliminary information about patients with undiagnosed CMT who develop ALL. Five children with ALL who were enrolled in POG B-precursor or T-cell ALL protocols from 1994 to 1999 subsequently were determined to have CMT hereditary neuropathy. Their clinical presentations and treatment records were reviewed in detail. Records of all patients entered on POG 9201 (lesser-risk ALL) were reviewed to identify all cases of significant vincristine toxicity noted in the first 6 months of treatment. The five identified patients all had substantial peripheral neurotoxicity that required alteration in treatment and/or orthopedic/physical therapy evaluation and follow-up. The POG 9201 review identified 25 of 686 patients (3.6%) with significant peripheral neuropathy. Three of 25 were diagnosed with CMT; the others have had no testing reported. A family history of CMT or other peripheral neuropathy should be sought at the time of diagnosis of ALL. Testing for CMT should be considered in any child with substantial vincristine-induced peripheral neurotoxicity. Treatment of such patients must be individualized. Testing of all patients with significant peripheral neuropathy would be necessary to determine the percentage of such neuropathy explained by underlying CMT.",Case Reports,6139.0,88.0,After profound peripheral neurotoxicity during induction chemotherapy for acute lymphoblastic ALL in the index patient with Charcot-Marie-Tooth hereditary neuropathy CMT study coordinators of the Pediatric Oncology Group POG front-line ALL protocols reviewed patient registrations to identify any other patients with possible CMT The goal was to provide preliminary information about patients with undiagnosed CMT who develop ALL Five children with ALL who were enrolled in POG B-precursor or T-cell ALL protocols from 1994 to 1999 subsequently were determined to have CMT hereditary neuropathy Their clinical presentations and treatment records were reviewed in detail Records of all patients entered on POG 9201 lesser-risk ALL were reviewed to identify all cases of significant vincristine toxicity noted in the first 6 months of treatment The five identified patients all had substantial peripheral neurotoxicity that required alteration in treatment and/or orthopedic/physical therapy evaluation and follow-up The POG 9201 review identified 25 of 686 patients 3.6 with significant peripheral neuropathy Three of 25 were diagnosed with CMT the others have had no testing reported A family history of CMT or other peripheral neuropathy should be sought at the time of diagnosis of ALL Testing for CMT should be considered in any child with substantial vincristine-induced peripheral neurotoxicity Treatment of such patients must be individualized Testing of all patients with significant peripheral neuropathy would be necessary to determine the percentage of such neuropathy explained by underlying CMT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[50, 4399, 672, 3561, 190, 504, 56, 9, 286, 1275, 62, 4, 3, 558, 69, 5, 33409, 23208, 14813, 2305, 1751, 5380, 45, 33410, 1, 3, 815, 413, 87, 17150, 3007, 328, 62, 2189, 446, 69, 17723, 6, 255, 500, 127, 7, 5, 899, 5380, 3, 1326, 10, 6, 377, 1676, 487, 545, 7, 5, 11615, 5380, 54, 690, 62, 365, 541, 5, 62, 54, 11, 346, 4, 17150, 132, 2765, 15, 102, 31, 62, 2189, 29, 3023, 6, 2043, 1611, 11, 509, 6, 47, 5380, 2305, 1751, 136, 38, 4261, 2, 24, 1064, 11, 446, 4, 5000, 1064, 1, 62, 7, 2836, 23, 17150, 43219, 5191, 43, 62, 11, 446, 6, 255, 62, 140, 1, 93, 2132, 155, 1051, 4, 3, 157, 49, 53, 1, 24, 3, 365, 108, 7, 62, 42, 1281, 672, 3561, 17, 616, 2611, 4, 24, 2, 15, 14123, 900, 36, 451, 2, 166, 126, 3, 17150, 43219, 206, 108, 243, 1, 12324, 7, 27, 49, 5, 93, 672, 1751, 169, 1, 243, 11, 265, 5, 5380, 3, 1749, 47, 42, 77, 471, 210, 8, 607, 532, 1, 5380, 15, 127, 672, 1751, 257, 40, 990, 28, 3, 98, 1, 147, 1, 62, 471, 9, 5380, 257, 40, 515, 4, 500, 2566, 5, 1281, 2132, 277, 672, 3561, 24, 1, 225, 7, 1642, 40, 2596, 471, 1, 62, 7, 5, 93, 672, 1751, 688, 40, 1493, 6, 223, 3, 1150, 1, 225, 1751, 3672, 20, 1181, 5380]",1606.0,12679647,250
Treatment-specific changes in gene expression discriminate in vivo drug response in human leukemia cells.,Nature genetics,Nat. Genet.,2003-05-01,"To elucidate the genomics of cellular responses to cancer treatment, we analyzed the expression of over 9,600 human genes in acute lymphoblastic leukemia cells before and after in vivo treatment with methotrexate and mercaptopurine given alone or in combination. Based on changes in gene expression, we identified 124 genes that accurately discriminated among the four treatments. Discriminating genes included those involved in apoptosis, mismatch repair, cell cycle control and stress response. Only 14% of genes that changed when these medications were given as single agents also changed when they were given together. These data indicate that lymphoid leukemia cells of different molecular subtypes share common pathways of genomic response to the same treatment, that changes in gene expression are treatment-specific and that gene expression can illuminate differences in cellular response to drug combinations versus single agents.",Journal Article,6109.0,215.0,"To elucidate the genomics of cellular responses to cancer treatment we analyzed the expression of over 9,600 human genes in acute lymphoblastic cells before and after in vivo treatment with methotrexate and mercaptopurine given alone or in combination Based on changes in gene expression we identified 124 genes that accurately discriminated among the four treatments Discriminating genes included those involved in apoptosis mismatch repair cell cycle control and stress response Only 14 of genes that changed when these medications were given as single agents also changed when they were given together These data indicate that lymphoid cells of different molecular subtypes share common pathways of genomic response to the same treatment that changes in gene expression are treatment-specific and that gene expression can illuminate differences in cellular response to drug combinations versus single agents",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 3061, 3, 4229, 1, 763, 253, 6, 12, 24, 21, 311, 3, 55, 1, 252, 83, 2383, 171, 214, 4, 286, 1275, 37, 348, 2, 50, 4, 386, 24, 5, 2116, 2, 9223, 447, 279, 15, 4, 150, 90, 23, 400, 4, 145, 55, 21, 108, 2834, 214, 17, 2141, 8752, 107, 3, 294, 640, 8059, 214, 159, 135, 646, 4, 351, 2617, 972, 31, 417, 182, 2, 1531, 51, 158, 213, 1, 214, 17, 2368, 198, 46, 2679, 11, 447, 22, 226, 183, 120, 2368, 198, 491, 11, 447, 1162, 46, 74, 1008, 17, 2303, 37, 1, 338, 219, 814, 4349, 186, 460, 1, 572, 51, 6, 3, 827, 24, 17, 400, 4, 145, 55, 32, 24, 112, 2, 17, 145, 55, 122, 12793, 362, 4, 763, 51, 6, 234, 1247, 185, 226, 183]",910.0,12704389,615
Molecular monitoring of cerebrospinal fluid can predict clinical relapse in acute lymphoblastic leukemia with eosinophilia.,Archives of pathology & laboratory medicine,Arch. Pathol. Lab. Med.,2003-05-01,"In a patient with precursor B-cell acute lymphoblastic leukemia (ALL) associated with eosinophilia that completely responded to induction chemotherapy, we assayed serial remission cerebrospinal fluid and bone marrow specimens for minimal residual disease using a quantitative polymerase chain reaction assay to assess for clone-specific immunoglobulin heavy-chain gene cluster (IGH) gene rearrangement. Cerebrospinal fluid eosinophilia and minimal residual disease were detected on day 406, preceding the morphologic diagnosis of central nervous system relapse on day 578. By day 841, the bone marrow had 35% blasts. Despite aggressive therapy, including unrelated umbilical cord blood transplantation, the patient developed testicular and bone marrow relapses and died of disease. We conclude that increasing levels of minimal residual disease in cerebrospinal fluid can predict recurrence of ALL prior to clinical and morphologic relapse. Furthermore, we demonstrate a novel translocation in this tumor, the t(5;9)(q31;p24), that possibly led to fusion of the interleukin-3 (IL3) (5q31) and JAK2 (9p24) genes and may explain the concomitant appearance of eosinophilia and ALL.",Case Reports,6109.0,19.0,In a patient with precursor B-cell acute lymphoblastic ALL associated with eosinophilia that completely responded to induction chemotherapy we assayed serial remission cerebrospinal fluid and marrow specimens for minimal residual disease using a quantitative polymerase chain reaction assay to assess for clone-specific immunoglobulin heavy-chain gene cluster IGH gene rearrangement Cerebrospinal fluid eosinophilia and minimal residual disease were detected on day 406 preceding the morphologic diagnosis of central nervous system relapse on day 578 By day 841 the marrow had 35 blasts Despite aggressive therapy including unrelated umbilical cord blood transplantation the patient developed and marrow relapses and died of disease We conclude that increasing levels of minimal residual disease in cerebrospinal fluid can predict recurrence of ALL prior to clinical and morphologic relapse Furthermore we demonstrate a novel translocation in this tumor the t 5 9 q31 p24 that possibly led to fusion of the interleukin-3 IL3 5q31 and JAK2 9p24 genes and may explain the concomitant appearance of eosinophilia and ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 8, 69, 5, 2765, 132, 31, 286, 1275, 62, 41, 5, 13555, 17, 2500, 2211, 6, 504, 56, 21, 4499, 2108, 734, 5156, 2357, 2, 581, 623, 9, 1048, 753, 34, 75, 8, 1156, 1451, 1260, 1329, 719, 6, 423, 9, 3910, 112, 2593, 4013, 1260, 145, 3132, 5221, 145, 2675, 5156, 2357, 13555, 2, 1048, 753, 34, 11, 530, 23, 218, 8522, 5892, 3, 2815, 147, 1, 854, 1880, 398, 429, 23, 218, 10431, 20, 218, 18269, 3, 581, 42, 465, 2438, 550, 571, 36, 141, 2092, 5998, 1885, 315, 497, 3, 69, 276, 2, 581, 3713, 2, 1016, 1, 34, 21, 2060, 17, 602, 148, 1, 1048, 753, 34, 4, 5156, 2357, 122, 678, 146, 1, 62, 324, 6, 38, 2, 2815, 429, 798, 21, 608, 8, 229, 2006, 4, 26, 30, 3, 102, 33, 83, 53499, 43136, 17, 2150, 836, 6, 1212, 1, 3, 1603, 27, 20283, 22069, 2, 2509, 10450, 214, 2, 68, 2943, 3, 1781, 3592, 1, 13555, 2, 62]",1116.0,12708906,87
Trends in leukemia incidence and survival in the United States (1973-1998).,Cancer,Cancer,2003-05-01,"It is estimated that each year, approximately 30,800 individuals will be diagnosed with leukemia in the United States and 21,700 individuals will die of the disease. Although the overall incidence of leukemia has been declining in the United States, recent reports suggest that incidence rates may be increasing for certain age and racial groups. Leukemia incidence (including acute lymphoblastic leukemia [ALL], acute myeloid leukemia [AML], chronic myeloid leukemia [CML], and chronic lymphoblastic leukemia [CLL]) and 5-year survival rates were obtained from the Surveillance, Epidemiology, and End Results (SEER) program. Specific rates for age (birth-19, 20-44, 45-64, and 65 + years), gender, and race (black, white) were also examined. A total of 66,404 cases of leukemia were identified for the period 1973-1998 in the nine reporting SEER sites. For children younger than 20 years old, the overall incidence rate of leukemia increased significantly (estimated annual percent change [EAPC] = 0.5%, 95% confidence interval [CI] = 0.1-0.9), whereas the rate decreased significantly among the group 65 years and older (EAPC = - 0.3, 95% CI = - 0.5 to - 0.1). Incidence rates for CLL and CML decreased significantly during this time period, whereas incidence rates for AML remained stable. Children younger than 20 years old experienced a 15% increase in the 5-year survival rates for both ALL and AML when comparing the two 10-year periods of 1974-1983 and 1984-1993. In contrast, there was little overall improvement in survival for adults 45 years and older. In particular, there was a notable decrease in the overall 5-year survival for blacks older than 65 years and for black males older than 44 years. Although the current study confirmed some of the results noted in other populations, the observed overall decline in leukemia survival for blacks is surprising and warrants further investigation.",Comparative Study,6109.0,165.0,"It is estimated that each year approximately 30,800 individuals will be diagnosed with in the United States and 21,700 individuals will die of the disease Although the overall incidence of has been declining in the United States recent reports suggest that incidence rates may be increasing for certain age and racial groups incidence including acute lymphoblastic ALL acute myeloid AML chronic myeloid CML and chronic lymphoblastic CLL and 5-year survival rates were obtained from the Surveillance Epidemiology and End Results SEER program Specific rates for age birth-19 20-44 45-64 and 65 years gender and race black white were also examined A total of 66,404 cases of were identified for the period 1973-1998 in the nine reporting SEER sites For children younger than 20 years old the overall incidence rate of increased significantly estimated annual percent change EAPC 0.5 95 confidence interval CI 0.1-0.9 whereas the rate decreased significantly among the group 65 years and older EAPC 0.3 95 CI 0.5 to 0.1 Incidence rates for CLL and CML decreased significantly during this time period whereas incidence rates for AML remained stable Children younger than 20 years old experienced a 15 increase in the 5-year survival rates for both ALL and AML when comparing the two 10-year periods of 1974-1983 and 1984-1993 In contrast there was little overall improvement in survival for adults 45 years and older In particular there was a notable decrease in the overall 5-year survival for blacks older than 65 years and for black males older than 44 years Although the current study confirmed some of the results noted in other populations the observed overall decline in survival for blacks is surprising and warrants further investigation",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[192, 16, 661, 17, 296, 111, 705, 201, 2796, 869, 303, 40, 265, 5, 4, 3, 1088, 907, 2, 239, 5692, 869, 303, 3384, 1, 3, 34, 242, 3, 63, 287, 1, 71, 85, 6896, 4, 3, 1088, 907, 435, 1198, 309, 17, 287, 151, 68, 40, 602, 9, 1840, 89, 2, 2257, 271, 287, 141, 286, 1275, 62, 286, 533, 329, 442, 533, 903, 2, 442, 1275, 552, 2, 33, 111, 25, 151, 11, 683, 29, 3, 617, 1284, 2, 396, 99, 1605, 1243, 112, 151, 9, 89, 3809, 326, 179, 584, 512, 660, 2, 556, 60, 1632, 2, 1047, 1445, 886, 11, 120, 409, 8, 181, 1, 700, 10315, 140, 1, 11, 108, 9, 3, 727, 4756, 1850, 4, 3, 762, 1760, 1605, 633, 9, 541, 773, 76, 179, 60, 1095, 3, 63, 287, 116, 1, 101, 97, 661, 2114, 714, 707, 22097, 13, 33, 48, 307, 268, 58, 13, 14, 13, 83, 547, 3, 116, 340, 97, 107, 3, 87, 556, 60, 2, 434, 22097, 13, 27, 48, 58, 13, 33, 6, 13, 14, 287, 151, 9, 552, 2, 903, 340, 97, 190, 26, 98, 727, 547, 287, 151, 9, 329, 958, 585, 541, 773, 76, 179, 60, 1095, 592, 8, 167, 344, 4, 3, 33, 111, 25, 151, 9, 110, 62, 2, 329, 198, 1430, 3, 100, 79, 111, 3338, 1, 10201, 6656, 2, 6036, 3343, 4, 748, 125, 10, 1215, 63, 767, 4, 25, 9, 857, 512, 60, 2, 434, 4, 1454, 125, 10, 8, 4090, 775, 4, 3, 63, 33, 111, 25, 9, 3544, 434, 76, 556, 60, 2, 9, 1445, 2296, 434, 76, 584, 60, 242, 3, 291, 45, 557, 476, 1, 3, 99, 1051, 4, 127, 1184, 3, 164, 63, 1858, 4, 25, 9, 3544, 16, 14157, 2, 2782, 195, 940]",1741.0,12712476,266
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling.,Blood,Blood,2003-05-01,"Contemporary treatment of pediatric acute lymphoblastic leukemia (ALL) requires the assignment of patients to specific risk groups. We have recently demonstrated that expression profiling of leukemic blasts can accurately identify the known prognostic subtypes of ALL, including T-cell lineage ALL (T-ALL), E2A-PBX1, TEL-AML1, MLL rearrangements, BCR-ABL, and hyperdiploid karyotypes with more than 50 chromosomes. As the next step toward developing this methodology into a frontline diagnostic tool, we have now analyzed leukemic blasts from 132 diagnostic samples using higher density oligonucleotide arrays that allow the interrogation of most of the identified genes in the human genome. Nearly 60% of the newly identified subtype discriminating genes are novel markers not identified in our previous study, and thus should provide new insights into the altered biology underlying these leukemias. Moreover, a proportion of the newly selected genes are highly ranked as class discriminators, and when incorporated into class-predicting algorithms resulted in an overall diagnostic accuracy of 97%. The performance of an array containing the identified discriminating genes should now be assessed in frontline clinical trials in order to determine the accuracy, practicality, and cost effectiveness of this methodology in the clinical setting.",Journal Article,6109.0,434.0,Contemporary treatment of pediatric acute lymphoblastic ALL requires the assignment of patients to specific risk groups We have recently demonstrated that expression profiling of leukemic blasts can accurately identify the known prognostic subtypes of ALL including T-cell lineage ALL T-ALL E2A-PBX1 TEL-AML1 MLL rearrangements BCR-ABL and hyperdiploid karyotypes with more than 50 chromosomes As the next step toward developing this methodology into a frontline diagnostic tool we have now analyzed leukemic blasts from 132 diagnostic samples using higher density oligonucleotide arrays that allow the interrogation of most of the identified genes in the human genome Nearly 60 of the newly identified subtype discriminating genes are novel markers not identified in our previous study and thus should provide new insights into the altered biology underlying these leukemias Moreover a proportion of the newly selected genes are highly ranked as class discriminators and when incorporated into class-predicting algorithms resulted in an overall diagnostic accuracy of 97 The performance of an array containing the identified discriminating genes should now be assessed in frontline clinical trials in order to determine the accuracy practicality and cost effectiveness of this methodology in the clinical setting,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2667, 24, 1, 815, 286, 1275, 62, 1706, 3, 4392, 1, 7, 6, 112, 43, 271, 21, 47, 761, 264, 17, 55, 1080, 1, 2015, 2438, 122, 2141, 255, 3, 440, 177, 814, 1, 62, 141, 102, 31, 2542, 62, 102, 62, 15127, 14434, 8573, 6535, 3049, 2072, 1062, 1425, 2, 8847, 6809, 5, 80, 76, 212, 3560, 22, 3, 1305, 2458, 1317, 931, 26, 3209, 237, 8, 3171, 752, 1515, 21, 47, 1134, 311, 2015, 2438, 29, 4255, 752, 347, 75, 142, 1263, 4727, 3923, 17, 1700, 3, 8956, 1, 96, 1, 3, 108, 214, 4, 3, 171, 898, 1857, 335, 1, 3, 732, 108, 875, 8059, 214, 32, 229, 525, 44, 108, 4, 114, 698, 45, 2, 631, 257, 377, 217, 1957, 237, 3, 1495, 891, 1181, 46, 2792, 1393, 8, 920, 1, 3, 732, 715, 214, 32, 561, 6441, 22, 1040, 37447, 2, 198, 2449, 237, 1040, 1434, 3529, 627, 4, 35, 63, 752, 1190, 1, 1015, 3, 528, 1, 35, 1926, 1101, 3, 108, 8059, 214, 257, 1134, 40, 275, 4, 3171, 38, 143, 4, 1732, 6, 223, 3, 1190, 23220, 2, 835, 1236, 1, 26, 3209, 4, 3, 38, 546]",1313.0,12730115,148
Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.,Haematologica,Haematologica,2003-05-01,"Numerous studies have reported the feasibility of performing allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning, although results in individual diseases are scarce, with no studies in patients with acute lymphoblastic leukemia (ALL). We sought to analyze the results of reduced intensity conditioning for allografts in adult patients with ALL. We report the results of a reduced intensity conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in 27 adult patients with high-risk ALL who were included in four prospective studies. The median age was 50 years; 23 (85%) patients were beyond first complete remission, 44% were chemorefractory and 41% were Philadelphia chromosome positive. Donors were mismatched related donors or volunteer unrelated donors in 12 cases (44%). The incidence of grades II-IV acute graft-versus-host disease (GVHD) was 48%, and 13 of 18 evaluable patients (72%) developed chronic GVHD. Currently nine patients are alive, with a median follow-up of 809 days (range, 381-1375). The 2-year incidence of transplant-related mortality was 23% (95% CI, 11% to 46%), and the 2-year probability of overall survival was 31% (95% CI, 12 to 48%), while the 2-year incidence of disease progression was 49% (95% CI, 33% to 72%). The 2-year incidence of disease progression in patients with and without GVHD was 35% (95% CI, 19% to 57%) and 70% (95% CI, 47% to 100%), respectively (p=0.05). This retrospective study suggests that allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning might be a useful therapeutic option for some patients with ALL who are ineligible for standard myeloablative conditioning. However, this treatment modality needs to be evaluated in prospective trials, and should not be employed outside clinical studies.",Journal Article,6109.0,95.0,Numerous studies have reported the feasibility of performing allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning although results in individual diseases are scarce with no studies in patients with acute lymphoblastic ALL We sought to analyze the results of reduced intensity conditioning for allografts in adult patients with ALL We report the results of a reduced intensity conditioning regimen followed by allogeneic hematopoietic stem cell transplantation in 27 adult patients with high-risk ALL who were included in four prospective studies The median age was 50 years 23 85 patients were beyond first complete remission 44 were chemorefractory and 41 were Philadelphia chromosome positive Donors were mismatched related donors or volunteer unrelated donors in 12 cases 44 The incidence of grades II-IV acute graft-versus-host disease GVHD was 48 and 13 of 18 evaluable patients 72 developed chronic GVHD Currently nine patients are alive with a median follow-up of 809 days range 381-1375 The 2-year incidence of transplant-related mortality was 23 95 CI 11 to 46 and the 2-year probability of overall survival was 31 95 CI 12 to 48 while the 2-year incidence of disease progression was 49 95 CI 33 to 72 The 2-year incidence of disease progression in patients with and without GVHD was 35 95 CI 19 to 57 and 70 95 CI 47 to 100 respectively p=0.05 This retrospective study suggests that allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning might be a useful therapeutic option for some patients with ALL who are ineligible for standard myeloablative conditioning However this treatment modality needs to be evaluated in prospective trials and should not be employed outside clinical studies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2331, 94, 47, 210, 3, 1437, 1, 3620, 1063, 1007, 452, 31, 497, 5, 405, 837, 1933, 242, 99, 4, 797, 1342, 32, 8113, 5, 77, 94, 4, 7, 5, 286, 1275, 62, 21, 990, 6, 1992, 3, 99, 1, 405, 837, 1933, 9, 10586, 4, 780, 7, 5, 62, 21, 414, 3, 99, 1, 8, 405, 837, 1933, 477, 370, 20, 1063, 1007, 452, 31, 497, 4, 428, 780, 7, 5, 64, 43, 62, 54, 11, 159, 4, 294, 482, 94, 3, 52, 89, 10, 212, 60, 382, 772, 7, 11, 1654, 157, 236, 734, 584, 11, 8923, 2, 605, 11, 3006, 1170, 109, 2344, 11, 5095, 139, 2344, 15, 15536, 2092, 2344, 4, 133, 140, 584, 3, 287, 1, 2276, 215, 478, 286, 1599, 185, 1204, 34, 1562, 10, 576, 2, 233, 1, 203, 859, 7, 720, 276, 442, 1562, 694, 762, 7, 32, 1701, 5, 8, 52, 166, 126, 1, 14494, 162, 184, 10155, 26164, 3, 18, 111, 287, 1, 941, 139, 282, 10, 382, 48, 58, 175, 6, 641, 2, 3, 18, 111, 1320, 1, 63, 25, 10, 456, 48, 58, 133, 6, 576, 369, 3, 18, 111, 287, 1, 34, 91, 10, 739, 48, 58, 466, 6, 720, 3, 18, 111, 287, 1, 34, 91, 4, 7, 5, 2, 187, 1562, 10, 465, 48, 58, 326, 6, 696, 2, 431, 48, 58, 662, 6, 394, 106, 19, 13, 474, 26, 459, 45, 844, 17, 1063, 1007, 452, 31, 497, 5, 405, 837, 1933, 822, 40, 8, 999, 189, 1501, 9, 476, 7, 5, 62, 54, 32, 3773, 9, 260, 3246, 1933, 137, 26, 24, 1396, 1891, 6, 40, 194, 4, 482, 143, 2, 257, 44, 40, 2516, 2513, 38, 94]",1764.0,12745275,667
Childhood leukemia: electric and magnetic fields as possible risk factors.,Environmental health perspectives,Environ. Health Perspect.,2003-06-01,"Numerous epidemiologic studies have reported associations between measures of power-line electric or magnetic fields (EMFs) and childhood leukemia. The basis for such associations remains unexplained. In children, acute lymphoblastic leukemia represents approximately three-quarters of all U.S. leukemia types. Some risk factors for childhood leukemia have been established, and others are suspected. Pathogenesis, as investigated in animal models, is consistent with the multistep model of acute leukemia development. Studies of carcinogenicity in animals, however, are overwhelmingly negative and do not support the hypothesis that EMF exposure is a significant risk factor for hematopoietic neoplasia. We may fail to observe effects from EMFs because, from a mechanistic perspective, the effects of EMFs on biology are very weak. Cells and organs function despite many sources of chemical ""noise"" (e.g., stochastic, temperature, concentration, mechanical, and electrical noise), which exceed the induced EMF ""signal"" by a large factor. However, the inability to detect EMF effects in bioassay systems may be caused by the choice made for ""EMF exposure."" ""Contact currents"" or ""contact voltages"" have been proposed as a novel exposure metric, because their magnitude is related to measured power-line magnetic fields. A contact current occurs when a person touches two conductive surfaces at different voltages. Modeled analyses support contact currents as a plausible metric because of correlations with residential magnetic fields and opportunity for exposure. The possible role of contact currents as an explanatory variable in the reported associations between EMFs and childhood leukemia will need to be clarified by further measurements, biophysical analyses, bioassay studies, and epidemiology.",Journal Article,6078.0,37.0,Numerous epidemiologic studies have reported associations between measures of power-line electric or magnetic fields EMFs and childhood The basis for such associations remains unexplained In children acute lymphoblastic represents approximately three-quarters of all U.S. types Some risk factors for childhood have been established and others are suspected Pathogenesis as investigated in animal models is consistent with the multistep model of acute development Studies of carcinogenicity in animals however are overwhelmingly negative and do not support the hypothesis that EMF exposure is a significant risk factor for hematopoietic neoplasia We may fail to observe effects from EMFs because from a mechanistic perspective the effects of EMFs on biology are very weak Cells and organs function despite many sources of chemical `` noise '' e.g. stochastic temperature concentration mechanical and electrical noise which exceed the induced EMF `` signal '' by a large factor However the inability to detect EMF effects in bioassay systems may be caused by the choice made for `` EMF exposure '' `` Contact currents '' or `` contact voltages '' have been proposed as a novel exposure metric because their magnitude is related to measured power-line magnetic fields A contact current occurs when a person touches two conductive surfaces at different voltages Modeled analyses support contact currents as a plausible metric because of correlations with residential magnetic fields and opportunity for exposure The possible role of contact currents as an explanatory variable in the reported associations between EMFs and childhood will need to be clarified by further measurements biophysical analyses bioassay studies and epidemiology,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2331, 3609, 94, 47, 210, 685, 59, 1018, 1, 2349, 328, 16190, 15, 1484, 3130, 33442, 2, 864, 3, 877, 9, 225, 685, 469, 8221, 4, 541, 286, 1275, 1449, 705, 169, 14497, 1, 62, 1767, 695, 630, 476, 43, 130, 9, 864, 47, 85, 635, 2, 1749, 32, 2768, 1384, 22, 565, 4, 2026, 274, 16, 925, 5, 3, 9417, 202, 1, 286, 193, 94, 1, 33443, 4, 2258, 137, 32, 18890, 199, 2, 1022, 44, 538, 3, 1492, 17, 33444, 645, 16, 8, 93, 43, 161, 9, 1007, 2298, 21, 68, 4373, 6, 4635, 176, 29, 33442, 408, 29, 8, 2716, 3727, 3, 176, 1, 33442, 23, 891, 32, 923, 4241, 37, 2, 2285, 343, 550, 445, 3375, 1, 3743, 7556, 522, 563, 499, 16303, 6882, 1227, 6065, 2, 15921, 7556, 92, 6818, 3, 277, 33444, 1235, 522, 20, 8, 375, 161, 137, 3, 4985, 6, 1426, 33444, 176, 4, 20294, 1530, 68, 40, 1546, 20, 3, 1866, 1229, 9, 33444, 645, 522, 4393, 37462, 522, 15, 4393, 43253, 522, 47, 85, 1587, 22, 8, 229, 645, 6515, 408, 136, 3131, 16, 139, 6, 644, 2349, 328, 1484, 3130, 8, 4393, 291, 1780, 198, 8, 2719, 26114, 100, 53551, 8835, 28, 338, 43253, 4666, 318, 538, 4393, 37462, 22, 8, 7761, 6515, 408, 1, 2553, 5, 16304, 1484, 3130, 2, 2666, 9, 645, 3, 899, 200, 1, 4393, 37462, 22, 35, 18277, 1347, 4, 3, 210, 685, 59, 33442, 2, 864, 303, 594, 6, 40, 9659, 20, 195, 1685, 18891, 318, 20294, 94, 2, 1284]",1733.0,12782499,293
Progress and challenges in the therapy of adult acute lymphoblastic leukemia.,Current opinion in hematology,Curr. Opin. Hematol.,2003-07-01,"Acute lymphoblastic leukemia is a heterogeneous disease with distinct biologic and prognostic groupings. Although current therapies result in high complete remission rates, long-term disease-free survival rates have remained disappointingly low. Results from recent studies using risk-tailored approaches suggest improvement in overall survival for high-risk groups, such as those with Philadelphia chromosome-positive acute lymphoblastic leukemia. Furthermore, the incorporation of imatinib mesylate into the treatment regimen for Philadelphia chromosome-positive acute lymphoblastic leukemia patients may lead to better outcomes. Finally, quantification of minimal residual disease at various time points during therapy is being investigated as a means to predict more accurately a patient's response to therapy, and to make therapeutic decisions.",Journal Article,6048.0,10.0,Acute lymphoblastic is a heterogeneous disease with distinct biologic and prognostic groupings Although current therapies result in high complete remission rates long-term disease-free survival rates have remained disappointingly low Results from recent studies using risk-tailored approaches suggest improvement in overall survival for high-risk groups such as those with Philadelphia chromosome-positive acute lymphoblastic Furthermore the incorporation of imatinib mesylate into the treatment regimen for Philadelphia chromosome-positive acute lymphoblastic patients may lead to better outcomes Finally quantification of minimal residual disease at various time points during therapy is being investigated as a means to predict more accurately a patient 's response to therapy and to make therapeutic decisions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 16, 8, 1564, 34, 5, 834, 1283, 2, 177, 10517, 242, 291, 235, 757, 4, 64, 236, 734, 151, 319, 337, 34, 115, 25, 151, 47, 958, 20189, 154, 99, 29, 435, 94, 75, 43, 3632, 611, 309, 767, 4, 63, 25, 9, 64, 43, 271, 225, 22, 135, 5, 3006, 1170, 109, 286, 1275, 798, 3, 2838, 1, 577, 2347, 237, 3, 24, 477, 9, 3006, 1170, 109, 286, 1275, 7, 68, 1122, 6, 380, 123, 1368, 4752, 1, 1048, 753, 34, 28, 747, 98, 862, 190, 36, 16, 486, 565, 22, 8, 2263, 6, 678, 80, 2141, 8, 69, 292, 51, 6, 36, 2, 6, 2378, 189, 1526]",813.0,12799534,545
Newly diagnosed childhood acute lymphoblastic leukemia: update on prognostic factors and treatment.,Current opinion in hematology,Curr. Opin. Hematol.,2003-07-01,"The development of effective therapy for children with acute lymphoblastic leukemia is one of the great successes of clinical hematology andoncology. Fifty years ago, childhood acute lymphoblastic leukemia was universally fatal, but current long-term event-free survival rates are nearly 80%. Despite this improved outcome, there are still many challenges facing investigators today. In some recent clinical trials, the outcome of ""high-risk"" patients has approached that of ""lower risk"" patients, suggesting that currently applied clinical factors, such as age and presenting leukocyte count, no longer identify the 20% of newly diagnosed patients who ultimately will relapse. Additionally, therapy remains nonspecific, toxic, and sometimes lethal. As more children with acute lymphoblastic leukemia survive into adolescence and adulthood, there is a need to address the late sequelae of current therapy and to develop more leukemia-specific treatments. Promising avenues of research, which may identify biologically distinctive subsets of acute lymphoblastic leukemia and potential targets for novel therapies, include studies of minimal residual disease, lymphoblast genetics (including genetic profiling studies), and host-related pharmacogenomics.",Journal Article,6048.0,33.0,The development of effective therapy for children with acute lymphoblastic is one of the great successes of clinical hematology andoncology Fifty years ago childhood acute lymphoblastic was universally fatal but current long-term event-free survival rates are nearly 80 Despite this improved outcome there are still many challenges facing investigators today In some recent clinical trials the outcome of `` high-risk '' patients has approached that of `` lower risk '' patients suggesting that currently applied clinical factors such as age and presenting leukocyte count no longer identify the 20 of newly diagnosed patients who ultimately will relapse Additionally therapy remains nonspecific toxic and sometimes lethal As more children with acute lymphoblastic survive into adolescence and adulthood there is a need to address the late sequelae of current therapy and to develop more leukemia-specific treatments Promising avenues of research which may identify biologically distinctive subsets of acute lymphoblastic and potential targets for novel therapies include studies of minimal residual disease lymphoblast genetics including genetic profiling studies and host-related pharmacogenomics,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 193, 1, 323, 36, 9, 541, 5, 286, 1275, 16, 104, 1, 3, 2797, 6697, 1, 38, 6216, 53575, 1461, 60, 5028, 864, 286, 1275, 10, 6813, 3034, 84, 291, 319, 337, 774, 115, 25, 151, 32, 1857, 493, 550, 26, 231, 228, 125, 32, 1234, 445, 1427, 7917, 2394, 5665, 4, 476, 435, 38, 143, 3, 228, 1, 64, 43, 522, 7, 71, 5738, 17, 1, 280, 43, 522, 7, 802, 17, 694, 1498, 38, 130, 225, 22, 89, 2, 1656, 3627, 1276, 77, 589, 255, 3, 179, 1, 732, 265, 7, 54, 2050, 303, 429, 1724, 36, 469, 5893, 1812, 2, 5164, 2266, 22, 80, 541, 5, 286, 1275, 4573, 237, 6964, 2, 6002, 125, 16, 8, 594, 6, 1539, 3, 807, 4156, 1, 291, 36, 2, 6, 690, 80, 2647, 112, 640, 721, 6612, 1, 389, 92, 68, 255, 2665, 5049, 1890, 1, 286, 1275, 2, 174, 637, 9, 229, 235, 643, 94, 1, 1048, 753, 34, 19414, 2894, 141, 336, 1080, 94, 2, 1204, 139, 7603]",1198.0,12799535,543
Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.,Clinical pharmacology and therapeutics,Clin. Pharmacol. Ther.,2003-06-01,"Methotrexate is postulated to enhance mercaptopurine activation to thioguanine (INN, tioguanine) nucleotides, but the interaction has never been studied in vivo in cancer cells. We investigated the effect of methotrexate on mercaptopurine disposition in plasma and leukemic blasts during up-front treatment of 233 children with newly diagnosed acute lymphoblastic leukemia. Children were randomized to receive intravenous mercaptopurine (1 g/m(2) over a 6-hour period) or to receive methotrexate (low dose, 6 oral doses of 30 mg/m(2), or high dose, 1 g/m(2) intravenously), followed by intravenous mercaptopurine. All combinations have been previously used in frontline trials for acute lymphoblastic leukemia. Compared with mercaptopurine alone, methotrexate resulted in higher plasma mercaptopurine concentrations (30.3 +/- 14.7 micromol/L versus 23.5 +/- 18.0 micromol/L, P <.001) but, conversely, a 13-fold lower thioguanine nucleotide concentration (0.57 +/- 0.66 pmol/5 x 10(6) cells versus 7.4 +/- 15.2 pmol/5 x 10(6) cells, P <.001) in bone marrow leukemic lymphoblasts. Methotrexate was also associated with higher plasma hypoxanthine concentrations compared with those of patients given mercaptopurine alone (8.7 +/- 13.5 micromol/L versus 3.8 +/- 2.5 micromol/L, P =.029). The percentage change in leukocyte counts measured over a 3-day period showed that mercaptopurine alone had little effect (mean decrease, 20% +/- 33%). In contrast, despite causing lower intracellular thiopurine active metabolite concentrations, methotrexate produced a greater decrease in leukocyte counts (mean, 53% +/- 35%) compared with those in patients receiving mercaptopurine alone (P <.0001). These pharmacologic findings in the target tissue are consistent with the recently demonstrated lack of clinical benefit of intravenous mercaptopurine in combination with methotrexate. We conclude that, in the setting of newly diagnosed acute lymphoblastic leukemia, methotrexate antagonizes thiopurine metabolite disposition in leukemic blasts after intravenous mercaptopurine.",Clinical Trial,6078.0,13.0,Methotrexate is postulated to enhance mercaptopurine activation to thioguanine INN tioguanine nucleotides but the interaction has never been studied in vivo in cancer cells We investigated the effect of methotrexate on mercaptopurine disposition in plasma and leukemic blasts during up-front treatment of 233 children with newly diagnosed acute lymphoblastic Children were randomized to receive intravenous mercaptopurine 1 g/m 2 over a 6-hour period or to receive methotrexate low dose 6 oral doses of 30 mg/m 2 or high dose 1 g/m 2 intravenously followed by intravenous mercaptopurine All combinations have been previously used in frontline trials for acute lymphoblastic Compared with mercaptopurine alone methotrexate resulted in higher plasma mercaptopurine concentrations 30.3 +/- 14.7 micromol/L versus 23.5 +/- 18.0 micromol/L P .001 but conversely a 13-fold lower thioguanine nucleotide concentration 0.57 +/- 0.66 pmol/5 x 10 6 cells versus 7.4 +/- 15.2 pmol/5 x 10 6 cells P .001 in marrow leukemic lymphoblasts Methotrexate was also associated with higher plasma hypoxanthine concentrations compared with those of patients given mercaptopurine alone 8.7 +/- 13.5 micromol/L versus 3.8 +/- 2.5 micromol/L P =.029 The percentage change in leukocyte counts measured over a 3-day period showed that mercaptopurine alone had little effect mean decrease 20 +/- 33 In contrast despite causing lower intracellular thiopurine active metabolite concentrations methotrexate produced a greater decrease in leukocyte counts mean 53 +/- 35 compared with those in patients receiving mercaptopurine alone P .0001 These pharmacologic findings in the target tissue are consistent with the recently demonstrated lack of clinical benefit of intravenous mercaptopurine in combination with methotrexate We conclude that in the setting of newly diagnosed acute lymphoblastic methotrexate antagonizes thiopurine metabolite disposition in leukemic blasts after intravenous mercaptopurine,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 16, 6507, 6, 1304, 9223, 363, 6, 17598, 37475, 53586, 11381, 84, 3, 915, 71, 1737, 85, 656, 4, 386, 4, 12, 37, 21, 565, 3, 254, 1, 2116, 23, 9223, 5814, 4, 554, 2, 2015, 2438, 190, 126, 3007, 24, 1, 7005, 541, 5, 732, 265, 286, 1275, 541, 11, 384, 6, 560, 1262, 9223, 14, 499, 188, 18, 252, 8, 49, 2583, 727, 15, 6, 560, 2116, 154, 61, 49, 518, 415, 1, 201, 81, 188, 18, 15, 64, 61, 14, 499, 188, 18, 1672, 370, 20, 1262, 9223, 62, 1247, 47, 85, 373, 95, 4, 3171, 143, 9, 286, 1275, 72, 5, 9223, 279, 2116, 627, 4, 142, 554, 9223, 1003, 201, 27, 213, 67, 6297, 805, 185, 382, 33, 203, 13, 6297, 805, 19, 144, 84, 3154, 8, 233, 1116, 280, 17598, 1579, 1227, 13, 696, 13, 700, 9835, 33, 1006, 79, 49, 37, 185, 67, 39, 167, 18, 9835, 33, 1006, 79, 49, 37, 19, 144, 4, 581, 2015, 10521, 2116, 10, 120, 41, 5, 142, 554, 26052, 1003, 72, 5, 135, 1, 7, 447, 9223, 279, 66, 67, 233, 33, 6297, 805, 185, 27, 66, 18, 33, 6297, 805, 19, 4770, 3, 1150, 707, 4, 3627, 1911, 644, 252, 8, 27, 218, 727, 224, 17, 9223, 279, 42, 1215, 254, 313, 775, 179, 466, 4, 748, 550, 3440, 280, 2087, 14062, 544, 3379, 1003, 2116, 1687, 8, 378, 775, 4, 3627, 1911, 313, 699, 465, 72, 5, 135, 4, 7, 357, 9223, 279, 19, 488, 46, 2788, 272, 4, 3, 283, 246, 32, 925, 5, 3, 761, 264, 926, 1, 38, 247, 1, 1262, 9223, 4, 150, 5, 2116, 21, 2060, 17, 4, 3, 546, 1, 732, 265, 286, 1275, 2116, 11574, 14062, 3379, 5814, 4, 2015, 2438, 50, 1262, 9223]",1974.0,12811360,480
Height and weight in children treated for acute lymphoblastic leukemia: relationship to CNS treatment.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-08-01,"We evaluated the long-term effects of treatment on height and weight in children with acute lymphoblastic leukemia (ALL) treated with one of the following three different CNS therapies: intrathecal therapy alone, intrathecal therapy with conventional cranial radiation, or intrathecal therapy with twice-daily radiation. Between 1987 and 1995, 618 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for ALL were measured for height and weight at diagnosis, and approximately every 6 months thereafter. Patient height, weight, and body mass index (BMI) were converted to z scores for age and sex using the 2000 Centers for Disease Control and Prevention growth charts for the United States. Children younger than 13 years at diagnosis had a statistically significant decrease in their height z scores and an increase in their BMI z scores, regardless of whether they had received cranial radiation. Young age at diagnosis and increased chemotherapy intensity were major risk factors. Unexpectedly, there was no significant difference in long-term height between children who received radiation and those who did not. Final height is compromised in survivors of ALL. The detrimental effects on height occur during therapy without the ability for long-term catch-up growth. Although patients became overweight for height, this seemed to be a result of relative height loss with normal weight gain rather than accelerated weight gain. The type of CNS treatment received did not affect changes in height, weight, or BMI.",Journal Article,6017.0,77.0,We evaluated the long-term effects of treatment on height and weight in children with acute lymphoblastic ALL treated with one of the following three different CNS therapies intrathecal therapy alone intrathecal therapy with conventional cranial radiation or intrathecal therapy with twice-daily radiation Between 1987 and 1995 618 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for ALL were measured for height and weight at diagnosis and approximately every 6 months thereafter Patient height weight and body mass index BMI were converted to z scores for age and sex using the 2000 Centers for Disease Control and Prevention growth charts for the United States Children younger than 13 years at diagnosis had a statistically significant decrease in their height z scores and an increase in their BMI z scores regardless of whether they had received cranial radiation Young age at diagnosis and increased chemotherapy intensity were major risk factors Unexpectedly there was no significant difference in long-term height between children who received radiation and those who did not Final height is compromised in survivors of ALL The detrimental effects on height occur during therapy without the ability for long-term catch-up growth Although patients became overweight for height this seemed to be a result of relative height loss with normal weight gain rather than accelerated weight gain The type of CNS treatment received did not affect changes in height weight or BMI,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 194, 3, 319, 337, 176, 1, 24, 23, 4594, 2, 924, 4, 541, 5, 286, 1275, 62, 73, 5, 104, 1, 3, 366, 169, 338, 1025, 235, 5126, 36, 279, 5126, 36, 5, 809, 2565, 121, 15, 5126, 36, 5, 936, 391, 121, 59, 5450, 2, 2323, 11955, 541, 73, 23, 100, 935, 4932, 4979, 12, 1377, 2404, 2189, 9, 62, 11, 644, 9, 4594, 2, 924, 28, 147, 2, 705, 454, 49, 53, 3972, 69, 4594, 924, 2, 642, 782, 558, 1140, 11, 4764, 6, 3905, 703, 9, 89, 2, 1035, 75, 3, 1081, 1168, 9, 34, 182, 2, 1070, 129, 4413, 9, 3, 1088, 907, 541, 773, 76, 233, 60, 28, 147, 42, 8, 712, 93, 775, 4, 136, 4594, 3905, 703, 2, 35, 344, 4, 136, 1140, 3905, 703, 1583, 1, 317, 491, 42, 103, 2565, 121, 1169, 89, 28, 147, 2, 101, 56, 837, 11, 458, 43, 130, 6016, 125, 10, 77, 93, 523, 4, 319, 337, 4594, 59, 541, 54, 103, 121, 2, 135, 54, 205, 44, 1457, 4594, 16, 4867, 4, 332, 1, 62, 3, 6227, 176, 23, 4594, 1271, 190, 36, 187, 3, 801, 9, 319, 337, 21074, 126, 129, 242, 7, 3451, 3566, 9, 4594, 26, 5025, 6, 40, 8, 757, 1, 580, 4594, 407, 5, 295, 924, 1803, 1832, 76, 2241, 924, 1803, 3, 267, 1, 1025, 24, 103, 205, 44, 1158, 400, 4, 4594, 924, 15, 1140]",1515.0,12885815,379
"Homocysteine, pharmacogenetics, and neurotoxicity in children with leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-08-01,"Despite its clinical success, methotrexate (MTX) therapy is associated with toxicities such as seizures, the pathogenesis of which remains unclear. It has been suggested that hyperhomocysteinemia is caused by MTX and is responsible for its neurotoxic effects. The purposes of this study were to explore whether hyperhomocysteinemia was related to MTX administration and toxicity and whether homocysteine or MTX toxicity differed by methylenetetrahydrofolate reductase (MTHFR) or reduced folate carrier (RFC) genetic polymorphisms. We studied 53 children with newly diagnosed acute lymphoblastic leukemia who were consecutively treated on a single clinical protocol that included two courses of high-dose MTX (high-dose methotrexate [HDMTX]; 2.5 or 5.0 g/m2 per day) as consolidation therapy. The study participants' median plasma homocysteine concentrations at 23 and 44 hours after HDMTX (9.00 micromol/L and 10.12 micromol/L, respectively) were greater than the concentrations immediately before HDMTX (5.77 micromol/L, P <.0001 for both comparisons). Seven days after HDMTX treatment, their plasma concentration returned to baseline. Nine patients experienced seizures, and five patients experienced thrombosis during the first 15 months of therapy, with a tendency for there to be higher plasma homocysteine in patients with seizures across all time points (P =.063) but not in patients with thrombosis (P =.59). We observed no significant differences in plasma or cerebrospinal fluid homocysteine levels or in toxicity based on the MTHFR 677C/T or RFC 80G/A genotypes. We conclude that homocysteine was transiently elevated after HDMTX and may be related to seizure risk in children with leukemia.",Journal Article,6017.0,168.0,Despite its clinical success methotrexate MTX therapy is associated with toxicities such as seizures the pathogenesis of which remains unclear It has been suggested that hyperhomocysteinemia is caused by MTX and is responsible for its neurotoxic effects The purposes of this study were to explore whether hyperhomocysteinemia was related to MTX administration and toxicity and whether homocysteine or MTX toxicity differed by methylenetetrahydrofolate reductase MTHFR or reduced folate carrier RFC genetic polymorphisms We studied 53 children with newly diagnosed acute lymphoblastic who were consecutively treated on a single clinical protocol that included two courses of high-dose MTX high-dose methotrexate HDMTX 2.5 or 5.0 g/m2 per day as consolidation therapy The study participants median plasma homocysteine concentrations at 23 and 44 hours after HDMTX 9.00 micromol/L and 10.12 micromol/L respectively were greater than the concentrations immediately before HDMTX 5.77 micromol/L P .0001 for both comparisons Seven days after HDMTX treatment their plasma concentration returned to baseline Nine patients experienced seizures and five patients experienced thrombosis during the first 15 months of therapy with a tendency for there to be higher plasma homocysteine in patients with seizures across all time points P =.063 but not in patients with thrombosis P =.59 We observed no significant differences in plasma or cerebrospinal fluid homocysteine levels or in toxicity based on the MTHFR 677C/T or RFC 80G/A genotypes We conclude that homocysteine was transiently elevated after HDMTX and may be related to seizure risk in children with,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[550, 211, 38, 1825, 2116, 3453, 36, 16, 41, 5, 385, 225, 22, 4448, 3, 1384, 1, 92, 469, 1200, 192, 71, 85, 1148, 17, 43338, 16, 1546, 20, 3453, 2, 16, 2327, 9, 211, 11148, 176, 3, 4624, 1, 26, 45, 11, 6, 1645, 317, 43338, 10, 139, 6, 3453, 634, 2, 155, 2, 317, 12798, 15, 3453, 155, 2512, 20, 15586, 4027, 8342, 15, 405, 3100, 4715, 9270, 336, 1203, 21, 656, 699, 541, 5, 732, 265, 286, 1275, 54, 11, 7380, 73, 23, 8, 226, 38, 1182, 17, 159, 100, 1993, 1, 64, 61, 3453, 64, 61, 2116, 10061, 18, 33, 15, 33, 13, 499, 821, 379, 218, 22, 2173, 36, 3, 45, 776, 52, 554, 12798, 1003, 28, 382, 2, 584, 1459, 50, 10061, 83, 2038, 6297, 805, 2, 79, 133, 6297, 805, 106, 11, 378, 76, 3, 1003, 3467, 348, 10061, 33, 849, 6297, 805, 19, 488, 9, 110, 2213, 648, 162, 50, 10061, 24, 136, 554, 1227, 5157, 6, 330, 762, 7, 592, 4448, 2, 365, 7, 592, 2839, 190, 3, 157, 167, 53, 1, 36, 5, 8, 7135, 9, 125, 6, 40, 142, 554, 12798, 4, 7, 5, 4448, 716, 62, 98, 862, 19, 10592, 84, 44, 4, 7, 5, 2839, 19, 728, 21, 164, 77, 93, 362, 4, 554, 15, 5156, 2357, 12798, 148, 15, 4, 155, 90, 23, 3, 8342, 26205, 102, 15, 9270, 53691, 8, 2071, 21, 2060, 17, 12798, 10, 9235, 804, 50, 10061, 2, 68, 40, 139, 6, 5866, 43, 4, 541, 5]",1647.0,12915598,22
Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2003-08-01,"Children who survive acute lymphoblastic leukemia are at risk for leukemia-related or treatment-related complications, which can adversely affect survival and socioeconomic status. We determined the long-term survival and the rates of health insurance coverage, marriage, and employment among patients who had attained at least 10 years of event-free survival. A total of 856 eligible patients were treated between 1962 and 1992 in 13 consecutive clinical trials. Survival rates, the cumulative risk of a second neoplasm, and selected indicators of socioeconomic status were analyzed for the entire group and for patients who did or did not receive cranial or craniospinal radiation therapy during initial treatment. Fifty-six patients had major adverse events, including 8 deaths during remission, 4 relapses, and 44 second neoplasms (41 of them radiation-related); most of the second neoplasms were benign or of a low grade of malignant potential. The risk of a second neoplasm was significantly higher in the 597 patients who received radiation therapy (irradiated group) than in the 259 patients who did not receive radiation therapy (nonirradiated group) (P=0.04; estimated cumulative risk [+/-SE] at 20 years, 20.9+/-3.9 percent vs. 0.95+/-0.9 percent). The death rate for the irradiated group slightly exceeded the expected rate in the general U.S. population (standardized mortality ratio, 1.90; 95 percent confidence interval, 1.12 to 3.00), whereas that for the nonirradiated group did not differ from the population norm (standardized mortality ratio, 1.75; 95 percent confidence interval, 0.34 to 5.00). The rates of health insurance coverage, marriage, and employment in the nonirradiated group were similar to the age- and sex-adjusted national averages. Despite having health insurance rates similar to those in the general population, men and women in the irradiated group had higher-than-average unemployment rates (15.1 percent vs. 5.4 percent and 35.4 percent vs. 5.2 percent, respectively), and women in the irradiated group were less likely to be married (35.2 percent vs. 48.8 percent). Children with acute lymphoblastic leukemia who did not receive radiation therapy and who have attained 10 or more years of event-free survival can expect a normal long-term survival. Irradiation is associated with the development of second neoplasms, a slight excess in mortality, and an increased unemployment rate.",Journal Article,6017.0,328.0,Children who survive acute lymphoblastic are at risk for leukemia-related or treatment-related complications which can adversely affect survival and socioeconomic status We determined the long-term survival and the rates of health insurance coverage marriage and employment among patients who had attained at least 10 years of event-free survival A total of 856 eligible patients were treated between 1962 and 1992 in 13 consecutive clinical trials Survival rates the cumulative risk of a second neoplasm and selected indicators of socioeconomic status were analyzed for the entire group and for patients who did or did not receive cranial or craniospinal radiation therapy during initial treatment Fifty-six patients had major adverse events including 8 deaths during remission 4 relapses and 44 second neoplasms 41 of them radiation-related most of the second neoplasms were benign or of a low grade of malignant potential The risk of a second neoplasm was significantly higher in the 597 patients who received radiation therapy irradiated group than in the 259 patients who did not receive radiation therapy nonirradiated group P=0.04 estimated cumulative risk +/-SE at 20 years 20.9+/-3.9 percent vs. 0.95+/-0.9 percent The death rate for the irradiated group slightly exceeded the expected rate in the general U.S. population standardized mortality ratio 1.90 95 percent confidence interval 1.12 to 3.00 whereas that for the nonirradiated group did not differ from the population norm standardized mortality ratio 1.75 95 percent confidence interval 0.34 to 5.00 The rates of health insurance coverage marriage and employment in the nonirradiated group were similar to the age- and sex-adjusted national averages Despite having health insurance rates similar to those in the general population men and women in the irradiated group had higher-than-average unemployment rates 15.1 percent vs. 5.4 percent and 35.4 percent vs. 5.2 percent respectively and women in the irradiated group were less likely to be married 35.2 percent vs. 48.8 percent Children with acute lymphoblastic who did not receive radiation therapy and who have attained 10 or more years of event-free survival can expect a normal long-term survival Irradiation is associated with the development of second neoplasms a slight excess in mortality and an increased unemployment rate,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 54, 4573, 286, 1275, 32, 28, 43, 9, 2647, 139, 15, 24, 139, 521, 92, 122, 4311, 1158, 25, 2, 3331, 156, 21, 509, 3, 319, 337, 25, 2, 3, 151, 1, 341, 1935, 2139, 14822, 2, 5141, 107, 7, 54, 42, 5105, 28, 506, 79, 60, 1, 774, 115, 25, 8, 181, 1, 13292, 625, 7, 11, 73, 59, 14754, 2, 2846, 4, 233, 935, 38, 143, 25, 151, 3, 967, 43, 1, 8, 419, 2131, 2, 715, 3539, 1, 3331, 156, 11, 311, 9, 3, 1797, 87, 2, 9, 7, 54, 205, 15, 205, 44, 560, 2565, 15, 5748, 121, 36, 190, 388, 24, 1461, 437, 7, 42, 458, 290, 281, 141, 66, 1043, 190, 734, 39, 3713, 2, 584, 419, 1179, 605, 1, 1370, 121, 139, 96, 1, 3, 419, 1179, 11, 1002, 15, 1, 8, 154, 88, 1, 393, 174, 3, 43, 1, 8, 419, 2131, 10, 97, 142, 4, 3, 14507, 7, 54, 103, 121, 36, 2398, 87, 76, 4, 3, 7696, 7, 54, 205, 44, 560, 121, 36, 10460, 87, 19, 13, 755, 661, 967, 43, 3428, 28, 179, 60, 179, 83, 27, 83, 714, 105, 13, 48, 13, 83, 714, 3, 273, 116, 9, 3, 2398, 87, 3223, 4726, 3, 1336, 116, 4, 3, 1083, 1767, 695, 266, 1670, 282, 197, 14, 424, 48, 714, 307, 268, 14, 133, 6, 27, 2038, 547, 17, 9, 3, 10460, 87, 205, 44, 1505, 29, 3, 266, 15929, 1670, 282, 197, 14, 481, 48, 714, 307, 268, 13, 562, 6, 33, 2038, 3, 151, 1, 341, 1935, 2139, 14822, 2, 5141, 4, 3, 10460, 87, 11, 288, 6, 3, 89, 2, 1035, 586, 657, 22137, 550, 1041, 341, 1935, 151, 288, 6, 135, 4, 3, 1083, 266, 325, 2, 117, 4, 3, 2398, 87, 42, 142, 76, 1011, 11966, 151, 167, 14, 714, 105, 33, 39, 714, 2, 465, 39, 714, 105, 33, 18, 714, 106, 2, 117, 4, 3, 2398, 87, 11, 299, 322, 6, 40, 5365, 465, 18, 714, 105, 576, 66, 714, 541, 5, 286, 1275, 54, 205, 44, 560, 121, 36, 2, 54, 47, 5105, 79, 15, 80, 60, 1, 774, 115, 25, 122, 8439, 8, 295, 319, 337, 25, 1104, 16, 41, 5, 3, 193, 1, 419, 1179, 8, 8041, 2612, 4, 282, 2, 35, 101, 11966, 116]",2353.0,12917300,101
Prescription medication use during pregnancy and risk of infant leukemia (United States).,Cancer causes & control : CCC,Cancer Causes Control,2003-06-01,"We explored whether maternal medication use during pregnancy may be an important etiologic area for investigation in studies of infant leukemia. In this case-control study, associations were explored between specific medications as recorded in the medical records of 243 mothers of infants who were diagnosed with leukemia at < 18 months of age and 393 mothers ol infants without leukemia identified through random digit dialing. Cases included 157 acute lymphoblastic (ALL), 77 acute myeloid (AML), and nine other leukemias. A total of 27 different drugs that were prescribed for at least six women were analyzed. Overall, non-statistically significant negative associations (Odds ratios, OR < 0.5) were observed with amoxicillin, nystatin, clomiphene, levothyroxine, cefaclor, and trimethobenzamide HCL. When cases were restricted to either myeloid or lymphoblastic leukemia, cotrimoxazole was prescribed for five ALL case mothers and no matched controls; no association with cotrimoxazole was observed with AML. Given the number of comparisons, chance cannot be ruled out for any of the associations found here. However, a strength of this study is the lack of recall bias. The disparate data observed between AML and ALL in some instances may indicate areas of interest; they will be explored further in a case-control study of infant leukemia that is currently underway.",Journal Article,6078.0,6.0,We explored whether maternal medication use during pregnancy may be an important etiologic area for investigation in studies of infant In this case-control study associations were explored between specific medications as recorded in the medical records of 243 mothers of infants who were diagnosed with at 18 months of age and 393 mothers ol infants without identified through random digit dialing Cases included 157 acute lymphoblastic ALL 77 acute myeloid AML and nine other leukemias A total of 27 different drugs that were prescribed for at least six women were analyzed Overall non-statistically significant negative associations Odds ratios OR 0.5 were observed with amoxicillin nystatin clomiphene levothyroxine cefaclor and trimethobenzamide HCL When cases were restricted to either myeloid or lymphoblastic cotrimoxazole was prescribed for five ALL case mothers and no matched controls no association with cotrimoxazole was observed with AML Given the number of comparisons chance can not be ruled out for any of the associations found here However a strength of this study is the lack of recall bias The disparate data observed between AML and ALL in some instances may indicate areas of interest they will be explored further in a case-control study of infant that is currently underway,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 1443, 317, 6039, 3012, 119, 190, 2290, 68, 40, 35, 305, 6604, 965, 9, 940, 4, 94, 1, 8027, 4, 26, 473, 182, 45, 685, 11, 1443, 59, 112, 2679, 22, 1872, 4, 3, 484, 1064, 1, 6346, 8605, 1, 5585, 54, 11, 265, 5, 28, 203, 53, 1, 89, 2, 9351, 8605, 15588, 5585, 187, 108, 298, 2324, 9553, 14758, 140, 159, 5311, 286, 1275, 62, 849, 286, 533, 329, 2, 762, 127, 2792, 8, 181, 1, 428, 338, 600, 17, 11, 2746, 9, 28, 506, 437, 117, 11, 311, 63, 220, 712, 93, 199, 685, 610, 1137, 15, 13, 33, 11, 164, 5, 33285, 53720, 53721, 22140, 53722, 2, 53723, 4623, 198, 140, 11, 2016, 6, 361, 533, 15, 1275, 43361, 10, 2746, 9, 365, 62, 473, 8605, 2, 77, 655, 535, 77, 248, 5, 43361, 10, 164, 5, 329, 447, 3, 207, 1, 2213, 3477, 122, 44, 40, 11901, 1205, 9, 500, 1, 3, 685, 204, 467, 137, 8, 3671, 1, 26, 45, 16, 3, 926, 1, 6169, 2947, 3, 7985, 74, 164, 59, 329, 2, 62, 4, 476, 5342, 68, 1008, 1361, 1, 1333, 491, 303, 40, 1443, 195, 4, 8, 473, 182, 45, 1, 8027, 17, 16, 694, 3948]",1297.0,12946039,211
Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal residual disease detection.,Blood,Blood,2003-08-28,"Immunoglobulin (Ig) and T-cell receptor (TCR) gene rearrangements provide clonal markers useful for diagnosis and measurement of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL). We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability, which has important implications for monitoring MRD, during the course of the disease. In 42%, all original Ig and/or TCR sequences were conserved. In 24%, one original sequence was preserved but the other lost, and in 14% the original sequences were conserved with new sequences identified at relapse. In 20% only new sequences were found at relapse. Using primers designed from the novel relapse sequences, the relapse clone could be identified as subdominant clones in the diagnostic sample in 8 of 14 patients. Alteration of these clonal gene rearrangements is a common feature in childhood ALL. MRD detection should include multiple gene targets to minimize false-negative samples or include also multicolor flow cytometry. In some cases the leukemic progenitor cell might arise earlier in lineage before DHJH recombination but retain the capacity to further differentiate into cells capable of altering the pattern of Ig and/or TCR rearrangements.",Comparative Study,5990.0,54.0,Immunoglobulin Ig and T-cell receptor TCR gene rearrangements provide clonal markers useful for diagnosis and measurement of minimal residual disease MRD in acute lymphoblastic ALL We analyzed the sequences of Ig and TCR gene rearrangements obtained at presentation and relapse in 41 children with ALL to study clonal stability which has important implications for monitoring MRD during the course of the disease In 42 all original Ig and/or TCR sequences were conserved In 24 one original sequence was preserved but the other lost and in 14 the original sequences were conserved with new sequences identified at relapse In 20 only new sequences were found at relapse Using primers designed from the novel relapse sequences the relapse clone could be identified as subdominant clones in the diagnostic sample in 8 of 14 patients Alteration of these clonal gene rearrangements is a common feature in childhood ALL MRD detection should include multiple gene targets to minimize false-negative samples or include also multicolor flow cytometry In some cases the leukemic progenitor cell might arise earlier in lineage before DHJH recombination but retain the capacity to further differentiate into cells capable of altering the pattern of Ig and/or TCR rearrangements,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2593, 4200, 2, 102, 31, 153, 4134, 145, 2072, 377, 1946, 525, 999, 9, 147, 2, 2204, 1, 1048, 753, 34, 2029, 4, 286, 1275, 62, 21, 311, 3, 2866, 1, 4200, 2, 4134, 145, 2072, 683, 28, 1031, 2, 429, 4, 605, 541, 5, 62, 6, 45, 1946, 2769, 92, 71, 305, 1268, 9, 1315, 2029, 190, 3, 906, 1, 3, 34, 4, 595, 62, 2279, 4200, 2, 15, 4134, 2866, 11, 5547, 4, 259, 104, 2279, 1532, 10, 5797, 84, 3, 127, 3009, 2, 4, 213, 3, 2279, 2866, 11, 5547, 5, 217, 2866, 108, 28, 429, 4, 179, 158, 217, 2866, 11, 204, 28, 429, 75, 10031, 1114, 29, 3, 229, 429, 2866, 3, 429, 3910, 359, 40, 108, 22, 33502, 2749, 4, 3, 752, 1000, 4, 66, 1, 213, 7, 2611, 1, 46, 1946, 145, 2072, 16, 8, 186, 2705, 4, 864, 62, 2029, 638, 257, 643, 232, 145, 637, 6, 3241, 2133, 199, 347, 15, 643, 120, 11920, 1412, 1914, 4, 476, 140, 3, 2015, 2520, 31, 822, 3043, 1677, 4, 2542, 348, 53725, 4017, 84, 6630, 3, 2162, 6, 195, 3723, 237, 37, 2787, 1, 4831, 3, 1177, 1, 4200, 2, 15, 4134, 2072]",1264.0,12946997,41
Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia.,Blood,Blood,2003-09-11,"Etoposide is a substrate for P-glycoprotein, CYP3A4, CYP3A5, and UGT1A1. Glucocorticoids modulate CYP3A and P-glycoprotein in preclinical models, but their effect on clinical etoposide disposition is unknown. We studied the pharmacokinetics of etoposide and its catechol metabolite in children with acute lymphoblastic leukemia, along with polymorphisms in CYP3A4, CYP3A5, MDR1, GSTP1, UGT1A1, and VDR. Plasma pharmacokinetics were assessed at day 29, after 1 month of prednisone (n = 102), and at week 54, without prednisone (n = 44). On day 29, etoposide clearance was higher (47.4 versus 29.2 mL/min/m2, P <.0001) than at week 54. The day 29 etoposide or catechol area under the curve (AUC) was correlated with neutropenia (P =.027 and P =.0008, respectively). The relationship between genotype and etoposide disposition differed by race and by prednisone use. The MDR1 exon 26 CC genotype predicted higher day 29 etoposide clearance (P =.002) for all patients, and the CYP3A5 AA and GSTP1 AA genotypes predicted lower clearance in blacks (P =.02 and.03, respectively). The UGT1A1 6/6, VDR intron 8 GG, and VDR Fok 1 CC genotypes predicted higher week 54 clearance in blacks (P =.039,.036, and.052, respectively). The UGT1A1 6/6 genotype predicted lower catechol AUC. Prednisone strongly induces etoposide clearance, genetic polymorphisms may predict the constitutive and induced clearance of etoposide, and the relationship between genotype and phenotype differs by race.",Journal Article,5976.0,102.0,Etoposide is a substrate for P-glycoprotein CYP3A4 CYP3A5 and UGT1A1 Glucocorticoids modulate CYP3A and P-glycoprotein in preclinical models but their effect on clinical etoposide disposition is unknown We studied the pharmacokinetics of etoposide and its catechol metabolite in children with acute lymphoblastic along with polymorphisms in CYP3A4 CYP3A5 MDR1 GSTP1 UGT1A1 and VDR Plasma pharmacokinetics were assessed at day 29 after 1 month of prednisone n 102 and at week 54 without prednisone n 44 On day 29 etoposide clearance was higher 47.4 versus 29.2 mL/min/m2 P .0001 than at week 54 The day 29 etoposide or catechol area under the curve AUC was correlated with neutropenia P =.027 and P =.0008 respectively The relationship between genotype and etoposide disposition differed by race and by prednisone use The MDR1 exon 26 CC genotype predicted higher day 29 etoposide clearance P =.002 for all patients and the CYP3A5 AA and GSTP1 AA genotypes predicted lower clearance in blacks P =.02 and.03 respectively The UGT1A1 6/6 VDR intron 8 GG and VDR Fok 1 CC genotypes predicted higher week 54 clearance in blacks P =.039 .036 and.052 respectively The UGT1A1 6/6 genotype predicted lower catechol AUC Prednisone strongly induces etoposide clearance genetic polymorphisms may predict the constitutive and induced clearance of etoposide and the relationship between genotype and phenotype differs by race,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1934, 16, 8, 4235, 9, 19, 4455, 6208, 10071, 2, 6192, 7307, 3319, 12768, 2, 19, 4455, 4, 693, 274, 84, 136, 254, 23, 38, 1934, 5814, 16, 860, 21, 656, 3, 1159, 1, 1934, 2, 211, 18913, 3379, 4, 541, 5, 286, 1275, 1510, 5, 1203, 4, 6208, 10071, 5921, 5689, 6192, 2, 4905, 554, 1159, 11, 275, 28, 218, 462, 50, 14, 811, 1, 1979, 78, 2867, 2, 28, 647, 667, 187, 1979, 78, 584, 23, 218, 462, 1934, 1960, 10, 142, 662, 39, 185, 462, 18, 542, 1538, 821, 19, 488, 76, 28, 647, 667, 3, 218, 462, 1934, 15, 18913, 965, 669, 3, 1496, 1376, 10, 438, 5, 778, 19, 4523, 2, 19, 7044, 106, 3, 858, 59, 1183, 2, 1934, 5814, 2512, 20, 1047, 2, 20, 1979, 119, 3, 5921, 1725, 432, 1951, 1183, 783, 142, 218, 462, 1934, 1960, 19, 1111, 9, 62, 7, 2, 3, 10071, 1519, 2, 5689, 1519, 2071, 783, 280, 1960, 4, 3544, 19, 588, 2, 680, 106, 3, 6192, 49, 49, 4905, 6259, 66, 4334, 2, 4905, 33506, 14, 1951, 2071, 783, 142, 647, 667, 1960, 4, 3544, 19, 5955, 5395, 2, 9194, 106, 3, 6192, 49, 49, 1183, 783, 280, 18913, 1376, 1979, 1327, 1516, 1934, 1960, 336, 1203, 68, 678, 3, 3178, 2, 277, 1960, 1, 1934, 2, 3, 858, 59, 1183, 2, 1005, 4990, 20, 1047]",1410.0,12969965,187
The biology and therapy of adult acute lymphoblastic leukemia.,Cancer,Cancer,2003-10-01,"Much progress has been made in understanding the biology of acute lymphoblastic leukemia (ALL). This has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. A review from the English literature, including original articles and related reviews from Medline (Pubmed) and abstracts based on publication of meeting material, was performed. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies in children with ALL has resulted in similar complete response rates in adults. Prognosis has especially improved in mature-B-cell and T-lineage ALL. The role of tyrosine kinase inhibitors in Philadelphia chromosome-positive ALL was evaluated in the current study. However, regardless of the ALL subgroup, long-term survival of adults is still inferior to that in children. Intense clinical and laboratory research is attempting to close the gap in outcome between children and adults with ALL. Investigations are focusing on 1) refinement of the basic treatment stratagem of induction, consolidation, and maintenance; 2) expansion of risk-based, subgroup-oriented therapies; 3) assessment of minimal residual disease, its impact on disease recurrence, and its practical implications in clinical practice; 4) salvage strategies; 5) the role of stem cell transplantation in ALL; and 6) the development of new drugs based on a better understanding of disease biology.",Journal Article,5956.0,115.0,Much progress has been made in understanding the biology of acute lymphoblastic ALL This has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities A review from the English literature including original articles and related reviews from Medline Pubmed and abstracts based on publication of meeting material was performed Changes in the pathologic classification of ALL have led to therapeutic consequences Adaptation of successful treatment strategies in children with ALL has resulted in similar complete response rates in adults Prognosis has especially improved in mature-B-cell and T-lineage ALL The role of tyrosine kinase inhibitors in Philadelphia chromosome-positive ALL was evaluated in the current study However regardless of the ALL subgroup long-term survival of adults is still inferior to that in children Intense clinical and laboratory research is attempting to close the gap in outcome between children and adults with ALL Investigations are focusing on 1 refinement of the basic treatment stratagem of induction consolidation and maintenance 2 expansion of risk-based subgroup-oriented therapies 3 assessment of minimal residual disease its impact on disease recurrence and its practical implications in clinical practice 4 salvage strategies 5 the role of stem cell transplantation in ALL and 6 the development of new drugs based on a better understanding of disease biology,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1802, 1466, 71, 85, 1229, 4, 612, 3, 891, 1, 286, 1275, 62, 26, 71, 5136, 237, 3, 2335, 1, 392, 1453, 1, 62, 2, 3, 731, 1, 43, 3716, 235, 217, 235, 32, 1478, 90, 23, 3, 2470, 1, 112, 1266, 219, 1171, 8, 206, 29, 3, 4201, 789, 141, 2279, 2384, 2, 139, 2004, 29, 3388, 3161, 2, 5159, 90, 23, 4397, 1, 2238, 3692, 10, 173, 400, 4, 3, 510, 947, 1, 62, 47, 836, 6, 189, 3255, 7275, 1, 1401, 24, 422, 4, 541, 5, 62, 71, 627, 4, 288, 236, 51, 151, 4, 857, 356, 71, 1093, 231, 4, 2908, 132, 31, 2, 102, 2542, 62, 3, 200, 1, 564, 216, 222, 4, 3006, 1170, 109, 62, 10, 194, 4, 3, 291, 45, 137, 1583, 1, 3, 62, 1363, 319, 337, 25, 1, 857, 16, 1234, 1663, 6, 17, 4, 541, 3933, 38, 2, 1624, 389, 16, 9632, 6, 2336, 3, 5285, 4, 228, 59, 541, 2, 857, 5, 62, 2492, 32, 3312, 23, 14, 7266, 1, 3, 2795, 24, 53763, 1, 504, 2173, 2, 1146, 18, 1422, 1, 43, 90, 1363, 8095, 235, 27, 455, 1, 1048, 753, 34, 211, 345, 23, 34, 146, 2, 211, 3320, 1268, 4, 38, 758, 39, 992, 422, 33, 3, 200, 1, 452, 31, 497, 4, 62, 2, 49, 3, 193, 1, 217, 600, 90, 23, 8, 380, 612, 1, 34, 891]",1544.0,14508819,266
Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-10-01,"T-cell acute lymphoblastic leukemia (T-ALL) accounts for 10% to 15% of newly diagnosed cases of childhood acute lymphoblastic leukemia (ALL). Historically, T-ALL patients have had a worse prognosis than other ALL patients. We reviewed the outcomes of 125 patients with T-ALL treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium trials between 1981 and 1995. Therapy included four- or five-agent remission induction; consolidation therapy with doxorubicin, vincristine, corticosteroid, mercaptopurine, and weekly high-dose asparaginase; and cranial radiation. T-ALL patients were treated the same as high-risk B-progenitor ALL patients. Fifteen patients with T-cell lymphoblastic lymphoma were also treated with the same high-risk regimen between 1981 and 2000. The 5-year event-free survival (EFS) rate for T-ALL patients was 75% +/- 4%. Fourteen of 15 patients with T-cell lymphoblastic lymphoma were long-term survivors. There was no significant difference in EFS comparing patients with T-ALL and B-progenitor ALL (P =.56), although T-ALL patients had significantly higher rates of induction failure (P <.0001), and central nervous system (CNS) relapse (P =.02). The median time to relapse in T-ALL patients was 1.2 years versus 2.5 years in B-progenitor ALL patients (P =.001). There were no pretreatment characteristics associated with worse prognosis in patients with T-ALL. T-ALL patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols. Patients with T-ALL remain at increased risk for induction failure, early relapse, and isolated CNS relapse. Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure.",Journal Article,5956.0,226.0,T-cell acute lymphoblastic T-ALL accounts for 10 to 15 of newly diagnosed cases of childhood acute lymphoblastic ALL Historically T-ALL patients have had a worse prognosis than other ALL patients We reviewed the outcomes of 125 patients with T-ALL treated on Dana-Farber Cancer Institute DFCI ALL Consortium trials between 1981 and 1995 Therapy included four- or five-agent remission induction consolidation therapy with doxorubicin vincristine corticosteroid mercaptopurine and weekly high-dose asparaginase and cranial radiation T-ALL patients were treated the same as high-risk B-progenitor ALL patients Fifteen patients with T-cell lymphoblastic were also treated with the same high-risk regimen between 1981 and 2000 The 5-year event-free survival EFS rate for T-ALL patients was 75 +/- 4 Fourteen of 15 patients with T-cell lymphoblastic were long-term survivors There was no significant difference in EFS comparing patients with T-ALL and B-progenitor ALL P =.56 although T-ALL patients had significantly higher rates of induction failure P .0001 and central nervous system CNS relapse P =.02 The median time to relapse in T-ALL patients was 1.2 years versus 2.5 years in B-progenitor ALL patients P =.001 There were no pretreatment characteristics associated with worse prognosis in patients with T-ALL T-ALL patients fared as well as B-progenitor patients on DFCI ALL Consortium protocols Patients with T-ALL remain at increased risk for induction failure early relapse and isolated CNS relapse Future studies should focus on the identification of and treatment for T-ALL patients at high risk for treatment failure,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[102, 31, 286, 1275, 102, 62, 4162, 9, 79, 6, 167, 1, 732, 265, 140, 1, 864, 286, 1275, 62, 3578, 102, 62, 7, 47, 42, 8, 639, 356, 76, 127, 62, 7, 21, 446, 3, 123, 1, 1731, 7, 5, 102, 62, 73, 23, 4932, 4979, 12, 1377, 11152, 62, 2404, 143, 59, 10264, 2, 2323, 36, 159, 294, 15, 365, 420, 734, 504, 2173, 36, 5, 856, 2132, 5654, 9223, 2, 709, 64, 61, 3709, 2, 2565, 121, 102, 62, 7, 11, 73, 3, 827, 22, 64, 43, 132, 2520, 62, 7, 3057, 7, 5, 102, 31, 1275, 11, 120, 73, 5, 3, 827, 64, 43, 477, 59, 10264, 2, 1081, 3, 33, 111, 774, 115, 25, 1683, 116, 9, 102, 62, 7, 10, 481, 39, 3225, 1, 167, 7, 5, 102, 31, 1275, 11, 319, 337, 332, 125, 10, 77, 93, 523, 4, 1683, 1430, 7, 5, 102, 62, 2, 132, 2520, 62, 19, 664, 242, 102, 62, 7, 42, 97, 142, 151, 1, 504, 496, 19, 488, 2, 854, 1880, 398, 1025, 429, 19, 588, 3, 52, 98, 6, 429, 4, 102, 62, 7, 10, 14, 18, 60, 185, 18, 33, 60, 4, 132, 2520, 62, 7, 19, 144, 125, 11, 77, 1194, 374, 41, 5, 639, 356, 4, 7, 5, 102, 62, 102, 62, 7, 13073, 22, 149, 22, 132, 2520, 7, 23, 11152, 62, 2404, 2189, 7, 5, 102, 62, 918, 28, 101, 43, 9, 504, 496, 191, 429, 2, 1355, 1025, 429, 508, 94, 257, 1222, 23, 3, 911, 1, 2, 24, 9, 102, 62, 7, 28, 64, 43, 9, 24, 496]",1624.0,14512392,228
Results of therapy for acute lymphoblastic leukemia in black and white children.,JAMA,JAMA,2003-10-01,"Treatment results for acute lymphoblastic leukemia (ALL) clearly have improved over the past decade, but black children have not fared as well as white children in large national trials. To compare the clinical outcomes of therapy for black and white children with ALL treated at a single institution. A retrospective analysis of 412 children and adolescents (68 black, 338 white, and 6 other race) with newly diagnosed ALL who were treated consecutively at a pediatric cancer center in Memphis, Tenn. Patients were enrolled from December 1991 to July 1998 in successive Total Therapy studies regardless of race, ethnicity, or ability to pay and received risk-directed therapy according to stringent criteria. All patients received the same intensive, remission-induction therapy followed by 120 weeks of risk-assigned postremission therapy that included reinduction treatment, pulses of high-dose methotrexate, and early intensification of intrathecal chemotherapy. Event-free and overall survival rates for black and white children were estimated by the method of Kaplan and Meier and compared with the Mantel-Haenszel test and by Cox proportional hazards regression analysis, adjusting for known prognostic factors. The 68 black children were significantly more likely than the 338 white children to have higher-risk prognostic features, including an initial leukocyte count greater than 100 x 10(3)/ microL, a T-cell immunophenotype, and the t(1;19) chromosomal translocation with E2A-PBX1 fusion, and were less likely to have hyperdiploid blast cells, a favorable prognostic factor in childhood ALL. However, the clinical outcomes for these 2 cohorts were not significantly different: 5-year event-free and overall survival rates were 80.7% (95% confidence interval [CI], 70.3%-91.1%) and 86.2% (95% CI, 77.2%-95.2%) for black children vs 79.4% (95% CI, 74.7%-84.1%) and 85.0% (95% CI, 80.9%-89.1%) for white children. Ten-year results also were comparable, but the CIs were wide because of the small numbers of patients who had been followed up for 10 years or more. The lack of a racial effect on the long-term outcome of therapy was still apparent in a multivariate Cox regression analysis, adjusting for sex, age, presenting leukocyte count, leukemic cell DNA index, immunophenotype, and central nervous system status. With equal access to effective antileukemic therapy, black and white children with ALL can expect the same high rate of cure.",Journal Article,5956.0,127.0,Treatment results for acute lymphoblastic ALL clearly have improved over the past decade but black children have not fared as well as white children in large national trials To compare the clinical outcomes of therapy for black and white children with ALL treated at a single institution A retrospective analysis of 412 children and adolescents 68 black 338 white and 6 other race with newly diagnosed ALL who were treated consecutively at a pediatric cancer center in Memphis Tenn Patients were enrolled from December 1991 to July 1998 in successive Total Therapy studies regardless of race ethnicity or ability to pay and received risk-directed therapy according to stringent criteria All patients received the same intensive remission-induction therapy followed by 120 weeks of risk-assigned postremission therapy that included reinduction treatment pulses of high-dose methotrexate and early intensification of intrathecal chemotherapy Event-free and overall survival rates for black and white children were estimated by the method of Kaplan and Meier and compared with the Mantel-Haenszel test and by Cox proportional hazards regression analysis adjusting for known prognostic factors The 68 black children were significantly more likely than the 338 white children to have higher-risk prognostic features including an initial leukocyte count greater than 100 x 10 3 microL a T-cell immunophenotype and the t 1 19 chromosomal translocation with E2A-PBX1 fusion and were less likely to have hyperdiploid blast cells a favorable prognostic factor in childhood ALL However the clinical outcomes for these 2 cohorts were not significantly different 5-year event-free and overall survival rates were 80.7 95 confidence interval CI 70.3 -91.1 and 86.2 95 CI 77.2 -95.2 for black children vs 79.4 95 CI 74.7 -84.1 and 85.0 95 CI 80.9 -89.1 for white children Ten-year results also were comparable but the CIs were wide because of the small numbers of patients who had been followed up for 10 years or more The lack of a racial effect on the long-term outcome of therapy was still apparent in a multivariate Cox regression analysis adjusting for sex age presenting leukocyte count leukemic cell DNA index immunophenotype and central nervous system status With equal access to effective antileukemic therapy black and white children with ALL can expect the same high rate of cure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 99, 9, 286, 1275, 62, 2536, 47, 231, 252, 3, 1219, 2025, 84, 1445, 541, 47, 44, 13073, 22, 149, 22, 886, 541, 4, 375, 657, 143, 6, 932, 3, 38, 123, 1, 36, 9, 1445, 2, 886, 541, 5, 62, 73, 28, 8, 226, 731, 8, 459, 65, 1, 9963, 541, 2, 3101, 806, 1445, 9982, 886, 2, 49, 127, 1047, 5, 732, 265, 62, 54, 11, 73, 7380, 28, 8, 815, 12, 574, 4, 18922, 43400, 7, 11, 346, 29, 1397, 3372, 6, 2066, 1850, 4, 6808, 181, 36, 94, 1583, 1, 1047, 2091, 15, 801, 6, 6974, 2, 103, 43, 1166, 36, 768, 6, 6763, 371, 62, 7, 103, 3, 827, 1686, 734, 504, 36, 370, 20, 2031, 244, 1, 43, 896, 8635, 36, 17, 159, 10177, 24, 15523, 1, 64, 61, 2116, 2, 191, 5091, 1, 5126, 56, 774, 115, 2, 63, 25, 151, 9, 1445, 2, 886, 541, 11, 661, 20, 3, 596, 1, 876, 2, 882, 2, 72, 5, 3, 11618, 14496, 412, 2, 20, 418, 831, 1017, 320, 65, 1358, 9, 440, 177, 130, 3, 806, 1445, 541, 11, 97, 80, 322, 76, 3, 9982, 886, 541, 6, 47, 142, 43, 177, 404, 141, 35, 388, 3627, 1276, 378, 76, 394, 1006, 79, 27, 5128, 8, 102, 31, 5496, 2, 3, 102, 14, 326, 1860, 2006, 5, 15127, 14434, 1212, 2, 11, 299, 322, 6, 47, 8847, 3112, 37, 8, 913, 177, 161, 4, 864, 62, 137, 3, 38, 123, 9, 46, 18, 736, 11, 44, 97, 338, 33, 111, 774, 115, 2, 63, 25, 151, 11, 493, 67, 48, 307, 268, 58, 431, 27, 970, 14, 2, 868, 18, 48, 58, 849, 18, 48, 18, 9, 1445, 541, 105, 842, 39, 48, 58, 794, 67, 874, 14, 2, 772, 13, 48, 58, 493, 83, 887, 14, 9, 886, 541, 1618, 111, 99, 120, 11, 1279, 84, 3, 1927, 11, 1019, 408, 1, 3, 302, 1870, 1, 7, 54, 42, 85, 370, 126, 9, 79, 60, 15, 80, 3, 926, 1, 8, 2257, 254, 23, 3, 319, 337, 228, 1, 36, 10, 1234, 2235, 4, 8, 331, 418, 320, 65, 1358, 9, 1035, 89, 1656, 3627, 1276, 2015, 31, 261, 558, 5496, 2, 854, 1880, 398, 156, 5, 2997, 1655, 6, 323, 4512, 36, 1445, 2, 886, 541, 5, 62, 122, 8439, 3, 827, 64, 116, 1, 1722]",2375.0,14559953,631
Thyroid carcinoma presenting in childhood or after treatment of childhood malignancies: An institutional experience and review of the literature.,Journal of pediatric surgery,J. Pediatr. Surg.,2003-11-01,"Thyroid carcinomas can occur as a primary malignancy (PTM) or secondary after another malignancy (STM). Information about the presentations and outcomes of patients with STM are limited. The authors sought to compare the clinical characteristics, course, and outcomes of patients with primary or secondary thyroid malignancies. The authors reviewed the medical records of 8 children with PTM and 17 children with STM referred to St Jude Children's Research Hospital between February 1962 and February 2002 for evaluation and treatment of malignant thyroid carcinoma. The 8 children who had primary thyroid carcinoma had it diagnosed at a median age of 12.5 years (range, 7.3 to 16.3 years). Seven patients had papillary carcinoma, and 1 patient had follicular carcinoma. Three of the 8 (37.5%) had metastatic disease involving regional lymph nodes; 2 patients (25.0%) had lung metastases. Six patients required radioactive iodine (I 131) ablation for residual or metastatic disease after surgical resection. All 8 patients remain alive a median of 22.6 years after diagnosis (range, 0.7 to 30.5 years); 1 continues to receive radioactive iodine (I 131) ablation for persistent disease. Seventeen patients had thyroid carcinoma as a second malignant neoplasm after treatment for acute lymphoblastic leukemia (n = 6), Hodgkin's disease (n = 5), central nervous system tumor (n = 2), Wilms' tumor (n = 1), retinoblastoma (n = 1), non-Hodgkin's lymphoma (n = 1), or neuroblastoma (n = 1). Patients with secondary thyroid carcinoma presented at a median age of 21.5 years (range, 15.3 to 42.6 years), a median of 16.2 years (range, 0.9 to 29.2 years) after diagnosis of the primary cancer. Twelve of the 17 patients (70.6%) had received radiation to the thyroid gland during therapy for the primary cancer. Four patients (23.5%) had metastatic disease involving regional lymph nodes. Six patients (35.3%) required I(131) ablation for residual or metastatic disease after thyroidectomy. At the time of this report, all 17 patients are alive and in continue to be free of disease. Pediatric thyroid carcinoma is uncommon and responds well to current therapy. Given the limited period of follow-up of our cohort of secondary malignant thyroid tumors that arise after childhood cancer, these lesions appear to have similar presentations and outcomes when compared with primary carcinomas and can therefore be managed in the same manner.",Journal Article,5925.0,60.0,carcinomas can occur as a primary malignancy PTM or secondary after another malignancy STM Information about the presentations and outcomes of patients with STM are limited The authors sought to compare the clinical characteristics course and outcomes of patients with primary or secondary malignancies The authors reviewed the medical records of 8 children with PTM and 17 children with STM referred to St Jude Children 's Research Hospital between February 1962 and February 2002 for evaluation and treatment of malignant carcinoma The 8 children who had primary carcinoma had it diagnosed at a median age of 12.5 years range 7.3 to 16.3 years Seven patients had papillary carcinoma and 1 patient had follicular carcinoma Three of the 8 37.5 had metastatic disease involving regional lymph nodes 2 patients 25.0 had metastases Six patients required radioactive iodine I 131 ablation for residual or metastatic disease after surgical resection All 8 patients remain alive a median of 22.6 years after diagnosis range 0.7 to 30.5 years 1 continues to receive radioactive iodine I 131 ablation for persistent disease Seventeen patients had carcinoma as a second malignant neoplasm after treatment for acute lymphoblastic n 6 's disease n 5 central nervous system tumor n 2 tumor n 1 n 1 's n 1 or n 1 Patients with secondary carcinoma presented at a median age of 21.5 years range 15.3 to 42.6 years a median of 16.2 years range 0.9 to 29.2 years after diagnosis of the primary cancer Twelve of the 17 patients 70.6 had received radiation to the gland during therapy for the primary cancer Four patients 23.5 had metastatic disease involving regional lymph nodes Six patients 35.3 required I 131 ablation for residual or metastatic disease after thyroidectomy At the time of this report all 17 patients are alive and in continue to be free of disease Pediatric carcinoma is uncommon and responds well to current therapy Given the limited period of follow-up of our cohort of secondary malignant tumors that arise after childhood cancer these lesions appear to have similar presentations and outcomes when compared with primary carcinomas and can therefore be managed in the same manner,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,"[826, 122, 1271, 22, 8, 86, 710, 23207, 15, 568, 50, 1809, 710, 20338, 487, 545, 3, 4261, 2, 123, 1, 7, 5, 20338, 32, 383, 3, 738, 990, 6, 932, 3, 38, 374, 906, 2, 123, 1, 7, 5, 86, 15, 568, 441, 3, 738, 446, 3, 484, 1064, 1, 66, 541, 5, 23207, 2, 269, 541, 5, 20338, 1995, 6, 3062, 4841, 541, 292, 389, 702, 59, 3010, 14754, 2, 3010, 1544, 9, 451, 2, 24, 1, 393, 134, 3, 66, 541, 54, 42, 86, 134, 42, 192, 265, 28, 8, 52, 89, 1, 133, 33, 60, 184, 67, 27, 6, 245, 27, 60, 648, 7, 42, 1796, 134, 2, 14, 69, 42, 1974, 134, 169, 1, 3, 66, 567, 33, 42, 113, 34, 1267, 951, 263, 502, 18, 7, 243, 13, 42, 196, 437, 7, 616, 4741, 4287, 70, 2229, 1650, 9, 753, 15, 113, 34, 50, 221, 170, 62, 66, 7, 918, 1701, 8, 52, 1, 350, 49, 60, 50, 147, 184, 13, 67, 6, 201, 33, 60, 14, 2274, 6, 560, 4741, 4287, 70, 2229, 1650, 9, 1882, 34, 3591, 7, 42, 134, 22, 8, 419, 393, 2131, 50, 24, 9, 286, 1275, 78, 49, 292, 34, 78, 33, 854, 1880, 398, 30, 78, 18, 30, 78, 14, 78, 14, 292, 78, 14, 15, 78, 14, 7, 5, 568, 134, 917, 28, 8, 52, 89, 1, 239, 33, 60, 184, 167, 27, 6, 595, 49, 60, 8, 52, 1, 245, 18, 60, 184, 13, 83, 6, 462, 18, 60, 50, 147, 1, 3, 86, 12, 2544, 1, 3, 269, 7, 431, 49, 42, 103, 121, 6, 3, 2326, 190, 36, 9, 3, 86, 12, 294, 7, 382, 33, 42, 113, 34, 1267, 951, 263, 502, 437, 7, 465, 27, 616, 70, 2229, 1650, 9, 753, 15, 113, 34, 50, 5949, 28, 3, 98, 1, 26, 414, 62, 269, 7, 32, 1701, 2, 4, 1906, 6, 40, 115, 1, 34, 815, 134, 16, 2052, 2, 7920, 149, 6, 291, 36, 447, 3, 383, 727, 1, 166, 126, 1, 114, 180, 1, 568, 393, 57, 17, 3043, 50, 864, 12, 46, 406, 1322, 6, 47, 288, 4261, 2, 123, 198, 72, 5, 86, 826, 2, 122, 673, 40, 2231, 4, 3, 827, 1708]",2184.0,14614703,53
IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL.,Blood,Blood,2003-11-13,"The specific targeting of critical signaling molecules may provide efficient therapies for T-cell acute lymphoblastic leukemia (T-ALL). However, target identification and drug development are limited by insufficient numbers of primary T-ALL cells and by their high rate of spontaneous apoptosis. We established a human interleukin-7 (IL-7)-dependent T-ALL cell line, TAIL7, that maintains several biologic and signaling properties of its parental leukemia cells. TAIL7 cells are pre-T-ALL cells that proliferate in response to IL-7 and IL-4. IL-7 stimulation of TAIL7 cells prevents spontaneous in vitro apoptosis and induces cell activation and cell cycle progression. The signaling events triggered by IL-7 include down-regulation of p27(kip1) and hyperphosphorylation of retinoblastoma protein (Rb). Stimulation of TAIL7 cells by IL-7 leads to phosphorylation of Janus kinase 3 (JAK3), signal transducer and activator of transcription 5 (STAT5), Akt/PKB (protein kinase B), and extracellular-regulated kinase 1 and 2 (Erk1/2). Importantly, specific blockade of JAK3 by its inhibitor WHI-P131 abrogates the IL-7-mediated proliferation and survival of TAIL7 cells, suggesting that activation of JAK3 is critical for IL-7 responsiveness by these cells. Because TAIL7 cells seem to be a biologic surrogate for primary leukemia T cells, this cell line constitutes a valuable tool for the study of the signaling pathways implicated in T-ALL. Exploitation of this cell line should allow the identification of molecular targets and promote the rational design and validation of antileukemia signaling inhibitors.",Journal Article,5913.0,40.0,The specific targeting of critical signaling molecules may provide efficient therapies for T-cell acute lymphoblastic T-ALL However target identification and drug development are limited by insufficient numbers of primary T-ALL cells and by their high rate of spontaneous apoptosis We established a human interleukin-7 IL-7 -dependent T-ALL cell line TAIL7 that maintains several biologic and signaling properties of its parental cells TAIL7 cells are pre-T-ALL cells that proliferate in response to IL-7 and IL-4 IL-7 stimulation of TAIL7 cells prevents spontaneous in vitro apoptosis and induces cell activation and cell cycle progression The signaling events triggered by IL-7 include down-regulation of p27 kip1 and hyperphosphorylation of protein Rb Stimulation of TAIL7 cells by IL-7 leads to phosphorylation of Janus kinase 3 JAK3 signal transducer and activator of transcription 5 STAT5 Akt/PKB protein kinase B and extracellular-regulated kinase 1 and 2 Erk1/2 Importantly specific blockade of JAK3 by its inhibitor WHI-P131 abrogates the IL-7-mediated proliferation and survival of TAIL7 cells suggesting that activation of JAK3 is critical for IL-7 responsiveness by these cells Because TAIL7 cells seem to be a biologic surrogate for primary T cells this cell line constitutes a valuable tool for the study of the signaling pathways implicated in T-ALL Exploitation of this cell line should allow the identification of molecular targets and promote the rational design and validation of antileukemia signaling inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 112, 529, 1, 740, 314, 1598, 68, 377, 2547, 235, 9, 102, 31, 286, 1275, 102, 62, 137, 283, 911, 2, 234, 193, 32, 383, 20, 3027, 1870, 1, 86, 102, 62, 37, 2, 20, 136, 64, 116, 1, 3280, 351, 21, 635, 8, 171, 1603, 67, 501, 67, 470, 102, 62, 31, 328, 28147, 17, 8107, 392, 1283, 2, 314, 1571, 1, 211, 3418, 37, 28147, 37, 32, 671, 102, 62, 37, 17, 9554, 4, 51, 6, 501, 67, 2, 501, 39, 501, 67, 2503, 1, 28147, 37, 5217, 3280, 4, 439, 351, 2, 1516, 31, 363, 2, 31, 417, 91, 3, 314, 281, 4173, 20, 501, 67, 643, 1328, 863, 1, 2804, 5584, 2, 23280, 1, 178, 2955, 2503, 1, 28147, 37, 20, 501, 67, 1940, 6, 982, 1, 6191, 216, 27, 18927, 1235, 5182, 2, 3393, 1, 866, 33, 5517, 649, 10662, 178, 216, 132, 2, 1976, 1065, 216, 14, 2, 18, 3533, 18, 1859, 112, 1189, 1, 18927, 20, 211, 230, 10465, 53858, 8044, 3, 501, 67, 517, 457, 2, 25, 1, 28147, 37, 802, 17, 363, 1, 18927, 16, 740, 9, 501, 67, 3642, 20, 46, 37, 408, 28147, 37, 3233, 6, 40, 8, 1283, 2592, 9, 86, 102, 37, 26, 31, 328, 6788, 8, 2926, 1515, 9, 3, 45, 1, 3, 314, 460, 1771, 4, 102, 62, 11588, 1, 26, 31, 328, 257, 1700, 3, 911, 1, 219, 637, 2, 1617, 3, 2696, 771, 2, 929, 1, 9169, 314, 222]",1532.0,14615384,433
Pediatric acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2003-01-01,"The outcome for children with acute lymphoblastic leukemia (ALL) has improved dramatically with current therapy resulting in an event free survival exceeding 75% for most patients. However significant challenges remain including developing better methods to predict which patients can be cured with less toxic treatment and which ones will benefit from augmented therapy. In addition, 25% of patients fail therapy and novel treatments that are focused on undermining specifically the leukemic process are needed urgently. In Section I, Dr. Carroll reviews current approaches to risk classification and proposes a system that incorporates well-established clinical parameters, genetic lesions of the blast as well as early response parameters. He then provides an overview of emerging technologies in genomics and proteomics and how they might lead to more rational, biologically based classification systems. In Section II, Drs. Mary Relling and Stella Davies describe emerging findings that relate to host features that influence outcome, the role of inherited germline variation. They highlight technical breakthroughs in assessing germline differences among patients. Polymorphisms of drug metabolizing genes have been shown to influence toxicity and the best example is the gene thiopurine methyltransferase (TPMT) a key enzyme in the metabolism of 6-mercaptopurine. Polymorphisms are associated with decreased activity that is also associated with increased toxicity. The role of polymorphisms in other genes whose products play an important role in drug metabolism as well as cytokine genes are discussed. In Sections III and IV, Drs. James Downing and Cheryl Willman review their findings using gene expression profiling to classify ALL. Both authors outline challenges in applying this methodology to analysis of clinical samples. Dr. Willman describes her laboratory's examination of infant leukemia and precursor B-ALL where unsupervised approaches have led to the identification of inherent biologic groups not predicted by conventional morphologic, immunophenotypic and cytogenetic variables. Dr. Downing describes his results from a pediatric ALL expression database using over 327 diagnostic samples, with 80% of the dataset consisting of samples from patients treated on a single institutional protocol. Seven distinct leukemia subtypes were identified representing known leukemia subtypes including: BCR-ABL, E2A-PBX1, TEL-AML1, rearrangements in the MLL gene, hyperdiploid karyotype (i.e., > 50 chromosomes), and T-ALL as well as a new leukemia subtype. A subset of genes have been identified whose expression appears to be predictive of outcome but independent verification is needed before this type of analysis can be integrated into treatment assignment. Chemotherapeutic agents kill cancer cells by activating apoptosis, or programmed cell death. In Section V, Dr. John Reed describes major apoptotic pathways and the specific role of key proteins in this response. The expression level of some of these proteins, such as BCL2, BAX, and caspase 3, has been shown to be predictive of ultimate outcome in hematopoietic tumors. New therapeutic approaches that modulate the apoptotic pathway are now available and Dr. Reed highlights those that may be applicable to the treatment of childhood ALL.",Journal Article,6229.0,114.0,The outcome for children with acute lymphoblastic ALL has improved dramatically with current therapy resulting in an event free survival exceeding 75 for most patients However significant challenges remain including developing better methods to predict which patients can be cured with less toxic treatment and which ones will benefit from augmented therapy In addition 25 of patients fail therapy and novel treatments that are focused on undermining specifically the leukemic process are needed urgently In Section I Dr. Carroll reviews current approaches to risk classification and proposes a system that incorporates well-established clinical parameters genetic lesions of the blast as well as early response parameters He then provides an overview of emerging technologies in genomics and proteomics and how they might lead to more rational biologically based classification systems In Section II Drs Mary Relling and Stella Davies describe emerging findings that relate to host features that influence outcome the role of inherited germline variation They highlight technical breakthroughs in assessing germline differences among patients Polymorphisms of drug metabolizing genes have been shown to influence toxicity and the best example is the gene thiopurine methyltransferase TPMT a key enzyme in the metabolism of 6-mercaptopurine Polymorphisms are associated with decreased activity that is also associated with increased toxicity The role of polymorphisms in other genes whose products play an important role in drug metabolism as well as cytokine genes are discussed In Sections III and IV Drs James Downing and Cheryl Willman review their findings using gene expression profiling to classify ALL Both authors outline challenges in applying this methodology to analysis of clinical samples Dr. Willman describes her laboratory 's examination of infant and precursor B-ALL where unsupervised approaches have led to the identification of inherent biologic groups not predicted by conventional morphologic immunophenotypic and cytogenetic variables Dr Downing describes his results from a pediatric ALL expression database using over 327 diagnostic samples with 80 of the dataset consisting of samples from patients treated on a single institutional protocol Seven distinct subtypes were identified representing known subtypes including BCR-ABL E2A-PBX1 TEL-AML1 rearrangements in the MLL gene hyperdiploid karyotype i.e. 50 chromosomes and T-ALL as well as a new subtype A subset of genes have been identified whose expression appears to be predictive of outcome but independent verification is needed before this type of analysis can be integrated into treatment assignment Chemotherapeutic agents kill cancer cells by activating apoptosis or programmed cell death In Section V Dr. John Reed describes major apoptotic pathways and the specific role of key proteins in this response The expression level of some of these proteins such as BCL2 BAX and caspase 3 has been shown to be predictive of ultimate outcome in hematopoietic tumors New therapeutic approaches that modulate the apoptotic pathway are now available and Dr. Reed highlights those that may be applicable to the treatment of childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 228, 9, 541, 5, 286, 1275, 62, 71, 231, 2729, 5, 291, 36, 1113, 4, 35, 774, 115, 25, 5178, 481, 9, 96, 7, 137, 93, 1427, 918, 141, 931, 380, 636, 6, 678, 92, 7, 122, 40, 3733, 5, 299, 1812, 24, 2, 92, 6737, 303, 247, 29, 4277, 36, 4, 352, 243, 1, 7, 4373, 36, 2, 229, 640, 17, 32, 1649, 23, 33557, 1225, 3, 2015, 1129, 32, 575, 5354, 4, 2917, 70, 3436, 37584, 2004, 291, 611, 6, 43, 947, 2, 9785, 8, 398, 17, 6175, 149, 635, 38, 1038, 336, 406, 1, 3, 3112, 22, 149, 22, 191, 51, 1038, 3174, 818, 777, 35, 2901, 1, 1478, 2590, 4, 4229, 2, 6478, 2, 832, 491, 822, 1122, 6, 80, 2696, 2665, 90, 947, 1530, 4, 2917, 215, 9227, 37329, 43085, 2, 53871, 37204, 897, 1478, 272, 17, 6509, 6, 1204, 404, 17, 1054, 228, 3, 200, 1, 2986, 1009, 1380, 491, 1817, 3359, 9985, 4, 1977, 1009, 362, 107, 7, 1203, 1, 234, 9800, 214, 47, 85, 443, 6, 1054, 155, 2, 3, 824, 2685, 16, 3, 145, 14062, 3747, 14852, 8, 825, 1644, 4, 3, 1600, 1, 49, 9223, 1203, 32, 41, 5, 340, 128, 17, 16, 120, 41, 5, 101, 155, 3, 200, 1, 1203, 4, 127, 214, 1310, 2766, 1343, 35, 305, 200, 4, 234, 1600, 22, 149, 22, 1675, 214, 32, 1588, 4, 3013, 316, 2, 478, 9227, 26239, 43444, 2, 43082, 33329, 206, 136, 272, 75, 145, 55, 1080, 6, 4896, 62, 110, 738, 5277, 1427, 4, 4798, 26, 3209, 6, 65, 1, 38, 347, 3436, 33329, 2677, 1084, 1624, 292, 1385, 1, 8027, 2, 2765, 132, 62, 1257, 6512, 611, 47, 836, 6, 3, 911, 1, 4943, 1283, 271, 44, 783, 20, 809, 2815, 6599, 2, 1266, 682, 3436, 43444, 2677, 3224, 99, 29, 8, 815, 62, 55, 609, 75, 252, 7749, 752, 347, 5, 493, 1, 3, 3014, 2273, 1, 347, 29, 7, 73, 23, 8, 226, 1115, 1182, 648, 834, 814, 11, 108, 2861, 440, 814, 141, 1062, 1425, 15127, 14434, 8573, 6535, 2072, 4, 3, 3049, 145, 8847, 3385, 70, 563, 212, 3560, 2, 102, 62, 22, 149, 22, 8, 217, 875, 8, 697, 1, 214, 47, 85, 108, 1310, 55, 1233, 6, 40, 464, 1, 228, 84, 306, 6720, 16, 575, 348, 26, 267, 1, 65, 122, 40, 2102, 237, 24, 4392, 1573, 183, 5097, 12, 37, 20, 1616, 351, 15, 1846, 31, 273, 4, 2917, 603, 3436, 9968, 10599, 2677, 458, 1631, 460, 2, 3, 112, 200, 1, 825, 652, 4, 26, 51, 3, 55, 301, 1, 476, 1, 46, 652, 225, 22, 3214, 3119, 2, 1469, 27, 71, 85, 443, 6, 40, 464, 1, 5768, 228, 4, 1007, 57, 217, 189, 611, 17, 3319, 3, 1631, 308, 32, 1134, 390, 2, 3436, 10599, 2527, 135, 17, 68, 40, 3801, 6, 3, 24, 1, 864, 62]",3215.0,14633779,321
Management of an anaphylactoid reaction to methotrexate with a stepwise graded challenge.,Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology,Pediatr Allergy Immunol,2003-10-01,"We report the management of a 15-year-old boy with an anaphylactic or anaphylactoid response to his first dose of methotrexate during induction therapy for acute lymphoblastic leukemia (ALL). Because weekly methotrexate therapy is an important component of continuation chemotherapy for pediatric ALL, a stepwise graded challenge was employed to achieve drug tolerance.",Case Reports,5956.0,10.0,We report the management of a 15-year-old boy with an anaphylactic or anaphylactoid response to his first dose of methotrexate during induction therapy for acute lymphoblastic ALL Because weekly methotrexate therapy is an important component of continuation chemotherapy for pediatric ALL a stepwise graded challenge was employed to achieve drug tolerance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 3, 284, 1, 8, 167, 111, 1095, 10802, 5, 35, 30202, 15, 30478, 51, 6, 3224, 157, 61, 1, 2116, 190, 504, 36, 9, 286, 1275, 62, 408, 709, 2116, 36, 16, 35, 305, 1249, 1, 6870, 56, 9, 815, 62, 8, 5497, 3468, 1745, 10, 2516, 6, 1359, 234, 2614]",355.0,14641613,13
Impact of CNS treatment on mood in adult survivors of childhood leukemia: a report from the Children's Cancer Group.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2003-12-01,"This study assessed the relationship between CNS treatment and psychologic mood using the Profile of Moods State (POMS), a standardized measure of affect, among a large sample of young adult survivors of childhood acute lymphoblastic leukemia (ALL; N = 555). Survivors of childhood ALL (ages 18 to 33 years at study entry) participated in a structured telephone interview eliciting demographic, health, and behavioral data and the POMS. Treatment data included total dose of CNS irradiation (CRT) and intrathecal methotrexate (MTX) obtained from medical records. Mood disturbance was reported by 24% of survivors. High-dose CRT and MTX predicted disturbance rates modestly and primarily in combination with education variables. Interactions between educational achievement, a history of attendance in special education classes, and sex were better predictors than treatment type or dose. Nonwhite males, those younger than 12.5 years of age at diagnosis, and those with negative perceptions of current health and cancer's impact on employment were also at greater risk for mood disturbance (P <.01 to.001). Although most survivors are doing well psychologically, a subset of long-term survivors show potentially serious mood disturbance. Mood disturbance seems to be a function of interactions between preexisting individual difference variables (eg, sex, race/ethnicity), treatment factors, and posttreatment educational experiences. Prevention strategies aimed at childhood cancer survivors at greatest risk for mood disturbance may be improved by focus on posttreatment psychosocial and educational supports.",Comparative Study,5895.0,50.0,This study assessed the relationship between CNS treatment and psychologic mood using the Profile of Moods State POMS a standardized measure of affect among a large sample of young adult survivors of childhood acute lymphoblastic ALL N 555 Survivors of childhood ALL ages 18 to 33 years at study entry participated in a structured telephone interview eliciting demographic health and behavioral data and the POMS Treatment data included total dose of CNS irradiation CRT and intrathecal methotrexate MTX obtained from medical records Mood disturbance was reported by 24 of survivors High-dose CRT and MTX predicted disturbance rates modestly and primarily in combination with education variables Interactions between educational achievement a history of attendance in special education classes and sex were better predictors than treatment type or dose Nonwhite males those younger than 12.5 years of age at diagnosis and those with negative perceptions of current health and cancer 's impact on employment were also at greater risk for mood disturbance P .01 to.001 Although most survivors are doing well psychologically a subset of long-term survivors show potentially serious mood disturbance Mood disturbance seems to be a function of interactions between preexisting individual difference variables eg sex race/ethnicity treatment factors and posttreatment educational experiences Prevention strategies aimed at childhood cancer survivors at greatest risk for mood disturbance may be improved by focus on posttreatment psychosocial and educational supports,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26, 45, 275, 3, 858, 59, 1025, 24, 2, 14388, 5234, 75, 3, 800, 1, 43450, 1309, 18320, 8, 1670, 1463, 1, 1158, 107, 8, 375, 1000, 1, 1169, 780, 332, 1, 864, 286, 1275, 62, 78, 10823, 332, 1, 864, 62, 2165, 203, 6, 466, 60, 28, 45, 3001, 3025, 4, 8, 5198, 4258, 4313, 10299, 1540, 341, 2, 4166, 74, 2, 3, 18320, 24, 74, 159, 181, 61, 1, 1025, 1104, 1089, 2, 5126, 2116, 3453, 683, 29, 484, 1064, 5234, 6663, 10, 210, 20, 259, 1, 332, 64, 61, 1089, 2, 3453, 783, 6663, 151, 5588, 2, 1561, 4, 150, 5, 1848, 682, 1286, 59, 3624, 5088, 8, 532, 1, 12349, 4, 3714, 1848, 3211, 2, 1035, 11, 380, 674, 76, 24, 267, 15, 61, 8335, 2296, 135, 773, 76, 133, 33, 60, 1, 89, 28, 147, 2, 135, 5, 199, 3746, 1, 291, 341, 2, 12, 292, 345, 23, 5141, 11, 120, 28, 378, 43, 9, 5234, 6663, 19, 355, 6, 144, 242, 96, 332, 32, 9647, 149, 24588, 8, 697, 1, 319, 337, 332, 514, 751, 1762, 5234, 6663, 5234, 6663, 2744, 6, 40, 8, 343, 1, 1286, 59, 5004, 797, 523, 682, 2887, 1035, 1047, 2091, 24, 130, 2, 3149, 3624, 4031, 1070, 422, 1295, 28, 864, 12, 332, 28, 2199, 43, 9, 5234, 6663, 68, 40, 231, 20, 1222, 23, 3149, 2322, 2, 3624, 2304]",1561.0,14645430,277
Reassessment of the prognostic significance of hypodiploidy in pediatric patients with acute lymphoblastic leukemia.,Cancer,Cancer,2003-12-01,"The purpose of the current study was to evaluate the cytogenetic features of the hypodiploid leukemic cells of pediatric patients with this rare subgroup of acute lymphoblastic leukemia (ALL). In addition, the authors determined whether subdivision of the hypodiploid category served a prognostic purpose for these patients. The authors evaluated the cytogenetic records of 979 patients with ALL admitted to St. Jude Children's Research Hospital (Memphis, TN) between 1984 and 1999. Of 67 patients (6.8%) whose leukemic cells contained a modal number (MN) of chromosomes less than or equal to 45 (i.e., hypodiploid leukemic cells), 57 had an MN of 45 and 10 had an MN of less than 45. In 19 patients, cells with an MN of 45 had a whole chromosome missing (42%), which was a sex chromosome in 12 patients (63%). Leukemic cells with an MN of 45 contained dicentric chromosomes (n = 33) formed from chromosome 9p (55%), 12p (18%), or both (21%). The ETV6-CBFA2 fusion was present in 39% of 28 evaluable B-lineage cases with an MN of 45. The event-free survival rate (EFS) for patients with hypodiploid leukemic cells of MN less than 45 (5-year EFS = 20.0% +/- 10.3%) was significantly (P < 0.001) lower than that for patients with leukemic cells of MN greater than or equal to 45 (5-year EFS = 74.9% +/- 1.6%). Low hypodiploidy (MN < 45) should be recognized as a high-risk feature in pediatric ALL. Only two hypodiploid groups (MN < 45 and MN = 45) may be necessary in prognostic assessments.",Journal Article,5895.0,70.0,The purpose of the current study was to evaluate the cytogenetic features of the hypodiploid leukemic cells of pediatric patients with this rare subgroup of acute lymphoblastic ALL In addition the authors determined whether subdivision of the hypodiploid category served a prognostic purpose for these patients The authors evaluated the cytogenetic records of 979 patients with ALL admitted to St. Jude Children 's Research Hospital Memphis TN between 1984 and 1999 Of 67 patients 6.8 whose leukemic cells contained a modal number MN of chromosomes less than or equal to 45 i.e. hypodiploid leukemic cells 57 had an MN of 45 and 10 had an MN of less than 45 In 19 patients cells with an MN of 45 had a whole chromosome missing 42 which was a sex chromosome in 12 patients 63 Leukemic cells with an MN of 45 contained dicentric chromosomes n 33 formed from chromosome 9p 55 12p 18 or both 21 The ETV6-CBFA2 fusion was present in 39 of 28 evaluable B-lineage cases with an MN of 45 The event-free survival rate EFS for patients with hypodiploid leukemic cells of MN less than 45 5-year EFS 20.0 +/- 10.3 was significantly P 0.001 lower than that for patients with leukemic cells of MN greater than or equal to 45 5-year EFS 74.9 +/- 1.6 Low hypodiploidy MN 45 should be recognized as a high-risk feature in pediatric ALL Only two hypodiploid groups MN 45 and MN 45 may be necessary in prognostic assessments,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 743, 1, 3, 291, 45, 10, 6, 376, 3, 1266, 404, 1, 3, 12135, 2015, 37, 1, 815, 7, 5, 26, 622, 1363, 1, 286, 1275, 62, 4, 352, 3, 738, 509, 317, 30512, 1, 3, 12135, 2169, 5275, 8, 177, 743, 9, 46, 7, 3, 738, 194, 3, 1266, 1064, 1, 18324, 7, 5, 62, 4319, 6, 3062, 4841, 541, 292, 389, 702, 18922, 3814, 59, 6036, 2, 2043, 1, 598, 7, 49, 66, 1310, 2015, 37, 3070, 8, 18935, 207, 4691, 1, 3560, 299, 76, 15, 2997, 6, 512, 70, 563, 12135, 2015, 37, 696, 42, 35, 4691, 1, 512, 2, 79, 42, 35, 4691, 1, 299, 76, 512, 4, 326, 7, 37, 5, 35, 4691, 1, 512, 42, 8, 902, 1170, 4593, 595, 92, 10, 8, 1035, 1170, 4, 133, 7, 676, 2015, 37, 5, 35, 4691, 1, 512, 3070, 33550, 3560, 78, 466, 3516, 29, 1170, 11234, 614, 18936, 203, 15, 110, 239, 3, 7306, 33205, 1212, 10, 364, 4, 587, 1, 339, 859, 132, 2542, 140, 5, 35, 4691, 1, 512, 3, 774, 115, 25, 116, 1683, 9, 7, 5, 12135, 2015, 37, 1, 4691, 299, 76, 512, 33, 111, 1683, 179, 13, 79, 27, 10, 97, 19, 13, 144, 280, 76, 17, 9, 7, 5, 2015, 37, 1, 4691, 378, 76, 15, 2997, 6, 512, 33, 111, 1683, 794, 83, 14, 49, 154, 14828, 4691, 512, 257, 40, 1904, 22, 8, 64, 43, 2705, 4, 815, 62, 158, 100, 12135, 271, 4691, 512, 2, 4691, 512, 68, 40, 1493, 4, 177, 2182]",1405.0,14669294,171
FLT3 mutations in childhood acute lymphoblastic leukemia.,Blood,Blood,2003-12-11,"Activating mutations of the FLT3 receptor tyrosine kinase are common in acute myelogenous leukemia (AML) but are rare in adult acute lymphoblastic leukemia (ALL). We have recently shown that FLT3 is highly expressed and often mutated in ALLs with rearrangement of the mixed lineage leukemia (MLL) gene on chromosome 11q23. Because hyperdiploid ALL samples also show high-level expression of FLT3, we searched for the presence of FLT3 mutations in leukemic blasts from 71 patients with ALL. The data show that approximately 25% (6 of 25) of hyperdiploid ALL samples possess FLT3 mutations, whereas only 1 of 29 TEL/AML1-rearranged samples harbored mutations (P =.04, Fisher exact test). Three mutations are novel in-frame deletions within a 7-amino acid region of the receptor juxtamembrane domain. Finally, 3 samples from patients whose disease would relapse harbored FLT3 mutations. These data suggest that patients with hyperdiploid or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors.",Journal Article,5885.0,180.0,Activating mutations of the FLT3 receptor tyrosine kinase are common in acute myelogenous AML but are rare in adult acute lymphoblastic ALL We have recently shown that FLT3 is highly expressed and often mutated in ALLs with rearrangement of the mixed lineage MLL gene on chromosome 11q23 Because hyperdiploid ALL samples also show high-level expression of FLT3 we searched for the presence of FLT3 mutations in leukemic blasts from 71 patients with ALL The data show that approximately 25 6 of 25 of hyperdiploid ALL samples possess FLT3 mutations whereas only 1 of 29 TEL/AML1-rearranged samples harbored mutations P =.04 Fisher exact test Three mutations are novel in-frame deletions within a 7-amino acid region of the receptor juxtamembrane domain Finally 3 samples from patients whose disease would relapse harbored FLT3 mutations These data suggest that patients with hyperdiploid or relapsed ALL might be considered candidates for therapy with newly described small-molecule FLT3 inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1616, 138, 1, 3, 1224, 153, 564, 216, 32, 186, 4, 286, 2194, 329, 84, 32, 622, 4, 780, 286, 1275, 62, 21, 47, 761, 443, 17, 1224, 16, 561, 570, 2, 629, 1185, 4, 10706, 5, 2675, 1, 3, 1739, 2542, 3049, 145, 23, 1170, 7975, 408, 8847, 62, 347, 120, 514, 64, 301, 55, 1, 1224, 21, 3080, 9, 3, 463, 1, 1224, 138, 4, 2015, 2438, 29, 792, 7, 5, 62, 3, 74, 514, 17, 705, 243, 49, 1, 243, 1, 8847, 62, 347, 5766, 1224, 138, 547, 158, 14, 1, 462, 8573, 6535, 3201, 347, 3253, 138, 19, 755, 3135, 2472, 412, 169, 138, 32, 229, 4, 5331, 2439, 262, 8, 67, 3078, 971, 1053, 1, 3, 153, 10541, 1398, 1368, 27, 347, 29, 7, 1310, 34, 688, 429, 3253, 1224, 138, 46, 74, 309, 17, 7, 5, 8847, 15, 591, 62, 822, 40, 515, 1931, 9, 36, 5, 732, 1027, 302, 1354, 1224, 222]",997.0,14670924,9
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood.,Blood,Blood,2003-12-11,"The clinical, cytogenetic, and molecular findings of 2 Fanconi anemia (FA) subtype D1 kindreds, initially identified through a young child with a solid tumor (medullobastoma, Wilms tumor), are described. Each kindred subsequently had a second affected child; one developed Wilms tumor followed by a medulloblastoma, and the other developed T-lineage acute lymphoblastic leukemia. Cytogenetic studies revealed an unusually high spontaneous chromosome aberration rate, contrasting with other FA subtypes. Molecular analysis revealed biallelic BRCA2/FANCD1 mutations. The patients did not exhibit bone marrow failure. Our studies suggest that the D1 subtype represents a severe end of the cytogenetic spectrum within FA, consistent with a critical downstream role of BRCA2 in the FA pathway. Furthermore, this FA subgroup may be preferentially associated with an increased predisposition to solid tumors in early childhood. Recognition of this constellation of findings has significant implications for medical management and genetic counseling of FA families.",Journal Article,5885.0,132.0,The clinical cytogenetic and molecular findings of 2 Fanconi anemia FA subtype D1 kindreds initially identified through a young child with a solid tumor medullobastoma tumor are described Each kindred subsequently had a second affected child one developed tumor followed by a medulloblastoma and the other developed T-lineage acute lymphoblastic Cytogenetic studies revealed an unusually high spontaneous chromosome aberration rate contrasting with other FA subtypes Molecular analysis revealed biallelic BRCA2/FANCD1 mutations The patients did not exhibit marrow failure Our studies suggest that the D1 subtype represents a severe end of the cytogenetic spectrum within FA consistent with a critical downstream role of BRCA2 in the FA pathway Furthermore this FA subgroup may be preferentially associated with an increased predisposition to solid tumors in early childhood Recognition of this constellation of findings has significant implications for medical management and genetic counseling of FA families,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 38, 1266, 2, 219, 272, 1, 18, 8057, 1545, 4307, 875, 2146, 10141, 1625, 108, 298, 8, 1169, 2566, 5, 8, 537, 30, 53897, 30, 32, 1027, 296, 16706, 1611, 42, 8, 419, 1424, 2566, 104, 276, 30, 370, 20, 8, 2714, 2, 3, 127, 276, 102, 2542, 286, 1275, 1266, 94, 553, 35, 15499, 64, 3280, 1170, 7794, 116, 14116, 5, 127, 4307, 814, 219, 65, 553, 6435, 1167, 30398, 138, 3, 7, 205, 44, 2239, 581, 496, 114, 94, 309, 17, 3, 2146, 875, 1449, 8, 905, 396, 1, 3, 1266, 1873, 262, 4307, 925, 5, 8, 740, 1489, 200, 1, 1167, 4, 3, 4307, 308, 798, 26, 4307, 1363, 68, 40, 3509, 41, 5, 35, 101, 2863, 6, 537, 57, 4, 191, 864, 2335, 1, 26, 13862, 1, 272, 71, 93, 1268, 9, 484, 284, 2, 336, 2011, 1, 4307, 1954]",1009.0,14670928,33
International collaboration on childhood leukemia.,International journal of hematology,Int. J. Hematol.,2003-12-01,"The current cure rate of childhood acute lymphoblastic leukemia has reached 80% in many industrialized countries, but in developing countries the rate is often less than 10%. To advance the cure rate, investigators have formed several parallel initiatives in both industrialized and developing countries through international collaboration and partnership. Among industrialized countries, investigators have combined data to conduct in-depth studies of the biology and heterogeneity of high-risk or drug-resistant subgroups of leukemia to identify optimal or novel treatments. Alliances have been established among government, local nongovernmental organizations, health care providers, and international groups to improve the survival rate of childhood leukemia in developing countries. ""Twinning"" partnerships between a well-established individual institution or study group and a pediatric cancer unit in a developing country has proved to be the most successful strategy to date.",Journal Article,5895.0,,The current cure rate of childhood acute lymphoblastic has reached 80 in many industrialized countries but in developing countries the rate is often less than 10 To advance the cure rate investigators have formed several parallel initiatives in both industrialized and developing countries through international collaboration and partnership Among industrialized countries investigators have combined data to conduct in-depth studies of the biology and heterogeneity of high-risk or drug-resistant subgroups of to identify optimal or novel treatments Alliances have been established among government local nongovernmental organizations health care providers and international groups to improve the survival rate of childhood in developing countries `` Twinning '' partnerships between a well-established individual institution or study group and a pediatric cancer unit in a developing country has proved to be the most successful strategy to date,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 291, 1722, 116, 1, 864, 286, 1275, 71, 1300, 493, 4, 445, 18328, 2115, 84, 4, 931, 2115, 3, 116, 16, 629, 299, 76, 79, 6, 3148, 3, 1722, 116, 2394, 47, 3516, 392, 2755, 6328, 4, 110, 18328, 2, 931, 2115, 298, 944, 4119, 2, 11012, 107, 18328, 2115, 2394, 47, 397, 74, 6, 4073, 4, 2436, 94, 1, 3, 891, 2, 1144, 1, 64, 43, 15, 234, 436, 1453, 1, 6, 255, 665, 15, 229, 640, 53936, 47, 85, 635, 107, 7608, 293, 43475, 6283, 341, 165, 1994, 2, 944, 271, 6, 401, 3, 25, 116, 1, 864, 4, 931, 2115, 33587, 522, 14532, 59, 8, 149, 635, 797, 731, 15, 45, 87, 2, 8, 815, 12, 2712, 4, 8, 931, 5978, 71, 4328, 6, 40, 3, 96, 1401, 692, 6, 1244]",947.0,14704030,891
Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study.,Pediatric blood & cancer,Pediatr Blood Cancer,2004-03-01,"Self-concept was compared between adult survivors of childhood acute lymphoblastic leukemia (ALL) and sibling controls. Adult survivor subgroups at greatest risk for negative self-concept were identified. Survivors (n = 578) aged > or =18 years, treated before age 20 years on Children's Cancer Group (CCG) ALL protocols, and 396 sibling controls completed a telephone interview and the Harter Adult Self-Perception Profile (ASPP). Survivors global self-worth scores were significantly lower than sibling controls (mean 3.09 vs. 3.18; P = 0.022). Unemployed survivors reported lower global self-worth scores than employed (mean 2.77 vs. 3.12; P = 0.0001), whereas employment status was not associated with self-worth in controls. Among survivors, predictors of negative self-concept included unemployment (odds ratio (OR) = 2.87; 95% CI: 1.50-5.50), and believing that cancer treatment limited employability (OR = 3.17; 95% CI: 1.79-5.62). Unemployment increased the odds for negative self-concept among survivors who received combinations of central nervous system (CNS) irradiation (CRT) and intrathecal methotrexate (IT-MTX), except high CRT with no or low dose IT-MTX. Employed survivors who perceived that treatment limited their employability showed increased odds of negative self-concept for all treatment groups compared to those who did not. Minority ethnic group membership was a borderline significant predictor of negative self-concept (OR = 1.79; 95% CI: 0.94-3.33). Global self-worth was significantly lower in ALL survivors than sibling controls, however, 81% of survivors had positive self-concept. Survivor subgroups most vulnerable to negative self-concept were the unemployed survivors, believing that cancer treatment affected employability, and ethnic minority group members. Targeted intervention may have greater clinical relevance for these subgroups.",Journal Article,5804.0,29.0,Self-concept was compared between adult survivors of childhood acute lymphoblastic ALL and sibling controls Adult survivor subgroups at greatest risk for negative self-concept were identified Survivors n 578 aged or =18 years treated before age 20 years on Children 's Cancer Group CCG ALL protocols and 396 sibling controls completed a telephone interview and the Harter Adult Self-Perception Profile ASPP Survivors global self-worth scores were significantly lower than sibling controls mean 3.09 vs. 3.18 P 0.022 Unemployed survivors reported lower global self-worth scores than employed mean 2.77 vs. 3.12 P 0.0001 whereas employment status was not associated with self-worth in controls Among survivors predictors of negative self-concept included unemployment odds ratio OR 2.87 95 CI 1.50-5.50 and believing that cancer treatment limited employability OR 3.17 95 CI 1.79-5.62 Unemployment increased the odds for negative self-concept among survivors who received combinations of central nervous system CNS irradiation CRT and intrathecal methotrexate IT-MTX except high CRT with no or low dose IT-MTX Employed survivors who perceived that treatment limited their employability showed increased odds of negative self-concept for all treatment groups compared to those who did not Minority ethnic group membership was a borderline significant predictor of negative self-concept OR 1.79 95 CI 0.94-3.33 Global self-worth was significantly lower in ALL survivors than sibling controls however 81 of survivors had positive self-concept Survivor subgroups most vulnerable to negative self-concept were the unemployed survivors believing that cancer treatment affected employability and ethnic minority group members Targeted intervention may have greater clinical relevance for these subgroups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1074, 2545, 10, 72, 59, 780, 332, 1, 864, 286, 1275, 62, 2, 3684, 535, 780, 2628, 1453, 28, 2199, 43, 9, 199, 1074, 2545, 11, 108, 332, 78, 10431, 1032, 15, 203, 60, 73, 348, 89, 179, 60, 23, 541, 292, 12, 87, 9457, 62, 2189, 2, 9987, 3684, 535, 781, 8, 4258, 4313, 2, 3, 53982, 780, 1074, 4886, 800, 53983, 332, 1648, 1074, 9498, 703, 11, 97, 280, 76, 3684, 535, 313, 27, 1730, 105, 27, 203, 19, 13, 4773, 15831, 332, 210, 280, 1648, 1074, 9498, 703, 76, 2516, 313, 18, 849, 105, 27, 133, 19, 13, 488, 547, 5141, 156, 10, 44, 41, 5, 1074, 9498, 4, 535, 107, 332, 674, 1, 199, 1074, 2545, 159, 11966, 610, 197, 15, 18, 912, 48, 58, 14, 212, 33, 212, 2, 26261, 17, 12, 24, 383, 33606, 15, 27, 269, 48, 58, 14, 842, 33, 744, 11966, 101, 3, 610, 9, 199, 1074, 2545, 107, 332, 54, 103, 1247, 1, 854, 1880, 398, 1025, 1104, 1089, 2, 5126, 2116, 192, 3453, 2187, 64, 1089, 5, 77, 15, 154, 61, 192, 3453, 2516, 332, 54, 2588, 17, 24, 383, 136, 33606, 224, 101, 610, 1, 199, 1074, 2545, 9, 62, 24, 271, 72, 6, 135, 54, 205, 44, 2652, 2871, 87, 9592, 10, 8, 2932, 93, 980, 1, 199, 1074, 2545, 15, 14, 842, 48, 58, 13, 960, 27, 466, 1648, 1074, 9498, 10, 97, 280, 4, 62, 332, 76, 3684, 535, 137, 865, 1, 332, 42, 109, 1074, 2545, 2628, 1453, 96, 5017, 6, 199, 1074, 2545, 11, 3, 15831, 332, 26261, 17, 12, 24, 1424, 33606, 2, 2871, 2652, 87, 1684, 238, 788, 68, 47, 378, 38, 2088, 9, 46, 1453]",1794.0,14752860,2
Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.,Cancer,Cancer,2004-02-01,"Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with combination chemotherapy containing methotrexate (MTX), drug resistance contributes to treatment failure for a substantial fraction of patients. The primary transporter for folates and MTX is the reduced folate carrier (RFC). Impaired drug transport is a documented mechanism of MTX resistance in patients with ALL; however, to the authors' knowledge it is not known whether inactivating RFC mutations are a contributing factor. The authors devised a genomic polymerase chain reaction-single strand conformational polymorphism assay followed by sequencing and screened the entire RFC coding region for sequence alterations in DNA from 246 leukemia specimens from patients with diverse ethnic variation, 24 at the time of recurrence and the rest at the time of diagnosis. This cohort was comprised of 203 B-precursor ALL specimens (82.5%), 32 T-lineage ALL specimens (13%), and 11 acute myeloblastic leukemia specimens (4.5%). Of 246 DNA samples, only 3 diagnosis B-precursor ALL specimens (1.2%) were found to harbor alterations in the RFC gene, including heterozygous single nucleotide changes resulting in D56H and D522N substitutions in the first extracellular loop and the C-terminus of this transporter, respectively. The third sample had a sequence alteration in exon 3 that could not be identified because of the lack of availability of DNA. Whereas inactivating RFC mutations are a frequent mechanism of MTX resistance in human leukemia cell lines and in patients with osteosarcoma, they are not common and do not appear to play any significant role in intrinsic or acquired resistance to MTX in childhood leukemia. This is the first study of RFC mutations in multiple pediatric leukemia specimens.",Journal Article,5833.0,36.0,Although the majority of children with acute lymphoblastic ALL are cured with combination chemotherapy containing methotrexate MTX drug resistance contributes to treatment failure for a substantial fraction of patients The primary transporter for folates and MTX is the reduced folate carrier RFC Impaired drug transport is a documented mechanism of MTX resistance in patients with ALL however to the authors knowledge it is not known whether inactivating RFC mutations are a contributing factor The authors devised a genomic polymerase chain reaction-single strand conformational polymorphism assay followed by sequencing and screened the entire RFC coding region for sequence alterations in DNA from 246 specimens from patients with diverse ethnic variation 24 at the time of recurrence and the rest at the time of diagnosis This cohort was comprised of 203 B-precursor ALL specimens 82.5 32 T-lineage ALL specimens 13 and 11 acute myeloblastic specimens 4.5 Of 246 DNA samples only 3 diagnosis B-precursor ALL specimens 1.2 were found to harbor alterations in the RFC gene including heterozygous single nucleotide changes resulting in D56H and D522N substitutions in the first extracellular loop and the C-terminus of this transporter respectively The third sample had a sequence alteration in exon 3 that could not be identified because of the lack of availability of DNA Whereas inactivating RFC mutations are a frequent mechanism of MTX resistance in human cell lines and in patients with they are not common and do not appear to play any significant role in intrinsic or acquired resistance to MTX in childhood This is the first study of RFC mutations in multiple pediatric specimens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 3, 686, 1, 541, 5, 286, 1275, 62, 32, 3733, 5, 150, 56, 1101, 2116, 3453, 234, 251, 2444, 6, 24, 496, 9, 8, 1281, 1509, 1, 7, 3, 86, 5246, 9, 28084, 2, 3453, 16, 3, 405, 3100, 4715, 9270, 2364, 234, 4294, 16, 8, 1405, 670, 1, 3453, 251, 4, 7, 5, 62, 137, 6, 3, 738, 922, 192, 16, 44, 440, 317, 6096, 9270, 138, 32, 8, 3156, 161, 3, 738, 10085, 8, 572, 1451, 1260, 1329, 226, 4787, 9011, 1907, 719, 370, 20, 615, 2, 2261, 3, 1797, 9270, 3097, 1053, 9, 1532, 593, 4, 261, 29, 6907, 623, 29, 7, 5, 1867, 2871, 1380, 259, 28, 3, 98, 1, 146, 2, 3, 3677, 28, 3, 98, 1, 147, 26, 180, 10, 2603, 1, 5426, 132, 2765, 62, 623, 878, 33, 531, 102, 2542, 62, 623, 233, 2, 175, 286, 21049, 623, 39, 33, 1, 6907, 261, 347, 158, 27, 147, 132, 2765, 62, 623, 14, 18, 11, 204, 6, 2760, 593, 4, 3, 9270, 145, 141, 4167, 226, 1579, 400, 1113, 4, 54005, 2, 54006, 7646, 4, 3, 157, 1976, 4432, 2, 3, 256, 9114, 1, 26, 5246, 106, 3, 1282, 1000, 42, 8, 1532, 2611, 4, 1725, 27, 17, 359, 44, 40, 108, 408, 1, 3, 926, 1, 2550, 1, 261, 547, 6096, 9270, 138, 32, 8, 908, 670, 1, 3453, 251, 4, 171, 31, 285, 2, 4, 7, 5, 491, 32, 44, 186, 2, 1022, 44, 1322, 6, 1343, 500, 93, 200, 4, 2354, 15, 1294, 251, 6, 3453, 4, 864, 26, 16, 3, 157, 45, 1, 9270, 138, 4, 232, 815, 623]",1690.0,14770434,32
Fertility of long-term male survivors of acute lymphoblastic leukemia diagnosed during childhood.,Pediatric blood & cancer,Pediatr Blood Cancer,2004-04-01,"Fertility impairments among men treated during childhood for cancer are known to occur after some, but not all, types of anti-cancer therapy. This is the first study to evaluate proven fertility among adult male survivors of childhood acute lymphoblastic leukemia (ALL). In a retrospective cohort study, proven fertility (ever fathered a pregnancy) was evaluated by self-report among 213 men treated for ALL before age 18 on protocols of the Children's Cancer Group (CCG). Controls (N = 145) were drawn from among male siblings. Overall, with a proportional hazards analysis, proven fertility of male survivors was not different from that of controls (relative fertility (RF) = 0.95, 95% CI 0.63-1.43). However, married men treated before age 10 with high dose (24 cGy) cranial radiotherapy (RT), without spinal RT, had only 9% of the fertility of controls (Relative risk, RR = 0.09, 95% CI 0.01-0.82). High dose cranial RT at older ages was not associated with a statistically significant fertility deficit (RR = 0.56, 95% CI 0.25-1.28). In this first study of proven fertility among men treated for childhood leukemia, the majority of survivors showed no evidence of fertility impairment compared to controls. However, men treated at a young age with high dose cranial RT may have impaired fertility. These results suggest that further investigation of men with these treatments is needed to confirm and extend these findings.",Journal Article,5773.0,45.0,Fertility impairments among men treated during childhood for cancer are known to occur after some but not all types of anti-cancer therapy This is the first study to evaluate proven fertility among adult male survivors of childhood acute lymphoblastic ALL In a retrospective cohort study proven fertility ever fathered a pregnancy was evaluated by self-report among 213 men treated for ALL before age 18 on protocols of the Children 's Cancer Group CCG Controls N 145 were drawn from among male siblings Overall with a proportional hazards analysis proven fertility of male survivors was not different from that of controls relative fertility RF 0.95 95 CI 0.63-1.43 However married men treated before age 10 with high dose 24 cGy cranial radiotherapy RT without spinal RT had only 9 of the fertility of controls Relative risk RR 0.09 95 CI 0.01-0.82 High dose cranial RT at older ages was not associated with a statistically significant fertility deficit RR 0.56 95 CI 0.25-1.28 In this first study of proven fertility among men treated for childhood the majority of survivors showed no evidence of fertility impairment compared to controls However men treated at a young age with high dose cranial RT may have impaired fertility These results suggest that further investigation of men with these treatments is needed to confirm and extend these findings,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2954, 6948, 107, 325, 73, 190, 864, 9, 12, 32, 440, 6, 1271, 50, 476, 84, 44, 62, 630, 1, 312, 12, 36, 26, 16, 3, 157, 45, 6, 376, 1930, 2954, 107, 780, 1045, 332, 1, 864, 286, 1275, 62, 4, 8, 459, 180, 45, 1930, 2954, 3353, 30450, 8, 2290, 10, 194, 20, 1074, 414, 107, 5833, 325, 73, 9, 62, 348, 89, 203, 23, 2189, 1, 3, 541, 292, 12, 87, 9457, 535, 78, 4058, 11, 5694, 29, 107, 1045, 2758, 63, 5, 8, 831, 1017, 65, 1930, 2954, 1, 1045, 332, 10, 44, 338, 29, 17, 1, 535, 580, 2954, 7279, 13, 48, 48, 58, 13, 676, 14, 601, 137, 5365, 325, 73, 348, 89, 79, 5, 64, 61, 259, 3071, 2565, 310, 240, 187, 1499, 240, 42, 158, 83, 1, 3, 2954, 1, 535, 580, 43, 861, 13, 1730, 48, 58, 13, 355, 13, 878, 64, 61, 2565, 240, 28, 434, 2165, 10, 44, 41, 5, 8, 712, 93, 2954, 6819, 861, 13, 664, 48, 58, 13, 243, 14, 339, 4, 26, 157, 45, 1, 1930, 2954, 107, 325, 73, 9, 864, 3, 686, 1, 332, 224, 77, 241, 1, 2954, 2315, 72, 6, 535, 137, 325, 73, 28, 8, 1169, 89, 5, 64, 61, 2565, 240, 68, 47, 2364, 2954, 46, 99, 309, 17, 195, 940, 1, 325, 5, 46, 640, 16, 575, 6, 1843, 2, 4087, 46, 272]",1355.0,14966835,85
"Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis.",Blood,Blood,2004-03-09,"Sequence analysis of the immunoglobulin heavy chain genes (IgH) has demonstrated preferential usage of specific variable (V), diversity (D), and joining (J) genes at different stages of B-cell development and in B-cell malignancies, and this has provided insight into B-cell maturation and selection. Knowledge of the association between rearrangement patterns based on updated databases and clinical characteristics of pediatric acute lymphoblastic leukemia (ALL) is limited. We analyzed 381 IgH sequences identified at presentation in 317 children with B-lineage ALL and assessed the V(H)D(H)J(H) gene utilization profiles. The D(H)J(H)-proximal V(H) segments and the D(H)2 gene family were significantly overrepresented. Only 21% of V(H)-J(H) joinings were potentially productive, a finding associated with a trend toward an increased risk of relapse. These results suggest that physical location at the V(H) locus is involved in preferential usage of D(H)J(H)-proximal V(H) segments whereas D(H) and J(H) segment usage is governed by position-independent molecular mechanisms. Molecular pathophysiology appears relevant to clinical outcome in patients who have only productive rearrangements, and specific rearrangement patterns are associated with differences in the tumor biology of childhood ALL.",Journal Article,5796.0,31.0,Sequence analysis of the immunoglobulin heavy chain genes IgH has demonstrated preferential usage of specific variable V diversity D and joining J genes at different stages of B-cell development and in B-cell malignancies and this has provided insight into B-cell maturation and selection Knowledge of the association between rearrangement patterns based on updated databases and clinical characteristics of pediatric acute lymphoblastic ALL is limited We analyzed 381 IgH sequences identified at presentation in 317 children with B-lineage ALL and assessed the V H D H J H gene utilization profiles The D H J H -proximal V H segments and the D H 2 gene family were significantly overrepresented Only 21 of V H -J H joinings were potentially productive a finding associated with a trend toward an increased risk of relapse These results suggest that physical location at the V H locus is involved in preferential usage of D H J H -proximal V H segments whereas D H and J H segment usage is governed by position-independent molecular mechanisms Molecular pathophysiology appears relevant to clinical outcome in patients who have only productive rearrangements and specific rearrangement patterns are associated with differences in the tumor biology of childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1532, 65, 1, 3, 2593, 4013, 1260, 214, 5221, 71, 264, 6629, 5015, 1, 112, 1347, 603, 3653, 427, 2, 10690, 3543, 214, 28, 338, 1153, 1, 132, 31, 193, 2, 4, 132, 31, 441, 2, 26, 71, 1052, 2670, 237, 132, 31, 4537, 2, 881, 922, 1, 3, 248, 59, 2675, 764, 90, 23, 2939, 2348, 2, 38, 374, 1, 815, 286, 1275, 62, 16, 383, 21, 311, 10155, 5221, 2866, 108, 28, 1031, 4, 7869, 541, 5, 132, 2542, 62, 2, 275, 3, 603, 555, 427, 555, 3543, 555, 145, 1961, 1241, 3, 427, 555, 3543, 555, 2805, 603, 555, 5138, 2, 3, 427, 555, 18, 145, 607, 11, 97, 13094, 158, 239, 1, 603, 555, 3543, 555, 54051, 11, 751, 10110, 8, 1567, 41, 5, 8, 853, 1317, 35, 101, 43, 1, 429, 46, 99, 309, 17, 900, 1147, 28, 3, 603, 555, 2474, 16, 646, 4, 6629, 5015, 1, 427, 555, 3543, 555, 2805, 603, 555, 5138, 547, 427, 555, 2, 3543, 555, 4610, 5015, 16, 18267, 20, 3559, 306, 219, 483, 219, 4320, 1233, 867, 6, 38, 228, 4, 7, 54, 47, 158, 10110, 2072, 2, 112, 2675, 764, 32, 41, 5, 362, 4, 3, 30, 891, 1, 864, 62]",1264.0,15010366,159
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias.,Blood,Blood,2004-03-25,"Activating FLT3 mutations are the most common genetic aberrations in acute myeloid leukemia (AML), resulting in the constitutive activation of this receptor tyrosine kinase (RTK), but such mutations are rarely found in acute lymphoblastic leukemia (ALL). Here we describe a unique subset of de novo adult T-cell ALL (T-ALL) cases that coexpress CD117/KIT and cytoplasmic CD3 (CD117/KIT(+) ALL). Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT(+) cases that were analyzed, but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression. Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL.",Journal Article,5780.0,77.0,Activating FLT3 mutations are the most common genetic aberrations in acute myeloid AML resulting in the constitutive activation of this receptor tyrosine kinase RTK but such mutations are rarely found in acute lymphoblastic ALL Here we describe a unique subset of de novo adult T-cell ALL T-ALL cases that coexpress CD117/KIT and cytoplasmic CD3 CD117/KIT ALL Activating mutations in the FLT3 RTK gene were found in each of 3 CD117/KIT cases that were analyzed but not in 52 other adult T-ALL samples from the same series that lacked CD117/KIT expression Our results indicate the need for clinical trials to test the efficacy of drugs that inhibit the FLT3 RTK in this subset of patients with T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1616, 1224, 138, 32, 3, 96, 186, 336, 2152, 4, 286, 533, 329, 1113, 4, 3, 3178, 363, 1, 26, 153, 564, 216, 5261, 84, 225, 138, 32, 2416, 204, 4, 286, 1275, 62, 467, 21, 897, 8, 991, 697, 1, 1566, 2018, 780, 102, 31, 62, 102, 62, 140, 17, 22044, 6999, 1164, 2, 2828, 3117, 6999, 1164, 62, 1616, 138, 4, 3, 1224, 5261, 145, 11, 204, 4, 296, 1, 27, 6999, 1164, 140, 17, 11, 311, 84, 44, 4, 653, 127, 780, 102, 62, 347, 29, 3, 827, 988, 17, 5005, 6999, 1164, 55, 114, 99, 1008, 3, 594, 9, 38, 143, 6, 412, 3, 209, 1, 600, 17, 1433, 3, 1224, 5261, 4, 26, 697, 1, 7, 5, 102, 62]",698.0,15044257,610
Recent advances in childhood acute lymphoblastic leukemia.,Journal of the Formosan Medical Association = Taiwan yi zhi,J. Formos. Med. Assoc.,2004-02-01,"Contemporary risk-directed therapy has advanced the cure rate for childhood acute lymphoblastic leukemia to near 80%. Molecular genetic analyses of leukemic cells, pharmacodynamic studies of antileukemic agents, and pharmacogenetic studies of the host's drug-metabolizing enzymes, drug transporters, and drug targets are providing a rational base for further improvement of treatment efficacy and the reduction of complications. Early treatment response, as defined by the measurement of minimal residual disease, which reflects both the drug responsiveness of leukemic cells and host pharmacodynamics/pharmacogenomics, is the most reliable prognostic indicator for gauging the intensity of treatment. Recent advances in high-throughput biotechnology, including gene expression profiling, proteomics and gene silencing promise to identify molecular targets for specific treatment. The ultimate goal is to elucidate central mechanisms of leukemogenesis so that preventive measures can be devised.",Journal Article,5833.0,9.0,Contemporary risk-directed therapy has advanced the cure rate for childhood acute lymphoblastic to near 80 Molecular genetic analyses of leukemic cells pharmacodynamic studies of antileukemic agents and pharmacogenetic studies of the host 's drug-metabolizing enzymes drug transporters and drug targets are providing a rational base for further improvement of treatment efficacy and the reduction of complications Early treatment response as defined by the measurement of minimal residual disease which reflects both the drug responsiveness of leukemic cells and host pharmacodynamics/pharmacogenomics is the most reliable prognostic indicator for gauging the intensity of treatment Recent advances in high-throughput biotechnology including gene expression profiling proteomics and gene silencing promise to identify molecular targets for specific treatment The ultimate goal is to elucidate central mechanisms of leukemogenesis so that preventive measures can be devised,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2667, 43, 1166, 36, 71, 131, 3, 1722, 116, 9, 864, 286, 1275, 6, 1829, 493, 219, 336, 318, 1, 2015, 37, 2424, 94, 1, 4512, 183, 2, 6578, 94, 1, 3, 1204, 292, 234, 9800, 3039, 234, 6733, 2, 234, 637, 32, 1736, 8, 2696, 1782, 9, 195, 767, 1, 24, 209, 2, 3, 628, 1, 521, 191, 24, 51, 22, 395, 20, 3, 2204, 1, 1048, 753, 34, 92, 5224, 110, 3, 234, 3642, 1, 2015, 37, 2, 1204, 3587, 7603, 16, 3, 96, 2450, 177, 3287, 9, 30583, 3, 837, 1, 24, 435, 954, 4, 64, 3643, 11767, 141, 145, 55, 1080, 6478, 2, 145, 2077, 1783, 6, 255, 219, 637, 9, 112, 24, 3, 5768, 1326, 16, 6, 3061, 854, 483, 1, 5661, 1743, 17, 3494, 1018, 122, 40, 10085]",972.0,15083238,701
Chromosome abnormalities may correlate with prognosis in Burkitt/Burkitt-like lymphomas of children and adolescents: a report from Children's Cancer Group Study CCG-E08.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2004-03-01,"Among pediatric non-Hodgkin lymphomas, the most frequent type is small noncleaved-cell lymphoma (including Burkitt and Burkitt-like). Specific chromosome abnormalities are associated with prognosis in childhood acute lymphoblastic leukemia (ALL); however, chromosome abnormalities have not been evaluated for prognostic value in pediatric Burkitt and Burkitt-like lymphomas. For Children's Cancer Group protocol CCG-E-08 Etiologic Study of Non-Hodgkin Lymphoma in Childhood, 19 patients were enrolled with cytogenetic analysis of Burkitt or Burkitt-like lymphoma and simultaneously enrolled on treatment protocols CCG-503 or CCG-552. Pathology material and karyotypes at initial diagnosis underwent central review. Demographics included an age range of 2 to 14 years (median 8 years) and a male:female ratio of 14:5. All patients had advanced disease (stages III and IV, or ALL). Disease relapsed in five patients (event-free survival 74%, median follow-up 10.4 years). Chromosome abnormalities were identified in 18 patients (95%) including t(8;14)(q24.1;q32) in 12 (63%); t(8;22)(q24.1;q11.2) in 1 (5%); partial duplication of 1q in 7 (37%); and 13q32 abnormalities in 2 (11%). In patients who had relapses, in addition to the t(8;14)(q24. ;q32), two had abnormalities of 13q32 and two had partial duplication of 1q. CMYC translocations were absent in Burkitt-like lymphomas from all three patients. Burkitt and Burkitt-like lymphomas in children have a high frequency of chromosome abnormalities. Burkitt lymphoma abnormalities often involve CMYC translocations, usually a t(8;14)(q24.1;q32). Additional chromosome abnormalities that involved 13q32 and partial duplication of 1q were associated with poor prognosis. Burkitt-like lymphomas were not associated with CMYC translocations. Further studies are warranted in larger cohorts of children and adolescents with Burkitt and Burkitt-like lymphomas.",Journal Article,5804.0,49.0,Among pediatric lymphomas the most frequent type is small noncleaved-cell including and Burkitt-like Specific chromosome abnormalities are associated with prognosis in childhood acute lymphoblastic ALL however chromosome abnormalities have not been evaluated for prognostic value in pediatric and Burkitt-like lymphomas For Children 's Cancer Group protocol CCG-E-08 Etiologic Study of in Childhood 19 patients were enrolled with cytogenetic analysis of or Burkitt-like and simultaneously enrolled on treatment protocols CCG-503 or CCG-552 Pathology material and karyotypes at initial diagnosis underwent central review Demographics included an age range of 2 to 14 years median 8 years and a male female ratio of 14:5 All patients had advanced disease stages III and IV or ALL Disease relapsed in five patients event-free survival 74 median follow-up 10.4 years Chromosome abnormalities were identified in 18 patients 95 including t 8 14 q24.1 q32 in 12 63 t 8 22 q24.1 q11.2 in 1 5 partial duplication of 1q in 7 37 and 13q32 abnormalities in 2 11 In patients who had relapses in addition to the t 8 14 q24 q32 two had abnormalities of 13q32 and two had partial duplication of 1q CMYC translocations were absent in Burkitt-like lymphomas from all three patients and Burkitt-like lymphomas in children have a high frequency of chromosome abnormalities abnormalities often involve CMYC translocations usually a t 8 14 q24.1 q32 Additional chromosome abnormalities that involved 13q32 and partial duplication of 1q were associated with poor prognosis Burkitt-like lymphomas were not associated with CMYC translocations Further studies are warranted in larger cohorts of children and adolescents with and Burkitt-like lymphomas,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[107, 815, 1557, 3, 96, 908, 267, 16, 302, 43600, 31, 141, 2, 14387, 733, 112, 1170, 1171, 32, 41, 5, 356, 4, 864, 286, 1275, 62, 137, 1170, 1171, 47, 44, 85, 194, 9, 177, 549, 4, 815, 2, 14387, 733, 1557, 9, 541, 292, 12, 87, 1182, 9457, 563, 1592, 6604, 45, 1, 4, 864, 326, 7, 11, 346, 5, 1266, 65, 1, 15, 14387, 733, 2, 3074, 346, 23, 24, 2189, 9457, 11167, 15, 9457, 10097, 1117, 3692, 2, 6809, 28, 388, 147, 208, 854, 206, 2221, 159, 35, 89, 184, 1, 18, 6, 213, 60, 52, 66, 60, 2, 8, 1045, 1061, 197, 1, 213, 33, 62, 7, 42, 131, 34, 1153, 316, 2, 478, 15, 62, 34, 591, 4, 365, 7, 774, 115, 25, 794, 52, 166, 126, 79, 39, 60, 1170, 1171, 11, 108, 4, 203, 7, 48, 141, 102, 66, 213, 13487, 14, 7576, 4, 133, 676, 102, 66, 350, 13487, 14, 11532, 18, 4, 14, 33, 450, 4616, 1, 10208, 4, 67, 567, 2, 37677, 1171, 4, 18, 175, 4, 7, 54, 42, 3713, 4, 352, 6, 3, 102, 66, 213, 13487, 7576, 100, 42, 1171, 1, 37677, 2, 100, 42, 450, 4616, 1, 10208, 16357, 3262, 11, 3269, 4, 14387, 733, 1557, 29, 62, 169, 7, 2, 14387, 733, 1557, 4, 541, 47, 8, 64, 675, 1, 1170, 1171, 1171, 629, 3882, 16357, 3262, 2082, 8, 102, 66, 213, 13487, 14, 7576, 402, 1170, 1171, 17, 646, 37677, 2, 450, 4616, 1, 10208, 11, 41, 5, 334, 356, 14387, 733, 1557, 11, 44, 41, 5, 16357, 3262, 195, 94, 32, 1197, 4, 1077, 736, 1, 541, 2, 3101, 5, 2, 14387, 733, 1557]",1725.0,15125609,429
Fertility in women treated with cranial radiotherapy for childhood acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2004-06-01,"Fertility impairments among women treated during childhood for cancer are known to occur after some, but not all, types of anticancer therapy. Although leukemia is the most common cancer of childhood, until now fertility in survivors has not been comprehensively assessed. We investigated functional impairment of fertility in women who were long-term survivors of acute lymphoblastic leukemia (ALL) with a retrospective cohort study. Proven fertility (defined as ever pregnant) was evaluated by self-report among 182 females treated on protocols of the Children's Cancer Group (age at interview, 22.6 years on average) and 170 controls drawn from among the survivors' female siblings (23.4 years). The interview included psychosocial inventories designed to detect mood problems. Significant fertility deficits were noted in female survivors treated with cranial radiotherapy (CRT) at any dose around the time of menarche (relative fertility (RF)) = 0.27, 95% CI = 0.09, 0.82, P = 0.03). Controlling for marital status, mood at interview, and many fertility-related situations did not change the association. This study provides evidence for fertility deficits after treatment for ALL with CRT, and, in addition, for the first time, suggests that girls treated around the time of menarche are especially at risk. Clinical confirmation of these results is needed. If gonadal damage occurs in women receiving these treatments, their risk for further sequelae, such as osteoporosis and heart disease, may be significantly raised, requiring active management and intervention.",Journal Article,5712.0,34.0,Fertility impairments among women treated during childhood for cancer are known to occur after some but not all types of anticancer therapy Although is the most common cancer of childhood until now fertility in survivors has not been comprehensively assessed We investigated functional impairment of fertility in women who were long-term survivors of acute lymphoblastic ALL with a retrospective cohort study Proven fertility defined as ever pregnant was evaluated by self-report among 182 females treated on protocols of the Children 's Cancer Group age at interview 22.6 years on average and 170 controls drawn from among the survivors female siblings 23.4 years The interview included psychosocial inventories designed to detect mood problems Significant fertility deficits were noted in female survivors treated with cranial radiotherapy CRT at any dose around the time of menarche relative fertility RF 0.27 95 CI 0.09 0.82 P 0.03 Controlling for marital status mood at interview and many fertility-related situations did not change the association This study provides evidence for fertility deficits after treatment for ALL with CRT and in addition for the first time suggests that girls treated around the time of menarche are especially at risk Clinical confirmation of these results is needed If gonadal damage occurs in women receiving these treatments their risk for further sequelae such as osteoporosis and disease may be significantly raised requiring active management and intervention,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[2954, 6948, 107, 117, 73, 190, 864, 9, 12, 32, 440, 6, 1271, 50, 476, 84, 44, 62, 630, 1, 1475, 36, 242, 16, 3, 96, 186, 12, 1, 864, 1100, 1134, 2954, 4, 332, 71, 44, 85, 5627, 275, 21, 565, 583, 2315, 1, 2954, 4, 117, 54, 11, 319, 337, 332, 1, 286, 1275, 62, 5, 8, 459, 180, 45, 1930, 2954, 395, 22, 3353, 6086, 10, 194, 20, 1074, 414, 107, 5160, 2451, 73, 23, 2189, 1, 3, 541, 292, 12, 87, 89, 28, 4313, 350, 49, 60, 23, 1011, 2, 5248, 535, 5694, 29, 107, 3, 332, 1061, 2758, 382, 39, 60, 3, 4313, 159, 2322, 43603, 1114, 6, 1426, 5234, 2408, 93, 2954, 2752, 11, 1051, 4, 1061, 332, 73, 5, 2565, 310, 1089, 28, 500, 61, 3337, 3, 98, 1, 6414, 580, 2954, 7279, 13, 428, 48, 58, 13, 1730, 13, 878, 19, 13, 680, 1893, 9, 5345, 156, 5234, 28, 4313, 2, 445, 2954, 139, 5990, 205, 44, 707, 3, 248, 26, 45, 777, 241, 9, 2954, 2752, 50, 24, 9, 62, 5, 1089, 2, 4, 352, 9, 3, 157, 98, 844, 17, 5989, 73, 3337, 3, 98, 1, 6414, 32, 1093, 28, 43, 38, 3551, 1, 46, 99, 16, 575, 492, 7999, 1350, 1780, 4, 117, 357, 46, 640, 136, 43, 9, 195, 4156, 225, 22, 4970, 2, 34, 68, 40, 97, 5673, 1888, 544, 284, 2, 788]",1500.0,15127413,793
Acute lymphoblastic leukemia with TEL-AML1 fusion has lower expression of genes involved in purine metabolism and lower de novo purine synthesis.,Blood,Blood,2004-05-13,"Because de novo purine synthesis (DNPS) is a target of widely used antileukemic agents (eg, methotrexate, mercaptopurine), we determined the rate of DNPS and the expression of genes involved in purine metabolism in different subtypes of acute lymphoblastic leukemia (ALL). Among 113 children with newly diagnosed ALL, lymphoblasts with the TEL-AML1 translocation had significantly lower DNPS than all other genetic subtypes of B-lineage ALL or T-lineage ALL (352 +/- 57 versus 1001 +/- 31 or versus 1315 +/- 76 fmol/nmol/h, P <.0001). By assessing the expression of 82 genes involved in purine metabolism (KEGG pathway database) in ALL blasts from 38 patients with B-lineage ALL (14 with TEL-AML1, 24 without), we identified 16 genes that were differentially expressed in TEL-AML1-positive and TEL-AML1-negative ALL (P <.001, false discovery rate [FDR] = 5%). The pattern of expression of these 16 genes discriminated TEL-AML1-positive ALL with a true accuracy of 84% in an independent test set (n = 17, confidence interval 70% to 94%, P <.001). Western blots of selected genes documented corresponding levels of the proteins encoded. Differentially expressed genes included HPRT, IMPDH, PAICS, and GART, all of which were expressed at a significantly lower level in TEL-AML1 ALL. These findings have established that TEL-AML1 ALL has significantly lower de novo purine synthesis and differential expression of genes involved in purine metabolism.",Journal Article,5731.0,31.0,Because de novo purine synthesis DNPS is a target of widely used antileukemic agents eg methotrexate mercaptopurine we determined the rate of DNPS and the expression of genes involved in purine metabolism in different subtypes of acute lymphoblastic ALL Among 113 children with newly diagnosed ALL lymphoblasts with the TEL-AML1 translocation had significantly lower DNPS than all other genetic subtypes of B-lineage ALL or T-lineage ALL 352 +/- 57 versus 1001 +/- 31 or versus 1315 +/- 76 fmol/nmol/h P .0001 By assessing the expression of 82 genes involved in purine metabolism KEGG pathway database in ALL blasts from 38 patients with B-lineage ALL 14 with TEL-AML1 24 without we identified 16 genes that were differentially expressed in TEL-AML1-positive and TEL-AML1-negative ALL P .001 false discovery rate FDR 5 The pattern of expression of these 16 genes discriminated TEL-AML1-positive ALL with a true accuracy of 84 in an independent test set n 17 confidence interval 70 to 94 P .001 Western blots of selected genes documented corresponding levels of the proteins encoded Differentially expressed genes included HPRT IMPDH PAICS and GART all of which were expressed at a significantly lower level in TEL-AML1 ALL These findings have established that TEL-AML1 ALL has significantly lower de novo purine synthesis and differential expression of genes involved in purine metabolism,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[408, 1566, 2018, 5006, 2525, 18803, 16, 8, 283, 1, 1792, 95, 4512, 183, 2887, 2116, 9223, 21, 509, 3, 116, 1, 18803, 2, 3, 55, 1, 214, 646, 4, 5006, 1600, 4, 338, 814, 1, 286, 1275, 62, 107, 4259, 541, 5, 732, 265, 62, 10521, 5, 3, 8573, 6535, 2006, 42, 97, 280, 18803, 76, 62, 127, 336, 814, 1, 132, 2542, 62, 15, 102, 2542, 62, 9550, 696, 185, 17672, 456, 15, 185, 24711, 846, 18804, 4694, 555, 19, 488, 20, 1977, 3, 55, 1, 878, 214, 646, 4, 5006, 1600, 21246, 308, 609, 4, 62, 2438, 29, 519, 7, 5, 132, 2542, 62, 213, 5, 8573, 6535, 259, 187, 21, 108, 245, 214, 17, 11, 2478, 570, 4, 8573, 6535, 109, 2, 8573, 6535, 199, 62, 19, 144, 2133, 1574, 116, 5929, 33, 3, 1177, 1, 55, 1, 46, 245, 214, 8752, 8573, 6535, 109, 62, 5, 8, 2501, 1190, 1, 874, 4, 35, 306, 412, 916, 78, 269, 307, 268, 431, 6, 960, 19, 144, 1521, 13483, 1, 715, 214, 1405, 1734, 148, 1, 3, 652, 4587, 2478, 570, 214, 159, 37684, 26292, 22207, 2, 54165, 62, 1, 92, 11, 570, 28, 8, 97, 280, 301, 4, 8573, 6535, 62, 46, 272, 47, 635, 17, 8573, 6535, 62, 71, 97, 280, 1566, 2018, 5006, 2525, 2, 1777, 55, 1, 214, 646, 4, 5006, 1600]",1388.0,15142881,273
Late-onset delayed excretion of methotrexate.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2004-05-18,"Pleural effusions, ascites, and renal dysfunction decrease the plasma excretion of methotrexate (MTX). However, it is not known what effect these complications have on MTX clearance when they arise after the plasma MTX concentration has fallen to an undetectable level. We describe the clinical course and pharmacokinetics of MTX in a patient with acute lymphoblastic leukemia who experienced pleural effusions, ascites, and renal failure during the weeks after treatment with high-dose MTX (1.63 g/m2 i.v. over 24 h). The patient's normal initial MTX clearance rate (107 ml/min/m2) was consistent with his undetectable plasma level of MTX on day 9 after the infusion. His plasma MTX concentration then gradually increased as his renal function declined, reaching a peak of 0.72 microM on day 15. This unusual finding of an undetectable plasma MTX concentration that subsequently rose to persistent, potentially toxic levels was explained only by a pharmacokinetic model that accounted both for a third space at the time of treatment and for the subsequent decrease in the systemic elimination rate. Therefore, the finding of a physiologic third space during MTX administration combined with the detection of renal dysfunction in the following weeks should be an indication for prolonged therapeutic drug monitoring.",Case Reports,5726.0,23.0,Pleural effusions ascites and dysfunction decrease the plasma excretion of methotrexate MTX However it is not known what effect these complications have on MTX clearance when they arise after the plasma MTX concentration has fallen to an undetectable level We describe the clinical course and pharmacokinetics of MTX in a patient with acute lymphoblastic who experienced pleural effusions ascites and failure during the weeks after treatment with high-dose MTX 1.63 g/m2 i.v over 24 h The patient 's normal initial MTX clearance rate 107 ml/min/m2 was consistent with his undetectable plasma level of MTX on day 9 after the infusion His plasma MTX concentration then gradually increased as his function declined reaching a peak of 0.72 microM on day 15 This unusual finding of an undetectable plasma MTX concentration that subsequently rose to persistent potentially toxic levels was explained only by a pharmacokinetic model that accounted both for a third space at the time of treatment and for the subsequent decrease in the systemic elimination rate Therefore the finding of a physiologic third space during MTX administration combined with the detection of dysfunction in the following weeks should be an indication for prolonged therapeutic drug monitoring,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2164, 5154, 3819, 2, 1527, 775, 3, 554, 8294, 1, 2116, 3453, 137, 192, 16, 44, 440, 2067, 254, 46, 521, 47, 23, 3453, 1960, 198, 491, 3043, 50, 3, 554, 3453, 1227, 71, 18310, 6, 35, 3920, 301, 21, 897, 3, 38, 906, 2, 1159, 1, 3453, 4, 8, 69, 5, 286, 1275, 54, 592, 2164, 5154, 3819, 2, 496, 190, 3, 244, 50, 24, 5, 64, 61, 3453, 14, 676, 499, 821, 70, 603, 252, 259, 555, 3, 69, 292, 295, 388, 3453, 1960, 116, 3650, 542, 1538, 821, 10, 925, 5, 3224, 3920, 554, 301, 1, 3453, 23, 218, 83, 50, 3, 904, 3224, 554, 3453, 1227, 818, 8092, 101, 22, 3224, 343, 3054, 6168, 8, 2944, 1, 13, 720, 3550, 23, 218, 167, 26, 4015, 1567, 1, 35, 3920, 554, 3453, 1227, 17, 1611, 7370, 6, 1882, 751, 1812, 148, 10, 3672, 158, 20, 8, 1456, 202, 17, 3688, 110, 9, 8, 1282, 3865, 28, 3, 98, 1, 24, 2, 9, 3, 706, 775, 4, 3, 403, 3730, 116, 673, 3, 1567, 1, 8, 4628, 1282, 3865, 190, 3453, 634, 397, 5, 3, 638, 1, 1527, 4, 3, 366, 244, 257, 40, 35, 3607, 9, 1069, 189, 234, 1315]",1262.0,15148625,68
Establishment of a pediatric oncology program and outcomes of childhood acute lymphoblastic leukemia in a resource-poor area.,JAMA,JAMA,2004-05-01,"The cure rate for childhood acute lymphoblastic leukemia (ALL) differs markedly between developed and developing countries. To assess the effect of a multidisciplinary team approach and protocol-based therapy on the event-free survival of children with ALL in an area with limited resources. DESIGN, POPULATION, AND SETTING: A retrospective cohort study at a pediatric hospital in the resource-poor city of Recife, Brazil. We reviewed medical records of the outcomes of 375 children with ALL diagnosed between 1980 and 2002. Eighty-three children were diagnosed in the early period (1980-1989), in the absence of a dedicated pediatric oncology unit, protocol-based therapy, specially trained nurses, 24-hour on-site physician coverage, and ready access to intensive care. Seventy-eight children were treated (all according to protocol) during the middle period (July 1994 to March 1997). During the recent period (April 1997 to December 2002), 214 children were treated with protocol in a dedicated pediatric oncology unit staffed 24 hours by pediatric oncologists and oncology nurses. Improvements were implemented gradually during the middle period and were completed during the recent period. Event-free survival was estimated by the Kaplan-Meier method. Events included death from toxicity, disease progression or relapse, and abandonment of treatment. The 5-year event-free survival improved steadily: 32% (95% CI, 21%-43%) in the early period, 47% (95% CI, 36%-58%) in the middle period, and 63% (95% CI, 55%-71%) in the recent period. The probability of cause-specific treatment failure in the early, middle, and late periods, respectively, within 1 year of diagnosis was 14% vs 3.8% vs 3.3% for relapse; 6.0% vs 12% vs 9.8% for death from infection; 2.4% vs 13% vs 4.2% for death from noninfectious toxicity; and 16% vs 1.3% vs 0.5% for abandonment of therapy. Treatment of childhood ALL in a dedicated pediatric oncology unit using a comprehensive multidisciplinary team approach, protocol-based therapy, and local support and funding is associated with improved outcomes in a resource-poor area.",Journal Article,5743.0,203.0,The cure rate for childhood acute lymphoblastic ALL differs markedly between developed and developing countries To assess the effect of a multidisciplinary team approach and protocol-based therapy on the event-free survival of children with ALL in an area with limited resources DESIGN POPULATION AND SETTING A retrospective cohort study at a pediatric hospital in the resource-poor city of Recife Brazil We reviewed medical records of the outcomes of 375 children with ALL diagnosed between 1980 and 2002 Eighty-three children were diagnosed in the early period 1980-1989 in the absence of a dedicated pediatric oncology unit protocol-based therapy specially trained nurses 24-hour on-site physician coverage and ready access to intensive care Seventy-eight children were treated all according to protocol during the middle period July 1994 to March 1997 During the recent period April 1997 to December 2002 214 children were treated with protocol in a dedicated pediatric oncology unit staffed 24 hours by pediatric oncologists and oncology nurses Improvements were implemented gradually during the middle period and were completed during the recent period Event-free survival was estimated by the Kaplan-Meier method Events included death from toxicity disease progression or relapse and abandonment of treatment The 5-year event-free survival improved steadily 32 95 CI 21 -43 in the early period 47 95 CI 36 -58 in the middle period and 63 95 CI 55 -71 in the recent period The probability of cause-specific treatment failure in the early middle and late periods respectively within 1 year of diagnosis was 14 vs 3.8 vs 3.3 for relapse 6.0 vs 12 vs 9.8 for death from infection 2.4 vs 13 vs 4.2 for death from noninfectious toxicity and 16 vs 1.3 vs 0.5 for abandonment of therapy Treatment of childhood ALL in a dedicated pediatric oncology unit using a comprehensive multidisciplinary team approach protocol-based therapy and local support and funding is associated with improved outcomes in a resource-poor area,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1722, 116, 9, 864, 286, 1275, 62, 4990, 2195, 59, 276, 2, 931, 2115, 6, 423, 3, 254, 1, 8, 1643, 2870, 353, 2, 1182, 90, 36, 23, 3, 774, 115, 25, 1, 541, 5, 62, 4, 35, 965, 5, 383, 2892, 771, 266, 2, 546, 8, 459, 180, 45, 28, 8, 815, 702, 4, 3, 3069, 334, 7235, 1, 43617, 10452, 21, 446, 484, 1064, 1, 3, 123, 1, 4175, 541, 5, 62, 265, 59, 4376, 2, 1544, 2207, 169, 541, 11, 265, 4, 3, 191, 727, 4376, 3965, 4, 3, 1127, 1, 8, 4827, 815, 413, 2712, 1182, 90, 36, 26287, 5946, 2707, 259, 2583, 23, 606, 1473, 2139, 2, 11307, 1655, 6, 1686, 165, 2073, 659, 541, 11, 73, 62, 768, 6, 1182, 190, 3, 3897, 727, 2066, 3023, 6, 2363, 2341, 190, 3, 435, 727, 2292, 2341, 6, 1397, 1544, 6900, 541, 11, 73, 5, 1182, 4, 8, 4827, 815, 413, 2712, 30602, 259, 1459, 20, 815, 1339, 2, 413, 2707, 1474, 11, 3426, 8092, 190, 3, 3897, 727, 2, 11, 781, 190, 3, 435, 727, 774, 115, 25, 10, 661, 20, 3, 876, 882, 596, 281, 159, 273, 29, 155, 34, 91, 15, 429, 2, 9839, 1, 24, 3, 33, 111, 774, 115, 25, 231, 7025, 531, 48, 58, 239, 601, 4, 3, 191, 727, 662, 48, 58, 511, 717, 4, 3, 3897, 727, 2, 676, 48, 58, 614, 792, 4, 3, 435, 727, 3, 1320, 1, 708, 112, 24, 496, 4, 3, 191, 3897, 2, 807, 3338, 106, 262, 14, 111, 1, 147, 10, 213, 105, 27, 66, 105, 27, 27, 9, 429, 49, 13, 105, 133, 105, 83, 66, 9, 273, 29, 930, 18, 39, 105, 233, 105, 39, 18, 9, 273, 29, 13602, 155, 2, 245, 105, 14, 27, 105, 13, 33, 9, 9839, 1, 36, 24, 1, 864, 62, 4, 8, 4827, 815, 413, 2712, 75, 8, 949, 1643, 2870, 353, 1182, 90, 36, 2, 293, 538, 2, 5468, 16, 41, 5, 231, 123, 4, 8, 3069, 334, 965]",2019.0,15161898,767
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.,Blood,Blood,2004-06-03,"Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL). We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution. Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy. Consolidative radiation therapy was given to patients with mediastinal disease at presentation. No consolidation with autologous or allogeneic stem cell transplantation was performed. At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease. Of the patients, 30 (91%) achieved complete remission, and 3 (9%) achieved partial response. Within a median of 13 months, 10 patients (30%) relapsed or progressed. Estimates for 3-year progression-free and overall survival for the 33 patients were 66% and 70%, respectively. Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively. No parameters (eg, age, stage, serum lactate dehydrogenase [LDH], beta(2) microglobulin) appeared to influence outcome except for CNS disease at presentation. Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome. Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or those with residual mediastinal disease.",Clinical Trial,5710.0,171.0,Therapy of lymphoblastic LL has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic ALL We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD fractionated cyclophosphamide vincristine Adriamycin and dexamethasone or modified hyper-CVAD used for ALL at our institution Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis followed by maintenance therapy Consolidative radiation therapy was given to patients with mediastinal disease at presentation No consolidation with autologous or allogeneic stem cell transplantation was performed At diagnosis 80 were T-cell immunophenotype 70 were stages III to IV 70 had mediastinal involvement and 9 had central nervous system CNS disease Of the patients 30 91 achieved complete remission and 3 9 achieved partial response Within a median of 13 months 10 patients 30 relapsed or progressed Estimates for 3-year progression-free and overall survival for the 33 patients were 66 and 70 respectively Estimates for the patients with known T-cell immunophenotype were 62 and 67 respectively No parameters eg age stage serum lactate dehydrogenase LDH beta 2 microglobulin appeared to influence outcome except for CNS disease at presentation Modification of the hyper-CVAD regimen with anthracycline intensification did not improve outcome Other modifications of the program could include incorporation of monoclonal antibodies and/or nucleoside analogs particularly for slow responders or those with residual mediastinal disease,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[36, 1, 1275, 15981, 71, 3937, 5, 119, 1, 56, 472, 4666, 50, 135, 9, 286, 1193, 62, 21, 73, 466, 7, 5, 15981, 5, 3, 1686, 56, 472, 4855, 5574, 3950, 1112, 2132, 7700, 2, 1217, 15, 1230, 4855, 5574, 95, 9, 62, 28, 114, 731, 504, 2173, 10, 468, 5, 66, 15, 83, 5181, 410, 1, 56, 252, 33, 6, 49, 53, 5, 5126, 56, 2049, 370, 20, 1146, 36, 6618, 121, 36, 10, 447, 6, 7, 5, 2626, 34, 28, 1031, 77, 2173, 5, 1028, 15, 1063, 452, 31, 497, 10, 173, 28, 147, 493, 11, 102, 31, 5496, 431, 11, 1153, 316, 6, 478, 431, 42, 2626, 799, 2, 83, 42, 854, 1880, 398, 1025, 34, 1, 3, 7, 201, 970, 513, 236, 734, 2, 27, 83, 513, 450, 51, 262, 8, 52, 1, 233, 53, 79, 7, 201, 591, 15, 1839, 1423, 9, 27, 111, 91, 115, 2, 63, 25, 9, 3, 466, 7, 11, 700, 2, 431, 106, 1423, 9, 3, 7, 5, 440, 102, 31, 5496, 11, 744, 2, 598, 106, 77, 1038, 2887, 89, 82, 524, 3330, 2374, 4592, 1090, 18, 5371, 2121, 6, 1054, 228, 2187, 9, 1025, 34, 28, 1031, 2437, 1, 3, 4855, 5574, 477, 5, 2044, 5091, 205, 44, 401, 228, 127, 2916, 1, 3, 1243, 359, 643, 2838, 1, 848, 890, 2, 15, 4032, 4063, 823, 9, 3645, 1983, 15, 135, 5, 753, 2626, 34]",1620.0,15178574,117
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.,Blood,Blood,2004-06-03,"The FLT3 receptor is activated by juxtamembrane insertion mutations and by activation loop point mutations in patients with acute myeloid leukemia (AML). In a systematic tyrosine kinase gene exon resequencing study, 21 of 24 FLT3 exons were sequenced in samples from 53 patients with AML, 9 patients with acute lymphoblastic leukemia (ALL), and 3 patients with myelodysplasia samples. Three patients had novel point mutations at residue N841 that resulted in a change to isoleucine in 2 samples and to tyrosine in 1 sample. Introduction of FLT3-N841I cDNA into Ba/F3 cells led to interleukin-3 (IL-3)-independent proliferation, receptor phosphorylation, and constitutive activation of signal transducer and activator of transcription 5 (STAT5) and extracellular regulatory kinase (ERK), suggesting that the N841I mutation confers constitutive activity to the receptor. An FLT3 inhibitor (PKC412) inhibited the growth of Ba/F3-FLT3N841I cells (IC(50) 10 nM), but not of wild-type Ba/F3 cells cultured with IL-3. PKC412 also reduced tyrosine phosphorylation of the mutant receptor and inhibited STAT5 phosphorylation. Examination of the FLT3 autoinhibited structure showed that N841 is the key residue in a hydrogen-bonding network that likely stabilizes the activation loop. These results suggest that mutations at N841 represent a significant new activating mutation in patients with AML and that patients with such mutations may respond to small-molecule FLT3 inhibitors such as PKC412.",Journal Article,5710.0,68.0,The FLT3 receptor is activated by juxtamembrane insertion mutations and by activation loop point mutations in patients with acute myeloid AML In a systematic tyrosine kinase gene exon resequencing study 21 of 24 FLT3 exons were sequenced in samples from 53 patients with AML 9 patients with acute lymphoblastic ALL and 3 patients with myelodysplasia samples Three patients had novel point mutations at residue N841 that resulted in a change to isoleucine in 2 samples and to tyrosine in 1 sample Introduction of FLT3-N841I cDNA into Ba/F3 cells led to interleukin-3 IL-3 -independent proliferation receptor phosphorylation and constitutive activation of signal transducer and activator of transcription 5 STAT5 and extracellular regulatory kinase ERK suggesting that the N841I mutation confers constitutive activity to the receptor An FLT3 inhibitor PKC412 inhibited the growth of Ba/F3-FLT3N841I cells IC 50 10 nM but not of wild-type Ba/F3 cells cultured with IL-3 PKC412 also reduced tyrosine phosphorylation of the mutant receptor and inhibited STAT5 phosphorylation Examination of the FLT3 autoinhibited structure showed that N841 is the key residue in a hydrogen-bonding network that likely stabilizes the activation loop These results suggest that mutations at N841 represent a significant new activating mutation in patients with AML and that patients with such mutations may respond to small-molecule FLT3 inhibitors such as PKC412,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1224, 153, 16, 735, 20, 10541, 5099, 138, 2, 20, 363, 4432, 741, 138, 4, 7, 5, 286, 533, 329, 4, 8, 1556, 564, 216, 145, 1725, 11819, 45, 239, 1, 259, 1224, 3885, 11, 4040, 4, 347, 29, 699, 7, 5, 329, 83, 7, 5, 286, 1275, 62, 2, 27, 7, 5, 6128, 347, 169, 7, 42, 229, 741, 138, 28, 7840, 37702, 17, 627, 4, 8, 707, 6, 21250, 4, 18, 347, 2, 6, 564, 4, 14, 1000, 2456, 1, 1224, 43626, 4212, 237, 6669, 6904, 37, 836, 6, 1603, 27, 501, 27, 306, 457, 153, 982, 2, 3178, 363, 1, 1235, 5182, 2, 3393, 1, 866, 33, 5517, 2, 1976, 1253, 216, 1819, 802, 17, 3, 43626, 258, 4020, 3178, 128, 6, 3, 153, 35, 1224, 230, 7154, 879, 3, 129, 1, 6669, 6904, 54203, 37, 2340, 212, 79, 2878, 84, 44, 1, 955, 267, 6669, 6904, 37, 3197, 5, 501, 27, 7154, 120, 405, 564, 982, 1, 3, 620, 153, 2, 879, 5517, 982, 1385, 1, 3, 1224, 33685, 2772, 224, 17, 37702, 16, 3, 825, 7840, 4, 8, 12808, 28239, 1801, 17, 322, 11019, 3, 363, 4432, 46, 99, 309, 17, 138, 28, 37702, 1231, 8, 93, 217, 1616, 258, 4, 7, 5, 329, 2, 17, 7, 5, 225, 138, 68, 1892, 6, 302, 1354, 1224, 222, 225, 22, 7154]",1440.0,15178581,691
Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins.,Journal of leukocyte biology,J. Leukoc. Biol.,2004-06-14,"Recurrent cytogenetic abnormalities in leukemic blasts make these an attractive source for dendritic cells (DC) to induce a leukemia-specific immune response. In this study, three leukemic cell lines were investigated: Kasumi-1 and SKNO-1 (two acute myeloid leukemia (AML) cell lines carrying the (8;21)-chromosomal translocation, resulting in the expression of the leukemia-specific fusion protein AML1-eight-twenty-one) and REH, an acute lymphoblastic leukemia cell line with the (12;21)-chromosomal translocation and expression of translocation ETS-like leukemia-AML1. These fusion proteins are implicated in the pathogenesis of the leukemic state by recruiting corepressors and histone deacetylases (HDAC), which interfere with normal cell differentiation. In vitro generation of DC was achieved using a cytokine cocktail containing tumor necrosis factor alpha, granulocyte macrophage-colony stimulating factor, c-kit ligand, and soluble CD40 ligand; yet, addition of the HDAC inhibitor (Hdi) trichostatin A enhanced DC differentiation with retention of the fusion transcripts. These leukemic DC showed high-level CD83 and human leukocyte antigen (HLA)-DR expression and had a high allostimulatory potential. Only DC generated from these cell lines after Hdi induced blast-specific cytotoxic T cell responses in HLA-A-matched T cells with a cytotoxicity of 42% in parental Kasumi-1 and 83% in parental REH cells, respectively. This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins.",Journal Article,5699.0,21.0,Recurrent cytogenetic abnormalities in leukemic blasts make these an attractive source for dendritic cells DC to induce a leukemia-specific immune response In this study three leukemic cell lines were investigated Kasumi-1 and SKNO-1 two acute myeloid AML cell lines carrying the 8 21 -chromosomal translocation resulting in the expression of the leukemia-specific fusion protein AML1-eight-twenty-one and REH an acute lymphoblastic cell line with the 12 21 -chromosomal translocation and expression of translocation ETS-like leukemia-AML1 These fusion proteins are implicated in the pathogenesis of the leukemic state by recruiting corepressors and histone deacetylases HDAC which interfere with normal cell differentiation In vitro generation of DC was achieved using a cytokine cocktail containing tumor necrosis factor alpha granulocyte macrophage-colony stimulating factor c-kit ligand and soluble CD40 ligand yet addition of the HDAC inhibitor Hdi trichostatin A enhanced DC differentiation with retention of the fusion transcripts These leukemic DC showed high-level CD83 and human leukocyte antigen HLA -DR expression and had a high allostimulatory potential Only DC generated from these cell lines after Hdi induced blast-specific cytotoxic T cell responses in HLA-A-matched T cells with a cytotoxicity of 42 in parental Kasumi-1 and 83 in parental REH cells respectively This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[387, 1266, 1171, 4, 2015, 2438, 2378, 46, 35, 3059, 2353, 9, 2464, 37, 2321, 6, 1290, 8, 2647, 112, 250, 51, 4, 26, 45, 169, 2015, 31, 285, 11, 565, 18159, 14, 2, 54213, 14, 100, 286, 533, 329, 31, 285, 2934, 3, 66, 239, 1860, 2006, 1113, 4, 3, 55, 1, 3, 2647, 112, 1212, 178, 6535, 659, 737, 104, 2, 23340, 35, 286, 1275, 31, 328, 5, 3, 133, 239, 1860, 2006, 2, 55, 1, 2006, 4802, 733, 2647, 6535, 46, 1212, 652, 32, 1771, 4, 3, 1384, 1, 3, 2015, 1309, 20, 9200, 21036, 2, 1508, 9758, 2654, 92, 6178, 5, 295, 31, 910, 4, 439, 914, 1, 2321, 10, 513, 75, 8, 1675, 11821, 1101, 30, 1523, 161, 950, 2764, 2674, 1975, 2122, 161, 256, 1164, 1232, 2, 2968, 5040, 1232, 1145, 352, 1, 3, 2654, 230, 6676, 13824, 8, 651, 2321, 910, 5, 3947, 1, 3, 1212, 2680, 46, 2015, 2321, 224, 64, 301, 16636, 2, 171, 3627, 448, 1160, 3436, 55, 2, 42, 8, 64, 54214, 174, 158, 2321, 1419, 29, 46, 31, 285, 50, 6676, 277, 3112, 112, 759, 102, 31, 253, 4, 1160, 8, 655, 102, 37, 5, 8, 1408, 1, 595, 4, 3418, 18159, 14, 2, 852, 4, 3418, 23340, 37, 106, 26, 202, 398, 844, 17, 3, 6676, 2304, 3, 4, 439, 910, 1, 2321, 29, 2015, 2438, 5, 6535, 1101, 1212, 652]",1522.0,15197237,440
Gene expression profiling of pediatric acute myelogenous leukemia.,Blood,Blood,2004-06-29,"Contemporary treatment of pediatric acute myeloid leukemia (AML) requires the assignment of patients to specific risk groups. To explore whether expression profiling of leukemic blasts could accurately distinguish between the known risk groups of AML, we analyzed 130 pediatric and 20 adult AML diagnostic bone marrow or peripheral blood samples using the Affymetrix U133A microarray. Class discriminating genes were identified for each of the major prognostic subtypes of pediatric AML, including t(15;17)[PML-RARalpha], t(8;21)[AML1-ETO], inv(16) [CBFbeta-MYH11], MLL chimeric fusion genes, and cases classified as FAB-M7. When subsets of these genes were used in supervised learning algorithms, an overall classification accuracy of more than 93% was achieved. Moreover, we were able to use the expression signatures generated from the pediatric samples to accurately classify adult de novo AMLs with the same genetic lesions. The class discriminating genes also provided novel insights into the molecular pathobiology of these leukemias. Finally, using a combined pediatric data set of 130 AMLs and 137 acute lymphoblastic leukemias, we identified an expression signature for cases with MLL chimeric fusion genes irrespective of lineage. Surprisingly, AMLs containing partial tandem duplications of MLL failed to cluster with MLL chimeric fusion gene cases, suggesting a significant difference in their underlying mechanism of transformation.",Journal Article,5684.0,330.0,Contemporary treatment of pediatric acute myeloid AML requires the assignment of patients to specific risk groups To explore whether expression profiling of leukemic blasts could accurately distinguish between the known risk groups of AML we analyzed 130 pediatric and 20 adult AML diagnostic marrow or peripheral blood samples using the Affymetrix U133A microarray Class discriminating genes were identified for each of the major prognostic subtypes of pediatric AML including t 15 17 PML-RARalpha t 8 21 AML1-ETO inv 16 CBFbeta-MYH11 MLL chimeric fusion genes and cases classified as FAB-M7 When subsets of these genes were used in supervised learning algorithms an overall classification accuracy of more than 93 was achieved Moreover we were able to use the expression signatures generated from the pediatric samples to accurately classify adult de novo AMLs with the same genetic lesions The class discriminating genes also provided novel insights into the molecular pathobiology of these leukemias Finally using a combined pediatric data set of 130 AMLs and 137 acute lymphoblastic leukemias we identified an expression signature for cases with MLL chimeric fusion genes irrespective of lineage Surprisingly AMLs containing partial tandem duplications of MLL failed to cluster with MLL chimeric fusion gene cases suggesting a significant difference in their underlying mechanism of transformation,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2667, 24, 1, 815, 286, 533, 329, 1706, 3, 4392, 1, 7, 6, 112, 43, 271, 6, 1645, 317, 55, 1080, 1, 2015, 2438, 359, 2141, 3081, 59, 3, 440, 43, 271, 1, 329, 21, 311, 3431, 815, 2, 179, 780, 329, 752, 581, 15, 672, 315, 347, 75, 3, 5318, 11318, 1727, 1040, 8059, 214, 11, 108, 9, 296, 1, 3, 458, 177, 814, 1, 815, 329, 141, 102, 167, 269, 5457, 10412, 102, 66, 239, 6535, 8566, 6397, 245, 15498, 11644, 3049, 2897, 1212, 214, 2, 140, 1373, 22, 9075, 14730, 198, 1890, 1, 46, 214, 11, 95, 4, 7762, 3434, 3529, 35, 63, 947, 1190, 1, 80, 76, 966, 10, 513, 1393, 21, 11, 1665, 6, 119, 3, 55, 2210, 1419, 29, 3, 815, 347, 6, 2141, 4896, 780, 1566, 2018, 9542, 5, 3, 827, 336, 406, 3, 1040, 8059, 214, 120, 1052, 229, 1957, 237, 3, 219, 8465, 1, 46, 2792, 1368, 75, 8, 397, 815, 74, 916, 1, 3431, 9542, 2, 4352, 286, 1275, 2792, 21, 108, 35, 55, 1651, 9, 140, 5, 3049, 2897, 1212, 214, 3500, 1, 2542, 5819, 9542, 1101, 450, 2905, 8910, 1, 3049, 1551, 6, 3132, 5, 3049, 2897, 1212, 145, 140, 802, 8, 93, 523, 4, 136, 1181, 670, 1, 1392]",1402.0,15226186,124
Outcomes of a randomized trial of hyperfractionated cranial radiation therapy for treatment of high-risk acute lymphoblastic leukemia: therapeutic efficacy and neurotoxicity.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2004-07-01,"We evaluated 8-year survival and late neuropsychologic toxicity in children with acute lymphoblastic leukemia treated in a randomized clinical trial to test whether hyperfractionated (twice daily) cranial radiation therapy (CRT) can reduce incidence and severity of late toxicities associated with 18 Gy of CRT. Between 1987 and 1995, 369 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for high-risk acute lymphoblastic leukemia were randomly assigned to conventionally fractionated CRT (CFX) or hyperfractionated CRT (HFX) to a total dose of 18 Gy. Neuropsychologic testing was completed for 125 of 287 children in continuous complete remission. Event-free and overall survival, as well as neuropsychologic function, were compared for the two arms of the protocol. Eight-year event-free survival (+/- SE) was 80% +/- 3% for children randomly assigned to CFX and 72% +/- 3% for HFX (P =.06). Overall survival was 85% +/- 3% for CFX and 78% +/- 3% for HFX (P =.06). CNS relapses occurred in 2.8% of patients receiving CFX and 2.7% receiving HFX (P =.99). Cognitive function for both groups was solidly in the average range, with no group differences in intelligence, academic achievement, visuospatial reasoning, or verbal learning. Children on the HFX arm exhibited a modest advantage for visual memory (P <.05). HFX provides no benefit in terms of cognitive late effects and may compromise antileukemic efficacy. HFX should not be substituted for conventionally dosed CRT in children who require radiation therapy for treatment of acute lymphoblastic leukemia.",Clinical Trial,5682.0,33.0,We evaluated 8-year survival and late neuropsychologic toxicity in children with acute lymphoblastic treated in a randomized clinical trial to test whether hyperfractionated twice daily cranial radiation therapy CRT can reduce incidence and severity of late toxicities associated with 18 Gy of CRT Between 1987 and 1995 369 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for high-risk acute lymphoblastic were randomly assigned to conventionally fractionated CRT CFX or hyperfractionated CRT HFX to a total dose of 18 Gy Neuropsychologic testing was completed for 125 of 287 children in continuous complete remission Event-free and overall survival as well as neuropsychologic function were compared for the two arms of the protocol Eight-year event-free survival +/- SE was 80 +/- 3 for children randomly assigned to CFX and 72 +/- 3 for HFX P =.06 Overall survival was 85 +/- 3 for CFX and 78 +/- 3 for HFX P =.06 CNS relapses occurred in 2.8 of patients receiving CFX and 2.7 receiving HFX P =.99 Cognitive function for both groups was solidly in the average range with no group differences in intelligence academic achievement visuospatial reasoning or verbal learning Children on the HFX arm exhibited a modest advantage for visual memory P .05 HFX provides no benefit in terms of cognitive late effects and may compromise antileukemic efficacy HFX should not be substituted for conventionally dosed CRT in children who require radiation therapy for treatment of acute lymphoblastic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 194, 66, 111, 25, 2, 807, 23281, 155, 4, 541, 5, 286, 1275, 73, 4, 8, 384, 38, 160, 6, 412, 317, 6201, 936, 391, 2565, 121, 36, 1089, 122, 969, 287, 2, 1702, 1, 807, 385, 41, 5, 203, 381, 1, 1089, 59, 5450, 2, 2323, 8718, 541, 73, 23, 100, 935, 4932, 4979, 12, 1377, 2404, 2189, 9, 64, 43, 286, 1275, 11, 1108, 896, 6, 6846, 3950, 1089, 21262, 15, 6201, 1089, 13604, 6, 8, 181, 61, 1, 203, 381, 23281, 471, 10, 781, 9, 1731, 1, 8488, 541, 4, 1314, 236, 734, 774, 115, 2, 63, 25, 22, 149, 22, 23281, 343, 11, 72, 9, 3, 100, 1335, 1, 3, 1182, 659, 111, 774, 115, 25, 3428, 10, 493, 27, 9, 541, 1108, 896, 6, 21262, 2, 720, 27, 9, 13604, 19, 1460, 63, 25, 10, 772, 27, 9, 21262, 2, 833, 27, 9, 13604, 19, 1460, 1025, 3713, 489, 4, 18, 66, 1, 7, 357, 21262, 2, 18, 67, 357, 13604, 19, 1058, 1863, 343, 9, 110, 271, 10, 37725, 4, 3, 1011, 184, 5, 77, 87, 362, 4, 9125, 1916, 5088, 28255, 15856, 15, 7028, 3434, 541, 23, 3, 13604, 475, 1416, 8, 1721, 1874, 9, 3046, 2407, 19, 474, 13604, 777, 77, 247, 4, 1794, 1, 1863, 807, 176, 2, 68, 4665, 4512, 209, 13604, 257, 44, 40, 10536, 9, 6846, 6268, 1089, 4, 541, 54, 1353, 121, 36, 9, 24, 1, 286, 1275]",1526.0,15226337,885
Parental exposure to medications and hydrocarbons and ras mutations in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2004-07-01,"Ras proto-oncogene mutations have been implicated in the pathogenesis of many malignancies, including leukemia. While both human and animal studies have linked several chemical carcinogens to specific ras mutations, little data exist regarding the association of ras mutations with parental exposures and risk of childhood leukemia. Using data from a large case-control study of childhood acute lymphoblastic leukemia (ALL; age <15 years) conducted by the Children's Cancer Group, we used a case-case comparison approach to examine whether reported parental exposure to hydrocarbons at work or use of specific medications are related to ras gene mutations in the leukemia cells of children with ALL. DNA was extracted from archived bone marrow slides or cryopreserved marrow samples for 837 ALL cases. We examined mutations in K-ras and N-ras genes at codons 12, 13, and 61 by PCR and allele-specific oligonucleotide hybridization and confirmed them by DNA sequencing. We interviewed mothers and, if available, fathers by telephone to collect exposure information. Odds ratios (ORs) and 95% confidence intervals (CIs) were derived from logistic regression to examine the association of parental exposures with ras mutations. A total of 127 (15.2%) cases had ras mutations (K-ras 4.7% and N-ras 10.68%). Both maternal (OR 3.2, 95% CI 1.7-6.1) and paternal (OR 2.0, 95% CI 1.1-3.7) reported use of mind-altering drugs were associated with N-ras mutations. Paternal use of amphetamines or diet pills was associated with N-ras mutations (OR 4.1, 95% CI 1.1-15.0); no association was observed with maternal use. Maternal exposure to solvents (OR 3.1, 95% CI 1.0-9.7) and plastic materials (OR 6.9, 95% CI 1.2-39.7) during pregnancy and plastic materials after pregnancy (OR 8.3, 95% CI 1.4-48.8) were related to K-ras mutation. Maternal ever exposure to oil and coal products before case diagnosis (OR 2.3, 95% CI 1.1-4.8) and during the postnatal period (OR 2.2, 95% CI 1.0-5.5) and paternal exposure to plastic materials before index pregnancy (OR 2.4, 95% CI 1.1-5.1) and other hydrocarbons during the postnatal period (OR 1.8, 95% CI 1.0-1.3) were associated with N-ras mutations. This study suggests that parental exposure to specific chemicals may be associated with distinct ras mutations in children who develop ALL.",Journal Article,5682.0,40.0,Ras proto-oncogene mutations have been implicated in the pathogenesis of many malignancies including While both human and animal studies have linked several chemical carcinogens to specific ras mutations little data exist regarding the association of ras mutations with parental exposures and risk of childhood Using data from a large case-control study of childhood acute lymphoblastic ALL age 15 years conducted by the Children 's Cancer Group we used a case-case comparison approach to examine whether reported parental exposure to hydrocarbons at work or use of specific medications are related to ras gene mutations in the cells of children with ALL DNA was extracted from archived marrow slides or cryopreserved marrow samples for 837 ALL cases We examined mutations in K-ras and N-ras genes at codons 12 13 and 61 by PCR and allele-specific oligonucleotide hybridization and confirmed them by DNA sequencing We interviewed mothers and if available fathers by telephone to collect exposure information Odds ratios ORs and 95 confidence intervals CIs were derived from logistic regression to examine the association of parental exposures with ras mutations A total of 127 15.2 cases had ras mutations K-ras 4.7 and N-ras 10.68 Both maternal OR 3.2 95 CI 1.7-6.1 and paternal OR 2.0 95 CI 1.1-3.7 reported use of mind-altering drugs were associated with N-ras mutations Paternal use of amphetamines or diet pills was associated with N-ras mutations OR 4.1 95 CI 1.1-15.0 no association was observed with maternal use Maternal exposure to solvents OR 3.1 95 CI 1.0-9.7 and plastic materials OR 6.9 95 CI 1.2-39.7 during pregnancy and plastic materials after pregnancy OR 8.3 95 CI 1.4-48.8 were related to K-ras mutation Maternal ever exposure to oil and coal products before case diagnosis OR 2.3 95 CI 1.1-4.8 and during the postnatal period OR 2.2 95 CI 1.0-5.5 and paternal exposure to plastic materials before index pregnancy OR 2.4 95 CI 1.1-5.1 and other hydrocarbons during the postnatal period OR 1.8 95 CI 1.0-1.3 were associated with N-ras mutations This study suggests that parental exposure to specific chemicals may be associated with distinct ras mutations in children who develop ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1102, 4976, 1836, 138, 47, 85, 1771, 4, 3, 1384, 1, 445, 441, 141, 369, 110, 171, 2, 2026, 94, 47, 1199, 392, 3743, 8850, 6, 112, 1102, 138, 1215, 74, 1923, 666, 3, 248, 1, 1102, 138, 5, 3418, 3401, 2, 43, 1, 864, 75, 74, 29, 8, 375, 473, 182, 45, 1, 864, 286, 1275, 62, 89, 167, 60, 426, 20, 3, 541, 292, 12, 87, 21, 95, 8, 473, 473, 1155, 353, 6, 1004, 317, 210, 3418, 645, 6, 28258, 28, 1357, 15, 119, 1, 112, 2679, 32, 139, 6, 1102, 145, 138, 4, 3, 37, 1, 541, 5, 62, 261, 10, 2484, 29, 6282, 581, 3830, 15, 10432, 581, 347, 9, 17243, 62, 140, 21, 409, 138, 4, 1634, 1102, 2, 78, 1102, 214, 28, 9107, 133, 233, 2, 713, 20, 604, 2, 1254, 112, 4727, 1554, 2, 557, 1370, 20, 261, 615, 21, 6713, 8605, 2, 492, 390, 17271, 20, 4258, 6, 6248, 645, 487, 610, 1137, 3694, 2, 48, 307, 1582, 1927, 11, 526, 29, 812, 320, 6, 1004, 3, 248, 1, 3418, 3401, 5, 1102, 138, 8, 181, 1, 4080, 167, 18, 140, 42, 1102, 138, 1634, 1102, 39, 67, 2, 78, 1102, 79, 806, 110, 6039, 15, 27, 18, 48, 58, 14, 67, 49, 14, 2, 10649, 15, 18, 13, 48, 58, 14, 14, 27, 67, 210, 119, 1, 8090, 4831, 600, 11, 41, 5, 78, 1102, 138, 10649, 119, 1, 37281, 15, 2453, 17655, 10, 41, 5, 78, 1102, 138, 15, 39, 14, 48, 58, 14, 14, 167, 13, 77, 248, 10, 164, 5, 6039, 119, 6039, 645, 6, 24732, 15, 27, 14, 48, 58, 14, 13, 83, 67, 2, 7409, 5102, 15, 49, 83, 48, 58, 14, 18, 587, 67, 190, 2290, 2, 7409, 5102, 50, 2290, 15, 66, 27, 48, 58, 14, 39, 576, 66, 11, 139, 6, 1634, 1102, 258, 6039, 3353, 645, 6, 9481, 2, 37730, 2766, 348, 473, 147, 15, 18, 27, 48, 58, 14, 14, 39, 66, 2, 190, 3, 15472, 727, 15, 18, 18, 48, 58, 14, 13, 33, 33, 2, 10649, 645, 6, 7409, 5102, 348, 558, 2290, 15, 18, 39, 48, 58, 14, 14, 33, 14, 2, 127, 28258, 190, 3, 15472, 727, 15, 14, 66, 48, 58, 14, 13, 14, 27, 11, 41, 5, 78, 1102, 138, 26, 45, 844, 17, 3418, 645, 6, 112, 14226, 68, 40, 41, 5, 834, 1102, 138, 4, 541, 54, 690, 62]",2202.0,15247135,111
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2004-07-01,"Doxorubicin chemotherapy is very effective in children with acute lymphoblastic leukemia (ALL) but also injures myocardial cells. Dexrazoxane, a free-radical scavenger, may protect the heart from doxorubicin-associated damage. To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes, we randomly assigned 101 children with ALL to receive doxorubicin alone (30 mg per square meter of body-surface area every three weeks for 10 doses) and 105 to receive dexrazoxane (300 mg per square meter) followed immediately by doxorubicin. Serial measurements of serum cardiac troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin. A total of 2377 serum samples (mean, 15.1 samples per patient) were obtained before, during, and after treatment with doxorubicin. Troponin T levels were evaluated in a blinded fashion to determine whether they were elevated (>0.01 ng per milliliter)--the primary end point--or extremely elevated (>0.025 ng per milliliter). Elevations of troponin T occurred in 35 percent of the patients (55 of 158). Patients treated with doxorubicin alone were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T levels (50 percent vs. 21 percent, P<0.001) and extremely elevated troponin T levels (32 percent vs. 10 percent, P<0.001). The median follow-up was 2.7 years. The rate of event-free survival at 2.5 years was 83 percent in both groups (P=0.87 by the log-rank test). Dexrazoxane prevents or reduces cardiac injury, as reflected by elevations in troponin T, that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin. Longer follow-up will be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years and on event-free survival.",Clinical Trial,5682.0,420.0,Doxorubicin chemotherapy is very effective in children with acute lymphoblastic ALL but also injures myocardial cells Dexrazoxane a free-radical scavenger may protect the from doxorubicin-associated damage To determine whether dexrazoxane decreases doxorubicin-associated injury of cardiomyocytes we randomly assigned 101 children with ALL to receive doxorubicin alone 30 mg per square meter of body-surface area every three weeks for 10 doses and 105 to receive dexrazoxane 300 mg per square meter followed immediately by doxorubicin Serial measurements of serum troponin T were obtained in 76 of 101 patients in the doxorubicin group and 82 of 105 patients in the group given dexrazoxane and doxorubicin A total of 2377 serum samples mean 15.1 samples per patient were obtained before during and after treatment with doxorubicin Troponin T levels were evaluated in a blinded fashion to determine whether they were elevated 0.01 ng per milliliter -- the primary end point -- or extremely elevated 0.025 ng per milliliter Elevations of troponin T occurred in 35 percent of the patients 55 of 158 Patients treated with doxorubicin alone were more likely than those who received dexrazoxane and doxorubicin to have elevated troponin T levels 50 percent vs. 21 percent P 0.001 and extremely elevated troponin T levels 32 percent vs. 10 percent P 0.001 The median follow-up was 2.7 years The rate of event-free survival at 2.5 years was 83 percent in both groups P=0.87 by the log-rank test Dexrazoxane prevents or reduces injury as reflected by elevations in troponin T that is associated with the use of doxorubicin for childhood ALL without compromising the antileukemic efficacy of doxorubicin Longer follow-up will be necessary to determine the influence of dexrazoxane on echocardiographic findings at four years and on event-free survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[856, 56, 16, 923, 323, 4, 541, 5, 286, 1275, 62, 84, 120, 43660, 5098, 37, 8473, 8, 115, 711, 12545, 68, 4869, 3, 29, 856, 41, 1350, 6, 223, 317, 8473, 2140, 856, 41, 2730, 1, 30627, 21, 1108, 896, 2338, 541, 5, 62, 6, 560, 856, 279, 201, 81, 379, 3219, 8591, 1, 642, 1255, 965, 454, 169, 244, 9, 79, 415, 2, 3263, 6, 560, 8473, 2036, 81, 379, 3219, 8591, 370, 3467, 20, 856, 2108, 1685, 1, 524, 9092, 102, 11, 683, 4, 846, 1, 2338, 7, 4, 3, 856, 87, 2, 878, 1, 3263, 7, 4, 3, 87, 447, 8473, 2, 856, 8, 181, 1, 30628, 524, 347, 313, 167, 14, 347, 379, 69, 11, 683, 348, 190, 2, 50, 24, 5, 856, 9092, 102, 148, 11, 194, 4, 8, 3288, 3240, 6, 223, 317, 491, 11, 804, 13, 355, 997, 379, 14835, 3, 86, 396, 741, 15, 2938, 804, 13, 4067, 997, 379, 14835, 4712, 1, 9092, 102, 489, 4, 465, 714, 1, 3, 7, 614, 1, 5162, 7, 73, 5, 856, 279, 11, 80, 322, 76, 135, 54, 103, 8473, 2, 856, 6, 47, 804, 9092, 102, 148, 212, 714, 105, 239, 714, 19, 13, 144, 2, 2938, 804, 9092, 102, 148, 531, 714, 105, 79, 714, 19, 13, 144, 3, 52, 166, 126, 10, 18, 67, 60, 3, 116, 1, 774, 115, 25, 28, 18, 33, 60, 10, 852, 714, 4, 110, 271, 19, 13, 912, 20, 3, 1066, 1026, 412, 8473, 5217, 15, 2389, 2730, 22, 4686, 20, 4712, 4, 9092, 102, 17, 16, 41, 5, 3, 119, 1, 856, 9, 864, 62, 187, 6102, 3, 4512, 209, 1, 856, 589, 166, 126, 303, 40, 1493, 6, 223, 3, 1054, 1, 8473, 23, 13220, 272, 28, 294, 60, 2, 23, 774, 115, 25]",1841.0,15247354,742
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.,Blood,Blood,2004-07-13,"St Jude Total Therapy Study XIIIB for childhood acute lymphoblastic leukemia (ALL) incorporated more stringent risk classification, early intensification of intrathecal chemotherapy, reinduction treatment, and the addition of dexamethasone to postremission therapy to increase the proportion of event-free survivors without jeopardizing their quality of life. Cranial irradiation was reserved for the 12% of patients who had T-cell ALL and a presenting leukocyte count of 100 x 10(9)/L or more, or CNS-3 (5 or more leukocytes/microL with identifiable blast cells in an atraumatic sample or the presence of cranial nerve palsy) status. Among the 247 consecutive patients enrolled in the study, 117 were classified as having lower-risk leukemia and received mainly antimetabolite-based continuation therapy; the 130 cases with higher-risk leukemia received more intensive continuation chemotherapy with multiple drug pairs administered in weekly rotation. The 5-year event-free survival estimate was 80.8% +/- 2.6% (SE); the 8-year rate was 78.6% +/- 5.8%. The 5-year cumulative risk of an isolated central nervous system (CNS) relapse was 1.7% +/- 0.8%, and that of isolated plus combined CNS relapse was 3.0% +/- 1.1%. The 5-year cumulative risks of etoposide-related myeloid malignancies were 1.8% +/- 1.3% in the lower-risk patients who received a cumulative dose of 1.2 g/m(2) and 5.0% +/- 2.0% in the higher-risk patients who received a cumulative dose of up to 14.4 g/m(2) (P = .18). Independent adverse prognostic features included the presence of MLL-AF4 or BCR-ABL fusion gene and minimal residual leukemia of 0.01% or more at the end of the 6-week remission induction phase. Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether.",Clinical Trial,5670.0,336.0,St Jude Total Therapy Study XIIIB for childhood acute lymphoblastic ALL incorporated more stringent risk classification early intensification of intrathecal chemotherapy reinduction treatment and the addition of dexamethasone to postremission therapy to increase the proportion of event-free survivors without jeopardizing their quality of life Cranial irradiation was reserved for the 12 of patients who had T-cell ALL and a presenting leukocyte count of 100 x 10 9 /L or more or CNS-3 5 or more leukocytes/microL with identifiable blast cells in an atraumatic sample or the presence of cranial nerve palsy status Among the 247 consecutive patients enrolled in the study 117 were classified as having lower-risk and received mainly antimetabolite-based continuation therapy the 130 cases with higher-risk received more intensive continuation chemotherapy with multiple drug pairs administered in weekly rotation The 5-year event-free survival estimate was 80.8 +/- 2.6 SE the 8-year rate was 78.6 +/- 5.8 The 5-year cumulative risk of an isolated central nervous system CNS relapse was 1.7 +/- 0.8 and that of isolated plus combined CNS relapse was 3.0 +/- 1.1 The 5-year cumulative risks of etoposide-related myeloid malignancies were 1.8 +/- 1.3 in the lower-risk patients who received a cumulative dose of 1.2 g/m 2 and 5.0 +/- 2.0 in the higher-risk patients who received a cumulative dose of up to 14.4 g/m 2 P .18 Independent adverse prognostic features included the presence of MLL-AF4 or BCR-ABL fusion gene and minimal residual of 0.01 or more at the end of the 6-week remission induction phase Our results suggest the efficacy of early intensification of intrathecal chemotherapy and provide the basis for studies omitting cranial irradiation altogether,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3062, 4841, 181, 36, 45, 30629, 9, 864, 286, 1275, 62, 2449, 80, 6763, 43, 947, 191, 5091, 1, 5126, 56, 10177, 24, 2, 3, 352, 1, 1217, 6, 8635, 36, 6, 344, 3, 920, 1, 774, 115, 332, 187, 30630, 136, 372, 1, 358, 2565, 1104, 10, 6468, 9, 3, 133, 1, 7, 54, 42, 102, 31, 62, 2, 8, 1656, 3627, 1276, 1, 394, 1006, 79, 83, 805, 15, 80, 15, 1025, 27, 33, 15, 80, 6884, 5128, 5, 6237, 3112, 37, 4, 35, 54279, 1000, 15, 3, 463, 1, 2565, 2476, 18801, 156, 107, 3, 7708, 935, 7, 346, 4, 3, 45, 3843, 11, 1373, 22, 1041, 280, 43, 2, 103, 2615, 12995, 90, 6870, 36, 3, 3431, 140, 5, 142, 43, 103, 80, 1686, 6870, 56, 5, 232, 234, 2773, 468, 4, 709, 6566, 3, 33, 111, 774, 115, 25, 1191, 10, 493, 66, 18, 49, 3428, 3, 66, 111, 116, 10, 833, 49, 33, 66, 3, 33, 111, 967, 43, 1, 35, 1355, 854, 1880, 398, 1025, 429, 10, 14, 67, 13, 66, 2, 17, 1, 1355, 349, 397, 1025, 429, 10, 27, 13, 14, 14, 3, 33, 111, 967, 1098, 1, 1934, 139, 533, 441, 11, 14, 66, 14, 27, 4, 3, 280, 43, 7, 54, 103, 8, 967, 61, 1, 14, 18, 499, 188, 18, 2, 33, 13, 18, 13, 4, 3, 142, 43, 7, 54, 103, 8, 967, 61, 1, 126, 6, 213, 39, 499, 188, 18, 19, 203, 306, 290, 177, 404, 159, 3, 463, 1, 3049, 17272, 15, 1062, 1425, 1212, 145, 2, 1048, 753, 1, 13, 355, 15, 80, 28, 3, 396, 1, 3, 49, 647, 734, 504, 124, 114, 99, 309, 3, 209, 1, 191, 5091, 1, 5126, 56, 2, 377, 3, 877, 9, 94, 12367, 2565, 1104, 6767]",1764.0,15251979,531
Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment.,The New England journal of medicine,N. Engl. J. Med.,2004-08-01,"Childhood acute lymphoblastic leukemia (ALL) is curable with chemotherapy in approximately 80 percent of patients. However, the cause of treatment failure in the remaining 20 percent of patients is largely unknown. We tested leukemia cells from 173 children for sensitivity in vitro to prednisolone, vincristine, asparaginase, and daunorubicin. The cells were then subjected to an assessment of gene expression with the use of 14,500 probe sets to identify differentially expressed genes in drug-sensitive and drug-resistant ALL. Gene-expression patterns that differed according to sensitivity or resistance to the four drugs were compared with treatment outcome in the original 173 patients and an independent cohort of 98 children treated with the same drugs at another institution. We identified sets of differentially expressed genes in B-lineage ALL that were sensitive or resistant to prednisolone (33 genes), vincristine (40 genes), asparaginase (35 genes), or daunorubicin (20 genes). A combined gene-expression score of resistance to the four drugs, as compared with sensitivity to the four, was significantly and independently related to treatment outcome in a multivariate analysis (hazard ratio for relapse, 3.0; P=0.027). Results were confirmed in an independent population of patients treated with the same medications (hazard ratio for relapse, 11.85; P=0.019). Of the 124 genes identified, 121 have not previously been associated with resistance to the four drugs we tested. Differential expression of a relatively small number of genes is associated with drug resistance and treatment outcome in childhood ALL.",Journal Article,5651.0,447.0,"Childhood acute lymphoblastic ALL is curable with chemotherapy in approximately 80 percent of patients However the cause of treatment failure in the remaining 20 percent of patients is largely unknown We tested cells from 173 children for sensitivity in vitro to prednisolone vincristine asparaginase and daunorubicin The cells were then subjected to an assessment of gene expression with the use of 14,500 probe sets to identify differentially expressed genes in drug-sensitive and drug-resistant ALL Gene-expression patterns that differed according to sensitivity or resistance to the four drugs were compared with treatment outcome in the original 173 patients and an independent cohort of 98 children treated with the same drugs at another institution We identified sets of differentially expressed genes in B-lineage ALL that were sensitive or resistant to prednisolone 33 genes vincristine 40 genes asparaginase 35 genes or daunorubicin 20 genes A combined gene-expression score of resistance to the four drugs as compared with sensitivity to the four was significantly and independently related to treatment outcome in a multivariate analysis hazard ratio for relapse 3.0 P=0.027 Results were confirmed in an independent population of patients treated with the same medications hazard ratio for relapse 11.85 P=0.019 Of the 124 genes identified 121 have not previously been associated with resistance to the four drugs we tested Differential expression of a relatively small number of genes is associated with drug resistance and treatment outcome in childhood ALL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[864, 286, 1275, 62, 16, 4151, 5, 56, 4, 705, 493, 714, 1, 7, 137, 3, 708, 1, 24, 496, 4, 3, 1844, 179, 714, 1, 7, 16, 1733, 860, 21, 650, 37, 29, 5785, 541, 9, 485, 4, 439, 6, 11253, 2132, 3709, 2, 5247, 3, 37, 11, 818, 4325, 6, 35, 455, 1, 145, 55, 5, 3, 119, 1, 213, 1666, 2888, 2270, 6, 255, 2478, 570, 214, 4, 234, 745, 2, 234, 436, 62, 145, 55, 764, 17, 2512, 768, 6, 485, 15, 251, 6, 3, 294, 600, 11, 72, 5, 24, 228, 4, 3, 2279, 5785, 7, 2, 35, 306, 180, 1, 1096, 541, 73, 5, 3, 827, 600, 28, 1809, 731, 21, 108, 2270, 1, 2478, 570, 214, 4, 132, 2542, 62, 17, 11, 745, 15, 436, 6, 11253, 466, 214, 2132, 327, 214, 3709, 465, 214, 15, 5247, 179, 214, 8, 397, 145, 55, 368, 1, 251, 6, 3, 294, 600, 22, 72, 5, 485, 6, 3, 294, 10, 97, 2, 1042, 139, 6, 24, 228, 4, 8, 331, 65, 360, 197, 9, 429, 27, 13, 19, 13, 4523, 99, 11, 557, 4, 35, 306, 266, 1, 7, 73, 5, 3, 827, 2679, 360, 197, 9, 429, 175, 772, 19, 13, 4049, 1, 3, 2834, 214, 108, 4141, 47, 44, 373, 85, 41, 5, 251, 6, 3, 294, 600, 21, 650, 1777, 55, 1, 8, 1352, 302, 207, 1, 214, 16, 41, 5, 234, 251, 2, 24, 228, 4, 864, 62]",1571.0,15295046,229
Genetic variation in the leptin receptor gene and obesity in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2004-09-01,"Overweight (body mass index [BMI] 25 to 29 kg/m2) and obesity (BMI > or = 30 kg/m2) frequently follow treatment for childhood acute lymphoblastic leukemia (ALL). Recent studies suggest that risk is most apparent in females treated with cranial radiation at a younger age. Because radiation at a young age may affect the hypothalamus causing leptin receptor insensitivity, we hypothesized that a polymorphism in the leptin receptor (LEPR) gene, Gln223Arg, might influence susceptibility to obesity in survivors of childhood ALL. We genotyped 600 non-Hispanic white adult ALL survivors enrolled onto the Childhood Cancer Survivor Study. BMI was compared between those with two copies of the Arg allele to those who had at least one copy of the Gln allele. Female survivors with BMI > or = 25 kg/m2 were more likely Arg homozygous than those with BMI less than 25 kg/m2 (24% v 12%; P =.007). This difference was not observed in males. Moreover, among females treated with > or = 20 Gy cranial radiation, Arg/Arg individuals had six times higher odds of having BMI > or = 25 kg/m2 (95% CI, 2.1 to 22.0) than those with a Gln allele (P =.04 for interaction). CONCLUSION LEPR polymorphism may influence obesity in female survivors of childhood ALL, particularly those exposed to cranial radiation. Because obesity is associated with increased morbidity and mortality in later life, identification of children at high risk might allow for early targeted interventions.",Journal Article,5620.0,102.0,Overweight body mass index BMI 25 to 29 kg/m2 and obesity BMI or 30 kg/m2 frequently follow treatment for childhood acute lymphoblastic ALL Recent studies suggest that risk is most apparent in females treated with cranial radiation at a younger age Because radiation at a young age may affect the hypothalamus causing leptin receptor insensitivity we hypothesized that a polymorphism in the leptin receptor LEPR gene Gln223Arg might influence susceptibility to obesity in survivors of childhood ALL We genotyped 600 non-Hispanic white adult ALL survivors enrolled onto the Childhood Cancer Survivor Study BMI was compared between those with two copies of the Arg allele to those who had at least one copy of the Gln allele Female survivors with BMI or 25 kg/m2 were more likely Arg homozygous than those with BMI less than 25 kg/m2 24 v 12 P =.007 This difference was not observed in males Moreover among females treated with or 20 Gy cranial radiation Arg/Arg individuals had six times higher odds of having BMI or 25 kg/m2 95 CI 2.1 to 22.0 than those with a Gln allele P =.04 for interaction CONCLUSION LEPR polymorphism may influence obesity in female survivors of childhood ALL particularly those exposed to cranial radiation Because obesity is associated with increased morbidity and mortality in later life identification of children at high risk might allow for early targeted interventions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3566, 642, 782, 558, 1140, 243, 6, 462, 503, 821, 2, 1661, 1140, 15, 201, 503, 821, 746, 166, 24, 9, 864, 286, 1275, 62, 435, 94, 309, 17, 43, 16, 96, 2235, 4, 2451, 73, 5, 2565, 121, 28, 8, 773, 89, 408, 121, 28, 8, 1169, 89, 68, 1158, 3, 12717, 3440, 6876, 153, 14488, 21, 1237, 17, 8, 1907, 4, 3, 6876, 153, 17276, 145, 54331, 822, 1054, 1432, 6, 1661, 4, 332, 1, 864, 62, 21, 3053, 2383, 220, 1776, 886, 780, 62, 332, 346, 3301, 3, 864, 12, 2628, 45, 1140, 10, 72, 59, 135, 5, 100, 5127, 1, 3, 7844, 1254, 6, 135, 54, 42, 28, 506, 104, 1337, 1, 3, 13076, 1254, 1061, 332, 5, 1140, 15, 243, 503, 821, 11, 80, 322, 7844, 3189, 76, 135, 5, 1140, 299, 76, 243, 503, 821, 259, 603, 133, 19, 1999, 26, 523, 10, 44, 164, 4, 2296, 1393, 107, 2451, 73, 5, 15, 179, 381, 2565, 121, 7844, 7844, 869, 42, 437, 1072, 142, 610, 1, 1041, 1140, 15, 243, 503, 821, 48, 58, 18, 14, 6, 350, 13, 76, 135, 5, 8, 13076, 1254, 19, 755, 9, 915, 1221, 17276, 1907, 68, 1054, 1661, 4, 1061, 332, 1, 864, 62, 823, 135, 2234, 6, 2565, 121, 408, 1661, 16, 41, 5, 101, 787, 2, 282, 4, 1559, 358, 911, 1, 541, 28, 64, 43, 822, 1700, 9, 191, 238, 1151]",1398.0,15337805,237
"Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.",Leukemia & lymphoma,Leuk. Lymphoma,2004-08-01,"Thromboembolism (TE) is a known complication of L-asparaginase (ASP) therapy of acute lymphoblastic leukemia (ALL), possibly attributable to reduced synthesis of natural anticoagulants, in particular antithrombin (AT). This retrospective single institution study was performed to determine the TE incidence among adults undergoing induction with contemporary, ASP-containing regimens. Ten of 54 (18.5%) consecutive adults developed symptomatic, objectively confirmed TE, at a median of 5.5 days after the first ASP dose. These were notable for CNS and upper extremity localization, varied significantly according to ALL immunophenotype (precursor B: 11% vs. T cell: 33%), without apparent effect of schedule or total dose of ASP. Median baseline AT level was 94% and fell to a nadir of 47% (P < 0.0001) during ASP therapy. Prophylactic AT had been given to 17 during ASP therapy. None of these developed TE vs. 10/37 (27%) without replacement (P = 0.021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions.",Journal Article,5651.0,39.0,Thromboembolism TE is a known complication of L-asparaginase ASP therapy of acute lymphoblastic ALL possibly attributable to reduced synthesis of natural anticoagulants in particular antithrombin AT This retrospective single institution study was performed to determine the TE incidence among adults undergoing induction with contemporary ASP-containing regimens Ten of 54 18.5 consecutive adults developed symptomatic objectively confirmed TE at a median of 5.5 days after the first ASP dose These were notable for CNS and upper extremity localization varied significantly according to ALL immunophenotype precursor B 11 vs. T cell 33 without apparent effect of schedule or total dose of ASP Median baseline AT level was 94 and fell to a nadir of 47 P 0.0001 during ASP therapy Prophylactic AT had been given to 17 during ASP therapy None of these developed TE vs. 10/37 27 without replacement P 0.021 These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3501, 6917, 16, 8, 440, 1447, 1, 805, 3709, 8501, 36, 1, 286, 1275, 62, 2150, 2971, 6, 405, 2525, 1, 1504, 9126, 4, 1454, 27947, 28, 26, 459, 226, 731, 45, 10, 173, 6, 223, 3, 6917, 287, 107, 857, 479, 504, 5, 2667, 8501, 1101, 472, 1618, 1, 667, 203, 33, 935, 857, 276, 1704, 8731, 557, 6917, 28, 8, 52, 1, 33, 33, 162, 50, 3, 157, 8501, 61, 46, 11, 4090, 9, 1025, 2, 1726, 2678, 2145, 2051, 97, 768, 6, 62, 5496, 2765, 132, 175, 105, 102, 31, 466, 187, 2235, 254, 1, 1055, 15, 181, 61, 1, 8501, 52, 330, 28, 301, 10, 960, 2, 7689, 6, 8, 3686, 1, 662, 19, 13, 488, 190, 8501, 36, 1862, 28, 42, 85, 447, 6, 269, 190, 8501, 36, 1292, 1, 46, 276, 6917, 105, 79, 567, 428, 187, 3892, 19, 13, 4630, 46, 2172, 7062, 195, 45, 6, 1803, 2670, 237, 34, 2, 15, 36, 112, 1384, 1, 6917, 4, 26, 266, 2, 7715, 9, 3, 482, 451, 1, 870, 1862, 1151]",1114.0,15370205,614
FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression.,Blood,Blood,2004-09-16,"FMS-like tyrosine kinase 3 (FLT3) is almost universally expressed in B-precursor childhood acute lymphoblastic leukemia (ALL). Cases of ALL with MLL gene rearrangements and those with high hyperdiploidy (> 50 chromosomes) express the highest levels of FLT3, and activating mutations of FLT3 occur in 18% of MLL-rearranged and 28% of hyperdiploid ALL cases. We determined the antileukemic activity of CEP-701, a potent and selective FLT3 inhibitor, in 8 ALL cell lines and 39 bone marrow samples obtained at diagnosis from infants and children with various subtypes of ALL. CEP-701 induced pronounced apoptotic responses in a higher percentage of samples that expressed high levels of FLT3 (74%, n = 23) compared with samples with low levels of expression (8%, n = 13; P = .0003). Sensitivity to FLT3 inhibition was particularly high in samples with MLL gene rearrangements (82%, n = 11; P = .0005), high hyperdiploidy (100%, n = 5; P = .0007), and/or FLT3 mutations (100%, n = 4; P = .0021). Seven of 7 sensitive samples examined by immunoblotting demonstrated constitutively phosphorylated FLT3 that was potently inhibited by CEP-701, whereas 0 of 6 resistant samples expressed constitutively phosphorylated FLT3. We conclude that the FLT3 inhibitor CEP-701 effectively suppresses FLT3-driven leukemic cell survival. Clinical testing of CEP-701 as a novel molecularly targeted agent for the treatment of childhood ALL is warranted.",Journal Article,5605.0,140.0,FMS-like tyrosine kinase 3 FLT3 is almost universally expressed in B-precursor childhood acute lymphoblastic ALL Cases of ALL with MLL gene rearrangements and those with high hyperdiploidy 50 chromosomes express the highest levels of FLT3 and activating mutations of FLT3 occur in 18 of MLL-rearranged and 28 of hyperdiploid ALL cases We determined the antileukemic activity of CEP-701 a potent and selective FLT3 inhibitor in 8 ALL cell lines and 39 marrow samples obtained at diagnosis from infants and children with various subtypes of ALL CEP-701 induced pronounced apoptotic responses in a higher percentage of samples that expressed high levels of FLT3 74 n 23 compared with samples with low levels of expression 8 n 13 P .0003 Sensitivity to FLT3 inhibition was particularly high in samples with MLL gene rearrangements 82 n 11 P .0005 high hyperdiploidy 100 n 5 P .0007 and/or FLT3 mutations 100 n 4 P .0021 Seven of 7 sensitive samples examined by immunoblotting demonstrated constitutively phosphorylated FLT3 that was potently inhibited by CEP-701 whereas 0 of 6 resistant samples expressed constitutively phosphorylated FLT3 We conclude that the FLT3 inhibitor CEP-701 effectively suppresses FLT3-driven leukemic cell survival Clinical testing of CEP-701 as a novel molecularly targeted agent for the treatment of childhood ALL is warranted,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5516, 733, 564, 216, 27, 1224, 16, 2214, 6813, 570, 4, 132, 2765, 864, 286, 1275, 62, 140, 1, 62, 5, 3049, 145, 2072, 2, 135, 5, 64, 11299, 212, 3560, 1669, 3, 1076, 148, 1, 1224, 2, 1616, 138, 1, 1224, 1271, 4, 203, 1, 3049, 3201, 2, 339, 1, 8847, 62, 140, 21, 509, 3, 4512, 128, 1, 5891, 6812, 8, 1157, 2, 1094, 1224, 230, 4, 66, 62, 31, 285, 2, 587, 581, 347, 683, 28, 147, 29, 5585, 2, 541, 5, 747, 814, 1, 62, 5891, 6812, 277, 3517, 1631, 253, 4, 8, 142, 1150, 1, 347, 17, 570, 64, 148, 1, 1224, 794, 78, 382, 72, 5, 347, 5, 154, 148, 1, 55, 66, 78, 233, 19, 4418, 485, 6, 1224, 297, 10, 823, 64, 4, 347, 5, 3049, 145, 2072, 878, 78, 175, 19, 4252, 64, 11299, 394, 78, 33, 19, 6626, 2, 15, 1224, 138, 394, 78, 39, 19, 15850, 648, 1, 67, 745, 347, 409, 20, 5293, 264, 2818, 2365, 1224, 17, 10, 4684, 879, 20, 5891, 6812, 547, 13, 1, 49, 436, 347, 570, 2818, 2365, 1224, 21, 2060, 17, 3, 1224, 230, 5891, 6812, 1856, 4079, 1224, 1621, 2015, 31, 25, 38, 471, 1, 5891, 6812, 22, 8, 229, 2372, 238, 420, 9, 3, 24, 1, 864, 62, 16, 1197]",1352.0,15374878,208
Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.,Cancer research,Cancer Res.,2004-09-01,"Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Small molecules that selectively inhibit FLT3 kinase activity induce apoptosis in blasts from AML patients with FLT3 mutations and prolong survival in animal models of FLT3-induced myeloproliferative disease. A spectrum of structurally different small molecules with activity against FLT3 have been described, and their efficacy for treatment of AML and ALL is now being investigated in clinical trials. Here, we describe the results of an in vitro screen designed to identify mutations in the ATP-binding pocket of FLT3 that confer resistance to tyrosine kinase inhibitors. Mutations at four different positions (Ala-627, Asn-676, Phe-691, and Gly-697) were identified that confer varying degrees of resistance to PKC412, SU5614, or K-252a. FLT3 proteins mutated at Ala-627, Asn-676, or Phe-691 remained sensitive to higher concentrations of the inhibitors, but the G697R mutation conferred high-level resistance to each of these inhibitors as well as to six additional experimental inhibitors. These data provide insights into potential mechanisms of acquired resistance of FLT3 to small molecule inhibitors and indicate that the G697R mutation may be a clinically problematic resistance mutation that warrants proactive screening for additional inhibitors.",Journal Article,5620.0,136.0,Mutations in the receptor tyrosine kinase FLT3 occur frequently in patients with acute myeloid AML and acute lymphoblastic ALL Small molecules that selectively inhibit FLT3 kinase activity induce apoptosis in blasts from AML patients with FLT3 mutations and prolong survival in animal models of FLT3-induced disease A spectrum of structurally different small molecules with activity against FLT3 have been described and their efficacy for treatment of AML and ALL is now being investigated in clinical trials Here we describe the results of an in vitro screen designed to identify mutations in the ATP-binding pocket of FLT3 that confer resistance to tyrosine kinase inhibitors Mutations at four different positions Ala-627 Asn-676 Phe-691 and Gly-697 were identified that confer varying degrees of resistance to PKC412 SU5614 or K-252a FLT3 proteins mutated at Ala-627 Asn-676 or Phe-691 remained sensitive to higher concentrations of the inhibitors but the G697R mutation conferred high-level resistance to each of these inhibitors as well as to six additional experimental inhibitors These data provide insights into potential mechanisms of acquired resistance of FLT3 to small molecule inhibitors and indicate that the G697R mutation may be a clinically problematic resistance mutation that warrants proactive screening for additional inhibitors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[138, 4, 3, 153, 564, 216, 1224, 1271, 746, 4, 7, 5, 286, 533, 329, 2, 286, 1275, 62, 302, 1598, 17, 2382, 1433, 1224, 216, 128, 1290, 351, 4, 2438, 29, 329, 7, 5, 1224, 138, 2, 3615, 25, 4, 2026, 274, 1, 1224, 277, 34, 8, 1873, 1, 8533, 338, 302, 1598, 5, 128, 480, 1224, 47, 85, 1027, 2, 136, 209, 9, 24, 1, 329, 2, 62, 16, 1134, 486, 565, 4, 38, 143, 467, 21, 897, 3, 99, 1, 35, 4, 439, 2413, 1114, 6, 255, 138, 4, 3, 3918, 791, 6575, 1, 1224, 17, 2913, 251, 6, 564, 216, 222, 138, 28, 294, 338, 7134, 8497, 13598, 18888, 11010, 15139, 11661, 2, 14477, 11989, 11, 108, 17, 2913, 2990, 4133, 1, 251, 6, 7154, 54365, 15, 1634, 54366, 1224, 652, 1185, 28, 8497, 13598, 18888, 11010, 15, 15139, 11661, 958, 745, 6, 142, 1003, 1, 3, 222, 84, 3, 43720, 258, 3851, 64, 301, 251, 6, 296, 1, 46, 222, 22, 149, 22, 6, 437, 402, 1560, 222, 46, 74, 377, 1957, 237, 174, 483, 1, 1294, 251, 1, 1224, 6, 302, 1354, 222, 2, 1008, 17, 3, 43720, 258, 68, 40, 8, 505, 6594, 251, 258, 17, 2782, 11662, 453, 9, 402, 222]",1349.0,15374944,488
Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience.,Cancer,Cancer,2004-10-01,"Despite improvements in supportive care, death due to treatment toxicity remains a significant problem for children treated for acute leukemia. To determine the causes of and risk factors for death unrelated to refractory leukemia, to disease recurrence, or to second malignancy, the authors reviewed the records of 1011 patients with acute lymphoblastic leukemia (ALL) and 260 patients with acute myeloid leukemia (AML) treated between 1984 and 1999 and between 1983 and 2002, respectively, at St. Jude Children's Research Hospital (Memphis, TN). Data for patients who underwent stem cell transplantation were censored at the time of transplantation. For patients with ALL, the estimated 10-year cumulative incidence of death was 2.9% +/- 5.3%. Age was the only predictor of death. Patients with ALL 1-9 years old had a significantly lower risk of death than did younger or older patients (P = 0.002). For patients with AML, the estimated 5-year cumulative incidence of death was 7.6% +/- 1.9%. Increasing age and increasing leukocyte count were significantly associated with increased risk of death. For patients with ALL and with AML, the incidence of death remained relatively constant during the time periods studied. Infection was the most common cause of death. In the current study, the authors determined that children > or = 10 years of age are at increased risk of death during therapy for ALL and AML.",Journal Article,5590.0,91.0,Despite improvements in supportive care death due to treatment toxicity remains a significant problem for children treated for acute To determine the causes of and risk factors for death unrelated to refractory to disease recurrence or to second malignancy the authors reviewed the records of 1011 patients with acute lymphoblastic ALL and 260 patients with acute myeloid AML treated between 1984 and 1999 and between 1983 and 2002 respectively at St. Jude Children 's Research Hospital Memphis TN Data for patients who underwent stem cell transplantation were censored at the time of transplantation For patients with ALL the estimated 10-year cumulative incidence of death was 2.9 +/- 5.3 Age was the only predictor of death Patients with ALL 1-9 years old had a significantly lower risk of death than did younger or older patients P 0.002 For patients with AML the estimated 5-year cumulative incidence of death was 7.6 +/- 1.9 Increasing age and increasing leukocyte count were significantly associated with increased risk of death For patients with ALL and with AML the incidence of death remained relatively constant during the time periods studied Infection was the most common cause of death In the current study the authors determined that children or 10 years of age are at increased risk of death during therapy for ALL and AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[550, 1474, 4, 1877, 165, 273, 520, 6, 24, 155, 469, 8, 93, 2497, 9, 541, 73, 9, 286, 6, 223, 3, 1626, 1, 2, 43, 130, 9, 273, 2092, 6, 430, 6, 34, 146, 15, 6, 419, 710, 3, 738, 446, 3, 1064, 1, 21275, 7, 5, 286, 1275, 62, 2, 6398, 7, 5, 286, 533, 329, 73, 59, 6036, 2, 2043, 2, 59, 6656, 2, 1544, 106, 28, 3062, 4841, 541, 292, 389, 702, 18922, 3814, 74, 9, 7, 54, 208, 452, 31, 497, 11, 7534, 28, 3, 98, 1, 497, 9, 7, 5, 62, 3, 661, 79, 111, 967, 287, 1, 273, 10, 18, 83, 33, 27, 89, 10, 3, 158, 980, 1, 273, 7, 5, 62, 14, 83, 60, 1095, 42, 8, 97, 280, 43, 1, 273, 76, 205, 773, 15, 434, 7, 19, 13, 1111, 9, 7, 5, 329, 3, 661, 33, 111, 967, 287, 1, 273, 10, 67, 49, 14, 83, 602, 89, 2, 602, 3627, 1276, 11, 97, 41, 5, 101, 43, 1, 273, 9, 7, 5, 62, 2, 5, 329, 3, 287, 1, 273, 958, 1352, 4982, 190, 3, 98, 3338, 656, 930, 10, 3, 96, 186, 708, 1, 273, 4, 3, 291, 45, 3, 738, 509, 17, 541, 15, 79, 60, 1, 89, 32, 28, 101, 43, 1, 273, 190, 36, 9, 62, 2, 329]",1338.0,15378506,67
Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2005-02-01,"Although most pediatric oncologists obtain routine blood counts in patients who have completed treatment for acute lymphoblastic leukemia (ALL), the value of this practice is unproven. We therefore sought to determine if detection of relapse by blood counts before the onset of symptoms provided any clinical benefit. We performed a retrospective review of 72 patients with ALL who suffered isolated or combined hematologic relapses after the completion of therapy. We compared attainment of second remission and survival after relapse among patients who were asymptomatic and diagnosed by routine blood count, those who had symptoms suggestive of relapse and were diagnosed at the time of a scheduled follow-up, and those whose relapse was diagnosed because of the appearance of symptoms. Only 11% of patients who suffered a relapse were asymptomatic at the time of relapse and diagnosed solely by routine blood counts. There were no significant differences in the survival distributions for the three groups of patients. In this cohort of patients with relapsed ALL, we found no evidence that detection of relapse by routine blood counts before the onset of symptoms leads to a better outcome.",Journal Article,5467.0,17.0,Although most pediatric oncologists obtain routine blood counts in patients who have completed treatment for acute lymphoblastic ALL the value of this practice is unproven We therefore sought to determine if detection of relapse by blood counts before the onset of symptoms provided any clinical benefit We performed a retrospective review of 72 patients with ALL who suffered isolated or combined hematologic relapses after the completion of therapy We compared attainment of second remission and survival after relapse among patients who were asymptomatic and diagnosed by routine blood count those who had symptoms suggestive of relapse and were diagnosed at the time of a scheduled follow-up and those whose relapse was diagnosed because of the appearance of symptoms Only 11 of patients who suffered a relapse were asymptomatic at the time of relapse and diagnosed solely by routine blood counts There were no significant differences in the survival distributions for the three groups of patients In this cohort of patients with relapsed ALL we found no evidence that detection of relapse by routine blood counts before the onset of symptoms leads to a better outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 96, 815, 1339, 3140, 1311, 315, 1911, 4, 7, 54, 47, 781, 24, 9, 286, 1275, 62, 3, 549, 1, 26, 758, 16, 10048, 21, 673, 990, 6, 223, 492, 638, 1, 429, 20, 315, 1911, 348, 3, 1707, 1, 507, 1052, 500, 38, 247, 21, 173, 8, 459, 206, 1, 720, 7, 5, 62, 54, 6388, 1355, 15, 397, 813, 3713, 50, 3, 1438, 1, 36, 21, 72, 7108, 1, 419, 734, 2, 25, 50, 429, 107, 7, 54, 11, 2100, 2, 265, 20, 1311, 315, 1276, 135, 54, 42, 507, 3832, 1, 429, 2, 11, 265, 28, 3, 98, 1, 8, 4394, 166, 126, 2, 135, 1310, 429, 10, 265, 408, 1, 3, 3592, 1, 507, 158, 175, 1, 7, 54, 6388, 8, 429, 11, 2100, 28, 3, 98, 1, 429, 2, 265, 5558, 20, 1311, 315, 1911, 125, 11, 77, 93, 362, 4, 3, 25, 4477, 9, 3, 169, 271, 1, 7, 4, 26, 180, 1, 7, 5, 591, 62, 21, 204, 77, 241, 17, 638, 1, 429, 20, 1311, 315, 1911, 348, 3, 1707, 1, 507, 1940, 6, 8, 380, 228]",1172.0,15390274,329
Pharmacogenetic risk factors for osteonecrosis of the hip among children with leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2004-10-01,"One of the adverse effects of therapy for acute lymphoblastic leukemia (ALL) is osteonecrosis of the hip. Putative risk factors for osteonecrosis have included being female, white race, and older age. Our goal was to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed ALL. Using a candidate gene approach, we determined the genotypes for 16 common polymorphisms in genes likely to affect the pharmacokinetics or pharmacodynamics of antileukemic medications in 64 children with ALL. Therapy included glucocorticoids and antifolates. Magnetic resonance imaging of both hips was used to diagnose osteonecrosis, and was performed at similar times from the start of ALL therapy (P =.61) in the 25 patients with and the 39 patients without osteonecrosis (median, 447 days and 443 days, respectively). In addition to age older than 10 years (odds ratio [OR], 24.2; P =.0001) and white race (OR, 11.1; P =.037), host factors for osteonecrosis included the vitamin D receptor FokI start site CC genotype (OR, 4.5; P =.045), and the thymidylate synthase low activity 2/2 enhancer repeat genotype (OR, 7.4; P =.049). Because folate-related and vitamin D-receptor genetic variants have been associated with bone and vasculature morbidity, these pharmacogenetic associations likely reflect the interaction of antileukemic medications with germline sensitivity to drug actions, and might identify ALL patients at highest risk to develop osteonecrosis.",Journal Article,5590.0,135.0,One of the adverse effects of therapy for acute lymphoblastic ALL is osteonecrosis of the hip Putative risk factors for osteonecrosis have included being female white race and older age Our goal was to define possible genetic risk factors for osteonecrosis among children treated for newly diagnosed ALL Using a candidate gene approach we determined the genotypes for 16 common polymorphisms in genes likely to affect the pharmacokinetics or pharmacodynamics of antileukemic medications in 64 children with ALL Therapy included glucocorticoids and antifolates Magnetic resonance imaging of both hips was used to diagnose osteonecrosis and was performed at similar times from the start of ALL therapy P =.61 in the 25 patients with and the 39 patients without osteonecrosis median 447 days and 443 days respectively In addition to age older than 10 years odds ratio OR 24.2 P =.0001 and white race OR 11.1 P =.037 host factors for osteonecrosis included the vitamin D receptor FokI start site CC genotype OR 4.5 P =.045 and the thymidylate synthase low activity 2/2 enhancer repeat genotype OR 7.4 P =.049 Because folate-related and vitamin D-receptor genetic variants have been associated with and vasculature morbidity these pharmacogenetic associations likely reflect the interaction of antileukemic medications with germline sensitivity to drug actions and might identify ALL patients at highest risk to develop osteonecrosis,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[104, 1, 3, 290, 176, 1, 36, 9, 286, 1275, 62, 16, 5404, 1, 3, 5628, 2743, 43, 130, 9, 5404, 47, 159, 486, 1061, 886, 1047, 2, 434, 89, 114, 1326, 10, 6, 1107, 899, 336, 43, 130, 9, 5404, 107, 541, 73, 9, 732, 265, 62, 75, 8, 1609, 145, 353, 21, 509, 3, 2071, 9, 245, 186, 1203, 4, 214, 322, 6, 1158, 3, 1159, 15, 3587, 1, 4512, 2679, 4, 660, 541, 5, 62, 36, 159, 7307, 2, 14893, 1484, 1535, 270, 1, 110, 22230, 10, 95, 6, 6073, 5404, 2, 10, 173, 28, 288, 1072, 29, 3, 2435, 1, 62, 36, 19, 713, 4, 3, 243, 7, 5, 2, 3, 587, 7, 187, 5404, 52, 9472, 162, 2, 10462, 162, 106, 4, 352, 6, 89, 434, 76, 79, 60, 610, 197, 15, 259, 18, 19, 488, 2, 886, 1047, 15, 175, 14, 19, 5171, 1204, 130, 9, 5404, 159, 3, 1610, 427, 153, 17254, 2435, 606, 1951, 1183, 15, 39, 33, 19, 4918, 2, 3, 6205, 3522, 154, 128, 18, 18, 4239, 2334, 1183, 15, 67, 39, 19, 5121, 408, 3100, 139, 2, 1610, 427, 153, 336, 839, 47, 85, 41, 5, 2, 3805, 787, 46, 6578, 685, 322, 2694, 3, 915, 1, 4512, 2679, 5, 1009, 485, 6, 234, 5592, 2, 822, 255, 62, 7, 28, 1076, 43, 6, 690, 5404]",1428.0,15459215,267
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia.,"Science (New York, N.Y.)",Science,2004-10-01,"Very rare cases of human T cell acute lymphoblastic leukemia (T-ALL) harbor chromosomal translocations that involve NOTCH1, a gene encoding a transmembrane receptor that regulates normal T cell development. Here, we report that more than 50% of human T-ALLs, including tumors from all major molecular oncogenic subtypes, have activating mutations that involve the extracellular heterodimerization domain and/or the C-terminal PEST domain of NOTCH1. These findings greatly expand the role of activated NOTCH1 in the molecular pathogenesis of human T-ALL and provide a strong rationale for targeted therapies that interfere with NOTCH signaling.",Journal Article,5590.0,1871.0,Very rare cases of human T cell acute lymphoblastic T-ALL harbor chromosomal translocations that involve NOTCH1 a gene encoding a transmembrane receptor that regulates normal T cell development Here we report that more than 50 of human T-ALLs including tumors from all major molecular oncogenic subtypes have activating mutations that involve the extracellular heterodimerization domain and/or the C-terminal PEST domain of NOTCH1 These findings greatly expand the role of activated NOTCH1 in the molecular pathogenesis of human T-ALL and provide a strong rationale for targeted therapies that interfere with NOTCH signaling,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[923, 622, 140, 1, 171, 102, 31, 286, 1275, 102, 62, 2760, 1860, 3262, 17, 3882, 4607, 8, 145, 2362, 8, 5527, 153, 17, 2468, 295, 102, 31, 193, 467, 21, 414, 17, 80, 76, 212, 1, 171, 102, 10706, 141, 57, 29, 62, 458, 219, 1302, 814, 47, 1616, 138, 17, 3882, 3, 1976, 16699, 1398, 2, 15, 3, 256, 2158, 33741, 1398, 1, 4607, 46, 272, 3510, 4082, 3, 200, 1, 735, 4607, 4, 3, 219, 1384, 1, 171, 102, 62, 2, 377, 8, 1082, 1728, 9, 238, 235, 17, 6178, 5, 3193, 314]",624.0,15472075,19
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.,Blood,Blood,2004-10-14,"Clofarabine (2-chloro-2'-fluoro-deoxy-9-beta-D-arabinofuranosyladenine) is a second-generation nucleoside analog with activity in acute leukemias. As clofarabine is a potent inhibitor of ribonucleotide reductase (RnR), we hypothesized that clofarabine will modulate ara-c triphosphate accumulation and increase the antileukemic activity of cytarabine (ara-C). We conducted a phase 1-2 study of clofarabine plus ara-C in 32 patients with relapsed acute leukemia (25 acute myeloid leukemia [AML], 2 acute lymphoblastic leukemia [ALL]), 4 high-risk myelodysplastic syndrome (MDS), and 1 blast-phase chronic myeloid leukemia (CML).(1) Clofarabine was given as a 1-hour intravenous infusion for 5 days (days 2 through 6) followed 4 hours later by ara-C at 1 g/m(2) per day as a 2-hour intravenous infusion for 5 days (days 1 through 5). The phase 2 dose of clofarabine was 40 mg/m(2) per day for 5 days. Among all patients, 7 (22%) achieved complete remission (CR), and 5 (16%) achieved CR with incomplete platelet recovery (CRp), for an overall response rate of 38%. No responses occurred in 3 patients with ALL and CML. One patient (3%) died during induction. Adverse events were mainly less than or equal to grade 2, including transient liver test abnormalities, nausea/vomiting, diarrhea, skin rashes, mucositis, and palmoplantar erythrodysesthesias. Plasma clofarabine levels generated clofarabine triphosphate accumulation, which resulted in an increase in ara-CTP in the leukemic blasts. The combination of clofarabine with ara-C is safe and active. Cellular pharmacology data support the biochemical modulation strategy.",Clinical Trial,5577.0,176.0,Clofarabine 2-chloro-2'-fluoro-deoxy-9-beta-D-arabinofuranosyladenine is a second-generation nucleoside analog with activity in acute leukemias As clofarabine is a potent inhibitor of ribonucleotide reductase RnR we hypothesized that clofarabine will modulate ara-c triphosphate accumulation and increase the antileukemic activity of cytarabine ara-C We conducted a phase 1-2 study of clofarabine plus ara-C in 32 patients with relapsed acute 25 acute myeloid AML 2 acute lymphoblastic ALL 4 high-risk syndrome MDS and 1 blast-phase chronic myeloid CML 1 Clofarabine was given as a 1-hour intravenous infusion for 5 days days 2 through 6 followed 4 hours later by ara-C at 1 g/m 2 per day as a 2-hour intravenous infusion for 5 days days 1 through 5 The phase 2 dose of clofarabine was 40 mg/m 2 per day for 5 days Among all patients 7 22 achieved complete remission CR and 5 16 achieved CR with incomplete platelet recovery CRp for an overall response rate of 38 No responses occurred in 3 patients with ALL and CML One patient 3 died during induction Adverse events were mainly less than or equal to grade 2 including transient test abnormalities nausea/vomiting diarrhea rashes mucositis and palmoplantar erythrodysesthesias Plasma clofarabine levels generated clofarabine triphosphate accumulation which resulted in an increase in ara-CTP in the leukemic blasts The combination of clofarabine with ara-C is safe and active Cellular pharmacology data support the biochemical modulation strategy,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,"[4149, 18, 14778, 6135, 6231, 6149, 83, 1090, 427, 54408, 16, 8, 419, 914, 4032, 3497, 5, 128, 4, 286, 2792, 22, 4149, 16, 8, 1157, 230, 1, 7050, 4027, 18376, 21, 1237, 17, 4149, 303, 3319, 3899, 256, 7345, 1835, 2, 344, 3, 4512, 128, 1, 1855, 3899, 256, 21, 426, 8, 124, 14, 18, 45, 1, 4149, 349, 3899, 256, 4, 531, 7, 5, 591, 286, 243, 286, 533, 329, 18, 286, 1275, 62, 39, 64, 43, 681, 1223, 2, 14, 3112, 124, 442, 533, 903, 14, 4149, 10, 447, 22, 8, 14, 2583, 1262, 904, 9, 33, 162, 162, 18, 298, 49, 370, 39, 1459, 1559, 20, 3899, 256, 28, 14, 499, 188, 18, 379, 218, 22, 8, 18, 2583, 1262, 904, 9, 33, 162, 162, 14, 298, 33, 3, 124, 18, 61, 1, 4149, 10, 327, 81, 188, 18, 379, 218, 9, 33, 162, 107, 62, 7, 67, 350, 513, 236, 734, 684, 2, 33, 245, 513, 684, 5, 2610, 1596, 1602, 3162, 9, 35, 63, 51, 116, 1, 519, 77, 253, 489, 4, 27, 7, 5, 62, 2, 903, 104, 69, 27, 1016, 190, 504, 290, 281, 11, 2615, 299, 76, 15, 2997, 6, 88, 18, 141, 2473, 412, 1171, 1218, 1966, 1172, 11775, 2606, 2, 26275, 43678, 554, 4149, 148, 1419, 4149, 7345, 1835, 92, 627, 4, 35, 344, 4, 3899, 7107, 4, 3, 2015, 2438, 3, 150, 1, 4149, 5, 3899, 256, 16, 1165, 2, 544, 763, 6852, 74, 538, 3, 1487, 2356, 692]",1497.0,15486072,450
Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.,"Genes, chromosomes & cancer",Genes Chromosomes Cancer,2005-01-01,"Cytogenetic abnormalities at the 12q12-q14 chromosomal locus are rarely detected in acute lymphoblastic leukemia (ALL). To examine submicroscopic deletions at this locus, we analyzed 78 adult precursor B- and T-cell ALL cases [27 with Philadelphia chromosome (Ph)-negative B-cell ALL, 20 with Ph-negative B-cell ALL with expression of one or two myeloid markers, 18 with Ph-positive B-cell ALL, and 13 with T-cell ALL] using a panel of 13 microsatellite (MST) markers that span the 12q12-q14.3 region. The status of MST markers was evaluated by use of polymerase chain reaction performed with fluorescence-labeled primers and automated fragment analysis. The MST marker analyses showed submicroscopic deletions at the 12q14.3 locus in 20 of the 78 ALL cases (26%). The frequency of deletions was highest in Ph-negative B-cell ALL (13 of 27, 48%) compared with that in Ph-negative B-cell ALL with expression of myeloid markers (4 of 20, 20%), Ph-positive B-cell ALL (2 of 18, 11%), and T-cell ALL (1 of 13, 8%). Deletion frequencies of MST markers along the 12q12-q14.3 locus suggest that the targeted gene of deletion is located within a 170-kb region bordered by the markers D12S1504 (approximately 65 kb upstream of HMGA2) and D12S1509 (in intron 3 of HMGA2) at the 12q14.3 locus. These submicroscopic deletions at the 12q14.3 locus may play a role in the pathogenesis of ALL, particularly in Ph-negative precursor B-cell ALL.",Journal Article,5498.0,4.0,Cytogenetic abnormalities at the 12q12-q14 chromosomal locus are rarely detected in acute lymphoblastic ALL To examine submicroscopic deletions at this locus we analyzed 78 adult precursor B- and T-cell ALL cases 27 with Philadelphia chromosome Ph -negative B-cell ALL 20 with Ph-negative B-cell ALL with expression of one or two myeloid markers 18 with Ph-positive B-cell ALL and 13 with T-cell ALL using a panel of 13 microsatellite MST markers that span the 12q12-q14.3 region The status of MST markers was evaluated by use of polymerase chain reaction performed with fluorescence-labeled primers and automated fragment analysis The MST marker analyses showed submicroscopic deletions at the 12q14.3 locus in 20 of the 78 ALL cases 26 The frequency of deletions was highest in Ph-negative B-cell ALL 13 of 27 48 compared with that in Ph-negative B-cell ALL with expression of myeloid markers 4 of 20 20 Ph-positive B-cell ALL 2 of 18 11 and T-cell ALL 1 of 13 8 Deletion frequencies of MST markers along the 12q12-q14.3 locus suggest that the targeted gene of deletion is located within a 170-kb region bordered by the markers D12S1504 approximately 65 kb upstream of HMGA2 and D12S1509 in intron 3 of HMGA2 at the 12q14.3 locus These submicroscopic deletions at the 12q14.3 locus may play a role in the pathogenesis of ALL particularly in Ph-negative precursor B-cell ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1266, 1171, 28, 3, 33751, 18847, 1860, 2474, 32, 2416, 530, 4, 286, 1275, 62, 6, 1004, 19675, 2439, 28, 26, 2474, 21, 311, 833, 780, 2765, 132, 2, 102, 31, 62, 140, 428, 5, 3006, 1170, 2058, 199, 132, 31, 62, 179, 5, 2058, 199, 132, 31, 62, 5, 55, 1, 104, 15, 100, 533, 525, 203, 5, 2058, 109, 132, 31, 62, 2, 233, 5, 102, 31, 62, 75, 8, 993, 1, 233, 2226, 8520, 525, 17, 7165, 3, 33751, 18847, 27, 1053, 3, 156, 1, 8520, 525, 10, 194, 20, 119, 1, 1451, 1260, 1329, 173, 5, 1591, 2841, 10031, 2, 3235, 5245, 65, 3, 8520, 952, 318, 224, 19675, 2439, 28, 3, 26320, 27, 2474, 4, 179, 1, 3, 833, 62, 140, 432, 3, 675, 1, 2439, 10, 1076, 4, 2058, 199, 132, 31, 62, 233, 1, 428, 576, 72, 5, 17, 4, 2058, 199, 132, 31, 62, 5, 55, 1, 533, 525, 39, 1, 179, 179, 2058, 109, 132, 31, 62, 18, 1, 203, 175, 2, 102, 31, 62, 14, 1, 233, 66, 1528, 2722, 1, 8520, 525, 1510, 3, 33751, 18847, 27, 2474, 309, 17, 3, 238, 145, 1, 1528, 16, 2308, 262, 8, 5248, 5116, 1053, 37794, 20, 3, 525, 54425, 705, 556, 5116, 3988, 1, 8542, 2, 54426, 4, 6259, 27, 1, 8542, 28, 3, 26320, 27, 2474, 46, 19675, 2439, 28, 3, 26320, 27, 2474, 68, 1343, 8, 200, 4, 3, 1384, 1, 62, 823, 4, 2058, 199, 2765, 132, 31, 62]",1375.0,15495192,115
"A phase I and pharmacodynamic study of fludarabine, carboplatin, and topotecan in patients with relapsed, refractory, or high-risk acute leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2004-10-01,"A novel regimen designed to maximize antileukemia activity of carboplatin through inhibiting repair of platinum-DNA adducts was conducted in poor prognosis, acute leukemia patients. Patients received fludarabine (10 to 15 mg/m(2) x 5 days), carboplatin (area under the curve 10 to 12 by continuous infusion over 5 days), followed by escalated doses of topotecan infused over 72 hours (fludarabine, carboplatin, topotecan regimen). Twenty-eight patients had acute myelogenous leukemia (7 untreated secondary acute myelogenous leukemia, 11 in first relapse, and 10 in second relapse or refractory), 1 patient had refractory/relapsed acute lymphoblastic leukemia, and 2 patients had untreated chronic myelogenous leukemia blast crisis. Six patients had failed an autologous stem cell transplant. Patients ranged from 19 to 76 (median 54) years. Measurement of platinum-DNA adducts were done in serial bone marrow specimens. Fifteen of 31 patients achieved bone marrow aplasia. Clinical responses included 2 complete response, 4 complete response with persistent thrombocytopenia, and 2 partial response. Prolonged myelosuppression was observed with median time to blood neutrophils >/=200/microl of 28 (0 to 43) days and time to platelets >/=20,000/microl (untransfused) of 40 (24 to 120) days. Grade 3 or greater infections occurred in all of the patients, and there were 2 infection-related deaths. The nonhematologic toxicity profile was acceptable. Five patients subsequently received allografts without early transplant-related mortality. Maximum tolerated dose of fludarabine, carboplatin, topotecan regimen was fludarabine 15 mg/m(2) x 5, carboplatin area under the curve 12, and topotecan 2.55 mg/m(2) over 72 hours. An increase in bone marrow, platinum-DNA adduct formation between the end of carboplatin infusion and 48 hours after the infusion correlated with bone marrow response. Fludarabine, carboplatin, topotecan regimen is a promising treatment based on potential pharmacodynamic interactions, which merits additional study in poor prognosis, acute leukemia patients.",Clinical Trial,5590.0,24.0,"A novel regimen designed to maximize antileukemia activity of carboplatin through inhibiting repair of platinum-DNA adducts was conducted in poor prognosis acute patients Patients received fludarabine 10 to 15 mg/m 2 x 5 days carboplatin area under the curve 10 to 12 by continuous infusion over 5 days followed by escalated doses of topotecan infused over 72 hours fludarabine carboplatin topotecan regimen Twenty-eight patients had acute myelogenous 7 untreated secondary acute myelogenous 11 in first relapse and 10 in second relapse or refractory 1 patient had refractory/relapsed acute lymphoblastic and 2 patients had untreated chronic myelogenous blast crisis Six patients had failed an autologous stem cell transplant Patients ranged from 19 to 76 median 54 years Measurement of platinum-DNA adducts were done in serial marrow specimens Fifteen of 31 patients achieved marrow aplasia Clinical responses included 2 complete response 4 complete response with persistent thrombocytopenia and 2 partial response Prolonged myelosuppression was observed with median time to blood neutrophils /=200/microl of 28 0 to 43 days and time to platelets /=20,000/microl untransfused of 40 24 to 120 days Grade 3 or greater infections occurred in all of the patients and there were 2 infection-related deaths The nonhematologic toxicity profile was acceptable Five patients subsequently received allografts without early transplant-related mortality Maximum tolerated dose of fludarabine carboplatin topotecan regimen was fludarabine 15 mg/m 2 x 5 carboplatin area under the curve 12 and topotecan 2.55 mg/m 2 over 72 hours An increase in marrow platinum-DNA adduct formation between the end of carboplatin infusion and 48 hours after the infusion correlated with marrow response Fludarabine carboplatin topotecan regimen is a promising treatment based on potential pharmacodynamic interactions which merits additional study in poor prognosis acute patients",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 229, 477, 1114, 6, 4116, 9169, 128, 1, 927, 298, 2062, 972, 1, 828, 261, 9722, 10, 426, 4, 334, 356, 286, 7, 7, 103, 2027, 79, 6, 167, 81, 188, 18, 1006, 33, 162, 927, 965, 669, 3, 1496, 79, 6, 133, 20, 1314, 904, 252, 33, 162, 370, 20, 2842, 415, 1, 2129, 4524, 252, 720, 1459, 2027, 927, 2129, 477, 737, 659, 7, 42, 286, 2194, 67, 1278, 568, 286, 2194, 175, 4, 157, 429, 2, 79, 4, 419, 429, 15, 430, 14, 69, 42, 430, 591, 286, 1275, 2, 18, 7, 42, 1278, 442, 2194, 3112, 6540, 437, 7, 42, 1551, 35, 1028, 452, 31, 941, 7, 1869, 29, 326, 6, 846, 52, 667, 60, 2204, 1, 828, 261, 9722, 11, 1822, 4, 2108, 581, 623, 3057, 1, 456, 7, 513, 581, 12307, 38, 253, 159, 18, 236, 51, 39, 236, 51, 5, 1882, 1340, 2, 18, 450, 51, 1069, 2858, 10, 164, 5, 52, 98, 6, 315, 5700, 1250, 5128, 1, 339, 13, 6, 601, 162, 2, 98, 6, 4407, 179, 984, 5128, 37795, 1, 327, 259, 6, 2031, 162, 88, 27, 15, 378, 1875, 489, 4, 62, 1, 3, 7, 2, 125, 11, 18, 930, 139, 1043, 3, 3534, 155, 800, 10, 1595, 365, 7, 1611, 103, 10586, 187, 191, 941, 139, 282, 689, 421, 61, 1, 2027, 927, 2129, 477, 10, 2027, 167, 81, 188, 18, 1006, 33, 927, 965, 669, 3, 1496, 133, 2, 2129, 18, 614, 81, 188, 18, 252, 720, 1459, 35, 344, 4, 581, 828, 261, 13038, 1264, 59, 3, 396, 1, 927, 904, 2, 576, 1459, 50, 3, 904, 438, 5, 581, 51, 2027, 927, 2129, 477, 16, 8, 721, 24, 90, 23, 174, 2424, 1286, 92, 4986, 402, 45, 4, 334, 356, 286, 7]",1950.0,15501959,93
Lymphoid gene expression as a predictor of risk of secondary brain tumors.,"Genes, chromosomes & cancer",Genes Chromosomes Cancer,2005-02-01,"Gene expression profiles are tissue-specific but may also reflect germ-line-driven expression patterns across tissue types. Previously, using a targeted pharmacologic approach, we identified germ-line polymorphisms in a single gene (thiopurine methyltransferase) associated with the risk of irradiation- and chemotherapy-induced secondary brain tumors in children with acute lymphoblastic leukemia (ALL). To identify additional candidate genetic risk factors, in identically treated patients, we compared the gene expression profiles of diagnostic ALL blasts of those who did develop irradiation-associated brain tumors (n = 9) with the profiles from those who did not (n = 33). Weighted rank regression was used to identify 33 probe sets associated with the time-dependent development of brain tumors; k-means clustering (k = 2) identified 2 groups that differed significantly in cumulative incidence of brain tumors (P = 0.012). Permutation analysis was used to estimate the probability (P = 0.18) of obtaining 2 such clusters by chance. Linear discriminant analysis (time-independent categorization of outcome) was used to identify 70 probe sets whose expression differentiated between the 2 groups of patients. Permutation analyses (n = 1,000) was used to estimate the probability of selecting these probe sets by chance (P = 0.055). Five probe sets were in common between the time-independent and time-dependent methods. The distinguishing genes are involved in neural growth (FGFR1) and in nuclear trafficking (HNRPL, KPNB1). These data suggest that gene expression profiling from accessible tissues may identify targets involved in therapy-related malignancies in unrelated tissues.",Comparative Study,5467.0,26.0,"Gene expression profiles are tissue-specific but may also reflect germ-line-driven expression patterns across tissue types Previously using a targeted pharmacologic approach we identified germ-line polymorphisms in a single gene thiopurine methyltransferase associated with the risk of irradiation- and chemotherapy-induced secondary brain tumors in children with acute lymphoblastic ALL To identify additional candidate genetic risk factors in identically treated patients we compared the gene expression profiles of diagnostic ALL blasts of those who did develop irradiation-associated brain tumors n 9 with the profiles from those who did not n 33 Weighted rank regression was used to identify 33 probe sets associated with the time-dependent development of brain tumors k-means clustering k 2 identified 2 groups that differed significantly in cumulative incidence of brain tumors P 0.012 Permutation analysis was used to estimate the probability P 0.18 of obtaining 2 such clusters by chance Linear discriminant analysis time-independent categorization of outcome was used to identify 70 probe sets whose expression differentiated between the 2 groups of patients Permutation analyses n 1,000 was used to estimate the probability of selecting these probe sets by chance P 0.055 Five probe sets were in common between the time-independent and time-dependent methods The distinguishing genes are involved in neural growth FGFR1 and in nuclear trafficking HNRPL KPNB1 These data suggest that gene expression profiling from accessible tissues may identify targets involved in therapy-related malignancies in unrelated tissues",0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[145, 55, 1241, 32, 246, 112, 84, 68, 120, 2694, 2280, 328, 1621, 55, 764, 716, 246, 630, 373, 75, 8, 238, 2788, 353, 21, 108, 2280, 328, 1203, 4, 8, 226, 145, 14062, 3747, 41, 5, 3, 43, 1, 1104, 2, 56, 277, 568, 342, 57, 4, 541, 5, 286, 1275, 62, 6, 255, 402, 1609, 336, 43, 130, 4, 20330, 73, 7, 21, 72, 3, 145, 55, 1241, 1, 752, 62, 2438, 1, 135, 54, 205, 690, 1104, 41, 342, 57, 78, 83, 5, 3, 1241, 29, 135, 54, 205, 44, 78, 466, 2337, 1026, 320, 10, 95, 6, 255, 466, 2888, 2270, 41, 5, 3, 98, 470, 193, 1, 342, 57, 1634, 2263, 3147, 1634, 18, 108, 18, 271, 17, 2512, 97, 4, 967, 287, 1, 342, 57, 19, 13, 3499, 10479, 65, 10, 95, 6, 1191, 3, 1320, 19, 13, 203, 1, 5244, 18, 225, 3780, 20, 3477, 1646, 12371, 65, 98, 306, 8872, 1, 228, 10, 95, 6, 255, 431, 2888, 2270, 1310, 55, 1442, 59, 3, 18, 271, 1, 7, 10479, 318, 78, 14, 984, 10, 95, 6, 1191, 3, 1320, 1, 3675, 46, 2888, 2270, 20, 3477, 19, 13, 9186, 365, 2888, 2270, 11, 4, 186, 59, 3, 98, 306, 2, 98, 470, 636, 3, 4508, 214, 32, 646, 4, 3922, 129, 4549, 2, 4, 928, 6105, 54475, 26346, 46, 74, 309, 17, 145, 55, 1080, 29, 5981, 742, 68, 255, 637, 646, 4, 36, 139, 441, 4, 2092, 742]",1626.0,15543619,99
Early complications in children with acute lymphoblastic leukemia presenting with hyperleukocytosis.,Pediatric blood & cancer,Pediatr Blood Cancer,2005-07-01,"The optimal management of childhood acute lymphoblastic leukemia (ALL) with hyperleukocytosis is unclear, largely because the risk of leukostasis-related complications is poorly characterized. We reviewed the presenting characteristics, initial management, and frequency and type of complications in all children seen at St. Jude Children's Research Hospital with previously untreated ALL and an initial leukocyte count >200 x 10(9)/L. A total of 178 children, representing 8% of all children with ALL, had an initial leukocyte count >200 x 10(9)/L; 67 patients had a leukocyte count >400 x 10(9)/L. Sixteen patients (9%) had neurological complications with 12 of these patients experiencing symptoms at presentation. Four patients (2%), all with initial leukocyte counts >400 x 10(9)/L, suffered a CNS hemorrhage. Pulmonary leukostasis occurred in 11 patients (6%). The degree of hyperleukocytosis was significantly predictive of neurological (P = 0.006) and respiratory (P = 0.014) complications. The majority of complications occurred at presentation. Cytoreduction (94 patients) decreased the leukocyte count but delayed initiation of chemotherapy (P = 0.013). Serious leukostasis-related complications are relatively uncommon in childhood ALL and most occur at presentation. Their incidence increases in proportion to the leukocyte count. A large subset of cases can be managed successfully without cytoreduction. Cytoreduction may be considered for patients with leukocyte counts >400 x 10(9)/L or patients who have complications at presentation.",Journal Article,5317.0,65.0,The optimal management of childhood acute lymphoblastic ALL with hyperleukocytosis is unclear largely because the risk of leukostasis-related complications is poorly characterized We reviewed the presenting characteristics initial management and frequency and type of complications in all children seen at St. Jude Children 's Research Hospital with previously untreated ALL and an initial leukocyte count 200 x 10 9 /L A total of 178 children representing 8 of all children with ALL had an initial leukocyte count 200 x 10 9 /L 67 patients had a leukocyte count 400 x 10 9 /L Sixteen patients 9 had neurological complications with 12 of these patients experiencing symptoms at presentation Four patients 2 all with initial leukocyte counts 400 x 10 9 /L suffered a CNS hemorrhage Pulmonary leukostasis occurred in 11 patients 6 The degree of hyperleukocytosis was significantly predictive of neurological P 0.006 and respiratory P 0.014 complications The majority of complications occurred at presentation Cytoreduction 94 patients decreased the leukocyte count but delayed initiation of chemotherapy P 0.013 Serious leukostasis-related complications are relatively uncommon in childhood ALL and most occur at presentation Their incidence increases in proportion to the leukocyte count A large subset of cases can be managed successfully without cytoreduction Cytoreduction may be considered for patients with leukocyte counts 400 x 10 9 /L or patients who have complications at presentation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 665, 284, 1, 864, 286, 1275, 62, 5, 15558, 16, 1200, 1733, 408, 3, 43, 1, 28283, 139, 521, 16, 1240, 765, 21, 446, 3, 1656, 374, 388, 284, 2, 675, 2, 267, 1, 521, 4, 62, 541, 527, 28, 3062, 4841, 541, 292, 389, 702, 5, 373, 1278, 62, 2, 35, 388, 3627, 1276, 1250, 1006, 79, 83, 805, 8, 181, 1, 7046, 541, 2861, 66, 1, 62, 541, 5, 62, 42, 35, 388, 3627, 1276, 1250, 1006, 79, 83, 805, 598, 7, 42, 8, 3627, 1276, 1524, 1006, 79, 83, 805, 3228, 7, 83, 42, 3622, 521, 5, 133, 1, 46, 7, 2985, 507, 28, 1031, 294, 7, 18, 62, 5, 388, 3627, 1911, 1524, 1006, 79, 83, 805, 6388, 8, 1025, 3599, 1087, 28283, 489, 4, 175, 7, 49, 3, 1444, 1, 15558, 10, 97, 464, 1, 3622, 19, 13, 1861, 2, 2718, 19, 13, 3618, 521, 3, 686, 1, 521, 489, 28, 1031, 2844, 960, 7, 340, 3, 3627, 1276, 84, 1612, 1118, 1, 56, 19, 13, 3612, 1762, 28283, 139, 521, 32, 1352, 2052, 4, 864, 62, 2, 96, 1271, 28, 1031, 136, 287, 1106, 4, 920, 6, 3, 3627, 1276, 8, 375, 697, 1, 140, 122, 40, 2231, 1878, 187, 2844, 2844, 68, 40, 515, 9, 7, 5, 3627, 1911, 1524, 1006, 79, 83, 805, 15, 7, 54, 47, 521, 28, 1031]",1492.0,15547931,29
Childhood and adolescent lymphoid and myeloid leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2004-01-01,"Remarkable progress has been made in the past decade in the treatment and in the understanding of the biology of childhood lymphoid and myeloid leukemias. With contemporary improved risk assessment, chemotherapy, hematopoietic stem cell transplantation and supportive care, approximately 80% of children with newly diagnosed acute lymphoblastic leukemia and 50% of those with myeloid neoplasm can be cured to date. Current emphasis is placed not only on increased cure rate but also on improved quality of life. In Section I, Dr. Ching-Hon Pui describes certain clinical and biologic features that still have prognostic and therapeutic relevance in the context of contemporary treatment programs. He emphasizes that treatment failure in some patients is not due to intrinsic drug resistance of leukemic cells but is rather caused by suboptimal drug dosing due to host compliance, pharmacodynamics, and pharmacogenetics. Hence, measurement of minimal residual disease, which accounts for both the genetic (primary and secondary) features of leukemic lymphoblasts and pharmacogenomic variables of the host, is the most reliable prognostic indicator. Finally, he contends that with optimal risk-directed systemic and intrathecal therapy, cranial irradiation may be omitted in all patients, regardless of the presenting features. In Section II, Dr. Martin Schrappe performs detailed analyses of the prognostic impact of presenting age, leukocyte count, sex, immunophenotype, genetic abnormality, early treatment response, and in vitro drug sensitivity/resistance in childhood acute lymphoblastic leukemia, based on the large database of the Berlin-Frankfurt-Mnster consortium. He also succinctly summarizes the important treatment components resulting in the improved outcome of children and young adolescents with this disease. He describes the treatment approach that led to the improved outcome of adolescent patients, a finding that may be applied to young adults in the second and third decade of life. Finally, he believes that treatment reduction under well-controlled clinical trials is feasible in a subgroup of patients with excellent early treatment response as evidenced by minimal residual disease measurement during induction and consolidation therapy. In Section III, Dr. Raul Ribeiro describes distinct morphologic and genetic subtypes of acute myeloid leukemia. The finding of essentially identical gene expression profiling by DNA microarray in certain specific genetic subtypes of childhood and adult acute myeloid leukemia suggests a shared leukemogenesis. He then describes the principles of treatment as well as the efficacy and toxicity of various forms of postremission therapy, emphasizing the need of tailoring therapy to both the disease and the age of the patient. Early results suggest that minimal residual disease measurement can also improve the risk assessment in acute myeloid leukemia, and that cranial irradiation can be omitted even in those with central-nervous-system leukemia at diagnosis. In Section IV, Dr. Charlotte Niemeyer describes a new classification of myelodysplastic and myeloproliferative diseases in childhood, which has greatly facilitated the diagnosis of myelodysplastic syndromes and juvenile myelomonocytic leukemia. The recent discovery of somatic mutations in PTPN11 has improved the understanding of the pathobiology and the diagnosis of juvenile myelomonocytic leukemia. Together with the findings of mutations in RAS and NF1 in the other patients, she suggests that pathological activation of RAS-dependent pathways plays a central role in the leukemogenesis of this disease. She then describes the various treatment approaches for both juvenile myelomonocytic leukemia and myelodysplastic syndromes in the US and Europe, emphasizing the differences between childhood and adult cases for the latter group of diseases. She also raises some controversial issues regarding treatment that will require well-controlled international clinical trials to address.",Journal Article,5864.0,115.0,Remarkable progress has been made in the past decade in the treatment and in the understanding of the biology of childhood lymphoid and myeloid leukemias With contemporary improved risk assessment chemotherapy hematopoietic stem cell transplantation and supportive care approximately 80 of children with newly diagnosed acute lymphoblastic and 50 of those with myeloid neoplasm can be cured to date Current emphasis is placed not only on increased cure rate but also on improved quality of life In Section I Dr. Ching-Hon Pui describes certain clinical and biologic features that still have prognostic and therapeutic relevance in the context of contemporary treatment programs He emphasizes that treatment failure in some patients is not due to intrinsic drug resistance of leukemic cells but is rather caused by suboptimal drug dosing due to host compliance pharmacodynamics and pharmacogenetics Hence measurement of minimal residual disease which accounts for both the genetic primary and secondary features of leukemic lymphoblasts and pharmacogenomic variables of the host is the most reliable prognostic indicator Finally he contends that with optimal risk-directed systemic and intrathecal therapy cranial irradiation may be omitted in all patients regardless of the presenting features In Section II Dr. Martin Schrappe performs detailed analyses of the prognostic impact of presenting age leukocyte count sex immunophenotype genetic abnormality early treatment response and in vitro drug sensitivity/resistance in childhood acute lymphoblastic based on the large database of the Berlin-Frankfurt-Mnster consortium He also succinctly summarizes the important treatment components resulting in the improved outcome of children and young adolescents with this disease He describes the treatment approach that led to the improved outcome of adolescent patients a finding that may be applied to young adults in the second and third decade of life Finally he believes that treatment reduction under well-controlled clinical trials is feasible in a subgroup of patients with excellent early treatment response as evidenced by minimal residual disease measurement during induction and consolidation therapy In Section III Dr. Raul Ribeiro describes distinct morphologic and genetic subtypes of acute myeloid The finding of essentially identical gene expression profiling by DNA microarray in certain specific genetic subtypes of childhood and adult acute myeloid suggests a shared leukemogenesis He then describes the principles of treatment as well as the efficacy and toxicity of various forms of postremission therapy emphasizing the need of tailoring therapy to both the disease and the age of the patient Early results suggest that minimal residual disease measurement can also improve the risk assessment in acute myeloid and that cranial irradiation can be omitted even in those with central-nervous-system at diagnosis In Section IV Dr. Charlotte Niemeyer describes a new classification of and diseases in childhood which has greatly facilitated the diagnosis of syndromes and juvenile myelomonocytic The recent discovery of somatic mutations in PTPN11 has improved the understanding of the pathobiology and the diagnosis of juvenile myelomonocytic Together with the findings of mutations in RAS and NF1 in the other patients she suggests that pathological activation of RAS-dependent pathways plays a central role in the leukemogenesis of this disease She then describes the various treatment approaches for both juvenile myelomonocytic and syndromes in the US and Europe emphasizing the differences between childhood and adult cases for the latter group of diseases She also raises some controversial issues regarding treatment that will require well-controlled international clinical trials to address,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3813, 1466, 71, 85, 1229, 4, 3, 1219, 2025, 4, 3, 24, 2, 4, 3, 612, 1, 3, 891, 1, 864, 2303, 2, 533, 2792, 5, 2667, 231, 43, 455, 56, 1007, 452, 31, 497, 2, 1877, 165, 705, 493, 1, 541, 5, 732, 265, 286, 1275, 2, 212, 1, 135, 5, 533, 2131, 122, 40, 3733, 6, 1244, 291, 3136, 16, 3295, 44, 158, 23, 101, 1722, 116, 84, 120, 23, 231, 372, 1, 358, 4, 2917, 70, 3436, 37328, 43083, 43084, 2677, 1840, 38, 2, 1283, 404, 17, 1234, 47, 177, 2, 189, 2088, 4, 3, 1533, 1, 2667, 24, 2251, 3174, 7519, 17, 24, 496, 4, 476, 7, 16, 44, 520, 6, 2354, 234, 251, 1, 2015, 37, 84, 16, 1832, 1546, 20, 3291, 234, 1280, 520, 6, 1204, 3336, 3587, 2, 8759, 3665, 2204, 1, 1048, 753, 34, 92, 4162, 9, 110, 3, 336, 86, 2, 568, 404, 1, 2015, 10521, 2, 6971, 682, 1, 3, 1204, 16, 3, 96, 2450, 177, 3287, 1368, 3174, 54488, 17, 5, 665, 43, 1166, 403, 2, 5126, 36, 2565, 1104, 68, 40, 7138, 4, 62, 7, 1583, 1, 3, 1656, 404, 4, 2917, 215, 3436, 33556, 54489, 13491, 2455, 318, 1, 3, 177, 345, 1, 1656, 89, 3627, 1276, 1035, 5496, 336, 3698, 191, 24, 51, 2, 4, 439, 234, 485, 251, 4, 864, 286, 1275, 90, 23, 3, 375, 609, 1, 3, 20405, 23389, 26350, 2404, 3174, 120, 43090, 2869, 3, 305, 24, 1628, 1113, 4, 3, 231, 228, 1, 541, 2, 1169, 3101, 5, 26, 34, 3174, 2677, 3, 24, 353, 17, 836, 6, 3, 231, 228, 1, 3678, 7, 8, 1567, 17, 68, 40, 1498, 6, 1169, 857, 4, 3, 419, 2, 1282, 2025, 1, 358, 1368, 3174, 28311, 17, 24, 628, 669, 149, 1149, 38, 143, 16, 1313, 4, 8, 1363, 1, 7, 5, 1503, 191, 24, 51, 22, 4728, 20, 1048, 753, 34, 2204, 190, 504, 2, 2173, 36, 4, 2917, 316, 3436, 54490, 54491, 2677, 834, 2815, 2, 336, 814, 1, 286, 533, 3, 1567, 1, 7257, 3038, 145, 55, 1080, 20, 261, 1727, 4, 1840, 112, 336, 814, 1, 864, 2, 780, 286, 533, 844, 8, 2664, 5661, 3174, 818, 2677, 3, 4650, 1, 24, 22, 149, 22, 3, 209, 2, 155, 1, 747, 2377, 1, 8635, 36, 6826, 3, 594, 1, 7101, 36, 6, 110, 3, 34, 2, 3, 89, 1, 3, 69, 191, 99, 309, 17, 1048, 753, 34, 2204, 122, 120, 401, 3, 43, 455, 4, 286, 533, 2, 17, 2565, 1104, 122, 40, 7138, 871, 4, 135, 5, 854, 1880, 398, 28, 147, 4, 2917, 478, 3436, 54492, 54493, 2677, 8, 217, 947, 1, 2, 1342, 4, 864, 92, 71, 3510, 4667, 3, 147, 1, 2040, 2, 7857, 5451, 3, 435, 1574, 1, 1119, 138, 4, 8403, 71, 231, 3, 612, 1, 3, 8465, 2, 3, 147, 1, 7857, 5451, 1162, 5, 3, 272, 1, 138, 4, 1102, 2, 3474, 4, 3, 127, 7, 3109, 844, 17, 1301, 363, 1, 1102, 470, 460, 1698, 8, 854, 200, 4, 3, 5661, 1, 26, 34, 3109, 818, 2677, 3, 747, 24, 611, 9, 110, 7857, 5451, 2, 2040, 4, 3, 843, 2, 3934, 6826, 3, 362, 59, 864, 2, 780, 140, 9, 3, 3286, 87, 1, 1342, 3109, 120, 5789, 476, 2010, 1553, 666, 24, 17, 303, 1353, 149, 1149, 944, 38, 143, 6, 1539]",3814.0,15561680,78
Improving the segmentation of therapy-induced leukoencephalopathy in children with acute lymphoblastic leukemia using a priori information and a gradient magnitude threshold.,Magnetic resonance in medicine,Magn Reson Med,2004-12-01,"Reliably quantifying therapy-induced leukoencephalopathy is a challenging task due to the similarity between its MR properties and those of normal tissues. Multispectral MR images were analyzed for 15 children treated for acute lymphoblastic leukemia. Three different analysis techniques were compared to examine improvements in the segmentation accuracy of leukoencephalopathy versus manual tracings by two experienced observers. The original technique used a white matter mask based on the segmentation of the first serial examination of each patient and no a priori information. The modified techniques combine spatially normalized a priori maps as input and a gradient magnitude threshold. The second technique used a 2D threshold, while the third algorithm utilized a 3D threshold. MR images were segmented with a Kohonen self-organizing map for all three algorithms. Kappa values were compared for the three techniques to each observer and statistically significant improvements were seen between the original and third algorithms (Observer 1: 0.651, 0.744, P = 0.015; Observer 2: 0.603, 0.699, P = 0.024). More accurate and reliable quantification reduces the amount of variance in MR measures and facilitates clinical trials to determine the clinical significance of leukoencephalopathy in this vulnerable population.",Journal Article,5529.0,16.0,Reliably quantifying therapy-induced leukoencephalopathy is a challenging task due to the similarity between its MR properties and those of normal tissues Multispectral MR images were analyzed for 15 children treated for acute lymphoblastic Three different analysis techniques were compared to examine improvements in the segmentation accuracy of leukoencephalopathy versus manual tracings by two experienced observers The original technique used a white matter mask based on the segmentation of the first serial examination of each patient and no a priori information The modified techniques combine spatially normalized a priori maps as input and a gradient magnitude threshold The second technique used a 2D threshold while the third algorithm utilized a 3D threshold MR images were segmented with a Kohonen self-organizing map for all three algorithms Kappa values were compared for the three techniques to each observer and statistically significant improvements were seen between the original and third algorithms Observer 1 0.651 0.744 P 0.015 Observer 2 0.603 0.699 P 0.024 More accurate and reliable quantification reduces the amount of variance in MR measures and facilitates clinical trials to determine the clinical significance of leukoencephalopathy in this vulnerable population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4092, 6602, 36, 277, 8744, 16, 8, 1950, 3488, 520, 6, 3, 6700, 59, 211, 1638, 1571, 2, 135, 1, 295, 742, 18997, 1638, 1572, 11, 311, 9, 167, 541, 73, 9, 286, 1275, 169, 338, 65, 1092, 11, 72, 6, 1004, 1474, 4, 3, 5913, 1190, 1, 8744, 185, 4590, 43797, 20, 100, 592, 8803, 3, 2279, 1312, 95, 8, 886, 5090, 10878, 90, 23, 3, 5913, 1, 3, 157, 2108, 1385, 1, 296, 69, 2, 77, 8, 7499, 487, 3, 1230, 1092, 4680, 11772, 4207, 8, 7499, 5845, 22, 5772, 2, 8, 7099, 3131, 2390, 3, 419, 1312, 95, 8, 4494, 2390, 369, 3, 1282, 2124, 2080, 8, 2265, 2390, 1638, 1572, 11, 9199, 5, 8, 37816, 1074, 15917, 3771, 9, 62, 169, 3529, 3096, 1030, 11, 72, 9, 3, 169, 1092, 6, 296, 8405, 2, 712, 93, 1474, 11, 527, 59, 3, 2279, 2, 1282, 3529, 8405, 14, 13, 13114, 13, 12614, 19, 13, 3433, 8405, 18, 13, 9696, 13, 14243, 19, 13, 4247, 80, 1481, 2, 2450, 4752, 2389, 3, 3108, 1, 4446, 4, 1638, 1018, 2, 4936, 38, 143, 6, 223, 3, 38, 724, 1, 8744, 4, 26, 5017, 266]",1293.0,15562471,62
Bone marrow recurrence after initial intensive treatment for childhood acute lymphoblastic leukemia.,Cancer,Cancer,2005-01-01,"The authors studied the clinical outcome of 106 children with acute lymphoblastic leukemia (ALL) who developed a bone marrow recurrence as the first adverse event after contemporary intensified therapy. Endpoints were the rates and lengths of second remission, the cumulative incidence of second hematologic recurrence, second event-free survival (EFS), and survival. Bone marrow recurrences were isolated in 79 patients, and combined with an extramedullary site in 27 patients. The median time to recurrence was 2.6 years (range, 0.3-11.6 years). Seventy-six patients (71.7%) attained a second remission (median length, 0.7 year; range, 0.03-13.3 years). The 5-year survival probability among all patients was 24.2% +/- 4.2% (standard error). On multivariate analysis, time to first disease recurrence and blast cell lineage were found to be independent predictors of a second EFS (P = 0.008 and P = 0.028, respectively). The 5-year EFS estimate in patients with an initial disease remission of >/= 36 months was 42.6% +/- 7.8% but was only 12.5% +/- 3.9% among children with a short duration of disease remission (< 36 months). These estimates were 28.7% +/- 4.9% and 5.0% +/- 3.4%, respectively, for B blast and T blast cell lineages. Despite acceptable long-term second EFS rates for certain subgroups, overall bone marrow recurrence after intensified first-line therapy for childhood ALL signals a poor outcome.",Journal Article,5498.0,66.0,The authors studied the clinical outcome of 106 children with acute lymphoblastic ALL who developed a marrow recurrence as the first adverse event after contemporary intensified therapy Endpoints were the rates and lengths of second remission the cumulative incidence of second hematologic recurrence second event-free survival EFS and survival marrow recurrences were isolated in 79 patients and combined with an extramedullary site in 27 patients The median time to recurrence was 2.6 years range 0.3-11.6 years Seventy-six patients 71.7 attained a second remission median length 0.7 year range 0.03-13.3 years The 5-year survival probability among all patients was 24.2 +/- 4.2 standard error On multivariate analysis time to first disease recurrence and blast cell lineage were found to be independent predictors of a second EFS P 0.008 and P 0.028 respectively The 5-year EFS estimate in patients with an initial disease remission of /= 36 months was 42.6 +/- 7.8 but was only 12.5 +/- 3.9 among children with a short duration of disease remission 36 months These estimates were 28.7 +/- 4.9 and 5.0 +/- 3.4 respectively for B blast and T blast cell lineages Despite acceptable long-term second EFS rates for certain subgroups overall marrow recurrence after intensified first-line therapy for childhood ALL signals a poor outcome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 738, 656, 3, 38, 228, 1, 3251, 541, 5, 286, 1275, 62, 54, 276, 8, 581, 146, 22, 3, 157, 290, 774, 50, 2667, 7311, 36, 1387, 11, 3, 151, 2, 7443, 1, 419, 734, 3, 967, 287, 1, 419, 813, 146, 419, 774, 115, 25, 1683, 2, 25, 581, 1593, 11, 1355, 4, 842, 7, 2, 397, 5, 35, 5508, 606, 4, 428, 7, 3, 52, 98, 6, 146, 10, 18, 49, 60, 184, 13, 27, 175, 49, 60, 2073, 437, 7, 792, 67, 5105, 8, 419, 734, 52, 1318, 13, 67, 111, 184, 13, 680, 233, 27, 60, 3, 33, 111, 25, 1320, 107, 62, 7, 10, 259, 18, 39, 18, 260, 3444, 23, 331, 65, 98, 6, 157, 34, 146, 2, 3112, 31, 2542, 11, 204, 6, 40, 306, 674, 1, 8, 419, 1683, 19, 13, 2155, 2, 19, 13, 4836, 106, 3, 33, 111, 1683, 1191, 4, 7, 5, 35, 388, 34, 734, 1, 511, 53, 10, 595, 49, 67, 66, 84, 10, 158, 133, 33, 27, 83, 107, 541, 5, 8, 978, 654, 1, 34, 734, 511, 53, 46, 1423, 11, 339, 67, 39, 83, 2, 33, 13, 27, 39, 106, 9, 132, 3112, 2, 102, 3112, 31, 7234, 550, 1595, 319, 337, 419, 1683, 151, 9, 1840, 1453, 63, 581, 146, 50, 7311, 157, 328, 36, 9, 864, 62, 2312, 8, 334, 228]",1335.0,15599932,308
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.,Cancer research,Cancer Res.,2004-12-01,"The SH2 domain-containing protein-tyrosine phosphatase PTPN11 (Shp2) is required for normal development and is an essential component of signaling pathways initiated by growth factors, cytokines, and extracellular matrix. In many of these pathways, Shp2 acts upstream of Ras. About 50% of patients with Noonan syndrome have germ-line PTPN11 gain of function mutations. Associations between Noonan syndrome and an increased risk of some malignancies, notably leukemia and neuroblastoma, have been reported, and recent data indicate that somatic PTPN11 mutations occur in children with sporadic juvenile myelomonocytic leukemia, myelodysplasic syndrome, B-cell acute lymphoblastic leukemia, and acute myelogenous leukemia (AML). Juvenile myelomonocytic leukemia patients without PTPN11 mutations have either homozygotic NF-1 deletion or activating RAS mutations. Given the role of Shp2 in Ras activation and the frequent mutation of RAS in human tumors, these data raise the possibility that PTPN11 mutations play a broader role in cancer. We asked whether PTPN11 mutations occur in other malignancies in which activating RAS mutations occur at low but significant frequency. Sequencing of PTPN11 from 13 different human neoplasms including breast, lung, gastric, and neuroblastoma tumors and adult AML and acute lymphoblastic leukemia revealed 11 missense mutations. Five are known mutations predicted to result in an activated form of Shp2, whereas six are new mutations. Biochemical analysis confirmed that several of the new mutations result in increased Shp2 activity. Our data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, especially neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy.",Journal Article,5529.0,336.0,The SH2 domain-containing protein-tyrosine phosphatase PTPN11 Shp2 is required for normal development and is an essential component of signaling pathways initiated by growth factors cytokines and extracellular matrix In many of these pathways Shp2 acts upstream of Ras About 50 of patients with Noonan syndrome have germ-line PTPN11 gain of function mutations Associations between Noonan syndrome and an increased risk of some malignancies notably and have been reported and recent data indicate that somatic PTPN11 mutations occur in children with sporadic juvenile myelomonocytic myelodysplasic syndrome B-cell acute lymphoblastic and acute myelogenous AML Juvenile myelomonocytic patients without PTPN11 mutations have either homozygotic NF-1 deletion or activating RAS mutations Given the role of Shp2 in Ras activation and the frequent mutation of RAS in human tumors these data raise the possibility that PTPN11 mutations play a broader role in cancer We asked whether PTPN11 mutations occur in other malignancies in which activating RAS mutations occur at low but significant frequency Sequencing of PTPN11 from 13 different human neoplasms including and tumors and adult AML and acute lymphoblastic revealed 11 missense mutations Five are known mutations predicted to result in an activated form of Shp2 whereas six are new mutations Biochemical analysis confirmed that several of the new mutations result in increased Shp2 activity Our data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers especially and AML and suggest that Shp2 may be a novel target for antineoplastic therapy,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,0,0,0,"[3, 16745, 1398, 1101, 178, 564, 2577, 8403, 15508, 16, 616, 9, 295, 193, 2, 16, 35, 1452, 1249, 1, 314, 460, 1917, 20, 129, 130, 1886, 2, 1976, 2248, 4, 445, 1, 46, 460, 15508, 4459, 3988, 1, 1102, 545, 212, 1, 7, 5, 26240, 681, 47, 2280, 328, 8403, 1803, 1, 343, 138, 685, 59, 26240, 681, 2, 35, 101, 43, 1, 476, 441, 2552, 2, 47, 85, 210, 2, 435, 74, 1008, 17, 1119, 8403, 138, 1271, 4, 541, 5, 1928, 7857, 5451, 43807, 681, 132, 31, 286, 1275, 2, 286, 2194, 329, 7857, 5451, 7, 187, 8403, 138, 47, 361, 43808, 1365, 14, 1528, 15, 1616, 1102, 138, 447, 3, 200, 1, 15508, 4, 1102, 363, 2, 3, 908, 258, 1, 1102, 4, 171, 57, 46, 74, 5008, 3, 2526, 17, 8403, 138, 1343, 8, 5410, 200, 4, 12, 21, 3732, 317, 8403, 138, 1271, 4, 127, 441, 4, 92, 1616, 1102, 138, 1271, 28, 154, 84, 93, 675, 615, 1, 8403, 29, 233, 338, 171, 1179, 141, 2, 57, 2, 780, 329, 2, 286, 1275, 553, 175, 4007, 138, 365, 32, 440, 138, 783, 6, 757, 4, 35, 735, 1297, 1, 15508, 547, 437, 32, 217, 138, 1487, 65, 557, 17, 392, 1, 3, 217, 138, 757, 4, 101, 15508, 128, 114, 74, 608, 17, 138, 4, 8403, 1271, 28, 154, 675, 4, 392, 171, 163, 1093, 2, 329, 2, 309, 17, 15508, 68, 40, 8, 229, 283, 9, 3940, 36]",1624.0,15604238,30
Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature.,American journal of hematology,Am. J. Hematol.,2005-01-01,"Survivors of childhood solid tumors including Ewing sarcoma (ES) have an increased risk of secondary malignant neoplasms (SMNs) as a consequence of exposure to chemotherapy and/or radiation (see: Bhatia S, Sklar C. Nat Rev Cancer 2002;2:124-132). The most common hematologic SMNs are myelodysplasia (MDS) and acute myelogenous leukemia (AML). Acute lymphoblastic leukemia (ALL) is uncommon in this patient population, and Philadelphia chromosome positive (Ph+) ALL in particular, is rare. We report herein two cases of young adult patients who were both diagnosed with Ph+ ALL 19 years after successful treatment for ES with combined modality therapy. A review of the relevant literature follows the case reports.",Case Reports,5498.0,9.0,Survivors of childhood solid tumors including ES have an increased risk of secondary malignant neoplasms SMNs as a consequence of exposure to chemotherapy and/or radiation see Bhatia S Sklar C. Nat Rev Cancer 2002 2:124-132 The most common hematologic SMNs are myelodysplasia MDS and acute myelogenous AML Acute lymphoblastic ALL is uncommon in this patient population and Philadelphia chromosome positive Ph+ ALL in particular is rare We report herein two cases of young adult patients who were both diagnosed with Ph+ ALL 19 years after successful treatment for ES with combined modality therapy A review of the relevant literature follows the case reports,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 537, 57, 141, 3011, 47, 35, 101, 43, 1, 568, 393, 1179, 6580, 22, 8, 4177, 1, 645, 6, 56, 2, 15, 121, 3764, 54543, 695, 54544, 256, 11145, 19684, 12, 1544, 18, 2834, 4255, 3, 96, 186, 813, 6580, 32, 6128, 1223, 2, 286, 2194, 329, 286, 1275, 62, 16, 2052, 4, 26, 69, 266, 2, 3006, 1170, 109, 2058, 62, 4, 1454, 16, 622, 21, 414, 1986, 100, 140, 1, 1169, 780, 7, 54, 11, 110, 265, 5, 2058, 62, 326, 60, 50, 1401, 24, 9, 3011, 5, 397, 1396, 36, 8, 206, 1, 3, 867, 789, 2962, 3, 473, 1198]",658.0,15609284,177
Folate pathway gene expression differs in subtypes of acute lymphoblastic leukemia and influences methotrexate pharmacodynamics.,The Journal of clinical investigation,J. Clin. Invest.,2005-01-01,"The ability of leukemia cells to accumulate methotrexate polyglutamate (MTXPG) is an important determinant of the antileukemic effects of methotrexate (MTX). We measured in vivo MTXPG accumulation in leukemia cells from 101 children with acute lymphoblastic leukemia (ALL) and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion, or T-lineage ALL, accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid (fewer than 50 chromosomes) ALL. To elucidate mechanisms underlying these differences in MTXPG accumulation, we used oligonucleotide microarrays to analyze expression of 32 folate pathway genes in diagnostic leukemia cells from 197 children. This revealed ALL subtype-specific patterns of folate pathway gene expression that were significantly related to MTXPG accumulation. We found significantly lower expression of the reduced folate carrier (SLC19A1, an MTX uptake transporter) in E2A-PBX1 ALL, significantly higher expression of breast cancer resistance protein (ABCG2, an MTX efflux transporter) in TEL-AML1 ALL, and lower expression of FPGS (which catalyzes formation of MTXPG) in T-lineage ALL, consistent with lower MTXPG accumulation in these ALL subtypes. These findings reveal distinct mechanisms of subtype-specific differences in MTXPG accumulation and point to new strategies to overcome these potential causes of treatment failure in childhood ALL.",Journal Article,5498.0,115.0,The ability of cells to accumulate methotrexate polyglutamate MTXPG is an important determinant of the antileukemic effects of methotrexate MTX We measured in vivo MTXPG accumulation in cells from 101 children with acute lymphoblastic ALL and established that B-lineage ALL with either TEL-AML1 or E2A-PBX1 gene fusion or T-lineage ALL accumulates significantly lower MTXPG compared with B-lineage ALL without these genetic abnormalities or compared with hyperdiploid fewer than 50 chromosomes ALL To elucidate mechanisms underlying these differences in MTXPG accumulation we used oligonucleotide microarrays to analyze expression of 32 folate pathway genes in diagnostic cells from 197 children This revealed ALL subtype-specific patterns of folate pathway gene expression that were significantly related to MTXPG accumulation We found significantly lower expression of the reduced folate carrier SLC19A1 an MTX uptake transporter in E2A-PBX1 ALL significantly higher expression of cancer resistance protein ABCG2 an MTX efflux transporter in TEL-AML1 ALL and lower expression of FPGS which catalyzes formation of MTXPG in T-lineage ALL consistent with lower MTXPG accumulation in these ALL subtypes These findings reveal distinct mechanisms of subtype-specific differences in MTXPG accumulation and point to new strategies to overcome these potential causes of treatment failure in childhood ALL,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 801, 1, 37, 6, 7859, 2116, 22006, 11572, 16, 35, 305, 4372, 1, 3, 4512, 176, 1, 2116, 3453, 21, 644, 4, 386, 11572, 1835, 4, 37, 29, 2338, 541, 5, 286, 1275, 62, 2, 635, 17, 132, 2542, 62, 5, 361, 8573, 6535, 15, 15127, 14434, 145, 1212, 15, 102, 2542, 62, 14390, 97, 280, 11572, 72, 5, 132, 2542, 62, 187, 46, 336, 1171, 15, 72, 5, 8847, 1497, 76, 212, 3560, 62, 6, 3061, 483, 1181, 46, 362, 4, 11572, 1835, 21, 95, 4727, 2774, 6, 1992, 55, 1, 531, 3100, 308, 214, 4, 752, 37, 29, 6114, 541, 26, 553, 62, 875, 112, 764, 1, 3100, 308, 145, 55, 17, 11, 97, 139, 6, 11572, 1835, 21, 204, 97, 280, 55, 1, 3, 405, 3100, 4715, 21301, 35, 3453, 1135, 5246, 4, 15127, 14434, 62, 97, 142, 55, 1, 12, 251, 178, 6447, 35, 3453, 7043, 5246, 4, 8573, 6535, 62, 2, 280, 55, 1, 14140, 92, 11074, 1264, 1, 11572, 4, 102, 2542, 62, 925, 5, 280, 11572, 1835, 4, 46, 62, 814, 46, 272, 2396, 834, 483, 1, 875, 112, 362, 4, 11572, 1835, 2, 741, 6, 217, 422, 6, 1768, 46, 174, 1626, 1, 24, 496, 4, 864, 62]",1397.0,15630450,14
Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the Bone Marrow Transplant Survivor Study.,Blood,Blood,2005-02-08,"We assessed late mortality in 854 individuals who had survived 2 or more years after autologous hematopoietic cell transplantation (HCT) for hematologic malignancies. Median age at HCT was 36.5 years, and median length of follow-up was 7.6 years. Overall survival was 68.8% +/- 1.8% at 10 years, and the cohort was at a 13-fold increased risk for late death (standardized mortality ratio [SMR] = 13.0) when compared with the general population. Mortality rates approached those of the general population after 10 years among patients at standard risk for relapse at HCT (SMR = 1.1) and in patients undergoing transplantation for acute myeloid leukemia (AML; SMR = 0.9). Relapse of primary disease (56%) and subsequent malignancies (25%) were leading causes of late death. Relapse-related mortality was increased among patients with Hodgkin disease (HD; relative risk [RR] = 3.6), non-Hodgkin lymphoma (NHL; RR = 2.1), and acute lymphoblastic leukemia (ALL; RR = 6.5). Total body irradiation (RR = 0.6) provided a protective effect. Nonrelapse-related mortality was increased after carmustine (RR = 2.3) and with use of peripheral blood stem cells (RR = 2.4). Survivors were more likely to report difficulty in holding jobs (RR = 9.4) and in obtaining health (RR = 7.7) or life insurance (RR = 8.4) when compared with siblings. Although mortality rates approach that of the general population after 10 years in certain subgroups, long-term survivors of autologous HCT continue to face challenges affecting their health and well-being.",Comparative Study,5460.0,162.0,We assessed late mortality in 854 individuals who had survived 2 or more years after autologous hematopoietic cell transplantation HCT for hematologic malignancies Median age at HCT was 36.5 years and median length of follow-up was 7.6 years Overall survival was 68.8 +/- 1.8 at 10 years and the cohort was at a 13-fold increased risk for late death standardized mortality ratio SMR 13.0 when compared with the general population Mortality rates approached those of the general population after 10 years among patients at standard risk for relapse at HCT SMR 1.1 and in patients undergoing transplantation for acute myeloid AML SMR 0.9 Relapse of primary disease 56 and subsequent malignancies 25 were leading causes of late death Relapse-related mortality was increased among patients with disease HD relative risk RR 3.6 NHL RR 2.1 and acute lymphoblastic ALL RR 6.5 Total body irradiation RR 0.6 provided a protective effect Nonrelapse-related mortality was increased after carmustine RR 2.3 and with use of peripheral blood stem cells RR 2.4 Survivors were more likely to report difficulty in holding jobs RR 9.4 and in obtaining health RR 7.7 or life insurance RR 8.4 when compared with siblings Although mortality rates approach that of the general population after 10 years in certain subgroups long-term survivors of autologous HCT continue to face challenges affecting their health and well-being,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 275, 807, 282, 4, 15284, 869, 54, 42, 2996, 18, 15, 80, 60, 50, 1028, 1007, 31, 497, 1085, 9, 813, 441, 52, 89, 28, 1085, 10, 511, 33, 60, 2, 52, 1318, 1, 166, 126, 10, 67, 49, 60, 63, 25, 10, 806, 66, 14, 66, 28, 79, 60, 2, 3, 180, 10, 28, 8, 233, 1116, 101, 43, 9, 807, 273, 1670, 282, 197, 7071, 233, 13, 198, 72, 5, 3, 1083, 266, 282, 151, 5738, 135, 1, 3, 1083, 266, 50, 79, 60, 107, 7, 28, 260, 43, 9, 429, 28, 1085, 7071, 14, 14, 2, 4, 7, 479, 497, 9, 286, 533, 329, 7071, 13, 83, 429, 1, 86, 34, 664, 2, 706, 441, 243, 11, 1049, 1626, 1, 807, 273, 429, 139, 282, 10, 101, 107, 7, 5, 34, 2701, 580, 43, 861, 27, 49, 1176, 861, 18, 14, 2, 286, 1275, 62, 861, 49, 33, 181, 642, 1104, 861, 13, 49, 1052, 8, 2864, 254, 4640, 139, 282, 10, 101, 50, 5818, 861, 18, 27, 2, 5, 119, 1, 672, 315, 452, 37, 861, 18, 39, 332, 11, 80, 322, 6, 414, 4035, 4, 14904, 15275, 861, 83, 39, 2, 4, 5244, 341, 861, 67, 67, 15, 358, 1935, 861, 66, 39, 198, 72, 5, 2758, 242, 282, 151, 353, 17, 1, 3, 1083, 266, 50, 79, 60, 4, 1840, 1453, 319, 337, 332, 1, 1028, 1085, 1906, 6, 3376, 1427, 2319, 136, 341, 2, 149, 486]",1405.0,15701723,500
"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.",Cancer cell,Cancer Cell,2005-02-01,"The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). We describe a novel selective inhibitor of Bcr-Abl, AMN107 (IC50 <30 nM), which is significantly more potent than imatinib, and active against a number of imatinib-resistant Bcr-Abl mutants. Crystallographic analysis of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl. Consistent with its in vitro and pharmacokinetic profile, AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells, and prolonged survival in imatinib-resistant CML mouse models. AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL.",Journal Article,5467.0,1151.0,The Bcr-Abl tyrosine kinase oncogene causes chronic myelogenous CML and Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL We describe a novel selective inhibitor of Bcr-Abl AMN107 IC50 30 nM which is significantly more potent than imatinib and active against a number of imatinib-resistant Bcr-Abl mutants Crystallographic analysis of Abl-AMN107 complexes provides a structural explanation for the differential activity of AMN107 and imatinib against imatinib-resistant Bcr-Abl Consistent with its in vitro and pharmacokinetic profile AMN107 prolonged survival of mice injected with Bcr-Abl-transformed hematopoietic cell lines or primary marrow cells and prolonged survival in imatinib-resistant CML mouse models AMN107 is a promising new inhibitor for the therapy of CML and Ph+ ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1062, 1425, 564, 216, 1836, 1626, 442, 2194, 903, 2, 3006, 1170, 109, 2058, 286, 1275, 62, 21, 897, 8, 229, 1094, 230, 1, 1062, 1425, 12189, 5211, 201, 2878, 92, 16, 97, 80, 1157, 76, 577, 2, 544, 480, 8, 207, 1, 577, 436, 1062, 1425, 3423, 33712, 65, 1, 1425, 12189, 3817, 777, 8, 3281, 6603, 9, 3, 1777, 128, 1, 12189, 2, 577, 480, 577, 436, 1062, 1425, 925, 5, 211, 4, 439, 2, 1456, 800, 12189, 1069, 25, 1, 399, 2651, 5, 1062, 1425, 2423, 1007, 31, 285, 15, 86, 581, 37, 2, 1069, 25, 4, 577, 436, 903, 830, 274, 12189, 16, 8, 721, 217, 230, 9, 3, 36, 1, 903, 2, 2058, 62]",795.0,15710326,260
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.,Blood,Blood,2005-02-15,"Acquired genetic characteristics of acute lymphoblastic leukemia (ALL) cells are used to individualize therapy, whereas germ line genetic characteristics generally are not. We determined whether ALL outcome was related to 16 genetic polymorphisms affecting the pharmacodynamics of antileukemic agents. Of 246 children, 116 were treated on the lower-risk (LR) and 130 on the higher-risk (HR) arms of a St Jude protocol. Patients in the HR group with the glutathione S-transferase (GSTM1) non-null genotype had greater risk of hematologic relapse (P = .03), which was further increased by the thymidylate synthetase (TYMS) 3/3 genotype (P = .03). These genotypes remained predictive in multivariate analyses (P < .001 and .003, respectively). No genotypes were predictive in the LR arm. Expression of these 2 genes in ALL blasts was lower in those with low-activity genotypes. For central nervous system relapse, among the HR group, the vitamin D receptor start site (P = .02) and intron 8 genotypes (P = .04) predisposed, whereas for LR patients the TYMS 3/3 genotype predisposed (P = .04). The GSTM1 non-null and TYMS 3/3 genotypes are plausibly linked to drug resistance. Polymorphisms interact to influence antileukemic outcome and represent determinants of response that can be used to optimize therapy.",Clinical Trial,5453.0,162.0,Acquired genetic characteristics of acute lymphoblastic ALL cells are used to individualize therapy whereas germ line genetic characteristics generally are not We determined whether ALL outcome was related to 16 genetic polymorphisms affecting the pharmacodynamics of antileukemic agents Of 246 children 116 were treated on the lower-risk LR and 130 on the higher-risk HR arms of a St Jude protocol Patients in the HR group with the glutathione S-transferase GSTM1 non-null genotype had greater risk of hematologic relapse P .03 which was further increased by the thymidylate synthetase TYMS 3/3 genotype P .03 These genotypes remained predictive in multivariate analyses P .001 and .003 respectively No genotypes were predictive in the LR arm Expression of these 2 genes in ALL blasts was lower in those with low-activity genotypes For central nervous system relapse among the HR group the vitamin D receptor start site P .02 and intron 8 genotypes P .04 predisposed whereas for LR patients the TYMS 3/3 genotype predisposed P .04 The GSTM1 non-null and TYMS 3/3 genotypes are plausibly linked to drug resistance Polymorphisms interact to influence antileukemic outcome and represent determinants of response that can be used to optimize therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1294, 336, 374, 1, 286, 1275, 62, 37, 32, 95, 6, 7177, 36, 547, 2280, 328, 336, 374, 1228, 32, 44, 21, 509, 317, 62, 228, 10, 139, 6, 245, 336, 1203, 2319, 3, 3587, 1, 4512, 183, 1, 6907, 541, 3790, 11, 73, 23, 3, 280, 43, 2030, 2, 3431, 23, 3, 142, 43, 168, 1335, 1, 8, 3062, 4841, 1182, 7, 4, 3, 168, 87, 5, 3, 4571, 695, 4402, 9410, 220, 3505, 1183, 42, 378, 43, 1, 813, 429, 19, 680, 92, 10, 195, 101, 20, 3, 6205, 12692, 8799, 27, 27, 1183, 19, 680, 46, 2071, 958, 464, 4, 331, 318, 19, 144, 2, 1421, 106, 77, 2071, 11, 464, 4, 3, 2030, 475, 55, 1, 46, 18, 214, 4, 62, 2438, 10, 280, 4, 135, 5, 154, 128, 2071, 9, 854, 1880, 398, 429, 107, 3, 168, 87, 3, 1610, 427, 153, 2435, 606, 19, 588, 2, 6259, 66, 2071, 19, 755, 11072, 547, 9, 2030, 7, 3, 8799, 27, 27, 1183, 11072, 19, 755, 3, 9410, 220, 3505, 2, 8799, 27, 27, 2071, 32, 30731, 1199, 6, 234, 251, 1203, 4491, 6, 1054, 4512, 228, 2, 1231, 3403, 1, 51, 17, 122, 40, 95, 6, 2465, 36]",1246.0,15713801,150
Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.,Experimental hematology,Exp. Hematol.,2005-03-01,"We and others have shown that B cell precursor acute lymphoblastic leukemia cells (ALL) stimulated with CD40 ligand become efficient antigen-presenting cells (APC) capable of expanding autologous, tumor-specific T cells from patients. Translation of these preclinical findings to a novel treatment strategy required four separate issues to be determined: (1) if a CD40-ALL vaccine could be generated for clinical use; (2) whether clinical translation could be achieved; (3) whether the vaccination was safe; and (4) whether a window of time could be identified that would optimize the efficacy of vaccination. Nine patients with relapsed/refractory ALL were enrolled in a phase I trial of vaccination with autologous CD40-ALL. Immunologic reconstitution was measured in a separate cohort of 23 patients with newly diagnosed ALL. We successfully prepared autologous vaccines for all nine patients in the phase I trial. CD40-ALL were potent APC, capable of stimulating allogeneic and peptide-specific T cells in vitro. Two patients were vaccinated without adverse events. Five patients died or progressed before vaccination, suggesting that rapid disease progression limits vaccination in patients with relapse disease, thus limiting clinical translation. We therefore sought to identify a window of time for vaccination during which this approach might be feasible. To achieve this end, we evaluated immunological reconstitution in newly diagnosed patients with ALL patients. Despite recovery of myelopoiesis, most patients had profound defects in T, B, and natural killer (NK) cell numbers that failed to recover at any point during therapy. Autologous tumor vaccination at a time of ALL relapse is not feasible. Alternative strategies for immunotherapy of ALL may require ex vivo generation of antigen specific T cells and adoptive therapy.",Clinical Trial,5439.0,27.0,We and others have shown that B cell precursor acute lymphoblastic cells ALL stimulated with CD40 ligand become efficient antigen-presenting cells APC capable of expanding autologous tumor-specific T cells from patients Translation of these preclinical findings to a novel treatment strategy required four separate issues to be determined 1 if a CD40-ALL vaccine could be generated for clinical use 2 whether clinical translation could be achieved 3 whether the vaccination was safe and 4 whether a window of time could be identified that would optimize the efficacy of vaccination Nine patients with relapsed/refractory ALL were enrolled in a phase I trial of vaccination with autologous CD40-ALL Immunologic reconstitution was measured in a separate cohort of 23 patients with newly diagnosed ALL We successfully prepared autologous vaccines for all nine patients in the phase I trial CD40-ALL were potent APC capable of stimulating allogeneic and peptide-specific T cells in vitro Two patients were vaccinated without adverse events Five patients died or progressed before vaccination suggesting that rapid disease progression limits vaccination in patients with relapse disease thus limiting clinical translation We therefore sought to identify a window of time for vaccination during which this approach might be feasible To achieve this end we evaluated immunological reconstitution in newly diagnosed patients with ALL patients Despite recovery of myelopoiesis most patients had profound defects in T B and natural killer NK cell numbers that failed to recover at any point during therapy Autologous tumor vaccination at a time of ALL relapse is not feasible Alternative strategies for immunotherapy of ALL may require ex vivo generation of antigen specific T cells and adoptive therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 2, 1749, 47, 443, 17, 132, 31, 2765, 286, 1275, 37, 62, 2816, 5, 5040, 1232, 1417, 2547, 448, 1656, 37, 2528, 2787, 1, 4304, 1028, 30, 112, 102, 37, 29, 7, 2691, 1, 46, 693, 272, 6, 8, 229, 24, 692, 616, 294, 2282, 1553, 6, 40, 509, 14, 492, 8, 5040, 62, 1274, 359, 40, 1419, 9, 38, 119, 18, 317, 38, 2691, 359, 40, 513, 27, 317, 3, 1915, 10, 1165, 2, 39, 317, 8, 5421, 1, 98, 359, 40, 108, 17, 688, 2465, 3, 209, 1, 1915, 762, 7, 5, 591, 430, 62, 11, 346, 4, 8, 124, 70, 160, 1, 1915, 5, 1028, 5040, 62, 3042, 5616, 10, 644, 4, 8, 2282, 180, 1, 382, 7, 5, 732, 265, 62, 21, 1878, 4421, 1028, 1842, 9, 62, 762, 7, 4, 3, 124, 70, 160, 5040, 62, 11, 1157, 2528, 2787, 1, 2122, 1063, 2, 1389, 112, 102, 37, 4, 439, 100, 7, 11, 5130, 187, 290, 281, 365, 7, 1016, 15, 1839, 348, 1915, 802, 17, 1321, 34, 91, 3526, 1915, 4, 7, 5, 429, 34, 631, 817, 38, 2691, 21, 673, 990, 6, 255, 8, 5421, 1, 98, 9, 1915, 190, 92, 26, 353, 822, 40, 1313, 6, 1359, 26, 396, 21, 194, 5073, 5616, 4, 732, 265, 7, 5, 62, 7, 550, 1602, 1, 23233, 96, 7, 42, 4399, 2945, 4, 102, 132, 2, 1504, 3458, 1765, 31, 1870, 17, 1551, 6, 9966, 28, 500, 741, 190, 36, 1028, 30, 1915, 28, 8, 98, 1, 62, 429, 16, 44, 1313, 1091, 422, 9, 726, 1, 62, 68, 1353, 2581, 386, 914, 1, 448, 112, 102, 37, 2, 3159, 36]",1793.0,15730852,728
Catastrophic antiphospholipid syndrome: atypical presentation in the setting of chronic graft versus host disease: case report and review of the literature.,Haematologica,Haematologica,2005-03-01,"A 44-year-old female developed a catastrophic thrombotic syndrome following allogeneic stem cell transplantation for acute lymphoblastic leukemia. In the context of chronic graft versus host disease, she developed a lethal multi-system thrombotic state as evidenced by stroke, renal failure and cardiac thrombi in association with elevated anticardiolipin antibody. The case is discussed in the framework of the existing literature and derives clinical practice recommendations for this rare but clinically devastating entity.",Case Reports,5439.0,5.0,A 44-year-old female developed a catastrophic thrombotic syndrome following allogeneic stem cell transplantation for acute lymphoblastic In the context of chronic graft versus host disease she developed a lethal multi-system thrombotic state as evidenced by stroke failure and thrombi in association with elevated anticardiolipin antibody The case is discussed in the framework of the existing literature and derives clinical practice recommendations for this rare but clinically devastating entity,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[8, 584, 111, 1095, 1061, 276, 8, 16253, 6108, 681, 366, 1063, 452, 31, 497, 9, 286, 1275, 4, 3, 1533, 1, 442, 1599, 185, 1204, 34, 3109, 276, 8, 2266, 1414, 398, 6108, 1309, 22, 4728, 20, 4408, 496, 2, 13622, 4, 248, 5, 804, 54668, 548, 3, 473, 16, 1588, 4, 3, 2586, 1, 3, 1692, 789, 2, 17214, 38, 758, 883, 9, 26, 622, 84, 505, 5778, 2983]",498.0,15753058,160
Maternal diet and infant leukemia: the DNA topoisomerase II inhibitor hypothesis: a report from the children's oncology group.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2005-03-01,"The MLL 11q23 translocation arises in utero and is present in 75% of infant leukemias. That MLL+ acute myeloid leukemia (AML) can arise following chemotherapy with DNA topoisomerase II (DNAt2) inhibitors suggests that these substances, which also occur naturally in foods, may contribute toward infant leukemia. We hypothesized that maternal consumption of dietary DNAt2 inhibitors during pregnancy would increase the risk of infant leukemia, particularly AML(MLL+). This Children's Oncology Group case-control study consisted of 240 incident cases of infant acute leukemia [AML and acute lymphoblastic leukemia (ALL)] diagnosed during 1996 to 2002 and 255 random digit dialed controls. Maternal diet during pregnancy was determined through a food frequency questionnaire. An index of specific foods identified a priori to contain DNAt2 inhibitors as well as vegetables and fruits were created and analyzed using unconditional logistic regression. There was little evidence of an association between the specific DNAt2 index and leukemia overall and by subtype. An exception was AML(MLL+); odds ratios (95% confidence intervals) comparing the second to fourth quartiles to the first were 1.9 (0.5-7.0), 2.1 (0.6-7.7), and 3.2 (0.9-11.9), respectively (P for trend = 0.10). For the vegetable and fruit index, there were significant or near-significant inverse linear trends for all leukemias combined, ALL(MLL+), and AML(MLL-). Overall, maternal consumption of fresh vegetables and fruits during pregnancy was associated with a decreased risk of infant leukemia, particularly MLL+. However, for AML(MLL+) cases, maternal consumption of specific DNAt2 inhibitors seemed to increase risk. Although based on small numbers, these data provide some support for distinct etiologic pathways in infant leukemia.",Journal Article,5439.0,134.0,The MLL 11q23 translocation arises in utero and is present in 75 of infant leukemias That MLL+ acute myeloid AML can arise following chemotherapy with DNA topoisomerase II DNAt2 inhibitors suggests that these substances which also occur naturally in foods may contribute toward infant We hypothesized that maternal consumption of dietary DNAt2 inhibitors during pregnancy would increase the risk of infant particularly AML MLL+ This Children 's Oncology Group case-control study consisted of 240 incident cases of infant acute AML and acute lymphoblastic ALL diagnosed during 1996 to 2002 and 255 random digit dialed controls Maternal diet during pregnancy was determined through a food frequency questionnaire An index of specific foods identified a priori to contain DNAt2 inhibitors as well as vegetables and fruits were created and analyzed using unconditional logistic regression There was little evidence of an association between the specific DNAt2 index and overall and by subtype An exception was AML MLL+ odds ratios 95 confidence intervals comparing the second to fourth quartiles to the first were 1.9 0.5-7.0 2.1 0.6-7.7 and 3.2 0.9-11.9 respectively P for trend 0.10 For the vegetable and fruit index there were significant or near-significant inverse linear trends for all leukemias combined ALL MLL+ and AML MLL- Overall maternal consumption of fresh vegetables and fruits during pregnancy was associated with a decreased risk of infant particularly MLL+ However for AML MLL+ cases maternal consumption of specific DNAt2 inhibitors seemed to increase risk Although based on small numbers these data provide some support for distinct etiologic pathways in infant,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3049, 7975, 2006, 6053, 4, 13767, 2, 16, 364, 4, 481, 1, 8027, 2792, 17, 3049, 286, 533, 329, 122, 3043, 366, 56, 5, 261, 3999, 215, 30745, 222, 844, 17, 46, 17124, 92, 120, 1271, 6045, 4, 7484, 68, 1248, 1317, 8027, 21, 1237, 17, 6039, 2421, 1, 2013, 30745, 222, 190, 2290, 688, 344, 3, 43, 1, 8027, 823, 329, 3049, 26, 541, 292, 413, 87, 473, 182, 45, 1695, 1, 4263, 2631, 140, 1, 8027, 286, 329, 2, 286, 1275, 62, 265, 190, 2648, 6, 1544, 2, 7826, 2324, 9553, 43893, 535, 6039, 2453, 190, 2290, 10, 509, 298, 8, 1773, 675, 1770, 35, 558, 1, 112, 7484, 108, 8, 7499, 6, 3725, 30745, 222, 22, 149, 22, 6024, 2, 7896, 11, 2466, 2, 311, 75, 6438, 812, 320, 125, 10, 1215, 241, 1, 35, 248, 59, 3, 112, 30745, 558, 2, 63, 2, 20, 875, 35, 4188, 10, 329, 3049, 610, 1137, 48, 307, 1582, 1430, 3, 419, 6, 3608, 6028, 6, 3, 157, 11, 14, 83, 13, 33, 67, 13, 18, 14, 13, 49, 67, 67, 2, 27, 18, 13, 83, 175, 83, 106, 19, 9, 853, 13, 79, 9, 3, 8450, 2, 7870, 558, 125, 11, 93, 15, 1829, 93, 2931, 1646, 1963, 9, 62, 2792, 397, 62, 3049, 2, 329, 3049, 63, 6039, 2421, 1, 4329, 6024, 2, 7896, 190, 2290, 10, 41, 5, 8, 340, 43, 1, 8027, 823, 3049, 137, 9, 329, 3049, 140, 6039, 2421, 1, 112, 30745, 222, 5025, 6, 344, 43, 242, 90, 23, 302, 1870, 46, 74, 377, 476, 538, 9, 834, 6604, 460, 4, 8027]",1677.0,15767345,131
Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia.,Cancer cell,Cancer Cell,2005-04-01,"Acute lymphoblastic leukemia (ALL) can be cured with combination chemotherapy in over 75% of children, but the cause of treatment failure in the remaining patients is unknown. We determined the sensitivity of ALL cells to individual antileukemic agents in 441 patients and used a genome-wide approach to identify 45 genes differentially expressed in ALL exhibiting crossresistance to prednisolone, vincristine, asparaginase, and daunorubicin. We also identified a distinct phenotype of discordant resistance to asparaginase and vincristine and 139 genes whose expression was associated with this novel phenotype. The expression of these genes discriminated treatment outcome in two independent patient populations, identifying a subset of patients with a markedly inferior outcome (37% +/- 13% 5 year DFS).",Journal Article,5408.0,128.0,Acute lymphoblastic ALL can be cured with combination chemotherapy in over 75 of children but the cause of treatment failure in the remaining patients is unknown We determined the sensitivity of ALL cells to individual antileukemic agents in 441 patients and used a genome-wide approach to identify 45 genes differentially expressed in ALL exhibiting crossresistance to prednisolone vincristine asparaginase and daunorubicin We also identified a distinct phenotype of discordant resistance to asparaginase and vincristine and 139 genes whose expression was associated with this novel phenotype The expression of these genes discriminated treatment outcome in two independent patient populations identifying a subset of patients with a markedly inferior outcome 37 +/- 13 5 year DFS,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 122, 40, 3733, 5, 150, 56, 4, 252, 481, 1, 541, 84, 3, 708, 1, 24, 496, 4, 3, 1844, 7, 16, 860, 21, 509, 3, 485, 1, 62, 37, 6, 797, 4512, 183, 4, 10258, 7, 2, 95, 8, 898, 1019, 353, 6, 255, 512, 214, 2478, 570, 4, 62, 4801, 43932, 6, 11253, 2132, 3709, 2, 5247, 21, 120, 108, 8, 834, 1005, 1, 4570, 251, 6, 3709, 2, 2132, 2, 4929, 214, 1310, 55, 10, 41, 5, 26, 229, 1005, 3, 55, 1, 46, 214, 8752, 24, 228, 4, 100, 306, 69, 1184, 1386, 8, 697, 1, 7, 5, 8, 2195, 1663, 228, 567, 233, 33, 111, 1010]",781.0,15837626,196
Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-04-01,"Cross-sectional studies show that cardiac abnormalities are common in long-term survivors of doxorubicin-treated childhood malignancies. Longitudinal data, however, are rare. Serial echocardiograms (N = 499) were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic leukemia (median age at diagnosis, 4.8 years; median follow-up after completion of doxorubicin, 11.8 years). Results were expressed as z scores to indicate the number of standard deviations (SDs) above (+) or below (-) the normal predicted value. Median individual and cumulative doxorubicin doses were 30 mg/m2 per dose and 352 mg/m2, respectively. Left ventricular fractional shortening was significantly reduced after doxorubicin therapy, and the reduction was related to cumulative dose. z scores for fractional shortening transiently improved before falling to -2.76 more than 12 years after diagnosis. Reduced fractional shortening was related to impaired contractility and increasing afterload, consequences of a progressive reduction of ventricular mass, and wall thickness relative to body-surface area. Left ventricular contractility fell significantly over time and was depressed at last follow-up in patients receiving more than 300 mg/m2 of doxorubicin. Systolic and diastolic blood pressures were below normal more than 9 years after diagnosis. Even patients receiving lower cumulative doxorubicin doses experienced reduced mass and dimension. Fractional shortening and dimension at the end of therapy predicted these parameters 11.8 years later. Cardiac abnormalities were persistent and progressive after doxorubicin therapy. Inadequate ventricular mass with chronic afterload excess was associated with progressive contractile deficit and possibly reduced cardiac output and restrictive cardiomyopathy. The deficits were worst after highest cumulative doses of doxorubicin, but appeared even after low doses.",Journal Article,5408.0,433.0,Cross-sectional studies show that abnormalities are common in long-term survivors of doxorubicin-treated childhood malignancies Longitudinal data however are rare Serial echocardiograms N 499 were obtained from 115 doxorubicin-treated long-term survivors of childhood acute lymphoblastic median age at diagnosis 4.8 years median follow-up after completion of doxorubicin 11.8 years Results were expressed as z scores to indicate the number of standard deviations SDs above or below the normal predicted value Median individual and cumulative doxorubicin doses were 30 mg/m2 per dose and 352 mg/m2 respectively Left ventricular fractional shortening was significantly reduced after doxorubicin therapy and the reduction was related to cumulative dose z scores for fractional shortening transiently improved before falling to -2.76 more than 12 years after diagnosis Reduced fractional shortening was related to impaired contractility and increasing afterload consequences of a progressive reduction of ventricular mass and wall thickness relative to body-surface area Left ventricular contractility fell significantly over time and was depressed at last follow-up in patients receiving more than 300 mg/m2 of doxorubicin Systolic and diastolic blood pressures were below normal more than 9 years after diagnosis Even patients receiving lower cumulative doxorubicin doses experienced reduced mass and dimension Fractional shortening and dimension at the end of therapy predicted these parameters 11.8 years later abnormalities were persistent and progressive after doxorubicin therapy Inadequate ventricular mass with chronic afterload excess was associated with progressive contractile deficit and possibly reduced output and restrictive cardiomyopathy The deficits were worst after highest cumulative doses of doxorubicin but appeared even after low doses,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[1383, 2832, 94, 514, 17, 1171, 32, 186, 4, 319, 337, 332, 1, 856, 73, 864, 441, 2380, 74, 137, 32, 622, 2108, 15097, 78, 11673, 11, 683, 29, 3670, 856, 73, 319, 337, 332, 1, 864, 286, 1275, 52, 89, 28, 147, 39, 66, 60, 52, 166, 126, 50, 1438, 1, 856, 175, 66, 60, 99, 11, 570, 22, 3905, 703, 6, 1008, 3, 207, 1, 260, 7810, 8668, 2090, 15, 2736, 3, 295, 783, 549, 52, 797, 2, 967, 856, 415, 11, 201, 81, 821, 379, 61, 2, 9550, 81, 821, 106, 1712, 4028, 7528, 9245, 10, 97, 405, 50, 856, 36, 2, 3, 628, 10, 139, 6, 967, 61, 3905, 703, 9, 7528, 9245, 9235, 231, 348, 15662, 6, 18, 846, 80, 76, 133, 60, 50, 147, 405, 7528, 9245, 10, 139, 6, 2364, 24430, 2, 602, 22054, 3255, 1, 8, 1014, 628, 1, 4028, 782, 2, 2397, 2903, 580, 6, 642, 1255, 965, 1712, 4028, 24430, 7689, 97, 252, 98, 2, 10, 9233, 28, 1060, 166, 126, 4, 7, 357, 80, 76, 2036, 81, 821, 1, 856, 8109, 2, 10059, 315, 14872, 11, 2736, 295, 80, 76, 83, 60, 50, 147, 871, 7, 357, 280, 967, 856, 415, 592, 405, 782, 2, 6384, 7528, 9245, 2, 6384, 28, 3, 396, 1, 36, 783, 46, 1038, 175, 66, 60, 1559, 1171, 11, 1882, 2, 1014, 50, 856, 36, 3358, 4028, 782, 5, 442, 22054, 2612, 10, 41, 5, 1014, 30759, 6819, 2, 2150, 405, 6911, 2, 11465, 6460, 3, 2752, 11, 4066, 50, 1076, 967, 415, 1, 856, 84, 2121, 871, 50, 154, 415]",1855.0,15837978,565
Global gene expression as a function of germline genetic variation.,Human molecular genetics,Hum. Mol. Genet.,2005-04-27,"Common, functional, germline genetic polymorphisms have been associated with clinical cancer outcomes. Little attention has been paid to the potential phenotypic consequences of germline genetic variation on downstream genes. We determined the germline status of 16 well-characterized functional polymorphisms in 126 children with newly diagnosed acute lymphoblastic leukemia (ALL). We assessed whether global gene expression profiles of diagnostic ALL blasts from the same patients differed by these germline polymorphic genotypes. Gene expression values were adjusted for ALL-subtype-specific patterns. Of the 16 loci, only the UGT1A1 promoter repeat polymorphism [A(TA)nTAA] (UGT1A1*28) and GSTM1 deletion were significant predictors of global gene expression in a supervised approach, which divided patients based on their germline genotypes [UGT1A1: 124 probe sets, false discovery rate (FDR)=13%, P< or =0.0031; GSTM1: 112 probe sets, FDR=42.5%, P< or =0.0084]. Genes whose expression distinguished the UGT1A1 (TA) 7/7 genotype from the other UGT1A1 genotypes included HDAC1, RELA and SLC2A1; those that distinguished the GSTM1 null genotype from non-null genotype included NBS1 and PRKR. In an unsupervised approach, the gene expression profiles using the entire array delineated two major clusters of patients. The only germline genotype frequency that differed between the two clusters was UGT1A1 (P=0.002; Fisher's exact test). Although their expression is limited to specific tissues, both GSTM1 and UGT1A1 are involved in the conjugation (and thus transport, excretion and lipophilicity) of a broad range of endobiotics and xenobiotics, which could plausibly have consequences for gene expression in different tissues.",Journal Article,5382.0,13.0,Common functional germline genetic polymorphisms have been associated with clinical cancer outcomes Little attention has been paid to the potential phenotypic consequences of germline genetic variation on downstream genes We determined the germline status of 16 well-characterized functional polymorphisms in 126 children with newly diagnosed acute lymphoblastic ALL We assessed whether global gene expression profiles of diagnostic ALL blasts from the same patients differed by these germline polymorphic genotypes Gene expression values were adjusted for ALL-subtype-specific patterns Of the 16 loci only the UGT1A1 promoter repeat polymorphism A TA nTAA UGT1A1*28 and GSTM1 deletion were significant predictors of global gene expression in a supervised approach which divided patients based on their germline genotypes UGT1A1 124 probe sets false discovery rate FDR =13 P or =0.0031 GSTM1 112 probe sets FDR=42.5 P or =0.0084 Genes whose expression distinguished the UGT1A1 TA 7/7 genotype from the other UGT1A1 genotypes included HDAC1 RELA and SLC2A1 those that distinguished the GSTM1 null genotype from non-null genotype included NBS1 and PRKR In an unsupervised approach the gene expression profiles using the entire array delineated two major clusters of patients The only germline genotype frequency that differed between the two clusters was UGT1A1 P=0.002 Fisher 's exact test Although their expression is limited to specific tissues both GSTM1 and UGT1A1 are involved in the conjugation and thus transport excretion and lipophilicity of a broad range of endobiotics and xenobiotics which could plausibly have consequences for gene expression in different tissues,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[186, 583, 1009, 336, 1203, 47, 85, 41, 5, 38, 12, 123, 1215, 2111, 71, 85, 8328, 6, 3, 174, 3290, 3255, 1, 1009, 336, 1380, 23, 1489, 214, 21, 509, 3, 1009, 156, 1, 245, 149, 765, 583, 1203, 4, 3927, 541, 5, 732, 265, 286, 1275, 62, 21, 275, 317, 1648, 145, 55, 1241, 1, 752, 62, 2438, 29, 3, 827, 7, 2512, 20, 46, 1009, 7087, 2071, 145, 55, 1030, 11, 586, 9, 62, 875, 112, 764, 1, 3, 245, 2012, 158, 3, 6192, 973, 2334, 1907, 8, 4330, 54764, 6192, 339, 2, 9410, 1528, 11, 93, 674, 1, 1648, 145, 55, 4, 8, 7762, 353, 92, 2176, 7, 90, 23, 136, 1009, 2071, 6192, 2834, 2888, 2270, 2133, 1574, 116, 5929, 233, 19, 15, 13, 20231, 9410, 3726, 2888, 2270, 5929, 595, 33, 19, 15, 13, 22283, 214, 1310, 55, 4735, 3, 6192, 4330, 67, 67, 1183, 29, 3, 127, 6192, 2071, 159, 14241, 8672, 2, 37900, 135, 17, 4735, 3, 9410, 3505, 1183, 29, 220, 3505, 1183, 159, 15519, 2, 54765, 4, 35, 6512, 353, 3, 145, 55, 1241, 75, 3, 1797, 1926, 5610, 100, 458, 3780, 1, 7, 3, 158, 1009, 1183, 675, 17, 2512, 59, 3, 100, 3780, 10, 6192, 19, 13, 1111, 3135, 292, 2472, 412, 242, 136, 55, 16, 383, 6, 112, 742, 110, 9410, 2, 6192, 32, 646, 4, 3, 9877, 2, 631, 4294, 8294, 2, 26111, 1, 8, 2094, 184, 1, 54766, 2, 24725, 92, 359, 30731, 47, 3255, 9, 145, 55, 4, 338, 742]",1675.0,15857854,811
Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate.,AJNR. American journal of neuroradiology,AJNR Am J Neuroradiol,2005-05-01,"An effective treatment for acute lymphoblastic leukemia (ALL), intravenous (IV) methotrexate (MTX) has a notable toxic effect on the CNS, with leukoencephalopathy (LE) being the most common form. The purpose of this study was to use objective quantitative MR imaging to prospectively assess potential risk factors on the temporal evolution of LE in patients treated for ALL. We evaluated the longitudinal prevalence of LE in 45 children treated for ALL in a single institutional protocol including seven courses of IV MTX and no cranial irradiation. Differences in signal intensity on T2-weighted and fluid-attenuated inversion recovery (FLAIR) images between hyperintense regions and normal-appearing genu were used to quantitatively detect LE. Cox proportional regression was used to estimate the effect of covariates (e.g., sex, MTX dose, age at diagnosis) on the prevalence of LE. After influential factors were identified, a generalized linear model was determined to predict the probability of LE in new patients. The model was necessary to facilitate statistical testing between examinations. Increasing exposure, which corresponding to more courses and higher doses of IV MTX, influenced the prevalence of LE. The prevalence of LE was significant reduced approximately 1.5 years after the completion of IV MTX. Higher doses and more courses of IV MTX placed patients at a higher risk for LE; many of the changes resolved after the completion of therapy. The effect of these changes on neurocognitive functioning and quality of life in survivors remains to be determined.",Journal Article,5378.0,83.0,An effective treatment for acute lymphoblastic ALL intravenous IV methotrexate MTX has a notable toxic effect on the CNS with leukoencephalopathy LE being the most common form The purpose of this study was to use objective quantitative MR imaging to prospectively assess potential risk factors on the temporal evolution of LE in patients treated for ALL We evaluated the longitudinal prevalence of LE in 45 children treated for ALL in a single institutional protocol including seven courses of IV MTX and no cranial irradiation Differences in signal intensity on T2-weighted and fluid-attenuated inversion recovery FLAIR images between hyperintense regions and normal-appearing genu were used to quantitatively detect LE Cox proportional regression was used to estimate the effect of covariates e.g. sex MTX dose age at diagnosis on the prevalence of LE After influential factors were identified a generalized linear model was determined to predict the probability of LE in new patients The model was necessary to facilitate statistical testing between examinations Increasing exposure which corresponding to more courses and higher doses of IV MTX influenced the prevalence of LE The prevalence of LE was significant reduced approximately 1.5 years after the completion of IV MTX Higher doses and more courses of IV MTX placed patients at a higher risk for LE many of the changes resolved after the completion of therapy The effect of these changes on neurocognitive functioning and quality of life in survivors remains to be determined,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[35, 323, 24, 9, 286, 1275, 62, 1262, 478, 2116, 3453, 71, 8, 4090, 1812, 254, 23, 3, 1025, 5, 8744, 4892, 486, 3, 96, 186, 1297, 3, 743, 1, 26, 45, 10, 6, 119, 461, 1156, 1638, 270, 6, 1143, 423, 174, 43, 130, 23, 3, 3264, 2554, 1, 4892, 4, 7, 73, 9, 62, 21, 194, 3, 2380, 1078, 1, 4892, 4, 512, 541, 73, 9, 62, 4, 8, 226, 1115, 1182, 141, 648, 1993, 1, 478, 3453, 2, 77, 2565, 1104, 362, 4, 1235, 837, 23, 1786, 2337, 2, 2357, 2656, 8487, 1602, 10144, 1572, 59, 13223, 1374, 2, 295, 6536, 19019, 11, 95, 6, 5889, 1426, 4892, 418, 831, 320, 10, 95, 6, 1191, 3, 254, 1, 2489, 563, 499, 1035, 3453, 61, 89, 28, 147, 23, 3, 1078, 1, 4892, 50, 11741, 130, 11, 108, 8, 4169, 1646, 202, 10, 509, 6, 678, 3, 1320, 1, 4892, 4, 217, 7, 3, 202, 10, 1493, 6, 1876, 1050, 471, 59, 4209, 602, 645, 92, 1734, 6, 80, 1993, 2, 142, 415, 1, 478, 3453, 2574, 3, 1078, 1, 4892, 3, 1078, 1, 4892, 10, 93, 405, 705, 14, 33, 60, 50, 3, 1438, 1, 478, 3453, 142, 415, 2, 80, 1993, 1, 478, 3453, 3295, 7, 28, 8, 142, 43, 9, 4892, 445, 1, 3, 400, 3862, 50, 3, 1438, 1, 36, 3, 254, 1, 46, 400, 23, 2958, 2702, 2, 372, 1, 358, 4, 332, 469, 6, 40, 509]",1537.0,15891195,619
High-dose methotrexate in acute lymphoblastic leukemia: where is the evidence for its continued use?,Pharmacotherapy,Pharmacotherapy,2005-05-01,"High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL). Its use has a strong pharmacologic rationale: to overcome mechanisms of resistance of the malignant cells and to achieve cytotoxic concentrations in sanctuary sites for lymphoblasts. Although therapeutic progress in ALL during the past 4 decades has been closely associated with more widespread use of intravenous methotrexate and in progressively larger doses, little data exist to clearly support the use of high-dose intravenous methotrexate over a regimen of prolonged administration of low-dose methotrexate. The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue. The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed. Despite its extensive use, high-dose intravenous methotrexate has not been proved conclusively to be more effective than less toxic, less labor intensive, and less costly methods of methotrexate administration.",Journal Article,5378.0,28.0,High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic ALL Its use has a strong pharmacologic rationale to overcome mechanisms of resistance of the malignant cells and to achieve cytotoxic concentrations in sanctuary sites for lymphoblasts Although therapeutic progress in ALL during the past 4 decades has been closely associated with more widespread use of intravenous methotrexate and in progressively larger doses little data exist to clearly support the use of high-dose intravenous methotrexate over a regimen of prolonged administration of low-dose methotrexate The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed Despite its extensive use high-dose intravenous methotrexate has not been proved conclusively to be more effective than less toxic less labor intensive and less costly methods of methotrexate administration,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[64, 61, 1262, 2116, 16, 35, 305, 1249, 1, 445, 323, 1573, 472, 9, 864, 286, 1275, 62, 211, 119, 71, 8, 1082, 2788, 1728, 6, 1768, 483, 1, 251, 1, 3, 393, 37, 2, 6, 1359, 759, 1003, 4, 14541, 633, 9, 10521, 242, 189, 1466, 4, 62, 190, 3, 1219, 39, 1968, 71, 85, 3210, 41, 5, 80, 3029, 119, 1, 1262, 2116, 2, 4, 6696, 1077, 415, 1215, 74, 1923, 6, 2536, 538, 3, 119, 1, 64, 61, 1262, 2116, 252, 8, 477, 1, 1069, 634, 1, 154, 61, 2116, 3, 18168, 5233, 1, 1262, 2116, 2615, 15651, 29, 94, 17, 95, 3038, 3296, 4256, 5, 154, 61, 2116, 15, 29, 94, 1, 2941, 5421, 36, 4, 1278, 541, 5, 62, 4, 92, 226, 260, 415, 1, 518, 2116, 11, 72, 5, 64, 61, 1262, 2116, 5, 3296, 4256, 3, 241, 6238, 634, 1, 1262, 2116, 9, 541, 5, 62, 16, 4331, 446, 550, 211, 1344, 119, 64, 61, 1262, 2116, 71, 44, 85, 4328, 14741, 6, 40, 80, 323, 76, 299, 1812, 299, 9557, 1686, 2, 299, 6288, 636, 1, 2116, 634]",1314.0,15899736,208
Gene expression and thioguanine nucleotide disposition in acute lymphoblastic leukemia after in vivo mercaptopurine treatment.,Blood,Blood,2005-05-19,"To elucidate interpatient variability in thioguanine nucleotide (TGN) concentrations in acute lymphoblastic leukemia (ALL) cells, we determined the TGN concentrations in leukemic blasts from 82 children with newly diagnosed ALL after intravenous administration of mercaptopurine (MP). Patients treated with MP alone achieved higher TGN concentrations than those treated with the combination of methotrexate plus mercaptopurine (MTX + MP). Analysis of the expression of approximately 9600 genes in ALL cells obtained at diagnosis identified 60 gene probes significantly associated with TGN accumulation in patients treated with MP alone and 75 gene probes in patients treated with MTX + MP, with no overlap between the 2 sets of genes. Genes significantly associated with intracellular TGN accumulation after MP alone included those encoding MP metabolic enzymes and transporters (eg, SLC29A1). Inhibition of SLC29A1 by nitrobenzylmercaptopurine ribonucleoside (NBMPR) caused a 33% to 45% reduction of TGN in ALL cells in vitro (P < .006), consistent with the gene expression findings. Genes associated with TGN concentration after combination therapy included those involved in protein and adenosine triphosphate (ATP)-biosynthesis. Together, these in vivo and in vitro data provide new insight into the genomic basis of interpatient differences in intracellular TGN accumulation and reveal significant differences between treatment with MP alone and treatment with MP and MTX.",Clinical Trial,5360.0,41.0,To elucidate interpatient variability in thioguanine nucleotide TGN concentrations in acute lymphoblastic ALL cells we determined the TGN concentrations in leukemic blasts from 82 children with newly diagnosed ALL after intravenous administration of mercaptopurine MP Patients treated with MP alone achieved higher TGN concentrations than those treated with the combination of methotrexate plus mercaptopurine MTX MP Analysis of the expression of approximately 9600 genes in ALL cells obtained at diagnosis identified 60 gene probes significantly associated with TGN accumulation in patients treated with MP alone and 75 gene probes in patients treated with MTX MP with no overlap between the 2 sets of genes Genes significantly associated with intracellular TGN accumulation after MP alone included those encoding MP metabolic enzymes and transporters eg SLC29A1 Inhibition of SLC29A1 by nitrobenzylmercaptopurine ribonucleoside NBMPR caused a 33 to 45 reduction of TGN in ALL cells in vitro P .006 consistent with the gene expression findings Genes associated with TGN concentration after combination therapy included those involved in protein and adenosine triphosphate ATP -biosynthesis Together these in vivo and in vitro data provide new insight into the genomic basis of interpatient differences in intracellular TGN accumulation and reveal significant differences between treatment with MP alone and treatment with MP and MTX,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 3061, 7423, 1982, 4, 17598, 1579, 17846, 1003, 4, 286, 1275, 62, 37, 21, 509, 3, 17846, 1003, 4, 2015, 2438, 29, 878, 541, 5, 732, 265, 62, 50, 1262, 634, 1, 9223, 4545, 7, 73, 5, 4545, 279, 513, 142, 17846, 1003, 76, 135, 73, 5, 3, 150, 1, 2116, 349, 9223, 3453, 4545, 65, 1, 3, 55, 1, 705, 54825, 214, 4, 62, 37, 683, 28, 147, 108, 335, 145, 3701, 97, 41, 5, 17846, 1835, 4, 7, 73, 5, 4545, 279, 2, 481, 145, 3701, 4, 7, 73, 5, 3453, 4545, 5, 77, 4526, 59, 3, 18, 2270, 1, 214, 214, 97, 41, 5, 2087, 17846, 1835, 50, 4545, 279, 159, 135, 2362, 4545, 1436, 3039, 2, 6733, 2887, 30775, 297, 1, 30775, 20, 54826, 43971, 54827, 1546, 8, 466, 6, 512, 628, 1, 17846, 4, 62, 37, 4, 439, 19, 1861, 925, 5, 3, 145, 55, 272, 214, 41, 5, 17846, 1227, 50, 150, 36, 159, 135, 646, 4, 178, 2, 4938, 7345, 3918, 6225, 1162, 46, 4, 386, 2, 4, 439, 74, 377, 217, 2670, 237, 3, 572, 877, 1, 7423, 362, 4, 2087, 17846, 1835, 2, 2396, 93, 362, 59, 24, 5, 4545, 279, 2, 24, 5, 4545, 2, 3453]",1433.0,15905191,655
Antigen-specific T-cell memory is preserved in children treated for acute lymphoblastic leukemia.,Blood,Blood,2005-05-26,"Despite profound T-cell immunodeficiency, most patients treated with chemotherapy do not succumb to infection. The basis for residual protective immunity in lymphopenic patients is not known. We prospectively measured T-cell numbers, thymopoiesis, and T-cell memory in 73 children undergoing a 2-year chemotherapy regimen for acute lymphoblastic leukemia (ALL) and compared them to an age-matched cohort of 805 healthy children. Most patients had profound defects in CD4 and CD8 T-cell numbers at diagnosis that did not recover during the 2 years of therapy. Thymic output and the fraction of naive T cells were significantly lower than in healthy controls. However, the remaining T-cell compartment was enriched for antigen-experienced, memory T cells defined both by phenotype and by function. This relative sparing of T-cell memory may, in part, account for the maintenance of protective immunity in lymphopenic patients treated for ALL. Moreover, because the memory T-cell compartment is least affected by ALL and its treatment, strategies to induce immunity to pathogens or tumor antigens in cancer patients may be most successful if they seek to expand pre-existing memory T cells.",Clinical Trial,5353.0,29.0,Despite profound T-cell immunodeficiency most patients treated with chemotherapy do not succumb to infection The basis for residual protective immunity in lymphopenic patients is not known We prospectively measured T-cell numbers thymopoiesis and T-cell memory in 73 children undergoing a 2-year chemotherapy regimen for acute lymphoblastic ALL and compared them to an age-matched cohort of 805 healthy children Most patients had profound defects in CD4 and CD8 T-cell numbers at diagnosis that did not recover during the 2 years of therapy Thymic output and the fraction of naive T cells were significantly lower than in healthy controls However the remaining T-cell compartment was enriched for antigen-experienced memory T cells defined both by phenotype and by function This relative sparing of T-cell memory may in part account for the maintenance of protective immunity in lymphopenic patients treated for ALL Moreover because the memory T-cell compartment is least affected by ALL and its treatment strategies to induce immunity to pathogens or tumor antigens in cancer patients may be most successful if they seek to expand pre-existing memory T cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[550, 4399, 102, 31, 5323, 96, 7, 73, 5, 56, 1022, 44, 9025, 6, 930, 3, 877, 9, 753, 2864, 1604, 4, 16749, 7, 16, 44, 440, 21, 1143, 644, 102, 31, 1870, 28406, 2, 102, 31, 2407, 4, 803, 541, 479, 8, 18, 111, 56, 477, 9, 286, 1275, 62, 2, 72, 1370, 6, 35, 89, 655, 180, 1, 13628, 1331, 541, 96, 7, 42, 4399, 2945, 4, 1440, 2, 968, 102, 31, 1870, 28, 147, 17, 205, 44, 9966, 190, 3, 18, 60, 1, 36, 3572, 6911, 2, 3, 1509, 1, 2462, 102, 37, 11, 97, 280, 76, 4, 1331, 535, 137, 3, 1844, 102, 31, 3616, 10, 2220, 9, 448, 592, 2407, 102, 37, 395, 110, 20, 1005, 2, 20, 343, 26, 580, 1851, 1, 102, 31, 2407, 68, 4, 760, 1967, 9, 3, 1146, 1, 2864, 1604, 4, 16749, 7, 73, 9, 62, 1393, 408, 3, 2407, 102, 31, 3616, 16, 506, 1424, 20, 62, 2, 211, 24, 422, 6, 1290, 1604, 6, 9275, 15, 30, 1575, 4, 12, 7, 68, 40, 96, 1401, 492, 491, 6606, 6, 4082, 671, 1692, 2407, 102, 37]",1159.0,15920008,589
Cord blood transplant in childhood ALL.,Pediatric blood & cancer,Pediatr Blood Cancer,2005-12-01,"Optimal therapy for high risk and relapsed acute lymphoblastic leukemia (ALL) remains uncertain. Wider availability of cord blood from related and unrelated donors has prompted studies of its use for hematopoietic stem cell transplant (HSCT). We evaluated 26 consecutive cord blood transplants (CBT) for ALL performed at our center from 1996 to 2002 on studies using consistent conditioning therapy and graft-versus-host disease (GVHD) prophylaxis. Median patient age was 8.5 years (range, 0.5-24 year). Cord blood (CB) was from unrelated donors in 25/26 cases. Median CB nucleated cell dose was 3.26e7/kg (range, 0.8-12.9). With median follow-up of 548 days, 16/26 patients (62%) are event-free survivors. Acute GVHD developed in 14/24 evaluable patients, reaching grade III-IV in 7 patients. Chronic GVHD occurred in 10/22 evaluable patients. Multivariate analysis showed higher total nucleated cell dose per kilogram to be the strongest predictor of event-free survival. We conclude that CBT can effectively treat ALL in children with high risk features and following relapse.",Journal Article,5164.0,17.0,Optimal therapy for high risk and relapsed acute lymphoblastic ALL remains uncertain Wider availability of cord blood from related and unrelated donors has prompted studies of its use for hematopoietic stem cell transplant HSCT We evaluated 26 consecutive cord blood transplants CBT for ALL performed at our center from 1996 to 2002 on studies using consistent conditioning therapy and graft-versus-host disease GVHD prophylaxis Median patient age was 8.5 years range 0.5-24 year Cord blood CB was from unrelated donors in 25/26 cases Median CB nucleated cell dose was 3.26e7/kg range 0.8-12.9 With median follow-up of 548 days 16/26 patients 62 are event-free survivors Acute GVHD developed in 14/24 evaluable patients reaching grade III-IV in 7 patients Chronic GVHD occurred in 10/22 evaluable patients Multivariate analysis showed higher total nucleated cell dose per kilogram to be the strongest predictor of event-free survival We conclude that CBT can effectively treat ALL in children with high risk features and following relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[665, 36, 9, 64, 43, 2, 591, 286, 1275, 62, 469, 2717, 7771, 2550, 1, 1885, 315, 29, 139, 2, 2092, 2344, 71, 4140, 94, 1, 211, 119, 9, 1007, 452, 31, 941, 1703, 21, 194, 432, 935, 1885, 315, 4016, 7548, 9, 62, 173, 28, 114, 574, 29, 2648, 6, 1544, 23, 94, 75, 925, 1933, 36, 2, 1599, 185, 1204, 34, 1562, 2049, 52, 69, 89, 10, 66, 33, 60, 184, 13, 33, 259, 111, 1885, 315, 4723, 10, 29, 2092, 2344, 4, 243, 432, 140, 52, 4723, 9862, 31, 61, 10, 27, 54841, 503, 184, 13, 66, 133, 83, 5, 52, 166, 126, 1, 14573, 162, 245, 432, 7, 744, 32, 774, 115, 332, 286, 1562, 276, 4, 213, 259, 859, 7, 6168, 88, 316, 478, 4, 67, 7, 442, 1562, 489, 4, 79, 350, 859, 7, 331, 65, 224, 142, 181, 9862, 31, 61, 379, 6543, 6, 40, 3, 3311, 980, 1, 774, 115, 25, 21, 2060, 17, 7548, 122, 1856, 943, 62, 4, 541, 5, 64, 43, 404, 2, 366, 429]",1038.0,15929135,875
Periconceptional vitamin useand leukemia risk in children with Down syndrome: a Children's Oncology Group study.,Cancer,Cancer,2005-07-01,"Periconceptional vitamin supplementation reduces the risk of neural tube defects, and possibly may reduce the risk of certain childhood malignancies, including acute lymphoblastic leukemia (ALL). Because children with Down syndrome (DS) experience a 20-fold higher risk of leukemia than the general population, the authors evaluated whether periconceptional vitamin supplementation reduced the risk of leukemia in children with DS. From 1997 to 2002, 158 children ages birth-18 years with DS and acute leukemia (n = 61 children with acute myeloid leukemia [AML] and n = 97 children with ALL) were enrolled through the Children's Oncology Group in North America. Children with DS alone (n = 173) were identified through the cases' pediatric clinics and frequency matched to cases on age. Mothers of cases and controls completed a telephone interview that included questions regarding vitamin supplement use in the periconceptional period and after knowledge of pregnancy. A decreased risk of leukemia was observed with vitamin supplementation in the periconceptional period (odds ratio [OR] = 0.63; 95% confidence interval [95% CI], 0.39-1.00). When stratified by leukemia type, the reduced risk was observed for ALL (OR = 0.51; 95% CI, 0.30-0.89), but not for AML (OR = 0.92; 95% CI, 0.48-1.76). Compared with vitamin use in the periconceptional period, use only after knowledge of pregnancy was associated with an increased risk of leukemia (OR = 1.61; 95% CI, 1.00-2.58). This was observed for both ALL and AML. These data added to a growing body of evidence that suggests that periconceptional vitamin use may be protective in the development of certain childhood cancers.",Journal Article,5317.0,41.0,Periconceptional vitamin supplementation reduces the risk of neural tube defects and possibly may reduce the risk of certain childhood malignancies including acute lymphoblastic ALL Because children with Down syndrome DS experience a 20-fold higher risk of than the general population the authors evaluated whether periconceptional vitamin supplementation reduced the risk of in children with DS From 1997 to 2002 158 children ages birth-18 years with DS and acute n 61 children with acute myeloid AML and n 97 children with ALL were enrolled through the Children 's Oncology Group in North America Children with DS alone n 173 were identified through the cases pediatric clinics and frequency matched to cases on age Mothers of cases and controls completed a telephone interview that included questions regarding vitamin supplement use in the periconceptional period and after knowledge of pregnancy A decreased risk of was observed with vitamin supplementation in the periconceptional period odds ratio OR 0.63 95 confidence interval 95 CI 0.39-1.00 When stratified by type the reduced risk was observed for ALL OR 0.51 95 CI 0.30-0.89 but not for AML OR 0.92 95 CI 0.48-1.76 Compared with vitamin use in the periconceptional period use only after knowledge of pregnancy was associated with an increased risk of OR 1.61 95 CI 1.00-2.58 This was observed for both ALL and AML These data added to a growing body of evidence that suggests that periconceptional vitamin use may be protective in the development of certain childhood cancers,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26405, 1610, 3890, 2389, 3, 43, 1, 3922, 2330, 2945, 2, 2150, 68, 969, 3, 43, 1, 1840, 864, 441, 141, 286, 1275, 62, 408, 541, 5, 1328, 681, 3602, 730, 8, 179, 1116, 142, 43, 1, 76, 3, 1083, 266, 3, 738, 194, 317, 26405, 1610, 3890, 405, 3, 43, 1, 4, 541, 5, 3602, 29, 2341, 6, 1544, 5162, 541, 2165, 3809, 203, 60, 5, 3602, 2, 286, 78, 713, 541, 5, 286, 533, 329, 2, 78, 1015, 541, 5, 62, 11, 346, 298, 3, 541, 292, 413, 87, 4, 2669, 4010, 541, 5, 3602, 279, 78, 5785, 11, 108, 298, 3, 140, 815, 4736, 2, 675, 655, 6, 140, 23, 89, 8605, 1, 140, 2, 535, 781, 8, 4258, 4313, 17, 159, 1937, 666, 1610, 5836, 119, 4, 3, 26405, 727, 2, 50, 922, 1, 2290, 8, 340, 43, 1, 10, 164, 5, 1610, 3890, 4, 3, 26405, 727, 610, 197, 15, 13, 676, 48, 307, 268, 48, 58, 13, 587, 14, 2038, 198, 1173, 20, 267, 3, 405, 43, 10, 164, 9, 62, 15, 13, 725, 48, 58, 13, 201, 13, 887, 84, 44, 9, 329, 15, 13, 937, 48, 58, 13, 576, 14, 846, 72, 5, 1610, 119, 4, 3, 26405, 727, 119, 158, 50, 922, 1, 2290, 10, 41, 5, 35, 101, 43, 1, 15, 14, 713, 48, 58, 14, 2038, 18, 717, 26, 10, 164, 9, 110, 62, 2, 329, 46, 74, 1953, 6, 8, 1921, 642, 1, 241, 17, 844, 17, 26405, 1610, 119, 68, 40, 2864, 4, 3, 193, 1, 1840, 864, 163]",1537.0,15952191,212
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia.,Blood,Blood,2005-06-14,"Acute lymphoblastic leukemia (ALL) in infants is characterized by rearrangements of the mixed lineage leukemia (MLL) gene, drug resistance, and a poor treatment outcome. Therefore, novel therapeutic strategies are needed to improve prognosis. Recently, we showed that FLT3 is highly expressed in MLL rearranged ALL (MLL). Here we demonstrate FLT3 expression in infants with MLL (n = 41) to be significantly higher compared to both infant (n = 8; P < .001) and noninfant patients with ALL (n = 23; P = .001) carrying germline MLL genes. Furthermore, leukemic cells from infants with MLL were significantly more sensitive to the Fms-like tyrosine kinase 3 (FLT3) inhibitor PKC412 (N-benzoyl staurosporine) than noninfant ALL cells, and at least as sensitive as internal tandem duplication-positive (ITD+) AML cells. Surprisingly, activation loop mutations only occurred in about 3% (1 of 36) of the cases and no FLT3/ITDs were observed. However, measuring FLT3 phosphorylation in infants with MLL expressing varying levels of wild-type FLT3 revealed that high-level FLT3 expression is associated with ligand-independent FLT3 activation. This suggests that infant MLL cells displaying activated FLT3 as a result of overexpression can be targeted by FLT3 inhibitors such as PKC412. However, at concentrations of PKC412 minimally required to fully inhibit FLT3 phosphorylation, the cytotoxic effects were only fractional. Thus, PKC412-induced apoptosis in infant MLL cells is unlikely to be a consequence of FLT3 inhibition alone but may involve inhibition of multiple other kinases by this drug.",Journal Article,5334.0,117.0,Acute lymphoblastic ALL in infants is characterized by rearrangements of the mixed lineage MLL gene drug resistance and a poor treatment outcome Therefore novel therapeutic strategies are needed to improve prognosis Recently we showed that FLT3 is highly expressed in MLL rearranged ALL MLL Here we demonstrate FLT3 expression in infants with MLL n 41 to be significantly higher compared to both infant n 8 P .001 and noninfant patients with ALL n 23 P .001 carrying germline MLL genes Furthermore leukemic cells from infants with MLL were significantly more sensitive to the Fms-like tyrosine kinase 3 FLT3 inhibitor PKC412 N-benzoyl staurosporine than noninfant ALL cells and at least as sensitive as internal tandem duplication-positive ITD+ AML cells Surprisingly activation loop mutations only occurred in about 3 1 of 36 of the cases and no FLT3/ITDs were observed However measuring FLT3 phosphorylation in infants with MLL expressing varying levels of wild-type FLT3 revealed that high-level FLT3 expression is associated with ligand-independent FLT3 activation This suggests that infant MLL cells displaying activated FLT3 as a result of overexpression can be targeted by FLT3 inhibitors such as PKC412 However at concentrations of PKC412 minimally required to fully inhibit FLT3 phosphorylation the cytotoxic effects were only fractional Thus PKC412-induced apoptosis in infant MLL cells is unlikely to be a consequence of FLT3 inhibition alone but may involve inhibition of multiple other kinases by this drug,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 4, 5585, 16, 765, 20, 2072, 1, 3, 1739, 2542, 3049, 145, 234, 251, 2, 8, 334, 24, 228, 673, 229, 189, 422, 32, 575, 6, 401, 356, 761, 21, 224, 17, 1224, 16, 561, 570, 4, 3049, 3201, 62, 3049, 467, 21, 608, 1224, 55, 4, 5585, 5, 3049, 78, 605, 6, 40, 97, 142, 72, 6, 110, 8027, 78, 66, 19, 144, 2, 33724, 7, 5, 62, 78, 382, 19, 144, 2934, 1009, 3049, 214, 798, 2015, 37, 29, 5585, 5, 3049, 11, 97, 80, 745, 6, 3, 5516, 733, 564, 216, 27, 1224, 230, 7154, 78, 33599, 16292, 76, 33724, 62, 37, 2, 28, 506, 22, 745, 22, 2329, 2905, 4616, 109, 2837, 329, 37, 5819, 363, 4432, 138, 158, 489, 4, 545, 27, 14, 1, 511, 1, 3, 140, 2, 77, 1224, 21984, 11, 164, 137, 2978, 1224, 982, 4, 5585, 5, 3049, 1046, 2990, 148, 1, 955, 267, 1224, 553, 17, 64, 301, 1224, 55, 16, 41, 5, 1232, 306, 1224, 363, 26, 844, 17, 8027, 3049, 37, 6609, 735, 1224, 22, 8, 757, 1, 851, 122, 40, 238, 20, 1224, 222, 225, 22, 7154, 137, 28, 1003, 1, 7154, 2144, 616, 6, 1910, 1433, 1224, 982, 3, 759, 176, 11, 158, 7528, 631, 7154, 277, 351, 4, 8027, 3049, 37, 16, 3568, 6, 40, 8, 4177, 1, 1224, 297, 279, 84, 68, 3882, 297, 1, 232, 127, 1549, 20, 26, 234]",1519.0,15956279,595
Bayesian error-in-variable survival model for the analysis of GeneChip arrays.,Biometrics,Biometrics,2005-06-01,"DNA microarrays in conjunction with statistical models may help gain a deeper understanding of the molecular basis for specific diseases. An intense area of research is concerned with the identification of genes related to particular phenotypes. The technology, however, is subject to various sources of error that may lead to expression readings that are substantially different from the true transcript levels. Few methods for microarray data analysis have accounted for measurement error in a substantial way and that is the purpose of this investigation. We describe a Bayesian error-in-variable model for the analysis of microarray data from a clinical study of patients with acute lymphoblastic leukemia. We focus in particular on the problem of identifying genes whose expression patterns are associated with duration of remission. This is a question of great practical interest since relapse is a major concern in the treatment of this disease. We explore the effects of ignoring the uncertainty in the expression estimates on the selection and ranking of genes.",Journal Article,5347.0,14.0,DNA microarrays in conjunction with statistical models may help gain a deeper understanding of the molecular basis for specific diseases An intense area of research is concerned with the identification of genes related to particular phenotypes The technology however is subject to various sources of error that may lead to expression readings that are substantially different from the true transcript levels Few methods for microarray data analysis have accounted for measurement error in a substantial way and that is the purpose of this investigation We describe a Bayesian error-in-variable model for the analysis of microarray data from a clinical study of patients with acute lymphoblastic We focus in particular on the problem of identifying genes whose expression patterns are associated with duration of remission This is a question of great practical interest since relapse is a major concern in the treatment of this disease We explore the effects of ignoring the uncertainty in the expression estimates on the selection and ranking of genes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[261, 2774, 4, 3357, 5, 1050, 274, 68, 987, 1803, 8, 6029, 612, 1, 3, 219, 877, 9, 112, 1342, 35, 3933, 965, 1, 389, 16, 9415, 5, 3, 911, 1, 214, 139, 6, 1454, 2618, 3, 2033, 137, 16, 2974, 6, 747, 3375, 1, 3444, 17, 68, 1122, 6, 55, 12816, 17, 32, 2109, 338, 29, 3, 2501, 3268, 148, 1021, 636, 9, 1727, 74, 65, 47, 3688, 9, 2204, 3444, 4, 8, 1281, 2255, 2, 17, 16, 3, 743, 1, 26, 940, 21, 897, 8, 5032, 3444, 4, 1347, 202, 9, 3, 65, 1, 1727, 74, 29, 8, 38, 45, 1, 7, 5, 286, 1275, 21, 1222, 4, 1454, 23, 3, 2497, 1, 1386, 214, 1310, 55, 764, 32, 41, 5, 654, 1, 734, 26, 16, 8, 2840, 1, 2797, 3320, 1333, 1192, 429, 16, 8, 458, 2893, 4, 3, 24, 1, 26, 34, 21, 1645, 3, 176, 1, 26416, 3, 4004, 4, 3, 55, 1423, 23, 3, 881, 2, 11185, 1, 214]",1051.0,16011696,834
Genomic analysis in lymphoid leukemias.,Reviews in clinical and experimental hematology,Rev Clin Exp Hematol,2005-06-01,"The introduction of microarray analysis represents a revolution in the scientific field, allowing to investigate thousand of genes in a single experiment. Important biological insights have been revealed by this technique in several tumors: in acute lymphoblastic leukemia (ALL), these studies have allowed to identify specific patterns associated with known molecular abnormalities, as well as with phenotypic characteristics and with different prognostic features. In chronic lymphocytic leukemia (CLL), this approach has helped to dissect that this disease is a single entity with distinct variants that are characterized by a diverse IgVH mutational status, that can be discriminated by a small set of genes, has allowed to define a similarity between this disease and memory B cells and has also led to hypothesize that CLL cells from IgVH unmutated patients may be continuously stimulated in vivo, thus showing a gene profile that is reminiscent of the B cell receptor. In multiple myeloma (MM), gene expression profiles has provided insights into the disease and has offered the opportunity of stratifying patients according to the degree of aggressiveness of the disease. Current efforts are directed to the identification of patterns that may distinguish patients with a different outcome, thus providing useful prognostic information and to design experiments that may allow the identification of new therapeutic targets.",Journal Article,5347.0,1.0,The introduction of microarray analysis represents a revolution in the scientific field allowing to investigate thousand of genes in a single experiment Important biological insights have been revealed by this technique in several tumors in acute lymphoblastic ALL these studies have allowed to identify specific patterns associated with known molecular abnormalities as well as with phenotypic characteristics and with different prognostic features In chronic lymphocytic CLL this approach has helped to dissect that this disease is a single entity with distinct variants that are characterized by a diverse IgVH mutational status that can be discriminated by a small set of genes has allowed to define a similarity between this disease and memory B cells and has also led to hypothesize that CLL cells from IgVH unmutated patients may be continuously stimulated in vivo thus showing a gene profile that is reminiscent of the B cell receptor In multiple MM gene expression profiles has provided insights into the disease and has offered the opportunity of stratifying patients according to the degree of aggressiveness of the disease Current efforts are directed to the identification of patterns that may distinguish patients with a different outcome thus providing useful prognostic information and to design experiments that may allow the identification of new therapeutic targets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 2456, 1, 1727, 65, 1449, 8, 11030, 4, 3, 3138, 1067, 2952, 6, 963, 6161, 1, 214, 4, 8, 226, 8722, 305, 1037, 1957, 47, 85, 553, 20, 26, 1312, 4, 392, 57, 4, 286, 1275, 62, 46, 94, 47, 2313, 6, 255, 112, 764, 41, 5, 440, 219, 1171, 22, 149, 22, 5, 3290, 374, 2, 5, 338, 177, 404, 4, 442, 1193, 552, 26, 353, 71, 6156, 6, 10830, 17, 26, 34, 16, 8, 226, 2983, 5, 834, 839, 17, 32, 765, 20, 8, 1867, 14484, 1619, 156, 17, 122, 40, 8752, 20, 8, 302, 916, 1, 214, 71, 2313, 6, 1107, 8, 6700, 59, 26, 34, 2, 2407, 132, 37, 2, 71, 120, 836, 6, 4919, 17, 552, 37, 29, 14484, 7216, 7, 68, 40, 4285, 2816, 4, 386, 631, 2069, 8, 145, 800, 17, 16, 17726, 1, 3, 132, 31, 153, 4, 232, 321, 145, 55, 1241, 71, 1052, 1957, 237, 3, 34, 2, 71, 2216, 3, 2666, 1, 5035, 7, 768, 6, 3, 1444, 1, 3908, 1, 3, 34, 291, 1413, 32, 1166, 6, 3, 911, 1, 764, 17, 68, 3081, 7, 5, 8, 338, 228, 631, 1736, 999, 177, 487, 2, 6, 771, 2332, 17, 68, 1700, 3, 911, 1, 217, 189, 637]",1384.0,16027105,474
"JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.",Blood,Blood,2005-07-21,"An activating 1849G>T mutation of JAK2 (Janus kinase 2) tyrosine kinase was recently described in chronic myeloproliferative disorders (MPDs). Its role in other hematologic neoplasms is unclear. We developed a quantitative pyrosequencing assay and analyzed 374 samples of hematologic neoplasms. The mutation was frequent in polycythemia vera (PV) (86%) and myelofibrosis (95%) but less prevalent in acute myeloid leukemia (AML) with an antecedent PV or myelofibrosis (5 [36%] of 14 patients). JAK2 mutation was also detected in 3 (19%) of 16 patients with Philadelphia-chromosome (Ph)-negative chronic myelogenous leukemia (CML), 2 (18%) of 11 patients with megakaryocytic AML, 7 (13%) of 52 patients with chronic myelomonocytic leukemia, and 1 (1%) of 68 patients with myelodysplastic syndromes. No mutation was found in Ph(+)CML (99 patients), AML M0-M6 (28 patients), or acute lymphoblastic leukemia (20 patients). We conclude that the JAK2 1849G>T mutation is common in Ph(-) MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias.",Journal Article,5297.0,302.0,An activating 1849G T mutation of JAK2 Janus kinase 2 tyrosine kinase was recently described in chronic disorders MPDs Its role in other hematologic neoplasms is unclear We developed a quantitative pyrosequencing assay and analyzed 374 samples of hematologic neoplasms The mutation was frequent in polycythemia vera PV 86 and myelofibrosis 95 but less prevalent in acute myeloid AML with an antecedent PV or myelofibrosis 5 36 of 14 patients JAK2 mutation was also detected in 3 19 of 16 patients with Philadelphia-chromosome Ph -negative chronic myelogenous CML 2 18 of 11 patients with megakaryocytic AML 7 13 of 52 patients with chronic myelomonocytic and 1 1 of 68 patients with syndromes No mutation was found in Ph CML 99 patients AML M0-M6 28 patients or acute lymphoblastic 20 patients We conclude that the JAK2 1849G T mutation is common in Ph MPD but not critical for transformation to the acute phase of these diseases and that it is generally rare in aggressive leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[35, 1616, 44054, 102, 258, 1, 2509, 6191, 216, 18, 564, 216, 10, 761, 1027, 4, 442, 1997, 24840, 211, 200, 4, 127, 813, 1179, 16, 1200, 21, 276, 8, 1156, 6031, 719, 2, 311, 10349, 347, 1, 813, 1179, 3, 258, 10, 908, 4, 5755, 5756, 3328, 868, 2, 4637, 48, 84, 299, 2485, 4, 286, 533, 329, 5, 35, 8775, 3328, 15, 4637, 33, 511, 1, 213, 7, 2509, 258, 10, 120, 530, 4, 27, 326, 1, 245, 7, 5, 3006, 1170, 2058, 199, 442, 2194, 903, 18, 203, 1, 175, 7, 5, 14385, 329, 67, 233, 1, 653, 7, 5, 442, 5451, 2, 14, 14, 1, 806, 7, 5, 2040, 77, 258, 10, 204, 4, 2058, 903, 1058, 7, 329, 4591, 30814, 339, 7, 15, 286, 1275, 179, 7, 21, 2060, 17, 3, 2509, 44054, 102, 258, 16, 186, 4, 2058, 7712, 84, 44, 740, 9, 1392, 6, 3, 286, 124, 1, 46, 1342, 2, 17, 192, 16, 1228, 622, 4, 571, 2792]",983.0,16037387,3
"AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.",Cancer,Cancer,2005-09-01,"Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic leukemia (ALL) either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response. The authors investigated the effects of a newly designed Bcr-Abl inhibitor, AMN107, by comparing its in vitro inhibitory potency on p190 Bcr-Abl ALL cell lines with that of imatinib. In two Philadelphia (Ph)-positive ALL cell lines, AMN107 was found to be 30-40 times more potent than imatinib in inhibiting cellular proliferation. AMN107 was also more effective than imatinib in inhibiting phosphorylation of p190 Bcr-Abl tyrosine kinase in cell lines and primary ALL cells. The inhibition of cellular proliferation was associated with the induction of apoptosis in only one of the cell lines. No activity was observed in cell lines lacking the BCR-ABL genotype. The results of the current study suggest the superior potency of AMN107 compared with imatinib in Ph-positive ALL and support clinical trials of AMN107 in patients with Ph-positive ALL.",Journal Article,5255.0,64.0,Previous studies have shown that patients with Bcr-Abl-positive acute lymphoblastic ALL either have primary disease that is refractory to imatinib mesylate or develop disease recurrence after an initial response The authors investigated the effects of a newly designed Bcr-Abl inhibitor AMN107 by comparing its in vitro inhibitory potency on p190 Bcr-Abl ALL cell lines with that of imatinib In two Philadelphia Ph -positive ALL cell lines AMN107 was found to be 30-40 times more potent than imatinib in inhibiting cellular proliferation AMN107 was also more effective than imatinib in inhibiting phosphorylation of p190 Bcr-Abl tyrosine kinase in cell lines and primary ALL cells The inhibition of cellular proliferation was associated with the induction of apoptosis in only one of the cell lines No activity was observed in cell lines lacking the BCR-ABL genotype The results of the current study suggest the superior potency of AMN107 compared with imatinib in Ph-positive ALL and support clinical trials of AMN107 in patients with Ph-positive ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[698, 94, 47, 443, 17, 7, 5, 1062, 1425, 109, 286, 1275, 62, 361, 47, 86, 34, 17, 16, 430, 6, 577, 2347, 15, 690, 34, 146, 50, 35, 388, 51, 3, 738, 565, 3, 176, 1, 8, 732, 1114, 1062, 1425, 230, 12189, 20, 1430, 211, 4, 439, 1810, 3593, 23, 18813, 1062, 1425, 62, 31, 285, 5, 17, 1, 577, 4, 100, 3006, 2058, 109, 62, 31, 285, 12189, 10, 204, 6, 40, 201, 327, 1072, 80, 1157, 76, 577, 4, 2062, 763, 457, 12189, 10, 120, 80, 323, 76, 577, 4, 2062, 982, 1, 18813, 1062, 1425, 564, 216, 4, 31, 285, 2, 86, 62, 37, 3, 297, 1, 763, 457, 10, 41, 5, 3, 504, 1, 351, 4, 158, 104, 1, 3, 31, 285, 77, 128, 10, 164, 4, 31, 285, 1941, 3, 1062, 1425, 1183, 3, 99, 1, 3, 291, 45, 309, 3, 1123, 3593, 1, 12189, 72, 5, 577, 4, 2058, 109, 62, 2, 538, 38, 143, 1, 12189, 4, 7, 5, 2058, 109, 62]",1051.0,16078266,222
"The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia.",Blood,Blood,2005-08-04,"Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies. Recently, we and others identified a single recurrent somatic activating mutation (JAK2V617F) in the Janus kinase 2 (JAK2) tyrosine kinase in the myeloproliferative disorders (MPDs) polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML)/atypical chronic myelogenous leukemia (aCML), myelodysplastic syndrome (MDS), B-lineage acute lymphoblastic leukemia (ALL), T-cell ALL, and chronic lymphocytic leukemia (CLL). Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML, 3 of whom had a preceding MPD. JAK2V617F mutations were identified in 9 (7.8%) of 116 CMML/a CML samples, and in 2 (4.2%) of 48 MDS samples. We did not identify the JAK2V617F disease allele in B-lineage ALL (n = 83), T-cell ALL (n = 93), or CLL (n = 45). These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies.",Clinical Trial,5283.0,292.0,Activating mutations in tyrosine kinases have been identified in hematopoietic and nonhematopoietic malignancies Recently we and others identified a single recurrent somatic activating mutation JAK2V617F in the Janus kinase 2 JAK2 tyrosine kinase in the disorders MPDs polycythemia vera essential thrombocythemia and myeloid metaplasia with myelofibrosis We used direct sequence analysis to determine if the JAK2V617F mutation was present in acute myeloid AML chronic myelomonocytic CMML /atypical chronic myelogenous aCML syndrome MDS B-lineage acute lymphoblastic ALL T-cell ALL and chronic lymphocytic CLL Analysis of 222 patients with AML identified JAK2V617F mutations in 4 patients with AML 3 of whom had a preceding MPD JAK2V617F mutations were identified in 9 7.8 of 116 CMML/a CML samples and in 2 4.2 of 48 MDS samples We did not identify the JAK2V617F disease allele in B-lineage ALL n 83 T-cell ALL n 93 or CLL n 45 These data indicate that the JAK2V617F allele is present in acute and chronic myeloid malignancies but not in lymphoid malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1616, 138, 4, 564, 1549, 47, 85, 108, 4, 1007, 2, 19463, 441, 761, 21, 2, 1749, 108, 8, 226, 387, 1119, 1616, 258, 9061, 4, 3, 6191, 216, 18, 2509, 564, 216, 4, 3, 1997, 24840, 5755, 5756, 1452, 8962, 2, 533, 6054, 5, 4637, 21, 95, 1196, 1532, 65, 6, 223, 492, 3, 9061, 258, 10, 364, 4, 286, 533, 329, 442, 5451, 3382, 1973, 442, 2194, 21345, 681, 1223, 132, 2542, 286, 1275, 62, 102, 31, 62, 2, 442, 1193, 552, 65, 1, 5647, 7, 5, 329, 108, 9061, 138, 4, 39, 7, 5, 329, 27, 1, 953, 42, 8, 5892, 7712, 9061, 138, 11, 108, 4, 83, 67, 66, 1, 3790, 3382, 8, 903, 347, 2, 4, 18, 39, 18, 1, 576, 1223, 347, 21, 205, 44, 255, 3, 9061, 34, 1254, 4, 132, 2542, 62, 78, 852, 102, 31, 62, 78, 966, 15, 552, 78, 512, 46, 74, 1008, 17, 3, 9061, 1254, 16, 364, 4, 286, 2, 442, 533, 441, 84, 44, 4, 2303, 441]",1059.0,16081687,7
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.,Blood,Blood,2005-08-16,"The international acute lymphoblastic leukemia (ALL) study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL. All patients received identical induction therapy, and 91% achieved complete remission (CR). Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation; the others were randomly assigned to autologous transplantation or to consolidation/maintenance therapy for 2.5 years. Patients who did not achieve CR after induction had an overall survival rate of 5% compared with 45% for patients who achieved CR. Factors at diagnosis predictive of overall survival and disease-free survival were age (P = .001), white blood cell count less than 30 x 10(9)/L for B lineage or less than 100 x 10(9)/L for T lineage (P = .001) and immunophenotype, T lineage versus B lineage (P = .001). The data demonstrate that achieving CR with induction therapy is indispensable for long-term survival in adult patients with ALL. Furthermore, with a response rate greater than 90%, the induction regimen was highly efficacious as remission-inducing therapy. This large database has validated several previously identified independent prognostic factors in ALL, such as age, white blood cell count at presentation, cytogenetics, and immunophenotype. However, the achievement of CR within 4 weeks does not appear to be an independent prognostic factor.",Comparative Study,5271.0,411.0,The international acute lymphoblastic ALL study was designed to prospectively define the optimal therapy for adults 60 years of age or younger with newly diagnosed ALL All patients received identical induction therapy and 91 achieved complete remission CR Patients 50 years of age or younger with a compatible sibling were assigned to undergo allogeneic transplantation the others were randomly assigned to autologous transplantation or to consolidation/maintenance therapy for 2.5 years Patients who did not achieve CR after induction had an overall survival rate of 5 compared with 45 for patients who achieved CR Factors at diagnosis predictive of overall survival and disease-free survival were age P .001 white blood cell count less than 30 x 10 9 /L for B lineage or less than 100 x 10 9 /L for T lineage P .001 and immunophenotype T lineage versus B lineage P .001 The data demonstrate that achieving CR with induction therapy is indispensable for long-term survival in adult patients with ALL Furthermore with a response rate greater than 90 the induction regimen was highly efficacious as remission-inducing therapy This large database has validated several previously identified independent prognostic factors in ALL such as age white blood cell count at presentation cytogenetics and immunophenotype However the achievement of CR within 4 weeks does not appear to be an independent prognostic factor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 944, 286, 1275, 62, 45, 10, 1114, 6, 1143, 1107, 3, 665, 36, 9, 857, 335, 60, 1, 89, 15, 773, 5, 732, 265, 62, 62, 7, 103, 3038, 504, 36, 2, 970, 513, 236, 734, 684, 7, 212, 60, 1, 89, 15, 773, 5, 8, 7293, 3684, 11, 896, 6, 1251, 1063, 497, 3, 1749, 11, 1108, 896, 6, 1028, 497, 15, 6, 2173, 1146, 36, 9, 18, 33, 60, 7, 54, 205, 44, 1359, 684, 50, 504, 42, 35, 63, 25, 116, 1, 33, 72, 5, 512, 9, 7, 54, 513, 684, 130, 28, 147, 464, 1, 63, 25, 2, 34, 115, 25, 11, 89, 19, 144, 886, 315, 31, 1276, 299, 76, 201, 1006, 79, 83, 805, 9, 132, 2542, 15, 299, 76, 394, 1006, 79, 83, 805, 9, 102, 2542, 19, 144, 2, 5496, 102, 2542, 185, 132, 2542, 19, 144, 3, 74, 608, 17, 1785, 684, 5, 504, 36, 16, 13338, 9, 319, 337, 25, 4, 780, 7, 5, 62, 798, 5, 8, 51, 116, 378, 76, 424, 3, 504, 477, 10, 561, 3289, 22, 734, 1958, 36, 26, 375, 609, 71, 938, 392, 373, 108, 306, 177, 130, 4, 62, 225, 22, 89, 886, 315, 31, 1276, 28, 1031, 2510, 2, 5496, 137, 3, 5088, 1, 684, 262, 39, 244, 1097, 44, 1322, 6, 40, 35, 306, 177, 161]",1410.0,16105981,826
Changes in bone mineral density in survivors of childhood acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2006-01-01,"There is little information about factors modulating bone mineral density (BMD) in survivors of childhood acute lymphoblastic leukemia (ALL). We analyzed data from 57 survivors (26 male, 52 Caucasian) who underwent two serial quantitative computed tomography (QCT) studies of BMD. Using multiple linear regression, we evaluated the association of BMD change with demographic variables, treatment history, hormone therapy, exercise, and tobacco and alcohol use. The median age was 3.4 years (range, 0.9-17.4 years) at diagnosis of ALL; the median age at the first QCT (Study I) was 15.0 years (range, 10.6-31.0 years) and at the second QCT (Study II) was 18.2 years (range, 14.2-35.3 years). Mean height increased 4.7 cm and mean weight increased 8.8 kg between Studies I and II. While the mean BMD increased 9.33 mg/cc (P = 0.003), the BMD Z-score increased only slightly (0.21 SD, P = 0.035). Cortical bone density increased significantly (approximately 25.3 mg/cc; P = 0.001), but the ratio of trabecular to cortical BMD decreased significantly (P = 0.045). Factors independently associated with unfavorable BMD changes included older age at diagnosis (P = 0.001), female sex (P = 0.018), and nutritional supplementation (0.032). Alcohol (P = 0.009) was an unfavorable factor in a univariable analysis. Bone mineral accretion during adolescence is attenuated in childhood ALL survivors by a comparative deficit in trabecular versus cortical bone deposition. BMD is influenced favorably by exercise in early adolescence and unfavorably by the use of nutritional supplements and alcohol. These results provide new information about behavioral factors that affect bone accrual in survivors of childhood ALL and warrant definitive evaluation in a larger cohort.",Journal Article,5133.0,66.0,There is little information about factors modulating mineral density BMD in survivors of childhood acute lymphoblastic ALL We analyzed data from 57 survivors 26 male 52 Caucasian who underwent two serial quantitative computed tomography QCT studies of BMD Using multiple linear regression we evaluated the association of BMD change with demographic variables treatment history hormone therapy exercise and tobacco and alcohol use The median age was 3.4 years range 0.9-17.4 years at diagnosis of ALL the median age at the first QCT Study I was 15.0 years range 10.6-31.0 years and at the second QCT Study II was 18.2 years range 14.2-35.3 years Mean height increased 4.7 cm and mean weight increased 8.8 kg between Studies I and II While the mean BMD increased 9.33 mg/cc P 0.003 the BMD Z-score increased only slightly 0.21 SD P 0.035 Cortical density increased significantly approximately 25.3 mg/cc P 0.001 but the ratio of trabecular to cortical BMD decreased significantly P 0.045 Factors independently associated with unfavorable BMD changes included older age at diagnosis P 0.001 female sex P 0.018 and nutritional supplementation 0.032 Alcohol P 0.009 was an unfavorable factor in a univariable analysis mineral accretion during adolescence is attenuated in childhood ALL survivors by a comparative deficit in trabecular versus cortical deposition BMD is influenced favorably by exercise in early adolescence and unfavorably by the use of nutritional supplements and alcohol These results provide new information about behavioral factors that affect accrual in survivors of childhood ALL and warrant definitive evaluation in a larger cohort,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[125, 16, 1215, 487, 545, 130, 3712, 5033, 1263, 3503, 4, 332, 1, 864, 286, 1275, 62, 21, 311, 74, 29, 696, 332, 432, 1045, 653, 3229, 54, 208, 100, 2108, 1156, 1220, 872, 19031, 94, 1, 3503, 75, 232, 1646, 320, 21, 194, 3, 248, 1, 3503, 707, 5, 1540, 682, 24, 532, 785, 36, 2277, 2, 2607, 2, 2197, 119, 3, 52, 89, 10, 27, 39, 60, 184, 13, 83, 269, 39, 60, 28, 147, 1, 62, 3, 52, 89, 28, 3, 157, 19031, 45, 70, 10, 167, 13, 60, 184, 79, 49, 456, 13, 60, 2, 28, 3, 419, 19031, 45, 215, 10, 203, 18, 60, 184, 213, 18, 465, 27, 60, 313, 4594, 101, 39, 67, 494, 2, 313, 924, 101, 66, 66, 503, 59, 94, 70, 2, 215, 369, 3, 313, 3503, 101, 83, 466, 81, 1951, 19, 13, 1421, 3, 3503, 3905, 368, 101, 158, 3223, 13, 239, 1270, 19, 13, 4514, 4500, 1263, 101, 97, 705, 243, 27, 81, 1951, 19, 13, 144, 84, 3, 197, 1, 12853, 6, 4500, 3503, 340, 97, 19, 13, 4918, 130, 1042, 41, 5, 2483, 3503, 400, 159, 434, 89, 28, 147, 19, 13, 144, 1061, 1035, 19, 13, 4047, 2, 5082, 3890, 13, 4708, 2197, 19, 13, 2376, 10, 35, 2483, 161, 4, 8, 4084, 65, 5033, 44082, 190, 6964, 16, 2656, 4, 864, 62, 332, 20, 8, 2352, 6819, 4, 12853, 185, 4500, 6686, 3503, 16, 2574, 5001, 20, 2277, 4, 191, 6964, 2, 44083, 20, 3, 119, 1, 5082, 6600, 2, 2197, 46, 99, 377, 217, 487, 545, 4166, 130, 17, 1158, 2262, 4, 332, 1, 864, 62, 2, 2946, 1057, 451, 4, 8, 1077, 180]",1649.0,16106430,185
Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children's Cancer Group study.,Blood,Blood,2005-08-18,"We assessed the outcome of children with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) receiving contemporary risk-based therapy by evaluating clinical and biologic features and outcome of children with ALL, with or without DS, enrolled in Children's Cancer Group (CCG) protocols between 1983 and 1995. Comparison of characteristics of children with ALL with (ALL-DS; n = 179) or without (ALL-NDS; n = 8268) DS showed no differences in initial white blood cell (WBC) count, central nervous system disease, and risk group. Children with ALL-DS did not present with unfavorable translocations and were older than 1 year of age at diagnosis with ALL. Event-free (56% vs 74%; P < .001) and disease-free (55% vs 73%; P < .001) survival at 10 years was significantly lower in the standard-risk ALL-DS population compared with ALL-NDS, but not in high-risk ALL-DS population (event-free survival, 62% vs 59%; P = .9; disease-free survival, 64% vs 59%; P = .9), and these differences persisted regardless of treatment era (early era [1983-1989] vs recent era [1989-1995]). Multivariate analysis revealed that presence of DS demonstrated an independent significant adverse prognostic effect for the standard-risk population, but not for the high-risk patients. These results suggest that intensification of therapy for patients with ALL-DS is needed to maintain outcome comparable with those of ALL-NDS patients.",Journal Article,5269.0,98.0,We assessed the outcome of children with Down syndrome DS and acute lymphoblastic ALL receiving contemporary risk-based therapy by evaluating clinical and biologic features and outcome of children with ALL with or without DS enrolled in Children 's Cancer Group CCG protocols between 1983 and 1995 Comparison of characteristics of children with ALL with ALL-DS n 179 or without ALL-NDS n 8268 DS showed no differences in initial white blood cell WBC count central nervous system disease and risk group Children with ALL-DS did not present with unfavorable translocations and were older than 1 year of age at diagnosis with ALL Event-free 56 vs 74 P .001 and disease-free 55 vs 73 P .001 survival at 10 years was significantly lower in the standard-risk ALL-DS population compared with ALL-NDS but not in high-risk ALL-DS population event-free survival 62 vs 59 P .9 disease-free survival 64 vs 59 P .9 and these differences persisted regardless of treatment era early era 1983-1989 vs recent era 1989-1995 Multivariate analysis revealed that presence of DS demonstrated an independent significant adverse prognostic effect for the standard-risk population but not for the high-risk patients These results suggest that intensification of therapy for patients with ALL-DS is needed to maintain outcome comparable with those of ALL-NDS patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 275, 3, 228, 1, 541, 5, 1328, 681, 3602, 2, 286, 1275, 62, 357, 2667, 43, 90, 36, 20, 1435, 38, 2, 1283, 404, 2, 228, 1, 541, 5, 62, 5, 15, 187, 3602, 346, 4, 541, 292, 12, 87, 9457, 2189, 59, 6656, 2, 2323, 1155, 1, 374, 1, 541, 5, 62, 5, 62, 3602, 78, 5977, 15, 187, 62, 30830, 78, 55021, 3602, 224, 77, 362, 4, 388, 886, 315, 31, 4685, 1276, 854, 1880, 398, 34, 2, 43, 87, 541, 5, 62, 3602, 205, 44, 364, 5, 2483, 3262, 2, 11, 434, 76, 14, 111, 1, 89, 28, 147, 5, 62, 774, 115, 664, 105, 794, 19, 144, 2, 34, 115, 614, 105, 803, 19, 144, 25, 28, 79, 60, 10, 97, 280, 4, 3, 260, 43, 62, 3602, 266, 72, 5, 62, 30830, 84, 44, 4, 64, 43, 62, 3602, 266, 774, 115, 25, 744, 105, 728, 19, 83, 34, 115, 25, 660, 105, 728, 19, 83, 2, 46, 362, 3760, 1583, 1, 24, 1713, 191, 1713, 6656, 3965, 105, 435, 1713, 3965, 2323, 331, 65, 553, 17, 463, 1, 3602, 264, 35, 306, 93, 290, 177, 254, 9, 3, 260, 43, 266, 84, 44, 9, 3, 64, 43, 7, 46, 99, 309, 17, 5091, 1, 36, 9, 7, 5, 62, 3602, 16, 575, 6, 3040, 228, 1279, 5, 135, 1, 62, 30830, 7]",1341.0,16109782,808
FLT3 internal tandem duplication mutations induce myeloproliferative or lymphoid disease in a transgenic mouse model.,Oncogene,Oncogene,2005-11-01,"Activating FMS-like tyrosine kinase 3 (FLT3) mutations have been identified in approximately 30% of patients with acute myelogenous leukemia (AML), and recently in a smaller subset of patients with acute lymphoblastic leukemia (ALL). To explore the in vivo consequences of an activating FLT3 internal tandem duplication mutation (FLT3-ITD), we created a transgenic mouse model in which FLT3-ITD was expressed under the control of the vav hematopoietic promoter. Five independent lines of vav-FLT3-ITD transgenic mice developed a myeloproliferative disease with high penetrance and a disease latency of 6-12 months. The phenotype was characterized by splenomegaly, megakaryocytic hyperplasia, and marked thrombocythemia, but without leukocytosis, polycythemia, or marrow fibrosis, displaying features reminiscent of the human disease essential thrombocythemia (ET). Clonal immature B- or T-lymphoid disease was observed in two additional founder mice, respectively, that could be secondarily transplanted to recipient mice that rapidly developed lymphoid disease. Treatment of these mice with the FLT3 tyrosine kinase inhibitor, PKC412, resulted in suppression of disease and a statistically significant prolongation of survival. These results demonstrate that FLT3-ITD is capable of inducing myeloproliferative as well as lymphoid disease, and indicate that small-molecule tyrosine kinase inhibitors may be an effective treatment for lymphoid malignancies in humans that are associated with activating mutations in FLT3.",Journal Article,5194.0,46.0,Activating FMS-like tyrosine kinase 3 FLT3 mutations have been identified in approximately 30 of patients with acute myelogenous AML and recently in a smaller subset of patients with acute lymphoblastic ALL To explore the in vivo consequences of an activating FLT3 internal tandem duplication mutation FLT3-ITD we created a transgenic mouse model in which FLT3-ITD was expressed under the control of the vav hematopoietic promoter Five independent lines of vav-FLT3-ITD transgenic mice developed a disease with high penetrance and a disease latency of 6-12 months The phenotype was characterized by splenomegaly megakaryocytic hyperplasia and marked thrombocythemia but without leukocytosis polycythemia or marrow fibrosis displaying features reminiscent of the human disease essential thrombocythemia ET Clonal immature B- or T-lymphoid disease was observed in two additional founder mice respectively that could be secondarily transplanted to recipient mice that rapidly developed lymphoid disease Treatment of these mice with the FLT3 tyrosine kinase inhibitor PKC412 resulted in suppression of disease and a statistically significant prolongation of survival These results demonstrate that FLT3-ITD is capable of inducing as well as lymphoid disease and indicate that small-molecule tyrosine kinase inhibitors may be an effective treatment for lymphoid malignancies in humans that are associated with activating mutations in FLT3,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1616, 5516, 733, 564, 216, 27, 1224, 138, 47, 85, 108, 4, 705, 201, 1, 7, 5, 286, 2194, 329, 2, 761, 4, 8, 2170, 697, 1, 7, 5, 286, 1275, 62, 6, 1645, 3, 4, 386, 3255, 1, 35, 1616, 1224, 2329, 2905, 4616, 258, 1224, 2837, 21, 2466, 8, 2862, 830, 202, 4, 92, 1224, 2837, 10, 570, 669, 3, 182, 1, 3, 37095, 1007, 973, 365, 306, 285, 1, 37095, 1224, 2837, 2862, 399, 276, 8, 34, 5, 64, 4792, 2, 8, 34, 5301, 1, 49, 133, 53, 3, 1005, 10, 765, 20, 6364, 14385, 3176, 2, 2003, 8962, 84, 187, 7463, 5755, 15, 581, 3000, 6609, 404, 17726, 1, 3, 171, 34, 1452, 8962, 2022, 1946, 5733, 132, 15, 102, 2303, 34, 10, 164, 4, 100, 402, 7243, 399, 106, 17, 359, 40, 12974, 4600, 6, 5783, 399, 17, 1755, 276, 2303, 34, 24, 1, 46, 399, 5, 3, 1224, 564, 216, 230, 7154, 627, 4, 1332, 1, 34, 2, 8, 712, 93, 4464, 1, 25, 46, 99, 608, 17, 1224, 2837, 16, 2787, 1, 1958, 22, 149, 22, 2303, 34, 2, 1008, 17, 302, 1354, 564, 216, 222, 68, 40, 35, 323, 24, 9, 2303, 441, 4, 3218, 17, 32, 41, 5, 1616, 138, 4, 1224]",1433.0,16116483,529
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.,Blood,Blood,2005-08-25,"Angiogenesis plays an important role in solid tumors and hematologic malignancies. The prognostic significance of angiogenic factors in adult acute lymphoblastic leukemia (ALL) remains ambiguous. We therefore analyzed the impact of angiogenic factor levels on overall survival of newly diagnosed adult ALL patients. Plasma levels of vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), interleukin-1 receptor alpha (IL-1Ralpha), IL-6, IL-8, VEGF receptors VEGFR1 and VEGFR2, and thrombopoietin (TPO) were measured in plasma samples of 95 patients by enzyme-linked immunosorbent assay (ELISA). In a univariate Cox proportional hazards model, higher levels of IL-1Ralpha, IL-8, VEGFR1, and VEGFR2 were predictive of poor survival. In contrast, higher levels of VEGF were predictive of longer survival, and higher levels of bFGF suggested a similar trend (P = .09). The multivariate model simultaneously included VEGF (relative risk [RR] for death, 8.01; P = .001 for levels less than or equal to 19.5 pg/mL), IL-1Ralpha (RR, 5.12; P = .007 for levels greater than 373 pg/mL), and VEGFR2 (RR, 4.01; P = .04 for levels greater than 8222 pg/mL) as independent factors for survival. Of interest is the association of high levels of VEGF with good prognosis and higher levels of VEGF receptors with poor outcome. These data reflect the complexity by which angiogenic factors may affect the clinical behavior of patients with ALL, and this complexity should be considered in any therapeutic strategy incorporating antiangiogenic agents.",Journal Article,5262.0,60.0,Angiogenesis plays an important role in solid tumors and hematologic malignancies The prognostic significance of angiogenic factors in adult acute lymphoblastic ALL remains ambiguous We therefore analyzed the impact of angiogenic factor levels on overall survival of newly diagnosed adult ALL patients Plasma levels of vascular endothelial growth factor VEGF basic fibroblast growth factor bFGF interleukin-1 receptor alpha IL-1Ralpha IL-6 IL-8 VEGF receptors VEGFR1 and VEGFR2 and thrombopoietin TPO were measured in plasma samples of 95 patients by enzyme-linked immunosorbent assay ELISA In a univariate Cox proportional hazards model higher levels of IL-1Ralpha IL-8 VEGFR1 and VEGFR2 were predictive of poor survival In contrast higher levels of VEGF were predictive of longer survival and higher levels of bFGF suggested a similar trend P .09 The multivariate model simultaneously included VEGF relative risk RR for death 8.01 P .001 for levels less than or equal to 19.5 pg/mL IL-1Ralpha RR 5.12 P .007 for levels greater than 373 pg/mL and VEGFR2 RR 4.01 P .04 for levels greater than 8222 pg/mL as independent factors for survival Of interest is the association of high levels of VEGF with good prognosis and higher levels of VEGF receptors with poor outcome These data reflect the complexity by which angiogenic factors may affect the clinical behavior of patients with ALL and this complexity should be considered in any therapeutic strategy incorporating antiangiogenic agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1056, 1698, 35, 305, 200, 4, 537, 57, 2, 813, 441, 3, 177, 724, 1, 2068, 130, 4, 780, 286, 1275, 62, 469, 11286, 21, 673, 311, 3, 345, 1, 2068, 161, 148, 23, 63, 25, 1, 732, 265, 780, 62, 7, 554, 148, 1, 756, 845, 129, 161, 618, 2795, 3758, 129, 161, 7964, 1603, 14, 153, 950, 501, 38009, 501, 49, 501, 66, 618, 1186, 7952, 2, 4609, 2, 15494, 14110, 11, 644, 4, 554, 347, 1, 48, 7, 20, 1644, 1199, 5339, 719, 3664, 4, 8, 880, 418, 831, 1017, 202, 142, 148, 1, 501, 38009, 501, 66, 7952, 2, 4609, 11, 464, 1, 334, 25, 4, 748, 142, 148, 1, 618, 11, 464, 1, 589, 25, 2, 142, 148, 1, 7964, 1148, 8, 288, 853, 19, 1730, 3, 331, 202, 3074, 159, 618, 580, 43, 861, 9, 273, 66, 355, 19, 144, 9, 148, 299, 76, 15, 2997, 6, 326, 33, 3234, 542, 501, 38009, 861, 33, 133, 19, 1999, 9, 148, 378, 76, 9342, 3234, 542, 2, 4609, 861, 39, 355, 19, 755, 9, 148, 378, 76, 55032, 3234, 542, 22, 306, 130, 9, 25, 1, 1333, 16, 3, 248, 1, 64, 148, 1, 618, 5, 1178, 356, 2, 142, 148, 1, 618, 1186, 5, 334, 228, 46, 74, 2694, 3, 3082, 20, 92, 2068, 130, 68, 1158, 3, 38, 1710, 1, 7, 5, 62, 2, 26, 3082, 257, 40, 515, 4, 500, 189, 692, 2570, 2168, 183]",1488.0,16123221,909
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications.,Blood,Blood,2005-09-13,"We evaluated the expression of 2 members of the Syk family, ZAP-70 and Syk, in acute lymphoblastic leukemia (ALL) samples, using data derived from a series of 33 T-ALL and 95 B-lineage adult ALL patients analyzed by oligonucleotide arrays. Of the B-lineage ALL cases, 37 were BCR/ABL+, 10 were ALL1/AF4+, 5 were E2A/PBX1+, and 43 carried no known molecular abnormality. ZAP-70 was highly expressed in T-ALL. A high ZAP-70 expression was also found in a proportion of B-lineage ALL, the highest levels being associated with the E2A/PBX1+ group and the lowest with ALL1/AF4+ cases (P < .001). A higher ZAP-70 expression was also observed in the pre-B group (P < .001). Remarkably, Syk expression was always preserved, suggesting that ZAP-70 expression is not substitutive of Syk. At the protein level, ZAP-70 was evaluated on 39 newly diagnosed ALL patients (25 adults, 14 children) and was detected in 23 cases (59%). ZAP-70 expression was consistently found in Ig mu+ cases. Evaluation of long-term outcome in cases without molecular abnormalities showed that the higher levels of ZAP-70 were coupled to a higher relapse rate. In ALL, ZAP-70 expression is associated with the E2A/PBX1 rearrangement and pre-B stage and may have a prognostic role and be a candidate molecule for targeted therapies.",Journal Article,5243.0,22.0,We evaluated the expression of 2 members of the Syk family ZAP-70 and Syk in acute lymphoblastic ALL samples using data derived from a series of 33 T-ALL and 95 B-lineage adult ALL patients analyzed by oligonucleotide arrays Of the B-lineage ALL cases 37 were BCR/ABL+ 10 were ALL1/AF4+ 5 were E2A/PBX1+ and 43 carried no known molecular abnormality ZAP-70 was highly expressed in T-ALL A high ZAP-70 expression was also found in a proportion of B-lineage ALL the highest levels being associated with the E2A/PBX1+ group and the lowest with ALL1/AF4+ cases P .001 A higher ZAP-70 expression was also observed in the pre-B group P .001 Remarkably Syk expression was always preserved suggesting that ZAP-70 expression is not substitutive of Syk At the protein level ZAP-70 was evaluated on 39 newly diagnosed ALL patients 25 adults 14 children and was detected in 23 cases 59 ZAP-70 expression was consistently found in Ig mu+ cases Evaluation of long-term outcome in cases without molecular abnormalities showed that the higher levels of ZAP-70 were coupled to a higher relapse rate In ALL ZAP-70 expression is associated with the E2A/PBX1 rearrangement and pre-B stage and may have a prognostic role and be a candidate molecule for targeted therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 194, 3, 55, 1, 18, 1684, 1, 3, 6792, 607, 6251, 431, 2, 6792, 4, 286, 1275, 62, 347, 75, 74, 526, 29, 8, 988, 1, 466, 102, 62, 2, 48, 132, 2542, 780, 62, 7, 311, 20, 4727, 3923, 1, 3, 132, 2542, 62, 140, 567, 11, 1062, 1425, 79, 11, 30178, 17272, 33, 11, 15127, 14434, 2, 601, 2629, 77, 440, 219, 3698, 6251, 431, 10, 561, 570, 4, 102, 62, 8, 64, 6251, 431, 55, 10, 120, 204, 4, 8, 920, 1, 132, 2542, 62, 3, 1076, 148, 486, 41, 5, 3, 15127, 14434, 87, 2, 3, 2101, 5, 30178, 17272, 140, 19, 144, 8, 142, 6251, 431, 55, 10, 120, 164, 4, 3, 671, 132, 87, 19, 144, 4856, 6792, 55, 10, 3763, 5797, 802, 17, 6251, 431, 55, 16, 44, 55063, 1, 6792, 28, 3, 178, 301, 6251, 431, 10, 194, 23, 587, 732, 265, 62, 7, 243, 857, 213, 541, 2, 10, 530, 4, 382, 140, 728, 6251, 431, 55, 10, 2433, 204, 4, 4200, 6601, 140, 451, 1, 319, 337, 228, 4, 140, 187, 219, 1171, 224, 17, 3, 142, 148, 1, 6251, 431, 11, 3332, 6, 8, 142, 429, 116, 4, 62, 6251, 431, 55, 16, 41, 5, 3, 15127, 14434, 2675, 2, 671, 132, 82, 2, 68, 47, 8, 177, 200, 2, 40, 8, 1609, 1354, 9, 238, 235]",1250.0,16160012,417
Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2005-09-17,"4-Amino-pteroyl-glutamic acid (Aminotrexate; AMT) has several advantages over the related antifolate methotrexate (MTX), including greater potency, complete oral bioavailability, and greater accumulation by leukemic blasts in vitro. We compared the pharmacodynamic properties of AMT (given orally at 4 mg/m2 in two divided doses per week) and MTX (100 mg/m2 in four divided doses per week) among children with acute lymphoblastic leukemia. We find AMT and MTX to have equivalent penetration into the bone marrow compartment of these patients, as indicated by the steady-state concentrations within mature red blood cells (RBCs). However, MTX concentrations in the cerebrospinal fluid after oral dosage are significantly greater than AMT. To confirm these clinical observations, mice were treated four weekly injections of AMT or MTX, at a 1:20 dosage ratio, and tissue antifolate content was then determined over the subsequent 22 days. We confirm the selective exclusion of AMT from the CNS compartment, while showing equivalent accumulation of AMT and MTX in the RBCs, liver, spleen, kidneys and testes. Finally, we demonstrate that AMT, MTX, and their predominant polyglutamate species are equipotent inhibitors of their target intracellular enzyme dihydrofolate reductase, emphasizing the critical nature of steady-state tissue accumulation in determining the relative cytotoxic potency of these two antifolates.",Comparative Study,5239.0,22.0,4-Amino-pteroyl-glutamic acid Aminotrexate AMT has several advantages over the related antifolate methotrexate MTX including greater potency complete oral bioavailability and greater accumulation by leukemic blasts in vitro We compared the pharmacodynamic properties of AMT given orally at 4 mg/m2 in two divided doses per week and MTX 100 mg/m2 in four divided doses per week among children with acute lymphoblastic We find AMT and MTX to have equivalent penetration into the marrow compartment of these patients as indicated by the steady-state concentrations within mature red blood cells RBCs However MTX concentrations in the cerebrospinal fluid after oral dosage are significantly greater than AMT To confirm these clinical observations mice were treated four weekly injections of AMT or MTX at a 1:20 dosage ratio and tissue antifolate content was then determined over the subsequent 22 days We confirm the selective exclusion of AMT from the CNS compartment while showing equivalent accumulation of AMT and MTX in the RBCs spleen kidneys and testes Finally we demonstrate that AMT MTX and their predominant polyglutamate species are equipotent inhibitors of their target intracellular enzyme dihydrofolate reductase emphasizing the critical nature of steady-state tissue accumulation in determining the relative cytotoxic potency of these two antifolates,0,0,1,0,0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[39, 3078, 43558, 12727, 971, 55083, 5383, 71, 392, 3126, 252, 3, 139, 12278, 2116, 3453, 141, 378, 3593, 236, 518, 5499, 2, 378, 1835, 20, 2015, 2438, 4, 439, 21, 72, 3, 2424, 1571, 1, 5383, 447, 1428, 28, 39, 81, 821, 4, 100, 2176, 415, 379, 647, 2, 3453, 394, 81, 821, 4, 294, 2176, 415, 379, 647, 107, 541, 5, 286, 1275, 21, 2469, 5383, 2, 3453, 6, 47, 2017, 4618, 237, 3, 581, 3616, 1, 46, 7, 22, 1103, 20, 3, 4152, 1309, 1003, 262, 2908, 3422, 315, 37, 15859, 137, 3453, 1003, 4, 3, 5156, 2357, 50, 518, 3323, 32, 97, 378, 76, 5383, 6, 1843, 46, 38, 2172, 399, 11, 73, 294, 709, 4344, 1, 5383, 15, 3453, 28, 8, 14, 179, 3323, 197, 2, 246, 12278, 2457, 10, 818, 509, 252, 3, 706, 350, 162, 21, 1843, 3, 1094, 4721, 1, 5383, 29, 3, 1025, 3616, 369, 2069, 2017, 1835, 1, 5383, 2, 3453, 4, 3, 15859, 4071, 7143, 2, 13100, 1368, 21, 608, 17, 5383, 3453, 2, 136, 2750, 22006, 2915, 32, 23478, 222, 1, 136, 283, 2087, 1644, 20298, 4027, 6826, 3, 740, 2202, 1, 4152, 1309, 246, 1835, 4, 2196, 3, 580, 759, 3593, 1, 46, 100, 14893]",1362.0,16170572,546
Genomic assessment of pediatric acute leukemia.,"Cancer journal (Sudbury, Mass.)",Cancer J,,"Advances in molecular genetics have revolutionized our understanding of acute myeloid and lymphoblastic leukemia. Structural and numerical chromosomal aberrations are common, and their detection is vital for leukemia diagnosis, risk stratification, and monitoring of response to therapy. Fusion proteins resulting from chromosomal translocations are necessary but not sufficient for leukemogenesis, and there is intense research activity to elucidate the cooperating molecular abnormalities that may be suitable targets for novel therapeutic approaches. Candidate gene approaches have identified mutations in kinases and transcription factors in a proportion of patients, but more comprehensive genomic approaches are required. Gene expression profiling accurately classifies known subtypes of acute leukemia and has highlighted potentially leukemogenic abnormalities in gene expression. Newer techniques, such as single-nucleotide polymorphism arrays to analyze changes in gene copy number and zygosity, cancer genome sequencing, and RNA interference, are promising tools to identify mutations, although at present, data from these approaches are limited. This review provides an overview of these techniques in clinical practice and as research tools to develop new therapeutic approaches in pediatric leukemia.",Journal Article,,8.0,Advances in molecular genetics have revolutionized our understanding of acute myeloid and lymphoblastic Structural and numerical chromosomal aberrations are common and their detection is vital for diagnosis risk stratification and monitoring of response to therapy Fusion proteins resulting from chromosomal translocations are necessary but not sufficient for leukemogenesis and there is intense research activity to elucidate the cooperating molecular abnormalities that may be suitable targets for novel therapeutic approaches Candidate gene approaches have identified mutations in kinases and transcription factors in a proportion of patients but more comprehensive genomic approaches are required Gene expression profiling accurately classifies known subtypes of acute and has highlighted potentially leukemogenic abnormalities in gene expression Newer techniques such as single-nucleotide polymorphism arrays to analyze changes in gene copy number and zygosity cancer genome sequencing and RNA interference are promising tools to identify mutations although at present data from these approaches are limited This review provides an overview of these techniques in clinical practice and as research tools to develop new therapeutic approaches in pediatric,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[954, 4, 219, 2894, 47, 5746, 114, 612, 1, 286, 533, 2, 1275, 3281, 2, 8736, 1860, 2152, 32, 186, 2, 136, 638, 16, 3511, 9, 147, 43, 1541, 2, 1315, 1, 51, 6, 36, 1212, 652, 1113, 29, 1860, 3262, 32, 1493, 84, 44, 1952, 9, 5661, 2, 125, 16, 3933, 389, 128, 6, 3061, 3, 11413, 219, 1171, 17, 68, 40, 2884, 637, 9, 229, 189, 611, 1609, 145, 611, 47, 108, 138, 4, 1549, 2, 866, 130, 4, 8, 920, 1, 7, 84, 80, 949, 572, 611, 32, 616, 145, 55, 1080, 2141, 15295, 440, 814, 1, 286, 2, 71, 3681, 751, 13519, 1171, 4, 145, 55, 2246, 1092, 225, 22, 226, 1579, 1907, 3923, 6, 1992, 400, 4, 145, 1337, 207, 2, 30849, 12, 898, 615, 2, 893, 3182, 32, 721, 1896, 6, 255, 138, 242, 28, 364, 74, 29, 46, 611, 32, 383, 26, 206, 777, 35, 2901, 1, 46, 1092, 4, 38, 758, 2, 22, 389, 1896, 6, 690, 217, 189, 611, 4, 815]",1259.0,16197717,352
A quantitative MR imaging assessment of leukoencephalopathy in children treated for acute lymphoblastic leukemia without irradiation.,AJNR. American journal of neuroradiology,AJNR Am J Neuroradiol,2005-10-01,"Intravenous methotrexate (IV-MTX), an effective treatment for acute lymphoblastic leukemia (ALL), has a significant toxic effect on the central nervous system, with leukoencephalopathy (LE) being the most common form. The purpose of this study was to use objective quantitative MR imaging to prospectively assess the temporal evolution of LE extent and intensity. Forty-five children (low-risk, 10 mol/L/12F; mean age, 5.0 years at diagnosis; standard/high-risk, 11 mol/L/12F; mean age, 9.2 years at diagnosis) treated for ALL on a single institutional protocol were evaluated longitudinally to assess the extent of LE (proportion of white matter impacted) through tissue segmentation and the relative intensity of LE through relative elevations in T1 and T2 relaxation rates. One-sided Wilcoxon-Mann-Whitney tests were used to assess differences in quantitative measures at 4 different points in therapy both within and between risk arms. The proportion of white matter affected in both patient groups increased significantly with additional courses of IV-MTX, whereas the intensity of LE also increased steadily; however, both the intensity and extent of LE declined significantly approximately 1.5 years after completion of IV-MTX. Increases in the T1 and T2 relaxation rates above normal-appearing white matter were significantly correlated with each other and were dependent on the proportion of white matter affected. Higher doses and more courses of IV-MTX were associated with increased intensity and extent of LE. There was a significant reduction in both the intensity and extent of LE after completion of therapy. The impact of these changes on neurocognitive functioning and quality of life in survivors remains to be determined.",Journal Article,5225.0,36.0,Intravenous methotrexate IV-MTX an effective treatment for acute lymphoblastic ALL has a significant toxic effect on the central nervous system with leukoencephalopathy LE being the most common form The purpose of this study was to use objective quantitative MR imaging to prospectively assess the temporal evolution of LE extent and intensity Forty-five children low-risk 10 mol/L/12F mean age 5.0 years at diagnosis standard/high-risk 11 mol/L/12F mean age 9.2 years at diagnosis treated for ALL on a single institutional protocol were evaluated longitudinally to assess the extent of LE proportion of white matter impacted through tissue segmentation and the relative intensity of LE through relative elevations in T1 and T2 relaxation rates One-sided Wilcoxon-Mann-Whitney tests were used to assess differences in quantitative measures at 4 different points in therapy both within and between risk arms The proportion of white matter affected in both patient groups increased significantly with additional courses of IV-MTX whereas the intensity of LE also increased steadily however both the intensity and extent of LE declined significantly approximately 1.5 years after completion of IV-MTX Increases in the T1 and T2 relaxation rates above normal-appearing white matter were significantly correlated with each other and were dependent on the proportion of white matter affected Higher doses and more courses of IV-MTX were associated with increased intensity and extent of LE There was a significant reduction in both the intensity and extent of LE after completion of therapy The impact of these changes on neurocognitive functioning and quality of life in survivors remains to be determined,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1262, 2116, 478, 3453, 35, 323, 24, 9, 286, 1275, 62, 71, 8, 93, 1812, 254, 23, 3, 854, 1880, 398, 5, 8744, 4892, 486, 3, 96, 186, 1297, 3, 743, 1, 26, 45, 10, 6, 119, 461, 1156, 1638, 270, 6, 1143, 423, 3, 3264, 2554, 1, 4892, 1039, 2, 837, 1213, 365, 541, 154, 43, 79, 5824, 805, 44132, 313, 89, 33, 13, 60, 28, 147, 260, 64, 43, 175, 5824, 805, 44132, 313, 89, 83, 18, 60, 28, 147, 73, 9, 62, 23, 8, 226, 1115, 1182, 11, 194, 9278, 6, 423, 3, 1039, 1, 4892, 920, 1, 886, 5090, 4619, 298, 246, 5913, 2, 3, 580, 837, 1, 4892, 298, 580, 4712, 4, 1534, 2, 1786, 9363, 151, 104, 1689, 3896, 7470, 7471, 895, 11, 95, 6, 423, 362, 4, 1156, 1018, 28, 39, 338, 862, 4, 36, 110, 262, 2, 59, 43, 1335, 3, 920, 1, 886, 5090, 1424, 4, 110, 69, 271, 101, 97, 5, 402, 1993, 1, 478, 3453, 547, 3, 837, 1, 4892, 120, 101, 7025, 137, 110, 3, 837, 2, 1039, 1, 4892, 3054, 97, 705, 14, 33, 60, 50, 1438, 1, 478, 3453, 1106, 4, 3, 1534, 2, 1786, 9363, 151, 2090, 295, 6536, 886, 5090, 11, 97, 438, 5, 296, 127, 2, 11, 470, 23, 3, 920, 1, 886, 5090, 1424, 142, 415, 2, 80, 1993, 1, 478, 3453, 11, 41, 5, 101, 837, 2, 1039, 1, 4892, 125, 10, 8, 93, 628, 4, 110, 3, 837, 2, 1039, 1, 4892, 50, 1438, 1, 36, 3, 345, 1, 46, 400, 23, 2958, 2702, 2, 372, 1, 358, 4, 332, 469, 6, 40, 509]",1700.0,16219848,542
Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2005-11-01,"We studied the frequency, causes, and predictors of adverse events in children with acute lymphoblastic leukemia (ALL) who had completed treatment on contemporary clinical protocols between 1984 and 1999. Our goal was to use the information to further refine therapy and advance cure rates. Cumulative incidence functions of any post-treatment failure or any post-treatment relapse were estimated by the method of Kalbfleisch and Prentice and compared with Gray's test. The Cox proportional hazards model was used to identify independent prognostic factors. Of the 827 patients who completed all treatment while in initial complete remission, 134 patients subsequently had major adverse events, including 90 leukemic relapses, 40 second malignancies, and four deaths in remission. The cumulative incidence of any adverse event was 14.0% +/- 1.2% (SE) at 5 years and 16.9% +/- 1.4% at 10 years. The risk of any leukemic relapse was 10.0% +/- 1.1% at 5 years and 11.4% +/- 1.2% at 10 years. Male sex was the only independent predictor of relapse (hazard ratio, 1.74; 95% CI, 1.11 to 2.74; P = .02). Further treatment refinements for children with ALL should aim not only to decrease the leukemic relapse rate, but also to reduce the risk of development of second malignancies.",Journal Article,5194.0,53.0,We studied the frequency causes and predictors of adverse events in children with acute lymphoblastic ALL who had completed treatment on contemporary clinical protocols between 1984 and 1999 Our goal was to use the information to further refine therapy and advance cure rates Cumulative incidence functions of any post-treatment failure or any post-treatment relapse were estimated by the method of Kalbfleisch and Prentice and compared with Gray 's test The Cox proportional hazards model was used to identify independent prognostic factors Of the 827 patients who completed all treatment while in initial complete remission 134 patients subsequently had major adverse events including 90 leukemic relapses 40 second malignancies and four deaths in remission The cumulative incidence of any adverse event was 14.0 +/- 1.2 SE at 5 years and 16.9 +/- 1.4 at 10 years The risk of any leukemic relapse was 10.0 +/- 1.1 at 5 years and 11.4 +/- 1.2 at 10 years Male sex was the only independent predictor of relapse hazard ratio 1.74 95 CI 1.11 to 2.74 P .02 Further treatment refinements for children with ALL should aim not only to decrease the leukemic relapse rate but also to reduce the risk of development of second malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 656, 3, 675, 1626, 2, 674, 1, 290, 281, 4, 541, 5, 286, 1275, 62, 54, 42, 781, 24, 23, 2667, 38, 2189, 59, 6036, 2, 2043, 114, 1326, 10, 6, 119, 3, 487, 6, 195, 5003, 36, 2, 3148, 1722, 151, 967, 287, 1681, 1, 500, 539, 24, 496, 15, 500, 539, 24, 429, 11, 661, 20, 3, 596, 1, 55142, 2, 26454, 2, 72, 5, 4163, 292, 412, 3, 418, 831, 1017, 202, 10, 95, 6, 255, 306, 177, 130, 1, 3, 13947, 7, 54, 781, 62, 24, 369, 4, 388, 236, 734, 4842, 7, 1611, 42, 458, 290, 281, 141, 424, 2015, 3713, 327, 419, 441, 2, 294, 1043, 4, 734, 3, 967, 287, 1, 500, 290, 774, 10, 213, 13, 14, 18, 3428, 28, 33, 60, 2, 245, 83, 14, 39, 28, 79, 60, 3, 43, 1, 500, 2015, 429, 10, 79, 13, 14, 14, 28, 33, 60, 2, 175, 39, 14, 18, 28, 79, 60, 1045, 1035, 10, 3, 158, 306, 980, 1, 429, 360, 197, 14, 794, 48, 58, 14, 175, 6, 18, 794, 19, 588, 195, 24, 10518, 9, 541, 5, 62, 257, 1130, 44, 158, 6, 775, 3, 2015, 429, 116, 84, 120, 6, 969, 3, 43, 1, 193, 1, 419, 441]",1229.0,16258093,635
Gene expression profiling identifies BAX-delta as a novel tumor antigen in acute lymphoblastic leukemia.,Cancer research,Cancer Res.,2005-11-01,"The identification of new tumor-associated antigens (TAA) is critical for the development of effective immunotherapeutic strategies, particularly in diseases like B-cell acute lymphoblastic leukemia (B-ALL), where few target epitopes are known. To accelerate the identification of novel TAA in B-ALL, we used a combination of expression profiling and reverse immunology. We compared gene expression profiles of primary B-ALL cells with their normal counterparts, B-cell precursors. Genes differentially expressed by B-ALL cells included many previously identified as TAA in other malignancies. Within this set of overexpressed genes, we focused on those that may be functionally important to the cancer cell. The apoptosis-related molecule, BAX, was highly correlated with the ALL class distinction. Therefore, we evaluated BAX and its isoforms as potential TAA. Peptides from the isoform BAX-delta bound with high affinity to HLA-A*0201 and HLA-DR1. CD8+ CTLs specific for BAX-delta epitopes or their heteroclitic peptides could be expanded from normal donors. BAX-delta-specific T cells lysed peptide-pulsed targets and BAX-delta-expressing leukemia cells in a MHC-restricted fashion. Moreover, primary B-ALL cells were recognized by BAX-delta-specific CTL, indicating that this antigen is naturally processed and presented by tumor cells. This study suggests that (a) BAX-delta may serve as a widely expressed TAA in B-ALL and (b) gene expression profiling can be a generalizable tool to identify immunologic targets for cancer immunotherapy.",Journal Article,5194.0,21.0,The identification of new tumor-associated antigens TAA is critical for the development of effective immunotherapeutic strategies particularly in diseases like B-cell acute lymphoblastic B-ALL where few target epitopes are known To accelerate the identification of novel TAA in B-ALL we used a combination of expression profiling and reverse immunology We compared gene expression profiles of primary B-ALL cells with their normal counterparts B-cell precursors Genes differentially expressed by B-ALL cells included many previously identified as TAA in other malignancies Within this set of overexpressed genes we focused on those that may be functionally important to the cancer cell The apoptosis-related molecule BAX was highly correlated with the ALL class distinction Therefore we evaluated BAX and its isoforms as potential TAA Peptides from the isoform BAX-delta bound with high affinity to HLA-A*0201 and HLA-DR1 CD8+ CTLs specific for BAX-delta epitopes or their heteroclitic peptides could be expanded from normal donors BAX-delta-specific T cells lysed peptide-pulsed targets and BAX-delta-expressing cells in a MHC-restricted fashion Moreover primary B-ALL cells were recognized by BAX-delta-specific CTL indicating that this antigen is naturally processed and presented by tumor cells This study suggests that a BAX-delta may serve as a widely expressed TAA in B-ALL and b gene expression profiling can be a generalizable tool to identify immunologic targets for cancer immunotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 911, 1, 217, 30, 41, 1575, 12469, 16, 740, 9, 3, 193, 1, 323, 3222, 422, 823, 4, 1342, 733, 132, 31, 286, 1275, 132, 62, 1257, 1021, 283, 4915, 32, 440, 6, 5792, 3, 911, 1, 229, 12469, 4, 132, 62, 21, 95, 8, 150, 1, 55, 1080, 2, 1772, 6534, 21, 72, 145, 55, 1241, 1, 86, 132, 62, 37, 5, 136, 295, 3953, 132, 31, 4881, 214, 2478, 570, 20, 132, 62, 37, 159, 445, 373, 108, 22, 12469, 4, 127, 441, 262, 26, 916, 1, 1711, 214, 21, 1649, 23, 135, 17, 68, 40, 3772, 305, 6, 3, 12, 31, 3, 351, 139, 1354, 3119, 10, 561, 438, 5, 3, 62, 1040, 6628, 673, 21, 194, 3119, 2, 211, 3913, 22, 174, 12469, 2491, 29, 3, 3995, 3119, 4305, 2951, 5, 64, 3601, 6, 1160, 8, 8529, 2, 1160, 30869, 968, 5416, 112, 9, 3119, 4305, 4915, 15, 136, 26148, 2491, 359, 40, 2064, 29, 295, 2344, 3119, 4305, 112, 102, 37, 14098, 1389, 5695, 637, 2, 3119, 4305, 1046, 37, 4, 8, 3658, 2016, 3240, 1393, 86, 132, 62, 37, 11, 1904, 20, 3119, 4305, 112, 3872, 1716, 17, 26, 448, 16, 6045, 5232, 2, 917, 20, 30, 37, 26, 45, 844, 17, 8, 3119, 4305, 68, 1833, 22, 8, 1792, 570, 12469, 4, 132, 62, 2, 132, 145, 55, 1080, 122, 40, 8, 12313, 1515, 6, 255, 3042, 637, 9, 12, 726]",1497.0,16267031,523
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2005-11-01,"Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia (ALL) in children is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented in a table in this review (Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Lymphoblastic Leukemia) and were reached unanimously by a panel of ALL experts. The priority areas of needed future research in pediatric ALL are unrelated marrow or blood donor versus unrelated cord blood donor allogeneic SCT; alternative, nonfamily allogeneic donor versus autologous SCT; better methods for identifying high-relapse-risk patients; assessments of the effect of current chemotherapy regimens on early relapse; and use of pre-SCT detection of minimal residual disease to predict post-SCT outcomes.",Journal Article,5194.0,58.0,Evidence supporting the role of hematopoietic stem cell transplantation SCT in the therapy of acute lymphoblastic ALL in children is presented and critically evaluated in this systematic evidence-based review Specific criteria were used for searching the published literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations Treatment recommendations based on the evidence are presented in a table in this review Summary of Treatment Recommendations Made by the Expert Panel for Pediatric Acute Lymphoblastic and were reached unanimously by a panel of ALL experts The priority areas of needed future research in pediatric ALL are unrelated marrow or blood donor versus unrelated cord blood donor allogeneic SCT alternative nonfamily allogeneic donor versus autologous SCT better methods for identifying high-relapse-risk patients assessments of the effect of current chemotherapy regimens on early relapse and use of pre-SCT detection of minimal residual disease to predict post-SCT outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[241, 1912, 3, 200, 1, 1007, 452, 31, 497, 1988, 4, 3, 36, 1, 286, 1275, 62, 4, 541, 16, 917, 2, 4331, 194, 4, 26, 1556, 241, 90, 206, 112, 371, 11, 95, 9, 10082, 3, 983, 789, 2, 9, 3452, 3, 372, 2, 3671, 1, 3, 241, 2, 3, 3671, 1, 3, 24, 883, 24, 883, 90, 23, 3, 241, 32, 917, 4, 8, 7016, 4, 26, 206, 1962, 1, 24, 883, 1229, 20, 3, 2005, 993, 9, 815, 286, 1275, 2, 11, 1300, 18248, 20, 8, 993, 1, 62, 3186, 3, 4690, 1361, 1, 575, 508, 389, 4, 815, 62, 32, 2092, 581, 15, 315, 1488, 185, 2092, 1885, 315, 1488, 1063, 1988, 1091, 55155, 1063, 1488, 185, 1028, 1988, 380, 636, 9, 1386, 64, 429, 43, 7, 2182, 1, 3, 254, 1, 291, 56, 472, 23, 191, 429, 2, 119, 1, 671, 1988, 638, 1, 1048, 753, 34, 6, 678, 539, 1988, 123]",1049.0,16275588,635
Adaphostin-induced oxidative stress overcomes BCR/ABL mutation-dependent and -independent imatinib resistance.,Blood,Blood,2005-11-15,"The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous leukemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML and Ph+ acute lymphoblastic leukemia (ALL) are often resistant. In particular, mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to second-generation kinase inhibitors such as BMS-354825 or AMN107. Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates. Recent findings have in addition implicated reactive oxygen species (ROS) in the cytotoxic mechanism of adaphostin. In view of this unique mode of action, we examined the effects of adaphostin on numerous imatinib-resistant leukemia models, including imatinib-resistant CML and Ph+ ALL cell lines, cells harboring point mutations in BCR/ABL, and specimens from imatinib-resistant CML patients, using assays for intracellular ROS, apoptosis, and clonogenicity. Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death. Collectively, these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL.",Journal Article,5180.0,58.0,The BCR/ABL kinase has been targeted for the treatment of chronic myelogenous CML by imatinib mesylate While imatinib has been extremely effective for chronic phase CML blast crisis CML and Ph+ acute lymphoblastic ALL are often resistant In particular mutation of the T315 residue in the bcr/abl activation loop renders cells highly resistant to imatinib and to second-generation kinase inhibitors such as BMS-354825 or AMN107 Adaphostin is a tyrphostin that was originally intended to inhibit the BCR/ABL kinase by competing with its peptide substrates Recent findings have in addition implicated reactive oxygen species ROS in the cytotoxic mechanism of adaphostin In view of this unique mode of action we examined the effects of adaphostin on numerous imatinib-resistant models including imatinib-resistant CML and Ph+ ALL cell lines cells harboring point mutations in BCR/ABL and specimens from imatinib-resistant CML patients using assays for intracellular ROS apoptosis and clonogenicity Every model of imatinib resistance examined remained fully sensitive to adaphostin-induced cell death Collectively these data suggest that ROS generation by adaphostin overcomes even the most potent imatinib resistance in CML and Ph+ ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1062, 1425, 216, 71, 85, 238, 9, 3, 24, 1, 442, 2194, 903, 20, 577, 2347, 369, 577, 71, 85, 2938, 323, 9, 442, 124, 903, 3112, 6540, 903, 2, 2058, 286, 1275, 62, 32, 629, 436, 4, 1454, 258, 1, 3, 21359, 7840, 4, 3, 1062, 1425, 363, 4432, 8080, 37, 561, 436, 6, 577, 2, 6, 419, 914, 216, 222, 225, 22, 3502, 23350, 15, 12189, 10028, 16, 8, 25963, 17, 10, 5045, 4081, 6, 1433, 3, 1062, 1425, 216, 20, 2573, 5, 211, 1389, 6063, 435, 272, 47, 4, 352, 1771, 2163, 2848, 2915, 2609, 4, 3, 759, 670, 1, 10028, 4, 3811, 1, 26, 991, 4530, 1, 1578, 21, 409, 3, 176, 1, 10028, 23, 2331, 577, 436, 274, 141, 577, 436, 903, 2, 2058, 62, 31, 285, 37, 2105, 741, 138, 4, 1062, 1425, 2, 623, 29, 577, 436, 903, 7, 75, 1013, 9, 2087, 2609, 351, 2, 9880, 454, 202, 1, 577, 251, 409, 958, 1910, 745, 6, 10028, 277, 31, 273, 2535, 46, 74, 309, 17, 2609, 914, 20, 10028, 8510, 871, 3, 96, 1157, 577, 251, 4, 903, 2, 2058, 62]",1231.0,16291594,674
Adult acute lymphoblastic leukemia.,Mayo Clinic proceedings,Mayo Clin. Proc.,2005-11-01,"Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities. Changes in the pathologic classification of ALL have led to therapeutic consequences. Adaptation of successful treatment strategies in children with ALL has resulted in similar complete remission rates in adults. Prognosis has Improved especially in mature B-cell ALL and T-cell lineage ALL. However, regardless of ALL subgroup, long-term survival in adults is still inferior to that in children. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success in adult ALL.",Journal Article,5194.0,,Much progress has been made in understanding the biology of and therapy for acute lymphoblastic ALL This progress has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities Changes in the pathologic classification of ALL have led to therapeutic consequences Adaptation of successful treatment strategies in children with ALL has resulted in similar complete remission rates in adults Prognosis has Improved especially in mature B-cell ALL and T-cell lineage ALL However regardless of ALL subgroup long-term survival in adults is still inferior to that in children Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics is vital to the therapeutic success in adult ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1802, 1466, 71, 85, 1229, 4, 612, 3, 891, 1, 2, 36, 9, 286, 1275, 62, 26, 1466, 71, 5136, 237, 3, 2335, 1, 392, 1453, 1, 62, 2, 3, 731, 1, 43, 3716, 235, 217, 235, 32, 1478, 90, 23, 3, 2470, 1, 112, 1266, 219, 1171, 400, 4, 3, 510, 947, 1, 62, 47, 836, 6, 189, 3255, 7275, 1, 1401, 24, 422, 4, 541, 5, 62, 71, 627, 4, 288, 236, 734, 151, 4, 857, 356, 71, 231, 1093, 4, 2908, 132, 31, 62, 2, 102, 31, 2542, 62, 137, 1583, 1, 62, 1363, 319, 337, 25, 4, 857, 16, 1234, 1663, 6, 17, 4, 541, 193, 1, 217, 600, 2, 183, 3632, 6, 697, 112, 1266, 219, 374, 16, 3511, 6, 3, 189, 1825, 4, 780, 62]",864.0,16295033,405
Phase II trial of oral aminopterin for adults and children with refractory acute leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-11-01,"To determine the antileukemic activity of weekly oral aminopterin in patients with refractory acute leukemia; to describe the pharmacodynamic properties of aminopterin; and to contrast the intracellular metabolism of aminopterin and methotrexate by patients' blasts in vitro. Forty-six patients were enrolled in three strata: children with acute lymphoblastic leukemia (ALL), adults with ALL, and patients with acute myeloid leukemia (AML). Aminopterin was given weekly, in two doses of 2 mg/m(2), 12 hours apart. Limited sampling pharmacokinetic analysis was done during the first week of therapy. Accumulation of [(3)H]aminopterin and [(3)H]methotrexate by leukemic blasts was studied in vitro. Six of 22 children with ALL (27%; 95% confidence interval, 8-47%) had clinically significant responses. None of those with AML and only two of 11 adults with ALL had responses meeting protocol definitions, although peripheral blast counts tended to decrease with therapy in all groups. Mucosal toxicity was minimal, even with limited use of leucovorin rescue. Complete bioavailability of aminopterin was confirmed, with a mean area under the curve of 0.52 +/- 0.03 micromol hour/L after oral dosing. No relationship between aminopterin pharmacokinetics and response was seen. In vitro, aminopterin showed more consistent metabolism by leukemic blasts to polyglutamates than methotrexate. Lineage-specific differences in the pattern of intracellular antifolylpolyglutamates were observed. Weekly oral aminopterin has significant activity among children with refractory ALL. With greater cellular accumulation and metabolism, more reliable bioavailability than methotrexate, and tolerable toxicity at this dose and schedule, aminopterin deserves further study as a potent alternative to methotrexate.","Clinical Trial, Phase II",5194.0,20.0,To determine the antileukemic activity of weekly oral aminopterin in patients with refractory acute to describe the pharmacodynamic properties of aminopterin and to contrast the intracellular metabolism of aminopterin and methotrexate by patients blasts in vitro Forty-six patients were enrolled in three strata children with acute lymphoblastic ALL adults with ALL and patients with acute myeloid AML Aminopterin was given weekly in two doses of 2 mg/m 2 12 hours apart Limited sampling pharmacokinetic analysis was done during the first week of therapy Accumulation of 3 H aminopterin and 3 H methotrexate by leukemic blasts was studied in vitro Six of 22 children with ALL 27 95 confidence interval 8-47 had clinically significant responses None of those with AML and only two of 11 adults with ALL had responses meeting protocol definitions although peripheral blast counts tended to decrease with therapy in all groups Mucosal toxicity was minimal even with limited use of leucovorin rescue Complete bioavailability of aminopterin was confirmed with a mean area under the curve of 0.52 +/- 0.03 micromol hour/L after oral dosing No relationship between aminopterin pharmacokinetics and response was seen In vitro aminopterin showed more consistent metabolism by leukemic blasts to polyglutamates than methotrexate Lineage-specific differences in the pattern of intracellular antifolylpolyglutamates were observed Weekly oral aminopterin has significant activity among children with refractory ALL With greater cellular accumulation and metabolism more reliable bioavailability than methotrexate and tolerable toxicity at this dose and schedule aminopterin deserves further study as a potent alternative to methotrexate,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 3, 4512, 128, 1, 709, 518, 16421, 4, 7, 5, 430, 286, 6, 897, 3, 2424, 1571, 1, 16421, 2, 6, 748, 3, 2087, 1600, 1, 16421, 2, 2116, 20, 7, 2438, 4, 439, 1213, 437, 7, 11, 346, 4, 169, 5758, 541, 5, 286, 1275, 62, 857, 5, 62, 2, 7, 5, 286, 533, 329, 16421, 10, 447, 709, 4, 100, 415, 1, 18, 81, 188, 18, 133, 1459, 5461, 383, 2874, 1456, 65, 10, 1822, 190, 3, 157, 647, 1, 36, 1835, 1, 27, 555, 16421, 2, 27, 555, 2116, 20, 2015, 2438, 10, 656, 4, 439, 437, 1, 350, 541, 5, 62, 428, 48, 307, 268, 66, 662, 42, 505, 93, 253, 1292, 1, 135, 5, 329, 2, 158, 100, 1, 175, 857, 5, 62, 42, 253, 2238, 1182, 3833, 242, 672, 3112, 1911, 3886, 6, 775, 5, 36, 4, 62, 271, 3068, 155, 10, 1048, 871, 5, 383, 119, 1, 3296, 4256, 236, 5499, 1, 16421, 10, 557, 5, 8, 313, 965, 669, 3, 1496, 1, 13, 653, 13, 680, 6297, 2583, 805, 50, 518, 1280, 77, 858, 59, 16421, 1159, 2, 51, 10, 527, 4, 439, 16421, 224, 80, 925, 1600, 20, 2015, 2438, 6, 16243, 76, 2116, 2542, 112, 362, 4, 3, 1177, 1, 2087, 55168, 11, 164, 709, 518, 16421, 71, 93, 128, 107, 541, 5, 430, 62, 5, 378, 763, 1835, 2, 1600, 80, 2450, 5499, 76, 2116, 2, 2668, 155, 28, 26, 61, 2, 1055, 16421, 8572, 195, 45, 22, 8, 1157, 1091, 6, 2116]",1723.0,16299240,304
The treatment of adolescents and young adults with acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2005-01-01,"Intensive chemotherapy regimens for children with acute lymphoblastic leukemia (ALL) have greatly improved, and the majority of children with precursor B-cell ALL are able to achieve a complete remission (CR), with an induction rate approaching 98% and a 5-year estimated event-free survival rate (EFS) of approximately 80%. Although there have been dramatic improvements over the last several decades in both the EFS and overall survival (OS) rates in young children with ALL, the results in adult clinical trials have not kept pace. Current adult treatment regimens result in CR rates in the 80% range, with EFS at 5 years of only 30%-40%. Adolescents and young adults represent a minority of patients enrolled onto either adult or pediatric clinical trials. As a result, little information is available regarding CR, EFS, and OS rates for this age group, and the appropriate treatment regimen for this group of patients remains elusive. Recent studies suggest that young adult patients have far superior outcomes when treated on more intensive pediatric regimens. In addition, new insights into the molecular pathogenesis of T cell ALL have led to new therapeutic strategies.",Journal Article,5498.0,51.0,Intensive chemotherapy regimens for children with acute lymphoblastic ALL have greatly improved and the majority of children with precursor B-cell ALL are able to achieve a complete remission CR with an induction rate approaching 98 and a 5-year estimated event-free survival rate EFS of approximately 80 Although there have been dramatic improvements over the last several decades in both the EFS and overall survival OS rates in young children with ALL the results in adult clinical trials have not kept pace Current adult treatment regimens result in CR rates in the 80 range with EFS at 5 years of only 30 -40 Adolescents and young adults represent a minority of patients enrolled onto either adult or pediatric clinical trials As a result little information is available regarding CR EFS and OS rates for this age group and the appropriate treatment regimen for this group of patients remains elusive Recent studies suggest that young adult patients have far superior outcomes when treated on more intensive pediatric regimens In addition new insights into the molecular pathogenesis of T cell ALL have led to new therapeutic strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1686, 56, 472, 9, 541, 5, 286, 1275, 62, 47, 3510, 231, 2, 3, 686, 1, 541, 5, 2765, 132, 31, 62, 32, 1665, 6, 1359, 8, 236, 734, 684, 5, 35, 504, 116, 7773, 1096, 2, 8, 33, 111, 661, 774, 115, 25, 116, 1683, 1, 705, 493, 242, 125, 47, 85, 3079, 1474, 252, 3, 1060, 392, 1968, 4, 110, 3, 1683, 2, 63, 25, 118, 151, 4, 1169, 541, 5, 62, 3, 99, 4, 780, 38, 143, 47, 44, 11322, 7265, 291, 780, 24, 472, 757, 4, 684, 151, 4, 3, 493, 184, 5, 1683, 28, 33, 60, 1, 158, 201, 327, 3101, 2, 1169, 857, 1231, 8, 2652, 1, 7, 346, 3301, 361, 780, 15, 815, 38, 143, 22, 8, 757, 1215, 487, 16, 390, 666, 684, 1683, 2, 118, 151, 9, 26, 89, 87, 2, 3, 870, 24, 477, 9, 26, 87, 1, 7, 469, 5327, 435, 94, 309, 17, 1169, 780, 7, 47, 3272, 1123, 123, 198, 73, 23, 80, 1686, 815, 472, 4, 352, 217, 1957, 237, 3, 219, 1384, 1, 102, 31, 62, 47, 836, 6, 217, 189, 422]",1141.0,16304369,853
Acute lymphoblastic leukemia: older patients and newer drugs.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2005-01-01,"Although the median age for adults with acute lymphoblastic leukemia (ALL) is older than 60 years, relatively few of these patients have been enrolled on prospective clinical trials. The presence of coexisting medical disorders and unfavorable cytogenetic and biological characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs. Selected patients have achieved remission and long-term survival following intensive chemotherapy. Preliminary data using several new agents that have shown promise for patients with ALL are described.",Journal Article,5498.0,21.0,Although the median age for adults with acute lymphoblastic ALL is older than 60 years relatively few of these patients have been enrolled on prospective clinical trials The presence of coexisting medical disorders and unfavorable cytogenetic and biological characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs Selected patients have achieved remission and long-term survival following intensive chemotherapy Preliminary data using several new agents that have shown promise for patients with ALL are described,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 3, 52, 89, 9, 857, 5, 286, 1275, 62, 16, 434, 76, 335, 60, 1352, 1021, 1, 46, 7, 47, 85, 346, 23, 482, 38, 143, 3, 463, 1, 8859, 484, 1997, 2, 2483, 1266, 2, 1037, 374, 262, 26, 266, 2740, 2658, 1427, 9, 1401, 24, 75, 809, 56, 2251, 715, 7, 47, 513, 734, 2, 319, 337, 25, 366, 1686, 56, 1676, 74, 75, 392, 217, 183, 17, 47, 443, 1783, 9, 7, 5, 62, 32, 1027]",595.0,16304370,878
Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2005-12-01,"The serine/threonine kinase inhibitor flavopiridol targets multiple cyclin-dependent kinases, induces checkpoint arrest, and interrupts transcriptional elongation. We designed a phase I clinical trial using a timed sequential therapy approach where flavopiridol was given for the dual purpose of initial cytoreduction and enhancing cell cycle progression of the remaining leukemia cell cohort followed by cycle-dependent drugs 1-beta-D-arabinofuranosylcytosine (ara-C) and mitoxantrone. Flavopiridol was given by 1-hour infusion daily for 3 days beginning day 1 followed by 2 g/m2/72 h ara-C beginning day 6 and 40 mg/m2 mitoxantrone beginning day 9. In vivo correlates included pharmacokinetics, modulation of blast cycle regulators, and serum and marrow supernatant vascular endothelial growth factor levels. Of 34 adults receiving induction therapy, 16 (47%) evinced direct leukemia cytotoxicity with > or =50% drop in peripheral blast counts and tumor lysis in 9 (26%). Four (12%) died during therapy (two fungal infections and two sudden death). Dose-limiting toxicity occurred at 60 mg/m2/d with profound neutropenia >40 days duration, and maximal tolerated dose was 50 mg/m2/d. Overall response rate was 31% in 26 acute myelogenous leukemia and 12.5% in acute lymphoblastic leukemia. Pharmacokinetics showed that a linear two-compartment model with first-order elimination provided the best fit of the observed concentration versus time data. Flavopiridol down-regulated one or more target proteins in marrow blasts in vivo. Vascular endothelial growth factor was detected in sera and marrow supernatant pretreatment, and sera obtained on day 3 inhibited bovine aortic endothelial cell proliferation by a mean of 32% (range, 10-80%). Our data suggest that flavopiridol is cytotoxic to leukemic cells and, when followed by ara-C and mitoxantrone, exerts biological and clinical effects in patients with relapsed and refractory acute leukemias. These findings warrant continuing development of flavopiridol at 50 mg/m2/d x 3 days in combination with cytotoxic and biological agents for acute leukemias.","Clinical Trial, Phase I",5164.0,63.0,The serine/threonine kinase inhibitor flavopiridol targets multiple cyclin-dependent kinases induces checkpoint arrest and interrupts transcriptional elongation We designed a phase I clinical trial using a timed sequential therapy approach where flavopiridol was given for the dual purpose of initial cytoreduction and enhancing cell cycle progression of the remaining cell cohort followed by cycle-dependent drugs 1-beta-D-arabinofuranosylcytosine ara-C and mitoxantrone Flavopiridol was given by 1-hour infusion daily for 3 days beginning day 1 followed by 2 g/m2/72 h ara-C beginning day 6 and 40 mg/m2 mitoxantrone beginning day 9 In vivo correlates included pharmacokinetics modulation of blast cycle regulators and serum and marrow supernatant vascular endothelial growth factor levels Of 34 adults receiving induction therapy 16 47 evinced direct cytotoxicity with or =50 drop in peripheral blast counts and tumor lysis in 9 26 Four 12 died during therapy two fungal infections and two sudden death Dose-limiting toxicity occurred at 60 mg/m2/d with profound neutropenia 40 days duration and maximal tolerated dose was 50 mg/m2/d Overall response rate was 31 in 26 acute myelogenous and 12.5 in acute lymphoblastic Pharmacokinetics showed that a linear two-compartment model with first-order elimination provided the best fit of the observed concentration versus time data Flavopiridol down-regulated one or more target proteins in marrow blasts in vivo Vascular endothelial growth factor was detected in sera and marrow supernatant pretreatment and sera obtained on day 3 inhibited bovine aortic endothelial cell proliferation by a mean of 32 range 10-80 Our data suggest that flavopiridol is cytotoxic to leukemic cells and when followed by ara-C and mitoxantrone exerts biological and clinical effects in patients with relapsed and refractory acute leukemias These findings warrant continuing development of flavopiridol at 50 mg/m2/d x 3 days in combination with cytotoxic and biological agents for acute leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3734, 5131, 216, 230, 3030, 637, 232, 1226, 470, 1549, 1516, 986, 1854, 2, 30880, 1431, 12359, 21, 1114, 8, 124, 70, 38, 160, 75, 8, 12200, 1787, 36, 353, 1257, 3030, 10, 447, 9, 3, 1828, 743, 1, 388, 2844, 2, 2430, 31, 417, 91, 1, 3, 1844, 31, 180, 370, 20, 417, 470, 600, 14, 1090, 427, 21019, 3899, 256, 2, 4419, 3030, 10, 447, 20, 14, 2583, 904, 391, 9, 27, 162, 2948, 218, 14, 370, 20, 18, 499, 821, 720, 555, 3899, 256, 2948, 218, 49, 2, 327, 81, 821, 4419, 2948, 218, 83, 4, 386, 1871, 159, 1159, 2356, 1, 3112, 417, 3196, 2, 524, 2, 581, 14542, 756, 845, 129, 161, 148, 1, 562, 857, 357, 504, 36, 245, 662, 44174, 1196, 1408, 5, 15, 212, 7215, 4, 672, 3112, 1911, 2, 30, 4783, 4, 83, 432, 294, 133, 1016, 190, 36, 100, 7800, 1875, 2, 100, 10643, 273, 61, 817, 155, 489, 28, 335, 81, 821, 427, 5, 4399, 778, 327, 162, 654, 2, 2725, 421, 61, 10, 212, 81, 821, 427, 63, 51, 116, 10, 456, 4, 432, 286, 2194, 2, 133, 33, 4, 286, 1275, 1159, 224, 17, 8, 1646, 100, 3616, 202, 5, 157, 1732, 3730, 1052, 3, 824, 2975, 1, 3, 164, 1227, 185, 98, 74, 3030, 1328, 1065, 104, 15, 80, 283, 652, 4, 581, 2438, 4, 386, 756, 845, 129, 161, 10, 530, 4, 4210, 2, 581, 14542, 1194, 2, 4210, 683, 23, 218, 27, 879, 14218, 3938, 845, 31, 457, 20, 8, 313, 1, 531, 184, 79, 493, 114, 74, 309, 17, 3030, 16, 759, 6, 2015, 37, 2, 198, 370, 20, 3899, 256, 2, 4419, 5685, 1037, 2, 38, 176, 4, 7, 5, 591, 2, 430, 286, 2792, 46, 272, 2946, 4346, 193, 1, 3030, 28, 212, 81, 821, 427, 1006, 27, 162, 4, 150, 5, 759, 2, 1037, 183, 9, 286, 2792]",2025.0,16322302,489
Favorable outcome for infant acute lymphoblastic leukemia after hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2005-12-01,"Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis when treated with standard chemotherapy. A subset of these infants, particularly those with mixed-lineage leukemia (MLL) rearrangements, has a high likelihood of relapse. Hematopoietic stem cell transplantation (HSCT) performed early in first remission may improve outcome. We present the results of 16 patients with infant ALL who were treated with HSCT in first remission. Six patients were < or =6 months of age at diagnosis, 11 had an initial white blood cell count of >50000/microL, and all patients with determinable cytogenetics had a high-risk karyotype [t(4:11) abnormality or other MLL rearrangement]. All patients received 150 cGy of total body irradiation for 8 doses (1200 cGy). Fifteen of 16 patients received etoposide at 1000 mg/m(2) as a continuous infusion over 24 hours and cyclophosphamide at 60 mg/kg/d for 3 days. Eight patients received HSCT from an HLA-identical sibling, and 8, from unrelated cord blood. Twelve (75%) patients remain long-term survivors (median follow-up, 4.7 years). Two patients, 1 of whom had minimal residual disease at HSCT, died after relapse following HSCT. Two patients died of transplant-related causes. The HSCT was well tolerated; 15 patients achieved neutrophil engraftment at a median of 16 days. Acute and chronic graft-versus-host disease were minimal in these patients. These results support the use of HSCT in the treatment of infant ALL, especially when used as consolidation in first remission. The risk of relapse seems to be decreased with this approach. Further work is being performed to determine the long-term effects from this therapy.",Journal Article,5164.0,19.0,Infants with acute lymphoblastic ALL have a poor prognosis when treated with standard chemotherapy A subset of these infants particularly those with mixed-lineage MLL rearrangements has a high likelihood of relapse Hematopoietic stem cell transplantation HSCT performed early in first remission may improve outcome We present the results of 16 patients with infant ALL who were treated with HSCT in first remission Six patients were or =6 months of age at diagnosis 11 had an initial white blood cell count of 50000/microL and all patients with determinable cytogenetics had a high-risk karyotype t 4:11 abnormality or other MLL rearrangement All patients received 150 cGy of total body irradiation for 8 doses 1200 cGy Fifteen of 16 patients received etoposide at 1000 mg/m 2 as a continuous infusion over 24 hours and cyclophosphamide at 60 mg/kg/d for 3 days Eight patients received HSCT from an HLA-identical sibling and 8 from unrelated cord blood Twelve 75 patients remain long-term survivors median follow-up 4.7 years Two patients 1 of whom had minimal residual disease at HSCT died after relapse following HSCT Two patients died of transplant-related causes The HSCT was well tolerated 15 patients achieved neutrophil engraftment at a median of 16 days Acute and chronic graft-versus-host disease were minimal in these patients These results support the use of HSCT in the treatment of infant ALL especially when used as consolidation in first remission The risk of relapse seems to be decreased with this approach Further work is being performed to determine the long-term effects from this therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5585, 5, 286, 1275, 62, 47, 8, 334, 356, 198, 73, 5, 260, 56, 8, 697, 1, 46, 5585, 823, 135, 5, 1739, 2542, 3049, 2072, 71, 8, 64, 1420, 1, 429, 1007, 452, 31, 497, 1703, 173, 191, 4, 157, 734, 68, 401, 228, 21, 364, 3, 99, 1, 245, 7, 5, 8027, 62, 54, 11, 73, 5, 1703, 4, 157, 734, 437, 7, 11, 15, 49, 53, 1, 89, 28, 147, 175, 42, 35, 388, 886, 315, 31, 1276, 1, 43258, 5128, 2, 62, 7, 5, 44178, 2510, 42, 8, 64, 43, 3385, 102, 39, 175, 3698, 15, 127, 3049, 2675, 62, 7, 103, 1577, 3071, 1, 181, 642, 1104, 9, 66, 415, 6847, 3071, 3057, 1, 245, 7, 103, 1934, 28, 2345, 81, 188, 18, 22, 8, 1314, 904, 252, 259, 1459, 2, 1112, 28, 335, 81, 503, 427, 9, 27, 162, 659, 7, 103, 1703, 29, 35, 1160, 3038, 3684, 2, 66, 29, 2092, 1885, 315, 2544, 481, 7, 918, 319, 337, 332, 52, 166, 126, 39, 67, 60, 100, 7, 14, 1, 953, 42, 1048, 753, 34, 28, 1703, 1016, 50, 429, 366, 1703, 100, 7, 1016, 1, 941, 139, 1626, 3, 1703, 10, 149, 421, 167, 7, 513, 2595, 2881, 28, 8, 52, 1, 245, 162, 286, 2, 442, 1599, 185, 1204, 34, 11, 1048, 4, 46, 7, 46, 99, 538, 3, 119, 1, 1703, 4, 3, 24, 1, 8027, 62, 1093, 198, 95, 22, 2173, 4, 157, 734, 3, 43, 1, 429, 2744, 6, 40, 340, 5, 26, 353, 195, 1357, 16, 486, 173, 6, 223, 3, 319, 337, 176, 29, 26, 36]",1608.0,16338622,351
Differentiation of naive cord-blood T cells into CD19-specific cytolytic effectors for posttransplantation adoptive immunotherapy.,Blood,Blood,2005-12-13,"Disease relapse is a barrier to achieving therapeutic success after unrelated umbilical cord-blood transplantation (UCBT) for B-lineage acute lymphoblastic leukemia (B-ALL). While adoptive transfer of donor-derived tumor-specific T cells is a conceptually attractive approach to eliminating residual disease after allogeneic hematopoietic stem cell transplantation, adoptive immunotherapy after UCBT is constrained by the difficulty of generating antigen-specific T cells from functionally naive umbilical cord-blood (UCB)-derived T cells. Therefore, to generate T cells that recognize B-ALL, we have developed a chimeric immunoreceptor to redirect the specificity of T cells for CD19, a B-lineage antigen, and expressed this transgene in UCB-derived T cells. An ex vivo process, which is compliant with current good manufacturing practice for T-cell trials, has been developed to genetically modify and numerically expand UCB-derived T cells into CD19-specific effector cells. These are capable of CD19-restricted cytokine production and cytolysis in vitro, as well as mediating regression of CD19+ tumor and being selectively eliminated in vivo. Moreover, time-lapse microscopy of the genetically modified T-cell clones revealed an ability to lyse CD19+ tumor cells specifically and repetitively. These data provide the rationale for infusing UCB-derived CD19-specific T cells after UCBT to reduce the incidence of CD19+ B-ALL relapse.",Journal Article,5152.0,76.0,Disease relapse is a barrier to achieving therapeutic success after unrelated umbilical cord-blood transplantation UCBT for B-lineage acute lymphoblastic B-ALL While adoptive transfer of donor-derived tumor-specific T cells is a conceptually attractive approach to eliminating residual disease after allogeneic hematopoietic stem cell transplantation adoptive immunotherapy after UCBT is constrained by the difficulty of generating antigen-specific T cells from functionally naive umbilical cord-blood UCB -derived T cells Therefore to generate T cells that recognize B-ALL we have developed a chimeric immunoreceptor to redirect the specificity of T cells for CD19 a B-lineage antigen and expressed this transgene in UCB-derived T cells An ex vivo process which is compliant with current good manufacturing practice for T-cell trials has been developed to genetically modify and numerically expand UCB-derived T cells into CD19-specific effector cells These are capable of CD19-restricted cytokine production and cytolysis in vitro as well as mediating regression of CD19+ tumor and being selectively eliminated in vivo Moreover time-lapse microscopy of the genetically modified T-cell clones revealed an ability to lyse CD19+ tumor cells specifically and repetitively These data provide the rationale for infusing UCB-derived CD19-specific T cells after UCBT to reduce the incidence of CD19+ B-ALL relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[34, 429, 16, 8, 3318, 6, 1785, 189, 1825, 50, 2092, 5998, 1885, 315, 497, 11305, 9, 132, 2542, 286, 1275, 132, 62, 369, 3159, 2602, 1, 1488, 526, 30, 112, 102, 37, 16, 8, 13825, 3059, 353, 6, 6923, 753, 34, 50, 1063, 1007, 452, 31, 497, 3159, 726, 50, 11305, 16, 9133, 20, 3, 4035, 1, 3997, 448, 112, 102, 37, 29, 3772, 2462, 5998, 1885, 315, 4056, 526, 102, 37, 673, 6, 2562, 102, 37, 17, 4237, 132, 62, 21, 47, 276, 8, 2897, 20236, 6, 14744, 3, 1121, 1, 102, 37, 9, 3158, 8, 132, 2542, 448, 2, 570, 26, 6632, 4, 4056, 526, 102, 37, 35, 2581, 386, 1129, 92, 16, 6982, 5, 291, 1178, 12869, 758, 9, 102, 31, 143, 71, 85, 276, 6, 2301, 4289, 2, 9055, 4082, 4056, 526, 102, 37, 237, 3158, 112, 2070, 37, 46, 32, 2787, 1, 3158, 2016, 1675, 1529, 2, 18878, 4, 439, 22, 149, 22, 3941, 320, 1, 3158, 30, 2, 486, 2382, 6173, 4, 386, 1393, 98, 21934, 3804, 1, 3, 2301, 1230, 102, 31, 2749, 553, 35, 801, 6, 11436, 3158, 30, 37, 1225, 2, 23171, 46, 74, 377, 3, 1728, 9, 21343, 4056, 526, 3158, 112, 102, 37, 50, 11305, 6, 969, 3, 287, 1, 3158, 132, 62, 429]",1407.0,16352804,29
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2006-01-01,"Evidence supporting the role of hematopoietic stem cell transplantation (SCT) in the therapy of acute lymphoblastic leukemia in adults (> or =15 years) is presented and critically evaluated in this systematic evidence-based review. Specific criteria were used for searching the published medical literature and for grading the quality and strength of the evidence, and the strength of the treatment recommendations. Treatment recommendations based on the evidence are presented and were reached unanimously by a panel of acute lymphoblastic leukemia experts. The priority areas of needed future research for adult acute lymphoblastic leukemia are: definition of patients at high risk in first complete remission, beyond Philadelphia chromosome positive; outcomes of SCT in older (>50 years) adults; determination if reduced intensity versus myeloablative conditioning regimens yield an equivalent graft-versus-leukemia effect with reduced toxicity; monitoring of minimal residual disease to achieve disease control before SCT; and the use of cord blood and other alternative sources of stem cells for use in adult SCT recipients.",Journal Article,5133.0,91.0,Evidence supporting the role of hematopoietic stem cell transplantation SCT in the therapy of acute lymphoblastic in adults or =15 years is presented and critically evaluated in this systematic evidence-based review Specific criteria were used for searching the published medical literature and for grading the quality and strength of the evidence and the strength of the treatment recommendations Treatment recommendations based on the evidence are presented and were reached unanimously by a panel of acute lymphoblastic experts The priority areas of needed future research for adult acute lymphoblastic are definition of patients at high risk in first complete remission beyond Philadelphia chromosome positive outcomes of SCT in older 50 years adults determination if reduced intensity versus myeloablative conditioning regimens yield an equivalent graft-versus-leukemia effect with reduced toxicity monitoring of minimal residual disease to achieve disease control before SCT and the use of cord blood and other alternative sources of stem cells for use in adult SCT recipients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[241, 1912, 3, 200, 1, 1007, 452, 31, 497, 1988, 4, 3, 36, 1, 286, 1275, 4, 857, 15, 167, 60, 16, 917, 2, 4331, 194, 4, 26, 1556, 241, 90, 206, 112, 371, 11, 95, 9, 10082, 3, 983, 484, 789, 2, 9, 3452, 3, 372, 2, 3671, 1, 3, 241, 2, 3, 3671, 1, 3, 24, 883, 24, 883, 90, 23, 3, 241, 32, 917, 2, 11, 1300, 18248, 20, 8, 993, 1, 286, 1275, 3186, 3, 4690, 1361, 1, 575, 508, 389, 9, 780, 286, 1275, 32, 2470, 1, 7, 28, 64, 43, 4, 157, 236, 734, 1654, 3006, 1170, 109, 123, 1, 1988, 4, 434, 212, 60, 857, 3104, 492, 405, 837, 185, 3246, 1933, 472, 2309, 35, 2017, 1599, 185, 2647, 254, 5, 405, 155, 1315, 1, 1048, 753, 34, 6, 1359, 34, 182, 348, 1988, 2, 3, 119, 1, 1885, 315, 2, 127, 1091, 3375, 1, 452, 37, 9, 119, 4, 780, 1988, 2190]",1082.0,16399566,378
Smaller white-matter volumes are associated with larger deficits in attention and learning among long-term survivors of acute lymphoblastic leukemia.,Cancer,Cancer,2006-02-01,"The primary objective of this study was to test the hypothesis that survivors of childhood acute lymphoblastic leukemia (ALL) have deficits in neurocognitive performance, and smaller white-matter volumes are associated with these deficits. The patients studied included 112 ALL survivors (84 patients who had received chemotherapy only, 28 patients who had received chemotherapy and irradiation; 63 males, 49 females; mean age +/- standard deviation, 4.1 yrs +/- 2.6 yrs at diagnosis; mean +/- standard deviation yrs since diagnosis, 6.0 +/- 3.5 yrs), and 33 healthy siblings who participated as a control group. Neurocognitive tests of attention, intelligence, and academic achievement were performed; and magnetic resonance images were obtained and subsequently were segmented to yield tissue volume measurements. Comparisons of neurocognitive measures and tissue volumes between groups were performed, and the correlations between volumes and neurocognitive performance measures were assessed. Most performance measures demonstrated statistically significant differences from the normative test scores, but only attention measures exceeded 1.0 standard deviation from normal. Patients who had received chemotherapy alone had significantly larger volumes of white matter than patients who had received treatment that also included cranial irradiation, but their volumes remained significantly smaller than the volumes in the control group. Smaller white-matter volumes were associated significantly with larger deficits in attention, intelligence, and academic achievement. Survivors of childhood ALL had significant deficits in attention and smaller white-matter volumes that were associated directly with impaired neurocognitive performance. Cranial irradiation exacerbated these deficits.",Comparative Study,5102.0,140.0,The primary objective of this study was to test the hypothesis that survivors of childhood acute lymphoblastic ALL have deficits in neurocognitive performance and smaller white-matter volumes are associated with these deficits The patients studied included 112 ALL survivors 84 patients who had received chemotherapy only 28 patients who had received chemotherapy and irradiation 63 males 49 females mean age +/- standard deviation 4.1 yrs +/- 2.6 yrs at diagnosis mean +/- standard deviation yrs since diagnosis 6.0 +/- 3.5 yrs and 33 healthy siblings who participated as a control group Neurocognitive tests of attention intelligence and academic achievement were performed and magnetic resonance images were obtained and subsequently were segmented to yield tissue volume measurements Comparisons of neurocognitive measures and tissue volumes between groups were performed and the correlations between volumes and neurocognitive performance measures were assessed Most performance measures demonstrated statistically significant differences from the normative test scores but only attention measures exceeded 1.0 standard deviation from normal Patients who had received chemotherapy alone had significantly larger volumes of white matter than patients who had received treatment that also included cranial irradiation but their volumes remained significantly smaller than the volumes in the control group Smaller white-matter volumes were associated significantly with larger deficits in attention intelligence and academic achievement Survivors of childhood ALL had significant deficits in attention and smaller white-matter volumes that were associated directly with impaired neurocognitive performance Cranial irradiation exacerbated these deficits,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 86, 461, 1, 26, 45, 10, 6, 412, 3, 1492, 17, 332, 1, 864, 286, 1275, 62, 47, 2752, 4, 2958, 528, 2, 2170, 886, 5090, 2225, 32, 41, 5, 46, 2752, 3, 7, 656, 159, 3726, 62, 332, 874, 7, 54, 42, 103, 56, 158, 339, 7, 54, 42, 103, 56, 2, 1104, 676, 2296, 739, 2451, 313, 89, 260, 3348, 39, 14, 10345, 18, 49, 10345, 28, 147, 313, 260, 3348, 10345, 1192, 147, 49, 13, 27, 33, 10345, 2, 466, 1331, 2758, 54, 3025, 22, 8, 182, 87, 2958, 895, 1, 2111, 9125, 2, 1916, 5088, 11, 173, 2, 1484, 1535, 1572, 11, 683, 2, 1611, 11, 9199, 6, 2309, 246, 433, 1685, 2213, 1, 2958, 1018, 2, 246, 2225, 59, 271, 11, 173, 2, 3, 2553, 59, 2225, 2, 2958, 528, 1018, 11, 275, 96, 528, 1018, 264, 712, 93, 362, 29, 3, 9658, 412, 703, 84, 158, 2111, 1018, 4726, 14, 13, 260, 3348, 29, 295, 7, 54, 42, 103, 56, 279, 42, 97, 1077, 2225, 1, 886, 5090, 76, 7, 54, 42, 103, 24, 17, 120, 159, 2565, 1104, 84, 136, 2225, 958, 97, 2170, 76, 3, 2225, 4, 3, 182, 87, 2170, 886, 5090, 2225, 11, 41, 97, 5, 1077, 2752, 4, 2111, 9125, 2, 1916, 5088, 332, 1, 864, 62, 42, 93, 2752, 4, 2111, 2, 2170, 886, 5090, 2225, 17, 11, 41, 1606, 5, 2364, 2958, 528, 2565, 1104, 10545, 46, 2752]",1754.0,16411228,44
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01.,Blood,Blood,2006-02-21,"In a retrospective analysis, we previously reported that children whose leukemia cells harbored the TEL/AML1 gene rearrangement have excellent outcomes. From 1996 to 2000, we conducted a prospective study to determine the incidence and outcomes of children with TEL/AML1-positive acute lymphoblastic leukemia (ALL). Children with newly diagnosed ALL were treated on DFCI ALL Consortium Protocol 95-01. Patients were risk stratified primarily by current National Cancer Institute (NCI)-Rome risk criteria. With a median follow-up of 5.2 years, the 5-year event-free survival for TEL/AML1-positive patients was 89% compared with 80% for TEL/AML1-negative B-precursor patients (P = .05). The 5-year overall survival rate was 97% among TEL/AML-positive patients compared with 89% among TEL/AML1-negative patients (P = .03). However, in a multivariable analysis, risk group (age and leukocyte count at diagnosis) and asparaginase treatment group, but not TEL/AML1 status, were found to be independent predictors of outcome. We conclude that TEL/AML1-positive patients have excellent outcomes, confirming our previous findings. However, factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients.","Clinical Trial, Phase III",5082.0,90.0,In a retrospective analysis we previously reported that children whose cells harbored the TEL/AML1 gene rearrangement have excellent outcomes From 1996 to 2000 we conducted a prospective study to determine the incidence and outcomes of children with TEL/AML1-positive acute lymphoblastic ALL Children with newly diagnosed ALL were treated on DFCI ALL Consortium Protocol 95-01 Patients were risk stratified primarily by current National Cancer Institute NCI -Rome risk criteria With a median follow-up of 5.2 years the 5-year event-free survival for TEL/AML1-positive patients was 89 compared with 80 for TEL/AML1-negative B-precursor patients P .05 The 5-year overall survival rate was 97 among TEL/AML-positive patients compared with 89 among TEL/AML1-negative patients P .03 However in a multivariable analysis risk group age and leukocyte count at diagnosis and asparaginase treatment group but not TEL/AML1 status were found to be independent predictors of outcome We conclude that TEL/AML1-positive patients have excellent outcomes confirming our previous findings However factors such as age at diagnosis and presenting leukocyte count should be taken into consideration when treating this group of patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 8, 459, 65, 21, 373, 210, 17, 541, 1310, 37, 3253, 3, 8573, 6535, 145, 2675, 47, 1503, 123, 29, 2648, 6, 1081, 21, 426, 8, 482, 45, 6, 223, 3, 287, 2, 123, 1, 541, 5, 8573, 6535, 109, 286, 1275, 62, 541, 5, 732, 265, 62, 11, 73, 23, 11152, 62, 2404, 1182, 48, 355, 7, 11, 43, 1173, 1561, 20, 291, 657, 12, 1377, 2580, 21042, 43, 371, 5, 8, 52, 166, 126, 1, 33, 18, 60, 3, 33, 111, 774, 115, 25, 9, 8573, 6535, 109, 7, 10, 887, 72, 5, 493, 9, 8573, 6535, 199, 132, 2765, 7, 19, 474, 3, 33, 111, 63, 25, 116, 10, 1015, 107, 8573, 329, 109, 7, 72, 5, 887, 107, 8573, 6535, 199, 7, 19, 680, 137, 4, 8, 658, 65, 43, 87, 89, 2, 3627, 1276, 28, 147, 2, 3709, 24, 87, 84, 44, 8573, 6535, 156, 11, 204, 6, 40, 306, 674, 1, 228, 21, 2060, 17, 8573, 6535, 109, 7, 47, 1503, 123, 5030, 114, 698, 272, 137, 130, 225, 22, 89, 28, 147, 2, 1656, 3627, 1276, 257, 40, 1633, 237, 2415, 198, 1367, 26, 87, 1, 7]",1214.0,16493009,26
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.,Cancer,Cancer,2006-04-01,"Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens. To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B-ALL, 31 patients with newly diagnosed BL or B-ALL received the hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen with rituximab. Their median age was 46 years; 29% were 60 years or older. Rituximab 375 mg/m(2) was given on Days 1 and 11 of hyper-CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses. Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease. There were no induction deaths. The 3-year overall survival (OS), event-free survival, and disease-free survival rates were 89%, 80%, and 88%, respectively. Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3-year OS rate of 89%. Multivariate analysis of current and historical (those treated with hyper-CVAD alone) groups identified age and treatment with rituximab as favorable factors. The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL, particularly in elderly patients.",Clinical Trial,5043.0,367.0,Adult Burkitt-type BL and acute lymphoblastic B-ALL are rare entities composing 1 to 5 of lymphomas NHL or ALL Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens but has improved with dose-intensive regimens To evaluate the addition of rituximab a CD20 monoclonal antibody to intensive chemotherapy in adults with BL or B-ALL 31 patients with newly diagnosed BL or B-ALL received the hyper-fractionated cyclophosphamide vincristine doxorubicin and dexamethasone hyper-CVAD regimen with rituximab Their median age was 46 years 29 were 60 years or older Rituximab 375 mg/m 2 was given on Days 1 and 11 of hyper-CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses Complete remission complete response CR was achieved in 24 of 28 86 evaluable patients 3 had a partial response and 1 had resistant disease There were no induction deaths The 3-year overall survival OS event-free survival and disease-free survival rates were 89 80 and 88 respectively Nine elderly patients achieved CR with all of them in continuous CR except 1 death in CR from infection with a 3-year OS rate of 89 Multivariate analysis of current and historical those treated with hyper-CVAD alone groups identified age and treatment with rituximab as favorable factors The addition of rituximab to hyper-CVAD may improve outcome in adult BL or B-ALL particularly in elderly patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[780, 14387, 267, 6331, 2, 286, 1275, 132, 62, 32, 622, 4613, 28512, 14, 6, 33, 1, 1557, 1176, 15, 62, 356, 1, 6331, 2, 132, 62, 71, 85, 334, 5, 809, 1176, 15, 62, 472, 84, 71, 231, 5, 61, 1686, 472, 6, 376, 3, 352, 1, 855, 8, 2198, 848, 548, 6, 1686, 56, 4, 857, 5, 6331, 15, 132, 62, 456, 7, 5, 732, 265, 6331, 15, 132, 62, 103, 3, 4855, 3950, 1112, 2132, 856, 2, 1217, 4855, 5574, 477, 5, 855, 136, 52, 89, 10, 641, 60, 462, 11, 335, 60, 15, 434, 855, 4175, 81, 188, 18, 10, 447, 23, 162, 14, 2, 175, 1, 4855, 5574, 1993, 2, 23, 162, 14, 2, 66, 1, 2116, 2, 1855, 1993, 236, 734, 236, 51, 684, 10, 513, 4, 259, 1, 339, 868, 859, 7, 27, 42, 8, 450, 51, 2, 14, 42, 436, 34, 125, 11, 77, 504, 1043, 3, 27, 111, 63, 25, 118, 774, 115, 25, 2, 34, 115, 25, 151, 11, 887, 493, 2, 889, 106, 762, 1216, 7, 513, 684, 5, 62, 1, 1370, 4, 1314, 684, 2187, 14, 273, 4, 684, 29, 930, 5, 8, 27, 111, 118, 116, 1, 887, 331, 65, 1, 291, 2, 2252, 135, 73, 5, 4855, 5574, 279, 271, 108, 89, 2, 24, 5, 855, 22, 913, 130, 3, 352, 1, 855, 6, 4855, 5574, 68, 401, 228, 4, 780, 6331, 15, 132, 62, 823, 4, 1216, 7]",1394.0,16502413,872
A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome.,Blood,Blood,2006-03-14,"Bone marrow normal lymphoid progenitors (CD19+, CD10+, and/or CD34+) are exquisitely sensitive to corticosteroids and other antileukemic drugs. We hypothesized that, in patients with B-lineage acute lymphoblastic leukemia (ALL), cells with this phenotype detected early in treatment should be leukemic rather than normal. We therefore developed a simple and inexpensive flow cytometric assay for such cells and prospectively applied it to bone marrow samples collected on day 19 from 380 children with B-lineage ALL. In 211 patients (55.5%), these cells represented 0.01% or more of the mononuclear cells; results correlated remarkably well with those of more complex flow cytometric and molecular minimal residual disease (MRD) evaluations. Among 84 uniformly treated children, the 10-year incidence of relapse or remission failure was 28.8% +/- 7.1% (SE) for the 42 patients with 0.01% or more leukemic cells on day 19 detected by the simplified assay versus 4.8% +/- 3.3% for the 42 patients with lower levels (P = .003). These assay results were the strongest predictor of outcome, even after adjustment for competing clinicobiologic variables. Thus, this new assay would enable most treatment centers to identify a high proportion of children with ALL who have an excellent early treatment response and a high likelihood of cure.",Evaluation Study,5061.0,97.0,marrow normal lymphoid progenitors CD19+ CD10+ and/or CD34+ are exquisitely sensitive to corticosteroids and other antileukemic drugs We hypothesized that in patients with B-lineage acute lymphoblastic ALL cells with this phenotype detected early in treatment should be leukemic rather than normal We therefore developed a simple and inexpensive flow cytometric assay for such cells and prospectively applied it to marrow samples collected on day 19 from 380 children with B-lineage ALL In 211 patients 55.5 these cells represented 0.01 or more of the mononuclear cells results correlated remarkably well with those of more complex flow cytometric and molecular minimal residual disease MRD evaluations Among 84 uniformly treated children the 10-year incidence of relapse or remission failure was 28.8 +/- 7.1 SE for the 42 patients with 0.01 or more leukemic cells on day 19 detected by the simplified assay versus 4.8 +/- 3.3 for the 42 patients with lower levels P .003 These assay results were the strongest predictor of outcome even after adjustment for competing clinicobiologic variables Thus this new assay would enable most treatment centers to identify a high proportion of children with ALL who have an excellent early treatment response and a high likelihood of cure,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[581, 295, 2303, 4321, 3158, 6289, 2, 15, 2215, 32, 11936, 745, 6, 3876, 2, 127, 4512, 600, 21, 1237, 17, 4, 7, 5, 132, 2542, 286, 1275, 62, 37, 5, 26, 1005, 530, 191, 4, 24, 257, 40, 2015, 1832, 76, 295, 21, 673, 276, 8, 2763, 2, 8168, 1412, 6226, 719, 9, 225, 37, 2, 1143, 1498, 192, 6, 581, 347, 786, 23, 218, 326, 29, 8389, 541, 5, 132, 2542, 62, 4, 5905, 7, 614, 33, 46, 37, 3324, 13, 355, 15, 80, 1, 3, 3041, 37, 99, 438, 4856, 149, 5, 135, 1, 80, 840, 1412, 6226, 2, 219, 1048, 753, 34, 2029, 3816, 107, 874, 4254, 73, 541, 3, 79, 111, 287, 1, 429, 15, 734, 496, 10, 339, 66, 67, 14, 3428, 9, 3, 595, 7, 5, 13, 355, 15, 80, 2015, 37, 23, 218, 326, 530, 20, 3, 8087, 719, 185, 39, 66, 27, 27, 9, 3, 595, 7, 5, 280, 148, 19, 1421, 46, 719, 99, 11, 3, 3311, 980, 1, 228, 871, 50, 1852, 9, 2573, 55347, 682, 631, 26, 217, 719, 688, 3047, 96, 24, 1168, 6, 255, 8, 64, 920, 1, 541, 5, 62, 54, 47, 35, 1503, 191, 24, 51, 2, 8, 64, 1420, 1, 1722]",1278.0,16537802,210
A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2006-04-01,"We compared the outcomes of 298 patients with acute lymphoblastic leukemia in first or second complete remission (CR1 or CR2) receiving HLA-matched sibling allografts after cyclophosphamide and total body irradiation (Cy-TBI) conditioning with 204 patients receiving etoposide and TBI. Consequently, 4 groups were compared: Cy-TBI <13 Gy (n = 217), Cy-TBI > or =13 Gy (n = 81), etoposide-TBI <13 Gy (n = 53), and etoposide-TBI > or =13 Gy (n = 151). Analyses of relapse, leukemia-free survival (LFS), and survival were performed separately for CR1 and CR2 transplantations. Transplant-related mortality did not differ by conditioning regimen. In CR1, there were also no significant differences in relapse, LFS, or survival by conditioning regimen. In CR2, these outcomes differed among conditioning groups. In comparison with Cy-TBI <13 Gy, the risks of relapse, treatment failure (inverse of LFS), and mortality tended to be lower with etoposide (regardless of TBI dose) or with TBI doses > or =13 Gy. For both CR1 and CR2 transplantations, causes of death were similar among the groups; disease recurrence accounted for 47% of deaths. We conclude that for HLA-identical sibling allografts for acute lymphoblastic leukemia in CR2, there is an advantage in substituting etoposide for Cy or, when Cy is used, in increasing the TBI dose to > or =13 Gy.",Clinical Trial,5043.0,113.0,We compared the outcomes of 298 patients with acute lymphoblastic in first or second complete remission CR1 or CR2 receiving HLA-matched sibling allografts after cyclophosphamide and total body irradiation Cy-TBI conditioning with 204 patients receiving etoposide and TBI Consequently 4 groups were compared Cy-TBI 13 Gy n 217 Cy-TBI or =13 Gy n 81 etoposide-TBI 13 Gy n 53 and etoposide-TBI or =13 Gy n 151 Analyses of relapse leukemia-free survival LFS and survival were performed separately for CR1 and CR2 transplantations Transplant-related mortality did not differ by conditioning regimen In CR1 there were also no significant differences in relapse LFS or survival by conditioning regimen In CR2 these outcomes differed among conditioning groups In comparison with Cy-TBI 13 Gy the risks of relapse treatment failure inverse of LFS and mortality tended to be lower with etoposide regardless of TBI dose or with TBI doses or =13 Gy For both CR1 and CR2 transplantations causes of death were similar among the groups disease recurrence accounted for 47 of deaths We conclude that for HLA-identical sibling allografts for acute lymphoblastic in CR2 there is an advantage in substituting etoposide for Cy or when Cy is used in increasing the TBI dose to or =13 Gy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 72, 3, 123, 1, 8651, 7, 5, 286, 1275, 4, 157, 15, 419, 236, 734, 4516, 15, 7865, 357, 1160, 655, 3684, 10586, 50, 1112, 2, 181, 642, 1104, 5757, 4889, 1933, 5, 5996, 7, 357, 1934, 2, 4889, 3244, 39, 271, 11, 72, 5757, 4889, 233, 381, 78, 6499, 5757, 4889, 15, 233, 381, 78, 865, 1934, 4889, 233, 381, 78, 699, 2, 1934, 4889, 15, 233, 381, 78, 5075, 318, 1, 429, 2647, 115, 25, 5674, 2, 25, 11, 173, 3582, 9, 4516, 2, 7865, 6779, 941, 139, 282, 205, 44, 1505, 20, 1933, 477, 4, 4516, 125, 11, 120, 77, 93, 362, 4, 429, 5674, 15, 25, 20, 1933, 477, 4, 7865, 46, 123, 2512, 107, 1933, 271, 4, 1155, 5, 5757, 4889, 233, 381, 3, 1098, 1, 429, 24, 496, 2931, 1, 5674, 2, 282, 3886, 6, 40, 280, 5, 1934, 1583, 1, 4889, 61, 15, 5, 4889, 415, 15, 233, 381, 9, 110, 4516, 2, 7865, 6779, 1626, 1, 273, 11, 288, 107, 3, 271, 34, 146, 3688, 9, 662, 1, 1043, 21, 2060, 17, 9, 1160, 3038, 3684, 10586, 9, 286, 1275, 4, 7865, 125, 16, 35, 1874, 4, 13623, 1934, 9, 5757, 15, 198, 5757, 16, 95, 4, 602, 3, 4889, 61, 6, 15, 233, 381]",1266.0,16545728,241
Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993.,Blood,Blood,2006-03-23,"Outcome of acute lymphoblastic leukemia (ALL) in adults with central nervous system (CNS) disease at diagnosis is unclear. We treated 1508 de novo ALL patients with 2-phase induction and then high-dose methotrexate with l-asparaginase. Patients up to 50 years old in first remission (CR1) with a matched related donor (MRD) underwent an allogeneic stem cell transplantation (SCT); the remainder in CR1 were randomized to an autologous SCT or intensive consolidation followed by maintenance chemotherapy. Philadelphia chromosome (Ph)-positive patients were offered a matched unrelated donor (MUD) allogeneic SCT. Seventy-seven of 1508 (5%) patients a median age of 29 years had CNS leukemia at presentation; 13 of the 77 (17%) had Ph-positive ALL. Sixty-nine of 77 (90%) patients attained CR1. Thirty-six patients underwent transplantation in CR1 (25 MRD, 5 MUD, and 6 autografts). Eleven of 25 patients with MRD transplantation remain alive at 21 to 102 months, 2 of 5 with MUD at 42 and 71 months, and 1 of 6 with autologous SCT at 35 months. Seven of 27 treated with consolidation/maintenance remain in CR1 56 to 137 months after diagnosis. Overall survival at 5 years was 29% in those with CNS involvement at diagnosis versus 38% (P = .03) for those without. CNS leukemia in adult ALL is uncommon at diagnosis. Adult Ph-negative ALL patients, however, can attain long-term disease-free survival using SCT as well as conventional chemotherapy.",Journal Article,5052.0,124.0,Outcome of acute lymphoblastic ALL in adults with central nervous system CNS disease at diagnosis is unclear We treated 1508 de novo ALL patients with 2-phase induction and then high-dose methotrexate with l-asparaginase Patients up to 50 years old in first remission CR1 with a matched related donor MRD underwent an allogeneic stem cell transplantation SCT the remainder in CR1 were randomized to an autologous SCT or intensive consolidation followed by maintenance chemotherapy Philadelphia chromosome Ph -positive patients were offered a matched unrelated donor MUD allogeneic SCT Seventy-seven of 1508 5 patients a median age of 29 years had CNS at presentation 13 of the 77 17 had Ph-positive ALL Sixty-nine of 77 90 patients attained CR1 Thirty-six patients underwent transplantation in CR1 25 MRD 5 MUD and 6 autografts Eleven of 25 patients with MRD transplantation remain alive at 21 to 102 months 2 of 5 with MUD at 42 and 71 months and 1 of 6 with autologous SCT at 35 months Seven of 27 treated with consolidation/maintenance remain in CR1 56 to 137 months after diagnosis Overall survival at 5 years was 29 in those with CNS involvement at diagnosis versus 38 P .03 for those without CNS in adult ALL is uncommon at diagnosis Adult Ph-negative ALL patients however can attain long-term disease-free survival using SCT as well as conventional chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[228, 1, 286, 1275, 62, 4, 857, 5, 854, 1880, 398, 1025, 34, 28, 147, 16, 1200, 21, 73, 28520, 1566, 2018, 62, 7, 5, 18, 124, 504, 2, 818, 64, 61, 2116, 5, 805, 3709, 7, 126, 6, 212, 60, 1095, 4, 157, 734, 4516, 5, 8, 655, 139, 1488, 2029, 208, 35, 1063, 452, 31, 497, 1988, 3, 7095, 4, 4516, 11, 384, 6, 35, 1028, 1988, 15, 1686, 2173, 370, 20, 1146, 56, 3006, 1170, 2058, 109, 7, 11, 2216, 8, 655, 2092, 1488, 7070, 1063, 1988, 2073, 648, 1, 28520, 33, 7, 8, 52, 89, 1, 462, 60, 42, 1025, 28, 1031, 233, 1, 3, 849, 269, 42, 2058, 109, 62, 1746, 762, 1, 849, 424, 7, 5105, 4516, 977, 437, 7, 208, 497, 4, 4516, 243, 2029, 33, 7070, 2, 49, 24879, 2627, 1, 243, 7, 5, 2029, 497, 918, 1701, 28, 239, 6, 2867, 53, 18, 1, 33, 5, 7070, 28, 595, 2, 792, 53, 2, 14, 1, 49, 5, 1028, 1988, 28, 465, 53, 648, 1, 428, 73, 5, 2173, 1146, 918, 4, 4516, 664, 6, 4352, 53, 50, 147, 63, 25, 28, 33, 60, 10, 462, 4, 135, 5, 1025, 799, 28, 147, 185, 519, 19, 680, 9, 135, 187, 1025, 4, 780, 62, 16, 2052, 28, 147, 780, 2058, 199, 62, 7, 137, 122, 10719, 319, 337, 34, 115, 25, 75, 1988, 22, 149, 22, 809, 56]",1368.0,16556888,147
Management of acute lymphoblastic leukemia in older patients.,Seminars in hematology,Semin. Hematol.,2006-04-01,"Although the median age for adults with acute lymphoblastic leukemia (ALL) is older than 60 years, relatively few of these patients have been enrolled on prospective clinical trials. The presence of coexisting medical disorders and unfavorable cytogenetic and biologic disease characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs. Selected patients have achieved remission and long-term survival following intensive chemotherapy. Philadelphia (Ph) chromosome (BCR/ABL)-positive ALL is particularly common among older patients. The availability of specific tyrosine kinase inhibitors is changing the prognosis for this challenging subset.",Journal Article,5043.0,42.0,Although the median age for adults with acute lymphoblastic ALL is older than 60 years relatively few of these patients have been enrolled on prospective clinical trials The presence of coexisting medical disorders and unfavorable cytogenetic and biologic disease characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs Selected patients have achieved remission and long-term survival following intensive chemotherapy Philadelphia Ph chromosome BCR/ABL -positive ALL is particularly common among older patients The availability of specific tyrosine kinase inhibitors is changing the prognosis for this challenging subset,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 3, 52, 89, 9, 857, 5, 286, 1275, 62, 16, 434, 76, 335, 60, 1352, 1021, 1, 46, 7, 47, 85, 346, 23, 482, 38, 143, 3, 463, 1, 8859, 484, 1997, 2, 2483, 1266, 2, 1283, 34, 374, 262, 26, 266, 2740, 2658, 1427, 9, 1401, 24, 75, 809, 56, 2251, 715, 7, 47, 513, 734, 2, 319, 337, 25, 366, 1686, 56, 3006, 2058, 1170, 1062, 1425, 109, 62, 16, 823, 186, 107, 434, 7, 3, 2550, 1, 112, 564, 216, 222, 16, 3600, 3, 356, 9, 26, 1950, 697]",702.0,16616046,814
Richter's transformation in chronic lymphocytic leukemia.,Seminars in oncology,Semin. Oncol.,2006-04-01,"Richter's syndrome (RS) is characterized by the development of high-grade non-Hodgkin's lymphoma (NHL) in a patient with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma. At The University of Texas M.D. Anderson Cancer Center the incidence of RS is 3.9%. The large cells of RS may arise through transformation of the original CLL clone or represent a new neoplasm. RS may be triggered by viral infections, such as Epstein-Barr virus (EBV). Trisomy 12 and chromosome 11 abnormalities, as well as multiple genetic defects, have been described in patients with RS. These abnormalities may cause CLL cells to proliferate and, by facilitating the acquisition of new genetic abnormalities, to transform into RS cells. The therapeutic strategies for RS typically include therapies developed for NHL or acute lymphoblastic leukemia. The reported response rates with these therapies are 5% to 43%, and the median survival duration ranges from 5 to 8 months. The median overall survival duration at our institution of patients with RS is 9.1 months (95% confidence interval, 7.8 to 11 months), and the median failure-free survival duration is 7.1 months (95% confidence interval, 5.1 to 10.4 months). Patients appear to benefit from cytoreductive therapy consisting of chemotherapy and immunotherapy, followed by allogeneic stem cell transplantation, as postremission therapy. As part of a program aiming to cure RS, we are currently conducting a clinical trial of oxaliplatin, fludarabine, and cytarabine in combination with rituximab and recommend postremission therapy, including allogeneic stem cell transplantation in patients with available donors.",Journal Article,5043.0,52.0,Richter 's syndrome RS is characterized by the development of high-grade 's NHL in a patient with chronic lymphocytic CLL or small lymphocytic At The University of Texas M.D Anderson Cancer Center the incidence of RS is 3.9 The large cells of RS may arise through transformation of the original CLL clone or represent a new neoplasm RS may be triggered by viral infections such as Epstein-Barr virus EBV Trisomy 12 and chromosome 11 abnormalities as well as multiple genetic defects have been described in patients with RS These abnormalities may cause CLL cells to proliferate and by facilitating the acquisition of new genetic abnormalities to transform into RS cells The therapeutic strategies for RS typically include therapies developed for NHL or acute lymphoblastic The reported response rates with these therapies are 5 to 43 and the median survival duration ranges from 5 to 8 months The median overall survival duration at our institution of patients with RS is 9.1 months 95 confidence interval 7.8 to 11 months and the median failure-free survival duration is 7.1 months 95 confidence interval 5.1 to 10.4 months Patients appear to benefit from cytoreductive therapy consisting of chemotherapy and immunotherapy followed by allogeneic stem cell transplantation as postremission therapy As part of a program aiming to cure RS we are currently conducting a clinical trial of oxaliplatin fludarabine and cytarabine in combination with rituximab and recommend postremission therapy including allogeneic stem cell transplantation in patients with available donors,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[8452, 292, 681, 2250, 16, 765, 20, 3, 193, 1, 64, 88, 292, 1176, 4, 8, 69, 5, 442, 1193, 552, 15, 302, 1193, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 3, 287, 1, 2250, 16, 27, 83, 3, 375, 37, 1, 2250, 68, 3043, 298, 1392, 1, 3, 2279, 552, 3910, 15, 1231, 8, 217, 2131, 2250, 68, 40, 4173, 20, 1667, 1875, 225, 22, 5212, 5190, 1450, 2672, 6317, 133, 2, 1170, 175, 1171, 22, 149, 22, 232, 336, 2945, 47, 85, 1027, 4, 7, 5, 2250, 46, 1171, 68, 708, 552, 37, 6, 9554, 2, 20, 5379, 3, 3405, 1, 217, 336, 1171, 6, 7136, 237, 2250, 37, 3, 189, 422, 9, 2250, 1969, 643, 235, 276, 9, 1176, 15, 286, 1275, 3, 210, 51, 151, 5, 46, 235, 32, 33, 6, 601, 2, 3, 52, 25, 654, 5632, 29, 33, 6, 66, 53, 3, 52, 63, 25, 654, 28, 114, 731, 1, 7, 5, 2250, 16, 83, 14, 53, 48, 307, 268, 67, 66, 6, 175, 53, 2, 3, 52, 496, 115, 25, 654, 16, 67, 14, 53, 48, 307, 268, 33, 14, 6, 79, 39, 53, 7, 1322, 6, 247, 29, 2604, 36, 2273, 1, 56, 2, 726, 370, 20, 1063, 452, 31, 497, 22, 8635, 36, 22, 760, 1, 8, 1243, 10279, 6, 1722, 2250, 21, 32, 694, 6018, 8, 38, 160, 1, 1476, 2027, 2, 1855, 4, 150, 5, 855, 2, 2237, 8635, 36, 141, 1063, 452, 31, 497, 4, 7, 5, 390, 2344]",1570.0,16616072,465
Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2.,Blood,Blood,2006-04-20,"In childhood acute lymphoblastic leukemia (ALL), early response to treatment is a powerful prognostic indicator. To identify genes associated with this response, we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease (MRD) levels on days 19 and 46 of remission induction treatment. After excluding genes associated with genetic subgroups, we identified 17 genes that were significantly associated with MRD. The caspase 8-associated protein 2 (CASP8AP2) gene was studied further because of its reported role in apoptosis and glucocorticoid signaling. In a separate cohort of 99 patients not included in the comparison of gene expression profiles and MRD, low levels of CASP8AP2 expression predicted a lower event-free survival (P = .02) and a higher rate of leukemia relapse (P = .01) and were an independent predictor of outcome. High levels of CASP8AP2 expression were associated with a greater propensity of leukemic lymphoblasts to undergo apoptosis. We conclude that measurement of CASP8AP2 expression at diagnosis offers a means to identify patients whose leukemic cells are highly susceptible to chemotherapy. Therefore, this gene is a strong candidate for inclusion in gene expression arrays specifically designed for leukemia diagnosis.",Journal Article,5024.0,69.0,In childhood acute lymphoblastic ALL early response to treatment is a powerful prognostic indicator To identify genes associated with this response we analyzed gene expression of diagnostic lymphoblasts from 189 children with ALL and compared the findings with minimal residual disease MRD levels on days 19 and 46 of remission induction treatment After excluding genes associated with genetic subgroups we identified 17 genes that were significantly associated with MRD The caspase 8-associated protein 2 CASP8AP2 gene was studied further because of its reported role in apoptosis and glucocorticoid signaling In a separate cohort of 99 patients not included in the comparison of gene expression profiles and MRD low levels of CASP8AP2 expression predicted a lower event-free survival P .02 and a higher rate of relapse P .01 and were an independent predictor of outcome High levels of CASP8AP2 expression were associated with a greater propensity of leukemic lymphoblasts to undergo apoptosis We conclude that measurement of CASP8AP2 expression at diagnosis offers a means to identify patients whose leukemic cells are highly susceptible to chemotherapy Therefore this gene is a strong candidate for inclusion in gene expression arrays specifically designed for diagnosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 864, 286, 1275, 62, 191, 51, 6, 24, 16, 8, 3757, 177, 3287, 6, 255, 214, 41, 5, 26, 51, 21, 311, 145, 55, 1, 752, 10521, 29, 5899, 541, 5, 62, 2, 72, 3, 272, 5, 1048, 753, 34, 2029, 148, 23, 162, 326, 2, 641, 1, 734, 504, 24, 50, 3207, 214, 41, 5, 336, 1453, 21, 108, 269, 214, 17, 11, 97, 41, 5, 2029, 3, 1469, 66, 41, 178, 18, 34072, 145, 10, 656, 195, 408, 1, 211, 210, 200, 4, 351, 2, 5399, 314, 4, 8, 2282, 180, 1, 1058, 7, 44, 159, 4, 3, 1155, 1, 145, 55, 1241, 2, 2029, 154, 148, 1, 34072, 55, 783, 8, 280, 774, 115, 25, 19, 588, 2, 8, 142, 116, 1, 429, 19, 355, 2, 11, 35, 306, 980, 1, 228, 64, 148, 1, 34072, 55, 11, 41, 5, 8, 378, 1925, 1, 2015, 10521, 6, 1251, 351, 21, 2060, 17, 2204, 1, 34072, 55, 28, 147, 2339, 8, 2263, 6, 255, 7, 1310, 2015, 37, 32, 561, 4012, 6, 56, 673, 26, 145, 16, 8, 1082, 1609, 9, 1680, 4, 145, 55, 3923, 1225, 1114, 9, 147]",1273.0,16627760,42
Leukemia-stimulated bone marrow endothelium promotes leukemia cell survival.,Experimental hematology,Exp. Hematol.,2006-05-01,"Extensive endothelial cell proliferation and marked neovascularization are the most pronounced microenvironmental changes consistently observed in the bone marrow (BM) of patients with acute lymphoblastic leukemia (ALL). It is not known whether ALL cells induce this phenotype and whether they receive critical signals from the tumor-associated BM endothelium. Here, we show that leukemia cells actively stimulate BM endothelium, promote de novo angiogenesis, and induce neovascularization in the leukemic BM. Soluble factors, present in the leukemic BM microenvironment, promote the proliferation, migration, and morphogenesis of BM endothelial cells, which are critical processes in tumor angiogenesis. We also show in vitro that leukemia cells display directional motion towards assembled BM endothelium and following adherence exhibit cell polarization, pseudopodia, and ultrastructural features that suggest the existence of leukemia-endothelium cross-talk. Finally, we show that BM endothelium promotes leukemia cell survival through a mechanism mediated through the anti-apoptotic molecule bcl-2. These studies indicate that ALL cells actively recruit BM endothelium and mediate the leukemia-associated neovascularization observed in ALL. Therefore, disruption of interactions between leukemia cells and BM endothelium may constitute a valid therapeutic strategy.",Journal Article,5013.0,37.0,Extensive endothelial cell proliferation and marked neovascularization are the most pronounced microenvironmental changes consistently observed in the marrow BM of patients with acute lymphoblastic ALL It is not known whether ALL cells induce this phenotype and whether they receive critical signals from the tumor-associated BM endothelium Here we show that cells actively stimulate BM endothelium promote de novo angiogenesis and induce neovascularization in the leukemic BM Soluble factors present in the leukemic BM microenvironment promote the proliferation migration and morphogenesis of BM endothelial cells which are critical processes in tumor angiogenesis We also show in vitro that cells display directional motion towards assembled BM endothelium and following adherence exhibit cell polarization pseudopodia and ultrastructural features that suggest the existence of leukemia-endothelium cross-talk Finally we show that BM endothelium promotes cell survival through a mechanism mediated through the anti-apoptotic molecule bcl-2 These studies indicate that ALL cells actively recruit BM endothelium and mediate the leukemia-associated neovascularization observed in ALL Therefore disruption of interactions between cells and BM endothelium may constitute a valid therapeutic strategy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1344, 845, 31, 457, 2, 2003, 10551, 32, 3, 96, 3517, 9300, 400, 2433, 164, 4, 3, 581, 1246, 1, 7, 5, 286, 1275, 62, 192, 16, 44, 440, 317, 62, 37, 1290, 26, 1005, 2, 317, 491, 560, 740, 2312, 29, 3, 30, 41, 1246, 5300, 467, 21, 514, 17, 37, 4489, 4223, 1246, 5300, 1617, 1566, 2018, 1056, 2, 1290, 10551, 4, 3, 2015, 1246, 2968, 130, 364, 4, 3, 2015, 1246, 995, 1617, 3, 457, 1381, 2, 13281, 1, 1246, 845, 37, 92, 32, 740, 1849, 4, 30, 1056, 21, 120, 514, 4, 439, 17, 37, 3640, 15325, 2967, 3113, 6154, 1246, 5300, 2, 366, 2149, 2239, 31, 9207, 44319, 2, 13755, 404, 17, 309, 3, 5335, 1, 2647, 5300, 1383, 6522, 1368, 21, 514, 17, 1246, 5300, 2148, 31, 25, 298, 8, 670, 517, 298, 3, 312, 1631, 1354, 1044, 18, 46, 94, 1008, 17, 62, 37, 4489, 8973, 1246, 5300, 2, 3367, 3, 2647, 41, 10551, 164, 4, 62, 673, 3220, 1, 1286, 59, 37, 2, 1246, 5300, 68, 4999, 8, 4406, 189, 692]",1296.0,16647567,327
Activity of alemtuzumab in patients with CD52-positive acute leukemia.,Cancer,Cancer,2006-06-01,"Alemtuzumab is a humanized monoclonal antibody directed against the cell surface antigen CD52 and has demonstrated activity in chronic lymphocytic leukemia and other CD52-positive lymphoproliferative disorders. Because CD52 also is expressed on acute leukemic blasts, the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). Fifteen patients with CD52-positive (> or = 20%), recurrent or refractory acute leukemia (9 patients with AML and 6 patients with ALL) received alemtuzumab at a dose of 30 mg intravenously given 3 times a week (dose escalation during Week 1) for a total of 4 to 12 weeks. The median age of the patients was 39 years (range, 18-71 years). Patients had received a median of 3 prior therapies (range, 1-5 prior therapies). Two patients (13%) achieved a bone marrow complete response and 1 patient achieved a substantial reduction in bone marrow blasts. No complete remissions were observed. Ten patients developed disease progression while on study. Alemtuzumab was myelosuppressive in nearly all patients. Infusion-related toxicities were common, but usually did not exceed Grade 2 (according to the National Cancer Institute Common Toxicity Criteria). Infectious episodes occurred in 13 patients (87%) and included pneumonia (6 patients), bacteremia (11 patients), fungemia (2 patients), and cytomegalovirus reactivation (2 patients). Single-agent alemtuzumab was found to have limited activity in recurrent or refractory acute leukemia. An evaluation in patients with a better prognosis, in combination with other agents or as part of consolidation therapy, is warranted.",Clinical Trial,4982.0,74.0,Alemtuzumab is a humanized monoclonal antibody directed against the cell surface antigen CD52 and has demonstrated activity in chronic lymphocytic and other CD52-positive lymphoproliferative disorders Because CD52 also is expressed on acute leukemic blasts the authors investigated the safety and efficacy of alemtuzumab in patients with acute myeloid AML and acute lymphoblastic ALL Fifteen patients with CD52-positive or 20 recurrent or refractory acute 9 patients with AML and 6 patients with ALL received alemtuzumab at a dose of 30 mg intravenously given 3 times a week dose escalation during Week 1 for a total of 4 to 12 weeks The median age of the patients was 39 years range 18-71 years Patients had received a median of 3 prior therapies range 1-5 prior therapies Two patients 13 achieved a marrow complete response and 1 patient achieved a substantial reduction in marrow blasts No complete remissions were observed Ten patients developed disease progression while on study Alemtuzumab was myelosuppressive in nearly all patients Infusion-related toxicities were common but usually did not exceed Grade 2 according to the National Cancer Institute Common Toxicity Criteria Infectious episodes occurred in 13 patients 87 and included pneumonia 6 patients bacteremia 11 patients fungemia 2 patients and cytomegalovirus reactivation 2 patients Single-agent alemtuzumab was found to have limited activity in recurrent or refractory acute An evaluation in patients with a better prognosis in combination with other agents or as part of consolidation therapy is warranted,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3579, 16, 8, 3619, 848, 548, 1166, 480, 3, 31, 1255, 448, 7189, 2, 71, 264, 128, 4, 442, 1193, 2, 127, 7189, 109, 4192, 1997, 408, 7189, 120, 16, 570, 23, 286, 2015, 2438, 3, 738, 565, 3, 367, 2, 209, 1, 3579, 4, 7, 5, 286, 533, 329, 2, 286, 1275, 62, 3057, 7, 5, 7189, 109, 15, 179, 387, 15, 430, 286, 83, 7, 5, 329, 2, 49, 7, 5, 62, 103, 3579, 28, 8, 61, 1, 201, 81, 1672, 447, 27, 1072, 8, 647, 61, 1125, 190, 647, 14, 9, 8, 181, 1, 39, 6, 133, 244, 3, 52, 89, 1, 3, 7, 10, 587, 60, 184, 203, 792, 60, 7, 42, 103, 8, 52, 1, 27, 324, 235, 184, 14, 33, 324, 235, 100, 7, 233, 513, 8, 581, 236, 51, 2, 14, 69, 513, 8, 1281, 628, 4, 581, 2438, 77, 236, 3166, 11, 164, 1618, 7, 276, 34, 91, 369, 23, 45, 3579, 10, 11109, 4, 1857, 62, 7, 904, 139, 385, 11, 186, 84, 2082, 205, 44, 6818, 88, 18, 768, 6, 3, 657, 12, 1377, 186, 155, 371, 3398, 3750, 489, 4, 233, 7, 912, 2, 159, 3485, 49, 7, 7085, 175, 7, 34088, 18, 7, 2, 7314, 3834, 18, 7, 226, 420, 3579, 10, 204, 6, 47, 383, 128, 4, 387, 15, 430, 286, 35, 451, 4, 7, 5, 8, 380, 356, 4, 150, 5, 127, 183, 15, 22, 760, 1, 2173, 36, 16, 1197]",1576.0,16688777,346
Expression of the outcome predictor in acute leukemia 1 (OPAL1) gene is not an independent prognostic factor in patients treated according to COALL or St Jude protocols.,Blood,Blood,2006-05-18,"New prognostic factors may result in better risk classification and improved treatment of children with acute lymphoblastic leukemia (ALL). Recently, high expression of a gene named OPAL1 (outcome predictor in acute leukemia) was reported to be associated with favorable prognosis in ALL. Therefore, we investigated whether OPAL1 expression was of prognostic importance in 2 independent cohorts of children with ALL treated on Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia (COALL)-92/97 (n = 180) and St Jude Total 13 protocols (n = 257). We observed a consistently higher (2.8-fold) expression of OPAL1 in TEL-AML1-positive ALL compared with TEL-AML1-negative ALL in both cohorts, but higher OPAL1 expression was not consistently associated with other favorable prognostic indicators such as age and white blood cell count, or ALL genetic subtype. Lower OPAL1 expression was also not associated with increased in vitro drug resistance. Multivariate analyses including known risk factors showed that OPAL1 expression was not independently related to prognosis in either the COALL or St Jude cohorts. In conclusion, OPAL1 expression may not be an independent prognostic feature in childhood ALL, and its previously reported prognostic impact appears to be treatment dependent.",Clinical Trial,4996.0,15.0,New prognostic factors may result in better risk classification and improved treatment of children with acute lymphoblastic ALL Recently high expression of a gene named OPAL1 outcome predictor in acute was reported to be associated with favorable prognosis in ALL Therefore we investigated whether OPAL1 expression was of prognostic importance in 2 independent cohorts of children with ALL treated on Cooperative Study Group for Childhood Acute Lymphoblastic COALL -92/97 n 180 and St Jude Total 13 protocols n 257 We observed a consistently higher 2.8-fold expression of OPAL1 in TEL-AML1-positive ALL compared with TEL-AML1-negative ALL in both cohorts but higher OPAL1 expression was not consistently associated with other favorable prognostic indicators such as age and white blood cell count or ALL genetic subtype Lower OPAL1 expression was also not associated with increased in vitro drug resistance Multivariate analyses including known risk factors showed that OPAL1 expression was not independently related to prognosis in either the COALL or St Jude cohorts In conclusion OPAL1 expression may not be an independent prognostic feature in childhood ALL and its previously reported prognostic impact appears to be treatment dependent,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[217, 177, 130, 68, 757, 4, 380, 43, 947, 2, 231, 24, 1, 541, 5, 286, 1275, 62, 761, 64, 55, 1, 8, 145, 8373, 26509, 228, 980, 4, 286, 10, 210, 6, 40, 41, 5, 913, 356, 4, 62, 673, 21, 565, 317, 26509, 55, 10, 1, 177, 1187, 4, 18, 306, 736, 1, 541, 5, 62, 73, 23, 1690, 45, 87, 9, 864, 286, 1275, 44352, 937, 1015, 78, 3172, 2, 3062, 4841, 181, 233, 2189, 78, 7941, 21, 164, 8, 2433, 142, 18, 66, 1116, 55, 1, 26509, 4, 8573, 6535, 109, 62, 72, 5, 8573, 6535, 199, 62, 4, 110, 736, 84, 142, 26509, 55, 10, 44, 2433, 41, 5, 127, 913, 177, 3539, 225, 22, 89, 2, 886, 315, 31, 1276, 15, 62, 336, 875, 280, 26509, 55, 10, 120, 44, 41, 5, 101, 4, 439, 234, 251, 331, 318, 141, 440, 43, 130, 224, 17, 26509, 55, 10, 44, 1042, 139, 6, 356, 4, 361, 3, 44352, 15, 3062, 4841, 736, 4, 1221, 26509, 55, 68, 44, 40, 35, 306, 177, 2705, 4, 864, 62, 2, 211, 373, 210, 177, 345, 1233, 6, 40, 24, 470]",1241.0,16709928,235
Child and maternal household chemical exposure and the risk of acute leukemia in children with Down's syndrome: a report from the Children's Oncology Group.,American journal of epidemiology,Am. J. Epidemiol.,2006-06-07,"Compared with the general pediatric population, children with Down's syndrome have a much higher risk of acute leukemia. This case-control study was designed to explore potential risk factors for acute lymphoblastic leukemia and acute myeloid leukemia in children with Down's syndrome living in the United States or Canada. Mothers of 158 children with Down's syndrome and acute leukemia (97 acute lymphoblastic leukemia, 61 acute myeloid leukemia) diagnosed between January 1997 and October 2002 and mothers of 173 children with Down's syndrome but without leukemia were interviewed by telephone. Positive associations were found between acute lymphoblastic leukemia and maternal exposure to professional pest exterminations (odds ratio = 2.25, 95% confidence interval: 1.13, 4.49), to any pesticide (odds ratio = 2.18, 95% confidence interval: 1.08, 4.39), and to any chemical (odds ratio = 2.72, 95% confidence interval: 1.17, 6.35). Most of the associations with acute myeloid leukemia were nonsignificant, and odds ratios were generally near or below 1.0. This exploratory study suggests that household chemical exposure may play a role in the development of acute lymphoblastic leukemia in children with Down's syndrome.",Journal Article,4976.0,37.0,Compared with the general pediatric population children with Down 's syndrome have a much higher risk of acute This case-control study was designed to explore potential risk factors for acute lymphoblastic and acute myeloid in children with Down 's syndrome living in the United States or Canada Mothers of 158 children with Down 's syndrome and acute 97 acute lymphoblastic 61 acute myeloid diagnosed between January 1997 and October 2002 and mothers of 173 children with Down 's syndrome but without were interviewed by telephone Positive associations were found between acute lymphoblastic and maternal exposure to professional pest exterminations odds ratio 2.25 95 confidence interval 1.13 4.49 to any pesticide odds ratio 2.18 95 confidence interval 1.08 4.39 and to any chemical odds ratio 2.72 95 confidence interval 1.17 6.35 Most of the associations with acute myeloid were nonsignificant and odds ratios were generally near or below 1.0 This exploratory study suggests that household chemical exposure may play a role in the development of acute lymphoblastic in children with Down 's syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[72, 5, 3, 1083, 815, 266, 541, 5, 1328, 292, 681, 47, 8, 1802, 142, 43, 1, 286, 26, 473, 182, 45, 10, 1114, 6, 1645, 174, 43, 130, 9, 286, 1275, 2, 286, 533, 4, 541, 5, 1328, 292, 681, 2798, 4, 3, 1088, 907, 15, 4740, 8605, 1, 5162, 541, 5, 1328, 292, 681, 2, 286, 1015, 286, 1275, 713, 286, 533, 265, 59, 1024, 2341, 2, 2551, 1544, 2, 8605, 1, 5785, 541, 5, 1328, 292, 681, 84, 187, 11, 6713, 20, 4258, 109, 685, 11, 204, 59, 286, 1275, 2, 6039, 645, 6, 5341, 33741, 55554, 610, 197, 18, 243, 48, 307, 268, 14, 233, 39, 739, 6, 500, 28547, 610, 197, 18, 203, 48, 307, 268, 14, 1592, 39, 587, 2, 6, 500, 3743, 610, 197, 18, 720, 48, 307, 268, 14, 269, 49, 465, 96, 1, 3, 685, 5, 286, 533, 11, 5542, 2, 610, 1137, 11, 1228, 1829, 15, 2736, 14, 13, 26, 2386, 45, 844, 17, 7353, 3743, 645, 68, 1343, 8, 200, 4, 3, 193, 1, 286, 1275, 4, 541, 5, 1328, 292, 681]",1104.0,16760223,159
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.,The New England journal of medicine,N. Engl. J. Med.,2006-06-01,"The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive (Ph-positive) leukemias, but relapse occurs, mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations. We evaluated dasatinib, a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations, in patients with chronic myelogenous leukemia (CML) or Ph-positive acute lymphoblastic leukemia (ALL). Patients with various phases of CML or with Ph-positive ALL who could not tolerate or were resistant to imatinib were enrolled in a phase 1 dose-escalation study. Dasatinib (15 to 240 mg per day) was administered orally in four-week treatment cycles, once or twice daily. A complete hematologic response was achieved in 37 of 40 patients with chronic-phase CML, and major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML, CML with blast crisis, or Ph-positive ALL. In these two phases, the rates of major cytogenetic response were 45 percent and 25 percent, respectively. Responses were maintained in 95 percent of patients with chronic-phase disease and in 82 percent of patients with accelerated-phase disease, with a median follow-up more than 12 months and 5 months, respectively. Nearly all patients with lymphoid blast crisis and Ph-positive ALL had a relapse within six months. Responses occurred among all BCR-ABL genotypes, with the exception of the T315I mutation, which confers resistance to both dasatinib and imatinib in vitro. Myelosuppression was common but not dose-limiting. Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who cannot tolerate or are resistant to imatinib. (ClinicalTrials.gov number, NCT00064233 [ClinicalTrials.gov].).","Clinical Trial, Phase I",4982.0,1321.0,The BCR-ABL tyrosine kinase inhibitor imatinib is effective in Philadelphia chromosome-positive Ph-positive leukemias but relapse occurs mainly as a result of the outgrowth of leukemic subclones with imatinib-resistant BCR-ABL mutations We evaluated dasatinib a BCR-ABL inhibitor that targets most imatinib-resistant BCR-ABL mutations in patients with chronic myelogenous CML or Ph-positive acute lymphoblastic ALL Patients with various phases of CML or with Ph-positive ALL who could not tolerate or were resistant to imatinib were enrolled in a phase 1 dose-escalation study Dasatinib 15 to 240 mg per day was administered orally in four-week treatment cycles once or twice daily A complete hematologic response was achieved in 37 of 40 patients with chronic-phase CML and major hematologic responses were seen in 31 of 44 patients with accelerated-phase CML CML with blast crisis or Ph-positive ALL In these two phases the rates of major cytogenetic response were 45 percent and 25 percent respectively Responses were maintained in 95 percent of patients with chronic-phase disease and in 82 percent of patients with accelerated-phase disease with a median follow-up more than 12 months and 5 months respectively Nearly all patients with lymphoid blast crisis and Ph-positive ALL had a relapse within six months Responses occurred among all BCR-ABL genotypes with the exception of the T315I mutation which confers resistance to both dasatinib and imatinib in vitro Myelosuppression was common but not dose-limiting Dasatinib induces hematologic and cytogenetic responses in patients with CML or Ph-positive ALL who can not tolerate or are resistant to imatinib ClinicalTrials.gov number NCT00064233 ClinicalTrials.gov,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1062, 1425, 564, 216, 230, 577, 16, 323, 4, 3006, 1170, 109, 2058, 109, 2792, 84, 429, 1780, 2615, 22, 8, 757, 1, 3, 7201, 1, 2015, 8881, 5, 577, 436, 1062, 1425, 138, 21, 194, 1674, 8, 1062, 1425, 230, 17, 637, 96, 577, 436, 1062, 1425, 138, 4, 7, 5, 442, 2194, 903, 15, 2058, 109, 286, 1275, 62, 7, 5, 747, 3523, 1, 903, 15, 5, 2058, 109, 62, 54, 359, 44, 5010, 15, 11, 436, 6, 577, 11, 346, 4, 8, 124, 14, 61, 1125, 45, 1674, 167, 6, 4263, 81, 379, 218, 10, 468, 1428, 4, 294, 647, 24, 410, 1059, 15, 936, 391, 8, 236, 813, 51, 10, 513, 4, 567, 1, 327, 7, 5, 442, 124, 903, 2, 458, 813, 253, 11, 527, 4, 456, 1, 584, 7, 5, 2241, 124, 903, 903, 5, 3112, 6540, 15, 2058, 109, 62, 4, 46, 100, 3523, 3, 151, 1, 458, 1266, 51, 11, 512, 714, 2, 243, 714, 106, 253, 11, 1955, 4, 48, 714, 1, 7, 5, 442, 124, 34, 2, 4, 878, 714, 1, 7, 5, 2241, 124, 34, 5, 8, 52, 166, 126, 80, 76, 133, 53, 2, 33, 53, 106, 1857, 62, 7, 5, 2303, 3112, 6540, 2, 2058, 109, 62, 42, 8, 429, 262, 437, 53, 253, 489, 107, 62, 1062, 1425, 2071, 5, 3, 4188, 1, 3, 6184, 258, 92, 4020, 251, 6, 110, 1674, 2, 577, 4, 439, 2858, 10, 186, 84, 44, 61, 817, 1674, 1516, 813, 2, 1266, 253, 4, 7, 5, 903, 15, 2058, 109, 62, 54, 122, 44, 5010, 15, 32, 436, 6, 577, 1252, 1239, 207, 55566, 1252, 1239]",1720.0,16775234,132
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.,The New England journal of medicine,N. Engl. J. Med.,2006-06-01,"Resistance to imatinib mesylate can occur in chronic myelogenous leukemia (CML). Preclinical in vitro studies have shown that nilotinib (AMN107), a new BCR-ABL tyrosine kinase inhibitor, is more potent than imatinib against CML cells by a factor of 20 to 50. In a phase 1 dose-escalation study, we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic leukemia (ALL) to receive nilotinib orally at doses of 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, and 1200 mg once daily and at 400 mg and 600 mg twice daily. Common adverse events were myelosuppression, transient indirect hyperbilirubinemia, and rashes. Of 33 patients with the blastic phase of disease, 13 had a hematologic response and 9 had a cytogenetic response; of 46 patients with the accelerated phase, 33 had a hematologic response and 22 had a cytogenetic response; 11 of 12 patients with the chronic phase had a complete hematologic remission. Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML. (ClinicalTrials.gov number, NCT00109707 [ClinicalTrials.gov].).","Clinical Trial, Phase I",4982.0,1041.0,Resistance to imatinib mesylate can occur in chronic myelogenous CML Preclinical in vitro studies have shown that nilotinib AMN107 a new BCR-ABL tyrosine kinase inhibitor is more potent than imatinib against CML cells by a factor of 20 to 50 In a phase 1 dose-escalation study we assigned 119 patients with imatinib-resistant CML or acute lymphoblastic ALL to receive nilotinib orally at doses of 50 mg 100 mg 200 mg 400 mg 600 mg 800 mg and 1200 mg once daily and at 400 mg and 600 mg twice daily Common adverse events were myelosuppression transient indirect hyperbilirubinemia and rashes Of 33 patients with the blastic phase of disease 13 had a hematologic response and 9 had a cytogenetic response of 46 patients with the accelerated phase 33 had a hematologic response and 22 had a cytogenetic response 11 of 12 patients with the chronic phase had a complete hematologic remission Nilotinib has a relatively favorable safety profile and is active in imatinib-resistant CML ClinicalTrials.gov number NCT00109707 ClinicalTrials.gov,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[251, 6, 577, 2347, 122, 1271, 4, 442, 2194, 903, 693, 4, 439, 94, 47, 443, 17, 2638, 12189, 8, 217, 1062, 1425, 564, 216, 230, 16, 80, 1157, 76, 577, 480, 903, 37, 20, 8, 161, 1, 179, 6, 212, 4, 8, 124, 14, 61, 1125, 45, 21, 896, 4299, 7, 5, 577, 436, 903, 15, 286, 1275, 62, 6, 560, 2638, 1428, 28, 415, 1, 212, 81, 394, 81, 1250, 81, 1524, 81, 2383, 81, 2796, 81, 2, 6847, 81, 1059, 391, 2, 28, 1524, 81, 2, 2383, 81, 936, 391, 186, 290, 281, 11, 2858, 2473, 6110, 7236, 2, 11775, 1, 466, 7, 5, 3, 6529, 124, 1, 34, 233, 42, 8, 813, 51, 2, 83, 42, 8, 1266, 51, 1, 641, 7, 5, 3, 2241, 124, 466, 42, 8, 813, 51, 2, 350, 42, 8, 1266, 51, 175, 1, 133, 7, 5, 3, 442, 124, 42, 8, 236, 813, 734, 2638, 71, 8, 1352, 913, 367, 800, 2, 16, 544, 4, 577, 436, 903, 1252, 1239, 207, 38200, 1252, 1239]",1035.0,16775235,19
Computer-aided detection of therapy-induced leukoencephalopathy in pediatric acute lymphoblastic leukemia patients treated with intravenous high-dose methotrexate.,Magnetic resonance imaging,Magn Reson Imaging,2006-04-27,"The purpose of this study was to use objective quantitative magnetic resonance imaging (MRI) methods to develop a computer-aided detection (CAD) tool to differentiate white matter (WM) hyperintensities into either leukoencephalopathy (LE) induced by chemotherapy or normal maturational processes in children treated for acute lymphoblastic leukemia without irradiation. A combined MRI set consisting of T1-weighted, T2-weighted, proton-density-weighted and fluid-attenuated inversion recovery images and WM, gray matter and cerebrospinal fluid proportional volume maps from a spatially normalized atlas were analyzed with a neural network segmentation based on a Kohonen self-organizing map (SOM). Segmented maps were manually classified to identify the most hyperintense WM region and the normal-appearing genu region. Signal intensity differences normalized to the genu within each examination were generated for four time points in 228 children. A second Kohonen SOM was trained on the first examination data and divided the WM into normal-appearing or LE groups. Reviewing labels from the CAD tool revealed a consistency measure of 89.8% (167 of 186) within patients. The overall agreement between the CAD tool and the consensus reading of two trained observers was 84.1% (535 of 636), with 84.2% (170 of 202) agreement in the training set and 84.1% (365 of 434) agreement in the testing set. These results suggest that subtle therapy-induced LE can be objectively and reproducibly detected in children treated for cancer using this CAD approach based on relative differences in quantitative signal intensity measures normalized within each examination.",Journal Article,5017.0,9.0,The purpose of this study was to use objective quantitative magnetic resonance imaging MRI methods to develop a computer-aided detection CAD tool to differentiate white matter WM hyperintensities into either leukoencephalopathy LE induced by chemotherapy or normal maturational processes in children treated for acute lymphoblastic without irradiation A combined MRI set consisting of T1-weighted T2-weighted proton-density-weighted and fluid-attenuated inversion recovery images and WM gray matter and cerebrospinal fluid proportional volume maps from a spatially normalized atlas were analyzed with a neural network segmentation based on a Kohonen self-organizing map SOM Segmented maps were manually classified to identify the most hyperintense WM region and the normal-appearing genu region Signal intensity differences normalized to the genu within each examination were generated for four time points in 228 children A second Kohonen SOM was trained on the first examination data and divided the WM into normal-appearing or LE groups Reviewing labels from the CAD tool revealed a consistency measure of 89.8 167 of 186 within patients The overall agreement between the CAD tool and the consensus reading of two trained observers was 84.1 535 of 636 with 84.2 170 of 202 agreement in the training set and 84.1 365 of 434 agreement in the testing set These results suggest that subtle therapy-induced LE can be objectively and reproducibly detected in children treated for cancer using this CAD approach based on relative differences in quantitative signal intensity measures normalized within each examination,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 119, 461, 1156, 1484, 1535, 270, 704, 636, 6, 690, 8, 4236, 8783, 638, 6378, 1515, 6, 3723, 886, 5090, 1518, 38213, 237, 361, 8744, 4892, 277, 20, 56, 15, 295, 30504, 1849, 4, 541, 73, 9, 286, 1275, 187, 1104, 8, 397, 704, 916, 2273, 1, 1534, 2337, 1786, 2337, 2095, 1263, 2337, 2, 2357, 2656, 8487, 1602, 1572, 2, 1518, 4163, 5090, 2, 5156, 2357, 831, 433, 5845, 29, 8, 11772, 4207, 2643, 11, 311, 5, 8, 3922, 1801, 5913, 90, 23, 8, 37816, 1074, 15917, 3771, 44410, 9199, 5845, 11, 8474, 1373, 6, 255, 3, 96, 13223, 1518, 1053, 2, 3, 295, 6536, 19019, 1053, 1235, 837, 362, 4207, 6, 3, 19019, 262, 296, 1385, 11, 1419, 9, 294, 98, 862, 4, 6736, 541, 8, 419, 37816, 44410, 10, 5946, 23, 3, 157, 1385, 74, 2, 2176, 3, 1518, 237, 295, 6536, 15, 4892, 271, 6979, 15691, 29, 3, 6378, 1515, 553, 8, 5358, 1463, 1, 887, 66, 5431, 1, 5869, 262, 7, 3, 63, 2024, 59, 3, 6378, 1515, 2, 3, 1391, 7299, 1, 100, 5946, 8803, 10, 874, 14, 10528, 1, 12181, 5, 874, 18, 5248, 1, 5918, 2024, 4, 3, 1741, 916, 2, 874, 14, 7405, 1, 11483, 2024, 4, 3, 471, 916, 46, 99, 309, 17, 7543, 36, 277, 4892, 122, 40, 8731, 2, 10580, 530, 4, 541, 73, 9, 12, 75, 26, 6378, 353, 90, 23, 580, 362, 4, 1156, 1235, 837, 1018, 4207, 262, 296, 1385]",1614.0,16824973,149
Epigenetic regulation of human gamma-glutamyl hydrolase activity in acute lymphoblastic leukemia cells.,American journal of human genetics,Am. J. Hum. Genet.,2006-06-06,"Gamma-glutamyl hydrolase (GGH) catalyzes degradation of the active polyglutamates of natural folates and the antifolate methotrexate (MTX). We found that GGH activity is directly related to GGH messenger RNA expression in acute lymphoblastic leukemia (ALL) cells of patients with a wild-type germline GGH genotype. We identified two CpG islands (CpG1 and CpG2) in the region extending from the GGH promoter through the first exon and into intron 1 and showed that methylation of both CpG islands in the GGH promoter (seen in leukemia cells from approximately 15% of patients with nonhyperdiploid B-lineage ALL) is associated with significantly reduced GGH mRNA expression and catalytic activity and with significantly higher accumulation of MTX polyglutamates (MTXPG(4-7)) in ALL cells. Furthermore, methylation of CpG1 was leukemia-cell specific and had a pronounced effect on GGH expression, whereas methylation of CpG2 was common in leukemia cells and normal leukocytes but did not significantly alter GGH expression. These findings indicate that GGH activity in human leukemia cells is regulated by epigenetic changes, in addition to previously recognized genetic polymorphisms and karyotypic abnormalities, which collectively determine interindividual differences in GGH activity and influence MTXPG accumulation in leukemia cells.",Journal Article,4977.0,29.0,Gamma-glutamyl hydrolase GGH catalyzes degradation of the active polyglutamates of natural folates and the antifolate methotrexate MTX We found that GGH activity is directly related to GGH messenger RNA expression in acute lymphoblastic ALL cells of patients with a wild-type germline GGH genotype We identified two CpG islands CpG1 and CpG2 in the region extending from the GGH promoter through the first exon and into intron 1 and showed that methylation of both CpG islands in the GGH promoter seen in cells from approximately 15 of patients with nonhyperdiploid B-lineage ALL is associated with significantly reduced GGH mRNA expression and catalytic activity and with significantly higher accumulation of MTX polyglutamates MTXPG 4-7 in ALL cells Furthermore methylation of CpG1 was leukemia-cell specific and had a pronounced effect on GGH expression whereas methylation of CpG2 was common in cells and normal leukocytes but did not significantly alter GGH expression These findings indicate that GGH activity in human cells is regulated by epigenetic changes in addition to previously recognized genetic polymorphisms and karyotypic abnormalities which collectively determine interindividual differences in GGH activity and influence MTXPG accumulation in cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1705, 15867, 18796, 10820, 11074, 2373, 1, 3, 544, 16243, 1, 1504, 28084, 2, 3, 12278, 2116, 3453, 21, 204, 17, 10820, 128, 16, 1606, 139, 6, 10820, 5992, 893, 55, 4, 286, 1275, 62, 37, 1, 7, 5, 8, 955, 267, 1009, 10820, 1183, 21, 108, 100, 2075, 6046, 44412, 2, 44413, 4, 3, 1053, 4782, 29, 3, 10820, 973, 298, 3, 157, 1725, 2, 237, 6259, 14, 2, 224, 17, 569, 1, 110, 2075, 6046, 4, 3, 10820, 973, 527, 4, 37, 29, 705, 167, 1, 7, 5, 26040, 132, 2542, 62, 16, 41, 5, 97, 405, 10820, 956, 55, 2, 4784, 128, 2, 5, 97, 142, 1835, 1, 3453, 16243, 11572, 39, 67, 4, 62, 37, 798, 569, 1, 44412, 10, 2647, 31, 112, 2, 42, 8, 3517, 254, 23, 10820, 55, 547, 569, 1, 44413, 10, 186, 4, 37, 2, 295, 6884, 84, 205, 44, 97, 2688, 10820, 55, 46, 272, 1008, 17, 10820, 128, 4, 171, 37, 16, 1065, 20, 1418, 400, 4, 352, 6, 373, 1904, 336, 1203, 2, 9465, 1171, 92, 2535, 223, 7882, 362, 4, 10820, 128, 2, 1054, 11572, 1835, 4, 37]",1268.0,16826517,447
A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia.,Haematologica,Haematologica,2006-07-25,"We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.","Clinical Trial, Phase II",4928.0,15.0,We designed a phase II trial of arsenic trioxide AT for the treatment of relapsed and refractory acute lymphoblastic ALL The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days Of 11 patients eligible eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive The median duration of therapy was 21 days range 7-28 One patient died of an infection There were no responses Ten patients have died The median survival was 3.2 months range 1.2-4.1 We conclude that AT is not active in the treatment of ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 1114, 8, 124, 215, 160, 1, 3217, 4574, 28, 9, 3, 24, 1, 591, 2, 430, 286, 1275, 62, 3, 61, 468, 10, 13, 243, 81, 503, 218, 1672, 9, 33, 67, 162, 379, 647, 9, 126, 6, 335, 162, 1, 175, 7, 625, 659, 42, 132, 31, 2, 169, 102, 31, 62, 2, 100, 11, 3006, 1170, 109, 3, 52, 654, 1, 36, 10, 239, 162, 184, 67, 339, 104, 69, 1016, 1, 35, 930, 125, 11, 77, 253, 1618, 7, 47, 1016, 3, 52, 25, 10, 27, 18, 53, 184, 14, 18, 39, 14, 21, 2060, 17, 28, 16, 44, 544, 4, 3, 24, 1, 62]",564.0,16870552,520
"Near-triploidy and near-tetraploidy in childhood acute lymphoblastic leukemia: association with B-lineage blast cells carrying the ETV6-RUNX1 fusion, T-lineage immunophenotype, and favorable outcome.",Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2006-08-01,"The prognostic significance of near-triploidy (68-80 chromosomes) and near-tetraploidy (>80 chromosomes) in childhood acute lymphoblastic leukemia (ALL) is unclear. Therefore, we retrospectively evaluated the incidence of and outcome associated with these subtypes of ALL. In 620 children with ALL diagnosed between 1988 and 1999, the leukemic cells were near-triploid (DNA index, 1.50-1.73) in 4 and near-tetraploid (DNA index, 1.79-2.28) in 14. Of 15 patients with B-lineage ALL, 11 (73.3%) had an ETV6-RUNX1 (previously TEL-AML1 and then ETV6-CBFA2) fusion. No differences in age (P = 0.99), leukocyte count (P = 0.99), or immunophenotype (P = 0.99) were observed between patients with near-triploidy and those with near-tetraploidy. Patients with near-triploidy or near-tetraploidy were more likely than those with high-hyperdiploidy (51-67 chromosomes) (n = 159) to be female (P = 0.05) and have T-lineage ALL (P = 0.02), L2 morphology (P < 0.0001), or the ETV6-RUNX1 fusion (P < 0.0001). The median follow-up period was 10.4 years. The 5-year event-free survival estimates (+/- SE) were 75% +/- 19% for patients with near-triploidy, 93% +/- 7% for those with near-tetraploidy, and 84% +/- 3% for those with high-hyperdiploidy. Although near-triploidy and near-tetraploidy are biologically different from high-hyperdiploidy, the favorable outcomes of patients with any one of these abnormalities suggest that patients with B-lineage ALL and a DNA index >or= 1.16 can be included in the low-risk arm of treatment protocols. We cannot make similar recommendations for patients with T-lineage ALL because of the small number of cases (n = 3) in this study.",Journal Article,4921.0,32.0,The prognostic significance of near-triploidy 68-80 chromosomes and near-tetraploidy 80 chromosomes in childhood acute lymphoblastic ALL is unclear Therefore we retrospectively evaluated the incidence of and outcome associated with these subtypes of ALL In 620 children with ALL diagnosed between 1988 and 1999 the leukemic cells were near-triploid DNA index 1.50-1.73 in 4 and near-tetraploid DNA index 1.79-2.28 in 14 Of 15 patients with B-lineage ALL 11 73.3 had an ETV6-RUNX1 previously TEL-AML1 and then ETV6-CBFA2 fusion No differences in age P 0.99 leukocyte count P 0.99 or immunophenotype P 0.99 were observed between patients with near-triploidy and those with near-tetraploidy Patients with near-triploidy or near-tetraploidy were more likely than those with high-hyperdiploidy 51-67 chromosomes n 159 to be female P 0.05 and have T-lineage ALL P 0.02 L2 morphology P 0.0001 or the ETV6-RUNX1 fusion P 0.0001 The median follow-up period was 10.4 years The 5-year event-free survival estimates +/- SE were 75 +/- 19 for patients with near-triploidy 93 +/- 7 for those with near-tetraploidy and 84 +/- 3 for those with high-hyperdiploidy Although near-triploidy and near-tetraploidy are biologically different from high-hyperdiploidy the favorable outcomes of patients with any one of these abnormalities suggest that patients with B-lineage ALL and a DNA index or= 1.16 can be included in the low-risk arm of treatment protocols We can not make similar recommendations for patients with T-lineage ALL because of the small number of cases n 3 in this study,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 177, 724, 1, 1829, 26526, 806, 493, 3560, 2, 1829, 17211, 493, 3560, 4, 864, 286, 1275, 62, 16, 1200, 673, 21, 894, 194, 3, 287, 1, 2, 228, 41, 5, 46, 814, 1, 62, 4, 10811, 541, 5, 62, 265, 59, 3314, 2, 2043, 3, 2015, 37, 11, 1829, 23252, 261, 558, 14, 212, 14, 803, 4, 39, 2, 1829, 19575, 261, 558, 14, 842, 18, 339, 4, 213, 1, 167, 7, 5, 132, 2542, 62, 175, 803, 27, 42, 35, 7306, 6092, 373, 8573, 6535, 2, 818, 7306, 33205, 1212, 77, 362, 4, 89, 19, 13, 1058, 3627, 1276, 19, 13, 1058, 15, 5496, 19, 13, 1058, 11, 164, 59, 7, 5, 1829, 26526, 2, 135, 5, 1829, 17211, 7, 5, 1829, 26526, 15, 1829, 17211, 11, 80, 322, 76, 135, 5, 64, 11299, 725, 598, 3560, 78, 5917, 6, 40, 1061, 19, 13, 474, 2, 47, 102, 2542, 62, 19, 13, 588, 5111, 2567, 19, 13, 488, 15, 3, 7306, 6092, 1212, 19, 13, 488, 3, 52, 166, 126, 727, 10, 79, 39, 60, 3, 33, 111, 774, 115, 25, 1423, 3428, 11, 481, 326, 9, 7, 5, 1829, 26526, 966, 67, 9, 135, 5, 1829, 17211, 2, 874, 27, 9, 135, 5, 64, 11299, 242, 1829, 26526, 2, 1829, 17211, 32, 2665, 338, 29, 64, 11299, 3, 913, 123, 1, 7, 5, 500, 104, 1, 46, 1171, 309, 17, 7, 5, 132, 2542, 62, 2, 8, 261, 558, 15, 14, 245, 122, 40, 159, 4, 3, 154, 43, 475, 1, 24, 2189, 21, 122, 44, 2378, 288, 883, 9, 7, 5, 102, 2542, 62, 408, 1, 3, 302, 207, 1, 140, 78, 27, 4, 26, 45]",1565.0,16875937,444
Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.,Blood,Blood,2006-08-08,"CD20 expression is associated with inferior survival in adults with acute lymphoblastic leukemia (ALL). We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated in 3 consecutive St Jude Total Therapy studies. CD20 expression (> 20%) was found in 169 patients (48%) and was more frequent in patients between 1 and 10 years of age than in those younger than 1 or older than 10 years (P = .001). None of 14 patients with MLL-AF4 expressed CD20. There was no association between CD20 expression and E2A-PBX, TEL-AML1, ploidy, white blood cell count at diagnosis, or sex. In contrast to the experience in adult ALL, our patients with CD20 expression tended to have a better treatment outcome than those without the expression: 5-year event-free survival 84% +/- 2.9% versus 78% +/- 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens.",Journal Article,4914.0,57.0,CD20 expression is associated with inferior survival in adults with acute lymphoblastic ALL We analyzed the prognostic impact of CD20 expression in 353 children with B-cell precursor ALL treated in 3 consecutive St Jude Total Therapy studies CD20 expression 20 was found in 169 patients 48 and was more frequent in patients between 1 and 10 years of age than in those younger than 1 or older than 10 years P .001 None of 14 patients with MLL-AF4 expressed CD20 There was no association between CD20 expression and E2A-PBX TEL-AML1 ploidy white blood cell count at diagnosis or sex In contrast to the experience in adult ALL our patients with CD20 expression tended to have a better treatment outcome than those without the expression 5-year event-free survival 84 +/- 2.9 versus 78 +/- 3.1 P .08 These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2198, 55, 16, 41, 5, 1663, 25, 4, 857, 5, 286, 1275, 62, 21, 311, 3, 177, 345, 1, 2198, 55, 4, 10065, 541, 5, 132, 31, 2765, 62, 73, 4, 27, 935, 3062, 4841, 181, 36, 94, 2198, 55, 179, 10, 204, 4, 5436, 7, 576, 2, 10, 80, 908, 4, 7, 59, 14, 2, 79, 60, 1, 89, 76, 4, 135, 773, 76, 14, 15, 434, 76, 79, 60, 19, 144, 1292, 1, 213, 7, 5, 3049, 17272, 570, 2198, 125, 10, 77, 248, 59, 2198, 55, 2, 15127, 55688, 8573, 6535, 9032, 886, 315, 31, 1276, 28, 147, 15, 1035, 4, 748, 6, 3, 730, 4, 780, 62, 114, 7, 5, 2198, 55, 3886, 6, 47, 8, 380, 24, 228, 76, 135, 187, 3, 55, 33, 111, 774, 115, 25, 874, 18, 83, 185, 833, 27, 14, 19, 1592, 46, 74, 309, 17, 2198, 55, 16, 44, 41, 5, 1663, 228, 4, 815, 7, 73, 5, 2667, 472]",932.0,16896151,330
Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia.,Blood,Blood,2006-08-17,"There is conflicting information about the influence of body mass index (BMI) on the pharmacokinetics, toxicity, and outcome of chemotherapy. We compared pharmacokinetics, outcome, and toxicity data across 4 BMI groups (underweight, BMI < or = 10th percentile; normal; at risk of overweight, BMI > or = 85th and < 95th percentile; overweight, BMI > or = 95th percentile) in 621 children with acute lymphoblastic leukemia (ALL) treated on 4 consecutive St Jude Total Therapy studies. Chemotherapy doses were not adjusted to ideal BMI. Estimates of overall survival (86.1% +/- 3.4%, 86.0% +/- 1.7%, 85.9% +/- 4.3%, and 78.2% +/- 5.5%, respectively; P = .533), event-free survival (76.2% +/- 4.2%, 78.7% +/- 2.1%, 73.4% +/- 5.5%, and 72.7% +/- 5.9%, respectively; P = .722), and cumulative incidence of relapse (16.0% +/- 3.7%, 14.4% +/- 1.8%, 20.6% +/- 5.1%, and 16.7% +/- 5.1%, respectively; P = .862) did not differ across the 4 groups. In addition, the intracellular levels of thioguanine nucleotides and methotrexate polyglutamates did not differ between the 4 BMI groups (P = .73 and P = .74, respectively). The 4 groups also did not differ in the overall incidence of grade 3 or 4 toxicity during the induction or postinduction periods. Further, the systemic clearance of methotrexate, teniposide, etoposide, and cytarabine did not differ with BMI (P > .3). We conclude that BMI does not affect the outcome or toxicity of chemotherapy in this patient population with ALL.",Clinical Trial,4905.0,56.0,There is conflicting information about the influence of body mass index BMI on the pharmacokinetics toxicity and outcome of chemotherapy We compared pharmacokinetics outcome and toxicity data across 4 BMI groups underweight BMI or 10th percentile normal at risk of overweight BMI or 85th and 95th percentile overweight BMI or 95th percentile in 621 children with acute lymphoblastic ALL treated on 4 consecutive St Jude Total Therapy studies Chemotherapy doses were not adjusted to ideal BMI Estimates of overall survival 86.1 +/- 3.4 86.0 +/- 1.7 85.9 +/- 4.3 and 78.2 +/- 5.5 respectively P .533 event-free survival 76.2 +/- 4.2 78.7 +/- 2.1 73.4 +/- 5.5 and 72.7 +/- 5.9 respectively P .722 and cumulative incidence of relapse 16.0 +/- 3.7 14.4 +/- 1.8 20.6 +/- 5.1 and 16.7 +/- 5.1 respectively P .862 did not differ across the 4 groups In addition the intracellular levels of thioguanine nucleotides and methotrexate polyglutamates did not differ between the 4 BMI groups P .73 and P .74 respectively The 4 groups also did not differ in the overall incidence of grade 3 or 4 toxicity during the induction or postinduction periods Further the systemic clearance of methotrexate teniposide etoposide and cytarabine did not differ with BMI P .3 We conclude that BMI does not affect the outcome or toxicity of chemotherapy in this patient population with ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[125, 16, 4274, 487, 545, 3, 1054, 1, 642, 782, 558, 1140, 23, 3, 1159, 155, 2, 228, 1, 56, 21, 72, 1159, 228, 2, 155, 74, 716, 39, 1140, 271, 8094, 1140, 15, 14199, 6392, 295, 28, 43, 1, 3566, 1140, 15, 34132, 2, 14610, 6392, 3566, 1140, 15, 14610, 6392, 4, 12202, 541, 5, 286, 1275, 62, 73, 23, 39, 935, 3062, 4841, 181, 36, 94, 56, 415, 11, 44, 586, 6, 3662, 1140, 1423, 1, 63, 25, 868, 14, 27, 39, 868, 13, 14, 67, 772, 83, 39, 27, 2, 833, 18, 33, 33, 106, 19, 9269, 774, 115, 25, 846, 18, 39, 18, 833, 67, 18, 14, 803, 39, 33, 33, 2, 720, 67, 33, 83, 106, 19, 13968, 2, 967, 287, 1, 429, 245, 13, 27, 67, 213, 39, 14, 66, 179, 49, 33, 14, 2, 245, 67, 33, 14, 106, 19, 10753, 205, 44, 1505, 716, 3, 39, 271, 4, 352, 3, 2087, 148, 1, 17598, 11381, 2, 2116, 16243, 205, 44, 1505, 59, 3, 39, 1140, 271, 19, 803, 2, 19, 794, 106, 3, 39, 271, 120, 205, 44, 1505, 4, 3, 63, 287, 1, 88, 27, 15, 39, 155, 190, 3, 504, 15, 12543, 3338, 195, 3, 403, 1960, 1, 2116, 20224, 1934, 2, 1855, 205, 44, 1505, 5, 1140, 19, 27, 21, 2060, 17, 1140, 1097, 44, 1158, 3, 228, 15, 155, 1, 56, 4, 26, 69, 266, 5, 62]",1359.0,16917005,670
Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: a combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG).,Blood,Blood,2006-09-26,"The Children's Cancer Group (CCG) and the Pediatric Oncology Group (POG) joined to form the Children's Oncology Group (COG) in 2000. This merger allowed analysis of clinical, biologic, and early response data predictive of event-free survival (EFS) in acute lymphoblastic leukemia (ALL) to develop a new classification system and treatment algorithm. From 11 779 children (age, 1 to 21.99 years) with newly diagnosed B-precursor ALL consecutively enrolled by the CCG (December 1988 to August 1995, n=4986) and POG (January 1986 to November 1999, n=6793), we retrospectively analyzed 6238 patients (CCG, 1182; POG, 5056) with informative cytogenetic data. Four risk groups were defined as very high risk (VHR; 5-year EFS, 45% or below), lower risk (5-year EFS, at least 85%), and standard and high risk (those remaining in the respective National Cancer Institute [NCI] risk groups). VHR criteria included extreme hypodiploidy (fewer than 44 chromosomes), t(9;22) and/or BCR/ABL, and induction failure. Lower-risk patients were NCI standard risk with either t(12;21) (TEL/AML1) or simultaneous trisomies of chromosomes 4, 10, and 17. Even with treatment differences, there was high concordance between the CCG and POG analyses. The COG risk classification scheme is being used for division of B-precursor ALL into lower- (27%), standard- (32%), high- (37%), and very-high- (4%) risk groups based on age, white blood cell (WBC) count, cytogenetics, day-14 marrow response, and end induction minimal residual disease (MRD) by flow cytometry in COG trials.",Journal Article,4865.0,270.0,The Children 's Cancer Group CCG and the Pediatric Oncology Group POG joined to form the Children 's Oncology Group COG in 2000 This merger allowed analysis of clinical biologic and early response data predictive of event-free survival EFS in acute lymphoblastic ALL to develop a new classification system and treatment algorithm From 11 779 children age 1 to 21.99 years with newly diagnosed B-precursor ALL consecutively enrolled by the CCG December 1988 to August 1995 n=4986 and POG January 1986 to November 1999 n=6793 we retrospectively analyzed 6238 patients CCG 1182 POG 5056 with informative cytogenetic data Four risk groups were defined as very high risk VHR 5-year EFS 45 or below lower risk 5-year EFS at least 85 and standard and high risk those remaining in the respective National Cancer Institute NCI risk groups VHR criteria included extreme hypodiploidy fewer than 44 chromosomes t 9 22 and/or BCR/ABL and induction failure Lower-risk patients were NCI standard risk with either t 12 21 TEL/AML1 or simultaneous trisomies of chromosomes 4 10 and 17 Even with treatment differences there was high concordance between the CCG and POG analyses The COG risk classification scheme is being used for division of B-precursor ALL into lower- 27 standard- 32 high- 37 and very-high- 4 risk groups based on age white blood cell WBC count cytogenetics day-14 marrow response and end induction minimal residual disease MRD by flow cytometry in COG trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 541, 292, 12, 87, 9457, 2, 3, 815, 413, 87, 17150, 17687, 6, 1297, 3, 541, 292, 413, 87, 6377, 4, 1081, 26, 38257, 2313, 65, 1, 38, 1283, 2, 191, 51, 74, 464, 1, 774, 115, 25, 1683, 4, 286, 1275, 62, 6, 690, 8, 217, 947, 398, 2, 24, 2124, 29, 175, 7173, 541, 89, 14, 6, 239, 1058, 60, 5, 732, 265, 132, 2765, 62, 7380, 346, 20, 3, 9457, 1397, 3314, 6, 2480, 2323, 78, 55794, 2, 17150, 1024, 3751, 6, 2868, 2043, 78, 55795, 21, 894, 311, 55796, 7, 9457, 34153, 17150, 44488, 5, 4189, 1266, 74, 294, 43, 271, 11, 395, 22, 923, 64, 43, 12957, 33, 111, 1683, 512, 15, 2736, 280, 43, 33, 111, 1683, 28, 506, 772, 2, 260, 2, 64, 43, 135, 1844, 4, 3, 3847, 657, 12, 1377, 2580, 43, 271, 12957, 371, 159, 5611, 14828, 1497, 76, 584, 3560, 102, 83, 350, 2, 15, 1062, 1425, 2, 504, 496, 280, 43, 7, 11, 2580, 260, 43, 5, 361, 102, 133, 239, 8573, 6535, 15, 2824, 15526, 1, 3560, 39, 79, 2, 269, 871, 5, 24, 362, 125, 10, 64, 1827, 59, 3, 9457, 2, 17150, 318, 3, 6377, 43, 947, 4633, 16, 486, 95, 9, 5750, 1, 132, 2765, 62, 237, 280, 428, 260, 531, 64, 567, 2, 923, 64, 39, 43, 271, 90, 23, 89, 886, 315, 31, 4685, 1276, 2510, 218, 213, 581, 51, 2, 396, 504, 1048, 753, 34, 2029, 20, 1412, 1914, 4, 6377, 143]",1461.0,17003380,522
Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.,Cancer cell,Cancer Cell,2006-09-28,"Drug resistance remains a major obstacle to successful cancer treatment. A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid (GC) sensitivity/resistance in acute lymphoblastic leukemia (ALL) cells. The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity. We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1. These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies. Furthermore, this approach represents a strategy for identification of promising combination therapies for cancer.",Comparative Study,4863.0,355.0,Drug resistance remains a major obstacle to successful cancer treatment A database of drug-associated gene expression profiles was screened for molecules whose profile overlapped with a gene expression signature of glucocorticoid GC sensitivity/resistance in acute lymphoblastic ALL cells The screen indicated that the mTOR inhibitor rapamycin profile matched the signature of GC sensitivity We tested the hypothesis that rapamycin would induce GC sensitivity in lymphoid malignancy cells and found that it sensitized to GC-induced apoptosis via modulation of antiapoptotic MCL1 These data indicate that MCL1 is an important regulator of GC-induced apoptosis and that the combination of rapamycin and glucocorticoids has potential utility in lymphoid malignancies Furthermore this approach represents a strategy for identification of promising combination therapies for cancer,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[234, 251, 469, 8, 458, 7414, 6, 1401, 12, 24, 8, 609, 1, 234, 41, 145, 55, 1241, 10, 2261, 9, 1598, 1310, 800, 12117, 5, 8, 145, 55, 1651, 1, 5399, 1709, 485, 251, 4, 286, 1275, 62, 37, 3, 2413, 1103, 17, 3, 873, 230, 1620, 800, 655, 3, 1651, 1, 1709, 485, 21, 650, 3, 1492, 17, 1620, 688, 1290, 1709, 485, 4, 2303, 710, 37, 2, 204, 17, 192, 4242, 6, 1709, 277, 351, 847, 2356, 1, 4176, 8132, 46, 74, 1008, 17, 8132, 16, 35, 305, 2452, 1, 1709, 277, 351, 2, 17, 3, 150, 1, 1620, 2, 7307, 71, 174, 1207, 4, 2303, 441, 798, 26, 353, 1449, 8, 692, 9, 911, 1, 721, 150, 235, 9, 12]",876.0,17010674,72
Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study.,Blood,Blood,2006-10-10,"Most adults with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR) will relapse. We examined the outcome of 609 adults with recurring ALL, all of whom were previously treated on the Medical Research Council (MRC) UKALL12/ECOG2993 study, where the overall survival (OS) of newly diagnosed patients is 38% (95% confidence interval [CI]=36%-41%) at 5 years. By contrast, OS at 5 years after relapse was 7% (95% CI=4%-9%). Factors predicting a good outcome after salvage therapy were young age (OS of 12% in patients younger than 20 years vs OS of 3% in patients older than 50 years; 2P<.001) and short duration of first remission (CR1) (OS of 11% in those with a CR1 of more than 2 years versus OS of 5% in those with a CR1 of less than 2 years; 2P<.001). Treatment received in CR1 did not influence outcome after relapse. In a very highly selected subgroup of patients who were able to receive HSCT after relapse, some were long-term survivors. We conclude from a large, unselected series with mature follow-up that most adults with recurring ALL, whatever their prior treatment, cannot be rescued using currently available therapies. Prevention of recurrence is the best strategy for long-term survival in this disease.",Clinical Trial,4851.0,444.0,Most adults with acute lymphoblastic ALL who achieve complete remission CR will relapse We examined the outcome of 609 adults with recurring ALL all of whom were previously treated on the Medical Research Council MRC UKALL12/ECOG2993 study where the overall survival OS of newly diagnosed patients is 38 95 confidence interval CI =36 -41 at 5 years By contrast OS at 5 years after relapse was 7 95 CI=4 -9 Factors predicting a good outcome after salvage therapy were young age OS of 12 in patients younger than 20 years vs OS of 3 in patients older than 50 years 2P .001 and short duration of first remission CR1 OS of 11 in those with a CR1 of more than 2 years versus OS of 5 in those with a CR1 of less than 2 years 2P .001 Treatment received in CR1 did not influence outcome after relapse In a very highly selected subgroup of patients who were able to receive HSCT after relapse some were long-term survivors We conclude from a large unselected series with mature follow-up that most adults with recurring ALL whatever their prior treatment can not be rescued using currently available therapies Prevention of recurrence is the best strategy for long-term survival in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[96, 857, 5, 286, 1275, 62, 54, 1359, 236, 734, 684, 303, 429, 21, 409, 3, 228, 1, 11954, 857, 5, 6385, 62, 62, 1, 953, 11, 373, 73, 23, 3, 484, 389, 9474, 10976, 55818, 34158, 45, 1257, 3, 63, 25, 118, 1, 732, 265, 7, 16, 519, 48, 307, 268, 58, 511, 605, 28, 33, 60, 20, 748, 118, 28, 33, 60, 50, 429, 10, 67, 48, 58, 39, 83, 130, 1434, 8, 1178, 228, 50, 992, 36, 11, 1169, 89, 118, 1, 133, 4, 7, 773, 76, 179, 60, 105, 118, 1, 27, 4, 7, 434, 76, 212, 60, 10957, 144, 2, 978, 654, 1, 157, 734, 4516, 118, 1, 175, 4, 135, 5, 8, 4516, 1, 80, 76, 18, 60, 185, 118, 1, 33, 4, 135, 5, 8, 4516, 1, 299, 76, 18, 60, 10957, 144, 24, 103, 4, 4516, 205, 44, 1054, 228, 50, 429, 4, 8, 923, 561, 715, 1363, 1, 7, 54, 11, 1665, 6, 560, 1703, 50, 429, 476, 11, 319, 337, 332, 21, 2060, 29, 8, 375, 3594, 988, 5, 2908, 166, 126, 17, 96, 857, 5, 6385, 62, 20522, 136, 324, 24, 122, 44, 40, 7008, 75, 694, 390, 235, 1070, 1, 146, 16, 3, 824, 692, 9, 319, 337, 25, 4, 26, 34]",1185.0,17032921,824
Delayed neurotoxicity associated with therapy for children with acute lymphoblastic leukemia.,Mental retardation and developmental disabilities research reviews,Ment Retard Dev Disabil Res Rev,2006-01-01,"Most children diagnosed today with acute lymphoblastic leukemia (ALL) will be cured. However, treatment entails risk of neurotoxicity, causing deficits in neurocognitive function that can persist in the years after treatment is completed. Many of the components of leukemia therapy can contribute to adverse neurologic sequelae, including craniospinal irradiation, nucleoside analogs, corticosteroids, and antifolates. In this review, we describe the characteristic radiographic findings and neurocognitive deficits seen among survivors of childhood ALL. We summarize what is known about the pathophysiology of delayed treatment-related neurotoxicity, with a focus on the toxicity resulting from pharmacologic disruption of folate physiology within the central nervous system. Finally, we suggest testable strategies to ameliorate the symptoms of treatment-related neurotoxicity or decrease its incidence.",Journal Article,5133.0,58.0,Most children diagnosed today with acute lymphoblastic ALL will be cured However treatment entails risk of neurotoxicity causing deficits in neurocognitive function that can persist in the years after treatment is completed Many of the components of therapy can contribute to adverse neurologic sequelae including craniospinal irradiation nucleoside analogs corticosteroids and antifolates In this review we describe the characteristic radiographic findings and neurocognitive deficits seen among survivors of childhood ALL We summarize what is known about the pathophysiology of delayed treatment-related neurotoxicity with a focus on the toxicity resulting from pharmacologic disruption of folate physiology within the central nervous system Finally we suggest testable strategies to ameliorate the symptoms of treatment-related neurotoxicity or decrease its incidence,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[96, 541, 265, 5665, 5, 286, 1275, 62, 303, 40, 3733, 137, 24, 14080, 43, 1, 3561, 3440, 2752, 4, 2958, 343, 17, 122, 5589, 4, 3, 60, 50, 24, 16, 781, 445, 1, 3, 1628, 1, 36, 122, 1248, 6, 290, 2543, 4156, 141, 5748, 1104, 4032, 4063, 3876, 2, 14893, 4, 26, 206, 21, 897, 3, 2037, 1580, 272, 2, 2958, 2752, 527, 107, 332, 1, 864, 62, 21, 2479, 2067, 16, 440, 545, 3, 4320, 1, 1612, 24, 139, 3561, 5, 8, 1222, 23, 3, 155, 1113, 29, 2788, 3220, 1, 3100, 7206, 262, 3, 854, 1880, 398, 1368, 21, 309, 21317, 422, 6, 9179, 3, 507, 1, 24, 139, 3561, 15, 775, 211, 287]",870.0,17061283,316
Retention of survivors of acute lymphoblastic leukemia in a longitudinal study of bone mineral density.,Journal of child health care : for professionals working with children in the hospital and community,J Child Health Care,2006-12-01,"Attrition in longitudinal studies of survivors of childhood cancer reduces these studies' statistical power, introduces bias and threatens internal and external validity. This study investigated the variables associated with dropout of survivors of acute lymphoblastic leukemia in a trial investigating the effect of vitamin D and calcium supplementation and nutritional counseling on bone mineral density (BMD). Twenty-five participants withdrew from the study. Common reasons given for withdrawing were intolerance of the study drug, family hardship and schedule conflicts. Few statistically and clinically significant differences identified participants who completed the study. Nurses need to be aware of the reasons that participants withdraw from clinical trials, as they are in a strategic position to encourage patients to participate in health promotion studies.",Journal Article,4799.0,3.0,Attrition in longitudinal studies of survivors of childhood cancer reduces these studies statistical power introduces bias and threatens internal and external validity This study investigated the variables associated with dropout of survivors of acute lymphoblastic in a trial investigating the effect of vitamin D and calcium supplementation and nutritional counseling on mineral density BMD Twenty-five participants withdrew from the study Common reasons given for withdrawing were intolerance of the study drug family hardship and schedule conflicts Few statistically and clinically significant differences identified participants who completed the study Nurses need to be aware of the reasons that participants withdraw from clinical trials as they are in a strategic position to encourage patients to participate in health promotion studies,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9174, 4, 2380, 94, 1, 332, 1, 864, 12, 2389, 46, 94, 1050, 2349, 13090, 2947, 2, 24738, 2329, 2, 1455, 3099, 26, 45, 565, 3, 682, 41, 5, 13929, 1, 332, 1, 286, 1275, 4, 8, 160, 3103, 3, 254, 1, 1610, 427, 2, 3299, 3890, 2, 5082, 2011, 23, 5033, 1263, 3503, 737, 365, 776, 7939, 29, 3, 45, 186, 2325, 447, 9, 44531, 11, 5266, 1, 3, 45, 234, 607, 11602, 2, 1055, 14959, 1021, 712, 2, 505, 93, 362, 108, 776, 54, 781, 3, 45, 2707, 594, 6, 40, 4749, 1, 3, 2325, 17, 776, 34175, 29, 38, 143, 22, 491, 32, 4, 8, 10968, 3559, 6, 7113, 7, 6, 3506, 4, 341, 5478, 94]",845.0,17101625,246
Complex secondary chromosome abnormalities in advanced stage anaplastic large cell lymphoma of children and adolescents: a report from CCG-E08.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2006-12-01,"Among pediatric non-Hodgkin lymphomas, one of the most distinctive types is anaplastic large cell lymphoma (ALCL). Specific chromosomal abnormalities are associated with prognosis in childhood acute lymphoblastic leukemia, but chromosome abnormalities have not been evaluated for prognostic value in pediatric ALCL. For Children's Cancer Group protocol CCG-E-08 Etiologic Study of Non-Hodgkin Lymphoma in Childhood, three patients were enrolled with cytogenetic analysis of ALCL and simultaneously enrolled on treatment protocol CCG-552. Pathology material and karyotypes at initial diagnosis underwent central review. Demographics included ages of 9, 12, and 14 years, and a male/female ratio of 1:2. All patients had advanced disease (stage III). Disease progressed or relapsed in two patients, and one died. Chromosomal abnormalities, including t(2;5)(p23;q35), the ALK/NPM fusion gene, and complex karyotypes with multiple additional abnormalities, were identified in all three patients. In two patients with progressive disease or relapse, additional chromosomal abnormalities at 1q21 and 10q24, possibly involving MCL1 and HOX11/TCL3, respectively, may have contributed to worse outcome. Pediatric ALCL cases frequently have complex karyotypes and usually involve ALK/NPM translocations in this limited study. Additional chromosome abnormalities may be involved in the pathogenesis of ALCL. Further studies are warranted in larger cohorts of children and adolescents with ALCL.",Journal Article,4799.0,9.0,Among pediatric lymphomas one of the most distinctive types is anaplastic large cell ALCL Specific chromosomal abnormalities are associated with prognosis in childhood acute lymphoblastic but chromosome abnormalities have not been evaluated for prognostic value in pediatric ALCL For Children 's Cancer Group protocol CCG-E-08 Etiologic Study of in Childhood three patients were enrolled with cytogenetic analysis of ALCL and simultaneously enrolled on treatment protocol CCG-552 Pathology material and karyotypes at initial diagnosis underwent central review Demographics included ages of 9 12 and 14 years and a male/female ratio of 1:2 All patients had advanced disease stage III Disease progressed or relapsed in two patients and one died Chromosomal abnormalities including t 2 5 p23 q35 the ALK/NPM fusion gene and complex karyotypes with multiple additional abnormalities were identified in all three patients In two patients with progressive disease or relapse additional chromosomal abnormalities at 1q21 and 10q24 possibly involving MCL1 and HOX11/TCL3 respectively may have contributed to worse outcome Pediatric ALCL cases frequently have complex karyotypes and usually involve ALK/NPM translocations in this limited study Additional chromosome abnormalities may be involved in the pathogenesis of ALCL Further studies are warranted in larger cohorts of children and adolescents with ALCL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[107, 815, 1557, 104, 1, 3, 96, 5049, 630, 16, 1841, 375, 31, 5200, 112, 1860, 1171, 32, 41, 5, 356, 4, 864, 286, 1275, 84, 1170, 1171, 47, 44, 85, 194, 9, 177, 549, 4, 815, 5200, 9, 541, 292, 12, 87, 1182, 9457, 563, 1592, 6604, 45, 1, 4, 864, 169, 7, 11, 346, 5, 1266, 65, 1, 5200, 2, 3074, 346, 23, 24, 1182, 9457, 10097, 1117, 3692, 2, 6809, 28, 388, 147, 208, 854, 206, 2221, 159, 2165, 1, 83, 133, 2, 213, 60, 2, 8, 1045, 1061, 197, 1, 14, 18, 62, 7, 42, 131, 34, 82, 316, 34, 1839, 15, 591, 4, 100, 7, 2, 104, 1016, 1860, 1171, 141, 102, 18, 33, 24619, 33460, 3, 1023, 11111, 1212, 145, 2, 840, 6809, 5, 232, 402, 1171, 11, 108, 4, 62, 169, 7, 4, 100, 7, 5, 1014, 34, 15, 429, 402, 1860, 1171, 28, 11232, 2, 26555, 2150, 1267, 8132, 2, 18191, 55899, 106, 68, 47, 3447, 6, 639, 228, 815, 5200, 140, 746, 47, 840, 6809, 2, 2082, 3882, 1023, 11111, 3262, 4, 26, 383, 45, 402, 1170, 1171, 68, 40, 646, 4, 3, 1384, 1, 5200, 195, 94, 32, 1197, 4, 1077, 736, 1, 541, 2, 3101, 5, 5200]",1400.0,17116485,317
Myths and lessons from the adult/pediatric interface in acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2006-01-01,"The development of effective therapy for children with acute lymphoblastic leukemia (ALL) is one of the great successes of clinical oncology, with long-term survival achieved in over 80% of patients. However, cure rates for adults with ALL remain relatively low, with only 40% of patients cured. With an age-unrestricted, biology-based approach, we anticipate a better understanding about why these outcome differences exist, and think that by extending successful pediatric clinical programs to include adult patients with ALL, we can directly compare uniformly treated adults and children in terms of response to therapy, toxicity and underlying biology.",Journal Article,5133.0,34.0,The development of effective therapy for children with acute lymphoblastic ALL is one of the great successes of clinical oncology with long-term survival achieved in over 80 of patients However cure rates for adults with ALL remain relatively low with only 40 of patients cured With an age-unrestricted biology-based approach we anticipate a better understanding about why these outcome differences exist and think that by extending successful pediatric clinical programs to include adult patients with ALL we can directly compare uniformly treated adults and children in terms of response to therapy toxicity and underlying biology,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 193, 1, 323, 36, 9, 541, 5, 286, 1275, 62, 16, 104, 1, 3, 2797, 6697, 1, 38, 413, 5, 319, 337, 25, 513, 4, 252, 493, 1, 7, 137, 1722, 151, 9, 857, 5, 62, 918, 1352, 154, 5, 158, 327, 1, 7, 3733, 5, 35, 89, 16806, 891, 90, 353, 21, 8469, 8, 380, 612, 545, 5283, 46, 228, 362, 1923, 2, 12748, 17, 20, 4782, 1401, 815, 38, 2251, 6, 643, 780, 7, 5, 62, 21, 122, 1606, 932, 4254, 73, 857, 2, 541, 4, 1794, 1, 51, 6, 36, 155, 2, 1181, 891]",632.0,17124051,730
Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2006-01-01,"Improved treatment for acute lymphoblastic leukemia (ALL) has virtually eliminated testicular relapse. However, the control of central nervous system (CNS) leukemia remains a therapeutic challenge in childhood ALL, partly because of the late complications arising from cranial irradiation. In most current pediatric protocols, cranial irradiation (12 to 18 Gy) is given to 5% to 25% of patients--those with T-cell ALL, overt CNS disease (CNS3 status) or high-risk cytogenetics. CNS control is a less urgent concern in adults with ALL, in whom systemic relapse remains the major problem. With current approaches, approximately 2% to 10% of patients can be expected to develop CNS relapse. Children with B-cell precursor ALL who have a late CNS relapse (after an initial remission of 18 months or more) and did not receive cranial irradiation have an excellent outcome after retrieval therapy, with a 5-year event-free survival (EFS) rate approaching that in newly diagnosed patients. Innovative treatment options are needed for children who develop CNS relapses after a short initial remission or after receiving cranial irradiation, and in any adults with CNS leukemia at diagnosis or relapse.",Journal Article,5133.0,85.0,Improved treatment for acute lymphoblastic ALL has virtually eliminated relapse However the control of central nervous system CNS remains a therapeutic challenge in childhood ALL partly because of the late complications arising from cranial irradiation In most current pediatric protocols cranial irradiation 12 to 18 Gy is given to 5 to 25 of patients -- those with T-cell ALL overt CNS disease CNS3 status or high-risk cytogenetics CNS control is a less urgent concern in adults with ALL in whom systemic relapse remains the major problem With current approaches approximately 2 to 10 of patients can be expected to develop CNS relapse Children with B-cell precursor ALL who have a late CNS relapse after an initial remission of 18 months or more and did not receive cranial irradiation have an excellent outcome after retrieval therapy with a 5-year event-free survival EFS rate approaching that in newly diagnosed patients Innovative treatment options are needed for children who develop CNS relapses after a short initial remission or after receiving cranial irradiation and in any adults with CNS at diagnosis or relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[231, 24, 9, 286, 1275, 62, 71, 5860, 6173, 429, 137, 3, 182, 1, 854, 1880, 398, 1025, 469, 8, 189, 1745, 4, 864, 62, 5180, 408, 1, 3, 807, 521, 2635, 29, 2565, 1104, 4, 96, 291, 815, 2189, 2565, 1104, 133, 6, 203, 381, 16, 447, 6, 33, 6, 243, 1, 7, 135, 5, 102, 31, 62, 7192, 1025, 34, 55905, 156, 15, 64, 43, 2510, 1025, 182, 16, 8, 299, 5013, 2893, 4, 857, 5, 62, 4, 953, 403, 429, 469, 3, 458, 2497, 5, 291, 611, 705, 18, 6, 79, 1, 7, 122, 40, 1336, 6, 690, 1025, 429, 541, 5, 132, 31, 2765, 62, 54, 47, 8, 807, 1025, 429, 50, 35, 388, 734, 1, 203, 53, 15, 80, 2, 205, 44, 560, 2565, 1104, 47, 35, 1503, 228, 50, 8372, 36, 5, 8, 33, 111, 774, 115, 25, 1683, 116, 7773, 17, 4, 732, 265, 7, 4019, 24, 838, 32, 575, 9, 541, 54, 690, 1025, 3713, 50, 8, 978, 388, 734, 15, 50, 357, 2565, 1104, 2, 4, 500, 857, 5, 1025, 28, 147, 15, 429]",1126.0,17124053,456
Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2006-12-01,"CD52 is a GPI-linked glycoprotein expressed by B cells, T cells, monocytes, and macrophages. The humanized monoclonal antibody alemtuzumab (CAMPATH-1H) is specific for CD52 and is Food and Drug Administration - approved for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored; however, a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed. We evaluated 294 hematologic neoplasms for the presence of CD52 using standard immunohistochemical techniques on paraffin-embedded biopsy specimens fixed with formalin, B-Plus, Zenker's acetic acid, or B5-formalin. The vast majority of low-grade B cell lymphoproliferative disorders (CLL/small lymphocytic leukemia, follicular lymphoma, lymphoplasmacytic lymphoma, hairy cell leukemia, and mucosa-associated lymphoid tissue lymphomas) express CD52. In addition, we found that the majority of precursor B cell acute lymphoblastic leukemia/lymphomas express this antigen. In contrast, there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas, with 25% of cases of diffuse large B cell lymphoma and Burkitt lymphoma demonstrating no detectable CD52. In addition, the majority of neoplasms of the T cell lineage are negative for the antigen, including most cases of precursor T cell acute lymphoblastic leukemia/lymphoma, anaplastic large cell lymphoma, and peripheral T cell lymphoma, not otherwise specified. Finally, the vast majority of cases of acute myeloid leukemia, Hodgkin lymphoma, and multiple myeloma are negative for CD52 expression. In contrast with CLL, the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy.",Journal Article,4799.0,102.0,CD52 is a GPI-linked glycoprotein expressed by B cells T cells monocytes and macrophages The humanized monoclonal antibody alemtuzumab CAMPATH-1H is specific for CD52 and is Food and Drug Administration approved for the treatment of relapsed or refractory chronic lymphocytic CLL The utility of CAMPATH in the treatment of other hematologic neoplasms has been explored however a comprehensive survey of CD52 expression among a broad spectrum of WHO-defined tumor types has not been completed We evaluated 294 hematologic neoplasms for the presence of CD52 using standard immunohistochemical techniques on paraffin-embedded biopsy specimens fixed with formalin B-Plus Zenker 's acetic acid or B5-formalin The vast majority of low-grade B cell lymphoproliferative disorders CLL/small lymphocytic follicular lymphoplasmacytic hairy cell and mucosa-associated lymphoid tissue lymphomas express CD52 In addition we found that the majority of precursor B cell acute lymphoblastic leukemia/lymphomas express this antigen In contrast there is surprising heterogeneity in CD52 expression among more aggressive B cell lymphomas with 25 of cases of diffuse large B cell and demonstrating no detectable CD52 In addition the majority of neoplasms of the T cell lineage are negative for the antigen including most cases of precursor T cell acute lymphoblastic leukemia/lymphoma anaplastic large cell and peripheral T cell not otherwise specified Finally the vast majority of cases of acute myeloid and multiple are negative for CD52 expression In contrast with CLL the variable expression of CD52 among other hematologic malignancies suggests that target validation on a case-by-case basis will likely be necessary to guide the rational analysis of CAMPATH therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[7189, 16, 8, 10344, 1199, 4455, 570, 20, 132, 37, 102, 37, 5078, 2, 2748, 3, 3619, 848, 548, 3579, 16622, 10147, 16, 112, 9, 7189, 2, 16, 1773, 2, 234, 634, 850, 9, 3, 24, 1, 591, 15, 430, 442, 1193, 552, 3, 1207, 1, 16622, 4, 3, 24, 1, 127, 813, 1179, 71, 85, 1443, 137, 8, 949, 1407, 1, 7189, 55, 107, 8, 2094, 1873, 1, 54, 395, 30, 630, 71, 44, 85, 781, 21, 194, 8375, 813, 1179, 9, 3, 463, 1, 7189, 75, 260, 1382, 1092, 23, 2487, 2505, 411, 623, 1959, 5, 3265, 132, 349, 55915, 292, 16812, 971, 15, 28617, 3265, 3, 4337, 686, 1, 154, 88, 132, 31, 4192, 1997, 552, 302, 1193, 1974, 5325, 7152, 31, 2, 2713, 41, 2303, 246, 1557, 1669, 7189, 4, 352, 21, 204, 17, 3, 686, 1, 2765, 132, 31, 286, 1275, 2647, 1557, 1669, 26, 448, 4, 748, 125, 16, 14157, 1144, 4, 7189, 55, 107, 80, 571, 132, 31, 1557, 5, 243, 1, 140, 1, 1388, 375, 132, 31, 2, 2219, 77, 2083, 7189, 4, 352, 3, 686, 1, 1179, 1, 3, 102, 31, 2542, 32, 199, 9, 3, 448, 141, 96, 140, 1, 2765, 102, 31, 286, 1275, 2647, 4763, 1841, 375, 31, 2, 672, 102, 31, 44, 2632, 3575, 1368, 3, 4337, 686, 1, 140, 1, 286, 533, 2, 232, 32, 199, 9, 7189, 55, 4, 748, 5, 552, 3, 1347, 55, 1, 7189, 107, 127, 813, 441, 844, 17, 283, 929, 23, 8, 473, 20, 473, 877, 303, 322, 40, 1493, 6, 1597, 3, 2696, 65, 1, 16622, 36]",1750.0,17145843,68
Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial.,Blood,Blood,2006-12-14,"Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies. However, its usefulness in adult acute lymphoblastic leukemia (ALL) is generally limited to the presence of the Philadelphia (Ph) chromosome because of the low incidence of other recurrent abnormalities. We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented. Patients with a Ph chromosome, t(4;11)(q21;q23), t(8;14)(q24.1;q32), complex karyotype (5 or more chromosomal abnormalities), or low hypodiploidy/near triploidy (Ho-Tr) all had inferior rates of event-free and overall survival when compared with other patients. In contrast, patients with high hyperdiploidy or a del(9p) had a significantly improved outcome. Multivariate analysis demonstrated that the prognostic relevance of t(8;14), complex karyotype, and Ho-Tr was independent of sex, age, white cell count, and T-cell status among Ph-negative patients. The observation that Ho-Tr and, for the first time, karyotype complexity confer an increased risk of treatment failure demonstrates that cytogenetic subgroups other than the Ph chromosome can and should be used to risk stratify adults with ALL in future trials.",Clinical Trial,4786.0,460.0,Pretreatment cytogenetics is a known predictor of outcome in hematologic malignancies However its usefulness in adult acute lymphoblastic ALL is generally limited to the presence of the Philadelphia Ph chromosome because of the low incidence of other recurrent abnormalities We present centrally reviewed cytogenetic data from 1522 adult patients enrolled on the Medical Research Council MRC UKALLXII/Eastern Cooperative Oncology Group ECOG 2993 trial The incidence and clinical associations for more than 20 specific chromosomal abnormalities are presented Patients with a Ph chromosome t 4 11 q21 q23 t 8 14 q24.1 q32 complex karyotype 5 or more chromosomal abnormalities or low hypodiploidy/near triploidy Ho-Tr all had inferior rates of event-free and overall survival when compared with other patients In contrast patients with high hyperdiploidy or a del 9p had a significantly improved outcome Multivariate analysis demonstrated that the prognostic relevance of t 8 14 complex karyotype and Ho-Tr was independent of sex age white cell count and T-cell status among Ph-negative patients The observation that Ho-Tr and for the first time karyotype complexity confer an increased risk of treatment failure demonstrates that cytogenetic subgroups other than the Ph chromosome can and should be used to risk stratify adults with ALL in future trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1194, 2510, 16, 8, 440, 980, 1, 228, 4, 813, 441, 137, 211, 5235, 4, 780, 286, 1275, 62, 16, 1228, 383, 6, 3, 463, 1, 3, 3006, 2058, 1170, 408, 1, 3, 154, 287, 1, 127, 387, 1171, 21, 364, 4604, 446, 1266, 74, 29, 31040, 780, 7, 346, 23, 3, 484, 389, 9474, 10976, 24975, 2118, 1690, 413, 87, 2351, 24976, 160, 3, 287, 2, 38, 685, 9, 80, 76, 179, 112, 1860, 1171, 32, 917, 7, 5, 8, 2058, 1170, 102, 39, 175, 10524, 11423, 102, 66, 213, 13487, 14, 7576, 840, 3385, 33, 15, 80, 1860, 1171, 15, 154, 14828, 1829, 26526, 11852, 7161, 62, 42, 1663, 151, 1, 774, 115, 2, 63, 25, 198, 72, 5, 127, 7, 4, 748, 7, 5, 64, 11299, 15, 8, 3084, 11234, 42, 8, 97, 231, 228, 331, 65, 264, 17, 3, 177, 2088, 1, 102, 66, 213, 840, 3385, 2, 11852, 7161, 10, 306, 1, 1035, 89, 886, 31, 1276, 2, 102, 31, 156, 107, 2058, 199, 7, 3, 1664, 17, 11852, 7161, 2, 9, 3, 157, 98, 3385, 3082, 2913, 35, 101, 43, 1, 24, 496, 1902, 17, 1266, 1453, 127, 76, 3, 2058, 1170, 122, 2, 257, 40, 95, 6, 43, 3570, 857, 5, 62, 4, 508, 143]",1351.0,17170120,272
Chromosome abnormalities in advanced stage lymphoblastic lymphoma of children and adolescents: a report from CCG-E08.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2007-01-01,"Among pediatric non-Hodgkin lymphomas, one of the most frequent types is lymphoblastic lymphoma (LBL). Specific chromosome abnormalities are associated with prognosis in childhood acute lymphoblastic leukemia, but have not been evaluated for prognostic value in pediatric LBL. For the Children's Cancer Group protocol CCG-E-08 Etiologic Study of Non-Hodgkin Lymphoma in Childhood, 13 patients were enrolled with cytogenetic analysis of LBL and on treatment protocol CCG-502. Pathology material and karyotypes at initial diagnosis were given central review. The patients were aged 6-13 years (median 9 years), with a male-to-female ratio of 12:1. All patients had advanced disease. Disease relapsed in six patients (event-free survival 54% +/- 14%, median 10.8 years). Chromosome abnormalities were identified in 11 (85%), and translocations at 14q11.2 likely involving the T-cell receptor alpha/delta locus (TCR A/D) occurred in 4 (31%). For patients with relapse, four had translocations t(1;14)(p32;q11.2), t(8;14)(q24.1;q11.2), t(11;14)(p13;q11.2), or t(9;17)(q34;q23), involving breakpoints in the regions of TAL1, MYC, LMO2, and NOTCH1, respectively. Pediatric advanced LBLs have a high frequency of chromosome abnormalities; in this limited study, these often involved translocations at 14q11.2, the site of TCR A/D. Translocations possibly involving TAL1, MYC, LMO2, or NOTCH1 may have contributed to poor outcome. Further studies are warranted in larger cohorts of children and adolescents with LBL to evaluate the prognostic significance.",Journal Article,4768.0,35.0,Among pediatric lymphomas one of the most frequent types is lymphoblastic LBL Specific chromosome abnormalities are associated with prognosis in childhood acute lymphoblastic but have not been evaluated for prognostic value in pediatric LBL For the Children 's Cancer Group protocol CCG-E-08 Etiologic Study of in Childhood 13 patients were enrolled with cytogenetic analysis of LBL and on treatment protocol CCG-502 Pathology material and karyotypes at initial diagnosis were given central review The patients were aged 6-13 years median 9 years with a male-to-female ratio of 12:1 All patients had advanced disease Disease relapsed in six patients event-free survival 54 +/- 14 median 10.8 years Chromosome abnormalities were identified in 11 85 and translocations at 14q11.2 likely involving the T-cell receptor alpha/delta locus TCR A/D occurred in 4 31 For patients with relapse four had translocations t 1 14 p32 q11.2 t 8 14 q24.1 q11.2 t 11 14 p13 q11.2 or t 9 17 q34 q23 involving breakpoints in the regions of TAL1 MYC LMO2 and NOTCH1 respectively Pediatric advanced LBLs have a high frequency of chromosome abnormalities in this limited study these often involved translocations at 14q11.2 the site of TCR A/D Translocations possibly involving TAL1 MYC LMO2 or NOTCH1 may have contributed to poor outcome Further studies are warranted in larger cohorts of children and adolescents with LBL to evaluate the prognostic significance,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[107, 815, 1557, 104, 1, 3, 96, 908, 630, 16, 1275, 8315, 112, 1170, 1171, 32, 41, 5, 356, 4, 864, 286, 1275, 84, 47, 44, 85, 194, 9, 177, 549, 4, 815, 8315, 9, 3, 541, 292, 12, 87, 1182, 9457, 563, 1592, 6604, 45, 1, 4, 864, 233, 7, 11, 346, 5, 1266, 65, 1, 8315, 2, 23, 24, 1182, 9457, 11344, 1117, 3692, 2, 6809, 28, 388, 147, 11, 447, 854, 206, 3, 7, 11, 1032, 49, 233, 60, 52, 83, 60, 5, 8, 1045, 6, 1061, 197, 1, 133, 14, 62, 7, 42, 131, 34, 34, 591, 4, 437, 7, 774, 115, 25, 667, 213, 52, 79, 66, 60, 1170, 1171, 11, 108, 4, 175, 772, 2, 3262, 28, 44573, 18, 322, 1267, 3, 102, 31, 153, 950, 4305, 2474, 4134, 8, 427, 489, 4, 39, 456, 9, 7, 5, 429, 294, 42, 3262, 102, 14, 213, 55957, 11532, 18, 102, 66, 213, 13487, 14, 11532, 18, 102, 175, 213, 7914, 11532, 18, 15, 102, 83, 269, 16609, 11423, 1267, 7843, 4, 3, 1374, 1, 18789, 1371, 11568, 2, 4607, 106, 815, 131, 55958, 47, 8, 64, 675, 1, 1170, 1171, 4, 26, 383, 45, 46, 629, 646, 3262, 28, 44573, 18, 3, 606, 1, 4134, 8, 427, 3262, 2150, 1267, 18789, 1371, 11568, 15, 4607, 68, 47, 3447, 6, 334, 228, 195, 94, 32, 1197, 4, 1077, 736, 1, 541, 2, 3101, 5, 8315, 6, 376, 3, 177, 724]",1440.0,17175373,715
Genomewide identification of prednisolone-responsive genes in acute lymphoblastic leukemia cells.,Blood,Blood,2007-01-11,"Glucocorticoids are keystone drugs in the treatment of childhood acute lymphoblastic leukemia (ALL). To get more insight in signal transduction pathways involved in glucocorticoid-induced apoptosis, Affymetrix U133A GeneChips were used to identify transcriptionally regulated genes on 3 and 8 hours of prednisolone exposure in leukemic cells of 13 children as compared with nonexposed cells. Following 3 hours of exposure no significant changes in gene expression could be identified. Following 8 hours of exposure, 51 genes were differentially expressed (P < .001 and false discovery rate < 10%) with 39 genes being up-regulated (median, 2.4-fold) and 12 genes were down-regulated (median, 1.7-fold). Twenty-one of those genes have not been identified before to be transcriptionally regulated by prednisolone. Two of the 3 most highly up-regulated genes were tumor suppressor genes, that is, thioredoxin-interacting protein (TXNIP; 3.7-fold) and zinc finger and BTB domain containing 16 (ZBTB16; 8.8-fold). About 50% of the differentially expressed genes were functionally categorized in 3 major routes, namely MAPK pathways (9 genes), NF-kappaB signaling (11 genes), and carbohydrate metabolism (5 genes). Biologic characterization of these genes and pathways might elucidate the action of glucocorticoids in ALL cells, possibly suggesting causes of glucocorticoid resistance and new potential targets for therapy.",Clinical Trial,4758.0,71.0,Glucocorticoids are keystone drugs in the treatment of childhood acute lymphoblastic ALL To get more insight in signal transduction pathways involved in glucocorticoid-induced apoptosis Affymetrix U133A GeneChips were used to identify transcriptionally regulated genes on 3 and 8 hours of prednisolone exposure in leukemic cells of 13 children as compared with nonexposed cells Following 3 hours of exposure no significant changes in gene expression could be identified Following 8 hours of exposure 51 genes were differentially expressed P .001 and false discovery rate 10 with 39 genes being up-regulated median 2.4-fold and 12 genes were down-regulated median 1.7-fold Twenty-one of those genes have not been identified before to be transcriptionally regulated by prednisolone Two of the 3 most highly up-regulated genes were tumor suppressor genes that is thioredoxin-interacting protein TXNIP 3.7-fold and zinc finger and BTB domain containing 16 ZBTB16 8.8-fold About 50 of the differentially expressed genes were functionally categorized in 3 major routes namely MAPK pathways 9 genes NF-kappaB signaling 11 genes and carbohydrate metabolism 5 genes Biologic characterization of these genes and pathways might elucidate the action of glucocorticoids in ALL cells possibly suggesting causes of glucocorticoid resistance and new potential targets for therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7307, 32, 23571, 600, 4, 3, 24, 1, 864, 286, 1275, 62, 6, 10743, 80, 2670, 4, 1235, 2761, 460, 646, 4, 5399, 277, 351, 5318, 11318, 38341, 11, 95, 6, 255, 6851, 1065, 214, 23, 27, 2, 66, 1459, 1, 11253, 645, 4, 2015, 37, 1, 233, 541, 22, 72, 5, 55995, 37, 366, 27, 1459, 1, 645, 77, 93, 400, 4, 145, 55, 359, 40, 108, 366, 66, 1459, 1, 645, 725, 214, 11, 2478, 570, 19, 144, 2, 2133, 1574, 116, 79, 5, 587, 214, 486, 126, 1065, 52, 18, 39, 1116, 2, 133, 214, 11, 1328, 1065, 52, 14, 67, 1116, 737, 104, 1, 135, 214, 47, 44, 85, 108, 348, 6, 40, 6851, 1065, 20, 11253, 100, 1, 3, 27, 96, 561, 126, 1065, 214, 11, 30, 1245, 214, 17, 16, 10825, 5505, 178, 22235, 27, 67, 1116, 2, 5988, 8079, 2, 15301, 1398, 1101, 245, 38342, 66, 66, 1116, 545, 212, 1, 3, 2478, 570, 214, 11, 3772, 2320, 4, 27, 458, 9421, 5046, 1748, 460, 83, 214, 1365, 2119, 314, 175, 214, 2, 6718, 1600, 33, 214, 1283, 2136, 1, 46, 214, 2, 460, 822, 3061, 3, 1578, 1, 7307, 4, 62, 37, 2150, 802, 1626, 1, 5399, 251, 2, 217, 174, 637, 9, 36]",1363.0,17218380,835
Detrimental effect of natural killer cell alloreactivity in T-replete hematopoietic cell transplantation (HCT) for leukemia patients.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-02-01,"In hematopoietic cell transplantation (HCT), natural killer cell alloreactivity conferred by inhibitory ligands of killer immunoglobulin-like receptors (iKIRLs) may result in beneficial or detrimental outcomes. More data may contribute to resolution of this complex issue. We analyzed 378 primary allogeneic transplants with T-replete grafts for acute lymphoblastic leukemia (n = 101), acute myeloid leukemia and myelodysplastic syndrome (n = 149), and chronic myeloid leukemia (n = 128). The cohort was divided into 3 groups: in group 1, HLA class I matched at the antigen level (n = 260); in group 2, HLA class I mismatched at the antigen level (n = 57); and in group 3, HLA class I and iKIRLs mismatched (n = 61). One-year overall survival (OS) across groups 1 (59%), 2 (49%), and 3 (30%) was significantly different (P = .002). In contrast to group 2, group 3 had statistically lower OS (P = .05) and event-free survival (P = .01). Relapse and relapse-free mortality appeared to contribute to the low OS in group 3. The detrimental effect of natural killer alloreactivity was also evident when HLA-matched transplants were analyzed for patients lacking iKIRLs. One-year OS in patients lacking the HLA-Cw group 1 or 2 iKIRL was significantly lower than that in patients having the iKIRLs (55% vs 67%, n = 246, P = .01). Our observations indicate that, in T-replete unrelated HCT, iKIRL mismatches and the absence of iKIRLs confer higher risk to patients after HCT.",Journal Article,4737.0,24.0,In hematopoietic cell transplantation HCT natural killer cell alloreactivity conferred by inhibitory ligands of killer immunoglobulin-like receptors iKIRLs may result in beneficial or detrimental outcomes More data may contribute to resolution of this complex issue We analyzed 378 primary allogeneic transplants with T-replete grafts for acute lymphoblastic n 101 acute myeloid and syndrome n 149 and chronic myeloid n 128 The cohort was divided into 3 groups in group 1 HLA class I matched at the antigen level n 260 in group 2 HLA class I mismatched at the antigen level n 57 and in group 3 HLA class I and iKIRLs mismatched n 61 One-year overall survival OS across groups 1 59 2 49 and 3 30 was significantly different P .002 In contrast to group 2 group 3 had statistically lower OS P .05 and event-free survival P .01 Relapse and relapse-free mortality appeared to contribute to the low OS in group 3 The detrimental effect of natural killer alloreactivity was also evident when HLA-matched transplants were analyzed for patients lacking iKIRLs One-year OS in patients lacking the HLA-Cw group 1 or 2 iKIRL was significantly lower than that in patients having the iKIRLs 55 vs 67 n 246 P .01 Our observations indicate that in T-replete unrelated HCT iKIRL mismatches and the absence of iKIRLs confer higher risk to patients after HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 1007, 31, 497, 1085, 1504, 3458, 31, 22039, 3851, 20, 1810, 3123, 1, 3458, 2593, 733, 1186, 31051, 68, 757, 4, 2524, 15, 6227, 123, 80, 74, 68, 1248, 6, 2125, 1, 26, 840, 2537, 21, 311, 10084, 86, 1063, 4016, 5, 102, 11151, 4713, 9, 286, 1275, 78, 2338, 286, 533, 2, 681, 78, 4928, 2, 442, 533, 78, 3990, 3, 180, 10, 2176, 237, 27, 271, 4, 87, 14, 1160, 1040, 70, 655, 28, 3, 448, 301, 78, 6398, 4, 87, 18, 1160, 1040, 70, 5095, 28, 3, 448, 301, 78, 696, 2, 4, 87, 27, 1160, 1040, 70, 2, 31051, 5095, 78, 713, 104, 111, 63, 25, 118, 716, 271, 14, 728, 18, 739, 2, 27, 201, 10, 97, 338, 19, 1111, 4, 748, 6, 87, 18, 87, 27, 42, 712, 280, 118, 19, 474, 2, 774, 115, 25, 19, 355, 429, 2, 429, 115, 282, 2121, 6, 1248, 6, 3, 154, 118, 4, 87, 27, 3, 6227, 254, 1, 1504, 3458, 22039, 10, 120, 2853, 198, 1160, 655, 4016, 11, 311, 9, 7, 1941, 31051, 104, 111, 118, 4, 7, 1941, 3, 1160, 7198, 87, 14, 15, 18, 34209, 10, 97, 280, 76, 17, 4, 7, 1041, 3, 31051, 614, 105, 598, 78, 6907, 19, 355, 114, 2172, 1008, 17, 4, 102, 11151, 2092, 1085, 34209, 11828, 2, 3, 1127, 1, 31051, 2913, 142, 43, 6, 7, 50, 1085]",1339.0,17241925,361
Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511.,Blood,Blood,2007-01-30,"CALGB 9511 used pegaspargase (PEG-ASP) in lieu of the native enzyme. The aim was to compare differences in overall survival (OS) and disease-free survival (DFS) between patients who did and did not achieve asparagine depletion, defined by enzyme levels greater than 0.03 U/mL plasma for 14 consecutive days after at least 1 of 4 planned PEG-ASP administrations. Samples were available from 85 eligible patients. On univariate analyses, the 22 patients who did not achieve asparagine depletion had inferior OS (P = .002; hazard ratio [HR] = 2.37; 95% CI = 1.38-4.09) and DFS (P = .012; HR = 2.21; 95% CI = 1.19-4.13). After adjusting for age, performance status, leukocyte count, and karyotype in a proportional hazards model, both the OS and DFS HRs decreased to 1.8 (P = .056; 95% CI = 1.0-3.2 and P = .084; 95% CI = 0.9-3.6, respectively). We conclude that effective asparagine depletion with PEG-ASP is feasible as part of an intensive multiagent therapeutic regimen in adult acute lymphoblastic leukemia and appears associated with improved outcomes.",Clinical Trial,4739.0,106.0,CALGB 9511 used pegaspargase PEG-ASP in lieu of the native enzyme The aim was to compare differences in overall survival OS and disease-free survival DFS between patients who did and did not achieve asparagine depletion defined by enzyme levels greater than 0.03 U/mL plasma for 14 consecutive days after at least 1 of 4 planned PEG-ASP administrations Samples were available from 85 eligible patients On univariate analyses the 22 patients who did not achieve asparagine depletion had inferior OS P .002 hazard ratio HR 2.37 95 CI 1.38-4.09 and DFS P .012 HR 2.21 95 CI 1.19-4.13 After adjusting for age performance status leukocyte count and karyotype in a proportional hazards model both the OS and DFS HRs decreased to 1.8 P .056 95 CI 1.0-3.2 and P .084 95 CI 0.9-3.6 respectively We conclude that effective asparagine depletion with PEG-ASP is feasible as part of an intensive multiagent therapeutic regimen in adult acute lymphoblastic and appears associated with improved outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4077, 56035, 95, 12209, 3145, 8501, 4, 14575, 1, 3, 4646, 1644, 3, 1130, 10, 6, 932, 362, 4, 63, 25, 118, 2, 34, 115, 25, 1010, 59, 7, 54, 205, 2, 205, 44, 1359, 14108, 2286, 395, 20, 1644, 148, 378, 76, 13, 680, 1767, 542, 554, 9, 213, 935, 162, 50, 28, 506, 14, 1, 39, 1465, 3145, 8501, 10306, 347, 11, 390, 29, 772, 625, 7, 23, 880, 318, 3, 350, 7, 54, 205, 44, 1359, 14108, 2286, 42, 1663, 118, 19, 1111, 360, 197, 168, 18, 567, 48, 58, 14, 519, 39, 1730, 2, 1010, 19, 3499, 168, 18, 239, 48, 58, 14, 326, 39, 233, 50, 1358, 9, 89, 528, 156, 3627, 1276, 2, 3385, 4, 8, 831, 1017, 202, 110, 3, 118, 2, 1010, 2733, 340, 6, 14, 66, 19, 9556, 48, 58, 14, 13, 27, 18, 2, 19, 14183, 48, 58, 13, 83, 27, 49, 106, 21, 2060, 17, 323, 14108, 2286, 5, 3145, 8501, 16, 1313, 22, 760, 1, 35, 1686, 7148, 189, 477, 4, 780, 286, 1275, 2, 1233, 41, 5, 231, 123]",988.0,17264295,396
Ancestry and pharmacogenetics of antileukemic drug toxicity.,Blood,Blood,2007-01-30,"Treatment-related toxicity in acute lymphoblastic leukemia (ALL) can not only be life threatening but may also affect relapse risk. In 240 patients, we determined whether toxicities were related to 16 polymorphisms in genes linked to the pharmacodynamics of ALL chemotherapy, adjusting for age, race (self-reported or via ancestry-informative markers), sex, and disease risk group (lower- vs higher-risk therapy). Toxicities (gastrointestinal, infectious, hepatic, and neurologic) were assessed in each treatment phase. During the induction phase, when drugs subject to the steroid/cytochrome P4503A pathway predominated, genotypes in that pathway were important: vitamin D receptor (odds ratio [OR], 6.85 [95% confidence interval [CI], 1.73-27.0]) and cytochrome P4503A5 (OR, 4.61 [95% CI, 1.11-19.2]) polymorphisms were related to gastrointestinal toxicity and infection, respectively. During the consolidation phase, when antifolates predominated, the reduced folate carrier polymorphism predicted gastrointestinal toxicity (OR, 10.4 [95% CI, 1.35-80.4]) as it also did during continuation (OR, 2.01 [95% CI, 1.06-4.11]). In all 3 treatment phases, a glucuronosyltransferase polymorphism predicted hyperbilirubinemia (P = .017, P < .001, and P < .001) and methotrexate clearance (P = .028), which was also independently associated with hyperbilirubinemia (P = .026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy.",Journal Article,4739.0,130.0,Treatment-related toxicity in acute lymphoblastic ALL can not only be life threatening but may also affect relapse risk In 240 patients we determined whether toxicities were related to 16 polymorphisms in genes linked to the pharmacodynamics of ALL chemotherapy adjusting for age race self-reported or via ancestry-informative markers sex and disease risk group lower- vs higher-risk therapy Toxicities infectious hepatic and neurologic were assessed in each treatment phase During the induction phase when drugs subject to the steroid/cytochrome P4503A pathway predominated genotypes in that pathway were important vitamin D receptor odds ratio OR 6.85 95 confidence interval CI 1.73-27.0 and cytochrome P4503A5 OR 4.61 95 CI 1.11-19.2 polymorphisms were related to toxicity and infection respectively During the consolidation phase when antifolates predominated the reduced folate carrier polymorphism predicted toxicity OR 10.4 95 CI 1.35-80.4 as it also did during continuation OR 2.01 95 CI 1.06-4.11 In all 3 treatment phases a glucuronosyltransferase polymorphism predicted hyperbilirubinemia P .017 P .001 and P .001 and methotrexate clearance P .028 which was also independently associated with hyperbilirubinemia P .026 The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 139, 155, 4, 286, 1275, 62, 122, 44, 158, 40, 358, 3691, 84, 68, 120, 1158, 429, 43, 4, 4263, 7, 21, 509, 317, 385, 11, 139, 6, 245, 1203, 4, 214, 1199, 6, 3, 3587, 1, 62, 56, 1358, 9, 89, 1047, 1074, 210, 15, 847, 3535, 4189, 525, 1035, 2, 34, 43, 87, 280, 105, 142, 43, 36, 385, 3398, 939, 2, 2543, 11, 275, 4, 296, 24, 124, 190, 3, 504, 124, 198, 600, 2974, 6, 3, 3853, 4155, 44605, 308, 16244, 2071, 4, 17, 308, 11, 305, 1610, 427, 153, 610, 197, 15, 49, 772, 48, 307, 268, 58, 14, 803, 428, 13, 2, 4155, 56037, 15, 39, 713, 48, 58, 14, 175, 326, 18, 1203, 11, 139, 6, 155, 2, 930, 106, 190, 3, 2173, 124, 198, 14893, 16244, 3, 405, 3100, 4715, 1907, 783, 155, 15, 79, 39, 48, 58, 14, 465, 493, 39, 22, 192, 120, 205, 190, 6870, 15, 18, 355, 48, 58, 14, 1460, 39, 175, 4, 62, 27, 24, 3523, 8, 16822, 1907, 783, 7236, 19, 3825, 19, 144, 2, 19, 144, 2, 2116, 1960, 19, 4836, 92, 10, 120, 1042, 41, 5, 7236, 19, 4554, 3, 1183, 1005, 685, 11, 288, 317, 318, 11, 586, 20, 1074, 210, 1047, 15, 3535, 4189, 336, 525, 2280, 328, 1203, 32, 93, 3403, 1, 155, 1, 4512, 36]",1460.0,17264302,52
Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-03-01,"Historically, adolescents with acute lymphoblastic leukemia (ALL) have had inferior outcomes when compared with younger children. We report the outcome of adolescents treated on Dana-Farber Cancer Institute (DFCI; Boston, MA) ALL Consortium Protocols conducted between 1991 and 2000. A total of 844 patients aged 1 to 18 years, with newly diagnosed ALL were enrolled onto two consecutive DFCI-ALL Consortium Protocols. We compared outcomes in three age groups: children aged 1 to 10 years (n = 685), young adolescents aged 10 to 15 years (n = 108), and older adolescents aged 15 to 18 years (n = 51). With a median follow-up of 6.5 years, the 5-year event-free survival (EFS) for those aged 1 to 10 years was 85% (SE, 1%), compared with 77% (SE, 4%) for those aged 10 to 15 years, and 78% (SE, 6%) for those aged 15 to 18 years (P = .09). Adolescents were more likely to present with T-cell phenotype (P < .001) and less likely to have the TEL-AML1 fusion (P = .05). The incidence of pancreatitis and thromboembolic complications, but not asparaginase allergy, was higher in patients 10 years of age compared with those younger than 10 years. However, there was no difference in the rate of treatment-related complications between the 10- to 15-year and 15- to 18-year age groups. Adolescents were more likely to present at diagnosis with biologically higher risk disease (T-cell phenotype and absence of the TEL-AML1 fusion) and more likely to experience treatment-related complications than younger children. However, the 5-year EFS for older adolescents was 78% +/- 6%, which is superior to published outcomes for similarly aged patients treated with other pediatric and adult ALL regimens. Based on this experience, we currently are piloting our regimen in patients aged 18 to 50 years.",Comparative Study,4709.0,130.0,Historically adolescents with acute lymphoblastic ALL have had inferior outcomes when compared with younger children We report the outcome of adolescents treated on Dana-Farber Cancer Institute DFCI Boston MA ALL Consortium Protocols conducted between 1991 and 2000 A total of 844 patients aged 1 to 18 years with newly diagnosed ALL were enrolled onto two consecutive DFCI-ALL Consortium Protocols We compared outcomes in three age groups children aged 1 to 10 years n 685 young adolescents aged 10 to 15 years n 108 and older adolescents aged 15 to 18 years n 51 With a median follow-up of 6.5 years the 5-year event-free survival EFS for those aged 1 to 10 years was 85 SE 1 compared with 77 SE 4 for those aged 10 to 15 years and 78 SE 6 for those aged 15 to 18 years P .09 Adolescents were more likely to present with T-cell phenotype P .001 and less likely to have the TEL-AML1 fusion P .05 The incidence of pancreatitis and thromboembolic complications but not asparaginase allergy was higher in patients 10 years of age compared with those younger than 10 years However there was no difference in the rate of treatment-related complications between the 10- to 15-year and 15- to 18-year age groups Adolescents were more likely to present at diagnosis with biologically higher risk disease T-cell phenotype and absence of the TEL-AML1 fusion and more likely to experience treatment-related complications than younger children However the 5-year EFS for older adolescents was 78 +/- 6 which is superior to published outcomes for similarly aged patients treated with other pediatric and adult ALL regimens Based on this experience we currently are piloting our regimen in patients aged 18 to 50 years,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3578, 3101, 5, 286, 1275, 62, 47, 42, 1663, 123, 198, 72, 5, 773, 541, 21, 414, 3, 228, 1, 3101, 73, 23, 4932, 4979, 12, 1377, 11152, 7026, 3687, 62, 2404, 2189, 426, 59, 3372, 2, 1081, 8, 181, 1, 15617, 7, 1032, 14, 6, 203, 60, 5, 732, 265, 62, 11, 346, 3301, 100, 935, 11152, 62, 2404, 2189, 21, 72, 123, 4, 169, 89, 271, 541, 1032, 14, 6, 79, 60, 78, 13123, 1169, 3101, 1032, 79, 6, 167, 60, 78, 3590, 2, 434, 3101, 1032, 167, 6, 203, 60, 78, 725, 5, 8, 52, 166, 126, 1, 49, 33, 60, 3, 33, 111, 774, 115, 25, 1683, 9, 135, 1032, 14, 6, 79, 60, 10, 772, 3428, 14, 72, 5, 849, 3428, 39, 9, 135, 1032, 79, 6, 167, 60, 2, 833, 3428, 49, 9, 135, 1032, 167, 6, 203, 60, 19, 1730, 3101, 11, 80, 322, 6, 364, 5, 102, 31, 1005, 19, 144, 2, 299, 322, 6, 47, 3, 8573, 6535, 1212, 19, 474, 3, 287, 1, 4535, 2, 4703, 521, 84, 44, 3709, 9842, 10, 142, 4, 7, 79, 60, 1, 89, 72, 5, 135, 773, 76, 79, 60, 137, 125, 10, 77, 523, 4, 3, 116, 1, 24, 139, 521, 59, 3, 79, 6, 167, 111, 2, 167, 6, 203, 111, 89, 271, 3101, 11, 80, 322, 6, 364, 28, 147, 5, 2665, 142, 43, 34, 102, 31, 1005, 2, 1127, 1, 3, 8573, 6535, 1212, 2, 80, 322, 6, 730, 24, 139, 521, 76, 773, 541, 137, 3, 33, 111, 1683, 9, 434, 3101, 10, 833, 49, 92, 16, 1123, 6, 983, 123, 9, 1813, 1032, 7, 73, 5, 127, 815, 2, 780, 62, 472, 90, 23, 26, 730, 21, 694, 32, 34225, 114, 477, 4, 7, 1032, 203, 6, 212, 60]",1705.0,17327603,368
Growth factors in leukemia.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2007-02-01,"The role of myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, in the management of acute myeloid and acute lymphoblastic leukemias has been evaluated extensively in multiple clinical trials. Growth factors have been given before, concurrently, or sequentially with chemotherapy with the goal of reducing the duration of neutropenia and consequently the incidence and severity of infections, and improving the rate of remissions and overall survival. They also have been studied as chemotherapy-sensitizing agents in an effort to recruit dormant myeloid stem cells into the sensitive phase of the cycle. Additionally, growth factors, shown to stimulate proliferation and differentiation of leukemia cells in vitro, were evaluated as monotherapy in patients with acute leukemia. Most studies show modest improvement in the duration of the neutropenia, which does not consistently correlate with the severity of infection, rate or duration of remissions, or disease-free and overall survival. Attempts to enhance the chemosensitivity of the leukemic cells and decrease drug resistance failed to improve the rate of remission and survival in several large series. However, more recent reports suggested an improved outcome in younger patients with acute myeloid leukemia with normal karyotype. Several anecdotal case reports have shown that growth factor monotherapy can induce a complete remission in patients with acute leukemia. Data from the published clinical trials do not seem to support emergence of drug-resistant leukemia, worsening toxicity, and bone marrow failure with growth factor administration.",Journal Article,4737.0,15.0,The role of myeloid growth factors such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of acute myeloid and acute lymphoblastic leukemias has been evaluated extensively in multiple clinical trials Growth factors have been given before concurrently or sequentially with chemotherapy with the goal of reducing the duration of neutropenia and consequently the incidence and severity of infections and improving the rate of remissions and overall survival They also have been studied as chemotherapy-sensitizing agents in an effort to recruit dormant myeloid stem cells into the sensitive phase of the cycle Additionally growth factors shown to stimulate proliferation and differentiation of cells in vitro were evaluated as monotherapy in patients with acute Most studies show modest improvement in the duration of the neutropenia which does not consistently correlate with the severity of infection rate or duration of remissions or disease-free and overall survival Attempts to enhance the chemosensitivity of the leukemic cells and decrease drug resistance failed to improve the rate of remission and survival in several large series However more recent reports suggested an improved outcome in younger patients with acute myeloid with normal karyotype Several anecdotal case reports have shown that growth factor monotherapy can induce a complete remission in patients with acute Data from the published clinical trials do not seem to support emergence of drug-resistant worsening toxicity and marrow failure with growth factor administration,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 200, 1, 533, 129, 130, 225, 22, 2764, 1975, 2122, 161, 2, 2764, 2674, 1975, 2122, 161, 4, 3, 284, 1, 286, 533, 2, 286, 1275, 2792, 71, 85, 194, 3576, 4, 232, 38, 143, 129, 130, 47, 85, 447, 348, 3294, 15, 5455, 5, 56, 5, 3, 1326, 1, 1818, 3, 654, 1, 778, 2, 3244, 3, 287, 2, 1702, 1, 1875, 2, 1673, 3, 116, 1, 3166, 2, 63, 25, 491, 120, 47, 85, 656, 22, 56, 5979, 183, 4, 35, 2919, 6, 8973, 10525, 533, 452, 37, 237, 3, 745, 124, 1, 3, 417, 1724, 129, 130, 443, 6, 4223, 457, 2, 910, 1, 37, 4, 439, 11, 194, 22, 1411, 4, 7, 5, 286, 96, 94, 514, 1721, 767, 4, 3, 654, 1, 3, 778, 92, 1097, 44, 2433, 1513, 5, 3, 1702, 1, 930, 116, 15, 654, 1, 3166, 15, 34, 115, 2, 63, 25, 4374, 6, 1304, 3, 5522, 1, 3, 2015, 37, 2, 775, 234, 251, 1551, 6, 401, 3, 116, 1, 734, 2, 25, 4, 392, 375, 988, 137, 80, 435, 1198, 1148, 35, 231, 228, 4, 773, 7, 5, 286, 533, 5, 295, 3385, 392, 9244, 473, 1198, 47, 443, 17, 129, 161, 1411, 122, 1290, 8, 236, 734, 4, 7, 5, 286, 74, 29, 3, 983, 38, 143, 1022, 44, 3233, 6, 538, 3397, 1, 234, 436, 4323, 155, 2, 581, 496, 5, 129, 161, 634]",1608.0,17335689,741
Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801.,Blood,Blood,2007-03-07,"Nelarabine (506U78) is a soluble pro-drug of 9-beta-D-arabinofuranosylguanine (ara-G), a deoxyguanosine derivative. We treated 26 patients with T-cell acute lymphoblastic leukemia (T-ALL) and 13 with T-cell lymphoblastic lymphoma (T-LBL) with nelarabine. All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission. Nelarabine was administered on an alternate day schedule (days 1, 3, and 5) at 1.5 g/m(2)/day. Cycles were repeated every 22 days. The median age was 34 years (range, 16-66 years); 32 (82%) patients were male. The rate of complete remission was 31% (95% confidence interval [CI], 17%, 48%) and the overall response rate was 41% (95% CI, 26%, 58%). The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia, occurring in 37% and 26% of patients, respectively. There was only one grade 4 adverse event of the nervous system, which was a reversible depressed level of consciousness. The median disease-free survival (DFS) was 20 weeks (95% CI, 11, 56), and the median overall survival was 20 weeks (95% CI, 13, 36). The 1-year overall survival was 28% (95% CI, 15%, 43%). Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL.",Clinical Trial,4703.0,151.0,Nelarabine 506U78 is a soluble pro-drug of 9-beta-D-arabinofuranosylguanine ara-G a deoxyguanosine derivative We treated 26 patients with T-cell acute lymphoblastic T-ALL and 13 with T-cell lymphoblastic T-LBL with nelarabine All patients were refractory to at least one multiagent regimen or had relapsed after achieving a complete remission Nelarabine was administered on an alternate day schedule days 1 3 and 5 at 1.5 g/m 2 /day Cycles were repeated every 22 days The median age was 34 years range 16-66 years 32 82 patients were male The rate of complete remission was 31 95 confidence interval CI 17 48 and the overall response rate was 41 95 CI 26 58 The principal toxicity was grade 3 or 4 neutropenia and thrombocytopenia occurring in 37 and 26 of patients respectively There was only one grade 4 adverse event of the nervous system which was a reversible depressed level of consciousness The median disease-free survival DFS was 20 weeks 95 CI 11 56 and the median overall survival was 20 weeks 95 CI 13 36 The 1-year overall survival was 28 95 CI 15 43 Nelarabine is well tolerated and has significant antitumor activity in relapsed or refractory T-ALL and T-LBL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[13149, 44649, 16, 8, 2968, 1805, 234, 1, 83, 1090, 427, 38235, 3899, 499, 8, 17863, 4819, 21, 73, 432, 7, 5, 102, 31, 286, 1275, 102, 62, 2, 233, 5, 102, 31, 1275, 102, 8315, 5, 13149, 62, 7, 11, 430, 6, 28, 506, 104, 7148, 477, 15, 42, 591, 50, 1785, 8, 236, 734, 13149, 10, 468, 23, 35, 4689, 218, 1055, 162, 14, 27, 2, 33, 28, 14, 33, 499, 188, 18, 218, 410, 11, 2113, 454, 350, 162, 3, 52, 89, 10, 562, 60, 184, 245, 700, 60, 531, 878, 7, 11, 1045, 3, 116, 1, 236, 734, 10, 456, 48, 307, 268, 58, 269, 576, 2, 3, 63, 51, 116, 10, 605, 48, 58, 432, 717, 3, 4312, 155, 10, 88, 27, 15, 39, 778, 2, 1340, 1821, 4, 567, 2, 432, 1, 7, 106, 125, 10, 158, 104, 88, 39, 290, 774, 1, 3, 1880, 398, 92, 10, 8, 2786, 9233, 301, 1, 15471, 3, 52, 34, 115, 25, 1010, 10, 179, 244, 48, 58, 175, 664, 2, 3, 52, 63, 25, 10, 179, 244, 48, 58, 233, 511, 3, 14, 111, 63, 25, 10, 339, 48, 58, 167, 601, 13149, 16, 149, 421, 2, 71, 93, 579, 128, 4, 591, 15, 430, 102, 62, 2, 102, 8315]",1173.0,17344466,884
Prophylaxis of Pneumocystis carinii pneumonia with atovaquone in children with leukemia.,Cancer,Cancer,2007-04-01,"Despite extensive studies of atovaquone in human immunodeficiency virus (HIV)-infected patients, there is little information about its efficacy as a prophylactic agent for Pneumocystis carinii pneumonia (PCP) in pediatric patients with cancer. Therefore, a retrospective analysis was conducted to determine the incidence of PCP in pediatric patients who received prophylactic atovaquone during treatment for acute leukemia. We reviewed the medical records of all patients treated at our institution for acute lymphoblastic leukemia or acute myeloid leukemia between 1994 and 2004. Only patients who were intolerant of trimethoprim-sulfamethoxazole (TMP-SMZ) and received atovaquone prophylaxis were included in the analysis. Eighty-six patients were unable to tolerate TMP-SMZ and received daily atovaquone for PCP prophylaxis. PCP was not diagnosed in any patient who received atovaquone prophylaxis: the upper limit of the 95% confidence interval (CI) was 1.74 per 100 person-years. Atovaquone is an efficacious alternative for PCP prophylaxis in pediatric patients who have leukemia and are intolerant of TMP-SMZ.",Journal Article,4678.0,20.0,Despite extensive studies of atovaquone in human immunodeficiency virus HIV -infected patients there is little information about its efficacy as a prophylactic agent for Pneumocystis carinii pneumonia PCP in pediatric patients with cancer Therefore a retrospective analysis was conducted to determine the incidence of PCP in pediatric patients who received prophylactic atovaquone during treatment for acute We reviewed the medical records of all patients treated at our institution for acute lymphoblastic or acute myeloid between 1994 and 2004 Only patients who were intolerant of trimethoprim-sulfamethoxazole TMP-SMZ and received atovaquone prophylaxis were included in the analysis Eighty-six patients were unable to tolerate TMP-SMZ and received daily atovaquone for PCP prophylaxis PCP was not diagnosed in any patient who received atovaquone prophylaxis the upper limit of the 95 confidence interval CI was 1.74 per 100 person-years Atovaquone is an efficacious alternative for PCP prophylaxis in pediatric patients who have and are intolerant of TMP-SMZ,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[550, 1344, 94, 1, 19798, 4, 171, 5323, 1450, 1942, 3369, 7, 125, 16, 1215, 487, 545, 211, 209, 22, 8, 1862, 420, 9, 13243, 21967, 3485, 8135, 4, 815, 7, 5, 12, 673, 8, 459, 65, 10, 426, 6, 223, 3, 287, 1, 8135, 4, 815, 7, 54, 103, 1862, 19798, 190, 24, 9, 286, 21, 446, 3, 484, 1064, 1, 62, 7, 73, 28, 114, 731, 9, 286, 1275, 15, 286, 533, 59, 3023, 2, 1131, 158, 7, 54, 11, 4944, 1, 23151, 23152, 17926, 38386, 2, 103, 19798, 2049, 11, 159, 4, 3, 65, 2207, 437, 7, 11, 4253, 6, 5010, 17926, 38386, 2, 103, 391, 19798, 9, 8135, 2049, 8135, 10, 44, 265, 4, 500, 69, 54, 103, 19798, 2049, 3, 1726, 2385, 1, 3, 48, 307, 268, 58, 10, 14, 794, 379, 394, 2719, 60, 19798, 16, 35, 3289, 1091, 9, 8135, 2049, 4, 815, 7, 54, 47, 2, 32, 4944, 1, 17926, 38386]",1062.0,17345613,430
Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia.,JAMA,JAMA,2007-03-01,"Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia. To investigate the cumulative incidence of secondary neoplasms in pediatric patients treated for acute lymphoblastic leukemia over 30 years and to characterize late-occurring tumors. Retrospective study of 2169 patients with acute lymphoblastic leukemia treated between 1962 and 1998 at St Jude Children's Research Hospital, Memphis, Tenn, who achieved complete remission and had a median follow-up time of 18.7 years (range, 2.4-41.3 years). Cumulative incidences of secondary neoplasms in first remission and standard incidence ratios of observed rates compared with rates of cancer development in the general US population. Secondary neoplasms developed as the first event in 123 patients and comprised 46 myeloid malignancies, 3 lymphomas, 14 basal cell carcinomas, 16 other carcinomas, 6 sarcomas, 16 meningiomas, and 22 other brain tumors. The cumulative incidence of secondary neoplasm was 4.17% (SE, 0.46%) at 15 years and increased substantially after 20 years, reaching 10.85% (SE, 1.27%) at 30 years. When meningiomas and basal cell carcinomas were excluded, the overall cumulative incidence was 3.99% (SE, 0.44%) at 15 years and 6.27% (SE, 0.83%) at 30 years, representing a 13.5-fold increase in overall risk compared with the general population. The cumulative incidence of each tumor type at 30 years was 2.19% (SE, 0.32%) for myeloid malignancy, 0.17% (SE, 0.10%) for lymphoma, 3.00% (SE, 0.59%) for brain tumor, 4.91% (SE, 1.04%) for carcinoma, and 0.57% (SE, 0.37%) for sarcoma. The cumulative incidence of secondary neoplasms increases steadily over 30 years after treatment of acute lymphoblastic leukemia. Although the majority of the late-occurring secondary neoplasms are low-grade tumors, the increase in incidence of more aggressive malignant neoplasms is significantly higher than expected in the general population. These results suggest that lifelong follow-up of acute lymphoblastic leukemia survivors is needed to ascertain the full impact of treatment and other leukemia-related factors on secondary neoplasm development.",Journal Article,4709.0,197.0,Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic To investigate the cumulative incidence of secondary neoplasms in pediatric patients treated for acute lymphoblastic over 30 years and to characterize late-occurring tumors Retrospective study of 2169 patients with acute lymphoblastic treated between 1962 and 1998 at St Jude Children 's Research Hospital Memphis Tenn who achieved complete remission and had a median follow-up time of 18.7 years range 2.4-41.3 years Cumulative incidences of secondary neoplasms in first remission and standard incidence ratios of observed rates compared with rates of cancer development in the general US population Secondary neoplasms developed as the first event in 123 patients and comprised 46 myeloid malignancies 3 lymphomas 14 basal cell carcinomas 16 other carcinomas 6 sarcomas 16 meningiomas and 22 other brain tumors The cumulative incidence of secondary neoplasm was 4.17 SE 0.46 at 15 years and increased substantially after 20 years reaching 10.85 SE 1.27 at 30 years When meningiomas and basal cell carcinomas were excluded the overall cumulative incidence was 3.99 SE 0.44 at 15 years and 6.27 SE 0.83 at 30 years representing a 13.5-fold increase in overall risk compared with the general population The cumulative incidence of each tumor type at 30 years was 2.19 SE 0.32 for myeloid malignancy 0.17 SE 0.10 for 3.00 SE 0.59 for brain tumor 4.91 SE 1.04 for carcinoma and 0.57 SE 0.37 for The cumulative incidence of secondary neoplasms increases steadily over 30 years after treatment of acute lymphoblastic Although the majority of the late-occurring secondary neoplasms are low-grade tumors the increase in incidence of more aggressive malignant neoplasms is significantly higher than expected in the general population These results suggest that lifelong follow-up of acute lymphoblastic survivors is needed to ascertain the full impact of treatment and other leukemia-related factors on secondary neoplasm development,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[1215, 16, 440, 545, 3, 287, 1, 568, 1179, 50, 167, 6, 179, 60, 4, 541, 2, 3101, 54, 11, 73, 9, 286, 1275, 6, 963, 3, 967, 287, 1, 568, 1179, 4, 815, 7, 73, 9, 286, 1275, 252, 201, 60, 2, 6, 1507, 807, 1821, 57, 459, 45, 1, 38398, 7, 5, 286, 1275, 73, 59, 14754, 2, 1850, 28, 3062, 4841, 541, 292, 389, 702, 18922, 43400, 54, 513, 236, 734, 2, 42, 8, 52, 166, 126, 98, 1, 203, 67, 60, 184, 18, 39, 605, 27, 60, 967, 3981, 1, 568, 1179, 4, 157, 734, 2, 260, 287, 1137, 1, 164, 151, 72, 5, 151, 1, 12, 193, 4, 3, 1083, 843, 266, 568, 1179, 276, 22, 3, 157, 774, 4, 2698, 7, 2, 2603, 641, 533, 441, 27, 1557, 213, 2135, 31, 826, 245, 127, 826, 49, 1479, 245, 3718, 2, 350, 127, 342, 57, 3, 967, 287, 1, 568, 2131, 10, 39, 269, 3428, 13, 641, 28, 167, 60, 2, 101, 2109, 50, 179, 60, 6168, 79, 772, 3428, 14, 428, 28, 201, 60, 198, 3718, 2, 2135, 31, 826, 11, 1800, 3, 63, 967, 287, 10, 27, 1058, 3428, 13, 584, 28, 167, 60, 2, 49, 428, 3428, 13, 852, 28, 201, 60, 2861, 8, 233, 33, 1116, 344, 4, 63, 43, 72, 5, 3, 1083, 266, 3, 967, 287, 1, 296, 30, 267, 28, 201, 60, 10, 18, 326, 3428, 13, 531, 9, 533, 710, 13, 269, 3428, 13, 79, 9, 27, 2038, 3428, 13, 728, 9, 342, 30, 39, 970, 3428, 14, 755, 9, 134, 2, 13, 696, 3428, 13, 567, 9, 3, 967, 287, 1, 568, 1179, 1106, 7025, 252, 201, 60, 50, 24, 1, 286, 1275, 242, 3, 686, 1, 3, 807, 1821, 568, 1179, 32, 154, 88, 57, 3, 344, 4, 287, 1, 80, 571, 393, 1179, 16, 97, 142, 76, 1336, 4, 3, 1083, 266, 46, 99, 309, 17, 9590, 166, 126, 1, 286, 1275, 332, 16, 575, 6, 6040, 3, 1647, 345, 1, 24, 2, 127, 2647, 139, 130, 23, 568, 2131, 193]",2074.0,17374815,481
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase.,The Journal of clinical investigation,J. Clin. Invest.,2007-03-22,"Because of their low asparagine synthetase (ASNS) expression and asparagine biosynthesis, acute lymphoblastic leukemia (ALL) cells are exquisitely sensitive to asparagine depletion. Consequently, asparaginase is a major component of ALL therapy, but the mechanisms regulating the susceptibility of leukemic cells to this agent are unclear. In 288 children with ALL, cellular ASNS expression was more likely to be high in T-lineage ALL and low in B-lineage ALL with TEL-AML1 or hyperdiploidy. However, ASNS expression levels in bone marrow-derived mesenchymal cells (MSCs), which form the microenvironment where leukemic cells grow, were on average 20 times higher than those in ALL cells. MSCs protected ALL cells from asparaginase cytotoxicity in coculture experiments. This protective effect correlated with levels of ASNS expression: downregulation by RNA interference decreased the capacity of MSCs to protect ALL cells from asparaginase, whereas enforced ASNS expression conferred enhanced protection. Asparagine secretion by MSCs was directly related to their ASNS expression levels, suggesting a mechanism - increased concentrations of asparagine in the leukemic cell microenvironment - for the protective effects we observed. These results provide what we believe to be a new basis for understanding asparaginase resistance in ALL and indicate that MSC niches in the bone marrow can form a safe haven for leukemic cells.",Journal Article,4688.0,209.0,Because of their low asparagine synthetase ASNS expression and asparagine biosynthesis acute lymphoblastic ALL cells are exquisitely sensitive to asparagine depletion Consequently asparaginase is a major component of ALL therapy but the mechanisms regulating the susceptibility of leukemic cells to this agent are unclear In 288 children with ALL cellular ASNS expression was more likely to be high in T-lineage ALL and low in B-lineage ALL with TEL-AML1 or hyperdiploidy However ASNS expression levels in marrow-derived mesenchymal cells MSCs which form the microenvironment where leukemic cells grow were on average 20 times higher than those in ALL cells MSCs protected ALL cells from asparaginase cytotoxicity in coculture experiments This protective effect correlated with levels of ASNS expression downregulation by RNA interference decreased the capacity of MSCs to protect ALL cells from asparaginase whereas enforced ASNS expression conferred enhanced protection Asparagine secretion by MSCs was directly related to their ASNS expression levels suggesting a mechanism increased concentrations of asparagine in the leukemic cell microenvironment for the protective effects we observed These results provide what we believe to be a new basis for understanding asparaginase resistance in ALL and indicate that MSC niches in the marrow can form a safe haven for leukemic cells,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[408, 1, 136, 154, 14108, 12692, 16063, 55, 2, 14108, 6225, 286, 1275, 62, 37, 32, 11936, 745, 6, 14108, 2286, 3244, 3709, 16, 8, 458, 1249, 1, 62, 36, 84, 3, 483, 2681, 3, 1432, 1, 2015, 37, 6, 26, 420, 32, 1200, 4, 8603, 541, 5, 62, 763, 16063, 55, 10, 80, 322, 6, 40, 64, 4, 102, 2542, 62, 2, 154, 4, 132, 2542, 62, 5, 8573, 6535, 15, 11299, 137, 16063, 55, 148, 4, 581, 526, 1569, 37, 4460, 92, 1297, 3, 995, 1257, 2015, 37, 6265, 11, 23, 1011, 179, 1072, 142, 76, 135, 4, 62, 37, 4460, 5541, 62, 37, 29, 3709, 1408, 4, 7604, 2332, 26, 2864, 254, 438, 5, 148, 1, 16063, 55, 2475, 20, 893, 3182, 340, 3, 2162, 1, 4460, 6, 4869, 62, 37, 29, 3709, 547, 7807, 16063, 55, 3851, 651, 3525, 14108, 2935, 20, 4460, 10, 1606, 139, 6, 136, 16063, 55, 148, 802, 8, 670, 101, 1003, 1, 14108, 4, 3, 2015, 31, 995, 9, 3, 2864, 176, 21, 164, 46, 99, 377, 2067, 21, 4629, 6, 40, 8, 217, 877, 9, 612, 3709, 251, 4, 62, 2, 1008, 17, 4150, 8005, 4, 3, 581, 122, 1297, 8, 1165, 17251, 9, 2015, 37]",1381.0,17380207,368
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2007-03-01,"Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia chromosome, which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene (bcr-abl) that gives rise to a constitutively activated Abl tyrosine kinase. This kinase led to the discovery of several small-molecule inhibitors, imatinib being the first and most successful of these. Resistance to imatinib results in some patients from Abl kinase point mutations. Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML. In this review, we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic leukemia with previous imatinib failure.",Journal Article,4709.0,9.0,Chronic myeloid CML is characterized by the presence of the Philadelphia chromosome which is associated with a balanced translocation involving chromosomes 9 and 22 to produce a fusion gene bcr-abl that gives rise to a constitutively activated Abl tyrosine kinase This kinase led to the discovery of several small-molecule inhibitors imatinib being the first and most successful of these Resistance to imatinib results in some patients from Abl kinase point mutations Overcoming imatinib resistance represents one of the biggest challenges facing clinicians in the modern management of CML In this review we discuss the current understanding of CML pathophysiology and mechanisms of imatinib resistance and how advancing this knowledge has led to the design of novel therapies in the area of blastic phase CML and Philadelphia chromosome-positive acute lymphoblastic with previous imatinib failure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[442, 533, 903, 16, 765, 20, 3, 463, 1, 3, 3006, 1170, 92, 16, 41, 5, 8, 4115, 2006, 1267, 3560, 83, 2, 350, 6, 2410, 8, 1212, 145, 1062, 1425, 17, 7989, 3693, 6, 8, 2818, 735, 1425, 564, 216, 26, 216, 836, 6, 3, 1574, 1, 392, 302, 1354, 222, 577, 486, 3, 157, 2, 96, 1401, 1, 46, 251, 6, 577, 99, 4, 476, 7, 29, 1425, 216, 741, 138, 5344, 577, 251, 1449, 104, 1, 3, 16883, 1427, 7917, 1490, 4, 3, 2366, 284, 1, 903, 4, 26, 206, 21, 1139, 3, 291, 612, 1, 903, 4320, 2, 483, 1, 577, 251, 2, 832, 5155, 26, 922, 71, 836, 6, 3, 771, 1, 229, 235, 4, 3, 965, 1, 6529, 124, 903, 2, 3006, 1170, 109, 286, 1275, 5, 698, 577, 496]",897.0,17382020,3
Decreased adult height in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,The Journal of pediatrics,J. Pediatr.,2007-04-01,"To determine risk factors associated with reduced adult height in survivors of childhood acute lymphoblastic leukemia (ALL). This was a cross-sectional study. Attained adult height was determined among 2434 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986, and compared with 3009 siblings. All survivor treatment exposure groups (chemotherapy alone, chemotherapy with cranial or craniospinal radiotherapy) had decreased adult height and an increased risk of adult short stature (height standard deviation score < -2) compared with siblings (P < .001). Compared with siblings, the risk of short stature for survivors treated with chemotherapy alone was elevated (OR, 3.4; 95% CI, 1.9, 6.0). Among survivors, significant risk factors for short stature included diagnosis of ALL before puberty, higher-dose cranial radiotherapy (> or = 20 Gy versus < 20 Gy), any radiotherapy to the spine, and female sex. Survivors of childhood ALL are at increased risk of adult short stature, including those treated with chemotherapy alone. Risk is highest for those treated with cranial and craniospinal radiotherapy at a young age.",Comparative Study,4678.0,56.0,To determine risk factors associated with reduced adult height in survivors of childhood acute lymphoblastic ALL This was a cross-sectional study Attained adult height was determined among 2434 ALL survivors participating in the Childhood Cancer Survivor Study a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986 and compared with 3009 siblings All survivor treatment exposure groups chemotherapy alone chemotherapy with cranial or craniospinal radiotherapy had decreased adult height and an increased risk of adult short stature height standard deviation score -2 compared with siblings P .001 Compared with siblings the risk of short stature for survivors treated with chemotherapy alone was elevated OR 3.4 95 CI 1.9 6.0 Among survivors significant risk factors for short stature included diagnosis of ALL before puberty higher-dose cranial radiotherapy or 20 Gy versus 20 Gy any radiotherapy to the spine and female sex Survivors of childhood ALL are at increased risk of adult short stature including those treated with chemotherapy alone Risk is highest for those treated with cranial and craniospinal radiotherapy at a young age,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 43, 130, 41, 5, 405, 780, 4594, 4, 332, 1, 864, 286, 1275, 62, 26, 10, 8, 1383, 2832, 45, 5105, 780, 4594, 10, 509, 107, 56145, 62, 332, 3052, 4, 3, 864, 12, 2628, 45, 8, 180, 1, 33, 111, 332, 1, 186, 815, 163, 265, 29, 4868, 6, 3751, 2, 72, 5, 44665, 2758, 62, 2628, 24, 645, 271, 56, 279, 56, 5, 2565, 15, 5748, 310, 42, 340, 780, 4594, 2, 35, 101, 43, 1, 780, 978, 13576, 4594, 260, 3348, 368, 18, 72, 5, 2758, 19, 144, 72, 5, 2758, 3, 43, 1, 978, 13576, 9, 332, 73, 5, 56, 279, 10, 804, 15, 27, 39, 48, 58, 14, 83, 49, 13, 107, 332, 93, 43, 130, 9, 978, 13576, 159, 147, 1, 62, 348, 10302, 142, 61, 2565, 310, 15, 179, 381, 185, 179, 381, 500, 310, 6, 3, 2342, 2, 1061, 1035, 332, 1, 864, 62, 32, 28, 101, 43, 1, 780, 978, 13576, 141, 135, 73, 5, 56, 279, 43, 16, 1076, 9, 135, 73, 5, 2565, 2, 5748, 310, 28, 8, 1169, 89]",1168.0,17382112,82
Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-04-01,"We evaluated the long-term effects of treatment on the body mass index (BMI) of children with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma who received one of three CNS-directed therapies: intrathecal methotrexate with intravenous high-dose methotrexate (1 g/m2), intrathecal methotrexate with 18 Gy cranial radiation, or intrathecal methotrexate with 24 Gy cranial radiation. Between 1979 and 1984, 456 children with newly diagnosed ALL and lymphoma were enrolled onto a single protocol at St Jude Children's Research Hospital (Memphis, TN). The heights and weights of 422 of the children were measured at diagnosis, during treatment, at the end of therapy, and approximately every 6 to 12 months thereafter. Patients who had attained their adult height at the time of analysis (n = 248) were placed in weight categories based on their BMI, BMI percentile, or weight-for-length percentile depending on age. The overall percentage of survivors who were overweight or obese approximated rates prevalent in the general population of the United States. Young age (< 6 years) and overweight/obesity at diagnosis were the best predictors of obesity at adult height. The rate of BMI increase did not differ significantly between children who received radiation and those who did not, nor between patients who received 18 or 24 Gy of cranial radiation. BMI weight category at diagnosis, rather than type of CNS treatment received, predicted adult weight in long-term survivors of childhood hematologic malignancies.",Journal Article,4678.0,82.0,We evaluated the long-term effects of treatment on the body mass index BMI of children with acute lymphoblastic ALL or lymphoblastic who received one of three CNS-directed therapies intrathecal methotrexate with intravenous high-dose methotrexate 1 g/m2 intrathecal methotrexate with 18 Gy cranial radiation or intrathecal methotrexate with 24 Gy cranial radiation Between 1979 and 1984 456 children with newly diagnosed ALL and were enrolled onto a single protocol at St Jude Children 's Research Hospital Memphis TN The heights and weights of 422 of the children were measured at diagnosis during treatment at the end of therapy and approximately every 6 to 12 months thereafter Patients who had attained their adult height at the time of analysis n 248 were placed in weight categories based on their BMI BMI percentile or weight-for-length percentile depending on age The overall percentage of survivors who were overweight or obese approximated rates prevalent in the general population of the United States Young age 6 years and overweight/obesity at diagnosis were the best predictors of obesity at adult height The rate of BMI increase did not differ significantly between children who received radiation and those who did not nor between patients who received 18 or 24 Gy of cranial radiation BMI weight category at diagnosis rather than type of CNS treatment received predicted adult weight in long-term survivors of childhood hematologic malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 194, 3, 319, 337, 176, 1, 24, 23, 3, 642, 782, 558, 1140, 1, 541, 5, 286, 1275, 62, 15, 1275, 54, 103, 104, 1, 169, 1025, 1166, 235, 5126, 2116, 5, 1262, 64, 61, 2116, 14, 499, 821, 5126, 2116, 5, 203, 381, 2565, 121, 15, 5126, 2116, 5, 259, 381, 2565, 121, 59, 9444, 2, 6036, 10981, 541, 5, 732, 265, 62, 2, 11, 346, 3301, 8, 226, 1182, 28, 3062, 4841, 541, 292, 389, 702, 18922, 3814, 3, 23162, 2, 7966, 1, 10581, 1, 3, 541, 11, 644, 28, 147, 190, 24, 28, 3, 396, 1, 36, 2, 705, 454, 49, 6, 133, 53, 3972, 7, 54, 42, 5105, 136, 780, 4594, 28, 3, 98, 1, 65, 78, 7100, 11, 3295, 4, 924, 1996, 90, 23, 136, 1140, 1140, 6392, 15, 924, 9, 1318, 6392, 3221, 23, 89, 3, 63, 1150, 1, 332, 54, 11, 3566, 15, 2209, 11946, 151, 2485, 4, 3, 1083, 266, 1, 3, 1088, 907, 1169, 89, 49, 60, 2, 3566, 1661, 28, 147, 11, 3, 824, 674, 1, 1661, 28, 780, 4594, 3, 116, 1, 1140, 344, 205, 44, 1505, 97, 59, 541, 54, 103, 121, 2, 135, 54, 205, 44, 2110, 59, 7, 54, 103, 203, 15, 259, 381, 1, 2565, 121, 1140, 924, 2169, 28, 147, 1832, 76, 267, 1, 1025, 24, 103, 783, 780, 924, 4, 319, 337, 332, 1, 864, 813, 441]",1461.0,17401007,467
A set of genes that regulate cell proliferation predicts treatment outcome in childhood acute lymphoblastic leukemia.,Blood,Blood,2007-04-24,"To identify novel predictors of outcome in childhood acute lymphoblastic leukemia (ALL), we analyzed gene expression in the leukemic cells of 187 children with newly diagnosed ALL and compared the findings with minimal residual disease (MRD) results obtained on day 19 of remission induction treatment. Genes that showed a significant relationship to MRD were then tested for their capacity to predict leukemic relapse in an independent cohort of 99 patients. We identified 674 probe sets that were associated with MRD on day 19 (P < .006); 40 of the identified genes predicted relapse (P < .03). Among these, 14 showed independent prognostic significance after adjustment for age, leukocyte count at diagnosis, and genetic subtype. More than half of the 40 genes and nearly all of the 14 genes were functionally related, as indicated by their roles in the regulation of cell proliferation. Underexpression of genes promoting cell proliferation was associated with resistance to chemotherapy. The biologic processes regulated by the genes we identified appear to be key determinants of the early cytoreductive response to remission induction therapy and subsequent clinical outcome in childhood ALL. Incorporation of the expression levels of these genes into existing strategies of risk classification could improve clinical management.",Journal Article,4655.0,89.0,To identify novel predictors of outcome in childhood acute lymphoblastic ALL we analyzed gene expression in the leukemic cells of 187 children with newly diagnosed ALL and compared the findings with minimal residual disease MRD results obtained on day 19 of remission induction treatment Genes that showed a significant relationship to MRD were then tested for their capacity to predict leukemic relapse in an independent cohort of 99 patients We identified 674 probe sets that were associated with MRD on day 19 P .006 40 of the identified genes predicted relapse P .03 Among these 14 showed independent prognostic significance after adjustment for age leukocyte count at diagnosis and genetic subtype More than half of the 40 genes and nearly all of the 14 genes were functionally related as indicated by their roles in the regulation of cell proliferation Underexpression of genes promoting cell proliferation was associated with resistance to chemotherapy The biologic processes regulated by the genes we identified appear to be key determinants of the early cytoreductive response to remission induction therapy and subsequent clinical outcome in childhood ALL Incorporation of the expression levels of these genes into existing strategies of risk classification could improve clinical management,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 255, 229, 674, 1, 228, 4, 864, 286, 1275, 62, 21, 311, 145, 55, 4, 3, 2015, 37, 1, 5568, 541, 5, 732, 265, 62, 2, 72, 3, 272, 5, 1048, 753, 34, 2029, 99, 683, 23, 218, 326, 1, 734, 504, 24, 214, 17, 224, 8, 93, 858, 6, 2029, 11, 818, 650, 9, 136, 2162, 6, 678, 2015, 429, 4, 35, 306, 180, 1, 1058, 7, 21, 108, 12258, 2888, 2270, 17, 11, 41, 5, 2029, 23, 218, 326, 19, 1861, 327, 1, 3, 108, 214, 783, 429, 19, 680, 107, 46, 213, 224, 306, 177, 724, 50, 1852, 9, 89, 3627, 1276, 28, 147, 2, 336, 875, 80, 76, 1303, 1, 3, 327, 214, 2, 1857, 62, 1, 3, 213, 214, 11, 3772, 139, 22, 1103, 20, 136, 1790, 4, 3, 863, 1, 31, 457, 22250, 1, 214, 2388, 31, 457, 10, 41, 5, 251, 6, 56, 3, 1283, 1849, 1065, 20, 3, 214, 21, 108, 1322, 6, 40, 825, 3403, 1, 3, 191, 2604, 51, 6, 734, 504, 36, 2, 706, 38, 228, 4, 864, 62, 2838, 1, 3, 55, 148, 1, 46, 214, 237, 1692, 422, 1, 43, 947, 359, 401, 38, 284]",1301.0,17456722,17
Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia.,Blood,Blood,2007-05-01,"One-hundred thirty-nine patients with acute lymphoblastic leukemia (ALL) and hypodiploidy (fewer than 45 chromosomes) were collected from 10 different national ALL study groups and single institutions. Patients were stratified by modal chromosome number into 4 groups: 24 to 29 (N = 46); 33 to 39 (N = 26); 40 to 43 (N = 13); and 44 (N = 54) chromosomes. Nine patients were Philadelphia chromosome (Ph) positive (4 cases: 44 chromosomes; 5 cases: 40-43 chromosomes) and were not considered further. Event-free survival (EFS) and overall survival (OS) of the remaining 130 patients were 38.5% +/- 4.4% and 49.8% +/- 4.2% at 8 years, respectively. There were no significant differences in outcome between patients with 24 to 29, 33 to 39, or 40 to 43 chromosomes. Compared with patients with fewer than 44 chromosomes, patients with 44 chromosomes had a significantly better EFS (P = .01; 8-year estimate, 52.2% vs 30.1%) and OS (P = .017; 69% vs 37.5%). For patients with 44 chromosomes, monosomy 7, the presence of a dicentric chromosome, or both predicted a worse EFS but similar OS. Doubling of the hypodiploid clone occurred in 32 patients (24-29 chromosomes [n = 25] and 33-39 chromosomes [n = 7]) and had no prognostic implication. Children and adolescents with ALL and hypodiploidy with fewer than 44 chromosomes have a poor outcome despite contemporary therapy.",Clinical Trial,4648.0,168.0,One-hundred thirty-nine patients with acute lymphoblastic ALL and hypodiploidy fewer than 45 chromosomes were collected from 10 different national ALL study groups and single institutions Patients were stratified by modal chromosome number into 4 groups 24 to 29 N 46 33 to 39 N 26 40 to 43 N 13 and 44 N 54 chromosomes Nine patients were Philadelphia chromosome Ph positive 4 cases 44 chromosomes 5 cases 40-43 chromosomes and were not considered further Event-free survival EFS and overall survival OS of the remaining 130 patients were 38.5 +/- 4.4 and 49.8 +/- 4.2 at 8 years respectively There were no significant differences in outcome between patients with 24 to 29 33 to 39 or 40 to 43 chromosomes Compared with patients with fewer than 44 chromosomes patients with 44 chromosomes had a significantly better EFS P .01 8-year estimate 52.2 vs 30.1 and OS P .017 69 vs 37.5 For patients with 44 chromosomes monosomy 7 the presence of a dicentric chromosome or both predicted a worse EFS but similar OS Doubling of the hypodiploid clone occurred in 32 patients 24-29 chromosomes n 25 and 33-39 chromosomes n 7 and had no prognostic implication Children and adolescents with ALL and hypodiploidy with fewer than 44 chromosomes have a poor outcome despite contemporary therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[104, 1128, 977, 762, 7, 5, 286, 1275, 62, 2, 14828, 1497, 76, 512, 3560, 11, 786, 29, 79, 338, 657, 62, 45, 271, 2, 226, 1764, 7, 11, 1173, 20, 18935, 1170, 207, 237, 39, 271, 259, 6, 462, 78, 641, 466, 6, 587, 78, 432, 327, 6, 601, 78, 233, 2, 584, 78, 667, 3560, 762, 7, 11, 3006, 1170, 2058, 109, 39, 140, 584, 3560, 33, 140, 327, 601, 3560, 2, 11, 44, 515, 195, 774, 115, 25, 1683, 2, 63, 25, 118, 1, 3, 1844, 3431, 7, 11, 519, 33, 39, 39, 2, 739, 66, 39, 18, 28, 66, 60, 106, 125, 11, 77, 93, 362, 4, 228, 59, 7, 5, 259, 6, 462, 466, 6, 587, 15, 327, 6, 601, 3560, 72, 5, 7, 5, 1497, 76, 584, 3560, 7, 5, 584, 3560, 42, 8, 97, 380, 1683, 19, 355, 66, 111, 1191, 653, 18, 105, 201, 14, 2, 118, 19, 3825, 790, 105, 567, 33, 9, 7, 5, 584, 3560, 7521, 67, 3, 463, 1, 8, 33550, 1170, 15, 110, 783, 8, 639, 1683, 84, 288, 118, 4342, 1, 3, 12135, 3910, 489, 4, 531, 7, 259, 462, 3560, 78, 243, 2, 466, 587, 3560, 78, 67, 2, 42, 77, 177, 8969, 541, 2, 3101, 5, 62, 2, 14828, 5, 1497, 76, 584, 3560, 47, 8, 334, 228, 550, 2667, 36]",1279.0,17473063,220
Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.,Blood,Blood,2007-05-07,"In a prospective trial in 284 children with B-lineage acute lymphoblastic leukemia (ALL), we assessed the clinical utility of real-time quantitative polymerase chain reaction analysis of antigen receptor gene rearrangements for detection of minimal residual disease (MRD) to identify children at high risk of relapse. At the end of induction therapy, the 5-year risk of relapse was 5% in 176 children with no detectable MRD and 44% in 108 children with detectable MRD (P < .001), with a linear association of the level of MRD and subsequent relapse. Recursive partitioning and clinical characteristics identified that the optimal cutoff level of MRD to predict outcome was 10(-3). The 5-year risk of relapse was 12% for children with MRD less than one leukemia cell per 10(3) normal cells (low MRD) but 72% for children with MRD levels greater than this level (high MRD) (P < .001) and children with high MRD had a 10.5-fold greater risk of relapse. Based upon these results we have altered our treatment regimen for children with B-lineage ALL and children with MRD levels greater than or equal to 10(-3) at the end of 4 weeks of multiagent induction chemotherapy now receive intensified treatment to attempt to decrease their risk of subsequent relapse.",Journal Article,4642.0,106.0,In a prospective trial in 284 children with B-lineage acute lymphoblastic ALL we assessed the clinical utility of real-time quantitative polymerase chain reaction analysis of antigen receptor gene rearrangements for detection of minimal residual disease MRD to identify children at high risk of relapse At the end of induction therapy the 5-year risk of relapse was 5 in 176 children with no detectable MRD and 44 in 108 children with detectable MRD P .001 with a linear association of the level of MRD and subsequent relapse Recursive partitioning and clinical characteristics identified that the optimal cutoff level of MRD to predict outcome was 10 -3 The 5-year risk of relapse was 12 for children with MRD less than one cell per 10 3 normal cells low MRD but 72 for children with MRD levels greater than this level high MRD P .001 and children with high MRD had a 10.5-fold greater risk of relapse Based upon these results we have altered our treatment regimen for children with B-lineage ALL and children with MRD levels greater than or equal to 10 -3 at the end of 4 weeks of multiagent induction chemotherapy now receive intensified treatment to attempt to decrease their risk of subsequent relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 8, 482, 160, 4, 8843, 541, 5, 132, 2542, 286, 1275, 62, 21, 275, 3, 38, 1207, 1, 1589, 98, 1156, 1451, 1260, 1329, 65, 1, 448, 153, 145, 2072, 9, 638, 1, 1048, 753, 34, 2029, 6, 255, 541, 28, 64, 43, 1, 429, 28, 3, 396, 1, 504, 36, 3, 33, 111, 43, 1, 429, 10, 33, 4, 5800, 541, 5, 77, 2083, 2029, 2, 584, 4, 3590, 541, 5, 2083, 2029, 19, 144, 5, 8, 1646, 248, 1, 3, 301, 1, 2029, 2, 706, 429, 4493, 4515, 2, 38, 374, 108, 17, 3, 665, 2779, 301, 1, 2029, 6, 678, 228, 10, 79, 27, 3, 33, 111, 43, 1, 429, 10, 133, 9, 541, 5, 2029, 299, 76, 104, 31, 379, 79, 27, 295, 37, 154, 2029, 84, 720, 9, 541, 5, 2029, 148, 378, 76, 26, 301, 64, 2029, 19, 144, 2, 541, 5, 64, 2029, 42, 8, 79, 33, 1116, 378, 43, 1, 429, 90, 1548, 46, 99, 21, 47, 1495, 114, 24, 477, 9, 541, 5, 132, 2542, 62, 2, 541, 5, 2029, 148, 378, 76, 15, 2997, 6, 79, 27, 28, 3, 396, 1, 39, 244, 1, 7148, 504, 56, 1134, 560, 7311, 24, 6, 3448, 6, 775, 136, 43, 1, 706, 429]",1206.0,17485550,278
Characterization of ABL1 expression in adult T-cell acute lymphoblastic leukemia by oligonucleotide array analysis.,Haematologica,Haematologica,2007-05-01,"Recent data have highlighted an involvement of ABL1 in T-cell acute lymphoblastic leukemia (T-ALL). Specifically, the presence of a fusion gene involving ABL1 and NUP214, both located at 9q34, has been reported. We sought to evaluate whether T-ALL patients with overexpression of ABL showed a peculiar gene expression pattern and were characterized by having specific rearrangements. We previously assessed the expression profile of 128 adults with ALL by oligonucleotide arrays: 33 had T-ALL. In the current study, we evaluated the expression levels of ABL1 in T-ALL cases and found three patients who had ABL1 levels comparable to those detected in BCR/ABL (+)cases and one who had a significantly higher level of ABL1 expression. In order to establish the incidence of ABL1 overexpression in T-ALL, we evaluated 17 additional patients by quantitative (Q)-polymerase chain reaction (PCR) and reverse transcription (RT)-PCR. The three cases with ABL1 expression levels comparable to those found in BCR/ABL (+)cases had a specific signature characterized by a high expression of genes involved in regulation of transcription. The fourth case, with the highest levels of ABL, harbored the NUP214-ABL1 rearrangement, which was confirmed by fluorescence in situ hybridization (FISH). Three of the four patients were refractory to induction chemotherapy. Of the 17 additional patients evaluated by Q-PCR and RT-PCR, none showed ABL1 overexpression. Overall, overexpression of ABL1 was found in 8% of T-ALL cases. These results underline the value of microarray analyses for the identification of specific signatures associated with ABL1 overexpression, as well as rearrangements, e.g. NUP214-ABL1, in adult T-ALL.",Evaluation Study,4648.0,12.0,Recent data have highlighted an involvement of ABL1 in T-cell acute lymphoblastic T-ALL Specifically the presence of a fusion gene involving ABL1 and NUP214 both located at 9q34 has been reported We sought to evaluate whether T-ALL patients with overexpression of ABL showed a peculiar gene expression pattern and were characterized by having specific rearrangements We previously assessed the expression profile of 128 adults with ALL by oligonucleotide arrays 33 had T-ALL In the current study we evaluated the expression levels of ABL1 in T-ALL cases and found three patients who had ABL1 levels comparable to those detected in BCR/ABL cases and one who had a significantly higher level of ABL1 expression In order to establish the incidence of ABL1 overexpression in T-ALL we evaluated 17 additional patients by quantitative Q -polymerase chain reaction PCR and reverse transcription RT -PCR The three cases with ABL1 expression levels comparable to those found in BCR/ABL cases had a specific signature characterized by a high expression of genes involved in regulation of transcription The fourth case with the highest levels of ABL harbored the NUP214-ABL1 rearrangement which was confirmed by fluorescence in situ hybridization FISH Three of the four patients were refractory to induction chemotherapy Of the 17 additional patients evaluated by Q-PCR and RT-PCR none showed ABL1 overexpression Overall overexpression of ABL1 was found in 8 of T-ALL cases These results underline the value of microarray analyses for the identification of specific signatures associated with ABL1 overexpression as well as rearrangements e.g NUP214-ABL1 in adult T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 74, 47, 3681, 35, 799, 1, 3557, 4, 102, 31, 286, 1275, 102, 62, 1225, 3, 463, 1, 8, 1212, 145, 1267, 3557, 2, 31098, 110, 2308, 28, 19805, 71, 85, 210, 21, 990, 6, 376, 317, 102, 62, 7, 5, 851, 1, 1425, 224, 8, 21179, 145, 55, 1177, 2, 11, 765, 20, 1041, 112, 2072, 21, 373, 275, 3, 55, 800, 1, 3990, 857, 5, 62, 20, 4727, 3923, 466, 42, 102, 62, 4, 3, 291, 45, 21, 194, 3, 55, 148, 1, 3557, 4, 102, 62, 140, 2, 204, 169, 7, 54, 42, 3557, 148, 1279, 6, 135, 530, 4, 1062, 1425, 140, 2, 104, 54, 42, 8, 97, 142, 301, 1, 3557, 55, 4, 1732, 6, 1811, 3, 287, 1, 3557, 851, 4, 102, 62, 21, 194, 269, 402, 7, 20, 1156, 4170, 1451, 1260, 1329, 604, 2, 1772, 866, 240, 604, 3, 169, 140, 5, 3557, 55, 148, 1279, 6, 135, 204, 4, 1062, 1425, 140, 42, 8, 112, 1651, 765, 20, 8, 64, 55, 1, 214, 646, 4, 863, 1, 866, 3, 3608, 473, 5, 3, 1076, 148, 1, 1425, 3253, 3, 31098, 3557, 2675, 92, 10, 557, 20, 1591, 4, 957, 1554, 1277, 169, 1, 3, 294, 7, 11, 430, 6, 504, 56, 1, 3, 269, 402, 7, 194, 20, 4170, 604, 2, 240, 604, 1292, 224, 3557, 851, 63, 851, 1, 3557, 10, 204, 4, 66, 1, 102, 62, 140, 46, 99, 22051, 3, 549, 1, 1727, 318, 9, 3, 911, 1, 112, 2210, 41, 5, 3557, 851, 22, 149, 22, 2072, 563, 499, 31098, 3557, 4, 780, 102, 62]",1658.0,17488685,844
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study.,Blood,Blood,2007-05-11,"Patients with Philadelphia (Ph) chromosome-positive acute lymphoblastic leukemia (ALL) have a rapid disease course and a poor prognosis. Dasatinib, a novel, oral, multitargeted kinase inhibitor of BCR-ABL and SRC family kinases, has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL. We present the interim results of a phase 2 study designed to further assess the efficacy, safety, and tolerability of dasatinib 140 mg in this patient population (n = 36). With a minimum follow-up of 8 months, treatment with dasatinib resulted in substantial hematologic and cytogenetic response rates. Major hematologic responses were achieved in 42% (15/36) of patients, 67% of whom remained progression-free. Complete cytogenetic responses were attained by 58% (21/36) of patients. The presence of BCR-ABL mutations conferring imatinib resistance did not preclude a response to dasatinib. Dasatinib was also tolerable, with 6% (2/36) of patients discontinuing therapy as a result of study-drug toxicity. Most adverse events (AEs) were grade 1 or 2; febrile neutropenia was the most frequent severe AE, but this and other cytopenias were manageable with dose reduction. Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL. This trial was registered at www.clinicaltrials.gov as #CA180015.","Clinical Trial, Phase II",4638.0,261.0,Patients with Philadelphia Ph chromosome-positive acute lymphoblastic ALL have a rapid disease course and a poor prognosis Dasatinib a novel oral multitargeted kinase inhibitor of BCR-ABL and SRC family kinases has previously induced responses in patients with imatinib-resistant or -intolerant Ph-positive ALL We present the interim results of a phase 2 study designed to further assess the efficacy safety and tolerability of dasatinib 140 mg in this patient population n 36 With a minimum follow-up of 8 months treatment with dasatinib resulted in substantial hematologic and cytogenetic response rates Major hematologic responses were achieved in 42 15/36 of patients 67 of whom remained progression-free Complete cytogenetic responses were attained by 58 21/36 of patients The presence of BCR-ABL mutations conferring imatinib resistance did not preclude a response to dasatinib Dasatinib was also tolerable with 6 2/36 of patients discontinuing therapy as a result of study-drug toxicity Most adverse events AEs were grade 1 or 2 febrile neutropenia was the most frequent severe AE but this and other cytopenias were manageable with dose reduction Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL This trial was registered at www.clinicaltrials.gov as CA180015,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7, 5, 3006, 2058, 1170, 109, 286, 1275, 62, 47, 8, 1321, 34, 906, 2, 8, 334, 356, 1674, 8, 229, 518, 5947, 216, 230, 1, 1062, 1425, 2, 2023, 607, 1549, 71, 373, 277, 253, 4, 7, 5, 577, 436, 15, 4944, 2058, 109, 62, 21, 364, 3, 2914, 99, 1, 8, 124, 18, 45, 1114, 6, 195, 423, 3, 209, 367, 2, 1543, 1, 1674, 3304, 81, 4, 26, 69, 266, 78, 511, 5, 8, 2499, 166, 126, 1, 66, 53, 24, 5, 1674, 627, 4, 1281, 813, 2, 1266, 51, 151, 458, 813, 253, 11, 513, 4, 595, 167, 511, 1, 7, 598, 1, 953, 958, 91, 115, 236, 1266, 253, 11, 5105, 20, 717, 239, 511, 1, 7, 3, 463, 1, 1062, 1425, 138, 7209, 577, 251, 205, 44, 6064, 8, 51, 6, 1674, 1674, 10, 120, 2668, 5, 49, 18, 511, 1, 7, 7971, 36, 22, 8, 757, 1, 45, 234, 155, 96, 290, 281, 1477, 11, 88, 14, 15, 18, 2498, 778, 10, 3, 96, 908, 905, 3633, 84, 26, 2, 127, 5635, 11, 2808, 5, 61, 628, 1674, 1449, 8, 1165, 2, 323, 24, 1501, 2, 35, 305, 189, 3148, 9, 7, 5, 2058, 109, 62, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 56258]",1347.0,17496201,364
The Health Utilities Index 3 invalidated when completed by nurses for pediatric oncology patients.,Cancer nursing,Cancer Nurs,,"When health-related quality of life instruments developed for and validated in 1 respondent group are completed by a different respondent group, findings could be invalid. The purpose of this study was to summarize the instrument outcomes when a widely used health-related quality of life instrument (the Health Utilities Index 3 [HUI3]) created from a population-based strategy was completed by pediatric oncology nurses for their patients during cancer treatment. Fifty-four nurses completed the HUI3 a total of 261 times at 1 to 3 sequential data points (106, 94, and 61, respectively) for pediatric patients who were enrolled on a frontline therapeutic clinical trial for acute lymphoblastic leukemia. Data were collected at 2 children's hospitals. HUI3 scores could not be calculated for 52% to 61% of the nurse reports at each of the 3 data points because of nurses' use of the ""do not know"" response option. Missing data of this proportion indicate that the nurse serving as a proxy rater independent of directly soliciting responses from the patient will not be able to rate certain attributes of the HUI3 more than half of the time despite having ongoing familiarity with the patient. Because of this, use of the HUI3 by nurse proxies for patients with pediatric acute lymphoblastic leukemia is not recommended.",Journal Article,,6.0,When health-related quality of life instruments developed for and validated in 1 respondent group are completed by a different respondent group findings could be invalid The purpose of this study was to summarize the instrument outcomes when a widely used health-related quality of life instrument the Health Utilities Index 3 HUI3 created from a population-based strategy was completed by pediatric oncology nurses for their patients during cancer treatment Fifty-four nurses completed the HUI3 a total of 261 times at 1 to 3 sequential data points 106 94 and 61 respectively for pediatric patients who were enrolled on a frontline therapeutic clinical trial for acute lymphoblastic Data were collected at 2 children 's hospitals HUI3 scores could not be calculated for 52 to 61 of the nurse reports at each of the 3 data points because of nurses use of the `` do not know '' response option Missing data of this proportion indicate that the nurse serving as a proxy rater independent of directly soliciting responses from the patient will not be able to rate certain attributes of the HUI3 more than half of the time despite having ongoing familiarity with the patient Because of this use of the HUI3 by nurse proxies for patients with pediatric acute lymphoblastic is not recommended,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[198, 341, 139, 372, 1, 358, 4730, 276, 9, 2, 938, 4, 14, 15190, 87, 32, 781, 20, 8, 338, 15190, 87, 272, 359, 40, 25008, 3, 743, 1, 26, 45, 10, 6, 2479, 3, 3877, 123, 198, 8, 1792, 95, 341, 139, 372, 1, 358, 3877, 3, 341, 7114, 558, 27, 26419, 2466, 29, 8, 266, 90, 692, 10, 781, 20, 815, 413, 2707, 9, 136, 7, 190, 12, 24, 1461, 294, 2707, 781, 3, 26419, 8, 181, 1, 7007, 1072, 28, 14, 6, 27, 1787, 74, 862, 3251, 960, 2, 713, 106, 9, 815, 7, 54, 11, 346, 23, 8, 3171, 189, 38, 160, 9, 286, 1275, 74, 11, 786, 28, 18, 541, 292, 1987, 26419, 703, 359, 44, 40, 981, 9, 653, 6, 713, 1, 3, 6756, 1198, 28, 296, 1, 3, 27, 74, 862, 408, 1, 2707, 119, 1, 3, 1022, 44, 6572, 522, 51, 1501, 4593, 74, 1, 26, 920, 1008, 17, 3, 6756, 6823, 22, 8, 8806, 13667, 306, 1, 1606, 44724, 253, 29, 3, 69, 303, 44, 40, 1665, 6, 116, 1840, 7372, 1, 3, 26419, 80, 76, 1303, 1, 3, 98, 550, 1041, 942, 10322, 5, 3, 69, 408, 1, 26, 119, 1, 3, 26419, 20, 6756, 17304, 9, 7, 5, 815, 286, 1275, 16, 44, 793]",1286.0,17510579,847
Hyperglycemia in patients with acute myeloid leukemia is associated with increased hospital mortality.,Cancer,Cancer,2007-07-01,"Hyperglycemia is often observed in medically ill patients. Previous studies have shown that patients with hyperglycemia during induction therapy for acute lymphoblastic leukemia develop more infections and have shorter disease-free survival. The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid leukemia (AML) and sought to determine whether this association exists in this population. The authors performed a retrospective cohort study to examine the relation between hyperglycemia and hospital mortality in patients with the diagnosis of AML. Two hundred eighty-three adult patients were treated over a 3-year period. All hospitalizations were reviewed during the study period, and glucose exposure and outcomes were quantified. Hyperglycemia during a patient's hospitalization was associated with increased hospital mortality (OR, 1.38; 95% CI, 1.23-1.55; P < .001) after adjusting for covariates, including disease state, treatment type, and response. The rise in mortality was evident at even mild levels (110-150 mg/dL) of glucose elevation. Although the odds of developing severe sepsis (OR, 1.24; 95% CI, 1.13.-1.38; P < .001) or severe sepsis with respiratory failure (OR, 2.04; 95% CI, 1.44-2.91; P < .001) were increased with hyperglycemia, sepsis did not appear to be the main factor responsible for the negative impact of hyperglycemia on hospital mortality. This study demonstrated an association between hospital mortality and even modest levels of hyperglycemia in AML patients. Prospective studies are needed to confirm this association and to discern causal pathways that mediate this effect.",Journal Article,4587.0,59.0,Hyperglycemia is often observed in medically ill patients Previous studies have shown that patients with hyperglycemia during induction therapy for acute lymphoblastic develop more infections and have shorter disease-free survival The authors hypothesized that hyperglycemia may be associated with adverse outcomes in patients with acute myeloid AML and sought to determine whether this association exists in this population The authors performed a retrospective cohort study to examine the relation between hyperglycemia and hospital mortality in patients with the diagnosis of AML Two hundred eighty-three adult patients were treated over a 3-year period All hospitalizations were reviewed during the study period and glucose exposure and outcomes were quantified Hyperglycemia during a patient 's hospitalization was associated with increased hospital mortality OR 1.38 95 CI 1.23-1.55 P .001 after adjusting for covariates including disease state treatment type and response The rise in mortality was evident at even mild levels 110-150 mg/dL of glucose elevation Although the odds of developing severe sepsis OR 1.24 95 CI 1.13.-1.38 P .001 or severe sepsis with respiratory failure OR 2.04 95 CI 1.44-2.91 P .001 were increased with hyperglycemia sepsis did not appear to be the main factor responsible for the negative impact of hyperglycemia on hospital mortality This study demonstrated an association between hospital mortality and even modest levels of hyperglycemia in AML patients Prospective studies are needed to confirm this association and to discern causal pathways that mediate this effect,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3992, 16, 629, 164, 4, 4381, 4993, 7, 698, 94, 47, 443, 17, 7, 5, 3992, 190, 504, 36, 9, 286, 1275, 690, 80, 1875, 2, 47, 985, 34, 115, 25, 3, 738, 1237, 17, 3992, 68, 40, 41, 5, 290, 123, 4, 7, 5, 286, 533, 329, 2, 990, 6, 223, 317, 26, 248, 2481, 4, 26, 266, 3, 738, 173, 8, 459, 180, 45, 6, 1004, 3, 2191, 59, 3992, 2, 702, 282, 4, 7, 5, 3, 147, 1, 329, 100, 1128, 2207, 169, 780, 7, 11, 73, 252, 8, 27, 111, 727, 62, 4888, 11, 446, 190, 3, 45, 727, 2, 2522, 645, 2, 123, 11, 2790, 3992, 190, 8, 69, 292, 2826, 10, 41, 5, 101, 702, 282, 15, 14, 519, 48, 58, 14, 382, 14, 614, 19, 144, 50, 1358, 9, 2489, 141, 34, 1309, 24, 267, 2, 51, 3, 3693, 4, 282, 10, 2853, 28, 871, 1980, 148, 3129, 1577, 81, 1826, 1, 2522, 3292, 242, 3, 610, 1, 931, 905, 4227, 15, 14, 259, 48, 58, 14, 233, 14, 519, 19, 144, 15, 905, 4227, 5, 2718, 496, 15, 18, 755, 48, 58, 14, 584, 18, 970, 19, 144, 11, 101, 5, 3992, 4227, 205, 44, 1322, 6, 40, 3, 1895, 161, 2327, 9, 3, 199, 345, 1, 3992, 23, 702, 282, 26, 45, 264, 35, 248, 59, 702, 282, 2, 871, 1721, 148, 1, 3992, 4, 329, 7, 482, 94, 32, 575, 6, 1843, 26, 248, 2, 6, 11643, 5163, 460, 17, 3367, 26, 254]",1608.0,17534900,696
A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.,Blood,Blood,2007-06-11,"Clofarabine has shown impressive response rates in patients with acute leukemias. In vitro investigations with clofarabine in combination with cyclophosphamide in primary cells have demonstrated synergistic cytotoxicity and inhibition of DNA repair. Based on these clinical and laboratory observations, we designed a mechanism-based combination protocol with clofarabine and cyclophosphamide for patients with relapsed acute leukemias. Eighteen patients were treated with cyclophosphamide (200 mg/m(2)) alone on day 0 and with clofarabine plus cyclophosphamide on day 1. Clinical responses, toxicity, DNA damage measured as H2AX phosphorylation, and accumulation of clofarabine triphosphate (TP) were analyzed. At dose level 1 (20 mg/m(2) clofarabine + cyclophosphamide, 6 patients) and dose level 0 (10 mg/m(2) clofarabine + cyclophosphamide, 12 patients) overall response rates were 50% and 30%, respectively, with responses in 4 (67%) of 6 patients with refractory acute lymphoblastic leukemia. Dose-limiting toxicity occurred at dose level 1 with prolonged marrow aplasia. Four (22%) patients died from prolonged aplasia (1), fungal pneumonia (1), or multiorgan failure (2). In 12 of 13 patient samples, increased DNA damage (gammaH2AX) was observed with clofarabine and cyclophosphamide compared with cyclophosphamide alone. In conclusion, pharmacodynamic end points along with clinical results suggest usefulness of this combination strategy, whereas toxicity data suggest reduction in chemotherapeutic intensity. This clinical trial is registered with the National Cancer Institute's PDQ at www.clinicaltrials.gov as no. JHOC-J0561.","Clinical Trial, Phase I",4607.0,79.0,Clofarabine has shown impressive response rates in patients with acute leukemias In vitro investigations with clofarabine in combination with cyclophosphamide in primary cells have demonstrated synergistic cytotoxicity and inhibition of DNA repair Based on these clinical and laboratory observations we designed a mechanism-based combination protocol with clofarabine and cyclophosphamide for patients with relapsed acute leukemias Eighteen patients were treated with cyclophosphamide 200 mg/m 2 alone on day 0 and with clofarabine plus cyclophosphamide on day 1 Clinical responses toxicity DNA damage measured as H2AX phosphorylation and accumulation of clofarabine triphosphate TP were analyzed At dose level 1 20 mg/m 2 clofarabine cyclophosphamide 6 patients and dose level 0 10 mg/m 2 clofarabine cyclophosphamide 12 patients overall response rates were 50 and 30 respectively with responses in 4 67 of 6 patients with refractory acute lymphoblastic Dose-limiting toxicity occurred at dose level 1 with prolonged marrow aplasia Four 22 patients died from prolonged aplasia 1 fungal pneumonia 1 or multiorgan failure 2 In 12 of 13 patient samples increased DNA damage gammaH2AX was observed with clofarabine and cyclophosphamide compared with cyclophosphamide alone In conclusion pharmacodynamic end points along with clinical results suggest usefulness of this combination strategy whereas toxicity data suggest reduction in chemotherapeutic intensity This clinical trial is registered with the National Cancer Institute 's PDQ at www.clinicaltrials.gov as no JHOC-J0561,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4149, 71, 443, 5790, 51, 151, 4, 7, 5, 286, 2792, 4, 439, 2492, 5, 4149, 4, 150, 5, 1112, 4, 86, 37, 47, 264, 1806, 1408, 2, 297, 1, 261, 972, 90, 23, 46, 38, 2, 1624, 2172, 21, 1114, 8, 670, 90, 150, 1182, 5, 4149, 2, 1112, 9, 7, 5, 591, 286, 2792, 3195, 7, 11, 73, 5, 1112, 1250, 81, 188, 18, 279, 23, 218, 13, 2, 5, 4149, 349, 1112, 23, 218, 14, 38, 253, 155, 261, 1350, 644, 22, 6286, 982, 2, 1835, 1, 4149, 7345, 5907, 11, 311, 28, 61, 301, 14, 179, 81, 188, 18, 4149, 1112, 49, 7, 2, 61, 301, 13, 79, 81, 188, 18, 4149, 1112, 133, 7, 63, 51, 151, 11, 212, 2, 201, 106, 5, 253, 4, 39, 598, 1, 49, 7, 5, 430, 286, 1275, 61, 817, 155, 489, 28, 61, 301, 14, 5, 1069, 581, 12307, 294, 350, 7, 1016, 29, 1069, 12307, 14, 7800, 3485, 14, 15, 11760, 496, 18, 4, 133, 1, 233, 69, 347, 101, 261, 1350, 22382, 10, 164, 5, 4149, 2, 1112, 72, 5, 1112, 279, 4, 1221, 2424, 396, 862, 1510, 5, 38, 99, 309, 5235, 1, 26, 150, 692, 547, 155, 74, 309, 628, 4, 1573, 837, 26, 38, 160, 16, 1653, 5, 3, 657, 12, 1377, 292, 44749, 28, 3064, 1252, 1239, 22, 77, 56324, 56325]",1575.0,17562873,220
Physical inactivity in adult survivors of childhood acute lymphoblastic leukemia: a report from the childhood cancer survivor study.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2007-07-01,"To determine if adult survivors of childhood acute lymphoblastic leukemia (ALL) are less active (and more inactive) than the general population and to identify modifying factors. Physical activity was assessed by self-report in 2,648 adult survivors of the Childhood Cancer Survivor Study. Participants in the Behavioral Risk Factor Surveillance System (BRFSS) survey administered through the Centers for Disease Control and Prevention (CDC) were used as a comparison group. Survivors had a mean age of 28.7 years (range, 18.0-44.0 years) and were a mean of 23.1 years from their cancer diagnosis (range, 16.0-33.8 years). In multivariate models, ALL survivors were more likely to not meet CDC recommendations for physical activity [odds ratio (OR), 1.44; 95% confidence interval (95% CI), 1.32-1.57] and more likely to be inactive (OR, 1.74; 95% CI, 1.56-1.94) in comparison with the BRFSS general population. Survivors treated with >20-Gy cranial radiotherapy were at particular risk. Compared with BRFSS participants and adjusted for age, race, and ethnicity, survivors were more likely to not meet CDC recommendations (females: OR, 2.07, 95% CI, 1.67-2.56; males: OR, 1.43, 95% CI, 1.16-1.76) and more likely to be inactive (females: OR, 1.86; 95% CI, 1.50-2.31; males: OR, 1.84; 95% CI, 1.45-2.32). Long-term survivors of childhood ALL are less likely to meet physical activity recommendations and more likely to report no leisure-time physical activity in the past month. This level of inactivity likely further increases their risk of cardiovascular disease, osteoporosis, and all-cause mortality.",Journal Article,4587.0,142.0,"To determine if adult survivors of childhood acute lymphoblastic ALL are less active and more inactive than the general population and to identify modifying factors Physical activity was assessed by self-report in 2,648 adult survivors of the Childhood Cancer Survivor Study Participants in the Behavioral Risk Factor Surveillance System BRFSS survey administered through the Centers for Disease Control and Prevention CDC were used as a comparison group Survivors had a mean age of 28.7 years range 18.0-44.0 years and were a mean of 23.1 years from their cancer diagnosis range 16.0-33.8 years In multivariate models ALL survivors were more likely to not meet CDC recommendations for physical activity odds ratio OR 1.44 95 confidence interval 95 CI 1.32-1.57 and more likely to be inactive OR 1.74 95 CI 1.56-1.94 in comparison with the BRFSS general population Survivors treated with 20-Gy cranial radiotherapy were at particular risk Compared with BRFSS participants and adjusted for age race and ethnicity survivors were more likely to not meet CDC recommendations females OR 2.07 95 CI 1.67-2.56 males OR 1.43 95 CI 1.16-1.76 and more likely to be inactive females OR 1.86 95 CI 1.50-2.31 males OR 1.84 95 CI 1.45-2.32 Long-term survivors of childhood ALL are less likely to meet physical activity recommendations and more likely to report no leisure-time physical activity in the past month This level of inactivity likely further increases their risk of cardiovascular disease osteoporosis and all-cause mortality",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 492, 780, 332, 1, 864, 286, 1275, 62, 32, 299, 544, 2, 80, 5002, 76, 3, 1083, 266, 2, 6, 255, 4898, 130, 900, 128, 10, 275, 20, 1074, 414, 4, 18, 15201, 780, 332, 1, 3, 864, 12, 2628, 45, 776, 4, 3, 4166, 43, 161, 617, 398, 34297, 1407, 468, 298, 3, 1168, 9, 34, 182, 2, 1070, 9665, 11, 95, 22, 8, 1155, 87, 332, 42, 8, 313, 89, 1, 339, 67, 60, 184, 203, 13, 584, 13, 60, 2, 11, 8, 313, 1, 382, 14, 60, 29, 136, 12, 147, 184, 245, 13, 466, 66, 60, 4, 331, 274, 62, 332, 11, 80, 322, 6, 44, 3362, 9665, 883, 9, 900, 128, 610, 197, 15, 14, 584, 48, 307, 268, 48, 58, 14, 531, 14, 696, 2, 80, 322, 6, 40, 5002, 15, 14, 794, 48, 58, 14, 664, 14, 960, 4, 1155, 5, 3, 34297, 1083, 266, 332, 73, 5, 179, 381, 2565, 310, 11, 28, 1454, 43, 72, 5, 34297, 776, 2, 586, 9, 89, 1047, 2, 2091, 332, 11, 80, 322, 6, 44, 3362, 9665, 883, 2451, 15, 18, 1615, 48, 58, 14, 598, 18, 664, 2296, 15, 14, 601, 48, 58, 14, 245, 14, 846, 2, 80, 322, 6, 40, 5002, 2451, 15, 14, 868, 48, 58, 14, 212, 18, 456, 2296, 15, 14, 874, 48, 58, 14, 512, 18, 531, 319, 337, 332, 1, 864, 62, 32, 299, 322, 6, 3362, 900, 128, 883, 2, 80, 322, 6, 414, 77, 21386, 98, 900, 128, 4, 3, 1219, 811, 26, 301, 1, 10050, 322, 195, 1106, 136, 43, 1, 2179, 34, 4970, 2, 62, 708, 282]",1522.0,17627001,16
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.,IDrugs : the investigational drugs journal,IDrugs,2007-07-01,"Chronic myelocytic leukemia (CML) is caused by the constitutively active tyrosine kinase Bcr-Abl. Inhibitors ofBcr-Abl have significantly improved the treatment of CML. Most notable is the inhibitor imatinib, which produces remissions in all phases of CML and is the current standard of care. However, imatinib resistance occurs in a significant proportion of patients, mainly through the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding. Attempts to circumvent resistance to imatinib led to the discovery of nilotinib (Tasigna; Novartis AG), a novel, potent and selective oral Bcr-Abl kinase inhibitor. Preclinical and clinical investigations have demonstrated that nilotinib effectively overcomes imatinib resistance. Efficacy has been observed in models of CML and other myeloproliferative disorders that are driven by Bcr-Abl and related kinases. In a phase II clinical trial in CML, major cytogenetic response rates were 52 and 33% for chronic- and accelerated-phase disease, respectively. Nilotinib has been filed for approval in the US and EU for use in Philadelphia-positive leukemias in patients who are resistant or intolerant to imatinib. Nilotinib is undergoing clinical trials in patients with newly diagnosed CML, acute lymphoblastic leukemia and gastrointestinal stromal tumors, among other indications.",Journal Article,4587.0,11.0,Chronic myelocytic CML is caused by the constitutively active tyrosine kinase Bcr-Abl Inhibitors ofBcr-Abl have significantly improved the treatment of CML Most notable is the inhibitor imatinib which produces remissions in all phases of CML and is the current standard of care However imatinib resistance occurs in a significant proportion of patients mainly through the development of mutations in the Bcr-Abl tyrosine kinase domain that impair imatinib binding Attempts to circumvent resistance to imatinib led to the discovery of nilotinib Tasigna Novartis AG a novel potent and selective oral Bcr-Abl kinase inhibitor Preclinical and clinical investigations have demonstrated that nilotinib effectively overcomes imatinib resistance Efficacy has been observed in models of CML and other disorders that are driven by Bcr-Abl and related kinases In a phase II clinical trial in CML major cytogenetic response rates were 52 and 33 for chronic- and accelerated-phase disease respectively Nilotinib has been filed for approval in the US and EU for use in Philadelphia-positive leukemias in patients who are resistant or intolerant to imatinib Nilotinib is undergoing clinical trials in patients with newly diagnosed CML acute lymphoblastic and stromal tumors among other indications,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,"[442, 19446, 903, 16, 1546, 20, 3, 2818, 544, 564, 216, 1062, 1425, 222, 56414, 1425, 47, 97, 231, 3, 24, 1, 903, 96, 4090, 16, 3, 230, 577, 92, 4042, 3166, 4, 62, 3523, 1, 903, 2, 16, 3, 291, 260, 1, 165, 137, 577, 251, 1780, 4, 8, 93, 920, 1, 7, 2615, 298, 3, 193, 1, 138, 4, 3, 1062, 1425, 564, 216, 1398, 17, 6267, 577, 791, 4374, 6, 8602, 251, 6, 577, 836, 6, 3, 1574, 1, 2638, 44787, 7855, 2741, 8, 229, 1157, 2, 1094, 518, 1062, 1425, 216, 230, 693, 2, 38, 2492, 47, 264, 17, 2638, 1856, 8510, 577, 251, 209, 71, 85, 164, 4, 274, 1, 903, 2, 127, 1997, 17, 32, 1621, 20, 1062, 1425, 2, 139, 1549, 4, 8, 124, 215, 38, 160, 4, 903, 458, 1266, 51, 151, 11, 653, 2, 466, 9, 442, 2, 2241, 124, 34, 106, 2638, 71, 85, 34302, 9, 1814, 4, 3, 843, 2, 13992, 9, 119, 4, 3006, 109, 2792, 4, 7, 54, 32, 436, 15, 4944, 6, 577, 2638, 16, 479, 38, 143, 4, 7, 5, 732, 265, 903, 286, 1275, 2, 1126, 57, 107, 127, 2406]",1282.0,17642017,100
BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia.,The Journal of pediatrics,J. Pediatr.,2007-08-01,We report a case of BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic leukemia. Primary BK virus infection was exacerbated by chemotherapy-induced immunodeficiency. Careful administration of chemotherapy and anti-viral therapy prevented further damage. This diagnosis should be considered in children who experience renal dysfunction during cancer treatment.,Case Reports,4556.0,16.0,We report a case of BK virus-induced tubulointerstitial nephritis in a child with acute lymphoblastic Primary BK virus infection was exacerbated by chemotherapy-induced immunodeficiency Careful administration of chemotherapy and anti-viral therapy prevented further damage This diagnosis should be considered in children who experience dysfunction during cancer treatment,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 8, 473, 1, 19745, 1450, 277, 20568, 17277, 4, 8, 2566, 5, 286, 1275, 86, 19745, 1450, 930, 10, 10545, 20, 56, 277, 5323, 3465, 634, 1, 56, 2, 312, 1667, 36, 3902, 195, 1350, 26, 147, 257, 40, 515, 4, 541, 54, 730, 1527, 190, 12, 24]",371.0,17643782,408
Chromosome 5q deletion: specific diagnoses and cytogenetic details among 358 consecutive cases from a single institution.,Leukemia research,Leuk. Res.,2007-08-20,"The purpose of this study was to define the spectrum of hematologic neoplasms and chromosomal breakpoints associated with del(5q); separate analyses were performed to account for prior cytotoxic treatment. A total of 358 consecutive del(5q) cases were identified; specific diagnoses included myelodysplastic syndrome (MDS; 53%), acute myeloid leukemia (AML; 22%), plasma cell proliferative disorder (PCPD; 9%), myeloproliferative disorder (MPD; 7%), acute lymphoblastic leukemia (ALL; 2%), PCPD with MDS (2%), MDS/MPD (2%), and malignant lymphoma (ML; 2%). The corresponding figures in the absence/presence of prior cytotoxic treatment (n=250/108) were 61%/34% for MDS, 24%/19% for AML, 4%/20% for PCPD, 6%/8% for MPD, 1%/4% for ALL, and 2%/4% for ML. del(5q) occurred as the sole cytogenetic abnormality in 88 cases (25%) including 76 without prior cytotoxic therapy. Among the latter, 82% had MDS, 8% AML, 5% MPD, 4% PCPD, and 1% ML. Chromosome 5 breakpoints included q13q33 in 49% of the cases, q15q33 in 22%, q22q33 in 8%, and q13 in 3% and their distribution was not affected by specific diagnosis or treatment history. del(5q)-associated lymphoid disorders featured a higher prevalence of previous cytotoxic therapy and smaller number del(5q)-positive metaphases, when compared to their counterparts with myeloid neoplasms. We conclude that del(5q), although most prevalent in MDS, is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify, for the most part, an occult myeloid clone.",Journal Article,4537.0,13.0,The purpose of this study was to define the spectrum of hematologic neoplasms and chromosomal breakpoints associated with del 5q separate analyses were performed to account for prior cytotoxic treatment A total of 358 consecutive del 5q cases were identified specific diagnoses included syndrome MDS 53 acute myeloid AML 22 plasma cell proliferative disorder PCPD 9 disorder MPD 7 acute lymphoblastic ALL 2 PCPD with MDS 2 MDS/MPD 2 and malignant ML 2 The corresponding figures in the absence/presence of prior cytotoxic treatment n=250/108 were 61 /34 for MDS 24 /19 for AML 4 /20 for PCPD 6 /8 for MPD 1 /4 for ALL and 2 /4 for ML del 5q occurred as the sole cytogenetic abnormality in 88 cases 25 including 76 without prior cytotoxic therapy Among the latter 82 had MDS 8 AML 5 MPD 4 PCPD and 1 ML Chromosome 5 breakpoints included q13q33 in 49 of the cases q15q33 in 22 q22q33 in 8 and q13 in 3 and their distribution was not affected by specific diagnosis or treatment history del 5q -associated lymphoid disorders featured a higher prevalence of previous cytotoxic therapy and smaller number del 5q -positive metaphases when compared to their counterparts with myeloid neoplasms We conclude that del 5q although most prevalent in MDS is seen across the spectrum of myeloid disorders including MPD and its occurrence in lymphoid disorders might signify for the most part an occult myeloid clone,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 1107, 3, 1873, 1, 813, 1179, 2, 1860, 7843, 41, 5, 3084, 5460, 2282, 318, 11, 173, 6, 1967, 9, 324, 759, 24, 8, 181, 1, 8396, 935, 3084, 5460, 140, 11, 108, 112, 2403, 159, 681, 1223, 699, 286, 533, 329, 350, 554, 31, 2441, 2645, 26626, 83, 2645, 7712, 67, 286, 1275, 62, 18, 26626, 5, 1223, 18, 1223, 7712, 18, 2, 393, 542, 18, 3, 1734, 9446, 4, 3, 1127, 463, 1, 324, 759, 24, 78, 2039, 3590, 11, 713, 562, 9, 1223, 259, 326, 9, 329, 39, 179, 9, 26626, 49, 66, 9, 7712, 14, 39, 9, 62, 2, 18, 39, 9, 542, 3084, 5460, 489, 22, 3, 4991, 1266, 3698, 4, 889, 140, 243, 141, 846, 187, 324, 759, 36, 107, 3, 3286, 878, 42, 1223, 66, 329, 33, 7712, 39, 26626, 2, 14, 542, 1170, 33, 7843, 159, 38527, 4, 739, 1, 3, 140, 56479, 4, 350, 56480, 4, 66, 2, 9938, 4, 27, 2, 136, 1395, 10, 44, 1424, 20, 112, 147, 15, 24, 532, 3084, 5460, 41, 2303, 1997, 11857, 8, 142, 1078, 1, 698, 759, 36, 2, 2170, 207, 3084, 5460, 109, 10653, 198, 72, 6, 136, 3953, 5, 533, 1179, 21, 2060, 17, 3084, 5460, 242, 96, 2485, 4, 1223, 16, 527, 716, 3, 1873, 1, 533, 1997, 141, 7712, 2, 211, 2291, 4, 2303, 1997, 822, 19016, 9, 3, 96, 760, 35, 2879, 533, 3910]",1399.0,17707907,650
Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Pediatric blood & cancer,Pediatr Blood Cancer,2008-04-01,"The objective of this study was to determine risk factors associated with abnormal timing of menarche among survivors of childhood acute lymphoblastic leukemia (ALL). Self-reported age of menarche was determined among 949 female ALL survivors participating in the Childhood Cancer Survivor Study (CCSS), a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986, and compared with 1,128 siblings. The majority of survivors (92%) and siblings (97%) reported menarche between the ages of 10 and 16. Survivors treated with chemotherapy alone, including those exposed to alkylating agents, experienced menarche at a similar rate to siblings. However, compared to chemotherapy alone, cranial radiotherapy was associated with early menarche (age < 10; OR 6.2, 95% CI 2.1, 18.5) while craniospinal radiotherapy was associated with both early (OR 8.6, 95% CI 1.9, 38.6) and late (age > 16; OR 4.8, 95% CI 1.4, 16.7) menarche. There were no differences in effect between <20 and >/=20 Gy radiotherapy doses. In multivariable analysis, younger age at diagnosis was an independent risk factor for early menarche. Few female childhood ALL survivors experienced menarche outside of the normal range. Alkylating agent exposure was not associated with abnormal timing. However, those exposed to cranial and craniospinal radiotherapy, especially at a young age, should be monitored closely for abnormal timing of menarche.",Journal Article,4312.0,47.0,"The objective of this study was to determine risk factors associated with abnormal timing of menarche among survivors of childhood acute lymphoblastic ALL Self-reported age of menarche was determined among 949 female ALL survivors participating in the Childhood Cancer Survivor Study CCSS a cohort of 5-year survivors of common pediatric cancers diagnosed from 1970 to 1986 and compared with 1,128 siblings The majority of survivors 92 and siblings 97 reported menarche between the ages of 10 and 16 Survivors treated with chemotherapy alone including those exposed to alkylating agents experienced menarche at a similar rate to siblings However compared to chemotherapy alone cranial radiotherapy was associated with early menarche age 10 OR 6.2 95 CI 2.1 18.5 while craniospinal radiotherapy was associated with both early OR 8.6 95 CI 1.9 38.6 and late age 16 OR 4.8 95 CI 1.4 16.7 menarche There were no differences in effect between 20 and /=20 Gy radiotherapy doses In multivariable analysis younger age at diagnosis was an independent risk factor for early menarche Few female childhood ALL survivors experienced menarche outside of the normal range Alkylating agent exposure was not associated with abnormal timing However those exposed to cranial and craniospinal radiotherapy especially at a young age should be monitored closely for abnormal timing of menarche",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 223, 43, 130, 41, 5, 1668, 1972, 1, 6414, 107, 332, 1, 864, 286, 1275, 62, 1074, 210, 89, 1, 6414, 10, 509, 107, 14916, 1061, 62, 332, 3052, 4, 3, 864, 12, 2628, 45, 4657, 8, 180, 1, 33, 111, 332, 1, 186, 815, 163, 265, 29, 4868, 6, 3751, 2, 72, 5, 14, 3990, 2758, 3, 686, 1, 332, 937, 2, 2758, 1015, 210, 6414, 59, 3, 2165, 1, 79, 2, 245, 332, 73, 5, 56, 279, 141, 135, 2234, 6, 3410, 183, 592, 6414, 28, 8, 288, 116, 6, 2758, 137, 72, 6, 56, 279, 2565, 310, 10, 41, 5, 191, 6414, 89, 79, 15, 49, 18, 48, 58, 18, 14, 203, 33, 369, 5748, 310, 10, 41, 5, 110, 191, 15, 66, 49, 48, 58, 14, 83, 519, 49, 2, 807, 89, 245, 15, 39, 66, 48, 58, 14, 39, 245, 67, 6414, 125, 11, 77, 362, 4, 254, 59, 179, 2, 179, 381, 310, 415, 4, 658, 65, 773, 89, 28, 147, 10, 35, 306, 43, 161, 9, 191, 6414, 1021, 1061, 864, 62, 332, 592, 6414, 2513, 1, 3, 295, 184, 3410, 420, 645, 10, 44, 41, 5, 1668, 1972, 137, 135, 2234, 6, 2565, 2, 5748, 310, 1093, 28, 8, 1169, 89, 257, 40, 2909, 3210, 9, 1668, 1972, 1, 6414]",1371.0,17729247,255
"Reproductive history, infertility treatment, and the risk of acute leukemia in children with down syndrome: a report from the Children's Oncology Group.",Cancer,Cancer,2007-11-01,"Children with Down syndrome (DS) have from 10 to 20 times the risk of developing acute leukemia than the general pediatric population. There is mixed evidence for associations between reproductive history or infertility and acute leukemia among children without DS. The authors conducted a case-control study of acute leukemia among children with DS to investigate possible risk factors in this population. From 1997 to 2002, 158 children aged <20 years with DS who had a diagnosis of acute leukemia (97 children with acute lymphoblastic leukemia [ALL] and 61 children with acute myeloid leukemia [AML]) were enrolled at Children's Oncology Group (COG) institutions. Controls with DS (n = 173) were selected from the cases' primary care clinic and frequency matched to cases on age. Telephone interviews were conducted with mothers of cases and controls assessing reproductive history, infertility, and infertility treatment. Null results were observed overall and by subtype for reproductive factors, including previous pregnancy outcomes and contraceptive use, and for most infertility outcomes. There was an increased risk of AML among children with DS whose parents had ever tried for >/=1 year to become pregnant (odds ratio [OR], 2.22; 95% confidence interval [95% CI], 1.14-4.33). A 1-year increase in maternal age also was associated with AML (OR, 1.06; 95% CI, 1.01-1.12). Although the questionnaire was limited in this area, the results suggested that the risk for AML may be raised in children with DS because of infertility. In that the risk of infertility, along with having a child with DS, increase with age, these results warrant more research.",Journal Article,4464.0,18.0,Children with Down syndrome DS have from 10 to 20 times the risk of developing acute than the general pediatric population There is mixed evidence for associations between reproductive history or infertility and acute among children without DS The authors conducted a case-control study of acute among children with DS to investigate possible risk factors in this population From 1997 to 2002 158 children aged 20 years with DS who had a diagnosis of acute 97 children with acute lymphoblastic ALL and 61 children with acute myeloid AML were enrolled at Children 's Oncology Group COG institutions Controls with DS n 173 were selected from the cases primary care clinic and frequency matched to cases on age Telephone interviews were conducted with mothers of cases and controls assessing reproductive history infertility and infertility treatment Null results were observed overall and by subtype for reproductive factors including previous pregnancy outcomes and contraceptive use and for most infertility outcomes There was an increased risk of AML among children with DS whose parents had ever tried for /=1 year to become pregnant odds ratio OR 2.22 95 confidence interval 95 CI 1.14-4.33 A 1-year increase in maternal age also was associated with AML OR 1.06 95 CI 1.01-1.12 Although the questionnaire was limited in this area the results suggested that the risk for AML may be raised in children with DS because of infertility In that the risk of infertility along with having a child with DS increase with age these results warrant more research,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 1328, 681, 3602, 47, 29, 79, 6, 179, 1072, 3, 43, 1, 931, 286, 76, 3, 1083, 815, 266, 125, 16, 1739, 241, 9, 685, 59, 3705, 532, 15, 5901, 2, 286, 107, 541, 187, 3602, 3, 738, 426, 8, 473, 182, 45, 1, 286, 107, 541, 5, 3602, 6, 963, 899, 43, 130, 4, 26, 266, 29, 2341, 6, 1544, 5162, 541, 1032, 179, 60, 5, 3602, 54, 42, 8, 147, 1, 286, 1015, 541, 5, 286, 1275, 62, 2, 713, 541, 5, 286, 533, 329, 11, 346, 28, 541, 292, 413, 87, 6377, 1764, 535, 5, 3602, 78, 5785, 11, 715, 29, 3, 140, 86, 165, 1188, 2, 675, 655, 6, 140, 23, 89, 4258, 4053, 11, 426, 5, 8605, 1, 140, 2, 535, 1977, 3705, 532, 5901, 2, 5901, 24, 3505, 99, 11, 164, 63, 2, 20, 875, 9, 3705, 130, 141, 698, 2290, 123, 2, 6780, 119, 2, 9, 96, 5901, 123, 125, 10, 35, 101, 43, 1, 329, 107, 541, 5, 3602, 1310, 2418, 42, 3353, 13780, 9, 14, 111, 6, 1417, 6086, 610, 197, 15, 18, 350, 48, 307, 268, 48, 58, 14, 213, 39, 466, 8, 14, 111, 344, 4, 6039, 89, 120, 10, 41, 5, 329, 15, 14, 1460, 48, 58, 14, 355, 14, 133, 242, 3, 1770, 10, 383, 4, 26, 965, 3, 99, 1148, 17, 3, 43, 9, 329, 68, 40, 5673, 4, 541, 5, 3602, 408, 1, 5901, 4, 17, 3, 43, 1, 5901, 1510, 5, 1041, 8, 2566, 5, 3602, 344, 5, 89, 46, 99, 2946, 80, 389]",1553.0,17849462,202
"Clofarabine: past, present, and future.",Leukemia & lymphoma,Leuk. Lymphoma,2007-10-01,"Clofarabine is a good generation purine nucleoside analogue designed to overcome the limitations and to incorporate the best qualities of both cladribine and fludarabine. Clofarabine is thought to work via three mechanisms: inhibition of ribonucleotide reductase; incorporation to DNA; and induction of apoptosis. Given these mechanism of action, clofarabine would be predicted to act synergistically with other chemotherapeutic agents such as other purine nucleoside analogues and DNA damaging or cross linking agents such as anthracyclines and platinum-based compounds. Intravenous clofarabine showed significant efficacy in pediatric leukemias (specifically, acute lymphoblastic leukemia (ALL)) and, in 2004, it was approved by the United States Food and Drug Administration (FDA) for the treatment of pediatric relapsed/refractory ALL after at least two regimens. In adults, clofarabine has shown significant efficacy in hematologic malignancies including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) alone and in combinations. Ongoing and future studies will examine the use of clofarabine in elderly patients with AML for whom standard regimens are too toxic, and in MDS intravenous and oral forms of the drug.",Journal Article,4495.0,60.0,Clofarabine is a good generation purine nucleoside analogue designed to overcome the limitations and to incorporate the best qualities of both cladribine and fludarabine Clofarabine is thought to work via three mechanisms inhibition of ribonucleotide reductase incorporation to DNA and induction of apoptosis Given these mechanism of action clofarabine would be predicted to act synergistically with other chemotherapeutic agents such as other purine nucleoside analogues and DNA damaging or cross linking agents such as anthracyclines and platinum-based compounds Intravenous clofarabine showed significant efficacy in pediatric leukemias specifically acute lymphoblastic ALL and in 2004 it was approved by the United States Food and Drug Administration FDA for the treatment of pediatric relapsed/refractory ALL after at least two regimens In adults clofarabine has shown significant efficacy in hematologic malignancies including acute myeloid AML and syndrome MDS alone and in combinations Ongoing and future studies will examine the use of clofarabine in elderly patients with AML for whom standard regimens are too toxic and in MDS intravenous and oral forms of the drug,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4149, 16, 8, 1178, 914, 5006, 4032, 4696, 1114, 6, 1768, 3, 1939, 2, 6, 3360, 3, 824, 15353, 1, 110, 8251, 2, 2027, 4149, 16, 2739, 6, 1357, 847, 169, 483, 297, 1, 7050, 4027, 2838, 6, 261, 2, 504, 1, 351, 447, 46, 670, 1, 1578, 4149, 688, 40, 783, 6, 2559, 4240, 5, 127, 1573, 183, 225, 22, 127, 5006, 4032, 4768, 2, 261, 4904, 15, 1383, 5806, 183, 225, 22, 3597, 2, 828, 90, 2411, 1262, 4149, 224, 93, 209, 4, 815, 2792, 1225, 286, 1275, 62, 2, 4, 1131, 192, 10, 850, 20, 3, 1088, 907, 1773, 2, 234, 634, 2078, 9, 3, 24, 1, 815, 591, 430, 62, 50, 28, 506, 100, 472, 4, 857, 4149, 71, 443, 93, 209, 4, 813, 441, 141, 286, 533, 329, 2, 681, 1223, 279, 2, 4, 1247, 942, 2, 508, 94, 303, 1004, 3, 119, 1, 4149, 4, 1216, 7, 5, 329, 9, 953, 260, 472, 32, 5044, 1812, 2, 4, 1223, 1262, 2, 518, 2377, 1, 3, 234]",1176.0,17852710,86
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2007-09-12,"Human T cells targeted to the B cell-specific CD19 antigen through retroviral-mediated transfer of a chimeric antigen receptor (CAR), termed 19z1, have shown significant but partial in vivo antitumor efficacy in a severe combined immunodeficient (SCID)-Beige systemic human acute lymphoblastic leukemia (NALM-6) tumor model. Here, we investigate the etiologies of treatment failure in this model and design approaches to enhance the efficacy of this adoptive strategy. A panel of modified CD19-targeted CARs designed to deliver combined activating and costimulatory signals to the T cell was generated and tested in vitro to identify an optimal second-generation CAR. Antitumor efficacy of T cells expressing this optimal costimulatory CAR, 19-28z, was analyzed in mice bearing systemic costimulatory ligand-deficient NALM-6 tumors. Expression of the 19-28z CAR, containing the signaling domain of the CD28 receptor, enhanced systemic T-cell antitumor activity when compared with 19z1 in treated mice. A treatment schedule of 4 weekly T-cell injections, designed to prolong in vivo T-cell function, further improved long-term survival. Bioluminescent imaging of tumor in treated mice failed to identify a conserved site of tumor relapse, consistent with successful homing by tumor-specific T cells to systemic sites of tumor involvement. Both in vivo costimulation and repeated administration enhance eradication of systemic tumor by genetically targeted T cells. The finding that modifications in CAR design as well as T-cell dosing allowed for the complete eradication of systemic disease affects the design of clinical trials using this treatment strategy.",Journal Article,4514.0,250.0,Human T cells targeted to the B cell-specific CD19 antigen through retroviral-mediated transfer of a chimeric antigen receptor CAR termed 19z1 have shown significant but partial in vivo antitumor efficacy in a severe combined immunodeficient SCID -Beige systemic human acute lymphoblastic NALM-6 tumor model Here we investigate the etiologies of treatment failure in this model and design approaches to enhance the efficacy of this adoptive strategy A panel of modified CD19-targeted CARs designed to deliver combined activating and costimulatory signals to the T cell was generated and tested in vitro to identify an optimal second-generation CAR Antitumor efficacy of T cells expressing this optimal costimulatory CAR 19-28z was analyzed in mice bearing systemic costimulatory ligand-deficient NALM-6 tumors Expression of the 19-28z CAR containing the signaling domain of the CD28 receptor enhanced systemic T-cell antitumor activity when compared with 19z1 in treated mice A treatment schedule of 4 weekly T-cell injections designed to prolong in vivo T-cell function further improved long-term survival Bioluminescent imaging of tumor in treated mice failed to identify a conserved site of tumor relapse consistent with successful homing by tumor-specific T cells to systemic sites of tumor involvement Both in vivo costimulation and repeated administration enhance eradication of systemic tumor by genetically targeted T cells The finding that modifications in CAR design as well as T-cell dosing allowed for the complete eradication of systemic disease affects the design of clinical trials using this treatment strategy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[171, 102, 37, 238, 6, 3, 132, 31, 112, 3158, 448, 298, 8658, 517, 2602, 1, 8, 2897, 448, 153, 1881, 4183, 44859, 47, 443, 93, 84, 450, 4, 386, 579, 209, 4, 8, 905, 397, 5031, 4129, 16620, 403, 171, 286, 1275, 30791, 49, 30, 202, 467, 21, 963, 3, 8523, 1, 24, 496, 4, 26, 202, 2, 771, 611, 6, 1304, 3, 209, 1, 26, 3159, 692, 8, 993, 1, 1230, 3158, 238, 7441, 1114, 6, 3392, 397, 1616, 2, 5555, 2312, 6, 3, 102, 31, 10, 1419, 2, 650, 4, 439, 6, 255, 35, 665, 419, 914, 1881, 579, 209, 1, 102, 37, 1046, 26, 665, 5555, 1881, 326, 19130, 10, 311, 4, 399, 1894, 403, 5555, 1232, 1971, 30791, 49, 57, 55, 1, 3, 326, 19130, 1881, 1101, 3, 314, 1398, 1, 3, 5603, 153, 651, 403, 102, 31, 579, 128, 198, 72, 5, 44859, 4, 73, 399, 8, 24, 1055, 1, 39, 709, 102, 31, 4344, 1114, 6, 3615, 4, 386, 102, 31, 343, 195, 231, 319, 337, 25, 12571, 270, 1, 30, 4, 73, 399, 1551, 6, 255, 8, 5547, 606, 1, 30, 429, 925, 5, 1401, 5515, 20, 30, 112, 102, 37, 6, 403, 633, 1, 30, 799, 110, 4, 386, 8085, 2, 2113, 634, 1304, 5173, 1, 403, 30, 20, 2301, 238, 102, 37, 3, 1567, 17, 2916, 4, 1881, 771, 22, 149, 22, 102, 31, 1280, 2313, 9, 3, 236, 5173, 1, 403, 34, 2561, 3, 771, 1, 38, 143, 75, 26, 24, 692]",1626.0,17855649,583
Aggressive Langerhans cell histiocytosis following T-ALL: clonally related neoplasms with persistent expression of constitutively active NOTCH1.,American journal of hematology,Am. J. Hematol.,2008-02-01,"Langerhans cell histiocytosis (LCH) and related entities are neoplasms of unknown pathogenesis. Here, we describe studies assessing the role of NOTCH1 mutations in LCH, which were based on a case of fatal Langerhans cell tumor after T-cell acute lymphoblastic leukemia (T-ALL). Although the two types of neoplasm in this patient were temporally and pathologically distinct, molecular analyses showed that they harbored the same T-cell receptor gene rearrangements and two activating NOTCH1 mutations involving exons 27 and 34. The exon 27 mutation altered a conserved cysteine residue in the N-terminal portion of the NOTCH1 heterodimerization domain, while the mutation in exon 34 introduced a premature stop codon that results in the deletion of C-terminal negative regulatory PEST domain. Analysis of cDNA prepared from the aggressive Langerhans cell tumor showed that the NOTCH1 mutations were aligned in cis, a configuration that caused synergistic increases in NOTCH1 signal strength in reporter gene assays. Immunohistochemistry confirmed that the Langerhans cell tumor also expressed NOTCH1 protein. Although these data suggested that NOTCH1 mutations might contribute to the pathogenesis of typical sporadic LCH and related neoplasms occurring in the absence of T-ALL, an analysis of 24 cases of LCH and Rosai-Dorfman Disease occurring in patients without an antecedent history of T-ALL revealed no mutations. Thus, activating NOTCH1 mutations appear to be unique to aggressive Langerhans cell tumors occurring after T-ALL. Persistent expression of NOTCH1 in such tumors suggests that Notch pathway inhibitors could have a role in the treatment of these unusual neoplasms.",Case Reports,4372.0,37.0,Langerhans cell histiocytosis LCH and related entities are neoplasms of unknown pathogenesis Here we describe studies assessing the role of NOTCH1 mutations in LCH which were based on a case of fatal Langerhans cell tumor after T-cell acute lymphoblastic T-ALL Although the two types of neoplasm in this patient were temporally and pathologically distinct molecular analyses showed that they harbored the same T-cell receptor gene rearrangements and two activating NOTCH1 mutations involving exons 27 and 34 The exon 27 mutation altered a conserved cysteine residue in the N-terminal portion of the NOTCH1 heterodimerization domain while the mutation in exon 34 introduced a premature stop codon that results in the deletion of C-terminal negative regulatory PEST domain Analysis of cDNA prepared from the aggressive Langerhans cell tumor showed that the NOTCH1 mutations were aligned in cis a configuration that caused synergistic increases in NOTCH1 signal strength in reporter gene assays Immunohistochemistry confirmed that the Langerhans cell tumor also expressed NOTCH1 protein Although these data suggested that NOTCH1 mutations might contribute to the pathogenesis of typical sporadic LCH and related neoplasms occurring in the absence of T-ALL an analysis of 24 cases of LCH and Rosai-Dorfman Disease occurring in patients without an antecedent history of T-ALL revealed no mutations Thus activating NOTCH1 mutations appear to be unique to aggressive Langerhans cell tumors occurring after T-ALL Persistent expression of NOTCH1 in such tumors suggests that Notch pathway inhibitors could have a role in the treatment of these unusual neoplasms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[15702, 31, 13976, 19131, 2, 139, 4613, 32, 1179, 1, 860, 1384, 467, 21, 897, 94, 1977, 3, 200, 1, 4607, 138, 4, 19131, 92, 11, 90, 23, 8, 473, 1, 3034, 15702, 31, 30, 50, 102, 31, 286, 1275, 102, 62, 242, 3, 100, 630, 1, 2131, 4, 26, 69, 11, 11114, 2, 2998, 834, 219, 318, 224, 17, 491, 3253, 3, 827, 102, 31, 153, 145, 2072, 2, 100, 1616, 4607, 138, 1267, 3885, 428, 2, 562, 3, 1725, 428, 258, 1495, 8, 5547, 6943, 7840, 4, 3, 78, 2158, 3206, 1, 3, 4607, 16699, 1398, 369, 3, 258, 4, 1725, 562, 3955, 8, 5682, 7142, 3673, 17, 99, 4, 3, 1528, 1, 256, 2158, 199, 1253, 33741, 1398, 65, 1, 4212, 4421, 29, 3, 571, 15702, 31, 30, 224, 17, 3, 4607, 138, 11, 13979, 4, 1927, 8, 13796, 17, 1546, 1806, 1106, 4, 4607, 1235, 3671, 4, 3674, 145, 1013, 888, 557, 17, 3, 15702, 31, 30, 120, 570, 4607, 178, 242, 46, 74, 1148, 17, 4607, 138, 822, 1248, 6, 3, 1384, 1, 3476, 1928, 19131, 2, 139, 1179, 1821, 4, 3, 1127, 1, 102, 62, 35, 65, 1, 259, 140, 1, 19131, 2, 38551, 38552, 34, 1821, 4, 7, 187, 35, 8775, 532, 1, 102, 62, 553, 77, 138, 631, 1616, 4607, 138, 1322, 6, 40, 991, 6, 571, 15702, 31, 57, 1821, 50, 102, 62, 1882, 55, 1, 4607, 4, 225, 57, 844, 17, 3193, 308, 222, 359, 47, 8, 200, 4, 3, 24, 1, 46, 4015, 1179]",1652.0,17874453,809
Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.,Blood,Blood,2007-10-01,"In childhood acute lymphoblastic leukemia (ALL), a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors, not only for achieving remission but also for relapse-free survival (RFS). However, in acute myeloid leukemia (AML) parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission (CR) or the assessment of residual leukemic bone marrow blasts during aplasia. We hypothesized that the time to circulating peripheral blood blast clearance, as a potential surrogate for in vivo chemosensitivity, would have prognostic relevance in AML also. In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy, we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS, superseding other known or established risk factors, including karyotype and number of inductions to achieve CR.",Journal Article,4495.0,50.0,In childhood acute lymphoblastic ALL a rapid decline of circulating leukemic blasts in response to induction chemotherapy or prednisone is one of the most important prognostic factors not only for achieving remission but also for relapse-free survival RFS However in acute myeloid AML parameters of chemosensitivity have been restricted mainly to the rapidity of achievement of complete remission CR or the assessment of residual leukemic marrow blasts during aplasia We hypothesized that the time to circulating peripheral blood blast clearance as a potential surrogate for in vivo chemosensitivity would have prognostic relevance in AML also In a retrospective analysis of a cohort of 86 adult patients with AML receiving uniform induction and consolidation chemotherapy we demonstrate that the time to clearance of circulating blasts during induction chemotherapy is an independent prognostic marker of RFS superseding other known or established risk factors including karyotype and number of inductions to achieve CR,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 864, 286, 1275, 62, 8, 1321, 1858, 1, 1033, 2015, 2438, 4, 51, 6, 504, 56, 15, 1979, 16, 104, 1, 3, 96, 305, 177, 130, 44, 158, 9, 1785, 734, 84, 120, 9, 429, 115, 25, 1272, 137, 4, 286, 533, 329, 1038, 1, 5522, 47, 85, 2016, 2615, 6, 3, 17112, 1, 5088, 1, 236, 734, 684, 15, 3, 455, 1, 753, 2015, 581, 2438, 190, 12307, 21, 1237, 17, 3, 98, 6, 1033, 672, 315, 3112, 1960, 22, 8, 174, 2592, 9, 4, 386, 5522, 688, 47, 177, 2088, 4, 329, 120, 4, 8, 459, 65, 1, 8, 180, 1, 868, 780, 7, 5, 329, 357, 3490, 504, 2, 2173, 56, 21, 608, 17, 3, 98, 6, 1960, 1, 1033, 2438, 190, 504, 56, 16, 35, 306, 177, 952, 1, 1272, 44884, 127, 440, 15, 635, 43, 130, 141, 3385, 2, 207, 1, 34346, 6, 1359, 684]",1020.0,17909077,186
"Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae.",Neuroradiology,Neuroradiology,2007-10-09,"During the past three decades, improvements in the treatment of childhood leukemia have resulted in high cure rates, particularly for acute lymphoblastic leukemia (ALL). Unfortunately, successful therapy has come with a price, as significant morbidity can result from neurological affects which harm the brain and spinal cord. The expectation and hope is that chemotherapy, as a primary means of CNS therapy, will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades. In this review we discuss the poignant, historical aspects of CNS leukemia therapy, outline current methods of systemic and CNS leukemia therapy, and present imaging findings we have encountered in childhood leukemia patients with a variety of acute neurological conditions. A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy. Specific features related to CNS leukemia and associated short-term toxicities, both disease- and therapy-related, are emphasized in this review with the specific neuroimaging findings. Specific CNS findings are similarly important when treating acute myelogenous leukemia (AML), and details of leukemic involvement and toxicities are also presented in this entity. Despite contemporary treatment approaches which favor the use of chemotherapy (including intrathecal therapy) over radiotherapy in the treatment of CNS leukemia, children still occasionally experience morbid neurotoxicity. Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children, and often suggest specific etiologies. Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy. It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute, specific, recognizable, and often serious neurological consequences.",Journal Article,4487.0,38.0,During the past three decades improvements in the treatment of childhood have resulted in high cure rates particularly for acute lymphoblastic ALL Unfortunately successful therapy has come with a price as significant morbidity can result from neurological affects which harm the brain and spinal cord The expectation and hope is that chemotherapy as a primary means of CNS therapy will result in acceptable disease control with less CNS morbidity than has been observed with combinations of chemotherapy and radiotherapy over the past several decades In this review we discuss the poignant historical aspects of CNS therapy outline current methods of systemic and CNS therapy and present imaging findings we have encountered in childhood patients with a variety of acute neurological conditions A major objective of our research is to understand the neuroimaging correlates of acute and chronic effects of cancer and therapy Specific features related to CNS and associated short-term toxicities both disease- and therapy-related are emphasized in this review with the specific neuroimaging findings Specific CNS findings are similarly important when treating acute myelogenous AML and details of leukemic involvement and toxicities are also presented in this entity Despite contemporary treatment approaches which favor the use of chemotherapy including intrathecal therapy over radiotherapy in the treatment of CNS children still occasionally experience morbid neurotoxicity Standard neuroimaging is sufficient to identify a variety of neurotoxic sequelae in children and often suggest specific etiologies Specific neuroimaging findings frequently indicate a need to alter antileukemia therapy It is important to appreciate that intrathecal and high doses of systemic chemotherapy are not innocuous and are associated with acute specific recognizable and often serious neurological consequences,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[190, 3, 1219, 169, 1968, 1474, 4, 3, 24, 1, 864, 47, 627, 4, 64, 1722, 151, 823, 9, 286, 1275, 62, 3869, 1401, 36, 71, 6235, 5, 8, 8816, 22, 93, 787, 122, 757, 29, 3622, 2561, 92, 7158, 3, 342, 2, 1499, 1885, 3, 9988, 2, 3045, 16, 17, 56, 22, 8, 86, 2263, 1, 1025, 36, 303, 757, 4, 1595, 34, 182, 5, 299, 1025, 787, 76, 71, 85, 164, 5, 1247, 1, 56, 2, 310, 252, 3, 1219, 392, 1968, 4, 26, 206, 21, 1139, 3, 56604, 2252, 2695, 1, 1025, 36, 5277, 291, 636, 1, 403, 2, 1025, 36, 2, 364, 270, 272, 21, 47, 3903, 4, 864, 7, 5, 8, 1362, 1, 286, 3622, 1298, 8, 458, 461, 1, 114, 389, 16, 6, 1640, 3, 7468, 1871, 1, 286, 2, 442, 176, 1, 12, 2, 36, 112, 404, 139, 6, 1025, 2, 41, 978, 337, 385, 110, 34, 2, 36, 139, 32, 8585, 4, 26, 206, 5, 3, 112, 7468, 272, 112, 1025, 272, 32, 1813, 305, 198, 1367, 286, 2194, 329, 2, 3791, 1, 2015, 799, 2, 385, 32, 120, 917, 4, 26, 2983, 550, 2667, 24, 611, 92, 4283, 3, 119, 1, 56, 141, 5126, 36, 252, 310, 4, 3, 24, 1, 1025, 541, 1234, 6319, 730, 8188, 3561, 260, 7468, 16, 1952, 6, 255, 8, 1362, 1, 11148, 4156, 4, 541, 2, 629, 309, 112, 8523, 112, 7468, 272, 746, 1008, 8, 594, 6, 2688, 9169, 36, 192, 16, 305, 6, 19754, 17, 5126, 2, 64, 415, 1, 403, 56, 32, 44, 33576, 2, 32, 41, 5, 286, 112, 13908, 2, 629, 1762, 3622, 3255]",1895.0,17924103,683
Dexamethasone alters sleep and fatigue in pediatric patients with acute lymphoblastic leukemia.,Cancer,Cancer,2007-11-01,"Dexamethasone improves the cure rate of childhood acute lymphoblastic leukemia (ALL) but causes physical and behavioral adverse events. The objective of the current study was to determine the effect of dexamethasone exposure on sleep and fatigue in pediatric patients with ALL. One hundred pediatric patients with low-risk or standard-risk ALL were enrolled on 1 of 3 protocols (St. Jude Total XV, Children's Oncology Group [COG] 9904, or COG 9905) at 3 institutions. The mean age of the cohort was 9.24 +/- 3.23 years (range, 5.03-18.14 years). The majority of patients were white (79%) males (62%) with standard-risk ALL (63%). The cohort was divided into 4 subgroups: St. Jude low-risk, St. Jude standard-risk, COG low-risk, and COG standard-risk. Patients wore a wrist actigraph to monitor sleep activity during 2 consecutive 5-day periods: During the first period, they did not receive dexamethasone; and, during the second period, they did. Patients and their parents completed fatigue instruments on Days 2 and 5 of each period, and parents completed sleep diaries. Actual sleep minutes, sleep duration, total daily nap minutes, and fatigue increased significantly during the dexamethasone treatment for 3 to 4 of the subgroups. Total daily nap minutes increased significantly for both standard-risk groups during the dexamethasone treatment. Parents reported significant increases in their child's nighttime awakenings, restless sleep, and nap time during dexamethasone treatment. Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue, confirming that sleep and fatigue are behavioral responses to dexamethasone.",Journal Article,4464.0,99.0,Dexamethasone improves the cure rate of childhood acute lymphoblastic ALL but causes physical and behavioral adverse events The objective of the current study was to determine the effect of dexamethasone exposure on sleep and fatigue in pediatric patients with ALL One hundred pediatric patients with low-risk or standard-risk ALL were enrolled on 1 of 3 protocols St. Jude Total XV Children 's Oncology Group COG 9904 or COG 9905 at 3 institutions The mean age of the cohort was 9.24 +/- 3.23 years range 5.03-18.14 years The majority of patients were white 79 males 62 with standard-risk ALL 63 The cohort was divided into 4 subgroups St. Jude low-risk St. Jude standard-risk COG low-risk and COG standard-risk Patients wore a wrist actigraph to monitor sleep activity during 2 consecutive 5-day periods During the first period they did not receive dexamethasone and during the second period they did Patients and their parents completed fatigue instruments on Days 2 and 5 of each period and parents completed sleep diaries Actual sleep minutes sleep duration total daily nap minutes and fatigue increased significantly during the dexamethasone treatment for 3 to 4 of the subgroups Total daily nap minutes increased significantly for both standard-risk groups during the dexamethasone treatment Parents reported significant increases in their child 's nighttime awakenings restless sleep and nap time during dexamethasone treatment Dexamethasone treatment during continuation therapy for childhood ALL significantly and adversely altered sleep and fatigue confirming that sleep and fatigue are behavioral responses to dexamethasone,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1217, 1804, 3, 1722, 116, 1, 864, 286, 1275, 62, 84, 1626, 900, 2, 4166, 290, 281, 3, 461, 1, 3, 291, 45, 10, 6, 223, 3, 254, 1, 1217, 645, 23, 2494, 2, 613, 4, 815, 7, 5, 62, 104, 1128, 815, 7, 5, 154, 43, 15, 260, 43, 62, 11, 346, 23, 14, 1, 27, 2189, 3062, 4841, 181, 16078, 541, 292, 413, 87, 6377, 56606, 15, 6377, 44902, 28, 27, 1764, 3, 313, 89, 1, 3, 180, 10, 83, 259, 27, 382, 60, 184, 33, 680, 203, 213, 60, 3, 686, 1, 7, 11, 886, 842, 2296, 744, 5, 260, 43, 62, 676, 3, 180, 10, 2176, 237, 39, 1453, 3062, 4841, 154, 43, 3062, 4841, 260, 43, 6377, 154, 43, 2, 6377, 260, 43, 7, 18527, 8, 21318, 24819, 6, 3334, 2494, 128, 190, 18, 935, 33, 218, 3338, 190, 3, 157, 727, 491, 205, 44, 560, 1217, 2, 190, 3, 419, 727, 491, 205, 7, 2, 136, 2418, 781, 613, 4730, 23, 162, 18, 2, 33, 1, 296, 727, 2, 2418, 781, 2494, 14133, 3480, 2494, 2511, 2494, 654, 181, 391, 13408, 2511, 2, 613, 101, 97, 190, 3, 1217, 24, 9, 27, 6, 39, 1, 3, 1453, 181, 391, 13408, 2511, 101, 97, 9, 110, 260, 43, 271, 190, 3, 1217, 24, 2418, 210, 93, 1106, 4, 136, 2566, 292, 28719, 34354, 44903, 2494, 2, 13408, 98, 190, 1217, 24, 1217, 24, 190, 6870, 36, 9, 864, 62, 97, 2, 4311, 1495, 2494, 2, 613, 5030, 17, 2494, 2, 613, 32, 4166, 253, 6, 1217]",1635.0,17926333,210
Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.,Blood,Blood,2007-10-25,"Vorinostat (suberoylanilide hydroxamic acid, SAHA) is a histone deacetylase inhibitor active clinically in cutaneous T-cell lymphoma and preclinically in leukemia. A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest. Patients with relapsed or refractory leukemias or myelodysplastic syndromes (MDS) and untreated patients who were not candidates for chemotherapy were eligible. Of 41 patients, 31 had acute myeloid leukemia (AML), 4 chronic lymphocytic leukemia, 3 MDS, 2 acute lymphoblastic leukemia, and 1 chronic myelocytic leukemia. The maximum tolerated dose (MTD) was 200 mg twice daily or 250 mg thrice daily. Dose-limiting toxicities were fatigue, nausea, vomiting, and diarrhea. Common drug-related adverse experiences were diarrhea, nausea, fatigue, and anorexia and were mild/moderate in severity. Grade 3/4 drug-related adverse experiences included fatigue (27%), thrombocytopenia (12%), and diarrhea (10%). There were no drug-related deaths; 7 patients had hematologic improvement response, including 2 complete responses and 2 complete responses with incomplete blood count recovery (all with AML treated at/below MTD). Increased histone acetylation was observed at all doses. Antioxidant gene expression may confer vorinostat resistance. Further evaluation of vorinostat in AML/MDS is warranted.","Clinical Trial, Phase I",4471.0,367.0,Vorinostat suberoylanilide hydroxamic acid SAHA is a histone deacetylase inhibitor active clinically in cutaneous T-cell and preclinically in A phase 1 study was conducted to evaluate the safety and activity of oral vorinostat 100 to 300 mg twice or thrice daily for 14 days followed by 1-week rest Patients with relapsed or refractory leukemias or syndromes MDS and untreated patients who were not candidates for chemotherapy were eligible Of 41 patients 31 had acute myeloid AML 4 chronic lymphocytic 3 MDS 2 acute lymphoblastic and 1 chronic myelocytic The maximum tolerated dose MTD was 200 mg twice daily or 250 mg thrice daily Dose-limiting toxicities were fatigue nausea vomiting and diarrhea Common drug-related adverse experiences were diarrhea nausea fatigue and anorexia and were mild/moderate in severity Grade 3/4 drug-related adverse experiences included fatigue 27 thrombocytopenia 12 and diarrhea 10 There were no drug-related deaths 7 patients had hematologic improvement response including 2 complete responses and 2 complete responses with incomplete blood count recovery all with AML treated at/below MTD Increased histone acetylation was observed at all doses Antioxidant gene expression may confer vorinostat resistance Further evaluation of vorinostat in AML/MDS is warranted,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[2371, 9258, 8856, 971, 5484, 16, 8, 1508, 2732, 230, 544, 505, 4, 1486, 102, 31, 2, 10838, 4, 8, 124, 14, 45, 10, 426, 6, 376, 3, 367, 2, 128, 1, 518, 2371, 394, 6, 2036, 81, 936, 15, 10058, 391, 9, 213, 162, 370, 20, 14, 647, 3677, 7, 5, 591, 15, 430, 2792, 15, 2040, 1223, 2, 1278, 7, 54, 11, 44, 1931, 9, 56, 11, 625, 1, 605, 7, 456, 42, 286, 533, 329, 39, 442, 1193, 27, 1223, 18, 286, 1275, 2, 14, 442, 19446, 3, 689, 421, 61, 961, 10, 1250, 81, 936, 391, 15, 2039, 81, 10058, 391, 61, 817, 385, 11, 613, 1218, 1966, 2, 1172, 186, 234, 139, 290, 4031, 11, 1172, 1218, 613, 2, 3373, 2, 11, 1980, 1163, 4, 1702, 88, 27, 39, 234, 139, 290, 4031, 159, 613, 428, 1340, 133, 2, 1172, 79, 125, 11, 77, 234, 139, 1043, 67, 7, 42, 813, 767, 51, 141, 18, 236, 253, 2, 18, 236, 253, 5, 2610, 315, 1276, 1602, 62, 5, 329, 73, 28, 2736, 961, 101, 1508, 4145, 10, 164, 28, 62, 415, 5536, 145, 55, 68, 2913, 2371, 251, 195, 451, 1, 2371, 4, 329, 1223, 16, 1197]",1298.0,17962510,192
Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2007-11-01,"We evaluated late neuropsychological toxicity in children treated for standard-risk acute lymphoblastic leukemia (ALL) who were randomly assigned to receive either cranial radiation therapy (CRT) with double intrathecal (IT) chemotherapy or intensive triple IT chemotherapy (no CRT) as CNS-directed therapy. Between 1996 and 2000, 164 children with standard-risk ALL treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 were randomly assigned to receive either 18 Gy CRT delivered in twice daily fractions (0.9 [DOSAGE ERROR CORRECTED] Gy) with double IT therapy (methotrexate and cytarabine) or intensive triple IT drug (methotrexate, cytarabine and hydrocortisone) without CRT. Neuropsychological testing was completed at a median 6 years postdiagnosis for 79 children (CRT, n = 39; triple IT, n = 40), all of whom were in continuous complete remission. Cognitive function for both groups was solidly in the average range, with no consistent group differences in basic cognitive skills. Children treated on the CRT plus double IT arm did, however, exhibit less fluent output and were less effective at modulating their behavior by parent report. This randomized trial revealed only subtle differences 6 years after diagnosis between children who received CNS therapy as CRT plus double IT drug or as intensive triple IT drug. In most situations where comparable therapeutic efficacy can be achieved without CRT, it is preferable to do so. Where therapeutically necessary, however, CRT at lower doses may not add risk for significant neurotoxicity.",Comparative Study,4464.0,76.0,We evaluated late neuropsychological toxicity in children treated for standard-risk acute lymphoblastic ALL who were randomly assigned to receive either cranial radiation therapy CRT with double intrathecal IT chemotherapy or intensive triple IT chemotherapy no CRT as CNS-directed therapy Between 1996 and 2000 164 children with standard-risk ALL treated on Dana-Farber Cancer Institute Consortium Protocol 95-01 were randomly assigned to receive either 18 Gy CRT delivered in twice daily fractions 0.9 DOSAGE ERROR CORRECTED Gy with double IT therapy methotrexate and cytarabine or intensive triple IT drug methotrexate cytarabine and hydrocortisone without CRT Neuropsychological testing was completed at a median 6 years postdiagnosis for 79 children CRT n 39 triple IT n 40 all of whom were in continuous complete remission Cognitive function for both groups was solidly in the average range with no consistent group differences in basic cognitive skills Children treated on the CRT plus double IT arm did however exhibit less fluent output and were less effective at modulating their behavior by parent report This randomized trial revealed only subtle differences 6 years after diagnosis between children who received CNS therapy as CRT plus double IT drug or as intensive triple IT drug In most situations where comparable therapeutic efficacy can be achieved without CRT it is preferable to do so Where therapeutically necessary however CRT at lower doses may not add risk for significant neurotoxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 194, 807, 8271, 155, 4, 541, 73, 9, 260, 43, 286, 1275, 62, 54, 11, 1108, 896, 6, 560, 361, 2565, 121, 36, 1089, 5, 1627, 5126, 192, 56, 15, 1686, 1500, 192, 56, 77, 1089, 22, 1025, 1166, 36, 59, 2648, 2, 1081, 5279, 541, 5, 260, 43, 62, 73, 23, 4932, 4979, 12, 1377, 2404, 1182, 48, 355, 11, 1108, 896, 6, 560, 361, 203, 381, 1089, 1623, 4, 936, 391, 1550, 13, 83, 3323, 3444, 3848, 381, 5, 1627, 192, 36, 2116, 2, 1855, 15, 1686, 1500, 192, 234, 2116, 1855, 2, 17127, 187, 1089, 8271, 471, 10, 781, 28, 8, 52, 49, 60, 7163, 9, 842, 541, 1089, 78, 587, 1500, 192, 78, 327, 62, 1, 953, 11, 4, 1314, 236, 734, 1863, 343, 9, 110, 271, 10, 37725, 4, 3, 1011, 184, 5, 77, 925, 87, 362, 4, 2795, 1863, 5909, 541, 73, 23, 3, 1089, 349, 1627, 192, 475, 205, 137, 2239, 299, 23480, 6911, 2, 11, 299, 323, 28, 3712, 136, 1710, 20, 3841, 414, 26, 384, 160, 553, 158, 7543, 362, 49, 60, 50, 147, 59, 541, 54, 103, 1025, 36, 22, 1089, 349, 1627, 192, 234, 15, 22, 1686, 1500, 192, 234, 4, 96, 5990, 1257, 1279, 189, 209, 122, 40, 513, 187, 1089, 192, 16, 7474, 6, 1022, 1743, 1257, 4602, 1493, 137, 1089, 28, 280, 415, 68, 44, 4178, 43, 9, 93, 3561]",1511.0,17971588,588
High-performance liquid chromatography separation of aminopterin-polyglutamates within red blood cells of children treated for acute lymphoblastic leukemia.,Translational research : the journal of laboratory and clinical medicine,Transl Res,2007-09-07,"Aminopterin (AMT), like the related compound methotrexate (MTX), is a drug with anticancer and antiinflammatory efficacy that works by interfering with synthetic reactions dependent on the vitamin folic acid. Red blood cell (RBC) precursors will accumulate antifolates like AMT and MTX through the same mechanism by which they take up folate. Intracellular folate and antifolates are then metabolized to polyglutamates that remain within the mature RBCs. RBC MTX has been correlated with toxicity and/or treatment efficacy among patients with acute lymphoblastic leukemia (ALL) or rheumatoid arthritis. Because AMT may offer clinically relevant advantages over MTX, we are testing whether it can be administered safely in multiagent therapy to children with ALL. Total RBC AMT was measured to monitor compliance with this oral, outpatient regimen, and to estimate AMT exposure to the bone marrow. Here we describe methods for quantifying each AMT-polyglutamate species within the RBCs of patients. The assay was linear over a concentration range of 62.5-500 nmol/L. Recovery of individual AMT-polyglutamates ranged from 85% to 92%, and the intraday coefficients of variation were 1.3% to 3.6%. Long-chain AMT-polyglutamates (triglutamate and tetraglutamate forms) accounted for over 40% of intracellular AMT within the RBCs of patients. Patients with long-chain AMT polyglutamate concentrations above the median tended to have lower mean neutrophil counts during weekly AMT therapy, which suggests that RBC AMT polyglutamate accumulation may correlate with hematologic toxicity. As AMT continues to be tested in clinical trials, the methods described here will be useful to define relationships between clinical response to AMT and RBC accumulation of AMT-polyglutamates.",Journal Article,4519.0,3.0,Aminopterin AMT like the related compound methotrexate MTX is a drug with anticancer and antiinflammatory efficacy that works by interfering with synthetic reactions dependent on the vitamin folic acid Red blood cell RBC precursors will accumulate antifolates like AMT and MTX through the same mechanism by which they take up folate Intracellular folate and antifolates are then metabolized to polyglutamates that remain within the mature RBCs RBC MTX has been correlated with toxicity and/or treatment efficacy among patients with acute lymphoblastic ALL or rheumatoid arthritis Because AMT may offer clinically relevant advantages over MTX we are testing whether it can be administered safely in multiagent therapy to children with ALL Total RBC AMT was measured to monitor compliance with this oral outpatient regimen and to estimate AMT exposure to the marrow Here we describe methods for quantifying each AMT-polyglutamate species within the RBCs of patients The assay was linear over a concentration range of 62.5-500 nmol/L Recovery of individual AMT-polyglutamates ranged from 85 to 92 and the intraday coefficients of variation were 1.3 to 3.6 Long-chain AMT-polyglutamates triglutamate and tetraglutamate forms accounted for over 40 of intracellular AMT within the RBCs of patients Patients with long-chain AMT polyglutamate concentrations above the median tended to have lower mean neutrophil counts during weekly AMT therapy which suggests that RBC AMT polyglutamate accumulation may correlate with hematologic toxicity As AMT continues to be tested in clinical trials the methods described here will be useful to define relationships between clinical response to AMT and RBC accumulation of AMT-polyglutamates,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[16421, 5383, 733, 3, 139, 2823, 2116, 3453, 16, 8, 234, 5, 1475, 2, 16754, 209, 17, 10275, 20, 3449, 5, 3273, 2428, 470, 23, 3, 1610, 7853, 971, 3422, 315, 31, 7256, 4881, 303, 7859, 14893, 733, 5383, 2, 3453, 298, 3, 827, 670, 20, 92, 491, 3585, 126, 3100, 2087, 3100, 2, 14893, 32, 818, 10523, 6, 16243, 17, 918, 262, 3, 2908, 15859, 7256, 3453, 71, 85, 438, 5, 155, 2, 15, 24, 209, 107, 7, 5, 286, 1275, 62, 15, 12269, 8646, 408, 5383, 68, 1918, 505, 867, 3126, 252, 3453, 21, 32, 471, 317, 192, 122, 40, 468, 2268, 4, 7148, 36, 6, 541, 5, 62, 181, 7256, 5383, 10, 644, 6, 3334, 3336, 5, 26, 518, 2379, 477, 2, 6, 1191, 5383, 645, 6, 3, 581, 467, 21, 897, 636, 9, 6602, 296, 5383, 22006, 2915, 262, 3, 15859, 1, 7, 3, 719, 10, 1646, 252, 8, 1227, 184, 1, 744, 33, 1666, 4694, 805, 1602, 1, 797, 5383, 16243, 1869, 29, 772, 6, 937, 2, 3, 56667, 5161, 1, 1380, 11, 14, 27, 6, 27, 49, 319, 1260, 5383, 16243, 56668, 2, 56669, 2377, 3688, 9, 252, 327, 1, 2087, 5383, 262, 3, 15859, 1, 7, 7, 5, 319, 1260, 5383, 22006, 1003, 2090, 3, 52, 3886, 6, 47, 280, 313, 2595, 1911, 190, 709, 5383, 36, 92, 844, 17, 7256, 5383, 22006, 1835, 68, 1513, 5, 813, 155, 22, 5383, 2274, 6, 40, 650, 4, 38, 143, 3, 636, 1027, 467, 303, 40, 999, 6, 1107, 2467, 59, 38, 51, 6, 5383, 2, 7256, 1835, 1, 5383, 16243]",1722.0,18022599,138
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy.,Blood,Blood,2007-11-26,"Alemtuzumab is an immunosuppressive antibody that depletes normal T cells and B cells. Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent. Approximately 20% to 25% of patients will experience cytomegalovirus (CMV) reactivation. We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily. The study design planned to enroll 128 patients, but stopping rules for early termination were met. Forty patients were evaluable. Median age was 58 years (range, 25-83 years); median number of prior therapies was 2 (range, 0-10). Diagnoses included chronic lymphocytic leukemia (29), T-cell prolymphocytic leukemia (3), hairy cell leukemia (1), adult T-cell leukemia/lymphoma (ATLL) (1), marginal zone leukemia (1), large granular lymphocyte leukemia (2), acute lymphoblastic leukemia (1), and T-cell lymphoma (2). Patients received various alemtuzumab-containing regimens, including single agent (5) or combined with: rituximab (2), pentostatin (6), fludarabine, cyclophosphamide, and rituximab (23), or fractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone (hyper-CVAD) (4). Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation. None of the 20 patients randomized to valganciclovir experienced CMV reactivation (P = .004). In conclusion, this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab. This trial was registered at www.ClinicalTrials.gov as #NCT00562770.",Journal Article,4439.0,70.0,Alemtuzumab is an immunosuppressive antibody that depletes normal T cells and B cells Prophylaxis for herpes virus and Pneumocystis carinii is standard with this agent Approximately 20 to 25 of patients will experience cytomegalovirus CMV reactivation We conducted a randomized trial wherein patients being treated with an alemtuzumab-containing regimen received prophylaxis with either valaciclovir 500 mg orally daily or valganciclovir 450 mg orally twice daily The study design planned to enroll 128 patients but stopping rules for early termination were met Forty patients were evaluable Median age was 58 years range 25-83 years median number of prior therapies was 2 range 0-10 Diagnoses included chronic lymphocytic 29 T-cell prolymphocytic 3 hairy cell 1 adult T-cell leukemia/lymphoma ATLL 1 marginal zone 1 large granular lymphocyte 2 acute lymphoblastic 1 and T-cell 2 Patients received various alemtuzumab-containing regimens including single agent 5 or combined with rituximab 2 pentostatin 6 fludarabine cyclophosphamide and rituximab 23 or fractionated cyclophosphamide vincristine adriamycin and dexamethasone hyper-CVAD 4 Seven of 20 patients enrolled on the valaciclovir arm experienced CMV reactivation None of the 20 patients randomized to valganciclovir experienced CMV reactivation P .004 In conclusion this agent was highly effective for prophylaxis of CMV reactivation in patients receiving alemtuzumab This trial was registered at www.ClinicalTrials.gov as NCT00562770,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3579, 16, 35, 2989, 548, 17, 15243, 295, 102, 37, 2, 132, 37, 2049, 9, 4716, 1450, 2, 13243, 21967, 16, 260, 5, 26, 420, 705, 179, 6, 243, 1, 7, 303, 730, 7314, 3879, 3834, 21, 426, 8, 384, 160, 7893, 7, 486, 73, 5, 35, 3579, 1101, 477, 103, 2049, 5, 361, 44949, 1666, 81, 1428, 391, 15, 44950, 5669, 81, 1428, 936, 391, 3, 45, 771, 1465, 6, 6559, 3990, 7, 84, 6811, 8679, 9, 191, 7202, 11, 543, 1213, 7, 11, 859, 52, 89, 10, 717, 60, 184, 243, 852, 60, 52, 207, 1, 324, 235, 10, 18, 184, 13, 79, 2403, 159, 442, 1193, 462, 102, 31, 14779, 27, 7152, 31, 14, 780, 102, 31, 2647, 4763, 12416, 14, 3450, 3614, 14, 375, 7694, 1448, 18, 286, 1275, 14, 2, 102, 31, 18, 7, 103, 747, 3579, 1101, 472, 141, 226, 420, 33, 15, 397, 5, 855, 18, 7596, 49, 2027, 1112, 2, 855, 382, 15, 3950, 1112, 2132, 7700, 2, 1217, 4855, 5574, 39, 648, 1, 179, 7, 346, 23, 3, 44949, 475, 592, 3879, 3834, 1292, 1, 3, 179, 7, 384, 6, 44950, 592, 3879, 3834, 19, 1520, 4, 1221, 26, 420, 10, 561, 323, 9, 2049, 1, 3879, 3834, 4, 7, 357, 3579, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 56693]",1493.0,18039954,41
"In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993).",Blood,Blood,2007-11-29,"An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic leukemia (ALL) and compare autologous transplantation with standard chemotherapy. Patients received 2 phases of induction and, if in remission, were assigned to allogeneic transplantation if they had a compatible sibling donor. Other patients were randomized to chemotherapy for 2.5 years versus an autologous transplantation. A donor versus no-donor analysis showed that Philadelphia chromosome-negative patients with a donor had a 5-year improved overall survival (OS), 53% versus 45% (P = .01), and the relapse rate was significantly lower (P < or = .001). The survival difference was significant in standard-risk patients, but not in high-risk patients with a high nonrelapse mortality rate in the high-risk donor group. Patients randomized to chemotherapy had a higher 5-year OS (46%) than those randomized to autologous transplantation (37%; P = .03). Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients. However, the transplantation-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk. There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group. This study is registered at http://clinicaltrials.gov as NCT00002514.",Journal Article,4436.0,478.0,An international collaboration was set up to prospectively evaluate the role of allogeneic transplantation for adults with acute lymphoblastic ALL and compare autologous transplantation with standard chemotherapy Patients received 2 phases of induction and if in remission were assigned to allogeneic transplantation if they had a compatible sibling donor Other patients were randomized to chemotherapy for 2.5 years versus an autologous transplantation A donor versus no-donor analysis showed that Philadelphia chromosome-negative patients with a donor had a 5-year improved overall survival OS 53 versus 45 P .01 and the relapse rate was significantly lower P or .001 The survival difference was significant in standard-risk patients but not in high-risk patients with a high nonrelapse mortality rate in the high-risk donor group Patients randomized to chemotherapy had a higher 5-year OS 46 than those randomized to autologous transplantation 37 P .03 Matched related allogeneic transplantations for ALL in first complete remission provide the most potent antileukemic therapy and considerable survival benefit for standard-risk patients However the transplantation-related mortality for high-risk older patients was unacceptably high and abrogated the reduction in relapse risk There is no evidence that a single autologous transplantation can replace consolidation/maintenance in any risk group This study is registered at http //clinicaltrials.gov as NCT00002514,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[35, 944, 4119, 10, 916, 126, 6, 1143, 376, 3, 200, 1, 1063, 497, 9, 857, 5, 286, 1275, 62, 2, 932, 1028, 497, 5, 260, 56, 7, 103, 18, 3523, 1, 504, 2, 492, 4, 734, 11, 896, 6, 1063, 497, 492, 491, 42, 8, 7293, 3684, 1488, 127, 7, 11, 384, 6, 56, 9, 18, 33, 60, 185, 35, 1028, 497, 8, 1488, 185, 77, 1488, 65, 224, 17, 3006, 1170, 199, 7, 5, 8, 1488, 42, 8, 33, 111, 231, 63, 25, 118, 699, 185, 512, 19, 355, 2, 3, 429, 116, 10, 97, 280, 19, 15, 144, 3, 25, 523, 10, 93, 4, 260, 43, 7, 84, 44, 4, 64, 43, 7, 5, 8, 64, 4640, 282, 116, 4, 3, 64, 43, 1488, 87, 7, 384, 6, 56, 42, 8, 142, 33, 111, 118, 641, 76, 135, 384, 6, 1028, 497, 567, 19, 680, 655, 139, 1063, 6779, 9, 62, 4, 157, 236, 734, 377, 3, 96, 1157, 4512, 36, 2, 2658, 25, 247, 9, 260, 43, 7, 137, 3, 497, 139, 282, 9, 64, 43, 434, 7, 10, 11934, 64, 2, 3728, 3, 628, 4, 429, 43, 125, 16, 77, 241, 17, 8, 226, 1028, 497, 122, 7195, 2173, 1146, 4, 500, 43, 87, 26, 45, 16, 1653, 28, 5196, 1252, 1239, 22, 31193]",1469.0,18048644,470
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2007-12-04,"Acute lymphoblastic leukemia (ALL) is the most common childhood cancer, whereas acute myeloid leukemia (AML) is the most common acute leukemia in adults. In general, ALL has a better prognosis than AML. To understand the distinct mechanisms in leukemogenesis between ALL and AML and to identify markers for diagnosis and treatment, we performed a large-scale genome-wide microRNA (miRNA, miR) expression profiling assay and identified 27 miRNAs that are differentially expressed between ALL and AML. Among them, miR-128a and -128b are significantly overexpressed, whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML. They are the most discriminatory miRNAs between ALL and AML. Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of >95% in the diagnosis of ALL and AML. The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98 acute leukemia samples covering most of the common cytogenetic subtypes, along with 10 normal control samples. Furthermore, we found that overexpression of miR-128 in ALL was at least partly associated with promoter hypomethylation and not with an amplification of its genomic locus. Taken together, we showed that expression signatures of as few as two miRNAs could accurately discriminate ALL from AML, and that epigenetic regulation might play an important role in the regulation of expression of miRNAs in acute leukemias.",Journal Article,4431.0,350.0,Acute lymphoblastic ALL is the most common childhood cancer whereas acute myeloid AML is the most common acute in adults In general ALL has a better prognosis than AML To understand the distinct mechanisms in leukemogenesis between ALL and AML and to identify markers for diagnosis and treatment we performed a large-scale genome-wide microRNA miRNA miR expression profiling assay and identified 27 miRNAs that are differentially expressed between ALL and AML Among them miR-128a and -128b are significantly overexpressed whereas let-7b and miR-223 are significantly down-regulated in ALL compared with AML They are the most discriminatory miRNAs between ALL and AML Using the expression signatures of a minimum of two of these miRNAs resulted in an accuracy rate of 95 in the diagnosis of ALL and AML The differential expression patterns of these four miRNAs were validated further through large-scale real-time PCR on 98 acute samples covering most of the common cytogenetic subtypes along with 10 normal control samples Furthermore we found that overexpression of miR-128 in ALL was at least partly associated with promoter hypomethylation and not with an amplification of its genomic locus Taken together we showed that expression signatures of as few as two miRNAs could accurately discriminate ALL from AML and that epigenetic regulation might play an important role in the regulation of expression of miRNAs in acute leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 3, 96, 186, 864, 12, 547, 286, 533, 329, 16, 3, 96, 186, 286, 4, 857, 4, 1083, 62, 71, 8, 380, 356, 76, 329, 6, 1640, 3, 834, 483, 4, 5661, 59, 62, 2, 329, 2, 6, 255, 525, 9, 147, 2, 24, 21, 173, 8, 375, 1124, 898, 1019, 3213, 2053, 722, 55, 1080, 719, 2, 108, 428, 2028, 17, 32, 2478, 570, 59, 62, 2, 329, 107, 1370, 722, 56725, 2, 56726, 32, 97, 1711, 547, 4642, 16856, 2, 722, 3907, 32, 97, 1328, 1065, 4, 62, 72, 5, 329, 491, 32, 3, 96, 7276, 2028, 59, 62, 2, 329, 75, 3, 55, 2210, 1, 8, 2499, 1, 100, 1, 46, 2028, 627, 4, 35, 1190, 116, 1, 48, 4, 3, 147, 1, 62, 2, 329, 3, 1777, 55, 764, 1, 46, 294, 2028, 11, 938, 195, 298, 375, 1124, 1589, 98, 604, 23, 1096, 286, 347, 9296, 96, 1, 3, 186, 1266, 814, 1510, 5, 79, 295, 182, 347, 798, 21, 204, 17, 851, 1, 722, 3990, 4, 62, 10, 28, 506, 5180, 41, 5, 973, 4441, 2, 44, 5, 35, 1073, 1, 211, 572, 2474, 1633, 1162, 21, 224, 17, 55, 2210, 1, 22, 1021, 22, 100, 2028, 359, 2141, 5696, 62, 29, 329, 2, 17, 1418, 863, 822, 1343, 35, 305, 200, 4, 3, 863, 1, 55, 1, 2028, 4, 286, 2792]",1433.0,18056805,1
BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.,Blood,Blood,2007-12-04,"Cancer cells acquire disruptions in normal signal transduction pathways and homeostatic mechanisms that would trigger apoptosis in normal cells. These abnormalities include genomic instability, oncogene activation, and growth factor independent proliferation. Therefore, cancer cells likely require a block in apoptosis in order to survive. Overexpression of the antiapoptotic protein BCL-2 provides a block in apoptosis that is frequently observed in cancer cells. We have developed methods for the detection and analysis of BCL-2 dependence and here apply them to acute lymphoblastic leukemia (ALL). BH3 profiling, a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway, indicated a dependence on BCL-2 of both ALL cell lines and primary samples. This dependence predicted that BCL-2 would be complexed with select pro-death BH3 family proteins, a prediction confirmed by the isolation of BCL-2 complexes with BIM. Furthermore, the BH3 profiling and protein analysis predicted that ALL cell lines and primary cells would be sensitive to ABT-737 as a single agent. Finally, BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines. The ALL cells studied exhibit BCL-2 dependence, supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies.",Journal Article,4431.0,147.0,Cancer cells acquire disruptions in normal signal transduction pathways and homeostatic mechanisms that would trigger apoptosis in normal cells These abnormalities include genomic instability oncogene activation and growth factor independent proliferation Therefore cancer cells likely require a block in apoptosis in order to survive Overexpression of the antiapoptotic protein BCL-2 provides a block in apoptosis that is frequently observed in cancer cells We have developed methods for the detection and analysis of BCL-2 dependence and here apply them to acute lymphoblastic ALL BH3 profiling a mitochondrial assay that classifies blocks in the intrinsic apoptotic pathway indicated a dependence on BCL-2 of both ALL cell lines and primary samples This dependence predicted that BCL-2 would be complexed with select pro-death BH3 family proteins a prediction confirmed by the isolation of BCL-2 complexes with BIM Furthermore the BH3 profiling and protein analysis predicted that ALL cell lines and primary cells would be sensitive to ABT-737 as a single agent Finally BH3 profiling and protein studies accurately predicted a relative degree of sensitivity to BCL-2 antagonism in cell lines The ALL cells studied exhibit BCL-2 dependence supporting clinical trials of BCL-2 antagonists in ALL as single agents or combination therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[12, 37, 6206, 11594, 4, 295, 1235, 2761, 460, 2, 11334, 483, 17, 688, 5781, 351, 4, 295, 37, 46, 1171, 643, 572, 1753, 1836, 363, 2, 129, 161, 306, 457, 673, 12, 37, 322, 1353, 8, 2381, 4, 351, 4, 1732, 6, 4573, 851, 1, 3, 4176, 178, 1044, 18, 777, 8, 2381, 4, 351, 17, 16, 746, 164, 4, 12, 37, 21, 47, 276, 636, 9, 3, 638, 2, 65, 1, 1044, 18, 3721, 2, 467, 4930, 1370, 6, 286, 1275, 62, 5486, 1080, 8, 2019, 719, 17, 15295, 2860, 4, 3, 2354, 1631, 308, 1103, 8, 3721, 23, 1044, 18, 1, 110, 62, 31, 285, 2, 86, 347, 26, 3721, 783, 17, 1044, 18, 688, 40, 17102, 5, 1717, 1805, 273, 5486, 607, 652, 8, 1590, 557, 20, 3, 5019, 1, 1044, 18, 3817, 5, 3595, 798, 3, 5486, 1080, 2, 178, 65, 783, 17, 62, 31, 285, 2, 86, 37, 688, 40, 745, 6, 3095, 4933, 22, 8, 226, 420, 1368, 5486, 1080, 2, 178, 94, 2141, 783, 8, 580, 1444, 1, 485, 6, 1044, 18, 7537, 4, 31, 285, 3, 62, 37, 656, 2239, 1044, 18, 3721, 1912, 38, 143, 1, 1044, 18, 4444, 4, 62, 22, 226, 183, 15, 150, 235]",1338.0,18056841,645
SOS1 mutations are rare in human malignancies: implications for Noonan Syndrome patients.,"Genes, chromosomes & cancer",Genes Chromosomes Cancer,2008-03-01,"Germ line gain-of-function mutations in several members of the RAS/ERK pathway, including PTPN11, KRAS, and RAF1, cause the autosomal dominant genetic disorder Noonan Syndrome (NS). NS patients are at increased risk of leukemia/myeloproliferative disease and possibly some solid tumors, such as neuroblastoma. Recently, SOS1 gain of function mutations have also been shown to cause NS. Somatic PTPN11, KRAS, and RAF1 mutations occur (although at different frequencies) in a variety of sporadic neoplasms, but whether SOS1 mutations are associated with human cancer has not been evaluated. We sequenced DNA from a total of 810 primary malignancies, including pancreatic, lung, breast, and colon carcinomas, and acute myelogenous leukemia, as well as several neuroblastoma cell lines. From this large, diverse series, missense SOS1 mutations were identified in a single pancreatic tumor, one lung adenocarcinoma, and a T-cell acute lymphoblastic leukemia cell line. Our findings suggest that SOS1 is not a significant human oncogene in most cancers. Furthermore, NS patients with SOS1 mutations may not be at increased risk of developing cancer.",Journal Article,4343.0,28.0,Germ line gain-of-function mutations in several members of the RAS/ERK pathway including PTPN11 KRAS and RAF1 cause the autosomal dominant genetic disorder Noonan Syndrome NS NS patients are at increased risk of leukemia/myeloproliferative disease and possibly some solid tumors such as Recently SOS1 gain of function mutations have also been shown to cause NS Somatic PTPN11 KRAS and RAF1 mutations occur although at different frequencies in a variety of sporadic neoplasms but whether SOS1 mutations are associated with human cancer has not been evaluated We sequenced DNA from a total of 810 primary malignancies including and carcinomas and acute myelogenous as well as several cell lines From this large diverse series missense SOS1 mutations were identified in a single tumor one adenocarcinoma and a T-cell acute lymphoblastic cell line Our findings suggest that SOS1 is not a significant human oncogene in most cancers Furthermore NS patients with SOS1 mutations may not be at increased risk of developing cancer,1,1,1,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2280, 328, 1803, 1, 343, 138, 4, 392, 1684, 1, 3, 1102, 1819, 308, 141, 8403, 723, 2, 13997, 708, 3, 6084, 2156, 336, 2645, 26240, 681, 4044, 4044, 7, 32, 28, 101, 43, 1, 2647, 10857, 34, 2, 2150, 476, 537, 57, 225, 22, 761, 15360, 1803, 1, 343, 138, 47, 120, 85, 443, 6, 708, 4044, 1119, 8403, 723, 2, 13997, 138, 1271, 242, 28, 338, 2722, 4, 8, 1362, 1, 1928, 1179, 84, 317, 15360, 138, 32, 41, 5, 171, 12, 71, 44, 85, 194, 21, 4040, 261, 29, 8, 181, 1, 13882, 86, 441, 141, 2, 826, 2, 286, 2194, 22, 149, 22, 392, 31, 285, 29, 26, 375, 1867, 988, 4007, 15360, 138, 11, 108, 4, 8, 226, 30, 104, 449, 2, 8, 102, 31, 286, 1275, 31, 328, 114, 272, 309, 17, 15360, 16, 44, 8, 93, 171, 1836, 4, 96, 163, 798, 4044, 7, 5, 15360, 138, 68, 44, 40, 28, 101, 43, 1, 931, 12]",1020.0,18064648,83
Alu elements mediate MYB gene tandem duplication in human T-ALL.,The Journal of experimental medicine,J. Exp. Med.,2007-12-10,"Recent studies have demonstrated that the MYB oncogene is frequently duplicated in human T cell acute lymphoblastic leukemia (T-ALL). We find that the human MYB locus is flanked by 257-bp Alu repeats and that the duplication is mediated somatically by homologous recombination between the flanking Alu elements on sister chromatids. Nested long-range PCR analysis indicated a low frequency of homologous recombination leading to MYB tandem duplication in the peripheral blood mononuclear cells of approximately 50% of healthy individuals, none of whom had a MYB duplication in the germline. We conclude that Alu-mediated MYB tandem duplication occurs at low frequency during normal thymocyte development and is clonally selected during the molecular pathogenesis of human T-ALL.",Journal Article,4425.0,59.0,Recent studies have demonstrated that the MYB oncogene is frequently duplicated in human T cell acute lymphoblastic T-ALL We find that the human MYB locus is flanked by 257-bp Alu repeats and that the duplication is mediated somatically by homologous recombination between the flanking Alu elements on sister chromatids Nested long-range PCR analysis indicated a low frequency of homologous recombination leading to MYB tandem duplication in the peripheral blood mononuclear cells of approximately 50 of healthy individuals none of whom had a MYB duplication in the germline We conclude that Alu-mediated MYB tandem duplication occurs at low frequency during normal thymocyte development and is clonally selected during the molecular pathogenesis of human T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 94, 47, 264, 17, 3, 6929, 1836, 16, 746, 13330, 4, 171, 102, 31, 286, 1275, 102, 62, 21, 2469, 17, 3, 171, 6929, 2474, 16, 33760, 20, 7941, 3044, 15265, 7197, 2, 17, 3, 4616, 16, 517, 12293, 20, 3894, 4017, 59, 3, 12472, 15265, 2531, 23, 17101, 44971, 4789, 319, 184, 604, 65, 1103, 8, 154, 675, 1, 3894, 4017, 1049, 6, 6929, 2905, 4616, 4, 3, 672, 315, 3041, 37, 1, 705, 212, 1, 1331, 869, 1292, 1, 953, 42, 8, 6929, 4616, 4, 3, 1009, 21, 2060, 17, 15265, 517, 6929, 2905, 4616, 1780, 28, 154, 675, 190, 295, 16236, 193, 2, 16, 9157, 715, 190, 3, 219, 1384, 1, 171, 102, 62]",761.0,18070937,5
"Three new drugs for acute lymphoblastic leukemia: nelarabine, clofarabine, and forodesine.",Seminars in oncology,Semin. Oncol.,2007-12-01,"The search for more effective and safer anti-leukemia therapies has led to the identification of several new agents that show activity against specific types of acute lymphoblastic leukemia (ALL). Recently, three novel purine nucleoside analogues (nelarabine, clofarabine, and forodesine) have shown promising activity in patients with relapsed or refractory ALL. Of these, nelarabine has shown clinically meaningful benefit in patients with T-cell ALL, with overall response rates ranging from 33% to 60%, the induction of durable complete remissions, and an overall 1-year survival rate of 28% in adults. Clofarabine has also shown promising clinical activity in pediatric patients, with an overall response rate of 30%, and some patients are able to proceed to allogeneic hematopoietic cell transplantation. Forodesine is the most recent novel agent, with a unique mechanism that has shown single-agent activity in relapsed and refractory T- and B-cell leukemias and cutaneous lymphomas. Although clinical experience is limited, treatment-related toxicities appear to be mild. The rationale, pharmacology, and clinical experience to date with these agents in the treatment of patients with refractory acute leukemia are reviewed, with a highlight on ALL.",Journal Article,4434.0,22.0,The search for more effective and safer anti-leukemia therapies has led to the identification of several new agents that show activity against specific types of acute lymphoblastic ALL Recently three novel purine nucleoside analogues nelarabine clofarabine and forodesine have shown promising activity in patients with relapsed or refractory ALL Of these nelarabine has shown clinically meaningful benefit in patients with T-cell ALL with overall response rates ranging from 33 to 60 the induction of durable complete remissions and an overall 1-year survival rate of 28 in adults Clofarabine has also shown promising clinical activity in pediatric patients with an overall response rate of 30 and some patients are able to proceed to allogeneic hematopoietic cell transplantation Forodesine is the most recent novel agent with a unique mechanism that has shown single-agent activity in relapsed and refractory T- and B-cell leukemias and cutaneous lymphomas Although clinical experience is limited treatment-related toxicities appear to be mild The rationale pharmacology and clinical experience to date with these agents in the treatment of patients with refractory acute are reviewed with a highlight on ALL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1901, 9, 80, 323, 2, 9276, 312, 2647, 235, 71, 836, 6, 3, 911, 1, 392, 217, 183, 17, 514, 128, 480, 112, 630, 1, 286, 1275, 62, 761, 169, 229, 5006, 4032, 4768, 13149, 4149, 2, 10483, 47, 443, 721, 128, 4, 7, 5, 591, 15, 430, 62, 1, 46, 13149, 71, 443, 505, 2538, 247, 4, 7, 5, 102, 31, 62, 5, 63, 51, 151, 2223, 29, 466, 6, 335, 3, 504, 1, 1480, 236, 3166, 2, 35, 63, 14, 111, 25, 116, 1, 339, 4, 857, 4149, 71, 120, 443, 721, 38, 128, 4, 815, 7, 5, 35, 63, 51, 116, 1, 201, 2, 476, 7, 32, 1665, 6, 6174, 6, 1063, 1007, 31, 497, 10483, 16, 3, 96, 435, 229, 420, 5, 8, 991, 670, 17, 71, 443, 226, 420, 128, 4, 591, 2, 430, 102, 2, 132, 31, 2792, 2, 1486, 1557, 242, 38, 730, 16, 383, 24, 139, 385, 1322, 6, 40, 1980, 3, 1728, 6852, 2, 38, 730, 6, 1244, 5, 46, 183, 4, 3, 24, 1, 7, 5, 430, 286, 32, 446, 5, 8, 1817, 23, 62]",1210.0,18086342,624
Forodesine treatment and post-transplant graft-versus-host disease in two patients with acute leukemia: facilitation of graft-versus-leukemia effect?,Seminars in oncology,Semin. Oncol.,2007-12-01,"This article presents two case studies of patients diagnosed with T-cell acute lymphoblastic leukemia who relapsed following allogeneic hematopoietic stem cell transplantation and were subsequently enrolled in a clinical trial in which they received forodesine hydrochloride, a rationally designed, potent, transition-state inhibitor of purine nucleoside phosphorylase. Forodesine induced complete remission in both patients. Graft-versus-host disease developed subsequently but was treated successfully with conventional immunosuppressive therapy. Both patients remain in complete remission at the most recent follow-up. We hypothesize that forodesine contributed to a primary anti-leukemic cytotoxic effect as well as a secondary immunologic effect by allowing the development of an ongoing graft-versus-leukemia effect in these patients.",Case Reports,4434.0,7.0,This article presents two case studies of patients diagnosed with T-cell acute lymphoblastic who relapsed following allogeneic hematopoietic stem cell transplantation and were subsequently enrolled in a clinical trial in which they received forodesine hydrochloride a rationally designed potent transition-state inhibitor of purine nucleoside phosphorylase Forodesine induced complete remission in both patients Graft-versus-host disease developed subsequently but was treated successfully with conventional immunosuppressive therapy Both patients remain in complete remission at the most recent follow-up We hypothesize that forodesine contributed to a primary anti-leukemic cytotoxic effect as well as a secondary immunologic effect by allowing the development of an ongoing graft-versus-leukemia effect in these patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26, 946, 2740, 100, 473, 94, 1, 7, 265, 5, 102, 31, 286, 1275, 54, 591, 366, 1063, 1007, 452, 31, 497, 2, 11, 1611, 346, 4, 8, 38, 160, 4, 92, 491, 103, 10483, 12268, 8, 6352, 1114, 1157, 1970, 1309, 230, 1, 5006, 4032, 10658, 10483, 277, 236, 734, 4, 110, 7, 1599, 185, 1204, 34, 276, 1611, 84, 10, 73, 1878, 5, 809, 2989, 36, 110, 7, 918, 4, 236, 734, 28, 3, 96, 435, 166, 126, 21, 4919, 17, 10483, 3447, 6, 8, 86, 312, 2015, 759, 254, 22, 149, 22, 8, 568, 3042, 254, 20, 2952, 3, 193, 1, 35, 942, 1599, 185, 2647, 254, 4, 46, 7]",823.0,18086346,669
Acute lymphoblastic leukemia in a patient with chronic cyanoacrylate exposure.,Acta haematologica,Acta Haematol.,2007-12-18,"Environmental agents have long been thought to be linked to the development of malignancies. Due to the difficulty in identifying and verifying exposures to such agents, only a few chemical compounds are clearly linked to malignancies. We report here the case of a 36-year-old man with pre-B cell acute lymphoblastic leukemia. This patient was using industrial strength glue to reattach a chipped tooth for approximately 1 year, and such use was associated with chronic exposure of his oral mucosa to this glue. This case raises the possibility that chronic exposure to cyanoacrylates, the adhesive agents in industrial strength glue, may be associated with the development of acute lymphoblastic leukemia in humans.",Case Reports,4417.0,2.0,Environmental agents have long been thought to be linked to the development of malignancies Due to the difficulty in identifying and verifying exposures to such agents only a few chemical compounds are clearly linked to malignancies We report here the case of a 36-year-old man with pre-B cell acute lymphoblastic This patient was using industrial strength glue to reattach a chipped tooth for approximately 1 year and such use was associated with chronic exposure of his oral mucosa to this glue This case raises the possibility that chronic exposure to cyanoacrylates the adhesive agents in industrial strength glue may be associated with the development of acute lymphoblastic in humans,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3766, 183, 47, 319, 85, 2739, 6, 40, 1199, 6, 3, 193, 1, 441, 520, 6, 3, 4035, 4, 1386, 2, 24489, 3401, 6, 225, 183, 158, 8, 1021, 3743, 2411, 32, 2536, 1199, 6, 441, 21, 414, 467, 3, 473, 1, 8, 511, 111, 1095, 3628, 5, 671, 132, 31, 286, 1275, 26, 69, 10, 75, 23458, 3671, 34393, 6, 56772, 8, 56773, 14813, 9, 705, 14, 111, 2, 225, 119, 10, 41, 5, 442, 645, 1, 3224, 518, 2713, 6, 26, 34393, 26, 473, 5789, 3, 2526, 17, 442, 645, 6, 56774, 3, 18897, 183, 4, 23458, 3671, 34393, 68, 40, 41, 5, 3, 193, 1, 286, 1275, 4, 3218]",689.0,18087146,319
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study.,Blood,Blood,2007-12-21,"We examined the prognostic impact of cytogenetics on the outcome of 200 acute lymphoblastic leukemia (ALL) patients 15 to 65 years of age enrolled in Southwest Oncology Group (SWOG)-9400 study. Evaluable cytogenetics or fluorescence in situ hybridization studies were available in 140 (70%) patients. Four karyotype categories (normal [n = 31, 22%], t(9;22)/BCR/ABL1 [n = 36, 26%], other unfavorable [-7, +8, or 11q23 rearrangement, n = 19, 13%], and miscellaneous [n = 54, 39%]) and the biologically and clinically relevant ALL ploidy subgroups were prospectively defined. Overall survival (OS) decreased significantly with increasing age (P = .009) and varied with karyotype category (P < .001). OS was worst for t(9;22)/BCR/ABL1 followed by other unfavorable karyotypes, with hazard ratios (HR) of 3.45 (95% confidence interval [CI], 1.88-6.31) and 2.14 (95% CI, 1.04-4.04), respectively, compared with normal diploid group. OS of the miscellaneous group was similar to that of the normal diploid group (HR = 0.82; 95% CI, 0.44-1.53). Relapse-free survival (RFS) was not significantly associated with age (P = .30) but was heterogeneous among karyotype categories (P < .001) primarily because of poor RFS in t(9;22)/BCR/ABL1 (HR = 3.49; 95% CI, 1.80-6.75) compared with the normal diploid group. After accounting for the variation among karyotype groups, age was not a significant prognostic factor for OS or RFS, highlighting cytogenetics as the most important prognostic factor in adult ALL. This trial was registered at www.ClinicalTrials.gov as #NCT00002665.",Journal Article,4414.0,141.0,We examined the prognostic impact of cytogenetics on the outcome of 200 acute lymphoblastic ALL patients 15 to 65 years of age enrolled in Southwest Oncology Group SWOG -9400 study Evaluable cytogenetics or fluorescence in situ hybridization studies were available in 140 70 patients Four karyotype categories normal n 31 22 t 9 22 /BCR/ABL1 n 36 26 other unfavorable -7 +8 or 11q23 rearrangement n 19 13 and miscellaneous n 54 39 and the biologically and clinically relevant ALL ploidy subgroups were prospectively defined Overall survival OS decreased significantly with increasing age P .009 and varied with karyotype category P .001 OS was worst for t 9 22 /BCR/ABL1 followed by other unfavorable karyotypes with hazard ratios HR of 3.45 95 confidence interval CI 1.88-6.31 and 2.14 95 CI 1.04-4.04 respectively compared with normal diploid group OS of the miscellaneous group was similar to that of the normal diploid group HR 0.82 95 CI 0.44-1.53 Relapse-free survival RFS was not significantly associated with age P .30 but was heterogeneous among karyotype categories P .001 primarily because of poor RFS in t 9 22 /BCR/ABL1 HR 3.49 95 CI 1.80-6.75 compared with the normal diploid group After accounting for the variation among karyotype groups age was not a significant prognostic factor for OS or RFS highlighting cytogenetics as the most important prognostic factor in adult ALL This trial was registered at www.ClinicalTrials.gov as NCT00002665,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 409, 3, 177, 345, 1, 2510, 23, 3, 228, 1, 1250, 286, 1275, 62, 7, 167, 6, 556, 60, 1, 89, 346, 4, 6625, 413, 87, 5462, 56790, 45, 859, 2510, 15, 1591, 4, 957, 1554, 94, 11, 390, 4, 3304, 431, 7, 294, 3385, 1996, 295, 78, 456, 350, 102, 83, 350, 1062, 3557, 78, 511, 432, 127, 2483, 67, 66, 15, 7975, 2675, 78, 326, 233, 2, 15106, 78, 667, 587, 2, 3, 2665, 2, 505, 867, 62, 9032, 1453, 11, 1143, 395, 63, 25, 118, 340, 97, 5, 602, 89, 19, 2376, 2, 2051, 5, 3385, 2169, 19, 144, 118, 10, 4066, 9, 102, 83, 350, 1062, 3557, 370, 20, 127, 2483, 6809, 5, 360, 1137, 168, 1, 27, 512, 48, 307, 268, 58, 14, 889, 49, 456, 2, 18, 213, 48, 58, 14, 755, 39, 755, 106, 72, 5, 295, 6815, 87, 118, 1, 3, 15106, 87, 10, 288, 6, 17, 1, 3, 295, 6815, 87, 168, 13, 878, 48, 58, 13, 584, 14, 699, 429, 115, 25, 1272, 10, 44, 97, 41, 5, 89, 19, 201, 84, 10, 1564, 107, 3385, 1996, 19, 144, 1561, 408, 1, 334, 1272, 4, 102, 83, 350, 1062, 3557, 168, 27, 739, 48, 58, 14, 493, 49, 481, 72, 5, 3, 295, 6815, 87, 50, 3116, 9, 3, 1380, 107, 3385, 271, 89, 10, 44, 8, 93, 177, 161, 9, 118, 15, 1272, 4051, 2510, 22, 3, 96, 305, 177, 161, 4, 780, 62, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 56791]",1457.0,18156492,657
A prognostic score for patients with acute leukemia or myelodysplastic syndromes undergoing allogeneic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2007-11-26,"Allogeneic hematopoietic stem cell transplantation (SCT) has the potential to cure patients with acute leukemia or myelodysplastic syndromes (MDS), but a number of prognostic factors can influence the outcome of transplantation. At present, no transplantation-specific risk score exists for this patient population. We propose a simple scoring system for patients with acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), or MDS, based on a retrospective analysis of 445 patients undergoing SCT at our institution (divided into training and validation subsets). The score depends on 5 variables: age, disease, stage at transplantation, cytogenetics, and pretransplantation ferritin. It divides patients into 3 groups of comparable size, with 5-year overall survival (OS) of 56% (low risk), 22% (intermediate risk), and 5% (high risk). This prognostic score could be useful in making treatment decisions for individual patients, in stratifying patients entering clinical trials, and in adjusting transplantation outcomes across centers under the new federal reporting rules.",Journal Article,4439.0,49.0,Allogeneic hematopoietic stem cell transplantation SCT has the potential to cure patients with acute or syndromes MDS but a number of prognostic factors can influence the outcome of transplantation At present no transplantation-specific risk score exists for this patient population We propose a simple scoring system for patients with acute myelogenous AML acute lymphoblastic ALL or MDS based on a retrospective analysis of 445 patients undergoing SCT at our institution divided into training and validation subsets The score depends on 5 variables age disease stage at transplantation cytogenetics and pretransplantation ferritin It divides patients into 3 groups of comparable size with 5-year overall survival OS of 56 low risk 22 intermediate risk and 5 high risk This prognostic score could be useful in making treatment decisions for individual patients in stratifying patients entering clinical trials and in adjusting transplantation outcomes across centers under the new federal reporting rules,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 1988, 71, 3, 174, 6, 1722, 7, 5, 286, 15, 2040, 1223, 84, 8, 207, 1, 177, 130, 122, 1054, 3, 228, 1, 497, 28, 364, 77, 497, 112, 43, 368, 2481, 9, 26, 69, 266, 21, 2548, 8, 2763, 2504, 398, 9, 7, 5, 286, 2194, 329, 286, 1275, 62, 15, 1223, 90, 23, 8, 459, 65, 1, 9398, 7, 479, 1988, 28, 114, 731, 2176, 237, 1741, 2, 929, 1890, 3, 368, 3828, 23, 33, 682, 89, 34, 82, 28, 497, 2510, 2, 9367, 9101, 192, 19735, 7, 237, 27, 271, 1, 1279, 444, 5, 33, 111, 63, 25, 118, 1, 664, 154, 43, 350, 919, 43, 2, 33, 64, 43, 26, 177, 368, 359, 40, 999, 4, 1079, 24, 1526, 9, 797, 7, 4, 5035, 7, 7653, 38, 143, 2, 4, 1358, 497, 123, 716, 1168, 669, 3, 217, 8536, 1760, 8679]",1005.0,18158958,248
"Relationships among severity of osteonecrosis, pain, range of motion, and functional mobility in children, adolescents, and young adults with acute lymphoblastic leukemia.",Physical therapy,Phys Ther,2008-01-17,"Up to 38% of children receiving treatment for acute lymphoblastic leukemia (ALL) develop osteonecrosis, often without symptoms. Little is known about the association between the degree of osteonecrosis and functional mobility in this population. The purpose of this study was to examine relationships among the degree of osteonecrosis, pain, range of motion (ROM), and functional mobility in people with ALL. Thirty-three subjects aged 5 to 27 years with ALL and osteonecrosis participated. The extent of osteonecrosis was determined by magnetic resonance imaging (MRI) of the hip and knee according to 2 classification systems, including the Association Research Circulation Osseous (ARCO) and a knee staging scale. Pain, hip and knee ROM, and the Timed Up and Down Stairs (TUDS) Test were used as measures. Correlations were observed between ARCO and hip pain (r=.34), between hip flexion ROM and hip pain (r=-.34), and between knee pain and time on the TUDS Test (r=-.35). Physical therapists should consider that people with ALL may have hip or knee osteonecrosis without clinical symptoms. This notion supports the need for MRI in addition to a comprehensive examination of functional mobility.",Journal Article,4387.0,27.0,Up to 38 of children receiving treatment for acute lymphoblastic ALL develop osteonecrosis often without symptoms Little is known about the association between the degree of osteonecrosis and functional mobility in this population The purpose of this study was to examine relationships among the degree of osteonecrosis pain range of motion ROM and functional mobility in people with ALL Thirty-three subjects aged 5 to 27 years with ALL and osteonecrosis participated The extent of osteonecrosis was determined by magnetic resonance imaging MRI of the hip and knee according to 2 classification systems including the Association Research Circulation Osseous ARCO and a knee staging scale Pain hip and knee ROM and the Timed Up and Down Stairs TUDS Test were used as measures Correlations were observed between ARCO and hip pain r=.34 between hip flexion ROM and hip pain r=-.34 and between knee pain and time on the TUDS Test r=-.35 Physical therapists should consider that people with ALL may have hip or knee osteonecrosis without clinical symptoms This notion supports the need for MRI in addition to a comprehensive examination of functional mobility,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[126, 6, 519, 1, 541, 357, 24, 9, 286, 1275, 62, 690, 5404, 629, 187, 507, 1215, 16, 440, 545, 3, 248, 59, 3, 1444, 1, 5404, 2, 583, 5717, 4, 26, 266, 3, 743, 1, 26, 45, 10, 6, 1004, 2467, 107, 3, 1444, 1, 5404, 559, 184, 1, 2967, 17113, 2, 583, 5717, 4, 3788, 5, 62, 977, 169, 976, 1032, 33, 6, 428, 60, 5, 62, 2, 5404, 3025, 3, 1039, 1, 5404, 10, 509, 20, 1484, 1535, 270, 704, 1, 3, 5628, 2, 12013, 768, 6, 18, 947, 1530, 141, 3, 248, 389, 4984, 5230, 45003, 2, 8, 12013, 632, 1124, 559, 5628, 2, 12013, 17113, 2, 3, 12200, 126, 2, 1328, 31218, 45004, 412, 11, 95, 22, 1018, 2553, 11, 164, 59, 45003, 2, 5628, 559, 668, 562, 59, 5628, 45005, 17113, 2, 5628, 559, 668, 562, 2, 59, 12013, 559, 2, 98, 23, 3, 45004, 412, 668, 465, 900, 22462, 257, 2419, 17, 3788, 5, 62, 68, 47, 5628, 15, 12013, 5404, 187, 38, 507, 26, 6691, 2304, 3, 594, 9, 704, 4, 352, 6, 8, 949, 1385, 1, 583, 5717]",1155.0,18202079,341
Diabetic ketoacidosis during therapy for pediatric acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2008-06-01,"Hyperglycemia is common during therapy for acute lymphoblastic leukemia (ALL), but diabetic ketoacidosis (DKA) occurs rarely. Morbidity due to DKA in children with ALL has not been systematically studied. We reviewed risk factors and clinical consequences of DKA in patients undergoing therapy for ALL at SJCRH between 1991 and 2006. DKA occurred in 6 of 797 evaluable patients. Only older age at diagnosis of ALL was a risk factor for DKA. Four of six patients with DKA as compared to 232 of the other 791 patients were older than 10 years (P = 0.03). Race, sex, body mass index, leukemia immunophenotype, ALL risk category, white blood cell count at diagnosis, and treatment protocol were not associated with DKA. All patients were managed with intravenous fluids, dietary modification, and short-term use of insulin. Patients were hospitalized for 4-12 days, with a median ICU stay of 1 day. In two patients, correction of hyperglycemia was too rapid, and two others experienced hypoglycemia due to insulin therapy. There were no permanent complications of DKA or its treatment. No patient required long-term insulin use. No patient had recurrent DKA; only one of the six patients had a subsequent hyperglycemia episode. All six patients are alive in remission 6-13 years after diagnosis. Patients with hyperglycemia during treatment for ALL should be screened for clinical evidence of DKA, which may require more intensive supportive care than those without ketoacidosis. The occurrence of DKA should not lead to alteration of ALL treatment.",Journal Article,4251.0,35.0,Hyperglycemia is common during therapy for acute lymphoblastic ALL but diabetic ketoacidosis DKA occurs rarely Morbidity due to DKA in children with ALL has not been systematically studied We reviewed risk factors and clinical consequences of DKA in patients undergoing therapy for ALL at SJCRH between 1991 and 2006 DKA occurred in 6 of 797 evaluable patients Only older age at diagnosis of ALL was a risk factor for DKA Four of six patients with DKA as compared to 232 of the other 791 patients were older than 10 years P 0.03 Race sex body mass index immunophenotype ALL risk category white blood cell count at diagnosis and treatment protocol were not associated with DKA All patients were managed with intravenous fluids dietary modification and short-term use of insulin Patients were hospitalized for 4-12 days with a median ICU stay of 1 day In two patients correction of hyperglycemia was too rapid and two others experienced hypoglycemia due to insulin therapy There were no permanent complications of DKA or its treatment No patient required long-term insulin use No patient had recurrent DKA only one of the six patients had a subsequent hyperglycemia episode All six patients are alive in remission 6-13 years after diagnosis Patients with hyperglycemia during treatment for ALL should be screened for clinical evidence of DKA which may require more intensive supportive care than those without ketoacidosis The occurrence of DKA should not lead to alteration of ALL treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3992, 16, 186, 190, 36, 9, 286, 1275, 62, 84, 5943, 25064, 20599, 1780, 2416, 787, 520, 6, 20599, 4, 541, 5, 62, 71, 44, 85, 3390, 656, 21, 446, 43, 130, 2, 38, 3255, 1, 20599, 4, 7, 479, 36, 9, 62, 28, 19696, 59, 3372, 2, 1324, 20599, 489, 4, 49, 1, 13379, 859, 7, 158, 434, 89, 28, 147, 1, 62, 10, 8, 43, 161, 9, 20599, 294, 1, 437, 7, 5, 20599, 22, 72, 6, 7186, 1, 3, 127, 14482, 7, 11, 434, 76, 79, 60, 19, 13, 680, 1047, 1035, 642, 782, 558, 5496, 62, 43, 2169, 886, 315, 31, 1276, 28, 147, 2, 24, 1182, 11, 44, 41, 5, 20599, 62, 7, 11, 2231, 5, 1262, 9332, 2013, 2437, 2, 978, 337, 119, 1, 1601, 7, 11, 4795, 9, 39, 133, 162, 5, 8, 52, 6195, 2020, 1, 14, 218, 4, 100, 7, 5360, 1, 3992, 10, 5044, 1321, 2, 100, 1749, 592, 13811, 520, 6, 1601, 36, 125, 11, 77, 4377, 521, 1, 20599, 15, 211, 24, 77, 69, 616, 319, 337, 1601, 119, 77, 69, 42, 387, 20599, 158, 104, 1, 3, 437, 7, 42, 8, 706, 3992, 6934, 62, 437, 7, 32, 1701, 4, 734, 49, 233, 60, 50, 147, 7, 5, 3992, 190, 24, 9, 62, 257, 40, 2261, 9, 38, 241, 1, 20599, 92, 68, 1353, 80, 1686, 1877, 165, 76, 135, 187, 25064, 3, 2291, 1, 20599, 257, 44, 1122, 6, 2611, 1, 62, 24]",1489.0,18266226,55
Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-03-01,"Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity. A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms (SMNs) in children with Hodgkin's disease. We report the absence of an association of SMNs in children with acute lymphoblastic leukemia (ALL) treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. Two hundred five children with high-risk (HR) ALL were randomly assigned to receive doxorubicin alone (n = 100) or doxorubicin with dexrazoxane (n = 105) during the induction and intensification phases of multiagent chemotherapy. We compared incidence of SMNs in these two groups. With a median follow-up of 6.2 years, no differences in the incidence of SMNs were noted between the group that received dexrazoxane and the group that did not (P = .66). One SMN (a melanoma located outside of the cranial radiation field) occurred in a patient who was randomly assigned to doxorubicin alone. No SMNs were observed in patients randomly assigned to receive dexrazoxane. Dexrazoxane was not associated with an increased risk of SMNs in children treated for HR ALL. Given the potential importance of dexrazoxane as a cardioprotectant, we recommend that dexrazoxane continue to be used and studied in doxorubicin-containing pediatric regimens.",Journal Article,4343.0,90.0,Dexrazoxane is a drug used to prevent anthracycline-induced cardiotoxicity A recent report found an association between the use of dexrazoxane and the risk of developing secondary malignant neoplasms SMNs in children with 's disease We report the absence of an association of SMNs in children with acute lymphoblastic ALL treated on Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 Two hundred five children with high-risk HR ALL were randomly assigned to receive doxorubicin alone n 100 or doxorubicin with dexrazoxane n 105 during the induction and intensification phases of multiagent chemotherapy We compared incidence of SMNs in these two groups With a median follow-up of 6.2 years no differences in the incidence of SMNs were noted between the group that received dexrazoxane and the group that did not P .66 One SMN a located outside of the cranial radiation field occurred in a patient who was randomly assigned to doxorubicin alone No SMNs were observed in patients randomly assigned to receive dexrazoxane Dexrazoxane was not associated with an increased risk of SMNs in children treated for HR ALL Given the potential importance of dexrazoxane as a cardioprotectant we recommend that dexrazoxane continue to be used and studied in doxorubicin-containing pediatric regimens,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8473, 16, 8, 234, 95, 6, 1682, 2044, 277, 4404, 8, 435, 414, 204, 35, 248, 59, 3, 119, 1, 8473, 2, 3, 43, 1, 931, 568, 393, 1179, 6580, 4, 541, 5, 292, 34, 21, 414, 3, 1127, 1, 35, 248, 1, 6580, 4, 541, 5, 286, 1275, 62, 73, 23, 4932, 4979, 12, 1377, 62, 2404, 1182, 48, 355, 100, 1128, 365, 541, 5, 64, 43, 168, 62, 11, 1108, 896, 6, 560, 856, 279, 78, 394, 15, 856, 5, 8473, 78, 3263, 190, 3, 504, 2, 5091, 3523, 1, 7148, 56, 21, 72, 287, 1, 6580, 4, 46, 100, 271, 5, 8, 52, 166, 126, 1, 49, 18, 60, 77, 362, 4, 3, 287, 1, 6580, 11, 1051, 59, 3, 87, 17, 103, 8473, 2, 3, 87, 17, 205, 44, 19, 700, 104, 6474, 8, 2308, 2513, 1, 3, 2565, 121, 1067, 489, 4, 8, 69, 54, 10, 1108, 896, 6, 856, 279, 77, 6580, 11, 164, 4, 7, 1108, 896, 6, 560, 8473, 8473, 10, 44, 41, 5, 35, 101, 43, 1, 6580, 4, 541, 73, 9, 168, 62, 447, 3, 174, 1187, 1, 8473, 22, 8, 28769, 21, 2237, 17, 8473, 1906, 6, 40, 95, 2, 656, 4, 856, 1101, 815, 472]",1294.0,18309945,109
"Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse.",Cancer,Cancer,2008-05-01,"The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse. Patients received topotecan (2.4 mg/m(2) daily as a 30-minute infusion) for 5 days before induction therapy with dexamethasone, vincristine, and asparaginase (native or pegylated Escherichia coli). The pharmacokinetics of topotecan were measured with the first dose of treatment in 23 patients. Twenty-eight of 31 patients with circulating blast cells were evaluable for response to topotecan. Twenty-five patients (89.3%) had a response (>25% decrease in circulating blast cells). The leukocyte count (P = .0001) and blast cell count (P = .0009) declined significantly during topotecan therapy. The median (range) topotecan lactone area under the concentration-time curve after the first dose was 85.4 L/hour/m(2) (range, 38.7-229.3 L/hour/m(2)). At the end of induction, 23 patients (74.2%) had a complete response, 1 patient (3.2%) had a partial response, 5 patients (16.1%) had no response, and 2 patients had died of infection. Six of the 17 patients who were studied for minimal residual disease (MRD) achieved MRD-negative status at the end of induction. The main toxicities were hematologic, gastrointestinal, and hepatic. The estimated 5-year survival rate, event-free survival rate, and cumulative incidence of second relapse were 24.1% +/- 7.9%, 18.2% +/- 7.4%, and 22.8% +/- 8.7%, respectively, in the 29 patients who had a hematologic first relapse. A regimen comprising single-agent topotecan given with a standard 3-drug combination was effective in inducing remission in pediatric patients with relapsed ALL and was tolerated well.","Clinical Trial, Phase II",4282.0,15.0,The authors evaluated the response rate toxicity and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic ALL in first relapse Patients received topotecan 2.4 mg/m 2 daily as a 30-minute infusion for 5 days before induction therapy with dexamethasone vincristine and asparaginase native or pegylated Escherichia coli The pharmacokinetics of topotecan were measured with the first dose of treatment in 23 patients Twenty-eight of 31 patients with circulating blast cells were evaluable for response to topotecan Twenty-five patients 89.3 had a response 25 decrease in circulating blast cells The leukocyte count P .0001 and blast cell count P .0009 declined significantly during topotecan therapy The median range topotecan lactone area under the concentration-time curve after the first dose was 85.4 L/hour/m 2 range 38.7-229.3 L/hour/m 2 At the end of induction 23 patients 74.2 had a complete response 1 patient 3.2 had a partial response 5 patients 16.1 had no response and 2 patients had died of infection Six of the 17 patients who were studied for minimal residual disease MRD achieved MRD-negative status at the end of induction The main toxicities were hematologic and hepatic The estimated 5-year survival rate event-free survival rate and cumulative incidence of second relapse were 24.1 +/- 7.9 18.2 +/- 7.4 and 22.8 +/- 8.7 respectively in the 29 patients who had a hematologic first relapse A regimen comprising single-agent topotecan given with a standard 3-drug combination was effective in inducing remission in pediatric patients with relapsed ALL and was tolerated well,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 738, 194, 3, 51, 116, 155, 2, 1159, 1, 2129, 447, 348, 260, 504, 36, 9, 864, 286, 1275, 62, 4, 157, 429, 7, 103, 2129, 18, 39, 81, 188, 18, 391, 22, 8, 201, 3949, 904, 9, 33, 162, 348, 504, 36, 5, 1217, 2132, 2, 3709, 4646, 15, 4424, 12832, 6959, 3, 1159, 1, 2129, 11, 644, 5, 3, 157, 61, 1, 24, 4, 382, 7, 737, 659, 1, 456, 7, 5, 1033, 3112, 37, 11, 859, 9, 51, 6, 2129, 737, 365, 7, 887, 27, 42, 8, 51, 243, 775, 4, 1033, 3112, 37, 3, 3627, 1276, 19, 488, 2, 3112, 31, 1276, 19, 7946, 3054, 97, 190, 2129, 36, 3, 52, 184, 2129, 8643, 965, 669, 3, 1227, 98, 1496, 50, 3, 157, 61, 10, 772, 39, 805, 2583, 188, 18, 184, 519, 67, 7584, 27, 805, 2583, 188, 18, 28, 3, 396, 1, 504, 382, 7, 794, 18, 42, 8, 236, 51, 14, 69, 27, 18, 42, 8, 450, 51, 33, 7, 245, 14, 42, 77, 51, 2, 18, 7, 42, 1016, 1, 930, 437, 1, 3, 269, 7, 54, 11, 656, 9, 1048, 753, 34, 2029, 513, 2029, 199, 156, 28, 3, 396, 1, 504, 3, 1895, 385, 11, 813, 2, 939, 3, 661, 33, 111, 25, 116, 774, 115, 25, 116, 2, 967, 287, 1, 419, 429, 11, 259, 14, 67, 83, 203, 18, 67, 39, 2, 350, 66, 66, 67, 106, 4, 3, 462, 7, 54, 42, 8, 813, 157, 429, 8, 477, 3538, 226, 420, 2129, 447, 5, 8, 260, 27, 234, 150, 10, 323, 4, 1958, 734, 4, 815, 7, 5, 591, 62, 2, 10, 421, 149]",1639.0,18318429,576
Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Blood,Blood,2008-03-11,"Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for late effects of cancer therapy. Five-year ALL survivors (< 21 years at diagnosis; n = 5760 eligible, 4151 participants), diagnosed from 1970 to 1986 were compared with the general population and a sibling cohort (n = 3899). Cumulative mortality of 5760 5-year survivors was 13% at 25 years from diagnosis. Recurrent ALL (n = 483) and second neoplasms (SNs; n = 89) were the major causes of death. Among 185 survivors, 199 SNs occurred, 53% in the CNS. Survivors reported more multiple chronic medical conditions (CMCs; odds ratio [OR], 2.8; 95% CI, 2.4-3.2) and severe or life-threatening CMCs (OR, 3.6; 95% CI, 3.0-4.5) than siblings. Cumulative incidence of severe CMCs, including death, 25 years from diagnosis was 21.3% (95% CI, 18.2-24.4; 23.3% [95% CI, 19.4-27.2] and 13.4% [95% CI, 8.4-18.4] for irradiated and nonirradiated survivors, respectively). Survivors reported more adverse general and mental health, functional impairment, and activity limitations compared with siblings (P < .001). Rates of marriage, college graduation, employment, and health insurance were all lower compared with sibling controls (P < .001). Long-term survivors of childhood ALL exhibit excess mortality and morbidity. Survivors who received radiation therapy as part of their treatment or had a leukemia relapse are at greatest risk for adverse outcomes.",Journal Article,4333.0,209.0,Survivors of childhood acute lymphoblastic ALL are at risk for late effects of cancer therapy Five-year ALL survivors 21 years at diagnosis n 5760 eligible 4151 participants diagnosed from 1970 to 1986 were compared with the general population and a sibling cohort n 3899 Cumulative mortality of 5760 5-year survivors was 13 at 25 years from diagnosis Recurrent ALL n 483 and second neoplasms SNs n 89 were the major causes of death Among 185 survivors 199 SNs occurred 53 in the CNS Survivors reported more multiple chronic medical conditions CMCs odds ratio OR 2.8 95 CI 2.4-3.2 and severe or life-threatening CMCs OR 3.6 95 CI 3.0-4.5 than siblings Cumulative incidence of severe CMCs including death 25 years from diagnosis was 21.3 95 CI 18.2-24.4 23.3 95 CI 19.4-27.2 and 13.4 95 CI 8.4-18.4 for irradiated and nonirradiated survivors respectively Survivors reported more adverse general and mental health functional impairment and activity limitations compared with siblings P .001 Rates of marriage college graduation employment and health insurance were all lower compared with sibling controls P .001 Long-term survivors of childhood ALL exhibit excess mortality and morbidity Survivors who received radiation therapy as part of their treatment or had a relapse are at greatest risk for adverse outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 32, 28, 43, 9, 807, 176, 1, 12, 36, 365, 111, 62, 332, 239, 60, 28, 147, 78, 38666, 625, 45059, 776, 265, 29, 4868, 6, 3751, 11, 72, 5, 3, 1083, 266, 2, 8, 3684, 180, 78, 34432, 967, 282, 1, 38666, 33, 111, 332, 10, 233, 28, 243, 60, 29, 147, 387, 62, 78, 10661, 2, 419, 1179, 7323, 78, 887, 11, 3, 458, 1626, 1, 273, 107, 5805, 332, 5840, 7323, 489, 699, 4, 3, 1025, 332, 210, 80, 232, 442, 484, 1298, 15315, 610, 197, 15, 18, 66, 48, 58, 18, 39, 27, 18, 2, 905, 15, 358, 3691, 15315, 15, 27, 49, 48, 58, 27, 13, 39, 33, 76, 2758, 967, 287, 1, 905, 15315, 141, 273, 243, 60, 29, 147, 10, 239, 27, 48, 58, 203, 18, 259, 39, 382, 27, 48, 58, 326, 39, 428, 18, 2, 233, 39, 48, 58, 66, 39, 203, 39, 9, 2398, 2, 10460, 332, 106, 332, 210, 80, 290, 1083, 2, 3031, 341, 583, 2315, 2, 128, 1939, 72, 5, 2758, 19, 144, 151, 1, 14822, 2979, 24985, 5141, 2, 341, 1935, 11, 62, 280, 72, 5, 3684, 535, 19, 144, 319, 337, 332, 1, 864, 62, 2239, 2612, 282, 2, 787, 332, 54, 103, 121, 36, 22, 760, 1, 136, 24, 15, 42, 8, 429, 32, 28, 2199, 43, 9, 290, 123]",1313.0,18334672,22
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate.,Leukemia research,Leuk. Res.,2008-03-19,"The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL). However, the possible long-term side effects of this combination are not yet known. Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid leukemia but not in patients with Ph-positive ALL. Here, we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic, cytogenetic, and major molecular responses. The patient then developed myelodysplastic syndrome and solitary central nervous system relapse of ALL.",Case Reports,4325.0,0.0,The addition of imatinib to high-intensity chemotherapy has improved the outcome of patients with Philadelphia chromosome Ph -positive acute lymphoblastic ALL However the possible long-term side effects of this combination are not yet known Development of new clonal abnormalities in complete cytogenetic remission after treatment with imatinib has been reported in patients with chronic myeloid but not in patients with Ph-positive ALL Here we present a patient with Ph-positive ALL who received hyperCVAD plus imatinib and achieved hematologic cytogenetic and major molecular responses The patient then developed syndrome and solitary central nervous system relapse of ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 352, 1, 577, 6, 64, 837, 56, 71, 231, 3, 228, 1, 7, 5, 3006, 1170, 2058, 109, 286, 1275, 62, 137, 3, 899, 319, 337, 1152, 176, 1, 26, 150, 32, 44, 1145, 440, 193, 1, 217, 1946, 1171, 4, 236, 1266, 734, 50, 24, 5, 577, 71, 85, 210, 4, 7, 5, 442, 533, 84, 44, 4, 7, 5, 2058, 109, 62, 467, 21, 364, 8, 69, 5, 2058, 109, 62, 54, 103, 13792, 349, 577, 2, 513, 813, 1266, 2, 458, 219, 253, 3, 69, 818, 276, 681, 2, 3144, 854, 1880, 398, 429, 1, 62]",674.0,18355919,8
Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission.,Blood,Blood,2008-04-08,"We report the retrospective outcomes of unrelated donor (URD) transplants in 169 patients with acute lymphoblastic leukemia (ALL) in first complete remission (CR1) who received transplants between 1995 and 2004. Median age was 33 years (range, 16-59 years). A total of 50% had a white blood cell count (WBC) more than 30 x 10(9)/L, 18% extramedullary disease, 42% achieved CR more than 8 weeks from diagnosis, 25% had adverse cytogenetics, and 19% had T-cell leukemia. A total of 41% were HLA well-matched, 41% partially matched with their donors, and 18% were HLA-mismatched. At 54-month median follow-up, incidences of acute grade 2-IV, III to IV, and chronic graft-versus-host disease were 50%, 25%, and 43%, respectively. Five-year treatment-related mortality (TRM), relapse, and overall survival were 42%, 20%, and 39%, respectively. In multivariate analyses, TRM was significantly higher with HLA-mismatched donors and T-cell depletion. Relapse risk was higher if the diagnostic WBC was more than 100 x 10(9)/L. Factors associated with poorer survival included WBC more than 100 x 10(9)/L, more than 8 weeks to CR1, cytomegalovirus seropositivity, HLA mismatching, and T-cell depletion. Nearly 40% of adults with ALL in CR1 survive 5 years after URD transplantation. Relapse risks were modest; TRM is the major cause of treatment failure. Selecting closely HLA-matched URD and reducing TRM should improve results.",Journal Article,4305.0,53.0,We report the retrospective outcomes of unrelated donor URD transplants in 169 patients with acute lymphoblastic ALL in first complete remission CR1 who received transplants between 1995 and 2004 Median age was 33 years range 16-59 years A total of 50 had a white blood cell count WBC more than 30 x 10 9 /L 18 extramedullary disease 42 achieved CR more than 8 weeks from diagnosis 25 had adverse cytogenetics and 19 had T-cell A total of 41 were HLA well-matched 41 partially matched with their donors and 18 were HLA-mismatched At 54-month median follow-up incidences of acute grade 2-IV III to IV and chronic graft-versus-host disease were 50 25 and 43 respectively Five-year treatment-related mortality TRM relapse and overall survival were 42 20 and 39 respectively In multivariate analyses TRM was significantly higher with HLA-mismatched donors and T-cell depletion Relapse risk was higher if the diagnostic WBC was more than 100 x 10 9 /L Factors associated with poorer survival included WBC more than 100 x 10 9 /L more than 8 weeks to CR1 cytomegalovirus seropositivity HLA mismatching and T-cell depletion Nearly 40 of adults with ALL in CR1 survive 5 years after URD transplantation Relapse risks were modest TRM is the major cause of treatment failure Selecting closely HLA-matched URD and reducing TRM should improve results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 3, 459, 123, 1, 2092, 1488, 5847, 4016, 4, 5436, 7, 5, 286, 1275, 62, 4, 157, 236, 734, 4516, 54, 103, 4016, 59, 2323, 2, 1131, 52, 89, 10, 466, 60, 184, 245, 728, 60, 8, 181, 1, 212, 42, 8, 886, 315, 31, 1276, 4685, 80, 76, 201, 1006, 79, 83, 805, 203, 5508, 34, 595, 513, 684, 80, 76, 66, 244, 29, 147, 243, 42, 290, 2510, 2, 326, 42, 102, 31, 8, 181, 1, 605, 11, 1160, 149, 655, 605, 2995, 655, 5, 136, 2344, 2, 203, 11, 1160, 5095, 28, 667, 811, 52, 166, 126, 3981, 1, 286, 88, 18, 478, 316, 6, 478, 2, 442, 1599, 185, 1204, 34, 11, 212, 243, 2, 601, 106, 365, 111, 24, 139, 282, 5064, 429, 2, 63, 25, 11, 595, 179, 2, 587, 106, 4, 331, 318, 5064, 10, 97, 142, 5, 1160, 5095, 2344, 2, 102, 31, 2286, 429, 43, 10, 142, 492, 3, 752, 4685, 10, 80, 76, 394, 1006, 79, 83, 805, 130, 41, 5, 1769, 25, 159, 4685, 80, 76, 394, 1006, 79, 83, 805, 80, 76, 66, 244, 6, 4516, 7314, 9525, 1160, 25074, 2, 102, 31, 2286, 1857, 327, 1, 857, 5, 62, 4, 4516, 4573, 33, 60, 50, 5847, 497, 429, 1098, 11, 1721, 5064, 16, 3, 458, 708, 1, 24, 496, 3675, 3210, 1160, 655, 5847, 2, 1818, 5064, 257, 401, 99]",1338.0,18398065,793
In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.,PLoS medicine,PLoS Med.,2008-04-01,"Childhood acute lymphoblastic leukemia (ALL) is the most common cancer in children, and can now be cured in approximately 80% of patients. Nevertheless, drug resistance is the major cause of treatment failure in children with ALL. The drug methotrexate (MTX), which is widely used to treat many human cancers, is used in essentially all treatment protocols worldwide for newly diagnosed ALL. Although MTX has been extensively studied for many years, relatively little is known about mechanisms of de novo resistance in primary cancer cells, including leukemia cells. This lack of knowledge is due in part to the fact that existing in vitro methods are not sufficiently reliable to permit assessment of MTX resistance in primary ALL cells. Therefore, we measured the in vivo antileukemic effects of MTX and identified genes whose expression differed significantly in patients with a good versus poor response to MTX. We utilized measures of decreased circulating leukemia cells of 293 newly diagnosed children after initial ""up-front"" in vivo MTX treatment (1 g/m(2)) to elucidate interpatient differences in the antileukemic effects of MTX. To identify genomic determinants of these effects, we performed a genome-wide assessment of gene expression in primary ALL cells from 161 of these newly diagnosed children (1-18 y). We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating leukemia cells after initial in vivo treatment with MTX. This finding was validated in an independent cohort of children with ALL. Furthermore, this measure of initial MTX in vivo response and the associated gene expression pattern were predictive of long-term disease-free survival (p < 0.001, p = 0.02). Together, these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response, pointing to new strategies to overcome MTX resistance in childhood ALL. Total XV, Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia, http://www.ClinicalTrials.gov (NCT00137111); Total XIIIBH, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Intermediate or High Risk of Treatment Failure (NCI-T93-0101D); Total XIIIBL, Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic Leukemia at Lower Risk of Treatment Failure (NCI-T93-0103D).",Journal Article,4312.0,58.0,Childhood acute lymphoblastic ALL is the most common cancer in children and can now be cured in approximately 80 of patients Nevertheless drug resistance is the major cause of treatment failure in children with ALL The drug methotrexate MTX which is widely used to treat many human cancers is used in essentially all treatment protocols worldwide for newly diagnosed ALL Although MTX has been extensively studied for many years relatively little is known about mechanisms of de novo resistance in primary cancer cells including cells This lack of knowledge is due in part to the fact that existing in vitro methods are not sufficiently reliable to permit assessment of MTX resistance in primary ALL cells Therefore we measured the in vivo antileukemic effects of MTX and identified genes whose expression differed significantly in patients with a good versus poor response to MTX We utilized measures of decreased circulating cells of 293 newly diagnosed children after initial `` up-front '' in vivo MTX treatment 1 g/m 2 to elucidate interpatient differences in the antileukemic effects of MTX To identify genomic determinants of these effects we performed a genome-wide assessment of gene expression in primary ALL cells from 161 of these newly diagnosed children 1-18 y We identified 48 genes and two cDNA clones whose expression was significantly related to the reduction of circulating cells after initial in vivo treatment with MTX This finding was validated in an independent cohort of children with ALL Furthermore this measure of initial MTX in vivo response and the associated gene expression pattern were predictive of long-term disease-free survival p 0.001 p 0.02 Together these data provide new insights into the genomic basis of MTX resistance and interpatient differences in MTX response pointing to new strategies to overcome MTX resistance in childhood ALL Total XV Therapy for Newly Diagnosed Patients With Acute Lymphoblastic http //www.ClinicalTrials.gov NCT00137111 Total XIIIBH Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic at Intermediate or High Risk of Treatment Failure NCI-T93-0101D Total XIIIBL Phase III Randomized Study of Antimetabolite-Based Induction plus High-Dose MTX Consolidation for Newly Diagnosed Pediatric Acute Lymphocytic at Lower Risk of Treatment Failure NCI-T93-0103D,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[864, 286, 1275, 62, 16, 3, 96, 186, 12, 4, 541, 2, 122, 1134, 40, 3733, 4, 705, 493, 1, 7, 3873, 234, 251, 16, 3, 458, 708, 1, 24, 496, 4, 541, 5, 62, 3, 234, 2116, 3453, 92, 16, 1792, 95, 6, 943, 445, 171, 163, 16, 95, 4, 7257, 62, 24, 2189, 2358, 9, 732, 265, 62, 242, 3453, 71, 85, 3576, 656, 9, 445, 60, 1352, 1215, 16, 440, 545, 483, 1, 1566, 2018, 251, 4, 86, 12, 37, 141, 37, 26, 926, 1, 922, 16, 520, 4, 760, 6, 3, 1991, 17, 1692, 4, 439, 636, 32, 44, 5938, 2450, 6, 5634, 455, 1, 3453, 251, 4, 86, 62, 37, 673, 21, 644, 3, 4, 386, 4512, 176, 1, 3453, 2, 108, 214, 1310, 55, 2512, 97, 4, 7, 5, 8, 1178, 185, 334, 51, 6, 3453, 21, 2080, 1018, 1, 340, 1033, 37, 1, 7541, 732, 265, 541, 50, 388, 126, 3007, 522, 4, 386, 3453, 24, 14, 499, 188, 18, 6, 3061, 7423, 362, 4, 3, 4512, 176, 1, 3453, 6, 255, 572, 3403, 1, 46, 176, 21, 173, 8, 898, 1019, 455, 1, 145, 55, 4, 86, 62, 37, 29, 5377, 1, 46, 732, 265, 541, 14, 203, 2055, 21, 108, 576, 214, 2, 100, 4212, 2749, 1310, 55, 10, 97, 139, 6, 3, 628, 1, 1033, 37, 50, 388, 4, 386, 24, 5, 3453, 26, 1567, 10, 938, 4, 35, 306, 180, 1, 541, 5, 62, 798, 26, 1463, 1, 388, 3453, 4, 386, 51, 2, 3, 41, 145, 55, 1177, 11, 464, 1, 319, 337, 34, 115, 25, 19, 13, 144, 19, 13, 588, 1162, 46, 74, 377, 217, 1957, 237, 3, 572, 877, 1, 3453, 251, 2, 7423, 362, 4, 3453, 51, 11548, 6, 217, 422, 6, 1768, 3453, 251, 4, 864, 62, 181, 16078, 36, 9, 732, 265, 7, 5, 286, 1275, 5196, 3064, 1252, 1239, 25075, 181, 57004, 124, 316, 384, 45, 1, 12995, 90, 504, 349, 64, 61, 3453, 2173, 9, 732, 265, 815, 286, 1193, 28, 919, 15, 64, 43, 1, 24, 496, 2580, 38692, 45092, 181, 57005, 124, 316, 384, 45, 1, 12995, 90, 504, 349, 64, 61, 3453, 2173, 9, 732, 265, 815, 286, 1193, 28, 280, 43, 1, 24, 496, 2580, 38692, 57006]",2411.0,18416598,558
Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-04-01,"Dexamethasone is used widely in oncology, but pharmacokinetic studies are lacking. We evaluated dexamethasone pharmacokinetics in children with acute lymphoblastic leukemia. We assessed 214 children with acute lymphoblastic leukemia who received 418 courses of oral dexamethasone (8 mg/m(2)/d) on days 1 and 8 of reinduction. Extensive asparaginase use preceded reinduction in the 101 children in the standard/high-risk treatment arm but not in the 113 children in the low-risk treatment arm. A one-compartment model with first-order absorption and disposition was fit to dexamethasone plasma concentrations by using maximum a posteriori probability estimation; we evaluated covariates by using linear mixed models. Interpatient and intrapatient variabilities in apparent clearance were substantial; they were 46% and 53%, respectively. Variability was explained by the serum albumin concentration (P < .0001), concomitant use of fentanyl (P = .008) and ketoconazole (P = .03), and age (P = .006). Apparent clearance was higher in the low-risk arm (P < .001) and was related to a greater serum albumin concentration (P < .001) and to a lower exposure to asparaginase than in the standard/high-risk arm. Hypoalbuminemia, a biomarker of asparaginase activity, was associated with a lower dexamethasone apparent clearance (P = .04) in patients in the standard/high-risk arm that was more pronounced in those not allergic to asparaginase. Ethnicity or gender did not explain apparent clearance variability. Dexamethasone pharmacokinetics are highly variable and are related to the concurrent use of particular drugs, age, and treatment intensity. Patients allergic to asparaginase may be doubly disadvantaged: they not only suffer from diminished exposure to asparaginase but also, by maintaining high clearance of dexamethasone, may experience fewer antileukemic effects of dexamethasone.",Controlled Clinical Trial,4312.0,84.0,Dexamethasone is used widely in oncology but pharmacokinetic studies are lacking We evaluated dexamethasone pharmacokinetics in children with acute lymphoblastic We assessed 214 children with acute lymphoblastic who received 418 courses of oral dexamethasone 8 mg/m 2 /d on days 1 and 8 of reinduction Extensive asparaginase use preceded reinduction in the 101 children in the standard/high-risk treatment arm but not in the 113 children in the low-risk treatment arm A one-compartment model with first-order absorption and disposition was fit to dexamethasone plasma concentrations by using maximum a posteriori probability estimation we evaluated covariates by using linear mixed models Interpatient and intrapatient variabilities in apparent clearance were substantial they were 46 and 53 respectively Variability was explained by the serum albumin concentration P .0001 concomitant use of fentanyl P .008 and ketoconazole P .03 and age P .006 Apparent clearance was higher in the low-risk arm P .001 and was related to a greater serum albumin concentration P .001 and to a lower exposure to asparaginase than in the standard/high-risk arm Hypoalbuminemia a biomarker of asparaginase activity was associated with a lower dexamethasone apparent clearance P .04 in patients in the standard/high-risk arm that was more pronounced in those not allergic to asparaginase Ethnicity or gender did not explain apparent clearance variability Dexamethasone pharmacokinetics are highly variable and are related to the concurrent use of particular drugs age and treatment intensity Patients allergic to asparaginase may be doubly disadvantaged they not only suffer from diminished exposure to asparaginase but also by maintaining high clearance of dexamethasone may experience fewer antileukemic effects of dexamethasone,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1217, 16, 95, 1792, 4, 413, 84, 1456, 94, 32, 1941, 21, 194, 1217, 1159, 4, 541, 5, 286, 1275, 21, 275, 6900, 541, 5, 286, 1275, 54, 103, 10387, 1993, 1, 518, 1217, 66, 81, 188, 18, 427, 23, 162, 14, 2, 66, 1, 10177, 1344, 3709, 119, 6083, 10177, 4, 3, 2338, 541, 4, 3, 260, 64, 43, 24, 475, 84, 44, 4, 3, 4259, 541, 4, 3, 154, 43, 24, 475, 8, 104, 3616, 202, 5, 157, 1732, 6125, 2, 5814, 10, 2975, 6, 1217, 554, 1003, 20, 75, 689, 8, 57010, 1320, 4470, 21, 194, 2489, 20, 75, 1646, 1739, 274, 7423, 2, 9838, 45095, 4, 2235, 1960, 11, 1281, 491, 11, 641, 2, 699, 106, 1982, 10, 3672, 20, 3, 524, 2799, 1227, 19, 488, 1781, 119, 1, 11053, 19, 2155, 2, 6074, 19, 680, 2, 89, 19, 1861, 2235, 1960, 10, 142, 4, 3, 154, 43, 475, 19, 144, 2, 10, 139, 6, 8, 378, 524, 2799, 1227, 19, 144, 2, 6, 8, 280, 645, 6, 3709, 76, 4, 3, 260, 64, 43, 475, 11667, 8, 901, 1, 3709, 128, 10, 41, 5, 8, 280, 1217, 2235, 1960, 19, 755, 4, 7, 4, 3, 260, 64, 43, 475, 17, 10, 80, 3517, 4, 135, 44, 7465, 6, 3709, 2091, 15, 1632, 205, 44, 2943, 2235, 1960, 1982, 1217, 1159, 32, 561, 1347, 2, 32, 139, 6, 3, 750, 119, 1, 1454, 600, 89, 2, 24, 837, 7, 7465, 6, 3709, 68, 40, 18820, 16700, 491, 44, 158, 6506, 29, 2849, 645, 6, 3709, 84, 120, 20, 3284, 64, 1960, 1, 1217, 68, 730, 1497, 4512, 176, 1, 1217]",1810.0,18421047,135
Prospective analysis of TEL gene rearrangements in childhood acute lymphoblastic leukemia: a Children's Oncology Group study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-05-01,"To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic leukemia (ALL). TEL gene status was determined for 926 patients with B-precursor ALL enrolled on the Pediatric Oncology Group ALinC 16 trials and patients were observed for a median time of 8 years. Rearrangements of the TEL gene were detected in 244 patients (26%). The estimated 5-year event-free survival rate (+/- SE) for patients with TEL rearrangements was 86% +/- 2%, compared with 72% +/- 2% for those with germline TEL (P < .0001). TEL rearrangements were associated with a superior outcome among patients with standard-risk ALL, high-risk ALL, and rapid early responses to therapy. In a multivariate analysis that included risk group, sex, and day 15 marrow status, TEL status was an independent predictor of outcome (P = .0002). We conclude that TEL gene status should be incorporated into risk classification schemes and suggest that patients who have standard-risk features, the TEL-AML1 fusion, and rapid early responses to therapy, should be treated with antimetabolite-based therapy designed to maintain their high cure rates and avoid late effects.",Journal Article,4282.0,55.0,To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic ALL TEL gene status was determined for 926 patients with B-precursor ALL enrolled on the Pediatric Oncology Group ALinC 16 trials and patients were observed for a median time of 8 years Rearrangements of the TEL gene were detected in 244 patients 26 The estimated 5-year event-free survival rate +/- SE for patients with TEL rearrangements was 86 +/- 2 compared with 72 +/- 2 for those with germline TEL P .0001 TEL rearrangements were associated with a superior outcome among patients with standard-risk ALL high-risk ALL and rapid early responses to therapy In a multivariate analysis that included risk group sex and day 15 marrow status TEL status was an independent predictor of outcome P .0002 We conclude that TEL gene status should be incorporated into risk classification schemes and suggest that patients who have standard-risk features the TEL-AML1 fusion and rapid early responses to therapy should be treated with antimetabolite-based therapy designed to maintain their high cure rates and avoid late effects,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 1143, 223, 3, 177, 724, 1, 3, 8573, 6535, 1212, 4, 541, 5, 286, 1275, 62, 8573, 145, 156, 10, 509, 9, 10119, 7, 5, 132, 2765, 62, 346, 23, 3, 815, 413, 87, 57038, 245, 143, 2, 7, 11, 164, 9, 8, 52, 98, 1, 66, 60, 2072, 1, 3, 8573, 145, 11, 530, 4, 6567, 7, 432, 3, 661, 33, 111, 774, 115, 25, 116, 3428, 9, 7, 5, 8573, 2072, 10, 868, 18, 72, 5, 720, 18, 9, 135, 5, 1009, 8573, 19, 488, 8573, 2072, 11, 41, 5, 8, 1123, 228, 107, 7, 5, 260, 43, 62, 64, 43, 62, 2, 1321, 191, 253, 6, 36, 4, 8, 331, 65, 17, 159, 43, 87, 1035, 2, 218, 167, 581, 156, 8573, 156, 10, 35, 306, 980, 1, 228, 19, 3531, 21, 2060, 17, 8573, 145, 156, 257, 40, 2449, 237, 43, 947, 7103, 2, 309, 17, 7, 54, 47, 260, 43, 404, 3, 8573, 6535, 1212, 2, 1321, 191, 253, 6, 36, 257, 40, 73, 5, 12995, 90, 36, 1114, 6, 3040, 136, 64, 1722, 151, 2, 3085, 807, 176]",1136.0,18445843,109
Concordant gene expression in leukemia cells and normal leukocytes is associated with germline cis-SNPs.,PloS one,PLoS ONE,2008-05-14,"The degree to which gene expression covaries between different primary tissues within an individual is not well defined. We hypothesized that expression that is concordant across tissues is more likely influenced by genetic variability than gene expression which is discordant between tissues. We quantified expression of 11,873 genes in paired samples of primary leukemia cells and normal leukocytes from 92 patients with acute lymphoblastic leukemia (ALL). Genetic variation at >500,000 single nucleotide polymorphisms (SNPs) was also assessed. The expression of only 176/11,783 (1.5%) genes was correlated (p<0.008, FDR = 25%) in the two tissue types, but expression of a high proportion (20 of these 176 genes) was significantly related to cis-SNP genotypes (adjusted p<0.05). In an independent set of 134 patients with ALL, 14 of these 20 genes were validated as having expression related to cis-SNPs, as were 9 of 20 genes in a second validation set of HapMap cell lines. Genes whose expression was concordant among tissue types were more likely to be associated with germline cis-SNPs than genes with discordant expression in these tissues; genes affected were involved in housekeeping functions (GSTM2, GAPDH and NCOR1) and purine metabolism.",Journal Article,4269.0,4.0,"The degree to which gene expression covaries between different primary tissues within an individual is not well defined We hypothesized that expression that is concordant across tissues is more likely influenced by genetic variability than gene expression which is discordant between tissues We quantified expression of 11,873 genes in paired samples of primary cells and normal leukocytes from 92 patients with acute lymphoblastic ALL Genetic variation at 500,000 single nucleotide polymorphisms SNPs was also assessed The expression of only 176/11,783 1.5 genes was correlated p 0.008 FDR 25 in the two tissue types but expression of a high proportion 20 of these 176 genes was significantly related to cis-SNP genotypes adjusted p 0.05 In an independent set of 134 patients with ALL 14 of these 20 genes were validated as having expression related to cis-SNPs as were 9 of 20 genes in a second validation set of HapMap cell lines Genes whose expression was concordant among tissue types were more likely to be associated with germline cis-SNPs than genes with discordant expression in these tissues genes affected were involved in housekeeping functions GSTM2 GAPDH and NCOR1 and purine metabolism",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1444, 6, 92, 145, 55, 57055, 59, 338, 86, 742, 262, 35, 797, 16, 44, 149, 395, 21, 1237, 17, 55, 17, 16, 3610, 716, 742, 16, 80, 322, 2574, 20, 336, 1982, 76, 145, 55, 92, 16, 4570, 59, 742, 21, 2790, 55, 1, 175, 13388, 214, 4, 2355, 347, 1, 86, 37, 2, 295, 6884, 29, 937, 7, 5, 286, 1275, 62, 336, 1380, 28, 1666, 984, 226, 1579, 1203, 1109, 10, 120, 275, 3, 55, 1, 158, 5800, 175, 14149, 14, 33, 214, 10, 438, 19, 13, 2155, 5929, 243, 4, 3, 100, 246, 630, 84, 55, 1, 8, 64, 920, 179, 1, 46, 5800, 214, 10, 97, 139, 6, 1927, 1845, 2071, 586, 19, 13, 474, 4, 35, 306, 916, 1, 4842, 7, 5, 62, 213, 1, 46, 179, 214, 11, 938, 22, 1041, 55, 139, 6, 1927, 1109, 22, 11, 83, 1, 179, 214, 4, 8, 419, 929, 916, 1, 13961, 31, 285, 214, 1310, 55, 10, 3610, 107, 246, 630, 11, 80, 322, 6, 40, 41, 5, 1009, 1927, 1109, 76, 214, 5, 4570, 55, 4, 46, 742, 214, 1424, 11, 646, 4, 24550, 1681, 57056, 12271, 2, 31284, 2, 5006, 1600]",1200.0,18478092,171
Genetic predictors of glucocorticoid-induced hypertension in children with acute lymphoblastic leukemia.,Pharmacogenetics and genomics,Pharmacogenet. Genomics,2008-06-01,"Glucocorticoids are used universally in the remission induction therapy for acute lymphoblastic leukemia (ALL). One of the adverse effects of glucocorticoids is hypertension. Our aim was to define the frequency of and clinical and genetic risk factors for steroid-induced hypertension. We determined the genotypes for 203 candidate polymorphisms in genes previously linked to hypertension or to the pharmacokinetics or pharmacodynamics of antileukemic agents. Hypertension was defined according to the guidelines of the American Academy of Pediatrics; patients were evaluated during the 28-day period of prednisone at 40 mg/m2/day during remission induction of childhood ALL. Of the 602 children with newly diagnosed ALL who were normotensive pretherapy, 270 (45%) developed hypertension during remission induction. None of the putative risk factors (age, sex, race, white blood cell count, risk group, body mass index, or serum creatinine) was associated with hypertension. Among the polymorphisms genotyped, we identified eight genes (CNTNAP2, LEPR, CRHR1, NTAN1, SLC12A3, ALPL, BGLAP, and APOB) containing variants that were associated with hypertension (chi2 P values 0.002-0.048), several of which interact with the hypothalamus-pituitary-adrenal axis. Polymorphisms in CYP3A4 and CYP3A5 were not associated with hypertension. Hypertension is common during ALL remission induction and is related to germline genetic variation.",Journal Article,4251.0,31.0,Glucocorticoids are used universally in the remission induction therapy for acute lymphoblastic ALL One of the adverse effects of glucocorticoids is hypertension Our aim was to define the frequency of and clinical and genetic risk factors for steroid-induced hypertension We determined the genotypes for 203 candidate polymorphisms in genes previously linked to hypertension or to the pharmacokinetics or pharmacodynamics of antileukemic agents Hypertension was defined according to the guidelines of the American Academy of Pediatrics patients were evaluated during the 28-day period of prednisone at 40 mg/m2/day during remission induction of childhood ALL Of the 602 children with newly diagnosed ALL who were normotensive pretherapy 270 45 developed hypertension during remission induction None of the putative risk factors age sex race white blood cell count risk group body mass index or serum creatinine was associated with hypertension Among the polymorphisms genotyped we identified eight genes CNTNAP2 LEPR CRHR1 NTAN1 SLC12A3 ALPL BGLAP and APOB containing variants that were associated with hypertension chi2 P values 0.002-0.048 several of which interact with the hypothalamus-pituitary-adrenal axis Polymorphisms in CYP3A4 and CYP3A5 were not associated with hypertension Hypertension is common during ALL remission induction and is related to germline genetic variation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7307, 32, 95, 6813, 4, 3, 734, 504, 36, 9, 286, 1275, 62, 104, 1, 3, 290, 176, 1, 7307, 16, 1824, 114, 1130, 10, 6, 1107, 3, 675, 1, 2, 38, 2, 336, 43, 130, 9, 3853, 277, 1824, 21, 509, 3, 2071, 9, 5426, 1609, 1203, 4, 214, 373, 1199, 6, 1824, 15, 6, 3, 1159, 15, 3587, 1, 4512, 183, 1824, 10, 395, 768, 6, 3, 677, 1, 3, 597, 16378, 1, 12616, 7, 11, 194, 190, 3, 339, 218, 727, 1, 1979, 28, 327, 81, 821, 218, 190, 734, 504, 1, 864, 62, 1, 3, 10588, 541, 5, 732, 265, 62, 54, 11, 34475, 8857, 6666, 512, 276, 1824, 190, 734, 504, 1292, 1, 3, 2743, 43, 130, 89, 1035, 1047, 886, 315, 31, 1276, 43, 87, 642, 782, 558, 15, 524, 3177, 10, 41, 5, 1824, 107, 3, 1203, 3053, 21, 108, 659, 214, 45137, 17276, 31289, 57080, 57081, 57082, 57083, 2, 57084, 1101, 839, 17, 11, 41, 5, 1824, 12474, 19, 1030, 13, 1111, 13, 4969, 392, 1, 92, 4491, 5, 3, 12717, 12098, 2987, 2310, 1203, 4, 6208, 2, 10071, 11, 44, 41, 5, 1824, 1824, 16, 186, 190, 62, 734, 504, 2, 16, 139, 6, 1009, 336, 1380]",1384.0,18496130,207
What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies.,Blood,Blood,2008-05-23,"We performed a retrospective comparison of presenting features, planned treatment, complete remission (CR) rate, and outcome of 321 adolescents and young adults (AYAs) ages 16 to 20 years with newly diagnosed acute lymphoblastic leukemia (ALL) who were treated on consecutive trials in either the Children's Cancer Group (CCG) or the Cancer and Leukemia Group B (CALGB) from 1988 to 2001. CR rates were identical, 90% for both CALGB and CCG AYAs. CCG AYAs had a 63% event-free survival (EFS) and 67% overall survival (OS) at 7 years in contrast to the CALGB AYAs, in which 7-year EFS was only 34% (P < .001; relative hazard rate [RHR] = 2.2) and OS was 46% (P < .001; RHR = 1.9). While CALGB AYAs aged 16 to 17 years achieved similar outcomes to all CCG AYAs with a 7-year EFS of 55%, the EFS for 18- to 20-year-old CALGB patients was only 29%. Comparison of the regimens showed that CCG AYAs received earlier and more intensive central nervous system prophylaxis and higher cumulative doses of nonmyelosuppressive agents. There were no differences in outcomes of those who reached maintenance therapy on time compared with those who were delayed. Based on these observations, a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated.",Clinical Trial,4260.0,332.0,We performed a retrospective comparison of presenting features planned treatment complete remission CR rate and outcome of 321 adolescents and young adults AYAs ages 16 to 20 years with newly diagnosed acute lymphoblastic ALL who were treated on consecutive trials in either the Children 's Cancer Group CCG or the Cancer and Group B CALGB from 1988 to 2001 CR rates were identical 90 for both CALGB and CCG AYAs CCG AYAs had a 63 event-free survival EFS and 67 overall survival OS at 7 years in contrast to the CALGB AYAs in which 7-year EFS was only 34 P .001 relative hazard rate RHR 2.2 and OS was 46 P .001 RHR 1.9 While CALGB AYAs aged 16 to 17 years achieved similar outcomes to all CCG AYAs with a 7-year EFS of 55 the EFS for 18- to 20-year-old CALGB patients was only 29 Comparison of the regimens showed that CCG AYAs received earlier and more intensive central nervous system prophylaxis and higher cumulative doses of nonmyelosuppressive agents There were no differences in outcomes of those who reached maintenance therapy on time compared with those who were delayed Based on these observations a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 173, 8, 459, 1155, 1, 1656, 404, 1465, 24, 236, 734, 684, 116, 2, 228, 1, 9976, 3101, 2, 1169, 857, 6145, 2165, 245, 6, 179, 60, 5, 732, 265, 286, 1275, 62, 54, 11, 73, 23, 935, 143, 4, 361, 3, 541, 292, 12, 87, 9457, 15, 3, 12, 2, 87, 132, 4077, 29, 3314, 6, 1758, 684, 151, 11, 3038, 424, 9, 110, 4077, 2, 9457, 6145, 9457, 6145, 42, 8, 676, 774, 115, 25, 1683, 2, 598, 63, 25, 118, 28, 67, 60, 4, 748, 6, 3, 4077, 6145, 4, 92, 67, 111, 1683, 10, 158, 562, 19, 144, 580, 360, 116, 17962, 18, 18, 2, 118, 10, 641, 19, 144, 17962, 14, 83, 369, 4077, 6145, 1032, 245, 6, 269, 60, 513, 288, 123, 6, 62, 9457, 6145, 5, 8, 67, 111, 1683, 1, 614, 3, 1683, 9, 203, 6, 179, 111, 1095, 4077, 7, 10, 158, 462, 1155, 1, 3, 472, 224, 17, 9457, 6145, 103, 1677, 2, 80, 1686, 854, 1880, 398, 2049, 2, 142, 967, 415, 1, 45142, 183, 125, 11, 77, 362, 4, 123, 1, 135, 54, 1300, 1146, 36, 23, 98, 72, 5, 135, 54, 11, 1612, 90, 23, 46, 2172, 8, 482, 45, 9, 6145, 5, 62, 75, 3, 80, 1401, 353, 1, 3, 9457, 71, 85, 1917]",1212.0,18502832,723
Long-term remission of Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation from matched sibling donors: a 20-year experience with the fractionated total body irradiation-etoposide regimen.,Blood,Blood,2008-06-02,"Allogeneic hematopoietic cell transplantation (HCT) is the only known curative modality for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph(+) ALL). Sixty-seven patients with HLA-matched sibling donors received fractionated total body irradiation (FTBI) and high-dose VP16, whereas 11 patients received FTBI/VP16/cyclophosphamide, and 1 patient received FTBI/VP16/busulfan. The median age was 36 years. At the time of HCT, 49 patients (62%) were in first complete remission (CR1) and 30 patients (38%) were beyond CR1 (> CR1). The median follow-up was 75 months (range, 14-245 months). The 10-year overall survival for the CR1 and beyond CR1 patients was 54% and 29% (P = .01), respectively, and event-free survival was 48% and 26% (P = .02), respectively. There was no significant difference in relapse incidence (28% vs 41%, P = .28), but nonrelapse mortality was significantly higher in the beyond CR1 patients, (31% vs 54%, P = .03, respectively). By univariate analysis, factors affecting event-free and overall survival were white blood cell count at diagnosis (< 30 x 10(9)/L vs > 30 x 10(9)/L) and disease status (CR1 vs > CR1). The median time to relapse for CR1 and for beyond CR1 patients was 12 months and 9 months, respectively. Our results indicate that FTBI/VP16 with or without cyclophosphamide confers long-term survival in Ph(+) ALL patients and that disease status at the time of HCT is an important predictor of outcome.",Journal Article,4250.0,81.0,Allogeneic hematopoietic cell transplantation HCT is the only known curative modality for patients with Philadelphia chromosome-positive acute lymphoblastic Ph ALL Sixty-seven patients with HLA-matched sibling donors received fractionated total body irradiation FTBI and high-dose VP16 whereas 11 patients received FTBI/VP16/cyclophosphamide and 1 patient received FTBI/VP16/busulfan The median age was 36 years At the time of HCT 49 patients 62 were in first complete remission CR1 and 30 patients 38 were beyond CR1 CR1 The median follow-up was 75 months range 14-245 months The 10-year overall survival for the CR1 and beyond CR1 patients was 54 and 29 P .01 respectively and event-free survival was 48 and 26 P .02 respectively There was no significant difference in relapse incidence 28 vs 41 P .28 but nonrelapse mortality was significantly higher in the beyond CR1 patients 31 vs 54 P .03 respectively By univariate analysis factors affecting event-free and overall survival were white blood cell count at diagnosis 30 x 10 9 /L vs 30 x 10 9 /L and disease status CR1 vs CR1 The median time to relapse for CR1 and for beyond CR1 patients was 12 months and 9 months respectively Our results indicate that FTBI/VP16 with or without cyclophosphamide confers long-term survival in Ph ALL patients and that disease status at the time of HCT is an important predictor of outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 1007, 31, 497, 1085, 16, 3, 158, 440, 1075, 1396, 9, 7, 5, 3006, 1170, 109, 286, 1275, 2058, 62, 1746, 648, 7, 5, 1160, 655, 3684, 2344, 103, 3950, 181, 642, 1104, 31092, 2, 64, 61, 16396, 547, 175, 7, 103, 31092, 16396, 1112, 2, 14, 69, 103, 31092, 16396, 3906, 3, 52, 89, 10, 511, 60, 28, 3, 98, 1, 1085, 739, 7, 744, 11, 4, 157, 236, 734, 4516, 2, 201, 7, 519, 11, 1654, 4516, 4516, 3, 52, 166, 126, 10, 481, 53, 184, 213, 7373, 53, 3, 79, 111, 63, 25, 9, 3, 4516, 2, 1654, 4516, 7, 10, 667, 2, 462, 19, 355, 106, 2, 774, 115, 25, 10, 576, 2, 432, 19, 588, 106, 125, 10, 77, 93, 523, 4, 429, 287, 339, 105, 605, 19, 339, 84, 4640, 282, 10, 97, 142, 4, 3, 1654, 4516, 7, 456, 105, 667, 19, 680, 106, 20, 880, 65, 130, 2319, 774, 115, 2, 63, 25, 11, 886, 315, 31, 1276, 28, 147, 201, 1006, 79, 83, 805, 105, 201, 1006, 79, 83, 805, 2, 34, 156, 4516, 105, 4516, 3, 52, 98, 6, 429, 9, 4516, 2, 9, 1654, 4516, 7, 10, 133, 53, 2, 83, 53, 106, 114, 99, 1008, 17, 31092, 16396, 5, 15, 187, 1112, 4020, 319, 337, 25, 4, 2058, 62, 7, 2, 17, 34, 156, 28, 3, 98, 1, 1085, 16, 35, 305, 980, 1, 228]",1379.0,18519812,906
Progress in the treatment of adults with acute lymphoblastic leukemia.,Current opinion in hematology,Curr. Opin. Hematol.,2008-07-01,"Despite improvements in the achievement of complete remission and progress in the supportive care of adults with acute lymphoblastic leukemia during the last decade, the majority of patients have eventually relapsed with overall survival in adult acute lymphoblastic leukemia of only 30-40%. However, the recent approach of adapting therapy according to biologic features appears to be resulting in significant progress for specific subsets of adults with acute lymphoblastic leukemia. The present review highlights some of these new risk-adapted approaches focusing on recent advances in treatment of Philadelphia chromosome positive acute lymphoblastic leukemia and mature B-cell acute lymphoblastic leukemia using biologically targeted therapies, and new approaches to treatment of acute lymphoblastic leukemia in older adolescents and young adults, adopting therapeutic strategies employed in the successful treatment of children with acute lymphoblastic leukemia. A recent study that examines the role of allogeneic stem cell transplant for adults with acute lymphoblastic leukemia in first remission will also be reviewed. The subset-specific approach to therapy of adult acute lymphoblastic leukemia is beginning to result in promising improvements in survival. Future improvements in survival of adults with acute lymphoblastic leukemia will depend on participation in large cooperative group trials using biologically defined protocols for this relatively rare and heterogeneous group of diseases.",Journal Article,4221.0,34.0,Despite improvements in the achievement of complete remission and progress in the supportive care of adults with acute lymphoblastic during the last decade the majority of patients have eventually relapsed with overall survival in adult acute lymphoblastic of only 30-40 However the recent approach of adapting therapy according to biologic features appears to be resulting in significant progress for specific subsets of adults with acute lymphoblastic The present review highlights some of these new risk-adapted approaches focusing on recent advances in treatment of Philadelphia chromosome positive acute lymphoblastic and mature B-cell acute lymphoblastic using biologically targeted therapies and new approaches to treatment of acute lymphoblastic in older adolescents and young adults adopting therapeutic strategies employed in the successful treatment of children with acute lymphoblastic A recent study that examines the role of allogeneic stem cell transplant for adults with acute lymphoblastic in first remission will also be reviewed The subset-specific approach to therapy of adult acute lymphoblastic is beginning to result in promising improvements in survival Future improvements in survival of adults with acute lymphoblastic will depend on participation in large cooperative group trials using biologically defined protocols for this relatively rare and heterogeneous group of diseases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[550, 1474, 4, 3, 5088, 1, 236, 734, 2, 1466, 4, 3, 1877, 165, 1, 857, 5, 286, 1275, 190, 3, 1060, 2025, 3, 686, 1, 7, 47, 3124, 591, 5, 63, 25, 4, 780, 286, 1275, 1, 158, 201, 327, 137, 3, 435, 353, 1, 14827, 36, 768, 6, 1283, 404, 1233, 6, 40, 1113, 4, 93, 1466, 9, 112, 1890, 1, 857, 5, 286, 1275, 3, 364, 206, 2527, 476, 1, 46, 217, 43, 3716, 611, 3312, 23, 435, 954, 4, 24, 1, 3006, 1170, 109, 286, 1275, 2, 2908, 132, 31, 286, 1275, 75, 2665, 238, 235, 2, 217, 611, 6, 24, 1, 286, 1275, 4, 434, 3101, 2, 1169, 857, 10096, 189, 422, 2516, 4, 3, 1401, 24, 1, 541, 5, 286, 1275, 8, 435, 45, 17, 4468, 3, 200, 1, 1063, 452, 31, 941, 9, 857, 5, 286, 1275, 4, 157, 734, 303, 120, 40, 446, 3, 697, 112, 353, 6, 36, 1, 780, 286, 1275, 16, 2948, 6, 757, 4, 721, 1474, 4, 25, 508, 1474, 4, 25, 1, 857, 5, 286, 1275, 303, 4533, 23, 2599, 4, 375, 1690, 87, 143, 75, 2665, 395, 2189, 9, 26, 1352, 622, 2, 1564, 87, 1, 1342]",1405.0,18536580,676
CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-06-01,"Corticosteroids are a critical component of therapy for acute lymphoblastic leukemia (ALL) but are associated with late effects, such as osteoporosis. Risk factors remain poorly defined. Because CRHR1 polymorphisms have been associated with other corticosteroid effects, our goal was to define whether CRHR1 polymorphisms predict which patients with ALL are likely to develop bone mineral deficits. The mean bone mineral density z scores of 309 long-term survivors of ALL were determined by quantitative computed tomography of the trabecular lumbar spine. We analyzed whether CRHR1 genotypes, adjusted for sex, ALL treatment regimen, and weight, could predict bone density. We found that three single nucleotide polymorphisms (SNPs), all in linkage disequilibrium, were associated with bone density in a sex-specific manner. Bone density was lower in males (P = .001), in nonblack patients (P < .08), in those who were not overweight (P < .001), and in those who received intensive antimetabolites and glucocorticoids (P < .001). After adjustment for these features, the G allele at the rs1876828 SNP was associated with lower z scores (P = .02) in males but tended to have the opposite association in females (P = .09). CRHR1 polymorphisms may impact the risk of bone density deficits in patients treated with corticosteroids and antimetabolites in a sex-specific manner.",Journal Article,4251.0,34.0,Corticosteroids are a critical component of therapy for acute lymphoblastic ALL but are associated with late effects such as osteoporosis Risk factors remain poorly defined Because CRHR1 polymorphisms have been associated with other corticosteroid effects our goal was to define whether CRHR1 polymorphisms predict which patients with ALL are likely to develop mineral deficits The mean mineral density z scores of 309 long-term survivors of ALL were determined by quantitative computed tomography of the trabecular lumbar spine We analyzed whether CRHR1 genotypes adjusted for sex ALL treatment regimen and weight could predict density We found that three single nucleotide polymorphisms SNPs all in linkage disequilibrium were associated with density in a sex-specific manner density was lower in males P .001 in nonblack patients P .08 in those who were not overweight P .001 and in those who received intensive antimetabolites and glucocorticoids P .001 After adjustment for these features the G allele at the rs1876828 SNP was associated with lower z scores P .02 in males but tended to have the opposite association in females P .09 CRHR1 polymorphisms may impact the risk of density deficits in patients treated with corticosteroids and antimetabolites in a sex-specific manner,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3876, 32, 8, 740, 1249, 1, 36, 9, 286, 1275, 62, 84, 32, 41, 5, 807, 176, 225, 22, 4970, 43, 130, 918, 1240, 395, 408, 31289, 1203, 47, 85, 41, 5, 127, 5654, 176, 114, 1326, 10, 6, 1107, 317, 31289, 1203, 678, 92, 7, 5, 62, 32, 322, 6, 690, 5033, 2752, 3, 313, 5033, 1263, 3905, 703, 1, 9440, 319, 337, 332, 1, 62, 11, 509, 20, 1156, 1220, 872, 1, 3, 12853, 6187, 2342, 21, 311, 317, 31289, 2071, 586, 9, 1035, 62, 24, 477, 2, 924, 359, 678, 1263, 21, 204, 17, 169, 226, 1579, 1203, 1109, 62, 4, 4820, 8459, 11, 41, 5, 1263, 4, 8, 1035, 112, 1708, 1263, 10, 280, 4, 2296, 19, 144, 4, 18496, 7, 19, 1592, 4, 135, 54, 11, 44, 3566, 19, 144, 2, 4, 135, 54, 103, 1686, 21195, 2, 7307, 19, 144, 50, 1852, 9, 46, 404, 3, 499, 1254, 28, 3, 57177, 1845, 10, 41, 5, 280, 3905, 703, 19, 588, 4, 2296, 84, 3886, 6, 47, 3, 7021, 248, 4, 2451, 19, 1730, 31289, 1203, 68, 345, 3, 43, 1, 1263, 2752, 4, 7, 73, 5, 3876, 2, 21195, 4, 8, 1035, 112, 1708]",1284.0,18565889,764
Osteonecrosis in adult survivors of childhood cancer: a report from the childhood cancer survivor study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-06-01,"Osteonecrosis (ON) is a potentially serious complication of therapy in survivors of childhood cancer. Our goals were to describe the incidence of ON and identify patient and treatment characteristics associated with elevated risk. The rate of self-reported ON was determined for 9,261 patients enrolled onto the Childhood Cancer Survivor Study, a cohort of 5-year survivors of childhood cancer diagnosed from 1970 to 1986, and compared with the rate in a random sample of 2,872 siblings of survivors. Survivors with positive responses were reinterviewed to confirm the diagnosis. Fifty-two cancer survivors reported ON in 78 joints, yielding 20-year cumulative incidence of 0.43% and a rate ratio (RR) of 6.2 (95% CI, 2.3 to 17.2) compared with siblings, adjusted for age and sex; 44% developed ON in a previous radiation field. The RR was greatest among survivors of stem-cell transplantation for acute lymphoblastic leukemia (ALL), acute myelogenous leukemia (AML), and chronic myelogenous leukemia (RR = 26.9, 66.5, and 93.1, respectively). Nontransplantation patients with ALL (RR = 6.5; 95% CI, 2.2 to 19.4), AML (RR = 11.2; 95% CI, 2.1 to 61.2), and bone sarcoma (RR = 7.3; 95% CI, 2.0 to 26.2) were at higher risk for ON. Older age at diagnosis, shorter elapsed time, older treatment era, exposure to dexamethasone (+/- prednisone), and gonadal and nongonadal radiation were independently associated with ON. ON among long-term survivors of childhood cancer is rare. However, compared with siblings, childhood cancer survivors have a significantly increased relative rate of ON, particularly those who were older at diagnosis and who received dexamethasone or radiation therapy. Future studies are needed to better delineate our findings, particularly the increased risk after gonadal radiation.",Journal Article,4251.0,80.0,"Osteonecrosis ON is a potentially serious complication of therapy in survivors of childhood cancer Our goals were to describe the incidence of ON and identify patient and treatment characteristics associated with elevated risk The rate of self-reported ON was determined for 9,261 patients enrolled onto the Childhood Cancer Survivor Study a cohort of 5-year survivors of childhood cancer diagnosed from 1970 to 1986 and compared with the rate in a random sample of 2,872 siblings of survivors Survivors with positive responses were reinterviewed to confirm the diagnosis Fifty-two cancer survivors reported ON in 78 joints yielding 20-year cumulative incidence of 0.43 and a rate ratio RR of 6.2 95 CI 2.3 to 17.2 compared with siblings adjusted for age and sex 44 developed ON in a previous radiation field The RR was greatest among survivors of stem-cell transplantation for acute lymphoblastic ALL acute myelogenous AML and chronic myelogenous RR 26.9 66.5 and 93.1 respectively Nontransplantation patients with ALL RR 6.5 95 CI 2.2 to 19.4 AML RR 11.2 95 CI 2.1 to 61.2 and RR 7.3 95 CI 2.0 to 26.2 were at higher risk for ON Older age at diagnosis shorter elapsed time older treatment era exposure to dexamethasone +/- prednisone and gonadal and nongonadal radiation were independently associated with ON ON among long-term survivors of childhood cancer is rare However compared with siblings childhood cancer survivors have a significantly increased relative rate of ON particularly those who were older at diagnosis and who received dexamethasone or radiation therapy Future studies are needed to better delineate our findings particularly the increased risk after gonadal radiation",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 23, 16, 8, 751, 1762, 1447, 1, 36, 4, 332, 1, 864, 12, 114, 2802, 11, 6, 897, 3, 287, 1, 23, 2, 255, 69, 2, 24, 374, 41, 5, 804, 43, 3, 116, 1, 1074, 210, 23, 10, 509, 9, 83, 7007, 7, 346, 3301, 3, 864, 12, 2628, 45, 8, 180, 1, 33, 111, 332, 1, 864, 12, 265, 29, 4868, 6, 3751, 2, 72, 5, 3, 116, 4, 8, 2324, 1000, 1, 18, 17900, 2758, 1, 332, 332, 5, 109, 253, 11, 57178, 6, 1843, 3, 147, 1461, 100, 12, 332, 210, 23, 4, 833, 16854, 4949, 179, 111, 967, 287, 1, 13, 601, 2, 8, 116, 197, 861, 1, 49, 18, 48, 58, 18, 27, 6, 269, 18, 72, 5, 2758, 586, 9, 89, 2, 1035, 584, 276, 23, 4, 8, 698, 121, 1067, 3, 861, 10, 2199, 107, 332, 1, 452, 31, 497, 9, 286, 1275, 62, 286, 2194, 329, 2, 442, 2194, 861, 432, 83, 700, 33, 2, 966, 14, 106, 22487, 7, 5, 62, 861, 49, 33, 48, 58, 18, 18, 6, 326, 39, 329, 861, 175, 18, 48, 58, 18, 14, 6, 713, 18, 2, 861, 67, 27, 48, 58, 18, 13, 6, 432, 18, 11, 28, 142, 43, 9, 23, 434, 89, 28, 147, 985, 10670, 98, 434, 24, 1713, 645, 6, 1217, 1979, 2, 7999, 2, 38753, 121, 11, 1042, 41, 5, 23, 23, 107, 319, 337, 332, 1, 864, 12, 16, 622, 137, 72, 5, 2758, 864, 12, 332, 47, 8, 97, 101, 580, 116, 1, 23, 823, 135, 54, 11, 434, 28, 147, 2, 54, 103, 1217, 15, 121, 36, 508, 94, 32, 575, 6, 380, 5092, 114, 272, 823, 3, 101, 43, 50, 7999, 121]",1690.0,18565890,95
"Implementing an intervention to improve bone mineral density in survivors of childhood acute lymphoblastic leukemia: BONEII, a prospective placebo-controlled double-blind randomized interventional longitudinal study design.",Contemporary clinical trials,Contemp Clin Trials,2008-05-18,"The BONEII study is a large two-phase study. The baseline study (Study 1) aims to estimate the prevalence of diminished bone mineral density (BMD) in patients treated for childhood acute lymphoblastic leukemia (ALL) and identify risk factors for BMD deficits. The interventional phase (Study 2) of BONEII has a placebo-controlled double-blind randomized longitudinal design to evaluate the effects of nutritional counseling and calcium and vitamin D supplementation on changes in BMD and serum and urine markers of bone metabolism. The extensive information being collected through this large study will serve as a repository of relational data about BMD and bone turnover and will support further investigations to assess the association of calcium metabolism, bone turnover, nutritional intake, lifestyle factors (such as exercise and the use of alcohol and tobacco), and the specific agents used in ALL therapy in this rapidly increasing population of childhood cancer survivors.",Clinical Trial,4265.0,16.0,The BONEII study is a large two-phase study The baseline study Study 1 aims to estimate the prevalence of diminished mineral density BMD in patients treated for childhood acute lymphoblastic ALL and identify risk factors for BMD deficits The interventional phase Study 2 of BONEII has a placebo-controlled double-blind randomized longitudinal design to evaluate the effects of nutritional counseling and calcium and vitamin D supplementation on changes in BMD and serum and urine markers of metabolism The extensive information being collected through this large study will serve as a repository of relational data about BMD and turnover and will support further investigations to assess the association of calcium metabolism turnover nutritional intake lifestyle factors such as exercise and the use of alcohol and tobacco and the specific agents used in ALL therapy in this rapidly increasing population of childhood cancer survivors,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 45180, 45, 16, 8, 375, 100, 124, 45, 3, 330, 45, 45, 14, 2970, 6, 1191, 3, 1078, 1, 2849, 5033, 1263, 3503, 4, 7, 73, 9, 864, 286, 1275, 62, 2, 255, 43, 130, 9, 3503, 2752, 3, 6182, 124, 45, 18, 1, 45180, 71, 8, 619, 1149, 1627, 3142, 384, 2380, 771, 6, 376, 3, 176, 1, 5082, 2011, 2, 3299, 2, 1610, 427, 3890, 23, 400, 4, 3503, 2, 524, 2, 2646, 525, 1, 1600, 3, 1344, 487, 486, 786, 298, 26, 375, 45, 303, 1833, 22, 8, 12841, 1, 12894, 74, 545, 3503, 2, 5445, 2, 303, 538, 195, 2492, 6, 423, 3, 248, 1, 3299, 1600, 5445, 5082, 1514, 3487, 130, 225, 22, 2277, 2, 3, 119, 1, 2197, 2, 2607, 2, 3, 112, 183, 95, 4, 62, 36, 4, 26, 1755, 602, 266, 1, 864, 12, 332]",935.0,18586578,387
Neuroleukemiosis: case report of leukemic nerve infiltration in acute lymphoblastic leukemia.,Muscle & nerve,Muscle Nerve,2008-09-01,"We describe a patient in remission from acute lymphoblastic leukemia who developed a painless common peroneal neuropathy. Magnetic resonance imaging (MRI) revealed nerve thickening and enhancement, while a positron emission tomography (PET) scan demonstrated increased fluorodeoxyglucose uptake in a large segment of the neurovascular bundle, suggesting peripheral nerve infiltration. Both findings resolved following treatment with chemotherapy that crossed the blood-nerve barrier. In selected patients presenting with peripheral neuropathy, MRI and PET scan can be helpful in the diagnosis of peripheral nerve infiltration.",Case Reports,4159.0,21.0,We describe a patient in remission from acute lymphoblastic who developed a painless common peroneal neuropathy Magnetic resonance imaging MRI revealed nerve thickening and enhancement while a positron emission tomography PET scan demonstrated increased fluorodeoxyglucose uptake in a large segment of the neurovascular bundle suggesting peripheral nerve infiltration Both findings resolved following treatment with chemotherapy that crossed the blood-nerve barrier In selected patients presenting with peripheral neuropathy MRI and PET scan can be helpful in the diagnosis of peripheral nerve infiltration,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 897, 8, 69, 4, 734, 29, 286, 1275, 54, 276, 8, 14963, 186, 34512, 1751, 1484, 1535, 270, 704, 553, 2476, 12085, 2, 2461, 369, 8, 1900, 1799, 872, 495, 1657, 264, 101, 4085, 1135, 4, 8, 375, 4610, 1, 3, 9848, 11261, 802, 672, 2476, 2084, 110, 272, 3862, 366, 24, 5, 56, 17, 7023, 3, 315, 2476, 3318, 4, 715, 7, 1656, 5, 672, 1751, 704, 2, 495, 1657, 122, 40, 3951, 4, 3, 147, 1, 672, 2476, 2084]",606.0,18642385,173
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.,Blood,Blood,2008-08-14,"Immunophenotypic classification of acute lymphoblastic leukemia (ALL) has well-recognized prognostic implications. The significance of CD20 expression has been evaluated in childhood precursor B-lineage ALL with conflicting results. We retrospectively analyzed the influence of CD20 expression on outcome in 253 adults with de novo precursor B-lineage ALL treated with either conventional (VAD/CVAD) or intensive (hyper-CVAD) frontline chemotherapy regimens in the pre-rituximab era. Overall, CD20 positivity of at least 20% was associated with lower 3-year rates of complete remission duration (CRD; 20% vs 55%, P < .001) and overall survival (OS; 27% vs 40%, p = .03). In the CD20 negative subset, the 3-year rates for CRD (58% vs 42%, p = .04) and OS (60% vs 28%, P < .001) were superior for hyper-CVAD compared with VAD/CVAD; rates were particularly favorable for the CD20 negative younger age group (68% and 85%, respectively). In contrast, 3-year CRD and OS rates were uniformly poor for the CD20-positive group regardless of therapy (27% or less). Multivariate analysis for event-free survival identified older age, leukocyte count higher than 30 x 10(9)/L, presence of Philadelphia chromosome, high systemic risk classification, and CD20 positivity as independent predictors of worse outcome. In conclusion, CD20 expression in de novo adult precursor B-lineage ALL appears to be associated with a poor prognosis. Incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation.",Journal Article,4177.0,100.0,Immunophenotypic classification of acute lymphoblastic ALL has well-recognized prognostic implications The significance of CD20 expression has been evaluated in childhood precursor B-lineage ALL with conflicting results We retrospectively analyzed the influence of CD20 expression on outcome in 253 adults with de novo precursor B-lineage ALL treated with either conventional VAD/CVAD or intensive hyper-CVAD frontline chemotherapy regimens in the pre-rituximab era Overall CD20 positivity of at least 20 was associated with lower 3-year rates of complete remission duration CRD 20 vs 55 P .001 and overall survival OS 27 vs 40 p .03 In the CD20 negative subset the 3-year rates for CRD 58 vs 42 p .04 and OS 60 vs 28 P .001 were superior for hyper-CVAD compared with VAD/CVAD rates were particularly favorable for the CD20 negative younger age group 68 and 85 respectively In contrast 3-year CRD and OS rates were uniformly poor for the CD20-positive group regardless of therapy 27 or less Multivariate analysis for event-free survival identified older age leukocyte count higher than 30 x 10 9 /L presence of Philadelphia chromosome high systemic risk classification and CD20 positivity as independent predictors of worse outcome In conclusion CD20 expression in de novo adult precursor B-lineage ALL appears to be associated with a poor prognosis Incorporation of monoclonal antibodies directed against CD20 into frontline chemotherapy regimens warrants investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6599, 947, 1, 286, 1275, 62, 71, 149, 1904, 177, 1268, 3, 724, 1, 2198, 55, 71, 85, 194, 4, 864, 2765, 132, 2542, 62, 5, 4274, 99, 21, 894, 311, 3, 1054, 1, 2198, 55, 23, 228, 4, 8105, 857, 5, 1566, 2018, 2765, 132, 2542, 62, 73, 5, 361, 809, 10167, 5574, 15, 1686, 4855, 5574, 3171, 56, 472, 4, 3, 671, 855, 1713, 63, 2198, 1887, 1, 28, 506, 179, 10, 41, 5, 280, 27, 111, 151, 1, 236, 734, 654, 9366, 179, 105, 614, 19, 144, 2, 63, 25, 118, 428, 105, 327, 19, 680, 4, 3, 2198, 199, 697, 3, 27, 111, 151, 9, 9366, 717, 105, 595, 19, 755, 2, 118, 335, 105, 339, 19, 144, 11, 1123, 9, 4855, 5574, 72, 5, 10167, 5574, 151, 11, 823, 913, 9, 3, 2198, 199, 773, 89, 87, 806, 2, 772, 106, 4, 748, 27, 111, 9366, 2, 118, 151, 11, 4254, 334, 9, 3, 2198, 109, 87, 1583, 1, 36, 428, 15, 299, 331, 65, 9, 774, 115, 25, 108, 434, 89, 3627, 1276, 142, 76, 201, 1006, 79, 83, 805, 463, 1, 3006, 1170, 64, 403, 43, 947, 2, 2198, 1887, 22, 306, 674, 1, 639, 228, 4, 1221, 2198, 55, 4, 1566, 2018, 780, 2765, 132, 2542, 62, 1233, 6, 40, 41, 5, 8, 334, 356, 2838, 1, 848, 890, 1166, 480, 2198, 237, 3171, 56, 472, 2782, 940]",1470.0,18703706,891
Twenty years of unrelated donor hematopoietic cell transplantation for adult recipients facilitated by the National Marrow Donor Program.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2008-09-01,"For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients. In this time period, the volunteer donor pool has expanded to nearly 12 million adult donors worldwide, improvements have occurred in the understanding and technology of HLA matching, there have been many changes in clinical practice and supportive care, and the more common graft source has shifted from bone marrow (BM) to peripheral blood stem cells (PBSCs). The percentage of older patients who are receiving unrelated donor transplants is increasing; currently over 1 in 10 adult transplant recipients is over the age of 60 years. Chronic myelogenous leukemia (CML) was previously the most common diagnosis for unrelated donor transplantation, but it now comprises less than 10% of transplants for adult recipients. Transplants for acute myelogenous leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), and myelodysplastic syndromes (MDS) all outnumber CML. Treatment-related mortality (TRM) has declined significantly over the years, particularly in association with myeloablative transplant preparative regimens. Correspondingly, survival within each disease category has improved. Particularly gratifying are the results in severe aplastic anemia (AA) where 2-year survival has doubled in just 10 years.",Historical Article,4159.0,91.0,For more than 20 years the National Marrow Donor Program has facilitated unrelated donor hematopoietic cell transplants for adult recipients In this time period the volunteer donor pool has expanded to nearly 12 million adult donors worldwide improvements have occurred in the understanding and technology of HLA matching there have been many changes in clinical practice and supportive care and the more common graft source has shifted from marrow BM to peripheral blood stem cells PBSCs The percentage of older patients who are receiving unrelated donor transplants is increasing currently over 1 in 10 adult transplant recipients is over the age of 60 years Chronic myelogenous CML was previously the most common diagnosis for unrelated donor transplantation but it now comprises less than 10 of transplants for adult recipients Transplants for acute myelogenous AML acute lymphoblastic ALL NHL and syndromes MDS all outnumber CML Treatment-related mortality TRM has declined significantly over the years particularly in association with myeloablative transplant preparative regimens Correspondingly survival within each disease category has improved Particularly gratifying are the results in severe aplastic anemia AA where 2-year survival has doubled in just 10 years,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 80, 76, 179, 60, 3, 657, 581, 1488, 1243, 71, 4667, 2092, 1488, 1007, 31, 4016, 9, 780, 2190, 4, 26, 98, 727, 3, 15536, 1488, 6545, 71, 2064, 6, 1857, 133, 3346, 780, 2344, 2358, 1474, 47, 489, 4, 3, 612, 2, 2033, 1, 1160, 2616, 125, 47, 85, 445, 400, 4, 38, 758, 2, 1877, 165, 2, 3, 80, 186, 1599, 2353, 71, 7289, 29, 581, 1246, 6, 672, 315, 452, 37, 13620, 3, 1150, 1, 434, 7, 54, 32, 357, 2092, 1488, 4016, 16, 602, 694, 252, 14, 4, 79, 780, 941, 2190, 16, 252, 3, 89, 1, 335, 60, 442, 2194, 903, 10, 373, 3, 96, 186, 147, 9, 2092, 1488, 497, 84, 192, 1134, 6704, 299, 76, 79, 1, 4016, 9, 780, 2190, 4016, 9, 286, 2194, 329, 286, 1275, 62, 1176, 2, 2040, 1223, 62, 31036, 903, 24, 139, 282, 5064, 71, 3054, 97, 252, 3, 60, 823, 4, 248, 5, 3246, 941, 6085, 472, 11599, 25, 262, 296, 34, 2169, 71, 231, 823, 34530, 32, 3, 99, 4, 905, 16315, 1545, 1519, 1257, 18, 111, 25, 71, 8431, 4, 4673, 79, 60]",1273.0,18721775,584
Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia.,Blood,Blood,2008-09-02,"The underlying pathways that lead to relapse in childhood acute lymphoblastic leukemia (ALL) are unknown. To comprehensively characterize the molecular evolution of relapsed childhood B-precursor ALL, we used human 500K single-nucleotide polymorphism arrays to identify somatic copy number alterations (CNAs) in 20 diagnosis/relapse pairs relative to germ line. We identified 758 CNAs, 66.4% of which were less than 1 Mb, and deletions outnumbered amplifications by approximately 2.5:1. Although CNAs persisting from diagnosis to relapse were observed in all 20 cases, 17 patients exhibited differential CNA patterns from diagnosis to relapse. Of the 396 CNAs observed in 20 relapse samples, only 69 (17.4%) were novel (absent in the matched diagnosis samples). EBF1 and IKZF1 deletions were particularly frequent in this relapsed ALL cohort (25.0% and 35.0%, respectively), suggesting their role in disease recurrence. In addition, we noted concordance in global gene expression and DNA copy number changes (P = 2.2 x 10(-16)). Finally, relapse-specific focal deletion of MSH6 and, consequently, reduced gene expression were found in 2 of 20 cases. In an independent cohort of children with ALL, reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone, thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse.",Journal Article,4158.0,128.0,The underlying pathways that lead to relapse in childhood acute lymphoblastic ALL are unknown To comprehensively characterize the molecular evolution of relapsed childhood B-precursor ALL we used human 500K single-nucleotide polymorphism arrays to identify somatic copy number alterations CNAs in 20 diagnosis/relapse pairs relative to germ line We identified 758 CNAs 66.4 of which were less than 1 Mb and deletions outnumbered amplifications by approximately 2.5:1 Although CNAs persisting from diagnosis to relapse were observed in all 20 cases 17 patients exhibited differential CNA patterns from diagnosis to relapse Of the 396 CNAs observed in 20 relapse samples only 69 17.4 were novel absent in the matched diagnosis samples EBF1 and IKZF1 deletions were particularly frequent in this relapsed ALL cohort 25.0 and 35.0 respectively suggesting their role in disease recurrence In addition we noted concordance in global gene expression and DNA copy number changes P 2.2 x 10 -16 Finally relapse-specific focal deletion of MSH6 and consequently reduced gene expression were found in 2 of 20 cases In an independent cohort of children with ALL reduced expression of MSH6 was associated with resistance to mercaptopurine and prednisone thereby providing a plausible mechanism by which this acquired deletion contributes to drug resistance at relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1181, 460, 17, 1122, 6, 429, 4, 864, 286, 1275, 62, 32, 860, 6, 5627, 1507, 3, 219, 2554, 1, 591, 864, 132, 2765, 62, 21, 95, 171, 34542, 226, 1579, 1907, 3923, 6, 255, 1119, 1337, 207, 593, 7452, 4, 179, 147, 429, 2773, 580, 6, 2280, 328, 21, 108, 13235, 7452, 700, 39, 1, 92, 11, 299, 76, 14, 2571, 2, 2439, 31314, 4877, 20, 705, 18, 33, 14, 242, 7452, 12099, 29, 147, 6, 429, 11, 164, 4, 62, 179, 140, 269, 7, 1416, 1777, 8986, 764, 29, 147, 6, 429, 1, 3, 9987, 7452, 164, 4, 179, 429, 347, 158, 790, 269, 39, 11, 229, 3269, 4, 3, 655, 147, 347, 23701, 2, 8422, 2439, 11, 823, 908, 4, 26, 591, 62, 180, 243, 13, 2, 465, 13, 106, 802, 136, 200, 4, 34, 146, 4, 352, 21, 1051, 1827, 4, 1648, 145, 55, 2, 261, 1337, 207, 400, 19, 18, 18, 1006, 79, 245, 1368, 429, 112, 2137, 1528, 1, 5176, 2, 3244, 405, 145, 55, 11, 204, 4, 18, 1, 179, 140, 4, 35, 306, 180, 1, 541, 5, 62, 405, 55, 1, 5176, 10, 41, 5, 251, 6, 9223, 2, 1979, 2267, 1736, 8, 7761, 670, 20, 92, 26, 1294, 1528, 2444, 6, 234, 251, 28, 429]",1353.0,18768390,836
Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2008-09-09,"Total-body irradiation (TBI) has an important role in patients undergoing hematopoietic cell transplantation (HCT), but is associated with significant toxicities. Targeted TBI using helical tomotherapy results in reduced doses to normal organs, which predicts for reduced toxicities compared with standard TBI. Thirteen patients with multiple myeloma were treated in an autologous tandem transplantation Phase I trial with high-dose melphalan, followed 6 weeks later by total-marrow irradiation (TMI) to skeletal bone. Dose levels were 10, 12, 14, and 16 Gy at 2 Gy daily/twice daily. In a separate allogeneic HCT trial, 8 patients (5 with acute myelogenous leukemia, 1 with acute lymphoblastic leukemia, 1 with non-Hodgkin's lymphoma, and 1 with multiple myeloma) were treated with TMI plus total lymphoid irradiation plus splenic radiotherapy to 12 Gy (1.5 Gy twice daily) combined with fludarabine/melphalan. For the 13 patients in the tandem autologous HCT trial, median age was 54 years (range, 42-66 years). Median organ doses were 15-65% that of the gross target volume dose. Primarily Grades 1-2 acute toxicities were observed. Six patients reported no vomiting; 9 patients, no mucositis; 6 patients, no fatigue; and 8 patients, no diarrhea. For the 8 patients in the allogeneic HCT trial, median age was 52 years (range, 24-61 years). Grades 2-3 nausea, vomiting, mucositis, and diarrhea were observed. In both trials, no Grade 4 nonhematologic toxicity was observed, and all patients underwent successful engraftment. This study shows that TMI using helical tomotherapy is clinically feasible. The reduced acute toxicities observed compare favorably with those seen with standard TBI. Initial results are encouraging and warrant further evaluation as a method to dose escalate with acceptable toxicity or to offer TBI-containing regimens to patients unable to tolerate standard approaches.",Clinical Trial,4151.0,87.0,Total-body irradiation TBI has an important role in patients undergoing hematopoietic cell transplantation HCT but is associated with significant toxicities Targeted TBI using helical tomotherapy results in reduced doses to normal organs which predicts for reduced toxicities compared with standard TBI Thirteen patients with multiple were treated in an autologous tandem transplantation Phase I trial with high-dose melphalan followed 6 weeks later by total-marrow irradiation TMI to skeletal Dose levels were 10 12 14 and 16 Gy at 2 Gy daily/twice daily In a separate allogeneic HCT trial 8 patients 5 with acute myelogenous 1 with acute lymphoblastic 1 with 's and 1 with multiple were treated with TMI plus total lymphoid irradiation plus splenic radiotherapy to 12 Gy 1.5 Gy twice daily combined with fludarabine/melphalan For the 13 patients in the tandem autologous HCT trial median age was 54 years range 42-66 years Median organ doses were 15-65 that of the gross target volume dose Primarily Grades 1-2 acute toxicities were observed Six patients reported no vomiting 9 patients no mucositis 6 patients no fatigue and 8 patients no diarrhea For the 8 patients in the allogeneic HCT trial median age was 52 years range 24-61 years Grades 2-3 nausea vomiting mucositis and diarrhea were observed In both trials no Grade 4 nonhematologic toxicity was observed and all patients underwent successful engraftment This study shows that TMI using helical tomotherapy is clinically feasible The reduced acute toxicities observed compare favorably with those seen with standard TBI Initial results are encouraging and warrant further evaluation as a method to dose escalate with acceptable toxicity or to offer TBI-containing regimens to patients unable to tolerate standard approaches,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[181, 642, 1104, 4889, 71, 35, 305, 200, 4, 7, 479, 1007, 31, 497, 1085, 84, 16, 41, 5, 93, 385, 238, 4889, 75, 6638, 7731, 99, 4, 405, 415, 6, 295, 2285, 92, 2623, 9, 405, 385, 72, 5, 260, 4889, 3170, 7, 5, 232, 11, 73, 4, 35, 1028, 2905, 497, 124, 70, 160, 5, 64, 61, 2370, 370, 49, 244, 1559, 20, 181, 581, 1104, 11845, 6, 2621, 61, 148, 11, 79, 133, 213, 2, 245, 381, 28, 18, 381, 391, 936, 391, 4, 8, 2282, 1063, 1085, 160, 66, 7, 33, 5, 286, 2194, 14, 5, 286, 1275, 14, 5, 292, 2, 14, 5, 232, 11, 73, 5, 11845, 349, 181, 2303, 1104, 349, 5237, 310, 6, 133, 381, 14, 33, 381, 936, 391, 397, 5, 2027, 2370, 9, 3, 233, 7, 4, 3, 2905, 1028, 1085, 160, 52, 89, 10, 667, 60, 184, 595, 700, 60, 52, 1259, 415, 11, 167, 556, 17, 1, 3, 1789, 283, 433, 61, 1561, 2276, 14, 18, 286, 385, 11, 164, 437, 7, 210, 77, 1966, 83, 7, 77, 2606, 49, 7, 77, 613, 2, 66, 7, 77, 1172, 9, 3, 66, 7, 4, 3, 1063, 1085, 160, 52, 89, 10, 653, 60, 184, 259, 713, 60, 2276, 18, 27, 1218, 1966, 2606, 2, 1172, 11, 164, 4, 110, 143, 77, 88, 39, 3534, 155, 10, 164, 2, 62, 7, 208, 1401, 2881, 26, 45, 1949, 17, 11845, 75, 6638, 7731, 16, 505, 1313, 3, 405, 286, 385, 164, 932, 5001, 5, 135, 527, 5, 260, 4889, 388, 99, 32, 2269, 2, 2946, 195, 451, 22, 8, 596, 6, 61, 10400, 5, 1595, 155, 15, 6, 1918, 4889, 1101, 472, 6, 7, 4253, 6, 5010, 260, 611]",1785.0,18786784,110
Cutaneous precursor B-cell lymphoblastic lymphoma in 2 adult patients: clinicopathologic and molecular cytogenetic studies with a review of the literature.,Archives of dermatology,Arch Dermatol,2008-09-01,"Precursor B-cell lymphoblastic lymphoma (B-LBL) is an uncommon high-grade neoplasm of immature B cells. In contrast to the more common lymphoblastic lymphoma of T-cell lineage, B-LBL can be an extranodal disease, with a propensity to involve skin and bone. Most reported cases of B-LBL in the skin, a rarity in adults, are manifestations of existing systemic disease. We report 2 unusual cases of primary cutaneous B-LBL in adults. Fluorescence in situ hybridization studies, not previously reported in primary cutaneous B-LBL to our knowledge, demonstrated rearrangement of the MLL gene in one patient and possible hyperdiploidy in the other, both reported in precursor acute lymphoblastic leukemia. Review of the literature identified 13 reported cases of B-LBL occurring primarily in the skin, in addition to our 2 cases. Precursor B-cell lymphoblastic lymphoma is more common in children and in young adults, with a tropism for the head and neck region. Histologically, B-LBL must be differentiated from other high-grade lymphoid tumors and small ""blue round cell"" tumors. Because of the common absence of mature B-cell markers in immunohistochemical studies and the frequent expression of CD99, B-LBL may present a diagnostic challenge. Although there is a suggestion in a limited number of patients that abbreviated therapy may provide long-term disease control, the risk of relapse remains significant, particularly if a patient's condition is misdiagnosed and the patient is treated as having mature B-cell lymphoma. In the absence of prospective studies for this population, patients with B-LBL are treated currently with intensive acute lymphoblastic leukemia regimens.",Case Reports,4159.0,35.0,Precursor B-cell lymphoblastic B-LBL is an uncommon high-grade neoplasm of immature B cells In contrast to the more common lymphoblastic of T-cell lineage B-LBL can be an extranodal disease with a propensity to involve and Most reported cases of B-LBL in the a rarity in adults are manifestations of existing systemic disease We report 2 unusual cases of primary cutaneous B-LBL in adults Fluorescence in situ hybridization studies not previously reported in primary cutaneous B-LBL to our knowledge demonstrated rearrangement of the MLL gene in one patient and possible hyperdiploidy in the other both reported in precursor acute lymphoblastic Review of the literature identified 13 reported cases of B-LBL occurring primarily in the in addition to our 2 cases Precursor B-cell lymphoblastic is more common in children and in young adults with a tropism for the head and region Histologically B-LBL must be differentiated from other high-grade lymphoid tumors and small `` blue round cell '' tumors Because of the common absence of mature B-cell markers in immunohistochemical studies and the frequent expression of CD99 B-LBL may present a diagnostic challenge Although there is a suggestion in a limited number of patients that abbreviated therapy may provide long-term disease control the risk of relapse remains significant particularly if a patient 's condition is misdiagnosed and the patient is treated as having mature B-cell In the absence of prospective studies for this population patients with B-LBL are treated currently with intensive acute lymphoblastic regimens,0,0,1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,"[2765, 132, 31, 1275, 132, 8315, 16, 35, 2052, 64, 88, 2131, 1, 5733, 132, 37, 4, 748, 6, 3, 80, 186, 1275, 1, 102, 31, 2542, 132, 8315, 122, 40, 35, 4093, 34, 5, 8, 1925, 6, 3882, 2, 96, 210, 140, 1, 132, 8315, 4, 3, 8, 4989, 4, 857, 32, 4282, 1, 1692, 403, 34, 21, 414, 18, 4015, 140, 1, 86, 1486, 132, 8315, 4, 857, 1591, 4, 957, 1554, 94, 44, 373, 210, 4, 86, 1486, 132, 8315, 6, 114, 922, 264, 2675, 1, 3, 3049, 145, 4, 104, 69, 2, 899, 11299, 4, 3, 127, 110, 210, 4, 2765, 286, 1275, 206, 1, 3, 789, 108, 233, 210, 140, 1, 132, 8315, 1821, 1561, 4, 3, 4, 352, 6, 114, 18, 140, 2765, 132, 31, 1275, 16, 80, 186, 4, 541, 2, 4, 1169, 857, 5, 8, 9237, 9, 3, 718, 2, 1053, 2161, 132, 8315, 1642, 40, 1442, 29, 127, 64, 88, 2303, 57, 2, 302, 3352, 4436, 31, 522, 57, 408, 1, 3, 186, 1127, 1, 2908, 132, 31, 525, 4, 1382, 94, 2, 3, 908, 55, 1, 13940, 132, 8315, 68, 364, 8, 752, 1745, 242, 125, 16, 8, 8634, 4, 8, 383, 207, 1, 7, 17, 9786, 36, 68, 377, 319, 337, 34, 182, 3, 43, 1, 429, 469, 93, 823, 492, 8, 69, 292, 2850, 16, 10688, 2, 3, 69, 16, 73, 22, 1041, 2908, 132, 31, 4, 3, 1127, 1, 482, 94, 9, 26, 266, 7, 5, 132, 8315, 32, 73, 694, 5, 1686, 286, 1275, 472]",1578.0,18794461,402
Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2008-10-01,"We examined the rate of increase in the body mass index (BMI; kg/m(2)) after final height attainment in survivors of acute lymphoblastic leukemia (ALL) and a noncancer comparison group. Childhood Cancer Survivor Study (CCSS) is a retrospectively ascertained cohort study that prospectively tracks the health status of adults who were diagnosed with childhood cancer between 1970 and 1986 and a comparison group of siblings. Changes in BMI from baseline enrollment to time of completion of follow-up (mean interval, 7.8 years) were calculated for 1,451 ALL survivors (mean age, 32.3 years at follow-up) and 2,167 siblings of childhood cancer survivors (mean age, 35.9 years). The mean BMI of the CCSS sibling comparison group increased with age (women, 0.25 units/yr, 95% CI, 0.22 to 0.28 units; men, 0.23 units/yr, 95% CI, 0.20 to 0.25 units). Compared with CCSS siblings, ALL survivors who were treated with cranial radiation therapy (CRT) had a significantly greater increase in BMI (women, 0.41 units/yr, 95% CI, 0.37 to 0.45 units; men, 0.29 units/yr; 95% CI, 0.26 to 0.32 units). The rate of BMI increase was not significantly increased for ALL survivors who were treated with chemotherapy alone. Younger age at CRT exposure significantly modified risk. CRT used in the treatment of childhood ALL is associated with a greater rate of increasing BMI, particularly among women treated with CRT during the first decade of life. Health care professionals should be aware of this risk and interventions to reduce or manage weight gain are essential in this high-risk population.",Journal Article,4129.0,163.0,"We examined the rate of increase in the body mass index BMI kg/m 2 after final height attainment in survivors of acute lymphoblastic ALL and a noncancer comparison group Childhood Cancer Survivor Study CCSS is a retrospectively ascertained cohort study that prospectively tracks the health status of adults who were diagnosed with childhood cancer between 1970 and 1986 and a comparison group of siblings Changes in BMI from baseline enrollment to time of completion of follow-up mean interval 7.8 years were calculated for 1,451 ALL survivors mean age 32.3 years at follow-up and 2,167 siblings of childhood cancer survivors mean age 35.9 years The mean BMI of the CCSS sibling comparison group increased with age women 0.25 units/yr 95 CI 0.22 to 0.28 units men 0.23 units/yr 95 CI 0.20 to 0.25 units Compared with CCSS siblings ALL survivors who were treated with cranial radiation therapy CRT had a significantly greater increase in BMI women 0.41 units/yr 95 CI 0.37 to 0.45 units men 0.29 units/yr 95 CI 0.26 to 0.32 units The rate of BMI increase was not significantly increased for ALL survivors who were treated with chemotherapy alone Younger age at CRT exposure significantly modified risk CRT used in the treatment of childhood ALL is associated with a greater rate of increasing BMI particularly among women treated with CRT during the first decade of life Health care professionals should be aware of this risk and interventions to reduce or manage weight gain are essential in this high-risk population",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 409, 3, 116, 1, 344, 4, 3, 642, 782, 558, 1140, 503, 188, 18, 50, 1457, 4594, 7108, 4, 332, 1, 286, 1275, 62, 2, 8, 5994, 1155, 87, 864, 12, 2628, 45, 4657, 16, 8, 894, 5240, 180, 45, 17, 1143, 14481, 3, 341, 156, 1, 857, 54, 11, 265, 5, 864, 12, 59, 4868, 2, 3751, 2, 8, 1155, 87, 1, 2758, 400, 4, 1140, 29, 330, 1798, 6, 98, 1, 1438, 1, 166, 126, 313, 268, 67, 66, 60, 11, 981, 9, 14, 9697, 62, 332, 313, 89, 531, 27, 60, 28, 166, 126, 2, 18, 5431, 2758, 1, 864, 12, 332, 313, 89, 465, 83, 60, 3, 313, 1140, 1, 3, 4657, 3684, 1155, 87, 101, 5, 89, 117, 13, 243, 2960, 2830, 48, 58, 13, 350, 6, 13, 339, 2960, 325, 13, 382, 2960, 2830, 48, 58, 13, 179, 6, 13, 243, 2960, 72, 5, 4657, 2758, 62, 332, 54, 11, 73, 5, 2565, 121, 36, 1089, 42, 8, 97, 378, 344, 4, 1140, 117, 13, 605, 2960, 2830, 48, 58, 13, 567, 6, 13, 512, 2960, 325, 13, 462, 2960, 2830, 48, 58, 13, 432, 6, 13, 531, 2960, 3, 116, 1, 1140, 344, 10, 44, 97, 101, 9, 62, 332, 54, 11, 73, 5, 56, 279, 773, 89, 28, 1089, 645, 97, 1230, 43, 1089, 95, 4, 3, 24, 1, 864, 62, 16, 41, 5, 8, 378, 116, 1, 602, 1140, 823, 107, 117, 73, 5, 1089, 190, 3, 157, 2025, 1, 358, 341, 165, 3409, 257, 40, 4749, 1, 26, 43, 2, 1151, 6, 969, 15, 4001, 924, 1803, 32, 1452, 4, 26, 64, 43, 266]",1517.0,18824710,387
Recurrent intrathecal methotrexate induced neurotoxicity in an adolescent with acute lymphoblastic leukemia: Serial clinical and radiologic findings.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-02-01,"Systemic and intrathecal methotrexate (MTX) are integral components of acute lymphoblastic leukemia (ALL) therapy, but can be associated with neurotoxicity. We describe here the case of an adolescent male with T-cell ALL who developed recurrent episodes of subacute neurotoxicity characterized by slurred speech, emotional lability, and hemiparesis after intrathecal MTX administration. Serial magnetic resonance imaging with diffusion-weighted imaging showed recurrent areas of restricted diffusion within cerebral hemispheric white matter, which correlated chronologically with the administration of intrathecal therapy and severity of clinical symptoms. Resolution of diffusion abnormalities did not preclude further toxicity and a large lesion could cause persisting symptoms.",Case Reports,4006.0,23.0,Systemic and intrathecal methotrexate MTX are integral components of acute lymphoblastic ALL therapy but can be associated with neurotoxicity We describe here the case of an adolescent male with T-cell ALL who developed recurrent episodes of subacute neurotoxicity characterized by slurred speech emotional lability and hemiparesis after intrathecal MTX administration Serial magnetic resonance imaging with diffusion-weighted imaging showed recurrent areas of restricted diffusion within cerebral hemispheric white matter which correlated chronologically with the administration of intrathecal therapy and severity of clinical symptoms Resolution of diffusion abnormalities did not preclude further toxicity and a large lesion could cause persisting symptoms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[403, 2, 5126, 2116, 3453, 32, 4450, 1628, 1, 286, 1275, 62, 36, 84, 122, 40, 41, 5, 3561, 21, 897, 467, 3, 473, 1, 35, 3678, 1045, 5, 102, 31, 62, 54, 276, 387, 3750, 1, 15181, 3561, 765, 20, 45277, 9637, 2671, 34560, 2, 20164, 50, 5126, 3453, 634, 2108, 1484, 1535, 270, 5, 3438, 2337, 270, 224, 387, 1361, 1, 2016, 3438, 262, 3549, 24493, 886, 5090, 92, 438, 34561, 5, 3, 634, 1, 5126, 36, 2, 1702, 1, 38, 507, 2125, 1, 3438, 1171, 205, 44, 6064, 195, 155, 2, 8, 375, 1180, 359, 708, 12099, 507]",759.0,18831032,5
H3K79 methylation profiles define murine and human MLL-AF4 leukemias.,Cancer cell,Cancer Cell,2008-11-01,"We created a mouse model wherein conditional expression of an Mll-AF4 fusion oncogene induces B precursor acute lymphoblastic (ALL) or acute myeloid leukemias (AML). Gene expression profile analysis of the ALL cells demonstrated significant overlap with human MLL-rearranged ALL. ChIP-chip analysis demonstrated histone H3 lysine 79 (H3K79) methylation profiles that correlated with Mll-AF4-associated gene expression profiles in murine ALLs and in human MLL-rearranged leukemias. Human MLL-rearranged ALLs could be distinguished from other ALLs by their H3K79 profiles, and suppression of the H3K79 methyltransferase DOT1L inhibited expression of critical MLL-AF4 target genes. We thus demonstrate that ectopic H3K79 methylation is a distinguishing feature of murine and human MLL-AF4 ALLs and is important for maintenance of MLL-AF4-driven gene expression.",Journal Article,4098.0,375.0,We created a mouse model wherein conditional expression of an Mll-AF4 fusion oncogene induces B precursor acute lymphoblastic ALL or acute myeloid leukemias AML Gene expression profile analysis of the ALL cells demonstrated significant overlap with human MLL-rearranged ALL ChIP-chip analysis demonstrated histone H3 lysine 79 H3K79 methylation profiles that correlated with Mll-AF4-associated gene expression profiles in murine ALLs and in human MLL-rearranged leukemias Human MLL-rearranged ALLs could be distinguished from other ALLs by their H3K79 profiles and suppression of the H3K79 methyltransferase DOT1L inhibited expression of critical MLL-AF4 target genes We thus demonstrate that ectopic H3K79 methylation is a distinguishing feature of murine and human MLL-AF4 ALLs and is important for maintenance of MLL-AF4-driven gene expression,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 2466, 8, 830, 202, 7893, 3212, 55, 1, 35, 3049, 17272, 1212, 1836, 1516, 132, 2765, 286, 1275, 62, 15, 286, 533, 2792, 329, 145, 55, 800, 65, 1, 3, 62, 37, 264, 93, 4526, 5, 171, 3049, 3201, 62, 4222, 4222, 65, 264, 1508, 3739, 6041, 842, 23715, 569, 1241, 17, 438, 5, 3049, 17272, 41, 145, 55, 1241, 4, 1471, 10706, 2, 4, 171, 3049, 3201, 2792, 171, 3049, 3201, 10706, 359, 40, 4735, 29, 127, 10706, 20, 136, 23715, 1241, 2, 1332, 1, 3, 23715, 3747, 16504, 879, 55, 1, 740, 3049, 17272, 283, 214, 21, 631, 608, 17, 3647, 23715, 569, 16, 8, 4508, 2705, 1, 1471, 2, 171, 3049, 17272, 10706, 2, 16, 305, 9, 1146, 1, 3049, 17272, 1621, 145, 55]",846.0,18977325,4
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells.,Blood,Blood,2008-10-31,"Treatment failure in pediatric acute lymphoblastic leukemia (ALL) is related to cellular resistance to glucocorticoids (eg, prednisolone). Recently, we demonstrated that genes associated with glucose metabolism are differentially expressed between prednisolone-sensitive and prednisolone-resistant precursor B-lineage leukemic patients. Here, we show that prednisolone resistance is associated with increased glucose consumption and that inhibition of glycolysis sensitizes prednisolone-resistant ALL cell lines to glucocorticoids. Treatment of prednisolone-resistant Jurkat and Molt4 cells with 2-deoxy-D-glucose (2-DG), lonidamine (LND), or 3-bromopyruvate (3-BrPA) increased the in vitro sensitivity to glucocorticoids, while treatment of the prednisolone-sensitive cell lines Tom-1 and RS4; 11 did not influence drug cytotoxicity. This sensitizing effect of the glycolysis inhibitors in glucocorticoid-resistant ALL cells was not found for other classes of antileukemic drugs (ie, vincristine and daunorubicin). Moreover, down-regulation of the expression of GAPDH by RNA interference also sensitized to prednisolone, comparable with treatment with glycolytic inhibitors. Importantly, the ability of 2-DG to reverse glucocorticoid resistance was not limited to cell lines, but was also observed in isolated primary ALL cells from patients. Together, these findings indicate the importance of the glycolytic pathway in glucocorticoid resistance in ALL and suggest that targeting glycolysis is a viable strategy for modulating prednisolone resistance in ALL.",Journal Article,4099.0,128.0,Treatment failure in pediatric acute lymphoblastic ALL is related to cellular resistance to glucocorticoids eg prednisolone Recently we demonstrated that genes associated with glucose metabolism are differentially expressed between prednisolone-sensitive and prednisolone-resistant precursor B-lineage leukemic patients Here we show that prednisolone resistance is associated with increased glucose consumption and that inhibition of glycolysis sensitizes prednisolone-resistant ALL cell lines to glucocorticoids Treatment of prednisolone-resistant Jurkat and Molt4 cells with 2-deoxy-D-glucose 2-DG lonidamine LND or 3-bromopyruvate 3-BrPA increased the in vitro sensitivity to glucocorticoids while treatment of the prednisolone-sensitive cell lines Tom-1 and RS4 11 did not influence drug cytotoxicity This sensitizing effect of the glycolysis inhibitors in glucocorticoid-resistant ALL cells was not found for other classes of antileukemic drugs ie vincristine and daunorubicin Moreover down-regulation of the expression of GAPDH by RNA interference also sensitized to prednisolone comparable with treatment with glycolytic inhibitors Importantly the ability of 2-DG to reverse glucocorticoid resistance was not limited to cell lines but was also observed in isolated primary ALL cells from patients Together these findings indicate the importance of the glycolytic pathway in glucocorticoid resistance in ALL and suggest that targeting glycolysis is a viable strategy for modulating prednisolone resistance in ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 496, 4, 815, 286, 1275, 62, 16, 139, 6, 763, 251, 6, 7307, 2887, 11253, 761, 21, 264, 17, 214, 41, 5, 2522, 1600, 32, 2478, 570, 59, 11253, 745, 2, 11253, 436, 2765, 132, 2542, 2015, 7, 467, 21, 514, 17, 11253, 251, 16, 41, 5, 101, 2522, 2421, 2, 17, 297, 1, 4484, 6229, 11253, 436, 62, 31, 285, 6, 7307, 24, 1, 11253, 436, 8433, 2, 28410, 37, 5, 18, 6149, 427, 2522, 18, 13746, 57468, 3400, 15, 27, 31367, 27, 14644, 101, 3, 4, 439, 485, 6, 7307, 369, 24, 1, 3, 11253, 745, 31, 285, 57469, 14, 2, 45308, 175, 205, 44, 1054, 234, 1408, 26, 5979, 254, 1, 3, 4484, 222, 4, 5399, 436, 62, 37, 10, 44, 204, 9, 127, 3211, 1, 4512, 600, 2523, 2132, 2, 5247, 1393, 1328, 863, 1, 3, 55, 1, 12271, 20, 893, 3182, 120, 4242, 6, 11253, 1279, 5, 24, 5, 6688, 222, 1859, 3, 801, 1, 18, 13746, 6, 1772, 5399, 251, 10, 44, 383, 6, 31, 285, 84, 10, 120, 164, 4, 1355, 86, 62, 37, 29, 7, 1162, 46, 272, 1008, 3, 1187, 1, 3, 6688, 308, 4, 5399, 251, 4, 62, 2, 309, 17, 529, 4484, 16, 8, 2663, 692, 9, 3712, 11253, 251, 4, 62]",1518.0,18978206,126
Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.,"Science (New York, N.Y.)",Science,2008-11-01,"Most children with acute lymphoblastic leukemia (ALL) can be cured, but the prognosis is dismal for the minority of patients who relapse after treatment. To explore the genetic basis of relapse, we performed genome-wide DNA copy number analyses on matched diagnosis and relapse samples from 61 pediatric patients with ALL. The diagnosis and relapse samples typically showed different patterns of genomic copy number abnormalities (CNAs), with the CNAs acquired at relapse preferentially affecting genes implicated in cell cycle regulation and B cell development. Most relapse samples lacked some of the CNAs present at diagnosis, which suggests that the cells responsible for relapse are ancestral to the primary leukemia cells. Backtracking studies revealed that cells corresponding to the relapse clone were often present as minor subpopulations at diagnosis. These data suggest that genomic abnormalities contributing to ALL relapse are selected for during treatment, and they point to new targets for therapeutic intervention.",Journal Article,4098.0,554.0,Most children with acute lymphoblastic ALL can be cured but the prognosis is dismal for the minority of patients who relapse after treatment To explore the genetic basis of relapse we performed genome-wide DNA copy number analyses on matched diagnosis and relapse samples from 61 pediatric patients with ALL The diagnosis and relapse samples typically showed different patterns of genomic copy number abnormalities CNAs with the CNAs acquired at relapse preferentially affecting genes implicated in cell cycle regulation and B cell development Most relapse samples lacked some of the CNAs present at diagnosis which suggests that the cells responsible for relapse are ancestral to the primary cells Backtracking studies revealed that cells corresponding to the relapse clone were often present as minor subpopulations at diagnosis These data suggest that genomic abnormalities contributing to ALL relapse are selected for during treatment and they point to new targets for therapeutic intervention,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[96, 541, 5, 286, 1275, 62, 122, 40, 3733, 84, 3, 356, 16, 3929, 9, 3, 2652, 1, 7, 54, 429, 50, 24, 6, 1645, 3, 336, 877, 1, 429, 21, 173, 898, 1019, 261, 1337, 207, 318, 23, 655, 147, 2, 429, 347, 29, 713, 815, 7, 5, 62, 3, 147, 2, 429, 347, 1969, 224, 338, 764, 1, 572, 1337, 207, 1171, 7452, 5, 3, 7452, 1294, 28, 429, 3509, 2319, 214, 1771, 4, 31, 417, 863, 2, 132, 31, 193, 96, 429, 347, 5005, 476, 1, 3, 7452, 364, 28, 147, 92, 844, 17, 3, 37, 2327, 9, 429, 32, 15165, 6, 3, 86, 37, 57514, 94, 553, 17, 37, 1734, 6, 3, 429, 3910, 11, 629, 364, 22, 2278, 4847, 28, 147, 46, 74, 309, 17, 572, 1171, 3156, 6, 62, 429, 32, 715, 9, 190, 24, 2, 491, 741, 6, 217, 637, 9, 189, 788]",997.0,19039135,12
Reference alignment of SNP microarray signals for copy number analysis of tumors.,"Bioinformatics (Oxford, England)",Bioinformatics,2008-12-03,"A new procedure to align single nucleotide polymorphism (SNP) microarray signals for copy number analysis is proposed. For each individual array, this reference alignment procedure (RAP) uses a set of selected markers as internal references to direct the signal alignment. RAP aligns the signals so that each array has a similar signal distribution among its reference markers. An accompanying reference selection algorithm (RSA) uses genotype calls and initial signal intensities to choose two-copy markers as the internal references for each array. After RSA and RAP are applied, each array has a similar distribution of signals of two-copy markers so that across-array signal comparisons are biologically meaningful. An upper bound for a statistical metric of signal misalignment is derived and provides a theoretical basis to choose RSA-RAP over other alignment procedures for copy number analysis of cancers. In our study of acute lymphoblastic leukemia, RSA-RAP gives copy number analysis results that show substantially better concordance with cytogenetics than do two other alignment procedures. Documented R code is freely available from www.stjuderesearch.org/depts/biostats/refnorm.",Journal Article,4066.0,40.0,A new procedure to align single nucleotide polymorphism SNP microarray signals for copy number analysis is proposed For each individual array this reference alignment procedure RAP uses a set of selected markers as internal references to direct the signal alignment RAP aligns the signals so that each array has a similar signal distribution among its reference markers An accompanying reference selection algorithm RSA uses genotype calls and initial signal intensities to choose two-copy markers as the internal references for each array After RSA and RAP are applied each array has a similar distribution of signals of two-copy markers so that across-array signal comparisons are biologically meaningful An upper bound for a statistical metric of signal misalignment is derived and provides a theoretical basis to choose RSA-RAP over other alignment procedures for copy number analysis of cancers In our study of acute lymphoblastic RSA-RAP gives copy number analysis results that show substantially better concordance with cytogenetics than do two other alignment procedures Documented R code is freely available from www.stjuderesearch.org/depts/biostats/refnorm,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 217, 1299, 6, 15366, 226, 1579, 1907, 1845, 1727, 2312, 9, 1337, 207, 65, 16, 1587, 9, 296, 797, 1926, 26, 2482, 8097, 1299, 16272, 4025, 8, 916, 1, 715, 525, 22, 2329, 9241, 6, 1196, 3, 1235, 8097, 16272, 38869, 3, 2312, 1743, 17, 296, 1926, 71, 8, 288, 1235, 1395, 107, 211, 2482, 525, 35, 9503, 2482, 881, 2124, 34595, 4025, 1183, 6467, 2, 388, 1235, 11565, 6, 6009, 100, 1337, 525, 22, 3, 2329, 9241, 9, 296, 1926, 50, 34595, 2, 16272, 32, 1498, 296, 1926, 71, 8, 288, 1395, 1, 2312, 1, 100, 1337, 525, 1743, 17, 716, 1926, 1235, 2213, 32, 2665, 2538, 35, 1726, 2951, 9, 8, 1050, 6515, 1, 1235, 23659, 16, 526, 2, 777, 8, 7060, 877, 6, 6009, 34595, 16272, 252, 127, 8097, 1369, 9, 1337, 207, 65, 1, 163, 4, 114, 45, 1, 286, 1275, 34595, 16272, 7989, 1337, 207, 65, 99, 17, 514, 2109, 380, 1827, 5, 2510, 76, 1022, 100, 127, 8097, 1369, 1405, 668, 5853, 16, 18794, 390, 29, 3064, 45344, 5598, 45345, 45346, 57527]",1167.0,19052058,42
Curcumin inhibits proliferation and induces apoptosis of leukemic cells expressing wild-type or T315I-BCR-ABL and prolongs survival of mice with acute lymphoblastic leukemia.,"Hematology (Amsterdam, Netherlands)",Hematology,2008-12-01,"Curcumin, a natural compound derived from tumeric, has been shown to induce apoptosis in the leukemic cell line K562 and other cancer cell lines. However, it is unknown whether curcumin also has an inhibitory effect on BCR-ABL-expressing B-lymphoid cells. We tested whether curcumin has an inhibitory effect on BCR-ABL B-cell acute lymphoblastic leukemia (B-ALL) in vitro and in vivo. Pre-B cells isolated from B6 mice expressing wild-type BCR-ABL (B6p210) and T315I mutant (B6T315I) were cultured in serial concentration of curcumin. Cultured cells were analyzed by automated cell counter, flow cytometry, western blotting, and transcription factor arrays. B-ALL was induced by transplantation of MSCV-GFP-p210 transduced donor marrow in lethally irradiated Balb/c mice. Diseased mice were treated with placebo or curcumin until death of the mice. Diseased mice were analyzed by flow cytometric and histopathological analyses. Curcumin inhibited the proliferation of B6p210 and B6T315I cells at concentration as low as 10 muM and induced apoptosis of the cells at concentrations of 30 muM. Using western blots and transcription factors arrays, we showed that curcumin decreased NF-kappaB levels and increased p53 levels. Curcumin decreased c-Abl levels in cells expressing the wild, but not the mutant, BCR-ABL oncogene. Curcumin treatment resulted in a statistically significant improved survival in diseased mice along with decreasing white blood and GFP cell counts. Curcumin is effective against leukemic cells expressing p210 BCR-ABL and T315I BCR-ABL and holds promise in treating BCR-ABL-induced B-ALL.",Journal Article,4068.0,21.0,Curcumin a natural compound derived from tumeric has been shown to induce apoptosis in the leukemic cell line K562 and other cancer cell lines However it is unknown whether curcumin also has an inhibitory effect on BCR-ABL-expressing B-lymphoid cells We tested whether curcumin has an inhibitory effect on BCR-ABL B-cell acute lymphoblastic B-ALL in vitro and in vivo Pre-B cells isolated from B6 mice expressing wild-type BCR-ABL B6p210 and T315I mutant B6T315I were cultured in serial concentration of curcumin Cultured cells were analyzed by automated cell counter flow cytometry western blotting and transcription factor arrays B-ALL was induced by transplantation of MSCV-GFP-p210 transduced donor marrow in lethally irradiated Balb/c mice Diseased mice were treated with placebo or curcumin until death of the mice Diseased mice were analyzed by flow cytometric and histopathological analyses Curcumin inhibited the proliferation of B6p210 and B6T315I cells at concentration as low as 10 muM and induced apoptosis of the cells at concentrations of 30 muM Using western blots and transcription factors arrays we showed that curcumin decreased NF-kappaB levels and increased p53 levels Curcumin decreased c-Abl levels in cells expressing the wild but not the mutant BCR-ABL oncogene Curcumin treatment resulted in a statistically significant improved survival in diseased mice along with decreasing white blood and GFP cell counts Curcumin is effective against leukemic cells expressing p210 BCR-ABL and T315I BCR-ABL and holds promise in treating BCR-ABL-induced B-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3775, 8, 1504, 2823, 526, 29, 57530, 71, 85, 443, 6, 1290, 351, 4, 3, 2015, 31, 328, 5208, 2, 127, 12, 31, 285, 137, 192, 16, 860, 317, 3775, 120, 71, 35, 1810, 254, 23, 1062, 1425, 1046, 132, 2303, 37, 21, 650, 317, 3775, 71, 35, 1810, 254, 23, 1062, 1425, 132, 31, 286, 1275, 132, 62, 4, 439, 2, 4, 386, 671, 132, 37, 1355, 29, 10169, 399, 1046, 955, 267, 1062, 1425, 45348, 2, 6184, 620, 45349, 11, 3197, 4, 2108, 1227, 1, 3775, 3197, 37, 11, 311, 20, 3235, 31, 10259, 1412, 1914, 1521, 3661, 2, 866, 161, 3923, 132, 62, 10, 277, 20, 497, 1, 28423, 4687, 11538, 5042, 1488, 581, 4, 26772, 2398, 8166, 256, 399, 10486, 399, 11, 73, 5, 619, 15, 3775, 1100, 273, 1, 3, 399, 10486, 399, 11, 311, 20, 1412, 6226, 2, 4370, 318, 3775, 879, 3, 457, 1, 45348, 2, 45349, 37, 28, 1227, 22, 154, 22, 79, 10615, 2, 277, 351, 1, 3, 37, 28, 1003, 1, 201, 10615, 75, 1521, 13483, 2, 866, 130, 3923, 21, 224, 17, 3775, 340, 1365, 2119, 148, 2, 101, 624, 148, 3775, 340, 256, 1425, 148, 4, 37, 1046, 3, 955, 84, 44, 3, 620, 1062, 1425, 1836, 3775, 24, 627, 4, 8, 712, 93, 231, 25, 4, 10486, 399, 1510, 5, 2777, 886, 315, 2, 4687, 31, 1911, 3775, 16, 323, 480, 2015, 37, 1046, 11538, 1062, 1425, 2, 6184, 1062, 1425, 2, 5253, 1783, 4, 1367, 1062, 1425, 277, 132, 62]",1573.0,19055861,504
The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation.,Blood,Blood,2008-12-04,"Do some patients benefit from an unrelated donor (URD) transplant because of a stronger graft-versus-leukemia (GVL) effect? We analyzed 4099 patients with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and chronic myeloid leukemia (CML) undergoing a myeloablative allogeneic hematopoietic cell transplantation (HCT) from an URD (8/8 human leukocyte antigen [HLA]-matched, n=941) or HLA-identical sibling donor (n=3158) between 1995 and 2004 reported to the CIBMTR. In the Cox regression model, acute and chronic GVHD were added as time-dependent variables. In multivariate analysis, URD transplant recipients had a higher risk for transplantation-related mortality (TRM; relative risk [RR], 2.76; P< .001) and relapse (RR, 1.50; P< .002) in patients with AML, but not ALL or CML. Chronic GVHD was associated with a lower relapse risk in all diagnoses. Leukemia-free survival (LFS) was decreased in patients with AML without acute GVHD receiving a URD transplant (RR, 2.02; P< .001) but was comparable to those receiving HLA-identical sibling transplants in patients with ALL and CML. In patients without GVHD, multivariate analysis showed similar risk of relapse but decreased LFS for URD transplants for all 3 diagnoses. In conclusion, risk of relapse was the same (ALL, CML) or worse (AML) in URD transplant recipients compared with HLA-identical sibling transplant recipients, suggesting a similar GVL effect.",Comparative Study,4065.0,128.0,Do some patients benefit from an unrelated donor URD transplant because of a stronger graft-versus-leukemia GVL effect We analyzed 4099 patients with acute myeloid AML acute lymphoblastic ALL and chronic myeloid CML undergoing a myeloablative allogeneic hematopoietic cell transplantation HCT from an URD 8/8 human leukocyte antigen HLA -matched n=941 or HLA-identical sibling donor n=3158 between 1995 and 2004 reported to the CIBMTR In the Cox regression model acute and chronic GVHD were added as time-dependent variables In multivariate analysis URD transplant recipients had a higher risk for transplantation-related mortality TRM relative risk RR 2.76 P .001 and relapse RR 1.50 P .002 in patients with AML but not ALL or CML Chronic GVHD was associated with a lower relapse risk in all diagnoses Leukemia-free survival LFS was decreased in patients with AML without acute GVHD receiving a URD transplant RR 2.02 P .001 but was comparable to those receiving HLA-identical sibling transplants in patients with ALL and CML In patients without GVHD multivariate analysis showed similar risk of relapse but decreased LFS for URD transplants for all 3 diagnoses In conclusion risk of relapse was the same ALL CML or worse AML in URD transplant recipients compared with HLA-identical sibling transplant recipients suggesting a similar GVL effect,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1022, 476, 7, 247, 29, 35, 2092, 1488, 5847, 941, 408, 1, 8, 3355, 1599, 185, 2647, 8149, 254, 21, 311, 45354, 7, 5, 286, 533, 329, 286, 1275, 62, 2, 442, 533, 903, 479, 8, 3246, 1063, 1007, 31, 497, 1085, 29, 35, 5847, 66, 66, 171, 3627, 448, 1160, 655, 78, 13164, 15, 1160, 3038, 3684, 1488, 78, 45355, 59, 2323, 2, 1131, 210, 6, 3, 11203, 4, 3, 418, 320, 202, 286, 2, 442, 1562, 11, 1953, 22, 98, 470, 682, 4, 331, 65, 5847, 941, 2190, 42, 8, 142, 43, 9, 497, 139, 282, 5064, 580, 43, 861, 18, 846, 19, 144, 2, 429, 861, 14, 212, 19, 1111, 4, 7, 5, 329, 84, 44, 62, 15, 903, 442, 1562, 10, 41, 5, 8, 280, 429, 43, 4, 62, 2403, 2647, 115, 25, 5674, 10, 340, 4, 7, 5, 329, 187, 286, 1562, 357, 8, 5847, 941, 861, 18, 588, 19, 144, 84, 10, 1279, 6, 135, 357, 1160, 3038, 3684, 4016, 4, 7, 5, 62, 2, 903, 4, 7, 187, 1562, 331, 65, 224, 288, 43, 1, 429, 84, 340, 5674, 9, 5847, 4016, 9, 62, 27, 2403, 4, 1221, 43, 1, 429, 10, 3, 827, 62, 903, 15, 639, 329, 4, 5847, 941, 2190, 72, 5, 1160, 3038, 3684, 941, 2190, 802, 8, 288, 8149, 254]",1345.0,19059878,562
Pegasparaginase: where do we stand?,Expert opinion on biological therapy,Expert Opin Biol Ther,2009-01-01,"The use of unmodified asparaginases (ASP) in the management of pediatric and adult acute lymphoblastic leukemia (ALL) is well established. Despite its well-proven clinical efficacy, the use of unmodified Escherichia coli ASP (EC-ASP) has been limited by frequent toxicities, especially the development of hypersensitivity reactions and neutralizing antibodies, and by the need for frequent administration. To overcome these limitations, EC-ASP enzyme was covalently linked to monomethoxypolyethylene glycol (PEG), forming the pegylated ASP (PEG-ASP) (Oncaspar). PEG-ASP has a prolonged half-life and is associated with decreased immunogenicity when compared with EC-ASP. Clinical trials have demonstrated the efficacy, safety and tolerability of PEG-ASP administered intramuscularly, subcutaneously or intravenously as part of multi-agent chemotherapy regimens in the management of newly diagnosed and relapsed pediatric and adult ALL. Here we discuss the pharmacology, pharmacokinetics, clinical trial results and potential side effects of PEG-ASP.",Journal Article,4037.0,42.0,The use of unmodified asparaginases ASP in the management of pediatric and adult acute lymphoblastic ALL is well established Despite its well-proven clinical efficacy the use of unmodified Escherichia coli ASP EC-ASP has been limited by frequent toxicities especially the development of hypersensitivity reactions and neutralizing antibodies and by the need for frequent administration To overcome these limitations EC-ASP enzyme was covalently linked to monomethoxypolyethylene glycol PEG forming the pegylated ASP PEG-ASP Oncaspar PEG-ASP has a prolonged half-life and is associated with decreased immunogenicity when compared with EC-ASP Clinical trials have demonstrated the efficacy safety and tolerability of PEG-ASP administered intramuscularly subcutaneously or intravenously as part of multi-agent chemotherapy regimens in the management of newly diagnosed and relapsed pediatric and adult ALL Here we discuss the pharmacology pharmacokinetics clinical trial results and potential side effects of PEG-ASP,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 119, 1, 10424, 38872, 8501, 4, 3, 284, 1, 815, 2, 780, 286, 1275, 62, 16, 149, 635, 550, 211, 149, 1930, 38, 209, 3, 119, 1, 10424, 12832, 6959, 8501, 2180, 8501, 71, 85, 383, 20, 908, 385, 1093, 3, 193, 1, 4034, 2428, 2, 5788, 890, 2, 20, 3, 594, 9, 908, 634, 6, 1768, 46, 1939, 2180, 8501, 1644, 10, 10732, 1199, 6, 57545, 10809, 3145, 4525, 3, 4424, 8501, 3145, 8501, 57546, 3145, 8501, 71, 8, 1069, 1303, 358, 2, 16, 41, 5, 340, 4050, 198, 72, 5, 2180, 8501, 38, 143, 47, 264, 3, 209, 367, 2, 1543, 1, 3145, 8501, 468, 12800, 3928, 15, 1672, 22, 760, 1, 1414, 420, 56, 472, 4, 3, 284, 1, 732, 265, 2, 591, 815, 2, 780, 62, 467, 21, 1139, 3, 6852, 1159, 38, 160, 99, 2, 174, 1152, 176, 1, 3145, 8501]",1013.0,19063697,143
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.,Blood,Blood,2008-12-09,"Methotrexate polyglutamates (MTXPGs) determine in vivo efficacy in acute lymphoblastic leukemia (ALL). MTXPG accumulation differs by leukemic subtypes, but genomic determinants of MTXPG variation in ALL remain unclear. We analyzed 3 types of whole genome variation: leukemia cell gene expression and somatic copy number variation, and inherited single nucleotide polymorphism (SNP) genotypes and determined their association with MTXPGs in leukemia cells. Seven genes (FHOD3, IMPA2, ME2, RASSF4, SLC39A6, SMAD2, and SMAD4) displayed all 3 types of genomic variation associated with MTXPGs (P < .05 for gene expression, P < .01 for copy number variation and SNPs): 6 on chromosome 18 and 1 on chromosome 10. Increased chromosome 18 (P = .002) or 10 (P = .036) copy number was associated with MTXPGs even after adjusting for ALL subtype. The expression of the top 7 genes in leukemia cells accounted for more variation in MTXPGs (46%) than did the expression of the top 7 genes in normal HapMap cell lines (20%). The top 7 inherited SNPs in patients accounted for approximately the same degree of variation (17%) in MTXPGs as did the top 7 SNP genotypes in HapMap cell lines (20%). We conclude that acquired genetic variation in leukemia cells has a stronger influence on MTXPG accumulation than inherited genetic variation.",Comparative Study,4060.0,35.0,Methotrexate polyglutamates MTXPGs determine in vivo efficacy in acute lymphoblastic ALL MTXPG accumulation differs by leukemic subtypes but genomic determinants of MTXPG variation in ALL remain unclear We analyzed 3 types of whole genome variation cell gene expression and somatic copy number variation and inherited single nucleotide polymorphism SNP genotypes and determined their association with MTXPGs in cells Seven genes FHOD3 IMPA2 ME2 RASSF4 SLC39A6 SMAD2 and SMAD4 displayed all 3 types of genomic variation associated with MTXPGs P .05 for gene expression P .01 for copy number variation and SNPs 6 on chromosome 18 and 1 on chromosome 10 Increased chromosome 18 P .002 or 10 P .036 copy number was associated with MTXPGs even after adjusting for ALL subtype The expression of the top 7 genes in cells accounted for more variation in MTXPGs 46 than did the expression of the top 7 genes in normal HapMap cell lines 20 The top 7 inherited SNPs in patients accounted for approximately the same degree of variation 17 in MTXPGs as did the top 7 SNP genotypes in HapMap cell lines 20 We conclude that acquired genetic variation in cells has a stronger influence on MTXPG accumulation than inherited genetic variation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 16243, 26082, 223, 4, 386, 209, 4, 286, 1275, 62, 11572, 1835, 4990, 20, 2015, 814, 84, 572, 3403, 1, 11572, 1380, 4, 62, 918, 1200, 21, 311, 27, 630, 1, 902, 898, 1380, 31, 145, 55, 2, 1119, 1337, 207, 1380, 2, 2986, 226, 1579, 1907, 1845, 2071, 2, 509, 136, 248, 5, 26082, 4, 37, 648, 214, 57555, 57556, 26775, 57557, 57558, 10286, 2, 4248, 2507, 62, 27, 630, 1, 572, 1380, 41, 5, 26082, 19, 474, 9, 145, 55, 19, 355, 9, 1337, 207, 1380, 2, 1109, 49, 23, 1170, 203, 2, 14, 23, 1170, 79, 101, 1170, 203, 19, 1111, 15, 79, 19, 5395, 1337, 207, 10, 41, 5, 26082, 871, 50, 1358, 9, 62, 875, 3, 55, 1, 3, 3150, 67, 214, 4, 37, 3688, 9, 80, 1380, 4, 26082, 641, 76, 205, 3, 55, 1, 3, 3150, 67, 214, 4, 295, 13961, 31, 285, 179, 3, 3150, 67, 2986, 1109, 4, 7, 3688, 9, 705, 3, 827, 1444, 1, 1380, 269, 4, 26082, 22, 205, 3, 3150, 67, 1845, 2071, 4, 13961, 31, 285, 179, 21, 2060, 17, 1294, 336, 1380, 4, 37, 71, 8, 3355, 1054, 23, 11572, 1835, 76, 2986, 336, 1380]",1224.0,19066393,497
Folate homeostasis in cerebrospinal fluid during therapy for acute lymphoblastic leukemia.,Pediatric neurology,Pediatr. Neurol.,2009-01-01,"The neurotoxic effects of therapy for childhood acute lymphoblastic leukemia can result in leukoencephalopathy or measurable deficits in cognitive function. However, there are no validated biomarkers that allow the identification of those patients at greatest risk. With the objective of identifying such predictors, cerebrospinal fluid collected from 53 patients over 2.5 years of therapy for childhood acute lymphoblastic leukemia was retrospectively studied. Cerebrospinal fluid folate, concentrated relative to serum folate prior to therapy, dropped during the first month of therapy and remained below baseline throughout treatment. Cerebrospinal fluid homocysteine was inversely related to cognitive function prior to treatment. Oral methotrexate was associated with decreased cerebrospinal fluid folate and increased cerebrospinal fluid homocysteine, but these changes were not seen with oral aminopterin. Of 36 patients who had imaging after completion of therapy, 9 had periventricular or subcortical white matter abnormalities consistent with leukoencephalopathy. Peak cerebrospinal fluid tau concentrations during therapy were higher among patients who had leukoencephalopathy after completion of therapy than among those with normal imaging studies at the end of therapy. If confirmed prospectively, these markers may allow the identification of those patients at greatest risk of developing treatment-induced neurocognitive dysfunction, thus guiding preventive interventions.",Journal Article,4037.0,23.0,The neurotoxic effects of therapy for childhood acute lymphoblastic can result in leukoencephalopathy or measurable deficits in cognitive function However there are no validated biomarkers that allow the identification of those patients at greatest risk With the objective of identifying such predictors cerebrospinal fluid collected from 53 patients over 2.5 years of therapy for childhood acute lymphoblastic was retrospectively studied Cerebrospinal fluid folate concentrated relative to serum folate prior to therapy dropped during the first month of therapy and remained below baseline throughout treatment Cerebrospinal fluid homocysteine was inversely related to cognitive function prior to treatment Oral methotrexate was associated with decreased cerebrospinal fluid folate and increased cerebrospinal fluid homocysteine but these changes were not seen with oral aminopterin Of 36 patients who had imaging after completion of therapy 9 had periventricular or subcortical white matter abnormalities consistent with leukoencephalopathy Peak cerebrospinal fluid tau concentrations during therapy were higher among patients who had leukoencephalopathy after completion of therapy than among those with normal imaging studies at the end of therapy If confirmed prospectively these markers may allow the identification of those patients at greatest risk of developing treatment-induced neurocognitive dysfunction thus guiding preventive interventions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 11148, 176, 1, 36, 9, 864, 286, 1275, 122, 757, 4, 8744, 15, 1884, 2752, 4, 1863, 343, 137, 125, 32, 77, 938, 582, 17, 1700, 3, 911, 1, 135, 7, 28, 2199, 43, 5, 3, 461, 1, 1386, 225, 674, 5156, 2357, 786, 29, 699, 7, 252, 18, 33, 60, 1, 36, 9, 864, 286, 1275, 10, 894, 656, 5156, 2357, 3100, 11389, 580, 6, 524, 3100, 324, 6, 36, 8801, 190, 3, 157, 811, 1, 36, 2, 958, 2736, 330, 2432, 24, 5156, 2357, 12798, 10, 2659, 139, 6, 1863, 343, 324, 6, 24, 518, 2116, 10, 41, 5, 340, 5156, 2357, 3100, 2, 101, 5156, 2357, 12798, 84, 46, 400, 11, 44, 527, 5, 518, 16421, 1, 511, 7, 54, 42, 270, 50, 1438, 1, 36, 83, 42, 31382, 15, 21484, 886, 5090, 1171, 925, 5, 8744, 2944, 5156, 2357, 8127, 1003, 190, 36, 11, 142, 107, 7, 54, 42, 8744, 50, 1438, 1, 36, 76, 107, 135, 5, 295, 270, 94, 28, 3, 396, 1, 36, 492, 557, 1143, 46, 525, 68, 1700, 3, 911, 1, 135, 7, 28, 2199, 43, 1, 931, 24, 277, 2958, 1527, 631, 5972, 3494, 1151]",1453.0,19068252,501
Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues.,Cancer,Cancer,2009-01-01,"Secondary acute leukemia is a devastating complication in children and adolescents who have been treated for cancer. Secondary acute lymphoblastic leukemia (s-ALL) was rarely reported previously but can be distinguished today from recurrent primary ALL by comparison of immunoglobulin and T-cell receptor rearrangement. Secondary acute myeloid leukemia (s-AML) is much more common, and some cases actually may be second primary cancers. Treatment-related and host-related characteristics and their interactions have been identified as risk factors for s-AML. The most widely recognized treatment-related risk factors are alkylating agents and topoisomerase II inhibitors (epipodophyllotoxins and anthracyclines). The magnitude of the risk associated with these factors depends on several variables, including the administration schedule, concomitant medications, and host factors. A high cumulative dose of alkylating agents is well known to predispose to s-AML. The prevalence of alkylator-associated s-AML has diminished among pediatric oncology patients with the reduction of cumulative alkylator dose and limited use of the more leukemogenic alkylators. The best-documented topoisomerase II inhibitor-associated s-AML is s-AML associated with epipodophyllotoxins. The risk of s-AML in these cases is influenced by the schedule of drug administration and by interaction with other antineoplastic agents but is not consistently found to be related to cumulative dose. The unpredictable risk of s-AML after epipodophyllotoxin therapy may discourage the use of these agents, even in patients at a high risk of disease recurrence, although the benefit of recurrence prevention may outweigh the risk of s-AML. Studies in survivors of adult cancers suggest that, contrary to previous beliefs, the outcome of s-AML is not necessarily worse than that of de novo AML when adjusted for cytogenetic features. More studies are needed to confirm this finding in the pediatric patient population.",Journal Article,4037.0,81.0,Secondary acute is a devastating complication in children and adolescents who have been treated for cancer Secondary acute lymphoblastic s-ALL was rarely reported previously but can be distinguished today from recurrent primary ALL by comparison of immunoglobulin and T-cell receptor rearrangement Secondary acute myeloid s-AML is much more common and some cases actually may be second primary cancers Treatment-related and host-related characteristics and their interactions have been identified as risk factors for s-AML The most widely recognized treatment-related risk factors are alkylating agents and topoisomerase II inhibitors epipodophyllotoxins and anthracyclines The magnitude of the risk associated with these factors depends on several variables including the administration schedule concomitant medications and host factors A high cumulative dose of alkylating agents is well known to predispose to s-AML The prevalence of alkylator-associated s-AML has diminished among pediatric oncology patients with the reduction of cumulative alkylator dose and limited use of the more leukemogenic alkylators The best-documented topoisomerase II inhibitor-associated s-AML is s-AML associated with epipodophyllotoxins The risk of s-AML in these cases is influenced by the schedule of drug administration and by interaction with other antineoplastic agents but is not consistently found to be related to cumulative dose The unpredictable risk of s-AML after epipodophyllotoxin therapy may discourage the use of these agents even in patients at a high risk of disease recurrence although the benefit of recurrence prevention may outweigh the risk of s-AML Studies in survivors of adult cancers suggest that contrary to previous beliefs the outcome of s-AML is not necessarily worse than that of de novo AML when adjusted for cytogenetic features More studies are needed to confirm this finding in the pediatric patient population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[568, 286, 16, 8, 5778, 1447, 4, 541, 2, 3101, 54, 47, 85, 73, 9, 12, 568, 286, 1275, 695, 62, 10, 2416, 210, 373, 84, 122, 40, 4735, 5665, 29, 387, 86, 62, 20, 1155, 1, 2593, 2, 102, 31, 153, 2675, 568, 286, 533, 695, 329, 16, 1802, 80, 186, 2, 476, 140, 6742, 68, 40, 419, 86, 163, 24, 139, 2, 1204, 139, 374, 2, 136, 1286, 47, 85, 108, 22, 43, 130, 9, 695, 329, 3, 96, 1792, 1904, 24, 139, 43, 130, 32, 3410, 183, 2, 3999, 215, 222, 25999, 2, 3597, 3, 3131, 1, 3, 43, 41, 5, 46, 130, 3828, 23, 392, 682, 141, 3, 634, 1055, 1781, 2679, 2, 1204, 130, 8, 64, 967, 61, 1, 3410, 183, 16, 149, 440, 6, 6043, 6, 695, 329, 3, 1078, 1, 9346, 41, 695, 329, 71, 2849, 107, 815, 413, 7, 5, 3, 628, 1, 967, 9346, 61, 2, 383, 119, 1, 3, 80, 13519, 12777, 3, 824, 1405, 3999, 215, 230, 41, 695, 329, 16, 695, 329, 41, 5, 25999, 3, 43, 1, 695, 329, 4, 46, 140, 16, 2574, 20, 3, 1055, 1, 234, 634, 2, 20, 915, 5, 127, 3940, 183, 84, 16, 44, 2433, 204, 6, 40, 139, 6, 967, 61, 3, 8907, 43, 1, 695, 329, 50, 38478, 36, 68, 22513, 3, 119, 1, 46, 183, 871, 4, 7, 28, 8, 64, 43, 1, 34, 146, 242, 3, 247, 1, 146, 1070, 68, 11592, 3, 43, 1, 695, 329, 94, 4, 332, 1, 780, 163, 309, 17, 7194, 6, 698, 5059, 3, 228, 1, 695, 329, 16, 44, 7766, 639, 76, 17, 1, 1566, 2018, 329, 198, 586, 9, 1266, 404, 80, 94, 32, 575, 6, 1843, 26, 1567, 4, 3, 815, 69, 266]",1931.0,19072983,210
"Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens.",Cancer,Cancer,2009-01-01,"Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic leukemia (ALL) and to the authors' knowledge have not been as well documented in adults as in children. A total of 641 patients with de novo ALL who were treated with the hyper-CVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone) regimen or its variants were analyzed. Sixteen patients (2.49%) developed secondary acute myelogenous leukemia (AML) (6 patients) or myelodysplastic syndrome (MDS) (10 patients). At the time of ALL diagnosis, the median age was 53 years; cytogenetics were normal in 11 patients, pseudo-diploidy with del(2) in 1 patient, t(9;22) in 1 patient, and unavailable in 3 patients. Frontline therapy included hyper-CVAD in 7 patients, hyper-CVAD with rituximab in 8 patients, and hyper-CVAD with imatinib in 1 patient. Karyotype at time of AML/MDS diagnosis was -5, -7 in 9 patients, normal in 1 patient, complex in 1 patient, inv(11) in 1 patient, t(4;11) in 1 patient, del(20) in 1 patient, and unavailable in 2 patients. Secondary AML/MDS developed at a median of 32 months after ALL diagnosis. Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS. One patient with MDS received arsenic trioxide, 1 received clofarabine, and 2 received decitabine. Response to treatment was complete remission in 3 patients, partial remission in 6 patients, and no response in 6 patients; 1 patient was untreated. Eight patients (1 with AML and 7 with MDS) underwent allogeneic stem cell transplantation, and all but 2 died at a median of 3 months (range, 0.5-11 months) after transplantation. The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months (range, 1+ to 26+ months). Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens, and response to therapy is poor.",Journal Article,4037.0,13.0,Secondary malignancies including myeloid neoplasms occur infrequently in acute lymphoblastic ALL and to the authors knowledge have not been as well documented in adults as in children A total of 641 patients with de novo ALL who were treated with the hyper-CVAD hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone regimen or its variants were analyzed Sixteen patients 2.49 developed secondary acute myelogenous AML 6 patients or syndrome MDS 10 patients At the time of ALL diagnosis the median age was 53 years cytogenetics were normal in 11 patients pseudo-diploidy with del 2 in 1 patient t 9 22 in 1 patient and unavailable in 3 patients Frontline therapy included hyper-CVAD in 7 patients hyper-CVAD with rituximab in 8 patients and hyper-CVAD with imatinib in 1 patient Karyotype at time of AML/MDS diagnosis was -5 -7 in 9 patients normal in 1 patient complex in 1 patient inv 11 in 1 patient t 4 11 in 1 patient del 20 in 1 patient and unavailable in 2 patients Secondary AML/MDS developed at a median of 32 months after ALL diagnosis Cytarabine plus anthracycline-based treatment was given to 12 patients with AML and high-risk MDS One patient with MDS received arsenic trioxide 1 received clofarabine and 2 received decitabine Response to treatment was complete remission in 3 patients partial remission in 6 patients and no response in 6 patients 1 patient was untreated Eight patients 1 with AML and 7 with MDS underwent allogeneic stem cell transplantation and all but 2 died at a median of 3 months range 0.5-11 months after transplantation The median overall survival after a diagnosis of secondary AML and MDS was 9.25 months range 1+ to 26+ months Secondary AML and MDS occur infrequently in adult patients with de novo ALL treated with the hyper-CVAD regimens and response to therapy is poor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[568, 441, 141, 533, 1179, 1271, 6440, 4, 286, 1275, 62, 2, 6, 3, 738, 922, 47, 44, 85, 22, 149, 1405, 4, 857, 22, 4, 541, 8, 181, 1, 15599, 7, 5, 1566, 2018, 62, 54, 11, 73, 5, 3, 4855, 5574, 6201, 1112, 2132, 856, 2, 1217, 477, 15, 211, 839, 11, 311, 3228, 7, 18, 739, 276, 568, 286, 2194, 329, 49, 7, 15, 681, 1223, 79, 7, 28, 3, 98, 1, 62, 147, 3, 52, 89, 10, 699, 60, 2510, 11, 295, 4, 175, 7, 13337, 19586, 5, 3084, 18, 4, 14, 69, 102, 83, 350, 4, 14, 69, 2, 9098, 4, 27, 7, 3171, 36, 159, 4855, 5574, 4, 67, 7, 4855, 5574, 5, 855, 4, 66, 7, 2, 4855, 5574, 5, 577, 4, 14, 69, 3385, 28, 98, 1, 329, 1223, 147, 10, 33, 67, 4, 83, 7, 295, 4, 14, 69, 840, 4, 14, 69, 6397, 175, 4, 14, 69, 102, 39, 175, 4, 14, 69, 3084, 179, 4, 14, 69, 2, 9098, 4, 18, 7, 568, 329, 1223, 276, 28, 8, 52, 1, 531, 53, 50, 62, 147, 1855, 349, 2044, 90, 24, 10, 447, 6, 133, 7, 5, 329, 2, 64, 43, 1223, 104, 69, 5, 1223, 103, 3217, 4574, 14, 103, 4149, 2, 18, 103, 3004, 51, 6, 24, 10, 236, 734, 4, 27, 7, 450, 734, 4, 49, 7, 2, 77, 51, 4, 49, 7, 14, 69, 10, 1278, 659, 7, 14, 5, 329, 2, 67, 5, 1223, 208, 1063, 452, 31, 497, 2, 62, 84, 18, 1016, 28, 8, 52, 1, 27, 53, 184, 13, 33, 175, 53, 50, 497, 3, 52, 63, 25, 50, 8, 147, 1, 568, 329, 2, 1223, 10, 83, 243, 53, 184, 14, 6, 432, 53, 568, 329, 2, 1223, 1271, 6440, 4, 780, 7, 5, 1566, 2018, 62, 73, 5, 3, 4855, 5574, 472, 2, 51, 6, 36, 16, 334]",1834.0,19090005,565
Global genomic characterization of acute lymphoblastic leukemia.,Seminars in hematology,Semin. Hematol.,2009-01-01,"A key goal in cancer research is to identify the total complement of genetic and epigenetic alterations that contribute to tumorigenesis. We are currently witnessing the rapid evolution and convergence of multiple genome-wide platforms that are making this goal a reality. Leading this effort are studies of the molecular lesions that underlie pediatric acute lymphoblastic leukemia (ALL). The recent application of microarray-based analyses of DNA copy number abnormalities (CNAs) in pediatric ALL, complemented by transcriptional profiling, resequencing and epigenetic approaches, has identified a high frequency of common genetic alterations in both B-progenitor and T-lineage ALL. These approaches have identified abnormalities in key pathways, including lymphoid differentiation, cell cycle regulation, tumor suppression, and drug responsiveness. Moreover, the nature and frequency of CNAs differ markedly among ALL genetic subtypes. In this article, we review the key findings from the published data on genome-wide analyses of ALL and highlight some of the technical aspects of data generation and analysis that must be carefully controlled to obtain optimal results.",Journal Article,4037.0,42.0,A key goal in cancer research is to identify the total complement of genetic and epigenetic alterations that contribute to tumorigenesis We are currently witnessing the rapid evolution and convergence of multiple genome-wide platforms that are making this goal a reality Leading this effort are studies of the molecular lesions that underlie pediatric acute lymphoblastic ALL The recent application of microarray-based analyses of DNA copy number abnormalities CNAs in pediatric ALL complemented by transcriptional profiling resequencing and epigenetic approaches has identified a high frequency of common genetic alterations in both B-progenitor and T-lineage ALL These approaches have identified abnormalities in key pathways including lymphoid differentiation cell cycle regulation tumor suppression and drug responsiveness Moreover the nature and frequency of CNAs differ markedly among ALL genetic subtypes In this article we review the key findings from the published data on genome-wide analyses of ALL and highlight some of the technical aspects of data generation and analysis that must be carefully controlled to obtain optimal results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 825, 1326, 4, 12, 389, 16, 6, 255, 3, 181, 3731, 1, 336, 2, 1418, 593, 17, 1248, 6, 1565, 21, 32, 694, 34161, 3, 1321, 2554, 2, 12312, 1, 232, 898, 1019, 4364, 17, 32, 1079, 26, 1326, 8, 9265, 1049, 26, 2919, 32, 94, 1, 3, 219, 406, 17, 5875, 815, 286, 1275, 62, 3, 435, 1581, 1, 1727, 90, 318, 1, 261, 1337, 207, 1171, 7452, 4, 815, 62, 13275, 20, 1431, 1080, 11819, 2, 1418, 611, 71, 108, 8, 64, 675, 1, 186, 336, 593, 4, 110, 132, 2520, 2, 102, 2542, 62, 46, 611, 47, 108, 1171, 4, 825, 460, 141, 2303, 910, 31, 417, 863, 30, 1332, 2, 234, 3642, 1393, 3, 2202, 2, 675, 1, 7452, 1505, 2195, 107, 62, 336, 814, 4, 26, 946, 21, 206, 3, 825, 272, 29, 3, 983, 74, 23, 898, 1019, 318, 1, 62, 2, 1817, 476, 1, 3, 3359, 2695, 1, 74, 914, 2, 65, 17, 1642, 40, 3900, 1149, 6, 3140, 665, 99]",1145.0,19100363,79
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2009-01-07,"Despite best current therapy, up to 20% of pediatric patients with acute lymphoblastic leukemia (ALL) have a relapse. Recent genomewide analyses have identified a high frequency of DNA copy-number abnormalities in ALL, but the prognostic implications of these abnormalities have not been defined. We studied a cohort of 221 children with high-risk B-cell-progenitor ALL with the use of single-nucleotide-polymorphism microarrays, transcriptional profiling, and resequencing of samples obtained at diagnosis. Children with known very-high-risk ALL subtypes (i.e., BCR-ABL1-positive ALL, hypodiploid ALL, and ALL in infants) were excluded from this cohort. A copy-number abnormality was identified as a predictor of poor outcome, and it was then tested in an independent validation cohort of 258 patients with B-cell-progenitor ALL. More than 50 recurring copy-number abnormalities were identified, most commonly involving genes that encode regulators of B-cell development (in 66.8% of patients in the original cohort); PAX5 was involved in 31.7% and IKZF1 in 28.6% of patients. Using copy-number abnormalities, we identified a predictor of poor outcome that was validated in the independent validation cohort. This predictor was strongly associated with alteration of IKZF1, a gene that encodes the lymphoid transcription factor IKAROS. The gene-expression signature of the group of patients with a poor outcome revealed increased expression of hematopoietic stem-cell genes and reduced expression of B-cell-lineage genes, and it was similar to the signature of BCR-ABL1-positive ALL, another high-risk subtype of ALL with a high frequency of IKZF1 deletion. Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL.",Journal Article,4031.0,785.0,Despite best current therapy up to 20 of pediatric patients with acute lymphoblastic ALL have a relapse Recent genomewide analyses have identified a high frequency of DNA copy-number abnormalities in ALL but the prognostic implications of these abnormalities have not been defined We studied a cohort of 221 children with high-risk B-cell-progenitor ALL with the use of single-nucleotide-polymorphism microarrays transcriptional profiling and resequencing of samples obtained at diagnosis Children with known very-high-risk ALL subtypes i.e. BCR-ABL1-positive ALL hypodiploid ALL and ALL in infants were excluded from this cohort A copy-number abnormality was identified as a predictor of poor outcome and it was then tested in an independent validation cohort of 258 patients with B-cell-progenitor ALL More than 50 recurring copy-number abnormalities were identified most commonly involving genes that encode regulators of B-cell development in 66.8 of patients in the original cohort PAX5 was involved in 31.7 and IKZF1 in 28.6 of patients Using copy-number abnormalities we identified a predictor of poor outcome that was validated in the independent validation cohort This predictor was strongly associated with alteration of IKZF1 a gene that encodes the lymphoid transcription factor IKAROS The gene-expression signature of the group of patients with a poor outcome revealed increased expression of hematopoietic stem-cell genes and reduced expression of B-cell-lineage genes and it was similar to the signature of BCR-ABL1-positive ALL another high-risk subtype of ALL with a high frequency of IKZF1 deletion Genetic alteration of IKZF1 is associated with a very poor outcome in B-cell-progenitor ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[550, 824, 291, 36, 126, 6, 179, 1, 815, 7, 5, 286, 1275, 62, 47, 8, 429, 435, 16484, 318, 47, 108, 8, 64, 675, 1, 261, 1337, 207, 1171, 4, 62, 84, 3, 177, 1268, 1, 46, 1171, 47, 44, 85, 395, 21, 656, 8, 180, 1, 5600, 541, 5, 64, 43, 132, 31, 2520, 62, 5, 3, 119, 1, 226, 1579, 1907, 2774, 1431, 1080, 2, 11819, 1, 347, 683, 28, 147, 541, 5, 440, 923, 64, 43, 62, 814, 70, 563, 1062, 3557, 109, 62, 12135, 62, 2, 62, 4, 5585, 11, 1800, 29, 26, 180, 8, 1337, 207, 3698, 10, 108, 22, 8, 980, 1, 334, 228, 2, 192, 10, 818, 650, 4, 35, 306, 929, 180, 1, 8289, 7, 5, 132, 31, 2520, 62, 80, 76, 212, 6385, 1337, 207, 1171, 11, 108, 96, 841, 1267, 214, 17, 6924, 3196, 1, 132, 31, 193, 4, 700, 66, 1, 7, 4, 3, 2279, 180, 6279, 10, 646, 4, 456, 67, 2, 8422, 4, 339, 49, 1, 7, 75, 1337, 207, 1171, 21, 108, 8, 980, 1, 334, 228, 17, 10, 938, 4, 3, 306, 929, 180, 26, 980, 10, 1327, 41, 5, 2611, 1, 8422, 8, 145, 17, 4322, 3, 2303, 866, 161, 20613, 3, 145, 55, 1651, 1, 3, 87, 1, 7, 5, 8, 334, 228, 553, 101, 55, 1, 1007, 452, 31, 214, 2, 405, 55, 1, 132, 31, 2542, 214, 2, 192, 10, 288, 6, 3, 1651, 1, 1062, 3557, 109, 62, 1809, 64, 43, 875, 1, 62, 5, 8, 64, 675, 1, 8422, 1528, 336, 2611, 1, 8422, 16, 41, 5, 8, 923, 334, 228, 4, 132, 31, 2520, 62]",1708.0,19129520,416
Acute mixed lineage leukemia in children: the experience of St Jude Children's Research Hospital.,Blood,Blood,2009-01-08,"To characterize the biology and optimal therapy of acute mixed-lineage leukemia in children, we reviewed the pathologic and clinical features, including response to therapy, of 35 patients with mixed-lineage leukemia. The majority of cases (91%) had blasts cells that simultaneously expressed either T-lineage plus myeloid markers (T/myeloid, n = 20) or B-lineage plus myeloid markers (B/myeloid, n = 12). Overall survival rates for the B/myeloid and T/myeloid subgroups were not significantly different from each other or from the rate for acute myeloid leukemia (AML) but were inferior to the outcome in children with acute lymphoblastic leukemia (ALL). Patients who failed to achieve complete remission with AML-directed therapy could often be induced with a regimen of prednisone, vincristine, and L-asparaginase. Analysis of gene-expression patterns identified a subset of biphenotypic leukemias that did not cluster with T-cell ALL, B-progenitor ALL, or AML. We propose that treatment for biphenotypic leukemia begin with one course of AML-type induction therapy, with a provision for a switch to lymphoid-type induction therapy with a glucocorticoid, vincristine, and L-asparaginase if the patient responds poorly. We also suggest that hematopoietic stem cell transplantation is often not required for cure of these patients.",Journal Article,4030.0,108.0,To characterize the biology and optimal therapy of acute mixed-lineage in children we reviewed the pathologic and clinical features including response to therapy of 35 patients with mixed-lineage The majority of cases 91 had blasts cells that simultaneously expressed either T-lineage plus myeloid markers T/myeloid n 20 or B-lineage plus myeloid markers B/myeloid n 12 Overall survival rates for the B/myeloid and T/myeloid subgroups were not significantly different from each other or from the rate for acute myeloid AML but were inferior to the outcome in children with acute lymphoblastic ALL Patients who failed to achieve complete remission with AML-directed therapy could often be induced with a regimen of prednisone vincristine and L-asparaginase Analysis of gene-expression patterns identified a subset of biphenotypic leukemias that did not cluster with T-cell ALL B-progenitor ALL or AML We propose that treatment for biphenotypic begin with one course of AML-type induction therapy with a provision for a switch to lymphoid-type induction therapy with a glucocorticoid vincristine and L-asparaginase if the patient responds poorly We also suggest that hematopoietic stem cell transplantation is often not required for cure of these patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 1507, 3, 891, 2, 665, 36, 1, 286, 1739, 2542, 4, 541, 21, 446, 3, 510, 2, 38, 404, 141, 51, 6, 36, 1, 465, 7, 5, 1739, 2542, 3, 686, 1, 140, 970, 42, 2438, 37, 17, 3074, 570, 361, 102, 2542, 349, 533, 525, 102, 533, 78, 179, 15, 132, 2542, 349, 533, 525, 132, 533, 78, 133, 63, 25, 151, 9, 3, 132, 533, 2, 102, 533, 1453, 11, 44, 97, 338, 29, 296, 127, 15, 29, 3, 116, 9, 286, 533, 329, 84, 11, 1663, 6, 3, 228, 4, 541, 5, 286, 1275, 62, 7, 54, 1551, 6, 1359, 236, 734, 5, 329, 1166, 36, 359, 629, 40, 277, 5, 8, 477, 1, 1979, 2132, 2, 805, 3709, 65, 1, 145, 55, 764, 108, 8, 697, 1, 20205, 2792, 17, 205, 44, 3132, 5, 102, 31, 62, 132, 2520, 62, 15, 329, 21, 2548, 17, 24, 9, 20205, 6886, 5, 104, 906, 1, 329, 267, 504, 36, 5, 8, 6832, 9, 8, 5096, 6, 2303, 267, 504, 36, 5, 8, 5399, 2132, 2, 805, 3709, 492, 3, 69, 7920, 1240, 21, 120, 309, 17, 1007, 452, 31, 497, 16, 629, 44, 616, 9, 1722, 1, 46, 7]",1253.0,19131545,113
Allogeneic hematopoietic cell transplantation is not recommended for all adults with standard-risk acute lymphoblastic leukemia in first complete remission.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-01-01,"Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, immunophenotype, and clinical, cytogenetic, and molecular features. Modern treatment strategies use a risk-adapted approach. The optimal postremission therapy for adults with ALL remains unclear. Treatment-related morbidity and mortality (TRM) are greater with hematopoietic cell transplantation (HCT) than chemotherapy although relapses are less common. Available data indicate no clear consensus as to whether there is an advantage to allogeneic HCT over chemotherapy for adults with ALL with standard-risk features while in the first complete remission (CR1). However, allogeneic HCT is recommended in CR1 for patients with high-risk ALL and for those in a second CR.",Journal Article,4037.0,10.0,Acute lymphoblastic ALL is a heterogeneous disease and outcomes vary by patient age immunophenotype and clinical cytogenetic and molecular features Modern treatment strategies use a risk-adapted approach The optimal postremission therapy for adults with ALL remains unclear Treatment-related morbidity and mortality TRM are greater with hematopoietic cell transplantation HCT than chemotherapy although relapses are less common Available data indicate no clear consensus as to whether there is an advantage to allogeneic HCT over chemotherapy for adults with ALL with standard-risk features while in the first complete remission CR1 However allogeneic HCT is recommended in CR1 for patients with high-risk ALL and for those in a second CR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 1564, 34, 2, 123, 2825, 20, 69, 89, 5496, 2, 38, 1266, 2, 219, 404, 2366, 24, 422, 119, 8, 43, 3716, 353, 3, 665, 8635, 36, 9, 857, 5, 62, 469, 1200, 24, 139, 787, 2, 282, 5064, 32, 378, 5, 1007, 31, 497, 1085, 76, 56, 242, 3713, 32, 299, 186, 390, 74, 1008, 77, 885, 1391, 22, 6, 317, 125, 16, 35, 1874, 6, 1063, 1085, 252, 56, 9, 857, 5, 62, 5, 260, 43, 404, 369, 4, 3, 157, 236, 734, 4516, 137, 1063, 1085, 16, 793, 4, 4516, 9, 7, 5, 64, 43, 62, 2, 9, 135, 4, 8, 419, 684]",738.0,19147070,127
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas.,Blood,Blood,2009-01-15,"Despite major advances in the treatment of non-Hodgkin lymphoma (NHL), including the use of chemotherapeutic agents and the anti-CD20 antibody rituximab, the majority of patients eventually relapse, and salvage treatments with non-cross-resistant compounds are needed to further improve patient survival. Here, we evaluated the antitumor effects of the microtubule destabilizing agent monomethyl auristatin E (MMAE) conjugated to the humanized anti-CD19 antibody hBU12 via a protease-sensitive valine-citrulline (vc) dipeptide linker. hBU12-vcMMAE induced potent tumor cell killing against rituximab-sensitive and -resistant NHL cell lines. CD19 can form heterodimers with CD21, and high levels of CD21 were reported to interfere negatively with the activity of CD19-targeted therapeutics. However, we observed comparable internalization, intracellular trafficking, and drug release in CD21(low) and CD21(high), rituximab-sensitive and -refractory lymphomas treated with hBU12-vcMMAE. Furthermore, high rates of durable regressions in mice implanted with these tumors were observed, suggesting that both rituximab resistance and CD21 expression levels do not impact on the activity of hBU12-vcMMAE. Combined, our data suggest that hBU12-vcMMAE may represent a promising addition to the treatment options for rituximab refractory NHL and other hematologic malignancies, including acute lymphoblastic leukemia.",Journal Article,4023.0,64.0,Despite major advances in the treatment of NHL including the use of chemotherapeutic agents and the anti-CD20 antibody rituximab the majority of patients eventually relapse and salvage treatments with non-cross-resistant compounds are needed to further improve patient survival Here we evaluated the antitumor effects of the microtubule destabilizing agent monomethyl auristatin E MMAE conjugated to the humanized anti-CD19 antibody hBU12 via a protease-sensitive valine-citrulline vc dipeptide linker hBU12-vcMMAE induced potent tumor cell killing against rituximab-sensitive and -resistant NHL cell lines CD19 can form heterodimers with CD21 and high levels of CD21 were reported to interfere negatively with the activity of CD19-targeted therapeutics However we observed comparable internalization intracellular trafficking and drug release in CD21 low and CD21 high rituximab-sensitive and -refractory lymphomas treated with hBU12-vcMMAE Furthermore high rates of durable regressions in mice implanted with these tumors were observed suggesting that both rituximab resistance and CD21 expression levels do not impact on the activity of hBU12-vcMMAE Combined our data suggest that hBU12-vcMMAE may represent a promising addition to the treatment options for rituximab refractory NHL and other hematologic malignancies including acute lymphoblastic,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[550, 458, 954, 4, 3, 24, 1, 1176, 141, 3, 119, 1, 1573, 183, 2, 3, 312, 2198, 548, 855, 3, 686, 1, 7, 3124, 429, 2, 992, 640, 5, 220, 1383, 436, 2411, 32, 575, 6, 195, 401, 69, 25, 467, 21, 194, 3, 579, 176, 1, 3, 4621, 19689, 420, 16034, 14235, 563, 12035, 3868, 6, 3, 3619, 312, 3158, 548, 31396, 847, 8, 5125, 745, 12255, 28269, 11468, 18273, 8437, 31396, 26321, 277, 1157, 30, 31, 3003, 480, 855, 745, 2, 436, 1176, 31, 285, 3158, 122, 1297, 15468, 5, 17134, 2, 64, 148, 1, 17134, 11, 210, 6, 6178, 2723, 5, 3, 128, 1, 3158, 238, 1943, 137, 21, 164, 1279, 7520, 2087, 6105, 2, 234, 2008, 4, 17134, 154, 2, 17134, 64, 855, 745, 2, 430, 1557, 73, 5, 31396, 26321, 798, 64, 151, 1, 1480, 5142, 4, 399, 3416, 5, 46, 57, 11, 164, 802, 17, 110, 855, 251, 2, 17134, 55, 148, 1022, 44, 345, 23, 3, 128, 1, 31396, 26321, 397, 114, 74, 309, 17, 31396, 26321, 68, 1231, 8, 721, 352, 6, 3, 24, 838, 9, 855, 430, 1176, 2, 127, 813, 441, 141, 286, 1275]",1350.0,19147785,34
Maternal health conditions during pregnancy and acute leukemia in children with Down syndrome: A Children's Oncology Group study.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-05-01,"Children with Down syndrome (DS) have about a 20-fold increased risk of developing leukemia. Early childhood infections may protect against acute lymphoid leukemia (ALL) in children with and without DS. We examined whether maternal infections and health conditions during pregnancy were associated with acute leukemia in children with DS. We conducted a case-control study of 158 children with DS and leukemia (including 97 cases with acute lymphoblastic leukemia (ALL) and 61 cases with acute myeloid leukemia (AML)) and 173 children with DS during the period 1997-2002. Maternal interview included information about 14 maternal conditions during gestation that are likely to induce an inflammatory response. We evaluated their prevalence in cases and controls. Five of these were common enough to allow analyses by leukemia subtype. Vaginal bleeding was the most frequent (18% cases, 25% controls) and was associated with a reduced risk (odds ratio (OR) = 0.57; 95% confidence interval (CI) = 0.33-0.99) for all cases combined. Other variables, while showing a potential trend toward reduced risk had effect estimates, which were imprecise and not statistically significant. In contrast, amniocentesis was marginally associated with an increased risk of AML (OR = 2.06, 95% CI = 0.90-4.69). Data from this exploratory investigation suggest that some health conditions during pregnancy may be relevant in childhood leukemogenesis. Larger epidemiological studies and other model systems (animal, clinical studies) may provide a clearer picture of the potential association and mechanisms.",Journal Article,3917.0,10.0,Children with Down syndrome DS have about a 20-fold increased risk of developing Early childhood infections may protect against acute lymphoid ALL in children with and without DS We examined whether maternal infections and health conditions during pregnancy were associated with acute in children with DS We conducted a case-control study of 158 children with DS and including 97 cases with acute lymphoblastic ALL and 61 cases with acute myeloid AML and 173 children with DS during the period 1997-2002 Maternal interview included information about 14 maternal conditions during gestation that are likely to induce an inflammatory response We evaluated their prevalence in cases and controls Five of these were common enough to allow analyses by subtype bleeding was the most frequent 18 cases 25 controls and was associated with a reduced risk odds ratio OR 0.57 95 confidence interval CI 0.33-0.99 for all cases combined Other variables while showing a potential trend toward reduced risk had effect estimates which were imprecise and not statistically significant In contrast amniocentesis was marginally associated with an increased risk of AML OR 2.06 95 CI 0.90-4.69 Data from this exploratory investigation suggest that some health conditions during pregnancy may be relevant in childhood leukemogenesis Larger epidemiological studies and other model systems animal clinical studies may provide a clearer picture of the potential association and mechanisms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 1328, 681, 3602, 47, 545, 8, 179, 1116, 101, 43, 1, 931, 191, 864, 1875, 68, 4869, 480, 286, 2303, 62, 4, 541, 5, 2, 187, 3602, 21, 409, 317, 6039, 1875, 2, 341, 1298, 190, 2290, 11, 41, 5, 286, 4, 541, 5, 3602, 21, 426, 8, 473, 182, 45, 1, 5162, 541, 5, 3602, 2, 141, 1015, 140, 5, 286, 1275, 62, 2, 713, 140, 5, 286, 533, 329, 2, 5785, 541, 5, 3602, 190, 3, 727, 2341, 1544, 6039, 4313, 159, 487, 545, 213, 6039, 1298, 190, 13250, 17, 32, 322, 6, 1290, 35, 1291, 51, 21, 194, 136, 1078, 4, 140, 2, 535, 365, 1, 46, 11, 186, 5151, 6, 1700, 318, 20, 875, 2294, 10, 3, 96, 908, 203, 140, 243, 535, 2, 10, 41, 5, 8, 405, 43, 610, 197, 15, 13, 696, 48, 307, 268, 58, 13, 466, 13, 1058, 9, 62, 140, 397, 127, 682, 369, 2069, 8, 174, 853, 1317, 405, 43, 42, 254, 1423, 92, 11, 18486, 2, 44, 712, 93, 4, 748, 57628, 10, 5007, 41, 5, 35, 101, 43, 1, 329, 15, 18, 1460, 48, 58, 13, 424, 39, 790, 74, 29, 26, 2386, 940, 309, 17, 476, 341, 1298, 190, 2290, 68, 40, 867, 4, 864, 5661, 1077, 4614, 94, 2, 127, 202, 1530, 2026, 38, 94, 68, 377, 8, 15960, 8951, 1, 3, 174, 248, 2, 483]",1464.0,19148952,252
The role of myeloid growth factors in acute leukemia.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2009-01-01,"Myeloid growth factors granulocyte-colony stimulating and granulocyte macrophage colony-stimulating factors have been extensively studied in acute leukemias. Whether administered before, during, or after chemotherapy for acute myeloid leukemia and acute lymphoblastic leukemia, these agents reduce the duration of neutropenia and seem to be safe and well tolerated. Despite consistently showing a shorter duration of neutropenia, multiple, prospective, randomized trials have documented only modest benefits in terms of reduction in the incidence and severity of infections, without substantial gains or impact in complete remission, overall survival, and disease-free survival rates. Growth factors have also been used to recruit quiescent leukemia cells into the S-phase of the cell cycle to increase their susceptibility to chemotherapy with the goal to reduce relapse and resistance. Randomized trials evaluating this priming strategy have consistently shown improvement in disease- or event-free survival in the intermediate-risk group of patients with acute myeloid leukemia, but no overall survival benefit. This article focuses on the clinical experience with these agents as adjuncts to the treatment of acute leukemias.",Journal Article,4037.0,8.0,Myeloid growth factors granulocyte-colony stimulating and granulocyte macrophage colony-stimulating factors have been extensively studied in acute leukemias Whether administered before during or after chemotherapy for acute myeloid and acute lymphoblastic these agents reduce the duration of neutropenia and seem to be safe and well tolerated Despite consistently showing a shorter duration of neutropenia multiple prospective randomized trials have documented only modest benefits in terms of reduction in the incidence and severity of infections without substantial gains or impact in complete remission overall survival and disease-free survival rates Growth factors have also been used to recruit quiescent cells into the S-phase of the cell cycle to increase their susceptibility to chemotherapy with the goal to reduce relapse and resistance Randomized trials evaluating this priming strategy have consistently shown improvement in disease- or event-free survival in the intermediate-risk group of patients with acute myeloid but no overall survival benefit This article focuses on the clinical experience with these agents as adjuncts to the treatment of acute leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[533, 129, 130, 2764, 1975, 2122, 2, 2764, 2674, 1975, 2122, 130, 47, 85, 3576, 656, 4, 286, 2792, 317, 468, 348, 190, 15, 50, 56, 9, 286, 533, 2, 286, 1275, 46, 183, 969, 3, 654, 1, 778, 2, 3233, 6, 40, 1165, 2, 149, 421, 550, 2433, 2069, 8, 985, 654, 1, 778, 232, 482, 384, 143, 47, 1405, 158, 1721, 1141, 4, 1794, 1, 628, 4, 3, 287, 2, 1702, 1, 1875, 187, 1281, 3849, 15, 345, 4, 236, 734, 63, 25, 2, 34, 115, 25, 151, 129, 130, 47, 120, 85, 95, 6, 8973, 6735, 37, 237, 3, 695, 124, 1, 3, 31, 417, 6, 344, 136, 1432, 6, 56, 5, 3, 1326, 6, 969, 429, 2, 251, 384, 143, 1435, 26, 4903, 692, 47, 2433, 443, 767, 4, 34, 15, 774, 115, 25, 4, 3, 919, 43, 87, 1, 7, 5, 286, 533, 84, 77, 63, 25, 247, 26, 946, 3026, 23, 3, 38, 730, 5, 46, 183, 22, 13885, 6, 3, 24, 1, 286, 2792]",1177.0,19176208,776
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.,JAMA,JAMA,2009-01-01,"Pediatric acute lymphoblastic leukemia (ALL) is the prototype for a drug-responsive malignancy. Although cure rates exceed 80%, considerable unexplained interindividual variability exists in treatment response. To assess the contribution of inherited genetic variation to therapy response and to identify germline single-nucleotide polymorphisms (SNPs) associated with risk of minimal residual disease (MRD) after remission induction chemotherapy. Genome-wide interrogation of 476,796 germline SNPs to identify genotypes that were associated with MRD in 2 independent cohorts of children with newly diagnosed ALL: 318 patients in St Jude Total Therapy protocols XIIIB and XV and 169 patients in Children's Oncology Group trial P9906. Patients were enrolled between 1994 and 2006 and last follow-up was in 2006. Minimal residual disease at the end of induction therapy, measured by flow cytometry. There were 102 SNPs associated with MRD in both cohorts (median odds ratio, 2.18; P < or = .0125), including 5 SNPs in the interleukin 15 (IL15) gene. Of these 102 SNPs, 21 were also associated with hematologic relapse (P < .05). Of 102 SNPs, 21 were also associated with antileukemic drug disposition, generally linking MRD eradication with greater drug exposure. In total, 63 of 102 SNPs were associated with early response, relapse, or drug disposition. Host genetic variations are associated with treatment response for childhood ALL, with polymorphisms related to leukemia cell biology and host drug disposition associated with lower risk of residual disease.",Journal Article,4037.0,165.0,"Pediatric acute lymphoblastic ALL is the prototype for a drug-responsive malignancy Although cure rates exceed 80 considerable unexplained interindividual variability exists in treatment response To assess the contribution of inherited genetic variation to therapy response and to identify germline single-nucleotide polymorphisms SNPs associated with risk of minimal residual disease MRD after remission induction chemotherapy Genome-wide interrogation of 476,796 germline SNPs to identify genotypes that were associated with MRD in 2 independent cohorts of children with newly diagnosed ALL 318 patients in St Jude Total Therapy protocols XIIIB and XV and 169 patients in Children 's Oncology Group trial P9906 Patients were enrolled between 1994 and 2006 and last follow-up was in 2006 Minimal residual disease at the end of induction therapy measured by flow cytometry There were 102 SNPs associated with MRD in both cohorts median odds ratio 2.18 P or .0125 including 5 SNPs in the interleukin 15 IL15 gene Of these 102 SNPs 21 were also associated with hematologic relapse P .05 Of 102 SNPs 21 were also associated with antileukemic drug disposition generally linking MRD eradication with greater drug exposure In total 63 of 102 SNPs were associated with early response relapse or drug disposition Host genetic variations are associated with treatment response for childhood ALL with polymorphisms related to cell biology and host drug disposition associated with lower risk of residual disease",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[815, 286, 1275, 62, 16, 3, 8743, 9, 8, 234, 2443, 710, 242, 1722, 151, 6818, 493, 2658, 8221, 7882, 1982, 2481, 4, 24, 51, 6, 423, 3, 2925, 1, 2986, 336, 1380, 6, 36, 51, 2, 6, 255, 1009, 226, 1579, 1203, 1109, 41, 5, 43, 1, 1048, 753, 34, 2029, 50, 734, 504, 56, 898, 1019, 8956, 1, 10652, 11656, 1009, 1109, 6, 255, 2071, 17, 11, 41, 5, 2029, 4, 18, 306, 736, 1, 541, 5, 732, 265, 62, 8797, 7, 4, 3062, 4841, 181, 36, 2189, 30629, 2, 16078, 2, 5436, 7, 4, 541, 292, 413, 87, 160, 45414, 7, 11, 346, 59, 3023, 2, 1324, 2, 1060, 166, 126, 10, 4, 1324, 1048, 753, 34, 28, 3, 396, 1, 504, 36, 644, 20, 1412, 1914, 125, 11, 2867, 1109, 41, 5, 2029, 4, 110, 736, 52, 610, 197, 18, 203, 19, 15, 38883, 141, 33, 1109, 4, 3, 1603, 167, 16940, 145, 1, 46, 2867, 1109, 239, 11, 120, 41, 5, 813, 429, 19, 474, 1, 2867, 1109, 239, 11, 120, 41, 5, 4512, 234, 5814, 1228, 5806, 2029, 5173, 5, 378, 234, 645, 4, 181, 676, 1, 2867, 1109, 11, 41, 5, 191, 51, 429, 15, 234, 5814, 1204, 336, 2293, 32, 41, 5, 24, 51, 9, 864, 62, 5, 1203, 139, 6, 31, 891, 2, 1204, 234, 5814, 41, 5, 280, 43, 1, 753, 34]",1501.0,19176441,436
T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome.,Cancer cell,Cancer Cell,2009-02-01,"Gamma-secretase inhibitors block the activation of NOTCH1 but have limited activity against T cell acute lymphoblastic leukemia (T-ALL) and cause severe gastrointestinal toxicity. In a recent study, Real et al. show that a potent gamma-secretase inhibitor potentiates the cytotoxicity of dexamethasone against glucocorticoid-resistant T-ALL cells, while dexamethasone abrogates the gastrointestinal toxicity induced by the gamma-secretase inhibitor.",Comment,4006.0,20.0,Gamma-secretase inhibitors block the activation of NOTCH1 but have limited activity against T cell acute lymphoblastic T-ALL and cause severe toxicity In a recent study Real et al show that a potent gamma-secretase inhibitor potentiates the cytotoxicity of dexamethasone against glucocorticoid-resistant T-ALL cells while dexamethasone abrogates the toxicity induced by the gamma-secretase inhibitor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1705, 10014, 222, 2381, 3, 363, 1, 4607, 84, 47, 383, 128, 480, 102, 31, 286, 1275, 102, 62, 2, 708, 905, 155, 4, 8, 435, 45, 1589, 2022, 2171, 514, 17, 8, 1157, 1705, 10014, 230, 8091, 3, 1408, 1, 1217, 480, 5399, 436, 102, 62, 37, 369, 1217, 8044, 3, 155, 277, 20, 3, 1705, 10014, 230]",399.0,19185842,351
Levetiracetam as monotherapy for seizures in a neonate with acute lymphoblastic leukemia.,European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society,Eur. J. Paediatr. Neurol.,2009-01-30,"Congenital acute lymphoblastic leukemia (ALL) is a relatively rare disorder that is characterized by frequent central nervous system involvement that may increase the risk for seizures. Appropriate choice of anticonvulsant therapy with respect to ongoing oncologic treatment is not established in this age group. We report the case of a neonate with ALL who was successfully treated for seizures with levetiracetam monotherapy. This full-term boy did well until 3 days of age when he had an episode of left extremity jerking (07/06/07). Computed tomography of the head demonstrated extensive multifocal intraparenchymal hemorrhages. Initial EEG demonstrated multifocal epileptiform activity. Patient was loaded with Phenobarbital at 20 mg/kg. Complete blood count revealed leukocytosis (78 x 103/mm(3)). Peripheral blood smear contained blastocytes and DNA analysis confirmed B-cell ALL. A second focal seizure was reported on the same day and he was re-loaded with Phenobarbital. Maintenance dosing of Phenobarbital was initiated and no further seizures were noted. A repeat EEG on 7/10/07 remained abnormal with excessive multifocal sharp waves. Continuation of anticonvulsant therapy was recommended. Given concern for interaction between Phenobarbital and planned chemotherapy regimen, oncology requested a non-enzyme inducing anticonvulsant. Phenobarbital was subsequently weaned and Levetiracetam monotherapy initiated at 40 mg/kg/day (07/10/2007). Currently, the patient is seizure free at 8 months of age on Levetiracetam monotherapy. The use of Levetiracetam as monotherapy in neonates has not been formally evaluated and experience is limited. We report the successful use of levetiracetam monotherapy after Phenobarbital load in a neonate with leukemia and localization-related epilepsy.",Case Reports,4008.0,13.0,Congenital acute lymphoblastic ALL is a relatively rare disorder that is characterized by frequent central nervous system involvement that may increase the risk for seizures Appropriate choice of anticonvulsant therapy with respect to ongoing oncologic treatment is not established in this age group We report the case of a neonate with ALL who was successfully treated for seizures with levetiracetam monotherapy This full-term boy did well until 3 days of age when he had an episode of left extremity jerking 07/06/07 Computed tomography of the head demonstrated extensive multifocal intraparenchymal hemorrhages Initial EEG demonstrated multifocal epileptiform activity Patient was loaded with Phenobarbital at 20 mg/kg Complete blood count revealed leukocytosis 78 x 103/mm 3 Peripheral blood smear contained blastocytes and DNA analysis confirmed B-cell ALL A second focal seizure was reported on the same day and he was re-loaded with Phenobarbital Maintenance dosing of Phenobarbital was initiated and no further seizures were noted A repeat EEG on 7/10/07 remained abnormal with excessive multifocal sharp waves Continuation of anticonvulsant therapy was recommended Given concern for interaction between Phenobarbital and planned chemotherapy regimen oncology requested a non-enzyme inducing anticonvulsant Phenobarbital was subsequently weaned and Levetiracetam monotherapy initiated at 40 mg/kg/day 07/10/2007 Currently the patient is seizure free at 8 months of age on Levetiracetam monotherapy The use of Levetiracetam as monotherapy in neonates has not been formally evaluated and experience is limited We report the successful use of levetiracetam monotherapy after Phenobarbital load in a neonate with and localization-related epilepsy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6711, 286, 1275, 62, 16, 8, 1352, 622, 2645, 17, 16, 765, 20, 908, 854, 1880, 398, 799, 17, 68, 344, 3, 43, 9, 4448, 870, 1866, 1, 16844, 36, 5, 2184, 6, 942, 1998, 24, 16, 44, 635, 4, 26, 89, 87, 21, 414, 3, 473, 1, 8, 26694, 5, 62, 54, 10, 1878, 73, 9, 4448, 5, 16899, 1411, 26, 1647, 337, 10802, 205, 149, 1100, 27, 162, 1, 89, 198, 3174, 42, 35, 6934, 1, 1712, 2678, 57651, 1615, 1460, 1615, 1220, 872, 1, 3, 718, 264, 1344, 3492, 14208, 13773, 388, 26403, 264, 3492, 43217, 128, 69, 10, 4805, 5, 21287, 28, 179, 81, 503, 236, 315, 1276, 553, 7463, 833, 1006, 3283, 321, 27, 672, 315, 8379, 3070, 57652, 2, 261, 65, 557, 132, 31, 62, 8, 419, 2137, 5866, 10, 210, 23, 3, 827, 218, 2, 3174, 10, 1491, 4805, 5, 21287, 1146, 1280, 1, 21287, 10, 1917, 2, 77, 195, 4448, 11, 1051, 8, 2334, 26403, 23, 67, 79, 1615, 958, 1668, 5, 4529, 3492, 9978, 19483, 6870, 1, 16844, 36, 10, 793, 447, 2893, 9, 915, 59, 21287, 2, 1465, 56, 477, 413, 12326, 8, 220, 1644, 1958, 16844, 21287, 10, 1611, 31403, 2, 16899, 1411, 1917, 28, 327, 81, 503, 218, 1615, 79, 1307, 694, 3, 69, 16, 5866, 115, 28, 66, 53, 1, 89, 23, 16899, 1411, 3, 119, 1, 16899, 22, 1411, 4, 23735, 71, 44, 85, 9790, 194, 2, 730, 16, 383, 21, 414, 3, 1401, 119, 1, 16899, 1411, 50, 21287, 3800, 4, 8, 26694, 5, 2, 2145, 139, 12354]",1751.0,19186085,104
The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo.,Blood,Blood,2009-02-03,"Therapeutic options for advanced B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) are limited. Available treatments can also deplete T lymphocytes, leaving patients at risk of life-threatening infections. In the National Cancer Institute cell line screen, the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in leukemia and selectivity for B cells. We investigated silvestrol efficacy using primary human B-leukemia cells, established B-leukemia cell lines, and animal models. In CLL cells, silvestrol LC(50) (concentration lethal to 50%) is 6.9 nM at 72 hours. At this concentration, there is no difference in sensitivity of cells from patients with or without the del(17p13.1) abnormality. In isolated cells and whole blood, silvestrol is more cytotoxic toward B cells than T cells. Silvestrol causes early reduction in Mcl-1 expression due to translational inhibition with subsequent mitochondrial damage, as evidenced by reactive oxygen species generation and membrane depolarization. In vivo, silvestrol causes significant B-cell reduction in Emu-Tcl-1 transgenic mice and significantly extends survival of 697 xenograft severe combined immunodeficient (SCID) mice without discernible toxicity. These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias.",Journal Article,4004.0,118.0,Therapeutic options for advanced B-cell acute lymphoblastic ALL and chronic lymphocytic CLL are limited Available treatments can also deplete T lymphocytes leaving patients at risk of life-threatening infections In the National Cancer Institute cell line screen the structurally unique natural product silvestrol produces an unusual pattern of cytotoxicity that suggests activity in and selectivity for B cells We investigated silvestrol efficacy using primary human B-leukemia cells established B-leukemia cell lines and animal models In CLL cells silvestrol LC 50 concentration lethal to 50 is 6.9 nM at 72 hours At this concentration there is no difference in sensitivity of cells from patients with or without the del 17p13.1 abnormality In isolated cells and whole blood silvestrol is more cytotoxic toward B cells than T cells Silvestrol causes early reduction in Mcl-1 expression due to translational inhibition with subsequent mitochondrial damage as evidenced by reactive oxygen species generation and membrane depolarization In vivo silvestrol causes significant B-cell reduction in Emu-Tcl-1 transgenic mice and significantly extends survival of 697 xenograft severe combined immunodeficient SCID mice without discernible toxicity These data indicate silvestrol has efficacy against B cells in vitro and in vivo and identify translational inhibition as a potential therapeutic target in B-cell leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[189, 838, 9, 131, 132, 31, 286, 1275, 62, 2, 442, 1193, 552, 32, 383, 390, 640, 122, 120, 9450, 102, 1594, 7806, 7, 28, 43, 1, 358, 3691, 1875, 4, 3, 657, 12, 1377, 31, 328, 2413, 3, 8533, 991, 1504, 2821, 10015, 4042, 35, 4015, 1177, 1, 1408, 17, 844, 128, 4, 2, 6072, 9, 132, 37, 21, 565, 10015, 209, 75, 86, 171, 132, 2647, 37, 635, 132, 2647, 31, 285, 2, 2026, 274, 4, 552, 37, 10015, 1837, 212, 1227, 2266, 6, 212, 16, 49, 83, 2878, 28, 720, 1459, 28, 26, 1227, 125, 16, 77, 523, 4, 485, 1, 37, 29, 7, 5, 15, 187, 3, 3084, 7526, 14, 3698, 4, 1355, 37, 2, 902, 315, 10015, 16, 80, 759, 1317, 132, 37, 76, 102, 37, 10015, 1626, 191, 628, 4, 1308, 14, 55, 520, 6, 2460, 297, 5, 706, 2019, 1350, 22, 4728, 20, 2163, 2848, 2915, 914, 2, 1905, 14809, 4, 386, 10015, 1626, 93, 132, 31, 628, 4, 28315, 8885, 14, 2862, 399, 2, 97, 8464, 25, 1, 11989, 1330, 905, 397, 5031, 4129, 399, 187, 19070, 155, 46, 74, 1008, 10015, 71, 209, 480, 132, 37, 4, 439, 2, 4, 386, 2, 255, 2460, 297, 22, 8, 174, 189, 283, 4, 132, 31, 2792]",1414.0,19190247,57
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.,"Journal of immunotherapy (Hagerstown, Md. : 1997)",J. Immunother.,,"On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models, we are launching phase I clinical trials in patients with chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia. We present here the validation of the bioprocess which we developed for the production and expansion of clinical grade autologous T cells derived from patients with CLL. We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine leukemia virus encoding a chimeric antigen receptor (CAR) targeted to CD19 (1928z) can be expanded with Dynabeads CD3/CD28. This bioprocess allows us to generate clinical doses of 1928z+ T cells in approximately 2 to 3 weeks in a large-scale semiclosed culture system using the Wave Bioreactor. These 1928z+ T cells remain biologically functional not only in vitro but also in severe combined immunodeficient-beige mice bearing disseminated tumors. The validation requirements in terms of T-cell expansion, T-cell transduction with the 1928z CAR, biologic activity, quality control testing, and release criteria were met for all 4 validation runs using apheresis products from patients with CLL. Additionally, after expansion of the T cells, the diversity of the skewed Vbeta T-cell receptor repertoire was significantly restored. This validated process will be used in phase I clinical trials in patients with chemorefractory CLL and in patients with relapsed acute lymphoblastic leukemia. It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor.",Journal Article,,159.0,On the basis of promising preclinical data demonstrating the eradication of systemic B-cell malignancies by CD19-targeted T lymphocytes in vivo in severe combined immunodeficient-beige mouse models we are launching phase I clinical trials in patients with chronic lymphocytic CLL and acute lymphoblastic We present here the validation of the bioprocess which we developed for the production and expansion of clinical grade autologous T cells derived from patients with CLL We demonstrate that T cells genetically modified with a replication-defective gammaretroviral vector derived from the Moloney murine virus encoding a chimeric antigen receptor CAR targeted to CD19 1928z can be expanded with Dynabeads CD3/CD28 This bioprocess allows us to generate clinical doses of 1928z+ T cells in approximately 2 to 3 weeks in a large-scale semiclosed culture system using the Wave Bioreactor These 1928z+ T cells remain biologically functional not only in vitro but also in severe combined immunodeficient-beige mice bearing disseminated tumors The validation requirements in terms of T-cell expansion T-cell transduction with the 1928z CAR biologic activity quality control testing and release criteria were met for all 4 validation runs using apheresis products from patients with CLL Additionally after expansion of the T cells the diversity of the skewed Vbeta T-cell receptor repertoire was significantly restored This validated process will be used in phase I clinical trials in patients with chemorefractory CLL and in patients with relapsed acute lymphoblastic It can also be adapted for other clinical trials involving the expansion and transduction of patient or donor T cells using any CAR or T-cell receptor,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[23, 3, 877, 1, 721, 693, 74, 2219, 3, 5173, 1, 403, 132, 31, 441, 20, 3158, 238, 102, 1594, 4, 386, 4, 905, 397, 5031, 16620, 830, 274, 21, 32, 28241, 124, 70, 38, 143, 4, 7, 5, 442, 1193, 552, 2, 286, 1275, 21, 364, 467, 3, 929, 1, 3, 34641, 92, 21, 276, 9, 3, 1529, 2, 1422, 1, 38, 88, 1028, 102, 37, 526, 29, 7, 5, 552, 21, 608, 17, 102, 37, 2301, 1230, 5, 8, 2079, 4552, 45448, 3374, 526, 29, 3, 33793, 1471, 1450, 2362, 8, 2897, 448, 153, 1881, 238, 6, 3158, 34642, 122, 40, 2064, 5, 57705, 3117, 5603, 26, 34641, 2333, 843, 6, 2562, 38, 415, 1, 34642, 102, 37, 4, 705, 18, 6, 27, 244, 4, 8, 375, 1124, 57706, 2099, 398, 75, 3, 10320, 38493, 46, 34642, 102, 37, 918, 2665, 583, 44, 158, 4, 439, 84, 120, 4, 905, 397, 5031, 16620, 399, 1894, 3605, 57, 3, 929, 4230, 4, 1794, 1, 102, 31, 1422, 102, 31, 2761, 5, 3, 34642, 1881, 1283, 128, 372, 182, 471, 2, 2008, 371, 11, 543, 9, 62, 39, 929, 31027, 75, 9456, 2766, 29, 7, 5, 552, 1724, 50, 1422, 1, 3, 102, 37, 3, 3653, 1, 3, 16082, 18819, 102, 31, 153, 5306, 10, 97, 4138, 26, 938, 1129, 303, 40, 95, 4, 124, 70, 38, 143, 4, 7, 5, 8923, 552, 2, 4, 7, 5, 591, 286, 1275, 192, 122, 120, 40, 3716, 9, 127, 38, 143, 1267, 3, 1422, 2, 2761, 1, 69, 15, 1488, 102, 37, 75, 500, 1881, 15, 102, 31, 153]",1713.0,19238016,268
Childhood acute lymphoblastic leukemia: update on prognostic factors.,Current opinion in pediatrics,Curr. Opin. Pediatr.,2009-02-01,"With current treatment regimens, event-free survival rates for childhood acute lymphoblastic leukemia (ALL) approach or exceed 80%. This success was achieved, in part, through the implementation of risk-stratified therapy. However, for the 15-20% of children with newly diagnosed ALL who will ultimately relapse, traditional risk assessment remains inadequate. This review highlights recent advances in our understanding of prognostic factors that may be used to refine risk group classification. An increasingly sophisticated understanding of genetic abnormalities in leukemia cells (including chromosomal abnormalities and patterns of gene expression), response to treatment, and host pharmacogenomics offers the potential to enhance or supplant currently applied prognostic criteria for use in treatment planning for childhood ALL. Identification of biologically distinctive subsets of ALL through cytogenetic, molecular, and gene expression studies, as well as investigations of minimal residual disease and host pharmacogenomics, offer promising avenues of research. Integration of molecular tools into clinical practice will ultimately allow for more precise risk stratification and individualized treatment planning.",Journal Article,4006.0,64.0,With current treatment regimens event-free survival rates for childhood acute lymphoblastic ALL approach or exceed 80 This success was achieved in part through the implementation of risk-stratified therapy However for the 15-20 of children with newly diagnosed ALL who will ultimately relapse traditional risk assessment remains inadequate This review highlights recent advances in our understanding of prognostic factors that may be used to refine risk group classification An increasingly sophisticated understanding of genetic abnormalities in cells including chromosomal abnormalities and patterns of gene expression response to treatment and host pharmacogenomics offers the potential to enhance or supplant currently applied prognostic criteria for use in treatment planning for childhood ALL Identification of biologically distinctive subsets of ALL through cytogenetic molecular and gene expression studies as well as investigations of minimal residual disease and host pharmacogenomics offer promising avenues of research Integration of molecular tools into clinical practice will ultimately allow for more precise risk stratification and individualized treatment planning,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5, 291, 24, 472, 774, 115, 25, 151, 9, 864, 286, 1275, 62, 353, 15, 6818, 493, 26, 1825, 10, 513, 4, 760, 298, 3, 2393, 1, 43, 1173, 36, 137, 9, 3, 167, 179, 1, 541, 5, 732, 265, 62, 54, 303, 2050, 429, 1847, 43, 455, 469, 3358, 26, 206, 2527, 435, 954, 4, 114, 612, 1, 177, 130, 17, 68, 40, 95, 6, 5003, 43, 87, 947, 35, 1635, 8023, 612, 1, 336, 1171, 4, 37, 141, 1860, 1171, 2, 764, 1, 145, 55, 51, 6, 24, 2, 1204, 7603, 2339, 3, 174, 6, 1304, 15, 20329, 694, 1498, 177, 371, 9, 119, 4, 24, 1349, 9, 864, 62, 911, 1, 2665, 5049, 1890, 1, 62, 298, 1266, 219, 2, 145, 55, 94, 22, 149, 22, 2492, 1, 1048, 753, 34, 2, 1204, 7603, 1918, 721, 6612, 1, 389, 2676, 1, 219, 1896, 237, 38, 758, 303, 2050, 1700, 9, 80, 3260, 43, 1541, 2, 2596, 24, 1349]",1181.0,19242236,305
Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International ALL Trial MRC UKALLXII/ECOG2993.,Blood,Blood,2009-02-24,"Prospective data on the value of allogeneic hematopoietic stem cell transplantation (alloHSCT) in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) are limited. The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling (sib) or matched unrelated donor (MUD) to patients younger than 55 years of age achieving complete remission (CR). The CR rate of 267 patients, median age 40, was 82%. Twenty-eight percent of patients proceeded to alloHSCT in first CR. Age older than 55 years or a pre-HSCT event were the most common reasons for failure to progress to alloHSCT. At 5 years, overall survival (OS) was 44% after sib alloHSCT, 36% after MUD alloHSCT, and 19% after chemotherapy. After adjustment for sex, age, and white blood count and excluding chemotherapy-treated patients who relapsed or died before the median time to alloHSCT, only relapse-free survival remained significantly superior in the alloHSCT group (odds ratio 0.31, 95% confidence interval 0.16-0.61). An intention-to-treat analysis, using the availability or not of a matched sibling donor, showed 5-year OS to be nonsignificantly better at 34% with a donor versus 25% with no donor. This prospective trial in adult Ph(+) ALL indicates a modest but significant benefit to alloHSCT. This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223.",Comparative Study,3983.0,187.0,Prospective data on the value of allogeneic hematopoietic stem cell transplantation alloHSCT in Philadelphia chromosome-positive Ph acute lymphoblastic ALL are limited The UKALLXII/ECOG 2993 study evaluated the outcome of assigning alloHSCT with a sibling sib or matched unrelated donor MUD to patients younger than 55 years of age achieving complete remission CR The CR rate of 267 patients median age 40 was 82 Twenty-eight percent of patients proceeded to alloHSCT in first CR Age older than 55 years or a pre-HSCT event were the most common reasons for failure to progress to alloHSCT At 5 years overall survival OS was 44 after sib alloHSCT 36 after MUD alloHSCT and 19 after chemotherapy After adjustment for sex age and white blood count and excluding chemotherapy-treated patients who relapsed or died before the median time to alloHSCT only relapse-free survival remained significantly superior in the alloHSCT group odds ratio 0.31 95 confidence interval 0.16-0.61 An intention-to-treat analysis using the availability or not of a matched sibling donor showed 5-year OS to be nonsignificantly better at 34 with a donor versus 25 with no donor This prospective trial in adult Ph ALL indicates a modest but significant benefit to alloHSCT This trial has been registered with clinicaltrials.gov under identifier NCT00002514 and as ISRCTN77346223,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[482, 74, 23, 3, 549, 1, 1063, 1007, 452, 31, 497, 10248, 4, 3006, 1170, 109, 2058, 286, 1275, 62, 32, 383, 3, 24975, 2351, 24976, 45, 194, 3, 228, 1, 9648, 10248, 5, 8, 3684, 8409, 15, 655, 2092, 1488, 7070, 6, 7, 773, 76, 614, 60, 1, 89, 1785, 236, 734, 684, 3, 684, 116, 1, 7559, 7, 52, 89, 327, 10, 878, 737, 659, 714, 1, 7, 6406, 6, 10248, 4, 157, 684, 89, 434, 76, 614, 60, 15, 8, 671, 1703, 774, 11, 3, 96, 186, 2325, 9, 496, 6, 1466, 6, 10248, 28, 33, 60, 63, 25, 118, 10, 584, 50, 8409, 10248, 511, 50, 7070, 10248, 2, 326, 50, 56, 50, 1852, 9, 1035, 89, 2, 886, 315, 1276, 2, 3207, 56, 73, 7, 54, 591, 15, 1016, 348, 3, 52, 98, 6, 10248, 158, 429, 115, 25, 958, 97, 1123, 4, 3, 10248, 87, 610, 197, 13, 456, 48, 307, 268, 13, 245, 13, 713, 35, 3205, 6, 943, 65, 75, 3, 2550, 15, 44, 1, 8, 655, 3684, 1488, 224, 33, 111, 118, 6, 40, 17078, 380, 28, 562, 5, 8, 1488, 185, 243, 5, 77, 1488, 26, 482, 160, 4, 780, 2058, 62, 2640, 8, 1721, 84, 93, 247, 6, 10248, 26, 160, 71, 85, 1653, 5, 1252, 1239, 669, 3719, 31193, 2, 22, 57709]",1352.0,19244158,574
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.,Blood,Blood,2009-03-12,"Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML). Occasionally, patients with Ph(+) ALL, or accelerated phase (AP) or blast phase (BP) CML achieve a major cytogenetic response (MCyR) but not a complete hematologic response (CHR). We analyzed 126 patients with CML in AP or BP, or with Ph(+) ALL treated with dasatinib or nilotinib after imatinib failure. Twenty patients received sequential treatment with both dasatinib and nilotinib for a total of 146 instances. CHR and MCyR rates were 54% and 37%, respectively in AP, 17% and 39% in BP, and 33% and 50% in Ph+ ALL. Failure to achieve a CHR at the time of achievement of a MCyR was associated with an inferior outcome, similar to that of patients without a MCyR (2-year survival rate, 37% and 35%, respectively). In contrast, patients with MCyR and concomitant CHR had a 77% 2-year survival rate. Twelve of 29 patients with MCyR without concomitant CHR later achieved a CHR; the 2-year survival rate for these patients was 55% compared with 22% for those who never achieved a CHR. These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome.",Clinical Trial,3967.0,24.0,Second-generation tyrosine kinase inhibitors are effective in Philadelphia chromosome-positive Ph acute lymphoblastic ALL and chronic myeloid CML Occasionally patients with Ph ALL or accelerated phase AP or blast phase BP CML achieve a major cytogenetic response MCyR but not a complete hematologic response CHR We analyzed 126 patients with CML in AP or BP or with Ph ALL treated with dasatinib or nilotinib after imatinib failure Twenty patients received sequential treatment with both dasatinib and nilotinib for a total of 146 instances CHR and MCyR rates were 54 and 37 respectively in AP 17 and 39 in BP and 33 and 50 in Ph+ ALL Failure to achieve a CHR at the time of achievement of a MCyR was associated with an inferior outcome similar to that of patients without a MCyR 2-year survival rate 37 and 35 respectively In contrast patients with MCyR and concomitant CHR had a 77 2-year survival rate Twelve of 29 patients with MCyR without concomitant CHR later achieved a CHR the 2-year survival rate for these patients was 55 compared with 22 for those who never achieved a CHR These results suggest that achievement of a MCyR without concomitant CHR is associated with poor outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[419, 914, 564, 216, 222, 32, 323, 4, 3006, 1170, 109, 2058, 286, 1275, 62, 2, 442, 533, 903, 6319, 7, 5, 2058, 62, 15, 2241, 124, 2517, 15, 3112, 124, 3044, 903, 1359, 8, 458, 1266, 51, 10240, 84, 44, 8, 236, 813, 51, 8158, 21, 311, 3927, 7, 5, 903, 4, 2517, 15, 3044, 15, 5, 2058, 62, 73, 5, 1674, 15, 2638, 50, 577, 496, 737, 7, 103, 1787, 24, 5, 110, 1674, 2, 2638, 9, 8, 181, 1, 4909, 5342, 8158, 2, 10240, 151, 11, 667, 2, 567, 106, 4, 2517, 269, 2, 587, 4, 3044, 2, 466, 2, 212, 4, 2058, 62, 496, 6, 1359, 8, 8158, 28, 3, 98, 1, 5088, 1, 8, 10240, 10, 41, 5, 35, 1663, 228, 288, 6, 17, 1, 7, 187, 8, 10240, 18, 111, 25, 116, 567, 2, 465, 106, 4, 748, 7, 5, 10240, 2, 1781, 8158, 42, 8, 849, 18, 111, 25, 116, 2544, 1, 462, 7, 5, 10240, 187, 1781, 8158, 1559, 513, 8, 8158, 3, 18, 111, 25, 116, 9, 46, 7, 10, 614, 72, 5, 350, 9, 135, 54, 1737, 513, 8, 8158, 46, 99, 309, 17, 5088, 1, 8, 10240, 187, 1781, 8158, 16, 41, 5, 334, 228]",1189.0,19282457,830
"Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemotherapy.",Cancer,Cancer,2009-05-01,"Among the well described cytogenetic abnormalities in adults with acute lymphoblastic leukemia (ALL), a translocation involving chromosomes 1 and 19 (t[1;19] [q23;p13]) occurs in a small subset but has been associated variously with an intermediate prognosis or a bad prognosis in different studies. Adults with ALL and t(1;19) who were treated at The University of Texas M. D. Anderson Cancer Center were reviewed. Their clinical features and outcomes were compared with those of patients who had other cytogenetic abnormalities. The study endpoints included the complete remission (CR) rate, the complete response duration (CRD), and overall survival (OS). Of 411 adults with pre-B-cell ALL, 12 patients had t(1;19). Ten of 12 patients with t(1;19) received hyperfractionated cyclophosphamide, vincristine, doxorubicin (Adriamycin), and dexamethasone alternating with methotrexate and high-dose cytarabine (hyper-CVAD) chemotherapy; and the other 2 patients received combined vincristine, doxorubicin, and dexamethasone (VAD). All 12 patients achieved CR, and the 3-year survival rate was 73%. Patients with t(1;19) had significantly better CRD and OS compared with all other patients combined and compared individually with patients who had Philadelphia chromosome-positive, t(4;11), and lymphoma-like abnormalities (deletion 6q, addition q14q, t[11;14], and t[14;18]). Adults with ALL and t(1;19) had an excellent prognosis when the received the hyper-CVAD regimen.",Journal Article,3917.0,20.0,Among the well described cytogenetic abnormalities in adults with acute lymphoblastic ALL a translocation involving chromosomes 1 and 19 t 1 19 q23 p13 occurs in a small subset but has been associated variously with an intermediate prognosis or a bad prognosis in different studies Adults with ALL and t 1 19 who were treated at The University of Texas M. D. Anderson Cancer Center were reviewed Their clinical features and outcomes were compared with those of patients who had other cytogenetic abnormalities The study endpoints included the complete remission CR rate the complete response duration CRD and overall survival OS Of 411 adults with pre-B-cell ALL 12 patients had t 1 19 Ten of 12 patients with t 1 19 received hyperfractionated cyclophosphamide vincristine doxorubicin Adriamycin and dexamethasone alternating with methotrexate and high-dose cytarabine hyper-CVAD chemotherapy and the other 2 patients received combined vincristine doxorubicin and dexamethasone VAD All 12 patients achieved CR and the 3-year survival rate was 73 Patients with t 1 19 had significantly better CRD and OS compared with all other patients combined and compared individually with patients who had Philadelphia chromosome-positive t 4 11 and lymphoma-like abnormalities deletion 6q addition q14q t 11 14 and t 14 18 Adults with ALL and t 1 19 had an excellent prognosis when the received the hyper-CVAD regimen,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[107, 3, 149, 1027, 1266, 1171, 4, 857, 5, 286, 1275, 62, 8, 2006, 1267, 3560, 14, 2, 326, 102, 14, 326, 11423, 7914, 1780, 4, 8, 302, 697, 84, 71, 85, 41, 28600, 5, 35, 919, 356, 15, 8, 5618, 356, 4, 338, 94, 857, 5, 62, 2, 102, 14, 326, 54, 11, 73, 28, 3, 1652, 1, 2738, 188, 427, 1929, 12, 574, 11, 446, 136, 38, 404, 2, 123, 11, 72, 5, 135, 1, 7, 54, 42, 127, 1266, 1171, 3, 45, 1387, 159, 3, 236, 734, 684, 116, 3, 236, 51, 654, 9366, 2, 63, 25, 118, 1, 9619, 857, 5, 671, 132, 31, 62, 133, 7, 42, 102, 14, 326, 1618, 1, 133, 7, 5, 102, 14, 326, 103, 6201, 1112, 2132, 856, 7700, 2, 1217, 5181, 5, 2116, 2, 64, 61, 1855, 4855, 5574, 56, 2, 3, 127, 18, 7, 103, 397, 2132, 856, 2, 1217, 10167, 62, 133, 7, 513, 684, 2, 3, 27, 111, 25, 116, 10, 803, 7, 5, 102, 14, 326, 42, 97, 380, 9366, 2, 118, 72, 5, 62, 127, 7, 397, 2, 72, 4257, 5, 7, 54, 42, 3006, 1170, 109, 102, 39, 175, 2, 4763, 733, 1171, 1528, 10961, 352, 57744, 102, 175, 213, 2, 102, 213, 203, 857, 5, 62, 2, 102, 14, 326, 42, 35, 1503, 356, 198, 3, 103, 3, 4855, 5574, 477]",1405.0,19298009,759
Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-08-01,"Asparaginase, an agent used in the treatment of acute lymphoblastic leukemia (ALL), is associated with the development of pancreatitis. The clinical course and long-term outcome of patients experiencing this complication has not been extensively detailed. We reviewed the clinical course for all children with ALL diagnosed with pancreatitis at the Dana-Farber Cancer Institute/Children's Hospital Boston between 1987 and 2003. The outcome of these patients was compared with that of patients with ALL who did not experience pancreatitis. Twenty-eight of 403 children (7%) were diagnosed with pancreatitis. Patients 10-18 years old at diagnosis had 2.4 times the risk of developing pancreatitis compared with younger patients. Pancreatitis typically occurred early in the course of therapy (median 4 weeks after first dose of asparaginase). Ninety-three percent of affected patients were hospitalized and 57% received parenteral nutrition. No patient developed chronic sequelae or died as a result of pancreatitis. Sixteen (57%) patients were re-treated with asparaginase, 10 of whom had another episode of pancreatitis. No significant differences in event-free survival were observed when comparing patients with and without a history of pancreatitis. Asparaginase-associated pancreatitis was more common in older children, and caused significant acute morbidity. It tended to occur after the first few doses of asparaginase, suggesting a predisposition to this complication rather than a cumulative drug effect. Re-treatment with asparaginase after an episode of pancreatitis was associated with a high risk of recurrent pancreatitis.",Journal Article,3825.0,75.0,Asparaginase an agent used in the treatment of acute lymphoblastic ALL is associated with the development of pancreatitis The clinical course and long-term outcome of patients experiencing this complication has not been extensively detailed We reviewed the clinical course for all children with ALL diagnosed with pancreatitis at the Dana-Farber Cancer Institute/Children 's Hospital Boston between 1987 and 2003 The outcome of these patients was compared with that of patients with ALL who did not experience pancreatitis Twenty-eight of 403 children 7 were diagnosed with pancreatitis Patients 10-18 years old at diagnosis had 2.4 times the risk of developing pancreatitis compared with younger patients Pancreatitis typically occurred early in the course of therapy median 4 weeks after first dose of asparaginase Ninety-three percent of affected patients were hospitalized and 57 received parenteral nutrition No patient developed chronic sequelae or died as a result of pancreatitis Sixteen 57 patients were re-treated with asparaginase 10 of whom had another episode of pancreatitis No significant differences in event-free survival were observed when comparing patients with and without a history of pancreatitis Asparaginase-associated pancreatitis was more common in older children and caused significant acute morbidity It tended to occur after the first few doses of asparaginase suggesting a predisposition to this complication rather than a cumulative drug effect Re-treatment with asparaginase after an episode of pancreatitis was associated with a high risk of recurrent pancreatitis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 35, 420, 95, 4, 3, 24, 1, 286, 1275, 62, 16, 41, 5, 3, 193, 1, 4535, 3, 38, 906, 2, 319, 337, 228, 1, 7, 2985, 26, 1447, 71, 44, 85, 3576, 2455, 21, 446, 3, 38, 906, 9, 62, 541, 5, 62, 265, 5, 4535, 28, 3, 4932, 4979, 12, 1377, 541, 292, 702, 7026, 59, 5450, 2, 1522, 3, 228, 1, 46, 7, 10, 72, 5, 17, 1, 7, 5, 62, 54, 205, 44, 730, 4535, 737, 659, 1, 10836, 541, 67, 11, 265, 5, 4535, 7, 79, 203, 60, 1095, 28, 147, 42, 18, 39, 1072, 3, 43, 1, 931, 4535, 72, 5, 773, 7, 4535, 1969, 489, 191, 4, 3, 906, 1, 36, 52, 39, 244, 50, 157, 61, 1, 3709, 2493, 169, 714, 1, 1424, 7, 11, 4795, 2, 696, 103, 8058, 5260, 77, 69, 276, 442, 4156, 15, 1016, 22, 8, 757, 1, 4535, 3228, 696, 7, 11, 1491, 73, 5, 3709, 79, 1, 953, 42, 1809, 6934, 1, 4535, 77, 93, 362, 4, 774, 115, 25, 11, 164, 198, 1430, 7, 5, 2, 187, 8, 532, 1, 4535, 3709, 41, 4535, 10, 80, 186, 4, 434, 541, 2, 1546, 93, 286, 787, 192, 3886, 6, 1271, 50, 3, 157, 1021, 415, 1, 3709, 802, 8, 2863, 6, 26, 1447, 1832, 76, 8, 967, 234, 254, 1491, 24, 5, 3709, 50, 35, 6934, 1, 4535, 10, 41, 5, 8, 64, 43, 1, 387, 4535]",1598.0,19405141,211
"High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia.",Blood,Blood,2009-05-20,"To more comprehensively assess the pathogenic contribution of the PTEN-PI3K-AKT pathway to T-cell acute lymphoblastic leukemia (T-ALL), we examined diagnostic DNA samples from children with T-ALL using array comparative genomic hybridization and sequence analysis. Alterations of PTEN, PI3K, or AKT were identified in 47.7% of 44 cases. There was a striking clustering of PTEN mutations in exon 7 in 12 cases, all of which were predicted to truncate the C2 domain without disrupting the phosphatase domain of PTEN. Induction chemotherapy failed to induce remission in 3 of the 4 patients whose lymphoblasts harbored PTEN deletions at the time of diagnosis, compared with none of the 12 patients with mutations of PTEN exon 7 (P = .007), suggesting that PTEN deletion has more adverse therapeutic consequences than mutational disruptions that preserve the phosphatase domain. These findings add significant support to the rationale for the development of therapies targeting the PTEN-PI3K-AKT pathway in T-ALL.",Journal Article,3898.0,294.0,To more comprehensively assess the pathogenic contribution of the PTEN-PI3K-AKT pathway to T-cell acute lymphoblastic T-ALL we examined diagnostic DNA samples from children with T-ALL using array comparative genomic hybridization and sequence analysis Alterations of PTEN PI3K or AKT were identified in 47.7 of 44 cases There was a striking clustering of PTEN mutations in exon 7 in 12 cases all of which were predicted to truncate the C2 domain without disrupting the phosphatase domain of PTEN Induction chemotherapy failed to induce remission in 3 of the 4 patients whose lymphoblasts harbored PTEN deletions at the time of diagnosis compared with none of the 12 patients with mutations of PTEN exon 7 P .007 suggesting that PTEN deletion has more adverse therapeutic consequences than mutational disruptions that preserve the phosphatase domain These findings add significant support to the rationale for the development of therapies targeting the PTEN-PI3K-AKT pathway in T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 80, 5627, 423, 3, 2806, 2925, 1, 3, 820, 974, 649, 308, 6, 102, 31, 286, 1275, 102, 62, 21, 409, 752, 261, 347, 29, 541, 5, 102, 62, 75, 1926, 2352, 572, 1554, 2, 1532, 65, 593, 1, 820, 974, 15, 649, 11, 108, 4, 662, 67, 1, 584, 140, 125, 10, 8, 5133, 3147, 1, 820, 138, 4, 1725, 67, 4, 133, 140, 62, 1, 92, 11, 783, 6, 45557, 3, 6706, 1398, 187, 6242, 3, 2577, 1398, 1, 820, 504, 56, 1551, 6, 1290, 734, 4, 27, 1, 3, 39, 7, 1310, 10521, 3253, 820, 2439, 28, 3, 98, 1, 147, 72, 5, 1292, 1, 3, 133, 7, 5, 138, 1, 820, 1725, 67, 19, 1999, 802, 17, 820, 1528, 71, 80, 290, 189, 3255, 76, 1619, 11594, 17, 6783, 3, 2577, 1398, 46, 272, 4178, 93, 538, 6, 3, 1728, 9, 3, 193, 1, 235, 529, 3, 820, 974, 649, 308, 4, 102, 62]",982.0,19458356,66
Risk of thyroid dysfunction and subsequent thyroid cancer among survivors of acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-09-01,"To determine the risk of thyroid dysfunction and subsequent thyroid cancer among childhood acute lymphoblastic leukemia (ALL) survivors. Rates of self-reported thyroid dysfunction and thyroid cancer were determined among 3,579 ALL survivors participating in the Childhood Cancer Survivor Study, a cohort of 5-year survivors of pediatric cancers diagnosed from 1970 to 1986, and compared with 3,846 siblings and population rates, respectively. The cumulative incidence of hypo- and hyperthyroidism among survivors 15 years following leukemia diagnosis was 1.6% (95% CI 1.1, 2.1) and 0.6% (95% CI 0.3, 1.1), respectively, both significantly increased compared with siblings. In multivariate analysis, survivors who received >or=20 Gy cranial radiotherapy plus any spinal radiotherapy had the highest risk of subsequent hypothyroidism (HR 8.3, 95% CI 3.3, 20.5) compared with those treated with chemotherapy alone. Craniospinal radiotherapy also was associated with an increased risk of subsequent hyperthyroidism (HR 6.1, 95% CI 1.1, 34.2) compared with chemotherapy alone, as well as an increased risk of subsequent thyroid cancers (SIR 30.3, 95% CI 14.5, 55.7) compared with population rates. In radiation dosimetry analysis, pituitary doses >or=20 Gy combined with thyroid doses >or=10 Gy were associated with hypothyroidism, whereas pituitary doses >or=20 Gy combined with thyroid doses >or=15 Gy were associated with hyperthyroidism. The risk of thyroid dysfunction and thyroid cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy. In these individuals, long-term surveillance is warranted as no obvious plateau in risk was seen, even after 25 years of follow-up.",Journal Article,3794.0,66.0,"To determine the risk of dysfunction and subsequent cancer among childhood acute lymphoblastic ALL survivors Rates of self-reported dysfunction and cancer were determined among 3,579 ALL survivors participating in the Childhood Cancer Survivor Study a cohort of 5-year survivors of pediatric cancers diagnosed from 1970 to 1986 and compared with 3,846 siblings and population rates respectively The cumulative incidence of hypo- and hyperthyroidism among survivors 15 years following diagnosis was 1.6 95 CI 1.1 2.1 and 0.6 95 CI 0.3 1.1 respectively both significantly increased compared with siblings In multivariate analysis survivors who received or=20 Gy cranial radiotherapy plus any spinal radiotherapy had the highest risk of subsequent hypothyroidism HR 8.3 95 CI 3.3 20.5 compared with those treated with chemotherapy alone Craniospinal radiotherapy also was associated with an increased risk of subsequent hyperthyroidism HR 6.1 95 CI 1.1 34.2 compared with chemotherapy alone as well as an increased risk of subsequent cancers SIR 30.3 95 CI 14.5 55.7 compared with population rates In radiation dosimetry analysis doses or=20 Gy combined with doses or=10 Gy were associated with hypothyroidism whereas doses or=20 Gy combined with doses or=15 Gy were associated with hyperthyroidism The risk of dysfunction and cancer was increased among childhood ALL survivors treated with craniospinal radiotherapy In these individuals long-term surveillance is warranted as no obvious plateau in risk was seen even after 25 years of follow-up",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,"[6, 223, 3, 43, 1, 1527, 2, 706, 12, 107, 864, 286, 1275, 62, 332, 151, 1, 1074, 210, 1527, 2, 12, 11, 509, 107, 27, 11414, 62, 332, 3052, 4, 3, 864, 12, 2628, 45, 8, 180, 1, 33, 111, 332, 1, 815, 163, 265, 29, 4868, 6, 3751, 2, 72, 5, 27, 14842, 2758, 2, 266, 151, 106, 3, 967, 287, 1, 22433, 2, 12096, 107, 332, 167, 60, 366, 147, 10, 14, 49, 48, 58, 14, 14, 18, 14, 2, 13, 49, 48, 58, 13, 27, 14, 14, 106, 110, 97, 101, 72, 5, 2758, 4, 331, 65, 332, 54, 103, 15, 179, 381, 2565, 310, 349, 500, 1499, 310, 42, 3, 1076, 43, 1, 706, 4147, 168, 66, 27, 48, 58, 27, 27, 179, 33, 72, 5, 135, 73, 5, 56, 279, 5748, 310, 120, 10, 41, 5, 35, 101, 43, 1, 706, 12096, 168, 49, 14, 48, 58, 14, 14, 562, 18, 72, 5, 56, 279, 22, 149, 22, 35, 101, 43, 1, 706, 163, 3636, 201, 27, 48, 58, 213, 33, 614, 67, 72, 5, 266, 151, 4, 121, 4113, 65, 415, 15, 179, 381, 397, 5, 415, 15, 79, 381, 11, 41, 5, 4147, 547, 415, 15, 179, 381, 397, 5, 415, 15, 167, 381, 11, 41, 5, 12096, 3, 43, 1, 1527, 2, 12, 10, 101, 107, 864, 62, 332, 73, 5, 5748, 310, 4, 46, 869, 319, 337, 617, 16, 1197, 22, 77, 6228, 6133, 4, 43, 10, 527, 871, 50, 243, 60, 1, 166, 126]",1542.0,19459201,165
Acute leukemia in adolescents and young adults.,Seminars in oncology,Semin. Oncol.,2009-06-01,"In many areas of medicine adolescents are regarded as a discrete group with specific therapeutic, psychological, educational, and resource needs. In the treatment of acute leukemia age is a predictor of response. Thus, in acute lymphoblastic leukemia (ALL) there is a clearly poorer treatment outcome after puberty, while in acute myeloid leukaemia (AML), which is more common in older adults, age is a continuous variable with poorer outcomes in each successive decade. Much is known about other prognostic factors and their relative incidence in each age stratum. Although there is some segregation of favorable factors with relative youth, age usually remains an independent factor with respect to prognosis. Adolescents may be included in pediatric or adult-oriented treatment protocols. Here we discuss the outcome of acute leukemia in adolescents and young adults, particularly with respect to whether they respond similarly to children or other adults.",Journal Article,3886.0,31.0,In many areas of medicine adolescents are regarded as a discrete group with specific therapeutic psychological educational and resource needs In the treatment of acute age is a predictor of response Thus in acute lymphoblastic ALL there is a clearly poorer treatment outcome after puberty while in acute myeloid leukaemia AML which is more common in older adults age is a continuous variable with poorer outcomes in each successive decade Much is known about other prognostic factors and their relative incidence in each age stratum Although there is some segregation of favorable factors with relative youth age usually remains an independent factor with respect to prognosis Adolescents may be included in pediatric or adult-oriented treatment protocols Here we discuss the outcome of acute in adolescents and young adults particularly with respect to whether they respond similarly to children or other adults,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 445, 1361, 1, 1807, 3101, 32, 7217, 22, 8, 5447, 87, 5, 112, 189, 2624, 3624, 2, 3069, 1891, 4, 3, 24, 1, 286, 89, 16, 8, 980, 1, 51, 631, 4, 286, 1275, 62, 125, 16, 8, 2536, 1769, 24, 228, 50, 10302, 369, 4, 286, 533, 2001, 329, 92, 16, 80, 186, 4, 434, 857, 89, 16, 8, 1314, 1347, 5, 1769, 123, 4, 296, 6808, 2025, 1802, 16, 440, 545, 127, 177, 130, 2, 136, 580, 287, 4, 296, 89, 4897, 242, 125, 16, 476, 11844, 1, 913, 130, 5, 580, 19875, 89, 2082, 469, 35, 306, 161, 5, 2184, 6, 356, 3101, 68, 40, 159, 4, 815, 15, 780, 8095, 24, 2189, 467, 21, 1139, 3, 228, 1, 286, 4, 3101, 2, 1169, 857, 823, 5, 2184, 6, 317, 491, 1892, 1813, 6, 541, 15, 127, 857]",912.0,19460579,62
JAK mutations in high-risk childhood acute lymphoblastic leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2009-05-22,"Pediatric acute lymphoblastic leukemia (ALL) is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations. Mutation of genes encoding tyrosine kinases is uncommon in ALL, with the exception of Philadelphia chromosome-positive ALL, where the t(9,22)(q34;q11) translocation encodes the constitutively active BCR-ABL1 tyrosine kinase. We recently identified a poor prognostic subgroup of pediatric BCR-ABL1-negative ALL patients characterized by deletion of IKZF1 (encoding the lymphoid transcription factor IKAROS) and a gene expression signature similar to BCR-ABL1-positive ALL, raising the possibility of activated tyrosine kinase signaling within this leukemia subtype. Here, we report activating mutations in the Janus kinases JAK1 (n = 3), JAK2 (n = 16), and JAK3 (n = 1) in 20 (10.7%) of 187 BCR-ABL1-negative, high-risk pediatric ALL cases. The JAK1 and JAK2 mutations involved highly conserved residues in the kinase and pseudokinase domains and resulted in constitutive JAK-STAT activation and growth factor independence of Ba/F3-EpoR cells. The presence of JAK mutations was significantly associated with alteration of IKZF1 (70% of all JAK-mutated cases and 87.5% of cases with JAK2 mutations; P = 0.001) and deletion of CDKN2A/B (70% of all JAK-mutated cases and 68.9% of JAK2-mutated cases). The JAK-mutated cases had a gene expression signature similar to BCR-ABL1 pediatric ALL, and they had a poor outcome. These results suggest that inhibition of JAK signaling is a logical target for therapeutic intervention in JAK mutated ALL.",Journal Article,3896.0,373.0,"Pediatric acute lymphoblastic ALL is a heterogeneous disease consisting of distinct clinical and biological subtypes that are characterized by specific chromosomal abnormalities or gene mutations Mutation of genes encoding tyrosine kinases is uncommon in ALL with the exception of Philadelphia chromosome-positive ALL where the t 9,22 q34 q11 translocation encodes the constitutively active BCR-ABL1 tyrosine kinase We recently identified a poor prognostic subgroup of pediatric BCR-ABL1-negative ALL patients characterized by deletion of IKZF1 encoding the lymphoid transcription factor IKAROS and a gene expression signature similar to BCR-ABL1-positive ALL raising the possibility of activated tyrosine kinase signaling within this subtype Here we report activating mutations in the Janus kinases JAK1 n 3 JAK2 n 16 and JAK3 n 1 in 20 10.7 of 187 BCR-ABL1-negative high-risk pediatric ALL cases The JAK1 and JAK2 mutations involved highly conserved residues in the kinase and pseudokinase domains and resulted in constitutive JAK-STAT activation and growth factor independence of Ba/F3-EpoR cells The presence of JAK mutations was significantly associated with alteration of IKZF1 70 of all JAK-mutated cases and 87.5 of cases with JAK2 mutations P 0.001 and deletion of CDKN2A/B 70 of all JAK-mutated cases and 68.9 of JAK2-mutated cases The JAK-mutated cases had a gene expression signature similar to BCR-ABL1 pediatric ALL and they had a poor outcome These results suggest that inhibition of JAK signaling is a logical target for therapeutic intervention in JAK mutated ALL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[815, 286, 1275, 62, 16, 8, 1564, 34, 2273, 1, 834, 38, 2, 1037, 814, 17, 32, 765, 20, 112, 1860, 1171, 15, 145, 138, 258, 1, 214, 2362, 564, 1549, 16, 2052, 4, 62, 5, 3, 4188, 1, 3006, 1170, 109, 62, 1257, 3, 102, 83, 350, 16609, 11532, 2006, 4322, 3, 2818, 544, 1062, 3557, 564, 216, 21, 761, 108, 8, 334, 177, 1363, 1, 815, 1062, 3557, 199, 62, 7, 765, 20, 1528, 1, 8422, 2362, 3, 2303, 866, 161, 20613, 2, 8, 145, 55, 1651, 288, 6, 1062, 3557, 109, 62, 6627, 3, 2526, 1, 735, 564, 216, 314, 262, 26, 875, 467, 21, 414, 1616, 138, 4, 3, 6191, 1549, 8075, 78, 27, 2509, 78, 245, 2, 18927, 78, 14, 4, 179, 79, 67, 1, 5568, 1062, 3557, 199, 64, 43, 815, 62, 140, 3, 8075, 2, 2509, 138, 646, 561, 5547, 6418, 4, 3, 216, 2, 39000, 2703, 2, 627, 4, 3178, 4653, 4168, 363, 2, 129, 161, 5773, 1, 6669, 6904, 12839, 37, 3, 463, 1, 4653, 138, 10, 97, 41, 5, 2611, 1, 8422, 431, 1, 62, 4653, 1185, 140, 2, 912, 33, 1, 140, 5, 2509, 138, 19, 13, 144, 2, 1528, 1, 3175, 132, 431, 1, 62, 4653, 1185, 140, 2, 806, 83, 1, 2509, 1185, 140, 3, 4653, 1185, 140, 42, 8, 145, 55, 1651, 288, 6, 1062, 3557, 815, 62, 2, 491, 42, 8, 334, 228, 46, 99, 309, 17, 297, 1, 4653, 314, 16, 8, 10405, 283, 9, 189, 788, 4, 4653, 1185, 62]",1580.0,19470474,416
Flow cytometric chemosensitivity assay as a predictive tool of early clinical response in acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2009-10-01,"Residual disease or rapidity of response to induction therapy is among the most powerful predictors of outcome in pediatric acute lymphoblastic leukemia (ALL). Utilizing a multiparameter flow cytometric chemosensitivity assay (FCCA), we studied the relationship between in vitro drug sensitivity of diagnostic leukemic blasts from 30 children with ALL and rapidity of response to induction therapy. We also analyzed the in vitro drug sensitivity of de novo leukemic blasts among various clinical subsets. Compared to rapid early responders (RERs), slow early responders (SERs) had a significantly greater in vitro drug resistance to dexamethasone (DEX; P = 0.04) and prednisone (P = 0.05). The studies with all other drugs showed a non-significant trend with the SER having a higher in vitro drug resistance compared to the RER. Risk group stratified analyses indicated that in vitro resistance to asparaginase (ASP), DEX, and vincristine (VCR) were each significantly related to having very high risk ALL. Additionally, a significantly higher in vitro drug resistance to ASP and VCR was associated with unfavorable lymphoblast genetics and ultimate relapse. Our data indicate that this FCCA is a potentially simple and rapid method to detect inherent resistance to initial ALL therapy very early in induction, thus allowing for treatment modification shortly thereafter.",Journal Article,3764.0,5.0,Residual disease or rapidity of response to induction therapy is among the most powerful predictors of outcome in pediatric acute lymphoblastic ALL Utilizing a multiparameter flow cytometric chemosensitivity assay FCCA we studied the relationship between in vitro drug sensitivity of diagnostic leukemic blasts from 30 children with ALL and rapidity of response to induction therapy We also analyzed the in vitro drug sensitivity of de novo leukemic blasts among various clinical subsets Compared to rapid early responders RERs slow early responders SERs had a significantly greater in vitro drug resistance to dexamethasone DEX P 0.04 and prednisone P 0.05 The studies with all other drugs showed a non-significant trend with the SER having a higher in vitro drug resistance compared to the RER Risk group stratified analyses indicated that in vitro resistance to asparaginase ASP DEX and vincristine VCR were each significantly related to having very high risk ALL Additionally a significantly higher in vitro drug resistance to ASP and VCR was associated with unfavorable lymphoblast genetics and ultimate relapse Our data indicate that this FCCA is a potentially simple and rapid method to detect inherent resistance to initial ALL therapy very early in induction thus allowing for treatment modification shortly thereafter,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[753, 34, 15, 17112, 1, 51, 6, 504, 36, 16, 107, 3, 96, 3757, 674, 1, 228, 4, 815, 286, 1275, 62, 2600, 8, 10757, 1412, 6226, 5522, 719, 45572, 21, 656, 3, 858, 59, 4, 439, 234, 485, 1, 752, 2015, 2438, 29, 201, 541, 5, 62, 2, 17112, 1, 51, 6, 504, 36, 21, 120, 311, 3, 4, 439, 234, 485, 1, 1566, 2018, 2015, 2438, 107, 747, 38, 1890, 72, 6, 1321, 191, 1983, 57955, 3645, 191, 1983, 20660, 42, 8, 97, 378, 4, 439, 234, 251, 6, 1217, 4844, 19, 13, 755, 2, 1979, 19, 13, 474, 3, 94, 5, 62, 127, 600, 224, 8, 220, 93, 853, 5, 3, 6963, 1041, 8, 142, 4, 439, 234, 251, 72, 6, 3, 57956, 43, 87, 1173, 318, 1103, 17, 4, 439, 251, 6, 3709, 8501, 4844, 2, 2132, 8886, 11, 296, 97, 139, 6, 1041, 923, 64, 43, 62, 1724, 8, 97, 142, 4, 439, 234, 251, 6, 8501, 2, 8886, 10, 41, 5, 2483, 19414, 2894, 2, 5768, 429, 114, 74, 1008, 17, 26, 45572, 16, 8, 751, 2763, 2, 1321, 596, 6, 1426, 4943, 251, 6, 388, 62, 36, 923, 191, 4, 504, 631, 2952, 9, 24, 2437, 6961, 3972]",1327.0,19499583,186
Treating childhood acute lymphoblastic leukemia without cranial irradiation.,The New England journal of medicine,N. Engl. J. Med.,2009-06-01,"Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic leukemia (ALL) who are at high risk for central nervous system (CNS) relapse. We conducted a clinical trial to test whether prophylactic cranial irradiation could be omitted from treatment in all children with newly diagnosed ALL. A total of 498 patients who could be evaluated were enrolled. Treatment intensity was based on presenting features and the level of minimal residual disease after remission-induction treatment. The duration of continuous complete remission in the 71 patients who previously would have received prophylactic cranial irradiation was compared with that of 56 historical controls who received it. The 5-year event-free and overall survival probabilities for all 498 patients were 85.6% (95% confidence interval [CI], 79.9 to 91.3) and 93.5% (95% CI, 89.8 to 97.2), respectively. The 5-year cumulative risk of isolated CNS relapse was 2.7% (95% CI, 1.1 to 4.3), and that of any CNS relapse (including isolated relapse and combined relapse) was 3.9% (95% CI, 1.9 to 5.9). The 71 patients had significantly longer continuous complete remission than the 56 historical controls (P=0.04). All 11 patients with isolated CNS relapse remained in second remission for 0.4 to 5.5 years. CNS leukemia (CNS-3 status) or a traumatic lumbar puncture with blast cells at diagnosis and a high level of minimal residual disease (> or = 1%) after 6 weeks of remission induction were significantly associated with poorer event-free survival. Risk factors for CNS relapse included the genetic abnormality t(1;19)(TCF3-PBX1), any CNS involvement at diagnosis, and T-cell immunophenotype. Common adverse effects included allergic reactions to asparaginase, osteonecrosis, thrombosis, and disseminated fungal infection. With effective risk-adjusted chemotherapy, prophylactic cranial irradiation can be safely omitted from the treatment of childhood ALL. (ClinicalTrials.gov number, NCT00137111.)",Journal Article,3886.0,683.0,Prophylactic cranial irradiation has been a standard treatment in children with acute lymphoblastic ALL who are at high risk for central nervous system CNS relapse We conducted a clinical trial to test whether prophylactic cranial irradiation could be omitted from treatment in all children with newly diagnosed ALL A total of 498 patients who could be evaluated were enrolled Treatment intensity was based on presenting features and the level of minimal residual disease after remission-induction treatment The duration of continuous complete remission in the 71 patients who previously would have received prophylactic cranial irradiation was compared with that of 56 historical controls who received it The 5-year event-free and overall survival probabilities for all 498 patients were 85.6 95 confidence interval CI 79.9 to 91.3 and 93.5 95 CI 89.8 to 97.2 respectively The 5-year cumulative risk of isolated CNS relapse was 2.7 95 CI 1.1 to 4.3 and that of any CNS relapse including isolated relapse and combined relapse was 3.9 95 CI 1.9 to 5.9 The 71 patients had significantly longer continuous complete remission than the 56 historical controls P=0.04 All 11 patients with isolated CNS relapse remained in second remission for 0.4 to 5.5 years CNS CNS-3 status or a traumatic lumbar puncture with blast cells at diagnosis and a high level of minimal residual disease or 1 after 6 weeks of remission induction were significantly associated with poorer event-free survival Risk factors for CNS relapse included the genetic abnormality t 1 19 TCF3-PBX1 any CNS involvement at diagnosis and T-cell immunophenotype Common adverse effects included allergic reactions to asparaginase osteonecrosis thrombosis and disseminated fungal infection With effective risk-adjusted chemotherapy prophylactic cranial irradiation can be safely omitted from the treatment of childhood ALL ClinicalTrials.gov number NCT00137111,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1862, 2565, 1104, 71, 85, 8, 260, 24, 4, 541, 5, 286, 1275, 62, 54, 32, 28, 64, 43, 9, 854, 1880, 398, 1025, 429, 21, 426, 8, 38, 160, 6, 412, 317, 1862, 2565, 1104, 359, 40, 7138, 29, 24, 4, 62, 541, 5, 732, 265, 62, 8, 181, 1, 8928, 7, 54, 359, 40, 194, 11, 346, 24, 837, 10, 90, 23, 1656, 404, 2, 3, 301, 1, 1048, 753, 34, 50, 734, 504, 24, 3, 654, 1, 1314, 236, 734, 4, 3, 792, 7, 54, 373, 688, 47, 103, 1862, 2565, 1104, 10, 72, 5, 17, 1, 664, 2252, 535, 54, 103, 192, 3, 33, 111, 774, 115, 2, 63, 25, 3518, 9, 62, 8928, 7, 11, 772, 49, 48, 307, 268, 58, 842, 83, 6, 970, 27, 2, 966, 33, 48, 58, 887, 66, 6, 1015, 18, 106, 3, 33, 111, 967, 43, 1, 1355, 1025, 429, 10, 18, 67, 48, 58, 14, 14, 6, 39, 27, 2, 17, 1, 500, 1025, 429, 141, 1355, 429, 2, 397, 429, 10, 27, 83, 48, 58, 14, 83, 6, 33, 83, 3, 792, 7, 42, 97, 589, 1314, 236, 734, 76, 3, 664, 2252, 535, 19, 13, 755, 62, 175, 7, 5, 1355, 1025, 429, 958, 4, 419, 734, 9, 13, 39, 6, 33, 33, 60, 1025, 1025, 27, 156, 15, 8, 11272, 6187, 12104, 5, 3112, 37, 28, 147, 2, 8, 64, 301, 1, 1048, 753, 34, 15, 14, 50, 49, 244, 1, 734, 504, 11, 97, 41, 5, 1769, 774, 115, 25, 43, 130, 9, 1025, 429, 159, 3, 336, 3698, 102, 14, 326, 25178, 14434, 500, 1025, 799, 28, 147, 2, 102, 31, 5496, 186, 290, 176, 159, 7465, 2428, 6, 3709, 5404, 2839, 2, 3605, 7800, 930, 5, 323, 43, 586, 56, 1862, 2565, 1104, 122, 40, 2268, 7138, 29, 3, 24, 1, 864, 62, 1252, 1239, 207, 25075]",1915.0,19553647,611
"Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose.",Blood,Blood,2009-07-16,"We report outcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplantation (URD-PBSC HCT) for acute myeloid leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome enrolled on a prospective National Marrow Donor Program trial from 1999 through 2003. Preparative regimens included myeloablative (MA; N = 611), reduced-intensity (RI; N = 160), and nonmyeloablative (NMA; N = 161). For MA recipients, CD34(+) counts greater than 3.8 x 10(6)/kg improved neutrophil and platelet engraftment, whereas improved overall survival (OS) and reduced transplant-related mortality (TRM) were seen for all preparative regimens when CD34(+) cell doses exceeded 4.5 x 10(6)/kg. Higher infused doses of CD34(+) cell dose did not result in increased rates of either acute or chronic graft-versus-host disease (GVHD). Three-year OS and disease-free survival (DFS) of recipients of MA, RI, and NMA approaches were similar (33%, 35%, and 32% OS; 33%, 30%, and 29% DFS, respectively). In summary, recipients of URD-PBSC HCT receiving preparative regimens differing in intensity experienced similar survival. Higher CD34(+) cell doses resulted in more rapid engraftment, less TRM, and better 3-year OS (39% versus 25%, MA, P = .004; 38% versus 21% RI/NMA, P = .004) but did not increase the risk of GVHD. This trial was registered at www.clinicaltrials.gov as #NCT00785525.",Clinical Trial,3841.0,91.0,We report outcomes of 932 recipients of unrelated donor peripheral blood stem cell hematopoietic cell transplantation URD-PBSC HCT for acute myeloid acute lymphoblastic chronic myelogenous and syndrome enrolled on a prospective National Marrow Donor Program trial from 1999 through 2003 Preparative regimens included myeloablative MA N 611 reduced-intensity RI N 160 and nonmyeloablative NMA N 161 For MA recipients CD34 counts greater than 3.8 x 10 6 /kg improved neutrophil and platelet engraftment whereas improved overall survival OS and reduced transplant-related mortality TRM were seen for all preparative regimens when CD34 cell doses exceeded 4.5 x 10 6 /kg Higher infused doses of CD34 cell dose did not result in increased rates of either acute or chronic graft-versus-host disease GVHD Three-year OS and disease-free survival DFS of recipients of MA RI and NMA approaches were similar 33 35 and 32 OS 33 30 and 29 DFS respectively In summary recipients of URD-PBSC HCT receiving preparative regimens differing in intensity experienced similar survival Higher CD34 cell doses resulted in more rapid engraftment less TRM and better 3-year OS 39 versus 25 MA P .004 38 versus 21 RI/NMA P .004 but did not increase the risk of GVHD This trial was registered at www.clinicaltrials.gov as NCT00785525,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 123, 1, 15542, 2190, 1, 2092, 1488, 672, 315, 452, 31, 1007, 31, 497, 5847, 6368, 1085, 9, 286, 533, 286, 1275, 442, 2194, 2, 681, 346, 23, 8, 482, 657, 581, 1488, 1243, 160, 29, 2043, 298, 1522, 6085, 472, 159, 3246, 3687, 78, 10711, 405, 837, 9836, 78, 3457, 2, 6094, 10370, 78, 5377, 9, 3687, 2190, 2215, 1911, 378, 76, 27, 66, 1006, 79, 49, 503, 231, 2595, 2, 1596, 2881, 547, 231, 63, 25, 118, 2, 405, 941, 139, 282, 5064, 11, 527, 9, 62, 6085, 472, 198, 2215, 31, 415, 4726, 39, 33, 1006, 79, 49, 503, 142, 4524, 415, 1, 2215, 31, 61, 205, 44, 757, 4, 101, 151, 1, 361, 286, 15, 442, 1599, 185, 1204, 34, 1562, 169, 111, 118, 2, 34, 115, 25, 1010, 1, 2190, 1, 3687, 9836, 2, 10370, 611, 11, 288, 466, 465, 2, 531, 118, 466, 201, 2, 462, 1010, 106, 4, 1962, 2190, 1, 5847, 6368, 1085, 357, 6085, 472, 5276, 4, 837, 592, 288, 25, 142, 2215, 31, 415, 627, 4, 80, 1321, 2881, 299, 5064, 2, 380, 27, 111, 118, 587, 185, 243, 3687, 19, 1520, 519, 185, 239, 9836, 10370, 19, 1520, 84, 205, 44, 344, 3, 43, 1, 1562, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 58080]",1306.0,19608747,805
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-07-27,"Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic leukemia (T-ALL) and, in pediatric disease, predicts for favorable outcome. Their prognostic significance in adult T-ALL is unclear. We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII (UKALLXII)/Eastern Cooperative Oncology Group (ECOG) E2993 protocol. NOTCH1 and FBXW7 were screened by a combination of denaturing high-performance liquid chromatography and sequencing in 88 adult patients with T-ALL treated on the UKALLXII/ECOG E2993 protocol and compared with clinical characteristics and outcome. NOTCH1 and FBXW7 mutations were common (60% and 18%, respectively) and were not associated with age or WBC count. NOTCH1 heterodimerization domain mutations were associated with FBXW7 mutations (P = .02), and NOTCH1 proline, glutamic acid, serine, threonine (PEST) rich domain and FBXW7 mutations were mutually exclusive. There were an equal number of high- and standard-risk patients in the NOTCH1 and FBXW7 mutated (MUT) groups. Patients wild type (WT) for both markers trended toward poorer event-free survival (EFS; MUT v WT, 51% v 27%, P = .10; hazard ratio, 0.6). Analysis by each marker individually was not significantly predictive of outcome (NOTCH1 MUT v WT, EFS 49% v 34%, P = .20; FBXW7 MUT v WT, EFS 53% v 41%, P.72). NOTCH1 and FBXW7 mutant-positive patients do not fare sufficiently well to warrant an individualized treatment approach in future studies.",Journal Article,3830.0,69.0,Notch pathway activation by mutations in either NOTCH1 and/or FBXW7 is one of the most common molecular events in T-cell acute lymphoblastic T-ALL and in pediatric disease predicts for favorable outcome Their prognostic significance in adult T-ALL is unclear We sought to evaluate the outcome according to mutation status of patients with adult T-ALL treated on the United Kingdom Acute Lymphoblastic Leukaemia XII UKALLXII /Eastern Cooperative Oncology Group ECOG E2993 protocol NOTCH1 and FBXW7 were screened by a combination of denaturing high-performance liquid chromatography and sequencing in 88 adult patients with T-ALL treated on the UKALLXII/ECOG E2993 protocol and compared with clinical characteristics and outcome NOTCH1 and FBXW7 mutations were common 60 and 18 respectively and were not associated with age or WBC count NOTCH1 heterodimerization domain mutations were associated with FBXW7 mutations P .02 and NOTCH1 proline glutamic acid serine threonine PEST rich domain and FBXW7 mutations were mutually exclusive There were an equal number of high- and standard-risk patients in the NOTCH1 and FBXW7 mutated MUT groups Patients wild type WT for both markers trended toward poorer event-free survival EFS MUT v WT 51 v 27 P .10 hazard ratio 0.6 Analysis by each marker individually was not significantly predictive of outcome NOTCH1 MUT v WT EFS 49 v 34 P .20 FBXW7 MUT v WT EFS 53 v 41 P.72 NOTCH1 and FBXW7 mutant-positive patients do not fare sufficiently well to warrant an individualized treatment approach in future studies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3193, 308, 363, 20, 138, 4, 361, 4607, 2, 15, 8352, 16, 104, 1, 3, 96, 186, 219, 281, 4, 102, 31, 286, 1275, 102, 62, 2, 4, 815, 34, 2623, 9, 913, 228, 136, 177, 724, 4, 780, 102, 62, 16, 1200, 21, 990, 6, 376, 3, 228, 768, 6, 258, 156, 1, 7, 5, 780, 102, 62, 73, 23, 3, 1088, 10782, 286, 1275, 2001, 39048, 24975, 2118, 1690, 413, 87, 2351, 28928, 1182, 4607, 2, 8352, 11, 2261, 20, 8, 150, 1, 20459, 64, 528, 3165, 5140, 2, 615, 4, 889, 780, 7, 5, 102, 62, 73, 23, 3, 24975, 2351, 28928, 1182, 2, 72, 5, 38, 374, 2, 228, 4607, 2, 8352, 138, 11, 186, 335, 2, 203, 106, 2, 11, 44, 41, 5, 89, 15, 4685, 1276, 4607, 16699, 1398, 138, 11, 41, 5, 8352, 138, 19, 588, 2, 4607, 13850, 12727, 971, 3734, 5131, 33741, 3697, 1398, 2, 8352, 138, 11, 5575, 4804, 125, 11, 35, 2997, 207, 1, 64, 2, 260, 43, 7, 4, 3, 4607, 2, 8352, 1185, 3857, 271, 7, 955, 267, 1820, 9, 110, 525, 6374, 1317, 1769, 774, 115, 25, 1683, 3857, 603, 1820, 725, 603, 428, 19, 79, 360, 197, 13, 49, 65, 20, 296, 952, 4257, 10, 44, 97, 464, 1, 228, 4607, 3857, 603, 1820, 1683, 739, 603, 562, 19, 179, 8352, 3857, 603, 1820, 1683, 699, 603, 605, 19, 720, 4607, 2, 8352, 620, 109, 7, 1022, 44, 11470, 5938, 149, 6, 2946, 35, 2596, 24, 353, 4, 508, 94]",1547.0,19635999,683
Cellular therapies in acute lymphoblastic leukemia.,Current opinion in molecular therapeutics,Curr. Opin. Mol. Ther.,2009-08-01,"The majority of adult patients with acute lymphoblastic leukemia (ALL) will die from the disease. Although the prognosis for pediatric patients is significantly better than for adult patients with ALL, the prognosis for patients with relapsed or refractory disease is poor in all cases. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) from a related donor offers a significant therapeutic benefit for pediatric patients, although the benefit of this therapy to adults with ALL is less established. Because most patients lack a suitable related donor, alternative approaches to allo-HSCT, including umbilical cord blood, and unrelated and haploidentical allo-HSCT, have been investigated in the clinical setting. Although treatment with donor-derived T-cells, so-called 'donor lymphocyte infusion', has demonstrated poor outcomes in patients with relapsed ALL following HSCT, modified adoptive T-cell regimens, including the infusion of enriched tumor-targeted donor T-cells and genetically targeted T-cells, are currently under clinical investigation. In addition, the resistance of ALL tumor cell lines to NK-cell-mediated lysis may be overcome by the genetic modification of NK cells to target ALL tumor cell antigens, and this approach will be evaluated in an upcoming clinical trial. Whether these novel adoptive cell therapies will ultimately result in improved clinical outcomes remains to be determined.",Journal Article,3825.0,8.0,The majority of adult patients with acute lymphoblastic ALL will die from the disease Although the prognosis for pediatric patients is significantly better than for adult patients with ALL the prognosis for patients with relapsed or refractory disease is poor in all cases Allogeneic hematopoietic stem cell transplantation allo-HSCT from a related donor offers a significant therapeutic benefit for pediatric patients although the benefit of this therapy to adults with ALL is less established Because most patients lack a suitable related donor alternative approaches to allo-HSCT including umbilical cord blood and unrelated and haploidentical allo-HSCT have been investigated in the clinical setting Although treatment with donor-derived T-cells so-called 'donor lymphocyte infusion has demonstrated poor outcomes in patients with relapsed ALL following HSCT modified adoptive T-cell regimens including the infusion of enriched tumor-targeted donor T-cells and genetically targeted T-cells are currently under clinical investigation In addition the resistance of ALL tumor cell lines to NK-cell-mediated lysis may be overcome by the genetic modification of NK cells to target ALL tumor cell antigens and this approach will be evaluated in an upcoming clinical trial Whether these novel adoptive cell therapies will ultimately result in improved clinical outcomes remains to be determined,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 686, 1, 780, 7, 5, 286, 1275, 62, 303, 3384, 29, 3, 34, 242, 3, 356, 9, 815, 7, 16, 97, 380, 76, 9, 780, 7, 5, 62, 3, 356, 9, 7, 5, 591, 15, 430, 34, 16, 334, 4, 62, 140, 1063, 1007, 452, 31, 497, 2564, 1703, 29, 8, 139, 1488, 2339, 8, 93, 189, 247, 9, 815, 7, 242, 3, 247, 1, 26, 36, 6, 857, 5, 62, 16, 299, 635, 408, 96, 7, 926, 8, 2884, 139, 1488, 1091, 611, 6, 2564, 1703, 141, 5998, 1885, 315, 2, 2092, 2, 5802, 2564, 1703, 47, 85, 565, 4, 3, 38, 546, 242, 24, 5, 1488, 526, 102, 37, 1743, 3472, 45633, 1448, 904, 71, 264, 334, 123, 4, 7, 5, 591, 62, 366, 1703, 1230, 3159, 102, 31, 472, 141, 3, 904, 1, 2220, 30, 238, 1488, 102, 37, 2, 2301, 238, 102, 37, 32, 694, 669, 38, 940, 4, 352, 3, 251, 1, 62, 30, 31, 285, 6, 1765, 31, 517, 4783, 68, 40, 1768, 20, 3, 336, 2437, 1, 1765, 37, 6, 283, 62, 30, 31, 1575, 2, 26, 353, 303, 40, 194, 4, 35, 11974, 38, 160, 317, 46, 229, 3159, 31, 235, 303, 2050, 757, 4, 231, 38, 123, 469, 6, 40, 509]",1391.0,19649982,281
Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2009-07-27,"Pediatric de novo acute myeloid leukemia (AML) is an aggressive malignancy with current therapy resulting in cure rates of only 60%. To better understand the cause of the marked heterogeneity in therapeutic response and to identify new prognostic markers and therapeutic targets a comprehensive list of the genetic mutations that underlie the pathogenesis of AML is needed. To approach this goal, we examined diagnostic leukemic samples from a cohort of 111 children with de novo AML using single-nucleotide-polymorphism microarrays and candidate gene resequencing. Our data demonstrate that, in contrast to pediatric acute lymphoblastic leukemia (ALL), de novo AML is characterized by a very low burden of genomic alterations, with a mean of only 2.38 somatic copy-number alterations per leukemia, and less than 1 nonsynonymous point mutation per leukemia in the 25 genes analyzed. Even more surprising was the observation that 34% of the leukemias lacked any identifiable copy-number alterations, and 28% of the leukemias with recurrent translocations lacked any identifiable sequence or numerical abnormalities. The only exception to the presence of few mutations was acute megakaryocytic leukemias, with the majority of these leukemias being characterized by a high number of copy-number alterations but rare point mutations. Despite the low overall number of lesions across the patient cohort, novel recurring regions of genetic alteration were identified that harbor known, and potential new cancer genes. These data reflect a remarkably low burden of genomic alterations within pediatric de novo AML, which is in stark contrast to most other human malignancies.",Journal Article,3830.0,119.0,Pediatric de novo acute myeloid AML is an aggressive malignancy with current therapy resulting in cure rates of only 60 To better understand the cause of the marked heterogeneity in therapeutic response and to identify new prognostic markers and therapeutic targets a comprehensive list of the genetic mutations that underlie the pathogenesis of AML is needed To approach this goal we examined diagnostic leukemic samples from a cohort of 111 children with de novo AML using single-nucleotide-polymorphism microarrays and candidate gene resequencing Our data demonstrate that in contrast to pediatric acute lymphoblastic ALL de novo AML is characterized by a very low burden of genomic alterations with a mean of only 2.38 somatic copy-number alterations per and less than 1 nonsynonymous point mutation per in the 25 genes analyzed Even more surprising was the observation that 34 of the leukemias lacked any identifiable copy-number alterations and 28 of the leukemias with recurrent translocations lacked any identifiable sequence or numerical abnormalities The only exception to the presence of few mutations was acute megakaryocytic leukemias with the majority of these leukemias being characterized by a high number of copy-number alterations but rare point mutations Despite the low overall number of lesions across the patient cohort novel recurring regions of genetic alteration were identified that harbor known and potential new cancer genes These data reflect a remarkably low burden of genomic alterations within pediatric de novo AML which is in stark contrast to most other human malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[815, 1566, 2018, 286, 533, 329, 16, 35, 571, 710, 5, 291, 36, 1113, 4, 1722, 151, 1, 158, 335, 6, 380, 1640, 3, 708, 1, 3, 2003, 1144, 4, 189, 51, 2, 6, 255, 217, 177, 525, 2, 189, 637, 8, 949, 4754, 1, 3, 336, 138, 17, 5875, 3, 1384, 1, 329, 16, 575, 6, 353, 26, 1326, 21, 409, 752, 2015, 347, 29, 8, 180, 1, 3167, 541, 5, 1566, 2018, 329, 75, 226, 1579, 1907, 2774, 2, 1609, 145, 11819, 114, 74, 608, 17, 4, 748, 6, 815, 286, 1275, 62, 1566, 2018, 329, 16, 765, 20, 8, 923, 154, 892, 1, 572, 593, 5, 8, 313, 1, 158, 18, 519, 1119, 1337, 207, 593, 379, 2, 299, 76, 14, 10233, 741, 258, 379, 4, 3, 243, 214, 311, 871, 80, 14157, 10, 3, 1664, 17, 562, 1, 3, 2792, 5005, 500, 6237, 1337, 207, 593, 2, 339, 1, 3, 2792, 5, 387, 3262, 5005, 500, 6237, 1532, 15, 8736, 1171, 3, 158, 4188, 6, 3, 463, 1, 1021, 138, 10, 286, 14385, 2792, 5, 3, 686, 1, 46, 2792, 486, 765, 20, 8, 64, 207, 1, 1337, 207, 593, 84, 622, 741, 138, 550, 3, 154, 63, 207, 1, 406, 716, 3, 69, 180, 229, 6385, 1374, 1, 336, 2611, 11, 108, 17, 2760, 440, 2, 174, 217, 12, 214, 46, 74, 2694, 8, 4856, 154, 892, 1, 572, 593, 262, 815, 1566, 2018, 329, 92, 16, 4, 16702, 748, 6, 96, 127, 171, 441]",1607.0,19651601,719
Outcome of congenital acute lymphoblastic leukemia treated on the Interfant-99 protocol.,Blood,Blood,2009-08-05,"Acute lymphoblastic leukemia (ALL) diagnosed in the first month of life (congenital ALL) is very rare. Although congenital ALL is often assumed to be fatal, no studies have been published on outcome except for case reports. The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol, a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid leukemia. Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants. Induction failure rate was 13% and not significantly different from that in older infants (7%, P = .14), but relapse rate was significantly higher in congenital ALL patients (2-year cumulative incidence [SE] was 60.0 [9.3] vs 34.2 [2.3], P < .001). Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20% (SE 9.1%). Early death in complete remission and treatment delays resulting from toxicity were not different. The survival of 17% after last follow-up, combined with a toxicity profile comparable with that in older infants, justifies treating congenital ALL with curative intent. This trial was registered at www.clinicaltrials.gov as no. NCT 00015873, and at www.controlled-trials.com as no. ISRCTN24251487.",Clinical Trial,3821.0,51.0,Acute lymphoblastic ALL diagnosed in the first month of life congenital ALL is very rare Although congenital ALL is often assumed to be fatal no studies have been published on outcome except for case reports The present study reports the outcome of 30 patients with congenital ALL treated with the uniform Interfant-99 protocol a hybrid regimen combining ALL treatment with elements designed for treatment of acute myeloid Congenital ALL was characterized by a higher white blood cell count and a strong trend for higher incidence of MLL rearrangements and CD10-negative B-lineage ALL compared with older infants Induction failure rate was 13 and not significantly different from that in older infants 7 P .14 but relapse rate was significantly higher in congenital ALL patients 2-year cumulative incidence SE was 60.0 9.3 vs 34.2 2.3 P .001 Two-year event-free survival and survival of congenital ALL patients treated with this protocol was 20 SE 9.1 Early death in complete remission and treatment delays resulting from toxicity were not different The survival of 17 after last follow-up combined with a toxicity profile comparable with that in older infants justifies treating congenital ALL with curative intent This trial was registered at www.clinicaltrials.gov as no NCT 00015873 and at www.controlled-trials.com as no ISRCTN24251487,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 265, 4, 3, 157, 811, 1, 358, 6711, 62, 16, 923, 622, 242, 6711, 62, 16, 629, 6719, 6, 40, 3034, 77, 94, 47, 85, 983, 23, 228, 2187, 9, 473, 1198, 3, 364, 45, 1198, 3, 228, 1, 201, 7, 5, 6711, 62, 73, 5, 3, 3490, 39061, 1058, 1182, 8, 4542, 477, 1525, 62, 24, 5, 2531, 1114, 9, 24, 1, 286, 533, 6711, 62, 10, 765, 20, 8, 142, 886, 315, 31, 1276, 2, 8, 1082, 853, 9, 142, 287, 1, 3049, 2072, 2, 6289, 199, 132, 2542, 62, 72, 5, 434, 5585, 504, 496, 116, 10, 233, 2, 44, 97, 338, 29, 17, 4, 434, 5585, 67, 19, 213, 84, 429, 116, 10, 97, 142, 4, 6711, 62, 7, 18, 111, 967, 287, 3428, 10, 335, 13, 83, 27, 105, 562, 18, 18, 27, 19, 144, 100, 111, 774, 115, 25, 2, 25, 1, 6711, 62, 7, 73, 5, 26, 1182, 10, 179, 3428, 83, 14, 191, 273, 4, 236, 734, 2, 24, 3257, 1113, 29, 155, 11, 44, 338, 3, 25, 1, 269, 50, 1060, 166, 126, 397, 5, 8, 155, 800, 1279, 5, 17, 4, 434, 5585, 13299, 1367, 6711, 62, 5, 1075, 1697, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 77, 6444, 58125, 2, 28, 3064, 1149, 143, 8264, 22, 77, 45639]",1340.0,19657114,547
Central nervous system disease in hematologic malignancies: historical perspective and practical applications.,Seminars in oncology,Semin. Oncol.,2009-08-01,"Acute lymphoblastic leukemia (ALL) 5-year survival rates are approaching 90% in children and 50% in adults who are receiving contemporary risk-directed treatment protocols. Current efforts focus not only on further improving cure rate but also on patient quality of life. Hence, all protocols decrease or limit the use of cranial irradiation as central nervous system (CNS)-directed therapy, even in patients with high-risk presenting features, such as the presence of leukemia cells in the cerebrospinal fluid (even resulting from traumatic lumbar puncture), adverse genetic features, T-cell immunophenotype, and a large leukemia cell burden. Current strategies for CNS-directed therapy involve effective systemic chemotherapy (eg, dexamethasone, high-dose methotrexate, intensive asparaginase) and early intensification and optimization of intrathecal therapy. Options under investigation for the treatment of relapsed or refractory CNS leukemia in ALL patients include thiotepa and intrathecal liposomal cytarabine. CNS involvement in non-Hodgkin lymphoma (NHL) is associated with young age, advanced stage, number of extranodal sites, elevated lactate dehydrogenase, and International Prognostic Index score. Refractory CNS lymphoma in patients with NHL carries a poor prognosis, with a median survival of 2 to 6 months; the most promising treatment, autologous stem cell transplant, can extend median survival from 10 to 26 months. CNS prophylaxis is required during the initial treatment of NHL subtypes that carry a high risk of CNS relapse, such as B-cell ALL, Burkitt lymphoma, and lymphoblastic lymphoma. The use of CNS prophylaxis in the treatment of diffuse large B-cell lymphoma is controversial because of the low risk of CNS relapse ( approximately 5%) in this population. In this article, we review current and past practice of intrathecal therapy in ALL and NHL and the risk models that aim to identify predictors of CNS relapse in NHL.",Journal Article,3825.0,101.0,Acute lymphoblastic ALL 5-year survival rates are approaching 90 in children and 50 in adults who are receiving contemporary risk-directed treatment protocols Current efforts focus not only on further improving cure rate but also on patient quality of life Hence all protocols decrease or limit the use of cranial irradiation as central nervous system CNS -directed therapy even in patients with high-risk presenting features such as the presence of cells in the cerebrospinal fluid even resulting from traumatic lumbar puncture adverse genetic features T-cell immunophenotype and a large cell burden Current strategies for CNS-directed therapy involve effective systemic chemotherapy eg dexamethasone high-dose methotrexate intensive asparaginase and early intensification and optimization of intrathecal therapy Options under investigation for the treatment of relapsed or refractory CNS in ALL patients include thiotepa and intrathecal liposomal cytarabine CNS involvement in NHL is associated with young age advanced stage number of extranodal sites elevated lactate dehydrogenase and International Prognostic Index score Refractory CNS in patients with NHL carries a poor prognosis with a median survival of 2 to 6 months the most promising treatment autologous stem cell transplant can extend median survival from 10 to 26 months CNS prophylaxis is required during the initial treatment of NHL subtypes that carry a high risk of CNS relapse such as B-cell ALL and lymphoblastic The use of CNS prophylaxis in the treatment of diffuse large B-cell is controversial because of the low risk of CNS relapse approximately 5 in this population In this article we review current and past practice of intrathecal therapy in ALL and NHL and the risk models that aim to identify predictors of CNS relapse in NHL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 33, 111, 25, 151, 32, 7773, 424, 4, 541, 2, 212, 4, 857, 54, 32, 357, 2667, 43, 1166, 24, 2189, 291, 1413, 1222, 44, 158, 23, 195, 1673, 1722, 116, 84, 120, 23, 69, 372, 1, 358, 3665, 62, 2189, 775, 15, 2385, 3, 119, 1, 2565, 1104, 22, 854, 1880, 398, 1025, 1166, 36, 871, 4, 7, 5, 64, 43, 1656, 404, 225, 22, 3, 463, 1, 37, 4, 3, 5156, 2357, 871, 1113, 29, 11272, 6187, 12104, 290, 336, 404, 102, 31, 5496, 2, 8, 375, 31, 892, 291, 422, 9, 1025, 1166, 36, 3882, 323, 403, 56, 2887, 1217, 64, 61, 2116, 1686, 3709, 2, 191, 5091, 2, 3980, 1, 5126, 36, 838, 669, 940, 9, 3, 24, 1, 591, 15, 430, 1025, 4, 62, 7, 643, 8182, 2, 5126, 3275, 1855, 1025, 799, 4, 1176, 16, 41, 5, 1169, 89, 131, 82, 207, 1, 4093, 633, 804, 3330, 2374, 2, 944, 177, 558, 368, 430, 1025, 4, 7, 5, 1176, 4942, 8, 334, 356, 5, 8, 52, 25, 1, 18, 6, 49, 53, 3, 96, 721, 24, 1028, 452, 31, 941, 122, 4087, 52, 25, 29, 79, 6, 432, 53, 1025, 2049, 16, 616, 190, 3, 388, 24, 1, 1176, 814, 17, 3542, 8, 64, 43, 1, 1025, 429, 225, 22, 132, 31, 62, 2, 1275, 3, 119, 1, 1025, 2049, 4, 3, 24, 1, 1388, 375, 132, 31, 16, 2010, 408, 1, 3, 154, 43, 1, 1025, 429, 705, 33, 4, 26, 266, 4, 26, 946, 21, 206, 291, 2, 1219, 758, 1, 5126, 36, 4, 62, 2, 1176, 2, 3, 43, 274, 17, 1130, 6, 255, 674, 1, 1025, 429, 4, 1176]",1806.0,19660680,360
Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2010-02-01,"Escherichia coli asparaginase is an important component of treatment for childhood acute lymphoblastic leukemia (ALL); however, hypersensitivity develops in up to 30% of patients. We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase, an alternative preparation, in E. coli asparaginase-allergic patients. Between 2000 and 2002, 215 children with newly diagnosed ALL were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 and were to receive 30 weekly doses of intramuscular E. coli asparaginase. If E. coli asparaginase allergy developed, patients were switched to twice-weekly intramuscular Erwinia asparaginase (25,000 IU/m(2)). Nadir serum asparaginase activity (NSAA) was measured every 3 weeks. Forty-two patients (20%) developed E. coli asparaginase allergy and switched to Erwinia. Of 38 patients with evaluable samples, 34 (89%) Erwinia-treated patients had at least one therapeutic NSAA (> or =0.1 IU/ml). The median NSAA was 0.247 IU/ml 3 days and 0.077 IU/ml 4 days after an Erwinia dose. Associated toxicities included allergy in 14 (33%) and pancreatitis in 3 patients (7%). At a median follow-up of 5.4 years, event-free survival (+/-standard error) of the 42 patients who switched to Erwinia was 86 +/- 5% compared with 81 +/- 3% for the 170 patients without E. coli asparaginase allergy (P = 0.55). Twice-weekly Erwinia asparaginase was well tolerated and achieved a therapeutically effective NSAA in most E. coli asparaginase-allergic patients. Development of E. coli allergy and subsequent treatment with twice-weekly Erwinia did not adversely impact event-free survival. Erwinia asparaginase should be considered for E. coli asparaginase-allergic patients.",Clinical Trial,3641.0,93.0,"Escherichia coli asparaginase is an important component of treatment for childhood acute lymphoblastic ALL however hypersensitivity develops in up to 30 of patients We assessed the nadir enzyme activity and tolerability of Erwinia asparaginase an alternative preparation in E. coli asparaginase-allergic patients Between 2000 and 2002 215 children with newly diagnosed ALL were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 and were to receive 30 weekly doses of intramuscular E. coli asparaginase If E. coli asparaginase allergy developed patients were switched to twice-weekly intramuscular Erwinia asparaginase 25,000 IU/m 2 Nadir serum asparaginase activity NSAA was measured every 3 weeks Forty-two patients 20 developed E. coli asparaginase allergy and switched to Erwinia Of 38 patients with evaluable samples 34 89 Erwinia-treated patients had at least one therapeutic NSAA or =0.1 IU/ml The median NSAA was 0.247 IU/ml 3 days and 0.077 IU/ml 4 days after an Erwinia dose Associated toxicities included allergy in 14 33 and pancreatitis in 3 patients 7 At a median follow-up of 5.4 years event-free survival +/-standard error of the 42 patients who switched to Erwinia was 86 +/- 5 compared with 81 +/- 3 for the 170 patients without E. coli asparaginase allergy P 0.55 Twice-weekly Erwinia asparaginase was well tolerated and achieved a therapeutically effective NSAA in most E. coli asparaginase-allergic patients Development of E. coli allergy and subsequent treatment with twice-weekly Erwinia did not adversely impact event-free survival Erwinia asparaginase should be considered for E. coli asparaginase-allergic patients",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[12832, 6959, 3709, 16, 35, 305, 1249, 1, 24, 9, 864, 286, 1275, 62, 137, 4034, 4734, 4, 126, 6, 201, 1, 7, 21, 275, 3, 3686, 1644, 128, 2, 1543, 1, 11358, 3709, 35, 1091, 4824, 4, 563, 6959, 3709, 7465, 7, 59, 1081, 2, 1544, 6511, 541, 5, 732, 265, 62, 11, 346, 23, 4932, 4979, 12, 1377, 62, 2404, 1182, 2038, 355, 2, 11, 6, 560, 201, 709, 415, 1, 10311, 563, 6959, 3709, 492, 563, 6959, 3709, 9842, 276, 7, 11, 7883, 6, 936, 709, 10311, 11358, 3709, 243, 984, 4588, 188, 18, 3686, 524, 3709, 128, 19885, 10, 644, 454, 27, 244, 1213, 100, 7, 179, 276, 563, 6959, 3709, 9842, 2, 7883, 6, 11358, 1, 519, 7, 5, 859, 347, 562, 887, 11358, 73, 7, 42, 28, 506, 104, 189, 19885, 15, 13, 14, 4588, 542, 3, 52, 19885, 10, 13, 7708, 4588, 542, 27, 162, 2, 13, 11263, 4588, 542, 39, 162, 50, 35, 11358, 61, 41, 385, 159, 9842, 4, 213, 466, 2, 4535, 4, 27, 7, 67, 28, 8, 52, 166, 126, 1, 33, 39, 60, 774, 115, 25, 260, 3444, 1, 3, 595, 7, 54, 7883, 6, 11358, 10, 868, 33, 72, 5, 865, 27, 9, 3, 5248, 7, 187, 563, 6959, 3709, 9842, 19, 13, 614, 936, 709, 11358, 3709, 10, 149, 421, 2, 513, 8, 4602, 323, 19885, 4, 96, 563, 6959, 3709, 7465, 7, 193, 1, 563, 6959, 9842, 2, 706, 24, 5, 936, 709, 11358, 205, 44, 4311, 345, 774, 115, 25, 11358, 3709, 257, 40, 515, 9, 563, 6959, 3709, 7465, 7]",1660.0,19672973,695
Germline genomic variants associated with childhood acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2009-08-16,"Using the Affymetrix 500K Mapping array and publicly available genotypes, we identified 18 SNPs whose allele frequency differed significantly(P < 1 x 10(-5)) between pediatric acute lymphoblastic leukemia (ALL) cases (n = 317) and non-ALL controls (n = 17,958). Two SNPs in ARID5B not only differed between ALL and non-ALL groups (rs10821936, P = 1.4 x 10(-15), odds ratio (OR) = 1.91; rs10994982, P = 5.7 x 10(-9), OR = 1.62) but also distinguished B-hyperdiploid ALL from other subtypes (rs10821936, P = 1.62 x 10(-5), OR = 2.17; rs10994982, P = 0.003, OR 1.72). These ARID5B SNPs also distinguished B-hyperdiploid ALL from other subtypes in an independent validation cohort (n = 124 children with ALL; P = 0.003 and P = 0.0008, OR 2.45 and 2.86, respectively) and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts. We conclude that germline variants affect susceptibility to, and characteristics of, specific ALL subtypes.",Journal Article,3810.0,322.0,"Using the Affymetrix 500K Mapping array and publicly available genotypes we identified 18 SNPs whose allele frequency differed significantly P 1 x 10 -5 between pediatric acute lymphoblastic ALL cases n 317 and non-ALL controls n 17,958 Two SNPs in ARID5B not only differed between ALL and non-ALL groups rs10821936 P 1.4 x 10 -15 odds ratio OR 1.91 rs10994982 P 5.7 x 10 -9 OR 1.62 but also distinguished B-hyperdiploid ALL from other subtypes rs10821936 P 1.62 x 10 -5 OR 2.17 rs10994982 P 0.003 OR 1.72 These ARID5B SNPs also distinguished B-hyperdiploid ALL from other subtypes in an independent validation cohort n 124 children with ALL P 0.003 and P 0.0008 OR 2.45 and 2.86 respectively and were associated with methotrexate accumulation and gene expression pattern in leukemic lymphoblasts We conclude that germline variants affect susceptibility to and characteristics of specific ALL subtypes",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[75, 3, 5318, 34542, 2568, 1926, 2, 6878, 390, 2071, 21, 108, 203, 1109, 1310, 1254, 675, 2512, 97, 19, 14, 1006, 79, 33, 59, 815, 286, 1275, 62, 140, 78, 7869, 2, 220, 62, 535, 78, 269, 16493, 100, 1109, 4, 17439, 44, 158, 2512, 59, 62, 2, 220, 62, 271, 31498, 19, 14, 39, 1006, 79, 167, 610, 197, 15, 14, 970, 39076, 19, 33, 67, 1006, 79, 83, 15, 14, 744, 84, 120, 4735, 132, 8847, 62, 29, 127, 814, 31498, 19, 14, 744, 1006, 79, 33, 15, 18, 269, 39076, 19, 13, 1421, 15, 14, 720, 46, 17439, 1109, 120, 4735, 132, 8847, 62, 29, 127, 814, 4, 35, 306, 929, 180, 78, 2834, 541, 5, 62, 19, 13, 1421, 2, 19, 13, 7044, 15, 18, 512, 2, 18, 868, 106, 2, 11, 41, 5, 2116, 1835, 2, 145, 55, 1177, 4, 2015, 10521, 21, 2060, 17, 1009, 839, 1158, 1432, 6, 2, 374, 1, 112, 62, 814]",901.0,19684603,869
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.,Cancer,Cancer,2009-12-01,"Dose intensification of chemotherapy has improved outcome for younger adults with de novo acute lymphoblastic leukemia (ALL). Novel formulations of standard chemotherapy agents may further reduce the incidence of disease recurrence after frontline chemotherapy. Vincristine (VCR) sulfate liposomes injection (VSLI) is a sphingomyelin/cholesterol nanoparticle encapsulated VCR formulation that improves the pharmacokinetic profile of VCR without augmenting neurotoxicity. A phase 1 trial of weekly, intravenous VSLI at 1.5 mg/m(2), 1.825 mg/m(2), 2.0 mg/m(2), 2.25 mg/m(2), or 2.4 mg/m(2) was conducted to determine the maximum tolerated dose (MTD) using a standard, 3 + 3 dose-escalation design. Dexamethasone (40 mg) was given on Days 1 through 4 and on Days 11 through 14 of each 4-week cycle. Thirty-six adults with relapsed/refractory ALL, all previously treated with conventional VCR, received at least 1 dose of VSLI. The MTD of VSLI was 2.25 mg/m(2) based on dose-limiting toxicities of grade 3 motor neuropathy, grade 4 seizure, and grade 4 hepatotoxicity in 1 patient each at the 2.4 mg/m(2) dose level. The most common toxicities attributed to VSLI included peripheral neuropathy (55%) and constipation (53%). A complete response (CR) was achieved in 7 of 36 patients (19%) based on an intent-to-treat analysis; the CR rate was 29% for the 14 patients who underwent therapy as their first salvage attempt. Four of 7 patients who achieved a CR underwent subsequent allogeneic stem cell transplantation in remission. In this study, VSLI plus dexamethasone appeared to be an effective salvage therapy option for relapsed/refractory ALL. A phase 2, international, multicenter clinical trial assessing the efficacy of single-agent VSLI as second salvage therapy for patients with previously treated ALL is underway.","Clinical Trial, Phase I",3703.0,41.0,Dose intensification of chemotherapy has improved outcome for younger adults with de novo acute lymphoblastic ALL Novel formulations of standard chemotherapy agents may further reduce the incidence of disease recurrence after frontline chemotherapy Vincristine VCR sulfate liposomes injection VSLI is a sphingomyelin/cholesterol nanoparticle encapsulated VCR formulation that improves the pharmacokinetic profile of VCR without augmenting neurotoxicity A phase 1 trial of weekly intravenous VSLI at 1.5 mg/m 2 1.825 mg/m 2 2.0 mg/m 2 2.25 mg/m 2 or 2.4 mg/m 2 was conducted to determine the maximum tolerated dose MTD using a standard 3 3 dose-escalation design Dexamethasone 40 mg was given on Days 1 through 4 and on Days 11 through 14 of each 4-week cycle Thirty-six adults with relapsed/refractory ALL all previously treated with conventional VCR received at least 1 dose of VSLI The MTD of VSLI was 2.25 mg/m 2 based on dose-limiting toxicities of grade 3 motor neuropathy grade 4 seizure and grade 4 hepatotoxicity in 1 patient each at the 2.4 mg/m 2 dose level The most common toxicities attributed to VSLI included peripheral neuropathy 55 and constipation 53 A complete response CR was achieved in 7 of 36 patients 19 based on an intent-to-treat analysis the CR rate was 29 for the 14 patients who underwent therapy as their first salvage attempt Four of 7 patients who achieved a CR underwent subsequent allogeneic stem cell transplantation in remission In this study VSLI plus dexamethasone appeared to be an effective salvage therapy option for relapsed/refractory ALL A phase 2 international multicenter clinical trial assessing the efficacy of single-agent VSLI as second salvage therapy for patients with previously treated ALL is underway,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[61, 5091, 1, 56, 71, 231, 228, 9, 773, 857, 5, 1566, 2018, 286, 1275, 62, 229, 5832, 1, 260, 56, 183, 68, 195, 969, 3, 287, 1, 34, 146, 50, 3171, 56, 2132, 8886, 6424, 7438, 1754, 14005, 16, 8, 20160, 5020, 4483, 7431, 8886, 3583, 17, 1804, 3, 1456, 800, 1, 8886, 187, 9015, 3561, 8, 124, 14, 160, 1, 709, 1262, 14005, 28, 14, 33, 81, 188, 18, 14, 9295, 81, 188, 18, 18, 13, 81, 188, 18, 18, 243, 81, 188, 18, 15, 18, 39, 81, 188, 18, 10, 426, 6, 223, 3, 689, 421, 61, 961, 75, 8, 260, 27, 27, 61, 1125, 771, 1217, 327, 81, 10, 447, 23, 162, 14, 298, 39, 2, 23, 162, 175, 298, 213, 1, 296, 39, 647, 417, 977, 437, 857, 5, 591, 430, 62, 62, 373, 73, 5, 809, 8886, 103, 28, 506, 14, 61, 1, 14005, 3, 961, 1, 14005, 10, 18, 243, 81, 188, 18, 90, 23, 61, 817, 385, 1, 88, 27, 3482, 1751, 88, 39, 5866, 2, 88, 39, 6667, 4, 14, 69, 296, 28, 3, 18, 39, 81, 188, 18, 61, 301, 3, 96, 186, 385, 3073, 6, 14005, 159, 672, 1751, 614, 2, 4532, 699, 8, 236, 51, 684, 10, 513, 4, 67, 1, 511, 7, 326, 90, 23, 35, 1697, 6, 943, 65, 3, 684, 116, 10, 462, 9, 3, 213, 7, 54, 208, 36, 22, 136, 157, 992, 3448, 294, 1, 67, 7, 54, 513, 8, 684, 208, 706, 1063, 452, 31, 497, 4, 734, 4, 26, 45, 14005, 349, 1217, 2121, 6, 40, 35, 323, 992, 36, 1501, 9, 591, 430, 62, 8, 124, 18, 944, 1570, 38, 160, 1977, 3, 209, 1, 226, 420, 14005, 22, 419, 992, 36, 9, 7, 5, 373, 73, 62, 16, 3948]",1754.0,19708032,799
Role of allogeneic hematopoietic cell transplantation in adults with acute lymphoblastic leukemia.,Current opinion in oncology,Curr Opin Oncol,2009-11-01,"Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, and outcomes vary by patient age, immunophenotype, and clinical, cytogenetic and molecular features. The optimal postremission therapy for adults with ALL remains unclear. Modern treatment strategies use a risk-adapted approach. The extension of 'pediatric-inspired' chemotherapy regimens into young and middle-age adults has improved their outcomes. Regimens that combine tyrosine kinase inhibitors with chemotherapy have improved the outcomes for patients with Philadelphia-chromosome-positive ALL. Improvements in transplantation technology with better donor matching and better supportive care have made this modality more widely available. Treatment-related morbidity and mortality are greater with hematopoietic cell transplantation (HCT) than with chemotherapy, although relapses are less common. Available data indicate no clear consensus as to whether there is an advantage to allogeneic HCT over modern chemotherapy for adults with ALL with standard risk features while in the first complete remission (CR1). However, allogeneic HCT is recommended in CR1 for patients with 'high-risk' ALL and for those in a second complete remission.",Journal Article,3733.0,6.0,Acute lymphoblastic ALL is a heterogeneous disease and outcomes vary by patient age immunophenotype and clinical cytogenetic and molecular features The optimal postremission therapy for adults with ALL remains unclear Modern treatment strategies use a risk-adapted approach The extension of 'pediatric-inspired chemotherapy regimens into young and middle-age adults has improved their outcomes Regimens that combine tyrosine kinase inhibitors with chemotherapy have improved the outcomes for patients with Philadelphia-chromosome-positive ALL Improvements in transplantation technology with better donor matching and better supportive care have made this modality more widely available Treatment-related morbidity and mortality are greater with hematopoietic cell transplantation HCT than with chemotherapy although relapses are less common Available data indicate no clear consensus as to whether there is an advantage to allogeneic HCT over modern chemotherapy for adults with ALL with standard risk features while in the first complete remission CR1 However allogeneic HCT is recommended in CR1 for patients with 'high-risk ALL and for those in a second complete remission,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 1564, 34, 2, 123, 2825, 20, 69, 89, 5496, 2, 38, 1266, 2, 219, 404, 3, 665, 8635, 36, 9, 857, 5, 62, 469, 1200, 2366, 24, 422, 119, 8, 43, 3716, 353, 3, 2401, 1, 58201, 13161, 56, 472, 237, 1169, 2, 3897, 89, 857, 71, 231, 136, 123, 472, 17, 4680, 564, 216, 222, 5, 56, 47, 231, 3, 123, 9, 7, 5, 3006, 1170, 109, 62, 1474, 4, 497, 2033, 5, 380, 1488, 2616, 2, 380, 1877, 165, 47, 1229, 26, 1396, 80, 1792, 390, 24, 139, 787, 2, 282, 32, 378, 5, 1007, 31, 497, 1085, 76, 5, 56, 242, 3713, 32, 299, 186, 390, 74, 1008, 77, 885, 1391, 22, 6, 317, 125, 16, 35, 1874, 6, 1063, 1085, 252, 2366, 56, 9, 857, 5, 62, 5, 260, 43, 404, 369, 4, 3, 157, 236, 734, 4516, 137, 1063, 1085, 16, 793, 4, 4516, 9, 7, 5, 24717, 43, 62, 2, 9, 135, 4, 8, 419, 236, 734]",1175.0,19713843,424
"Two ""childhood"" malignancies in an elderly individual: a case report and discussion.","Medical oncology (Northwood, London, England)",Med. Oncol.,2009-09-04,"Rhabdomyosarcoma (RMS) is the most common soft-tissue tumor in childhood, but is extremely rare in elderly. We present a rare case of cardiac RMS, which developed 1 year after the diagnosis and management of acute lymphoblastic leukemia in a 68-year-old female. The occurrence of such phenomena is intriguing, especially in an individual without prior history of malignancy at a younger age. Through the review of the existing literature, we attempt to approach the pathogenesis and clinical manifestations of this rare clinical entity.",Case Reports,3791.0,0.0,RMS is the most common soft-tissue tumor in childhood but is extremely rare in elderly We present a rare case of RMS which developed 1 year after the diagnosis and management of acute lymphoblastic in a 68-year-old female The occurrence of such phenomena is intriguing especially in an individual without prior history of malignancy at a younger age Through the review of the existing literature we attempt to approach the pathogenesis and clinical manifestations of this rare clinical entity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[3413, 16, 3, 96, 186, 1214, 246, 30, 4, 864, 84, 16, 2938, 622, 4, 1216, 21, 364, 8, 622, 473, 1, 3413, 92, 276, 14, 111, 50, 3, 147, 2, 284, 1, 286, 1275, 4, 8, 806, 111, 1095, 1061, 3, 2291, 1, 225, 11549, 16, 9382, 1093, 4, 35, 797, 187, 324, 532, 1, 710, 28, 8, 773, 89, 298, 3, 206, 1, 3, 1692, 789, 21, 3448, 6, 353, 3, 1384, 2, 38, 4282, 1, 26, 622, 38, 2983]",492.0,19760524,836
High-risk childhood acute lymphoblastic leukemia.,Clinical lymphoma & myeloma,Clin Lymphoma Myeloma,2009-01-01,"Although most children with acute lymphoblastic leukemia (ALL) are cured, certain subsets have a high risk of relapse. Relapse risk can be predicted by early response to therapy, clinical and pharmacogenetic features of the host, and genetic characteristics of leukemic cells. Though early treatment response can be assessed by the peripheral blast cell count after 1 week of single-agent glucocorticoid treatment or percent of bone marrow blasts by morphology after 1 or 2 weeks of multiagent induction treatment, determination of minimal residual disease by polymerase chain reaction (PCR) or flow cytometry after 2 to 6 weeks of induction is the most precise and useful measure. Augmented therapy has improved outcome for the poor responders to initial treatment. Infants with mixed-lineage leukemia (MLL)-rearranged ALL comprise a very poor-risk group wherein further intensification of chemotherapy causes significant toxicity. Hybrid protocols incorporating drugs effective for acute myeloid leukemia could improve survival, a strategy being tested in international trials. Studies on the biology of MLL-induced leukemogenesis have prompted the development of novel targeted agents, currently under evaluation in clinical trials. Short-term outcomes of patients with Philadelphia chromosome (Ph)-positive ALL have improved significantly by adding tyrosine kinase inhibitors to standard chemotherapy regimens. New agents and methods to overcome resistance are under investigation, and allogeneic stem cell transplantation is recommended for certain subsets of patients, for example those with Ph+ and T-cell ALL with poor early response. Genome-wide interrogation of leukemic cell genetic abnormalities and germline genetic variations promise to identify new molecular targets for therapy.",Journal Article,4037.0,38.0,Although most children with acute lymphoblastic ALL are cured certain subsets have a high risk of relapse Relapse risk can be predicted by early response to therapy clinical and pharmacogenetic features of the host and genetic characteristics of leukemic cells Though early treatment response can be assessed by the peripheral blast cell count after 1 week of single-agent glucocorticoid treatment or percent of marrow blasts by morphology after 1 or 2 weeks of multiagent induction treatment determination of minimal residual disease by polymerase chain reaction PCR or flow cytometry after 2 to 6 weeks of induction is the most precise and useful measure Augmented therapy has improved outcome for the poor responders to initial treatment Infants with mixed-lineage MLL -rearranged ALL comprise a very poor-risk group wherein further intensification of chemotherapy causes significant toxicity Hybrid protocols incorporating drugs effective for acute myeloid could improve survival a strategy being tested in international trials Studies on the biology of MLL-induced leukemogenesis have prompted the development of novel targeted agents currently under evaluation in clinical trials Short-term outcomes of patients with Philadelphia chromosome Ph -positive ALL have improved significantly by adding tyrosine kinase inhibitors to standard chemotherapy regimens New agents and methods to overcome resistance are under investigation and allogeneic stem cell transplantation is recommended for certain subsets of patients for example those with Ph+ and T-cell ALL with poor early response Genome-wide interrogation of leukemic cell genetic abnormalities and germline genetic variations promise to identify new molecular targets for therapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 96, 541, 5, 286, 1275, 62, 32, 3733, 1840, 1890, 47, 8, 64, 43, 1, 429, 429, 43, 122, 40, 783, 20, 191, 51, 6, 36, 38, 2, 6578, 404, 1, 3, 1204, 2, 336, 374, 1, 2015, 37, 2471, 191, 24, 51, 122, 40, 275, 20, 3, 672, 3112, 31, 1276, 50, 14, 647, 1, 226, 420, 5399, 24, 15, 714, 1, 581, 2438, 20, 2567, 50, 14, 15, 18, 244, 1, 7148, 504, 24, 3104, 1, 1048, 753, 34, 20, 1451, 1260, 1329, 604, 15, 1412, 1914, 50, 18, 6, 49, 244, 1, 504, 16, 3, 96, 3260, 2, 999, 1463, 4277, 36, 71, 231, 228, 9, 3, 334, 1983, 6, 388, 24, 5585, 5, 1739, 2542, 3049, 3201, 62, 5238, 8, 923, 334, 43, 87, 7893, 195, 5091, 1, 56, 1626, 93, 155, 4542, 2189, 2570, 600, 323, 9, 286, 533, 359, 401, 25, 8, 692, 486, 650, 4, 944, 143, 94, 23, 3, 891, 1, 3049, 277, 5661, 47, 4140, 3, 193, 1, 229, 238, 183, 694, 669, 451, 4, 38, 143, 978, 337, 123, 1, 7, 5, 3006, 1170, 2058, 109, 62, 47, 231, 97, 20, 2726, 564, 216, 222, 6, 260, 56, 472, 217, 183, 2, 636, 6, 1768, 251, 32, 669, 940, 2, 1063, 452, 31, 497, 16, 793, 9, 1840, 1890, 1, 7, 9, 2685, 135, 5, 2058, 2, 102, 31, 62, 5, 334, 191, 51, 898, 1019, 8956, 1, 2015, 31, 336, 1171, 2, 1009, 336, 2293, 1783, 6, 255, 217, 219, 637, 9, 36]",1738.0,19778845,307
Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2009-11-01,"Acute lymphoblastic leukemia (ALL) with high-risk features has a poor prognosis in adults despite aggressive chemotherapy. Reduced-intensity conditioning (RIC) is a lower toxicity alternative for high-risk patients requiring hematopoietic cell transplantation (HCT); however, it has not been widely used for ALL. We conducted a retrospective study of 24 high-risk adult ALL patients who received an RIC regimen of fludarabine (Flu)/melphalan (Mel) prior to allogeneic peripheral blood stem cell transplantation (PBSCT) between 6/14/02 and 6/15/07 at the City of Hope. Indications for the RIC regimen were: (1) aged 50 years or older (42%), (2) compromised organ function (54%), or (3) recipient of a previous HCT (37.5%). Patients had a median age of 47.5 years and the median follow-up was 28.5 months for living patients. Both overall survival (OS) and disease-free survival (DFS) at 2 years was 61.5%. Relapse incidence was 21.1% and nonrelapse mortality (NRM) was 21.5% at 2 years. Chronic graft-versus-host (cGVHD) developed in 86% of evaluable patients. In this series, no significant correlations were made between outcomes and patient age, presence of Philadelphia chromosome, relatedness of donor source, or prior HCT. These high survival rates for high-risk ALL patients following RIC HCT may offer a promising option for patients not eligible for a standard myeloablative transplant.",Evaluation Study,3733.0,50.0,Acute lymphoblastic ALL with high-risk features has a poor prognosis in adults despite aggressive chemotherapy Reduced-intensity conditioning RIC is a lower toxicity alternative for high-risk patients requiring hematopoietic cell transplantation HCT however it has not been widely used for ALL We conducted a retrospective study of 24 high-risk adult ALL patients who received an RIC regimen of fludarabine Flu /melphalan Mel prior to allogeneic peripheral blood stem cell transplantation PBSCT between 6/14/02 and 6/15/07 at the City of Hope Indications for the RIC regimen were 1 aged 50 years or older 42 2 compromised organ function 54 or 3 recipient of a previous HCT 37.5 Patients had a median age of 47.5 years and the median follow-up was 28.5 months for living patients Both overall survival OS and disease-free survival DFS at 2 years was 61.5 Relapse incidence was 21.1 and nonrelapse mortality NRM was 21.5 at 2 years Chronic graft-versus-host cGVHD developed in 86 of evaluable patients In this series no significant correlations were made between outcomes and patient age presence of Philadelphia chromosome relatedness of donor source or prior HCT These high survival rates for high-risk ALL patients following RIC HCT may offer a promising option for patients not eligible for a standard myeloablative transplant,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 5, 64, 43, 404, 71, 8, 334, 356, 4, 857, 550, 571, 56, 405, 837, 1933, 3365, 16, 8, 280, 155, 1091, 9, 64, 43, 7, 1888, 1007, 31, 497, 1085, 137, 192, 71, 44, 85, 1792, 95, 9, 62, 21, 426, 8, 459, 45, 1, 259, 64, 43, 780, 62, 7, 54, 103, 35, 3365, 477, 1, 2027, 5119, 2370, 7383, 324, 6, 1063, 672, 315, 452, 31, 497, 14460, 59, 49, 213, 588, 2, 49, 167, 1615, 28, 3, 7235, 1, 3045, 2406, 9, 3, 3365, 477, 11, 14, 1032, 212, 60, 15, 434, 595, 18, 4867, 1259, 343, 667, 15, 27, 5783, 1, 8, 698, 1085, 567, 33, 7, 42, 8, 52, 89, 1, 662, 33, 60, 2, 3, 52, 166, 126, 10, 339, 33, 53, 9, 2798, 7, 110, 63, 25, 118, 2, 34, 115, 25, 1010, 28, 18, 60, 10, 713, 33, 429, 287, 10, 239, 14, 2, 4640, 282, 4296, 10, 239, 33, 28, 18, 60, 442, 1599, 185, 1204, 6670, 276, 4, 868, 1, 859, 7, 4, 26, 988, 77, 93, 2553, 11, 1229, 59, 123, 2, 69, 89, 463, 1, 3006, 1170, 22542, 1, 1488, 2353, 15, 324, 1085, 46, 64, 25, 151, 9, 64, 43, 62, 7, 366, 3365, 1085, 68, 1918, 8, 721, 1501, 9, 7, 44, 625, 9, 8, 260, 3246, 941]",1328.0,19822300,726
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2009-10-01,"Significant advances have been achieved in the treatment of acute lymphoblastic leukemia (ALL) with the incorporation of targeted therapy agents. Targeting leukemia surface antigens with monoclonal antibodies is another promising strategy. This article comprehensively reviews available data regarding the use of rituximab for the treatment of Burkitt-type leukemia/lymphoma and CD20-positive precursor B-cell ALL. The incorporation of rituximab into frontline chemotherapy regimens for Burkitt-type leukemia/lymphoma appears to improve outcome. Preliminary data regarding the use of rituximab in frontline therapy for CD20- positive precursor B-cell ALL suggest its use may also be beneficial, particularly for the younger subsets.",Journal Article,3764.0,33.0,Significant advances have been achieved in the treatment of acute lymphoblastic ALL with the incorporation of targeted therapy agents Targeting surface antigens with monoclonal antibodies is another promising strategy This article comprehensively reviews available data regarding the use of rituximab for the treatment of Burkitt-type leukemia/lymphoma and CD20-positive precursor B-cell ALL The incorporation of rituximab into frontline chemotherapy regimens for Burkitt-type leukemia/lymphoma appears to improve outcome Preliminary data regarding the use of rituximab in frontline therapy for CD20- positive precursor B-cell ALL suggest its use may also be beneficial particularly for the younger subsets,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[93, 954, 47, 85, 513, 4, 3, 24, 1, 286, 1275, 62, 5, 3, 2838, 1, 238, 36, 183, 529, 1255, 1575, 5, 848, 890, 16, 1809, 721, 692, 26, 946, 5627, 2004, 390, 74, 666, 3, 119, 1, 855, 9, 3, 24, 1, 14387, 267, 2647, 4763, 2, 2198, 109, 2765, 132, 31, 62, 3, 2838, 1, 855, 237, 3171, 56, 472, 9, 14387, 267, 2647, 4763, 1233, 6, 401, 228, 1676, 74, 666, 3, 119, 1, 855, 4, 3171, 36, 9, 2198, 109, 2765, 132, 31, 62, 309, 211, 119, 68, 120, 40, 2524, 823, 9, 3, 773, 1890]",706.0,19825447,569
Risk-adapted treatment of pediatric acute lymphoblastic leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2009-10-01,"Optimal use of antileukemic agents and stringent application of risk-directed therapy in clinical trials have resulted in steady improvement in the outcome of children with acute lymphoblastic leukemia, with current cure rates exceeding 80% in developed countries. The intensity of treatment varies substantially among subsets of patients, as therapy is designed to reduce acute and long-term toxicity in low-risk groups while improving outcomes in poor risk groups by treatment intensification. Recent advances in genome-wide screening techniques, pharmacogenomic studies, and development of molecular therapeutics are ushering in an era of more refined personalized therapy.",Journal Article,3764.0,23.0,Optimal use of antileukemic agents and stringent application of risk-directed therapy in clinical trials have resulted in steady improvement in the outcome of children with acute lymphoblastic with current cure rates exceeding 80 in developed countries The intensity of treatment varies substantially among subsets of patients as therapy is designed to reduce acute and long-term toxicity in low-risk groups while improving outcomes in poor risk groups by treatment intensification Recent advances in genome-wide screening techniques pharmacogenomic studies and development of molecular therapeutics are ushering in an era of more refined personalized therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[665, 119, 1, 4512, 183, 2, 6763, 1581, 1, 43, 1166, 36, 4, 38, 143, 47, 627, 4, 4152, 767, 4, 3, 228, 1, 541, 5, 286, 1275, 5, 291, 1722, 151, 5178, 493, 4, 276, 2115, 3, 837, 1, 24, 4037, 2109, 107, 1890, 1, 7, 22, 36, 16, 1114, 6, 969, 286, 2, 319, 337, 155, 4, 154, 43, 271, 369, 1673, 123, 4, 334, 43, 271, 20, 24, 5091, 435, 954, 4, 898, 1019, 453, 1092, 6971, 94, 2, 193, 1, 219, 1943, 32, 28591, 4, 35, 1713, 1, 80, 5332, 2175, 36]",659.0,19825448,404
Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2009-10-01,"Acute lymphoblastic leukemia (ALL) is a hematologic malignancy of the bone marrow characterized by the rapid proliferation and subsequent accumulation of immature lymphocytes. ALL accounts for 20% of all acute leukemias that are seen in adults over the age of 20 years. In the past 2 decades, there has been substantial improvement in the understanding of the molecular biology of the disease and in the management of adult patients who have this disorder, including allogeneic transplantation This article reviews the biology of adult ALL, the relationship of specific disease characteristics to the natural history of the disease and the role of allogeneic hematopoietic cell transplantation in the management of adult patients with this disease.",Journal Article,3764.0,4.0,Acute lymphoblastic ALL is a hematologic malignancy of the marrow characterized by the rapid proliferation and subsequent accumulation of immature lymphocytes ALL accounts for 20 of all acute leukemias that are seen in adults over the age of 20 years In the past 2 decades there has been substantial improvement in the understanding of the molecular biology of the disease and in the management of adult patients who have this disorder including allogeneic transplantation This article reviews the biology of adult ALL the relationship of specific disease characteristics to the natural history of the disease and the role of allogeneic hematopoietic cell transplantation in the management of adult patients with this disease,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 813, 710, 1, 3, 581, 765, 20, 3, 1321, 457, 2, 706, 1835, 1, 5733, 1594, 62, 4162, 9, 179, 1, 62, 286, 2792, 17, 32, 527, 4, 857, 252, 3, 89, 1, 179, 60, 4, 3, 1219, 18, 1968, 125, 71, 85, 1281, 767, 4, 3, 612, 1, 3, 219, 891, 1, 3, 34, 2, 4, 3, 284, 1, 780, 7, 54, 47, 26, 2645, 141, 1063, 497, 26, 946, 2004, 3, 891, 1, 780, 62, 3, 858, 1, 112, 34, 374, 6, 3, 1504, 532, 1, 3, 34, 2, 3, 200, 1, 1063, 1007, 31, 497, 4, 3, 284, 1, 780, 7, 5, 26, 34]",725.0,19825450,78
Philadelphia chromosome-positive acute lymphoblastic leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2009-10-01,"The Philadelphia (Ph) chromosome, a short chromosome 22, is the most frequent cytogenetic abnormality in adult patients with acute lymphoblastic leukemia (ALL). It occurs in approximately 20% to 30% of adults and in about 5% of children with this disease. The incidence rises with age and occurs in approximately 50% of patients older than 50 years. This article reviews the treatment regimens for Ph+ ALL, including imatinib and second generation tyrosine kinase inhibitors (TKIs). The introduction of effective TKIs in the treatment of Ph+ ALL has introduced several avenues of research in a disease that was hitherto difficult to treat.",Journal Article,3764.0,42.0,The Philadelphia Ph chromosome a short chromosome 22 is the most frequent cytogenetic abnormality in adult patients with acute lymphoblastic ALL It occurs in approximately 20 to 30 of adults and in about 5 of children with this disease The incidence rises with age and occurs in approximately 50 of patients older than 50 years This article reviews the treatment regimens for Ph+ ALL including imatinib and second generation tyrosine kinase inhibitors TKIs The introduction of effective TKIs in the treatment of Ph+ ALL has introduced several avenues of research in a disease that was hitherto difficult to treat,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3006, 2058, 1170, 8, 978, 1170, 350, 16, 3, 96, 908, 1266, 3698, 4, 780, 7, 5, 286, 1275, 62, 192, 1780, 4, 705, 179, 6, 201, 1, 857, 2, 4, 545, 33, 1, 541, 5, 26, 34, 3, 287, 13502, 5, 89, 2, 1780, 4, 705, 212, 1, 7, 434, 76, 212, 60, 26, 946, 2004, 3, 24, 472, 9, 2058, 62, 141, 577, 2, 419, 914, 564, 216, 222, 1671, 3, 2456, 1, 323, 1671, 4, 3, 24, 1, 2058, 62, 71, 3955, 392, 6612, 1, 389, 4, 8, 34, 17, 10, 14471, 1740, 6, 943]",612.0,19825452,719
Looking toward the future: novel strategies based on molecular pathogenesis of acute lymphoblastic leukemia.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2009-10-01,"There has been exponential growth in our understanding of the pathobiology of acute lymphoblastic leukemia (ALL) leading to the discovery of new prognostic markers and potential new treatment strategies. The inferior treatment outcome observed in adults with ALL in comparison with children with ALL means that new therapeutic approaches are required, preferably based on novel molecular insights. In this concluding article, the important themes that have been discussed in earlier articles are reviewed. Looking toward the future, the authors highlight several of the new therapeutic agents and discuss some of the recently described molecular genetic aberrations that might serve as therapeutic targets for future drug development.",Journal Article,3764.0,1.0,There has been exponential growth in our understanding of the pathobiology of acute lymphoblastic ALL leading to the discovery of new prognostic markers and potential new treatment strategies The inferior treatment outcome observed in adults with ALL in comparison with children with ALL means that new therapeutic approaches are required preferably based on novel molecular insights In this concluding article the important themes that have been discussed in earlier articles are reviewed Looking toward the future the authors highlight several of the new therapeutic agents and discuss some of the recently described molecular genetic aberrations that might serve as therapeutic targets for future drug development,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[125, 71, 85, 9379, 129, 4, 114, 612, 1, 3, 8465, 1, 286, 1275, 62, 1049, 6, 3, 1574, 1, 217, 177, 525, 2, 174, 217, 24, 422, 3, 1663, 24, 228, 164, 4, 857, 5, 62, 4, 1155, 5, 541, 5, 62, 2263, 17, 217, 189, 611, 32, 616, 10590, 90, 23, 229, 219, 1957, 4, 26, 21173, 946, 3, 305, 6514, 17, 47, 85, 1588, 4, 1677, 2384, 32, 446, 9095, 1317, 3, 508, 3, 738, 1817, 392, 1, 3, 217, 189, 183, 2, 1139, 476, 1, 3, 761, 1027, 219, 336, 2152, 17, 822, 1833, 22, 189, 637, 9, 508, 234, 193]",716.0,19825455,334
Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.,Hematology/oncology clinics of North America,Hematol. Oncol. Clin. North Am.,2009-10-01,"Nelarabine (506U78) is a soluble prodrug of 9- Darabinofuranosylguanine (ara-G), a deoxyguanosine derivative. Nelarabine has significant activity in patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma (T-LBL). Principal toxicity is grade 3 or 4 neutropenia and thrombocytopenia. Neurologic toxicity with Guillain-Barr syndrome, depressed level of consciousness, and peripheral neuropathy are concerning side effects. Nelarabine is well tolerated and has significant antitumor activity in T-ALL and T-LBL. Nelarabine was approved by the Food and Drug Administration for patients with T-ALL/LBL who failed at least two prior regimens. Nelarabine is being explored in children and will be explored in the near future in adults with newly diagnosed T-ALL.",Journal Article,3764.0,33.0,Nelarabine 506U78 is a soluble prodrug of 9- Darabinofuranosylguanine ara-G a deoxyguanosine derivative Nelarabine has significant activity in patients with T-cell acute lymphoblastic T-ALL and T-LBL Principal toxicity is grade 3 or 4 neutropenia and thrombocytopenia Neurologic toxicity with Guillain-Barr syndrome depressed level of consciousness and peripheral neuropathy are concerning side effects Nelarabine is well tolerated and has significant antitumor activity in T-ALL and T-LBL Nelarabine was approved by the Food and Drug Administration for patients with T-ALL/LBL who failed at least two prior regimens Nelarabine is being explored in children and will be explored in the near future in adults with newly diagnosed T-ALL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[13149, 44649, 16, 8, 2968, 5227, 1, 83, 58326, 3899, 499, 8, 17863, 4819, 13149, 71, 93, 128, 4, 7, 5, 102, 31, 286, 1275, 102, 62, 2, 102, 8315, 4312, 155, 16, 88, 27, 15, 39, 778, 2, 1340, 2543, 155, 5, 34780, 39133, 681, 9233, 301, 1, 15471, 2, 672, 1751, 32, 4243, 1152, 176, 13149, 16, 149, 421, 2, 71, 93, 579, 128, 4, 102, 62, 2, 102, 8315, 13149, 10, 850, 20, 3, 1773, 2, 234, 634, 9, 7, 5, 102, 62, 8315, 54, 1551, 28, 506, 100, 324, 472, 13149, 16, 486, 1443, 4, 541, 2, 303, 40, 1443, 4, 3, 1829, 508, 4, 857, 5, 732, 265, 102, 62]",735.0,19825456,408
"T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).",Blood,Blood,2009-12-01,"The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood. We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors. Complete remission was obtained in 94% of patients, and 48% survived 5 years. Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival (P = .01 and < .001, respectively). NOTCH1 and CDKN2A mutations were seen in 61% and 42% of those tested. Complex cytogenetic abnormalities were associated with poorer survival (19% vs 51% at 5 years, P = .006). Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant). For 99 patients randomized between autograft and chemotherapy, 5-year survival was 51% in each arm. Patients with a matched sibling donor had superior 5-year survival to those without donors (61% vs 46%, chi(2), P = .02); this was the result of less relapse (25% vs 51% at 5 years, P < .001). Only 8 of 123 relapsed patients survive. This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.",Journal Article,3703.0,184.0,The biology and outcome of adult T-cell acute lymphoblastic are poorly understood We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial UKALL XII/ECOG 2993 with the aim of describing the outcome and identifying prognostic factors Complete remission was obtained in 94 of patients and 48 survived 5 years Positivity of blasts for CD1a and lack of expression of CD13 were associated with better survival P .01 and .001 respectively NOTCH1 and CDKN2A mutations were seen in 61 and 42 of those tested Complex cytogenetic abnormalities were associated with poorer survival 19 vs 51 at 5 years P .006 Central nervous system involvement at diagnosis did not affect survival 47 vs 48 P not significant For 99 patients randomized between autograft and chemotherapy 5-year survival was 51 in each arm Patients with a matched sibling donor had superior 5-year survival to those without donors 61 vs 46 chi 2 P .02 this was the result of less relapse 25 vs 51 at 5 years P .001 Only 8 of 123 relapsed patients survive This study provides a baseline for trials of new drugs such as nelarabine and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 891, 2, 228, 1, 780, 102, 31, 286, 1275, 32, 1240, 1784, 21, 364, 467, 3, 38, 2, 1283, 404, 1, 8664, 7, 73, 4254, 23, 3, 482, 160, 58332, 39048, 2351, 24976, 5, 3, 1130, 1, 4950, 3, 228, 2, 1386, 177, 130, 236, 734, 10, 683, 4, 960, 1, 7, 2, 576, 2996, 33, 60, 1887, 1, 2438, 9, 18288, 2, 926, 1, 55, 1, 13518, 11, 41, 5, 380, 25, 19, 355, 2, 144, 106, 4607, 2, 3175, 138, 11, 527, 4, 713, 2, 595, 1, 135, 650, 840, 1266, 1171, 11, 41, 5, 1769, 25, 326, 105, 725, 28, 33, 60, 19, 1861, 854, 1880, 398, 799, 28, 147, 205, 44, 1158, 25, 662, 105, 576, 19, 44, 93, 9, 1058, 7, 384, 59, 15685, 2, 56, 33, 111, 25, 10, 725, 4, 296, 475, 7, 5, 8, 655, 3684, 1488, 42, 1123, 33, 111, 25, 6, 135, 187, 2344, 713, 105, 641, 3163, 18, 19, 588, 26, 10, 3, 757, 1, 299, 429, 243, 105, 725, 28, 33, 60, 19, 144, 158, 66, 1, 2698, 591, 7, 4573, 26, 45, 777, 8, 330, 9, 143, 1, 217, 600, 225, 22, 13149, 2, 68, 1700, 43, 3716, 36, 4, 7, 5, 334, 356, 102, 31, 62]",1213.0,19828704,898
Effect of allopurinol versus urate oxidase on methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia.,Cancer,Cancer,2010-01-01,"Allopurinol and urate oxidase are both effective in preventing or treating hyperuricemia during remission induction therapy for lymphoid malignancies, but to the authors' knowledge, their effects on concomitant anticancer drug therapy have not been compared. The authors compared plasma methotrexate pharmacokinetics in pediatric patients with newly diagnosed acute lymphoblastic leukemia who received concomitant allopurinol (n = 20) versus those treated with nonrecombinant or recombinant urate oxidase (n = 96) during high-dose methotrexate administration before conventional remission induction therapy. The minimum plasma concentration of uric acid was significantly (P < .0001) lower after urate oxidase treatment than the concentration after allopurinol treatment. Methotrexate clearance was significantly higher (median, 117.1 mL/minute/m(2) vs 91.1 mL/minute/m(2); P = .019) in patients who received urate oxidase. A higher proportion of patients in the allopurinol group had elevated methotrexate plasma concentrations (36% vs 7%; P = .003) and experienced mucositis (45% vs 16%; P = .003) after methotrexate treatment compared with the urate oxidase group. The lower rate of methotrexate clearance in patients who received allopurinol likely reflected a less potent hypouricemic effect of allopurinol, leading to precipitation of uric acid in renal tubules. Hence, during remission induction therapy for lymphoid malignancies, the authors concluded that renally excreted drugs should be monitored closely, especially in patients who are receiving allopurinol.",Comparative Study,3672.0,7.0,Allopurinol and urate oxidase are both effective in preventing or treating hyperuricemia during remission induction therapy for lymphoid malignancies but to the authors knowledge their effects on concomitant anticancer drug therapy have not been compared The authors compared plasma methotrexate pharmacokinetics in pediatric patients with newly diagnosed acute lymphoblastic who received concomitant allopurinol n 20 versus those treated with nonrecombinant or recombinant urate oxidase n 96 during high-dose methotrexate administration before conventional remission induction therapy The minimum plasma concentration of uric acid was significantly P .0001 lower after urate oxidase treatment than the concentration after allopurinol treatment Methotrexate clearance was significantly higher median 117.1 mL/minute/m 2 vs 91.1 mL/minute/m 2 P .019 in patients who received urate oxidase A higher proportion of patients in the allopurinol group had elevated methotrexate plasma concentrations 36 vs 7 P .003 and experienced mucositis 45 vs 16 P .003 after methotrexate treatment compared with the urate oxidase group The lower rate of methotrexate clearance in patients who received allopurinol likely reflected a less potent hypouricemic effect of allopurinol leading to precipitation of uric acid in tubules Hence during remission induction therapy for lymphoid malignancies the authors concluded that renally excreted drugs should be monitored closely especially in patients who are receiving allopurinol,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[22090, 2, 20281, 10447, 32, 110, 323, 4, 3017, 15, 1367, 14780, 190, 734, 504, 36, 9, 2303, 441, 84, 6, 3, 738, 922, 136, 176, 23, 1781, 1475, 234, 36, 47, 44, 85, 72, 3, 738, 72, 554, 2116, 1159, 4, 815, 7, 5, 732, 265, 286, 1275, 54, 103, 1781, 22090, 78, 179, 185, 135, 73, 5, 43810, 15, 2835, 20281, 10447, 78, 921, 190, 64, 61, 2116, 634, 348, 809, 734, 504, 36, 3, 2499, 554, 1227, 1, 16387, 971, 10, 97, 19, 488, 280, 50, 20281, 10447, 24, 76, 3, 1227, 50, 22090, 24, 2116, 1960, 10, 97, 142, 52, 3843, 14, 542, 3949, 188, 18, 105, 970, 14, 542, 3949, 188, 18, 19, 4049, 4, 7, 54, 103, 20281, 10447, 8, 142, 920, 1, 7, 4, 3, 22090, 87, 42, 804, 2116, 554, 1003, 511, 105, 67, 19, 1421, 2, 592, 2606, 512, 105, 245, 19, 1421, 50, 2116, 24, 72, 5, 3, 20281, 10447, 87, 3, 280, 116, 1, 2116, 1960, 4, 7, 54, 103, 22090, 322, 4686, 8, 299, 1157, 58335, 254, 1, 22090, 1049, 6, 18912, 1, 16387, 971, 4, 17166, 3665, 190, 734, 504, 36, 9, 2303, 441, 3, 738, 4724, 17, 23124, 14119, 600, 257, 40, 2909, 3210, 1093, 4, 7, 54, 32, 357, 22090]",1507.0,19834958,176
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2009-10-18,"Aneuploidy and translocations are hallmarks of B-progenitor acute lymphoblastic leukemia (ALL), but many individuals with this cancer lack recurring chromosomal alterations. Here we report a recurring interstitial deletion of the pseudoautosomal region 1 of chromosomes X and Y in B-progenitor ALL that juxtaposes the first, noncoding exon of P2RY8 with the coding region of CRLF2. We identified the P2RY8-CRLF2 fusion in 7% of individuals with B-progenitor ALL and 53% of individuals with ALL associated with Down syndrome. CRLF2 alteration was associated with activating JAK mutations, and expression of human P2RY8-CRLF2 together with mutated mouse Jak2 resulted in constitutive Jak-Stat activation and cytokine-independent growth of Ba/F3 cells overexpressing interleukin-7 receptor alpha. Our findings indicate that these two genetic lesions together contribute to leukemogenesis in B-progenitor ALL.",Journal Article,3747.0,384.0,Aneuploidy and translocations are hallmarks of B-progenitor acute lymphoblastic ALL but many individuals with this cancer lack recurring chromosomal alterations Here we report a recurring interstitial deletion of the pseudoautosomal region 1 of chromosomes X and Y in B-progenitor ALL that juxtaposes the first noncoding exon of P2RY8 with the coding region of CRLF2 We identified the P2RY8-CRLF2 fusion in 7 of individuals with B-progenitor ALL and 53 of individuals with ALL associated with Down syndrome CRLF2 alteration was associated with activating JAK mutations and expression of human P2RY8-CRLF2 together with mutated mouse Jak2 resulted in constitutive Jak-Stat activation and cytokine-independent growth of Ba/F3 cells overexpressing interleukin-7 receptor alpha Our findings indicate that these two genetic lesions together contribute to leukemogenesis in B-progenitor ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7437, 2, 3262, 32, 7693, 1, 132, 2520, 286, 1275, 62, 84, 445, 869, 5, 26, 12, 926, 6385, 1860, 593, 467, 21, 414, 8, 6385, 4543, 1528, 1, 3, 45726, 1053, 14, 1, 3560, 1006, 2, 2055, 4, 132, 2520, 62, 17, 33319, 3, 157, 6420, 1725, 1, 25205, 5, 3, 3097, 1053, 1, 8895, 21, 108, 3, 25205, 8895, 1212, 4, 67, 1, 869, 5, 132, 2520, 62, 2, 699, 1, 869, 5, 62, 41, 5, 1328, 681, 8895, 2611, 10, 41, 5, 1616, 4653, 138, 2, 55, 1, 171, 25205, 8895, 1162, 5, 1185, 830, 2509, 627, 4, 3178, 4653, 4168, 363, 2, 1675, 306, 129, 1, 6669, 6904, 37, 2810, 1603, 67, 153, 950, 114, 272, 1008, 17, 46, 100, 336, 406, 1162, 1248, 6, 5661, 4, 132, 2520, 62]",884.0,19838194,284
DNA variants in region for noncoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2009-10-27,"Dihydrofolate reductase (DHFR) is the major target of methotrexate, a key component in childhood acute lymphoblastic leukemia (ALL) treatment. We recently reported an association of DHFR promoter polymorphisms with ALL outcome. Lower event-free survival correlated with haplotype *1, defined by A(-317) and C(-1610) alleles. Haplotype *1 was also associated higher DHFR expression. Here, we analyzed adjacent 400-bp region participating in DHFR regulation as both a major promoter and a noncoding minor transcript. Six polymorphisms were identified, of which five were single nucleotide polymorphisms and one was length polymorphism composed of variable number of 9-bp elements and 9-bp insertion/deletion. Haplotype analysis including all promoter polymorphisms revealed diversification of haplotype *1 into five subtypes (*1a-*1e). DNA variations of major promoter/noncoding transcript region and haplotype *1 subtypes were subsequently analyzed for the association with ALL outcome. Lower event-free survival was associated with an A allele of G(308)A polymorphism (P = 0.02) and with *1b haplotype (P = 0.01). This association was particularly striking in high-risk patients (P = 0.001) and was subsequently confirmed in independent patient cohort (P = 0.02). Haplotype *1b was the only haplotype *1 subtype associated with higher mRNA levels. The study provides a new insight into DHFR regulatory variations predisposing to an event in ALL patients.",Journal Article,3738.0,31.0,Dihydrofolate reductase DHFR is the major target of methotrexate a key component in childhood acute lymphoblastic ALL treatment We recently reported an association of DHFR promoter polymorphisms with ALL outcome Lower event-free survival correlated with haplotype *1 defined by A -317 and C -1610 alleles Haplotype *1 was also associated higher DHFR expression Here we analyzed adjacent 400-bp region participating in DHFR regulation as both a major promoter and a noncoding minor transcript Six polymorphisms were identified of which five were single nucleotide polymorphisms and one was length polymorphism composed of variable number of 9-bp elements and 9-bp insertion/deletion Haplotype analysis including all promoter polymorphisms revealed diversification of haplotype *1 into five subtypes *1a-*1e DNA variations of major promoter/noncoding transcript region and haplotype *1 subtypes were subsequently analyzed for the association with ALL outcome Lower event-free survival was associated with an A allele of G 308 A polymorphism P 0.02 and with *1b haplotype P 0.01 This association was particularly striking in high-risk patients P 0.001 and was subsequently confirmed in independent patient cohort P 0.02 Haplotype *1b was the only haplotype *1 subtype associated with higher mRNA levels The study provides a new insight into DHFR regulatory variations predisposing to an event in ALL patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[20298, 4027, 13055, 16, 3, 458, 283, 1, 2116, 8, 825, 1249, 4, 864, 286, 1275, 62, 24, 21, 761, 210, 35, 248, 1, 13055, 973, 1203, 5, 62, 228, 280, 774, 115, 25, 438, 5, 4179, 14, 395, 20, 8, 7869, 2, 256, 45746, 2558, 4179, 14, 10, 120, 41, 142, 13055, 55, 467, 21, 311, 2086, 1524, 3044, 1053, 3052, 4, 13055, 863, 22, 110, 8, 458, 973, 2, 8, 6420, 2278, 3268, 437, 1203, 11, 108, 1, 92, 365, 11, 226, 1579, 1203, 2, 104, 10, 1318, 1907, 3317, 1, 1347, 207, 1, 83, 3044, 2531, 2, 83, 3044, 5099, 1528, 4179, 65, 141, 62, 973, 1203, 553, 21584, 1, 4179, 14, 237, 365, 814, 6345, 25057, 261, 2293, 1, 458, 973, 6420, 3268, 1053, 2, 4179, 14, 814, 11, 1611, 311, 9, 3, 248, 5, 62, 228, 280, 774, 115, 25, 10, 41, 5, 35, 8, 1254, 1, 499, 7786, 8, 1907, 19, 13, 588, 2, 5, 4693, 4179, 19, 13, 355, 26, 248, 10, 823, 5133, 4, 64, 43, 7, 19, 13, 144, 2, 10, 1611, 557, 4, 306, 69, 180, 19, 13, 588, 4179, 4693, 10, 3, 158, 4179, 14, 875, 41, 5, 142, 956, 148, 3, 45, 777, 8, 217, 2670, 237, 13055, 1253, 2293, 6885, 6, 35, 774, 4, 62, 7]",1405.0,19861437,458
Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia.,Blood,Blood,2009-10-30,"To determine whether gene expression profiling could improve outcome prediction in children with acute lymphoblastic leukemia (ALL) at high risk for relapse, we profiled pretreatment leukemic cells in 207 uniformly treated children with high-risk B-precursor ALL. A 38-gene expression classifier predictive of relapse-free survival (RFS) could distinguish 2 groups with differing relapse risks: low (4-year RFS, 81%, n = 109) versus high (4-year RFS, 50%, n = 98; P < .001). In multivariate analysis, the gene expression classifier (P = .001) and flow cytometric measures of minimal residual disease (MRD; P = .001) each provided independent prognostic information. Together, they could be used to classify children with high-risk ALL into low- (87% RFS), intermediate- (62% RFS), or high- (29% RFS) risk groups (P < .001). A 21-gene expression classifier predictive of end-induction MRD effectively substituted for flow MRD, yielding a combined classifier that could distinguish these 3 risk groups at diagnosis (P < .001). These classifiers were further validated on an independent high-risk ALL cohort (P = .006) and retainedindependent prognostic significance (P < .001) in the presence of other recently described poor prognostic factors (IKAROS/IKZF1 deletions, JAK mutations, and kinase expression signatures). Thus, gene expression classifiers improve ALL risk classification and allow prospective identification of children who respond or fail current treatment regimens. These trials were registered at http://clinicaltrials.gov under NCT00005603.",Clinical Trial,3735.0,118.0,To determine whether gene expression profiling could improve outcome prediction in children with acute lymphoblastic ALL at high risk for relapse we profiled pretreatment leukemic cells in 207 uniformly treated children with high-risk B-precursor ALL A 38-gene expression classifier predictive of relapse-free survival RFS could distinguish 2 groups with differing relapse risks low 4-year RFS 81 n 109 versus high 4-year RFS 50 n 98 P .001 In multivariate analysis the gene expression classifier P .001 and flow cytometric measures of minimal residual disease MRD P .001 each provided independent prognostic information Together they could be used to classify children with high-risk ALL into low- 87 RFS intermediate- 62 RFS or high- 29 RFS risk groups P .001 A 21-gene expression classifier predictive of end-induction MRD effectively substituted for flow MRD yielding a combined classifier that could distinguish these 3 risk groups at diagnosis P .001 These classifiers were further validated on an independent high-risk ALL cohort P .006 and retainedindependent prognostic significance P .001 in the presence of other recently described poor prognostic factors IKAROS/IKZF1 deletions JAK mutations and kinase expression signatures Thus gene expression classifiers improve ALL risk classification and allow prospective identification of children who respond or fail current treatment regimens These trials were registered at http //clinicaltrials.gov under NCT00005603,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 317, 145, 55, 1080, 359, 401, 228, 1590, 4, 541, 5, 286, 1275, 62, 28, 64, 43, 9, 429, 21, 5490, 1194, 2015, 37, 4, 5292, 4254, 73, 541, 5, 64, 43, 132, 2765, 62, 8, 519, 145, 55, 4951, 464, 1, 429, 115, 25, 1272, 359, 3081, 18, 271, 5, 5276, 429, 1098, 154, 39, 111, 1272, 865, 78, 3486, 185, 64, 39, 111, 1272, 212, 78, 1096, 19, 144, 4, 331, 65, 3, 145, 55, 4951, 19, 144, 2, 1412, 6226, 1018, 1, 1048, 753, 34, 2029, 19, 144, 296, 1052, 306, 177, 487, 1162, 491, 359, 40, 95, 6, 4896, 541, 5, 64, 43, 62, 237, 154, 912, 1272, 919, 744, 1272, 15, 64, 462, 1272, 43, 271, 19, 144, 8, 239, 145, 55, 4951, 464, 1, 396, 504, 2029, 1856, 10536, 9, 1412, 2029, 4949, 8, 397, 4951, 17, 359, 3081, 46, 27, 43, 271, 28, 147, 19, 144, 46, 8616, 11, 195, 938, 23, 35, 306, 64, 43, 62, 180, 19, 1861, 2, 58375, 177, 724, 19, 144, 4, 3, 463, 1, 127, 761, 1027, 334, 177, 130, 20613, 8422, 2439, 4653, 138, 2, 216, 55, 2210, 631, 145, 55, 8616, 401, 62, 43, 947, 2, 1700, 482, 911, 1, 541, 54, 1892, 15, 4373, 291, 24, 472, 46, 143, 11, 1653, 28, 5196, 1252, 1239, 669, 39148]",1473.0,19880498,576
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-11-09,"Methotrexate plasma concentration is related to its clinical effects. Our aim was to identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic leukemia (ALL). We performed a genome-wide analysis of 500,568 germline single-nucleotide polymorphisms (SNPs) to identify how inheritance affects methotrexate plasma disposition among 434 children with ALL who received 3,014 courses of methotrexate at 2 to 5 g/m(2). SNPs were validated in an independent cohort of 206 patients. Adjusting for age, race, sex, and methotrexate regimen, the most significant associations were with SNPs in the organic anion transporter polypeptide, SLCO1B1. Two SNPs in SLCO1B1, rs11045879 (P = 1.7 x 10(-10)) and rs4149081 (P = 1.7 x 10(-9)), were in linkage disequilibrium (LD) with each other (r(2) = 1) and with a functional polymorphism in SLCO1B1, T521C (rs4149056; r(2) > 0.84). rs11045879 and rs4149081 were validated in an independent cohort of 206 patients (P = .018 and P = .017), as were other SLCO1B1 SNPs residing in different LD blocks. SNPs in SLCO1B1 were also associated with GI toxicity (odds ratio, 15.3 to 16.4; P = .03 to .004). A genome-wide interrogation identified inherited variations in a plausible, yet heretofore low-priority candidate gene, SLCO1B1, as important determinants of methotrexate's pharmacokinetics and clinical effects.",Journal Article,3725.0,221.0,"Methotrexate plasma concentration is related to its clinical effects Our aim was to identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in children with newly diagnosed acute lymphoblastic ALL We performed a genome-wide analysis of 500,568 germline single-nucleotide polymorphisms SNPs to identify how inheritance affects methotrexate plasma disposition among 434 children with ALL who received 3,014 courses of methotrexate at 2 to 5 g/m 2 SNPs were validated in an independent cohort of 206 patients Adjusting for age race sex and methotrexate regimen the most significant associations were with SNPs in the organic anion transporter polypeptide SLCO1B1 Two SNPs in SLCO1B1 rs11045879 P 1.7 x 10 -10 and rs4149081 P 1.7 x 10 -9 were in linkage disequilibrium LD with each other r 2 1 and with a functional polymorphism in SLCO1B1 T521C rs4149056 r 2 0.84 rs11045879 and rs4149081 were validated in an independent cohort of 206 patients P .018 and P .017 as were other SLCO1B1 SNPs residing in different LD blocks SNPs in SLCO1B1 were also associated with GI toxicity odds ratio 15.3 to 16.4 P .03 to .004 A genome-wide interrogation identified inherited variations in a plausible yet heretofore low-priority candidate gene SLCO1B1 as important determinants of methotrexate 's pharmacokinetics and clinical effects",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 554, 1227, 16, 139, 6, 211, 38, 176, 114, 1130, 10, 6, 255, 3, 336, 877, 1, 7882, 1982, 4, 2116, 1159, 4, 541, 5, 732, 265, 286, 1275, 62, 21, 173, 8, 898, 1019, 65, 1, 1666, 11177, 1009, 226, 1579, 1203, 1109, 6, 255, 832, 10070, 2561, 2116, 554, 5814, 107, 11483, 541, 5, 62, 54, 103, 27, 3618, 1993, 1, 2116, 28, 18, 6, 33, 499, 188, 18, 1109, 11, 938, 4, 35, 306, 180, 1, 5956, 7, 1358, 9, 89, 1047, 1035, 2, 2116, 477, 3, 96, 93, 685, 11, 5, 1109, 4, 3, 9486, 22387, 5246, 8720, 13693, 100, 1109, 4, 13693, 45759, 19, 14, 67, 1006, 79, 79, 2, 45760, 19, 14, 67, 1006, 79, 83, 11, 4, 4820, 8459, 5403, 5, 296, 127, 668, 18, 14, 2, 5, 8, 583, 1907, 4, 13693, 58408, 34797, 668, 18, 13, 874, 45759, 2, 45760, 11, 938, 4, 35, 306, 180, 1, 5956, 7, 19, 4047, 2, 19, 3825, 22, 11, 127, 13693, 1109, 8230, 4, 338, 5403, 2860, 1109, 4, 13693, 11, 120, 41, 5, 2104, 155, 610, 197, 167, 27, 6, 245, 39, 19, 680, 6, 1520, 8, 898, 1019, 8956, 108, 2986, 2293, 4, 8, 7761, 1145, 18184, 154, 4690, 1609, 145, 13693, 22, 305, 3403, 1, 2116, 292, 1159, 2, 38, 176]",1354.0,19901119,373
Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2009-11-16,"Children with acute lymphoblastic leukemia (ALL) are often cured, but the therapies they receive may be neurotoxic. Little is known about the incidence and severity of late-occurring neurologic sequelae in ALL survivors. Data were analyzed to determine the incidence of adverse long-term neurologic outcomes and treatment-related risk factors. We analyzed adverse neurologic outcomes that occurred after diagnosis in 4,151 adult survivors of childhood ALL who participated in the Childhood Cancer Survivor Study (CCSS), a retrospective cohort of 5-year survivors of childhood cancer diagnosed between 1970 and 1986. A randomly selected cohort of the survivors' siblings served as a comparison group. Self-reported auditory-vestibular-visual sensory deficits, focal neurologic dysfunction, seizures, and serious headaches were assessed. The median age at outcome assessment was 20.2 years for survivors. The median follow-up time to death or last survey since ALL diagnosis was 14.1 years. Of the survivors, 64.5% received cranial radiation and 94% received intrathecal chemotherapy. Compared with the sibling cohort, survivors were at elevated risk for late-onset auditory-vestibular-visual sensory deficits (rate ratio [RR], 1.8; 95% CI, 1.5 to 2.2), coordination problems (RR, 4.1; 95% CI, 3.1 to 5.3), motor problems (RR, 5.0; 95% CI, 3.8 to 6.7), seizures (RR, 4.6; 95% CI, 3.4 to 6.2), and headaches (RR, 1.6; 95% CI, 1.4 to 1.7). In multivariable analysis, relapse was the most influential factor that increased risk of late neurologic complications. Children treated with regimens that include cranial radiation for ALL and those who suffer a relapse are at increased risk for late-onset neurologic sequelae.",Journal Article,3718.0,54.0,"Children with acute lymphoblastic ALL are often cured but the therapies they receive may be neurotoxic Little is known about the incidence and severity of late-occurring neurologic sequelae in ALL survivors Data were analyzed to determine the incidence of adverse long-term neurologic outcomes and treatment-related risk factors We analyzed adverse neurologic outcomes that occurred after diagnosis in 4,151 adult survivors of childhood ALL who participated in the Childhood Cancer Survivor Study CCSS a retrospective cohort of 5-year survivors of childhood cancer diagnosed between 1970 and 1986 A randomly selected cohort of the survivors siblings served as a comparison group Self-reported auditory-vestibular-visual sensory deficits focal neurologic dysfunction seizures and serious headaches were assessed The median age at outcome assessment was 20.2 years for survivors The median follow-up time to death or last survey since ALL diagnosis was 14.1 years Of the survivors 64.5 received cranial radiation and 94 received intrathecal chemotherapy Compared with the sibling cohort survivors were at elevated risk for late-onset auditory-vestibular-visual sensory deficits rate ratio RR 1.8 95 CI 1.5 to 2.2 coordination problems RR 4.1 95 CI 3.1 to 5.3 motor problems RR 5.0 95 CI 3.8 to 6.7 seizures RR 4.6 95 CI 3.4 to 6.2 and headaches RR 1.6 95 CI 1.4 to 1.7 In multivariable analysis relapse was the most influential factor that increased risk of late neurologic complications Children treated with regimens that include cranial radiation for ALL and those who suffer a relapse are at increased risk for late-onset neurologic sequelae",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 286, 1275, 62, 32, 629, 3733, 84, 3, 235, 491, 560, 68, 40, 11148, 1215, 16, 440, 545, 3, 287, 2, 1702, 1, 807, 1821, 2543, 4156, 4, 62, 332, 74, 11, 311, 6, 223, 3, 287, 1, 290, 319, 337, 2543, 123, 2, 24, 139, 43, 130, 21, 311, 290, 2543, 123, 17, 489, 50, 147, 4, 39, 5075, 780, 332, 1, 864, 62, 54, 3025, 4, 3, 864, 12, 2628, 45, 4657, 8, 459, 180, 1, 33, 111, 332, 1, 864, 12, 265, 59, 4868, 2, 3751, 8, 1108, 715, 180, 1, 3, 332, 2758, 5275, 22, 8, 1155, 87, 1074, 210, 11991, 9633, 3046, 4148, 2752, 2137, 2543, 1527, 4448, 2, 1762, 9783, 11, 275, 3, 52, 89, 28, 228, 455, 10, 179, 18, 60, 9, 332, 3, 52, 166, 126, 98, 6, 273, 15, 1060, 1407, 1192, 62, 147, 10, 213, 14, 60, 1, 3, 332, 660, 33, 103, 2565, 121, 2, 960, 103, 5126, 56, 72, 5, 3, 3684, 180, 332, 11, 28, 804, 43, 9, 807, 1707, 11991, 9633, 3046, 4148, 2752, 116, 197, 861, 14, 66, 48, 58, 14, 33, 6, 18, 18, 6373, 2408, 861, 39, 14, 48, 58, 27, 14, 6, 33, 27, 3482, 2408, 861, 33, 13, 48, 58, 27, 66, 6, 49, 67, 4448, 861, 39, 49, 48, 58, 27, 39, 6, 49, 18, 2, 9783, 861, 14, 49, 48, 58, 14, 39, 6, 14, 67, 4, 658, 65, 429, 10, 3, 96, 11741, 161, 17, 101, 43, 1, 807, 2543, 521, 541, 73, 5, 472, 17, 643, 2565, 121, 9, 62, 2, 135, 54, 6506, 8, 429, 32, 28, 101, 43, 9, 807, 1707, 2543, 4156]",1643.0,19917844,31
Conservative management of pancreatic pseudocysts in children with acute lymphoblastic leukemia.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2009-12-01,"Treatment with asparaginase for acute lymphoblastic leukemia can cause acute pancreatitis. Complication of pancreatitis by pancreatic pseudocyst formation can prolong the hospital stay, delay chemotherapy, and necessitate long-term parenteral nutrition. We report 5 children with acute lymphoblastic leukemia who developed acute pancreatitis complicated by pancreatic pseudocysts. They required modifications to their chemotherapy regimen and prolonged parenteral nutrition but no surgical intervention. All 5 patients survive in first remission and their pseudocysts resolved after 3 to 37 months or continued to decrease in size at last follow-up. These cases illustrate that nonsurgical management of pancreatic pseudocyst is safe, though pseudocyst resolution may require many months. In addition, these patients demonstrate that oral feeding can be initiated after the acute episode of pancreatitis resolves even if a pseudocyst is present.",Case Reports,3703.0,7.0,Treatment with asparaginase for acute lymphoblastic can cause acute pancreatitis Complication of pancreatitis by pseudocyst formation can prolong the hospital stay delay chemotherapy and necessitate long-term parenteral nutrition We report 5 children with acute lymphoblastic who developed acute pancreatitis complicated by pseudocysts They required modifications to their chemotherapy regimen and prolonged parenteral nutrition but no surgical intervention All 5 patients survive in first remission and their pseudocysts resolved after 3 to 37 months or continued to decrease in size at last follow-up These cases illustrate that nonsurgical management of pseudocyst is safe though pseudocyst resolution may require many months In addition these patients demonstrate that oral feeding can be initiated after the acute episode of pancreatitis resolves even if a pseudocyst is present,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 5, 3709, 9, 286, 1275, 122, 708, 286, 4535, 1447, 1, 4535, 20, 21365, 1264, 122, 3615, 3, 702, 2020, 1984, 56, 2, 12084, 319, 337, 8058, 5260, 21, 414, 33, 541, 5, 286, 1275, 54, 276, 286, 4535, 4286, 20, 22035, 491, 616, 2916, 6, 136, 56, 477, 2, 1069, 8058, 5260, 84, 77, 221, 788, 62, 33, 7, 4573, 4, 157, 734, 2, 136, 22035, 3862, 50, 27, 6, 567, 53, 15, 1351, 6, 775, 4, 444, 28, 1060, 166, 126, 46, 140, 4746, 17, 5544, 284, 1, 21365, 16, 1165, 2471, 21365, 2125, 68, 1353, 445, 53, 4, 352, 46, 7, 608, 17, 518, 5595, 122, 40, 1917, 50, 3, 286, 6934, 1, 4535, 21321, 871, 492, 8, 21365, 16, 364]",883.0,19956023,731
Role of reduced intensity transplant in adult patients with acute lymphoblastic leukemia: If and when?,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2009-12-01,"Although allogeneic transplantation is a potentially curative therapy for adults with acute lymphoblastic leukemia (ALL), the high risk of the ablative regimen limits its use, especially in older patients where the need for better therapy is greatest. Recent observations suggesting that a donor derived graft vs leukemia effect is important is facilitating cure after an allogeneic transplant has kindled interest in utilizing a reduced-intensity approach, which relies in large part on this effect to control and cure the disease. Several trials have now been reported that suggest that a reduced-intensity conditioning (RIC) approach might be very effective, especially in patients who are in the first remission of the disease from either related, unrelated, or cord blood transplant donors, with approximately 50% of patients alive and in remission two years after transplant. These studies suggest that prospective studies of RIC should be conducted in patients with ALL in first remission who are at high risk for relapse based on age or comorbidity to determine its role in the overall management of adult patients with this disease.",Journal Article,3703.0,2.0,Although allogeneic transplantation is a potentially curative therapy for adults with acute lymphoblastic ALL the high risk of the ablative regimen limits its use especially in older patients where the need for better therapy is greatest Recent observations suggesting that a donor derived graft vs effect is important is facilitating cure after an allogeneic transplant has kindled interest in utilizing a reduced-intensity approach which relies in large part on this effect to control and cure the disease Several trials have now been reported that suggest that a reduced-intensity conditioning RIC approach might be very effective especially in patients who are in the first remission of the disease from either related unrelated or cord blood transplant donors with approximately 50 of patients alive and in remission two years after transplant These studies suggest that prospective studies of RIC should be conducted in patients with ALL in first remission who are at high risk for relapse based on age or comorbidity to determine its role in the overall management of adult patients with this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 1063, 497, 16, 8, 751, 1075, 36, 9, 857, 5, 286, 1275, 62, 3, 64, 43, 1, 3, 4504, 477, 3526, 211, 119, 1093, 4, 434, 7, 1257, 3, 594, 9, 380, 36, 16, 2199, 435, 2172, 802, 17, 8, 1488, 526, 1599, 105, 254, 16, 305, 16, 5379, 1722, 50, 35, 1063, 941, 71, 58452, 1333, 4, 2600, 8, 405, 837, 353, 92, 6495, 4, 375, 760, 23, 26, 254, 6, 182, 2, 1722, 3, 34, 392, 143, 47, 1134, 85, 210, 17, 309, 17, 8, 405, 837, 1933, 3365, 353, 822, 40, 923, 323, 1093, 4, 7, 54, 32, 4, 3, 157, 734, 1, 3, 34, 29, 361, 139, 2092, 15, 1885, 315, 941, 2344, 5, 705, 212, 1, 7, 1701, 2, 4, 734, 100, 60, 50, 941, 46, 94, 309, 17, 482, 94, 1, 3365, 257, 40, 426, 4, 7, 5, 62, 4, 157, 734, 54, 32, 28, 64, 43, 9, 429, 90, 23, 89, 15, 1879, 6, 223, 211, 200, 4, 3, 63, 284, 1, 780, 7, 5, 26, 34]",1107.0,19959108,503
Association of high-level MCL-1 expression with in vitro and in vivo prednisone resistance in MLL-rearranged infant acute lymphoblastic leukemia.,Blood,Blood,2009-12-04,"MLL-rearranged acute lymphoblastic leukemia (ALL) represents an unfavorable type of leukemia that often is highly resistant to glucocorticoids such as prednisone and dexamethasone. Because response to prednisone largely determines clinical outcome of pediatric patients with ALL, overcoming resistance to this drug may be an important step toward improving prognosis. Here, we show how gene expression profiling identifies high-level MCL-1 expression to be associated with prednisolone resistance in MLL-rearranged infant ALL, as well as in more favorable types of childhood ALL. To validate this observation, we determined MCL-1 expression with quantitative reverse transcription-polymerase chain reaction in a cohort of MLL-rearranged infant ALL and pediatric noninfant ALL samples and confirmed that high-level MCL-1 expression is associated with prednisolone resistance in vitro. In addition, MCL-1 expression appeared to be significantly higher in MLL-rearranged infant patients who showed a poor response to prednisone in vivo compared with prednisone good responders. Finally, down-regulation of MCL-1 in prednisolone-resistant MLL-rearranged leukemia cells by RNA interference, to some extent, led to prednisolone sensitization. Collectively, our findings suggest a potential role for MCL-1 in glucocorticoid resistance in MLL-rearranged infant ALL, but at the same time strongly imply that high-level MCL-1 expression is not the sole mechanism providing resistance to these drugs.",Journal Article,3700.0,52.0,MLL-rearranged acute lymphoblastic ALL represents an unfavorable type of that often is highly resistant to glucocorticoids such as prednisone and dexamethasone Because response to prednisone largely determines clinical outcome of pediatric patients with ALL overcoming resistance to this drug may be an important step toward improving prognosis Here we show how gene expression profiling identifies high-level MCL-1 expression to be associated with prednisolone resistance in MLL-rearranged infant ALL as well as in more favorable types of childhood ALL To validate this observation we determined MCL-1 expression with quantitative reverse transcription-polymerase chain reaction in a cohort of MLL-rearranged infant ALL and pediatric noninfant ALL samples and confirmed that high-level MCL-1 expression is associated with prednisolone resistance in vitro In addition MCL-1 expression appeared to be significantly higher in MLL-rearranged infant patients who showed a poor response to prednisone in vivo compared with prednisone good responders Finally down-regulation of MCL-1 in prednisolone-resistant MLL-rearranged cells by RNA interference to some extent led to prednisolone sensitization Collectively our findings suggest a potential role for MCL-1 in glucocorticoid resistance in MLL-rearranged infant ALL but at the same time strongly imply that high-level MCL-1 expression is not the sole mechanism providing resistance to these drugs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3049, 3201, 286, 1275, 62, 1449, 35, 2483, 267, 1, 17, 629, 16, 561, 436, 6, 7307, 225, 22, 1979, 2, 1217, 408, 51, 6, 1979, 1733, 9476, 38, 228, 1, 815, 7, 5, 62, 5344, 251, 6, 26, 234, 68, 40, 35, 305, 2458, 1317, 1673, 356, 467, 21, 514, 832, 145, 55, 1080, 2953, 64, 301, 1308, 14, 55, 6, 40, 41, 5, 11253, 251, 4, 3049, 3201, 8027, 62, 22, 149, 22, 4, 80, 913, 630, 1, 864, 62, 6, 2183, 26, 1664, 21, 509, 1308, 14, 55, 5, 1156, 1772, 866, 1451, 1260, 1329, 4, 8, 180, 1, 3049, 3201, 8027, 62, 2, 815, 33724, 62, 347, 2, 557, 17, 64, 301, 1308, 14, 55, 16, 41, 5, 11253, 251, 4, 439, 4, 352, 1308, 14, 55, 2121, 6, 40, 97, 142, 4, 3049, 3201, 8027, 7, 54, 224, 8, 334, 51, 6, 1979, 4, 386, 72, 5, 1979, 1178, 1983, 1368, 1328, 863, 1, 1308, 14, 4, 11253, 436, 3049, 3201, 37, 20, 893, 3182, 6, 476, 1039, 836, 6, 11253, 6272, 2535, 114, 272, 309, 8, 174, 200, 9, 1308, 14, 4, 5399, 251, 4, 3049, 3201, 8027, 62, 84, 28, 3, 827, 98, 1327, 8360, 17, 64, 301, 1308, 14, 55, 16, 44, 3, 4991, 670, 1736, 251, 6, 46, 600]",1443.0,19965632,529
Current treatment options for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2010-02-01,"The clinical management of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) has been challenging primarily due to the aggressive nature of the disease and limited effective treatment options. The outcome for patients who receive conventional chemotherapy alone is poor, with remission duration of around 12 months and disease-free survival (DFS) rates of not more than 10%. Allogeneic stem cell transplantation (alloSCT) has been the only known curative treatment option, but is limited by the availability of a matched donor and the risk of treatment-related mortality. Given the role of BCR-ABL in the leukemogenesis of Ph+ ALL, current treatments have focused on inhibition of this oncogenic tyrosine kinase. Early studies demonstrate that the use of the BCR-ABL tyrosine kinase inhibitor (TKI), imatinib, before alloSCT results in improved response rates and DFS when combined with standard chemotherapy regimens. Remission duration also is improved when combination chemotherapy and imatinib are administered intensively, even in the absence of allogeneic stem cell transplant. However, resistant disease remains an important problem, and the mechanisms underlying resistance in Ph+ ALL are multifactorial. Novel TKIs are currently under development and are effective in some patients with imatinib-resistant disease. The dual BCR-ABL/SRC family kinase inhibitor, dasatinib, has shown promising activity in the treatment of Ph+ ALL after imatinib failure and has recently been approved in this indication. Other TKI-based therapies are also showing potential in imatinib-resistant disease. This article reviews current and emerging treatments in Ph+ ALL.",Journal Article,3641.0,16.0,The clinical management of patients with Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL has been challenging primarily due to the aggressive nature of the disease and limited effective treatment options The outcome for patients who receive conventional chemotherapy alone is poor with remission duration of around 12 months and disease-free survival DFS rates of not more than 10 Allogeneic stem cell transplantation alloSCT has been the only known curative treatment option but is limited by the availability of a matched donor and the risk of treatment-related mortality Given the role of BCR-ABL in the leukemogenesis of Ph+ ALL current treatments have focused on inhibition of this oncogenic tyrosine kinase Early studies demonstrate that the use of the BCR-ABL tyrosine kinase inhibitor TKI imatinib before alloSCT results in improved response rates and DFS when combined with standard chemotherapy regimens Remission duration also is improved when combination chemotherapy and imatinib are administered intensively even in the absence of allogeneic stem cell transplant However resistant disease remains an important problem and the mechanisms underlying resistance in Ph+ ALL are multifactorial Novel TKIs are currently under development and are effective in some patients with imatinib-resistant disease The dual BCR-ABL/SRC family kinase inhibitor dasatinib has shown promising activity in the treatment of Ph+ ALL after imatinib failure and has recently been approved in this indication Other TKI-based therapies are also showing potential in imatinib-resistant disease This article reviews current and emerging treatments in Ph+ ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 38, 284, 1, 7, 5, 3006, 1170, 109, 2058, 286, 1275, 62, 71, 85, 1950, 1561, 520, 6, 3, 571, 2202, 1, 3, 34, 2, 383, 323, 24, 838, 3, 228, 9, 7, 54, 560, 809, 56, 279, 16, 334, 5, 734, 654, 1, 3337, 133, 53, 2, 34, 115, 25, 1010, 151, 1, 44, 80, 76, 79, 1063, 452, 31, 497, 7253, 71, 85, 3, 158, 440, 1075, 24, 1501, 84, 16, 383, 20, 3, 2550, 1, 8, 655, 1488, 2, 3, 43, 1, 24, 139, 282, 447, 3, 200, 1, 1062, 1425, 4, 3, 5661, 1, 2058, 62, 291, 640, 47, 1649, 23, 297, 1, 26, 1302, 564, 216, 191, 94, 608, 17, 3, 119, 1, 3, 1062, 1425, 564, 216, 230, 1379, 577, 348, 7253, 99, 4, 231, 51, 151, 2, 1010, 198, 397, 5, 260, 56, 472, 734, 654, 120, 16, 231, 198, 150, 56, 2, 577, 32, 468, 13240, 871, 4, 3, 1127, 1, 1063, 452, 31, 941, 137, 436, 34, 469, 35, 305, 2497, 2, 3, 483, 1181, 251, 4, 2058, 62, 32, 7059, 229, 1671, 32, 694, 669, 193, 2, 32, 323, 4, 476, 7, 5, 577, 436, 34, 3, 1828, 1062, 1425, 2023, 607, 216, 230, 1674, 71, 443, 721, 128, 4, 3, 24, 1, 2058, 62, 50, 577, 496, 2, 71, 761, 85, 850, 4, 26, 3607, 127, 1379, 90, 235, 32, 120, 2069, 174, 4, 577, 436, 34, 26, 946, 2004, 291, 2, 1478, 640, 4, 2058, 62]",1657.0,20001232,358
Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia.,Blood,Blood,2009-12-10,"Over the past several decades, L-asparaginase, an important component of therapy for acute lymphoblastic leukemia (ALL), has typically been administered intramuscularly rather than intravenously in North America because of concerns regarding anaphylaxis. We evaluated the feasibility of giving polyethylene glycosylated (PEG)-asparaginase, the polyethylene glycol conjugate of Escherichia coli L-asparaginase, by intravenous infusion in children with ALL. Between 2005 and 2007, 197 patients (age, 1-17 years) were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-01 and received a single dose of intravenous PEG-asparaginase (2500 IU/m(2)) over 1 hour during remission induction. Serum asparaginase activity more than 0.1 IU/mL was detected in 95%, 88%, and 7% of patients at 11, 18, and 25 days after dosing, respectively. Toxicities included allergy (1.5%), venous thrombosis (2%), and pancreatitis (4.6%). We conclude that intravenous administration of PEG-asparaginase is tolerable in children with ALL, and potentially therapeutic enzyme activity is maintained for at least 2 weeks after a single dose in most patients. This trial was registered at www.clinicaltrials.gov as #NCT00400946.",Clinical Trial,3694.0,71.0,Over the past several decades L-asparaginase an important component of therapy for acute lymphoblastic ALL has typically been administered intramuscularly rather than intravenously in North America because of concerns regarding anaphylaxis We evaluated the feasibility of giving polyethylene glycosylated PEG -asparaginase the polyethylene glycol conjugate of Escherichia coli L-asparaginase by intravenous infusion in children with ALL Between 2005 and 2007 197 patients age 1-17 years were enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-01 and received a single dose of intravenous PEG-asparaginase 2500 IU/m 2 over 1 hour during remission induction Serum asparaginase activity more than 0.1 IU/mL was detected in 95 88 and 7 of patients at 11 18 and 25 days after dosing respectively Toxicities included allergy 1.5 venous thrombosis 2 and pancreatitis 4.6 We conclude that intravenous administration of PEG-asparaginase is tolerable in children with ALL and potentially therapeutic enzyme activity is maintained for at least 2 weeks after a single dose in most patients This trial was registered at www.clinicaltrials.gov as NCT00400946,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[252, 3, 1219, 392, 1968, 805, 3709, 35, 305, 1249, 1, 36, 9, 286, 1275, 62, 71, 1969, 85, 468, 12800, 1832, 76, 1672, 4, 2669, 4010, 408, 1, 2061, 666, 19433, 21, 194, 3, 1437, 1, 7375, 12997, 13260, 3145, 3709, 3, 12997, 10809, 3998, 1, 12832, 6959, 805, 3709, 20, 1262, 904, 4, 541, 5, 62, 59, 1242, 2, 1307, 6114, 7, 89, 14, 269, 60, 11, 346, 23, 4932, 4979, 12, 1377, 62, 2404, 1182, 474, 355, 2, 103, 8, 226, 61, 1, 1262, 3145, 3709, 11735, 4588, 188, 18, 252, 14, 2583, 190, 734, 504, 524, 3709, 128, 80, 76, 13, 14, 4588, 542, 10, 530, 4, 48, 889, 2, 67, 1, 7, 28, 175, 203, 2, 243, 162, 50, 1280, 106, 385, 159, 9842, 14, 33, 2167, 2839, 18, 2, 4535, 39, 49, 21, 2060, 17, 1262, 634, 1, 3145, 3709, 16, 2668, 4, 541, 5, 62, 2, 751, 189, 1644, 128, 16, 1955, 9, 28, 506, 18, 244, 50, 8, 226, 61, 4, 96, 7, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 34806]",1161.0,20007809,674
Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2009-12-15,"The prognosis for adults with precursor B-cell acute lymphoblastic leukemia (B-ALL) remains poor, in part from a lack of therapeutic targets. We identified the type I cytokine receptor subunit CRLF2 in a functional screen for B-ALL-derived mRNA transcripts that can substitute for IL3 signaling. We demonstrate that CRLF2 is overexpressed in approximately 15% of adult and high-risk pediatric B-ALL that lack MLL, TCF3, TEL, and BCR/ABL rearrangements, but not in B-ALL with these rearrangements or other lymphoid malignancies. CRLF2 overexpression can result from translocation with the IGH locus or intrachromosomal deletion and is associated with poor outcome. CRLF2 overexpressing B-ALLs share a transcriptional signature that significantly overlaps with a BCR/ABL signature, and is enriched for genes involved in cytokine receptor and JAK-STAT signaling. In a subset of cases, CRLF2 harbors a Phe232Cys gain-of-function mutation that promotes constitutive dimerization and cytokine independent growth. A mutually exclusive subset harbors activating mutations in JAK2. In fact, all 22 B-ALLs with mutant JAK2 that we analyzed overexpress CRLF2, distinguishing CRLF2 as the key scaffold for mutant JAK2 signaling in B-ALL. Expression of WT CRLF2 with mutant JAK2 also promotes cytokine independent growth that, unlike CRLF2 Phe232Cys or ligand-induced signaling by WT CRLF2, is accompanied by JAK2 phosphorylation. Finally, cells dependent on CRLF2 signaling are sensitive to small molecule inhibitors of either JAKs or protein kinase C family kinases. Together, these findings implicate CRLF2 as an important factor in B-ALL with diagnostic, prognostic, and therapeutic implications.",Journal Article,3689.0,210.0,The prognosis for adults with precursor B-cell acute lymphoblastic B-ALL remains poor in part from a lack of therapeutic targets We identified the type I cytokine receptor subunit CRLF2 in a functional screen for B-ALL-derived mRNA transcripts that can substitute for IL3 signaling We demonstrate that CRLF2 is overexpressed in approximately 15 of adult and high-risk pediatric B-ALL that lack MLL TCF3 TEL and BCR/ABL rearrangements but not in B-ALL with these rearrangements or other lymphoid malignancies CRLF2 overexpression can result from translocation with the IGH locus or intrachromosomal deletion and is associated with poor outcome CRLF2 overexpressing B-ALLs share a transcriptional signature that significantly overlaps with a BCR/ABL signature and is enriched for genes involved in cytokine receptor and JAK-STAT signaling In a subset of cases CRLF2 harbors a Phe232Cys gain-of-function mutation that promotes constitutive dimerization and cytokine independent growth A mutually exclusive subset harbors activating mutations in JAK2 In fact all 22 B-ALLs with mutant JAK2 that we analyzed overexpress CRLF2 distinguishing CRLF2 as the key scaffold for mutant JAK2 signaling in B-ALL Expression of WT CRLF2 with mutant JAK2 also promotes cytokine independent growth that unlike CRLF2 Phe232Cys or ligand-induced signaling by WT CRLF2 is accompanied by JAK2 phosphorylation Finally cells dependent on CRLF2 signaling are sensitive to small molecule inhibitors of either JAKs or protein kinase C family kinases Together these findings implicate CRLF2 as an important factor in B-ALL with diagnostic prognostic and therapeutic implications,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 9, 857, 5, 2765, 132, 31, 286, 1275, 132, 62, 469, 334, 4, 760, 29, 8, 926, 1, 189, 637, 21, 108, 3, 267, 70, 1675, 153, 3350, 8895, 4, 8, 583, 2413, 9, 132, 62, 526, 956, 2680, 17, 122, 12577, 9, 20283, 314, 21, 608, 17, 8895, 16, 1711, 4, 705, 167, 1, 780, 2, 64, 43, 815, 132, 62, 17, 926, 3049, 25178, 8573, 2, 1062, 1425, 2072, 84, 44, 4, 132, 62, 5, 46, 2072, 15, 127, 2303, 441, 8895, 851, 122, 757, 29, 2006, 5, 3, 5221, 2474, 15, 24924, 1528, 2, 16, 41, 5, 334, 228, 8895, 2810, 132, 10706, 4349, 8, 1431, 1651, 17, 97, 16388, 5, 8, 1062, 1425, 1651, 2, 16, 2220, 9, 214, 646, 4, 1675, 153, 2, 4653, 4168, 314, 4, 8, 697, 1, 140, 8895, 8475, 8, 45801, 1803, 1, 343, 258, 17, 2148, 3178, 7509, 2, 1675, 306, 129, 8, 5575, 4804, 697, 8475, 1616, 138, 4, 2509, 4, 1991, 62, 350, 132, 10706, 5, 620, 2509, 17, 21, 311, 5612, 8895, 4508, 8895, 22, 3, 825, 11547, 9, 620, 2509, 314, 4, 132, 62, 55, 1, 1820, 8895, 5, 620, 2509, 120, 2148, 1675, 306, 129, 17, 4246, 8895, 45801, 15, 1232, 277, 314, 20, 1820, 8895, 16, 2756, 20, 2509, 982, 1368, 37, 470, 23, 8895, 314, 32, 745, 6, 302, 1354, 222, 1, 361, 28197, 15, 178, 216, 256, 607, 1549, 1162, 46, 272, 5545, 8895, 22, 35, 305, 161, 4, 132, 62, 5, 752, 177, 2, 189, 1268]",1649.0,20018760,233
Emerging therapy for the treatment of acute lymphoblastic leukemia.,Expert opinion on emerging drugs,Expert Opin Emerg Drugs,2010-03-01,"Over the last few decades, advances in acute lymphoblastic leukemia (ALL) therapy have led to long-term survival rates of > 80% in children; however, comparable rates have yet to be achieved in adults, and a large majority of patients relapse from their disease. The review describes historical therapy and advancements in ALL treatment over the past few decades, while providing a concise review of the future direction of ALL therapy. Literature was collected through peer reviewed journals and the Pharmaprojects drug profile for ALL. Current information regarding prognostic factors for relapse, salvage therapy options and emerging drugs are provided in the review. Development of new drugs with novel mechanisms, unique formulations of existing medications, as well as manipulation of current combinations of drugs remain vital to the success in adult ALL.",Journal Article,3613.0,11.0,Over the last few decades advances in acute lymphoblastic ALL therapy have led to long-term survival rates of 80 in children however comparable rates have yet to be achieved in adults and a large majority of patients relapse from their disease The review describes historical therapy and advancements in ALL treatment over the past few decades while providing a concise review of the future direction of ALL therapy Literature was collected through peer reviewed journals and the Pharmaprojects drug profile for ALL Current information regarding prognostic factors for relapse salvage therapy options and emerging drugs are provided in the review Development of new drugs with novel mechanisms unique formulations of existing medications as well as manipulation of current combinations of drugs remain vital to the success in adult ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[252, 3, 1060, 1021, 1968, 954, 4, 286, 1275, 62, 36, 47, 836, 6, 319, 337, 25, 151, 1, 493, 4, 541, 137, 1279, 151, 47, 1145, 6, 40, 513, 4, 857, 2, 8, 375, 686, 1, 7, 429, 29, 136, 34, 3, 206, 2677, 2252, 36, 2, 6217, 4, 62, 24, 252, 3, 1219, 1021, 1968, 369, 1736, 8, 11071, 206, 1, 3, 508, 4651, 1, 62, 36, 789, 10, 786, 298, 5084, 446, 6871, 2, 3, 58537, 234, 800, 9, 62, 291, 487, 666, 177, 130, 9, 429, 992, 36, 838, 2, 1478, 600, 32, 1052, 4, 3, 206, 193, 1, 217, 600, 5, 229, 483, 991, 5832, 1, 1692, 2679, 22, 149, 22, 6239, 1, 291, 1247, 1, 600, 918, 3511, 6, 3, 1825, 4, 780, 62]",835.0,20055690,904
Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia.,Blood,Blood,2010-01-08,"Eph receptors and their ephrin ligands are involved in normal hematopoietic development and tumorigenesis. Using methylated CpG island amplification/DNA promoter microarray, we identified several EPH receptor and EPHRIN genes as potential hypermethylation targets in acute lymphoblastic leukemia (ALL). We subsequently studied the DNA methylation status of the Eph/ephrin family by bisulfite pyrosequencing. Hypermethylation of EPHA2, -A4, -A5, -A6, -A7, -A10, EPHB1, -B2, -B3, -B4, EFNA1, -A3, -A5, and EFNB1 and -B2 genes was detected in leukemia cell lines and primary ALL bone marrow samples. Expression analysis of EPHB4, EFNB2, and EFNA5 genes demonstrated that DNA methylation was associated with gene silencing. We cloned the promoter region of EPHB4 and demonstrated that promoter hypermethylation can result in EPHB4 transcriptional silencing. Restoration of EPHB4 expression by lentiviral transduction resulted in reduced proliferation and apoptotic cell death in Raji cells in which EPHB4 is methylated and silenced. Finally, we demonstrated that phosphorylated Akt is down-regulated in Raji cells transduced with EPHB4. These results suggest that epigenetic silencing by hypermethylation of EPH/EPHRIN family genes contributes to ALL pathogenesis and that EPHB4 can function as a tumor suppressor in ALL.",Journal Article,3665.0,65.0,Eph receptors and their ephrin ligands are involved in normal hematopoietic development and tumorigenesis Using methylated CpG island amplification/DNA promoter microarray we identified several EPH receptor and EPHRIN genes as potential hypermethylation targets in acute lymphoblastic ALL We subsequently studied the DNA methylation status of the Eph/ephrin family by bisulfite pyrosequencing Hypermethylation of EPHA2 -A4 -A5 -A6 -A7 -A10 EPHB1 -B2 -B3 -B4 EFNA1 -A3 -A5 and EFNB1 and -B2 genes was detected in cell lines and primary ALL marrow samples Expression analysis of EPHB4 EFNB2 and EFNA5 genes demonstrated that DNA methylation was associated with gene silencing We cloned the promoter region of EPHB4 and demonstrated that promoter hypermethylation can result in EPHB4 transcriptional silencing Restoration of EPHB4 expression by lentiviral transduction resulted in reduced proliferation and apoptotic cell death in Raji cells in which EPHB4 is methylated and silenced Finally we demonstrated that phosphorylated Akt is down-regulated in Raji cells transduced with EPHB4 These results suggest that epigenetic silencing by hypermethylation of EPH/EPHRIN family genes contributes to ALL pathogenesis and that EPHB4 can function as a tumor suppressor in ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[13916, 1186, 2, 136, 8611, 3123, 32, 646, 4, 295, 1007, 193, 2, 1565, 75, 2963, 2075, 3454, 1073, 261, 973, 1727, 21, 108, 392, 13916, 153, 2, 8611, 214, 22, 174, 2575, 637, 4, 286, 1275, 62, 21, 1611, 656, 3, 261, 569, 156, 1, 3, 13916, 8611, 607, 20, 6181, 6031, 2575, 1, 5511, 14090, 39205, 18419, 42796, 26368, 25220, 6617, 12631, 14476, 58543, 7024, 39205, 2, 58544, 2, 6617, 214, 10, 530, 4, 31, 285, 2, 86, 62, 581, 347, 55, 65, 1, 4208, 39206, 2, 39207, 214, 264, 17, 261, 569, 10, 41, 5, 145, 2077, 21, 8560, 3, 973, 1053, 1, 4208, 2, 264, 17, 973, 2575, 122, 757, 4, 4208, 1431, 2077, 5194, 1, 4208, 55, 20, 7823, 2761, 627, 4, 405, 457, 2, 1631, 31, 273, 4, 9868, 37, 4, 92, 4208, 16, 2963, 2, 5442, 1368, 21, 264, 17, 2365, 649, 16, 1328, 1065, 4, 9868, 37, 5042, 5, 4208, 46, 99, 309, 17, 1418, 2077, 20, 2575, 1, 13916, 8611, 607, 214, 2444, 6, 62, 1384, 2, 17, 4208, 122, 343, 22, 8, 30, 1245, 4, 62]",1266.0,20061560,590
Adult acute lymphoblastic leukemia: concepts and strategies.,Cancer,Cancer,2010-03-01,"Acute lymphoblastic leukemia (ALL), a clonal expansion of hematopoietic blasts, is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued. Although ALL is a success story in pediatric oncology, results in adults lag behind those in children. An expansion of new drugs, more reliable immunologic and molecular techniques for the assessment of minimal residual disease, and efforts at more precise risk stratification are generating new aspects of adult ALL therapy. For this review, the authors summarized pertinent and recent literature on ALL biology and therapy, and they discuss current strategies and potential implications of novel approaches to the management of adult ALL. Cancer 2010. (c) 2010 American Cancer Society.",Journal Article,3613.0,149.0,Acute lymphoblastic ALL a clonal expansion of hematopoietic blasts is a highly heterogeneous disease comprising many entities for which distinct treatment strategies are pursued Although ALL is a success story in pediatric oncology results in adults lag behind those in children An expansion of new drugs more reliable immunologic and molecular techniques for the assessment of minimal residual disease and efforts at more precise risk stratification are generating new aspects of adult ALL therapy For this review the authors summarized pertinent and recent literature on ALL biology and therapy and they discuss current strategies and potential implications of novel approaches to the management of adult ALL Cancer 2010 c 2010 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 8, 1946, 1422, 1, 1007, 2438, 16, 8, 561, 1564, 34, 3538, 445, 4613, 9, 92, 834, 24, 422, 32, 5299, 242, 62, 16, 8, 1825, 15108, 4, 815, 413, 99, 4, 857, 7650, 5219, 135, 4, 541, 35, 1422, 1, 217, 600, 80, 2450, 3042, 2, 219, 1092, 9, 3, 455, 1, 1048, 753, 34, 2, 1413, 28, 80, 3260, 43, 1541, 32, 3997, 217, 2695, 1, 780, 62, 36, 9, 26, 206, 3, 738, 3989, 5799, 2, 435, 789, 23, 62, 891, 2, 36, 2, 491, 1139, 291, 422, 2, 174, 1268, 1, 229, 611, 6, 3, 284, 1, 780, 62, 12, 1120, 256, 1120, 597, 12, 1174]",753.0,20101737,7
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation.,Blood,Blood,2010-01-28,"Viral infections and leukemic relapse account for the majority of treatment failures in patients with B-cell acute lymphoblastic leukemia (B-ALL) receiving allogeneic hematopoietic stem cell (HSC) or cord blood (CB) transplants. Adoptive transfer of virus-specific cytotoxic T lymphocytes (CTLs) provides protection against common viruses causing serious infections after HSC transplantation without concomitant graft-versus-host disease. We have now generated CTL lines from peripheral blood (PB) or CB units that recognize multiple common viruses and provide antileukemic activity by transgenic expression of a chimeric antigen receptor (CAR) targeting CD19 expressed on B-ALL. PB-derived CAR(+) CTLs produced interferon-gamma (IFNgamma) in response to cytomegalovirus-pp65, adenovirus-hexon, and Epstein-Barr virus pepmixes (from 205 +/- 104 to 1034 +/- 304 spot-forming cells [SFCs]/10(5) T cells) and lysed primary B-ALL blasts in (51)Cr-release assays (mean, 66% +/- 5% specific lysis; effector-target [E/T] ratio, 40:1) and the CD19(+) Raji cell line (mean, 78% +/- 17%) in contrast to nontransduced controls (8% +/- 8% and 3% +/- 2%). CB-derived CAR(+) CTLs showed similar antiviral and antitumor function and both PB and CB CAR(+) CTLs completely eliminated B-ALL blasts over 5 days of coculture. This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse.",Journal Article,3645.0,84.0,Viral infections and leukemic relapse account for the majority of treatment failures in patients with B-cell acute lymphoblastic B-ALL receiving allogeneic hematopoietic stem cell HSC or cord blood CB transplants Adoptive transfer of virus-specific cytotoxic T lymphocytes CTLs provides protection against common viruses causing serious infections after HSC transplantation without concomitant graft-versus-host disease We have now generated CTL lines from peripheral blood PB or CB units that recognize multiple common viruses and provide antileukemic activity by transgenic expression of a chimeric antigen receptor CAR targeting CD19 expressed on B-ALL PB-derived CAR CTLs produced interferon-gamma IFNgamma in response to cytomegalovirus-pp65 adenovirus-hexon and Epstein-Barr virus pepmixes from 205 +/- 104 to 1034 +/- 304 spot-forming cells SFCs /10 5 T cells and lysed primary B-ALL blasts in 51 Cr-release assays mean 66 +/- 5 specific lysis effector-target E/T ratio 40:1 and the CD19 Raji cell line mean 78 +/- 17 in contrast to nontransduced controls 8 +/- 8 and 3 +/- 2 CB-derived CAR CTLs showed similar antiviral and antitumor function and both PB and CB CAR CTLs completely eliminated B-ALL blasts over 5 days of coculture This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1667, 1875, 2, 2015, 429, 1967, 9, 3, 686, 1, 24, 3368, 4, 7, 5, 132, 31, 286, 1275, 132, 62, 357, 1063, 1007, 452, 31, 5596, 15, 1885, 315, 4723, 4016, 3159, 2602, 1, 1450, 112, 759, 102, 1594, 5416, 777, 3525, 480, 186, 4405, 3440, 1762, 1875, 50, 5596, 497, 187, 1781, 1599, 185, 1204, 34, 21, 47, 1134, 1419, 3872, 285, 29, 672, 315, 3767, 15, 4723, 2960, 17, 4237, 232, 186, 4405, 2, 377, 4512, 128, 20, 2862, 55, 1, 8, 2897, 448, 153, 1881, 529, 3158, 570, 23, 132, 62, 3767, 526, 1881, 5416, 1687, 1688, 1705, 12490, 4, 51, 6, 7314, 22108, 4488, 39167, 2, 5212, 5190, 1450, 58596, 29, 5286, 3407, 6, 18943, 8940, 6901, 4525, 37, 39220, 79, 33, 102, 37, 2, 14098, 86, 132, 62, 2438, 4, 725, 684, 2008, 1013, 313, 700, 33, 112, 4783, 2070, 283, 563, 102, 197, 327, 14, 2, 3, 3158, 9868, 31, 328, 313, 833, 269, 4, 748, 6, 33450, 535, 66, 66, 2, 27, 18, 4723, 526, 1881, 5416, 224, 288, 6264, 2, 579, 343, 2, 110, 3767, 2, 4723, 1881, 5416, 2500, 6173, 132, 62, 2438, 252, 33, 162, 1, 7604, 26, 353, 68, 4361, 2524, 9, 7, 5, 64, 43, 132, 62, 54, 47, 761, 103, 35, 5596, 15, 4723, 941, 2, 32, 28, 43, 1, 930, 2, 429]",1399.0,20110422,436
Inactivation of LEF1 in T-cell acute lymphoblastic leukemia.,Blood,Blood,2010-02-01,"To further unravel the molecular pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL), we performed high-resolution array comparative genomic hybridization on diagnostic specimens from 47 children with T-ALL and identified monoallelic or biallelic LEF1 microdeletions in 11% (5 of 47) of these primary samples. An additional 7% (3 of 44) of the cases harbored nonsynonymous sequence alterations of LEF1, 2 of which produced premature stop codons. Gene expression microarrays showed increased expression of MYC and MYC targets in cases with LEF1 inactivation, as well as differentiation arrest at an early cortical stage of thymocyte development characterized by expression of CD1B, CD1E, and CD8, with absent CD34 expression. LEF1 inactivation was associated with a younger age at the time of T-ALL diagnosis, as well as activating NOTCH1 mutations, biallelic INK4a/ARF deletions, and PTEN loss-of-function mutations or activating mutations of PI3K or AKT genes. These cases generally lacked overexpression of the TAL1, HOX11, HOX11L2, or the HOXA cluster genes, which have been used to define separate molecular pathways leading to T-ALL. Our findings suggest that LEF1 inactivation is an important step in the molecular pathogenesis of T-ALL in a subset of young children.",Journal Article,3641.0,79.0,To further unravel the molecular pathogenesis of T-cell acute lymphoblastic T-ALL we performed high-resolution array comparative genomic hybridization on diagnostic specimens from 47 children with T-ALL and identified monoallelic or biallelic LEF1 microdeletions in 11 5 of 47 of these primary samples An additional 7 3 of 44 of the cases harbored nonsynonymous sequence alterations of LEF1 2 of which produced premature stop codons Gene expression microarrays showed increased expression of MYC and MYC targets in cases with LEF1 inactivation as well as differentiation arrest at an early cortical stage of thymocyte development characterized by expression of CD1B CD1E and CD8 with absent CD34 expression LEF1 inactivation was associated with a younger age at the time of T-ALL diagnosis as well as activating NOTCH1 mutations biallelic INK4a/ARF deletions and PTEN loss-of-function mutations or activating mutations of PI3K or AKT genes These cases generally lacked overexpression of the TAL1 HOX11 HOX11L2 or the HOXA cluster genes which have been used to define separate molecular pathways leading to T-ALL Our findings suggest that LEF1 inactivation is an important step in the molecular pathogenesis of T-ALL in a subset of young children,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 195, 14282, 3, 219, 1384, 1, 102, 31, 286, 1275, 102, 62, 21, 173, 64, 2125, 1926, 2352, 572, 1554, 23, 752, 623, 29, 662, 541, 5, 102, 62, 2, 108, 11950, 15, 6435, 12009, 23749, 4, 175, 33, 1, 662, 1, 46, 86, 347, 35, 402, 67, 27, 1, 584, 1, 3, 140, 3253, 10233, 1532, 593, 1, 12009, 18, 1, 92, 1687, 5682, 7142, 9107, 145, 55, 2774, 224, 101, 55, 1, 1371, 2, 1371, 637, 4, 140, 5, 12009, 2297, 22, 149, 22, 910, 1854, 28, 35, 191, 4500, 82, 1, 16236, 193, 765, 20, 55, 1, 38374, 58611, 2, 968, 5, 3269, 2215, 55, 12009, 2297, 10, 41, 5, 8, 773, 89, 28, 3, 98, 1, 102, 62, 147, 22, 149, 22, 1616, 4607, 138, 6435, 6276, 5509, 2439, 2, 820, 407, 1, 343, 138, 15, 1616, 138, 1, 974, 15, 649, 214, 46, 140, 1228, 5005, 851, 1, 3, 18789, 18191, 33252, 15, 3, 31577, 3132, 214, 92, 47, 85, 95, 6, 1107, 2282, 219, 460, 1049, 6, 102, 62, 114, 272, 309, 17, 12009, 2297, 16, 35, 305, 2458, 4, 3, 219, 1384, 1, 102, 62, 4, 8, 697, 1, 1169, 541]",1245.0,20124220,650
Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study.,American journal of hematology,Am. J. Hematol.,2010-03-01,"Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) intolerant or resistant to imatinib. In patients with chronic-phase chronic myelogenous leukemia, once-daily dosing has similar efficacy with improved safety, compared with twice-daily dosing. A phase 3 study (n = 611) assessed the efficacy and safety of dasatinib 140 mg once daily versus 70 mg twice-daily in patients with advanced phase chronic myelogenous leukemia or Ph+ ALL resistant or intolerant to imatinib. Here, results from the Ph+ ALL subset (n = 84) with a 2-year follow-up are reported. Patients were randomly assigned to receive dasatinib either 140 mg once daily (n = 40) or 70 mg twice daily (n = 44). The rate of confirmed major hematologic response with once-daily dosing (38%) was similar to that with twice-daily dosing (32%). The rate of major cytogenetic response with once-daily dosing (70%) was higher than that with twice-daily dosing (52%). Compared with the twice-daily schedule, the once-daily schedule had longer progression-free survival (median, 3.0 months versus 4.0 months, respectively) and shorter overall survival (median, 9.1 months versus 6.5 months, respectively). Overall safety profiles were similar between two groups, with nonhematologic adverse events being mostly grade 1 or 2. Pleural effusion was less frequent with once-daily dosing than with twice-daily dosing (all grades, 18% versus 32%). Notably, none of the differences between the two schedules was statistically significant. Compared with the 70 mg twice daily, dasatinib 140 mg once daily had similar overall efficacy and safety in patients with imatinib-resistant or intolerant Ph+ ALL. (clinicaltrials.gov identifier: NCT00123487).","Clinical Trial, Phase III",3613.0,67.0,Dasatinib 70 mg twice daily is indicated for Philadelphia chromosome-positive acute lymphoblastic Ph+ ALL intolerant or resistant to imatinib In patients with chronic-phase chronic myelogenous once-daily dosing has similar efficacy with improved safety compared with twice-daily dosing A phase 3 study n 611 assessed the efficacy and safety of dasatinib 140 mg once daily versus 70 mg twice-daily in patients with advanced phase chronic myelogenous or Ph+ ALL resistant or intolerant to imatinib Here results from the Ph+ ALL subset n 84 with a 2-year follow-up are reported Patients were randomly assigned to receive dasatinib either 140 mg once daily n 40 or 70 mg twice daily n 44 The rate of confirmed major hematologic response with once-daily dosing 38 was similar to that with twice-daily dosing 32 The rate of major cytogenetic response with once-daily dosing 70 was higher than that with twice-daily dosing 52 Compared with the twice-daily schedule the once-daily schedule had longer progression-free survival median 3.0 months versus 4.0 months respectively and shorter overall survival median 9.1 months versus 6.5 months respectively Overall safety profiles were similar between two groups with nonhematologic adverse events being mostly grade 1 or 2 Pleural effusion was less frequent with once-daily dosing than with twice-daily dosing all grades 18 versus 32 Notably none of the differences between the two schedules was statistically significant Compared with the 70 mg twice daily dasatinib 140 mg once daily had similar overall efficacy and safety in patients with imatinib-resistant or intolerant Ph+ ALL clinicaltrials.gov identifier NCT00123487,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1674, 431, 81, 936, 391, 16, 1103, 9, 3006, 1170, 109, 286, 1275, 2058, 62, 4944, 15, 436, 6, 577, 4, 7, 5, 442, 124, 442, 2194, 1059, 391, 1280, 71, 288, 209, 5, 231, 367, 72, 5, 936, 391, 1280, 8, 124, 27, 45, 78, 10711, 275, 3, 209, 2, 367, 1, 1674, 3304, 81, 1059, 391, 185, 431, 81, 936, 391, 4, 7, 5, 131, 124, 442, 2194, 15, 2058, 62, 436, 15, 4944, 6, 577, 467, 99, 29, 3, 2058, 62, 697, 78, 874, 5, 8, 18, 111, 166, 126, 32, 210, 7, 11, 1108, 896, 6, 560, 1674, 361, 3304, 81, 1059, 391, 78, 327, 15, 431, 81, 936, 391, 78, 584, 3, 116, 1, 557, 458, 813, 51, 5, 1059, 391, 1280, 519, 10, 288, 6, 17, 5, 936, 391, 1280, 531, 3, 116, 1, 458, 1266, 51, 5, 1059, 391, 1280, 431, 10, 142, 76, 17, 5, 936, 391, 1280, 653, 72, 5, 3, 936, 391, 1055, 3, 1059, 391, 1055, 42, 589, 91, 115, 25, 52, 27, 13, 53, 185, 39, 13, 53, 106, 2, 985, 63, 25, 52, 83, 14, 53, 185, 49, 33, 53, 106, 63, 367, 1241, 11, 288, 59, 100, 271, 5, 3534, 290, 281, 486, 2754, 88, 14, 15, 18, 2164, 4433, 10, 299, 908, 5, 1059, 391, 1280, 76, 5, 936, 391, 1280, 62, 2276, 203, 185, 531, 2552, 1292, 1, 3, 362, 59, 3, 100, 2314, 10, 712, 93, 72, 5, 3, 431, 81, 936, 391, 1674, 3304, 81, 1059, 391, 42, 288, 63, 209, 2, 367, 4, 7, 5, 577, 436, 15, 4944, 2058, 62, 1252, 1239, 3719, 58630]",1665.0,20131302,182
"Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia.",Blood,Blood,2010-02-04,"Gene expression profiling of 207 uniformly treated children with high-risk B-progenitor acute lymphoblastic leukemia revealed 29 of 207 cases (14%) with markedly elevated expression of CRLF2 (cytokine receptor-like factor 2). Each of the 29 cases harbored a genomic rearrangement of CRLF2: 18 of 29 (62%) had a translocation of the immunoglobulin heavy chain gene IGH@ on 14q32 to CRLF2 in the pseudoautosomal region 1 of Xp22.3/Yp11.3, whereas 10 (34%) cases had a 320-kb interstitial deletion centromeric of CRLF2, resulting in a P2RY8-CRLF2 fusion. One case had both IGH@-CRLF2 and P2RY8-CRLF2, and another had a novel CRLF2 rearrangement. Only 2 of 29 cases were Down syndrome. CRLF2 rearrangements were significantly associated with activating mutations of JAK1 or JAK2, deletion or mutation of IKZF1, and Hispanic/Latino ethnicity (Fisher exact test, P < .001 for each). Within this cohort, patients with CRLF2 rearrangements had extremely poor treatment outcomes compared with those without CRLF2 rearrangements (35.3% vs 71.3% relapse-free survival at 4 years; P < .001). Together, these observations suggest that activation of CRLF2 expression, mutation of JAK kinases, and alterations of IKZF1 cooperate to promote B-cell leukemogenesis and identify these pathways as important therapeutic targets in this disease.",Clinical Trial,3638.0,314.0,Gene expression profiling of 207 uniformly treated children with high-risk B-progenitor acute lymphoblastic revealed 29 of 207 cases 14 with markedly elevated expression of CRLF2 cytokine receptor-like factor 2 Each of the 29 cases harbored a genomic rearrangement of CRLF2 18 of 29 62 had a translocation of the immunoglobulin heavy chain gene IGH on 14q32 to CRLF2 in the pseudoautosomal region 1 of Xp22.3/Yp11.3 whereas 10 34 cases had a 320-kb interstitial deletion centromeric of CRLF2 resulting in a P2RY8-CRLF2 fusion One case had both IGH -CRLF2 and P2RY8-CRLF2 and another had a novel CRLF2 rearrangement Only 2 of 29 cases were Down syndrome CRLF2 rearrangements were significantly associated with activating mutations of JAK1 or JAK2 deletion or mutation of IKZF1 and Hispanic/Latino ethnicity Fisher exact test P .001 for each Within this cohort patients with CRLF2 rearrangements had extremely poor treatment outcomes compared with those without CRLF2 rearrangements 35.3 vs 71.3 relapse-free survival at 4 years P .001 Together these observations suggest that activation of CRLF2 expression mutation of JAK kinases and alterations of IKZF1 cooperate to promote B-cell leukemogenesis and identify these pathways as important therapeutic targets in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[145, 55, 1080, 1, 5292, 4254, 73, 541, 5, 64, 43, 132, 2520, 286, 1275, 553, 462, 1, 5292, 140, 213, 5, 2195, 804, 55, 1, 8895, 1675, 153, 733, 161, 18, 296, 1, 3, 462, 140, 3253, 8, 572, 2675, 1, 8895, 203, 1, 462, 744, 42, 8, 2006, 1, 3, 2593, 4013, 1260, 145, 5221, 23, 12077, 6, 8895, 4, 3, 45726, 1053, 14, 1, 58634, 27, 58635, 27, 547, 79, 562, 140, 42, 8, 5904, 5116, 4543, 1528, 15531, 1, 8895, 1113, 4, 8, 25205, 8895, 1212, 104, 473, 42, 110, 5221, 8895, 2, 25205, 8895, 2, 1809, 42, 8, 229, 8895, 2675, 158, 18, 1, 462, 140, 11, 1328, 681, 8895, 2072, 11, 97, 41, 5, 1616, 138, 1, 8075, 15, 2509, 1528, 15, 258, 1, 8422, 2, 1776, 10247, 2091, 3135, 2472, 412, 19, 144, 9, 296, 262, 26, 180, 7, 5, 8895, 2072, 42, 2938, 334, 24, 123, 72, 5, 135, 187, 8895, 2072, 465, 27, 105, 792, 27, 429, 115, 25, 28, 39, 60, 19, 144, 1162, 46, 2172, 309, 17, 363, 1, 8895, 55, 258, 1, 4653, 1549, 2, 593, 1, 8422, 8647, 6, 1617, 132, 31, 5661, 2, 255, 46, 460, 22, 305, 189, 637, 4, 26, 34]",1274.0,20139093,271
Overexpression of human CAP10-like protein 46 KD in T-acute lymphoblastic leukemia and acute myelogenous leukemia.,Genetic testing and molecular biomarkers,Genet Test Mol Biomarkers,2010-02-01,"We earlier identified a novel gene human CAP10-like protein 46 KD (hCLP46) from human acute myelogenous leukemia (AML) transformed from myelodysplastic syndrome CD34(+) cells, but the function of this gene remains unclear. In this study, a real-time polymerase chain reaction-based assay was developed to quantify expression of hCLP46 in the peripheral blood of AML and T-acute lymphoblastic leukemia (T-ALL) primary samples and in six leukemic cell lines. Also, we investigated expression of CDKN2A/B and the apoptosis in U937 cells when hCLP46 is downregulated in vitro. Our findings showed that hCLP46 was overexpressed in AML, T-ALL, and the leukemic cell lines. Suppressing hCLP46 overexpression had no effect on expression of CDKN2A/B and apoptosis of U937 cells. Considering that hCLP46 has the capability of modifying the Notch pathway, our finding adds weight to the importance of Notch signaling in hematopoiesis and suggests that overexpression of hCLP46 might be an early event in the pathogenesis of AML and T-ALL.",Journal Article,3641.0,16.0,We earlier identified a novel gene human CAP10-like protein 46 KD hCLP46 from human acute myelogenous AML transformed from syndrome CD34 cells but the function of this gene remains unclear In this study a real-time polymerase chain reaction-based assay was developed to quantify expression of hCLP46 in the peripheral blood of AML and T-acute lymphoblastic T-ALL primary samples and in six leukemic cell lines Also we investigated expression of CDKN2A/B and the apoptosis in U937 cells when hCLP46 is downregulated in vitro Our findings showed that hCLP46 was overexpressed in AML T-ALL and the leukemic cell lines Suppressing hCLP46 overexpression had no effect on expression of CDKN2A/B and apoptosis of U937 cells Considering that hCLP46 has the capability of modifying the Notch pathway our finding adds weight to the importance of Notch signaling in hematopoiesis and suggests that overexpression of hCLP46 might be an early event in the pathogenesis of AML and T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 1677, 108, 8, 229, 145, 171, 58648, 733, 178, 641, 6271, 26912, 29, 171, 286, 2194, 329, 2423, 29, 681, 2215, 37, 84, 3, 343, 1, 26, 145, 469, 1200, 4, 26, 45, 8, 1589, 98, 1451, 1260, 1329, 90, 719, 10, 276, 6, 3091, 55, 1, 26912, 4, 3, 672, 315, 1, 329, 2, 102, 286, 1275, 102, 62, 86, 347, 2, 4, 437, 2015, 31, 285, 120, 21, 565, 55, 1, 3175, 132, 2, 3, 351, 4, 7000, 37, 198, 26912, 16, 3315, 4, 439, 114, 272, 224, 17, 26912, 10, 1711, 4, 329, 102, 62, 2, 3, 2015, 31, 285, 4669, 26912, 851, 42, 77, 254, 23, 55, 1, 3175, 132, 2, 351, 1, 7000, 37, 3075, 17, 26912, 71, 3, 6188, 1, 4898, 3, 3193, 308, 114, 1567, 6659, 924, 6, 3, 1187, 1, 3193, 314, 4, 5114, 2, 844, 17, 851, 1, 26912, 822, 40, 35, 191, 774, 4, 3, 1384, 1, 329, 2, 102, 62]",972.0,20143914,72
Intraventricular meningioma after cranial irradiation for childhood leukemia.,Journal of child neurology,J. Child Neurol.,2010-03-05,"Meningiomas are among the most common brain tumors in adults. They are most commonly located over the cerebral convexities and are infrequently found in an intraventricular location. Ionizing cranial radiation is a risk factor for late occurrence of meningiomas within the radiation field. While pathologic grading of meningiomas is straightforward, significant variability often exists between pathologists in applying standard grading criteria. This has implications for prognosis. Radiation-induced meningiomas may also have predilection to recur. The authors describe a case of an intraventricular meningioma occurring 23 years after cranial irradiation for childhood acute lymphoblastic leukemia.",Case Reports,3609.0,4.0,Meningiomas are among the most common brain tumors in adults They are most commonly located over the cerebral convexities and are infrequently found in an intraventricular location Ionizing cranial radiation is a risk factor for late occurrence of meningiomas within the radiation field While pathologic grading of meningiomas is straightforward significant variability often exists between pathologists in applying standard grading criteria This has implications for prognosis Radiation-induced meningiomas may also have predilection to recur The authors describe a case of an intraventricular meningioma occurring 23 years after cranial irradiation for childhood acute lymphoblastic,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3718, 32, 107, 3, 96, 186, 342, 57, 4, 857, 491, 32, 96, 841, 2308, 252, 3, 3549, 58720, 2, 32, 6440, 204, 4, 35, 7199, 1147, 4341, 2565, 121, 16, 8, 43, 161, 9, 807, 2291, 1, 3718, 262, 3, 121, 1067, 369, 510, 3452, 1, 3718, 16, 12753, 93, 1982, 629, 2481, 59, 3354, 4, 4798, 260, 3452, 371, 26, 71, 1268, 9, 356, 121, 277, 3718, 68, 120, 47, 8904, 6, 5609, 3, 738, 897, 8, 473, 1, 35, 7199, 3944, 1821, 382, 60, 50, 2565, 1104, 9, 864, 286, 1275]",684.0,20207611,493
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies.,Cancer,Cancer,2010-05-01,"Central nervous system (CNS) recurrence continues to be a significant complication in the treatment of adult patients with acute lymphoblastic leukemia (ALL). Preventing CNS recurrence has been a therapeutic challenge and has not been addressed critically in many clinical trials. Adult studies modeled on childhood ALL studies have used multiple treatment modalities, including radiation therapy, systemic therapy, intrathecal therapy, and combinations thereof. Cranial irradiation is effective but is offset by substantial toxicity, including neurologic sequelae. Systemic chemotherapy, especially with cytarabine (AraC) and methotrexate, has demonstrated promise in decreasing CNS recurrence, but therapeutic levels of drugs in the cerebrospinal fluid (CSF) are not maintained. Intrathecal chemotherapy with or without high-dose systemic therapy is the most common approach to CNS prophylaxis. Liposomal AraC recently has become available and confers prolonged levels of free AraC in the CSF, a critical requirement for CNS prophylactic therapy. This review discusses the various modalities used for CNS prophylaxis in patients with ALL and the emerging trends, with specific emphasis on the outcome in terms of event-free survival and toxicity.",Journal Article,3552.0,55.0,Central nervous system CNS recurrence continues to be a significant complication in the treatment of adult patients with acute lymphoblastic ALL Preventing CNS recurrence has been a therapeutic challenge and has not been addressed critically in many clinical trials Adult studies modeled on childhood ALL studies have used multiple treatment modalities including radiation therapy systemic therapy intrathecal therapy and combinations thereof Cranial irradiation is effective but is offset by substantial toxicity including neurologic sequelae Systemic chemotherapy especially with cytarabine AraC and methotrexate has demonstrated promise in decreasing CNS recurrence but therapeutic levels of drugs in the cerebrospinal fluid CSF are not maintained Intrathecal chemotherapy with or without high-dose systemic therapy is the most common approach to CNS prophylaxis Liposomal AraC recently has become available and confers prolonged levels of free AraC in the CSF a critical requirement for CNS prophylactic therapy This review discusses the various modalities used for CNS prophylaxis in patients with ALL and the emerging trends with specific emphasis on the outcome in terms of event-free survival and toxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[854, 1880, 398, 1025, 146, 2274, 6, 40, 8, 93, 1447, 4, 3, 24, 1, 780, 7, 5, 286, 1275, 62, 3017, 1025, 146, 71, 85, 8, 189, 1745, 2, 71, 44, 85, 2814, 4331, 4, 445, 38, 143, 780, 94, 4666, 23, 864, 62, 94, 47, 95, 232, 24, 1558, 141, 121, 36, 403, 36, 5126, 36, 2, 1247, 13902, 2565, 1104, 16, 323, 84, 16, 9500, 20, 1281, 155, 141, 2543, 4156, 403, 56, 1093, 5, 1855, 12792, 2, 2116, 71, 264, 1783, 4, 2777, 1025, 146, 84, 189, 148, 1, 600, 4, 3, 5156, 2357, 1211, 32, 44, 1955, 5126, 56, 5, 15, 187, 64, 61, 403, 36, 16, 3, 96, 186, 353, 6, 1025, 2049, 3275, 12792, 761, 71, 1417, 390, 2, 4020, 1069, 148, 1, 115, 12792, 4, 3, 1211, 8, 740, 4701, 9, 1025, 1862, 36, 26, 206, 2759, 3, 747, 1558, 95, 9, 1025, 2049, 4, 7, 5, 62, 2, 3, 1478, 1963, 5, 112, 3136, 23, 3, 228, 4, 1794, 1, 774, 115, 25, 2, 155]",1213.0,20209620,15
Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia.,Blood,Blood,2010-03-19,"Minimal residual disease (MRD) at the end of remission-induction therapy predicts relapse in acute lymphoblastic leukemia (ALL). We examined the clinical significance of levels below the usual threshold value for MRD positivity (0.01%) in 455 children with B-lineage ALL, using polymerase chain reaction amplification of antigen-receptor genes capable of detecting at least 1 leukemic cell per 100 000 normal mononucleated cells (0.001%). Of the 455 clinical samples studied on day 46 of therapy, 139 (30.5%) had MRD 0.001% or more with 63 of these (45.3%) showing levels of 0.001% to less than 0.01%, whereas 316 (69.5%) had levels that were either less than 0.001% or undetectable. MRD measurements of 0.001% to less than 0.01% were not significantly related to presenting characteristics but were associated with a poorer leukemia cell clearance on day 19 of remission induction therapy. Patients with this low level of MRD had a 12.7% (+/- 5.1%; SE) cumulative risk of relapse at 5 years, compared with 5.0% (+/- 1.5%) for those with lower or undetectable MRD (P < .047). Thus, low levels of MRD (0.001%-< 0.01%) at the end of remission induction therapy have prognostic significance in childhood ALL, suggesting that patients with this finding should be monitored closely for adverse events.",Comparative Study,3595.0,95.0,Minimal residual disease MRD at the end of remission-induction therapy predicts relapse in acute lymphoblastic ALL We examined the clinical significance of levels below the usual threshold value for MRD positivity 0.01 in 455 children with B-lineage ALL using polymerase chain reaction amplification of antigen-receptor genes capable of detecting at least 1 leukemic cell per 100 000 normal mononucleated cells 0.001 Of the 455 clinical samples studied on day 46 of therapy 139 30.5 had MRD 0.001 or more with 63 of these 45.3 showing levels of 0.001 to less than 0.01 whereas 316 69.5 had levels that were either less than 0.001 or undetectable MRD measurements of 0.001 to less than 0.01 were not significantly related to presenting characteristics but were associated with a poorer cell clearance on day 19 of remission induction therapy Patients with this low level of MRD had a 12.7 +/- 5.1 SE cumulative risk of relapse at 5 years compared with 5.0 +/- 1.5 for those with lower or undetectable MRD P .047 Thus low levels of MRD 0.001 0.01 at the end of remission induction therapy have prognostic significance in childhood ALL suggesting that patients with this finding should be monitored closely for adverse events,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1048, 753, 34, 2029, 28, 3, 396, 1, 734, 504, 36, 2623, 429, 4, 286, 1275, 62, 21, 409, 3, 38, 724, 1, 148, 2736, 3, 3521, 2390, 549, 9, 2029, 1887, 13, 355, 4, 10997, 541, 5, 132, 2542, 62, 75, 1451, 1260, 1329, 1073, 1, 448, 153, 214, 2787, 1, 2502, 28, 506, 14, 2015, 31, 379, 394, 984, 295, 58763, 37, 13, 144, 1, 3, 10997, 38, 347, 656, 23, 218, 641, 1, 36, 4929, 201, 33, 42, 2029, 13, 144, 15, 80, 5, 676, 1, 46, 512, 27, 2069, 148, 1, 13, 144, 6, 299, 76, 13, 355, 547, 8500, 790, 33, 42, 148, 17, 11, 361, 299, 76, 13, 144, 15, 3920, 2029, 1685, 1, 13, 144, 6, 299, 76, 13, 355, 11, 44, 97, 139, 6, 1656, 374, 84, 11, 41, 5, 8, 1769, 31, 1960, 23, 218, 326, 1, 734, 504, 36, 7, 5, 26, 154, 301, 1, 2029, 42, 8, 133, 67, 33, 14, 3428, 967, 43, 1, 429, 28, 33, 60, 72, 5, 33, 13, 14, 33, 9, 135, 5, 280, 15, 3920, 2029, 19, 5296, 631, 154, 148, 1, 2029, 13, 144, 13, 355, 28, 3, 396, 1, 734, 504, 36, 47, 177, 724, 4, 864, 62, 802, 17, 7, 5, 26, 1567, 257, 40, 2909, 3210, 9, 290, 281]",1222.0,20304809,252
Infant leukemia and parental infertility or its treatment: a Children's Oncology Group report.,"Human reproduction (Oxford, England)",Hum. Reprod.,2010-04-10,"Little is known about the potential risk factors for infant leukemia. With its very young age at diagnosis, exposures occurring in the perinatal period are suspected. Parental infertility and infertility treatment have been studied with regard to childhood cancer in general, but rarely in individual cancer subtypes. A case-control study of infant leukemia was conducted through the Children's Oncology Group, including cases diagnosed from January 1996 to December 2006 and controls selected through random digit dialing and birth certificate tracing. Maternal phone interviews were conducted to obtain information about infertility, infertility treatment and demographic factors. All cases as well as subgroups defined by mixed lineage leukemia (MLL) translocation status and leukemia subtype were examined. Statistical analysis was performed using multivariate logistic regression models. No significant associations between infertility or its treatment and combined infant leukemia were found. In subgroup analyses, there was a significant increase in the risk of MLL--leukemia for children born to women not trying to conceive compared with those trying for <1 year for all types combined [odds ratio (OR) = 1.62, 95% confidence interval (CI) = 1.01-2.59] and for acute lymphoblastic leukemia (OR = 2.50, 95% CI = 1.36-4.61). There were no positive associations between parental infertility or infertility treatment and infant leukemia. While this is the largest study to date, both selection and recall bias may have impacted the results. However, for infant leukemia, we can potentially rule out large increases in risk associated with parental infertility or its treatment.",Journal Article,3573.0,,Little is known about the potential risk factors for infant With its very young age at diagnosis exposures occurring in the perinatal period are suspected Parental infertility and infertility treatment have been studied with regard to childhood cancer in general but rarely in individual cancer subtypes A case-control study of infant was conducted through the Children 's Oncology Group including cases diagnosed from January 1996 to December 2006 and controls selected through random digit dialing and birth certificate tracing Maternal phone interviews were conducted to obtain information about infertility infertility treatment and demographic factors All cases as well as subgroups defined by mixed lineage MLL translocation status and subtype were examined Statistical analysis was performed using multivariate logistic regression models No significant associations between infertility or its treatment and combined infant were found In subgroup analyses there was a significant increase in the risk of MLL -- for children born to women not trying to conceive compared with those trying for 1 year for all types combined odds ratio OR 1.62 95 confidence interval CI 1.01-2.59 and for acute lymphoblastic OR 2.50 95 CI 1.36-4.61 There were no positive associations between parental infertility or infertility treatment and infant While this is the largest study to date both selection and recall bias may have impacted the results However for infant we can potentially rule out large increases in risk associated with parental infertility or its treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1215, 16, 440, 545, 3, 174, 43, 130, 9, 8027, 5, 211, 923, 1169, 89, 28, 147, 3401, 1821, 4, 3, 29004, 727, 32, 2768, 3418, 5901, 2, 5901, 24, 47, 85, 656, 5, 2539, 6, 864, 12, 4, 1083, 84, 2416, 4, 797, 12, 814, 8, 473, 182, 45, 1, 8027, 10, 426, 298, 3, 541, 292, 413, 87, 141, 140, 265, 29, 1024, 2648, 6, 1397, 1324, 2, 535, 715, 298, 2324, 9553, 14758, 2, 3809, 17216, 15457, 6039, 8772, 4053, 11, 426, 6, 3140, 487, 545, 5901, 5901, 24, 2, 1540, 130, 62, 140, 22, 149, 22, 1453, 395, 20, 1739, 2542, 3049, 2006, 156, 2, 875, 11, 409, 1050, 65, 10, 173, 75, 331, 812, 320, 274, 77, 93, 685, 59, 5901, 15, 211, 24, 2, 397, 8027, 11, 204, 4, 1363, 318, 125, 10, 8, 93, 344, 4, 3, 43, 1, 3049, 9, 541, 8234, 6, 117, 44, 14453, 6, 34874, 72, 5, 135, 14453, 9, 14, 111, 9, 62, 630, 397, 610, 197, 15, 14, 744, 48, 307, 268, 58, 14, 355, 18, 728, 2, 9, 286, 1275, 15, 18, 212, 48, 58, 14, 511, 39, 713, 125, 11, 77, 109, 685, 59, 3418, 5901, 15, 5901, 24, 2, 8027, 369, 26, 16, 3, 2166, 45, 6, 1244, 110, 881, 2, 6169, 2947, 68, 47, 4619, 3, 99, 137, 9, 8027, 21, 122, 751, 5340, 1205, 375, 1106, 4, 43, 41, 5, 3418, 5901, 15, 211, 24]",1561.0,20382971,118
Adolescent oncology: who cares?-the new KID on the block.,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2010-04-11,"The paper reports a case of a 25-year-old male with a new diagnosis of acute lymphoblastic leukemia admitted in a predominantly older adult cancer ward. It explores the emerging area of adolescent oncology. Despite the advances of modern cancer medicine in both survival and outcomes, these adolescent and young adult cancer patients are an underserved group. Their medical, physical, psychological, and emotional needs are different and ought to be managed differently, just like pediatric or geriatric subpopulations. Cancer adds an enormous burden to the already turbulent period of adolescence. Cancer incidence in the 15-29-year age group is at least three times than that of those younger than 15 years of age, and it kills more young adults than any disease except depression-induced suicide. The need for optimizing and personalizing care in this age group is highlighted.",Case Reports,3572.0,5.0,The paper reports a case of a 25-year-old male with a new diagnosis of acute lymphoblastic admitted in a predominantly older adult cancer ward It explores the emerging area of adolescent oncology Despite the advances of modern cancer medicine in both survival and outcomes these adolescent and young adult cancer patients are an underserved group Their medical physical psychological and emotional needs are different and ought to be managed differently just like pediatric or geriatric subpopulations Cancer adds an enormous burden to the already turbulent period of adolescence Cancer incidence in the 15-29-year age group is at least three times than that of those younger than 15 years of age and it kills more young adults than any disease except depression-induced suicide The need for optimizing and personalizing care in this age group is highlighted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2817, 1198, 8, 473, 1, 8, 243, 111, 1095, 1045, 5, 8, 217, 147, 1, 286, 1275, 4319, 4, 8, 2117, 434, 780, 12, 20431, 192, 6829, 3, 1478, 965, 1, 3678, 413, 550, 3, 954, 1, 2366, 12, 1807, 4, 110, 25, 2, 123, 46, 3678, 2, 1169, 780, 12, 7, 32, 35, 6960, 87, 136, 484, 900, 2624, 2, 2671, 1891, 32, 338, 2, 39289, 6, 40, 2231, 7663, 4673, 733, 815, 15, 3914, 4847, 12, 6659, 35, 8790, 892, 6, 3, 3298, 45973, 727, 1, 6964, 12, 287, 4, 3, 167, 462, 111, 89, 87, 16, 28, 506, 169, 1072, 76, 17, 1, 135, 773, 76, 167, 60, 1, 89, 2, 192, 10955, 80, 1169, 857, 76, 500, 34, 2187, 1774, 277, 7974, 3, 594, 9, 4336, 2, 15389, 165, 4, 26, 89, 87, 16, 3681]",858.0,20383720,18
The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission.,Blood,Blood,2010-04-19,"We examined the efficacy of reduced-intensity conditioning (RIC) and compared outcomes of 93 patients older than 16 years after RIC with 1428 patients receiving full-intensity conditioning for allografts using sibling and unrelated donors for Philadelphia-negative acute lymphoblastic leukemia (ALL) in first or second complete remission. RIC conditioning included busulfan 9 mg/kg or less (27), melphalan 150 mg/m(2) or less (23), low-dose total body irradiation (TBI; 36), and others (7). The RIC group was older (median 45 vs 28 years, P < .001) and more received peripheral blood grafts (73% vs 43%, P < .001) but had similar other prognostic factors. The RIC versus full-intensity conditioning groups had slightly, but not significantly, less acute grade II-IV graft-versus-host disease (39% vs 46%) and chronic graft-versus-host disease (34% vs 42%), yet similar transplantation-related mortality. RIC led to slightly more relapse (35% vs 26%, P = .08) yet similar age-adjusted survival (38% vs 43%, P = .39). Multivariate analysis showed that conditioning intensity did not affect transplantation-related mortality (P = .92) or relapse risk (P = .14). Multivariate analysis demonstrated significantly improved overall survival with: Karnofsky performance status more than 80, first complete remission, lower white blood count, well-matched unrelated or sibling donors, transplantation since 2001, age younger than 30 years, and conditioning with TBI, but no independent impact of conditioning intensity. RIC merits further investigation in prospective trials of adult ALL.",Journal Article,3564.0,119.0,We examined the efficacy of reduced-intensity conditioning RIC and compared outcomes of 93 patients older than 16 years after RIC with 1428 patients receiving full-intensity conditioning for allografts using sibling and unrelated donors for Philadelphia-negative acute lymphoblastic ALL in first or second complete remission RIC conditioning included busulfan 9 mg/kg or less 27 melphalan 150 mg/m 2 or less 23 low-dose total body irradiation TBI 36 and others 7 The RIC group was older median 45 vs 28 years P .001 and more received peripheral blood grafts 73 vs 43 P .001 but had similar other prognostic factors The RIC versus full-intensity conditioning groups had slightly but not significantly less acute grade II-IV graft-versus-host disease 39 vs 46 and chronic graft-versus-host disease 34 vs 42 yet similar transplantation-related mortality RIC led to slightly more relapse 35 vs 26 P .08 yet similar age-adjusted survival 38 vs 43 P .39 Multivariate analysis showed that conditioning intensity did not affect transplantation-related mortality P .92 or relapse risk P .14 Multivariate analysis demonstrated significantly improved overall survival with Karnofsky performance status more than 80 first complete remission lower white blood count well-matched unrelated or sibling donors transplantation since 2001 age younger than 30 years and conditioning with TBI but no independent impact of conditioning intensity RIC merits further investigation in prospective trials of adult ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 409, 3, 209, 1, 405, 837, 1933, 3365, 2, 72, 123, 1, 966, 7, 434, 76, 245, 60, 50, 3365, 5, 39294, 7, 357, 1647, 837, 1933, 9, 10586, 75, 3684, 2, 2092, 2344, 9, 3006, 199, 286, 1275, 62, 4, 157, 15, 419, 236, 734, 3365, 1933, 159, 3906, 83, 81, 503, 15, 299, 428, 2370, 1577, 81, 188, 18, 15, 299, 382, 154, 61, 181, 642, 1104, 4889, 511, 2, 1749, 67, 3, 3365, 87, 10, 434, 52, 512, 105, 339, 60, 19, 144, 2, 80, 103, 672, 315, 4713, 803, 105, 601, 19, 144, 84, 42, 288, 127, 177, 130, 3, 3365, 185, 1647, 837, 1933, 271, 42, 3223, 84, 44, 97, 299, 286, 88, 215, 478, 1599, 185, 1204, 34, 587, 105, 641, 2, 442, 1599, 185, 1204, 34, 562, 105, 595, 1145, 288, 497, 139, 282, 3365, 836, 6, 3223, 80, 429, 465, 105, 432, 19, 1592, 1145, 288, 89, 586, 25, 519, 105, 601, 19, 587, 331, 65, 224, 17, 1933, 837, 205, 44, 1158, 497, 139, 282, 19, 937, 15, 429, 43, 19, 213, 331, 65, 264, 97, 231, 63, 25, 5, 2857, 528, 156, 80, 76, 493, 157, 236, 734, 280, 886, 315, 1276, 149, 655, 2092, 15, 3684, 2344, 497, 1192, 1758, 89, 773, 76, 201, 60, 2, 1933, 5, 4889, 84, 77, 306, 345, 1, 1933, 837, 3365, 4986, 195, 940, 4, 482, 143, 1, 780, 62]",1492.0,20404137,797
"Deficient innate immunity, thymopoiesis, and gene expression response to radiation in survivors of childhood acute lymphoblastic leukemia.",Cancer epidemiology,Cancer Epidemiol,2010-04-22,"Survivors of childhood acute lymphoblastic leukemia (ALL) are at an increased risk of developing secondary malignant neoplasms. Radiation and chemotherapy can cause mutations and cytogenetic abnormalities and induce genomic instability. Host immunity and appropriate DNA damage responses are critical inhibitors of carcinogenesis. Therefore, we sought to determine the long-term effects of ALL treatment on immune function and response to DNA damage. Comparative studies on 14 survivors in first complete remission and 16 siblings were conducted. In comparison to siblings on the cells that were involved in adaptive immunity, the patients had either higher numbers (CD19+ B cells and CD4+CD25+ T regulatory cells) or similar numbers (alphabetaT cells and CD45RO+/RA- memory T cells) in the blood. In contrast, patients had lower numbers of all lymphocyte subsets involved in innate immunity (gammadeltaT cells and all NK subsets, including KIR2DL1+ cells, KIR2DL2/L3+ cells, and CD16+ cells), and lower natural cytotoxicity against K562 leukemia cells. Thymopoiesis was lower in patients, as demonstrated by less CD45RO-/RA+ nave T cell and less SjTREC levels in the blood, whereas the Vbeta spectratype complexity score was similar. Array of gene expression response to low-dose radiation showed that about 70% of the probesets had a reduced response in patients. One of these genes, SCHIP-1, was also among the top-ranked single nucleotide polymorphisms (SNPs) during the whole-genome scanning by SNP microarray analysis. ALL survivors were deficient in innate immunity, thymopoiesis, and DNA damage responses to radiation. These defects may contribute to their increased likelihood of second malignancy.",Journal Article,3561.0,13.0,Survivors of childhood acute lymphoblastic ALL are at an increased risk of developing secondary malignant neoplasms Radiation and chemotherapy can cause mutations and cytogenetic abnormalities and induce genomic instability Host immunity and appropriate DNA damage responses are critical inhibitors of carcinogenesis Therefore we sought to determine the long-term effects of ALL treatment on immune function and response to DNA damage Comparative studies on 14 survivors in first complete remission and 16 siblings were conducted In comparison to siblings on the cells that were involved in adaptive immunity the patients had either higher numbers CD19+ B cells and CD4+CD25+ T regulatory cells or similar numbers alphabetaT cells and CD45RO+/RA- memory T cells in the blood In contrast patients had lower numbers of all lymphocyte subsets involved in innate immunity gammadeltaT cells and all NK subsets including KIR2DL1+ cells KIR2DL2/L3+ cells and CD16+ cells and lower natural cytotoxicity against K562 cells Thymopoiesis was lower in patients as demonstrated by less CD45RO-/RA+ nave T cell and less SjTREC levels in the blood whereas the Vbeta spectratype complexity score was similar Array of gene expression response to low-dose radiation showed that about 70 of the probesets had a reduced response in patients One of these genes SCHIP-1 was also among the top-ranked single nucleotide polymorphisms SNPs during the whole-genome scanning by SNP microarray analysis ALL survivors were deficient in innate immunity thymopoiesis and DNA damage responses to radiation These defects may contribute to their increased likelihood of second malignancy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 32, 28, 35, 101, 43, 1, 931, 568, 393, 1179, 121, 2, 56, 122, 708, 138, 2, 1266, 1171, 2, 1290, 572, 1753, 1204, 1604, 2, 870, 261, 1350, 253, 32, 740, 222, 1, 1719, 673, 21, 990, 6, 223, 3, 319, 337, 176, 1, 62, 24, 23, 250, 343, 2, 51, 6, 261, 1350, 2352, 94, 23, 213, 332, 4, 157, 236, 734, 2, 245, 2758, 11, 426, 4, 1155, 6, 2758, 23, 3, 37, 17, 11, 646, 4, 2454, 1604, 3, 7, 42, 361, 142, 1870, 3158, 132, 37, 2, 1440, 4531, 102, 1253, 37, 15, 288, 1870, 58866, 37, 2, 11469, 4631, 2407, 102, 37, 4, 3, 315, 4, 748, 7, 42, 280, 1870, 1, 62, 1448, 1890, 646, 4, 3939, 1604, 58867, 37, 2, 62, 1765, 1890, 141, 26842, 37, 31546, 6869, 37, 2, 11287, 37, 2, 280, 1504, 1408, 480, 5208, 37, 28406, 10, 280, 4, 7, 22, 264, 20, 299, 11469, 4631, 2809, 102, 31, 2, 299, 34875, 148, 4, 3, 315, 547, 3, 18819, 58868, 3082, 368, 10, 288, 1926, 1, 145, 55, 51, 6, 154, 61, 121, 224, 17, 545, 431, 1, 3, 30454, 42, 8, 405, 51, 4, 7, 104, 1, 46, 214, 58869, 14, 10, 120, 107, 3, 3150, 6441, 226, 1579, 1203, 1109, 190, 3, 902, 898, 3702, 20, 1845, 1727, 65, 62, 332, 11, 1971, 4, 3939, 1604, 28406, 2, 261, 1350, 253, 6, 121, 46, 2945, 68, 1248, 6, 136, 101, 1420, 1, 419, 710]",1654.0,20413363,419
Recurrent deletion of 9q34 in adult normal karyotype precursor B-cell acute lymphoblastic leukemia.,Cancer genetics and cytogenetics,Cancer Genet. Cytogenet.,2010-05-01,"The prognosis of adult normal karyotype (NK) precursor B-cell acute lymphoblastic leukemia (B-ALL) has not improved over the last decade, mainly because separation into distinct molecular subsets has been lacking and no targeted treatments are available. We screened the genome of blasts from 10 adult NK B-ALL patients for novel genomic alterations by array comparative genomic hybridization and verified our results with fluorescent in situ hybridization and gene expression profile with the same probes. The results demonstrate cryptic deletions of 9q34 involving SET, PKN3, NUP188, ABL1, and NUP214 in three of the samples. The smallest deletion resulted in the likely juxtaposition of the SET and NUP214 genes. This aberration has not been described before in adult NK B-ALL. Larger number of samples is warranted to determine the prognostic significance of this cryptic deletion.",Journal Article,3552.0,8.0,The prognosis of adult normal karyotype NK precursor B-cell acute lymphoblastic B-ALL has not improved over the last decade mainly because separation into distinct molecular subsets has been lacking and no targeted treatments are available We screened the genome of blasts from 10 adult NK B-ALL patients for novel genomic alterations by array comparative genomic hybridization and verified our results with fluorescent in situ hybridization and gene expression profile with the same probes The results demonstrate cryptic deletions of 9q34 involving SET PKN3 NUP188 ABL1 and NUP214 in three of the samples The smallest deletion resulted in the likely juxtaposition of the SET and NUP214 genes This aberration has not been described before in adult NK B-ALL Larger number of samples is warranted to determine the prognostic significance of this cryptic deletion,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 1, 780, 295, 3385, 1765, 2765, 132, 31, 286, 1275, 132, 62, 71, 44, 231, 252, 3, 1060, 2025, 2615, 408, 5422, 237, 834, 219, 1890, 71, 85, 1941, 2, 77, 238, 640, 32, 390, 21, 2261, 3, 898, 1, 2438, 29, 79, 780, 1765, 132, 62, 7, 9, 229, 572, 593, 20, 1926, 2352, 572, 1554, 2, 4815, 114, 99, 5, 2910, 4, 957, 1554, 2, 145, 55, 800, 5, 3, 827, 3701, 3, 99, 608, 10294, 2439, 1, 19805, 1267, 916, 58879, 58880, 3557, 2, 31098, 4, 169, 1, 3, 347, 3, 11249, 1528, 627, 4, 3, 322, 20172, 1, 3, 916, 2, 31098, 214, 26, 7794, 71, 44, 85, 1027, 348, 4, 780, 1765, 132, 62, 1077, 207, 1, 347, 16, 1197, 6, 223, 3, 177, 724, 1, 26, 10294, 1528]",861.0,20417863,311
Modern treatment programs for adults with acute lymphoblastic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2007-07-01,"The current treatment programs for adult patients with acute lymphoblastic leukemia are modeled on pediatric regimens. The result has been complete remission rates comparable to those seen in children, but a significant proportion of adult patients relapse. Salvage therapy for patients with acute lymphoblastic leukemia continues to have limited success. Advances in molecular biology have discovered new targets for therapeutic intervention, and the introduction of some targeted agents, such as the new tyrosine kinase inhibitors and monoclonal antibodies, has led to improvements in response and survival in some subsets. The development of techniques for identification and monitoring of minimal residual leukemia has provided possible ways to predict relapse and consider early intervention. It is likely that we will further refine therapeutic approaches and improve patient outcome through the translation of biologic and molecular discoveries into effective and risk-adapted strategies.",Journal Article,4587.0,1.0,The current treatment programs for adult patients with acute lymphoblastic are modeled on pediatric regimens The result has been complete remission rates comparable to those seen in children but a significant proportion of adult patients relapse Salvage therapy for patients with acute lymphoblastic continues to have limited success Advances in molecular biology have discovered new targets for therapeutic intervention and the introduction of some targeted agents such as the new tyrosine kinase inhibitors and monoclonal antibodies has led to improvements in response and survival in some subsets The development of techniques for identification and monitoring of minimal residual has provided possible ways to predict relapse and consider early intervention It is likely that we will further refine therapeutic approaches and improve patient outcome through the translation of biologic and molecular discoveries into effective and risk-adapted strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 291, 24, 2251, 9, 780, 7, 5, 286, 1275, 32, 4666, 23, 815, 472, 3, 757, 71, 85, 236, 734, 151, 1279, 6, 135, 527, 4, 541, 84, 8, 93, 920, 1, 780, 7, 429, 992, 36, 9, 7, 5, 286, 1275, 2274, 6, 47, 383, 1825, 954, 4, 219, 891, 47, 2747, 217, 637, 9, 189, 788, 2, 3, 2456, 1, 476, 238, 183, 225, 22, 3, 217, 564, 216, 222, 2, 848, 890, 71, 836, 6, 1474, 4, 51, 2, 25, 4, 476, 1890, 3, 193, 1, 1092, 9, 911, 2, 1315, 1, 1048, 753, 71, 1052, 899, 4245, 6, 678, 429, 2, 2419, 191, 788, 192, 16, 322, 17, 21, 303, 195, 5003, 189, 611, 2, 401, 69, 228, 298, 3, 2691, 1, 1283, 2, 219, 5012, 237, 323, 2, 43, 3716, 422]",958.0,20425366,699
Novel therapies for relapsed acute lymphoblastic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2009-07-01,"The outcome of salvage therapy for relapsed acute lymphoblastic leukemia (ALL) remains poor. Salvage therapy mimics regimens with activity in newly diagnosed ALL. Novel strategies under investigation as monotherapy or in combination with chemotherapy improve the treatment of relapsed disease. For some ALL subsets, specific therapies are indicated. The addition of targeted therapy in Philadelphia chromo some-positive ALL has improved responses in relapsed patients without resistance to available tyrosine kinase inhibitors. Nelarabine demonstrates activity as monotherapy in T-cell ALL and is approved by the US Food and Drug Administration. Clofarabine, a second-generation purine analogue approved in pediatric leukemia, has shown activity in adult acute leukemias including ALL and acute myeloid leukemia. The role of pegaspargase in adult ALL requires further investigation. The benefit of matched related-donor allogeneic stem cell transplantation is significant for standard-risk ALL but not for high-risk ALL. Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics remains vital to success in treating adult ALL.",Journal Article,3856.0,13.0,The outcome of salvage therapy for relapsed acute lymphoblastic ALL remains poor Salvage therapy mimics regimens with activity in newly diagnosed ALL Novel strategies under investigation as monotherapy or in combination with chemotherapy improve the treatment of relapsed disease For some ALL subsets specific therapies are indicated The addition of targeted therapy in Philadelphia chromo some-positive ALL has improved responses in relapsed patients without resistance to available tyrosine kinase inhibitors Nelarabine demonstrates activity as monotherapy in T-cell ALL and is approved by the US Food and Drug Administration Clofarabine a second-generation purine analogue approved in pediatric has shown activity in adult acute leukemias including ALL and acute myeloid The role of pegaspargase in adult ALL requires further investigation The benefit of matched related-donor allogeneic stem cell transplantation is significant for standard-risk ALL but not for high-risk ALL Development of new drugs and agents tailored to subset-specific cytogenetic-molecular characteristics remains vital to success in treating adult ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 228, 1, 992, 36, 9, 591, 286, 1275, 62, 469, 334, 992, 36, 7557, 472, 5, 128, 4, 732, 265, 62, 229, 422, 669, 940, 22, 1411, 15, 4, 150, 5, 56, 401, 3, 24, 1, 591, 34, 9, 476, 62, 1890, 112, 235, 32, 1103, 3, 352, 1, 238, 36, 4, 3006, 58899, 476, 109, 62, 71, 231, 253, 4, 591, 7, 187, 251, 6, 390, 564, 216, 222, 13149, 1902, 128, 22, 1411, 4, 102, 31, 62, 2, 16, 850, 20, 3, 843, 1773, 2, 234, 634, 4149, 8, 419, 914, 5006, 4696, 850, 4, 815, 71, 443, 128, 4, 780, 286, 2792, 141, 62, 2, 286, 533, 3, 200, 1, 12209, 4, 780, 62, 1706, 195, 940, 3, 247, 1, 655, 139, 1488, 1063, 452, 31, 497, 16, 93, 9, 260, 43, 62, 84, 44, 9, 64, 43, 62, 193, 1, 217, 600, 2, 183, 3632, 6, 697, 112, 1266, 219, 374, 469, 3511, 6, 1825, 4, 1367, 780, 62]",1128.0,20425428,208
New agents for the treatment of patients with acute lymphoblastic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2008-07-01,"Acute lymphoblastic leukemia (ALL) has a bimodal age distribution with a peak occurring during early childhood and a second peak after age 45. Although all patients are treated with similar intensive chemotherapy regimens, good outcomes have occurred more frequently in children than adults. Most children with ALL have been able to achieve a complete remission (CR) with an induction rate of about 98% and a 5-year estimated event-free survival rate (EFS) rate of about 80%. Unfortunately, the results for adults are less encouraging. Current adult treatment regimens result in CR rates approaching 80%, with EFS at 5 years of only 30% to 40%. Regardless of age, patients with relapsed or refractory ALL have extremely poor outcomes, because CR rates are low and seldom durable. Clearly, new agents are required to improve the outcome of patients with relapsed or refractory ALL.",Journal Article,4221.0,1.0,Acute lymphoblastic ALL has a bimodal age distribution with a peak occurring during early childhood and a second peak after age 45 Although all patients are treated with similar intensive chemotherapy regimens good outcomes have occurred more frequently in children than adults Most children with ALL have been able to achieve a complete remission CR with an induction rate of about 98 and a 5-year estimated event-free survival rate EFS rate of about 80 Unfortunately the results for adults are less encouraging Current adult treatment regimens result in CR rates approaching 80 with EFS at 5 years of only 30 to 40 Regardless of age patients with relapsed or refractory ALL have extremely poor outcomes because CR rates are low and seldom durable Clearly new agents are required to improve the outcome of patients with relapsed or refractory ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 71, 8, 18225, 89, 1395, 5, 8, 2944, 1821, 190, 191, 864, 2, 8, 419, 2944, 50, 89, 512, 242, 62, 7, 32, 73, 5, 288, 1686, 56, 472, 1178, 123, 47, 489, 80, 746, 4, 541, 76, 857, 96, 541, 5, 62, 47, 85, 1665, 6, 1359, 8, 236, 734, 684, 5, 35, 504, 116, 1, 545, 1096, 2, 8, 33, 111, 661, 774, 115, 25, 116, 1683, 116, 1, 545, 493, 3869, 3, 99, 9, 857, 32, 299, 2269, 291, 780, 24, 472, 757, 4, 684, 151, 7773, 493, 5, 1683, 28, 33, 60, 1, 158, 201, 6, 327, 1583, 1, 89, 7, 5, 591, 15, 430, 62, 47, 2938, 334, 123, 408, 684, 151, 32, 154, 2, 10805, 1480, 2536, 217, 183, 32, 616, 6, 401, 3, 228, 1, 7, 5, 591, 15, 430, 62]",847.0,20425458,532
Approaches to treatment for acute lymphoblastic leukemia in adolescents and young adults.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2008-07-01,"Acute lymphoblastic leukemia affects infants, children, adolescents, and adults. Although most children have a high likelihood of cure, outcomes in adults have much room for improvement. In between lies the adolescent and young adult population, not only in terms of age but also in clinical success rates. This review describes biology, prognostic factors, and treatment approaches in adolescents and young adults with acute lymphoblastic leukemia. Assessing the outcomes in adult and pediatric clinical trials that enroll adolescents and young adults can be especially useful in determining how best to treat these patients. Current new treatment strategies are also discussed.",Journal Article,4221.0,0.0,Acute lymphoblastic affects infants children adolescents and adults Although most children have a high likelihood of cure outcomes in adults have much room for improvement In between lies the adolescent and young adult population not only in terms of age but also in clinical success rates This review describes biology prognostic factors and treatment approaches in adolescents and young adults with acute lymphoblastic Assessing the outcomes in adult and pediatric clinical trials that enroll adolescents and young adults can be especially useful in determining how best to treat these patients Current new treatment strategies are also discussed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 2561, 5585, 541, 3101, 2, 857, 242, 96, 541, 47, 8, 64, 1420, 1, 1722, 123, 4, 857, 47, 1802, 4698, 9, 767, 4, 59, 9247, 3, 3678, 2, 1169, 780, 266, 44, 158, 4, 1794, 1, 89, 84, 120, 4, 38, 1825, 151, 26, 206, 2677, 891, 177, 130, 2, 24, 611, 4, 3101, 2, 1169, 857, 5, 286, 1275, 1977, 3, 123, 4, 780, 2, 815, 38, 143, 17, 6559, 3101, 2, 1169, 857, 122, 40, 1093, 999, 4, 2196, 832, 824, 6, 943, 46, 7, 291, 217, 24, 422, 32, 120, 1588]",648.0,20425459,117
Acute lymphoblastic leukemia in adolescents and young adults.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2008-07-01,"Age at diagnosis remains one of the strongest prognostic factors in acute lymphoblastic leukemia (ALL), with older patients having inferior outcomes compared with younger patients. Adolescents and young adults (AYAs) with ALL (age 15-30 years) represent a patient subgroup with distinctive biology whose optimal therapy has yet to be determined. Compared with younger children with ALL, AYAs are more likely to present with unfavorable presenting characteristics (such as high presenting leukocyte counts, T-cell phenotype, and the Philadelphia chromosome). Additionally, AYAs with ALL experience more regimen-related toxicity than younger patients. Recent retrospective studies suggest that patients age 15 to 21 years treated on pediatric ALL regimens have better outcomes than similarly aged patients treated on adult ALL regimens. Pilot prospective studies are under way to test the feasibility of administering pediatric ALL regimens to AYAs with ALL, with promising preliminary results.",Journal Article,4221.0,10.0,Age at diagnosis remains one of the strongest prognostic factors in acute lymphoblastic ALL with older patients having inferior outcomes compared with younger patients Adolescents and young adults AYAs with ALL age 15-30 years represent a patient subgroup with distinctive biology whose optimal therapy has yet to be determined Compared with younger children with ALL AYAs are more likely to present with unfavorable presenting characteristics such as high presenting leukocyte counts T-cell phenotype and the Philadelphia chromosome Additionally AYAs with ALL experience more regimen-related toxicity than younger patients Recent retrospective studies suggest that patients age 15 to 21 years treated on pediatric ALL regimens have better outcomes than similarly aged patients treated on adult ALL regimens Pilot prospective studies are under way to test the feasibility of administering pediatric ALL regimens to AYAs with ALL with promising preliminary results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[89, 28, 147, 469, 104, 1, 3, 3311, 177, 130, 4, 286, 1275, 62, 5, 434, 7, 1041, 1663, 123, 72, 5, 773, 7, 3101, 2, 1169, 857, 6145, 5, 62, 89, 167, 201, 60, 1231, 8, 69, 1363, 5, 5049, 891, 1310, 665, 36, 71, 1145, 6, 40, 509, 72, 5, 773, 541, 5, 62, 6145, 32, 80, 322, 6, 364, 5, 2483, 1656, 374, 225, 22, 64, 1656, 3627, 1911, 102, 31, 1005, 2, 3, 3006, 1170, 1724, 6145, 5, 62, 730, 80, 477, 139, 155, 76, 773, 7, 435, 459, 94, 309, 17, 7, 89, 167, 6, 239, 60, 73, 23, 815, 62, 472, 47, 380, 123, 76, 1813, 1032, 7, 73, 23, 780, 62, 472, 2281, 482, 94, 32, 669, 2255, 6, 412, 3, 1437, 1, 5776, 815, 62, 472, 6, 6145, 5, 62, 5, 721, 1676, 99]",963.0,20425461,165
Neurocognitive functioning in adult survivors of childhood non-central nervous system cancers.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2010-05-10,"BACKGROUND We sought to measure self-reported neurocognitive functioning among survivors of non-central nervous system (CNS) childhood cancers, overall and compared with a sibling cohort, and to identify factors associated with worse functioning. METHODS In a retrospective cohort study, 5937 adult survivors of non-CNS cancers and 382 siblings completed a validated neuropsychological instrument with subscales in task efficiency, emotional regulation, organization, and memory. Scores were converted to T scores; scores in the worst 10% of siblings' scores (ie, T score > or =63) were defined as impaired. Non-CNS cancer survivors and siblings were compared with multivariable linear regression and log-binomial regression. Among survivors, log-binomial models assessed the association of patient and treatment factors with neurocognitive dysfunction. All statistical tests were two-sided. RESULTS Non-CNS cancer survivors had similar or slightly worse (<0.5 standard deviation) mean test scores for all four subscales than siblings. However, frequencies of impaired survivors were approximately 50% higher than siblings in task efficiency (13.0% of survivors vs 7.3% of siblings), memory (12.5% vs 7.6%), and emotional regulation (21.2% vs 14.4%). Impaired task efficiency was most often identified in patients with acute lymphoblastic leukemia who received cranial radiation therapy (18.1% with impairment), myeloid leukemia who received cranial radiation therapy (21.2%), and non-Hodgkin lymphoma (13.9%). In adjusted analysis, diagnosis age of younger than 6 years, female sex, cranial radiation therapy, and hearing impairment were associated with impairment. CONCLUSION A statistically and clinically significantly higher percentage of self-reported neurocognitive impairment was found among survivors of non-CNS cancers than among siblings.",Journal Article,3543.0,103.0,BACKGROUND We sought to measure self-reported neurocognitive functioning among survivors of non-central nervous system CNS childhood cancers overall and compared with a sibling cohort and to identify factors associated with worse functioning METHODS In a retrospective cohort study 5937 adult survivors of non-CNS cancers and 382 siblings completed a validated neuropsychological instrument with subscales in task efficiency emotional regulation organization and memory Scores were converted to T scores scores in the worst 10 of siblings scores ie T score or =63 were defined as impaired Non-CNS cancer survivors and siblings were compared with multivariable linear regression and log-binomial regression Among survivors log-binomial models assessed the association of patient and treatment factors with neurocognitive dysfunction All statistical tests were two-sided RESULTS Non-CNS cancer survivors had similar or slightly worse 0.5 standard deviation mean test scores for all four subscales than siblings However frequencies of impaired survivors were approximately 50 higher than siblings in task efficiency 13.0 of survivors vs 7.3 of siblings memory 12.5 vs 7.6 and emotional regulation 21.2 vs 14.4 Impaired task efficiency was most often identified in patients with acute lymphoblastic who received cranial radiation therapy 18.1 with impairment myeloid who received cranial radiation therapy 21.2 and 13.9 In adjusted analysis diagnosis age of younger than 6 years female sex cranial radiation therapy and hearing impairment were associated with impairment CONCLUSION A statistically and clinically significantly higher percentage of self-reported neurocognitive impairment was found among survivors of non-CNS cancers than among siblings,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2426, 21, 990, 6, 1463, 1074, 210, 2958, 2702, 107, 332, 1, 220, 854, 1880, 398, 1025, 864, 163, 63, 2, 72, 5, 8, 3684, 180, 2, 6, 255, 130, 41, 5, 639, 2702, 636, 4, 8, 459, 180, 45, 58932, 780, 332, 1, 220, 1025, 163, 2, 9625, 2758, 781, 8, 938, 8271, 3877, 5, 6472, 4, 3488, 2904, 2671, 863, 2533, 2, 2407, 703, 11, 4764, 6, 102, 703, 703, 4, 3, 4066, 79, 1, 2758, 703, 2523, 102, 368, 15, 676, 11, 395, 22, 2364, 220, 1025, 12, 332, 2, 2758, 11, 72, 5, 658, 1646, 320, 2, 1066, 8538, 320, 107, 332, 1066, 8538, 274, 275, 3, 248, 1, 69, 2, 24, 130, 5, 2958, 1527, 62, 1050, 895, 11, 100, 1689, 99, 220, 1025, 12, 332, 42, 288, 15, 3223, 639, 13, 33, 260, 3348, 313, 412, 703, 9, 62, 294, 6472, 76, 2758, 137, 2722, 1, 2364, 332, 11, 705, 212, 142, 76, 2758, 4, 3488, 2904, 233, 13, 1, 332, 105, 67, 27, 1, 2758, 2407, 133, 33, 105, 67, 49, 2, 2671, 863, 239, 18, 105, 213, 39, 2364, 3488, 2904, 10, 96, 629, 108, 4, 7, 5, 286, 1275, 54, 103, 2565, 121, 36, 203, 14, 5, 2315, 533, 54, 103, 2565, 121, 36, 239, 18, 2, 233, 83, 4, 586, 65, 147, 89, 1, 773, 76, 49, 60, 1061, 1035, 2565, 121, 36, 2, 4396, 2315, 11, 41, 5, 2315, 1221, 8, 712, 2, 505, 97, 142, 1150, 1, 1074, 210, 2958, 2315, 10, 204, 107, 332, 1, 220, 1025, 163, 76, 107, 2758]",1748.0,20458059,86
Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias.,Haematologica,Haematologica,2010-05-11,"A pharmacokinetically derived schedule of flavopiridol administered as a 30 min intravenous bolus followed by 4-hour continuous intravenous infusion (IVB/CIVI) is active in fludarabine-refractory chronic lymphocytic leukemia, but no studies examining the feasibility and maximum tolerated dose of this schedule have been reported in acute leukemia. We conducted a phase I dose escalation trial of single-agent flavopiridol in adults with relapsed/refractory acute leukemias, utilizing a modification of the intravenous bolus/continuous intravenous infusion approach, intensifying treatment for administration on days 1, 2, and 3 of 21-day cycles. Twenty-four adults with relapsed/refractory acute myeloid leukemia (n=19) or acute lymphoblastic leukemia (n=5) were enrolled. The median age was 62 years (range, 23-78). The maximum tolerated dose of flavopiridol was 40 mg/m(2) intravenous bolus plus 60 mg/m(2) continuous intravenous infusion (40/60). The dose limiting toxicity was secretory diarrhea. Life-threatening hyperacute tumor lysis syndrome requiring hemodialysis on day 1 was observed in one patient. Pharmacokinetics were dose-dependent with increased clearance observed at the two highest dose levels. Diarrhea occurrence and severity significantly correlated with flavopiridol concentrations at the end of the 4-hour infusion, volume of distribution, and elimination half-life. Modest anti-leukemic activity was observed, with most patients experiencing dramatic but transient reduction/clearance of circulating blasts lasting for 10-14 days. One refractory acute myeloid leukemia patient had short-lived complete remission with incomplete count recovery. Flavopiridol as a single agent given by intravenous bolus/continuous intravenous infusion causes marked, immediate cytoreduction in relapsed/refractory acute leukemias, but objective clinical responses were uncommon. With this schedule, the dose is limited by secretory diarrhea.","Clinical Trial, Phase I",3542.0,40.0,A pharmacokinetically derived schedule of flavopiridol administered as a 30 min intravenous bolus followed by 4-hour continuous intravenous infusion IVB/CIVI is active in fludarabine-refractory chronic lymphocytic but no studies examining the feasibility and maximum tolerated dose of this schedule have been reported in acute We conducted a phase I dose escalation trial of single-agent flavopiridol in adults with relapsed/refractory acute leukemias utilizing a modification of the intravenous bolus/continuous intravenous infusion approach intensifying treatment for administration on days 1 2 and 3 of 21-day cycles Twenty-four adults with relapsed/refractory acute myeloid n=19 or acute lymphoblastic n=5 were enrolled The median age was 62 years range 23-78 The maximum tolerated dose of flavopiridol was 40 mg/m 2 intravenous bolus plus 60 mg/m 2 continuous intravenous infusion 40/60 The dose limiting toxicity was secretory diarrhea Life-threatening hyperacute tumor lysis syndrome requiring hemodialysis on day 1 was observed in one patient Pharmacokinetics were dose-dependent with increased clearance observed at the two highest dose levels Diarrhea occurrence and severity significantly correlated with flavopiridol concentrations at the end of the 4-hour infusion volume of distribution and elimination half-life Modest anti-leukemic activity was observed with most patients experiencing dramatic but transient reduction/clearance of circulating blasts lasting for 10-14 days One refractory acute myeloid patient had short-lived complete remission with incomplete count recovery Flavopiridol as a single agent given by intravenous bolus/continuous intravenous infusion causes marked immediate cytoreduction in relapsed/refractory acute leukemias but objective clinical responses were uncommon With this schedule the dose is limited by secretory diarrhea,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[8, 14920, 526, 1055, 1, 3030, 468, 22, 8, 201, 1538, 1262, 3604, 370, 20, 39, 2583, 1314, 1262, 904, 7042, 18907, 16, 544, 4, 2027, 430, 442, 1193, 84, 77, 94, 3282, 3, 1437, 2, 689, 421, 61, 1, 26, 1055, 47, 85, 210, 4, 286, 21, 426, 8, 124, 70, 61, 1125, 160, 1, 226, 420, 3030, 4, 857, 5, 591, 430, 286, 2792, 2600, 8, 2437, 1, 3, 1262, 3604, 1314, 1262, 904, 353, 20150, 24, 9, 634, 23, 162, 14, 18, 2, 27, 1, 239, 218, 410, 737, 294, 857, 5, 591, 430, 286, 533, 78, 326, 15, 286, 1275, 78, 33, 11, 346, 3, 52, 89, 10, 744, 60, 184, 382, 833, 3, 689, 421, 61, 1, 3030, 10, 327, 81, 188, 18, 1262, 3604, 349, 335, 81, 188, 18, 1314, 1262, 904, 327, 335, 3, 61, 817, 155, 10, 7106, 1172, 358, 3691, 44487, 30, 4783, 681, 1888, 11170, 23, 218, 14, 10, 164, 4, 104, 69, 1159, 11, 61, 470, 5, 101, 1960, 164, 28, 3, 100, 1076, 61, 148, 1172, 2291, 2, 1702, 97, 438, 5, 3030, 1003, 28, 3, 396, 1, 3, 39, 2583, 904, 433, 1, 1395, 2, 3730, 1303, 358, 1721, 312, 2015, 128, 10, 164, 5, 96, 7, 2985, 3079, 84, 2473, 628, 1960, 1, 1033, 2438, 3443, 9, 79, 213, 162, 104, 430, 286, 533, 69, 42, 978, 4813, 236, 734, 5, 2610, 1276, 1602, 3030, 22, 8, 226, 420, 447, 20, 1262, 3604, 1314, 1262, 904, 1626, 2003, 2181, 2844, 4, 591, 430, 286, 2792, 84, 461, 38, 253, 11, 2052, 5, 26, 1055, 3, 61, 16, 383, 20, 7106, 1172]",1867.0,20460644,184
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia.,Blood,Blood,2010-05-13,"The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL). Dasatinib has significant clinical activity in patients with imatinib resistance. We examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph(+) ALL. Newly diagnosed patients received dasatinib 50 mg by mouth twice per day (or 100 mg daily) for the first 14 days of each of 8 cycles of alternating hyper-CVAD, and high-dose cytarabine and methotrexate. Patients in complete remission received maintenance daily dasatinib and monthly vincristine and prednisone for 2 years, followed by dasatinib indefinitely. Thirty-five patients with untreated Ph(+) ALL with a median age of 53 years (range, 21-79 years) were treated; 33 patients (94%) achieved complete remission. Two patients died of infections before response assessment. Grade 3 and 4 adverse events included hemorrhage and pleural and pericardial effusions. With a median follow-up of 14 months (range, 4-37 months), the median disease-free survival and median overall survival have not been reached, with an estimated 2-year survival of 64%. The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph(+) ALL. This study was registered at www.ClinicalTrials.gov as NCT00390793.","Clinical Trial, Phase II",3540.0,214.0,The combination of cytotoxic chemotherapy and imatinib has improved the outcome for patients with Philadelphia chromosome-positive Ph acute lymphoblastic ALL Dasatinib has significant clinical activity in patients with imatinib resistance We examined the efficacy and safety of combining chemotherapy with dasatinib for patients with Ph ALL Newly diagnosed patients received dasatinib 50 mg by mouth twice per day or 100 mg daily for the first 14 days of each of 8 cycles of alternating hyper-CVAD and high-dose cytarabine and methotrexate Patients in complete remission received maintenance daily dasatinib and monthly vincristine and prednisone for 2 years followed by dasatinib indefinitely Thirty-five patients with untreated Ph ALL with a median age of 53 years range 21-79 years were treated 33 patients 94 achieved complete remission Two patients died of infections before response assessment Grade 3 and 4 adverse events included hemorrhage and pleural and pericardial effusions With a median follow-up of 14 months range 4-37 months the median disease-free survival and median overall survival have not been reached with an estimated 2-year survival of 64 The combination of chemotherapy with dasatinib is effective in achieving long-term remissions in patients with newly diagnosed Ph ALL This study was registered at www.ClinicalTrials.gov as NCT00390793,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 150, 1, 759, 56, 2, 577, 71, 231, 3, 228, 9, 7, 5, 3006, 1170, 109, 2058, 286, 1275, 62, 1674, 71, 93, 38, 128, 4, 7, 5, 577, 251, 21, 409, 3, 209, 2, 367, 1, 1525, 56, 5, 1674, 9, 7, 5, 2058, 62, 732, 265, 7, 103, 1674, 212, 81, 20, 5831, 936, 379, 218, 15, 394, 81, 391, 9, 3, 157, 213, 162, 1, 296, 1, 66, 410, 1, 5181, 4855, 5574, 2, 64, 61, 1855, 2, 2116, 7, 4, 236, 734, 103, 1146, 391, 1674, 2, 3889, 2132, 2, 1979, 9, 18, 60, 370, 20, 1674, 13931, 977, 365, 7, 5, 1278, 2058, 62, 5, 8, 52, 89, 1, 699, 60, 184, 239, 842, 60, 11, 73, 466, 7, 960, 513, 236, 734, 100, 7, 1016, 1, 1875, 348, 51, 455, 88, 27, 2, 39, 290, 281, 159, 3599, 2, 2164, 2, 6657, 5154, 5, 8, 52, 166, 126, 1, 213, 53, 184, 39, 567, 53, 3, 52, 34, 115, 25, 2, 52, 63, 25, 47, 44, 85, 1300, 5, 35, 661, 18, 111, 25, 1, 660, 3, 150, 1, 56, 5, 1674, 16, 323, 4, 1785, 319, 337, 3166, 4, 7, 5, 732, 265, 2058, 62, 26, 45, 10, 1653, 28, 3064, 1252, 1239, 22, 58949]",1365.0,20466853,296
The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo.,PloS one,PLoS ONE,2010-06-03,"While deacetylase (DAC) inhibitors show promise for the treatment of B-cell malignancies, those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only, and have shown suboptimal activity or unacceptable toxicities. We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies. In mantle cell lymphoma (JeKo-1), Burkitt's lymphoma (Raji), and acute lymphoblastic leukemia (697) cell lines, the 48-hr IC(50) (50% growth inhibitory concentration) of AR-42 is 0.61 microM or less. In chronic lymphocytic leukemia (CLL) patient cells, the 48-hr LC(50) (concentration lethal to 50%) of AR-42 is 0.76 microM. AR-42 produces dose- and time-dependent acetylation both of histones and tubulin, and induces caspase-dependent apoptosis that is not reduced in the presence of stromal cells. AR-42 also sensitizes CLL cells to TNF-Related Apoptosis Inducing Ligand (TRAIL), potentially through reduction of c-FLIP. AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity. Together, these data demonstrate that AR-42 has in vitro and in vivo efficacy at tolerable doses. These results strongly support upcoming phase I testing of AR-42 in B-cell malignancies.",Journal Article,3519.0,42.0,While deacetylase DAC inhibitors show promise for the treatment of B-cell malignancies those introduced to date are weak inhibitors of class I and II DACs or potent inhibitors of class I DAC only and have shown suboptimal activity or unacceptable toxicities We therefore investigated the novel DAC inhibitor AR-42 to determine its efficacy in B-cell malignancies In mantle cell JeKo-1 's Raji and acute lymphoblastic 697 cell lines the 48-hr IC 50 50 growth inhibitory concentration of AR-42 is 0.61 microM or less In chronic lymphocytic CLL patient cells the 48-hr LC 50 concentration lethal to 50 of AR-42 is 0.76 microM AR-42 produces dose- and time-dependent acetylation both of histones and tubulin and induces caspase-dependent apoptosis that is not reduced in the presence of stromal cells AR-42 also sensitizes CLL cells to TNF-Related Apoptosis Inducing Ligand TRAIL potentially through reduction of c-FLIP AR-42 significantly reduced leukocyte counts and/or prolonged survival in three separate mouse models of B-cell malignancy without evidence of toxicity Together these data demonstrate that AR-42 has in vitro and in vivo efficacy at tolerable doses These results strongly support upcoming phase I testing of AR-42 in B-cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,1,0,0,0,0,0,"[369, 2732, 6140, 222, 514, 1783, 9, 3, 24, 1, 132, 31, 441, 135, 3955, 6, 1244, 32, 4241, 222, 1, 1040, 70, 2, 215, 59052, 15, 1157, 222, 1, 1040, 70, 6140, 158, 2, 47, 443, 3291, 128, 15, 3215, 385, 21, 673, 565, 3, 229, 6140, 230, 754, 595, 6, 223, 211, 209, 4, 132, 31, 441, 4, 2757, 31, 22435, 14, 292, 9868, 2, 286, 1275, 11989, 31, 285, 3, 576, 168, 2340, 212, 212, 129, 1810, 1227, 1, 754, 595, 16, 13, 713, 3550, 15, 299, 4, 442, 1193, 552, 69, 37, 3, 576, 168, 1837, 212, 1227, 2266, 6, 212, 1, 754, 595, 16, 13, 846, 3550, 754, 595, 4042, 61, 2, 98, 470, 4145, 110, 1, 8457, 2, 5303, 2, 1516, 1469, 470, 351, 17, 16, 44, 405, 4, 3, 463, 1, 1126, 37, 754, 595, 120, 6229, 552, 37, 6, 2254, 139, 351, 1958, 1232, 2585, 751, 298, 628, 1, 256, 9334, 754, 595, 97, 405, 3627, 1911, 2, 15, 1069, 25, 4, 169, 2282, 830, 274, 1, 132, 31, 710, 187, 241, 1, 155, 1162, 46, 74, 608, 17, 754, 595, 71, 4, 439, 2, 4, 386, 209, 28, 2668, 415, 46, 99, 1327, 538, 11974, 124, 70, 471, 1, 754, 595, 4, 132, 31, 441]",1251.0,20532179,641
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells.,Investigational new drugs,Invest New Drugs,2010-06-09,"The prognosis of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is poor. Chemotherapy is rarely curative and tyrosine kinase inhibitors (TKIs) induce only transient responses. Heat shock protein 90 (Hsp90) is a chaperone protein that is important in signal transduction, cell cycle control, and transcription regulation in both normal and leukemia cells. In the current study, we tested the growth inhibitory and apoptotic effects of a novel Hsp90 inhibitor, EC141 on the Ph+ ALL lines Z-119, Z-181, and Z-33, as well as primary bone marrow-derived blasts from patients with newly diagnosed Ph+ ALL. We found that EC141 inhibited the growth of Ph+ ALL cells in a concentration-dependent manner with IC(50) ranged from 1 to 10nM. EC141 also inhibited the proliferation of primary bone marrow-derived blasts using the ALL blast colony assay. EC141 down-regulated Hsp90 and up-regulated Hsp70 protein levels, inhibited CrkL phosphorylation, and induced degradation of Bcr-Abl p190 protein through ubiquitin-dependent proteasomal pathway. Furthermore, exposure of Ph+ ALL cells to EC141 resulted in activation of caspase-3, cleavage of poly (ADP-ribose) polymerase (PARP), and induction of apoptosis. In conclusion, our data suggest that EC141 is a potent Hsp90 inhibitor with activity against Ph+ ALL. Further studies to investigate the anticancer effect of EC141 either as a single agent, or in combination in Ph+ ALL and other hematological malignancies are warranted.",Journal Article,3513.0,7.0,The prognosis of patients with Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL is poor Chemotherapy is rarely curative and tyrosine kinase inhibitors TKIs induce only transient responses Heat shock protein 90 Hsp90 is a chaperone protein that is important in signal transduction cell cycle control and transcription regulation in both normal and cells In the current study we tested the growth inhibitory and apoptotic effects of a novel Hsp90 inhibitor EC141 on the Ph+ ALL lines Z-119 Z-181 and Z-33 as well as primary marrow-derived blasts from patients with newly diagnosed Ph+ ALL We found that EC141 inhibited the growth of Ph+ ALL cells in a concentration-dependent manner with IC 50 ranged from 1 to 10 nM EC141 also inhibited the proliferation of primary marrow-derived blasts using the ALL blast colony assay EC141 down-regulated Hsp90 and up-regulated Hsp70 protein levels inhibited CrkL phosphorylation and induced degradation of Bcr-Abl p190 protein through ubiquitin-dependent proteasomal pathway Furthermore exposure of Ph+ ALL cells to EC141 resulted in activation of caspase-3 cleavage of poly ADP-ribose polymerase PARP and induction of apoptosis In conclusion our data suggest that EC141 is a potent Hsp90 inhibitor with activity against Ph+ ALL Further studies to investigate the anticancer effect of EC141 either as a single agent or in combination in Ph+ ALL and other hematological malignancies are warranted,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 1, 7, 5, 3006, 1170, 109, 2058, 286, 1275, 62, 16, 334, 56, 16, 2416, 1075, 2, 564, 216, 222, 1671, 1290, 158, 2473, 253, 3545, 3971, 178, 424, 2515, 16, 8, 7255, 178, 17, 16, 305, 4, 1235, 2761, 31, 417, 182, 2, 866, 863, 4, 110, 295, 2, 37, 4, 3, 291, 45, 21, 650, 3, 129, 1810, 2, 1631, 176, 1, 8, 229, 2515, 230, 26951, 23, 3, 2058, 62, 285, 3905, 4299, 3905, 5540, 2, 3905, 466, 22, 149, 22, 86, 581, 526, 2438, 29, 7, 5, 732, 265, 2058, 62, 21, 204, 17, 26951, 879, 3, 129, 1, 2058, 62, 37, 4, 8, 1227, 470, 1708, 5, 2340, 212, 1869, 29, 14, 6, 79, 2878, 26951, 120, 879, 3, 457, 1, 86, 581, 526, 2438, 75, 3, 62, 3112, 1975, 719, 26951, 1328, 1065, 2515, 2, 126, 1065, 6126, 178, 148, 879, 13765, 982, 2, 277, 2373, 1, 1062, 1425, 18813, 178, 298, 4213, 470, 10033, 308, 798, 645, 1, 2058, 62, 37, 6, 26951, 627, 4, 363, 1, 1469, 27, 3155, 1, 2699, 3638, 3507, 1451, 2041, 2, 504, 1, 351, 4, 1221, 114, 74, 309, 17, 26951, 16, 8, 1157, 2515, 230, 5, 128, 480, 2058, 62, 195, 94, 6, 963, 3, 1475, 254, 1, 26951, 361, 22, 8, 226, 420, 15, 4, 150, 4, 2058, 62, 2, 127, 2890, 441, 32, 1197]",1444.0,20533075,0
"Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.",Cancer,Cancer,2010-10-01,"In previous studies of frontline therapy for adult acute lymphoblastic leukemia (ALL), early treatment with higher doses of anthracyclines has been reported to improve outcome. The current study was conducted to evaluate whether addition of anthracycline-based consolidation chemotherapy (Course 2) with liposomal daunorubicin (150 mg/m2 intravenously [IV] on Days 1 and 2) and cytarabine (1.5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome. Sixty-eight consecutive adults with de novo ALL or lymphoblastic lymphoma were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression20%. Sixty-three (93%) patients achieved complete response (CR). With a median follow-up of 90 months, the 5-year CR duration (CRD) and overall survival (OS) rates were 46% and 44%, respectively. Compared with 208 patients treated with standard hyper-CVAD (rates of 45% and 47%, respectively; P=not significant), outcome with the modified hyper-CVAD regimen was not improved overall. Outcome was improved by the addition of rituximab for the CD20-positive subset (rates of CRD and OS of 50% and 53%, respectively), whereas anthracycline intensification worsened outcome for the CD20-negative subset (rates of CRD and OS of 41% and 35%, respectively; P=.01) compared with standard hyper-CVAD. A high mortality rate related to infections in CR was noted among patients aged 60 years or older. In the context of the hyper-CVAD regimen, early anthracycline intensification did not improve outcome for adults with de novo ALL or lymphoblastic lymphoma.",Journal Article,3399.0,12.0,In previous studies of frontline therapy for adult acute lymphoblastic ALL early treatment with higher doses of anthracyclines has been reported to improve outcome The current study was conducted to evaluate whether addition of anthracycline-based consolidation chemotherapy Course 2 with liposomal daunorubicin 150 mg/m2 intravenously IV on Days 1 and 2 and cytarabine 1.5 g/m2 IV on Days 1 and 2 to the standard hyper-CVAD regimen fractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with high dose methotrexate and cytarabine would improve outcome Sixty-eight consecutive adults with de novo ALL or lymphoblastic were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression20 Sixty-three 93 patients achieved complete response CR With a median follow-up of 90 months the 5-year CR duration CRD and overall survival OS rates were 46 and 44 respectively Compared with 208 patients treated with standard hyper-CVAD rates of 45 and 47 respectively P=not significant outcome with the modified hyper-CVAD regimen was not improved overall Outcome was improved by the addition of rituximab for the CD20-positive subset rates of CRD and OS of 50 and 53 respectively whereas anthracycline intensification worsened outcome for the CD20-negative subset rates of CRD and OS of 41 and 35 respectively P=.01 compared with standard hyper-CVAD A high mortality rate related to infections in CR was noted among patients aged 60 years or older In the context of the hyper-CVAD regimen early anthracycline intensification did not improve outcome for adults with de novo ALL or lymphoblastic,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 698, 94, 1, 3171, 36, 9, 780, 286, 1275, 62, 191, 24, 5, 142, 415, 1, 3597, 71, 85, 210, 6, 401, 228, 3, 291, 45, 10, 426, 6, 376, 317, 352, 1, 2044, 90, 2173, 56, 906, 18, 5, 3275, 5247, 1577, 81, 821, 1672, 478, 23, 162, 14, 2, 18, 2, 1855, 14, 33, 499, 821, 478, 23, 162, 14, 2, 18, 6, 3, 260, 4855, 5574, 477, 3950, 1112, 2132, 856, 2, 1217, 5181, 5, 64, 61, 2116, 2, 1855, 688, 401, 228, 1746, 659, 935, 857, 5, 1566, 2018, 62, 15, 1275, 11, 73, 5, 26, 1230, 4855, 5574, 477, 10078, 1, 855, 9, 2198, 59109, 1746, 169, 966, 7, 513, 236, 51, 684, 5, 8, 52, 166, 126, 1, 424, 53, 3, 33, 111, 684, 654, 9366, 2, 63, 25, 118, 151, 11, 641, 2, 584, 106, 72, 5, 5920, 7, 73, 5, 260, 4855, 5574, 151, 1, 512, 2, 662, 106, 19, 44, 93, 228, 5, 3, 1230, 4855, 5574, 477, 10, 44, 231, 63, 228, 10, 231, 20, 3, 352, 1, 855, 9, 3, 2198, 109, 697, 151, 1, 9366, 2, 118, 1, 212, 2, 699, 106, 547, 2044, 5091, 5890, 228, 9, 3, 2198, 199, 697, 151, 1, 9366, 2, 118, 1, 605, 2, 465, 106, 19, 355, 72, 5, 260, 4855, 5574, 8, 64, 282, 116, 139, 6, 1875, 4, 684, 10, 1051, 107, 7, 1032, 335, 60, 15, 434, 4, 3, 1533, 1, 3, 4855, 5574, 477, 191, 2044, 5091, 205, 44, 401, 228, 9, 857, 5, 1566, 2018, 62, 15, 1275]",1638.0,20572037,868
Attention and working memory abilities in children treated for acute lymphoblastic leukemia.,Cancer,Cancer,2010-10-01,"To extend investigation beyond global cognitive measures prevalent in the literature, this study examined attention and working memory (WM) abilities of survivors of childhood acute lymphoblastic leukemia (ALL), the separate contributions of attention and WM to intelligence quotient (IQ), and their association with neuroimaging changes. Ninety-seven children with ALL received risk-directed therapy based on presenting clinical and biological factors. During consolidation therapy, low-risk patients received half the dose of intravenous methotrexate that standard-risk/high-risk patients received, and fewer doses of triple intrathecal therapy. Patients were classified according to end of consolidation magnetic resonance imaging scans (normal or leukoencephalopathy), and continuous measures of white matter structure were computed. As part of the protocol study, children completed cognitive assessment 2 years later (completion of therapy), using Digit Span Forward (DSF) for attention and Digit Span Backward (DSB) for WM. For the total sample and the standard-/high-risk group, Total Digit Span (TDS), DSF, and DSB were impaired relative to norms (P<.05). In the low-risk group, only DSB was impaired (P<.0001). Across groups, a higher percentage of patients performed below the average range (scale score<7) on DSB (66%) compared with the DSF (14%) or TDS (18%). Regression analysis indicated that DSB predicted estimated IQ (P<.05), after accounting for DSF. Leukoencephalopathy was predictive of lower TDS (P<.05). WM appears to be especially sensitive to treatment-related changes in ALL survivors, detecting difficulties potentially missed by global intelligence measures. These findings may facilitate the identification of vulnerable neural pathways and the development of targeted cognitive interventions.",Journal Article,3399.0,57.0,To extend investigation beyond global cognitive measures prevalent in the literature this study examined attention and working memory WM abilities of survivors of childhood acute lymphoblastic ALL the separate contributions of attention and WM to intelligence quotient IQ and their association with neuroimaging changes Ninety-seven children with ALL received risk-directed therapy based on presenting clinical and biological factors During consolidation therapy low-risk patients received half the dose of intravenous methotrexate that standard-risk/high-risk patients received and fewer doses of triple intrathecal therapy Patients were classified according to end of consolidation magnetic resonance imaging scans normal or leukoencephalopathy and continuous measures of white matter structure were computed As part of the protocol study children completed cognitive assessment 2 years later completion of therapy using Digit Span Forward DSF for attention and Digit Span Backward DSB for WM For the total sample and the standard-/high-risk group Total Digit Span TDS DSF and DSB were impaired relative to norms P .05 In the low-risk group only DSB was impaired P .0001 Across groups a higher percentage of patients performed below the average range scale score 7 on DSB 66 compared with the DSF 14 or TDS 18 Regression analysis indicated that DSB predicted estimated IQ P .05 after accounting for DSF Leukoencephalopathy was predictive of lower TDS P .05 WM appears to be especially sensitive to treatment-related changes in ALL survivors detecting difficulties potentially missed by global intelligence measures These findings may facilitate the identification of vulnerable neural pathways and the development of targeted cognitive interventions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 4087, 940, 1654, 1648, 1863, 1018, 2485, 4, 3, 789, 26, 45, 409, 2111, 2, 2644, 2407, 1518, 7965, 1, 332, 1, 864, 286, 1275, 62, 3, 2282, 5621, 1, 2111, 2, 1518, 6, 9125, 15164, 7666, 2, 136, 248, 5, 7468, 400, 2493, 648, 541, 5, 62, 103, 43, 1166, 36, 90, 23, 1656, 38, 2, 1037, 130, 190, 2173, 36, 154, 43, 7, 103, 1303, 3, 61, 1, 1262, 2116, 17, 260, 43, 64, 43, 7, 103, 2, 1497, 415, 1, 1500, 5126, 36, 7, 11, 1373, 768, 6, 396, 1, 2173, 1484, 1535, 270, 1441, 295, 15, 8744, 2, 1314, 1018, 1, 886, 5090, 2772, 11, 1220, 22, 760, 1, 3, 1182, 45, 541, 781, 1863, 455, 18, 60, 1559, 1438, 1, 36, 75, 9553, 7165, 4674, 16510, 9, 2111, 2, 9553, 7165, 10877, 8414, 9, 1518, 9, 3, 181, 1000, 2, 3, 260, 64, 43, 87, 181, 9553, 7165, 18557, 16510, 2, 8414, 11, 2364, 580, 6, 9875, 19, 474, 4, 3, 154, 43, 87, 158, 8414, 10, 2364, 19, 488, 716, 271, 8, 142, 1150, 1, 7, 173, 2736, 3, 1011, 184, 1124, 368, 67, 23, 8414, 700, 72, 5, 3, 16510, 213, 15, 18557, 203, 320, 65, 1103, 17, 8414, 783, 661, 7666, 19, 474, 50, 3116, 9, 16510, 8744, 10, 464, 1, 280, 18557, 19, 474, 1518, 1233, 6, 40, 1093, 745, 6, 24, 139, 400, 4, 62, 332, 2502, 4679, 751, 5149, 20, 1648, 9125, 1018, 46, 272, 68, 1876, 3, 911, 1, 5017, 3922, 460, 2, 3, 193, 1, 238, 1863, 1151]",1751.0,20572038,587
Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study.,Blood,Blood,2010-06-30,"To define a role for hematopoietic stem cell transplantation (HSCT) in infants with acute lymphoblastic leukemia and rearrangements of the mixed-lineage-leukemia gene (MLL(+)), we compared the outcome of MLL(+) patients from trial Interfant-99 who either received chemotherapy only or HSCT. Of 376 patients with a known MLL status in the trial, 297 (79%) were MLL(+). Among the 277 of 297 MLL(+) patients (93%) in first remission (CR), there appeared to be a significant difference in disease-free survival (adjusted by waiting time to HSCT) between the 37 (13%) who received HSCT and the 240 (87%) who received chemotherapy only (P = .03). However, the advantage was restricted to a subgroup with 2 additional unfavorable prognostic features: age less than 6 months and either poor response to steroids at day 8 or leukocytes more than or equal to 300 g/L. Ninety-seven of 297 MLL(+) patients (33%) had such high-risk criteria, with 87 achieving CR. In this group, HSCT was associated with a 64% reduction in the risk of failure resulting from relapse or death in CR (hazard ratio = 0.36, 95% confidence interval, 0.15-0.86). In the remaining patients, there was no advantage for HSCT over chemotherapy only. In summary, HSCT seems to be a valuable option for a subgroup of infant MLL(+) acute lymphoblastic leukemia carrying further poor prognostic factors. The trial was registered at www.clinicaltrials.gov as #NCT00015873 and at www.controlled-trials.com as #ISRCTN24251487.",Journal Article,3492.0,77.0,To define a role for hematopoietic stem cell transplantation HSCT in infants with acute lymphoblastic and rearrangements of the mixed-lineage-leukemia gene MLL we compared the outcome of MLL patients from trial Interfant-99 who either received chemotherapy only or HSCT Of 376 patients with a known MLL status in the trial 297 79 were MLL Among the 277 of 297 MLL patients 93 in first remission CR there appeared to be a significant difference in disease-free survival adjusted by waiting time to HSCT between the 37 13 who received HSCT and the 240 87 who received chemotherapy only P .03 However the advantage was restricted to a subgroup with 2 additional unfavorable prognostic features age less than 6 months and either poor response to steroids at day 8 or leukocytes more than or equal to 300 g/L Ninety-seven of 297 MLL patients 33 had such high-risk criteria with 87 achieving CR In this group HSCT was associated with a 64 reduction in the risk of failure resulting from relapse or death in CR hazard ratio 0.36 95 confidence interval 0.15-0.86 In the remaining patients there was no advantage for HSCT over chemotherapy only In summary HSCT seems to be a valuable option for a subgroup of infant MLL acute lymphoblastic carrying further poor prognostic factors The trial was registered at www.clinicaltrials.gov as NCT00015873 and at www.controlled-trials.com as ISRCTN24251487,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 1107, 8, 200, 9, 1007, 452, 31, 497, 1703, 4, 5585, 5, 286, 1275, 2, 2072, 1, 3, 1739, 2542, 2647, 145, 3049, 21, 72, 3, 228, 1, 3049, 7, 29, 160, 39061, 1058, 54, 361, 103, 56, 158, 15, 1703, 1, 9534, 7, 5, 8, 440, 3049, 156, 4, 3, 160, 8526, 842, 11, 3049, 107, 3, 7996, 1, 8526, 3049, 7, 966, 4, 157, 734, 684, 125, 2121, 6, 40, 8, 93, 523, 4, 34, 115, 25, 586, 20, 7598, 98, 6, 1703, 59, 3, 567, 233, 54, 103, 1703, 2, 3, 4263, 912, 54, 103, 56, 158, 19, 680, 137, 3, 1874, 10, 2016, 6, 8, 1363, 5, 18, 402, 2483, 177, 404, 89, 299, 76, 49, 53, 2, 361, 334, 51, 6, 4580, 28, 218, 66, 15, 6884, 80, 76, 15, 2997, 6, 2036, 499, 805, 2493, 648, 1, 8526, 3049, 7, 466, 42, 225, 64, 43, 371, 5, 912, 1785, 684, 4, 26, 87, 1703, 10, 41, 5, 8, 660, 628, 4, 3, 43, 1, 496, 1113, 29, 429, 15, 273, 4, 684, 360, 197, 13, 511, 48, 307, 268, 13, 167, 13, 868, 4, 3, 1844, 7, 125, 10, 77, 1874, 9, 1703, 252, 56, 158, 4, 1962, 1703, 2744, 6, 40, 8, 2926, 1501, 9, 8, 1363, 1, 8027, 3049, 286, 1275, 2934, 195, 334, 177, 130, 3, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 59123, 2, 28, 3064, 1149, 143, 8264, 22, 45639]",1388.0,20592248,521
Hematopoietic stem-cell transplantation for acute leukemia in relapse or primary induction failure.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-07-12,"Patients with acute leukemia refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell transplantation (HSCT). However, HSCT when a patient is not in complete remission (CR) is of uncertain benefit. We hypothesized that pretransplantation variables may define subgroups that have a better prognosis. Overall, 2,255 patients who underwent transplantation for acute leukemia in relapse or with primary induction failure after myeloablative conditioning regimen between 1995 and 2004 were reported to the Center for International Blood and Marrow Transplant Research. The median follow-up of survivors was 61 months. We performed multivariate analysis of pretransplantation variables and developed a predictive scoring system for survival. The 3-year overall survival (OS) rates were 19% for acute myeloid leukemia (AML) and 16% for acute lymphoblastic leukemia (ALL). For AML, five adverse pretransplantation variables significantly influenced survival: first CR duration less than 6 months, circulating blasts, donor other than HLA-identical sibling, Karnofsky or Lansky score less than 90, and poor-risk cytogenetics. For ALL, survival was worse with the following: first refractory or second or greater relapse, > or = 25% marrow blasts, cytomegalovirus-seropositive donor, and age of 10 years or older. Patients with AML who had a predictive score of 0 had 42% OS at 3 years, whereas OS was 6% for a score > or = 3. Patients with ALL who had a score of 0 or 1 had 46% 3-year OS but only 10% OS rate for a score > or = 3. Pretransplantation variables delineate subgroups with different outcomes. HSCT during relapse can achieve long-term survival in selected patients with acute leukemia.",Clinical Trial,3480.0,229.0,"Patients with acute refractory to induction or reinduction chemotherapy have poor prognoses if they do not undergo hematopoietic stem-cell transplantation HSCT However HSCT when a patient is not in complete remission CR is of uncertain benefit We hypothesized that pretransplantation variables may define subgroups that have a better prognosis Overall 2,255 patients who underwent transplantation for acute in relapse or with primary induction failure after myeloablative conditioning regimen between 1995 and 2004 were reported to the Center for International Blood and Marrow Transplant Research The median follow-up of survivors was 61 months We performed multivariate analysis of pretransplantation variables and developed a predictive scoring system for survival The 3-year overall survival OS rates were 19 for acute myeloid AML and 16 for acute lymphoblastic ALL For AML five adverse pretransplantation variables significantly influenced survival first CR duration less than 6 months circulating blasts donor other than HLA-identical sibling Karnofsky or Lansky score less than 90 and poor-risk cytogenetics For ALL survival was worse with the following first refractory or second or greater relapse or 25 marrow blasts cytomegalovirus-seropositive donor and age of 10 years or older Patients with AML who had a predictive score of 0 had 42 OS at 3 years whereas OS was 6 for a score or 3 Patients with ALL who had a score of 0 or 1 had 46 3-year OS but only 10 OS rate for a score or 3 Pretransplantation variables delineate subgroups with different outcomes HSCT during relapse can achieve long-term survival in selected patients with acute",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7, 5, 286, 430, 6, 504, 15, 10177, 56, 47, 334, 5362, 492, 491, 1022, 44, 1251, 1007, 452, 31, 497, 1703, 137, 1703, 198, 8, 69, 16, 44, 4, 236, 734, 684, 16, 1, 2717, 247, 21, 1237, 17, 9367, 682, 68, 1107, 1453, 17, 47, 8, 380, 356, 63, 18, 7826, 7, 54, 208, 497, 9, 286, 4, 429, 15, 5, 86, 504, 496, 50, 3246, 1933, 477, 59, 2323, 2, 1131, 11, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 3, 52, 166, 126, 1, 332, 10, 713, 53, 21, 173, 331, 65, 1, 9367, 682, 2, 276, 8, 464, 2504, 398, 9, 25, 3, 27, 111, 63, 25, 118, 151, 11, 326, 9, 286, 533, 329, 2, 245, 9, 286, 1275, 62, 9, 329, 365, 290, 9367, 682, 97, 2574, 25, 157, 684, 654, 299, 76, 49, 53, 1033, 2438, 1488, 127, 76, 1160, 3038, 3684, 2857, 15, 25271, 368, 299, 76, 424, 2, 334, 43, 2510, 9, 62, 25, 10, 639, 5, 3, 366, 157, 430, 15, 419, 15, 378, 429, 15, 243, 581, 2438, 7314, 9909, 1488, 2, 89, 1, 79, 60, 15, 434, 7, 5, 329, 54, 42, 8, 464, 368, 1, 13, 42, 595, 118, 28, 27, 60, 547, 118, 10, 49, 9, 8, 368, 15, 27, 7, 5, 62, 54, 42, 8, 368, 1, 13, 15, 14, 42, 641, 27, 111, 118, 84, 158, 79, 118, 116, 9, 8, 368, 15, 27, 9367, 682, 5092, 1453, 5, 338, 123, 1703, 190, 429, 122, 1359, 319, 337, 25, 4, 715, 7, 5, 286]",1649.0,20625136,854
Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-07-19,"To identify children with T-cell acute lymphoblastic leukemia (T-ALL) at high risk of induction chemotherapy failure by using DNA copy number analysis of leukemic cells collected at diagnosis. Array comparative genomic hybridization (CGH) was performed on genomic DNA extracted from diagnostic lymphoblasts from 47 children with T-ALL treated on Children's Oncology Group Study P9404 or Dana-Farber Cancer Institute Protocol 00-01. These samples represented nine patients who did not achieve an initial complete remission, 13 who relapsed, and 25 who became long-term, event-free survivors. The findings were confirmed in an independent cohort of patients by quantitative DNA polymerase chain reaction (DNA-PCR), an assay that is well suited for clinical application. Analysis of the CGH findings in patients in whom induction chemotherapy failed compared with those in whom induction chemotherapy was successful identified the absence of biallelic TCRgamma locus deletion (ABD), a characteristic of early thymocyte precursors before V(D)J recombination, as the most robust predictor of induction failure (P < .001). This feature was also associated with markedly inferior event-free (P = .002) and overall survival (P < .001) rates: 25% versus 58% and 25% versus 72%, respectively. Using a rapid and inexpensive quantitative DNA-PCR assay, we validated ABD as a predictor of a poor response to induction chemotherapy in an independent series of patients. Lymphoblasts from children with T-ALL should be evaluated at diagnosis for deletion within the TCRgamma locus. Patients lacking biallelic deletion, which confers a high probability of induction failure with contemporary therapy, should be assigned to alternative therapy in the context of a prospective clinical trial.",Journal Article,3473.0,59.0,To identify children with T-cell acute lymphoblastic T-ALL at high risk of induction chemotherapy failure by using DNA copy number analysis of leukemic cells collected at diagnosis Array comparative genomic hybridization CGH was performed on genomic DNA extracted from diagnostic lymphoblasts from 47 children with T-ALL treated on Children 's Oncology Group Study P9404 or Dana-Farber Cancer Institute Protocol 00-01 These samples represented nine patients who did not achieve an initial complete remission 13 who relapsed and 25 who became long-term event-free survivors The findings were confirmed in an independent cohort of patients by quantitative DNA polymerase chain reaction DNA-PCR an assay that is well suited for clinical application Analysis of the CGH findings in patients in whom induction chemotherapy failed compared with those in whom induction chemotherapy was successful identified the absence of biallelic TCRgamma locus deletion ABD a characteristic of early thymocyte precursors before V D J recombination as the most robust predictor of induction failure P .001 This feature was also associated with markedly inferior event-free P .002 and overall survival P .001 rates 25 versus 58 and 25 versus 72 respectively Using a rapid and inexpensive quantitative DNA-PCR assay we validated ABD as a predictor of a poor response to induction chemotherapy in an independent series of patients Lymphoblasts from children with T-ALL should be evaluated at diagnosis for deletion within the TCRgamma locus Patients lacking biallelic deletion which confers a high probability of induction failure with contemporary therapy should be assigned to alternative therapy in the context of a prospective clinical trial,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 255, 541, 5, 102, 31, 286, 1275, 102, 62, 28, 64, 43, 1, 504, 56, 496, 20, 75, 261, 1337, 207, 65, 1, 2015, 37, 786, 28, 147, 1926, 2352, 572, 1554, 8224, 10, 173, 23, 572, 261, 2484, 29, 752, 10521, 29, 662, 541, 5, 102, 62, 73, 23, 541, 292, 413, 87, 45, 59171, 15, 4932, 4979, 12, 1377, 1182, 2038, 355, 46, 347, 3324, 762, 7, 54, 205, 44, 1359, 35, 388, 236, 734, 233, 54, 591, 2, 243, 54, 3451, 319, 337, 774, 115, 332, 3, 272, 11, 557, 4, 35, 306, 180, 1, 7, 20, 1156, 261, 1451, 1260, 1329, 261, 604, 35, 719, 17, 16, 149, 7247, 9, 38, 1581, 65, 1, 3, 8224, 272, 4, 7, 4, 953, 504, 56, 1551, 72, 5, 135, 4, 953, 504, 56, 10, 1401, 108, 3, 1127, 1, 6435, 46129, 2474, 1528, 26963, 8, 2037, 1, 191, 16236, 4881, 348, 603, 427, 3543, 4017, 22, 3, 96, 1922, 980, 1, 504, 496, 19, 144, 26, 2705, 10, 120, 41, 5, 2195, 1663, 774, 115, 19, 1111, 2, 63, 25, 19, 144, 151, 243, 185, 717, 2, 243, 185, 720, 106, 75, 8, 1321, 2, 8168, 1156, 261, 604, 719, 21, 938, 26963, 22, 8, 980, 1, 8, 334, 51, 6, 504, 56, 4, 35, 306, 988, 1, 7, 10521, 29, 541, 5, 102, 62, 257, 40, 194, 28, 147, 9, 1528, 262, 3, 46129, 2474, 7, 1941, 6435, 1528, 92, 4020, 8, 64, 1320, 1, 504, 496, 5, 2667, 36, 257, 40, 896, 6, 1091, 36, 4, 3, 1533, 1, 8, 482, 38, 160]",1722.0,20644084,574
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-07-26,"The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia (ALL) prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone). Other modifications (irrespective of CD20 expression) included early anthracycline intensification, alterations in number of risk-adapted intrathecal chemotherapy treatments for CNS prophylaxis, additional early and late intensifications, and extension of maintenance phase chemotherapy by 6 months. Two hundred eighty-two adolescents and adults with de novo Philadelphia chromosome (Ph)-negative precursor B-lineage ALL were treated with standard or modified hyper-CVAD regimens. The latter incorporated standard-dose rituximab if CD20 expression > or = 20%. The complete remission (CR) rate was 95% with 3-year rates of CR duration (CRD) and survival (OS) of 60% and 50%, respectively. In the younger (age < 60 years) CD20-positive subset, rates of CRD and OS were superior with the modified hyper-CVAD and rituximab regimens compared with standard hyper-CVAD (70% v 38%; P < .001% and 75% v 47%, P = .003). In contrast, rates of CRD and OS for CD20-negative counterparts treated with modified versus standard hyper-CVAD regimens were similar (72% v 68%, P = not significant [NS] and 64% v 65%, P = NS, respectively). Older patients with CD20-positive ALL did not benefit from rituximab-based chemoimmunotherapy (rates of CRD 45% v 50%, P = NS and OS 28% v 32%, P = NS, respectively), related in part to deaths in CR. The incorporation of rituximab into the hyper-CVAD regimen appears to improve outcome for younger patients with CD20-positive Ph-negative precursor B-lineage ALL.",Clinical Trial,3466.0,233.0,The adverse prognosis of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic ALL prompted incorporation of monoclonal antibody therapy with rituximab into the intensive chemotherapy regimen hyper-CVAD fractionated cyclophosphamide vincristine doxorubicin dexamethasone Other modifications irrespective of CD20 expression included early anthracycline intensification alterations in number of risk-adapted intrathecal chemotherapy treatments for CNS prophylaxis additional early and late intensifications and extension of maintenance phase chemotherapy by 6 months Two hundred eighty-two adolescents and adults with de novo Philadelphia chromosome Ph -negative precursor B-lineage ALL were treated with standard or modified hyper-CVAD regimens The latter incorporated standard-dose rituximab if CD20 expression or 20 The complete remission CR rate was 95 with 3-year rates of CR duration CRD and survival OS of 60 and 50 respectively In the younger age 60 years CD20-positive subset rates of CRD and OS were superior with the modified hyper-CVAD and rituximab regimens compared with standard hyper-CVAD 70 v 38 P .001 and 75 v 47 P .003 In contrast rates of CRD and OS for CD20-negative counterparts treated with modified versus standard hyper-CVAD regimens were similar 72 v 68 P not significant NS and 64 v 65 P NS respectively Older patients with CD20-positive ALL did not benefit from rituximab-based chemoimmunotherapy rates of CRD 45 v 50 P NS and OS 28 v 32 P NS respectively related in part to deaths in CR The incorporation of rituximab into the hyper-CVAD regimen appears to improve outcome for younger patients with CD20-positive Ph-negative precursor B-lineage ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 290, 356, 1, 2198, 55, 4, 857, 5, 1566, 2018, 2765, 132, 2542, 286, 1275, 62, 4140, 2838, 1, 848, 548, 36, 5, 855, 237, 3, 1686, 56, 477, 4855, 5574, 3950, 1112, 2132, 856, 1217, 127, 2916, 3500, 1, 2198, 55, 159, 191, 2044, 5091, 593, 4, 207, 1, 43, 3716, 5126, 56, 640, 9, 1025, 2049, 402, 191, 2, 807, 59211, 2, 2401, 1, 1146, 124, 56, 20, 49, 53, 100, 1128, 2207, 100, 3101, 2, 857, 5, 1566, 2018, 3006, 1170, 2058, 199, 2765, 132, 2542, 62, 11, 73, 5, 260, 15, 1230, 4855, 5574, 472, 3, 3286, 2449, 260, 61, 855, 492, 2198, 55, 15, 179, 3, 236, 734, 684, 116, 10, 48, 5, 27, 111, 151, 1, 684, 654, 9366, 2, 25, 118, 1, 335, 2, 212, 106, 4, 3, 773, 89, 335, 60, 2198, 109, 697, 151, 1, 9366, 2, 118, 11, 1123, 5, 3, 1230, 4855, 5574, 2, 855, 472, 72, 5, 260, 4855, 5574, 431, 603, 519, 19, 144, 2, 481, 603, 662, 19, 1421, 4, 748, 151, 1, 9366, 2, 118, 9, 2198, 199, 3953, 73, 5, 1230, 185, 260, 4855, 5574, 472, 11, 288, 720, 603, 806, 19, 44, 93, 4044, 2, 660, 603, 556, 19, 4044, 106, 434, 7, 5, 2198, 109, 62, 205, 44, 247, 29, 855, 90, 4438, 151, 1, 9366, 512, 603, 212, 19, 4044, 2, 118, 339, 603, 531, 19, 4044, 106, 139, 4, 760, 6, 1043, 4, 684, 3, 2838, 1, 855, 237, 3, 4855, 5574, 477, 1233, 6, 401, 228, 9, 773, 7, 5, 2198, 109, 2058, 199, 2765, 132, 2542, 62]",1701.0,20660823,85
Histone H4 acetylation by immunohistochemistry and prognosis in newly diagnosed adult acute lymphoblastic leukemia (ALL) patients.,BMC cancer,BMC Cancer,2010-07-21,"Histone deacetylase (HDAC) inhibitors are a novel anti-tumor therapy. To determine whether HDAC inhibitors may be useful in the treatment of adult acute lymphoblastic leukemia (ALL), we examined the acetylation of histone H4 by immunohistochemistry in newly diagnosed ALL patients and evaluated the impact of acetylation on complete remission (CR) rate, relapse-free survival (RFS), and overall survival (OS). Patients > or = 18 years of age and an available diagnostic bone marrow biopsy were evaluated. Cox proportional hazards analysis was used to identify univariate and multivariate correlates of CR, RFS, and OS. The variables histone H4 acetylation (positive or negative), white blood count, cytogenetic (CG) risk group (CALGB criteria), and age were used in multivariate analysis. On multivariate analysis, histone acetylation was associated with a trend towards an improved OS (for all CG risk groups) (HR = 0.51, p = 0.09). In patients without poor risk CG, there was an impressive association between the presence of histone acetylation and an improved CR rate (OR 3.43, p = 0.035), RFS (HR 0.07, p = 0.005), and OS (HR 0.24, p = 0.007). This association remained statistically significant in multivariate analysis. These data provide a rationale for the design of novel regimens incorporating HDAC inhibitors in ALL.",Journal Article,3471.0,23.0,Histone deacetylase HDAC inhibitors are a novel anti-tumor therapy To determine whether HDAC inhibitors may be useful in the treatment of adult acute lymphoblastic ALL we examined the acetylation of histone H4 by immunohistochemistry in newly diagnosed ALL patients and evaluated the impact of acetylation on complete remission CR rate relapse-free survival RFS and overall survival OS Patients or 18 years of age and an available diagnostic marrow biopsy were evaluated Cox proportional hazards analysis was used to identify univariate and multivariate correlates of CR RFS and OS The variables histone H4 acetylation positive or negative white blood count cytogenetic CG risk group CALGB criteria and age were used in multivariate analysis On multivariate analysis histone acetylation was associated with a trend towards an improved OS for all CG risk groups HR 0.51 p 0.09 In patients without poor risk CG there was an impressive association between the presence of histone acetylation and an improved CR rate OR 3.43 p 0.035 RFS HR 0.07 p 0.005 and OS HR 0.24 p 0.007 This association remained statistically significant in multivariate analysis These data provide a rationale for the design of novel regimens incorporating HDAC inhibitors in ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1508, 2732, 2654, 222, 32, 8, 229, 312, 30, 36, 6, 223, 317, 2654, 222, 68, 40, 999, 4, 3, 24, 1, 780, 286, 1275, 62, 21, 409, 3, 4145, 1, 1508, 7812, 20, 888, 4, 732, 265, 62, 7, 2, 194, 3, 345, 1, 4145, 23, 236, 734, 684, 116, 429, 115, 25, 1272, 2, 63, 25, 118, 7, 15, 203, 60, 1, 89, 2, 35, 390, 752, 581, 411, 11, 194, 418, 831, 1017, 65, 10, 95, 6, 255, 880, 2, 331, 1871, 1, 684, 1272, 2, 118, 3, 682, 1508, 7812, 4145, 109, 15, 199, 886, 315, 1276, 1266, 6773, 43, 87, 4077, 371, 2, 89, 11, 95, 4, 331, 65, 23, 331, 65, 1508, 4145, 10, 41, 5, 8, 853, 3113, 35, 231, 118, 9, 62, 6773, 43, 271, 168, 13, 725, 19, 13, 1730, 4, 7, 187, 334, 43, 6773, 125, 10, 35, 5790, 248, 59, 3, 463, 1, 1508, 4145, 2, 35, 231, 684, 116, 15, 27, 601, 19, 13, 4514, 1272, 168, 13, 1615, 19, 13, 1614, 2, 118, 168, 13, 259, 19, 13, 1999, 26, 248, 958, 712, 93, 4, 331, 65, 46, 74, 377, 8, 1728, 9, 3, 771, 1, 229, 472, 2570, 2654, 222, 4, 62]",1249.0,20663136,849
One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-07-30,"Approximately 13% of patients lacking an HLA-identical sibling have a one-antigen-mismatched related donor (MMRD). Historically, outcomes from the use of a one-antigen MMRD were considered equivalent to those from the use of a matched unrelated donor (UD). Recent improvements in UD stem cell transplantation (SCT) resulting from better molecular HLA matching justifies investigating whether UD should be preferred over MMRD in adult patients with acute leukemia. Here, we compared the outcomes of MMRD (n = 89) and HLA-A, -B, -C, and -DRB1 allele-matched UD (n = 700) SCT reported to the Center for International Blood and Marrow Transplant Research between 1995 and 2005. The patients underwent transplantation for acute myelogenous leukemia or acute lymphoblastic leukemia in first or second complete remission. Donor type was not associated with hematologic recovery. Univariate and multivariate comparisons of MMRD versus HLA-matched UD transplants showed no statistically significant differences in overall survival, disease-free survival, treatment-related mortality, relapse, or 100-day grade III-IV acute graft-versus-host disease (GVHD). MMRD SCT was associated with a lower rate of chronic GVHD at 1 year (35% vs 47%; P = .03), which was confirmed by multivariate analysis (relative risk, 0.58; 95% confidence interval, 0.39-0.85; P < .01). According to our data, HLA-matched UD and MMRD SCT are associated with comparable survival. Given that less chronic GVHD was observed in the MMRD transplantations, this option, when available, remains the first choice in patients with acute leukemia without an HLA-identical sibling in need of allogeneic SCT.",Journal Article,3462.0,39.0,Approximately 13 of patients lacking an HLA-identical sibling have a one-antigen-mismatched related donor MMRD Historically outcomes from the use of a one-antigen MMRD were considered equivalent to those from the use of a matched unrelated donor UD Recent improvements in UD stem cell transplantation SCT resulting from better molecular HLA matching justifies investigating whether UD should be preferred over MMRD in adult patients with acute Here we compared the outcomes of MMRD n 89 and HLA-A -B -C and -DRB1 allele-matched UD n 700 SCT reported to the Center for International Blood and Marrow Transplant Research between 1995 and 2005 The patients underwent transplantation for acute myelogenous or acute lymphoblastic in first or second complete remission Donor type was not associated with hematologic recovery Univariate and multivariate comparisons of MMRD versus HLA-matched UD transplants showed no statistically significant differences in overall survival disease-free survival treatment-related mortality relapse or 100-day grade III-IV acute graft-versus-host disease GVHD MMRD SCT was associated with a lower rate of chronic GVHD at 1 year 35 vs 47 P .03 which was confirmed by multivariate analysis relative risk 0.58 95 confidence interval 0.39-0.85 P .01 According to our data HLA-matched UD and MMRD SCT are associated with comparable survival Given that less chronic GVHD was observed in the MMRD transplantations this option when available remains the first choice in patients with acute without an HLA-identical sibling in need of allogeneic SCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[705, 233, 1, 7, 1941, 35, 1160, 3038, 3684, 47, 8, 104, 448, 5095, 139, 1488, 14341, 3578, 123, 29, 3, 119, 1, 8, 104, 448, 14341, 11, 515, 2017, 6, 135, 29, 3, 119, 1, 8, 655, 2092, 1488, 15574, 435, 1474, 4, 15574, 452, 31, 497, 1988, 1113, 29, 380, 219, 1160, 2616, 13299, 3103, 317, 15574, 257, 40, 2514, 252, 14341, 4, 780, 7, 5, 286, 467, 21, 72, 3, 123, 1, 14341, 78, 887, 2, 1160, 8, 132, 256, 2, 8147, 1254, 655, 15574, 78, 5692, 1988, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 59, 2323, 2, 1242, 3, 7, 208, 497, 9, 286, 2194, 15, 286, 1275, 4, 157, 15, 419, 236, 734, 1488, 267, 10, 44, 41, 5, 813, 1602, 880, 2, 331, 2213, 1, 14341, 185, 1160, 655, 15574, 4016, 224, 77, 712, 93, 362, 4, 63, 25, 34, 115, 25, 24, 139, 282, 429, 15, 394, 218, 88, 316, 478, 286, 1599, 185, 1204, 34, 1562, 14341, 1988, 10, 41, 5, 8, 280, 116, 1, 442, 1562, 28, 14, 111, 465, 105, 662, 19, 680, 92, 10, 557, 20, 331, 65, 580, 43, 13, 717, 48, 307, 268, 13, 587, 13, 772, 19, 355, 768, 6, 114, 74, 1160, 655, 15574, 2, 14341, 1988, 32, 41, 5, 1279, 25, 447, 17, 299, 442, 1562, 10, 164, 4, 3, 14341, 6779, 26, 1501, 198, 390, 469, 3, 157, 1866, 4, 7, 5, 286, 187, 35, 1160, 3038, 3684, 4, 594, 1, 1063, 1988]",1568.0,20674756,824
"Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome.",Blood,Blood,2010-08-10,"To resolve the genetic heterogeneity within pediatric high-risk B-precursor acute lymphoblastic leukemia (ALL), a clinically defined poor-risk group with few known recurring cytogenetic abnormalities, we performed gene expression profiling in a cohort of 207 uniformly treated children with high-risk ALL. Expression profiles were correlated with genome-wide DNA copy number abnormalities and clinical and outcome features. Unsupervised clustering of gene expression profiling data revealed 8 unique cluster groups within these high-risk ALL patients, 2 of which were associated with known chromosomal translocations (t(1;19)(TCF3-PBX1) or MLL), and 6 of which lacked any previously known cytogenetic lesion. One unique cluster was characterized by high expression of distinct outlier genes AGAP1, CCNJ, CHST2/7, CLEC12A/B, and PTPRM; ERG DNA deletions; and 4-year relapse-free survival of 94.7%  5.1%, compared with 63.5%  3.7% for the cohort (P = .01). A second cluster, characterized by high expression of BMPR1B, CRLF2, GPR110, and MUC4; frequent deletion of EBF1, IKZF1, RAG1-2, and IL3RA-CSF2RA; JAK mutations and CRLF2 rearrangements (P < .0001); and Hispanic ethnicity (P < .001) had a very poor 4-year relapse-free survival (21.0%  9.5%; P < .001). These studies reveal striking clinical and genetic heterogeneity in high-risk ALL and point to novel genes that may serve as new targets for diagnosis, risk classification, and therapy.",Journal Article,3451.0,240.0,To resolve the genetic heterogeneity within pediatric high-risk B-precursor acute lymphoblastic ALL a clinically defined poor-risk group with few known recurring cytogenetic abnormalities we performed gene expression profiling in a cohort of 207 uniformly treated children with high-risk ALL Expression profiles were correlated with genome-wide DNA copy number abnormalities and clinical and outcome features Unsupervised clustering of gene expression profiling data revealed 8 unique cluster groups within these high-risk ALL patients 2 of which were associated with known chromosomal translocations t 1 19 TCF3-PBX1 or MLL and 6 of which lacked any previously known cytogenetic lesion One unique cluster was characterized by high expression of distinct outlier genes AGAP1 CCNJ CHST2/7 CLEC12A/B and PTPRM ERG DNA deletions and 4-year relapse-free survival of 94.7  5.1 compared with 63.5  3.7 for the cohort P .01 A second cluster characterized by high expression of BMPR1B CRLF2 GPR110 and MUC4 frequent deletion of EBF1 IKZF1 RAG1-2 and IL3RA-CSF2RA JAK mutations and CRLF2 rearrangements P .0001 and Hispanic ethnicity P .001 had a very poor 4-year relapse-free survival 21.0  9.5 P .001 These studies reveal striking clinical and genetic heterogeneity in high-risk ALL and point to novel genes that may serve as new targets for diagnosis risk classification and therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 8244, 3, 336, 1144, 262, 815, 64, 43, 132, 2765, 286, 1275, 62, 8, 505, 395, 334, 43, 87, 5, 1021, 440, 6385, 1266, 1171, 21, 173, 145, 55, 1080, 4, 8, 180, 1, 5292, 4254, 73, 541, 5, 64, 43, 62, 55, 1241, 11, 438, 5, 898, 1019, 261, 1337, 207, 1171, 2, 38, 2, 228, 404, 6512, 3147, 1, 145, 55, 1080, 74, 553, 66, 991, 3132, 271, 262, 46, 64, 43, 62, 7, 18, 1, 92, 11, 41, 5, 440, 1860, 3262, 102, 14, 326, 25178, 14434, 15, 3049, 2, 49, 1, 92, 5005, 500, 373, 440, 1266, 1180, 104, 991, 3132, 10, 765, 20, 64, 55, 1, 834, 9602, 214, 59238, 59239, 59240, 67, 59241, 132, 2, 46168, 3032, 261, 2439, 2, 39, 111, 429, 115, 25, 1, 960, 67, 810, 33, 14, 72, 5, 676, 33, 810, 27, 67, 9, 3, 180, 19, 355, 8, 419, 3132, 765, 20, 64, 55, 1, 59242, 8895, 59243, 2, 8929, 908, 1528, 1, 23701, 8422, 25255, 18, 2, 46169, 59244, 4653, 138, 2, 8895, 2072, 19, 488, 2, 1776, 2091, 19, 144, 42, 8, 923, 334, 39, 111, 429, 115, 25, 239, 13, 810, 83, 33, 19, 144, 46, 94, 2396, 5133, 38, 2, 336, 1144, 4, 64, 43, 62, 2, 741, 6, 229, 214, 17, 68, 1833, 22, 217, 637, 9, 147, 43, 947, 2, 36]",1379.0,20699438,351
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2010-08-20,"Biomarkers to predict response to therapy in adults with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) are not yet established. In this study, we performed a meta-analysis of earlier genome-wide gene expression studies to identify pathway-based genes that are associated with therapeutic response. The predictive power of these genes was validated by transcript profiling in diagnostic bone marrow samples from Ph+ ALL patients using a quantitative real-time PCR array. Gene expression was correlated with cytogenetic and molecular characteristics, including presence of ABL1 mutations and IKZF1 deletion. A total of 43 de novo Ph+ ALL patients treated uniformly with tyrosine kinase inhibitors combined with chemotherapy were selected to validate 46 identified genes. A 9-gene signature was established to distinguish optimal responders from patients with persistent residual disease and early molecular recurrence. The signature was subsequently validated with 87% predictive accuracy in an independent validation set of patients. When initially optimal responders relapsed, their gene expression patterns also shifted. Optimal responders showed upregulation of genes involved in proliferation and apoptosis pathways, whereas poor responders had higher expression of genes that facilitate tumor cell survival in hypoxic conditions as well as development of drug resistance. This unique 9-gene signature may better enable stratification of patients to proper therapeutic regimens and provides new insights into mechanisms of Ph+ ALL response to therapy.",Journal Article,3441.0,6.0,Biomarkers to predict response to therapy in adults with Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL are not yet established In this study we performed a meta-analysis of earlier genome-wide gene expression studies to identify pathway-based genes that are associated with therapeutic response The predictive power of these genes was validated by transcript profiling in diagnostic marrow samples from Ph+ ALL patients using a quantitative real-time PCR array Gene expression was correlated with cytogenetic and molecular characteristics including presence of ABL1 mutations and IKZF1 deletion A total of 43 de novo Ph+ ALL patients treated uniformly with tyrosine kinase inhibitors combined with chemotherapy were selected to validate 46 identified genes A 9-gene signature was established to distinguish optimal responders from patients with persistent residual disease and early molecular recurrence The signature was subsequently validated with 87 predictive accuracy in an independent validation set of patients When initially optimal responders relapsed their gene expression patterns also shifted Optimal responders showed upregulation of genes involved in proliferation and apoptosis pathways whereas poor responders had higher expression of genes that facilitate tumor cell survival in hypoxic conditions as well as development of drug resistance This unique 9-gene signature may better enable stratification of patients to proper therapeutic regimens and provides new insights into mechanisms of Ph+ ALL response to therapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[582, 6, 678, 51, 6, 36, 4, 857, 5, 3006, 1170, 109, 2058, 286, 1275, 62, 32, 44, 1145, 635, 4, 26, 45, 21, 173, 8, 1742, 65, 1, 1677, 898, 1019, 145, 55, 94, 6, 255, 308, 90, 214, 17, 32, 41, 5, 189, 51, 3, 464, 2349, 1, 46, 214, 10, 938, 20, 3268, 1080, 4, 752, 581, 347, 29, 2058, 62, 7, 75, 8, 1156, 1589, 98, 604, 1926, 145, 55, 10, 438, 5, 1266, 2, 219, 374, 141, 463, 1, 3557, 138, 2, 8422, 1528, 8, 181, 1, 601, 1566, 2018, 2058, 62, 7, 73, 4254, 5, 564, 216, 222, 397, 5, 56, 11, 715, 6, 2183, 641, 108, 214, 8, 83, 145, 1651, 10, 635, 6, 3081, 665, 1983, 29, 7, 5, 1882, 753, 34, 2, 191, 219, 146, 3, 1651, 10, 1611, 938, 5, 912, 464, 1190, 4, 35, 306, 929, 916, 1, 7, 198, 1625, 665, 1983, 591, 136, 145, 55, 764, 120, 7289, 665, 1983, 224, 2218, 1, 214, 646, 4, 457, 2, 351, 460, 547, 334, 1983, 42, 142, 55, 1, 214, 17, 1876, 30, 31, 25, 4, 4744, 1298, 22, 149, 22, 193, 1, 234, 251, 26, 991, 83, 145, 1651, 68, 380, 3047, 1541, 1, 7, 6, 4576, 189, 472, 2, 777, 217, 1957, 237, 483, 1, 2058, 62, 51, 6, 36]",1549.0,20729815,215
L-asparaginase treatment in acute lymphoblastic leukemia: a focus on Erwinia asparaginase.,Cancer,Cancer,2010-09-07,"Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic leukemia (ALL) and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols. Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL. Three asparaginase preparations are available: the native asparaginase derived from Escherichia coli (E. coli asparaginase), a pegylated form of this enzyme (PEG-asparaginase), and a product isolated from Erwinia chrysanthemi, ie, Erwinia asparaginase. Clinical hypersensitivity reactions and silent inactivation due to antibodies against E. coli asparaginase, lead to inactivation of E. coli asparaginase in up to 60% of cases. Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL. Typically, patients exhibiting sensitivity to one formulation of asparaginase are switched to another to ensure they receive the most efficacious treatment regimen possible. Erwinia asparaginase is used as a second- or third-line treatment in European and US protocols. Despite the universal inclusion of asparaginase in such treatment protocols, debate on the optimal formulation and dosage of these agents continues. This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL.",Journal Article,3423.0,261.0,Asparaginases are a cornerstone of treatment protocols for acute lymphoblastic ALL and are used for remission induction and intensification treatment in all pediatric regimens and in the majority of adult treatment protocols Extensive clinical data have shown that intensive asparaginase treatment improves clinical outcomes in childhood ALL Three asparaginase preparations are available the native asparaginase derived from Escherichia coli E. coli asparaginase a pegylated form of this enzyme PEG-asparaginase and a product isolated from Erwinia chrysanthemi ie Erwinia asparaginase Clinical hypersensitivity reactions and silent inactivation due to antibodies against E. coli asparaginase lead to inactivation of E. coli asparaginase in up to 60 of cases Current treatment protocols include E. coli asparaginase or PEG-asparaginase for first-line treatment of ALL Typically patients exhibiting sensitivity to one formulation of asparaginase are switched to another to ensure they receive the most efficacious treatment regimen possible Erwinia asparaginase is used as a second- or third-line treatment in European and US protocols Despite the universal inclusion of asparaginase in such treatment protocols debate on the optimal formulation and dosage of these agents continues This article provides an overview of available evidence for optimal use of Erwinia asparaginase in the treatment of ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[38872, 32, 8, 7019, 1, 24, 2189, 9, 286, 1275, 62, 2, 32, 95, 9, 734, 504, 2, 5091, 24, 4, 62, 815, 472, 2, 4, 3, 686, 1, 780, 24, 2189, 1344, 38, 74, 47, 443, 17, 1686, 3709, 24, 1804, 38, 123, 4, 864, 62, 169, 3709, 7791, 32, 390, 3, 4646, 3709, 526, 29, 12832, 6959, 563, 6959, 3709, 8, 4424, 1297, 1, 26, 1644, 3145, 3709, 2, 8, 2821, 1355, 29, 11358, 23864, 2523, 11358, 3709, 38, 4034, 2428, 2, 9890, 2297, 520, 6, 890, 480, 563, 6959, 3709, 1122, 6, 2297, 1, 563, 6959, 3709, 4, 126, 6, 335, 1, 140, 291, 24, 2189, 643, 563, 6959, 3709, 15, 3145, 3709, 9, 157, 328, 24, 1, 62, 1969, 7, 4801, 485, 6, 104, 3583, 1, 3709, 32, 7883, 6, 1809, 6, 3478, 491, 560, 3, 96, 3289, 24, 477, 899, 11358, 3709, 16, 95, 22, 8, 419, 15, 1282, 328, 24, 4, 1865, 2, 843, 2189, 550, 3, 4967, 1680, 1, 3709, 4, 225, 24, 2189, 5220, 23, 3, 665, 3583, 2, 3323, 1, 46, 183, 2274, 26, 946, 777, 35, 2901, 1, 390, 241, 9, 665, 119, 1, 11358, 3709, 4, 3, 24, 1, 62]",1400.0,20824725,555
The controversy of varicella vaccination in children with acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2010-09-16,"The available guidelines for varicella vaccination of susceptible children with acute lymphoblastic leukemia (ALL) have become increasingly conservative. However, vaccination of those who have remained in continuous complete remission for 1 year and are receiving chemotherapy is still considered a reasonable option. There is little available data to allow a comparison of the risk versus benefit of vaccinating these patients. We retrospectively reviewed mortality due to varicella in the records of 15 pediatric ALL study groups throughout Europe, Asia, and North America during the period 1984-2008. We found that 20 of 35,128 children with ALL (0.057%; 95% confidence interval [CI], 0.037-0.088%) died of VZV infection. The mortality rate was lower in North America (3 of 11,558 children, 0.026%; 95% CI, 0.009-0.076%) than in the Asian countries (2 of 4,882 children, 0.041%; 95% CI, 0.011-0.149%) and in Europe (15 of 18,688 children, 0.080%; 95% CI, 0.049-0.132%) consistent with the generally higher rate of VZV vaccination in North America. Fourteen of the 20 patients (70%) died during the first year of treatment for ALL. One death was attributed to varicella vaccination. The negligible rate of fatal varicella infection in children with ALL, the risk that accompanies vaccination, and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL.",Journal Article,3414.0,22.0,"The available guidelines for varicella vaccination of susceptible children with acute lymphoblastic ALL have become increasingly conservative However vaccination of those who have remained in continuous complete remission for 1 year and are receiving chemotherapy is still considered a reasonable option There is little available data to allow a comparison of the risk versus benefit of vaccinating these patients We retrospectively reviewed mortality due to varicella in the records of 15 pediatric ALL study groups throughout Europe Asia and North America during the period 1984-2008 We found that 20 of 35,128 children with ALL 0.057 95 confidence interval CI 0.037-0.088 died of VZV infection The mortality rate was lower in North America 3 of 11,558 children 0.026 95 CI 0.009-0.076 than in the Asian countries 2 of 4,882 children 0.041 95 CI 0.011-0.149 and in Europe 15 of 18,688 children 0.080 95 CI 0.049-0.132 consistent with the generally higher rate of VZV vaccination in North America Fourteen of the 20 patients 70 died during the first year of treatment for ALL One death was attributed to varicella vaccination The negligible rate of fatal varicella infection in children with ALL the risk that accompanies vaccination and the necessity of withholding chemotherapy for vaccination appear to outweigh the potential benefit of varicella vaccination for children during treatment of ALL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 390, 677, 9, 17098, 1915, 1, 4012, 541, 5, 286, 1275, 62, 47, 1417, 1635, 4476, 137, 1915, 1, 135, 54, 47, 958, 4, 1314, 236, 734, 9, 14, 111, 2, 32, 357, 56, 16, 1234, 515, 8, 3203, 1501, 125, 16, 1215, 390, 74, 6, 1700, 8, 1155, 1, 3, 43, 185, 247, 1, 20348, 46, 7, 21, 894, 446, 282, 520, 6, 17098, 4, 3, 1064, 1, 167, 815, 62, 45, 271, 2432, 3934, 5958, 2, 2669, 4010, 190, 3, 727, 6036, 1375, 21, 204, 17, 179, 1, 465, 3990, 541, 5, 62, 13, 10807, 48, 307, 268, 58, 13, 5171, 13, 13848, 1016, 1, 15871, 930, 3, 282, 116, 10, 280, 4, 2669, 4010, 27, 1, 175, 12570, 541, 13, 4554, 48, 58, 13, 2376, 13, 13973, 76, 4, 3, 2399, 2115, 18, 1, 39, 14556, 541, 13, 5937, 48, 58, 13, 3651, 13, 4928, 2, 4, 3934, 167, 1, 203, 13899, 541, 13, 15490, 48, 58, 13, 5121, 13, 4255, 925, 5, 3, 1228, 142, 116, 1, 15871, 1915, 4, 2669, 4010, 3225, 1, 3, 179, 7, 431, 1016, 190, 3, 157, 111, 1, 24, 9, 62, 104, 273, 10, 3073, 6, 17098, 1915, 3, 6821, 116, 1, 3034, 17098, 930, 4, 541, 5, 62, 3, 43, 17, 14783, 1915, 2, 3, 7378, 1, 16673, 56, 9, 1915, 1322, 6, 11592, 3, 174, 247, 1, 17098, 1915, 9, 541, 190, 24, 1, 62]",1399.0,20848637,6
Clinical outcome of children with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia treated between 1995 and 2005.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-09-27,"In a previous analysis of 326 children with Philadelphia chromosome (Ph) -positive acute lymphoblastic leukemia (ALL) treated between 1986 and 1996, hematopoietic stem-cell transplantation from HLA-matched related donors, but not from unrelated donors, offered a superior outcome than chemotherapy alone. To evaluate the impact of recent improvements in chemotherapy and transplantation, we performed a similar analysis on patients treated in the following decade. We analyzed 610 patients with Ph-positive ALL treated between 1995 and 2005 without tyrosine kinase inhibitor therapy. The median follow-up duration was 6.3 years. Complete remission was achieved in 89% of patients. The 7-year event-free survival and overall survival rates were superior in the present cohort compared with the previous cohort (32.0%  2.0% v 25.0%  3.0, respectively, P = .007; and 44.9%  2.2% v 36.0%  3.0%, respectively, P = .017). Compared with chemotherapy alone, transplantation with matched related donors or unrelated donors in first remission (325 patients) showed an advantage with increasing follow-up, suggesting greater protection against late relapses (hazard ratio at 5 years, 0.37; P < .001). In the multivariate Cox regression analysis accounting for treatment (transplantation v no transplantation), age, leukocyte count, and early response had independent impact on treatment outcome. Clinical outcome of children and adolescents with Ph-positive ALL has improved with advances in transplantation and chemotherapy. Transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone. Age, leukocyte count, and early treatment response were independent prognostic indicators. The results of this study will serve as a historical reference to evaluate the therapeutic impact of tyrosine kinase inhibitors on the outcome of Ph-positive ALL.",Journal Article,3403.0,127.0,In a previous analysis of 326 children with Philadelphia chromosome Ph -positive acute lymphoblastic ALL treated between 1986 and 1996 hematopoietic stem-cell transplantation from HLA-matched related donors but not from unrelated donors offered a superior outcome than chemotherapy alone To evaluate the impact of recent improvements in chemotherapy and transplantation we performed a similar analysis on patients treated in the following decade We analyzed 610 patients with Ph-positive ALL treated between 1995 and 2005 without tyrosine kinase inhibitor therapy The median follow-up duration was 6.3 years Complete remission was achieved in 89 of patients The 7-year event-free survival and overall survival rates were superior in the present cohort compared with the previous cohort 32.0  2.0 v 25.0  3.0 respectively P .007 and 44.9  2.2 v 36.0  3.0 respectively P .017 Compared with chemotherapy alone transplantation with matched related donors or unrelated donors in first remission 325 patients showed an advantage with increasing follow-up suggesting greater protection against late relapses hazard ratio at 5 years 0.37 P .001 In the multivariate Cox regression analysis accounting for treatment transplantation v no transplantation age leukocyte count and early response had independent impact on treatment outcome Clinical outcome of children and adolescents with Ph-positive ALL has improved with advances in transplantation and chemotherapy Transplantations with matched related donors and unrelated donors were equivalent and offered better disease control compared with chemotherapy alone Age leukocyte count and early treatment response were independent prognostic indicators The results of this study will serve as a historical reference to evaluate the therapeutic impact of tyrosine kinase inhibitors on the outcome of Ph-positive ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 8, 698, 65, 1, 9588, 541, 5, 3006, 1170, 2058, 109, 286, 1275, 62, 73, 59, 3751, 2, 2648, 1007, 452, 31, 497, 29, 1160, 655, 139, 2344, 84, 44, 29, 2092, 2344, 2216, 8, 1123, 228, 76, 56, 279, 6, 376, 3, 345, 1, 435, 1474, 4, 56, 2, 497, 21, 173, 8, 288, 65, 23, 7, 73, 4, 3, 366, 2025, 21, 311, 11302, 7, 5, 2058, 109, 62, 73, 59, 2323, 2, 1242, 187, 564, 216, 230, 36, 3, 52, 166, 126, 654, 10, 49, 27, 60, 236, 734, 10, 513, 4, 887, 1, 7, 3, 67, 111, 774, 115, 25, 2, 63, 25, 151, 11, 1123, 4, 3, 364, 180, 72, 5, 3, 698, 180, 531, 13, 810, 18, 13, 603, 243, 13, 810, 27, 13, 106, 19, 1999, 2, 584, 83, 810, 18, 18, 603, 511, 13, 810, 27, 13, 106, 19, 3825, 72, 5, 56, 279, 497, 5, 655, 139, 2344, 15, 2092, 2344, 4, 157, 734, 7139, 7, 224, 35, 1874, 5, 602, 166, 126, 802, 378, 3525, 480, 807, 3713, 360, 197, 28, 33, 60, 13, 567, 19, 144, 4, 3, 331, 418, 320, 65, 3116, 9, 24, 497, 603, 77, 497, 89, 3627, 1276, 2, 191, 51, 42, 306, 345, 23, 24, 228, 38, 228, 1, 541, 2, 3101, 5, 2058, 109, 62, 71, 231, 5, 954, 4, 497, 2, 56, 6779, 5, 655, 139, 2344, 2, 2092, 2344, 11, 2017, 2, 2216, 380, 34, 182, 72, 5, 56, 279, 89, 3627, 1276, 2, 191, 24, 51, 11, 306, 177, 3539, 3, 99, 1, 26, 45, 303, 1833, 22, 8, 2252, 2482, 6, 376, 3, 189, 345, 1, 564, 216, 222, 23, 3, 228, 1, 2058, 109, 62]",1858.0,20876426,679
"Adolescent cancer survivors' smoking intentions are associated with aggression, attention, and smoking history.",Journal of cancer survivorship : research and practice,J Cancer Surviv,2010-10-05,"The present study examines behavioral and psychosocial factors associated with smoking intentions and experimentation among adolescent survivors of pediatric cancer. Adolescent survivors of brain tumor and acute lymphoblastic leukemia (n = 99) provided information about their smoking histories and their intentions to smoke in the future. Behavior rating scales were completed by survivors, parents, and teachers. Past experimentation with smoking and higher levels of self-reported aggression were associated with intentions to smoke in the future (OR = 4.18, 95% CI 1.02-17.04, and OR = 1.08, 95% CI 1.01-1.15, respectively), while teacher-ratings of inattention in the classroom were negatively associated with intentions to smoke (OR = 0.94, 95% CI.88-.99), all p <.05. Experimentation with smoking was more likely among older survivors (OR = 1.76, 95% CI 1.16-2.66, p <.01) and those whose parents had divorced (OR = 4.40, 95% CI 1.21-16.06, p <.05). A concerning minority of adolescent survivors have clear intentions to smoke, a behavior that adds to their overall health risk. Smoking intentions and experimentation are important precursors to regular smoking. Prevention efforts are needed to interrupt the progression from intentions and experimentation to established smoking and nicotine dependence in this medically vulnerable population. Assessment of an adolescent's history of parental divorce, past experimentation with smoking, and aggressive behavior will identify those survivors who are likely to consider smoking in the future. Screening for these characteristics will allow clinicians to be more vigilant in health promotion.",Journal Article,3395.0,7.0,The present study examines behavioral and psychosocial factors associated with smoking intentions and experimentation among adolescent survivors of pediatric cancer Adolescent survivors of brain tumor and acute lymphoblastic n 99 provided information about their smoking histories and their intentions to smoke in the future Behavior rating scales were completed by survivors parents and teachers Past experimentation with smoking and higher levels of self-reported aggression were associated with intentions to smoke in the future OR 4.18 95 CI 1.02-17.04 and OR 1.08 95 CI 1.01-1.15 respectively while teacher-ratings of inattention in the classroom were negatively associated with intentions to smoke OR 0.94 95 CI.88-.99 all p .05 Experimentation with smoking was more likely among older survivors OR 1.76 95 CI 1.16-2.66 p .01 and those whose parents had divorced OR 4.40 95 CI 1.21-16.06 p .05 A concerning minority of adolescent survivors have clear intentions to smoke a behavior that adds to their overall health risk Smoking intentions and experimentation are important precursors to regular smoking Prevention efforts are needed to interrupt the progression from intentions and experimentation to established smoking and nicotine dependence in this medically vulnerable population Assessment of an adolescent 's history of parental divorce past experimentation with smoking and aggressive behavior will identify those survivors who are likely to consider smoking in the future Screening for these characteristics will allow clinicians to be more vigilant in health promotion,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 364, 45, 4468, 4166, 2, 2322, 130, 41, 5, 979, 11081, 2, 17997, 107, 3678, 332, 1, 815, 12, 3678, 332, 1, 342, 30, 2, 286, 1275, 78, 1058, 1052, 487, 545, 136, 979, 5329, 2, 136, 11081, 6, 6113, 4, 3, 508, 1710, 5477, 5083, 11, 781, 20, 332, 2418, 2, 46262, 1219, 17997, 5, 979, 2, 142, 148, 1, 1074, 210, 28326, 11, 41, 5, 11081, 6, 6113, 4, 3, 508, 15, 39, 203, 48, 58, 14, 588, 269, 755, 2, 15, 14, 1592, 48, 58, 14, 355, 14, 167, 106, 369, 46263, 5548, 1, 23873, 4, 3, 34992, 11, 2723, 41, 5, 11081, 6, 6113, 15, 13, 960, 48, 58, 889, 1058, 62, 19, 474, 17997, 5, 979, 10, 80, 322, 107, 434, 332, 15, 14, 846, 48, 58, 14, 245, 18, 700, 19, 355, 2, 135, 1310, 2418, 42, 14310, 15, 39, 327, 48, 58, 14, 239, 245, 1460, 19, 474, 8, 4243, 2652, 1, 3678, 332, 47, 885, 11081, 6, 6113, 8, 1710, 17, 6659, 6, 136, 63, 341, 43, 979, 11081, 2, 17997, 32, 305, 4881, 6, 3316, 979, 1070, 1413, 32, 575, 6, 15870, 3, 91, 29, 11081, 2, 17997, 6, 635, 979, 2, 8344, 3721, 4, 26, 4381, 5017, 266, 455, 1, 35, 3678, 292, 532, 1, 3418, 25289, 1219, 17997, 5, 979, 2, 571, 1710, 303, 255, 135, 332, 54, 32, 322, 6, 2419, 979, 4, 3, 508, 453, 9, 46, 374, 303, 1700, 1490, 6, 40, 80, 13071, 4, 341, 5478]",1585.0,20922493,6
Interferon- secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells.,Leukemia research,Leuk. Res.,2010-10-12,"Interferon (IFN)- plays an important role in immunity and anti-tumor activity. It is produced by lymphocytes, but was recently shown to be also produced by human myeloid dendritic cells (DCs). We have shown that human mature t(9;22) acute lymphoblastic leukemia-derived (ALL) DCs induced autologous cytotoxic T cell responses and therefore asked whether t(9;22) ALL-DC secreted IFN-. IFN- varied among three cell line-derived ALL-DCs; median production from seven patient ALL-DCs was 3450 pg/ml (range 1450-8675). IFN- production was dependent on maturation of ALL-DCs. This is the first demonstration of IFN- production by t(9;22) ALL-DCs.",Journal Article,3388.0,5.0,Interferon IFN - plays an important role in immunity and anti-tumor activity It is produced by lymphocytes but was recently shown to be also produced by human myeloid dendritic cells DCs We have shown that human mature t 9 22 acute lymphoblastic leukemia-derived ALL DCs induced autologous cytotoxic T cell responses and therefore asked whether t 9 22 ALL-DC secreted IFN- IFN- varied among three cell line-derived ALL-DCs median production from seven patient ALL-DCs was 3450 pg/ml range 1450-8675 IFN- production was dependent on maturation of ALL-DCs This is the first demonstration of IFN- production by t 9 22 ALL-DCs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1688, 1256, 2655, 1698, 35, 305, 200, 4, 1604, 2, 312, 30, 128, 192, 16, 1687, 20, 1594, 84, 10, 761, 443, 6, 40, 120, 1687, 20, 171, 533, 2464, 37, 3110, 21, 47, 443, 17, 171, 2908, 102, 83, 350, 286, 1275, 2647, 526, 62, 3110, 277, 1028, 759, 102, 31, 253, 2, 673, 3732, 317, 102, 83, 350, 62, 2321, 3613, 1256, 2655, 1256, 2655, 2051, 107, 169, 31, 328, 526, 62, 3110, 52, 1529, 29, 648, 69, 62, 3110, 10, 59444, 3234, 542, 184, 39449, 59445, 1256, 2655, 1529, 10, 470, 23, 4537, 1, 62, 3110, 26, 16, 3, 157, 6533, 1, 1256, 2655, 1529, 20, 102, 83, 350, 62, 3110]",627.0,20943267,356
Dose escalation of lenalidomide in relapsed or refractory acute leukemias.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-10-18,"Lenalidomide is effective in myeloma and low-risk myelodysplastic syndromes with deletion 5q. We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute leukemia. Thirty-one adults with acute myeloid leukemia (AML) and four adults with acute lymphoblastic leukemia (ALL) were enrolled. Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity (DLT) and maximum-tolerated dose (MTD), as well as to provide pharmacokinetic and preliminary efficacy data. Patients had a median age of 63 years (range, 22 to 79 years) and a median of two prior therapies (range, one to four therapies). The DLT was fatigue; 50 mg/d was the MTD. Infectious complications were frequent. Plasma lenalidomide concentration increased proportionally with dose. In AML, five (16%) of 31 patients achieved complete remission (CR); three of three patients with cytogenetic abnormalities achieved cytogenetic CR (none with deletion 5q). Response duration ranged from 5.6 to 14 months. All responses occurred in AML with low presenting WBC count. No patient with ALL responded. Two of four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after development of cutaneous graft-versus-host disease, without donor leukocyte infusion. Lenalidomide was safely escalated to 50 mg daily for 21 days, every 4 weeks, and was active with relatively low toxicity in patients with relapsed/refractory AML. Remissions achieved after transplantation suggest a possible immunomodulatory effect of lenalidomide, and results provide enthusiasm for further studies in AML, either alone or in combination with conventional agents or other immunotherapies.","Clinical Trial, Phase I",3382.0,72.0,Lenalidomide is effective in and low-risk syndromes with deletion 5q We report results of a phase I dose-escalation trial of lenalidomide in relapsed or refractory acute Thirty-one adults with acute myeloid AML and four adults with acute lymphoblastic ALL were enrolled Lenalidomide was given orally at escalating doses of 25 to 75 mg daily on days 1 through 21 of 28-day cycles to determine the dose-limiting toxicity DLT and maximum-tolerated dose MTD as well as to provide pharmacokinetic and preliminary efficacy data Patients had a median age of 63 years range 22 to 79 years and a median of two prior therapies range one to four therapies The DLT was fatigue 50 mg/d was the MTD Infectious complications were frequent Plasma lenalidomide concentration increased proportionally with dose In AML five 16 of 31 patients achieved complete remission CR three of three patients with cytogenetic abnormalities achieved cytogenetic CR none with deletion 5q Response duration ranged from 5.6 to 14 months All responses occurred in AML with low presenting WBC count No patient with ALL responded Two of four patients who received lenalidomide as initial therapy for AML relapse after allogeneic transplantation achieved durable CR after development of cutaneous graft-versus-host disease without donor leukocyte infusion Lenalidomide was safely escalated to 50 mg daily for 21 days every 4 weeks and was active with relatively low toxicity in patients with relapsed/refractory AML Remissions achieved after transplantation suggest a possible immunomodulatory effect of lenalidomide and results provide enthusiasm for further studies in AML either alone or in combination with conventional agents or other immunotherapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1288, 16, 323, 4, 2, 154, 43, 2040, 5, 1528, 5460, 21, 414, 99, 1, 8, 124, 70, 61, 1125, 160, 1, 1288, 4, 591, 15, 430, 286, 977, 104, 857, 5, 286, 533, 329, 2, 294, 857, 5, 286, 1275, 62, 11, 346, 1288, 10, 447, 1428, 28, 2922, 415, 1, 243, 6, 481, 81, 391, 23, 162, 14, 298, 239, 1, 339, 218, 410, 6, 223, 3, 61, 817, 155, 2059, 2, 689, 421, 61, 961, 22, 149, 22, 6, 377, 1456, 2, 1676, 209, 74, 7, 42, 8, 52, 89, 1, 676, 60, 184, 350, 6, 842, 60, 2, 8, 52, 1, 100, 324, 235, 184, 104, 6, 294, 235, 3, 2059, 10, 613, 212, 81, 427, 10, 3, 961, 3398, 521, 11, 908, 554, 1288, 1227, 101, 11142, 5, 61, 4, 329, 365, 245, 1, 456, 7, 513, 236, 734, 684, 169, 1, 169, 7, 5, 1266, 1171, 513, 1266, 684, 1292, 5, 1528, 5460, 51, 654, 1869, 29, 33, 49, 6, 213, 53, 62, 253, 489, 4, 329, 5, 154, 1656, 4685, 1276, 77, 69, 5, 62, 2211, 100, 1, 294, 7, 54, 103, 1288, 22, 388, 36, 9, 329, 429, 50, 1063, 497, 513, 1480, 684, 50, 193, 1, 1486, 1599, 185, 1204, 34, 187, 1488, 3627, 904, 1288, 10, 2268, 2842, 6, 212, 81, 391, 9, 239, 162, 454, 39, 244, 2, 10, 544, 5, 1352, 154, 155, 4, 7, 5, 591, 430, 329, 3166, 513, 50, 497, 309, 8, 899, 2555, 254, 1, 1288, 2, 99, 377, 8582, 9, 195, 94, 4, 329, 361, 279, 15, 4, 150, 5, 809, 183, 15, 127, 2811]",1716.0,20956622,318
Very late recurrences of leukemia: why does leukemia awake after many years of dormancy?,Leukemia research,Leuk. Res.,2011-02-01,"We report a heterogeneous group of very late recurrences of leukemia occurring more than 10 years after initial treatment including 2 cases of childhood acute lymphoblastic leukemia (ALL) which recurred after more than 20 years of remission, 2 cases of donor cell leukemia which developed more than 10 years after allograft for acute myeloid leukemia (AML) and high risk myelodysplastic syndrome (MDS) and 2 cases of chronic myeloid leukemia (CML) relapsing 13 and 17 years after allograft. Case descriptions are followed by a discussion regarding possible mechanisms leading to leukemia recurrence and a review of the literature.",Case Reports,3276.0,15.0,We report a heterogeneous group of very late recurrences of occurring more than 10 years after initial treatment including 2 cases of childhood acute lymphoblastic ALL which recurred after more than 20 years of remission 2 cases of donor cell which developed more than 10 years after allograft for acute myeloid AML and high risk syndrome MDS and 2 cases of chronic myeloid CML relapsing 13 and 17 years after allograft Case descriptions are followed by a discussion regarding possible mechanisms leading to recurrence and a review of the literature,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 8, 1564, 87, 1, 923, 807, 1593, 1, 1821, 80, 76, 79, 60, 50, 388, 24, 141, 18, 140, 1, 864, 286, 1275, 62, 92, 3363, 50, 80, 76, 179, 60, 1, 734, 18, 140, 1, 1488, 31, 92, 276, 80, 76, 79, 60, 50, 9568, 9, 286, 533, 329, 2, 64, 43, 681, 1223, 2, 18, 140, 1, 442, 533, 903, 6758, 233, 2, 269, 60, 50, 9568, 473, 11798, 32, 370, 20, 8, 2488, 666, 899, 483, 1049, 6, 146, 2, 8, 206, 1, 3, 789]",549.0,20970853,25
Nutritional intake of long-term survivors of childhood acute lymphoblastic leukemia: evidence for bone health interventional opportunities.,Pediatric blood & cancer,Pediatr Blood Cancer,2010-12-01,"Survivors of childhood acute lymphoblastic leukemia (ALL) are vulnerable to exaggeration of the aging process including decreased bone mineral density (BMD). As little is known about their dietary or nutrient intake that may affect their long-term bone health, we examined nutrient intake in long-term survivors of childhood ALL. Survivors (n = 164) of childhood ALL who had completed treatment for at least 5 years and were in continuous remission, completed a 110-item food questionnaire that reflected dietary intake over the previous year. The analyzed cohort comprised 34 females and 38 males younger than 19 years and 45 females and 47 males at least 19 years. Reported nutrient intake and food selection were compared with age-specific Recommended Dietary Allowance and USDA Pyramid Food Guide. Body mass index was compared to the general US population, adjusted for age, gender, Tanner stage and race. Less than 30% of participants met recommended dietary intakes for vitamin D, calcium, potassium, or magnesium regardless of age. Mean daily caloric intake was 2,204 kcal (51% from carbohydrates) for younger and 2,160 kcal (49% from carbohydrates) for older participants. Energy intake from sweets was 70% higher than recommended. Participants < 19 years were less likely to have a healthy weight (odds ratio 0.48, 95% CI 0.30-0.79); > 19 years more likely to be overweight (odds ratio 1.95, 95% CI 1.11-3.32, P < 0.002). Survivors of childhood ALL need careful dietary intervention to optimize long-term health.",Journal Article,3338.0,38.0,"Survivors of childhood acute lymphoblastic ALL are vulnerable to exaggeration of the aging process including decreased mineral density BMD As little is known about their dietary or nutrient intake that may affect their long-term health we examined nutrient intake in long-term survivors of childhood ALL Survivors n 164 of childhood ALL who had completed treatment for at least 5 years and were in continuous remission completed a 110-item food questionnaire that reflected dietary intake over the previous year The analyzed cohort comprised 34 females and 38 males younger than 19 years and 45 females and 47 males at least 19 years Reported nutrient intake and food selection were compared with age-specific Recommended Dietary Allowance and USDA Pyramid Food Guide Body mass index was compared to the general US population adjusted for age gender Tanner stage and race Less than 30 of participants met recommended dietary intakes for vitamin D calcium potassium or magnesium regardless of age Mean daily caloric intake was 2,204 kcal 51 from carbohydrates for younger and 2,160 kcal 49 from carbohydrates for older participants Energy intake from sweets was 70 higher than recommended Participants 19 years were less likely to have a healthy weight odds ratio 0.48 95 CI 0.30-0.79 19 years more likely to be overweight odds ratio 1.95 95 CI 1.11-3.32 P 0.002 Survivors of childhood ALL need careful dietary intervention to optimize long-term health",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 32, 5017, 6, 59482, 1, 3, 4220, 1129, 141, 340, 5033, 1263, 3503, 22, 1215, 16, 440, 545, 136, 2013, 15, 8749, 1514, 17, 68, 1158, 136, 319, 337, 341, 21, 409, 8749, 1514, 4, 319, 337, 332, 1, 864, 62, 332, 78, 5279, 1, 864, 62, 54, 42, 781, 24, 9, 28, 506, 33, 60, 2, 11, 4, 1314, 734, 781, 8, 3129, 3471, 1773, 1770, 17, 4686, 2013, 1514, 252, 3, 698, 111, 3, 311, 180, 2603, 562, 2451, 2, 519, 2296, 773, 76, 326, 60, 2, 512, 2451, 2, 662, 2296, 28, 506, 326, 60, 210, 8749, 1514, 2, 1773, 881, 11, 72, 5, 89, 112, 793, 2013, 26693, 2, 29085, 59483, 1773, 1597, 642, 782, 558, 10, 72, 6, 3, 1083, 843, 266, 586, 9, 89, 1632, 17471, 82, 2, 1047, 299, 76, 201, 1, 776, 543, 793, 2013, 5397, 9, 1610, 427, 3299, 13036, 15, 8089, 1583, 1, 89, 313, 391, 15667, 1514, 10, 18, 5996, 15632, 725, 29, 22196, 9, 773, 2, 18, 3457, 15632, 739, 29, 22196, 9, 434, 776, 2803, 1514, 29, 26621, 10, 431, 142, 76, 793, 776, 326, 60, 11, 299, 322, 6, 47, 8, 1331, 924, 610, 197, 13, 576, 48, 58, 13, 201, 13, 842, 326, 60, 80, 322, 6, 40, 3566, 610, 197, 14, 48, 48, 58, 14, 175, 27, 531, 19, 13, 1111, 332, 1, 864, 62, 594, 3465, 2013, 788, 6, 2465, 319, 337, 341]",1451.0,20981691,458
Targeting neuropilin-1 in human leukemia and lymphoma.,Blood,Blood,2010-11-09,"Targeted drug delivery offers an opportunity for the development of safer and more effective therapies for the treatment of cancer. In this study, we sought to identify short, cell-internalizing peptide ligands that could serve as directive agents for specific drug delivery in hematologic malignancies. By screening of human leukemia cells with a combinatorial phage display peptide library, we isolated a peptide motif, sequence Phe-Phe/Tyr-Any-Leu-Arg-Ser (F(F)/(Y)XLRS), which bound to different leukemia cell lines and to patient-derived bone marrow samples. The motif was internalized through a receptor-mediated pathway, and we next identified the corresponding receptor as the transmembrane glycoprotein neuropilin-1 (NRP-1). Moreover, we observed a potent anti-leukemia cell effect when the targeting motif was synthesized in tandem to the pro-apoptotic sequence (D)(KLAKLAK). Finally, our results confirmed increased expression of NRP-1 in representative human leukemia and lymphoma cell lines and in a panel of bone marrow specimens obtained from patients with acute lymphoblastic leukemia or acute myelogenous leukemia compared with normal bone marrow. These results indicate that NRP-1 could potentially be used as a target for ligand-directed therapy in human leukemias and lymphomas and that the prototype CGFYWLRSC-GG-(D)(KLAKLAK) is a promising drug candidate in this setting.",Journal Article,3360.0,71.0,Targeted drug delivery offers an opportunity for the development of safer and more effective therapies for the treatment of cancer In this study we sought to identify short cell-internalizing peptide ligands that could serve as directive agents for specific drug delivery in hematologic malignancies By screening of human cells with a combinatorial phage display peptide library we isolated a peptide motif sequence Phe-Phe/Tyr-Any-Leu-Arg-Ser F F Y XLRS which bound to different cell lines and to patient-derived marrow samples The motif was internalized through a receptor-mediated pathway and we next identified the corresponding receptor as the transmembrane glycoprotein neuropilin-1 NRP-1 Moreover we observed a potent anti-leukemia cell effect when the targeting motif was synthesized in tandem to the pro-apoptotic sequence D KLAKLAK  Finally our results confirmed increased expression of NRP-1 in representative human and cell lines and in a panel of marrow specimens obtained from patients with acute lymphoblastic or acute myelogenous compared with normal marrow These results indicate that NRP-1 could potentially be used as a target for ligand-directed therapy in human leukemias and lymphomas and that the prototype CGFYWLRSC-GG- D KLAKLAK  is a promising drug candidate in this setting,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[238, 234, 989, 2339, 35, 2666, 9, 3, 193, 1, 9276, 2, 80, 323, 235, 9, 3, 24, 1, 12, 4, 26, 45, 21, 990, 6, 255, 978, 31, 15932, 1389, 3123, 17, 359, 1833, 22, 16936, 183, 9, 112, 234, 989, 4, 813, 441, 20, 453, 1, 171, 37, 5, 8, 3866, 8648, 3640, 1389, 4157, 21, 1355, 8, 1389, 5298, 1532, 15139, 15139, 11106, 500, 11539, 7844, 6963, 1068, 1068, 2055, 59521, 92, 2951, 6, 338, 31, 285, 2, 6, 69, 526, 581, 347, 3, 5298, 10, 12149, 298, 8, 153, 517, 308, 2, 21, 1305, 108, 3, 1734, 153, 22, 3, 5527, 4455, 15253, 14, 11164, 14, 1393, 21, 164, 8, 1157, 312, 2647, 31, 254, 198, 3, 529, 5298, 10, 5134, 4, 2905, 6, 3, 1805, 1631, 1532, 427, 46315, 46316, 1368, 114, 99, 557, 101, 55, 1, 11164, 14, 4, 3724, 171, 2, 31, 285, 2, 4, 8, 993, 1, 581, 623, 683, 29, 7, 5, 286, 1275, 15, 286, 2194, 72, 5, 295, 581, 46, 99, 1008, 17, 11164, 14, 359, 751, 40, 95, 22, 8, 283, 9, 1232, 1166, 36, 4, 171, 2792, 2, 1557, 2, 17, 3, 8743, 59522, 4334, 427, 46315, 46316, 16, 8, 721, 234, 1609, 4, 26, 546]",1302.0,21063027,173
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome.,BMC medical genetics,BMC Med. Genet.,2010-11-16,"Myelodysplastic syndrome (MDS) may be induced by certain mutagenic environmental or chemotherapeutic toxins; however, the role of susceptibility genes remains unclear. The G/G genotype of the single-nucleotide polymorphism (SNP) rs1617640 in the erythropoietin (EPO) promoter has been shown to be associated with decreased EPO expression. We examined the association of rs1617640 genotype with MDS. We genotyped the EPO rS1617640 SNP in 189 patients with MDS, 257 with acute myeloid leukemia (AML), 106 with acute lymphoblastic leukemia, 97 with chronic lymphocytic leukemia, 353 with chronic myeloid leukemia, and 95 healthy controls. The G/G genotype was significantly more common in MDS patients (47/187; 25.1%) than in controls (6/95; 6.3%) or in patients with other leukemias (101/813; 12.4%) (all P < 0.001). Individuals with the G/G genotype were more likely than those with other genotypes to have MDS (odd ratio = 4.98; 95% CI = 2.04-12.13). Clinical and follow up data were available for 112 MDS patients and 186 AML patients. There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or AML. In the MDS group, the GG genotype was significantly associated with shorter complete remission duration, as compared with the TT genotype (P = 0.03). Time to neutrophils recovery after therapy was significantly longer in MDS patients with the G/G genotype (P = 0.02). These findings suggest a strong association between the rs1617640 G/G genotype and MDS. Further studies are warranted to investigate the utility of screening for this marker in individuals exposed to environmental toxins or chemotherapy.",Journal Article,3353.0,17.0,syndrome MDS may be induced by certain mutagenic environmental or chemotherapeutic toxins however the role of susceptibility genes remains unclear The G/G genotype of the single-nucleotide polymorphism SNP rs1617640 in the erythropoietin EPO promoter has been shown to be associated with decreased EPO expression We examined the association of rs1617640 genotype with MDS We genotyped the EPO rS1617640 SNP in 189 patients with MDS 257 with acute myeloid AML 106 with acute lymphoblastic 97 with chronic lymphocytic 353 with chronic myeloid and 95 healthy controls The G/G genotype was significantly more common in MDS patients 47/187 25.1 than in controls 6/95 6.3 or in patients with other leukemias 101/813 12.4 all P 0.001 Individuals with the G/G genotype were more likely than those with other genotypes to have MDS odd ratio 4.98 95 CI 2.04-12.13 Clinical and follow up data were available for 112 MDS patients and 186 AML patients There was no correlation between EPO promoter genotype and response to therapy or overall survival in MDS or AML In the MDS group the GG genotype was significantly associated with shorter complete remission duration as compared with the TT genotype P 0.03 Time to neutrophils recovery after therapy was significantly longer in MDS patients with the G/G genotype P 0.02 These findings suggest a strong association between the rs1617640 G/G genotype and MDS Further studies are warranted to investigate the utility of screening for this marker in individuals exposed to environmental toxins or chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[681, 1223, 68, 40, 277, 20, 1840, 14578, 3766, 15, 1573, 13820, 137, 3, 200, 1, 1432, 214, 469, 1200, 3, 499, 499, 1183, 1, 3, 226, 1579, 1907, 1845, 35006, 4, 3, 6266, 5423, 973, 71, 85, 443, 6, 40, 41, 5, 340, 5423, 55, 21, 409, 3, 248, 1, 35006, 1183, 5, 1223, 21, 3053, 3, 5423, 35006, 1845, 4, 5899, 7, 5, 1223, 7941, 5, 286, 533, 329, 3251, 5, 286, 1275, 1015, 5, 442, 1193, 10065, 5, 442, 533, 2, 48, 1331, 535, 3, 499, 499, 1183, 10, 97, 80, 186, 4, 1223, 7, 662, 5568, 243, 14, 76, 4, 535, 49, 48, 49, 27, 15, 4, 7, 5, 127, 2792, 2338, 15980, 133, 39, 62, 19, 13, 144, 869, 5, 3, 499, 499, 1183, 11, 80, 322, 76, 135, 5, 127, 2071, 6, 47, 1223, 12108, 197, 39, 1096, 48, 58, 18, 755, 133, 233, 38, 2, 166, 126, 74, 11, 390, 9, 3726, 1223, 7, 2, 5869, 329, 7, 125, 10, 77, 816, 59, 5423, 973, 1183, 2, 51, 6, 36, 15, 63, 25, 4, 1223, 15, 329, 4, 3, 1223, 87, 3, 4334, 1183, 10, 97, 41, 5, 985, 236, 734, 654, 22, 72, 5, 3, 3504, 1183, 19, 13, 680, 98, 6, 5700, 1602, 50, 36, 10, 97, 589, 4, 1223, 7, 5, 3, 499, 499, 1183, 19, 13, 588, 46, 272, 309, 8, 1082, 248, 59, 3, 35006, 499, 499, 1183, 2, 1223, 195, 94, 32, 1197, 6, 963, 3, 1207, 1, 453, 9, 26, 952, 4, 869, 2234, 6, 3766, 13820, 15, 56]",1543.0,21078205,198
Recent research advances in childhood acute lymphoblastic leukemia.,Journal of the Formosan Medical Association = Taiwan yi zhi,J. Formos. Med. Assoc.,2010-11-01,"Recent progress in risk-adapted treatment for childhood acute lymphoblastic leukemia has secured 5-year event-free survival rates of approximately 80% and 5-year survival rates approaching 90%. With improved systemic and intrathecal chemotherapy, it is now feasible to omit safely in all patients prophylactic cranial irradiation, which was once a standard treatment. As high-resolution, genome-wide analyses of leukemic and normal host cells continue to identify novel subtypes of lymphoblastic leukemia and provide new insights into leukemogenesis, we can look forward to the time when all cases of this disease will be classified according to specific genetic abnormalities, some of which will yield ""druggable"" targets for more effective and less toxic treatments. Meanwhile, it is sobering to consider that a significant fraction of leukemia survivors will develop serious health problems within 30 years of their initial diagnosis. This underlines the need to introduce early countermeasures to reduce late therapy-related effects. The ultimate challenge is to gain a clear understanding of the factors that give rise to childhood leukemia in the first place, and enable preventive strategies to be devised and implemented.",Journal Article,3368.0,,Recent progress in risk-adapted treatment for childhood acute lymphoblastic has secured 5-year event-free survival rates of approximately 80 and 5-year survival rates approaching 90 With improved systemic and intrathecal chemotherapy it is now feasible to omit safely in all patients prophylactic cranial irradiation which was once a standard treatment As high-resolution genome-wide analyses of leukemic and normal host cells continue to identify novel subtypes of lymphoblastic and provide new insights into leukemogenesis we can look forward to the time when all cases of this disease will be classified according to specific genetic abnormalities some of which will yield `` druggable '' targets for more effective and less toxic treatments Meanwhile it is sobering to consider that a significant fraction of survivors will develop serious health problems within 30 years of their initial diagnosis This underlines the need to introduce early countermeasures to reduce late therapy-related effects The ultimate challenge is to gain a clear understanding of the factors that give rise to childhood in the first place and enable preventive strategies to be devised and implemented,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 1466, 4, 43, 3716, 24, 9, 864, 286, 1275, 71, 23531, 33, 111, 774, 115, 25, 151, 1, 705, 493, 2, 33, 111, 25, 151, 7773, 424, 5, 231, 403, 2, 5126, 56, 192, 16, 1134, 1313, 6, 15339, 2268, 4, 62, 7, 1862, 2565, 1104, 92, 10, 1059, 8, 260, 24, 22, 64, 2125, 898, 1019, 318, 1, 2015, 2, 295, 1204, 37, 1906, 6, 255, 229, 814, 1, 1275, 2, 377, 217, 1957, 237, 5661, 21, 122, 5316, 4674, 6, 3, 98, 198, 62, 140, 1, 26, 34, 303, 40, 1373, 768, 6, 112, 336, 1171, 476, 1, 92, 303, 2309, 9309, 522, 637, 9, 80, 323, 2, 299, 1812, 640, 8197, 192, 16, 30431, 6, 2419, 17, 8, 93, 1509, 1, 332, 303, 690, 1762, 341, 2408, 262, 201, 60, 1, 136, 388, 147, 26, 25041, 3, 594, 6, 7630, 191, 46348, 6, 969, 807, 36, 139, 176, 3, 5768, 1745, 16, 6, 1803, 8, 885, 612, 1, 3, 130, 17, 4978, 3693, 6, 864, 4, 3, 157, 3536, 2, 3047, 3494, 422, 6, 40, 10085, 2, 3426]",1182.0,21126650,126
Gastrointestinal cancer educational case series: management of metastatic adenocarcinoma of unknown primary origin in a Ph+ ALL survivor.,Journal of gastrointestinal cancer,J Gastrointest Cancer,2011-09-01,"Secondary malignancies and chronic end-organ sequelae are significant and steadily rising consequences of cancer therapy. The workup and management of a carcinoma of unknown primary must consider the patient's clinical presentation, radiologic and pathologic findings, and comorbidities. We present the case of a 50-year-old female survivor of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with significant treatment-related end-organ sequelae who developed a metastatic adenocarcinoma of unknown primary 15years following curative therapy for her ALL. The complex management issues related to the investigations and choice of therapy for this patient are reviewed. This case discusses key issues related to the workup and management of a carcinoma of unknown primary. In addition, it illustrates the importance of taking patient comorbidities into consideration and tailoring investigations and therapy accordingly.",Case Reports,3064.0,0.0,Secondary malignancies and chronic end-organ sequelae are significant and steadily rising consequences of cancer therapy The workup and management of a carcinoma of unknown primary must consider the patient 's clinical presentation radiologic and pathologic findings and comorbidities We present the case of a 50-year-old female survivor of Philadelphia chromosome-positive acute lymphoblastic Ph+ ALL with significant treatment-related end-organ sequelae who developed a metastatic adenocarcinoma of unknown primary 15 years following curative therapy for her ALL The complex management issues related to the investigations and choice of therapy for this patient are reviewed This case discusses key issues related to the workup and management of a carcinoma of unknown primary In addition it illustrates the importance of taking patient comorbidities into consideration and tailoring investigations and therapy accordingly,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[568, 441, 2, 442, 396, 1259, 4156, 32, 93, 2, 7025, 3699, 3255, 1, 12, 36, 3, 4755, 2, 284, 1, 8, 134, 1, 860, 86, 1642, 2419, 3, 69, 292, 38, 1031, 2812, 2, 510, 272, 2, 1909, 21, 364, 3, 473, 1, 8, 212, 111, 1095, 1061, 2628, 1, 3006, 1170, 109, 286, 1275, 2058, 62, 5, 93, 24, 139, 396, 1259, 4156, 54, 276, 8, 113, 449, 1, 860, 86, 167, 60, 366, 1075, 36, 9, 1084, 62, 3, 840, 284, 1553, 139, 6, 3, 2492, 2, 1866, 1, 36, 9, 26, 69, 32, 446, 26, 473, 2759, 825, 1553, 139, 6, 3, 4755, 2, 284, 1, 8, 134, 1, 860, 86, 4, 352, 192, 6342, 3, 1187, 1, 2727, 69, 1909, 237, 2415, 2, 7101, 2492, 2, 36, 4705]",924.0,21128012,596
"Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia.",Blood,Blood,2010-12-10,"Osteonecrosis is a severe glucocorticoid-induced complication of acute lymphoblastic leukemia treatment. We prospectively screened children (n = 364) with magnetic resonance imaging of hips and knees, regardless of symptoms; the cumulative incidence of any (grade 1-4) versus symptomatic (grade 2-4) osteonecrosis was 71.8% versus 17.6%, respectively. We investigated whether age, race, sex, acute lymphoblastic leukemia treatment arm, body mass, serum lipids, albumin and cortisol levels, dexamethasone pharmacokinetics, and genome-wide germline genetic polymorphisms were associated with symptomatic osteonecrosis. Age more than 10 years (odds ratio, = 4.85; 95% confidence interval, 2.5-9.2; P = .00001) and more intensive treatment (odds ratio = 2.5; 95% confidence interval, 1.2-4.9; P = .011) were risk factors and included as covariates in all analyses. Lower albumin (P = .05) and elevated cholesterol (P = .02) associated with symptomatic osteonecrosis, and severe (grade 3 or 4) osteonecrosis was linked to poor dexamethasone clearance (P = .0005). Adjusting for clinical features, polymorphisms of ACP1 (eg, rs12714403, P = 1.9  10(-6), odds ratio = 5.6; 95% confidence interval, 2.7-11.3), which regulates lipid levels and osteoblast differentiation, were associated with risk of osteonecrosis as well as with lower albumin and higher cholesterol. Overall, older age, lower albumin, higher lipid levels, and dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic variation.",Clinical Trial,3329.0,153.0,Osteonecrosis is a severe glucocorticoid-induced complication of acute lymphoblastic treatment We prospectively screened children n 364 with magnetic resonance imaging of hips and knees regardless of symptoms the cumulative incidence of any grade 1-4 versus symptomatic grade 2-4 osteonecrosis was 71.8 versus 17.6 respectively We investigated whether age race sex acute lymphoblastic treatment arm body mass serum lipids albumin and cortisol levels dexamethasone pharmacokinetics and genome-wide germline genetic polymorphisms were associated with symptomatic osteonecrosis Age more than 10 years odds ratio 4.85 95 confidence interval 2.5-9.2 P .00001 and more intensive treatment odds ratio 2.5 95 confidence interval 1.2-4.9 P .011 were risk factors and included as covariates in all analyses Lower albumin P .05 and elevated cholesterol P .02 associated with symptomatic osteonecrosis and severe grade 3 or 4 osteonecrosis was linked to poor dexamethasone clearance P .0005 Adjusting for clinical features polymorphisms of ACP1 eg rs12714403 P 1.9 10 -6 odds ratio 5.6 95 confidence interval 2.7-11.3 which regulates lipid levels and osteoblast differentiation were associated with risk of osteonecrosis as well as with lower albumin and higher cholesterol Overall older age lower albumin higher lipid levels and dexamethasone exposure were associated with osteonecrosis and may be linked by inherited genomic variation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 16, 8, 905, 5399, 277, 1447, 1, 286, 1275, 24, 21, 1143, 2261, 541, 78, 10106, 5, 1484, 1535, 270, 1, 22230, 2, 28503, 1583, 1, 507, 3, 967, 287, 1, 500, 88, 14, 39, 185, 1704, 88, 18, 39, 5404, 10, 792, 66, 185, 269, 49, 106, 21, 565, 317, 89, 1047, 1035, 286, 1275, 24, 475, 642, 782, 524, 9176, 2799, 2, 9572, 148, 1217, 1159, 2, 898, 1019, 1009, 336, 1203, 11, 41, 5, 1704, 5404, 89, 80, 76, 79, 60, 610, 197, 39, 772, 48, 307, 268, 18, 33, 83, 18, 19, 7868, 2, 80, 1686, 24, 610, 197, 18, 33, 48, 307, 268, 14, 18, 39, 83, 19, 3651, 11, 43, 130, 2, 159, 22, 2489, 4, 62, 318, 280, 2799, 19, 474, 2, 804, 5020, 19, 588, 41, 5, 1704, 5404, 2, 905, 88, 27, 15, 39, 5404, 10, 1199, 6, 334, 1217, 1960, 19, 4252, 1358, 9, 38, 404, 1203, 1, 59634, 2887, 59635, 19, 14, 83, 79, 49, 610, 197, 33, 49, 48, 307, 268, 18, 67, 175, 27, 92, 2468, 3121, 148, 2, 7418, 910, 11, 41, 5, 43, 1, 5404, 22, 149, 22, 5, 280, 2799, 2, 142, 5020, 63, 434, 89, 280, 2799, 142, 3121, 148, 2, 1217, 645, 11, 41, 5, 5404, 2, 68, 40, 1199, 20, 2986, 572, 1380]",1424.0,21148812,572
Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.,PLoS computational biology,PLoS Comput. Biol.,2010-12-02,"Methotrexate (MTX) is widely used for the treatment of childhood acute lymphoblastic leukemia (ALL). The accumulation of MTX and its active metabolites, methotrexate polyglutamates (MTXPG), in ALL cells is an important determinant of its antileukemic effects. We studied 194 of 356 patients enrolled on St. Jude Total XV protocol for newly diagnosed ALL with the goal of characterizing the intracellular pharmacokinetics of MTXPG in leukemia cells; relating these pharmacokinetics to ALL lineage, ploidy and molecular subtype; and using a folate pathway model to simulate optimal treatment strategies. Serial MTX concentrations were measured in plasma and intracellular MTXPG concentrations were measured in circulating leukemia cells. A pharmacokinetic model was developed which accounted for the plasma disposition of MTX along with the transport and metabolism of MTXPG. In addition, a folate pathway model was adapted to simulate the effects of treatment strategies on the inhibition of de novo purine synthesis (DNPS). The intracellular MTXPG pharmacokinetic model parameters differed significantly by lineage, ploidy, and molecular subtypes of ALL. Folylpolyglutamate synthetase (FPGS) activity was higher in B vs T lineage ALL (p<0.005), MTX influx and FPGS activity were higher in hyperdiploid vs non-hyperdiploid ALL (p<0.03), MTX influx and FPGS activity were lower in the t(12;21) (ETV6-RUNX1) subtype (p<0.05), and the ratio of FPGS to -glutamyl hydrolase (GGH) activity was lower in the t(1;19) (TCF3-PBX1) subtype (p<0.03) than other genetic subtypes. In addition, the folate pathway model showed differential inhibition of DNPS relative to MTXPG accumulation, MTX dose, and schedule. This study has provided new insights into the intracellular disposition of MTX in leukemia cells and how it affects treatment efficacy.",Journal Article,3337.0,29.0,Methotrexate MTX is widely used for the treatment of childhood acute lymphoblastic ALL The accumulation of MTX and its active metabolites methotrexate polyglutamates MTXPG in ALL cells is an important determinant of its antileukemic effects We studied 194 of 356 patients enrolled on St. Jude Total XV protocol for newly diagnosed ALL with the goal of characterizing the intracellular pharmacokinetics of MTXPG in cells relating these pharmacokinetics to ALL lineage ploidy and molecular subtype and using a folate pathway model to simulate optimal treatment strategies Serial MTX concentrations were measured in plasma and intracellular MTXPG concentrations were measured in circulating cells A pharmacokinetic model was developed which accounted for the plasma disposition of MTX along with the transport and metabolism of MTXPG In addition a folate pathway model was adapted to simulate the effects of treatment strategies on the inhibition of de novo purine synthesis DNPS The intracellular MTXPG pharmacokinetic model parameters differed significantly by lineage ploidy and molecular subtypes of ALL Folylpolyglutamate synthetase FPGS activity was higher in B vs T lineage ALL p 0.005 MTX influx and FPGS activity were higher in hyperdiploid vs non-hyperdiploid ALL p 0.03 MTX influx and FPGS activity were lower in the t 12 21 ETV6-RUNX1 subtype p 0.05 and the ratio of FPGS to -glutamyl hydrolase GGH activity was lower in the t 1 19 TCF3-PBX1 subtype p 0.03 than other genetic subtypes In addition the folate pathway model showed differential inhibition of DNPS relative to MTXPG accumulation MTX dose and schedule This study has provided new insights into the intracellular disposition of MTX in cells and how it affects treatment efficacy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 3453, 16, 1792, 95, 9, 3, 24, 1, 864, 286, 1275, 62, 3, 1835, 1, 3453, 2, 211, 544, 3406, 2116, 16243, 11572, 4, 62, 37, 16, 35, 305, 4372, 1, 211, 4512, 176, 21, 656, 5434, 1, 8664, 7, 346, 23, 3062, 4841, 181, 16078, 1182, 9, 732, 265, 62, 5, 3, 1326, 1, 5723, 3, 2087, 1159, 1, 11572, 4, 37, 7750, 46, 1159, 6, 62, 2542, 9032, 2, 219, 875, 2, 75, 8, 3100, 308, 202, 6, 9236, 665, 24, 422, 2108, 3453, 1003, 11, 644, 4, 554, 2, 2087, 11572, 1003, 11, 644, 4, 1033, 37, 8, 1456, 202, 10, 276, 92, 3688, 9, 3, 554, 5814, 1, 3453, 1510, 5, 3, 4294, 2, 1600, 1, 11572, 4, 352, 8, 3100, 308, 202, 10, 3716, 6, 9236, 3, 176, 1, 24, 422, 23, 3, 297, 1, 1566, 2018, 5006, 2525, 18803, 3, 2087, 11572, 1456, 202, 1038, 2512, 97, 20, 2542, 9032, 2, 219, 814, 1, 62, 30336, 12692, 14140, 128, 10, 142, 4, 132, 105, 102, 2542, 62, 19, 13, 1614, 3453, 11560, 2, 14140, 128, 11, 142, 4, 8847, 105, 220, 8847, 62, 19, 13, 680, 3453, 11560, 2, 14140, 128, 11, 280, 4, 3, 102, 133, 239, 7306, 6092, 875, 19, 13, 474, 2, 3, 197, 1, 14140, 6, 2655, 15867, 18796, 10820, 128, 10, 280, 4, 3, 102, 14, 326, 25178, 14434, 875, 19, 13, 680, 76, 127, 336, 814, 4, 352, 3, 3100, 308, 202, 224, 1777, 297, 1, 18803, 580, 6, 11572, 1835, 3453, 61, 2, 1055, 26, 45, 71, 1052, 217, 1957, 237, 3, 2087, 5814, 1, 3453, 4, 37, 2, 832, 192, 2561, 24, 209]",1749.0,21152005,644
Improved prognosis for older adolescents with acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2010-12-20,"The prognosis for older adolescents and young adults with acute lymphoblastic leukemia (ALL) has been historically much worse than that for younger patients. We reviewed the outcome of older adolescents (age 15 to 18 years) treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group. Between 1991 and 2007, 963 pediatric patients, including 89 older adolescents, were enrolled on Total Therapy studies XIIIA, XIIIB, XIV, and XV. In the first three studies, treatment selection was based on presenting clinical features and leukemic cell genetics. In study XV, the level of residual disease was used to guide treatment, which featured intensive methotrexate, glucocorticoid, vincristine, and asparaginase, as well as early triple intrathecal therapy for higher-risk ALL. The 89 older adolescents were significantly more likely to have T-cell ALL, the t(4;11)(MLL-AF4), and detectable minimal residual disease during or at the end of remission induction; they were less likely to have the t(12;21)(ETV6-RUNX1) compared with younger patients. In the first three studies, the 44 older adolescents had significantly poorer event-free survival and overall survival than the 403 younger patients. This gap in prognosis was abolished in study XV: event-free survival rates at 5 years were 86.4%  5.2% (standard error) for the 45 older adolescents and 87.4%  1.7% for the 453 younger patients; overall survival rates were 87.9%  5.1% versus 94.1%  1.2%, respectively. Most older adolescents with ALL can be cured with risk-adjusted intensive chemotherapy without stem-cell transplantation.",Clinical Trial,3319.0,83.0,The prognosis for older adolescents and young adults with acute lymphoblastic ALL has been historically much worse than that for younger patients We reviewed the outcome of older adolescents age 15 to 18 years treated in four consecutive Total Therapy studies to determine if recent improved treatment extended to this high-risk group Between 1991 and 2007 963 pediatric patients including 89 older adolescents were enrolled on Total Therapy studies XIIIA XIIIB XIV and XV In the first three studies treatment selection was based on presenting clinical features and leukemic cell genetics In study XV the level of residual disease was used to guide treatment which featured intensive methotrexate glucocorticoid vincristine and asparaginase as well as early triple intrathecal therapy for higher-risk ALL The 89 older adolescents were significantly more likely to have T-cell ALL the t 4 11 MLL-AF4 and detectable minimal residual disease during or at the end of remission induction they were less likely to have the t 12 21 ETV6-RUNX1 compared with younger patients In the first three studies the 44 older adolescents had significantly poorer event-free survival and overall survival than the 403 younger patients This gap in prognosis was abolished in study XV event-free survival rates at 5 years were 86.4  5.2 standard error for the 45 older adolescents and 87.4  1.7 for the 453 younger patients overall survival rates were 87.9  5.1 versus 94.1  1.2 respectively Most older adolescents with ALL can be cured with risk-adjusted intensive chemotherapy without stem-cell transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 9, 434, 3101, 2, 1169, 857, 5, 286, 1275, 62, 71, 85, 3578, 1802, 639, 76, 17, 9, 773, 7, 21, 446, 3, 228, 1, 434, 3101, 89, 167, 6, 203, 60, 73, 4, 294, 935, 181, 36, 94, 6, 223, 492, 435, 231, 24, 1747, 6, 26, 64, 43, 87, 59, 3372, 2, 1307, 23665, 815, 7, 141, 887, 434, 3101, 11, 346, 23, 181, 36, 94, 39176, 30629, 59668, 2, 16078, 4, 3, 157, 169, 94, 24, 881, 10, 90, 23, 1656, 38, 404, 2, 2015, 31, 2894, 4, 45, 16078, 3, 301, 1, 753, 34, 10, 95, 6, 1597, 24, 92, 11857, 1686, 2116, 5399, 2132, 2, 3709, 22, 149, 22, 191, 1500, 5126, 36, 9, 142, 43, 62, 3, 887, 434, 3101, 11, 97, 80, 322, 6, 47, 102, 31, 62, 3, 102, 39, 175, 3049, 17272, 2, 2083, 1048, 753, 34, 190, 15, 28, 3, 396, 1, 734, 504, 491, 11, 299, 322, 6, 47, 3, 102, 133, 239, 7306, 6092, 72, 5, 773, 7, 4, 3, 157, 169, 94, 3, 584, 434, 3101, 42, 97, 1769, 774, 115, 25, 2, 63, 25, 76, 3, 10836, 773, 7, 26, 5285, 4, 356, 10, 6020, 4, 45, 16078, 774, 115, 25, 151, 28, 33, 60, 11, 868, 39, 810, 33, 18, 260, 3444, 9, 3, 512, 434, 3101, 2, 912, 39, 810, 14, 67, 9, 3, 9861, 773, 7, 63, 25, 151, 11, 912, 83, 810, 33, 14, 185, 960, 14, 810, 14, 18, 106, 96, 434, 3101, 5, 62, 122, 40, 3733, 5, 43, 586, 1686, 56, 187, 452, 31, 497]",1594.0,21172890,770
Association of the highly prevalent TP53 R337H mutation with pediatric choroid plexus carcinoma and osteosarcoma in southeast Brazil.,Cancer,Cancer,2010-12-29,"The inherited, low-penetrance arginine-to-histidine substitution at codon 337 (R337H) of the tumor protein 53 gene (TP53) is clustered in southeast Brazil (estimated frequency, 0.3%). Although its tumorigenic effect initially appeared to be tissue-specific, recent evidence suggests its association with a broader range of tumors. Therefore, the authors of this report investigated the spectrum of pediatric malignancies associated with the TP53 R337H mutation at a single referral institution in southeast Brazil. Genomic DNA samples from 493 children with malignancies were screened for the R337H mutation. Available tumor samples from carriers were investigated for loss of heterozygosity (LOH) and nuclear p53 accumulation. Clinical data were obtained from medical records. Sixty-five of 70 patients (93%) with adrenocortical tumors (ACTs), 9 of 13 patients (69%) with choroid plexus carcinoma (CPC), and 3 of 41 patients (7.3%) with osteosarcoma carried the mutation. The proportion of CPC to choroid plexus papilloma (CPP) was much higher than that reported elsewhere. Osteosarcoma in carriers had a significantly poorer outcome (P = .02). The mutation was not identified in patients who had acute lymphoblastic leukemia (ALL) (n = 187), recurrent ALL (n = 49), acute myeloid leukemia (n = 44), lymphoma (n = 30), non-CPC central nervous system tumors (n = 26), Ewing sarcoma (n = 25), or rhabdomyosarcoma (n = 8). Among the tumors that were available for analysis, LOH with retention of the mutant allele was confirmed in 21 of 21 ACTs, in 2 of 2 CPCs, and in 2 of 3 osteosarcomas that were positive for R337H. CPCs and osteosarcomas that were positive for R337H had marked nuclear accumulation of p53. The current findings demonstrated compellingly that the TP53 R337H mutation is associated not only with ACT but also with CPC and, to a lesser extent, with osteosarcoma, both of which are core-component tumors of the Li-Fraumeni syndrome.",Journal Article,3310.0,45.0,The inherited low-penetrance arginine-to-histidine substitution at codon 337 R337H of the tumor protein 53 gene TP53 is clustered in southeast Brazil estimated frequency 0.3 Although its tumorigenic effect initially appeared to be tissue-specific recent evidence suggests its association with a broader range of tumors Therefore the authors of this report investigated the spectrum of pediatric malignancies associated with the TP53 R337H mutation at a single referral institution in southeast Brazil Genomic DNA samples from 493 children with malignancies were screened for the R337H mutation Available tumor samples from carriers were investigated for loss of heterozygosity LOH and nuclear p53 accumulation Clinical data were obtained from medical records Sixty-five of 70 patients 93 with tumors ACTs 9 of 13 patients 69 with choroid plexus carcinoma CPC and 3 of 41 patients 7.3 with carried the mutation The proportion of CPC to choroid plexus papilloma CPP was much higher than that reported elsewhere in carriers had a significantly poorer outcome P .02 The mutation was not identified in patients who had acute lymphoblastic ALL n 187 recurrent ALL n 49 acute myeloid n 44 n 30 non-CPC central nervous system tumors n 26 n 25 or n 8 Among the tumors that were available for analysis LOH with retention of the mutant allele was confirmed in 21 of 21 ACTs in 2 of 2 CPCs and in 2 of 3 osteosarcomas that were positive for R337H CPCs and osteosarcomas that were positive for R337H had marked nuclear accumulation of p53 The current findings demonstrated compellingly that the TP53 R337H mutation is associated not only with ACT but also with CPC and to a lesser extent with both of which are core-component tumors of the Li-Fraumeni syndrome,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2986, 154, 4792, 5392, 6, 15954, 5029, 28, 3673, 8275, 29109, 1, 3, 30, 178, 699, 145, 1206, 16, 6464, 4, 21377, 10452, 661, 675, 13, 27, 242, 211, 3795, 254, 1625, 2121, 6, 40, 246, 112, 435, 241, 844, 211, 248, 5, 8, 5410, 184, 1, 57, 673, 3, 738, 1, 26, 414, 565, 3, 1873, 1, 815, 441, 41, 5, 3, 1206, 29109, 258, 28, 8, 226, 2096, 731, 4, 21377, 10452, 572, 261, 347, 29, 11304, 541, 5, 441, 11, 2261, 9, 3, 29109, 258, 390, 30, 347, 29, 1316, 11, 565, 9, 407, 1, 3963, 2594, 2, 928, 624, 1835, 38, 74, 11, 683, 29, 484, 1064, 1746, 365, 1, 431, 7, 966, 5, 57, 4459, 83, 1, 233, 7, 790, 5, 12169, 9576, 134, 9305, 2, 27, 1, 605, 7, 67, 27, 5, 2629, 3, 258, 3, 920, 1, 9305, 6, 12169, 9576, 7017, 17117, 10, 1802, 142, 76, 17, 210, 7116, 4, 1316, 42, 8, 97, 1769, 228, 19, 588, 3, 258, 10, 44, 108, 4, 7, 54, 42, 286, 1275, 62, 78, 5568, 387, 62, 78, 739, 286, 533, 78, 584, 78, 201, 220, 9305, 854, 1880, 398, 57, 78, 432, 78, 243, 15, 78, 66, 107, 3, 57, 17, 11, 390, 9, 65, 2594, 5, 3947, 1, 3, 620, 1254, 10, 557, 4, 239, 1, 239, 4459, 4, 18, 1, 18, 12903, 2, 4, 18, 1, 27, 11089, 17, 11, 109, 9, 29109, 12903, 2, 11089, 17, 11, 109, 9, 29109, 42, 2003, 928, 1835, 1, 624, 3, 291, 272, 264, 46385, 17, 3, 1206, 29109, 258, 16, 41, 44, 158, 5, 2559, 84, 120, 5, 9305, 2, 6, 8, 5191, 1039, 5, 110, 1, 92, 32, 1793, 1249, 57, 1, 3, 5066, 9130, 681]",1747.0,21192060,494
Use of matched unrelated donors compared with matched related donors is associated with lower relapse and superior progression-free survival after reduced-intensity conditioning hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2010-12-27,"As success of reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) relies primarily on graft-versus-leukemia (GVL) activity, increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes. To assess whether use of unrelated donors (URD) engenders more potent GVL in RIC HSCT compared to matched related donors (MRD), we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD (n = 246) and MRD (n = 187) RIC HSCT for hematologic malignancies at our institution. Diseases included: acute myelogenous leukemia (AML) (127), non-Hodgkin lymphoma (NHL) (71), chronic lymphocytic leukemia (CLL) (68), myelodysplastic syndrome (MDS) (64), Hodgkin disease (HD) (40), chronic myeloid leukemia (CML) (25), multiple myeloma (MM) (23), myeloproliferative disorder (MPD) (12), acute lymphoblastic leukemia (ALL) (7), and other leukemia (1). All received uniform fludarabine and intravenous busulfan conditioning, and GVHD prophylaxis with tacrolimus/mini-methroxate (mini-MTX) or tacrolimus/sirolimus  mini-MTX. Unrelated donors were younger compared to MRD (median donor age: 33 years versus 52 years, P < .0001), and provided larger CD34(+) products (median CD34(+) cells infused: 8.7  10(6)/kg versus 7.5  10(6)/kg, P = .002). Distribution of diseases, disease risk, prior transplant, and cytomegalovirus (CMV) status was similar in both cohorts. Cumulative incidence of grade II-IV acute GVHD (at day +180), 2-year chronic GVHD, and 2-year nonrelapse mortality (NRM) were 20% versus 16%, 55% versus 50%, and 8% versus 6% in URD and MRD, respectively (P= NS). Cumulative incidence of relapse at 2 years was lower in URD, 52% versus 65% (P = .005). With median follow-up of 26.5 and 35.8 months, 2-year progression-free survival (PFS) was significantly better in unrelated donor transplants, 39.5% for URD, and 29% for MRD (P = .01). Overall survival (OS) at 2years were 56% for URD versus 50% for MRD (P = .53). In multivariable analysis, URD was associated with a lower risk of relapse (hazard ratio [HR] 0.67, P = .002) and superior PFS (HR 0.69, P = .002). These results suggest that URD is associated with greater GVL activity than MRD, and could have practice changing impact on future donor selection in RIC HSCT.",Comparative Study,3312.0,45.0,As success of reduced-intensity conditioning RIC hematopoietic stem cell transplantation HSCT relies primarily on graft-versus-leukemia GVL activity increased minor HLA disparity in unrelated compared to related donors could have a significant impact on transplant outcomes To assess whether use of unrelated donors URD engenders more potent GVL in RIC HSCT compared to matched related donors MRD we retrospectively studied 433 consecutive T-replete 6/6 HLA matched URD n 246 and MRD n 187 RIC HSCT for hematologic malignancies at our institution Diseases included acute myelogenous AML 127 NHL 71 chronic lymphocytic CLL 68 syndrome MDS 64 disease HD 40 chronic myeloid CML 25 multiple MM 23 disorder MPD 12 acute lymphoblastic ALL 7 and other 1 All received uniform fludarabine and intravenous busulfan conditioning and GVHD prophylaxis with tacrolimus/mini-methroxate mini-MTX or tacrolimus/sirolimus  mini-MTX Unrelated donors were younger compared to MRD median donor age 33 years versus 52 years P .0001 and provided larger CD34 products median CD34 cells infused 8.7 10 6 /kg versus 7.5 10 6 /kg P .002 Distribution of diseases disease risk prior transplant and cytomegalovirus CMV status was similar in both cohorts Cumulative incidence of grade II-IV acute GVHD at day +180 2-year chronic GVHD and 2-year nonrelapse mortality NRM were 20 versus 16 55 versus 50 and 8 versus 6 in URD and MRD respectively P NS Cumulative incidence of relapse at 2 years was lower in URD 52 versus 65 P .005 With median follow-up of 26.5 and 35.8 months 2-year progression-free survival PFS was significantly better in unrelated donor transplants 39.5 for URD and 29 for MRD P .01 Overall survival OS at 2 years were 56 for URD versus 50 for MRD P .53 In multivariable analysis URD was associated with a lower risk of relapse hazard ratio HR 0.67 P .002 and superior PFS HR 0.69 P .002 These results suggest that URD is associated with greater GVL activity than MRD and could have practice changing impact on future donor selection in RIC HSCT,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[22, 1825, 1, 405, 837, 1933, 3365, 1007, 452, 31, 497, 1703, 6495, 1561, 23, 1599, 185, 2647, 8149, 128, 101, 2278, 1160, 4326, 4, 2092, 72, 6, 139, 2344, 359, 47, 8, 93, 345, 23, 941, 123, 6, 423, 317, 119, 1, 2092, 2344, 5847, 39508, 80, 1157, 8149, 4, 3365, 1703, 72, 6, 655, 139, 2344, 2029, 21, 894, 656, 13224, 935, 102, 11151, 49, 49, 1160, 655, 5847, 78, 6907, 2, 2029, 78, 5568, 3365, 1703, 9, 813, 441, 28, 114, 731, 1342, 159, 286, 2194, 329, 4080, 1176, 792, 442, 1193, 552, 806, 681, 1223, 660, 34, 2701, 327, 442, 533, 903, 243, 232, 321, 382, 2645, 7712, 133, 286, 1275, 62, 67, 2, 127, 14, 62, 103, 3490, 2027, 2, 1262, 3906, 1933, 2, 1562, 2049, 5, 5643, 7313, 59688, 7313, 3453, 15, 5643, 4519, 810, 7313, 3453, 2092, 2344, 11, 773, 72, 6, 2029, 52, 1488, 89, 466, 60, 185, 653, 60, 19, 488, 2, 1052, 1077, 2215, 2766, 52, 2215, 37, 4524, 66, 67, 79, 49, 503, 185, 67, 33, 79, 49, 503, 19, 1111, 1395, 1, 1342, 34, 43, 324, 941, 2, 7314, 3879, 156, 10, 288, 4, 110, 736, 967, 287, 1, 88, 215, 478, 286, 1562, 28, 218, 3172, 18, 111, 442, 1562, 2, 18, 111, 4640, 282, 4296, 11, 179, 185, 245, 614, 185, 212, 2, 66, 185, 49, 4, 5847, 2, 2029, 106, 19, 4044, 967, 287, 1, 429, 28, 18, 60, 10, 280, 4, 5847, 653, 185, 556, 19, 1614, 5, 52, 166, 126, 1, 432, 33, 2, 465, 66, 53, 18, 111, 91, 115, 25, 300, 10, 97, 380, 4, 2092, 1488, 4016, 587, 33, 9, 5847, 2, 462, 9, 2029, 19, 355, 63, 25, 118, 28, 18, 60, 11, 664, 9, 5847, 185, 212, 9, 2029, 19, 699, 4, 658, 65, 5847, 10, 41, 5, 8, 280, 43, 1, 429, 360, 197, 168, 13, 598, 19, 1111, 2, 1123, 300, 168, 13, 790, 19, 1111, 46, 99, 309, 17, 5847, 16, 41, 5, 378, 8149, 128, 76, 2029, 2, 359, 47, 758, 3600, 345, 23, 508, 1488, 881, 4, 3365, 1703]",2034.0,21193054,804
High-risk pediatric acute lymphoblastic leukemia: to transplant or not to transplant?,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-01-01,"Because survival with both chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT) approaches to high-risk pediatric acute lymphoblastic leukemia (ALL) generally improves through the years, regular comparisons of outcomes with either approach for a given indication are needed to decide when HSCT is indicated. Improvements in risk classification are allowing clinicians to identify patients at high risk for relapse early in their course of therapy. Whether patients defined as high risk by new methods will benefit from HSCT requires careful testing. Standardization and improvement of transplant approaches has led to equivalent survival outcomes with matched sibling and well-matched unrelated donors; however, survival using mismatched and haploidentical donors is generally worse. Trials comparing chemotherapy and HSCT must obtain sufficient data about therapy and stratify the analysis to assess the outcomes of best-chemotherapy with best-HSCT approaches.",Journal Article,3307.0,,Because survival with both chemotherapy and allogeneic hematopoietic stem cell transplantation HSCT approaches to high-risk pediatric acute lymphoblastic ALL generally improves through the years regular comparisons of outcomes with either approach for a given indication are needed to decide when HSCT is indicated Improvements in risk classification are allowing clinicians to identify patients at high risk for relapse early in their course of therapy Whether patients defined as high risk by new methods will benefit from HSCT requires careful testing Standardization and improvement of transplant approaches has led to equivalent survival outcomes with matched sibling and well-matched unrelated donors however survival using mismatched and haploidentical donors is generally worse Trials comparing chemotherapy and HSCT must obtain sufficient data about therapy and stratify the analysis to assess the outcomes of best-chemotherapy with best-HSCT approaches,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[408, 25, 5, 110, 56, 2, 1063, 1007, 452, 31, 497, 1703, 611, 6, 64, 43, 815, 286, 1275, 62, 1228, 1804, 298, 3, 60, 3316, 2213, 1, 123, 5, 361, 353, 9, 8, 447, 3607, 32, 575, 6, 11008, 198, 1703, 16, 1103, 1474, 4, 43, 947, 32, 2952, 1490, 6, 255, 7, 28, 64, 43, 9, 429, 191, 4, 136, 906, 1, 36, 317, 7, 395, 22, 64, 43, 20, 217, 636, 303, 247, 29, 1703, 1706, 3465, 471, 6213, 2, 767, 1, 941, 611, 71, 836, 6, 2017, 25, 123, 5, 655, 3684, 2, 149, 655, 2092, 2344, 137, 25, 75, 5095, 2, 5802, 2344, 16, 1228, 639, 143, 1430, 56, 2, 1703, 1642, 3140, 1952, 74, 545, 36, 2, 3570, 3, 65, 6, 423, 3, 123, 1, 824, 56, 5, 824, 1703, 611]",962.0,21195303,591
"Biology, risk stratification, and therapy of pediatric acute leukemias: an update.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-01-10,"We review recent advances in the biologic understanding and treatment of childhood acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), identify therapeutically challenging subgroups, and suggest future directions of research. A review of English literature on childhood acute leukemias from the past 5 years was performed. Contemporary treatments have resulted in 5-year event-free survival rates of approximately 80% for childhood ALL and almost 60% for pediatric AML. The advent of high-resolution genome-wide analyses has provided new insights into leukemogenesis and identified many novel subtypes of leukemia. Virtually all ALL and the vast majority of AML cases can be classified according to specific genetic abnormalities. Cooperative mutations involved in cell differentiation, cell cycle regulation, tumor suppression, drug responsiveness, and apoptosis have also been identified in many cases. The development of new formulations of existing drugs, molecularly targeted therapy, and immunotherapies promises to further advance the cure rates and improve quality of life of patients. The application of new high-throughput sequencing techniques to define the complete DNA sequence of leukemia and host normal cells and the development of new agents targeted to leukemogenic pathways promise to further improve outcome in the coming decade.",Journal Article,3298.0,495.0,We review recent advances in the biologic understanding and treatment of childhood acute lymphoblastic ALL and acute myeloid AML identify therapeutically challenging subgroups and suggest future directions of research A review of English literature on childhood acute leukemias from the past 5 years was performed Contemporary treatments have resulted in 5-year event-free survival rates of approximately 80 for childhood ALL and almost 60 for pediatric AML The advent of high-resolution genome-wide analyses has provided new insights into leukemogenesis and identified many novel subtypes of Virtually all ALL and the vast majority of AML cases can be classified according to specific genetic abnormalities Cooperative mutations involved in cell differentiation cell cycle regulation tumor suppression drug responsiveness and apoptosis have also been identified in many cases The development of new formulations of existing drugs molecularly targeted therapy and immunotherapies promises to further advance the cure rates and improve quality of life of patients The application of new high-throughput sequencing techniques to define the complete DNA sequence of and host normal cells and the development of new agents targeted to leukemogenic pathways promise to further improve outcome in the coming decade,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 206, 435, 954, 4, 3, 1283, 612, 2, 24, 1, 864, 286, 1275, 62, 2, 286, 533, 329, 255, 4602, 1950, 1453, 2, 309, 508, 3540, 1, 389, 8, 206, 1, 4201, 789, 23, 864, 286, 2792, 29, 3, 1219, 33, 60, 10, 173, 2667, 640, 47, 627, 4, 33, 111, 774, 115, 25, 151, 1, 705, 493, 9, 864, 62, 2, 2214, 335, 9, 815, 329, 3, 4114, 1, 64, 2125, 898, 1019, 318, 71, 1052, 217, 1957, 237, 5661, 2, 108, 445, 229, 814, 1, 5860, 62, 62, 2, 3, 4337, 686, 1, 329, 140, 122, 40, 1373, 768, 6, 112, 336, 1171, 1690, 138, 646, 4, 31, 910, 31, 417, 863, 30, 1332, 234, 3642, 2, 351, 47, 120, 85, 108, 4, 445, 140, 3, 193, 1, 217, 5832, 1, 1692, 600, 2372, 238, 36, 2, 2811, 13313, 6, 195, 3148, 3, 1722, 151, 2, 401, 372, 1, 358, 1, 7, 3, 1581, 1, 217, 64, 3643, 615, 1092, 6, 1107, 3, 236, 261, 1532, 1, 2, 1204, 295, 37, 2, 3, 193, 1, 217, 183, 238, 6, 13519, 460, 1783, 6, 195, 401, 228, 4, 3, 10671, 2025]",1308.0,21220611,772
Adolescents and young adults with acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2010-01-01,"During the last decade, increasing attention has been paid to a unique group of patients with acute lymphoblastic leukemia (ALL) who lie at the crossroad of therapeutic care by pediatric and adult hematologists/oncologists. ALL is a disease that affects infants, children, adolescents, and adult patients. With current therapies, the vast majority of children with ALL are now long-term survivors; unfortunately, the same good results have not yet been obtained for adults with ALL. This review will describe current controversies surrounding the treatment of adolescents and young adults with ALL--a group who finds themselves in the transition from ""pediatric"" to ""adult"" treatment approaches. The review focuses on recent insights into disease biology, prognostic factors, and treatment outcomes that have led to a series of prospective clinical trials specifically designed for adolescents and younger adults (AYAs) with ALL. These trials have been designed to provide important new clinical, psychosocial, and biological insights, and to further improve the survival of this challenging and unique group of patients.",Journal Article,3672.0,79.0,During the last decade increasing attention has been paid to a unique group of patients with acute lymphoblastic ALL who lie at the crossroad of therapeutic care by pediatric and adult hematologists/oncologists ALL is a disease that affects infants children adolescents and adult patients With current therapies the vast majority of children with ALL are now long-term survivors unfortunately the same good results have not yet been obtained for adults with ALL This review will describe current controversies surrounding the treatment of adolescents and young adults with ALL -- a group who finds themselves in the transition from `` pediatric '' to `` adult '' treatment approaches The review focuses on recent insights into disease biology prognostic factors and treatment outcomes that have led to a series of prospective clinical trials specifically designed for adolescents and younger adults AYAs with ALL These trials have been designed to provide important new clinical psychosocial and biological insights and to further improve the survival of this challenging and unique group of patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[190, 3, 1060, 2025, 602, 2111, 71, 85, 8328, 6, 8, 991, 87, 1, 7, 5, 286, 1275, 62, 54, 13004, 28, 3, 39524, 1, 189, 165, 20, 815, 2, 780, 11474, 1339, 62, 16, 8, 34, 17, 2561, 5585, 541, 3101, 2, 780, 7, 5, 291, 235, 3, 4337, 686, 1, 541, 5, 62, 32, 1134, 319, 337, 332, 3869, 3, 827, 1178, 99, 47, 44, 1145, 85, 683, 9, 857, 5, 62, 26, 206, 303, 897, 291, 6613, 2976, 3, 24, 1, 3101, 2, 1169, 857, 5, 62, 8, 87, 54, 17650, 5374, 4, 3, 1970, 29, 815, 522, 6, 780, 522, 24, 611, 3, 206, 3026, 23, 435, 1957, 237, 34, 891, 177, 130, 2, 24, 123, 17, 47, 836, 6, 8, 988, 1, 482, 38, 143, 1225, 1114, 9, 3101, 2, 773, 857, 6145, 5, 62, 46, 143, 47, 85, 1114, 6, 377, 305, 217, 38, 2322, 2, 1037, 1957, 2, 6, 195, 401, 3, 25, 1, 26, 1950, 2, 991, 87, 1, 7]",1100.0,21239766,759
Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the children's oncology group phase I consortium.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-01-24,"PURPOSE Dasatinib is an orally available tyrosine kinase inhibitor with low nanomolar activity against SRC family kinases, BCR-ABL, c-KIT, EPHA2, and the PDGF- receptor. Dasatinib was found to have selective activity in several tumor models in the Pediatric Preclinical Testing Program. PATIENTS AND METHODS A phase I study of dasatinib in pediatric patients with refractory solid tumors or imatinib-refractory, Philadelphia chromosome-positive leukemia was performed. Dose levels of 50, 65, 85, and 110 mg/m/dose, administered orally twice daily for 28 days, with courses repeated without interruption, were studied. Pharmacokinetic studies were performed with the initial dose. A total of 39 patients (solid tumors, n = 28; chronic myeloid leukemia [CML], n = 9; acute lymphoblastic leukemia, n = 2) were enrolled. No dose-limiting toxicities (DLTs) were observed at the 50, 65, and 85 mg/m dose levels. At 110 mg/m, two of six patients experienced DLT including grade 2 diarrhea and headache. In children with leukemia, grade 4 hypokalemia (50 mg/m), grade 3 diarrhea (85 mg/m), and grade 2 creatinine elevation (50 mg/m) were observed. DLT in later courses included pleural effusions, hemangiomatosis, and GI hemorrhage. There were three complete cytogenetic responses, three partial cytogenetic responses, and two partial/minimal cytogenetic responses observed in evaluable patients with CML. CONCLUSION Overall, drug disposition and tolerability of dasatinib were similar to those observed in adult patients.","Clinical Trial, Phase I",3284.0,69.0,PURPOSE Dasatinib is an orally available tyrosine kinase inhibitor with low nanomolar activity against SRC family kinases BCR-ABL c-KIT EPHA2 and the PDGF- receptor Dasatinib was found to have selective activity in several tumor models in the Pediatric Preclinical Testing Program PATIENTS AND METHODS A phase I study of dasatinib in pediatric patients with refractory solid tumors or imatinib-refractory Philadelphia chromosome-positive was performed Dose levels of 50 65 85 and 110 mg/m/dose administered orally twice daily for 28 days with courses repeated without interruption were studied Pharmacokinetic studies were performed with the initial dose A total of 39 patients solid tumors n 28 chronic myeloid CML n 9 acute lymphoblastic n 2 were enrolled No dose-limiting toxicities DLTs were observed at the 50 65 and 85 mg/m dose levels At 110 mg/m two of six patients experienced DLT including grade 2 diarrhea and headache In children with grade 4 hypokalemia 50 mg/m grade 3 diarrhea 85 mg/m and grade 2 creatinine elevation 50 mg/m were observed DLT in later courses included pleural effusions hemangiomatosis and GI hemorrhage There were three complete cytogenetic responses three partial cytogenetic responses and two partial/minimal cytogenetic responses observed in evaluable patients with CML CONCLUSION Overall drug disposition and tolerability of dasatinib were similar to those observed in adult patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[743, 1674, 16, 35, 1428, 390, 564, 216, 230, 5, 154, 7927, 128, 480, 2023, 607, 1549, 1062, 1425, 256, 1164, 5511, 2, 3, 4546, 1458, 153, 1674, 10, 204, 6, 47, 1094, 128, 4, 392, 30, 274, 4, 3, 815, 693, 471, 1243, 7, 2, 636, 8, 124, 70, 45, 1, 1674, 4, 815, 7, 5, 430, 537, 57, 15, 577, 430, 3006, 1170, 109, 10, 173, 61, 148, 1, 212, 556, 772, 2, 3129, 81, 4709, 61, 468, 1428, 936, 391, 9, 339, 162, 5, 1993, 2113, 187, 4823, 11, 656, 1456, 94, 11, 173, 5, 3, 388, 61, 8, 181, 1, 587, 7, 537, 57, 78, 339, 442, 533, 903, 78, 83, 286, 1275, 78, 18, 11, 346, 77, 61, 817, 385, 2506, 11, 164, 28, 3, 212, 556, 2, 772, 81, 4709, 61, 148, 28, 3129, 81, 4709, 100, 1, 437, 7, 592, 2059, 141, 88, 18, 1172, 2, 4538, 4, 541, 5, 88, 39, 7799, 212, 81, 4709, 88, 27, 1172, 772, 81, 4709, 2, 88, 18, 3177, 3292, 212, 81, 4709, 11, 164, 2059, 4, 1559, 1993, 159, 2164, 5154, 39531, 2, 2104, 3599, 125, 11, 169, 236, 1266, 253, 169, 450, 1266, 253, 2, 100, 450, 1048, 1266, 253, 164, 4, 859, 7, 5, 903, 1221, 63, 234, 5814, 2, 1543, 1, 1674, 11, 288, 6, 135, 164, 4, 780, 7]",1428.0,21263099,489
Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.,Experimental hematology,Exp. Hematol.,2011-01-26,"Rationally designed therapies aim at the specific disruption of critical signaling pathways activated by malignant transformation or signals from the tumor microenvironment. Because mammalian target of rapamycin (mTOR) is an important signal integrator and a key translational regulator, we evaluated its potential involvement in T-cell acute lymphoblastic leukemia (T-ALL) and whether mTOR blockade synergizes with chemotherapeutic agents or other signaling antagonists to inhibit primary leukemia T cells. mTOR signaling status was assessed using biochemical, immunostaining, and molecular regulation studies and functional assays performed to assess the impact of mTOR blockade on T-ALL proliferation, survival, and cell cycle. We observed that mTOR signaling is highly activated in all T-ALL patients tested, with phosphorylation of its downstream substrates eIF4G and S6 ribosomal protein. mTOR activation was detected in vivo and was further increased in vitro by stimulation with interleukin-7, a potentially leukemogenic cytokine normally produced by the bone marrow microenvironment. In T-ALL cells, mTOR blockade was associated with accumulation of the cyclin-dependent kinase inhibitor p27(kip1), which preferentially adopted a nuclear localization. Functional studies using rapamycin or CCI-779 showed a dominant inhibitory effect of mTOR blockade on interleukin-7-induced proliferation, survival, and cell-cycle progression of T-ALL cells. Furthermore, mTOR blockade markedly potentiated the antileukemia effects of dexamethasone and doxorubicin, and showed highly synergistic interactions in combination with specific inhibitors of phosphatidylinositol 3-kinase/Akt and Janus kinase 3 signaling. This study shows activation of mTOR signaling in primary T-ALL cells evolving in the leukemic bone marrow, and supports the inclusion of mTOR antagonists in current therapeutic regimens for this cancer.",Journal Article,3282.0,,Rationally designed therapies aim at the specific disruption of critical signaling pathways activated by malignant transformation or signals from the tumor microenvironment Because mammalian target of rapamycin mTOR is an important signal integrator and a key translational regulator we evaluated its potential involvement in T-cell acute lymphoblastic T-ALL and whether mTOR blockade synergizes with chemotherapeutic agents or other signaling antagonists to inhibit primary T cells mTOR signaling status was assessed using biochemical immunostaining and molecular regulation studies and functional assays performed to assess the impact of mTOR blockade on T-ALL proliferation survival and cell cycle We observed that mTOR signaling is highly activated in all T-ALL patients tested with phosphorylation of its downstream substrates eIF4G and S6 ribosomal protein mTOR activation was detected in vivo and was further increased in vitro by stimulation with interleukin-7 a potentially leukemogenic cytokine normally produced by the marrow microenvironment In T-ALL cells mTOR blockade was associated with accumulation of the cyclin-dependent kinase inhibitor p27 kip1 which preferentially adopted a nuclear localization Functional studies using rapamycin or CCI-779 showed a dominant inhibitory effect of mTOR blockade on interleukin-7-induced proliferation survival and cell-cycle progression of T-ALL cells Furthermore mTOR blockade markedly potentiated the antileukemia effects of dexamethasone and doxorubicin and showed highly synergistic interactions in combination with specific inhibitors of phosphatidylinositol 3-kinase/Akt and Janus kinase 3 signaling This study shows activation of mTOR signaling in primary T-ALL cells evolving in the leukemic marrow and supports the inclusion of mTOR antagonists in current therapeutic regimens for this cancer,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6352, 1114, 235, 1130, 28, 3, 112, 3220, 1, 740, 314, 460, 735, 20, 393, 1392, 15, 2312, 29, 3, 30, 995, 408, 2359, 283, 1, 1620, 873, 16, 35, 305, 1235, 46428, 2, 8, 825, 2460, 2452, 21, 194, 211, 174, 799, 4, 102, 31, 286, 1275, 102, 62, 2, 317, 873, 1189, 10824, 5, 1573, 183, 15, 127, 314, 4444, 6, 1433, 86, 102, 37, 873, 314, 156, 10, 275, 75, 1487, 5027, 2, 219, 863, 94, 2, 583, 1013, 173, 6, 423, 3, 345, 1, 873, 1189, 23, 102, 62, 457, 25, 2, 31, 417, 21, 164, 17, 873, 314, 16, 561, 735, 4, 62, 102, 62, 7, 650, 5, 982, 1, 211, 1489, 6063, 23334, 2, 4977, 8194, 178, 873, 363, 10, 530, 4, 386, 2, 10, 195, 101, 4, 439, 20, 2503, 5, 1603, 67, 8, 751, 13519, 1675, 6150, 1687, 20, 3, 581, 995, 4, 102, 62, 37, 873, 1189, 10, 41, 5, 1835, 1, 3, 1226, 470, 216, 230, 2804, 5584, 92, 3509, 4457, 8, 928, 2145, 583, 94, 75, 1620, 15, 4934, 7173, 224, 8, 2156, 1810, 254, 1, 873, 1189, 23, 1603, 67, 277, 457, 25, 2, 31, 417, 91, 1, 102, 62, 37, 798, 873, 1189, 2195, 6707, 3, 9169, 176, 1, 1217, 2, 856, 2, 224, 561, 1806, 1286, 4, 150, 5, 112, 222, 1, 3415, 27, 216, 649, 2, 6191, 216, 27, 314, 26, 45, 1949, 363, 1, 873, 314, 4, 86, 102, 62, 37, 3276, 4, 3, 2015, 581, 2, 2304, 3, 1680, 1, 873, 4444, 4, 291, 189, 472, 9, 26, 12]",1856.0,21277936,7
Symptoms of attention-deficit/hyperactivity disorder in long-term survivors of childhood leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2011-01-28,"Survivors of childhood acute lymphoblastic leukemia (ALL) sometimes have clinical features that suggest attention-deficit/hyperactivity disorder (ADHD), though few studies have examined specific symptoms in survivors. Long-term survivors of childhood ALL (n = 161) received a neurological examination, while parents completed rating scales to establish formal criteria for ADHD. Symptom profiles were generated and compared across demographic and treatment characteristics, as well as medical tests associated with brain pathology. Prevalence rates of ADHD were similar in survivors (10.5%) compared to those reported in the general population (7-10%). However, 25.5% of survivors reported symptoms that impair functioning in multiple settings, with attention problems being most common. These symptoms were associated with cranial radiation therapy (CRT) (mean inattentive symptoms [SD] = 3.6 [3.19] for group treated with CRT vs. 1.6 [2.40] for non-CRT group, P = 0.0006), and survivors who demonstrated impaired anti-saccades during the neurologic exam (mean inattentive symptoms [SD] = 3.4 [3.29] for those with impaired anti-saccades vs. 1.4 [2.41] for those with normal anti-saccades; P = 0.0004). The presence of a neurologically-based phenotype of attention problems in survivors of leukemia that is not fully captured by the syndrome of ADHD suggests that treatments specific to childhood ALL should be explored.",Journal Article,3280.0,13.0,Survivors of childhood acute lymphoblastic ALL sometimes have clinical features that suggest attention-deficit/hyperactivity disorder ADHD though few studies have examined specific symptoms in survivors Long-term survivors of childhood ALL n 161 received a neurological examination while parents completed rating scales to establish formal criteria for ADHD Symptom profiles were generated and compared across demographic and treatment characteristics as well as medical tests associated with brain pathology Prevalence rates of ADHD were similar in survivors 10.5 compared to those reported in the general population 7-10 However 25.5 of survivors reported symptoms that impair functioning in multiple settings with attention problems being most common These symptoms were associated with cranial radiation therapy CRT mean inattentive symptoms SD 3.6 3.19 for group treated with CRT vs. 1.6 2.40 for non-CRT group P 0.0006 and survivors who demonstrated impaired anti-saccades during the neurologic exam mean inattentive symptoms SD 3.4 3.29 for those with impaired anti-saccades vs. 1.4 2.41 for those with normal anti-saccades P 0.0004 The presence of a neurologically-based phenotype of attention problems in survivors of that is not fully captured by the syndrome of ADHD suggests that treatments specific to childhood ALL should be explored,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 5164, 47, 38, 404, 17, 309, 2111, 6819, 18391, 2645, 18022, 2471, 1021, 94, 47, 409, 112, 507, 4, 332, 319, 337, 332, 1, 864, 62, 78, 5377, 103, 8, 3622, 1385, 369, 2418, 781, 5477, 5083, 6, 1811, 5057, 371, 9, 18022, 934, 1241, 11, 1419, 2, 72, 716, 1540, 2, 24, 374, 22, 149, 22, 484, 895, 41, 5, 342, 1117, 1078, 151, 1, 18022, 11, 288, 4, 332, 79, 33, 72, 6, 135, 210, 4, 3, 1083, 266, 67, 79, 137, 243, 33, 1, 332, 210, 507, 17, 6267, 2702, 4, 232, 1947, 5, 2111, 2408, 486, 96, 186, 46, 507, 11, 41, 5, 2565, 121, 36, 1089, 313, 46429, 507, 1270, 27, 49, 27, 326, 9, 87, 73, 5, 1089, 105, 14, 49, 18, 327, 9, 220, 1089, 87, 19, 13, 6013, 2, 332, 54, 264, 2364, 312, 31744, 190, 3, 2543, 6747, 313, 46429, 507, 1270, 27, 39, 27, 462, 9, 135, 5, 2364, 312, 31744, 105, 14, 39, 18, 605, 9, 135, 5, 295, 312, 31744, 19, 13, 5295, 3, 463, 1, 8, 17139, 90, 1005, 1, 2111, 2408, 4, 332, 1, 17, 16, 44, 1910, 4954, 20, 3, 681, 1, 18022, 844, 17, 640, 112, 6, 864, 62, 257, 40, 1443]",1347.0,21280202,83
First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-01-31,"This phase I dose-escalation trial was performed to determine the maximum-tolerated dose, dose-limiting toxicities, and pharmacokinetics of CPX-351. CPX-351 induction was administered on days 1, 3, and 5 by 90-minute infusion to 48 relapsed or refractory patients with acute myeloid leukemia (AML) or high-risk myelodysplasia. Doses started at 3 units/m(2) with dose doublings in single-patient cohorts until a pharmacodynamic effect (treatment-related adverse events or reduction in bone marrow cellularity or blast count) was observed, followed by 33% escalations in three patient cohorts until dose-limiting toxicity (DLT) occurred. The maximum-tolerated dose was 101 units/m(2). DLTs consisted of hypertensive crisis, congestive heart failure, and prolonged cytopenias. Adverse events were consistent with cytarabine and daunorubicin treatment. Response occurred at doses as low as 32 units/m(2). Of 43 patients with AML, nine had complete response (CR) and one had CR with incomplete platelet recovery; of patients with acute lymphoblastic leukemia, one of three had CR. Eight CRs were achieved among the 31 patients with prior cytarabine and daunorubicin treatment. CR in AML occurred in five of 26 patients age  60 years and in five of 17 patients younger than age 60 years. Median half-life was 31.1 hours (cytarabine) and 21.9 hours (daunorubicin), with both drugs and their metabolites detectable > 7 days after the last dose. The targeted 5:1 molar ratio was maintained at all dose levels for up to 24 hours. The recommended dose of CPX-351 for phase II study is 101 units/m(2). Further exploration of efficacy and safety is ongoing in phase II trials in newly diagnosed and first-relapse patients with AML.","Clinical Trial, Phase I",3277.0,174.0,This phase I dose-escalation trial was performed to determine the maximum-tolerated dose dose-limiting toxicities and pharmacokinetics of CPX-351 CPX-351 induction was administered on days 1 3 and 5 by 90-minute infusion to 48 relapsed or refractory patients with acute myeloid AML or high-risk myelodysplasia Doses started at 3 units/m 2 with dose doublings in single-patient cohorts until a pharmacodynamic effect treatment-related adverse events or reduction in marrow cellularity or blast count was observed followed by 33 escalations in three patient cohorts until dose-limiting toxicity DLT occurred The maximum-tolerated dose was 101 units/m 2 DLTs consisted of hypertensive crisis congestive failure and prolonged cytopenias Adverse events were consistent with cytarabine and daunorubicin treatment Response occurred at doses as low as 32 units/m 2 Of 43 patients with AML nine had complete response CR and one had CR with incomplete platelet recovery of patients with acute lymphoblastic one of three had CR Eight CRs were achieved among the 31 patients with prior cytarabine and daunorubicin treatment CR in AML occurred in five of 26 patients age  60 years and in five of 17 patients younger than age 60 years Median half-life was 31.1 hours cytarabine and 21.9 hours daunorubicin with both drugs and their metabolites detectable 7 days after the last dose The targeted 5:1 molar ratio was maintained at all dose levels for up to 24 hours The recommended dose of CPX-351 for phase II study is 101 units/m 2 Further exploration of efficacy and safety is ongoing in phase II trials in newly diagnosed and first-relapse patients with AML,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[26, 124, 70, 61, 1125, 160, 10, 173, 6, 223, 3, 689, 421, 61, 61, 817, 385, 2, 1159, 1, 12228, 7270, 12228, 7270, 504, 10, 468, 23, 162, 14, 27, 2, 33, 20, 424, 3949, 904, 6, 576, 591, 15, 430, 7, 5, 286, 533, 329, 15, 64, 43, 6128, 415, 3461, 28, 27, 2960, 188, 18, 5, 61, 34744, 4, 226, 69, 736, 1100, 8, 2424, 254, 24, 139, 290, 281, 15, 628, 4, 581, 6363, 15, 3112, 1276, 10, 164, 370, 20, 466, 11388, 4, 169, 69, 736, 1100, 61, 817, 155, 2059, 489, 3, 689, 421, 61, 10, 2338, 2960, 188, 18, 2506, 1695, 1, 14919, 6540, 6395, 496, 2, 1069, 5635, 290, 281, 11, 925, 5, 1855, 2, 5247, 24, 51, 489, 28, 415, 22, 154, 22, 531, 2960, 188, 18, 1, 601, 7, 5, 329, 762, 42, 236, 51, 684, 2, 104, 42, 684, 5, 2610, 1596, 1602, 1, 7, 5, 286, 1275, 104, 1, 169, 42, 684, 659, 3115, 11, 513, 107, 3, 456, 7, 5, 324, 1855, 2, 5247, 24, 684, 4, 329, 489, 4, 365, 1, 432, 7, 89, 749, 335, 60, 2, 4, 365, 1, 269, 7, 773, 76, 89, 335, 60, 52, 1303, 358, 10, 456, 14, 1459, 1855, 2, 239, 83, 1459, 5247, 5, 110, 600, 2, 136, 3406, 2083, 67, 162, 50, 3, 1060, 61, 3, 238, 33, 14, 14566, 197, 10, 1955, 28, 62, 61, 148, 9, 126, 6, 259, 1459, 3, 793, 61, 1, 12228, 7270, 9, 124, 215, 45, 16, 2338, 2960, 188, 18, 195, 3370, 1, 209, 2, 367, 16, 942, 4, 124, 215, 143, 4, 732, 265, 2, 157, 429, 7, 5, 329]",1646.0,21282541,197
Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2011-02-06,"Although five-year survival rates for childhood acute lymphoblastic leukemia (ALL) are now over 80% in most industrialized countries, not all children have benefited equally from this progress. Ethnic differences in survival after childhood ALL have been reported in many clinical studies, with poorer survival observed among African Americans or those with Hispanic ethnicity when compared with European Americans or Asians. The causes of ethnic differences remain uncertain, although both genetic and non-genetic factors are likely important. Interrogating genome-wide germline SNP genotypes in an unselected large cohort of children with ALL, we observed that the component of genomic variation that co-segregated with Native American ancestry was associated with risk of relapse (P = 0.0029) even after adjusting for known prognostic factors (P = 0.017). Ancestry-related differences in relapse risk were abrogated by the addition of a single extra phase of chemotherapy, indicating that modifications to therapy can mitigate the ancestry-related risk of relapse.",Journal Article,3271.0,161.0,Although five-year survival rates for childhood acute lymphoblastic ALL are now over 80 in most industrialized countries not all children have benefited equally from this progress Ethnic differences in survival after childhood ALL have been reported in many clinical studies with poorer survival observed among African Americans or those with Hispanic ethnicity when compared with European Americans or Asians The causes of ethnic differences remain uncertain although both genetic and non-genetic factors are likely important Interrogating genome-wide germline SNP genotypes in an unselected large cohort of children with ALL we observed that the component of genomic variation that co-segregated with Native American ancestry was associated with risk of relapse P 0.0029 even after adjusting for known prognostic factors P 0.017 Ancestry-related differences in relapse risk were abrogated by the addition of a single extra phase of chemotherapy indicating that modifications to therapy can mitigate the ancestry-related risk of relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 365, 111, 25, 151, 9, 864, 286, 1275, 62, 32, 1134, 252, 493, 4, 96, 18328, 2115, 44, 62, 541, 47, 7067, 4142, 29, 26, 1466, 2871, 362, 4, 25, 50, 864, 62, 47, 85, 210, 4, 445, 38, 94, 5, 1769, 25, 164, 107, 1410, 2731, 15, 135, 5, 1776, 2091, 198, 72, 5, 1865, 2731, 15, 5108, 3, 1626, 1, 2871, 362, 918, 2717, 242, 110, 336, 2, 220, 336, 130, 32, 322, 305, 16989, 898, 1019, 1009, 1845, 2071, 4, 35, 3594, 375, 180, 1, 541, 5, 62, 21, 164, 17, 3, 1249, 1, 572, 1380, 17, 1269, 11324, 5, 4646, 597, 3535, 10, 41, 5, 43, 1, 429, 19, 13, 16808, 871, 50, 1358, 9, 440, 177, 130, 19, 13, 3825, 3535, 139, 362, 4, 429, 43, 11, 3728, 20, 3, 352, 1, 8, 226, 3420, 124, 1, 56, 1716, 17, 2916, 6, 36, 122, 5626, 3, 3535, 139, 43, 1, 429]",1037.0,21297632,738
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2011-02-01,"Although imatinib revolutionized the management of chronic myeloid leukemia (CML), recent data indicate a transformation in the treatment approach likely in the near future. The superiority of second-generation tyrosine kinase inhibitors (TKIs) over imatinib in newly diagnosed disease has been recognized. Several investigational agents specific for those patients with the T315I mutation remain under evaluation. In Philadelphia-positive (Ph-positive) acute lymphoblastic leukemia (ALL), the addition of imatinib improved response rates. However, short remission durations with single agent therapy limit the benefit on survival. Early molecular remissions achieved with dasatinib will enable more patients to proceed to stem cell transplant (SCT), with increased likelihood of positive outcomes post-SCT.",Journal Article,3276.0,11.0,Although imatinib revolutionized the management of chronic myeloid CML recent data indicate a transformation in the treatment approach likely in the near future The superiority of second-generation tyrosine kinase inhibitors TKIs over imatinib in newly diagnosed disease has been recognized Several investigational agents specific for those patients with the T315I mutation remain under evaluation In Philadelphia-positive Ph-positive acute lymphoblastic ALL the addition of imatinib improved response rates However short remission durations with single agent therapy limit the benefit on survival Early molecular remissions achieved with dasatinib will enable more patients to proceed to stem cell transplant SCT with increased likelihood of positive outcomes post-SCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 577, 5746, 3, 284, 1, 442, 533, 903, 435, 74, 1008, 8, 1392, 4, 3, 24, 353, 322, 4, 3, 1829, 508, 3, 5233, 1, 419, 914, 564, 216, 222, 1671, 252, 577, 4, 732, 265, 34, 71, 85, 1904, 392, 3093, 183, 112, 9, 135, 7, 5, 3, 6184, 258, 918, 669, 451, 4, 3006, 109, 2058, 109, 286, 1275, 62, 3, 352, 1, 577, 231, 51, 151, 137, 978, 734, 4864, 5, 226, 420, 36, 2385, 3, 247, 23, 25, 191, 219, 3166, 513, 5, 1674, 303, 3047, 80, 7, 6, 6174, 6, 452, 31, 941, 1988, 5, 101, 1420, 1, 109, 123, 539, 1988]",769.0,21299461,28
Neuropathic pain during treatment for childhood acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2011-02-11,"Improved cure rates for childhood acute lymphoblastic leukemia (ALL) over the past 2 decades have allowed greater attention to patients' quality of life. Neuropathic pain (NP) is an unpleasant side effect of chemotherapeutic agents for leukemia, especially vincristine. We retrospectively reviewed the records of 498 patients treated on a single protocol for ALL to investigate the risk factors, the incidence, and the use of therapeutic and prophylactic gabapentin treatment for NP. White non-Hispanic race was the only patient variable predictive of NP. One hundred and seventy-four of 498 patients (34.9%) experienced 207 episodes of NP; 16% (28 of 174) patients experienced at least one recurrence of pain after the initial episode. No statistical significance was found in the relation between the severity (grade) of the NP episode and the cumulative dose of vincristine (P = 0.45) or the vincristine dose that immediately preceded the diagnosis (1.5 mg/m(2) versus 2.0 mg/m(2) [correction made here after initial online publication], P = 0.59). Of 180 episodes with treatment data, 62.2% (112) and 37.8% (68) were treated with gabapentin or opioids, respectively. The selection of treatment with gabapentin or opioids was not influenced by the pain intensity score at the time of diagnosis of NP (P = 0.91). The mean gabapentin dose used for 112 episodes was 15.5 mg/kg/day (SD 7.9). We found no evidence that gabapentin prevented recurrence of NP. Our results highlight the need for prospective randomized studies to elucidate the value of gabapentin regimen for prevention or treatment of vincristine-related pain during treatment of childhood leukemia.",Historical Article,3266.0,33.0,Improved cure rates for childhood acute lymphoblastic ALL over the past 2 decades have allowed greater attention to patients quality of life Neuropathic pain NP is an unpleasant side effect of chemotherapeutic agents for especially vincristine We retrospectively reviewed the records of 498 patients treated on a single protocol for ALL to investigate the risk factors the incidence and the use of therapeutic and prophylactic gabapentin treatment for NP White non-Hispanic race was the only patient variable predictive of NP One hundred and seventy-four of 498 patients 34.9 experienced 207 episodes of NP 16 28 of 174 patients experienced at least one recurrence of pain after the initial episode No statistical significance was found in the relation between the severity grade of the NP episode and the cumulative dose of vincristine P 0.45 or the vincristine dose that immediately preceded the diagnosis 1.5 mg/m 2 versus 2.0 mg/m 2 correction made here after initial online publication P 0.59 Of 180 episodes with treatment data 62.2 112 and 37.8 68 were treated with gabapentin or opioids respectively The selection of treatment with gabapentin or opioids was not influenced by the pain intensity score at the time of diagnosis of NP P 0.91 The mean gabapentin dose used for 112 episodes was 15.5 mg/kg/day SD 7.9 We found no evidence that gabapentin prevented recurrence of NP Our results highlight the need for prospective randomized studies to elucidate the value of gabapentin regimen for prevention or treatment of vincristine-related pain during treatment of childhood,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[231, 1722, 151, 9, 864, 286, 1275, 62, 252, 3, 1219, 18, 1968, 47, 2313, 378, 2111, 6, 7, 372, 1, 358, 8228, 559, 3769, 16, 35, 27032, 1152, 254, 1, 1573, 183, 9, 1093, 2132, 21, 894, 446, 3, 1064, 1, 8928, 7, 73, 23, 8, 226, 1182, 9, 62, 6, 963, 3, 43, 130, 3, 287, 2, 3, 119, 1, 189, 2, 1862, 11018, 24, 9, 3769, 886, 220, 1776, 1047, 10, 3, 158, 69, 1347, 464, 1, 3769, 104, 1128, 2, 2073, 294, 1, 8928, 7, 562, 83, 592, 5292, 3750, 1, 3769, 245, 339, 1, 5811, 7, 592, 28, 506, 104, 146, 1, 559, 50, 3, 388, 6934, 77, 1050, 724, 10, 204, 4, 3, 2191, 59, 3, 1702, 88, 1, 3, 3769, 6934, 2, 3, 967, 61, 1, 2132, 19, 13, 512, 15, 3, 2132, 61, 17, 3467, 6083, 3, 147, 14, 33, 81, 188, 18, 185, 18, 13, 81, 188, 18, 5360, 1229, 467, 50, 388, 4123, 4397, 19, 13, 728, 1, 3172, 3750, 5, 24, 74, 744, 18, 3726, 2, 567, 66, 806, 11, 73, 5, 11018, 15, 4353, 106, 3, 881, 1, 24, 5, 11018, 15, 4353, 10, 44, 2574, 20, 3, 559, 837, 368, 28, 3, 98, 1, 147, 1, 3769, 19, 13, 970, 3, 313, 11018, 61, 95, 9, 3726, 3750, 10, 167, 33, 81, 503, 218, 1270, 67, 83, 21, 204, 77, 241, 17, 11018, 3902, 146, 1, 3769, 114, 99, 1817, 3, 594, 9, 482, 384, 94, 6, 3061, 3, 549, 1, 11018, 477, 9, 1070, 15, 24, 1, 2132, 139, 559, 190, 24, 1, 864]",1580.0,21319291,698
Treatment of acute lymphoblastic leukemia in adults.,Critical reviews in oncology/hematology,Crit. Rev. Oncol. Hematol.,2011-02-25,"Acute lymphoblastic leukemia (ALL) in adults is an uncommon but devastating malignant proliferation of lymphoid precursors. Treatment programs for adult patients are largely based on pediatric regimens. However, cure rates in adults have been limited to 30-40% for the past several decades as opposed to the 80% cure rate in children. Treatment of adolescents and young adults is evolving with the adoption of more aggressive ""pediatric-inspired"" treatment programs. The role of allogeneic stem cell transplant is first remission remains controversial in spite of recent data suggesting improved outcomes in patients younger than 35. Kinase inhibitors in combination with standard chemotherapy have significantly improved outcomes in ALL associated with the Philadelphia chromosome. The treatment of ALL in the elderly remains challenging. Promising new agents such as nelarabine and clofarabine may improve the outlook. This article reviews the current state of the art for the treatment of ALL in adults.",Journal Article,3252.0,22.0,Acute lymphoblastic ALL in adults is an uncommon but devastating malignant proliferation of lymphoid precursors Treatment programs for adult patients are largely based on pediatric regimens However cure rates in adults have been limited to 30-40 for the past several decades as opposed to the 80 cure rate in children Treatment of adolescents and young adults is evolving with the adoption of more aggressive `` pediatric-inspired '' treatment programs The role of allogeneic stem cell transplant is first remission remains controversial in spite of recent data suggesting improved outcomes in patients younger than 35 Kinase inhibitors in combination with standard chemotherapy have significantly improved outcomes in ALL associated with the Philadelphia chromosome The treatment of ALL in the elderly remains challenging Promising new agents such as nelarabine and clofarabine may improve the outlook This article reviews the current state of the art for the treatment of ALL in adults,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 4, 857, 16, 35, 2052, 84, 5778, 393, 457, 1, 2303, 4881, 24, 2251, 9, 780, 7, 32, 1733, 90, 23, 815, 472, 137, 1722, 151, 4, 857, 47, 85, 383, 6, 201, 327, 9, 3, 1219, 392, 1968, 22, 6101, 6, 3, 493, 1722, 116, 4, 541, 24, 1, 3101, 2, 1169, 857, 16, 3276, 5, 3, 4350, 1, 80, 571, 815, 13161, 522, 24, 2251, 3, 200, 1, 1063, 452, 31, 941, 16, 157, 734, 469, 2010, 4, 9018, 1, 435, 74, 802, 231, 123, 4, 7, 773, 76, 465, 216, 222, 4, 150, 5, 260, 56, 47, 97, 231, 123, 4, 62, 41, 5, 3, 3006, 1170, 3, 24, 1, 62, 4, 3, 1216, 469, 1950, 721, 217, 183, 225, 22, 13149, 2, 4149, 68, 401, 3, 8628, 26, 946, 2004, 3, 291, 1309, 1, 3, 4363, 9, 3, 24, 1, 62, 4, 857]",987.0,21353591,567
Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.,Cancer,Cancer,2011-03-01,"Philadelphia chromosome (Ph)-positive B-lymphoblastic leukemia exhibits immunophenotypic, karyotypic, and molecular genetic heterogeneity. The prognostic significance of these parameters was assessed in the context of intensive tyrosine kinase inhibitor (TKI)-based chemotherapy. The authors studied 65 adult patients with Ph-positive acute lymphoblastic leukemia (ALL) who received treatment with TKI-based therapy, correlated their clinicopathologic heterogeneity with patient outcome, and compared the findings with those from 60 adult patients with diploid B-cell ALL who received similar chemotherapy without a TKI. Ph-positive ALL was associated with older age (P = .01), the common-B immunophenotype characterized by a greater frequency of CD13 (alanine aminopeptidase) coexpression (P = .004), CD66c (carcinoembryonic antigen-related cell adhesion molecule 3) expression (P = .007), and CD25 (interleukin-2 receptor alpha chain) expression (P < .001) and with a lower frequency of CD15 (3-fucosyl-N-acetyl-lactosamine) expression (P < .001). Conventional karyotypic analyses indicated that the Ph chromosome was the sole abnormality in 19 patients (30%), was present with other aberrancies in 43 patients (65%), and was absent (detectable only by fluorescence in situ hybridization [FISH] or quantitative reverse transcriptase-polymerase chain reaction [RT-PCR] analysis) in 3 patients (5%). The presence of the breakpoint cluster region-v-Abelson murine leukemia viral oncogene homolog fusion gene (BCR-ABL) was confirmed in all patients by FISH or RT-PCR (the 190-kDa protein [p190] construct was present in 49 patients [77%], and the p210 fusion transcript construct was present in 15 patients [23%]). The presence of a supernumerary Ph chromosome was correlated with a higher incidence of CD20 (B-lymphocyte antigen, nonglycosylated phosphoprotein) expression (P < .001), whereas the p210 construct was correlated with aberrant CD25 expression (P = .05). Outcomes were not influenced by the degree of karyotypic complexity (including the presence or absence of a supernumerary Ph chromosome), CD20 expression, or myeloid antigen expression (CD13, CD33 [myeloid lineage transmembrane receptor], CD66c). CD25 expression was associated with inferior survival in univariate analysis (P = .051) but not in multivariate analysis (P = .092). In the context of intensive, TKI-based chemotherapy, the immunophenotypic, karyotypic, and molecular heterogeneity of Ph-positive ALL no longer influences outcome.",Journal Article,3248.0,29.0,Philadelphia chromosome Ph -positive B-lymphoblastic exhibits immunophenotypic karyotypic and molecular genetic heterogeneity The prognostic significance of these parameters was assessed in the context of intensive tyrosine kinase inhibitor TKI -based chemotherapy The authors studied 65 adult patients with Ph-positive acute lymphoblastic ALL who received treatment with TKI-based therapy correlated their clinicopathologic heterogeneity with patient outcome and compared the findings with those from 60 adult patients with diploid B-cell ALL who received similar chemotherapy without a TKI Ph-positive ALL was associated with older age P .01 the common-B immunophenotype characterized by a greater frequency of CD13 alanine aminopeptidase coexpression P .004 CD66c carcinoembryonic antigen-related cell adhesion molecule 3 expression P .007 and CD25 interleukin-2 receptor alpha chain expression P .001 and with a lower frequency of CD15 3-fucosyl-N-acetyl-lactosamine expression P .001 Conventional karyotypic analyses indicated that the Ph chromosome was the sole abnormality in 19 patients 30 was present with other aberrancies in 43 patients 65 and was absent detectable only by fluorescence in situ hybridization FISH or quantitative reverse transcriptase-polymerase chain reaction RT-PCR analysis in 3 patients 5 The presence of the breakpoint cluster region-v-Abelson murine viral oncogene homolog fusion gene BCR-ABL was confirmed in all patients by FISH or RT-PCR the 190-kDa protein p190 construct was present in 49 patients 77 and the p210 fusion transcript construct was present in 15 patients 23 The presence of a supernumerary Ph chromosome was correlated with a higher incidence of CD20 B-lymphocyte antigen nonglycosylated phosphoprotein expression P .001 whereas the p210 construct was correlated with aberrant CD25 expression P .05 Outcomes were not influenced by the degree of karyotypic complexity including the presence or absence of a supernumerary Ph chromosome CD20 expression or myeloid antigen expression CD13 CD33 myeloid lineage transmembrane receptor CD66c CD25 expression was associated with inferior survival in univariate analysis P .051 but not in multivariate analysis P .092 In the context of intensive TKI-based chemotherapy the immunophenotypic karyotypic and molecular heterogeneity of Ph-positive ALL no longer influences outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 2058, 109, 132, 1275, 4273, 6599, 9465, 2, 219, 336, 1144, 3, 177, 724, 1, 46, 1038, 10, 275, 4, 3, 1533, 1, 1686, 564, 216, 230, 1379, 90, 56, 3, 738, 656, 556, 780, 7, 5, 2058, 109, 286, 1275, 62, 54, 103, 24, 5, 1379, 90, 36, 438, 136, 1399, 1144, 5, 69, 228, 2, 72, 3, 272, 5, 135, 29, 335, 780, 7, 5, 6815, 132, 31, 62, 54, 103, 288, 56, 187, 8, 1379, 2058, 109, 62, 10, 41, 5, 434, 89, 19, 355, 3, 186, 132, 5496, 765, 20, 8, 378, 675, 1, 13518, 5411, 18319, 7588, 19, 1520, 37140, 5139, 448, 139, 31, 2128, 1354, 27, 55, 19, 1999, 2, 4531, 1603, 18, 153, 950, 1260, 55, 19, 144, 2, 5, 8, 280, 675, 1, 15084, 27, 22229, 78, 7055, 39565, 55, 19, 144, 809, 9465, 318, 1103, 17, 3, 2058, 1170, 10, 3, 4991, 3698, 4, 326, 7, 201, 10, 364, 5, 127, 17158, 4, 601, 7, 556, 2, 10, 3269, 2083, 158, 20, 1591, 4, 957, 1554, 1277, 15, 1156, 1772, 4456, 1451, 1260, 1329, 240, 604, 65, 4, 27, 7, 33, 3, 463, 1, 3, 8567, 3132, 1053, 603, 16881, 1471, 1667, 1836, 3412, 1212, 145, 1062, 1425, 10, 557, 4, 62, 7, 20, 1277, 15, 240, 604, 3, 5974, 6362, 178, 18813, 3883, 10, 364, 4, 739, 7, 849, 2, 3, 11538, 1212, 3268, 3883, 10, 364, 4, 167, 7, 382, 3, 463, 1, 8, 24651, 2058, 1170, 10, 438, 5, 8, 142, 287, 1, 2198, 132, 1448, 448, 59882, 12302, 55, 19, 144, 547, 3, 11538, 3883, 10, 438, 5, 1898, 4531, 55, 19, 474, 123, 11, 44, 2574, 20, 3, 1444, 1, 9465, 3082, 141, 3, 463, 15, 1127, 1, 8, 24651, 2058, 1170, 2198, 55, 15, 533, 448, 55, 13518, 6353, 533, 2542, 5527, 153, 37140, 4531, 55, 10, 41, 5, 1663, 25, 4, 880, 65, 19, 9891, 84, 44, 4, 331, 65, 19, 14874, 4, 3, 1533, 1, 1686, 1379, 90, 56, 3, 6599, 9465, 2, 219, 1144, 1, 2058, 109, 62, 77, 589, 3859, 228]",2370.0,21365622,7
Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2011-03-22,"Clinical trials using vaccine measles virus (MV) as anticancer therapy are already underway. We compared the oncolytic potential of MV in two B-cell malignancies; adult acute lymphoblastic leukemia (ALL, an aggressive leukemia) and chronic lymphocytic leukemia (CLL, an indolent leukemia overexpressing Bcl-2) using patient-derived material. In vitro, distinct cytopathological effects were observed between MV-infected primary ALL and CLL cells, with large multinucleated syncytia forming in ALL cultures compared to minimal cell-to-cell fusion in infected CLL cells. Cell viability and immunoblotting studies confirmed rapid cell death in MV-infected ALL cultures and slower MV oncolysis of CLL cells. In cell lines, overexpression of Bcl-2 diminished MV-induced cell death providing a possible mechanism for the slower kinetic of MV oncolysis in CLL. In vivo, intratumoral MV treatment of established subcutaneous ALL xenografts had striking antitumor activity leading to complete resolution of all tumors. The antitumor activity of MV was also evident in disseminated ALL xenograft models. In summary, both ALL and CLL are targets for MV-mediated lysis albeit with different kinetics. The marked sensitivity of both primary ALL cells and ALL xenografts to MV oncolysis highlights the tremendous potential of MV as a novel replicating-virus therapy for adult ALL.",Journal Article,3227.0,,Clinical trials using vaccine measles virus MV as anticancer therapy are already underway We compared the oncolytic potential of MV in two B-cell malignancies adult acute lymphoblastic ALL an aggressive and chronic lymphocytic CLL an indolent overexpressing Bcl-2 using patient-derived material In vitro distinct cytopathological effects were observed between MV-infected primary ALL and CLL cells with large multinucleated syncytia forming in ALL cultures compared to minimal cell-to-cell fusion in infected CLL cells Cell viability and immunoblotting studies confirmed rapid cell death in MV-infected ALL cultures and slower MV oncolysis of CLL cells In cell lines overexpression of Bcl-2 diminished MV-induced cell death providing a possible mechanism for the slower kinetic of MV oncolysis in CLL In vivo intratumoral MV treatment of established subcutaneous ALL xenografts had striking antitumor activity leading to complete resolution of all tumors The antitumor activity of MV was also evident in disseminated ALL xenograft models In summary both ALL and CLL are targets for MV-mediated lysis albeit with different kinetics The marked sensitivity of both primary ALL cells and ALL xenografts to MV oncolysis highlights the tremendous potential of MV as a novel replicating-virus therapy for adult ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[38, 143, 75, 1274, 7424, 1450, 3491, 22, 1475, 36, 32, 3298, 3948, 21, 72, 3, 3236, 174, 1, 3491, 4, 100, 132, 31, 441, 780, 286, 1275, 62, 35, 571, 2, 442, 1193, 552, 35, 2316, 2810, 1044, 18, 75, 69, 526, 3692, 4, 439, 834, 43365, 176, 11, 164, 59, 3491, 3369, 86, 62, 2, 552, 37, 5, 375, 15649, 22231, 4525, 4, 62, 3231, 72, 6, 1048, 31, 6, 31, 1212, 4, 3369, 552, 37, 31, 2120, 2, 5293, 94, 557, 1321, 31, 273, 4, 3491, 3369, 62, 3231, 2, 6715, 3491, 9739, 1, 552, 37, 4, 31, 285, 851, 1, 1044, 18, 2849, 3491, 277, 31, 273, 1736, 8, 899, 670, 9, 3, 6715, 7009, 1, 3491, 9739, 4, 552, 4, 386, 2074, 3491, 24, 1, 635, 2529, 62, 1348, 42, 5133, 579, 128, 1049, 6, 236, 2125, 1, 62, 57, 3, 579, 128, 1, 3491, 10, 120, 2853, 4, 3605, 62, 1330, 274, 4, 1962, 110, 62, 2, 552, 32, 637, 9, 3491, 517, 4783, 5993, 5, 338, 3839, 3, 2003, 485, 1, 110, 86, 62, 37, 2, 62, 1348, 6, 3491, 9739, 2527, 3, 6678, 174, 1, 3491, 22, 8, 229, 13012, 1450, 36, 9, 780, 62]",1307.0,21427708,893
Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2011-03-28,"To determine whether shortening the infusion duration of high-dose methotrexate (HDMTX; 1 g/m(2)) affects the in vivo accumulation of active methotrexate polyglutamates (MTXPG(1-7)) in leukemia cells and whether this differs among major acute lymphoblastic leukemia (ALL) subtypes. From June 2000 through October 2007, 356 children with ALL were randomly assigned to receive initial single-agent treatment with HDMTX (1 g/m(2)) as either a 24-hour infusion or a 4-hour infusion at two pediatric hospitals in the United States. The primary outcome measures were the accumulation of MTXPG(1-7) in leukemia cells and the antileukemic effects (eg, inhibition of de novo purine synthesis in bone marrow ALL cells, and decrease in circulating ALL cells). The 24-hour infusion resulted in significantly higher amounts of MTXPG(1-7) in bone marrow leukemia cells (median: 1,695 v 1,150 pmol/10(9) cells, P = .0059), and better antileukemic effects. The 24-hour infusion had the greatest effect on MTXPG(1-7) accumulation in hyperdiploid ALL (median: 3,919 v 2,417 pmol/10(9) cells, P = .0038); T-cell ALL exhibited smaller differences in MTXPG(1-7) but greater antileukemic effects with the longer infusion (median decrease in leukemia cells: 88.4% v 51.8%, P = .0075). In contrast, infusion duration had no significant impact on MTXPG(1-7) accumulation or antileukemic effects in ALL with the t(12;21)/(ETV6-RUNX1) chromosomal translocation. Shortening the infusion time of HDMTX reduces accumulation of active methotrexate in leukemia cells and decreases antileukemic effects, with differing consequences among major ALL subtypes.",Journal Article,3221.0,32.0,"To determine whether shortening the infusion duration of high-dose methotrexate HDMTX 1 g/m 2 affects the in vivo accumulation of active methotrexate polyglutamates MTXPG 1-7 in cells and whether this differs among major acute lymphoblastic ALL subtypes From June 2000 through October 2007 356 children with ALL were randomly assigned to receive initial single-agent treatment with HDMTX 1 g/m 2 as either a 24-hour infusion or a 4-hour infusion at two pediatric hospitals in the United States The primary outcome measures were the accumulation of MTXPG 1-7 in cells and the antileukemic effects eg inhibition of de novo purine synthesis in marrow ALL cells and decrease in circulating ALL cells The 24-hour infusion resulted in significantly higher amounts of MTXPG 1-7 in marrow cells median 1,695 v 1,150 pmol/10 9 cells P .0059 and better antileukemic effects The 24-hour infusion had the greatest effect on MTXPG 1-7 accumulation in hyperdiploid ALL median 3,919 v 2,417 pmol/10 9 cells P .0038 T-cell ALL exhibited smaller differences in MTXPG 1-7 but greater antileukemic effects with the longer infusion median decrease in cells 88.4 v 51.8 P .0075 In contrast infusion duration had no significant impact on MTXPG 1-7 accumulation or antileukemic effects in ALL with the t 12 21 ETV6-RUNX1 chromosomal translocation Shortening the infusion time of HDMTX reduces accumulation of active methotrexate in cells and decreases antileukemic effects with differing consequences among major ALL subtypes",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 317, 9245, 3, 904, 654, 1, 64, 61, 2116, 10061, 14, 499, 188, 18, 2561, 3, 4, 386, 1835, 1, 544, 2116, 16243, 11572, 14, 67, 4, 37, 2, 317, 26, 4990, 107, 458, 286, 1275, 62, 814, 29, 1924, 1081, 298, 2551, 1307, 8664, 541, 5, 62, 11, 1108, 896, 6, 560, 388, 226, 420, 24, 5, 10061, 14, 499, 188, 18, 22, 361, 8, 259, 2583, 904, 15, 8, 39, 2583, 904, 28, 100, 815, 1987, 4, 3, 1088, 907, 3, 86, 228, 1018, 11, 3, 1835, 1, 11572, 14, 67, 4, 37, 2, 3, 4512, 176, 2887, 297, 1, 1566, 2018, 5006, 2525, 4, 581, 62, 37, 2, 775, 4, 1033, 62, 37, 3, 259, 2583, 904, 627, 4, 97, 142, 4939, 1, 11572, 14, 67, 4, 581, 37, 52, 14, 15214, 603, 14, 1577, 9835, 79, 83, 37, 19, 26709, 2, 380, 4512, 176, 3, 259, 2583, 904, 42, 3, 2199, 254, 23, 11572, 14, 67, 1835, 4, 8847, 62, 52, 27, 16514, 603, 18, 9947, 9835, 79, 83, 37, 19, 22350, 102, 31, 62, 1416, 2170, 362, 4, 11572, 14, 67, 84, 378, 4512, 176, 5, 3, 589, 904, 52, 775, 4, 37, 889, 39, 603, 725, 66, 19, 23345, 4, 748, 904, 654, 42, 77, 93, 345, 23, 11572, 14, 67, 1835, 15, 4512, 176, 4, 62, 5, 3, 102, 133, 239, 7306, 6092, 1860, 2006, 9245, 3, 904, 98, 1, 10061, 2389, 1835, 1, 544, 2116, 4, 37, 2, 2140, 4512, 176, 5, 5276, 3255, 107, 458, 62, 814]",1502.0,21444869,58
"Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2011-02-01,"The prognosis of adult patients with relapsed acute lymphoblastic leukemia (ALL) remains poor. Recent studies in adolescents and young adults reported better outcomes when therapy was intensified. Based on hyper-CVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) as a backbone, we designed an augmented version with intensified doses of vincristine, dexamethasone, and asparaginase (L-asparaginase in the first 62 patients and pegaspargase in the remainder) starting from course 1. Ninety patients have been enrolled, with a median age of 34 years (range, 14-70 years). Most patients (78%) had pre-B ALL and were in first salvage (76%), with a first remission duration of 12.6 months (range, 1-78 months). Ten patients had primary refractory disease. Of 88 evaluable patients, 41 (47%) achieved complete remission (CR), with a median time to CR of 29 days (range, 18-80 days). Eight patients (9%) died within the first 30 days. Median CR duration, progression-free survival, and overall survival were 5, 6.2, and 6 months, respectively. Median overall survival of CR patients was 10.2 months (range, 1.4-69.5+ months). Twenty-eight patients (32%) proceeded to stem cell transplantation. Myelosuppression-associated complications were frequent. Pegaspargase was equally effective and easier to administer than L-asparaginase. Augmented hyper-CVAD may be suitable to be studied in younger adults with untreated ALL.",Clinical Trial,3276.0,41.0,The prognosis of adult patients with relapsed acute lymphoblastic ALL remains poor Recent studies in adolescents and young adults reported better outcomes when therapy was intensified Based on hyper-CVAD cyclophosphamide/vincristine/doxorubicin/dexamethasone as a backbone we designed an augmented version with intensified doses of vincristine dexamethasone and asparaginase L-asparaginase in the first 62 patients and pegaspargase in the remainder starting from course 1 Ninety patients have been enrolled with a median age of 34 years range 14-70 years Most patients 78 had pre-B ALL and were in first salvage 76 with a first remission duration of 12.6 months range 1-78 months Ten patients had primary refractory disease Of 88 evaluable patients 41 47 achieved complete remission CR with a median time to CR of 29 days range 18-80 days Eight patients 9 died within the first 30 days Median CR duration progression-free survival and overall survival were 5 6.2 and 6 months respectively Median overall survival of CR patients was 10.2 months range 1.4-69.5+ months Twenty-eight patients 32 proceeded to stem cell transplantation Myelosuppression-associated complications were frequent Pegaspargase was equally effective and easier to administer than L-asparaginase Augmented hyper-CVAD may be suitable to be studied in younger adults with untreated ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 1, 780, 7, 5, 591, 286, 1275, 62, 469, 334, 435, 94, 4, 3101, 2, 1169, 857, 210, 380, 123, 198, 36, 10, 7311, 90, 23, 4855, 5574, 1112, 2132, 856, 1217, 22, 8, 7066, 21, 1114, 35, 4277, 2256, 5, 7311, 415, 1, 2132, 1217, 2, 3709, 805, 3709, 4, 3, 157, 744, 7, 2, 12209, 4, 3, 7095, 1723, 29, 906, 14, 2493, 7, 47, 85, 346, 5, 8, 52, 89, 1, 562, 60, 184, 213, 431, 60, 96, 7, 833, 42, 671, 132, 62, 2, 11, 4, 157, 992, 846, 5, 8, 157, 734, 654, 1, 133, 49, 53, 184, 14, 833, 53, 1618, 7, 42, 86, 430, 34, 1, 889, 859, 7, 605, 662, 513, 236, 734, 684, 5, 8, 52, 98, 6, 684, 1, 462, 162, 184, 203, 493, 162, 659, 7, 83, 1016, 262, 3, 157, 201, 162, 52, 684, 654, 91, 115, 25, 2, 63, 25, 11, 33, 49, 18, 2, 49, 53, 106, 52, 63, 25, 1, 684, 7, 10, 79, 18, 53, 184, 14, 39, 790, 33, 53, 737, 659, 7, 531, 6406, 6, 452, 31, 497, 2858, 41, 521, 11, 908, 12209, 10, 4142, 323, 2, 12734, 6, 6888, 76, 805, 3709, 4277, 4855, 5574, 68, 40, 2884, 6, 40, 656, 4, 773, 857, 5, 1278, 62]",1354.0,21454191,216
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia.,Cancer,Cancer,2011-03-31,"CXC chemokine receptor 4 (CXCR4) is activated by phosphorylation (pCXCR4) and is essential for the migration of hematopoietic precursors to bone marrow. CXCR4 overexpression predicts a poor prognosis in patients with acute myeloid leukemia. Data regarding the prognostic impact of CXCR4 in patients with B-acute lymphoblastic leukemia (B-ALL) are sparse and limited to the pediatric population. The authors analyzed CXCR4 and pCXCR4 expression in 54 adults with newly diagnosed B-ALL. CXCR4 was assessed by flow cytometry (FC) and immunohistochemistry (IHC) using an anti-CXCR4 antibody. pCXCR4 expression was assessed using an anti-pCXCR4 antibody. The study group included 30 men and 24 women with a median age of 42 years (range, 17-84 years). Philadelphia chromosome was present in 19 patients. The median follow-up was 16 months (range, 17-84 months). Forty-nine patients had a complete response, and 12 patients relapsed with a median relapse free survival >120 weeks. Fifteen patients (28%) died with a median survival >125 weeks. CXCR4 detected by FC and IHC was highly correlated (P < .001). CXCR4 was not associated with clinical or laboratory findings or survival. In contrast, pCXCR4 was associated with higher leukocyte count (P = .006) and serum bilirubin level (P = .03). In multivariate analysis, pCXCR4 expression (P = .027), high serum creatinine level (P < .01), presence of the Philadelphia chromosome (P = .017), and late clinical response (P < .001) were associated with worse overall survival. The current results indicated that detection of the activated form of CXCR4, pCXCR4, provides independent prognostic information in adult patients with B-ALL.",Journal Article,3218.0,21.0,CXC chemokine receptor 4 CXCR4 is activated by phosphorylation pCXCR4 and is essential for the migration of hematopoietic precursors to marrow CXCR4 overexpression predicts a poor prognosis in patients with acute myeloid Data regarding the prognostic impact of CXCR4 in patients with B-acute lymphoblastic B-ALL are sparse and limited to the pediatric population The authors analyzed CXCR4 and pCXCR4 expression in 54 adults with newly diagnosed B-ALL CXCR4 was assessed by flow cytometry FC and immunohistochemistry IHC using an anti-CXCR4 antibody pCXCR4 expression was assessed using an anti-pCXCR4 antibody The study group included 30 men and 24 women with a median age of 42 years range 17-84 years Philadelphia chromosome was present in 19 patients The median follow-up was 16 months range 17-84 months Forty-nine patients had a complete response and 12 patients relapsed with a median relapse free survival 120 weeks Fifteen patients 28 died with a median survival 125 weeks CXCR4 detected by FC and IHC was highly correlated P .001 CXCR4 was not associated with clinical or laboratory findings or survival In contrast pCXCR4 was associated with higher leukocyte count P .006 and serum bilirubin level P .03 In multivariate analysis pCXCR4 expression P .027 high serum creatinine level P .01 presence of the Philadelphia chromosome P .017 and late clinical response P .001 were associated with worse overall survival The current results indicated that detection of the activated form of CXCR4 pCXCR4 provides independent prognostic information in adult patients with B-ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[16813, 3596, 153, 39, 2318, 16, 735, 20, 982, 20731, 2, 16, 1452, 9, 3, 1381, 1, 1007, 4881, 6, 581, 2318, 851, 2623, 8, 334, 356, 4, 7, 5, 286, 533, 74, 666, 3, 177, 345, 1, 2318, 4, 7, 5, 132, 286, 1275, 132, 62, 32, 7425, 2, 383, 6, 3, 815, 266, 3, 738, 311, 2318, 2, 20731, 55, 4, 667, 857, 5, 732, 265, 132, 62, 2318, 10, 275, 20, 1412, 1914, 4127, 2, 888, 1289, 75, 35, 312, 2318, 548, 20731, 55, 10, 275, 75, 35, 312, 20731, 548, 3, 45, 87, 159, 201, 325, 2, 259, 117, 5, 8, 52, 89, 1, 595, 60, 184, 269, 874, 60, 3006, 1170, 10, 364, 4, 326, 7, 3, 52, 166, 126, 10, 245, 53, 184, 269, 874, 53, 1213, 762, 7, 42, 8, 236, 51, 2, 133, 7, 591, 5, 8, 52, 429, 115, 25, 2031, 244, 3057, 7, 339, 1016, 5, 8, 52, 25, 1731, 244, 2318, 530, 20, 4127, 2, 1289, 10, 561, 438, 19, 144, 2318, 10, 44, 41, 5, 38, 15, 1624, 272, 15, 25, 4, 748, 20731, 10, 41, 5, 142, 3627, 1276, 19, 1861, 2, 524, 5009, 301, 19, 680, 4, 331, 65, 20731, 55, 19, 4523, 64, 524, 3177, 301, 19, 355, 463, 1, 3, 3006, 1170, 19, 3825, 2, 807, 38, 51, 19, 144, 11, 41, 5, 639, 63, 25, 3, 291, 99, 1103, 17, 638, 1, 3, 735, 1297, 1, 2318, 20731, 777, 306, 177, 487, 4, 780, 7, 5, 132, 62]",1579.0,21456010,438
Philadelphia chromosome-positive acute lymphoblastic leukemia: current treatment and future perspectives.,Cancer,Cancer,2010-11-08,"The Philadelphia chromosome (Ph) is the most common cytogenetic abnormality associated with adult acute lymphoblastic leukemia (ALL). Before the advent of tyrosine kinase inhibitors (TKIs), Ph-positive ALL carried a dismal prognosis and was characterized by a poor response to most chemotherapy combinations, short remission durations, and poor survival rates. Outcomes for patients with Ph-positive ALL improved substantially with the introduction of TKIs, and the TKI imatinib induced complete remissions in >95% of patients with newly diagnosed Ph-positive ALL when it was combined with chemotherapy. However, imatinib resistance remains a problem in a substantial proportion of patients with Ph-positive ALL, and multiple molecular mechanisms that contribute to imatinib resistance have been identified. Second-generation TKIs (eg, dasatinib and nilotinib) have demonstrated promising efficacy in the treatment of imatinib-resistant, Ph-positive ALL. Future strategies for Ph-positive ALL include novel, molecularly targeted treatment modalities and further evaluations of TKIs in combination with established antileukemic agents. For this article, the authors reviewed past, current, and future treatment approaches for adult and elderly patients with Ph-positive ALL with a focus on TKIs and combined chemotherapeutic regimens.",Journal Article,3361.0,80.0,The Philadelphia chromosome Ph is the most common cytogenetic abnormality associated with adult acute lymphoblastic ALL Before the advent of tyrosine kinase inhibitors TKIs Ph-positive ALL carried a dismal prognosis and was characterized by a poor response to most chemotherapy combinations short remission durations and poor survival rates Outcomes for patients with Ph-positive ALL improved substantially with the introduction of TKIs and the TKI imatinib induced complete remissions in 95 of patients with newly diagnosed Ph-positive ALL when it was combined with chemotherapy However imatinib resistance remains a problem in a substantial proportion of patients with Ph-positive ALL and multiple molecular mechanisms that contribute to imatinib resistance have been identified Second-generation TKIs eg dasatinib and nilotinib have demonstrated promising efficacy in the treatment of imatinib-resistant Ph-positive ALL Future strategies for Ph-positive ALL include novel molecularly targeted treatment modalities and further evaluations of TKIs in combination with established antileukemic agents For this article the authors reviewed past current and future treatment approaches for adult and elderly patients with Ph-positive ALL with a focus on TKIs and combined chemotherapeutic regimens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3006, 1170, 2058, 16, 3, 96, 186, 1266, 3698, 41, 5, 780, 286, 1275, 62, 348, 3, 4114, 1, 564, 216, 222, 1671, 2058, 109, 62, 2629, 8, 3929, 356, 2, 10, 765, 20, 8, 334, 51, 6, 96, 56, 1247, 978, 734, 4864, 2, 334, 25, 151, 123, 9, 7, 5, 2058, 109, 62, 231, 2109, 5, 3, 2456, 1, 1671, 2, 3, 1379, 577, 277, 236, 3166, 4, 48, 1, 7, 5, 732, 265, 2058, 109, 62, 198, 192, 10, 397, 5, 56, 137, 577, 251, 469, 8, 2497, 4, 8, 1281, 920, 1, 7, 5, 2058, 109, 62, 2, 232, 219, 483, 17, 1248, 6, 577, 251, 47, 85, 108, 419, 914, 1671, 2887, 1674, 2, 2638, 47, 264, 721, 209, 4, 3, 24, 1, 577, 436, 2058, 109, 62, 508, 422, 9, 2058, 109, 62, 643, 229, 2372, 238, 24, 1558, 2, 195, 3816, 1, 1671, 4, 150, 5, 635, 4512, 183, 9, 26, 946, 3, 738, 446, 1219, 291, 2, 508, 24, 611, 9, 780, 2, 1216, 7, 5, 2058, 109, 62, 5, 8, 1222, 23, 1671, 2, 397, 1573, 472]",1295.0,21472706,216
HDAC inhibitors potentiate the activity of the BCR/ABL kinase inhibitor KW-2449 in imatinib-sensitive or -resistant BCR/ABL+ leukemia cells in vitro and in vivo.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2011-04-07,"The purpose of this study was to determine whether histone deacetylase (HDAC) inhibitors (HDACI) such as vorinostat or entinostat (SNDX-275) could increase the lethality of the dual Bcr/Abl-Aurora kinase inhibitor KW-2449 in various Bcr/Abl(+) human leukemia cells, including those resistant to imatinib mesylate (IM). Bcr/Abl(+) chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) cells, including those resistant to IM (T315I, E255K), were exposed to KW-2449 in the presence or absence of vorinostat or SNDX-275, after which apoptosis and effects on signaling pathways were examined. In vivo studies combining HDACIs and KW2449 were carried out by using a systemic IM-resistant ALL xenograft model. Coadministration of HDACIs synergistically increased KW-2449 lethality in vitro in multiple CML and Ph(+) ALL cell types including human IM resistant cells (e.g., BV-173/E255K and Adult/T315I). Combined treatment resulted in inactivation of Bcr/Abl and downstream targets (e.g., STAT5 and CRKL), as well as increased reactive oxygen species (ROS) generation and DNA damage (H2A.X). The latter events and cell death were significantly attenuated by free radical scavengers (TBAP). Increased lethality was also observed in primary CD34(+) cells from patients with CML, but not in normal CD34(+) cells. Finally, minimally active vorinostat or SNDX275 doses markedly increased KW2449 antitumor effects and significantly prolonged the survival of murine xenografts bearing IM-resistant ALL cells (BV173/E255K). HDACIs increase KW-2449 lethality in Bcr/Abl(+) cells in association with inhibition of Bcr/Abl, generation of ROS, and induction of DNA damage. This strategy preferentially targets primary Bcr/Abl(+) hematopoietic cells and exhibits enhanced in vivo activity. Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl(+) leukemias.",Journal Article,3211.0,55.0,The purpose of this study was to determine whether histone deacetylase HDAC inhibitors HDACI such as vorinostat or entinostat SNDX-275 could increase the lethality of the dual Bcr/Abl-Aurora kinase inhibitor KW-2449 in various Bcr/Abl human cells including those resistant to imatinib mesylate IM Bcr/Abl chronic myelogenous CML and acute lymphoblastic ALL cells including those resistant to IM T315I E255K were exposed to KW-2449 in the presence or absence of vorinostat or SNDX-275 after which apoptosis and effects on signaling pathways were examined In vivo studies combining HDACIs and KW2449 were carried out by using a systemic IM-resistant ALL xenograft model Coadministration of HDACIs synergistically increased KW-2449 lethality in vitro in multiple CML and Ph ALL cell types including human IM resistant cells e.g. BV-173/E255K and Adult/T315I Combined treatment resulted in inactivation of Bcr/Abl and downstream targets e.g. STAT5 and CRKL as well as increased reactive oxygen species ROS generation and DNA damage H2A.X The latter events and cell death were significantly attenuated by free radical scavengers TBAP Increased lethality was also observed in primary CD34 cells from patients with CML but not in normal CD34 cells Finally minimally active vorinostat or SNDX275 doses markedly increased KW2449 antitumor effects and significantly prolonged the survival of murine xenografts bearing IM-resistant ALL cells BV173/E255K HDACIs increase KW-2449 lethality in Bcr/Abl cells in association with inhibition of Bcr/Abl generation of ROS and induction of DNA damage This strategy preferentially targets primary Bcr/Abl hematopoietic cells and exhibits enhanced in vivo activity Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl leukemias,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 317, 1508, 2732, 2654, 222, 4265, 225, 22, 2371, 15, 7616, 16941, 5620, 359, 344, 3, 3266, 1, 3, 1828, 1062, 1425, 4095, 216, 230, 10963, 23890, 4, 747, 1062, 1425, 171, 37, 141, 135, 436, 6, 577, 2347, 2820, 1062, 1425, 442, 2194, 903, 2, 286, 1275, 62, 37, 141, 135, 436, 6, 2820, 6184, 16677, 11, 2234, 6, 10963, 23890, 4, 3, 463, 15, 1127, 1, 2371, 15, 16941, 5620, 50, 92, 351, 2, 176, 23, 314, 460, 11, 409, 4, 386, 94, 1525, 6250, 2, 46521, 11, 2629, 1205, 20, 75, 8, 403, 2820, 436, 62, 1330, 202, 5777, 1, 6250, 4240, 101, 10963, 23890, 3266, 4, 439, 4, 232, 903, 2, 2058, 62, 31, 630, 141, 171, 2820, 436, 37, 563, 499, 3835, 5785, 16677, 2, 780, 6184, 397, 24, 627, 4, 2297, 1, 1062, 1425, 2, 1489, 637, 563, 499, 5517, 2, 13765, 22, 149, 22, 101, 2163, 2848, 2915, 2609, 914, 2, 261, 1350, 25344, 1006, 3, 3286, 281, 2, 31, 273, 11, 97, 2656, 20, 115, 711, 26237, 28455, 101, 3266, 10, 120, 164, 4, 86, 2215, 37, 29, 7, 5, 903, 84, 44, 4, 295, 2215, 37, 1368, 2144, 544, 2371, 15, 60007, 415, 2195, 101, 46521, 579, 176, 2, 97, 1069, 3, 25, 1, 1471, 1348, 1894, 2820, 436, 62, 37, 46522, 16677, 6250, 344, 10963, 23890, 3266, 4, 1062, 1425, 37, 4, 248, 5, 297, 1, 1062, 1425, 914, 1, 2609, 2, 504, 1, 261, 1350, 26, 692, 3509, 637, 86, 1062, 1425, 1007, 37, 2, 4273, 651, 4, 386, 128, 1525, 10963, 23890, 5, 6250, 2782, 2111, 4, 2820, 436, 1062, 1425, 2792]",1777.0,21474579,326
New markers for minimal residual disease detection in acute lymphoblastic leukemia.,Blood,Blood,2011-04-12,"To identify new markers for minimal residual disease (MRD) detection in acute lymphoblastic leukemia (ALL), we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19CD10 B-cell progenitors (n = 4). Expression of 30 genes differentially expressed by  3-fold in at least 25% of cases of ALL (or 40% of ALL subtypes) was tested by flow cytometry in 200 B-lineage ALL and 61 nonleukemic BM samples, including samples containing hematogones. Of the 30 markers, 22 (CD44, BCL2, HSPB1, CD73, CD24, CD123, CD72, CD86, CD200, CD79b, CD164, CD304, CD97, CD102, CD99, CD300a, CD130, PBX1, CTNNA1, ITGB7, CD69, CD49f) were differentially expressed in up to 81.4% of ALL cases; expression of some markers was associated with the presence of genetic abnormalities. Results of MRD detection by flow cytometry with these markers correlated well with those of molecular testing (52 follow-up samples from 18 patients); sequential studies during treatment and diagnosis-relapse comparisons documented their stability. When incorporated in 6-marker combinations, the new markers afforded the detection of 1 leukemic cell among 10(5) BM cells. These new markers should allow MRD studies in all B-lineage ALL patients, and substantially improve their sensitivity.",Comparative Study,3206.0,162.0,To identify new markers for minimal residual disease MRD detection in acute lymphoblastic ALL we compared genome-wide gene expression of lymphoblasts from 270 patients with newly diagnosed childhood ALL to that of normal CD19CD10 B-cell progenitors n 4 Expression of 30 genes differentially expressed by  3-fold in at least 25 of cases of ALL or 40 of ALL subtypes was tested by flow cytometry in 200 B-lineage ALL and 61 nonleukemic BM samples including samples containing hematogones Of the 30 markers 22 CD44 BCL2 HSPB1 CD73 CD24 CD123 CD72 CD86 CD200 CD79b CD164 CD304 CD97 CD102 CD99 CD300a CD130 PBX1 CTNNA1 ITGB7 CD69 CD49f were differentially expressed in up to 81.4 of ALL cases expression of some markers was associated with the presence of genetic abnormalities Results of MRD detection by flow cytometry with these markers correlated well with those of molecular testing 52 follow-up samples from 18 patients sequential studies during treatment and diagnosis-relapse comparisons documented their stability When incorporated in 6-marker combinations the new markers afforded the detection of 1 leukemic cell among 10 5 BM cells These new markers should allow MRD studies in all B-lineage ALL patients and substantially improve their sensitivity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 255, 217, 525, 9, 1048, 753, 34, 2029, 638, 4, 286, 1275, 62, 21, 72, 898, 1019, 145, 55, 1, 10521, 29, 6666, 7, 5, 732, 265, 864, 62, 6, 17, 1, 295, 60017, 132, 31, 4321, 78, 39, 55, 1, 201, 214, 2478, 570, 20, 749, 27, 1116, 4, 28, 506, 243, 1, 140, 1, 62, 15, 327, 1, 62, 814, 10, 650, 20, 1412, 1914, 4, 1250, 132, 2542, 62, 2, 713, 20986, 1246, 347, 141, 347, 1101, 46534, 1, 3, 201, 525, 350, 3035, 3214, 14032, 16135, 6879, 8849, 60018, 12514, 20730, 21656, 60019, 60020, 30887, 60021, 13940, 46535, 37582, 14434, 17917, 39617, 16337, 20504, 11, 2478, 570, 4, 126, 6, 865, 39, 1, 62, 140, 55, 1, 476, 525, 10, 41, 5, 3, 463, 1, 336, 1171, 99, 1, 2029, 638, 20, 1412, 1914, 5, 46, 525, 438, 149, 5, 135, 1, 219, 471, 653, 166, 126, 347, 29, 203, 7, 1787, 94, 190, 24, 2, 147, 429, 2213, 1405, 136, 2769, 198, 2449, 4, 49, 952, 1247, 3, 217, 525, 9150, 3, 638, 1, 14, 2015, 31, 107, 79, 33, 1246, 37, 46, 217, 525, 257, 1700, 2029, 94, 4, 62, 132, 2542, 62, 7, 2, 2109, 401, 136, 485]",1258.0,21487112,3
Long-term risk for subsequent leukemia after treatment for childhood cancer: a report from the Childhood Cancer Survivor Study.,Blood,Blood,2011-04-15,"Previous investigations of cancer survivors report that the cumulative incidence of subsequent leukemia plateaus between 10 and 15 years after primary therapy. Risk beyond 15 years has not been comprehensively assessed, primarily because of lack of long-term follow-up. Among 5-year survivors from the Childhood Cancer Survivor Study cohort, 13 pathologically confirmed cases of subsequent leukemia occurred  15 years after primary malignancy, with a mean latency of 21.6 years (range, 15-32 years). Seven were acute myeloid leukemia (2 acute promyelocytic leukemia with t(15;17), 2 with confirmed preceding myelodysplastic syndrome), 4 acute lymphoblastic leukemia (2 pre-B lineage, 1 T cell, 1 unknown), and 2 other. Two acute myeloid leukemia cases had the 7q- deletion. The standardized incidence ratio was 3.5 (95% confidence interval, 1.9-6.0). Median survival from diagnosis of subsequent leukemia was 2 years. This is the first description of a statistically significant increased risk of subsequent leukemia  15 years from primary diagnosis of childhood cancer.",Journal Article,3203.0,18.0,Previous investigations of cancer survivors report that the cumulative incidence of subsequent plateaus between 10 and 15 years after primary therapy Risk beyond 15 years has not been comprehensively assessed primarily because of lack of long-term follow-up Among 5-year survivors from the Childhood Cancer Survivor Study cohort 13 pathologically confirmed cases of subsequent occurred  15 years after primary malignancy with a mean latency of 21.6 years range 15-32 years Seven were acute myeloid 2 acute promyelocytic with t 15 17 2 with confirmed preceding syndrome 4 acute lymphoblastic 2 pre-B lineage 1 T cell 1 unknown and 2 other Two acute myeloid cases had the 7q- deletion The standardized incidence ratio was 3.5 95 confidence interval 1.9-6.0 Median survival from diagnosis of subsequent was 2 years This is the first description of a statistically significant increased risk of subsequent  15 years from primary diagnosis of childhood cancer,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[698, 2492, 1, 12, 332, 414, 17, 3, 967, 287, 1, 706, 28925, 59, 79, 2, 167, 60, 50, 86, 36, 43, 1654, 167, 60, 71, 44, 85, 5627, 275, 1561, 408, 1, 926, 1, 319, 337, 166, 126, 107, 33, 111, 332, 29, 3, 864, 12, 2628, 45, 180, 233, 2998, 557, 140, 1, 706, 489, 749, 167, 60, 50, 86, 710, 5, 8, 313, 5301, 1, 239, 49, 60, 184, 167, 531, 60, 648, 11, 286, 533, 18, 286, 4300, 5, 102, 167, 269, 18, 5, 557, 5892, 681, 39, 286, 1275, 18, 671, 132, 2542, 14, 102, 31, 14, 860, 2, 18, 127, 100, 286, 533, 140, 42, 3, 9723, 1528, 3, 1670, 287, 197, 10, 27, 33, 48, 307, 268, 14, 83, 49, 13, 52, 25, 29, 147, 1, 706, 10, 18, 60, 26, 16, 3, 157, 5263, 1, 8, 712, 93, 101, 43, 1, 706, 749, 167, 60, 29, 86, 147, 1, 864, 12]",956.0,21498675,181
Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells.,The AAPS journal,AAPS J,2011-05-04,"Protein synthesis is a powerful therapeutic target in leukemias and other cancers, but few pharmacologically viable agents are available that affect this process directly. The plant-derived agent silvestrol specifically inhibits translation initiation by interfering with eIF4A/mRNA assembly with eIF4F. Silvestrol has potent in vitro and in vivo activity in multiple cancer models including acute lymphoblastic leukemia (ALL) and is under pre-clinical development by the US National Cancer Institute, but no information is available about potential mechanisms of resistance. In a separate report, we showed that intraperitoneal silvestrol is approximately 100% bioavailable systemically, although oral doses were only 1% bioavailable despite an apparent lack of metabolism. To explore mechanisms of silvestrol resistance and the possible role of efflux transporters in silvestrol disposition, we characterized multi-drug resistance transporter expression and function in a silvestrol-resistant ALL cell line generated via culture of the 697 ALL cell line in gradually increasing silvestrol concentrations. This resistant cell line, 697-R, shows significant upregulation of ABCB1 mRNA and P-glycoprotein (Pgp) as well as cross-resistance to known Pgp substrates vincristine and romidepsin. Furthermore, 697-R cells readily efflux the fluorescent Pgp substrate rhodamine 123. This effect is prevented by Pgp inhibitors verapamil and cyclosporin A, as well as siRNA to ABCB1, with concomitant re-sensitization to silvestrol. Together, these data indicate that silvestrol is a substrate of Pgp, a potential obstacle that must be considered in the development of silvestrol for oral delivery or targeting to tumors protected by Pgp overexpression.",Journal Article,3184.0,38.0,Protein synthesis is a powerful therapeutic target in leukemias and other cancers but few pharmacologically viable agents are available that affect this process directly The plant-derived agent silvestrol specifically inhibits translation initiation by interfering with eIF4A/mRNA assembly with eIF4F Silvestrol has potent in vitro and in vivo activity in multiple cancer models including acute lymphoblastic ALL and is under pre-clinical development by the US National Cancer Institute but no information is available about potential mechanisms of resistance In a separate report we showed that intraperitoneal silvestrol is approximately 100 bioavailable systemically although oral doses were only 1 bioavailable despite an apparent lack of metabolism To explore mechanisms of silvestrol resistance and the possible role of efflux transporters in silvestrol disposition we characterized multi-drug resistance transporter expression and function in a silvestrol-resistant ALL cell line generated via culture of the 697 ALL cell line in gradually increasing silvestrol concentrations This resistant cell line 697-R shows significant upregulation of ABCB1 mRNA and P-glycoprotein Pgp as well as cross-resistance to known Pgp substrates vincristine and romidepsin Furthermore 697-R cells readily efflux the fluorescent Pgp substrate rhodamine 123 This effect is prevented by Pgp inhibitors verapamil and cyclosporin A as well as siRNA to ABCB1 with concomitant re-sensitization to silvestrol Together these data indicate that silvestrol is a substrate of Pgp a potential obstacle that must be considered in the development of silvestrol for oral delivery or targeting to tumors protected by Pgp overexpression,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[178, 2525, 16, 8, 3757, 189, 283, 4, 2792, 2, 127, 163, 84, 1021, 7854, 2663, 183, 32, 390, 17, 1158, 26, 1129, 1606, 3, 9045, 526, 420, 10015, 1225, 1576, 2691, 1118, 20, 3449, 5, 34836, 956, 7210, 5, 23339, 10015, 71, 1157, 4, 439, 2, 4, 386, 128, 4, 232, 12, 274, 141, 286, 1275, 62, 2, 16, 669, 671, 38, 193, 20, 3, 843, 657, 12, 1377, 84, 77, 487, 16, 390, 545, 174, 483, 1, 251, 4, 8, 2282, 414, 21, 224, 17, 3339, 10015, 16, 705, 394, 6582, 6327, 242, 518, 415, 11, 158, 14, 6582, 550, 35, 2235, 926, 1, 1600, 6, 1645, 483, 1, 10015, 251, 2, 3, 899, 200, 1, 7043, 6733, 4, 10015, 5814, 21, 765, 1414, 234, 251, 5246, 55, 2, 343, 4, 8, 10015, 436, 62, 31, 328, 1419, 847, 2099, 1, 3, 11989, 62, 31, 328, 4, 8092, 602, 10015, 1003, 26, 436, 31, 328, 11989, 668, 1949, 93, 2218, 1, 6560, 956, 2, 19, 4455, 7131, 22, 149, 22, 1383, 251, 6, 440, 7131, 6063, 2132, 2, 6256, 798, 11989, 668, 37, 3860, 7043, 3, 2910, 7131, 4235, 18742, 2698, 26, 254, 16, 3902, 20, 7131, 222, 27836, 2, 20208, 8, 22, 149, 22, 1919, 6, 6560, 5, 1781, 1491, 6272, 6, 10015, 1162, 46, 74, 1008, 17, 10015, 16, 8, 4235, 1, 7131, 8, 174, 7414, 17, 1642, 40, 515, 4, 3, 193, 1, 10015, 9, 518, 989, 15, 529, 6, 57, 5541, 20, 7131, 851]",1707.0,21538216,189
Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.,Pediatric blood & cancer,Pediatr Blood Cancer,2011-05-10,"Although corticosteroids remain a mainstay of treatment for acute lymphoblastic leukemia (ALL), they can cause troublesome neurobehavioral changes during active treatment, especially in young children. We evaluated acute neurobehavioral side effects of corticosteroid therapy in preschool versus school-age children by obtaining structured reports weekly for 1 month. Parents of 62 children (2-17 years) treated on Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 00-01 participated during the continuation phase of treatment. Patients received cyclical twice-daily 5-day courses of prednisone (PRED; 40mg/m(2) /day) or dexamethasone (DEX; 6mg/m(2) /day). Parents completed behavior rating scales about their child weekly during one steroid cycle [baseline (Day 0), active steroid (Day 7), post-steroid (Days 14 and 21)]. Behavioral side effects increased significantly (P<0.001) during the steroid week for preschool children (<6 years) on measures of emotional control, mood, behavior regulation, and executive functions, returning to baseline during the two ""off-steroid"" weeks. In contrast, school-age children ( 6 years) did not demonstrate an increase in side effects during the steroid week. Steroid type (PRED vs. DEX) was not a significant predictor of neurobehavioral side effects. Preschool children are at greater risk for neurobehavioral side effects during active steroid treatment for ALL than school-age children and adolescents. DEX was not associated with more neurobehavioral side effects than PRED. Counseling of families about side-effects should be adapted according to age. The observed effects, moreover, were transient, reducing concerns about longer-term neurobehavioral toxicities.",Journal Article,3178.0,20.0,Although corticosteroids remain a mainstay of treatment for acute lymphoblastic ALL they can cause troublesome neurobehavioral changes during active treatment especially in young children We evaluated acute neurobehavioral side effects of corticosteroid therapy in preschool versus school-age children by obtaining structured reports weekly for 1 month Parents of 62 children 2-17 years treated on Dana-Farber Cancer Institute DFCI ALL Consortium Protocol 00-01 participated during the continuation phase of treatment Patients received cyclical twice-daily 5-day courses of prednisone PRED 40 mg/m 2 /day or dexamethasone DEX 6 mg/m 2 /day Parents completed behavior rating scales about their child weekly during one steroid cycle baseline Day 0 active steroid Day 7 post-steroid Days 14 and 21 Behavioral side effects increased significantly P 0.001 during the steroid week for preschool children 6 years on measures of emotional control mood behavior regulation and executive functions returning to baseline during the two `` off-steroid '' weeks In contrast school-age children  6 years did not demonstrate an increase in side effects during the steroid week Steroid type PRED vs. DEX was not a significant predictor of neurobehavioral side effects Preschool children are at greater risk for neurobehavioral side effects during active steroid treatment for ALL than school-age children and adolescents DEX was not associated with more neurobehavioral side effects than PRED Counseling of families about side-effects should be adapted according to age The observed effects moreover were transient reducing concerns about longer-term neurobehavioral toxicities,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 3876, 918, 8, 4041, 1, 24, 9, 286, 1275, 62, 491, 122, 708, 22115, 20714, 400, 190, 544, 24, 1093, 4, 1169, 541, 21, 194, 286, 20714, 1152, 176, 1, 5654, 36, 4, 39640, 185, 5953, 89, 541, 20, 5244, 5198, 1198, 709, 9, 14, 811, 2418, 1, 744, 541, 18, 269, 60, 73, 23, 4932, 4979, 12, 1377, 11152, 62, 2404, 1182, 2038, 355, 3025, 190, 3, 6870, 124, 1, 24, 7, 103, 19179, 936, 391, 33, 218, 1993, 1, 1979, 39641, 327, 81, 188, 18, 218, 15, 1217, 4844, 49, 81, 188, 18, 218, 2418, 781, 1710, 5477, 5083, 545, 136, 2566, 709, 190, 104, 3853, 417, 330, 218, 13, 544, 3853, 218, 67, 539, 3853, 162, 213, 2, 239, 4166, 1152, 176, 101, 97, 19, 13, 144, 190, 3, 3853, 647, 9, 39640, 541, 49, 60, 23, 1018, 1, 2671, 182, 5234, 1710, 863, 2, 6481, 1681, 17207, 6, 330, 190, 3, 100, 1889, 3853, 522, 244, 4, 748, 5953, 89, 541, 749, 49, 60, 205, 44, 608, 35, 344, 4, 1152, 176, 190, 3, 3853, 647, 3853, 267, 39641, 105, 4844, 10, 44, 8, 93, 980, 1, 20714, 1152, 176, 39640, 541, 32, 28, 378, 43, 9, 20714, 1152, 176, 190, 544, 3853, 24, 9, 62, 76, 5953, 89, 541, 2, 3101, 4844, 10, 44, 41, 5, 80, 20714, 1152, 176, 76, 39641, 2011, 1, 1954, 545, 1152, 176, 257, 40, 3716, 768, 6, 89, 3, 164, 176, 1393, 11, 2473, 1818, 2061, 545, 589, 337, 20714, 385]",1662.0,21560226,11
Managing Philadelphia chromosome-positive acute lymphoblastic leukemia: role of tyrosine kinase inhibitors.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2011-04-08,"Before the introduction of tyrosine kinase inhibitors, the prognosis for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia was poor. The treatment of choice, stem cell transplantation, is a potentially curative option, but it is available only for a minority of patients and is associated with significant risk of morbidity and mortality. Although imatinib is largely effective, a substantial proportion of patients become resistant or intolerant to it. The activity of imatinib may be enhanced by coadministration with chemotherapy; such treatment is effective in many patients. Dasatinib is established as a second-line treatment in patients with resistance to or intolerance of imatinib. Recent data suggest that dasatinib, either alone or in combination with chemotherapy, has utility as first-line therapy. Dasatinib is more potent than imatinib, is less susceptible to drug-resistance mechanisms, and has been shown to penetrate the blood-brain barrier, making it potentially effective for treating central nervous system disease. Patients who relapse during treatment with dasatinib frequently carry the T315I mutation of BCR-ABL. Future regimens combining dasatinib with an agent able to inhibit this mutation may further improve outcome.",Journal Article,3210.0,14.0,Before the introduction of tyrosine kinase inhibitors the prognosis for patients with Philadelphia chromosome-positive acute lymphoblastic was poor The treatment of choice stem cell transplantation is a potentially curative option but it is available only for a minority of patients and is associated with significant risk of morbidity and mortality Although imatinib is largely effective a substantial proportion of patients become resistant or intolerant to it The activity of imatinib may be enhanced by coadministration with chemotherapy such treatment is effective in many patients Dasatinib is established as a second-line treatment in patients with resistance to or intolerance of imatinib Recent data suggest that dasatinib either alone or in combination with chemotherapy has utility as first-line therapy Dasatinib is more potent than imatinib is less susceptible to drug-resistance mechanisms and has been shown to penetrate the blood-brain barrier making it potentially effective for treating central nervous system disease Patients who relapse during treatment with dasatinib frequently carry the T315I mutation of BCR-ABL Future regimens combining dasatinib with an agent able to inhibit this mutation may further improve outcome,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[348, 3, 2456, 1, 564, 216, 222, 3, 356, 9, 7, 5, 3006, 1170, 109, 286, 1275, 10, 334, 3, 24, 1, 1866, 452, 31, 497, 16, 8, 751, 1075, 1501, 84, 192, 16, 390, 158, 9, 8, 2652, 1, 7, 2, 16, 41, 5, 93, 43, 1, 787, 2, 282, 242, 577, 16, 1733, 323, 8, 1281, 920, 1, 7, 1417, 436, 15, 4944, 6, 192, 3, 128, 1, 577, 68, 40, 651, 20, 5777, 5, 56, 225, 24, 16, 323, 4, 445, 7, 1674, 16, 635, 22, 8, 419, 328, 24, 4, 7, 5, 251, 6, 15, 5266, 1, 577, 435, 74, 309, 17, 1674, 361, 279, 15, 4, 150, 5, 56, 71, 1207, 22, 157, 328, 36, 1674, 16, 80, 1157, 76, 577, 16, 299, 4012, 6, 234, 251, 483, 2, 71, 85, 443, 6, 14514, 3, 315, 342, 3318, 1079, 192, 751, 323, 9, 1367, 854, 1880, 398, 34, 7, 54, 429, 190, 24, 5, 1674, 746, 3542, 3, 6184, 258, 1, 1062, 1425, 508, 472, 1525, 1674, 5, 35, 420, 1665, 6, 1433, 26, 258, 68, 195, 401, 228]",1243.0,21575924,48
High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia.,Blood,Blood,2011-05-25,"We evaluated 190 children with very high-risk leukemia, who underwent allogeneic hematopoietic cell transplantation in 2 sequential treatment eras, to determine whether those treated with contemporary protocols had a high risk of relapse or toxic death, and whether non-HLA-identical transplantations yielded poor outcomes. For the recent cohorts, the 5-year overall survival rates were 65% for the 37 patients with acute lymphoblastic leukemia and 74% for the 46 with acute myeloid leukemia; these rates compared favorably with those of earlier cohorts (28%, n = 57; and 34%, n = 50, respectively). Improvement in the recent cohorts was observed regardless of donor type (sibling, 70% vs 24%; unrelated, 61% vs 37%; and haploidentical, 88% vs 19%), attributable to less infection (hazard ratio [HR] = 0.12; P = .005), regimen-related toxicity (HR = 0.25; P = .002), and leukemia-related death (HR = 0.40; P = .01). Survival probability was dependent on leukemia status (first remission vs more advanced disease; HR = 0.63; P = .03) or minimal residual disease (positive vs negative; HR = 2.10; P = .01) at the time of transplantation. We concluded that transplantation has improved over time and should be considered for all children with very high-risk leukemia, regardless of matched donor availability.",Evaluation Study,3163.0,111.0,We evaluated 190 children with very high-risk who underwent allogeneic hematopoietic cell transplantation in 2 sequential treatment eras to determine whether those treated with contemporary protocols had a high risk of relapse or toxic death and whether non-HLA-identical transplantations yielded poor outcomes For the recent cohorts the 5-year overall survival rates were 65 for the 37 patients with acute lymphoblastic and 74 for the 46 with acute myeloid these rates compared favorably with those of earlier cohorts 28 n 57 and 34 n 50 respectively Improvement in the recent cohorts was observed regardless of donor type sibling 70 vs 24 unrelated 61 vs 37 and haploidentical 88 vs 19 attributable to less infection hazard ratio HR 0.12 P .005 regimen-related toxicity HR 0.25 P .002 and leukemia-related death HR 0.40 P .01 Survival probability was dependent on status first remission vs more advanced disease HR 0.63 P .03 or minimal residual disease positive vs negative HR 2.10 P .01 at the time of transplantation We concluded that transplantation has improved over time and should be considered for all children with very high-risk regardless of matched donor availability,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 194, 5974, 541, 5, 923, 64, 43, 54, 208, 1063, 1007, 31, 497, 4, 18, 1787, 24, 7225, 6, 223, 317, 135, 73, 5, 2667, 2189, 42, 8, 64, 43, 1, 429, 15, 1812, 273, 2, 317, 220, 1160, 3038, 6779, 2178, 334, 123, 9, 3, 435, 736, 3, 33, 111, 63, 25, 151, 11, 556, 9, 3, 567, 7, 5, 286, 1275, 2, 794, 9, 3, 641, 5, 286, 533, 46, 151, 72, 5001, 5, 135, 1, 1677, 736, 339, 78, 696, 2, 562, 78, 212, 106, 767, 4, 3, 435, 736, 10, 164, 1583, 1, 1488, 267, 3684, 431, 105, 259, 2092, 713, 105, 567, 2, 5802, 889, 105, 326, 2971, 6, 299, 930, 360, 197, 168, 13, 133, 19, 1614, 477, 139, 155, 168, 13, 243, 19, 1111, 2, 2647, 139, 273, 168, 13, 327, 19, 355, 25, 1320, 10, 470, 23, 156, 157, 734, 105, 80, 131, 34, 168, 13, 676, 19, 680, 15, 1048, 753, 34, 109, 105, 199, 168, 18, 79, 19, 355, 28, 3, 98, 1, 497, 21, 4724, 17, 497, 71, 231, 252, 98, 2, 257, 40, 515, 9, 62, 541, 5, 923, 64, 43, 1583, 1, 655, 1488, 2550]",1181.0,21613256,887
Association of muscle strength and bone mineral density in adult survivors of childhood acute lymphoblastic leukemia.,Archives of physical medicine and rehabilitation,Arch Phys Med Rehabil,2011-06-01,"To investigate the association between bone mineral density (BMD) and muscle strength in survivors of childhood acute lymphoblastic leukemia (ALL), a population at increased risk for both decreased BMD and muscle strength from cancer and its treatment. Cohort data from the St Jude Lifetime Cohort (SJLIFE) study. Department of Cancer Control at St Jude Children's Research Hospital. Subjects were adults enrolled in St Jude Lifetime Cohort study and treated for childhood ALL between 1962 and 1999. As part of a comprehensive evaluation, participants had dual energy x-ray absorptiometry (DEXA) scans and muscle strength testing. The participants consisted of 261 women and 232 men who were 20.4 to 49.8 years old (median, 35.7y), and 12.7 to 46.5 years from diagnosis of childhood ALL (median, 27.2y). Not applicable. BMD was determined by DEXA scan. Muscle strength of upper and lower extremities was assessed with physical performance testing. After adjusting for covariates, we found significant (P<0.005) associations between BMD and muscle strength in lower extremities (R(2) range, 0.33-0.40) and strong, significant associations in upper extremities (left-side R(2)=0.558; right-side R(2)=0.560). Muscle strength was associated with BMD in the extremities of long-term survivors of childhood ALL, a finding suggesting that muscle strengthening interventions may improve bone health in them.",Journal Article,3156.0,15.0,To investigate the association between mineral density BMD and muscle strength in survivors of childhood acute lymphoblastic ALL a population at increased risk for both decreased BMD and muscle strength from cancer and its treatment Cohort data from the St Jude Lifetime Cohort SJLIFE study Department of Cancer Control at St Jude Children 's Research Hospital Subjects were adults enrolled in St Jude Lifetime Cohort study and treated for childhood ALL between 1962 and 1999 As part of a comprehensive evaluation participants had dual energy x-ray absorptiometry DEXA scans and muscle strength testing The participants consisted of 261 women and 232 men who were 20.4 to 49.8 years old median 35.7y and 12.7 to 46.5 years from diagnosis of childhood ALL median 27.2y Not applicable BMD was determined by DEXA scan Muscle strength of upper and lower extremities was assessed with physical performance testing After adjusting for covariates we found significant P 0.005 associations between BMD and muscle strength in lower extremities R 2 range 0.33-0.40 and strong significant associations in upper extremities left-side R 2 =0.558 right-side R 2 =0.560 Muscle strength was associated with BMD in the extremities of long-term survivors of childhood ALL a finding suggesting that muscle strengthening interventions may improve health in them,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 963, 3, 248, 59, 5033, 1263, 3503, 2, 1502, 3671, 4, 332, 1, 864, 286, 1275, 62, 8, 266, 28, 101, 43, 9, 110, 340, 3503, 2, 1502, 3671, 29, 12, 2, 211, 24, 180, 74, 29, 3, 3062, 4841, 2898, 180, 13437, 45, 4271, 1, 12, 182, 28, 3062, 4841, 541, 292, 389, 702, 976, 11, 857, 346, 4, 3062, 4841, 2898, 180, 45, 2, 73, 9, 864, 62, 59, 14754, 2, 2043, 22, 760, 1, 8, 949, 451, 776, 42, 1828, 2803, 1006, 5520, 14257, 31814, 1441, 2, 1502, 3671, 471, 3, 776, 1695, 1, 7007, 117, 2, 7186, 325, 54, 11, 179, 39, 6, 739, 66, 60, 1095, 52, 465, 60161, 2, 133, 67, 6, 641, 33, 60, 29, 147, 1, 864, 62, 52, 428, 23795, 44, 3801, 3503, 10, 509, 20, 31814, 1657, 1502, 3671, 1, 1726, 2, 280, 6387, 10, 275, 5, 900, 528, 471, 50, 1358, 9, 2489, 21, 204, 93, 19, 13, 1614, 685, 59, 3503, 2, 1502, 3671, 4, 280, 6387, 668, 18, 184, 13, 466, 13, 327, 2, 1082, 93, 685, 4, 1726, 6387, 1712, 1152, 668, 18, 13, 12570, 1913, 1152, 668, 18, 13, 7356, 1502, 3671, 10, 41, 5, 3503, 4, 3, 6387, 1, 319, 337, 332, 1, 864, 62, 8, 1567, 802, 17, 1502, 14200, 1151, 68, 401, 341, 4, 1370]",1341.0,21621662,698
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2011-09-01,"The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic leukemia. The result of this abnormality is the BCR-ABL protein, a constitutively active kinase involved in cell signaling and survival. When managed with multiagent chemotherapy regimens alone, patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome-negative. Small-molecule tyrosine kinase inhibitors, such as imatinib and dasatinib, directly inhibit the BCR-ABL kinase, offering a targeted approach as a therapeutic option. As a result of several clinical trials with adequate follow-up, imatinib combined with chemotherapy represents the current standard of care for patients with newly diagnosed disease. Allogeneic stem cell transplantation has previously been the only modality to offer the potential for a cure, and it still should be considered for all patients deemed able to tolerate such an intervention. Second-generation tyrosine kinase inhibitors, such as dasatinib, may further improve the outcome in these patients. The role of molecular monitoring and the use of tyrosine kinase inhibitors after stem cell transplantation are areas of active investigation, and the results of ongoing trials will help to clarify the optimal management of these patients.",Journal Article,3064.0,14.0,The Philadelphia chromosome is the most common cytogenetic abnormality found in adult patients diagnosed with acute lymphoblastic The result of this abnormality is the BCR-ABL protein a constitutively active kinase involved in cell signaling and survival When managed with multiagent chemotherapy regimens alone patients have traditionally had an inferior outcome in terms of remission duration and overall survival when compared with patients who are Philadelphia chromosome-negative Small-molecule tyrosine kinase inhibitors such as imatinib and dasatinib directly inhibit the BCR-ABL kinase offering a targeted approach as a therapeutic option As a result of several clinical trials with adequate follow-up imatinib combined with chemotherapy represents the current standard of care for patients with newly diagnosed disease Allogeneic stem cell transplantation has previously been the only modality to offer the potential for a cure and it still should be considered for all patients deemed able to tolerate such an intervention Second-generation tyrosine kinase inhibitors such as dasatinib may further improve the outcome in these patients The role of molecular monitoring and the use of tyrosine kinase inhibitors after stem cell transplantation are areas of active investigation and the results of ongoing trials will help to clarify the optimal management of these patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3006, 1170, 16, 3, 96, 186, 1266, 3698, 204, 4, 780, 7, 265, 5, 286, 1275, 3, 757, 1, 26, 3698, 16, 3, 1062, 1425, 178, 8, 2818, 544, 216, 646, 4, 31, 314, 2, 25, 198, 2231, 5, 7148, 56, 472, 279, 7, 47, 4206, 42, 35, 1663, 228, 4, 1794, 1, 734, 654, 2, 63, 25, 198, 72, 5, 7, 54, 32, 3006, 1170, 199, 302, 1354, 564, 216, 222, 225, 22, 577, 2, 1674, 1606, 1433, 3, 1062, 1425, 216, 5846, 8, 238, 353, 22, 8, 189, 1501, 22, 8, 757, 1, 392, 38, 143, 5, 1658, 166, 126, 577, 397, 5, 56, 1449, 3, 291, 260, 1, 165, 9, 7, 5, 732, 265, 34, 1063, 452, 31, 497, 71, 373, 85, 3, 158, 1396, 6, 1918, 3, 174, 9, 8, 1722, 2, 192, 1234, 257, 40, 515, 9, 62, 7, 3779, 1665, 6, 5010, 225, 35, 788, 419, 914, 564, 216, 222, 225, 22, 1674, 68, 195, 401, 3, 228, 4, 46, 7, 3, 200, 1, 219, 1315, 2, 3, 119, 1, 564, 216, 222, 50, 452, 31, 497, 32, 1361, 1, 544, 940, 2, 3, 99, 1, 942, 143, 303, 987, 6, 3968, 3, 665, 284, 1, 46, 7]",1382.0,21660654,417
CREST maps somatic structural variation in cancer genomes with base-pair resolution.,Nature methods,Nat. Methods,2011-06-12,"We developed 'clipping reveals structure' (CREST), an algorithm that uses next-generation sequencing reads with partial alignments to a reference genome to directly map structural variations at the nucleotide level of resolution. Application of CREST to whole-genome sequencing data from five pediatric T-lineage acute lymphoblastic leukemias (T-ALLs) and a human melanoma cell line, COLO-829, identified 160 somatic structural variations. Experimental validation exceeded 80%, demonstrating that CREST had a high predictive accuracy.",Journal Article,3145.0,300.0,We developed 'clipping reveals structure CREST an algorithm that uses next-generation sequencing reads with partial alignments to a reference genome to directly map structural variations at the nucleotide level of resolution Application of CREST to whole-genome sequencing data from five pediatric T-lineage acute lymphoblastic leukemias T-ALLs and a human cell line COLO-829 identified 160 somatic structural variations Experimental validation exceeded 80 demonstrating that CREST had a high predictive accuracy,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 276, 60225, 4054, 2772, 10686, 35, 2124, 17, 4025, 1305, 914, 615, 11062, 5, 450, 39683, 6, 8, 2482, 898, 6, 1606, 3771, 3281, 2293, 28, 3, 1579, 301, 1, 2125, 1581, 1, 10686, 6, 902, 898, 615, 74, 29, 365, 815, 102, 2542, 286, 1275, 2792, 102, 10706, 2, 8, 171, 31, 328, 26229, 13904, 108, 3457, 1119, 3281, 2293, 1560, 929, 4726, 493, 2219, 17, 10686, 42, 8, 64, 464, 1190]",512.0,21666668,546
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.,Blood,Blood,2011-06-16,"We sequenced 120 candidate genes in 187 high-risk childhood B-precursor acute lymphoblastic leukemias, the largest pediatric cancer genome sequencing effort reported to date. Integrated analysis of 179 validated somatic sequence mutations with genome-wide copy number alterations and gene expression profiles revealed a high frequency of recurrent somatic alterations in key signaling pathways, including B-cell development/differentiation (68% of cases), the TP53/RB tumor suppressor pathway (54%), Ras signaling (50%), and Janus kinases (11%). Recurrent mutations were also found in ETV6 (6 cases), TBL1XR1 (3), CREBBP (3), MUC4 (2), ASMTL (2), and ADARB2 (2). The frequency of mutations within the 4 major pathways varied markedly across genetic subtypes. Among 23 leukemias expressing a BCR-ABL1-like gene expression profile, 96% had somatic alterations in B-cell development/differentiation, 57% in JAK, and 52% in both pathways, whereas only 9% had Ras pathway mutations. In contrast, 21 cases defined by a distinct gene expression profile coupled with focal ERG deletion rarely had B-cell development/differentiation or JAK kinase alterations but had a high frequency (62%) of Ras signaling pathway mutations. These data extend the range of genes that are recurrently mutated in high-risk childhood B-precursor acute lymphoblastic leukemia and highlight important new therapeutic targets for selected patient subsets.",Journal Article,3141.0,168.0,We sequenced 120 candidate genes in 187 high-risk childhood B-precursor acute lymphoblastic leukemias the largest pediatric cancer genome sequencing effort reported to date Integrated analysis of 179 validated somatic sequence mutations with genome-wide copy number alterations and gene expression profiles revealed a high frequency of recurrent somatic alterations in key signaling pathways including B-cell development/differentiation 68 of cases the TP53/RB tumor suppressor pathway 54 Ras signaling 50 and Janus kinases 11 Recurrent mutations were also found in ETV6 6 cases TBL1XR1 3 CREBBP 3 MUC4 2 ASMTL 2 and ADARB2 2 The frequency of mutations within the 4 major pathways varied markedly across genetic subtypes Among 23 leukemias expressing a BCR-ABL1-like gene expression profile 96 had somatic alterations in B-cell development/differentiation 57 in JAK and 52 in both pathways whereas only 9 had Ras pathway mutations In contrast 21 cases defined by a distinct gene expression profile coupled with focal ERG deletion rarely had B-cell development/differentiation or JAK kinase alterations but had a high frequency 62 of Ras signaling pathway mutations These data extend the range of genes that are recurrently mutated in high-risk childhood B-precursor acute lymphoblastic and highlight important new therapeutic targets for selected patient subsets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 4040, 2031, 1609, 214, 4, 5568, 64, 43, 864, 132, 2765, 286, 1275, 2792, 3, 2166, 815, 12, 898, 615, 2919, 210, 6, 1244, 2102, 65, 1, 5977, 938, 1119, 1532, 138, 5, 898, 1019, 1337, 207, 593, 2, 145, 55, 1241, 553, 8, 64, 675, 1, 387, 1119, 593, 4, 825, 314, 460, 141, 132, 31, 193, 910, 806, 1, 140, 3, 1206, 2955, 30, 1245, 308, 667, 1102, 314, 212, 2, 6191, 1549, 175, 387, 138, 11, 120, 204, 4, 7306, 49, 140, 31805, 27, 13439, 27, 8929, 18, 60235, 18, 2, 34344, 18, 3, 675, 1, 138, 262, 3, 39, 458, 460, 2051, 2195, 716, 336, 814, 107, 382, 2792, 1046, 8, 1062, 3557, 733, 145, 55, 800, 921, 42, 1119, 593, 4, 132, 31, 193, 910, 696, 4, 4653, 2, 653, 4, 110, 460, 547, 158, 83, 42, 1102, 308, 138, 4, 748, 239, 140, 395, 20, 8, 834, 145, 55, 800, 3332, 5, 2137, 3032, 1528, 2416, 42, 132, 31, 193, 910, 15, 4653, 216, 593, 84, 42, 8, 64, 675, 744, 1, 1102, 314, 308, 138, 46, 74, 4087, 3, 184, 1, 214, 17, 32, 8820, 1185, 4, 64, 43, 864, 132, 2765, 286, 1275, 2, 1817, 305, 217, 189, 637, 9, 715, 69, 1890]",1362.0,21680795,79
Maternal exposure to household chemicals and risk of infant leukemia: a report from the Children's Oncology Group.,Cancer causes & control : CCC,Cancer Causes Control,2011-06-21,"Utilizing data from the largest study to date, we examined associations between maternal preconception/prenatal exposure to household chemicals and infant acute leukemia. We present data from a Children's Oncology Group case-control study of 443 infants (<1year of age) diagnosed with acute leukemia [including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)] between 1996 and 2006 and 324 population controls. Mothers recalled household chemical use 1month before and throughout pregnancy. We used unconditional logistic regression adjusted for birth year, maternal age, and race/ethnicity to calculate odds ratios (ORs) and 95% confidence intervals (CIs). We did not find evidence for an association between infant leukemia and eight of nine chemical categories. However, exposure to petroleum products during pregnancy was associated with AML (OR=2.54; 95% CI:1.40-4.62) and leukemia without mixed lineage leukemia (MLL) gene rearrangements (""MLL-"") (OR=2.69; 95% CI: 1.47-4.93). No associations were observed for exposure in the month before pregnancy. Gestational exposure to petroleum products was associated with infant leukemia, particularly AML, and MLL- cases. Benzene is implicated as a potential carcinogen within this exposure category, but a clear biological mechanism has yet to be elucidated.",Journal Article,3136.0,22.0,Utilizing data from the largest study to date we examined associations between maternal preconception/prenatal exposure to household chemicals and infant acute We present data from a Children 's Oncology Group case-control study of 443 infants 1 year of age diagnosed with acute including acute lymphoblastic ALL and acute myeloid AML between 1996 and 2006 and 324 population controls Mothers recalled household chemical use 1 month before and throughout pregnancy We used unconditional logistic regression adjusted for birth year maternal age and race/ethnicity to calculate odds ratios ORs and 95 confidence intervals CIs We did not find evidence for an association between infant and eight of nine chemical categories However exposure to petroleum products during pregnancy was associated with AML OR 2.54 95 CI:1.40-4.62 and without mixed lineage MLL gene rearrangements `` MLL- '' OR 2.69 95 CI 1.47-4.93 No associations were observed for exposure in the month before pregnancy Gestational exposure to petroleum products was associated with infant particularly AML and MLL- cases Benzene is implicated as a potential carcinogen within this exposure category but a clear biological mechanism has yet to be elucidated,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2600, 74, 29, 3, 2166, 45, 6, 1244, 21, 409, 685, 59, 6039, 25985, 15621, 645, 6, 7353, 14226, 2, 8027, 286, 21, 364, 74, 29, 8, 541, 292, 413, 87, 473, 182, 45, 1, 10462, 5585, 14, 111, 1, 89, 265, 5, 286, 141, 286, 1275, 62, 2, 286, 533, 329, 59, 2648, 2, 1324, 2, 8393, 266, 535, 8605, 11742, 7353, 3743, 119, 14, 811, 348, 2, 2432, 2290, 21, 95, 6438, 812, 320, 586, 9, 3809, 111, 6039, 89, 2, 1047, 2091, 6, 3232, 610, 1137, 3694, 2, 48, 307, 1582, 1927, 21, 205, 44, 2469, 241, 9, 35, 248, 59, 8027, 2, 659, 1, 762, 3743, 1996, 137, 645, 6, 46631, 2766, 190, 2290, 10, 41, 5, 329, 15, 18, 667, 48, 58, 14, 327, 39, 744, 2, 187, 1739, 2542, 3049, 145, 2072, 3049, 522, 15, 18, 790, 48, 58, 14, 662, 39, 966, 77, 685, 11, 164, 9, 645, 4, 3, 811, 348, 2290, 9383, 645, 6, 46631, 2766, 10, 41, 5, 8027, 823, 329, 2, 3049, 140, 27070, 16, 1771, 22, 8, 174, 7290, 262, 26, 645, 2169, 84, 8, 885, 1037, 670, 71, 1145, 6, 40, 3901]",1220.0,21691732,15
Neuropsychological outcomes of standard risk and high risk patients treated for acute lymphoblastic leukemia on Dana-Farber ALL consortium protocol 95-01 at 5 years post-diagnosis.,Pediatric blood & cancer,Pediatr Blood Cancer,2011-06-30,"Children treated for acute lymphoblastic leukemia (ALL) as High Risk (HR) patients may be more vulnerable to neurocognitive late effects because of the greater intensity of their therapy. We compared neuropsychological outcomes in children treated for Standard Risk (SR) or HR ALL on Dana-Farber Cancer Institute (DFCI) Consortium ALL Protocol 95-01. We also evaluated their performance relative to normative expectations. Between 1996 and 2000, 498 children with newly diagnosed ALL were treated on Protocol 95-01, 298 of whom were eligible for neuropsychological follow-up. A feature of this protocol was modification of risk group criteria to treat more children as SR rather than HR patients, intended to minimize toxicities. Testing was completed at a median of 5.3 years post-diagnosis for 211 patients (70.8%; ages 6-25 years; 45.5% male; 40% HR), all of whom were in continuous complete remission. Test scores for both groups were generally at or above normative expectation, with the exception of verbal working memory, processing complex visual information, and parent ratings of metacognitive skills. After adjusting for covariates, the SR group performed better on measures of IQ and academic achievement, working memory and visual learning. Effect sizes, however, were only in the small to moderate range. HR patients exhibited neuropsychological deficits relative to SR patients, though the differences were modest in degree. Modification of the risk group criteria to treat more children on the SR protocol therefore likely afforded some benefit in terms of neurocognitive late effects.",Journal Article,3127.0,18.0,Children treated for acute lymphoblastic ALL as High Risk HR patients may be more vulnerable to neurocognitive late effects because of the greater intensity of their therapy We compared neuropsychological outcomes in children treated for Standard Risk SR or HR ALL on Dana-Farber Cancer Institute DFCI Consortium ALL Protocol 95-01 We also evaluated their performance relative to normative expectations Between 1996 and 2000 498 children with newly diagnosed ALL were treated on Protocol 95-01 298 of whom were eligible for neuropsychological follow-up A feature of this protocol was modification of risk group criteria to treat more children as SR rather than HR patients intended to minimize toxicities Testing was completed at a median of 5.3 years post-diagnosis for 211 patients 70.8 ages 6-25 years 45.5 male 40 HR all of whom were in continuous complete remission Test scores for both groups were generally at or above normative expectation with the exception of verbal working memory processing complex visual information and parent ratings of metacognitive skills After adjusting for covariates the SR group performed better on measures of IQ and academic achievement working memory and visual learning Effect sizes however were only in the small to moderate range HR patients exhibited neuropsychological deficits relative to SR patients though the differences were modest in degree Modification of the risk group criteria to treat more children on the SR protocol therefore likely afforded some benefit in terms of neurocognitive late effects,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 73, 9, 286, 1275, 62, 22, 64, 43, 168, 7, 68, 40, 80, 5017, 6, 2958, 807, 176, 408, 1, 3, 378, 837, 1, 136, 36, 21, 72, 8271, 123, 4, 541, 73, 9, 260, 43, 7460, 15, 168, 62, 23, 4932, 4979, 12, 1377, 11152, 2404, 62, 1182, 48, 355, 21, 120, 194, 136, 528, 580, 6, 9658, 5591, 59, 2648, 2, 1081, 8928, 541, 5, 732, 265, 62, 11, 73, 23, 1182, 48, 355, 8651, 1, 953, 11, 625, 9, 8271, 166, 126, 8, 2705, 1, 26, 1182, 10, 2437, 1, 43, 87, 371, 6, 943, 80, 541, 22, 7460, 1832, 76, 168, 7, 4081, 6, 3241, 385, 471, 10, 781, 28, 8, 52, 1, 33, 27, 60, 539, 147, 9, 5905, 7, 431, 66, 2165, 49, 243, 60, 512, 33, 1045, 327, 168, 62, 1, 953, 11, 4, 1314, 236, 734, 412, 703, 9, 110, 271, 11, 1228, 28, 15, 2090, 9658, 9988, 5, 3, 4188, 1, 7028, 2644, 2407, 3325, 840, 3046, 487, 2, 3841, 5548, 1, 60302, 5909, 50, 1358, 9, 2489, 3, 7460, 87, 173, 380, 23, 1018, 1, 7666, 2, 1916, 5088, 2644, 2407, 2, 3046, 3434, 254, 4131, 137, 11, 158, 4, 3, 302, 6, 1163, 184, 168, 7, 1416, 8271, 2752, 580, 6, 7460, 7, 2471, 3, 362, 11, 1721, 4, 1444, 2437, 1, 3, 43, 87, 371, 6, 943, 80, 541, 23, 3, 7460, 1182, 673, 322, 9150, 476, 247, 4, 1794, 1, 2958, 807, 176]",1553.0,21721112,431
"Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial.",Cancer,Cancer,2011-07-12,"Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute leukemia. This study was designed to determine whether epoetin alpha would decrease the number of transfusion events and units of packed erythrocytes (PRBCs) transfused, and the secondary objective was to study the effects of epoetin alpha on quality of life (QOL) and complete remission (CR) rates. Patients with acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), or Burkitt lymphoma (BL) who were receiving frontline myelosuppressive chemotherapy were randomized to receive epoetin alpha or no epoetin during the first 6 cycles of their planned chemotherapy. QOL was assessed by using the Edmonton Symptom Assessment Scale (ESAS) and the Functional Assessment of Cancer Therapy (FACT)-Anemia questionnaires. Fifty-five patients were randomized to receive epoetin alpha, and 54 patients received no epoetin. Transfusion data were available for 79 of 81 evaluable patients (98%) who completed the treatment/observation period. The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met. A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin (P = .04). There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments. The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha. Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration. No difference in QOL was observed.",Journal Article,3115.0,16.0,Anemia is an expected consequence of intensive chemotherapy regimens administered to patients with acute This study was designed to determine whether epoetin alpha would decrease the number of transfusion events and units of packed erythrocytes PRBCs transfused and the secondary objective was to study the effects of epoetin alpha on quality of life QOL and complete remission CR rates Patients with acute lymphoblastic ALL lymphoblastic LL or BL who were receiving frontline myelosuppressive chemotherapy were randomized to receive epoetin alpha or no epoetin during the first 6 cycles of their planned chemotherapy QOL was assessed by using the Edmonton Symptom Assessment Scale ESAS and the Functional Assessment of Cancer Therapy FACT -Anemia questionnaires Fifty-five patients were randomized to receive epoetin alpha and 54 patients received no epoetin Transfusion data were available for 79 of 81 evaluable patients 98 who completed the treatment/observation period The trial was stopped early because of poor accrual before the target of 123 evaluable patients was met A mean of 10.6 units of PRBCs over 5 months were administered to those who received epoetin alpha compared with 13 units for those who did not receive epoetin P .04 There was no significant difference in QOL as assessed by the FACT-Anemia or ESAS instruments The CR rate and the 3-year CR duration were not affected adversely by use of epoetin alpha Epoetin alpha decreased the number of PRBC transfusions and did not appear to have a negative impact on remission duration No difference in QOL was observed,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1545, 16, 35, 1336, 4177, 1, 1686, 56, 472, 468, 6, 7, 5, 286, 26, 45, 10, 1114, 6, 223, 317, 7305, 950, 688, 775, 3, 207, 1, 2785, 281, 2, 2960, 1, 14203, 18561, 35155, 12320, 2, 3, 568, 461, 10, 6, 45, 3, 176, 1, 7305, 950, 23, 372, 1, 358, 1001, 2, 236, 734, 684, 151, 7, 5, 286, 1275, 62, 1275, 15981, 15, 6331, 54, 11, 357, 3171, 11109, 56, 11, 384, 6, 560, 7305, 950, 15, 77, 7305, 190, 3, 157, 49, 410, 1, 136, 1465, 56, 1001, 10, 275, 20, 75, 3, 5656, 934, 455, 1124, 3243, 2, 3, 583, 455, 1, 12, 36, 1991, 1545, 2956, 1461, 365, 7, 11, 384, 6, 560, 7305, 950, 2, 667, 7, 103, 77, 7305, 2785, 74, 11, 390, 9, 842, 1, 865, 859, 7, 1096, 54, 781, 3, 24, 1664, 727, 3, 160, 10, 4403, 191, 408, 1, 334, 2262, 348, 3, 283, 1, 2698, 859, 7, 10, 543, 8, 313, 1, 79, 49, 2960, 1, 35155, 252, 33, 53, 11, 468, 6, 135, 54, 103, 7305, 950, 72, 5, 233, 2960, 9, 135, 54, 205, 44, 560, 7305, 19, 755, 125, 10, 77, 93, 523, 4, 1001, 22, 275, 20, 3, 1991, 1545, 15, 3243, 4730, 3, 684, 116, 2, 3, 27, 111, 684, 654, 11, 44, 1424, 4311, 20, 119, 1, 7305, 950, 7305, 950, 340, 3, 207, 1, 20458, 4987, 2, 205, 44, 1322, 6, 47, 8, 199, 345, 23, 734, 654, 77, 523, 4, 1001, 10, 164]",1584.0,21751205,522
Neuromuscular impairments in adult survivors of childhood acute lymphoblastic leukemia: associations with physical performance and chemotherapy doses.,Cancer,Cancer,2011-07-15,"Treatment regimens for childhood acute lymphoblastic leukemia (ALL) contain neurotoxic agents that may interfere with neuromuscular health. In this study, the authors examined associations between neuromuscular impairments and physical function and between neuromuscular impairments and doses of vincristine and intrathecal methotrexate used to treat leukemia among survivors of childhood ALL. ALL survivors >10 years from diagnosis participated in neuromuscular performance testing. Treatment data were abstracted from medical records. Regression models were used to evaluate associations between treatment factors, neuromuscular impairments, and physical performance. Among 415 survivors (median age, 35 years; age range, 21-52 years), balance, mobility, and 6-minute walk (6MW) distances were 1.3 standard deviations below age-specific and sex-specific values in 15.4%, 3.6%, and 46.5% of participants, respectively. Impairments included absent Achilles tendon reflexes (39.5%), active dorsiflexion range of motion (ROM) <5 degrees (33.5%), and impaired knee extension strength (30.1%). In adjusted models (including cranial radiation), survivors who received cumulative intrathecal methotrexate doses 215 mg/m(2) were 3.4 times more likely (95% confidence interval, 1.2-9.8 times more likely) to have impaired ROM than survivors who received no intrathecal methotrexate, and survivors who received cumulative vincristine doses 39 mg/m(2) were 1.5 times more likely (95% CI, 1.0-2.5 times more likely) to have impaired ROM than survivors who received lower cumulative doses of vincristine. Higher intrathecal methotrexate doses were associated with reduced knee extension strength and 6MW distances. Neuromuscular impairments were prevalent in childhood ALL survivors and interfered with physical performance. Higher cumulative doses of vincristine and/or intrathecal methotrexate were associated with long-term neuromuscular impairments, which have implications on future function as these survivors age.",Journal Article,3112.0,72.0,Treatment regimens for childhood acute lymphoblastic ALL contain neurotoxic agents that may interfere with neuromuscular health In this study the authors examined associations between neuromuscular impairments and physical function and between neuromuscular impairments and doses of vincristine and intrathecal methotrexate used to treat among survivors of childhood ALL ALL survivors 10 years from diagnosis participated in neuromuscular performance testing Treatment data were abstracted from medical records Regression models were used to evaluate associations between treatment factors neuromuscular impairments and physical performance Among 415 survivors median age 35 years age range 21-52 years balance mobility and 6-minute walk 6MW distances were 1.3 standard deviations below age-specific and sex-specific values in 15.4 3.6 and 46.5 of participants respectively Impairments included absent Achilles tendon reflexes 39.5 active dorsiflexion range of motion ROM 5 degrees 33.5 and impaired knee extension strength 30.1 In adjusted models including cranial radiation survivors who received cumulative intrathecal methotrexate doses 215 mg/m 2 were 3.4 times more likely 95 confidence interval 1.2-9.8 times more likely to have impaired ROM than survivors who received no intrathecal methotrexate and survivors who received cumulative vincristine doses 39 mg/m 2 were 1.5 times more likely 95 CI 1.0-2.5 times more likely to have impaired ROM than survivors who received lower cumulative doses of vincristine Higher intrathecal methotrexate doses were associated with reduced knee extension strength and 6MW distances Neuromuscular impairments were prevalent in childhood ALL survivors and interfered with physical performance Higher cumulative doses of vincristine and/or intrathecal methotrexate were associated with long-term neuromuscular impairments which have implications on future function as these survivors age,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 472, 9, 864, 286, 1275, 62, 3725, 11148, 183, 17, 68, 6178, 5, 14209, 341, 4, 26, 45, 3, 738, 409, 685, 59, 14209, 6948, 2, 900, 343, 2, 59, 14209, 6948, 2, 415, 1, 2132, 2, 5126, 2116, 95, 6, 943, 107, 332, 1, 864, 62, 62, 332, 79, 60, 29, 147, 3025, 4, 14209, 528, 471, 24, 74, 11, 4106, 29, 484, 1064, 320, 274, 11, 95, 6, 376, 685, 59, 24, 130, 14209, 6948, 2, 900, 528, 107, 10069, 332, 52, 89, 465, 60, 89, 184, 239, 653, 60, 3459, 5717, 2, 49, 3949, 8200, 21543, 11022, 11, 14, 27, 260, 7810, 2736, 89, 112, 2, 1035, 112, 1030, 4, 167, 39, 27, 49, 2, 641, 33, 1, 776, 106, 6948, 159, 3269, 21442, 23606, 46679, 587, 33, 544, 35156, 184, 1, 2967, 17113, 33, 4133, 466, 33, 2, 2364, 12013, 2401, 3671, 201, 14, 4, 586, 274, 141, 2565, 121, 332, 54, 103, 967, 5126, 2116, 415, 60363, 81, 188, 18, 11, 27, 39, 1072, 80, 322, 48, 307, 268, 14, 18, 83, 66, 1072, 80, 322, 6, 47, 2364, 17113, 76, 332, 54, 103, 77, 5126, 2116, 2, 332, 54, 103, 967, 2132, 415, 27080, 81, 188, 18, 11, 14, 33, 1072, 80, 322, 48, 58, 14, 13, 18, 33, 1072, 80, 322, 6, 47, 2364, 17113, 76, 332, 54, 103, 280, 967, 415, 1, 2132, 142, 5126, 2116, 415, 11, 41, 5, 405, 12013, 2401, 3671, 2, 21543, 11022, 14209, 6948, 11, 2485, 4, 864, 62, 332, 2, 13569, 5, 900, 528, 142, 967, 415, 1, 2132, 2, 15, 5126, 2116, 11, 41, 5, 319, 337, 14209, 6948, 92, 47, 1268, 23, 508, 343, 22, 46, 332, 89]",1930.0,21766297,445
The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of adult acute lymphoblastic leukemia: update of the 2006 evidence-based review.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-07-29,"Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of acute lymphoblastic leukemia (ALL) in adults is presented and critically evaluated in this update. Treatment recommendations changed or modified based on new evidence include: (1) myeloablative allogeneic SCT is an appropriate treatment for adult (<35 years) ALL in first complete remission for all disease risk groups; and (2) reduced-intensity conditioning may produce similar outcomes to myeloablative regimens. Treatment recommendations unchanged or strengthened by new evidence include: (1) allogeneic SCT is recommended over chemotherapy for ALL in second complete remission or greater; (2) allogeneic is superior to autologous SCT; and (3) there are similar survival outcomes after related and unrelated allogeneic SCT. New treatment recommendations based on new evidence include: (1) in the absence of a suitable allogeneic donor, autologous SCT may be an appropriate therapy, but results in a high relapse rate; (2) it is appropriate to consider cord blood transplantation for patients with no HLA well-matched donor; and (3) imatinib therapy before and/or after SCT (for Ph+ ALL) yields significantly superior survival outcomes. Areas of needed research in the treatment of adult ALL with SCT were identified and presented in the review.",Journal Article,3098.0,,Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation SCT in the treatment of acute lymphoblastic ALL in adults is presented and critically evaluated in this update Treatment recommendations changed or modified based on new evidence include 1 myeloablative allogeneic SCT is an appropriate treatment for adult 35 years ALL in first complete remission for all disease risk groups and 2 reduced-intensity conditioning may produce similar outcomes to myeloablative regimens Treatment recommendations unchanged or strengthened by new evidence include 1 allogeneic SCT is recommended over chemotherapy for ALL in second complete remission or greater 2 allogeneic is superior to autologous SCT and 3 there are similar survival outcomes after related and unrelated allogeneic SCT New treatment recommendations based on new evidence include 1 in the absence of a suitable allogeneic donor autologous SCT may be an appropriate therapy but results in a high relapse rate 2 it is appropriate to consider cord blood transplantation for patients with no HLA well-matched donor and 3 imatinib therapy before and/or after SCT for Ph+ ALL yields significantly superior survival outcomes Areas of needed research in the treatment of adult ALL with SCT were identified and presented in the review,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[38, 389, 983, 1192, 3, 157, 241, 90, 206, 23, 3, 200, 1, 1007, 452, 31, 497, 1988, 4, 3, 24, 1, 286, 1275, 62, 4, 857, 16, 917, 2, 4331, 194, 4, 26, 2991, 24, 883, 2368, 15, 1230, 90, 23, 217, 241, 643, 14, 3246, 1063, 1988, 16, 35, 870, 24, 9, 780, 465, 60, 62, 4, 157, 236, 734, 9, 62, 34, 43, 271, 2, 18, 405, 837, 1933, 68, 2410, 288, 123, 6, 3246, 472, 24, 883, 4639, 15, 12766, 20, 217, 241, 643, 14, 1063, 1988, 16, 793, 252, 56, 9, 62, 4, 419, 236, 734, 15, 378, 18, 1063, 16, 1123, 6, 1028, 1988, 2, 27, 125, 32, 288, 25, 123, 50, 139, 2, 2092, 1063, 1988, 217, 24, 883, 90, 23, 217, 241, 643, 14, 4, 3, 1127, 1, 8, 2884, 1063, 1488, 1028, 1988, 68, 40, 35, 870, 36, 84, 99, 4, 8, 64, 429, 116, 18, 192, 16, 870, 6, 2419, 1885, 315, 497, 9, 7, 5, 77, 1160, 149, 655, 1488, 2, 27, 577, 36, 348, 2, 15, 50, 1988, 9, 2058, 62, 4788, 97, 1123, 25, 123, 1361, 1, 575, 389, 4, 3, 24, 1, 780, 62, 5, 1988, 11, 108, 2, 917, 4, 3, 206]",1345.0,21803017,494
Characterization of the CDR3 structure of the V21 T cell clone in patients with P210(BCR-ABL)-positive chronic myeloid leukemia and B-cell acute lymphoblastic leukemia.,Human immunology,Hum. Immunol.,2011-07-20,"The clonally expanded T cells identified in most cancer patients that respond to tumor-associated antigen such as P210(BCR-ABL) protein have definite, specific antitumor cytotoxicity. T cell receptor (TCR) V CDR3 repertoire diversity was analyzed in patients with chronic myeloid leukemia (CML) and BCR-ABL(+) B-cell acute lymphoblastic leukemia (B-ALL) by GeneScan. A high frequency of oligoclonal expansion of the TCR V21 subfamily was observed in the peripheral blood of CML and B-ALL patients. These clonally expanded V21 T cells were correlated with the pathophysiologic process of CML. A conserved amino acid motif (SLxxV) was observed within the CDR3 region in only 3 patients with CML. Preferential usage of the J segments was also observed in a minority of patients. The 3-dimensional structures of the CDR3 region containing the same motif or using the same J segment displayed low similarity; on the contrary, the conformation of the CDR3 region containing no conserved motif in some T cell clones was highly similar. In conclusion, our findings indicate a high frequency of TCR V21 subfamily expansion in p210(BCR-ABL)-positive CML and B-ALL patients. The characterization of the CDR3 structure was complex. Regrettably, at this time it was not possible to confirm that the V21 T cell clones were derived from the stimulation of p210(BCR-ABL) protein.",Journal Article,3107.0,11.0,The clonally expanded T cells identified in most cancer patients that respond to tumor-associated antigen such as P210 BCR-ABL protein have definite specific antitumor cytotoxicity T cell receptor TCR V CDR3 repertoire diversity was analyzed in patients with chronic myeloid CML and BCR-ABL B-cell acute lymphoblastic B-ALL by GeneScan A high frequency of oligoclonal expansion of the TCR V21 subfamily was observed in the peripheral blood of CML and B-ALL patients These clonally expanded V21 T cells were correlated with the pathophysiologic process of CML A conserved amino acid motif SLxxV was observed within the CDR3 region in only 3 patients with CML Preferential usage of the J segments was also observed in a minority of patients The 3-dimensional structures of the CDR3 region containing the same motif or using the same J segment displayed low similarity on the contrary the conformation of the CDR3 region containing no conserved motif in some T cell clones was highly similar In conclusion our findings indicate a high frequency of TCR V21 subfamily expansion in p210 BCR-ABL -positive CML and B-ALL patients The characterization of the CDR3 structure was complex Regrettably at this time it was not possible to confirm that the V21 T cell clones were derived from the stimulation of p210 BCR-ABL protein,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 9157, 2064, 102, 37, 108, 4, 96, 12, 7, 17, 1892, 6, 30, 41, 448, 225, 22, 11538, 1062, 1425, 178, 47, 8442, 112, 579, 1408, 102, 31, 153, 4134, 21676, 14485, 5306, 3653, 10, 311, 4, 7, 5, 442, 533, 903, 2, 1062, 1425, 132, 31, 286, 1275, 132, 62, 20, 37527, 8, 64, 675, 1, 18201, 1422, 1, 3, 4134, 35168, 13989, 10, 164, 4, 3, 672, 315, 1, 903, 2, 132, 62, 7, 46, 9157, 2064, 35168, 102, 37, 11, 438, 5, 3, 11575, 1129, 1, 903, 8, 5547, 3078, 971, 5298, 60424, 10, 164, 262, 3, 14485, 1053, 4, 158, 27, 7, 5, 903, 6629, 5015, 1, 3, 46709, 5138, 10, 120, 164, 4, 8, 2652, 1, 7, 3, 27, 2201, 2414, 1, 3, 14485, 1053, 1101, 3, 827, 5298, 15, 75, 3, 827, 46709, 4610, 2507, 154, 6700, 23, 3, 7194, 3, 7788, 1, 3, 14485, 1053, 1101, 77, 5547, 5298, 4, 476, 102, 31, 2749, 10, 561, 288, 4, 1221, 114, 272, 1008, 8, 64, 675, 1, 4134, 35168, 13989, 1422, 4, 11538, 1062, 1425, 109, 903, 2, 132, 62, 7, 3, 2136, 1, 3, 14485, 2772, 10, 840, 60425, 28, 26, 98, 192, 10, 44, 899, 6, 1843, 17, 3, 35168, 102, 31, 2749, 11, 526, 29, 3, 2503, 1, 11538, 1062, 1425, 178]",1324.0,21820025,346
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.,Blood,Blood,2011-08-17,"We report the findings from the first 10 patients with chemotherapy-refractory chronic lymphocytic leukemia (CLL) or relapsed B-cell acute lymphoblastic leukemia (ALL) we have enrolled for treatment with autologous T cells modified to express 19-28z, a second-generation chimeric antigen (Ag) receptor specific to the B-cell lineage Ag CD19. Eight of the 9 treated patients tolerated 19-28z(+) T-cell infusions well. Three of 4 evaluable patients with bulky CLL who received prior conditioning with cyclophosphamide exhibited either a significant reduction or a mixed response in lymphadenopathy without concomitant development of B-cell aplasia. In contrast, one patient with relapsed ALL who was treated in remission with a similar T-cell dose developed a predicted B-cell aplasia. The short-term persistence of infused T cells was enhanced by prior cyclophosphamide administration and inversely proportional to the peripheral blood tumor burden. Further analyses showed rapid trafficking of modified T cells to tumor and retained ex vivo cytotoxic potential of CD19-targeted T cells retrieved 8 days after infusion. We conclude that this adoptive T-cell approach is promising and more likely to show clinical benefit in the setting of prior conditioning chemotherapy and low tumor burden or minimal residual disease. These studies are registered at www.clinicaltrials.org as #NCT00466531 (CLL protocol) and #NCT01044069 (B-ALL protocol).","Clinical Trial, Phase I",3079.0,738.0,We report the findings from the first 10 patients with chemotherapy-refractory chronic lymphocytic CLL or relapsed B-cell acute lymphoblastic ALL we have enrolled for treatment with autologous T cells modified to express 19-28z a second-generation chimeric antigen Ag receptor specific to the B-cell lineage Ag CD19 Eight of the 9 treated patients tolerated 19-28z T-cell infusions well Three of 4 evaluable patients with bulky CLL who received prior conditioning with cyclophosphamide exhibited either a significant reduction or a mixed response in lymphadenopathy without concomitant development of B-cell aplasia In contrast one patient with relapsed ALL who was treated in remission with a similar T-cell dose developed a predicted B-cell aplasia The short-term persistence of infused T cells was enhanced by prior cyclophosphamide administration and inversely proportional to the peripheral blood tumor burden Further analyses showed rapid trafficking of modified T cells to tumor and retained ex vivo cytotoxic potential of CD19-targeted T cells retrieved 8 days after infusion We conclude that this adoptive T-cell approach is promising and more likely to show clinical benefit in the setting of prior conditioning chemotherapy and low tumor burden or minimal residual disease These studies are registered at www.clinicaltrials.org as NCT00466531 CLL protocol and NCT01044069 B-ALL protocol,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[21, 414, 3, 272, 29, 3, 157, 79, 7, 5, 56, 430, 442, 1193, 552, 15, 591, 132, 31, 286, 1275, 62, 21, 47, 346, 9, 24, 5, 1028, 102, 37, 1230, 6, 1669, 326, 19130, 8, 419, 914, 2897, 448, 2741, 153, 112, 6, 3, 132, 31, 2542, 2741, 3158, 659, 1, 3, 83, 73, 7, 421, 326, 19130, 102, 31, 3435, 149, 169, 1, 39, 859, 7, 5, 4112, 552, 54, 103, 324, 1933, 5, 1112, 1416, 361, 8, 93, 628, 15, 8, 1739, 51, 4, 4962, 187, 1781, 193, 1, 132, 31, 12307, 4, 748, 104, 69, 5, 591, 62, 54, 10, 73, 4, 734, 5, 8, 288, 102, 31, 61, 276, 8, 783, 132, 31, 12307, 3, 978, 337, 4108, 1, 4524, 102, 37, 10, 651, 20, 324, 1112, 634, 2, 2659, 831, 6, 3, 672, 315, 30, 892, 195, 318, 224, 1321, 6105, 1, 1230, 102, 37, 6, 30, 2, 3532, 2581, 386, 759, 174, 1, 3158, 238, 102, 37, 4539, 66, 162, 50, 904, 21, 2060, 17, 26, 3159, 102, 31, 353, 16, 721, 2, 80, 322, 6, 514, 38, 247, 4, 3, 546, 1, 324, 1933, 56, 2, 154, 30, 892, 15, 1048, 753, 34, 46, 94, 32, 1653, 28, 3064, 1252, 5598, 22, 60468, 552, 1182, 2, 35182, 132, 62, 1182]",1397.0,21849486,16
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104.,PloS one,PLoS ONE,2011-08-11,"Recent studies indicate that interactions between leukemia cells and the bone marrow (BM) microenvironment promote leukemia cell survival and confer resistance to anti-leukemic drugs. There is evidence that BM microenvironment contains hypoxic areas that confer survival advantage to hematopoietic cells. In the present study we investigated whether hypoxia in leukemic BM contributes to the protective role of the BM microenvironment. We observed a marked expansion of hypoxic BM areas in immunodeficient mice engrafted with acute lymphoblastic leukemia (ALL) cells. Consistent with this finding, we found that hypoxia promotes chemoresistance in various ALL derived cell lines. These findings suggest to employ hypoxia-activated prodrugs to eliminate leukemia cells within hypoxic niches. Using several xenograft models, we demonstrated that administration of the hypoxia-activated dinitrobenzamide mustard, PR-104 prolonged survival and decreased leukemia burden of immune-deficient mice injected with primary acute lymphoblastic leukemia cells. Together, these findings strongly suggest that targeting hypoxia in leukemic BM is feasible and may significantly improve leukemia therapy.",Journal Article,3085.0,73.0,Recent studies indicate that interactions between cells and the marrow BM microenvironment promote cell survival and confer resistance to anti-leukemic drugs There is evidence that BM microenvironment contains hypoxic areas that confer survival advantage to hematopoietic cells In the present study we investigated whether hypoxia in leukemic BM contributes to the protective role of the BM microenvironment We observed a marked expansion of hypoxic BM areas in immunodeficient mice engrafted with acute lymphoblastic ALL cells Consistent with this finding we found that hypoxia promotes chemoresistance in various ALL derived cell lines These findings suggest to employ hypoxia-activated prodrugs to eliminate cells within hypoxic niches Using several xenograft models we demonstrated that administration of the hypoxia-activated dinitrobenzamide mustard PR-104 prolonged survival and decreased burden of immune-deficient mice injected with primary acute lymphoblastic cells Together these findings strongly suggest that targeting hypoxia in leukemic BM is feasible and may significantly improve therapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 94, 1008, 17, 1286, 59, 37, 2, 3, 581, 1246, 995, 1617, 31, 25, 2, 2913, 251, 6, 312, 2015, 600, 125, 16, 241, 17, 1246, 995, 4862, 4744, 1361, 17, 2913, 25, 1874, 6, 1007, 37, 4, 3, 364, 45, 21, 565, 317, 1823, 4, 2015, 1246, 2444, 6, 3, 2864, 200, 1, 3, 1246, 995, 21, 164, 8, 2003, 1422, 1, 4744, 1246, 1361, 4, 5031, 399, 6914, 5, 286, 1275, 62, 37, 925, 5, 26, 1567, 21, 204, 17, 1823, 2148, 3782, 4, 747, 62, 526, 31, 285, 46, 272, 309, 6, 9431, 1823, 735, 8318, 6, 4964, 37, 262, 4744, 8005, 75, 392, 1330, 274, 21, 264, 17, 634, 1, 3, 1823, 735, 60478, 16777, 998, 3407, 1069, 25, 2, 340, 892, 1, 250, 1971, 399, 2651, 5, 86, 286, 1275, 37, 1162, 46, 272, 1327, 309, 17, 529, 1823, 4, 2015, 1246, 16, 1313, 2, 68, 97, 401, 36]",1104.0,21853076,556
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-08-23,"The introduction of tyrosine kinase inhibitors (TKI) has revolutionized therapy for patients with acute lymphoblastic leukemia (ALL) who have the Philadelphia (Ph) chromosome. A retrospective analysis was conducted on 102 adults and 11 children who received a first-matched related (n = 60), matched unrelated (n = 40), mismatched cord blood (n = 12), or haploidentical (n = 1) allogeneic hematopoietic stem cell transplantation (HSCT) for Ph-positive (Ph+) ALL in first complete remission (n = 71), second complete remission (n = 11), or with active disease (n = 31) between 1990 and 2009. Sixty-seven patients received TKI with upfront ALL therapy, and 32 patients received TKI maintenance following HSCT. With median follow-up of 5 years among survivors (range: 1.1-20.4 years), overall survival (OS) was significantly better for patients transplanted in first remission compared with HSCT in advanced disease: 43% versus 16%, P = .002. Disease stage and age at time of HSCT, the development of acute graft-versus-host disease (aGVHD), and decade of HSCT were found to significantly impact OS, progression-free survival (PFS), and nonrelapse mortality (NRM) in multivariate analyses. Allogeneic HSCT provides durable remission for patients with Ph+ ALL in first remission. Neither TKI use pre- nor post-HSCT were found to significantly impact transplant outcomes in univariate and multivariate analyses.",Journal Article,3073.0,42.0,The introduction of tyrosine kinase inhibitors TKI has revolutionized therapy for patients with acute lymphoblastic ALL who have the Philadelphia Ph chromosome A retrospective analysis was conducted on 102 adults and 11 children who received a first-matched related n 60 matched unrelated n 40 mismatched cord blood n 12 or haploidentical n 1 allogeneic hematopoietic stem cell transplantation HSCT for Ph-positive Ph+ ALL in first complete remission n 71 second complete remission n 11 or with active disease n 31 between 1990 and 2009 Sixty-seven patients received TKI with upfront ALL therapy and 32 patients received TKI maintenance following HSCT With median follow-up of 5 years among survivors range 1.1-20.4 years overall survival OS was significantly better for patients transplanted in first remission compared with HSCT in advanced disease 43 versus 16 P .002 Disease stage and age at time of HSCT the development of acute graft-versus-host disease aGVHD and decade of HSCT were found to significantly impact OS progression-free survival PFS and nonrelapse mortality NRM in multivariate analyses Allogeneic HSCT provides durable remission for patients with Ph+ ALL in first remission Neither TKI use pre- nor post-HSCT were found to significantly impact transplant outcomes in univariate and multivariate analyses,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2456, 1, 564, 216, 222, 1379, 71, 5746, 36, 9, 7, 5, 286, 1275, 62, 54, 47, 3, 3006, 2058, 1170, 8, 459, 65, 10, 426, 23, 2867, 857, 2, 175, 541, 54, 103, 8, 157, 655, 139, 78, 335, 655, 2092, 78, 327, 5095, 1885, 315, 78, 133, 15, 5802, 78, 14, 1063, 1007, 452, 31, 497, 1703, 9, 2058, 109, 2058, 62, 4, 157, 236, 734, 78, 792, 419, 236, 734, 78, 175, 15, 5, 544, 34, 78, 456, 59, 2289, 2, 1238, 1746, 648, 7, 103, 1379, 5, 2941, 62, 36, 2, 531, 7, 103, 1379, 1146, 366, 1703, 5, 52, 166, 126, 1, 33, 60, 107, 332, 184, 14, 14, 179, 39, 60, 63, 25, 118, 10, 97, 380, 9, 7, 4600, 4, 157, 734, 72, 5, 1703, 4, 131, 34, 601, 185, 245, 19, 1111, 34, 82, 2, 89, 28, 98, 1, 1703, 3, 193, 1, 286, 1599, 185, 1204, 34, 5873, 2, 2025, 1, 1703, 11, 204, 6, 97, 345, 118, 91, 115, 25, 300, 2, 4640, 282, 4296, 4, 331, 318, 1063, 1703, 777, 1480, 734, 9, 7, 5, 2058, 62, 4, 157, 734, 2174, 1379, 119, 671, 2110, 539, 1703, 11, 204, 6, 97, 345, 941, 123, 4, 880, 2, 331, 318]",1324.0,21867666,853
The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia.,Blood,Blood,2011-08-30,"The BCL11B transcription factor is required for normal T-cell development, and has recently been implicated in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL) induced by TLX overexpression or Atm deficiency. To comprehensively assess the contribution of BCL11B inactivation to human T-ALL, we performed DNA copy number and sequencing analyses of T-ALL diagnostic specimens, revealing monoallelic BCL11B deletions or missense mutations in 9% (n = 10 of 117) of cases. Structural homology modeling revealed that several of the BCL11B mutations disrupted the structure of zinc finger domains required for this transcription factor to bind DNA. BCL11B haploinsufficiency occurred across each of the major molecular subtypes of T-ALL, including early T-cell precursor, HOXA-positive, LEF1-inactivated, and TAL1-positive subtypes, which have differentiation arrest at diverse stages of thymocyte development. Our findings provide compelling evidence that BCL11B is a haploinsufficient tumor suppressor that collaborates with all major T-ALL oncogenic lesions in human thymocyte transformation.",Clinical Trial,3066.0,101.0,The BCL11B transcription factor is required for normal T-cell development and has recently been implicated in the pathogenesis of T-cell acute lymphoblastic T-ALL induced by TLX overexpression or Atm deficiency To comprehensively assess the contribution of BCL11B inactivation to human T-ALL we performed DNA copy number and sequencing analyses of T-ALL diagnostic specimens revealing monoallelic BCL11B deletions or missense mutations in 9 n 10 of 117 of cases Structural homology modeling revealed that several of the BCL11B mutations disrupted the structure of zinc finger domains required for this transcription factor to bind DNA BCL11B haploinsufficiency occurred across each of the major molecular subtypes of T-ALL including early T-cell precursor HOXA-positive LEF1-inactivated and TAL1-positive subtypes which have differentiation arrest at diverse stages of thymocyte development Our findings provide compelling evidence that BCL11B is a haploinsufficient tumor suppressor that collaborates with all major T-ALL oncogenic lesions in human thymocyte transformation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 25260, 866, 161, 16, 616, 9, 295, 102, 31, 193, 2, 71, 761, 85, 1771, 4, 3, 1384, 1, 102, 31, 286, 1275, 102, 62, 277, 20, 46747, 851, 15, 3552, 2299, 6, 5627, 423, 3, 2925, 1, 25260, 2297, 6, 171, 102, 62, 21, 173, 261, 1337, 207, 2, 615, 318, 1, 102, 62, 752, 623, 6475, 11950, 25260, 2439, 15, 4007, 138, 4, 83, 78, 79, 1, 3843, 1, 140, 3281, 7984, 2057, 553, 17, 392, 1, 3, 25260, 138, 5576, 3, 2772, 1, 5988, 8079, 2703, 616, 9, 26, 866, 161, 6, 4060, 261, 25260, 9292, 489, 716, 296, 1, 3, 458, 219, 814, 1, 102, 62, 141, 191, 102, 31, 2765, 31577, 109, 12009, 5458, 2, 18789, 109, 814, 92, 47, 910, 1854, 28, 1867, 1153, 1, 16236, 193, 114, 272, 377, 6051, 241, 17, 25260, 16, 8, 15916, 30, 1245, 17, 35189, 5, 62, 458, 102, 62, 1302, 406, 4, 171, 16236, 1392]",1074.0,21878675,652
Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.,The Journal of experimental medicine,J. Exp. Med.,2011-09-19,"Activating mutations in protein tyrosine phosphatase 11 (Ptpn11) have been identified in childhood acute leukemias, in addition to juvenile myelomonocytic leukemia (JMML), which is a myeloproliferative disorder (MPD). It is not clear whether activating mutations of this phosphatase play a causal role in the pathogenesis of acute leukemias. If so, the cell origin of leukemia-initiating stem cells (LSCs) remains to be determined. Ptpn11(E76K) mutation is the most common and most active Ptpn11 mutation found in JMML and acute leukemias. However, the pathogenic effects of this mutation have not been well characterized. We have created Ptpn11(E76K) conditional knock-in mice. Global Ptpn11(E76K/+) mutation results in early embryonic lethality. Induced knock-in of this mutation in pan hematopoietic cells leads to MPD as a result of aberrant activation of hematopoietic stem cells (HSCs) and myeloid progenitors. These animals subsequently progress to acute leukemias. Intriguingly, in addition to acute myeloid leukemia (AML), T cell acute lymphoblastic leukemia/lymphoma (T-ALL) and B-ALL are evolved. Moreover, tissue-specific knock-in of Ptpn11(E76K/+) mutation in lineage-committed myeloid, T lymphoid, and B lymphoid progenitors also results in AML, T-ALL, and B-ALL, respectively. Further analyses have revealed that Shp2 (encoded by Ptpn11) is distributed to centrosomes and that Ptpn11(E76K/+) mutation promotes LSC development, partly by causing centrosome amplification and genomic instability. Thus, Ptpn11(E76K) mutation has non-lineage-specific effects on malignant transformation of hematopoietic cells and initiates acute leukemias at various stages of hematopoiesis.",Journal Article,3046.0,65.0,Activating mutations in protein tyrosine phosphatase 11 Ptpn11 have been identified in childhood acute leukemias in addition to juvenile myelomonocytic JMML which is a disorder MPD It is not clear whether activating mutations of this phosphatase play a causal role in the pathogenesis of acute leukemias If so the cell origin of leukemia-initiating stem cells LSCs remains to be determined Ptpn11 E76K mutation is the most common and most active Ptpn11 mutation found in JMML and acute leukemias However the pathogenic effects of this mutation have not been well characterized We have created Ptpn11 E76K conditional knock-in mice Global Ptpn11 E76K/+ mutation results in early embryonic lethality Induced knock-in of this mutation in pan hematopoietic cells leads to MPD as a result of aberrant activation of hematopoietic stem cells HSCs and myeloid progenitors These animals subsequently progress to acute leukemias Intriguingly in addition to acute myeloid AML T cell acute lymphoblastic leukemia/lymphoma T-ALL and B-ALL are evolved Moreover tissue-specific knock-in of Ptpn11 E76K/+ mutation in lineage-committed myeloid T lymphoid and B lymphoid progenitors also results in AML T-ALL and B-ALL respectively Further analyses have revealed that Shp2 encoded by Ptpn11 is distributed to centrosomes and that Ptpn11 E76K/+ mutation promotes LSC development partly by causing centrosome amplification and genomic instability Thus Ptpn11 E76K mutation has non-lineage-specific effects on malignant transformation of hematopoietic cells and initiates acute leukemias at various stages of hematopoiesis,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1616, 138, 4, 178, 564, 2577, 175, 8403, 47, 85, 108, 4, 864, 286, 2792, 4, 352, 6, 7857, 5451, 16768, 92, 16, 8, 2645, 7712, 192, 16, 44, 885, 317, 1616, 138, 1, 26, 2577, 1343, 8, 5163, 200, 4, 3, 1384, 1, 286, 2792, 492, 1743, 3, 31, 1938, 1, 2647, 2637, 452, 37, 7033, 469, 6, 40, 509, 8403, 29202, 258, 16, 3, 96, 186, 2, 96, 544, 8403, 258, 204, 4, 16768, 2, 286, 2792, 137, 3, 2806, 176, 1, 26, 258, 47, 44, 85, 149, 765, 21, 47, 2466, 8403, 29202, 3212, 6252, 4, 399, 1648, 8403, 29202, 258, 99, 4, 191, 5390, 3266, 277, 6252, 4, 1, 26, 258, 4, 3055, 1007, 37, 1940, 6, 7712, 22, 8, 757, 1, 1898, 363, 1, 1007, 452, 37, 6185, 2, 533, 4321, 46, 2258, 1611, 1466, 6, 286, 2792, 11550, 4, 352, 6, 286, 533, 329, 102, 31, 286, 1275, 2647, 4763, 102, 62, 2, 132, 62, 32, 3937, 1393, 246, 112, 6252, 4, 1, 8403, 29202, 258, 4, 2542, 9552, 533, 102, 2303, 2, 132, 2303, 4321, 120, 99, 4, 329, 102, 62, 2, 132, 62, 106, 195, 318, 47, 553, 17, 15508, 4587, 20, 8403, 16, 4737, 6, 23761, 2, 17, 8403, 29202, 258, 2148, 6643, 193, 5180, 20, 3440, 7432, 1073, 2, 572, 1753, 631, 8403, 29202, 258, 71, 220, 2542, 112, 176, 23, 393, 1392, 1, 1007, 37, 2, 11935, 286, 2792, 28, 747, 1153, 1, 5114]",1601.0,21930766,467
Somatic deletions of genes regulating MSH2 protein stability cause DNA mismatch repair deficiency and drug resistance in human leukemia cells.,Nature medicine,Nat. Med.,2011-09-25,"DNA mismatch repair enzymes (for example, MSH2) maintain genomic integrity, and their deficiency predisposes to several human cancers and to drug resistance. We found that leukemia cells from a substantial proportion of children (11%) with newly diagnosed acute lymphoblastic leukemia have low or undetectable MSH2 protein levels, despite abundant wild-type MSH2 mRNA. Leukemia cells with low levels of MSH2 contained partial or complete somatic deletions of one to four genes that regulate MSH2 degradation (FRAP1 (also known as MTOR), HERC1, PRKCZ and PIK3C2B); we also found these deletions in individuals with adult acute lymphoblastic leukemia (16%) and sporadic colorectal cancer (13.5%). Knockdown of these genes in human leukemia cells recapitulated the MSH2 protein deficiency by enhancing MSH2 degradation, leading to substantial reduction in DNA mismatch repair and increased resistance to thiopurines. These findings reveal a previously unrecognized mechanism whereby somatic deletions of genes regulating MSH2 degradation result in undetectable levels of MSH2 protein in leukemia cells, DNA mismatch repair deficiency and drug resistance.",Journal Article,3040.0,68.0,DNA mismatch repair enzymes for example MSH2 maintain genomic integrity and their deficiency predisposes to several human cancers and to drug resistance We found that cells from a substantial proportion of children 11 with newly diagnosed acute lymphoblastic have low or undetectable MSH2 protein levels despite abundant wild-type MSH2 mRNA cells with low levels of MSH2 contained partial or complete somatic deletions of one to four genes that regulate MSH2 degradation FRAP1 also known as MTOR HERC1 PRKCZ and PIK3C2B we also found these deletions in individuals with adult acute lymphoblastic 16 and sporadic cancer 13.5 Knockdown of these genes in human cells recapitulated the MSH2 protein deficiency by enhancing MSH2 degradation leading to substantial reduction in DNA mismatch repair and increased resistance to thiopurines These findings reveal a previously unrecognized mechanism whereby somatic deletions of genes regulating MSH2 degradation result in undetectable levels of MSH2 protein in cells DNA mismatch repair deficiency and drug resistance,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[261, 2617, 972, 3039, 9, 2685, 4272, 3040, 572, 4797, 2, 136, 2299, 10563, 6, 392, 171, 163, 2, 6, 234, 251, 21, 204, 17, 37, 29, 8, 1281, 920, 1, 541, 26972, 5, 732, 265, 286, 1275, 47, 154, 15, 3920, 4272, 178, 148, 550, 4834, 955, 267, 4272, 956, 37, 5, 154, 148, 1, 4272, 3070, 450, 15, 236, 1119, 2439, 1, 104, 6, 294, 214, 17, 2288, 4272, 2373, 23161, 120, 440, 22, 873, 60587, 60588, 2, 46791, 21, 120, 204, 46, 2439, 4, 869, 5, 780, 286, 1275, 245, 2, 1928, 12, 233, 33, 1563, 1, 46, 214, 4, 171, 37, 8064, 3, 4272, 178, 2299, 20, 2430, 4272, 2373, 1049, 6, 1281, 628, 4, 261, 2617, 972, 2, 101, 251, 6, 39767, 46, 272, 2396, 8, 373, 6055, 670, 6131, 1119, 2439, 1, 214, 2681, 4272, 2373, 757, 4, 3920, 148, 1, 4272, 178, 4, 37, 261, 2617, 972, 2299, 2, 234, 251]",1059.0,21946537,127
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.,Blood,Blood,2011-10-03,"The outcomes in children with refractory/relapsed (R/R) acute lymphoblastic leukemia (ALL) are dismal. The efficacy and safety of intravenous clofarabine 40 mg/m(2) per day, cyclophosphamide 440 mg/m(2) per day, and etoposide 100 mg/m(2) per day for 5 consecutive days in pediatric patients with R/R ALL was evaluated in this phase 2 study. The primary endpoint was overall response rate (complete remission [CR] plus CR without platelet recovery [CRp]). Among the 25 patients (median age, 14 years; pre-B cell ALL, 84%;  2 prior regimens: 84%; refractory to previous regimen: 60%), the overall response rate was 44% (7 CR, 4 CRp) with a 67.3-week median duration or remission censored at last follow-up. Most patients proceeded to alternative therapy, and 10 patients (40%) received hematopoietic stem cell transplantation. Six patients (24%) died because of treatment-related adverse events associated with infection, hepatotoxicity, and/or multiorgan failure. The study protocol was amended to exclude patients with prior hematopoietic stem cell transplantation after 4 of the first 8 patients developed severe hepatotoxicity suggestive of veno-occlusive disease. No additional cases of veno-occlusive disease occurred. The regimen offered encouraging response rates and sustained remission in R/R patients. Future investigation should include exploration of patient selection, dosing, and supportive care. This trial was registered at www.clinicaltrials.gov as #NCT00315705.","Clinical Trial, Phase II",3032.0,75.0,The outcomes in children with refractory/relapsed R/R acute lymphoblastic ALL are dismal The efficacy and safety of intravenous clofarabine 40 mg/m 2 per day cyclophosphamide 440 mg/m 2 per day and etoposide 100 mg/m 2 per day for 5 consecutive days in pediatric patients with R/R ALL was evaluated in this phase 2 study The primary endpoint was overall response rate complete remission CR plus CR without platelet recovery CRp Among the 25 patients median age 14 years pre-B cell ALL 84  2 prior regimens 84 refractory to previous regimen 60 the overall response rate was 44 7 CR 4 CRp with a 67.3-week median duration or remission censored at last follow-up Most patients proceeded to alternative therapy and 10 patients 40 received hematopoietic stem cell transplantation Six patients 24 died because of treatment-related adverse events associated with infection hepatotoxicity and/or multiorgan failure The study protocol was amended to exclude patients with prior hematopoietic stem cell transplantation after 4 of the first 8 patients developed severe hepatotoxicity suggestive of veno-occlusive disease No additional cases of veno-occlusive disease occurred The regimen offered encouraging response rates and sustained remission in R/R patients Future investigation should include exploration of patient selection dosing and supportive care This trial was registered at www.clinicaltrials.gov as NCT00315705,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 123, 4, 541, 5, 430, 591, 668, 668, 286, 1275, 62, 32, 3929, 3, 209, 2, 367, 1, 1262, 4149, 327, 81, 188, 18, 379, 218, 1112, 9596, 81, 188, 18, 379, 218, 2, 1934, 394, 81, 188, 18, 379, 218, 9, 33, 935, 162, 4, 815, 7, 5, 668, 668, 62, 10, 194, 4, 26, 124, 18, 45, 3, 86, 1138, 10, 63, 51, 116, 236, 734, 684, 349, 684, 187, 1596, 1602, 3162, 107, 3, 243, 7, 52, 89, 213, 60, 671, 132, 31, 62, 874, 749, 18, 324, 472, 874, 430, 6, 698, 477, 335, 3, 63, 51, 116, 10, 584, 67, 684, 39, 3162, 5, 8, 598, 27, 647, 52, 654, 15, 734, 7534, 28, 1060, 166, 126, 96, 7, 6406, 6, 1091, 36, 2, 79, 7, 327, 103, 1007, 452, 31, 497, 437, 7, 259, 1016, 408, 1, 24, 139, 290, 281, 41, 5, 930, 6667, 2, 15, 11760, 496, 3, 45, 1182, 10, 7595, 6, 6262, 7, 5, 324, 1007, 452, 31, 497, 50, 39, 1, 3, 157, 66, 7, 276, 905, 6667, 3832, 1, 10273, 8376, 34, 77, 402, 140, 1, 10273, 8376, 34, 489, 3, 477, 2216, 2269, 51, 151, 2, 2275, 734, 4, 668, 668, 7, 508, 940, 257, 643, 3370, 1, 69, 881, 1280, 2, 1877, 165, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 60612]",1415.0,21967976,707
ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia.,Blood,Blood,2011-10-04,"Asparaginase is a standard and critical component in the therapy of childhood acute lymphoblastic leukemia. Asparagine synthetase (ASNS) and the basic region leucine zipper activating transcription factor 5 (ATF5) and arginosuccinate synthase 1 (ASS1) have been shown to mediate the antileukemic effect of asparaginase and to display variable expression between leukemia cells that are resistant and sensitive to treatment. Fourteen polymorphisms in the regulatory and coding regions of these genes were investigated for an association with acute lymphoblastic leukemia outcome. Lower event-free survival (EFS) was associated with ATF5 T1562C, tandem-repeat ASNS polymorphism, derived haplotype, and ASS1 G1343T and G34T substitutions (P  .03). Associations were limited to patients who received Escherichia coli asparaginase. Variations that sustained correction for multiple testing (ATF5 T1562C, P = .005; ASNS tandem-repeat and related haplotype, P  .01) were subsequently analyzed in the replication cohort. The E coli-dependent association of the ATF5 T1562 allele with reduced EFS was confirmed (P = .01). A gene-reporter assay showed that the haplotype tagged by T1562 had higher promoter activity (P  .01). The remaining regulatory polymorphisms also appeared to affect ATF5 function; 2 additional high-activity haplotypes were identified (P  .02) and were further corroborated by quantitative mRNA analysis in lymphoblastoid cell lines. The ATF5-regulated increase in ASNS expression in response to more efficacious E coli-induced asparagine depletion may explain our observed results.",Journal Article,3031.0,33.0,Asparaginase is a standard and critical component in the therapy of childhood acute lymphoblastic Asparagine synthetase ASNS and the basic region leucine zipper activating transcription factor 5 ATF5 and arginosuccinate synthase 1 ASS1 have been shown to mediate the antileukemic effect of asparaginase and to display variable expression between cells that are resistant and sensitive to treatment Fourteen polymorphisms in the regulatory and coding regions of these genes were investigated for an association with acute lymphoblastic outcome Lower event-free survival EFS was associated with ATF5 T1562C tandem-repeat ASNS polymorphism derived haplotype and ASS1 G1343T and G34T substitutions P  .03 Associations were limited to patients who received Escherichia coli asparaginase Variations that sustained correction for multiple testing ATF5 T1562C P .005 ASNS tandem-repeat and related haplotype P  .01 were subsequently analyzed in the replication cohort The E coli-dependent association of the ATF5 T1562 allele with reduced EFS was confirmed P .01 A gene-reporter assay showed that the haplotype tagged by T1562 had higher promoter activity P  .01 The remaining regulatory polymorphisms also appeared to affect ATF5 function 2 additional high-activity haplotypes were identified P  .02 and were further corroborated by quantitative mRNA analysis in lymphoblastoid cell lines The ATF5-regulated increase in ASNS expression in response to more efficacious E coli-induced asparagine depletion may explain our observed results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 16, 8, 260, 2, 740, 1249, 4, 3, 36, 1, 864, 286, 1275, 14108, 12692, 16063, 2, 3, 2795, 1053, 10316, 19564, 1616, 866, 161, 33, 24945, 2, 60614, 3522, 14, 13442, 47, 85, 443, 6, 3367, 3, 4512, 254, 1, 3709, 2, 6, 3640, 1347, 55, 59, 37, 17, 32, 436, 2, 745, 6, 24, 3225, 1203, 4, 3, 1253, 2, 3097, 1374, 1, 46, 214, 11, 565, 9, 35, 248, 5, 286, 1275, 228, 280, 774, 115, 25, 1683, 10, 41, 5, 24945, 46806, 2905, 2334, 16063, 1907, 526, 4179, 2, 13442, 60615, 2, 60616, 7646, 19, 1552, 680, 685, 11, 383, 6, 7, 54, 103, 12832, 6959, 3709, 2293, 17, 2275, 5360, 9, 232, 471, 24945, 46806, 19, 1614, 16063, 2905, 2334, 2, 139, 4179, 19, 1552, 355, 11, 1611, 311, 4, 3, 2079, 180, 3, 563, 6959, 470, 248, 1, 3, 24945, 46807, 1254, 5, 405, 1683, 10, 557, 19, 355, 8, 145, 3674, 719, 224, 17, 3, 4179, 9874, 20, 46807, 42, 142, 973, 128, 19, 1552, 355, 3, 1844, 1253, 1203, 120, 2121, 6, 1158, 24945, 343, 18, 402, 64, 128, 5940, 11, 108, 19, 1552, 588, 2, 11, 195, 10049, 20, 1156, 956, 65, 4, 10994, 31, 285, 3, 24945, 1065, 344, 4, 16063, 55, 4, 51, 6, 80, 3289, 563, 6959, 277, 14108, 2286, 68, 2943, 114, 164, 99]",1533.0,21972289,406
Family history of cancer and non-malignant diseases and risk of childhood acute lymphoblastic leukemia: a Children's Oncology Group Study.,Cancer epidemiology,Cancer Epidemiol,2011-10-21,"Studies of family history of cancer and non-malignant diseases in childhood acute lymphoblastic leukemia (ALL) show inconsistent findings. Most studies show no increased risk with family history of cancer. Non-malignant diseases such as allergic diseases, autoimmune diseases, birth defects and thyroid diseases have been reported to be associated with ALL. We conducted a case-control study of family history of cancer and selected non-malignant conditions (allergic diseases, autoimmune diseases, birth defects, and thyroid diseases). ALL cases were obtained from Children's Cancer Group institutions from January 1989 to June 1993. Controls were recruited via random digit dialing. Family history for first degree relatives and grandparents of ALL cases and controls was collected by structured telephone questionnaires. Conditional logistical regression was used to calculate odds ratios adjusting for potential confounders. We found a borderline association of ALL and having a family member with a history of cancer in cases (n=1842) compared to controls (n=1986) (OR=0.98, 95%CI=0.93, 1.00) and an inverse association for esophageal cancer based on small numbers. Family history of food and drug allergies demonstrated a modestly reduced risk (OR=0.83, 95%CI=0.73, 0.95) as did family history of rheumatoid arthritis (OR=0.79, 95%CI=0.65, 0.96). There were no associations with family history of any autoimmune diseases, immunodeficiencies, birth defects, thyroid diseases and risk of childhood ALL. These results show no association of overall family history of cancer with childhood ALL, while providing additional evidence for an inverse association with family history of allergic disease. Two potentially new associations of ALL with family history of esophageal cancer and rheumatoid arthritis require confirmation in other studies and validation with medical records.",Journal Article,3014.0,11.0,Studies of family history of cancer and non-malignant diseases in childhood acute lymphoblastic ALL show inconsistent findings Most studies show no increased risk with family history of cancer Non-malignant diseases such as allergic diseases autoimmune diseases birth defects and diseases have been reported to be associated with ALL We conducted a case-control study of family history of cancer and selected non-malignant conditions allergic diseases autoimmune diseases birth defects and diseases ALL cases were obtained from Children 's Cancer Group institutions from January 1989 to June 1993 Controls were recruited via random digit dialing Family history for first degree relatives and grandparents of ALL cases and controls was collected by structured telephone questionnaires Conditional logistical regression was used to calculate odds ratios adjusting for potential confounders We found a borderline association of ALL and having a family member with a history of cancer in cases n=1842 compared to controls n=1986 OR=0.98 95 CI=0.93 1.00 and an inverse association for cancer based on small numbers Family history of food and drug allergies demonstrated a modestly reduced risk OR=0.83 95 CI=0.73 0.95 as did family history of rheumatoid arthritis OR=0.79 95 CI=0.65 0.96 There were no associations with family history of any autoimmune diseases immunodeficiencies birth defects diseases and risk of childhood ALL These results show no association of overall family history of cancer with childhood ALL while providing additional evidence for an inverse association with family history of allergic disease Two potentially new associations of ALL with family history of cancer and rheumatoid arthritis require confirmation in other studies and validation with medical records,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,1,0,"[94, 1, 607, 532, 1, 12, 2, 220, 393, 1342, 4, 864, 286, 1275, 62, 514, 4923, 272, 96, 94, 514, 77, 101, 43, 5, 607, 532, 1, 12, 220, 393, 1342, 225, 22, 7465, 1342, 3445, 1342, 3809, 2945, 2, 1342, 47, 85, 210, 6, 40, 41, 5, 62, 21, 426, 8, 473, 182, 45, 1, 607, 532, 1, 12, 2, 715, 220, 393, 1298, 7465, 1342, 3445, 1342, 3809, 2945, 2, 1342, 62, 140, 11, 683, 29, 541, 292, 12, 87, 1764, 29, 1024, 3965, 6, 1924, 3343, 535, 11, 2619, 847, 2324, 9553, 14758, 607, 532, 9, 157, 1444, 3335, 2, 46840, 1, 62, 140, 2, 535, 10, 786, 20, 5198, 4258, 2956, 3212, 9773, 320, 10, 95, 6, 3232, 610, 1137, 1358, 9, 174, 4423, 21, 204, 8, 2932, 248, 1, 62, 2, 1041, 8, 607, 2693, 5, 8, 532, 1, 12, 4, 140, 78, 25986, 72, 6, 535, 78, 3751, 15, 13, 1096, 48, 58, 13, 966, 14, 2038, 2, 35, 2931, 248, 9, 12, 90, 23, 302, 1870, 607, 532, 1, 1773, 2, 234, 16021, 264, 8, 5588, 405, 43, 15, 13, 852, 48, 58, 13, 803, 13, 48, 22, 205, 607, 532, 1, 12269, 8646, 15, 13, 842, 48, 58, 13, 556, 13, 921, 125, 11, 77, 685, 5, 607, 532, 1, 500, 3445, 1342, 60715, 3809, 2945, 1342, 2, 43, 1, 864, 62, 46, 99, 514, 77, 248, 1, 63, 607, 532, 1, 12, 5, 864, 62, 369, 1736, 402, 241, 9, 35, 2931, 248, 5, 607, 532, 1, 7465, 34, 100, 751, 217, 685, 1, 62, 5, 607, 532, 1, 12, 2, 12269, 8646, 1353, 3551, 4, 127, 94, 2, 929, 5, 484, 1064]",1785.0,22018949,65
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.,"Science (New York, N.Y.)",Science,2011-10-27,"Cytotoxic chemotherapy targets elements common to all nucleated human cells, such as DNA and microtubules, yet it selectively kills tumor cells. Here we show that clinical response to these drugs correlates with, and may be partially governed by, the pretreatment proximity of tumor cell mitochondria to the apoptotic threshold, a property called mitochondrial priming. We used BH3 profiling to measure priming in tumor cells from patients with multiple myeloma, acute myelogenous and lymphoblastic leukemia, and ovarian cancer. This assay measures mitochondrial response to peptides derived from proapoptotic BH3 domains of proteins critical for death signaling to mitochondria. Patients with highly primed cancers exhibited superior clinical response to chemotherapy. In contrast, chemoresistant cancers and normal tissues were poorly primed. Manipulation of mitochondrial priming might enhance the efficacy of cytotoxic agents.",Journal Article,3008.0,321.0,Cytotoxic chemotherapy targets elements common to all nucleated human cells such as DNA and microtubules yet it selectively kills tumor cells Here we show that clinical response to these drugs correlates with and may be partially governed by the pretreatment proximity of tumor cell mitochondria to the apoptotic threshold a property called mitochondrial priming We used BH3 profiling to measure priming in tumor cells from patients with multiple acute myelogenous and lymphoblastic and cancer This assay measures mitochondrial response to peptides derived from proapoptotic BH3 domains of proteins critical for death signaling to mitochondria Patients with highly primed cancers exhibited superior clinical response to chemotherapy In contrast chemoresistant cancers and normal tissues were poorly primed Manipulation of mitochondrial priming might enhance the efficacy of cytotoxic agents,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[759, 56, 637, 2531, 186, 6, 62, 9862, 171, 37, 225, 22, 261, 2, 9870, 1145, 192, 2382, 10955, 30, 37, 467, 21, 514, 17, 38, 51, 6, 46, 600, 1871, 5, 2, 68, 40, 2995, 18267, 20, 3, 1194, 6167, 1, 30, 31, 5443, 6, 3, 1631, 2390, 8, 9267, 3472, 2019, 4903, 21, 95, 5486, 1080, 6, 1463, 4903, 4, 30, 37, 29, 7, 5, 232, 286, 2194, 2, 1275, 2, 12, 26, 719, 1018, 2019, 51, 6, 2491, 526, 29, 4118, 5486, 2703, 1, 652, 740, 9, 273, 314, 6, 5443, 7, 5, 561, 7239, 163, 1416, 1123, 38, 51, 6, 56, 4, 748, 5530, 163, 2, 295, 742, 11, 1240, 7239, 6239, 1, 2019, 4903, 822, 1304, 3, 209, 1, 759, 183]",890.0,22033517,20
Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.,Blood,Blood,2011-11-23,"We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmaco-kinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti-asparaginase antibody levels on risk of relapse was assessed in 410 children who were treated on a front-line clinical trial for acute lymphoblastic leukemia and were evaluable for all pharmacologic measures, using multivariate analyses, adjusting for standard clinical and biologic prognostic factors. Dexamethasone clearance (mean  SD) was higher (P = 3  10(-8)) in patients whose sera was positive (17.7  18.6 L/h per m(2)) versus nega-tive (10.6  5.99 L/h per m(2)) for anti-asparaginase antibodies. In multivariate analyses, higher dexamethasone clearance was associated with a higher risk of any relapse (P = .01) and of central nervous system relapse (P = .014). Central nervous system relapse was also more common in patients with anti-asparaginase antibodies (P = .019). In conclusion, systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies. Lower exposure to both drugs was associated with an increased risk of relapse.",Evaluation Study,2981.0,54.0,We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone both critical chemotherapeutic agents for acute lymphoblastic Whether interpatient pharmaco-kinetic differences in dexamethasone contribute to relapse risk has never been studied The impact of plasma clearance of dexamethasone and anti-asparaginase antibody levels on risk of relapse was assessed in 410 children who were treated on a front-line clinical trial for acute lymphoblastic and were evaluable for all pharmacologic measures using multivariate analyses adjusting for standard clinical and biologic prognostic factors Dexamethasone clearance mean  SD was higher P 3 10 -8 in patients whose sera was positive 17.7  18.6 L/h per m 2 versus nega-tive 10.6  5.99 L/h per m 2 for anti-asparaginase antibodies In multivariate analyses higher dexamethasone clearance was associated with a higher risk of any relapse P .01 and of central nervous system relapse P .014 Central nervous system relapse was also more common in patients with anti-asparaginase antibodies P .019 In conclusion systemic clearance of dexamethasone is higher in patients with anti-asparaginase antibodies Lower exposure to both drugs was associated with an increased risk of relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 47, 373, 1237, 17, 142, 403, 645, 6, 3709, 68, 708, 101, 645, 6, 1217, 110, 740, 1573, 183, 9, 286, 1275, 317, 7423, 33954, 7009, 362, 4, 1217, 1248, 6, 429, 43, 71, 1737, 85, 656, 3, 345, 1, 554, 1960, 1, 1217, 2, 312, 3709, 548, 148, 23, 43, 1, 429, 10, 275, 4, 7690, 541, 54, 11, 73, 23, 8, 3007, 328, 38, 160, 9, 286, 1275, 2, 11, 859, 9, 62, 2788, 1018, 75, 331, 318, 1358, 9, 260, 38, 2, 1283, 177, 130, 1217, 1960, 313, 810, 1270, 10, 142, 19, 27, 79, 66, 4, 7, 1310, 4210, 10, 109, 269, 67, 810, 203, 49, 805, 555, 379, 188, 18, 185, 60818, 28532, 79, 49, 810, 33, 1058, 805, 555, 379, 188, 18, 9, 312, 3709, 890, 4, 331, 318, 142, 1217, 1960, 10, 41, 5, 8, 142, 43, 1, 500, 429, 19, 355, 2, 1, 854, 1880, 398, 429, 19, 3618, 854, 1880, 398, 429, 10, 120, 80, 186, 4, 7, 5, 312, 3709, 890, 19, 4049, 4, 1221, 403, 1960, 1, 1217, 16, 142, 4, 7, 5, 312, 3709, 890, 280, 645, 6, 110, 600, 10, 41, 5, 35, 101, 43, 1, 429]",1284.0,22117041,308
Should the presence of minimal residual disease (MRD) in morphologic complete remission alter post-remission strategy in AML?,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2011-11-09,"Minimal residual disease (MRD) monitoring, particularly via multiparameter flow (MPF) cytometry assessed after chemotherapy, has been very useful in the prognostic and therapeutic approach for children with acute lymphoblastic leukemia. While many studies suggest that MRD monitoring (using MPF or other techniques that are more sensitive than morphologic examination) might be able to accurately predict patient outcome, there is very little data suggesting that treatment decisions should be altered based on such measurements. Proving that MPF-defined MRD should prompt a change in treatment plan optimally requires a contemporaneous control group or at least a historical control treated in standard fashion.",Journal Article,2995.0,,Minimal residual disease MRD monitoring particularly via multiparameter flow MPF cytometry assessed after chemotherapy has been very useful in the prognostic and therapeutic approach for children with acute lymphoblastic While many studies suggest that MRD monitoring using MPF or other techniques that are more sensitive than morphologic examination might be able to accurately predict patient outcome there is very little data suggesting that treatment decisions should be altered based on such measurements Proving that MPF-defined MRD should prompt a change in treatment plan optimally requires a contemporaneous control group or at least a historical control treated in standard fashion,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1048, 753, 34, 2029, 1315, 823, 847, 10757, 1412, 39829, 1914, 275, 50, 56, 71, 85, 923, 999, 4, 3, 177, 2, 189, 353, 9, 541, 5, 286, 1275, 369, 445, 94, 309, 17, 2029, 1315, 75, 39829, 15, 127, 1092, 17, 32, 80, 745, 76, 2815, 1385, 822, 40, 1665, 6, 2141, 678, 69, 228, 125, 16, 923, 1215, 74, 802, 17, 24, 1526, 257, 40, 1495, 90, 23, 225, 1685, 14761, 17, 39829, 395, 2029, 257, 4776, 8, 707, 4, 24, 2242, 5074, 1706, 8, 11633, 182, 87, 15, 28, 506, 8, 2252, 182, 73, 4, 260, 3240]",691.0,22127313,80
Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition.,Genome research,Genome Res.,2011-12-06,"Methotrexate is used to treat autoimmune diseases and malignancies, including acute lymphoblastic leukemia (ALL). Inter-individual variation in clearance of methotrexate results in heterogeneous systemic exposure, clinical efficacy, and toxicity. In a genome-wide association study of children with ALL, we identified SLCO1B1 as harboring multiple common polymorphisms associated with methotrexate clearance. The extent of influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored. We tested the hypothesis that rare variants in SLCO1B1 could affect methotrexate clearance and compared the influence of common versus rare variants in addition to clinical covariates on clearance. From deep resequencing of SLCO1B1 exons in 699 children, we identified 93 SNPs, 15 of which were non-synonymous (NS). Three of these NS SNPs were common, with a minor allele frequency (MAF) >5%, one had low frequency (MAF 1%-5%), and 11 were rare (MAF <1%). NS SNPs (common or rare) predicted to be functionally damaging were more likely to be found among patients with the lowest methotrexate clearance than patients with high clearance. We verified lower function in vitro of four SLCO1B1 haplotypes that were associated with reduced methotrexate clearance. In a multivariate stepwise regression analysis adjusting for other genetic and non-genetic covariates, SLCO1B1 variants accounted for 10.7% of the population variability in clearance. Of that variability, common NS variants accounted for the majority, but rare damaging NS variants constituted 17.8% of SLCO1B1's effects (1.9% of total variation) and had larger effect sizes than common NS variants. Our results show that rare variants are likely to have an important effect on pharmacogenetic phenotypes.",Journal Article,2968.0,136.0,Methotrexate is used to treat autoimmune diseases and malignancies including acute lymphoblastic ALL Inter-individual variation in clearance of methotrexate results in heterogeneous systemic exposure clinical efficacy and toxicity In a genome-wide association study of children with ALL we identified SLCO1B1 as harboring multiple common polymorphisms associated with methotrexate clearance The extent of influence of rare versus common variants on pharmacogenomic phenotypes remains largely unexplored We tested the hypothesis that rare variants in SLCO1B1 could affect methotrexate clearance and compared the influence of common versus rare variants in addition to clinical covariates on clearance From deep resequencing of SLCO1B1 exons in 699 children we identified 93 SNPs 15 of which were non-synonymous NS Three of these NS SNPs were common with a minor allele frequency MAF 5 one had low frequency MAF 1 -5 and 11 were rare MAF 1 NS SNPs common or rare predicted to be functionally damaging were more likely to be found among patients with the lowest methotrexate clearance than patients with high clearance We verified lower function in vitro of four SLCO1B1 haplotypes that were associated with reduced methotrexate clearance In a multivariate stepwise regression analysis adjusting for other genetic and non-genetic covariates SLCO1B1 variants accounted for 10.7 of the population variability in clearance Of that variability common NS variants accounted for the majority but rare damaging NS variants constituted 17.8 of SLCO1B1 's effects 1.9 of total variation and had larger effect sizes than common NS variants Our results show that rare variants are likely to have an important effect on pharmacogenetic phenotypes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 16, 95, 6, 943, 3445, 1342, 2, 441, 141, 286, 1275, 62, 3606, 797, 1380, 4, 1960, 1, 2116, 99, 4, 1564, 403, 645, 38, 209, 2, 155, 4, 8, 898, 1019, 248, 45, 1, 541, 5, 62, 21, 108, 13693, 22, 2105, 232, 186, 1203, 41, 5, 2116, 1960, 3, 1039, 1, 1054, 1, 622, 185, 186, 839, 23, 6971, 2618, 469, 1733, 8398, 21, 650, 3, 1492, 17, 622, 839, 4, 13693, 359, 1158, 2116, 1960, 2, 72, 3, 1054, 1, 186, 185, 622, 839, 4, 352, 6, 38, 2489, 23, 1960, 29, 2369, 11819, 1, 13693, 3885, 4, 14243, 541, 21, 108, 966, 1109, 167, 1, 92, 11, 220, 9287, 4044, 169, 1, 46, 4044, 1109, 11, 186, 5, 8, 2278, 1254, 675, 12406, 33, 104, 42, 154, 675, 12406, 14, 33, 2, 175, 11, 622, 12406, 14, 4044, 1109, 186, 15, 622, 783, 6, 40, 3772, 4904, 11, 80, 322, 6, 40, 204, 107, 7, 5, 3, 2101, 2116, 1960, 76, 7, 5, 64, 1960, 21, 4815, 280, 343, 4, 439, 1, 294, 13693, 5940, 17, 11, 41, 5, 405, 2116, 1960, 4, 8, 331, 5497, 320, 65, 1358, 9, 127, 336, 2, 220, 336, 2489, 13693, 839, 3688, 9, 79, 67, 1, 3, 266, 1982, 4, 1960, 1, 17, 1982, 186, 4044, 839, 3688, 9, 3, 686, 84, 622, 4904, 4044, 839, 8917, 269, 66, 1, 13693, 292, 176, 14, 83, 1, 181, 1380, 2, 42, 1077, 254, 4131, 76, 186, 4044, 839, 114, 99, 514, 17, 622, 839, 32, 322, 6, 47, 35, 305, 254, 23, 6578, 2618]",1731.0,22147369,360
Late effects of acute lymphoblastic leukemia therapy in patients diagnosed at 0-20 years of age.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2011-01-01,"Survival rates for children with acute lymphoblastic leukemia (ALL) have increased dramatically over the past 4 decades, with 5-year survival rates of > 90% in recent trials. With the increasing number of children and adolescents cured of ALL, identifying and characterizing the occurrence of long-term adverse late effects has become increasingly important. In this young population, successful treatment of ALL is associated with increased risk of adverse outcomes such as late mortality, second neoplasms, chronic health conditions, endocrine dysfunction, and psychological function. Research efforts conducted through large survivor cohorts, such as the Childhood Cancer Survivor Study, are providing new and important insights into the very long-term consequences of ALL therapy, while providing direction for screening recommendations and intervention-based approaches for reducing late morbidity and mortality.",Journal Article,3307.0,40.0,Survival rates for children with acute lymphoblastic ALL have increased dramatically over the past 4 decades with 5-year survival rates of 90 in recent trials With the increasing number of children and adolescents cured of ALL identifying and characterizing the occurrence of long-term adverse late effects has become increasingly important In this young population successful treatment of ALL is associated with increased risk of adverse outcomes such as late mortality second neoplasms chronic health conditions endocrine dysfunction and psychological function Research efforts conducted through large survivor cohorts such as the Childhood Cancer Survivor Study are providing new and important insights into the very long-term consequences of ALL therapy while providing direction for screening recommendations and intervention-based approaches for reducing late morbidity and mortality,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[25, 151, 9, 541, 5, 286, 1275, 62, 47, 101, 2729, 252, 3, 1219, 39, 1968, 5, 33, 111, 25, 151, 1, 424, 4, 435, 143, 5, 3, 602, 207, 1, 541, 2, 3101, 3733, 1, 62, 1386, 2, 5723, 3, 2291, 1, 319, 337, 290, 807, 176, 71, 1417, 1635, 305, 4, 26, 1169, 266, 1401, 24, 1, 62, 16, 41, 5, 101, 43, 1, 290, 123, 225, 22, 807, 282, 419, 1179, 442, 341, 1298, 1293, 1527, 2, 2624, 343, 389, 1413, 426, 298, 375, 2628, 736, 225, 22, 3, 864, 12, 2628, 45, 32, 1736, 217, 2, 305, 1957, 237, 3, 923, 319, 337, 3255, 1, 62, 36, 369, 1736, 4651, 9, 453, 883, 2, 788, 90, 611, 9, 1818, 807, 787, 2, 282]",889.0,22160040,855
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?,Haematologica,Haematologica,2011-12-29,"Precursor B-acute lymphoblastic leukemia occurring in patients with a history of malignancies is uncommon, and this condition is not well understood. A retrospective review of 457 adults with precursor B-acute lymphoblastic leukemia treated at our hospital identified 44 (9.6%) patients with prior malignancies. The clinical and genetic characteristics of this group of patients was compared with those of their counterparts with de novo disease and the relationship with prior chemoradiation therapy was assessed. Thirty of 44(6.2%) patients received cytotoxic therapies, whereas 14 patients did not. The former group showed a significantly shorter interval from prior malignancy to onset of precursor B-acute lymphoblastic leukemia (36 versus 144 months; P = 0.002). Compared with 413 de novo cases, the frequencies of t(4;11)(q21;q23) (P<0.001) and hypodiploidy (P = 0.009) with loss of chromosome 5, 7 or 17 were significantly higher in patients who received topoisomerase II inhibitor and/or alkylating agents. By contrast, Philadelphia-positive and normal karyotype were more frequent in patients who either did not receive chemotherapy or received only local radiation or nucleoside analogs. Patients with precursor B-acute lymphoblastic leukemia following prior malignancies and chemoradiation were older, had a lower complete remission rate and showed an inferior survival in univariate, but not multivariate analysis. The data support the interpretation that therapy-related precursor B-acute lymphoblastic leukemia does occur. In particular, cases associated with t(4;11)(q21;q23) or hypodiploidy with -5, -7, -17 are likely to be therapy-related and have a poor prognosis. The inferior outcome of these patients may be attributable to the high-risk cytogenetic abnormalities that are found in this group of patients.",Journal Article,2945.0,24.0,Precursor B-acute lymphoblastic occurring in patients with a history of malignancies is uncommon and this condition is not well understood A retrospective review of 457 adults with precursor B-acute lymphoblastic treated at our hospital identified 44 9.6 patients with prior malignancies The clinical and genetic characteristics of this group of patients was compared with those of their counterparts with de novo disease and the relationship with prior chemoradiation therapy was assessed Thirty of 44 6.2 patients received cytotoxic therapies whereas 14 patients did not The former group showed a significantly shorter interval from prior malignancy to onset of precursor B-acute lymphoblastic 36 versus 144 months P 0.002 Compared with 413 de novo cases the frequencies of t 4 11 q21 q23 P 0.001 and hypodiploidy P 0.009 with loss of chromosome 5 7 or 17 were significantly higher in patients who received topoisomerase II inhibitor and/or alkylating agents By contrast Philadelphia-positive and normal karyotype were more frequent in patients who either did not receive chemotherapy or received only local radiation or nucleoside analogs Patients with precursor B-acute lymphoblastic following prior malignancies and chemoradiation were older had a lower complete remission rate and showed an inferior survival in univariate but not multivariate analysis The data support the interpretation that therapy-related precursor B-acute lymphoblastic does occur In particular cases associated with t 4 11 q21 q23 or hypodiploidy with -5 -7 -17 are likely to be therapy-related and have a poor prognosis The inferior outcome of these patients may be attributable to the high-risk cytogenetic abnormalities that are found in this group of patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2765, 132, 286, 1275, 1821, 4, 7, 5, 8, 532, 1, 441, 16, 2052, 2, 26, 2850, 16, 44, 149, 1784, 8, 459, 206, 1, 13372, 857, 5, 2765, 132, 286, 1275, 73, 28, 114, 702, 108, 584, 83, 49, 7, 5, 324, 441, 3, 38, 2, 336, 374, 1, 26, 87, 1, 7, 10, 72, 5, 135, 1, 136, 3953, 5, 1566, 2018, 34, 2, 3, 858, 5, 324, 975, 36, 10, 275, 977, 1, 584, 49, 18, 7, 103, 759, 235, 547, 213, 7, 205, 44, 3, 3623, 87, 224, 8, 97, 985, 268, 29, 324, 710, 6, 1707, 1, 2765, 132, 286, 1275, 511, 185, 4415, 53, 19, 13, 1111, 72, 5, 10436, 1566, 2018, 140, 3, 2722, 1, 102, 39, 175, 10524, 11423, 19, 13, 144, 2, 14828, 19, 13, 2376, 5, 407, 1, 1170, 33, 67, 15, 269, 11, 97, 142, 4, 7, 54, 103, 3999, 215, 230, 2, 15, 3410, 183, 20, 748, 3006, 109, 2, 295, 3385, 11, 80, 908, 4, 7, 54, 361, 205, 44, 560, 56, 15, 103, 158, 293, 121, 15, 4032, 4063, 7, 5, 2765, 132, 286, 1275, 366, 324, 441, 2, 975, 11, 434, 42, 8, 280, 236, 734, 116, 2, 224, 35, 1663, 25, 4, 880, 84, 44, 331, 65, 3, 74, 538, 3, 3037, 17, 36, 139, 2765, 132, 286, 1275, 1097, 1271, 4, 1454, 140, 41, 5, 102, 39, 175, 10524, 11423, 15, 14828, 5, 33, 67, 269, 32, 322, 6, 40, 36, 139, 2, 47, 8, 334, 356, 3, 1663, 228, 1, 46, 7, 68, 40, 2971, 6, 3, 64, 43, 1266, 1171, 17, 32, 204, 4, 26, 87, 1, 7]",1742.0,22207681,334
Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2011-12-29,"Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation (SCT) in the treatment of pediatric acute lymphoblastic leukemia (ALL) is presented and critically evaluated in this update. Treatment recommendations are provided by an expert panel. Allogeneic SCT is recommended for children who: are in second complete remission (CR2) after experiencing an early marrow relapse for precursor-B ALL; experienced primary induction failure, but subsequently achieved a CR1; have T-lineage ALL in CR2; or have ALL in third or greater remission. Although the 2005 pediatric ALL evidence-based review (EBR) recommended allogeneic SCT for children with Philadelphia chromosome positive (Ph+) ALL in CR1, preliminary tyrosine kinase inhibitor (TKI) data demonstrate that early outcomes are comparable for allogeneic SCT and chemotherapy + imatinib. Based on the evidence, autologous SCT is not recommended for ALL in CR1. Allogeneic SCT is not recommended for: T-lineage ALL in CR1; mixed-lineage leukemia (MLL)+ ALL when it is the sole adverse risk factor; isolated central nervous system (CNS) relapse in precursor-B ALL. Based on expert opinion, allogeneic SCT may be considered for hypodiploid ALL and persistent minimal residual disease [corrected] (MRD) positivity in ALL in CR1 or greater, although these are areas that need further study. Treatment recommendations pertaining to various transplantation techniques are also provided, as are areas of needed future research.",Journal Article,2945.0,33.0,Clinical research published since the first evidence-based review on the role of hematopoietic stem cell transplantation SCT in the treatment of pediatric acute lymphoblastic ALL is presented and critically evaluated in this update Treatment recommendations are provided by an expert panel Allogeneic SCT is recommended for children who are in second complete remission CR2 after experiencing an early marrow relapse for precursor-B ALL experienced primary induction failure but subsequently achieved a CR1 have T-lineage ALL in CR2 or have ALL in third or greater remission Although the 2005 pediatric ALL evidence-based review EBR recommended allogeneic SCT for children with Philadelphia chromosome positive Ph+ ALL in CR1 preliminary tyrosine kinase inhibitor TKI data demonstrate that early outcomes are comparable for allogeneic SCT and chemotherapy imatinib Based on the evidence autologous SCT is not recommended for ALL in CR1 Allogeneic SCT is not recommended for T-lineage ALL in CR1 mixed-lineage MLL ALL when it is the sole adverse risk factor isolated central nervous system CNS relapse in precursor-B ALL Based on expert opinion allogeneic SCT may be considered for hypodiploid ALL and persistent minimal residual disease corrected MRD positivity in ALL in CR1 or greater although these are areas that need further study Treatment recommendations pertaining to various transplantation techniques are also provided as are areas of needed future research,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[38, 389, 983, 1192, 3, 157, 241, 90, 206, 23, 3, 200, 1, 1007, 452, 31, 497, 1988, 4, 3, 24, 1, 815, 286, 1275, 62, 16, 917, 2, 4331, 194, 4, 26, 2991, 24, 883, 32, 1052, 20, 35, 2005, 993, 1063, 1988, 16, 793, 9, 541, 54, 32, 4, 419, 236, 734, 7865, 50, 2985, 35, 191, 581, 429, 9, 2765, 132, 62, 592, 86, 504, 496, 84, 1611, 513, 8, 4516, 47, 102, 2542, 62, 4, 7865, 15, 47, 62, 4, 1282, 15, 378, 734, 242, 3, 1242, 815, 62, 241, 90, 206, 17983, 793, 1063, 1988, 9, 541, 5, 3006, 1170, 109, 2058, 62, 4, 4516, 1676, 564, 216, 230, 1379, 74, 608, 17, 191, 123, 32, 1279, 9, 1063, 1988, 2, 56, 577, 90, 23, 3, 241, 1028, 1988, 16, 44, 793, 9, 62, 4, 4516, 1063, 1988, 16, 44, 793, 9, 102, 2542, 62, 4, 4516, 1739, 2542, 3049, 62, 198, 192, 16, 3, 4991, 290, 43, 161, 1355, 854, 1880, 398, 1025, 429, 4, 2765, 132, 62, 90, 23, 2005, 3564, 1063, 1988, 68, 40, 515, 9, 12135, 62, 2, 1882, 1048, 753, 34, 3848, 2029, 1887, 4, 62, 4, 4516, 15, 378, 242, 46, 32, 1361, 17, 594, 195, 45, 24, 883, 6553, 6, 747, 497, 1092, 32, 120, 1052, 22, 32, 1361, 1, 575, 508, 389]",1467.0,22209888,403
Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults.,Current opinion in oncology,Curr Opin Oncol,2012-03-01,"Acute lymphoblastic leukemia (ALL) is a heterogeneous disease, for which treatment guidelines are still evolving. Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative therapeutic modality for ALL, and this review describes the recent studies and current practice patterns concerning the who, when, and how of allo-HCT in the management of ALL. Allogeneic stem cell transplantation is the treatment of choice for patients with ALL after first relapse and is also recommended for high-risk patients in first complete remission (CR1). Minimal residual disease evaluation and monitoring is developing as an important prognostic factor and could guide physicians in determining which patients, especially those with standard risk, might require transplant. Tyrosine kinase inhibitor (TKI) therapy allows a much higher proportion of Philadelphia-chromosome-positive ALL patients to attain remission and proceed to transplant with improved results; posttransplant TKI maintenance therapy may also provide survival benefit. Reduced-intensity conditioning regimens are a reasonable alternative for patients who would otherwise be ineligible for transplant because of age or comorbidity. For patients with high-risk features, there is general agreement that allo-HCT in CR1 is a potentially curative option; however, there is no consensus on early transplant for standard-risk patients.",Journal Article,2882.0,15.0,Acute lymphoblastic ALL is a heterogeneous disease for which treatment guidelines are still evolving Allogeneic hematopoietic cell transplantation allo-HCT is a potentially curative therapeutic modality for ALL and this review describes the recent studies and current practice patterns concerning the who when and how of allo-HCT in the management of ALL Allogeneic stem cell transplantation is the treatment of choice for patients with ALL after first relapse and is also recommended for high-risk patients in first complete remission CR1 Minimal residual disease evaluation and monitoring is developing as an important prognostic factor and could guide physicians in determining which patients especially those with standard risk might require transplant Tyrosine kinase inhibitor TKI therapy allows a much higher proportion of Philadelphia-chromosome-positive ALL patients to attain remission and proceed to transplant with improved results posttransplant TKI maintenance therapy may also provide survival benefit Reduced-intensity conditioning regimens are a reasonable alternative for patients who would otherwise be ineligible for transplant because of age or comorbidity For patients with high-risk features there is general agreement that allo-HCT in CR1 is a potentially curative option however there is no consensus on early transplant for standard-risk patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 1564, 34, 9, 92, 24, 677, 32, 1234, 3276, 1063, 1007, 31, 497, 2564, 1085, 16, 8, 751, 1075, 189, 1396, 9, 62, 2, 26, 206, 2677, 3, 435, 94, 2, 291, 758, 764, 4243, 3, 54, 198, 2, 832, 1, 2564, 1085, 4, 3, 284, 1, 62, 1063, 452, 31, 497, 16, 3, 24, 1, 1866, 9, 7, 5, 62, 50, 157, 429, 2, 16, 120, 793, 9, 64, 43, 7, 4, 157, 236, 734, 4516, 1048, 753, 34, 451, 2, 1315, 16, 931, 22, 35, 305, 177, 161, 2, 359, 1597, 1261, 4, 2196, 92, 7, 1093, 135, 5, 260, 43, 822, 1353, 941, 564, 216, 230, 1379, 36, 2333, 8, 1802, 142, 920, 1, 3006, 1170, 109, 62, 7, 6, 10719, 734, 2, 6174, 6, 941, 5, 231, 99, 7346, 1379, 1146, 36, 68, 120, 377, 25, 247, 405, 837, 1933, 472, 32, 8, 3203, 1091, 9, 7, 54, 688, 2632, 40, 3773, 9, 941, 408, 1, 89, 15, 1879, 9, 7, 5, 64, 43, 404, 125, 16, 1083, 2024, 17, 2564, 1085, 4, 4516, 16, 8, 751, 1075, 1501, 137, 125, 16, 77, 1391, 23, 191, 941, 9, 260, 43, 7]",1372.0,22234252,419
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.,The Journal of experimental medicine,J. Exp. Med.,2012-01-23,"Enzymatic inhibitors of Janus kinase 2 (JAK2) are in clinical development for the treatment of myeloproliferative neoplasms (MPNs), B cell acute lymphoblastic leukemia (B-ALL) with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 (CRLF2), and other tumors with constitutive JAK2 signaling. In this study, we identify G935R, Y931C, and E864K mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors, whether present in cis with JAK2 V617F (observed in MPNs) or JAK2 R683G (observed in B-ALL). G935R, Y931C, and E864K do not reduce the sensitivity of JAK2-dependent cells to inhibitors of heat shock protein 90 (HSP90), which promote the degradation of both wild-type and mutant JAK2. HSP90 inhibitors were 100-1,000-fold more potent against CRLF2-rearranged B-ALL cells, which correlated with JAK2 degradation and more extensive blockade of JAK2/STAT5, MAP kinase, and AKT signaling. In addition, the HSP90 inhibitor AUY922 prolonged survival of mice xenografted with primary human CRLF2-rearranged B-ALL further than an enzymatic JAK2 inhibitor. Thus, HSP90 is a promising therapeutic target in JAK2-driven cancers, including those with genetic resistance to JAK enzymatic inhibitors.",Journal Article,2920.0,107.0,"Enzymatic inhibitors of Janus kinase 2 JAK2 are in clinical development for the treatment of neoplasms MPNs B cell acute lymphoblastic B-ALL with rearrangements of the cytokine receptor subunit cytokine receptor-like factor 2 CRLF2 and other tumors with constitutive JAK2 signaling In this study we identify G935R Y931C and E864K mutations within the JAK2 kinase domain that confer resistance across a panel of JAK inhibitors whether present in cis with JAK2 V617F observed in MPNs or JAK2 R683G observed in B-ALL G935R Y931C and E864K do not reduce the sensitivity of JAK2-dependent cells to inhibitors of heat shock protein 90 HSP90 which promote the degradation of both wild-type and mutant JAK2 HSP90 inhibitors were 100-1,000-fold more potent against CRLF2-rearranged B-ALL cells which correlated with JAK2 degradation and more extensive blockade of JAK2/STAT5 MAP kinase and AKT signaling In addition the HSP90 inhibitor AUY922 prolonged survival of mice xenografted with primary human CRLF2-rearranged B-ALL further than an enzymatic JAK2 inhibitor Thus HSP90 is a promising therapeutic target in JAK2-driven cancers including those with genetic resistance to JAK enzymatic inhibitors",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5226, 222, 1, 6191, 216, 18, 2509, 32, 4, 38, 193, 9, 3, 24, 1, 1179, 6880, 132, 31, 286, 1275, 132, 62, 5, 2072, 1, 3, 1675, 153, 3350, 1675, 153, 733, 161, 18, 8895, 2, 127, 57, 5, 3178, 2509, 314, 4, 26, 45, 21, 255, 47020, 47021, 2, 47022, 138, 262, 3, 2509, 216, 1398, 17, 2913, 251, 716, 8, 993, 1, 4653, 222, 317, 364, 4, 1927, 5, 2509, 5657, 164, 4, 6880, 15, 2509, 61036, 164, 4, 132, 62, 47020, 47021, 2, 47022, 1022, 44, 969, 3, 485, 1, 2509, 470, 37, 6, 222, 1, 3545, 3971, 178, 424, 2515, 92, 1617, 3, 2373, 1, 110, 955, 267, 2, 620, 2509, 2515, 222, 11, 394, 14, 984, 1116, 80, 1157, 480, 8895, 3201, 132, 62, 37, 92, 438, 5, 2509, 2373, 2, 80, 1344, 1189, 1, 2509, 5517, 3771, 216, 2, 649, 314, 4, 352, 3, 2515, 230, 11217, 1069, 25, 1, 399, 8047, 5, 86, 171, 8895, 3201, 132, 62, 195, 76, 35, 5226, 2509, 230, 631, 2515, 16, 8, 721, 189, 283, 4, 2509, 1621, 163, 141, 135, 5, 336, 251, 6, 4653, 5226, 222]",1191.0,22271575,411
Are the psychological needs of adolescent survivors of pediatric cancer adequately identified and treated?,Psycho-oncology,Psychooncology,2012-01-25,"To describe the psychological needs of adolescent survivors of acute lymphoblastic leukemia (ALL) or brain tumor (BT), we examined the following: (i) the occurrence of cognitive, behavioral, and emotional concerns identified during a comprehensive psychological evaluation and (ii) the frequency of referrals for psychological follow-up services to address identified concerns. Psychological concerns were identified on measures according to predetermined criteria for 100 adolescent survivors. Referrals for psychological follow-up services were made for concerns previously unidentified in formal assessment or not adequately addressed by current services. Most survivors (82%) exhibited at least one concern across domains: behavioral (76%), cognitive (47%), and emotional (19%). Behavioral concerns emerged most often on scales associated with executive dysfunction, inattention, learning, and peer difficulties. Cranial radiation therapy was associated with cognitive concerns, (2) (1, N = 100) = 5.63, p < 0.05. Lower income was associated with more cognitive concerns for ALL survivors, t(47) = 3.28, p < 0.01, and more behavioral concerns for BT survivors, t(48) = 2.93, p < 0.01. Of the survivors with concerns, 38% were referred for psychological follow-up services. Lower-income ALL survivors received more referrals for follow-up, (2) (1, N = 41) = 8.05, p < 0.01. Referred survivors had more concerns across domains than non-referred survivors, ALL: t(39) = 2.96, p < 0.01; BT: t(39) = 3.52, p < 0.01. Trends suggest ALL survivors may be at risk for experiencing unaddressed cognitive needs. Many adolescent survivors of cancer experience psychological difficulties that are not adequately managed by current services, underscoring the need for long-term surveillance. In addition to prescribing regular psychological evaluations, clinicians should closely monitor whether current support services appropriately meet survivors' needs, particularly for lower-income survivors and those treated with cranial radiation therapy.",Journal Article,2918.0,30.0,To describe the psychological needs of adolescent survivors of acute lymphoblastic ALL or brain tumor BT we examined the following i the occurrence of cognitive behavioral and emotional concerns identified during a comprehensive psychological evaluation and ii the frequency of referrals for psychological follow-up services to address identified concerns Psychological concerns were identified on measures according to predetermined criteria for 100 adolescent survivors Referrals for psychological follow-up services were made for concerns previously unidentified in formal assessment or not adequately addressed by current services Most survivors 82 exhibited at least one concern across domains behavioral 76 cognitive 47 and emotional 19 Behavioral concerns emerged most often on scales associated with executive dysfunction inattention learning and peer difficulties Cranial radiation therapy was associated with cognitive concerns  2 1 N 100 5.63 p 0.05 Lower income was associated with more cognitive concerns for ALL survivors t 47 3.28 p 0.01 and more behavioral concerns for BT survivors t 48 2.93 p 0.01 Of the survivors with concerns 38 were referred for psychological follow-up services Lower-income ALL survivors received more referrals for follow-up  2 1 N 41 8.05 p 0.01 Referred survivors had more concerns across domains than non-referred survivors ALL t 39 2.96 p 0.01 BT t 39 3.52 p 0.01 Trends suggest ALL survivors may be at risk for experiencing unaddressed cognitive needs Many adolescent survivors of cancer experience psychological difficulties that are not adequately managed by current services underscoring the need for long-term surveillance In addition to prescribing regular psychological evaluations clinicians should closely monitor whether current support services appropriately meet survivors needs particularly for lower-income survivors and those treated with cranial radiation therapy,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 897, 3, 2624, 1891, 1, 3678, 332, 1, 286, 1275, 62, 15, 342, 30, 3641, 21, 409, 3, 366, 70, 3, 2291, 1, 1863, 4166, 2, 2671, 2061, 108, 190, 8, 949, 2624, 451, 2, 215, 3, 675, 1, 6902, 9, 2624, 166, 126, 2142, 6, 1539, 108, 2061, 2624, 2061, 11, 108, 23, 1018, 768, 6, 10848, 371, 9, 394, 3678, 332, 6902, 9, 2624, 166, 126, 2142, 11, 1229, 9, 2061, 373, 10039, 4, 5057, 455, 15, 44, 4215, 2814, 20, 291, 2142, 96, 332, 878, 1416, 28, 506, 104, 2893, 716, 2703, 4166, 846, 1863, 662, 2, 2671, 326, 4166, 2061, 2054, 96, 629, 23, 5083, 41, 5, 6481, 1527, 23873, 3434, 2, 5084, 4679, 2565, 121, 36, 10, 41, 5, 1863, 2061, 5112, 18, 14, 78, 394, 33, 676, 19, 13, 474, 280, 2306, 10, 41, 5, 80, 1863, 2061, 9, 62, 332, 102, 662, 27, 339, 19, 13, 355, 2, 80, 4166, 2061, 9, 3641, 332, 102, 576, 18, 966, 19, 13, 355, 1, 3, 332, 5, 2061, 519, 11, 1995, 9, 2624, 166, 126, 2142, 280, 2306, 62, 332, 103, 80, 6902, 9, 166, 126, 5112, 18, 14, 78, 605, 66, 474, 19, 13, 355, 1995, 332, 42, 80, 2061, 716, 2703, 76, 220, 1995, 332, 62, 102, 587, 18, 921, 19, 13, 355, 3641, 102, 587, 27, 653, 19, 13, 355, 1963, 309, 62, 332, 68, 40, 28, 43, 9, 2985, 29248, 1863, 1891, 445, 3678, 332, 1, 12, 730, 2624, 4679, 17, 32, 44, 4215, 2231, 20, 291, 2142, 8369, 3, 594, 9, 319, 337, 617, 4, 352, 6, 6840, 3316, 2624, 3816, 1490, 257, 3210, 3334, 317, 291, 538, 2142, 4544, 3362, 332, 1891, 823, 9, 280, 2306, 332, 2, 135, 73, 5, 2565, 121, 36]",1926.0,22278930,2
ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-01-30,"Recent genome-wide screens have identified genetic variations in ARID5B associated with susceptibility to childhood acute lymphoblastic leukemia (ALL). We sought to determine the contribution of ARID5B single nucleotide polymorphisms (SNPs) to racial disparities in ALL susceptibility and treatment outcome. We compared the association between ARID5B SNP genotype and ALL susceptibility in whites (> 95% European genetic ancestry; 978 cases and 1,046 controls) versus in Hispanics (> 10% Native American ancestry; 330 cases and 541 controls). We determined the relationships between ARID5B SNP genotype and ALL relapse risk in 1,605 children treated on the Children's Oncology Group (COG) P9904/9905 clinical trials. Among 49 ARID5B SNPs interrogated, 10 were significantly associated with ALL susceptibility in both whites and Hispanics (P < .05), with risk alleles consistently more frequent in Hispanics than in whites. rs10821936 exhibited the most significant association in both races (P = 8.4  10(-20) in whites; P = 1  10(-6) in Hispanics), and genotype at this SNP was highly correlated with local Native American genetic ancestry (P = 1.8  10(-8)). Multivariate analyses in Hispanics identified an additional SNP associated with ALL susceptibility independent of rs10821936. Eight ARID5B SNPs were associated with both ALL susceptibility and relapse hazard; the alleles related to higher ALL incidence were always linked to poorer treatment outcome and were more frequent in Hispanics. ARID5B polymorphisms are important determinants of childhood ALL susceptibility and treatment outcome, and they contribute to racial disparities in this disease.",Journal Article,2913.0,99.0,"Recent genome-wide screens have identified genetic variations in ARID5B associated with susceptibility to childhood acute lymphoblastic ALL We sought to determine the contribution of ARID5B single nucleotide polymorphisms SNPs to racial disparities in ALL susceptibility and treatment outcome We compared the association between ARID5B SNP genotype and ALL susceptibility in whites 95 European genetic ancestry 978 cases and 1,046 controls versus in Hispanics 10 Native American ancestry 330 cases and 541 controls We determined the relationships between ARID5B SNP genotype and ALL relapse risk in 1,605 children treated on the Children 's Oncology Group COG P9904/9905 clinical trials Among 49 ARID5B SNPs interrogated 10 were significantly associated with ALL susceptibility in both whites and Hispanics P .05 with risk alleles consistently more frequent in Hispanics than in whites rs10821936 exhibited the most significant association in both races P 8.4 10 -20 in whites P 1 10 -6 in Hispanics and genotype at this SNP was highly correlated with local Native American genetic ancestry P 1.8 10 -8 Multivariate analyses in Hispanics identified an additional SNP associated with ALL susceptibility independent of rs10821936 Eight ARID5B SNPs were associated with both ALL susceptibility and relapse hazard the alleles related to higher ALL incidence were always linked to poorer treatment outcome and were more frequent in Hispanics ARID5B polymorphisms are important determinants of childhood ALL susceptibility and treatment outcome and they contribute to racial disparities in this disease",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 898, 1019, 7508, 47, 108, 336, 2293, 4, 17439, 41, 5, 1432, 6, 864, 286, 1275, 62, 21, 990, 6, 223, 3, 2925, 1, 17439, 226, 1579, 1203, 1109, 6, 2257, 2227, 4, 62, 1432, 2, 24, 228, 21, 72, 3, 248, 59, 17439, 1845, 1183, 2, 62, 1432, 4, 2556, 48, 1865, 336, 3535, 14270, 140, 2, 14, 4902, 535, 185, 4, 3850, 79, 4646, 597, 3535, 7105, 140, 2, 10749, 535, 21, 509, 3, 2467, 59, 17439, 1845, 1183, 2, 62, 429, 43, 4, 14, 14247, 541, 73, 23, 3, 541, 292, 413, 87, 6377, 39885, 44902, 38, 143, 107, 739, 17439, 1109, 7227, 79, 11, 97, 41, 5, 62, 1432, 4, 110, 2556, 2, 3850, 19, 474, 5, 43, 2558, 2433, 80, 908, 4, 3850, 76, 4, 2556, 31498, 1416, 3, 96, 93, 248, 4, 110, 9290, 19, 66, 39, 79, 179, 4, 2556, 19, 14, 79, 49, 4, 3850, 2, 1183, 28, 26, 1845, 10, 561, 438, 5, 293, 4646, 597, 336, 3535, 19, 14, 66, 79, 66, 331, 318, 4, 3850, 108, 35, 402, 1845, 41, 5, 62, 1432, 306, 1, 31498, 659, 17439, 1109, 11, 41, 5, 110, 62, 1432, 2, 429, 360, 3, 2558, 139, 6, 142, 62, 287, 11, 3763, 1199, 6, 1769, 24, 228, 2, 11, 80, 908, 4, 3850, 17439, 1203, 32, 305, 3403, 1, 864, 62, 1432, 2, 24, 228, 2, 491, 1248, 6, 2257, 2227, 4, 26, 34]",1596.0,22291082,51
Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-02-27,"Doxorubicin causes cardiac injury and cardiomyopathy in children with acute lymphoblastic leukemia (ALL). Measuring biomarkers during therapy might help individualize treatment by immediately identifying cardiac injury and cardiomyopathy. Children with high-risk ALL were randomly assigned to receive doxorubicin alone (n = 100; 75 analyzed) or doxorubicin with dexrazoxane (n = 105; 81 analyzed). Echocardiograms and serial serum measurements of cardiac troponin T (cTnT; cardiac injury biomarker), N-terminal pro-brain natriuretic peptide (NT-proBNP; cardiomyopathy biomarker), and high-sensitivity C-reactive protein (hsCRP; inflammatory biomarker) were obtained before, during, and after treatment. cTnT levels were increased in 12% of children in the doxorubicin group and in 13% of the doxorubicin-dexrazoxane group before treatment but in 47% and 13%, respectively, after treatment (P = .005). NT-proBNP levels were increased in 89% of children in the doxorubicin group and in 92% of children in the doxorubicin-dexrazoxane group before treatment but in only 48% and 20%, respectively, after treatment (P = .07). The percentage of children with increased hsCRP levels did not differ between groups at any time. In the first 90 days of treatment, detectable increases in cTnT were associated with abnormally reduced left ventricular (LV) mass and LV end-diastolic posterior wall thickness 4 years later (P < .01); increases in NT-proBNP were related to an abnormal LV thickness-to-dimension ratio, suggesting LV remodeling, 4 years later (P = .01). Increases in hsCRP were not associated with any echocardiographic variables. cTnT and NT-proBNP may hold promise as biomarkers of cardiotoxicity in children with high-risk ALL. Definitive validation studies are required to fully establish their range of clinical utility.",Journal Article,2885.0,186.0,Doxorubicin causes injury and cardiomyopathy in children with acute lymphoblastic ALL Measuring biomarkers during therapy might help individualize treatment by immediately identifying injury and cardiomyopathy Children with high-risk ALL were randomly assigned to receive doxorubicin alone n 100 75 analyzed or doxorubicin with dexrazoxane n 105 81 analyzed Echocardiograms and serial serum measurements of troponin T cTnT injury biomarker N-terminal pro-brain natriuretic peptide NT-proBNP cardiomyopathy biomarker and high-sensitivity C-reactive protein hsCRP inflammatory biomarker were obtained before during and after treatment cTnT levels were increased in 12 of children in the doxorubicin group and in 13 of the doxorubicin-dexrazoxane group before treatment but in 47 and 13 respectively after treatment P .005 NT-proBNP levels were increased in 89 of children in the doxorubicin group and in 92 of children in the doxorubicin-dexrazoxane group before treatment but in only 48 and 20 respectively after treatment P .07 The percentage of children with increased hsCRP levels did not differ between groups at any time In the first 90 days of treatment detectable increases in cTnT were associated with abnormally reduced left ventricular LV mass and LV end-diastolic posterior wall thickness 4 years later P .01 increases in NT-proBNP were related to an abnormal LV thickness-to-dimension ratio suggesting LV remodeling 4 years later P .01 Increases in hsCRP were not associated with any echocardiographic variables cTnT and NT-proBNP may hold promise as biomarkers of cardiotoxicity in children with high-risk ALL Definitive validation studies are required to fully establish their range of clinical utility,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[856, 1626, 2730, 2, 6460, 4, 541, 5, 286, 1275, 62, 2978, 582, 190, 36, 822, 987, 7177, 24, 20, 3467, 1386, 2730, 2, 6460, 541, 5, 64, 43, 62, 11, 1108, 896, 6, 560, 856, 279, 78, 394, 481, 311, 15, 856, 5, 8473, 78, 3263, 865, 311, 15097, 2, 2108, 524, 1685, 1, 9092, 102, 29263, 2730, 901, 78, 2158, 1805, 342, 12994, 1389, 5314, 12031, 6460, 901, 2, 64, 485, 256, 2163, 178, 10377, 1291, 901, 11, 683, 348, 190, 2, 50, 24, 29263, 148, 11, 101, 4, 133, 1, 541, 4, 3, 856, 87, 2, 4, 233, 1, 3, 856, 8473, 87, 348, 24, 84, 4, 662, 2, 233, 106, 50, 24, 19, 1614, 5314, 12031, 148, 11, 101, 4, 887, 1, 541, 4, 3, 856, 87, 2, 4, 937, 1, 541, 4, 3, 856, 8473, 87, 348, 24, 84, 4, 158, 576, 2, 179, 106, 50, 24, 19, 1615, 3, 1150, 1, 541, 5, 101, 10377, 148, 205, 44, 1505, 59, 271, 28, 500, 98, 4, 3, 157, 424, 162, 1, 24, 2083, 1106, 4, 29263, 11, 41, 5, 11749, 405, 1712, 4028, 4072, 782, 2, 4072, 396, 10059, 3028, 2397, 2903, 39, 60, 1559, 19, 355, 1106, 4, 5314, 12031, 11, 139, 6, 35, 1668, 4072, 2903, 6, 6384, 197, 802, 4072, 4429, 39, 60, 1559, 19, 355, 1106, 4, 10377, 11, 44, 41, 5, 500, 13220, 682, 29263, 2, 5314, 12031, 68, 4164, 1783, 22, 582, 1, 4404, 4, 541, 5, 64, 43, 62, 1057, 929, 94, 32, 616, 6, 1910, 1811, 136, 184, 1, 38, 1207]",1715.0,22370326,451
The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2012-06-01,"Allogeneic hematopoietic stem cell transplantation (alloHSCT) is an effective post-remission therapy in patients with acute lymphoblastic leukemia (ALL), but is associated with significant toxicity, so the optimal timing and use of this modality remains an issue of debate. Increased advances in reduced-intensity transplant preparative regimens and alternative donors has increased the accessibility of allogeneic transplantation. A risk adapted paradigm, using minimal residual disease analysis, may help in the selection of patients at highest risk for relapse, who may benefit most from alloHSCT. In this review, we summarize the indications for allogeneic transplantation within the risk-oriented paradigm, and also explore the latest literature on reduced intensity transplant regimens, as well as alternative donor transplantation for patients with ALL.",Journal Article,2790.0,11.0,Allogeneic hematopoietic stem cell transplantation alloHSCT is an effective post-remission therapy in patients with acute lymphoblastic ALL but is associated with significant toxicity so the optimal timing and use of this modality remains an issue of debate Increased advances in reduced-intensity transplant preparative regimens and alternative donors has increased the accessibility of allogeneic transplantation A risk adapted paradigm using minimal residual disease analysis may help in the selection of patients at highest risk for relapse who may benefit most from alloHSCT In this review we summarize the indications for allogeneic transplantation within the risk-oriented paradigm and also explore the latest literature on reduced intensity transplant regimens as well as alternative donor transplantation for patients with ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 10248, 16, 35, 323, 539, 734, 36, 4, 7, 5, 286, 1275, 62, 84, 16, 41, 5, 93, 155, 1743, 3, 665, 1972, 2, 119, 1, 26, 1396, 469, 35, 2537, 1, 5220, 101, 954, 4, 405, 837, 941, 6085, 472, 2, 1091, 2344, 71, 101, 3, 9571, 1, 1063, 497, 8, 43, 3716, 2431, 75, 1048, 753, 34, 65, 68, 987, 4, 3, 881, 1, 7, 28, 1076, 43, 9, 429, 54, 68, 247, 96, 29, 10248, 4, 26, 206, 21, 2479, 3, 2406, 9, 1063, 497, 262, 3, 43, 8095, 2431, 2, 120, 1645, 3, 5923, 789, 23, 405, 837, 941, 472, 22, 149, 22, 1091, 1488, 497, 9, 7, 5, 62]",835.0,22410763,167
Antibody therapy for acute lymphoblastic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2012-06-01,"Advances in chemotherapy administration have made acute lymphoblastic leukemia (ALL) a curable disease; however, most patients will relapse, despite readily attaining a complete remission. Treatment of relapse has shown dismal results with little advances made in the recent decades. Antigenic-directed therapy of ALL can complement cytotoxic chemotherapy and has shown encouraging results. This review will evaluate four antigens in ALL (CD20, CD22, CD52, and CD19) and therapeutic strategies to target them. We will review the clinical and preclinical data surrounding rituximab, epratuzumab, inotuzumab ozogamicin, alemtuzumab, blinatumomab, and chimeric antigen receptor-modified T-cell therapy.",Journal Article,2790.0,13.0,Advances in chemotherapy administration have made acute lymphoblastic ALL a curable disease however most patients will relapse despite readily attaining a complete remission Treatment of relapse has shown dismal results with little advances made in the recent decades Antigenic-directed therapy of ALL can complement cytotoxic chemotherapy and has shown encouraging results This review will evaluate four antigens in ALL CD20 CD22 CD52 and CD19 and therapeutic strategies to target them We will review the clinical and preclinical data surrounding rituximab epratuzumab inotuzumab ozogamicin alemtuzumab blinatumomab and chimeric antigen receptor-modified T-cell therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[954, 4, 56, 634, 47, 1229, 286, 1275, 62, 8, 4151, 34, 137, 96, 7, 303, 429, 550, 3860, 11437, 8, 236, 734, 24, 1, 429, 71, 443, 3929, 99, 5, 1215, 954, 1229, 4, 3, 435, 1968, 8357, 1166, 36, 1, 62, 122, 3731, 759, 56, 2, 71, 443, 2269, 99, 26, 206, 303, 376, 294, 1575, 4, 62, 2198, 7599, 7189, 2, 3158, 2, 189, 422, 6, 283, 1370, 21, 303, 206, 3, 38, 2, 693, 74, 2976, 855, 14801, 6730, 5566, 3579, 7182, 2, 2897, 448, 153, 1230, 102, 31, 36]",670.0,22422550,424
Pharmacokinetic modeling of an induction regimen for in vivo combined testing of novel drugs against pediatric acute lymphoblastic leukemia xenografts.,PloS one,PLoS ONE,2012-03-29,"Current regimens for induction therapy of pediatric acute lymphoblastic leukemia (ALL), or for re-induction post relapse, use a combination of vincristine (VCR), a glucocorticoid, and L-asparaginase (ASP) with or without an anthracycline. With cure rates now approximately 80%, robust pre-clinical models are necessary to prioritize active new drugs for clinical trials in relapsed/refractory patients, and the ability of these models to predict synergy/antagonism with established therapy is an essential attribute. In this study, we report optimization of an induction-type regimen by combining VCR, dexamethasone (DEX) and ASP (VXL) against ALL xenograft models established from patient biopsies in immune-deficient mice. We demonstrate that the VXL combination was synergistic in vitro against leukemia cell lines as well as in vivo against ALL xenografts. In vivo, VXL treatment caused delays in progression of individual xenografts ranging from 22 to >146 days. The median progression delay of xenografts derived from long-term surviving patients was 2-fold greater than that of xenografts derived from patients who died of their disease. Pharmacokinetic analysis revealed that systemic DEX exposure in mice increased 2-fold when administered in combination with VCR and ASP, consistent with clinical findings, which may contribute to the observed synergy between the 3 drugs. Finally, as proof-of-principle we tested the in vivo efficacy of combining VXL with either the Bcl-2/Bcl-xL/Bcl-w inhibitor, ABT-737, or arsenic trioxide to provide evidence of a robust in vivo platform to prioritize new drugs for clinical trials in children with relapsed/refractory ALL.",Journal Article,2854.0,31.0,Current regimens for induction therapy of pediatric acute lymphoblastic ALL or for re-induction post relapse use a combination of vincristine VCR a glucocorticoid and L-asparaginase ASP with or without an anthracycline With cure rates now approximately 80 robust pre-clinical models are necessary to prioritize active new drugs for clinical trials in relapsed/refractory patients and the ability of these models to predict synergy/antagonism with established therapy is an essential attribute In this study we report optimization of an induction-type regimen by combining VCR dexamethasone DEX and ASP VXL against ALL xenograft models established from patient biopsies in immune-deficient mice We demonstrate that the VXL combination was synergistic in vitro against cell lines as well as in vivo against ALL xenografts In vivo VXL treatment caused delays in progression of individual xenografts ranging from 22 to 146 days The median progression delay of xenografts derived from long-term surviving patients was 2-fold greater than that of xenografts derived from patients who died of their disease Pharmacokinetic analysis revealed that systemic DEX exposure in mice increased 2-fold when administered in combination with VCR and ASP consistent with clinical findings which may contribute to the observed synergy between the 3 drugs Finally as proof-of-principle we tested the in vivo efficacy of combining VXL with either the Bcl-2/Bcl-xL/Bcl-w inhibitor ABT-737 or arsenic trioxide to provide evidence of a robust in vivo platform to prioritize new drugs for clinical trials in children with relapsed/refractory ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[291, 472, 9, 504, 36, 1, 815, 286, 1275, 62, 15, 9, 1491, 504, 539, 429, 119, 8, 150, 1, 2132, 8886, 8, 5399, 2, 805, 3709, 8501, 5, 15, 187, 35, 2044, 5, 1722, 151, 1134, 705, 493, 1922, 671, 38, 274, 32, 1493, 6, 7716, 544, 217, 600, 9, 38, 143, 4, 591, 430, 7, 2, 3, 801, 1, 46, 274, 6, 678, 3439, 7537, 5, 635, 36, 16, 35, 1452, 13530, 4, 26, 45, 21, 414, 3980, 1, 35, 504, 267, 477, 20, 1525, 8886, 1217, 4844, 2, 8501, 35339, 480, 62, 1330, 274, 635, 29, 69, 1154, 4, 250, 1971, 399, 21, 608, 17, 3, 35339, 150, 10, 1806, 4, 439, 480, 31, 285, 22, 149, 22, 4, 386, 480, 62, 1348, 4, 386, 35339, 24, 1546, 3257, 4, 91, 1, 797, 1348, 2223, 29, 350, 6, 4909, 162, 3, 52, 91, 1984, 1, 1348, 526, 29, 319, 337, 3050, 7, 10, 18, 1116, 378, 76, 17, 1, 1348, 526, 29, 7, 54, 1016, 1, 136, 34, 1456, 65, 553, 17, 403, 4844, 645, 4, 399, 101, 18, 1116, 198, 468, 4, 150, 5, 8886, 2, 8501, 925, 5, 38, 272, 92, 68, 1248, 6, 3, 164, 3439, 59, 3, 27, 600, 1368, 22, 3840, 1, 4968, 21, 650, 3, 4, 386, 209, 1, 1525, 35339, 5, 361, 3, 1044, 18, 1044, 3870, 1044, 5444, 230, 3095, 4933, 15, 3217, 4574, 6, 377, 241, 1, 8, 1922, 4, 386, 2243, 6, 7716, 217, 600, 9, 38, 143, 4, 541, 5, 591, 430, 62]",1619.0,22479469,82
Outcomes after induction failure in childhood acute lymphoblastic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2012-04-01,"Failure of remission-induction therapy is a rare but highly adverse event in children and adolescents with acute lymphoblastic leukemia (ALL). We identified induction failure, defined by the persistence of leukemic blasts in blood, bone marrow, or any extramedullary site after 4 to 6 weeks of remission-induction therapy, in 1041 of 44,017 patients (2.4%) 0 to 18 years of age with newly diagnosed ALL who were treated by a total of 14 cooperative study groups between 1985 and 2000. We analyzed the relationships among disease characteristics, treatments administered, and outcomes in these patients. Patients with induction failure frequently presented with high-risk features, including older age, high leukocyte count, leukemia with a T-cell phenotype, the Philadelphia chromosome, and 11q23 rearrangement. With a median follow-up period of 8.3 years (range, 1.5 to 22.1), the 10-year survival rate (SE) was estimated at only 321%. An age of 10 years or older, T-cell leukemia, the presence of an 11q23 rearrangement, and 25% or more blasts in the bone marrow at the end of induction therapy were associated with a particularly poor outcome. High hyperdiploidy (a modal chromosome number >50) and an age of 1 to 5 years were associated with a favorable outcome in patients with precursor B-cell leukemia. Allogeneic stem-cell transplantation from matched, related donors was associated with improved outcomes in T-cell leukemia. Children younger than 6 years of age with precursor B-cell leukemia and no adverse genetic features had a 10-year survival rate of 725% when treated with chemotherapy only. Pediatric ALL with induction failure is highly heterogeneous. Patients who have T-cell leukemia appear to have a better outcome with allogeneic stem-cell transplantation than with chemotherapy, whereas patients who have precursor B-cell leukemia without other adverse features appear to have a better outcome with chemotherapy. (Funded by Deutsche Krebshilfe and others.).",Journal Article,2851.0,,"Failure of remission-induction therapy is a rare but highly adverse event in children and adolescents with acute lymphoblastic ALL We identified induction failure defined by the persistence of leukemic blasts in blood marrow or any extramedullary site after 4 to 6 weeks of remission-induction therapy in 1041 of 44,017 patients 2.4 0 to 18 years of age with newly diagnosed ALL who were treated by a total of 14 cooperative study groups between 1985 and 2000 We analyzed the relationships among disease characteristics treatments administered and outcomes in these patients Patients with induction failure frequently presented with high-risk features including older age high leukocyte count with a T-cell phenotype the Philadelphia chromosome and 11q23 rearrangement With a median follow-up period of 8.3 years range 1.5 to 22.1 the 10-year survival rate SE was estimated at only 321 An age of 10 years or older T-cell the presence of an 11q23 rearrangement and 25 or more blasts in the marrow at the end of induction therapy were associated with a particularly poor outcome High hyperdiploidy a modal chromosome number 50 and an age of 1 to 5 years were associated with a favorable outcome in patients with precursor B-cell Allogeneic stem-cell transplantation from matched related donors was associated with improved outcomes in T-cell Children younger than 6 years of age with precursor B-cell and no adverse genetic features had a 10-year survival rate of 725 when treated with chemotherapy only Pediatric ALL with induction failure is highly heterogeneous Patients who have T-cell appear to have a better outcome with allogeneic stem-cell transplantation than with chemotherapy whereas patients who have precursor B-cell without other adverse features appear to have a better outcome with chemotherapy Funded by Deutsche Krebshilfe and others",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[496, 1, 734, 504, 36, 16, 8, 622, 84, 561, 290, 774, 4, 541, 2, 3101, 5, 286, 1275, 62, 21, 108, 504, 496, 395, 20, 3, 4108, 1, 2015, 2438, 4, 315, 581, 15, 500, 5508, 606, 50, 39, 6, 49, 244, 1, 734, 504, 36, 4, 31953, 1, 584, 3825, 7, 18, 39, 13, 6, 203, 60, 1, 89, 5, 732, 265, 62, 54, 11, 73, 20, 8, 181, 1, 213, 1690, 45, 271, 59, 4675, 2, 1081, 21, 311, 3, 2467, 107, 34, 374, 640, 468, 2, 123, 4, 46, 7, 7, 5, 504, 496, 746, 917, 5, 64, 43, 404, 141, 434, 89, 64, 3627, 1276, 5, 8, 102, 31, 1005, 3, 3006, 1170, 2, 7975, 2675, 5, 8, 52, 166, 126, 727, 1, 66, 27, 60, 184, 14, 33, 6, 350, 14, 3, 79, 111, 25, 116, 31666, 10, 661, 28, 158, 61321, 35, 89, 1, 79, 60, 15, 434, 102, 31, 3, 463, 1, 35, 7975, 2675, 2, 243, 15, 80, 2438, 4, 3, 581, 28, 3, 396, 1, 504, 36, 11, 41, 5, 8, 823, 334, 228, 64, 11299, 8, 18935, 1170, 207, 212, 2, 35, 89, 1, 14, 6, 33, 60, 11, 41, 5, 8, 913, 228, 4, 7, 5, 2765, 132, 31, 1063, 452, 31, 497, 29, 655, 139, 2344, 10, 41, 5, 231, 123, 4, 102, 31, 541, 773, 76, 49, 60, 1, 89, 5, 2765, 132, 31, 2, 77, 290, 336, 404, 42, 8, 79, 111, 25, 116, 1, 61322, 198, 73, 5, 56, 158, 815, 62, 5, 504, 496, 16, 561, 1564, 7, 54, 47, 102, 31, 1322, 6, 47, 8, 380, 228, 5, 1063, 452, 31, 497, 76, 5, 56, 547, 7, 54, 47, 2765, 132, 31, 187, 127, 290, 404, 1322, 6, 47, 8, 380, 228, 5, 56, 3827, 20, 35341, 47161, 2, 1749]",1852.0,22494120,273
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.,Blood,Blood,2012-04-19,"In patients with acute leukemia, detection of minimal residual disease (MRD) before allogeneic hematopoietic cell transplantation (HCT) correlates with risk of relapse. However, the level of MRD that is most likely to preclude cure by HCT is unclear, and the benefit of further chemotherapy to reduce MRD before HCT is unknown. In 122 children with very-high-risk acute lymphoblastic leukemia (ALL; n = 64) or acute myeloid leukemia (AML, n = 58), higher MRD levels at the time of HCT predicted a poorer survival after HCT (P = .0019); MRD was an independent prognostic factor in a multivariate analysis (P = .0035). However, the increase in risk of death associated with a similar increment of MRD was greater in ALL than in AML, suggesting that a pretransplantation reduction of leukemia burden would have a higher impact in ALL. At any given MRD level, survival rates were higher for patients treated in recent protocols: the 5-year overall survival for patients with ALL was 49% if MRD was detectable and 88% if it was not and the corresponding rates for patients with AML were 67% and 80%, respectively. Although MRD before HCT is a strong prognostic factor, its impact has diminished and should not be regarded as a contraindication for HCT.",Journal Article,2833.0,113.0,In patients with acute detection of minimal residual disease MRD before allogeneic hematopoietic cell transplantation HCT correlates with risk of relapse However the level of MRD that is most likely to preclude cure by HCT is unclear and the benefit of further chemotherapy to reduce MRD before HCT is unknown In 122 children with very-high-risk acute lymphoblastic ALL n 64 or acute myeloid AML n 58 higher MRD levels at the time of HCT predicted a poorer survival after HCT P .0019 MRD was an independent prognostic factor in a multivariate analysis P .0035 However the increase in risk of death associated with a similar increment of MRD was greater in ALL than in AML suggesting that a pretransplantation reduction of burden would have a higher impact in ALL At any given MRD level survival rates were higher for patients treated in recent protocols the 5-year overall survival for patients with ALL was 49 if MRD was detectable and 88 if it was not and the corresponding rates for patients with AML were 67 and 80 respectively Although MRD before HCT is a strong prognostic factor its impact has diminished and should not be regarded as a contraindication for HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 7, 5, 286, 638, 1, 1048, 753, 34, 2029, 348, 1063, 1007, 31, 497, 1085, 1871, 5, 43, 1, 429, 137, 3, 301, 1, 2029, 17, 16, 96, 322, 6, 6064, 1722, 20, 1085, 16, 1200, 2, 3, 247, 1, 195, 56, 6, 969, 2029, 348, 1085, 16, 860, 4, 3285, 541, 5, 923, 64, 43, 286, 1275, 62, 78, 660, 15, 286, 533, 329, 78, 717, 142, 2029, 148, 28, 3, 98, 1, 1085, 783, 8, 1769, 25, 50, 1085, 19, 12960, 2029, 10, 35, 306, 177, 161, 4, 8, 331, 65, 19, 15569, 137, 3, 344, 4, 43, 1, 273, 41, 5, 8, 288, 9705, 1, 2029, 10, 378, 4, 62, 76, 4, 329, 802, 17, 8, 9367, 628, 1, 892, 688, 47, 8, 142, 345, 4, 62, 28, 500, 447, 2029, 301, 25, 151, 11, 142, 9, 7, 73, 4, 435, 2189, 3, 33, 111, 63, 25, 9, 7, 5, 62, 10, 739, 492, 2029, 10, 2083, 2, 889, 492, 192, 10, 44, 2, 3, 1734, 151, 9, 7, 5, 329, 11, 598, 2, 493, 106, 242, 2029, 348, 1085, 16, 8, 1082, 177, 161, 211, 345, 71, 2849, 2, 257, 44, 40, 7217, 22, 8, 8363, 9, 1085]",1168.0,22517895,731
Tyrosine kinase inhibitors in acute and chronic leukemias.,Expert opinion on pharmacotherapy,Expert Opin Pharmacother,2012-05-01,"Since the initial approval of imatinib much has been learned about its resistance mechanisms, and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy. Targeted therapy with TKIs has continued to be an area of active research and development in the care of acute and chronic leukemia patients. This article reviews current approved and investigational TKI treatments for chronic myelogenous leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph + ALL) and acute myelogenous leukemia (AML). There are now more potent BCR-ABL TKIs approved, which allow for additional options when determining front-line and second-line CML and Ph + ALL treatments. The T315I mutation is an ever-present challenge. Ponatinib, a pan BCR-ABL TKI, while still under investigation, is very hopeful with its ability to overcome T315I mutations in resistant CML and Ph + ALL patients. Because nilotinib and dasatinib have not been directly compared, at present we recommend selecting one or the other based on the side-effect profile, drug interactions, patient comorbidities, and mutational status. FLT-3 inhibition is of particular interest in AML patients with FLT-3 internal tandem duplication mutations; this type of targeted therapy continues to be studied.",Journal Article,2821.0,44.0,Since the initial approval of imatinib much has been learned about its resistance mechanisms and efforts have continued to improve upon BCR-ABL tyrosine kinase inhibitor therapy Targeted therapy with TKIs has continued to be an area of active research and development in the care of acute and chronic patients This article reviews current approved and investigational TKI treatments for chronic myelogenous CML Philadelphia-chromosome positive acute lymphoblastic Ph ALL and acute myelogenous AML There are now more potent BCR-ABL TKIs approved which allow for additional options when determining front-line and second-line CML and Ph ALL treatments The T315I mutation is an ever-present challenge Ponatinib a pan BCR-ABL TKI while still under investigation is very hopeful with its ability to overcome T315I mutations in resistant CML and Ph ALL patients Because nilotinib and dasatinib have not been directly compared at present we recommend selecting one or the other based on the side-effect profile drug interactions patient comorbidities and mutational status FLT-3 inhibition is of particular interest in AML patients with FLT-3 internal tandem duplication mutations this type of targeted therapy continues to be studied,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1192, 3, 388, 1814, 1, 577, 1802, 71, 85, 6426, 545, 211, 251, 483, 2, 1413, 47, 1351, 6, 401, 1548, 1062, 1425, 564, 216, 230, 36, 238, 36, 5, 1671, 71, 1351, 6, 40, 35, 965, 1, 544, 389, 2, 193, 4, 3, 165, 1, 286, 2, 442, 7, 26, 946, 2004, 291, 850, 2, 3093, 1379, 640, 9, 442, 2194, 903, 3006, 1170, 109, 286, 1275, 2058, 62, 2, 286, 2194, 329, 125, 32, 1134, 80, 1157, 1062, 1425, 1671, 850, 92, 1700, 9, 402, 838, 198, 2196, 3007, 328, 2, 419, 328, 903, 2, 2058, 62, 640, 3, 6184, 258, 16, 35, 3353, 364, 1745, 5715, 8, 3055, 1062, 1425, 1379, 369, 1234, 669, 940, 16, 923, 19712, 5, 211, 801, 6, 1768, 6184, 138, 4, 436, 903, 2, 2058, 62, 7, 408, 2638, 2, 1674, 47, 44, 85, 1606, 72, 28, 364, 21, 2237, 3675, 104, 15, 3, 127, 90, 23, 3, 1152, 254, 800, 234, 1286, 69, 1909, 2, 1619, 156, 4368, 27, 297, 16, 1, 1454, 1333, 4, 329, 7, 5, 4368, 27, 2329, 2905, 4616, 138, 26, 267, 1, 238, 36, 2274, 6, 40, 656]",1227.0,22519766,542
Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2012-04-24,"Although L-asparaginase (ASP) is associated with several toxicities, its myelosuppressive effect has not been well characterized. On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic leukemia, the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients, except ASP was given only during Consolidation. Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate. The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents.",Clinical Trial,2828.0,11.0,Although L-asparaginase ASP is associated with several toxicities its myelosuppressive effect has not been well characterized On DFCI ALL Consortium Protocol 05-01 for children with newly diagnosed acute lymphoblastic the Consolidation phase and the initial portion of the Continuation phase were identical for standard risk patients except ASP was given only during Consolidation Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate The myelosuppressive effect of ASP should be considered when designing treatment regimens to avoid excessive toxicity and dose reductions of other critical chemotherapy agents,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 805, 3709, 8501, 16, 41, 5, 392, 385, 211, 11109, 254, 71, 44, 85, 149, 765, 23, 11152, 62, 2404, 1182, 474, 355, 9, 541, 5, 732, 265, 286, 1275, 3, 2173, 124, 2, 3, 388, 3206, 1, 3, 6870, 124, 11, 3038, 9, 260, 43, 7, 2187, 8501, 10, 447, 158, 190, 2173, 1430, 3, 100, 24, 3523, 553, 17, 154, 315, 1911, 190, 2173, 5, 8501, 627, 4, 80, 3323, 2153, 1, 49, 9223, 2, 2116, 3, 11109, 254, 1, 8501, 257, 40, 515, 198, 5048, 24, 472, 6, 3085, 4529, 155, 2, 61, 2153, 1, 127, 740, 56, 183]",724.0,22532399,333
"Treatment outcomes in black and white children with cancer: results from the SEER database and St Jude Children's Research Hospital, 1992 through 2007.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-04-30,"Treatment outcome for black patients with cancer has been significantly worse than for their white counterparts. We determined whether recent improved treatment had narrowed the gap in outcome between black and white pediatric patients. In a parallel comparison, we analyzed survival by disease category between black and white patients with childhood cancer registered in one of the 17 cancer registries of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) program or treated at St Jude Children's Research Hospital, which provides comprehensive treatment to all patients regardless of their ability to pay, from 1992 to 2000 and from 2001 to 2007. Analysis of the SEER data indicated that in both study periods, black patients had significantly poorer rates of survival than did white patients, with the exception of a few types of cancer. Despite significantly improved treatment outcomes for patients who were treated from 2001 to 2007, the racial difference in survival has actually widened for acute myeloid leukemia and neuroblastoma. By contrast, in the cohorts treated at St Jude Children's Research Hospital, there were no significant differences in survival between black and white patients in either study period, regardless of the cancer type. Importantly, the outcome of treatment for acute lymphoblastic leukemia, acute myeloid leukemia, and retinoblastoma has improved in parallel for both races during the most recent study period. With equal access to comprehensive treatment, black and white children with cancer can achieve the same high cure rates.",Journal Article,2822.0,69.0,Treatment outcome for black patients with cancer has been significantly worse than for their white counterparts We determined whether recent improved treatment had narrowed the gap in outcome between black and white pediatric patients In a parallel comparison we analyzed survival by disease category between black and white patients with childhood cancer registered in one of the 17 cancer registries of the National Cancer Institute 's Surveillance Epidemiology and End Results SEER program or treated at St Jude Children 's Research Hospital which provides comprehensive treatment to all patients regardless of their ability to pay from 1992 to 2000 and from 2001 to 2007 Analysis of the SEER data indicated that in both study periods black patients had significantly poorer rates of survival than did white patients with the exception of a few types of cancer Despite significantly improved treatment outcomes for patients who were treated from 2001 to 2007 the racial difference in survival has actually widened for acute myeloid and By contrast in the cohorts treated at St Jude Children 's Research Hospital there were no significant differences in survival between black and white patients in either study period regardless of the cancer type Importantly the outcome of treatment for acute lymphoblastic acute myeloid and has improved in parallel for both races during the most recent study period With equal access to comprehensive treatment black and white children with cancer can achieve the same high cure rates,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 228, 9, 1445, 7, 5, 12, 71, 85, 97, 639, 76, 9, 136, 886, 3953, 21, 509, 317, 435, 231, 24, 42, 17829, 3, 5285, 4, 228, 59, 1445, 2, 886, 815, 7, 4, 8, 2755, 1155, 21, 311, 25, 20, 34, 2169, 59, 1445, 2, 886, 7, 5, 864, 12, 1653, 4, 104, 1, 3, 269, 12, 3768, 1, 3, 657, 12, 1377, 292, 617, 1284, 2, 396, 99, 1605, 1243, 15, 73, 28, 3062, 4841, 541, 292, 389, 702, 92, 777, 949, 24, 6, 62, 7, 1583, 1, 136, 801, 6, 6974, 29, 2846, 6, 1081, 2, 29, 1758, 6, 1307, 65, 1, 3, 1605, 74, 1103, 17, 4, 110, 45, 3338, 1445, 7, 42, 97, 1769, 151, 1, 25, 76, 205, 886, 7, 5, 3, 4188, 1, 8, 1021, 630, 1, 12, 550, 97, 231, 24, 123, 9, 7, 54, 11, 73, 29, 1758, 6, 1307, 3, 2257, 523, 4, 25, 71, 6742, 21990, 9, 286, 533, 2, 20, 748, 4, 3, 736, 73, 28, 3062, 4841, 541, 292, 389, 702, 125, 11, 77, 93, 362, 4, 25, 59, 1445, 2, 886, 7, 4, 361, 45, 727, 1583, 1, 3, 12, 267, 1859, 3, 228, 1, 24, 9, 286, 1275, 286, 533, 2, 71, 231, 4, 2755, 9, 110, 9290, 190, 3, 96, 435, 45, 727, 5, 2997, 1655, 6, 949, 24, 1445, 2, 886, 541, 5, 12, 122, 1359, 3, 827, 64, 1722, 151]",1524.0,22547602,450
Cardiac failure 30 years after treatment containing anthracycline for childhood acute lymphoblastic leukemia.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2012-07-01,"In 1977, a 5-year-old girl diagnosed with acute lymphoblastic leukemia was treated on Dana-Farber Cancer Institute Childhood Acute Lymphoblastic Leukemia Protocol 77-01, receiving a cumulative doxorubicin dose of 465 mg/m(2), cranial radiation, and other drugs. After being in continuous complete remission for 34 months, she developed heart failure and was treated with digoxin and furosemide. At 16 years of age, she was diagnosed and treated for dilated cardiomyopathy. Over the years, she continued to have bouts of heart failure, which became less responsive to treatment. At 36 years of age, she received a heart transplant. Six months later, she stopped taking her medications and suffered a sudden cardiac death.",Case Reports,2760.0,10.0,In 1977 a 5-year-old girl diagnosed with acute lymphoblastic was treated on Dana-Farber Cancer Institute Childhood Acute Lymphoblastic Protocol 77-01 receiving a cumulative doxorubicin dose of 465 mg/m 2 cranial radiation and other drugs After being in continuous complete remission for 34 months she developed failure and was treated with digoxin and furosemide At 16 years of age she was diagnosed and treated for dilated cardiomyopathy Over the years she continued to have bouts of failure which became less responsive to treatment At 36 years of age she received a transplant Six months later she stopped taking her medications and suffered a sudden death,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[4, 11792, 8, 33, 111, 1095, 12079, 265, 5, 286, 1275, 10, 73, 23, 4932, 4979, 12, 1377, 864, 286, 1275, 1182, 849, 355, 357, 8, 967, 856, 61, 1, 9940, 81, 188, 18, 2565, 121, 2, 127, 600, 50, 486, 4, 1314, 236, 734, 9, 562, 53, 3109, 276, 496, 2, 10, 73, 5, 17484, 2, 18204, 28, 245, 60, 1, 89, 3109, 10, 265, 2, 73, 9, 11536, 6460, 252, 3, 60, 3109, 1351, 6, 47, 61451, 1, 496, 92, 3451, 299, 2443, 6, 24, 28, 511, 60, 1, 89, 3109, 103, 8, 941, 437, 53, 1559, 3109, 4403, 2727, 1084, 2679, 2, 6388, 8, 10643, 273]",659.0,22584777,451
Dose escalation of total marrow irradiation with concurrent chemotherapy in patients with advanced acute leukemia undergoing allogeneic hematopoietic cell transplantation.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-05-15,"We have demonstrated that toxicities are acceptable with total marrow irradiation (TMI) at 16 Gy without chemotherapy or TMI at 12 Gy and the reduced intensity regimen of fludarabine/melphalan in patients undergoing hematopoietic cell transplantation (HCT). This article reports results of a study of TMI combined with higher intensity chemotherapy regimens in 2 phase I trials in patients with advanced acute myelogenous leukemia or acute lymphoblastic leukemia (AML/ALL) who would do poorly on standard intent-to-cure HCT regimens. Trial 1 consisted of TMI on Days -10 to -6, etoposide (VP16) on Day -5 (60 mg/kg), and cyclophosphamide (CY) on Day -3 (100 mg/kg). TMI dose was 12 (n=3 patients), 13.5 (n=3 patients), and 15 (n=6 patients) Gy at 1.5 Gy twice daily. Trial 2 consisted of busulfan (BU) on Days -12 to -8 (800 M min), TMI on Days -8 to -4, and VP16 on Day -3 (30 mg/kg). TMI dose was 12 (n=18) and 13.5 (n=2) Gy at 1.5 Gy twice daily. Trial 1 had 12 patients with a median age of 33 years. Six patients had induction failures (IF), and 6 had first relapses (1RL), 9 with leukemia blast involvement of bone marrow ranging from 10%-98%, 5 with circulating blasts (24%-85%), and 2 with chloromas. No dose-limiting toxicities were observed. Eleven patients achieved complete remission at Day 30. With a median follow-up of 14.75 months, 5 patients remained in complete remission from 13.5-37.7 months. Trial 2 had 20 patients with a median age of 41 years. Thirteen patients had IF, and 5 had 1RL, 2 in second relapse, 19 with marrow blasts (3%-100%) and 13 with peripheral blasts (6%-63%). Grade 4 dose-limiting toxicities were seen at 13.5 Gy (stomatitis and hepatotoxicity). Stomatitis was the most frequent toxicity in both trials. TMI dose escalation to 15 Gy is possible when combined with CY/VP16 and is associated with acceptable toxicities and encouraging outcomes. TMI dose escalation is not possible with BU/VP16 due to dose-limiting toxicities. Future efforts will focus on whether further dose escalation with CY/VP16 is safe, with the goal of improving disease control in this high-risk population.","Clinical Trial, Phase I",2807.0,31.0,We have demonstrated that toxicities are acceptable with total marrow irradiation TMI at 16 Gy without chemotherapy or TMI at 12 Gy and the reduced intensity regimen of fludarabine/melphalan in patients undergoing hematopoietic cell transplantation HCT This article reports results of a study of TMI combined with higher intensity chemotherapy regimens in 2 phase I trials in patients with advanced acute myelogenous or acute lymphoblastic AML/ALL who would do poorly on standard intent-to-cure HCT regimens Trial 1 consisted of TMI on Days -10 to -6 etoposide VP16 on Day -5 60 mg/kg and cyclophosphamide CY on Day -3 100 mg/kg TMI dose was 12 n=3 patients 13.5 n=3 patients and 15 n=6 patients Gy at 1.5 Gy twice daily Trial 2 consisted of busulfan BU on Days -12 to -8 800 M min TMI on Days -8 to -4 and VP16 on Day -3 30 mg/kg TMI dose was 12 n=18 and 13.5 n=2 Gy at 1.5 Gy twice daily Trial 1 had 12 patients with a median age of 33 years Six patients had induction failures IF and 6 had first relapses 1RL 9 with blast involvement of marrow ranging from 10 -98 5 with circulating blasts 24 -85 and 2 with chloromas No dose-limiting toxicities were observed Eleven patients achieved complete remission at Day 30 With a median follow-up of 14.75 months 5 patients remained in complete remission from 13.5-37.7 months Trial 2 had 20 patients with a median age of 41 years Thirteen patients had IF and 5 had 1RL 2 in second relapse 19 with marrow blasts 3 -100 and 13 with peripheral blasts 6 -63 Grade 4 dose-limiting toxicities were seen at 13.5 Gy stomatitis and hepatotoxicity Stomatitis was the most frequent toxicity in both trials TMI dose escalation to 15 Gy is possible when combined with CY/VP16 and is associated with acceptable toxicities and encouraging outcomes TMI dose escalation is not possible with BU/VP16 due to dose-limiting toxicities Future efforts will focus on whether further dose escalation with CY/VP16 is safe with the goal of improving disease control in this high-risk population,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 47, 264, 17, 385, 32, 1595, 5, 181, 581, 1104, 11845, 28, 245, 381, 187, 56, 15, 11845, 28, 133, 381, 2, 3, 405, 837, 477, 1, 2027, 2370, 4, 7, 479, 1007, 31, 497, 1085, 26, 946, 1198, 99, 1, 8, 45, 1, 11845, 397, 5, 142, 837, 56, 472, 4, 18, 124, 70, 143, 4, 7, 5, 131, 286, 2194, 15, 286, 1275, 329, 62, 54, 688, 1022, 1240, 23, 260, 1697, 6, 1722, 1085, 472, 160, 14, 1695, 1, 11845, 23, 162, 79, 6, 49, 1934, 16396, 23, 218, 33, 335, 81, 503, 2, 1112, 5757, 23, 218, 27, 394, 81, 503, 11845, 61, 10, 133, 78, 27, 7, 233, 33, 78, 27, 7, 2, 167, 78, 49, 7, 381, 28, 14, 33, 381, 936, 391, 160, 18, 1695, 1, 3906, 3667, 23, 162, 133, 6, 66, 2796, 4810, 1538, 11845, 23, 162, 66, 6, 39, 2, 16396, 23, 218, 27, 201, 81, 503, 11845, 61, 10, 133, 78, 203, 2, 233, 33, 78, 18, 381, 28, 14, 33, 381, 936, 391, 160, 14, 42, 133, 7, 5, 8, 52, 89, 1, 466, 60, 437, 7, 42, 504, 3368, 492, 2, 49, 42, 157, 3713, 39714, 83, 5, 3112, 799, 1, 581, 2223, 29, 79, 1096, 33, 5, 1033, 2438, 259, 772, 2, 18, 5, 35366, 77, 61, 817, 385, 11, 164, 2627, 7, 513, 236, 734, 28, 218, 201, 5, 8, 52, 166, 126, 1, 213, 481, 53, 33, 7, 958, 4, 236, 734, 29, 233, 33, 567, 67, 53, 160, 18, 42, 179, 7, 5, 8, 52, 89, 1, 605, 60, 3170, 7, 42, 492, 2, 33, 42, 39714, 18, 4, 419, 429, 326, 5, 581, 2438, 27, 394, 2, 233, 5, 672, 2438, 49, 676, 88, 39, 61, 817, 385, 11, 527, 28, 233, 33, 381, 4486, 2, 6667, 4486, 10, 3, 96, 908, 155, 4, 110, 143, 11845, 61, 1125, 6, 167, 381, 16, 899, 198, 397, 5, 5757, 16396, 2, 16, 41, 5, 1595, 385, 2, 2269, 123, 11845, 61, 1125, 16, 44, 899, 5, 3667, 16396, 520, 6, 61, 817, 385, 508, 1413, 303, 1222, 23, 317, 195, 61, 1125, 5, 5757, 16396, 16, 1165, 5, 3, 1326, 1, 1673, 34, 182, 4, 26, 64, 43, 266]",2013.0,22592050,186
Differential effects of radiotherapy on growth and endocrine function among acute leukemia survivors: a childhood cancer survivor study report.,Pediatric blood & cancer,Pediatr Blood Cancer,2012-05-24,"The differential effects of cranial radiotherapy (CRT), spinal radiotherapy (SRT), and total body irradiation (TBI) on growth and endocrine outcomes have rarely been examined in combination among childhood acute leukemia survivors. Self-reported height/weight, hypothyroidism, and pregnancy/live birth were determined among acute lymphoblastic and myeloid leukemia survivors (n = 3,467) participating in the Childhood Cancer Survivor Study, an ongoing cohort study of 5-year survivors of pediatric cancers diagnosed from 1970 to 1986. Compared with no radiotherapy, risk estimates were consistent across outcomes (adult short stature, hypothyroidism, absence of pregnancy/live birth) with CRT treatment associated with 2-3-fold increased risks, TBI associated with 5-10 fold increased risks, and CRT+TBI associated with >10 fold increased risks. Exposure to any SRT further increased risk of these outcomes 2-3-fold. Changes in body composition were more nuanced as CRT only was associated with an increased risk of being overweight/obese (OR 1.6, 95% CI 1.3-1.9) whereas TBI only was associated with an increased risk of being underweight (OR 6.0, 95% CI 2.4-14.9). Although patients treated with CRT+TBI were at greatest risk for short stature, hypothyroidism, and a reduced likelihood of pregnancy/live birth, those treated with either modality alone had significantly increased risks as well, including altered body composition. Any SRT exposure further increased risk in an independent fashion.",Journal Article,2798.0,29.0,"The differential effects of cranial radiotherapy CRT spinal radiotherapy SRT and total body irradiation TBI on growth and endocrine outcomes have rarely been examined in combination among childhood acute survivors Self-reported height/weight hypothyroidism and pregnancy/live birth were determined among acute lymphoblastic and myeloid survivors n 3,467 participating in the Childhood Cancer Survivor Study an ongoing cohort study of 5-year survivors of pediatric cancers diagnosed from 1970 to 1986 Compared with no radiotherapy risk estimates were consistent across outcomes adult short stature hypothyroidism absence of pregnancy/live birth with CRT treatment associated with 2-3-fold increased risks TBI associated with 5-10 fold increased risks and CRT TBI associated with 10 fold increased risks Exposure to any SRT further increased risk of these outcomes 2-3-fold Changes in body composition were more nuanced as CRT only was associated with an increased risk of being overweight/obese OR 1.6 95 CI 1.3-1.9 whereas TBI only was associated with an increased risk of being underweight OR 6.0 95 CI 2.4-14.9 Although patients treated with CRT TBI were at greatest risk for short stature hypothyroidism and a reduced likelihood of pregnancy/live birth those treated with either modality alone had significantly increased risks as well including altered body composition Any SRT exposure further increased risk in an independent fashion",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1777, 176, 1, 2565, 310, 1089, 1499, 310, 4411, 2, 181, 642, 1104, 4889, 23, 129, 2, 1293, 123, 47, 2416, 85, 409, 4, 150, 107, 864, 286, 332, 1074, 210, 4594, 924, 4147, 2, 2290, 3812, 3809, 11, 509, 107, 286, 1275, 2, 533, 332, 78, 27, 10993, 3052, 4, 3, 864, 12, 2628, 45, 35, 942, 180, 45, 1, 33, 111, 332, 1, 815, 163, 265, 29, 4868, 6, 3751, 72, 5, 77, 310, 43, 1423, 11, 925, 716, 123, 780, 978, 13576, 4147, 1127, 1, 2290, 3812, 3809, 5, 1089, 24, 41, 5, 18, 27, 1116, 101, 1098, 4889, 41, 5, 33, 79, 1116, 101, 1098, 2, 1089, 4889, 41, 5, 79, 1116, 101, 1098, 645, 6, 500, 4411, 195, 101, 43, 1, 46, 123, 18, 27, 1116, 400, 4, 642, 3761, 11, 80, 19838, 22, 1089, 158, 10, 41, 5, 35, 101, 43, 1, 486, 3566, 2209, 15, 14, 49, 48, 58, 14, 27, 14, 83, 547, 4889, 158, 10, 41, 5, 35, 101, 43, 1, 486, 8094, 15, 49, 13, 48, 58, 18, 39, 213, 83, 242, 7, 73, 5, 1089, 4889, 11, 28, 2199, 43, 9, 978, 13576, 4147, 2, 8, 405, 1420, 1, 2290, 3812, 3809, 135, 73, 5, 361, 1396, 279, 42, 97, 101, 1098, 22, 149, 141, 1495, 642, 3761, 500, 4411, 645, 195, 101, 43, 4, 35, 306, 3240]",1439.0,22628201,556
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2012-06-01,"Hyperglycemia during hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine, with methylprednisolone premedication) chemotherapy is associated with poor outcomes of acute lymphoblastic leukemia (ALL). To examine whether intensive insulin therapy could improve outcomes, a randomized trial was conducted that compared glargine plus aspart vs. conventional therapy. Intensive insulin did not improve ALL clinical outcomes despite improved glycemic control. Secondary analysis suggests that the choice of antidiabetic pharmacotherapy may influence ALL outcomes. Hyperglycemia during hyper-CVAD (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine, with methylprednisolone premedication) chemotherapy is associated with poor outcomes of acute lymphoblastic leukemia (ALL). To examine whether an intensive insulin regimen could improve outcomes compared with conventional antidiabetic pharmacotherapy, a randomized trial was conducted that compared glargine plus aspart vs. conventional therapy (control). Between April 2004 and July 2008, 52 patients newly diagnosed with ALL, Burkitt lymphoma, or lymphoblastic lymphoma who were on hyper-CVAD in the inpatient setting and had a random serum glucose level >180 mg/dL on 2 occasions during chemotherapy were enrolled. The trial was terminated early due to futility regarding ALL clinical outcomes despite improved glycemic control. Secondary analysis revealed that molar insulin-to-C-peptide ratio (I/C) > 0.175 (a surrogate measure of exogenous insulin usage) was associated with decreased overall survival, complete remission duration and progression-free survival (PFS), whereas metformin and/or thiazolidinedione usage were associated with increased PFS. In multivariate analyses, factors that significantly predicted short overall survival included age  60 years (P = .0002), I/C  0.175 (P = .0016), and average glucose level  180 mg/dL (P = .0236). Factors that significantly predicted short PFS included age  60 years (P = .0008), I/C  0.175 (P = .0002), high systemic risk (P = .0173) and average glucose level  180 mg/dL (P = .0249). I/C  0.175 was the only significant (P = .0042) factor that predicted short complete remission duration. A glargine-plus-aspart intensive insulin regimen did not improve ALL outcomes in patients with hyperglycemia. Exogenous insulin may be associated with poor outcomes, whereas metformin and thiazolidinediones may be associated with improved outcomes. Analysis of these results suggests that the choice of antidiabetic pharmacotherapy may influence ALL outcomes.",Journal Article,2790.0,22.0,Hyperglycemia during hyper-CVAD fractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with methotrexate and high-dose cytarabine with methylprednisolone premedication chemotherapy is associated with poor outcomes of acute lymphoblastic ALL To examine whether intensive insulin therapy could improve outcomes a randomized trial was conducted that compared glargine plus aspart vs. conventional therapy Intensive insulin did not improve ALL clinical outcomes despite improved glycemic control Secondary analysis suggests that the choice of antidiabetic pharmacotherapy may influence ALL outcomes Hyperglycemia during hyper-CVAD fractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with methotrexate and high-dose cytarabine with methylprednisolone premedication chemotherapy is associated with poor outcomes of acute lymphoblastic ALL To examine whether an intensive insulin regimen could improve outcomes compared with conventional antidiabetic pharmacotherapy a randomized trial was conducted that compared glargine plus aspart vs. conventional therapy control Between April 2004 and July 2008 52 patients newly diagnosed with ALL or lymphoblastic who were on hyper-CVAD in the inpatient setting and had a random serum glucose level 180 mg/dL on 2 occasions during chemotherapy were enrolled The trial was terminated early due to futility regarding ALL clinical outcomes despite improved glycemic control Secondary analysis revealed that molar insulin-to-C-peptide ratio I/C 0.175 a surrogate measure of exogenous insulin usage was associated with decreased overall survival complete remission duration and progression-free survival PFS whereas metformin and/or thiazolidinedione usage were associated with increased PFS In multivariate analyses factors that significantly predicted short overall survival included age  60 years P .0002 I/C  0.175 P .0016 and average glucose level  180 mg/dL P .0236 Factors that significantly predicted short PFS included age  60 years P .0008 I/C  0.175 P .0002 high systemic risk P .0173 and average glucose level  180 mg/dL P .0249 I/C  0.175 was the only significant P .0042 factor that predicted short complete remission duration A glargine-plus-aspart intensive insulin regimen did not improve ALL outcomes in patients with hyperglycemia Exogenous insulin may be associated with poor outcomes whereas metformin and thiazolidinediones may be associated with improved outcomes Analysis of these results suggests that the choice of antidiabetic pharmacotherapy may influence ALL outcomes,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3992, 190, 4855, 5574, 3950, 1112, 2132, 856, 2, 1217, 5181, 5, 2116, 2, 64, 61, 1855, 5, 10787, 8656, 56, 16, 41, 5, 334, 123, 1, 286, 1275, 62, 6, 1004, 317, 1686, 1601, 36, 359, 401, 123, 8, 384, 160, 10, 426, 17, 72, 27186, 349, 27187, 105, 809, 36, 1686, 1601, 205, 44, 401, 62, 38, 123, 550, 231, 7804, 182, 568, 65, 844, 17, 3, 1866, 1, 15704, 14878, 68, 1054, 62, 123, 3992, 190, 4855, 5574, 3950, 1112, 2132, 856, 2, 1217, 5181, 5, 2116, 2, 64, 61, 1855, 5, 10787, 8656, 56, 16, 41, 5, 334, 123, 1, 286, 1275, 62, 6, 1004, 317, 35, 1686, 1601, 477, 359, 401, 123, 72, 5, 809, 15704, 14878, 8, 384, 160, 10, 426, 17, 72, 27186, 349, 27187, 105, 809, 36, 182, 59, 2292, 1131, 2, 2066, 1375, 653, 7, 732, 265, 5, 62, 15, 1275, 54, 11, 23, 4855, 5574, 4, 3, 2420, 546, 2, 42, 8, 2324, 524, 2522, 301, 3172, 81, 1826, 23, 3107, 19704, 190, 56, 11, 346, 3, 160, 10, 5640, 191, 520, 6, 7566, 666, 62, 38, 123, 550, 231, 7804, 182, 568, 65, 553, 17, 14566, 1601, 6, 256, 1389, 197, 70, 256, 13, 3300, 8, 2592, 1463, 1, 4181, 1601, 5015, 10, 41, 5, 340, 63, 25, 236, 734, 654, 2, 91, 115, 25, 300, 547, 2791, 2, 15, 22100, 5015, 11, 41, 5, 101, 300, 4, 331, 318, 130, 17, 97, 783, 978, 63, 25, 159, 89, 749, 335, 60, 19, 3531, 70, 256, 749, 13, 3300, 19, 13230, 2, 1011, 2522, 301, 749, 3172, 81, 1826, 19, 25174, 130, 17, 97, 783, 978, 300, 159, 89, 749, 335, 60, 19, 7044, 70, 256, 749, 13, 3300, 19, 3531, 64, 403, 43, 19, 28583, 2, 1011, 2522, 301, 749, 3172, 81, 1826, 19, 30226, 70, 256, 749, 13, 3300, 10, 3, 158, 93, 19, 21111, 161, 17, 783, 978, 236, 734, 654, 8, 27186, 349, 27187, 1686, 1601, 477, 205, 44, 401, 62, 123, 4, 7, 5, 3992, 4181, 1601, 68, 40, 41, 5, 334, 123, 547, 2791, 2, 23153, 68, 40, 41, 5, 231, 123, 65, 1, 46, 99, 844, 17, 3, 1866, 1, 15704, 14878, 68, 1054, 62, 123]",2594.0,22658895,548
Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells.,"Cell cycle (Georgetown, Tex.)",Cell Cycle,2012-06-15,"Hyperglycemia during hyper-CVAD chemotherapy is associated with poor outcomes of acute lymphoblastic leukemia (ALL) (Cancer 2004; 100: 1179-85). The optimal clinical strategy to manage hyperglycemia during hyper-CVAD is unclear. To examine whether anti-diabetic pharmacotherapy can influence chemosensitivity of ALL cells, we examined the impacts of different anti-diabetic agents on ALL cell lines and patient samples. Pharmacologically achievable concentrations of insulin, aspart and glargine significantly increased the number of ALL cells, and aspart and glargine did so at lower concentrations than human insulin. In contrast, metformin and rosiglitazone significantly decreased the cell number. Human insulin and analogs activated AKT/mTOR signaling and stimulated ALL cell proliferation (as measured by flow cytometric methods), but metformin and rosiglitazone blocked AKT/mTOR signaling and inhibited proliferation. Metformin 500 M and rosiglitazone 10 M were found to sensitize Reh cells to daunorubicin, while aspart, glargine and human insulin (all at 1.25 mIU/L) enhanced chemoresistance. Metformin and rosiglitazone enhanced daunorubicin-induced apoptosis, while insulin, aspart and glargine antagonized daunorubicin-induced apoptosis. In addition, metformin increased etoposide-induced and L-asparaginase-induced apoptosis; rosiglitazone increased etoposide-induced and vincristine-induced apoptosis. In conclusion, our results suggest that use of insulins to control hyperglycemia in ALL patients may contribute to anthracycline chemoresistance, while metformin and thiazolidinediones may improve chemosensitivity to anthracycline as well as other chemotherapy drugs through their different impacts on AKT/mTOR signaling in leukemic cells. Our data suggest that the choice of anti-diabetic pharmacotherapy during chemotherapy may influence clinical outcomes in ALL.",Journal Article,2776.0,,Hyperglycemia during hyper-CVAD chemotherapy is associated with poor outcomes of acute lymphoblastic ALL Cancer 2004 100 1179-85 The optimal clinical strategy to manage hyperglycemia during hyper-CVAD is unclear To examine whether anti-diabetic pharmacotherapy can influence chemosensitivity of ALL cells we examined the impacts of different anti-diabetic agents on ALL cell lines and patient samples Pharmacologically achievable concentrations of insulin aspart and glargine significantly increased the number of ALL cells and aspart and glargine did so at lower concentrations than human insulin In contrast metformin and rosiglitazone significantly decreased the cell number Human insulin and analogs activated AKT/mTOR signaling and stimulated ALL cell proliferation as measured by flow cytometric methods but metformin and rosiglitazone blocked AKT/mTOR signaling and inhibited proliferation Metformin 500 M and rosiglitazone 10 M were found to sensitize Reh cells to daunorubicin while aspart glargine and human insulin all at 1.25 mIU/L enhanced chemoresistance Metformin and rosiglitazone enhanced daunorubicin-induced apoptosis while insulin aspart and glargine antagonized daunorubicin-induced apoptosis In addition metformin increased etoposide-induced and L-asparaginase-induced apoptosis rosiglitazone increased etoposide-induced and vincristine-induced apoptosis In conclusion our results suggest that use of insulins to control hyperglycemia in ALL patients may contribute to anthracycline chemoresistance while metformin and thiazolidinediones may improve chemosensitivity to anthracycline as well as other chemotherapy drugs through their different impacts on AKT/mTOR signaling in leukemic cells Our data suggest that the choice of anti-diabetic pharmacotherapy during chemotherapy may influence clinical outcomes in ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3992, 190, 4855, 5574, 56, 16, 41, 5, 334, 123, 1, 286, 1275, 62, 12, 1131, 394, 24966, 772, 3, 665, 38, 692, 6, 4001, 3992, 190, 4855, 5574, 16, 1200, 6, 1004, 317, 312, 5943, 14878, 122, 1054, 5522, 1, 62, 37, 21, 409, 3, 4719, 1, 338, 312, 5943, 183, 23, 62, 31, 285, 2, 69, 347, 7854, 6171, 1003, 1, 1601, 27187, 2, 27186, 97, 101, 3, 207, 1, 62, 37, 2, 27187, 2, 27186, 205, 1743, 28, 280, 1003, 76, 171, 1601, 4, 748, 2791, 2, 9046, 97, 340, 3, 31, 207, 171, 1601, 2, 4063, 735, 649, 873, 314, 2, 2816, 62, 31, 457, 22, 644, 20, 1412, 6226, 636, 84, 2791, 2, 9046, 2582, 649, 873, 314, 2, 879, 457, 2791, 1666, 4810, 2, 9046, 79, 4810, 11, 204, 6, 5745, 23340, 37, 6, 5247, 369, 27187, 27186, 2, 171, 1601, 62, 28, 14, 243, 8356, 805, 651, 3782, 2791, 2, 9046, 651, 5247, 277, 351, 369, 1601, 27187, 2, 27186, 15259, 5247, 277, 351, 4, 352, 2791, 101, 1934, 277, 2, 805, 3709, 277, 351, 9046, 101, 1934, 277, 2, 2132, 277, 351, 4, 1221, 114, 99, 309, 17, 119, 1, 61530, 6, 182, 3992, 4, 62, 7, 68, 1248, 6, 2044, 3782, 369, 2791, 2, 23153, 68, 401, 5522, 6, 2044, 22, 149, 22, 127, 56, 600, 298, 136, 338, 4719, 23, 649, 873, 314, 4, 2015, 37, 114, 74, 309, 17, 3, 1866, 1, 312, 5943, 14878, 190, 56, 68, 1054, 38, 123, 4, 62]",1840.0,22659796,685
Philadelphia-positive acute lymphoblastic leukemia: current treatment options.,Current oncology reports,Curr Oncol Rep,2012-10-01,"The Philadelphia chromosome (Ph), t(9;22), is seen in about 20% to 30% of adults diagnosed with acute lymphoblastic leukemia (ALL). It has been associated with poorer prognosis compared with Ph-negative ALL. Tyrosine kinase inhibitors (TKIs) targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL. Imatinib has been the most widely used TKI with several published trials showing it produced better outcomes when combined with chemotherapy. Dasatinib, a more potent inhibitor than imatinib, has also been evaluated with promising results. However, relapses still occur at a high rate, and allogeneic stem cell transplant is considered, so far, a better curative option in first remission. Additional strategies have also included incorporation of TKIs in the post-transplant setting and the use of newer third generation TKIs. This review provides an update on emerging therapies for adults with Ph-positive ALL.",Journal Article,2668.0,39.0,The Philadelphia chromosome Ph t 9 22 is seen in about 20 to 30 of adults diagnosed with acute lymphoblastic ALL It has been associated with poorer prognosis compared with Ph-negative ALL Tyrosine kinase inhibitors TKIs targeting the BCR-ABL oncogenic protein from this translocation have been incorporated into treatment regimens used to treat patients with Ph-positive ALL Imatinib has been the most widely used TKI with several published trials showing it produced better outcomes when combined with chemotherapy Dasatinib a more potent inhibitor than imatinib has also been evaluated with promising results However relapses still occur at a high rate and allogeneic stem cell transplant is considered so far a better curative option in first remission Additional strategies have also included incorporation of TKIs in the post-transplant setting and the use of newer third generation TKIs This review provides an update on emerging therapies for adults with Ph-positive ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3006, 1170, 2058, 102, 83, 350, 16, 527, 4, 545, 179, 6, 201, 1, 857, 265, 5, 286, 1275, 62, 192, 71, 85, 41, 5, 1769, 356, 72, 5, 2058, 199, 62, 564, 216, 222, 1671, 529, 3, 1062, 1425, 1302, 178, 29, 26, 2006, 47, 85, 2449, 237, 24, 472, 95, 6, 943, 7, 5, 2058, 109, 62, 577, 71, 85, 3, 96, 1792, 95, 1379, 5, 392, 983, 143, 2069, 192, 1687, 380, 123, 198, 397, 5, 56, 1674, 8, 80, 1157, 230, 76, 577, 71, 120, 85, 194, 5, 721, 99, 137, 3713, 1234, 1271, 28, 8, 64, 116, 2, 1063, 452, 31, 941, 16, 515, 1743, 3272, 8, 380, 1075, 1501, 4, 157, 734, 402, 422, 47, 120, 159, 2838, 1, 1671, 4, 3, 539, 941, 546, 2, 3, 119, 1, 2246, 1282, 914, 1671, 26, 206, 777, 35, 2991, 23, 1478, 235, 9, 857, 5, 2058, 109, 62]",977.0,22669492,169
Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2012-06-12,"Treatment of the central nervous system (CNS) is an essential therapy component for childhood acute lymphoblastic leukemia (ALL). Individual patient data from 47 trials addressing 16 CNS treatment comparisons were analyzed. Event-free survival (EFS) was similar for radiotherapy versus intrathecal (IT), and radiotherapy plus IT versus IV methotrexate (IV MTX) plus IT. Triple intrathecal therapy (TIT) gave similar EFS but poorer survival than intrathecal methotrexate (IT MTX), but additional IV MTX improved both outcomes. One trial resulted in similar EFS and survival with IV MTX plus IT MTX versus TIT alone. Radiotherapy can generally be replaced by IT therapy. TIT should be used with effective systemic therapy such as IV MTX.",Journal Article,2779.0,41.0,Treatment of the central nervous system CNS is an essential therapy component for childhood acute lymphoblastic ALL Individual patient data from 47 trials addressing 16 CNS treatment comparisons were analyzed Event-free survival EFS was similar for radiotherapy versus intrathecal IT and radiotherapy plus IT versus IV methotrexate IV MTX plus IT Triple intrathecal therapy TIT gave similar EFS but poorer survival than intrathecal methotrexate IT MTX but additional IV MTX improved both outcomes One trial resulted in similar EFS and survival with IV MTX plus IT MTX versus TIT alone Radiotherapy can generally be replaced by IT therapy TIT should be used with effective systemic therapy such as IV MTX,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 3, 854, 1880, 398, 1025, 16, 35, 1452, 36, 1249, 9, 864, 286, 1275, 62, 797, 69, 74, 29, 662, 143, 3432, 245, 1025, 24, 2213, 11, 311, 774, 115, 25, 1683, 10, 288, 9, 310, 185, 5126, 192, 2, 310, 349, 192, 185, 478, 2116, 478, 3453, 349, 192, 1500, 5126, 36, 40016, 6421, 288, 1683, 84, 1769, 25, 76, 5126, 2116, 192, 3453, 84, 402, 478, 3453, 231, 110, 123, 104, 160, 627, 4, 288, 1683, 2, 25, 5, 478, 3453, 349, 192, 3453, 185, 40016, 279, 310, 122, 1228, 40, 6928, 20, 192, 36, 40016, 257, 40, 95, 5, 323, 403, 36, 225, 22, 478, 3453]",703.0,22693038,624
How I treat hematologic emergencies in adults with acute leukemia.,Blood,Blood,2012-06-13,"Acute myeloid leukemia and acute lymphoblastic leukemia remain devastating diseases. Only approximately 40% of younger and 10% of older adults are long-term survivors. Although curing the leukemia is always the most formidable challenge, complications from the disease itself and its treatment are associated with significant morbidity and mortality. Such complications, discussed herein, include tumor lysis, hyperleukocytosis, cytarabine-induced cellebellar toxicity, acute promyelocytic leukemia differentiation syndrome, thrombohemorrhagic syndrome in acute promyelocytic leukemia, L-asparaginase-associated thrombosis, leukemic meningitis, neutropenic fever, neutropenic enterocolitis, and transfussion-associated GVHD. Whereas clinical trials form the backbone for the management of acute leukemia, emergent clinical situations, predictable or not, are common and do not readily lend themselves to clinical trial evaluation. Furthermore, practice guidelines are often lacking. Not only are prospective trials impractical because of the emergent nature of the issue at hand, but clinicians are often reluctant to randomize such patients. Extensive practical experience is crucial and, even if there is no consensus, management of such emergencies should be guided by an understanding of the underlying pathophysiologic mechanisms.",Case Reports,2778.0,40.0,Acute myeloid and acute lymphoblastic remain devastating diseases Only approximately 40 of younger and 10 of older adults are long-term survivors Although curing the is always the most formidable challenge complications from the disease itself and its treatment are associated with significant morbidity and mortality Such complications discussed herein include tumor lysis hyperleukocytosis cytarabine-induced cellebellar toxicity acute promyelocytic differentiation syndrome thrombohemorrhagic syndrome in acute promyelocytic L-asparaginase-associated thrombosis leukemic meningitis neutropenic fever neutropenic enterocolitis and transfussion-associated GVHD Whereas clinical trials form the backbone for the management of acute emergent clinical situations predictable or not are common and do not readily lend themselves to clinical trial evaluation Furthermore practice guidelines are often lacking Not only are prospective trials impractical because of the emergent nature of the issue at hand but clinicians are often reluctant to randomize such patients Extensive practical experience is crucial and even if there is no consensus management of such emergencies should be guided by an understanding of the underlying pathophysiologic mechanisms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 533, 2, 286, 1275, 918, 5778, 1342, 158, 705, 327, 1, 773, 2, 79, 1, 434, 857, 32, 319, 337, 332, 242, 12775, 3, 16, 3763, 3, 96, 11940, 1745, 521, 29, 3, 34, 4045, 2, 211, 24, 32, 41, 5, 93, 787, 2, 282, 225, 521, 1588, 1986, 643, 30, 4783, 15558, 1855, 277, 61572, 155, 286, 4300, 910, 681, 35385, 681, 4, 286, 4300, 805, 3709, 41, 2839, 2015, 10792, 3659, 2775, 3659, 14829, 2, 61573, 41, 1562, 547, 38, 143, 1297, 3, 7066, 9, 3, 284, 1, 286, 4348, 38, 5990, 7639, 15, 44, 32, 186, 2, 1022, 44, 3860, 12248, 5374, 6, 38, 160, 451, 798, 758, 677, 32, 629, 1941, 44, 158, 32, 482, 143, 16835, 408, 1, 3, 4348, 2202, 1, 3, 2537, 28, 2833, 84, 1490, 32, 629, 14770, 6, 26129, 225, 7, 1344, 3320, 730, 16, 2653, 2, 871, 492, 125, 16, 77, 1391, 284, 1, 225, 31618, 257, 40, 1808, 20, 35, 612, 1, 3, 1181, 11575, 483]",1252.0,22700723,137
Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.,American journal of hematology,Am. J. Hematol.,2012-06-22,"We investigated the prognostic impact of absolute lymphocyte count (ALC) following induction chemotherapy in newly diagnosed adult acute lymphoblastic leukemia (ALL). Patients with ALC 350 cells/L at day 28 had a median overall survival (OS) of 47.4 months when compared with 17.6 months for those with an ALC <350 cells/L (HR = 1.98, P = 0.007). Among patients who achieved a complete remission, median event-free survival (EFS) for those with ALC 350 cells/L on day 28 was 42.1 months when compared with 13.9 months in those with ALC <350 cells/L (HR = 2.08, P = 0.006). In multivariable analysis, the ALC on day 28 (<350 cells/L vs. 350 cells/L, P  .0004 for OS and EFS) along with WBC at diagnosis (6.0 or >30.0 K/L vs. >6.0-30.0 K/L, P  0.002 for OS and EFS) and cytogenetics (abnormal vs. normal, P = 0.002 for OS and P = 0.02 for EFS) were independent prognostic factors of both OS and EFS. Combining these three factors segregates patients in three well-defined risk groups. These data suggest that ALC can be used in combination with other prognostic features to better predict outcome and that targeting the immune system to improve ALC may be a worthwhile strategy in ALL.",Journal Article,2769.0,22.0,We investigated the prognostic impact of absolute lymphocyte count ALC following induction chemotherapy in newly diagnosed adult acute lymphoblastic ALL Patients with ALC 350 cells/L at day 28 had a median overall survival OS of 47.4 months when compared with 17.6 months for those with an ALC 350 cells/L HR 1.98 P 0.007 Among patients who achieved a complete remission median event-free survival EFS for those with ALC 350 cells/L on day 28 was 42.1 months when compared with 13.9 months in those with ALC 350 cells/L HR 2.08 P 0.006 In multivariable analysis the ALC on day 28 350 cells/L vs. 350 cells/L P  .0004 for OS and EFS along with WBC at diagnosis 6.0 or 30.0 K/L vs. 6.0-30.0 K/L P  0.002 for OS and EFS and cytogenetics abnormal vs. normal P 0.002 for OS and P 0.02 for EFS were independent prognostic factors of both OS and EFS Combining these three factors segregates patients in three well-defined risk groups These data suggest that ALC can be used in combination with other prognostic features to better predict outcome and that targeting the immune system to improve ALC may be a worthwhile strategy in ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 565, 3, 177, 345, 1, 1766, 1448, 1276, 3749, 366, 504, 56, 4, 732, 265, 780, 286, 1275, 62, 7, 5, 3749, 40027, 37, 5513, 28, 218, 339, 42, 8, 52, 63, 25, 118, 1, 662, 39, 53, 198, 72, 5, 269, 49, 53, 9, 135, 5, 35, 3749, 5408, 37, 5513, 168, 14, 1096, 19, 13, 1999, 107, 7, 54, 513, 8, 236, 734, 52, 774, 115, 25, 1683, 9, 135, 5, 3749, 40027, 37, 5513, 23, 218, 339, 10, 595, 14, 53, 198, 72, 5, 233, 83, 53, 4, 135, 5, 3749, 5408, 37, 5513, 168, 18, 1592, 19, 13, 1861, 4, 658, 65, 3, 3749, 23, 218, 339, 5408, 37, 5513, 105, 40027, 37, 5513, 19, 1552, 5295, 9, 118, 2, 1683, 1510, 5, 4685, 28, 147, 10020, 13, 15, 201, 13, 1634, 5513, 105, 49, 13, 201, 13, 1634, 5513, 19, 1552, 13, 1111, 9, 118, 2, 1683, 2, 2510, 1668, 105, 295, 19, 13, 1111, 9, 118, 2, 19, 13, 588, 9, 1683, 11, 306, 177, 130, 1, 110, 118, 2, 1683, 1525, 46, 169, 130, 23175, 7, 4, 169, 149, 395, 43, 271, 46, 74, 309, 17, 3749, 122, 40, 95, 4, 150, 5, 127, 177, 404, 6, 380, 678, 228, 2, 17, 529, 3, 250, 398, 6, 401, 3749, 68, 40, 8, 16203, 692, 4, 62]",1140.0,22729847,290
Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?,Blood,Blood,2012-06-22,"Improved supportive care, more precise risk stratification, and personalized chemotherapy based on the characteristics of leukemic cells and hosts (eg, pharmacokinetics and pharmacogenetics) have pushed the cure rate of childhood acute lymphoblastic leukemia to near 90%. Further increase in cure rate can be expected from the discovery of additional recurrent molecular lesions, coupled with the development of novel targeted treatment through high-throughput genomics and innovative drug-screening systems. We discuss specific areas of research that promise to further refine current treatment and to improve the cure rate and quality of life of the patients.",Journal Article,2769.0,314.0,Improved supportive care more precise risk stratification and personalized chemotherapy based on the characteristics of leukemic cells and hosts eg pharmacokinetics and pharmacogenetics have pushed the cure rate of childhood acute lymphoblastic to near 90 Further increase in cure rate can be expected from the discovery of additional recurrent molecular lesions coupled with the development of novel targeted treatment through high-throughput genomics and innovative drug-screening systems We discuss specific areas of research that promise to further refine current treatment and to improve the cure rate and quality of life of the patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[231, 1877, 165, 80, 3260, 43, 1541, 2, 2175, 56, 90, 23, 3, 374, 1, 2015, 37, 2, 9867, 2887, 1159, 2, 8759, 47, 28557, 3, 1722, 116, 1, 864, 286, 1275, 6, 1829, 424, 195, 344, 4, 1722, 116, 122, 40, 1336, 29, 3, 1574, 1, 402, 387, 219, 406, 3332, 5, 3, 193, 1, 229, 238, 24, 298, 64, 3643, 4229, 2, 4019, 234, 453, 1530, 21, 1139, 112, 1361, 1, 389, 17, 1783, 6, 195, 5003, 291, 24, 2, 6, 401, 3, 1722, 116, 2, 372, 1, 358, 1, 3, 7]",642.0,22730540,627
Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802.,Cancer,Cancer,2012-06-28,"Cancer and Leukemia Group B (CALGB) Study 19802, a phase 2 study, evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival (DFS) in adults with acute lymphoblastic leukemia (ALL) and whether high-dose systemic and intrathecal methotrexate could replace cranial radiotherapy for central nervous system (CNS) prophylaxis. One hundred sixty-one eligible, previously untreated patients ages 16 to 82 years (median age, 40 years) were enrolled, and 33 (20%) were aged 60 years. One hundred twenty-eight patients (80%) achieved complete remission (CR). Dose intensification of daunorubicin and cytarabine was feasible. At a median follow-up of 10.4 years for surviving patients, the 5-year DFS rate was 25% (95% confidence interval, 18%-33%), and the overall survival (OS) rate was 30% (95% confidence interval, 23%-37%). Patients aged <60 years who received the 80 mg/m(2) dose of daunorubicin had a DFS of 33% (95% confidence interval, 22%-44%) and an OS of 39% (95% confidence interval, 29%-49%) at 5 years. Eighty-four patients (52%) relapsed, including 9 patients (6%) who had isolated CNS relapses. The omission of cranial irradiation did not result in higher than historic CNS relapse rates. Intensive systemic, oral, and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL. This intensive approach using higher doses of daunorubicin and cytarabine failed to result in an overall improvement in DFS or OS compared with historic CALGB studies. Future therapeutic strategies for adults with ALL should be tailored to specific age and molecular genetic subsets.","Clinical Trial, Phase II",2763.0,63.0,Cancer and Group B CALGB Study 19802 a phase 2 study evaluated whether dose intensification of daunorubicin and cytarabine could improve disease-free survival DFS in adults with acute lymphoblastic ALL and whether high-dose systemic and intrathecal methotrexate could replace cranial radiotherapy for central nervous system CNS prophylaxis One hundred sixty-one eligible previously untreated patients ages 16 to 82 years median age 40 years were enrolled and 33 20 were aged 60 years One hundred twenty-eight patients 80 achieved complete remission CR Dose intensification of daunorubicin and cytarabine was feasible At a median follow-up of 10.4 years for surviving patients the 5-year DFS rate was 25 95 confidence interval 18 -33 and the overall survival OS rate was 30 95 confidence interval 23 -37 Patients aged 60 years who received the 80 mg/m 2 dose of daunorubicin had a DFS of 33 95 confidence interval 22 -44 and an OS of 39 95 confidence interval 29 -49 at 5 years Eighty-four patients 52 relapsed including 9 patients 6 who had isolated CNS relapses The omission of cranial irradiation did not result in higher than historic CNS relapse rates Intensive systemic oral and intrathecal methotrexate dosing permitted the omission of CNS irradiation in adult patients with ALL This intensive approach using higher doses of daunorubicin and cytarabine failed to result in an overall improvement in DFS or OS compared with historic CALGB studies Future therapeutic strategies for adults with ALL should be tailored to specific age and molecular genetic subsets,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[12, 2, 87, 132, 4077, 45, 61624, 8, 124, 18, 45, 194, 317, 61, 5091, 1, 5247, 2, 1855, 359, 401, 34, 115, 25, 1010, 4, 857, 5, 286, 1275, 62, 2, 317, 64, 61, 403, 2, 5126, 2116, 359, 7195, 2565, 310, 9, 854, 1880, 398, 1025, 2049, 104, 1128, 1746, 104, 625, 373, 1278, 7, 2165, 245, 6, 878, 60, 52, 89, 327, 60, 11, 346, 2, 466, 179, 11, 1032, 6690, 60, 104, 1128, 737, 659, 7, 493, 513, 236, 734, 684, 61, 5091, 1, 5247, 2, 1855, 10, 1313, 28, 8, 52, 166, 126, 1, 79, 39, 60, 9, 3050, 7, 3, 33, 111, 1010, 116, 10, 243, 48, 307, 268, 203, 466, 2, 3, 63, 25, 118, 116, 10, 201, 48, 307, 268, 382, 567, 7, 1032, 335, 60, 54, 103, 3, 493, 81, 188, 18, 61, 1, 5247, 42, 8, 1010, 1, 466, 48, 307, 268, 350, 584, 2, 35, 118, 1, 587, 48, 307, 268, 462, 739, 28, 33, 60, 2207, 294, 7, 653, 591, 141, 83, 7, 49, 54, 42, 1355, 1025, 3713, 3, 5736, 1, 2565, 1104, 205, 44, 757, 4, 142, 76, 6875, 1025, 429, 151, 1686, 403, 518, 2, 5126, 2116, 1280, 5449, 3, 5736, 1, 1025, 1104, 4, 780, 7, 5, 62, 26, 1686, 353, 75, 142, 415, 1, 5247, 2, 1855, 1551, 6, 757, 4, 35, 63, 767, 4, 1010, 15, 118, 72, 5, 6875, 4077, 94, 508, 189, 422, 9, 857, 5, 62, 257, 40, 3632, 6, 112, 89, 2, 219, 336, 1890]",1567.0,22744771,717
Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2012-06-29,"We investigated the safety and early disease control data for i.v. busulfan (Bu) in combination with clofarabine (Clo) in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation (SCT). Fifty-one patients (median age, 36 years; range, 20-64 years) received a matched sibling (n = 24), syngeneic (n = 2), or matched unrelated donor transplant (n = 25) for acute lymphoblastic leukemia in first complete remission (n = 30), second complete remission (n = 13), or active disease (n = 8). More than one-half of the patients had a high-risk cytogenetic profile, as defined by the presence of t(9;22) (n = 17), t(4;11) (n = 3), or complex cytogenetics (n = 7). Clo 40 mg/m(2) was given once daily, with each dose followed by pharmacokinetically dosed Bu infused over 3 hours daily for 4 days, followed by hematopoietic SCT 2 days later. The Bu dose was based on drug clearance, as determined by the patient's response to a 32-mg/m(2) Bu test dose given 48 hours before the high-dose regimen. The target daily area under the receiver-operating characteristic curve was 5500 M/min for patients age <60 years and 4000 M/min for those age 60 years. The regimen was well tolerated, with a 100-day nonrelapse mortality rate of 6%. With a median follow-up of 14 months among surviving patients (range, 6-28 months), the 1-year overall survival, disease-free survival, and nonrelapse mortality rates were 67% (95% confidence interval [CI], 55%-83%), 54% (95% CI, 41%-71%), and 32% (95% CI, 16%-45%), respectively. For patients undergoing SCT in first remission, these respective rates were 74%, 64%, and 25%. Our data indicate that the combination of Clo and Bu provides effective disease control while maintaining a favorable safety profile.","Clinical Trial, Phase II",2762.0,26.0,We investigated the safety and early disease control data for i.v busulfan Bu in combination with clofarabine Clo in patients with acute lymphoblastic undergoing allogeneic hematopoietic stem cell transplantation SCT Fifty-one patients median age 36 years range 20-64 years received a matched sibling n 24 syngeneic n 2 or matched unrelated donor transplant n 25 for acute lymphoblastic in first complete remission n 30 second complete remission n 13 or active disease n 8 More than one-half of the patients had a high-risk cytogenetic profile as defined by the presence of t 9 22 n 17 t 4 11 n 3 or complex cytogenetics n 7 Clo 40 mg/m 2 was given once daily with each dose followed by pharmacokinetically dosed Bu infused over 3 hours daily for 4 days followed by hematopoietic SCT 2 days later The Bu dose was based on drug clearance as determined by the patient 's response to a 32-mg/m 2 Bu test dose given 48 hours before the high-dose regimen The target daily area under the receiver-operating characteristic curve was 5500 M/min for patients age 60 years and 4000 M/min for those age 60 years The regimen was well tolerated with a 100-day nonrelapse mortality rate of 6 With a median follow-up of 14 months among surviving patients range 6-28 months the 1-year overall survival disease-free survival and nonrelapse mortality rates were 67 95 confidence interval CI 55 -83 54 95 CI 41 -71 and 32 95 CI 16 -45 respectively For patients undergoing SCT in first remission these respective rates were 74 64 and 25 Our data indicate that the combination of Clo and Bu provides effective disease control while maintaining a favorable safety profile,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 565, 3, 367, 2, 191, 34, 182, 74, 9, 70, 603, 3906, 3667, 4, 150, 5, 4149, 7676, 4, 7, 5, 286, 1275, 479, 1063, 1007, 452, 31, 497, 1988, 1461, 104, 7, 52, 89, 511, 60, 184, 179, 660, 60, 103, 8, 655, 3684, 78, 259, 5174, 78, 18, 15, 655, 2092, 1488, 941, 78, 243, 9, 286, 1275, 4, 157, 236, 734, 78, 201, 419, 236, 734, 78, 233, 15, 544, 34, 78, 66, 80, 76, 104, 1303, 1, 3, 7, 42, 8, 64, 43, 1266, 800, 22, 395, 20, 3, 463, 1, 102, 83, 350, 78, 269, 102, 39, 175, 78, 27, 15, 840, 2510, 78, 67, 7676, 327, 81, 188, 18, 10, 447, 1059, 391, 5, 296, 61, 370, 20, 14920, 6268, 3667, 4524, 252, 27, 1459, 391, 9, 39, 162, 370, 20, 1007, 1988, 18, 162, 1559, 3, 3667, 61, 10, 90, 23, 234, 1960, 22, 509, 20, 3, 69, 292, 51, 6, 8, 531, 81, 188, 18, 3667, 412, 61, 447, 576, 1459, 348, 3, 64, 61, 477, 3, 283, 391, 965, 669, 3, 3185, 2584, 2037, 1496, 10, 25980, 4810, 1538, 9, 7, 89, 335, 60, 2, 10660, 4810, 1538, 9, 135, 89, 6690, 60, 3, 477, 10, 149, 421, 5, 8, 394, 218, 4640, 282, 116, 1, 49, 5, 8, 52, 166, 126, 1, 213, 53, 107, 3050, 7, 184, 49, 339, 53, 3, 14, 111, 63, 25, 34, 115, 25, 2, 4640, 282, 151, 11, 598, 48, 307, 268, 58, 614, 852, 667, 48, 58, 605, 792, 2, 531, 48, 58, 245, 512, 106, 9, 7, 479, 1988, 4, 157, 734, 46, 3847, 151, 11, 794, 660, 2, 243, 114, 74, 1008, 17, 3, 150, 1, 7676, 2, 3667, 777, 323, 34, 182, 369, 3284, 8, 913, 367, 800]",1652.0,22750645,682
Acute lymphoblastic leukemia.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2012-07-01,"The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment approaches based on the Philadelphia chromosome status and age (adults vs. adolescents/young adults), assessment of minimal residual disease, and supportive care considerations. It is recommended that patients be treated at specialized centers with expertise in the management of ALL.",Journal Article,2760.0,38.0,The inaugural NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines for acute lymphoblastic ALL were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011 These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL risk assessment risk-stratified treatment approaches based on the Philadelphia chromosome status and age adults vs. adolescents/young adults assessment of minimal residual disease and supportive care considerations It is recommended that patients be treated at specialized centers with expertise in the management of ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 31999, 1944, 38, 758, 677, 4, 413, 1944, 677, 9, 286, 1275, 62, 11, 276, 22, 8, 757, 1, 6941, 4440, 20, 8, 1414, 15726, 993, 1, 3186, 4, 1132, 46, 1944, 677, 377, 883, 23, 3, 752, 451, 2, 4755, 9, 62, 43, 455, 43, 1173, 24, 611, 90, 23, 3, 3006, 1170, 156, 2, 89, 857, 105, 3101, 1169, 857, 455, 1, 1048, 753, 34, 2, 1877, 165, 3891, 192, 16, 793, 17, 7, 40, 73, 28, 4791, 1168, 5, 4935, 4, 3, 284, 1, 62]",615.0,22773801,257
PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.,Human molecular genetics,Hum. Mol. Genet.,2012-07-30,"Treatment-related toxicity can be life-threatening and is the primary cause of interruption or discontinuation of chemotherapy for acute lymphoblastic leukemia (ALL), leading to an increased risk of relapse. Mercaptopurine is an essential component of continuation therapy in all ALL treatment protocols worldwide. Genetic polymorphisms in thiopurine S-methyltransferase (TPMT) are known to have a marked effect on mercaptopurine metabolism and toxicity; however, some patients with wild-type TPMT develop toxicity during mercaptopurine treatment for reasons that are not well understood. To identify additional genetic determinants of mercaptopurine toxicity, a genome-wide analysis was performed in a panel of human HapMap cell lines to identify trans-acting genes whose expression and/or single-nucleotide polymorphisms (SNPs) are related to TPMT activity, then validated in patients with ALL. The highest ranking gene with both mRNA expression and SNPs associated with TPMT activity in HapMap cell lines was protein kinase C and casein kinase substrate in neurons 2 (PACSIN2). The association of a PACSIN2 SNP (rs2413739) with TPMT activity was confirmed in patients and knock-down of PACSIN2 mRNA in human leukemia cells (NALM6) resulted in significantly lower TPMT activity. Moreover, this PACSIN2 SNP was significantly associated with the incidence of severe gastrointestinal (GI) toxicity during consolidation therapy containing mercaptopurine, and remained significant in a multivariate analysis including TPMT and SLCO1B1 as covariates, consistent with its influence on TPMT activity. The association with GI toxicity was also validated in a separate cohort of pediatric patients with ALL. These data indicate that polymorphism in PACSIN2 significantly modulates TPMT activity and influences the risk of GI toxicity associated with mercaptopurine therapy.",Journal Article,2731.0,39.0,Treatment-related toxicity can be life-threatening and is the primary cause of interruption or discontinuation of chemotherapy for acute lymphoblastic ALL leading to an increased risk of relapse Mercaptopurine is an essential component of continuation therapy in all ALL treatment protocols worldwide Genetic polymorphisms in thiopurine S-methyltransferase TPMT are known to have a marked effect on mercaptopurine metabolism and toxicity however some patients with wild-type TPMT develop toxicity during mercaptopurine treatment for reasons that are not well understood To identify additional genetic determinants of mercaptopurine toxicity a genome-wide analysis was performed in a panel of human HapMap cell lines to identify trans-acting genes whose expression and/or single-nucleotide polymorphisms SNPs are related to TPMT activity then validated in patients with ALL The highest ranking gene with both mRNA expression and SNPs associated with TPMT activity in HapMap cell lines was protein kinase C and casein kinase substrate in neurons 2 PACSIN2 The association of a PACSIN2 SNP rs2413739 with TPMT activity was confirmed in patients and knock-down of PACSIN2 mRNA in human cells NALM6 resulted in significantly lower TPMT activity Moreover this PACSIN2 SNP was significantly associated with the incidence of severe GI toxicity during consolidation therapy containing mercaptopurine and remained significant in a multivariate analysis including TPMT and SLCO1B1 as covariates consistent with its influence on TPMT activity The association with GI toxicity was also validated in a separate cohort of pediatric patients with ALL These data indicate that polymorphism in PACSIN2 significantly modulates TPMT activity and influences the risk of GI toxicity associated with mercaptopurine therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 139, 155, 122, 40, 358, 3691, 2, 16, 3, 86, 708, 1, 4823, 15, 2007, 1, 56, 9, 286, 1275, 62, 1049, 6, 35, 101, 43, 1, 429, 9223, 16, 35, 1452, 1249, 1, 6870, 36, 4, 62, 62, 24, 2189, 2358, 336, 1203, 4, 14062, 695, 3747, 14852, 32, 440, 6, 47, 8, 2003, 254, 23, 9223, 1600, 2, 155, 137, 476, 7, 5, 955, 267, 14852, 690, 155, 190, 9223, 24, 9, 2325, 17, 32, 44, 149, 1784, 6, 255, 402, 336, 3403, 1, 9223, 155, 8, 898, 1019, 65, 10, 173, 4, 8, 993, 1, 171, 13961, 31, 285, 6, 255, 3437, 5375, 214, 1310, 55, 2, 15, 226, 1579, 1203, 1109, 32, 139, 6, 14852, 128, 818, 938, 4, 7, 5, 62, 3, 1076, 11185, 145, 5, 110, 956, 55, 2, 1109, 41, 5, 14852, 128, 4, 13961, 31, 285, 10, 178, 216, 256, 2, 18145, 216, 4235, 4, 11930, 18, 32011, 3, 248, 1, 8, 32011, 1845, 61717, 5, 14852, 128, 10, 557, 4, 7, 2, 6252, 1328, 1, 32011, 956, 4, 171, 37, 40068, 627, 4, 97, 280, 14852, 128, 1393, 26, 32011, 1845, 10, 97, 41, 5, 3, 287, 1, 905, 2104, 155, 190, 2173, 36, 1101, 9223, 2, 958, 93, 4, 8, 331, 65, 141, 14852, 2, 13693, 22, 2489, 925, 5, 211, 1054, 23, 14852, 128, 3, 248, 5, 2104, 155, 10, 120, 938, 4, 8, 2282, 180, 1, 815, 7, 5, 62, 46, 74, 1008, 17, 1907, 4, 32011, 97, 5259, 14852, 128, 2, 3859, 3, 43, 1, 2104, 155, 41, 5, 9223, 36]",1799.0,22846425,43
Relapsed or refractory pediatric acute lymphoblastic leukemia: current and emerging treatments.,Paediatric drugs,Paediatr Drugs,2012-12-01,"Relapsed acute lymphoblastic leukemia (ALL) represents a major cause of morbidity and mortality in pediatrics. With contemporary chemotherapy, >85% of patients with newly diagnosed ALL survive. Unfortunately, 20% of these patients will relapse and for these children, outcomes remain poor despite our best known chemotherapy protocols. Most of these children will achieve a second complete remission, but maintaining this remission remains difficult. Because relapsed ALL is such a significant cause of morbidity and mortality, it is the focus of much research interest. Efforts have been made and continue to focus on understanding the underlying biology that drives relapse. The role of hematopoietic stem cell transplantation in relapsed ALL remains unclear, but many clinicians still favor this for high-risk patients given the poor prognosis with current chemotherapy alone. It is important to use new drugs with little cross-resistance in the treatment of relapsed ALL. New classes of agents are currently being studied. We also discuss prognostic factors and the biology of relapsed ALL.",Journal Article,2607.0,9.0,Relapsed acute lymphoblastic ALL represents a major cause of morbidity and mortality in pediatrics With contemporary chemotherapy 85 of patients with newly diagnosed ALL survive Unfortunately 20 of these patients will relapse and for these children outcomes remain poor despite our best known chemotherapy protocols Most of these children will achieve a second complete remission but maintaining this remission remains difficult Because relapsed ALL is such a significant cause of morbidity and mortality it is the focus of much research interest Efforts have been made and continue to focus on understanding the underlying biology that drives relapse The role of hematopoietic stem cell transplantation in relapsed ALL remains unclear but many clinicians still favor this for high-risk patients given the poor prognosis with current chemotherapy alone It is important to use new drugs with little cross-resistance in the treatment of relapsed ALL New classes of agents are currently being studied We also discuss prognostic factors and the biology of relapsed ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[591, 286, 1275, 62, 1449, 8, 458, 708, 1, 787, 2, 282, 4, 12616, 5, 2667, 56, 772, 1, 7, 5, 732, 265, 62, 4573, 3869, 179, 1, 46, 7, 303, 429, 2, 9, 46, 541, 123, 918, 334, 550, 114, 824, 440, 56, 2189, 96, 1, 46, 541, 303, 1359, 8, 419, 236, 734, 84, 3284, 26, 734, 469, 1740, 408, 591, 62, 16, 225, 8, 93, 708, 1, 787, 2, 282, 192, 16, 3, 1222, 1, 1802, 389, 1333, 1413, 47, 85, 1229, 2, 1906, 6, 1222, 23, 612, 3, 1181, 891, 17, 5267, 429, 3, 200, 1, 1007, 452, 31, 497, 4, 591, 62, 469, 1200, 84, 445, 1490, 1234, 4283, 26, 9, 64, 43, 7, 447, 3, 334, 356, 5, 291, 56, 279, 192, 16, 305, 6, 119, 217, 600, 5, 1215, 1383, 251, 4, 3, 24, 1, 591, 62, 217, 3211, 1, 183, 32, 694, 486, 656, 21, 120, 1139, 177, 130, 2, 3, 891, 1, 591, 62]",1064.0,22880941,117
Prospective randomized crossover evaluation of three anesthetic regimens for painful procedures in children with cancer.,The Journal of pediatrics,J. Pediatr.,2012-08-09,"To identify the most effective sedation regimen for bone marrow aspiration and lumbar puncture procedures with a prospective trial of 3 combinations of sedation/analgesia. In this double-blind crossover study, we randomly assigned 162 children with acute lymphoblastic leukemia or lymphoblastic lymphoma to receive fentanyl 1 mcg/kg, fentanyl 0.5 mcg/kg, or placebo, in addition to propofol and topical anesthetic for 355 procedures. We found no significant differences among the 3 regimens in the frequency of pain (pain score > 0) or severe pain (pain score  5) during recovery, or a >20% increase in hemodynamic/respiratory variables during anesthesia. Treatment with fentanyl 1 mcg/kg was associated with a lower frequency of movement during procedure compared with treatment with fentanyl 0.5 mcg/kg (P = .0476) or treatment with placebo (P = .0545). The placebo group required longer time to recover (median, 18 minutes) compared with the fentanyl 0.5 mcg/kg group (median, 9 minutes) (median difference 2.0, P = .007) and the fentanyl 1 mcg/kg (median 8 minutes), (median difference 2.0, P = .15). The placebo group also required larger total dose of propofol (median 5 mg/kg) compared with that of the fentanyl 1 mcg/kg group (median, 3.5 mg/kg) and the fentanyl 0.5 mcg/kg group (median 3.5 mg/kg) (median differences 1.5, P < .00005, in both comparisons). The addition of fentanyl 1 mcg/kg to propofol for brief painful procedures reduces movement, propofol dose, and recovery time.",Comparative Study,2721.0,12.0,To identify the most effective sedation regimen for marrow aspiration and lumbar puncture procedures with a prospective trial of 3 combinations of sedation/analgesia In this double-blind crossover study we randomly assigned 162 children with acute lymphoblastic or lymphoblastic to receive fentanyl 1 mcg/kg fentanyl 0.5 mcg/kg or placebo in addition to propofol and topical anesthetic for 355 procedures We found no significant differences among the 3 regimens in the frequency of pain pain score 0 or severe pain pain score  5 during recovery or a 20 increase in hemodynamic/respiratory variables during anesthesia Treatment with fentanyl 1 mcg/kg was associated with a lower frequency of movement during procedure compared with treatment with fentanyl 0.5 mcg/kg P .0476 or treatment with placebo P .0545 The placebo group required longer time to recover median 18 minutes compared with the fentanyl 0.5 mcg/kg group median 9 minutes median difference 2.0 P .007 and the fentanyl 1 mcg/kg median 8 minutes median difference 2.0 P .15 The placebo group also required larger total dose of propofol median 5 mg/kg compared with that of the fentanyl 1 mcg/kg group median 3.5 mg/kg and the fentanyl 0.5 mcg/kg group median 3.5 mg/kg median differences 1.5 P .00005 in both comparisons The addition of fentanyl 1 mcg/kg to propofol for brief painful procedures reduces movement propofol dose and recovery time,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 255, 3, 96, 323, 7764, 477, 9, 581, 3256, 2, 6187, 12104, 1369, 5, 8, 482, 160, 1, 27, 1247, 1, 7764, 7737, 4, 26, 1627, 3142, 5265, 45, 21, 1108, 896, 5441, 541, 5, 286, 1275, 15, 1275, 6, 560, 11053, 14, 7969, 503, 11053, 13, 33, 7969, 503, 15, 619, 4, 352, 6, 29334, 2, 5879, 14926, 9, 8370, 1369, 21, 204, 77, 93, 362, 107, 3, 27, 472, 4, 3, 675, 1, 559, 559, 368, 13, 15, 905, 559, 559, 368, 749, 33, 190, 1602, 15, 8, 179, 344, 4, 10554, 2718, 682, 190, 6433, 24, 5, 11053, 14, 7969, 503, 10, 41, 5, 8, 280, 675, 1, 7950, 190, 1299, 72, 5, 24, 5, 11053, 13, 33, 7969, 503, 19, 61759, 15, 24, 5, 619, 19, 61760, 3, 619, 87, 616, 589, 98, 6, 9966, 52, 203, 2511, 72, 5, 3, 11053, 13, 33, 7969, 503, 87, 52, 83, 2511, 52, 523, 18, 13, 19, 1999, 2, 3, 11053, 14, 7969, 503, 52, 66, 2511, 52, 523, 18, 13, 19, 167, 3, 619, 87, 120, 616, 1077, 181, 61, 1, 29334, 52, 33, 81, 503, 72, 5, 17, 1, 3, 11053, 14, 7969, 503, 87, 52, 27, 33, 81, 503, 2, 3, 11053, 13, 33, 7969, 503, 87, 52, 27, 33, 81, 503, 52, 362, 14, 33, 19, 21189, 4, 110, 2213, 3, 352, 1, 11053, 14, 7969, 503, 6, 29334, 9, 3190, 7041, 1369, 2389, 7950, 29334, 61, 2, 1602, 98]",1408.0,22883421,705
Functional and structural differences in the hippocampus associated with memory deficits in adult survivors of acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2012-08-08,"Radiation and chemotherapy targeted to the central nervous system (CNS) can cause cognitive impairment, including impaired memory. These memory impairments may be referable to damage to hippocampal structures resulting from CNS treatment. In the present study, we explored episodic memory and its neuroimaging correlates in 10 adult survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy and both systemic and intrathecal chemotherapy and 10 controls matched for age and sex, using a subsequent memory paradigm after episodic encoding of visual scenes. We report behavioral, structural, and functional changes in the brains of the adult survivors. They demonstrated poorer recognition memory, hippocampal atrophy, and altered blood oxygenation level-dependent (BOLD) signal in the hippocampus. Whole brain statistical map analysis revealed increased BOLD signal/activation in several brain regions during unsuccessful encoding in ALL survivors, potentially reflecting ineffective neural recruitment. Individual differences in memory performance in ALL participants were related to magnitude of BOLD response in regions associated with successful encoding. Taken together, these findings describe long term neuroimaging correlates of cognitive dysfunction after childhood exposure to CNS-targeted cancer therapies, suggesting enduring damage to episodic memory systems.",Journal Article,2722.0,29.0,Radiation and chemotherapy targeted to the central nervous system CNS can cause cognitive impairment including impaired memory These memory impairments may be referable to damage to hippocampal structures resulting from CNS treatment In the present study we explored episodic memory and its neuroimaging correlates in 10 adult survivors of childhood acute lymphoblastic ALL treated with cranial radiation therapy and both systemic and intrathecal chemotherapy and 10 controls matched for age and sex using a subsequent memory paradigm after episodic encoding of visual scenes We report behavioral structural and functional changes in the brains of the adult survivors They demonstrated poorer recognition memory hippocampal atrophy and altered blood oxygenation level-dependent BOLD signal in the hippocampus Whole brain statistical map analysis revealed increased BOLD signal/activation in several brain regions during unsuccessful encoding in ALL survivors potentially reflecting ineffective neural recruitment Individual differences in memory performance in ALL participants were related to magnitude of BOLD response in regions associated with successful encoding Taken together these findings describe long term neuroimaging correlates of cognitive dysfunction after childhood exposure to CNS-targeted cancer therapies suggesting enduring damage to episodic memory systems,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[121, 2, 56, 238, 6, 3, 854, 1880, 398, 1025, 122, 708, 1863, 2315, 141, 2364, 2407, 46, 2407, 6948, 68, 40, 26021, 6, 1350, 6, 16469, 2414, 1113, 29, 1025, 24, 4, 3, 364, 45, 21, 1443, 23258, 2407, 2, 211, 7468, 1871, 4, 79, 780, 332, 1, 864, 286, 1275, 62, 73, 5, 2565, 121, 36, 2, 110, 403, 2, 5126, 56, 2, 79, 535, 655, 9, 89, 2, 1035, 75, 8, 706, 2407, 2431, 50, 23258, 2362, 1, 3046, 61766, 21, 414, 4166, 3281, 2, 583, 400, 4, 3, 13859, 1, 3, 780, 332, 491, 264, 1769, 2335, 2407, 16469, 7637, 2, 1495, 315, 9593, 301, 470, 17515, 1235, 4, 3, 17944, 902, 342, 1050, 3771, 65, 553, 101, 17515, 1235, 363, 4, 392, 342, 1374, 190, 7581, 2362, 4, 62, 332, 751, 4777, 3957, 3922, 3202, 797, 362, 4, 2407, 528, 4, 62, 776, 11, 139, 6, 3131, 1, 17515, 51, 4, 1374, 41, 5, 1401, 2362, 1633, 1162, 46, 272, 897, 319, 337, 7468, 1871, 1, 1863, 1527, 50, 864, 645, 6, 1025, 238, 12, 235, 802, 23790, 1350, 6, 23258, 2407, 1530]",1377.0,22887801,372
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia.,Cancer cell,Cancer Cell,2012-08-01,"Genomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic leukemia (B-ALL) with alteration of IKZF1, a gene expression profile similar to BCR-ABL1-positive ALL and poor outcome (Ph-like ALL). The genetic alterations that activate kinase signaling in Ph-like ALL are poorly understood. We performed transcriptome and whole genome sequencing on 15 cases of Ph-like ALL and identified rearrangements involving ABL1, JAK2, PDGFRB, CRLF2, and EPOR, activating mutations of IL7R and FLT3, and deletion of SH2B3, which encodes the JAK2-negative regulator LNK. Importantly, several of these alterations induce transformation that is attenuated with tyrosine kinase inhibitors, suggesting the treatment outcome of these patients may be improved with targeted therapy.",Journal Article,2729.0,388.0,Genomic profiling has identified a subtype of high-risk B-progenitor acute lymphoblastic B-ALL with alteration of IKZF1 a gene expression profile similar to BCR-ABL1-positive ALL and poor outcome Ph-like ALL The genetic alterations that activate kinase signaling in Ph-like ALL are poorly understood We performed transcriptome and whole genome sequencing on 15 cases of Ph-like ALL and identified rearrangements involving ABL1 JAK2 PDGFRB CRLF2 and EPOR activating mutations of IL7R and FLT3 and deletion of SH2B3 which encodes the JAK2-negative regulator LNK Importantly several of these alterations induce transformation that is attenuated with tyrosine kinase inhibitors suggesting the treatment outcome of these patients may be improved with targeted therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[572, 1080, 71, 108, 8, 875, 1, 64, 43, 132, 2520, 286, 1275, 132, 62, 5, 2611, 1, 8422, 8, 145, 55, 800, 288, 6, 1062, 3557, 109, 62, 2, 334, 228, 2058, 733, 62, 3, 336, 593, 17, 2977, 216, 314, 4, 2058, 733, 62, 32, 1240, 1784, 21, 173, 3917, 2, 902, 898, 615, 23, 167, 140, 1, 2058, 733, 62, 2, 108, 2072, 1267, 3557, 2509, 10231, 8895, 2, 12839, 1616, 138, 1, 22756, 2, 1224, 2, 1528, 1, 22757, 92, 4322, 3, 2509, 199, 2452, 40080, 1859, 392, 1, 46, 593, 1290, 1392, 17, 16, 2656, 5, 564, 216, 222, 802, 3, 24, 228, 1, 46, 7, 68, 40, 231, 5, 238, 36]",762.0,22897847,25
Secondary acute myelogenous leukemia (AML) with trisomy 10 and del(9q) following precursor B-cell acute lymphoblastic leukemia (ALL) with a hyperdiploid karyotype.,Cancer genetics,Cancer Genet,2012-09-01,"Acute myelogenous leukemia (AML) secondary to acute lymphoblastic leukemia (ALL) in children is uncommon and usually occurs within 10 years of completing therapy for ALL. A variety of recurrent cytogenetic abnormalities have been described, suggesting significant biological heterogeneity. We report a case of highly refractory secondary AML with trisomy 10 and del(9q) occurring in an adolescent female 12 years after she was treated successfully for precursor B-cell ALL with chemotherapy only.",Case Reports,2698.0,0.0,Acute myelogenous AML secondary to acute lymphoblastic ALL in children is uncommon and usually occurs within 10 years of completing therapy for ALL A variety of recurrent cytogenetic abnormalities have been described suggesting significant biological heterogeneity We report a case of highly refractory secondary AML with trisomy 10 and del 9q occurring in an adolescent female 12 years after she was treated successfully for precursor B-cell ALL with chemotherapy only,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 2194, 329, 568, 6, 286, 1275, 62, 4, 541, 16, 2052, 2, 2082, 1780, 262, 79, 60, 1, 4144, 36, 9, 62, 8, 1362, 1, 387, 1266, 1171, 47, 85, 1027, 802, 93, 1037, 1144, 21, 414, 8, 473, 1, 561, 430, 568, 329, 5, 6317, 79, 2, 3084, 20998, 1821, 4, 35, 3678, 1061, 133, 60, 50, 3109, 10, 73, 1878, 9, 2765, 132, 31, 62, 5, 56, 158]",469.0,22944559,28
Association of bone mineral density with incidental renal stone in long-term survivors of childhood acute lymphoblastic leukemia.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2012-09-06,"Our objective was to evaluate the association between low bone mineral density (BMD) and incidental renal stones among long-term survivors of childhood acute lymphoblastic leukemia (ALL). Adult participants who were 10+years from their childhood ALL diagnosis and members of the St. Jude Lifetime Cohort study were recruited between December 2007 and March 2011. During their risk-based medical evaluations, they underwent quantitative computed tomography (QCT) to evaluate BMD. Incidental renal stones were identified by radiologists' review of axial QCT source images. Demographic and dietary information were abstracted from health surveys and the Block Food Frequency questionnaire, respectively. The multivariable logistic regression model was used for analysis. At a median of 26.1years from diagnosis, BMD Z scores were -2 in 34 of 662 (5.2%) and renal stones detected in 73 of 662 (11%) participants. Adjusted for age, renal radiation, dietary vitamin D, gender, and body mass index, when compared to those with BMD Z scores 0, the risk of renal stones was increased among those with BMD Z scores -2 (odds ratio [OR], 2.92; 95% confidence interval [CI] 1.14-7.48). Risk of renal stones significantly increased for older age (45-54 vs.18-24years; OR, 3.70; 95% CI 1.11-12.35) whereas the risk was higher but nonsignificant for >141.5IU (sample median) daily intake of vitamin D (OR, 1.64; 95% CI 0.98-2.75). Older ALL survivors with BMD Z scores -2 are at risk for renal stones and should be counseled so that appropriate follow-up care can be provided for those among whom renal stones are detected.",Journal Article,2693.0,3.0,Our objective was to evaluate the association between low mineral density BMD and incidental stones among long-term survivors of childhood acute lymphoblastic ALL Adult participants who were 10+ years from their childhood ALL diagnosis and members of the St. Jude Lifetime Cohort study were recruited between December 2007 and March 2011 During their risk-based medical evaluations they underwent quantitative computed tomography QCT to evaluate BMD Incidental stones were identified by radiologists review of axial QCT source images Demographic and dietary information were abstracted from health surveys and the Block Food Frequency questionnaire respectively The multivariable logistic regression model was used for analysis At a median of 26.1 years from diagnosis BMD Z scores were -2 in 34 of 662 5.2 and stones detected in 73 of 662 11 participants Adjusted for age radiation dietary vitamin D gender and body mass index when compared to those with BMD Z scores 0 the risk of stones was increased among those with BMD Z scores -2 odds ratio OR 2.92 95 confidence interval CI 1.14-7.48 Risk of stones significantly increased for older age 45-54 vs.18-24 years OR 3.70 95 CI 1.11-12.35 whereas the risk was higher but nonsignificant for 141.5 IU sample median daily intake of vitamin D OR 1.64 95 CI 0.98-2.75 Older ALL survivors with BMD Z scores -2 are at risk for stones and should be counseled so that appropriate follow-up care can be provided for those among whom stones are detected,0,0,1,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[114, 461, 10, 6, 376, 3, 248, 59, 154, 5033, 1263, 3503, 2, 4490, 21948, 107, 319, 337, 332, 1, 864, 286, 1275, 62, 780, 776, 54, 11, 79, 60, 29, 136, 864, 62, 147, 2, 1684, 1, 3, 3062, 4841, 2898, 180, 45, 11, 2619, 59, 1397, 1307, 2, 2363, 1132, 190, 136, 43, 90, 484, 3816, 491, 208, 1156, 1220, 872, 19031, 6, 376, 3503, 4490, 21948, 11, 108, 20, 3915, 206, 1, 5229, 19031, 2353, 1572, 1540, 2, 2013, 487, 11, 4106, 29, 341, 3666, 2, 3, 2381, 1773, 675, 1770, 106, 3, 658, 812, 320, 202, 10, 95, 9, 65, 28, 8, 52, 1, 432, 14, 60, 29, 147, 3503, 3905, 703, 11, 1552, 18, 4, 562, 1, 12487, 33, 18, 2, 21948, 530, 4, 803, 1, 12487, 175, 776, 586, 9, 89, 121, 2013, 1610, 427, 1632, 2, 642, 782, 558, 198, 72, 6, 135, 5, 3503, 3905, 703, 8898, 3, 43, 1, 21948, 10, 101, 107, 135, 5, 3503, 3905, 703, 1552, 18, 610, 197, 15, 18, 937, 48, 307, 268, 58, 14, 213, 67, 576, 43, 1, 21948, 97, 101, 9, 434, 89, 512, 667, 105, 203, 259, 60, 15, 27, 431, 48, 58, 14, 175, 133, 465, 547, 3, 43, 10, 142, 84, 5542, 9, 4379, 33, 4588, 1000, 52, 391, 1514, 1, 1610, 427, 15, 14, 660, 48, 58, 13, 1096, 18, 481, 434, 62, 332, 5, 3503, 3905, 703, 1552, 18, 32, 28, 43, 9, 21948, 2, 257, 40, 10411, 1743, 17, 870, 166, 126, 165, 122, 40, 1052, 9, 135, 107, 953, 21948, 32, 530]",1498.0,22956305,268
T cell-depleted stem cell transplantation for adults with high-risk acute lymphoblastic leukemia: long-term survival for patients in first complete remission with a decreased risk of graft-versus-host disease.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2012-09-13,"Consolidation with allogeneic hematopoietic stem cell transplantation (allo-HSCT) provides a survival benefit to patients with acute lymphoblastic leukemia (ALL). We have previously reported comparable survival and relapse rates after T cell-depleted (TCD) allo-HSCT compared with unmodified transplantations for acute myelogenous leukemia, myelodysplastic syndrome, and non-Hodgkin lymphoma with significantly decreased graft-versus-host disease (GVHD). We performed a 56-patient retrospective study to evaluate TCD allo-HSCT for the treatment of ALL after myeloablative total body irradiation-based therapy. The 2-year and 5-year overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 (95% confidence interval [CI], 0.26-0.52) and 0.32 (95% CI, 0.19-0.44), respectively, and the 2-year and 5-year disease-free survival rates were 0.38 (95% CI, 0.25-0.50) and 0.32 (95% CI, 0.20-0.44). There was a trend toward improved survival of patients who underwent TCD allo-HSCT in first complete remission compared with those who did so in other remission states. The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 (95% CI, 0.10-0.31), and no patients developed grade IV acute GVHD. The cumulative incidence of chronic GVHD in 41 evaluable patients at 2 and 5 years was 0.15 (95% CI, 0.04-0.26), and that of extensive chronic GVHD at 2 and 5 years was 0.05 (95% CI, 0-11.6). We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD.",Journal Article,2686.0,28.0,Consolidation with allogeneic hematopoietic stem cell transplantation allo-HSCT provides a survival benefit to patients with acute lymphoblastic ALL We have previously reported comparable survival and relapse rates after T cell-depleted TCD allo-HSCT compared with unmodified transplantations for acute myelogenous syndrome and with significantly decreased graft-versus-host disease GVHD We performed a 56-patient retrospective study to evaluate TCD allo-HSCT for the treatment of ALL after myeloablative total body irradiation-based therapy The 2-year and 5-year overall survival rates for patients with ALL after TCD allo-HSCT were 0.39 95 confidence interval CI 0.26-0.52 and 0.32 95 CI 0.19-0.44 respectively and the 2-year and 5-year disease-free survival rates were 0.38 95 CI 0.25-0.50 and 0.32 95 CI 0.20-0.44 There was a trend toward improved survival of patients who underwent TCD allo-HSCT in first complete remission compared with those who did so in other remission states The cumulative incidence of grade II-IV acute GVHD at 1 year was 0.20 95 CI 0.10-0.31 and no patients developed grade IV acute GVHD The cumulative incidence of chronic GVHD in 41 evaluable patients at 2 and 5 years was 0.15 95 CI 0.04-0.26 and that of extensive chronic GVHD at 2 and 5 years was 0.05 95 CI 0-11.6 We demonstrate OS and DFS rates that compare favorably to unmodified allo-HSCT with lower rates of GVHD,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2173, 5, 1063, 1007, 452, 31, 497, 2564, 1703, 777, 8, 25, 247, 6, 7, 5, 286, 1275, 62, 21, 47, 373, 210, 1279, 25, 2, 429, 151, 50, 102, 31, 4358, 8827, 2564, 1703, 72, 5, 10424, 6779, 9, 286, 2194, 681, 2, 5, 97, 340, 1599, 185, 1204, 34, 1562, 21, 173, 8, 664, 69, 459, 45, 6, 376, 8827, 2564, 1703, 9, 3, 24, 1, 62, 50, 3246, 181, 642, 1104, 90, 36, 3, 18, 111, 2, 33, 111, 63, 25, 151, 9, 7, 5, 62, 50, 8827, 2564, 1703, 11, 13, 587, 48, 307, 268, 58, 13, 432, 13, 653, 2, 13, 531, 48, 58, 13, 326, 13, 584, 106, 2, 3, 18, 111, 2, 33, 111, 34, 115, 25, 151, 11, 13, 519, 48, 58, 13, 243, 13, 212, 2, 13, 531, 48, 58, 13, 179, 13, 584, 125, 10, 8, 853, 1317, 231, 25, 1, 7, 54, 208, 8827, 2564, 1703, 4, 157, 236, 734, 72, 5, 135, 54, 205, 1743, 4, 127, 734, 907, 3, 967, 287, 1, 88, 215, 478, 286, 1562, 28, 14, 111, 10, 13, 179, 48, 58, 13, 79, 13, 456, 2, 77, 7, 276, 88, 478, 286, 1562, 3, 967, 287, 1, 442, 1562, 4, 605, 859, 7, 28, 18, 2, 33, 60, 10, 13, 167, 48, 58, 13, 755, 13, 432, 2, 17, 1, 1344, 442, 1562, 28, 18, 2, 33, 60, 10, 13, 474, 48, 58, 13, 175, 49, 21, 608, 118, 2, 1010, 151, 17, 932, 5001, 6, 10424, 2564, 1703, 5, 280, 151, 1, 1562]",1403.0,22982534,664
Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.,Blood,Blood,2012-09-24,"With the use of risk-directed therapy for childhood acute lymphoblastic leukemia (ALL), outcome has improved dramatically in the past 40 years. However, a substantial portion of patients, many of whom have no known risk factors, experience relapse. Taking a genome-wide approach, in the present study, we evaluated the relationships between genotypes at 444 044 single nucleotide polymorphisms (SNPs) with the risk of relapse in 2535 children with newly diagnosed ALL after adjusting for genetic ancestry and treatment regimen. We identified 134 SNPs that were reproducibly associated with ALL relapse. Of 134 relapse SNPs, 133 remained prognostic after adjusting for all known relapse risk factors, including minimal residual disease, and 111 were significant even among patients who were negative for minimal residual disease after remission induction therapy. The C allele at rs7142143 in the PYGL gene was associated with 3.6-fold higher risk of relapse than the T allele (P = 6.7  10(-9)). Fourteen of the 134 relapse SNPs, including variants in PDE4B and ABCB1, were also associated with antileukemic drug pharmacokinetics and/or pharmacodynamics. In the present study, we systematically identified host genetic variations related to treatment outcome of childhood ALL, most of which were prognostic independent of known risk factors for relapse, and some of which also influenced outcome by affecting host dis-position of antileukemic drugs. All trials are registered at www.clinicaltrials.gov or www.cancer.gov (COG P9904: NCT00005585; COG P9905: NCT00005596; COG P9906: NCT00005603; St Jude Total XIIIB: NCI-T93-0101D; and St Jude Total XV: NCT00137111).",Journal Article,2675.0,69.0,With the use of risk-directed therapy for childhood acute lymphoblastic ALL outcome has improved dramatically in the past 40 years However a substantial portion of patients many of whom have no known risk factors experience relapse Taking a genome-wide approach in the present study we evaluated the relationships between genotypes at 444 044 single nucleotide polymorphisms SNPs with the risk of relapse in 2535 children with newly diagnosed ALL after adjusting for genetic ancestry and treatment regimen We identified 134 SNPs that were reproducibly associated with ALL relapse Of 134 relapse SNPs 133 remained prognostic after adjusting for all known relapse risk factors including minimal residual disease and 111 were significant even among patients who were negative for minimal residual disease after remission induction therapy The C allele at rs7142143 in the PYGL gene was associated with 3.6-fold higher risk of relapse than the T allele P 6.7 10 -9 Fourteen of the 134 relapse SNPs including variants in PDE4B and ABCB1 were also associated with antileukemic drug pharmacokinetics and/or pharmacodynamics In the present study we systematically identified host genetic variations related to treatment outcome of childhood ALL most of which were prognostic independent of known risk factors for relapse and some of which also influenced outcome by affecting host dis-position of antileukemic drugs All trials are registered at www.clinicaltrials.gov or www.cancer.gov COG P9904 NCT00005585 COG P9905 NCT00005596 COG P9906 NCT00005603 St Jude Total XIIIB NCI-T93-0101D and St Jude Total XV NCT00137111,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5, 3, 119, 1, 43, 1166, 36, 9, 864, 286, 1275, 62, 228, 71, 231, 2729, 4, 3, 1219, 327, 60, 137, 8, 1281, 3206, 1, 7, 445, 1, 953, 47, 77, 440, 43, 130, 730, 429, 2727, 8, 898, 1019, 353, 4, 3, 364, 45, 21, 194, 3, 2467, 59, 2071, 28, 10325, 6194, 226, 1579, 1203, 1109, 5, 3, 43, 1, 429, 4, 40113, 541, 5, 732, 265, 62, 50, 1358, 9, 336, 3535, 2, 24, 477, 21, 108, 4842, 1109, 17, 11, 10580, 41, 5, 62, 429, 1, 4842, 429, 1109, 5026, 958, 177, 50, 1358, 9, 62, 440, 429, 43, 130, 141, 1048, 753, 34, 2, 3167, 11, 93, 871, 107, 7, 54, 11, 199, 9, 1048, 753, 34, 50, 734, 504, 36, 3, 256, 1254, 28, 61918, 4, 3, 47413, 145, 10, 41, 5, 27, 49, 1116, 142, 43, 1, 429, 76, 3, 102, 1254, 19, 49, 67, 79, 83, 3225, 1, 3, 4842, 429, 1109, 141, 839, 4, 45970, 2, 6560, 11, 120, 41, 5, 4512, 234, 1159, 2, 15, 3587, 4, 3, 364, 45, 21, 3390, 108, 1204, 336, 2293, 139, 6, 24, 228, 1, 864, 62, 96, 1, 92, 11, 177, 306, 1, 440, 43, 130, 9, 429, 2, 476, 1, 92, 120, 2574, 228, 20, 2319, 1204, 23485, 3559, 1, 4512, 600, 62, 143, 32, 1653, 28, 3064, 1252, 1239, 15, 3064, 12, 1239, 6377, 39885, 47414, 6377, 47415, 47416, 6377, 45414, 39148, 3062, 4841, 181, 30629, 2580, 38692, 45092, 2, 3062, 4841, 181, 16078, 25075]",1610.0,23007406,198
Population PK/PD model of homocysteine concentrations after high-dose methotrexate treatment in patients with acute lymphoblastic leukemia.,PloS one,PLoS ONE,2012-09-25,"Elevated homocysteine concentrations have been associated with methotrexate-induced neurotoxicity. Based on methotrexate and homocysteine plasma concentrations of 494 children with acute lymphoblastic leukemia treated with high-dose methotrexate in the TOTAL XV study, a pharmacokinetic/pharmacodynamic (PK/PD) model was built with NONMEM. Several compartment and indirect response models were investigated. The pharmacokinetic disposition of methotrexate was best described by a two-compartment model. Homocysteine concentrations were included by an indirect response model where methotrexate inhibition of the homocysteine elimination rate was described by an E(max) model. The homocysteine baseline level was found to be age-dependent. Simulations revealed that folinate rescue therapy does not affect peak concentrations of homocysteine but leads to a modestly reduced homocysteine exposure. In conclusion, our PK/PD model describes the increase of methotrexate-induced HCY concentrations with satisfactory precision and can be applied to assess the effect of folinate regimens on the HCY concentration-time course.",Journal Article,2674.0,14.0,Elevated homocysteine concentrations have been associated with methotrexate-induced neurotoxicity Based on methotrexate and homocysteine plasma concentrations of 494 children with acute lymphoblastic treated with high-dose methotrexate in the TOTAL XV study a pharmacokinetic/pharmacodynamic PK/PD model was built with NONMEM Several compartment and indirect response models were investigated The pharmacokinetic disposition of methotrexate was best described by a two-compartment model Homocysteine concentrations were included by an indirect response model where methotrexate inhibition of the homocysteine elimination rate was described by an E max model The homocysteine baseline level was found to be age-dependent Simulations revealed that folinate rescue therapy does not affect peak concentrations of homocysteine but leads to a modestly reduced homocysteine exposure In conclusion our PK/PD model describes the increase of methotrexate-induced HCY concentrations with satisfactory precision and can be applied to assess the effect of folinate regimens on the HCY concentration-time course,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[804, 12798, 1003, 47, 85, 41, 5, 2116, 277, 3561, 90, 23, 2116, 2, 12798, 554, 1003, 1, 10919, 541, 5, 286, 1275, 73, 5, 64, 61, 2116, 4, 3, 181, 16078, 45, 8, 1456, 2424, 2395, 333, 202, 10, 6859, 5, 23535, 392, 3616, 2, 6110, 51, 274, 11, 565, 3, 1456, 5814, 1, 2116, 10, 824, 1027, 20, 8, 100, 3616, 202, 12798, 1003, 11, 159, 20, 35, 6110, 51, 202, 1257, 2116, 297, 1, 3, 12798, 3730, 116, 10, 1027, 20, 35, 563, 2649, 202, 3, 12798, 330, 301, 10, 204, 6, 40, 89, 470, 7490, 553, 17, 35082, 4256, 36, 1097, 44, 1158, 2944, 1003, 1, 12798, 84, 1940, 6, 8, 5588, 405, 12798, 645, 4, 1221, 114, 2395, 333, 202, 2677, 3, 344, 1, 2116, 277, 38027, 1003, 5, 7972, 2720, 2, 122, 40, 1498, 6, 423, 3, 254, 1, 35082, 472, 23, 3, 38027, 1227, 98, 906]",1097.0,23049924,57
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies.,"Oncology (Williston Park, N.Y.)","Oncology (Williston Park, N.Y.)",2012-09-01,"Acute lymphoblastic leukemia (ALL) in adults is a very challenging disease. Adults tend to present with higher-risk features and are unable to tolerate chemotherapy regimens as intense as those administered to children. The overall treatment plan for adult ALL is modeled after the pediatric paradigm and includes multi-agent chemotherapy in the forms of induction, consolidation, maintenance, and central nervous system prophylaxis. Most patients will go into complete remission but often relapse; relapse is typically indicative of chemotherapy-refractory disease. Salvage therapy generally consists of cytotoxic agents from drug classes the patient has had limited or no exposure to. The results of conventional chemotherapy for relapsed ALL are unacceptable. The goal of therapy in these patients is to achieve a second remission followed by allogeneic stem-cell transplantation. Monoclonal antibodies directed at cell-surface antigens offer a targeted approach to treating leukemia and other cancers. Anti-CD20 monoclonal antibodies have been shown to improve survival when used in the frontline setting. Novel, highly active antibodies directed at CD19 and CD22 are being investigated in the relapsed and refractory settings. These agents will likely be explored as components of first-line therapy as clinical development continues.",Journal Article,2698.0,11.0,Acute lymphoblastic ALL in adults is a very challenging disease Adults tend to present with higher-risk features and are unable to tolerate chemotherapy regimens as intense as those administered to children The overall treatment plan for adult ALL is modeled after the pediatric paradigm and includes multi-agent chemotherapy in the forms of induction consolidation maintenance and central nervous system prophylaxis Most patients will go into complete remission but often relapse relapse is typically indicative of chemotherapy-refractory disease Salvage therapy generally consists of cytotoxic agents from drug classes the patient has had limited or no exposure to The results of conventional chemotherapy for relapsed ALL are unacceptable The goal of therapy in these patients is to achieve a second remission followed by allogeneic stem-cell transplantation Monoclonal antibodies directed at cell-surface antigens offer a targeted approach to treating and other cancers Anti-CD20 monoclonal antibodies have been shown to improve survival when used in the frontline setting Novel highly active antibodies directed at CD19 and CD22 are being investigated in the relapsed and refractory settings These agents will likely be explored as components of first-line therapy as clinical development continues,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 4, 857, 16, 8, 923, 1950, 34, 857, 5406, 6, 364, 5, 142, 43, 404, 2, 32, 4253, 6, 5010, 56, 472, 22, 3933, 22, 135, 468, 6, 541, 3, 63, 24, 2242, 9, 780, 62, 16, 4666, 50, 3, 815, 2431, 2, 1920, 1414, 420, 56, 4, 3, 2377, 1, 504, 2173, 1146, 2, 854, 1880, 398, 2049, 96, 7, 303, 3537, 237, 236, 734, 84, 629, 429, 429, 16, 1969, 5572, 1, 56, 430, 34, 992, 36, 1228, 5132, 1, 759, 183, 29, 234, 3211, 3, 69, 71, 42, 383, 15, 77, 645, 6, 3, 99, 1, 809, 56, 9, 591, 62, 32, 3215, 3, 1326, 1, 36, 4, 46, 7, 16, 6, 1359, 8, 419, 734, 370, 20, 1063, 452, 31, 497, 848, 890, 1166, 28, 31, 1255, 1575, 1918, 8, 238, 353, 6, 1367, 2, 127, 163, 312, 2198, 848, 890, 47, 85, 443, 6, 401, 25, 198, 95, 4, 3, 3171, 546, 229, 561, 544, 890, 1166, 28, 3158, 2, 7599, 32, 486, 565, 4, 3, 591, 2, 430, 1947, 46, 183, 303, 322, 40, 1443, 22, 1628, 1, 157, 328, 36, 22, 38, 193, 2274]",1303.0,23061343,194
Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia.,Blood,Blood,2012-10-16,"The persistence of minimal residual disease (MRD) during therapy is the strongest adverse prognostic factor in acute lymphoblastic leukemia (ALL). We developed a high-throughput sequencing method that universally amplifies antigen-receptor gene segments and identifies all clonal gene rearrangements (ie, leukemia-specific sequences) at diagnosis, allowing monitoring of disease progression and clonal evolution during therapy. In the present study, the assay specifically detected 1 leukemic cell among greater than 1 million leukocytes in spike-in experiments. We compared this method with the gold-standard MRD assays multiparameter flow cytometry and allele-specific oligonucleotide polymerase chain reaction (ASO-PCR) using diagnostic and follow-up samples from 106 patients with ALL. Sequencing detected MRD in all 28 samples shown to be positive by flow cytometry and in 35 of the 36 shown to be positive by ASO-PCR and revealed MRD in 10 and 3 additional samples that were negative by flow cytometry and ASO-PCR, respectively. We conclude that this new method allows monitoring of treatment response in ALL and other lymphoid malignancies with great sensitivity and precision. The www.clinicaltrials.gov identifier number for the Total XV study is NCT00137111.",Evaluation Study,2653.0,222.0,The persistence of minimal residual disease MRD during therapy is the strongest adverse prognostic factor in acute lymphoblastic ALL We developed a high-throughput sequencing method that universally amplifies antigen-receptor gene segments and identifies all clonal gene rearrangements ie leukemia-specific sequences at diagnosis allowing monitoring of disease progression and clonal evolution during therapy In the present study the assay specifically detected 1 leukemic cell among greater than 1 million leukocytes in spike-in experiments We compared this method with the gold-standard MRD assays multiparameter flow cytometry and allele-specific oligonucleotide polymerase chain reaction ASO-PCR using diagnostic and follow-up samples from 106 patients with ALL Sequencing detected MRD in all 28 samples shown to be positive by flow cytometry and in 35 of the 36 shown to be positive by ASO-PCR and revealed MRD in 10 and 3 additional samples that were negative by flow cytometry and ASO-PCR respectively We conclude that this new method allows monitoring of treatment response in ALL and other lymphoid malignancies with great sensitivity and precision The www.clinicaltrials.gov identifier number for the Total XV study is NCT00137111,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 4108, 1, 1048, 753, 34, 2029, 190, 36, 16, 3, 3311, 290, 177, 161, 4, 286, 1275, 62, 21, 276, 8, 64, 3643, 615, 596, 17, 6813, 19051, 448, 153, 145, 5138, 2, 2953, 62, 1946, 145, 2072, 2523, 2647, 112, 2866, 28, 147, 2952, 1315, 1, 34, 91, 2, 1946, 2554, 190, 36, 4, 3, 364, 45, 3, 719, 1225, 530, 14, 2015, 31, 107, 378, 76, 14, 3346, 6884, 4, 10712, 4, 2332, 21, 72, 26, 596, 5, 3, 4159, 260, 2029, 1013, 10757, 1412, 1914, 2, 1254, 112, 4727, 1451, 1260, 1329, 13359, 604, 75, 752, 2, 166, 126, 347, 29, 3251, 7, 5, 62, 615, 530, 2029, 4, 62, 339, 347, 443, 6, 40, 109, 20, 1412, 1914, 2, 4, 465, 1, 3, 511, 443, 6, 40, 109, 20, 13359, 604, 2, 553, 2029, 4, 79, 2, 27, 402, 347, 17, 11, 199, 20, 1412, 1914, 2, 13359, 604, 106, 21, 2060, 17, 26, 217, 596, 2333, 1315, 1, 24, 51, 4, 62, 2, 127, 2303, 441, 5, 2797, 485, 2, 2720, 3, 3064, 1252, 1239, 3719, 207, 9, 3, 181, 16078, 45, 16, 25075]",1240.0,23074282,302
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia.,Cancer discovery,Cancer Discov,2012-10-29,"Genetic lesions such as BCR-ABL1, E2A-PBX1, and MLL rearrangements (MLLr) are associated with unfavorable outcomes in adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Leukemia oncoproteins may directly or indirectly disrupt cytosine methylation patterning to mediate the malignant phenotype. We postulated that DNA methylation signatures in these aggressive B-ALLs would point toward disease mechanisms and useful biomarkers and therapeutic targets. We therefore conducted DNA methylation and gene expression profiling on a cohort of 215 adult patients with B-ALL enrolled in a single phase III clinical trial (ECOG E2993) and normal control B cells. In BCR-ABL1-positive B-ALLs, aberrant cytosine methylation patterning centered around a cytokine network defined by hypomethylation and overexpression of IL2RA(CD25). The E2993 trial clinical data showed that CD25 expression was strongly associated with a poor outcome in patients with ALL regardless of BCR-ABL1 status, suggesting CD25 as a novel prognostic biomarker for risk stratification in B-ALLs. In E2A-PBX1-positive B-ALLs, aberrant DNA methylation patterning was strongly associated with direct fusion protein binding as shown by the E2A-PBX1 chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), suggesting that E2A-PBX1 fusion protein directly remodels the epigenome to impose an aggressive B-ALL phenotype. MLLr B-ALL featured prominent cytosine hypomethylation, which was linked with MLL fusion protein binding, H3K79 dimethylation, and transcriptional upregulation, affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as FLT3 and BCL6. Notably, BCL6 blockade or loss of function suppressed proliferation and survival of MLLr leukemia cells, suggesting BCL6-targeted therapy as a new therapeutic strategy for MLLr B-ALLs. We conducted the first integrative epigenomic study in adult B-ALLs, as a correlative study to the ECOG E2993 phase III clinical trial. This study links for the first time the direct actions of oncogenic fusion proteins with disruption of epigenetic regulation mediated by cytosine methylation. We identify a novel clinically actionable biomarker in B-ALLs: IL2RA (CD25), which is linked with BCR-ABL1 and an inflammatory signaling network associated with chemotherapy resistance. We show that BCL6 is a novel MLL fusion protein target that is required to maintain the proliferation and survival of primary human adult MLLr cells and provide the basis for a clinical trial with BCL6 inhibitors for patients with MLLr.",Journal Article,2640.0,49.0,Genetic lesions such as BCR-ABL1 E2A-PBX1 and MLL rearrangements MLLr are associated with unfavorable outcomes in adult B-cell precursor acute lymphoblastic B-ALL oncoproteins may directly or indirectly disrupt cytosine methylation patterning to mediate the malignant phenotype We postulated that DNA methylation signatures in these aggressive B-ALLs would point toward disease mechanisms and useful biomarkers and therapeutic targets We therefore conducted DNA methylation and gene expression profiling on a cohort of 215 adult patients with B-ALL enrolled in a single phase III clinical trial ECOG E2993 and normal control B cells In BCR-ABL1-positive B-ALLs aberrant cytosine methylation patterning centered around a cytokine network defined by hypomethylation and overexpression of IL2RA CD25 The E2993 trial clinical data showed that CD25 expression was strongly associated with a poor outcome in patients with ALL regardless of BCR-ABL1 status suggesting CD25 as a novel prognostic biomarker for risk stratification in B-ALLs In E2A-PBX1-positive B-ALLs aberrant DNA methylation patterning was strongly associated with direct fusion protein binding as shown by the E2A-PBX1 chromatin immunoprecipitation ChIP sequencing ChIP-seq suggesting that E2A-PBX1 fusion protein directly remodels the epigenome to impose an aggressive B-ALL phenotype MLLr B-ALL featured prominent cytosine hypomethylation which was linked with MLL fusion protein binding H3K79 dimethylation and transcriptional upregulation affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as FLT3 and BCL6 Notably BCL6 blockade or loss of function suppressed proliferation and survival of MLLr cells suggesting BCL6-targeted therapy as a new therapeutic strategy for MLLr B-ALLs We conducted the first integrative epigenomic study in adult B-ALLs as a correlative study to the ECOG E2993 phase III clinical trial This study links for the first time the direct actions of oncogenic fusion proteins with disruption of epigenetic regulation mediated by cytosine methylation We identify a novel clinically actionable biomarker in B-ALLs IL2RA CD25 which is linked with BCR-ABL1 and an inflammatory signaling network associated with chemotherapy resistance We show that BCL6 is a novel MLL fusion protein target that is required to maintain the proliferation and survival of primary human adult MLLr cells and provide the basis for a clinical trial with BCL6 inhibitors for patients with MLLr,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[336, 406, 225, 22, 1062, 3557, 15127, 14434, 2, 3049, 2072, 29366, 32, 41, 5, 2483, 123, 4, 780, 132, 31, 2765, 286, 1275, 132, 62, 8241, 68, 1606, 15, 7792, 6619, 6903, 569, 23991, 6, 3367, 3, 393, 1005, 21, 6507, 17, 261, 569, 2210, 4, 46, 571, 132, 10706, 688, 741, 1317, 34, 483, 2, 999, 582, 2, 189, 637, 21, 673, 426, 261, 569, 2, 145, 55, 1080, 23, 8, 180, 1, 6511, 780, 7, 5, 132, 62, 346, 4, 8, 226, 124, 316, 38, 160, 2351, 28928, 2, 295, 182, 132, 37, 4, 1062, 3557, 109, 132, 10706, 1898, 6903, 569, 23991, 4846, 3337, 8, 1675, 1801, 395, 20, 4441, 2, 851, 1, 27229, 4531, 3, 28928, 160, 38, 74, 224, 17, 4531, 55, 10, 1327, 41, 5, 8, 334, 228, 4, 7, 5, 62, 1583, 1, 1062, 3557, 156, 802, 4531, 22, 8, 229, 177, 901, 9, 43, 1541, 4, 132, 10706, 4, 15127, 14434, 109, 132, 10706, 1898, 261, 569, 23991, 10, 1327, 41, 5, 1196, 1212, 178, 791, 22, 443, 20, 3, 15127, 14434, 2287, 4857, 4222, 615, 4222, 4185, 802, 17, 15127, 14434, 1212, 178, 1606, 35464, 3, 10206, 6, 15099, 35, 571, 132, 62, 1005, 29366, 132, 62, 11857, 3689, 6903, 4441, 92, 10, 1199, 5, 3049, 1212, 178, 791, 23715, 25086, 2, 1431, 2218, 2319, 8, 916, 1, 440, 2, 732, 108, 3049, 1212, 1196, 637, 5, 1302, 128, 225, 22, 1224, 2, 8148, 2552, 8148, 1189, 15, 407, 1, 343, 1908, 457, 2, 25, 1, 29366, 37, 802, 8148, 238, 36, 22, 8, 217, 189, 692, 9, 29366, 132, 10706, 21, 426, 3, 157, 4324, 9822, 45, 4, 780, 132, 10706, 22, 8, 3679, 45, 6, 3, 2351, 28928, 124, 316, 38, 160, 26, 45, 6491, 9, 3, 157, 98, 3, 1196, 5592, 1, 1302, 1212, 652, 5, 3220, 1, 1418, 863, 517, 20, 6903, 569, 21, 255, 8, 229, 505, 2856, 901, 4, 132, 10706, 27229, 4531, 92, 16, 1199, 5, 1062, 3557, 2, 35, 1291, 314, 1801, 41, 5, 56, 251, 21, 514, 17, 8148, 16, 8, 229, 3049, 1212, 178, 283, 17, 16, 616, 6, 3040, 3, 457, 2, 25, 1, 86, 171, 780, 29366, 37, 2, 377, 3, 877, 9, 8, 38, 160, 5, 8148, 222, 9, 7, 5, 29366]",2503.0,23107779,377
Trends in transfusion burden among long-term survivors of childhood hematological malignancies.,Leukemia & lymphoma,Leuk. Lymphoma,2012-12-22,"The risk from cumulative erythrocyte transfusions is poorly understood in oncology populations. This analysis among long-term survivors explored variation in transfusional burden over progressive eras of treatment identifying those at risk for iron overload. Transfusion records of 982 survivors of hematological malignancies treated at St. Jude were reviewed. After exclusions, 881 (90%) were assessed for cumulative volume, weight-adjusted volume and transfusion number. Treatment intensity was assigned using the Intensity of Treatment Rating Scale version 3.0 (ITR-3). Hematopoietic stem cell transplant and acute myeloid leukemia survivors had greater transfusional burden than conventional therapy recipients and acute lymphoblastic leukemia survivors, respectively. Survivors of 5-10 years were more likely than survivors of > 10 years to receive  10 transfusions (odds ratio = 2.0, 95% confidence interval 1.5-2.8). Those with higher ITR-3 scores and more recent decades of treatment had a higher transfusional burden. Comprehensive transfusion histories are useful in identifying those at highest risk for iron overload.",Journal Article,2586.0,13.0,The risk from cumulative erythrocyte transfusions is poorly understood in oncology populations This analysis among long-term survivors explored variation in transfusional burden over progressive eras of treatment identifying those at risk for iron overload Transfusion records of 982 survivors of hematological malignancies treated at St. Jude were reviewed After exclusions 881 90 were assessed for cumulative volume weight-adjusted volume and transfusion number Treatment intensity was assigned using the Intensity of Treatment Rating Scale version 3.0 ITR-3 Hematopoietic stem cell transplant and acute myeloid survivors had greater transfusional burden than conventional therapy recipients and acute lymphoblastic survivors respectively Survivors of 5-10 years were more likely than survivors of 10 years to receive  10 transfusions odds ratio 2.0 95 confidence interval 1.5-2.8 Those with higher ITR-3 scores and more recent decades of treatment had a higher transfusional burden Comprehensive transfusion histories are useful in identifying those at highest risk for iron overload,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 43, 29, 967, 16470, 4987, 16, 1240, 1784, 4, 413, 1184, 26, 65, 107, 319, 337, 332, 1443, 1380, 4, 27843, 892, 252, 1014, 7225, 1, 24, 1386, 135, 28, 43, 9, 4231, 13143, 2785, 1064, 1, 14862, 332, 1, 2890, 441, 73, 28, 3062, 4841, 11, 446, 50, 17835, 13057, 424, 11, 275, 9, 967, 433, 924, 586, 433, 2, 2785, 207, 24, 837, 10, 896, 75, 3, 837, 1, 24, 5477, 1124, 2256, 27, 13, 7562, 27, 1007, 452, 31, 941, 2, 286, 533, 332, 42, 378, 27843, 892, 76, 809, 36, 2190, 2, 286, 1275, 332, 106, 332, 1, 33, 79, 60, 11, 80, 322, 76, 332, 1, 79, 60, 6, 560, 749, 79, 4987, 610, 197, 18, 13, 48, 307, 268, 14, 33, 18, 66, 135, 5, 142, 7562, 27, 703, 2, 80, 435, 1968, 1, 24, 42, 8, 142, 27843, 892, 949, 2785, 5329, 32, 999, 4, 1386, 135, 28, 1076, 43, 9, 4231, 13143]",1087.0,23163568,16
Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.,Pediatrics,Pediatrics,2012-11-19,"Doxorubicin, effective against many malignancies, is limited by cardiotoxicity. Continuous-infusion doxorubicin, compared with bolus-infusion, reduces early cardiotoxicity in adults. Its effectiveness in reducing late cardiotoxicity in children remains uncertain. We determined continuous-infusion doxorubicin cardioprotective efficacy in long-term survivors of childhood acute lymphoblastic leukemia (ALL). The Dana-Farber Cancer Institute ALL Consortium Protocol 91-01 enrolled pediatric patients between 1991 and 1995. Newly diagnosed high-risk patients were randomly assigned to receive a total of 360 mg/m(2) of doxorubicin in 30 mg/m(2) doses every 3 weeks, by either continuous (over 48 hours) or bolus-infusion (within 15 minutes). Echocardiograms at baseline, during, and after doxorubicin therapy were blindly remeasured centrally. Primary outcomes were late left ventricular (LV) structure and function. A total of 102 children were randomized to each treatment group. We analyzed 484 serial echocardiograms from 92 patients (n = 49 continuous; n = 43 bolus) with 1 echocardiogram 3 years after assignment. Both groups had similar demographics and normal baseline LV characteristics. Cardiac follow-up after randomization (median, 8 years) showed changes from baseline within the randomized groups (depressed systolic function, systolic dilation, reduced wall thickness, and reduced mass) at 3, 6, and 8 years; there were no statistically significant differences between randomized groups. Ten-year ALL event-free survival rates did not differ between the 2 groups (continuous-infusion, 83% versus bolus-infusion, 78%; P = .24). In survivors of childhood high-risk ALL, continuous-infusion doxorubicin, compared with bolus-infusion, provided no long-term cardioprotection or improvement in ALL event-free survival, hence provided no benefit over bolus-infusion.",Comparative Study,2619.0,88.0,Doxorubicin effective against many malignancies is limited by cardiotoxicity Continuous-infusion doxorubicin compared with bolus-infusion reduces early cardiotoxicity in adults Its effectiveness in reducing late cardiotoxicity in children remains uncertain We determined continuous-infusion doxorubicin cardioprotective efficacy in long-term survivors of childhood acute lymphoblastic ALL The Dana-Farber Cancer Institute ALL Consortium Protocol 91-01 enrolled pediatric patients between 1991 and 1995 Newly diagnosed high-risk patients were randomly assigned to receive a total of 360 mg/m 2 of doxorubicin in 30 mg/m 2 doses every 3 weeks by either continuous over 48 hours or bolus-infusion within 15 minutes Echocardiograms at baseline during and after doxorubicin therapy were blindly remeasured centrally Primary outcomes were late left ventricular LV structure and function A total of 102 children were randomized to each treatment group We analyzed 484 serial echocardiograms from 92 patients n 49 continuous n 43 bolus with 1 echocardiogram 3 years after assignment Both groups had similar demographics and normal baseline LV characteristics follow-up after randomization median 8 years showed changes from baseline within the randomized groups depressed systolic function systolic dilation reduced wall thickness and reduced mass at 3 6 and 8 years there were no statistically significant differences between randomized groups Ten-year ALL event-free survival rates did not differ between the 2 groups continuous-infusion 83 versus bolus-infusion 78 P .24 In survivors of childhood high-risk ALL continuous-infusion doxorubicin compared with bolus-infusion provided no long-term cardioprotection or improvement in ALL event-free survival hence provided no benefit over bolus-infusion,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[856, 323, 480, 445, 441, 16, 383, 20, 4404, 1314, 904, 856, 72, 5, 3604, 904, 2389, 191, 4404, 4, 857, 211, 1236, 4, 1818, 807, 4404, 4, 541, 469, 2717, 21, 509, 1314, 904, 856, 17618, 209, 4, 319, 337, 332, 1, 864, 286, 1275, 62, 3, 4932, 4979, 12, 1377, 62, 2404, 1182, 970, 355, 346, 815, 7, 59, 3372, 2, 2323, 732, 265, 64, 43, 7, 11, 1108, 896, 6, 560, 8, 181, 1, 6739, 81, 188, 18, 1, 856, 4, 201, 81, 188, 18, 415, 454, 27, 244, 20, 361, 1314, 252, 576, 1459, 15, 3604, 904, 262, 167, 2511, 15097, 28, 330, 190, 2, 50, 856, 36, 11, 18490, 42870, 4604, 86, 123, 11, 807, 1712, 4028, 4072, 2772, 2, 343, 8, 181, 1, 2867, 541, 11, 384, 6, 296, 24, 87, 21, 311, 9802, 2108, 15097, 29, 937, 7, 78, 739, 1314, 78, 601, 3604, 5, 3567, 11906, 2608, 60, 50, 4392, 110, 271, 42, 288, 2221, 2, 295, 330, 4072, 374, 166, 126, 50, 3644, 52, 66, 60, 224, 400, 29, 330, 262, 3, 384, 271, 9233, 8109, 343, 8109, 8062, 405, 2397, 2903, 2, 405, 782, 28, 27, 49, 2, 66, 60, 125, 11, 77, 712, 93, 362, 59, 384, 271, 1618, 111, 62, 774, 115, 25, 151, 205, 44, 1505, 59, 3, 18, 271, 1314, 904, 852, 185, 3604, 904, 833, 19, 259, 4, 332, 1, 864, 64, 43, 62, 1314, 904, 856, 72, 5, 3604, 904, 1052, 77, 319, 337, 23760, 15, 767, 4, 62, 774, 115, 25, 3665, 1052, 77, 247, 252, 3604, 904]",1795.0,23166343,219
"High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2012-11-19,"Relapsed adult acute lymphoblastic leukemia (ALL) is associated with high reinduction mortality, chemotherapy resistance, and rapid progression leading to death. Vincristine sulfate liposome injection (VSLI), sphingomyelin and cholesterol nanoparticle vincristine (VCR), facilitates VCR dose-intensification and densification plus enhances target tissue delivery. We evaluated high-dose VSLI monotherapy in adults with Philadelphia chromosome (Ph) -negative ALL that was multiply relapsed, relapsed and refractory to reinduction, and/or relapsed after hematopoietic cell transplantation (HCT). Sixty-five adults with Ph-negative ALL in second or greater relapse or whose disease had progressed following two or more leukemia therapies were treated in this pivotal phase II, multinational trial. Intravenous VSLI 2.25 mg/m(2), without dose capping, was administered once per week until response, progression, toxicity, or pursuit of HCT. The primary end point was achievement of complete response (CR) or CR with incomplete hematologic recovery (CRi). The CR/CRi rate was 20% and overall response rate was 35%. VSLI monotherapy was effective as third-, fourth-, and fifth-line therapy and in patients refractory to other single- and multiagent reinduction therapies. Median CR/CRi duration was 23 weeks (range, 5 to 66 weeks); 12 patients bridged to a post-VSLI HCT, and five patients were long-term survivors. VSLI was generally well tolerated and associated with a low 30-day mortality rate (12%). High-dose VSLI monotherapy resulted in meaningful clinical outcomes including durable responses and bridging to HCT in advanced ALL settings. The toxicity profile of VSLI was predictable, manageable, and comparable to standard VCR despite the delivery of large, normally unachievable, individual and cumulative doses of VCR.","Clinical Trial, Phase II",2619.0,113.0,Relapsed adult acute lymphoblastic ALL is associated with high reinduction mortality chemotherapy resistance and rapid progression leading to death Vincristine sulfate liposome injection VSLI sphingomyelin and cholesterol nanoparticle vincristine VCR facilitates VCR dose-intensification and densification plus enhances target tissue delivery We evaluated high-dose VSLI monotherapy in adults with Philadelphia chromosome Ph -negative ALL that was multiply relapsed relapsed and refractory to reinduction and/or relapsed after hematopoietic cell transplantation HCT Sixty-five adults with Ph-negative ALL in second or greater relapse or whose disease had progressed following two or more therapies were treated in this pivotal phase II multinational trial Intravenous VSLI 2.25 mg/m 2 without dose capping was administered once per week until response progression toxicity or pursuit of HCT The primary end point was achievement of complete response CR or CR with incomplete hematologic recovery CRi The CR/CRi rate was 20 and overall response rate was 35 VSLI monotherapy was effective as third- fourth- and fifth-line therapy and in patients refractory to other single- and multiagent reinduction therapies Median CR/CRi duration was 23 weeks range 5 to 66 weeks 12 patients bridged to a post-VSLI HCT and five patients were long-term survivors VSLI was generally well tolerated and associated with a low 30-day mortality rate 12 High-dose VSLI monotherapy resulted in meaningful clinical outcomes including durable responses and bridging to HCT in advanced ALL settings The toxicity profile of VSLI was predictable manageable and comparable to standard VCR despite the delivery of large normally unachievable individual and cumulative doses of VCR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[591, 780, 286, 1275, 62, 16, 41, 5, 64, 10177, 282, 56, 251, 2, 1321, 91, 1049, 6, 273, 2132, 6424, 8645, 1754, 14005, 20160, 2, 5020, 4483, 2132, 8886, 4936, 8886, 61, 5091, 2, 62126, 349, 2519, 283, 246, 989, 21, 194, 64, 61, 14005, 1411, 4, 857, 5, 3006, 1170, 2058, 199, 62, 17, 10, 14421, 591, 591, 2, 430, 6, 10177, 2, 15, 591, 50, 1007, 31, 497, 1085, 1746, 365, 857, 5, 2058, 199, 62, 4, 419, 15, 378, 429, 15, 1310, 34, 42, 1839, 366, 100, 15, 80, 235, 11, 73, 4, 26, 3754, 124, 215, 8243, 160, 1262, 14005, 18, 243, 81, 188, 18, 187, 61, 19476, 10, 468, 1059, 379, 647, 1100, 51, 91, 155, 15, 13649, 1, 1085, 3, 86, 396, 741, 10, 5088, 1, 236, 51, 684, 15, 684, 5, 2610, 813, 1602, 6341, 3, 684, 6341, 116, 10, 179, 2, 63, 51, 116, 10, 465, 14005, 1411, 10, 323, 22, 1282, 3608, 2, 5780, 328, 36, 2, 4, 7, 430, 6, 127, 226, 2, 7148, 10177, 235, 52, 684, 6341, 654, 10, 382, 244, 184, 33, 6, 700, 244, 133, 7, 20738, 6, 8, 539, 14005, 1085, 2, 365, 7, 11, 319, 337, 332, 14005, 10, 1228, 149, 421, 2, 41, 5, 8, 154, 201, 218, 282, 116, 133, 64, 61, 14005, 1411, 627, 4, 2538, 38, 123, 141, 1480, 253, 2, 15636, 6, 1085, 4, 131, 62, 1947, 3, 155, 800, 1, 14005, 10, 7639, 2808, 2, 1279, 6, 260, 8886, 550, 3, 989, 1, 375, 6150, 34011, 797, 2, 967, 415, 1, 8886]",1750.0,23169518,36
CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations.,Leukemia & lymphoma,Leuk. Lymphoma,2013-01-03,"Aberrant expression of the B lymphoid marker, CD19, in acute myeloid leukemia (AML) has frequently been associated with t(8;21)(q22;q22). However, AML cases lacking t(8;21) may occasionally express CD19. We asked whether CD19 expression is restricted to the karyotypically abnormal leukemic cells in primary leukemia samples. We compared, by fluorescence in situ hybridization, CD19-positive and CD19-negative cells from nine patients with acute leukemia: three non-t(8;21) AML, three t(8;21) AML and three cases of acute lymphoblastic leukemia. There were no significant differences in karyotypic pattern between the CD19-positive and CD19-negative leukemic cells, raising the concern that therapeutically targeting CD19 for acute leukemia may not eradicate all malignant clones.",Journal Article,2574.0,10.0,Aberrant expression of the B lymphoid marker CD19 in acute myeloid AML has frequently been associated with t 8 21 q22 q22 However AML cases lacking t 8 21 may occasionally express CD19 We asked whether CD19 expression is restricted to the karyotypically abnormal leukemic cells in primary samples We compared by fluorescence in situ hybridization CD19-positive and CD19-negative cells from nine patients with acute three non-t 8 21 AML three t 8 21 AML and three cases of acute lymphoblastic There were no significant differences in karyotypic pattern between the CD19-positive and CD19-negative leukemic cells raising the concern that therapeutically targeting CD19 for acute may not eradicate all malignant clones,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1898, 55, 1, 3, 132, 2303, 952, 3158, 4, 286, 533, 329, 71, 746, 85, 41, 5, 102, 66, 239, 8026, 8026, 137, 329, 140, 1941, 102, 66, 239, 68, 6319, 1669, 3158, 21, 3732, 317, 3158, 55, 16, 2016, 6, 3, 34083, 1668, 2015, 37, 4, 86, 347, 21, 72, 20, 1591, 4, 957, 1554, 3158, 109, 2, 3158, 199, 37, 29, 762, 7, 5, 286, 169, 220, 102, 66, 239, 329, 169, 102, 66, 239, 329, 2, 169, 140, 1, 286, 1275, 125, 11, 77, 93, 362, 4, 9465, 1177, 59, 3, 3158, 109, 2, 3158, 199, 2015, 37, 6627, 3, 2893, 17, 4602, 529, 3158, 9, 286, 68, 44, 5650, 62, 393, 2749]",715.0,23193950,188
Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2012-12-03,"Corticosteroids are widely used for the treatment of B-cell malignancies, including non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and acute lymphoblastic leukemia; however, this class of drug is associated with undesirable off-target effects. Herein, we developed novel milatuzumab-conjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74(+) B-cell malignancies and explored its effect against the disease. The targeting efficiency of milatuzumab-targeted liposomes to CD74(+) cells was evaluated in vitro. The effect of CD74-targeted liposomal dexamethasone was compared with free dexamethasone in primary CLL cells and cell lines in vitro. The therapeutic efficacy of CD74-targeted liposomal dexamethasone was evaluated in a Raji-severe combined immunodeficient (SCID) xenograft model in vivo. Milatuzumab-targeted liposomes promoted selective incorporation of carrier molecules into transformed CD74-positive B cells as compared with CD74-negative T-cells. The CD74-dexamethasone-targeted liposomes (CD74-IL-DEX) promoted and increased killing in CD74-positive tumor cells and primary CLL cells. Furthermore, the targeted drug liposomes showed enhanced therapeutic efficacy against a CD74-positive B-cell model as compared with free, or non-targeted, liposomal dexamethasone in SCID mice engrafted with Raji cells in vivo. These studies provide evidence and support for a potential use of CD74-targeted liposomal dexamethasone as a new therapy for B-cell malignancies.",Journal Article,2605.0,28.0,Corticosteroids are widely used for the treatment of B-cell malignancies including chronic lymphocytic CLL and acute lymphoblastic however this class of drug is associated with undesirable off-target effects Herein we developed novel milatuzumab-conjugated liposomes as a targeted dexamethasone carrier for therapeutic delivery in CD74 B-cell malignancies and explored its effect against the disease The targeting efficiency of milatuzumab-targeted liposomes to CD74 cells was evaluated in vitro The effect of CD74-targeted liposomal dexamethasone was compared with free dexamethasone in primary CLL cells and cell lines in vitro The therapeutic efficacy of CD74-targeted liposomal dexamethasone was evaluated in a Raji-severe combined immunodeficient SCID xenograft model in vivo Milatuzumab-targeted liposomes promoted selective incorporation of carrier molecules into transformed CD74-positive B cells as compared with CD74-negative T-cells The CD74-dexamethasone-targeted liposomes CD74-IL-DEX promoted and increased killing in CD74-positive tumor cells and primary CLL cells Furthermore the targeted drug liposomes showed enhanced therapeutic efficacy against a CD74-positive B-cell model as compared with free or non-targeted liposomal dexamethasone in SCID mice engrafted with Raji cells in vivo These studies provide evidence and support for a potential use of CD74-targeted liposomal dexamethasone as a new therapy for B-cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3876, 32, 1792, 95, 9, 3, 24, 1, 132, 31, 441, 141, 442, 1193, 552, 2, 286, 1275, 137, 26, 1040, 1, 234, 16, 41, 5, 13572, 1889, 283, 176, 1986, 21, 276, 229, 12038, 3868, 7438, 22, 8, 238, 1217, 4715, 9, 189, 989, 4, 7780, 132, 31, 441, 2, 1443, 211, 254, 480, 3, 34, 3, 529, 2904, 1, 12038, 238, 7438, 6, 7780, 37, 10, 194, 4, 439, 3, 254, 1, 7780, 238, 3275, 1217, 10, 72, 5, 115, 1217, 4, 86, 552, 37, 2, 31, 285, 4, 439, 3, 189, 209, 1, 7780, 238, 3275, 1217, 10, 194, 4, 8, 9868, 905, 397, 5031, 4129, 1330, 202, 4, 386, 12038, 238, 7438, 2992, 1094, 2838, 1, 4715, 1598, 237, 2423, 7780, 109, 132, 37, 22, 72, 5, 7780, 199, 102, 37, 3, 7780, 1217, 238, 7438, 7780, 501, 4844, 2992, 2, 101, 3003, 4, 7780, 109, 30, 37, 2, 86, 552, 37, 798, 3, 238, 234, 7438, 224, 651, 189, 209, 480, 8, 7780, 109, 132, 31, 202, 22, 72, 5, 115, 15, 220, 238, 3275, 1217, 4, 4129, 399, 6914, 5, 9868, 37, 4, 386, 46, 94, 377, 241, 2, 538, 9, 8, 174, 119, 1, 7780, 238, 3275, 1217, 22, 8, 217, 36, 9, 132, 31, 441]",1447.0,23209030,340
Tyrosine kinome sequencing of pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group TARGET Project.,Blood,Blood,2012-12-04,"One recently identified subtype of pediatric B-precursor acute lymphoblastic leukemia (ALL) has been termed BCR-ABL1-like or Ph-like because of similarity of the gene expression profile to BCR-ABL1 positive ALL suggesting the presence of lesions activating tyrosine kinases, frequent alteration of IKZF1, and poor outcome. Prior studies demonstrated that approximately half of these patients had genomic lesions leading to CRLF2 overexpression, with half of such cases harboring somatic mutations in the Janus kinases JAK1 and JAK2. To determine whether mutations in other tyrosine kinases might also occur in ALL, we sequenced the tyrosine kinome and downstream signaling genes in 45 high-risk pediatric ALL cases with either a Ph-like gene expression profile or other alterations suggestive of activated kinase signaling. Aside from JAK mutations and 1 FLT3 mutation, no somatic mutations were found in any other tyrosine kinases, suggesting that alternative mechanisms are responsible for activated kinase signaling in high-risk ALL.",Journal Article,2604.0,99.0,One recently identified subtype of pediatric B-precursor acute lymphoblastic ALL has been termed BCR-ABL1-like or Ph-like because of similarity of the gene expression profile to BCR-ABL1 positive ALL suggesting the presence of lesions activating tyrosine kinases frequent alteration of IKZF1 and poor outcome Prior studies demonstrated that approximately half of these patients had genomic lesions leading to CRLF2 overexpression with half of such cases harboring somatic mutations in the Janus kinases JAK1 and JAK2 To determine whether mutations in other tyrosine kinases might also occur in ALL we sequenced the tyrosine kinome and downstream signaling genes in 45 high-risk pediatric ALL cases with either a Ph-like gene expression profile or other alterations suggestive of activated kinase signaling Aside from JAK mutations and 1 FLT3 mutation no somatic mutations were found in any other tyrosine kinases suggesting that alternative mechanisms are responsible for activated kinase signaling in high-risk ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[104, 761, 108, 875, 1, 815, 132, 2765, 286, 1275, 62, 71, 85, 4183, 1062, 3557, 733, 15, 2058, 733, 408, 1, 6700, 1, 3, 145, 55, 800, 6, 1062, 3557, 109, 62, 802, 3, 463, 1, 406, 1616, 564, 1549, 908, 2611, 1, 8422, 2, 334, 228, 324, 94, 264, 17, 705, 1303, 1, 46, 7, 42, 572, 406, 1049, 6, 8895, 851, 5, 1303, 1, 225, 140, 2105, 1119, 138, 4, 3, 6191, 1549, 8075, 2, 2509, 6, 223, 317, 138, 4, 127, 564, 1549, 822, 120, 1271, 4, 62, 21, 4040, 3, 564, 14328, 2, 1489, 314, 214, 4, 512, 64, 43, 815, 62, 140, 5, 361, 8, 2058, 733, 145, 55, 800, 15, 127, 593, 3832, 1, 735, 216, 314, 11731, 29, 4653, 138, 2, 14, 1224, 258, 77, 1119, 138, 11, 204, 4, 500, 127, 564, 1549, 802, 17, 1091, 483, 32, 2327, 9, 735, 216, 314, 4, 64, 43, 62]",1015.0,23212523,146
Rare allelic forms of PRDM9 associated with childhood leukemogenesis.,Genome research,Genome Res.,2012-12-05,"One of the most rapidly evolving genes in humans, PRDM9, is a key determinant of the distribution of meiotic recombination events. Mutations in this meiotic-specific gene have previously been associated with male infertility in humans and recent studies suggest that PRDM9 may be involved in pathological genomic rearrangements. In studying genomes from families with children affected by B-cell precursor acute lymphoblastic leukemia (B-ALL), we characterized meiotic recombination patterns within a family with two siblings having hyperdiploid childhood B-ALL and observed unusual localization of maternal recombination events. The mother of the family carries a rare PRDM9 allele, potentially explaining the unusual patterns found. From exomes sequenced in 44 additional parents of children affected with B-ALL, we discovered a substantial and significant excess of rare allelic forms of PRDM9. The rare PRDM9 alleles are transmitted to the affected children in half the cases; nonetheless there remains a significant excess of rare alleles among patients relative to controls. We successfully replicated this latter observation in an independent cohort of 50 children with B-ALL, where we found an excess of rare PRDM9 alleles in aneuploid and infant B-ALL patients. PRDM9 variability in humans is thought to influence genomic instability, and these data support a potential role for PRDM9 variation in risk of acquiring aneuploidies or genomic rearrangements associated with childhood leukemogenesis.",Journal Article,2603.0,26.0,One of the most rapidly evolving genes in humans PRDM9 is a key determinant of the distribution of meiotic recombination events Mutations in this meiotic-specific gene have previously been associated with male infertility in humans and recent studies suggest that PRDM9 may be involved in pathological genomic rearrangements In studying genomes from families with children affected by B-cell precursor acute lymphoblastic B-ALL we characterized meiotic recombination patterns within a family with two siblings having hyperdiploid childhood B-ALL and observed unusual localization of maternal recombination events The mother of the family carries a rare PRDM9 allele potentially explaining the unusual patterns found From exomes sequenced in 44 additional parents of children affected with B-ALL we discovered a substantial and significant excess of rare allelic forms of PRDM9 The rare PRDM9 alleles are transmitted to the affected children in half the cases nonetheless there remains a significant excess of rare alleles among patients relative to controls We successfully replicated this latter observation in an independent cohort of 50 children with B-ALL where we found an excess of rare PRDM9 alleles in aneuploid and infant B-ALL patients PRDM9 variability in humans is thought to influence genomic instability and these data support a potential role for PRDM9 variation in risk of acquiring aneuploidies or genomic rearrangements associated with childhood leukemogenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[104, 1, 3, 96, 1755, 3276, 214, 4, 3218, 25488, 16, 8, 825, 4372, 1, 3, 1395, 1, 22661, 4017, 281, 138, 4, 26, 22661, 112, 145, 47, 373, 85, 41, 5, 1045, 5901, 4, 3218, 2, 435, 94, 309, 17, 25488, 68, 40, 646, 4, 1301, 572, 2072, 4, 4559, 5085, 29, 1954, 5, 541, 1424, 20, 132, 31, 2765, 286, 1275, 132, 62, 21, 765, 22661, 4017, 764, 262, 8, 607, 5, 100, 2758, 1041, 8847, 864, 132, 62, 2, 164, 4015, 2145, 1, 6039, 4017, 281, 3, 9733, 1, 3, 607, 4942, 8, 622, 25488, 1254, 751, 8290, 3, 4015, 764, 204, 29, 12233, 4040, 4, 584, 402, 2418, 1, 541, 1424, 5, 132, 62, 21, 2747, 8, 1281, 2, 93, 2612, 1, 622, 3861, 2377, 1, 25488, 3, 622, 25488, 2558, 32, 12959, 6, 3, 1424, 541, 4, 1303, 3, 140, 4648, 125, 469, 8, 93, 2612, 1, 622, 2558, 107, 7, 580, 6, 535, 21, 1878, 6714, 26, 3286, 1664, 4, 35, 306, 180, 1, 212, 541, 5, 132, 62, 1257, 21, 204, 35, 2612, 1, 622, 25488, 2558, 4, 11781, 2, 8027, 132, 62, 7, 25488, 1982, 4, 3218, 16, 2739, 6, 1054, 572, 1753, 2, 46, 74, 538, 8, 174, 200, 9, 25488, 1380, 4, 43, 1, 12720, 47526, 15, 572, 2072, 41, 5, 864, 5661]",1478.0,23222848,419
A case of nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement: an unusual presentation of a rare disease.,The American journal of surgical pathology,Am. J. Surg. Pathol.,2013-01-01,"Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment. Although rare cases of PDGFRA rearrangement-associated acute myeloid or lymphoblastic leukemia can occur, nonleukemic myeloid sarcoma has not been reported, and its sensitivity to imatinib treatment is unknown. Herein, we report a 31-year-old man with nonleukemic myeloid sarcoma and marked peripheral blood and bone marrow eosinophilia. Fluorescent in situ hybridization studies demonstrated that both bone marrow hematopoietic precursors and blasts of the myeloid sarcoma were positive for FIP1L1-PDGFRA rearrangement. The patient consequently received imatinib treatment at a dosage of 100 mg daily. After 3 weeks of therapy, his eosinophilia and myeloid sarcoma completely resolved, and at evaluation after 3 months he had attained bone marrow cytogenetic remission. To our knowledge, this is the first case of a nonleukemic myeloid sarcoma with the FIP1L1-PDGFRA rearrangement. Despite its aggressive clinical behavior attributed to myeloid sarcoma in general, the presence of PDGFRA rearrangement in this case conferred a high sensitivity to imatinib treatment and a favorable clinical outcome.",Case Reports,2576.0,7.0,Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment Although rare cases of PDGFRA rearrangement-associated acute myeloid or lymphoblastic can occur nonleukemic myeloid has not been reported and its sensitivity to imatinib treatment is unknown Herein we report a 31-year-old man with nonleukemic myeloid and marked peripheral blood and marrow eosinophilia Fluorescent in situ hybridization studies demonstrated that both marrow hematopoietic precursors and blasts of the myeloid were positive for FIP1L1-PDGFRA rearrangement The patient consequently received imatinib treatment at a dosage of 100 mg daily After 3 weeks of therapy his eosinophilia and myeloid completely resolved and at evaluation after 3 months he had attained marrow cytogenetic remission To our knowledge this is the first case of a nonleukemic myeloid with the FIP1L1-PDGFRA rearrangement Despite its aggressive clinical behavior attributed to myeloid in general the presence of PDGFRA rearrangement in this case conferred a high sensitivity to imatinib treatment and a favorable clinical outcome,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[2675, 1, 3, 4006, 145, 5849, 8, 834, 87, 1, 1007, 1179, 17, 841, 364, 5, 1882, 13555, 2, 32, 561, 745, 6, 154, 61, 577, 2347, 24, 242, 622, 140, 1, 4006, 2675, 41, 286, 533, 15, 1275, 122, 1271, 20986, 533, 71, 44, 85, 210, 2, 211, 485, 6, 577, 24, 16, 860, 1986, 21, 414, 8, 456, 111, 1095, 3628, 5, 20986, 533, 2, 2003, 672, 315, 2, 581, 13555, 2910, 4, 957, 1554, 94, 264, 17, 110, 581, 1007, 4881, 2, 2438, 1, 3, 533, 11, 109, 9, 21746, 4006, 2675, 3, 69, 3244, 103, 577, 24, 28, 8, 3323, 1, 394, 81, 391, 50, 27, 244, 1, 36, 3224, 13555, 2, 533, 2500, 3862, 2, 28, 451, 50, 27, 53, 3174, 42, 5105, 581, 1266, 734, 6, 114, 922, 26, 16, 3, 157, 473, 1, 8, 20986, 533, 5, 3, 21746, 4006, 2675, 550, 211, 571, 38, 1710, 3073, 6, 533, 4, 1083, 3, 463, 1, 4006, 2675, 4, 26, 473, 3851, 8, 64, 485, 6, 577, 24, 2, 8, 913, 38, 228]",1215.0,23232855,163
"When, how, and what cell source for hematopoietic cell transplantation in first complete remission adult acute lymphoblastic leukemia?",Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2012-01-01,"Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease affected by many patient- and disease-related factors, including age, immunologic subtype, and clinical, genetic, and molecular features. Allogeneic hematopoietic cell transplantation (HCT) has occupied an increasing therapeutic role as a result of significant improvements in supportive care and histocompatibility testing. ALL Philadelphia chromosome-negative patients formerly excluded now are considered HCT candidates and survival rates with alternative donors may approach those obtained with matched-related donors. Reduced-intensity conditioning rather than myeloablative conditioning appears to provide comparable patient outcome results although these observations have not been validated in prospective studies. Improved tools can identify patients thought to be in remission based on morphology but who have active disease at the molecular or immunophenotypic level (minimal residual disease). Using B-cell antigen panels, clone-specific immunoglobulins, or T-cell receptor rearrangements to detect positivity at thresholds of at least 1 in 10(4) cells, such patients may be taken to HCT. The ongoing advances in conventional therapy intensity, however, now yield improved results and ongoing reassessment of the place of HCT needs to be continued; every effort should be made to enroll eligible patients in clinical trials.",Journal Article,2942.0,8.0,Adult acute lymphoblastic ALL is a heterogeneous disease affected by many patient- and disease-related factors including age immunologic subtype and clinical genetic and molecular features Allogeneic hematopoietic cell transplantation HCT has occupied an increasing therapeutic role as a result of significant improvements in supportive care and histocompatibility testing ALL Philadelphia chromosome-negative patients formerly excluded now are considered HCT candidates and survival rates with alternative donors may approach those obtained with matched-related donors Reduced-intensity conditioning rather than myeloablative conditioning appears to provide comparable patient outcome results although these observations have not been validated in prospective studies Improved tools can identify patients thought to be in remission based on morphology but who have active disease at the molecular or immunophenotypic level minimal residual disease Using B-cell antigen panels clone-specific immunoglobulins or T-cell receptor rearrangements to detect positivity at thresholds of at least 1 in 10 4 cells such patients may be taken to HCT The ongoing advances in conventional therapy intensity however now yield improved results and ongoing reassessment of the place of HCT needs to be continued every effort should be made to enroll eligible patients in clinical trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[780, 286, 1275, 62, 16, 8, 1564, 34, 1424, 20, 445, 69, 2, 34, 139, 130, 141, 89, 3042, 875, 2, 38, 336, 2, 219, 404, 1063, 1007, 31, 497, 1085, 71, 14798, 35, 602, 189, 200, 22, 8, 757, 1, 93, 1474, 4, 1877, 165, 2, 6537, 471, 62, 3006, 1170, 199, 7, 7350, 1800, 1134, 32, 515, 1085, 1931, 2, 25, 151, 5, 1091, 2344, 68, 353, 135, 683, 5, 655, 139, 2344, 405, 837, 1933, 1832, 76, 3246, 1933, 1233, 6, 377, 1279, 69, 228, 99, 242, 46, 2172, 47, 44, 85, 938, 4, 482, 94, 231, 1896, 122, 255, 7, 2739, 6, 40, 4, 734, 90, 23, 2567, 84, 54, 47, 544, 34, 28, 3, 219, 15, 6599, 301, 1048, 753, 34, 75, 132, 31, 448, 4383, 3910, 112, 13373, 15, 102, 31, 153, 2072, 6, 1426, 1887, 28, 4634, 1, 28, 506, 14, 4, 79, 39, 37, 225, 7, 68, 40, 1633, 6, 1085, 3, 942, 954, 4, 809, 36, 837, 137, 1134, 2309, 231, 99, 2, 942, 8756, 1, 3, 3536, 1, 1085, 1891, 6, 40, 1351, 454, 2919, 257, 40, 1229, 6, 6559, 625, 7, 4, 38, 143]",1370.0,23233608,757
Genome-wide study of methotrexate clearance replicates SLCO1B1.,Blood,Blood,2012-12-11,"Methotrexate clearance can influence the cure of and toxicity in children with acute lymphoblastic leukemia (ALL). We estimated methotrexate plasma clearance for 1279 patients with ALL treated with methotrexate (24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose) on the Childrens Oncology Group P9904 and P9905 protocols. Methotrexate clearance was lower in older children (P = 7 x 10(-7)), girls (P = 2.7 x 10(-4)), and those who received a delayed-intensification phase (P = .0022). A genome-wide analysis showed that methotrexate clearance was associated with polymorphisms in the organic anion transporter gene SLCO1B1 (P = 2.1 x 10(-11)). This replicates findings using different schedules of high-dose methotrexate in St Jude ALL treatment protocols; a combined meta-analysis yields a P value of 5.7 x 10(-19) for the association of methotrexate clearance with SLCO1B1 SNP rs4149056. Validation of this variant with 5 different treatment regimens of methotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance. This study is registered at http://www.clinicaltrials.gov as NCT00005585 and NCT00005596.",Journal Article,2597.0,91.0,Methotrexate clearance can influence the cure of and toxicity in children with acute lymphoblastic ALL We estimated methotrexate plasma clearance for 1279 patients with ALL treated with methotrexate 24-hour infusion of a 1 g/m2 dose or 4-hour infusion of a 2 g/m2 dose on the Children s Oncology Group P9904 and P9905 protocols Methotrexate clearance was lower in older children P 7 x 10 -7 girls P 2.7 x 10 -4 and those who received a delayed-intensification phase P .0022 A genome-wide analysis showed that methotrexate clearance was associated with polymorphisms in the organic anion transporter gene SLCO1B1 P 2.1 x 10 -11 This replicates findings using different schedules of high-dose methotrexate in St Jude ALL treatment protocols a combined meta-analysis yields a P value of 5.7 x 10 -19 for the association of methotrexate clearance with SLCO1B1 SNP rs4149056 Validation of this variant with 5 different treatment regimens of methotrexate solidifies the robustness of this pharmacogenomic determinant of methotrexate clearance This study is registered at http //www.clinicaltrials.gov as NCT00005585 and NCT00005596,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 1960, 122, 1054, 3, 1722, 1, 2, 155, 4, 541, 5, 286, 1275, 62, 21, 661, 2116, 554, 1960, 9, 31493, 7, 5, 62, 73, 5, 2116, 259, 2583, 904, 1, 8, 14, 499, 821, 61, 15, 39, 2583, 904, 1, 8, 18, 499, 821, 61, 23, 3, 541, 695, 413, 87, 39885, 2, 47415, 2189, 2116, 1960, 10, 280, 4, 434, 541, 19, 67, 1006, 79, 67, 5989, 19, 18, 67, 1006, 79, 39, 2, 135, 54, 103, 8, 1612, 5091, 124, 19, 18474, 8, 898, 1019, 65, 224, 17, 2116, 1960, 10, 41, 5, 1203, 4, 3, 9486, 22387, 5246, 145, 13693, 19, 18, 14, 1006, 79, 175, 26, 10579, 272, 75, 338, 2314, 1, 64, 61, 2116, 4, 3062, 4841, 62, 24, 2189, 8, 397, 1742, 65, 4788, 8, 19, 549, 1, 33, 67, 1006, 79, 326, 9, 3, 248, 1, 2116, 1960, 5, 13693, 1845, 34797, 929, 1, 26, 1142, 5, 33, 338, 24, 472, 1, 2116, 62193, 3, 7031, 1, 26, 6971, 4372, 1, 2116, 1960, 26, 45, 16, 1653, 28, 5196, 3064, 1252, 1239, 22, 47414, 2, 47416]",1125.0,23233662,45
The myth of the second remission of acute leukemia in the adult.,Blood,Blood,2012-12-14,"Although the majority of adult patients with both acute lymphoblastic leukemia and acute myelogenous leukemia achieve remission with upfront chemotherapy, many patients still suffer relapse. Often, the strategy is proposed of treating patients with relapsed leukemia into a second remission (CR2) and then proceeding to allogeneic transplantation as the definitive curative approach. However, the long-term outcomes of such a strategy are poor: the 5-year overall survival from first relapse for patients with acute leukemia is only approximately 10%. This Perspective highlights the fact that most patients do not achieve CR2 and therefore never really have an opportunity for a potential curative therapy. Although patients who undergo transplantation after relapse may be cured, those who do not achieve CR2 are rarely candidates for transplantation; therefore, the overall outcome for patients who relapse is dismal. There is therefore an urgent need not only for more effective upfront therapy to prevent relapse, but also for the development of therapies that can serve as effective bridging treatments between relapse and transplantation. We suggest that more optimal use of minimal residual disease detection during first remission may also improve the chances for successful transplantation therapy via earlier reinduction therapy, allowing transplantation before overt relapse.",Journal Article,2594.0,112.0,Although the majority of adult patients with both acute lymphoblastic and acute myelogenous achieve remission with upfront chemotherapy many patients still suffer relapse Often the strategy is proposed of treating patients with relapsed into a second remission CR2 and then proceeding to allogeneic transplantation as the definitive curative approach However the long-term outcomes of such a strategy are poor the 5-year overall survival from first relapse for patients with acute is only approximately 10 This Perspective highlights the fact that most patients do not achieve CR2 and therefore never really have an opportunity for a potential curative therapy Although patients who undergo transplantation after relapse may be cured those who do not achieve CR2 are rarely candidates for transplantation therefore the overall outcome for patients who relapse is dismal There is therefore an urgent need not only for more effective upfront therapy to prevent relapse but also for the development of therapies that can serve as effective bridging treatments between relapse and transplantation We suggest that more optimal use of minimal residual disease detection during first remission may also improve the chances for successful transplantation therapy via earlier reinduction therapy allowing transplantation before overt relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 3, 686, 1, 780, 7, 5, 110, 286, 1275, 2, 286, 2194, 1359, 734, 5, 2941, 56, 445, 7, 1234, 6506, 429, 629, 3, 692, 16, 1587, 1, 1367, 7, 5, 591, 237, 8, 419, 734, 7865, 2, 818, 13053, 6, 1063, 497, 22, 3, 1057, 1075, 353, 137, 3, 319, 337, 123, 1, 225, 8, 692, 32, 334, 3, 33, 111, 63, 25, 29, 157, 429, 9, 7, 5, 286, 16, 158, 705, 79, 26, 3727, 2527, 3, 1991, 17, 96, 7, 1022, 44, 1359, 7865, 2, 673, 1737, 20765, 47, 35, 2666, 9, 8, 174, 1075, 36, 242, 7, 54, 1251, 497, 50, 429, 68, 40, 3733, 135, 54, 1022, 44, 1359, 7865, 32, 2416, 1931, 9, 497, 673, 3, 63, 228, 9, 7, 54, 429, 16, 3929, 125, 16, 673, 35, 5013, 594, 44, 158, 9, 80, 323, 2941, 36, 6, 1682, 429, 84, 120, 9, 3, 193, 1, 235, 17, 122, 1833, 22, 323, 15636, 640, 59, 429, 2, 497, 21, 309, 17, 80, 665, 119, 1, 1048, 753, 34, 638, 190, 157, 734, 68, 120, 401, 3, 10726, 9, 1401, 497, 36, 847, 1677, 10177, 36, 2952, 497, 348, 7192, 429]",1332.0,23243288,772
Historical trends in the use of radiation therapy for pediatric cancers: 1973-2008.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2012-12-27,"This study was undertaken to assess historical trends in the use of radiation therapy (RT) for pediatric cancers over the past 4 decades. The National Cancer Institute's Surveillance, Epidemiology, and End Results database of the 9 original tumor registries (SEER-9) was queried to identify patients aged 0 to 19 years with acute lymphoblastic leukemia, acute myeloid leukemia, bone and joint cancer, cancer of the brain and nervous system, Hodgkin lymphoma, neuroblastoma, non-Hodgkin lymphoma, soft tissue cancer, Wilms tumor, or retinoblastoma from 1973 to 2008. Patients were grouped into 4-year time epochs. The number and percentage of patients who received RT as part of their initial treatment were calculated per epoch by each diagnosis group from 1973 to 2008. RT use for acute lymphoblastic leukemia, non-Hodgkin lymphoma, and retinoblastoma declined sharply from 57%, 57%, and 30% in 1973 to 1976 to 11%, 15%, and 2%, respectively, in 2005 to 2008. Similarly, smaller declines in RT use were also seen in brain cancer (70%-39%), bone cancer (41%-21%), Wilms tumor (75%-53%), and neuroblastoma (60%-25%). RT use curves for Wilms tumor and neuroblastoma were nonlinear with nadirs in 1993 to 1996 at 39% and 19%, respectively. There were minimal changes in RT use for Hodgkin lymphoma, soft tissue cancer, or acute myeloid leukemia, roughly stable at 72%, 40%, and 11%, respectively. Almost all patients treated with RT were given external beam RT exclusively. However, from 1985 to 2008, treatments involving brachytherapy, radioisotopes, or combination therapy increased in frequency, comprising 1.8%, 4.6%, and 11.9% of RT treatments in brain cancer, soft tissue cancer, and retinoblastoma, respectively. The use of RT is declining over time in 7 of 10 pediatric cancer categories. A limitation of this study is a potential under-ascertainment of RT use in the SEER-9 database including the delayed use of RT.",Journal Article,2581.0,41.0,This study was undertaken to assess historical trends in the use of radiation therapy RT for pediatric cancers over the past 4 decades The National Cancer Institute 's Surveillance Epidemiology and End Results database of the 9 original tumor registries SEER-9 was queried to identify patients aged 0 to 19 years with acute lymphoblastic acute myeloid and joint cancer cancer of the brain and nervous system soft tissue cancer tumor or from 1973 to 2008 Patients were grouped into 4-year time epochs The number and percentage of patients who received RT as part of their initial treatment were calculated per epoch by each diagnosis group from 1973 to 2008 RT use for acute lymphoblastic and declined sharply from 57 57 and 30 in 1973 to 1976 to 11 15 and 2 respectively in 2005 to 2008 Similarly smaller declines in RT use were also seen in brain cancer 70 -39 cancer 41 -21 tumor 75 -53 and 60 -25 RT use curves for tumor and were nonlinear with nadirs in 1993 to 1996 at 39 and 19 respectively There were minimal changes in RT use for soft tissue cancer or acute myeloid roughly stable at 72 40 and 11 respectively Almost all patients treated with RT were given external beam RT exclusively However from 1985 to 2008 treatments involving brachytherapy radioisotopes or combination therapy increased in frequency comprising 1.8 4.6 and 11.9 of RT treatments in brain cancer soft tissue cancer and respectively The use of RT is declining over time in 7 of 10 pediatric cancer categories A limitation of this study is a potential under-ascertainment of RT use in the SEER-9 database including the delayed use of RT,0,0,1,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26, 45, 10, 2789, 6, 423, 2252, 1963, 4, 3, 119, 1, 121, 36, 240, 9, 815, 163, 252, 3, 1219, 39, 1968, 3, 657, 12, 1377, 292, 617, 1284, 2, 396, 99, 609, 1, 3, 83, 2279, 30, 3768, 1605, 83, 10, 3547, 6, 255, 7, 1032, 13, 6, 326, 60, 5, 286, 1275, 286, 533, 2, 2093, 12, 12, 1, 3, 342, 2, 1880, 398, 1214, 246, 12, 30, 15, 29, 4756, 6, 1375, 7, 11, 3706, 237, 39, 111, 98, 62247, 3, 207, 2, 1150, 1, 7, 54, 103, 240, 22, 760, 1, 136, 388, 24, 11, 981, 379, 7959, 20, 296, 147, 87, 29, 4756, 6, 1375, 240, 119, 9, 286, 1275, 2, 3054, 10833, 29, 696, 696, 2, 201, 4, 4756, 6, 8586, 6, 175, 167, 2, 18, 106, 4, 1242, 6, 1375, 1813, 2170, 4264, 4, 240, 119, 11, 120, 527, 4, 342, 12, 431, 587, 12, 605, 239, 30, 481, 699, 2, 335, 243, 240, 119, 2400, 9, 30, 2, 11, 7488, 5, 13866, 4, 3343, 6, 2648, 28, 587, 2, 326, 106, 125, 11, 1048, 400, 4, 240, 119, 9, 1214, 246, 12, 15, 286, 533, 7954, 585, 28, 720, 327, 2, 175, 106, 2214, 62, 7, 73, 5, 240, 11, 447, 1455, 1345, 240, 4437, 137, 29, 4675, 6, 1375, 640, 1267, 1536, 17592, 15, 150, 36, 101, 4, 675, 3538, 14, 66, 39, 49, 2, 175, 83, 1, 240, 640, 4, 342, 12, 1214, 246, 12, 2, 106, 3, 119, 1, 240, 16, 6896, 252, 98, 4, 67, 1, 79, 815, 12, 1996, 8, 5039, 1, 26, 45, 16, 8, 174, 669, 10798, 1, 240, 119, 4, 3, 1605, 83, 609, 141, 3, 1612, 119, 1, 240]",1614.0,23273995,276
In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice.,PloS one,PLoS ONE,2012-12-31,"Xenograft mouse models represent helpful tools for preclinical studies on human tumors. For modeling the complexity of the human disease, primary tumor cells are by far superior to established cell lines. As qualified exemplary model, patients' acute lymphoblastic leukemia cells reliably engraft in mice inducing orthotopic disseminated leukemia closely resembling the disease in men. Unfortunately, disease monitoring of acute lymphoblastic leukemia in mice is hampered by lack of a suitable readout parameter. Patients' acute lymphoblastic leukemia cells were lentivirally transduced to express the membrane-bound form of Gaussia luciferase. In vivo imaging was established in individual patients' leukemias and extensively validated. Bioluminescence in vivo imaging enabled reliable and continuous follow-up of individual mice. Light emission strictly correlated to post mortem quantification of leukemic burden and revealed a logarithmic, time and cell number dependent growth pattern. Imaging conveniently quantified frequencies of leukemia initiating cells in limiting dilution transplantation assays. Upon detecting a single leukemia cell within more than 10,000 bone marrow cells, imaging enabled monitoring minimal residual disease, time to tumor re-growth and relapse. Imaging quantified therapy effects precisely and with low variances, discriminating treatment failure from partial and complete responses. For the first time, we characterized in detail how in vivo imaging reforms preclinical studies on patient-derived tumors upon increasing monitoring resolution. In the future, in vivo imaging will enable performing precise preclinical studies on a broad range of highly demanding clinical challenges, such as treatment failure, resistance in leukemia initiating cells, minimal residual disease and relapse.",Journal Article,2577.0,27.0,"Xenograft mouse models represent helpful tools for preclinical studies on human tumors For modeling the complexity of the human disease primary tumor cells are by far superior to established cell lines As qualified exemplary model patients acute lymphoblastic cells reliably engraft in mice inducing orthotopic disseminated closely resembling the disease in men Unfortunately disease monitoring of acute lymphoblastic in mice is hampered by lack of a suitable readout parameter Patients acute lymphoblastic cells were lentivirally transduced to express the membrane-bound form of Gaussia luciferase In vivo imaging was established in individual patients leukemias and extensively validated Bioluminescence in vivo imaging enabled reliable and continuous follow-up of individual mice Light emission strictly correlated to post mortem quantification of leukemic burden and revealed a logarithmic time and cell number dependent growth pattern Imaging conveniently quantified frequencies of initiating cells in limiting dilution transplantation assays Upon detecting a single cell within more than 10,000 marrow cells imaging enabled monitoring minimal residual disease time to tumor re-growth and relapse Imaging quantified therapy effects precisely and with low variances discriminating treatment failure from partial and complete responses For the first time we characterized in detail how in vivo imaging reforms preclinical studies on patient-derived tumors upon increasing monitoring resolution In the future in vivo imaging will enable performing precise preclinical studies on a broad range of highly demanding clinical challenges such as treatment failure resistance in initiating cells minimal residual disease and relapse",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1330, 830, 274, 1231, 3951, 1896, 9, 693, 94, 23, 171, 57, 9, 2057, 3, 3082, 1, 3, 171, 34, 86, 30, 37, 32, 20, 3272, 1123, 6, 635, 31, 285, 22, 9575, 31871, 202, 7, 286, 1275, 37, 4092, 12343, 4, 399, 1958, 2157, 3605, 3210, 8855, 3, 34, 4, 325, 3869, 34, 1315, 1, 286, 1275, 4, 399, 16, 6786, 20, 926, 1, 8, 2884, 18589, 4219, 7, 286, 1275, 37, 11, 62285, 5042, 6, 1669, 3, 1905, 2951, 1297, 1, 39321, 3864, 4, 386, 270, 10, 635, 4, 797, 7, 2792, 2, 3576, 938, 7956, 4, 386, 270, 4387, 2450, 2, 1314, 166, 126, 1, 797, 399, 1691, 1799, 10395, 438, 6, 539, 34229, 4752, 1, 2015, 892, 2, 553, 8, 20397, 98, 2, 31, 207, 470, 129, 1177, 270, 23200, 2790, 2722, 1, 2637, 37, 4, 817, 10446, 497, 1013, 1548, 2502, 8, 226, 31, 262, 80, 76, 79, 984, 581, 37, 270, 4387, 1315, 1048, 753, 34, 98, 6, 30, 1491, 129, 2, 429, 270, 2790, 36, 176, 7428, 2, 5, 154, 24607, 8059, 24, 496, 29, 450, 2, 236, 253, 9, 3, 157, 98, 21, 765, 4, 5000, 832, 4, 386, 270, 29388, 693, 94, 23, 69, 526, 57, 1548, 602, 1315, 2125, 4, 3, 508, 4, 386, 270, 303, 3047, 3620, 3260, 693, 94, 23, 8, 2094, 184, 1, 561, 14562, 38, 1427, 225, 22, 24, 496, 251, 4, 2637, 37, 1048, 753, 34, 2, 429]",1728.0,23300782,584
Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-01-10,"No highly effective salvage therapy exists for patients with relapsed acute lymphoblastic leukemia (ALL). Inotuzumab ozogamicin (IO) is a CD22 monoclonal antibody attached to calicheamycin that targets B lymphocytes in early stages of development, successfully inducing remission in patients with multiply relapsed ALL. We describe our findings in 26 patients who received allogeneic hematopoietic stem cell transplantation (SCT) after treatment with IO between September 2010 and October 2011. Patients with a median age of 33 years (range, 5-70 years) received an allogeneic matched sibling donor (n = 9), matched- or 1-antigen mismatched unrelated donor (n = 16), or cord blood donor SCT (n = 1) while in complete remission (n = 23) or with active disease (n = 3). At the time of SCT, 15 patients were in complete remission without evidence of minimal residual disease (MRD) measured by multiparameter flow cytometry. Patients were heavily pretreated, including 5 patients who had received previous allogeneic SCT. Patients received a median of 3 courses of IO (range, 1-5 courses) before SCT. Seven patients are alive at a median follow-up of 13 months (range, 5-16 months), with 1-year event-free and overall survival (OS) of 22% and 20%, respectively. Patients without MRD at time of SCT had a markedly better 1-year OS of 42%. The cumulative incidence of nonrelapse mortality (NRM) at 6 months and 1 year were 40% and 60%, respectively, with 5 deaths attributed to venoocclusive disease (VOD). Treatment with IO allows more patients to undergo transplantation while in remission, with favorable overall survival in patients without MRD who undergo transplantation. Reduction in hepatic toxicity is needed to improve overall results.",Journal Article,2567.0,38.0,No highly effective salvage therapy exists for patients with relapsed acute lymphoblastic ALL Inotuzumab ozogamicin IO is a CD22 monoclonal antibody attached to calicheamycin that targets B lymphocytes in early stages of development successfully inducing remission in patients with multiply relapsed ALL We describe our findings in 26 patients who received allogeneic hematopoietic stem cell transplantation SCT after treatment with IO between September 2010 and October 2011 Patients with a median age of 33 years range 5-70 years received an allogeneic matched sibling donor n 9 matched- or 1-antigen mismatched unrelated donor n 16 or cord blood donor SCT n 1 while in complete remission n 23 or with active disease n 3 At the time of SCT 15 patients were in complete remission without evidence of minimal residual disease MRD measured by multiparameter flow cytometry Patients were heavily pretreated including 5 patients who had received previous allogeneic SCT Patients received a median of 3 courses of IO range 1-5 courses before SCT Seven patients are alive at a median follow-up of 13 months range 5-16 months with 1-year event-free and overall survival OS of 22 and 20 respectively Patients without MRD at time of SCT had a markedly better 1-year OS of 42 The cumulative incidence of nonrelapse mortality NRM at 6 months and 1 year were 40 and 60 respectively with 5 deaths attributed to venoocclusive disease VOD Treatment with IO allows more patients to undergo transplantation while in remission with favorable overall survival in patients without MRD who undergo transplantation Reduction in hepatic toxicity is needed to improve overall results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[77, 561, 323, 992, 36, 2481, 9, 7, 5, 591, 286, 1275, 62, 6730, 5566, 9927, 16, 8, 7599, 848, 548, 10409, 6, 62314, 17, 637, 132, 1594, 4, 191, 1153, 1, 193, 1878, 1958, 734, 4, 7, 5, 14421, 591, 62, 21, 897, 114, 272, 4, 432, 7, 54, 103, 1063, 1007, 452, 31, 497, 1988, 50, 24, 5, 9927, 59, 2636, 1120, 2, 2551, 1132, 7, 5, 8, 52, 89, 1, 466, 60, 184, 33, 431, 60, 103, 35, 1063, 655, 3684, 1488, 78, 83, 655, 15, 14, 448, 5095, 2092, 1488, 78, 245, 15, 1885, 315, 1488, 1988, 78, 14, 369, 4, 236, 734, 78, 382, 15, 5, 544, 34, 78, 27, 28, 3, 98, 1, 1988, 167, 7, 11, 4, 236, 734, 187, 241, 1, 1048, 753, 34, 2029, 644, 20, 10757, 1412, 1914, 7, 11, 2447, 2193, 141, 33, 7, 54, 42, 103, 698, 1063, 1988, 7, 103, 8, 52, 1, 27, 1993, 1, 9927, 184, 14, 33, 1993, 348, 1988, 648, 7, 32, 1701, 28, 8, 52, 166, 126, 1, 233, 53, 184, 33, 245, 53, 5, 14, 111, 774, 115, 2, 63, 25, 118, 1, 350, 2, 179, 106, 7, 187, 2029, 28, 98, 1, 1988, 42, 8, 2195, 380, 14, 111, 118, 1, 595, 3, 967, 287, 1, 4640, 282, 4296, 28, 49, 53, 2, 14, 111, 11, 327, 2, 335, 106, 5, 33, 1043, 3073, 6, 20232, 34, 8768, 24, 5, 9927, 2333, 80, 7, 6, 1251, 497, 369, 4, 734, 5, 913, 63, 25, 4, 7, 187, 2029, 54, 1251, 497, 628, 4, 939, 155, 16, 575, 6, 401, 63, 99]",1660.0,23313065,44
The genomic landscape of hypodiploid acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2013-01-20,"The genetic basis of hypodiploid acute lymphoblastic leukemia (ALL), a subtype of ALL characterized by aneuploidy and poor outcome, is unknown. Genomic profiling of 124 hypodiploid ALL cases, including whole-genome and exome sequencing of 40 cases, identified two subtypes that differ in the severity of aneuploidy, transcriptional profiles and submicroscopic genetic alterations. Near-haploid ALL with 24-31 chromosomes harbor alterations targeting receptor tyrosine kinase signaling and Ras signaling (71%) and the lymphoid transcription factor gene IKZF3 (encoding AIOLOS; 13%). In contrast, low-hypodiploid ALL with 32-39 chromosomes are characterized by alterations in TP53 (91.2%) that are commonly present in nontumor cells, IKZF2 (encoding HELIOS; 53%) and RB1 (41%). Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase (PI3K)-signaling pathways and are sensitive to PI3K inhibitors, indicating that these drugs should be explored as a new therapeutic strategy for this aggressive form of leukemia.",Journal Article,2557.0,312.0,The genetic basis of hypodiploid acute lymphoblastic ALL a subtype of ALL characterized by aneuploidy and poor outcome is unknown Genomic profiling of 124 hypodiploid ALL cases including whole-genome and exome sequencing of 40 cases identified two subtypes that differ in the severity of aneuploidy transcriptional profiles and submicroscopic genetic alterations Near-haploid ALL with 24-31 chromosomes harbor alterations targeting receptor tyrosine kinase signaling and Ras signaling 71 and the lymphoid transcription factor gene IKZF3 encoding AIOLOS 13 In contrast low-hypodiploid ALL with 32-39 chromosomes are characterized by alterations in TP53 91.2 that are commonly present in nontumor cells IKZF2 encoding HELIOS 53 and RB1 41 Both near-haploid and low-hypodiploid leukemic cells show activation of Ras-signaling and phosphoinositide 3-kinase PI3K -signaling pathways and are sensitive to PI3K inhibitors indicating that these drugs should be explored as a new therapeutic strategy for this aggressive form of,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 336, 877, 1, 12135, 286, 1275, 62, 8, 875, 1, 62, 765, 20, 7437, 2, 334, 228, 16, 860, 572, 1080, 1, 2834, 12135, 62, 140, 141, 902, 898, 2, 2865, 615, 1, 327, 140, 108, 100, 814, 17, 1505, 4, 3, 1702, 1, 7437, 1431, 1241, 2, 19675, 336, 593, 1829, 38794, 62, 5, 259, 456, 3560, 2760, 593, 529, 153, 564, 216, 314, 2, 1102, 314, 792, 2, 3, 2303, 866, 161, 145, 27251, 2362, 40234, 233, 4, 748, 154, 12135, 62, 5, 531, 587, 3560, 32, 765, 20, 593, 4, 1206, 970, 18, 17, 32, 841, 364, 4, 9618, 37, 35520, 2362, 29391, 699, 2, 4596, 605, 110, 1829, 38794, 2, 154, 12135, 2015, 37, 514, 363, 1, 1102, 314, 2, 4497, 27, 216, 974, 314, 460, 2, 32, 745, 6, 974, 222, 1716, 17, 46, 600, 257, 40, 1443, 22, 8, 217, 189, 692, 9, 26, 571, 1297, 1]",1019.0,23334668,44
"The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial.",Haematologica,Haematologica,2013-01-24,"The biology and outcome of adult t(4;11)(q21;q23)/MLL-AFF1 acute lymphoblastic leukemia are poorly understood. We describe the outcome and delineate prognostic factors and optimal post-remission therapy in 85 consecutive patients (median age 38 years) treated uniformly in the prospective trial UKALLXII/ECOG2993. The immunophenotype of this leukemia was pro-B (CD10(NEG)). Immaturity was further suggested by high expression of the stem-cell antigens, CD133 and CD135, although CD34 expression was significantly lower than in t(4;11)-negative patients. Complete remission was achieved in 77 (93%) patients but only 35% survived 5 years (95% CI: 25-45%); the relapse rate was 45% (95% CI: 33-58%). Thirty-one patients underwent allogeneic transplantation in first remission (15 sibling donors and 16 unrelated donors): with 5-year survival rates of 56% and 67% respectively, only 2/31 patients relapsed. This compares with a 24% survival rate and 59% relapse rate in 46 patients who received post-remission chemotherapy. A major determinant of outcome was age with 71% of patients aged <25 years surviving. Younger patients had lower relapse rates (19%) but most received allografts in first complete remission. In conclusion, multivariate analysis did not demonstrate an advantage of allografting over chemotherapy but only five younger patients received chemotherapy. Prospective trials are required to determine whether poor outcomes in older patients can be improved by reduced-intensity conditioning allografts. NCT00002514 www.clinicaltrials.gov.",Journal Article,2553.0,25.0,The biology and outcome of adult t 4 11 q21 q23 /MLL-AFF1 acute lymphoblastic are poorly understood We describe the outcome and delineate prognostic factors and optimal post-remission therapy in 85 consecutive patients median age 38 years treated uniformly in the prospective trial UKALLXII/ECOG2993 The immunophenotype of this was pro-B CD10 NEG Immaturity was further suggested by high expression of the stem-cell antigens CD133 and CD135 although CD34 expression was significantly lower than in t 4 11 -negative patients Complete remission was achieved in 77 93 patients but only 35 survived 5 years 95 CI 25-45 the relapse rate was 45 95 CI 33-58 Thirty-one patients underwent allogeneic transplantation in first remission 15 sibling donors and 16 unrelated donors with 5-year survival rates of 56 and 67 respectively only 2/31 patients relapsed This compares with a 24 survival rate and 59 relapse rate in 46 patients who received post-remission chemotherapy A major determinant of outcome was age with 71 of patients aged 25 years surviving Younger patients had lower relapse rates 19 but most received allografts in first complete remission In conclusion multivariate analysis did not demonstrate an advantage of allografting over chemotherapy but only five younger patients received chemotherapy Prospective trials are required to determine whether poor outcomes in older patients can be improved by reduced-intensity conditioning allografts NCT00002514 www.clinicaltrials.gov,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 891, 2, 228, 1, 780, 102, 39, 175, 10524, 11423, 3049, 62384, 286, 1275, 32, 1240, 1784, 21, 897, 3, 228, 2, 5092, 177, 130, 2, 665, 539, 734, 36, 4, 772, 935, 7, 52, 89, 519, 60, 73, 4254, 4, 3, 482, 160, 24975, 34158, 3, 5496, 1, 26, 10, 1805, 132, 6289, 8696, 40242, 10, 195, 1148, 20, 64, 55, 1, 3, 452, 31, 1575, 5512, 2, 62385, 242, 2215, 55, 10, 97, 280, 76, 4, 102, 39, 175, 199, 7, 236, 734, 10, 513, 4, 849, 966, 7, 84, 158, 465, 2996, 33, 60, 48, 58, 243, 512, 3, 429, 116, 10, 512, 48, 58, 466, 717, 977, 104, 7, 208, 1063, 497, 4, 157, 734, 167, 3684, 2344, 2, 245, 2092, 2344, 5, 33, 111, 25, 151, 1, 664, 2, 598, 106, 158, 18, 456, 7, 591, 26, 5815, 5, 8, 259, 25, 116, 2, 728, 429, 116, 4, 641, 7, 54, 103, 539, 734, 56, 8, 458, 4372, 1, 228, 10, 89, 5, 792, 1, 7, 1032, 243, 60, 3050, 773, 7, 42, 280, 429, 151, 326, 84, 96, 103, 10586, 4, 157, 236, 734, 4, 1221, 331, 65, 205, 44, 608, 35, 1874, 1, 16181, 252, 56, 84, 158, 365, 773, 7, 103, 56, 482, 143, 32, 616, 6, 223, 317, 334, 123, 4, 434, 7, 122, 40, 231, 20, 405, 837, 1933, 10586, 31193, 3064, 1252, 1239]",1484.0,23349309,641
Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-01-28,"We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase (EC-Asnase) in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL). Patients achieving complete remission (CR) on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 were eligible for random assignment to 1) dexamethasone or prednisone, administered as 5-day pulses, every 3 weeks, and 2) weekly EC-Asnase, administered as a 25,000 IU/m(2) fixed dose (FD) or individualized dose (ID) starting at 12,500-IU/m(2), adjusted every 3 weeks based on nadir serum asparaginase activity (NSAA) determinations. Between 2000 and 2004, 492 evaluable patients (ages 1 to 18 years) enrolled; 473 patients (96%) achieved CR. Four hundred eight patients (86%) participated in the corticosteroid randomization and 384 patients (81%) in the EC-Asnase randomization. With 4.9 years of median follow-up, dexamethasone was associated with superior 5-year event-free survival (EFS; 90% v 81% for prednisone; P = .01) but higher rates of infection (P = .03) and, in older children, higher cumulative incidence of osteonecrosis (P = .02) and fracture (P = .06). ID EC-Asnase had superior 5-year EFS (90% v 82% for FD; P = .04), but did not reduce the frequency of asparaginase-related toxicity. Multivariable analysis identified both dexamethasone and ID EC-Asnase as independent predictors of favorable EFS. There was no overall difference in skeletal toxicity by corticosteroid type; dexamethasone was associated with more infections and, in older children, increased incidence of osteonecrosis and fracture. There was no difference in asparaginase-related toxicity by EC-Asnase dosing method. Dexamethasone and ID EC-Asnase were each associated with superior EFS. Monitoring NSAA during treatment with EC-Asnase may be an effective strategy to improve outcome in pediatric ALL.",Journal Article,2549.0,158.0,"We assessed the toxicity and efficacy of dexamethasone and a novel dosing method of Escherichia coli L-asparaginase EC-Asnase in children and adolescents with newly diagnosed acute lymphoblastic ALL Patients achieving complete remission CR on Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 were eligible for random assignment to 1 dexamethasone or prednisone administered as 5-day pulses every 3 weeks and 2 weekly EC-Asnase administered as a 25,000 IU/m 2 fixed dose FD or individualized dose ID starting at 12,500-IU/m 2 adjusted every 3 weeks based on nadir serum asparaginase activity NSAA determinations Between 2000 and 2004 492 evaluable patients ages 1 to 18 years enrolled 473 patients 96 achieved CR Four hundred eight patients 86 participated in the corticosteroid randomization and 384 patients 81 in the EC-Asnase randomization With 4.9 years of median follow-up dexamethasone was associated with superior 5-year event-free survival EFS 90 v 81 for prednisone P .01 but higher rates of infection P .03 and in older children higher cumulative incidence of osteonecrosis P .02 and fracture P .06 ID EC-Asnase had superior 5-year EFS 90 v 82 for FD P .04 but did not reduce the frequency of asparaginase-related toxicity Multivariable analysis identified both dexamethasone and ID EC-Asnase as independent predictors of favorable EFS There was no overall difference in skeletal toxicity by corticosteroid type dexamethasone was associated with more infections and in older children increased incidence of osteonecrosis and fracture There was no difference in asparaginase-related toxicity by EC-Asnase dosing method Dexamethasone and ID EC-Asnase were each associated with superior EFS Monitoring NSAA during treatment with EC-Asnase may be an effective strategy to improve outcome in pediatric ALL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 275, 3, 155, 2, 209, 1, 1217, 2, 8, 229, 1280, 596, 1, 12832, 6959, 805, 3709, 2180, 16558, 4, 541, 2, 3101, 5, 732, 265, 286, 1275, 62, 7, 1785, 236, 734, 684, 23, 4932, 4979, 12, 1377, 62, 2404, 1182, 2038, 355, 11, 625, 9, 2324, 4392, 6, 14, 1217, 15, 1979, 468, 22, 33, 218, 15523, 454, 27, 244, 2, 18, 709, 2180, 16558, 468, 22, 8, 243, 984, 4588, 188, 18, 1959, 61, 8485, 15, 2596, 61, 4937, 1723, 28, 133, 1666, 4588, 188, 18, 586, 454, 27, 244, 90, 23, 3686, 524, 3709, 128, 19885, 11894, 59, 1081, 2, 1131, 11628, 859, 7, 2165, 14, 6, 203, 60, 346, 10098, 7, 921, 513, 684, 294, 1128, 659, 7, 868, 3025, 4, 3, 5654, 3644, 2, 12612, 7, 865, 4, 3, 2180, 16558, 3644, 5, 39, 83, 60, 1, 52, 166, 126, 1217, 10, 41, 5, 1123, 33, 111, 774, 115, 25, 1683, 424, 603, 865, 9, 1979, 19, 355, 84, 142, 151, 1, 930, 19, 680, 2, 4, 434, 541, 142, 967, 287, 1, 5404, 19, 588, 2, 3956, 19, 1460, 4937, 2180, 16558, 42, 1123, 33, 111, 1683, 424, 603, 878, 9, 8485, 19, 755, 84, 205, 44, 969, 3, 675, 1, 3709, 139, 155, 658, 65, 108, 110, 1217, 2, 4937, 2180, 16558, 22, 306, 674, 1, 913, 1683, 125, 10, 77, 63, 523, 4, 2621, 155, 20, 5654, 267, 1217, 10, 41, 5, 80, 1875, 2, 4, 434, 541, 101, 287, 1, 5404, 2, 3956, 125, 10, 77, 523, 4, 3709, 139, 155, 20, 2180, 16558, 1280, 596, 1217, 2, 4937, 2180, 16558, 11, 296, 41, 5, 1123, 1683, 1315, 19885, 190, 24, 5, 2180, 16558, 68, 40, 35, 323, 692, 6, 401, 228, 4, 815, 62]",1820.0,23358966,381
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL.,Nature medicine,Nat. Med.,2013-02-03,"Acute lymphoblastic leukemia (ALL) is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors. Despite intensive chemotherapy, 20% of pediatric patients and over 50% of adult patients with ALL do not achieve a complete remission or relapse after intensified chemotherapy, making disease relapse and resistance to therapy the most substantial challenge in the treatment of this disease. Using whole-exome sequencing, we identify mutations in the cytosolic 5'-nucleotidase II gene (NT5C2), which encodes a 5'-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) relapse T cell ALLs and 1/35 (3%) relapse B-precursor ALLs. NT5C2 mutant proteins show increased nucleotidase activity in vitro and conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL lymphoblasts. These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL.",Journal Article,2543.0,190.0,Acute lymphoblastic ALL is an aggressive hematological tumor resulting from the malignant transformation of lymphoid progenitors Despite intensive chemotherapy 20 of pediatric patients and over 50 of adult patients with ALL do not achieve a complete remission or relapse after intensified chemotherapy making disease relapse and resistance to therapy the most substantial challenge in the treatment of this disease Using whole-exome sequencing we identify mutations in the cytosolic 5'-nucleotidase II gene NT5C2 which encodes a 5'-nucleotidase enzyme that is responsible for the inactivation of nucleoside-analog chemotherapy drugs in 20/103 19 relapse T cell ALLs and 1/35 3 relapse B-precursor ALLs NT5C2 mutant proteins show increased nucleotidase activity in vitro and conferred resistance to chemotherapy with 6-mercaptopurine and 6-thioguanine when expressed in ALL lymphoblasts These results support a prominent role for activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and chemotherapy resistance in ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 35, 571, 2890, 30, 1113, 29, 3, 393, 1392, 1, 2303, 4321, 550, 1686, 56, 179, 1, 815, 7, 2, 252, 212, 1, 780, 7, 5, 62, 1022, 44, 1359, 8, 236, 734, 15, 429, 50, 7311, 56, 1079, 34, 429, 2, 251, 6, 36, 3, 96, 1281, 1745, 4, 3, 24, 1, 26, 34, 75, 902, 2865, 615, 21, 255, 138, 4, 3, 7698, 7344, 35141, 215, 145, 17003, 92, 4322, 8, 7344, 35141, 1644, 17, 16, 2327, 9, 3, 2297, 1, 4032, 3497, 56, 600, 4, 179, 3283, 326, 429, 102, 31, 10706, 2, 14, 465, 27, 429, 132, 2765, 10706, 17003, 620, 652, 514, 101, 35141, 128, 4, 439, 2, 3851, 251, 6, 56, 5, 49, 9223, 2, 49, 17598, 198, 570, 4, 62, 10521, 46, 99, 538, 8, 3689, 200, 9, 1616, 138, 4, 17003, 2, 101, 4032, 3497, 1600, 4, 34, 91, 2, 56, 251, 4, 62]",1059.0,23377281,743
Lmo2 induces hematopoietic stem cell-like features in T-cell progenitor cells prior to leukemia.,"Stem cells (Dayton, Ohio)",Stem Cells,2013-05-01,"LIM domain only 2 (Lmo2) is frequently deregulated in sporadic and gene therapy-induced acute T-cell lymphoblastic leukemia (T-ALL) where its overexpression is an important initiating mutational event. In transgenic and retroviral mouse models, Lmo2 expression can be enforced in multiple hematopoietic lineages but leukemia only arises from T cells. These data suggest that Lmo2 confers clonal growth advantage in T-cell progenitors. We analyzed proliferation, differentiation, and cell death in CD2-Lmo2 transgenic thymic progenitor cells to understand the cellular effects of enforced Lmo2 expression. Most impressively, Lmo2 transgenic T-cell progenitor cells were blocked in differentiation, quiescent, and immortalized in vitro on OP9-DL1 stromal cells. These cellular effects were concordant with a transcriptional signature in Lmo2 transgenic T-cell progenitor cells that is also present in hematopoietic stem cells (HSCs) and early T-cell precursor ALL. These results are significant in light of the crucial role of Lmo2 in the maintenance of the HSC. The cellular effects and transcriptional effects have implications for LMO2-dependent leukemogenesis and the treatment of LMO2-induced T-ALL.",Journal Article,2456.0,26.0,LIM domain only 2 Lmo2 is frequently deregulated in sporadic and gene therapy-induced acute T-cell lymphoblastic T-ALL where its overexpression is an important initiating mutational event In transgenic and retroviral mouse models Lmo2 expression can be enforced in multiple hematopoietic lineages but only arises from T cells These data suggest that Lmo2 confers clonal growth advantage in T-cell progenitors We analyzed proliferation differentiation and cell death in CD2-Lmo2 transgenic thymic progenitor cells to understand the cellular effects of enforced Lmo2 expression Most impressively Lmo2 transgenic T-cell progenitor cells were blocked in differentiation quiescent and immortalized in vitro on OP9-DL1 stromal cells These cellular effects were concordant with a transcriptional signature in Lmo2 transgenic T-cell progenitor cells that is also present in hematopoietic stem cells HSCs and early T-cell precursor ALL These results are significant in light of the crucial role of Lmo2 in the maintenance of the HSC The cellular effects and transcriptional effects have implications for LMO2-dependent leukemogenesis and the treatment of LMO2-induced T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,"[19837, 1398, 158, 18, 11568, 16, 746, 5415, 4, 1928, 2, 145, 36, 277, 286, 102, 31, 1275, 102, 62, 1257, 211, 851, 16, 35, 305, 2637, 1619, 774, 4, 2862, 2, 8658, 830, 274, 11568, 55, 122, 40, 7807, 4, 232, 1007, 7234, 84, 158, 6053, 29, 102, 37, 46, 74, 309, 17, 11568, 4020, 1946, 129, 1874, 4, 102, 31, 4321, 21, 311, 457, 910, 2, 31, 273, 4, 11048, 11568, 2862, 3572, 2520, 37, 6, 1640, 3, 763, 176, 1, 7807, 11568, 55, 96, 35522, 11568, 2862, 102, 31, 2520, 37, 11, 2582, 4, 910, 6735, 2, 6090, 4, 439, 23, 62419, 13436, 1126, 37, 46, 763, 176, 11, 3610, 5, 8, 1431, 1651, 4, 11568, 2862, 102, 31, 2520, 37, 17, 16, 120, 364, 4, 1007, 452, 37, 6185, 2, 191, 102, 31, 2765, 62, 46, 99, 32, 93, 4, 1691, 1, 3, 2653, 200, 1, 11568, 4, 3, 1146, 1, 3, 5596, 3, 763, 176, 2, 1431, 176, 47, 1268, 9, 11568, 470, 5661, 2, 3, 24, 1, 11568, 277, 102, 62]",1164.0,23378057,79
Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-02-05,"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an exceedingly rare disorder categorized under acute myeloid leukemia by the World Health Organization. Phenotypically, malignant cells coexpress CD4(+) and CD56(+) without coexpressing common lymphoid or myeloid lineage markers. BPDCN frequently expresses CD123, TCL1, BDCA-2, and CD2AP. Restriction of CD2AP expression to plasmacytoid dendritic cells makes it a useful tool to help confirm diagnosis. Clonal complex chromosome aberrations are described in two-thirds of cases. Eighty percent of BPDCN cases present with nonspecific dermatological manifestations, prompting inclusion in the differential diagnosis of atypical skin rashes refractory to standard treatment. Prognosis is poor, with a median survival of less than 18 months. No prospective randomized data exist to define the most optimal frontline chemotherapy. Current practice considers acute myeloid leukemia-like or acute lymphoblastic leukemia-like regimens acceptable for induction treatment. Unfortunately, responses are short-lived, with second remissions difficult to achieve, underscoring the need to consider hematopoietic cell transplantation early in the disease course. Allografting, especially if offered in first remission, can result in long-term remissions. Preclinical data suggest a potential role for immunomodulatory agents in BPCDN. However, further research efforts are needed to better understand BPDCN biology and to establish evidence-based treatment algorithms that might ultimately improve overall prognosis of this disease. ",Journal Article,2541.0,46.0,Blastic plasmacytoid dendritic cell neoplasm BPDCN is an exceedingly rare disorder categorized under acute myeloid by the World Health Organization Phenotypically malignant cells coexpress CD4 and CD56 without coexpressing common lymphoid or myeloid lineage markers BPDCN frequently expresses CD123 TCL1 BDCA-2 and CD2AP Restriction of CD2AP expression to plasmacytoid dendritic cells makes it a useful tool to help confirm diagnosis Clonal complex chromosome aberrations are described in two-thirds of cases Eighty percent of BPDCN cases present with nonspecific dermatological manifestations prompting inclusion in the differential diagnosis of atypical rashes refractory to standard treatment Prognosis is poor with a median survival of less than 18 months No prospective randomized data exist to define the most optimal frontline chemotherapy Current practice considers acute myeloid leukemia-like or acute lymphoblastic leukemia-like regimens acceptable for induction treatment Unfortunately responses are short-lived with second remissions difficult to achieve underscoring the need to consider hematopoietic cell transplantation early in the disease course Allografting especially if offered in first remission can result in long-term remissions Preclinical data suggest a potential role for immunomodulatory agents in BPCDN However further research efforts are needed to better understand BPDCN biology and to establish evidence-based treatment algorithms that might ultimately improve overall prognosis of this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,"[6529, 7978, 2464, 31, 2131, 8556, 16, 35, 10303, 622, 2645, 2320, 669, 286, 533, 20, 3, 1956, 341, 2533, 8495, 393, 37, 22044, 1440, 2, 5803, 187, 16629, 186, 2303, 15, 533, 2542, 525, 8556, 746, 8293, 8849, 8979, 40262, 18, 2, 40263, 4575, 1, 40263, 55, 6, 7978, 2464, 37, 4677, 192, 8, 999, 1515, 6, 987, 1843, 147, 1946, 840, 1170, 2152, 32, 1027, 4, 100, 5438, 1, 140, 2207, 714, 1, 8556, 140, 364, 5, 5893, 14906, 4282, 8499, 1680, 4, 3, 1777, 147, 1, 1973, 11775, 430, 6, 260, 24, 356, 16, 334, 5, 8, 52, 25, 1, 299, 76, 203, 53, 77, 482, 384, 74, 1923, 6, 1107, 3, 96, 665, 3171, 56, 291, 758, 9961, 286, 533, 2647, 733, 15, 286, 1275, 2647, 733, 472, 1595, 9, 504, 24, 3869, 253, 32, 978, 4813, 5, 419, 3166, 1740, 6, 1359, 8369, 3, 594, 6, 2419, 1007, 31, 497, 191, 4, 3, 34, 906, 16181, 1093, 492, 2216, 4, 157, 734, 122, 757, 4, 319, 337, 3166, 693, 74, 309, 8, 174, 200, 9, 2555, 183, 4, 62446, 137, 195, 389, 1413, 32, 575, 6, 380, 1640, 8556, 891, 2, 6, 1811, 241, 90, 24, 3529, 17, 822, 2050, 401, 63, 356, 1, 26, 34]",1527.0,23396213,450
Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2013-02-15,"Dendritic cell leukemia (DCL) or hematodermic tumor is an uncommon subtype of acute leukemia. In contrast to adult cases, children tend to have a less aggressive course. The diagnosis of DCL should be considered when its characteristic morphologic features are present and leukemic cells co-express CD4 and CD56. Cases of DCL among pediatric patients have been reported to respond to therapeutic regimens for acute lymphoblastic leukemia, but details regarding the specifics of therapy are lacking.",Case Reports,2531.0,2.0,Dendritic cell DCL or hematodermic tumor is an uncommon subtype of acute In contrast to adult cases children tend to have a less aggressive course The diagnosis of DCL should be considered when its characteristic morphologic features are present and leukemic cells co-express CD4 and CD56 Cases of DCL among pediatric patients have been reported to respond to therapeutic regimens for acute lymphoblastic but details regarding the specifics of therapy are lacking,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2464, 31, 40274, 15, 34949, 30, 16, 35, 2052, 875, 1, 286, 4, 748, 6, 780, 140, 541, 5406, 6, 47, 8, 299, 571, 906, 3, 147, 1, 40274, 257, 40, 515, 198, 211, 2037, 2815, 404, 32, 364, 2, 2015, 37, 1269, 1669, 1440, 2, 5803, 140, 1, 40274, 107, 815, 7, 47, 85, 210, 6, 1892, 6, 189, 472, 9, 286, 1275, 84, 3791, 666, 3, 24852, 1, 36, 32, 1941]",463.0,23417921,104
Slower processing speed after treatment for pediatric brain tumor and acute lymphoblastic leukemia.,Psycho-oncology,Psychooncology,2013-02-28,"Acute lymphoblastic leukemia (ALL) and brain tumor (BT) survivors are at risk for post-treatment IQ declines. The extent to which lower scores represent global cognitive decline versus domain-specific impairment remains unclear. This study examined discrepancies between processing speed and estimated IQ (EIQ) scores and identified clinical characteristics associated with score discrepancies in a sample of pediatric cancer survivors. Survivors (50 ALL, 50 BT) ages 12-17 years completed cognitive testing. The Wechsler Abbreviated Scale of Intelligence provided an untimed measure of general reasoning ability (EIQ). The age-appropriate Wechsler Intelligence Scale provided a Processing Speed Index (PSI) score. Scores were examined and compared. Survivors' PSI scores were lower than their EIQ scores (BT t(45)=6.3, p<0.001; ALL t(49)=6.9, p<0.001). For BT survivors, lower PSI scores were associated with history of craniospinal irradiation, t(44)=3.3, p<0.01. For ALL survivors, lower PSI scores were associated with male gender, grade retention, and time since diagnosis, F(3, 46)=10.1, p<0.001. Clinically significant EIQ-PSI score discrepancies were identified in 41.3% of BT and 14.0% of ALL survivors. Many pediatric BT and ALL survivors exhibit slower processing speed than expected for age, whereas general reasoning ability remains largely intact. Risk factors associated with larger EIQ-PSI discrepancies include the following: BT diagnosis, craniospinal irradiation (BT only), male gender, and younger age at diagnosis (ALL only). Grade retention was frequent and associated with lower EIQ scores (both groups) and PSI scores (ALL only). Describing post-treatment cognitive declines using global measures of intellectual ability may underestimate dysfunction or fail to isolate specific underlying deficits contributing to impairment.",Journal Article,2518.0,37.0,Acute lymphoblastic ALL and brain tumor BT survivors are at risk for post-treatment IQ declines The extent to which lower scores represent global cognitive decline versus domain-specific impairment remains unclear This study examined discrepancies between processing speed and estimated IQ EIQ scores and identified clinical characteristics associated with score discrepancies in a sample of pediatric cancer survivors Survivors 50 ALL 50 BT ages 12-17 years completed cognitive testing The Wechsler Abbreviated Scale of Intelligence provided an untimed measure of general reasoning ability EIQ The age-appropriate Wechsler Intelligence Scale provided a Processing Speed Index PSI score Scores were examined and compared Survivors PSI scores were lower than their EIQ scores BT t 45 =6.3 p 0.001 ALL t 49 =6.9 p 0.001 For BT survivors lower PSI scores were associated with history of craniospinal irradiation t 44 =3.3 p 0.01 For ALL survivors lower PSI scores were associated with male gender grade retention and time since diagnosis F 3 46 =10.1 p 0.001 Clinically significant EIQ-PSI score discrepancies were identified in 41.3 of BT and 14.0 of ALL survivors Many pediatric BT and ALL survivors exhibit slower processing speed than expected for age whereas general reasoning ability remains largely intact Risk factors associated with larger EIQ-PSI discrepancies include the following BT diagnosis craniospinal irradiation BT only male gender and younger age at diagnosis ALL only Grade retention was frequent and associated with lower EIQ scores both groups and PSI scores ALL only Describing post-treatment cognitive declines using global measures of intellectual ability may underestimate dysfunction or fail to isolate specific underlying deficits contributing to impairment,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 2, 342, 30, 3641, 332, 32, 28, 43, 9, 539, 24, 7666, 4264, 3, 1039, 6, 92, 280, 703, 1231, 1648, 1863, 1858, 185, 1398, 112, 2315, 469, 1200, 26, 45, 409, 7631, 59, 3325, 5051, 2, 661, 7666, 29405, 703, 2, 108, 38, 374, 41, 5, 368, 7631, 4, 8, 1000, 1, 815, 12, 332, 332, 212, 62, 212, 3641, 2165, 133, 269, 60, 781, 1863, 471, 3, 17526, 9786, 1124, 1, 9125, 1052, 35, 62505, 1463, 1, 1083, 15856, 801, 29405, 3, 89, 870, 17526, 9125, 1124, 1052, 8, 3325, 5051, 558, 15885, 368, 703, 11, 409, 2, 72, 332, 15885, 703, 11, 280, 76, 136, 29405, 703, 3641, 102, 512, 49, 27, 19, 13, 144, 62, 102, 739, 49, 83, 19, 13, 144, 9, 3641, 332, 280, 15885, 703, 11, 41, 5, 532, 1, 5748, 1104, 102, 584, 27, 27, 19, 13, 355, 9, 62, 332, 280, 15885, 703, 11, 41, 5, 1045, 1632, 88, 3947, 2, 98, 1192, 147, 1068, 27, 641, 79, 14, 19, 13, 144, 505, 93, 29405, 15885, 368, 7631, 11, 108, 4, 605, 27, 1, 3641, 2, 213, 13, 1, 62, 332, 445, 815, 3641, 2, 62, 332, 2239, 6715, 3325, 5051, 76, 1336, 9, 89, 547, 1083, 15856, 801, 469, 1733, 2964, 43, 130, 41, 5, 1077, 29405, 15885, 7631, 643, 3, 366, 3641, 147, 5748, 1104, 3641, 158, 1045, 1632, 2, 773, 89, 28, 147, 62, 158, 88, 3947, 10, 908, 2, 41, 5, 280, 29405, 703, 110, 271, 2, 15885, 703, 62, 158, 4950, 539, 24, 1863, 4264, 75, 1648, 1018, 1, 12346, 801, 68, 10397, 1527, 15, 4373, 6, 7910, 112, 1181, 2752, 3156, 6, 2315]",1783.0,23447439,630
Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.,Cancer,Cancer,2013-03-01,"Absolute lymphocyte counts (ALC) during treatment have been associated with outcome in children and adults with hematologic malignancies. However, the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic leukemia (ALL) treated in recent trials is unknown. Outcomes of 399 patients aged 18 years with newly diagnosed ALL who were enrolled in the Total Therapy XV study at St. Jude Children's Research Hospital were analyzed according to ALC at the end of remission induction therapy. An ALC 500 cells/L was significantly more prevalent among patients with B-lineage ALL, in those with favorable presenting features, and in those who achieved negative minimal residual disease (MRD) status on day 43 of treatment. Both overall survival (OS) and event-free survival (EFS) were superior among patients with higher ALC, but only the association with OS was statistically significant in a univariate analysis. In multivariable analyses, ALC was not a significant predictor of outcome after controlling for age, leukocyte count, lineage, risk group, and MRD status at the end of induction (P > .1 for all comparisons). However, among MRD-negative patients, those with low ALC had a 5-year OS rate of 84.2%  8.9% versus 97.3%  1.0% for patients with higher ALC (P = .036). ALC at the end of induction is related to favorable presenting features and good initial treatment response but does not independently predict outcome in the context of contemporary, MRD-guided therapy.",Journal Article,2517.0,18.0,Absolute lymphocyte counts ALC during treatment have been associated with outcome in children and adults with hematologic malignancies However the impact of ALC relative to that of other prognostic factors on the outcome of children with acute lymphoblastic ALL treated in recent trials is unknown Outcomes of 399 patients aged 18 years with newly diagnosed ALL who were enrolled in the Total Therapy XV study at St. Jude Children 's Research Hospital were analyzed according to ALC at the end of remission induction therapy An ALC 500 cells/L was significantly more prevalent among patients with B-lineage ALL in those with favorable presenting features and in those who achieved negative minimal residual disease MRD status on day 43 of treatment Both overall survival OS and event-free survival EFS were superior among patients with higher ALC but only the association with OS was statistically significant in a univariate analysis In multivariable analyses ALC was not a significant predictor of outcome after controlling for age leukocyte count lineage risk group and MRD status at the end of induction P .1 for all comparisons However among MRD-negative patients those with low ALC had a 5-year OS rate of 84.2  8.9 versus 97.3  1.0 for patients with higher ALC P .036 ALC at the end of induction is related to favorable presenting features and good initial treatment response but does not independently predict outcome in the context of contemporary MRD-guided therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1766, 1448, 1911, 3749, 190, 24, 47, 85, 41, 5, 228, 4, 541, 2, 857, 5, 813, 441, 137, 3, 345, 1, 3749, 580, 6, 17, 1, 127, 177, 130, 23, 3, 228, 1, 541, 5, 286, 1275, 62, 73, 4, 435, 143, 16, 860, 123, 1, 9623, 7, 1032, 21752, 60, 5, 732, 265, 62, 54, 11, 346, 4, 3, 181, 36, 16078, 45, 28, 3062, 4841, 541, 292, 389, 702, 11, 311, 768, 6, 3749, 28, 3, 396, 1, 734, 504, 36, 35, 3749, 35133, 37, 5513, 10, 97, 80, 2485, 107, 7, 5, 132, 2542, 62, 4, 135, 5, 913, 1656, 404, 2, 4, 135, 54, 513, 199, 1048, 753, 34, 2029, 156, 23, 218, 601, 1, 24, 110, 63, 25, 118, 2, 774, 115, 25, 1683, 11, 1123, 107, 7, 5, 142, 3749, 84, 158, 3, 248, 5, 118, 10, 712, 93, 4, 8, 880, 65, 4, 658, 318, 3749, 10, 44, 8, 93, 980, 1, 228, 50, 1893, 9, 89, 3627, 1276, 2542, 43, 87, 2, 2029, 156, 28, 3, 396, 1, 504, 19, 14, 9, 62, 2213, 137, 107, 2029, 199, 7, 135, 5, 154, 3749, 42, 8, 33, 111, 118, 116, 1, 874, 18, 810, 66, 83, 185, 1015, 27, 810, 14, 13, 9, 7, 5, 142, 3749, 19, 5395, 3749, 28, 3, 396, 1, 504, 16, 139, 6, 913, 1656, 404, 2, 1178, 388, 24, 51, 84, 1097, 44, 1042, 678, 228, 4, 3, 1533, 1, 2667, 2029, 1808, 36]",1480.0,23456849,715
Novel susceptibility variants at 10p12.31-12.2 for childhood acute lymphoblastic leukemia in ethnically diverse populations.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2013-03-19,"Acute lymphoblastic leukemia (ALL) is the most common cancer in children and the incidence of ALL varies by ethnicity. Although accumulating evidence indicates inherited predisposition to ALL, the genetic basis of ALL susceptibility in diverse ancestry has not been comprehensively examined. We performed a multiethnic genome-wide association study in 1605 children with ALL and 6661 control subjects after adjusting for population structure, with validation in three replication series of 845 case subjects and 4316 control subjects. Association was tested by two-sided logistic regression. A novel ALL susceptibility locus at 10p12.31-12.2 (BMI1-PIP4K2A, rs7088318, P = 1.1  10(-11)) was identified in the genome-wide association study, with independent replication in European Americans, African Americans, and Hispanic Americans (P = .001, .009, and .04, respectively). Association was also validated at four known ALL susceptibility loci: ARID5B, IKZF1, CEBPE, and CDKN2A/2B. Associations at ARID5B, IKZF1, and BMI1-PIP4K2A variants were consistent across ethnicity, with multiple independent signals at IKZF1 and BMI1-PIP4K2A loci. The frequency of ARID5B and BMI1-PIP4K2A variants differed by ethnicity, in parallel with ethnic differences in ALL incidence. Suggestive evidence for modifying effects of age on genetic predisposition to ALL was also observed. ARID5B, IKZF1, CEBPE, and BMI1-PIP4K2A variants cumulatively conferred strong predisposition to ALL, with children carrying six to eight copies of risk alleles at a ninefold (95% confidence interval = 6.9 to 11.8) higher ALL risk relative to those carrying zero to one risk allele at these four single nucleotide polymorphisms. These findings indicate strong associations between inherited genetic variation and ALL susceptibility in children and shed new light on ALL molecular etiology in diverse ancestry.",Journal Article,2499.0,124.0,Acute lymphoblastic ALL is the most common cancer in children and the incidence of ALL varies by ethnicity Although accumulating evidence indicates inherited predisposition to ALL the genetic basis of ALL susceptibility in diverse ancestry has not been comprehensively examined We performed a multiethnic genome-wide association study in 1605 children with ALL and 6661 control subjects after adjusting for population structure with validation in three replication series of 845 case subjects and 4316 control subjects Association was tested by two-sided logistic regression A novel ALL susceptibility locus at 10p12.31-12.2 BMI1-PIP4K2A rs7088318 P 1.1 10 -11 was identified in the genome-wide association study with independent replication in European Americans African Americans and Hispanic Americans P .001 .009 and .04 respectively Association was also validated at four known ALL susceptibility loci ARID5B IKZF1 CEBPE and CDKN2A/2B Associations at ARID5B IKZF1 and BMI1-PIP4K2A variants were consistent across ethnicity with multiple independent signals at IKZF1 and BMI1-PIP4K2A loci The frequency of ARID5B and BMI1-PIP4K2A variants differed by ethnicity in parallel with ethnic differences in ALL incidence Suggestive evidence for modifying effects of age on genetic predisposition to ALL was also observed ARID5B IKZF1 CEBPE and BMI1-PIP4K2A variants cumulatively conferred strong predisposition to ALL with children carrying six to eight copies of risk alleles at a ninefold 95 confidence interval 6.9 to 11.8 higher ALL risk relative to those carrying zero to one risk allele at these four single nucleotide polymorphisms These findings indicate strong associations between inherited genetic variation and ALL susceptibility in children and shed new light on ALL molecular etiology in diverse ancestry,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 3, 96, 186, 12, 4, 541, 2, 3, 287, 1, 62, 4037, 20, 2091, 242, 6233, 241, 2640, 2986, 2863, 6, 62, 3, 336, 877, 1, 62, 1432, 4, 1867, 3535, 71, 44, 85, 5627, 409, 21, 173, 8, 17756, 898, 1019, 248, 45, 4, 44157, 541, 5, 62, 2, 47664, 182, 976, 50, 1358, 9, 266, 2772, 5, 929, 4, 169, 2079, 988, 1, 15676, 473, 976, 2, 47665, 182, 976, 248, 10, 650, 20, 100, 1689, 812, 320, 8, 229, 62, 1432, 2474, 28, 32114, 456, 133, 18, 10251, 32115, 62598, 19, 14, 14, 79, 175, 10, 108, 4, 3, 898, 1019, 248, 45, 5, 306, 2079, 4, 1865, 2731, 1410, 2731, 2, 1776, 2731, 19, 144, 2376, 2, 755, 106, 248, 10, 120, 938, 28, 294, 440, 62, 1432, 2012, 17439, 8422, 40308, 2, 3175, 3381, 685, 28, 17439, 8422, 2, 10251, 32115, 839, 11, 925, 716, 2091, 5, 232, 306, 2312, 28, 8422, 2, 10251, 32115, 2012, 3, 675, 1, 17439, 2, 10251, 32115, 839, 2512, 20, 2091, 4, 2755, 5, 2871, 362, 4, 62, 287, 3832, 241, 9, 4898, 176, 1, 89, 23, 336, 2863, 6, 62, 10, 120, 164, 17439, 8422, 40308, 2, 10251, 32115, 839, 18939, 3851, 1082, 2863, 6, 62, 5, 541, 2934, 437, 6, 659, 5127, 1, 43, 2558, 28, 8, 28647, 48, 307, 268, 49, 83, 6, 175, 66, 142, 62, 43, 580, 6, 135, 2934, 5115, 6, 104, 43, 1254, 28, 46, 294, 226, 1579, 1203, 46, 272, 1008, 1082, 685, 59, 2986, 336, 1380, 2, 62, 1432, 4, 541, 2, 5816, 217, 1691, 23, 62, 219, 2855, 4, 1867, 3535]",1815.0,23512250,387
CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia.,Science translational medicine,Sci Transl Med,2013-03-01,"Adults with relapsed B cell acute lymphoblastic leukemia (B-ALL) have a dismal prognosis. Only those patients able to achieve a second remission with no minimal residual disease (MRD) have a hope for long-term survival in the context of a subsequent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We have treated five relapsed B-ALL subjects with autologous T cells expressing a CD19-specific CD28/CD3 second-generation dual-signaling chimeric antigen receptor (CAR) termed 19-28z. All patients with persistent morphological disease or MRD(+) disease upon T cell infusion demonstrated rapid tumor eradication and achieved MRD(-) complete remissions as assessed by deep sequencing polymerase chain reaction. Therapy was well tolerated, although significant cytokine elevations, specifically observed in those patients with morphologic evidence of disease at the time of treatment, required lymphotoxic steroid therapy to ameliorate cytokine-mediated toxicities. Indeed, cytokine elevations directly correlated to tumor burden at the time of CAR-modified T cell infusions. Tumor cells from one patient with relapsed disease after CAR-modified T cell therapy, who was ineligible for additional allo-HSCT or T cell therapy, exhibited persistent expression of CD19 and sensitivity to autologous 19-28z T cell-mediated cytotoxicity, which suggests potential clinical benefit of additional CAR-modified T cell infusions. These results demonstrate the marked antitumor efficacy of 19-28z CAR-modified T cells in patients with relapsed/refractory B-ALL and the reliability of this therapy to induce profound molecular remissions, forming a highly effective bridge to potentially curative therapy with subsequent allo-HSCT.",Clinical Trial,2517.0,1042.0,Adults with relapsed B cell acute lymphoblastic B-ALL have a dismal prognosis Only those patients able to achieve a second remission with no minimal residual disease MRD have a hope for long-term survival in the context of a subsequent allogeneic hematopoietic stem cell transplantation allo-HSCT We have treated five relapsed B-ALL subjects with autologous T cells expressing a CD19-specific CD28/CD3 second-generation dual-signaling chimeric antigen receptor CAR termed 19-28z All patients with persistent morphological disease or MRD disease upon T cell infusion demonstrated rapid tumor eradication and achieved MRD complete remissions as assessed by deep sequencing polymerase chain reaction Therapy was well tolerated although significant cytokine elevations specifically observed in those patients with morphologic evidence of disease at the time of treatment required lymphotoxic steroid therapy to ameliorate cytokine-mediated toxicities Indeed cytokine elevations directly correlated to tumor burden at the time of CAR-modified T cell infusions Tumor cells from one patient with relapsed disease after CAR-modified T cell therapy who was ineligible for additional allo-HSCT or T cell therapy exhibited persistent expression of CD19 and sensitivity to autologous 19-28z T cell-mediated cytotoxicity which suggests potential clinical benefit of additional CAR-modified T cell infusions These results demonstrate the marked antitumor efficacy of 19-28z CAR-modified T cells in patients with relapsed/refractory B-ALL and the reliability of this therapy to induce profound molecular remissions forming a highly effective bridge to potentially curative therapy with subsequent allo-HSCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[857, 5, 591, 132, 31, 286, 1275, 132, 62, 47, 8, 3929, 356, 158, 135, 7, 1665, 6, 1359, 8, 419, 734, 5, 77, 1048, 753, 34, 2029, 47, 8, 3045, 9, 319, 337, 25, 4, 3, 1533, 1, 8, 706, 1063, 1007, 452, 31, 497, 2564, 1703, 21, 47, 73, 365, 591, 132, 62, 976, 5, 1028, 102, 37, 1046, 8, 3158, 112, 5603, 27267, 419, 914, 1828, 314, 2897, 448, 153, 1881, 4183, 326, 19130, 62, 7, 5, 1882, 4268, 34, 15, 2029, 34, 1548, 102, 31, 904, 264, 1321, 30, 5173, 2, 513, 2029, 236, 3166, 22, 275, 20, 2369, 615, 1451, 1260, 1329, 36, 10, 149, 421, 242, 93, 1675, 4712, 1225, 164, 4, 135, 7, 5, 2815, 241, 1, 34, 28, 3, 98, 1, 24, 616, 62599, 3853, 36, 6, 9179, 1675, 517, 385, 4462, 1675, 4712, 1606, 438, 6, 30, 892, 28, 3, 98, 1, 1881, 1230, 102, 31, 3435, 30, 37, 29, 104, 69, 5, 591, 34, 50, 1881, 1230, 102, 31, 36, 54, 10, 3773, 9, 402, 2564, 1703, 15, 102, 31, 36, 1416, 1882, 55, 1, 3158, 2, 485, 6, 1028, 326, 19130, 102, 31, 517, 1408, 92, 844, 174, 38, 247, 1, 402, 1881, 1230, 102, 31, 3435, 46, 99, 608, 3, 2003, 579, 209, 1, 326, 19130, 1881, 1230, 102, 37, 4, 7, 5, 591, 430, 132, 62, 2, 3, 4217, 1, 26, 36, 6, 1290, 4399, 219, 3166, 4525, 8, 561, 323, 7728, 6, 751, 1075, 36, 5, 706, 2564, 1703]",1692.0,23515080,292
Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.,Leukemia & lymphoma,Leuk. Lymphoma,2013-06-21,"Conventional cytotoxic chemotherapy for adult acute lymphoblastic leukemia (ALL) is not adequate to cure most patients of the disease. Complete remission is achieved in the majority of patients, but responses are often not durable. Allogeneic stem cell transplant is used for patients with high risk features, including those who are positive for minimal residual disease after induction and consolidation therapy. Nevertheless, transplant is a toxic intervention, and does not guarantee long-term disease-free survival. Monoclonal antibodies target surface antigens present on leukemic blasts, with the aim of minimizing off-target toxicity. Rituximab, an antibody directed against CD20, prolongs the survival of younger adults with ALL when added to chemotherapy in the frontline setting. Novel agents, such as the cytotoxin-antibody conjugate inotuzumab, and the bispecific T-cell engaging compound blinatumomab, have exhibited marked antileukemic activity in the relapsed setting. As these agents continue in clinical development, it will be important to eventually incorporate them in the frontline treatment approach. We review current strategies for treating adult ALL, with a focus on novel and targeted therapies that are under development.",Journal Article,2405.0,9.0,Conventional cytotoxic chemotherapy for adult acute lymphoblastic ALL is not adequate to cure most patients of the disease Complete remission is achieved in the majority of patients but responses are often not durable Allogeneic stem cell transplant is used for patients with high risk features including those who are positive for minimal residual disease after induction and consolidation therapy Nevertheless transplant is a toxic intervention and does not guarantee long-term disease-free survival Monoclonal antibodies target surface antigens present on leukemic blasts with the aim of minimizing off-target toxicity Rituximab an antibody directed against CD20 prolongs the survival of younger adults with ALL when added to chemotherapy in the frontline setting Novel agents such as the cytotoxin-antibody conjugate inotuzumab and the bispecific T-cell engaging compound blinatumomab have exhibited marked antileukemic activity in the relapsed setting As these agents continue in clinical development it will be important to eventually incorporate them in the frontline treatment approach We review current strategies for treating adult ALL with a focus on novel and targeted therapies that are under development,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[809, 759, 56, 9, 780, 286, 1275, 62, 16, 44, 1658, 6, 1722, 96, 7, 1, 3, 34, 236, 734, 16, 513, 4, 3, 686, 1, 7, 84, 253, 32, 629, 44, 1480, 1063, 452, 31, 941, 16, 95, 9, 7, 5, 64, 43, 404, 141, 135, 54, 32, 109, 9, 1048, 753, 34, 50, 504, 2, 2173, 36, 3873, 941, 16, 8, 1812, 788, 2, 1097, 44, 19141, 319, 337, 34, 115, 25, 848, 890, 283, 1255, 1575, 364, 23, 2015, 2438, 5, 3, 1130, 1, 4501, 1889, 283, 155, 855, 35, 548, 1166, 480, 2198, 5613, 3, 25, 1, 773, 857, 5, 62, 198, 1953, 6, 56, 4, 3, 3171, 546, 229, 183, 225, 22, 3, 13870, 548, 3998, 6730, 2, 3, 7408, 102, 31, 8534, 2823, 7182, 47, 1416, 2003, 4512, 128, 4, 3, 591, 546, 22, 46, 183, 1906, 4, 38, 193, 192, 303, 40, 305, 6, 3124, 3360, 1370, 4, 3, 3171, 24, 353, 21, 206, 291, 422, 9, 1367, 780, 62, 5, 8, 1222, 23, 229, 2, 238, 235, 17, 32, 669, 193]",1217.0,23547835,50
The treatment of adolescents and young adults with acute lymphoblastic leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2013-06-01,"Adolescents and young adult (AYA) patients with acute lymphoblastic leukemia (ALL), 16-40 years of age, were historically not the focus of prospective studies on ALL treatment. This population has unique genetic, immunophenotypic, and clinical features, differing from both pediatric and older adult patients, with outcomes somewhere between these two populations. However, it has been suggested that outcomes (event-free and overall survival) for these patients are better when they are treated with pediatric-inspired therapeutic regimens. This has been attributed to increased dose and frequency of non-myelosuppressive therapy, earlier and more frequent central nervous system prophylaxis, and longer maintenance therapy. However, management by the treating oncologist and adherence by the patients are equally vital. Ultimately, the combination of improved treatment regimens and organizational management are required to improve outcomes of ALL in the AYA population.",Journal Article,2425.0,15.0,Adolescents and young adult AYA patients with acute lymphoblastic ALL 16-40 years of age were historically not the focus of prospective studies on ALL treatment This population has unique genetic immunophenotypic and clinical features differing from both pediatric and older adult patients with outcomes somewhere between these two populations However it has been suggested that outcomes event-free and overall survival for these patients are better when they are treated with pediatric-inspired therapeutic regimens This has been attributed to increased dose and frequency of non-myelosuppressive therapy earlier and more frequent central nervous system prophylaxis and longer maintenance therapy However management by the treating oncologist and adherence by the patients are equally vital Ultimately the combination of improved treatment regimens and organizational management are required to improve outcomes of ALL in the AYA population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3101, 2, 1169, 780, 4598, 7, 5, 286, 1275, 62, 245, 327, 60, 1, 89, 11, 3578, 44, 3, 1222, 1, 482, 94, 23, 62, 24, 26, 266, 71, 991, 336, 6599, 2, 38, 404, 5276, 29, 110, 815, 2, 434, 780, 7, 5, 123, 28008, 59, 46, 100, 1184, 137, 192, 71, 85, 1148, 17, 123, 774, 115, 2, 63, 25, 9, 46, 7, 32, 380, 198, 491, 32, 73, 5, 815, 13161, 189, 472, 26, 71, 85, 3073, 6, 101, 61, 2, 675, 1, 220, 11109, 36, 1677, 2, 80, 908, 854, 1880, 398, 2049, 2, 589, 1146, 36, 137, 284, 20, 3, 1367, 2709, 2, 2149, 20, 3, 7, 32, 4142, 3511, 2050, 3, 150, 1, 231, 24, 472, 2, 14839, 284, 32, 616, 6, 401, 123, 1, 62, 4, 3, 4598, 266]",941.0,23559026,567
Evaluation of memory impairment in aging adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiotherapy.,Journal of the National Cancer Institute,J. Natl. Cancer Inst.,2013-04-12,"Cranial radiotherapy (CRT) is a known risk factor for neurocognitive impairment in survivors of childhood cancer and may increase risk for mild cognitive impairment and dementia in adulthood. We performed a cross-sectional evaluation of survivors of childhood acute lymphoblastic leukemia (ALL) treated with 18 Gy (n = 127) or 24 Gy (n = 138) CRT. Impairment (age-adjusted score >1 standard deviation below expected mean, two-sided exact binomial test) on the Wechsler Memory Scale IV (WMS-IV) was measured. A subset of survivors (n = 85) completed structural and functional neuroimaging. Survivors who received 24 Gy, but not 18 Gy, CRT had impairment in immediate (impairment rate = 33.8%, 95% confidence interval [CI] = 25.9% to 42.4%; P < .001) and delayed memory (impairment rate = 30.2%, 95% CI = 22.6% to 38.6%; P < .001). The mean score for long-term narrative memory among survivors who received 24 Gy CRT was equivalent to that for individuals older than 69 years. Impaired immediate memory was associated with smaller right (P = .02) and left (P = .008) temporal lobe volumes, and impaired delayed memory was associated with thinner parietal and frontal cortices. Lower hippocampal volumes and increased functional magnetic resonance imaging activation were observed with memory impairment. Reduced cognitive status (Brief Cognitive Status Exam from the WMS-IV) was identified after 24 Gy (18.5%, 95% CI = 12.4% to 26.1%; P < .001), but not 18 Gy (8.7%, 95% CI = 4.4% to 15.0%; P = .11), CRT, suggesting a dose-response effect. Employment rates were equivalent (63.8% for 24 Gy CRT and 63.0% for 18 Gy CRT). Adult survivors who received 24 Gy CRT had reduced cognitive status and memory, with reduced integrity in neuroanatomical regions essential in memory formation, consistent with early onset mild cognitive impairment.",Journal Article,2475.0,,Cranial radiotherapy CRT is a known risk factor for neurocognitive impairment in survivors of childhood cancer and may increase risk for mild cognitive impairment and dementia in adulthood We performed a cross-sectional evaluation of survivors of childhood acute lymphoblastic ALL treated with 18 Gy n 127 or 24 Gy n 138 CRT Impairment age-adjusted score 1 standard deviation below expected mean two-sided exact binomial test on the Wechsler Memory Scale IV WMS-IV was measured A subset of survivors n 85 completed structural and functional neuroimaging Survivors who received 24 Gy but not 18 Gy CRT had impairment in immediate impairment rate 33.8 95 confidence interval CI 25.9 to 42.4 P .001 and delayed memory impairment rate 30.2 95 CI 22.6 to 38.6 P .001 The mean score for long-term narrative memory among survivors who received 24 Gy CRT was equivalent to that for individuals older than 69 years Impaired immediate memory was associated with smaller right P .02 and left P .008 temporal lobe volumes and impaired delayed memory was associated with thinner parietal and frontal cortices Lower hippocampal volumes and increased functional magnetic resonance imaging activation were observed with memory impairment Reduced cognitive status Brief Cognitive Status Exam from the WMS-IV was identified after 24 Gy 18.5 95 CI 12.4 to 26.1 P .001 but not 18 Gy 8.7 95 CI 4.4 to 15.0 P .11 CRT suggesting a dose-response effect Employment rates were equivalent 63.8 for 24 Gy CRT and 63.0 for 18 Gy CRT Adult survivors who received 24 Gy CRT had reduced cognitive status and memory with reduced integrity in neuroanatomical regions essential in memory formation consistent with early onset mild cognitive impairment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2565, 310, 1089, 16, 8, 440, 43, 161, 9, 2958, 2315, 4, 332, 1, 864, 12, 2, 68, 344, 43, 9, 1980, 1863, 2315, 2, 10843, 4, 6002, 21, 173, 8, 1383, 2832, 451, 1, 332, 1, 864, 286, 1275, 62, 73, 5, 203, 381, 78, 4080, 15, 259, 381, 78, 4478, 1089, 2315, 89, 586, 368, 14, 260, 3348, 2736, 1336, 313, 100, 1689, 2472, 8538, 412, 23, 3, 17526, 2407, 1124, 478, 47703, 478, 10, 644, 8, 697, 1, 332, 78, 772, 781, 3281, 2, 583, 7468, 332, 54, 103, 259, 381, 84, 44, 203, 381, 1089, 42, 2315, 4, 2181, 2315, 116, 466, 66, 48, 307, 268, 58, 243, 83, 6, 595, 39, 19, 144, 2, 1612, 2407, 2315, 116, 201, 18, 48, 58, 350, 49, 6, 519, 49, 19, 144, 3, 313, 368, 9, 319, 337, 8963, 2407, 107, 332, 54, 103, 259, 381, 1089, 10, 2017, 6, 17, 9, 869, 434, 76, 790, 60, 2364, 2181, 2407, 10, 41, 5, 2170, 1913, 19, 588, 2, 1712, 19, 2155, 3264, 4940, 2225, 2, 2364, 1612, 2407, 10, 41, 5, 21936, 14423, 2, 8082, 21721, 280, 16469, 2225, 2, 101, 583, 1484, 1535, 270, 363, 11, 164, 5, 2407, 2315, 405, 1863, 156, 3190, 1863, 156, 6747, 29, 3, 47703, 478, 10, 108, 50, 259, 381, 203, 33, 48, 58, 133, 39, 6, 432, 14, 19, 144, 84, 44, 203, 381, 66, 67, 48, 58, 39, 39, 6, 167, 13, 19, 175, 1089, 802, 8, 61, 51, 254, 5141, 151, 11, 2017, 676, 66, 9, 259, 381, 1089, 2, 676, 13, 9, 203, 381, 1089, 780, 332, 54, 103, 259, 381, 1089, 42, 405, 1863, 156, 2, 2407, 5, 405, 4797, 4, 34963, 1374, 1452, 4, 2407, 1264, 925, 5, 191, 1707, 1980, 1863, 2315]",1716.0,23584394,5
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.,PloS one,PLoS ONE,2013-04-09,"Although many adults with B cell acute lymphoblastic leukemia (B-ALL) are induced into remission, most will relapse, underscoring the dire need for novel therapies for this disease. We developed murine CD19-specific chimeric antigen receptors (CARs) and an immunocompetent mouse model of B-ALL that recapitulates the disease at genetic, cellular, and pathologic levels. Mouse T cells transduced with an all-murine CD3/CD28-based CAR that is equivalent to the one being used in our clinical trials, eradicate B-ALL in mice and mediate long-term B cell aplasias. In this model, we find that increasing conditioning chemotherapy increases tumor eradication, B cell aplasia, and CAR-modified T cell persistence. Quantification of recipient B lineage cells allowed us to estimate an in vivo effector to endogenous target ratio for B cell aplasia maintenance. In mice exhibiting a dramatic B cell reduction we identified a small population of progenitor B cells in the bone marrow that may serve as a reservoir for long-term CAR-modified T cell stimulation. Lastly, we determine that infusion of CD8+ CAR-modified T cells alone is sufficient to maintain long-term B cell eradication. The mouse model we report here should prove valuable for investigating CAR-based and other therapies for adult B-ALL.",Journal Article,2478.0,82.0,Although many adults with B cell acute lymphoblastic B-ALL are induced into remission most will relapse underscoring the dire need for novel therapies for this disease We developed murine CD19-specific chimeric antigen receptors CARs and an immunocompetent mouse model of B-ALL that recapitulates the disease at genetic cellular and pathologic levels Mouse T cells transduced with an all-murine CD3/CD28-based CAR that is equivalent to the one being used in our clinical trials eradicate B-ALL in mice and mediate long-term B cell aplasias In this model we find that increasing conditioning chemotherapy increases tumor eradication B cell aplasia and CAR-modified T cell persistence Quantification of recipient B lineage cells allowed us to estimate an in vivo effector to endogenous target ratio for B cell aplasia maintenance In mice exhibiting a dramatic B cell reduction we identified a small population of progenitor B cells in the marrow that may serve as a reservoir for long-term CAR-modified T cell stimulation Lastly we determine that infusion of CD8+ CAR-modified T cells alone is sufficient to maintain long-term B cell eradication The mouse model we report here should prove valuable for investigating CAR-based and other therapies for adult B-ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 445, 857, 5, 132, 31, 286, 1275, 132, 62, 32, 277, 237, 734, 96, 303, 429, 8369, 3, 24848, 594, 9, 229, 235, 9, 26, 34, 21, 276, 1471, 3158, 112, 2897, 448, 1186, 7441, 2, 35, 6749, 830, 202, 1, 132, 62, 17, 11076, 3, 34, 28, 336, 763, 2, 510, 148, 830, 102, 37, 5042, 5, 35, 62, 1471, 27267, 5603, 90, 1881, 17, 16, 2017, 6, 3, 104, 486, 95, 4, 114, 38, 143, 5650, 132, 62, 4, 399, 2, 3367, 319, 337, 132, 31, 62704, 4, 26, 202, 21, 2469, 17, 602, 1933, 56, 1106, 30, 5173, 132, 31, 12307, 2, 1881, 1230, 102, 31, 4108, 4752, 1, 5783, 132, 2542, 37, 2313, 843, 6, 1191, 35, 4, 386, 2070, 6, 2682, 283, 197, 9, 132, 31, 12307, 1146, 4, 399, 4801, 8, 3079, 132, 31, 628, 21, 108, 8, 302, 266, 1, 2520, 132, 37, 4, 3, 581, 17, 68, 1833, 22, 8, 10470, 9, 319, 337, 1881, 1230, 102, 31, 2503, 6354, 21, 223, 17, 904, 1, 968, 1881, 1230, 102, 37, 279, 16, 1952, 6, 3040, 319, 337, 132, 31, 5173, 3, 830, 202, 21, 414, 467, 257, 4361, 2926, 9, 3103, 1881, 90, 2, 127, 235, 9, 780, 132, 62]",1261.0,23585892,248
B-lymphoblastic leukemia/lymphoma associated with t(8;13)(p11;q12)/ ZMYM2 (ZNF198)-FGFR1 : rare case and review of the literature.,Acta haematologica,Acta Haematol.,2013-04-16,"Myeloid and lymphoid neoplasms with fibroblastic growth factor receptor-1 (FGFR1) abnormalities originate from mutated pluripotent stem cells and have a heterogeneous clinical presentation. There are 12 identified partner genes commonly involved in FGFR1 translocation at an 8p11 breakpoint. In FGFR1-related neoplasms, T-lymphoblastic lymphoma with eosinophilia is the most common clinical scenario, whereas acute B-lymphoblastic leukemia/lymphoma (B-ALL/LBL) is rare. To date, only 7 cases of B-ALL/LBL with FGFR1 abnormalities have been reported. Here, we report an additional case of a 64-year-old gentleman with leukocytosis, eosinophilia and diffuse mediastinal and general lymphadenopathy. Bone marrow examination showed patchy infiltrates of immature precursors/blasts, along with myeloid/eosinophilic hyperplasia. Immunophenotyping confirmed increased B lymphoblasts (30-40%). Karyotyping revealed cytogenetic abnormalities, including t(8;13)(p11;q12)/ZMYM2 (ZNF198)-FGFR1 and trisomy 21. The patient did not respond to hyper-CVAD chemotherapy and within 4 months developed acute myelomonocytic leukemia and expired 11 months after the initial diagnosis. Similar cases from the literature are reviewed. ",Case Reports,2471.0,,Myeloid and lymphoid neoplasms with fibroblastic growth factor receptor-1 FGFR1 abnormalities originate from mutated pluripotent stem cells and have a heterogeneous clinical presentation There are 12 identified partner genes commonly involved in FGFR1 translocation at an 8p11 breakpoint In FGFR1-related neoplasms T-lymphoblastic with eosinophilia is the most common clinical scenario whereas acute B-lymphoblastic leukemia/lymphoma B-ALL/LBL is rare To date only 7 cases of B-ALL/LBL with FGFR1 abnormalities have been reported Here we report an additional case of a 64-year-old gentleman with leukocytosis eosinophilia and diffuse mediastinal and general lymphadenopathy marrow examination showed patchy infiltrates of immature precursors/blasts along with myeloid/eosinophilic hyperplasia Immunophenotyping confirmed increased B lymphoblasts 30-40 Karyotyping revealed cytogenetic abnormalities including t 8 13 p11 q12 /ZMYM2 ZNF198 -FGFR1 and trisomy 21 The patient did not respond to hyper-CVAD chemotherapy and within 4 months developed acute myelomonocytic and expired 11 months after the initial diagnosis Similar cases from the literature are reviewed,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[533, 2, 2303, 1179, 5, 15226, 129, 161, 153, 14, 4549, 1171, 8838, 29, 1185, 13007, 452, 37, 2, 47, 8, 1564, 38, 1031, 125, 32, 133, 108, 4852, 214, 841, 646, 4, 4549, 2006, 28, 35, 22674, 8567, 4, 4549, 139, 1179, 102, 1275, 5, 13555, 16, 3, 96, 186, 38, 5456, 547, 286, 132, 1275, 2647, 4763, 132, 62, 8315, 16, 622, 6, 1244, 158, 67, 140, 1, 132, 62, 8315, 5, 4549, 1171, 47, 85, 210, 467, 21, 414, 35, 402, 473, 1, 8, 660, 111, 1095, 28444, 5, 7463, 13555, 2, 1388, 2626, 2, 1083, 4962, 581, 1385, 224, 17750, 5942, 1, 5733, 4881, 2438, 1510, 5, 533, 9757, 3176, 9416, 557, 101, 132, 10521, 201, 327, 10406, 553, 1266, 1171, 141, 102, 66, 233, 11230, 12964, 47708, 62712, 4549, 2, 6317, 239, 3, 69, 205, 44, 1892, 6, 4855, 5574, 56, 2, 262, 39, 53, 276, 286, 5451, 2, 13758, 175, 53, 50, 3, 388, 147, 288, 140, 29, 3, 789, 32, 446]",1162.0,23594707,217
Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.,Blood,Blood,2013-05-01,"Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great challenges in cancer therapeutics; however, it is uncertain which Ras effectors are required for tumor initiation and maintenance. To address this question, we expressed oncogenic K-Ras(D12) proteins with ""second site"" amino acid substitutions that impair PI3 kinase/Akt or Raf/MEK/ERK activation in bone marrow cells and transplanted them into recipient mice. In spite of attenuated signaling properties, defective K-Ras oncoproteins initiated aggressive clonal T-lineage acute lymphoblastic leukemia (T-ALL). Murine T-ALLs expressing second site mutant proteins restored full oncogenic Ras activity through diverse mechanisms, which included acquiring novel somatic third site Kras(D12) mutations and silencing PTEN. T-ALL cell lines lacking PTEN had elevated levels of phosphorylated Akt, a gene expression pattern similar to human early T-cell precursor ALL, and were resistant to the potent and selective MEK inhibitor PD0325901. Our data, which demonstrate strong selective pressure to overcome the defective activation of PI3 kinase/Akt and Raf/MEK/ERK, implicate both Ras effector pathways as drivers of aberrant growth in T-ALL and further suggest that leukemia cells will deploy multiple mechanisms to develop resistance to targeted inhibitors in vivo.",Journal Article,2456.0,20.0,Reversing the aberrant biochemical output of oncogenic Ras proteins is one of the great challenges in cancer therapeutics however it is uncertain which Ras effectors are required for tumor initiation and maintenance To address this question we expressed oncogenic K-Ras D12 proteins with `` second site '' amino acid substitutions that impair PI3 kinase/Akt or Raf/MEK/ERK activation in marrow cells and transplanted them into recipient mice In spite of attenuated signaling properties defective K-Ras oncoproteins initiated aggressive clonal T-lineage acute lymphoblastic T-ALL Murine T-ALLs expressing second site mutant proteins restored full oncogenic Ras activity through diverse mechanisms which included acquiring novel somatic third site Kras D12 mutations and silencing PTEN T-ALL cell lines lacking PTEN had elevated levels of phosphorylated Akt a gene expression pattern similar to human early T-cell precursor ALL and were resistant to the potent and selective MEK inhibitor PD0325901 Our data which demonstrate strong selective pressure to overcome the defective activation of PI3 kinase/Akt and Raf/MEK/ERK implicate both Ras effector pathways as drivers of aberrant growth in T-ALL and further suggest that cells will deploy multiple mechanisms to develop resistance to targeted inhibitors in vivo,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9953, 3, 1898, 1487, 6911, 1, 1302, 1102, 652, 16, 104, 1, 3, 2797, 1427, 4, 12, 1943, 137, 192, 16, 2717, 92, 1102, 4926, 32, 616, 9, 30, 1118, 2, 1146, 6, 1539, 26, 2840, 21, 570, 1302, 1634, 1102, 47730, 652, 5, 419, 606, 522, 3078, 971, 7646, 17, 6267, 6892, 216, 649, 15, 2212, 1693, 1819, 363, 4, 581, 37, 2, 4600, 1370, 237, 5783, 399, 4, 9018, 1, 2656, 314, 1571, 4552, 1634, 1102, 8241, 1917, 571, 1946, 102, 2542, 286, 1275, 102, 62, 1471, 102, 10706, 1046, 419, 606, 620, 652, 4138, 1647, 1302, 1102, 128, 298, 1867, 483, 92, 159, 12720, 229, 1119, 1282, 606, 723, 47730, 138, 2, 2077, 820, 102, 62, 31, 285, 1941, 820, 42, 804, 148, 1, 2365, 649, 8, 145, 55, 1177, 288, 6, 171, 191, 102, 31, 2765, 62, 2, 11, 436, 6, 3, 1157, 2, 1094, 1693, 230, 17885, 114, 74, 92, 608, 1082, 1094, 3738, 6, 1768, 3, 4552, 363, 1, 6892, 216, 649, 2, 2212, 1693, 1819, 5545, 110, 1102, 2070, 460, 22, 3391, 1, 1898, 129, 4, 102, 62, 2, 195, 309, 17, 37, 303, 39686, 232, 483, 6, 690, 251, 6, 238, 222, 4, 386]",1312.0,23637129,225
Epigenetic inactivation of Notch-Hes pathway in human B-cell acute lymphoblastic leukemia.,PloS one,PLoS ONE,2013-04-26,"The Notch pathway can have both oncogenic and tumor suppressor roles, depending on cell context. For example, Notch signaling promotes T cell differentiation and is leukemogenic in T cells, whereas it inhibits early B cell differentiation and acts as a tumor suppressor in B cell leukemia where it induces growth arrest and apoptosis. The regulatory mechanisms that contribute to these opposing roles are not understood. Aberrant promoter DNA methylation and histone modifications are associated with silencing of tumor suppressor genes and have been implicated in leukemogenesis. Using methylated CpG island amplification (MCA)/DNA promoter microarray, we identified Notch3 and Hes5 as hypermethylated in human B cell acute lymphoblastic leukemia (ALL). We investigated the methylation status of other Notch pathway genes by bisulfite pyrosequencing. Notch3, JAG1, Hes2, Hes4 and Hes5 were frequently hypermethylated in B leukemia cell lines and primary B-ALL, in contrast to T-ALL cell lines and patient samples. Aberrant methylation of Notch3 and Hes5 in B-ALL was associated with gene silencing and was accompanied by decrease of H3K4 trimethylation and H3K9 acetylation and gain of H3K9 trimethylation and H3K27 trimethylation. 5-aza-2'-deoxycytidine treatment restored Hes5 expression and decreased promoter hypermethylation in most leukemia cell lines and primary B-ALL samples. Restoration of Hes5 expression by lentiviral transduction resulted in growth arrest and apoptosis in Hes5 negative B-ALL cells but not in Hes5 expressing T-ALL cells. These data suggest that epigenetic modifications are implicated in silencing of tumor suppressor of Notch/Hes pathway in B-ALL.",Journal Article,2461.0,30.0,The Notch pathway can have both oncogenic and tumor suppressor roles depending on cell context For example Notch signaling promotes T cell differentiation and is leukemogenic in T cells whereas it inhibits early B cell differentiation and acts as a tumor suppressor in B cell where it induces growth arrest and apoptosis The regulatory mechanisms that contribute to these opposing roles are not understood Aberrant promoter DNA methylation and histone modifications are associated with silencing of tumor suppressor genes and have been implicated in leukemogenesis Using methylated CpG island amplification MCA /DNA promoter microarray we identified Notch3 and Hes5 as hypermethylated in human B cell acute lymphoblastic ALL We investigated the methylation status of other Notch pathway genes by bisulfite pyrosequencing Notch3 JAG1 Hes2 Hes4 and Hes5 were frequently hypermethylated in B cell lines and primary B-ALL in contrast to T-ALL cell lines and patient samples Aberrant methylation of Notch3 and Hes5 in B-ALL was associated with gene silencing and was accompanied by decrease of H3K4 trimethylation and H3K9 acetylation and gain of H3K9 trimethylation and H3K27 trimethylation 5-aza-2'-deoxycytidine treatment restored Hes5 expression and decreased promoter hypermethylation in most cell lines and primary B-ALL samples Restoration of Hes5 expression by lentiviral transduction resulted in growth arrest and apoptosis in Hes5 negative B-ALL cells but not in Hes5 expressing T-ALL cells These data suggest that epigenetic modifications are implicated in silencing of tumor suppressor of Notch/Hes pathway in B-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3193, 308, 122, 47, 110, 1302, 2, 30, 1245, 1790, 3221, 23, 31, 1533, 9, 2685, 3193, 314, 2148, 102, 31, 910, 2, 16, 13519, 4, 102, 37, 547, 192, 1576, 191, 132, 31, 910, 2, 4459, 22, 8, 30, 1245, 4, 132, 31, 1257, 192, 1516, 129, 1854, 2, 351, 3, 1253, 483, 17, 1248, 6, 46, 9187, 1790, 32, 44, 1784, 1898, 973, 261, 569, 2, 1508, 2916, 32, 41, 5, 2077, 1, 30, 1245, 214, 2, 47, 85, 1771, 4, 5661, 75, 2963, 2075, 3454, 1073, 13304, 261, 973, 1727, 21, 108, 9390, 2, 25372, 22, 6936, 4, 171, 132, 31, 286, 1275, 62, 21, 565, 3, 569, 156, 1, 127, 3193, 308, 214, 20, 6181, 6031, 9390, 23975, 46664, 47731, 2, 25372, 11, 746, 6936, 4, 132, 31, 285, 2, 86, 132, 62, 4, 748, 6, 102, 62, 31, 285, 2, 69, 347, 1898, 569, 1, 9390, 2, 25372, 4, 132, 62, 10, 41, 5, 145, 2077, 2, 10, 2756, 20, 775, 1, 16549, 13980, 2, 12917, 4145, 2, 1803, 1, 12917, 13980, 2, 14308, 13980, 33, 3924, 6135, 6750, 24, 4138, 25372, 55, 2, 340, 973, 2575, 4, 96, 31, 285, 2, 86, 132, 62, 347, 5194, 1, 25372, 55, 20, 7823, 2761, 627, 4, 129, 1854, 2, 351, 4, 25372, 199, 132, 62, 37, 84, 44, 4, 25372, 1046, 102, 62, 37, 46, 74, 309, 17, 1418, 2916, 32, 1771, 4, 2077, 1, 30, 1245, 1, 3193, 11853, 308, 4, 132, 62]",1622.0,23637910,899
Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-04-30,"For patients with acute lymphoblastic leukemia (ALL) who relapse after allogeneic hematopoietic stem cell transplantation (HSCT), treatment options are limited, and the clinical course and prognostic factors affecting outcome have not been well characterized. We retrospectively analyzed outcomes of 123 adult patients with ALL who relapsed after a first HSCT performed at our center between 1993 and 2011. First-line salvage included second HSCT (n = 19), donor lymphocyte infusion with or without prior chemotherapy (n = 11), radiation therapy (n = 6), cytoreductive chemotherapy (n = 30), mild chemotherapy (n = 27), or palliative care (n = 23), with median postrelapse overall survival (OS) of 10 months, 6.5 months, 3 months, 4 months, 4 months, and 1 month, respectively. Despite a complete remission rate of 38% after first-line salvage in the treated patients, the OS rate remained limited with 1- and 2- year OS rates of 17% (95% confidence interval, 13 to 29) and 10% (95% confidence interval, 6 to 20), respectively. On univariate analysis, adverse factors for OS included active disease at the time of first HSCT and short time to progression from first HSCT (<6 months). There was no difference in the 6-month survival postrelapse in patients with isolated extramedullary relapse (44%) compared with combined extramedullary and bone marrow relapse (29%) or those with isolated bone marrow relapse (34%) (P = .8). Our data provide more insight into the disease behavior and treatment outcomes of ALL at relapse after HSCT against which future trials may be compared.",Journal Article,2457.0,30.0,For patients with acute lymphoblastic ALL who relapse after allogeneic hematopoietic stem cell transplantation HSCT treatment options are limited and the clinical course and prognostic factors affecting outcome have not been well characterized We retrospectively analyzed outcomes of 123 adult patients with ALL who relapsed after a first HSCT performed at our center between 1993 and 2011 First-line salvage included second HSCT n 19 donor lymphocyte infusion with or without prior chemotherapy n 11 radiation therapy n 6 cytoreductive chemotherapy n 30 mild chemotherapy n 27 or palliative care n 23 with median postrelapse overall survival OS of 10 months 6.5 months 3 months 4 months 4 months and 1 month respectively Despite a complete remission rate of 38 after first-line salvage in the treated patients the OS rate remained limited with 1- and 2- year OS rates of 17 95 confidence interval 13 to 29 and 10 95 confidence interval 6 to 20 respectively On univariate analysis adverse factors for OS included active disease at the time of first HSCT and short time to progression from first HSCT 6 months There was no difference in the 6-month survival postrelapse in patients with isolated extramedullary relapse 44 compared with combined extramedullary and marrow relapse 29 or those with isolated marrow relapse 34 P .8 Our data provide more insight into the disease behavior and treatment outcomes of ALL at relapse after HSCT against which future trials may be compared,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 7, 5, 286, 1275, 62, 54, 429, 50, 1063, 1007, 452, 31, 497, 1703, 24, 838, 32, 383, 2, 3, 38, 906, 2, 177, 130, 2319, 228, 47, 44, 85, 149, 765, 21, 894, 311, 123, 1, 2698, 780, 7, 5, 62, 54, 591, 50, 8, 157, 1703, 173, 28, 114, 574, 59, 3343, 2, 1132, 157, 328, 992, 159, 419, 1703, 78, 326, 1488, 1448, 904, 5, 15, 187, 324, 56, 78, 175, 121, 36, 78, 49, 2604, 56, 78, 201, 1980, 56, 78, 428, 15, 994, 165, 78, 382, 5, 52, 15138, 63, 25, 118, 1, 79, 53, 49, 33, 53, 27, 53, 39, 53, 39, 53, 2, 14, 811, 106, 550, 8, 236, 734, 116, 1, 519, 50, 157, 328, 992, 4, 3, 73, 7, 3, 118, 116, 958, 383, 5, 14, 2, 18, 111, 118, 151, 1, 269, 48, 307, 268, 233, 6, 462, 2, 79, 48, 307, 268, 49, 6, 179, 106, 23, 880, 65, 290, 130, 9, 118, 159, 544, 34, 28, 3, 98, 1, 157, 1703, 2, 978, 98, 6, 91, 29, 157, 1703, 49, 53, 125, 10, 77, 523, 4, 3, 49, 811, 25, 15138, 4, 7, 5, 1355, 5508, 429, 584, 72, 5, 397, 5508, 2, 581, 429, 462, 15, 135, 5, 1355, 581, 429, 562, 19, 66, 114, 74, 377, 80, 2670, 237, 3, 34, 1710, 2, 24, 123, 1, 62, 28, 429, 50, 1703, 480, 92, 508, 143, 68, 40, 72]",1478.0,23644077,629
Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-05-06,"Survivors of childhood acute lymphoblastic leukemia (ALL) are at increased risk for neurocognitive problems, with significant interindividual variability in outcome. This study examined genetic polymorphisms associated with variability in neurocognitive outcome. Neurocognitive outcomes were evaluated at the end of therapy in 243 survivors treated on an institutional protocol featuring risk-adapted chemotherapy without prophylactic cranial irradiation. Polymorphisms in genes related to pharmacokinetics or pharmacodynamics of antileukemic agents, drug metabolism, oxidative stress, and attention problems in noncancer populations were examined as predictors of outcome, using multiple general linear models and controlling for age at diagnosis, sex, race, and treatment intensity. Compared with national norms, the cohort demonstrated significantly higher rates of problems on direct assessment of sustained attention (P = .01) and on parent ratings of attention problems (P = .02). Children with the A2756G polymorphism in methionine synthase (MS) were more likely to demonstrate deficits in attentiveness (P = .03) and response speed (P = .02), whereas those with various polymorphisms in glutathione S-transferase demonstrated increased performance variability (P = .01) and reduced attentiveness (P = .003). Polymorphisms in monoamine oxidase (T1460CA) were associated with increased attention variability (P = .03). Parent-reported attention problems were more common in children with the Cys112Arg polymorphism in apoliopoprotein E4 (P = .01). These results are consistent with our previous report of association between attention problems and MS in an independent cohort of long-term survivors of childhood ALL treated with chemotherapy only. The results also raise the possibility of an impact from genetic predispositions related to oxidative stress and CNS integrity.",Journal Article,2451.0,52.0,Survivors of childhood acute lymphoblastic ALL are at increased risk for neurocognitive problems with significant interindividual variability in outcome This study examined genetic polymorphisms associated with variability in neurocognitive outcome Neurocognitive outcomes were evaluated at the end of therapy in 243 survivors treated on an institutional protocol featuring risk-adapted chemotherapy without prophylactic cranial irradiation Polymorphisms in genes related to pharmacokinetics or pharmacodynamics of antileukemic agents drug metabolism oxidative stress and attention problems in noncancer populations were examined as predictors of outcome using multiple general linear models and controlling for age at diagnosis sex race and treatment intensity Compared with national norms the cohort demonstrated significantly higher rates of problems on direct assessment of sustained attention P .01 and on parent ratings of attention problems P .02 Children with the A2756G polymorphism in methionine synthase MS were more likely to demonstrate deficits in attentiveness P .03 and response speed P .02 whereas those with various polymorphisms in glutathione S-transferase demonstrated increased performance variability P .01 and reduced attentiveness P .003 Polymorphisms in monoamine oxidase T1460CA were associated with increased attention variability P .03 Parent-reported attention problems were more common in children with the Cys112Arg polymorphism in apoliopoprotein E4 P .01 These results are consistent with our previous report of association between attention problems and MS in an independent cohort of long-term survivors of childhood ALL treated with chemotherapy only The results also raise the possibility of an impact from genetic predispositions related to oxidative stress and CNS integrity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 32, 28, 101, 43, 9, 2958, 2408, 5, 93, 7882, 1982, 4, 228, 26, 45, 409, 336, 1203, 41, 5, 1982, 4, 2958, 228, 2958, 123, 11, 194, 28, 3, 396, 1, 36, 4, 6346, 332, 73, 23, 35, 1115, 1182, 15937, 43, 3716, 56, 187, 1862, 2565, 1104, 1203, 4, 214, 139, 6, 1159, 15, 3587, 1, 4512, 183, 234, 1600, 3495, 1531, 2, 2111, 2408, 4, 5994, 1184, 11, 409, 22, 674, 1, 228, 75, 232, 1083, 1646, 274, 2, 1893, 9, 89, 28, 147, 1035, 1047, 2, 24, 837, 72, 5, 657, 9875, 3, 180, 264, 97, 142, 151, 1, 2408, 23, 1196, 455, 1, 2275, 2111, 19, 355, 2, 23, 3841, 5548, 1, 2111, 2408, 19, 588, 541, 5, 3, 34643, 1907, 4, 5686, 3522, 2307, 11, 80, 322, 6, 608, 2752, 4, 40357, 19, 680, 2, 51, 5051, 19, 588, 547, 135, 5, 747, 1203, 4, 4571, 695, 4402, 264, 101, 528, 1982, 19, 355, 2, 405, 40357, 19, 1421, 1203, 4, 30972, 10447, 62779, 11, 41, 5, 101, 2111, 1982, 19, 680, 3841, 210, 2111, 2408, 11, 80, 186, 4, 541, 5, 3, 62780, 1907, 4, 62781, 22245, 19, 355, 46, 99, 32, 925, 5, 114, 698, 414, 1, 248, 59, 2111, 2408, 2, 2307, 4, 35, 306, 180, 1, 319, 337, 332, 1, 864, 62, 73, 5, 56, 158, 3, 99, 120, 5008, 3, 2526, 1, 35, 345, 29, 336, 19697, 139, 6, 3495, 1531, 2, 1025, 4797]",1814.0,23650422,467
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.,Blood,Blood,2013-05-15,"Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging (BiTE) antibody with efficacy in refractory B-precursor acute lymphoblastic leukemia. Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome (CRS). We hypothesized that patients with more severe toxicity may experience abnormal macrophage activation triggered by the release of cytokines by T-cell receptor-activated cytotoxic T cells engaged by BiTE antibodies and leading to hemophagocytic lymphohistiocytosis (HLH). We prospectively monitored a patient during blinatumomab treatment and observed that he developed HLH. He became ill 36 hours into the infusion with fever, respiratory failure, and circulatory collapse. He developed hyperferritinemia, cytopenias, hypofibrinogenemia, and a cytokine profile diagnostic for HLH. The HLH continued to progress after discontinuation of blinatumomab; however, he had rapid improvement after IL-6 receptor-directed therapy with tocilizumab. Patients treated with T cell-activating therapies, including blinatumomab, should be monitored for HLH, and cytokine-directed therapy may be considered in cases of life-threatening CRS. This trial was registered at www.clinicaltrials.gov as #NCT00103285. ",Case Reports,2442.0,266.0,Blinatumomab is a CD19/CD3-bispecific T-cell receptor-engaging BiTE antibody with efficacy in refractory B-precursor acute lymphoblastic Some patients treated with blinatumomab and other T cell-activating therapies develop cytokine release syndrome CRS We hypothesized that patients with more severe toxicity may experience abnormal macrophage activation triggered by the release of cytokines by T-cell receptor-activated cytotoxic T cells engaged by BiTE antibodies and leading to hemophagocytic lymphohistiocytosis HLH We prospectively monitored a patient during blinatumomab treatment and observed that he developed HLH He became ill 36 hours into the infusion with fever respiratory failure and circulatory collapse He developed hyperferritinemia cytopenias hypofibrinogenemia and a cytokine profile diagnostic for HLH The HLH continued to progress after discontinuation of blinatumomab however he had rapid improvement after IL-6 receptor-directed therapy with tocilizumab Patients treated with T cell-activating therapies including blinatumomab should be monitored for HLH and cytokine-directed therapy may be considered in cases of life-threatening CRS This trial was registered at www.clinicaltrials.gov as NCT00103285,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7182, 16, 8, 3158, 3117, 7408, 102, 31, 153, 8534, 15382, 548, 5, 209, 4, 430, 132, 2765, 286, 1275, 476, 7, 73, 5, 7182, 2, 127, 102, 31, 1616, 235, 690, 1675, 2008, 681, 3115, 21, 1237, 17, 7, 5, 80, 905, 155, 68, 730, 1668, 2674, 363, 4173, 20, 3, 2008, 1, 1886, 20, 102, 31, 153, 735, 759, 102, 37, 9173, 20, 15382, 890, 2, 1049, 6, 23367, 27288, 10117, 21, 1143, 2909, 8, 69, 190, 7182, 24, 2, 164, 17, 3174, 276, 10117, 3174, 3451, 4993, 511, 1459, 237, 3, 904, 5, 2775, 2718, 496, 2, 17647, 11817, 3174, 276, 39944, 5635, 40365, 2, 8, 1675, 800, 752, 9, 10117, 3, 10117, 1351, 6, 1466, 50, 2007, 1, 7182, 137, 3174, 42, 1321, 767, 50, 501, 49, 153, 1166, 36, 5, 29436, 7, 73, 5, 102, 31, 1616, 235, 141, 7182, 257, 40, 2909, 9, 10117, 2, 1675, 1166, 36, 68, 40, 515, 4, 140, 1, 358, 3691, 3115, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 62805]",1226.0,23678006,537
Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia.,Blood,Blood,2013-05-17,"Adult T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematologic tumor associated with poor outcome. In this study, we analyzed the prognostic relevance of genetic alterations, immunophenotypic markers, and microarray gene expression signatures in a panel of 53 adult T-ALL patients treated in the Eastern Cooperative Oncology Group E2993 clinical trial. An early immature gene expression signature, the absence of bi-allelic TCRG deletion, CD13 surface expression, heterozygous deletions of the short arm of chromosome 17, and mutations in IDH1/IDH2 and DNMT3A genes are associated with poor prognosis in this series. In contrast, expression of CD8 or CD62L, homozygous deletion of CDKN2A/CDKN2B, NOTCH1 and/or FBXW7 mutations, and mutations or deletions in the BCL11B tumor suppressor gene were associated with improved overall survival. Importantly, the prognostic relevance of CD13 expression and homozygous CDKN2A/CDKN2B deletions was restricted to cortical and mature T-ALLs. Conversely, mutations in IDH1/IDH2 and DNMT3A were specifically associated with poor outcome in early immature adult T-ALLs. This trial was registered at www.clinicaltrials.gov as #NCT00002514. ","Clinical Trial, Phase III",2440.0,70.0,Adult T-cell acute lymphoblastic T-ALL is an aggressive hematologic tumor associated with poor outcome In this study we analyzed the prognostic relevance of genetic alterations immunophenotypic markers and microarray gene expression signatures in a panel of 53 adult T-ALL patients treated in the Eastern Cooperative Oncology Group E2993 clinical trial An early immature gene expression signature the absence of bi-allelic TCRG deletion CD13 surface expression heterozygous deletions of the short arm of chromosome 17 and mutations in IDH1/IDH2 and DNMT3A genes are associated with poor prognosis in this series In contrast expression of CD8 or CD62L homozygous deletion of CDKN2A/CDKN2B NOTCH1 and/or FBXW7 mutations and mutations or deletions in the BCL11B tumor suppressor gene were associated with improved overall survival Importantly the prognostic relevance of CD13 expression and homozygous CDKN2A/CDKN2B deletions was restricted to cortical and mature T-ALLs Conversely mutations in IDH1/IDH2 and DNMT3A were specifically associated with poor outcome in early immature adult T-ALLs This trial was registered at www.clinicaltrials.gov as NCT00002514,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[780, 102, 31, 286, 1275, 102, 62, 16, 35, 571, 813, 30, 41, 5, 334, 228, 4, 26, 45, 21, 311, 3, 177, 2088, 1, 336, 593, 6599, 525, 2, 1727, 145, 55, 2210, 4, 8, 993, 1, 699, 780, 102, 62, 7, 73, 4, 3, 2118, 1690, 413, 87, 28928, 38, 160, 35, 191, 5733, 145, 55, 1651, 3, 1127, 1, 3984, 3861, 62812, 1528, 13518, 1255, 55, 4167, 2439, 1, 3, 978, 475, 1, 1170, 269, 2, 138, 4, 2662, 4520, 2, 6199, 214, 32, 41, 5, 334, 356, 4, 26, 988, 4, 748, 55, 1, 968, 15, 12401, 3189, 1528, 1, 3175, 12634, 4607, 2, 15, 8352, 138, 2, 138, 15, 2439, 4, 3, 25260, 30, 1245, 145, 11, 41, 5, 231, 63, 25, 1859, 3, 177, 2088, 1, 13518, 55, 2, 3189, 3175, 12634, 2439, 10, 2016, 6, 4500, 2, 2908, 102, 10706, 3154, 138, 4, 2662, 4520, 2, 6199, 11, 1225, 41, 5, 334, 228, 4, 191, 5733, 780, 102, 10706, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 31193]",1157.0,23687089,546
Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-05-20,"Second malignant neoplasms (SMNs) after diagnosis of childhood acute lymphoblastic leukemia (ALL) are rare events. We analyzed data on risk factors and outcomes of 642 children with SMNs occurring after treatment for ALL from 18 collaborative study groups between 1980 and 2007. Acute myeloid leukemia (AML; n = 186), myelodysplastic syndrome (MDS; n = 69), and nonmeningioma brain tumor (n = 116) were the most common types of SMNs and had the poorest outcome (5-year survival rate, 18.1%  2.9%, 31.1%  6.2%, and 18.3%  3.8%, respectively). Five-year survival estimates for AML were 11.2%  2.9% for 125 patients diagnosed before 2000 and 34.1%  6.3% for 61 patients diagnosed after 2000 (P < .001); 5-year survival estimates for MDS were 17.1%  6.4% (n = 36) and 48.2%  10.6% (n = 33; P = .005). Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies after adjusting for waiting time to transplantation. Five-year survival rates were above 90% for patients with meningioma, Hodgkin lymphoma, thyroid carcinoma, basal cell carcinoma, and parotid gland tumor, and 68.5%  6.4% for those with non-Hodgkin lymphoma. Eighty-nine percent of patients with brain tumors had received cranial irradiation. Solid tumors were associated with cyclophosphamide exposure, and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methotrexate of at least 25 mg/m(2) per week and mercaptopurine of at least 75 mg/m(2) per day. Myeloid malignancies with monosomy 7/5q- were associated with high hyperdiploid ALL karyotypes, whereas 11q23/MLL-rearranged AML or MDS was associated with ALL harboring translocations of t(9;22), t(4;11), t(1;19), and t(12;21) (P = .03). SMNs, except for brain tumors, AML, and MDS, have outcomes similar to their primary counterparts.",Journal Article,2437.0,63.0,Second malignant neoplasms SMNs after diagnosis of childhood acute lymphoblastic ALL are rare events We analyzed data on risk factors and outcomes of 642 children with SMNs occurring after treatment for ALL from 18 collaborative study groups between 1980 and 2007 Acute myeloid AML n 186 syndrome MDS n 69 and nonmeningioma brain tumor n 116 were the most common types of SMNs and had the poorest outcome 5-year survival rate 18.1  2.9 31.1  6.2 and 18.3  3.8 respectively Five-year survival estimates for AML were 11.2  2.9 for 125 patients diagnosed before 2000 and 34.1  6.3 for 61 patients diagnosed after 2000 P .001 5-year survival estimates for MDS were 17.1  6.4 n 36 and 48.2  10.6 n 33 P .005 Allogeneic stem-cell transplantation failed to improve outcome of secondary myeloid malignancies after adjusting for waiting time to transplantation Five-year survival rates were above 90 for patients with meningioma carcinoma basal cell carcinoma and parotid gland tumor and 68.5  6.4 for those with Eighty-nine percent of patients with brain tumors had received cranial irradiation Solid tumors were associated with cyclophosphamide exposure and myeloid malignancy was associated with topoisomerase II inhibitors and starting doses of methotrexate of at least 25 mg/m 2 per week and mercaptopurine of at least 75 mg/m 2 per day Myeloid malignancies with monosomy 7/5q- were associated with high hyperdiploid ALL karyotypes whereas 11q23/MLL-rearranged AML or MDS was associated with ALL harboring translocations of t 9 22 t 4 11 t 1 19 and t 12 21 P .03 SMNs except for brain tumors AML and MDS have outcomes similar to their primary counterparts,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,1,0,"[419, 393, 1179, 6580, 50, 147, 1, 864, 286, 1275, 62, 32, 622, 281, 21, 311, 74, 23, 43, 130, 2, 123, 1, 11994, 541, 5, 6580, 1821, 50, 24, 9, 62, 29, 203, 3737, 45, 271, 59, 4376, 2, 1307, 286, 533, 329, 78, 5869, 681, 1223, 78, 790, 2, 62818, 342, 30, 78, 3790, 11, 3, 96, 186, 630, 1, 6580, 2, 42, 3, 11136, 228, 33, 111, 25, 116, 203, 14, 810, 18, 83, 456, 14, 810, 49, 18, 2, 203, 27, 810, 27, 66, 106, 365, 111, 25, 1423, 9, 329, 11, 175, 18, 810, 18, 83, 9, 1731, 7, 265, 348, 1081, 2, 562, 14, 810, 49, 27, 9, 713, 7, 265, 50, 1081, 19, 144, 33, 111, 25, 1423, 9, 1223, 11, 269, 14, 810, 49, 39, 78, 511, 2, 576, 18, 810, 79, 49, 78, 466, 19, 1614, 1063, 452, 31, 497, 1551, 6, 401, 228, 1, 568, 533, 441, 50, 1358, 9, 7598, 98, 6, 497, 365, 111, 25, 151, 11, 2090, 424, 9, 7, 5, 3944, 134, 2135, 31, 134, 2, 5838, 2326, 30, 2, 806, 33, 810, 49, 39, 9, 135, 5, 2207, 762, 714, 1, 7, 5, 342, 57, 42, 103, 2565, 1104, 537, 57, 11, 41, 5, 1112, 645, 2, 533, 710, 10, 41, 5, 3999, 215, 222, 2, 1723, 415, 1, 2116, 1, 28, 506, 243, 81, 188, 18, 379, 647, 2, 9223, 1, 28, 506, 481, 81, 188, 18, 379, 218, 533, 441, 5, 7521, 67, 5460, 11, 41, 5, 64, 8847, 62, 6809, 547, 7975, 3049, 3201, 329, 15, 1223, 10, 41, 5, 62, 2105, 3262, 1, 102, 83, 350, 102, 39, 175, 102, 14, 326, 2, 102, 133, 239, 19, 680, 6580, 2187, 9, 342, 57, 329, 2, 1223, 47, 123, 288, 6, 136, 86, 3953]",1659.0,23690411,319
"ARID5B and IKZF1 variants, selected demographic factors, and childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group.",Leukemia research,Leuk. Res.,2013-05-18,"Interactions between common germline variants in ARID5B and IKZF1 and other known childhood acute lymphoblastic leukemia (ALL) risk factors were queried using biospecimens and data from 770 ALL cases and 384 controls. Case-control comparisons revealed dose-dependent associations between ARID5B rs10821936, ARID5B rs10994982, and IKZF1 rs11978267 and childhood ALL overall, and B lineage and B lineage hyperdiploid ALL examined separately (all allelic odds ratios 1.33, Ptrend0.001). No heterogeneity was observed between ORs for males and females (all Pinteraction0.48). Likewise, no significant genotype-birth weight interactions were detected (all Pinteraction0.12) among cases. These results indicate similar ALL risk across strata of known risk factors. ",Journal Article,2439.0,24.0,Interactions between common germline variants in ARID5B and IKZF1 and other known childhood acute lymphoblastic ALL risk factors were queried using biospecimens and data from 770 ALL cases and 384 controls Case-control comparisons revealed dose-dependent associations between ARID5B rs10821936 ARID5B rs10994982 and IKZF1 rs11978267 and childhood ALL overall and B lineage and B lineage hyperdiploid ALL examined separately all allelic odds ratios 1.33 Ptrend0.001 No heterogeneity was observed between ORs for males and females all Pinteraction0.48 Likewise no significant genotype-birth weight interactions were detected all Pinteraction0.12 among cases These results indicate similar ALL risk across strata of known risk factors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1286, 59, 186, 1009, 839, 4, 17439, 2, 8422, 2, 127, 440, 864, 286, 1275, 62, 43, 130, 11, 3547, 75, 12419, 2, 74, 29, 13611, 62, 140, 2, 12612, 535, 473, 182, 2213, 553, 61, 470, 685, 59, 17439, 31498, 17439, 39076, 2, 8422, 62824, 2, 864, 62, 63, 2, 132, 2542, 2, 132, 2542, 8847, 62, 409, 3582, 62, 3861, 610, 1137, 3567, 466, 62825, 144, 77, 1144, 10, 164, 59, 3694, 9, 2296, 2, 2451, 62, 47755, 576, 6269, 77, 93, 1183, 3809, 924, 1286, 11, 530, 62, 47755, 133, 107, 140, 46, 99, 1008, 288, 62, 43, 716, 5758, 1, 440, 43, 130]",735.0,23692655,541
"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-05-28,"Over the past four decades, allogeneic hematopoietic cell transplantation (alloHCT) has evolved as a curative modality for patients with hematologic diseases. This study describes changes in use, technique, and survival in a population-based cohort. The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research. AlloHCT as treatment for acute lymphoblastic (ALL) and myeloid leukemias (AML), myelodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,668 patients annually. From 1994 to 2005, use of both peripheral (7% to 63%) [corrected] and cord blood increased (2% to 10%), whereas use of marrow decreased (90% to 27%). Despite a median age increase from 33 to 40 years and 165% [corrected] increase in unrelated donors for alloHCT, overall survival (OS) at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT (85% to 94%; P < .001) and unrelated alloHCT (63% to 86%; P < .001); 1-year OS improved among those undergoing unrelated alloHCT (48% to 63%; P = .003) but not among those undergoing sibling alloHCT. Similar results were seen for ALL and MDS. Day-100 OS after cord blood alloHCT improved significantly from 60% to 78% (P < .001) for AML, ALL, MDS, and chronic myeloid leukemia. Use of reduced-intensity regimens increased, yielding OS rates similar to those of myeloablative regimens. Survival for those undergoing alloHCT has significantly improved over time. However, new approaches are needed to further improve 1-year OS.",Journal Article,2429.0,137.0,"Over the past four decades allogeneic hematopoietic cell transplantation alloHCT has evolved as a curative modality for patients with hematologic diseases This study describes changes in use technique and survival in a population-based cohort The study included 38,060 patients with hematologic malignancies or disorders who underwent first alloHCT in a US or Canadian center from 1994 to 2005 and were reported to the Center for International Blood and Marrow Transplant Research AlloHCT as treatment for acute lymphoblastic ALL and myeloid leukemias AML syndrome MDS and and lymphomas increased by 45 from 2,520 to 3,668 patients annually From 1994 to 2005 use of both peripheral 7 to 63 corrected and cord blood increased 2 to 10 whereas use of marrow decreased 90 to 27 Despite a median age increase from 33 to 40 years and 165 corrected increase in unrelated donors for alloHCT overall survival OS at day 100 significantly improved for patients with AML in first complete remission after myeloablative sibling alloHCT 85 to 94 P .001 and unrelated alloHCT 63 to 86 P .001 1-year OS improved among those undergoing unrelated alloHCT 48 to 63 P .003 but not among those undergoing sibling alloHCT Similar results were seen for ALL and MDS Day-100 OS after cord blood alloHCT improved significantly from 60 to 78 P .001 for AML ALL MDS and chronic myeloid Use of reduced-intensity regimens increased yielding OS rates similar to those of myeloablative regimens Survival for those undergoing alloHCT has significantly improved over time However new approaches are needed to further improve 1-year OS",0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[252, 3, 1219, 294, 1968, 1063, 1007, 31, 497, 5514, 71, 3937, 22, 8, 1075, 1396, 9, 7, 5, 813, 1342, 26, 45, 2677, 400, 4, 119, 1312, 2, 25, 4, 8, 266, 90, 180, 3, 45, 159, 519, 9972, 7, 5, 813, 441, 15, 1997, 54, 208, 157, 5514, 4, 8, 843, 15, 7170, 574, 29, 3023, 6, 1242, 2, 11, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 5514, 22, 24, 9, 286, 1275, 62, 2, 533, 2792, 329, 681, 1223, 2, 2, 1557, 101, 20, 512, 29, 18, 9158, 6, 27, 13642, 7, 4226, 29, 3023, 6, 1242, 119, 1, 110, 672, 67, 6, 676, 3848, 2, 1885, 315, 101, 18, 6, 79, 547, 119, 1, 581, 340, 424, 6, 428, 550, 8, 52, 89, 344, 29, 466, 6, 327, 60, 2, 4966, 3848, 344, 4, 2092, 2344, 9, 5514, 63, 25, 118, 28, 218, 394, 97, 231, 9, 7, 5, 329, 4, 157, 236, 734, 50, 3246, 3684, 5514, 772, 6, 960, 19, 144, 2, 2092, 5514, 676, 6, 868, 19, 144, 14, 111, 118, 231, 107, 135, 479, 2092, 5514, 576, 6, 676, 19, 1421, 84, 44, 107, 135, 479, 3684, 5514, 288, 99, 11, 527, 9, 62, 2, 1223, 218, 394, 118, 50, 1885, 315, 5514, 231, 97, 29, 335, 6, 833, 19, 144, 9, 329, 62, 1223, 2, 442, 533, 119, 1, 405, 837, 472, 101, 4949, 118, 151, 288, 6, 135, 1, 3246, 472, 25, 9, 135, 479, 5514, 71, 97, 231, 252, 98, 137, 217, 611, 32, 575, 6, 195, 401, 14, 111, 118]",1600.0,23715573,351
Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment.,Blood,Blood,2013-06-05,"Mesenchymal stromal cells (MSCs) are a major component of the leukemia bone marrow (BM) microenvironment. Connective tissue growth factor (CTGF) is highly expressed in MSCs, but its role in the BM stroma is unknown. Therefore, we knocked down (KD) CTGF expression in human BM-derived MSCs by CTGF short hairpin RNA. CTGF KD MSCs exhibited fivefold lower proliferation compared with control MSCs and had markedly fewer S-phase cells. CTGF KD MSCs differentiated into adipocytes at a sixfold higher rate than controls in vitro and in vivo. To study the effect of CTGF on engraftment of leukemia cells into BM, an in vivo model of humanized extramedullary BM (EXM-BM) was developed in NOD/SCID/IL-2rg(null) mice. Transplanted Nalm-6 or Molm-13 human leukemia cells engrafted at a threefold higher rate in adipocyte-rich CTGF KD MSC-derived EXM-BM than in control EXM-BM. Leptin was found to be highly expressed in CTGF KD EXM-BM and in BM samples of patients with acute myeloid and acute lymphoblastic leukemia, whereas it was not expressed in normal controls. Given the established role of the leptin receptor in leukemia cells, the data suggest an important role of CTGF in MSC differentiation into adipocytes and of leptin in homing and progression of leukemia. ",Journal Article,2421.0,53.0,Mesenchymal stromal cells MSCs are a major component of the marrow BM microenvironment Connective tissue growth factor CTGF is highly expressed in MSCs but its role in the BM stroma is unknown Therefore we knocked down KD CTGF expression in human BM-derived MSCs by CTGF short hairpin RNA CTGF KD MSCs exhibited fivefold lower proliferation compared with control MSCs and had markedly fewer S-phase cells CTGF KD MSCs differentiated into adipocytes at a sixfold higher rate than controls in vitro and in vivo To study the effect of CTGF on engraftment of cells into BM an in vivo model of humanized extramedullary BM EXM-BM was developed in NOD/SCID/IL-2rg null mice Transplanted Nalm-6 or Molm-13 human cells engrafted at a threefold higher rate in adipocyte-rich CTGF KD MSC-derived EXM-BM than in control EXM-BM Leptin was found to be highly expressed in CTGF KD EXM-BM and in BM samples of patients with acute myeloid and acute lymphoblastic whereas it was not expressed in normal controls Given the established role of the leptin receptor in cells the data suggest an important role of CTGF in MSC differentiation into adipocytes and of leptin in homing and progression of,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,"[1569, 1126, 37, 4460, 32, 8, 458, 1249, 1, 3, 581, 1246, 995, 10990, 246, 129, 161, 14345, 16, 561, 570, 4, 4460, 84, 211, 200, 4, 3, 1246, 2477, 16, 860, 673, 21, 10237, 1328, 6271, 14345, 55, 4, 171, 1246, 526, 4460, 20, 14345, 978, 5957, 893, 14345, 6271, 4460, 1416, 19529, 280, 457, 72, 5, 182, 4460, 2, 42, 2195, 1497, 695, 124, 37, 14345, 6271, 4460, 1442, 237, 8725, 28, 8, 22121, 142, 116, 76, 535, 4, 439, 2, 4, 386, 6, 45, 3, 254, 1, 14345, 23, 2881, 1, 37, 237, 1246, 35, 4, 386, 202, 1, 3619, 5508, 1246, 24029, 1246, 10, 276, 4, 7324, 4129, 501, 62901, 3505, 399, 4600, 30791, 49, 15, 21445, 233, 171, 37, 6914, 28, 8, 10182, 142, 116, 4, 9111, 3697, 14345, 6271, 4150, 526, 24029, 1246, 76, 4, 182, 24029, 1246, 6876, 10, 204, 6, 40, 561, 570, 4, 14345, 6271, 24029, 1246, 2, 4, 1246, 347, 1, 7, 5, 286, 533, 2, 286, 1275, 547, 192, 10, 44, 570, 4, 295, 535, 447, 3, 635, 200, 1, 3, 6876, 153, 4, 37, 3, 74, 309, 35, 305, 200, 1, 14345, 4, 4150, 910, 237, 8725, 2, 1, 6876, 4, 5515, 2, 91, 1]",1177.0,23741006,93
Long-term decline in intelligence among adult survivors of childhood acute lymphoblastic leukemia treated with cranial radiation.,Blood,Blood,2013-06-06,"Survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation therapy (CRT) are at risk for cognitive impairment, although whether impairment progresses with age into adulthood is unknown. We report change in intelligence for 102 adult survivors of childhood ALL (age range, 26.6-54.7 years) during a median interval of 28.5 years. Survivors demonstrated lower Performance intelligence (mean, 95.3; standard deviation, 16.5; P = .005) but not Verbal IQ (mean, 97.4; standard deviation, 15.44; P = .09) at initial testing. Verbal intelligence declined an average of 10.3 points (P < .0001) during the follow-up interval with no decline in Performance intelligence. Decline was associated with current attention problems (P = .002) but not gender, CRT dose, age at CRT exposure, or years between testing. Results suggest long-term survivors of childhood ALL treated with CRT are at risk for progressive decline in verbal intellect, which may be driven by attention deficits. This trial was registered at clinicaltrials.gov as no. NCT00760656. ",Clinical Trial,2420.0,31.0,Survivors of childhood acute lymphoblastic ALL treated with cranial radiation therapy CRT are at risk for cognitive impairment although whether impairment progresses with age into adulthood is unknown We report change in intelligence for 102 adult survivors of childhood ALL age range 26.6-54.7 years during a median interval of 28.5 years Survivors demonstrated lower Performance intelligence mean 95.3 standard deviation 16.5 P .005 but not Verbal IQ mean 97.4 standard deviation 15.44 P .09 at initial testing Verbal intelligence declined an average of 10.3 points P .0001 during the follow-up interval with no decline in Performance intelligence Decline was associated with current attention problems P .002 but not gender CRT dose age at CRT exposure or years between testing Results suggest long-term survivors of childhood ALL treated with CRT are at risk for progressive decline in verbal intellect which may be driven by attention deficits This trial was registered at clinicaltrials.gov as no NCT00760656,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 73, 5, 2565, 121, 36, 1089, 32, 28, 43, 9, 1863, 2315, 242, 317, 2315, 6752, 5, 89, 237, 6002, 16, 860, 21, 414, 707, 4, 9125, 9, 2867, 780, 332, 1, 864, 62, 89, 184, 432, 49, 667, 67, 60, 190, 8, 52, 268, 1, 339, 33, 60, 332, 264, 280, 528, 9125, 313, 48, 27, 260, 3348, 245, 33, 19, 1614, 84, 44, 7028, 7666, 313, 1015, 39, 260, 3348, 167, 584, 19, 1730, 28, 388, 471, 7028, 9125, 3054, 35, 1011, 1, 79, 27, 862, 19, 488, 190, 3, 166, 126, 268, 5, 77, 1858, 4, 528, 9125, 1858, 10, 41, 5, 291, 2111, 2408, 19, 1111, 84, 44, 1632, 1089, 61, 89, 28, 1089, 645, 15, 60, 59, 471, 99, 309, 319, 337, 332, 1, 864, 62, 73, 5, 1089, 32, 28, 43, 9, 1014, 1858, 4, 7028, 47773, 92, 68, 40, 1621, 20, 2111, 2752, 26, 160, 10, 1653, 28, 1252, 1239, 22, 77, 47774]",1014.0,23744583,64
Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments.,Cancer chemotherapy and pharmacology,Cancer Chemother. Pharmacol.,2013-06-13,"It is advantageous to individualize high-dose methotrexate (HDMTX) to maintain adequate exposure while minimizing toxicities. Previously, we accomplished this through within-course dose adjustments. In this study, we evaluated a strategy to individualize HDMTX based on clearance of each individual's previous course of HDMTX in 485 patients with newly diagnosed acute lymphoblastic leukemia. Doses were individualized to achieve a steady-state plasma concentration (Cpss) of 33 or 65M (approximately 2.5 or 5g/m(2)/day) for low- and standard-/high-risk patients, respectively. Individualized doses resulted in 70 and 63% of courses being within 20% of the targeted Cpss in the low- and standard-/high-risk arms, respectively, compared to 60% (p<0.001) and 61% (p=0.43) with conventionally dosed therapy. Only 1.3% of the individualized courses in the standard-/high-risk arm had a Cpss greater than 50% above the target compared to 7.3% (p<0.001) in conventionally dosed therapy. We observed a low rate (8.5% of courses) of grade 3-4 toxicities. The odds of gastrointestinal toxicity were related to methotrexate plasma concentrations in both the low (p=0.021)- and standard-/high-risk groups (p=0.003). Individualizing HDMTX based on the clearance from the prior course resulted in fewer extreme Cpss values and less delayed excretion compared to conventional dosing.",Journal Article,2413.0,17.0,It is advantageous to individualize high-dose methotrexate HDMTX to maintain adequate exposure while minimizing toxicities Previously we accomplished this through within-course dose adjustments In this study we evaluated a strategy to individualize HDMTX based on clearance of each individual 's previous course of HDMTX in 485 patients with newly diagnosed acute lymphoblastic Doses were individualized to achieve a steady-state plasma concentration Cpss of 33 or 65 M approximately 2.5 or 5 g/m 2 /day for low- and standard-/high-risk patients respectively Individualized doses resulted in 70 and 63 of courses being within 20 of the targeted Cpss in the low- and standard-/high-risk arms respectively compared to 60 p 0.001 and 61 p 0.43 with conventionally dosed therapy Only 1.3 of the individualized courses in the standard-/high-risk arm had a Cpss greater than 50 above the target compared to 7.3 p 0.001 in conventionally dosed therapy We observed a low rate 8.5 of courses of grade 3-4 toxicities The odds of toxicity were related to methotrexate plasma concentrations in both the low p 0.021 and standard-/high-risk groups p 0.003 Individualizing HDMTX based on the clearance from the prior course resulted in fewer extreme Cpss values and less delayed excretion compared to conventional dosing,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[192, 16, 10650, 6, 7177, 64, 61, 2116, 10061, 6, 3040, 1658, 645, 369, 4501, 385, 373, 21, 5741, 26, 298, 262, 906, 61, 6017, 4, 26, 45, 21, 194, 8, 692, 6, 7177, 10061, 90, 23, 1960, 1, 296, 797, 292, 698, 906, 1, 10061, 4, 10326, 7, 5, 732, 265, 286, 1275, 415, 11, 2596, 6, 1359, 8, 4152, 1309, 554, 1227, 19332, 1, 466, 15, 556, 4810, 705, 18, 33, 15, 33, 499, 188, 18, 218, 9, 154, 2, 260, 64, 43, 7, 106, 2596, 415, 627, 4, 431, 2, 676, 1, 1993, 486, 262, 179, 1, 3, 238, 19332, 4, 3, 154, 2, 260, 64, 43, 1335, 106, 72, 6, 335, 19, 13, 144, 2, 713, 19, 13, 601, 5, 6846, 6268, 36, 158, 14, 27, 1, 3, 2596, 1993, 4, 3, 260, 64, 43, 475, 42, 8, 19332, 378, 76, 212, 2090, 3, 283, 72, 6, 67, 27, 19, 13, 144, 4, 6846, 6268, 36, 21, 164, 8, 154, 116, 66, 33, 1, 1993, 1, 88, 27, 39, 385, 3, 610, 1, 155, 11, 139, 6, 2116, 554, 1003, 4, 110, 3, 154, 19, 13, 4630, 2, 260, 64, 43, 271, 19, 13, 1421, 12747, 10061, 90, 23, 3, 1960, 29, 3, 324, 906, 627, 4, 1497, 5611, 19332, 1030, 2, 299, 1612, 8294, 72, 6, 809, 1280]",1306.0,23760811,783
Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-06-15,"The discovery that purine nucleoside phosphorylase (PNP) deficiency leads to T-cell lymphopenia was the basis for introducing PNP inhibitors for T-cell leukemias. Forodesine is an orally bioavailable PNP inhibitor with picomolar potency. Because T lymphoblasts and indolent chronic lymphocytic leukemia (CLL) B cells inherently elicit favorable pharmacokinetics to accumulate deoxyguanosine triphosphate (dGTP), forodesine demonstrated promising activity in preclinical and clinical settings for patients with T-cell acute lymphoblastic leukemia (T-ALL) and B-cell CLL (B-CLL). However, the use of forodesine in B-cell ALL (B-ALL) is unknown. Leukemic blasts obtained from pediatric patients with de novo B-ALL (n= 10) were incubated with forodesine and deoxyguanosine (dGuo), and the biological end points of apoptosis, intracellular dGTP accumulation, and inhibition of RNA and DNA synthesis were measured. Additionally, adult patients with B-ALL (n= 2) were intravenously infused with 80 mg/m(2)/d dailyfor 5 days. After therapy, clinical response, toxicity, laboratory biomarkers including PNP enzyme inhibition, and plasma forodesine, dGuo, and intracellular dGTP levels were analyzed. Our invitro investigations demonstrated that forodesine treatment inhibited proliferation and induced modest apoptosis in de novo B-ALL lymphoblasts. There was time-dependent accumulation of dGTP and inhibition of RNA and DNA synthesis. During therapy, neither patient achieved a complete response (CR), but there was disease stabilization for several weeks in both patients. There was significant maintained inhibition of PNP enzyme in red blood cells, accumulation of forodesine and dGuo in plasma, and intracellular dGTP accumulation in both patients. Our preclinical and clinical investigations suggest that forodesine has activity in B-ALL. However, it needs to be either infused with dGuo or combined with established chemotherapeutic agents based on mechanistic rationale.","Clinical Trial, Phase I",2411.0,8.0,The discovery that purine nucleoside phosphorylase PNP deficiency leads to T-cell lymphopenia was the basis for introducing PNP inhibitors for T-cell leukemias Forodesine is an orally bioavailable PNP inhibitor with picomolar potency Because T lymphoblasts and indolent chronic lymphocytic CLL B cells inherently elicit favorable pharmacokinetics to accumulate deoxyguanosine triphosphate dGTP forodesine demonstrated promising activity in preclinical and clinical settings for patients with T-cell acute lymphoblastic T-ALL and B-cell CLL B-CLL However the use of forodesine in B-cell ALL B-ALL is unknown Leukemic blasts obtained from pediatric patients with de novo B-ALL n 10 were incubated with forodesine and deoxyguanosine dGuo and the biological end points of apoptosis intracellular dGTP accumulation and inhibition of RNA and DNA synthesis were measured Additionally adult patients with B-ALL n 2 were intravenously infused with 80 mg/m 2 /d daily for 5 days After therapy clinical response toxicity laboratory biomarkers including PNP enzyme inhibition and plasma forodesine dGuo and intracellular dGTP levels were analyzed Our in vitro investigations demonstrated that forodesine treatment inhibited proliferation and induced modest apoptosis in de novo B-ALL lymphoblasts There was time-dependent accumulation of dGTP and inhibition of RNA and DNA synthesis During therapy neither patient achieved a complete response CR but there was disease stabilization for several weeks in both patients There was significant maintained inhibition of PNP enzyme in red blood cells accumulation of forodesine and dGuo in plasma and intracellular dGTP accumulation in both patients Our preclinical and clinical investigations suggest that forodesine has activity in B-ALL However it needs to be either infused with dGuo or combined with established chemotherapeutic agents based on mechanistic rationale,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 1574, 17, 5006, 4032, 10658, 13133, 2299, 1940, 6, 102, 31, 3655, 10, 3, 877, 9, 11165, 13133, 222, 9, 102, 31, 2792, 10483, 16, 35, 1428, 6582, 13133, 230, 5, 28450, 3593, 408, 102, 10521, 2, 2316, 442, 1193, 552, 132, 37, 11183, 5487, 913, 1159, 6, 7859, 17863, 7345, 16319, 10483, 264, 721, 128, 4, 693, 2, 38, 1947, 9, 7, 5, 102, 31, 286, 1275, 102, 62, 2, 132, 31, 552, 132, 552, 137, 3, 119, 1, 10483, 4, 132, 31, 62, 132, 62, 16, 860, 2015, 2438, 683, 29, 815, 7, 5, 1566, 2018, 132, 62, 78, 79, 11, 8303, 5, 10483, 2, 17863, 17864, 2, 3, 1037, 396, 862, 1, 351, 2087, 16319, 1835, 2, 297, 1, 893, 2, 261, 2525, 11, 644, 1724, 780, 7, 5, 132, 62, 78, 18, 11, 1672, 4524, 5, 493, 81, 188, 18, 427, 391, 9, 33, 162, 50, 36, 38, 51, 155, 1624, 582, 141, 13133, 1644, 297, 2, 554, 10483, 17864, 2, 2087, 16319, 148, 11, 311, 114, 4, 439, 2492, 264, 17, 10483, 24, 879, 457, 2, 277, 1721, 351, 4, 1566, 2018, 132, 62, 10521, 125, 10, 98, 470, 1835, 1, 16319, 2, 297, 1, 893, 2, 261, 2525, 190, 36, 2174, 69, 513, 8, 236, 51, 684, 84, 125, 10, 34, 3184, 9, 392, 244, 4, 110, 7, 125, 10, 93, 1955, 297, 1, 13133, 1644, 4, 3422, 315, 37, 1835, 1, 10483, 2, 17864, 4, 554, 2, 2087, 16319, 1835, 4, 110, 7, 114, 693, 2, 38, 2492, 309, 17, 10483, 71, 128, 4, 132, 62, 137, 192, 1891, 6, 40, 361, 4524, 5, 17864, 15, 397, 5, 635, 1573, 183, 90, 23, 2716, 1728]",1902.0,23773454,573
Dexamethasone exposure and memory function in adult survivors of childhood acute lymphoblastic leukemia: A report from the SJLIFE cohort.,Pediatric blood & cancer,Pediatr Blood Cancer,2013-06-18,"Dexamethasone is used in acute lymphoblastic leukemia (ALL) treatment, though long-term impact on central nervous system (CNS) function is unclear. As glucocorticoids influence hippocampal function, we investigated memory networks in survivors of childhood ALL treated with dexamethasone or prednisone. Neurocognitive assessment and functional magnetic resonance imaging (fMRI) were conducted in 38 adult survivors randomly recruited from cohorts treated on one of two standard treatment protocols, which differed primarily in the glucocorticoid administered during continuation therapy (dexamethasone [n=18] vs. prednisone [n=20]). Groups did not differ in age at diagnosis, age at evaluation, or cumulative intravenous or intrathecal methotrexate exposure. Survivors treated with dexamethasone demonstrated lower performance on multiple memory-dependent measures, including story memory (P=0.01) and word recognition (P=0.04), compared to survivors treated with only prednisone. Dexamethasone treatment was associated with decreased fMRI activity in the left retrosplenial brain region (effect size=1.3), though the small sample size limited statistical significance (P=0.08). Story memory was associated with altered activation in left inferior frontal-temporal brain regions (P=0.007). Results from this pilot study suggest that adult survivors of ALL treated with dexamethasone are at increased risk for memory deficits and altered neural activity in specific brain regions and networks associated with memory function.",Journal Article,2408.0,27.0,Dexamethasone is used in acute lymphoblastic ALL treatment though long-term impact on central nervous system CNS function is unclear As glucocorticoids influence hippocampal function we investigated memory networks in survivors of childhood ALL treated with dexamethasone or prednisone Neurocognitive assessment and functional magnetic resonance imaging fMRI were conducted in 38 adult survivors randomly recruited from cohorts treated on one of two standard treatment protocols which differed primarily in the glucocorticoid administered during continuation therapy dexamethasone n 18 vs. prednisone n 20 Groups did not differ in age at diagnosis age at evaluation or cumulative intravenous or intrathecal methotrexate exposure Survivors treated with dexamethasone demonstrated lower performance on multiple memory-dependent measures including story memory P 0.01 and word recognition P 0.04 compared to survivors treated with only prednisone Dexamethasone treatment was associated with decreased fMRI activity in the left retrosplenial brain region effect size 1.3 though the small sample size limited statistical significance P 0.08 Story memory was associated with altered activation in left inferior frontal-temporal brain regions P 0.007 Results from this pilot study suggest that adult survivors of ALL treated with dexamethasone are at increased risk for memory deficits and altered neural activity in specific brain regions and networks associated with memory function,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1217, 16, 95, 4, 286, 1275, 62, 24, 2471, 319, 337, 345, 23, 854, 1880, 398, 1025, 343, 16, 1200, 22, 7307, 1054, 16469, 343, 21, 565, 2407, 3991, 4, 332, 1, 864, 62, 73, 5, 1217, 15, 1979, 2958, 455, 2, 583, 1484, 1535, 270, 20824, 11, 426, 4, 519, 780, 332, 1108, 2619, 29, 736, 73, 23, 104, 1, 100, 260, 24, 2189, 92, 2512, 1561, 4, 3, 5399, 468, 190, 6870, 36, 1217, 78, 203, 105, 1979, 78, 179, 271, 205, 44, 1505, 4, 89, 28, 147, 89, 28, 451, 15, 967, 1262, 15, 5126, 2116, 645, 332, 73, 5, 1217, 264, 280, 528, 23, 232, 2407, 470, 1018, 141, 15108, 2407, 19, 13, 355, 2, 15952, 2335, 19, 13, 755, 72, 6, 332, 73, 5, 158, 1979, 1217, 24, 10, 41, 5, 340, 20824, 128, 4, 3, 1712, 62954, 342, 1053, 254, 444, 14, 27, 2471, 3, 302, 1000, 444, 383, 1050, 724, 19, 13, 1592, 15108, 2407, 10, 41, 5, 1495, 363, 4, 1712, 1663, 8082, 3264, 342, 1374, 19, 13, 1999, 99, 29, 26, 2281, 45, 309, 17, 780, 332, 1, 62, 73, 5, 1217, 32, 28, 101, 43, 9, 2407, 2752, 2, 1495, 3922, 128, 4, 112, 342, 1374, 2, 3991, 41, 5, 2407, 343]",1477.0,23775832,150
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancies.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-06-18,"Allogeneic hematopoietic stem cell transplantation (HSCT) can achieve durable remissions in a number of patients with advanced hematologic malignancies. Little is known about the safety of HSCT in patients age 70 or older. Consecutive patients (n = 54) age 70 or older underwent HSCT between 2007 and 2012. Diseases included acute myelogenous leukemia (n = 25), myelodysplastic syndrome (n = 12), chronic lymphocytic leukemia (n = 5), non-Hodgkin lymphoma (n = 4), acute lymphoblastic leukemia (n = 3), myeloproliferative neoplasm (n = 4), and chronic myelogenous leukemia (n = 1). Median follow-up for survivors was 21 months. All patients received reduced-intensity conditioning regimens, primarily busulfan/fludarabine. All patients received unmanipulated peripheral blood stem cell grafts: 44 from 8/8 matched unrelated donors, 8 from matched related donors, and 2 from 7/8 matched unrelated donors. Graft-versus-host disease (GVHD) prophylaxis was calcineurin inhibitor-based in all patients. The median age at transplantation was 71 years (range, 70 to 76); the median HCT comorbidity index score was 1 (range, 0 to 5). Two patients died before hematopoietic recovery (1 with graft failure and 1 with disease progression), and 1 patient relapsed before hematopoietic recovery; otherwise, all engrafted with median donor chimerism of 94% at 1 month. Cumulative incidence of grades II to IV acute GVHD was 13% and of grades III to IV acute GVHD, 9.3%. At 2 years, the cumulative incidence of chronic GVHD was 36%, progression-free survival was 39%, overall survival was 39%, and relapse was 56%. Nonrelapse mortality was 3.7% at day +100 and 5.6% at 2 years. We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older.",Journal Article,2408.0,46.0,Allogeneic hematopoietic stem cell transplantation HSCT can achieve durable remissions in a number of patients with advanced hematologic malignancies Little is known about the safety of HSCT in patients age 70 or older Consecutive patients n 54 age 70 or older underwent HSCT between 2007 and 2012 Diseases included acute myelogenous n 25 syndrome n 12 chronic lymphocytic n 5 n 4 acute lymphoblastic n 3 neoplasm n 4 and chronic myelogenous n 1 Median follow-up for survivors was 21 months All patients received reduced-intensity conditioning regimens primarily busulfan/fludarabine All patients received unmanipulated peripheral blood stem cell grafts 44 from 8/8 matched unrelated donors 8 from matched related donors and 2 from 7/8 matched unrelated donors Graft-versus-host disease GVHD prophylaxis was calcineurin inhibitor-based in all patients The median age at transplantation was 71 years range 70 to 76 the median HCT comorbidity index score was 1 range 0 to 5 Two patients died before hematopoietic recovery 1 with graft failure and 1 with disease progression and 1 patient relapsed before hematopoietic recovery otherwise all engrafted with median donor chimerism of 94 at 1 month Cumulative incidence of grades II to IV acute GVHD was 13 and of grades III to IV acute GVHD 9.3 At 2 years the cumulative incidence of chronic GVHD was 36 progression-free survival was 39 overall survival was 39 and relapse was 56 Nonrelapse mortality was 3.7 at day +100 and 5.6 at 2 years We conclude that allogeneic HSCT is a safe and effective option for carefully selected patients age 70 or older,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1063, 1007, 452, 31, 497, 1703, 122, 1359, 1480, 3166, 4, 8, 207, 1, 7, 5, 131, 813, 441, 1215, 16, 440, 545, 3, 367, 1, 1703, 4, 7, 89, 431, 15, 434, 935, 7, 78, 667, 89, 431, 15, 434, 208, 1703, 59, 1307, 2, 1195, 1342, 159, 286, 2194, 78, 243, 681, 78, 133, 442, 1193, 78, 33, 78, 39, 286, 1275, 78, 27, 2131, 78, 39, 2, 442, 2194, 78, 14, 52, 166, 126, 9, 332, 10, 239, 53, 62, 7, 103, 405, 837, 1933, 472, 1561, 3906, 2027, 62, 7, 103, 14413, 672, 315, 452, 31, 4713, 584, 29, 66, 66, 655, 2092, 2344, 66, 29, 655, 139, 2344, 2, 18, 29, 67, 66, 655, 2092, 2344, 1599, 185, 1204, 34, 1562, 2049, 10, 12028, 230, 90, 4, 62, 7, 3, 52, 89, 28, 497, 10, 792, 60, 184, 431, 6, 846, 3, 52, 1085, 1879, 558, 368, 10, 14, 184, 13, 6, 33, 100, 7, 1016, 348, 1007, 1602, 14, 5, 1599, 496, 2, 14, 5, 34, 91, 2, 14, 69, 591, 348, 1007, 1602, 2632, 62, 6914, 5, 52, 1488, 6047, 1, 960, 28, 14, 811, 967, 287, 1, 2276, 215, 6, 478, 286, 1562, 10, 233, 2, 1, 2276, 316, 6, 478, 286, 1562, 83, 27, 28, 18, 60, 3, 967, 287, 1, 442, 1562, 10, 511, 91, 115, 25, 10, 587, 63, 25, 10, 587, 2, 429, 10, 664, 4640, 282, 10, 27, 67, 28, 218, 394, 2, 33, 49, 28, 18, 60, 21, 2060, 17, 1063, 1703, 16, 8, 1165, 2, 323, 1501, 9, 3900, 715, 7, 89, 431, 15, 434]",1597.0,23791626,743
Unrelated donor allogeneic hematopoietic cell transplantation is underused as a curative therapy in eligible patients from the United States.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2013-06-25,"Allogeneic hematopoietic cell transplantation (alloHCT) is a curative therapy for hematologic disorders including acute lymphoblastic and myeloid leukemia, chronic lymphocytic and myeloid leukemia, Hodgkin's and non-Hodgkin lymphoma, multiple myeloma, and myelodysplastic syndrome. To determine the utilization of alloHCT from unrelated donors (URDs) in the United States, we calculated the number of patients diagnosed with hematologic disorders age 20 to 74 years based on 2004 to 2008 Surveillance, Epidemiology and End Results and 2007 US Census data, estimated the percentage of patients who would be eligible for URD alloHCT after discounting the mortality rate during induction therapy and the rate of severe comorbidities, and compared these with the actual 2007 alloHCTs facilitated by the National Marrow Donor Program. We found that the number of URD alloHCT as a percentage of the estimated potential transplantations ranged from 11% for multiple myeloma to 54% for chronic myeloid leukemia, with an average percentage of 26% for all the disorders considered. In an analysis stratified by age groups (20 to 44, 45 to 64, and 65 to 74 years), the utilization of URD alloHCT was higher in younger patients than in older patients for all disorders. Of acute lymphoblastic and myeloid leukemia patients, approximately 66% underwent URD alloHCT later in the course of their disease (in second or greater complete remission). URD alloHCT is likely underused for potentially curable hematologic disorders, particularly in older patients. Understanding the reasons for low use of alloHCT may lead to strategies to expand the use of this curative therapy for more patients with hematologic disorders. ",Journal Article,2401.0,15.0,Allogeneic hematopoietic cell transplantation alloHCT is a curative therapy for hematologic disorders including acute lymphoblastic and myeloid chronic lymphocytic and myeloid 's and multiple and syndrome To determine the utilization of alloHCT from unrelated donors URDs in the United States we calculated the number of patients diagnosed with hematologic disorders age 20 to 74 years based on 2004 to 2008 Surveillance Epidemiology and End Results and 2007 US Census data estimated the percentage of patients who would be eligible for URD alloHCT after discounting the mortality rate during induction therapy and the rate of severe comorbidities and compared these with the actual 2007 alloHCTs facilitated by the National Marrow Donor Program We found that the number of URD alloHCT as a percentage of the estimated potential transplantations ranged from 11 for multiple to 54 for chronic myeloid with an average percentage of 26 for all the disorders considered In an analysis stratified by age groups 20 to 44 45 to 64 and 65 to 74 years the utilization of URD alloHCT was higher in younger patients than in older patients for all disorders Of acute lymphoblastic and myeloid patients approximately 66 underwent URD alloHCT later in the course of their disease in second or greater complete remission URD alloHCT is likely underused for potentially curable hematologic disorders particularly in older patients Understanding the reasons for low use of alloHCT may lead to strategies to expand the use of this curative therapy for more patients with hematologic disorders,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[1063, 1007, 31, 497, 5514, 16, 8, 1075, 36, 9, 813, 1997, 141, 286, 1275, 2, 533, 442, 1193, 2, 533, 292, 2, 232, 2, 681, 6, 223, 3, 1961, 1, 5514, 29, 2092, 2344, 15979, 4, 3, 1088, 907, 21, 981, 3, 207, 1, 7, 265, 5, 813, 1997, 89, 179, 6, 794, 60, 90, 23, 1131, 6, 1375, 617, 1284, 2, 396, 99, 2, 1307, 843, 7319, 74, 661, 3, 1150, 1, 7, 54, 688, 40, 625, 9, 5847, 5514, 50, 34483, 3, 282, 116, 190, 504, 36, 2, 3, 116, 1, 905, 1909, 2, 72, 46, 5, 3, 3480, 1307, 63006, 4667, 20, 3, 657, 581, 1488, 1243, 21, 204, 17, 3, 207, 1, 5847, 5514, 22, 8, 1150, 1, 3, 661, 174, 6779, 1869, 29, 175, 9, 232, 6, 667, 9, 442, 533, 5, 35, 1011, 1150, 1, 432, 9, 62, 3, 1997, 515, 4, 35, 65, 1173, 20, 89, 271, 179, 6, 584, 512, 6, 660, 2, 556, 6, 794, 60, 3, 1961, 1, 5847, 5514, 10, 142, 4, 773, 7, 76, 4, 434, 7, 9, 62, 1997, 1, 286, 1275, 2, 533, 7, 705, 700, 208, 5847, 5514, 1559, 4, 3, 906, 1, 136, 34, 4, 419, 15, 378, 236, 734, 5847, 5514, 16, 322, 11166, 9, 751, 4151, 813, 1997, 823, 4, 434, 7, 612, 3, 2325, 9, 154, 119, 1, 5514, 68, 1122, 6, 422, 6, 4082, 3, 119, 1, 26, 1075, 36, 9, 80, 7, 5, 813, 1997]",1574.0,23811537,684
Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01.,Pediatric blood & cancer,Pediatr Blood Cancer,2013-07-06,"Dexamethasone is more efficacious than prednisone in the treatment of acute lymphoblastic leukemia (ALL), but has also been associated with greater toxicity. We compared neuropsychological outcomes for patients treated on DFCI ALL Consortium Protocol 00-01, which included a randomized comparison of the two steroid preparations during post-induction therapy in children and adolescents with ALL. Between 2000 and 2005, 408 children with standard-risk or high-risk ALL treated on Dana-Farber Cancer Institute Consortium Protocol 00-01 were randomly assigned to prednisone or dexamethasone administered as 5-day pulses every 3 weeks for 2 years, beginning at week 7 of treatment. Blinded neuropsychological testing was completed for 170 randomized patients (prednisone, N=76; dexamethasone, N=94), all of whom were in continuous complete remission after completion of therapy. Outcomes were comparable for most variables, although patients on the dexamethasone arm performed more poorly on a measure of fluid reasoning (P=0.02). They also tended to be more likely to be enrolled in special education (dexamethasone, 33% vs. prednisone, 20%, P=0.09). Dexamethasone has well documented benefit in treatment of ALL. Although formal testing provided little indication of increased risk for neurotoxicity relative to prednisone, the somewhat greater utilization of special education services by patients treated with dexamethasone merits further investigation.",Journal Article,2390.0,15.0,Dexamethasone is more efficacious than prednisone in the treatment of acute lymphoblastic ALL but has also been associated with greater toxicity We compared neuropsychological outcomes for patients treated on DFCI ALL Consortium Protocol 00-01 which included a randomized comparison of the two steroid preparations during post-induction therapy in children and adolescents with ALL Between 2000 and 2005 408 children with standard-risk or high-risk ALL treated on Dana-Farber Cancer Institute Consortium Protocol 00-01 were randomly assigned to prednisone or dexamethasone administered as 5-day pulses every 3 weeks for 2 years beginning at week 7 of treatment Blinded neuropsychological testing was completed for 170 randomized patients prednisone N 76 dexamethasone N 94 all of whom were in continuous complete remission after completion of therapy Outcomes were comparable for most variables although patients on the dexamethasone arm performed more poorly on a measure of fluid reasoning P 0.02 They also tended to be more likely to be enrolled in special education dexamethasone 33 vs. prednisone 20 P 0.09 Dexamethasone has well documented benefit in treatment of ALL Although formal testing provided little indication of increased risk for neurotoxicity relative to prednisone the somewhat greater utilization of special education services by patients treated with dexamethasone merits further investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1217, 16, 80, 3289, 76, 1979, 4, 3, 24, 1, 286, 1275, 62, 84, 71, 120, 85, 41, 5, 378, 155, 21, 72, 8271, 123, 9, 7, 73, 23, 11152, 62, 2404, 1182, 2038, 355, 92, 159, 8, 384, 1155, 1, 3, 100, 3853, 7791, 190, 539, 504, 36, 4, 541, 2, 3101, 5, 62, 59, 1081, 2, 1242, 13356, 541, 5, 260, 43, 15, 64, 43, 62, 73, 23, 4932, 4979, 12, 1377, 2404, 1182, 2038, 355, 11, 1108, 896, 6, 1979, 15, 1217, 468, 22, 33, 218, 15523, 454, 27, 244, 9, 18, 60, 2948, 28, 647, 67, 1, 24, 3288, 8271, 471, 10, 781, 9, 5248, 384, 7, 1979, 78, 846, 1217, 78, 960, 62, 1, 953, 11, 4, 1314, 236, 734, 50, 1438, 1, 36, 123, 11, 1279, 9, 96, 682, 242, 7, 23, 3, 1217, 475, 173, 80, 1240, 23, 8, 1463, 1, 2357, 15856, 19, 13, 588, 491, 120, 3886, 6, 40, 80, 322, 6, 40, 346, 4, 3714, 1848, 1217, 466, 105, 1979, 179, 19, 13, 1730, 1217, 71, 149, 1405, 247, 4, 24, 1, 62, 242, 5057, 471, 1052, 1215, 3607, 1, 101, 43, 9, 3561, 580, 6, 1979, 3, 6122, 378, 1961, 1, 3714, 1848, 2142, 20, 7, 73, 5, 1217, 4986, 195, 940]",1414.0,23832430,32
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.,Blood,Blood,2013-07-08,"From 2001 to 2011, 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia were treated with chemotherapy + imatinib (n = 54) or + dasatinib (n = 68). One hundred fifteen (94%) achieved complete remission (CR) including 101 patients who achieved it with only 1 induction course and had at least 1 minimal residual disease (MRD) assessment; 25 patients underwent an allogeneic stem cell transplant in first CR and were excluded, leaving 76 patients as the subject of this report. MRD monitoring by multiparameter flow cytometry (MFC) and real-time quantitative polymerase chain reaction (PCR) was performed at the end of induction and at ~3-month intervals thereafter. Median age was 54 years (range, 21-84 years). There was no difference in survival by achievement of at least a major molecular response (MMR; BCR-ABL/ABL < 0.1%) at CR (P = .22). Patients achieving MMR at 3, 6, 9, and 12 months had a better survival (P = .02, .04, .05, and .01, respectively). Negative MFC at CR did not predict for improved survival (P = .2). At 3 and 12 months, negative MRD by MFC was associated with improved survival (P = .04 and .001). MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR.",Journal Article,2388.0,116.0,From 2001 to 2011 122 patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic were treated with chemotherapy imatinib n 54 or dasatinib n 68 One hundred fifteen 94 achieved complete remission CR including 101 patients who achieved it with only 1 induction course and had at least 1 minimal residual disease MRD assessment 25 patients underwent an allogeneic stem cell transplant in first CR and were excluded leaving 76 patients as the subject of this report MRD monitoring by multiparameter flow cytometry MFC and real-time quantitative polymerase chain reaction PCR was performed at the end of induction and at ~3-month intervals thereafter Median age was 54 years range 21-84 years There was no difference in survival by achievement of at least a major molecular response MMR BCR-ABL/ABL 0.1 at CR P .22 Patients achieving MMR at 3 6 9 and 12 months had a better survival P .02 .04 .05 and .01 respectively Negative MFC at CR did not predict for improved survival P .2 At 3 and 12 months negative MRD by MFC was associated with improved survival P .04 and .001 MRD monitoring by PCR and MFC identifies patients who benefit from treatment intensification in first CR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[29, 1758, 6, 1132, 3285, 7, 5, 732, 265, 3006, 1170, 109, 286, 1275, 11, 73, 5, 56, 577, 78, 667, 15, 1674, 78, 806, 104, 1128, 3057, 960, 513, 236, 734, 684, 141, 2338, 7, 54, 513, 192, 5, 158, 14, 504, 906, 2, 42, 28, 506, 14, 1048, 753, 34, 2029, 455, 243, 7, 208, 35, 1063, 452, 31, 941, 4, 157, 684, 2, 11, 1800, 7806, 846, 7, 22, 3, 2974, 1, 26, 414, 2029, 1315, 20, 10757, 1412, 1914, 9439, 2, 1589, 98, 1156, 1451, 1260, 1329, 604, 10, 173, 28, 3, 396, 1, 504, 2, 28, 27, 811, 1582, 3972, 52, 89, 10, 667, 60, 184, 239, 874, 60, 125, 10, 77, 523, 4, 25, 20, 5088, 1, 28, 506, 8, 458, 219, 51, 2205, 1062, 1425, 1425, 13, 14, 28, 684, 19, 350, 7, 1785, 2205, 28, 27, 49, 83, 2, 133, 53, 42, 8, 380, 25, 19, 588, 755, 474, 2, 355, 106, 199, 9439, 28, 684, 205, 44, 678, 9, 231, 25, 19, 18, 28, 27, 2, 133, 53, 199, 2029, 20, 9439, 10, 41, 5, 231, 25, 19, 755, 2, 144, 2029, 1315, 20, 604, 2, 9439, 2953, 7, 54, 247, 29, 24, 5091, 4, 157, 684]",1195.0,23836561,837
Novel targeted therapies in acute lymphoblastic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2013-08-28,"Chemotherapy alone cures only 25-45% of adult patients with acute lymphoblastic leukemia (ALL), making novel treatment agents and strategies desperately needed. The addition of monoclonal antibodies (rituximab, alemtuzumab, epratzumab) to chemotherapy has demonstrated encouraging results in patients with newly diagnosed and relapsed ALL. The anti-CD22 immunoconjugate, inotuzumab ozogamicin, and the anti-CD19 BiTE() antibody, blinatumomab, have demonstrated impressive single agent activity in patients with relapsed or refractory B-ALL. Early reports of chimeric antigen receptor therapies have been promising in patients with relapsed ALL. Other agents targeting NOTCH1, FLT3, the proteasome and DNA methylation are early in development. These new agents hope to improve the outcome of ALL therapy with less toxicity. The challenge going forward will be to find safe and effective combinations and determine where in the treatment schema these agents will be most effective in ALL therapy.",Journal Article,2337.0,16.0,Chemotherapy alone cures only 25-45 of adult patients with acute lymphoblastic ALL making novel treatment agents and strategies desperately needed The addition of monoclonal antibodies rituximab alemtuzumab epratzumab to chemotherapy has demonstrated encouraging results in patients with newly diagnosed and relapsed ALL The anti-CD22 immunoconjugate inotuzumab ozogamicin and the anti-CD19 BiTE  antibody blinatumomab have demonstrated impressive single agent activity in patients with relapsed or refractory B-ALL Early reports of chimeric antigen receptor therapies have been promising in patients with relapsed ALL Other agents targeting NOTCH1 FLT3 the proteasome and DNA methylation are early in development These new agents hope to improve the outcome of ALL therapy with less toxicity The challenge going forward will be to find safe and effective combinations and determine where in the treatment schema these agents will be most effective in ALL therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[56, 279, 9154, 158, 243, 512, 1, 780, 7, 5, 286, 1275, 62, 1079, 229, 24, 183, 2, 422, 11769, 575, 3, 352, 1, 848, 890, 855, 3579, 63063, 6, 56, 71, 264, 2269, 99, 4, 7, 5, 732, 265, 2, 591, 62, 3, 312, 7599, 13498, 6730, 5566, 2, 3, 312, 3158, 15382, 6081, 548, 7182, 47, 264, 5790, 226, 420, 128, 4, 7, 5, 591, 15, 430, 132, 62, 191, 1198, 1, 2897, 448, 153, 235, 47, 85, 721, 4, 7, 5, 591, 62, 127, 183, 529, 4607, 1224, 3, 1694, 2, 261, 569, 32, 191, 4, 193, 46, 217, 183, 3045, 6, 401, 3, 228, 1, 62, 36, 5, 299, 155, 3, 1745, 11587, 4674, 303, 40, 6, 2469, 1165, 2, 323, 1247, 2, 223, 1257, 4, 3, 24, 8371, 46, 183, 303, 40, 96, 323, 4, 62, 36]",964.0,23841506,538
Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia.,Cancer,Cancer,2013-07-16,"Doxorubicin is associated with progressive cardiac dysfunction, possibly through the formation of doxorubicin-iron complexes leading to free-radical injury. The authors determined the frequency of hemochromatosis (HFE) gene mutations associated with hereditary hemochromatosis and their relationship with doxorubicin-associated cardiotoxicity in survivors of childhood high-risk acute lymphoblastic leukemia. Peripheral blood was tested for 2 common HFE allelic variants: C282Y and H63D. Serum cardiac troponin-T (cTnT) and N-terminal pro-brain natriuretic peptide (NT-proBNP), which are biomarkers of cardiac injury and cardiomyopathy, respectively, were assayed during therapy. Left ventricular (LV) structure and function were assessed with echocardiography. A total of 184 patients had DNA results for at least 1 variant, and 167 had DNA results for both: 24% carried H63D and 10% carried C282Y. Heterozygous C282Y genotype was associated with multiple elevations in cTnT concentrations (P=.039), but not NT-proBNP. At a median of 2.2 years (range, 1.0 years-3.6 years) after diagnosis, the mean Z-scores for LV fractional shortening (-0.71 [standard error (SE), 0.25]; P=.008), mass (-0.84 [SE, 0.17]; P<.001), and end-systolic (-4.36 [SE, 0.26], P<.001) and end-diastolic (-0.68 [SE, 0.25]; P=.01) posterior wall thickness were found to be abnormal in children with either allele (n=32). Noncarriers (n=63) also were found to have below-normal LV mass (-0.45 [SE, 0.15]; P=.006) and end-systolic posterior wall thickness (-4.06 [SE, 0.17]; P<.001). Later follow-up demonstrated similar results. Doxorubicin-associated myocardial injury was associated with C282Y HFE carriers. Although LV mass and wall thickness were found to be abnormally low overall, they were even lower in HFE carriers, who also had reduced LV function. Screening newly diagnosed cancer patients for HFE mutations may identify those at risk for doxorubicin-induced cardiotoxicity.",Journal Article,2380.0,80.0,Doxorubicin is associated with progressive dysfunction possibly through the formation of doxorubicin-iron complexes leading to free-radical injury The authors determined the frequency of hemochromatosis HFE gene mutations associated with hereditary hemochromatosis and their relationship with doxorubicin-associated cardiotoxicity in survivors of childhood high-risk acute lymphoblastic Peripheral blood was tested for 2 common HFE allelic variants C282Y and H63D Serum troponin-T cTnT and N-terminal pro-brain natriuretic peptide NT-proBNP which are biomarkers of injury and cardiomyopathy respectively were assayed during therapy Left ventricular LV structure and function were assessed with echocardiography A total of 184 patients had DNA results for at least 1 variant and 167 had DNA results for both 24 carried H63D and 10 carried C282Y Heterozygous C282Y genotype was associated with multiple elevations in cTnT concentrations P .039 but not NT-proBNP At a median of 2.2 years range 1.0 years-3.6 years after diagnosis the mean Z-scores for LV fractional shortening -0.71 standard error SE 0.25 P .008 mass -0.84 SE 0.17 P .001 and end-systolic -4.36 SE 0.26 P .001 and end-diastolic -0.68 SE 0.25 P .01 posterior wall thickness were found to be abnormal in children with either allele n 32 Noncarriers n 63 also were found to have below-normal LV mass -0.45 SE 0.15 P .006 and end-systolic posterior wall thickness -4.06 SE 0.17 P .001 Later follow-up demonstrated similar results Doxorubicin-associated myocardial injury was associated with C282Y HFE carriers Although LV mass and wall thickness were found to be abnormally low overall they were even lower in HFE carriers who also had reduced LV function Screening newly diagnosed cancer patients for HFE mutations may identify those at risk for doxorubicin-induced cardiotoxicity,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[856, 16, 41, 5, 1014, 1527, 2150, 298, 3, 1264, 1, 856, 4231, 3817, 1049, 6, 115, 711, 2730, 3, 738, 509, 3, 675, 1, 30789, 20443, 145, 138, 41, 5, 2305, 30789, 2, 136, 858, 5, 856, 41, 4404, 4, 332, 1, 864, 64, 43, 286, 1275, 672, 315, 10, 650, 9, 18, 186, 20443, 3861, 839, 30790, 2, 37936, 524, 9092, 102, 29263, 2, 78, 2158, 1805, 342, 12994, 1389, 5314, 12031, 92, 32, 582, 1, 2730, 2, 6460, 106, 11, 4499, 190, 36, 1712, 4028, 4072, 2772, 2, 343, 11, 275, 5, 9484, 8, 181, 1, 5894, 7, 42, 261, 99, 9, 28, 506, 14, 1142, 2, 5431, 42, 261, 99, 9, 110, 259, 2629, 37936, 2, 79, 2629, 30790, 4167, 30790, 1183, 10, 41, 5, 232, 4712, 4, 29263, 1003, 19, 5955, 84, 44, 5314, 12031, 28, 8, 52, 1, 18, 18, 60, 184, 14, 13, 60, 27, 49, 60, 50, 147, 3, 313, 3905, 703, 9, 4072, 7528, 9245, 13, 792, 260, 3444, 3428, 13, 243, 19, 2155, 782, 13, 874, 3428, 13, 269, 19, 144, 2, 396, 8109, 39, 511, 3428, 13, 432, 19, 144, 2, 396, 10059, 13, 806, 3428, 13, 243, 19, 355, 3028, 2397, 2903, 11, 204, 6, 40, 1668, 4, 541, 5, 361, 1254, 78, 531, 10667, 78, 676, 120, 11, 204, 6, 47, 2736, 295, 4072, 782, 13, 512, 3428, 13, 167, 19, 1861, 2, 396, 8109, 3028, 2397, 2903, 39, 1460, 3428, 13, 269, 19, 144, 1559, 166, 126, 264, 288, 99, 856, 41, 5098, 2730, 10, 41, 5, 30790, 20443, 1316, 242, 4072, 782, 2, 2397, 2903, 11, 204, 6, 40, 11749, 154, 63, 491, 11, 871, 280, 4, 20443, 1316, 54, 120, 42, 405, 4072, 343, 453, 732, 265, 12, 7, 9, 20443, 138, 68, 255, 135, 28, 43, 9, 856, 277, 4404]",1841.0,23861158,589
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.,mAbs,MAbs,2013-06-07,"TRU-016 is a SMIP(TM) (monospecific protein therapeutic) molecule against the tetraspanin transmembrane family protein CD37 that is currently in Phase 2 trials in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin Lymphoma (NHL). In an attempt to enhance the ADCC function of SMIP-016, the chimeric version of TRU-016, SMIP-016(GV) was engineered with a modification in a glycosylation site in the Fc domain. The wild-type and glycovariant SMIP proteins mediate comparable Type I antibody-like direct cytotoxicity in the presence of anti-human Fc crosslinker and show a similar tyrosine phosphorylation pattern post-treatment. However, NK cells stimulated with the SMIP-016(GV) exhibit enhanced activation and release 3-fold more interferon- compared with SMIP-016. SMIP-016(GV) shows enhanced ADCC function against cells expressing CD37 with NK cell effectors derived from both normal and CLL-affected individuals. Enhanced ADCC is observed against CLL cells and is sustained at concentrations of SMIP-016(GV) as low at 5E(-6) g/mL on cells expressing minimal CD37 antigen. In support of the biological relevance of this, SMIP-016(GV) mediates effective ADCC against primary acute lymphoblastic leukemia (ALL) cells with low surface expression of CD37. Collectively, these data suggest potential use of the novel therapeutic agent SMIP-016(GV) with enhanced effector function for B cell malignancies, including CLL and ALL therapy. ",Journal Article,2419.0,7.0,TRU-016 is a SMIP TM monospecific protein therapeutic molecule against the tetraspanin transmembrane family protein CD37 that is currently in Phase 2 trials in Chronic Lymphocytic CLL and NHL In an attempt to enhance the ADCC function of SMIP-016 the chimeric version of TRU-016 SMIP-016 GV was engineered with a modification in a glycosylation site in the Fc domain The wild-type and glycovariant SMIP proteins mediate comparable Type I antibody-like direct cytotoxicity in the presence of anti-human Fc crosslinker and show a similar tyrosine phosphorylation pattern post-treatment However NK cells stimulated with the SMIP-016 GV exhibit enhanced activation and release 3-fold more interferon- compared with SMIP-016 SMIP-016 GV shows enhanced ADCC function against cells expressing CD37 with NK cell effectors derived from both normal and CLL-affected individuals Enhanced ADCC is observed against CLL cells and is sustained at concentrations of SMIP-016 GV as low at 5E -6 g/mL on cells expressing minimal CD37 antigen In support of the biological relevance of this SMIP-016 GV mediates effective ADCC against primary acute lymphoblastic ALL cells with low surface expression of CD37 Collectively these data suggest potential use of the novel therapeutic agent SMIP-016 GV with enhanced effector function for B cell malignancies including CLL and ALL therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[23092, 3820, 16, 8, 18502, 6547, 63125, 178, 189, 1354, 480, 3, 22598, 5527, 607, 178, 10006, 17, 16, 694, 4, 124, 18, 143, 4, 442, 1193, 552, 2, 1176, 4, 35, 3448, 6, 1304, 3, 5551, 343, 1, 18502, 3820, 3, 2897, 2256, 1, 23092, 3820, 18502, 3820, 17398, 10, 2794, 5, 8, 2437, 4, 8, 9520, 606, 4, 3, 4127, 1398, 3, 955, 267, 2, 63126, 18502, 652, 3367, 1279, 267, 70, 548, 733, 1196, 1408, 4, 3, 463, 1, 312, 171, 4127, 63127, 2, 514, 8, 288, 564, 982, 1177, 539, 24, 137, 1765, 37, 2816, 5, 3, 18502, 3820, 17398, 2239, 651, 363, 2, 2008, 27, 1116, 80, 1688, 2655, 72, 5, 18502, 3820, 18502, 3820, 17398, 1949, 651, 5551, 343, 480, 37, 1046, 10006, 5, 1765, 31, 4926, 526, 29, 110, 295, 2, 552, 1424, 869, 651, 5551, 16, 164, 480, 552, 37, 2, 16, 2275, 28, 1003, 1, 18502, 3820, 17398, 22, 154, 28, 47667, 49, 7570, 542, 23, 37, 1046, 1048, 10006, 448, 4, 538, 1, 3, 1037, 2088, 1, 26, 18502, 3820, 17398, 3961, 323, 5551, 480, 86, 286, 1275, 62, 37, 5, 154, 1255, 55, 1, 10006, 2535, 46, 74, 309, 174, 119, 1, 3, 229, 189, 420, 18502, 3820, 17398, 5, 651, 2070, 343, 9, 132, 31, 441, 141, 552, 2, 62, 36]",1365.0,23883821,568
Bim polymorphisms: influence on function and response to treatment in children with acute lymphoblastic leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2013-08-01,"Corticosteroids induce apoptosis in the malignant lymphoid cells and are critical component of combination therapy for acute lymphoblastic leukemia (ALL). Several genome-wide microarray studies showed major implication of proapoptotic Bim in mediating corticosteroid-related resistance in leukemia cells. We investigated Bim gene polymorphisms and their association with childhood ALL outcome, and the mechanism underlying the observed finding. Lower overall survival (OS) was associated with Bim C29201T located in Bcl-2 homology 3 (BH3) domain (P = 0.01). An association remained significant in multivariate model (P = 0.007), was more apparent in high-risk patients (P = 0.004) and patients treated with dexamethasone (P = 0.009), and was subsequently confirmed in the replication patient cohort (P = 0.03). RNA analysis revealed that C29201T affects generation of  isoforms (1) that lack proapoptotic BH3 domain. The phenotypic effect was minor suggesting the influence of additional factors that may act in conjunction with Bim genotype. Combined analysis with Mcl gene polymorphism (G-486T) revealed profound reduction in OS in individuals with both risk genotypes (P < 0.0005 in discovery and P = 0.002 in replication cohort) and particularly in high-risk patients (P  0.008). Increased expression of prosurvival Mcl1 and presence of Bim isoforms lacking proapoptotic function might explain marked reduction of OS in a disease and dose-dependent manner in ALL patients carrying Bim- and Mcl1-risk genotypes.",Journal Article,2364.0,20.0,Corticosteroids induce apoptosis in the malignant lymphoid cells and are critical component of combination therapy for acute lymphoblastic ALL Several genome-wide microarray studies showed major implication of proapoptotic Bim in mediating corticosteroid-related resistance in cells We investigated Bim gene polymorphisms and their association with childhood ALL outcome and the mechanism underlying the observed finding Lower overall survival OS was associated with Bim C29201T located in Bcl-2 homology 3 BH3 domain P 0.01 An association remained significant in multivariate model P 0.007 was more apparent in high-risk patients P 0.004 and patients treated with dexamethasone P 0.009 and was subsequently confirmed in the replication patient cohort P 0.03 RNA analysis revealed that C29201T affects generation of  isoforms 1 that lack proapoptotic BH3 domain The phenotypic effect was minor suggesting the influence of additional factors that may act in conjunction with Bim genotype Combined analysis with Mcl gene polymorphism G-486T revealed profound reduction in OS in individuals with both risk genotypes P 0.0005 in discovery and P 0.002 in replication cohort and particularly in high-risk patients P  0.008 Increased expression of prosurvival Mcl1 and presence of Bim isoforms lacking proapoptotic function might explain marked reduction of OS in a disease and dose-dependent manner in ALL patients carrying Bim- and Mcl1-risk genotypes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3876, 1290, 351, 4, 3, 393, 2303, 37, 2, 32, 740, 1249, 1, 150, 36, 9, 286, 1275, 62, 392, 898, 1019, 1727, 94, 224, 458, 8969, 1, 4118, 3595, 4, 3941, 5654, 139, 251, 4, 37, 21, 565, 3595, 145, 1203, 2, 136, 248, 5, 864, 62, 228, 2, 3, 670, 1181, 3, 164, 1567, 280, 63, 25, 118, 10, 41, 5, 3595, 47868, 2308, 4, 1044, 18, 7984, 27, 5486, 1398, 19, 13, 355, 35, 248, 958, 93, 4, 331, 202, 19, 13, 1999, 10, 80, 2235, 4, 64, 43, 7, 19, 13, 1520, 2, 7, 73, 5, 1217, 19, 13, 2376, 2, 10, 1611, 557, 4, 3, 2079, 69, 180, 19, 13, 680, 893, 65, 553, 17, 47868, 2561, 914, 1, 2655, 3913, 63172, 17, 926, 4118, 5486, 1398, 3, 3290, 254, 10, 2278, 802, 3, 1054, 1, 402, 130, 17, 68, 2559, 4, 3357, 5, 3595, 1183, 397, 65, 5, 1308, 145, 1907, 499, 63173, 553, 4399, 628, 4, 118, 4, 869, 5, 110, 43, 2071, 19, 13, 4252, 4, 1574, 2, 19, 13, 1111, 4, 2079, 180, 2, 823, 4, 64, 43, 7, 19, 1552, 13, 2155, 101, 55, 1, 7331, 8132, 2, 463, 1, 3595, 3913, 1941, 4118, 343, 822, 2943, 2003, 628, 1, 118, 4, 8, 34, 2, 61, 470, 1708, 4, 62, 7, 2934, 3595, 2, 8132, 43, 2071]",1449.0,23908358,255
Genetic loss of SH2B3 in acute lymphoblastic leukemia.,Blood,Blood,2013-08-01,"The SH2B adaptor protein 3 (SH2B3) gene encodes a negative regulator of cytokine signaling with a critical role in the homeostasis of hematopoietic stem cells and lymphoid progenitors. Here, we report the identification of germline homozygous SH2B3 mutations in 2 siblings affected with developmental delay and autoimmunity, one in whom B-precursor acute lymphoblastic leukemia (ALL) developed. Mechanistically, loss of SH2B3 increases Janus kinase-signal transducer and activator of transcription signaling, promotes lymphoid cell proliferation, and accelerates leukemia development in a mouse model of NOTCH1-induced ALL. Moreover, extended mutation analysis showed homozygous somatic mutations in SH2B3 in 2 of 167 ALLs analyzed. Overall, these results demonstrate a Knudson tumor suppressor role for SH2B3 in the pathogenesis of ALL and highlight a possible link between genetic predisposition factors in the pathogenesis of autoimmunity and leukemogenesis. ",Case Reports,2364.0,61.0,The SH2B adaptor protein 3 SH2B3 gene encodes a negative regulator of cytokine signaling with a critical role in the homeostasis of hematopoietic stem cells and lymphoid progenitors Here we report the identification of germline homozygous SH2B3 mutations in 2 siblings affected with developmental delay and autoimmunity one in whom B-precursor acute lymphoblastic ALL developed Mechanistically loss of SH2B3 increases Janus kinase-signal transducer and activator of transcription signaling promotes lymphoid cell proliferation and accelerates development in a mouse model of NOTCH1-induced ALL Moreover extended mutation analysis showed homozygous somatic mutations in SH2B3 in 2 of 167 ALLs analyzed Overall these results demonstrate a Knudson tumor suppressor role for SH2B3 in the pathogenesis of ALL and highlight a possible link between genetic predisposition factors in the pathogenesis of autoimmunity and leukemogenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 63174, 10171, 178, 27, 22757, 145, 4322, 8, 199, 2452, 1, 1675, 314, 5, 8, 740, 200, 4, 3, 4975, 1, 1007, 452, 37, 2, 2303, 4321, 467, 21, 414, 3, 911, 1, 1009, 3189, 22757, 138, 4, 18, 2758, 1424, 5, 4566, 1984, 2, 7628, 104, 4, 953, 132, 2765, 286, 1275, 62, 276, 4187, 407, 1, 22757, 1106, 6191, 216, 1235, 5182, 2, 3393, 1, 866, 314, 2148, 2303, 31, 457, 2, 13912, 193, 4, 8, 830, 202, 1, 4607, 277, 62, 1393, 1747, 258, 65, 224, 3189, 1119, 138, 4, 22757, 4, 18, 1, 5431, 10706, 311, 63, 46, 99, 608, 8, 46905, 30, 1245, 200, 9, 22757, 4, 3, 1384, 1, 62, 2, 1817, 8, 899, 3460, 59, 336, 2863, 130, 4, 3, 1384, 1, 7628, 2, 5661]",927.0,23908464,92
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia.,The Journal of clinical investigation,J. Clin. Invest.,2013-06-10,"Acute lymphoblastic leukemia (ALL) is the commonest childhood malignancy and is characterized by recurring structural genetic alterations. Previous studies of DNA methylation suggest epigenetic alterations may also be important, but an integrated genome-wide analysis of genetic and epigenetic alterations in ALL has not been performed. We analyzed 137 B-lineage and 30 T-lineage childhood ALL cases using microarray analysis of DNA copy number alterations and gene expression, and genome-wide cytosine methylation profiling using the HpaII tiny fragment enrichment by ligation-mediated PCR (HELP) assay. We found that the different genetic subtypes of ALL are characterized by distinct DNA methylation signatures that exhibit significant correlation with gene expression profiles. We also identified an epigenetic signature common to all cases, with correlation to gene expression in 65% of these genes, suggesting that a core set of epigenetically deregulated genes is central to the initiation or maintenance of lymphoid transformation. Finally, we identified aberrant methylation in multiple genes also targeted by recurring DNA copy number alterations in ALL, suggesting that these genes are inactivated far more frequently than suggested by structural genomic analyses alone. Together, these results demonstrate subtype- and disease-specific alterations in cytosine methylation in ALL that influence transcriptional activity, and are likely to exert a key role in leukemogenesis. ",Journal Article,2416.0,70.0,Acute lymphoblastic ALL is the commonest childhood malignancy and is characterized by recurring structural genetic alterations Previous studies of DNA methylation suggest epigenetic alterations may also be important but an integrated genome-wide analysis of genetic and epigenetic alterations in ALL has not been performed We analyzed 137 B-lineage and 30 T-lineage childhood ALL cases using microarray analysis of DNA copy number alterations and gene expression and genome-wide cytosine methylation profiling using the HpaII tiny fragment enrichment by ligation-mediated PCR HELP assay We found that the different genetic subtypes of ALL are characterized by distinct DNA methylation signatures that exhibit significant correlation with gene expression profiles We also identified an epigenetic signature common to all cases with correlation to gene expression in 65 of these genes suggesting that a core set of epigenetically deregulated genes is central to the initiation or maintenance of lymphoid transformation Finally we identified aberrant methylation in multiple genes also targeted by recurring DNA copy number alterations in ALL suggesting that these genes are inactivated far more frequently than suggested by structural genomic analyses alone Together these results demonstrate subtype- and disease-specific alterations in cytosine methylation in ALL that influence transcriptional activity and are likely to exert a key role in leukemogenesis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 3, 13637, 864, 710, 2, 16, 765, 20, 6385, 3281, 336, 593, 698, 94, 1, 261, 569, 309, 1418, 593, 68, 120, 40, 305, 84, 35, 2102, 898, 1019, 65, 1, 336, 2, 1418, 593, 4, 62, 71, 44, 85, 173, 21, 311, 4352, 132, 2542, 2, 201, 102, 2542, 864, 62, 140, 75, 1727, 65, 1, 261, 1337, 207, 593, 2, 145, 55, 2, 898, 1019, 6903, 569, 1080, 75, 3, 30320, 29009, 5245, 3020, 20, 5307, 517, 604, 987, 719, 21, 204, 17, 3, 338, 336, 814, 1, 62, 32, 765, 20, 834, 261, 569, 2210, 17, 2239, 93, 816, 5, 145, 55, 1241, 21, 120, 108, 35, 1418, 1651, 186, 6, 62, 140, 5, 816, 6, 145, 55, 4, 556, 1, 46, 214, 802, 17, 8, 1793, 916, 1, 8976, 5415, 214, 16, 854, 6, 3, 1118, 15, 1146, 1, 2303, 1392, 1368, 21, 108, 1898, 569, 4, 232, 214, 120, 238, 20, 6385, 261, 1337, 207, 593, 4, 62, 802, 17, 46, 214, 32, 5458, 3272, 80, 746, 76, 1148, 20, 3281, 572, 318, 279, 1162, 46, 99, 608, 875, 2, 34, 112, 593, 4, 6903, 569, 4, 62, 17, 1054, 1431, 128, 2, 32, 322, 6, 5448, 8, 825, 200, 4, 5661]",1456.0,23921123,0
A 50-year journey to cure childhood acute lymphoblastic leukemia.,Seminars in hematology,Semin. Hematol.,2013-07-01,"The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St. Jude Children's Research Hospital, and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic leukemia (ALL). We thought it fitting, therefore, to mark these events by traveling back in time to point out some of the achievements, institutions, study groups, and individuals that have made cure of childhood ALL a reality. In many instances, progress was driven by new ideas, while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy. We also discuss a number of contemporary advances that point the way to exciting future directions. Whatever pathways are taken, a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance, rather than duplicate or compromise, recent gains in outcome with classic cytotoxic chemotherapy. The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL. It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure, not palliation, as their mindset. ",Journal Article,2395.0,120.0,The 50th anniversary of Seminars in Hematology coincides with the 50th anniversary of St. Jude Children 's Research Hospital and both milestones are inexorably linked to studies contributing to the cure of childhood acute lymphoblastic ALL We thought it fitting therefore to mark these events by traveling back in time to point out some of the achievements institutions study groups and individuals that have made cure of childhood ALL a reality In many instances progress was driven by new ideas while in others it was driven by new experimental tools that allowed more precise assessment of the biology of leukemic blasts and their utility in selecting therapy We also discuss a number of contemporary advances that point the way to exciting future directions Whatever pathways are taken a clear challenge will be to use emerging genome-based or immunologic-based treatment options in ways that will enhance rather than duplicate or compromise recent gains in outcome with classic cytotoxic chemotherapy The theme of this journey serves as a reminder of the chief ingredient of any research directed to a catastrophic disease such as ALL It is the audacity of a small group of investigators who confronted a childhood cancer with the goal of cure not palliation as their mindset,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 25065, 20622, 1, 35644, 4, 6216, 17155, 5, 3, 25065, 20622, 1, 3062, 4841, 541, 292, 389, 702, 2, 110, 12118, 32, 63238, 1199, 6, 94, 3156, 6, 3, 1722, 1, 864, 286, 1275, 62, 21, 2739, 192, 9748, 673, 6, 8863, 46, 281, 20, 20802, 4636, 4, 98, 6, 741, 1205, 476, 1, 3, 14207, 1764, 45, 271, 2, 869, 17, 47, 1229, 1722, 1, 864, 62, 8, 9265, 4, 445, 5342, 1466, 10, 1621, 20, 217, 17120, 369, 4, 1749, 192, 10, 1621, 20, 217, 1560, 1896, 17, 2313, 80, 3260, 455, 1, 3, 891, 1, 2015, 2438, 2, 136, 1207, 4, 3675, 36, 21, 120, 1139, 8, 207, 1, 2667, 954, 17, 741, 3, 2255, 6, 4963, 508, 3540, 20522, 460, 32, 1633, 8, 885, 1745, 303, 40, 6, 119, 1478, 898, 90, 15, 3042, 90, 24, 838, 4, 4245, 17, 303, 1304, 1832, 76, 13533, 15, 4665, 435, 3849, 4, 228, 5, 3168, 759, 56, 3, 10293, 1, 26, 18510, 4711, 22, 8, 19448, 1, 3, 14557, 26729, 1, 500, 389, 1166, 6, 8, 16253, 34, 225, 22, 62, 192, 16, 3, 63239, 1, 8, 302, 87, 1, 2394, 54, 18989, 8, 864, 12, 5, 3, 1326, 1, 1722, 44, 3695, 22, 136, 63240]",1280.0,23953334,382
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2013-09-08,"Somatic alterations of the lymphoid transcription factor gene PAX5 (also known as BSAP) are a hallmark of B cell precursor acute lymphoblastic leukemia (B-ALL), but inherited mutations of PAX5 have not previously been described. Here we report a new heterozygous germline variant, c.547G>A (p.Gly183Ser), affecting the octapeptide domain of PAX5 that was found to segregate with disease in two unrelated kindreds with autosomal dominant B-ALL. Leukemic cells from all affected individuals in both families exhibited 9p deletion, with loss of heterozygosity and retention of the mutant PAX5 allele at 9p13. Two additional sporadic ALL cases with 9p loss harbored somatic PAX5 substitutions affecting Gly183. Functional and gene expression analysis of the PAX5 mutation demonstrated that it had significantly reduced transcriptional activity. These data extend the role of PAX5 alterations in the pathogenesis of pre-B cell ALL and implicate PAX5 in a new syndrome of susceptibility to pre-B cell neoplasia. ",Journal Article,2326.0,147.0,Somatic alterations of the lymphoid transcription factor gene PAX5 also known as BSAP are a hallmark of B cell precursor acute lymphoblastic B-ALL but inherited mutations of PAX5 have not previously been described Here we report a new heterozygous germline variant c.547G A p.Gly183Ser affecting the octapeptide domain of PAX5 that was found to segregate with disease in two unrelated kindreds with autosomal dominant B-ALL Leukemic cells from all affected individuals in both families exhibited 9p deletion with loss of heterozygosity and retention of the mutant PAX5 allele at 9p13 Two additional sporadic ALL cases with 9p loss harbored somatic PAX5 substitutions affecting Gly183 Functional and gene expression analysis of the PAX5 mutation demonstrated that it had significantly reduced transcriptional activity These data extend the role of PAX5 alterations in the pathogenesis of pre-B cell ALL and implicate PAX5 in a new syndrome of susceptibility to pre-B cell neoplasia,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1119, 593, 1, 3, 2303, 866, 161, 145, 6279, 120, 440, 22, 23176, 32, 8, 4683, 1, 132, 31, 2765, 286, 1275, 132, 62, 84, 2986, 138, 1, 6279, 47, 44, 373, 85, 1027, 467, 21, 414, 8, 217, 4167, 1009, 1142, 256, 63326, 8, 19, 63327, 2319, 3, 30737, 1398, 1, 6279, 17, 10, 204, 6, 13258, 5, 34, 4, 100, 2092, 10141, 5, 6084, 2156, 132, 62, 2015, 37, 29, 62, 1424, 869, 4, 110, 1954, 1416, 11234, 1528, 5, 407, 1, 3963, 2, 3947, 1, 3, 620, 6279, 1254, 28, 45583, 100, 402, 1928, 62, 140, 5, 11234, 407, 3253, 1119, 6279, 7646, 2319, 63328, 583, 2, 145, 55, 65, 1, 3, 6279, 258, 264, 17, 192, 42, 97, 405, 1431, 128, 46, 74, 4087, 3, 200, 1, 6279, 593, 4, 3, 1384, 1, 671, 132, 31, 62, 2, 5545, 6279, 4, 8, 217, 681, 1, 1432, 6, 671, 132, 31, 2298]",980.0,24013638,88
Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia.,Haematologica,Haematologica,2013-09-13,"The introduction of multiagent treatment protocols has led to a remarkable increase in survival rates for children diagnosed with acute lymphoblastic leukemia, yet for a subpopulation of patients, resistance to chemotherapeutics remains an obstacle to successful treatment. Here we investigate the role of the mitochondrial (or intrinsic) apoptosis pathway in modulating the onset and outcomes of childhood acute lymphoblastic leukemia. Cell death is a highly regulated process that plays an essential role in regulating cell homeostasis, particularly in tissues with high intrinsic proliferating capacity such as the hematopoietic system. Following the underlying paradigm that cis-acting genetic variation can influence disease risk and outcomes by modulating gene expression, we performed a systematic analysis of the proximal promoter regions of 21 genes involved in apoptosis. Using gene reporter assays, we show that promoter variations in 11 intrinsic apoptosis genes, including ADPRT, APAF1, BCL2, BAD, BID, MCL1, BIRC4, BCL2L1, ENDOG, YWHAB, and YWHAQ, influence promoter activity in an allele-specific manner. We also show that correlated promoter variation and increased expression of MCL1 is associated with reduced overall survival among high-risk patients receiving higher doses of corticosteroid, suggesting that increased expression of this anti-apoptosis gene could lead to reduced cell death and influence treatment response in a disease- and dose-responsive manner. ",Journal Article,2321.0,4.0,The introduction of multiagent treatment protocols has led to a remarkable increase in survival rates for children diagnosed with acute lymphoblastic yet for a subpopulation of patients resistance to chemotherapeutics remains an obstacle to successful treatment Here we investigate the role of the mitochondrial or intrinsic apoptosis pathway in modulating the onset and outcomes of childhood acute lymphoblastic Cell death is a highly regulated process that plays an essential role in regulating cell homeostasis particularly in tissues with high intrinsic proliferating capacity such as the hematopoietic system Following the underlying paradigm that cis-acting genetic variation can influence disease risk and outcomes by modulating gene expression we performed a systematic analysis of the proximal promoter regions of 21 genes involved in apoptosis Using gene reporter assays we show that promoter variations in 11 intrinsic apoptosis genes including ADPRT APAF1 BCL2 BAD BID MCL1 BIRC4 BCL2L1 ENDOG YWHAB and YWHAQ influence promoter activity in an allele-specific manner We also show that correlated promoter variation and increased expression of MCL1 is associated with reduced overall survival among high-risk patients receiving higher doses of corticosteroid suggesting that increased expression of this anti-apoptosis gene could lead to reduced cell death and influence treatment response in a disease- and dose-responsive manner,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2456, 1, 7148, 24, 2189, 71, 836, 6, 8, 3813, 344, 4, 25, 151, 9, 541, 265, 5, 286, 1275, 1145, 9, 8, 5518, 1, 7, 251, 6, 6097, 469, 35, 7414, 6, 1401, 24, 467, 21, 963, 3, 200, 1, 3, 2019, 15, 2354, 351, 308, 4, 3712, 3, 1707, 2, 123, 1, 864, 286, 1275, 31, 273, 16, 8, 561, 1065, 1129, 17, 1698, 35, 1452, 200, 4, 2681, 31, 4975, 823, 4, 742, 5, 64, 2354, 5639, 2162, 225, 22, 3, 1007, 398, 366, 3, 1181, 2431, 17, 1927, 5375, 336, 1380, 122, 1054, 34, 43, 2, 123, 20, 3712, 145, 55, 21, 173, 8, 1556, 65, 1, 3, 2805, 973, 1374, 1, 239, 214, 646, 4, 351, 75, 145, 3674, 1013, 21, 514, 17, 973, 2293, 4, 175, 2354, 351, 214, 141, 34070, 47934, 3214, 5618, 2793, 8132, 63381, 24035, 44668, 63382, 2, 63383, 1054, 973, 128, 4, 35, 1254, 112, 1708, 21, 120, 514, 17, 438, 973, 1380, 2, 101, 55, 1, 8132, 16, 41, 5, 405, 63, 25, 107, 64, 43, 7, 357, 142, 415, 1, 5654, 802, 17, 101, 55, 1, 26, 312, 351, 145, 359, 1122, 6, 405, 31, 273, 2, 1054, 24, 51, 4, 8, 34, 2, 61, 2443, 1708]",1440.0,24038028,331
Current treatment and outcome for childhood acute leukemia in Tanzania.,Pediatric blood & cancer,Pediatr Blood Cancer,2013-08-26,"In order to understand the disparity in childhood leukemia survival in low-income countries (LICs) compared to high-income countries (HICs), we evaluated the resources available at Tanzania's national pediatric oncology ward, and clinical characteristics, disease course and outcomes of children diagnosed with acute leukemia from 2008 through 2010. A chart review and assessment of services was performed to assess childhood leukemia diagnoses, treatment, and outcomes in Tanzania at the Ocean Road Cancer Institute (ORCI) from January 1, 2008 to December 31, 2010. Results were compared to those from a 2005 evaluation that showed only one of 20 children with leukemia surviving at 1 year. During the study period, 106 patients presented with leukemia, including 81 patients with acute lymphoblastic leukemia (ALL) and 25 with acute myeloid leukemia (AML). Forty-nine of 58 (84%) patients with ALL, and six of 17 (35%) with AML who received therapy and had complete data, achieved complete remission. Estimated 2-year event-free survival for all patients with ALL was 33%; for AML it was 0%. Ten patients died prior to initiation of therapy, 19 died of toxicity, and eight abandoned therapy. Though leukemia survival in Tanzania remains far below that in HICs, survival rates for ALL have significantly improved in recent years due to standardization of treatment regimens and better staff, though AML outcome remains dismal. Ongoing improvements in pediatric leukemia outcomes will require strategies to improve awareness and early access to treatment coupled with improvements in diagnostic capabilities, supportive care, and training.",Journal Article,2339.0,12.0,In order to understand the disparity in childhood survival in low-income countries LICs compared to high-income countries HICs we evaluated the resources available at Tanzania 's national pediatric oncology ward and clinical characteristics disease course and outcomes of children diagnosed with acute from 2008 through 2010 A chart review and assessment of services was performed to assess childhood diagnoses treatment and outcomes in Tanzania at the Ocean Road Cancer Institute ORCI from January 1 2008 to December 31 2010 Results were compared to those from a 2005 evaluation that showed only one of 20 children with surviving at 1 year During the study period 106 patients presented with including 81 patients with acute lymphoblastic ALL and 25 with acute myeloid AML Forty-nine of 58 84 patients with ALL and six of 17 35 with AML who received therapy and had complete data achieved complete remission Estimated 2-year event-free survival for all patients with ALL was 33 for AML it was 0 Ten patients died prior to initiation of therapy 19 died of toxicity and eight abandoned therapy Though survival in Tanzania remains far below that in HICs survival rates for ALL have significantly improved in recent years due to standardization of treatment regimens and better staff though AML outcome remains dismal Ongoing improvements in pediatric outcomes will require strategies to improve awareness and early access to treatment coupled with improvements in diagnostic capabilities supportive care and training,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 1732, 6, 1640, 3, 4326, 4, 864, 25, 4, 154, 2306, 2115, 23780, 72, 6, 64, 2306, 2115, 20833, 21, 194, 3, 2892, 390, 28, 24082, 292, 657, 815, 413, 20431, 2, 38, 374, 34, 906, 2, 123, 1, 541, 265, 5, 286, 29, 1375, 298, 1120, 8, 2937, 206, 2, 455, 1, 2142, 10, 173, 6, 423, 864, 2403, 24, 2, 123, 4, 24082, 28, 3, 63387, 13375, 12, 1377, 63388, 29, 1024, 14, 1375, 6, 1397, 456, 1120, 99, 11, 72, 6, 135, 29, 8, 1242, 451, 17, 224, 158, 104, 1, 179, 541, 5, 3050, 28, 14, 111, 190, 3, 45, 727, 3251, 7, 917, 5, 141, 865, 7, 5, 286, 1275, 62, 2, 243, 5, 286, 533, 329, 1213, 762, 1, 717, 874, 7, 5, 62, 2, 437, 1, 269, 465, 5, 329, 54, 103, 36, 2, 42, 236, 74, 513, 236, 734, 661, 18, 111, 774, 115, 25, 9, 62, 7, 5, 62, 10, 466, 9, 329, 192, 10, 13, 1618, 7, 1016, 324, 6, 1118, 1, 36, 326, 1016, 1, 155, 2, 659, 13015, 36, 2471, 25, 4, 24082, 469, 3272, 2736, 17, 4, 20833, 25, 151, 9, 62, 47, 97, 231, 4, 435, 60, 520, 6, 6213, 1, 24, 472, 2, 380, 5898, 2471, 329, 228, 469, 3929, 942, 1474, 4, 815, 123, 303, 1353, 422, 6, 401, 3310, 2, 191, 1655, 6, 24, 3332, 5, 1474, 4, 752, 8190, 1877, 165, 2, 1741]",1514.0,24039163,764
Unrelated umbilical cord blood transplant for adult acute lymphoblastic leukemia in first and second complete remission: a comparison with allografts from adult unrelated donors.,Haematologica,Haematologica,2013-09-20,"Allogeneic hematopoietic cell transplantation has an established role in the treatment of adults with acute lymphoblastic leukemia whose survival when recipients of grafts from adult unrelated donors approaches that of recipients of grafts from sibling donors. Our aim was to determine the role of mismatched unrelated cord blood grafts in transplantation for 802 adults with acute lymphoblastic leukemia in first or second complete remission. Using Cox regression we compared outcomes after 116 mismatched single or double cord blood transplants, 546 peripheral blood progenitor cell transplants and 140 bone marrow transplants. The characteristics of the recipients and their diseases were similar except cord blood recipients were younger, more likely to be non-Caucasians and more likely to have a low white blood cell count at diagnosis. There were differences in donor-recipient human leukocyte antigen-match depending on the source of the graft. Most adult donor transplants were matched at the allele-level considering human leukocyte antigens-A, -B, -C and -DRB1. In contrast, most cord blood transplants were mismatched and considered antigen-level matching; 57% were mismatched at two loci and 29% at one locus whereas only 29% of adult donor transplants were mismatched at one locus and none at two loci. There were no differences in the 3-year probabilities of survival between recipients of cord blood (44%), matched adult donor (44%) and mismatched adult donor (43%) transplants. Cord blood transplants engrafted slower and were associated with less grade 2-4 acute but similar chronic graft-versus-host disease, relapse, and transplant-related mortality. The survival of cord blood graft recipients was similar to that of recipients of matched or mismatched unrelated adult donor grafts and so cord blood should be considered a valid alternative source of stem cells for adults with acute lymphoblastic leukemia in the absence of a matched unrelated adult donor. ",Clinical Trial,2314.0,48.0,Allogeneic hematopoietic cell transplantation has an established role in the treatment of adults with acute lymphoblastic whose survival when recipients of grafts from adult unrelated donors approaches that of recipients of grafts from sibling donors Our aim was to determine the role of mismatched unrelated cord blood grafts in transplantation for 802 adults with acute lymphoblastic in first or second complete remission Using Cox regression we compared outcomes after 116 mismatched single or double cord blood transplants 546 peripheral blood progenitor cell transplants and 140 marrow transplants The characteristics of the recipients and their diseases were similar except cord blood recipients were younger more likely to be non-Caucasians and more likely to have a low white blood cell count at diagnosis There were differences in donor-recipient human leukocyte antigen-match depending on the source of the graft Most adult donor transplants were matched at the allele-level considering human leukocyte antigens-A -B -C and -DRB1 In contrast most cord blood transplants were mismatched and considered antigen-level matching 57 were mismatched at two loci and 29 at one locus whereas only 29 of adult donor transplants were mismatched at one locus and none at two loci There were no differences in the 3-year probabilities of survival between recipients of cord blood 44 matched adult donor 44 and mismatched adult donor 43 transplants Cord blood transplants engrafted slower and were associated with less grade 2-4 acute but similar chronic graft-versus-host disease relapse and transplant-related mortality The survival of cord blood graft recipients was similar to that of recipients of matched or mismatched unrelated adult donor grafts and so cord blood should be considered a valid alternative source of stem cells for adults with acute lymphoblastic in the absence of a matched unrelated adult donor,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 1007, 31, 497, 71, 35, 635, 200, 4, 3, 24, 1, 857, 5, 286, 1275, 1310, 25, 198, 2190, 1, 4713, 29, 780, 2092, 2344, 611, 17, 1, 2190, 1, 4713, 29, 3684, 2344, 114, 1130, 10, 6, 223, 3, 200, 1, 5095, 2092, 1885, 315, 4713, 4, 497, 9, 15135, 857, 5, 286, 1275, 4, 157, 15, 419, 236, 734, 75, 418, 320, 21, 72, 123, 50, 3790, 5095, 226, 15, 1627, 1885, 315, 4016, 11912, 672, 315, 2520, 31, 4016, 2, 3304, 581, 4016, 3, 374, 1, 3, 2190, 2, 136, 1342, 11, 288, 2187, 1885, 315, 2190, 11, 773, 80, 322, 6, 40, 220, 5396, 2, 80, 322, 6, 47, 8, 154, 886, 315, 31, 1276, 28, 147, 125, 11, 362, 4, 1488, 5783, 171, 3627, 448, 5364, 3221, 23, 3, 2353, 1, 3, 1599, 96, 780, 1488, 4016, 11, 655, 28, 3, 1254, 301, 3075, 171, 3627, 1575, 8, 132, 256, 2, 8147, 4, 748, 96, 1885, 315, 4016, 11, 5095, 2, 515, 448, 301, 2616, 696, 11, 5095, 28, 100, 2012, 2, 462, 28, 104, 2474, 547, 158, 462, 1, 780, 1488, 4016, 11, 5095, 28, 104, 2474, 2, 1292, 28, 100, 2012, 125, 11, 77, 362, 4, 3, 27, 111, 3518, 1, 25, 59, 2190, 1, 1885, 315, 584, 655, 780, 1488, 584, 2, 5095, 780, 1488, 601, 4016, 1885, 315, 4016, 6914, 6715, 2, 11, 41, 5, 299, 88, 18, 39, 286, 84, 288, 442, 1599, 185, 1204, 34, 429, 2, 941, 139, 282, 3, 25, 1, 1885, 315, 1599, 2190, 10, 288, 6, 17, 1, 2190, 1, 655, 15, 5095, 2092, 780, 1488, 4713, 2, 1743, 1885, 315, 257, 40, 515, 8, 4406, 1091, 2353, 1, 452, 37, 9, 857, 5, 286, 1275, 4, 3, 1127, 1, 8, 655, 2092, 780, 1488]",1915.0,24056817,101
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2013-09-29,"Epigenetic dysregulation is an emerging hallmark of cancers. We developed a high-information-content mass spectrometry approach to profile global histone modifications in human cancers. When applied to 115 lines from the Cancer Cell Line Encyclopedia, this approach identified distinct molecular chromatin signatures. One signature was characterized by increased histone 3 lysine 36 (H3K36) dimethylation, exhibited by several lines harboring translocations in NSD2, which encodes a methyltransferase. A previously unknown NSD2 p.Glu1099Lys (p.E1099K) variant was identified in nontranslocated acute lymphoblastic leukemia (ALL) cell lines sharing this signature. Ectopic expression of the variant induced a chromatin signature characteristic of NSD2 hyperactivation and promoted transformation. NSD2 knockdown selectively inhibited the proliferation of NSD2-mutant lines and impaired the in vivo growth of an NSD2-mutant ALL xenograft. Sequencing analysis of >1,000 pediatric cancer genomes identified the NSD2 p.E1099K alteration in 14% of t(12;21) ETV6-RUNX1-containing ALLs. These findings identify NSD2 as a potential therapeutic target for pediatric ALL and provide a general framework for the functional annotation of cancer epigenomes.",Journal Article,2305.0,133.0,"Epigenetic dysregulation is an emerging hallmark of cancers We developed a high-information-content mass spectrometry approach to profile global histone modifications in human cancers When applied to 115 lines from the Cancer Cell Line Encyclopedia this approach identified distinct molecular chromatin signatures One signature was characterized by increased histone 3 lysine 36 H3K36 dimethylation exhibited by several lines harboring translocations in NSD2 which encodes a methyltransferase A previously unknown NSD2 p.Glu1099Lys p.E1099K variant was identified in nontranslocated acute lymphoblastic ALL cell lines sharing this signature Ectopic expression of the variant induced a chromatin signature characteristic of NSD2 hyperactivation and promoted transformation NSD2 knockdown selectively inhibited the proliferation of NSD2-mutant lines and impaired the in vivo growth of an NSD2-mutant ALL xenograft Sequencing analysis of 1,000 pediatric cancer genomes identified the NSD2 p.E1099K alteration in 14 of t 12 21 ETV6-RUNX1-containing ALLs These findings identify NSD2 as a potential therapeutic target for pediatric ALL and provide a general framework for the functional annotation of cancer epigenomes",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1418, 3935, 16, 35, 1478, 4683, 1, 163, 21, 276, 8, 64, 487, 2457, 782, 3680, 353, 6, 800, 1648, 1508, 2916, 4, 171, 163, 198, 1498, 6, 3670, 285, 29, 3, 12, 31, 328, 15765, 26, 353, 108, 834, 219, 2287, 2210, 104, 1651, 10, 765, 20, 101, 1508, 27, 6041, 511, 29483, 25086, 1416, 20, 392, 285, 2105, 3262, 4, 20022, 92, 4322, 8, 3747, 8, 373, 860, 20022, 19, 63428, 19, 40496, 1142, 10, 108, 4, 63429, 286, 1275, 62, 31, 285, 7436, 26, 1651, 3647, 55, 1, 3, 1142, 277, 8, 2287, 1651, 2037, 1, 20022, 9801, 2, 2992, 1392, 20022, 1563, 2382, 879, 3, 457, 1, 20022, 620, 285, 2, 2364, 3, 4, 386, 129, 1, 35, 20022, 620, 62, 1330, 615, 65, 1, 14, 984, 815, 12, 5085, 108, 3, 20022, 19, 40496, 2611, 4, 213, 1, 102, 133, 239, 7306, 6092, 1101, 10706, 46, 272, 255, 20022, 22, 8, 174, 189, 283, 9, 815, 62, 2, 377, 8, 1083, 2586, 9, 3, 583, 8407, 1, 12, 29484]",1213.0,24076604,465
Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance).,Haematologica,Haematologica,2013-09-27,"Allogeneic stem cell transplantation is the standard approach to Philadelphia chromosome positive acute lymphoblastic leukemia. We hypothesized that imatinib plus sequential chemotherapy will result in significant leukemia cell cytoreduction in patients with Philadelphia chromosome positive acute lymphoblastic leukemia, allowing collection of normal hematopoietic stem cells uncontaminated by residual BCR/ABL1(+) lymphoblasts and thus reduce the likelihood of relapse after autologous stem cell transplantation for patients under 60 years of age without sibling donors. We enrolled 58 patients; 19 underwent autologous and 15 underwent allogeneic stem cell transplantation on study. Imatinib plus sequential chemotherapy resulted in reverse-transcriptase polymerase chain reaction-negative stem cells in 9 patients and remained minimally positive in 4 (6 were not evaluable). Overall survival (median 6.0 years vs. not reached) and disease-free survival (median 3.5 vs. 4.1 years) were similar between those who underwent autologous and those who underwent allogeneic stem cell transplantation. We conclude that autologous stem cell transplantation represents a safe and effective alternative for allogeneic stem cell transplantation in Philadelphia chromosome positive acute lymphoblastic leukemia patients without sibling donors (clinicaltrials.gov identifier:00039377). ",Journal Article,2307.0,47.0,Allogeneic stem cell transplantation is the standard approach to Philadelphia chromosome positive acute lymphoblastic We hypothesized that imatinib plus sequential chemotherapy will result in significant cell cytoreduction in patients with Philadelphia chromosome positive acute lymphoblastic allowing collection of normal hematopoietic stem cells uncontaminated by residual BCR/ABL1 lymphoblasts and thus reduce the likelihood of relapse after autologous stem cell transplantation for patients under 60 years of age without sibling donors We enrolled 58 patients 19 underwent autologous and 15 underwent allogeneic stem cell transplantation on study Imatinib plus sequential chemotherapy resulted in reverse-transcriptase polymerase chain reaction-negative stem cells in 9 patients and remained minimally positive in 4 6 were not evaluable Overall survival median 6.0 years vs. not reached and disease-free survival median 3.5 vs. 4.1 years were similar between those who underwent autologous and those who underwent allogeneic stem cell transplantation We conclude that autologous stem cell transplantation represents a safe and effective alternative for allogeneic stem cell transplantation in Philadelphia chromosome positive acute lymphoblastic patients without sibling donors clinicaltrials.gov identifier:00039377,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 452, 31, 497, 16, 3, 260, 353, 6, 3006, 1170, 109, 286, 1275, 21, 1237, 17, 577, 349, 1787, 56, 303, 757, 4, 93, 31, 2844, 4, 7, 5, 3006, 1170, 109, 286, 1275, 2952, 2442, 1, 295, 1007, 452, 37, 38233, 20, 753, 1062, 3557, 10521, 2, 631, 969, 3, 1420, 1, 429, 50, 1028, 452, 31, 497, 9, 7, 669, 335, 60, 1, 89, 187, 3684, 2344, 21, 346, 717, 7, 326, 208, 1028, 2, 167, 208, 1063, 452, 31, 497, 23, 45, 577, 349, 1787, 56, 627, 4, 1772, 4456, 1451, 1260, 1329, 199, 452, 37, 4, 83, 7, 2, 958, 2144, 109, 4, 39, 49, 11, 44, 859, 63, 25, 52, 49, 13, 60, 105, 44, 1300, 2, 34, 115, 25, 52, 27, 33, 105, 39, 14, 60, 11, 288, 59, 135, 54, 208, 1028, 2, 135, 54, 208, 1063, 452, 31, 497, 21, 2060, 17, 1028, 452, 31, 497, 1449, 8, 1165, 2, 323, 1091, 9, 1063, 452, 31, 497, 4, 3006, 1170, 109, 286, 1275, 7, 187, 3684, 2344, 1252, 1239, 3719, 63435]",1320.0,24077846,46
Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy.,Pharmacotherapy,Pharmacotherapy,2013-10-17,"Because the incidence rate of renal impairment is 2-10% for patients treated with high-dose methotrexate and renal impairment develops in 0-12.4% of patients treated for osteosarcoma, we sought to evaluate the efficacy of glucarpidase, a recently approved drug that rapidly hydrolyzes methotrexate to inactive metabolites, which allows for nonrenal clearance in patients with delayed renal methotrexate elimination. Pooled analysis of efficacy data from four multicenter single-arm compassionate-use clinical trials using protocols from 1993 to 2007. Of 476 patients with renal toxicity and delayed methotrexate elimination who were treated with intravenous glucarpidase for rescue after high-dose methotrexate, 169 patients had at least one preglucarpidase (baseline) plasma methotrexate concentration greater than 1mol/L and one postglucarpidase methotrexate concentration measurement by high-performance liquid chromatography and were included in the efficacy analysis; renal recovery was assessed in 436 patients who had at least one recorded preglucarpidase and postglucarpidase serum creatinine concentration measurement. Efficacy was defined as rapid and sustained clinically important reduction (RSCIR) in plasma methotrexate concentration, with a concentration of 1mol/L or lower at all postglucarpidase determinations. Median age of efficacy-evaluable patients was 20years (range 5weeks-84years). Osteosarcoma (36%), non-Hodgkin lymphoma (27%), and acute lymphoblastic leukemia (20%) were the most frequent underlying diagnoses. Median preglucarpidase serum methotrexate was 11.7mol/L. At the first (median 15minutes) through the last (median 40hours) postglucarpidase measurement, plasma methotrexate concentrations demonstrated consistent 99% median reduction. RSCIR was achieved by 83 (59%) of 140 patients. A total of 64% of patients with renal impairment greater than or equal to Common Terminology Criteria for Adverse Events grade 2 recovered to grade 0 or 1 at a median of 12.5days after glucarpidase administration. Glucarpidase caused a clinically important 99% or greater sustained reduction of serum methotrexate levels and provided noninvasive rescue from methotrexate toxicity in renally impaired patients.",Journal Article,2287.0,28.0,Because the incidence rate of impairment is 2-10 for patients treated with high-dose methotrexate and impairment develops in 0-12.4 of patients treated for we sought to evaluate the efficacy of glucarpidase a recently approved drug that rapidly hydrolyzes methotrexate to inactive metabolites which allows for nonrenal clearance in patients with delayed methotrexate elimination Pooled analysis of efficacy data from four multicenter single-arm compassionate-use clinical trials using protocols from 1993 to 2007 Of 476 patients with toxicity and delayed methotrexate elimination who were treated with intravenous glucarpidase for rescue after high-dose methotrexate 169 patients had at least one preglucarpidase baseline plasma methotrexate concentration greater than 1 mol/L and one postglucarpidase methotrexate concentration measurement by high-performance liquid chromatography and were included in the efficacy analysis recovery was assessed in 436 patients who had at least one recorded preglucarpidase and postglucarpidase serum creatinine concentration measurement Efficacy was defined as rapid and sustained clinically important reduction RSCIR in plasma methotrexate concentration with a concentration of 1 mol/L or lower at all postglucarpidase determinations Median age of efficacy-evaluable patients was 20 years range 5 weeks-84 years 36 27 and acute lymphoblastic 20 were the most frequent underlying diagnoses Median preglucarpidase serum methotrexate was 11.7 mol/L At the first median 15 minutes through the last median 40 hours postglucarpidase measurement plasma methotrexate concentrations demonstrated consistent 99 median reduction RSCIR was achieved by 83 59 of 140 patients A total of 64 of patients with impairment greater than or equal to Common Terminology Criteria for Adverse Events grade 2 recovered to grade 0 or 1 at a median of 12.5 days after glucarpidase administration Glucarpidase caused a clinically important 99 or greater sustained reduction of serum methotrexate levels and provided noninvasive rescue from methotrexate toxicity in renally impaired patients,0,0,1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[408, 3, 287, 116, 1, 2315, 16, 18, 79, 9, 7, 73, 5, 64, 61, 2116, 2, 2315, 4734, 4, 13, 133, 39, 1, 7, 73, 9, 21, 990, 6, 376, 3, 209, 1, 19340, 8, 761, 850, 234, 17, 1755, 29421, 2116, 6, 5002, 3406, 92, 2333, 9, 21280, 1960, 4, 7, 5, 1612, 2116, 3730, 1830, 65, 1, 209, 74, 29, 294, 1570, 226, 475, 9949, 119, 38, 143, 75, 2189, 29, 3343, 6, 1307, 1, 10652, 7, 5, 155, 2, 1612, 2116, 3730, 54, 11, 73, 5, 1262, 19340, 9, 4256, 50, 64, 61, 2116, 5436, 7, 42, 28, 506, 104, 40513, 330, 554, 2116, 1227, 378, 76, 14, 7674, 805, 2, 104, 35689, 2116, 1227, 2204, 20, 64, 528, 3165, 5140, 2, 11, 159, 4, 3, 209, 65, 1602, 10, 275, 4, 10601, 7, 54, 42, 28, 506, 104, 1872, 40513, 2, 35689, 524, 3177, 1227, 2204, 209, 10, 395, 22, 1321, 2, 2275, 505, 305, 628, 48011, 4, 554, 2116, 1227, 5, 8, 1227, 1, 14, 7674, 805, 15, 280, 28, 62, 35689, 11894, 52, 89, 1, 209, 859, 7, 10, 179, 60, 184, 33, 244, 874, 60, 511, 428, 2, 286, 1275, 179, 11, 3, 96, 908, 1181, 2403, 52, 40513, 524, 2116, 10, 175, 67, 7674, 805, 28, 3, 157, 52, 167, 2511, 298, 3, 1060, 52, 327, 1459, 35689, 2204, 554, 2116, 1003, 264, 925, 1058, 52, 628, 48011, 10, 513, 20, 852, 728, 1, 3304, 7, 8, 181, 1, 660, 1, 7, 5, 2315, 378, 76, 15, 2997, 6, 186, 3462, 371, 9, 290, 281, 88, 18, 5784, 6, 88, 13, 15, 14, 28, 8, 52, 1, 133, 33, 162, 50, 19340, 634, 19340, 1546, 8, 505, 305, 1058, 15, 378, 2275, 628, 1, 524, 2116, 148, 2, 1052, 2957, 4256, 29, 2116, 155, 4, 23124, 2364, 7]",2103.0,24132809,145
Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse.,Nature genetics,Nat. Genet.,2013-10-20,"Recent genomic profiling of childhood acute lymphoblastic leukemia (ALL) identified a high-risk subtype with an expression signature resembling that of Philadelphia chromosome-positive ALL and poor prognosis (Ph-like ALL). However, the role of inherited genetic variation in Ph-like ALL pathogenesis remains unknown. In a genome-wide association study (GWAS) of 511 ALL cases and 6,661 non-ALL controls, we identified a susceptibility locus for Ph-like ALL (GATA3, rs3824662; P = 2.17  10(-14), odds ratio (OR) = 3.85 for Ph-like ALL versus non-ALL; P = 1.05  10(-8), OR = 3.25 for Ph-like ALL versus non-Ph-like ALL), with independent validation. The rs3824662 risk allele was associated with somatic lesions underlying Ph-like ALL (CRLF2 rearrangement, JAK gene mutation and IKZF1 deletion) and with variation in GATA3 expression. Finally, genotype at the GATA3 SNP was also associated with early treatment response and risk of ALL relapse. Our results provide insights into interactions between inherited and somatic variants and their role in ALL pathogenesis and prognosis. ",Journal Article,2284.0,131.0,"Recent genomic profiling of childhood acute lymphoblastic ALL identified a high-risk subtype with an expression signature resembling that of Philadelphia chromosome-positive ALL and poor prognosis Ph-like ALL However the role of inherited genetic variation in Ph-like ALL pathogenesis remains unknown In a genome-wide association study GWAS of 511 ALL cases and 6,661 non-ALL controls we identified a susceptibility locus for Ph-like ALL GATA3 rs3824662 P 2.17 10 -14 odds ratio OR 3.85 for Ph-like ALL versus non-ALL P 1.05 10 -8 OR 3.25 for Ph-like ALL versus non-Ph-like ALL with independent validation The rs3824662 risk allele was associated with somatic lesions underlying Ph-like ALL CRLF2 rearrangement JAK gene mutation and IKZF1 deletion and with variation in GATA3 expression Finally genotype at the GATA3 SNP was also associated with early treatment response and risk of ALL relapse Our results provide insights into interactions between inherited and somatic variants and their role in ALL pathogenesis and prognosis",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 572, 1080, 1, 864, 286, 1275, 62, 108, 8, 64, 43, 875, 5, 35, 55, 1651, 8855, 17, 1, 3006, 1170, 109, 62, 2, 334, 356, 2058, 733, 62, 137, 3, 200, 1, 2986, 336, 1380, 4, 2058, 733, 62, 1384, 469, 860, 4, 8, 898, 1019, 248, 45, 3297, 1, 10532, 62, 140, 2, 49, 12745, 220, 62, 535, 21, 108, 8, 1432, 2474, 9, 2058, 733, 62, 8140, 32197, 19, 18, 269, 79, 213, 610, 197, 15, 27, 772, 9, 2058, 733, 62, 185, 220, 62, 19, 14, 474, 79, 66, 15, 27, 243, 9, 2058, 733, 62, 185, 220, 2058, 733, 62, 5, 306, 929, 3, 32197, 43, 1254, 10, 41, 5, 1119, 406, 1181, 2058, 733, 62, 8895, 2675, 4653, 145, 258, 2, 8422, 1528, 2, 5, 1380, 4, 8140, 55, 1368, 1183, 28, 3, 8140, 1845, 10, 120, 41, 5, 191, 24, 51, 2, 43, 1, 62, 429, 114, 99, 377, 1957, 237, 1286, 59, 2986, 2, 1119, 839, 2, 136, 200, 4, 62, 1384, 2, 356]",1029.0,24141364,428
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth.,Annals of hematology,Ann. Hematol.,2013-10-24,"Connective tissue growth factor (CTGF/CCN2) is involved in extracellular matrix production, tumor cell proliferation, adhesion, migration, and metastasis. Recent studies have shown that CTGF expression is elevated in precursor B-acute lymphoblastic leukemia (ALL) and that increased expression of CTGF is associated with inferior outcome in B-ALL. In this study, we characterized the functional role and downstream signaling pathways of CTGF in ALL cells. First, we utilized lentiviral shRNA to knockdown CTGF in RS4;11 and REH ALL cells expressing high levels of CTGF mRNA. Silencing of CTGF resulted in significant suppression of leukemia cell growth compared to control vector, which was associated with AKT/mTOR inactivation and increased levels of cyclin-dependent kinase inhibitor p27. CTGF knockdown sensitized ALL cells to vincristine and methotrexate. Treatment with an anti-CTGF monoclonal antibody, FG-3019, significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy (vincristine, L-asparaginase and dexamethasone). Data suggest that CTGF represents a targetable molecular aberration in B-ALL, and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients. ",Journal Article,2280.0,22.0,Connective tissue growth factor CTGF/CCN2 is involved in extracellular matrix production tumor cell proliferation adhesion migration and metastasis Recent studies have shown that CTGF expression is elevated in precursor B-acute lymphoblastic ALL and that increased expression of CTGF is associated with inferior outcome in B-ALL In this study we characterized the functional role and downstream signaling pathways of CTGF in ALL cells First we utilized lentiviral shRNA to knockdown CTGF in RS4 11 and REH ALL cells expressing high levels of CTGF mRNA Silencing of CTGF resulted in significant suppression of cell growth compared to control vector which was associated with AKT/mTOR inactivation and increased levels of cyclin-dependent kinase inhibitor p27 CTGF knockdown sensitized ALL cells to vincristine and methotrexate Treatment with an anti-CTGF monoclonal antibody FG-3019 significantly prolonged survival of mice injected with primary xenograft B-ALL cells when co-treated with conventional chemotherapy vincristine L-asparaginase and dexamethasone Data suggest that CTGF represents a targetable molecular aberration in B-ALL and blocking CTGF signaling in conjunction with administration of chemotherapy may represent a novel therapeutic approach for ALL patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[10990, 246, 129, 161, 14345, 63548, 16, 646, 4, 1976, 2248, 1529, 30, 31, 457, 2128, 1381, 2, 278, 435, 94, 47, 443, 17, 14345, 55, 16, 804, 4, 2765, 132, 286, 1275, 62, 2, 17, 101, 55, 1, 14345, 16, 41, 5, 1663, 228, 4, 132, 62, 4, 26, 45, 21, 765, 3, 583, 200, 2, 1489, 314, 460, 1, 14345, 4, 62, 37, 157, 21, 2080, 7823, 3976, 6, 1563, 14345, 4, 45308, 175, 2, 23340, 62, 37, 1046, 64, 148, 1, 14345, 956, 2077, 1, 14345, 627, 4, 93, 1332, 1, 31, 129, 72, 6, 182, 3374, 92, 10, 41, 5, 649, 873, 2297, 2, 101, 148, 1, 1226, 470, 216, 230, 2804, 14345, 1563, 4242, 62, 37, 6, 2132, 2, 2116, 24, 5, 35, 312, 14345, 848, 548, 19903, 63549, 97, 1069, 25, 1, 399, 2651, 5, 86, 1330, 132, 62, 37, 198, 1269, 73, 5, 809, 56, 2132, 805, 3709, 2, 1217, 74, 309, 17, 14345, 1449, 8, 3985, 219, 7794, 4, 132, 62, 2, 2521, 14345, 314, 4, 3357, 5, 634, 1, 56, 68, 1231, 8, 229, 189, 353, 9, 62, 7]",1274.0,24154679,624
Neurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2013-11-04,"To determine rates, patterns, and predictors of neurocognitive impairment in adults decades after treatment for childhood acute lymphoblastic leukemia (ALL). Survivors of childhood ALL treated at St Jude Children's Research Hospital who were still alive at 10 or more years after diagnosis and were age  18 years were recruited for neurocognitive testing. In all, 1,014 survivors were eligible, 738 (72.8%) agreed to participate, and 567 (76.8%) of these were evaluated. Mean age was 33 years; mean time since diagnosis was 26 years. Medical record abstraction was performed for data on doses of cranial radiation therapy (CRT) and cumulative chemotherapy. Multivariable modeling was conducted and glmulti package was used to select the best model with minimum Akaike information criterion. Impairment rates across neurocognitive domains ranged from 28.6% to 58.9%, and those treated with chemotherapy only demonstrated increased impairment in all domains (all P values < .006). In survivors who received no CRT, dexamethasone was associated with impaired attention (relative risk [RR], 2.12; 95% CI, 1.11 to 4.03) and executive function (RR, 2.42; 95% CI, 1.20 to 4.91). The impact of CRT was dependent on young age at diagnosis for intelligence, academic, and memory functions. Risk for executive function problems increased with survival time in a CRT dose-dependent fashion. In all survivors, self-reported behavior problems increased by 5% (RR, 1.05; 95% CI, 1.01 to 1.09) with each year from diagnosis. Impairment was associated with reduced educational attainment and unemployment. This study demonstrates persistent and significant neurocognitive impairment in adult survivors of childhood ALL and warrants ongoing monitoring of brain health to facilitate successful adult development and to detect early onset of decline as survivors mature.",Journal Article,2269.0,136.0,"To determine rates patterns and predictors of neurocognitive impairment in adults decades after treatment for childhood acute lymphoblastic ALL Survivors of childhood ALL treated at St Jude Children 's Research Hospital who were still alive at 10 or more years after diagnosis and were age  18 years were recruited for neurocognitive testing In all 1,014 survivors were eligible 738 72.8 agreed to participate and 567 76.8 of these were evaluated Mean age was 33 years mean time since diagnosis was 26 years Medical record abstraction was performed for data on doses of cranial radiation therapy CRT and cumulative chemotherapy Multivariable modeling was conducted and glmulti package was used to select the best model with minimum Akaike information criterion Impairment rates across neurocognitive domains ranged from 28.6 to 58.9 and those treated with chemotherapy only demonstrated increased impairment in all domains all P values .006 In survivors who received no CRT dexamethasone was associated with impaired attention relative risk RR 2.12 95 CI 1.11 to 4.03 and executive function RR 2.42 95 CI 1.20 to 4.91 The impact of CRT was dependent on young age at diagnosis for intelligence academic and memory functions Risk for executive function problems increased with survival time in a CRT dose-dependent fashion In all survivors self-reported behavior problems increased by 5 RR 1.05 95 CI 1.01 to 1.09 with each year from diagnosis Impairment was associated with reduced educational attainment and unemployment This study demonstrates persistent and significant neurocognitive impairment in adult survivors of childhood ALL and warrants ongoing monitoring of brain health to facilitate successful adult development and to detect early onset of decline as survivors mature",0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 223, 151, 764, 2, 674, 1, 2958, 2315, 4, 857, 1968, 50, 24, 9, 864, 286, 1275, 62, 332, 1, 864, 62, 73, 28, 3062, 4841, 541, 292, 389, 702, 54, 11, 1234, 1701, 28, 79, 15, 80, 60, 50, 147, 2, 11, 89, 749, 203, 60, 11, 2619, 9, 2958, 471, 4, 62, 14, 3618, 332, 11, 625, 15999, 720, 66, 4681, 6, 3506, 2, 12120, 846, 66, 1, 46, 11, 194, 313, 89, 10, 466, 60, 313, 98, 1192, 147, 10, 432, 60, 484, 3237, 11553, 10, 173, 9, 74, 23, 415, 1, 2565, 121, 36, 1089, 2, 967, 56, 658, 2057, 10, 426, 2, 63585, 8913, 10, 95, 6, 1717, 3, 824, 202, 5, 2499, 13429, 487, 4643, 2315, 151, 716, 2958, 2703, 1869, 29, 339, 49, 6, 717, 83, 2, 135, 73, 5, 56, 158, 264, 101, 2315, 4, 62, 2703, 62, 19, 1030, 1861, 4, 332, 54, 103, 77, 1089, 1217, 10, 41, 5, 2364, 2111, 580, 43, 861, 18, 133, 48, 58, 14, 175, 6, 39, 680, 2, 6481, 343, 861, 18, 595, 48, 58, 14, 179, 6, 39, 970, 3, 345, 1, 1089, 10, 470, 23, 1169, 89, 28, 147, 9, 9125, 1916, 2, 2407, 1681, 43, 9, 6481, 343, 2408, 101, 5, 25, 98, 4, 8, 1089, 61, 470, 3240, 4, 62, 332, 1074, 210, 1710, 2408, 101, 20, 33, 861, 14, 474, 48, 58, 14, 355, 6, 14, 1730, 5, 296, 111, 29, 147, 2315, 10, 41, 5, 405, 3624, 7108, 2, 11966, 26, 45, 1902, 1882, 2, 93, 2958, 2315, 4, 780, 332, 1, 864, 62, 2, 2782, 942, 1315, 1, 342, 341, 6, 1876, 1401, 780, 193, 2, 6, 1426, 191, 1707, 1, 1858, 22, 332, 2908]",1782.0,24190124,768
Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition.,"Neoplasia (New York, N.Y.)",Neoplasia,2013-10-01,"ETS gene fusions, which result in overexpression of an ETS transcription factor, are considered driving mutations in approximately half of all prostate cancers. Dysregulation of ETS transcription factors is also known to exist in Ewing's sarcoma, breast cancer, and acute lymphoblastic leukemia. We previously discovered that ERG, the predominant ETS family member in prostate cancer, interacts with the DNA damage response protein poly (ADP-ribose) polymerase 1 (PARP1) in human prostate cancer specimens. Therefore, we hypothesized that the ERG-PARP1 interaction may confer radiation resistance by increasing DNA repair efficiency and that this radio-resistance could be reversed through PARP1 inhibition. Using lentiviral approaches, we established isogenic models of ERG overexpression in PC3 and DU145 prostate cancer cell lines. In both cell lines, ERG overexpression increased clonogenic survival following radiation by 1.25 (0.07) fold (mean  SEM) and also resulted in increased PARP1 activity. PARP1 inhibition with olaparib preferentially radiosensitized ERG-positive cells by a factor of 1.52 (0.03) relative to ERG-negative cells (P < .05). Neutral and alkaline COMET assays and immunofluorescence microscopy assessing -H2AX foci showed increased short- and long-term efficiencies of DNA repair, respectively, following radiation that was preferentially reversed by PARP1 inhibition. These findings were verified in an in vivo xenograft model. Our findings demonstrate that ERG overexpression confers radiation resistance through increased efficiency of DNA repair following radiation that can be reversed through inhibition of PARP1. These results motivate the use of PARP1 inhibitors as radiosensitizers in patients with localized ETS fusion-positive cancers. ",Journal Article,2303.0,32.0,ETS gene fusions which result in overexpression of an ETS transcription factor are considered driving mutations in approximately half of all cancers Dysregulation of ETS transcription factors is also known to exist in 's cancer and acute lymphoblastic We previously discovered that ERG the predominant ETS family member in cancer interacts with the DNA damage response protein poly ADP-ribose polymerase 1 PARP1 in human cancer specimens Therefore we hypothesized that the ERG-PARP1 interaction may confer radiation resistance by increasing DNA repair efficiency and that this radio-resistance could be reversed through PARP1 inhibition Using lentiviral approaches we established isogenic models of ERG overexpression in PC3 and DU145 cancer cell lines In both cell lines ERG overexpression increased clonogenic survival following radiation by 1.25 0.07 fold mean  SEM and also resulted in increased PARP1 activity PARP1 inhibition with olaparib preferentially radiosensitized ERG-positive cells by a factor of 1.52 0.03 relative to ERG-negative cells P .05 Neutral and alkaline COMET assays and immunofluorescence microscopy assessing -H2AX foci showed increased short- and long-term efficiencies of DNA repair respectively following radiation that was preferentially reversed by PARP1 inhibition These findings were verified in an in vivo xenograft model Our findings demonstrate that ERG overexpression confers radiation resistance through increased efficiency of DNA repair following radiation that can be reversed through inhibition of PARP1 These results motivate the use of PARP1 inhibitors as radiosensitizers in patients with localized ETS fusion-positive cancers,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[4802, 145, 2530, 92, 757, 4, 851, 1, 35, 4802, 866, 161, 32, 515, 4057, 138, 4, 705, 1303, 1, 62, 163, 3935, 1, 4802, 866, 130, 16, 120, 440, 6, 1923, 4, 292, 12, 2, 286, 1275, 21, 373, 2747, 17, 3032, 3, 2750, 4802, 607, 2693, 4, 12, 5528, 5, 3, 261, 1350, 51, 178, 2699, 3638, 3507, 1451, 14, 6033, 4, 171, 12, 623, 673, 21, 1237, 17, 3, 3032, 6033, 915, 68, 2913, 121, 251, 20, 602, 261, 972, 2904, 2, 17, 26, 6477, 251, 359, 40, 3682, 298, 6033, 297, 75, 7823, 611, 21, 635, 7208, 274, 1, 3032, 851, 4, 4505, 2, 7360, 12, 31, 285, 4, 110, 31, 285, 3032, 851, 101, 3798, 25, 366, 121, 20, 14, 243, 18068, 1615, 1116, 313, 810, 8719, 2, 120, 627, 4, 101, 6033, 128, 6033, 297, 5, 4024, 3509, 13830, 3032, 109, 37, 20, 8, 161, 1, 14, 653, 18068, 680, 580, 6, 3032, 199, 37, 19, 474, 6338, 2, 5355, 11175, 1013, 2, 4130, 3804, 1977, 2655, 6286, 3340, 224, 101, 978, 2, 319, 337, 19615, 1, 261, 972, 106, 366, 121, 17, 10, 3509, 3682, 20, 6033, 297, 46, 272, 11, 4815, 4, 35, 4, 386, 1330, 202, 114, 272, 608, 17, 3032, 851, 4020, 121, 251, 298, 101, 2904, 1, 261, 972, 366, 121, 17, 122, 40, 3682, 298, 297, 1, 6033, 46, 99, 15484, 3, 119, 1, 6033, 222, 22, 11763, 4, 7, 5, 909, 4802, 1212, 109, 163]",1676.0,24204199,4
Acute lymphoblastic leukemia in children with Down syndrome: a retrospective analysis from the Ponte di Legno study group.,Blood,Blood,2013-11-12,"Children with Down syndrome (DS) have an increased risk of B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). The prognostic factors and outcome of DS-ALL patients treated in contemporary protocols are uncertain. We studied 653 DS-ALL patients enrolled in 16 international trials from 1995 to 2004. Non-DS BCP-ALL patients from the Dutch Child Oncology Group and Berlin-Frankfurt-Mnster were reference cohorts. DS-ALL patients had a higher 8-year cumulative incidence of relapse (26%  2% vs 15%  1%, P < .001) and 2-year treatment-related mortality (TRM) (7%  1% vs 2.0%  <1%, P < .0001) than non-DS patients, resulting in lower 8-year event-free survival (EFS) (64%  2% vs 81%  2%, P < .0001) and overall survival (74%  2% vs 89%  1%, P < .0001). Independent favorable prognostic factors include age <6 years (hazard ratio [HR] = 0.58, P = .002), white blood cell (WBC) count <10  10(9)/L (HR = 0.60, P = .005), and ETV6-RUNX1 (HR = 0.14, P = .006) for EFS and age (HR = 0.48, P < .001), ETV6-RUNX1 (HR = 0.1, P = .016) and high hyperdiploidy (HeH) (HR = 0.29, P = .04) for relapse-free survival. TRM was the major cause of death in ETV6-RUNX1 and HeH DS-ALLs. Thus, while relapse is the main contributor to poorer survival in DS-ALL, infection-associated TRM was increased in all protocol elements, unrelated to treatment phase or regimen. Future strategies to improve outcome in DS-ALL should include improved supportive care throughout therapy and reduction of therapy in newly identified good-prognosis subgroups. ",Journal Article,2261.0,,Children with Down syndrome DS have an increased risk of B-cell precursor BCP acute lymphoblastic ALL The prognostic factors and outcome of DS-ALL patients treated in contemporary protocols are uncertain We studied 653 DS-ALL patients enrolled in 16 international trials from 1995 to 2004 Non-DS BCP-ALL patients from the Dutch Child Oncology Group and Berlin-Frankfurt-Mnster were reference cohorts DS-ALL patients had a higher 8-year cumulative incidence of relapse 26  2 vs 15  1 P .001 and 2-year treatment-related mortality TRM 7  1 vs 2.0  1 P .0001 than non-DS patients resulting in lower 8-year event-free survival EFS 64  2 vs 81  2 P .0001 and overall survival 74  2 vs 89  1 P .0001 Independent favorable prognostic factors include age 6 years hazard ratio HR 0.58 P .002 white blood cell WBC count 10 10 9 /L HR 0.60 P .005 and ETV6-RUNX1 HR 0.14 P .006 for EFS and age HR 0.48 P .001 ETV6-RUNX1 HR 0.1 P .016 and high hyperdiploidy HeH HR 0.29 P .04 for relapse-free survival TRM was the major cause of death in ETV6-RUNX1 and HeH DS-ALLs Thus while relapse is the main contributor to poorer survival in DS-ALL infection-associated TRM was increased in all protocol elements unrelated to treatment phase or regimen Future strategies to improve outcome in DS-ALL should include improved supportive care throughout therapy and reduction of therapy in newly identified good-prognosis subgroups,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 1328, 681, 3602, 47, 35, 101, 43, 1, 132, 31, 2765, 13168, 286, 1275, 62, 3, 177, 130, 2, 228, 1, 3602, 62, 7, 73, 4, 2667, 2189, 32, 2717, 21, 656, 12567, 3602, 62, 7, 346, 4, 245, 944, 143, 29, 2323, 6, 1131, 220, 3602, 13168, 62, 7, 29, 3, 19120, 2566, 413, 87, 2, 20405, 23389, 26350, 11, 2482, 736, 3602, 62, 7, 42, 8, 142, 66, 111, 967, 287, 1, 429, 432, 810, 18, 105, 167, 810, 14, 19, 144, 2, 18, 111, 24, 139, 282, 5064, 67, 810, 14, 105, 18, 13, 810, 14, 19, 488, 76, 220, 3602, 7, 1113, 4, 280, 66, 111, 774, 115, 25, 1683, 660, 810, 18, 105, 865, 810, 18, 19, 488, 2, 63, 25, 794, 810, 18, 105, 887, 810, 14, 19, 488, 306, 913, 177, 130, 643, 89, 49, 60, 360, 197, 168, 13, 717, 19, 1111, 886, 315, 31, 4685, 1276, 79, 79, 83, 805, 168, 13, 335, 19, 1614, 2, 7306, 6092, 168, 13, 213, 19, 1861, 9, 1683, 2, 89, 168, 13, 576, 19, 144, 7306, 6092, 168, 13, 14, 19, 3820, 2, 64, 11299, 23621, 168, 13, 462, 19, 755, 9, 429, 115, 25, 5064, 10, 3, 458, 708, 1, 273, 4, 7306, 6092, 2, 23621, 3602, 10706, 631, 369, 429, 16, 3, 1895, 8039, 6, 1769, 25, 4, 3602, 62, 930, 41, 5064, 10, 101, 4, 62, 1182, 2531, 2092, 6, 24, 124, 15, 477, 508, 422, 6, 401, 228, 4, 3602, 62, 257, 643, 231, 1877, 165, 2432, 36, 2, 628, 1, 36, 4, 732, 108, 1178, 356, 1453]",1412.0,24222333,833
UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia.,Blood,Blood,2013-11-25,"The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblastic leukemia (ALL) enrolled 266 patients between 1993 and 2003 (pre-imatinib cohort). In 2003 imatinib was introduced as a single-agent course following induction (N = 86, late imatinib). In 2005 imatinib was added to the second phase of induction (N = 89, early imatinib). The complete remission (CR) rate was 92% in the imatinib cohort vs 82% in the preimatinib cohort (P = .004). At 4 years, the overall survival (OS) of all patients in the imatinib cohort was 38% vs 22% in the preimatinib cohort (P = .003). The magnitude of the difference between the preimatinib and imatinib cohorts in event-free survival (EFS), OS, and relapse-free survival (RFS) seen in univariate analysis was even greater in the multivariate analysis. In the preimatinib cohort, 31% of those starting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the imatinib cohort. A Cox multivariate analysis taking alloHSCT into account showed a modest additional benefit to imatinib (hazard ratio for EFS = 0.64, 95% confidence interval 0.44-0.93, P = .02), but no significant benefit for OS and RFS. Adding imatinib to standard therapy improves CR rate and long-term OS for adults with ALL. A proportion of the OS benefit derives from the fact that imatinib facilitates alloHSCT. This trial was registered at clinicaltrials.gov as NCT00002514. ",Journal Article,2248.0,157.0,The Philadelphia chromosome positive arm of the UKALLXII/ECOG2993 study for adult acute lymphoblastic ALL enrolled 266 patients between 1993 and 2003 pre-imatinib cohort In 2003 imatinib was introduced as a single-agent course following induction N 86 late imatinib In 2005 imatinib was added to the second phase of induction N 89 early imatinib The complete remission CR rate was 92 in the imatinib cohort vs 82 in the preimatinib cohort P .004 At 4 years the overall survival OS of all patients in the imatinib cohort was 38 vs 22 in the preimatinib cohort P .003 The magnitude of the difference between the preimatinib and imatinib cohorts in event-free survival EFS OS and relapse-free survival RFS seen in univariate analysis was even greater in the multivariate analysis In the preimatinib cohort 31 of those starting treatment achieved hematopoietic stem cell transplant alloHSCT compared with 46 in the imatinib cohort A Cox multivariate analysis taking alloHSCT into account showed a modest additional benefit to imatinib hazard ratio for EFS 0.64 95 confidence interval 0.44-0.93 P .02 but no significant benefit for OS and RFS Adding imatinib to standard therapy improves CR rate and long-term OS for adults with ALL A proportion of the OS benefit derives from the fact that imatinib facilitates alloHSCT This trial was registered at clinicaltrials.gov as NCT00002514,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3006, 1170, 109, 475, 1, 3, 24975, 34158, 45, 9, 780, 286, 1275, 62, 346, 8786, 7, 59, 3343, 2, 1522, 671, 577, 180, 4, 1522, 577, 10, 3955, 22, 8, 226, 420, 906, 366, 504, 78, 868, 807, 577, 4, 1242, 577, 10, 1953, 6, 3, 419, 124, 1, 504, 78, 887, 191, 577, 3, 236, 734, 684, 116, 10, 937, 4, 3, 577, 180, 105, 878, 4, 3, 26482, 180, 19, 1520, 28, 39, 60, 3, 63, 25, 118, 1, 62, 7, 4, 3, 577, 180, 10, 519, 105, 350, 4, 3, 26482, 180, 19, 1421, 3, 3131, 1, 3, 523, 59, 3, 26482, 2, 577, 736, 4, 774, 115, 25, 1683, 118, 2, 429, 115, 25, 1272, 527, 4, 880, 65, 10, 871, 378, 4, 3, 331, 65, 4, 3, 26482, 180, 456, 1, 135, 1723, 24, 513, 1007, 452, 31, 941, 10248, 72, 5, 641, 4, 3, 577, 180, 8, 418, 331, 65, 2727, 10248, 237, 1967, 224, 8, 1721, 402, 247, 6, 577, 360, 197, 9, 1683, 13, 660, 48, 307, 268, 13, 584, 13, 966, 19, 588, 84, 77, 93, 247, 9, 118, 2, 1272, 2726, 577, 6, 260, 36, 1804, 684, 116, 2, 319, 337, 118, 9, 857, 5, 62, 8, 920, 1, 3, 118, 247, 17214, 29, 3, 1991, 17, 577, 4936, 10248, 26, 160, 10, 1653, 28, 1252, 1239, 22, 31193]",1378.0,24277073,764
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.,Cancer cell,Cancer Cell,2013-11-27,"Glucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic leukemia (T-ALL). Here, we identify the AKT1 kinase as a major negative regulator of the NR3C1 glucocorticoid receptor protein activity driving glucocorticoid resistance in T-ALL. Mechanistically, AKT1 impairs glucocorticoid-induced gene expression by direct phosphorylation of NR3C1 at position S134 and blocking glucocorticoid-induced NR3C1 translocation to the nucleus. Moreover, we demonstrate that loss of PTEN and consequent AKT1 activation can effectively block glucocorticoid-induced apoptosis and induce resistance to glucocorticoid therapy. Conversely, pharmacologic inhibition of AKT with MK2206 effectively restores glucocorticoid-induced NR3C1 translocation to the nucleus, increases the response of T-ALL cells to glucocorticoid therapy, and effectively reverses glucocorticoid resistance in vitro and in vivo.",Journal Article,2246.0,116.0,Glucocorticoid resistance is a major driver of therapeutic failure in T cell acute lymphoblastic T-ALL Here we identify the AKT1 kinase as a major negative regulator of the NR3C1 glucocorticoid receptor protein activity driving glucocorticoid resistance in T-ALL Mechanistically AKT1 impairs glucocorticoid-induced gene expression by direct phosphorylation of NR3C1 at position S134 and blocking glucocorticoid-induced NR3C1 translocation to the nucleus Moreover we demonstrate that loss of PTEN and consequent AKT1 activation can effectively block glucocorticoid-induced apoptosis and induce resistance to glucocorticoid therapy Conversely pharmacologic inhibition of AKT with MK2206 effectively restores glucocorticoid-induced NR3C1 translocation to the nucleus increases the response of T-ALL cells to glucocorticoid therapy and effectively reverses glucocorticoid resistance in vitro and in vivo,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5399, 251, 16, 8, 458, 2228, 1, 189, 496, 4, 102, 31, 286, 1275, 102, 62, 467, 21, 255, 3, 4958, 216, 22, 8, 458, 199, 2452, 1, 3, 29479, 5399, 153, 178, 128, 4057, 5399, 251, 4, 102, 62, 4187, 4958, 8312, 5399, 277, 145, 55, 20, 1196, 982, 1, 29479, 28, 3559, 63673, 2, 2521, 5399, 277, 29479, 2006, 6, 3, 4262, 1393, 21, 608, 17, 407, 1, 820, 2, 8436, 4958, 363, 122, 1856, 2381, 5399, 277, 351, 2, 1290, 251, 6, 5399, 36, 3154, 2788, 297, 1, 649, 5, 13434, 1856, 8489, 5399, 277, 29479, 2006, 6, 3, 4262, 1106, 3, 51, 1, 102, 62, 37, 6, 5399, 36, 2, 1856, 10984, 5399, 251, 4, 439, 2, 4, 386]",899.0,24291004,467
Bacteremia due to Aeromonas hydrophila in acute lymphoblastic leukemia.,Journal of the College of Physicians and Surgeons--Pakistan : JCPSP,J Coll Physicians Surg Pak,2013-12-01,"Aeromonas hydrophila (A. hydrophila) is a low virulent organism but may cause devastating fatal infections in immunocompromised host especially in liver cirrhosis. It is rarely reported to cause septicemia in a patient with Acute Lymphoblastic Leukemia (ALL). The mortality rate of septicemia due to A. hydrophila is 29% to 73%. We report a case of 59-year-old female patient who was a known case of ALL, presented with the complaints of fever, lethargy and generalized weakness for one month. After taking blood samples for investigations, empirical antimicrobial therapy was started. She did not improve after 48 hours of therapy. Meanwhile blood culture revealed pure growth of A. hydrophila. After sensitivity report was available, ciprofloxacin was started. Patient became afebrile after 48 hours of treatment with ciprofloxacin. It is very vital to correctly identified and treat bacteremia due to A. hydrophila especially in the underlying leukemic patient. ",Case Reports,2242.0,2.0,Aeromonas hydrophila A. hydrophila is a low virulent organism but may cause devastating fatal infections in immunocompromised host especially in cirrhosis It is rarely reported to cause septicemia in a patient with Acute Lymphoblastic ALL The mortality rate of septicemia due to A. hydrophila is 29 to 73 We report a case of 59-year-old female patient who was a known case of ALL presented with the complaints of fever lethargy and generalized weakness for one month After taking blood samples for investigations empirical antimicrobial therapy was started She did not improve after 48 hours of therapy Meanwhile blood culture revealed pure growth of A. hydrophila After sensitivity report was available ciprofloxacin was started Patient became afebrile after 48 hours of treatment with ciprofloxacin It is very vital to correctly identified and treat bacteremia due to A. hydrophila especially in the underlying leukemic patient,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[44755, 32212, 8, 32212, 16, 8, 154, 17099, 15564, 84, 68, 708, 5778, 3034, 1875, 4, 7796, 1204, 1093, 4, 3563, 192, 16, 2416, 210, 6, 708, 26701, 4, 8, 69, 5, 286, 1275, 62, 3, 282, 116, 1, 26701, 520, 6, 8, 32212, 16, 462, 6, 803, 21, 414, 8, 473, 1, 728, 111, 1095, 1061, 69, 54, 10, 8, 440, 473, 1, 62, 917, 5, 3, 6938, 1, 2775, 18194, 2, 4169, 6408, 9, 104, 811, 50, 2727, 315, 347, 9, 2492, 7273, 9816, 36, 10, 3461, 3109, 205, 44, 401, 50, 576, 1459, 1, 36, 8197, 315, 2099, 553, 3092, 129, 1, 8, 32212, 50, 485, 414, 10, 390, 12697, 10, 3461, 69, 3451, 40551, 50, 576, 1459, 1, 24, 5, 12697, 192, 16, 923, 3511, 6, 4911, 108, 2, 943, 7085, 520, 6, 8, 32212, 1093, 4, 3, 1181, 2015, 69]",929.0,24304996,563
Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.,International journal of hematology,Int. J. Hematol.,2013-12-06,"The genetic modification of autologous T cells with chimeric antigen receptors (CARs) represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies. By targeting the CD19 antigen, we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic leukemia (B-ALL). We demonstrated rapid induction of deep molecular remissions in adults, which has been recently confirmed in a case report involving a child with B-ALL. In contrast to the results when treating B-ALL, outcomes have been more modest in patients with chronic lymphocytic leukemia (CLL) or other non-hodgkin's lymphoma (NHL). We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL. Lastly, we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple myeloma and acute myeloid leukemia. We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies. ",Journal Article,2237.0,66.0,The genetic modification of autologous T cells with chimeric antigen receptors CARs represents a breakthrough for gene engineering as a cancer therapy for hematologic malignancies By targeting the CD19 antigen we have demonstrated robust and rapid anti-leukemia activity in patients with heavily pre-treated and chemotherapy-refractory B cell acute lymphoblastic B-ALL We demonstrated rapid induction of deep molecular remissions in adults which has been recently confirmed in a case report involving a child with B-ALL In contrast to the results when treating B-ALL outcomes have been more modest in patients with chronic lymphocytic CLL or other 's NHL We review the clinical trial experience targeting B-ALL and CLL and speculate on the possible reasons for the different outcomes and propose potential optimization to CAR T cell therapy when targeting CLL or other indolent NHL Lastly we discuss the pre-clinical development and potential for clinical translation for using CAR T cells against multiple and acute myeloid We highlight the potential risks and benefits by targeting these poor outcome hematologic malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 336, 2437, 1, 1028, 102, 37, 5, 2897, 448, 1186, 7441, 1449, 8, 6022, 9, 145, 6717, 22, 8, 12, 36, 9, 813, 441, 20, 529, 3, 3158, 448, 21, 47, 264, 1922, 2, 1321, 312, 2647, 128, 4, 7, 5, 2447, 671, 73, 2, 56, 430, 132, 31, 286, 1275, 132, 62, 21, 264, 1321, 504, 1, 2369, 219, 3166, 4, 857, 92, 71, 85, 761, 557, 4, 8, 473, 414, 1267, 8, 2566, 5, 132, 62, 4, 748, 6, 3, 99, 198, 1367, 132, 62, 123, 47, 85, 80, 1721, 4, 7, 5, 442, 1193, 552, 15, 127, 292, 1176, 21, 206, 3, 38, 160, 730, 529, 132, 62, 2, 552, 2, 11778, 23, 3, 899, 2325, 9, 3, 338, 123, 2, 2548, 174, 3980, 6, 1881, 102, 31, 36, 198, 529, 552, 15, 127, 2316, 1176, 6354, 21, 1139, 3, 671, 38, 193, 2, 174, 9, 38, 2691, 9, 75, 1881, 102, 37, 480, 232, 2, 286, 533, 21, 1817, 3, 174, 1098, 2, 1141, 20, 529, 46, 334, 228, 813, 441]",1127.0,24311149,701
New immune strategies for the treatment of acute lymphoblastic leukemia: antibodies and chimeric antigen receptors.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2013-01-01,"The prognosis of adult acute lymphoblastic leukemia (ALL) remains poor and novel treatment strategies are needed. Antibody-based therapies represent such an approach. ALL cells express various surface antigens that are targets for monoclonal antibodies. This review focuses on 4 major classes of antibody therapy: (1) naked antibodies, (2) T-cell-engaging bispecific single-chain antibodies, (3) immunoconjugates/immunotoxins, and (4) chimeric antigen receptors. Preclinical and clinical data are reviewed. This area of research represents an exciting new approach to help improve the outcome of this disease. Several clinical trials are currently incorporating this therapy in the treatment of newly diagnosed and relapsed adult ALL patients. ",Journal Article,2576.0,13.0,The prognosis of adult acute lymphoblastic ALL remains poor and novel treatment strategies are needed Antibody-based therapies represent such an approach ALL cells express various surface antigens that are targets for monoclonal antibodies This review focuses on 4 major classes of antibody therapy 1 naked antibodies 2 T-cell-engaging bispecific single-chain antibodies 3 immunoconjugates/immunotoxins and 4 chimeric antigen receptors Preclinical and clinical data are reviewed This area of research represents an exciting new approach to help improve the outcome of this disease Several clinical trials are currently incorporating this therapy in the treatment of newly diagnosed and relapsed adult ALL patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 1, 780, 286, 1275, 62, 469, 334, 2, 229, 24, 422, 32, 575, 548, 90, 235, 1231, 225, 35, 353, 62, 37, 1669, 747, 1255, 1575, 17, 32, 637, 9, 848, 890, 26, 206, 3026, 23, 39, 458, 3211, 1, 548, 36, 14, 11975, 890, 18, 102, 31, 8534, 7408, 226, 1260, 890, 27, 15109, 17170, 2, 39, 2897, 448, 1186, 693, 2, 38, 74, 32, 446, 26, 965, 1, 389, 1449, 35, 4963, 217, 353, 6, 987, 401, 3, 228, 1, 26, 34, 392, 38, 143, 32, 694, 2570, 26, 36, 4, 3, 24, 1, 732, 265, 2, 591, 780, 62, 7]",713.0,24319174,288
Emerging drugs for acute lymphocytic leukemia.,Expert opinion on emerging drugs,Expert Opin Emerg Drugs,2013-12-20,"Acute lymphoblastic leukemia (ALL) is typically treated with complex multi-agent chemotherapy regimens over a prolonged time period. Long-term outcomes depend on the age of the patient and the biological characteristics of the leukemic cells. While pediatric patients achieve cure more often than adults, therapy can continue to be improved for all patients with this disease. The current management strategy for ALL is reviewed. Recently, targeted therapies have been shown to improve survival in subsets of patients, most notably in those with Philadelphia chromosome-positive ALL or with leukemic cells that express the surface antigen CD20. Several innovative compounds are under investigation, and the most promising ones to date will be discussed. The incorporation of monoclonal antibody therapy represents a targeted and powerful approach to the management of ALL. Bispecific T-cell engaging agents, such as blinatumomab, are able to facilitate immune-mediated killing of leukemia cells. Immunoconjugates (i.e., monoclonal antibodies linked to various cytotoxins) allow small doses of very potent chemotherapy to be delivered directly to a leukemia cell with hope of sparing normal tissue. As the genetic and molecular characterization of ALL is more completely understood, patients will receive treatment plans that are more individualized than previously possible.",Journal Article,2223.0,3.0,Acute lymphoblastic ALL is typically treated with complex multi-agent chemotherapy regimens over a prolonged time period Long-term outcomes depend on the age of the patient and the biological characteristics of the leukemic cells While pediatric patients achieve cure more often than adults therapy can continue to be improved for all patients with this disease The current management strategy for ALL is reviewed Recently targeted therapies have been shown to improve survival in subsets of patients most notably in those with Philadelphia chromosome-positive ALL or with leukemic cells that express the surface antigen CD20 Several innovative compounds are under investigation and the most promising ones to date will be discussed The incorporation of monoclonal antibody therapy represents a targeted and powerful approach to the management of ALL Bispecific T-cell engaging agents such as blinatumomab are able to facilitate immune-mediated killing of cells Immunoconjugates i.e. monoclonal antibodies linked to various cytotoxins allow small doses of very potent chemotherapy to be delivered directly to a cell with hope of sparing normal tissue As the genetic and molecular characterization of ALL is more completely understood patients will receive treatment plans that are more individualized than previously possible,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 1969, 73, 5, 840, 1414, 420, 56, 472, 252, 8, 1069, 98, 727, 319, 337, 123, 4533, 23, 3, 89, 1, 3, 69, 2, 3, 1037, 374, 1, 3, 2015, 37, 369, 815, 7, 1359, 1722, 80, 629, 76, 857, 36, 122, 1906, 6, 40, 231, 9, 62, 7, 5, 26, 34, 3, 291, 284, 692, 9, 62, 16, 446, 761, 238, 235, 47, 85, 443, 6, 401, 25, 4, 1890, 1, 7, 96, 2552, 4, 135, 5, 3006, 1170, 109, 62, 15, 5, 2015, 37, 17, 1669, 3, 1255, 448, 2198, 392, 4019, 2411, 32, 669, 940, 2, 3, 96, 721, 6737, 6, 1244, 303, 40, 1588, 3, 2838, 1, 848, 548, 36, 1449, 8, 238, 2, 3757, 353, 6, 3, 284, 1, 62, 7408, 102, 31, 8534, 183, 225, 22, 7182, 32, 1665, 6, 1876, 250, 517, 3003, 1, 37, 15109, 70, 563, 848, 890, 1199, 6, 747, 20269, 1700, 302, 415, 1, 923, 1157, 56, 6, 40, 1623, 1606, 6, 8, 31, 5, 3045, 1, 1851, 295, 246, 22, 3, 336, 2, 219, 2136, 1, 62, 16, 80, 2500, 1784, 7, 303, 560, 24, 1853, 17, 32, 80, 2596, 76, 373, 899]",1325.0,24354521,626
Genomics of racial and ethnic disparities in childhood acute lymphoblastic leukemia.,Cancer,Cancer,2013-12-30,"Although the cure rates of childhood acute lymphoblastic leukemia (ALL) have improved dramatically in the past 40 years, not all children have benefited equally from this impressive progress. Racial and ethnic disparities in the incidence and treatment outcome of childhood ALL persist, with Hispanic children having an elevated risk of developing ALL and one of the lowest survival rates after ALL therapy. A critical barrier to progress is the lack of an understanding of the causes of ALL disparities, particularly racial and ethnic differences in ALL biology. In this review, the authors summarize the current knowledge on population variation in childhood ALL incidence and treatment outcome, discuss the contributing genetic and nongenetic variables, and highlight possible therapeutic interventions to mitigate disparities in ALL.",Journal Article,2213.0,64.0,Although the cure rates of childhood acute lymphoblastic ALL have improved dramatically in the past 40 years not all children have benefited equally from this impressive progress Racial and ethnic disparities in the incidence and treatment outcome of childhood ALL persist with Hispanic children having an elevated risk of developing ALL and one of the lowest survival rates after ALL therapy A critical barrier to progress is the lack of an understanding of the causes of ALL disparities particularly racial and ethnic differences in ALL biology In this review the authors summarize the current knowledge on population variation in childhood ALL incidence and treatment outcome discuss the contributing genetic and nongenetic variables and highlight possible therapeutic interventions to mitigate disparities in ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 3, 1722, 151, 1, 864, 286, 1275, 62, 47, 231, 2729, 4, 3, 1219, 327, 60, 44, 62, 541, 47, 7067, 4142, 29, 26, 5790, 1466, 2257, 2, 2871, 2227, 4, 3, 287, 2, 24, 228, 1, 864, 62, 5589, 5, 1776, 541, 1041, 35, 804, 43, 1, 931, 62, 2, 104, 1, 3, 2101, 25, 151, 50, 62, 36, 8, 740, 3318, 6, 1466, 16, 3, 926, 1, 35, 612, 1, 3, 1626, 1, 62, 2227, 823, 2257, 2, 2871, 362, 4, 62, 891, 4, 26, 206, 3, 738, 2479, 3, 291, 922, 23, 266, 1380, 4, 864, 62, 287, 2, 24, 228, 1139, 3, 3156, 336, 2, 25199, 682, 2, 1817, 899, 189, 1151, 6, 5626, 2227, 4, 62]",816.0,24382716,845
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.,Frontiers in bioscience (Elite edition),Front Biosci (Elite Ed),2014-01-01,"Antibody-drug conjugates (ADCs) represent a major advance in the treatment of acute lymphoblastic leukemia (ALL). CD22 expression, seen in majority of patients with B-lineage ALL, is an ideal target for ADCs. Inotuzumab ozogamicin is an ADC comprised of a humanized IgG4 monoclonal antibody covalently linked to calecheamicin. Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive non-Hodgkin lymphoma. Studies exploring the combination of inotuzumab ozogamicin with chemotherapy are ongoing. ",Journal Article,2211.0,8.0,Antibody-drug conjugates ADCs represent a major advance in the treatment of acute lymphoblastic ALL CD22 expression seen in majority of patients with B-lineage ALL is an ideal target for ADCs Inotuzumab ozogamicin is an ADC comprised of a humanized IgG4 monoclonal antibody covalently linked to calecheamicin Inotuzumab ozogamicin has shown promising single-agent activity in patients with ALL and in CD22 positive Studies exploring the combination of inotuzumab ozogamicin with chemotherapy are ongoing,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[548, 234, 5968, 7825, 1231, 8, 458, 3148, 4, 3, 24, 1, 286, 1275, 62, 7599, 55, 527, 4, 686, 1, 7, 5, 132, 2542, 62, 16, 35, 3662, 283, 9, 7825, 6730, 5566, 16, 35, 3309, 2603, 1, 8, 3619, 11211, 848, 548, 10732, 1199, 6, 47071, 6730, 5566, 71, 443, 721, 226, 420, 128, 4, 7, 5, 62, 2, 4, 7599, 109, 94, 4378, 3, 150, 1, 6730, 5566, 5, 56, 32, 942]",503.0,24389139,75
c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells.,Blood,Blood,2014-01-06,"Although prognosis has improved for children with T-cell acute lymphoblastic leukemia (T-ALL), 20% to 30% of patients undergo induction failure (IF) or relapse. Leukemia-initiating cells (LICs) are hypothesized to be resistant to chemotherapy and to mediate relapse. We and others have shown that Notch1 directly regulates c-Myc, a known regulator of quiescence in stem and progenitor populations, leading us to examine whether c-Myc inhibition results in efficient targeting of T-ALL-initiating cells. We demonstrate that c-Myc suppression by small hairpin RNA or pharmacologic approaches prevents leukemia initiation in mice by eliminating LIC activity. Consistent with its anti-LIC activity in mice, treatment with the BET bromodomain BRD4 inhibitor JQ1 reduces C-MYC expression and inhibits the growth of relapsed and IF pediatric T-ALL samples in vitro. These findings demonstrate a critical role for c-Myc in LIC maintenance and provide evidence that MYC inhibition may be an effective therapy for relapsed/IF T-ALL patients. ",Journal Article,2206.0,84.0,Although prognosis has improved for children with T-cell acute lymphoblastic T-ALL 20 to 30 of patients undergo induction failure IF or relapse Leukemia-initiating cells LICs are hypothesized to be resistant to chemotherapy and to mediate relapse We and others have shown that Notch1 directly regulates c-Myc a known regulator of quiescence in stem and progenitor populations leading us to examine whether c-Myc inhibition results in efficient targeting of T-ALL-initiating cells We demonstrate that c-Myc suppression by small hairpin RNA or pharmacologic approaches prevents initiation in mice by eliminating LIC activity Consistent with its anti-LIC activity in mice treatment with the BET bromodomain BRD4 inhibitor JQ1 reduces C-MYC expression and inhibits the growth of relapsed and IF pediatric T-ALL samples in vitro These findings demonstrate a critical role for c-Myc in LIC maintenance and provide evidence that MYC inhibition may be an effective therapy for relapsed/IF T-ALL patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 356, 71, 231, 9, 541, 5, 102, 31, 286, 1275, 102, 62, 179, 6, 201, 1, 7, 1251, 504, 496, 492, 15, 429, 2647, 2637, 37, 23780, 32, 1237, 6, 40, 436, 6, 56, 2, 6, 3367, 429, 21, 2, 1749, 47, 443, 17, 4607, 1606, 2468, 256, 1371, 8, 440, 2452, 1, 13957, 4, 452, 2, 2520, 1184, 1049, 843, 6, 1004, 317, 256, 1371, 297, 99, 4, 2547, 529, 1, 102, 62, 2637, 37, 21, 608, 17, 256, 1371, 1332, 20, 302, 5957, 893, 15, 2788, 611, 5217, 1118, 4, 399, 20, 6923, 13960, 128, 925, 5, 211, 312, 13960, 128, 4, 399, 24, 5, 3, 4661, 7904, 8141, 230, 10635, 2389, 256, 1371, 55, 2, 1576, 3, 129, 1, 591, 2, 492, 815, 102, 62, 347, 4, 439, 46, 272, 608, 8, 740, 200, 9, 256, 1371, 4, 13960, 1146, 2, 377, 241, 17, 1371, 297, 68, 40, 35, 323, 36, 9, 591, 492, 102, 62, 7]",995.0,24394663,6
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2014-01-12,"The ETV6-RUNX1 fusion gene, found in 25% of childhood acute lymphoblastic leukemia (ALL) cases, is acquired in utero but requires additional somatic mutations for overt leukemia. We used exome and low-coverage whole-genome sequencing to characterize secondary events associated with leukemic transformation. RAG-mediated deletions emerge as the dominant mutational process, characterized by recombination signal sequence motifs near breakpoints, incorporation of non-templated sequence at junctions, 30-fold enrichment at promoters and enhancers of genes actively transcribed in B cell development and an unexpectedly high ratio of recurrent to non-recurrent structural variants. Single-cell tracking shows that this mechanism is active throughout leukemic evolution, with evidence of localized clustering and reiterated deletions. Integration of data on point mutations and rearrangements identifies ATF7IP and MGA as two new tumor-suppressor genes in ALL. Thus, a remarkably parsimonious mutational process transforms ETV6-RUNX1-positive lymphoblasts, targeting the promoters, enhancers and first exons of genes that normally regulate B cell differentiation. ",Journal Article,2200.0,173.0,The ETV6-RUNX1 fusion gene found in 25 of childhood acute lymphoblastic ALL cases is acquired in utero but requires additional somatic mutations for overt We used exome and low-coverage whole-genome sequencing to characterize secondary events associated with leukemic transformation RAG-mediated deletions emerge as the dominant mutational process characterized by recombination signal sequence motifs near breakpoints incorporation of non-templated sequence at junctions 30-fold enrichment at promoters and enhancers of genes actively transcribed in B cell development and an unexpectedly high ratio of recurrent to non-recurrent structural variants Single-cell tracking shows that this mechanism is active throughout leukemic evolution with evidence of localized clustering and reiterated deletions Integration of data on point mutations and rearrangements identifies ATF7IP and MGA as two new tumor-suppressor genes in ALL Thus a remarkably parsimonious mutational process transforms ETV6-RUNX1-positive lymphoblasts targeting the promoters enhancers and first exons of genes that normally regulate B cell differentiation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 7306, 6092, 1212, 145, 204, 4, 243, 1, 864, 286, 1275, 62, 140, 16, 1294, 4, 13767, 84, 1706, 402, 1119, 138, 9, 7192, 21, 95, 2865, 2, 154, 2139, 902, 898, 615, 6, 1507, 568, 281, 41, 5, 2015, 1392, 16970, 517, 2439, 6371, 22, 3, 2156, 1619, 1129, 765, 20, 4017, 1235, 1532, 8578, 1829, 7843, 2838, 1, 220, 25588, 1532, 28, 10262, 19254, 1116, 3020, 28, 4347, 2, 9139, 1, 214, 4489, 10088, 4, 132, 31, 193, 2, 35, 6016, 64, 197, 1, 387, 6, 220, 387, 3281, 839, 226, 31, 7447, 1949, 17, 26, 670, 16, 544, 2432, 2015, 2554, 5, 241, 1, 909, 3147, 2, 30381, 2439, 2676, 1, 74, 23, 741, 138, 2, 2072, 2953, 46557, 2, 22763, 22, 100, 217, 30, 1245, 214, 4, 62, 631, 8, 4856, 18393, 1619, 1129, 22028, 7306, 6092, 109, 10521, 529, 3, 4347, 9139, 2, 157, 3885, 1, 214, 17, 6150, 2288, 132, 31, 910]",1125.0,24413735,453
Targeting STAT5 in hematologic malignancies through inhibition of the bromodomain and extra-terminal (BET) bromodomain protein BRD2.,Molecular cancer therapeutics,Mol. Cancer Ther.,2014-01-16,"The transcription factor signal STAT5 is constitutively activated in a wide range of leukemias and lymphomas, and drives the expression of genes necessary for proliferation, survival, and self-renewal. Thus, targeting STAT5 is an appealing therapeutic strategy for hematologic malignancies. Given the importance of bromodomain-containing proteins in transcriptional regulation, we considered the hypothesis that a pharmacologic bromodomain inhibitor could inhibit STAT5-dependent gene expression. We found that the small-molecule bromodomain and extra-terminal (BET) bromodomain inhibitor JQ1 decreases STAT5-dependent (but not STAT3-dependent) transcription of both heterologous reporter genes and endogenous STAT5 target genes. JQ1 reduces STAT5 function in leukemia and lymphoma cells with constitutive STAT5 activation, or inducibly activated by cytokine stimulation. Among the BET bromodomain subfamily of proteins, it seems that BRD2 is the critical mediator for STAT5 activity. In experimental models of acute T-cell lymphoblastic leukemias, where activated STAT5 contributes to leukemia cell survival, Brd2 knockdown or JQ1 treatment shows strong synergy with tyrosine kinase inhibitors (TKI) in inducing apoptosis in leukemia cells. In contrast, mononuclear cells isolated form umbilical cord blood, which is enriched in normal hematopoietic precursor cells, were unaffected by these combinations. These findings indicate a unique functional association between BRD2 and STAT5, and suggest that combinations of JQ1 and TKIs may be an important rational strategy for treating leukemias and lymphomas driven by constitutive STAT5 activation.",Journal Article,2196.0,38.0,The transcription factor signal STAT5 is constitutively activated in a wide range of leukemias and lymphomas and drives the expression of genes necessary for proliferation survival and self-renewal Thus targeting STAT5 is an appealing therapeutic strategy for hematologic malignancies Given the importance of bromodomain-containing proteins in transcriptional regulation we considered the hypothesis that a pharmacologic bromodomain inhibitor could inhibit STAT5-dependent gene expression We found that the small-molecule bromodomain and extra-terminal BET bromodomain inhibitor JQ1 decreases STAT5-dependent but not STAT3-dependent transcription of both heterologous reporter genes and endogenous STAT5 target genes JQ1 reduces STAT5 function in and cells with constitutive STAT5 activation or inducibly activated by cytokine stimulation Among the BET bromodomain subfamily of proteins it seems that BRD2 is the critical mediator for STAT5 activity In experimental models of acute T-cell lymphoblastic leukemias where activated STAT5 contributes to cell survival Brd2 knockdown or JQ1 treatment shows strong synergy with tyrosine kinase inhibitors TKI in inducing apoptosis in cells In contrast mononuclear cells isolated form umbilical cord blood which is enriched in normal hematopoietic precursor cells were unaffected by these combinations These findings indicate a unique functional association between BRD2 and STAT5 and suggest that combinations of JQ1 and TKIs may be an important rational strategy for treating leukemias and lymphomas driven by constitutive STAT5 activation,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 866, 161, 1235, 5517, 16, 2818, 735, 4, 8, 1019, 184, 1, 2792, 2, 1557, 2, 5267, 3, 55, 1, 214, 1493, 9, 457, 25, 2, 1074, 4495, 631, 529, 5517, 16, 35, 9458, 189, 692, 9, 813, 441, 447, 3, 1187, 1, 7904, 1101, 652, 4, 1431, 863, 21, 515, 3, 1492, 17, 8, 2788, 7904, 230, 359, 1433, 5517, 470, 145, 55, 21, 204, 17, 3, 302, 1354, 7904, 2, 3420, 2158, 4661, 7904, 230, 10635, 2140, 5517, 470, 84, 44, 1439, 470, 866, 1, 110, 15488, 3674, 214, 2, 2682, 5517, 283, 214, 10635, 2389, 5517, 343, 4, 2, 37, 5, 3178, 5517, 363, 15, 26188, 735, 20, 1675, 2503, 107, 3, 4661, 7904, 13989, 1, 652, 192, 2744, 17, 22827, 16, 3, 740, 3810, 9, 5517, 128, 4, 1560, 274, 1, 286, 102, 31, 1275, 2792, 1257, 735, 5517, 2444, 6, 31, 25, 22827, 1563, 15, 10635, 24, 1949, 1082, 3439, 5, 564, 216, 222, 1379, 4, 1958, 351, 4, 37, 4, 748, 3041, 37, 1355, 1297, 5998, 1885, 315, 92, 16, 2220, 4, 295, 1007, 2765, 37, 11, 4585, 20, 46, 1247, 46, 272, 1008, 8, 991, 583, 248, 59, 22827, 2, 5517, 2, 309, 17, 1247, 1, 10635, 2, 1671, 68, 40, 35, 305, 2696, 692, 9, 1367, 2792, 2, 1557, 1621, 20, 3178, 5517, 363]",1584.0,24435449,327
Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial.,Pediatric blood & cancer,Pediatr Blood Cancer,2014-01-16,"L-Asparaginase is an integral component of standard chemotherapy regimens for the treatment of acute lymphoblastic leukemia (ALL). Clinical hypersensitivity, a common reason for treatment discontinuation, has been reported in 10-30% of patients receiving Escherichia coli-derived asparaginase. After hypersensitivity, E. coli-derived asparaginase should be discontinued and an alternative asparaginase preparation, such as asparaginase Erwinia chrysanthemi, may be initiated. We conducted a compassionate-use study to collect additional safety information on asparaginase Erwinia chrysanthemi and to support FDA approval of the product. Patients with ALL or lymphoblastic lymphoma (LBL; N = 1368) who developed a hypersensitivity reaction (grade 2) to an E. coli-derived asparaginase participated in this trial. The recommended asparaginase Erwinia chrysanthemi dose was 25,000 IU/m(2) three days per week (Monday/Wednesday/Friday) for two consecutive weeks for each missed pegylated E. coli-derived asparaginase dose and 25,000 IU/m(2) for each missed nonpegylated asparaginase dose for the completion of their planned asparaginase treatment. Adverse event reports and/or case report forms were completed for 940 patients. The most common adverse event (AE) was hypersensitivity (13.6%). Eighteen patients (1.9%) died during the study. Most patients (77.6%) completed their planned asparaginase treatment with asparaginase Erwinia chrysanthemi. There was no apparent difference in the incidence of the most commonly reported AEs with asparaginase treatment by age, administration, or disease state. This study further established the safety profile of asparaginase Erwinia chrysanthemi in patients with ALL or LBL who had a hypersensitivity reaction to an E. coli-derived asparaginase.",Clinical Trial,2196.0,26.0,"L-Asparaginase is an integral component of standard chemotherapy regimens for the treatment of acute lymphoblastic ALL Clinical hypersensitivity a common reason for treatment discontinuation has been reported in 10-30 of patients receiving Escherichia coli-derived asparaginase After hypersensitivity E. coli-derived asparaginase should be discontinued and an alternative asparaginase preparation such as asparaginase Erwinia chrysanthemi may be initiated We conducted a compassionate-use study to collect additional safety information on asparaginase Erwinia chrysanthemi and to support FDA approval of the product Patients with ALL or lymphoblastic LBL N 1368 who developed a hypersensitivity reaction grade 2 to an E. coli-derived asparaginase participated in this trial The recommended asparaginase Erwinia chrysanthemi dose was 25,000 IU/m 2 three days per week Monday/Wednesday/Friday for two consecutive weeks for each missed pegylated E. coli-derived asparaginase dose and 25,000 IU/m 2 for each missed nonpegylated asparaginase dose for the completion of their planned asparaginase treatment Adverse event reports and/or case report forms were completed for 940 patients The most common adverse event AE was hypersensitivity 13.6 Eighteen patients 1.9 died during the study Most patients 77.6 completed their planned asparaginase treatment with asparaginase Erwinia chrysanthemi There was no apparent difference in the incidence of the most commonly reported AEs with asparaginase treatment by age administration or disease state This study further established the safety profile of asparaginase Erwinia chrysanthemi in patients with ALL or LBL who had a hypersensitivity reaction to an E. coli-derived asparaginase",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[805, 3709, 16, 35, 4450, 1249, 1, 260, 56, 472, 9, 3, 24, 1, 286, 1275, 62, 38, 4034, 8, 186, 3852, 9, 24, 2007, 71, 85, 210, 4, 79, 201, 1, 7, 357, 12832, 6959, 526, 3709, 50, 4034, 563, 6959, 526, 3709, 257, 40, 2402, 2, 35, 1091, 3709, 4824, 225, 22, 3709, 11358, 23864, 68, 40, 1917, 21, 426, 8, 9949, 119, 45, 6, 6248, 402, 367, 487, 23, 3709, 11358, 23864, 2, 6, 538, 2078, 1814, 1, 3, 2821, 7, 5, 62, 15, 1275, 8315, 78, 23300, 54, 276, 8, 4034, 1329, 88, 3107, 6, 35, 563, 6959, 526, 3709, 3025, 4, 26, 160, 3, 793, 3709, 11358, 23864, 61, 10, 243, 984, 4588, 188, 18, 169, 162, 379, 647, 9339, 14412, 9872, 9, 100, 935, 244, 9, 296, 5149, 4424, 563, 6959, 526, 3709, 61, 2, 243, 984, 4588, 188, 18, 9, 296, 5149, 19495, 3709, 61, 9, 3, 1438, 1, 136, 1465, 3709, 24, 290, 774, 1198, 2, 15, 473, 414, 2377, 11, 781, 9, 11733, 7, 3, 96, 186, 290, 774, 3633, 10, 4034, 233, 49, 3195, 7, 14, 83, 1016, 190, 3, 45, 96, 7, 849, 49, 781, 136, 1465, 3709, 24, 5, 3709, 11358, 23864, 125, 10, 77, 2235, 523, 4, 3, 287, 1, 3, 96, 841, 210, 1477, 5, 3709, 24, 20, 89, 634, 15, 34, 1309, 26, 45, 195, 635, 3, 367, 800, 1, 3709, 11358, 23864, 4, 7, 5, 62, 15, 8315, 54, 42, 8, 4034, 1329, 6, 35, 563, 6959, 526, 3709]",1725.0,24436152,406
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2013-12-17,"Clofarabine is a nucleoside analogue with activity in children with acute lymphoblastic leukemia (ALL). Based on the hypothesis that clofarabine inhibits DNA repair after exposure to DNA-damaging agents, we designed a phase I and extension study to evaluate the combination of clofarabine and cyclophosphamide in adult patients with relapsed/refractory ALL. The continual reassessment method (CRM) was used to define the maximum tolerated dose (MTD). Fifty patients with a median age of 30 years (range, 21-72 years) were enrolled, 30 of whom were part of the phase I group. Clofarabine 40 mg/m(2) intravenously daily 3 days and cyclophosphamide 200 mg/m(2) intravenously every 12 hours 3 days were established as the MTDs. Dose limiting toxicity (DLT) included diarrhea, transaminase elevations, and skin rashes. The response rate of the whole study group was 14%, including 10% of patients who achieved complete remission (CR) or CR without platelet recovery (CRp). Three responses occurred in patients with primary refractory disease. Early mortality (< 30 days) was 6%. The median duration of response was 69 days (range, 5-315 days). Median overall survival was about 3 months. Compared with day 1 (cyclophosphamide alone), H2AX phosphorylation was increased on day 2 when clofarabine and cyclophosphamide were administered as a couplet (n= 8). The combination of clofarabine plus cyclophosphamide at the doses used in this study in a group of heavily pretreated patients with ALL is only moderately effective. Other doses, alternative schedules, or a more favorable patient population may achieve better results.","Clinical Trial, Phase I",2226.0,8.0,Clofarabine is a nucleoside analogue with activity in children with acute lymphoblastic ALL Based on the hypothesis that clofarabine inhibits DNA repair after exposure to DNA-damaging agents we designed a phase I and extension study to evaluate the combination of clofarabine and cyclophosphamide in adult patients with relapsed/refractory ALL The continual reassessment method CRM was used to define the maximum tolerated dose MTD Fifty patients with a median age of 30 years range 21-72 years were enrolled 30 of whom were part of the phase I group Clofarabine 40 mg/m 2 intravenously daily 3 days and cyclophosphamide 200 mg/m 2 intravenously every 12 hours 3 days were established as the MTDs Dose limiting toxicity DLT included diarrhea transaminase elevations and rashes The response rate of the whole study group was 14 including 10 of patients who achieved complete remission CR or CR without platelet recovery CRp Three responses occurred in patients with primary refractory disease Early mortality 30 days was 6 The median duration of response was 69 days range 5-315 days Median overall survival was about 3 months Compared with day 1 cyclophosphamide alone H2AX phosphorylation was increased on day 2 when clofarabine and cyclophosphamide were administered as a couplet n 8 The combination of clofarabine plus cyclophosphamide at the doses used in this study in a group of heavily pretreated patients with ALL is only moderately effective Other doses alternative schedules or a more favorable patient population may achieve better results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,"[4149, 16, 8, 4032, 4696, 5, 128, 4, 541, 5, 286, 1275, 62, 90, 23, 3, 1492, 17, 4149, 1576, 261, 972, 50, 645, 6, 261, 4904, 183, 21, 1114, 8, 124, 70, 2, 2401, 45, 6, 376, 3, 150, 1, 4149, 2, 1112, 4, 780, 7, 5, 591, 430, 62, 3, 9451, 8756, 596, 12620, 10, 95, 6, 1107, 3, 689, 421, 61, 961, 1461, 7, 5, 8, 52, 89, 1, 201, 60, 184, 239, 720, 60, 11, 346, 201, 1, 953, 11, 760, 1, 3, 124, 70, 87, 4149, 327, 81, 188, 18, 1672, 391, 27, 162, 2, 1112, 1250, 81, 188, 18, 1672, 454, 133, 1459, 27, 162, 11, 635, 22, 3, 9375, 61, 817, 155, 2059, 159, 1172, 6997, 4712, 2, 11775, 3, 51, 116, 1, 3, 902, 45, 87, 10, 213, 141, 79, 1, 7, 54, 513, 236, 734, 684, 15, 684, 187, 1596, 1602, 3162, 169, 253, 489, 4, 7, 5, 86, 430, 34, 191, 282, 201, 162, 10, 49, 3, 52, 654, 1, 51, 10, 790, 162, 184, 33, 7362, 162, 52, 63, 25, 10, 545, 27, 53, 72, 5, 218, 14, 1112, 279, 6286, 982, 10, 101, 23, 218, 18, 198, 4149, 2, 1112, 11, 468, 22, 8, 33499, 78, 66, 3, 150, 1, 4149, 349, 1112, 28, 3, 415, 95, 4, 26, 45, 4, 8, 87, 1, 2447, 2193, 7, 5, 62, 16, 158, 3508, 323, 127, 415, 1091, 2314, 15, 8, 80, 913, 69, 266, 68, 1359, 380, 99]",1550.0,24440659,453
Eating behavior and BMI in adolescent survivors of brain tumor and acute lymphoblastic leukemia.,Journal of pediatric oncology nursing : official journal of the Association of Pediatric Oncology Nurses,J Pediatr Oncol Nurs,2014-01-22,"Elevated body mass index (BMI) has been reported in pediatric cancer survivors. It is unclear whether this is related to altered energy intake (via disordered eating), decreased energy expenditure (via limited exercise), or treatment-related direct/indirect changes. The aims of this study are to describe the occurrence of overweight and obesity, exercise frequency, and the extent of disordered eating patterns in this sample of survivors, and to examine relationships among BMI, eating patterns, exercise frequency, and demographic and disease and treatment-related variables to identify those survivors most at risk for overweight/obesity. This cross-sectional study recruited 98 cancer survivors (50 acute lymphoblastic leukemia [ALL], 48 brain tumor [BT]), aged 12 to 17 years and 12 months posttreatment from a large pediatric oncology hospital. Survivors completed health behavior measures assessing disordered eating patterns and physical activity. Clinical variables were obtained through medical record review. Univariate analyses were conducted to make comparisons on health behaviors by diagnosis, gender, treatment history, and BMI category. Fifty-two percent of ALL survivors and 41.7% of BT survivors were classified as overweight/obese. Overweight/obesity status was associated with higher cognitive restraint (odds ratio = 1.0; 95% confidence interval = 1.0-1.1). Only 12% of ALL survivors and 8.3% of BT survivors met Centers for Disease Control and Prevention guidelines for physical activity. Males reported more physical activity, t(96) = 2.2, P < .05. Overweight/obese survivors may attempt to purposefully restrict their food intake and rely less on physiological cues to regulate consumption. Survivors should be screened at follow-up for weight-related concerns.",Journal Article,2190.0,11.0,Elevated body mass index BMI has been reported in pediatric cancer survivors It is unclear whether this is related to altered energy intake via disordered eating decreased energy expenditure via limited exercise or treatment-related direct/indirect changes The aims of this study are to describe the occurrence of overweight and obesity exercise frequency and the extent of disordered eating patterns in this sample of survivors and to examine relationships among BMI eating patterns exercise frequency and demographic and disease and treatment-related variables to identify those survivors most at risk for overweight/obesity This cross-sectional study recruited 98 cancer survivors 50 acute lymphoblastic ALL 48 brain tumor BT aged 12 to 17 years and 12 months posttreatment from a large pediatric oncology hospital Survivors completed health behavior measures assessing disordered eating patterns and physical activity Clinical variables were obtained through medical record review Univariate analyses were conducted to make comparisons on health behaviors by diagnosis gender treatment history and BMI category Fifty-two percent of ALL survivors and 41.7 of BT survivors were classified as overweight/obese Overweight/obesity status was associated with higher cognitive restraint odds ratio 1.0 95 confidence interval 1.0-1.1 Only 12 of ALL survivors and 8.3 of BT survivors met Centers for Disease Control and Prevention guidelines for physical activity Males reported more physical activity t 96 2.2 P .05 Overweight/obese survivors may attempt to purposefully restrict their food intake and rely less on physiological cues to regulate consumption Survivors should be screened at follow-up for weight-related concerns,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[804, 642, 782, 558, 1140, 71, 85, 210, 4, 815, 12, 332, 192, 16, 1200, 317, 26, 16, 139, 6, 1495, 2803, 1514, 847, 16904, 9660, 340, 2803, 8699, 847, 383, 2277, 15, 24, 139, 1196, 6110, 400, 3, 2970, 1, 26, 45, 32, 6, 897, 3, 2291, 1, 3566, 2, 1661, 2277, 675, 2, 3, 1039, 1, 16904, 9660, 764, 4, 26, 1000, 1, 332, 2, 6, 1004, 2467, 107, 1140, 9660, 764, 2277, 675, 2, 1540, 2, 34, 2, 24, 139, 682, 6, 255, 135, 332, 96, 28, 43, 9, 3566, 1661, 26, 1383, 2832, 45, 2619, 1096, 12, 332, 212, 286, 1275, 62, 576, 342, 30, 3641, 1032, 133, 6, 269, 60, 2, 9612, 53, 3149, 29, 8, 375, 815, 413, 702, 332, 781, 341, 1710, 1018, 1977, 16904, 9660, 764, 2, 900, 128, 38, 682, 11, 683, 298, 484, 3237, 206, 880, 318, 11, 426, 6, 2378, 2213, 23, 341, 3704, 20, 147, 1632, 24, 532, 2, 1140, 2169, 1461, 100, 714, 1, 62, 332, 2, 605, 67, 1, 3641, 332, 11, 1373, 22, 3566, 2209, 3566, 1661, 156, 10, 41, 5, 142, 1863, 23826, 610, 197, 14, 13, 48, 307, 268, 14, 13, 14, 14, 158, 133, 1, 62, 332, 2, 66, 27, 1, 3641, 332, 543, 1168, 9, 34, 182, 2, 1070, 677, 9, 900, 128, 2296, 210, 80, 900, 128, 102, 921, 18, 18, 19, 474, 3566, 2209, 332, 68, 3448, 6, 40593, 14206, 136, 1773, 1514, 2, 5533, 299, 23, 4733, 15209, 6, 2288, 2421, 332, 257, 40, 2261, 28, 166, 126, 9, 924, 139, 2061]",1724.0,24451908,16
"Aberrant expression of SALL4 in acute B cell lymphoblastic leukemia: mechanism, function, and implication for a potential novel therapeutic target.",Experimental hematology,Exp. Hematol.,2014-01-23,"Treatment for high-risk pediatric and adult acute B cell lymphoblastic leukemia (B-ALL) remains challenging. Exploring novel pathways in B-ALL could lead to new therapy. Our previous study has shown that stem cell factor SALL4 is aberrantly expressed in B-ALL, but its functional roles and the mechanism that accounts for its upregulation in B-ALL remain unexplored. To address this question, we first surveyed the existing B-ALL cell lines and primary patient samples for SALL4 expression. We then selected the B-ALL cell lines with the highest SALL4 expression for functional studies. RNA interference was used to downregulate SALL4 expression in these cell lines. When compared with control cells, SALL4 knockdown cells exhibited decreased cell proliferation, increased apoptosis in vitro, and decreased engraftment in a xenotransplant model in vivo. Gene expression analysis showed that in SALL4 knockdown B-ALL cells, multiple caspase members involved in cell apoptosis pathway were upregulated. Next, we explored the mechanisms of aberrant SALL4 expression in B-ALL. We found that hypomethylation of the SALL4 CpG islands was correlated with its high expression. Furthermore, treatment of low SALL4-expressing B-ALL cell lines with DNA methylation inhibitor led to demethylation of the SALL4 CpG and increased SALL4 expression. In summary, to our knowledge, we are the first to show that the aberrant expression of SALL4 in B-ALL is associated with hypomethylation, and that SALL4 plays a key role in B-ALL cell survival and could be a potential novel target in B-ALL treatment.",Clinical Trial,2189.0,15.0,Treatment for high-risk pediatric and adult acute B cell lymphoblastic B-ALL remains challenging Exploring novel pathways in B-ALL could lead to new therapy Our previous study has shown that stem cell factor SALL4 is aberrantly expressed in B-ALL but its functional roles and the mechanism that accounts for its upregulation in B-ALL remain unexplored To address this question we first surveyed the existing B-ALL cell lines and primary patient samples for SALL4 expression We then selected the B-ALL cell lines with the highest SALL4 expression for functional studies RNA interference was used to downregulate SALL4 expression in these cell lines When compared with control cells SALL4 knockdown cells exhibited decreased cell proliferation increased apoptosis in vitro and decreased engraftment in a xenotransplant model in vivo Gene expression analysis showed that in SALL4 knockdown B-ALL cells multiple caspase members involved in cell apoptosis pathway were upregulated Next we explored the mechanisms of aberrant SALL4 expression in B-ALL We found that hypomethylation of the SALL4 CpG islands was correlated with its high expression Furthermore treatment of low SALL4-expressing B-ALL cell lines with DNA methylation inhibitor led to demethylation of the SALL4 CpG and increased SALL4 expression In summary to our knowledge we are the first to show that the aberrant expression of SALL4 in B-ALL is associated with hypomethylation and that SALL4 plays a key role in B-ALL cell survival and could be a potential novel target in B-ALL treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 9, 64, 43, 815, 2, 780, 286, 132, 31, 1275, 132, 62, 469, 1950, 4378, 229, 460, 4, 132, 62, 359, 1122, 6, 217, 36, 114, 698, 45, 71, 443, 17, 452, 31, 161, 16439, 16, 5619, 570, 4, 132, 62, 84, 211, 583, 1790, 2, 3, 670, 17, 4162, 9, 211, 2218, 4, 132, 62, 918, 8398, 6, 1539, 26, 2840, 21, 157, 3696, 3, 1692, 132, 62, 31, 285, 2, 86, 69, 347, 9, 16439, 55, 21, 818, 715, 3, 132, 62, 31, 285, 5, 3, 1076, 16439, 55, 9, 583, 94, 893, 3182, 10, 95, 6, 10261, 16439, 55, 4, 46, 31, 285, 198, 72, 5, 182, 37, 16439, 1563, 37, 1416, 340, 31, 457, 101, 351, 4, 439, 2, 340, 2881, 4, 8, 28800, 202, 4, 386, 145, 55, 65, 224, 17, 4, 16439, 1563, 132, 62, 37, 232, 1469, 1684, 646, 4, 31, 351, 308, 11, 2684, 1305, 21, 1443, 3, 483, 1, 1898, 16439, 55, 4, 132, 62, 21, 204, 17, 4441, 1, 3, 16439, 2075, 6046, 10, 438, 5, 211, 64, 55, 798, 24, 1, 154, 16439, 1046, 132, 62, 31, 285, 5, 261, 569, 230, 836, 6, 6800, 1, 3, 16439, 2075, 2, 101, 16439, 55, 4, 1962, 6, 114, 922, 21, 32, 3, 157, 6, 514, 17, 3, 1898, 55, 1, 16439, 4, 132, 62, 16, 41, 5, 4441, 2, 17, 16439, 1698, 8, 825, 200, 4, 132, 62, 31, 25, 2, 359, 40, 8, 174, 229, 283, 4, 132, 62, 24]",1550.0,24463278,206
Incidental detection of late subsequent intracranial neoplasms with magnetic resonance imaging among adult survivors of childhood cancer.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2014-02-02,"Survivors of childhood cancer are at an increased risk of developing subsequent neoplasms. In long-term survivors of childhood malignancies treated with and without cranial radiation therapy (CRT), undergoing unenhanced magnetic resonance imaging (MRI) of the brain, we estimated detection of intracranial neoplasms. To investigate neurocognitive outcomes, 219 survivors of childhood cancer underwent unenhanced screening MRI of the brain. Of the survivors, 164 had been treated for acute lymphoblastic leukemia (ALL) (125 received CRT) and 55 for Hodgkin lymphoma (HL) (none received CRT). MRI examinations were reviewed and systematically coded by a single neuroradiologist. Demographic and treatment characteristics were compared for survivors with and without subsequent neoplasms. Nineteen of the 219 survivors (8.7 %) had a total of 31 subsequent intracranial neoplasms identified by neuroimaging at a median time of 25 years (range 12-46 years) from diagnosis. All neoplasms occurred after CRT, except for a single vestibular schwannoma within the cervical radiation field in a HL survivor. The prevalence of subsequent neoplasms after CRT exposure was 14.4 % (18 of 125). By noncontrast MRI, intracranial neoplasms were most suggestive of meningiomas. Most patients presented with no specific, localizing neurological complaints. In addition to the schwannoma, six tumors were resected based on results of MRI screening, all of which were meningiomas on histologic review. Unenhanced brain MRI of long-term survivors of childhood cancer detected a substantial number of intracranial neoplasms. Screening for early detection of intracranial neoplasms among aging survivors of childhood cancer who received CRT should be evaluated. The high prevalence of incidentally detected subsequent intracranial neoplasms after CRT in long-term survivors of childhood cancer and the minimal symptoms reported by those with intracranial tumors in our study indicate that brain MRI screening of long-term survivors who received CRT may be warranted. Prospective studies of such screening are needed.",Journal Article,2179.0,6.0,Survivors of childhood cancer are at an increased risk of developing subsequent neoplasms In long-term survivors of childhood malignancies treated with and without cranial radiation therapy CRT undergoing unenhanced magnetic resonance imaging MRI of the brain we estimated detection of intracranial neoplasms To investigate neurocognitive outcomes 219 survivors of childhood cancer underwent unenhanced screening MRI of the brain Of the survivors 164 had been treated for acute lymphoblastic ALL 125 received CRT and 55 for HL none received CRT MRI examinations were reviewed and systematically coded by a single neuroradiologist Demographic and treatment characteristics were compared for survivors with and without subsequent neoplasms Nineteen of the 219 survivors 8.7 had a total of 31 subsequent intracranial neoplasms identified by neuroimaging at a median time of 25 years range 12-46 years from diagnosis All neoplasms occurred after CRT except for a single vestibular schwannoma within the radiation field in a HL survivor The prevalence of subsequent neoplasms after CRT exposure was 14.4 18 of 125 By noncontrast MRI intracranial neoplasms were most suggestive of meningiomas Most patients presented with no specific localizing neurological complaints In addition to the schwannoma six tumors were resected based on results of MRI screening all of which were meningiomas on histologic review Unenhanced brain MRI of long-term survivors of childhood cancer detected a substantial number of intracranial neoplasms Screening for early detection of intracranial neoplasms among aging survivors of childhood cancer who received CRT should be evaluated The high prevalence of incidentally detected subsequent intracranial neoplasms after CRT in long-term survivors of childhood cancer and the minimal symptoms reported by those with intracranial tumors in our study indicate that brain MRI screening of long-term survivors who received CRT may be warranted Prospective studies of such screening are needed,0,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,0,"[332, 1, 864, 12, 32, 28, 35, 101, 43, 1, 931, 706, 1179, 4, 319, 337, 332, 1, 864, 441, 73, 5, 2, 187, 2565, 121, 36, 1089, 479, 23920, 1484, 1535, 270, 704, 1, 3, 342, 21, 661, 638, 1, 2089, 1179, 6, 963, 2958, 123, 6679, 332, 1, 864, 12, 208, 23920, 453, 704, 1, 3, 342, 1, 3, 332, 5279, 42, 85, 73, 9, 286, 1275, 62, 1731, 103, 1089, 2, 614, 9, 1718, 1292, 103, 1089, 704, 4209, 11, 446, 2, 3390, 8259, 20, 8, 226, 21256, 1540, 2, 24, 374, 11, 72, 9, 332, 5, 2, 187, 706, 1179, 3498, 1, 3, 6679, 332, 66, 67, 42, 8, 181, 1, 456, 706, 2089, 1179, 108, 20, 7468, 28, 8, 52, 98, 1, 243, 60, 184, 133, 641, 60, 29, 147, 62, 1179, 489, 50, 1089, 2187, 9, 8, 226, 9633, 9601, 262, 3, 121, 1067, 4, 8, 1718, 2628, 3, 1078, 1, 706, 1179, 50, 1089, 645, 10, 213, 39, 203, 1, 1731, 20, 35381, 704, 2089, 1179, 11, 96, 3832, 1, 3718, 96, 7, 917, 5, 77, 112, 14384, 3622, 6938, 4, 352, 6, 3, 9601, 437, 57, 11, 1133, 90, 23, 99, 1, 704, 453, 62, 1, 92, 11, 3718, 23, 884, 206, 23920, 342, 704, 1, 319, 337, 332, 1, 864, 12, 530, 8, 1281, 207, 1, 2089, 1179, 453, 9, 191, 638, 1, 2089, 1179, 107, 4220, 332, 1, 864, 12, 54, 103, 1089, 257, 40, 194, 3, 64, 1078, 1, 5925, 530, 706, 2089, 1179, 50, 1089, 4, 319, 337, 332, 1, 864, 12, 2, 3, 1048, 507, 210, 20, 135, 5, 2089, 57, 4, 114, 45, 1008, 17, 342, 704, 453, 1, 319, 337, 332, 54, 103, 1089, 68, 40, 1197, 482, 94, 1, 225, 453, 32, 575]",2010.0,24488818,38
Impact of tyrosine kinase inhibitors on minimal residual disease and outcome in childhood Philadelphia chromosome-positive acute lymphoblastic leukemia.,Cancer,Cancer,2014-02-05,"Breakpoint cluster region-Abelson murine leukemia viral oncogene homolog 1 (BCR-ABL1) tyrosine kinase inhibitors (TKIs) improve the outcome of patients with childhood Philadelphia chromosome (Ph)-positive acute lymphoblastic leukemia (ALL) when they are incorporated into postremission induction chemotherapy. To date, no data are available on the impact of TKIs on minimal residual disease (MRD) at the end of induction therapy among patients who have a poor early response to 2 weeks of induction therapy that does not include TKIs. The authors analyzed the early response to TKIs during remission induction in children with Ph-positive ALL who were treated at St. Jude Children's Research Hospital. MRD was measured on days 15 and 42 of induction. TKIs were incorporated into induction therapy on day 22 in the post-TKI era. TKIs produced a marked drop in MRD levels: at the end of remission induction, 9 of 11 patients who received imatinib or dasatinib and conventional induction chemotherapy achieved MRD-negative status compared with only 2 of 16 patients who received chemotherapy alone (P <.001). The 5-year event-free survival rate ( standard deviation) was 68.6%  19.2% for the 11 patients who received TKIs versus 31.6%  9.9% for the 19 patients who did not (P =.022); notably, 2 of the former group underwent hematopoietic stem cell transplantation versus 15 of the latter group (P =.002). MRD levels and outcomes did not differ significantly among 498 patients with standard-risk/high-risk, Ph-negative ALL who were treated in the pre-TKI or post-TKI eras. TKIs administered in the early phases of therapy can dramatically reduce MRD and improve the outcome of childhood Ph-positive ALL.",Journal Article,2176.0,36.0,Breakpoint cluster region-Abelson murine viral oncogene homolog 1 BCR-ABL1 tyrosine kinase inhibitors TKIs improve the outcome of patients with childhood Philadelphia chromosome Ph -positive acute lymphoblastic ALL when they are incorporated into postremission induction chemotherapy To date no data are available on the impact of TKIs on minimal residual disease MRD at the end of induction therapy among patients who have a poor early response to 2 weeks of induction therapy that does not include TKIs The authors analyzed the early response to TKIs during remission induction in children with Ph-positive ALL who were treated at St. Jude Children 's Research Hospital MRD was measured on days 15 and 42 of induction TKIs were incorporated into induction therapy on day 22 in the post-TKI era TKIs produced a marked drop in MRD levels at the end of remission induction 9 of 11 patients who received imatinib or dasatinib and conventional induction chemotherapy achieved MRD-negative status compared with only 2 of 16 patients who received chemotherapy alone P .001 The 5-year event-free survival rate  standard deviation was 68.6  19.2 for the 11 patients who received TKIs versus 31.6  9.9 for the 19 patients who did not P .022 notably 2 of the former group underwent hematopoietic stem cell transplantation versus 15 of the latter group P .002 MRD levels and outcomes did not differ significantly among 498 patients with standard-risk/high-risk Ph-negative ALL who were treated in the pre-TKI or post-TKI eras TKIs administered in the early phases of therapy can dramatically reduce MRD and improve the outcome of childhood Ph-positive ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8567, 3132, 1053, 16881, 1471, 1667, 1836, 3412, 14, 1062, 3557, 564, 216, 222, 1671, 401, 3, 228, 1, 7, 5, 864, 3006, 1170, 2058, 109, 286, 1275, 62, 198, 491, 32, 2449, 237, 8635, 504, 56, 6, 1244, 77, 74, 32, 390, 23, 3, 345, 1, 1671, 23, 1048, 753, 34, 2029, 28, 3, 396, 1, 504, 36, 107, 7, 54, 47, 8, 334, 191, 51, 6, 18, 244, 1, 504, 36, 17, 1097, 44, 643, 1671, 3, 738, 311, 3, 191, 51, 6, 1671, 190, 734, 504, 4, 541, 5, 2058, 109, 62, 54, 11, 73, 28, 3062, 4841, 541, 292, 389, 702, 2029, 10, 644, 23, 162, 167, 2, 595, 1, 504, 1671, 11, 2449, 237, 504, 36, 23, 218, 350, 4, 3, 539, 1379, 1713, 1671, 1687, 8, 2003, 7215, 4, 2029, 148, 28, 3, 396, 1, 734, 504, 83, 1, 175, 7, 54, 103, 577, 15, 1674, 2, 809, 504, 56, 513, 2029, 199, 156, 72, 5, 158, 18, 1, 245, 7, 54, 103, 56, 279, 19, 144, 3, 33, 111, 774, 115, 25, 116, 810, 260, 3348, 10, 806, 49, 810, 326, 18, 9, 3, 175, 7, 54, 103, 1671, 185, 456, 49, 810, 83, 83, 9, 3, 326, 7, 54, 205, 44, 19, 4773, 2552, 18, 1, 3, 3623, 87, 208, 1007, 452, 31, 497, 185, 167, 1, 3, 3286, 87, 19, 1111, 2029, 148, 2, 123, 205, 44, 1505, 97, 107, 8928, 7, 5, 260, 43, 64, 43, 2058, 199, 62, 54, 11, 73, 4, 3, 671, 1379, 15, 539, 1379, 7225, 1671, 468, 4, 3, 191, 3523, 1, 36, 122, 2729, 969, 2029, 2, 401, 3, 228, 1, 864, 2058, 109, 62]",1648.0,24501014,677
Pharmacokinetic evaluation of vincristine for the treatment of lymphoid malignancies.,Expert opinion on drug metabolism & toxicology,Expert Opin Drug Metab Toxicol,2014-02-10,"Vincristine is a key agent for the treatment of acute lymphoblastic leukemia (ALL) and other lymphoid malignancies. The strong antineoplastic activity of vincristine has been limited by its pharmacological characteristics. This paper reviews the role of vincristine in the treatment of lymphoid malignancies. This review summarizes its efficacy and toxicity, and focuses on the pharmacokinetic features of vincristine that affect clinical outcomes. As a single agent, vincristine is associated with brief and incomplete responses, but in combination with other agents, vincristine has dramatically improved the outcomes of lymphoid malignancies such as ALL. Vincristine is a key drug of hyper-fractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, an intensive chemotherapeutic regimen for the treatment of ALL, and of cyclophosphamid, adriamycin, vincristine and prednisone, which has been used extensively in the treatment of patients with aggressive or indolent lymphomas and Richter syndrome. The strong antileukemic activity of vincristine has been limited by its variable and unpredictable pharmacological characteristics, narrow therapeutic index and neurotoxicity profile. These characteristics prompted the development of liposomal vincristine, which has optimized its clinical application. Liposomal vincristine has promising antileukemic activity, and it is approved by the FDA as a single agent for the treatment of relapsed/refractory Philadelphia chromosome-negative ALL.",Journal Article,2171.0,15.0,Vincristine is a key agent for the treatment of acute lymphoblastic ALL and other lymphoid malignancies The strong antineoplastic activity of vincristine has been limited by its pharmacological characteristics This paper reviews the role of vincristine in the treatment of lymphoid malignancies This review summarizes its efficacy and toxicity and focuses on the pharmacokinetic features of vincristine that affect clinical outcomes As a single agent vincristine is associated with brief and incomplete responses but in combination with other agents vincristine has dramatically improved the outcomes of lymphoid malignancies such as ALL Vincristine is a key drug of hyper-fractionated cyclophosphamide vincristine doxorubicin and dexamethasone an intensive chemotherapeutic regimen for the treatment of ALL and of cyclophosphamid adriamycin vincristine and prednisone which has been used extensively in the treatment of patients with aggressive or indolent lymphomas and Richter syndrome The strong antileukemic activity of vincristine has been limited by its variable and unpredictable pharmacological characteristics narrow therapeutic index and neurotoxicity profile These characteristics prompted the development of liposomal vincristine which has optimized its clinical application Liposomal vincristine has promising antileukemic activity and it is approved by the FDA as a single agent for the treatment of relapsed/refractory Philadelphia chromosome-negative ALL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2132, 16, 8, 825, 420, 9, 3, 24, 1, 286, 1275, 62, 2, 127, 2303, 441, 3, 1082, 3940, 128, 1, 2132, 71, 85, 383, 20, 211, 3419, 374, 26, 2817, 2004, 3, 200, 1, 2132, 4, 3, 24, 1, 2303, 441, 26, 206, 2869, 211, 209, 2, 155, 2, 3026, 23, 3, 1456, 404, 1, 2132, 17, 1158, 38, 123, 22, 8, 226, 420, 2132, 16, 41, 5, 3190, 2, 2610, 253, 84, 4, 150, 5, 127, 183, 2132, 71, 2729, 231, 3, 123, 1, 2303, 441, 225, 22, 62, 2132, 16, 8, 825, 234, 1, 4855, 3950, 1112, 2132, 856, 2, 1217, 35, 1686, 1573, 477, 9, 3, 24, 1, 62, 2, 1, 63938, 7700, 2132, 2, 1979, 92, 71, 85, 95, 3576, 4, 3, 24, 1, 7, 5, 571, 15, 2316, 1557, 2, 8452, 681, 3, 1082, 4512, 128, 1, 2132, 71, 85, 383, 20, 211, 1347, 2, 8907, 3419, 374, 6958, 189, 558, 2, 3561, 800, 46, 374, 4140, 3, 193, 1, 3275, 2132, 92, 71, 4039, 211, 38, 1581, 3275, 2132, 71, 721, 4512, 128, 2, 192, 16, 850, 20, 3, 2078, 22, 8, 226, 420, 9, 3, 24, 1, 591, 430, 3006, 1170, 199, 62]",1471.0,24512004,69
Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-02-10,"Asparaginase treatment is standard in all pediatric acute lymphoblastic leukemia (ALL) regimens, whereas in adults, it is either excluded or administered for a shorter duration. Several adult ALL protocols are adapting pediatric regimens, but the optimal implementation of asparaginase is not well studied, considering its potential higher toxicity. We studied a pegaspargase dosing strategy based on its pharmacokinetic characteristics in adults. Between 2004 and 2009, 51 adults age 18 to 57 years with newly diagnosed ALL were treated with a regimen adapted from a pediatric trial that included six doses of intravenous pegaspargase at 2,000 IU/m(2) per dose. Intervals between doses were longer than 4 weeks and rationally synchronized with other chemotherapy drugs to prevent overlapping toxicities. Pegaspargase was administered with steroids to reduce hypersensitivity. Asparaginase-related toxicities were monitored after 173 pegaspargase doses. The most common grade 3/4 asparaginase-related toxicities were lengthy hyperbilirubinemia and transaminitis, occasionally resulting in subsequent treatment delays. All toxicities resolved spontaneously. Forty-five percent of patients were able to receive all six doses of pegaspargase, and 61% received  three doses. In only 20% of patients, the drug was discontinued after pegaspargase-related serious toxicity. Ninety-six percent achieved complete remission, almost all within 4 weeks, and a low induction death rate was seen. Seven-year disease-free and overall survival were 58% and 51%, respectively. Our dose and schedule of pegaspargase, based on its pharmacokinetics, and our detailed toxicity profile could be applied for safer adaptation of pediatric ALL protocols in adults.",Clinical Trial,2171.0,55.0,"Asparaginase treatment is standard in all pediatric acute lymphoblastic ALL regimens whereas in adults it is either excluded or administered for a shorter duration Several adult ALL protocols are adapting pediatric regimens but the optimal implementation of asparaginase is not well studied considering its potential higher toxicity We studied a pegaspargase dosing strategy based on its pharmacokinetic characteristics in adults Between 2004 and 2009 51 adults age 18 to 57 years with newly diagnosed ALL were treated with a regimen adapted from a pediatric trial that included six doses of intravenous pegaspargase at 2,000 IU/m 2 per dose Intervals between doses were longer than 4 weeks and rationally synchronized with other chemotherapy drugs to prevent overlapping toxicities Pegaspargase was administered with steroids to reduce hypersensitivity Asparaginase-related toxicities were monitored after 173 pegaspargase doses The most common grade 3/4 asparaginase-related toxicities were lengthy hyperbilirubinemia and transaminitis occasionally resulting in subsequent treatment delays All toxicities resolved spontaneously Forty-five percent of patients were able to receive all six doses of pegaspargase and 61 received  three doses In only 20 of patients the drug was discontinued after pegaspargase-related serious toxicity Ninety-six percent achieved complete remission almost all within 4 weeks and a low induction death rate was seen Seven-year disease-free and overall survival were 58 and 51 respectively Our dose and schedule of pegaspargase based on its pharmacokinetics and our detailed toxicity profile could be applied for safer adaptation of pediatric ALL protocols in adults",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 24, 16, 260, 4, 62, 815, 286, 1275, 62, 472, 547, 4, 857, 192, 16, 361, 1800, 15, 468, 9, 8, 985, 654, 392, 780, 62, 2189, 32, 14827, 815, 472, 84, 3, 665, 2393, 1, 3709, 16, 44, 149, 656, 3075, 211, 174, 142, 155, 21, 656, 8, 12209, 1280, 692, 90, 23, 211, 1456, 374, 4, 857, 59, 1131, 2, 1238, 725, 857, 89, 203, 6, 696, 60, 5, 732, 265, 62, 11, 73, 5, 8, 477, 3716, 29, 8, 815, 160, 17, 159, 437, 415, 1, 1262, 12209, 28, 18, 984, 4588, 188, 18, 379, 61, 1582, 59, 415, 11, 589, 76, 39, 244, 2, 6352, 18278, 5, 127, 56, 600, 6, 1682, 4551, 385, 12209, 10, 468, 5, 4580, 6, 969, 4034, 3709, 139, 385, 11, 2909, 50, 5785, 12209, 415, 3, 96, 186, 88, 27, 39, 3709, 139, 385, 11, 14487, 7236, 2, 8181, 6319, 1113, 4, 706, 24, 3257, 62, 385, 3862, 6459, 1213, 365, 714, 1, 7, 11, 1665, 6, 560, 62, 437, 415, 1, 12209, 2, 713, 103, 749, 169, 415, 4, 158, 179, 1, 7, 3, 234, 10, 2402, 50, 12209, 139, 1762, 155, 2493, 437, 714, 513, 236, 734, 2214, 62, 262, 39, 244, 2, 8, 154, 504, 273, 116, 10, 527, 648, 111, 34, 115, 2, 63, 25, 11, 717, 2, 725, 106, 114, 61, 2, 1055, 1, 12209, 90, 23, 211, 1159, 2, 114, 2455, 155, 800, 359, 40, 1498, 9, 9276, 7275, 1, 815, 62, 2189, 4, 857]",1697.0,24516026,385
Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-02-18,"Methotrexate (MTX) can cause significant clinical neurotoxicity and asymptomatic leukoencephalopathy. We sought to identify clinical, pharmacokinetic, and genetic risk factors for these MTX-related toxicities during childhood acute lymphoblastic leukemia (ALL) therapy and provide data on safety of intrathecal and high-dose MTX rechallenge in patients with neurotoxicity. Prospective brain magnetic resonance imaging was performed at four time points for 369 children with ALL treated in a contemporary study that included five courses of high-dose MTX and 13 to 25 doses of triple intrathecal therapy. Logistic regression modeling was used to evaluate clinical and pharmacokinetic factors, and a genome-wide association study (GWAS) was performed to identify germline polymorphisms for their association with neurotoxicities. Fourteen patients (3.8%) developed MTX-related clinical neurotoxicity. Of 13 patients rechallenged with intrathecal and/or high-dose MTX, 12 did not experience recurrence of neurotoxicity. Leukoencephalopathy was found in 73 (20.6%) of 355 asymptomatic patients and in all symptomatic patients and persisted in 74% of asymptomatic and 58% of symptomatic patients at the end of therapy. A high 42-hour plasma MTX to leucovorin ratio (measure of MTX exposure) was associated with increased risk of leukoencephalopathy in multivariable analysis (P = .038). GWAS revealed polymorphisms in genes enriched for neurodevelopmental pathways with plausible mechanistic roles in neurotoxicity. MTX-related clinical neurotoxicity is transient, and most patients can receive subsequent MTX without recurrence of acute or subacute symptoms. All symptomatic patients and one in five asymptomatic patients develop leukoencephalopathy that can persist until the end of therapy. Polymorphisms in genes related to neurogenesis may contribute to susceptibility to MTX-related neurotoxicity.",Journal Article,2163.0,102.0,Methotrexate MTX can cause significant clinical neurotoxicity and asymptomatic leukoencephalopathy We sought to identify clinical pharmacokinetic and genetic risk factors for these MTX-related toxicities during childhood acute lymphoblastic ALL therapy and provide data on safety of intrathecal and high-dose MTX rechallenge in patients with neurotoxicity Prospective brain magnetic resonance imaging was performed at four time points for 369 children with ALL treated in a contemporary study that included five courses of high-dose MTX and 13 to 25 doses of triple intrathecal therapy Logistic regression modeling was used to evaluate clinical and pharmacokinetic factors and a genome-wide association study GWAS was performed to identify germline polymorphisms for their association with neurotoxicities Fourteen patients 3.8 developed MTX-related clinical neurotoxicity Of 13 patients rechallenged with intrathecal and/or high-dose MTX 12 did not experience recurrence of neurotoxicity Leukoencephalopathy was found in 73 20.6 of 355 asymptomatic patients and in all symptomatic patients and persisted in 74 of asymptomatic and 58 of symptomatic patients at the end of therapy A high 42-hour plasma MTX to leucovorin ratio measure of MTX exposure was associated with increased risk of leukoencephalopathy in multivariable analysis P .038 GWAS revealed polymorphisms in genes enriched for neurodevelopmental pathways with plausible mechanistic roles in neurotoxicity MTX-related clinical neurotoxicity is transient and most patients can receive subsequent MTX without recurrence of acute or subacute symptoms All symptomatic patients and one in five asymptomatic patients develop leukoencephalopathy that can persist until the end of therapy Polymorphisms in genes related to neurogenesis may contribute to susceptibility to MTX-related neurotoxicity,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 3453, 122, 708, 93, 38, 3561, 2, 2100, 8744, 21, 990, 6, 255, 38, 1456, 2, 336, 43, 130, 9, 46, 3453, 139, 385, 190, 864, 286, 1275, 62, 36, 2, 377, 74, 23, 367, 1, 5126, 2, 64, 61, 3453, 9423, 4, 7, 5, 3561, 482, 342, 1484, 1535, 270, 10, 173, 28, 294, 98, 862, 9, 8718, 541, 5, 62, 73, 4, 8, 2667, 45, 17, 159, 365, 1993, 1, 64, 61, 3453, 2, 233, 6, 243, 415, 1, 1500, 5126, 36, 812, 320, 2057, 10, 95, 6, 376, 38, 2, 1456, 130, 2, 8, 898, 1019, 248, 45, 3297, 10, 173, 6, 255, 1009, 1203, 9, 136, 248, 5, 20989, 3225, 7, 27, 66, 276, 3453, 139, 38, 3561, 1, 233, 7, 16853, 5, 5126, 2, 15, 64, 61, 3453, 133, 205, 44, 730, 146, 1, 3561, 8744, 10, 204, 4, 803, 179, 49, 1, 8370, 2100, 7, 2, 4, 62, 1704, 7, 2, 3760, 4, 794, 1, 2100, 2, 717, 1, 1704, 7, 28, 3, 396, 1, 36, 8, 64, 595, 2583, 554, 3453, 6, 3296, 197, 1463, 1, 3453, 645, 10, 41, 5, 101, 43, 1, 8744, 4, 658, 65, 19, 5215, 3297, 553, 1203, 4, 214, 2220, 9, 19352, 460, 5, 7761, 2716, 1790, 4, 3561, 3453, 139, 38, 3561, 16, 2473, 2, 96, 7, 122, 560, 706, 3453, 187, 146, 1, 286, 15, 15181, 507, 62, 1704, 7, 2, 104, 4, 365, 2100, 7, 690, 8744, 17, 122, 5589, 1100, 3, 396, 1, 36, 1203, 4, 214, 139, 6, 19128, 68, 1248, 6, 1432, 6, 3453, 139, 3561]",1852.0,24550419,123
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.,Science translational medicine,Sci Transl Med,2014-02-01,"We report on 16 patients with relapsed or refractory B cell acute lymphoblastic leukemia (B-ALL) that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor (CAR) specific to the CD19 antigen. The overall complete response rate was 88%, which allowed us to transition most of these patients to a standard-of-care allogeneic hematopoietic stem cell transplant (allo-SCT). This therapy was as effective in high-risk patients with Philadelphia chromosome-positive (Ph(+)) disease as in those with relapsed disease after previous allo-SCT. Through systematic analysis of clinical data and serum cytokine levels over the first 21 days after T cell infusion, we have defined diagnostic criteria for a severe cytokine release syndrome (sCRS), with the goal of better identifying the subset of patients who will likely require therapeutic intervention with corticosteroids or interleukin-6 receptor blockade to curb the sCRS. Additionally, we found that serum C-reactive protein, a readily available laboratory study, can serve as a reliable indicator for the severity of the CRS. Together, our data provide strong support for conducting a multicenter phase 2 study to further evaluate 19-28z CAR T cells in B-ALL and a road map for patient management at centers now contemplating the use of CAR T cell therapy. ",Journal Article,2180.0,1102.0,We report on 16 patients with relapsed or refractory B cell acute lymphoblastic B-ALL that we treated with autologous T cells expressing the 19-28z chimeric antigen receptor CAR specific to the CD19 antigen The overall complete response rate was 88 which allowed us to transition most of these patients to a standard-of-care allogeneic hematopoietic stem cell transplant allo-SCT This therapy was as effective in high-risk patients with Philadelphia chromosome-positive Ph disease as in those with relapsed disease after previous allo-SCT Through systematic analysis of clinical data and serum cytokine levels over the first 21 days after T cell infusion we have defined diagnostic criteria for a severe cytokine release syndrome sCRS with the goal of better identifying the subset of patients who will likely require therapeutic intervention with corticosteroids or interleukin-6 receptor blockade to curb the sCRS Additionally we found that serum C-reactive protein a readily available laboratory study can serve as a reliable indicator for the severity of the CRS Together our data provide strong support for conducting a multicenter phase 2 study to further evaluate 19-28z CAR T cells in B-ALL and a road map for patient management at centers now contemplating the use of CAR T cell therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 414, 23, 245, 7, 5, 591, 15, 430, 132, 31, 286, 1275, 132, 62, 17, 21, 73, 5, 1028, 102, 37, 1046, 3, 326, 19130, 2897, 448, 153, 1881, 112, 6, 3, 3158, 448, 3, 63, 236, 51, 116, 10, 889, 92, 2313, 843, 6, 1970, 96, 1, 46, 7, 6, 8, 260, 1, 165, 1063, 1007, 452, 31, 941, 2564, 1988, 26, 36, 10, 22, 323, 4, 64, 43, 7, 5, 3006, 1170, 109, 2058, 34, 22, 4, 135, 5, 591, 34, 50, 698, 2564, 1988, 298, 1556, 65, 1, 38, 74, 2, 524, 1675, 148, 252, 3, 157, 239, 162, 50, 102, 31, 904, 21, 47, 395, 752, 371, 9, 8, 905, 1675, 2008, 681, 16959, 5, 3, 1326, 1, 380, 1386, 3, 697, 1, 7, 54, 303, 322, 1353, 189, 788, 5, 3876, 15, 1603, 49, 153, 1189, 6, 22642, 3, 16959, 1724, 21, 204, 17, 524, 256, 2163, 178, 8, 3860, 390, 1624, 45, 122, 1833, 22, 8, 2450, 3287, 9, 3, 1702, 1, 3, 3115, 1162, 114, 74, 377, 1082, 538, 9, 6018, 8, 1570, 124, 18, 45, 6, 195, 376, 326, 19130, 1881, 102, 37, 4, 132, 62, 2, 8, 13375, 3771, 9, 69, 284, 28, 1168, 1134, 28027, 3, 119, 1, 1881, 102, 31, 36]",1295.0,24553386,624
Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-03-07,"Adolescents and young adults (AYAs, ages 15 to 40 years) with cancer have not experienced survival improvements to the same extent as younger and older patients. We compared changes in survival after myeloablative allogeneic hematopoietic cell transplantation (HCT) for acute lymphoblastic leukemia (ALL) among children (n = 981), AYAs (n = 1218), and older adults (n = 469) who underwent transplantation over 3 time periods: 1990 to 1995, 1996 to 2001, and 2002 to 2007. Five-year survival varied inversely with age group. Survival improved over time in AYAs and paralleled that seen in children; however, overall survival did not change over time for older adults. Survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era. For all cohorts, relapse rates did not change over time. A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to describe differences by center type. In this subgroup, there were differences in transplantation practices among pediatric and adult centers, although HCT outcomes did not differ by center type. Survival for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children.",Journal Article,2146.0,20.0,Adolescents and young adults AYAs ages 15 to 40 years with cancer have not experienced survival improvements to the same extent as younger and older patients We compared changes in survival after myeloablative allogeneic hematopoietic cell transplantation HCT for acute lymphoblastic ALL among children n 981 AYAs n 1218 and older adults n 469 who underwent transplantation over 3 time periods 1990 to 1995 1996 to 2001 and 2002 to 2007 Five-year survival varied inversely with age group Survival improved over time in AYAs and paralleled that seen in children however overall survival did not change over time for older adults Survival improvements were primarily related to lower rates of early treatment-related mortality in the most recent era For all cohorts relapse rates did not change over time A subset of 222 AYAs between the ages of 15 and 25 at 46 pediatric or 49 adult centers were also analyzed to describe differences by center type In this subgroup there were differences in transplantation practices among pediatric and adult centers although HCT outcomes did not differ by center type Survival for AYAs undergoing myeloablative allogeneic HCT for ALL improved at a similar rate as survival for children,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3101, 2, 1169, 857, 6145, 2165, 167, 6, 327, 60, 5, 12, 47, 44, 592, 25, 1474, 6, 3, 827, 1039, 22, 773, 2, 434, 7, 21, 72, 400, 4, 25, 50, 3246, 1063, 1007, 31, 497, 1085, 9, 286, 1275, 62, 107, 541, 78, 17946, 6145, 78, 31156, 2, 434, 857, 78, 9747, 54, 208, 497, 252, 27, 98, 3338, 2289, 6, 2323, 2648, 6, 1758, 2, 1544, 6, 1307, 365, 111, 25, 2051, 2659, 5, 89, 87, 25, 231, 252, 98, 4, 6145, 2, 10591, 17, 527, 4, 541, 137, 63, 25, 205, 44, 707, 252, 98, 9, 434, 857, 25, 1474, 11, 1561, 139, 6, 280, 151, 1, 191, 24, 139, 282, 4, 3, 96, 435, 1713, 9, 62, 736, 429, 151, 205, 44, 707, 252, 98, 8, 697, 1, 5647, 6145, 59, 3, 2165, 1, 167, 2, 243, 28, 641, 815, 15, 739, 780, 1168, 11, 120, 311, 6, 897, 362, 20, 574, 267, 4, 26, 1363, 125, 11, 362, 4, 497, 2634, 107, 815, 2, 780, 1168, 242, 1085, 123, 205, 44, 1505, 20, 574, 267, 25, 9, 6145, 479, 3246, 1063, 1085, 9, 62, 231, 28, 8, 288, 116, 22, 25, 9, 541]",1220.0,24607554,3
Bone turnover in long-term survivors of childhood acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2014-03-20,"We investigated the effects of demographic, lifestyle (self-reported smoking status and physical activity levels), cancer-related treatment factors (radiation and chemotherapy), and diet (calcium and vitamin D intake) on bone turnover and the relationship of bone turnover to lumbar spine bone mineral density (BMD) Z-scores (LS-BMD Z-scores) determined by quantitative computed tomography (QCT) in 418 5-year survivors of childhood acute lymphoblastic leukemia (ALL). Bone turnover was assessed by biomarkers including serum bone-specific alkaline phosphatase (BALP), osteocalcin (OC), and urinary N-telopeptide of type I collagen indexed to creatinine (NTX/Cr). The 215 males ranged in age from 9 to 36 years (median age 17 years). Age and tanner score were inversely associated with all biomarkers (BALP, OC, NTX/Cr) (P<0.001). Males had higher BALP and OC than females (P<0.001). Body mass index (BMI) was inversely associated with OC and NTX/Cr (P<0.001). There was no significant association of biomarkers with lifestyle related factors, ALL treatment-related factors, dietary calcium, vitamin D, or LS-BMD Z-score. In this population of long-term survivors of ALL, bone turnover was significantly associated with age, gender, tanner stage, and BMI. ALL-related treatments did not influence bone turnover and bone turnover was not predictive of volumetric LS-BMD Z-score.",Journal Article,2133.0,7.0,We investigated the effects of demographic lifestyle self-reported smoking status and physical activity levels cancer-related treatment factors radiation and chemotherapy and diet calcium and vitamin D intake on turnover and the relationship of turnover to lumbar spine mineral density BMD Z-scores LS-BMD Z-scores determined by quantitative computed tomography QCT in 418 5-year survivors of childhood acute lymphoblastic ALL turnover was assessed by biomarkers including serum bone-specific alkaline phosphatase BALP osteocalcin OC and urinary N-telopeptide of type I collagen indexed to creatinine NTX/Cr The 215 males ranged in age from 9 to 36 years median age 17 years Age and tanner score were inversely associated with all biomarkers BALP OC NTX/Cr P 0.001 Males had higher BALP and OC than females P 0.001 Body mass index BMI was inversely associated with OC and NTX/Cr P 0.001 There was no significant association of biomarkers with lifestyle related factors ALL treatment-related factors dietary calcium vitamin D or LS-BMD Z-score In this population of long-term survivors of ALL turnover was significantly associated with age gender tanner stage and BMI ALL-related treatments did not influence turnover and turnover was not predictive of volumetric LS-BMD Z-score,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 565, 3, 176, 1, 1540, 3487, 1074, 210, 979, 156, 2, 900, 128, 148, 12, 139, 24, 130, 121, 2, 56, 2, 2453, 3299, 2, 1610, 427, 1514, 23, 5445, 2, 3, 858, 1, 5445, 6, 6187, 2342, 5033, 1263, 3503, 3905, 703, 3153, 3503, 3905, 703, 509, 20, 1156, 1220, 872, 19031, 4, 10387, 4126, 111, 332, 1, 864, 286, 1275, 62, 5445, 10, 275, 20, 582, 141, 524, 3417, 112, 5355, 2577, 40657, 15282, 2950, 2, 1660, 78, 9466, 1, 267, 70, 3945, 20500, 6, 3177, 8110, 684, 3, 6511, 2296, 1869, 4, 89, 29, 83, 6, 511, 60, 52, 89, 269, 60, 89, 2, 17471, 368, 11, 2659, 41, 5, 62, 582, 40657, 2950, 8110, 684, 19, 13, 144, 2296, 42, 142, 40657, 2, 2950, 76, 2451, 19, 13, 144, 642, 782, 558, 1140, 10, 2659, 41, 5, 2950, 2, 8110, 684, 19, 13, 144, 125, 10, 77, 93, 248, 1, 582, 5, 3487, 139, 130, 62, 24, 139, 130, 2013, 3299, 1610, 427, 15, 3153, 3503, 3905, 368, 4, 26, 266, 1, 319, 337, 332, 1, 62, 5445, 10, 97, 41, 5, 89, 1632, 17471, 82, 2, 1140, 62, 139, 640, 205, 44, 1054, 5445, 2, 5445, 10, 44, 464, 1, 4083, 3153, 3503, 3905, 368]",1278.0,24648266,181
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.,American journal of hematology,Am. J. Hematol.,2014-03-01,"Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phase of chronic myelogenous leukemia (CML-LB) (n515) with the combination of dasatinib and the hyper CVAD regimen. Prior regimens included hyper CVAD plus imatinib(n511, 4 had transplant in first CR), other combination chemotherapy (n512), monotherapy with kinase inhibitors other than dasatinib (n59), and investigational agents (n52). Pretreatment ABL mutations were noted in 10 patients. The overall response rate was 91%, with 24 patients (71%) achieving complete response(CR), and 7(21%) CR with incomplete platelet recovery (CRp). Two patients died during induction and one had progressive disease. Twenty-six patients (84%) achieved complete cytogenetic remission after one cycle of therapy. Overall, 13 patients (42%) achieved complete molecular response, and 11 patients (35%) had major molecular response (BCR-ABL/ABL<0.1%). Nine patients proceeded to allogeneic transplantation.Grades 3 and 4 toxicities included hemorrhage, pleural and pericardial effusions and infections. The median follow-up for patients with CML-LB is 37.5 months (range, 770 months) with a 3-year overall survival of 70%;68% remained in CR at 3 years. For ALL patients, the median follow-up is 52 months (range, 4559 months)with a 3-year survival of 26%; 30% remain in CR at 3 years. The combination of Hyper CVAD regimen with dasatinib is effective in patients with relapsed Ph-positive ALL and CML-LB.","Clinical Trial, Phase II",2152.0,35.0,Dasatinib is a second generation tyrosine kinase inhibitor with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic ALL n519 or lymphoid blast phase of chronic myelogenous CML-LB n515 with the combination of dasatinib and the hyper CVAD regimen Prior regimens included hyper CVAD plus imatinib n511 4 had transplant in first CR other combination chemotherapy n512 monotherapy with kinase inhibitors other than dasatinib n59 and investigational agents n52 Pretreatment ABL mutations were noted in 10 patients The overall response rate was 91 with 24 patients 71 achieving complete response CR and 7 21 CR with incomplete platelet recovery CRp Two patients died during induction and one had progressive disease Twenty-six patients 84 achieved complete cytogenetic remission after one cycle of therapy Overall 13 patients 42 achieved complete molecular response and 11 patients 35 had major molecular response BCR-ABL/ABL 0.1 Nine patients proceeded to allogeneic transplantation.Grades 3 and 4 toxicities included hemorrhage pleural and pericardial effusions and infections The median follow-up for patients with CML-LB is 37.5 months range 770 months with a 3-year overall survival of 70 68 remained in CR at 3 years For ALL patients the median follow-up is 52 months range 4559 months with a 3-year survival of 26 30 remain in CR at 3 years The combination of Hyper CVAD regimen with dasatinib is effective in patients with relapsed Ph-positive ALL and CML-LB,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1674, 16, 8, 419, 914, 564, 216, 230, 5, 128, 4, 577, 436, 2058, 109, 62, 21, 47, 73, 562, 7, 5, 591, 3006, 1170, 109, 286, 1275, 62, 64282, 15, 2303, 3112, 124, 1, 442, 2194, 903, 13121, 64283, 5, 3, 150, 1, 1674, 2, 3, 4855, 5574, 477, 324, 472, 159, 4855, 5574, 349, 577, 64284, 39, 42, 941, 4, 157, 684, 127, 150, 56, 64285, 1411, 5, 216, 222, 127, 76, 1674, 64286, 2, 3093, 183, 64287, 1194, 1425, 138, 11, 1051, 4, 79, 7, 3, 63, 51, 116, 10, 970, 5, 259, 7, 792, 1785, 236, 51, 684, 2, 67, 239, 684, 5, 2610, 1596, 1602, 3162, 100, 7, 1016, 190, 504, 2, 104, 42, 1014, 34, 737, 437, 7, 874, 513, 236, 1266, 734, 50, 104, 417, 1, 36, 63, 233, 7, 595, 513, 236, 219, 51, 2, 175, 7, 465, 42, 458, 219, 51, 1062, 1425, 1425, 13, 14, 762, 7, 6406, 6, 1063, 497, 2276, 27, 2, 39, 385, 159, 3599, 2164, 2, 6657, 5154, 2, 1875, 3, 52, 166, 126, 9, 7, 5, 903, 13121, 16, 567, 33, 53, 184, 64288, 53, 5, 8, 27, 111, 63, 25, 1, 431, 806, 958, 4, 684, 28, 27, 60, 9, 62, 7, 3, 52, 166, 126, 16, 653, 53, 184, 64289, 53, 5, 8, 27, 111, 25, 1, 432, 201, 918, 4, 684, 28, 27, 60, 3, 150, 1, 4855, 5574, 477, 5, 1674, 16, 323, 4, 7, 5, 591, 2058, 109, 62, 2, 903, 13121]",1551.0,24779033,136
Inhibition of calcineurin combined with dasatinib has direct and indirect anti-leukemia effects against BCR-ABL1(+) leukemia.,American journal of hematology,Am. J. Hematol.,2014-06-19,"Treatment of BCR-ABL1(+) leukemia has been revolutionized with the development of tyrosine kinase inhibitors. However, patients with BCR-ABL1(+) acute lymphoblastic leukemia and subsets of patients with chronic myeloid leukemia are at high risk of relapse despite kinase inhibition therapy, necessitating novel treatment strategies. We previously reported synthetic lethality in BCR-ABL1(+) leukemia cells by blocking both calcineurin/NFAT signaling and BCR-ABL1, independent of drug efflux inhibition by cyclosporine. Here, using RNA-interference we confirm that calcineurin inhibition sensitizes BCR-ABL1(+) cells to tyrosine kinase inhibition in vitro. However, when we performed pharmacokinetic and pharmacodynamic studies of dasatinib and cyclosporine in mice, we found that co-administration of cyclosporine increases peak concentrations and the area under the curve of dasatinib, which contributes to the enhanced disease control. We also report the clinical experience of two subjects in whom we observed more hematopoietic toxicity than expected while enrolled in a Phase Ib trial designed to assess the safety and tolerability of adding cyclosporine to dasatinib in humans. Thus, the anti-leukemia benefit of co-administration of cyclosporine and dasatinib is mechanistically pleiotropic, but may not be tolerable, at least as administered in this trial. These data highlight some of the challenges associated with combining targeted agents to treat leukemia.","Clinical Trial, Phase I",2042.0,8.0,Treatment of BCR-ABL1 has been revolutionized with the development of tyrosine kinase inhibitors However patients with BCR-ABL1 acute lymphoblastic and subsets of patients with chronic myeloid are at high risk of relapse despite kinase inhibition therapy necessitating novel treatment strategies We previously reported synthetic lethality in BCR-ABL1 cells by blocking both calcineurin/NFAT signaling and BCR-ABL1 independent of drug efflux inhibition by cyclosporine Here using RNA-interference we confirm that calcineurin inhibition sensitizes BCR-ABL1 cells to tyrosine kinase inhibition in vitro However when we performed pharmacokinetic and pharmacodynamic studies of dasatinib and cyclosporine in mice we found that co-administration of cyclosporine increases peak concentrations and the area under the curve of dasatinib which contributes to the enhanced disease control We also report the clinical experience of two subjects in whom we observed more hematopoietic toxicity than expected while enrolled in a Phase Ib trial designed to assess the safety and tolerability of adding cyclosporine to dasatinib in humans Thus the anti-leukemia benefit of co-administration of cyclosporine and dasatinib is mechanistically pleiotropic but may not be tolerable at least as administered in this trial These data highlight some of the challenges associated with combining targeted agents to treat,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 1062, 3557, 71, 85, 5746, 5, 3, 193, 1, 564, 216, 222, 137, 7, 5, 1062, 3557, 286, 1275, 2, 1890, 1, 7, 5, 442, 533, 32, 28, 64, 43, 1, 429, 550, 216, 297, 36, 8365, 229, 24, 422, 21, 373, 210, 3273, 3266, 4, 1062, 3557, 37, 20, 2521, 110, 12028, 19518, 314, 2, 1062, 3557, 306, 1, 234, 7043, 297, 20, 9112, 467, 75, 893, 3182, 21, 1843, 17, 12028, 297, 6229, 1062, 3557, 37, 6, 564, 216, 297, 4, 439, 137, 198, 21, 173, 1456, 2, 2424, 94, 1, 1674, 2, 9112, 4, 399, 21, 204, 17, 1269, 634, 1, 9112, 1106, 2944, 1003, 2, 3, 965, 669, 3, 1496, 1, 1674, 92, 2444, 6, 3, 651, 34, 182, 21, 120, 414, 3, 38, 730, 1, 100, 976, 4, 953, 21, 164, 80, 1007, 155, 76, 1336, 369, 346, 4, 8, 124, 3180, 160, 1114, 6, 423, 3, 367, 2, 1543, 1, 2726, 9112, 6, 1674, 4, 3218, 631, 3, 312, 2647, 247, 1, 1269, 634, 1, 9112, 2, 1674, 16, 4187, 7872, 84, 68, 44, 40, 2668, 28, 506, 22, 468, 4, 26, 160, 46, 74, 1817, 476, 1, 3, 1427, 41, 5, 1525, 238, 183, 6, 943]",1394.0,24891015,119
Polymorphisms of asparaginase pathway and asparaginase-related complications in children with acute lymphoblastic leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2014-06-06,"Asparaginase (ASNase) is a standard and critical component in the therapy of childhood acute lymphoblastic leukemia (ALL), but it is also associated with several toxicities. We recently reported the results of an association study between ASNase pathway genes and event-free survival (EFS) in childhood patients with ALL. The same polymorphisms were interrogated here in relation to allergies, pancreatitis, and thrombotic events following treatment with E. coli ASNase. Among patients of the discovery group, allergies, and pancreatitis were more frequent in individuals who are homozygous for the triple-repeat allele (3R) of the asparagine synthetase (ASNS) gene, resulting in remarkably higher risk of these toxicities associated with 3R3R genotype [OR for allergies, 14.6; 95% confidence interval (CI), 3.6-58.7; P < 0.0005 and OR for pancreatitis, 8.6; 95% CI, 2.0-37.3; P = 0.01]. In contrast, the ASNS haplotype *1 harboring double-repeat (2R) allele had protective effect against these adverse reactions (P  0.01). The same haplotype was previously reported to confer reduction in EFS. The risk effect of 3R3R genotype was not replicated in the validation cohort, whereas the protective effect of haplotype *1 against allergies was maintained (P  0.002). Analysis with additional polymorphisms in ASNS locus in lymphoblastoid cell lines showed that haplotype *1 is diversified in several subtypes of which one was associated with reduced in vitro sensitivity to ASNase (rs10486009, P = 0.01) possibly explaining an association seen in clinical setting. This finding might have implication for treatment individualization in ALL and other cancers using asparagine depletion strategies. Clin Cancer Res; 21(2); 329-34. 2014 AACR. See related commentary by Avramis, p. 230.",Journal Article,2055.0,32.0,Asparaginase ASNase is a standard and critical component in the therapy of childhood acute lymphoblastic ALL but it is also associated with several toxicities We recently reported the results of an association study between ASNase pathway genes and event-free survival EFS in childhood patients with ALL The same polymorphisms were interrogated here in relation to allergies pancreatitis and thrombotic events following treatment with E. coli ASNase Among patients of the discovery group allergies and pancreatitis were more frequent in individuals who are homozygous for the triple-repeat allele 3R of the asparagine synthetase ASNS gene resulting in remarkably higher risk of these toxicities associated with 3R3R genotype OR for allergies 14.6 95 confidence interval CI 3.6-58.7 P 0.0005 and OR for pancreatitis 8.6 95 CI 2.0-37.3 P 0.01 In contrast the ASNS haplotype *1 harboring double-repeat 2R allele had protective effect against these adverse reactions P  0.01 The same haplotype was previously reported to confer reduction in EFS The risk effect of 3R3R genotype was not replicated in the validation cohort whereas the protective effect of haplotype *1 against allergies was maintained P  0.002 Analysis with additional polymorphisms in ASNS locus in lymphoblastoid cell lines showed that haplotype *1 is diversified in several subtypes of which one was associated with reduced in vitro sensitivity to ASNase rs10486009 P 0.01 possibly explaining an association seen in clinical setting This finding might have implication for treatment individualization in ALL and other cancers using asparagine depletion strategies Clin Cancer Res 21 2 329-34 2014 AACR See related commentary by Avramis p. 230,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 16558, 16, 8, 260, 2, 740, 1249, 4, 3, 36, 1, 864, 286, 1275, 62, 84, 192, 16, 120, 41, 5, 392, 385, 21, 761, 210, 3, 99, 1, 35, 248, 45, 59, 16558, 308, 214, 2, 774, 115, 25, 1683, 4, 864, 7, 5, 62, 3, 827, 1203, 11, 7227, 467, 4, 2191, 6, 16021, 4535, 2, 6108, 281, 366, 24, 5, 563, 6959, 16558, 107, 7, 1, 3, 1574, 87, 16021, 2, 4535, 11, 80, 908, 4, 869, 54, 32, 3189, 9, 3, 1500, 2334, 1254, 22255, 1, 3, 14108, 12692, 16063, 145, 1113, 4, 4856, 142, 43, 1, 46, 385, 41, 5, 48415, 1183, 15, 9, 16021, 213, 49, 48, 307, 268, 58, 27, 49, 717, 67, 19, 13, 4252, 2, 15, 9, 4535, 66, 49, 48, 58, 18, 13, 567, 27, 19, 13, 355, 4, 748, 3, 16063, 4179, 14, 2105, 1627, 2334, 8145, 1254, 42, 2864, 254, 480, 46, 290, 2428, 19, 1552, 13, 355, 3, 827, 4179, 10, 373, 210, 6, 2913, 628, 4, 1683, 3, 43, 254, 1, 48415, 1183, 10, 44, 6714, 4, 3, 929, 180, 547, 3, 2864, 254, 1, 4179, 14, 480, 16021, 10, 1955, 19, 1552, 13, 1111, 65, 5, 402, 1203, 4, 16063, 2474, 4, 10994, 31, 285, 224, 17, 4179, 14, 16, 25188, 4, 392, 814, 1, 92, 104, 10, 41, 5, 405, 4, 439, 485, 6, 16558, 64478, 19, 13, 355, 2150, 8290, 35, 248, 527, 4, 38, 546, 26, 1567, 822, 47, 8969, 9, 24, 9764, 4, 62, 2, 127, 163, 75, 14108, 2286, 422, 2459, 12, 1936, 239, 18, 8766, 562, 19354, 1630, 3764, 139, 4662, 20, 64479, 19, 6136]",1710.0,24907114,615
The poison oligonucleotide F10 is highly effective against acute lymphoblastic leukemia while sparing normal hematopoietic cells.,Oncotarget,Oncotarget,2014-06-01,"F10 is an oligonucleotide based on the thymidylate synthase (TS) inhibitory 5-fluorouracil (5-FU) metabolite, 5-fluoro-2'-deoxyuridine-5'-O-monophosphate. We sought to determine the activity of F10 against preclinical models of acute lymphoblastic leukemia (ALL). F10 treatment resulted in robust induction of apoptosis that could not be equaled by 100 fold more 5-FU. F10 was more potent than Ara-C and doxorubicin against a panel of murine and human ALL cells with an average IC50 value of 1.48 nM (range 0.07 to 5.4 nM). F10 was more than 1000 times more potent than 5-FU. In vivo, F10 treatment significantly increased survival in 2 separate syngeneic ALL mouse models and 3 separate xenograft models. F10 also protected mice from leukemia-induced weight loss. In ALL cells made resistant to Ara-C, F10 remained highly active in vitro and in vivo. Using labeled F10, uptake by the ALL cell lines DG75 and SUP-B15 was rapid and profoundly temperature-dependent. Both cell lines demonstrated increased uptake compared to normal murine lineage- depleted marrow cells. Consistent with this decreased uptake, F10 treatment did not alter the ability of human hematopoietic stem cells to engraft in immunodeficient mice. ",Journal Article,2060.0,7.0,F10 is an oligonucleotide based on the thymidylate synthase TS inhibitory 5-fluorouracil 5-FU metabolite 5-fluoro-2'-deoxyuridine-5'-O-monophosphate We sought to determine the activity of F10 against preclinical models of acute lymphoblastic ALL F10 treatment resulted in robust induction of apoptosis that could not be equaled by 100 fold more 5-FU F10 was more potent than Ara-C and doxorubicin against a panel of murine and human ALL cells with an average IC50 value of 1.48 nM range 0.07 to 5.4 nM F10 was more than 1000 times more potent than 5-FU In vivo F10 treatment significantly increased survival in 2 separate syngeneic ALL mouse models and 3 separate xenograft models F10 also protected mice from leukemia-induced weight loss In ALL cells made resistant to Ara-C F10 remained highly active in vitro and in vivo Using labeled F10 uptake by the ALL cell lines DG75 and SUP-B15 was rapid and profoundly temperature-dependent Both cell lines demonstrated increased uptake compared to normal murine lineage- depleted marrow cells Consistent with this decreased uptake F10 treatment did not alter the ability of human hematopoietic stem cells to engraft in immunodeficient mice,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[13068, 16, 35, 4727, 90, 23, 3, 6205, 3522, 3527, 1810, 33, 1404, 33, 1296, 3379, 33, 6231, 6135, 15904, 7344, 1990, 15642, 21, 990, 6, 223, 3, 128, 1, 13068, 480, 693, 274, 1, 286, 1275, 62, 13068, 24, 627, 4, 1922, 504, 1, 351, 17, 359, 44, 40, 64542, 20, 394, 1116, 80, 33, 1296, 13068, 10, 80, 1157, 76, 3899, 256, 2, 856, 480, 8, 993, 1, 1471, 2, 171, 62, 37, 5, 35, 1011, 5211, 549, 1, 14, 576, 2878, 184, 13, 1615, 6, 33, 39, 2878, 13068, 10, 80, 76, 2345, 1072, 80, 1157, 76, 33, 1296, 4, 386, 13068, 24, 97, 101, 25, 4, 18, 2282, 5174, 62, 830, 274, 2, 27, 2282, 1330, 274, 13068, 120, 5541, 399, 29, 2647, 277, 924, 407, 4, 62, 37, 1229, 436, 6, 3899, 256, 13068, 958, 561, 544, 4, 439, 2, 4, 386, 75, 2841, 13068, 1135, 20, 3, 62, 31, 285, 64543, 2, 172, 48449, 10, 1321, 2, 8802, 6882, 470, 110, 31, 285, 264, 101, 1135, 72, 6, 295, 1471, 2542, 4358, 581, 37, 925, 5, 26, 340, 1135, 13068, 24, 205, 44, 2688, 3, 801, 1, 171, 1007, 452, 37, 6, 12343, 4, 5031, 399]",1184.0,24961587,4
Feasibility and initial effectiveness of home exercise during maintenance therapy for childhood acute lymphoblastic leukemia.,Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association,Pediatr Phys Ther,2014-01-01,"Children with acute lymphoblastic leukemia (ALL) are at increased risk of obesity and deconditioning from cancer therapy. This pilot study assessed feasibility/initial efficacy of an exercise intervention for patients with ALL undergoing maintenance therapy. Participants were aged 5 to 10 years, receiving maintenance therapy, in first remission. A 6-month home-based intervention, with written and video instruction, was supervised with weekly calls from an exercise coach. Pre- and poststudy testing addressed strength, flexibility, fitness, and motor function. Seventeen patients enrolled (participation 63%). Twelve (71%) finished the intervention, completing 81.7  7.2% of prescribed sessions. Improvements of 5% or more occurred in 67% for knee and 75% for grip strength, 58% for hamstring/low-back and 83% for ankle flexibility, 75% for the 6-Minute Walk Test, and 33% for performance on the Bruininks-Oseretsky Test of Motor Proficiency Version 2. This pilot study demonstrated that exercise intervention during ALL therapy is feasible and has promise for efficacy.",Journal Article,2211.0,21.0,Children with acute lymphoblastic ALL are at increased risk of obesity and deconditioning from cancer therapy This pilot study assessed feasibility/initial efficacy of an exercise intervention for patients with ALL undergoing maintenance therapy Participants were aged 5 to 10 years receiving maintenance therapy in first remission A 6-month home-based intervention with written and video instruction was supervised with weekly calls from an exercise coach Pre- and poststudy testing addressed strength flexibility fitness and motor function Seventeen patients enrolled participation 63 Twelve 71 finished the intervention completing 81.7  7.2 of prescribed sessions Improvements of 5 or more occurred in 67 for knee and 75 for grip strength 58 for hamstring/low-back and 83 for ankle flexibility 75 for the 6-Minute Walk Test and 33 for performance on the Bruininks-Oseretsky Test of Motor Proficiency Version 2 This pilot study demonstrated that exercise intervention during ALL therapy is feasible and has promise for efficacy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 286, 1275, 62, 32, 28, 101, 43, 1, 1661, 2, 48455, 29, 12, 36, 26, 2281, 45, 275, 1437, 388, 209, 1, 35, 2277, 788, 9, 7, 5, 62, 479, 1146, 36, 776, 11, 1032, 33, 6, 79, 60, 357, 1146, 36, 4, 157, 734, 8, 49, 811, 3249, 90, 788, 5, 6538, 2, 4139, 19661, 10, 7762, 5, 709, 6467, 29, 35, 2277, 40766, 671, 2, 38684, 471, 2814, 3671, 9794, 5959, 2, 3482, 343, 3591, 7, 346, 2599, 676, 2544, 792, 20455, 3, 788, 4144, 865, 67, 810, 67, 18, 1, 2746, 4390, 1474, 1, 33, 15, 80, 489, 4, 598, 9, 12013, 2, 481, 9, 16562, 3671, 717, 9, 48456, 154, 4636, 2, 852, 9, 17288, 9794, 481, 9, 3, 49, 3949, 8200, 412, 2, 466, 9, 528, 23, 3, 48457, 48458, 412, 1, 3482, 11266, 2256, 18, 26, 2281, 45, 264, 17, 2277, 788, 190, 62, 36, 16, 1313, 2, 71, 1783, 9, 209]",1030.0,24979081,282
Maturation stage of T-cell acute lymphoblastic leukemia determines BCL-2 versus BCL-XL dependence and sensitivity to ABT-199.,Cancer discovery,Cancer Discov,2014-07-03,"Acute lymphoblastic leukemia (ALL) is a hematopoietic malignancy derived from immature B-lymphoid and T-lymphoid cells (T-ALL). In T-ALL, there is an early T-cell progenitor (ETP) subgroup that has a very high risk for relapse. In this study, we used mitochondrial BH3 profiling to determine antiapoptotic protein dependencies in T-ALL. We found that T-ALL cell lines and primary patient samples are dependent upon BCL-XL, except when the cancer bears an ETP phenotype, in which case it is BCL-2 dependent. These distinctions directly relate to differential sensitivity to the BH3 mimetics ABT-263 and ABT-199, both in vitro and in vivo. We thus describe for the first time a change of antiapoptotic protein dependence that is related to the differentiation stage of the leukemic clone. Our findings demonstrate that BCL-2 is a clinically relevant target for therapeutic intervention with ABT-199 in ETP-ALL. ETP T-ALL is a treatment-resistant subtype of T-ALL for which novel targeted therapies are urgently needed. We have discovered, through BH3 profiling, that ETP-ALL is BCL-2 dependent and is very sensitive to in vitro and in vivo treatment with ABT-199, a drug well tolerated in clinical trials.",Journal Article,2028.0,78.0,Acute lymphoblastic ALL is a hematopoietic malignancy derived from immature B-lymphoid and T-lymphoid cells T-ALL In T-ALL there is an early T-cell progenitor ETP subgroup that has a very high risk for relapse In this study we used mitochondrial BH3 profiling to determine antiapoptotic protein dependencies in T-ALL We found that T-ALL cell lines and primary patient samples are dependent upon BCL-XL except when the cancer bears an ETP phenotype in which case it is BCL-2 dependent These distinctions directly relate to differential sensitivity to the BH3 mimetics ABT-263 and ABT-199 both in vitro and in vivo We thus describe for the first time a change of antiapoptotic protein dependence that is related to the differentiation stage of the leukemic clone Our findings demonstrate that BCL-2 is a clinically relevant target for therapeutic intervention with ABT-199 in ETP-ALL ETP T-ALL is a treatment-resistant subtype of T-ALL for which novel targeted therapies are urgently needed We have discovered through BH3 profiling that ETP-ALL is BCL-2 dependent and is very sensitive to in vitro and in vivo treatment with ABT-199 a drug well tolerated in clinical trials,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 1007, 710, 526, 29, 5733, 132, 2303, 2, 102, 2303, 37, 102, 62, 4, 102, 62, 125, 16, 35, 191, 102, 31, 2520, 11985, 1363, 17, 71, 8, 923, 64, 43, 9, 429, 4, 26, 45, 21, 95, 2019, 5486, 1080, 6, 223, 4176, 178, 11508, 4, 102, 62, 21, 204, 17, 102, 62, 31, 285, 2, 86, 69, 347, 32, 470, 1548, 1044, 3870, 2187, 198, 3, 12, 15827, 35, 11985, 1005, 4, 92, 473, 192, 16, 1044, 18, 470, 46, 16834, 1606, 6509, 6, 1777, 485, 6, 3, 5486, 12446, 3095, 6098, 2, 3095, 5840, 110, 4, 439, 2, 4, 386, 21, 631, 897, 9, 3, 157, 98, 8, 707, 1, 4176, 178, 3721, 17, 16, 139, 6, 3, 910, 82, 1, 3, 2015, 3910, 114, 272, 608, 17, 1044, 18, 16, 8, 505, 867, 283, 9, 189, 788, 5, 3095, 5840, 4, 11985, 62, 11985, 102, 62, 16, 8, 24, 436, 875, 1, 102, 62, 9, 92, 229, 238, 235, 32, 5354, 575, 21, 47, 2747, 298, 5486, 1080, 17, 11985, 62, 16, 1044, 18, 470, 2, 16, 923, 745, 6, 4, 439, 2, 4, 386, 24, 5, 3095, 5840, 8, 234, 149, 421, 4, 38, 143]",1171.0,24994123,200
The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia.,Haematologica,Haematologica,2014-07-04,"The transcription factor Sox4 plays an indispensable role in the development of early progenitor B cells from hematopoietic stem cells. However, its role in B-cell acute lymphoblastic leukemia, a malignant counterpart of normal progenitor B cells, is not fully understood. Here we show that SOX4 is highly expressed in human acute lymphoblastic leukemia cells. To systematically study the function of Sox4 in acute lymphoblastic leukemia, we established a genetically defined mouse leukemia model by transforming progenitor B cells carrying a floxed Sox4 allele and inducing deletion of the allele by the self-excising Cre recombinase. This model allowed us to work with two groups of leukemic cells that had either one copy or both copies of Sox4 deleted. We found that depletion of Sox4 in transformed cells in vitro reduced cell growth in vitro and the progression of leukemia in vivo. Moreover, depletion of Sox4 in leukemic cells in vivo prolonged the survival of the mice, suggesting that it could be a potential target in acute lymphoblastic leukemia therapy. Our microarray and bioChIP studies revealed that Tcf7l1 was the key gene directly regulated by Sox4. Knockdown of Tcf7l1 reduced cell proliferation, just as did knockout of Sox4, and ectopic expression of Tcf7l1 could reverse the effect of Sox4 knockout on cell proliferation. These data suggest that Sox4 and Tcf7l1 form a functional axis that promotes the progression of BCR-ABL-positive acute lymphoblastic leukemia. ",Journal Article,2027.0,16.0,The transcription factor Sox4 plays an indispensable role in the development of early progenitor B cells from hematopoietic stem cells However its role in B-cell acute lymphoblastic a malignant counterpart of normal progenitor B cells is not fully understood Here we show that SOX4 is highly expressed in human acute lymphoblastic cells To systematically study the function of Sox4 in acute lymphoblastic we established a genetically defined mouse model by transforming progenitor B cells carrying a floxed Sox4 allele and inducing deletion of the allele by the self-excising Cre recombinase This model allowed us to work with two groups of leukemic cells that had either one copy or both copies of Sox4 deleted We found that depletion of Sox4 in transformed cells in vitro reduced cell growth in vitro and the progression of in vivo Moreover depletion of Sox4 in leukemic cells in vivo prolonged the survival of the mice suggesting that it could be a potential target in acute lymphoblastic therapy Our microarray and bioChIP studies revealed that Tcf7l1 was the key gene directly regulated by Sox4 Knockdown of Tcf7l1 reduced cell proliferation just as did knockout of Sox4 and ectopic expression of Tcf7l1 could reverse the effect of Sox4 knockout on cell proliferation These data suggest that Sox4 and Tcf7l1 form a functional axis that promotes the progression of BCR-ABL-positive acute lymphoblastic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 866, 161, 16572, 1698, 35, 13338, 200, 4, 3, 193, 1, 191, 2520, 132, 37, 29, 1007, 452, 37, 137, 211, 200, 4, 132, 31, 286, 1275, 8, 393, 10423, 1, 295, 2520, 132, 37, 16, 44, 1910, 1784, 467, 21, 514, 17, 16572, 16, 561, 570, 4, 171, 286, 1275, 37, 6, 3390, 45, 3, 343, 1, 16572, 4, 286, 1275, 21, 635, 8, 2301, 395, 830, 202, 20, 3621, 2520, 132, 37, 2934, 8, 28322, 16572, 1254, 2, 1958, 1528, 1, 3, 1254, 20, 3, 1074, 37678, 7102, 23393, 26, 202, 2313, 843, 6, 1357, 5, 100, 271, 1, 2015, 37, 17, 42, 361, 104, 1337, 15, 110, 5127, 1, 16572, 4389, 21, 204, 17, 2286, 1, 16572, 4, 2423, 37, 4, 439, 405, 31, 129, 4, 439, 2, 3, 91, 1, 4, 386, 1393, 2286, 1, 16572, 4, 2015, 37, 4, 386, 1069, 3, 25, 1, 3, 399, 802, 17, 192, 359, 40, 8, 174, 283, 4, 286, 1275, 36, 114, 1727, 2, 48466, 94, 553, 17, 35837, 10, 3, 825, 145, 1606, 1065, 20, 16572, 1563, 1, 35837, 405, 31, 457, 4673, 22, 205, 5687, 1, 16572, 2, 3647, 55, 1, 35837, 359, 1772, 3, 254, 1, 16572, 5687, 23, 31, 457, 46, 74, 309, 17, 16572, 2, 35837, 1297, 8, 583, 2310, 17, 2148, 3, 91, 1, 1062, 1425, 109, 286, 1275]",1405.0,24997151,173
Neurologic morbidity and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross-sectional study.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2014-07-10,"Childhood acute lymphoblastic leukemia (ALL) is treated with potentially neurotoxic drugs and neurologic complications in long-term survivors are inadequately studied. This study investigated neurologic morbidity and its effect on quality of life in long-term survivors of childhood ALL. Prospective, single institution, cross-sectional, institutional review board-approved study of long-term ALL survivors. Participants were recruited from institutional clinics. Participants answered an investigator-administered questionnaire followed by evaluation by a neurologist. Quality of life (QOL) was also assessed. Of the 162 participants recruited over a 3-year period, 83.3% reported at least one neurologic symptom of interest, 16.7% had single symptom, 11.1% had two symptoms, and 55.6% had three or more symptoms. Symptoms were mild and disability was low in the majority of participants with neurologic symptoms. Median age at ALL diagnosis was 3.9 years (0.4-18.6), median age at study enrollment was 15.7 years (6.9-28.9), and median time from completion of ALL therapy was 7.4 years (1.9-20.3). On multivariable analyses, female sex correlated with presence of dizziness, urinary incontinence, constipation, and neuropathy; use of10 doses of triple intrathecal chemotherapy correlated with urinary incontinence, back pain, and neuropathy; cranial radiation with ataxia; history of ALL relapse with fatigue; and CNS leukemia at diagnosis with seizures. Decline in mental QOL was associated with migraine and tension type headaches, while physical QOL was impaired by presence of dizziness and falls. Overall, good QOL and physical function was maintained by a majority of participants. Neurologic symptoms were present in 83% long-term ALL survivors. Symptoms related morbidity and QOL impairment is low in majority of survivors. Female sex, 10 doses of intrathecal chemotherapy, and history of ALL relapse predispose to impaired QOL. This study will educate survivors and their care providers regarding cancer or treatment-related neurologic symptoms and morbidity. This study will help them understand factors contributing to impaired QOL when present.",Journal Article,2021.0,19.0,Childhood acute lymphoblastic ALL is treated with potentially neurotoxic drugs and neurologic complications in long-term survivors are inadequately studied This study investigated neurologic morbidity and its effect on quality of life in long-term survivors of childhood ALL Prospective single institution cross-sectional institutional review board-approved study of long-term ALL survivors Participants were recruited from institutional clinics Participants answered an investigator-administered questionnaire followed by evaluation by a neurologist Quality of life QOL was also assessed Of the 162 participants recruited over a 3-year period 83.3 reported at least one neurologic symptom of interest 16.7 had single symptom 11.1 had two symptoms and 55.6 had three or more symptoms Symptoms were mild and disability was low in the majority of participants with neurologic symptoms Median age at ALL diagnosis was 3.9 years 0.4-18.6 median age at study enrollment was 15.7 years 6.9-28.9 and median time from completion of ALL therapy was 7.4 years 1.9-20.3 On multivariable analyses female sex correlated with presence of dizziness urinary incontinence constipation and neuropathy use of 10 doses of triple intrathecal chemotherapy correlated with urinary incontinence back pain and neuropathy cranial radiation with ataxia history of ALL relapse with fatigue and CNS at diagnosis with seizures Decline in mental QOL was associated with migraine and tension type headaches while physical QOL was impaired by presence of dizziness and falls Overall good QOL and physical function was maintained by a majority of participants Neurologic symptoms were present in 83 long-term ALL survivors Symptoms related morbidity and QOL impairment is low in majority of survivors Female sex 10 doses of intrathecal chemotherapy and history of ALL relapse predispose to impaired QOL This study will educate survivors and their care providers regarding cancer or treatment-related neurologic symptoms and morbidity This study will help them understand factors contributing to impaired QOL when present,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[864, 286, 1275, 62, 16, 73, 5, 751, 11148, 600, 2, 2543, 521, 4, 319, 337, 332, 32, 12730, 656, 26, 45, 565, 2543, 787, 2, 211, 254, 23, 372, 1, 358, 4, 319, 337, 332, 1, 864, 62, 482, 226, 731, 1383, 2832, 1115, 206, 2620, 850, 45, 1, 319, 337, 62, 332, 776, 11, 2619, 29, 1115, 4736, 776, 9029, 35, 3464, 468, 1770, 370, 20, 451, 20, 8, 40248, 372, 1, 358, 1001, 10, 120, 275, 1, 3, 5441, 776, 2619, 252, 8, 27, 111, 727, 852, 27, 210, 28, 506, 104, 2543, 934, 1, 1333, 245, 67, 42, 226, 934, 175, 14, 42, 100, 507, 2, 614, 49, 42, 169, 15, 80, 507, 507, 11, 1980, 2, 5868, 10, 154, 4, 3, 686, 1, 776, 5, 2543, 507, 52, 89, 28, 62, 147, 10, 27, 83, 60, 13, 39, 203, 49, 52, 89, 28, 45, 1798, 10, 167, 67, 60, 49, 83, 339, 83, 2, 52, 98, 29, 1438, 1, 62, 36, 10, 67, 39, 60, 14, 83, 179, 27, 23, 658, 318, 1061, 1035, 438, 5, 463, 1, 11489, 1660, 6152, 4532, 2, 1751, 119, 1, 4556, 415, 1, 1500, 5126, 56, 438, 5, 1660, 6152, 4636, 559, 2, 1751, 2565, 121, 5, 8299, 532, 1, 62, 429, 5, 613, 2, 1025, 28, 147, 5, 4448, 1858, 4, 3031, 1001, 10, 41, 5, 14170, 2, 11988, 267, 9783, 369, 900, 1001, 10, 2364, 20, 463, 1, 11489, 2, 9134, 63, 1178, 1001, 2, 900, 343, 10, 1955, 20, 8, 686, 1, 776, 2543, 507, 11, 364, 4, 852, 319, 337, 62, 332, 507, 139, 787, 2, 1001, 2315, 16, 154, 4, 686, 1, 332, 1061, 1035, 4556, 415, 1, 5126, 56, 2, 532, 1, 62, 429, 6043, 6, 2364, 1001, 26, 45, 303, 10407, 332, 2, 136, 165, 1994, 666, 12, 15, 24, 139, 2543, 507, 2, 787, 26, 45, 303, 987, 1370, 1640, 130, 3156, 6, 2364, 1001, 198, 364]",2088.0,25008582,446
Central nervous system relapse in adults with acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-07-10,"Central nervous system (CNS) relapse after allogeneic hematopoietic stem cell transplantation (HSCT) confers a poor prognosis in adult patients with acute lymphoblastic leukemia (ALL). Preventing CNS relapse after HSCT remains a therapeutic challenge, and criteria for post-HSCT CNS prophylaxis have not been addressed. In a 3-center retrospective analysis, we reviewed the data for 457 adult patients with ALL who received a first allogeneic HSCT in first or second complete remission (CR). All patients received CNS prophylaxis as part of their upfront therapy for ALL, but post-transplantation CNS prophylaxis practice varied by institution and was administered to 48% of the patients. Eighteen patients (4%) developed CNS relapse after HSCT (isolated CNS relapse, n = 8; combined bone marrow and CNS relapse, n = 10). Patients with a previous history of CNS involvement with leukemia had a significantly higher rate for CNS relapse (P = .002), and pretransplantation CNS involvement was the only risk factor for post-transplantation CNS relapse found in this study. We failed to find a significant effect of post-transplantation CNS prophylaxis to prevent relapse after transplantation. Furthermore, no benefit for post-transplantation CNS prophylaxis could be detected when a subgroup analysis of patients with (P = .10) and without previous CNS involvement (P = .52) was performed. Finally, we could not find any significant effect for intensity of the transplantation conditioning regimen on CNS relapse after HSCT. In conclusion, CNS relapse is an uncommon event after HSCT for patients with ALL in CR1 or CR2, but with higher risk among patients with CNS involvement before transplantation. Furthermore, neither the use of post-HSCT CNS prophylaxis nor the intensity of the HSCT conditioning regimen made a significant difference in the rate of post-HSCT CNS relapse.",Journal Article,2021.0,19.0,Central nervous system CNS relapse after allogeneic hematopoietic stem cell transplantation HSCT confers a poor prognosis in adult patients with acute lymphoblastic ALL Preventing CNS relapse after HSCT remains a therapeutic challenge and criteria for post-HSCT CNS prophylaxis have not been addressed In a 3-center retrospective analysis we reviewed the data for 457 adult patients with ALL who received a first allogeneic HSCT in first or second complete remission CR All patients received CNS prophylaxis as part of their upfront therapy for ALL but post-transplantation CNS prophylaxis practice varied by institution and was administered to 48 of the patients Eighteen patients 4 developed CNS relapse after HSCT isolated CNS relapse n 8 combined marrow and CNS relapse n 10 Patients with a previous history of CNS involvement with had a significantly higher rate for CNS relapse P .002 and pretransplantation CNS involvement was the only risk factor for post-transplantation CNS relapse found in this study We failed to find a significant effect of post-transplantation CNS prophylaxis to prevent relapse after transplantation Furthermore no benefit for post-transplantation CNS prophylaxis could be detected when a subgroup analysis of patients with P .10 and without previous CNS involvement P .52 was performed Finally we could not find any significant effect for intensity of the transplantation conditioning regimen on CNS relapse after HSCT In conclusion CNS relapse is an uncommon event after HSCT for patients with ALL in CR1 or CR2 but with higher risk among patients with CNS involvement before transplantation Furthermore neither the use of post-HSCT CNS prophylaxis nor the intensity of the HSCT conditioning regimen made a significant difference in the rate of post-HSCT CNS relapse,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[854, 1880, 398, 1025, 429, 50, 1063, 1007, 452, 31, 497, 1703, 4020, 8, 334, 356, 4, 780, 7, 5, 286, 1275, 62, 3017, 1025, 429, 50, 1703, 469, 8, 189, 1745, 2, 371, 9, 539, 1703, 1025, 2049, 47, 44, 85, 2814, 4, 8, 27, 574, 459, 65, 21, 446, 3, 74, 9, 13372, 780, 7, 5, 62, 54, 103, 8, 157, 1063, 1703, 4, 157, 15, 419, 236, 734, 684, 62, 7, 103, 1025, 2049, 22, 760, 1, 136, 2941, 36, 9, 62, 84, 539, 497, 1025, 2049, 758, 2051, 20, 731, 2, 10, 468, 6, 576, 1, 3, 7, 3195, 7, 39, 276, 1025, 429, 50, 1703, 1355, 1025, 429, 78, 66, 397, 581, 2, 1025, 429, 78, 79, 7, 5, 8, 698, 532, 1, 1025, 799, 5, 42, 8, 97, 142, 116, 9, 1025, 429, 19, 1111, 2, 9367, 1025, 799, 10, 3, 158, 43, 161, 9, 539, 497, 1025, 429, 204, 4, 26, 45, 21, 1551, 6, 2469, 8, 93, 254, 1, 539, 497, 1025, 2049, 6, 1682, 429, 50, 497, 798, 77, 247, 9, 539, 497, 1025, 2049, 359, 40, 530, 198, 8, 1363, 65, 1, 7, 5, 19, 79, 2, 187, 698, 1025, 799, 19, 653, 10, 173, 1368, 21, 359, 44, 2469, 500, 93, 254, 9, 837, 1, 3, 497, 1933, 477, 23, 1025, 429, 50, 1703, 4, 1221, 1025, 429, 16, 35, 2052, 774, 50, 1703, 9, 7, 5, 62, 4, 4516, 15, 7865, 84, 5, 142, 43, 107, 7, 5, 1025, 799, 348, 497, 798, 2174, 3, 119, 1, 539, 1703, 1025, 2049, 2110, 3, 837, 1, 3, 1703, 1933, 477, 1229, 8, 93, 523, 4, 3, 116, 1, 539, 1703, 1025, 429]",1800.0,25017763,464
"Skeletal, neuromuscular and fitness impairments among children with newly diagnosed acute lymphoblastic leukemia.",Leukemia & lymphoma,Leuk. Lymphoma,2014-08-20,"This study describes skeletal, neuromuscular and fitness impairments among 109 children (median age 10 [range 4-18] years, 65.1% male, 63.3% white) with acute lymphoblastic leukemia (ALL). Outcomes were measured 7-10 days after diagnosis and compared to age- and sex-specific expected values. Associations between function and health-related quality of life (HRQL) were evaluated with logistic regression. Children with ALL had sub-optimal bone mineral density (BMD) Z-score/height (mean  standard error: - 0.53  0.16 vs. 0.00  0.14, p < 0.01), body mass index percentile (57.6  3.15 vs. 50.0  3.27%, p = 0.02), quadriceps strength (201.9  8.3 vs. 236.1  5.4 N, p < 0.01), 6 min walk distance (385.0  13.1 vs. 628.2  7.1 m, p < 0.001) and Bruininks-Oseretsky Test of Motor Proficiency scores (23  2.5 vs. 50  3.4%, p < 0.01). Quadriceps weakness was associated with a 20.9-fold (95% confidence interval 2.5-173.3) increase in poor physical HRQL. Children with newly diagnosed ALL have weakness and poor endurance and may benefit from early rehabilitation that includes strengthening and aerobic conditioning. ",Journal Article,1980.0,25.0,This study describes skeletal neuromuscular and fitness impairments among 109 children median age 10 range 4-18 years 65.1 male 63.3 white with acute lymphoblastic ALL Outcomes were measured 7-10 days after diagnosis and compared to age- and sex-specific expected values Associations between function and health-related quality of life HRQL were evaluated with logistic regression Children with ALL had sub-optimal mineral density BMD Z-score/height mean  standard error 0.53  0.16 vs. 0.00  0.14 p 0.01 body mass index percentile 57.6  3.15 vs. 50.0  3.27 p 0.02 quadriceps strength 201.9  8.3 vs. 236.1  5.4 N p 0.01 6 min walk distance 385.0  13.1 vs. 628.2  7.1 m p 0.001 and Bruininks-Oseretsky Test of Motor Proficiency scores 23  2.5 vs. 50  3.4 p 0.01 Quadriceps weakness was associated with a 20.9-fold 95 confidence interval 2.5-173.3 increase in poor physical HRQL Children with newly diagnosed ALL have weakness and poor endurance and may benefit from early rehabilitation that includes strengthening and aerobic conditioning,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26, 45, 2677, 2621, 14209, 2, 5959, 6948, 107, 3486, 541, 52, 89, 79, 184, 39, 203, 60, 556, 14, 1045, 676, 27, 886, 5, 286, 1275, 62, 123, 11, 644, 67, 79, 162, 50, 147, 2, 72, 6, 89, 2, 1035, 112, 1336, 1030, 685, 59, 343, 2, 341, 139, 372, 1, 358, 7332, 11, 194, 5, 812, 320, 541, 5, 62, 42, 551, 665, 5033, 1263, 3503, 3905, 368, 4594, 313, 810, 260, 3444, 13, 699, 810, 13, 245, 105, 13, 2038, 810, 13, 213, 19, 13, 355, 642, 782, 558, 6392, 696, 49, 810, 27, 167, 105, 212, 13, 810, 27, 428, 19, 13, 588, 29587, 3671, 4766, 83, 810, 66, 27, 105, 6383, 14, 810, 33, 39, 78, 19, 13, 355, 49, 1538, 8200, 3019, 11297, 13, 810, 233, 14, 105, 12385, 18, 810, 67, 14, 188, 19, 13, 144, 2, 48457, 48458, 412, 1, 3482, 11266, 703, 382, 810, 18, 33, 105, 212, 810, 27, 39, 19, 13, 355, 29587, 6408, 10, 41, 5, 8, 179, 83, 1116, 48, 307, 268, 18, 33, 5785, 27, 344, 4, 334, 900, 7332, 541, 5, 732, 265, 62, 47, 6408, 2, 334, 15794, 2, 68, 247, 29, 191, 4182, 17, 1920, 14200, 2, 6523, 1933]",1048.0,25030039,359
"Headache types, related morbidity, and quality of life in survivors of childhood acute lymphoblastic leukemia: a prospective cross sectional study.",European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society,Eur. J. Paediatr. Neurol.,2014-07-05,"Increased headache prevalence was recently reported in survivors of childhood ALL. Headache sub types, related morbidity, and effect on quality of life has not been reported thus far. To study headache prevalence and type, related disability, and quality of life in a cohort of childhood acute lymphoblastic leukemia (ALL) survivors. Childhood ALL survivors in at least 1-year of remission and 5 years from diagnosis completed questionnaires and were evaluated by a neurologist. Disability was evaluated with Pediatric Migraine Disability Assessment scale and the Short Form-36 Health Survey assessed quality of life. Thirty nine of 72 (54%) females and 37 of 90 (41%) males reported headaches. Median time from ALL diagnosis to first headache was 5.2 years and median age at headache onset was 10.1 years in 76 participants with headache. Migraine headaches were diagnosed in 51 (31%) and episodic tension-type headaches in 49 (30%); migraine and tension-type headaches co-existed in 24 (15%) and 18 (11%) participants had chronic daily headaches. Fatigue was associated with migraine headache while hypertension and female gender associated with tension type headache. Headache-related disability was mild in 22 (29%), moderate in 7 (9%), and severe in 5 (7%) survivors, and was absent in the remaining 42 (55%) survivors with headache. Both migraine and tension type headaches associated with reduced mental component scores, while headache related disability associated with a reduced physical component scores. Headaches are common in ALL survivors but only a minority has significant disability or impairment of quality of life.",Journal Article,2026.0,5.0,Increased headache prevalence was recently reported in survivors of childhood ALL Headache sub types related morbidity and effect on quality of life has not been reported thus far To study headache prevalence and type related disability and quality of life in a cohort of childhood acute lymphoblastic ALL survivors Childhood ALL survivors in at least 1-year of remission and 5 years from diagnosis completed questionnaires and were evaluated by a neurologist Disability was evaluated with Pediatric Migraine Disability Assessment scale and the Short Form-36 Health Survey assessed quality of life Thirty nine of 72 54 females and 37 of 90 41 males reported headaches Median time from ALL diagnosis to first headache was 5.2 years and median age at headache onset was 10.1 years in 76 participants with headache Migraine headaches were diagnosed in 51 31 and episodic tension-type headaches in 49 30 migraine and tension-type headaches co-existed in 24 15 and 18 11 participants had chronic daily headaches Fatigue was associated with migraine headache while hypertension and female gender associated with tension type headache Headache-related disability was mild in 22 29 moderate in 7 9 and severe in 5 7 survivors and was absent in the remaining 42 55 survivors with headache Both migraine and tension type headaches associated with reduced mental component scores while headache related disability associated with a reduced physical component scores Headaches are common in ALL survivors but only a minority has significant disability or impairment of quality of life,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[101, 4538, 1078, 10, 761, 210, 4, 332, 1, 864, 62, 4538, 551, 630, 139, 787, 2, 254, 23, 372, 1, 358, 71, 44, 85, 210, 631, 3272, 6, 45, 4538, 1078, 2, 267, 139, 5868, 2, 372, 1, 358, 4, 8, 180, 1, 864, 286, 1275, 62, 332, 864, 62, 332, 4, 28, 506, 14, 111, 1, 734, 2, 33, 60, 29, 147, 781, 2956, 2, 11, 194, 20, 8, 40248, 5868, 10, 194, 5, 815, 14170, 5868, 455, 1124, 2, 3, 978, 1297, 511, 341, 1407, 275, 372, 1, 358, 977, 762, 1, 720, 667, 2451, 2, 567, 1, 424, 605, 2296, 210, 9783, 52, 98, 29, 62, 147, 6, 157, 4538, 10, 33, 18, 60, 2, 52, 89, 28, 4538, 1707, 10, 79, 14, 60, 4, 846, 776, 5, 4538, 14170, 9783, 11, 265, 4, 725, 456, 2, 23258, 11988, 267, 9783, 4, 739, 201, 14170, 2, 11988, 267, 9783, 1269, 6810, 4, 259, 167, 2, 203, 175, 776, 42, 442, 391, 9783, 613, 10, 41, 5, 14170, 4538, 369, 1824, 2, 1061, 1632, 41, 5, 11988, 267, 4538, 4538, 139, 5868, 10, 1980, 4, 350, 462, 1163, 4, 67, 83, 2, 905, 4, 33, 67, 332, 2, 10, 3269, 4, 3, 1844, 595, 614, 332, 5, 4538, 110, 14170, 2, 11988, 267, 9783, 41, 5, 405, 3031, 1249, 703, 369, 4538, 139, 5868, 41, 5, 8, 405, 900, 1249, 703, 9783, 32, 186, 4, 62, 332, 84, 158, 8, 2652, 71, 93, 5868, 15, 2315, 1, 372, 1, 358]",1572.0,25030329,328
Augmented Berlin-Frankfurt-Mnster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).,Cancer,Cancer,2014-07-17,"Various trials have reported improved outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) who received treatment with pediatric-based regimens. Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Mnster (ABFM) regimen in AYA patients. The results were compared with those from a similar population that received the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen. Eighty-five patients ages 12 to 40 years who had Philadelphia chromosome (Ph)-negative ALL received the ABFM regimen from October 2006 through April 2012. Their outcome was compared with outcomes in 71 historic AYA patients who received hyper-CVAD from the authors' institution. Patient and disease characteristics, as well as minimal residual disease status, were analyzed for their impact on outcomes. The complete response rate with ABFM was 94%. The 3-year complete remission duration (CRD) and overall survival (OS) rates were 70% and 74%, respectively. For patients aged 21 years, the 3-year CRD and OS rates were 72% and 85%, respectively; and, for patients ages 21 to 40 years, the respective rates were 69% and 60%. The initial white blood cell count was an independent predictive factor of OS and CRD. The minimal residual disease status on days 29 and 84 of therapy also were predictive of long-term outcomes. Severe regimen toxicities included transient hepatotoxicity in 35% to 39% of patients, pancreatitis in 11% of patients, osteonecrosis in 11% of patients, and thrombosis in 22% of patients. The 3-year OS rate was 74% in the ABFM group versus 71% in the hyper-CVAD group, and the corresponding 3-year CRD rate was 70% versus 66%, respectively. ABFM was tolerable in AYA patients with ALL but was not associated with significant improvements in CRD and OS compared with hyper-CVAD.",Journal Article,2014.0,49.0,Various trials have reported improved outcomes for adolescents and young adults AYAs with acute lymphoblastic ALL who received treatment with pediatric-based regimens Those reports prompted the current investigation of the pediatric augmented Berlin-Frankfurt-Mnster ABFM regimen in AYA patients The results were compared with those from a similar population that received the hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone hyper-CVAD regimen Eighty-five patients ages 12 to 40 years who had Philadelphia chromosome Ph -negative ALL received the ABFM regimen from October 2006 through April 2012 Their outcome was compared with outcomes in 71 historic AYA patients who received hyper-CVAD from the authors institution Patient and disease characteristics as well as minimal residual disease status were analyzed for their impact on outcomes The complete response rate with ABFM was 94 The 3-year complete remission duration CRD and overall survival OS rates were 70 and 74 respectively For patients aged 21 years the 3-year CRD and OS rates were 72 and 85 respectively and for patients ages 21 to 40 years the respective rates were 69 and 60 The initial white blood cell count was an independent predictive factor of OS and CRD The minimal residual disease status on days 29 and 84 of therapy also were predictive of long-term outcomes Severe regimen toxicities included transient hepatotoxicity in 35 to 39 of patients pancreatitis in 11 of patients osteonecrosis in 11 of patients and thrombosis in 22 of patients The 3-year OS rate was 74 in the ABFM group versus 71 in the hyper-CVAD group and the corresponding 3-year CRD rate was 70 versus 66 respectively ABFM was tolerable in AYA patients with ALL but was not associated with significant improvements in CRD and OS compared with hyper-CVAD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[747, 143, 47, 210, 231, 123, 9, 3101, 2, 1169, 857, 6145, 5, 286, 1275, 62, 54, 103, 24, 5, 815, 90, 472, 135, 1198, 4140, 3, 291, 940, 1, 3, 815, 4277, 20405, 23389, 26350, 20857, 477, 4, 4598, 7, 3, 99, 11, 72, 5, 135, 29, 8, 288, 266, 17, 103, 3, 6201, 1112, 2132, 856, 2, 1217, 4855, 5574, 477, 2207, 365, 7, 2165, 133, 6, 327, 60, 54, 42, 3006, 1170, 2058, 199, 62, 103, 3, 20857, 477, 29, 2551, 1324, 298, 2292, 1195, 136, 228, 10, 72, 5, 123, 4, 792, 6875, 4598, 7, 54, 103, 4855, 5574, 29, 3, 738, 731, 69, 2, 34, 374, 22, 149, 22, 1048, 753, 34, 156, 11, 311, 9, 136, 345, 23, 123, 3, 236, 51, 116, 5, 20857, 10, 960, 3, 27, 111, 236, 734, 654, 9366, 2, 63, 25, 118, 151, 11, 431, 2, 794, 106, 9, 7, 1032, 22725, 60, 3, 27, 111, 9366, 2, 118, 151, 11, 720, 2, 772, 106, 2, 9, 7, 2165, 239, 6, 327, 60, 3, 3847, 151, 11, 790, 2, 335, 3, 388, 886, 315, 31, 1276, 10, 35, 306, 464, 161, 1, 118, 2, 9366, 3, 1048, 753, 34, 156, 23, 162, 462, 2, 874, 1, 36, 120, 11, 464, 1, 319, 337, 123, 905, 477, 385, 159, 2473, 6667, 4, 465, 6, 587, 1, 7, 4535, 4, 175, 1, 7, 5404, 4, 175, 1, 7, 2, 2839, 4, 350, 1, 7, 3, 27, 111, 118, 116, 10, 794, 4, 3, 20857, 87, 185, 792, 4, 3, 4855, 5574, 87, 2, 3, 1734, 27, 111, 9366, 116, 10, 431, 185, 700, 106, 20857, 10, 2668, 4, 4598, 7, 5, 62, 84, 10, 44, 41, 5, 93, 1474, 4, 9366, 2, 118, 72, 5, 4855, 5574]",1828.0,25042398,753
Outcomes of children with BCR-ABL1like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2014-09-01,"BCR-ABL1like acute lymphoblastic leukemia (ALL) is a recently identified B-cell ALL (B-ALL)subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein. We examined the outcome of children with BCR-ABL1like ALL treated with risk-directed therapy based on minimal residual disease (MRD) levels during remission induction. Among 422 patients with B-ALL enrolled onto the Total Therapy XV study between 2000 and 2007, 344 had adequate samples for gene expression profiling. Next-generation sequencing and/or analysis of genes known to be altered in B-ALL were performed in patients with BCR-ABL1likeALL who had available material. Outcome was compared between patients with and those without BCR-ABL1like ALL. Forty (11.6%) of the 344 patients had BCR-ABL1like ALL. They were significantly more likely to be male, have Down syndrome, and have higher MRD levels on day 19 and at the end of induction than did other patients with B-ALL. Among 25 patients comprehensively studied for genetic abnormalities, 11 harbored a genomic rearrangement of CRLF2, six had fusion transcripts responsive to ABL tyrosine kinase inhibitors or JAK inhibitors, and seven had mutations involving the Ras signaling pathway. There were no significant differences in event-free survival (90.0% +/- 4.7% [SE] v. 88.4% +/- .9% at 5 years; P = .41or in overall survival (92.5% +/- 4.2% v. 95.1% +/- 1.3% at 5 years; P = .41) between patients with and without BCR-ABL1like ALL. Patients who have BCR-ABL1like ALL with poor initial treatment response can be salvaged with MRD-based risk-directed therapy and may benefit from identification of kinase-activating lesions for targeted therapies.",Journal Article,1968.0,115.0,BCR-ABL1like acute lymphoblastic ALL is a recently identified B-cell ALL B-ALL subtype with poor outcome that exhibits a gene expression profile similar to BCR-ABL1-positive ALL but lacks the BCR-ABL1 fusion protein We examined the outcome of children with BCR-ABL1like ALL treated with risk-directed therapy based on minimal residual disease MRD levels during remission induction Among 422 patients with B-ALL enrolled onto the Total Therapy XV study between 2000 and 2007 344 had adequate samples for gene expression profiling Next-generation sequencing and/or analysis of genes known to be altered in B-ALL were performed in patients with BCR-ABL1likeALL who had available material Outcome was compared between patients with and those without BCR-ABL1like ALL Forty 11.6 of the 344 patients had BCR-ABL1like ALL They were significantly more likely to be male have Down syndrome and have higher MRD levels on day 19 and at the end of induction than did other patients with B-ALL Among 25 patients comprehensively studied for genetic abnormalities 11 harbored a genomic rearrangement of CRLF2 six had fusion transcripts responsive to ABL tyrosine kinase inhibitors or JAK inhibitors and seven had mutations involving the Ras signaling pathway There were no significant differences in event-free survival 90.0 +/- 4.7 SE v. 88.4 +/- .9 at 5 years P .41or in overall survival 92.5 +/- 4.2 v. 95.1 +/- 1.3 at 5 years P .41 between patients with and without BCR-ABL1like ALL Patients who have BCR-ABL1like ALL with poor initial treatment response can be salvaged with MRD-based risk-directed therapy and may benefit from identification of kinase-activating lesions for targeted therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1062, 29591, 286, 1275, 62, 16, 8, 761, 108, 132, 31, 62, 132, 62, 875, 5, 334, 228, 17, 4273, 8, 145, 55, 800, 288, 6, 1062, 3557, 109, 62, 84, 6856, 3, 1062, 3557, 1212, 178, 21, 409, 3, 228, 1, 541, 5, 1062, 29591, 62, 73, 5, 43, 1166, 36, 90, 23, 1048, 753, 34, 2029, 148, 190, 734, 504, 107, 10581, 7, 5, 132, 62, 346, 3301, 3, 181, 36, 16078, 45, 59, 1081, 2, 1307, 6993, 42, 1658, 347, 9, 145, 55, 1080, 1305, 914, 615, 2, 15, 65, 1, 214, 440, 6, 40, 1495, 4, 132, 62, 11, 173, 4, 7, 5, 1062, 64642, 54, 42, 390, 3692, 228, 10, 72, 59, 7, 5, 2, 135, 187, 1062, 29591, 62, 1213, 175, 49, 1, 3, 6993, 7, 42, 1062, 29591, 62, 491, 11, 97, 80, 322, 6, 40, 1045, 47, 1328, 681, 2, 47, 142, 2029, 148, 23, 218, 326, 2, 28, 3, 396, 1, 504, 76, 205, 127, 7, 5, 132, 62, 107, 243, 7, 5627, 656, 9, 336, 1171, 175, 3253, 8, 572, 2675, 1, 8895, 437, 42, 1212, 2680, 2443, 6, 1425, 564, 216, 222, 15, 4653, 222, 2, 648, 42, 138, 1267, 3, 1102, 314, 308, 125, 11, 77, 93, 362, 4, 774, 115, 25, 424, 13, 39, 67, 3428, 603, 889, 39, 83, 28, 33, 60, 19, 64643, 4, 63, 25, 937, 33, 39, 18, 603, 48, 14, 14, 27, 28, 33, 60, 19, 605, 59, 7, 5, 2, 187, 1062, 29591, 62, 7, 54, 47, 1062, 29591, 62, 5, 334, 388, 24, 51, 122, 40, 9459, 5, 2029, 90, 43, 1166, 36, 2, 68, 247, 29, 911, 1, 216, 1616, 406, 9, 238, 235]",1691.0,25049327,771
Hospital length of stay in the first 100 days after allogeneic hematopoietic cell transplantation for acute leukemia in remission: comparison among alternative graft sources.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2014-07-23,"Several studies have shown comparable survival outcomes with different graft sources, but the relative resource needs of hematopoietic cell transplantation (HCT) by graft source have not been well studied. We compared total hospital length of stay in the first 100 days after HCT in 1577 patients with acute leukemia in remission who underwent HCT with an umbilical cord blood (UCB), matched unrelated donor (MUD), or mismatched unrelated donor (MMUD) graft between 2008 and 2011. To ensure a relatively homogenous study population, the analysis was limited to patients with acute myelogenous leukemia and acute lymphoblastic leukemia in first or second complete remission who underwent HCT in the United States. To account for early deaths, we compared the number of days alive and out of the hospital in the first 100 days post-transplantation. For children who received myeloablative conditioning, the median time alive and out of the hospital in the first 100 days was 50 days for single UCB recipients, 54 days for double UCB recipients, and 60 days for MUD bone marrow (BM) recipients. In multivariate analysis, use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM. For adults who received myeloablative conditioning, the median time alive and out of the hospital in first 100 days was 52 days for single UCB recipients, 55 days for double UCB recipients, 69 days for MUD BM recipients, 75 days for MUD peripheral blood stem cell (PBSC) recipients, 63 days for MMUD BM recipients, and 67 days for MMUD PBSC recipients. In multivariate analysis, UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources. For adults who received a reduced-intensity preparative regimen, the median time alive and out of the hospital during the first 100 days was 65 days for single UCB recipients, 63 days for double UCB recipients, 79 days for MUD PBSC recipients, and 79 days for MMUD PBSC recipients. Similar to the other 2 groups, receipt of UCB was associated with a fewer days alive and out of the hospital. In conclusion, length of stay in the first 100 days post-transplantation varies by graft source and is longer for UCB HCT recipients. These data provide insight into the resource needs of patients who undergo HCT with these various graft sources.",Comparative Study,2008.0,21.0,Several studies have shown comparable survival outcomes with different graft sources but the relative resource needs of hematopoietic cell transplantation HCT by graft source have not been well studied We compared total hospital length of stay in the first 100 days after HCT in 1577 patients with acute in remission who underwent HCT with an umbilical cord blood UCB matched unrelated donor MUD or mismatched unrelated donor MMUD graft between 2008 and 2011 To ensure a relatively homogenous study population the analysis was limited to patients with acute myelogenous and acute lymphoblastic in first or second complete remission who underwent HCT in the United States To account for early deaths we compared the number of days alive and out of the hospital in the first 100 days post-transplantation For children who received myeloablative conditioning the median time alive and out of the hospital in the first 100 days was 50 days for single UCB recipients 54 days for double UCB recipients and 60 days for MUD marrow BM recipients In multivariate analysis use of UCB was significantly associated with fewer days alive and out of the hospital compared with MUD BM For adults who received myeloablative conditioning the median time alive and out of the hospital in first 100 days was 52 days for single UCB recipients 55 days for double UCB recipients 69 days for MUD BM recipients 75 days for MUD peripheral blood stem cell PBSC recipients 63 days for MMUD BM recipients and 67 days for MMUD PBSC recipients In multivariate analysis UCB and MMUD BM recipients had fewer days alive and out of the hospital compared with recipients of other graft sources For adults who received a reduced-intensity preparative regimen the median time alive and out of the hospital during the first 100 days was 65 days for single UCB recipients 63 days for double UCB recipients 79 days for MUD PBSC recipients and 79 days for MMUD PBSC recipients Similar to the other 2 groups receipt of UCB was associated with a fewer days alive and out of the hospital In conclusion length of stay in the first 100 days post-transplantation varies by graft source and is longer for UCB HCT recipients These data provide insight into the resource needs of patients who undergo HCT with these various graft sources,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[392, 94, 47, 443, 1279, 25, 123, 5, 338, 1599, 3375, 84, 3, 580, 3069, 1891, 1, 1007, 31, 497, 1085, 20, 1599, 2353, 47, 44, 85, 149, 656, 21, 72, 181, 702, 1318, 1, 2020, 4, 3, 157, 394, 162, 50, 1085, 4, 46906, 7, 5, 286, 4, 734, 54, 208, 1085, 5, 35, 5998, 1885, 315, 4056, 655, 2092, 1488, 7070, 15, 5095, 2092, 1488, 17047, 1599, 59, 1375, 2, 1132, 6, 3478, 8, 1352, 10408, 45, 266, 3, 65, 10, 383, 6, 7, 5, 286, 2194, 2, 286, 1275, 4, 157, 15, 419, 236, 734, 54, 208, 1085, 4, 3, 1088, 907, 6, 1967, 9, 191, 1043, 21, 72, 3, 207, 1, 162, 1701, 2, 1205, 1, 3, 702, 4, 3, 157, 394, 162, 539, 497, 9, 541, 54, 103, 3246, 1933, 3, 52, 98, 1701, 2, 1205, 1, 3, 702, 4, 3, 157, 394, 162, 10, 212, 162, 9, 226, 4056, 2190, 667, 162, 9, 1627, 4056, 2190, 2, 335, 162, 9, 7070, 581, 1246, 2190, 4, 331, 65, 119, 1, 4056, 10, 97, 41, 5, 1497, 162, 1701, 2, 1205, 1, 3, 702, 72, 5, 7070, 1246, 9, 857, 54, 103, 3246, 1933, 3, 52, 98, 1701, 2, 1205, 1, 3, 702, 4, 157, 394, 162, 10, 653, 162, 9, 226, 4056, 2190, 614, 162, 9, 1627, 4056, 2190, 790, 162, 9, 7070, 1246, 2190, 481, 162, 9, 7070, 672, 315, 452, 31, 6368, 2190, 676, 162, 9, 17047, 1246, 2190, 2, 598, 162, 9, 17047, 6368, 2190, 4, 331, 65, 4056, 2, 17047, 1246, 2190, 42, 1497, 162, 1701, 2, 1205, 1, 3, 702, 72, 5, 2190, 1, 127, 1599, 3375, 9, 857, 54, 103, 8, 405, 837, 6085, 477, 3, 52, 98, 1701, 2, 1205, 1, 3, 702, 190, 3, 157, 394, 162, 10, 556, 162, 9, 226, 4056, 2190, 676, 162, 9, 1627, 4056, 2190, 842, 162, 9, 7070, 6368, 2190, 2, 842, 162, 9, 17047, 6368, 2190, 288, 6, 3, 127, 18, 271, 1699, 1, 4056, 10, 41, 5, 8, 1497, 162, 1701, 2, 1205, 1, 3, 702, 4, 1221, 1318, 1, 2020, 4, 3, 157, 394, 162, 539, 497, 4037, 20, 1599, 2353, 2, 16, 589, 9, 4056, 1085, 2190, 46, 74, 377, 2670, 237, 3, 3069, 1891, 1, 7, 54, 1251, 1085, 5, 46, 747, 1599, 3375]",2286.0,25064747,498
Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia.,Pharmacogenomics,Pharmacogenomics,2014-06-01,"Vincristine (VCR) is a standard component in the treatment of childhood acute lymphoblastic leukemia (ALL). VCR cytotoxicity is primarily due to its ability to disrupt the formation of microtubules of the mitotic spindle. Seventeen polymorphisms in regulatory and coding regions of genes controlling VCR targets (TUBB1, MAP4, ACTG1 and CAPG) or potentially influencing VCR levels (ABCB1 and CYP3A5) were investigated for an association with peripheral neuropathy and outcome in childhood ALL patients. High-grade neurotoxicity was more frequent in carriers of the A allele of synonymous (Ala310) G to A (rs1135989) variation in the ACTG1 gene. Substitution (rs4728709) in the promoter of the ABCB1 gene had a protective effect against lower grade neurotoxicity and C to A variation (rs3770102) located 17 nucleotides upstream from the transcription start site had a protective effect against high-grade neurotoxicity. Patients with the ABCB1 3435TT genotype had lower event-free survival; the association with event-free survival was not supported by the analysis in the replication patient set. The polymorphisms in the ACTG1, CAPG and ABCB1 genes may modulate VCR-related neurotoxicity, whereas the risk of relapse seems not to be affected by the genes of the VCR pathway.",Journal Article,2060.0,31.0,Vincristine VCR is a standard component in the treatment of childhood acute lymphoblastic ALL VCR cytotoxicity is primarily due to its ability to disrupt the formation of microtubules of the mitotic spindle Seventeen polymorphisms in regulatory and coding regions of genes controlling VCR targets TUBB1 MAP4 ACTG1 and CAPG or potentially influencing VCR levels ABCB1 and CYP3A5 were investigated for an association with peripheral neuropathy and outcome in childhood ALL patients High-grade neurotoxicity was more frequent in carriers of the A allele of synonymous Ala310 G to A rs1135989 variation in the ACTG1 gene Substitution rs4728709 in the promoter of the ABCB1 gene had a protective effect against lower grade neurotoxicity and C to A variation rs3770102 located 17 nucleotides upstream from the transcription start site had a protective effect against high-grade neurotoxicity Patients with the ABCB1 3435TT genotype had lower event-free survival the association with event-free survival was not supported by the analysis in the replication patient set The polymorphisms in the ACTG1 CAPG and ABCB1 genes may modulate VCR-related neurotoxicity whereas the risk of relapse seems not to be affected by the genes of the VCR pathway,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2132, 8886, 16, 8, 260, 1249, 4, 3, 24, 1, 864, 286, 1275, 62, 8886, 1408, 16, 1561, 520, 6, 211, 801, 6, 6619, 3, 1264, 1, 9870, 1, 3, 2346, 4052, 3591, 1203, 4, 1253, 2, 3097, 1374, 1, 214, 1893, 8886, 637, 64695, 35860, 40795, 2, 32075, 15, 751, 4743, 8886, 148, 6560, 2, 10071, 11, 565, 9, 35, 248, 5, 672, 1751, 2, 228, 4, 864, 62, 7, 64, 88, 3561, 10, 80, 908, 4, 1316, 1, 3, 8, 1254, 1, 9287, 64696, 499, 6, 8, 64697, 1380, 4, 3, 40795, 145, 5029, 64698, 4, 3, 973, 1, 3, 6560, 145, 42, 8, 2864, 254, 480, 280, 88, 3561, 2, 256, 6, 8, 1380, 64699, 2308, 269, 11381, 3988, 29, 3, 866, 2435, 606, 42, 8, 2864, 254, 480, 64, 88, 3561, 7, 5, 3, 6560, 64700, 1183, 42, 280, 774, 115, 25, 3, 248, 5, 774, 115, 25, 10, 44, 2708, 20, 3, 65, 4, 3, 2079, 69, 916, 3, 1203, 4, 3, 40795, 32075, 2, 6560, 214, 68, 3319, 8886, 139, 3561, 547, 3, 43, 1, 429, 2744, 44, 6, 40, 1424, 20, 3, 214, 1, 3, 8886, 308]",1237.0,25084203,830
Executive function late effects in survivors of pediatric brain tumors and acute lymphoblastic leukemia.,Journal of clinical and experimental neuropsychology,J Clin Exp Neuropsychol,2014-08-15,"Survivors of pediatric brain tumors (BT) and acute lymphoblastic leukemia (ALL) are at risk for neurocognitive late effects related to executive function. Survivors of BT (48) and ALL (50) completed neurocognitive assessment. Executive function was compared to estimated IQ and population norms by diagnostic group. Both BT and ALL demonstrated relative executive function weaknesses. As a group, BT survivors demonstrated weaker executive functioning than expected for age. Those BT survivors with deficits exhibited a profile suggestive of global executive dysfunction, while affected ALL survivors tended to demonstrate specific rapid naming deficits. Findings suggest that pediatric BT and ALL survivors may exhibit different profiles of executive function late effects, which may necessitate distinct intervention plans.",Journal Article,1985.0,22.0,Survivors of pediatric brain tumors BT and acute lymphoblastic ALL are at risk for neurocognitive late effects related to executive function Survivors of BT 48 and ALL 50 completed neurocognitive assessment Executive function was compared to estimated IQ and population norms by diagnostic group Both BT and ALL demonstrated relative executive function weaknesses As a group BT survivors demonstrated weaker executive functioning than expected for age Those BT survivors with deficits exhibited a profile suggestive of global executive dysfunction while affected ALL survivors tended to demonstrate specific rapid naming deficits Findings suggest that pediatric BT and ALL survivors may exhibit different profiles of executive function late effects which may necessitate distinct intervention plans,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 815, 342, 57, 3641, 2, 286, 1275, 62, 32, 28, 43, 9, 2958, 807, 176, 139, 6, 6481, 343, 332, 1, 3641, 576, 2, 62, 212, 781, 2958, 455, 6481, 343, 10, 72, 6, 661, 7666, 2, 266, 9875, 20, 752, 87, 110, 3641, 2, 62, 264, 580, 6481, 343, 12165, 22, 8, 87, 3641, 332, 264, 9087, 6481, 2702, 76, 1336, 9, 89, 135, 3641, 332, 5, 2752, 1416, 8, 800, 3832, 1, 1648, 6481, 1527, 369, 1424, 62, 332, 3886, 6, 608, 112, 1321, 22220, 2752, 272, 309, 17, 815, 3641, 2, 62, 332, 68, 2239, 338, 1241, 1, 6481, 343, 807, 176, 92, 68, 12084, 834, 788, 1853]",798.0,25126830,0
Inhibition of leukemia cell engraftment and disease progression in mice by osteoblasts.,Blood,Blood,2014-08-18,"The bone marrow niche is thought to act as a permissive microenvironment required for emergence or progression of hematologic cancers. We hypothesized that osteoblasts, components of the niche involved in hematopoietic stem cell (HSC) function, influence the fate of leukemic blasts. We show that osteoblast numbers decrease by 55% in myelodysplasia and acute myeloid leukemia patients. Further, genetic depletion of osteoblasts in mouse models of acute leukemia increased circulating blasts and tumor engraftment in the marrow and spleen leading to higher tumor burden and shorter survival. Myelopoiesis increased and was coupled with a reduction in B lymphopoiesis and compromised erythropoiesis, suggesting that hematopoietic lineage/progression was altered. Treatment of mice with acute myeloid or lymphoblastic leukemia with a pharmacologic inhibitor of the synthesis of duodenal serotonin, a hormone suppressing osteoblast numbers, inhibited loss of osteoblasts. Maintenance of the osteoblast pool restored normal marrow function, reduced tumor burden, and prolonged survival. Leukemia prevention was attributable to maintenance of osteoblast numbers because inhibition of serotonin receptors alone in leukemic blasts did not affect leukemia progression. These results suggest that osteoblasts play a fundamental role in propagating leukemia in the marrow and may be a therapeutic target to induce hostility of the niche to leukemia blasts.",Journal Article,1982.0,56.0,The marrow niche is thought to act as a permissive microenvironment required for emergence or progression of hematologic cancers We hypothesized that osteoblasts components of the niche involved in hematopoietic stem cell HSC function influence the fate of leukemic blasts We show that osteoblast numbers decrease by 55 in myelodysplasia and acute myeloid patients Further genetic depletion of osteoblasts in mouse models of acute increased circulating blasts and tumor engraftment in the marrow and spleen leading to higher tumor burden and shorter survival Myelopoiesis increased and was coupled with a reduction in B lymphopoiesis and compromised erythropoiesis suggesting that hematopoietic lineage/progression was altered Treatment of mice with acute myeloid or lymphoblastic with a pharmacologic inhibitor of the synthesis of duodenal serotonin a hormone suppressing osteoblast numbers inhibited loss of osteoblasts Maintenance of the osteoblast pool restored normal marrow function reduced tumor burden and prolonged survival prevention was attributable to maintenance of osteoblast numbers because inhibition of serotonin receptors alone in leukemic blasts did not affect progression These results suggest that osteoblasts play a fundamental role in propagating in the marrow and may be a therapeutic target to induce hostility of the niche to blasts,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 581, 4385, 16, 2739, 6, 2559, 22, 8, 11080, 995, 616, 9, 3397, 15, 91, 1, 813, 163, 21, 1237, 17, 5965, 1628, 1, 3, 4385, 646, 4, 1007, 452, 31, 5596, 343, 1054, 3, 7878, 1, 2015, 2438, 21, 514, 17, 7418, 1870, 775, 20, 614, 4, 6128, 2, 286, 533, 7, 195, 336, 2286, 1, 5965, 4, 830, 274, 1, 286, 101, 1033, 2438, 2, 30, 2881, 4, 3, 581, 2, 4071, 1049, 6, 142, 30, 892, 2, 985, 25, 23233, 101, 2, 10, 3332, 5, 8, 628, 4, 132, 30689, 2, 4867, 10297, 802, 17, 1007, 2542, 91, 10, 1495, 24, 1, 399, 5, 286, 533, 15, 1275, 5, 8, 2788, 230, 1, 3, 2525, 1, 4748, 8306, 8, 785, 4669, 7418, 1870, 879, 407, 1, 5965, 1146, 1, 3, 7418, 6545, 4138, 295, 581, 343, 405, 30, 892, 2, 1069, 25, 1070, 10, 2971, 6, 1146, 1, 7418, 1870, 408, 297, 1, 8306, 1186, 279, 4, 2015, 2438, 205, 44, 1158, 91, 46, 99, 309, 17, 5965, 1343, 8, 4595, 200, 4, 14999, 4, 3, 581, 2, 68, 40, 8, 189, 283, 6, 1290, 39440, 1, 3, 4385, 6, 2438]",1358.0,25139351,59
Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation.,Blood,Blood,2014-08-26,"We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplantation (HCT) to determine the clinical implications of donor-recipient HLA matching. Adult and pediatric patients who had first undergone myeloablative-unrelated bone marrow or peripheral blood HCT for acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, and myelodysplastic syndrome between 1999 and 2011 were included. All had high-resolution typing for HLA-A, -B, -C, and -DRB1. Of the total (n = 8003), cases were 8/8 (n = 5449), 7/8 (n = 2071), or 6/8 (n = 483) matched. HLA mismatch (6-7/8) conferred significantly increased risk for grades II to IV and III to IV acute graft vs host disease (GVHD), chronic GVHD, transplant-related mortality (TRM), and overall mortality compared with HLA-matched cases (8/8). Type (allele/antigen) and locus (HLA-A, -B, -C, and -DRB1) of mismatch were not associated with overall mortality. Among 8/8 matched cases, HLA-DPB1 and -DQB1 mismatch resulted in increased acute GVHD, and HLA-DPB1 mismatch had decreased relapse. Nonpermissive HLA-DPB1 allele mismatch was associated with higher TRM compared with permissive HLA-DPB1 mismatch or HLA-DPB1 match and increased overall mortality compared with permissive HLA-DPB1 mismatch in 8/8 (and 10/10) matched cases. Full matching at HLA-A, -B, -C, and -DRB1 is required for optimal unrelated donor HCT survival, and avoidance of nonpermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated. ",Journal Article,1974.0,118.0,We examined current outcomes of unrelated donor allogeneic hematopoietic cell transplantation HCT to determine the clinical implications of donor-recipient HLA matching Adult and pediatric patients who had first undergone myeloablative-unrelated marrow or peripheral blood HCT for acute myelogenous acute lymphoblastic chronic myelogenous and syndrome between 1999 and 2011 were included All had high-resolution typing for HLA-A -B -C and -DRB1 Of the total n 8003 cases were 8/8 n 5449 7/8 n 2071 or 6/8 n 483 matched HLA mismatch 6-7/8 conferred significantly increased risk for grades II to IV and III to IV acute graft vs host disease GVHD chronic GVHD transplant-related mortality TRM and overall mortality compared with HLA-matched cases 8/8 Type allele/antigen and locus HLA-A -B -C and -DRB1 of mismatch were not associated with overall mortality Among 8/8 matched cases HLA-DPB1 and -DQB1 mismatch resulted in increased acute GVHD and HLA-DPB1 mismatch had decreased relapse Nonpermissive HLA-DPB1 allele mismatch was associated with higher TRM compared with permissive HLA-DPB1 mismatch or HLA-DPB1 match and increased overall mortality compared with permissive HLA-DPB1 mismatch in 8/8 and 10/10 matched cases Full matching at HLA-A -B -C and -DRB1 is required for optimal unrelated donor HCT survival and avoidance of nonpermissive HLA-DPB1 mismatches in otherwise HLA-matched pairs is indicated,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 409, 291, 123, 1, 2092, 1488, 1063, 1007, 31, 497, 1085, 6, 223, 3, 38, 1268, 1, 1488, 5783, 1160, 2616, 780, 2, 815, 7, 54, 42, 157, 1989, 3246, 2092, 581, 15, 672, 315, 1085, 9, 286, 2194, 286, 1275, 442, 2194, 2, 681, 59, 2043, 2, 1132, 11, 159, 62, 42, 64, 2125, 10656, 9, 1160, 8, 132, 256, 2, 8147, 1, 3, 181, 78, 64809, 140, 11, 66, 66, 78, 64810, 67, 66, 78, 48547, 15, 49, 66, 78, 10661, 655, 1160, 2617, 49, 67, 66, 3851, 97, 101, 43, 9, 2276, 215, 6, 478, 2, 316, 6, 478, 286, 1599, 105, 1204, 34, 1562, 442, 1562, 941, 139, 282, 5064, 2, 63, 282, 72, 5, 1160, 655, 140, 66, 66, 267, 1254, 448, 2, 2474, 1160, 8, 132, 256, 2, 8147, 1, 2617, 11, 44, 41, 5, 63, 282, 107, 66, 66, 655, 140, 1160, 13735, 2, 25301, 2617, 627, 4, 101, 286, 1562, 2, 1160, 13735, 2617, 42, 340, 429, 24146, 1160, 13735, 1254, 2617, 10, 41, 5, 142, 5064, 72, 5, 11080, 1160, 13735, 2617, 15, 1160, 13735, 5364, 2, 101, 63, 282, 72, 5, 11080, 1160, 13735, 2617, 4, 66, 66, 2, 79, 79, 655, 140, 1647, 2616, 28, 1160, 8, 132, 256, 2, 8147, 16, 616, 9, 665, 2092, 1488, 1085, 25, 2, 5863, 1, 24146, 1160, 13735, 11828, 4, 2632, 1160, 655, 2773, 16, 1103]",1407.0,25161269,25
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia.,The New England journal of medicine,N. Engl. J. Med.,2014-09-01,"Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is characterized by a gene-expression profile similar to that of BCR-ABL1-positive ALL, alterations of lymphoid transcription factor genes, and a poor outcome. The frequency and spectrum of genetic alterations in Ph-like ALL and its responsiveness to tyrosine kinase inhibition are undefined, especially in adolescents and adults. We performed genomic profiling of 1725 patients with precursor B-cell ALL and detailed genomic analysis of 154 patients with Ph-like ALL. We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL. Ph-like ALL increased in frequency from 10% among children with standard-risk ALL to 27% among young adults with ALL and was associated with a poor outcome. Kinase-activating alterations were identified in 91% of patients with Ph-like ALL; rearrangements involving ABL1, ABL2, CRLF2, CSF1R, EPOR, JAK2, NTRK3, PDGFRB, PTK2B, TSLP, or TYK2 and sequence mutations involving FLT3, IL7R, or SH2B3 were most common. Expression of ABL1, ABL2, CSF1R, JAK2, and PDGFRB fusions resulted in cytokine-independent proliferation and activation of phosphorylated STAT5. Cell lines and human leukemic cells expressing ABL1, ABL2, CSF1R, and PDGFRB fusions were sensitive in vitro to dasatinib, EPOR and JAK2 rearrangements were sensitive to ruxolitinib, and the ETV6-NTRK3 fusion was sensitive to crizotinib. Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways, all of which may be amenable to inhibition with approved tyrosine kinase inhibitors. Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of leukemia. (Funded by the American Lebanese Syrian Associated Charities and others.).",Journal Article,1968.0,559.0,Philadelphia chromosome-like acute lymphoblastic Ph-like ALL is characterized by a gene-expression profile similar to that of BCR-ABL1-positive ALL alterations of lymphoid transcription factor genes and a poor outcome The frequency and spectrum of genetic alterations in Ph-like ALL and its responsiveness to tyrosine kinase inhibition are undefined especially in adolescents and adults We performed genomic profiling of 1725 patients with precursor B-cell ALL and detailed genomic analysis of 154 patients with Ph-like ALL We examined the functional effects of fusion proteins and the efficacy of tyrosine kinase inhibitors in mouse pre-B cells and xenografts of human Ph-like ALL Ph-like ALL increased in frequency from 10 among children with standard-risk ALL to 27 among young adults with ALL and was associated with a poor outcome Kinase-activating alterations were identified in 91 of patients with Ph-like ALL rearrangements involving ABL1 ABL2 CRLF2 CSF1R EPOR JAK2 NTRK3 PDGFRB PTK2B TSLP or TYK2 and sequence mutations involving FLT3 IL7R or SH2B3 were most common Expression of ABL1 ABL2 CSF1R JAK2 and PDGFRB fusions resulted in cytokine-independent proliferation and activation of phosphorylated STAT5 Cell lines and human leukemic cells expressing ABL1 ABL2 CSF1R and PDGFRB fusions were sensitive in vitro to dasatinib EPOR and JAK2 rearrangements were sensitive to ruxolitinib and the ETV6-NTRK3 fusion was sensitive to crizotinib Ph-like ALL was found to be characterized by a range of genomic alterations that activate a limited number of signaling pathways all of which may be amenable to inhibition with approved tyrosine kinase inhibitors Trials identifying Ph-like ALL are needed to assess whether adding tyrosine kinase inhibitors to current therapy will improve the survival of patients with this type of Funded by the American Lebanese Syrian Associated Charities and others,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 733, 286, 1275, 2058, 733, 62, 16, 765, 20, 8, 145, 55, 800, 288, 6, 17, 1, 1062, 3557, 109, 62, 593, 1, 2303, 866, 161, 214, 2, 8, 334, 228, 3, 675, 2, 1873, 1, 336, 593, 4, 2058, 733, 62, 2, 211, 3642, 6, 564, 216, 297, 32, 5425, 1093, 4, 3101, 2, 857, 21, 173, 572, 1080, 1, 46993, 7, 5, 2765, 132, 31, 62, 2, 2455, 572, 65, 1, 4838, 7, 5, 2058, 733, 62, 21, 409, 3, 583, 176, 1, 1212, 652, 2, 3, 209, 1, 564, 216, 222, 4, 830, 671, 132, 37, 2, 1348, 1, 171, 2058, 733, 62, 2058, 733, 62, 101, 4, 675, 29, 79, 107, 541, 5, 260, 43, 62, 6, 428, 107, 1169, 857, 5, 62, 2, 10, 41, 5, 8, 334, 228, 216, 1616, 593, 11, 108, 4, 970, 1, 7, 5, 2058, 733, 62, 2072, 1267, 3557, 18452, 8895, 11978, 12839, 2509, 11004, 10231, 64902, 45159, 15, 22684, 2, 1532, 138, 1267, 1224, 22756, 15, 22757, 11, 96, 186, 55, 1, 3557, 18452, 11978, 2509, 2, 10231, 2530, 627, 4, 1675, 306, 457, 2, 363, 1, 2365, 5517, 31, 285, 2, 171, 2015, 37, 1046, 3557, 18452, 11978, 2, 10231, 2530, 11, 745, 4, 439, 6, 1674, 12839, 2, 2509, 2072, 11, 745, 6, 4894, 2, 3, 7306, 11004, 1212, 10, 745, 6, 2284, 2058, 733, 62, 10, 204, 6, 40, 765, 20, 8, 184, 1, 572, 593, 17, 2977, 8, 383, 207, 1, 314, 460, 62, 1, 92, 68, 40, 4070, 6, 297, 5, 850, 564, 216, 222, 143, 1386, 2058, 733, 62, 32, 575, 6, 423, 317, 2726, 564, 216, 222, 6, 291, 36, 303, 401, 3, 25, 1, 7, 5, 26, 267, 1, 3827, 20, 3, 597, 14666, 13671, 41, 14667, 2, 1749]",1899.0,25207766,509
Utility of the N-back task in survivors of childhood acute lymphoblastic leukemia.,Journal of clinical and experimental neuropsychology,J Clin Exp Neuropsychol,2014-09-25,"The N-back task is often used in functional brain imaging studies to activate working memory networks; however, limited information is available on its association to clinical outcomes in children or cancer survivors. A total of 137 survivors of acute lymphoblastic leukemia (ALL; mean current age = 14.3 years, SD = 4.8; time since diagnosis = 7.6 years, SD = 1.6) completed the N-back task and comprehensive neurocognitive testing, including standardized measures of attention, processing speed, and working memory. Results indicated that females demonstrated significantly slower reaction times (0-back p = .02; 1-back p = .03) than males. Survivors <15 years old at the time of testing demonstrated a significant decrease in accuracy as working memory load increased compared to survivors 15 years old (p < .001). Performance on the N-back task was associated with nonverbal working memory (rs = .56, p < .001) in survivors 15 years of age. For younger survivors, N-back performance was more strongly associated with attention skills. Results suggest the N-back assesses different cognitive constructs at younger compared to older childhood ages. These age differences should be considered in interpreting functional brain imaging results. ",Journal Article,1944.0,6.0,The N-back task is often used in functional brain imaging studies to activate working memory networks however limited information is available on its association to clinical outcomes in children or cancer survivors A total of 137 survivors of acute lymphoblastic ALL mean current age 14.3 years SD 4.8 time since diagnosis 7.6 years SD 1.6 completed the N-back task and comprehensive neurocognitive testing including standardized measures of attention processing speed and working memory Results indicated that females demonstrated significantly slower reaction times 0-back p .02 1-back p .03 than males Survivors 15 years old at the time of testing demonstrated a significant decrease in accuracy as working memory load increased compared to survivors 15 years old p .001 Performance on the N-back task was associated with nonverbal working memory rs .56 p .001 in survivors 15 years of age For younger survivors N-back performance was more strongly associated with attention skills Results suggest the N-back assesses different cognitive constructs at younger compared to older childhood ages These age differences should be considered in interpreting functional brain imaging results,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 78, 4636, 3488, 16, 629, 95, 4, 583, 342, 270, 94, 6, 2977, 2644, 2407, 3991, 137, 383, 487, 16, 390, 23, 211, 248, 6, 38, 123, 4, 541, 15, 12, 332, 8, 181, 1, 4352, 332, 1, 286, 1275, 62, 313, 291, 89, 213, 27, 60, 1270, 39, 66, 98, 1192, 147, 67, 49, 60, 1270, 14, 49, 781, 3, 78, 4636, 3488, 2, 949, 2958, 471, 141, 1670, 1018, 1, 2111, 3325, 5051, 2, 2644, 2407, 99, 1103, 17, 2451, 264, 97, 6715, 1329, 1072, 13, 4636, 19, 588, 14, 4636, 19, 680, 76, 2296, 332, 167, 60, 1095, 28, 3, 98, 1, 471, 264, 8, 93, 775, 4, 1190, 22, 2644, 2407, 3800, 101, 72, 6, 332, 10249, 60, 1095, 19, 144, 528, 23, 3, 78, 4636, 3488, 10, 41, 5, 37734, 2644, 2407, 2250, 664, 19, 144, 4, 332, 10249, 60, 1, 89, 9, 773, 332, 78, 4636, 528, 10, 80, 1327, 41, 5, 2111, 5909, 99, 309, 3, 78, 4636, 7777, 338, 1863, 5500, 28, 773, 72, 6, 434, 864, 2165, 46, 89, 362, 257, 40, 515, 4, 8876, 583, 342, 270, 99]",1189.0,25252969,134
NK cell genotype and phenotype at diagnosis of acute lymphoblastic leukemia correlate with postinduction residual disease.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2014-10-03,"Not all natural killer (NK) cells are equally cytotoxic against leukemia because of differences in receptor gene content and surface expression. We correlated NK cell genotype and phenotype at diagnosis of childhood acute lymphoblastic leukemia (ALL) with minimal residual disease (MRD) after induction chemotherapy. The NK cells and leukemia blasts of 244 patients were analyzed at diagnosis by killer-cell immunoglobulin-like receptor (KIR) typing and immunophenotyping. The results were correlated statistically with postinduction MRD status. The odds of being MRD positive in patients with KIR telomeric (Tel)-A/B genotype were 2.85 times the odds in those with Tel-A/A genotype (P = 0.035). MRD-positive patients were more likely to have KIR2DL5A (P = 0.006) and expressed less activating receptor NKp46 and FASL on their NK cells (P = 0.0074 and P = 0.029, respectively). The odds of being MRD positive increased by 2.01-fold for every percentage increase in NK cells expressing KIR2DL1 in the presence of HLA-C2 ligand (P = 0.034). The quantity of granzyme B inhibitor PI-9 in the leukemia blasts was greater in patients who were MRD positive (P = 0.038). Collectively, five NK cell-related factors (Tel-B-associated KIR2DL5A, NKp46, FASL, granzyme B, and PI-9) are strongly associated with MRD positivity at the end of induction with 100% sensitivity and 80% specificity. Our data support the hypothesis that NK cells with a strong effector phenotype in the setting of decreased leukemia resistance are associated with better leukemia control.",Journal Article,1936.0,13.0,Not all natural killer NK cells are equally cytotoxic against because of differences in receptor gene content and surface expression We correlated NK cell genotype and phenotype at diagnosis of childhood acute lymphoblastic ALL with minimal residual disease MRD after induction chemotherapy The NK cells and blasts of 244 patients were analyzed at diagnosis by killer-cell immunoglobulin-like receptor KIR typing and immunophenotyping The results were correlated statistically with postinduction MRD status The odds of being MRD positive in patients with KIR telomeric Tel -A/B genotype were 2.85 times the odds in those with Tel-A/A genotype P 0.035 MRD-positive patients were more likely to have KIR2DL5A P 0.006 and expressed less activating receptor NKp46 and FASL on their NK cells P 0.0074 and P 0.029 respectively The odds of being MRD positive increased by 2.01-fold for every percentage increase in NK cells expressing KIR2DL1 in the presence of HLA-C2 ligand P 0.034 The quantity of granzyme B inhibitor PI-9 in the blasts was greater in patients who were MRD positive P 0.038 Collectively five NK cell-related factors Tel-B-associated KIR2DL5A NKp46 FASL granzyme B and PI-9 are strongly associated with MRD positivity at the end of induction with 100 sensitivity and 80 specificity Our data support the hypothesis that NK cells with a strong effector phenotype in the setting of decreased resistance are associated with better control,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[44, 62, 1504, 3458, 1765, 37, 32, 4142, 759, 480, 408, 1, 362, 4, 153, 145, 2457, 2, 1255, 55, 21, 438, 1765, 31, 1183, 2, 1005, 28, 147, 1, 864, 286, 1275, 62, 5, 1048, 753, 34, 2029, 50, 504, 56, 3, 1765, 37, 2, 2438, 1, 6567, 7, 11, 311, 28, 147, 20, 3458, 31, 2593, 733, 153, 6989, 10656, 2, 9416, 3, 99, 11, 438, 712, 5, 12543, 2029, 156, 3, 610, 1, 486, 2029, 109, 4, 7, 5, 6989, 10944, 8573, 8, 132, 1183, 11, 18, 772, 1072, 3, 610, 4, 135, 5, 8573, 8, 8, 1183, 19, 13, 4514, 2029, 109, 7, 11, 80, 322, 6, 47, 48628, 19, 13, 1861, 2, 570, 299, 1616, 153, 19261, 2, 8761, 23, 136, 1765, 37, 19, 13, 22236, 2, 19, 13, 4770, 106, 3, 610, 1, 486, 2029, 109, 101, 20, 18, 355, 1116, 9, 454, 1150, 344, 4, 1765, 37, 1046, 26842, 4, 3, 463, 1, 1160, 6706, 1232, 19, 13, 5337, 3, 7701, 1, 9965, 132, 230, 2928, 83, 4, 3, 2438, 10, 378, 4, 7, 54, 11, 2029, 109, 19, 13, 5215, 2535, 365, 1765, 31, 139, 130, 8573, 132, 41, 48628, 19261, 8761, 9965, 132, 2, 2928, 83, 32, 1327, 41, 5, 2029, 1887, 28, 3, 396, 1, 504, 5, 394, 485, 2, 493, 1121, 114, 74, 538, 3, 1492, 17, 1765, 37, 5, 8, 1082, 2070, 1005, 4, 3, 546, 1, 340, 251, 32, 41, 5, 380, 182]",1446.0,25281696,259
Therapy-related myelodysplastic syndrome/acute leukemia after multiple myeloma in the era of novel agents.,Leukemia & lymphoma,Leuk. Lymphoma,2014-11-03,"Survival for patients with multiple myeloma has increased. Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia. We reviewed the cases of all patients with multiple myeloma who had subsequent development of myelodysplastic syndrome (MDS) or acute non-lymphoblastic leukemia (ANLL) during a 12-year period in three centers. Of 55 patients identified, two received only lenalidomide before myelodysplasia developed. The median time between the diagnoses of multiple myeloma and MDS/ANLL was 52.7 months. Median survival after the diagnosis of MDS or ANLL was 6.7 months. Treatment of MDS comprised allogeneic stem cell transplant in eight patients (median survival, 219 days; one patient alive at 624 days) and a hypomethylating agent in 21 patients (response of stable or better in five patients). Myelodysplasia remains a devastating complication of therapy for multiple myeloma, with short survival and poor response rates to available modalities. ",Journal Article,1905.0,8.0,Survival for patients with multiple has increased Both melphalan and lenalidomide are associated with subsequent development of myelodysplasia We reviewed the cases of all patients with multiple who had subsequent development of syndrome MDS or acute non-lymphoblastic ANLL during a 12-year period in three centers Of 55 patients identified two received only lenalidomide before myelodysplasia developed The median time between the diagnoses of multiple and MDS/ANLL was 52.7 months Median survival after the diagnosis of MDS or ANLL was 6.7 months Treatment of MDS comprised allogeneic stem cell transplant in eight patients median survival 219 days one patient alive at 624 days and a hypomethylating agent in 21 patients response of stable or better in five patients Myelodysplasia remains a devastating complication of therapy for multiple with short survival and poor response rates to available modalities,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[25, 9, 7, 5, 232, 71, 101, 110, 2370, 2, 1288, 32, 41, 5, 706, 193, 1, 6128, 21, 446, 3, 140, 1, 62, 7, 5, 232, 54, 42, 706, 193, 1, 681, 1223, 15, 286, 220, 1275, 27864, 190, 8, 133, 111, 727, 4, 169, 1168, 1, 614, 7, 108, 100, 103, 158, 1288, 348, 6128, 276, 3, 52, 98, 59, 3, 2403, 1, 232, 2, 1223, 27864, 10, 653, 67, 53, 52, 25, 50, 3, 147, 1, 1223, 15, 27864, 10, 49, 67, 53, 24, 1, 1223, 2603, 1063, 452, 31, 941, 4, 659, 7, 52, 25, 6679, 162, 104, 69, 1701, 28, 10999, 162, 2, 8, 4931, 420, 4, 239, 7, 51, 1, 585, 15, 380, 4, 365, 7, 6128, 469, 8, 5778, 1447, 1, 36, 9, 232, 5, 978, 25, 2, 334, 51, 151, 6, 390, 1558]",911.0,25284489,571
"Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.",Cancer control : journal of the Moffitt Cancer Center,Cancer Control,2014-10-01,"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy with an aggressive clinical course. Most patients with BPDCN have skin lesions and simultaneous involvement of the peripheral blood, bone marrow, and lymph nodes. A search of PubMed and Medline was conducted for English-written articles relating to BPDCN, CD4(+)CD56(+) hematodermic neoplasm, and blastic natural killer cell lymphoma. Data regarding diagnosis, prognosis, and treatment were analyzed. BPDCN is derived from precursor plasmacytoid dendritic cells. The diagnosis of BPDCN is based on the characteristic cytology and immunophenotype of malignant cells coexpressing CD4, CD56, CD123, blood dendritic cell antigens 2 and 4, and CD2AP markers. Multiple chromosomal abnormalities and gene mutations previously reported in patients with myeloid and selected lymphoid neoplasms were identified in approximately 60% of patients with BPDCN. Prospectively controlled studies to guide treatment decisions are lacking. The overall response rate with aggressive acute lymphoblastic leukemia-type induction regimens was as high as 90%, but the durability of response was short. Median survival rates ranged between 12 and 16 months. Patients with relapsed disease may respond to L-asparaginase-containing regimens. Allogeneic hematopoietic stem cell transplantation, particularly when performed during the first remission, may produce durable remissions in selected adults. BPDCN is a rare aggressive disease that typically affects elderly patients. The most commonly affected nonhematopoietic organ is the skin. Although BPDCN is initially sensitive to conventional chemotherapy regimens, this response is relatively short and long-term prognosis is poor. In the near future, novel targeted therapies may improve outcomes for patients with BPDCN.",Journal Article,1938.0,45.0,Blastic plasmacytoid dendritic cell neoplasm BPDCN is a rare hematological malignancy with an aggressive clinical course Most patients with BPDCN have lesions and simultaneous involvement of the peripheral blood marrow and lymph nodes A search of PubMed and Medline was conducted for English-written articles relating to BPDCN CD4 CD56 hematodermic neoplasm and blastic natural killer cell Data regarding diagnosis prognosis and treatment were analyzed BPDCN is derived from precursor plasmacytoid dendritic cells The diagnosis of BPDCN is based on the characteristic cytology and immunophenotype of malignant cells coexpressing CD4 CD56 CD123 blood dendritic cell antigens 2 and 4 and CD2AP markers Multiple chromosomal abnormalities and gene mutations previously reported in patients with myeloid and selected lymphoid neoplasms were identified in approximately 60 of patients with BPDCN Prospectively controlled studies to guide treatment decisions are lacking The overall response rate with aggressive acute lymphoblastic leukemia-type induction regimens was as high as 90 but the durability of response was short Median survival rates ranged between 12 and 16 months Patients with relapsed disease may respond to L-asparaginase-containing regimens Allogeneic hematopoietic stem cell transplantation particularly when performed during the first remission may produce durable remissions in selected adults BPDCN is a rare aggressive disease that typically affects elderly patients The most commonly affected nonhematopoietic organ is the Although BPDCN is initially sensitive to conventional chemotherapy regimens this response is relatively short and long-term prognosis is poor In the near future novel targeted therapies may improve outcomes for patients with BPDCN,0,0,1,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,"[6529, 7978, 2464, 31, 2131, 8556, 16, 8, 622, 2890, 710, 5, 35, 571, 38, 906, 96, 7, 5, 8556, 47, 406, 2, 2824, 799, 1, 3, 672, 315, 581, 2, 263, 502, 8, 1901, 1, 3161, 2, 3388, 10, 426, 9, 4201, 6538, 2384, 7750, 6, 8556, 1440, 5803, 34949, 2131, 2, 6529, 1504, 3458, 31, 74, 666, 147, 356, 2, 24, 11, 311, 8556, 16, 526, 29, 2765, 7978, 2464, 37, 3, 147, 1, 8556, 16, 90, 23, 3, 2037, 2045, 2, 5496, 1, 393, 37, 16629, 1440, 5803, 8849, 315, 2464, 31, 1575, 18, 2, 39, 2, 40263, 525, 232, 1860, 1171, 2, 145, 138, 373, 210, 4, 7, 5, 533, 2, 715, 2303, 1179, 11, 108, 4, 705, 335, 1, 7, 5, 8556, 1143, 1149, 94, 6, 1597, 24, 1526, 32, 1941, 3, 63, 51, 116, 5, 571, 286, 1275, 2647, 267, 504, 472, 10, 22, 64, 22, 424, 84, 3, 6867, 1, 51, 10, 978, 52, 25, 151, 1869, 59, 133, 2, 245, 53, 7, 5, 591, 34, 68, 1892, 6, 805, 3709, 1101, 472, 1063, 1007, 452, 31, 497, 823, 198, 173, 190, 3, 157, 734, 68, 2410, 1480, 3166, 4, 715, 857, 8556, 16, 8, 622, 571, 34, 17, 1969, 2561, 1216, 7, 3, 96, 841, 1424, 19463, 1259, 16, 3, 242, 8556, 16, 1625, 745, 6, 809, 56, 472, 26, 51, 16, 1352, 978, 2, 319, 337, 356, 16, 334, 4, 3, 1829, 508, 229, 238, 235, 68, 401, 123, 9, 7, 5, 8556]",1771.0,25310209,272
Regional brain glucose metabolism and neurocognitive function in adult survivors of childhood cancer treated with cranial radiation.,"Journal of nuclear medicine : official publication, Society of Nuclear Medicine",J. Nucl. Med.,2014-10-14,"The objective of this study was to examine associations between regional brain metabolism, as measured by (18)F-FDG PET, and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic leukemia (ALL) treated with cranial radiation. Thirty-eight adult survivors of ALL were randomly selected from a large cohort treated with cranial radiation therapy (19 with 18 Gy and 19 with 24 Gy of exposure). At a mean age of 26.4 (range, 22.3-37.4) years, and 23.5 (range, 20.4-32.8) years since diagnosis, patients underwent comprehensive neurocognitive evaluations and brain (18)F-FDG PET imaging during a resting condition. (18)F-FDG PET images were analyzed stereotactically, and pixel values were normalized to global activity. Predefined region-of-interest and voxel-based correlation analyses were performed. Compared with national norms, survivors demonstrated lower vocabulary (P < 0.001), reading (P < 0.001), mathematics (P < 0.001), working memory (P < 0.001), oral naming speed (P < 0.001), and cognitive flexibility (P < 0.001). Metabolic activity was higher in basal gangliar structures for those treated with 24 Gy of cranial radiation therapy (P = 0.04). Metabolic activity was positively correlated with oral naming speed in both lateral frontal lobes ( = 0.48 and 0.47 for right and left frontal regions, respectively, P < 0.01) and negatively correlated with cognitive flexibility in the sections of the basal ganglia (P < 0.01 for both caudate and putamen). Neurocognitive impairment in long-term survivors of ALL treated with cranial radiation appears to be associated with increased metabolic activity in frontal cerebral cortical and subcortical regions in the basal ganglia, suggesting decreased efficiency of the frontostriatal brain circuit.",Journal Article,1925.0,10.0,The objective of this study was to examine associations between regional brain metabolism as measured by 18 F-FDG PET and neurocognitive outcomes in adult survivors of childhood acute lymphoblastic ALL treated with cranial radiation Thirty-eight adult survivors of ALL were randomly selected from a large cohort treated with cranial radiation therapy 19 with 18 Gy and 19 with 24 Gy of exposure At a mean age of 26.4 range 22.3-37.4 years and 23.5 range 20.4-32.8 years since diagnosis patients underwent comprehensive neurocognitive evaluations and brain 18 F-FDG PET imaging during a resting condition 18 F-FDG PET images were analyzed stereotactically and pixel values were normalized to global activity Predefined region-of-interest and voxel-based correlation analyses were performed Compared with national norms survivors demonstrated lower vocabulary P 0.001 reading P 0.001 mathematics P 0.001 working memory P 0.001 oral naming speed P 0.001 and cognitive flexibility P 0.001 Metabolic activity was higher in basal gangliar structures for those treated with 24 Gy of cranial radiation therapy P 0.04 Metabolic activity was positively correlated with oral naming speed in both lateral frontal lobes  0.48 and 0.47 for right and left frontal regions respectively P 0.01 and negatively correlated with cognitive flexibility in the sections of the basal ganglia P 0.01 for both caudate and putamen Neurocognitive impairment in long-term survivors of ALL treated with cranial radiation appears to be associated with increased metabolic activity in frontal cerebral cortical and subcortical regions in the basal ganglia suggesting decreased efficiency of the frontostriatal brain circuit,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 461, 1, 26, 45, 10, 6, 1004, 685, 59, 951, 342, 1600, 22, 644, 20, 203, 1068, 1285, 495, 2, 2958, 123, 4, 780, 332, 1, 864, 286, 1275, 62, 73, 5, 2565, 121, 977, 659, 780, 332, 1, 62, 11, 1108, 715, 29, 8, 375, 180, 73, 5, 2565, 121, 36, 326, 5, 203, 381, 2, 326, 5, 259, 381, 1, 645, 28, 8, 313, 89, 1, 432, 39, 184, 350, 27, 567, 39, 60, 2, 382, 33, 184, 179, 39, 531, 66, 60, 1192, 147, 7, 208, 949, 2958, 3816, 2, 342, 203, 1068, 1285, 495, 270, 190, 8, 11620, 2850, 203, 1068, 1285, 495, 1572, 11, 311, 18855, 2, 13070, 1030, 11, 4207, 6, 1648, 128, 5944, 1053, 1, 1333, 2, 8400, 90, 816, 318, 11, 173, 72, 5, 657, 9875, 332, 264, 280, 27249, 19, 13, 144, 7299, 19, 13, 144, 28421, 19, 13, 144, 2644, 2407, 19, 13, 144, 518, 22220, 5051, 19, 13, 144, 2, 1863, 9794, 19, 13, 144, 1436, 128, 10, 142, 4, 2135, 65074, 2414, 9, 135, 73, 5, 259, 381, 1, 2565, 121, 36, 19, 13, 755, 1436, 128, 10, 2375, 438, 5, 518, 22220, 5051, 4, 110, 3855, 8082, 9231, 7128, 13, 576, 2, 13, 662, 9, 1913, 2, 1712, 8082, 1374, 106, 19, 13, 355, 2, 2723, 438, 5, 1863, 9794, 4, 3, 3013, 1, 3, 2135, 15381, 19, 13, 355, 9, 110, 10199, 2, 40167, 2958, 2315, 4, 319, 337, 332, 1, 62, 73, 5, 2565, 121, 1233, 6, 40, 41, 5, 101, 1436, 128, 4, 8082, 3549, 4500, 2, 21484, 1374, 4, 3, 2135, 15381, 802, 340, 2904, 1, 3, 35910, 342, 14944]",1691.0,25315244,73
"Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.",Blood,Blood,2014-10-14,"High-dose, posttransplantation cyclophosphamide (PTCy) reduces severe graft-versus-host disease (GVHD) after allogeneic blood or marrow transplantation (alloBMT), but the impact of PTCy on long-term, disease-specific outcomes is unclear. We conducted a retrospective study of 209 consecutive adult patients transplanted for acute myeloid leukemia (AML, n = 138), myelodysplastic syndrome (n = 28), or acute lymphoblastic leukemia (ALL, n = 43) using PTCy as sole GVHD prophylaxis after myeloablative conditioning and HLA-matched-related or -unrelated T-cell-replete allografting. At alloBMT, 30% of patients were not in morphologic complete remission. The cumulative incidences of grades II to IV and III to IV acute GVHD at 100 days and chronic GVHD at 2 years were 45%, 11%, and 13%, respectively. Forty-three percent of patients did not require immunosuppression for any reason beyond PTCy. At 3 years, relapse cumulative incidence was 36%, disease-free survival was 46%, survival free of disease and chronic GVHD was 39%, and overall survival was 58%. Lack of remission at alloBMT, adverse cytogenetics, and low allograft nucleated cell dose were associated with inferior survival for AML patients. Minimal residual disease but not t(9;22) was associated with inferior outcomes for ALL patients. The ability to limit posttransplantation immunosuppression makes PTCy a promising transplantation platform for the integration of postgrafting strategies to prevent relapse. ",Journal Article,1925.0,78.0,High-dose posttransplantation cyclophosphamide PTCy reduces severe graft-versus-host disease GVHD after allogeneic blood or marrow transplantation alloBMT but the impact of PTCy on long-term disease-specific outcomes is unclear We conducted a retrospective study of 209 consecutive adult patients transplanted for acute myeloid AML n 138 syndrome n 28 or acute lymphoblastic ALL n 43 using PTCy as sole GVHD prophylaxis after myeloablative conditioning and HLA-matched-related or -unrelated T-cell-replete allografting At alloBMT 30 of patients were not in morphologic complete remission The cumulative incidences of grades II to IV and III to IV acute GVHD at 100 days and chronic GVHD at 2 years were 45 11 and 13 respectively Forty-three percent of patients did not require immunosuppression for any reason beyond PTCy At 3 years relapse cumulative incidence was 36 disease-free survival was 46 survival free of disease and chronic GVHD was 39 and overall survival was 58 Lack of remission at alloBMT adverse cytogenetics and low allograft nucleated cell dose were associated with inferior survival for AML patients Minimal residual disease but not t 9 22 was associated with inferior outcomes for ALL patients The ability to limit posttransplantation immunosuppression makes PTCy a promising transplantation platform for the integration of postgrafting strategies to prevent relapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[64, 61, 8046, 1112, 10932, 2389, 905, 1599, 185, 1204, 34, 1562, 50, 1063, 315, 15, 581, 497, 13051, 84, 3, 345, 1, 10932, 23, 319, 337, 34, 112, 123, 16, 1200, 21, 426, 8, 459, 45, 1, 5941, 935, 780, 7, 4600, 9, 286, 533, 329, 78, 4478, 681, 78, 339, 15, 286, 1275, 62, 78, 601, 75, 10932, 22, 4991, 1562, 2049, 50, 3246, 1933, 2, 1160, 655, 139, 15, 2092, 102, 31, 11151, 16181, 28, 13051, 201, 1, 7, 11, 44, 4, 2815, 236, 734, 3, 967, 3981, 1, 2276, 215, 6, 478, 2, 316, 6, 478, 286, 1562, 28, 394, 162, 2, 442, 1562, 28, 18, 60, 11, 512, 175, 2, 233, 106, 1213, 169, 714, 1, 7, 205, 44, 1353, 3646, 9, 500, 3852, 1654, 10932, 28, 27, 60, 429, 967, 287, 10, 511, 34, 115, 25, 10, 641, 25, 115, 1, 34, 2, 442, 1562, 10, 587, 2, 63, 25, 10, 717, 926, 1, 734, 28, 13051, 290, 2510, 2, 154, 9568, 9862, 31, 61, 11, 41, 5, 1663, 25, 9, 329, 7, 1048, 753, 34, 84, 44, 102, 83, 350, 10, 41, 5, 1663, 123, 9, 62, 7, 3, 801, 6, 2385, 8046, 3646, 4677, 10932, 8, 721, 497, 2243, 9, 3, 2676, 1, 28085, 422, 6, 1682, 429]",1386.0,25316679,41
Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies.,Archives of toxicology,Arch. Toxicol.,2014-10-21,"Despite the clinical efficacy achieved with frontline therapies for BCR-ABL-positive disease, such as imatinib and second-generation ABL inhibitors like nilotinib or dasatinib that were originally designed to override insensitivity to imatinib, drug resistance still remains a challenge, especially for patients with advanced-stage chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. The discovery of BCR-ABL point mutations has been a great asset to furthering our understanding of a major cause of drug resistance, as has discovery of multidrug resistance proteins, dysregulation of signaling molecules downstream of BCR-ABL, and insights into the underlying causes of stromal-mediated chemoresistance. Such elucidation of mechanisms of resistance associated with leukemic cell survival is essential for the optimization of current therapies and enhancement of patient survival via delaying or preventing disease recurrence. Here, we present an overview of the use of nilotinib in combination with other agents against BCR-ABL-positive leukemia, as well as solid tumors, for the purpose of increasing clinical efficacy and overriding drug resistance. ",Journal Article,1918.0,2.0,Despite the clinical efficacy achieved with frontline therapies for BCR-ABL-positive disease such as imatinib and second-generation ABL inhibitors like nilotinib or dasatinib that were originally designed to override insensitivity to imatinib drug resistance still remains a challenge especially for patients with advanced-stage chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic The discovery of BCR-ABL point mutations has been a great asset to furthering our understanding of a major cause of drug resistance as has discovery of multidrug resistance proteins dysregulation of signaling molecules downstream of BCR-ABL and insights into the underlying causes of stromal-mediated chemoresistance Such elucidation of mechanisms of resistance associated with leukemic cell survival is essential for the optimization of current therapies and enhancement of patient survival via delaying or preventing disease recurrence Here we present an overview of the use of nilotinib in combination with other agents against BCR-ABL-positive as well as solid tumors for the purpose of increasing clinical efficacy and overriding drug resistance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,"[550, 3, 38, 209, 513, 5, 3171, 235, 9, 1062, 1425, 109, 34, 225, 22, 577, 2, 419, 914, 1425, 222, 733, 2638, 15, 1674, 17, 11, 5045, 1114, 6, 17358, 14488, 6, 577, 234, 251, 1234, 469, 8, 1745, 1093, 9, 7, 5, 131, 82, 442, 533, 15, 3006, 1170, 109, 286, 1275, 3, 1574, 1, 1062, 1425, 741, 138, 71, 85, 8, 2797, 35891, 6, 30835, 114, 612, 1, 8, 458, 708, 1, 234, 251, 22, 71, 1574, 1, 4814, 251, 652, 3935, 1, 314, 1598, 1489, 1, 1062, 1425, 2, 1957, 237, 3, 1181, 1626, 1, 1126, 517, 3782, 225, 7481, 1, 483, 1, 251, 41, 5, 2015, 31, 25, 16, 1452, 9, 3, 3980, 1, 291, 235, 2, 2461, 1, 69, 25, 847, 7151, 15, 3017, 34, 146, 467, 21, 364, 35, 2901, 1, 3, 119, 1, 2638, 4, 150, 5, 127, 183, 480, 1062, 1425, 109, 22, 149, 22, 537, 57, 9, 3, 743, 1, 602, 38, 209, 2, 23487, 234, 251]",1151.0,25331939,145
Structure-guided development of deoxycytidine kinase inhibitors with nanomolar affinity and improved metabolic stability.,Journal of medicinal chemistry,J. Med. Chem.,2014-11-07,"Recently, we have shown that small molecule dCK inhibitors in combination with pharmacological perturbations of de novo dNTP biosynthetic pathways could eliminate acute lymphoblastic leukemia cells in animal models. However, our previous lead compound had a short half-life in vivo. Therefore, we set out to develop dCK inhibitors with favorable pharmacokinetic properties. We delineated the sites of the inhibitor for modification, guided by crystal structures of dCK in complex with the lead compound and with derivatives. Crystal structure of the complex between dCK and the racemic mixture of our new lead compound indicated that the R-isomer is responsible for kinase inhibition. This was corroborated by kinetic analysis of the purified enantiomers, which showed that the R-isomer has >60-fold higher affinity than the S-isomer for dCK. This new lead compound has significantly improved metabolic stability, making it a prime candidate for dCK-inhibitor based therapies against hematological malignancies and, potentially, other cancers. ",Journal Article,1901.0,9.0,Recently we have shown that small molecule dCK inhibitors in combination with pharmacological perturbations of de novo dNTP biosynthetic pathways could eliminate acute lymphoblastic cells in animal models However our previous lead compound had a short half-life in vivo Therefore we set out to develop dCK inhibitors with favorable pharmacokinetic properties We delineated the sites of the inhibitor for modification guided by crystal structures of dCK in complex with the lead compound and with derivatives Crystal structure of the complex between dCK and the racemic mixture of our new lead compound indicated that the R-isomer is responsible for kinase inhibition This was corroborated by kinetic analysis of the purified enantiomers which showed that the R-isomer has 60-fold higher affinity than the S-isomer for dCK This new lead compound has significantly improved metabolic stability making it a prime candidate for dCK-inhibitor based therapies against hematological malignancies and potentially other cancers,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[761, 21, 47, 443, 17, 302, 1354, 16320, 222, 4, 150, 5, 3419, 7013, 1, 1566, 2018, 25152, 16581, 460, 359, 4964, 286, 1275, 37, 4, 2026, 274, 137, 114, 698, 1122, 2823, 42, 8, 978, 1303, 358, 4, 386, 673, 21, 916, 1205, 6, 690, 16320, 222, 5, 913, 1456, 1571, 21, 5610, 3, 633, 1, 3, 230, 9, 2437, 1808, 20, 9197, 2414, 1, 16320, 4, 840, 5, 3, 1122, 2823, 2, 5, 6490, 9197, 2772, 1, 3, 840, 59, 16320, 2, 3, 27401, 6972, 1, 114, 217, 1122, 2823, 1103, 17, 3, 668, 23360, 16, 2327, 9, 216, 297, 26, 10, 10049, 20, 7009, 65, 1, 3, 5963, 40877, 92, 224, 17, 3, 668, 23360, 71, 335, 1116, 142, 3601, 76, 3, 695, 23360, 9, 16320, 26, 217, 1122, 2823, 71, 97, 231, 1436, 2769, 1079, 192, 8, 8180, 1609, 9, 16320, 230, 90, 235, 480, 2890, 441, 2, 751, 127, 163]",1018.0,25341194,376
"Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia.",American journal of hematology,Am. J. Hematol.,2014-11-19,"Newer approaches are needed for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). Asparaginase-based regimens are active in the treatment of pediatric ALL and may be important in salvage therapy for adult patients. We conducted a pilot trial combining methotrexate, vincristine, PEGylated-asparaginase, and dexamethasone (MOpAD) in adults with relapsed or refractory ALL. We added tyrosine kinase inhibitors in patients with Philadelphia chromosome positive (Ph+) ALL and rituximab in patients with CD20 positive B-cell ALL. Among 37 patients treated (median age 42 years; median 2 prior therapies), the complete remission (CR) rate was 28% and an overall response rate (ORR) was 39%. The median CR duration was 4.3 months. Patients with Ph+ ALL had CR and ORR of 50% and 67%, respectively and the CR and ORR in patients with T-cell leukemia were 45% and 56%, respectively. The median survival in patients with CR/CRp was 10.4 versus 3.4 months in nonresponders (P=0.02). The most common grade 3 or 4 nonhematologic toxicities were elevations in bilirubin and transaminases, nausea, peripheral neuropathy, and hyperglycemia, which were managed with supportive care, dose adjustments, and interruptions.","Clinical Trial, Phase II",1889.0,12.0,Newer approaches are needed for the treatment of relapsed and refractory acute lymphoblastic ALL Asparaginase-based regimens are active in the treatment of pediatric ALL and may be important in salvage therapy for adult patients We conducted a pilot trial combining methotrexate vincristine PEGylated-asparaginase and dexamethasone MOpAD in adults with relapsed or refractory ALL We added tyrosine kinase inhibitors in patients with Philadelphia chromosome positive Ph+ ALL and rituximab in patients with CD20 positive B-cell ALL Among 37 patients treated median age 42 years median 2 prior therapies the complete remission CR rate was 28 and an overall response rate ORR was 39 The median CR duration was 4.3 months Patients with Ph+ ALL had CR and ORR of 50 and 67 respectively and the CR and ORR in patients with T-cell were 45 and 56 respectively The median survival in patients with CR/CRp was 10.4 versus 3.4 months in nonresponders P 0.02 The most common grade 3 or 4 nonhematologic toxicities were elevations in bilirubin and transaminases nausea peripheral neuropathy and hyperglycemia which were managed with supportive care dose adjustments and interruptions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2246, 611, 32, 575, 9, 3, 24, 1, 591, 2, 430, 286, 1275, 62, 3709, 90, 472, 32, 544, 4, 3, 24, 1, 815, 62, 2, 68, 40, 305, 4, 992, 36, 9, 780, 7, 21, 426, 8, 2281, 160, 1525, 2116, 2132, 4424, 3709, 2, 1217, 65137, 4, 857, 5, 591, 15, 430, 62, 21, 1953, 564, 216, 222, 4, 7, 5, 3006, 1170, 109, 2058, 62, 2, 855, 4, 7, 5, 2198, 109, 132, 31, 62, 107, 567, 7, 73, 52, 89, 595, 60, 52, 18, 324, 235, 3, 236, 734, 684, 116, 10, 339, 2, 35, 63, 51, 116, 1735, 10, 587, 3, 52, 684, 654, 10, 39, 27, 53, 7, 5, 2058, 62, 42, 684, 2, 1735, 1, 212, 2, 598, 106, 2, 3, 684, 2, 1735, 4, 7, 5, 102, 31, 11, 512, 2, 664, 106, 3, 52, 25, 4, 7, 5, 684, 3162, 10, 79, 39, 185, 27, 39, 53, 4, 4498, 19, 13, 588, 3, 96, 186, 88, 27, 15, 39, 3534, 385, 11, 4712, 4, 5009, 2, 9359, 1218, 672, 1751, 2, 3992, 92, 11, 2231, 5, 1877, 165, 61, 6017, 2, 7406]",1169.0,25368968,461
Mixed phenotype acute leukemia: A study of 61 cases using World Health Organization and European Group for the Immunological Classification of Leukaemias criteria.,American journal of clinical pathology,Am. J. Clin. Pathol.,2014-12-01,"The 2008 World Health Organization (WHO) classification system grouped bilineal and biphenotypic acute leukemias together under a new heading of mixed phenotype acute leukemia (MPAL). The lineage-specific marker criteria have also changed for a diagnosis of MPAL. The goal of this study was to characterize clinical significance of this new group. Sixty-one patients diagnosed with MPAL using either European Group for the Immunological Classification of Leukaemias (EGIL) criteria or 2008 WHO criteria were included in this study. Sixteen patients (26%) diagnosed with acute biphenotypic leukemia using EGIL criteria did not fulfill 2008 WHO criteria for MPAL. Cytogenetic data were available for 32 patients, and the most common abnormality was t(9;22) (five of 32 cases). Clinical outcome data suggested that younger patients with MPAL (21 years) had better overall survival (OS) in both the EGIL and WHO groups (EGIL, P = .0403; WHO, P = .0601). Compared with 177 patients with acute myeloid leukemia (AML), MPAL patients had better OS (P = .0003) and progression-free survival (P = .0001). However, no difference in OS between MPAL and 387 patients with acute lymphoblastic leukemia was present (P = .599). As defined by the 2008 WHO classification, fewer patients are now classified as having MPAL than with the EGIL criteria. In this study, patients with MPAL have a better clinical outcome compared with patients with AML.",Journal Article,1877.0,35.0,The 2008 World Health Organization WHO classification system grouped bilineal and biphenotypic acute leukemias together under a new heading of mixed phenotype acute MPAL The lineage-specific marker criteria have also changed for a diagnosis of MPAL The goal of this study was to characterize clinical significance of this new group Sixty-one patients diagnosed with MPAL using either European Group for the Immunological Classification of Leukaemias EGIL criteria or 2008 WHO criteria were included in this study Sixteen patients 26 diagnosed with acute biphenotypic using EGIL criteria did not fulfill 2008 WHO criteria for MPAL Cytogenetic data were available for 32 patients and the most common abnormality was t 9 22 five of 32 cases Clinical outcome data suggested that younger patients with MPAL 21 years had better overall survival OS in both the EGIL and WHO groups EGIL P .0403 WHO P .0601 Compared with 177 patients with acute myeloid AML MPAL patients had better OS P .0003 and progression-free survival P .0001 However no difference in OS between MPAL and 387 patients with acute lymphoblastic was present P .599 As defined by the 2008 WHO classification fewer patients are now classified as having MPAL than with the EGIL criteria In this study patients with MPAL have a better clinical outcome compared with patients with AML,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1375, 1956, 341, 2533, 54, 947, 398, 3706, 65160, 2, 20205, 286, 2792, 1162, 669, 8, 217, 28780, 1, 1739, 1005, 286, 9407, 3, 2542, 112, 952, 371, 47, 120, 2368, 9, 8, 147, 1, 9407, 3, 1326, 1, 26, 45, 10, 6, 1507, 38, 724, 1, 26, 217, 87, 1746, 104, 7, 265, 5, 9407, 75, 361, 1865, 87, 9, 3, 5073, 947, 1, 12160, 26135, 371, 15, 1375, 54, 371, 11, 159, 4, 26, 45, 3228, 7, 432, 265, 5, 286, 20205, 75, 26135, 371, 205, 44, 11246, 1375, 54, 371, 9, 9407, 1266, 74, 11, 390, 9, 531, 7, 2, 3, 96, 186, 3698, 10, 102, 83, 350, 365, 1, 531, 140, 38, 228, 74, 1148, 17, 773, 7, 5, 9407, 22725, 60, 42, 380, 63, 25, 118, 4, 110, 3, 26135, 2, 54, 271, 26135, 19, 65161, 54, 19, 65162, 72, 5, 4699, 7, 5, 286, 533, 329, 9407, 7, 42, 380, 118, 19, 4418, 2, 91, 115, 25, 19, 488, 137, 77, 523, 4, 118, 59, 9407, 2, 9513, 7, 5, 286, 1275, 10, 364, 19, 13029, 22, 395, 20, 3, 1375, 54, 947, 1497, 7, 32, 1134, 1373, 22, 1041, 9407, 76, 5, 3, 26135, 371, 4, 26, 45, 7, 5, 9407, 47, 8, 380, 38, 228, 72, 5, 7, 5, 329]",1340.0,25389334,309
Oncogene regulation. An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element.,"Science (New York, N.Y.)",Science,2014-11-13,"In certain human cancers, the expression of critical oncogenes is driven from large regulatory elements, called super-enhancers, that recruit much of the cell's transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 (H3K27ac). In a subset of T-cell acute lymphoblastic leukemia (T-ALL) cases, we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site, which creates a super-enhancer upstream of the TAL1 oncogene. MYB binds to this new site and recruits its H3K27 acetylase-binding partner CBP, as well as core components of a major leukemogenic transcriptional complex that contains RUNX1, GATA-3, and TAL1 itself. Additionally, most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP, which suggests a general role for MYB in super-enhancer initiation. Thus, this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells. ",Journal Article,1895.0,285.0,In certain human cancers the expression of critical oncogenes is driven from large regulatory elements called super-enhancers that recruit much of the cell 's transcriptional apparatus and are defined by extensive acetylation of histone H3 lysine 27 H3K27ac In a subset of T-cell acute lymphoblastic T-ALL cases we found that heterozygous somatic mutations are acquired that introduce binding motifs for the MYB transcription factor in a precise noncoding site which creates a super-enhancer upstream of the TAL1 oncogene MYB binds to this new site and recruits its H3K27 acetylase-binding partner CBP as well as core components of a major leukemogenic transcriptional complex that contains RUNX1 GATA-3 and TAL1 itself Additionally most endogenous super-enhancers found in T-ALL cells are occupied by MYB and CBP which suggests a general role for MYB in super-enhancer initiation Thus this study identifies a genetic mechanism responsible for the generation of oncogenic super-enhancers in malignant cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 1840, 171, 163, 3, 55, 1, 740, 3326, 16, 1621, 29, 375, 1253, 2531, 3472, 10582, 9139, 17, 8973, 1802, 1, 3, 31, 292, 1431, 10180, 2, 32, 395, 20, 1344, 4145, 1, 1508, 3739, 6041, 428, 24152, 4, 8, 697, 1, 102, 31, 286, 1275, 102, 62, 140, 21, 204, 17, 4167, 1119, 138, 32, 1294, 17, 7630, 791, 8578, 9, 3, 6929, 866, 161, 4, 8, 3260, 6420, 606, 92, 9803, 8, 10582, 4239, 3988, 1, 3, 18789, 1836, 6929, 3333, 6, 26, 217, 606, 2, 14063, 211, 14308, 30973, 791, 4852, 8663, 22, 149, 22, 1793, 1628, 1, 8, 458, 13519, 1431, 840, 17, 4862, 6092, 9429, 27, 2, 18789, 4045, 1724, 96, 2682, 10582, 9139, 204, 4, 102, 62, 37, 32, 14798, 20, 6929, 2, 8663, 92, 844, 8, 1083, 200, 9, 6929, 4, 10582, 4239, 1118, 631, 26, 45, 2953, 8, 336, 670, 2327, 9, 3, 914, 1, 1302, 10582, 9139, 4, 393, 37]",1006.0,25394790,2
Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.,Pediatric blood & cancer,Pediatr Blood Cancer,2014-11-18,"Infants with acute lymphoblastic leukemia (ALL) have a poor prognosis. Intensification of therapy has resulted in fewer relapses but increased early deaths, resulting in failure to improve survival. AALL0631 is a Phase 3 study for infants (<366 days of age) with newly diagnosed ALL. Induction initially (Cohort 1) consisted of 3 weeks of therapy based on COG P9407. Due to excessive early mortality, induction was amended to a less intensive 5 weeks of therapy based on Interfant-99. Additionally, enhanced supportive care guidelines were incorporated with hospitalization during induction until evidence of marrow recovery and recommendations for prevention/treatment of infections (Cohort 2). Induction mortality was significantly lower for patients in Cohort 2 (2/123, 1.6%) versus Cohort 1 (4/26, 15.4%; P=0.009). All induction deaths were infection related except one due to progressive disease (Cohort 2). Sterile site infections were lower for patients in Cohort 2 (24/123, 19.5%) versus Cohort 1 (15/26, 57.7%; P=0.0002), with a significantly lower rate of Gram positive infections during induction for patients in Cohort 2, P=0.0002. No clinically significant differences in grades 3-5 non-infectious toxicities were observed between the two cohorts. Higher complete response rates were observed at end induction intensification for Cohort 2 (week 9, 94/100, 94%) versus Cohort 1 (week 7, 17/25, 68%; P=0.0.0012). De-intensification of induction therapy and enhanced supportive care guidelines significantly decreased induction mortality and sterile site infections, without decreasing complete remission rates.","Clinical Trial, Phase III",1890.0,10.0,Infants with acute lymphoblastic ALL have a poor prognosis Intensification of therapy has resulted in fewer relapses but increased early deaths resulting in failure to improve survival AALL0631 is a Phase 3 study for infants 366 days of age with newly diagnosed ALL Induction initially Cohort 1 consisted of 3 weeks of therapy based on COG P9407 Due to excessive early mortality induction was amended to a less intensive 5 weeks of therapy based on Interfant-99 Additionally enhanced supportive care guidelines were incorporated with hospitalization during induction until evidence of marrow recovery and recommendations for prevention/treatment of infections Cohort 2 Induction mortality was significantly lower for patients in Cohort 2 2/123 1.6 versus Cohort 1 4/26 15.4 P 0.009 All induction deaths were infection related except one due to progressive disease Cohort 2 Sterile site infections were lower for patients in Cohort 2 24/123 19.5 versus Cohort 1 15/26 57.7 P 0.0002 with a significantly lower rate of Gram positive infections during induction for patients in Cohort 2 P 0.0002 No clinically significant differences in grades 3-5 non-infectious toxicities were observed between the two cohorts Higher complete response rates were observed at end induction intensification for Cohort 2 week 9 94/100 94 versus Cohort 1 week 7 17/25 68 P 0.0.0012 De-intensification of induction therapy and enhanced supportive care guidelines significantly decreased induction mortality and sterile site infections without decreasing complete remission rates,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5585, 5, 286, 1275, 62, 47, 8, 334, 356, 5091, 1, 36, 71, 627, 4, 1497, 3713, 84, 101, 191, 1043, 1113, 4, 496, 6, 401, 25, 65204, 16, 8, 124, 27, 45, 9, 5585, 9797, 162, 1, 89, 5, 732, 265, 62, 504, 1625, 180, 14, 1695, 1, 27, 244, 1, 36, 90, 23, 6377, 65205, 520, 6, 4529, 191, 282, 504, 10, 7595, 6, 8, 299, 1686, 33, 244, 1, 36, 90, 23, 39061, 1058, 1724, 651, 1877, 165, 677, 11, 2449, 5, 2826, 190, 504, 1100, 241, 1, 581, 1602, 2, 883, 9, 1070, 24, 1, 1875, 180, 18, 504, 282, 10, 97, 280, 9, 7, 4, 180, 18, 18, 2698, 14, 49, 185, 180, 14, 39, 432, 167, 39, 19, 13, 2376, 62, 504, 1043, 11, 930, 139, 2187, 104, 520, 6, 1014, 34, 180, 18, 14406, 606, 1875, 11, 280, 9, 7, 4, 180, 18, 259, 2698, 326, 33, 185, 180, 14, 167, 432, 696, 67, 19, 13, 3531, 5, 8, 97, 280, 116, 1, 6653, 109, 1875, 190, 504, 9, 7, 4, 180, 18, 19, 13, 3531, 77, 505, 93, 362, 4, 2276, 27, 33, 220, 3398, 385, 11, 164, 59, 3, 100, 736, 142, 236, 51, 151, 11, 164, 28, 396, 504, 5091, 9, 180, 18, 647, 83, 960, 394, 960, 185, 180, 14, 647, 67, 269, 243, 806, 19, 13, 13, 10095, 1566, 5091, 1, 504, 36, 2, 651, 1877, 165, 677, 97, 340, 504, 282, 2, 14406, 606, 1875, 187, 2777, 236, 734, 151]",1554.0,25407157,585
Biology of childhood acute lymphoblastic leukemia.,Pediatric clinics of North America,Pediatr. Clin. North Am.,2015-02-01,"Giant strides have been made in the management of childhood acute lymphoblastic leukemia (ALL) over previous decades. Extensive collaborative efforts internationally have played a vital role in the remarkable progress made in not only improving therapeutic outcomes but also deciphering the complex biology of childhood ALL. This review summarizes various insights gained from biological studies of childhood ALL, with a focus on recent studies, and also discusses genomic lesions and epigenetic regulatory mechanisms associated with leukemic transformation. The importance of studying the biology of the host so as to understand additional heterogeneity in treatment response and toxicities is highlighted. ",Journal Article,1815.0,56.0,Giant strides have been made in the management of childhood acute lymphoblastic ALL over previous decades Extensive collaborative efforts internationally have played a vital role in the remarkable progress made in not only improving therapeutic outcomes but also deciphering the complex biology of childhood ALL This review summarizes various insights gained from biological studies of childhood ALL with a focus on recent studies and also discusses genomic lesions and epigenetic regulatory mechanisms associated with leukemic transformation The importance of studying the biology of the host so as to understand additional heterogeneity in treatment response and toxicities is highlighted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6470, 10698, 47, 85, 1229, 4, 3, 284, 1, 864, 286, 1275, 62, 252, 698, 1968, 1344, 3737, 1413, 12828, 47, 7680, 8, 3511, 200, 4, 3, 3813, 1466, 1229, 4, 44, 158, 1673, 189, 123, 84, 120, 27305, 3, 840, 891, 1, 864, 62, 26, 206, 2869, 747, 1957, 3711, 29, 1037, 94, 1, 864, 62, 5, 8, 1222, 23, 435, 94, 2, 120, 2759, 572, 406, 2, 1418, 1253, 483, 41, 5, 2015, 1392, 3, 1187, 1, 4559, 3, 891, 1, 3, 1204, 1743, 22, 6, 1640, 402, 1144, 4, 24, 51, 2, 385, 16, 3681]",690.0,25435111,637
A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults.,Blood,Blood,2014-12-02,"Acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYA) is characterized by distinct presenting features and inferior prognosis compared with pediatric ALL. We performed a genome-wide association study (GWAS) to comprehensively identify inherited genetic variants associated with susceptibility to AYA ALL. In the discovery GWAS, we compared genotype frequency at 635297 single nucleotide polymorphisms (SNPs) in 308 AYA ALL cases and 6,661 non-ALL controls by using a logistic regression model with genetic ancestry as a covariate. SNPs that reached P  5  10(-8) in GWAS were tested in an independent cohort of 162 AYA ALL cases and 5,755 non-ALL controls. We identified a single genome-wide significant susceptibility locus in GATA3: rs3824662, odds ratio (OR), 1.77 (P = 2.8  10(-10)) and rs3781093, OR, 1.73 (P = 3.2  10(-9)). These findings were validated in the replication cohort. The risk allele at rs3824662 was most frequent in Philadelphia chromosome (Ph)-like ALL but also conferred susceptibility to non-Ph-like ALL in AYAs. In 1,827 non-selected ALL cases, the risk allele frequency at this SNP was positively correlated with age at diagnosis (P = 6.29  10(-11)). Our results from this first GWAS of AYA ALL susceptibility point to unique biology underlying leukemogenesis and potentially distinct disease etiology by age group. ",Journal Article,1876.0,55.0,"Acute lymphoblastic ALL in adolescents and young adults AYA is characterized by distinct presenting features and inferior prognosis compared with pediatric ALL We performed a genome-wide association study GWAS to comprehensively identify inherited genetic variants associated with susceptibility to AYA ALL In the discovery GWAS we compared genotype frequency at 635 297 single nucleotide polymorphisms SNPs in 308 AYA ALL cases and 6,661 non-ALL controls by using a logistic regression model with genetic ancestry as a covariate SNPs that reached P  5 10 -8 in GWAS were tested in an independent cohort of 162 AYA ALL cases and 5,755 non-ALL controls We identified a single genome-wide significant susceptibility locus in GATA3 rs3824662 odds ratio OR 1.77 P 2.8 10 -10 and rs3781093 OR 1.73 P 3.2 10 -9 These findings were validated in the replication cohort The risk allele at rs3824662 was most frequent in Philadelphia chromosome Ph -like ALL but also conferred susceptibility to non-Ph-like ALL in AYAs In 1,827 non-selected ALL cases the risk allele frequency at this SNP was positively correlated with age at diagnosis P 6.29 10 -11 Our results from this first GWAS of AYA ALL susceptibility point to unique biology underlying leukemogenesis and potentially distinct disease etiology by age group",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 4, 3101, 2, 1169, 857, 4598, 16, 765, 20, 834, 1656, 404, 2, 1663, 356, 72, 5, 815, 62, 21, 173, 8, 898, 1019, 248, 45, 3297, 6, 5627, 255, 2986, 336, 839, 41, 5, 1432, 6, 4598, 62, 4, 3, 1574, 3297, 21, 72, 1183, 675, 28, 12254, 8526, 226, 1579, 1203, 1109, 4, 7786, 4598, 62, 140, 2, 49, 12745, 220, 62, 535, 20, 75, 8, 812, 320, 202, 5, 336, 3535, 22, 8, 6322, 1109, 17, 1300, 19, 1552, 33, 79, 66, 4, 3297, 11, 650, 4, 35, 306, 180, 1, 5441, 4598, 62, 140, 2, 33, 14753, 220, 62, 535, 21, 108, 8, 226, 898, 1019, 93, 1432, 2474, 4, 8140, 32197, 610, 197, 15, 14, 849, 19, 18, 66, 79, 79, 2, 65300, 15, 14, 803, 19, 27, 18, 79, 83, 46, 272, 11, 938, 4, 3, 2079, 180, 3, 43, 1254, 28, 32197, 10, 96, 908, 4, 3006, 1170, 2058, 733, 62, 84, 120, 3851, 1432, 6, 220, 2058, 733, 62, 4, 6145, 4, 14, 13947, 220, 715, 62, 140, 3, 43, 1254, 675, 28, 26, 1845, 10, 2375, 438, 5, 89, 28, 147, 19, 49, 462, 79, 175, 114, 99, 29, 26, 157, 3297, 1, 4598, 62, 1432, 741, 6, 991, 891, 1181, 5661, 2, 751, 834, 34, 2855, 20, 89, 87]",1305.0,25468567,64
Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.,Frontiers of medicine,Front Med,2014-12-15,"With the cure rate of childhood acute lymphoblastic leukemia (ALL) approaching 90%, further improvement in the treatment outcome and quality of life of patients will require better understanding of the mechanisms of drug resistance, identifying new leukemic cell genetic lesions that are amendable to available target therapy, and optimizing treatment based on host pharmacodynamics and pharmacogenomics. Deeper characterization of leukemic cell genetic abnormalities has discovered new subtypes of leukemia such as early T-cell precursor ALL and Philadelphia chromosome-like ALL, and identified many genomic alterations that have diagnostic, prognostic, or therapeutic implications. In this regard, several novel fusion transcripts are responsive to ABL tyrosine kinase inhibitors and potentially to JAK inhibitors. Genome-wide analyses have also unraveled the role of inherited cancer predisposing genes and small nucleotide polymorphisms of several genes in the development of childhood ALL. These advances promise to lead to more sophisticated personalized treatment strategies in the near future. ",Journal Article,1863.0,16.0,With the cure rate of childhood acute lymphoblastic ALL approaching 90 further improvement in the treatment outcome and quality of life of patients will require better understanding of the mechanisms of drug resistance identifying new leukemic cell genetic lesions that are amendable to available target therapy and optimizing treatment based on host pharmacodynamics and pharmacogenomics Deeper characterization of leukemic cell genetic abnormalities has discovered new subtypes of such as early T-cell precursor ALL and Philadelphia chromosome-like ALL and identified many genomic alterations that have diagnostic prognostic or therapeutic implications In this regard several novel fusion transcripts are responsive to ABL tyrosine kinase inhibitors and potentially to JAK inhibitors Genome-wide analyses have also unraveled the role of inherited cancer predisposing genes and small nucleotide polymorphisms of several genes in the development of childhood ALL These advances promise to lead to more sophisticated personalized treatment strategies in the near future,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5, 3, 1722, 116, 1, 864, 286, 1275, 62, 7773, 424, 195, 767, 4, 3, 24, 228, 2, 372, 1, 358, 1, 7, 303, 1353, 380, 612, 1, 3, 483, 1, 234, 251, 1386, 217, 2015, 31, 336, 406, 17, 32, 35866, 6, 390, 283, 36, 2, 4336, 24, 90, 23, 1204, 3587, 2, 7603, 6029, 2136, 1, 2015, 31, 336, 1171, 71, 2747, 217, 814, 1, 225, 22, 191, 102, 31, 2765, 62, 2, 3006, 1170, 733, 62, 2, 108, 445, 572, 593, 17, 47, 752, 177, 15, 189, 1268, 4, 26, 2539, 392, 229, 1212, 2680, 32, 2443, 6, 1425, 564, 216, 222, 2, 751, 6, 4653, 222, 898, 1019, 318, 47, 120, 20632, 3, 200, 1, 2986, 12, 6885, 214, 2, 302, 1579, 1203, 1, 392, 214, 4, 3, 193, 1, 864, 62, 46, 954, 1783, 6, 1122, 6, 80, 8023, 2175, 24, 422, 4, 3, 1829, 508]",1068.0,25511622,420
Emotional distress in parents of long-term survivors of childhood acute lymphoblastic leukemia.,Psycho-oncology,Psychooncology,2014-12-29,"The current study investigated the occurrence of emotional distress in parents of long-term survivors of childhood acute lymphoblastic leukemia (ALL) and identified factors associated with parent emotional distress symptoms. Parents of 127 long-term survivors of childhood ALL treated on a chemotherapy-only protocol at St. Jude Children's Research Hospital participated in the study. Parents completed standard ratings of emotional distress, caregiver strain, and child physical, emotional, and psychosocial functioning. Multivariable hierarchical linear regression analyses were used to examine associations between symptoms of caregiver strain, survivor functioning, and parent emotional distress. Covariates included parent education, survivor age, survivor sex, and time since childhood cancer diagnosis. On average, few parents reported significant symptoms of emotional distress. Clinically significant levels of anxiety and depression were reported by 7.1% and 3.1% of parents, respectively. Only 3.9% of parents endorsed significant symptoms of posttraumatic stress. Perceived caregiver strain was significantly associated with symptoms of parent anxiety, depression, and posttraumatic stress. Parent-report of child emotional functioning was significantly associated with symptoms of parent anxiety. Most parents of long-term survivors of ALL exhibit low levels of emotional distress in the context of rates observed in the general population. Perceived caregiver strain was significantly associated with parent emotional distress. Further research is required to examine specific sources of caregiver strain, as well as other risk and protective factors associated with parent emotional distress symptoms.",Journal Article,1849.0,7.0,The current study investigated the occurrence of emotional distress in parents of long-term survivors of childhood acute lymphoblastic ALL and identified factors associated with parent emotional distress symptoms Parents of 127 long-term survivors of childhood ALL treated on a chemotherapy-only protocol at St. Jude Children 's Research Hospital participated in the study Parents completed standard ratings of emotional distress caregiver strain and child physical emotional and psychosocial functioning Multivariable hierarchical linear regression analyses were used to examine associations between symptoms of caregiver strain survivor functioning and parent emotional distress Covariates included parent education survivor age survivor sex and time since childhood cancer diagnosis On average few parents reported significant symptoms of emotional distress Clinically significant levels of anxiety and depression were reported by 7.1 and 3.1 of parents respectively Only 3.9 of parents endorsed significant symptoms of posttraumatic stress Perceived caregiver strain was significantly associated with symptoms of parent anxiety depression and posttraumatic stress Parent-report of child emotional functioning was significantly associated with symptoms of parent anxiety Most parents of long-term survivors of ALL exhibit low levels of emotional distress in the context of rates observed in the general population Perceived caregiver strain was significantly associated with parent emotional distress Further research is required to examine specific sources of caregiver strain as well as other risk and protective factors associated with parent emotional distress symptoms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 291, 45, 565, 3, 2291, 1, 2671, 1462, 4, 2418, 1, 319, 337, 332, 1, 864, 286, 1275, 62, 2, 108, 130, 41, 5, 3841, 2671, 1462, 507, 2418, 1, 4080, 319, 337, 332, 1, 864, 62, 73, 23, 8, 56, 158, 1182, 28, 3062, 4841, 541, 292, 389, 702, 3025, 4, 3, 45, 2418, 781, 260, 5548, 1, 2671, 1462, 4828, 5041, 2, 2566, 900, 2671, 2, 2322, 2702, 658, 4466, 1646, 320, 318, 11, 95, 6, 1004, 685, 59, 507, 1, 4828, 5041, 2628, 2702, 2, 3841, 2671, 1462, 2489, 159, 3841, 1848, 2628, 89, 2628, 1035, 2, 98, 1192, 864, 12, 147, 23, 1011, 1021, 2418, 210, 93, 507, 1, 2671, 1462, 505, 93, 148, 1, 2021, 2, 1774, 11, 210, 20, 67, 14, 2, 27, 14, 1, 2418, 106, 158, 27, 83, 1, 2418, 6864, 93, 507, 1, 12148, 1531, 2588, 4828, 5041, 10, 97, 41, 5, 507, 1, 3841, 2021, 1774, 2, 12148, 1531, 3841, 414, 1, 2566, 2671, 2702, 10, 97, 41, 5, 507, 1, 3841, 2021, 96, 2418, 1, 319, 337, 332, 1, 62, 2239, 154, 148, 1, 2671, 1462, 4, 3, 1533, 1, 151, 164, 4, 3, 1083, 266, 2588, 4828, 5041, 10, 97, 41, 5, 3841, 2671, 1462, 195, 389, 16, 616, 6, 1004, 112, 3375, 1, 4828, 5041, 22, 149, 22, 127, 43, 2, 2864, 130, 41, 5, 3841, 2671, 1462, 507]",1676.0,25557175,141
mTOR kinase inhibitors synergize with histone deacetylase inhibitors to kill B-cell acute lymphoblastic leukemia cells.,Oncotarget,Oncotarget,2015-02-01,"High activity of the mechanistic target of rapamycin (mTOR) is associated with poor prognosis in pre-B-cell acute lymphoblastic leukemia (B-ALL), suggesting that inhibiting mTOR might be clinically useful. However, emerging data indicate that mTOR inhibitors are most effective when combined with other target agents. One strategy is to combine with histone deacetylase (HDAC) inhibitors, since B-ALL is often characterized by epigenetic changes that silence the expression of pro-apoptotic factors. Here we tested combinations of mTOR and pan-HDAC inhibitors on B-ALL cells, including both Philadelphia chromosome-positive (Ph+) and non-Ph cell lines. We found that mTOR kinase inhibitors (TOR-KIs) synergize with HDAC inhibitors to cause apoptosis in B-ALL cells and the effect is greater when compared to rapamycin plus HDAC inhibitors. The combination of TOR-KIs with the clinically approved HDAC inhibitor vorinostat increased apoptosis in primary pediatric B-ALL cells in vitro. Mechanistically, TOR-KI and HDAC inhibitor combinations increased expression of pro-death genes, including targets of the Forkhead Box O (FOXO) transcription factors, and increased sensitivity to apoptotic triggers at the mitochondria. These findings suggest that targeting epigenetic factors can unmask the cytotoxic potential of TOR-KIs towards B-ALL cells. ",Journal Article,1815.0,19.0,High activity of the mechanistic target of rapamycin mTOR is associated with poor prognosis in pre-B-cell acute lymphoblastic B-ALL suggesting that inhibiting mTOR might be clinically useful However emerging data indicate that mTOR inhibitors are most effective when combined with other target agents One strategy is to combine with histone deacetylase HDAC inhibitors since B-ALL is often characterized by epigenetic changes that silence the expression of pro-apoptotic factors Here we tested combinations of mTOR and pan-HDAC inhibitors on B-ALL cells including both Philadelphia chromosome-positive Ph+ and non-Ph cell lines We found that mTOR kinase inhibitors TOR-KIs synergize with HDAC inhibitors to cause apoptosis in B-ALL cells and the effect is greater when compared to rapamycin plus HDAC inhibitors The combination of TOR-KIs with the clinically approved HDAC inhibitor vorinostat increased apoptosis in primary pediatric B-ALL cells in vitro Mechanistically TOR-KI and HDAC inhibitor combinations increased expression of pro-death genes including targets of the Forkhead Box O FOXO transcription factors and increased sensitivity to apoptotic triggers at the mitochondria These findings suggest that targeting epigenetic factors can unmask the cytotoxic potential of TOR-KIs towards B-ALL cells,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[64, 128, 1, 3, 2716, 283, 1, 1620, 873, 16, 41, 5, 334, 356, 4, 671, 132, 31, 286, 1275, 132, 62, 802, 17, 2062, 873, 822, 40, 505, 999, 137, 1478, 74, 1008, 17, 873, 222, 32, 96, 323, 198, 397, 5, 127, 283, 183, 104, 692, 16, 6, 4680, 5, 1508, 2732, 2654, 222, 1192, 132, 62, 16, 629, 765, 20, 1418, 400, 17, 13557, 3, 55, 1, 1805, 1631, 130, 467, 21, 650, 1247, 1, 873, 2, 3055, 2654, 222, 23, 132, 62, 37, 141, 110, 3006, 1170, 109, 2058, 2, 220, 2058, 31, 285, 21, 204, 17, 873, 216, 222, 18879, 16496, 8717, 5, 2654, 222, 6, 708, 351, 4, 132, 62, 37, 2, 3, 254, 16, 378, 198, 72, 6, 1620, 349, 2654, 222, 3, 150, 1, 18879, 16496, 5, 3, 505, 850, 2654, 230, 2371, 101, 351, 4, 86, 815, 132, 62, 37, 4, 439, 4187, 18879, 2311, 2, 2654, 230, 1247, 101, 55, 1, 1805, 273, 214, 141, 637, 1, 3, 8106, 4971, 1990, 16779, 866, 130, 2, 101, 485, 6, 1631, 5951, 28, 3, 5443, 46, 272, 309, 17, 529, 1418, 130, 122, 34258, 3, 759, 174, 1, 18879, 16496, 3113, 132, 62, 37]",1308.0,25576920,153
Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2015-01-13,"Adoptive cell therapy with genetically modified T cells expressing a chimeric antigen receptor (CAR) is a promising therapy for patients with B-cell acute lymphoblastic leukemia. However, CAR-modified T cells (CAR T cells) have mostly failed in patients with solid tumors or low-grade B-cell malignancies including chronic lymphocytic leukemia with bulky lymph node involvement. Herein, we enhance the antitumor efficacy of CAR T cells through the constitutive expression of CD40 ligand (CD40L, CD154). T cells genetically modified to constitutively express CD40L (CD40L-modified T cells) demonstrated increased proliferation and secretion of proinflammatory TH1 cytokines. Further, CD40L-modified T cells augmented the immunogenicity of CD40(+) tumor cells by the upregulated surface expression of costimulatory molecules (CD80 and CD86), adhesion molecules (CD54, CD58, and CD70), human leukocyte antigen (HLA) molecules (Class I and HLA-DR), and the Fas-death receptor (CD95). Additionally, CD40L-modified T cells induced maturation and secretion of the proinflammatory cytokine interleukin-12 by monocyte-derived dendritic cells. Finally, tumor-targeted CD19-specific CAR/CD40L T cells exhibited increased cytotoxicity against CD40(+) tumors and extended the survival of tumor-bearing mice in a xenotransplant model of CD19(+) systemic lymphoma. This preclinical data supports the clinical application of CAR T cells additionally modified to constitutively express CD40L with anticipated enhanced antitumor efficacy. ",Journal Article,1834.0,93.0,Adoptive cell therapy with genetically modified T cells expressing a chimeric antigen receptor CAR is a promising therapy for patients with B-cell acute lymphoblastic However CAR-modified T cells CAR T cells have mostly failed in patients with solid tumors or low-grade B-cell malignancies including chronic lymphocytic with bulky lymph node involvement Herein we enhance the antitumor efficacy of CAR T cells through the constitutive expression of CD40 ligand CD40L CD154 T cells genetically modified to constitutively express CD40L CD40L-modified T cells demonstrated increased proliferation and secretion of proinflammatory TH1 cytokines Further CD40L-modified T cells augmented the immunogenicity of CD40 tumor cells by the upregulated surface expression of costimulatory molecules CD80 and CD86 adhesion molecules CD54 CD58 and CD70 human leukocyte antigen HLA molecules Class I and HLA-DR and the Fas-death receptor CD95 Additionally CD40L-modified T cells induced maturation and secretion of the proinflammatory cytokine interleukin-12 by monocyte-derived dendritic cells Finally tumor-targeted CD19-specific CAR/CD40L T cells exhibited increased cytotoxicity against CD40 tumors and extended the survival of tumor-bearing mice in a xenotransplant model of CD19 systemic This preclinical data supports the clinical application of CAR T cells additionally modified to constitutively express CD40L with anticipated enhanced antitumor efficacy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3159, 31, 36, 5, 2301, 1230, 102, 37, 1046, 8, 2897, 448, 153, 1881, 16, 8, 721, 36, 9, 7, 5, 132, 31, 286, 1275, 137, 1881, 1230, 102, 37, 1881, 102, 37, 47, 2754, 1551, 4, 7, 5, 537, 57, 15, 154, 88, 132, 31, 441, 141, 442, 1193, 5, 4112, 263, 289, 799, 1986, 21, 1304, 3, 579, 209, 1, 1881, 102, 37, 298, 3, 3178, 55, 1, 5040, 1232, 8285, 18281, 102, 37, 2301, 1230, 6, 2818, 1669, 8285, 8285, 1230, 102, 37, 264, 101, 457, 2, 2935, 1, 5767, 4714, 1886, 195, 8285, 1230, 102, 37, 4277, 3, 4050, 1, 5040, 30, 37, 20, 3, 2684, 1255, 55, 1, 5555, 1598, 9850, 2, 12514, 2128, 1598, 30653, 23366, 2, 10354, 171, 3627, 448, 1160, 1598, 1040, 70, 2, 1160, 3436, 2, 3, 3625, 273, 153, 6550, 1724, 8285, 1230, 102, 37, 277, 4537, 2, 2935, 1, 3, 5767, 1675, 1603, 133, 20, 5231, 526, 2464, 37, 1368, 30, 238, 3158, 112, 1881, 8285, 102, 37, 1416, 101, 1408, 480, 5040, 57, 2, 1747, 3, 25, 1, 30, 1894, 399, 4, 8, 28800, 202, 1, 3158, 403, 26, 693, 74, 2304, 3, 38, 1581, 1, 1881, 102, 37, 1724, 1230, 6, 2818, 1669, 8285, 5, 4078, 651, 579, 209]",1447.0,25582824,451
How I treat mixed-phenotype acute leukemia.,Blood,Blood,2015-01-20,"Mixed-phenotype acute leukemia (MPAL) encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible. A variety of different terms and classification systems have been used historically to describe this entity. MPAL is currently defined by a limited set of lineage-specific markers proposed in the 2008 World Health Organization monograph on classification of tumors of hematopoietic and lymphoid tissues. In adult patients, MPAL is characterized by relative therapeutic resistance that may be attributed in part to the high proportion of patients with adverse cytogenetic abnormalities. No prospective, controlled trials exist to guide therapy. The limited available data suggest that an ""acute lymphoblastic leukemia-like"" regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyrosine kinase inhibitor in patients with t(9;22) translocation is recommended. The role of immunophenotypic and genetic markers in guiding chemotherapy choice and postremission strategy, as well as the utility of targeted therapies in non-Ph-positive MPALs is unknown. ",Case Reports,1827.0,64.0,Mixed-phenotype acute MPAL encompasses a heterogeneous group of rare leukemias in which assigning a single lineage of origin is not possible A variety of different terms and classification systems have been used historically to describe this entity MPAL is currently defined by a limited set of lineage-specific markers proposed in the 2008 World Health Organization monograph on classification of tumors of hematopoietic and lymphoid tissues In adult patients MPAL is characterized by relative therapeutic resistance that may be attributed in part to the high proportion of patients with adverse cytogenetic abnormalities No prospective controlled trials exist to guide therapy The limited available data suggest that an `` acute lymphoblastic leukemia-like '' regimen followed by allogeneic stem-cell transplant may be advisable addition of a tyrosine kinase inhibitor in patients with t 9 22 translocation is recommended The role of immunophenotypic and genetic markers in guiding chemotherapy choice and postremission strategy as well as the utility of targeted therapies in non-Ph-positive MPALs is unknown,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1739, 1005, 286, 9407, 9485, 8, 1564, 87, 1, 622, 2792, 4, 92, 9648, 8, 226, 2542, 1, 1938, 16, 44, 899, 8, 1362, 1, 338, 1794, 2, 947, 1530, 47, 85, 95, 3578, 6, 897, 26, 2983, 9407, 16, 694, 395, 20, 8, 383, 916, 1, 2542, 112, 525, 1587, 4, 3, 1375, 1956, 341, 2533, 17923, 23, 947, 1, 57, 1, 1007, 2, 2303, 742, 4, 780, 7, 9407, 16, 765, 20, 580, 189, 251, 17, 68, 40, 3073, 4, 760, 6, 3, 64, 920, 1, 7, 5, 290, 1266, 1171, 77, 482, 1149, 143, 1923, 6, 1597, 36, 3, 383, 390, 74, 309, 17, 35, 286, 1275, 2647, 733, 522, 477, 370, 20, 1063, 452, 31, 941, 68, 40, 19443, 352, 1, 8, 564, 216, 230, 4, 7, 5, 102, 83, 350, 2006, 16, 793, 3, 200, 1, 6599, 2, 336, 525, 4, 5972, 56, 1866, 2, 8635, 692, 22, 149, 22, 3, 1207, 1, 238, 235, 4, 220, 2058, 109, 40969, 16, 860]",1111.0,25605373,160
Utility of early screening magnetic resonance imaging for extensive hip osteonecrosis in pediatric patients treated with glucocorticoids.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-01-20,"Hip osteonecrosis frequently complicates treatment with glucocorticoids. When extensive (affecting  30% of the epiphyseal surface), 80% of joints collapse within 2 years, so interventions are needed to prevent this outcome. This prospective cohort magnetic resonance imaging (MRI) screening study included all consecutive children treated for acute lymphoblastic leukemia on a single protocol. Hip MRI was performed at 6.5 and 9 months from diagnosis (early screening) and at completion of chemotherapy (final evaluation) to determine whether screening could identify extensive hip osteonecrosis before symptom development. Of 498 patients, 462 underwent screening MRI. Extensive asymptomatic osteonecrosis was identified by early screening in 26 patients (41 hips); another four patients (seven hips) were detected after the screening period, such that screening sensitivity was 84.1% and specificity was 99.4%. The number of joints screened to detect one lesion was 20.1 joints for all patients, 4.4 joints for patients older than 10 years, and 198 joints for patients  10 years old (P < .001). Of the 40 extensive lesions in patients older than 10 years, 19 required total hip arthroplasty and none improved. Of eight extensive lesions in younger patients, none required arthroplasty and four improved. In patients age 10 years old or younger who require prolonged glucocorticoid therapy, screening for extensive hip osteonecrosis is unnecessary because their risk is low and lesions tend to heal. In children older than 10 years, early screening successfully identifies extensive asymptomatic lesions in patients who would be eligible for studies of interventions to prevent or delay joint collapse.",Clinical Trial,1827.0,32.0,Hip osteonecrosis frequently complicates treatment with glucocorticoids When extensive affecting  30 of the epiphyseal surface 80 of joints collapse within 2 years so interventions are needed to prevent this outcome This prospective cohort magnetic resonance imaging MRI screening study included all consecutive children treated for acute lymphoblastic on a single protocol Hip MRI was performed at 6.5 and 9 months from diagnosis early screening and at completion of chemotherapy final evaluation to determine whether screening could identify extensive hip osteonecrosis before symptom development Of 498 patients 462 underwent screening MRI Extensive asymptomatic osteonecrosis was identified by early screening in 26 patients 41 hips another four patients seven hips were detected after the screening period such that screening sensitivity was 84.1 and specificity was 99.4 The number of joints screened to detect one lesion was 20.1 joints for all patients 4.4 joints for patients older than 10 years and 198 joints for patients  10 years old P .001 Of the 40 extensive lesions in patients older than 10 years 19 required total hip arthroplasty and none improved Of eight extensive lesions in younger patients none required arthroplasty and four improved In patients age 10 years old or younger who require prolonged glucocorticoid therapy screening for extensive hip osteonecrosis is unnecessary because their risk is low and lesions tend to heal In children older than 10 years early screening successfully identifies extensive asymptomatic lesions in patients who would be eligible for studies of interventions to prevent or delay joint collapse,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5628, 5404, 746, 12340, 24, 5, 7307, 198, 1344, 2319, 749, 201, 1, 3, 40970, 1255, 493, 1, 16854, 11817, 262, 18, 60, 1743, 1151, 32, 575, 6, 1682, 26, 228, 26, 482, 180, 1484, 1535, 270, 704, 453, 45, 159, 62, 935, 541, 73, 9, 286, 1275, 23, 8, 226, 1182, 5628, 704, 10, 173, 28, 49, 33, 2, 83, 53, 29, 147, 191, 453, 2, 28, 1438, 1, 56, 1457, 451, 6, 223, 317, 453, 359, 255, 1344, 5628, 5404, 348, 934, 193, 1, 8928, 7, 12185, 208, 453, 704, 1344, 2100, 5404, 10, 108, 20, 191, 453, 4, 432, 7, 605, 22230, 1809, 294, 7, 648, 22230, 11, 530, 50, 3, 453, 727, 225, 17, 453, 485, 10, 874, 14, 2, 1121, 10, 1058, 39, 3, 207, 1, 16854, 2261, 6, 1426, 104, 1180, 10, 179, 14, 16854, 9, 62, 7, 39, 39, 16854, 9, 7, 434, 76, 79, 60, 2, 6189, 16854, 9, 7, 1552, 79, 60, 1095, 19, 144, 1, 3, 327, 1344, 406, 4, 7, 434, 76, 79, 60, 326, 616, 181, 5628, 23597, 2, 1292, 231, 1, 659, 1344, 406, 4, 773, 7, 1292, 616, 23597, 2, 294, 231, 4, 7, 89, 79, 60, 1095, 15, 773, 54, 1353, 1069, 5399, 36, 453, 9, 1344, 5628, 5404, 16, 4224, 408, 136, 43, 16, 154, 2, 406, 5406, 6, 33546, 4, 541, 434, 76, 79, 60, 191, 453, 1878, 2953, 1344, 2100, 406, 4, 7, 54, 688, 40, 625, 9, 94, 1, 1151, 6, 1682, 15, 1984, 2093, 11817]",1654.0,25605853,346
Pharmacogenetics predictive of response and toxicity in acute lymphoblastic leukemia therapy.,Blood reviews,Blood Rev.,2015-01-10,"Acute lymphoblastic leukemia (ALL) is a relatively rare disease in adults accounting for no more than 20% of all cases of acute leukemia. By contrast with the pediatric population, in whom significant improvements in long term survival and even cure have been achieved over the last 30years, adult ALL remains a significant challenge. Overall survival in this group remains a relatively poor 20-40%. Modern research has focused on improved pharmacokinetics, novel pharmacogenetics and personalized principles to optimize the efficacy of the treatment while reducing toxicity. Here we review the pharmacogenetics of medications used in the management of patients with ALL, including l-asparaginase, glucocorticoids, 6-mercaptopurine, methotrexate, vincristine and tyrosine kinase inhibitors. Incorporating recent pharmacogenetic data, mainly from pediatric ALL, will provide novel perspective of predicting response and toxicity in both pediatric and adult ALL therapies. ",Journal Article,1837.0,25.0,Acute lymphoblastic ALL is a relatively rare disease in adults accounting for no more than 20 of all cases of acute By contrast with the pediatric population in whom significant improvements in long term survival and even cure have been achieved over the last 30years adult ALL remains a significant challenge Overall survival in this group remains a relatively poor 20-40 Modern research has focused on improved pharmacokinetics novel pharmacogenetics and personalized principles to optimize the efficacy of the treatment while reducing toxicity Here we review the pharmacogenetics of medications used in the management of patients with ALL including l-asparaginase glucocorticoids 6-mercaptopurine methotrexate vincristine and tyrosine kinase inhibitors Incorporating recent pharmacogenetic data mainly from pediatric ALL will provide novel perspective of predicting response and toxicity in both pediatric and adult ALL therapies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 1352, 622, 34, 4, 857, 3116, 9, 77, 80, 76, 179, 1, 62, 140, 1, 286, 20, 748, 5, 3, 815, 266, 4, 953, 93, 1474, 4, 319, 337, 25, 2, 871, 1722, 47, 85, 513, 252, 3, 1060, 48812, 780, 62, 469, 8, 93, 1745, 63, 25, 4, 26, 87, 469, 8, 1352, 334, 179, 327, 2366, 389, 71, 1649, 23, 231, 1159, 229, 8759, 2, 2175, 4650, 6, 2465, 3, 209, 1, 3, 24, 369, 1818, 155, 467, 21, 206, 3, 8759, 1, 2679, 95, 4, 3, 284, 1, 7, 5, 62, 141, 805, 3709, 7307, 49, 9223, 2116, 2132, 2, 564, 216, 222, 2570, 435, 6578, 74, 2615, 29, 815, 62, 303, 377, 229, 3727, 1, 1434, 51, 2, 155, 4, 110, 815, 2, 780, 62, 235]",932.0,25614322,779
Inherited NUDT15 variant is a genetic determinant of mercaptopurine intolerance in children with acute lymphoblastic leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-01-26,"Mercaptopurine (MP) is the mainstay of curative therapy for acute lymphoblastic leukemia (ALL). We performed a genome-wide association study (GWAS) to identify comprehensively the genetic basis of MP intolerance in children with ALL. The discovery GWAS and replication cohorts included 657 and 371 children from two prospective clinical trials. MP dose intensity was a marker for drug tolerance and toxicities and was defined as prescribed dose divided by the planned protocol dose during maintenance therapy; its association with genotype was evaluated using a linear mixed-effects model. MP dose intensity varied by race and ethnicity and was negatively correlated with East Asian genetic ancestry (P < .001). The GWAS revealed two genome-wide significant loci associated with dose intensity: rs1142345 in TPMT (Tyr240Cys, present in *3A and *3C variants; P = 8.6  10(-9)) and rs116855232 in NUDT15 (P = 8.8  10(-9)), with independent replication. Patients with TT genotype at rs116855232 were exquisitely sensitive to MP, with an average dose intensity of 8.3%, compared with those with TC and CC genotypes, who tolerated 63% and 83.5% of the planned dose, respectively. The NUDT15 variant was most common in East Asians and Hispanics, rare in Europeans, and not observed in Africans, contributing to ancestry-related differences in MP tolerance. Of children homozygous for either TPMT or NUDT15 variants or heterozygous for both, 100% required  50% MP dose reduction, compared with only 7.7% of others. We describe a germline variant in NUDT15 strongly associated with MP intolerance in childhood ALL, which may have implications for treatment individualization in this disease.",Clinical Trial,1821.0,141.0,Mercaptopurine MP is the mainstay of curative therapy for acute lymphoblastic ALL We performed a genome-wide association study GWAS to identify comprehensively the genetic basis of MP intolerance in children with ALL The discovery GWAS and replication cohorts included 657 and 371 children from two prospective clinical trials MP dose intensity was a marker for drug tolerance and toxicities and was defined as prescribed dose divided by the planned protocol dose during maintenance therapy its association with genotype was evaluated using a linear mixed-effects model MP dose intensity varied by race and ethnicity and was negatively correlated with East Asian genetic ancestry P .001 The GWAS revealed two genome-wide significant loci associated with dose intensity rs1142345 in TPMT Tyr240Cys present in *3A and *3C variants P 8.6 10 -9 and rs116855232 in NUDT15 P 8.8 10 -9 with independent replication Patients with TT genotype at rs116855232 were exquisitely sensitive to MP with an average dose intensity of 8.3 compared with those with TC and CC genotypes who tolerated 63 and 83.5 of the planned dose respectively The NUDT15 variant was most common in East Asians and Hispanics rare in Europeans and not observed in Africans contributing to ancestry-related differences in MP tolerance Of children homozygous for either TPMT or NUDT15 variants or heterozygous for both 100 required  50 MP dose reduction compared with only 7.7 of others We describe a germline variant in NUDT15 strongly associated with MP intolerance in childhood ALL which may have implications for treatment individualization in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9223, 4545, 16, 3, 4041, 1, 1075, 36, 9, 286, 1275, 62, 21, 173, 8, 898, 1019, 248, 45, 3297, 6, 255, 5627, 3, 336, 877, 1, 4545, 5266, 4, 541, 5, 62, 3, 1574, 3297, 2, 2079, 736, 159, 13141, 2, 9196, 541, 29, 100, 482, 38, 143, 4545, 61, 837, 10, 8, 952, 9, 234, 2614, 2, 385, 2, 10, 395, 22, 2746, 61, 2176, 20, 3, 1465, 1182, 61, 190, 1146, 36, 211, 248, 5, 1183, 10, 194, 75, 8, 1646, 1739, 176, 202, 4545, 61, 837, 2051, 20, 1047, 2, 2091, 2, 10, 2723, 438, 5, 6633, 2399, 336, 3535, 19, 144, 3, 3297, 553, 100, 898, 1019, 93, 2012, 41, 5, 61, 837, 65544, 4, 14852, 65545, 364, 4, 6981, 2, 17346, 839, 19, 66, 49, 79, 83, 2, 48820, 4, 18089, 19, 66, 66, 79, 83, 5, 306, 2079, 7, 5, 3504, 1183, 28, 48820, 11, 11936, 745, 6, 4545, 5, 35, 1011, 61, 837, 1, 66, 27, 72, 5, 135, 5, 3072, 2, 1951, 2071, 54, 421, 676, 2, 852, 33, 1, 3, 1465, 61, 106, 3, 18089, 1142, 10, 96, 186, 4, 6633, 5108, 2, 3850, 622, 4, 15345, 2, 44, 164, 4, 37760, 3156, 6, 3535, 139, 362, 4, 4545, 2614, 1, 541, 3189, 9, 361, 14852, 15, 18089, 839, 15, 4167, 9, 110, 394, 616, 749, 212, 4545, 61, 628, 72, 5, 158, 67, 67, 1, 1749, 21, 897, 8, 1009, 1142, 4, 18089, 1327, 41, 5, 4545, 5266, 4, 864, 62, 92, 68, 47, 1268, 9, 24, 9764, 4, 26, 34]",1621.0,25624441,402
Myelopathy following intrathecal chemotherapy in adults: a single institution experience.,Journal of neuro-oncology,J. Neurooncol.,2015-02-10,"Methotrexate and cytarabine arabinoside are frequently administered intrathecally in the prophylaxis and treatment of patients with hematological malignancies. Myelopathy as a complication of intrathecal (IT) chemotherapy is rare in adults, with most of the cases described in the literature occurring in the pediatric population. Between January 2010 and March 2014, 587 newly diagnosed B cell acute lymphoblastic leukemia and 24 chronic myeloid leukemia lymphoid blast phase patients were seen at The University of Texas MD Anderson Cancer Center. This case series discusses seven adult cases deemed to have IT chemotherapy-induced myelopathy between 2010 and 2014 at MD Anderson Cancer Center. Five out of the seven patients had T2 abnormalities involving the dorsal columns of the spinal cord. An elevated myelin basic protein level was noted in the two patients in whom it was checked. The wide range of dosage and timing with respect to IT chemotherapy administration suggests an idiosyncratic reaction or individual threshold to the development of myelopathy. By describing the largest case series of myelopathy in adults, we aim to raise awareness about this rare albeit devastating complication. Based on the seven cases described we would recommend-MRI of the spine with T2-weighted imaging in the sagittal and axial planes in leukemia patients with unexplained myelopathy and consideration to delay IT chemotherapy until after an extensive work-up to rule out CNS leukemia. Though more data are needed on the use of folate metabolites, preliminary results have shown some promise in the treatment of methotrexate-induced myelopathy and may be a potential consideration for future patients suspected to have chemotherapy induced myelopathy.",Clinical Study,1806.0,16.0,Methotrexate and cytarabine arabinoside are frequently administered intrathecally in the prophylaxis and treatment of patients with hematological malignancies Myelopathy as a complication of intrathecal IT chemotherapy is rare in adults with most of the cases described in the literature occurring in the pediatric population Between January 2010 and March 2014 587 newly diagnosed B cell acute lymphoblastic and 24 chronic myeloid lymphoid blast phase patients were seen at The University of Texas MD Anderson Cancer Center This case series discusses seven adult cases deemed to have IT chemotherapy-induced myelopathy between 2010 and 2014 at MD Anderson Cancer Center Five out of the seven patients had T2 abnormalities involving the dorsal columns of the spinal cord An elevated myelin basic protein level was noted in the two patients in whom it was checked The wide range of dosage and timing with respect to IT chemotherapy administration suggests an idiosyncratic reaction or individual threshold to the development of myelopathy By describing the largest case series of myelopathy in adults we aim to raise awareness about this rare albeit devastating complication Based on the seven cases described we would recommend-MRI of the spine with T2-weighted imaging in the sagittal and axial planes in patients with unexplained myelopathy and consideration to delay IT chemotherapy until after an extensive work-up to rule out CNS Though more data are needed on the use of folate metabolites preliminary results have shown some promise in the treatment of methotrexate-induced myelopathy and may be a potential consideration for future patients suspected to have chemotherapy induced myelopathy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2116, 2, 1855, 11563, 32, 746, 468, 38336, 4, 3, 2049, 2, 24, 1, 7, 5, 2890, 441, 10415, 22, 8, 1447, 1, 5126, 192, 56, 16, 622, 4, 857, 5, 96, 1, 3, 140, 1027, 4, 3, 789, 1821, 4, 3, 815, 266, 59, 1024, 1120, 2, 2363, 1409, 13934, 732, 265, 132, 31, 286, 1275, 2, 259, 442, 533, 2303, 3112, 124, 7, 11, 527, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 26, 473, 988, 2759, 648, 780, 140, 3779, 6, 47, 192, 56, 277, 10415, 59, 1120, 2, 1409, 28, 2244, 1929, 12, 574, 365, 1205, 1, 3, 648, 7, 42, 1786, 1171, 1267, 3, 12891, 29180, 1, 3, 1499, 1885, 35, 804, 23428, 2795, 178, 301, 10, 1051, 4, 3, 100, 7, 4, 953, 192, 10, 14749, 3, 1019, 184, 1, 3323, 2, 1972, 5, 2184, 6, 192, 56, 634, 844, 35, 34647, 1329, 15, 797, 2390, 6, 3, 193, 1, 10415, 20, 4950, 3, 2166, 473, 988, 1, 10415, 4, 857, 21, 1130, 6, 5008, 3310, 545, 26, 622, 5993, 5778, 1447, 90, 23, 3, 648, 140, 1027, 21, 688, 2237, 704, 1, 3, 2342, 5, 1786, 2337, 270, 4, 3, 15902, 2, 5229, 15959, 4, 7, 5, 8221, 10415, 2, 2415, 6, 1984, 192, 56, 1100, 50, 35, 1344, 1357, 126, 6, 5340, 1205, 1025, 2471, 80, 74, 32, 575, 23, 3, 119, 1, 3100, 3406, 1676, 99, 47, 443, 476, 1783, 4, 3, 24, 1, 2116, 277, 10415, 2, 68, 40, 8, 174, 2415, 9, 508, 7, 2768, 6, 47, 56, 277, 10415]",1698.0,25666482,312
Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.,Expert opinion on biological therapy,Expert Opin Biol Ther,2015-02-09,"Over 20 years ago, chimeric antigen receptors (CARs) were created to endow T cells with new antigen-specificity and create a therapy that could eradicate cancer and provide life-long protection against recurrence. Steady progress has led to significant improvements with CAR design and CAR T-cell production, allowing evaluation of CAR T cells in patients. The initial trials have targeted CD19, which is expressed on normal and malignant B cells. We review data from trials for patients with chronic lymphocytic leukemia (CLL) and B-cell acute lymphoblastic leukemia (B-ALL). In addition, we discuss the on-target toxicities, B-cell aplasia and cytokine release syndrome (CRS), which is uniquely associated with T-cell immunotherapies. We compare the results when targeting the same antigen in CLL or B-ALL and speculate on reasons for outcome differences and future directions to enhance outcomes. Furthermore, the dramatic results targeting B-ALL require further analysis in Phase II trials, and we discuss important components of these future trials. We also suggest a management scheme for CRS. The next several years will be critical and may lead to the first clinical indication of a gene-engineered cell therapy for cancer.",Journal Article,1807.0,5.0,Over 20 years ago chimeric antigen receptors CARs were created to endow T cells with new antigen-specificity and create a therapy that could eradicate cancer and provide life-long protection against recurrence Steady progress has led to significant improvements with CAR design and CAR T-cell production allowing evaluation of CAR T cells in patients The initial trials have targeted CD19 which is expressed on normal and malignant B cells We review data from trials for patients with chronic lymphocytic CLL and B-cell acute lymphoblastic B-ALL In addition we discuss the on-target toxicities B-cell aplasia and cytokine release syndrome CRS which is uniquely associated with T-cell immunotherapies We compare the results when targeting the same antigen in CLL or B-ALL and speculate on reasons for outcome differences and future directions to enhance outcomes Furthermore the dramatic results targeting B-ALL require further analysis in Phase II trials and we discuss important components of these future trials We also suggest a management scheme for CRS The next several years will be critical and may lead to the first clinical indication of a gene-engineered cell therapy for cancer,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[252, 179, 60, 5028, 2897, 448, 1186, 7441, 11, 2466, 6, 20817, 102, 37, 5, 217, 448, 1121, 2, 3736, 8, 36, 17, 359, 5650, 12, 2, 377, 358, 319, 3525, 480, 146, 4152, 1466, 71, 836, 6, 93, 1474, 5, 1881, 771, 2, 1881, 102, 31, 1529, 2952, 451, 1, 1881, 102, 37, 4, 7, 3, 388, 143, 47, 238, 3158, 92, 16, 570, 23, 295, 2, 393, 132, 37, 21, 206, 74, 29, 143, 9, 7, 5, 442, 1193, 552, 2, 132, 31, 286, 1275, 132, 62, 4, 352, 21, 1139, 3, 23, 283, 385, 132, 31, 12307, 2, 1675, 2008, 681, 3115, 92, 16, 7089, 41, 5, 102, 31, 2811, 21, 932, 3, 99, 198, 529, 3, 827, 448, 4, 552, 15, 132, 62, 2, 11778, 23, 2325, 9, 228, 362, 2, 508, 3540, 6, 1304, 123, 798, 3, 3079, 99, 529, 132, 62, 1353, 195, 65, 4, 124, 215, 143, 2, 21, 1139, 305, 1628, 1, 46, 508, 143, 21, 120, 309, 8, 284, 4633, 9, 3115, 3, 1305, 392, 60, 303, 40, 740, 2, 68, 1122, 6, 3, 157, 38, 3607, 1, 8, 145, 2794, 31, 36, 9, 12]",1188.0,25666545,149
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.,Haematologica,Haematologica,2015-02-14,"We have previously reported on the efficacy and tolerability of hyper-CVAD regimen (cyclophosphamide, vincristine, Adriamycin, and dexamethasone) and imatinib followed by imatinib-based consolidation/maintenance therapy in 20 patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Here, we present the 13-year follow up of our study. Fifty-four patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia were enrolled: 39 (72%) with de novo disease, 6 (11%) whose disease was primary refractory after induction (without a tyrosine kinase inhibitor), and 9 (17%) in complete remission after one course of induction therapy (without tyrosine kinase inhibitor). Forty-two (93%) of the 45 patients treated for active disease achieved complete remission, one achieved complete remission with incomplete recovery of platelets, one achieved partial remission and one died during induction. Nineteen (35%) patients are alive and 18 are in complete remission. The 5-year overall survival rate for all patients was 43%. Significant negative predictors of overall survival were age over 60 years, p190 molecular transcript, and active disease at enrollment. Sixteen (30%) patients underwent allogeneic stem cell transplantation. Median overall survival was not significantly greater for patients who underwent transplant. Patients with residual molecular disease at three months had improved complete remission duration with transplant. The median time to hematologic recovery and severe toxicities with combination were not significantly different from those observed with conventional chemotherapy. Only one patient discontinued therapy due to toxicity. HyperCVAD chemotherapy and imatinib is an effective regimen for Philadelphia-positive acute lymphoblastic leukemia. Transplant may not be indicated in all patients with Philadelphia-positive acute lymphoblastic leukemia. (clinicaltrials.gov identifier: NCT00038610). ","Clinical Trial, Phase II",1802.0,77.0,We have previously reported on the efficacy and tolerability of hyper-CVAD regimen cyclophosphamide vincristine Adriamycin and dexamethasone and imatinib followed by imatinib-based consolidation/maintenance therapy in 20 patients with newly diagnosed Philadelphia-positive acute lymphoblastic Here we present the 13-year follow up of our study Fifty-four patients with newly diagnosed Philadelphia-positive acute lymphoblastic were enrolled 39 72 with de novo disease 6 11 whose disease was primary refractory after induction without a tyrosine kinase inhibitor and 9 17 in complete remission after one course of induction therapy without tyrosine kinase inhibitor Forty-two 93 of the 45 patients treated for active disease achieved complete remission one achieved complete remission with incomplete recovery of platelets one achieved partial remission and one died during induction Nineteen 35 patients are alive and 18 are in complete remission The 5-year overall survival rate for all patients was 43 Significant negative predictors of overall survival were age over 60 years p190 molecular transcript and active disease at enrollment Sixteen 30 patients underwent allogeneic stem cell transplantation Median overall survival was not significantly greater for patients who underwent transplant Patients with residual molecular disease at three months had improved complete remission duration with transplant The median time to hematologic recovery and severe toxicities with combination were not significantly different from those observed with conventional chemotherapy Only one patient discontinued therapy due to toxicity HyperCVAD chemotherapy and imatinib is an effective regimen for Philadelphia-positive acute lymphoblastic Transplant may not be indicated in all patients with Philadelphia-positive acute lymphoblastic clinicaltrials.gov identifier NCT00038610,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 47, 373, 210, 23, 3, 209, 2, 1543, 1, 4855, 5574, 477, 1112, 2132, 7700, 2, 1217, 2, 577, 370, 20, 577, 90, 2173, 1146, 36, 4, 179, 7, 5, 732, 265, 3006, 109, 286, 1275, 467, 21, 364, 3, 233, 111, 166, 126, 1, 114, 45, 1461, 294, 7, 5, 732, 265, 3006, 109, 286, 1275, 11, 346, 587, 720, 5, 1566, 2018, 34, 49, 175, 1310, 34, 10, 86, 430, 50, 504, 187, 8, 564, 216, 230, 2, 83, 269, 4, 236, 734, 50, 104, 906, 1, 504, 36, 187, 564, 216, 230, 1213, 100, 966, 1, 3, 512, 7, 73, 9, 544, 34, 513, 236, 734, 104, 513, 236, 734, 5, 2610, 1602, 1, 4407, 104, 513, 450, 734, 2, 104, 1016, 190, 504, 3498, 465, 7, 32, 1701, 2, 203, 32, 4, 236, 734, 3, 33, 111, 63, 25, 116, 9, 62, 7, 10, 601, 93, 199, 674, 1, 63, 25, 11, 89, 252, 335, 60, 18813, 219, 3268, 2, 544, 34, 28, 1798, 3228, 201, 7, 208, 1063, 452, 31, 497, 52, 63, 25, 10, 44, 97, 378, 9, 7, 54, 208, 941, 7, 5, 753, 219, 34, 28, 169, 53, 42, 231, 236, 734, 654, 5, 941, 3, 52, 98, 6, 813, 1602, 2, 905, 385, 5, 150, 11, 44, 97, 338, 29, 135, 164, 5, 809, 56, 158, 104, 69, 2402, 36, 520, 6, 155, 13792, 56, 2, 577, 16, 35, 323, 477, 9, 3006, 109, 286, 1275, 941, 68, 44, 40, 1103, 4, 62, 7, 5, 3006, 109, 286, 1275, 1252, 1239, 3719, 65644]",1870.0,25682595,578
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.,Haematologica,Haematologica,2015-02-14,"We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs. PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-104A and further reduced to the amine and hydroxyl-amine nitrogen mustards that induce DNA cross-linking in hypoxic cells under low oxygen concentrations. In this phase I/II study, patients with relapsed/refractory acute myeloid leukemia (n=40) after 1 or 2 prior treatments or acute lymphoblastic leukemia (n=10) after any number of prior treatments received PR104; dose ranged from 1.1 to 4 g/m(2). The most common treatment-related grade 3/4 adverse events were myelosuppression (anemia 62%, neutropenia 50%, thrombocytopenia 46%), febrile neutropenia (40%), infection (24%), and enterocolitis (14%). Ten of 31 patients with acute myeloid leukemia (32%) and 2 of 10 patients with acute lymphoblastic leukemia (20%) who received 3 g/m(2) or 4 g/m(2) had a response (complete response, n=1; complete response without platelet recovery, n=5; morphological leukemia-free state, n=6). The extent of hypoxia was evaluated by the hypoxia tracer pimonidazole administered prior to a bone marrow biopsy and by immunohistochemical assessments of hypoxia-inducible factor alpha and carbonic anhydrase IX. A high fraction of leukemic cells expressed these markers, and PR104 administration resulted in measurable decrease of the proportions of hypoxic cells. These findings indicate that hypoxia is a prevalent feature of the leukemic microenvironment and that targeting hypoxia with hypoxia-activated prodrugs warrants further evaluation in acute leukemia. The trial is registered at clinicaltrials.gov identifier: 01037556. ","Clinical Trial, Phase I",1802.0,36.0,We previously demonstrated vast expansion of hypoxic areas in the leukemic microenvironment and provided a rationale for using hypoxia-activated prodrugs PR104 is a phosphate ester that is rapidly hydrolyzed in vivo to the corresponding alcohol PR-104A and further reduced to the amine and hydroxyl-amine nitrogen mustards that induce DNA cross-linking in hypoxic cells under low oxygen concentrations In this phase I/II study patients with relapsed/refractory acute myeloid n=40 after 1 or 2 prior treatments or acute lymphoblastic n=10 after any number of prior treatments received PR104 dose ranged from 1.1 to 4 g/m 2 The most common treatment-related grade 3/4 adverse events were myelosuppression anemia 62 neutropenia 50 thrombocytopenia 46 febrile neutropenia 40 infection 24 and enterocolitis 14 Ten of 31 patients with acute myeloid 32 and 2 of 10 patients with acute lymphoblastic 20 who received 3 g/m 2 or 4 g/m 2 had a response complete response n=1 complete response without platelet recovery n=5 morphological leukemia-free state n=6 The extent of hypoxia was evaluated by the hypoxia tracer pimonidazole administered prior to a marrow biopsy and by immunohistochemical assessments of hypoxia-inducible factor alpha and carbonic anhydrase IX A high fraction of leukemic cells expressed these markers and PR104 administration resulted in measurable decrease of the proportions of hypoxic cells These findings indicate that hypoxia is a prevalent feature of the leukemic microenvironment and that targeting hypoxia with hypoxia-activated prodrugs warrants further evaluation in acute The trial is registered at clinicaltrials.gov identifier 01037556,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 373, 264, 4337, 1422, 1, 4744, 1361, 4, 3, 2015, 995, 2, 1052, 8, 1728, 9, 75, 1823, 735, 8318, 40997, 16, 8, 4849, 9617, 17, 16, 1755, 21165, 4, 386, 6, 3, 1734, 2197, 998, 39649, 2, 195, 405, 6, 3, 20420, 2, 18595, 20420, 9788, 39648, 17, 1290, 261, 1383, 5806, 4, 4744, 37, 669, 154, 2848, 1003, 4, 26, 124, 70, 215, 45, 7, 5, 591, 430, 286, 533, 78, 327, 50, 14, 15, 18, 324, 640, 15, 286, 1275, 78, 79, 50, 500, 207, 1, 324, 640, 103, 40997, 61, 1869, 29, 14, 14, 6, 39, 499, 188, 18, 3, 96, 186, 24, 139, 88, 27, 39, 290, 281, 11, 2858, 1545, 744, 778, 212, 1340, 641, 2498, 778, 327, 930, 259, 2, 14829, 213, 1618, 1, 456, 7, 5, 286, 533, 531, 2, 18, 1, 79, 7, 5, 286, 1275, 179, 54, 103, 27, 499, 188, 18, 15, 39, 499, 188, 18, 42, 8, 51, 236, 51, 78, 14, 236, 51, 187, 1596, 1602, 78, 33, 4268, 2647, 115, 1309, 78, 49, 3, 1039, 1, 1823, 10, 194, 20, 3, 1823, 6160, 28399, 468, 324, 6, 8, 581, 411, 2, 20, 1382, 2182, 1, 1823, 2877, 161, 950, 2, 11190, 11191, 8032, 8, 64, 1509, 1, 2015, 37, 570, 46, 525, 2, 40997, 634, 627, 4, 1884, 775, 1, 3, 4117, 1, 4744, 37, 46, 272, 1008, 17, 1823, 16, 8, 2485, 2705, 1, 3, 2015, 995, 2, 17, 529, 1823, 5, 1823, 735, 8318, 2782, 195, 451, 4, 286, 3, 160, 16, 1653, 28, 1252, 1239, 3719, 65645]",1663.0,25682597,6
Balancing cure and long-term risks in acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2014-11-18,"Cure rates for children and adolescents with acute lymphoblastic leukemia (ALL) have improved dramatically over the last few decades. With this success has come increasing recognition of the adverse late effects of treatment. The significant long-term sequelae in the earliest cohort of long-term survivors treated in the 1970s and 1980s are well documented. To reduce the incidence of these late effects, the majority of pediatric patients treated on more contemporary regimens receive less intensive treatment than did those treated 30-40 years ago. However, current therapies are not risk free; children treated with contemporary regimens remain at risk for developing long-term toxicities, including cardiac dysfunction, osteonecrosis, neurocognitive impairment, and second malignant neoplasms. One of the great challenges facing clinical investigators today is to identify interventions that will reduce the frequency and severity of long-term toxicities without adversely affecting cure rates. The use of dexrazoxane as a cardioprotectant (to prevent anthracycline-associated cardiotoxicity) and alternate-week dosing of dexamethasone (to reduce the risk of osteonecrosis) are examples of 2 such successful strategies. This article provides an overview of the long-term toxicities associated with current therapies and reviews results of clinical trials designed to minimize the burden of cure in long-term survivors. ",Journal Article,1890.0,20.0,Cure rates for children and adolescents with acute lymphoblastic ALL have improved dramatically over the last few decades With this success has come increasing recognition of the adverse late effects of treatment The significant long-term sequelae in the earliest cohort of long-term survivors treated in the 1970s and 1980s are well documented To reduce the incidence of these late effects the majority of pediatric patients treated on more contemporary regimens receive less intensive treatment than did those treated 30-40 years ago However current therapies are not risk free children treated with contemporary regimens remain at risk for developing long-term toxicities including dysfunction osteonecrosis neurocognitive impairment and second malignant neoplasms One of the great challenges facing clinical investigators today is to identify interventions that will reduce the frequency and severity of long-term toxicities without adversely affecting cure rates The use of dexrazoxane as a cardioprotectant to prevent anthracycline-associated cardiotoxicity and alternate-week dosing of dexamethasone to reduce the risk of osteonecrosis are examples of 2 such successful strategies This article provides an overview of the long-term toxicities associated with current therapies and reviews results of clinical trials designed to minimize the burden of cure in long-term survivors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[1722, 151, 9, 541, 2, 3101, 5, 286, 1275, 62, 47, 231, 2729, 252, 3, 1060, 1021, 1968, 5, 26, 1825, 71, 6235, 602, 2335, 1, 3, 290, 807, 176, 1, 24, 3, 93, 319, 337, 4156, 4, 3, 6995, 180, 1, 319, 337, 332, 73, 4, 3, 10868, 2, 8361, 32, 149, 1405, 6, 969, 3, 287, 1, 46, 807, 176, 3, 686, 1, 815, 7, 73, 23, 80, 2667, 472, 560, 299, 1686, 24, 76, 205, 135, 73, 201, 327, 60, 5028, 137, 291, 235, 32, 44, 43, 115, 541, 73, 5, 2667, 472, 918, 28, 43, 9, 931, 319, 337, 385, 141, 1527, 5404, 2958, 2315, 2, 419, 393, 1179, 104, 1, 3, 2797, 1427, 7917, 38, 2394, 5665, 16, 6, 255, 1151, 17, 303, 969, 3, 675, 2, 1702, 1, 319, 337, 385, 187, 4311, 2319, 1722, 151, 3, 119, 1, 8473, 22, 8, 28769, 6, 1682, 2044, 41, 4404, 2, 4689, 647, 1280, 1, 1217, 6, 969, 3, 43, 1, 5404, 32, 4416, 1, 18, 225, 1401, 422, 26, 946, 777, 35, 2901, 1, 3, 319, 337, 385, 41, 5, 291, 235, 2, 2004, 99, 1, 38, 143, 1114, 6, 3241, 3, 892, 1, 1722, 4, 319, 337, 332]",1385.0,25696854,775
Chimeric antigen receptor T-cell therapy for ALL.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2014-11-18,"Relapsed and refractory leukemias pose substantial challenges in both children and adults, with very little progress being made in more than a decade. Targeted immunotherapy using chimeric antigen receptor (CAR)-modified T cells has emerged as a potent therapy with an innovative mechanism. Dramatic clinical responses with complete remission rates as high as 90% have been reported using CAR-modified T cells directed against the B-cell-specific antigen CD19 in patients with relapsed/refractory acute lymphoblastic leukemia. Supraphysiologic T-cell proliferation, a hallmark of this therapy, contributes to both efficacy and the most notable toxicity, cytokine release syndrome, posing a unique challenge for toxicity management. Further studies are necessary to identify additional targets, standardize approaches to cytokine release syndrome management, and determine the durability of remissions. ",Journal Article,1890.0,31.0,Relapsed and refractory leukemias pose substantial challenges in both children and adults with very little progress being made in more than a decade Targeted immunotherapy using chimeric antigen receptor CAR -modified T cells has emerged as a potent therapy with an innovative mechanism Dramatic clinical responses with complete remission rates as high as 90 have been reported using CAR-modified T cells directed against the B-cell-specific antigen CD19 in patients with relapsed/refractory acute lymphoblastic Supraphysiologic T-cell proliferation a hallmark of this therapy contributes to both efficacy and the most notable toxicity cytokine release syndrome posing a unique challenge for toxicity management Further studies are necessary to identify additional targets standardize approaches to cytokine release syndrome management and determine the durability of remissions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[591, 2, 430, 2792, 6015, 1281, 1427, 4, 110, 541, 2, 857, 5, 923, 1215, 1466, 486, 1229, 4, 80, 76, 8, 2025, 238, 726, 75, 2897, 448, 153, 1881, 1230, 102, 37, 71, 2054, 22, 8, 1157, 36, 5, 35, 4019, 670, 3079, 38, 253, 5, 236, 734, 151, 22, 64, 22, 424, 47, 85, 210, 75, 1881, 1230, 102, 37, 1166, 480, 3, 132, 31, 112, 448, 3158, 4, 7, 5, 591, 430, 286, 1275, 16712, 102, 31, 457, 8, 4683, 1, 26, 36, 2444, 6, 110, 209, 2, 3, 96, 4090, 155, 1675, 2008, 681, 20297, 8, 991, 1745, 9, 155, 284, 195, 94, 32, 1493, 6, 255, 402, 637, 9211, 611, 6, 1675, 2008, 681, 284, 2, 223, 3, 6867, 1, 3166]",878.0,25696911,32
Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.,JAMA,JAMA,2015-02-01,"With cure rates of childhood acute lymphoblastic leukemia (ALL) exceeding 85%, there is a need to mitigate treatment toxicities that can compromise quality of life, including peripheral neuropathy from vincristine treatment. To identify genetic germline variants associated with the occurrence or severity of vincristine-induced peripheral neuropathy in children with ALL. Genome-wide association study of patients in 1 of 2 prospective clinical trials for childhood ALL that included treatment with 36 to 39 doses of vincristine. Genome-wide single-nucleotide polymorphism (SNP) analysis and vincristine-induced peripheral neuropathy were assessed in 321 patients from whom DNA was available: 222 patients (median age, 6.0 years; range, 0.1-18.8 years) enrolled in 1994-1998 in the St Jude Children's Research Hospital protocol Total XIIIB with toxic effects follow-up through January 2001, and 99 patients (median age, 11.4 years; range, 3.0-23.8 years) enrolled in 2007-2010 in the Children's Oncology Group (COG) protocol AALL0433 with toxic effects follow-up through May 2011. Human leukemia cells and induced pluripotent stem cell neurons were used to assess the effects of lower CEP72 expression on vincristine sensitivity. Treatment with vincristine at a dose of 1.5 or 2.0 mg/m2. Vincristine-induced peripheral neuropathy was assessed at clinic visits using National Cancer Institute criteria and prospectively graded as mild (grade 1), moderate (grade 2), serious/disabling (grade 3), or life threatening (grade 4). Grade 2 to 4 vincristine-induced neuropathy during continuation therapy occurred in 28.8% of patients (64/222) in the St Jude cohort and in 22.2% (22/99) in the COG cohort. A SNP in the promoter region of the CEP72 gene, which encodes a centrosomal protein involved in microtubule formation, had a significant association with vincristine neuropathy (meta-analysis P=6.310(-9)). This SNP had a minor allele frequency of 37% (235/642), with 50 of 321 patients (16%; 95% CI, 11.6%-19.5%) homozygous for the risk allele (TT at rs924607). Among patients with the high-risk CEP72 genotype (TT at rs924607), 28 of 50 (56%; 95% CI, 41.2%-70.0%) developed at least 1 episode of grade 2 to 4 neuropathy, a higher rate than in patients with the CEP72 CC or CT genotypes (58/271 patients [21.4%; 95% CI, 16.9%-26.7%]; P=2.410(-6)). The severity of neuropathy was greater in patients homozygous for the TT genotype compared with patients with the CC or CT genotype (2.4-fold by Poisson regression [P<.0001] and 2.7-fold based on mean grade of neuropathy: 1.23 [95% CI, 0.74-1.72] vs 0.45 [95% CI, 0.3-0.6]; P=.004 by t test). Reducing CEP72 expression in human neurons and leukemia cells increased their sensitivity to vincristine. In this preliminary study of children with ALL, an inherited polymorphism in the promoter region of CEP72 was associated with increased risk and severity of vincristine-related peripheral neuropathy. If replicated in additional populations, this finding may provide a basis for safer dosing of this widely prescribed anticancer agent.",Journal Article,1815.0,103.0,With cure rates of childhood acute lymphoblastic ALL exceeding 85 there is a need to mitigate treatment toxicities that can compromise quality of life including peripheral neuropathy from vincristine treatment To identify genetic germline variants associated with the occurrence or severity of vincristine-induced peripheral neuropathy in children with ALL Genome-wide association study of patients in 1 of 2 prospective clinical trials for childhood ALL that included treatment with 36 to 39 doses of vincristine Genome-wide single-nucleotide polymorphism SNP analysis and vincristine-induced peripheral neuropathy were assessed in 321 patients from whom DNA was available 222 patients median age 6.0 years range 0.1-18.8 years enrolled in 1994-1998 in the St Jude Children 's Research Hospital protocol Total XIIIB with toxic effects follow-up through January 2001 and 99 patients median age 11.4 years range 3.0-23.8 years enrolled in 2007-2010 in the Children 's Oncology Group COG protocol AALL0433 with toxic effects follow-up through May 2011 Human cells and induced pluripotent stem cell neurons were used to assess the effects of lower CEP72 expression on vincristine sensitivity Treatment with vincristine at a dose of 1.5 or 2.0 mg/m2 Vincristine-induced peripheral neuropathy was assessed at clinic visits using National Cancer Institute criteria and prospectively graded as mild grade 1 moderate grade 2 serious/disabling grade 3 or life threatening grade 4 Grade 2 to 4 vincristine-induced neuropathy during continuation therapy occurred in 28.8 of patients 64/222 in the St Jude cohort and in 22.2 22/99 in the COG cohort A SNP in the promoter region of the CEP72 gene which encodes a centrosomal protein involved in microtubule formation had a significant association with vincristine neuropathy meta-analysis P 6.310 -9 This SNP had a minor allele frequency of 37 235/642 with 50 of 321 patients 16 95 CI 11.6 -19.5 homozygous for the risk allele TT at rs924607 Among patients with the high-risk CEP72 genotype TT at rs924607 28 of 50 56 95 CI 41.2 -70.0 developed at least 1 episode of grade 2 to 4 neuropathy a higher rate than in patients with the CEP72 CC or CT genotypes 58/271 patients 21.4 95 CI 16.9 -26.7 P 2.410 -6 The severity of neuropathy was greater in patients homozygous for the TT genotype compared with patients with the CC or CT genotype 2.4-fold by Poisson regression P .0001 and 2.7-fold based on mean grade of neuropathy 1.23 95 CI 0.74-1.72 vs 0.45 95 CI 0.3-0.6 P .004 by t test Reducing CEP72 expression in human neurons and cells increased their sensitivity to vincristine In this preliminary study of children with ALL an inherited polymorphism in the promoter region of CEP72 was associated with increased risk and severity of vincristine-related peripheral neuropathy If replicated in additional populations this finding may provide a basis for safer dosing of this widely prescribed anticancer agent,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5, 1722, 151, 1, 864, 286, 1275, 62, 5178, 772, 125, 16, 8, 594, 6, 5626, 24, 385, 17, 122, 4665, 372, 1, 358, 141, 672, 1751, 29, 2132, 24, 6, 255, 336, 1009, 839, 41, 5, 3, 2291, 15, 1702, 1, 2132, 277, 672, 1751, 4, 541, 5, 62, 898, 1019, 248, 45, 1, 7, 4, 14, 1, 18, 482, 38, 143, 9, 864, 62, 17, 159, 24, 5, 511, 6, 587, 415, 1, 2132, 898, 1019, 226, 1579, 1907, 1845, 65, 2, 2132, 277, 672, 1751, 11, 275, 4, 9976, 7, 29, 953, 261, 10, 390, 5647, 7, 52, 89, 49, 13, 60, 184, 13, 14, 203, 66, 60, 346, 4, 3023, 1850, 4, 3, 3062, 4841, 541, 292, 389, 702, 1182, 181, 30629, 5, 1812, 176, 166, 126, 298, 1024, 1758, 2, 1058, 7, 52, 89, 175, 39, 60, 184, 27, 13, 382, 66, 60, 346, 4, 1307, 1120, 4, 3, 541, 292, 413, 87, 6377, 1182, 65689, 5, 1812, 176, 166, 126, 298, 68, 1132, 171, 37, 2, 277, 13007, 452, 31, 11930, 11, 95, 6, 423, 3, 176, 1, 280, 27424, 55, 23, 2132, 485, 24, 5, 2132, 28, 8, 61, 1, 14, 33, 15, 18, 13, 81, 821, 2132, 277, 672, 1751, 10, 275, 28, 1188, 2690, 75, 657, 12, 1377, 371, 2, 1143, 3468, 22, 1980, 88, 14, 1163, 88, 18, 1762, 12492, 88, 27, 15, 358, 3691, 88, 39, 88, 18, 6, 39, 2132, 277, 1751, 190, 6870, 36, 489, 4, 339, 66, 1, 7, 660, 5647, 4, 3, 3062, 4841, 180, 2, 4, 350, 18, 350, 1058, 4, 3, 6377, 180, 8, 1845, 4, 3, 973, 1053, 1, 3, 27424, 145, 92, 4322, 8, 25042, 178, 646, 4, 4621, 1264, 42, 8, 93, 248, 5, 2132, 1751, 1742, 65, 19, 49, 20823, 83, 26, 1845, 42, 8, 2278, 1254, 675, 1, 567, 6465, 11994, 5, 212, 1, 9976, 7, 245, 48, 58, 175, 49, 326, 33, 3189, 9, 3, 43, 1254, 3504, 28, 48871, 107, 7, 5, 3, 64, 43, 27424, 1183, 3504, 28, 48871, 339, 1, 212, 664, 48, 58, 605, 18, 431, 13, 276, 28, 506, 14, 6934, 1, 88, 18, 6, 39, 1751, 8, 142, 116, 76, 4, 7, 5, 3, 27424, 1951, 15, 425, 2071, 717, 8957, 7, 239, 39, 48, 58, 245, 83, 432, 67, 19, 18, 39599, 49, 3, 1702, 1, 1751, 10, 378, 4, 7, 3189, 9, 3, 3504, 1183, 72, 5, 7, 5, 3, 1951, 15, 425, 1183, 18, 39, 1116, 20, 7668, 320, 19, 488, 2, 18, 67, 1116, 90, 23, 313, 88, 1, 1751, 14, 382, 48, 58, 13, 794, 14, 720, 105, 13, 512, 48, 58, 13, 27, 13, 49, 19, 1520, 20, 102, 412, 1818, 27424, 55, 4, 171, 11930, 2, 37, 101, 136, 485, 6, 2132, 4, 26, 1676, 45, 1, 541, 5, 62, 35, 2986, 1907, 4, 3, 973, 1053, 1, 27424, 10, 41, 5, 101, 43, 2, 1702, 1, 2132, 139, 672, 1751, 492, 6714, 4, 402, 1184, 26, 1567, 68, 377, 8, 877, 9, 9276, 1280, 1, 26, 1792, 2746, 1475, 420]",2948.0,25710658,496
Tyrosine kinase inhibitors induce mesenchymal stem cell-mediated resistance in BCR-ABL+ acute lymphoblastic leukemia.,Blood,Blood,2015-02-23,"Tyrosine kinase inhibitors (TKIs) are used as a frontline therapy for BCR-ABL(+) acute lymphoblastic leukemia (ALL). However, resistance to TKI therapy arises rapidly, and its underlying molecular mechanisms are poorly understood. In this study, we identified a novel cascade of events initiated by TKIs and traversing through mesenchymal stem cells (MSCs) to leukemic cells, leading to resistance. MSCs exposed to TKIs acquired a new functional status with the expression of genes encoding for chemo-attractants, adhesion molecules, and prosurvival growth factors, and this priming enabled leukemic cells to form clusters underneath the MSCs. This cluster formation was associated with the protection of ALL cells from therapy as leukemic cells switched from BCR-ABL signaling to IL-7R/Janus kinase signaling to survive in the MSC milieu. Our findings illustrate a novel perspective in the evolution of TKI resistance and provide insights for advancing the treatment of BCR-ABL(+) ALL. ",Journal Article,1793.0,15.0,Tyrosine kinase inhibitors TKIs are used as a frontline therapy for BCR-ABL acute lymphoblastic ALL However resistance to TKI therapy arises rapidly and its underlying molecular mechanisms are poorly understood In this study we identified a novel cascade of events initiated by TKIs and traversing through mesenchymal stem cells MSCs to leukemic cells leading to resistance MSCs exposed to TKIs acquired a new functional status with the expression of genes encoding for chemo-attractants adhesion molecules and prosurvival growth factors and this priming enabled leukemic cells to form clusters underneath the MSCs This cluster formation was associated with the protection of ALL cells from therapy as leukemic cells switched from BCR-ABL signaling to IL-7R/Janus kinase signaling to survive in the MSC milieu Our findings illustrate a novel perspective in the evolution of TKI resistance and provide insights for advancing the treatment of BCR-ABL ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[564, 216, 222, 1671, 32, 95, 22, 8, 3171, 36, 9, 1062, 1425, 286, 1275, 62, 137, 251, 6, 1379, 36, 6053, 1755, 2, 211, 1181, 219, 483, 32, 1240, 1784, 4, 26, 45, 21, 108, 8, 229, 4678, 1, 281, 1917, 20, 1671, 2, 48874, 298, 1569, 452, 37, 4460, 6, 2015, 37, 1049, 6, 251, 4460, 2234, 6, 1671, 1294, 8, 217, 583, 156, 5, 3, 55, 1, 214, 2362, 9, 3341, 45835, 2128, 1598, 2, 7331, 129, 130, 2, 26, 4903, 4387, 2015, 37, 6, 1297, 3780, 39080, 3, 4460, 26, 3132, 1264, 10, 41, 5, 3, 3525, 1, 62, 37, 29, 36, 22, 2015, 37, 7883, 29, 1062, 1425, 314, 6, 501, 25964, 6191, 216, 314, 6, 4573, 4, 3, 4150, 6795, 114, 272, 4746, 8, 229, 3727, 4, 3, 2554, 1, 1379, 251, 2, 377, 1957, 9, 5155, 3, 24, 1, 1062, 1425, 62]",952.0,25712988,632
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-02-27,"Previous studies suggest a potential therapeutic role for mTOR inhibition in lymphoid malignancies. This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in relapsed/refractory acute lymphoblastic leukemia (ALL). Twenty-four patients were treated; 15 received everolimus 5 mg/day and 9 received 10 mg/day with HyperCVAD. The median age of patients was 25 years (range, 11-64) and median number of prior treatments was 2 (range, 1-7). Grade 3 mucositis was the dose-limiting toxicity and the maximum tolerated everolimus dose was 5 mg/day. Responses included complete remission (CR) in 6 patients (25%), CR without platelet recovery (CRp) in 1 (4%), and CR without recovery of counts (CRi) in 1 (4%), for an overall response rate of 33%. In addition, partial response (PR) was noted in 2 patients (8%). Seven of 11 patients treated in first salvage achieved CR/CRp (64%). The median OS was 29 weeks for patients in first salvage versus 15 weeks for patients in second salvage and beyond (P  0.001). A response was noted in 5 of 10 (50%) heavily pretreated T-ALL patients (median of 4 prior salvage regimens). Everolimus significantly inhibited phosphorylation of S6RP, but this did not correlate with response. No significant decreases in p4EBP1 and pAkt levels were noted. Responders had higher everolimus dose-adjusted area under the curve (P = 0.025) and lower clearance (P = 0.025) than nonresponders. The combination of HyperCVAD and everolimus is well tolerated and moderately effective in relapsed ALL, specifically T-ALL.","Clinical Trial, Phase I",1789.0,27.0,Previous studies suggest a potential therapeutic role for mTOR inhibition in lymphoid malignancies This single-center phase I/II study was designed to test the safety and efficacy of the mTOR inhibitor everolimus in combination with HyperCVAD chemotherapy in relapsed/refractory acute lymphoblastic ALL Twenty-four patients were treated 15 received everolimus 5 mg/day and 9 received 10 mg/day with HyperCVAD The median age of patients was 25 years range 11-64 and median number of prior treatments was 2 range 1-7 Grade 3 mucositis was the dose-limiting toxicity and the maximum tolerated everolimus dose was 5 mg/day Responses included complete remission CR in 6 patients 25 CR without platelet recovery CRp in 1 4 and CR without recovery of counts CRi in 1 4 for an overall response rate of 33 In addition partial response PR was noted in 2 patients 8 Seven of 11 patients treated in first salvage achieved CR/CRp 64 The median OS was 29 weeks for patients in first salvage versus 15 weeks for patients in second salvage and beyond P  0.001 A response was noted in 5 of 10 50 heavily pretreated T-ALL patients median of 4 prior salvage regimens Everolimus significantly inhibited phosphorylation of S6RP but this did not correlate with response No significant decreases in p4EBP1 and pAkt levels were noted Responders had higher everolimus dose-adjusted area under the curve P 0.025 and lower clearance P 0.025 than nonresponders The combination of HyperCVAD and everolimus is well tolerated and moderately effective in relapsed ALL specifically T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[698, 94, 309, 8, 174, 189, 200, 9, 873, 297, 4, 2303, 441, 26, 226, 574, 124, 70, 215, 45, 10, 1114, 6, 412, 3, 367, 2, 209, 1, 3, 873, 230, 1400, 4, 150, 5, 13792, 56, 4, 591, 430, 286, 1275, 62, 737, 294, 7, 11, 73, 167, 103, 1400, 33, 81, 218, 2, 83, 103, 79, 81, 218, 5, 13792, 3, 52, 89, 1, 7, 10, 243, 60, 184, 175, 660, 2, 52, 207, 1, 324, 640, 10, 18, 184, 14, 67, 88, 27, 2606, 10, 3, 61, 817, 155, 2, 3, 689, 421, 1400, 61, 10, 33, 81, 218, 253, 159, 236, 734, 684, 4, 49, 7, 243, 684, 187, 1596, 1602, 3162, 4, 14, 39, 2, 684, 187, 1602, 1, 1911, 6341, 4, 14, 39, 9, 35, 63, 51, 116, 1, 466, 4, 352, 450, 51, 998, 10, 1051, 4, 18, 7, 66, 648, 1, 175, 7, 73, 4, 157, 992, 513, 684, 3162, 660, 3, 52, 118, 10, 462, 244, 9, 7, 4, 157, 992, 185, 167, 244, 9, 7, 4, 419, 992, 2, 1654, 19, 1552, 13, 144, 8, 51, 10, 1051, 4, 33, 1, 79, 212, 2447, 2193, 102, 62, 7, 52, 1, 39, 324, 992, 472, 1400, 97, 879, 982, 1, 29010, 84, 26, 205, 44, 1513, 5, 51, 77, 93, 2140, 4, 23944, 2, 6724, 148, 11, 1051, 1983, 42, 142, 1400, 61, 586, 965, 669, 3, 1496, 19, 13, 4067, 2, 280, 1960, 19, 13, 4067, 76, 4498, 3, 150, 1, 13792, 2, 1400, 16, 149, 421, 2, 3508, 323, 4, 591, 62, 1225, 102, 62]",1555.0,25724525,334
The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias.,Nature genetics,Nat. Genet.,2015-03-02,"Infant acute lymphoblastic leukemia (ALL) with MLL rearrangements (MLL-R) represents a distinct leukemia with a poor prognosis. To define its mutational landscape, we performed whole-genome, exome, RNA and targeted DNA sequencing on 65 infants (47 MLL-R and 18 non-MLL-R cases) and 20 older children (MLL-R cases) with leukemia. Our data show that infant MLL-R ALL has one of the lowest frequencies of somatic mutations of any sequenced cancer, with the predominant leukemic clone carrying a mean of 1.3 non-silent mutations. Despite this paucity of mutations, we detected activating mutations in kinase-PI3K-RAS signaling pathway components in 47% of cases. Surprisingly, these mutations were often subclonal and were frequently lost at relapse. In contrast to infant cases, MLL-R leukemia in older children had more somatic mutations (mean of 6.5 mutations/case versus 1.3 mutations/case, P = 7.15  10(-5)) and had frequent mutations (45%) in epigenetic regulators, a category of genes that, with the exception of MLL, was rarely mutated in infant MLL-R ALL. ",Journal Article,1786.0,167.0,Infant acute lymphoblastic ALL with MLL rearrangements MLL-R represents a distinct with a poor prognosis To define its mutational landscape we performed whole-genome exome RNA and targeted DNA sequencing on 65 infants 47 MLL-R and 18 non-MLL-R cases and 20 older children MLL-R cases with Our data show that infant MLL-R ALL has one of the lowest frequencies of somatic mutations of any sequenced cancer with the predominant leukemic clone carrying a mean of 1.3 non-silent mutations Despite this paucity of mutations we detected activating mutations in kinase-PI3K-RAS signaling pathway components in 47 of cases Surprisingly these mutations were often subclonal and were frequently lost at relapse In contrast to infant cases MLL-R in older children had more somatic mutations mean of 6.5 mutations/case versus 1.3 mutations/case P 7.15 10 -5 and had frequent mutations 45 in epigenetic regulators a category of genes that with the exception of MLL was rarely mutated in infant MLL-R ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8027, 286, 1275, 62, 5, 3049, 2072, 3049, 668, 1449, 8, 834, 5, 8, 334, 356, 6, 1107, 211, 1619, 2801, 21, 173, 902, 898, 2865, 893, 2, 238, 261, 615, 23, 556, 5585, 662, 3049, 668, 2, 203, 220, 3049, 668, 140, 2, 179, 434, 541, 3049, 668, 140, 5, 114, 74, 514, 17, 8027, 3049, 668, 62, 71, 104, 1, 3, 2101, 2722, 1, 1119, 138, 1, 500, 4040, 12, 5, 3, 2750, 2015, 3910, 2934, 8, 313, 1, 14, 27, 220, 9890, 138, 550, 26, 4832, 1, 138, 21, 530, 1616, 138, 4, 216, 974, 1102, 314, 308, 1628, 4, 662, 1, 140, 5819, 46, 138, 11, 629, 9210, 2, 11, 746, 3009, 28, 429, 4, 748, 6, 8027, 140, 3049, 668, 4, 434, 541, 42, 80, 1119, 138, 313, 1, 49, 33, 138, 473, 185, 14, 27, 138, 473, 19, 67, 167, 79, 33, 2, 42, 908, 138, 512, 4, 1418, 3196, 8, 2169, 1, 214, 17, 5, 3, 4188, 1, 3049, 10, 2416, 1185, 4, 8027, 3049, 668, 62]",989.0,25730765,2
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.,Expert review of anticancer therapy,Expert Rev Anticancer Ther,2015-03-12,"The introduction of tyrosine kinase inhibitors has improved outcomes in Philadelphia chromosome-positive acute lymphoblastic leukemia, yet relapse due to the development of resistance mutations remains a major obstacle. Ponatinib is a novel tyrosine kinase inhibitor designed to overcome single-resistance mutations in the ABL kinase. Three clinical trials confirmed the efficacy of ponatinib in the relapsed and front-line setting in Philadelphia positive acute lymphoblastic leukemia, even in the presence of the T315I mutation, which confers resistance to other tyrosine kinase inhibitors. The rate of relapse appears to be very low when used in combination with chemotherapy, suggesting a role for ponatinib in newly diagnosed patients. A major concern with the use of ponatinib is the associated high risk of life-threatening vascular thrombotic events. Potential strategies to reduce this risk include minimizing the use of ponatinib in patients with significant baseline cardiovascular risk, careful surveillance and treatment of cardiovascular risk-factors and dose reduction of ponatinib.",Journal Article,1776.0,11.0,The introduction of tyrosine kinase inhibitors has improved outcomes in Philadelphia chromosome-positive acute lymphoblastic yet relapse due to the development of resistance mutations remains a major obstacle Ponatinib is a novel tyrosine kinase inhibitor designed to overcome single-resistance mutations in the ABL kinase Three clinical trials confirmed the efficacy of ponatinib in the relapsed and front-line setting in Philadelphia positive acute lymphoblastic even in the presence of the T315I mutation which confers resistance to other tyrosine kinase inhibitors The rate of relapse appears to be very low when used in combination with chemotherapy suggesting a role for ponatinib in newly diagnosed patients A major concern with the use of ponatinib is the associated high risk of life-threatening vascular thrombotic events Potential strategies to reduce this risk include minimizing the use of ponatinib in patients with significant baseline cardiovascular risk careful surveillance and treatment of cardiovascular risk-factors and dose reduction of ponatinib,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2456, 1, 564, 216, 222, 71, 231, 123, 4, 3006, 1170, 109, 286, 1275, 1145, 429, 520, 6, 3, 193, 1, 251, 138, 469, 8, 458, 7414, 5715, 16, 8, 229, 564, 216, 230, 1114, 6, 1768, 226, 251, 138, 4, 3, 1425, 216, 169, 38, 143, 557, 3, 209, 1, 5715, 4, 3, 591, 2, 3007, 328, 546, 4, 3006, 109, 286, 1275, 871, 4, 3, 463, 1, 3, 6184, 258, 92, 4020, 251, 6, 127, 564, 216, 222, 3, 116, 1, 429, 1233, 6, 40, 923, 154, 198, 95, 4, 150, 5, 56, 802, 8, 200, 9, 5715, 4, 732, 265, 7, 8, 458, 2893, 5, 3, 119, 1, 5715, 16, 3, 41, 64, 43, 1, 358, 3691, 756, 6108, 281, 174, 422, 6, 969, 26, 43, 643, 4501, 3, 119, 1, 5715, 4, 7, 5, 93, 330, 2179, 43, 3465, 617, 2, 24, 1, 2179, 43, 130, 2, 61, 628, 1, 5715]",1068.0,25764322,163
Advances in the treatment of relapsed/refractory acute lymphoblastic leukemia: a case study compendium.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2014-12-01,"Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy characterized by proliferation of immature lymphoid cells throughout the bone marrow and peripheral blood. Most cases are diagnosed before the age of 20 years. Adults have a worse prognosis than children. Approximately half of adult ALL patients relapse after their initial treatment. There is no standard treatment for ALL; strategies vary according to the patients age, comorbidities, and Philadelphia chromosome status. Regimens used in pediatric patients are being adapted for use in adults. Frontline management can include hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with cycles of high-dose methotrexate and cytarabine (hyper-CVAD) and the Berlin-Frankfurt-Mnster regimen. Relapsed/refractory patients have several options, including a regimen consisting of fludarabine, high-dose cytarabine, and granulocyte colonystimulating factor (FLAG); tyrosine kinase inhibitors; and chemotherapy. The US Food and Drug Administration recently approved 3 therapies for these patients: clofarabine, nelarabine, and vincristine sulfate liposome injection, a modified formulation of vincristine that allows the drug to be administered at a higher dosage. Several novel strategies are currently under investigation, including the monoclonal antibody blinatumomab, a bispecific T-cell engager that targets the B-cellspecific antigen CD19 and activates T cells to exert cytotoxic activity against the target B cell. This clinical roundtable monograph features case studies that illustrate important points in the management of adult patients with relapsed/refractory ALL.",Case Reports,1877.0,1.0,Acute lymphoblastic ALL is a heterogeneous hematologic malignancy characterized by proliferation of immature lymphoid cells throughout the marrow and peripheral blood Most cases are diagnosed before the age of 20 years Adults have a worse prognosis than children Approximately half of adult ALL patients relapse after their initial treatment There is no standard treatment for ALL strategies vary according to the patient s age comorbidities and Philadelphia chromosome status Regimens used in pediatric patients are being adapted for use in adults Frontline management can include hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with cycles of high-dose methotrexate and cytarabine hyper-CVAD and the Berlin-Frankfurt-Mnster regimen Relapsed/refractory patients have several options including a regimen consisting of fludarabine high-dose cytarabine and granulocyte colonystimulating factor FLAG tyrosine kinase inhibitors and chemotherapy The US Food and Drug Administration recently approved 3 therapies for these patients clofarabine nelarabine and vincristine sulfate liposome injection a modified formulation of vincristine that allows the drug to be administered at a higher dosage Several novel strategies are currently under investigation including the monoclonal antibody blinatumomab a bispecific T-cell engager that targets the B-cellspecific antigen CD19 and activates T cells to exert cytotoxic activity against the target B cell This clinical roundtable monograph features case studies that illustrate important points in the management of adult patients with relapsed/refractory ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 1564, 813, 710, 765, 20, 457, 1, 5733, 2303, 37, 2432, 3, 581, 2, 672, 315, 96, 140, 32, 265, 348, 3, 89, 1, 179, 60, 857, 47, 8, 639, 356, 76, 541, 705, 1303, 1, 780, 62, 7, 429, 50, 136, 388, 24, 125, 16, 77, 260, 24, 9, 62, 422, 2825, 768, 6, 3, 69, 695, 89, 1909, 2, 3006, 1170, 156, 472, 95, 4, 815, 7, 32, 486, 3716, 9, 119, 4, 857, 3171, 284, 122, 643, 6201, 1112, 2132, 856, 2, 1217, 5181, 5, 410, 1, 64, 61, 2116, 2, 1855, 4855, 5574, 2, 3, 20405, 23389, 26350, 477, 591, 430, 7, 47, 392, 838, 141, 8, 477, 2273, 1, 2027, 64, 61, 1855, 2, 2764, 65756, 161, 12546, 564, 216, 222, 2, 56, 3, 843, 1773, 2, 234, 634, 761, 850, 27, 235, 9, 46, 7, 4149, 13149, 2, 2132, 6424, 8645, 1754, 8, 1230, 3583, 1, 2132, 17, 2333, 3, 234, 6, 40, 468, 28, 8, 142, 3323, 392, 229, 422, 32, 694, 669, 940, 141, 3, 848, 548, 7182, 8, 7408, 102, 31, 19374, 17, 637, 3, 132, 65757, 448, 3158, 2, 3932, 102, 37, 6, 5448, 759, 128, 480, 3, 283, 132, 31, 26, 38, 14446, 17923, 404, 473, 94, 17, 4746, 305, 862, 4, 3, 284, 1, 780, 7, 5, 591, 430, 62]",1642.0,25768269,216
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas.,Expert opinion on biological therapy,Expert Opin Biol Ther,2015-04-01,"The expression profile of the CD22 antigen and its role in B-cell function make it an important target in B-cell leukemias and lymphomas. Inotuzumab ozogamicin (IO), a humanized monoclonal antibody targeting CD22, is one of the most promising monoclonal antibodies for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). This article reviews the current literature of IO in adult leukemias and lymphomas. Single-agent IO has demonstrated activity in patients with relapsed B-cell ALL and non-Hodgkin lymphoma (NHL). It has also demonstrated favorable early results when combined with chemotherapy in older patients with ALL. There is potential for IO to be combined with other targeted therapies under development for these diseases; data are still early and further studies of IO are warranted. While the pivotal randomized study of IO for relapsed NHL versus physician's choice did not show a statistically significant advantage in response rate, the results of the pivotal study in ALL are not yet available.",Journal Article,1756.0,10.0,The expression profile of the CD22 antigen and its role in B-cell function make it an important target in B-cell leukemias and lymphomas Inotuzumab ozogamicin IO a humanized monoclonal antibody targeting CD22 is one of the most promising monoclonal antibodies for the treatment of relapsed/refractory B-cell acute lymphoblastic ALL This article reviews the current literature of IO in adult leukemias and lymphomas Single-agent IO has demonstrated activity in patients with relapsed B-cell ALL and NHL It has also demonstrated favorable early results when combined with chemotherapy in older patients with ALL There is potential for IO to be combined with other targeted therapies under development for these diseases data are still early and further studies of IO are warranted While the pivotal randomized study of IO for relapsed NHL versus physician 's choice did not show a statistically significant advantage in response rate the results of the pivotal study in ALL are not yet available,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 55, 800, 1, 3, 7599, 448, 2, 211, 200, 4, 132, 31, 343, 2378, 192, 35, 305, 283, 4, 132, 31, 2792, 2, 1557, 6730, 5566, 9927, 8, 3619, 848, 548, 529, 7599, 16, 104, 1, 3, 96, 721, 848, 890, 9, 3, 24, 1, 591, 430, 132, 31, 286, 1275, 62, 26, 946, 2004, 3, 291, 789, 1, 9927, 4, 780, 2792, 2, 1557, 226, 420, 9927, 71, 264, 128, 4, 7, 5, 591, 132, 31, 62, 2, 1176, 192, 71, 120, 264, 913, 191, 99, 198, 397, 5, 56, 4, 434, 7, 5, 62, 125, 16, 174, 9, 9927, 6, 40, 397, 5, 127, 238, 235, 669, 193, 9, 46, 1342, 74, 32, 1234, 191, 2, 195, 94, 1, 9927, 32, 1197, 369, 3, 3754, 384, 45, 1, 9927, 9, 591, 1176, 185, 1473, 292, 1866, 205, 44, 514, 8, 712, 93, 1874, 4, 51, 116, 3, 99, 1, 3, 3754, 45, 4, 62, 32, 44, 1145, 390]",993.0,25775418,290
How I treat acute lymphoblastic leukemia in older adolescents and young adults.,Blood,Blood,2015-03-24,"At the intersection between children and older adults, the care of adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) poses unique challenges and issues beyond those faced by other age groups. Although the survival of AYA patients is inferior to younger children, growing evidence suggests that AYA patients have improved outcomes, with disease-free survival rates of 60% to 70%, when treated with pediatric-based approaches. A holistic approach, incorporating a multidisciplinary team, is a key component of successful treatment of these AYA patients. With the appropriate support and management of toxicities during and following treatment, these regimens are well tolerated in the AYA population. Even with the significant progress that has been made during the last decade, patients with persistence of minimal residual disease (MRD) during intensive therapy still have a poor prognosis. With new insights into disease pathogenesis in AYA ALL and the availability of disease-specific kinase inhibitors and novel targeted antibodies, future studies will focus on individualized therapy to eradicate MRD and result in further improvements in survival. This case-based review will discuss the biology, pharmacology, and psychosocial aspects of AYA patients with ALL, highlighting our current approach to the management of these unique patients. ",Case Reports,1764.0,59.0,At the intersection between children and older adults the care of adolescent and young adult AYA patients with acute lymphoblastic ALL poses unique challenges and issues beyond those faced by other age groups Although the survival of AYA patients is inferior to younger children growing evidence suggests that AYA patients have improved outcomes with disease-free survival rates of 60 to 70 when treated with pediatric-based approaches A holistic approach incorporating a multidisciplinary team is a key component of successful treatment of these AYA patients With the appropriate support and management of toxicities during and following treatment these regimens are well tolerated in the AYA population Even with the significant progress that has been made during the last decade patients with persistence of minimal residual disease MRD during intensive therapy still have a poor prognosis With new insights into disease pathogenesis in AYA ALL and the availability of disease-specific kinase inhibitors and novel targeted antibodies future studies will focus on individualized therapy to eradicate MRD and result in further improvements in survival This case-based review will discuss the biology pharmacology and psychosocial aspects of AYA patients with ALL highlighting our current approach to the management of these unique patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[28, 3, 15566, 59, 541, 2, 434, 857, 3, 165, 1, 3678, 2, 1169, 780, 4598, 7, 5, 286, 1275, 62, 7056, 991, 1427, 2, 1553, 1654, 135, 6933, 20, 127, 89, 271, 242, 3, 25, 1, 4598, 7, 16, 1663, 6, 773, 541, 1921, 241, 844, 17, 4598, 7, 47, 231, 123, 5, 34, 115, 25, 151, 1, 335, 6, 431, 198, 73, 5, 815, 90, 611, 8, 19531, 353, 2570, 8, 1643, 2870, 16, 8, 825, 1249, 1, 1401, 24, 1, 46, 4598, 7, 5, 3, 870, 538, 2, 284, 1, 385, 190, 2, 366, 24, 46, 472, 32, 149, 421, 4, 3, 4598, 266, 871, 5, 3, 93, 1466, 17, 71, 85, 1229, 190, 3, 1060, 2025, 7, 5, 4108, 1, 1048, 753, 34, 2029, 190, 1686, 36, 1234, 47, 8, 334, 356, 5, 217, 1957, 237, 34, 1384, 4, 4598, 62, 2, 3, 2550, 1, 34, 112, 216, 222, 2, 229, 238, 890, 508, 94, 303, 1222, 23, 2596, 36, 6, 5650, 2029, 2, 757, 4, 195, 1474, 4, 25, 26, 473, 90, 206, 303, 1139, 3, 891, 6852, 2, 2322, 2695, 1, 4598, 7, 5, 62, 4051, 114, 291, 353, 6, 3, 284, 1, 46, 991, 7]",1340.0,25805810,662
Energy balance and fitness in adult survivors of childhood acute lymphoblastic leukemia.,Blood,Blood,2015-03-26,"There is limited information on body composition, energy balance, and fitness among survivors of childhood acute lymphoblastic leukemia (ALL), especially those treated without cranial radiation therapy (CRT). This analysis compares these metrics among 365 ALL survivors with a mean age of 28.6  5.9 years (149 treated with and 216 without CRT) and 365 age-, sex-, and race-matched peers. We also report risk factors for outcomes among survivors treated without CRT. Male survivors not exposed to CRT had abnormal body composition when compared with peers (% body fat, 26.2  8.2 vs 22.7  7.1). Survivors without CRT had similar energy balance but had significantly impaired quadriceps strength (-21.9  6.0 Newton-meters [Nm]/kg, 60/s) and endurance (-11.4  4.6 Nm/kg, 300/s), exercise capacity (-2.0  2.1 ml/kg per minute), low-back and hamstring flexibility (-4.7  1.6 cm), and dorsiflexion range of motion (-3.1  0.9) and higher modified total neuropathy scores (+1.6  1.1) than peers. Cumulative asparaginase dose 120,000 IU/m(2) was associated with impaired flexibility, vincristine dose 39 mg/m(2) with peripheral neuropathy, glucocorticoid (prednisone equivalent) dose 8000 mg/m(2) with hand weakness, and intrathecal methotrexate dose 225 mg with dorsiflexion weakness. Physical inactivity was associated with hand weakness and decreased exercise capacity. Smoking was associated with peripheral neuropathy. Elimination of CRT from ALL therapy has improved, but not eliminated, body-composition outcomes. Survivors remain at risk for impaired fitness.",Clinical Trial,1762.0,38.0,"There is limited information on body composition energy balance and fitness among survivors of childhood acute lymphoblastic ALL especially those treated without cranial radiation therapy CRT This analysis compares these metrics among 365 ALL survivors with a mean age of 28.6  5.9 years 149 treated with and 216 without CRT and 365 age- sex- and race-matched peers We also report risk factors for outcomes among survivors treated without CRT Male survivors not exposed to CRT had abnormal body composition when compared with peers body fat 26.2  8.2 vs 22.7  7.1 Survivors without CRT had similar energy balance but had significantly impaired quadriceps strength -21.9  6.0 Newton-meters Nm /kg 60/s and endurance -11.4  4.6 Nm/kg 300/s exercise capacity -2.0  2.1 ml/kg per minute low-back and hamstring flexibility -4.7  1.6 cm and dorsiflexion range of motion -3.1  0.9 and higher modified total neuropathy scores +1.6  1.1 than peers Cumulative asparaginase dose 120,000 IU/m 2 was associated with impaired flexibility vincristine dose 39 mg/m 2 with peripheral neuropathy glucocorticoid prednisone equivalent dose 8000 mg/m 2 with hand weakness and intrathecal methotrexate dose 225 mg with dorsiflexion weakness Physical inactivity was associated with hand weakness and decreased exercise capacity Smoking was associated with peripheral neuropathy Elimination of CRT from ALL therapy has improved but not eliminated body-composition outcomes Survivors remain at risk for impaired fitness",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[125, 16, 383, 487, 23, 642, 3761, 2803, 3459, 2, 5959, 107, 332, 1, 864, 286, 1275, 62, 1093, 135, 73, 187, 2565, 121, 36, 1089, 26, 65, 5815, 46, 3589, 107, 7405, 62, 332, 5, 8, 313, 89, 1, 339, 49, 810, 33, 83, 60, 4928, 73, 5, 2, 6287, 187, 1089, 2, 7405, 89, 1035, 2, 1047, 655, 11187, 21, 120, 414, 43, 130, 9, 123, 107, 332, 73, 187, 1089, 1045, 332, 44, 2234, 6, 1089, 42, 1668, 642, 3761, 198, 72, 5, 11187, 642, 2300, 432, 18, 810, 66, 18, 105, 350, 67, 810, 67, 14, 332, 187, 1089, 42, 288, 2803, 3459, 84, 42, 97, 2364, 29587, 3671, 239, 83, 810, 49, 13, 28506, 17798, 2878, 503, 46965, 695, 2, 15794, 175, 39, 810, 39, 49, 2878, 503, 65849, 695, 2277, 2162, 18, 13, 810, 18, 14, 542, 503, 379, 3949, 154, 4636, 2, 48456, 9794, 39, 67, 810, 14, 49, 494, 2, 35156, 184, 1, 2967, 27, 14, 810, 13, 25684, 2, 142, 1230, 181, 1751, 703, 14, 49, 810, 14, 14, 76, 11187, 967, 3709, 61, 48931, 984, 4588, 188, 18, 10, 41, 5, 2364, 9794, 2132, 61, 27080, 81, 188, 18, 5, 672, 1751, 5399, 1979, 2017, 61, 48932, 81, 188, 18, 5, 2833, 6408, 2, 5126, 2116, 61, 65850, 81, 5, 35156, 6408, 900, 10050, 10, 41, 5, 2833, 6408, 2, 340, 2277, 2162, 979, 10, 41, 5, 672, 1751, 3730, 1, 1089, 29, 62, 36, 71, 231, 84, 44, 6173, 642, 3761, 123, 332, 918, 28, 43, 9, 2364, 5959]",1510.0,25814529,313
Identification of novel therapeutic targets in acute leukemias with NRAS mutations using a pharmacologic approach.,Blood,Blood,2015-04-01,"Oncogenic forms of NRAS are frequently associated with hematologic malignancies and other cancers, making them important therapeutic targets. Inhibition of individual downstream effector molecules (eg, RAF kinase) have been complicated by the rapid development of resistance or activation of bypass pathways. For the purpose of identifying novel targets in NRAS-transformed cells, we performed a chemical screen using mutant NRAS transformed Ba/F3 cells to identify compounds with selective cytotoxicity. One of the compounds identified, GNF-7, potently and selectively inhibited NRAS-dependent cells in preclinical models of acute myelogenous leukemia and acute lymphoblastic leukemia. Mechanistic analysis revealed that its effects were mediated in part through combined inhibition of ACK1/AKT and of mitogen-activated protein kinase kinase kinase kinase 2 (germinal center kinase). Similar to genetic synthetic lethal approaches, these results suggest that small molecule screens can be used to identity novel therapeutic targets in cells addicted to RAS oncogenes. ",Journal Article,1756.0,7.0,Oncogenic forms of NRAS are frequently associated with hematologic malignancies and other cancers making them important therapeutic targets Inhibition of individual downstream effector molecules eg RAF kinase have been complicated by the rapid development of resistance or activation of bypass pathways For the purpose of identifying novel targets in NRAS-transformed cells we performed a chemical screen using mutant NRAS transformed Ba/F3 cells to identify compounds with selective cytotoxicity One of the compounds identified GNF-7 potently and selectively inhibited NRAS-dependent cells in preclinical models of acute myelogenous and acute lymphoblastic Mechanistic analysis revealed that its effects were mediated in part through combined inhibition of ACK1/AKT and of mitogen-activated protein kinase kinase kinase kinase 2 germinal center kinase Similar to genetic synthetic lethal approaches these results suggest that small molecule screens can be used to identity novel therapeutic targets in cells addicted to RAS oncogenes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1302, 2377, 1, 2845, 32, 746, 41, 5, 813, 441, 2, 127, 163, 1079, 1370, 305, 189, 637, 297, 1, 797, 1489, 2070, 1598, 2887, 2212, 216, 47, 85, 4286, 20, 3, 1321, 193, 1, 251, 15, 363, 1, 5481, 460, 9, 3, 743, 1, 1386, 229, 637, 4, 2845, 2423, 37, 21, 173, 8, 3743, 2413, 75, 620, 2845, 2423, 6669, 6904, 37, 6, 255, 2411, 5, 1094, 1408, 104, 1, 3, 2411, 108, 65887, 67, 4684, 2, 2382, 879, 2845, 470, 37, 4, 693, 274, 1, 286, 2194, 2, 286, 1275, 2716, 65, 553, 17, 211, 176, 11, 517, 4, 760, 298, 397, 297, 1, 41041, 649, 2, 1, 2625, 735, 178, 216, 216, 216, 216, 18, 6312, 574, 216, 288, 6, 336, 3273, 2266, 611, 46, 99, 309, 17, 302, 1354, 7508, 122, 40, 95, 6, 7710, 229, 189, 637, 4, 37, 10448, 6, 1102, 3326]",1034.0,25833960,318
The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-03-31,"Limited clinical data are available to assess whether the sequencing of cyclophosphamide (Cy) and total body irradiation (TBI) changes outcomes. We evaluated the sequence in 1769 (CyTBI, n= 948; TBICy, n= 821) recipients of related or unrelated hematopoietic cell transplantation who received TBI (1200 to 1500 cGY) for acute leukemia from 2003 to 2010. The 2 cohorts were comparable for median age, performance score, type of leukemia, first complete remission, Philadelphia chromosome-positive acute lymphoblastic leukemia, HLA-matched siblings, stem cell source, antithymocyte globulin use, TBI dose, and type of graft-versus-host disease (GVHD) prophylaxis. The sequence of TBI did not significantly affect transplantation-related mortality (24% versus 23% at 3 years, P= .67; relative risk, 1.01; P= .91), leukemia relapse (27% versus 29% at 3 years, P= .34; relative risk, .89, P= .18), leukemia-free survival (49% versus 48% at 3 years, P= .27; relative risk, .93; P= .29), chronic GVHD (45% versus 47% at 1 year, P= .39; relative risk, .9; P= .11), or overall survival (53% versus 52% at 3 years, P= .62; relative risk, .96; P= .57) for CyTBI and TBICy, respectively. Corresponding cumulative incidences of sinusoidal obstruction syndrome were 4% and 6% at 100 days (P= .08), respectively. This study demonstrates that the sequence of Cy and TBI does not impact transplantation outcomes and complications in patients with acute leukemia undergoing hematopoietic cell transplantation with myeloablative conditioning. ",Journal Article,1757.0,5.0,Limited clinical data are available to assess whether the sequencing of cyclophosphamide Cy and total body irradiation TBI changes outcomes We evaluated the sequence in 1769 CyTBI n 948 TBICy n 821 recipients of related or unrelated hematopoietic cell transplantation who received TBI 1200 to 1500 cGY for acute from 2003 to 2010 The 2 cohorts were comparable for median age performance score type of first complete remission Philadelphia chromosome-positive acute lymphoblastic HLA-matched siblings stem cell source antithymocyte globulin use TBI dose and type of graft-versus-host disease GVHD prophylaxis The sequence of TBI did not significantly affect transplantation-related mortality 24 versus 23 at 3 years P .67 relative risk 1.01 P .91 relapse 27 versus 29 at 3 years P .34 relative risk .89 P .18 leukemia-free survival 49 versus 48 at 3 years P .27 relative risk .93 P .29 chronic GVHD 45 versus 47 at 1 year P .39 relative risk .9 P .11 or overall survival 53 versus 52 at 3 years P .62 relative risk .96 P .57 for CyTBI and TBICy respectively Corresponding cumulative incidences of sinusoidal obstruction syndrome were 4 and 6 at 100 days P .08 respectively This study demonstrates that the sequence of Cy and TBI does not impact transplantation outcomes and complications in patients with acute undergoing hematopoietic cell transplantation with myeloablative conditioning,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[383, 38, 74, 32, 390, 6, 423, 317, 3, 615, 1, 1112, 5757, 2, 181, 642, 1104, 4889, 400, 123, 21, 194, 3, 1532, 4, 48942, 19524, 78, 19199, 48943, 78, 10680, 2190, 1, 139, 15, 2092, 1007, 31, 497, 54, 103, 4889, 6847, 6, 7204, 3071, 9, 286, 29, 1522, 6, 1120, 3, 18, 736, 11, 1279, 9, 52, 89, 528, 368, 267, 1, 157, 236, 734, 3006, 1170, 109, 286, 1275, 1160, 655, 2758, 452, 31, 2353, 11016, 7819, 119, 4889, 61, 2, 267, 1, 1599, 185, 1204, 34, 1562, 2049, 3, 1532, 1, 4889, 205, 44, 97, 1158, 497, 139, 282, 259, 185, 382, 28, 27, 60, 19, 598, 580, 43, 14, 355, 19, 970, 429, 428, 185, 462, 28, 27, 60, 19, 562, 580, 43, 887, 19, 203, 2647, 115, 25, 739, 185, 576, 28, 27, 60, 19, 428, 580, 43, 966, 19, 462, 442, 1562, 512, 185, 662, 28, 14, 111, 19, 587, 580, 43, 83, 19, 175, 15, 63, 25, 699, 185, 653, 28, 27, 60, 19, 744, 580, 43, 921, 19, 696, 9, 19524, 2, 48943, 106, 1734, 967, 3981, 1, 9820, 3191, 681, 11, 39, 2, 49, 28, 394, 162, 19, 1592, 106, 26, 45, 1902, 17, 3, 1532, 1, 5757, 2, 4889, 1097, 44, 345, 497, 123, 2, 521, 4, 7, 5, 286, 479, 1007, 31, 497, 5, 3246, 1933]",1387.0,25840335,879
Impact of Additional Cytogenetic Abnormalities in Adults with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-04-01,"The occurrence of additional cytogenetic abnormalities (ACAs) is common in Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) but is of unknown significance in the tyrosine kinase inhibitor (TKI) era. We retrospectively analyzed data from a consecutive case series of adults with Ph+ ALL who had undergone allogeneic hematopoietic cell transplantation (alloHCT) at City of Hope between 2003 and 2014. Among 130 adults with Ph+ ALL who had TKI therapy before alloHCT, 78 patients had available data on conventional cytogenetics at diagnosis and were eligible for outcomes analysis. ACAs were observed in 41 patients (53%). There were no statistically significant differences in median age, median initial WBC count, post-HCT TKI maintenance, or disease status at the time of transplant between the Ph-only and ACA cohorts; however, the Ph-only cohort had a higher rate of minimal residual disease positivity at the time of HCT. Three-year leukemia-free survival (79.8% versus 39.5%, P= .01) and 3-year overall survival (83% versus 45.6%, P= .02) were superior in the Ph-only cohort compared with the ACA cohort, respectively. Monosomy 7 was the most common additional aberration observed in our ACA cohort (n= 12). Thus, when TKI therapy and alloHCT are used as part of adult Ph+ ALL therapy, the presence of ACAs appears to have a significant deleterious effect on outcomes post-HCT. ",Journal Article,1756.0,11.0,The occurrence of additional cytogenetic abnormalities ACAs is common in Philadelphia chromosome-positive acute lymphoblastic Ph+ ALL but is of unknown significance in the tyrosine kinase inhibitor TKI era We retrospectively analyzed data from a consecutive case series of adults with Ph+ ALL who had undergone allogeneic hematopoietic cell transplantation alloHCT at City of Hope between 2003 and 2014 Among 130 adults with Ph+ ALL who had TKI therapy before alloHCT 78 patients had available data on conventional cytogenetics at diagnosis and were eligible for outcomes analysis ACAs were observed in 41 patients 53 There were no statistically significant differences in median age median initial WBC count post-HCT TKI maintenance or disease status at the time of transplant between the Ph-only and ACA cohorts however the Ph-only cohort had a higher rate of minimal residual disease positivity at the time of HCT Three-year leukemia-free survival 79.8 versus 39.5 P .01 and 3-year overall survival 83 versus 45.6 P .02 were superior in the Ph-only cohort compared with the ACA cohort respectively Monosomy 7 was the most common additional aberration observed in our ACA cohort n 12 Thus when TKI therapy and alloHCT are used as part of adult Ph+ ALL therapy the presence of ACAs appears to have a significant deleterious effect on outcomes post-HCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2291, 1, 402, 1266, 1171, 12238, 16, 186, 4, 3006, 1170, 109, 286, 1275, 2058, 62, 84, 16, 1, 860, 724, 4, 3, 564, 216, 230, 1379, 1713, 21, 894, 311, 74, 29, 8, 935, 473, 988, 1, 857, 5, 2058, 62, 54, 42, 1989, 1063, 1007, 31, 497, 5514, 28, 7235, 1, 3045, 59, 1522, 2, 1409, 107, 3431, 857, 5, 2058, 62, 54, 42, 1379, 36, 348, 5514, 833, 7, 42, 390, 74, 23, 809, 2510, 28, 147, 2, 11, 625, 9, 123, 65, 12238, 11, 164, 4, 605, 7, 699, 125, 11, 77, 712, 93, 362, 4, 52, 89, 52, 388, 4685, 1276, 539, 1085, 1379, 1146, 15, 34, 156, 28, 3, 98, 1, 941, 59, 3, 2058, 158, 2, 6285, 736, 137, 3, 2058, 158, 180, 42, 8, 142, 116, 1, 1048, 753, 34, 1887, 28, 3, 98, 1, 1085, 169, 111, 2647, 115, 25, 842, 66, 185, 587, 33, 19, 355, 2, 27, 111, 63, 25, 852, 185, 512, 49, 19, 588, 11, 1123, 4, 3, 2058, 158, 180, 72, 5, 3, 6285, 180, 106, 7521, 67, 10, 3, 96, 186, 402, 7794, 164, 4, 114, 6285, 180, 78, 133, 631, 198, 1379, 36, 2, 5514, 32, 95, 22, 760, 1, 780, 2058, 62, 36, 3, 463, 1, 12238, 1233, 6, 47, 8, 93, 3586, 254, 23, 123, 539, 1085]",1352.0,25842050,694
PAX5 is a tumor suppressor in mouse mutagenesis models of acute lymphoblastic leukemia.,Blood,Blood,2015-04-08,"Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic leukemia (B-ALL) and most commonly involve PAX5, encoding the DNA-binding transcription factor paired-box 5. The majority of PAX5 alterations in ALL are heterozygous, and key PAX5 target genes are expressed in leukemic cells, suggesting that PAX5 may be a haploinsufficient tumor suppressor. To examine the role of PAX5 alterations in leukemogenesis, we performed mutagenesis screens of mice heterozygous for a loss-of-function Pax5 allele. Both chemical and retroviral mutagenesis resulted in a significantly increased penetrance and reduced latency of leukemia, with a shift to B-lymphoid lineage. Genomic profiling identified a high frequency of secondary genomic mutations, deletions, and retroviral insertions targeting B-lymphoid development, including Pax5, and additional genes and pathways mutated in ALL, including tumor suppressors, Ras, and Janus kinase-signal transducer and activator of transcription signaling. These results show that in contrast to simple Pax5 haploinsufficiency, multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL. This cross-species analysis also validates the importance of concomitant alterations of multiple cellular growth, signaling, and tumor suppression pathways in the pathogenesis of B-ALL. ",Journal Article,1749.0,32.0,Alterations of genes encoding transcriptional regulators of lymphoid development are a hallmark of B-progenitor acute lymphoblastic B-ALL and most commonly involve PAX5 encoding the DNA-binding transcription factor paired-box 5 The majority of PAX5 alterations in ALL are heterozygous and key PAX5 target genes are expressed in leukemic cells suggesting that PAX5 may be a haploinsufficient tumor suppressor To examine the role of PAX5 alterations in leukemogenesis we performed mutagenesis screens of mice heterozygous for a loss-of-function Pax5 allele Both chemical and retroviral mutagenesis resulted in a significantly increased penetrance and reduced latency of with a shift to B-lymphoid lineage Genomic profiling identified a high frequency of secondary genomic mutations deletions and retroviral insertions targeting B-lymphoid development including Pax5 and additional genes and pathways mutated in ALL including tumor suppressors Ras and Janus kinase-signal transducer and activator of transcription signaling These results show that in contrast to simple Pax5 haploinsufficiency multiple sequential alterations targeting lymphoid development are central to leukemogenesis and contribute to the arrest in lymphoid maturation characteristic of ALL This cross-species analysis also validates the importance of concomitant alterations of multiple cellular growth signaling and tumor suppression pathways in the pathogenesis of B-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[593, 1, 214, 2362, 1431, 3196, 1, 2303, 193, 32, 8, 4683, 1, 132, 2520, 286, 1275, 132, 62, 2, 96, 841, 3882, 6279, 2362, 3, 261, 791, 866, 161, 2355, 4971, 33, 3, 686, 1, 6279, 593, 4, 62, 32, 4167, 2, 825, 6279, 283, 214, 32, 570, 4, 2015, 37, 802, 17, 6279, 68, 40, 8, 15916, 30, 1245, 6, 1004, 3, 200, 1, 6279, 593, 4, 5661, 21, 173, 8595, 7508, 1, 399, 4167, 9, 8, 407, 1, 343, 6279, 1254, 110, 3743, 2, 8658, 8595, 627, 4, 8, 97, 101, 4792, 2, 405, 5301, 1, 5, 8, 3024, 6, 132, 2303, 2542, 572, 1080, 108, 8, 64, 675, 1, 568, 572, 138, 2439, 2, 8658, 6315, 529, 132, 2303, 193, 141, 6279, 2, 402, 214, 2, 460, 1185, 4, 62, 141, 30, 5704, 1102, 2, 6191, 216, 1235, 5182, 2, 3393, 1, 866, 314, 46, 99, 514, 17, 4, 748, 6, 2763, 6279, 9292, 232, 1787, 593, 529, 2303, 193, 32, 854, 6, 5661, 2, 1248, 6, 3, 1854, 4, 2303, 4537, 2037, 1, 62, 26, 1383, 2915, 65, 120, 11235, 3, 1187, 1, 1781, 593, 1, 232, 763, 129, 314, 2, 30, 1332, 460, 4, 3, 1384, 1, 132, 62]",1440.0,25855603,88
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy.,Haematologica,Haematologica,2015-04-17,"Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant. A phase 1 dose escalation study of danusertib was conducted in patients with accelerated or blastic phase chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia. Two dosing schedules were studied: schedule A, in which danusertib was given by 3-hour intravenous infusion daily for 7 consecutive days (days 1-7) in a 14-day cycle, and schedule B, in which the danusertib was given by 3-hour intravenous infusion daily for 14 consecutive days (days 1-14) in a 21-day cycle. A total of 37 patients were treated, 29 with schedule A and eight with schedule B. The recommended phase 2 dose for schedule A was 180 mg/m(2). Enrollment to schedule B was stopped early because of logistical problems with the frequency of infusions. Febrile neutropenia and mucositis were dose-limiting toxicities in schedule A. Four patients with T315I ABL kinase mutation, all treated with schedule A, responded. Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies. This study was registered with the European Clinical Trails Data Base (EudraCT number 2007-004070-18). ","Clinical Trial, Phase I",1740.0,27.0,Danusertib is a pan-aurora kinase inhibitor with potent activity against Abl kinase including the gatekeeper T315I mutant A phase 1 dose escalation study of danusertib was conducted in patients with accelerated or blastic phase chronic myeloid or Philadelphia chromosome-positive acute lymphoblastic Two dosing schedules were studied schedule A in which danusertib was given by 3-hour intravenous infusion daily for 7 consecutive days days 1-7 in a 14-day cycle and schedule B in which the danusertib was given by 3-hour intravenous infusion daily for 14 consecutive days days 1-14 in a 21-day cycle A total of 37 patients were treated 29 with schedule A and eight with schedule B The recommended phase 2 dose for schedule A was 180 mg/m 2 Enrollment to schedule B was stopped early because of logistical problems with the frequency of infusions Febrile neutropenia and mucositis were dose-limiting toxicities in schedule A Four patients with T315I ABL kinase mutation all treated with schedule A responded Danusertib has an acceptable toxicity profile and is active in patients with Bcr-Abl-associated advanced hematologic malignancies This study was registered with the European Clinical Trails Data Base EudraCT number 2007-004070-18,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[20672, 16, 8, 3055, 4095, 216, 230, 5, 1157, 128, 480, 1425, 216, 141, 3, 10899, 6184, 620, 8, 124, 14, 61, 1125, 45, 1, 20672, 10, 426, 4, 7, 5, 2241, 15, 6529, 124, 442, 533, 15, 3006, 1170, 109, 286, 1275, 100, 1280, 2314, 11, 656, 1055, 8, 4, 92, 20672, 10, 447, 20, 27, 2583, 1262, 904, 391, 9, 67, 935, 162, 162, 14, 67, 4, 8, 213, 218, 417, 2, 1055, 132, 4, 92, 3, 20672, 10, 447, 20, 27, 2583, 1262, 904, 391, 9, 213, 935, 162, 162, 14, 213, 4, 8, 239, 218, 417, 8, 181, 1, 567, 7, 11, 73, 462, 5, 1055, 8, 2, 659, 5, 1055, 132, 3, 793, 124, 18, 61, 9, 1055, 8, 10, 3172, 81, 188, 18, 1798, 6, 1055, 132, 10, 4403, 191, 408, 1, 9773, 2408, 5, 3, 675, 1, 3435, 2498, 778, 2, 2606, 11, 61, 817, 385, 4, 1055, 8, 294, 7, 5, 6184, 1425, 216, 258, 62, 73, 5, 1055, 8, 2211, 20672, 71, 35, 1595, 155, 800, 2, 16, 544, 4, 7, 5, 1062, 1425, 41, 131, 813, 441, 26, 45, 10, 1653, 5, 3, 1865, 38, 26125, 74, 1782, 14681, 207, 1307, 66003, 203]",1236.0,25887498,347
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia.,Cancer,Cancer,2015-04-17,"Significant advances have been made in the last decade toward a better understanding of the disease pathogenesis and the development of novel therapies that target specific subsets of adult acute lymphoblastic leukemia (ALL). Risk-adapted strategies are transforming the disease treatment and prognosis. With current treatment regimens, long-term survival is achieved by approximately 50% of patients with B-cell ALL, 50% to 60% of patients with Philadelphia chromosome-positive ALL, and approximately 80% of patients with Burkitt's leukemia. Genomic profiling in ALL has identified new prognostic markers, new therapeutic targets, and novel ALL subtypes. These may be amenable to future targeted therapies that can further improve outcomes. The early recognition of early precursor T-cell ALL, a distinct pathobiological entity with a poor prognosis, is essential for the development of an effective clinical management strategy. The role of monoclonal antibodies and cytotoxic T-cell therapies continues to be defined. Many of the approaches are currently being evaluated for ALL salvage. Their incorporation into frontline adult ALL therapy, in concomitant or sequential strategies, may increase the cure rates to levels achieved in pediatric ALL and may reduce the need for prolonged intensive and maintenance chemotherapy.",Journal Article,1740.0,67.0,Significant advances have been made in the last decade toward a better understanding of the disease pathogenesis and the development of novel therapies that target specific subsets of adult acute lymphoblastic ALL Risk-adapted strategies are transforming the disease treatment and prognosis With current treatment regimens long-term survival is achieved by approximately 50 of patients with B-cell ALL 50 to 60 of patients with Philadelphia chromosome-positive ALL and approximately 80 of patients with 's Genomic profiling in ALL has identified new prognostic markers new therapeutic targets and novel ALL subtypes These may be amenable to future targeted therapies that can further improve outcomes The early recognition of early precursor T-cell ALL a distinct pathobiological entity with a poor prognosis is essential for the development of an effective clinical management strategy The role of monoclonal antibodies and cytotoxic T-cell therapies continues to be defined Many of the approaches are currently being evaluated for ALL salvage Their incorporation into frontline adult ALL therapy in concomitant or sequential strategies may increase the cure rates to levels achieved in pediatric ALL and may reduce the need for prolonged intensive and maintenance chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[93, 954, 47, 85, 1229, 4, 3, 1060, 2025, 1317, 8, 380, 612, 1, 3, 34, 1384, 2, 3, 193, 1, 229, 235, 17, 283, 112, 1890, 1, 780, 286, 1275, 62, 43, 3716, 422, 32, 3621, 3, 34, 24, 2, 356, 5, 291, 24, 472, 319, 337, 25, 16, 513, 20, 705, 212, 1, 7, 5, 132, 31, 62, 212, 6, 335, 1, 7, 5, 3006, 1170, 109, 62, 2, 705, 493, 1, 7, 5, 292, 572, 1080, 4, 62, 71, 108, 217, 177, 525, 217, 189, 637, 2, 229, 62, 814, 46, 68, 40, 4070, 6, 508, 238, 235, 17, 122, 195, 401, 123, 3, 191, 2335, 1, 191, 2765, 102, 31, 62, 8, 834, 22217, 2983, 5, 8, 334, 356, 16, 1452, 9, 3, 193, 1, 35, 323, 38, 284, 692, 3, 200, 1, 848, 890, 2, 759, 102, 31, 235, 2274, 6, 40, 395, 445, 1, 3, 611, 32, 694, 486, 194, 9, 62, 992, 136, 2838, 237, 3171, 780, 62, 36, 4, 1781, 15, 1787, 422, 68, 344, 3, 1722, 151, 6, 148, 513, 4, 815, 62, 2, 68, 969, 3, 594, 9, 1069, 1686, 2, 1146, 56]",1278.0,25891003,641
Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2015-06-01,"The prognosis of acute lymphoblastic leukemia (ALL) in adults remains poor, and novel treatment options are needed to improve outcomes. Immunotherapeutic strategies have been a recent focus in this area, targeting specific surface antigens on the ALL blast cells. Our review concentrates on four major class of antibody therapies, namely, (1) naked and unconjugated antibodies, (2) immunoconjugates and immunotoxins, (3) bi-specific T cell engaging (BiTE) therapy, and (4) chimeric antigen receptor (CAR) expressing T cells. We review preclinical and clinical data, and update on the latest advances in this exciting field, and suggest how these therapies can be incorporated into the treatment algorithm for ALL. ",Journal Article,1695.0,6.0,The prognosis of acute lymphoblastic ALL in adults remains poor and novel treatment options are needed to improve outcomes Immunotherapeutic strategies have been a recent focus in this area targeting specific surface antigens on the ALL blast cells Our review concentrates on four major class of antibody therapies namely 1 naked and unconjugated antibodies 2 immunoconjugates and immunotoxins 3 bi-specific T cell engaging BiTE therapy and 4 chimeric antigen receptor CAR expressing T cells We review preclinical and clinical data and update on the latest advances in this exciting field and suggest how these therapies can be incorporated into the treatment algorithm for ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 1, 286, 1275, 62, 4, 857, 469, 334, 2, 229, 24, 838, 32, 575, 6, 401, 123, 3222, 422, 47, 85, 8, 435, 1222, 4, 26, 965, 529, 112, 1255, 1575, 23, 3, 62, 3112, 37, 114, 206, 37422, 23, 294, 458, 1040, 1, 548, 235, 5046, 14, 11975, 2, 11116, 890, 18, 15109, 2, 17170, 27, 3984, 112, 102, 31, 8534, 15382, 36, 2, 39, 2897, 448, 153, 1881, 1046, 102, 37, 21, 206, 693, 2, 38, 74, 2, 2991, 23, 3, 5923, 954, 4, 26, 4963, 1067, 2, 309, 832, 46, 235, 122, 40, 2449, 237, 3, 24, 2124, 9, 62]",677.0,25899862,297
Association of Attention Deficit Disorder With Bedside Anti-saccades in Survivors of Childhood Leukemia.,Journal of child neurology,J. Child Neurol.,2015-04-26,"Impaired attention is well recognized in childhood cancer survivors. We prospectively evaluated 162 long-term survivors of childhood acute lymphoblastic leukemia to study an association between presence of neurologic soft signs as measured by Zurich Neuromotor Scale, bedside evaluation of anti-saccades, and attention deficit disorder. Attention deficit disorder was recognized in 10.5% of the study cohort. We did not find an association of attention deficit with presence of any soft sign. However, there was an association between presence of abnormal anti-saccades and attention deficit (P = .04). These results will require further validation and if confirmed may introduce a quick bedside method of assessing impaired attention in cancer survivors. ",Journal Article,1731.0,2.0,Impaired attention is well recognized in childhood cancer survivors We prospectively evaluated 162 long-term survivors of childhood acute lymphoblastic to study an association between presence of neurologic soft signs as measured by Zurich Neuromotor Scale bedside evaluation of anti-saccades and attention deficit disorder Attention deficit disorder was recognized in 10.5 of the study cohort We did not find an association of attention deficit with presence of any soft sign However there was an association between presence of abnormal anti-saccades and attention deficit P .04 These results will require further validation and if confirmed may introduce a quick bedside method of assessing impaired attention in cancer survivors,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2364, 2111, 16, 149, 1904, 4, 864, 12, 332, 21, 1143, 194, 5441, 319, 337, 332, 1, 864, 286, 1275, 6, 45, 35, 248, 59, 463, 1, 2543, 1214, 3408, 22, 644, 20, 66035, 30607, 1124, 8516, 451, 1, 312, 31744, 2, 2111, 6819, 2645, 2111, 6819, 2645, 10, 1904, 4, 79, 33, 1, 3, 45, 180, 21, 205, 44, 2469, 35, 248, 1, 2111, 6819, 5, 463, 1, 500, 1214, 7636, 137, 125, 10, 35, 248, 59, 463, 1, 1668, 312, 31744, 2, 2111, 6819, 19, 755, 46, 99, 303, 1353, 195, 929, 2, 492, 557, 68, 7630, 8, 14431, 8516, 596, 1, 1977, 2364, 2111, 4, 12, 332]",732.0,25918118,176
NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells.,Nature genetics,Nat. Genet.,2015-05-04,"Glucocorticoids are universally used in the treatment of acute lymphoblastic leukemia (ALL), and resistance to glucocorticoids in leukemia cells confers poor prognosis. To elucidate mechanisms of glucocorticoid resistance, we determined the prednisolone sensitivity of primary leukemia cells from 444 patients newly diagnosed with ALL and found significantly higher expression of CASP1 (encoding caspase 1) and its activator NLRP3 in glucocorticoid-resistant leukemia cells, resulting from significantly lower somatic methylation of the CASP1 and NLRP3 promoters. Overexpression of CASP1 resulted in cleavage of the glucocorticoid receptor, diminished the glucocorticoid-induced transcriptional response and increased glucocorticoid resistance. Knockdown or inhibition of CASP1 significantly increased glucocorticoid receptor levels and mitigated glucocorticoid resistance in CASP1-overexpressing ALL. Our findings establish a new mechanism by which the NLRP3-CASP1 inflammasome modulates cellular levels of the glucocorticoid receptor and diminishes cell sensitivity to glucocorticoids. The broad impact on the glucocorticoid transcriptional response suggests that this mechanism could also modify glucocorticoid effects in other diseases. ",Journal Article,1723.0,55.0,Glucocorticoids are universally used in the treatment of acute lymphoblastic ALL and resistance to glucocorticoids in cells confers poor prognosis To elucidate mechanisms of glucocorticoid resistance we determined the prednisolone sensitivity of primary cells from 444 patients newly diagnosed with ALL and found significantly higher expression of CASP1 encoding caspase 1 and its activator NLRP3 in glucocorticoid-resistant cells resulting from significantly lower somatic methylation of the CASP1 and NLRP3 promoters Overexpression of CASP1 resulted in cleavage of the glucocorticoid receptor diminished the glucocorticoid-induced transcriptional response and increased glucocorticoid resistance Knockdown or inhibition of CASP1 significantly increased glucocorticoid receptor levels and mitigated glucocorticoid resistance in CASP1-overexpressing ALL Our findings establish a new mechanism by which the NLRP3-CASP1 inflammasome modulates cellular levels of the glucocorticoid receptor and diminishes cell sensitivity to glucocorticoids The broad impact on the glucocorticoid transcriptional response suggests that this mechanism could also modify glucocorticoid effects in other diseases,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7307, 32, 6813, 95, 4, 3, 24, 1, 286, 1275, 62, 2, 251, 6, 7307, 4, 37, 4020, 334, 356, 6, 3061, 483, 1, 5399, 251, 21, 509, 3, 11253, 485, 1, 86, 37, 29, 10325, 7, 732, 265, 5, 62, 2, 204, 97, 142, 55, 1, 29671, 2362, 1469, 14, 2, 211, 3393, 25689, 4, 5399, 436, 37, 1113, 29, 97, 280, 1119, 569, 1, 3, 29671, 2, 25689, 4347, 851, 1, 29671, 627, 4, 3155, 1, 3, 5399, 153, 2849, 3, 5399, 277, 1431, 51, 2, 101, 5399, 251, 1563, 15, 297, 1, 29671, 97, 101, 5399, 153, 148, 2, 10042, 5399, 251, 4, 29671, 2810, 62, 114, 272, 1811, 8, 217, 670, 20, 92, 3, 25689, 29671, 17524, 5259, 763, 148, 1, 3, 5399, 153, 2, 14436, 31, 485, 6, 7307, 3, 2094, 345, 23, 3, 5399, 1431, 51, 844, 17, 26, 670, 359, 120, 4289, 5399, 176, 4, 127, 1342]",1190.0,25938942,132
Blinatumomab: enlisting serial killer T-cells in the war against hematologic malignancies.,Expert opinion on biological therapy,Expert Opin Biol Ther,2015-06-01,"The approval of blinatumomab signals the long awaited arrival of immunotherapy for acute lymphoblastic leukemia (ALL). Previous options for relapsed or refractory disease were restricted to cytotoxic chemotherapy with limited efficacy and significant toxicity. Through an innovative mechanism of action, blinatumomab stimulates a polyclonal antitumor T-cell response, yielding unprecedented single agent efficacy in the relapsed/refractory setting. Success comes at the cost of immunological toxicities rarely encountered with previous therapies and challenging administration logistics requiring clinical expertise. All published clinical and preclinical studies using blinatumomab were reviewed in addition to all registered ongoing clinical trials and data published in abstract form. The search was limited to the English language. The pharmacology, clinical efficacy, toxicity profile, and logistical considerations for drug administration are discussed. Blinatumomab is an exciting addition to the treatment armamentarium for relapsed/refractory ALL, yet several questions remain regarding optimal implementation into the current treatment paradigm. A unique toxicity profile should be weighed against promising benefits in a poor prognosis population. Other emerging therapies, such as chimeric antigen receptor-modified T-cells and inotuzumab ozogamicin, with different side effect profiles and administration schedules, may prove to be more beneficial for specific patient populations.",Journal Article,1695.0,8.0,The approval of blinatumomab signals the long awaited arrival of immunotherapy for acute lymphoblastic ALL Previous options for relapsed or refractory disease were restricted to cytotoxic chemotherapy with limited efficacy and significant toxicity Through an innovative mechanism of action blinatumomab stimulates a polyclonal antitumor T-cell response yielding unprecedented single agent efficacy in the relapsed/refractory setting Success comes at the cost of immunological toxicities rarely encountered with previous therapies and challenging administration logistics requiring clinical expertise All published clinical and preclinical studies using blinatumomab were reviewed in addition to all registered ongoing clinical trials and data published in abstract form The search was limited to the English language The pharmacology clinical efficacy toxicity profile and logistical considerations for drug administration are discussed Blinatumomab is an exciting addition to the treatment armamentarium for relapsed/refractory ALL yet several questions remain regarding optimal implementation into the current treatment paradigm A unique toxicity profile should be weighed against promising benefits in a poor prognosis population Other emerging therapies such as chimeric antigen receptor-modified T-cells and inotuzumab ozogamicin with different side effect profiles and administration schedules may prove to be more beneficial for specific patient populations,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1814, 1, 7182, 2312, 3, 319, 9958, 13286, 1, 726, 9, 286, 1275, 62, 698, 838, 9, 591, 15, 430, 34, 11, 2016, 6, 759, 56, 5, 383, 209, 2, 93, 155, 298, 35, 4019, 670, 1, 1578, 7182, 6200, 8, 6350, 579, 102, 31, 51, 4949, 5934, 226, 420, 209, 4, 3, 591, 430, 546, 1825, 10705, 28, 3, 835, 1, 5073, 385, 2416, 3903, 5, 698, 235, 2, 1950, 634, 17179, 1888, 38, 4935, 62, 983, 38, 2, 693, 94, 75, 7182, 11, 446, 4, 352, 6, 62, 1653, 942, 38, 143, 2, 74, 983, 4, 8161, 1297, 3, 1901, 10, 383, 6, 3, 4201, 4794, 3, 6852, 38, 209, 155, 800, 2, 9773, 3891, 9, 234, 634, 32, 1588, 7182, 16, 35, 4963, 352, 6, 3, 24, 5543, 9, 591, 430, 62, 1145, 392, 1937, 918, 666, 665, 2393, 237, 3, 291, 24, 2431, 8, 991, 155, 800, 257, 40, 10271, 480, 721, 1141, 4, 8, 334, 356, 266, 127, 1478, 235, 225, 22, 2897, 448, 153, 1230, 102, 37, 2, 6730, 5566, 5, 338, 1152, 254, 1241, 2, 634, 2314, 68, 4361, 6, 40, 80, 2524, 9, 112, 69, 1184]",1464.0,25985814,89
Genome-wide analysis links NFATC2 with asparaginase hypersensitivity.,Blood,Blood,2015-05-18,"Asparaginase is used to treat acute lymphoblastic leukemia (ALL); however, hypersensitivity reactions can lead to suboptimal asparaginase exposure. Our objective was to use a genome-wide approach to identify loci associated with asparaginase hypersensitivity in children with ALL enrolled on St. Jude Children's Research Hospital (SJCRH) protocols Total XIIIA (n = 154), Total XV (n = 498), and Total XVI (n = 271), or Children's Oncology Group protocols POG 9906 (n = 222) and AALL0232 (n = 2163). Germline DNA was genotyped using the Affymetrix 500K, Affymetrix 6.0, or the Illumina Exome BeadChip array. In multivariate logistic regression, the intronic rs6021191 variant in nuclear factor of activated T cells 2 (NFATC2) had the strongest association with hypersensitivity (P = 4.1  10(-8); odds ratio [OR] = 3.11). RNA-seq data available from 65 SJCRH ALL tumor samples and 52 Yoruba HapMap samples showed that samples carrying the rs6021191 variant had higher NFATC2 expression compared with noncarriers (P = 1.1  10(-3) and 0.03, respectively). The top ranked nonsynonymous polymorphism was rs17885382 in HLA-DRB1 (P = 3.2  10(-6); OR = 1.63), which is in near complete linkage disequilibrium with the HLA-DRB1*07:01 allele we previously observed in a candidate gene study. The strongest risk factors for asparaginase allergy are variants within genes regulating the immune response. ",Journal Article,1709.0,33.0,Asparaginase is used to treat acute lymphoblastic ALL however hypersensitivity reactions can lead to suboptimal asparaginase exposure Our objective was to use a genome-wide approach to identify loci associated with asparaginase hypersensitivity in children with ALL enrolled on St. Jude Children 's Research Hospital SJCRH protocols Total XIIIA n 154 Total XV n 498 and Total XVI n 271 or Children 's Oncology Group protocols POG 9906 n 222 and AALL0232 n 2163 Germline DNA was genotyped using the Affymetrix 500K Affymetrix 6.0 or the Illumina Exome BeadChip array In multivariate logistic regression the intronic rs6021191 variant in nuclear factor of activated T cells 2 NFATC2 had the strongest association with hypersensitivity P 4.1 10 -8 odds ratio OR 3.11 RNA-seq data available from 65 SJCRH ALL tumor samples and 52 Yoruba HapMap samples showed that samples carrying the rs6021191 variant had higher NFATC2 expression compared with noncarriers P 1.1 10 -3 and 0.03 respectively The top ranked nonsynonymous polymorphism was rs17885382 in HLA-DRB1 P 3.2 10 -6 OR 1.63 which is in near complete linkage disequilibrium with the HLA-DRB1*07:01 allele we previously observed in a candidate gene study The strongest risk factors for asparaginase allergy are variants within genes regulating the immune response,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 16, 95, 6, 943, 286, 1275, 62, 137, 4034, 2428, 122, 1122, 6, 3291, 3709, 645, 114, 461, 10, 6, 119, 8, 898, 1019, 353, 6, 255, 2012, 41, 5, 3709, 4034, 4, 541, 5, 62, 346, 23, 3062, 4841, 541, 292, 389, 702, 19696, 2189, 181, 39176, 78, 4838, 181, 16078, 78, 8928, 2, 181, 25082, 78, 8957, 15, 541, 292, 413, 87, 2189, 17150, 66135, 78, 5647, 2, 32436, 78, 41094, 1009, 261, 10, 3053, 75, 3, 5318, 34542, 5318, 49, 13, 15, 3, 7457, 2865, 16111, 1926, 4, 331, 812, 320, 3, 7998, 49061, 1142, 4, 928, 161, 1, 735, 102, 37, 18, 29320, 42, 3, 3311, 248, 5, 4034, 19, 39, 14, 79, 66, 610, 197, 15, 27, 175, 893, 4185, 74, 390, 29, 556, 19696, 62, 30, 347, 2, 653, 39700, 13961, 347, 224, 17, 347, 2934, 3, 49061, 1142, 42, 142, 29320, 55, 72, 5, 10667, 19, 14, 14, 79, 27, 2, 13, 680, 106, 3, 3150, 6441, 10233, 1907, 10, 66136, 4, 1160, 8147, 19, 27, 18, 79, 49, 15, 14, 676, 92, 16, 4, 1829, 236, 4820, 8459, 5, 3, 1160, 8147, 1615, 355, 1254, 21, 373, 164, 4, 8, 1609, 145, 45, 3, 3311, 43, 130, 9, 3709, 9842, 32, 839, 262, 214, 2681, 3, 250, 51]",1314.0,25987655,38
Polymorphisms in Genes Related to Oxidative Stress Are Associated With Inferior Cognitive Function After Therapy for Childhood Acute Lymphoblastic Leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-05-18,"Survivors of childhood acute lymphoblastic leukemia (ALL) exhibit increased rates of neurocognitive deficits. This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline. Neurocognitive testing was conducted in 350 pediatric leukemia survivors, treated on Dana-Farber Cancer Institute ALL Consortium Protocols 95-01 or 00-01. Genomic DNA was isolated from bone marrow collected at remission. Candidate polymorphisms were selected on the basis of prior literature, targeting genes related to drug metabolism, oxidative damage, altered neurotransmission, neuroinflammation, and folate physiology. Single nucleotide polymorphisms were detected using either a customized multiplexed Sequenom MassARRAY assay or polymerase chain reaction-based allelic discrimination assays. Multivariable logistic regression models were used to estimate the effects of genotype on neurocognitive outcomes, adjusted for the effects of demographic and treatment variables. False-discovery rate correction was made for multiple hypothesis testing, indicated as a Q value. Inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes related to oxidative stress and/or neuroinflammation: NOS3 (IQ, Q = 0.008; Vocabulary Q = 0.011; Matrix Reasoning Q = 0.008), SLCO2A1 (IQ Q = 0.043; Digit Span Q = 0.006; Block Design Q = 0.076), and COMT (Behavioral Assessment System for Children-2 Attention Q = 0.080; and Hyperactivity Q = 0.084). Survivors homozygous for NOS3 894T, with at least one SLCO2A1 variant G allele or with at least one GSTP1 variant allele, had lower mean estimated IQ scores than those without these genotypes. These data are consistent with the hypothesis that oxidative damage contributes to chemotherapy-associated neurocognitive decline among children with leukemia.",Journal Article,1709.0,32.0,Survivors of childhood acute lymphoblastic ALL exhibit increased rates of neurocognitive deficits This study was conducted to test whether interpatient variability in neurocognitive outcomes can be explained by polymorphisms in candidate genes conferring susceptibility to neurocognitive decline Neurocognitive testing was conducted in 350 pediatric survivors treated on Dana-Farber Cancer Institute ALL Consortium Protocols 95-01 or 00-01 Genomic DNA was isolated from marrow collected at remission Candidate polymorphisms were selected on the basis of prior literature targeting genes related to drug metabolism oxidative damage altered neurotransmission neuroinflammation and folate physiology Single nucleotide polymorphisms were detected using either a customized multiplexed Sequenom MassARRAY assay or polymerase chain reaction-based allelic discrimination assays Multivariable logistic regression models were used to estimate the effects of genotype on neurocognitive outcomes adjusted for the effects of demographic and treatment variables False-discovery rate correction was made for multiple hypothesis testing indicated as a Q value Inferior cognitive or behavioral outcomes were associated with polymorphisms in three genes related to oxidative stress and/or neuroinflammation NOS3 IQ Q 0.008 Vocabulary Q 0.011 Matrix Reasoning Q 0.008 SLCO2A1 IQ Q 0.043 Digit Span Q 0.006 Block Design Q 0.076 and COMT Behavioral Assessment System for Children-2 Attention Q 0.080 and Hyperactivity Q 0.084 Survivors homozygous for NOS3 894T with at least one SLCO2A1 variant G allele or with at least one GSTP1 variant allele had lower mean estimated IQ scores than those without these genotypes These data are consistent with the hypothesis that oxidative damage contributes to chemotherapy-associated neurocognitive decline among children with,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 2239, 101, 151, 1, 2958, 2752, 26, 45, 10, 426, 6, 412, 317, 7423, 1982, 4, 2958, 123, 122, 40, 3672, 20, 1203, 4, 1609, 214, 7209, 1432, 6, 2958, 1858, 2958, 471, 10, 426, 4, 5408, 815, 332, 73, 23, 4932, 4979, 12, 1377, 62, 2404, 2189, 48, 355, 15, 2038, 355, 572, 261, 10, 1355, 29, 581, 786, 28, 734, 1609, 1203, 11, 715, 23, 3, 877, 1, 324, 789, 529, 214, 139, 6, 234, 1600, 3495, 1350, 1495, 66137, 24169, 2, 3100, 7206, 226, 1579, 1203, 11, 530, 75, 361, 8, 8959, 7734, 9070, 12442, 719, 15, 1451, 1260, 1329, 90, 3861, 3520, 1013, 658, 812, 320, 274, 11, 95, 6, 1191, 3, 176, 1, 1183, 23, 2958, 123, 586, 9, 3, 176, 1, 1540, 2, 24, 682, 2133, 1574, 116, 5360, 10, 1229, 9, 232, 1492, 471, 1103, 22, 8, 4170, 549, 1663, 1863, 15, 4166, 123, 11, 41, 5, 1203, 4, 169, 214, 139, 6, 3495, 1531, 2, 15, 24169, 22631, 7666, 4170, 13, 2155, 27249, 4170, 13, 3651, 2248, 15856, 4170, 13, 2155, 49063, 7666, 4170, 13, 5653, 9553, 7165, 4170, 13, 1861, 2381, 771, 4170, 13, 13973, 2, 13098, 4166, 455, 398, 9, 541, 18, 2111, 4170, 13, 15490, 2, 18391, 4170, 13, 14183, 332, 3189, 9, 22631, 66138, 5, 28, 506, 104, 49063, 1142, 499, 1254, 15, 5, 28, 506, 104, 5689, 1142, 1254, 42, 280, 313, 661, 7666, 703, 76, 135, 187, 46, 2071, 46, 74, 32, 925, 5, 3, 1492, 17, 3495, 1350, 2444, 6, 56, 41, 2958, 1858, 107, 541, 5]",1845.0,25987702,4
Monoclonal antibodies in acute lymphoblastic leukemia.,Blood,Blood,2015-05-21,"With modern intensive combination polychemotherapy, the complete response (CR) rate in adults with acute lymphoblastic leukemia (ALL) is 80% to 90%, and the cure rate is 40% to 50%. Hence, there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy. ALL leukemic cells express several surface antigens amenable to target therapies, including CD20, CD22, and CD19. Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target toxicity. When added to frontline chemotherapy, rituximab, an antibody directed against CD20, increases cure rates of adults with Burkitt leukemia from 40% to 80% and those with pre-B ALL from 35% to 50%. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has resulted in marrow CR rates of 55% and a median survival of 6 to 7 months when given to patients with refractory-relapsed ALL. Blinatumomab, a biallelic T cell engaging the CD3-CD19 monoclonal antibody, also resulted in overall response rates of 40% to 50% and a median survival of 6.5 months in a similar refractory-relapsed population. Other promising monoclonal antibodies targeting CD20 (ofatumumab and obinutuzumab) or CD19 or CD20 and bound to different cytotoxins or immunotoxins are under development. Combined modalities of chemotherapy and the novel monoclonal antibodies are under investigation. ",Journal Article,1706.0,82.0,With modern intensive combination polychemotherapy the complete response CR rate in adults with acute lymphoblastic ALL is 80 to 90 and the cure rate is 40 to 50 Hence there is a need to develop effective salvage therapies and combine novel agents with standard effective chemotherapy ALL leukemic cells express several surface antigens amenable to target therapies including CD20 CD22 and CD19 Monoclonal antibodies target these leukemic surface antigens selectively and minimize off-target toxicity When added to frontline chemotherapy rituximab an antibody directed against CD20 increases cure rates of adults with from 40 to 80 and those with pre-B ALL from 35 to 50 Inotuzumab ozogamicin a CD22 monoclonal antibody bound to calicheamicin has resulted in marrow CR rates of 55 and a median survival of 6 to 7 months when given to patients with refractory-relapsed ALL Blinatumomab a biallelic T cell engaging the CD3-CD19 monoclonal antibody also resulted in overall response rates of 40 to 50 and a median survival of 6.5 months in a similar refractory-relapsed population Other promising monoclonal antibodies targeting CD20 ofatumumab and obinutuzumab or CD19 or CD20 and bound to different cytotoxins or immunotoxins are under development Combined modalities of chemotherapy and the novel monoclonal antibodies are under investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5, 2366, 1686, 150, 21292, 3, 236, 51, 684, 116, 4, 857, 5, 286, 1275, 62, 16, 493, 6, 424, 2, 3, 1722, 116, 16, 327, 6, 212, 3665, 125, 16, 8, 594, 6, 690, 323, 992, 235, 2, 4680, 229, 183, 5, 260, 323, 56, 62, 2015, 37, 1669, 392, 1255, 1575, 4070, 6, 283, 235, 141, 2198, 7599, 2, 3158, 848, 890, 283, 46, 2015, 1255, 1575, 2382, 2, 3241, 1889, 283, 155, 198, 1953, 6, 3171, 56, 855, 35, 548, 1166, 480, 2198, 1106, 1722, 151, 1, 857, 5, 29, 327, 6, 493, 2, 135, 5, 671, 132, 62, 29, 465, 6, 212, 6730, 5566, 8, 7599, 848, 548, 2951, 6, 13499, 71, 627, 4, 581, 684, 151, 1, 614, 2, 8, 52, 25, 1, 49, 6, 67, 53, 198, 447, 6, 7, 5, 430, 591, 62, 7182, 8, 6435, 102, 31, 8534, 3, 3117, 3158, 848, 548, 120, 627, 4, 63, 51, 151, 1, 327, 6, 212, 2, 8, 52, 25, 1, 49, 33, 53, 4, 8, 288, 430, 591, 266, 127, 721, 848, 890, 529, 2198, 5732, 2, 10380, 15, 3158, 15, 2198, 2, 2951, 6, 338, 20269, 15, 17170, 32, 669, 193, 397, 1558, 1, 56, 2, 3, 229, 848, 890, 32, 669, 940]",1342.0,25999456,542
Supportive medical care for children with acute lymphoblastic leukemia in low- and middle-income countries.,Expert review of hematology,Expert Rev Hematol,2015-05-26,"In the last two decades, remarkable progress in the treatment of children with acute lymphoblastic leukemia has been achieved in many low- and middle-income countries (LMIC), but survival rates remain significantly lower than those in high-income countries. Inadequate supportive care and consequent excess mortality from toxicity are important causes of treatment failure for children with acute lymphoblastic leukemia in LMIC. This article summarizes practical supportive care recommendations for healthcare providers practicing in LMIC, starting with core approaches in oncology nursing care, management of tumor lysis syndrome and mediastinal masses, nutritional support, use of blood products for anemia and thrombocytopenia, and palliative care. Prevention and treatment of infectious diseases are described in a parallel paper. ",Journal Article,1701.0,4.0,In the last two decades remarkable progress in the treatment of children with acute lymphoblastic has been achieved in many low- and middle-income countries LMIC but survival rates remain significantly lower than those in high-income countries Inadequate supportive care and consequent excess mortality from toxicity are important causes of treatment failure for children with acute lymphoblastic in LMIC This article summarizes practical supportive care recommendations for healthcare providers practicing in LMIC starting with core approaches in oncology nursing care management of tumor lysis syndrome and mediastinal masses nutritional support use of blood products for anemia and thrombocytopenia and palliative care Prevention and treatment of infectious diseases are described in a parallel paper,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 3, 1060, 100, 1968, 3813, 1466, 4, 3, 24, 1, 541, 5, 286, 1275, 71, 85, 513, 4, 445, 154, 2, 3897, 2306, 2115, 12950, 84, 25, 151, 918, 97, 280, 76, 135, 4, 64, 2306, 2115, 3358, 1877, 165, 2, 8436, 2612, 282, 29, 155, 32, 305, 1626, 1, 24, 496, 9, 541, 5, 286, 1275, 4, 12950, 26, 946, 2869, 3320, 1877, 165, 883, 9, 2819, 1994, 6734, 4, 12950, 1723, 5, 1793, 611, 4, 413, 5652, 165, 284, 1, 30, 4783, 681, 2, 2626, 2692, 5082, 538, 119, 1, 315, 2766, 9, 1545, 2, 1340, 2, 994, 165, 1070, 2, 24, 1, 3398, 1342, 32, 1027, 4, 8, 2755, 2817]",803.0,26013005,31
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome.,American journal of hematology,Am. J. Hematol.,2015-07-27,"Bone marrow necrosis (BMN) is characterized by infarction of the medullary stroma, leading to marrow necrosis with preserved cortical bone. In reported small series, BMN in hematological malignancies is associated with poor prognosis. We sought to find the impact of BMN on clinical outcome in a relatively larger cohort of patients with acute leukemias. Overall we evaluated 1,691 patients; 1,051 with acute myeloid leukemia (AML) and 640 with acute lymphocytic leukemia referred to our institution between 2002 and 2013. Patients with AML and acute lymphoblastic leukemia (ALL) were evaluated separately to determine the incidence of BMN, associated clinical features and its prognostic significance. At initial diagnosis, BMN was observed in 25 (2.4%) patients with AML and 20 (3.2%) patients with ALL. In AML, BMN was significantly associated with French-American-British AML M5 morphology (32% vs. 10%, P=0.002). The complete remission (CR) rate in AML with and without BMN was 32% and 59% respectively (P=0.008). Likewise, CR rate in ALL with BMN was also inferior, 70% vs. 92% (P=0.005). The median overall survival (OS) in AML with BMN was significantly poorer, 3.7 months compared to 14 months without BMN (P=0.003). Similarly, the median OS in ALL with and without BMN was 61.7 and 72 months respectively (P=0.33). BMN is not a rare entity in AML and ALL, but is infrequent. BMN in AML and in ALL is suggestive of inferior response and poor prognosis.",Clinical Trial,1639.0,5.0,"marrow necrosis BMN is characterized by infarction of the medullary stroma leading to marrow necrosis with preserved cortical In reported small series BMN in hematological malignancies is associated with poor prognosis We sought to find the impact of BMN on clinical outcome in a relatively larger cohort of patients with acute leukemias Overall we evaluated 1,691 patients 1,051 with acute myeloid AML and 640 with acute lymphocytic referred to our institution between 2002 and 2013 Patients with AML and acute lymphoblastic ALL were evaluated separately to determine the incidence of BMN associated clinical features and its prognostic significance At initial diagnosis BMN was observed in 25 2.4 patients with AML and 20 3.2 patients with ALL In AML BMN was significantly associated with French-American-British AML M5 morphology 32 vs. 10 P 0.002 The complete remission CR rate in AML with and without BMN was 32 and 59 respectively P 0.008 Likewise CR rate in ALL with BMN was also inferior 70 vs. 92 P 0.005 The median overall survival OS in AML with BMN was significantly poorer 3.7 months compared to 14 months without BMN P 0.003 Similarly the median OS in ALL with and without BMN was 61.7 and 72 months respectively P 0.33 BMN is not a rare entity in AML and ALL but is infrequent BMN in AML and in ALL is suggestive of inferior response and poor prognosis",0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[581, 1523, 20067, 16, 765, 20, 6124, 1, 3, 4564, 2477, 1049, 6, 581, 1523, 5, 5797, 4500, 4, 210, 302, 988, 20067, 4, 2890, 441, 16, 41, 5, 334, 356, 21, 990, 6, 2469, 3, 345, 1, 20067, 23, 38, 228, 4, 8, 1352, 1077, 180, 1, 7, 5, 286, 2792, 63, 21, 194, 14, 11661, 7, 14, 9891, 5, 286, 533, 329, 2, 10972, 5, 286, 1193, 1995, 6, 114, 731, 59, 1544, 2, 1346, 7, 5, 329, 2, 286, 1275, 62, 11, 194, 3582, 6, 223, 3, 287, 1, 20067, 41, 38, 404, 2, 211, 177, 724, 28, 388, 147, 20067, 10, 164, 4, 243, 18, 39, 7, 5, 329, 2, 179, 27, 18, 7, 5, 62, 4, 329, 20067, 10, 97, 41, 5, 9254, 597, 11754, 329, 10272, 2567, 531, 105, 79, 19, 13, 1111, 3, 236, 734, 684, 116, 4, 329, 5, 2, 187, 20067, 10, 531, 2, 728, 106, 19, 13, 2155, 6269, 684, 116, 4, 62, 5, 20067, 10, 120, 1663, 431, 105, 937, 19, 13, 1614, 3, 52, 63, 25, 118, 4, 329, 5, 20067, 10, 97, 1769, 27, 67, 53, 72, 6, 213, 53, 187, 20067, 19, 13, 1421, 1813, 3, 52, 118, 4, 62, 5, 2, 187, 20067, 10, 713, 67, 2, 720, 53, 106, 19, 13, 466, 20067, 16, 44, 8, 622, 2983, 4, 329, 2, 62, 84, 16, 4475, 20067, 4, 329, 2, 4, 62, 16, 3832, 1, 1663, 51, 2, 334, 356]",1367.0,26017166,418
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors.,American journal of hematology,Am. J. Hematol.,2015-06-01,"Long-term efficacy and safety of bosutinib (4 years follow-up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated-phase [AP, n = 79] chronic myeloid leukemia [CML], blast-phase [BP, n = 64] CML, acute lymphoblastic leukemia [ALL, n = 24]). Fourteen AP, 2 BP, and 1 ALL patient remained on bosutinib at 4 years (vs. 38, 8, 1 at 1 year); median (range) treatment durations: 10.2 (0.1-88.6), 2.8 (0.03-55.9), 0.97 (0.3-89.2) months. Among AP and BP patients, 57% and 28% newly attained or maintained baseline overall hematologic response (OHR); 40% and 37% attained/maintained major cytogenetic response (MCyR) by 4 years (most by 12 months). In responders at 1 versus 4 years, Kaplan-Meier (KM) probabilities of maintaining OHR were 78% versus 49% (AP) and 28% versus 19% (BP); KM probabilities of maintaining MCyR were 65% versus 49% (AP) and 21% versus 21% (BP). Most common AEs (AP, BP) were gastrointestinal (96%; 83%), primarily diarrhea (85%; 64%), which was typically low grade (maximum grade 1/2: 81%; 59%) and transient; no patient discontinued due to diarrhea. Serious AEs occurred in 44 (56%) AP and 37 (58%) BP patients, most commonly pneumonia (n = 9) for AP and pyrexia (n = 6) for BP; 11 and 13 died within 30 days of last dose (2 considered bosutinib-related [AP] per investigator). Responses were durable in 50% AP responders at 4 years (25% BP patients responded at year 1, suggesting possible bridge-to-transplant role in BP patients); toxicity was manageable.","Clinical Trial, Phase I",1695.0,38.0,Long-term efficacy and safety of bosutinib 4 years follow-up from last enrolled patient were evaluated in an ongoing phase 1/2 study in the advanced cohort with prior treatment failure accelerated-phase AP n 79 chronic myeloid CML blast-phase BP n 64 CML acute lymphoblastic ALL n 24 Fourteen AP 2 BP and 1 ALL patient remained on bosutinib at 4 years vs. 38 8 1 at 1 year median range treatment durations 10.2 0.1-88.6 2.8 0.03-55.9 0.97 0.3-89.2 months Among AP and BP patients 57 and 28 newly attained or maintained baseline overall hematologic response OHR 40 and 37 attained/maintained major cytogenetic response MCyR by 4 years most by 12 months In responders at 1 versus 4 years Kaplan-Meier KM probabilities of maintaining OHR were 78 versus 49 AP and 28 versus 19 BP KM probabilities of maintaining MCyR were 65 versus 49 AP and 21 versus 21 BP Most common AEs AP BP were 96 83 primarily diarrhea 85 64 which was typically low grade maximum grade 1/2 81 59 and transient no patient discontinued due to diarrhea Serious AEs occurred in 44 56 AP and 37 58 BP patients most commonly pneumonia n 9 for AP and pyrexia n 6 for BP 11 and 13 died within 30 days of last dose 2 considered bosutinib-related AP per investigator Responses were durable in 50 AP responders at 4 years 25 BP patients responded at year 1 suggesting possible bridge-to-transplant role in BP patients toxicity was manageable,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[319, 337, 209, 2, 367, 1, 5936, 5915, 60, 166, 126, 29, 1060, 346, 69, 11, 194, 4, 35, 942, 124, 14, 18, 45, 4, 3, 131, 180, 5, 324, 24, 496, 2241, 124, 2517, 78, 842, 442, 533, 903, 3112, 124, 3044, 78, 660, 903, 286, 1275, 62, 78, 259, 3225, 2517, 18, 3044, 2, 14, 62, 69, 958, 23, 5936, 28, 39, 60, 105, 519, 66, 14, 28, 14, 111, 52, 184, 24, 4864, 79, 18, 13, 14, 889, 49, 18, 66, 13, 680, 614, 83, 13, 1015, 13, 27, 887, 18, 53, 107, 2517, 2, 3044, 7, 696, 2, 339, 732, 5105, 15, 1955, 330, 63, 813, 51, 41109, 327, 2, 567, 5105, 1955, 458, 1266, 51, 10240, 20, 39, 60, 96, 20, 133, 53, 4, 1983, 28, 14, 185, 39, 60, 876, 882, 12524, 3518, 1, 3284, 41109, 11, 833, 185, 739, 2517, 2, 339, 185, 326, 3044, 12524, 3518, 1, 3284, 10240, 11, 556, 185, 739, 2517, 2, 239, 185, 239, 3044, 96, 186, 1477, 2517, 3044, 11, 921, 852, 1561, 1172, 772, 660, 92, 10, 1969, 154, 88, 689, 88, 14, 18, 865, 728, 2, 2473, 77, 69, 2402, 520, 6, 1172, 1762, 1477, 489, 4, 584, 664, 2517, 2, 567, 717, 3044, 7, 96, 841, 3485, 78, 83, 9, 2517, 2, 8417, 78, 49, 9, 3044, 175, 2, 233, 1016, 262, 201, 162, 1, 1060, 61, 18, 515, 5936, 139, 2517, 379, 3464, 253, 11, 1480, 4, 23911, 2517, 1983, 28, 39, 60, 32100, 3044, 7, 2211, 28, 111, 14, 802, 899, 7728, 6, 941, 200, 4, 3044, 7, 155, 10, 2808]",1403.0,26040495,137
CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?,Immunotherapy,Immunotherapy,2015-01-01,"Chimeric antigen receptor (CAR) T-cell therapy has recently come into the spotlight due to impressive results in patients with B-cell acute lymphoblastic leukemia. By targeting CD19, a marker expressed most B-cell tumors, as well as normal B cells, CAR T-cell therapy has been investigated as a treatment strategy for B-cell leukemia and lymphoma. This review will discuss the successes of this therapy for the treatment of B-cell acute lymphoblastic leukemia and the challenges to this therapeutic strategy. We will also discuss application of CAR T-cell therapy to chronic lymphocytic leukemia and other B-cell malignancies including a follicular lymphoma, diffuse large B-cell lymphoma, as well as acute and plasma cell malignancies. ",Journal Article,1846.0,25.0,Chimeric antigen receptor CAR T-cell therapy has recently come into the spotlight due to impressive results in patients with B-cell acute lymphoblastic By targeting CD19 a marker expressed most B-cell tumors as well as normal B cells CAR T-cell therapy has been investigated as a treatment strategy for B-cell and This review will discuss the successes of this therapy for the treatment of B-cell acute lymphoblastic and the challenges to this therapeutic strategy We will also discuss application of CAR T-cell therapy to chronic lymphocytic and other B-cell malignancies including a follicular diffuse large B-cell as well as acute and plasma cell malignancies,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[2897, 448, 153, 1881, 102, 31, 36, 71, 761, 6235, 237, 3, 25558, 520, 6, 5790, 99, 4, 7, 5, 132, 31, 286, 1275, 20, 529, 3158, 8, 952, 570, 96, 132, 31, 57, 22, 149, 22, 295, 132, 37, 1881, 102, 31, 36, 71, 85, 565, 22, 8, 24, 692, 9, 132, 31, 2, 26, 206, 303, 1139, 3, 6697, 1, 26, 36, 9, 3, 24, 1, 132, 31, 286, 1275, 2, 3, 1427, 6, 26, 189, 692, 21, 303, 120, 1139, 1581, 1, 1881, 102, 31, 36, 6, 442, 1193, 2, 127, 132, 31, 441, 141, 8, 1974, 1388, 375, 132, 31, 22, 149, 22, 286, 2, 554, 31, 441]",662.0,26065479,24
Cytogenetic Variation of B-Lymphoblastic Leukemia With Intrachromosomal Amplification of Chromosome 21 (iAMP21): A Multi-Institutional Series Review.,American journal of clinical pathology,Am. J. Clin. Pathol.,2015-07-01,"B-lymphoblastic leukemia (B-ALL) with intrachromosomal amplification of chromosome 21 (iAMP21) is a relatively uncommon manifestation of acute leukemia and limited predominantly to the pediatric population. Case-specific information regarding flow cytometric, morphologic, and laboratory findings of this subtype of leukemia is currently lacking. We searched the databases of three large institutions for lymphoblastic leukemia with iAMP21 from 2005 through 2012 and analyzed the clinicopathologic features. We identified 17 cases with five or more RUNX1 signals on interphase nuclei, 14 of which were consistent with the Children's Oncology Group (COG) definition for iAMP21namely, the presence of three or more RUNX1 signals on one marker chromosome. These cases showed a statistically significant lower peripheral WBC count and older age at diagnosis compared with all pediatric cases of B-ALL. We also identified three cases with increased RUNX1 signals scattered on multiple marker chromosomes that did not meet the COG definition of iAMP21 but showed similar 21q instability and older age at presentation. Our findings not only demonstrate that B-ALL with iAMP21 is truly a distinct clinicopathologic entity but also suggest that a subset of cases of B-ALL with iAMP21 can show variable cytogenetic features.",Journal Article,1665.0,7.0,B-lymphoblastic B-ALL with intrachromosomal amplification of chromosome 21 iAMP21 is a relatively uncommon manifestation of acute and limited predominantly to the pediatric population Case-specific information regarding flow cytometric morphologic and laboratory findings of this subtype of is currently lacking We searched the databases of three large institutions for lymphoblastic with iAMP21 from 2005 through 2012 and analyzed the clinicopathologic features We identified 17 cases with five or more RUNX1 signals on interphase nuclei 14 of which were consistent with the Children 's Oncology Group COG definition for iAMP21namely the presence of three or more RUNX1 signals on one marker chromosome These cases showed a statistically significant lower peripheral WBC count and older age at diagnosis compared with all pediatric cases of B-ALL We also identified three cases with increased RUNX1 signals scattered on multiple marker chromosomes that did not meet the COG definition of iAMP21 but showed similar 21q instability and older age at presentation Our findings not only demonstrate that B-ALL with iAMP21 is truly a distinct clinicopathologic entity but also suggest that a subset of cases of B-ALL with iAMP21 can show variable cytogenetic features,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[132, 1275, 132, 62, 5, 24924, 1073, 1, 1170, 239, 32443, 16, 8, 1352, 2052, 6746, 1, 286, 2, 383, 2117, 6, 3, 815, 266, 473, 112, 487, 666, 1412, 6226, 2815, 2, 1624, 272, 1, 26, 875, 1, 16, 694, 1941, 21, 3080, 3, 2348, 1, 169, 375, 1764, 9, 1275, 5, 32443, 29, 1242, 298, 1195, 2, 311, 3, 1399, 404, 21, 108, 269, 140, 5, 365, 15, 80, 6092, 2312, 23, 8081, 4725, 213, 1, 92, 11, 925, 5, 3, 541, 292, 413, 87, 6377, 2470, 9, 66293, 3, 463, 1, 169, 15, 80, 6092, 2312, 23, 104, 952, 1170, 46, 140, 224, 8, 712, 93, 280, 672, 4685, 1276, 2, 434, 89, 28, 147, 72, 5, 62, 815, 140, 1, 132, 62, 21, 120, 108, 169, 140, 5, 101, 6092, 2312, 9638, 23, 232, 952, 3560, 17, 205, 44, 3362, 3, 6377, 2470, 1, 32443, 84, 224, 288, 25998, 1753, 2, 434, 89, 28, 1031, 114, 272, 44, 158, 608, 17, 132, 62, 5, 32443, 16, 7260, 8, 834, 1399, 2983, 84, 120, 309, 17, 8, 697, 1, 140, 1, 132, 62, 5, 32443, 122, 514, 1347, 1266, 404]",1263.0,26071468,901
"Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia.","Future oncology (London, England)",Future Oncol,2015-01-01,"The treatment of acute lymphoblastic leukemia (ALL) in adults remains challenging and novel therapies are needed. The antigen, CD19, is expressed by >90% of pre-B ALLs and represents an attractive therapeutic target. The bispecific T-cell-engaging antibody, blinatumomab, targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL. In this review, we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab. In addition, the preclinical studies, clinical studies and toxicities are summarized.",Journal Article,1846.0,2.0,The treatment of acute lymphoblastic ALL in adults remains challenging and novel therapies are needed The antigen CD19 is expressed by 90 of pre-B ALLs and represents an attractive therapeutic target The bispecific T-cell-engaging antibody blinatumomab targets CD19 and has demonstrated encouraging results in minimal residual disease positive and relapsed/refractory pre-B ALL In this review we discuss in detail the mechanism of action and key pharmacologic aspects of blinatumomab In addition the preclinical studies clinical studies and toxicities are summarized,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 24, 1, 286, 1275, 62, 4, 857, 469, 1950, 2, 229, 235, 32, 575, 3, 448, 3158, 16, 570, 20, 424, 1, 671, 132, 10706, 2, 1449, 35, 3059, 189, 283, 3, 7408, 102, 31, 8534, 548, 7182, 637, 3158, 2, 71, 264, 2269, 99, 4, 1048, 753, 34, 109, 2, 591, 430, 671, 132, 62, 4, 26, 206, 21, 1139, 4, 5000, 3, 670, 1, 1578, 2, 825, 2788, 2695, 1, 7182, 4, 352, 3, 693, 94, 38, 94, 2, 385, 32, 3989]",566.0,26075441,466
Germline ETV6 Mutations Confer Susceptibility to Acute Lymphoblastic Leukemia and Thrombocytopenia.,PLoS genetics,PLoS Genet.,2015-06-23,"Somatic mutations affecting ETV6 often occur in acute lymphoblastic leukemia (ALL), the most common childhood malignancy. The genetic factors that predispose to ALL remain poorly understood. Here we identify a novel germline ETV6 p. L349P mutation in a kindred affected by thrombocytopenia and ALL. A second ETV6 p. N385fs mutation was identified in an unrelated kindred characterized by thrombocytopenia, ALL and secondary myelodysplasia/acute myeloid leukemia. Leukemic cells from the proband in the second kindred showed deletion of wild type ETV6 with retention of the ETV6 p. N385fs. Enforced expression of the ETV6 mutants revealed normal transcript and protein levels, but impaired nuclear localization. Accordingly, these mutants exhibited significantly reduced ability to regulate the transcription of ETV6 target genes. Our findings highlight a novel role for ETV6 in leukemia predisposition. ",Journal Article,1673.0,72.0,Somatic mutations affecting ETV6 often occur in acute lymphoblastic ALL the most common childhood malignancy The genetic factors that predispose to ALL remain poorly understood Here we identify a novel germline ETV6 p. L349P mutation in a kindred affected by thrombocytopenia and ALL A second ETV6 p. N385fs mutation was identified in an unrelated kindred characterized by thrombocytopenia ALL and secondary myelodysplasia/acute myeloid Leukemic cells from the proband in the second kindred showed deletion of wild type ETV6 with retention of the ETV6 p. N385fs Enforced expression of the ETV6 mutants revealed normal transcript and protein levels but impaired nuclear localization Accordingly these mutants exhibited significantly reduced ability to regulate the transcription of ETV6 target genes Our findings highlight a novel role for ETV6 in predisposition,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1119, 138, 2319, 7306, 629, 1271, 4, 286, 1275, 62, 3, 96, 186, 864, 710, 3, 336, 130, 17, 6043, 6, 62, 918, 1240, 1784, 467, 21, 255, 8, 229, 1009, 7306, 19, 66344, 258, 4, 8, 16706, 1424, 20, 1340, 2, 62, 8, 419, 7306, 19, 49145, 258, 10, 108, 4, 35, 2092, 16706, 765, 20, 1340, 62, 2, 568, 6128, 286, 533, 2015, 37, 29, 3, 10421, 4, 3, 419, 16706, 224, 1528, 1, 955, 267, 7306, 5, 3947, 1, 3, 7306, 19, 49145, 7807, 55, 1, 3, 7306, 3423, 553, 295, 3268, 2, 178, 148, 84, 2364, 928, 2145, 4705, 46, 3423, 1416, 97, 405, 801, 6, 2288, 3, 866, 1, 7306, 283, 214, 114, 272, 1817, 8, 229, 200, 9, 7306, 4, 2863]",861.0,26102509,392
Non-Hodgkin Lymphoma in Children.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2015-09-01,"The non-Hodgkin lymphomas (NHLs) of childhood include high-grade mature B cell lymphoma [Burkitt lymphoma (BL), diffuse large B cell lymphoma (DLBCL), and primary mediastinal large B cell lymphoma (PMLBCL)], anaplastic large cell lymphoma (ALCL), and lymphoblastic lymphoma (LL). The prognosis for children with NHL is generally excellent, although there are some higher risk groups. In this regard, PMLBCL is generally associated with a poorer outcome than BL or DLBCL of comparable stage. The long-term event-free survival for children with ALCL is approximately 70%. Novel biological agents, including those that target CD-30 or ALK, may hold promise for improving treatment results. Children with LL are treated with regimens derived from those used to treat acute lymphoblastic leukemia (ALL). Recent biological study of LL may provide insights into revising treatment stratification. The challenge in pediatric NHL, a group that already has a relatively good prognosis, is to improve treatment outcome without increasing concerning late effects. ",Journal Article,1603.0,12.0,The lymphomas NHLs of childhood include high-grade mature B cell BL diffuse large B cell DLBCL and primary mediastinal large B cell PMLBCL anaplastic large cell ALCL and lymphoblastic LL The prognosis for children with NHL is generally excellent although there are some higher risk groups In this regard PMLBCL is generally associated with a poorer outcome than BL or DLBCL of comparable stage The long-term event-free survival for children with ALCL is approximately 70 Novel biological agents including those that target CD-30 or ALK may hold promise for improving treatment results Children with LL are treated with regimens derived from those used to treat acute lymphoblastic ALL Recent biological study of LL may provide insights into revising treatment stratification The challenge in pediatric NHL a group that already has a relatively good prognosis is to improve treatment outcome without increasing concerning late effects,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1557, 11440, 1, 864, 643, 64, 88, 2908, 132, 31, 6331, 1388, 375, 132, 31, 1446, 2, 86, 2626, 375, 132, 31, 23071, 1841, 375, 31, 5200, 2, 1275, 15981, 3, 356, 9, 541, 5, 1176, 16, 1228, 1503, 242, 125, 32, 476, 142, 43, 271, 4, 26, 2539, 23071, 16, 1228, 41, 5, 8, 1769, 228, 76, 6331, 15, 1446, 1, 1279, 82, 3, 319, 337, 774, 115, 25, 9, 541, 5, 5200, 16, 705, 431, 229, 1037, 183, 141, 135, 17, 283, 4420, 201, 15, 1023, 68, 4164, 1783, 9, 1673, 24, 99, 541, 5, 15981, 32, 73, 5, 472, 526, 29, 135, 95, 6, 943, 286, 1275, 62, 435, 1037, 45, 1, 15981, 68, 377, 1957, 237, 41149, 24, 1541, 3, 1745, 4, 815, 1176, 8, 87, 17, 3298, 71, 8, 1352, 1178, 356, 16, 6, 401, 24, 228, 187, 602, 4243, 807, 176]",933.0,26174528,362
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia.,Cancer cell,Cancer Cell,2015-07-01,"A variety of cancers depend on JAK2 signaling, including the high-risk subset of B cell acute lymphoblastic leukemias (B-ALLs) with CRLF2 rearrangements. Type I JAK2 inhibitors induce paradoxical JAK2 hyperphosphorylation in these leukemias and have limited activity. To improve the efficacy of JAK2 inhibition in B-ALL, we developed the type II inhibitor CHZ868, which stabilizes JAK2 in an inactive conformation. CHZ868 potently suppressed the growth of CRLF2-rearranged human B-ALL cells, abrogated JAK2 signaling, and improved survival in mice with human or murine B-ALL. CHZ868 and dexamethasone synergistically induced apoptosis in JAK2-dependent B-ALLs and further improved invivo survival compared to CHZ868 alone. These data support the testing of type II JAK2 inhibition in patients with JAK2-dependent leukemias and other disorders. ",Journal Article,1665.0,44.0,A variety of cancers depend on JAK2 signaling including the high-risk subset of B cell acute lymphoblastic leukemias B-ALLs with CRLF2 rearrangements Type I JAK2 inhibitors induce paradoxical JAK2 hyperphosphorylation in these leukemias and have limited activity To improve the efficacy of JAK2 inhibition in B-ALL we developed the type II inhibitor CHZ868 which stabilizes JAK2 in an inactive conformation CHZ868 potently suppressed the growth of CRLF2-rearranged human B-ALL cells abrogated JAK2 signaling and improved survival in mice with human or murine B-ALL CHZ868 and dexamethasone synergistically induced apoptosis in JAK2-dependent B-ALLs and further improved in vivo survival compared to CHZ868 alone These data support the testing of type II JAK2 inhibition in patients with JAK2-dependent leukemias and other disorders,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 1362, 1, 163, 4533, 23, 2509, 314, 141, 3, 64, 43, 697, 1, 132, 31, 286, 1275, 2792, 132, 10706, 5, 8895, 2072, 267, 70, 2509, 222, 1290, 9330, 2509, 23280, 4, 46, 2792, 2, 47, 383, 128, 6, 401, 3, 209, 1, 2509, 297, 4, 132, 62, 21, 276, 3, 267, 215, 230, 32459, 92, 11019, 2509, 4, 35, 5002, 7788, 32459, 4684, 1908, 3, 129, 1, 8895, 3201, 171, 132, 62, 37, 3728, 2509, 314, 2, 231, 25, 4, 399, 5, 171, 15, 1471, 132, 62, 32459, 2, 1217, 4240, 277, 351, 4, 2509, 470, 132, 10706, 2, 195, 231, 4, 386, 25, 72, 6, 32459, 279, 46, 74, 538, 3, 471, 1, 267, 215, 2509, 297, 4, 7, 5, 2509, 470, 2792, 2, 127, 1997]",831.0,26175414,48
High Disease-Free Survival with Enhanced Protection against Relapse after Double-Unit Cord Blood Transplantation When Compared with T Cell-Depleted Unrelated Donor Transplantation in Patients with Acute Leukemia and Chronic Myelogenous Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-07-31,"Double-unit cord blood (DCB) grafts are a rapidly available stem cell source for adults with high-risk leukemias. However, how disease-free survival (DFS) after DCB transplantation (DCBT) compares to that of unrelated donor transplantation (URDT) is not fully established. We analyzed 166 allograft recipients (66 8/8 HLA-matched URDT, 45 7/8 HLA-matched URDT, and 55 DCBT) ages 16 to 60 years with high-risk acute leukemia or chronic myelogenous leukemia (CML). URDT and DCBT recipients were similar except DCBT recipients were more likely to have lower weight and non-European ancestry and to receive intermediate-intensity conditioning. All URDT recipients received a CD34(+) cell-selected (T cell-depleted) graft. Overall, differences between the 3-year transplantation-related mortality were not significant (8/8 URDT, 18%; 7/8 URDT, 39%; and DCBT, 24%; P= .108), whereas the 3-year relapse risk was decreased after DCBT (8/8 URDT, 23%; 7/8 URDT, 20%; and DCBT 9%, P= .037). Three-year DFS was 57% in 8/8 URDT, 41% in 7/8 URDT, and 68% in DCBT recipients (P= .068), and the 3-year DFS in DCBT recipients was higher than that of 7/8 URDT recipients (P= .021). In multivariate analysis in acute leukemia patients, factors adversely associated with DFS were female gender (hazard ratio [HR], 1.68; P= .031), diagnosis of acute lymphoblastic leukemia (HR, 2.09; P= .004), and 7/8 T cell-depleted URDT (HR, 1.91; P= .037). High DFS can be achieved in adults with acute leukemia and CML with low relapse rates after DCBT. Our findings support performing DCBT in adults in preference to HLA-mismatched T cell-depleted URDT and suggest DCBT is a readily available alternative to T cell-depleted 8/8 URDT, especially in patients requiring urgent transplantation. ",Clinical Trial,1635.0,18.0,Double-unit cord blood DCB grafts are a rapidly available stem cell source for adults with high-risk leukemias However how disease-free survival DFS after DCB transplantation DCBT compares to that of unrelated donor transplantation URDT is not fully established We analyzed 166 allograft recipients 66 8/8 HLA-matched URDT 45 7/8 HLA-matched URDT and 55 DCBT ages 16 to 60 years with high-risk acute or chronic myelogenous CML URDT and DCBT recipients were similar except DCBT recipients were more likely to have lower weight and non-European ancestry and to receive intermediate-intensity conditioning All URDT recipients received a CD34 cell-selected T cell-depleted graft Overall differences between the 3-year transplantation-related mortality were not significant 8/8 URDT 18 7/8 URDT 39 and DCBT 24 P .108 whereas the 3-year relapse risk was decreased after DCBT 8/8 URDT 23 7/8 URDT 20 and DCBT 9 P .037 Three-year DFS was 57 in 8/8 URDT 41 in 7/8 URDT and 68 in DCBT recipients P .068 and the 3-year DFS in DCBT recipients was higher than that of 7/8 URDT recipients P .021 In multivariate analysis in acute patients factors adversely associated with DFS were female gender hazard ratio HR 1.68 P .031 diagnosis of acute lymphoblastic HR 2.09 P .004 and 7/8 T cell-depleted URDT HR 1.91 P .037 High DFS can be achieved in adults with acute and CML with low relapse rates after DCBT Our findings support performing DCBT in adults in preference to HLA-mismatched T cell-depleted URDT and suggest DCBT is a readily available alternative to T cell-depleted 8/8 URDT especially in patients requiring urgent transplantation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1627, 2712, 1885, 315, 18701, 4713, 32, 8, 1755, 390, 452, 31, 2353, 9, 857, 5, 64, 43, 2792, 137, 832, 34, 115, 25, 1010, 50, 18701, 497, 15075, 5815, 6, 17, 1, 2092, 1488, 497, 18702, 16, 44, 1910, 635, 21, 311, 5812, 9568, 2190, 700, 66, 66, 1160, 655, 18702, 512, 67, 66, 1160, 655, 18702, 2, 614, 15075, 2165, 245, 6, 335, 60, 5, 64, 43, 286, 15, 442, 2194, 903, 18702, 2, 15075, 2190, 11, 288, 2187, 15075, 2190, 11, 80, 322, 6, 47, 280, 924, 2, 220, 1865, 3535, 2, 6, 560, 919, 837, 1933, 62, 18702, 2190, 103, 8, 2215, 31, 715, 102, 31, 4358, 1599, 63, 362, 59, 3, 27, 111, 497, 139, 282, 11, 44, 93, 66, 66, 18702, 203, 67, 66, 18702, 587, 2, 15075, 259, 19, 3590, 547, 3, 27, 111, 429, 43, 10, 340, 50, 15075, 66, 66, 18702, 382, 67, 66, 18702, 179, 2, 15075, 83, 19, 5171, 169, 111, 1010, 10, 696, 4, 66, 66, 18702, 605, 4, 67, 66, 18702, 2, 806, 4, 15075, 2190, 19, 13402, 2, 3, 27, 111, 1010, 4, 15075, 2190, 10, 142, 76, 17, 1, 67, 66, 18702, 2190, 19, 4630, 4, 331, 65, 4, 286, 7, 130, 4311, 41, 5, 1010, 11, 1061, 1632, 360, 197, 168, 14, 806, 19, 5304, 147, 1, 286, 1275, 168, 18, 1730, 19, 1520, 2, 67, 66, 102, 31, 4358, 18702, 168, 14, 970, 19, 5171, 64, 1010, 122, 40, 513, 4, 857, 5, 286, 2, 903, 5, 154, 429, 151, 50, 15075, 114, 272, 538, 3620, 15075, 4, 857, 4, 3863, 6, 1160, 5095, 102, 31, 4358, 18702, 2, 309, 15075, 16, 8, 3860, 390, 1091, 6, 102, 31, 4358, 66, 66, 18702, 1093, 4, 7, 1888, 5013, 497]",1625.0,26238810,121
Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia.,PloS one,PLoS ONE,2015-08-07,"Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of dexamethasone in an effort to reduce the incidence of osteonecrosis. However, it is not known whether discontinuous dosing would compromise antileukemic efficacy of glucocorticoids. Therefore, we tested the efficacy of discontinuous dexamethasone against continuous dexamethasone in murine models bearing human acute lymphoblastic leukemia xenografts (n = 8 patient samples) or murine BCR-ABL+ acute lymphoblastic leukemia. Plasma dexamethasone concentrations (7.9 to 212 nM) were similar to those achieved in children with acute lymphoblastic leukemia using conventional dosages. The median leukemia-free survival ranged from 16 to 59 days; dexamethasone prolonged survival from a median of 4 to 129 days in all seven dexamethasone-sensitive acute lymphoblastic leukemias. In the majority of cases (7 of 8 xenografts and the murine BCR-ABL model) we demonstrated equal efficacy of the two dexamethasone dosing regimens; whereas for one acute lymphoblastic leukemia sample, the discontinuous regimen yielded inferior antileukemic efficacy (log-rank p = 0.002). Our results support the clinical practice of using discontinuous rather than continuous dexamethasone dosing in patients with acute lymphoblastic leukemia. ",Journal Article,1628.0,6.0,Osteonecrosis is one of the most common serious toxicities resulting from the treatment of acute lymphoblastic In recent years pediatric acute lymphoblastic clinical trials have used discontinuous rather than continuous dosing of dexamethasone in an effort to reduce the incidence of osteonecrosis However it is not known whether discontinuous dosing would compromise antileukemic efficacy of glucocorticoids Therefore we tested the efficacy of discontinuous dexamethasone against continuous dexamethasone in murine models bearing human acute lymphoblastic xenografts n 8 patient samples or murine BCR-ABL+ acute lymphoblastic Plasma dexamethasone concentrations 7.9 to 212 nM were similar to those achieved in children with acute lymphoblastic using conventional dosages The median leukemia-free survival ranged from 16 to 59 days dexamethasone prolonged survival from a median of 4 to 129 days in all seven dexamethasone-sensitive acute lymphoblastic leukemias In the majority of cases 7 of 8 xenografts and the murine BCR-ABL model we demonstrated equal efficacy of the two dexamethasone dosing regimens whereas for one acute lymphoblastic sample the discontinuous regimen yielded inferior antileukemic efficacy log-rank p 0.002 Our results support the clinical practice of using discontinuous rather than continuous dexamethasone dosing in patients with acute lymphoblastic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 16, 104, 1, 3, 96, 186, 1762, 385, 1113, 29, 3, 24, 1, 286, 1275, 4, 435, 60, 815, 286, 1275, 38, 143, 47, 95, 19022, 1832, 76, 1314, 1280, 1, 1217, 4, 35, 2919, 6, 969, 3, 287, 1, 5404, 137, 192, 16, 44, 440, 317, 19022, 1280, 688, 4665, 4512, 209, 1, 7307, 673, 21, 650, 3, 209, 1, 19022, 1217, 480, 1314, 1217, 4, 1471, 274, 1894, 171, 286, 1275, 1348, 78, 66, 69, 347, 15, 1471, 1062, 1425, 286, 1275, 554, 1217, 1003, 67, 83, 6, 6586, 2878, 11, 288, 6, 135, 513, 4, 541, 5, 286, 1275, 75, 809, 7352, 3, 52, 2647, 115, 25, 1869, 29, 245, 6, 728, 162, 1217, 1069, 25, 29, 8, 52, 1, 39, 6, 4649, 162, 4, 62, 648, 1217, 745, 286, 1275, 2792, 4, 3, 686, 1, 140, 67, 1, 66, 1348, 2, 3, 1471, 1062, 1425, 202, 21, 264, 2997, 209, 1, 3, 100, 1217, 1280, 472, 547, 9, 104, 286, 1275, 1000, 3, 19022, 477, 2178, 1663, 4512, 209, 1066, 1026, 19, 13, 1111, 114, 99, 538, 3, 38, 758, 1, 75, 19022, 1832, 76, 1314, 1217, 1280, 4, 7, 5, 286, 1275]",1377.0,26252865,8
Feasibility Study of a Novel Experimental Induction Protocol Combining B43-PAP (Anti-CD19) Immunotoxin With Standard Induction Chemotherapy in Children and Adolescents With Relapsed B-Lineage ALL: A Report From the Children's Oncology Group.,"Journal of immunotherapy (Hagerstown, Md. : 1997)",J. Immunother.,2015-09-01,"B43-pokeweed antiviral protein (B43-PAP) is a high-affinity anti-CD19 immunotoxin that is capable of causing apoptotic death in B-lineage leukemic cells with a drug-resistant phenotype. B43-PAP exhibited in vivo antileukemic activity in preclinical studies as well as on a single-agent phase I clinical trial. This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic leukemia (B-ALL). Pharmacokinetic profile and immunogenicity of B43-PAP were assessed. B43-PAP in combination with standard 3 and 4-drug induction chemotherapy was administered on days 9-13 and 21-25 of a 28-day treatment course with vincristine, prednisone, L-asparaginase, daunomycin, and intrathecal methotrexate. Thirty patients with relapsed B-ALL were enrolled on study CCG-0957. Grade III/IV nonhematologic dose-limiting toxicities were encountered in 4 patients evaluable for toxicity and included myalgias, motor dysfunction, pulmonary toxicity, and elevated liver transaminase. Dose-limiting toxicities occurred only with the 4-drug regimen. Fourteen patients achieved a complete remission at the end of induction among the 20 patients evaluable for response. B43-PAP in combination with standard induction chemotherapy can be safely administered and exhibits clinical antileukemic activity against relapsed B-ALL.","Clinical Trial, Phase I",1603.0,4.0,B43-pokeweed antiviral protein B43-PAP is a high-affinity anti-CD19 immunotoxin that is capable of causing apoptotic death in B-lineage leukemic cells with a drug-resistant phenotype B43-PAP exhibited in vivo antileukemic activity in preclinical studies as well as on a single-agent phase I clinical trial This pediatric phase I/II study evaluated the toxicity profile and efficacy of B43-PAP immunotoxin in combination with standard induction chemotherapy in children and adolescents with relapsed CD19-positive B-lineage acute lymphoblastic B-ALL Pharmacokinetic profile and immunogenicity of B43-PAP were assessed B43-PAP in combination with standard 3 and 4-drug induction chemotherapy was administered on days 9-13 and 21-25 of a 28-day treatment course with vincristine prednisone L-asparaginase daunomycin and intrathecal methotrexate Thirty patients with relapsed B-ALL were enrolled on study CCG-0957 Grade III/IV nonhematologic dose-limiting toxicities were encountered in 4 patients evaluable for toxicity and included myalgias motor dysfunction pulmonary toxicity and elevated transaminase Dose-limiting toxicities occurred only with the 4-drug regimen Fourteen patients achieved a complete remission at the end of induction among the 20 patients evaluable for response B43-PAP in combination with standard induction chemotherapy can be safely administered and exhibits clinical antileukemic activity against relapsed B-ALL,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[27468, 41175, 6264, 178, 27468, 4290, 16, 8, 64, 3601, 312, 3158, 14464, 17, 16, 2787, 1, 3440, 1631, 273, 4, 132, 2542, 2015, 37, 5, 8, 234, 436, 1005, 27468, 4290, 1416, 4, 386, 4512, 128, 4, 693, 94, 22, 149, 22, 23, 8, 226, 420, 124, 70, 38, 160, 26, 815, 124, 70, 215, 45, 194, 3, 155, 800, 2, 209, 1, 27468, 4290, 14464, 4, 150, 5, 260, 504, 56, 4, 541, 2, 3101, 5, 591, 3158, 109, 132, 2542, 286, 1275, 132, 62, 1456, 800, 2, 4050, 1, 27468, 4290, 11, 275, 27468, 4290, 4, 150, 5, 260, 27, 2, 39, 234, 504, 56, 10, 468, 23, 162, 83, 233, 2, 239, 243, 1, 8, 339, 218, 24, 906, 5, 2132, 1979, 805, 3709, 33534, 2, 5126, 2116, 977, 7, 5, 591, 132, 62, 11, 346, 23, 45, 9457, 66624, 88, 316, 478, 3534, 61, 817, 385, 11, 3903, 4, 39, 7, 859, 9, 155, 2, 159, 11571, 3482, 1527, 1087, 155, 2, 804, 6997, 61, 817, 385, 489, 158, 5, 3, 39, 234, 477, 3225, 7, 513, 8, 236, 734, 28, 3, 396, 1, 504, 107, 3, 179, 7, 859, 9, 51, 27468, 4290, 4, 150, 5, 260, 504, 56, 122, 40, 2268, 468, 2, 4273, 38, 4512, 128, 480, 591, 132, 62]",1435.0,26261894,448
Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia.,Blood,Blood,2015-08-11,"Glucocorticoids are important therapy for acute lymphoblastic leukemia (ALL) and their major adverse effect is osteonecrosis. Our goal was to identify genetic and nongenetic risk factors for osteonecrosis. We performed a genome-wide association study of single nucleotide polymorphisms (SNPs) in a discovery cohort comprising 2285 children with ALL, treated on the Children's Oncology Group AALL0232 protocol (NCT00075725), adjusting for covariates. The minor allele at SNP rs10989692 (near the glutamate receptor GRIN3A locus) was associated with osteonecrosis (hazard ratio = 2.03; P = 3.59  10(-7)). The association was supported by 2 replication cohorts, including 361 children with ALL on St. Jude's Total XV protocol (NCT00137111) and 309 non-ALL patients from Vanderbilt University's BioVU repository treated with glucocorticoids (odds ratio [OR] = 1.87 and 2.26; P = .063 and .0074, respectively). In a meta-analysis, rs10989692 was also highest ranked (P = 2.68  10(-8)), and the glutamate pathway was the top ranked pathway (P = 9.8  10(-4)). Osteonecrosis-associated glutamate receptor variants were also associated with other vascular phenotypes including cerebral ischemia (OR = 1.64; P = 2.5  10(-3)), and arterial embolism and thrombosis (OR = 1.88; P = 4.2  10(-3)). In conclusion, osteonecrosis was associated with inherited variations near glutamate receptor genes. Further understanding this association may allow interventions to decrease osteonecrosis. These trials are registered at www.clinicaltrials.gov as #NCT00075725 and #NCT00137111. ",Journal Article,1624.0,50.0,Glucocorticoids are important therapy for acute lymphoblastic ALL and their major adverse effect is osteonecrosis Our goal was to identify genetic and nongenetic risk factors for osteonecrosis We performed a genome-wide association study of single nucleotide polymorphisms SNPs in a discovery cohort comprising 2285 children with ALL treated on the Children 's Oncology Group AALL0232 protocol NCT00075725 adjusting for covariates The minor allele at SNP rs10989692 near the glutamate receptor GRIN3A locus was associated with osteonecrosis hazard ratio 2.03 P 3.59 10 -7 The association was supported by 2 replication cohorts including 361 children with ALL on St. Jude 's Total XV protocol NCT00137111 and 309 non-ALL patients from Vanderbilt University 's BioVU repository treated with glucocorticoids odds ratio OR 1.87 and 2.26 P .063 and .0074 respectively In a meta-analysis rs10989692 was also highest ranked P 2.68 10 -8 and the glutamate pathway was the top ranked pathway P 9.8 10 -4 Osteonecrosis-associated glutamate receptor variants were also associated with other vascular phenotypes including cerebral ischemia OR 1.64 P 2.5 10 -3 and arterial embolism and thrombosis OR 1.88 P 4.2 10 -3 In conclusion osteonecrosis was associated with inherited variations near glutamate receptor genes Further understanding this association may allow interventions to decrease osteonecrosis These trials are registered at www.clinicaltrials.gov as NCT00075725 and NCT00137111,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7307, 32, 305, 36, 9, 286, 1275, 62, 2, 136, 458, 290, 254, 16, 5404, 114, 1326, 10, 6, 255, 336, 2, 25199, 43, 130, 9, 5404, 21, 173, 8, 898, 1019, 248, 45, 1, 226, 1579, 1203, 1109, 4, 8, 1574, 180, 3538, 35767, 541, 5, 62, 73, 23, 3, 541, 292, 413, 87, 32436, 1182, 40762, 1358, 9, 2489, 3, 2278, 1254, 28, 1845, 49234, 1829, 3, 8334, 153, 66632, 2474, 10, 41, 5, 5404, 360, 197, 18, 680, 19, 27, 728, 79, 67, 3, 248, 10, 2708, 20, 18, 2079, 736, 141, 9234, 541, 5, 62, 23, 3062, 4841, 292, 181, 16078, 1182, 25075, 2, 9440, 220, 62, 7, 29, 22779, 1652, 292, 41182, 12841, 73, 5, 7307, 610, 197, 15, 14, 912, 2, 18, 432, 19, 10592, 2, 22236, 106, 4, 8, 1742, 65, 49234, 10, 120, 1076, 6441, 19, 18, 806, 79, 66, 2, 3, 8334, 308, 10, 3, 3150, 6441, 308, 19, 83, 66, 79, 39, 5404, 41, 8334, 153, 839, 11, 120, 41, 5, 127, 756, 2618, 141, 3549, 5675, 15, 14, 660, 19, 18, 33, 79, 27, 2, 3127, 5475, 2, 2839, 15, 14, 889, 19, 39, 18, 79, 27, 4, 1221, 5404, 10, 41, 5, 2986, 2293, 1829, 8334, 153, 214, 195, 612, 26, 248, 68, 1700, 1151, 6, 775, 5404, 46, 143, 32, 1653, 28, 3064, 1252, 1239, 22, 40762, 2, 25075]",1477.0,26265699,351
"Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-08-17,"Blinatumomab is a CD19/CD3 bispescific antibody designed to redirect T cells toward malignant B cells and induce their lysis. It recently gained accelerated approval by the FDA for the treatment of relapsed or refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia (RR-ALL). In the phase II trial that served as the basis for approval, blinatumomab demonstrated significant single-agent activity and induced remission [complete remission (CR) and CR with incomplete recovery of peripheral blood counts (CRh)] in 43% of 189 adult patients with RR-ALL; the majority of responders (82%) also attained negative minimal residual disease (MRD(-)) status that did not generally translate into long-term remissions in most cases. Additional studies show that blinatumomab can induce high response rates associated with lasting remissions in patients in first remission treated for MRD positivity, suggesting a role for blinatumomab in the upfront, MRD-positive setting. Blinatumomab infusion follows a predictable immunopharmacologic profile, including early cytokine release that can be associated with a clinical syndrome, T-cell expansion, and B-cell depletion. Neurologic toxicities represent a unique toxicity that shares similarities with adverse effects of other T-cell engaging therapies. Further studies are needed to clarify the optimal disease setting and timing for blinatumomab therapy. Additional insights into the pathogenesis, risk factors, and prevention of neurologic toxicities as well as a better understanding of the clinical consequences and biologic pathways that are associated with drug resistance are needed.",Journal Article,1618.0,12.0,Blinatumomab is a CD19/CD3 bispescific antibody designed to redirect T cells toward malignant B cells and induce their lysis It recently gained accelerated approval by the FDA for the treatment of relapsed or refractory Philadelphia chromosome-negative B-cell acute lymphoblastic RR-ALL In the phase II trial that served as the basis for approval blinatumomab demonstrated significant single-agent activity and induced remission complete remission CR and CR with incomplete recovery of peripheral blood counts CRh in 43 of 189 adult patients with RR-ALL the majority of responders 82 also attained negative minimal residual disease MRD status that did not generally translate into long-term remissions in most cases Additional studies show that blinatumomab can induce high response rates associated with lasting remissions in patients in first remission treated for MRD positivity suggesting a role for blinatumomab in the upfront MRD-positive setting Blinatumomab infusion follows a predictable immunopharmacologic profile including early cytokine release that can be associated with a clinical syndrome T-cell expansion and B-cell depletion Neurologic toxicities represent a unique toxicity that shares similarities with adverse effects of other T-cell engaging therapies Further studies are needed to clarify the optimal disease setting and timing for blinatumomab therapy Additional insights into the pathogenesis risk factors and prevention of neurologic toxicities as well as a better understanding of the clinical consequences and biologic pathways that are associated with drug resistance are needed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7182, 16, 8, 3158, 3117, 66667, 548, 1114, 6, 14744, 102, 37, 1317, 393, 132, 37, 2, 1290, 136, 4783, 192, 761, 3711, 2241, 1814, 20, 3, 2078, 9, 3, 24, 1, 591, 15, 430, 3006, 1170, 199, 132, 31, 286, 1275, 861, 62, 4, 3, 124, 215, 160, 17, 5275, 22, 3, 877, 9, 1814, 7182, 264, 93, 226, 420, 128, 2, 277, 734, 236, 734, 684, 2, 684, 5, 2610, 1602, 1, 672, 315, 1911, 18100, 4, 601, 1, 5899, 780, 7, 5, 861, 62, 3, 686, 1, 1983, 878, 120, 5105, 199, 1048, 753, 34, 2029, 156, 17, 205, 44, 1228, 4509, 237, 319, 337, 3166, 4, 96, 140, 402, 94, 514, 17, 7182, 122, 1290, 64, 51, 151, 41, 5, 3443, 3166, 4, 7, 4, 157, 734, 73, 9, 2029, 1887, 802, 8, 200, 9, 7182, 4, 3, 2941, 2029, 109, 546, 7182, 904, 2962, 8, 7639, 66668, 800, 141, 191, 1675, 2008, 17, 122, 40, 41, 5, 8, 38, 681, 102, 31, 1422, 2, 132, 31, 2286, 2543, 385, 1231, 8, 991, 155, 17, 10641, 6089, 5, 290, 176, 1, 127, 102, 31, 8534, 235, 195, 94, 32, 575, 6, 3968, 3, 665, 34, 546, 2, 1972, 9, 7182, 36, 402, 1957, 237, 3, 1384, 43, 130, 2, 1070, 1, 2543, 385, 22, 149, 22, 8, 380, 612, 1, 3, 38, 3255, 2, 1283, 460, 17, 32, 41, 5, 234, 251, 32, 575]",1608.0,26283683,189
Childhood Acute Lymphoblastic Leukemia: Progress Through Collaboration.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-08-24,"To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic leukemia (ALL) in children and adolescents. A review of English literature on childhood ALL focusing on collaborative studies was performed. The resulting article was reviewed and revised by the committee chairs of the major ALL study groups. With long-term survival rates for ALL approaching 90% and the advent of high-resolution genome-wide analyses, several international study groups or consortia were established to conduct collaborative research to further improve outcome. As a result, treatment strategies have been improved for several subtypes of ALL, such as infant, MLL-rearranged, Philadelphia chromosome-positive, and Philadelphia chromosome-like ALL. Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy. Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL. The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment, which will further advance the current high cure rate and the quality of life for children and adolescents with ALL.",Historical Article,1611.0,265.0,To review the impact of collaborative studies on advances in the biology and treatment of acute lymphoblastic ALL in children and adolescents A review of English literature on childhood ALL focusing on collaborative studies was performed The resulting article was reviewed and revised by the committee chairs of the major ALL study groups With long-term survival rates for ALL approaching 90 and the advent of high-resolution genome-wide analyses several international study groups or consortia were established to conduct collaborative research to further improve outcome As a result treatment strategies have been improved for several subtypes of ALL such as infant MLL-rearranged Philadelphia chromosome-positive and Philadelphia chromosome-like ALL Many recurrent genetic abnormalities that respond to tyrosine kinase inhibitors and multiple genetic determinants of drug resistance and toxicities have been identified to help develop targeted therapy Several genetic polymorphisms have been recognized that show susceptibility to developing ALL and that help explain the racial/ethnic differences in the incidence of ALL The information gained from collaborative studies has helped decipher the heterogeneity of ALL to help improve personalized treatment which will further advance the current high cure rate and the quality of life for children and adolescents with ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 206, 3, 345, 1, 3737, 94, 23, 954, 4, 3, 891, 2, 24, 1, 286, 1275, 62, 4, 541, 2, 3101, 8, 206, 1, 4201, 789, 23, 864, 62, 3312, 23, 3737, 94, 10, 173, 3, 1113, 946, 10, 446, 2, 4218, 20, 3, 2002, 49260, 1, 3, 458, 62, 45, 271, 5, 319, 337, 25, 151, 9, 62, 7773, 424, 2, 3, 4114, 1, 64, 2125, 898, 1019, 318, 392, 944, 45, 271, 15, 14303, 11, 635, 6, 4073, 3737, 389, 6, 195, 401, 228, 22, 8, 757, 24, 422, 47, 85, 231, 9, 392, 814, 1, 62, 225, 22, 8027, 3049, 3201, 3006, 1170, 109, 2, 3006, 1170, 733, 62, 445, 387, 336, 1171, 17, 1892, 6, 564, 216, 222, 2, 232, 336, 3403, 1, 234, 251, 2, 385, 47, 85, 108, 6, 987, 690, 238, 36, 392, 336, 1203, 47, 85, 1904, 17, 514, 1432, 6, 931, 62, 2, 17, 987, 2943, 3, 2257, 2871, 362, 4, 3, 287, 1, 62, 3, 487, 3711, 29, 3737, 94, 71, 6156, 11805, 3, 1144, 1, 62, 6, 987, 401, 2175, 24, 92, 303, 195, 3148, 3, 291, 64, 1722, 116, 2, 3, 372, 1, 358, 9, 541, 2, 3101, 5, 62]",1374.0,26304874,858
"Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-08-24,"Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate. The benefit of the addition of rituximab has not been established except in the case of primary mediastinal B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer leukemia-derived protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable, even with intensive approaches. Event-free survival rates of approximately 75% have been achieved in anaplastic large-cell lymphomas with various regimens that generally include a short intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application. ALK inhibitor therapeutic approaches are currently under investigation. For all pediatric lymphomas, the intensity of induction/consolidation therapy correlates with acute toxicities, but because of low cumulative doses of anthracyclines and alkylating agents, minimal or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease, using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse. ",Journal Article,1611.0,65.0,is the fourth most common malignancy in children has an even higher incidence in adolescents and is primarily represented by only a few histologic subtypes Dramatic progress has been achieved with survival rates exceeding 80 in large part because of a better understanding of the biology of the different subtypes and national and international collaborations Most patients with and diffuse large B-cell are cured with short intensive pulse chemotherapy containing cyclophosphamide cytarabine and high-dose methotrexate The benefit of the addition of rituximab has not been established except in the case of primary mediastinal B-cell Lymphoblastic is treated with intensive semi-continuous longer leukemia-derived protocols Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable even with intensive approaches Event-free survival rates of approximately 75 have been achieved in anaplastic large-cell lymphomas with various regimens that generally include a short intensive B-like regimen Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application ALK inhibitor therapeutic approaches are currently under investigation For all pediatric lymphomas the intensity of induction/consolidation therapy correlates with acute toxicities but because of low cumulative doses of anthracyclines and alkylating agents minimal or no long-term toxicity is expected Challenges that remain include defining the value of prognostic factors such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease using new biologic technologies to improve risk stratification and developing innovative therapies both in the first-line setting and for relapse,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[16, 3, 3608, 96, 186, 710, 4, 541, 71, 35, 871, 142, 287, 4, 3101, 2, 16, 1561, 3324, 20, 158, 8, 1021, 884, 814, 3079, 1466, 71, 85, 513, 5, 25, 151, 5178, 493, 4, 375, 760, 408, 1, 8, 380, 612, 1, 3, 891, 1, 3, 338, 814, 2, 657, 2, 944, 10493, 96, 7, 5, 2, 1388, 375, 132, 31, 32, 3733, 5, 978, 1686, 7877, 56, 1101, 1112, 1855, 2, 64, 61, 2116, 3, 247, 1, 3, 352, 1, 855, 71, 44, 85, 635, 2187, 4, 3, 473, 1, 86, 2626, 132, 31, 1275, 16, 73, 5, 1686, 6399, 1314, 589, 2647, 526, 2189, 3713, 4, 132, 31, 2, 1275, 1557, 32, 622, 2, 6440, 4151, 871, 5, 1686, 611, 774, 115, 25, 151, 1, 705, 481, 47, 85, 513, 4, 1841, 375, 31, 1557, 5, 747, 472, 17, 1228, 643, 8, 978, 1686, 132, 733, 477, 1604, 2744, 6, 1343, 35, 305, 200, 4, 356, 2, 1891, 195, 3370, 6, 223, 211, 189, 1581, 1023, 230, 189, 611, 32, 694, 669, 940, 9, 62, 815, 1557, 3, 837, 1, 504, 2173, 36, 1871, 5, 286, 385, 84, 408, 1, 154, 967, 415, 1, 3597, 2, 3410, 183, 1048, 15, 77, 319, 337, 155, 16, 1336, 1427, 17, 918, 643, 2847, 3, 549, 1, 177, 130, 225, 22, 191, 51, 23, 1900, 1799, 872, 1220, 872, 2, 1048, 3605, 2, 753, 34, 75, 217, 1283, 2590, 6, 401, 43, 1541, 2, 931, 4019, 235, 110, 4, 3, 157, 328, 546, 2, 9, 429]",1780.0,26304908,526
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.,Cancer,Cancer,2015-08-26,"The long-term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) is not well established. Patients received dasatinib with 8 cycles of alternating hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and high-dose cytarabine and methotrexate. Patients in complete remission (CR) continued maintenance dasatinib, vincristine, and prednisone for 2 years, which was followed by dasatinib indefinitely. Patients eligible for allogeneic stem cell transplantation (SCT) received it during their first CR. Seventy-two patients with a median age of 55 years (range, 21-80 years) were treated; 69 (96%) achieved CR. Among them, 57 (83%) achieved cytogenetic CR after 1 cycle, and 64 (93%) achieved a major molecular response at a median of 4 weeks (range, 2-38 weeks). Sixty-five patients (94%) were negative for minimal residual disease assessed by flow cytometry at a median of 3 weeks (range, 2-37 weeks). Dasatinib-related grade 3 and 4 adverse events included bleeding, pleural/pericardial effusions, and elevated transaminases. With a median follow-up of 67 months (range, 33-97 months), 33 patients (46%) were alive, and 30 (43%) were in CR; 12 underwent allogeneic SCT. Thirty-nine patients died (3 at induction, 19 after relapse, 7 after SCT performed during first CR, and 10 during CR). The median disease-free survival and overall survival were 31 (range, 0.3-97 months) and 47 months (range, 0.2-97 months), respectively. Seven relapsed patients had BCR-ABL kinase domain mutations, including 4 with T315I. A combination of chemotherapy with dasatinib is effective in achieving long-term remission for patients with newly diagnosed Ph+ALL.","Clinical Trial, Phase II",1609.0,69.0,The long-term efficacy of a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL is not well established Patients received dasatinib with 8 cycles of alternating hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone and high-dose cytarabine and methotrexate Patients in complete remission CR continued maintenance dasatinib vincristine and prednisone for 2 years which was followed by dasatinib indefinitely Patients eligible for allogeneic stem cell transplantation SCT received it during their first CR Seventy-two patients with a median age of 55 years range 21-80 years were treated 69 96 achieved CR Among them 57 83 achieved cytogenetic CR after 1 cycle and 64 93 achieved a major molecular response at a median of 4 weeks range 2-38 weeks Sixty-five patients 94 were negative for minimal residual disease assessed by flow cytometry at a median of 3 weeks range 2-37 weeks Dasatinib-related grade 3 and 4 adverse events included bleeding pleural/pericardial effusions and elevated transaminases With a median follow-up of 67 months range 33-97 months 33 patients 46 were alive and 30 43 were in CR 12 underwent allogeneic SCT Thirty-nine patients died 3 at induction 19 after relapse 7 after SCT performed during first CR and 10 during CR The median disease-free survival and overall survival were 31 range 0.3-97 months and 47 months range 0.2-97 months respectively Seven relapsed patients had BCR-ABL kinase domain mutations including 4 with T315I A combination of chemotherapy with dasatinib is effective in achieving long-term remission for patients with newly diagnosed Ph ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 319, 337, 209, 1, 8, 150, 1, 56, 2, 1674, 4, 7, 5, 3006, 1170, 109, 2058, 286, 1275, 62, 16, 44, 149, 635, 7, 103, 1674, 5, 66, 410, 1, 5181, 6201, 1112, 2132, 856, 2, 1217, 2, 64, 61, 1855, 2, 2116, 7, 4, 236, 734, 684, 1351, 1146, 1674, 2132, 2, 1979, 9, 18, 60, 92, 10, 370, 20, 1674, 13931, 7, 625, 9, 1063, 452, 31, 497, 1988, 103, 192, 190, 136, 157, 684, 2073, 100, 7, 5, 8, 52, 89, 1, 614, 60, 184, 239, 493, 60, 11, 73, 790, 921, 513, 684, 107, 1370, 696, 852, 513, 1266, 684, 50, 14, 417, 2, 660, 966, 513, 8, 458, 219, 51, 28, 8, 52, 1, 39, 244, 184, 18, 519, 244, 1746, 365, 7, 960, 11, 199, 9, 1048, 753, 34, 275, 20, 1412, 1914, 28, 8, 52, 1, 27, 244, 184, 18, 567, 244, 1674, 139, 88, 27, 2, 39, 290, 281, 159, 2294, 2164, 6657, 5154, 2, 804, 9359, 5, 8, 52, 166, 126, 1, 598, 53, 184, 466, 1015, 53, 466, 7, 641, 11, 1701, 2, 201, 601, 11, 4, 684, 133, 208, 1063, 1988, 977, 762, 7, 1016, 27, 28, 504, 326, 50, 429, 67, 50, 1988, 173, 190, 157, 684, 2, 79, 190, 684, 3, 52, 34, 115, 25, 2, 63, 25, 11, 456, 184, 13, 27, 1015, 53, 2, 662, 53, 184, 13, 18, 1015, 53, 106, 648, 591, 7, 42, 1062, 1425, 216, 1398, 138, 141, 39, 5, 6184, 8, 150, 1, 56, 5, 1674, 16, 323, 4, 1785, 319, 337, 734, 9, 7, 5, 732, 265, 2058, 62]",1678.0,26308885,729
In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-08-29,"The inclusion of antithymocyte globulin (ATG) in cord blood transplantation is controversial. We evaluated outcomes according to ATG inclusion in 297 children and adolescents with acute lymphoblastic leukemia (ALL) who received myeloablative total body irradiation-based conditioning and either single-unit (74%) or double-unit (26%) grafts. Ninety-two patients (31%) received ATG and 205 (69%) did not. ATG recipients were more likely to be cytomegalovirus seronegative. The incidences of day 100 grades II to IV acute graft-versus-host disease (GVHD; 30% versus 54%, P = .0002) and chronic GVHD (22% versus 43%, P = .0008) were lower with ATG compared with non-ATG regimens. However, day 100 grades III to IV acute GVHD was comparable (11% versus 17%, P = .15). The 3-year incidences of transplant-related mortality (16% versus 17%, P = .98), relapse (17% versus 27%, P = .12), and leukemia-free survival (66% versus 55%, P = .23) in ATG and non-ATG recipients were similar. There were no differences in viral reactivation between treatment groups (60% versus 58%, P = .83). Therefore, the data suggest that incorporation of ATG with myeloablative conditioning regimens may be useful in reducing the risk of acute and chronic GVHD without any deleterious effect on transplant-related mortality, relapse, or leukemia-free survival in children and adolescents with ALL.",Journal Article,1606.0,13.0,The inclusion of antithymocyte globulin ATG in cord blood transplantation is controversial We evaluated outcomes according to ATG inclusion in 297 children and adolescents with acute lymphoblastic ALL who received myeloablative total body irradiation-based conditioning and either single-unit 74 or double-unit 26 grafts Ninety-two patients 31 received ATG and 205 69 did not ATG recipients were more likely to be cytomegalovirus seronegative The incidences of day 100 grades II to IV acute graft-versus-host disease GVHD 30 versus 54 P .0002 and chronic GVHD 22 versus 43 P .0008 were lower with ATG compared with non-ATG regimens However day 100 grades III to IV acute GVHD was comparable 11 versus 17 P .15 The 3-year incidences of transplant-related mortality 16 versus 17 P .98 relapse 17 versus 27 P .12 and leukemia-free survival 66 versus 55 P .23 in ATG and non-ATG recipients were similar There were no differences in viral reactivation between treatment groups 60 versus 58 P .83 Therefore the data suggest that incorporation of ATG with myeloablative conditioning regimens may be useful in reducing the risk of acute and chronic GVHD without any deleterious effect on transplant-related mortality relapse or leukemia-free survival in children and adolescents with ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1680, 1, 11016, 7819, 7168, 4, 1885, 315, 497, 16, 2010, 21, 194, 123, 768, 6, 7168, 1680, 4, 8526, 541, 2, 3101, 5, 286, 1275, 62, 54, 103, 3246, 181, 642, 1104, 90, 1933, 2, 361, 226, 2712, 794, 15, 1627, 2712, 432, 4713, 2493, 100, 7, 456, 103, 7168, 2, 5286, 790, 205, 44, 7168, 2190, 11, 80, 322, 6, 40, 7314, 14924, 3, 3981, 1, 218, 394, 2276, 215, 6, 478, 286, 1599, 185, 1204, 34, 1562, 201, 185, 667, 19, 3531, 2, 442, 1562, 350, 185, 601, 19, 7044, 11, 280, 5, 7168, 72, 5, 220, 7168, 472, 137, 218, 394, 2276, 316, 6, 478, 286, 1562, 10, 1279, 175, 185, 269, 19, 167, 3, 27, 111, 3981, 1, 941, 139, 282, 245, 185, 269, 19, 1096, 429, 269, 185, 428, 19, 133, 2, 2647, 115, 25, 700, 185, 614, 19, 382, 4, 7168, 2, 220, 7168, 2190, 11, 288, 125, 11, 77, 362, 4, 1667, 3834, 59, 24, 271, 335, 185, 717, 19, 852, 673, 3, 74, 309, 17, 2838, 1, 7168, 5, 3246, 1933, 472, 68, 40, 999, 4, 1818, 3, 43, 1, 286, 2, 442, 1562, 187, 500, 3586, 254, 23, 941, 139, 282, 429, 15, 2647, 115, 25, 4, 541, 2, 3101, 5, 62]",1279.0,26327630,36
Activity and Toxicity of Intravenous Erwinia Asparaginase Following Allergy to E. coli-Derived Asparaginase in Children and Adolescents With Acute Lymphoblastic Leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2015-09-16,"Erwinia asparaginase is antigenically distinct from E.coli-derived asparaginase and may be used after E.coli-derived asparaginase hypersensitivity. In a single-arm, multicenter study, we evaluated nadir serum asparaginase activity (NSAA) and toxicity with intravenously administered asparaginase Erwinia chrysanthemi (IV-Erwinia) in children and adolescents with acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma with hypersensitivity to E.coli-derived asparaginase. Between 2012 and 2013, 30 patients (age 1-17 years) enrolled from 10 centers. Patients received IV-Erwinia, 25,000 IU/m(2)/dose on Monday/Wednesday/Friday, for 2 consecutive-weeks (6 doses = 1 cycle) for each dose of pegaspargase remaining in the original treatment plan. The primary objective was to determine the proportion of patients achieving NSAA  0.1 IU/ml 48 hr after dose 5 in Cycle 1. Secondary objectives included determining the proportion achieving NSAA  0.1 IU/ml 72 hr after Cycle 1 dose 6, and the frequency of asparaginase-related toxicities. Twenty-six patients completed Cycle 1; 24 were evaluable for NSAA assessment. In Cycle 1, NSAA  0.10 IU/ml was detected in 83% of patients (95% confidence interval [CI], 63-95%) 48 hr post-dose 5 (mean  SD; 0.32 IU/ml  0.23), and in 43% (95% CI, 22-66%) 72 hr post-dose 6 (mean  SD; 0.089 IU/ml  0.072). For all 30 patients over all cycles, hypersensitivity/infusional reactions with IV-Erwinia occurred in 37%, pancreatitis 7%, and thrombosis 3%. IV-Erwinia administration in children/adolescents appeared feasible and tolerable. A therapeutically-effective NSAA ( 0.10 IU/ml) was achieved in most patients at 48 hr, but in fewer than half 72 hr post-dosing, suggesting that monitoring NSAA levels and/or every 48 hr dosing may be indicated.",Clinical Trial,1588.0,23.0,"Erwinia asparaginase is antigenically distinct from E.coli-derived asparaginase and may be used after E.coli-derived asparaginase hypersensitivity In a single-arm multicenter study we evaluated nadir serum asparaginase activity NSAA and toxicity with intravenously administered asparaginase Erwinia chrysanthemi IV-Erwinia in children and adolescents with acute lymphoblastic ALL or lymphoblastic with hypersensitivity to E.coli-derived asparaginase Between 2012 and 2013 30 patients age 1-17 years enrolled from 10 centers Patients received IV-Erwinia 25,000 IU/m 2 /dose on Monday/Wednesday/Friday for 2 consecutive-weeks 6 doses 1 cycle for each dose of pegaspargase remaining in the original treatment plan The primary objective was to determine the proportion of patients achieving NSAA  0.1 IU/ml 48 hr after dose 5 in Cycle 1 Secondary objectives included determining the proportion achieving NSAA  0.1 IU/ml 72 hr after Cycle 1 dose 6 and the frequency of asparaginase-related toxicities Twenty-six patients completed Cycle 1 24 were evaluable for NSAA assessment In Cycle 1 NSAA  0.10 IU/ml was detected in 83 of patients 95 confidence interval CI 63-95 48 hr post-dose 5 mean  SD 0.32 IU/ml  0.23 and in 43 95 CI 22-66 72 hr post-dose 6 mean  SD 0.089 IU/ml  0.072 For all 30 patients over all cycles hypersensitivity/infusional reactions with IV-Erwinia occurred in 37 pancreatitis 7 and thrombosis 3 IV-Erwinia administration in children/adolescents appeared feasible and tolerable A therapeutically-effective NSAA  0.10 IU/ml was achieved in most patients at 48 hr but in fewer than half 72 hr post-dosing suggesting that monitoring NSAA levels and/or every 48 hr dosing may be indicated",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[11358, 3709, 16, 38369, 834, 29, 563, 6959, 526, 3709, 2, 68, 40, 95, 50, 563, 6959, 526, 3709, 4034, 4, 8, 226, 475, 1570, 45, 21, 194, 3686, 524, 3709, 128, 19885, 2, 155, 5, 1672, 468, 3709, 11358, 23864, 478, 11358, 4, 541, 2, 3101, 5, 286, 1275, 62, 15, 1275, 5, 4034, 6, 563, 6959, 526, 3709, 59, 1195, 2, 1346, 201, 7, 89, 14, 269, 60, 346, 29, 79, 1168, 7, 103, 478, 11358, 243, 984, 4588, 188, 18, 61, 23, 9339, 14412, 9872, 9, 18, 935, 244, 49, 415, 14, 417, 9, 296, 61, 1, 12209, 1844, 4, 3, 2279, 24, 2242, 3, 86, 461, 10, 6, 223, 3, 920, 1, 7, 1785, 19885, 749, 13, 14, 4588, 542, 576, 168, 50, 61, 33, 4, 417, 14, 568, 2409, 159, 2196, 3, 920, 1785, 19885, 749, 13, 14, 4588, 542, 720, 168, 50, 417, 14, 61, 49, 2, 3, 675, 1, 3709, 139, 385, 737, 437, 7, 781, 417, 14, 259, 11, 859, 9, 19885, 455, 4, 417, 14, 19885, 749, 13, 79, 4588, 542, 10, 530, 4, 852, 1, 7, 48, 307, 268, 58, 676, 48, 576, 168, 539, 61, 33, 313, 810, 1270, 13, 531, 4588, 542, 810, 13, 382, 2, 4, 601, 48, 58, 350, 700, 720, 168, 539, 61, 49, 313, 810, 1270, 13, 12877, 4588, 542, 810, 13, 14298, 9, 62, 201, 7, 252, 62, 410, 4034, 4825, 2428, 5, 478, 11358, 489, 4, 567, 4535, 67, 2, 2839, 27, 478, 11358, 634, 4, 541, 3101, 2121, 1313, 2, 2668, 8, 4602, 323, 19885, 749, 13, 79, 4588, 542, 10, 513, 4, 96, 7, 28, 576, 168, 84, 4, 1497, 76, 1303, 720, 168, 539, 1280, 802, 17, 1315, 19885, 148, 2, 15, 454, 576, 168, 1280, 68, 40, 1103]",1708.0,26376459,109
Novel Management Options for Adult Patients With Progressive Acute Lymphoblastic Leukemia: A Case-Study Compendium.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2015-06-01,"Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy characterized by highly proliferative immature lymphoid cells in the bone marrow and peripheral blood. In adults, ALL accounts for approximately 20% of all adult leukemias. ALL carries a poor prognosis in adults. The 5-year overall survival is 24% in patients ages 40 to 59 years and 18% in patients ages 60 to 69 years. ALL can be grouped into different categories according to its cell lineage (B cell or T cell), the presence or absence of the Philadelphia chromosome, and various cytogenetic and molecular classifications. A main goal of treatment is to allow the patient to achieve a complete remission and to consolidate this remission with either a maintenance regimen or an allogeneic stem cell transplant. Although the overall rate of complete remission following frontline therapy for newly diagnosed ALL is high, the majority of patients experience a disease relapse. In general, the duration of initial complete remission impacts the patients prognosis and response to further therapies. Subsequent treatments must balance the goal of achieving a remission with the need for the patient to maintain or improve quality of life. Recently approved agents, such as blinatumomab and vincristine sulfate liposome injection, offer the promise of a second remission that can serve as a bridge to allogeneic stem cell transplant while still maintaining quality of life. A novel approach using adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells is associated with extremely robust responses.",Case Reports,1695.0,0.0,Acute lymphoblastic ALL is a heterogeneous hematologic malignancy characterized by highly proliferative immature lymphoid cells in the marrow and peripheral blood In adults ALL accounts for approximately 20 of all adult leukemias ALL carries a poor prognosis in adults The 5-year overall survival is 24 in patients ages 40 to 59 years and 18 in patients ages 60 to 69 years ALL can be grouped into different categories according to its cell lineage B cell or T cell the presence or absence of the Philadelphia chromosome and various cytogenetic and molecular classifications A main goal of treatment is to allow the patient to achieve a complete remission and to consolidate this remission with either a maintenance regimen or an allogeneic stem cell transplant Although the overall rate of complete remission following frontline therapy for newly diagnosed ALL is high the majority of patients experience a disease relapse In general the duration of initial complete remission impacts the patient s prognosis and response to further therapies Subsequent treatments must balance the goal of achieving a remission with the need for the patient to maintain or improve quality of life Recently approved agents such as blinatumomab and vincristine sulfate liposome injection offer the promise of a second remission that can serve as a bridge to allogeneic stem cell transplant while still maintaining quality of life A novel approach using adoptive cellular immunotherapy with chimeric antigen receptor CAR T cells is associated with extremely robust responses,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 8, 1564, 813, 710, 765, 20, 561, 2441, 5733, 2303, 37, 4, 3, 581, 2, 672, 315, 4, 857, 62, 4162, 9, 705, 179, 1, 62, 780, 2792, 62, 4942, 8, 334, 356, 4, 857, 3, 33, 111, 63, 25, 16, 259, 4, 7, 2165, 327, 6, 728, 60, 2, 203, 4, 7, 2165, 335, 6, 790, 60, 62, 122, 40, 3706, 237, 338, 1996, 768, 6, 211, 31, 2542, 132, 31, 15, 102, 31, 3, 463, 15, 1127, 1, 3, 3006, 1170, 2, 747, 1266, 2, 219, 5787, 8, 1895, 1326, 1, 24, 16, 6, 1700, 3, 69, 6, 1359, 8, 236, 734, 2, 6, 16671, 26, 734, 5, 361, 8, 1146, 477, 15, 35, 1063, 452, 31, 941, 242, 3, 63, 116, 1, 236, 734, 366, 3171, 36, 9, 732, 265, 62, 16, 64, 3, 686, 1, 7, 730, 8, 34, 429, 4, 1083, 3, 654, 1, 388, 236, 734, 4719, 3, 69, 695, 356, 2, 51, 6, 195, 235, 706, 640, 1642, 3459, 3, 1326, 1, 1785, 8, 734, 5, 3, 594, 9, 3, 69, 6, 3040, 15, 401, 372, 1, 358, 761, 850, 183, 225, 22, 7182, 2, 2132, 6424, 8645, 1754, 1918, 3, 1783, 1, 8, 419, 734, 17, 122, 1833, 22, 8, 7728, 6, 1063, 452, 31, 941, 369, 1234, 3284, 372, 1, 358, 8, 229, 353, 75, 3159, 763, 726, 5, 2897, 448, 153, 1881, 102, 37, 16, 41, 5, 2938, 1922, 253]",1556.0,26431322,553
"Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia.",Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2015-10-12,"RG7112 is a small-molecule MDM2 antagonist. MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias. Thus, a phase I study of RG7112 in patients with hematologic malignancies was conducted. Primary study objectives included determination of the dose and safety profile of RG7112. Secondary objectives included evaluation of pharmacokinetics; pharmacodynamics, such as TP53-mutation status and MDM2 expression; and preliminary clinical activity. Patients were divided into two cohorts: Stratum A [relapsed/refractory acute myeloid leukemia (AML; except acute promyelocytic leukemia), acute lymphoblastic leukemia, and chronic myelogenous leukemia] and Stratum B (relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic leukemia; CLL/sCLL). Some Stratum A patients were treated at the MTD to assess clinical activity. RG7112 was administered to 116 patients (96 patients in Stratum A and 20 patients in Stratum B). All patients experienced at least 1 adverse event, and 3 dose-limiting toxicities were reported. Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure. Antileukemia activity was observed in the 30 patients with AML assessed at the MTD, including 5 patients who met International Working Group (IWG) criteria for response. Exploratory analysis revealed TP53 mutations in 14% of Stratum A patients and in 40% of Stratum B patients. Two patients with TP53 mutations exhibited clinical activity. p53 target genes were induced only in TP53 wild-type leukemic cells. Baseline expression levels of MDM2 correlated positively with clinical response. RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL. MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes. We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies.","Clinical Trial, Phase I",1562.0,93.0,RG7112 is a small-molecule MDM2 antagonist MDM2 is a negative regulator of the tumor suppressor p53 and frequently overexpressed in leukemias Thus a phase I study of RG7112 in patients with hematologic malignancies was conducted Primary study objectives included determination of the dose and safety profile of RG7112 Secondary objectives included evaluation of pharmacokinetics pharmacodynamics such as TP53-mutation status and MDM2 expression and preliminary clinical activity Patients were divided into two cohorts Stratum A relapsed/refractory acute myeloid AML except acute promyelocytic acute lymphoblastic and chronic myelogenous and Stratum B relapsed/refractory chronic lymphocytic leukemia/small cell lymphocytic CLL/sCLL Some Stratum A patients were treated at the MTD to assess clinical activity RG7112 was administered to 116 patients 96 patients in Stratum A and 20 patients in Stratum B All patients experienced at least 1 adverse event and 3 dose-limiting toxicities were reported Pharmacokinetic analysis indicated that twice-daily dosing enhanced daily exposure Antileukemia activity was observed in the 30 patients with AML assessed at the MTD including 5 patients who met International Working Group IWG criteria for response Exploratory analysis revealed TP53 mutations in 14 of Stratum A patients and in 40 of Stratum B patients Two patients with TP53 mutations exhibited clinical activity p53 target genes were induced only in TP53 wild-type leukemic cells Baseline expression levels of MDM2 correlated positively with clinical response RG7112 demonstrated clinical activity against relapsed/refractory AML and CLL/sCLL MDM2 inhibition resulted in p53 stabilization and transcriptional activation of p53-target genes We provide proof-of-concept that MDM2 inhibition restores p53 function and generates clinical responses in hematologic malignancies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[22908, 16, 8, 302, 1354, 3277, 3137, 3277, 16, 8, 199, 2452, 1, 3, 30, 1245, 624, 2, 746, 1711, 4, 2792, 631, 8, 124, 70, 45, 1, 22908, 4, 7, 5, 813, 441, 10, 426, 86, 45, 2409, 159, 3104, 1, 3, 61, 2, 367, 800, 1, 22908, 568, 2409, 159, 451, 1, 1159, 3587, 225, 22, 1206, 258, 156, 2, 3277, 55, 2, 1676, 38, 128, 7, 11, 2176, 237, 100, 736, 4897, 8, 591, 430, 286, 533, 329, 2187, 286, 4300, 286, 1275, 2, 442, 2194, 2, 4897, 132, 591, 430, 442, 1193, 2647, 302, 31, 1193, 552, 49333, 476, 4897, 8, 7, 11, 73, 28, 3, 961, 6, 423, 38, 128, 22908, 10, 468, 6, 3790, 7, 921, 7, 4, 4897, 8, 2, 179, 7, 4, 4897, 132, 62, 7, 592, 28, 506, 14, 290, 774, 2, 27, 61, 817, 385, 11, 210, 1456, 65, 1103, 17, 936, 391, 1280, 651, 391, 645, 9169, 128, 10, 164, 4, 3, 201, 7, 5, 329, 275, 28, 3, 961, 141, 33, 7, 54, 543, 944, 2644, 87, 14620, 371, 9, 51, 2386, 65, 553, 1206, 138, 4, 213, 1, 4897, 8, 7, 2, 4, 327, 1, 4897, 132, 7, 100, 7, 5, 1206, 138, 1416, 38, 128, 624, 283, 214, 11, 277, 158, 4, 1206, 955, 267, 2015, 37, 330, 55, 148, 1, 3277, 438, 2375, 5, 38, 51, 22908, 264, 38, 128, 480, 591, 430, 329, 2, 552, 49333, 3277, 297, 627, 4, 624, 3184, 2, 1431, 363, 1, 624, 283, 214, 21, 377, 3840, 1, 2545, 17, 3277, 297, 8489, 624, 343, 2, 7919, 38, 253, 4, 813, 441]",1871.0,26459177,331
Computerized Cognitive Training for Amelioration of Cognitive Late Effects Among Childhood Cancer Survivors: A Randomized Controlled Trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2015-10-12,"Children receiving CNS-directed therapy for cancer are at risk for cognitive problems, with few available empirically supported interventions. Cognitive problems indicate neurodevelopmental disruption that may be modifiable with intervention. This study evaluated short-term efficacy of a computerized cognitive training program and neural correlates of cognitive change. A total of 68 survivors of childhood acute lymphoblastic leukemia (ALL) or brain tumor (BT) with identified cognitive deficits were randomly assigned to computerized cognitive intervention (male, n = 18; female, n = 16; ALL, n = 23; BT, n = 11; mean age  standard deviation, 12.21  2.47 years) or waitlist (male, n = 18; female, n = 16; ALL, n = 24; BT, n = 10; median age  standard deviation, 11.82  2.42 years). Intervention participants were asked to complete 25 training sessions at home with weekly, telephone-based coaching. Cognitive assessments and functional magnetic resonance imaging scans (intervention group) were completed pre- and postintervention, with immediate change in spatial span backward as the primary outcome. Survivors completing the intervention (n = 30; 88%) demonstrated greater improvement than controls on measures of working memory (mean  SEM; eg, Wechsler Intelligence Scale for Children [fourth edition; WISC-IV] spatial span backward, 3.13  0.58 v 0.75  0.43; P = .002; effect size [ES], 0.84), attention (eg, WISC-IV spatial span forward, 3.30  0.71 v 1.25  0.39; P = .01; ES, 0.65), and processing speed (eg, Conners' Continuous Performance Test hit reaction time, -2.10  1.47 v 2.54  1.25; P = .02; ES, .61) and showed greater reductions in reported executive dysfunction (eg, Conners' Parent Rating Scale III, -6.73  1.51 v 0.41  1.53; P = .002; ES, 0.84). Functional magnetic resonance imaging revealed significant pre- to post-training reduction in activation of left lateral prefrontal and bilateral medial frontal areas. Study findings show computerized cognitive training is feasible and efficacious for childhood cancer survivors, with evidence for training-related neuroplasticity.",Comparative Study,1562.0,62.0,Children receiving CNS-directed therapy for cancer are at risk for cognitive problems with few available empirically supported interventions Cognitive problems indicate neurodevelopmental disruption that may be modifiable with intervention This study evaluated short-term efficacy of a computerized cognitive training program and neural correlates of cognitive change A total of 68 survivors of childhood acute lymphoblastic ALL or brain tumor BT with identified cognitive deficits were randomly assigned to computerized cognitive intervention male n 18 female n 16 ALL n 23 BT n 11 mean age  standard deviation 12.21  2.47 years or waitlist male n 18 female n 16 ALL n 24 BT n 10 median age  standard deviation 11.82  2.42 years Intervention participants were asked to complete 25 training sessions at home with weekly telephone-based coaching Cognitive assessments and functional magnetic resonance imaging scans intervention group were completed pre- and postintervention with immediate change in spatial span backward as the primary outcome Survivors completing the intervention n 30 88 demonstrated greater improvement than controls on measures of working memory mean  SEM eg Wechsler Intelligence Scale for Children fourth edition WISC-IV spatial span backward 3.13  0.58 v 0.75  0.43 P .002 effect size ES 0.84 attention eg WISC-IV spatial span forward 3.30  0.71 v 1.25  0.39 P .01 ES 0.65 and processing speed eg Conners Continuous Performance Test hit reaction time -2.10  1.47 v 2.54  1.25 P .02 ES .61 and showed greater reductions in reported executive dysfunction eg Conners Parent Rating Scale III -6.73  1.51 v 0.41  1.53 P .002 ES 0.84 Functional magnetic resonance imaging revealed significant pre- to post-training reduction in activation of left lateral prefrontal and bilateral medial frontal areas Study findings show computerized cognitive training is feasible and efficacious for childhood cancer survivors with evidence for training-related neuroplasticity,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 357, 1025, 1166, 36, 9, 12, 32, 28, 43, 9, 1863, 2408, 5, 1021, 390, 9654, 2708, 1151, 1863, 2408, 1008, 19352, 3220, 17, 68, 40, 5222, 5, 788, 26, 45, 194, 978, 337, 209, 1, 8, 4912, 1863, 1741, 1243, 2, 3922, 1871, 1, 1863, 707, 8, 181, 1, 806, 332, 1, 864, 286, 1275, 62, 15, 342, 30, 3641, 5, 108, 1863, 2752, 11, 1108, 896, 6, 4912, 1863, 788, 1045, 78, 203, 1061, 78, 245, 62, 78, 382, 3641, 78, 175, 313, 89, 810, 260, 3348, 133, 239, 810, 18, 662, 60, 15, 17391, 1045, 78, 203, 1061, 78, 245, 62, 78, 259, 3641, 78, 79, 52, 89, 810, 260, 3348, 175, 878, 810, 18, 595, 60, 788, 776, 11, 3732, 6, 236, 243, 1741, 4390, 28, 3249, 5, 709, 4258, 90, 16681, 1863, 2182, 2, 583, 1484, 1535, 270, 1441, 788, 87, 11, 781, 671, 2, 10118, 5, 2181, 707, 4, 5104, 7165, 10877, 22, 3, 86, 228, 332, 4144, 3, 788, 78, 201, 889, 264, 378, 767, 76, 535, 23, 1018, 1, 2644, 2407, 313, 810, 8719, 2887, 17526, 9125, 1124, 9, 541, 3608, 3580, 49336, 478, 5104, 7165, 10877, 27, 233, 810, 13, 717, 603, 13, 481, 810, 13, 601, 19, 1111, 254, 444, 3011, 13, 874, 2111, 2887, 49336, 478, 5104, 7165, 4674, 27, 201, 810, 13, 792, 603, 14, 243, 810, 13, 587, 19, 355, 3011, 13, 556, 2, 3325, 5051, 2887, 24487, 1314, 528, 412, 6519, 1329, 98, 18, 79, 810, 14, 662, 603, 18, 667, 810, 14, 243, 19, 588, 3011, 713, 2, 224, 378, 2153, 4, 210, 6481, 1527, 2887, 24487, 3841, 5477, 1124, 316, 49, 803, 810, 14, 725, 603, 13, 605, 810, 14, 699, 19, 1111, 3011, 13, 874, 583, 1484, 1535, 270, 553, 93, 671, 6, 539, 1741, 628, 4, 363, 1, 1712, 3855, 31982, 2, 1607, 8392, 8082, 1361, 45, 272, 514, 4912, 1863, 1741, 16, 1313, 2, 3289, 9, 864, 12, 332, 5, 241, 9, 1741, 139, 66939]",1994.0,26460306,40
Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.,Leukemia research,Leuk. Res.,2015-10-01,"In acute lymphoblastic leukemia (ALL) the bone marrow microenvironment provides growth and survival signals that may confer resistance to chemotherapy. Granulocyte colony-stimulating factor (G-CSF) potently inhibits lymphopoiesis by targeting stromal cells that comprise the lymphoid niche in the bone marrow. To determine whether lymphoid niche disruption by G-CSF sensitizes ALL cells to chemotherapy, we conducted a pilot study of G-CSF in combination with chemotherapy in patients with relapsed or refractory ALL. Thirteen patients were treated on study; three patients achieved a complete remission (CR/CRi) for an overall response rate of 23%. In the healthy volunteers, G-CSF treatment disrupted the lymphoid niche, as evidenced by reduced expression of CXCL12, interleukin-7, and osteocalcin. However, in most patients with relapsed/refractory ALL expression of these genes was markedly suppressed at baseline. Thus, although G-CSF treatment was associated with ALL cell mobilization into the blood, and increased apoptosis of bone marrow resident ALL cells, alterations in the bone marrow microenvironment were modest and highly variable. These data suggest that disruption of lymphoid niches by G-CSF to sensitize ALL cells to chemotherapy may be best accomplished in the consolidation where the bone marrow microenvironment is more likely to be normal. ",Clinical Trial,1573.0,9.0,In acute lymphoblastic ALL the marrow microenvironment provides growth and survival signals that may confer resistance to chemotherapy Granulocyte colony-stimulating factor G-CSF potently inhibits lymphopoiesis by targeting stromal cells that comprise the lymphoid niche in the marrow To determine whether lymphoid niche disruption by G-CSF sensitizes ALL cells to chemotherapy we conducted a pilot study of G-CSF in combination with chemotherapy in patients with relapsed or refractory ALL Thirteen patients were treated on study three patients achieved a complete remission CR/CRi for an overall response rate of 23 In the healthy volunteers G-CSF treatment disrupted the lymphoid niche as evidenced by reduced expression of CXCL12 interleukin-7 and osteocalcin However in most patients with relapsed/refractory ALL expression of these genes was markedly suppressed at baseline Thus although G-CSF treatment was associated with ALL cell mobilization into the blood and increased apoptosis of marrow resident ALL cells alterations in the marrow microenvironment were modest and highly variable These data suggest that disruption of lymphoid niches by G-CSF to sensitize ALL cells to chemotherapy may be best accomplished in the consolidation where the marrow microenvironment is more likely to be normal,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,"[4, 286, 1275, 62, 3, 581, 995, 777, 129, 2, 25, 2312, 17, 68, 2913, 251, 6, 56, 2764, 1975, 2122, 161, 499, 1211, 4684, 1576, 30689, 20, 529, 1126, 37, 17, 5238, 3, 2303, 4385, 4, 3, 581, 6, 223, 317, 2303, 4385, 3220, 20, 499, 1211, 6229, 62, 37, 6, 56, 21, 426, 8, 2281, 45, 1, 499, 1211, 4, 150, 5, 56, 4, 7, 5, 591, 15, 430, 62, 3170, 7, 11, 73, 23, 45, 169, 7, 513, 8, 236, 734, 684, 6341, 9, 35, 63, 51, 116, 1, 382, 4, 3, 1331, 5495, 499, 1211, 24, 5576, 3, 2303, 4385, 22, 4728, 20, 405, 55, 1, 5807, 1603, 67, 2, 15282, 137, 4, 96, 7, 5, 591, 430, 62, 55, 1, 46, 214, 10, 2195, 1908, 28, 330, 631, 242, 499, 1211, 24, 10, 41, 5, 62, 31, 4030, 237, 3, 315, 2, 101, 351, 1, 581, 8185, 62, 37, 593, 4, 3, 581, 995, 11, 1721, 2, 561, 1347, 46, 74, 309, 17, 3220, 1, 2303, 8005, 20, 499, 1211, 6, 5745, 62, 37, 6, 56, 68, 40, 824, 5741, 4, 3, 2173, 1257, 3, 581, 995, 16, 80, 322, 6, 40, 295]",1304.0,26467815,234
"Acute Lymphoblastic Leukemia, Version 2.2015.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2015-10-01,"Treatment of acute lymphoblastic leukemia (ALL) continues to advance, as evidenced by the improved risk stratification of patients and development of newer treatment options. Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis. Identification of Ikaros mutations has also emerged as a prognostic factor. In addition to improved prognostication, treatment options for patients with ALL have expanded, particularly with regard to relapsed/refractory ALL. Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy, including blinatumomab and chimeric antigen receptor T-cell therapy, have improved survival. Furthermore, incorporation of minimal residual disease (MRD) monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations. This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis, treatment of relapsed/refractory ALL, and incorporation of MRD monitoring. To view the most recent complete version of these guidelines, visit NCCN.org. ",Journal Article,1573.0,41.0,Treatment of acute lymphoblastic ALL continues to advance as evidenced by the improved risk stratification of patients and development of newer treatment options Identification of ALL subtypes based on immunophenotyping and cytogenetic and molecular markers has resulted in the inclusion of Philadelphia-like ALL and early T-cell precursor ALL as subtypes that affect prognosis Identification of Ikaros mutations has also emerged as a prognostic factor In addition to improved prognostication treatment options for patients with ALL have expanded particularly with regard to relapsed/refractory ALL Continued development of second-generation tyrosine kinase inhibitors and the emergence of immunotherapy including blinatumomab and chimeric antigen receptor T-cell therapy have improved survival Furthermore incorporation of minimal residual disease MRD monitoring has shown insight into patient outcomes and may lead to treatment modification or alternative treatment strategies in select populations This excerpt focuses on the sections of the ALL guidelines specific to clinical presentation and diagnosis treatment of relapsed/refractory ALL and incorporation of MRD monitoring To view the most recent complete version of these guidelines visit NCCN.org,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 286, 1275, 62, 2274, 6, 3148, 22, 4728, 20, 3, 231, 43, 1541, 1, 7, 2, 193, 1, 2246, 24, 838, 911, 1, 62, 814, 90, 23, 9416, 2, 1266, 2, 219, 525, 71, 627, 4, 3, 1680, 1, 3006, 733, 62, 2, 191, 102, 31, 2765, 62, 22, 814, 17, 1158, 356, 911, 1, 20613, 138, 71, 120, 2054, 22, 8, 177, 161, 4, 352, 6, 231, 4260, 24, 838, 9, 7, 5, 62, 47, 2064, 823, 5, 2539, 6, 591, 430, 62, 1351, 193, 1, 419, 914, 564, 216, 222, 2, 3, 3397, 1, 726, 141, 7182, 2, 2897, 448, 153, 102, 31, 36, 47, 231, 25, 798, 2838, 1, 1048, 753, 34, 2029, 1315, 71, 443, 2670, 237, 69, 123, 2, 68, 1122, 6, 24, 2437, 15, 1091, 24, 422, 4, 1717, 1184, 26, 40632, 3026, 23, 3, 3013, 1, 3, 62, 677, 112, 6, 38, 1031, 2, 147, 24, 1, 591, 430, 62, 2, 2838, 1, 2029, 1315, 6, 3811, 3, 96, 435, 236, 2256, 1, 46, 677, 2807, 1944, 5598]",1256.0,26483064,425
Implications and Management of Central Nervous SystemInvolvement before Allogeneic Hematopoietic CellTransplantation in Acute Lymphoblastic Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-10-19,"Acute lymphoblastic leukemia (ALL) with a history of central nervous system (CNS) involvement, either at diagnosis or relapse, poses challenges when the decision is made to proceed with allogeneic hematopoietic cell transplantation (alloHCT), as there is no evidence-based consensus on the best peri-transplantation approach to reduce subsequent CNS relapse risk. Here, we retrospectively analyzed outcomes of 87 patients with ALL and a history of CNS involvement who later underwent alloHCT. Patients with pretransplantation CNS involvement had higher risk of CNS relapse after transplantation (2-year CNS relapse: 9.6% versus 1.4%, P < .0001), inferior event-free survival (EFS) (hazard ratio [HR], 1.52; P = .003), and worse overall survival (OS) (HR, 1.55; P = .003) compared with patients without pretransplantation CNS involvement (n = 543). There was no difference in post-transplantation CNS relapse, EFS, or OS among patients presenting with CNS involvement at diagnosis, those with isolated CNS relapse, and those with combined bone marrow and CNS relapse before HCT. Interestingly, neither pretransplantation cranial irradiation, use of total body irradiation-based conditioning, nor post-transplantation prophylactic intrathecal chemotherapy were associated with a reduction of CNS relapse risk after transplantation. Thus, among the patients in the cohort studied, there was no clear benefit of CNS-directed therapy in the peri-transplantation period among patients who had prior CNS involvement and underwent subsequent alloHCT.",Comparative Study,1555.0,11.0,Acute lymphoblastic ALL with a history of central nervous system CNS involvement either at diagnosis or relapse poses challenges when the decision is made to proceed with allogeneic hematopoietic cell transplantation alloHCT as there is no evidence-based consensus on the best peri-transplantation approach to reduce subsequent CNS relapse risk Here we retrospectively analyzed outcomes of 87 patients with ALL and a history of CNS involvement who later underwent alloHCT Patients with pretransplantation CNS involvement had higher risk of CNS relapse after transplantation 2-year CNS relapse 9.6 versus 1.4 P .0001 inferior event-free survival EFS hazard ratio HR 1.52 P .003 and worse overall survival OS HR 1.55 P .003 compared with patients without pretransplantation CNS involvement n 543 There was no difference in post-transplantation CNS relapse EFS or OS among patients presenting with CNS involvement at diagnosis those with isolated CNS relapse and those with combined marrow and CNS relapse before HCT Interestingly neither pretransplantation cranial irradiation use of total body irradiation-based conditioning nor post-transplantation prophylactic intrathecal chemotherapy were associated with a reduction of CNS relapse risk after transplantation Thus among the patients in the cohort studied there was no clear benefit of CNS-directed therapy in the peri-transplantation period among patients who had prior CNS involvement and underwent subsequent alloHCT,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 5, 8, 532, 1, 854, 1880, 398, 1025, 799, 361, 28, 147, 15, 429, 7056, 1427, 198, 3, 948, 16, 1229, 6, 6174, 5, 1063, 1007, 31, 497, 5514, 22, 125, 16, 77, 241, 90, 1391, 23, 3, 824, 6164, 497, 353, 6, 969, 706, 1025, 429, 43, 467, 21, 894, 311, 123, 1, 912, 7, 5, 62, 2, 8, 532, 1, 1025, 799, 54, 1559, 208, 5514, 7, 5, 9367, 1025, 799, 42, 142, 43, 1, 1025, 429, 50, 497, 18, 111, 1025, 429, 83, 49, 185, 14, 39, 19, 488, 1663, 774, 115, 25, 1683, 360, 197, 168, 14, 653, 19, 1421, 2, 639, 63, 25, 118, 168, 14, 614, 19, 1421, 72, 5, 7, 187, 9367, 1025, 799, 78, 11943, 125, 10, 77, 523, 4, 539, 497, 1025, 429, 1683, 15, 118, 107, 7, 1656, 5, 1025, 799, 28, 147, 135, 5, 1355, 1025, 429, 2, 135, 5, 397, 581, 2, 1025, 429, 348, 1085, 2873, 2174, 9367, 2565, 1104, 119, 1, 181, 642, 1104, 90, 1933, 2110, 539, 497, 1862, 5126, 56, 11, 41, 5, 8, 628, 1, 1025, 429, 43, 50, 497, 631, 107, 3, 7, 4, 3, 180, 656, 125, 10, 77, 885, 247, 1, 1025, 1166, 36, 4, 3, 6164, 497, 727, 107, 7, 54, 42, 324, 1025, 799, 2, 208, 706, 5514]",1471.0,26493564,315
"Evaluation and Outcome of Central Nervous System Involvement in Pediatric Acute Lymphoblastic Leukemia in Dar es Salaam, Tanzania.",Pediatric blood & cancer,Pediatr Blood Cancer,2015-11-03,"Outcomes for acute lymphoblastic leukemia (ALL) in low-income countries lag far behind high-income countries (HIC). We explored the impact of central nervous system (CNS) involvement on outcome of pediatric patients with ALL in Tanzania. Comprehensive chart review was performed to characterize CNS involvement, treatment, and outcomes of pediatric patients with ALL at Muhimbili National Hospital in Dar es Salaam, Tanzania between January 1, 2011 and December 31, 2013. One hundred fifty-six patients with confirmed ALL had accessible data, and 128 initiated therapy. Sixteen percent of 156 patients had a documented cerebral spinal fluid analysis by cytospin. Seventy patients (45%) had a documented lumbar puncture with intrathecal (IT) therapy within 1 week of diagnosis. Thirteen patients presented with CNS involvement at diagnosis based on cytospin and/or unequivocal symptoms. Twenty-one patients (16%) experienced CNS relapse, three of whom had CNS disease at diagnosis. Median event-free survival (EFS) for all patients was 7.9 months and estimated EFS at 24 months was 31%. For the patients with CNS involvement at diagnosis, the estimated EFS at 24 months was 45%. Only three of 21 patients with CNS relapse were still alive with a median follow up of 3 months. The rate of CNS disease in patients with ALL in Dar es Salaam at diagnosis and relapse was higher than that reported in HIC, and overall survival was lower. Improving outcomes will require further advances including consistent CNS prophylaxis and may include targeting high-risk patients with additional IT treatments.",Journal Article,1540.0,0.0,Outcomes for acute lymphoblastic ALL in low-income countries lag far behind high-income countries HIC We explored the impact of central nervous system CNS involvement on outcome of pediatric patients with ALL in Tanzania Comprehensive chart review was performed to characterize CNS involvement treatment and outcomes of pediatric patients with ALL at Muhimbili National Hospital in Dar es Salaam Tanzania between January 1 2011 and December 31 2013 One hundred fifty-six patients with confirmed ALL had accessible data and 128 initiated therapy Sixteen percent of 156 patients had a documented cerebral spinal fluid analysis by cytospin Seventy patients 45 had a documented lumbar puncture with intrathecal IT therapy within 1 week of diagnosis Thirteen patients presented with CNS involvement at diagnosis based on cytospin and/or unequivocal symptoms Twenty-one patients 16 experienced CNS relapse three of whom had CNS disease at diagnosis Median event-free survival EFS for all patients was 7.9 months and estimated EFS at 24 months was 31 For the patients with CNS involvement at diagnosis the estimated EFS at 24 months was 45 Only three of 21 patients with CNS relapse were still alive with a median follow up of 3 months The rate of CNS disease in patients with ALL in Dar es Salaam at diagnosis and relapse was higher than that reported in HIC and overall survival was lower Improving outcomes will require further advances including consistent CNS prophylaxis and may include targeting high-risk patients with additional IT treatments,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[123, 9, 286, 1275, 62, 4, 154, 2306, 2115, 7650, 3272, 5219, 64, 2306, 2115, 13390, 21, 1443, 3, 345, 1, 854, 1880, 398, 1025, 799, 23, 228, 1, 815, 7, 5, 62, 4, 24082, 949, 2937, 206, 10, 173, 6, 1507, 1025, 799, 24, 2, 123, 1, 815, 7, 5, 62, 28, 67072, 657, 702, 4, 49377, 3011, 49378, 24082, 59, 1024, 14, 1132, 2, 1397, 456, 1346, 104, 1128, 1461, 437, 7, 5, 557, 62, 42, 5981, 74, 2, 3990, 1917, 36, 3228, 714, 1, 5693, 7, 42, 8, 1405, 3549, 1499, 2357, 65, 20, 23127, 2073, 7, 512, 42, 8, 1405, 6187, 12104, 5, 5126, 192, 36, 262, 14, 647, 1, 147, 3170, 7, 917, 5, 1025, 799, 28, 147, 90, 23, 23127, 2, 15, 14775, 507, 737, 104, 7, 245, 592, 1025, 429, 169, 1, 953, 42, 1025, 34, 28, 147, 52, 774, 115, 25, 1683, 9, 62, 7, 10, 67, 83, 53, 2, 661, 1683, 28, 259, 53, 10, 456, 9, 3, 7, 5, 1025, 799, 28, 147, 3, 661, 1683, 28, 259, 53, 10, 512, 158, 169, 1, 239, 7, 5, 1025, 429, 11, 1234, 1701, 5, 8, 52, 166, 126, 1, 27, 53, 3, 116, 1, 1025, 34, 4, 7, 5, 62, 4, 49377, 3011, 49378, 28, 147, 2, 429, 10, 142, 76, 17, 210, 4, 13390, 2, 63, 25, 10, 280, 1673, 123, 303, 1353, 195, 954, 141, 925, 1025, 2049, 2, 68, 643, 529, 64, 43, 7, 5, 402, 192, 640]",1544.0,26529141,186
De Novo MYC and BCL2 Double-hit B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) in Pediatric and Young Adult Patients Associated With Poor Prognosis.,Pediatric hematology and oncology,Pediatr Hematol Oncol,2015-11-11,"MYC and BCL2 translocations in B-cell lymphomas are defined as ""double-hit"" associated with poor prognosis in adult patients. Such double-hit events are extremely rare in B-cell precursor acute lymphoblastic leukemia (BCP-ALL), especially in pediatric patients or young adults. This study is to investigate the clinical manifestation of de novo MYCyBCL2 double-hit BCP-ALL in young patients. Two pediatric and one young adult patients were identified after a retrospective data review and all without previous history of lymphoma. There were two females and one male aged 15, 18, and 24, respectively. All patients had an unremarkable medical history before presenting with extensive bone marrow and central nervous system involvement at diagnosis. Flow cytometry immunophenotypic analysis showed an immature B-cell immunophenotype (CD10+, CD19+, TdT+, surface Ig-) and immunohistochemistry showed high expression of MYC and BCL2 in all cases. All patients showed complex karyotypes associated with 8q24 abnormalities in the form of t(8;9)(q24;p13) or t(8;14)(q24;q32) and t(14;18)(q32;q21) and fluorescence in situ hybridization confirmed MYC and BCL2 rearrangements. Two patients died of refractory disease or disease progression 7 and 13 months after initial diagnosis, respectively, and the third patient was treated with protocol AALL0232 under the Children's Oncology Group study, achieved complete remission and remained in remission for 53 months at last follow-up. Our study showed that De novo MYCyBCL2 double-hit BCP-ALL is a rare disease that also occurs in pediatric and young adult patients and associated with complex karyotypes and poor prognosis. Younger patients may benefit from intensified chemotherapy. ",Journal Article,1532.0,10.0,MYC and BCL2 translocations in B-cell lymphomas are defined as `` double-hit '' associated with poor prognosis in adult patients Such double-hit events are extremely rare in B-cell precursor acute lymphoblastic BCP-ALL especially in pediatric patients or young adults This study is to investigate the clinical manifestation of de novo MYCyBCL2 double-hit BCP-ALL in young patients Two pediatric and one young adult patients were identified after a retrospective data review and all without previous history of There were two females and one male aged 15 18 and 24 respectively All patients had an unremarkable medical history before presenting with extensive marrow and central nervous system involvement at diagnosis Flow cytometry immunophenotypic analysis showed an immature B-cell immunophenotype CD10+ CD19+ TdT+ surface Ig- and immunohistochemistry showed high expression of MYC and BCL2 in all cases All patients showed complex karyotypes associated with 8q24 abnormalities in the form of t 8 9 q24 p13 or t 8 14 q24 q32 and t 14 18 q32 q21 and fluorescence in situ hybridization confirmed MYC and BCL2 rearrangements Two patients died of refractory disease or disease progression 7 and 13 months after initial diagnosis respectively and the third patient was treated with protocol AALL0232 under the Children 's Oncology Group study achieved complete remission and remained in remission for 53 months at last follow-up Our study showed that De novo MYCyBCL2 double-hit BCP-ALL is a rare disease that also occurs in pediatric and young adult patients and associated with complex karyotypes and poor prognosis Younger patients may benefit from intensified chemotherapy,0,0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1371, 2, 3214, 3262, 4, 132, 31, 1557, 32, 395, 22, 1627, 6519, 522, 41, 5, 334, 356, 4, 780, 7, 225, 1627, 6519, 281, 32, 2938, 622, 4, 132, 31, 2765, 286, 1275, 13168, 62, 1093, 4, 815, 7, 15, 1169, 857, 26, 45, 16, 6, 963, 3, 38, 6746, 1, 1566, 2018, 49399, 1627, 6519, 13168, 62, 4, 1169, 7, 100, 815, 2, 104, 1169, 780, 7, 11, 108, 50, 8, 459, 74, 206, 2, 62, 187, 698, 532, 1, 125, 11, 100, 2451, 2, 104, 1045, 1032, 167, 203, 2, 259, 106, 62, 7, 42, 35, 20197, 484, 532, 348, 1656, 5, 1344, 581, 2, 854, 1880, 398, 799, 28, 147, 1412, 1914, 6599, 65, 224, 35, 5733, 132, 31, 5496, 6289, 3158, 10970, 1255, 4200, 2, 888, 224, 64, 55, 1, 1371, 2, 3214, 4, 62, 140, 62, 7, 224, 840, 6809, 41, 5, 6069, 1171, 4, 3, 1297, 1, 102, 66, 83, 13487, 7914, 15, 102, 66, 213, 13487, 7576, 2, 102, 213, 203, 7576, 10524, 2, 1591, 4, 957, 1554, 557, 1371, 2, 3214, 2072, 100, 7, 1016, 1, 430, 34, 15, 34, 91, 67, 2, 233, 53, 50, 388, 147, 106, 2, 3, 1282, 69, 10, 73, 5, 1182, 32436, 669, 3, 541, 292, 413, 87, 45, 513, 236, 734, 2, 958, 4, 734, 9, 699, 53, 28, 1060, 166, 126, 114, 45, 224, 17, 1566, 2018, 49399, 1627, 6519, 13168, 62, 16, 8, 622, 34, 17, 120, 1780, 4, 815, 2, 1169, 780, 7, 2, 41, 5, 840, 6809, 2, 334, 356, 773, 7, 68, 247, 29, 7311, 56]",1674.0,26558423,7
CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date.,"Cancer journal (Sudbury, Mass.)",Cancer J,,"Recently, immunotherapy for cancer has begun to garner traction with encouraging results in a number of malignancies. Included within this arena has been the genetic engineering of autologous T cells with chimeric antigen receptors (CARs) against tumor target. The majority of this experience has included the use of CAR T cells directed against CD19 for B-cell hematologic malignancies. The most striking efficacy to date with CAR T cells directed against CD19 has been in relapsed and refractory B-cell acute lymphoblastic leukemia, with the overwhelming majority of patients experiencing complete remissions. In addition, single-center and largely early-phase studies have demonstrated responses in patients with varying histologic findings of relapsed and refractory B-cell non-Hodgkin lymphoma. The favorable response rates seen with this technology have been tempered by the high risk of toxicity, particularly in the form of cytokine-release syndrome and neurotoxicity. Agents such as tocilizumab and corticosteroids have been used to treat these toxicities. The current state of the science includes strategies to circumvent and treat toxicity, manufacturing, and study of later-generation CAR constructs with the intention of improving efficacy and development of CARs against other tumor targets for both hematologic and solid tumor malignancies. The observation of an early efficacy ensures further integration and development of this modality into future immunotherapeutic strategies for various cancers. ",Journal Article,,17.0,Recently immunotherapy for cancer has begun to garner traction with encouraging results in a number of malignancies Included within this arena has been the genetic engineering of autologous T cells with chimeric antigen receptors CARs against tumor target The majority of this experience has included the use of CAR T cells directed against CD19 for B-cell hematologic malignancies The most striking efficacy to date with CAR T cells directed against CD19 has been in relapsed and refractory B-cell acute lymphoblastic with the overwhelming majority of patients experiencing complete remissions In addition single-center and largely early-phase studies have demonstrated responses in patients with varying histologic findings of relapsed and refractory B-cell The favorable response rates seen with this technology have been tempered by the high risk of toxicity particularly in the form of cytokine-release syndrome and neurotoxicity Agents such as tocilizumab and corticosteroids have been used to treat these toxicities The current state of the science includes strategies to circumvent and treat toxicity manufacturing and study of later-generation CAR constructs with the intention of improving efficacy and development of CARs against other tumor targets for both hematologic and solid tumor malignancies The observation of an early efficacy ensures further integration and development of this modality into future immunotherapeutic strategies for various cancers,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[761, 726, 9, 12, 71, 6973, 6, 30702, 22614, 5, 2269, 99, 4, 8, 207, 1, 441, 159, 262, 26, 10730, 71, 85, 3, 336, 6717, 1, 1028, 102, 37, 5, 2897, 448, 1186, 7441, 480, 30, 283, 3, 686, 1, 26, 730, 71, 159, 3, 119, 1, 1881, 102, 37, 1166, 480, 3158, 9, 132, 31, 813, 441, 3, 96, 5133, 209, 6, 1244, 5, 1881, 102, 37, 1166, 480, 3158, 71, 85, 4, 591, 2, 430, 132, 31, 286, 1275, 5, 3, 10075, 686, 1, 7, 2985, 236, 3166, 4, 352, 226, 574, 2, 1733, 191, 124, 94, 47, 264, 253, 4, 7, 5, 2990, 884, 272, 1, 591, 2, 430, 132, 31, 3, 913, 51, 151, 527, 5, 26, 2033, 47, 85, 18555, 20, 3, 64, 43, 1, 155, 823, 4, 3, 1297, 1, 1675, 2008, 681, 2, 3561, 183, 225, 22, 29436, 2, 3876, 47, 85, 95, 6, 943, 46, 385, 3, 291, 1309, 1, 3, 3797, 1920, 422, 6, 8602, 2, 943, 155, 12869, 2, 45, 1, 1559, 914, 1881, 5500, 5, 3, 3205, 1, 1673, 209, 2, 193, 1, 7441, 480, 127, 30, 637, 9, 110, 813, 2, 537, 30, 441, 3, 1664, 1, 35, 191, 209, 18467, 195, 2676, 2, 193, 1, 26, 1396, 237, 508, 3222, 422, 9, 747, 163]",1469.0,26588678,242
The use of novel monoclonal antibodies in the treatment of acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2015-01-01,"Regardless of age, patients with relapsed or refractory acute lymphoblastic leukemia (ALL) have extremely poor outcomes. The success of reinduction chemotherapy remains dismal, because complete remission rates are low and seldom durable. Clearly, new and novel strategies are needed to improve the outcome of patients with relapsed or refractory ALL. Patients with early relapse, especially those still receiving chemotherapy, tend to have a much poorer outcome and are often chemotherapy resistant. Although high-dose approaches may overcome chemotherapy resistance, long-term disease-free and overall survival remains limited. Several approaches have been used to target antigens, including cluster of differentiation (CD) 19, CD20, CD22, and CD52, on the surface of the malignant lymphoblast with striking efficacy. This review will focus on the clinical application of the major classes of antibodies, including naked antibodies, drug-antibody conjugates, immunotoxins, and T cell-engaging bispecific antibodies. Hopefully, these novel monoclonal antibodies will result in a significant improvement in the outcome of patients with relapsed or refractory ALL. ",Journal Article,1846.0,12.0,Regardless of age patients with relapsed or refractory acute lymphoblastic ALL have extremely poor outcomes The success of reinduction chemotherapy remains dismal because complete remission rates are low and seldom durable Clearly new and novel strategies are needed to improve the outcome of patients with relapsed or refractory ALL Patients with early relapse especially those still receiving chemotherapy tend to have a much poorer outcome and are often chemotherapy resistant Although high-dose approaches may overcome chemotherapy resistance long-term disease-free and overall survival remains limited Several approaches have been used to target antigens including cluster of differentiation CD 19 CD20 CD22 and CD52 on the surface of the malignant lymphoblast with striking efficacy This review will focus on the clinical application of the major classes of antibodies including naked antibodies drug-antibody conjugates immunotoxins and T cell-engaging bispecific antibodies Hopefully these novel monoclonal antibodies will result in a significant improvement in the outcome of patients with relapsed or refractory ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1583, 1, 89, 7, 5, 591, 15, 430, 286, 1275, 62, 47, 2938, 334, 123, 3, 1825, 1, 10177, 56, 469, 3929, 408, 236, 734, 151, 32, 154, 2, 10805, 1480, 2536, 217, 2, 229, 422, 32, 575, 6, 401, 3, 228, 1, 7, 5, 591, 15, 430, 62, 7, 5, 191, 429, 1093, 135, 1234, 357, 56, 5406, 6, 47, 8, 1802, 1769, 228, 2, 32, 629, 56, 436, 242, 64, 61, 611, 68, 1768, 56, 251, 319, 337, 34, 115, 2, 63, 25, 469, 383, 392, 611, 47, 85, 95, 6, 283, 1575, 141, 3132, 1, 910, 4420, 326, 2198, 7599, 2, 7189, 23, 3, 1255, 1, 3, 393, 19414, 5, 5133, 209, 26, 206, 303, 1222, 23, 3, 38, 1581, 1, 3, 458, 3211, 1, 890, 141, 11975, 890, 234, 548, 5968, 17170, 2, 102, 31, 8534, 7408, 890, 7464, 46, 229, 848, 890, 303, 757, 4, 8, 93, 767, 4, 3, 228, 1, 7, 5, 591, 15, 430, 62]",1125.0,26637749,103
Acute respiratory infections in children and adolescents with acute lymphoblastic leukemia.,Cancer,Cancer,2015-12-23,"Knowledge regarding the incidence, clinical course, and impact of respiratory viral infections in children with acute lymphoblastic leukemia (ALL) is limited. A retrospective cohort of patients with newly diagnosed ALL who were treated on the Total Therapy XVI protocol at St Jude Children's Research Hospital between 2007 and 2011 was evaluated. Of 223 children, 95 (43%) developed 133 episodes of viral acute respiratory illness (ARI) (incidence, 1.1 per 1000 patient-days). ARI without viral etiology was identified in 65 patients (29%) and no ARI was detected in 63 patients (28%). There were no significant associations noted between race, sex, age, or ALL risk group and the development of ARI. Children receiving induction chemotherapy were found to be at the highest risk of viral ARI (incidence, 2.3 per 1000 patient-days). Influenza virus was the most common virus (38%) followed by respiratory syncytial virus (33%). Of 133 episodes of viral ARI, 61% of patients were hospitalized, 26% experienced a complicated course, 80% had their chemotherapy delayed, and 0.7% of patients died. Twenty-four patients (18%) developed viral lower respiratory tract infections (LRTI), 5 of whom (21%) had complications. Patients with viral LRTI had a significantly lower nadir absolute lymphocyte count; were sicker at the time of presentation; and were more likely to have respiratory syncytial virus, to be hospitalized, and to have their chemotherapy delayed for longer compared with those with viral upper respiratory tract infections. Despite the low incidence of viral ARI in children with ALL, the associated morbidity, mortality, and delay in chemotherapy remain clinically significant. Viral LRTI was especially associated with high morbidity requiring intensive care-level support. Cancer 2016;122:798-805.  2015 American Cancer Society.",Journal Article,1490.0,17.0,Knowledge regarding the incidence clinical course and impact of respiratory viral infections in children with acute lymphoblastic ALL is limited A retrospective cohort of patients with newly diagnosed ALL who were treated on the Total Therapy XVI protocol at St Jude Children 's Research Hospital between 2007 and 2011 was evaluated Of 223 children 95 43 developed 133 episodes of viral acute respiratory illness ARI incidence 1.1 per 1000 patient-days ARI without viral etiology was identified in 65 patients 29 and no ARI was detected in 63 patients 28 There were no significant associations noted between race sex age or ALL risk group and the development of ARI Children receiving induction chemotherapy were found to be at the highest risk of viral ARI incidence 2.3 per 1000 patient-days Influenza virus was the most common virus 38 followed by respiratory syncytial virus 33 Of 133 episodes of viral ARI 61 of patients were hospitalized 26 experienced a complicated course 80 had their chemotherapy delayed and 0.7 of patients died Twenty-four patients 18 developed viral lower respiratory tract infections LRTI 5 of whom 21 had complications Patients with viral LRTI had a significantly lower nadir absolute lymphocyte count were sicker at the time of presentation and were more likely to have respiratory syncytial virus to be hospitalized and to have their chemotherapy delayed for longer compared with those with viral upper respiratory tract infections Despite the low incidence of viral ARI in children with ALL the associated morbidity mortality and delay in chemotherapy remain clinically significant Viral LRTI was especially associated with high morbidity requiring intensive care-level support Cancer 2016 122:798-805  2015 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[922, 666, 3, 287, 38, 906, 2, 345, 1, 2718, 1667, 1875, 4, 541, 5, 286, 1275, 62, 16, 383, 8, 459, 180, 1, 7, 5, 732, 265, 62, 54, 11, 73, 23, 3, 181, 36, 25082, 1182, 28, 3062, 4841, 541, 292, 389, 702, 59, 1307, 2, 1132, 10, 194, 1, 3907, 541, 48, 601, 276, 5026, 3750, 1, 1667, 286, 2718, 2973, 18048, 287, 14, 14, 379, 2345, 69, 162, 18048, 187, 1667, 2855, 10, 108, 4, 556, 7, 462, 2, 77, 18048, 10, 530, 4, 676, 7, 339, 125, 11, 77, 93, 685, 1051, 59, 1047, 1035, 89, 15, 62, 43, 87, 2, 3, 193, 1, 18048, 541, 357, 504, 56, 11, 204, 6, 40, 28, 3, 1076, 43, 1, 1667, 18048, 287, 18, 27, 379, 2345, 69, 162, 7219, 1450, 10, 3, 96, 186, 1450, 519, 370, 20, 2718, 16744, 1450, 466, 1, 5026, 3750, 1, 1667, 18048, 713, 1, 7, 11, 4795, 432, 592, 8, 4286, 906, 493, 42, 136, 56, 1612, 2, 13, 67, 1, 7, 1016, 737, 294, 7, 203, 276, 1667, 280, 2718, 1696, 1875, 20901, 33, 1, 953, 239, 42, 521, 7, 5, 1667, 20901, 42, 8, 97, 280, 3686, 1766, 1448, 1276, 11, 28028, 28, 3, 98, 1, 1031, 2, 11, 80, 322, 6, 47, 2718, 16744, 1450, 6, 40, 4795, 2, 6, 47, 136, 56, 1612, 9, 589, 72, 5, 135, 5, 1667, 1726, 2718, 1696, 1875, 550, 3, 154, 287, 1, 1667, 18048, 4, 541, 5, 62, 3, 41, 787, 282, 2, 1984, 4, 56, 918, 505, 93, 1667, 20901, 10, 1093, 41, 5, 64, 787, 1888, 1686, 165, 301, 538, 12, 1390, 3285, 13049, 13628, 2206, 1483, 597, 12, 1174]",1766.0,26700662,777
Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission.,American journal of hematology,Am. J. Hematol.,2016-03-01,"For adults with Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL) in first complete remission (CR1), allogeneic hematopoietic cell transplantation (HCT) is an established curative strategy. However, pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT. We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen. At 4 years of follow-up, incidence of relapse after HCT was 24% (95% CI 19-28) versus 23% (95% CI 15-32) for the non-HCT (chemo) cohort (P=0.97). Treatment-related mortality (TRM) was higher in the HCT cohort [HCT 37% (95% CI 31-42) versus chemo 6% (95% CI 3-12), P<0.0001]. DFS in the HCT cohort was 40% (95% CI 35-45) versus 71% (95% CI 60-79) for chemo, P<0.0001. Similarly, OS favored chemo [HCT 45% (95% CI 40-50)] versus chemo 73% [(95% CI 63-81), P<0.0001]. In multivariable analysis, the sole factor predictive of shorter OS was the administration of HCT [hazard ratio 3.12 (1.99-4.90), P<0.0001]. For younger adults with Ph- ALL, pediatric-inspired chemotherapy had lower TRM, no increase in relapse, and superior overall survival compared to HCT. Am. J. Hematol. 91:322-329, 2016.  2015 Wiley Periodicals, Inc. ",Comparative Study,1421.0,31.0,For adults with Philadelphia chromosome-negative Ph- acute lymphoblastic ALL in first complete remission CR1 allogeneic hematopoietic cell transplantation HCT is an established curative strategy However pediatric-inspired chemotherapy may also offer durable leukemia-free survival in the absence of HCT We compared 422 HCT recipients aged 18-50 years with Ph-ALL in CR1 reported to the CIBMTR with an age-matched concurrent cohort of 108 Ph- ALL CR1 patients who received a Dana-Farber Consortium pediatric-inspired non-HCT regimen At 4 years of follow-up incidence of relapse after HCT was 24 95 CI 19-28 versus 23 95 CI 15-32 for the non-HCT chemo cohort P=0.97 Treatment-related mortality TRM was higher in the HCT cohort HCT 37 95 CI 31-42 versus chemo 6 95 CI 3-12 P 0.0001 DFS in the HCT cohort was 40 95 CI 35-45 versus 71 95 CI 60-79 for chemo P 0.0001 Similarly OS favored chemo HCT 45 95 CI 40-50 versus chemo 73 95 CI 63-81 P 0.0001 In multivariable analysis the sole factor predictive of shorter OS was the administration of HCT hazard ratio 3.12 1.99-4.90 P 0.0001 For younger adults with Ph- ALL pediatric-inspired chemotherapy had lower TRM no increase in relapse and superior overall survival compared to HCT Am J. Hematol 91:322-329 2016  2015 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 857, 5, 3006, 1170, 199, 2058, 286, 1275, 62, 4, 157, 236, 734, 4516, 1063, 1007, 31, 497, 1085, 16, 35, 635, 1075, 692, 137, 815, 13161, 56, 68, 120, 1918, 1480, 2647, 115, 25, 4, 3, 1127, 1, 1085, 21, 72, 10581, 1085, 2190, 1032, 203, 212, 60, 5, 2058, 62, 4, 4516, 210, 6, 3, 11203, 5, 35, 89, 655, 750, 180, 1, 3590, 2058, 62, 4516, 7, 54, 103, 8, 4932, 4979, 2404, 815, 13161, 220, 1085, 477, 28, 39, 60, 1, 166, 126, 287, 1, 429, 50, 1085, 10, 259, 48, 58, 326, 339, 185, 382, 48, 58, 167, 531, 9, 3, 220, 1085, 3341, 180, 19, 13, 1015, 24, 139, 282, 5064, 10, 142, 4, 3, 1085, 180, 1085, 567, 48, 58, 456, 595, 185, 3341, 49, 48, 58, 27, 133, 19, 13, 488, 1010, 4, 3, 1085, 180, 10, 327, 48, 58, 465, 512, 185, 792, 48, 58, 335, 842, 9, 3341, 19, 13, 488, 1813, 118, 5269, 3341, 1085, 512, 48, 58, 327, 212, 185, 3341, 803, 48, 58, 676, 865, 19, 13, 488, 4, 658, 65, 3, 4991, 161, 464, 1, 985, 118, 10, 3, 634, 1, 1085, 360, 197, 27, 133, 14, 1058, 39, 424, 19, 13, 488, 9, 773, 857, 5, 2058, 62, 815, 13161, 56, 42, 280, 5064, 77, 344, 4, 429, 2, 1123, 63, 25, 72, 6, 1085, 5886, 3543, 13175, 970, 8024, 8766, 1390, 2206, 1483, 4692, 5493, 3479]",1283.0,26701142,672
Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2015-12-21,"The American Society for Blood and Marrow Transplantation (ASBMT) Clinical Case Forum (CCF) was launched in 2014 as an online secure tool to enhance interaction and communication among hematopoietic cell transplantation (HCT) professionals worldwide through the discussion of challenging clinical care issues. After 14 months, we reviewed clinical and demographical data of cases posted in the CCF from January 29, 2014 to March 18, 2015. A total of 137 cases were posted during the study period. Ninety-two cases (67%) were allogeneic HCT, 29 (21%) were autologous HCT, and in 16 (12%), the type of transplantation (autologous versus allogeneic) was still under consideration. The diseases most frequently discussed included non-Hodgkin lymphoma (NHL; n = 30, 22%), acute myeloid leukemia (n = 23, 17%), and multiple myeloma (MM; n = 20, 15%). When compared with the US transplantation activity reported by the US Department of Health and Human Services, NHL and acute lymphoblastic leukemia cases were over-represented in the CCF, whereas MM was under-represented (P < .001). A total of 259 topics were addressed in the CCF with a median of 2 topics/case (range, 1 to 6). Particularly common topics included whether transplantation was indicated (n = 57, 41%), conditioning regimen choice (n = 44, 32%), and post-HCT complications after day 100 (n = 43, 31%). The ASBMT CCF is a successful tool for collaborative discussion of complex cases in the HCT community worldwide and may allow identification of areas of controversy or unmet need from clinical, educational and research perspectives.",Journal Article,1492.0,4.0,The American Society for Blood and Marrow Transplantation ASBMT Clinical Case Forum CCF was launched in 2014 as an online secure tool to enhance interaction and communication among hematopoietic cell transplantation HCT professionals worldwide through the discussion of challenging clinical care issues After 14 months we reviewed clinical and demographical data of cases posted in the CCF from January 29 2014 to March 18 2015 A total of 137 cases were posted during the study period Ninety-two cases 67 were allogeneic HCT 29 21 were autologous HCT and in 16 12 the type of transplantation autologous versus allogeneic was still under consideration The diseases most frequently discussed included NHL n 30 22 acute myeloid n 23 17 and multiple MM n 20 15 When compared with the US transplantation activity reported by the US Department of Health and Human Services NHL and acute lymphoblastic cases were over-represented in the CCF whereas MM was under-represented P .001 A total of 259 topics were addressed in the CCF with a median of 2 topics/case range 1 to 6 Particularly common topics included whether transplantation was indicated n 57 41 conditioning regimen choice n 44 32 and post-HCT complications after day 100 n 43 31 The ASBMT CCF is a successful tool for collaborative discussion of complex cases in the HCT community worldwide and may allow identification of areas of controversy or unmet need from clinical educational and research perspectives,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 597, 1174, 9, 315, 2, 581, 497, 36166, 38, 473, 8037, 18605, 10, 13234, 4, 1409, 22, 35, 4123, 14520, 1515, 6, 1304, 915, 2, 2063, 107, 1007, 31, 497, 1085, 3409, 2358, 298, 3, 2488, 1, 1950, 38, 165, 1553, 50, 213, 53, 21, 446, 38, 2, 49494, 74, 1, 140, 17878, 4, 3, 18605, 29, 1024, 462, 1409, 6, 2363, 203, 1483, 8, 181, 1, 4352, 140, 11, 17878, 190, 3, 45, 727, 2493, 100, 140, 598, 11, 1063, 1085, 462, 239, 11, 1028, 1085, 2, 4, 245, 133, 3, 267, 1, 497, 1028, 185, 1063, 10, 1234, 669, 2415, 3, 1342, 96, 746, 1588, 159, 1176, 78, 201, 350, 286, 533, 78, 382, 269, 2, 232, 321, 78, 179, 167, 198, 72, 5, 3, 843, 497, 128, 210, 20, 3, 843, 4271, 1, 341, 2, 171, 2142, 1176, 2, 286, 1275, 140, 11, 252, 3324, 4, 3, 18605, 547, 321, 10, 669, 3324, 19, 144, 8, 181, 1, 7696, 4461, 11, 2814, 4, 3, 18605, 5, 8, 52, 1, 18, 4461, 473, 184, 14, 6, 49, 823, 186, 4461, 159, 317, 497, 10, 1103, 78, 696, 605, 1933, 477, 1866, 78, 584, 531, 2, 539, 1085, 521, 50, 218, 394, 78, 601, 456, 3, 36166, 18605, 16, 8, 1401, 1515, 9, 3737, 2488, 1, 840, 140, 4, 3, 1085, 1714, 2358, 2, 68, 1700, 911, 1, 1361, 1, 4089, 15, 3715, 594, 29, 38, 3624, 2, 389, 5856]",1463.0,26718665,67
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype.,Blood,Blood,2016-01-08,"Early T-cell precursor (ETP) acute lymphoblastic leukemia/lymphoma (ALL/LBL) is a recently recognized high-risk T lymphoblastic leukemia/lymphoma (T-ALL/LBL) subgroup. The optimal therapeutic approaches to adult patients with ETP-ALL/LBL are poorly characterized. In this study, we compared the outcomes of adults with ETP-ALL/LBL who received treatment on frontline regimens with those of patients with other T-ALL/LBL immunophenotypic subtypes. Patients with newly diagnosed T-ALL/LBL who received frontline chemotherapy between the years 2000 and 2014 at The University of Texas MD Anderson Cancer Center were identified and immunophenotypically categorized into early, thymic, and mature per the World Health Organization (WHO) classification using CD1a and surface CD3 status. Patients with ETP-ALL/LBL were identified on the basis of the following immunophenotypes: CD1a(-), CD8(-), CD5(-)(dim), and positivity for 1 or more stem cell or myeloid antigens. A total of 111 patients with T-ALL/LBL (68% T-ALL; 32% T-LBL) with adequate immunophenotype data were identified. The median age was 30 years (range, 13-79). There was no difference in the outcomes of patients based on the WHO subtypes. Nineteen patients (17%) had ETP-ALL/LBL. The complete remission rate /complete remission with incomplete platelet recovery rate in patients with ETP-ALL/LBL was significantly lower than that of non-ETP-ALL/LBL patients (73% vs 91%;P= .03). The median overall survival for patients with ETP-ALL/LBL was 20 months vs not reached for the non-ETP-ALL/LBL patients (P= .008). ETP-ALL/LBL represents a high-risk disease subtype of adult ALL. Novel treatment strategies are needed to improve treatment outcomes in this T-ALL/LBL subset. ",Journal Article,1474.0,84.0,Early T-cell precursor ETP acute lymphoblastic leukemia/lymphoma ALL/LBL is a recently recognized high-risk T lymphoblastic leukemia/lymphoma T-ALL/LBL subgroup The optimal therapeutic approaches to adult patients with ETP-ALL/LBL are poorly characterized In this study we compared the outcomes of adults with ETP-ALL/LBL who received treatment on frontline regimens with those of patients with other T-ALL/LBL immunophenotypic subtypes Patients with newly diagnosed T-ALL/LBL who received frontline chemotherapy between the years 2000 and 2014 at The University of Texas MD Anderson Cancer Center were identified and immunophenotypically categorized into early thymic and mature per the World Health Organization WHO classification using CD1a and surface CD3 status Patients with ETP-ALL/LBL were identified on the basis of the following immunophenotypes CD1a CD8 CD5 dim and positivity for 1 or more stem cell or myeloid antigens A total of 111 patients with T-ALL/LBL 68 T-ALL 32 T-LBL with adequate immunophenotype data were identified The median age was 30 years range 13-79 There was no difference in the outcomes of patients based on the WHO subtypes Nineteen patients 17 had ETP-ALL/LBL The complete remission rate /complete remission with incomplete platelet recovery rate in patients with ETP-ALL/LBL was significantly lower than that of non-ETP-ALL/LBL patients 73 vs 91 P= .03 The median overall survival for patients with ETP-ALL/LBL was 20 months vs not reached for the non-ETP-ALL/LBL patients P= .008 ETP-ALL/LBL represents a high-risk disease subtype of adult ALL Novel treatment strategies are needed to improve treatment outcomes in this T-ALL/LBL subset,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[191, 102, 31, 2765, 11985, 286, 1275, 2647, 4763, 62, 8315, 16, 8, 761, 1904, 64, 43, 102, 1275, 2647, 4763, 102, 62, 8315, 1363, 3, 665, 189, 611, 6, 780, 7, 5, 11985, 62, 8315, 32, 1240, 765, 4, 26, 45, 21, 72, 3, 123, 1, 857, 5, 11985, 62, 8315, 54, 103, 24, 23, 3171, 472, 5, 135, 1, 7, 5, 127, 102, 62, 8315, 6599, 814, 7, 5, 732, 265, 102, 62, 8315, 54, 103, 3171, 56, 59, 3, 60, 1081, 2, 1409, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 11, 108, 2, 24516, 2320, 237, 191, 3572, 2, 2908, 379, 3, 1956, 341, 2533, 54, 947, 75, 18288, 2, 1255, 3117, 156, 7, 5, 11985, 62, 8315, 11, 108, 23, 3, 877, 1, 3, 366, 16679, 18288, 968, 6349, 8657, 2, 1887, 9, 14, 15, 80, 452, 31, 15, 533, 1575, 8, 181, 1, 3167, 7, 5, 102, 62, 8315, 806, 102, 62, 531, 102, 8315, 5, 1658, 5496, 74, 11, 108, 3, 52, 89, 10, 201, 60, 184, 233, 842, 125, 10, 77, 523, 4, 3, 123, 1, 7, 90, 23, 3, 54, 814, 3498, 7, 269, 42, 11985, 62, 8315, 3, 236, 734, 116, 236, 734, 5, 2610, 1596, 1602, 116, 4, 7, 5, 11985, 62, 8315, 10, 97, 280, 76, 17, 1, 220, 11985, 62, 8315, 7, 803, 105, 970, 19, 680, 3, 52, 63, 25, 9, 7, 5, 11985, 62, 8315, 10, 179, 53, 105, 44, 1300, 9, 3, 220, 11985, 62, 8315, 7, 19, 2155, 11985, 62, 8315, 1449, 8, 64, 43, 34, 875, 1, 780, 62, 229, 24, 422, 32, 575, 6, 401, 24, 123, 4, 26, 102, 62, 8315, 697]",1673.0,26747249,221
Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary Therapy.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-01-11,"We sought to determine whether cranial radiotherapy (CRT) is necessary to prevent relapse in any subgroup of children with acute lymphoblastic leukemia (ALL). We obtained aggregate data on relapse and survival outcomes for 16,623 patients age 1 to 18 years old with newly diagnosed ALL treated between 1996 and 2007 by 10 cooperative study groups from around the world. The proportion of patients eligible for prophylactic CRT varied from 0% to 33% by trial and was not related to the proportion eligible for allogeneic stem-cell transplantation in first complete remission. Using a random effects model, with CRT as a dichotomous covariate, we performed a single-arm meta-analysis to compare event-free survival and cumulative incidence of isolated or any CNS relapse and isolated bone marrow relapse in high-risk subgroups of patients who either did or did not receive CRT. Although there was significant heterogeneity in all outcome end points according to trial, CRT was associated with a reduced risk of relapse only in the small subgroup of patients with overt CNS disease at diagnosis, who had a significantly lower risk of isolated CNS relapse (4% with CRT v 17% without CRT; P = .02) and a trend toward lower risk of any CNS relapse (7% with CRT v 17% without CRT; P = .09). However, this group had a relatively high rate of events regardless of whether or not they received CRT (32% [95% CI, 26% to 39%] v 34% [95% CI, 19% to 54%]; P = .8). CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols.",Journal Article,1471.0,36.0,"We sought to determine whether cranial radiotherapy CRT is necessary to prevent relapse in any subgroup of children with acute lymphoblastic ALL We obtained aggregate data on relapse and survival outcomes for 16,623 patients age 1 to 18 years old with newly diagnosed ALL treated between 1996 and 2007 by 10 cooperative study groups from around the world The proportion of patients eligible for prophylactic CRT varied from 0 to 33 by trial and was not related to the proportion eligible for allogeneic stem-cell transplantation in first complete remission Using a random effects model with CRT as a dichotomous covariate we performed a single-arm meta-analysis to compare event-free survival and cumulative incidence of isolated or any CNS relapse and isolated marrow relapse in high-risk subgroups of patients who either did or did not receive CRT Although there was significant heterogeneity in all outcome end points according to trial CRT was associated with a reduced risk of relapse only in the small subgroup of patients with overt CNS disease at diagnosis who had a significantly lower risk of isolated CNS relapse 4 with CRT v 17 without CRT P .02 and a trend toward lower risk of any CNS relapse 7 with CRT v 17 without CRT P .09 However this group had a relatively high rate of events regardless of whether or not they received CRT 32 95 CI 26 to 39 v 34 95 CI 19 to 54 P .8 CRT does not have an impact on the risk of relapse in children with ALL treated on contemporary protocols",0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 990, 6, 223, 317, 2565, 310, 1089, 16, 1493, 6, 1682, 429, 4, 500, 1363, 1, 541, 5, 286, 1275, 62, 21, 683, 7494, 74, 23, 429, 2, 25, 123, 9, 245, 16099, 7, 89, 14, 6, 203, 60, 1095, 5, 732, 265, 62, 73, 59, 2648, 2, 1307, 20, 79, 1690, 45, 271, 29, 3337, 3, 1956, 3, 920, 1, 7, 625, 9, 1862, 1089, 2051, 29, 13, 6, 466, 20, 160, 2, 10, 44, 139, 6, 3, 920, 625, 9, 1063, 452, 31, 497, 4, 157, 236, 734, 75, 8, 2324, 176, 202, 5, 1089, 22, 8, 14455, 6322, 21, 173, 8, 226, 475, 1742, 65, 6, 932, 774, 115, 25, 2, 967, 287, 1, 1355, 15, 500, 1025, 429, 2, 1355, 581, 429, 4, 64, 43, 1453, 1, 7, 54, 361, 205, 15, 205, 44, 560, 1089, 242, 125, 10, 93, 1144, 4, 62, 228, 396, 862, 768, 6, 160, 1089, 10, 41, 5, 8, 405, 43, 1, 429, 158, 4, 3, 302, 1363, 1, 7, 5, 7192, 1025, 34, 28, 147, 54, 42, 8, 97, 280, 43, 1, 1355, 1025, 429, 39, 5, 1089, 603, 269, 187, 1089, 19, 588, 2, 8, 853, 1317, 280, 43, 1, 500, 1025, 429, 67, 5, 1089, 603, 269, 187, 1089, 19, 1730, 137, 26, 87, 42, 8, 1352, 64, 116, 1, 281, 1583, 1, 317, 15, 44, 491, 103, 1089, 531, 48, 58, 432, 6, 587, 603, 562, 48, 58, 326, 6, 667, 19, 66, 1089, 1097, 44, 47, 35, 345, 23, 3, 43, 1, 429, 4, 541, 5, 62, 73, 23, 2667, 2189]",1492.0,26755523,700
Reduction in Late Mortality among 5-Year Survivors of Childhood Cancer.,The New England journal of medicine,N. Engl. J. Med.,2016-01-13,"Among patients in whom childhood cancer was diagnosed in the 1970s and 1980s, 18% of those who survived for 5 years died within the subsequent 25 years. In recent decades, cancer treatments have been modified with the goal of reducing life-threatening late effects. We evaluated late mortality among 34,033 patients in the Childhood Cancer Survivor Study cohort who survived at least 5 years after childhood cancer (i.e., cancer diagnosed before the age of 21 years) for which treatment was initiated during the period from 1970 through 1999. The median follow-up was 21 years (range, 5 to 38). We evaluated demographic and disease factors that were associated with death from health-related causes (i.e., conditions that exclude recurrence or progression of the original cancer and external causes but include the late effects of cancer therapy) using cumulative incidence and piecewise exponential models to estimate relative rates and 95% confidence intervals. Of the 3958 deaths that occurred during the study period, 1618 (41%) were attributable to health-related causes, including 746 deaths from subsequent neoplasms, 241 from cardiac causes, 137 from pulmonary causes, and 494 from other causes. A reduction in 15-year mortality was observed for death from any cause (from 12.4% in the early 1970s to 6.0% in the 1990s, P<0.001 for trend) and from health-related causes (from 3.5% to 2.1%, P<0.001 for trend). These reductions were attributable to decreases in the rates of death from subsequent neoplasm (P<0.001), cardiac causes (P<0.001), and pulmonary causes (P=0.04). Changes in therapy according to decade included reduced rates of cranial radiotherapy for acute lymphoblastic leukemia (85% in the 1970s, 51% in the 1980s, and 19% in the 1990s), of abdominal radiotherapy for Wilms' tumor (78%, 53%, and 43%, respectively), of chest radiotherapy for Hodgkin's lymphoma (87%, 79%, and 61%, respectively), and of anthracycline exposure. Reduction in treatment exposure was associated with reduced late mortality among survivors of acute lymphoblastic leukemia and Wilms' tumor. The strategy of lowering therapeutic exposure has contributed to an observed decline in late mortality among 5-year survivors of childhood cancer. (Funded by the National Cancer Institute and the American Lebanese-Syrian Associated Charities.).",Journal Article,1469.0,190.0,"Among patients in whom childhood cancer was diagnosed in the 1970s and 1980s 18 of those who survived for 5 years died within the subsequent 25 years In recent decades cancer treatments have been modified with the goal of reducing life-threatening late effects We evaluated late mortality among 34,033 patients in the Childhood Cancer Survivor Study cohort who survived at least 5 years after childhood cancer i.e. cancer diagnosed before the age of 21 years for which treatment was initiated during the period from 1970 through 1999 The median follow-up was 21 years range 5 to 38 We evaluated demographic and disease factors that were associated with death from health-related causes i.e. conditions that exclude recurrence or progression of the original cancer and external causes but include the late effects of cancer therapy using cumulative incidence and piecewise exponential models to estimate relative rates and 95 confidence intervals Of the 3958 deaths that occurred during the study period 1618 41 were attributable to health-related causes including 746 deaths from subsequent neoplasms 241 from causes 137 from pulmonary causes and 494 from other causes A reduction in 15-year mortality was observed for death from any cause from 12.4 in the early 1970s to 6.0 in the 1990s P 0.001 for trend and from health-related causes from 3.5 to 2.1 P 0.001 for trend These reductions were attributable to decreases in the rates of death from subsequent neoplasm P 0.001 causes P 0.001 and pulmonary causes P=0.04 Changes in therapy according to decade included reduced rates of cranial radiotherapy for acute lymphoblastic 85 in the 1970s 51 in the 1980s and 19 in the 1990s of abdominal radiotherapy for tumor 78 53 and 43 respectively of chest radiotherapy for 's 87 79 and 61 respectively and of anthracycline exposure Reduction in treatment exposure was associated with reduced late mortality among survivors of acute lymphoblastic and tumor The strategy of lowering therapeutic exposure has contributed to an observed decline in late mortality among 5-year survivors of childhood cancer Funded by the National Cancer Institute and the American Lebanese-Syrian Associated Charities",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[107, 7, 4, 953, 864, 12, 10, 265, 4, 3, 10868, 2, 8361, 203, 1, 135, 54, 2996, 9, 33, 60, 1016, 262, 3, 706, 243, 60, 4, 435, 1968, 12, 640, 47, 85, 1230, 5, 3, 1326, 1, 1818, 358, 3691, 807, 176, 21, 194, 807, 282, 107, 562, 5254, 7, 4, 3, 864, 12, 2628, 45, 180, 54, 2996, 28, 506, 33, 60, 50, 864, 12, 70, 563, 12, 265, 348, 3, 89, 1, 239, 60, 9, 92, 24, 10, 1917, 190, 3, 727, 29, 4868, 298, 2043, 3, 52, 166, 126, 10, 239, 60, 184, 33, 6, 519, 21, 194, 1540, 2, 34, 130, 17, 11, 41, 5, 273, 29, 341, 139, 1626, 70, 563, 1298, 17, 6262, 146, 15, 91, 1, 3, 2279, 12, 2, 1455, 1626, 84, 643, 3, 807, 176, 1, 12, 36, 75, 967, 287, 2, 17879, 9379, 274, 6, 1191, 580, 151, 2, 48, 307, 1582, 1, 3, 67483, 1043, 17, 489, 190, 3, 45, 727, 38718, 605, 11, 2971, 6, 341, 139, 1626, 141, 13595, 1043, 29, 706, 1179, 7086, 29, 1626, 4352, 29, 1087, 1626, 2, 10919, 29, 127, 1626, 8, 628, 4, 167, 111, 282, 10, 164, 9, 273, 29, 500, 708, 29, 133, 39, 4, 3, 191, 10868, 6, 49, 13, 4, 3, 7524, 19, 13, 144, 9, 853, 2, 29, 341, 139, 1626, 29, 27, 33, 6, 18, 14, 19, 13, 144, 9, 853, 46, 2153, 11, 2971, 6, 2140, 4, 3, 151, 1, 273, 29, 706, 2131, 19, 13, 144, 1626, 19, 13, 144, 2, 1087, 1626, 19, 13, 755, 400, 4, 36, 768, 6, 2025, 159, 405, 151, 1, 2565, 310, 9, 286, 1275, 772, 4, 3, 10868, 725, 4, 3, 8361, 2, 326, 4, 3, 7524, 1, 1467, 310, 9, 30, 833, 699, 2, 601, 106, 1, 1662, 310, 9, 292, 912, 842, 2, 713, 106, 2, 1, 2044, 645, 628, 4, 24, 645, 10, 41, 5, 405, 807, 282, 107, 332, 1, 286, 1275, 2, 30, 3, 692, 1, 8326, 189, 645, 71, 3447, 6, 35, 164, 1858, 4, 807, 282, 107, 33, 111, 332, 1, 864, 12, 3827, 20, 3, 657, 12, 1377, 2, 3, 597, 14666, 13671, 41, 14667]",2190.0,26761625,523
Impaired mitochondrial function is abrogated by dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors.,Cancer,Cancer,2016-01-13,"Impaired cardiac function in doxorubicin-treated childhood cancer survivors is partly mediated by the disruption of mitochondrial energy production. Doxorubicin intercalates into mitochondrial DNA (mtDNA) and disrupts genes encoding for polypeptides that make adenosine triphosphate. This cross-sectional study examined mtDNA copy numbers per cell and oxidative phosphorylation (OXPHOS) in peripheral blood mononuclear cells (PBMCs) in 64 childhood survivors of high-risk acute lymphoblastic leukemia (ALL) who had been treated on Dana-Farber Cancer Institute childhood ALL protocols and had received doxorubicin alone (42%) or doxorubicin with the cardioprotectant dexrazoxane (58%). The number of mtDNA copies per cell and the OXPHOS enzyme activity of nicotinamide adenine dinucleotide dehydrogenase (complex I [CI]) and cytochrome c oxidase (complex IV [CIV]) were measured with quantitative real-time polymerase chain reaction immunoassays and thin-layer chromatography, respectively. At a median follow-up of 7.8 years after treatment, the median number of mtDNA copies per cell for patients treated with doxorubicin alone (1106.3) was significantly higher than the median number for those who had also received dexrazoxane (310.5; P = .001). No significant differences were detected between the groups for CI or CIV activity. Doxorubicin-treated survivors had an increased number of PBMC mtDNA copies per cell, and concomitant use of dexrazoxane was associated with a lower number of mtDNA copies per cell. Because of a possible compensatory increase in mtDNA copies per cell to maintain mitochondrial function in the setting of mitochondrial dysfunction, overall OXPHOS activity was not different between the groups. The long-term sustainability of this compensatory response in these survivors at risk for cardiac dysfunction over their lifespan is concerning.",Journal Article,1469.0,17.0,Impaired function in doxorubicin-treated childhood cancer survivors is partly mediated by the disruption of mitochondrial energy production Doxorubicin intercalates into mitochondrial DNA mtDNA and disrupts genes encoding for polypeptides that make adenosine triphosphate This cross-sectional study examined mtDNA copy numbers per cell and oxidative phosphorylation OXPHOS in peripheral blood mononuclear cells PBMCs in 64 childhood survivors of high-risk acute lymphoblastic ALL who had been treated on Dana-Farber Cancer Institute childhood ALL protocols and had received doxorubicin alone 42 or doxorubicin with the cardioprotectant dexrazoxane 58 The number of mtDNA copies per cell and the OXPHOS enzyme activity of nicotinamide adenine dinucleotide dehydrogenase complex I CI and cytochrome c oxidase complex IV CIV were measured with quantitative real-time polymerase chain reaction immunoassays and thin-layer chromatography respectively At a median follow-up of 7.8 years after treatment the median number of mtDNA copies per cell for patients treated with doxorubicin alone 1106.3 was significantly higher than the median number for those who had also received dexrazoxane 310.5 P .001 No significant differences were detected between the groups for CI or CIV activity Doxorubicin-treated survivors had an increased number of PBMC mtDNA copies per cell and concomitant use of dexrazoxane was associated with a lower number of mtDNA copies per cell Because of a possible compensatory increase in mtDNA copies per cell to maintain mitochondrial function in the setting of mitochondrial dysfunction overall OXPHOS activity was not different between the groups The long-term sustainability of this compensatory response in these survivors at risk for dysfunction over their lifespan is concerning,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[2364, 343, 4, 856, 73, 864, 12, 332, 16, 5180, 517, 20, 3, 3220, 1, 2019, 2803, 1529, 856, 35047, 237, 2019, 261, 6079, 2, 7754, 214, 2362, 9, 19538, 17, 2378, 4938, 7345, 26, 1383, 2832, 45, 409, 6079, 1337, 1870, 379, 31, 2, 3495, 982, 12680, 4, 672, 315, 3041, 37, 4617, 4, 660, 864, 332, 1, 64, 43, 286, 1275, 62, 54, 42, 85, 73, 23, 4932, 4979, 12, 1377, 864, 62, 2189, 2, 42, 103, 856, 279, 595, 15, 856, 5, 3, 28769, 8473, 717, 3, 207, 1, 6079, 5127, 379, 31, 2, 3, 12680, 1644, 128, 1, 17382, 16307, 11816, 2374, 840, 70, 58, 2, 4155, 256, 10447, 840, 478, 17086, 11, 644, 5, 1156, 1589, 98, 1451, 1260, 1329, 14785, 2, 5648, 8056, 5140, 106, 28, 8, 52, 166, 126, 1, 67, 66, 60, 50, 24, 3, 52, 207, 1, 6079, 5127, 379, 31, 9, 7, 73, 5, 856, 279, 26133, 27, 10, 97, 142, 76, 3, 52, 207, 9, 135, 54, 42, 120, 103, 8473, 8292, 33, 19, 144, 77, 93, 362, 11, 530, 59, 3, 271, 9, 58, 15, 17086, 128, 856, 73, 332, 42, 35, 101, 207, 1, 5063, 6079, 5127, 379, 31, 2, 1781, 119, 1, 8473, 10, 41, 5, 8, 280, 207, 1, 6079, 5127, 379, 31, 408, 1, 8, 899, 7084, 344, 4, 6079, 5127, 379, 31, 6, 3040, 2019, 343, 4, 3, 546, 1, 2019, 1527, 63, 12680, 128, 10, 44, 338, 59, 3, 271, 3, 319, 337, 18060, 1, 26, 7084, 51, 4, 46, 332, 28, 43, 9, 1527, 252, 136, 11637, 16, 4243]",1802.0,26762648,370
Asparaginase Erwinia chrysanthemi as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia who have developed hypersensitivity to E. coli-derived asparaginase.,Expert review of hematology,Expert Rev Hematol,2016-02-19,"Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic leukemia since the 1970s. There are two major preparations available and FDA approved in the United States today, one derived from Escherichia coli and the other from Erwinia chrysanthemi. Erwinia asparaginase is antigenically distinct from and has a considerably shorter biological half-life than E coli asparaginase. Erwinia asparaginase has been used in cases of hypersensitivity to E. coli-derived asparaginases, which has been reported in up to 30% of patients. While PEG asparaginase is increasingly used in front-line therapy for ALL, hypersensitivity still occurs with this preparation, and a change to a non-cross-reactive preparation may be necessary. ",Journal Article,1432.0,9.0,Asparaginase has been a mainstay of therapy in the treatment of acute lymphoblastic since the 1970s There are two major preparations available and FDA approved in the United States today one derived from Escherichia coli and the other from Erwinia chrysanthemi Erwinia asparaginase is antigenically distinct from and has a considerably shorter biological half-life than E coli asparaginase Erwinia asparaginase has been used in cases of hypersensitivity to E. coli-derived asparaginases which has been reported in up to 30 of patients While PEG asparaginase is increasingly used in front-line therapy for ALL hypersensitivity still occurs with this preparation and a change to a non-cross-reactive preparation may be necessary,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 71, 85, 8, 4041, 1, 36, 4, 3, 24, 1, 286, 1275, 1192, 3, 10868, 125, 32, 100, 458, 7791, 390, 2, 2078, 850, 4, 3, 1088, 907, 5665, 104, 526, 29, 12832, 6959, 2, 3, 127, 29, 11358, 23864, 11358, 3709, 16, 38369, 834, 29, 2, 71, 8, 5597, 985, 1037, 1303, 358, 76, 563, 6959, 3709, 11358, 3709, 71, 85, 95, 4, 140, 1, 4034, 6, 563, 6959, 526, 38872, 92, 71, 85, 210, 4, 126, 6, 201, 1, 7, 369, 3145, 3709, 16, 1635, 95, 4, 3007, 328, 36, 9, 62, 4034, 1234, 1780, 5, 26, 4824, 2, 8, 707, 6, 8, 220, 1383, 2163, 4824, 68, 40, 1493]",726.0,26765930,554
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2015-12-21,"Long-term disease-free survival in adult patients with acute lymphoblastic leukemia (ALL) remains unsatisfactory, and the treatment options are limited for those patients with relapse or a failure to respond after initial therapy. We conducted a dose-escalation/expansion phase II, multicenter, single-arm study to determine the optimal dose of coltuximab ravtansine (SAR3419), an anti-CD19 antibody-drug conjugate, in this setting. The dose-escalation part of the study determined the selected dose of coltuximab ravtansine for the evaluation of efficacy and safety in the dose-expansion phase. Patients received coltuximab ravtansine induction therapy ( 8 weekly doses). The responding patients were eligible for maintenance therapy (biweekly administration for  24 weeks). Three dose levels of coltuximab ravtansine were examined: 55, 70, and 90 mg/m(2). The primary endpoint was the objective response rate (ORR). The secondary endpoints included the duration of response (DOR) and safety. A total of 36 patients were treated: 19 during dose escalation and 17 during dose expansion. One dose-limiting toxicity was observed at 90 mg/m(2) (grade 3 peripheral motor neuropathy); therefore, 70 mg/m(2) was selected for the dose-expansion phase. Five patients discontinued therapy because of adverse events (AEs). The most common AEs were pyrexia, diarrhea, and nausea. Of the 17 evaluable patients treated at the selected dose, 4 had a disease response (estimated ORR using the Bayesian method: 25.5% (80% confidence interval, 14.2%-39.6%). The DOR was 1.9 months (range, 1-5.6 months). Because of these results, the study was prematurely discontinued. Coltuximab ravtansine was well tolerated but was associated with a low clinical response rate in patients with relapsed or refractory ALL.","Clinical Trial, Phase II",1492.0,32.0,Long-term disease-free survival in adult patients with acute lymphoblastic ALL remains unsatisfactory and the treatment options are limited for those patients with relapse or a failure to respond after initial therapy We conducted a dose-escalation/expansion phase II multicenter single-arm study to determine the optimal dose of coltuximab ravtansine SAR3419 an anti-CD19 antibody-drug conjugate in this setting The dose-escalation part of the study determined the selected dose of coltuximab ravtansine for the evaluation of efficacy and safety in the dose-expansion phase Patients received coltuximab ravtansine induction therapy  8 weekly doses The responding patients were eligible for maintenance therapy biweekly administration for  24 weeks Three dose levels of coltuximab ravtansine were examined 55 70 and 90 mg/m 2 The primary endpoint was the objective response rate ORR The secondary endpoints included the duration of response DOR and safety A total of 36 patients were treated 19 during dose escalation and 17 during dose expansion One dose-limiting toxicity was observed at 90 mg/m 2 grade 3 peripheral motor neuropathy therefore 70 mg/m 2 was selected for the dose-expansion phase Five patients discontinued therapy because of adverse events AEs The most common AEs were pyrexia diarrhea and nausea Of the 17 evaluable patients treated at the selected dose 4 had a disease response estimated ORR using the Bayesian method 25.5 80 confidence interval 14.2 -39.6 The DOR was 1.9 months range 1-5.6 months Because of these results the study was prematurely discontinued Coltuximab ravtansine was well tolerated but was associated with a low clinical response rate in patients with relapsed or refractory ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[319, 337, 34, 115, 25, 4, 780, 7, 5, 286, 1275, 62, 469, 9573, 2, 3, 24, 838, 32, 383, 9, 135, 7, 5, 429, 15, 8, 496, 6, 1892, 50, 388, 36, 21, 426, 8, 61, 1125, 1422, 124, 215, 1570, 226, 475, 45, 6, 223, 3, 665, 61, 1, 32548, 25720, 27194, 35, 312, 3158, 548, 234, 3998, 4, 26, 546, 3, 61, 1125, 760, 1, 3, 45, 509, 3, 715, 61, 1, 32548, 25720, 9, 3, 451, 1, 209, 2, 367, 4, 3, 61, 1422, 124, 7, 103, 32548, 25720, 504, 36, 1552, 66, 709, 415, 3, 3261, 7, 11, 625, 9, 1146, 36, 7551, 634, 9, 1552, 259, 244, 169, 61, 148, 1, 32548, 25720, 11, 409, 614, 431, 2, 424, 81, 188, 18, 3, 86, 1138, 10, 3, 461, 51, 116, 1735, 3, 568, 1387, 159, 3, 654, 1, 51, 8619, 2, 367, 8, 181, 1, 511, 7, 11, 73, 326, 190, 61, 1125, 2, 269, 190, 61, 1422, 104, 61, 817, 155, 10, 164, 28, 424, 81, 188, 18, 88, 27, 672, 3482, 1751, 673, 431, 81, 188, 18, 10, 715, 9, 3, 61, 1422, 124, 365, 7, 2402, 36, 408, 1, 290, 281, 1477, 3, 96, 186, 1477, 11, 8417, 1172, 2, 1218, 1, 3, 269, 859, 7, 73, 28, 3, 715, 61, 39, 42, 8, 34, 51, 661, 1735, 75, 3, 5032, 596, 243, 33, 493, 307, 268, 213, 18, 587, 49, 3, 8619, 10, 14, 83, 53, 184, 14, 33, 49, 53, 408, 1, 46, 99, 3, 45, 10, 9771, 2402, 32548, 25720, 10, 149, 421, 84, 10, 41, 5, 8, 154, 38, 51, 116, 4, 7, 5, 591, 15, 430, 62]",1723.0,26775883,222
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.,Immunotherapy,Immunotherapy,2016-01-18,"Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin, which is under investigation for the treatment of relapsed/refractory acute lymphoblastic leukemia. CD22 is commonly expressed in 90-100% of malignant mature B-lymphocyte lineage. The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al. gave the opportunity for heavily pretreated patients with acute lymphoblastic leukemia to go for allogeneic stem cell transplant. Inotuzumab is well-tolerated with the exception of veno-occlusive disease. Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients. ",Journal Article,1464.0,8.0,Inotuzumab ozogamicin is a humanized anti-CD22 monoclonal antibody bound to a toxic natural calicheamicin which is under investigation for the treatment of relapsed/refractory acute lymphoblastic CD22 is commonly expressed in 90-100 of malignant mature B-lymphocyte lineage The first Phase II study with inotuzumab ozogamicin conducted by Kantarjian et al gave the opportunity for heavily pretreated patients with acute lymphoblastic to go for allogeneic stem cell transplant Inotuzumab is well-tolerated with the exception of veno-occlusive disease Overall inotuzumab ozogamicin is potentially an encouraging and promising therapy for patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6730, 5566, 16, 8, 3619, 312, 7599, 848, 548, 2951, 6, 8, 1812, 1504, 13499, 92, 16, 669, 940, 9, 3, 24, 1, 591, 430, 286, 1275, 7599, 16, 841, 570, 4, 424, 394, 1, 393, 2908, 132, 1448, 2542, 3, 157, 124, 215, 45, 5, 6730, 5566, 426, 20, 37325, 2022, 2171, 6421, 3, 2666, 9, 2447, 2193, 7, 5, 286, 1275, 6, 3537, 9, 1063, 452, 31, 941, 6730, 16, 149, 421, 5, 3, 4188, 1, 10273, 8376, 34, 63, 6730, 5566, 16, 751, 35, 2269, 2, 721, 36, 9, 7]",644.0,26780449,302
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.,Expert review of hematology,Expert Rev Hematol,2016-03-22,"Over 90% of leukemic blasts in patients with acute lymphoblastic leukemia express the marker CD22. Inotuzumab ozogamicin (INO) is a CD22-directed humanized monoclonal antibody conjugated to the potent cytotoxin, calicheamicin, via an acid labile linker. INO has shown high rates of response in the treatment of relapsed and refractory (R/R) ALL in single-agent studies, with fewer adverse effects than traditional cytotoxic chemotherapy. Given this experience, studies are now being done to evaluate INO in combination with low-intensity chemotherapy as frontline treatment for older adults with ALL and patients with R/R disease. Herein we will discuss the use of INO in the treatment of acute lymphoblastic leukemia. ",Journal Article,1400.0,4.0,Over 90 of leukemic blasts in patients with acute lymphoblastic express the marker CD22 Inotuzumab ozogamicin INO is a CD22-directed humanized monoclonal antibody conjugated to the potent cytotoxin calicheamicin via an acid labile linker INO has shown high rates of response in the treatment of relapsed and refractory R/R ALL in single-agent studies with fewer adverse effects than traditional cytotoxic chemotherapy Given this experience studies are now being done to evaluate INO in combination with low-intensity chemotherapy as frontline treatment for older adults with ALL and patients with R/R disease Herein we will discuss the use of INO in the treatment of acute lymphoblastic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[252, 424, 1, 2015, 2438, 4, 7, 5, 286, 1275, 1669, 3, 952, 7599, 6730, 5566, 8709, 16, 8, 7599, 1166, 3619, 848, 548, 3868, 6, 3, 1157, 13870, 13499, 847, 35, 971, 19462, 8437, 8709, 71, 443, 64, 151, 1, 51, 4, 3, 24, 1, 591, 2, 430, 668, 668, 62, 4, 226, 420, 94, 5, 1497, 290, 176, 76, 1847, 759, 56, 447, 26, 730, 94, 32, 1134, 486, 1822, 6, 376, 8709, 4, 150, 5, 154, 837, 56, 22, 3171, 24, 9, 434, 857, 5, 62, 2, 7, 5, 668, 668, 34, 1986, 21, 303, 1139, 3, 119, 1, 8709, 4, 3, 24, 1, 286, 1275]",686.0,26783163,186
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia.,American journal of hematology,Am. J. Hematol.,2016-02-09,"In acute myelogenous leukemia, the persistent detection of abnormal cytogenetics at complete remission (ACCR) is associated with inferior outcomes. However, the prognostic significance of ACCR in adult patients with acute lymphoblastic leukemia (ALL) is unknown. We evaluated 272 adult patients with ALL and abnormal cytogenetics at baseline who were treated with frontline induction chemotherapy, achieved complete remission (CR) and had cytogenetic analysis performed at the time of CR. ACCR was observed in 26 patients (9.6%). Median relapse-free survival was 22 months (95% CI, 12 months to not reached) for patients with ACCR vs. 48 months (range, 30-125 months) in patients with normal cytogenetics at CR (NCCR; P=0.31). Median overall survival also did not differ significantly between the ACCR (99 months [range, 17 months to not reached]) and NCCR groups (67 months [range, 47 months to not reached], P=0.86). The specificity of ACCR for minimal residual disease (MRD) positivity by multi-parameter flow cytometry (MFC) was 43%, and there was overall poor correlation between these two methods for the detection of residual disease. When patients were stratified by MRD status, the presence or absence of persistent cytogenetic abnormalities at CR did not add additional prognostic information. This study suggests that there is poor association between MRD assessment by MFC and the presence or absence of cytogenetic abnormalities at CR in adult patients with ALL. ACCR was not associated with adverse outcomes in ALL and did not add additional prognostic information when MRD status by MFC was known.",Journal Article,1442.0,2.0,In acute myelogenous the persistent detection of abnormal cytogenetics at complete remission ACCR is associated with inferior outcomes However the prognostic significance of ACCR in adult patients with acute lymphoblastic ALL is unknown We evaluated 272 adult patients with ALL and abnormal cytogenetics at baseline who were treated with frontline induction chemotherapy achieved complete remission CR and had cytogenetic analysis performed at the time of CR ACCR was observed in 26 patients 9.6 Median relapse-free survival was 22 months 95 CI 12 months to not reached for patients with ACCR vs. 48 months range 30-125 months in patients with normal cytogenetics at CR NCCR P 0.31 Median overall survival also did not differ significantly between the ACCR 99 months range 17 months to not reached and NCCR groups 67 months range 47 months to not reached P 0.86 The specificity of ACCR for minimal residual disease MRD positivity by multi-parameter flow cytometry MFC was 43 and there was overall poor correlation between these two methods for the detection of residual disease When patients were stratified by MRD status the presence or absence of persistent cytogenetic abnormalities at CR did not add additional prognostic information This study suggests that there is poor association between MRD assessment by MFC and the presence or absence of cytogenetic abnormalities at CR in adult patients with ALL ACCR was not associated with adverse outcomes in ALL and did not add additional prognostic information when MRD status by MFC was known,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 286, 2194, 3, 1882, 638, 1, 1668, 2510, 28, 236, 734, 27503, 16, 41, 5, 1663, 123, 137, 3, 177, 724, 1, 27503, 4, 780, 7, 5, 286, 1275, 62, 16, 860, 21, 194, 6905, 780, 7, 5, 62, 2, 1668, 2510, 28, 330, 54, 11, 73, 5, 3171, 504, 56, 513, 236, 734, 684, 2, 42, 1266, 65, 173, 28, 3, 98, 1, 684, 27503, 10, 164, 4, 432, 7, 83, 49, 52, 429, 115, 25, 10, 350, 53, 48, 58, 133, 53, 6, 44, 1300, 9, 7, 5, 27503, 105, 576, 53, 184, 201, 1731, 53, 4, 7, 5, 295, 2510, 28, 684, 49537, 19, 13, 456, 52, 63, 25, 120, 205, 44, 1505, 97, 59, 3, 27503, 1058, 53, 184, 269, 53, 6, 44, 1300, 2, 49537, 271, 598, 53, 184, 662, 53, 6, 44, 1300, 19, 13, 868, 3, 1121, 1, 27503, 9, 1048, 753, 34, 2029, 1887, 20, 1414, 4219, 1412, 1914, 9439, 10, 601, 2, 125, 10, 63, 334, 816, 59, 46, 100, 636, 9, 3, 638, 1, 753, 34, 198, 7, 11, 1173, 20, 2029, 156, 3, 463, 15, 1127, 1, 1882, 1266, 1171, 28, 684, 205, 44, 4178, 402, 177, 487, 26, 45, 844, 17, 125, 16, 334, 248, 59, 2029, 455, 20, 9439, 2, 3, 463, 15, 1127, 1, 1266, 1171, 28, 684, 4, 780, 7, 5, 62, 27503, 10, 44, 41, 5, 290, 123, 4, 62, 2, 205, 44, 4178, 402, 177, 487, 198, 2029, 156, 20, 9439, 10, 440]",1544.0,26800008,237
Longitudinal Assessment of Neurocognitive Outcomes in Survivors of Childhood Acute Lymphoblastic Leukemia Treated on a Contemporary Chemotherapy Protocol.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-02-08,"Survivors of childhood acute lymphoblastic leukemia (ALL) treated with CNS-directed chemotherapy are at risk for neurocognitive deficits. Prospective longitudinal studies are needed to clarify the neurodevelopmental trajectory in this vulnerable population. Patients enrolled in the St. Jude Total Therapy Study XV, which omitted prophylactic cranial radiation therapy in all patients, completed comprehensive neuropsychological assessments at induction (n = 142), end of maintenance (n = 243), and 2 years after completion of therapy (n = 211). We report on longitudinal change in neurocognitive function and predictors of neurocognitive outcomes 2 years after completing therapy. Neurocognitive function was largely age appropriate 2 years after completing therapy; however, the overall group demonstrated significant attention deficits and a significantly greater frequency of learning problems as compared with national normative data (all P  .005). Higher-intensity CNS-directed chemotherapy conferred elevated risk for difficulties in attention, processing speed, and academics (all P  .01). The rate and direction of change in performance and caregiver-reported attention difficulties differed significantly by age at diagnosis and sex. End-of-therapy attention problems predicted lower academic scores 2 years later, with small to moderate effect sizes (r= 0.17 to 0.25, all P  .05). Two years after chemotherapy-only treatment, neurocognitive function is largely age appropriate. Nonetheless, survivors remain at elevated risk for attention problems that impact real-world functioning. Attention problems at the end of therapy predicted decreased academics 2 years later, suggesting an amplified functional impact of discrete neurocognitive difficulties. Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols.",Comparative Study,1443.0,48.0,Survivors of childhood acute lymphoblastic ALL treated with CNS-directed chemotherapy are at risk for neurocognitive deficits Prospective longitudinal studies are needed to clarify the neurodevelopmental trajectory in this vulnerable population Patients enrolled in the St. Jude Total Therapy Study XV which omitted prophylactic cranial radiation therapy in all patients completed comprehensive neuropsychological assessments at induction n 142 end of maintenance n 243 and 2 years after completion of therapy n 211 We report on longitudinal change in neurocognitive function and predictors of neurocognitive outcomes 2 years after completing therapy Neurocognitive function was largely age appropriate 2 years after completing therapy however the overall group demonstrated significant attention deficits and a significantly greater frequency of learning problems as compared with national normative data all P  .005 Higher-intensity CNS-directed chemotherapy conferred elevated risk for difficulties in attention processing speed and academics all P  .01 The rate and direction of change in performance and caregiver-reported attention difficulties differed significantly by age at diagnosis and sex End-of-therapy attention problems predicted lower academic scores 2 years later with small to moderate effect sizes r= 0.17 to 0.25 all P  .05 Two years after chemotherapy-only treatment neurocognitive function is largely age appropriate Nonetheless survivors remain at elevated risk for attention problems that impact real-world functioning Attention problems at the end of therapy predicted decreased academics 2 years later suggesting an amplified functional impact of discrete neurocognitive difficulties Age at diagnosis and patient sex may alter neurocognitive development in survivors of childhood ALL treated with chemotherapy-only protocols,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 73, 5, 1025, 1166, 56, 32, 28, 43, 9, 2958, 2752, 482, 2380, 94, 32, 575, 6, 3968, 3, 19352, 6118, 4, 26, 5017, 266, 7, 346, 4, 3, 3062, 4841, 181, 36, 45, 16078, 92, 7138, 1862, 2565, 121, 36, 4, 62, 7, 781, 949, 8271, 2182, 28, 504, 78, 4785, 396, 1, 1146, 78, 6346, 2, 18, 60, 50, 1438, 1, 36, 78, 5905, 21, 414, 23, 2380, 707, 4, 2958, 343, 2, 674, 1, 2958, 123, 18, 60, 50, 4144, 36, 2958, 343, 10, 1733, 89, 870, 18, 60, 50, 4144, 36, 137, 3, 63, 87, 264, 93, 2111, 2752, 2, 8, 97, 378, 675, 1, 3434, 2408, 22, 72, 5, 657, 9658, 74, 62, 19, 1552, 1614, 142, 837, 1025, 1166, 56, 3851, 804, 43, 9, 4679, 4, 2111, 3325, 5051, 2, 32322, 62, 19, 1552, 355, 3, 116, 2, 4651, 1, 707, 4, 528, 2, 4828, 210, 2111, 4679, 2512, 97, 20, 89, 28, 147, 2, 1035, 396, 1, 36, 2111, 2408, 783, 280, 1916, 703, 18, 60, 1559, 5, 302, 6, 1163, 254, 4131, 67607, 13, 269, 6, 13, 243, 62, 19, 1552, 474, 100, 60, 50, 56, 158, 24, 2958, 343, 16, 1733, 89, 870, 4648, 332, 918, 28, 804, 43, 9, 2111, 2408, 17, 345, 1589, 1956, 2702, 2111, 2408, 28, 3, 396, 1, 36, 783, 340, 32322, 18, 60, 1559, 802, 35, 2429, 583, 345, 1, 5447, 2958, 4679, 89, 28, 147, 2, 69, 1035, 68, 2688, 2958, 193, 4, 332, 1, 864, 62, 73, 5, 56, 158, 2189]",1856.0,26858334,300
Truncating Erythropoietin Receptor Rearrangements in Acute Lymphoblastic Leukemia.,Cancer cell,Cancer Cell,2016-02-01,"Chromosomal rearrangements are a hallmark of acute lymphoblastic leukemia (ALL) and are important ALL initiating events. We describe four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromosome-like (Ph-like) ALL. All of these rearrangements result in truncation of the cytoplasmic tail of EPOR at residues similar to those mutated in primary familial congenital polycythemia, with preservation of the proximal tyrosine essential for receptor activation and loss of distal regulatory residues. This resulted in deregulated EPOR expression, hypersensitivity to erythropoietin stimulation, and heightened JAK-STAT activation. Expression of truncated EPOR in mouse B cell progenitors induced ALL invivo. Human leukemic cells with EPOR rearrangements were sensitive to JAK-STAT inhibition, suggesting a therapeutic option in high-risk ALL. ",Journal Article,1450.0,51.0,Chromosomal rearrangements are a hallmark of acute lymphoblastic ALL and are important ALL initiating events We describe four different rearrangements of the erythropoietin receptor gene EPOR in Philadelphia chromosome-like Ph-like ALL All of these rearrangements result in truncation of the cytoplasmic tail of EPOR at residues similar to those mutated in primary familial congenital polycythemia with preservation of the proximal tyrosine essential for receptor activation and loss of distal regulatory residues This resulted in deregulated EPOR expression hypersensitivity to erythropoietin stimulation and heightened JAK-STAT activation Expression of truncated EPOR in mouse B cell progenitors induced ALL in vivo Human leukemic cells with EPOR rearrangements were sensitive to JAK-STAT inhibition suggesting a therapeutic option in high-risk ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1860, 2072, 32, 8, 4683, 1, 286, 1275, 62, 2, 32, 305, 62, 2637, 281, 21, 897, 294, 338, 2072, 1, 3, 6266, 153, 145, 12839, 4, 3006, 1170, 733, 2058, 733, 62, 62, 1, 46, 2072, 757, 4, 11944, 1, 3, 2828, 5809, 1, 12839, 28, 6418, 288, 6, 135, 1185, 4, 86, 2200, 6711, 5755, 5, 2224, 1, 3, 2805, 564, 1452, 9, 153, 363, 2, 407, 1, 2107, 1253, 6418, 26, 627, 4, 5415, 12839, 55, 4034, 6, 6266, 2503, 2, 7145, 4653, 4168, 363, 55, 1, 6502, 12839, 4, 830, 132, 31, 4321, 277, 62, 4, 386, 171, 2015, 37, 5, 12839, 2072, 11, 745, 6, 4653, 4168, 297, 802, 8, 189, 1501, 4, 64, 43, 62]",850.0,26859458,266
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.,Nature genetics,Nat. Genet.,2016-02-15,"Widely used as anticancer and immunosuppressive agents, thiopurines have narrow therapeutic indices owing to frequent toxicities, partly explained by TPMT genetic polymorphisms. Recent studies identified germline NUDT15 variation as another critical determinant of thiopurine intolerance, but the underlying molecular mechanisms and the clinical implications of this pharmacogenetic association remain unknown. In 270 children enrolled in clinical trials for acute lymphoblastic leukemia in Guatemala, Singapore and Japan, we identified four NUDT15 coding variants (p.Arg139Cys, p.Arg139His, p.Val18Ile and p.Val18_Val19insGlyVal) that resulted in 74.4-100% loss of nucleotide diphosphatase activity. Loss-of-function NUDT15 diplotypes were consistently associated with thiopurine intolerance across the three cohorts (P = 0.021, 2.1  10(-5) and 0.0054, respectively; meta-analysis P = 4.45  10(-8), allelic effect size = -11.5). Mechanistically, NUDT15 inactivated thiopurine metabolites and decreased thiopurine cytotoxicity in vitro, and patients with defective NUDT15 alleles showed excessive levels of thiopurine active metabolites and toxicity. Taken together, these results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may inform personalized thiopurine therapy. ",Journal Article,1436.0,137.0,Widely used as anticancer and immunosuppressive agents thiopurines have narrow therapeutic indices owing to frequent toxicities partly explained by TPMT genetic polymorphisms Recent studies identified germline NUDT15 variation as another critical determinant of thiopurine intolerance but the underlying molecular mechanisms and the clinical implications of this pharmacogenetic association remain unknown In 270 children enrolled in clinical trials for acute lymphoblastic in Guatemala Singapore and Japan we identified four NUDT15 coding variants p.Arg139Cys p.Arg139His p.Val18Ile and p.Val18_Val19insGlyVal that resulted in 74.4-100 loss of nucleotide diphosphatase activity Loss-of-function NUDT15 diplotypes were consistently associated with thiopurine intolerance across the three cohorts P 0.021 2.1 10 -5 and 0.0054 respectively meta-analysis P 4.45 10 -8 allelic effect size -11.5 Mechanistically NUDT15 inactivated thiopurine metabolites and decreased thiopurine cytotoxicity in vitro and patients with defective NUDT15 alleles showed excessive levels of thiopurine active metabolites and toxicity Taken together these results indicate that a comprehensive pharmacogenetic model integrating NUDT15 variants may inform personalized thiopurine therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1792, 95, 22, 1475, 2, 2989, 183, 39767, 47, 6958, 189, 3824, 3421, 6, 908, 385, 5180, 3672, 20, 14852, 336, 1203, 435, 94, 108, 1009, 18089, 1380, 22, 1809, 740, 4372, 1, 14062, 5266, 84, 3, 1181, 219, 483, 2, 3, 38, 1268, 1, 26, 6578, 248, 918, 860, 4, 6666, 541, 346, 4, 38, 143, 9, 286, 1275, 4, 27061, 15622, 2, 6157, 21, 108, 294, 18089, 3097, 839, 19, 67639, 19, 67640, 19, 67641, 2, 19, 67642, 67643, 17, 627, 4, 794, 39, 394, 407, 1, 1579, 49571, 128, 407, 1, 343, 18089, 28685, 11, 2433, 41, 5, 14062, 5266, 716, 3, 169, 736, 19, 13, 4630, 18, 14, 79, 33, 2, 13, 26390, 106, 1742, 65, 19, 39, 512, 79, 66, 3861, 254, 444, 175, 33, 4187, 18089, 5458, 14062, 3406, 2, 340, 14062, 1408, 4, 439, 2, 7, 5, 4552, 18089, 2558, 224, 4529, 148, 1, 14062, 544, 3406, 2, 155, 1633, 1162, 46, 99, 1008, 17, 8, 949, 6578, 202, 4568, 18089, 839, 68, 2295, 2175, 14062, 36]",1260.0,26878724,757
Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL).,Leukemia & lymphoma,Leuk. Lymphoma,2016-02-16,"The Cancer Institute of New Jersey Acute Lymphoblastic Leukemia trial (CINJALL) employed a post-induction regimen centered on intensive oral antimetabolite therapy, with no intravenous methotrexate (MTX). Fifty-eight patients enrolled between 2001 and 2005. A high rate of induction death (n=3) or induction failure (n=1) was observed. Among those who entered remission, five-year DFS is 808.9% for those at standard risk of relapse and 767.8% for high-risk patients, with median follow up over six years. The estimated cumulative incidence of testicular relapse among boys was elevated (137.2%) compared to the rate observed on contemporary protocols. We conclude that post-induction therapy using intensive oral antimetabolites for children with acute lymphoblastic leukemia (ALL) can result in overall long-term DFS comparable to that observed among children treated with regimens including intravenous MTX. However, an increased risk of late extramedullary relapse among boys was observed, supporting the prevailing opinion that high-dose MTX improves outcome for children with ALL.",Journal Article,1435.0,2.0,The Cancer Institute of New Jersey Acute Lymphoblastic trial CINJALL employed a post-induction regimen centered on intensive oral antimetabolite therapy with no intravenous methotrexate MTX Fifty-eight patients enrolled between 2001 and 2005 A high rate of induction death n 3 or induction failure n 1 was observed Among those who entered remission five-year DFS is 80  8.9 for those at standard risk of relapse and 76  7.8 for high-risk patients with median follow up over six years The estimated cumulative incidence of relapse among boys was elevated 13  7.2 compared to the rate observed on contemporary protocols We conclude that post-induction therapy using intensive oral antimetabolites for children with acute lymphoblastic ALL can result in overall long-term DFS comparable to that observed among children treated with regimens including intravenous MTX However an increased risk of late extramedullary relapse among boys was observed supporting the prevailing opinion that high-dose MTX improves outcome for children with ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 12, 1377, 1, 217, 14472, 286, 1275, 160, 67646, 2516, 8, 539, 504, 477, 4846, 23, 1686, 518, 12995, 36, 5, 77, 1262, 2116, 3453, 1461, 659, 7, 346, 59, 1758, 2, 1242, 8, 64, 116, 1, 504, 273, 78, 27, 15, 504, 496, 78, 14, 10, 164, 107, 135, 54, 2836, 734, 365, 111, 1010, 16, 493, 810, 66, 83, 9, 135, 28, 260, 43, 1, 429, 2, 846, 810, 67, 66, 9, 64, 43, 7, 5, 52, 166, 126, 252, 437, 60, 3, 661, 967, 287, 1, 429, 107, 12958, 10, 804, 233, 810, 67, 18, 72, 6, 3, 116, 164, 23, 2667, 2189, 21, 2060, 17, 539, 504, 36, 75, 1686, 518, 21195, 9, 541, 5, 286, 1275, 62, 122, 757, 4, 63, 319, 337, 1010, 1279, 6, 17, 164, 107, 541, 73, 5, 472, 141, 1262, 3453, 137, 35, 101, 43, 1, 807, 5508, 429, 107, 12958, 10, 164, 1912, 3, 17895, 3564, 17, 64, 61, 3453, 1804, 228, 9, 541, 5, 62]",1039.0,26879921,725
Clinical impact of ABL1 kinase domain mutations and IKZF1 deletion in adults under age 60 with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL): molecular analysis of CALGB (Alliance) 10001 and 9665.,Leukemia & lymphoma,Leuk. Lymphoma,2016-02-18,"Recent studies have identified oncogenic lesions in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) and ABL1 kinase mutations that confer resistance to tyrosine kinase inhibitors. We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001, a previously reported Phase II study of imatinib, chemotherapy, and hematopoietic cell transplant in adult Ph+ALL. Of the 58 enrolled, 22 relapsed. By direct sequencing, an ABL1 kinase mutation known to induce imatinib resistance was present at relapse in 13 of 20. Using quantitative PCR assays, the mutations were detectable at diagnosis or early during treatment in most (62%) relapsed patients. Aberrations in IKZF1, CDKN2A/B, and PAX5 were assessed in 28 samples using SNP arrays and genomic DNA sequencing. Of these, 22 (79%) had IKZF1 deletion. The combination of IKZF1 deletion and p210 BCR-ABL1 (p<0.0001), high white blood cell count (p=0.021), and minimal residual disease (p=0.013) were associated with worse disease-free survival.",Journal Article,1433.0,16.0,Recent studies have identified oncogenic lesions in Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL and ABL1 kinase mutations that confer resistance to tyrosine kinase inhibitors We sought to determine the prevalence and clinical impact of these lesions in patients on CALGB 10001 a previously reported Phase II study of imatinib chemotherapy and hematopoietic cell transplant in adult Ph ALL Of the 58 enrolled 22 relapsed By direct sequencing an ABL1 kinase mutation known to induce imatinib resistance was present at relapse in 13 of 20 Using quantitative PCR assays the mutations were detectable at diagnosis or early during treatment in most 62 relapsed patients Aberrations in IKZF1 CDKN2A/B and PAX5 were assessed in 28 samples using SNP arrays and genomic DNA sequencing Of these 22 79 had IKZF1 deletion The combination of IKZF1 deletion and p210 BCR-ABL1 p 0.0001 high white blood cell count p 0.021 and minimal residual disease p 0.013 were associated with worse disease-free survival,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 94, 47, 108, 1302, 406, 4, 3006, 1170, 109, 2058, 286, 1275, 62, 2, 3557, 216, 138, 17, 2913, 251, 6, 564, 216, 222, 21, 990, 6, 223, 3, 1078, 2, 38, 345, 1, 46, 406, 4, 7, 23, 4077, 67658, 8, 373, 210, 124, 215, 45, 1, 577, 56, 2, 1007, 31, 941, 4, 780, 2058, 62, 1, 3, 717, 346, 350, 591, 20, 1196, 615, 35, 3557, 216, 258, 440, 6, 1290, 577, 251, 10, 364, 28, 429, 4, 233, 1, 179, 75, 1156, 604, 1013, 3, 138, 11, 2083, 28, 147, 15, 191, 190, 24, 4, 96, 744, 591, 7, 2152, 4, 8422, 3175, 132, 2, 6279, 11, 275, 4, 339, 347, 75, 1845, 3923, 2, 572, 261, 615, 1, 46, 350, 842, 42, 8422, 1528, 3, 150, 1, 8422, 1528, 2, 11538, 1062, 3557, 19, 13, 488, 64, 886, 315, 31, 1276, 19, 13, 4630, 2, 1048, 753, 34, 19, 13, 3612, 11, 41, 5, 639, 34, 115, 25]",1008.0,26892479,176
Social Media and the Adolescent and Young Adult (AYA) Patient with Cancer.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2016-12-01,"Over 70,000 adolescent and young adults (AYA) aged 15 to 39years are diagnosed with cancer each year in the US. The National Cancer Institute (NCI) has identified AYA cancer patients as a unique population. The most common cancers in this age group include tumors typically seen in pediatric patients such as acute lymphoblastic leukemia (ALL) and brain tumors, as well as cancers more typically seen in adult patients such as breast cancer and melanoma. In addition, some cancers have their highest incidence in AYA patients, such as Hodgkin Lymphoma, testicular cancer, and bone tumors. AYA patients face additional unique issues due to their age, not just questions about treatment choices due to lack of data but also questions about fertility, relationships, loss of autonomy, and interruptions in school/work with potentially significant financial complications. This age group also has very high rates of social media usage with up to 90% of adults aged 18 to 29 using social networking sites. In this review, we will describe the use of social media in AYAs with cancer and highlight some of the online resources for AYAs.",Journal Article,1146.0,35.0,"Over 70,000 adolescent and young adults AYA aged 15 to 39 years are diagnosed with cancer each year in the US The National Cancer Institute NCI has identified AYA cancer patients as a unique population The most common cancers in this age group include tumors typically seen in pediatric patients such as acute lymphoblastic ALL and brain tumors as well as cancers more typically seen in adult patients such as cancer and In addition some cancers have their highest incidence in AYA patients such as cancer and tumors AYA patients face additional unique issues due to their age not just questions about treatment choices due to lack of data but also questions about fertility relationships loss of autonomy and interruptions in school/work with potentially significant financial complications This age group also has very high rates of social media usage with up to 90 of adults aged 18 to 29 using social networking sites In this review we will describe the use of social media in AYAs with cancer and highlight some of the online resources for AYAs",1,0,1,0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[252, 431, 984, 3678, 2, 1169, 857, 4598, 1032, 167, 6, 587, 60, 32, 265, 5, 12, 296, 111, 4, 3, 843, 3, 657, 12, 1377, 2580, 71, 108, 4598, 12, 7, 22, 8, 991, 266, 3, 96, 186, 163, 4, 26, 89, 87, 643, 57, 1969, 527, 4, 815, 7, 225, 22, 286, 1275, 62, 2, 342, 57, 22, 149, 22, 163, 80, 1969, 527, 4, 780, 7, 225, 22, 12, 2, 4, 352, 476, 163, 47, 136, 1076, 287, 4, 4598, 7, 225, 22, 12, 2, 57, 4598, 7, 3376, 402, 991, 1553, 520, 6, 136, 89, 44, 4673, 1937, 545, 24, 5218, 520, 6, 926, 1, 74, 84, 120, 1937, 545, 2954, 2467, 407, 1, 14086, 2, 7406, 4, 5953, 1357, 5, 751, 93, 3021, 521, 26, 89, 87, 120, 71, 923, 64, 151, 1, 2032, 4769, 5015, 5, 126, 6, 424, 1, 857, 1032, 203, 6, 462, 75, 2032, 29346, 633, 4, 26, 206, 21, 303, 897, 3, 119, 1, 2032, 4769, 4, 6145, 5, 12, 2, 1817, 476, 1, 3, 4123, 2892, 9, 6145]",1049.0,26893061,23
Dietary Protein Intake and Lean Muscle Mass in Survivors of Childhood Acute Lymphoblastic Leukemia: Report From the St. Jude Lifetime Cohort Study.,Physical therapy,Phys Ther,2016-02-18,"Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for low lean muscle mass and muscle weakness, which may contribute to inactivity and early development of chronic diseases typically seen in older adults. Although increasing protein intake, in combination with resistance training, improves lean muscle mass in other populations, it is not known whether muscular tissue among survivors of ALL, whose impairments are treatment-related, will respond similarly. The aim of this study was to evaluate associations among dietary protein intake, resistance training, and lean muscle mass in survivors of ALL and age-, sex-, and race-matched controls. This was a cross-sectional study. Lean muscle mass was determined with dual-energy x-ray absorptiometry, dietary information with 24-hour recalls, and participation in resistance training with a questionnaire. Participants were 365 survivors of ALL (52% male; 87% white; median age=28.5 years, range=23.6-31.7) and 365 controls with no previous cancer. Compared with controls, survivors of ALL had lower lean muscle mass (55.0 versus 57.2 kg, respectively) and lower percentage of lean muscle mass (68.6% versus 71.4%, respectively) than controls. Similar proportions of survivors (71.1%) and controls (69.7%) met recommended dietary protein intake (0.8 g/kg/d). Survivors (45.4%) were less likely to report resistance training than controls (53.8%). In adjusted models, 1-g higher protein intake per kilogram of body mass per day was associated with a 7.9% increase and resistance training 1wk, with a 2.8% increase in lean muscle mass. The cross-sectional study design limits temporal evaluation of the association between protein intake and lean muscle mass. The findings suggest that survivors of childhood ALL with low lean muscle mass may benefit from optimizing dietary protein intake in combination with resistance training. Research is needed to determine whether resistance training with protein supplementation improves lean muscle mass in survivors of childhood ALL.",Journal Article,1433.0,2.0,Survivors of childhood acute lymphoblastic ALL are at risk for low lean muscle mass and muscle weakness which may contribute to inactivity and early development of chronic diseases typically seen in older adults Although increasing protein intake in combination with resistance training improves lean muscle mass in other populations it is not known whether muscular tissue among survivors of ALL whose impairments are treatment-related will respond similarly The aim of this study was to evaluate associations among dietary protein intake resistance training and lean muscle mass in survivors of ALL and age- sex- and race-matched controls This was a cross-sectional study Lean muscle mass was determined with dual-energy x-ray absorptiometry dietary information with 24-hour recalls and participation in resistance training with a questionnaire Participants were 365 survivors of ALL 52 male 87 white median age=28.5 years range=23.6-31.7 and 365 controls with no previous cancer Compared with controls survivors of ALL had lower lean muscle mass 55.0 versus 57.2 kg respectively and lower percentage of lean muscle mass 68.6 versus 71.4 respectively than controls Similar proportions of survivors 71.1 and controls 69.7 met recommended dietary protein intake 0.8 g/kg/d Survivors 45.4 were less likely to report resistance training than controls 53.8 In adjusted models 1-g higher protein intake per kilogram of body mass per day was associated with a 7.9 increase and resistance training 1wk with a 2.8 increase in lean muscle mass The cross-sectional study design limits temporal evaluation of the association between protein intake and lean muscle mass The findings suggest that survivors of childhood ALL with low lean muscle mass may benefit from optimizing dietary protein intake in combination with resistance training Research is needed to determine whether resistance training with protein supplementation improves lean muscle mass in survivors of childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 32, 28, 43, 9, 154, 6949, 1502, 782, 2, 1502, 6408, 92, 68, 1248, 6, 10050, 2, 191, 193, 1, 442, 1342, 1969, 527, 4, 434, 857, 242, 602, 178, 1514, 4, 150, 5, 251, 1741, 1804, 6949, 1502, 782, 4, 127, 1184, 192, 16, 44, 440, 317, 8620, 246, 107, 332, 1, 62, 1310, 6948, 32, 24, 139, 303, 1892, 1813, 3, 1130, 1, 26, 45, 10, 6, 376, 685, 107, 2013, 178, 1514, 251, 1741, 2, 6949, 1502, 782, 4, 332, 1, 62, 2, 89, 1035, 2, 1047, 655, 535, 26, 10, 8, 1383, 2832, 45, 6949, 1502, 782, 10, 509, 5, 1828, 2803, 1006, 5520, 14257, 2013, 487, 5, 259, 2583, 29108, 2, 2599, 4, 251, 1741, 5, 8, 1770, 776, 11, 7405, 332, 1, 62, 653, 1045, 912, 886, 52, 89, 339, 33, 60, 184, 382, 49, 456, 67, 2, 7405, 535, 5, 77, 698, 12, 72, 5, 535, 332, 1, 62, 42, 280, 6949, 1502, 782, 614, 13, 185, 696, 18, 503, 106, 2, 280, 1150, 1, 6949, 1502, 782, 806, 49, 185, 792, 39, 106, 76, 535, 288, 4117, 1, 332, 792, 14, 2, 535, 790, 67, 543, 793, 2013, 178, 1514, 13, 66, 499, 503, 427, 332, 512, 39, 11, 299, 322, 6, 414, 251, 1741, 76, 535, 699, 66, 4, 586, 274, 14, 499, 142, 178, 1514, 379, 6543, 1, 642, 782, 379, 218, 10, 41, 5, 8, 67, 83, 344, 2, 251, 1741, 67662, 5, 8, 18, 66, 344, 4, 6949, 1502, 782, 3, 1383, 2832, 45, 771, 3526, 3264, 451, 1, 3, 248, 59, 178, 1514, 2, 6949, 1502, 782, 3, 272, 309, 17, 332, 1, 864, 62, 5, 154, 6949, 1502, 782, 68, 247, 29, 4336, 2013, 178, 1514, 4, 150, 5, 251, 1741, 389, 16, 575, 6, 223, 317, 251, 1741, 5, 178, 3890, 1804, 6949, 1502, 782, 4, 332, 1, 864, 62]",1975.0,26893509,3
Ezh2 Controls an Early Hematopoietic Program and Growth and Survival Signaling in Early T Cell Precursor Acute Lymphoblastic Leukemia.,Cell reports,Cell Rep,2016-02-18,"Early Tcell precursor acute lymphoblastic leukemia (ETP-ALL) is an aggressive subtype of ALL distinguished by stem-cell-associated and myeloid transcriptional programs. Inactivating alterations of Polycomb repressive complex 2 components are frequent in human ETP-ALL, but their functional role is largely undefined. We have studied the involvement of Ezh2 in a murine model of NRASQ61K-driven leukemia that recapitulates phenotypic and transcriptional features of ETP-ALL. Homozygous inactivation of Ezh2 cooperated with oncogenic NRASQ61K to accelerate leukemia onset. Inactivation of Ezh2 accentuated expression of genes highly expressed in human ETP-ALL and in normal murine early thymic progenitors. Moreover, we found that Ezh2 contributes tothesilencing of stem-cell- and early-progenitor-cell-associated genes. Loss of Ezh2 also resulted inincreased activation of STAT3 by tyrosine 705 phosphorylation. Our data mechanistically link Ezh2 inactivation to stem-cell-associated transcriptional programs and increased growth/survival signaling, features that convey an adverse prognosis in patients. ",Journal Article,1433.0,32.0,Early T cell precursor acute lymphoblastic ETP-ALL is an aggressive subtype of ALL distinguished by stem-cell-associated and myeloid transcriptional programs Inactivating alterations of Polycomb repressive complex 2 components are frequent in human ETP-ALL but their functional role is largely undefined We have studied the involvement of Ezh2 in a murine model of NRASQ61K-driven that recapitulates phenotypic and transcriptional features of ETP-ALL Homozygous inactivation of Ezh2 cooperated with oncogenic NRASQ61K to accelerate onset Inactivation of Ezh2 accentuated expression of genes highly expressed in human ETP-ALL and in normal murine early thymic progenitors Moreover we found that Ezh2 contributes to the silencing of stem-cell- and early-progenitor-cell-associated genes Loss of Ezh2 also resulted in increased activation of STAT3 by tyrosine 705 phosphorylation Our data mechanistically link Ezh2 inactivation to stem-cell-associated transcriptional programs and increased growth/survival signaling features that convey an adverse prognosis in patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[191, 102, 31, 2765, 286, 1275, 11985, 62, 16, 35, 571, 875, 1, 62, 4735, 20, 452, 31, 41, 2, 533, 1431, 2251, 6096, 593, 1, 8666, 9851, 840, 18, 1628, 32, 908, 4, 171, 11985, 62, 84, 136, 583, 200, 16, 1733, 5425, 21, 47, 656, 3, 799, 1, 3755, 4, 8, 1471, 202, 1, 41357, 1621, 17, 11076, 3290, 2, 1431, 404, 1, 11985, 62, 3189, 2297, 1, 3755, 14151, 5, 1302, 41357, 6, 5792, 1707, 2297, 1, 3755, 25356, 55, 1, 214, 561, 570, 4, 171, 11985, 62, 2, 4, 295, 1471, 191, 3572, 4321, 1393, 21, 204, 17, 3755, 2444, 6, 3, 2077, 1, 452, 31, 2, 191, 2520, 31, 41, 214, 407, 1, 3755, 120, 627, 4, 101, 363, 1, 1439, 20, 564, 11303, 982, 114, 74, 4187, 3460, 3755, 2297, 6, 452, 31, 41, 1431, 2251, 2, 101, 129, 25, 314, 404, 17, 11415, 35, 290, 356, 4, 7]",1067.0,26904942,137
Impact of Socioeconomic Status on Timing of Relapse and Overall Survival for Children Treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010).,Pediatric blood & cancer,Pediatr Blood Cancer,2016-02-23,"Population-based evidence suggests that lower socioeconomic status (SES) negatively impacts the overall survival (OS) of children with leukemia; however, the relationships between SES and treatment-related mortality, relapse, and timing of relapse remain unclear. We examined OS, event-free survival (EFS) and cumulative incidence (CI) and timing of relapse by community-level poverty for 575 children aged 1-18 years with newly diagnosed acute lymphoblastic leukemia (ALL) treated on consecutive phase III multicenter Dana-Farber Cancer Institute ALL Consortium Protocols between 2000 and 2010. Children were categorized into high- and low-poverty areas for the analysis using aggregate U.S. Census data linked to zip code. Children living in high-poverty areas experienced a 5-year OS of 85% as compared with 92% for those in low-poverty areas (P = 0.02); poverty remained marginally significant (P = 0.07) after adjustment for immunophenotype, age, and white blood cell count. There were no differences detected in EFS or CI relapse by poverty area. However, 92% of the relapses observed in children from high-poverty areas occurred <36 months from complete remission, compared to 48% of those in children from low-poverty areas (P = 0.008). U.S. children with ALL living in high-poverty areas have a higher risk of early relapse when compared with those living in low-poverty areas despite uniform treatment. This may in part explain decreased OS observed in these children. This finding highlights disparities in childhood cancer outcomes by SES despite uniform treatment. Further investigations of the mechanistic pathways underlying this finding are needed.",Journal Article,1428.0,28.0,Population-based evidence suggests that lower socioeconomic status SES negatively impacts the overall survival OS of children with however the relationships between SES and treatment-related mortality relapse and timing of relapse remain unclear We examined OS event-free survival EFS and cumulative incidence CI and timing of relapse by community-level poverty for 575 children aged 1-18 years with newly diagnosed acute lymphoblastic ALL treated on consecutive phase III multicenter Dana-Farber Cancer Institute ALL Consortium Protocols between 2000 and 2010 Children were categorized into high- and low-poverty areas for the analysis using aggregate U.S. Census data linked to zip code Children living in high-poverty areas experienced a 5-year OS of 85 as compared with 92 for those in low-poverty areas P 0.02 poverty remained marginally significant P 0.07 after adjustment for immunophenotype age and white blood cell count There were no differences detected in EFS or CI relapse by poverty area However 92 of the relapses observed in children from high-poverty areas occurred 36 months from complete remission compared to 48 of those in children from low-poverty areas P 0.008 U.S. children with ALL living in high-poverty areas have a higher risk of early relapse when compared with those living in low-poverty areas despite uniform treatment This may in part explain decreased OS observed in these children This finding highlights disparities in childhood cancer outcomes by SES despite uniform treatment Further investigations of the mechanistic pathways underlying this finding are needed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[266, 90, 241, 844, 17, 280, 3331, 156, 5699, 2723, 4719, 3, 63, 25, 118, 1, 541, 5, 137, 3, 2467, 59, 5699, 2, 24, 139, 282, 429, 2, 1972, 1, 429, 918, 1200, 21, 409, 118, 774, 115, 25, 1683, 2, 967, 287, 58, 2, 1972, 1, 429, 20, 1714, 301, 7583, 9, 10454, 541, 1032, 14, 203, 60, 5, 732, 265, 286, 1275, 62, 73, 23, 935, 124, 316, 1570, 4932, 4979, 12, 1377, 62, 2404, 2189, 59, 1081, 2, 1120, 541, 11, 2320, 237, 64, 2, 154, 7583, 1361, 9, 3, 65, 75, 7494, 1767, 695, 7319, 74, 1199, 6, 11458, 5853, 541, 2798, 4, 64, 7583, 1361, 592, 8, 33, 111, 118, 1, 772, 22, 72, 5, 937, 9, 135, 4, 154, 7583, 1361, 19, 13, 588, 7583, 958, 5007, 93, 19, 13, 1615, 50, 1852, 9, 5496, 89, 2, 886, 315, 31, 1276, 125, 11, 77, 362, 530, 4, 1683, 15, 58, 429, 20, 7583, 965, 137, 937, 1, 3, 3713, 164, 4, 541, 29, 64, 7583, 1361, 489, 511, 53, 29, 236, 734, 72, 6, 576, 1, 135, 4, 541, 29, 154, 7583, 1361, 19, 13, 2155, 1767, 695, 541, 5, 62, 2798, 4, 64, 7583, 1361, 47, 8, 142, 43, 1, 191, 429, 198, 72, 5, 135, 2798, 4, 154, 7583, 1361, 550, 3490, 24, 26, 68, 4, 760, 2943, 340, 118, 164, 4, 46, 541, 26, 1567, 2527, 2227, 4, 864, 12, 123, 20, 5699, 550, 3490, 24, 195, 2492, 1, 3, 2716, 460, 1181, 26, 1567, 32, 575]",1599.0,26913850,28
Consensus expert recommendations for identification and management of asparaginase hypersensitivity and silent inactivation.,Haematologica,Haematologica,2016-03-01,"L-asparaginase is an integral component of therapy for acute lymphoblastic leukemia. However, asparaginase-related complications, including the development of hypersensitivity reactions, can limit its use in individual patients. Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity. Also problematic in the use of asparaginase is the potential for the development of silent inactivation, with the formation of neutralizing antibodies and reduced asparaginase activity in the absence of a clinically evident allergic reaction. Here we present guidelines for the identification and management of clinical hypersensitivity and silent inactivation with Escherichia coli- and Erwinia chrysanthemi- derived asparaginase preparations. These guidelines were developed by a consensus panel of experts following a review of the available published data. We provide a consensus of expert opinions on the role of serum asparaginase level assessment, indications for switching asparaginase preparation, and monitoring after change in asparaginase preparation. ",Journal Article,1421.0,51.0,L-asparaginase is an integral component of therapy for acute lymphoblastic However asparaginase-related complications including the development of hypersensitivity reactions can limit its use in individual patients Of considerable concern in the setting of clinical allergy is the development of neutralizing antibodies and associated asparaginase inactivity Also problematic in the use of asparaginase is the potential for the development of silent inactivation with the formation of neutralizing antibodies and reduced asparaginase activity in the absence of a clinically evident allergic reaction Here we present guidelines for the identification and management of clinical hypersensitivity and silent inactivation with Escherichia coli- and Erwinia chrysanthemi- derived asparaginase preparations These guidelines were developed by a consensus panel of experts following a review of the available published data We provide a consensus of expert opinions on the role of serum asparaginase level assessment indications for switching asparaginase preparation and monitoring after change in asparaginase preparation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[805, 3709, 16, 35, 4450, 1249, 1, 36, 9, 286, 1275, 137, 3709, 139, 521, 141, 3, 193, 1, 4034, 2428, 122, 2385, 211, 119, 4, 797, 7, 1, 2658, 2893, 4, 3, 546, 1, 38, 9842, 16, 3, 193, 1, 5788, 890, 2, 41, 3709, 10050, 120, 6594, 4, 3, 119, 1, 3709, 16, 3, 174, 9, 3, 193, 1, 9890, 2297, 5, 3, 1264, 1, 5788, 890, 2, 405, 3709, 128, 4, 3, 1127, 1, 8, 505, 2853, 7465, 1329, 467, 21, 364, 677, 9, 3, 911, 2, 284, 1, 38, 4034, 2, 9890, 2297, 5, 12832, 6959, 2, 11358, 23864, 526, 3709, 7791, 46, 677, 11, 276, 20, 8, 1391, 993, 1, 3186, 366, 8, 206, 1, 3, 390, 983, 74, 21, 377, 8, 1391, 1, 2005, 7856, 23, 3, 200, 1, 524, 3709, 301, 455, 2406, 9, 7718, 3709, 4824, 2, 1315, 50, 707, 4, 3709, 4824]",1115.0,26928249,210
Modifiable Factors Associated With Aging Phenotypes Among Adult Survivors of Childhood Acute Lymphoblastic Leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-03-21,"Survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for low bone mineral density (BMD) and frail health, outcomes potentially modifiable by altering health behaviors and/or treating endocrine abnormalities. We evaluated associations between lifestyle and hormonal deficits with risk of low BMD and frailty among survivors of ALL. Participants included 862 survivors of ALL (median age, 31.3 years [range, 18.4 to 59.7 years]) enrolled in the St Jude Lifetime Cohort study. Bone density was measured using quantitative computed tomography of L1 through L2 vertebrae; low BMD was defined as an age- and sex-standardized z score < -1. The presence of frailty or prefrailty was defined as having at least two of the following: low muscle mass, self-reported exhaustion, low energy expenditure, slow walking speed, and weakness. Hormonal deficiencies were determined according to medical history, medications, and laboratory findings (insulin-like growth factor 1, follicle-stimulating hormone, luteinizing hormone, and testosterone levels). Logistic regression was used to examine associations between lifestyle (smoking, alcohol consumption, and activity levels) and deficiencies in growth hormone (GHD) and/or sex steroids with low BMD and frailty. Thirty percent of survivors met criteria for low BMD, and 18.6% for frailty/prefrailty. After adjusting for body mass index, low BMD was associated with GHD (odds ratio [OR], 1.59; 95% CI, 1.02 to 2.13) and current smoking (OR, 1.71; 95% CI, 1.02 to 2.85) among men; and GHD (OR, 2.18; 95% CI, 1.26 to 3.78) and moderate alcohol consumption (OR, 2.09; 95% CI, 1.14 to 3.83) among women. After adjusting for current age, the odds of frailty/prefrailty were increased among men with GHD (OR, 2.97; 95% CI, 1.56 to 5.67) and those who smoked (OR, 3.26; 95% CI, 1.65 to 6.43); there were no significant associations among women. The findings suggest that survivors of ALL should receive counseling regarding lifestyle and undergo screening for hormonal deficits to minimize the risk of low BMD and frailty.",Journal Article,1401.0,14.0,Survivors of childhood acute lymphoblastic ALL are at risk for low mineral density BMD and frail health outcomes potentially modifiable by altering health behaviors and/or treating endocrine abnormalities We evaluated associations between lifestyle and hormonal deficits with risk of low BMD and frailty among survivors of ALL Participants included 862 survivors of ALL median age 31.3 years range 18.4 to 59.7 years enrolled in the St Jude Lifetime Cohort study density was measured using quantitative computed tomography of L1 through L2 vertebrae low BMD was defined as an age- and sex-standardized z score -1 The presence of frailty or prefrailty was defined as having at least two of the following low muscle mass self-reported exhaustion low energy expenditure slow walking speed and weakness Hormonal deficiencies were determined according to medical history medications and laboratory findings insulin-like growth factor 1 follicle-stimulating hormone luteinizing hormone and testosterone levels Logistic regression was used to examine associations between lifestyle smoking alcohol consumption and activity levels and deficiencies in growth hormone GHD and/or sex steroids with low BMD and frailty Thirty percent of survivors met criteria for low BMD and 18.6 for frailty/prefrailty After adjusting for body mass index low BMD was associated with GHD odds ratio OR 1.59 95 CI 1.02 to 2.13 and current smoking OR 1.71 95 CI 1.02 to 2.85 among men and GHD OR 2.18 95 CI 1.26 to 3.78 and moderate alcohol consumption OR 2.09 95 CI 1.14 to 3.83 among women After adjusting for current age the odds of frailty/prefrailty were increased among men with GHD OR 2.97 95 CI 1.56 to 5.67 and those who smoked OR 3.26 95 CI 1.65 to 6.43 there were no significant associations among women The findings suggest that survivors of ALL should receive counseling regarding lifestyle and undergo screening for hormonal deficits to minimize the risk of low BMD and frailty,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 62, 32, 28, 43, 9, 154, 5033, 1263, 3503, 2, 7226, 341, 123, 751, 5222, 20, 4831, 341, 3704, 2, 15, 1367, 1293, 1171, 21, 194, 685, 59, 3487, 2, 1761, 2752, 5, 43, 1, 154, 3503, 2, 5289, 107, 332, 1, 62, 776, 159, 10753, 332, 1, 62, 52, 89, 456, 27, 60, 184, 203, 39, 6, 728, 67, 60, 346, 4, 3, 3062, 4841, 2898, 180, 45, 1263, 10, 644, 75, 1156, 1220, 872, 1, 729, 298, 5111, 7565, 154, 3503, 10, 395, 22, 35, 89, 2, 1035, 1670, 3905, 368, 14, 3, 463, 1, 5289, 15, 29779, 10, 395, 22, 1041, 28, 506, 100, 1, 3, 366, 154, 1502, 782, 1074, 210, 7960, 154, 2803, 8699, 3645, 7467, 5051, 2, 6408, 1761, 7159, 11, 509, 768, 6, 484, 532, 2679, 2, 1624, 272, 1601, 733, 129, 161, 14, 9109, 2122, 785, 8223, 785, 2, 2660, 148, 812, 320, 10, 95, 6, 1004, 685, 59, 3487, 979, 2197, 2421, 2, 128, 148, 2, 7159, 4, 129, 785, 14863, 2, 15, 1035, 4580, 5, 154, 3503, 2, 5289, 977, 714, 1, 332, 543, 371, 9, 154, 3503, 2, 203, 49, 9, 5289, 29779, 50, 1358, 9, 642, 782, 558, 154, 3503, 10, 41, 5, 14863, 610, 197, 15, 14, 728, 48, 58, 14, 588, 6, 18, 233, 2, 291, 979, 15, 14, 792, 48, 58, 14, 588, 6, 18, 772, 107, 325, 2, 14863, 15, 18, 203, 48, 58, 14, 432, 6, 27, 833, 2, 1163, 2197, 2421, 15, 18, 1730, 48, 58, 14, 213, 6, 27, 852, 107, 117, 50, 1358, 9, 291, 89, 3, 610, 1, 5289, 29779, 11, 101, 107, 325, 5, 14863, 15, 18, 1015, 48, 58, 14, 664, 6, 33, 598, 2, 135, 54, 7047, 15, 27, 432, 48, 58, 14, 556, 6, 49, 601, 125, 11, 77, 93, 685, 107, 117, 3, 272, 309, 17, 332, 1, 62, 257, 560, 2011, 666, 3487, 2, 1251, 453, 9, 1761, 2752, 6, 3241, 3, 43, 1, 154, 3503, 2, 5289]",1961.0,27001572,483
Cytogenetics Does Not Impact Outcomes in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-04-01,"The prognostic relevance of cytogenetics at diagnosis on the outcome of allogeneic hematopoietic stem cell transplantation (alloHCT) for adult acute lymphoblastic leukemia (ALL) remains unclear. We retrospectively analyzed outcomes of 333 adult ALL patients who underwent alloHCT at our institution over a 10-year period. Patients were classified according to disease status at transplantation (complete response [CR] 1 [n=202] or> CR1) and according to cytogenetic risk, defined as good (2%), intermediate (42%), poor (46%), or unknown (10%) based on available outcome data for each of the cytogenetic abnormalities. Three-year overall survival (OS), leukemia-free survival (LFS), and relapse incidence (RI) were 55.7%, 47.9% and 27.5%, respectively; 1-year nonrelapse mortality (NRM) was 17.3%. For patients undergoing alloHCT in CR1, 3-year OS, LFS, and RI were 69.8%, 62.3%, and 17.1%, respectively. In multivariable analysis, cytogenetic risk did not impact OS or LFS for the whole cohort or for patients who underwent transplantation in CR1. Disease status at alloHCT was an independent predictor for LFS (CR1 versus others: hazard ratio [HR], 3.17; P<.01) and OS (CR1 versus others: HR, 2.90; P<.01). Graft-versus-host disease prophylaxis with tacrolimus/sirolimus was associated with a low NRM of 11.5% in the alloHCT recipients in CR1. Our data indicate that cytogenetic risk is not an independent predictor of outcomes in alloHCT performed to treat adult ALL.",Journal Article,1390.0,6.0,The prognostic relevance of cytogenetics at diagnosis on the outcome of allogeneic hematopoietic stem cell transplantation alloHCT for adult acute lymphoblastic ALL remains unclear We retrospectively analyzed outcomes of 333 adult ALL patients who underwent alloHCT at our institution over a 10-year period Patients were classified according to disease status at transplantation complete response CR 1 n 202 or CR1 and according to cytogenetic risk defined as good 2 intermediate 42 poor 46 or unknown 10 based on available outcome data for each of the cytogenetic abnormalities Three-year overall survival OS leukemia-free survival LFS and relapse incidence RI were 55.7 47.9 and 27.5 respectively 1-year nonrelapse mortality NRM was 17.3 For patients undergoing alloHCT in CR1 3-year OS LFS and RI were 69.8 62.3 and 17.1 respectively In multivariable analysis cytogenetic risk did not impact OS or LFS for the whole cohort or for patients who underwent transplantation in CR1 Disease status at alloHCT was an independent predictor for LFS CR1 versus others hazard ratio HR 3.17 P .01 and OS CR1 versus others HR 2.90 P .01 Graft-versus-host disease prophylaxis with tacrolimus/sirolimus was associated with a low NRM of 11.5 in the alloHCT recipients in CR1 Our data indicate that cytogenetic risk is not an independent predictor of outcomes in alloHCT performed to treat adult ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 177, 2088, 1, 2510, 28, 147, 23, 3, 228, 1, 1063, 1007, 452, 31, 497, 5514, 9, 780, 286, 1275, 62, 469, 1200, 21, 894, 311, 123, 1, 9616, 780, 62, 7, 54, 208, 5514, 28, 114, 731, 252, 8, 79, 111, 727, 7, 11, 1373, 768, 6, 34, 156, 28, 497, 236, 51, 684, 14, 78, 5918, 15, 4516, 2, 768, 6, 1266, 43, 395, 22, 1178, 18, 919, 595, 334, 641, 15, 860, 79, 90, 23, 390, 228, 74, 9, 296, 1, 3, 1266, 1171, 169, 111, 63, 25, 118, 2647, 115, 25, 5674, 2, 429, 287, 9836, 11, 614, 67, 662, 83, 2, 428, 33, 106, 14, 111, 4640, 282, 4296, 10, 269, 27, 9, 7, 479, 5514, 4, 4516, 27, 111, 118, 5674, 2, 9836, 11, 790, 66, 744, 27, 2, 269, 14, 106, 4, 658, 65, 1266, 43, 205, 44, 345, 118, 15, 5674, 9, 3, 902, 180, 15, 9, 7, 54, 208, 497, 4, 4516, 34, 156, 28, 5514, 10, 35, 306, 980, 9, 5674, 4516, 185, 1749, 360, 197, 168, 27, 269, 19, 355, 2, 118, 4516, 185, 1749, 168, 18, 424, 19, 355, 1599, 185, 1204, 34, 2049, 5, 5643, 4519, 10, 41, 5, 8, 154, 4296, 1, 175, 33, 4, 3, 5514, 2190, 4, 4516, 114, 74, 1008, 17, 1266, 43, 16, 44, 35, 306, 980, 1, 123, 4, 5514, 173, 6, 943, 780, 62]",1384.0,27044907,518
Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-04-25,"Acute pancreatitis is one of the common causes of asparaginase intolerance. The mechanism is unknown, and genetic predisposition to asparaginase-induced pancreatitis has not been previously identified. To determine clinical risk factors for asparaginase-induced pancreatitis, we studied a cohort of 5,185 children and young adults with acute lymphoblastic leukemia, including 117 (2.3%) who were diagnosed with at least one episode of acute pancreatitis during therapy. A genome-wide association study was performed in the cohort and in an independent case-control group of 213 patients to identify genetic risk factors. Risk factors associated with pancreatitis included genetically defined Native American ancestry (P < .001), older age (P < .001), and higher cumulative dose of asparaginase (P < .001). No common variants reached genome-wide significance in the genome-wide association study, but a rare nonsense variant rs199695765 in CPA2, encoding carboxypeptidase A2, was highly associated with pancreatitis (hazard ratio, 587; 95% CI, 66.8 to 5166; P = 9.0  10(-9)). A gene-level analysis showed an excess of additional CPA2 variants in patients who did versus those who did not develop pancreatitis (P = .001). Sixteen CPA2 single-nucleotide polymorphisms were associated (P < .05) with pancreatitis, and 13 of 24 patients who carried at least one of these variants developed pancreatitis. Biologic functions that were overrepresented by common variants modestly associated with pancreatitis included purine metabolism and cytoskeleton regulation. Older age, higher exposure to asparaginase, and higher Native American ancestry were independent risk factors for pancreatitis in patients with acute lymphoblastic leukemia. Those who inherit a nonsense rare variant in the CPA2 gene had a markedly increased risk of asparaginase-induced pancreatitis.",Journal Article,1366.0,28.0,"Acute pancreatitis is one of the common causes of asparaginase intolerance The mechanism is unknown and genetic predisposition to asparaginase-induced pancreatitis has not been previously identified To determine clinical risk factors for asparaginase-induced pancreatitis we studied a cohort of 5,185 children and young adults with acute lymphoblastic including 117 2.3 who were diagnosed with at least one episode of acute pancreatitis during therapy A genome-wide association study was performed in the cohort and in an independent case-control group of 213 patients to identify genetic risk factors Risk factors associated with pancreatitis included genetically defined Native American ancestry P .001 older age P .001 and higher cumulative dose of asparaginase P .001 No common variants reached genome-wide significance in the genome-wide association study but a rare nonsense variant rs199695765 in CPA2 encoding carboxypeptidase A2 was highly associated with pancreatitis hazard ratio 587 95 CI 66.8 to 5166 P 9.0 10 -9 A gene-level analysis showed an excess of additional CPA2 variants in patients who did versus those who did not develop pancreatitis P .001 Sixteen CPA2 single-nucleotide polymorphisms were associated P .05 with pancreatitis and 13 of 24 patients who carried at least one of these variants developed pancreatitis Biologic functions that were overrepresented by common variants modestly associated with pancreatitis included purine metabolism and cytoskeleton regulation Older age higher exposure to asparaginase and higher Native American ancestry were independent risk factors for pancreatitis in patients with acute lymphoblastic Those who inherit a nonsense rare variant in the CPA2 gene had a markedly increased risk of asparaginase-induced pancreatitis",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 4535, 16, 104, 1, 3, 186, 1626, 1, 3709, 5266, 3, 670, 16, 860, 2, 336, 2863, 6, 3709, 277, 4535, 71, 44, 85, 373, 108, 6, 223, 38, 43, 130, 9, 3709, 277, 4535, 21, 656, 8, 180, 1, 33, 5805, 541, 2, 1169, 857, 5, 286, 1275, 141, 3843, 18, 27, 54, 11, 265, 5, 28, 506, 104, 6934, 1, 286, 4535, 190, 36, 8, 898, 1019, 248, 45, 10, 173, 4, 3, 180, 2, 4, 35, 306, 473, 182, 87, 1, 5833, 7, 6, 255, 336, 43, 130, 43, 130, 41, 5, 4535, 159, 2301, 395, 4646, 597, 3535, 19, 144, 434, 89, 19, 144, 2, 142, 967, 61, 1, 3709, 19, 144, 77, 186, 839, 1300, 898, 1019, 724, 4, 3, 898, 1019, 248, 45, 84, 8, 622, 9168, 1142, 68051, 4, 36230, 2362, 33631, 4099, 10, 561, 41, 5, 4535, 360, 197, 13934, 48, 58, 700, 66, 6, 68052, 19, 83, 13, 79, 83, 8, 145, 301, 65, 224, 35, 2612, 1, 402, 36230, 839, 4, 7, 54, 205, 185, 135, 54, 205, 44, 690, 4535, 19, 144, 3228, 36230, 226, 1579, 1203, 11, 41, 19, 474, 5, 4535, 2, 233, 1, 259, 7, 54, 2629, 28, 506, 104, 1, 46, 839, 276, 4535, 1283, 1681, 17, 11, 13094, 20, 186, 839, 5588, 41, 5, 4535, 159, 5006, 1600, 2, 11229, 863, 434, 89, 142, 645, 6, 3709, 2, 142, 4646, 597, 3535, 11, 306, 43, 130, 9, 4535, 4, 7, 5, 286, 1275, 135, 54, 35063, 8, 9168, 622, 1142, 4, 3, 36230, 145, 42, 8, 2195, 101, 43, 1, 3709, 277, 4535]",1783.0,27114598,262
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies.,Cancer,Cancer,2016-05-03,"Older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL) are reported to have a poor prognosis and few therapeutic options. In the current study, the authors evaluated treatment with single-agent blinatumomab in adults aged 65 years with r/r ALL. A total of 261 adults with r/r ALL who were examined across two phase 2 studies received blinatumomab in cycles of 4-week continuous infusion and 2-week treatment-free intervals. The primary endpoint in each study was complete remission (CR) or CR with partial hematologic recovery (CRh) during the first 2 cycles. Data were pooled and analyzed according to patient age at screening (aged 65 years vs aged <65 years). Of 36 older adults, 56% (95% confidence interval [95% CI], 38%-72%) achieved CR/CRh during the first 2 cycles compared with 46% (225 patients) (95% CI, 40%-53%) of younger adults. Complete minimal residual disease responses were 60% in older and 70% in younger responders. Three older responders (15%) and 61 younger responders (59%) proceeded to allogeneic hematopoietic stem cell transplantation. Kaplan-Meier curves overlapped for relapse-free and overall survival for both age groups. Older adults were found to have a similar incidence of grade 3 adverse events (AEs) as younger adults (86% vs 80%) but more grade 3 neurologic events (28% vs 13%). Cytokine release syndrome occurred in 7 older (19%) (1 case of grade 3) and 23 younger (10%) (4 cases of grade 3) adults. There were no treatment-related fatal AEs reported. Older adults with r/r ALL who were treated with single-agent blinatumomab were found to have similar hematologic response rates and incidence of grade 3 AEs compared with younger adults but had more neurologic events, which were reversible and primarily resolved with treatment interruption. Cancer 2016;122:2178-85.  2016 American Cancer Society.",Journal Article,1358.0,42.0,Older adults with relapsed/refractory B-precursor acute lymphoblastic r/r ALL are reported to have a poor prognosis and few therapeutic options In the current study the authors evaluated treatment with single-agent blinatumomab in adults aged 65 years with r/r ALL A total of 261 adults with r/r ALL who were examined across two phase 2 studies received blinatumomab in cycles of 4-week continuous infusion and 2-week treatment-free intervals The primary endpoint in each study was complete remission CR or CR with partial hematologic recovery CRh during the first 2 cycles Data were pooled and analyzed according to patient age at screening aged 65 years vs aged 65 years Of 36 older adults 56 95 confidence interval 95 CI 38 -72 achieved CR/CRh during the first 2 cycles compared with 46 225 patients 95 CI 40 -53 of younger adults Complete minimal residual disease responses were 60 in older and 70 in younger responders Three older responders 15 and 61 younger responders 59 proceeded to allogeneic hematopoietic stem cell transplantation Kaplan-Meier curves overlapped for relapse-free and overall survival for both age groups Older adults were found to have a similar incidence of grade 3 adverse events AEs as younger adults 86 vs 80 but more grade 3 neurologic events 28 vs 13 Cytokine release syndrome occurred in 7 older 19 1 case of grade 3 and 23 younger 10 4 cases of grade 3 adults There were no treatment-related fatal AEs reported Older adults with r/r ALL who were treated with single-agent blinatumomab were found to have similar hematologic response rates and incidence of grade 3 AEs compared with younger adults but had more neurologic events which were reversible and primarily resolved with treatment interruption Cancer 2016 122:2178-85  2016 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[434, 857, 5, 591, 430, 132, 2765, 286, 1275, 668, 668, 62, 32, 210, 6, 47, 8, 334, 356, 2, 1021, 189, 838, 4, 3, 291, 45, 3, 738, 194, 24, 5, 226, 420, 7182, 4, 857, 1032, 5827, 60, 5, 668, 668, 62, 8, 181, 1, 7007, 857, 5, 668, 668, 62, 54, 11, 409, 716, 100, 124, 18, 94, 103, 7182, 4, 410, 1, 39, 647, 1314, 904, 2, 18, 647, 24, 115, 1582, 3, 86, 1138, 4, 296, 45, 10, 236, 734, 684, 15, 684, 5, 450, 813, 1602, 18100, 190, 3, 157, 18, 410, 74, 11, 1830, 2, 311, 768, 6, 69, 89, 28, 453, 1032, 5827, 60, 105, 1032, 556, 60, 1, 511, 434, 857, 664, 48, 307, 268, 48, 58, 519, 720, 513, 684, 18100, 190, 3, 157, 18, 410, 72, 5, 641, 4011, 7, 48, 58, 327, 699, 1, 773, 857, 236, 1048, 753, 34, 253, 11, 335, 4, 434, 2, 431, 4, 773, 1983, 169, 434, 1983, 167, 2, 713, 773, 1983, 728, 6406, 6, 1063, 1007, 452, 31, 497, 876, 882, 2400, 12117, 9, 429, 115, 2, 63, 25, 9, 110, 89, 271, 434, 857, 11, 204, 6, 47, 8, 288, 287, 1, 88, 2608, 290, 281, 1477, 22, 773, 857, 868, 105, 493, 84, 80, 88, 2608, 2543, 281, 339, 105, 233, 1675, 2008, 681, 489, 4, 67, 434, 326, 14, 473, 1, 88, 27, 2, 382, 773, 79, 39, 140, 1, 88, 2608, 857, 125, 11, 77, 24, 139, 3034, 1477, 210, 434, 857, 5, 668, 668, 62, 54, 11, 73, 5, 226, 420, 7182, 11, 204, 6, 47, 288, 813, 51, 151, 2, 287, 1, 88, 2608, 1477, 72, 5, 773, 857, 84, 42, 80, 2543, 281, 92, 11, 2786, 2, 1561, 3862, 5, 24, 4823, 12, 1390, 3285, 48822, 772, 2206, 1390, 597, 12, 1174]",1797.0,27143254,658
Allogeneic transplantation is not superior to chemotherapy in most patients over 40years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission.,American journal of hematology,Am. J. Hematol.,2016-06-03,"Survival of patients 40years of age with Philadelphia-negative acute lymphoblastic leukemia (ALL) remains poor with current therapeutic approaches. It is unknown whether allogeneic hematopoietic stem-cell transplantation (HSCT) in first remission confers a survival benefit compared to a chemotherapy-only approach. We retrospectively compared the outcome of patients >40years treated with HSCT or chemotherapy alone in first remission (n=40 in each cohort). Three-year overall survival (OS) and disease-free survival (DFS) were not significantly different between the chemotherapy-only and HSCT groups (OS, 46% [31-68] vs. 40% [27-59], P=0.35; DFS, 31% [18-52] vs. 40% [27-59], P=0.98). The 3-year cumulative incidence of relapse (CIR) and non-relapse mortality (NRM) were 61% [41-76] and 9% [2-21] for the chemotherapy-only group and 28% [15-43] and 32% [17-47] for the transplant group (CIR, P=0.011; NRM, P=0.014). Allogeneic transplantation for patients 40years with Ph-negative ALL in first remission is associated with a lower CIR, but this benefit is offset by considerable NRM as compared with chemotherapy-only approach. HSCT may be beneficial in patients with high-risk disease features. Am. J. Hematol. 91:793-799, 2016.  2016 Wiley Periodicals, Inc.",Journal Article,1327.0,8.0,Survival of patients 40 years of age with Philadelphia-negative acute lymphoblastic ALL remains poor with current therapeutic approaches It is unknown whether allogeneic hematopoietic stem-cell transplantation HSCT in first remission confers a survival benefit compared to a chemotherapy-only approach We retrospectively compared the outcome of patients 40 years treated with HSCT or chemotherapy alone in first remission n 40 in each cohort Three-year overall survival OS and disease-free survival DFS were not significantly different between the chemotherapy-only and HSCT groups OS 46 31-68 vs. 40 27-59 P 0.35 DFS 31 18-52 vs. 40 27-59 P 0.98 The 3-year cumulative incidence of relapse CIR and non-relapse mortality NRM were 61 41-76 and 9 2-21 for the chemotherapy-only group and 28 15-43 and 32 17-47 for the transplant group CIR P 0.011 NRM P 0.014 Allogeneic transplantation for patients 40 years with Ph-negative ALL in first remission is associated with a lower CIR but this benefit is offset by considerable NRM as compared with chemotherapy-only approach HSCT may be beneficial in patients with high-risk disease features Am J. Hematol 91:793-799 2016  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[25, 1, 7, 8483, 60, 1, 89, 5, 3006, 199, 286, 1275, 62, 469, 334, 5, 291, 189, 611, 192, 16, 860, 317, 1063, 1007, 452, 31, 497, 1703, 4, 157, 734, 4020, 8, 25, 247, 72, 6, 8, 56, 158, 353, 21, 894, 72, 3, 228, 1, 7, 327, 60, 73, 5, 1703, 15, 56, 279, 4, 157, 734, 78, 327, 4, 296, 180, 169, 111, 63, 25, 118, 2, 34, 115, 25, 1010, 11, 44, 97, 338, 59, 3, 56, 158, 2, 1703, 271, 118, 641, 456, 806, 105, 327, 428, 728, 19, 13, 465, 1010, 456, 203, 653, 105, 327, 428, 728, 19, 13, 1096, 3, 27, 111, 967, 287, 1, 429, 6757, 2, 220, 429, 282, 4296, 11, 713, 605, 846, 2, 83, 18, 239, 9, 3, 56, 158, 87, 2, 339, 167, 601, 2, 531, 269, 662, 9, 3, 941, 87, 6757, 19, 13, 3651, 4296, 19, 13, 3618, 1063, 497, 9, 7, 8483, 60, 5, 2058, 199, 62, 4, 157, 734, 16, 41, 5, 8, 280, 6757, 84, 26, 247, 16, 9500, 20, 2658, 4296, 22, 72, 5, 56, 158, 353, 1703, 68, 40, 2524, 4, 7, 5, 64, 43, 34, 404, 5886, 3543, 13175, 970, 12282, 13096, 1390, 2206, 1390, 4692, 5493, 3479]",1194.0,27153389,626
"Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.",American journal of hematology,Am. J. Hematol.,2016-06-25,"Tumor hypoxia causes resistance to radiation and chemotherapy. Evofosfamide (TH-302) has exhibited specific hypoxia-dependent cytotoxicity against primary acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) samples in vitro. Based on these findings, a Phase I study of evofosfamide was designed for patients with relapsed/refractory leukemia (NCT01149915). In this open-label study, patients were treated with evofosfamide as a 30-60 min/day infusion on Days 1-5 of a 21-day cycle (Arm A, n=38) or as a continuous infusion over 120 hr over Days 1-5 of a 21-day cycle (Arm B, n=11). Forty-nine patients were treated including 39 (80%) with AML and 9 (18%) with ALL. Patients had received a median of five prior therapies. In Arm A, the dose-limiting toxicities (DLTs) were grade 3 esophagitis, observed at a dose of 550 mg/m(2) . The maximum tolerated dose (MTD) was a daily dose of 460 mg/m(2) . In Arm B, the DLTs were grade 3 stomatitis and hyperbilirubinemia, observed at a daily dose of 460 mg/m(2) . The continuous infusion MTD was a daily dose of 330 mg/m(2) . Hypoxia markers HIF-1 and CAIX were highly expressed in leukemic bone marrow and were significantly reduced after evofosfamide therapy. The combined overall response rate in Arms A and B was 6% (2 CR/CRi and 1 PR), with all responses seen in Arm A. Evofosfamide has shown limited activity in heavily pretreated leukemia patients. Further evaluation investigating evofosfamide in combination with cytotoxic or demethylating agents is warranted. Am. J. Hematol. 91:800-805, 2016.  2016 Wiley Periodicals, Inc.","Clinical Trial, Phase I",1305.0,11.0,Tumor hypoxia causes resistance to radiation and chemotherapy Evofosfamide TH-302 has exhibited specific hypoxia-dependent cytotoxicity against primary acute lymphoblastic ALL and acute myeloid AML samples in vitro Based on these findings a Phase I study of evofosfamide was designed for patients with relapsed/refractory NCT01149915 In this open-label study patients were treated with evofosfamide as a 30-60 min/day infusion on Days 1-5 of a 21-day cycle Arm A n 38 or as a continuous infusion over 120 hr over Days 1-5 of a 21-day cycle Arm B n 11 Forty-nine patients were treated including 39 80 with AML and 9 18 with ALL Patients had received a median of five prior therapies In Arm A the dose-limiting toxicities DLTs were grade 3 esophagitis observed at a dose of 550 mg/m 2 The maximum tolerated dose MTD was a daily dose of 460 mg/m 2 In Arm B the DLTs were grade 3 stomatitis and hyperbilirubinemia observed at a daily dose of 460 mg/m 2 The continuous infusion MTD was a daily dose of 330 mg/m 2 Hypoxia markers HIF-1 and CAIX were highly expressed in leukemic marrow and were significantly reduced after evofosfamide therapy The combined overall response rate in Arms A and B was 6 2 CR/CRi and 1 PR with all responses seen in Arm A. Evofosfamide has shown limited activity in heavily pretreated patients Further evaluation investigating evofosfamide in combination with cytotoxic or demethylating agents is warranted Am J. Hematol 91:800-805 2016  2016 Wiley Periodicals Inc,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[30, 1823, 1626, 251, 6, 121, 2, 56, 14713, 4517, 4952, 71, 1416, 112, 1823, 470, 1408, 480, 86, 286, 1275, 62, 2, 286, 533, 329, 347, 4, 439, 90, 23, 46, 272, 8, 124, 70, 45, 1, 14713, 10, 1114, 9, 7, 5, 591, 430, 68149, 4, 26, 1020, 1756, 45, 7, 11, 73, 5, 14713, 22, 8, 201, 335, 1538, 218, 904, 23, 162, 14, 33, 1, 8, 239, 218, 417, 475, 8, 78, 519, 15, 22, 8, 1314, 904, 252, 2031, 168, 252, 162, 14, 33, 1, 8, 239, 218, 417, 475, 132, 78, 175, 1213, 762, 7, 11, 73, 141, 587, 493, 5, 329, 2, 83, 203, 5, 62, 7, 42, 103, 8, 52, 1, 365, 324, 235, 4, 475, 8, 3, 61, 817, 385, 2506, 11, 88, 27, 5135, 164, 28, 8, 61, 1, 7935, 81, 188, 18, 3, 689, 421, 61, 961, 10, 8, 391, 61, 1, 11021, 81, 188, 18, 4, 475, 132, 3, 2506, 11, 88, 27, 4486, 2, 7236, 164, 28, 8, 391, 61, 1, 11021, 81, 188, 18, 3, 1314, 904, 961, 10, 8, 391, 61, 1, 7105, 81, 188, 18, 1823, 525, 2940, 3305, 2, 8421, 11, 561, 570, 4, 2015, 581, 2, 11, 97, 405, 50, 14713, 36, 3, 397, 63, 51, 116, 4, 1335, 8, 2, 132, 10, 49, 18, 684, 6341, 2, 14, 998, 5, 62, 253, 527, 4, 475, 8, 14713, 71, 443, 383, 128, 4, 2447, 2193, 7, 195, 451, 3103, 14713, 4, 150, 5, 759, 15, 8399, 183, 16, 1197, 5886, 3543, 13175, 970, 2796, 13628, 1390, 2206, 1390, 4692, 5493, 3479]",1490.0,27169385,331
Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia.,Cancer,Cancer,2016-05-12,"Outcomes among older patients with acute lymphoblastic leukemia remain poor. This study sought to determine the efficacy of an intensified, multi-agent approach derived from a Dana-Farber consortium trial in younger adults for patients older than 50 years (trial identifier NCT00973752). The primary endpoint was overall survival (OS) at 1 year. Patients received induction chemotherapy with vincristine, prednisone, doxorubicin, and pegylated asparaginase. Imatinib was incorporated for Philadelphia chromosome-positive disease. After induction, the first consolidation incorporated clofarabine. Patients in remission could proceed to allogeneic hematopoietic cell transplantation (HCT) after induction and consolidation I. Those not receiving HCT went on to receive central nervous system, consolidation II, and continuation phases of treatment. Thirty patients were enrolled: 19 achieved a complete remission (CR) after induction and 1 achieved CR after consolidation I for a CR rate of 67%. Sixteen patients underwent HCT. The proportion surviving at 1 year was 63%, and this met the primary endpoint. The 2-year OS rate was 52% (n = 30), and the 2-year disease-free survival rate was 52% for patients achieving CR (n = 20). There was no survival advantage among those undergoing HCT. Therapy-related hyperbilirubinemia prompted adjustments and limitations to asparaginase dosing. Intensified chemotherapy can result in improved outcomes in comparison with historical data. Additional studies of similarly intensive regimens are warranted in this population. Cancer 2016;122:2379-2388.  2016 American Cancer Society.","Clinical Trial, Phase II",1349.0,12.0,Outcomes among older patients with acute lymphoblastic remain poor This study sought to determine the efficacy of an intensified multi-agent approach derived from a Dana-Farber consortium trial in younger adults for patients older than 50 years trial identifier NCT00973752 The primary endpoint was overall survival OS at 1 year Patients received induction chemotherapy with vincristine prednisone doxorubicin and pegylated asparaginase Imatinib was incorporated for Philadelphia chromosome-positive disease After induction the first consolidation incorporated clofarabine Patients in remission could proceed to allogeneic hematopoietic cell transplantation HCT after induction and consolidation I Those not receiving HCT went on to receive central nervous system consolidation II and continuation phases of treatment Thirty patients were enrolled 19 achieved a complete remission CR after induction and 1 achieved CR after consolidation I for a CR rate of 67 Sixteen patients underwent HCT The proportion surviving at 1 year was 63 and this met the primary endpoint The 2-year OS rate was 52 n 30 and the 2-year disease-free survival rate was 52 for patients achieving CR n 20 There was no survival advantage among those undergoing HCT Therapy-related hyperbilirubinemia prompted adjustments and limitations to asparaginase dosing Intensified chemotherapy can result in improved outcomes in comparison with historical data Additional studies of similarly intensive regimens are warranted in this population Cancer 2016 122:2379-2388  2016 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[123, 107, 434, 7, 5, 286, 1275, 918, 334, 26, 45, 990, 6, 223, 3, 209, 1, 35, 7311, 1414, 420, 353, 526, 29, 8, 4932, 4979, 2404, 160, 4, 773, 857, 9, 7, 434, 76, 212, 60, 160, 3719, 68157, 3, 86, 1138, 10, 63, 25, 118, 28, 14, 111, 7, 103, 504, 56, 5, 2132, 1979, 856, 2, 4424, 3709, 577, 10, 2449, 9, 3006, 1170, 109, 34, 50, 504, 3, 157, 2173, 2449, 4149, 7, 4, 734, 359, 6174, 6, 1063, 1007, 31, 497, 1085, 50, 504, 2, 2173, 70, 135, 44, 357, 1085, 7109, 23, 6, 560, 854, 1880, 398, 2173, 215, 2, 6870, 3523, 1, 24, 977, 7, 11, 346, 326, 513, 8, 236, 734, 684, 50, 504, 2, 14, 513, 684, 50, 2173, 70, 9, 8, 684, 116, 1, 598, 3228, 7, 208, 1085, 3, 920, 3050, 28, 14, 111, 10, 676, 2, 26, 543, 3, 86, 1138, 3, 18, 111, 118, 116, 10, 653, 78, 201, 2, 3, 18, 111, 34, 115, 25, 116, 10, 653, 9, 7, 1785, 684, 78, 179, 125, 10, 77, 25, 1874, 107, 135, 479, 1085, 36, 139, 7236, 4140, 6017, 2, 1939, 6, 3709, 1280, 7311, 56, 122, 757, 4, 231, 123, 4, 1155, 5, 2252, 74, 402, 94, 1, 1813, 1686, 472, 32, 1197, 4, 26, 266, 12, 1390, 3285, 68158, 49734, 2206, 1390, 597, 12, 1174]",1564.0,27171984,672
"Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Mnster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen.",American journal of hematology,Am. J. Hematol.,2016-06-30,"Several studies reported improved outcomes of adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL) treated with pediatric-based ALL regimens. This prompted the prospective investigation of a pediatric Augmented Berlin-Frankfurt-Mnster (ABFM) regimen, and its comparison with hyper-fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone (hyper-CVAD) in AYA patients. One hundred and six AYA patients (median age 22 years) with Philadelphia chromosome- (Ph) negative ALL received ABFM from October 2006 through March 2014. Their outcome was compared to 102 AYA patients (median age 27 years), treated with hyper-CVAD at our institution. The complete remission (CR) rate was 93% with ABFM and 98% with hyper-CVAD. The 5-year complete remission duration (CRD) were 53 and 55%, respectively (P=0.98). The 5-year overall survival (OS) rates were 60 and 60%, respectively. The MRD status on Day 29 and Day 84 of therapy was predictive of long-term outcomes on both ABFM and hyper-CVAD. Severe regimen toxicities with ABFM included hepatotoxicity in 41%, pancreatitis in 11%, osteonecrosis in 9%, and thrombosis in 19%. Myelosuppression-associated complications were most significant with hyper-CVAD. In summary, ABFM and hyper-CVAD resulted in similar efficacy outcomes, but were associated with different toxicity profiles, asparaginase-related with ABFM and myelosuppression-related with hyper-CVAD. Am. J. Hematol. 91:819-823, 2016.  2016 Wiley Periodicals, Inc.",Comparative Study,1300.0,36.0,Several studies reported improved outcomes of adolescents and young adults AYA with acute lymphoblastic ALL treated with pediatric-based ALL regimens This prompted the prospective investigation of a pediatric Augmented Berlin-Frankfurt-Mnster ABFM regimen and its comparison with hyper-fractionated cyclophosphamide vincristine Adriamycin and dexamethasone hyper-CVAD in AYA patients One hundred and six AYA patients median age 22 years with Philadelphia chromosome- Ph negative ALL received ABFM from October 2006 through March 2014 Their outcome was compared to 102 AYA patients median age 27 years treated with hyper-CVAD at our institution The complete remission CR rate was 93 with ABFM and 98 with hyper-CVAD The 5-year complete remission duration CRD were 53 and 55 respectively P 0.98 The 5-year overall survival OS rates were 60 and 60 respectively The MRD status on Day 29 and Day 84 of therapy was predictive of long-term outcomes on both ABFM and hyper-CVAD Severe regimen toxicities with ABFM included hepatotoxicity in 41 pancreatitis in 11 osteonecrosis in 9 and thrombosis in 19 Myelosuppression-associated complications were most significant with hyper-CVAD In summary ABFM and hyper-CVAD resulted in similar efficacy outcomes but were associated with different toxicity profiles asparaginase-related with ABFM and myelosuppression-related with hyper-CVAD Am J. Hematol 91:819-823 2016  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[392, 94, 210, 231, 123, 1, 3101, 2, 1169, 857, 4598, 5, 286, 1275, 62, 73, 5, 815, 90, 62, 472, 26, 4140, 3, 482, 940, 1, 8, 815, 4277, 20405, 23389, 26350, 20857, 477, 2, 211, 1155, 5, 4855, 3950, 1112, 2132, 7700, 2, 1217, 4855, 5574, 4, 4598, 7, 104, 1128, 2, 437, 4598, 7, 52, 89, 350, 60, 5, 3006, 1170, 2058, 199, 62, 103, 20857, 29, 2551, 1324, 298, 2363, 1409, 136, 228, 10, 72, 6, 2867, 4598, 7, 52, 89, 428, 60, 73, 5, 4855, 5574, 28, 114, 731, 3, 236, 734, 684, 116, 10, 966, 5, 20857, 2, 1096, 5, 4855, 5574, 3, 33, 111, 236, 734, 654, 9366, 11, 699, 2, 614, 106, 19, 13, 1096, 3, 33, 111, 63, 25, 118, 151, 11, 335, 2, 335, 106, 3, 2029, 156, 23, 218, 462, 2, 218, 874, 1, 36, 10, 464, 1, 319, 337, 123, 23, 110, 20857, 2, 4855, 5574, 905, 477, 385, 5, 20857, 159, 6667, 4, 605, 4535, 4, 175, 5404, 4, 83, 2, 2839, 4, 326, 2858, 41, 521, 11, 96, 93, 5, 4855, 5574, 4, 1962, 20857, 2, 4855, 5574, 627, 4, 288, 209, 123, 84, 11, 41, 5, 338, 155, 1241, 3709, 139, 5, 20857, 2, 2858, 139, 5, 4855, 5574, 5886, 3543, 13175, 970, 16447, 12613, 1390, 2206, 1390, 4692, 5493, 3479]",1432.0,27178680,711
The Role of Leukapheresis in the Current Management of Hyperleukocytosis in Newly Diagnosed Childhood Acute Lymphoblastic Leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2016-05-17,"Hyperleukocytosis in children with acute lymphoblastic leukemia (ALL) has been associated with early morbidity and mortality. The use of leukapheresis in these children treated with contemporary therapy remains controversial. We analyzed clinical data from patients enrolled onto frontline protocols for ALL (Total Therapy XV and XVI) between 2003 and 2014. We documented adverse events within the first 14 days in patients with a white blood cell (WBC) count 200  10(9) /l and reviewed their management. Fifty-three (7.8%) of 678 consecutive pediatric patients with newly diagnosed ALL presented with hyperleukocytosis (median WBC count 393  10(9) /l; range 200-1,014). Two deaths in patients without initial hyperleukocytosis occurred within the first 2 weeks from diagnosis secondary to bacterial sepsis. A total of 21 (40%) patients with ALL and hyperleukocytosis developed grade 3 or 4 adverse events regardless of the use of leukapheresis (P > 0.99 and P = 0.19). Sixteen of 53 (30%) patients with ALL received low-dose chemotherapy for leukocytoreduction initially. One-third of patients received urate oxidase, and none of the patients with hyperleukocytosis required hemodialysis. The early morbidity and mortality commonly associated with hyperleukocytosis in children with newly diagnosed ALL can be avoided with contemporary supportive care and conservative management possibly obviating the need for costly and potentially dangerous leukapheresis.",Journal Article,1344.0,7.0,"Hyperleukocytosis in children with acute lymphoblastic ALL has been associated with early morbidity and mortality The use of leukapheresis in these children treated with contemporary therapy remains controversial We analyzed clinical data from patients enrolled onto frontline protocols for ALL Total Therapy XV and XVI between 2003 and 2014 We documented adverse events within the first 14 days in patients with a white blood cell WBC count 200 10 9 /l and reviewed their management Fifty-three 7.8 of 678 consecutive pediatric patients with newly diagnosed ALL presented with hyperleukocytosis median WBC count 393 10 9 /l range 200-1,014 Two deaths in patients without initial hyperleukocytosis occurred within the first 2 weeks from diagnosis secondary to bacterial sepsis A total of 21 40 patients with ALL and hyperleukocytosis developed grade 3 or 4 adverse events regardless of the use of leukapheresis P 0.99 and P 0.19 Sixteen of 53 30 patients with ALL received low-dose chemotherapy for leukocytoreduction initially One-third of patients received urate oxidase and none of the patients with hyperleukocytosis required hemodialysis The early morbidity and mortality commonly associated with hyperleukocytosis in children with newly diagnosed ALL can be avoided with contemporary supportive care and conservative management possibly obviating the need for costly and potentially dangerous leukapheresis",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[15558, 4, 541, 5, 286, 1275, 62, 71, 85, 41, 5, 191, 787, 2, 282, 3, 119, 1, 12554, 4, 46, 541, 73, 5, 2667, 36, 469, 2010, 21, 311, 38, 74, 29, 7, 346, 3301, 3171, 2189, 9, 62, 181, 36, 16078, 2, 25082, 59, 1522, 2, 1409, 21, 1405, 290, 281, 262, 3, 157, 213, 162, 4, 7, 5, 8, 886, 315, 31, 4685, 1276, 27529, 79, 83, 805, 2, 446, 136, 284, 1461, 169, 67, 66, 1, 14892, 935, 815, 7, 5, 732, 265, 62, 917, 5, 15558, 52, 4685, 1276, 9351, 79, 83, 805, 184, 1250, 14, 3618, 100, 1043, 4, 7, 187, 388, 15558, 489, 262, 3, 157, 18, 244, 29, 147, 568, 6, 5117, 4227, 8, 181, 1, 239, 327, 7, 5, 62, 2, 15558, 276, 88, 27, 15, 39, 290, 281, 1583, 1, 3, 119, 1, 12554, 19, 13, 1058, 2, 19, 13, 326, 3228, 1, 699, 201, 7, 5, 62, 103, 154, 61, 56, 9, 68189, 1625, 104, 1282, 1, 7, 103, 20281, 10447, 2, 1292, 1, 3, 7, 5, 15558, 616, 11170, 3, 191, 787, 2, 282, 841, 41, 5, 15558, 4, 541, 5, 732, 265, 62, 122, 40, 5617, 5, 2667, 1877, 165, 2, 4476, 284, 2150, 21174, 3, 594, 9, 6288, 2, 751, 22026, 12554]",1413.0,27187265,628
Characterization of leukemias with ETV6-ABL1 fusion.,Haematologica,Haematologica,2016-05-26,"To characterize the incidence, clinical features and genetics of ETV6-ABL1 leukemias, representing targetable kinase-activating lesions, we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies [22 cases of acute lymphoblastic leukemia (13 children, 9 adults) and 22 myeloid malignancies (18 myeloproliferative neoplasms, 4 acute myeloid leukemias)]. The presence of the ETV6-ABL1 fusion was ascertained by cytogenetics, fluorescence in-situ hybridization, reverse transcriptase-polymerase chain reaction and RNA sequencing. Genomic and gene expression profiling was performed by single nucleotide polymorphism and expression arrays. Systematic screening of more than 4,500 cases revealed that in acute lymphoblastic leukemia ETV6-ABL1 is rare in childhood (0.17% cases) and slightly more common in adults (0.38%). There is no systematic screening of myeloproliferative neoplasms; however, the number of ETV6-ABL1-positive cases and the relative incidence of acute lymphoblastic leukemia and myeloproliferative neoplasms suggest that in adulthood ETV6-ABL1 is more common in BCR-ABL1-negative chronic myeloid leukemia-like myeloproliferations than in acute lymphoblastic leukemia. The genomic profile of ETV6-ABL1 acute lymphoblastic leukemia resembled that of BCR-ABL1 and BCR-ABL1-like cases with 80% of patients having concurrent CDKN2A/B and IKZF1 deletions. In the gene expression profiling all the ETV6-ABL1-positive samples clustered in close vicinity to BCR-ABL1 cases. All but one of the cases of ETV6-ABL1 acute lymphoblastic leukemia were classified as BCR-ABL1-like by a standardized assay. Over 60% of patients died, irrespectively of the disease or age subgroup examined. In conclusion, ETV6-ABL1 fusion occurs in both lymphoid and myeloid leukemias; the genomic profile and clinical behavior resemble BCR-ABL1-positive malignancies, including the unfavorable prognosis, particularly of acute leukemias. The poor outcome suggests that treatment with tyrosine kinase inhibitors should be considered for patients with this fusion.",Journal Article,1335.0,23.0,"To characterize the incidence clinical features and genetics of ETV6-ABL1 leukemias representing targetable kinase-activating lesions we analyzed 44 new and published cases of ETV6-ABL1-positive hematologic malignancies 22 cases of acute lymphoblastic 13 children 9 adults and 22 myeloid malignancies 18 neoplasms 4 acute myeloid leukemias The presence of the ETV6-ABL1 fusion was ascertained by cytogenetics fluorescence in-situ hybridization reverse transcriptase-polymerase chain reaction and RNA sequencing Genomic and gene expression profiling was performed by single nucleotide polymorphism and expression arrays Systematic screening of more than 4,500 cases revealed that in acute lymphoblastic ETV6-ABL1 is rare in childhood 0.17 cases and slightly more common in adults 0.38 There is no systematic screening of neoplasms however the number of ETV6-ABL1-positive cases and the relative incidence of acute lymphoblastic and neoplasms suggest that in adulthood ETV6-ABL1 is more common in BCR-ABL1-negative chronic myeloid leukemia-like myeloproliferations than in acute lymphoblastic The genomic profile of ETV6-ABL1 acute lymphoblastic resembled that of BCR-ABL1 and BCR-ABL1-like cases with 80 of patients having concurrent CDKN2A/B and IKZF1 deletions In the gene expression profiling all the ETV6-ABL1-positive samples clustered in close vicinity to BCR-ABL1 cases All but one of the cases of ETV6-ABL1 acute lymphoblastic were classified as BCR-ABL1-like by a standardized assay Over 60 of patients died irrespectively of the disease or age subgroup examined In conclusion ETV6-ABL1 fusion occurs in both lymphoid and myeloid leukemias the genomic profile and clinical behavior resemble BCR-ABL1-positive malignancies including the unfavorable prognosis particularly of acute leukemias The poor outcome suggests that treatment with tyrosine kinase inhibitors should be considered for patients with this fusion",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 1507, 3, 287, 38, 404, 2, 2894, 1, 7306, 3557, 2792, 2861, 3985, 216, 1616, 406, 21, 311, 584, 217, 2, 983, 140, 1, 7306, 3557, 109, 813, 441, 350, 140, 1, 286, 1275, 233, 541, 83, 857, 2, 350, 533, 441, 203, 1179, 39, 286, 533, 2792, 3, 463, 1, 3, 7306, 3557, 1212, 10, 5240, 20, 2510, 1591, 4, 957, 1554, 1772, 4456, 1451, 1260, 1329, 2, 893, 615, 572, 2, 145, 55, 1080, 10, 173, 20, 226, 1579, 1907, 2, 55, 3923, 1556, 453, 1, 80, 76, 39, 1666, 140, 553, 17, 4, 286, 1275, 7306, 3557, 16, 622, 4, 864, 13, 269, 140, 2, 3223, 80, 186, 4, 857, 13, 519, 125, 16, 77, 1556, 453, 1, 1179, 137, 3, 207, 1, 7306, 3557, 109, 140, 2, 3, 580, 287, 1, 286, 1275, 2, 1179, 309, 17, 4, 6002, 7306, 3557, 16, 80, 186, 4, 1062, 3557, 199, 442, 533, 2647, 733, 68270, 76, 4, 286, 1275, 3, 572, 800, 1, 7306, 3557, 286, 1275, 11311, 17, 1, 1062, 3557, 2, 1062, 3557, 733, 140, 5, 493, 1, 7, 1041, 750, 3175, 132, 2, 8422, 2439, 4, 3, 145, 55, 1080, 62, 3, 7306, 3557, 109, 347, 6464, 4, 2336, 19775, 6, 1062, 3557, 140, 62, 84, 104, 1, 3, 140, 1, 7306, 3557, 286, 1275, 11, 1373, 22, 1062, 3557, 733, 20, 8, 1670, 719, 252, 335, 1, 7, 1016, 45054, 1, 3, 34, 15, 89, 1363, 409, 4, 1221, 7306, 3557, 1212, 1780, 4, 110, 2303, 2, 533, 2792, 3, 572, 800, 2, 38, 1710, 8247, 1062, 3557, 109, 441, 141, 3, 2483, 356, 823, 1, 286, 2792, 3, 334, 228, 844, 17, 24, 5, 564, 216, 222, 257, 40, 515, 9, 7, 5, 26, 1212]",1921.0,27229714,195
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.,Blood,Blood,2016-05-27,"The impact of achieving complete molecular response (CMR) in Philadelphia chromosome-positive (Ph(+)) acute lymphoblastic leukemia (ALL) remains undefined. We evaluated the impact of CMR on outcomes among 85 patients with Ph(+) ALL who received first-line hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine plus a tyrosine kinase inhibitor, had minimal residual disease (MRD) assessments for BCR-ABL1 by quantitative polymerase chain reaction at complete remission (CR) and at 3-month time points, and did not undergo allogeneic stem cell transplantation (SCT). MRD status at 3 months had better discrimination for overall survival (OS; P = .005) and relapse-free survival (RFS; P = .002) than did MRD status at CR (P = .11 and P = .04, respectively). At 3 months, achievement of CMR vs response less than CMR was associated with longer median OS (127 vs 38 months, respectively; P = .009) and RFS (126 vs 18 months, respectively; P = .007). By multivariate analysis, only CMR at 3 months was prognostic for OS (hazard ratio, 0.42; 95% confidence interval, 0.21-0.82; P = .01). Patients with Ph(+) ALL who achieve CMR at 3 months have superior survival compared with those with lesser molecular responses and have excellent long-term outcomes even without SCT.",Journal Article,1334.0,60.0,The impact of achieving complete molecular response CMR in Philadelphia chromosome-positive Ph acute lymphoblastic ALL remains undefined We evaluated the impact of CMR on outcomes among 85 patients with Ph ALL who received first-line hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with methotrexate and high-dose cytarabine plus a tyrosine kinase inhibitor had minimal residual disease MRD assessments for BCR-ABL1 by quantitative polymerase chain reaction at complete remission CR and at 3-month time points and did not undergo allogeneic stem cell transplantation SCT MRD status at 3 months had better discrimination for overall survival OS P .005 and relapse-free survival RFS P .002 than did MRD status at CR P .11 and P .04 respectively At 3 months achievement of CMR vs response less than CMR was associated with longer median OS 127 vs 38 months respectively P .009 and RFS 126 vs 18 months respectively P .007 By multivariate analysis only CMR at 3 months was prognostic for OS hazard ratio 0.42 95 confidence interval 0.21-0.82 P .01 Patients with Ph ALL who achieve CMR at 3 months have superior survival compared with those with lesser molecular responses and have excellent long-term outcomes even without SCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 345, 1, 1785, 236, 219, 51, 7334, 4, 3006, 1170, 109, 2058, 286, 1275, 62, 469, 5425, 21, 194, 3, 345, 1, 7334, 23, 123, 107, 772, 7, 5, 2058, 62, 54, 103, 157, 328, 6201, 1112, 2132, 856, 2, 1217, 5181, 5, 2116, 2, 64, 61, 1855, 349, 8, 564, 216, 230, 42, 1048, 753, 34, 2029, 2182, 9, 1062, 3557, 20, 1156, 1451, 1260, 1329, 28, 236, 734, 684, 2, 28, 27, 811, 98, 862, 2, 205, 44, 1251, 1063, 452, 31, 497, 1988, 2029, 156, 28, 27, 53, 42, 380, 3520, 9, 63, 25, 118, 19, 1614, 2, 429, 115, 25, 1272, 19, 1111, 76, 205, 2029, 156, 28, 684, 19, 175, 2, 19, 755, 106, 28, 27, 53, 5088, 1, 7334, 105, 51, 299, 76, 7334, 10, 41, 5, 589, 52, 118, 4080, 105, 519, 53, 106, 19, 2376, 2, 1272, 3927, 105, 203, 53, 106, 19, 1999, 20, 331, 65, 158, 7334, 28, 27, 53, 10, 177, 9, 118, 360, 197, 13, 595, 48, 307, 268, 13, 239, 13, 878, 19, 355, 7, 5, 2058, 62, 54, 1359, 7334, 28, 27, 53, 47, 1123, 25, 72, 5, 135, 5, 5191, 219, 253, 2, 47, 1503, 319, 337, 123, 871, 187, 1988]",1263.0,27235138,0
Biology and clinical application of CAR T cells for B cell malignancies.,International journal of hematology,Int. J. Hematol.,2016-06-04,"Chimeric antigen receptor (CAR)-modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies. CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy. We review here the T cell biology and cell engineering research that led to the development of second generation CARs, the selection of CD19 as a CAR target, and the preclinical studies in animal models that laid the foundation for clinical trials targeting CD19+ malignancies. We further summarize the status of CD19 CAR clinical therapy for non-Hodgkin lymphoma and B cell acute lymphoblastic leukemia, including their efficacy, toxicities (cytokine release syndrome, neurotoxicity and B cell aplasia) and current management in humans. We conclude with an overview of recent pre-clinical advances in CAR design that argues favorably for the advancement of CAR therapy to tackle other hematological malignancies as well as solid tumors. ",Journal Article,1326.0,35.0,Chimeric antigen receptor CAR -modified T cells have generated broad interest in oncology following a series of dramatic clinical successes in patients with chemorefractory B cell malignancies CAR therapy now appears to be on the cusp of regulatory approval as a cell-based immunotherapy We review here the T cell biology and cell engineering research that led to the development of second generation CARs the selection of CD19 as a CAR target and the preclinical studies in animal models that laid the foundation for clinical trials targeting CD19+ malignancies We further summarize the status of CD19 CAR clinical therapy for and B cell acute lymphoblastic including their efficacy toxicities cytokine release syndrome neurotoxicity and B cell aplasia and current management in humans We conclude with an overview of recent pre-clinical advances in CAR design that argues favorably for the advancement of CAR therapy to tackle other hematological malignancies as well as solid tumors,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2897, 448, 153, 1881, 1230, 102, 37, 47, 1419, 2094, 1333, 4, 413, 366, 8, 988, 1, 3079, 38, 6697, 4, 7, 5, 8923, 132, 31, 441, 1881, 36, 1134, 1233, 6, 40, 23, 3, 68341, 1, 1253, 1814, 22, 8, 31, 90, 726, 21, 206, 467, 3, 102, 31, 891, 2, 31, 6717, 389, 17, 836, 6, 3, 193, 1, 419, 914, 7441, 3, 881, 1, 3158, 22, 8, 1881, 283, 2, 3, 693, 94, 4, 2026, 274, 17, 23409, 3, 3247, 9, 38, 143, 529, 3158, 441, 21, 195, 2479, 3, 156, 1, 3158, 1881, 38, 36, 9, 2, 132, 31, 286, 1275, 141, 136, 209, 385, 1675, 2008, 681, 3561, 2, 132, 31, 12307, 2, 291, 284, 4, 3218, 21, 2060, 5, 35, 2901, 1, 435, 671, 38, 954, 4, 1881, 771, 17, 14473, 5001, 9, 3, 7496, 1, 1881, 36, 6, 24165, 127, 2890, 441, 22, 149, 22, 537, 57]",985.0,27262700,363
Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2016-07-01,"Curative-intent therapy leads to complete remissions in many adults with acute myeloid leukemia (AML), but relapse remains common. Numerous studies have unequivocally demonstrated that the persistence of measurable ('minimal') residual disease (MRD) at the submicroscopic level during morphologic remission identifies patients at high risk of disease recurrence and short survival. This association has provided the impetus to customize anti-leukemia therapy based on MRD data, a strategy that is now routinely pursued in acute promyelocytic leukemia (APL). While it is currently uncertain whether this approach will improve outcomes in AML other than APL, randomized studies have validated MRD-based risk-stratified treatment algorithms in acute lymphoblastic leukemia. Here, we review the available studies examining MRD-directed therapy in AML, appraise their strengths and limitations, and discuss avenues for future investigation.",Journal Article,1299.0,7.0,Curative-intent therapy leads to complete remissions in many adults with acute myeloid AML but relapse remains common Numerous studies have unequivocally demonstrated that the persistence of measurable 'minimal residual disease MRD at the submicroscopic level during morphologic remission identifies patients at high risk of disease recurrence and short survival This association has provided the impetus to customize anti-leukemia therapy based on MRD data a strategy that is now routinely pursued in acute promyelocytic APL While it is currently uncertain whether this approach will improve outcomes in AML other than APL randomized studies have validated MRD-based risk-stratified treatment algorithms in acute lymphoblastic Here we review the available studies examining MRD-directed therapy in AML appraise their strengths and limitations and discuss avenues for future investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1075, 1697, 36, 1940, 6, 236, 3166, 4, 445, 857, 5, 286, 533, 329, 84, 429, 469, 186, 2331, 94, 47, 15095, 264, 17, 3, 4108, 1, 1884, 68348, 753, 34, 2029, 28, 3, 19675, 301, 190, 2815, 734, 2953, 7, 28, 64, 43, 1, 34, 146, 2, 978, 25, 26, 248, 71, 1052, 3, 11582, 6, 22144, 312, 2647, 36, 90, 23, 2029, 74, 8, 692, 17, 16, 1134, 3066, 5299, 4, 286, 4300, 2578, 369, 192, 16, 694, 2717, 317, 26, 353, 303, 401, 123, 4, 329, 127, 76, 2578, 384, 94, 47, 938, 2029, 90, 43, 1173, 24, 3529, 4, 286, 1275, 467, 21, 206, 3, 390, 94, 3282, 2029, 1166, 36, 4, 329, 18976, 136, 9127, 2, 1939, 2, 1139, 6612, 9, 508, 940]",888.0,27269126,660
Chemotherapy Pharmacodynamics and Neuroimaging and Neurocognitive Outcomes in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-06-06,"To examine associations among methotrexate pharmacodynamics, neuroimaging, and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic leukemia treated on a contemporary chemotherapy-only protocol. This longitudinal study linked pharmacokinetic assays collected during therapy to neurocognitive and brain imaging outcomes during long-term follow-up. A total of 218 (72.2%) of 302 eligible long-term survivors were recruited for outcome studies when they were more than 5 years post-diagnosis and older than 8 years of age. At long-term follow-up, survivors were an average of 13.8 years old and 7.7 years from diagnosis, and 51% were male. Neurocognitive testing, functional magnetic resonance imaging (MRI) during an executive function task, and structural MRI with diffusion tensor imaging were conducted. Generalized linear models were developed to identify predictors, and models were adjusted for age at diagnosis, sex, and parent education. Intelligence was within normal limits (mean, 98; standard deviation, 14) compared with population expectations (mean, 100; standard deviation, 15), though measures of executive function, processing speed, and memory were less than population means (all P < .02 after correction for false discovery rates). Higher plasma concentration of methotrexate was associated with a poorer executive function score (P < .02). Higher plasma methotrexate was also associated with higher functional MRI activity, with thicker cortices in dorsolateral prefrontal brain regions, and with white matter microstructure in the frontostriatal tact. Neurocognitive impairment was associated with these imaging findings as well. Associations did not change after adjustment for age or dose of leucovorin rescue. Survivors of childhood acute lymphoblastic leukemia treated on contemporary chemotherapy-only protocols demonstrate executive dysfunction. A higher plasma concentration of methotrexate was associated with executive dysfunction as well as with a thicker cortex and higher activity in frontal brain regions, regions often associated with executive function.",Journal Article,1324.0,42.0,To examine associations among methotrexate pharmacodynamics neuroimaging and neurocognitive outcomes in long-term survivors of childhood acute lymphoblastic treated on a contemporary chemotherapy-only protocol This longitudinal study linked pharmacokinetic assays collected during therapy to neurocognitive and brain imaging outcomes during long-term follow-up A total of 218 72.2 of 302 eligible long-term survivors were recruited for outcome studies when they were more than 5 years post-diagnosis and older than 8 years of age At long-term follow-up survivors were an average of 13.8 years old and 7.7 years from diagnosis and 51 were male Neurocognitive testing functional magnetic resonance imaging MRI during an executive function task and structural MRI with diffusion tensor imaging were conducted Generalized linear models were developed to identify predictors and models were adjusted for age at diagnosis sex and parent education Intelligence was within normal limits mean 98 standard deviation 14 compared with population expectations mean 100 standard deviation 15 though measures of executive function processing speed and memory were less than population means all P .02 after correction for false discovery rates Higher plasma concentration of methotrexate was associated with a poorer executive function score P .02 Higher plasma methotrexate was also associated with higher functional MRI activity with thicker cortices in dorsolateral prefrontal brain regions and with white matter microstructure in the frontostriatal tact Neurocognitive impairment was associated with these imaging findings as well Associations did not change after adjustment for age or dose of leucovorin rescue Survivors of childhood acute lymphoblastic treated on contemporary chemotherapy-only protocols demonstrate executive dysfunction A higher plasma concentration of methotrexate was associated with executive dysfunction as well as with a thicker cortex and higher activity in frontal brain regions regions often associated with executive function,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 1004, 685, 107, 2116, 3587, 7468, 2, 2958, 123, 4, 319, 337, 332, 1, 864, 286, 1275, 73, 23, 8, 2667, 56, 158, 1182, 26, 2380, 45, 1199, 1456, 1013, 786, 190, 36, 6, 2958, 2, 342, 270, 123, 190, 319, 337, 166, 126, 8, 181, 1, 6070, 720, 18, 1, 4952, 625, 319, 337, 332, 11, 2619, 9, 228, 94, 198, 491, 11, 80, 76, 33, 60, 539, 147, 2, 434, 76, 66, 60, 1, 89, 28, 319, 337, 166, 126, 332, 11, 35, 1011, 1, 233, 66, 60, 1095, 2, 67, 67, 60, 29, 147, 2, 725, 11, 1045, 2958, 471, 583, 1484, 1535, 270, 704, 190, 35, 6481, 343, 3488, 2, 3281, 704, 5, 3438, 12210, 270, 11, 426, 4169, 1646, 274, 11, 276, 6, 255, 674, 2, 274, 11, 586, 9, 89, 28, 147, 1035, 2, 3841, 1848, 9125, 10, 262, 295, 3526, 313, 1096, 260, 3348, 213, 72, 5, 266, 5591, 313, 394, 260, 3348, 167, 2471, 1018, 1, 6481, 343, 3325, 5051, 2, 2407, 11, 299, 76, 266, 2263, 62, 19, 588, 50, 5360, 9, 2133, 1574, 151, 142, 554, 1227, 1, 2116, 10, 41, 5, 8, 1769, 6481, 343, 368, 19, 588, 142, 554, 2116, 10, 120, 41, 5, 142, 583, 704, 128, 5, 15308, 21721, 4, 49795, 31982, 342, 1374, 2, 5, 886, 5090, 40081, 4, 3, 35910, 68362, 2958, 2315, 10, 41, 5, 46, 270, 272, 22, 149, 685, 205, 44, 707, 50, 1852, 9, 89, 15, 61, 1, 3296, 4256, 332, 1, 864, 286, 1275, 73, 23, 2667, 56, 158, 2189, 608, 6481, 1527, 8, 142, 554, 1227, 1, 2116, 10, 41, 5, 6481, 1527, 22, 149, 22, 5, 8, 15308, 7417, 2, 142, 128, 4, 8082, 342, 1374, 1374, 629, 41, 5, 6481, 343]",2045.0,27269941,298
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.,The New England journal of medicine,N. Engl. J. Med.,2016-06-12,"The prognosis for adults with relapsed acute lymphoblastic leukemia is poor. We sought to determine whether inotuzumab ozogamicin, an anti-CD22 antibody conjugated to calicheamicin, results in better outcomes in patients with relapsed or refractory acute lymphoblastic leukemia than does standard therapy. In this phase 3 trial, we randomly assigned adults with relapsed or refractory acute lymphoblastic leukemia to receive either inotuzumab ozogamicin (inotuzumab ozogamicin group) or standard intensive chemotherapy (standard-therapy group). The primary end points were complete remission (including complete remission with incomplete hematologic recovery) and overall survival. Of the 326 patients who underwent randomization, the first 218 (109 in each group) were included in the primary intention-to-treat analysis of complete remission. The rate of complete remission was significantly higher in the inotuzumab ozogamicin group than in the standard-therapy group (80.7% [95% confidence interval {CI}, 72.1 to 87.7] vs. 29.4% [95% CI, 21.0 to 38.8], P<0.001). Among the patients who had complete remission, a higher percentage in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease (0.01% marrow blasts) (78.4% vs. 28.1%, P<0.001); the duration of remission was longer in the inotuzumab ozogamicin group (median, 4.6 months [95% CI, 3.9 to 5.4] vs. 3.1 months [95% CI, 1.4 to 4.9]; hazard ratio, 0.55 [95% CI, 0.31 to 0.96]; P=0.03). In the survival analysis, which included all 326 patients, progression-free survival was significantly longer in the inotuzumab ozogamicin group (median, 5.0 months [95% CI, 3.7 to 5.6] vs. 1.8 months [95% CI, 1.5 to 2.2]; hazard ratio, 0.45 [97.5% CI, 0.34 to 0.61]; P<0.001); the median overall survival was 7.7 months (95% CI, 6.0 to 9.2) versus 6.7 months (95% CI, 4.9 to 8.3), and the hazard ratio was 0.77 (97.5% CI, 0.58 to 1.03) (P=0.04). In the safety population, the most frequent grade 3 or higher nonhematologic adverse events with inotuzumab ozogamicin were liver-related. Veno-occlusive liver disease of any grade occurred in 15 patients (11%) who received inotuzumab ozogamicin and in 1 patient (1%) who received standard therapy. The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy, and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease. Both progression-free and overall survival were longer with inotuzumab ozogamicin. Veno-occlusive liver disease was a major adverse event associated with inotuzumab ozogamicin. (Funded by Pfizer; INO-VATE ALL ClinicalTrials.gov number, NCT01564784.).","Clinical Trial, Phase III",1318.0,360.0,The prognosis for adults with relapsed acute lymphoblastic is poor We sought to determine whether inotuzumab ozogamicin an anti-CD22 antibody conjugated to calicheamicin results in better outcomes in patients with relapsed or refractory acute lymphoblastic than does standard therapy In this phase 3 trial we randomly assigned adults with relapsed or refractory acute lymphoblastic to receive either inotuzumab ozogamicin inotuzumab ozogamicin group or standard intensive chemotherapy standard-therapy group The primary end points were complete remission including complete remission with incomplete hematologic recovery and overall survival Of the 326 patients who underwent randomization the first 218 109 in each group were included in the primary intention-to-treat analysis of complete remission The rate of complete remission was significantly higher in the inotuzumab ozogamicin group than in the standard-therapy group 80.7 95 confidence interval CI 72.1 to 87.7 vs. 29.4 95 CI 21.0 to 38.8 P 0.001 Among the patients who had complete remission a higher percentage in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease 0.01 marrow blasts 78.4 vs. 28.1 P 0.001 the duration of remission was longer in the inotuzumab ozogamicin group median 4.6 months 95 CI 3.9 to 5.4 vs. 3.1 months 95 CI 1.4 to 4.9 hazard ratio 0.55 95 CI 0.31 to 0.96 P=0.03 In the survival analysis which included all 326 patients progression-free survival was significantly longer in the inotuzumab ozogamicin group median 5.0 months 95 CI 3.7 to 5.6 vs. 1.8 months 95 CI 1.5 to 2.2 hazard ratio 0.45 97.5 CI 0.34 to 0.61 P 0.001 the median overall survival was 7.7 months 95 CI 6.0 to 9.2 versus 6.7 months 95 CI 4.9 to 8.3 and the hazard ratio was 0.77 97.5 CI 0.58 to 1.03 P=0.04 In the safety population the most frequent grade 3 or higher nonhematologic adverse events with inotuzumab ozogamicin were liver-related Veno-occlusive disease of any grade occurred in 15 patients 11 who received inotuzumab ozogamicin and in 1 patient 1 who received standard therapy The rate of complete remission was higher with inotuzumab ozogamicin than with standard therapy and a higher percentage of patients in the inotuzumab ozogamicin group had results below the threshold for minimal residual disease Both progression-free and overall survival were longer with inotuzumab ozogamicin Veno-occlusive disease was a major adverse event associated with inotuzumab ozogamicin Funded by Pfizer INO-VATE ALL ClinicalTrials.gov number NCT01564784,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 9, 857, 5, 591, 286, 1275, 16, 334, 21, 990, 6, 223, 317, 6730, 5566, 35, 312, 7599, 548, 3868, 6, 13499, 99, 4, 380, 123, 4, 7, 5, 591, 15, 430, 286, 1275, 76, 1097, 260, 36, 4, 26, 124, 27, 160, 21, 1108, 896, 857, 5, 591, 15, 430, 286, 1275, 6, 560, 361, 6730, 5566, 6730, 5566, 87, 15, 260, 1686, 56, 260, 36, 87, 3, 86, 396, 862, 11, 236, 734, 141, 236, 734, 5, 2610, 813, 1602, 2, 63, 25, 1, 3, 9588, 7, 54, 208, 3644, 3, 157, 6070, 3486, 4, 296, 87, 11, 159, 4, 3, 86, 3205, 6, 943, 65, 1, 236, 734, 3, 116, 1, 236, 734, 10, 97, 142, 4, 3, 6730, 5566, 87, 76, 4, 3, 260, 36, 87, 493, 67, 48, 307, 268, 58, 720, 14, 6, 912, 67, 105, 462, 39, 48, 58, 239, 13, 6, 519, 66, 19, 13, 144, 107, 3, 7, 54, 42, 236, 734, 8, 142, 1150, 4, 3, 6730, 5566, 87, 42, 99, 2736, 3, 2390, 9, 1048, 753, 34, 13, 355, 581, 2438, 833, 39, 105, 339, 14, 19, 13, 144, 3, 654, 1, 734, 10, 589, 4, 3, 6730, 5566, 87, 52, 39, 49, 53, 48, 58, 27, 83, 6, 33, 39, 105, 27, 14, 53, 48, 58, 14, 39, 6, 39, 83, 360, 197, 13, 614, 48, 58, 13, 456, 6, 13, 921, 19, 13, 680, 4, 3, 25, 65, 92, 159, 62, 9588, 7, 91, 115, 25, 10, 97, 589, 4, 3, 6730, 5566, 87, 52, 33, 13, 53, 48, 58, 27, 67, 6, 33, 49, 105, 14, 66, 53, 48, 58, 14, 33, 6, 18, 18, 360, 197, 13, 512, 1015, 33, 58, 13, 562, 6, 13, 713, 19, 13, 144, 3, 52, 63, 25, 10, 67, 67, 53, 48, 58, 49, 13, 6, 83, 18, 185, 49, 67, 53, 48, 58, 39, 83, 6, 66, 27, 2, 3, 360, 197, 10, 13, 849, 1015, 33, 58, 13, 717, 6, 14, 680, 19, 13, 755, 4, 3, 367, 266, 3, 96, 908, 88, 27, 15, 142, 3534, 290, 281, 5, 6730, 5566, 11, 4094, 139, 10273, 8376, 34, 1, 500, 88, 489, 4, 167, 7, 175, 54, 103, 6730, 5566, 2, 4, 14, 69, 14, 54, 103, 260, 36, 3, 116, 1, 236, 734, 10, 142, 5, 6730, 5566, 76, 5, 260, 36, 2, 8, 142, 1150, 1, 7, 4, 3, 6730, 5566, 87, 42, 99, 2736, 3, 2390, 9, 1048, 753, 34, 110, 91, 115, 2, 63, 25, 11, 589, 5, 6730, 5566, 10273, 8376, 34, 10, 8, 458, 290, 774, 41, 5, 6730, 5566, 3827, 20, 8982, 8709, 32612, 62, 1252, 1239, 207, 49811]",2551.0,27292104,85
Dietary intake and childhood leukemia: The Diet and Acute Lymphoblastic Leukemia Treatment (DALLT) cohort study.,"Nutrition (Burbank, Los Angeles County, Calif.)",Nutrition,2016-03-28,"Children with acute lymphoblastic leukemia (ALL) are at elevated risk for nutrition-related morbidity both during and after therapy. We present the demographic characteristics and nutrient intake at study entry of a prospective cohort in which evaluating dietary intake in children diagnosed with ALL was investigated. Dietary intake data were collected for participants enrolled on the Dana-Farber Cancer Institute ALL Consortium Protocol. Dietary intake was assessed with a food frequency questionnaire and was compared with the dietary reference intake by ALL risk group (standard and high risk). Dietary intake data were collected from 81% of participants (n=640). We found that 27% of participants were overweight/obese. Intake of total calories and other nutrients exceeded the dietary reference intake in up to 79% of children. This was evident in both risk groups and was pronounced among younger children. For micronutrients, dietary intake of calcium, vitamin D (females only), and zinc differed significantly between patients with standard-risk and those with high-risk ALL. This study was successful in collecting dietary intake data at the time of cancer diagnosis in a multicenter setting in a pediatric population at high-risk for nutrition-related morbidity. We identified ""at-risk"" dietary intakes, which vary by sex and ALL risk group; such patients may benefit from future dietary interventions.",Clinical Trial,1394.0,10.0,Children with acute lymphoblastic ALL are at elevated risk for nutrition-related morbidity both during and after therapy We present the demographic characteristics and nutrient intake at study entry of a prospective cohort in which evaluating dietary intake in children diagnosed with ALL was investigated Dietary intake data were collected for participants enrolled on the Dana-Farber Cancer Institute ALL Consortium Protocol Dietary intake was assessed with a food frequency questionnaire and was compared with the dietary reference intake by ALL risk group standard and high risk Dietary intake data were collected from 81 of participants n 640 We found that 27 of participants were overweight/obese Intake of total calories and other nutrients exceeded the dietary reference intake in up to 79 of children This was evident in both risk groups and was pronounced among younger children For micronutrients dietary intake of calcium vitamin D females only and zinc differed significantly between patients with standard-risk and those with high-risk ALL This study was successful in collecting dietary intake data at the time of cancer diagnosis in a multicenter setting in a pediatric population at high-risk for nutrition-related morbidity We identified `` at-risk '' dietary intakes which vary by sex and ALL risk group such patients may benefit from future dietary interventions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 286, 1275, 62, 32, 28, 804, 43, 9, 5260, 139, 787, 110, 190, 2, 50, 36, 21, 364, 3, 1540, 374, 2, 8749, 1514, 28, 45, 3001, 1, 8, 482, 180, 4, 92, 1435, 2013, 1514, 4, 541, 265, 5, 62, 10, 565, 2013, 1514, 74, 11, 786, 9, 776, 346, 23, 3, 4932, 4979, 12, 1377, 62, 2404, 1182, 2013, 1514, 10, 275, 5, 8, 1773, 675, 1770, 2, 10, 72, 5, 3, 2013, 2482, 1514, 20, 62, 43, 87, 260, 2, 64, 43, 2013, 1514, 74, 11, 786, 29, 865, 1, 776, 78, 10972, 21, 204, 17, 428, 1, 776, 11, 3566, 2209, 1514, 1, 181, 21122, 2, 127, 8926, 4726, 3, 2013, 2482, 1514, 4, 126, 6, 842, 1, 541, 26, 10, 2853, 4, 110, 43, 271, 2, 10, 3517, 107, 773, 541, 9, 22003, 2013, 1514, 1, 3299, 1610, 427, 2451, 158, 2, 5988, 2512, 97, 59, 7, 5, 260, 43, 2, 135, 5, 64, 43, 62, 26, 45, 10, 1401, 4, 7251, 2013, 1514, 74, 28, 3, 98, 1, 12, 147, 4, 8, 1570, 546, 4, 8, 815, 266, 28, 64, 43, 9, 5260, 139, 787, 21, 108, 28, 43, 522, 2013, 5397, 92, 2825, 20, 1035, 2, 62, 43, 87, 225, 7, 68, 247, 29, 508, 2013, 1151]",1382.0,27318855,254
Long-Term Efficacy of Computerized Cognitive Training Among Survivors of Childhood Cancer: A Single-Blind Randomized Controlled Trial.,Journal of pediatric psychology,J Pediatr Psychol,2017-03-01,"To investigate the long-term efficacy of computerized cognitive training in improving cognitive outcomes among childhood cancer survivors. Sixty-eight survivors of childhood acute lymphoblastic leukemia (ALL) or brain tumor (BT) were randomly assigned to computerized cognitive intervention (23 ALL/11 BT, age = 12.21  2.47) or a waitlist control group (24 ALL/10 BT, age = 11.82  2.42). Cognitive assessments were completed pre-, immediately post-, and 6 months postintervention. A prior report showed training led to immediate improvement in working memory, attention and processing speed. In the current study, piecewise linear mixed effects modeling revealed that working memory and processing speed were unchanged from immediate to 6 months postintervention (intervention  =-.04 to .01, p = .26 to .95; control  =-.06 to .01, p = .23-.97), but group differences on an attention measure did not persist. Cognitive benefits are maintained 6 months following computerized cognitive training, adding to potential clinical utility of this intervention approach.",Journal Article,1056.0,17.0,To investigate the long-term efficacy of computerized cognitive training in improving cognitive outcomes among childhood cancer survivors Sixty-eight survivors of childhood acute lymphoblastic ALL or brain tumor BT were randomly assigned to computerized cognitive intervention 23 ALL/11 BT age 12.21  2.47 or a waitlist control group 24 ALL/10 BT age 11.82  2.42 Cognitive assessments were completed pre- immediately post- and 6 months postintervention A prior report showed training led to immediate improvement in working memory attention and processing speed In the current study piecewise linear mixed effects modeling revealed that working memory and processing speed were unchanged from immediate to 6 months postintervention intervention -.04 to .01 p .26 to .95 control -.06 to .01 p .23-.97 but group differences on an attention measure did not persist Cognitive benefits are maintained 6 months following computerized cognitive training adding to potential clinical utility of this intervention approach,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 963, 3, 319, 337, 209, 1, 4912, 1863, 1741, 4, 1673, 1863, 123, 107, 864, 12, 332, 1746, 659, 332, 1, 864, 286, 1275, 62, 15, 342, 30, 3641, 11, 1108, 896, 6, 4912, 1863, 788, 382, 62, 175, 3641, 89, 133, 239, 810, 18, 662, 15, 8, 17391, 182, 87, 259, 62, 79, 3641, 89, 175, 878, 810, 18, 595, 1863, 2182, 11, 781, 671, 3467, 539, 2, 49, 53, 10118, 8, 324, 414, 224, 1741, 836, 6, 2181, 767, 4, 2644, 2407, 2111, 2, 3325, 5051, 4, 3, 291, 45, 17879, 1646, 1739, 176, 2057, 553, 17, 2644, 2407, 2, 3325, 5051, 11, 4639, 29, 2181, 6, 49, 53, 10118, 788, 755, 6, 355, 19, 432, 6, 48, 182, 1460, 6, 355, 19, 382, 1015, 84, 87, 362, 23, 35, 2111, 1463, 205, 44, 5589, 1863, 1141, 32, 1955, 49, 53, 366, 4912, 1863, 1741, 2726, 6, 174, 38, 1207, 1, 26, 788, 353]",1015.0,27342301,79
Uric Acid and Neurocognitive Function in Survivors of Childhood Acute Lymphoblastic Leukemia Treated with Chemotherapy Only.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2016-06-26,"Hyperuricemia is implicated in cardiovascular and cerebrovascular diseases. This study evaluated associations between uric acid (UA), cardiovascular health, and neurocognitive function in adolescent and adult survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. 126 adolescent [mean (SD) age 14.6 (5.0); 7.8 (1.7) years postdiagnosis] and 226 adult survivors [age 25.4 (4.2) years; 18.1 (4.4) years postdiagnosis] completed comprehensive neurocognitive testing. Concurrent UA measurements were conducted for both groups. For adult survivors, cardiovascular risk factors were assessed, and UA measurements during adolescence [12.3 (4.0) years before neurocognitive testing] were also collected. UA levels were categorized into quartiles for age- and gender-based ranking, and associations with neurocognitive outcomes were examined. Survivors demonstrated worse attention, processing speed, and executive functions than population norms (P values < 0.05). Adolescent survivors with elevated UA had poorer attention (P = 0.04), visual-processing speed (P = 0.03), and cognitive flexibility (P = 0.02). UA was not associated with neurocognitive outcomes in adult survivors. Adult survivors developed dyslipidemia (46%), hypertension (32%), and abdominal obesity (26%), and high UA during adolescence was associated with these cardiovascular risk factors as adults (all P values < 0.01). Fine-motor processing speed was slower in adult survivors with dyslipidemia (P = 0.04) and abdominal obesity (P = 0.04). Poorer attention was marginally associated with hypertension (P = 0.06). Elevated UA is associated with neurocognitive performance in adolescent survivors. In adult survivors, relative elevation of UA during adolescence was predictive of cardiovascular health, which was associated with poorer neurocognitive outcomes. Future studies should evaluate the mediating role of chronic cardiovascular health conditions between elevated UA and subsequent neurocognitive impairment in survivors. Cancer Epidemiol Biomarkers Prev; 25(8); 1259-67. 2016 AACR.",Journal Article,1304.0,4.0,Hyperuricemia is implicated in cardiovascular and cerebrovascular diseases This study evaluated associations between uric acid UA cardiovascular health and neurocognitive function in adolescent and adult survivors of childhood acute lymphoblastic treated with chemotherapy only 126 adolescent mean SD age 14.6 5.0 7.8 1.7 years postdiagnosis and 226 adult survivors age 25.4 4.2 years 18.1 4.4 years postdiagnosis completed comprehensive neurocognitive testing Concurrent UA measurements were conducted for both groups For adult survivors cardiovascular risk factors were assessed and UA measurements during adolescence 12.3 4.0 years before neurocognitive testing were also collected UA levels were categorized into quartiles for age- and gender-based ranking and associations with neurocognitive outcomes were examined Survivors demonstrated worse attention processing speed and executive functions than population norms P values 0.05 Adolescent survivors with elevated UA had poorer attention P 0.04 visual-processing speed P 0.03 and cognitive flexibility P 0.02 UA was not associated with neurocognitive outcomes in adult survivors Adult survivors developed dyslipidemia 46 hypertension 32 and abdominal obesity 26 and high UA during adolescence was associated with these cardiovascular risk factors as adults all P values 0.01 Fine-motor processing speed was slower in adult survivors with dyslipidemia P 0.04 and abdominal obesity P 0.04 Poorer attention was marginally associated with hypertension P 0.06 Elevated UA is associated with neurocognitive performance in adolescent survivors In adult survivors relative elevation of UA during adolescence was predictive of cardiovascular health which was associated with poorer neurocognitive outcomes Future studies should evaluate the mediating role of chronic cardiovascular health conditions between elevated UA and subsequent neurocognitive impairment in survivors Cancer Epidemiol Biomarkers Prev 25 8 1259-67 2016 AACR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[14780, 16, 1771, 4, 2179, 2, 9261, 1342, 26, 45, 194, 685, 59, 16387, 971, 17572, 2179, 341, 2, 2958, 343, 4, 3678, 2, 780, 332, 1, 864, 286, 1275, 73, 5, 56, 158, 3927, 3678, 313, 1270, 89, 213, 49, 33, 13, 67, 66, 14, 67, 60, 7163, 2, 7400, 780, 332, 89, 243, 39, 39, 18, 60, 203, 14, 39, 39, 60, 7163, 781, 949, 2958, 471, 750, 17572, 1685, 11, 426, 9, 110, 271, 9, 780, 332, 2179, 43, 130, 11, 275, 2, 17572, 1685, 190, 6964, 133, 27, 39, 13, 60, 348, 2958, 471, 11, 120, 786, 17572, 148, 11, 2320, 237, 6028, 9, 89, 2, 1632, 90, 11185, 2, 685, 5, 2958, 123, 11, 409, 332, 264, 639, 2111, 3325, 5051, 2, 6481, 1681, 76, 266, 9875, 19, 1030, 13, 474, 3678, 332, 5, 804, 17572, 42, 1769, 2111, 19, 13, 755, 3046, 3325, 5051, 19, 13, 680, 2, 1863, 9794, 19, 13, 588, 17572, 10, 44, 41, 5, 2958, 123, 4, 780, 332, 780, 332, 276, 13981, 641, 1824, 531, 2, 1467, 1661, 432, 2, 64, 17572, 190, 6964, 10, 41, 5, 46, 2179, 43, 130, 22, 857, 62, 19, 1030, 13, 355, 2924, 3482, 3325, 5051, 10, 6715, 4, 780, 332, 5, 13981, 19, 13, 755, 2, 1467, 1661, 19, 13, 755, 1769, 2111, 10, 5007, 41, 5, 1824, 19, 13, 1460, 804, 17572, 16, 41, 5, 2958, 528, 4, 3678, 332, 4, 780, 332, 580, 3292, 1, 17572, 190, 6964, 10, 464, 1, 2179, 341, 92, 10, 41, 5, 1769, 2958, 123, 508, 94, 257, 376, 3, 3941, 200, 1, 442, 2179, 341, 1298, 59, 804, 17572, 2, 706, 2958, 2315, 4, 332, 12, 9813, 582, 7902, 243, 66, 41485, 598, 3456, 1630]",1979.0,27345588,5
Dasatinib-Induced Colitis after Allogeneic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-06-23,"The tyrosine kinase inhibitor dasatinib is often used after allogeneic hematopoietic cell transplantation to treat minimal residual disease in Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Colitis, sometimes hemorrhagic, has occasionally been described with the use of dasatinib for both chronic myeloid leukemia and Ph+ ALL. The pathogenesis of dasatinib-induced colitis is unclear but may be related to effects of dasatinib on immune function. We describe a series of 5 patients who had 7 episodes of colitis during dasatinib use. No patient had obvious large granular lymphocytosis in peripheral blood. The histopathologic and immunohistochemical features of these cases were indistinguishable from control cases of gut graft-versus-host disease (GVHD). In all patients symptoms resolved upon discontinuation of dasatinib in addition to therapy with local or low-dose systemic steroids. An additional 3 patients who developed cytomegalovirus (CMV) colitis while on dasatinib therapy were identified and studied. Dasatinib colitis may have an immune-mediated mechanism similar to GVHD, and dasatinib use may be associated with CMV colitis. Awareness of this association is important for avoiding unnecessary intensification of immunosuppression for suspected gut GVHD.",Journal Article,1307.0,2.0,The tyrosine kinase inhibitor dasatinib is often used after allogeneic hematopoietic cell transplantation to treat minimal residual disease in Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL Colitis sometimes hemorrhagic has occasionally been described with the use of dasatinib for both chronic myeloid and Ph+ ALL The pathogenesis of dasatinib-induced colitis is unclear but may be related to effects of dasatinib on immune function We describe a series of 5 patients who had 7 episodes of colitis during dasatinib use No patient had obvious large granular lymphocytosis in peripheral blood The histopathologic and immunohistochemical features of these cases were indistinguishable from control cases of gut graft-versus-host disease GVHD In all patients symptoms resolved upon discontinuation of dasatinib in addition to therapy with local or low-dose systemic steroids An additional 3 patients who developed cytomegalovirus CMV colitis while on dasatinib therapy were identified and studied Dasatinib colitis may have an immune-mediated mechanism similar to GVHD and dasatinib use may be associated with CMV colitis Awareness of this association is important for avoiding unnecessary intensification of immunosuppression for suspected gut GVHD,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 564, 216, 230, 1674, 16, 629, 95, 50, 1063, 1007, 31, 497, 6, 943, 1048, 753, 34, 4, 3006, 1170, 109, 2058, 286, 1275, 62, 4132, 5164, 6998, 71, 6319, 85, 1027, 5, 3, 119, 1, 1674, 9, 110, 442, 533, 2, 2058, 62, 3, 1384, 1, 1674, 277, 4132, 16, 1200, 84, 68, 40, 139, 6, 176, 1, 1674, 23, 250, 343, 21, 897, 8, 988, 1, 33, 7, 54, 42, 67, 3750, 1, 4132, 190, 1674, 119, 77, 69, 42, 6228, 375, 7694, 8125, 4, 672, 315, 3, 2630, 2, 1382, 404, 1, 46, 140, 11, 11112, 29, 182, 140, 1, 7600, 1599, 185, 1204, 34, 1562, 4, 62, 7, 507, 3862, 1548, 2007, 1, 1674, 4, 352, 6, 36, 5, 293, 15, 154, 61, 403, 4580, 35, 402, 27, 7, 54, 276, 7314, 3879, 4132, 369, 23, 1674, 36, 11, 108, 2, 656, 1674, 4132, 68, 47, 35, 250, 517, 670, 288, 6, 1562, 2, 1674, 119, 68, 40, 41, 5, 3879, 4132, 3310, 1, 26, 248, 16, 305, 9, 6048, 4224, 5091, 1, 3646, 9, 2768, 7600, 1562]",1260.0,27346662,42
At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies.,Journal of leukocyte biology,J. Leukoc. Biol.,2016-06-27,"T cells kill microbial-infected and malignant cells by detection of nonself antigens with the TCR. Tumor reactivity can be encoded genetically by introducing a chimeric antigen receptor (CAR) into T cells. CARs are composed of an antigen-binding domain and an intracellular T cell activation domain. Early human trials evaluating CD19-targeted CAR T cells for chronic lymphocytic leukemia (CLL) showed limited responses until CARs included a costimulation domain, and conditioning chemotherapy was given before T cell infusion. Clinical trials evaluating CD19-targeted CAR T cells for B cell acute lymphoblastic leukemia (B-ALL) are demonstrating response rates up to 90%. However, these clinical outcomes are associated with a cytokine release syndrome (CRS), which is caused by T cell activation and manifests as high-grade fever, hypotension, and other cardiovascular complications. It is currently managed conservatively but can be treated with cytokine-directed therapy or with high-dose steroids. Current efforts are dedicated to confirming the clinical efficacy and managing toxicities in multicenter Phase II trials. We present a thorough overview of the preclinical and clinical development of CAR T cell therapy that will highlight important areas for the basic researcher to investigate in the laboratory and contribute to this exciting field.",Journal Article,1303.0,15.0,T cells kill microbial-infected and malignant cells by detection of nonself antigens with the TCR Tumor reactivity can be encoded genetically by introducing a chimeric antigen receptor CAR into T cells CARs are composed of an antigen-binding domain and an intracellular T cell activation domain Early human trials evaluating CD19-targeted CAR T cells for chronic lymphocytic CLL showed limited responses until CARs included a costimulation domain and conditioning chemotherapy was given before T cell infusion Clinical trials evaluating CD19-targeted CAR T cells for B cell acute lymphoblastic B-ALL are demonstrating response rates up to 90 However these clinical outcomes are associated with a cytokine release syndrome CRS which is caused by T cell activation and manifests as high-grade fever hypotension and other cardiovascular complications It is currently managed conservatively but can be treated with cytokine-directed therapy or with high-dose steroids Current efforts are dedicated to confirming the clinical efficacy and managing toxicities in multicenter Phase II trials We present a thorough overview of the preclinical and clinical development of CAR T cell therapy that will highlight important areas for the basic researcher to investigate in the laboratory and contribute to this exciting field,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[102, 37, 5097, 9138, 3369, 2, 393, 37, 20, 638, 1, 49855, 1575, 5, 3, 4134, 30, 4601, 122, 40, 4587, 2301, 20, 11165, 8, 2897, 448, 153, 1881, 237, 102, 37, 7441, 32, 3317, 1, 35, 448, 791, 1398, 2, 35, 2087, 102, 31, 363, 1398, 191, 171, 143, 1435, 3158, 238, 1881, 102, 37, 9, 442, 1193, 552, 224, 383, 253, 1100, 7441, 159, 8, 8085, 1398, 2, 1933, 56, 10, 447, 348, 102, 31, 904, 38, 143, 1435, 3158, 238, 1881, 102, 37, 9, 132, 31, 286, 1275, 132, 62, 32, 2219, 51, 151, 126, 6, 424, 137, 46, 38, 123, 32, 41, 5, 8, 1675, 2008, 681, 3115, 92, 16, 1546, 20, 102, 31, 363, 2, 15096, 22, 64, 88, 2775, 6577, 2, 127, 2179, 521, 192, 16, 694, 2231, 10296, 84, 122, 40, 73, 5, 1675, 1166, 36, 15, 5, 64, 61, 4580, 291, 1413, 32, 4827, 6, 5030, 3, 38, 209, 2, 3969, 385, 4, 1570, 124, 215, 143, 21, 364, 8, 5506, 2901, 1, 3, 693, 2, 38, 193, 1, 1881, 102, 31, 36, 17, 303, 1817, 305, 1361, 9, 3, 2795, 24904, 6, 963, 4, 3, 1624, 2, 1248, 6, 26, 4963, 1067]",1313.0,27354412,17
Outcome of Second Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Lymphoblastic Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2016-06-08,"The outcome of patients with acute lymphoblastic leukemia (ALL) relapsing after allogeneic hematopoietic cell transplantation (AlloHCT) is poor. Although morphologic remission can sometimes be achieved, such remissions are usually transient if not consolidated by a second AlloHCT (AlloHCT2). We retrospectively analyzed the outcomes of 27 patients with ALL who had undergone AlloHCT2 for relapsed disease at our center during a 12-year period. With a median follow-up of 50.9 months for living patients, the 2-year overall and event-free survival were 40.7% and 29.6%, respectively. Patients with either a disease-free interval or interval between transplants of > 1 year had better overall survival (P= .02 and P= .0005) after AlloHCT2. AlloHCT2 remains a potential curative option in a subset of patients with relapsed ALL after the first AlloHCT.",Journal Article,1322.0,1.0,The outcome of patients with acute lymphoblastic ALL relapsing after allogeneic hematopoietic cell transplantation AlloHCT is poor Although morphologic remission can sometimes be achieved such remissions are usually transient if not consolidated by a second AlloHCT AlloHCT2 We retrospectively analyzed the outcomes of 27 patients with ALL who had undergone AlloHCT2 for relapsed disease at our center during a 12-year period With a median follow-up of 50.9 months for living patients the 2-year overall and event-free survival were 40.7 and 29.6 respectively Patients with either a disease-free interval or interval between transplants of 1 year had better overall survival P .02 and P .0005 after AlloHCT2 AlloHCT2 remains a potential curative option in a subset of patients with relapsed ALL after the first AlloHCT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 228, 1, 7, 5, 286, 1275, 62, 6758, 50, 1063, 1007, 31, 497, 5514, 16, 334, 242, 2815, 734, 122, 5164, 40, 513, 225, 3166, 32, 2082, 2473, 492, 44, 18934, 20, 8, 419, 5514, 36267, 21, 894, 311, 3, 123, 1, 428, 7, 5, 62, 54, 42, 1989, 36267, 9, 591, 34, 28, 114, 574, 190, 8, 133, 111, 727, 5, 8, 52, 166, 126, 1, 212, 83, 53, 9, 2798, 7, 3, 18, 111, 63, 2, 774, 115, 25, 11, 327, 67, 2, 462, 49, 106, 7, 5, 361, 8, 34, 115, 268, 15, 268, 59, 4016, 1, 14, 111, 42, 380, 63, 25, 19, 588, 2, 19, 4252, 50, 36267, 36267, 469, 8, 174, 1075, 1501, 4, 8, 697, 1, 7, 5, 591, 62, 50, 3, 157, 5514]",818.0,27394652,854
Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.,EBioMedicine,EBioMedicine,2016-05-13,"Genomic landscapes of 92 adult and 111 pediatric patients with B-cell acute lymphoblastic leukemia (B-ALL) were investigated using next-generation sequencing and copy number alteration analysis. Recurrent gene mutations and fusions were tested in an additional 87 adult and 93 pediatric patients. Among the 29 newly identified in-frame gene fusions, those involving MEF2D and ZNF384 were clinically relevant and were demonstrated to perturb B-cell differentiation, with EP300-ZNF384 inducing leukemia in mice. Eight gene expression subgroups associated with characteristic genetic abnormalities were identified, including leukemia with MEF2D and ZNF384 fusions in two distinct clusters. In subgroup G4 which was characterized by ERG deletion, DUX4-IGH fusion was detected in most cases. This comprehensive dataset allowed us to compare the features of molecular pathogenesis between adult and pediatric B-ALL and to identify signatures possibly related to the inferior outcome of adults to that of children. We found that, besides the known discrepancies in frequencies of prognostic markers, adult patients had more cooperative mutations and greater enrichment for alterations of epigenetic modifiers and genes linked to B-cell development, suggesting difference in the target cells of transformation between adult and pediatric patients and may explain in part the disparity in their responses to treatment. ",Journal Article,1348.0,65.0,Genomic landscapes of 92 adult and 111 pediatric patients with B-cell acute lymphoblastic B-ALL were investigated using next-generation sequencing and copy number alteration analysis Recurrent gene mutations and fusions were tested in an additional 87 adult and 93 pediatric patients Among the 29 newly identified in-frame gene fusions those involving MEF2D and ZNF384 were clinically relevant and were demonstrated to perturb B-cell differentiation with EP300-ZNF384 inducing in mice Eight gene expression subgroups associated with characteristic genetic abnormalities were identified including with MEF2D and ZNF384 fusions in two distinct clusters In subgroup G4 which was characterized by ERG deletion DUX4-IGH fusion was detected in most cases This comprehensive dataset allowed us to compare the features of molecular pathogenesis between adult and pediatric B-ALL and to identify signatures possibly related to the inferior outcome of adults to that of children We found that besides the known discrepancies in frequencies of prognostic markers adult patients had more cooperative mutations and greater enrichment for alterations of epigenetic modifiers and genes linked to B-cell development suggesting difference in the target cells of transformation between adult and pediatric patients and may explain in part the disparity in their responses to treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[572, 17498, 1, 937, 780, 2, 3167, 815, 7, 5, 132, 31, 286, 1275, 132, 62, 11, 565, 75, 1305, 914, 615, 2, 1337, 207, 2611, 65, 387, 145, 138, 2, 2530, 11, 650, 4, 35, 402, 912, 780, 2, 966, 815, 7, 107, 3, 462, 732, 108, 4, 5331, 145, 2530, 135, 1267, 21835, 2, 20919, 11, 505, 867, 2, 11, 264, 6, 23844, 132, 31, 910, 5, 15423, 20919, 1958, 4, 399, 659, 145, 55, 1453, 41, 5, 2037, 336, 1171, 11, 108, 141, 5, 21835, 2, 20919, 2530, 4, 100, 834, 3780, 4, 1363, 10102, 92, 10, 765, 20, 3032, 1528, 18043, 5221, 1212, 10, 530, 4, 96, 140, 26, 949, 3014, 2313, 843, 6, 932, 3, 404, 1, 219, 1384, 59, 780, 2, 815, 132, 62, 2, 6, 255, 2210, 2150, 139, 6, 3, 1663, 228, 1, 857, 6, 17, 1, 541, 21, 204, 17, 7301, 3, 440, 7631, 4, 2722, 1, 177, 525, 780, 7, 42, 80, 1690, 138, 2, 378, 3020, 9, 593, 1, 1418, 5663, 2, 214, 1199, 6, 132, 31, 193, 802, 523, 4, 3, 283, 37, 1, 1392, 59, 780, 2, 815, 7, 2, 68, 2943, 4, 760, 3, 4326, 4, 136, 253, 6, 24]",1366.0,27428428,86
How Variable Is Our Delivery of Information? Approaches to Patient Education About Oral Chemotherapy in the Pediatric Oncology Clinic.,Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners,J Pediatr Health Care,2016-07-25,"In pediatric patients with acute lymphoblastic leukemia, adherence to oral chemotherapy relies largely on a parent's comprehension of the drug's indication and administration guidelines. We assessed how pediatric oncology providers educate families about oral chemotherapy. We conducted a cross-sectional survey of 68 physicians and nurses from 9 institutions in the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. The inter-individual approach to patient education is variable and may consist of handouts, treatment calendars, and discussions. The extent of teaching often varies depending on a provider's subjective assessment of a family's needs. Twenty-five percent of providers suggested standardizing patient teaching. When developing educational models, care teams should consider approaches that (a) objectively identify families in need of extensive teaching, (b) designate allotted teaching time by nursing staff during clinic visits, and (c) maintain the variation and dynamism that informs a successful provider-patient relationship.",Journal Article,1275.0,3.0,In pediatric patients with acute lymphoblastic adherence to oral chemotherapy relies largely on a parent 's comprehension of the drug 's indication and administration guidelines We assessed how pediatric oncology providers educate families about oral chemotherapy We conducted a cross-sectional survey of 68 physicians and nurses from 9 institutions in the Dana-Farber Cancer Institute Acute Lymphoblastic Consortium The inter-individual approach to patient education is variable and may consist of handouts treatment calendars and discussions The extent of teaching often varies depending on a provider 's subjective assessment of a family 's needs Twenty-five percent of providers suggested standardizing patient teaching When developing educational models care teams should consider approaches that a objectively identify families in need of extensive teaching b designate allotted teaching time by nursing staff during clinic visits and c maintain the variation and dynamism that informs a successful provider-patient relationship,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 815, 7, 5, 286, 1275, 2149, 6, 518, 56, 6495, 1733, 23, 8, 3841, 292, 13093, 1, 3, 234, 292, 3607, 2, 634, 677, 21, 275, 832, 815, 413, 1994, 10407, 1954, 545, 518, 56, 21, 426, 8, 1383, 2832, 1407, 1, 806, 1261, 2, 2707, 29, 83, 1764, 4, 3, 4932, 4979, 12, 1377, 286, 1275, 2404, 3, 3606, 797, 353, 6, 69, 1848, 16, 1347, 2, 68, 10451, 1, 49912, 24, 30211, 2, 3173, 3, 1039, 1, 6292, 629, 4037, 3221, 23, 8, 3094, 292, 5571, 455, 1, 8, 607, 292, 1891, 737, 365, 714, 1, 1994, 1148, 15343, 69, 6292, 198, 931, 3624, 274, 165, 6127, 257, 2419, 611, 17, 8, 8731, 255, 1954, 4, 594, 1, 1344, 6292, 132, 22143, 31441, 6292, 98, 20, 5652, 5898, 190, 1188, 2690, 2, 256, 3040, 3, 1380, 2, 49845, 17, 12219, 8, 1401, 3094, 69, 858]",1034.0,27461368,232
Delays in postremission chemotherapy for Philadelphia chromosome negative acute lymphoblastic leukemia are associated with inferior outcomes in patients who undergo allogeneic transplant: An analysis from ECOG 2993/MRC UK ALLXII.,American journal of hematology,Am. J. Hematol.,2016-08-22,"Adults with acute lymphoblastic leukemia (ALL) have a poorer prognosis than children due to a high risk of relapse. One explanation may be variable adherence to dose-intense chemotherapy. However, little is known about risk factors for delays in therapy and their impact on survival. We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL. Logistic regression was used to identify risk factors for a very long delay (VLD, >4 weeks) in start of intensification therapy. Cox regression was used to evaluate the impact of delays on overall survival (OS) and event-free survival (EFS). We evaluated 1076 Philadelphia chromosome negative (Ph-) patients who completed induction chemotherapy, achieved complete remission, and started intensification. Factors independently associated with VLD included duration of hospitalization (odds ratio [OR]=1.2, P<0.001) during Phase I; thrombocytopenia during Phase I (OR=1.16, P=0.004) or Phase II (OR 1.13, P=0.001); chemotherapy dose reductions during Induction Phase I (OR=1.72, P<0.014); female sex (OR=1.53, P=0.010); Black (OR=3.24, P=0.003) and Asian (OR=2.26, P=0.021) race; and increasing age (OR=1.31, P<0.001). In multivariate Cox regression, patients who underwent allogeneic stem cell transplant (alloHCT) had significantly worse OS (HR 1.4, P=0.03) and EFS (HR 1.4, P=0.02) after experiencing a VLD compared to alloHCT patients who experienced 4 weeks delay. Specific populations (female, older, Black, and Asian patients) were more likely to experience delays in chemotherapy, as were those with significant toxicity during induction. VLDs in therapy negatively affected outcomes in patients undergoing allografting. Am. J. Hematol. 91:1107-1112, 2016.  2016 Wiley Periodicals, Inc.","Clinical Trial, Phase I",1247.0,4.0,Adults with acute lymphoblastic ALL have a poorer prognosis than children due to a high risk of relapse One explanation may be variable adherence to dose-intense chemotherapy However little is known about risk factors for delays in therapy and their impact on survival We conducted an analysis of ECOG 2993/UKALLXII trial to study delays in postremission chemotherapy in adults with newly diagnosed ALL Logistic regression was used to identify risk factors for a very long delay VLD 4 weeks in start of intensification therapy Cox regression was used to evaluate the impact of delays on overall survival OS and event-free survival EFS We evaluated 1076 Philadelphia chromosome negative Ph- patients who completed induction chemotherapy achieved complete remission and started intensification Factors independently associated with VLD included duration of hospitalization odds ratio OR 1.2 P 0.001 during Phase I thrombocytopenia during Phase I OR 1.16 P 0.004 or Phase II OR 1.13 P 0.001 chemotherapy dose reductions during Induction Phase I OR 1.72 P 0.014 female sex OR 1.53 P 0.010 Black OR 3.24 P 0.003 and Asian OR 2.26 P 0.021 race and increasing age OR 1.31 P 0.001 In multivariate Cox regression patients who underwent allogeneic stem cell transplant alloHCT had significantly worse OS HR 1.4 P 0.03 and EFS HR 1.4 P 0.02 after experiencing a VLD compared to alloHCT patients who experienced 4 weeks delay Specific populations female older Black and Asian patients were more likely to experience delays in chemotherapy as were those with significant toxicity during induction VLDs in therapy negatively affected outcomes in patients undergoing allografting Am J. Hematol 91:1107-1112 2016  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[857, 5, 286, 1275, 62, 47, 8, 1769, 356, 76, 541, 520, 6, 8, 64, 43, 1, 429, 104, 6603, 68, 40, 1347, 2149, 6, 61, 3933, 56, 137, 1215, 16, 440, 545, 43, 130, 9, 3257, 4, 36, 2, 136, 345, 23, 25, 21, 426, 35, 65, 1, 2351, 24976, 24975, 160, 6, 45, 3257, 4, 8635, 56, 4, 857, 5, 732, 265, 62, 812, 320, 10, 95, 6, 255, 43, 130, 9, 8, 923, 319, 1984, 41513, 39, 244, 4, 2435, 1, 5091, 36, 418, 320, 10, 95, 6, 376, 3, 345, 1, 3257, 23, 63, 25, 118, 2, 774, 115, 25, 1683, 21, 194, 35614, 3006, 1170, 199, 2058, 7, 54, 781, 504, 56, 513, 236, 734, 2, 3461, 5091, 130, 1042, 41, 5, 41513, 159, 654, 1, 2826, 610, 197, 15, 14, 18, 19, 13, 144, 190, 124, 70, 1340, 190, 124, 70, 15, 14, 245, 19, 13, 1520, 15, 124, 215, 15, 14, 233, 19, 13, 144, 56, 61, 2153, 190, 504, 124, 70, 15, 14, 720, 19, 13, 3618, 1061, 1035, 15, 14, 699, 19, 13, 4873, 1445, 15, 27, 259, 19, 13, 1421, 2, 2399, 15, 18, 432, 19, 13, 4630, 1047, 2, 602, 89, 15, 14, 456, 19, 13, 144, 4, 331, 418, 320, 7, 54, 208, 1063, 452, 31, 941, 5514, 42, 97, 639, 118, 168, 14, 39, 19, 13, 680, 2, 1683, 168, 14, 39, 19, 13, 588, 50, 2985, 8, 41513, 72, 6, 5514, 7, 54, 592, 11720, 244, 1984, 112, 1184, 1061, 434, 1445, 2, 2399, 7, 11, 80, 322, 6, 730, 3257, 4, 56, 22, 11, 135, 5, 93, 155, 190, 504, 68664, 4, 36, 2723, 1424, 123, 4, 7, 479, 16181, 5886, 3543, 13175, 970, 49917, 20805, 1390, 2206, 1390, 4692, 5493, 3479]",1726.0,27468137,698
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis.,Cancer,Cancer,2016-08-01,"The clinical efficacy of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (HCVAD) plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in a randomized clinical trial. The authors analyzed 110 patients with newly diagnosed Ph+ ALL who were enrolled in 2 consecutive, prospective, phase 2 clinical trials of frontline HCVAD with either dasatinib (63 patients) or ponatinib (47 patients). Propensity score analysis with 1:1 matching with the nearest neighbor matching method and inverse probability of treatment weighting (IPTW) analysis based on the propensity scores were performed to assess response rates, event-free survival (EFS), and overall survival (OS) between the cohorts. Propensity score matching identified 41 patients in each cohort. With propensity score matching, the 3-year EFS rates for patients treated with HCVAD plus ponatinib and HCVAD plus dasatinib were 69% and 46%, respectively (P =.04), and the 3-year OS rates were 83% and 56%, respectively (P =.03). IPTW analysis using prematching cohorts demonstrated that patients treated with HCVAD plus ponatinib had significantly higher rates of minimal residual disease negativity by flow cytometry on day 21, complete cytogenetic response at complete response, major molecular response at complete response and at 3 months, and complete molecular response at 3 months. IPTW confirmed that treatment with HCVAD plus ponatinib was associated with longer EFS (P =.003) and OS (P =.001) compared with treatment with HCVAD plus dasatinib. The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL. Cancer 2016;122:3650-6.  2016 American Cancer Society.","Clinical Trial, Phase II",1268.0,54.0,The clinical efficacy of hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone HCVAD plus ponatinib has not been compared with that of HCVAD plus dasatinib in patients with Philadelphia chromosome-positive acute lymphoblastic Ph+ ALL in a randomized clinical trial The authors analyzed 110 patients with newly diagnosed Ph+ ALL who were enrolled in 2 consecutive prospective phase 2 clinical trials of frontline HCVAD with either dasatinib 63 patients or ponatinib 47 patients Propensity score analysis with 1:1 matching with the nearest neighbor matching method and inverse probability of treatment weighting IPTW analysis based on the propensity scores were performed to assess response rates event-free survival EFS and overall survival OS between the cohorts Propensity score matching identified 41 patients in each cohort With propensity score matching the 3-year EFS rates for patients treated with HCVAD plus ponatinib and HCVAD plus dasatinib were 69 and 46 respectively P =.04 and the 3-year OS rates were 83 and 56 respectively P =.03 IPTW analysis using prematching cohorts demonstrated that patients treated with HCVAD plus ponatinib had significantly higher rates of minimal residual disease negativity by flow cytometry on day 21 complete cytogenetic response at complete response major molecular response at complete response and at 3 months and complete molecular response at 3 months IPTW confirmed that treatment with HCVAD plus ponatinib was associated with longer EFS P =.003 and OS P =.001 compared with treatment with HCVAD plus dasatinib The clinical outcome of patients treated with HCVAD plus ponatinib appears to be superior to that of patients treated with HCVAD plus dasatinib among individuals with Ph+ ALL Cancer 2016 122:3650-6  2016 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 38, 209, 1, 6201, 1112, 2132, 856, 2, 1217, 14372, 349, 5715, 71, 44, 85, 72, 5, 17, 1, 14372, 349, 1674, 4, 7, 5, 3006, 1170, 109, 286, 1275, 2058, 62, 4, 8, 384, 38, 160, 3, 738, 311, 3129, 7, 5, 732, 265, 2058, 62, 54, 11, 346, 4, 18, 935, 482, 124, 18, 38, 143, 1, 3171, 14372, 5, 361, 1674, 676, 7, 15, 5715, 662, 7, 1925, 368, 65, 5, 14, 14, 2616, 5, 3, 11252, 26023, 2616, 596, 2, 2931, 1320, 1, 24, 7775, 11890, 65, 90, 23, 3, 1925, 703, 11, 173, 6, 423, 51, 151, 774, 115, 25, 1683, 2, 63, 25, 118, 59, 3, 736, 1925, 368, 2616, 108, 605, 7, 4, 296, 180, 5, 1925, 368, 2616, 3, 27, 111, 1683, 151, 9, 7, 73, 5, 14372, 349, 5715, 2, 14372, 349, 1674, 11, 790, 2, 641, 106, 19, 755, 2, 3, 27, 111, 118, 151, 11, 852, 2, 664, 106, 19, 680, 11890, 65, 75, 68686, 736, 264, 17, 7, 73, 5, 14372, 349, 5715, 42, 97, 142, 151, 1, 1048, 753, 34, 6014, 20, 1412, 1914, 23, 218, 239, 236, 1266, 51, 28, 236, 51, 458, 219, 51, 28, 236, 51, 2, 28, 27, 53, 2, 236, 219, 51, 28, 27, 53, 11890, 557, 17, 24, 5, 14372, 349, 5715, 10, 41, 5, 589, 1683, 19, 1421, 2, 118, 19, 144, 72, 5, 24, 5, 14372, 349, 1674, 3, 38, 228, 1, 7, 73, 5, 14372, 349, 5715, 1233, 6, 40, 1123, 6, 17, 1, 7, 73, 5, 14372, 349, 1674, 107, 869, 5, 2058, 62, 12, 1390, 3285, 68687, 49, 2206, 1390, 597, 12, 1174]",1812.0,27479888,183
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.,The Journal of clinical investigation,J. Clin. Invest.,2016-08-02,"T cells expressing antigen-specific chimeric antigen receptors (CARs) improve outcomes for CD19-expressing B cell malignancies. We evaluated a human application of T cells that were genetically modified using the Sleeping Beauty (SB) transposon/transposase system to express a CD19-specific CAR. T cells were genetically modified using DNA plasmids from the SB platform to stably express a second-generation CD19-specific CAR and selectively propagated ex vivo with activating and propagating cells (AaPCs) and cytokines. Twenty-six patients with advanced non-Hodgkin lymphoma and acute lymphoblastic leukemia safely underwent hematopoietic stem cell transplantation (HSCT) and infusion of CAR T cells as adjuvant therapy in the autologous (n = 7) or allogeneic settings (n = 19). SB-mediated genetic transposition and stimulation resulted in 2,200- to 2,500-fold ex vivo expansion of genetically modified T cells, with 84% CAR expression, and without integration hotspots. Following autologous HSCT, the 30-month progression-free and overall survivals were 83% and 100%, respectively. After allogeneic HSCT, the respective 12-month rates were 53% and 63%. No acute or late toxicities and no exacerbation of graft-versus-host disease were observed. Despite a low antigen burden and unsupportive recipient cytokine environment, CAR T cells persisted for an average of 201 days for autologous recipients and 51 days for allogeneic recipients. CD19-specific CAR T cells generated with SB and AaPC platforms were safe, and may provide additional cancer control as planned infusions after HSCT. These results support further clinical development of this nonviral gene therapy approach. Autologous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT01492036. National Cancer Institute, private foundations, and institutional funds. Please see Acknowledgments for details.","Clinical Trial, Phase I",1267.0,158.0,"T cells expressing antigen-specific chimeric antigen receptors CARs improve outcomes for CD19-expressing B cell malignancies We evaluated a human application of T cells that were genetically modified using the Sleeping Beauty SB transposon/transposase system to express a CD19-specific CAR T cells were genetically modified using DNA plasmids from the SB platform to stably express a second-generation CD19-specific CAR and selectively propagated ex vivo with activating and propagating cells AaPCs and cytokines Twenty-six patients with advanced and acute lymphoblastic safely underwent hematopoietic stem cell transplantation HSCT and infusion of CAR T cells as adjuvant therapy in the autologous n 7 or allogeneic settings n 19 SB-mediated genetic transposition and stimulation resulted in 2,200- to 2,500-fold ex vivo expansion of genetically modified T cells with 84 CAR expression and without integration hotspots Following autologous HSCT the 30-month progression-free and overall survivals were 83 and 100 respectively After allogeneic HSCT the respective 12-month rates were 53 and 63 No acute or late toxicities and no exacerbation of graft-versus-host disease were observed Despite a low antigen burden and unsupportive recipient cytokine environment CAR T cells persisted for an average of 201 days for autologous recipients and 51 days for allogeneic recipients CD19-specific CAR T cells generated with SB and AaPC platforms were safe and may provide additional cancer control as planned infusions after HSCT These results support further clinical development of this nonviral gene therapy approach Autologous NCT00968760 allogeneic NCT01497184 long-term follow-up NCT01492036 National Cancer Institute private foundations and institutional funds Please see Acknowledgments for details",0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[102, 37, 1046, 448, 112, 2897, 448, 1186, 7441, 401, 123, 9, 3158, 1046, 132, 31, 441, 21, 194, 8, 171, 1581, 1, 102, 37, 17, 11, 2301, 1230, 75, 3, 13358, 16570, 5343, 14042, 18066, 398, 6, 1669, 8, 3158, 112, 1881, 102, 37, 11, 2301, 1230, 75, 261, 12473, 29, 3, 5343, 2243, 6, 5834, 1669, 8, 419, 914, 3158, 112, 1881, 2, 2382, 11917, 2581, 386, 5, 1616, 2, 14999, 37, 40729, 2, 1886, 737, 437, 7, 5, 131, 2, 286, 1275, 2268, 208, 1007, 452, 31, 497, 1703, 2, 904, 1, 1881, 102, 37, 22, 249, 36, 4, 3, 1028, 78, 67, 15, 1063, 1947, 78, 326, 5343, 517, 336, 19640, 2, 2503, 627, 4, 18, 1250, 6, 18, 1666, 1116, 2581, 386, 1422, 1, 2301, 1230, 102, 37, 5, 874, 1881, 55, 2, 187, 2676, 11193, 366, 1028, 1703, 3, 201, 811, 91, 115, 2, 63, 3794, 11, 852, 2, 394, 106, 50, 1063, 1703, 3, 3847, 133, 811, 151, 11, 699, 2, 676, 77, 286, 15, 807, 385, 2, 77, 12195, 1, 1599, 185, 1204, 34, 11, 164, 550, 8, 154, 448, 892, 2, 32145, 5783, 1675, 3087, 1881, 102, 37, 3760, 9, 35, 1011, 1, 4766, 162, 9, 1028, 2190, 2, 725, 162, 9, 1063, 2190, 3158, 112, 1881, 102, 37, 1419, 5, 5343, 2, 8990, 4364, 11, 1165, 2, 68, 377, 402, 12, 182, 22, 1465, 3435, 50, 1703, 46, 99, 538, 195, 38, 193, 1, 26, 18434, 145, 36, 353, 1028, 68697, 1063, 68698, 319, 337, 166, 126, 68699, 657, 12, 1377, 4745, 21739, 2, 1115, 20478, 25553, 3764, 68700, 9, 3791]",1798.0,27482888,617
Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2016-10-01,"While the majority of children and adolescents with newly diagnosed childhood acute lymphoblastic leukemia (ALL) will be cured, as many as 20% of patients will experience relapse. On current treatment regimens, the intensity of upfront treatment is stratified based upon prognostic factors with the aim of improving cure rates (for those at the highest risk of relapse) and minimizing treatment-related morbidity (for lower-risk patients). Here we review advances in the understanding of prognostic factors and their application. We also highlight novel treatment approaches aimed at improving outcomes in childhood ALL.",Journal Article,1207.0,10.0,While the majority of children and adolescents with newly diagnosed childhood acute lymphoblastic ALL will be cured as many as 20 of patients will experience relapse On current treatment regimens the intensity of upfront treatment is stratified based upon prognostic factors with the aim of improving cure rates for those at the highest risk of relapse and minimizing treatment-related morbidity for lower-risk patients Here we review advances in the understanding of prognostic factors and their application We also highlight novel treatment approaches aimed at improving outcomes in childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[369, 3, 686, 1, 541, 2, 3101, 5, 732, 265, 864, 286, 1275, 62, 303, 40, 3733, 22, 445, 22, 179, 1, 7, 303, 730, 429, 23, 291, 24, 472, 3, 837, 1, 2941, 24, 16, 1173, 90, 1548, 177, 130, 5, 3, 1130, 1, 1673, 1722, 151, 9, 135, 28, 3, 1076, 43, 1, 429, 2, 4501, 24, 139, 787, 9, 280, 43, 7, 467, 21, 206, 954, 4, 3, 612, 1, 177, 130, 2, 136, 1581, 21, 120, 1817, 229, 24, 611, 1295, 28, 1673, 123, 4, 864, 62]",598.0,27502091,457
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.,Cancer,Cancer,2016-08-10,"The role of day 14 (D14) bone marrow (BM) assessment in detecting increased blasts in patients undergoing induction for acute lymphoblastic leukemia (ALL) is not well defined. This study evaluated 389 adolescent and adult patients with previously untreated Philadelphia chromosome-negative ALL who received frontline induction chemotherapy and for whom a D14 BM assessment was performed. A D14 BM blast proportion<10% (including blast-free aplastic BM) was observed in 319 patients (82%), 10% to 29% was observed in 31 patients (8%), and 30% was observed in 39 patients (10%). The composite complete remission (CR)/complete remission with inadequate platelet recovery (CRp) rates for these groups were 99.7%, 87%, and 79%, respectively. The median event-free survival (EFS) was 49, 33, and 9 months, respectively (P<.001). The median overall survival (OS) was 88, 37, and 21 months, respectively (P<.001). The D14 BM blast group was the only factor predictive for the achievement of CR/CRp (P<.001). According to a multivariate analysis, the D14 BM blast group was independently prognostic for both EFS (hazard ratio [HR], 1.44; 95% confidence interval [CI], 1.12-1.85; P=.004) and OS (HR, 1.45; 95% CI, 1.14-1.85; P=.003). However, when minimal residual disease (MRD) assessment at the time of CR was added to the model, the D14 BM blast group was no longer prognostic for EFS or OS. An assessment of residual D14 BM blasts in patients with ALL is highly predictive of the achievement of CR with induction chemotherapy and of EFS and OS. However, the D14 BM blast assessment is less prognostic of long-term outcomes when an MRD assessment is also available. Cancer 2016;122:3812-3820.  2016 American Cancer Society.",Journal Article,1259.0,5.0,The role of day 14 D14 marrow BM assessment in detecting increased blasts in patients undergoing induction for acute lymphoblastic ALL is not well defined This study evaluated 389 adolescent and adult patients with previously untreated Philadelphia chromosome-negative ALL who received frontline induction chemotherapy and for whom a D14 BM assessment was performed A D14 BM blast proportion 10 including blast-free aplastic BM was observed in 319 patients 82 10 to 29 was observed in 31 patients 8 and 30 was observed in 39 patients 10 The composite complete remission CR /complete remission with inadequate platelet recovery CRp rates for these groups were 99.7 87 and 79 respectively The median event-free survival EFS was 49 33 and 9 months respectively P .001 The median overall survival OS was 88 37 and 21 months respectively P .001 The D14 BM blast group was the only factor predictive for the achievement of CR/CRp P .001 According to a multivariate analysis the D14 BM blast group was independently prognostic for both EFS hazard ratio HR 1.44 95 confidence interval CI 1.12-1.85 P .004 and OS HR 1.45 95 CI 1.14-1.85 P .003 However when minimal residual disease MRD assessment at the time of CR was added to the model the D14 BM blast group was no longer prognostic for EFS or OS An assessment of residual D14 BM blasts in patients with ALL is highly predictive of the achievement of CR with induction chemotherapy and of EFS and OS However the D14 BM blast assessment is less prognostic of long-term outcomes when an MRD assessment is also available Cancer 2016 122:3812-3820  2016 American Cancer Society,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 200, 1, 218, 213, 22944, 581, 1246, 455, 4, 2502, 101, 2438, 4, 7, 479, 504, 9, 286, 1275, 62, 16, 44, 149, 395, 26, 45, 194, 9182, 3678, 2, 780, 7, 5, 373, 1278, 3006, 1170, 199, 62, 54, 103, 3171, 504, 56, 2, 9, 953, 8, 22944, 1246, 455, 10, 173, 8, 22944, 1246, 3112, 920, 79, 141, 3112, 115, 16315, 1246, 10, 164, 4, 9052, 7, 878, 79, 6, 462, 10, 164, 4, 456, 7, 66, 2, 7783, 10, 164, 4, 587, 7, 79, 3, 3308, 236, 734, 684, 236, 734, 5, 3358, 1596, 1602, 3162, 151, 9, 46, 271, 11, 1058, 67, 912, 2, 842, 106, 3, 52, 774, 115, 25, 1683, 10, 739, 466, 2, 83, 53, 106, 19, 144, 3, 52, 63, 25, 118, 10, 889, 567, 2, 239, 53, 106, 19, 144, 3, 22944, 1246, 3112, 87, 10, 3, 158, 161, 464, 9, 3, 5088, 1, 684, 3162, 19, 144, 768, 6, 8, 331, 65, 3, 22944, 1246, 3112, 87, 10, 1042, 177, 9, 110, 1683, 360, 197, 168, 14, 584, 48, 307, 268, 58, 14, 133, 14, 772, 19, 1520, 2, 118, 168, 14, 512, 48, 58, 14, 213, 14, 772, 19, 1421, 137, 198, 1048, 753, 34, 2029, 455, 28, 3, 98, 1, 684, 10, 1953, 6, 3, 202, 3, 22944, 1246, 3112, 87, 10, 77, 589, 177, 9, 1683, 15, 118, 35, 455, 1, 753, 22944, 1246, 2438, 4, 7, 5, 62, 16, 561, 464, 1, 3, 5088, 1, 684, 5, 504, 56, 2, 1, 1683, 2, 118, 137, 3, 22944, 1246, 3112, 455, 16, 299, 177, 1, 319, 337, 123, 198, 35, 2029, 455, 16, 120, 390, 12, 1390, 3285, 68751, 41525, 2206, 1390, 597, 12, 1174]",1619.0,27508525,11
"Secondary malignancies in patients with multiple myeloma, Waldenstrm macroglobulinemia and monoclonal gammopathy of undetermined significance.",Leukemia & lymphoma,Leuk. Lymphoma,2016-08-22,"In recent years, the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy. However, the risk of secondary malignancies has increased, thought to be due to a combination of environmental and disease-related factors, as well as treatment. In the present review, we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) and Waldenstrm macroglobulinemia (WM). Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In patients with MM, the risk of AML, acute lymphoblastic leukemia and some solid tumors appears increased. Finally, in WM patients, there seems to be increased risk of AML, diffuse large B-cell lymphoma, thyroid cancer and melanoma.",Journal Article,1247.0,9.0,In recent years the survival of patients with plasma cell dyscrasias has improved due to improvements in anticancer and supportive therapy However the risk of secondary malignancies has increased thought to be due to a combination of environmental and disease-related factors as well as treatment In the present review we evaluate the risk of secondary malignancies in patients with monoclonal gammopathy of undetermined significance MGUS multiple MM and Waldenstrm macroglobulinemia WM Patients with MGUS appear to have a higher risk of developing myeloid malignancies such as syndromes MDS and acute myeloid AML In patients with MM the risk of AML acute lymphoblastic and some solid tumors appears increased Finally in WM patients there seems to be increased risk of AML diffuse large B-cell cancer and,0,0,1,0,0,1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,"[4, 435, 60, 3, 25, 1, 7, 5, 554, 31, 17162, 71, 231, 520, 6, 1474, 4, 1475, 2, 1877, 36, 137, 3, 43, 1, 568, 441, 71, 101, 2739, 6, 40, 520, 6, 8, 150, 1, 3766, 2, 34, 139, 130, 22, 149, 22, 24, 4, 3, 364, 206, 21, 376, 3, 43, 1, 568, 441, 4, 7, 5, 848, 5334, 1, 5206, 724, 3226, 232, 321, 2, 3700, 3389, 1518, 7, 5, 3226, 1322, 6, 47, 8, 142, 43, 1, 931, 533, 441, 225, 22, 2040, 1223, 2, 286, 533, 329, 4, 7, 5, 321, 3, 43, 1, 329, 286, 1275, 2, 476, 537, 57, 1233, 101, 1368, 4, 1518, 7, 125, 2744, 6, 40, 101, 43, 1, 329, 1388, 375, 132, 31, 12, 2]",805.0,27546465,349
Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells.,Cytotherapy,Cytotherapy,2016-08-31,"The past several years have been marked by extraordinary advances in clinical applications of immunotherapy. In particular, adoptive cellular therapy utilizing chimeric antigen receptor (CAR)-modified T cells targeted to CD19 has demonstrated substantial clinical efficacy in children and adults with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL) and durable clinical benefit in a smaller subset of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or B-cell non-Hodgkin lymphoma (B-NHL). Early-phase clinical trials are currently assessing CAR T-cell safety and efficacy in additional malignancies. Here, we discuss clinical results from the largest series to date investigating CD19-targeted CAR T cells in B-ALL, CLL, and B-NHL, including discussion of differences in CAR T-cell design and production and treatment approach, as well as clinical efficacy, nature of severe cytokine release syndrome and neurologic toxicities, and CAR T-cell expansion and persistence. We additionally review the current and forthcoming use of CAR T cells in multiple myeloma and several solid tumors and highlight challenges and opportunities afforded by the current state of CAR T-cell therapies, including strategies to overcome inhibitory aspects of the tumor microenvironment and enhance antitumor efficacy.",Journal Article,1238.0,55.0,The past several years have been marked by extraordinary advances in clinical applications of immunotherapy In particular adoptive cellular therapy utilizing chimeric antigen receptor CAR -modified T cells targeted to CD19 has demonstrated substantial clinical efficacy in children and adults with relapsed or refractory B-cell acute lymphoblastic B-ALL and durable clinical benefit in a smaller subset of patients with relapsed or refractory chronic lymphocytic CLL or B-cell B-NHL Early-phase clinical trials are currently assessing CAR T-cell safety and efficacy in additional malignancies Here we discuss clinical results from the largest series to date investigating CD19-targeted CAR T cells in B-ALL CLL and B-NHL including discussion of differences in CAR T-cell design and production and treatment approach as well as clinical efficacy nature of severe cytokine release syndrome and neurologic toxicities and CAR T-cell expansion and persistence We additionally review the current and forthcoming use of CAR T cells in multiple and several solid tumors and highlight challenges and opportunities afforded by the current state of CAR T-cell therapies including strategies to overcome inhibitory aspects of the tumor microenvironment and enhance antitumor efficacy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3, 1219, 392, 60, 47, 85, 2003, 20, 17915, 954, 4, 38, 2911, 1, 726, 4, 1454, 3159, 763, 36, 2600, 2897, 448, 153, 1881, 1230, 102, 37, 238, 6, 3158, 71, 264, 1281, 38, 209, 4, 541, 2, 857, 5, 591, 15, 430, 132, 31, 286, 1275, 132, 62, 2, 1480, 38, 247, 4, 8, 2170, 697, 1, 7, 5, 591, 15, 430, 442, 1193, 552, 15, 132, 31, 132, 1176, 191, 124, 38, 143, 32, 694, 1977, 1881, 102, 31, 367, 2, 209, 4, 402, 441, 467, 21, 1139, 38, 99, 29, 3, 2166, 988, 6, 1244, 3103, 3158, 238, 1881, 102, 37, 4, 132, 62, 552, 2, 132, 1176, 141, 2488, 1, 362, 4, 1881, 102, 31, 771, 2, 1529, 2, 24, 353, 22, 149, 22, 38, 209, 2202, 1, 905, 1675, 2008, 681, 2, 2543, 385, 2, 1881, 102, 31, 1422, 2, 4108, 21, 1724, 206, 3, 291, 2, 16039, 119, 1, 1881, 102, 37, 4, 232, 2, 392, 537, 57, 2, 1817, 1427, 2, 2605, 9150, 20, 3, 291, 1309, 1, 1881, 102, 31, 235, 141, 422, 6, 1768, 1810, 2695, 1, 3, 30, 995, 2, 1304, 579, 209]",1271.0,27592405,529
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.,Cancer,Cancer,2016-09-07,"Minimal residual disease (MRD) assessment predicts survival for patients with newly diagnosed acute lymphoblastic leukemia (ALL). Its significance in relapsed/refractory ALL is less clear. This study identified 78 patients with relapsed/refractory B-cell ALL who achieved a morphologic response with inotuzumab ozogamicin (n=41), blinatumomab (n=11), or mini-hyperfractionated cyclophosphamide, vincristine, and doxorubicin plus inotuzumab (n=26) during either salvage 1 (S1; n=46) or salvage 2 (S2; n=32) and had undergone an MRD assessment by multiparameter flow cytometry at the time of remission. MRD negativity was achieved in 41 patients overall (53%). The MRD negativity rate was 57% in S1 and 47% in S2. Among patients in S1, achieving MRD negativity was associated with longer event-free survival (EFS; median, 18 vs 7 months; 2-year EFS rate, 46% vs 17%; P=.06) and overall survival (OS; median, 27 vs 9 months; 2-year OS, 52% vs 36%; P=.15). EFS and OS were similar in S2, regardless of the MRD response. Among MRD-negative patients who underwent allogeneic stem cell transplantation (SCT), EFS and OS were superior for those who underwent SCT in S1 rather than S2 (P=.003 and P=.04, respectively). Patients in S1 who achieved MRD negativity and subsequently underwent SCT had the best outcomes with a 2-year OS rate of 65%. Patients with relapsed/refractory ALL who achieve MRD negativity in S1 can have long-term survival. Patients in S2 generally have poor outcomes, regardless of their MRD status. Cancer 2017;123:294-302.  2016 American Cancer Society.",Journal Article,1231.0,32.0,Minimal residual disease MRD assessment predicts survival for patients with newly diagnosed acute lymphoblastic ALL Its significance in relapsed/refractory ALL is less clear This study identified 78 patients with relapsed/refractory B-cell ALL who achieved a morphologic response with inotuzumab ozogamicin n 41 blinatumomab n 11 or mini-hyperfractionated cyclophosphamide vincristine and doxorubicin plus inotuzumab n 26 during either salvage 1 S1 n 46 or salvage 2 S2 n 32 and had undergone an MRD assessment by multiparameter flow cytometry at the time of remission MRD negativity was achieved in 41 patients overall 53 The MRD negativity rate was 57 in S1 and 47 in S2 Among patients in S1 achieving MRD negativity was associated with longer event-free survival EFS median 18 vs 7 months 2-year EFS rate 46 vs 17 P .06 and overall survival OS median 27 vs 9 months 2-year OS 52 vs 36 P .15 EFS and OS were similar in S2 regardless of the MRD response Among MRD-negative patients who underwent allogeneic stem cell transplantation SCT EFS and OS were superior for those who underwent SCT in S1 rather than S2 P .003 and P .04 respectively Patients in S1 who achieved MRD negativity and subsequently underwent SCT had the best outcomes with a 2-year OS rate of 65 Patients with relapsed/refractory ALL who achieve MRD negativity in S1 can have long-term survival Patients in S2 generally have poor outcomes regardless of their MRD status Cancer 2017 123:294-302  2016 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1048, 753, 34, 2029, 455, 2623, 25, 9, 7, 5, 732, 265, 286, 1275, 62, 211, 724, 4, 591, 430, 62, 16, 299, 885, 26, 45, 108, 833, 7, 5, 591, 430, 132, 31, 62, 54, 513, 8, 2815, 51, 5, 6730, 5566, 78, 605, 7182, 78, 175, 15, 7313, 6201, 1112, 2132, 2, 856, 349, 6730, 78, 432, 190, 361, 992, 14, 11836, 78, 641, 15, 992, 18, 10355, 78, 531, 2, 42, 1989, 35, 2029, 455, 20, 10757, 1412, 1914, 28, 3, 98, 1, 734, 2029, 6014, 10, 513, 4, 605, 7, 63, 699, 3, 2029, 6014, 116, 10, 696, 4, 11836, 2, 662, 4, 10355, 107, 7, 4, 11836, 1785, 2029, 6014, 10, 41, 5, 589, 774, 115, 25, 1683, 52, 203, 105, 67, 53, 18, 111, 1683, 116, 641, 105, 269, 19, 1460, 2, 63, 25, 118, 52, 428, 105, 83, 53, 18, 111, 118, 653, 105, 511, 19, 167, 1683, 2, 118, 11, 288, 4, 10355, 1583, 1, 3, 2029, 51, 107, 2029, 199, 7, 54, 208, 1063, 452, 31, 497, 1988, 1683, 2, 118, 11, 1123, 9, 135, 54, 208, 1988, 4, 11836, 1832, 76, 10355, 19, 1421, 2, 19, 755, 106, 7, 4, 11836, 54, 513, 2029, 6014, 2, 1611, 208, 1988, 42, 3, 824, 123, 5, 8, 18, 111, 118, 116, 1, 556, 7, 5, 591, 430, 62, 54, 1359, 2029, 6014, 4, 11836, 122, 47, 319, 337, 25, 7, 4, 10355, 1228, 47, 334, 123, 1583, 1, 136, 2029, 156, 12, 1759, 2698, 8375, 4952, 2206, 1390, 597, 12, 1174]",1494.0,27602508,458
Adoption of pediatric-inspired acute lymphoblastic leukemia regimens by adult oncologists treating adolescents and young adults: A population-based study.,Cancer,Cancer,2016-09-13,"Studies have demonstrated superior outcomes for adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) who are treated using pediatric versus adult therapeutic regimens. To the best of our knowledge, whether adult oncologists in the United States have adopted this approach to ALL in AYA patients is currently unknown. The objective of the current study was to provide a population-based description of ALL treatment patterns in AYA individuals over the past decade. Data regarding AYA patients aged 15 to 39 years and diagnosed with ALL between 2004 and 2014 while living in the Greater Bay Area were obtained from the Greater Bay Area Cancer Registry (GBACR). Treating facilities were designated as pediatric or adult centers; induction treatment regimens were abstracted from registry text data fields. Of 304 patients diagnosed in the GBACR catchment region, complete treatment data were available for 229 (75%). The location of care was identified for 296 patients (97%) treated at 31 unique centers. Approximately 70% of AYA patients received induction therapy at an adult treatment center. All AYA patients who were treated at pediatric centers received pediatric ALL regimens. Among AYA patients treated by adult oncologists with complete treatment data, none received a pediatric regimen before 2008. Between 2008 and 2012, while the US Adult Intergroup C10403 pediatric-inspired ALL protocol was open to accrual, 31% of AYA patients treated by adult oncologists received pediatric regimens. This rate fell to 21% from 2013 through 2014. Adult facilities treating2 AYA patients with ALL per year captured in the GBACR were more likely to administer pediatric regimens than lower volume centers (P=.03). As of 2014, only a minority of AYA patients with ALL received pediatric ALL regimens at adult cancer centers. Cancer 2017;122-130.  2016 American Cancer Society.",Journal Article,1225.0,16.0,Studies have demonstrated superior outcomes for adolescent and young adult AYA patients with acute lymphoblastic ALL who are treated using pediatric versus adult therapeutic regimens To the best of our knowledge whether adult oncologists in the United States have adopted this approach to ALL in AYA patients is currently unknown The objective of the current study was to provide a population-based description of ALL treatment patterns in AYA individuals over the past decade Data regarding AYA patients aged 15 to 39 years and diagnosed with ALL between 2004 and 2014 while living in the Greater Bay Area were obtained from the Greater Bay Area Cancer Registry GBACR Treating facilities were designated as pediatric or adult centers induction treatment regimens were abstracted from registry text data fields Of 304 patients diagnosed in the GBACR catchment region complete treatment data were available for 229 75 The location of care was identified for 296 patients 97 treated at 31 unique centers Approximately 70 of AYA patients received induction therapy at an adult treatment center All AYA patients who were treated at pediatric centers received pediatric ALL regimens Among AYA patients treated by adult oncologists with complete treatment data none received a pediatric regimen before 2008 Between 2008 and 2012 while the US Adult Intergroup C10403 pediatric-inspired ALL protocol was open to accrual 31 of AYA patients treated by adult oncologists received pediatric regimens This rate fell to 21 from 2013 through 2014 Adult facilities treating  2 AYA patients with ALL per year captured in the GBACR were more likely to administer pediatric regimens than lower volume centers P .03 As of 2014 only a minority of AYA patients with ALL received pediatric ALL regimens at adult cancer centers Cancer 2017 122-130  2016 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[94, 47, 264, 1123, 123, 9, 3678, 2, 1169, 780, 4598, 7, 5, 286, 1275, 62, 54, 32, 73, 75, 815, 185, 780, 189, 472, 6, 3, 824, 1, 114, 922, 317, 780, 1339, 4, 3, 1088, 907, 47, 4457, 26, 353, 6, 62, 4, 4598, 7, 16, 694, 860, 3, 461, 1, 3, 291, 45, 10, 6, 377, 8, 266, 90, 5263, 1, 62, 24, 764, 4, 4598, 869, 252, 3, 1219, 2025, 74, 666, 4598, 7, 1032, 167, 6, 587, 60, 2, 265, 5, 62, 59, 1131, 2, 1409, 369, 2798, 4, 3, 378, 7444, 965, 11, 683, 29, 3, 378, 7444, 965, 12, 1608, 41553, 1367, 4351, 11, 4107, 22, 815, 15, 780, 1168, 504, 24, 472, 11, 4106, 29, 1608, 6153, 74, 3130, 1, 8940, 7, 265, 4, 3, 41553, 22948, 1053, 236, 24, 74, 11, 390, 9, 7584, 481, 3, 1147, 1, 165, 10, 108, 9, 10340, 7, 1015, 73, 28, 456, 991, 1168, 705, 431, 1, 4598, 7, 103, 504, 36, 28, 35, 780, 24, 574, 62, 4598, 7, 54, 11, 73, 28, 815, 1168, 103, 815, 62, 472, 107, 4598, 7, 73, 20, 780, 1339, 5, 236, 24, 74, 1292, 103, 8, 815, 477, 348, 1375, 59, 1375, 2, 1195, 369, 3, 843, 780, 4839, 68980, 815, 13161, 62, 1182, 10, 1020, 6, 2262, 456, 1, 4598, 7, 73, 20, 780, 1339, 103, 815, 472, 26, 116, 7689, 6, 239, 29, 1346, 298, 1409, 780, 4351, 1367, 749, 18, 4598, 7, 5, 62, 379, 111, 4954, 4, 3, 41553, 11, 80, 322, 6, 6888, 815, 472, 76, 280, 433, 1168, 19, 680, 22, 1, 1409, 158, 8, 2652, 1, 4598, 7, 5, 62, 103, 815, 62, 472, 28, 780, 12, 1168, 12, 1759, 3285, 3431, 2206, 1390, 597, 12, 1174]",1855.0,27622953,370
The use of Erwinia asparaginase for adult patients with acute lymphoblastic leukemia after pegaspargase intolerance.,Leukemia research,Leuk. Res.,2016-08-26,"Asparaginase administration has become a crucial component of front-line pediatric and pediatric-insipired multi-agent regimens for the treatment of acute lymphoblastic leukemia (ALL). The aim of this retrospective study was to assess the safety and feasibility of switching to Erwinia asparaginase after pegaspargase intolerance in adult ALL patients treated at Memorial Sloan Kettering Cancer Center. Our analysis included 10 patients, with a median age of 39 years (range 20-72), male predominance (90%), and a typical B-cell to T-cell ratio (70:30%) for ALL. Nine patients were switched to Erwinia asparaginase after pegaspargase hypersensitivity and one patient after grade 4 hyperbilirubinemia secondary to pegaspargase. With Erwinia asparaginase, no hypersensitivity reactions occurred and no patient developed other known clinical asparaginase-related toxicities. Laboratory adverse effects consisted of mostly mild elevation in liver enzymes. No morphologic relapses have occurred in any patient switched to Erwinia asparaginase in first remission at a follow up of 0.4-34.6 months. These findings are unique in that all of our patients received Erwinia asparaginase after hypersensitivity or intolerance to pegaspargase and 50% of them were older than 40 years of age, a population with very limited Erwinia asparaginase data. Our observations provide preliminary information that treatment with Erwinia asparaginase can proceed as scheduled in adult patients, despite pegaspargase hypersensitivity and possibly liver intolerance.",Journal Article,1243.0,5.0,Asparaginase administration has become a crucial component of front-line pediatric and pediatric-insipired multi-agent regimens for the treatment of acute lymphoblastic ALL The aim of this retrospective study was to assess the safety and feasibility of switching to Erwinia asparaginase after pegaspargase intolerance in adult ALL patients treated at Memorial Sloan Kettering Cancer Center Our analysis included 10 patients with a median age of 39 years range 20-72 male predominance 90 and a typical B-cell to T-cell ratio 70:30 for ALL Nine patients were switched to Erwinia asparaginase after pegaspargase hypersensitivity and one patient after grade 4 hyperbilirubinemia secondary to pegaspargase With Erwinia asparaginase no hypersensitivity reactions occurred and no patient developed other known clinical asparaginase-related toxicities Laboratory adverse effects consisted of mostly mild elevation in enzymes No morphologic relapses have occurred in any patient switched to Erwinia asparaginase in first remission at a follow up of 0.4-34.6 months These findings are unique in that all of our patients received Erwinia asparaginase after hypersensitivity or intolerance to pegaspargase and 50 of them were older than 40 years of age a population with very limited Erwinia asparaginase data Our observations provide preliminary information that treatment with Erwinia asparaginase can proceed as scheduled in adult patients despite pegaspargase hypersensitivity and possibly intolerance,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 634, 71, 1417, 8, 2653, 1249, 1, 3007, 328, 815, 2, 815, 68989, 1414, 420, 472, 9, 3, 24, 1, 286, 1275, 62, 3, 1130, 1, 26, 459, 45, 10, 6, 423, 3, 367, 2, 1437, 1, 7718, 6, 11358, 3709, 50, 12209, 5266, 4, 780, 62, 7, 73, 28, 2563, 2783, 2784, 12, 574, 114, 65, 159, 79, 7, 5, 8, 52, 89, 1, 587, 60, 184, 179, 720, 1045, 7593, 424, 2, 8, 3476, 132, 31, 6, 102, 31, 197, 431, 201, 9, 62, 762, 7, 11, 7883, 6, 11358, 3709, 50, 12209, 4034, 2, 104, 69, 50, 88, 39, 7236, 568, 6, 12209, 5, 11358, 3709, 77, 4034, 2428, 489, 2, 77, 69, 276, 127, 440, 38, 3709, 139, 385, 1624, 290, 176, 1695, 1, 2754, 1980, 3292, 4, 3039, 77, 2815, 3713, 47, 489, 4, 500, 69, 7883, 6, 11358, 3709, 4, 157, 734, 28, 8, 166, 126, 1, 13, 39, 562, 49, 53, 46, 272, 32, 991, 4, 17, 62, 1, 114, 7, 103, 11358, 3709, 50, 4034, 15, 5266, 6, 12209, 2, 212, 1, 1370, 11, 434, 76, 327, 60, 1, 89, 8, 266, 5, 923, 383, 11358, 3709, 74, 114, 2172, 377, 1676, 487, 17, 24, 5, 11358, 3709, 122, 6174, 22, 4394, 4, 780, 7, 550, 12209, 4034, 2, 2150, 5266]",1493.0,27631159,384
miR-125b regulates differentiation and metabolic reprogramming of T cell acute lymphoblastic leukemia by directly targeting A20.,Oncotarget,Oncotarget,2016-11-01,"T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematopoietic malignancy. Although it has been reported that overexpression of miR-125b leads to T-ALL development, the underlying mechanisms of miR-125b action are still unclear. The goal of this study is to delineate the role of miR-125b in T-ALL development. We found that miR-125b is highly expressed in undifferentiated leukemic T cells (CD4-negative) while its expression is low in differentiated T cells (CD4-positive). Overexpression of miR-125b increased the CD4-negative population in T cells, whereas depletion of miR-125b by miR-125b-sponge decreased the CD4-negative cell population. We identified that A20 (TNFAIP3) is a direct target of miR-125b in T cells. Overexpression of miR-125b also increased glucose uptake and oxygen consumption in T cells through targeting A20. Furthermore, restoration of A20 in miR-125b-overexpressing cells decreased the CD4-negative population in T cell leukemia, and decreased glucose uptake and oxygen consumption to the basal level of T cells transfected with vector. In conclusion, our data demonstrate that miR-125b regulates differentiation and reprogramming of T cell glucose metabolism via targeting A20. Since both de-differentiation and dysregulated glucose metabolism contribute to the development of T-cell leukemia, these findings provide novel insights into the understanding and treatment of T-ALL.",Journal Article,1176.0,9.0,T-cell acute lymphoblastic T-ALL is an aggressive hematopoietic malignancy Although it has been reported that overexpression of miR-125b leads to T-ALL development the underlying mechanisms of miR-125b action are still unclear The goal of this study is to delineate the role of miR-125b in T-ALL development We found that miR-125b is highly expressed in undifferentiated leukemic T cells CD4-negative while its expression is low in differentiated T cells CD4-positive Overexpression of miR-125b increased the CD4-negative population in T cells whereas depletion of miR-125b by miR-125b-sponge decreased the CD4-negative cell population We identified that A20 TNFAIP3 is a direct target of miR-125b in T cells Overexpression of miR-125b also increased glucose uptake and oxygen consumption in T cells through targeting A20 Furthermore restoration of A20 in miR-125b-overexpressing cells decreased the CD4-negative population in T cell and decreased glucose uptake and oxygen consumption to the basal level of T cells transfected with vector In conclusion our data demonstrate that miR-125b regulates differentiation and reprogramming of T cell glucose metabolism via targeting A20 Since both de-differentiation and dysregulated glucose metabolism contribute to the development of T-cell these findings provide novel insights into the understanding and treatment of T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[102, 31, 286, 1275, 102, 62, 16, 35, 571, 1007, 710, 242, 192, 71, 85, 210, 17, 851, 1, 722, 12241, 1940, 6, 102, 62, 193, 3, 1181, 483, 1, 722, 12241, 1578, 32, 1234, 1200, 3, 1326, 1, 26, 45, 16, 6, 5092, 3, 200, 1, 722, 12241, 4, 102, 62, 193, 21, 204, 17, 722, 12241, 16, 561, 570, 4, 4480, 2015, 102, 37, 1440, 199, 369, 211, 55, 16, 154, 4, 1442, 102, 37, 1440, 109, 851, 1, 722, 12241, 101, 3, 1440, 199, 266, 4, 102, 37, 547, 2286, 1, 722, 12241, 20, 722, 12241, 17857, 340, 3, 1440, 199, 31, 266, 21, 108, 17, 18392, 19881, 16, 8, 1196, 283, 1, 722, 12241, 4, 102, 37, 851, 1, 722, 12241, 120, 101, 2522, 1135, 2, 2848, 2421, 4, 102, 37, 298, 529, 18392, 798, 5194, 1, 18392, 4, 722, 12241, 2810, 37, 340, 3, 1440, 199, 266, 4, 102, 31, 2, 340, 2522, 1135, 2, 2848, 2421, 6, 3, 2135, 301, 1, 102, 37, 3245, 5, 3374, 4, 1221, 114, 74, 608, 17, 722, 12241, 2468, 910, 2, 7394, 1, 102, 31, 2522, 1600, 847, 529, 18392, 1192, 110, 1566, 910, 2, 4288, 2522, 1600, 1248, 6, 3, 193, 1, 102, 31, 46, 272, 377, 229, 1957, 237, 3, 612, 2, 24, 1, 102, 62]",1369.0,27637078,624
"Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.",American journal of hematology,Am. J. Hematol.,2016-12-07,"Phosphatidylinositol-3-kinase (PI3K) signaling plays a crucial role in oncogene-mediated tumor growth and proliferation. Buparlisib (BKM120) is an oral pan-class I PI3K inhibitor. This phase I study was conducted to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of BKM120 in patients (pts) with relapsed/refractory acute leukemias. Fourteen pts (12 acute myeloid leukemia, 1 acute lymphoblastic leukemia, and 1 mixed phenotype leukemia) were enrolled. Twelve pts received BKM-120 80 mg/day and two 100 mg/day. The MTD was 80 mg/day. Of the 14 patients treated, the best response was stable disease in one patient that lasted 82 days. The median survival for all patients was 75 days (range 10-568). Three patients with a 3q26 chromosome abnormality had a significantly improved median survival of 360 days (range 278-568) as compared to a median survival of 57 days (range, 10-125) among the 11 other patients. The most frequent drug-related toxicities included confusion, mucositis, dysphagia, and fatigue. Western blot profiling revealed a decrease in p-pS6K/total pS6K in 5/7 (71%) available patient samples with a mean quantitative inhibition of 65% (range, 32-100%) and a decrease in p-FOXO3/total FOXO3 in 4/6 (67%) samples with a mean quantitative inhibition of 93% (range, 89-100%). BKM120 administered at 80 mg/day showed modest efficacy and was tolerable in advanced acute leukemias. Am. J. Hematol. 92:7-11, 2017.  2016 Wiley Periodicals, Inc.","Clinical Trial, Phase I",1140.0,19.0,Phosphatidylinositol-3-kinase PI3K signaling plays a crucial role in oncogene-mediated tumor growth and proliferation Buparlisib BKM120 is an oral pan-class I PI3K inhibitor This phase I study was conducted to determine the dose limiting toxicity DLT and maximum tolerated dose MTD of BKM120 in patients pts with relapsed/refractory acute leukemias Fourteen pts 12 acute myeloid 1 acute lymphoblastic and 1 mixed phenotype were enrolled Twelve pts received BKM-120 80 mg/day and two 100 mg/day The MTD was 80 mg/day Of the 14 patients treated the best response was stable disease in one patient that lasted 82 days The median survival for all patients was 75 days range 10-568 Three patients with a 3q26 chromosome abnormality had a significantly improved median survival of 360 days range 278-568 as compared to a median survival of 57 days range 10-125 among the 11 other patients The most frequent drug-related toxicities included confusion mucositis dysphagia and fatigue Western blot profiling revealed a decrease in p-pS6K/total pS6K in 5/7 71 available patient samples with a mean quantitative inhibition of 65 range 32-100 and a decrease in p-FOXO3/total FOXO3 in 4/6 67 samples with a mean quantitative inhibition of 93 range 89-100 BKM120 administered at 80 mg/day showed modest efficacy and was tolerable in advanced acute leukemias Am J. Hematol 92:7-11 2017  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3415, 27, 216, 974, 314, 1698, 8, 2653, 200, 4, 1836, 517, 30, 129, 2, 457, 11066, 13435, 16, 35, 518, 3055, 1040, 70, 974, 230, 26, 124, 70, 45, 10, 426, 6, 223, 3, 61, 817, 155, 2059, 2, 689, 421, 61, 961, 1, 13435, 4, 7, 3637, 5, 591, 430, 286, 2792, 3225, 3637, 133, 286, 533, 14, 286, 1275, 2, 14, 1739, 1005, 11, 346, 2544, 3637, 103, 47855, 2031, 493, 81, 218, 2, 100, 394, 81, 218, 3, 961, 10, 493, 81, 218, 1, 3, 213, 7, 73, 3, 824, 51, 10, 585, 34, 4, 104, 69, 17, 6854, 878, 162, 3, 52, 25, 9, 62, 7, 10, 481, 162, 184, 79, 11177, 169, 7, 5, 8, 10678, 1170, 3698, 42, 8, 97, 231, 52, 25, 1, 6739, 162, 184, 9128, 11177, 22, 72, 6, 8, 52, 25, 1, 696, 162, 184, 79, 1731, 107, 3, 175, 127, 7, 3, 96, 908, 234, 139, 385, 159, 7399, 2606, 4561, 2, 613, 1521, 2639, 1080, 553, 8, 775, 4, 19, 29398, 181, 29398, 4, 33, 67, 792, 390, 69, 347, 5, 8, 313, 1156, 297, 1, 556, 184, 531, 394, 2, 8, 775, 4, 19, 22669, 181, 22669, 4, 39, 49, 598, 347, 5, 8, 313, 1156, 297, 1, 966, 184, 887, 394, 13435, 468, 28, 493, 81, 218, 224, 1721, 209, 2, 10, 2668, 4, 131, 286, 2792, 5886, 3543, 13175, 937, 67, 175, 1759, 2206, 1390, 4692, 5493, 3479]",1399.0,27673440,423
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease.,Cancer,Cancer,2016-10-03,"The introduction of novel prognostic factors such as minimal residual disease (MRD) and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic leukemia (ALL). This study assessed the impact of baseline cytogenetics on the outcomes of 428 adult patients with Philadelphia chromosome-negative ALL who were receiving frontline chemotherapy. Three hundred thirty patients (77%) were treated with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone-based regimens, and 98 (23%) were treated with the augmented Berlin-Frankfurt-Munster regimen. The median age was 40 years (range, 13-86 years). One hundred eighty-six patients (43%) had diploid cytogenetics, 32 (7%) had complex cytogenetics (defined as5 chromosomal abnormalities), 27 (6%) had low hypodiploidy/near-triploidy (Ho-Tr), 24 (6%) had high hyperdiploidy, and 24 (6%) had a mixed-lineage leukemia (MLL) rearrangement. Patients with an MLL rearrangement, Ho-Tr, or a complex karyotype had significantly worse relapse-free survival (RFS) and overall survival (OS) than the diploid group. According to a multivariate analysis including all the baseline characteristics and MRD status, Ho-Tr and a complex karyotype were independent predictive factors for worse RFS and OS. Furthermore, survival among all cytogenetic groups was similar, regardless of the treatment received. A complex karyotype and Ho-Tr are adverse prognostic factors for adults with ALL independently of the MRD status. These findings suggest that pretreatment cytogenetics remain a valuable prognostic tool in this population. Cancer 2017;123:459-467.  2016 American Cancer Society.",Journal Article,1205.0,20.0,The introduction of novel prognostic factors such as minimal residual disease MRD and genomic profiling has led to the reevaluation of the role of cytogenetics and other conventional factors in risk stratification for acute lymphoblastic ALL This study assessed the impact of baseline cytogenetics on the outcomes of 428 adult patients with Philadelphia chromosome-negative ALL who were receiving frontline chemotherapy Three hundred thirty patients 77 were treated with hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone-based regimens and 98 23 were treated with the augmented Berlin-Frankfurt-Munster regimen The median age was 40 years range 13-86 years One hundred eighty-six patients 43 had diploid cytogenetics 32 7 had complex cytogenetics defined as  5 chromosomal abnormalities 27 6 had low hypodiploidy/near-triploidy Ho-Tr 24 6 had high hyperdiploidy and 24 6 had a mixed-lineage MLL rearrangement Patients with an MLL rearrangement Ho-Tr or a complex karyotype had significantly worse relapse-free survival RFS and overall survival OS than the diploid group According to a multivariate analysis including all the baseline characteristics and MRD status Ho-Tr and a complex karyotype were independent predictive factors for worse RFS and OS Furthermore survival among all cytogenetic groups was similar regardless of the treatment received A complex karyotype and Ho-Tr are adverse prognostic factors for adults with ALL independently of the MRD status These findings suggest that pretreatment cytogenetics remain a valuable prognostic tool in this population Cancer 2017 123:459-467  2016 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2456, 1, 229, 177, 130, 225, 22, 1048, 753, 34, 2029, 2, 572, 1080, 71, 836, 6, 3, 15828, 1, 3, 200, 1, 2510, 2, 127, 809, 130, 4, 43, 1541, 9, 286, 1275, 62, 26, 45, 275, 3, 345, 1, 330, 2510, 23, 3, 123, 1, 10222, 780, 7, 5, 3006, 1170, 199, 62, 54, 11, 357, 3171, 56, 169, 1128, 977, 7, 849, 11, 73, 5, 6201, 1112, 2132, 856, 2, 1217, 90, 472, 2, 1096, 382, 11, 73, 5, 3, 4277, 20405, 23389, 69114, 477, 3, 52, 89, 10, 327, 60, 184, 233, 868, 60, 104, 1128, 2207, 437, 7, 601, 42, 6815, 2510, 531, 67, 42, 840, 2510, 395, 22, 749, 33, 1860, 1171, 428, 49, 42, 154, 14828, 1829, 26526, 11852, 7161, 259, 49, 42, 64, 11299, 2, 259, 49, 42, 8, 1739, 2542, 3049, 2675, 7, 5, 35, 3049, 2675, 11852, 7161, 15, 8, 840, 3385, 42, 97, 639, 429, 115, 25, 1272, 2, 63, 25, 118, 76, 3, 6815, 87, 768, 6, 8, 331, 65, 141, 62, 3, 330, 374, 2, 2029, 156, 11852, 7161, 2, 8, 840, 3385, 11, 306, 464, 130, 9, 639, 1272, 2, 118, 798, 25, 107, 62, 1266, 271, 10, 288, 1583, 1, 3, 24, 103, 8, 840, 3385, 2, 11852, 7161, 32, 290, 177, 130, 9, 857, 5, 62, 1042, 1, 3, 2029, 156, 46, 272, 309, 17, 1194, 2510, 918, 8, 2926, 177, 1515, 4, 26, 266, 12, 1759, 2698, 10986, 10993, 2206, 1390, 597, 12, 1174]",1653.0,27696391,462
Reduced intensity conditioned allograft yields favorable survival for older adults with B-cell acute lymphoblastic leukemia.,American journal of hematology,Am. J. Hematol.,2016-11-12,"Older adults with B-cell acute lymphoblastic leukemia (B-ALL) have poor survival. We examined the effectiveness of reduced intensity conditioning (RIC) hematopoietic cell transplant (HCT) in adults with B-ALL age 55 years and older and explored prognostic factors associated with long-term outcomes. Using CIBMTR registry data, we evaluated 273 patients (median age 61, range 55-72) with B-ALL with disease status in CR1 (71%), >CR2 (17%) and Primary Induction Failure (PIF)/Relapse (11%), who underwent RIC HCT between 2001 and 2012 using mostly unrelated donor (59%) or HLA-matched sibling (32%). Among patients with available cytogenetic data, the Philadelphia chromosome (Ph+) was present in 50%. The 3-year cumulative incidences of nonrelapse mortality (NRM) and relapse were 25% (95% confidence intervals (CI): 20-31%) and 47% (95% CI: 41-53%), respectively. Three-year overall survival (OS) was 38% (95% CI: 33-44%). Relapse remained the leading cause of death accounting for 49% of all deaths. In univariate analysis, 3 year risk of NRM was significantly higher with reduced Karnofsky performance status (KPS <90: 34% (95% CI: 25-43%) versus KPS 90 (18%; 95% CI: 12-24%, P=0.006). Mortality was increased in older adults (66+ vs. 55-60: Relative Risk [RR] 1.51 95% CI: 1.00-2.29, P=0.05) and those with advanced disease (RR 2.13; 95% CI: 1.36-3.34, P=0.001). Survival of patients in CR1 yields 45% (95% CI: 38-52%) at 3 years and no relapse occurred after 2 years. We report promising OS and acceptable NRM using RIC HCT in older patients with B-ALL. Disease status in CR1 and good performance status are associated with improved outcomes. Am. J. Hematol. 92:42-49, 2017.  2016 Wiley Periodicals, Inc.",Journal Article,1165.0,21.0,Older adults with B-cell acute lymphoblastic B-ALL have poor survival We examined the effectiveness of reduced intensity conditioning RIC hematopoietic cell transplant HCT in adults with B-ALL age 55 years and older and explored prognostic factors associated with long-term outcomes Using CIBMTR registry data we evaluated 273 patients median age 61 range 55-72 with B-ALL with disease status in CR1 71 CR2 17 and Primary Induction Failure PIF /Relapse 11 who underwent RIC HCT between 2001 and 2012 using mostly unrelated donor 59 or HLA-matched sibling 32 Among patients with available cytogenetic data the Philadelphia chromosome Ph+ was present in 50 The 3-year cumulative incidences of nonrelapse mortality NRM and relapse were 25 95 confidence intervals CI 20-31 and 47 95 CI 41-53 respectively Three-year overall survival OS was 38 95 CI 33-44 Relapse remained the leading cause of death accounting for 49 of all deaths In univariate analysis 3 year risk of NRM was significantly higher with reduced Karnofsky performance status KPS 90 34 95 CI 25-43 versus KPS 90 18 95 CI 12-24 P 0.006 Mortality was increased in older adults 66+ vs. 55-60 Relative Risk RR 1.51 95 CI 1.00-2.29 P 0.05 and those with advanced disease RR 2.13 95 CI 1.36-3.34 P 0.001 Survival of patients in CR1 yields 45 95 CI 38-52 at 3 years and no relapse occurred after 2 years We report promising OS and acceptable NRM using RIC HCT in older patients with B-ALL Disease status in CR1 and good performance status are associated with improved outcomes Am J. Hematol 92:42-49 2017  2016 Wiley Periodicals Inc,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[434, 857, 5, 132, 31, 286, 1275, 132, 62, 47, 334, 25, 21, 409, 3, 1236, 1, 405, 837, 1933, 3365, 1007, 31, 941, 1085, 4, 857, 5, 132, 62, 89, 614, 60, 2, 434, 2, 1443, 177, 130, 41, 5, 319, 337, 123, 75, 11203, 1608, 74, 21, 194, 9385, 7, 52, 89, 713, 184, 614, 720, 5, 132, 62, 5, 34, 156, 4, 4516, 792, 7865, 269, 2, 86, 504, 496, 22770, 429, 175, 54, 208, 3365, 1085, 59, 1758, 2, 1195, 75, 2754, 2092, 1488, 728, 15, 1160, 655, 3684, 531, 107, 7, 5, 390, 1266, 74, 3, 3006, 1170, 2058, 10, 364, 4, 212, 3, 27, 111, 967, 3981, 1, 4640, 282, 4296, 2, 429, 11, 243, 48, 307, 1582, 58, 179, 456, 2, 662, 48, 58, 605, 699, 106, 169, 111, 63, 25, 118, 10, 519, 48, 58, 466, 584, 429, 958, 3, 1049, 708, 1, 273, 3116, 9, 739, 1, 62, 1043, 4, 880, 65, 27, 111, 43, 1, 4296, 10, 97, 142, 5, 405, 2857, 528, 156, 2988, 424, 562, 48, 58, 243, 601, 185, 2988, 9613, 203, 48, 58, 133, 259, 19, 13, 1861, 282, 10, 101, 4, 434, 857, 700, 105, 614, 335, 580, 43, 861, 14, 725, 48, 58, 14, 2038, 18, 462, 19, 13, 474, 2, 135, 5, 131, 34, 861, 18, 233, 48, 58, 14, 511, 27, 562, 19, 13, 144, 25, 1, 7, 4, 4516, 4788, 512, 48, 58, 519, 653, 28, 27, 60, 2, 77, 429, 489, 50, 18, 60, 21, 414, 721, 118, 2, 1595, 4296, 75, 3365, 1085, 4, 434, 7, 5, 132, 62, 34, 156, 4, 4516, 2, 1178, 528, 156, 32, 41, 5, 231, 123, 5886, 3543, 13175, 937, 595, 739, 1759, 2206, 1390, 4692, 5493, 3479]",1587.0,27712033,183
Feasibility of baseline neurocognitive assessment using Cogstate during the first month of therapy for childhood leukemia.,Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer,Support Care Cancer,2016-10-10,"Neurocognitive impairment is frequently observed among acute lymphoblastic leukemia (ALL) survivors within the domains of intelligence, attention, processing speed, working memory, learning, and memory. However, few have investigated treatment-induced changes in neurocognitive function during the first months of treatment. Additionally, dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid (CSF). Identification of acute declines in neurocognitive function, as well as predictive genotypes or biomarkers, could guide therapeutic trials of protective interventions. This study collects CSF while prospectively assessing neurocognitive functioning (working memory, executive function, learning, processing speed, and attention) of ALL patients using the Cogstate computerized battery at six time points during and after the 2years of leukemia treatment on a Dana-Farber Cancer Institute ALL Consortium trial. Baseline data collected during the first 3weeks of induction chemotherapy indicate reliable data as all subjects (N=34) completed Cogstate baseline testing, while completion and performance checks indicate that 100% of subjects completed testing and complied with test requirements. The majority (85%) exhibited normal function compared with age peers. Preliminary analysis of CSF biomarkers (folate, homocysteine, 8-isoprostane, and myelin basic protein) similarly reveals values at baseline within expected normal ranges. The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning. Consequently, serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline, warranting proactive interventions to improve their level of functioning both during treatment and into survivorship.",Journal Article,1198.0,6.0,Neurocognitive impairment is frequently observed among acute lymphoblastic ALL survivors within the domains of intelligence attention processing speed working memory learning and memory However few have investigated treatment-induced changes in neurocognitive function during the first months of treatment Additionally dysfunction during treatment may be preceded by changes in biomarkers measured within cerebrospinal fluid CSF Identification of acute declines in neurocognitive function as well as predictive genotypes or biomarkers could guide therapeutic trials of protective interventions This study collects CSF while prospectively assessing neurocognitive functioning working memory executive function learning processing speed and attention of ALL patients using the Cogstate computerized battery at six time points during and after the 2 years of treatment on a Dana-Farber Cancer Institute ALL Consortium trial Baseline data collected during the first 3 weeks of induction chemotherapy indicate reliable data as all subjects N 34 completed Cogstate baseline testing while completion and performance checks indicate that 100 of subjects completed testing and complied with test requirements The majority 85 exhibited normal function compared with age peers Preliminary analysis of CSF biomarkers folate homocysteine 8-isoprostane and myelin basic protein similarly reveals values at baseline within expected normal ranges The first month of induction therapy for ALL is a reliable baseline for detecting treatment-induced changes in neurocognitive functioning Consequently serial data collection might identify subgroups of ALL patients at increased risk for neurocognitive decline warranting proactive interventions to improve their level of functioning both during treatment and into survivorship,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2958, 2315, 16, 746, 164, 107, 286, 1275, 62, 332, 262, 3, 2703, 1, 9125, 2111, 3325, 5051, 2644, 2407, 3434, 2, 2407, 137, 1021, 47, 565, 24, 277, 400, 4, 2958, 343, 190, 3, 157, 53, 1, 24, 1724, 1527, 190, 24, 68, 40, 6083, 20, 400, 4, 582, 644, 262, 5156, 2357, 1211, 911, 1, 286, 4264, 4, 2958, 343, 22, 149, 22, 464, 2071, 15, 582, 359, 1597, 189, 143, 1, 2864, 1151, 26, 45, 18403, 1211, 369, 1143, 1977, 2958, 2702, 2644, 2407, 6481, 343, 3434, 3325, 5051, 2, 2111, 1, 62, 7, 75, 3, 20922, 4912, 11665, 28, 437, 98, 862, 190, 2, 50, 3, 18, 60, 1, 24, 23, 8, 4932, 4979, 12, 1377, 62, 2404, 160, 330, 74, 786, 190, 3, 157, 27, 244, 1, 504, 56, 1008, 2450, 74, 22, 62, 976, 78, 562, 781, 20922, 330, 471, 369, 1438, 2, 528, 33821, 1008, 17, 394, 1, 976, 781, 471, 2, 26387, 5, 412, 4230, 3, 686, 772, 1416, 295, 343, 72, 5, 89, 11187, 1676, 65, 1, 1211, 582, 3100, 12798, 66, 45206, 2, 23428, 2795, 178, 1813, 4054, 1030, 28, 330, 262, 1336, 295, 5632, 3, 157, 811, 1, 504, 36, 9, 62, 16, 8, 2450, 330, 9, 2502, 24, 277, 400, 4, 2958, 2702, 3244, 2108, 74, 2442, 822, 255, 1453, 1, 62, 7, 28, 101, 43, 9, 2958, 1858, 7643, 11662, 1151, 6, 401, 136, 301, 1, 2702, 110, 190, 24, 2, 237, 2560]",1807.0,27726029,472
Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.,Oncotarget,Oncotarget,2016-12-01,"Marsdenia tenacissimae extraction (MTE) as a traditional Chinese herb has long been used to treat some diseases such as tumors in China. However, the potential effectiveness of MTE in leukemia has not yet been fully understood, and the related molecular mechanism is still unknown. In the present study, we aimed to evaluate the effects of MTE on the proliferation and apoptosis of Jurkat cells (T-ALL lines) and lymphocytes from T-ALL (T-cell acute lymphoblastic leukemia) patients. Firstly, CCK8 assays and flow cytometry assays revealed that MTE dose-dependently reduced the proliferation of Jurkat cells by arresting cell cycle at S phase. Secondly, Annexin V-FITC/PI-stained flow cytometry and TUNEL staining assays showed that MTE promoted the apoptosis of Jurkat cells. Mechanistically, MTE enhanced PTEN (phosphatases and tensin homolog) level and inactivated PI3K/AKT/mTOR signaling pathway in Jurkat cells, which mediated the inhibition of cell proliferation by MTE and MTE-induced apoptosis. Finally, MTE significantly inhibited the proliferation and promoted the apoptosis of lymphocytes from T-ALL patients, compared with lymphocytes from healthy peoples. Taken together, these results reveal an unrecognized function of MTE in inhibiting the proliferation and inducing the apoptosis of T-ALL cells, and identify a pathway of PTEN/PI3K/AKT/mTOR for the effects of MTE on leukemia therapy.",Journal Article,1146.0,17.0,Marsdenia tenacissimae extraction MTE as a traditional Chinese herb has long been used to treat some diseases such as tumors in China However the potential effectiveness of MTE in has not yet been fully understood and the related molecular mechanism is still unknown In the present study we aimed to evaluate the effects of MTE on the proliferation and apoptosis of Jurkat cells T-ALL lines and lymphocytes from T-ALL T-cell acute lymphoblastic patients Firstly CCK8 assays and flow cytometry assays revealed that MTE dose-dependently reduced the proliferation of Jurkat cells by arresting cell cycle at S phase Secondly Annexin V-FITC/PI-stained flow cytometry and TUNEL staining assays showed that MTE promoted the apoptosis of Jurkat cells Mechanistically MTE enhanced PTEN phosphatases and tensin homolog level and inactivated PI3K/AKT/mTOR signaling pathway in Jurkat cells which mediated the inhibition of cell proliferation by MTE and MTE-induced apoptosis Finally MTE significantly inhibited the proliferation and promoted the apoptosis of lymphocytes from T-ALL patients compared with lymphocytes from healthy peoples Taken together these results reveal an unrecognized function of MTE in inhibiting the proliferation and inducing the apoptosis of T-ALL cells and identify a pathway of PTEN/PI3K/AKT/mTOR for the effects of MTE on therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[69194, 69195, 5763, 21866, 22, 8, 1847, 3656, 21322, 71, 319, 85, 95, 6, 943, 476, 1342, 225, 22, 57, 4, 5055, 137, 3, 174, 1236, 1, 21866, 4, 71, 44, 1145, 85, 1910, 1784, 2, 3, 139, 219, 670, 16, 1234, 860, 4, 3, 364, 45, 21, 1295, 6, 376, 3, 176, 1, 21866, 23, 3, 457, 2, 351, 1, 8433, 37, 102, 62, 285, 2, 1594, 29, 102, 62, 102, 31, 286, 1275, 7, 16535, 29844, 1013, 2, 1412, 1914, 1013, 553, 17, 21866, 61, 12968, 405, 3, 457, 1, 8433, 37, 20, 18265, 31, 417, 28, 695, 124, 18904, 4850, 603, 12990, 2928, 3386, 1412, 1914, 2, 8159, 1029, 1013, 224, 17, 21866, 2992, 3, 351, 1, 8433, 37, 4187, 21866, 651, 820, 14428, 2, 6111, 3412, 301, 2, 5458, 974, 649, 873, 314, 308, 4, 8433, 37, 92, 517, 3, 297, 1, 31, 457, 20, 21866, 2, 21866, 277, 351, 1368, 21866, 97, 879, 3, 457, 2, 2992, 3, 351, 1, 1594, 29, 102, 62, 7, 72, 5, 1594, 29, 1331, 69196, 1633, 1162, 46, 99, 2396, 35, 6055, 343, 1, 21866, 4, 2062, 3, 457, 2, 1958, 3, 351, 1, 102, 62, 37, 2, 255, 8, 308, 1, 820, 974, 649, 873, 9, 3, 176, 1, 21866, 23, 36]",1347.0,27756877,17
Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2016-10-24,"Chromosomal rearrangements deregulating hematopoietic transcription factors are common in acute lymphoblastic leukemia (ALL). Here we show that deregulation of the homeobox transcription factor gene DUX4 and the ETS transcription factor gene ERG is a hallmark of a subtype of B-progenitor ALL that comprises up to 7% of B-ALL. DUX4 rearrangement and overexpression was present in all cases and was accompanied by transcriptional deregulation of ERG, expression of a novel ERG isoform, ERGalt, and frequent ERG deletion. ERGalt uses a non-canonical first exon whose transcription was initiated by DUX4 binding. ERGalt retains the DNA-binding and transactivation domains of ERG, but it inhibits wild-type ERG transcriptional activity and is transforming. These results illustrate a unique paradigm of transcription factor deregulation in leukemia in which DUX4 deregulation results in loss of function of ERG, either by deletion or induced expression of an isoform that is a dominant-negative inhibitor of wild-type ERG function.",Journal Article,1184.0,68.0,Chromosomal rearrangements deregulating hematopoietic transcription factors are common in acute lymphoblastic ALL Here we show that deregulation of the homeobox transcription factor gene DUX4 and the ETS transcription factor gene ERG is a hallmark of a subtype of B-progenitor ALL that comprises up to 7 of B-ALL DUX4 rearrangement and overexpression was present in all cases and was accompanied by transcriptional deregulation of ERG expression of a novel ERG isoform ERGalt and frequent ERG deletion ERGalt uses a non-canonical first exon whose transcription was initiated by DUX4 binding ERGalt retains the DNA-binding and transactivation domains of ERG but it inhibits wild-type ERG transcriptional activity and is transforming These results illustrate a unique paradigm of transcription factor deregulation in in which DUX4 deregulation results in loss of function of ERG either by deletion or induced expression of an isoform that is a dominant-negative inhibitor of wild-type ERG function,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1860, 2072, 34885, 1007, 866, 130, 32, 186, 4, 286, 1275, 62, 467, 21, 514, 17, 4765, 1, 3, 10337, 866, 161, 145, 18043, 2, 3, 4802, 866, 161, 145, 3032, 16, 8, 4683, 1, 8, 875, 1, 132, 2520, 62, 17, 6704, 126, 6, 67, 1, 132, 62, 18043, 2675, 2, 851, 10, 364, 4, 62, 140, 2, 10, 2756, 20, 1431, 4765, 1, 3032, 55, 1, 8, 229, 3032, 3995, 41583, 2, 908, 3032, 1528, 41583, 4025, 8, 220, 4471, 157, 1725, 1310, 866, 10, 1917, 20, 18043, 791, 41583, 10785, 3, 261, 791, 2, 8355, 2703, 1, 3032, 84, 192, 1576, 955, 267, 3032, 1431, 128, 2, 16, 3621, 46, 99, 4746, 8, 991, 2431, 1, 866, 161, 4765, 4, 4, 92, 18043, 4765, 99, 4, 407, 1, 343, 1, 3032, 361, 20, 1528, 15, 277, 55, 1, 35, 3995, 17, 16, 8, 2156, 199, 230, 1, 955, 267, 3032, 343]",995.0,27776115,79
Adult Acute Lymphoblastic Leukemia.,Mayo Clinic proceedings,Mayo Clin. Proc.,2016-11-01,"Conventional cytotoxic chemotherapy used to treat acute lymphoblastic leukemia (ALL) results in high cure rates in pediatric patients but is suboptimal in the treatment of adult patients. The 5-year overall survival is approximately 90% in children and 30% to 40% in adults and elderly patients. Adults with ALL tend to have higher risk factors at diagnosis, more comorbidities, and increasing age that often requires dose reductions. Major advancements have been made in redefining the pathologic classification of ALL, identifying new cytogenetic-molecular abnormalities, and developing novel targeted agents in order to improve survival. The addition of new monoclonal antibodies and tyrosine kinase inhibitors to conventional chemotherapy in the frontline setting has resulted in increased rates of complete remission and overall survival. These new developments are changing the treatment of adult ALL from a ""one therapy fits all"" approach to individualized treatment based on patient's cytogenetic and molecular profile.",Journal Article,1176.0,38.0,Conventional cytotoxic chemotherapy used to treat acute lymphoblastic ALL results in high cure rates in pediatric patients but is suboptimal in the treatment of adult patients The 5-year overall survival is approximately 90 in children and 30 to 40 in adults and elderly patients Adults with ALL tend to have higher risk factors at diagnosis more comorbidities and increasing age that often requires dose reductions Major advancements have been made in redefining the pathologic classification of ALL identifying new cytogenetic-molecular abnormalities and developing novel targeted agents in order to improve survival The addition of new monoclonal antibodies and tyrosine kinase inhibitors to conventional chemotherapy in the frontline setting has resulted in increased rates of complete remission and overall survival These new developments are changing the treatment of adult ALL from a `` one therapy fits all '' approach to individualized treatment based on patient 's cytogenetic and molecular profile,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[809, 759, 56, 95, 6, 943, 286, 1275, 62, 99, 4, 64, 1722, 151, 4, 815, 7, 84, 16, 3291, 4, 3, 24, 1, 780, 7, 3, 33, 111, 63, 25, 16, 705, 424, 4, 541, 2, 201, 6, 327, 4, 857, 2, 1216, 7, 857, 5, 62, 5406, 6, 47, 142, 43, 130, 28, 147, 80, 1909, 2, 602, 89, 17, 629, 1706, 61, 2153, 458, 6217, 47, 85, 1229, 4, 24826, 3, 510, 947, 1, 62, 1386, 217, 1266, 219, 1171, 2, 931, 229, 238, 183, 4, 1732, 6, 401, 25, 3, 352, 1, 217, 848, 890, 2, 564, 216, 222, 6, 809, 56, 4, 3, 3171, 546, 71, 627, 4, 101, 151, 1, 236, 734, 2, 63, 25, 46, 217, 3703, 32, 3600, 3, 24, 1, 780, 62, 29, 8, 104, 36, 11688, 62, 522, 353, 6, 2596, 24, 90, 23, 69, 292, 1266, 2, 219, 800]",1008.0,27814839,845
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-11-02,"We investigated the long-term safety and disease control data obtained with i.v. busulfan (Bu) combined with clofarabine (Clo) in patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic hematopoietic stem cell transplantation (HSCT). A total of 107 patients, median age 38 years (range, 19 to 64 years) received a matched sibling donor (n=52) or matched unrelated donor (n=55) transplant for ALL in first complete remission (n=62), second complete remission (n=28), or more advanced disease (n=17). Nearly one-half of the patients had a high-risk cytogenetic profile as defined by the presence of t(9;22) (n=34), t(4;11) (n=4), or complex cytogenetics (n=7). Clo 40mg/m<sup>2</sup> was given once daily, with each dose followed by pharmacokinetically dosed Bu infused over 3 hours daily for 4 days, followed by hematopoietic cell infusion after 2 days of rest. The Bu dose was based on the drug clearance as determined by a test Bu dose of 32mg/m<sup>2</sup>. The target daily area under the curve was 5500 mol/min for patients aged <60 years and 4000 mol/min for patients aged >59 years. With a median follow-up of 3.3 years among surviving patients (range, 1 to 5.8 years), the 2-year progression-free survival (PFS) for patients undergoing HSCT in first complete remission (CR1), second complete remission (CR2), or more advanced disease was 62%, 34%, and 35%, respectively. The regimen was well tolerated, with nonrelapse mortality (NRM) of 10% at 100 days and 31% at 2 years post-HSCT. The incidence of grade II-IV and III-IV acute graft-versus-host disease (GVHD) was 35% and 10%, respectively; 18% patients developed extensive chronic GVHD. The 2-year overall survival (OS) for patients undergoing HSCT in CR1, CR2, or more advanced disease was 70%, 57%, and 35%, respectively. Among 11 patients aged >59 years treated with reduced-dose Bu in CR1 (n=7) or CR2 (n=4), 4 remain alive and disease-free, with a median follow-up of 2.6 years (range, 2 to 4.7 years). Only the presence of minimal residual disease at the time of transplantation was associated with significantly worse PFS and OS in multivariate analysis. Our data indicate that the Clo-Bu combination provides effective disease control while maintaining a favorable safety profile. OS and NRM rates compare favorably with those for traditional myeloablative total body irradiation-based conditioning regimens.",Clinical Trial,1175.0,12.0,We investigated the long-term safety and disease control data obtained with i.v busulfan Bu combined with clofarabine Clo in patients with acute lymphoblastic ALL undergoing allogeneic hematopoietic stem cell transplantation HSCT A total of 107 patients median age 38 years range 19 to 64 years received a matched sibling donor n 52 or matched unrelated donor n 55 transplant for ALL in first complete remission n 62 second complete remission n 28 or more advanced disease n 17 Nearly one-half of the patients had a high-risk cytogenetic profile as defined by the presence of t 9 22 n 34 t 4 11 n 4 or complex cytogenetics n 7 Clo 40 mg/m sup 2 /sup was given once daily with each dose followed by pharmacokinetically dosed Bu infused over 3 hours daily for 4 days followed by hematopoietic cell infusion after 2 days of rest The Bu dose was based on the drug clearance as determined by a test Bu dose of 32 mg/m sup 2 /sup The target daily area under the curve was 5500 mol/min for patients aged 60 years and 4000 mol/min for patients aged 59 years With a median follow-up of 3.3 years among surviving patients range 1 to 5.8 years the 2-year progression-free survival PFS for patients undergoing HSCT in first complete remission CR1 second complete remission CR2 or more advanced disease was 62 34 and 35 respectively The regimen was well tolerated with nonrelapse mortality NRM of 10 at 100 days and 31 at 2 years post-HSCT The incidence of grade II-IV and III-IV acute graft-versus-host disease GVHD was 35 and 10 respectively 18 patients developed extensive chronic GVHD The 2-year overall survival OS for patients undergoing HSCT in CR1 CR2 or more advanced disease was 70 57 and 35 respectively Among 11 patients aged 59 years treated with reduced-dose Bu in CR1 n 7 or CR2 n 4 4 remain alive and disease-free with a median follow-up of 2.6 years range 2 to 4.7 years Only the presence of minimal residual disease at the time of transplantation was associated with significantly worse PFS and OS in multivariate analysis Our data indicate that the Clo-Bu combination provides effective disease control while maintaining a favorable safety profile OS and NRM rates compare favorably with those for traditional myeloablative total body irradiation-based conditioning regimens,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 565, 3, 319, 337, 367, 2, 34, 182, 74, 683, 5, 70, 603, 3906, 3667, 397, 5, 4149, 7676, 4, 7, 5, 286, 1275, 62, 479, 1063, 1007, 452, 31, 497, 1703, 8, 181, 1, 3650, 7, 52, 89, 519, 60, 184, 326, 6, 660, 60, 103, 8, 655, 3684, 1488, 78, 653, 15, 655, 2092, 1488, 78, 614, 941, 9, 62, 4, 157, 236, 734, 78, 744, 419, 236, 734, 78, 339, 15, 80, 131, 34, 78, 269, 1857, 104, 1303, 1, 3, 7, 42, 8, 64, 43, 1266, 800, 22, 395, 20, 3, 463, 1, 102, 83, 350, 78, 562, 102, 39, 175, 78, 39, 15, 840, 2510, 78, 67, 7676, 327, 81, 188, 172, 18, 172, 10, 447, 1059, 391, 5, 296, 61, 370, 20, 14920, 6268, 3667, 4524, 252, 27, 1459, 391, 9, 39, 162, 370, 20, 1007, 31, 904, 50, 18, 162, 1, 3677, 3, 3667, 61, 10, 90, 23, 3, 234, 1960, 22, 509, 20, 8, 412, 3667, 61, 1, 531, 81, 188, 172, 18, 172, 3, 283, 391, 965, 669, 3, 1496, 10, 25980, 27474, 1538, 9, 7, 1032, 335, 60, 2, 10660, 27474, 1538, 9, 7, 1032, 728, 60, 5, 8, 52, 166, 126, 1, 27, 27, 60, 107, 3050, 7, 184, 14, 6, 33, 66, 60, 3, 18, 111, 91, 115, 25, 300, 9, 7, 479, 1703, 4, 157, 236, 734, 4516, 419, 236, 734, 7865, 15, 80, 131, 34, 10, 744, 562, 2, 465, 106, 3, 477, 10, 149, 421, 5, 4640, 282, 4296, 1, 79, 28, 394, 162, 2, 456, 28, 18, 60, 539, 1703, 3, 287, 1, 88, 215, 478, 2, 316, 478, 286, 1599, 185, 1204, 34, 1562, 10, 465, 2, 79, 106, 203, 7, 276, 1344, 442, 1562, 3, 18, 111, 63, 25, 118, 9, 7, 479, 1703, 4, 4516, 7865, 15, 80, 131, 34, 10, 431, 696, 2, 465, 106, 107, 175, 7, 1032, 728, 60, 73, 5, 405, 61, 3667, 4, 4516, 78, 67, 15, 7865, 78, 39, 39, 918, 1701, 2, 34, 115, 5, 8, 52, 166, 126, 1, 18, 49, 60, 184, 18, 6, 39, 67, 60, 158, 3, 463, 1, 1048, 753, 34, 28, 3, 98, 1, 497, 10, 41, 5, 97, 639, 300, 2, 118, 4, 331, 65, 114, 74, 1008, 17, 3, 7676, 3667, 150, 777, 323, 34, 182, 369, 3284, 8, 913, 367, 800, 118, 2, 4296, 151, 932, 5001, 5, 135, 9, 1847, 3246, 181, 642, 1104, 90, 1933, 472]",2282.0,27816651,727
Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).,Leukemia & lymphoma,Leuk. Lymphoma,2016-11-17,"Philadelphia (Ph)-like acute lymphoblastic leukemia (ALL) is a molecular subtype of high-risk B-cell ALL characterized by formation of abnormal gene fusions involving tyrosine kinase (TK) and cytokine receptor genes and activation of TK signaling. Because of the diversity of associated genetic changes, the detection of Ph-like ALL cases currently requires multiple cytogenetic and molecular assays; thus, our goal was to develop a consolidated workflow for detecting genetic abnormalities in Ph-like ALL. We found that total and targeted RNA sequencing (RNAseq)-based approach allowed the detection of abnormal fusion transcripts (EBF1-PDGFRB, P2RY8-CRLF2, RCSD1-ABL1, and RCSD1-ABL2). The bioinformatics algorithm accurately detected the fusion transcripts without prior input about possible events. Additionally, we showed that RNAseq analysis enabled evaluation for disease-associated sequence variants in expressed transcripts. While total RNAseq can be a second tier approach allowing discovery of novel genetic alterations, the targeted RNAseq workflow offers a clinically applicable method for the detection of fusion transcripts.",Journal Article,1160.0,5.0,Philadelphia Ph -like acute lymphoblastic ALL is a molecular subtype of high-risk B-cell ALL characterized by formation of abnormal gene fusions involving tyrosine kinase TK and cytokine receptor genes and activation of TK signaling Because of the diversity of associated genetic changes the detection of Ph-like ALL cases currently requires multiple cytogenetic and molecular assays thus our goal was to develop a consolidated workflow for detecting genetic abnormalities in Ph-like ALL We found that total and targeted RNA sequencing RNAseq -based approach allowed the detection of abnormal fusion transcripts EBF1-PDGFRB P2RY8-CRLF2 RCSD1-ABL1 and RCSD1-ABL2 The bioinformatics algorithm accurately detected the fusion transcripts without prior input about possible events Additionally we showed that RNAseq analysis enabled evaluation for disease-associated sequence variants in expressed transcripts While total RNAseq can be a second tier approach allowing discovery of novel genetic alterations the targeted RNAseq workflow offers a clinically applicable method for the detection of fusion transcripts,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 2058, 733, 286, 1275, 62, 16, 8, 219, 875, 1, 64, 43, 132, 31, 62, 765, 20, 1264, 1, 1668, 145, 2530, 1267, 564, 216, 5067, 2, 1675, 153, 214, 2, 363, 1, 5067, 314, 408, 1, 3, 3653, 1, 41, 336, 400, 3, 638, 1, 2058, 733, 62, 140, 694, 1706, 232, 1266, 2, 219, 1013, 631, 114, 1326, 10, 6, 690, 8, 18934, 8825, 9, 2502, 336, 1171, 4, 2058, 733, 62, 21, 204, 17, 181, 2, 238, 893, 615, 13213, 90, 353, 2313, 3, 638, 1, 1668, 1212, 2680, 23701, 10231, 25205, 8895, 50097, 3557, 2, 50097, 18452, 3, 6579, 2124, 2141, 530, 3, 1212, 2680, 187, 324, 5772, 545, 899, 281, 1724, 21, 224, 17, 13213, 65, 4387, 451, 9, 34, 41, 1532, 839, 4, 570, 2680, 369, 181, 13213, 122, 40, 8, 419, 8377, 353, 2952, 1574, 1, 229, 336, 593, 3, 238, 13213, 8825, 2339, 8, 505, 3801, 596, 9, 3, 638, 1, 1212, 2680]",1108.0,27855558,350
Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2016-11-14,"Haploidentical transplantation performed with post-transplantation cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis has been associated with favorable outcomes for patients with acute myeloid leukemia and lymphomas. However, it remains unclear if such approach is effective for patients with acute lymphoblastic leukemia (ALL). We analyzed outcomes of 109 consecutively treated ALL patients 18 years of age and older at 5 institutions. The median age was 32 years and the median follow-up for survivors was 13 months. Thirty-two patients were in first complete remission (CR1), while the rest were beyond CR1. Neutrophil engraftment occurred in 95% of the patients. The cumulative incidences of grades II to IV and III and IV acute GVHD at day 100 after transplantation were 32% and 11%, respectively, whereas chronic GVHD, nonrelapse mortality, relapse rate, and disease-free survival (DFS) at 1 year after transplantation were 32%, 21%, 27%, and 51%, respectively. Patients in CR1 had 52% DFS at 3 years. These results suggest that haploidentical transplants performed with PTCy-based GVHD prophylaxis provide a very suitable alternative to HLA-matched transplantations for patients with ALL.",Journal Article,1163.0,18.0,Haploidentical transplantation performed with post-transplantation cyclophosphamide PTCy -based graft-versus-host disease GVHD prophylaxis has been associated with favorable outcomes for patients with acute myeloid and lymphomas However it remains unclear if such approach is effective for patients with acute lymphoblastic ALL We analyzed outcomes of 109 consecutively treated ALL patients 18 years of age and older at 5 institutions The median age was 32 years and the median follow-up for survivors was 13 months Thirty-two patients were in first complete remission CR1 while the rest were beyond CR1 Neutrophil engraftment occurred in 95 of the patients The cumulative incidences of grades II to IV and III and IV acute GVHD at day 100 after transplantation were 32 and 11 respectively whereas chronic GVHD nonrelapse mortality relapse rate and disease-free survival DFS at 1 year after transplantation were 32 21 27 and 51 respectively Patients in CR1 had 52 DFS at 3 years These results suggest that haploidentical transplants performed with PTCy-based GVHD prophylaxis provide a very suitable alternative to HLA-matched transplantations for patients with ALL,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5802, 497, 173, 5, 539, 497, 1112, 10932, 90, 1599, 185, 1204, 34, 1562, 2049, 71, 85, 41, 5, 913, 123, 9, 7, 5, 286, 533, 2, 1557, 137, 192, 469, 1200, 492, 225, 353, 16, 323, 9, 7, 5, 286, 1275, 62, 21, 311, 123, 1, 3486, 7380, 73, 62, 7, 203, 60, 1, 89, 2, 434, 28, 33, 1764, 3, 52, 89, 10, 531, 60, 2, 3, 52, 166, 126, 9, 332, 10, 233, 53, 977, 100, 7, 11, 4, 157, 236, 734, 4516, 369, 3, 3677, 11, 1654, 4516, 2595, 2881, 489, 4, 48, 1, 3, 7, 3, 967, 3981, 1, 2276, 215, 6, 478, 2, 316, 2, 478, 286, 1562, 28, 218, 394, 50, 497, 11, 531, 2, 175, 106, 547, 442, 1562, 4640, 282, 429, 116, 2, 34, 115, 25, 1010, 28, 14, 111, 50, 497, 11, 531, 239, 428, 2, 725, 106, 7, 4, 4516, 42, 653, 1010, 28, 27, 60, 46, 99, 309, 17, 5802, 4016, 173, 5, 10932, 90, 1562, 2049, 377, 8, 923, 2884, 1091, 6, 1160, 655, 6779, 9, 7, 5, 62]",1165.0,27856368,867
Synchronous occurrence of acute lymphoblastic leukemia and wilms tumor in two patients: underlying etiology and combined treatment plan.,Pediatric blood & cancer,Pediatr Blood Cancer,2016-11-15,"Synchronous cancers are extraordinarily rare in pediatric patients and present a therapeutic challenge. Patient A presented with synchronous unilateral Wilms tumor (WT) and standard-risk (SR) B-precursor acute lymphoblastic leukemia (ALL). Genetic testing revealed bialleleic BRCA2/FANCD1 mutations. Patient B, after SR B-precursor ALL induction therapy, was noted on fever workup to have a renal mass; pathology demonstrated lesion indeterminate between WT and nephrogenic rest. Therapy was customized for each patient to treat both cancers. Both patients have ongoing remission from their cancers, without excessive toxicity. We report two regimens for treating synchronous WT and ALL and recommend screening such patients for cancer predisposition.",Case Reports,1162.0,0.0,Synchronous cancers are extraordinarily rare in pediatric patients and present a therapeutic challenge Patient A presented with synchronous unilateral tumor WT and standard-risk SR B-precursor acute lymphoblastic ALL Genetic testing revealed bialleleic BRCA2/FANCD1 mutations Patient B after SR B-precursor ALL induction therapy was noted on fever workup to have a mass pathology demonstrated lesion indeterminate between WT and nephrogenic rest Therapy was customized for each patient to treat both cancers Both patients have ongoing remission from their cancers without excessive toxicity We report two regimens for treating synchronous WT and ALL and recommend screening such patients for cancer predisposition,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2734, 163, 32, 16830, 622, 4, 815, 7, 2, 364, 8, 189, 1745, 69, 8, 917, 5, 2734, 3208, 30, 1820, 2, 260, 43, 7460, 132, 2765, 286, 1275, 62, 336, 471, 553, 69361, 1167, 30398, 138, 69, 132, 50, 7460, 132, 2765, 62, 504, 36, 10, 1051, 23, 2775, 4755, 6, 47, 8, 782, 1117, 264, 1180, 5167, 59, 1820, 2, 21953, 3677, 36, 10, 8959, 9, 296, 69, 6, 943, 110, 163, 110, 7, 47, 942, 734, 29, 136, 163, 187, 4529, 155, 21, 414, 100, 472, 9, 1367, 2734, 1820, 2, 62, 2, 2237, 453, 225, 7, 9, 12, 2863]",713.0,27862952,175
"Activating NOTCH1 Mutations Define a Distinct Subgroup of Patients With Adenoid Cystic Carcinoma Who Have Poor Prognosis, Propensity to Bone and Liver Metastasis, and Potential Responsiveness to Notch1 Inhibitors.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-11-21,"Purpose Adenoid cystic carcinomas (ACCs) represent a heterogeneous group of chemotherapy refractory tumors, with a subset demonstrating an aggressive phenotype. We investigated the molecular underpinnings of this phenotype and assessed the Notch1 pathway as a potential therapeutic target. Methods We genotyped 102 ACCs that had available pathologic and clinical data. Notch1 activation was assessed by immunohistochemistry for Notch1 intracellular domain. Luciferase reporter assays were used to confirm Notch1 target gene expression in vitro. The Notch1 inhibitor brontictuzumab was tested in patient-derived xenografts from patients with ACC and in a patient with ACC who was enrolled in a phase I study. Results NOTCH1 mutations occurred predominantly (14 of 15 patients) in the negative regulatory region and Pro-Glu-Ser-Thr-rich domains, the same two hotspots seen in T-cell acute lymphoblastic leukemias, and led to pathway activation in vitro. NOTCH1-mutant tumors demonstrated significantly higher levels of Notch1 pathway activation than wild-type tumors on the basis of Notch1 intracellular domain staining ( P = .004). NOTCH1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype ( P < .001), advanced-stage disease at diagnosis ( P = .02), higher rate of liver and bone metastasis ( P  .02), shorter relapse-free survival (median, 13 v 34 months; P = .01), and shorter overall survival (median 30 v 122 months; P = .001) when compared with NOTCH1 wild-type tumors. Significant tumor growth inhibition with brontictuzumab was observed exclusively in the ACC patient-derived xenograft model that harbored a NOTCH1 activating mutation. Furthermore, an index patient with NOTCH1-mutant ACC had a partial response to brontictuzumab. Conclusion NOTCH1 mutations define a distinct disease phenotype characterized by solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 inhibitors. Clinical studies targeting Notch1 in a genotype-defined ACC subgroup are warranted.",Journal Article,1156.0,32.0,Purpose Adenoid cystic carcinomas ACCs represent a heterogeneous group of chemotherapy refractory tumors with a subset demonstrating an aggressive phenotype We investigated the molecular underpinnings of this phenotype and assessed the Notch1 pathway as a potential therapeutic target Methods We genotyped 102 ACCs that had available pathologic and clinical data Notch1 activation was assessed by immunohistochemistry for Notch1 intracellular domain Luciferase reporter assays were used to confirm Notch1 target gene expression in vitro The Notch1 inhibitor brontictuzumab was tested in patient-derived xenografts from patients with ACC and in a patient with ACC who was enrolled in a phase I study Results NOTCH1 mutations occurred predominantly 14 of 15 patients in the negative regulatory region and Pro-Glu-Ser-Thr-rich domains the same two hotspots seen in T-cell acute lymphoblastic leukemias and led to pathway activation in vitro NOTCH1-mutant tumors demonstrated significantly higher levels of Notch1 pathway activation than wild-type tumors on the basis of Notch1 intracellular domain staining P .004 NOTCH1 mutations define a distinct aggressive ACC subgroup with a significantly higher likelihood of solid subtype P .001 advanced-stage disease at diagnosis P .02 higher rate of and metastasis P  .02 shorter relapse-free survival median 13 v 34 months P .01 and shorter overall survival median 30 v 122 months P .001 when compared with NOTCH1 wild-type tumors Significant tumor growth inhibition with brontictuzumab was observed exclusively in the ACC patient-derived xenograft model that harbored a NOTCH1 activating mutation Furthermore an index patient with NOTCH1-mutant ACC had a partial response to brontictuzumab Conclusion NOTCH1 mutations define a distinct disease phenotype characterized by solid histology and metastasis poor prognosis and potential responsiveness to Notch1 inhibitors Clinical studies targeting Notch1 in a genotype-defined ACC subgroup are warranted,0,0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[743, 8124, 2965, 826, 15742, 1231, 8, 1564, 87, 1, 56, 430, 57, 5, 8, 697, 2219, 35, 571, 1005, 21, 565, 3, 219, 8807, 1, 26, 1005, 2, 275, 3, 4607, 308, 22, 8, 174, 189, 283, 636, 21, 3053, 2867, 15742, 17, 42, 390, 510, 2, 38, 74, 4607, 363, 10, 275, 20, 888, 9, 4607, 2087, 1398, 3864, 3674, 1013, 11, 95, 6, 1843, 4607, 283, 145, 55, 4, 439, 3, 4607, 230, 41608, 10, 650, 4, 69, 526, 1348, 29, 7, 5, 3267, 2, 4, 8, 69, 5, 3267, 54, 10, 346, 4, 8, 124, 70, 45, 99, 4607, 138, 489, 2117, 213, 1, 167, 7, 4, 3, 199, 1253, 1053, 2, 1805, 13496, 6963, 11105, 3697, 2703, 3, 827, 100, 11193, 527, 4, 102, 31, 286, 1275, 2792, 2, 836, 6, 308, 363, 4, 439, 4607, 620, 57, 264, 97, 142, 148, 1, 4607, 308, 363, 76, 955, 267, 57, 23, 3, 877, 1, 4607, 2087, 1398, 1029, 19, 1520, 4607, 138, 1107, 8, 834, 571, 3267, 1363, 5, 8, 97, 142, 1420, 1, 537, 875, 19, 144, 131, 82, 34, 28, 147, 19, 588, 142, 116, 1, 2, 278, 19, 1552, 588, 985, 429, 115, 25, 52, 233, 603, 562, 53, 19, 355, 2, 985, 63, 25, 52, 201, 603, 3285, 53, 19, 144, 198, 72, 5, 4607, 955, 267, 57, 93, 30, 129, 297, 5, 41608, 10, 164, 4437, 4, 3, 3267, 69, 526, 1330, 202, 17, 3253, 8, 4607, 1616, 258, 798, 35, 558, 69, 5, 4607, 620, 3267, 42, 8, 450, 51, 6, 41608, 1221, 4607, 138, 1107, 8, 834, 34, 1005, 765, 20, 537, 784, 2, 278, 334, 356, 2, 174, 3642, 6, 4607, 222, 38, 94, 529, 4607, 4, 8, 1183, 395, 3267, 1363, 32, 1197]",1992.0,27870570,0
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-11-21,"Purpose Philadelphia chromosome (Ph) -like acute lymphoblastic leukemia (ALL) is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors. We sought to define the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventional chemotherapy. Patients and Methods The frequency of Ph-like ALL was assessed by gene expression profiling of 798 patients with B-cell ALL age 21 to 86 years. Event-free survival and overall survival were determined for Ph-like ALL versus non-Ph-like ALL patients. Detailed genomic analysis was performed on 180 of 194 patients with Ph-like ALL. Results Patients with Ph-like ALL accounted for more than 20% of adults with ALL, including 27.9% of young adults (age 21 to 39 years), 20.4% of adults (age 40 to 59 years), and 24.0% of older adults (age 60 to 86 years). Overall, patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 49.3% [95% CI, 42.8% to 56.2%; n = 247], respectively; P < .001). We identified kinase-activating alterations in 88% of patients with Ph-like ALL, including CRLF2 rearrangements (51%), ABL class fusions (9.8%), JAK2 or EPOR rearrangements (12.4%), other JAK-STAT sequence mutations (7.2%), other kinase alterations (4.1%), and Ras pathway mutations (3.6%). Eleven new kinase rearrangements were identified, including four involving new kinase or cytokine receptor genes and seven involving new partners for previously identified genes. Conclusion Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome. The diverse range of kinase-activating alterations in Ph-like ALL has important therapeutic implications. Trials comparing the addition of tyrosine kinase inhibitors to conventional therapy are required to evaluate the clinical utility of these agents in the treatment of Ph-like ALL.",Journal Article,1156.0,98.0,Purpose Philadelphia chromosome Ph -like acute lymphoblastic ALL is a high-risk subtype of childhood ALL characterized by kinase-activating alterations that are amenable to treatment with tyrosine kinase inhibitors We sought to define the prevalence and genomic landscape of Ph-like ALL in adults and assess response to conventional chemotherapy Patients and Methods The frequency of Ph-like ALL was assessed by gene expression profiling of 798 patients with B-cell ALL age 21 to 86 years Event-free survival and overall survival were determined for Ph-like ALL versus non-Ph-like ALL patients Detailed genomic analysis was performed on 180 of 194 patients with Ph-like ALL Results Patients with Ph-like ALL accounted for more than 20 of adults with ALL including 27.9 of young adults age 21 to 39 years 20.4 of adults age 40 to 59 years and 24.0 of older adults age 60 to 86 years Overall patients with Ph-like ALL had an inferior 5-year event-free survival compared with patients with non-Ph-like ALL 22.5 95 CI 14.9 to 29.3 n 155 v 49.3 95 CI 42.8 to 56.2 n 247 respectively P .001 We identified kinase-activating alterations in 88 of patients with Ph-like ALL including CRLF2 rearrangements 51 ABL class fusions 9.8 JAK2 or EPOR rearrangements 12.4 other JAK-STAT sequence mutations 7.2 other kinase alterations 4.1 and Ras pathway mutations 3.6 Eleven new kinase rearrangements were identified including four involving new kinase or cytokine receptor genes and seven involving new partners for previously identified genes Conclusion Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome The diverse range of kinase-activating alterations in Ph-like ALL has important therapeutic implications Trials comparing the addition of tyrosine kinase inhibitors to conventional therapy are required to evaluate the clinical utility of these agents in the treatment of Ph-like ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[743, 3006, 1170, 2058, 733, 286, 1275, 62, 16, 8, 64, 43, 875, 1, 864, 62, 765, 20, 216, 1616, 593, 17, 32, 4070, 6, 24, 5, 564, 216, 222, 21, 990, 6, 1107, 3, 1078, 2, 572, 2801, 1, 2058, 733, 62, 4, 857, 2, 423, 51, 6, 809, 56, 7, 2, 636, 3, 675, 1, 2058, 733, 62, 10, 275, 20, 145, 55, 1080, 1, 13049, 7, 5, 132, 31, 62, 89, 239, 6, 868, 60, 774, 115, 25, 2, 63, 25, 11, 509, 9, 2058, 733, 62, 185, 220, 2058, 733, 62, 7, 2455, 572, 65, 10, 173, 23, 3172, 1, 5434, 7, 5, 2058, 733, 62, 99, 7, 5, 2058, 733, 62, 3688, 9, 80, 76, 179, 1, 857, 5, 62, 141, 428, 83, 1, 1169, 857, 89, 239, 6, 587, 60, 179, 39, 1, 857, 89, 327, 6, 728, 60, 2, 259, 13, 1, 434, 857, 89, 335, 6, 868, 60, 63, 7, 5, 2058, 733, 62, 42, 35, 1663, 33, 111, 774, 115, 25, 72, 5, 7, 5, 220, 2058, 733, 62, 350, 33, 48, 58, 213, 83, 6, 462, 27, 78, 3735, 603, 739, 27, 48, 58, 595, 66, 6, 664, 18, 78, 7708, 106, 19, 144, 21, 108, 216, 1616, 593, 4, 889, 1, 7, 5, 2058, 733, 62, 141, 8895, 2072, 725, 1425, 1040, 2530, 83, 66, 2509, 15, 12839, 2072, 133, 39, 127, 4653, 4168, 1532, 138, 67, 18, 127, 216, 593, 39, 14, 2, 1102, 308, 138, 27, 49, 2627, 217, 216, 2072, 11, 108, 141, 294, 1267, 217, 216, 15, 1675, 153, 214, 2, 648, 1267, 217, 4005, 9, 373, 108, 214, 1221, 2058, 733, 62, 16, 8, 561, 2485, 875, 1, 62, 4, 857, 2, 16, 41, 5, 334, 228, 3, 1867, 184, 1, 216, 1616, 593, 4, 2058, 733, 62, 71, 305, 189, 1268, 143, 1430, 3, 352, 1, 564, 216, 222, 6, 809, 36, 32, 616, 6, 376, 3, 38, 1207, 1, 46, 183, 4, 3, 24, 1, 2058, 733, 62]",1915.0,27870571,846
Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia.,Cancer research,Cancer Res.,2016-11-21,"Current standard of care for patients with pediatric acute lymphoblastic leukemia (ALL) is mainly effective, with high remission rates after treatment. However, the genetic perturbations that give rise to this disease remain largely undefined, limiting the ability to address resistant tumors or develop less toxic targeted therapies. Here, we report the use of next-generation sequencing to interrogate the genetic and pathogenic mechanisms of 240 pediatric ALL cases with their matched remission samples. Commonly mutated genes fell into several categories, including RAS/receptor tyrosine kinases, epigenetic regulators, transcription factors involved in lineage commitment, and the p53/cell-cycle pathway. Unique recurrent mutational hotspots were observed in epigenetic regulators CREBBP (R1446C/H), WHSC1 (E1099K), and the tyrosine kinase FLT3 (K663R, N676K). The mutant WHSC1 was established as a gain-of-function oncogene, while the epigenetic regulator ARID1A and transcription factor CTCF were functionally identified as potential tumor suppressors. Analysis of 28 diagnosis/relapse trio patients plus 10 relapse cases revealed four evolutionary paths and uncovered the ordering of acquisition of mutations in these patients. This study provides a detailed mutational portrait of pediatric ALL and gives insights into the molecular pathogenesis of this disease. Cancer Res; 77(2); 390-400. 2016 AACR.",Journal Article,1156.0,29.0,Current standard of care for patients with pediatric acute lymphoblastic ALL is mainly effective with high remission rates after treatment However the genetic perturbations that give rise to this disease remain largely undefined limiting the ability to address resistant tumors or develop less toxic targeted therapies Here we report the use of next-generation sequencing to interrogate the genetic and pathogenic mechanisms of 240 pediatric ALL cases with their matched remission samples Commonly mutated genes fell into several categories including RAS/receptor tyrosine kinases epigenetic regulators transcription factors involved in lineage commitment and the p53/cell-cycle pathway Unique recurrent mutational hotspots were observed in epigenetic regulators CREBBP R1446C/H WHSC1 E1099K and the tyrosine kinase FLT3 K663R N676K The mutant WHSC1 was established as a gain-of-function oncogene while the epigenetic regulator ARID1A and transcription factor CTCF were functionally identified as potential tumor suppressors Analysis of 28 diagnosis/relapse trio patients plus 10 relapse cases revealed four evolutionary paths and uncovered the ordering of acquisition of mutations in these patients This study provides a detailed mutational portrait of pediatric ALL and gives insights into the molecular pathogenesis of this disease Cancer Res 77 2 390-400 2016 AACR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[291, 260, 1, 165, 9, 7, 5, 815, 286, 1275, 62, 16, 2615, 323, 5, 64, 734, 151, 50, 24, 137, 3, 336, 7013, 17, 4978, 3693, 6, 26, 34, 918, 1733, 5425, 817, 3, 801, 6, 1539, 436, 57, 15, 690, 299, 1812, 238, 235, 467, 21, 414, 3, 119, 1, 1305, 914, 615, 6, 8415, 3, 336, 2, 2806, 483, 1, 4263, 815, 62, 140, 5, 136, 655, 734, 347, 841, 1185, 214, 7689, 237, 392, 1996, 141, 1102, 153, 564, 1549, 1418, 3196, 866, 130, 646, 4, 2542, 11082, 2, 3, 624, 31, 417, 308, 991, 387, 1619, 11193, 11, 164, 4, 1418, 3196, 13439, 69377, 555, 35593, 40496, 2, 3, 564, 216, 1224, 69378, 28457, 3, 620, 35593, 10, 635, 22, 8, 1803, 1, 343, 1836, 369, 3, 1418, 2452, 5430, 2, 866, 161, 16716, 11, 3772, 108, 22, 174, 30, 5704, 65, 1, 339, 147, 429, 29720, 7, 349, 79, 429, 140, 553, 294, 8705, 17836, 2, 5601, 3, 10013, 1, 3405, 1, 138, 4, 46, 7, 26, 45, 777, 8, 2455, 1619, 22439, 1, 815, 62, 2, 7989, 1957, 237, 3, 219, 1384, 1, 26, 34, 12, 1936, 849, 18, 7992, 1524, 3456, 1630]",1369.0,27872090,425
Whole-transcriptome sequencing identifies a distinct subtype of acute lymphoblastic leukemia with predominant genomic abnormalities of EP300 and CREBBP.,Genome research,Genome Res.,2016-11-30,"Chromosomal translocations are a genomic hallmark of many hematologic malignancies. Often as initiating events, these structural abnormalities result in fusion proteins involving transcription factors important for hematopoietic differentiation and/or signaling molecules regulating cell proliferation and cell cycle. In contrast, epigenetic regulator genes are more frequently targeted by somatic sequence mutations, possibly as secondary events to further potentiate leukemogenesis. Through comprehensive whole-transcriptome sequencing of 231 children with acute lymphoblastic leukemia (ALL), we identified 58 putative functional and predominant fusion genes in 54.1% of patients (n = 125), 31 of which have not been reported previously. In particular, we described a distinct ALL subtype with a characteristic gene expression signature predominantly driven by chromosomal rearrangements of the ZNF384 gene with histone acetyltransferases EP300 and CREBBP ZNF384-rearranged ALL showed significant up-regulation of CLCF1 and BTLA expression, and ZNF384 fusion proteins consistently showed higher activity to promote transcription of these target genes relative to wild-type ZNF384 in vitro. Ectopic expression of EP300-ZNF384 and CREBBP-ZNF384 fusion altered differentiation of mouse hematopoietic stem and progenitor cells and also potentiated oncogenic transformation in vitro. EP300- and CREBBP-ZNF384 fusions resulted in loss of histone lysine acetyltransferase activity in a dominant-negative fashion, with concomitant global reduction of histone acetylation and increased sensitivity of leukemia cells to histone deacetylase inhibitors. In conclusion, our results indicate that gene fusion is a common class of genomic abnormalities in childhood ALL and that recurrent translocations involving EP300 and CREBBP may cause epigenetic deregulation with potential for therapeutic targeting.",Journal Article,1147.0,20.0,Chromosomal translocations are a genomic hallmark of many hematologic malignancies Often as initiating events these structural abnormalities result in fusion proteins involving transcription factors important for hematopoietic differentiation and/or signaling molecules regulating cell proliferation and cell cycle In contrast epigenetic regulator genes are more frequently targeted by somatic sequence mutations possibly as secondary events to further potentiate leukemogenesis Through comprehensive whole-transcriptome sequencing of 231 children with acute lymphoblastic ALL we identified 58 putative functional and predominant fusion genes in 54.1 of patients n 125 31 of which have not been reported previously In particular we described a distinct ALL subtype with a characteristic gene expression signature predominantly driven by chromosomal rearrangements of the ZNF384 gene with histone acetyltransferases EP300 and CREBBP ZNF384-rearranged ALL showed significant up-regulation of CLCF1 and BTLA expression and ZNF384 fusion proteins consistently showed higher activity to promote transcription of these target genes relative to wild-type ZNF384 in vitro Ectopic expression of EP300-ZNF384 and CREBBP-ZNF384 fusion altered differentiation of mouse hematopoietic stem and progenitor cells and also potentiated oncogenic transformation in vitro EP300- and CREBBP-ZNF384 fusions resulted in loss of histone lysine acetyltransferase activity in a dominant-negative fashion with concomitant global reduction of histone acetylation and increased sensitivity of cells to histone deacetylase inhibitors In conclusion our results indicate that gene fusion is a common class of genomic abnormalities in childhood ALL and that recurrent translocations involving EP300 and CREBBP may cause epigenetic deregulation with potential for therapeutic targeting,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1860, 3262, 32, 8, 572, 4683, 1, 445, 813, 441, 629, 22, 2637, 281, 46, 3281, 1171, 757, 4, 1212, 652, 1267, 866, 130, 305, 9, 1007, 910, 2, 15, 314, 1598, 2681, 31, 457, 2, 31, 417, 4, 748, 1418, 2452, 214, 32, 80, 746, 238, 20, 1119, 1532, 138, 2150, 22, 568, 281, 6, 195, 6428, 5661, 298, 949, 902, 3917, 615, 1, 3652, 541, 5, 286, 1275, 62, 21, 108, 717, 2743, 583, 2, 2750, 1212, 214, 4, 667, 14, 1, 7, 78, 1731, 456, 1, 92, 47, 44, 85, 210, 373, 4, 1454, 21, 1027, 8, 834, 62, 875, 5, 8, 2037, 145, 55, 1651, 2117, 1621, 20, 1860, 2072, 1, 3, 20919, 145, 5, 1508, 18849, 15423, 2, 13439, 20919, 3201, 62, 224, 93, 126, 863, 1, 69424, 2, 11879, 55, 2, 20919, 1212, 652, 2433, 224, 142, 128, 6, 1617, 866, 1, 46, 283, 214, 580, 6, 955, 267, 20919, 4, 439, 3647, 55, 1, 15423, 20919, 2, 13439, 20919, 1212, 1495, 910, 1, 830, 1007, 452, 2, 2520, 37, 2, 120, 6707, 1302, 1392, 4, 439, 15423, 2, 13439, 20919, 2530, 627, 4, 407, 1, 1508, 6041, 14528, 128, 4, 8, 2156, 199, 3240, 5, 1781, 1648, 628, 1, 1508, 4145, 2, 101, 485, 1, 37, 6, 1508, 2732, 222, 4, 1221, 114, 99, 1008, 17, 145, 1212, 16, 8, 186, 1040, 1, 572, 1171, 4, 864, 62, 2, 17, 387, 3262, 1267, 15423, 2, 13439, 68, 708, 1418, 4765, 5, 174, 9, 189, 529]",1851.0,27903646,365
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-11-30,"<b>Purpose:</b> The oncogenic miR-155 is upregulated in many human cancers, and its expression is increased in more aggressive and therapy-resistant tumors, but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood. The main objectives of this study were to determine the role of miR-155 in resistance to chemotherapy and to evaluate anti-miR-155 treatment to chemosensitize tumors.<b>Experimental Design:</b> We performed <i>in vitro</i> studies on cell lines to investigate the role of miR-155 in therapy resistance. To assess the effects of miR-155 inhibition on chemoresistance, we used an <i>in vivo</i> orthotopic lung cancer model of athymic nude mice, which we treated with anti-miR-155 alone or in combination with chemotherapy. To analyze the association of miR-155 expression and the combination of miR-155 and <i>TP53</i> expression with cancer survival, we studied 956 patients with lung cancer, chronic lymphocytic leukemia, and acute lymphoblastic leukemia.<b>Results:</b> We demonstrate that miR-155 induces resistance to multiple chemotherapeutic agents <i>in vitro</i>, and that downregulation of miR-155 successfully resensitizes tumors to chemotherapy <i>in vivo</i> We show that anti-miR-155-DOPC can be considered non-toxic <i>in vivo</i> We further demonstrate that miR-155 and <i>TP53</i> are linked in a negative feedback mechanism and that a combination of high expression of miR-155 and low expression of <i>TP53</i> is significantly associated with shorter survival in lung cancer.<b>Conclusions:</b> Our findings support the existence of an miR-155/TP53 feedback loop, which is involved in resistance to chemotherapy and which can be specifically targeted to overcome drug resistance, an important cause of cancer-related death. <i>Clin Cancer Res; 23(11); 2891-904. 2016 AACR</i>.",Journal Article,1147.0,49.0,b Purpose /b The oncogenic miR-155 is upregulated in many human cancers and its expression is increased in more aggressive and therapy-resistant tumors but the molecular mechanisms underlying miR-155-induced therapy resistance are not fully understood The main objectives of this study were to determine the role of miR-155 in resistance to chemotherapy and to evaluate anti-miR-155 treatment to chemosensitize tumors. b Experimental Design /b We performed i in vitro /i studies on cell lines to investigate the role of miR-155 in therapy resistance To assess the effects of miR-155 inhibition on chemoresistance we used an i in vivo /i orthotopic cancer model of athymic nude mice which we treated with anti-miR-155 alone or in combination with chemotherapy To analyze the association of miR-155 expression and the combination of miR-155 and i TP53 /i expression with cancer survival we studied 956 patients with cancer chronic lymphocytic and acute lymphoblastic leukemia. b Results /b We demonstrate that miR-155 induces resistance to multiple chemotherapeutic agents i in vitro /i and that downregulation of miR-155 successfully resensitizes tumors to chemotherapy i in vivo /i We show that anti-miR-155-DOPC can be considered non-toxic i in vivo /i We further demonstrate that miR-155 and i TP53 /i are linked in a negative feedback mechanism and that a combination of high expression of miR-155 and low expression of i TP53 /i is significantly associated with shorter survival in cancer. b Conclusions /b Our findings support the existence of an miR-155/TP53 feedback loop which is involved in resistance to chemotherapy and which can be specifically targeted to overcome drug resistance an important cause of cancer-related death i Clin Cancer Res 23 11 2891-904 2016 AACR /i,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[132, 743, 132, 3, 1302, 722, 3735, 16, 2684, 4, 445, 171, 163, 2, 211, 55, 16, 101, 4, 80, 571, 2, 36, 436, 57, 84, 3, 219, 483, 1181, 722, 3735, 277, 36, 251, 32, 44, 1910, 1784, 3, 1895, 2409, 1, 26, 45, 11, 6, 223, 3, 200, 1, 722, 3735, 4, 251, 6, 56, 2, 6, 376, 312, 722, 3735, 24, 6, 39955, 57, 132, 1560, 771, 132, 21, 173, 70, 4, 439, 70, 94, 23, 31, 285, 6, 963, 3, 200, 1, 722, 3735, 4, 36, 251, 6, 423, 3, 176, 1, 722, 3735, 297, 23, 3782, 21, 95, 35, 70, 4, 386, 70, 2157, 12, 202, 1, 6396, 2598, 399, 92, 21, 73, 5, 312, 722, 3735, 279, 15, 4, 150, 5, 56, 6, 1992, 3, 248, 1, 722, 3735, 55, 2, 3, 150, 1, 722, 3735, 2, 70, 1206, 70, 55, 5, 12, 25, 21, 656, 14137, 7, 5, 12, 442, 1193, 2, 286, 1275, 2647, 132, 99, 132, 21, 608, 17, 722, 3735, 1516, 251, 6, 232, 1573, 183, 70, 4, 439, 70, 2, 17, 2475, 1, 722, 3735, 1878, 32683, 57, 6, 56, 70, 4, 386, 70, 21, 514, 17, 312, 722, 3735, 8476, 122, 40, 515, 220, 1812, 70, 4, 386, 70, 21, 195, 608, 17, 722, 3735, 2, 70, 1206, 70, 32, 1199, 4, 8, 199, 3983, 670, 2, 17, 8, 150, 1, 64, 55, 1, 722, 3735, 2, 154, 55, 1, 70, 1206, 70, 16, 97, 41, 5, 985, 25, 4, 12, 132, 2130, 132, 114, 272, 538, 3, 5335, 1, 35, 722, 3735, 1206, 3983, 4432, 92, 16, 646, 4, 251, 6, 56, 2, 92, 122, 40, 1225, 238, 6, 1768, 234, 251, 35, 305, 708, 1, 12, 139, 273, 70, 2459, 12, 1936, 382, 175, 23972, 13145, 3456, 1630, 70]",1783.0,27903673,458
Association between dehydroepiandrosterone-sulfate and attention in long-term survivors of childhood acute lymphoblastic leukemia treated with only chemotherapy.,Psychoneuroendocrinology,Psychoneuroendocrinology,2016-11-16,"Long-term survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive impairment, as well as compromised hypothalamic-pituitary-adrenal (HPA) function. Dehydroepiandrosterone-sulfate (DHEAS) is an adrenal androgen commonly used as a marker of HPA function. In the general population, a low level of DHEAS has been associated with poorer cognition. At 2years post-treatment, we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL (mean[standard deviation] age at evaluation 14.5[4.7] years; 7.5[1.9] years post-diagnosis) who were treated with only chemotherapy and without prophylactic cranial irradiation. Male survivors with low-normal levels of DHEAS had worse performance than male survivors with high levels of DHEAS on multiple measures of attention (all P's<0.05). However, association between DHEAS and attention measures were not found in female survivors. Our results suggest that survivors of ALL who suffer from partial but persistent adrenal insufficiency may be at risk for neurocognitive deficits. This finding should be validated in a larger prospective study, with attention to sex differences in the potential impact of adrenal insufficiency on neurocognitive outcomes.",Journal Article,1161.0,4.0,Long-term survivors of childhood acute lymphoblastic ALL are at risk for neurocognitive impairment as well as compromised hypothalamic-pituitary-adrenal HPA function Dehydroepiandrosterone-sulfate DHEAS is an adrenal androgen commonly used as a marker of HPA function In the general population a low level of DHEAS has been associated with poorer cognition At 2years post-treatment we examined the association of DHEAS with attention outcomes in 35 male and 34 female long-term survivors of childhood ALL mean standard deviation age at evaluation 14.5 4.7 years 7.5 1.9 years post-diagnosis who were treated with only chemotherapy and without prophylactic cranial irradiation Male survivors with low-normal levels of DHEAS had worse performance than male survivors with high levels of DHEAS on multiple measures of attention all P 's 0.05 However association between DHEAS and attention measures were not found in female survivors Our results suggest that survivors of ALL who suffer from partial but persistent adrenal insufficiency may be at risk for neurocognitive deficits This finding should be validated in a larger prospective study with attention to sex differences in the potential impact of adrenal insufficiency on neurocognitive outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[319, 337, 332, 1, 864, 286, 1275, 62, 32, 28, 43, 9, 2958, 2315, 22, 149, 22, 4867, 7531, 12098, 2987, 14513, 343, 12317, 6424, 16919, 16, 35, 2987, 687, 841, 95, 22, 8, 952, 1, 14513, 343, 4, 3, 1083, 266, 8, 154, 301, 1, 16919, 71, 85, 41, 5, 1769, 8130, 28, 69429, 539, 24, 21, 409, 3, 248, 1, 16919, 5, 2111, 123, 4, 465, 1045, 2, 562, 1061, 319, 337, 332, 1, 864, 62, 313, 260, 3348, 89, 28, 451, 213, 33, 39, 67, 60, 67, 33, 14, 83, 60, 539, 147, 54, 11, 73, 5, 158, 56, 2, 187, 1862, 2565, 1104, 1045, 332, 5, 154, 295, 148, 1, 16919, 42, 639, 528, 76, 1045, 332, 5, 64, 148, 1, 16919, 23, 232, 1018, 1, 2111, 62, 19, 292, 13, 474, 137, 248, 59, 16919, 2, 2111, 1018, 11, 44, 204, 4, 1061, 332, 114, 99, 309, 17, 332, 1, 62, 54, 6506, 29, 450, 84, 1882, 2987, 4360, 68, 40, 28, 43, 9, 2958, 2752, 26, 1567, 257, 40, 938, 4, 8, 1077, 482, 45, 5, 2111, 6, 1035, 362, 4, 3, 174, 345, 1, 2987, 4360, 23, 2958, 123]",1250.0,27907849,453
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults.,Blood,Blood,2016-12-05,"Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) is a high-risk subtype of ALL in children. There are conflicting data on the incidence and prognosis of Ph-like ALL in adults. Patients with newly diagnosed B-cell ALL (B-ALL) who received frontline chemotherapy at MD Anderson Cancer Center underwent gene expression profiling of leukemic cells. Of 148 patients, 33.1% had Ph-like, 31.1% had Ph<sup>+</sup>, and 35.8% had other B-ALL subtypes (B-other). Within the Ph-like ALL cohort, 61% had cytokine receptor-like factor 2 (CRLF2) overexpression. Patients with Ph-like ALL had significantly worse overall survival (OS), and event-free survival compared with B-other with a 5-year survival of 23% (vs 59% for B-other, P = .006). Sixty-eight percent of patients with Ph-like ALL were of Hispanic ethnicity. The following were associated with inferior OS on multivariable analysis: age (hazard ratio [HR], 3.299; P < .001), white blood cell count (HR, 1.910; P = .017), platelet count (HR, 7.437; P = .005), and Ph-like ALL (HR, 1.818; P = .03). Next-generation sequencing of the CRLF2<sup>+</sup> group identified mutations in the JAK-STAT and Ras pathway in 85% of patients, and 20% had a CRLF2 mutation. Within the CRLF2<sup>+</sup> group, JAK2 mutation was associated with inferior outcomes. Our findings show high frequency of Ph-like ALL in adults, an increased frequency of Ph-like ALL in adults of Hispanic ethnicity, significantly inferior outcomes of adult patients with Ph-like ALL, and significantly worse outcomes in the CRLF2<sup>+</sup> subset of Ph-like ALL. Novel strategies are needed to improve the outcome of these patients.",Journal Article,1142.0,76.0,Philadelphia chromosome Ph -like acute lymphoblastic ALL is a high-risk subtype of ALL in children There are conflicting data on the incidence and prognosis of Ph-like ALL in adults Patients with newly diagnosed B-cell ALL B-ALL who received frontline chemotherapy at MD Anderson Cancer Center underwent gene expression profiling of leukemic cells Of 148 patients 33.1 had Ph-like 31.1 had Ph sup /sup and 35.8 had other B-ALL subtypes B-other Within the Ph-like ALL cohort 61 had cytokine receptor-like factor 2 CRLF2 overexpression Patients with Ph-like ALL had significantly worse overall survival OS and event-free survival compared with B-other with a 5-year survival of 23 vs 59 for B-other P .006 Sixty-eight percent of patients with Ph-like ALL were of Hispanic ethnicity The following were associated with inferior OS on multivariable analysis age hazard ratio HR 3.299 P .001 white blood cell count HR 1.910 P .017 platelet count HR 7.437 P .005 and Ph-like ALL HR 1.818 P .03 Next-generation sequencing of the CRLF2 sup /sup group identified mutations in the JAK-STAT and Ras pathway in 85 of patients and 20 had a CRLF2 mutation Within the CRLF2 sup /sup group JAK2 mutation was associated with inferior outcomes Our findings show high frequency of Ph-like ALL in adults an increased frequency of Ph-like ALL in adults of Hispanic ethnicity significantly inferior outcomes of adult patients with Ph-like ALL and significantly worse outcomes in the CRLF2 sup /sup subset of Ph-like ALL Novel strategies are needed to improve the outcome of these patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 2058, 733, 286, 1275, 62, 16, 8, 64, 43, 875, 1, 62, 4, 541, 125, 32, 4274, 74, 23, 3, 287, 2, 356, 1, 2058, 733, 62, 4, 857, 7, 5, 732, 265, 132, 31, 62, 132, 62, 54, 103, 3171, 56, 28, 2244, 1929, 12, 574, 208, 145, 55, 1080, 1, 2015, 37, 1, 4647, 7, 466, 14, 42, 2058, 733, 456, 14, 42, 2058, 172, 172, 2, 465, 66, 42, 127, 132, 62, 814, 132, 127, 262, 3, 2058, 733, 62, 180, 713, 42, 1675, 153, 733, 161, 18, 8895, 851, 7, 5, 2058, 733, 62, 42, 97, 639, 63, 25, 118, 2, 774, 115, 25, 72, 5, 132, 127, 5, 8, 33, 111, 25, 1, 382, 105, 728, 9, 132, 127, 19, 1861, 1746, 659, 714, 1, 7, 5, 2058, 733, 62, 11, 1, 1776, 2091, 3, 366, 11, 41, 5, 1663, 118, 23, 658, 65, 89, 360, 197, 168, 27, 8769, 19, 144, 886, 315, 31, 1276, 168, 14, 15500, 19, 3825, 1596, 1276, 168, 67, 12592, 19, 1614, 2, 2058, 733, 62, 168, 14, 13520, 19, 680, 1305, 914, 615, 1, 3, 8895, 172, 172, 87, 108, 138, 4, 3, 4653, 4168, 2, 1102, 308, 4, 772, 1, 7, 2, 179, 42, 8, 8895, 258, 262, 3, 8895, 172, 172, 87, 2509, 258, 10, 41, 5, 1663, 123, 114, 272, 514, 64, 675, 1, 2058, 733, 62, 4, 857, 35, 101, 675, 1, 2058, 733, 62, 4, 857, 1, 1776, 2091, 97, 1663, 123, 1, 780, 7, 5, 2058, 733, 62, 2, 97, 639, 123, 4, 3, 8895, 172, 172, 697, 1, 2058, 733, 62, 229, 422, 32, 575, 6, 401, 3, 228, 1, 46, 7]",1565.0,27919910,508
CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2016-10-01,"Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors. One type of immunotherapy involves the adoptive transfer of T cells that have been genetically modified with a chimeric antigen receptor (CAR) to target a tumor. These hybrid proteins are composed of the antigen-binding domains of an antibody fused to T-cell receptor signaling machinery. CAR T cells that target CD19 recently have made the jump from the laboratory to the clinic, and the results have been remarkable. CD19-targeted CAR T cells have induced complete remissions of disease in up to 90% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), who have an expected complete response rate of 30% in response to chemotherapy. The high efficacy of CAR T cells in B-ALL suggests that regulatory approval of this therapy for this routinely fatal leukemia is on the horizon. We review the preclinical development of CAR T cells and their early clinical application for lymphoma. We also provide a comprehensive analysis of the use of CAR T cells in patients with B-ALL. In addition, we discuss the unique toxicities associated with this therapy and the management schemes that have been developed.",Journal Article,1207.0,31.0,Immunotherapy has demonstrated significant potential for the treatment of patients with chemotherapy-resistant hematologic malignancies and solid tumors One type of immunotherapy involves the adoptive transfer of T cells that have been genetically modified with a chimeric antigen receptor CAR to target a tumor These hybrid proteins are composed of the antigen-binding domains of an antibody fused to T-cell receptor signaling machinery CAR T cells that target CD19 recently have made the jump from the laboratory to the clinic and the results have been remarkable CD19-targeted CAR T cells have induced complete remissions of disease in up to 90 of patients with relapsed or refractory B-cell acute lymphoblastic B-ALL who have an expected complete response rate of 30 in response to chemotherapy The high efficacy of CAR T cells in B-ALL suggests that regulatory approval of this therapy for this routinely fatal is on the horizon We review the preclinical development of CAR T cells and their early clinical application for We also provide a comprehensive analysis of the use of CAR T cells in patients with B-ALL In addition we discuss the unique toxicities associated with this therapy and the management schemes that have been developed,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[726, 71, 264, 93, 174, 9, 3, 24, 1, 7, 5, 56, 436, 813, 441, 2, 537, 57, 104, 267, 1, 726, 2921, 3, 3159, 2602, 1, 102, 37, 17, 47, 85, 2301, 1230, 5, 8, 2897, 448, 153, 1881, 6, 283, 8, 30, 46, 4542, 652, 32, 3317, 1, 3, 448, 791, 2703, 1, 35, 548, 6263, 6, 102, 31, 153, 314, 6415, 1881, 102, 37, 17, 283, 3158, 761, 47, 1229, 3, 50138, 29, 3, 1624, 6, 3, 1188, 2, 3, 99, 47, 85, 3813, 3158, 238, 1881, 102, 37, 47, 277, 236, 3166, 1, 34, 4, 126, 6, 424, 1, 7, 5, 591, 15, 430, 132, 31, 286, 1275, 132, 62, 54, 47, 35, 1336, 236, 51, 116, 1, 201, 4, 51, 6, 56, 3, 64, 209, 1, 1881, 102, 37, 4, 132, 62, 844, 17, 1253, 1814, 1, 26, 36, 9, 26, 3066, 3034, 16, 23, 3, 8704, 21, 206, 3, 693, 193, 1, 1881, 102, 37, 2, 136, 191, 38, 1581, 9, 21, 120, 377, 8, 949, 65, 1, 3, 119, 1, 1881, 102, 37, 4, 7, 5, 132, 62, 4, 352, 21, 1139, 3, 991, 385, 41, 5, 26, 36, 2, 3, 284, 7103, 17, 47, 85, 276]",1243.0,27930631,191
A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2016-12-13,"Bone fractures and osteonecrosis frequently complicate therapy for childhood acute lymphoblastic leukemia (ALL). Bone toxicity has been associated with exposure to corticosteroids and methotrexate (MTX) and age greater than 10 years. We tested whether common genetic polymorphisms were associated with bone toxicity during treatment for ALL. A total of 615 of 794 children enrolled on Dana Farber Cancer Institute ALL Consortium protocol 05-001 (NCT00400946) met eligibility criteria for inclusion in this analysis. Nineteen candidate polymorphisms were selected a priori, targeting genes related to glucocorticoid metabolism, oxidative damage, and folate physiology. Polymorphisms were genotyped using either PCR-based allelic discrimination or PCR product length analysis. Twenty percent of subjects were homozygous for two 28 bp repeats (2R/2R, where 2R is two 28-nucleotide repeats within the 5' untranslated region [UTR] of the thymidylate synthase [TS] gene) within the 5' UTR of the gene for TS. This 2R/2R genotype was associated with increased risk of osteonecrosis among children younger than 10 years at diagnosis (multivariable hazard ratio [HR] 2.71; 95%confidence interval [CI] 1.23-5.95; P = 0.013), and with bone fracture among children  10 years (multivariable HR 2.10; 95%CI 1.11-3.96; P = 0.022). No significant association was observed between TS genotype and red blood cell (RBC) folate, RBC MTX, or relapse risk. A common genetic variant is associated with increased risk of osteonecrosis among children younger than 10 years at diagnosis and with bone fractures among older children. These findings suggest that children and adolescents with the 2R/2R TS genotype should be closely monitored for the development of bone toxicity during therapy for ALL, and support a clinical trial testing the efficacy of protective interventions specifically in this vulnerable population.",Journal Article,1134.0,6.0,fractures and osteonecrosis frequently complicate therapy for childhood acute lymphoblastic ALL toxicity has been associated with exposure to corticosteroids and methotrexate MTX and age greater than 10 years We tested whether common genetic polymorphisms were associated with toxicity during treatment for ALL A total of 615 of 794 children enrolled on Dana Farber Cancer Institute ALL Consortium protocol 05-001 NCT00400946 met eligibility criteria for inclusion in this analysis Nineteen candidate polymorphisms were selected a priori targeting genes related to glucocorticoid metabolism oxidative damage and folate physiology Polymorphisms were genotyped using either PCR-based allelic discrimination or PCR product length analysis Twenty percent of subjects were homozygous for two 28 bp repeats 2R/2R where 2R is two 28-nucleotide repeats within the 5 untranslated region UTR of the thymidylate synthase TS gene within the 5 UTR of the gene for TS This 2R/2R genotype was associated with increased risk of osteonecrosis among children younger than 10 years at diagnosis multivariable hazard ratio HR 2.71 95 confidence interval CI 1.23-5.95 P 0.013 and with fracture among children  10 years multivariable HR 2.10 95 CI 1.11-3.96 P 0.022 No significant association was observed between TS genotype and red blood cell RBC folate RBC MTX or relapse risk A common genetic variant is associated with increased risk of osteonecrosis among children younger than 10 years at diagnosis and with fractures among older children These findings suggest that children and adolescents with the 2R/2R TS genotype should be closely monitored for the development of toxicity during therapy for ALL and support a clinical trial testing the efficacy of protective interventions specifically in this vulnerable population,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3909, 2, 5404, 746, 11157, 36, 9, 864, 286, 1275, 62, 155, 71, 85, 41, 5, 645, 6, 3876, 2, 2116, 3453, 2, 89, 378, 76, 79, 60, 21, 650, 317, 186, 336, 1203, 11, 41, 5, 155, 190, 24, 9, 62, 8, 181, 1, 11970, 1, 13085, 541, 346, 23, 4932, 4979, 12, 1377, 62, 2404, 1182, 474, 144, 34806, 543, 2317, 371, 9, 1680, 4, 26, 65, 3498, 1609, 1203, 11, 715, 8, 7499, 529, 214, 139, 6, 5399, 1600, 3495, 1350, 2, 3100, 7206, 1203, 11, 3053, 75, 361, 604, 90, 3861, 3520, 15, 604, 2821, 1318, 65, 737, 714, 1, 976, 11, 3189, 9, 100, 339, 3044, 7197, 8145, 8145, 1257, 8145, 16, 100, 339, 1579, 7197, 262, 3, 33, 7379, 1053, 8196, 1, 3, 6205, 3522, 3527, 145, 262, 3, 33, 8196, 1, 3, 145, 9, 3527, 26, 8145, 8145, 1183, 10, 41, 5, 101, 43, 1, 5404, 107, 541, 773, 76, 79, 60, 28, 147, 658, 360, 197, 168, 18, 792, 48, 307, 268, 58, 14, 382, 33, 48, 19, 13, 3612, 2, 5, 3956, 107, 541, 749, 79, 60, 658, 168, 18, 79, 48, 58, 14, 175, 27, 921, 19, 13, 4773, 77, 93, 248, 10, 164, 59, 3527, 1183, 2, 3422, 315, 31, 7256, 3100, 7256, 3453, 15, 429, 43, 8, 186, 336, 1142, 16, 41, 5, 101, 43, 1, 5404, 107, 541, 773, 76, 79, 60, 28, 147, 2, 5, 3909, 107, 434, 541, 46, 272, 309, 17, 541, 2, 3101, 5, 3, 8145, 8145, 3527, 1183, 257, 40, 3210, 2909, 9, 3, 193, 1, 155, 190, 36, 9, 62, 2, 538, 8, 38, 160, 471, 3, 209, 1, 2864, 1151, 1225, 4, 26, 5017, 266]",1808.0,27957785,110
Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2016-10-31,"Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts. We evaluated the safety, pharmacokinetics, recommended dosage, and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (BCP-ALL). Methods This open-label study enrolled children < 18 years old with relapsed/refractory BCP-ALL in a phase I dosage-escalation part and a phase II part, using 6-week treatment cycles. Primary end points were maximum-tolerated dosage (phase I) and complete remission rate within the first two cycles (phase II). Results We treated 49 patients in phase I and 44 patients in phase II. Four patients had dose-limiting toxicities in cycle 1 (phase I). Three experienced grade 4 cytokine-release syndrome (one attributed to grade 5 cardiac failure); one had fatal respiratory failure. The maximum-tolerated dosage was 15 g/m<sup>2</sup>/d. Blinatumomab pharmacokinetics was linear across dosage levels and consistent among age groups. On the basis of the phase I data, the recommended blinatumomab dosage for children with relapsed/refractory ALL was 5 g/m<sup>2</sup>/d for the first 7 days, followed by 15 g/m<sup>2</sup>/d thereafter. Among the 70 patients who received the recommended dosage, 27 (39%; 95% CI, 27% to 51%) achieved complete remission within the first two cycles, 14 (52%) of whom achieved complete minimal residual disease response. The most frequent grade  3 adverse events were anemia (36%), thrombocytopenia (21%), and hypokalemia (17%). Three patients (4%) and one patient (1%) had cytokine-release syndrome of grade 3 and 4, respectively. Two patients (3%) interrupted treatment after grade 2 seizures. Conclusion This trial, which to the best of our knowledge was the first such trial in pediatrics, demonstrated antileukemic activity of single-agent blinatumomab with complete minimal residual disease response in children with relapsed/refractory BCP-ALL. Blinatumomab may represent an important new treatment option in this setting, requiring further investigation in curative indications.","Clinical Trial, Phase I",1177.0,153.0,Purpose Blinatumomab is a bispecific T-cell engager antibody construct targeting CD19 on B-cell lymphoblasts We evaluated the safety pharmacokinetics recommended dosage and potential for efficacy of blinatumomab in children with relapsed/refractory B-cell precursor acute lymphoblastic BCP-ALL Methods This open-label study enrolled children 18 years old with relapsed/refractory BCP-ALL in a phase I dosage-escalation part and a phase II part using 6-week treatment cycles Primary end points were maximum-tolerated dosage phase I and complete remission rate within the first two cycles phase II Results We treated 49 patients in phase I and 44 patients in phase II Four patients had dose-limiting toxicities in cycle 1 phase I Three experienced grade 4 cytokine-release syndrome one attributed to grade 5 failure one had fatal respiratory failure The maximum-tolerated dosage was 15 g/m sup 2 /sup /d Blinatumomab pharmacokinetics was linear across dosage levels and consistent among age groups On the basis of the phase I data the recommended blinatumomab dosage for children with relapsed/refractory ALL was 5 g/m sup 2 /sup /d for the first 7 days followed by 15 g/m sup 2 /sup /d thereafter Among the 70 patients who received the recommended dosage 27 39 95 CI 27 to 51 achieved complete remission within the first two cycles 14 52 of whom achieved complete minimal residual disease response The most frequent grade  3 adverse events were anemia 36 thrombocytopenia 21 and hypokalemia 17 Three patients 4 and one patient 1 had cytokine-release syndrome of grade 3 and 4 respectively Two patients 3 interrupted treatment after grade 2 seizures Conclusion This trial which to the best of our knowledge was the first such trial in pediatrics demonstrated antileukemic activity of single-agent blinatumomab with complete minimal residual disease response in children with relapsed/refractory BCP-ALL Blinatumomab may represent an important new treatment option in this setting requiring further investigation in curative indications,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[743, 7182, 16, 8, 7408, 102, 31, 19374, 548, 3883, 529, 3158, 23, 132, 31, 10521, 21, 194, 3, 367, 1159, 793, 3323, 2, 174, 9, 209, 1, 7182, 4, 541, 5, 591, 430, 132, 31, 2765, 286, 1275, 13168, 62, 636, 26, 1020, 1756, 45, 346, 541, 203, 60, 1095, 5, 591, 430, 13168, 62, 4, 8, 124, 70, 3323, 1125, 760, 2, 8, 124, 215, 760, 75, 49, 647, 24, 410, 86, 396, 862, 11, 689, 421, 3323, 124, 70, 2, 236, 734, 116, 262, 3, 157, 100, 410, 124, 215, 99, 21, 73, 739, 7, 4, 124, 70, 2, 584, 7, 4, 124, 215, 294, 7, 42, 61, 817, 385, 4, 417, 14, 124, 70, 169, 592, 88, 39, 1675, 2008, 681, 104, 3073, 6, 88, 33, 496, 104, 42, 3034, 2718, 496, 3, 689, 421, 3323, 10, 167, 7570, 188, 172, 18, 172, 427, 7182, 1159, 10, 1646, 716, 3323, 148, 2, 925, 107, 89, 271, 23, 3, 877, 1, 3, 124, 70, 74, 3, 793, 7182, 3323, 9, 541, 5, 591, 430, 62, 10, 33, 7570, 188, 172, 18, 172, 427, 9, 3, 157, 67, 162, 370, 20, 167, 7570, 188, 172, 18, 172, 427, 3972, 107, 3, 431, 7, 54, 103, 3, 793, 3323, 428, 587, 48, 58, 428, 6, 725, 513, 236, 734, 262, 3, 157, 100, 410, 213, 653, 1, 953, 513, 236, 1048, 753, 34, 51, 3, 96, 908, 88, 749, 27, 290, 281, 11, 1545, 511, 1340, 239, 2, 7799, 269, 169, 7, 39, 2, 104, 69, 14, 42, 1675, 2008, 681, 1, 88, 27, 2, 39, 106, 100, 7, 27, 12981, 24, 50, 88, 18, 4448, 1221, 26, 160, 92, 6, 3, 824, 1, 114, 922, 10, 3, 157, 225, 160, 4, 12616, 264, 4512, 128, 1, 226, 420, 7182, 5, 236, 1048, 753, 34, 51, 4, 541, 5, 591, 430, 13168, 62, 7182, 68, 1231, 35, 305, 217, 24, 1501, 4, 26, 546, 1888, 195, 940, 4, 1075, 2406]",2037.0,27998223,55
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor.,American journal of hematology,Am. J. Hematol.,2017-02-03,"In patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) treated with chemotherapy plus a tyrosine kinase inhibitor (TKI), the prognostic impact of additional chromosomal abnormalities (ACAs) is not well-established. We evaluated the prognostic impact of individual ACAs in 152 patients with Ph+ ALL receiving first-line intensive chemotherapy plus either imatinib (n = 36), dasatinib (n = 74), or ponatinib (n = 42). ACAs were identified in 118 patients (78%). Compared to outcomes of patients without ACAs, ACAs were not associated with differences in either relapse-free survival (RFS; P=0.42) or overall survival (OS; P=0.51). When individual ACAs were evaluated, +der(22)t(9;22) and/or -9/9p in the absence of high hyperdiploidy (HeH) was present in 16% of patients and constituted a poor-risk ACA group. Patients with one or more poor-risk ACAs in the absence of HeH had significantly shorter RFS (5-year RFS rate 33% versus 59%, P=0.01) and OS (5-year OS rate 24% versus 63%, P=0.003). Poor-risk ACAs were prognostic in patients who received imatinib and dasatinib but not in those who received ponatinib. By multivariate analysis, this poor-risk ACA group was independently associated with worse RFS (HR 2.03 [95% CI 1.08-3.30], P=0.03) and OS (HR 2.02 [95% CI 1.10-3.71], P=0.02). Patients with Ph+ ALL who have +der(22)t(9;22) and/or -9/9p in the absence of HeH have relatively poor outcomes when treated with chemotherapy plus a TKI.",Journal Article,1082.0,14.0,In patients with Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL treated with chemotherapy plus a tyrosine kinase inhibitor TKI the prognostic impact of additional chromosomal abnormalities ACAs is not well-established We evaluated the prognostic impact of individual ACAs in 152 patients with Ph+ ALL receiving first-line intensive chemotherapy plus either imatinib n 36 dasatinib n 74 or ponatinib n 42 ACAs were identified in 118 patients 78 Compared to outcomes of patients without ACAs ACAs were not associated with differences in either relapse-free survival RFS P 0.42 or overall survival OS P 0.51 When individual ACAs were evaluated +der 22 t 9 22 and/or -9/9p in the absence of high hyperdiploidy HeH was present in 16 of patients and constituted a poor-risk ACA group Patients with one or more poor-risk ACAs in the absence of HeH had significantly shorter RFS 5-year RFS rate 33 versus 59 P 0.01 and OS 5-year OS rate 24 versus 63 P 0.003 Poor-risk ACAs were prognostic in patients who received imatinib and dasatinib but not in those who received ponatinib By multivariate analysis this poor-risk ACA group was independently associated with worse RFS HR 2.03 95 CI 1.08-3.30 P 0.03 and OS HR 2.02 95 CI 1.10-3.71 P 0.02 Patients with Ph+ ALL who have +der 22 t 9 22 and/or -9/9p in the absence of HeH have relatively poor outcomes when treated with chemotherapy plus a TKI,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 7, 5, 3006, 1170, 109, 2058, 286, 1275, 62, 73, 5, 56, 349, 8, 564, 216, 230, 1379, 3, 177, 345, 1, 402, 1860, 1171, 12238, 16, 44, 149, 635, 21, 194, 3, 177, 345, 1, 797, 12238, 4, 5370, 7, 5, 2058, 62, 357, 157, 328, 1686, 56, 349, 361, 577, 78, 511, 1674, 78, 794, 15, 5715, 78, 595, 12238, 11, 108, 4, 4002, 7, 833, 72, 6, 123, 1, 7, 187, 12238, 12238, 11, 44, 41, 5, 362, 4, 361, 429, 115, 25, 1272, 19, 13, 595, 15, 63, 25, 118, 19, 13, 725, 198, 797, 12238, 11, 194, 13324, 350, 102, 83, 350, 2, 15, 83, 11234, 4, 3, 1127, 1, 64, 11299, 23621, 10, 364, 4, 245, 1, 7, 2, 8917, 8, 334, 43, 6285, 87, 7, 5, 104, 15, 80, 334, 43, 12238, 4, 3, 1127, 1, 23621, 42, 97, 985, 1272, 33, 111, 1272, 116, 466, 185, 728, 19, 13, 355, 2, 118, 33, 111, 118, 116, 259, 185, 676, 19, 13, 1421, 334, 43, 12238, 11, 177, 4, 7, 54, 103, 577, 2, 1674, 84, 44, 4, 135, 54, 103, 5715, 20, 331, 65, 26, 334, 43, 6285, 87, 10, 1042, 41, 5, 639, 1272, 168, 18, 680, 48, 58, 14, 1592, 27, 201, 19, 13, 680, 2, 118, 168, 18, 588, 48, 58, 14, 79, 27, 792, 19, 13, 588, 7, 5, 2058, 62, 54, 47, 13324, 350, 102, 83, 350, 2, 15, 83, 11234, 4, 3, 1127, 1, 23621, 47, 1352, 334, 123, 198, 73, 5, 56, 349, 8, 1379]",1398.0,28006851,595
Osteonecrosis is unrelated to hip anatomy in children with acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2016-12-30,"Osteonecrosis is a debilitating toxicity associated with acute lymphoblastic leukemia (ALL) treatment. A recent report associated interindividual differences in hip anatomy with the development of idiopathic osteonecrosis in adults. To evaluate the impact of hip anatomy on the development of therapy-related osteonecrosis, we retrospectively evaluated the femoral neck-shaft angle, femoral neck offset, and lateral center-edge angle using x-rays of 18 osteonecrosis cases and 46 control children treated for newly diagnosed ALL on a single protocol. Despite adequate statistical power, we found no association between hip anatomy and osteonecrosis. Investigation of other factors contributing to ALL-associated osteonecrosis is warranted.",Journal Article,1117.0,1.0,Osteonecrosis is a debilitating toxicity associated with acute lymphoblastic ALL treatment A recent report associated interindividual differences in hip anatomy with the development of idiopathic osteonecrosis in adults To evaluate the impact of hip anatomy on the development of therapy-related osteonecrosis we retrospectively evaluated the femoral neck-shaft angle femoral offset and lateral center-edge angle using x-rays of 18 osteonecrosis cases and 46 control children treated for newly diagnosed ALL on a single protocol Despite adequate statistical power we found no association between hip anatomy and osteonecrosis Investigation of other factors contributing to ALL-associated osteonecrosis is warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 16, 8, 8099, 155, 41, 5, 286, 1275, 62, 24, 8, 435, 414, 41, 7882, 362, 4, 5628, 5081, 5, 3, 193, 1, 7540, 5404, 4, 857, 6, 376, 3, 345, 1, 5628, 5081, 23, 3, 193, 1, 36, 139, 5404, 21, 894, 194, 3, 7649, 4606, 34670, 8939, 7649, 9500, 2, 3855, 574, 7951, 8939, 75, 1006, 8558, 1, 203, 5404, 140, 2, 641, 182, 541, 73, 9, 732, 265, 62, 23, 8, 226, 1182, 550, 1658, 1050, 2349, 21, 204, 77, 248, 59, 5628, 5081, 2, 5404, 940, 1, 127, 130, 3156, 6, 62, 41, 5404, 16, 1197]",714.0,28035753,334
Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-01-03,"We used next-generation sequencing (NGS) of the immunoglobulin genes to evaluate residual disease in 153 specimens from 32 patients with adult B cell acute lymphoblastic leukemia enrolled in a single multicenter study. The sequencing results were compared with multiparameter flow cytometry (MFC) data in 66 specimens (25 patients) analyzed by both methods. There was a strong concordance (82%) between the methods in the qualitative determination of the presence of disease. However, in 17% of cases, leukemia was detected by sequencing but not by MFC. In 54 bone marrow (BM) and peripheral blood (PB) paired specimens, the burden of leukemia detected by NGS was lower in PB than in BM, although it was still detectable in 68% of the 28 paired specimens with positive BM. Lastly, patients without disease detected by NGS or MFC had a 5-year relapse free survival of>80%. The results suggest that residual disease detection by immunoglobulin gene sequencing is an extremely sensitive technique and may identify patients that might benefit from transplantation. Moreover, the increased sensitivity of the method may allow frequent peripheral blood testing to supplement marrow sampling to measure disease response.","Clinical Trial, Phase II",1113.0,17.0,We used next-generation sequencing NGS of the immunoglobulin genes to evaluate residual disease in 153 specimens from 32 patients with adult B cell acute lymphoblastic enrolled in a single multicenter study The sequencing results were compared with multiparameter flow cytometry MFC data in 66 specimens 25 patients analyzed by both methods There was a strong concordance 82 between the methods in the qualitative determination of the presence of disease However in 17 of cases was detected by sequencing but not by MFC In 54 marrow BM and peripheral blood PB paired specimens the burden of detected by NGS was lower in PB than in BM although it was still detectable in 68 of the 28 paired specimens with positive BM Lastly patients without disease detected by NGS or MFC had a 5-year relapse free survival of 80 The results suggest that residual disease detection by immunoglobulin gene sequencing is an extremely sensitive technique and may identify patients that might benefit from transplantation Moreover the increased sensitivity of the method may allow frequent peripheral blood testing to supplement marrow sampling to measure disease response,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 95, 1305, 914, 615, 2650, 1, 3, 2593, 214, 6, 376, 753, 34, 4, 4251, 623, 29, 531, 7, 5, 780, 132, 31, 286, 1275, 346, 4, 8, 226, 1570, 45, 3, 615, 99, 11, 72, 5, 10757, 1412, 1914, 9439, 74, 4, 700, 623, 243, 7, 311, 20, 110, 636, 125, 10, 8, 1082, 1827, 878, 59, 3, 636, 4, 3, 3926, 3104, 1, 3, 463, 1, 34, 137, 4, 269, 1, 140, 10, 530, 20, 615, 84, 44, 20, 9439, 4, 667, 581, 1246, 2, 672, 315, 3767, 2355, 623, 3, 892, 1, 530, 20, 2650, 10, 280, 4, 3767, 76, 4, 1246, 242, 192, 10, 1234, 2083, 4, 806, 1, 3, 339, 2355, 623, 5, 109, 1246, 6354, 7, 187, 34, 530, 20, 2650, 15, 9439, 42, 8, 33, 111, 429, 115, 25, 1, 493, 3, 99, 309, 17, 753, 34, 638, 20, 2593, 145, 615, 16, 35, 2938, 745, 1312, 2, 68, 255, 7, 17, 822, 247, 29, 497, 1393, 3, 101, 485, 1, 3, 596, 68, 1700, 908, 672, 315, 471, 6, 5836, 581, 2874, 6, 1463, 34, 51]",1151.0,28062215,151
Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy.,Current opinion in hematology,Curr. Opin. Hematol.,2017-03-01,"Mixed-phenotype acute leukemia (MPAL) is a rare disease that poses many diagnostic and therapeutic challenges. Patients with MPAL are considered to have poor outcomes. The difficulties in classifying this leukemia, the lack of prospectively collected data concerning therapeutic outcomes, and rare incidence result in much uncertainty as to the best approach for patients with MPAL. Recent studies demonstrated that most MPALs are associated with cytogenetic abnormalities; genetic sequencing studies disclose a high frequency of somatic mutations in genes encoding epigenetic regulators, tumor suppressors, and transcription factors. The limited available data suggest that higher remission rates are achieved with acute lymphoblastic leukemia-like induction regimens compared with acute myeloid leukemia-type approaches. Allogeneic transplantation in first remission may be associated with improved survival compared with consolidation chemotherapy. Advances in understanding the genetic landscape of MPAL may allow a more biologically driven classification of this heterogeneous group of leukemias in the future that will lead to optimized therapies for individual patients. Most data that inform therapy are based on retrospective, uncontrolled studies; prospective trials that incorporate targeted approaches based on genetics and immunophenotype are needed.",Journal Article,1056.0,15.0,Mixed-phenotype acute MPAL is a rare disease that poses many diagnostic and therapeutic challenges Patients with MPAL are considered to have poor outcomes The difficulties in classifying this the lack of prospectively collected data concerning therapeutic outcomes and rare incidence result in much uncertainty as to the best approach for patients with MPAL Recent studies demonstrated that most MPALs are associated with cytogenetic abnormalities genetic sequencing studies disclose a high frequency of somatic mutations in genes encoding epigenetic regulators tumor suppressors and transcription factors The limited available data suggest that higher remission rates are achieved with acute lymphoblastic leukemia-like induction regimens compared with acute myeloid leukemia-type approaches Allogeneic transplantation in first remission may be associated with improved survival compared with consolidation chemotherapy Advances in understanding the genetic landscape of MPAL may allow a more biologically driven classification of this heterogeneous group of leukemias in the future that will lead to optimized therapies for individual patients Most data that inform therapy are based on retrospective uncontrolled studies prospective trials that incorporate targeted approaches based on genetics and immunophenotype are needed,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1739, 1005, 286, 9407, 16, 8, 622, 34, 17, 7056, 445, 752, 2, 189, 1427, 7, 5, 9407, 32, 515, 6, 47, 334, 123, 3, 4679, 4, 8681, 26, 3, 926, 1, 1143, 786, 74, 4243, 189, 123, 2, 622, 287, 757, 4, 1802, 4004, 22, 6, 3, 824, 353, 9, 7, 5, 9407, 435, 94, 264, 17, 96, 40969, 32, 41, 5, 1266, 1171, 336, 615, 94, 20165, 8, 64, 675, 1, 1119, 138, 4, 214, 2362, 1418, 3196, 30, 5704, 2, 866, 130, 3, 383, 390, 74, 309, 17, 142, 734, 151, 32, 513, 5, 286, 1275, 2647, 733, 504, 472, 72, 5, 286, 533, 2647, 267, 611, 1063, 497, 4, 157, 734, 68, 40, 41, 5, 231, 25, 72, 5, 2173, 56, 954, 4, 612, 3, 336, 2801, 1, 9407, 68, 1700, 8, 80, 2665, 1621, 947, 1, 26, 1564, 87, 1, 2792, 4, 3, 508, 17, 303, 1122, 6, 4039, 235, 9, 797, 7, 96, 74, 17, 2295, 36, 32, 90, 23, 459, 6180, 94, 482, 143, 17, 3360, 238, 611, 90, 23, 2894, 2, 5496, 32, 575]",1328.0,28099272,281
Neurocognitive outcomes among children who experienced seizures during treatment for acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2017-01-28,"Limited information is available regarding neurocognitive outcomes of children who experience seizures during treatment for acute lymphoblastic leukemia (ALL). Accordingly, the main objectives of this study were to determine the incidence and risk factors for treatment-related seizures among children with ALL, and the neurocognitive outcomes associated with treatment-related seizures. Prospective neuropsychological assessment and magnetic resonance imaging (MRI) were planned for all 498 patients with newly diagnosed ALL enrolled on the St. Jude Total Therapy XV (TOTXV) protocol at three time points. The study database was reviewed retrospectively to identify those with treatment-related seizure. To assess neurocognitive changes associated with seizure, each patient with treatment-related seizure was matched with two cohort patients without seizure for age at treatment, gender, race, and treatment intensity. Nineteen patients developed seizure, with a 2-year cumulative risk of 3.82  0.86% (SE). No risk factors were identified to be associated with the development of seizure, with a possible exception of intensive chemotherapy used on the standard/high-risk arm as compared to the low-risk arm. Neuropsychological performance of the seizure group, as compared to normative scores and nonseizure control cohort, indicated problems in attention, working memory, and processing speed. Cognitive deficits persisted 2 years after therapy, with additional declines in intellectual function observed. MRI indicated early neurotoxicity among the seizure group, as evidenced by greater leukoencephalopathy on initial examinations. Treatment-related seizures were associated with leukoencephalopathy and decreased neuropsychological performance. Prospective studies are needed to detect changes in neurocognitive status associated with long-term functional impairment.",Clinical Trial,1088.0,1.0,Limited information is available regarding neurocognitive outcomes of children who experience seizures during treatment for acute lymphoblastic ALL Accordingly the main objectives of this study were to determine the incidence and risk factors for treatment-related seizures among children with ALL and the neurocognitive outcomes associated with treatment-related seizures Prospective neuropsychological assessment and magnetic resonance imaging MRI were planned for all 498 patients with newly diagnosed ALL enrolled on the St. Jude Total Therapy XV TOTXV protocol at three time points The study database was reviewed retrospectively to identify those with treatment-related seizure To assess neurocognitive changes associated with seizure each patient with treatment-related seizure was matched with two cohort patients without seizure for age at treatment gender race and treatment intensity Nineteen patients developed seizure with a 2-year cumulative risk of 3.82  0.86 SE No risk factors were identified to be associated with the development of seizure with a possible exception of intensive chemotherapy used on the standard/high-risk arm as compared to the low-risk arm Neuropsychological performance of the seizure group as compared to normative scores and nonseizure control cohort indicated problems in attention working memory and processing speed Cognitive deficits persisted 2 years after therapy with additional declines in intellectual function observed MRI indicated early neurotoxicity among the seizure group as evidenced by greater leukoencephalopathy on initial examinations Treatment-related seizures were associated with leukoencephalopathy and decreased neuropsychological performance Prospective studies are needed to detect changes in neurocognitive status associated with long-term functional impairment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[383, 487, 16, 390, 666, 2958, 123, 1, 541, 54, 730, 4448, 190, 24, 9, 286, 1275, 62, 4705, 3, 1895, 2409, 1, 26, 45, 11, 6, 223, 3, 287, 2, 43, 130, 9, 24, 139, 4448, 107, 541, 5, 62, 2, 3, 2958, 123, 41, 5, 24, 139, 4448, 482, 8271, 455, 2, 1484, 1535, 270, 704, 11, 1465, 9, 62, 8928, 7, 5, 732, 265, 62, 346, 23, 3, 3062, 4841, 181, 36, 16078, 69740, 1182, 28, 169, 98, 862, 3, 45, 609, 10, 446, 894, 6, 255, 135, 5, 24, 139, 5866, 6, 423, 2958, 400, 41, 5, 5866, 296, 69, 5, 24, 139, 5866, 10, 655, 5, 100, 180, 7, 187, 5866, 9, 89, 28, 24, 1632, 1047, 2, 24, 837, 3498, 7, 276, 5866, 5, 8, 18, 111, 967, 43, 1, 27, 878, 810, 13, 868, 3428, 77, 43, 130, 11, 108, 6, 40, 41, 5, 3, 193, 1, 5866, 5, 8, 899, 4188, 1, 1686, 56, 95, 23, 3, 260, 64, 43, 475, 22, 72, 6, 3, 154, 43, 475, 8271, 528, 1, 3, 5866, 87, 22, 72, 6, 9658, 703, 2, 39266, 182, 180, 1103, 2408, 4, 2111, 2644, 2407, 2, 3325, 5051, 1863, 2752, 3760, 18, 60, 50, 36, 5, 402, 4264, 4, 12346, 343, 164, 704, 1103, 191, 3561, 107, 3, 5866, 87, 22, 4728, 20, 378, 8744, 23, 388, 4209, 24, 139, 4448, 11, 41, 5, 8744, 2, 340, 8271, 528, 482, 94, 32, 575, 6, 1426, 400, 4, 2958, 156, 41, 5, 319, 337, 583, 2315]",1831.0,28130818,89
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia.,Clinical cancer research : an official journal of the American Association for Cancer Research,Clin. Cancer Res.,2016-11-09,"<b>Purpose:</b> Although significant progress has been made in the treatment of T-cell acute lymphoblastic leukemia (T-ALL), many patients will require additional therapy for relapsed/refractory disease. Cyclin D3 (CCND3) and CDK6 are highly expressed in T-ALL and have been effectively targeted in mutant NOTCH1-driven mouse models of this disease with a CDK4/6 small-molecule inhibitor. Combination therapy, however, will be needed for the successful treatment of human disease.<b>Experimental Design:</b> We performed preclinical drug testing using a panel of T-ALL cell lines first with LEE011, a CDK4/6 inhibitor, and next with the combination of LEE011 with a panel of drugs relevant to T-ALL treatment. We then tested the combination of LEE011 with dexamethasone or everolimus in three orthotopic mouse models and measured on-target drug activity.<b>Results:</b> We first determined that both <i>NOTCH1</i>-mutant and wild-type T-ALL are highly sensitive to pharmacologic inhibition of CDK4/6 when wild-type RB is expressed. Next, we determined that CDK4/6 inhibitors are antagonistic when used either concurrently or in sequence with many of the drugs used to treat relapsed T-ALL (methotrexate, mercaptopurine, asparaginase, and doxorubicin) but are synergistic with glucocorticoids, an mTOR inhibitor, and gamma secretase inhibitor. The combinations of LEE011 with the glucocorticoid dexamethasone or the mTOR inhibitor everolimus were tested <i>in vivo</i> and prolonged survival in three orthotopic mouse models of T-ALL. On-target activity was measured in peripheral blood and tissue of treated mice.<b>Conclusions:</b> We conclude that LEE011 is active in T-ALL and that combination therapy with corticosteroids and/or mTOR inhibitors warrants further investigation. <i>Clin Cancer Res; 23(4); 1012-24. 2016 AACR</i><i>See related commentary by Carroll et al., p. 873</i>.",Journal Article,1168.0,28.0,b Purpose /b Although significant progress has been made in the treatment of T-cell acute lymphoblastic T-ALL many patients will require additional therapy for relapsed/refractory disease Cyclin D3 CCND3 and CDK6 are highly expressed in T-ALL and have been effectively targeted in mutant NOTCH1-driven mouse models of this disease with a CDK4/6 small-molecule inhibitor Combination therapy however will be needed for the successful treatment of human disease. b Experimental Design /b We performed preclinical drug testing using a panel of T-ALL cell lines first with LEE011 a CDK4/6 inhibitor and next with the combination of LEE011 with a panel of drugs relevant to T-ALL treatment We then tested the combination of LEE011 with dexamethasone or everolimus in three orthotopic mouse models and measured on-target drug activity. b Results /b We first determined that both i NOTCH1 /i -mutant and wild-type T-ALL are highly sensitive to pharmacologic inhibition of CDK4/6 when wild-type RB is expressed Next we determined that CDK4/6 inhibitors are antagonistic when used either concurrently or in sequence with many of the drugs used to treat relapsed T-ALL methotrexate mercaptopurine asparaginase and doxorubicin but are synergistic with glucocorticoids an mTOR inhibitor and gamma secretase inhibitor The combinations of LEE011 with the glucocorticoid dexamethasone or the mTOR inhibitor everolimus were tested i in vivo /i and prolonged survival in three orthotopic mouse models of T-ALL On-target activity was measured in peripheral blood and tissue of treated mice. b Conclusions /b We conclude that LEE011 is active in T-ALL and that combination therapy with corticosteroids and/or mTOR inhibitors warrants further investigation i Clin Cancer Res 23 4 1012-24 2016 AACR /i i See related commentary by Carroll et al. p. 873 /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[132, 743, 132, 242, 93, 1466, 71, 85, 1229, 4, 3, 24, 1, 102, 31, 286, 1275, 102, 62, 445, 7, 303, 1353, 402, 36, 9, 591, 430, 34, 1226, 6037, 25000, 2, 9518, 32, 561, 570, 4, 102, 62, 2, 47, 85, 1856, 238, 4, 620, 4607, 1621, 830, 274, 1, 26, 34, 5, 8, 3254, 49, 302, 1354, 230, 150, 36, 137, 303, 40, 575, 9, 3, 1401, 24, 1, 171, 34, 132, 1560, 771, 132, 21, 173, 693, 234, 471, 75, 8, 993, 1, 102, 62, 31, 285, 157, 5, 18081, 8, 3254, 49, 230, 2, 1305, 5, 3, 150, 1, 18081, 5, 8, 993, 1, 600, 867, 6, 102, 62, 24, 21, 818, 650, 3, 150, 1, 18081, 5, 1217, 15, 1400, 4, 169, 2157, 830, 274, 2, 644, 23, 283, 234, 128, 132, 99, 132, 21, 157, 509, 17, 110, 70, 4607, 70, 620, 2, 955, 267, 102, 62, 32, 561, 745, 6, 2788, 297, 1, 3254, 49, 198, 955, 267, 2955, 16, 570, 1305, 21, 509, 17, 3254, 49, 222, 32, 9863, 198, 95, 361, 3294, 15, 4, 1532, 5, 445, 1, 3, 600, 95, 6, 943, 591, 102, 62, 2116, 9223, 3709, 2, 856, 84, 32, 1806, 5, 7307, 35, 873, 230, 2, 1705, 10014, 230, 3, 1247, 1, 18081, 5, 3, 5399, 1217, 15, 3, 873, 230, 1400, 11, 650, 70, 4, 386, 70, 2, 1069, 25, 4, 169, 2157, 830, 274, 1, 102, 62, 23, 283, 128, 10, 644, 4, 672, 315, 2, 246, 1, 73, 399, 132, 2130, 132, 21, 2060, 17, 18081, 16, 544, 4, 102, 62, 2, 17, 150, 36, 5, 3876, 2, 15, 873, 222, 2782, 195, 940, 70, 2459, 12, 1936, 382, 39, 23213, 259, 3456, 1630, 70, 70, 3764, 139, 4662, 20, 37584, 2022, 2171, 19, 13388, 70]",1833.0,28151717,319
Synergistic antileukemic therapies in <i>NOTCH1</i>-induced T-ALL.,Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2017-02-07,"The <i>Notch1</i> gene is a major oncogenic driver and therapeutic target in T-cell acute lymphoblastic leukemia (T-ALL). However, inhibition of NOTCH signaling with -secretase inhibitors (GSIs) has shown limited antileukemic activity in clinical trials. Here we performed an expression-based virtual screening to identify highly active antileukemic drugs that synergize with NOTCH1 inhibition in T-ALL. Among these, withaferin A demonstrated the strongest cytotoxic and GSI-synergistic antileukemic effects in vitro and in vivo. Mechanistically, network perturbation analyses showed eIF2A-phosphorylation-mediated inhibition of protein translation as a critical mediator of the antileukemic effects of withaferin A and its interaction with NOTCH1 inhibition. Overall, these results support a role for anti-NOTCH1 therapies and protein translation inhibitor combinations in the treatment of T-ALL.",Journal Article,1078.0,12.0,The i Notch1 /i gene is a major oncogenic driver and therapeutic target in T-cell acute lymphoblastic T-ALL However inhibition of NOTCH signaling with -secretase inhibitors GSIs has shown limited antileukemic activity in clinical trials Here we performed an expression-based virtual screening to identify highly active antileukemic drugs that synergize with NOTCH1 inhibition in T-ALL Among these withaferin A demonstrated the strongest cytotoxic and GSI-synergistic antileukemic effects in vitro and in vivo Mechanistically network perturbation analyses showed eIF2A-phosphorylation-mediated inhibition of protein translation as a critical mediator of the antileukemic effects of withaferin A and its interaction with NOTCH1 inhibition Overall these results support a role for anti-NOTCH1 therapies and protein translation inhibitor combinations in the treatment of T-ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 70, 4607, 70, 145, 16, 8, 458, 1302, 2228, 2, 189, 283, 4, 102, 31, 286, 1275, 102, 62, 137, 297, 1, 3193, 314, 5, 2655, 10014, 222, 45400, 71, 443, 383, 4512, 128, 4, 38, 143, 467, 21, 173, 35, 55, 90, 8455, 453, 6, 255, 561, 544, 4512, 600, 17, 8717, 5, 4607, 297, 4, 102, 62, 107, 46, 21604, 8, 264, 3, 3311, 759, 2, 16937, 1806, 4512, 176, 4, 439, 2, 4, 386, 4187, 1801, 10564, 318, 224, 41443, 982, 517, 297, 1, 178, 2691, 22, 8, 740, 3810, 1, 3, 4512, 176, 1, 21604, 8, 2, 211, 915, 5, 4607, 297, 63, 46, 99, 538, 8, 200, 9, 312, 4607, 235, 2, 178, 2691, 230, 1247, 4, 3, 24, 1, 102, 62]",873.0,28174276,500
Adolescents and Young Adults with Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia: Impact of Care at Specialized Cancer Centers on Survival Outcome.,"Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology",Cancer Epidemiol. Biomarkers Prev.,2017-02-16,"<b>Background:</b> Adolescents and young adults (AYA; 15-39 years) with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) experience inferior survival when compared with children. Impact of care at NCI-designated Comprehensive Cancer Centers (CCC) or Children's Oncology Group sites (COG) on survival disparities remains unstudied.<b>Methods:</b> Using the Los Angeles cancer registry, we identified 1,870 ALL or AML patients between 1 and 39 years at diagnosis. Cox regression analyses assessed risk of mortality; younger age + CCC/COG served as the referent group. Logistic regression was used to determine odds of care at CCC/COG, adjusting for variables above.<b>Results:</b> ALL outcome: AYAs at non-CCC/COG experienced inferior survival (15-21 years: HR = 1.9, <i>P</i> = 0.005; 22-29 years: HR = 2.6, <i>P</i> < 0.001; 30-39 years: HR = 3.0, <i>P</i> < 0.001). Outcome at CCC/COG was comparable between children and young AYAs (15-21 years: HR = 1.3, <i>P</i> = 0.3; 22-29 years: HR = 1.2, <i>P</i> = 0.2) but was inferior for 30- to 39-year-olds (HR = 3.4, <i>P</i> < 0.001). AML outcome: AYAs at non-CCC/COG experienced inferior outcome (15-21 years: HR = 1.8, <i>P</i> = 0.02; 22-39 years: HR = 1.4, <i>P</i> = 0.06). Outcome at CCC/COG was comparable between children and 15- to 21-year-olds (HR = 1.3, <i>P</i> = 0.4) but was inferior for 22- to 39-year-olds (HR = 1.7, <i>P</i> = 0.05). Access: 15- to 21-year-olds were less likely to use CCC/COG than children (<i>P</i> < 0.001). In 22- to 39-year-olds, public/uninsured (ALL: <i>P</i> = 0.004; AML<0.001), African American/Hispanics (ALL: <i>P</i> = 0.03), and 30- to 39-year-olds (ALL: <i>P</i> = 0.03) were less likely to use CCC/COG.<b>Conclusions:</b> Poor survival in AYAs with ALL and AML is mitigated by care at CCC/COG. Barriers to CCC/COG care include public/uninsured, and African American/Hispanic race/ethnicity.<b>Impact:</b> Care at CCC/COG explains, in part, inferior outcomes in AYAs with ALL and AML. Key sociodemographic factors serve as barriers to care at specialized centers. <i>Cancer Epidemiol Biomarkers Prev; 26(3); 312-20. 2017 AACR</i>.",Journal Article,1069.0,19.0,"b Background /b Adolescents and young adults AYA 15-39 years with acute lymphoblastic ALL and acute myeloid AML experience inferior survival when compared with children Impact of care at NCI-designated Comprehensive Cancer Centers CCC or Children 's Oncology Group sites COG on survival disparities remains unstudied. b Methods /b Using the Los Angeles cancer registry we identified 1,870 ALL or AML patients between 1 and 39 years at diagnosis Cox regression analyses assessed risk of mortality younger age CCC/COG served as the referent group Logistic regression was used to determine odds of care at CCC/COG adjusting for variables above. b Results /b ALL outcome AYAs at non-CCC/COG experienced inferior survival 15-21 years HR 1.9 i P /i 0.005 22-29 years HR 2.6 i P /i 0.001 30-39 years HR 3.0 i P /i 0.001 Outcome at CCC/COG was comparable between children and young AYAs 15-21 years HR 1.3 i P /i 0.3 22-29 years HR 1.2 i P /i 0.2 but was inferior for 30- to 39-year-olds HR 3.4 i P /i 0.001 AML outcome AYAs at non-CCC/COG experienced inferior outcome 15-21 years HR 1.8 i P /i 0.02 22-39 years HR 1.4 i P /i 0.06 Outcome at CCC/COG was comparable between children and 15- to 21-year-olds HR 1.3 i P /i 0.4 but was inferior for 22- to 39-year-olds HR 1.7 i P /i 0.05 Access 15- to 21-year-olds were less likely to use CCC/COG than children i P /i 0.001 In 22- to 39-year-olds public/uninsured ALL i P /i 0.004 AML 0.001 African American/Hispanics ALL i P /i 0.03 and 30- to 39-year-olds ALL i P /i 0.03 were less likely to use CCC/COG. b Conclusions /b Poor survival in AYAs with ALL and AML is mitigated by care at CCC/COG Barriers to CCC/COG care include public/uninsured and African American/Hispanic race/ethnicity. b Impact /b Care at CCC/COG explains in part inferior outcomes in AYAs with ALL and AML Key sociodemographic factors serve as barriers to care at specialized centers i Cancer Epidemiol Biomarkers Prev 26 3 312-20 2017 AACR /i",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[132, 2426, 132, 3101, 2, 1169, 857, 4598, 167, 587, 60, 5, 286, 1275, 62, 2, 286, 533, 329, 730, 1663, 25, 198, 72, 5, 541, 345, 1, 165, 28, 2580, 4107, 949, 12, 1168, 5730, 15, 541, 292, 413, 87, 633, 6377, 23, 25, 2227, 469, 20848, 132, 636, 132, 75, 3, 3649, 6694, 12, 1608, 21, 108, 14, 11939, 62, 15, 329, 7, 59, 14, 2, 587, 60, 28, 147, 418, 320, 318, 275, 43, 1, 282, 773, 89, 5730, 6377, 5275, 22, 3, 9881, 87, 812, 320, 10, 95, 6, 223, 610, 1, 165, 28, 5730, 6377, 1358, 9, 682, 2090, 132, 99, 132, 62, 228, 6145, 28, 220, 5730, 6377, 592, 1663, 25, 167, 239, 60, 168, 14, 83, 70, 19, 70, 13, 1614, 350, 462, 60, 168, 18, 49, 70, 19, 70, 13, 144, 201, 587, 60, 168, 27, 13, 70, 19, 70, 13, 144, 228, 28, 5730, 6377, 10, 1279, 59, 541, 2, 1169, 6145, 167, 239, 60, 168, 14, 27, 70, 19, 70, 13, 27, 350, 462, 60, 168, 14, 18, 70, 19, 70, 13, 18, 84, 10, 1663, 9, 201, 6, 587, 111, 12801, 168, 27, 39, 70, 19, 70, 13, 144, 329, 228, 6145, 28, 220, 5730, 6377, 592, 1663, 228, 167, 239, 60, 168, 14, 66, 70, 19, 70, 13, 588, 350, 587, 60, 168, 14, 39, 70, 19, 70, 13, 1460, 228, 28, 5730, 6377, 10, 1279, 59, 541, 2, 167, 6, 239, 111, 12801, 168, 14, 27, 70, 19, 70, 13, 39, 84, 10, 1663, 9, 350, 6, 587, 111, 12801, 168, 14, 67, 70, 19, 70, 13, 474, 1655, 167, 6, 239, 111, 12801, 11, 299, 322, 6, 119, 5730, 6377, 76, 541, 70, 19, 70, 13, 144, 4, 350, 6, 587, 111, 12801, 3067, 4955, 62, 70, 19, 70, 13, 1520, 329, 13, 144, 1410, 597, 3850, 62, 70, 19, 70, 13, 680, 2, 201, 6, 587, 111, 12801, 62, 70, 19, 70, 13, 680, 11, 299, 322, 6, 119, 5730, 6377, 132, 2130, 132, 334, 25, 4, 6145, 5, 62, 2, 329, 16, 10042, 20, 165, 28, 5730, 6377, 2160, 6, 5730, 6377, 165, 643, 3067, 4955, 2, 1410, 597, 1776, 1047, 2091, 132, 345, 132, 165, 28, 5730, 6377, 10558, 4, 760, 1663, 123, 4, 6145, 5, 62, 2, 329, 825, 4221, 130, 1833, 22, 2160, 6, 165, 28, 4791, 1168, 70, 12, 9813, 582, 7902, 432, 27, 8187, 179, 3194, 1630, 70]",1955.0,28209594,601
"Temporal Trends in Treatment and Subsequent Neoplasm Risk Among 5-Year Survivors of Childhood Cancer, 1970-2015.",JAMA,JAMA,2017-02-01,"Cancer treatments are associated with subsequent neoplasms in survivors of childhood cancer. It is unknown whether temporal changes in therapy are associated with changes in subsequent neoplasm risk. To quantify the association between temporal changes in treatment dosing and subsequent neoplasm risk. Retrospective, multicenter cohort study of 5-year cancer survivors diagnosed before age 21 years from pediatric tertiary hospitals in the United States and Canada between 1970-1999, with follow-up through December 2015. Radiation and chemotherapy dose changes over time. Subsequent neoplasm 15-year cumulative incidence, cumulative burden, and standardized incidence ratios for subsequent malignancies, compared by treatment decade. Multivariable models assessed relative rates (RRs) of subsequent neoplasms by 5-year increments, adjusting for demographic and clinical characteristics. Mediation analyses assessed whether changes in rates of subsequent neoplasms over time were mediated by treatment variable modifications. Among 23603 survivors of childhood cancer (mean age at diagnosis, 7.7 years; 46% female) the most common initial diagnoses were acute lymphoblastic leukemia, Hodgkin lymphoma, and astrocytoma. During a mean follow-up of 20.5 years (374638 person-years at risk), 1639 survivors experienced 3115 subsequent neoplasms, including 1026 malignancies, 233 benign meningiomas, and 1856 nonmelanoma skin cancers. The most common subsequent malignancies were breast and thyroid cancers. Proportions of individuals receiving radiation decreased (77% for 1970s vs 33% for 1990s), as did median dose (30 Gy [interquartile range, 24-44] for 1970s vs 26 Gy [interquartile range, 18-45] for 1990s). Fifteen-year cumulative incidence of subsequent malignancies decreased by decade of diagnosis (2.1% [95% CI, 1.7%-2.4%] for 1970s, 1.7% [95% CI, 1.5%-2.0%] for 1980s, 1.3% [95% CI, 1.1%-1.5%] for 1990s). Reference absolute rates per 1000 person-years were 1.12 (95% CI, 0.84-1.57) for subsequent malignancies, 0.16 (95% CI, 0.06-0.41) for meningiomas, and 1.71 (95% CI, 0.88-3.33) for nonmelanoma skin cancers for survivors with reference characteristics (no chemotherapy, splenectomy, or radiation therapy; male; attained age 28 years). Standardized incidence ratios declined for subsequent malignancies over treatment decades, with advancing attained age. Relative rates declined with each 5-year increment for subsequent malignancies (RR, 0.87 [95% CI, 0.82-0.93]; P<.001), meningiomas (RR, 0.85 [95% CI, 0.75-0.97]; P=.03), and nonmelanoma skin cancers (RR, 0.75 [95% CI, 0.67-0.84]; P<.001). Radiation dose changes were associated with reduced risk for subsequent malignancies, meningiomas, and nonmelanoma skin cancers. Among survivors of childhood cancer, the risk of subsequent malignancies at 15 years after initial cancer diagnosis remained increased for those diagnosed in the 1990s, although the risk was lower compared with those diagnosed in the 1970s. This lower risk was associated with reduction in therapeutic radiation dose.",Journal Article,1084.0,66.0,Cancer treatments are associated with subsequent neoplasms in survivors of childhood cancer It is unknown whether temporal changes in therapy are associated with changes in subsequent neoplasm risk To quantify the association between temporal changes in treatment dosing and subsequent neoplasm risk Retrospective multicenter cohort study of 5-year cancer survivors diagnosed before age 21 years from pediatric tertiary hospitals in the United States and Canada between 1970-1999 with follow-up through December 2015 Radiation and chemotherapy dose changes over time Subsequent neoplasm 15-year cumulative incidence cumulative burden and standardized incidence ratios for subsequent malignancies compared by treatment decade Multivariable models assessed relative rates RRs of subsequent neoplasms by 5-year increments adjusting for demographic and clinical characteristics Mediation analyses assessed whether changes in rates of subsequent neoplasms over time were mediated by treatment variable modifications Among 23 603 survivors of childhood cancer mean age at diagnosis 7.7 years 46 female the most common initial diagnoses were acute lymphoblastic and astrocytoma During a mean follow-up of 20.5 years 374 638 person-years at risk 1639 survivors experienced 3115 subsequent neoplasms including 1026 malignancies 233 benign meningiomas and 1856 nonmelanoma cancers The most common subsequent malignancies were and cancers Proportions of individuals receiving radiation decreased 77 for 1970s vs 33 for 1990s as did median dose 30 Gy interquartile range 24-44 for 1970s vs 26 Gy interquartile range 18-45 for 1990s Fifteen-year cumulative incidence of subsequent malignancies decreased by decade of diagnosis 2.1 95 CI 1.7 -2.4 for 1970s 1.7 95 CI 1.5 -2.0 for 1980s 1.3 95 CI 1.1 -1.5 for 1990s Reference absolute rates per 1000 person-years were 1.12 95 CI 0.84-1.57 for subsequent malignancies 0.16 95 CI 0.06-0.41 for meningiomas and 1.71 95 CI 0.88-3.33 for nonmelanoma cancers for survivors with reference characteristics no chemotherapy splenectomy or radiation therapy male attained age 28 years Standardized incidence ratios declined for subsequent malignancies over treatment decades with advancing attained age Relative rates declined with each 5-year increment for subsequent malignancies RR 0.87 95 CI 0.82-0.93 P .001 meningiomas RR 0.85 95 CI 0.75-0.97 P .03 and nonmelanoma cancers RR 0.75 95 CI 0.67-0.84 P .001 Radiation dose changes were associated with reduced risk for subsequent malignancies meningiomas and nonmelanoma cancers Among survivors of childhood cancer the risk of subsequent malignancies at 15 years after initial cancer diagnosis remained increased for those diagnosed in the 1990s although the risk was lower compared with those diagnosed in the 1970s This lower risk was associated with reduction in therapeutic radiation dose,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,1,0,"[12, 640, 32, 41, 5, 706, 1179, 4, 332, 1, 864, 12, 192, 16, 860, 317, 3264, 400, 4, 36, 32, 41, 5, 400, 4, 706, 2131, 43, 6, 3091, 3, 248, 59, 3264, 400, 4, 24, 1280, 2, 706, 2131, 43, 459, 1570, 180, 45, 1, 33, 111, 12, 332, 265, 348, 89, 239, 60, 29, 815, 2557, 1987, 4, 3, 1088, 907, 2, 4740, 59, 4868, 2043, 5, 166, 126, 298, 1397, 1483, 121, 2, 56, 61, 400, 252, 98, 706, 2131, 167, 111, 967, 287, 967, 892, 2, 1670, 287, 1137, 9, 706, 441, 72, 20, 24, 2025, 658, 274, 275, 580, 151, 4739, 1, 706, 1179, 20, 33, 111, 8225, 1358, 9, 1540, 2, 38, 374, 13484, 318, 275, 317, 400, 4, 151, 1, 706, 1179, 252, 98, 11, 517, 20, 24, 1347, 2916, 107, 382, 9696, 332, 1, 864, 12, 313, 89, 28, 147, 67, 67, 60, 641, 1061, 3, 96, 186, 388, 2403, 11, 286, 1275, 2, 3822, 190, 8, 313, 166, 126, 1, 179, 33, 60, 10349, 11864, 2719, 60, 28, 43, 46769, 332, 592, 69965, 706, 1179, 141, 35197, 441, 7005, 1002, 3718, 2, 45144, 7814, 163, 3, 96, 186, 706, 441, 11, 2, 163, 4117, 1, 869, 357, 121, 340, 849, 9, 10868, 105, 466, 9, 7524, 22, 205, 52, 61, 201, 381, 2899, 184, 259, 584, 9, 10868, 105, 432, 381, 2899, 184, 203, 512, 9, 7524, 3057, 111, 967, 287, 1, 706, 441, 340, 20, 2025, 1, 147, 18, 14, 48, 58, 14, 67, 18, 39, 9, 10868, 14, 67, 48, 58, 14, 33, 18, 13, 9, 8361, 14, 27, 48, 58, 14, 14, 14, 33, 9, 7524, 2482, 1766, 151, 379, 2345, 2719, 60, 11, 14, 133, 48, 58, 13, 874, 14, 696, 9, 706, 441, 13, 245, 48, 58, 13, 1460, 13, 605, 9, 3718, 2, 14, 792, 48, 58, 13, 889, 27, 466, 9, 7814, 163, 9, 332, 5, 2482, 374, 77, 56, 6569, 15, 121, 36, 1045, 5105, 89, 339, 60, 1670, 287, 1137, 3054, 9, 706, 441, 252, 24, 1968, 5, 5155, 5105, 89, 580, 151, 3054, 5, 296, 33, 111, 9705, 9, 706, 441, 861, 13, 912, 48, 58, 13, 878, 13, 966, 19, 144, 3718, 861, 13, 772, 48, 58, 13, 481, 13, 1015, 19, 680, 2, 7814, 163, 861, 13, 481, 48, 58, 13, 598, 13, 874, 19, 144, 121, 61, 400, 11, 41, 5, 405, 43, 9, 706, 441, 3718, 2, 7814, 163, 107, 332, 1, 864, 12, 3, 43, 1, 706, 441, 28, 167, 60, 50, 388, 12, 147, 958, 101, 9, 135, 265, 4, 3, 7524, 242, 3, 43, 10, 280, 72, 5, 135, 265, 4, 3, 10868, 26, 280, 43, 10, 41, 5, 628, 4, 189, 121, 61]",2868.0,28245323,505
Improved survival after acute graft-<i>versus</i>-host disease diagnosis in the modern era.,Haematologica,Haematologica,2017-03-16,"A cute graft-<i>versus</i>-host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation. While improvements in treatment and supportive care have occurred, it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft-<i>versus</i>-host disease. We examined outcome following diagnosis of grade II-IV acute graft-<i>versus</i>-host disease according to time period, and explored effects according to original graft-<i>versus</i>-host disease prophylaxis regimen and maximum overall grade of acute graft-<i>versus</i>-host disease. Between 1999 and 2012, 2,905 patients with acute myeloid leukemia (56%), acute lymphoblastic leukemia (30%) or myelodysplastic syndromes (14%) received a sibling (24%) or unrelated donor (76%) blood (66%) or marrow (34%) transplant and developed grade II-IV acute graft-<i>versus</i>-host disease (n=497 for 1999-2001, n=962 for 2002-2005, n=1,446 for 2006-2010). The median (range) follow-up was 144 (4-174), 97 (4-147) and 60 (8-99) months for 1999-2001, 2002-2005, and 2006-2010, respectively. Among the cohort with grade II-IV acute graft-<i>versus</i>-host disease, there was a decrease in the proportion of grade III-IV disease over time with 56%, 47%, and 37% for 1999-2001, 2002-2005, and 2006-2012, respectively (<i>P</i><0.001). Considering the total study population, univariate analysis demonstrated significant improvements in overall survival and treatment-related mortality over time, and deaths from organ failure and infection declined. On multivariate analysis, significant improvements in overall survival (<i>P</i>=0.003) and treatment-related mortality (<i>P</i>=0.008) were only noted among those originally treated with tacrolimus-based graft-<i>versus</i>-host disease prophylaxis, and these effects were most apparent among those with overall grade II acute graft-<i>versus</i>-host disease. In conclusion, survival has improved over time for tacrolimus-treated transplant recipients with acute graft-<i>versus</i>-host disease.",Journal Article,1041.0,15.0,"A cute graft- i versus /i -host disease remains a major threat to a successful outcome after allogeneic hematopoietic cell transplantation While improvements in treatment and supportive care have occurred it is unknown whether these advances have resulted in improved outcome specifically among those diagnosed with acute graft- i versus /i -host disease We examined outcome following diagnosis of grade II-IV acute graft- i versus /i -host disease according to time period and explored effects according to original graft- i versus /i -host disease prophylaxis regimen and maximum overall grade of acute graft- i versus /i -host disease Between 1999 and 2012 2,905 patients with acute myeloid 56 acute lymphoblastic 30 or syndromes 14 received a sibling 24 or unrelated donor 76 blood 66 or marrow 34 transplant and developed grade II-IV acute graft- i versus /i -host disease n=497 for 1999-2001 n=962 for 2002-2005 n=1,446 for 2006-2010 The median range follow-up was 144 4-174 97 4-147 and 60 8-99 months for 1999-2001 2002-2005 and 2006-2010 respectively Among the cohort with grade II-IV acute graft- i versus /i -host disease there was a decrease in the proportion of grade III-IV disease over time with 56 47 and 37 for 1999-2001 2002-2005 and 2006-2012 respectively i P /i 0.001 Considering the total study population univariate analysis demonstrated significant improvements in overall survival and treatment-related mortality over time and deaths from organ failure and infection declined On multivariate analysis significant improvements in overall survival i P /i =0.003 and treatment-related mortality i P /i =0.008 were only noted among those originally treated with tacrolimus-based graft- i versus /i -host disease prophylaxis and these effects were most apparent among those with overall grade II acute graft- i versus /i -host disease In conclusion survival has improved over time for tacrolimus-treated transplant recipients with acute graft- i versus /i -host disease",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 70060, 1599, 70, 185, 70, 1204, 34, 469, 8, 458, 10965, 6, 8, 1401, 228, 50, 1063, 1007, 31, 497, 369, 1474, 4, 24, 2, 1877, 165, 47, 489, 192, 16, 860, 317, 46, 954, 47, 627, 4, 231, 228, 1225, 107, 135, 265, 5, 286, 1599, 70, 185, 70, 1204, 34, 21, 409, 228, 366, 147, 1, 88, 215, 478, 286, 1599, 70, 185, 70, 1204, 34, 768, 6, 98, 727, 2, 1443, 176, 768, 6, 2279, 1599, 70, 185, 70, 1204, 34, 2049, 477, 2, 689, 63, 88, 1, 286, 1599, 70, 185, 70, 1204, 34, 59, 2043, 2, 1195, 18, 13300, 7, 5, 286, 533, 664, 286, 1275, 201, 15, 2040, 213, 103, 8, 3684, 259, 15, 2092, 1488, 846, 315, 700, 15, 581, 562, 941, 2, 276, 88, 215, 478, 286, 1599, 70, 185, 70, 1204, 34, 78, 11178, 9, 2043, 1758, 78, 18823, 9, 1544, 1242, 78, 14, 9849, 9, 1324, 1120, 3, 52, 184, 166, 126, 10, 4415, 39, 5811, 1015, 39, 4961, 2, 335, 66, 1058, 53, 9, 2043, 1758, 1544, 1242, 2, 1324, 1120, 106, 107, 3, 180, 5, 88, 215, 478, 286, 1599, 70, 185, 70, 1204, 34, 125, 10, 8, 775, 4, 3, 920, 1, 88, 316, 478, 34, 252, 98, 5, 664, 662, 2, 567, 9, 2043, 1758, 1544, 1242, 2, 1324, 1195, 106, 70, 19, 70, 13, 144, 3075, 3, 181, 45, 266, 880, 65, 264, 93, 1474, 4, 63, 25, 2, 24, 139, 282, 252, 98, 2, 1043, 29, 1259, 496, 2, 930, 3054, 23, 331, 65, 93, 1474, 4, 63, 25, 70, 19, 70, 13, 1421, 2, 24, 139, 282, 70, 19, 70, 13, 2155, 11, 158, 1051, 107, 135, 5045, 73, 5, 5643, 90, 1599, 70, 185, 70, 1204, 34, 2049, 2, 46, 176, 11, 96, 2235, 107, 135, 5, 63, 88, 215, 286, 1599, 70, 185, 70, 1204, 34, 4, 1221, 25, 71, 231, 252, 98, 9, 5643, 73, 941, 2190, 5, 286, 1599, 70, 185, 70, 1204, 34]",1988.0,28302712,21
Pharmacogenetic Predictors of Treatment-Related Toxicity Among Children With Acute Lymphoblastic Leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2017-06-01,"The aim of this review is to summarize the most recent and most robust pharmacogenetic predictors of treatment-related toxicity (TRT) in childhood acute lymphoblastic leukemia (ALL). Multiple studies have examined the toxicities of the primary chemotherapeutic agents used to treat childhood ALL in relation to host genetic factors. However, few results have been replicated independently, largely due to cohort differences in ancestry, chemotherapy treatment protocols, and definitions of toxicities. To date, there is only one widely accepted clinical guideline for dose modification based on gene status: thiopurine dosing based on TPMT genotype. Based on recent data, it is likely that this guideline will be modified to incorporate other gene variants, such as NUDT15. We highlight genetic variants that have been consistently associated with TRT across treatment groups, as well as those that best illustrate the underlying pathophysiology of TRT. In the coming decade, we expect that survivorship care will routinely specify screening recommendations based on genetics. Furthermore, clinical trials testing protective interventions may modify inclusion criteria based on genetically determined risk of specific TRTs.",Journal Article,964.0,7.0,The aim of this review is to summarize the most recent and most robust pharmacogenetic predictors of treatment-related toxicity TRT in childhood acute lymphoblastic ALL Multiple studies have examined the toxicities of the primary chemotherapeutic agents used to treat childhood ALL in relation to host genetic factors However few results have been replicated independently largely due to cohort differences in ancestry chemotherapy treatment protocols and definitions of toxicities To date there is only one widely accepted clinical guideline for dose modification based on gene status thiopurine dosing based on TPMT genotype Based on recent data it is likely that this guideline will be modified to incorporate other gene variants such as NUDT15 We highlight genetic variants that have been consistently associated with TRT across treatment groups as well as those that best illustrate the underlying pathophysiology of TRT In the coming decade we expect that survivorship care will routinely specify screening recommendations based on genetics Furthermore clinical trials testing protective interventions may modify inclusion criteria based on genetically determined risk of specific TRTs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 1130, 1, 26, 206, 16, 6, 2479, 3, 96, 435, 2, 96, 1922, 6578, 674, 1, 24, 139, 155, 7778, 4, 864, 286, 1275, 62, 232, 94, 47, 409, 3, 385, 1, 3, 86, 1573, 183, 95, 6, 943, 864, 62, 4, 2191, 6, 1204, 336, 130, 137, 1021, 99, 47, 85, 6714, 1042, 1733, 520, 6, 180, 362, 4, 3535, 56, 24, 2189, 2, 3833, 1, 385, 6, 1244, 125, 16, 158, 104, 1792, 3058, 38, 2009, 9, 61, 2437, 90, 23, 145, 156, 14062, 1280, 90, 23, 14852, 1183, 90, 23, 435, 74, 192, 16, 322, 17, 26, 2009, 303, 40, 1230, 6, 3360, 127, 145, 839, 225, 22, 18089, 21, 1817, 336, 839, 17, 47, 85, 2433, 41, 5, 7778, 716, 24, 271, 22, 149, 22, 135, 17, 824, 4746, 3, 1181, 4320, 1, 7778, 4, 3, 10671, 2025, 21, 8439, 17, 2560, 165, 303, 3066, 16038, 453, 883, 90, 23, 2894, 798, 38, 143, 471, 2864, 1151, 68, 4289, 1680, 371, 90, 23, 2301, 509, 43, 1, 112, 70069]",1191.0,28317081,330
Acute lymphoblastic leukemia in adolescents and young adults.,Cancer,Cancer,2017-03-22,"Acute lymphoblastic leukemia (ALL) in the adolescent and young adult (AYA) population is a difficult clinical problem. The AYA population, generally regarded as patients aged 15 to 39 years, currently draws a good deal of attention, particularly in the area of therapy selection. The current trend is to treat this group of patients with leukemia regimens based on pediatric protocols, and results comparing pediatric approaches versus adult approaches to treatment are maturing. Results are pending from a large US trial in which pediatric-based treatment is given to AYA patients with ALL. In tandem with these new clinical trials, researchers have reported disease features in the AYA group that may explain some of the differences in response to treatment observed in the AYA population compared with the pediatric population. In addition, unique social factors in this age group add to the complexity of ALL therapy in the AYA population. AYA patients are developing independence and separating from their parents. They tend to be noncompliant. Young adults suffer from a lack of health care insurance and poor access to clinical trials, and have specific concerns regarding toxicities, in particular fertility. Cancer 2017;123:2398-403.  2017 American Cancer Society.",Journal Article,1035.0,11.0,Acute lymphoblastic ALL in the adolescent and young adult AYA population is a difficult clinical problem The AYA population generally regarded as patients aged 15 to 39 years currently draws a good deal of attention particularly in the area of therapy selection The current trend is to treat this group of patients with regimens based on pediatric protocols and results comparing pediatric approaches versus adult approaches to treatment are maturing Results are pending from a large US trial in which pediatric-based treatment is given to AYA patients with ALL In tandem with these new clinical trials researchers have reported disease features in the AYA group that may explain some of the differences in response to treatment observed in the AYA population compared with the pediatric population In addition unique social factors in this age group add to the complexity of ALL therapy in the AYA population AYA patients are developing independence and separating from their parents They tend to be noncompliant Young adults suffer from a lack of health care insurance and poor access to clinical trials and have specific concerns regarding toxicities in particular fertility Cancer 2017 123:2398-403  2017 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 4, 3, 3678, 2, 1169, 780, 4598, 266, 16, 8, 1740, 38, 2497, 3, 4598, 266, 1228, 7217, 22, 7, 1032, 167, 6, 587, 60, 694, 16359, 8, 1178, 9081, 1, 2111, 823, 4, 3, 965, 1, 36, 881, 3, 291, 853, 16, 6, 943, 26, 87, 1, 7, 5, 472, 90, 23, 815, 2189, 2, 99, 1430, 815, 611, 185, 780, 611, 6, 24, 32, 17724, 99, 32, 9453, 29, 8, 375, 843, 160, 4, 92, 815, 90, 24, 16, 447, 6, 4598, 7, 5, 62, 4, 2905, 5, 46, 217, 38, 143, 4211, 47, 210, 34, 404, 4, 3, 4598, 87, 17, 68, 2943, 476, 1, 3, 362, 4, 51, 6, 24, 164, 4, 3, 4598, 266, 72, 5, 3, 815, 266, 4, 352, 991, 2032, 130, 4, 26, 89, 87, 4178, 6, 3, 3082, 1, 62, 36, 4, 3, 4598, 266, 4598, 7, 32, 931, 5773, 2, 13366, 29, 136, 2418, 491, 5406, 6, 40, 24642, 1169, 857, 6506, 29, 8, 926, 1, 341, 165, 1935, 2, 334, 1655, 6, 38, 143, 2, 47, 112, 2061, 666, 385, 4, 1454, 2954, 12, 1759, 2698, 49747, 10836, 2206, 1759, 597, 12, 1174]",1233.0,28328172,146
CRLF2-Positive B-Cell Acute Lymphoblastic Leukemia in Adult Patients: A Single-Institution Experience.,American journal of clinical pathology,Am. J. Clin. Pathol.,2017-04-01,"Cytokine receptor-like factor 2 ( CRLF2 ) rearrangement is found in approximately 50% of pediatric Ph-like B-cell acute lymphoblastic leukemia (B-ALL), and around 50% of CRLF2 +cases harbor JAK mutations. We analyzed CRLF2 expression and studied its correlation with CRLF2 rearrangement in adult patients with B-ALL. Multiparameter flow cytometry (MFC) was performed consecutively in 126 patients. CRLF2 overexpression was detected in 30 (27%) patients, 28 (41%) of 69 patients with B-ALL not otherwise specified, 14 (21%) of 67 untreated patients, and 16 (27%) of 59 patients with relapsed B-ALL, with the highest among Hispanic patients (25/55, 45%). Of CRLF2+cases, 21 (100%) of 21 cases showed CRLF2 rearrangement by fluorescence in situ hybridization, preferentially involving IGH@CRLF2 (15/15). The entire coding region of JAK2 was sequenced in 14 patients with CRLF2+B-ALL, and nine (64%) were positive for JAK2 mutations. MFC allows a rapid, inexpensive, and reliable detection of B-ALL with CRLF2 rearrangement that would further facilitate testing for JAK2 mutations for targetable therapy.",Journal Article,1025.0,11.0,Cytokine receptor-like factor 2 CRLF2 rearrangement is found in approximately 50 of pediatric Ph-like B-cell acute lymphoblastic B-ALL and around 50 of CRLF2 cases harbor JAK mutations We analyzed CRLF2 expression and studied its correlation with CRLF2 rearrangement in adult patients with B-ALL Multiparameter flow cytometry MFC was performed consecutively in 126 patients CRLF2 overexpression was detected in 30 27 patients 28 41 of 69 patients with B-ALL not otherwise specified 14 21 of 67 untreated patients and 16 27 of 59 patients with relapsed B-ALL with the highest among Hispanic patients 25/55 45 Of CRLF2+ cases 21 100 of 21 cases showed CRLF2 rearrangement by fluorescence in situ hybridization preferentially involving IGH CRLF2 15/15 The entire coding region of JAK2 was sequenced in 14 patients with CRLF2+ B-ALL and nine 64 were positive for JAK2 mutations MFC allows a rapid inexpensive and reliable detection of B-ALL with CRLF2 rearrangement that would further facilitate testing for JAK2 mutations for targetable therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1675, 153, 733, 161, 18, 8895, 2675, 16, 204, 4, 705, 212, 1, 815, 2058, 733, 132, 31, 286, 1275, 132, 62, 2, 3337, 212, 1, 8895, 140, 2760, 4653, 138, 21, 311, 8895, 55, 2, 656, 211, 816, 5, 8895, 2675, 4, 780, 7, 5, 132, 62, 10757, 1412, 1914, 9439, 10, 173, 7380, 4, 3927, 7, 8895, 851, 10, 530, 4, 201, 428, 7, 339, 605, 1, 790, 7, 5, 132, 62, 44, 2632, 3575, 213, 239, 1, 598, 1278, 7, 2, 245, 428, 1, 728, 7, 5, 591, 132, 62, 5, 3, 1076, 107, 1776, 7, 243, 614, 512, 1, 8895, 140, 239, 394, 1, 239, 140, 224, 8895, 2675, 20, 1591, 4, 957, 1554, 3509, 1267, 5221, 8895, 167, 167, 3, 1797, 3097, 1053, 1, 2509, 10, 4040, 4, 213, 7, 5, 8895, 132, 62, 2, 762, 660, 11, 109, 9, 2509, 138, 9439, 2333, 8, 1321, 8168, 2, 2450, 638, 1, 132, 62, 5, 8895, 2675, 17, 688, 195, 1876, 471, 9, 2509, 138, 9, 3985, 36]",1041.0,28340183,684
"Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.",Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,J Oncol Pharm Pract,2017-03-29,"Asparaginase is a critical component of acute lymphoblastic leukemia (ALL) treatment in children; however, its use in adults is often avoided as a result of toxicities including hepatotoxicity, thrombosis, and pancreatitis which have been reported more commonly in adults than in children. In this retrospective analysis, short-acting L-asparaginase (L-ASP) and long-acting polyethylene glycol (PEG)-asparaginase (PEG-ASP) were compared for grade 3-4 toxicities and characterized by patient and drug-related factors to identify strategies for toxicity avoidance in adults with ALL. Asparaginase was administered during sequential courses of chemotherapy using a pediatric-inspired treatment regimen. Forty-eight patients who received PEG-ASP and nine patients who received L-ASP were identified. The rates of toxicity were as follows for the PEG-ASP and L-ASP groups, respectively: hepatotoxicity (60% vs. 33%, P=0.275), pancreatitis (17% vs. 22%, P=0.650), thrombosis (19.0% vs. 0%, P=0.328), or any grade 3-4 toxicity (71% vs. 44%, P=0.143). Toxicity did not correlate with dose, either by individual dose based on flat or BSA-based measures. Logistic regression identified obesity as a risk factor for heptatotoxicity (OR=8.44, 95% CI: 1.395-51.117). Hypofibrinogenemia was identified as a pharmacodynamic marker for predicting hepatotoxicity. In conclusion, grade 3-4 toxicity was not statistically different between adult ALL patients receiving PEG-ASP and L-ASP, but toxicity was strongly associated with obesity and hypofibrinogenemia, not dose.",Journal Article,1028.0,11.0,Asparaginase is a critical component of acute lymphoblastic ALL treatment in children however its use in adults is often avoided as a result of toxicities including hepatotoxicity thrombosis and pancreatitis which have been reported more commonly in adults than in children In this retrospective analysis short-acting L-asparaginase L-ASP and long-acting polyethylene glycol PEG -asparaginase PEG-ASP were compared for grade 3-4 toxicities and characterized by patient and drug-related factors to identify strategies for toxicity avoidance in adults with ALL Asparaginase was administered during sequential courses of chemotherapy using a pediatric-inspired treatment regimen Forty-eight patients who received PEG-ASP and nine patients who received L-ASP were identified The rates of toxicity were as follows for the PEG-ASP and L-ASP groups respectively hepatotoxicity 60 vs. 33 P 0.275 pancreatitis 17 vs. 22 P 0.650 thrombosis 19.0 vs. 0 P 0.328 or any grade 3-4 toxicity 71 vs. 44 P 0.143 Toxicity did not correlate with dose either by individual dose based on flat or BSA-based measures Logistic regression identified obesity as a risk factor for heptatotoxicity OR 8.44 95 CI 1.395-51.117 Hypofibrinogenemia was identified as a pharmacodynamic marker for predicting hepatotoxicity In conclusion grade 3-4 toxicity was not statistically different between adult ALL patients receiving PEG-ASP and L-ASP but toxicity was strongly associated with obesity and hypofibrinogenemia not dose,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 16, 8, 740, 1249, 1, 286, 1275, 62, 24, 4, 541, 137, 211, 119, 4, 857, 16, 629, 5617, 22, 8, 757, 1, 385, 141, 6667, 2839, 2, 4535, 92, 47, 85, 210, 80, 841, 4, 857, 76, 4, 541, 4, 26, 459, 65, 978, 5375, 805, 3709, 805, 8501, 2, 319, 5375, 12997, 10809, 3145, 3709, 3145, 8501, 11, 72, 9, 88, 27, 39, 385, 2, 765, 20, 69, 2, 234, 139, 130, 6, 255, 422, 9, 155, 5863, 4, 857, 5, 62, 3709, 10, 468, 190, 1787, 1993, 1, 56, 75, 8, 815, 13161, 24, 477, 1213, 659, 7, 54, 103, 3145, 8501, 2, 762, 7, 54, 103, 805, 8501, 11, 108, 3, 151, 1, 155, 11, 22, 2962, 9, 3, 3145, 8501, 2, 805, 8501, 271, 106, 6667, 335, 105, 466, 19, 13, 5620, 4535, 269, 105, 350, 19, 13, 8642, 2839, 326, 13, 105, 13, 19, 13, 8584, 15, 500, 88, 27, 39, 155, 792, 105, 584, 19, 13, 4400, 155, 205, 44, 1513, 5, 61, 361, 20, 797, 61, 90, 23, 7767, 15, 8321, 90, 1018, 812, 320, 108, 1661, 22, 8, 43, 161, 9, 70110, 15, 66, 584, 48, 58, 14, 10300, 725, 3843, 40365, 10, 108, 22, 8, 2424, 952, 9, 1434, 6667, 4, 1221, 88, 27, 39, 155, 10, 44, 712, 338, 59, 780, 62, 7, 357, 3145, 8501, 2, 805, 8501, 84, 155, 10, 1327, 41, 5, 1661, 2, 40365, 44, 61]",1488.0,28355969,430
Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches.,Biochimica et biophysica acta. Reviews on cancer,Biochim Biophys Acta Rev Cancer,2017-03-28,"Acute myeloid leukemia and acute lymphoblastic leukemia cells hijack hematopoietic stem cell (HSC) niches in the bone marrow and become leukemic stem cells (LSCs) at the expense of normal HSCs. LSCs are quiescent and resistant to chemotherapy and can cause relapse of the disease. HSCs in niches are needed to generate blood cell precursors that are committed to unilineage differentiation and eventually production of mature blood cells, including red blood cells, megakaryocytes, myeloid cells and lymphocytes. Thus far, three types of HSC niches are recognized: endosteal, reticular and perivascular niches. However, we argue here that there is only one type of HSC niche, which consists of a periarteriolar compartment and a perisinusoidal compartment. In the periarteriolar compartment, hypoxia and low levels of reactive oxygen species preserve the HSC pool. In the perisinusoidal compartment, hypoxia in combination with higher levels of reactive oxygen species enables proliferation of progenitor cells and their mobilization into the circulation. Because HSC niches offer protection to LSCs against chemotherapy, we review novel therapeutic strategies to inhibit homing of LSCs in niches for the prevention of dedifferentiation of leukemic cells into LSCs and to stimulate migration of leukemic cells out of niches. These strategies enhance differentiation and proliferation and thus sensitize leukemic cells to chemotherapy. Finally, we list clinical trials of therapies that tackle LSCs in HSC niches to circumvent their protection against chemotherapy.",Journal Article,1029.0,16.0,Acute myeloid and acute lymphoblastic cells hijack hematopoietic stem cell HSC niches in the marrow and become leukemic stem cells LSCs at the expense of normal HSCs LSCs are quiescent and resistant to chemotherapy and can cause relapse of the disease HSCs in niches are needed to generate blood cell precursors that are committed to unilineage differentiation and eventually production of mature blood cells including red blood cells megakaryocytes myeloid cells and lymphocytes Thus far three types of HSC niches are recognized endosteal reticular and perivascular niches However we argue here that there is only one type of HSC niche which consists of a periarteriolar compartment and a perisinusoidal compartment In the periarteriolar compartment hypoxia and low levels of reactive oxygen species preserve the HSC pool In the perisinusoidal compartment hypoxia in combination with higher levels of reactive oxygen species enables proliferation of progenitor cells and their mobilization into the circulation Because HSC niches offer protection to LSCs against chemotherapy we review novel therapeutic strategies to inhibit homing of LSCs in niches for the prevention of dedifferentiation of leukemic cells into LSCs and to stimulate migration of leukemic cells out of niches These strategies enhance differentiation and proliferation and thus sensitize leukemic cells to chemotherapy Finally we list clinical trials of therapies that tackle LSCs in HSC niches to circumvent their protection against chemotherapy,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 533, 2, 286, 1275, 37, 34675, 1007, 452, 31, 5596, 8005, 4, 3, 581, 2, 1417, 2015, 452, 37, 7033, 28, 3, 8563, 1, 295, 6185, 7033, 32, 6735, 2, 436, 6, 56, 2, 122, 708, 429, 1, 3, 34, 6185, 4, 8005, 32, 575, 6, 2562, 315, 31, 4881, 17, 32, 9552, 6, 33238, 910, 2, 3124, 1529, 1, 2908, 315, 37, 141, 3422, 315, 37, 15110, 533, 37, 2, 1594, 631, 3272, 169, 630, 1, 5596, 8005, 32, 1904, 28333, 24829, 2, 9551, 8005, 137, 21, 7004, 467, 17, 125, 16, 158, 104, 267, 1, 5596, 4385, 92, 5132, 1, 8, 50302, 3616, 2, 8, 39320, 3616, 4, 3, 50302, 3616, 1823, 2, 154, 148, 1, 2163, 2848, 2915, 6783, 3, 5596, 6545, 4, 3, 39320, 3616, 1823, 4, 150, 5, 142, 148, 1, 2163, 2848, 2915, 4843, 457, 1, 2520, 37, 2, 136, 4030, 237, 3, 4984, 408, 5596, 8005, 1918, 3525, 6, 7033, 480, 56, 21, 206, 229, 189, 422, 6, 1433, 5515, 1, 7033, 4, 8005, 9, 3, 1070, 1, 9496, 1, 2015, 37, 237, 7033, 2, 6, 4223, 1381, 1, 2015, 37, 1205, 1, 8005, 46, 422, 1304, 910, 2, 457, 2, 631, 5745, 2015, 37, 6, 56, 1368, 21, 4754, 38, 143, 1, 235, 17, 24165, 7033, 4, 5596, 8005, 6, 8602, 136, 3525, 480, 56]",1515.0,28363872,100
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.,Cancer,Cancer,2017-04-07,"Effective treatment options for patients with chronic myeloid leukemia (CML) or Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) who have the threonine to isoleucine mutation at codon 315 (T315I) are few. The objective of this study was to compare overall survival (OS) between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation (allo-SCT). A post hoc, retrospective, indirect comparison of OS among patients who received single-agent ponatinib in the Ponatinib Ph+ ALL and CML Evaluation (PACE) trial with those who underwent allo-SCT as reported to the European Bone Marrow Transplant registry, stratified by CML disease phase and Ph+ ALL, was conducted. Kaplan-Meier survival curves and multivariate Cox proportional-hazards models were used to compare OS between intervention groups, adjusting for time from diagnosis to intervention, age, sex, and geographic region; 24-month and 48-month OS rates and median OS were reported. After adjustment for potential confounders, 24-month and 48-month OS rates were significantly higher in patients with chronic-phase CML (CP-CML) who received ponatinib compared with those who underwent allo-SCT (24 months: 84% vs 60.5%, respectively; P=.004; 48 months: 72.7% vs 55.8%, respectively; P=.013), with a hazard ratio (HR) of 0.37 (95% confidence interval [CI], 0.16-0.84; P=.017). In patients who had accelerated-phase CML, OS rates were not significantly different between the groups (HR, 0.90; 95% CI, 0.20-4.10; P=.889). In patients who had blast-crisis CML and those with Ph+ ALL, ponatinib was associated with shorter OS compared with allo-SCT (blast-crisis CML: HR, 2.29 [95% CI, 1.08-4.82; P=.030]; Ph+ ALL: HR, 2.77 [95% CI, 0.73-10.56; P=.146]). Although allo-SCT remains an important treatment option for patients with T315I-positive advanced CML and Ph+ ALL, ponatinib represents a valuable alternative for patients with T315I-positive CP-CML. Cancer 2017;123:2875-80.  2017 American Cancer Society.",Comparative Study,1019.0,25.0,Effective treatment options for patients with chronic myeloid CML or Philadelphia-positive Ph+ acute lymphoblastic ALL who have the threonine to isoleucine mutation at codon 315 T315I are few The objective of this study was to compare overall survival OS between patients with CML and those with Ph+ ALL who received treatment with ponatinib versus allogeneic stem cell transplantation allo-SCT A post hoc retrospective indirect comparison of OS among patients who received single-agent ponatinib in the Ponatinib Ph+ ALL and CML Evaluation PACE trial with those who underwent allo-SCT as reported to the European Marrow Transplant registry stratified by CML disease phase and Ph+ ALL was conducted Kaplan-Meier survival curves and multivariate Cox proportional-hazards models were used to compare OS between intervention groups adjusting for time from diagnosis to intervention age sex and geographic region 24-month and 48-month OS rates and median OS were reported After adjustment for potential confounders 24-month and 48-month OS rates were significantly higher in patients with chronic-phase CML CP-CML who received ponatinib compared with those who underwent allo-SCT 24 months 84 vs 60.5 respectively P .004 48 months 72.7 vs 55.8 respectively P .013 with a hazard ratio HR of 0.37 95 confidence interval CI 0.16-0.84 P .017 In patients who had accelerated-phase CML OS rates were not significantly different between the groups HR 0.90 95 CI 0.20-4.10 P .889 In patients who had blast-crisis CML and those with Ph+ ALL ponatinib was associated with shorter OS compared with allo-SCT blast-crisis CML HR 2.29 95 CI 1.08-4.82 P .030 Ph+ ALL HR 2.77 95 CI 0.73-10.56 P .146 Although allo-SCT remains an important treatment option for patients with T315I-positive advanced CML and Ph+ ALL ponatinib represents a valuable alternative for patients with T315I-positive CP-CML Cancer 2017 123:2875-80  2017 American Cancer Society,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[323, 24, 838, 9, 7, 5, 442, 533, 903, 15, 3006, 109, 2058, 286, 1275, 62, 54, 47, 3, 5131, 6, 21250, 258, 28, 3673, 7362, 6184, 32, 1021, 3, 461, 1, 26, 45, 10, 6, 932, 63, 25, 118, 59, 7, 5, 903, 2, 135, 5, 2058, 62, 54, 103, 24, 5, 5715, 185, 1063, 452, 31, 497, 2564, 1988, 8, 539, 5428, 459, 6110, 1155, 1, 118, 107, 7, 54, 103, 226, 420, 5715, 4, 3, 5715, 2058, 62, 2, 903, 451, 7265, 160, 5, 135, 54, 208, 2564, 1988, 22, 210, 6, 3, 1865, 581, 941, 1608, 1173, 20, 903, 34, 124, 2, 2058, 62, 10, 426, 876, 882, 25, 2400, 2, 331, 418, 831, 1017, 274, 11, 95, 6, 932, 118, 59, 788, 271, 1358, 9, 98, 29, 147, 6, 788, 89, 1035, 2, 3466, 1053, 259, 811, 2, 576, 811, 118, 151, 2, 52, 118, 11, 210, 50, 1852, 9, 174, 4423, 259, 811, 2, 576, 811, 118, 151, 11, 97, 142, 4, 7, 5, 442, 124, 903, 2541, 903, 54, 103, 5715, 72, 5, 135, 54, 208, 2564, 1988, 259, 53, 874, 105, 335, 33, 106, 19, 1520, 576, 53, 720, 67, 105, 614, 66, 106, 19, 3612, 5, 8, 360, 197, 168, 1, 13, 567, 48, 307, 268, 58, 13, 245, 13, 874, 19, 3825, 4, 7, 54, 42, 2241, 124, 903, 118, 151, 11, 44, 97, 338, 59, 3, 271, 168, 13, 424, 48, 58, 13, 179, 39, 79, 19, 13993, 4, 7, 54, 42, 3112, 6540, 903, 2, 135, 5, 2058, 62, 5715, 10, 41, 5, 985, 118, 72, 5, 2564, 1988, 3112, 6540, 903, 168, 18, 462, 48, 58, 14, 1592, 39, 878, 19, 6542, 2058, 62, 168, 18, 849, 48, 58, 13, 803, 79, 664, 19, 4909, 242, 2564, 1988, 469, 35, 305, 24, 1501, 9, 7, 5, 6184, 109, 131, 903, 2, 2058, 62, 5715, 1449, 8, 2926, 1091, 9, 7, 5, 6184, 109, 2541, 903, 12, 1759, 2698, 70154, 493, 2206, 1759, 597, 12, 1174]",1932.0,28387926,134
Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-04-07,"Allogeneic hematopoietic cell transplantation (HCT) is recommended for patients with T cell acute lymphoblastic leukemia (T-ALL) in second or later complete remission (CR) and high-risk patients in first CR. Given its relative rarity, data on outcomes of HCT for T-ALL are limited. We conducted a multicenter retrospective cohort study using data from 208 adult patients who underwent HCT between 2000 and 2014 to describe outcomes of allogeneic HCT for T-ALL in the contemporary era. The median age at HCT was 37 years, and the majority of patients underwent HCT in CR, using total body irradiation (TBI)-based myeloablative conditioning regimens. One-quarter of the patients underwent alternative donor HCT using a mismatched, umbilical cord blood, or haploidentical donor. With a median follow up of 38 months, overall survival at 5 years was 34%. The corresponding cumulative incidence of non-relapse mortality and relapse was 26% and 41%, respectively. In multivariable analysis, factors significantly associated with overall survival were the use of TBI (HR, 0.57; P=.021), age >35 years (HR, 1.55; P=.025), and disease status at HCT (HR, 1.98; P=.005 for relapsed/refractory disease compared with CR). Relapse was the most common cause of death (58% of patients). Allogeneic HCT remains a potentially curative option in selected patients with adult T-ALL, although relapse is a major cause of treatment failure.",Journal Article,1019.0,5.0,Allogeneic hematopoietic cell transplantation HCT is recommended for patients with T cell acute lymphoblastic T-ALL in second or later complete remission CR and high-risk patients in first CR Given its relative rarity data on outcomes of HCT for T-ALL are limited We conducted a multicenter retrospective cohort study using data from 208 adult patients who underwent HCT between 2000 and 2014 to describe outcomes of allogeneic HCT for T-ALL in the contemporary era The median age at HCT was 37 years and the majority of patients underwent HCT in CR using total body irradiation TBI -based myeloablative conditioning regimens One-quarter of the patients underwent alternative donor HCT using a mismatched umbilical cord blood or haploidentical donor With a median follow up of 38 months overall survival at 5 years was 34 The corresponding cumulative incidence of non-relapse mortality and relapse was 26 and 41 respectively In multivariable analysis factors significantly associated with overall survival were the use of TBI HR 0.57 P .021 age 35 years HR 1.55 P .025 and disease status at HCT HR 1.98 P .005 for relapsed/refractory disease compared with CR Relapse was the most common cause of death 58 of patients Allogeneic HCT remains a potentially curative option in selected patients with adult T-ALL although relapse is a major cause of treatment failure,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 1007, 31, 497, 1085, 16, 793, 9, 7, 5, 102, 31, 286, 1275, 102, 62, 4, 419, 15, 1559, 236, 734, 684, 2, 64, 43, 7, 4, 157, 684, 447, 211, 580, 4989, 74, 23, 123, 1, 1085, 9, 102, 62, 32, 383, 21, 426, 8, 1570, 459, 180, 45, 75, 74, 29, 5920, 780, 7, 54, 208, 1085, 59, 1081, 2, 1409, 6, 897, 123, 1, 1063, 1085, 9, 102, 62, 4, 3, 2667, 1713, 3, 52, 89, 28, 1085, 10, 567, 60, 2, 3, 686, 1, 7, 208, 1085, 4, 684, 75, 181, 642, 1104, 4889, 90, 3246, 1933, 472, 104, 8034, 1, 3, 7, 208, 1091, 1488, 1085, 75, 8, 5095, 5998, 1885, 315, 15, 5802, 1488, 5, 8, 52, 166, 126, 1, 519, 53, 63, 25, 28, 33, 60, 10, 562, 3, 1734, 967, 287, 1, 220, 429, 282, 2, 429, 10, 432, 2, 605, 106, 4, 658, 65, 130, 97, 41, 5, 63, 25, 11, 3, 119, 1, 4889, 168, 13, 696, 19, 4630, 89, 465, 60, 168, 14, 614, 19, 4067, 2, 34, 156, 28, 1085, 168, 14, 1096, 19, 1614, 9, 591, 430, 34, 72, 5, 684, 429, 10, 3, 96, 186, 708, 1, 273, 717, 1, 7, 1063, 1085, 469, 8, 751, 1075, 1501, 4, 715, 7, 5, 780, 102, 62, 242, 429, 16, 8, 458, 708, 1, 24, 496]",1362.0,28396160,546
A phase 1 study of the CXCR4 antagonist plerixafor in combination with high-dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10-03).,Pediatric blood & cancer,Pediatr Blood Cancer,2017-04-14,"Plerixafor, a reversible CXCR4 antagonist, inhibits interactions between leukemic blasts and the bone marrow stromal microenvironment and may enhance chemosensitivity. A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and myelodysplastic syndrome (MDS) was performed to determine a tolerable and biologically active dose. Plerixafor was administered daily for 5 days at four dose levels (6, 9, 12, and 15 mg/m<sup>2</sup> /dose) followed 4 hr later by high-dose cytarabine (every 12 hr) and etoposide (daily). Nineteen patients (13 with AML, 5 with ALL, 1 with MDS) were treated. The most common grade 3 or greater nonhematologic toxicities attributable to plerixafor were febrile neutropenia and hypokalemia. There were no dose-limiting toxicities (DLTs). Plerixafor exposure increased with increasing dose levels and clearance was similar on days 1 and 5. Eighteen patients were evaluable for response. Two patients achieved complete remission (CR) and one patient achieved CR with incomplete hematologic recovery (CRi): all three had AML. No responses were seen in patients with ALL or MDS. Plerixafor mobilized leukemic blasts into the peripheral blood in 14 of 16 evaluable patients (median 3.4-fold increase), and the degree of mobilization correlated with surface CXCR4 expression. Plerixafor, in combination with high-dose cytarabine and etoposide, was well tolerated in children and young adults with relapsed/refractory acute leukemias and MDS. While biologic responses were observed, clinical responses in this heavily pretreated cohort were modest.","Clinical Trial, Phase I",1012.0,18.0,Plerixafor a reversible CXCR4 antagonist inhibits interactions between leukemic blasts and the marrow stromal microenvironment and may enhance chemosensitivity A phase 1 trial of plerixafor in combination with intensive chemotherapy in children and young adults with relapsed or refractory acute lymphoblastic ALL acute myeloid AML and syndrome MDS was performed to determine a tolerable and biologically active dose Plerixafor was administered daily for 5 days at four dose levels 6 9 12 and 15 mg/m sup 2 /sup /dose followed 4 hr later by high-dose cytarabine every 12 hr and etoposide daily Nineteen patients 13 with AML 5 with ALL 1 with MDS were treated The most common grade 3 or greater nonhematologic toxicities attributable to plerixafor were febrile neutropenia and hypokalemia There were no dose-limiting toxicities DLTs Plerixafor exposure increased with increasing dose levels and clearance was similar on days 1 and 5 Eighteen patients were evaluable for response Two patients achieved complete remission CR and one patient achieved CR with incomplete hematologic recovery CRi all three had AML No responses were seen in patients with ALL or MDS Plerixafor mobilized leukemic blasts into the peripheral blood in 14 of 16 evaluable patients median 3.4-fold increase and the degree of mobilization correlated with surface CXCR4 expression Plerixafor in combination with high-dose cytarabine and etoposide was well tolerated in children and young adults with relapsed/refractory acute leukemias and MDS While biologic responses were observed clinical responses in this heavily pretreated cohort were modest,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,"[5583, 8, 2786, 2318, 3137, 1576, 1286, 59, 2015, 2438, 2, 3, 581, 1126, 995, 2, 68, 1304, 5522, 8, 124, 14, 160, 1, 5583, 4, 150, 5, 1686, 56, 4, 541, 2, 1169, 857, 5, 591, 15, 430, 286, 1275, 62, 286, 533, 329, 2, 681, 1223, 10, 173, 6, 223, 8, 2668, 2, 2665, 544, 61, 5583, 10, 468, 391, 9, 33, 162, 28, 294, 61, 148, 49, 83, 133, 2, 167, 81, 188, 172, 18, 172, 61, 370, 39, 168, 1559, 20, 64, 61, 1855, 454, 133, 168, 2, 1934, 391, 3498, 7, 233, 5, 329, 33, 5, 62, 14, 5, 1223, 11, 73, 3, 96, 186, 88, 27, 15, 378, 3534, 385, 2971, 6, 5583, 11, 2498, 778, 2, 7799, 125, 11, 77, 61, 817, 385, 2506, 5583, 645, 101, 5, 602, 61, 148, 2, 1960, 10, 288, 23, 162, 14, 2, 33, 3195, 7, 11, 859, 9, 51, 100, 7, 513, 236, 734, 684, 2, 104, 69, 513, 684, 5, 2610, 813, 1602, 6341, 62, 169, 42, 329, 77, 253, 11, 527, 4, 7, 5, 62, 15, 1223, 5583, 7695, 2015, 2438, 237, 3, 672, 315, 4, 213, 1, 245, 859, 7, 52, 27, 39, 1116, 344, 2, 3, 1444, 1, 4030, 438, 5, 1255, 2318, 55, 5583, 4, 150, 5, 64, 61, 1855, 2, 1934, 10, 149, 421, 4, 541, 2, 1169, 857, 5, 591, 430, 286, 2792, 2, 1223, 369, 1283, 253, 11, 164, 38, 253, 4, 26, 2447, 2193, 180, 11, 1721]",1617.0,28409853,293
Effect of cranial irradiation on sperm concentration of adult survivors of childhood acute lymphoblastic leukemia: a report from the St. Jude Lifetime Cohort Study.,"Human reproduction (Oxford, England)",Hum. Reprod.,2017-06-01,"Does lower dose (<26 Gy) cranial radiation therapy (CRT) used for central nervous system prophylaxis in acute lymphoblastic leukemia (ALL) adversely affect sperm concentration or morphology? CRT doses <26 Gy had no demonstrable adverse effect on sperm concentration or morphology. Treatment with alkylating agents produces oligospermia and azoospermia in some patients. No prior study has been large enough to evaluate the independent effects of alkylating agents and lower dose (<26 Gy) CRT on sperm concentration or morphology. This cross-sectional study included male adult survivors of pediatric ALL who had received alkylating agent chemotherapy with or without CRT and who enrolled in the St. Jude Lifetime Cohort Study (SJLIFE) from September 2007 to October 2013. The inclusion criteria were males, 18 years of age, 10 years after diagnosis, treated at St. Jude Children's Research Hospital for ALL, and received alkylating agent chemotherapy. Semen analyses were performed on 173 of the 241 (78.1%) adult survivors of pediatric ALL who had received alkylating agent chemotherapy with or without CRT. Cumulative alkylating agent treatment was quantified using the cyclophosphamide equivalent dose (CED). Log-binomial multivariable models were used to calculate relative risks (RRs) and 95% CI. Compared to those without CRT, risk of oligospermia or azoospermia was not increased for CRT <20 Gy (P = 0.95) or 20-26 Gy (P = 0.58). Participants 5-9 years of age at diagnosis compared to those 0-4 years of age (RR = 1.30, 95% CI, 1.05-.61) or those treated with 8-12 g/m2 CED (RR = 2.06, 95% CI, 1.08-3.94) or 12 g/m2 CED (RR = 2.12, 95% CI, 1.09-4.12) compared to those treated with >0 to <4 g/m2 CED had an increased risk for oligospermia or azoospermia. Our study relied on the results of one semen analysis. ALL survivors who did not participate in SJLIFE or who declined to submit a semen analysis may also have biased our results regarding the proportion with azoospermia or oligospermia, since those who provided a semen specimen were less likely to have previously fathered children compared to those who did not. The lower rate of previous parenthood among participants may have resulted in a higher observed frequency of azoospermia and oligospermia. Treatment with <26 Gy CRT did not increase the risk of oligospermia or azoospermia, although a CED exceeding 8 g/m2 and an age at diagnosis of 5-9 years did increase risk of oligospermia and azoospermia. These findings can be used to counsel adult survivors of pediatric ALL. This work was supported by the National Institutes of Health (grant numbers CA 21765, CA 195547, CA00874) and the American Lebanese Syrian Associated Charities (ALSAC). The authors have no competing interests to declare.",Comparative Study,964.0,5.0,Does lower dose 26 Gy cranial radiation therapy CRT used for central nervous system prophylaxis in acute lymphoblastic ALL adversely affect sperm concentration or morphology CRT doses 26 Gy had no demonstrable adverse effect on sperm concentration or morphology Treatment with alkylating agents produces oligospermia and azoospermia in some patients No prior study has been large enough to evaluate the independent effects of alkylating agents and lower dose 26 Gy CRT on sperm concentration or morphology This cross-sectional study included male adult survivors of pediatric ALL who had received alkylating agent chemotherapy with or without CRT and who enrolled in the St. Jude Lifetime Cohort Study SJLIFE from September 2007 to October 2013 The inclusion criteria were males 18 years of age 10 years after diagnosis treated at St. Jude Children 's Research Hospital for ALL and received alkylating agent chemotherapy Semen analyses were performed on 173 of the 241 78.1 adult survivors of pediatric ALL who had received alkylating agent chemotherapy with or without CRT Cumulative alkylating agent treatment was quantified using the cyclophosphamide equivalent dose CED Log-binomial multivariable models were used to calculate relative risks RRs and 95 CI Compared to those without CRT risk of oligospermia or azoospermia was not increased for CRT 20 Gy P 0.95 or 20-26 Gy P 0.58 Participants 5-9 years of age at diagnosis compared to those 0-4 years of age RR 1.30 95 CI 1.05-.61 or those treated with 8-12 g/m2 CED RR 2.06 95 CI 1.08-3.94 or 12 g/m2 CED RR 2.12 95 CI 1.09-4.12 compared to those treated with 0 to 4 g/m2 CED had an increased risk for oligospermia or azoospermia Our study relied on the results of one semen analysis ALL survivors who did not participate in SJLIFE or who declined to submit a semen analysis may also have biased our results regarding the proportion with azoospermia or oligospermia since those who provided a semen specimen were less likely to have previously fathered children compared to those who did not The lower rate of previous parenthood among participants may have resulted in a higher observed frequency of azoospermia and oligospermia Treatment with 26 Gy CRT did not increase the risk of oligospermia or azoospermia although a CED exceeding 8 g/m2 and an age at diagnosis of 5-9 years did increase risk of oligospermia and azoospermia These findings can be used to counsel adult survivors of pediatric ALL This work was supported by the National Institutes of Health grant numbers CA 21765 CA 195547 CA00874 and the American Lebanese Syrian Associated Charities ALSAC The authors have no competing interests to declare,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1097, 280, 61, 432, 381, 2565, 121, 36, 1089, 95, 9, 854, 1880, 398, 2049, 4, 286, 1275, 62, 4311, 1158, 9986, 1227, 15, 2567, 1089, 415, 432, 381, 42, 77, 11411, 290, 254, 23, 9986, 1227, 15, 2567, 24, 5, 3410, 183, 4042, 20934, 2, 18721, 4, 476, 7, 77, 324, 45, 71, 85, 375, 5151, 6, 376, 3, 306, 176, 1, 3410, 183, 2, 280, 61, 432, 381, 1089, 23, 9986, 1227, 15, 2567, 26, 1383, 2832, 45, 159, 1045, 780, 332, 1, 815, 62, 54, 42, 103, 3410, 420, 56, 5, 15, 187, 1089, 2, 54, 346, 4, 3, 3062, 4841, 2898, 180, 45, 13437, 29, 2636, 1307, 6, 2551, 1346, 3, 1680, 371, 11, 2296, 6624, 60, 1, 89, 4556, 60, 50, 147, 73, 28, 3062, 4841, 541, 292, 389, 702, 9, 62, 2, 103, 3410, 420, 56, 21792, 318, 11, 173, 23, 5785, 1, 3, 7086, 833, 14, 780, 332, 1, 815, 62, 54, 42, 103, 3410, 420, 56, 5, 15, 187, 1089, 967, 3410, 420, 24, 10, 2790, 75, 3, 1112, 2017, 61, 7097, 1066, 8538, 658, 274, 11, 95, 6, 3232, 580, 1098, 4739, 2, 48, 58, 72, 6, 135, 187, 1089, 43, 1, 20934, 15, 18721, 10, 44, 101, 9, 1089, 179, 381, 19, 13, 48, 15, 179, 432, 381, 19, 13, 717, 776, 33, 83, 60, 1, 89, 28, 147, 72, 6, 135, 13, 39, 60, 1, 89, 861, 14, 201, 48, 58, 14, 474, 713, 15, 135, 73, 5, 66, 133, 499, 821, 7097, 861, 18, 1460, 48, 58, 14, 1592, 27, 960, 15, 9612, 499, 821, 7097, 861, 18, 133, 48, 58, 14, 1730, 39, 133, 72, 6, 135, 73, 5, 13, 6, 39, 499, 821, 7097, 42, 35, 101, 43, 9, 20934, 15, 18721, 114, 45, 9896, 23, 3, 99, 1, 104, 21792, 65, 62, 332, 54, 205, 44, 3506, 4, 13437, 15, 54, 3054, 6, 21113, 8, 21792, 65, 68, 120, 47, 11627, 114, 99, 666, 3, 920, 5, 18721, 15, 20934, 1192, 135, 54, 1052, 8, 21792, 2360, 11, 299, 322, 6, 47, 373, 30450, 541, 72, 6, 135, 54, 205, 44, 3, 280, 116, 1, 698, 34872, 107, 776, 68, 47, 627, 4, 8, 142, 164, 675, 1, 18721, 2, 20934, 24, 5, 432, 381, 1089, 205, 44, 344, 3, 43, 1, 20934, 15, 18721, 242, 8, 7097, 5178, 66, 499, 821, 2, 35, 89, 28, 147, 1, 33, 83, 60, 205, 344, 43, 1, 20934, 2, 18721, 46, 272, 122, 40, 95, 6, 9892, 780, 332, 1, 815, 62, 26, 1357, 10, 2708, 20, 3, 657, 5973, 1, 341, 11041, 1870, 1568, 70277, 1568, 70278, 70279, 2, 3, 597, 14666, 13671, 41, 14667, 41742, 3, 738, 47, 77, 2573, 15015, 6, 22083]",2672.0,28444255,403
"Impact of sleep, fatigue, and systemic inflammation on neurocognitive and behavioral outcomes in long-term survivors of childhood acute lymphoblastic leukemia.",Cancer,Cancer,2017-04-27,"Long-term survivors of childhood acute lymphoblastic leukemia (ALL) are at risk for neurocognitive impairment, which may be associated with fatigue, sleep problems, systemic inflammation, and oxidative stress. We examined these associations among survivors of childhood ALL treated with chemotherapy only. Survivors of childhood ALL (male, n=35 and female, n=35; mean age, 14.3 years [standard deviation, 4.7 years] and mean years from diagnosis, 7.4 years [standard deviation, 1.9 years]) completed neurocognitive testing, behavioral ratings, and reported sleep quality and fatigue symptoms 5 years after diagnosis. Serum was collected concurrently and assayed for interleukin (IL)-1 and IL-6, tumor necrosis factor  (TNF-), high-sensitivity C-reactive protein (hsCRP), malondialdehyde, myeloperoxidase, and oxidized low-density lipoprotein. General linear modeling was used to assess associations among biomarkers and functional outcomes, adjusting for age and stratified by sex. Survivors performed worse than population norms on executive function and processing speed and reported more behavioral problems (P < .05 adjusted for multiple comparison). In female survivors, fatigue was associated with poor executive function (r = 0.41; P = .02), processing speed (r = 0.56; P < .001), and attention (r = 0.36-0.55; P < .05). Female survivors with frequent nighttime awakening displayed more inattention (P = .01), hyperactivity (P = .03), and aggression (P = .01). Worse executive function, processing speed, and behavioral symptoms were observed in female survivors with higher levels of IL-6, IL-1, and hsCRP (P < .05). Male survivors with high levels of TNF- demonstrated worse organization (P = .03), but no significant associations between neurocognitive outcomes and sleep/fatigue measures were observed. Neurocognitive function in female survivors of childhood ALL appears more susceptible to the effects of sleep disturbance and fatigue. Systemic inflammation may play a role in neurocognitive impairment and behavioral symptoms. Cancer 2017;123:3410-9.  2017 American Cancer Society.",Journal Article,999.0,11.0,Long-term survivors of childhood acute lymphoblastic ALL are at risk for neurocognitive impairment which may be associated with fatigue sleep problems systemic inflammation and oxidative stress We examined these associations among survivors of childhood ALL treated with chemotherapy only Survivors of childhood ALL male n 35 and female n 35 mean age 14.3 years standard deviation 4.7 years and mean years from diagnosis 7.4 years standard deviation 1.9 years completed neurocognitive testing behavioral ratings and reported sleep quality and fatigue symptoms 5 years after diagnosis Serum was collected concurrently and assayed for interleukin IL -1 and IL-6 tumor necrosis factor TNF- high-sensitivity C-reactive protein hsCRP malondialdehyde myeloperoxidase and oxidized low-density lipoprotein General linear modeling was used to assess associations among biomarkers and functional outcomes adjusting for age and stratified by sex Survivors performed worse than population norms on executive function and processing speed and reported more behavioral problems P .05 adjusted for multiple comparison In female survivors fatigue was associated with poor executive function r 0.41 P .02 processing speed r 0.56 P .001 and attention r 0.36-0.55 P .05 Female survivors with frequent nighttime awakening displayed more inattention P .01 hyperactivity P .03 and aggression P .01 Worse executive function processing speed and behavioral symptoms were observed in female survivors with higher levels of IL-6 IL-1 and hsCRP P .05 Male survivors with high levels of TNF- demonstrated worse organization P .03 but no significant associations between neurocognitive outcomes and sleep/fatigue measures were observed Neurocognitive function in female survivors of childhood ALL appears more susceptible to the effects of sleep disturbance and fatigue Systemic inflammation may play a role in neurocognitive impairment and behavioral symptoms Cancer 2017 123:3410-9  2017 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[319, 337, 332, 1, 864, 286, 1275, 62, 32, 28, 43, 9, 2958, 2315, 92, 68, 40, 41, 5, 613, 2494, 2408, 403, 1815, 2, 3495, 1531, 21, 409, 46, 685, 107, 332, 1, 864, 62, 73, 5, 56, 158, 332, 1, 864, 62, 1045, 78, 465, 2, 1061, 78, 465, 313, 89, 213, 27, 60, 260, 3348, 39, 67, 60, 2, 313, 60, 29, 147, 67, 39, 60, 260, 3348, 14, 83, 60, 781, 2958, 471, 4166, 5548, 2, 210, 2494, 372, 2, 613, 507, 33, 60, 50, 147, 524, 10, 786, 3294, 2, 4499, 9, 1603, 501, 8215, 2, 501, 49, 30, 1523, 161, 2254, 2014, 64, 485, 256, 2163, 178, 10377, 50342, 16722, 2, 16109, 154, 1263, 8984, 1083, 1646, 2057, 10, 95, 6, 423, 685, 107, 582, 2, 583, 123, 1358, 9, 89, 2, 1173, 20, 1035, 332, 173, 639, 76, 266, 9875, 23, 6481, 343, 2, 3325, 5051, 2, 210, 80, 4166, 2408, 19, 474, 586, 9, 232, 1155, 4, 1061, 332, 613, 10, 41, 5, 334, 6481, 343, 668, 13, 605, 19, 588, 3325, 5051, 668, 13, 664, 19, 144, 2, 2111, 668, 13, 511, 13, 614, 19, 474, 1061, 332, 5, 908, 28719, 70297, 2507, 80, 23873, 19, 355, 18391, 19, 680, 2, 28326, 19, 355, 639, 6481, 343, 3325, 5051, 2, 4166, 507, 11, 164, 4, 1061, 332, 5, 142, 148, 1, 501, 49, 501, 8215, 2, 10377, 19, 474, 1045, 332, 5, 64, 148, 1, 2254, 2014, 264, 639, 2533, 19, 680, 84, 77, 93, 685, 59, 2958, 123, 2, 2494, 613, 1018, 11, 164, 2958, 343, 4, 1061, 332, 1, 864, 62, 1233, 80, 4012, 6, 3, 176, 1, 2494, 6663, 2, 613, 403, 1815, 68, 1343, 8, 200, 4, 2958, 2315, 2, 4166, 507, 12, 1759, 2698, 43159, 83, 2206, 1759, 597, 12, 1174]",1989.0,28452142,32
Osteonecrosis of the Shoulders in Pediatric Patients Treated for Leukemia or Lymphoma: Single-Institutional Experience.,Journal of pediatric orthopedics,J Pediatr Orthop,2019-02-01,"Osteonecrosis of the hips and knees is an often debilitating adverse event in children treated with glucocorticoids for leukemia and lymphoma but the impact of shoulder involvement has been understudied. Thus, we investigated the severity and functional impairment of shoulder osteonecrosis in a well-characterized population of pediatric patients treated for acute lymphoblastic leukemia or lymphoma. We retrospectively reviewed orthopaedic clinic and physical therapy evaluations to determine range of motion (ROM), pain, and impact of magnetic resonance-defined osteonecrosis (ON) on activities of daily living. Adverse events were classified according to the National Cancer Institute's Common Terminology Criteria for Adverse Events version 4.03. We identified 35 patients (22 female), median age at cancer diagnosis 14.2 (range, 4.3 to 19) years; median age at ON diagnosis 16.7 (range, 5.5 to 28) years. Median time to last follow-up from diagnosis of primary malignancy was 6.4 (range, 0 to 12.7) years and from diagnosis of ON was 4.0 (range, 0 to 8.9) years. Twenty-two patients had magnetic resonance evidence of ON; 43 shoulders involved at least 30% of the articular surface of the capital humeral epiphyses.Common Terminology Criteria for Adverse Events mean scores for initial assessments of 55 shoulders (29 patients) showed moderate negative impact of ON on activity of daily living (1.94), decreased ROM limiting athletic activity (0.98), and mild to moderate levels of pain (1.38). Analysis of this group's most recent assessment showed improvement in pain and ON over time, with an average pain grade of 0.58 indicating no pain to mild pain, and 1.37 for ON grade, indicating asymptomatic to mildly symptomatic impact on activities of daily living. We also found minimal worsening average ROM grades (1.11). Shoulder ON is an underappreciated adverse late effect of therapy in children treated for leukemia/lymphoma which can limit quality of life and functionality. In most cases, pain and disability can be improved with treatment. Level IV-case series.",Journal Article,354.0,1.0,Osteonecrosis of the hips and knees is an often debilitating adverse event in children treated with glucocorticoids for and but the impact of shoulder involvement has been understudied Thus we investigated the severity and functional impairment of shoulder osteonecrosis in a well-characterized population of pediatric patients treated for acute lymphoblastic or We retrospectively reviewed orthopaedic clinic and physical therapy evaluations to determine range of motion ROM pain and impact of magnetic resonance-defined osteonecrosis ON on activities of daily living Adverse events were classified according to the National Cancer Institute 's Common Terminology Criteria for Adverse Events version 4.03 We identified 35 patients 22 female median age at cancer diagnosis 14.2 range 4.3 to 19 years median age at ON diagnosis 16.7 range 5.5 to 28 years Median time to last follow-up from diagnosis of primary malignancy was 6.4 range 0 to 12.7 years and from diagnosis of ON was 4.0 range 0 to 8.9 years Twenty-two patients had magnetic resonance evidence of ON 43 shoulders involved at least 30 of the articular surface of the capital humeral epiphyses.Common Terminology Criteria for Adverse Events mean scores for initial assessments of 55 shoulders 29 patients showed moderate negative impact of ON on activity of daily living 1.94 decreased ROM limiting athletic activity 0.98 and mild to moderate levels of pain 1.38 Analysis of this group 's most recent assessment showed improvement in pain and ON over time with an average pain grade of 0.58 indicating no pain to mild pain and 1.37 for ON grade indicating asymptomatic to mildly symptomatic impact on activities of daily living We also found minimal worsening average ROM grades 1.11 Shoulder ON is an underappreciated adverse late effect of therapy in children treated for leukemia/lymphoma which can limit quality of life and functionality In most cases pain and disability can be improved with treatment Level IV-case series,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 1, 3, 22230, 2, 28503, 16, 35, 629, 8099, 290, 774, 4, 541, 73, 5, 7307, 9, 2, 84, 3, 345, 1, 13115, 799, 71, 85, 8207, 631, 21, 565, 3, 1702, 2, 583, 2315, 1, 13115, 5404, 4, 8, 149, 765, 266, 1, 815, 7, 73, 9, 286, 1275, 15, 21, 894, 446, 25732, 1188, 2, 900, 36, 3816, 6, 223, 184, 1, 2967, 17113, 559, 2, 345, 1, 1484, 1535, 395, 5404, 23, 23, 2042, 1, 391, 2798, 290, 281, 11, 1373, 768, 6, 3, 657, 12, 1377, 292, 186, 3462, 371, 9, 290, 281, 2256, 39, 680, 21, 108, 465, 7, 350, 1061, 52, 89, 28, 12, 147, 213, 18, 184, 39, 27, 6, 326, 60, 52, 89, 28, 23, 147, 245, 67, 184, 33, 33, 6, 339, 60, 52, 98, 6, 1060, 166, 126, 29, 147, 1, 86, 710, 10, 49, 39, 184, 13, 6, 133, 67, 60, 2, 29, 147, 1, 23, 10, 39, 13, 184, 13, 6, 66, 83, 60, 737, 100, 7, 42, 1484, 1535, 241, 1, 23, 601, 33686, 646, 28, 506, 201, 1, 3, 21258, 1255, 1, 3, 17386, 34719, 48685, 186, 3462, 371, 9, 290, 281, 313, 703, 9, 388, 2182, 1, 614, 33686, 462, 7, 224, 1163, 199, 345, 1, 23, 23, 128, 1, 391, 2798, 14, 960, 340, 17113, 817, 50172, 128, 13, 1096, 2, 1980, 6, 1163, 148, 1, 559, 14, 519, 65, 1, 26, 87, 292, 96, 435, 455, 224, 767, 4, 559, 2, 23, 252, 98, 5, 35, 1011, 559, 88, 1, 13, 717, 1716, 77, 559, 6, 1980, 559, 2, 14, 567, 9, 23, 88, 1716, 2100, 6, 9443, 1704, 345, 23, 2042, 1, 391, 2798, 21, 120, 204, 1048, 4323, 1011, 17113, 2276, 14, 175, 13115, 23, 16, 35, 19049, 290, 807, 254, 1, 36, 4, 541, 73, 9, 2647, 4763, 92, 122, 2385, 372, 1, 358, 2, 8592, 4, 96, 140, 559, 2, 5868, 122, 40, 231, 5, 24, 301, 478, 473, 988]",1988.0,28452860,822
Understanding predictors of continued long-term pediatric cancer care across the region: A report from the Consortium for New England Childhood Cancer Survivors.,Pediatric blood & cancer,Pediatr Blood Cancer,2017-04-28,"Many survivors of childhood cancer do not receive recommended longitudinal oncology care. Factors present at the time of childhood cancer diagnosis may identify patients who are vulnerable to poor adherence to follow-up. This cohort of survivors of acute lymphoblastic leukemia (ALL) diagnosed from 1996 to 1999 at seven Consortium for New England Childhood Cancer Survivors institutions was evaluated for attendance at oncology clinics at 5 and 10 years from diagnosis. Demographic, socioeconomic, disease, and treatment characteristics were analyzed as risk factors for nonadherence to follow-up. Of 317 patients, 90% were alive 5 years from diagnosis and 88% of those remained in active follow-up. At 10 years from diagnosis, 88% were alive, 73% of whom continued in active follow-up. Insurance status at diagnosis was significantly associated with adherence at both 5 and 10 years. At 10 years, initial enrollment on therapeutic study was associated with increased attendance and central nervous system (CNS) leukemia with decreased attendance. In multivariable modeling of follow-up at 5 years, patients who were adults were less likely to participate and those with private insurance at diagnosis more likely to participate. At 10 years, insurance status at diagnosis remained a predictor of adherence to follow-up. In this regional cohort, many patients who are survivors of ALL continue to participate in oncology care at 5 and 10 years from diagnosis. Factors known at diagnosis including insurance status, CNS leukemia, older age, and enrollment on therapeutic study were associated with differential attendance to follow-up visits.",Clinical Trial,998.0,3.0,Many survivors of childhood cancer do not receive recommended longitudinal oncology care Factors present at the time of childhood cancer diagnosis may identify patients who are vulnerable to poor adherence to follow-up This cohort of survivors of acute lymphoblastic ALL diagnosed from 1996 to 1999 at seven Consortium for New England Childhood Cancer Survivors institutions was evaluated for attendance at oncology clinics at 5 and 10 years from diagnosis Demographic socioeconomic disease and treatment characteristics were analyzed as risk factors for nonadherence to follow-up Of 317 patients 90 were alive 5 years from diagnosis and 88 of those remained in active follow-up At 10 years from diagnosis 88 were alive 73 of whom continued in active follow-up Insurance status at diagnosis was significantly associated with adherence at both 5 and 10 years At 10 years initial enrollment on therapeutic study was associated with increased attendance and central nervous system CNS with decreased attendance In multivariable modeling of follow-up at 5 years patients who were adults were less likely to participate and those with private insurance at diagnosis more likely to participate At 10 years insurance status at diagnosis remained a predictor of adherence to follow-up In this regional cohort many patients who are survivors of ALL continue to participate in oncology care at 5 and 10 years from diagnosis Factors known at diagnosis including insurance status CNS older age and enrollment on therapeutic study were associated with differential attendance to follow-up visits,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[445, 332, 1, 864, 12, 1022, 44, 560, 793, 2380, 413, 165, 130, 364, 28, 3, 98, 1, 864, 12, 147, 68, 255, 7, 54, 32, 5017, 6, 334, 2149, 6, 166, 126, 26, 180, 1, 332, 1, 286, 1275, 62, 265, 29, 2648, 6, 2043, 28, 648, 2404, 9, 217, 12578, 864, 12, 332, 1764, 10, 194, 9, 12349, 28, 413, 4736, 28, 33, 2, 79, 60, 29, 147, 1540, 3331, 34, 2, 24, 374, 11, 311, 22, 43, 130, 9, 9271, 6, 166, 126, 1, 7869, 7, 424, 11, 1701, 33, 60, 29, 147, 2, 889, 1, 135, 958, 4, 544, 166, 126, 28, 79, 60, 29, 147, 889, 11, 1701, 803, 1, 953, 1351, 4, 544, 166, 126, 1935, 156, 28, 147, 10, 97, 41, 5, 2149, 28, 110, 33, 2, 79, 60, 28, 79, 60, 388, 1798, 23, 189, 45, 10, 41, 5, 101, 12349, 2, 854, 1880, 398, 1025, 5, 340, 12349, 4, 658, 2057, 1, 166, 126, 28, 33, 60, 7, 54, 11, 857, 11, 299, 322, 6, 3506, 2, 135, 5, 4745, 1935, 28, 147, 80, 322, 6, 3506, 28, 79, 60, 1935, 156, 28, 147, 958, 8, 980, 1, 2149, 6, 166, 126, 4, 26, 951, 180, 445, 7, 54, 32, 332, 1, 62, 1906, 6, 3506, 4, 413, 165, 28, 33, 2, 79, 60, 29, 147, 130, 440, 28, 147, 141, 1935, 156, 1025, 434, 89, 2, 1798, 23, 189, 45, 11, 41, 5, 1777, 12349, 6, 166, 126, 2690]",1582.0,28453181,23
Managing CNS disease in adults with acute lymphoblastic leukemia.,Leukemia & lymphoma,Leuk. Lymphoma,2017-05-23,The central nervous system (CNS) is an important site of involvement by acute lymphoblastic leukemia (ALL) in adults. The prevalence is sufficiently high that prophylactic treatment is routinely given to this sanctuary site in order to eradicate occult disease that might otherwise lead to a relapse. A lumbar puncture should be routinely performed in all newly diagnosed patients with ALL. The risks of CNS leukemia vary by phenotype and genotype. Preventive treatment of the CNS during post-remission therapy has become an integral part of all current ALL treatment protocols. Most treatment regimens combine multiple doses of intrathecal chemotherapy with high-dose systemic methotrexate and/or cytarabine. Cranial irradiation is less commonly used for prophylaxis but is still the most effective treatment for overt CNS leukemia. Recurrences within the CNS usually coincide with or predict soon afterwards for systemic relapse in the marrow and blood.,Journal Article,973.0,5.0,The central nervous system CNS is an important site of involvement by acute lymphoblastic ALL in adults The prevalence is sufficiently high that prophylactic treatment is routinely given to this sanctuary site in order to eradicate occult disease that might otherwise lead to a relapse A lumbar puncture should be routinely performed in all newly diagnosed patients with ALL The risks of CNS vary by phenotype and genotype Preventive treatment of the CNS during post-remission therapy has become an integral part of all current ALL treatment protocols Most treatment regimens combine multiple doses of intrathecal chemotherapy with high-dose systemic methotrexate and/or cytarabine Cranial irradiation is less commonly used for prophylaxis but is still the most effective treatment for overt CNS Recurrences within the CNS usually coincide with or predict soon afterwards for systemic relapse in the marrow and blood,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 854, 1880, 398, 1025, 16, 35, 305, 606, 1, 799, 20, 286, 1275, 62, 4, 857, 3, 1078, 16, 5938, 64, 17, 1862, 24, 16, 3066, 447, 6, 26, 14541, 606, 4, 1732, 6, 5650, 2879, 34, 17, 822, 2632, 1122, 6, 8, 429, 8, 6187, 12104, 257, 40, 3066, 173, 4, 62, 732, 265, 7, 5, 62, 3, 1098, 1, 1025, 2825, 20, 1005, 2, 1183, 3494, 24, 1, 3, 1025, 190, 539, 734, 36, 71, 1417, 35, 4450, 760, 1, 62, 291, 62, 24, 2189, 96, 24, 472, 4680, 232, 415, 1, 5126, 56, 5, 64, 61, 403, 2116, 2, 15, 1855, 2565, 1104, 16, 299, 841, 95, 9, 2049, 84, 16, 1234, 3, 96, 323, 24, 9, 7192, 1025, 1593, 262, 3, 1025, 2082, 19664, 5, 15, 678, 6176, 20509, 9, 403, 429, 4, 3, 581, 2, 315]",916.0,28535095,359
Germline ETV6 mutations and predisposition to hematological malignancies.,International journal of hematology,Int. J. Hematol.,2017-05-29,"Patients with thrombocytopenia 5 have an autosomal dominant disorder of decreased platelet number with tendency to bleed, usually presenting in childhood, and have been found to have germline mutations in ETV6, which encodes a master hematopoietic transcription factor. Some patients who present similarly have inherited mutations in RUNX1 or ANKRD26. All three germline syndromes are also associated with a predisposition to myelodysplastic syndrome (MDS) and acute leukemia (AL). Since the first description of germline ETV6 mutations, 18 families have been reported. The common phenotype is mild to moderate thrombocytopenia with a variable predisposition to acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and MDS. This review will focus upon the role of ETV6 in hematopoiesis, especially in myeloid differentiation and maturation, and will describe the functional effects of mutant ETV6. The review will also provide an overview of common clinical features as well as recommendations for patient screening and follow-up and will debate whether additional clinical features should be included with the germline ETV6 syndrome.",Journal Article,967.0,12.0,Patients with thrombocytopenia 5 have an autosomal dominant disorder of decreased platelet number with tendency to bleed usually presenting in childhood and have been found to have germline mutations in ETV6 which encodes a master hematopoietic transcription factor Some patients who present similarly have inherited mutations in RUNX1 or ANKRD26 All three germline syndromes are also associated with a predisposition to syndrome MDS and acute AL Since the first description of germline ETV6 mutations 18 families have been reported The common phenotype is mild to moderate thrombocytopenia with a variable predisposition to acute lymphoblastic ALL acute myeloid AML and MDS This review will focus upon the role of ETV6 in hematopoiesis especially in myeloid differentiation and maturation and will describe the functional effects of mutant ETV6 The review will also provide an overview of common clinical features as well as recommendations for patient screening and follow-up and will debate whether additional clinical features should be included with the germline ETV6 syndrome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7, 5, 1340, 33, 47, 35, 6084, 2156, 2645, 1, 340, 1596, 207, 5, 7135, 6, 19502, 2082, 1656, 4, 864, 2, 47, 85, 204, 6, 47, 1009, 138, 4, 7306, 92, 4322, 8, 7561, 1007, 866, 161, 476, 7, 54, 364, 1813, 47, 2986, 138, 4, 6092, 15, 50410, 62, 169, 1009, 2040, 32, 120, 41, 5, 8, 2863, 6, 681, 1223, 2, 286, 2171, 1192, 3, 157, 5263, 1, 1009, 7306, 138, 203, 1954, 47, 85, 210, 3, 186, 1005, 16, 1980, 6, 1163, 1340, 5, 8, 1347, 2863, 6, 286, 1275, 62, 286, 533, 329, 2, 1223, 26, 206, 303, 1222, 1548, 3, 200, 1, 7306, 4, 5114, 1093, 4, 533, 910, 2, 4537, 2, 303, 897, 3, 583, 176, 1, 620, 7306, 3, 206, 303, 120, 377, 35, 2901, 1, 186, 38, 404, 22, 149, 22, 883, 9, 69, 453, 2, 166, 126, 2, 303, 5220, 317, 402, 38, 404, 257, 40, 159, 5, 3, 1009, 7306, 681]",1081.0,28555414,10
mTORC1 Inhibition Induces Resistance to Methotrexate and 6-Mercaptopurine in Ph<sup>+</sup> and Ph-like B-ALL.,Molecular cancer therapeutics,Mol. Cancer Ther.,2017-05-31,"Elevated activity of mTOR is associated with poor prognosis and higher incidence of relapse in B-cell acute lymphoblastic leukemia (B-ALL). Thus, ongoing clinical trials are testing mTOR inhibitors in combination with chemotherapy in B-ALL. However, the combination of mTOR inhibitors with standard of care chemotherapy drugs has not been studied extensively in high-risk B-ALL subtypes. Therefore, we tested whether mTOR inhibition can augment the efficacy of current chemotherapy agents in Ph<sup>+</sup> and Ph-like B-ALL models. Surprisingly, inhibiting mTOR complex 1 (mTORC1) protected B-ALL cells from killing by methotrexate and 6-mercaptopurine, two antimetabolite drugs used in maintenance chemotherapy. The cytoprotective effects correlated with decreased cell-cycle progression and were recapitulated using cell-cycle inhibitors, palbociclib or aphidicolin. Dasatinib, a tyrosine kinase inhibitor currently used in Ph<sup>+</sup> patients, inhibits ABL kinase upstream of mTOR. Dasatinib resistance is mainly caused by ABL kinase mutations, but is also observed in a subset of ABL unmutated cases. We identified dasatinib-resistant Ph+ cell lines and patient samples in which dasatinib can effectively reduce ABL kinase activity and mTORC1 signaling without causing cell death. In these cases, dasatinib protected leukemia cells from killing by 6-mercaptopurine. Using xenograft models, we observed that mTOR inhibition or dasatinib increased the numbers of leukemia cells that emerge after cessation of chemotherapy treatment. These results demonstrate that inhibitors targeting mTOR or upstream signaling nodes should be used with caution when combined with chemotherapeutic agents that rely on cell-cycle progression to kill B-ALL cells. <i>Mol Cancer Ther; 16(9); 1942-53. 2017 AACR</i>.",Journal Article,965.0,4.0,Elevated activity of mTOR is associated with poor prognosis and higher incidence of relapse in B-cell acute lymphoblastic B-ALL Thus ongoing clinical trials are testing mTOR inhibitors in combination with chemotherapy in B-ALL However the combination of mTOR inhibitors with standard of care chemotherapy drugs has not been studied extensively in high-risk B-ALL subtypes Therefore we tested whether mTOR inhibition can augment the efficacy of current chemotherapy agents in Ph sup /sup and Ph-like B-ALL models Surprisingly inhibiting mTOR complex 1 mTORC1 protected B-ALL cells from killing by methotrexate and 6-mercaptopurine two antimetabolite drugs used in maintenance chemotherapy The cytoprotective effects correlated with decreased cell-cycle progression and were recapitulated using cell-cycle inhibitors palbociclib or aphidicolin Dasatinib a tyrosine kinase inhibitor currently used in Ph sup /sup patients inhibits ABL kinase upstream of mTOR Dasatinib resistance is mainly caused by ABL kinase mutations but is also observed in a subset of ABL unmutated cases We identified dasatinib-resistant Ph+ cell lines and patient samples in which dasatinib can effectively reduce ABL kinase activity and mTORC1 signaling without causing cell death In these cases dasatinib protected cells from killing by 6-mercaptopurine Using xenograft models we observed that mTOR inhibition or dasatinib increased the numbers of cells that emerge after cessation of chemotherapy treatment These results demonstrate that inhibitors targeting mTOR or upstream signaling nodes should be used with caution when combined with chemotherapeutic agents that rely on cell-cycle progression to kill B-ALL cells i Mol Cancer Ther 16 9 1942-53 2017 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[804, 128, 1, 873, 16, 41, 5, 334, 356, 2, 142, 287, 1, 429, 4, 132, 31, 286, 1275, 132, 62, 631, 942, 38, 143, 32, 471, 873, 222, 4, 150, 5, 56, 4, 132, 62, 137, 3, 150, 1, 873, 222, 5, 260, 1, 165, 56, 600, 71, 44, 85, 656, 3576, 4, 64, 43, 132, 62, 814, 673, 21, 650, 317, 873, 297, 122, 4369, 3, 209, 1, 291, 56, 183, 4, 2058, 172, 172, 2, 2058, 733, 132, 62, 274, 5819, 2062, 873, 840, 14, 5023, 5541, 132, 62, 37, 29, 3003, 20, 2116, 2, 49, 9223, 100, 12995, 600, 95, 4, 1146, 56, 3, 10677, 176, 438, 5, 340, 31, 417, 91, 2, 11, 8064, 75, 31, 417, 222, 4895, 15, 30489, 1674, 8, 564, 216, 230, 694, 95, 4, 2058, 172, 172, 7, 1576, 1425, 216, 3988, 1, 873, 1674, 251, 16, 2615, 1546, 20, 1425, 216, 138, 84, 16, 120, 164, 4, 8, 697, 1, 1425, 7216, 140, 21, 108, 1674, 436, 2058, 31, 285, 2, 69, 347, 4, 92, 1674, 122, 1856, 969, 1425, 216, 128, 2, 5023, 314, 187, 3440, 31, 273, 4, 46, 140, 1674, 5541, 37, 29, 3003, 20, 49, 9223, 75, 1330, 274, 21, 164, 17, 873, 297, 15, 1674, 101, 3, 1870, 1, 37, 17, 6371, 50, 3345, 1, 56, 24, 46, 99, 608, 17, 222, 529, 873, 15, 3988, 314, 502, 257, 40, 95, 5, 5526, 198, 397, 5, 1573, 183, 17, 5533, 23, 31, 417, 91, 6, 5097, 132, 62, 37, 70, 5824, 12, 7770, 245, 83, 24525, 699, 3194, 1630, 70]",1737.0,28566433,65
Whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients.,Oncotarget,Oncotarget,2017-07-01,"Allergy, pancreatitis and thrombosis are common side-effects of childhood acute lymphoblastic leukemia (ALL) treatment that are associated with the use of asparaginase (ASNase), a key component in most ALL treatment protocols. Starting with predicted functional germline variants obtained through whole-exome sequencing (WES) data of the Quebec childhood ALL cohort we performed exome-wide association studies with ASNase-related toxicities. A subset of top-ranking variants was further confirmed by genotyping (N=302) followed by validation in an independent replication group (N=282); except for thrombosis which was not available for that dataset. SNPs in 12 genes were associated with ASNase complications in discovery cohort including 3 that were associated with allergy, 3 with pancreatitis and 6 with thrombosis. The risk was further increased through combined SNPs effect (p0.002), suggesting synergistic interactions between the SNPs identified in each of the studied toxicities. Interestingly, rs3809849 in the MYBBP1A gene was associated with allergy (p= 0.0006), pancreatitis (p=0.002), thrombosis (p=0.02), event-free survival (p=0.02) and overall survival (p=0.003). Furthermore, rs11556218 in IL16 and rs34708521 in SPEF2 were both associated with thrombosis (p=0.01 and p=0.03, respectively) and pancreatitis (p=0.02). The association of SNPs in MYBBP1A, SPEF2 and IL16 geneswith pancreatitis was replicated in the validation cohort (p 0.05) as well as in combined cohort (p=0.0003, p=0.008 and p=0.02, respectively). The synergistic effect of combining risk loci had the highest power to predict the development of pancreatitis in both cohorts and was further potentiated in the combined cohort (p=1x10-8).The present work demonstrates that using WES data is a successful ""hypothesis-free"" strategy for identifying significant genetic markers modulating the effect of the treatment in childhood ALL.",Journal Article,934.0,,Allergy pancreatitis and thrombosis are common side-effects of childhood acute lymphoblastic ALL treatment that are associated with the use of asparaginase ASNase a key component in most ALL treatment protocols Starting with predicted functional germline variants obtained through whole-exome sequencing WES data of the Quebec childhood ALL cohort we performed exome-wide association studies with ASNase-related toxicities A subset of top-ranking variants was further confirmed by genotyping N=302 followed by validation in an independent replication group N=282 except for thrombosis which was not available for that dataset SNPs in 12 genes were associated with ASNase complications in discovery cohort including 3 that were associated with allergy 3 with pancreatitis and 6 with thrombosis The risk was further increased through combined SNPs effect p0.002 suggesting synergistic interactions between the SNPs identified in each of the studied toxicities Interestingly rs3809849 in the MYBBP1A gene was associated with allergy p= 0.0006 pancreatitis p=0.002 thrombosis p=0.02 event-free survival p=0.02 and overall survival p=0.003 Furthermore rs11556218 in IL16 and rs34708521 in SPEF2 were both associated with thrombosis p=0.01 and p=0.03 respectively and pancreatitis p=0.02 The association of SNPs in MYBBP1A SPEF2 and IL16 geneswith pancreatitis was replicated in the validation cohort p 0.05 as well as in combined cohort p=0.0003 p=0.008 and p=0.02 respectively The synergistic effect of combining risk loci had the highest power to predict the development of pancreatitis in both cohorts and was further potentiated in the combined cohort p=1x10-8 .The present work demonstrates that using WES data is a successful `` hypothesis-free '' strategy for identifying significant genetic markers modulating the effect of the treatment in childhood ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9842, 4535, 2, 2839, 32, 186, 1152, 176, 1, 864, 286, 1275, 62, 24, 17, 32, 41, 5, 3, 119, 1, 3709, 16558, 8, 825, 1249, 4, 96, 62, 24, 2189, 1723, 5, 783, 583, 1009, 839, 683, 298, 902, 2865, 615, 9148, 74, 1, 3, 19440, 864, 62, 180, 21, 173, 2865, 1019, 248, 94, 5, 16558, 139, 385, 8, 697, 1, 3150, 11185, 839, 10, 195, 557, 20, 2686, 78, 4952, 370, 20, 929, 4, 35, 306, 2079, 87, 78, 8219, 2187, 9, 2839, 92, 10, 44, 390, 9, 17, 3014, 1109, 4, 133, 214, 11, 41, 5, 16558, 521, 4, 1574, 180, 141, 27, 17, 11, 41, 5, 9842, 27, 5, 4535, 2, 49, 5, 2839, 3, 43, 10, 195, 101, 298, 397, 1109, 254, 12444, 1111, 802, 1806, 1286, 59, 3, 1109, 108, 4, 296, 1, 3, 656, 385, 2873, 70496, 4, 3, 50417, 145, 10, 41, 5, 9842, 19, 13, 6013, 4535, 19, 13, 1111, 2839, 19, 13, 588, 774, 115, 25, 19, 13, 588, 2, 63, 25, 19, 13, 1421, 798, 70497, 4, 41026, 2, 70498, 4, 50418, 11, 110, 41, 5, 2839, 19, 13, 355, 2, 19, 13, 680, 106, 2, 4535, 19, 13, 588, 3, 248, 1, 1109, 4, 50417, 50418, 2, 41026, 70499, 4535, 10, 6714, 4, 3, 929, 180, 19, 8710, 474, 22, 149, 22, 4, 397, 180, 19, 13, 4418, 19, 13, 2155, 2, 19, 13, 588, 106, 3, 1806, 254, 1, 1525, 43, 2012, 42, 3, 1076, 2349, 6, 678, 3, 193, 1, 4535, 4, 110, 736, 2, 10, 195, 6707, 4, 3, 397, 180, 19, 28716, 66, 3, 364, 1357, 1902, 17, 75, 9148, 74, 16, 8, 1401, 1492, 115, 522, 692, 9, 1386, 93, 336, 525, 3712, 3, 254, 1, 3, 24, 4, 864, 62]",1859.0,28574850,276
Treatment of acute lymphoblastic leukemia in older adults: now and the future.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2017-04-01,"Acute lymphoblastic leukemia (ALL) is an uncommon disease with poor outcomes in older patients. Although intensive chemotherapy can induce complete responses in older patients, the mortality rate is unacceptably high. The 5-year survival rate for patients achieving a remission ranges from 17% to 23%. ALL is usually more aggressive in older patients, and these patients' reduced functional capacity renders them less able to tolerate treatment. The need for less-intensive, more-efficient treatment modalities in this population of frail and high-risk patients is evident. Clinicians should strongly consider treatment in clinical trials for their older patients. If such trials are not available on site, physicians should refer older patients to tertiary centers for possible enrollment in a study. Significant advances have been made in the past decade toward understanding the biology of ALL and in developing novel therapeutic agents. Blinatumomab, inotuzumab ozogamicin, and newer-generation tyrosine kinase inhibitors appear to be promising agents. Clinical studies show remarkable results with these agents, either alone or in combination with low-dose chemotherapy. Now that clinical trials are being designed with less-intensive treatment regimens and broad entry criteria, older age is less likely to be an exclusionary factor. However, clinical trials that enroll older patients with ALL should include detailed documentation of their underlying comorbidities, cognitive function, and performance status.",Journal Article,1025.0,8.0,Acute lymphoblastic ALL is an uncommon disease with poor outcomes in older patients Although intensive chemotherapy can induce complete responses in older patients the mortality rate is unacceptably high The 5-year survival rate for patients achieving a remission ranges from 17 to 23 ALL is usually more aggressive in older patients and these patients reduced functional capacity renders them less able to tolerate treatment The need for less-intensive more-efficient treatment modalities in this population of frail and high-risk patients is evident Clinicians should strongly consider treatment in clinical trials for their older patients If such trials are not available on site physicians should refer older patients to tertiary centers for possible enrollment in a study Significant advances have been made in the past decade toward understanding the biology of ALL and in developing novel therapeutic agents Blinatumomab inotuzumab ozogamicin and newer-generation tyrosine kinase inhibitors appear to be promising agents Clinical studies show remarkable results with these agents either alone or in combination with low-dose chemotherapy Now that clinical trials are being designed with less-intensive treatment regimens and broad entry criteria older age is less likely to be an exclusionary factor However clinical trials that enroll older patients with ALL should include detailed documentation of their underlying comorbidities cognitive function and performance status,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 35, 2052, 34, 5, 334, 123, 4, 434, 7, 242, 1686, 56, 122, 1290, 236, 253, 4, 434, 7, 3, 282, 116, 16, 11934, 64, 3, 33, 111, 25, 116, 9, 7, 1785, 8, 734, 5632, 29, 269, 6, 382, 62, 16, 2082, 80, 571, 4, 434, 7, 2, 46, 7, 405, 583, 2162, 8080, 1370, 299, 1665, 6, 5010, 24, 3, 594, 9, 299, 1686, 80, 2547, 24, 1558, 4, 26, 266, 1, 7226, 2, 64, 43, 7, 16, 2853, 1490, 257, 1327, 2419, 24, 4, 38, 143, 9, 136, 434, 7, 492, 225, 143, 32, 44, 390, 23, 606, 1261, 257, 7851, 434, 7, 6, 2557, 1168, 9, 899, 1798, 4, 8, 45, 93, 954, 47, 85, 1229, 4, 3, 1219, 2025, 1317, 612, 3, 891, 1, 62, 2, 4, 931, 229, 189, 183, 7182, 6730, 5566, 2, 2246, 914, 564, 216, 222, 1322, 6, 40, 721, 183, 38, 94, 514, 3813, 99, 5, 46, 183, 361, 279, 15, 4, 150, 5, 154, 61, 56, 1134, 17, 38, 143, 32, 486, 1114, 5, 299, 1686, 24, 472, 2, 2094, 3001, 371, 434, 89, 16, 299, 322, 6, 40, 35, 41001, 161, 137, 38, 143, 17, 6559, 434, 7, 5, 62, 257, 643, 2455, 4965, 1, 136, 1181, 1909, 1863, 343, 2, 528, 156]",1480.0,28591103,428
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens.,Cancer,Cancer,2017-06-13,"Tumor protein 53 (TP53) mutations are uncommon in adult patients with acute lymphoblastic leukemia (ALL) and predict a poor outcome. TP53 mutation analysis was performed in 164 newly diagnosed adult patients with ALL using a combination of targeted amplicon-based next-generation sequencing and Sanger sequencing. TP53 mutations were detected in 25 patients (15%), with a median allelic frequency of 42.2% (range, 5.6%-93.8%). The majority of mutations were single-nucleotide variants of missense type and involved the DNA-binding domain. TP53-mutated (TP53<sup>mut</sup> ) ALL was found to be significantly associated with older age, lower median white blood cell and platelet counts, lower frequency of Philadelphia chromosome and a higher frequency of low hypodiploid karyotype compared with ALL with wild-type TP53 (TP53<sup>wt</sup> ). To evaluate the prognostic effect of TP53 mutations, the authors selected 146 patients with B-cell immunophenotype ALL (24 with TP53<sup>mut</sup> and 122 with TP53<sup>wt</sup> ) who were uniformly treated with frontline hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD)-based regimens; >90% of these individuals also received a monoclonal antibody. Over a median follow-up duration of 15 months, there was no significant difference in the median overall survival, event-free survival, and duration of complete remission noted between patients with TP53<sup>mut</sup> ALL and those with TP53<sup>wt</sup> ALL. Hyper-CVAD-based regimens appear to negate the poor prognostic impact of TP53 mutations in patients with adult B-cell immunophenotype ALL. Cancer 2017;123:3717-24.  2017 American Cancer Society.",Journal Article,952.0,6.0,Tumor protein 53 TP53 mutations are uncommon in adult patients with acute lymphoblastic ALL and predict a poor outcome TP53 mutation analysis was performed in 164 newly diagnosed adult patients with ALL using a combination of targeted amplicon-based next-generation sequencing and Sanger sequencing TP53 mutations were detected in 25 patients 15 with a median allelic frequency of 42.2 range 5.6 -93.8 The majority of mutations were single-nucleotide variants of missense type and involved the DNA-binding domain TP53-mutated TP53 sup mut /sup ALL was found to be significantly associated with older age lower median white blood cell and platelet counts lower frequency of Philadelphia chromosome and a higher frequency of low hypodiploid karyotype compared with ALL with wild-type TP53 TP53 sup wt /sup To evaluate the prognostic effect of TP53 mutations the authors selected 146 patients with B-cell immunophenotype ALL 24 with TP53 sup mut /sup and 122 with TP53 sup wt /sup who were uniformly treated with frontline hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone hyper-CVAD -based regimens 90 of these individuals also received a monoclonal antibody Over a median follow-up duration of 15 months there was no significant difference in the median overall survival event-free survival and duration of complete remission noted between patients with TP53 sup mut /sup ALL and those with TP53 sup wt /sup ALL Hyper-CVAD-based regimens appear to negate the poor prognostic impact of TP53 mutations in patients with adult B-cell immunophenotype ALL Cancer 2017 123:3717-24  2017 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[30, 178, 699, 1206, 138, 32, 2052, 4, 780, 7, 5, 286, 1275, 62, 2, 678, 8, 334, 228, 1206, 258, 65, 10, 173, 4, 5279, 732, 265, 780, 7, 5, 62, 75, 8, 150, 1, 238, 9161, 90, 1305, 914, 615, 2, 7285, 615, 1206, 138, 11, 530, 4, 243, 7, 167, 5, 8, 52, 3861, 675, 1, 595, 18, 184, 33, 49, 966, 66, 3, 686, 1, 138, 11, 226, 1579, 839, 1, 4007, 267, 2, 646, 3, 261, 791, 1398, 1206, 1185, 1206, 172, 3857, 172, 62, 10, 204, 6, 40, 97, 41, 5, 434, 89, 280, 52, 886, 315, 31, 2, 1596, 1911, 280, 675, 1, 3006, 1170, 2, 8, 142, 675, 1, 154, 12135, 3385, 72, 5, 62, 5, 955, 267, 1206, 1206, 172, 1820, 172, 6, 376, 3, 177, 254, 1, 1206, 138, 3, 738, 715, 4909, 7, 5, 132, 31, 5496, 62, 259, 5, 1206, 172, 3857, 172, 2, 3285, 5, 1206, 172, 1820, 172, 54, 11, 4254, 73, 5, 3171, 6201, 1112, 2132, 856, 2, 1217, 4855, 5574, 90, 472, 424, 1, 46, 869, 120, 103, 8, 848, 548, 252, 8, 52, 166, 126, 654, 1, 167, 53, 125, 10, 77, 93, 523, 4, 3, 52, 63, 25, 774, 115, 25, 2, 654, 1, 236, 734, 1051, 59, 7, 5, 1206, 172, 3857, 172, 62, 2, 135, 5, 1206, 172, 1820, 172, 62, 4855, 5574, 90, 472, 1322, 6, 19730, 3, 334, 177, 345, 1, 1206, 138, 4, 7, 5, 780, 132, 31, 5496, 62, 12, 1759, 2698, 70577, 259, 2206, 1759, 597, 12, 1174]",1630.0,28608976,194
Genetics of pleiotropic effects of dexamethasone.,Pharmacogenetics and genomics,Pharmacogenet. Genomics,2017-08-01,"Glucocorticoids such as dexamethasone have pleiotropic effects, including desired antileukemic, anti-inflammatory, or immunosuppressive effects, and undesired metabolic or toxic effects. The most serious adverse effects of dexamethasone among patients with acute lymphoblastic leukemia are osteonecrosis and thrombosis. To identify inherited genomic variation involved in these severe adverse effects, we carried out genome-wide association studies (GWAS) by analyzing 14 pleiotropic glucocorticoid phenotypes in 391 patients with acute lymphoblastic leukemia. We used the Projection Onto the Most Interesting Statistical Evidence integrative analysis technique to identify genetic variants associated with pleiotropic dexamethasone phenotypes, stratifying for age, sex, race, and treatment, and compared the results with conventional single-phenotype GWAS. The phenotypes were osteonecrosis, central nervous system toxicity, hyperglycemia, hypokalemia, thrombosis, dexamethasone exposure, BMI, growth trajectory, and levels of cortisol, albumin, and asparaginase antibodies, and changes in cholesterol, triglycerides, and low-density lipoproteins after dexamethasone. The integrative analysis identified more pleiotropic single nucleotide polymorphism variants (P=1.4610(-215), and these variants were more likely to be in gene-regulatory regions (P=1.2210(-6)) than traditional single-phenotype GWAS. The integrative analysis yielded genomic variants (rs2243057 and rs6453253) in F2RL1, a receptor that functions in hemostasis, thrombosis, and inflammation, which were associated with pleiotropic effects, including osteonecrosis and thrombosis, and were in regulatory gene regions. The integrative pleiotropic analysis identified risk variants for osteonecrosis and thrombosis not identified by single-phenotype analysis that may have importance for patients with underlying sensitivity to multiple dexamethasone adverse effects.",Comparative Study,903.0,4.0,Glucocorticoids such as dexamethasone have pleiotropic effects including desired antileukemic anti-inflammatory or immunosuppressive effects and undesired metabolic or toxic effects The most serious adverse effects of dexamethasone among patients with acute lymphoblastic are osteonecrosis and thrombosis To identify inherited genomic variation involved in these severe adverse effects we carried out genome-wide association studies GWAS by analyzing 14 pleiotropic glucocorticoid phenotypes in 391 patients with acute lymphoblastic We used the Projection Onto the Most Interesting Statistical Evidence integrative analysis technique to identify genetic variants associated with pleiotropic dexamethasone phenotypes stratifying for age sex race and treatment and compared the results with conventional single-phenotype GWAS The phenotypes were osteonecrosis central nervous system toxicity hyperglycemia hypokalemia thrombosis dexamethasone exposure BMI growth trajectory and levels of cortisol albumin and asparaginase antibodies and changes in cholesterol triglycerides and low-density lipoproteins after dexamethasone The integrative analysis identified more pleiotropic single nucleotide polymorphism variants P=1.4610 -215 and these variants were more likely to be in gene-regulatory regions P=1.2210 -6 than traditional single-phenotype GWAS The integrative analysis yielded genomic variants rs2243057 and rs6453253 in F2RL1 a receptor that functions in hemostasis thrombosis and inflammation which were associated with pleiotropic effects including osteonecrosis and thrombosis and were in regulatory gene regions The integrative pleiotropic analysis identified risk variants for osteonecrosis and thrombosis not identified by single-phenotype analysis that may have importance for patients with underlying sensitivity to multiple dexamethasone adverse effects,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7307, 225, 22, 1217, 47, 7872, 176, 141, 6115, 4512, 312, 1291, 15, 2989, 176, 2, 25210, 1436, 15, 1812, 176, 3, 96, 1762, 290, 176, 1, 1217, 107, 7, 5, 286, 1275, 32, 5404, 2, 2839, 6, 255, 2986, 572, 1380, 646, 4, 46, 905, 290, 176, 21, 2629, 1205, 898, 1019, 248, 94, 3297, 20, 4449, 213, 7872, 5399, 2618, 4, 10881, 7, 5, 286, 1275, 21, 95, 3, 11326, 3301, 3, 96, 6597, 1050, 241, 4324, 65, 1312, 6, 255, 336, 839, 41, 5, 7872, 1217, 2618, 5035, 9, 89, 1035, 1047, 2, 24, 2, 72, 3, 99, 5, 809, 226, 1005, 3297, 3, 2618, 11, 5404, 854, 1880, 398, 155, 3992, 7799, 2839, 1217, 645, 1140, 129, 6118, 2, 148, 1, 9572, 2799, 2, 3709, 890, 2, 400, 4, 5020, 15000, 2, 154, 1263, 19941, 50, 1217, 3, 4324, 65, 108, 80, 7872, 226, 1579, 1907, 839, 19, 14, 70624, 6511, 2, 46, 839, 11, 80, 322, 6, 40, 4, 145, 1253, 1374, 19, 14, 47794, 49, 76, 1847, 226, 1005, 3297, 3, 4324, 65, 2178, 572, 839, 70625, 2, 70626, 4, 48120, 8, 153, 17, 1681, 4, 16020, 2839, 2, 1815, 92, 11, 41, 5, 7872, 176, 141, 5404, 2, 2839, 2, 11, 4, 1253, 145, 1374, 3, 4324, 7872, 65, 108, 43, 839, 9, 5404, 2, 2839, 44, 108, 20, 226, 1005, 65, 17, 68, 47, 1187, 9, 7, 5, 1181, 485, 6, 232, 1217, 290, 176]",1869.0,28628558,529
The novel phospholipid mimetic KPC34 is highly active against preclinical models of Philadelphia chromosome positive acute lymphoblastic leukemia.,PloS one,PLoS ONE,2017-06-23,"Philadelphia chromosome positive B cell acute lymphoblastic leukemia (Ph+ ALL) is an aggressive cancer of the bone marrow. The addition of tyrosine kinase inhibitors (TKIs) has improved outcomes but many patients still suffer relapse and novel therapeutic agents are needed. KPC34 is an orally available, novel phospholipid conjugate of gemcitabine, rationally designed to overcome multiple mechanisms of resistance, inhibit the classical and novel isoforms of protein kinase C, is able to cross the blood brain barrier and is orally bioavailable. KPC34 had an IC50 in the nanomolar range against multiple ALL cell lines tested but was lowest for Ph+ lines. In mice bearing either nave or resistant Ph+ ALL, KPC34 treatment resulted in significantly improved survival compared to cytarabine and gemcitabine. Treatment with KPC34 and doxorubicin was more effective than doxorubicin and cytarabine. Mice with recurrence of their ALL after initial treatment with cytarabine and doxorubicin saw dramatic improvements in hind limb paralysis after treatment with KPC34 demonstrating activity against established CNS disease. Consistent with this KPC34 was better than gemcitabine at reducing CNS leukemic burden. These promising pre-clinical results justify the continued development of KPC34 for the treatment of Ph+ALL.",Journal Article,942.0,2.0,Philadelphia chromosome positive B cell acute lymphoblastic Ph+ ALL is an aggressive cancer of the marrow The addition of tyrosine kinase inhibitors TKIs has improved outcomes but many patients still suffer relapse and novel therapeutic agents are needed KPC34 is an orally available novel phospholipid conjugate of gemcitabine rationally designed to overcome multiple mechanisms of resistance inhibit the classical and novel isoforms of protein kinase C is able to cross the blood brain barrier and is orally bioavailable KPC34 had an IC50 in the nanomolar range against multiple ALL cell lines tested but was lowest for Ph+ lines In mice bearing either nave or resistant Ph+ ALL KPC34 treatment resulted in significantly improved survival compared to cytarabine and gemcitabine Treatment with KPC34 and doxorubicin was more effective than doxorubicin and cytarabine Mice with recurrence of their ALL after initial treatment with cytarabine and doxorubicin saw dramatic improvements in hind limb paralysis after treatment with KPC34 demonstrating activity against established CNS disease Consistent with this KPC34 was better than gemcitabine at reducing CNS leukemic burden These promising pre-clinical results justify the continued development of KPC34 for the treatment of Ph+ALL,0,0,1,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 109, 132, 31, 286, 1275, 2058, 62, 16, 35, 571, 12, 1, 3, 581, 3, 352, 1, 564, 216, 222, 1671, 71, 231, 123, 84, 445, 7, 1234, 6506, 429, 2, 229, 189, 183, 32, 575, 27621, 16, 35, 1428, 390, 229, 13476, 3998, 1, 679, 6352, 1114, 6, 1768, 232, 483, 1, 251, 1433, 3, 3781, 2, 229, 3913, 1, 178, 216, 256, 16, 1665, 6, 1383, 3, 315, 342, 3318, 2, 16, 1428, 6582, 27621, 42, 35, 5211, 4, 3, 7927, 184, 480, 232, 62, 31, 285, 650, 84, 10, 2101, 9, 2058, 285, 4, 399, 1894, 361, 2809, 15, 436, 2058, 62, 27621, 24, 627, 4, 97, 231, 25, 72, 6, 1855, 2, 679, 24, 5, 27621, 2, 856, 10, 80, 323, 76, 856, 2, 1855, 399, 5, 146, 1, 136, 62, 50, 388, 24, 5, 1855, 2, 856, 9257, 3079, 1474, 4, 15899, 3930, 11737, 50, 24, 5, 27621, 2219, 128, 480, 635, 1025, 34, 925, 5, 26, 27621, 10, 380, 76, 679, 28, 1818, 1025, 2015, 892, 46, 721, 671, 38, 99, 6665, 3, 1351, 193, 1, 27621, 9, 3, 24, 1, 2058, 62]",1284.0,28644853,251
Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2017-08-01,"Over half of patients diagnosed with B-cell acute lymphoblastic leukemia (ALL) develop relapsed or refractory disease. Traditional chemotherapy salvage is inadequate, and new therapies are needed. Chimeric antigen receptor (CAR) T cell therapy is a novel, immunologic approach where T cells are genetically engineered to express a CAR conferring specificity against a target cell surface antigen, most commonly the pan-B-cell marker CD19. After infusion, CAR T cells expand and persist, allowing ongoing tumor surveillance. Several anti-CD19 CAR T cell constructs have induced high response rates in heavily pre-treated populations, although durability of response varied. Severe toxicity (cytokine release syndrome and neurotoxicity) is the primary constraint to broad implementation of CAR T cell therapy. Here, we review the experience of CAR T cell therapy for ALL and ongoing efforts to modify existing technology to improve efficacy and decrease toxicity. As an anti-CD19 CAR T cell construct may be FDA approved soon, we focus on issues relevant to practicing clinicians.",Journal Article,903.0,6.0,Over half of patients diagnosed with B-cell acute lymphoblastic ALL develop relapsed or refractory disease Traditional chemotherapy salvage is inadequate and new therapies are needed Chimeric antigen receptor CAR T cell therapy is a novel immunologic approach where T cells are genetically engineered to express a CAR conferring specificity against a target cell surface antigen most commonly the pan-B-cell marker CD19 After infusion CAR T cells expand and persist allowing ongoing tumor surveillance Several anti-CD19 CAR T cell constructs have induced high response rates in heavily pre-treated populations although durability of response varied Severe toxicity cytokine release syndrome and neurotoxicity is the primary constraint to broad implementation of CAR T cell therapy Here we review the experience of CAR T cell therapy for ALL and ongoing efforts to modify existing technology to improve efficacy and decrease toxicity As an anti-CD19 CAR T cell construct may be FDA approved soon we focus on issues relevant to practicing clinicians,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[252, 1303, 1, 7, 265, 5, 132, 31, 286, 1275, 62, 690, 591, 15, 430, 34, 1847, 56, 992, 16, 3358, 2, 217, 235, 32, 575, 2897, 448, 153, 1881, 102, 31, 36, 16, 8, 229, 3042, 353, 1257, 102, 37, 32, 2301, 2794, 6, 1669, 8, 1881, 7209, 1121, 480, 8, 283, 31, 1255, 448, 96, 841, 3, 3055, 132, 31, 952, 3158, 50, 904, 1881, 102, 37, 4082, 2, 5589, 2952, 942, 30, 617, 392, 312, 3158, 1881, 102, 31, 5500, 47, 277, 64, 51, 151, 4, 2447, 671, 73, 1184, 242, 6867, 1, 51, 2051, 905, 155, 1675, 2008, 681, 2, 3561, 16, 3, 86, 11482, 6, 2094, 2393, 1, 1881, 102, 31, 36, 467, 21, 206, 3, 730, 1, 1881, 102, 31, 36, 9, 62, 2, 942, 1413, 6, 4289, 1692, 2033, 6, 401, 209, 2, 775, 155, 22, 35, 312, 3158, 1881, 102, 31, 3883, 68, 40, 2078, 850, 6176, 21, 1222, 23, 1553, 867, 6, 6734, 1490]",1047.0,28656487,645
Novel variants in <i>NUDT15</i> and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry.,Blood,Blood,2017-06-28,"Prolonged exposure to thiopurines (eg, mercaptopurine [MP]) is essential for curative therapy in acute lymphoblastic leukemia (ALL), but is also associated with frequent dose-limiting hematopoietic toxicities, which is partly explained by inherited genetic polymorphisms in drug metabolizing enzymes (eg, <i>TPMT</i>). Recently, our group and others identified germ line genetic variants in <i>NUDT15</i> as another major cause of thiopurine-related myelosuppression, particularly in Asian and Hispanic people. In this article, we describe 3 novel <i>NUDT15</i> coding variants (p.R34T, p.K35E, and p.G17_V18del) in 5 children with ALL enrolled in frontline protocols in Singapore, Taiwan, and at St. Jude Children's Research Hospital. Patients carrying these variants experienced significant toxicity and reduced tolerance to MP across treatment protocols. Functionally, all 3 variants led to partial to complete loss of NUDT15 nucleotide diphosphatase activity and negatively influenced protein stability. In particular, the p.G17_V18del variant protein showed extremely low thermostability and was completely void of catalytic activity, thus likely to confer a high risk of thiopurine intolerance. This in-frame deletion was only seen in African and European patients, and is the first <i>NUDT15</i> risk variant identified in non-Asian, non-Hispanic populations. In conclusion, we discovered 3 novel loss-of-function variants in <i>NUDT15</i> associated with MP toxicity, enabling more comprehensive pharmacogenetics-based thiopurine dose adjustments across diverse populations.",Journal Article,937.0,31.0,Prolonged exposure to thiopurines eg mercaptopurine MP is essential for curative therapy in acute lymphoblastic ALL but is also associated with frequent dose-limiting hematopoietic toxicities which is partly explained by inherited genetic polymorphisms in drug metabolizing enzymes eg i TPMT /i Recently our group and others identified germ line genetic variants in i NUDT15 /i as another major cause of thiopurine-related myelosuppression particularly in Asian and Hispanic people In this article we describe 3 novel i NUDT15 /i coding variants p.R34T p.K35E and p.G17_V18del in 5 children with ALL enrolled in frontline protocols in Singapore Taiwan and at St. Jude Children 's Research Hospital Patients carrying these variants experienced significant toxicity and reduced tolerance to MP across treatment protocols Functionally all 3 variants led to partial to complete loss of NUDT15 nucleotide diphosphatase activity and negatively influenced protein stability In particular the p.G17_V18del variant protein showed extremely low thermostability and was completely void of catalytic activity thus likely to confer a high risk of thiopurine intolerance This in-frame deletion was only seen in African and European patients and is the first i NUDT15 /i risk variant identified in non-Asian non-Hispanic populations In conclusion we discovered 3 novel loss-of-function variants in i NUDT15 /i associated with MP toxicity enabling more comprehensive pharmacogenetics-based thiopurine dose adjustments across diverse populations,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1069, 645, 6, 39767, 2887, 9223, 4545, 16, 1452, 9, 1075, 36, 4, 286, 1275, 62, 84, 16, 120, 41, 5, 908, 61, 817, 1007, 385, 92, 16, 5180, 3672, 20, 2986, 336, 1203, 4, 234, 9800, 3039, 2887, 70, 14852, 70, 761, 114, 87, 2, 1749, 108, 2280, 328, 336, 839, 4, 70, 18089, 70, 22, 1809, 458, 708, 1, 14062, 139, 2858, 823, 4, 2399, 2, 1776, 3788, 4, 26, 946, 21, 897, 27, 229, 70, 18089, 70, 3097, 839, 19, 70717, 19, 70718, 2, 19, 41811, 50471, 4, 33, 541, 5, 62, 346, 4, 3171, 2189, 4, 15622, 9033, 2, 28, 3062, 4841, 541, 292, 389, 702, 7, 2934, 46, 839, 592, 93, 155, 2, 405, 2614, 6, 4545, 716, 24, 2189, 3772, 62, 27, 839, 836, 6, 450, 6, 236, 407, 1, 18089, 1579, 49571, 128, 2, 2723, 2574, 178, 2769, 4, 1454, 3, 19, 41811, 50471, 1142, 178, 224, 2938, 154, 70719, 2, 10, 2500, 25489, 1, 4784, 128, 631, 322, 6, 2913, 8, 64, 43, 1, 14062, 5266, 26, 4, 5331, 1528, 10, 158, 527, 4, 1410, 2, 1865, 7, 2, 16, 3, 157, 70, 18089, 70, 43, 1142, 108, 4, 220, 2399, 220, 1776, 1184, 4, 1221, 21, 2747, 27, 229, 407, 1, 343, 839, 4, 70, 18089, 70, 41, 5, 4545, 155, 5257, 80, 949, 8759, 90, 14062, 61, 6017, 716, 1867, 1184]",1528.0,28659275,308
Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment.,Practical radiation oncology,Pract Radiat Oncol,2017-05-10,"Craniospinal irradiation (CSI) improves local control of leukemia/lymphoma with central nervous system (CNS) involvement; however, for adult patients anticipating stem cell transplant (SCT), cumulative treatment toxicity is a major concern. We evaluated toxicities and outcomes for patients receiving proton or photon CSI before SCT. We identified 37 consecutive leukemia/lymphoma patients with CNS involvement who received CSI before SCT at our institution. Photon versus proton toxicities during CSI, transplant, and through 100 days posttransplant were compared using Fisher exact and Wilcoxon rank sum tests. Long-term neurotoxicity, disease response, and overall survival were analyzed. Thirty-seven patients (23 photon, 14 proton) underwent CSI for CNS involvement of acute lymphoblastic leukemia (49%), acute myeloblastic leukemia (22%), chronic lymphocytic leukemia (3%), chronic myelocytic leukemia (14%), lymphoma (11%), and myeloma (3%). CSI was used for consolidation (30 patients, 81%) and gross disease treatment (7 patients, 19%). Median radiation dose (interquartile range) was 24 Gy (23.4-24) for photons and 21.8 Gy (21.3-23.6) for protons (P = .03). Proton CSI was associated with lower rates of Radiation Therapy Oncology Group grade 1-3 mucositis during CSI (7% vs 44%, P = .03): 1 grade 3 with protons versus 5 grade 1, 3 grade 2, and 2 grade 3 with photons. During CSI, other toxicities (infection, gastrointestinal symptoms) did not differ. Allogeneic stem cell transplant (SCT) was used in 95% of patients, with 53% of patients in remission before SCT. Myeloablative conditioning was used for 76%. During SCT admission and 100 days post-SCT, toxicities did not differ by CSI technique. Successful engraftment occurred in 95% of patients (P = .67). Progression or death occurred for 47% of patients, with only 1 CNS relapse. In our cohort, CSI offered excellent local control for CNS-involved hematologic malignancies in the pre-SCT setting. Acute mucositis occurred less frequently with proton CSI with comparable peritransplant/long-term toxicity profile, suggesting the need to further explore the benefit/toxicity profile of this technique.",Clinical Trial,986.0,5.0,Craniospinal irradiation CSI improves local control of leukemia/lymphoma with central nervous system CNS involvement however for adult patients anticipating stem cell transplant SCT cumulative treatment toxicity is a major concern We evaluated toxicities and outcomes for patients receiving proton or photon CSI before SCT We identified 37 consecutive leukemia/lymphoma patients with CNS involvement who received CSI before SCT at our institution Photon versus proton toxicities during CSI transplant and through 100 days posttransplant were compared using Fisher exact and Wilcoxon rank sum tests Long-term neurotoxicity disease response and overall survival were analyzed Thirty-seven patients 23 photon 14 proton underwent CSI for CNS involvement of acute lymphoblastic 49 acute myeloblastic 22 chronic lymphocytic 3 chronic myelocytic 14 11 and 3 CSI was used for consolidation 30 patients 81 and gross disease treatment 7 patients 19 Median radiation dose interquartile range was 24 Gy 23.4-24 for photons and 21.8 Gy 21.3-23.6 for protons P .03 Proton CSI was associated with lower rates of Radiation Therapy Oncology Group grade 1-3 mucositis during CSI 7 vs 44 P .03 1 grade 3 with protons versus 5 grade 1 3 grade 2 and 2 grade 3 with photons During CSI other toxicities infection symptoms did not differ Allogeneic stem cell transplant SCT was used in 95 of patients with 53 of patients in remission before SCT Myeloablative conditioning was used for 76 During SCT admission and 100 days post-SCT toxicities did not differ by CSI technique Successful engraftment occurred in 95 of patients P .67 Progression or death occurred for 47 of patients with only 1 CNS relapse In our cohort CSI offered excellent local control for CNS-involved hematologic malignancies in the pre-SCT setting Acute mucositis occurred less frequently with proton CSI with comparable peritransplant/long-term toxicity profile suggesting the need to further explore the benefit/toxicity profile of this technique,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[5748, 1104, 4293, 1804, 293, 182, 1, 2647, 4763, 5, 854, 1880, 398, 1025, 799, 137, 9, 780, 7, 23574, 452, 31, 941, 1988, 967, 24, 155, 16, 8, 458, 2893, 21, 194, 385, 2, 123, 9, 7, 357, 2095, 15, 4216, 4293, 348, 1988, 21, 108, 567, 935, 2647, 4763, 7, 5, 1025, 799, 54, 103, 4293, 348, 1988, 28, 114, 731, 4216, 185, 2095, 385, 190, 4293, 941, 2, 298, 394, 162, 7346, 11, 72, 75, 3135, 2472, 2, 3896, 1026, 3216, 895, 319, 337, 3561, 34, 51, 2, 63, 25, 11, 311, 977, 648, 7, 382, 4216, 213, 2095, 208, 4293, 9, 1025, 799, 1, 286, 1275, 739, 286, 21049, 350, 442, 1193, 27, 442, 19446, 213, 175, 2, 27, 4293, 10, 95, 9, 2173, 201, 7, 865, 2, 1789, 34, 24, 67, 7, 326, 52, 121, 61, 2899, 184, 10, 259, 381, 382, 39, 259, 9, 7862, 2, 239, 66, 381, 239, 27, 382, 49, 9, 6684, 19, 680, 2095, 4293, 10, 41, 5, 280, 151, 1, 121, 36, 413, 87, 88, 14, 27, 2606, 190, 4293, 67, 105, 584, 19, 680, 14, 88, 27, 5, 6684, 185, 33, 88, 14, 27, 88, 18, 2, 18, 88, 27, 5, 7862, 190, 4293, 127, 385, 930, 507, 205, 44, 1505, 1063, 452, 31, 941, 1988, 10, 95, 4, 48, 1, 7, 5, 699, 1, 7, 4, 734, 348, 1988, 3246, 1933, 10, 95, 9, 846, 190, 1988, 3411, 2, 394, 162, 539, 1988, 385, 205, 44, 1505, 20, 4293, 1312, 1401, 2881, 489, 4, 48, 1, 7, 19, 598, 91, 15, 273, 489, 9, 662, 1, 7, 5, 158, 14, 1025, 429, 4, 114, 180, 4293, 2216, 1503, 293, 182, 9, 1025, 646, 813, 441, 4, 3, 671, 1988, 546, 286, 2606, 489, 299, 746, 5, 2095, 4293, 5, 1279, 21203, 319, 337, 155, 800, 802, 3, 594, 6, 195, 1645, 3, 247, 155, 800, 1, 26, 1312]",1994.0,28666906,356
The genomic landscape of pediatric and young adult T-lineage acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2017-07-03,"Genetic alterations that activate NOTCH1 signaling and T cell transcription factors, coupled with inactivation of the INK4/ARF tumor suppressors, are hallmarks of T-lineage acute lymphoblastic leukemia (T-ALL), but detailed genome-wide sequencing of large T-ALL cohorts has not been carried out. Using integrated genomic analysis of 264 T-ALL cases, we identified 106 putative driver genes, half of which had not previously been described in childhood T-ALL (for example, CCND3, CTCF, MYB, SMARCA4, ZFP36L2 and MYCN). We describe new mechanisms of coding and noncoding alteration and identify ten recurrently altered pathways, with associations between mutated genes and pathways, and stage or subtype of T-ALL. For example, NRAS/FLT3 mutations were associated with immature T-ALL, JAK3/STAT5B mutations in HOXA1 deregulated ALL, PTPN2 mutations in TLX1 deregulated T-ALL, and PIK3R1/PTEN mutations in TAL1 deregulated ALL, which suggests that different signaling pathways have distinct roles according to maturational stage. This genomic landscape provides a logical framework for the development of faithful genetic models and new therapeutic approaches.",Journal Article,932.0,155.0,Genetic alterations that activate NOTCH1 signaling and T cell transcription factors coupled with inactivation of the INK4/ARF tumor suppressors are hallmarks of T-lineage acute lymphoblastic T-ALL but detailed genome-wide sequencing of large T-ALL cohorts has not been carried out Using integrated genomic analysis of 264 T-ALL cases we identified 106 putative driver genes half of which had not previously been described in childhood T-ALL for example CCND3 CTCF MYB SMARCA4 ZFP36L2 and MYCN We describe new mechanisms of coding and noncoding alteration and identify ten recurrently altered pathways with associations between mutated genes and pathways and stage or subtype of T-ALL For example NRAS/FLT3 mutations were associated with immature T-ALL JAK3/STAT5B mutations in HOXA1 deregulated ALL PTPN2 mutations in TLX1 deregulated T-ALL and PIK3R1/PTEN mutations in TAL1 deregulated ALL which suggests that different signaling pathways have distinct roles according to maturational stage This genomic landscape provides a logical framework for the development of faithful genetic models and new therapeutic approaches,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[336, 593, 17, 2977, 4607, 314, 2, 102, 31, 866, 130, 3332, 5, 2297, 1, 3, 19792, 5509, 30, 5704, 32, 7693, 1, 102, 2542, 286, 1275, 102, 62, 84, 2455, 898, 1019, 615, 1, 375, 102, 62, 736, 71, 44, 85, 2629, 1205, 75, 2102, 572, 65, 1, 6528, 102, 62, 140, 21, 108, 3251, 2743, 2228, 214, 1303, 1, 92, 42, 44, 373, 85, 1027, 4, 864, 102, 62, 9, 2685, 25000, 16716, 6929, 12457, 70743, 2, 4068, 21, 897, 217, 483, 1, 3097, 2, 6420, 2611, 2, 255, 1618, 8820, 1495, 460, 5, 685, 59, 1185, 214, 2, 460, 2, 82, 15, 875, 1, 102, 62, 9, 2685, 2845, 1224, 138, 11, 41, 5, 5733, 102, 62, 18927, 18085, 138, 4, 35758, 5415, 62, 70744, 138, 4, 29907, 5415, 102, 62, 2, 12936, 820, 138, 4, 18789, 5415, 62, 92, 844, 17, 338, 314, 460, 47, 834, 1790, 768, 6, 30504, 82, 26, 572, 2801, 777, 8, 10405, 2586, 9, 3, 193, 1, 17954, 336, 274, 2, 217, 189, 611]",1121.0,28671688,228
Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response.,Leukemia & lymphoma,Leuk. Lymphoma,2017-07-11,"Outcomes of relapsed adult acute lymphoblastic leukemia (ALL) have improved over time with the introduction of new therapies as well as better supportive care. However, there is still a need for easy-to-use and accurate prognostic tools for patients in first relapse. Whether complete response (CR) with incomplete count recovery (CRh) can be grouped with CR in relapsed ALL trials has not been formally studied. We analyzed 106 ALL patients at first relapse who were treated at three academic centers and achieved CR/CRh. White blood cell count at initial diagnosis and receiving hematopoietic cell transplant (HCT) were independent predictors of overall survival after relapse, while minimal residual disease (MRD) positivity and performance of HCT were predictors of relapse free survival (RFS). Patients who achieved MRD negativity and underwent HCT had the best outcomes. Our results suggest that MRD is a more powerful predictor of outcome than CRh.",Journal Article,924.0,2.0,Outcomes of relapsed adult acute lymphoblastic ALL have improved over time with the introduction of new therapies as well as better supportive care However there is still a need for easy-to-use and accurate prognostic tools for patients in first relapse Whether complete response CR with incomplete count recovery CRh can be grouped with CR in relapsed ALL trials has not been formally studied We analyzed 106 ALL patients at first relapse who were treated at three academic centers and achieved CR/CRh White blood cell count at initial diagnosis and receiving hematopoietic cell transplant HCT were independent predictors of overall survival after relapse while minimal residual disease MRD positivity and performance of HCT were predictors of relapse free survival RFS Patients who achieved MRD negativity and underwent HCT had the best outcomes Our results suggest that MRD is a more powerful predictor of outcome than CRh,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[123, 1, 591, 780, 286, 1275, 62, 47, 231, 252, 98, 5, 3, 2456, 1, 217, 235, 22, 149, 22, 380, 1877, 165, 137, 125, 16, 1234, 8, 594, 9, 6261, 6, 119, 2, 1481, 177, 1896, 9, 7, 4, 157, 429, 317, 236, 51, 684, 5, 2610, 1276, 1602, 18100, 122, 40, 3706, 5, 684, 4, 591, 62, 143, 71, 44, 85, 9790, 656, 21, 311, 3251, 62, 7, 28, 157, 429, 54, 11, 73, 28, 169, 1916, 1168, 2, 513, 684, 18100, 886, 315, 31, 1276, 28, 388, 147, 2, 357, 1007, 31, 941, 1085, 11, 306, 674, 1, 63, 25, 50, 429, 369, 1048, 753, 34, 2029, 1887, 2, 528, 1, 1085, 11, 674, 1, 429, 115, 25, 1272, 7, 54, 513, 2029, 6014, 2, 208, 1085, 42, 3, 824, 123, 114, 99, 309, 17, 2029, 16, 8, 80, 3757, 980, 1, 228, 76, 18100]",925.0,28693363,828
Philadelphia chromosome-like acute lymphoblastic leukemia: progress in a new cancer subtype.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2017-07-01,"Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a newly described, high-risk subtype of B-cell ALL. It is characterized by a gene expression profile similar to that of Ph-positive ALL; however, the BCR-ABL1 fusion is not present. The World Health Organization classification of myeloid neoplasms and acute leukemia recently was updated to include the Ph-like or BCR-ABL1-like ALL subtype of B-cell ALL as a provisional entity. Unlike Ph-positive ALL, which is characterized by the pathognomonic BCR-ABL1 fusion, Ph-like ALL is characterized by a multitude of different genetic rearrangements and mutations. In this review, we outline the age-related and geographic incidence of Ph-like ALL, the association with worse clinical outcomes, and early evidence for the use of ruxolitinib (a Janus kinase 2 inhibitor) and dasatinib (a tyrosine kinase inhibitor targeting ABL1).",Journal Article,934.0,7.0,Philadelphia chromosome-like Ph-like acute lymphoblastic ALL is a newly described high-risk subtype of B-cell ALL It is characterized by a gene expression profile similar to that of Ph-positive ALL however the BCR-ABL1 fusion is not present The World Health Organization classification of myeloid neoplasms and acute recently was updated to include the Ph-like or BCR-ABL1-like ALL subtype of B-cell ALL as a provisional entity Unlike Ph-positive ALL which is characterized by the pathognomonic BCR-ABL1 fusion Ph-like ALL is characterized by a multitude of different genetic rearrangements and mutations In this review we outline the age-related and geographic incidence of Ph-like ALL the association with worse clinical outcomes and early evidence for the use of ruxolitinib a Janus kinase 2 inhibitor and dasatinib a tyrosine kinase inhibitor targeting ABL1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 733, 2058, 733, 286, 1275, 62, 16, 8, 732, 1027, 64, 43, 875, 1, 132, 31, 62, 192, 16, 765, 20, 8, 145, 55, 800, 288, 6, 17, 1, 2058, 109, 62, 137, 3, 1062, 3557, 1212, 16, 44, 364, 3, 1956, 341, 2533, 947, 1, 533, 1179, 2, 286, 761, 10, 2939, 6, 643, 3, 2058, 733, 15, 1062, 3557, 733, 62, 875, 1, 132, 31, 62, 22, 8, 11335, 2983, 4246, 2058, 109, 62, 92, 16, 765, 20, 3, 18167, 1062, 3557, 1212, 2058, 733, 62, 16, 765, 20, 8, 9540, 1, 338, 336, 2072, 2, 138, 4, 26, 206, 21, 5277, 3, 89, 139, 2, 3466, 287, 1, 2058, 733, 62, 3, 248, 5, 639, 38, 123, 2, 191, 241, 9, 3, 119, 1, 4894, 8, 6191, 216, 18, 230, 2, 1674, 8, 564, 216, 230, 529, 3557]",861.0,28749919,238
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.,"Future oncology (London, England)",Future Oncol,2017-08-04,"Treatment of adult acute lymphoblastic leukemia (ALL) has largely relied on cytotoxic chemotherapy agents borrowed from successful treatment regimens of pediatric ALL. However, the high cure rates seen in pediatric ALL have not been replicated in adults. In recent years, the development of monoclonal antibodies targeting cell surface antigens, such as CD19 and CD20, have significantly improved outcomes when used alone or in combination with cytotoxic chemotherapy. With these novel agents come challenges in managing adverse events, understanding mechanisms of resistance and determining their optimal place in therapy alongside conventional chemotherapy and allogeneic stem cell transplant. Herein we discuss the above challenges with the next addition to the armamentarium of antileukemic agents, inotuzumab ozogamicin, an antibody-drug conjugate against CD22.",Journal Article,900.0,4.0,Treatment of adult acute lymphoblastic ALL has largely relied on cytotoxic chemotherapy agents borrowed from successful treatment regimens of pediatric ALL However the high cure rates seen in pediatric ALL have not been replicated in adults In recent years the development of monoclonal antibodies targeting cell surface antigens such as CD19 and CD20 have significantly improved outcomes when used alone or in combination with cytotoxic chemotherapy With these novel agents come challenges in managing adverse events understanding mechanisms of resistance and determining their optimal place in therapy alongside conventional chemotherapy and allogeneic stem cell transplant Herein we discuss the above challenges with the next addition to the armamentarium of antileukemic agents inotuzumab ozogamicin an antibody-drug conjugate against CD22,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 780, 286, 1275, 62, 71, 1733, 9896, 23, 759, 56, 183, 45955, 29, 1401, 24, 472, 1, 815, 62, 137, 3, 64, 1722, 151, 527, 4, 815, 62, 47, 44, 85, 6714, 4, 857, 4, 435, 60, 3, 193, 1, 848, 890, 529, 31, 1255, 1575, 225, 22, 3158, 2, 2198, 47, 97, 231, 123, 198, 95, 279, 15, 4, 150, 5, 759, 56, 5, 46, 229, 183, 6235, 1427, 4, 3969, 290, 281, 612, 483, 1, 251, 2, 2196, 136, 665, 3536, 4, 36, 10150, 809, 56, 2, 1063, 452, 31, 941, 1986, 21, 1139, 3, 2090, 1427, 5, 3, 1305, 352, 6, 3, 5543, 1, 4512, 183, 6730, 5566, 35, 548, 234, 3998, 480, 7599]",843.0,28776425,468
Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant.,Blood,Blood,2017-08-15,"Multiple candidate gene-association studies of non-HLA single-nucleotide polymorphisms (SNPs) and outcomes after blood or marrow transplant (BMT) have been conducted. We identified 70 publications reporting 45 SNPs in 36 genes significantly associated with disease-related mortality, progression-free survival, transplant-related mortality, and/or overall survival after BMT. Replication and validation of these SNP associations were performed using DISCOVeRY-BMT (Determining the Influence of Susceptibility COnveying Variants Related to one-Year mortality after BMT), a well-powered genome-wide association study consisting of 2 cohorts, totaling 2888 BMT recipients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, and their HLA-matched unrelated donors, reported to the Center for International Blood and Marrow Transplant Research. Gene-based tests were used to assess the aggregate effect of SNPs on outcome. None of the previously reported significant SNPs replicated at <i>P</i> < .05 in DISCOVeRY-BMT. Validation analyses showed association with one previously reported donor SNP at <i>P</i> < .05 and survival; more associations would be anticipated by chance alone. No gene-based tests were significant at <i>P</i> < .05. Functional annotation with publicly available data shows these candidate SNPs most likely do not have biochemical function; only 13% of candidate SNPs correlate with gene expression or are predicted to impact transcription factor binding. Of these, half do not impact the candidate gene of interest; the other half correlate with expression of multiple genes. These findings emphasize the peril of pursing candidate approaches and the importance of adequately powered tests of unbiased genome-wide associations with BMT clinical outcomes given the ultimate goal of improving patient outcomes.",Journal Article,889.0,17.0,Multiple candidate gene-association studies of non-HLA single-nucleotide polymorphisms SNPs and outcomes after blood or marrow transplant BMT have been conducted We identified 70 publications reporting 45 SNPs in 36 genes significantly associated with disease-related mortality progression-free survival transplant-related mortality and/or overall survival after BMT Replication and validation of these SNP associations were performed using DISCOVeRY-BMT Determining the Influence of Susceptibility COnveying Variants Related to one-Year mortality after BMT a well-powered genome-wide association study consisting of 2 cohorts totaling 2888 BMT recipients with acute myeloid acute lymphoblastic or syndrome and their HLA-matched unrelated donors reported to the Center for International Blood and Marrow Transplant Research Gene-based tests were used to assess the aggregate effect of SNPs on outcome None of the previously reported significant SNPs replicated at i P /i .05 in DISCOVeRY-BMT Validation analyses showed association with one previously reported donor SNP at i P /i .05 and survival more associations would be anticipated by chance alone No gene-based tests were significant at i P /i .05 Functional annotation with publicly available data shows these candidate SNPs most likely do not have biochemical function only 13 of candidate SNPs correlate with gene expression or are predicted to impact transcription factor binding Of these half do not impact the candidate gene of interest the other half correlate with expression of multiple genes These findings emphasize the peril of pursing candidate approaches and the importance of adequately powered tests of unbiased genome-wide associations with BMT clinical outcomes given the ultimate goal of improving patient outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[232, 1609, 145, 248, 94, 1, 220, 1160, 226, 1579, 1203, 1109, 2, 123, 50, 315, 15, 581, 941, 4611, 47, 85, 426, 21, 108, 431, 4463, 1760, 512, 1109, 4, 511, 214, 97, 41, 5, 34, 139, 282, 91, 115, 25, 941, 139, 282, 2, 15, 63, 25, 50, 4611, 2079, 2, 929, 1, 46, 1845, 685, 11, 173, 75, 1574, 4611, 2196, 3, 1054, 1, 1432, 26423, 839, 139, 6, 104, 111, 282, 50, 4611, 8, 149, 6855, 898, 1019, 248, 45, 2273, 1, 18, 736, 12739, 71031, 4611, 2190, 5, 286, 533, 286, 1275, 15, 681, 2, 136, 1160, 655, 2092, 2344, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 145, 90, 895, 11, 95, 6, 423, 3, 7494, 254, 1, 1109, 23, 228, 1292, 1, 3, 373, 210, 93, 1109, 6714, 28, 70, 19, 70, 474, 4, 1574, 4611, 929, 318, 224, 248, 5, 104, 373, 210, 1488, 1845, 28, 70, 19, 70, 474, 2, 25, 80, 685, 688, 40, 4078, 20, 3477, 279, 77, 145, 90, 895, 11, 93, 28, 70, 19, 70, 474, 583, 8407, 5, 6878, 390, 74, 1949, 46, 1609, 1109, 96, 322, 1022, 44, 47, 1487, 343, 158, 233, 1, 1609, 1109, 1513, 5, 145, 55, 15, 32, 783, 6, 345, 866, 161, 791, 1, 46, 1303, 1022, 44, 345, 3, 1609, 145, 1, 1333, 3, 127, 1303, 1513, 5, 55, 1, 232, 214, 46, 272, 5560, 3, 50527, 1, 71032, 1609, 611, 2, 3, 1187, 1, 4215, 6855, 895, 1, 7271, 898, 1019, 685, 5, 4611, 38, 123, 447, 3, 5768, 1326, 1, 1673, 69, 123]",1788.0,28811306,460
Philadelphia Chromosome-like Acute Lymphoblastic Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2017-08-01,"Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a recently described B-cell precursor ALL with a gene expression profile and a high frequency of IKZF1 gene alteration similar to that of Ph-positive ALL. Its prevalence is approximately 12% in children, 21% in adolescents (16-20 years of age), and 20% to 24% in adults older than 40 years, with a peak (27%) in young adults 21 to 39 years old. It occurs more often in male individuals and patients with Down syndrome. Ph-like ALL is overrepresented in those with Hispanic ethnicity and is associated with inherited genetic variants in GATA3 (rs3824662). It is a clinically and biologically heterogeneous subtype of B-ALL. Although most patients with Ph-like ALL have positive minimal residual disease after remission induction and poor event-free survival, approximately 40% of pediatric patients responded well to chemotherapy and can be cured with relatively low intensity of treatment. The treatment outcome correlated negatively with increasing age at presentation. Ph-like ALL is characterized by a wide range of genetic alterations that dysregulate several cytokine receptor and kinase signaling pathways, including CRLF2 rearrangement in half of the cases and translocation of nonreceptor tyrosine kinases (predominantly ABL-class and Janus kinases). Patients with ABL-class fusions respond clinically to ABL1 tyrosine kinase inhibitors, whereas mutations activating the JAK-STAT pathway are amendable to treatment with JAK inhibitors invitro or in preclinical models. Prospective studies are needed to determine if incorporation of tyrosine kinase inhibitor targeting kinase alterations into intensive chemotherapy regimens will improve outcome of patients with Ph-like ALL.",Journal Article,903.0,24.0,Philadelphia chromosome-like acute lymphoblastic Ph-like ALL is a recently described B-cell precursor ALL with a gene expression profile and a high frequency of IKZF1 gene alteration similar to that of Ph-positive ALL Its prevalence is approximately 12 in children 21 in adolescents 16-20 years of age and 20 to 24 in adults older than 40 years with a peak 27 in young adults 21 to 39 years old It occurs more often in male individuals and patients with Down syndrome Ph-like ALL is overrepresented in those with Hispanic ethnicity and is associated with inherited genetic variants in GATA3 rs3824662 It is a clinically and biologically heterogeneous subtype of B-ALL Although most patients with Ph-like ALL have positive minimal residual disease after remission induction and poor event-free survival approximately 40 of pediatric patients responded well to chemotherapy and can be cured with relatively low intensity of treatment The treatment outcome correlated negatively with increasing age at presentation Ph-like ALL is characterized by a wide range of genetic alterations that dysregulate several cytokine receptor and kinase signaling pathways including CRLF2 rearrangement in half of the cases and translocation of nonreceptor tyrosine kinases predominantly ABL-class and Janus kinases Patients with ABL-class fusions respond clinically to ABL1 tyrosine kinase inhibitors whereas mutations activating the JAK-STAT pathway are amendable to treatment with JAK inhibitors in vitro or in preclinical models Prospective studies are needed to determine if incorporation of tyrosine kinase inhibitor targeting kinase alterations into intensive chemotherapy regimens will improve outcome of patients with Ph-like ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 733, 286, 1275, 2058, 733, 62, 16, 8, 761, 1027, 132, 31, 2765, 62, 5, 8, 145, 55, 800, 2, 8, 64, 675, 1, 8422, 145, 2611, 288, 6, 17, 1, 2058, 109, 62, 211, 1078, 16, 705, 133, 4, 541, 239, 4, 3101, 245, 179, 60, 1, 89, 2, 179, 6, 259, 4, 857, 434, 76, 327, 60, 5, 8, 2944, 428, 4, 1169, 857, 239, 6, 587, 60, 1095, 192, 1780, 80, 629, 4, 1045, 869, 2, 7, 5, 1328, 681, 2058, 733, 62, 16, 13094, 4, 135, 5, 1776, 2091, 2, 16, 41, 5, 2986, 336, 839, 4, 8140, 32197, 192, 16, 8, 505, 2, 2665, 1564, 875, 1, 132, 62, 242, 96, 7, 5, 2058, 733, 62, 47, 109, 1048, 753, 34, 50, 734, 504, 2, 334, 774, 115, 25, 705, 327, 1, 815, 7, 2211, 149, 6, 56, 2, 122, 40, 3733, 5, 1352, 154, 837, 1, 24, 3, 24, 228, 438, 2723, 5, 602, 89, 28, 1031, 2058, 733, 62, 16, 765, 20, 8, 1019, 184, 1, 336, 593, 17, 31563, 392, 1675, 153, 2, 216, 314, 460, 141, 8895, 2675, 4, 1303, 1, 3, 140, 2, 2006, 1, 17242, 564, 1549, 2117, 1425, 1040, 2, 6191, 1549, 7, 5, 1425, 1040, 2530, 1892, 505, 6, 3557, 564, 216, 222, 547, 138, 1616, 3, 4653, 4168, 308, 32, 35866, 6, 24, 5, 4653, 222, 4, 439, 15, 4, 693, 274, 482, 94, 32, 575, 6, 223, 492, 2838, 1, 564, 216, 230, 529, 216, 593, 237, 1686, 56, 472, 303, 401, 228, 1, 7, 5, 2058, 733, 62]",1718.0,28842136,533
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.,JAMA oncology,JAMA Oncol,2018-02-01,"The outcome of patients with relapsed or refractory (R/R) acute lymphoblastic leukemia (ALL) is poor. Inotuzumab ozogamicin, a CD22 monoclonal antibody bound to calicheamicin, has single-agent activity in R/R ALL. To evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy in patients with R/R ALL. A single-arm, phase 2 study of adults with R/R B-cell ALL conducted at The University of Texas MD Anderson Cancer Center, Houston. The chemotherapy used was lower intensity than hyper-CVAD (cyclophosphamide, vincristine, doxorubicin [trade name, Adriamycin; Pfizer], and dexamethasone) and is referred to as mini-hyper-CVD (mini-HCVD: cyclophosphamide and dexamethasone at 50% dose reduction, no anthracycline, methotrexate at 75% dose reduction, and cytarabine at 0.5 g/m24 doses). Inotuzumab was given on day 3 of the first 4 courses at 1.8 to 1.3 mg/m2 for cycle 1 followed by 1.3 to 1.0 mg/m2 for subsequent cycles. The primary end points were the overall response rate and overall survival (OS). Secondary end points included safety, relapse-free survival (RFS), the rate of allogeneic stem cell transplantation (ASCT), and the minimal residual disease (MRD) negativity rate. Fifty-nine patients (30 women and 29 men) with a median age of 35 years (range, 18-87 years) were treated. Overall, 46 patients (78%) responded, 35 of them (59%) achieving complete response. The overall MRD negativity rate among responders was 82%. Twenty-six patients (44%) received ASCT. Grade 3 to 4 toxic effects included prolonged thrombocytopenia (81%; n=48), infections (73%; n=43), and hyperbilirubinemia (14%; n=8). Veno-occlusive disease (VOD) occurred in 9 patients (15%). With a median follow-up of 24 months, the median RFS and OS were 8 and 11 months, respectively. The 1-year RFS and OS rates were 40% and 46%, respectively. The 1-year OS rates for patients treated in salvage 1, salvage 2, and salvage 3 or beyond were 57%, 26%, and 39%, respectively (P=.03). The combination of inotuzumab with low-intensity mini-HCVD chemotherapy shows encouraging results in R/R ALL. The risk of VOD should be considered carefully in patients with previous liver damage and among transplant candidates. clinicaltrials.gov Identifier: NCT01371630.","Clinical Trial, Phase II",719.0,46.0,The outcome of patients with relapsed or refractory R/R acute lymphoblastic ALL is poor Inotuzumab ozogamicin a CD22 monoclonal antibody bound to calicheamicin has single-agent activity in R/R ALL To evaluate the efficacy and safety of inotuzumab ozogamicin plus low-intensity chemotherapy in patients with R/R ALL A single-arm phase 2 study of adults with R/R B-cell ALL conducted at The University of Texas MD Anderson Cancer Center Houston The chemotherapy used was lower intensity than hyper-CVAD cyclophosphamide vincristine doxorubicin trade name Adriamycin Pfizer and dexamethasone and is referred to as mini-hyper-CVD mini-HCVD cyclophosphamide and dexamethasone at 50 dose reduction no anthracycline methotrexate at 75 dose reduction and cytarabine at 0.5 g/m2 4 doses Inotuzumab was given on day 3 of the first 4 courses at 1.8 to 1.3 mg/m2 for cycle 1 followed by 1.3 to 1.0 mg/m2 for subsequent cycles The primary end points were the overall response rate and overall survival OS Secondary end points included safety relapse-free survival RFS the rate of allogeneic stem cell transplantation ASCT and the minimal residual disease MRD negativity rate Fifty-nine patients 30 women and 29 men with a median age of 35 years range 18-87 years were treated Overall 46 patients 78 responded 35 of them 59 achieving complete response The overall MRD negativity rate among responders was 82 Twenty-six patients 44 received ASCT Grade 3 to 4 toxic effects included prolonged thrombocytopenia 81 n 48 infections 73 n 43 and hyperbilirubinemia 14 n 8 Veno-occlusive disease VOD occurred in 9 patients 15 With a median follow-up of 24 months the median RFS and OS were 8 and 11 months respectively The 1-year RFS and OS rates were 40 and 46 respectively The 1-year OS rates for patients treated in salvage 1 salvage 2 and salvage 3 or beyond were 57 26 and 39 respectively P .03 The combination of inotuzumab with low-intensity mini-HCVD chemotherapy shows encouraging results in R/R ALL The risk of VOD should be considered carefully in patients with previous damage and among transplant candidates clinicaltrials.gov Identifier NCT01371630,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 228, 1, 7, 5, 591, 15, 430, 668, 668, 286, 1275, 62, 16, 334, 6730, 5566, 8, 7599, 848, 548, 2951, 6, 13499, 71, 226, 420, 128, 4, 668, 668, 62, 6, 376, 3, 209, 2, 367, 1, 6730, 5566, 349, 154, 837, 56, 4, 7, 5, 668, 668, 62, 8, 226, 475, 124, 18, 45, 1, 857, 5, 668, 668, 132, 31, 62, 426, 28, 3, 1652, 1, 2738, 2244, 1929, 12, 574, 6212, 3, 56, 95, 10, 280, 837, 76, 4855, 5574, 1112, 2132, 856, 10550, 9812, 7700, 8982, 2, 1217, 2, 16, 1995, 6, 22, 7313, 4855, 5264, 7313, 32786, 1112, 2, 1217, 28, 212, 61, 628, 77, 2044, 2116, 28, 481, 61, 628, 2, 1855, 28, 13, 33, 499, 821, 39, 415, 6730, 10, 447, 23, 218, 27, 1, 3, 157, 39, 1993, 28, 14, 66, 6, 14, 27, 81, 821, 9, 417, 14, 370, 20, 14, 27, 6, 14, 13, 81, 821, 9, 706, 410, 3, 86, 396, 862, 11, 3, 63, 51, 116, 2, 63, 25, 118, 568, 396, 862, 159, 367, 429, 115, 25, 1272, 3, 116, 1, 1063, 452, 31, 497, 1584, 2, 3, 1048, 753, 34, 2029, 6014, 116, 1461, 762, 7, 201, 117, 2, 462, 325, 5, 8, 52, 89, 1, 465, 60, 184, 203, 912, 60, 11, 73, 63, 641, 7, 833, 2211, 465, 1, 1370, 728, 1785, 236, 51, 3, 63, 2029, 6014, 116, 107, 1983, 10, 878, 737, 437, 7, 584, 103, 1584, 88, 27, 6, 39, 1812, 176, 159, 1069, 1340, 865, 78, 576, 1875, 803, 78, 601, 2, 7236, 213, 78, 66, 10273, 8376, 34, 8768, 489, 4, 83, 7, 167, 5, 8, 52, 166, 126, 1, 259, 53, 3, 52, 1272, 2, 118, 11, 66, 2, 175, 53, 106, 3, 14, 111, 1272, 2, 118, 151, 11, 327, 2, 641, 106, 3, 14, 111, 118, 151, 9, 7, 73, 4, 992, 14, 992, 18, 2, 992, 27, 15, 1654, 11, 696, 432, 2, 587, 106, 19, 680, 3, 150, 1, 6730, 5, 154, 837, 7313, 32786, 56, 1949, 2269, 99, 4, 668, 668, 62, 3, 43, 1, 8768, 257, 40, 515, 3900, 4, 7, 5, 698, 1350, 2, 107, 941, 1931, 1252, 1239, 3719, 50549]",2140.0,28859185,169
"NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.",Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2017-09-01,"The prognosis for patients with newly diagnosed acute lymphoblastic leukemia (ALL) has improved with the use of more intensive chemotherapy regimens, tyrosine kinase inhibitors, targeted agents, and allogeneic hematopoietic cell transplantation. However, the management of relapsed or refractory (R/R) ALL remains challenging and prognosis is poor. The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence. These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates, and provide a summary of the panel's discussion and underlying data supporting the most recent recommendations for R/R ALL management.",Guideline,872.0,24.0,The prognosis for patients with newly diagnosed acute lymphoblastic ALL has improved with the use of more intensive chemotherapy regimens tyrosine kinase inhibitors targeted agents and allogeneic hematopoietic cell transplantation However the management of relapsed or refractory R/R ALL remains challenging and prognosis is poor The NCCN Guidelines for ALL provide recommendations on standard treatment approaches based on current evidence These NCCN Guidelines Insights summarize treatment recommendations for R/R ALL and highlight important updates and provide a summary of the panel 's discussion and underlying data supporting the most recent recommendations for R/R ALL management,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 356, 9, 7, 5, 732, 265, 286, 1275, 62, 71, 231, 5, 3, 119, 1, 80, 1686, 56, 472, 564, 216, 222, 238, 183, 2, 1063, 1007, 31, 497, 137, 3, 284, 1, 591, 15, 430, 668, 668, 62, 469, 1950, 2, 356, 16, 334, 3, 1944, 677, 9, 62, 377, 883, 23, 260, 24, 611, 90, 23, 291, 241, 46, 1944, 677, 1957, 2479, 24, 883, 9, 668, 668, 62, 2, 1817, 305, 5454, 2, 377, 8, 1962, 1, 3, 993, 292, 2488, 2, 1181, 74, 1912, 3, 96, 435, 883, 9, 668, 668, 62, 284]",686.0,28874594,700
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2017-08-18,"The treatment of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia has been revolutionized with the introduction of tyrosine kinase inhibitors (TKIs) and the combination of these agents with chemotherapy. Blinatumomab is a bispecific anti-CD3/CD19 monoclonal antibody with clinical activity as single-agent in the relapsed setting and independent of BCR-ABL1 mutational status, including T315I. The combination of blinatumomab with a TKI may further improve outcomes for this high-risk population, including higher eradication of minimal residual disease and minimize the use of chemotherapy. We retrospectively studied 12 adults with relapsed/refractory Ph+ acute lymphoblastic leukemia (n= 9) and chronic myeloid leukemia in blast crisis (n= 3), treated with the combination blinatumomab and a TKI (ponatinib, n= 8; dasatinib, n= 3; bosutinib, n=1). All patients have previously failed at least 1 line of chemotherapy, including allogeneic stem cell transplantation, and 1 class of TKIs. Patients were treated for either overt hematologic relapse (n= 6) or persistent minimal residual disease following other regimens (n= 6). The complete hematologic, cytogenetic, and molecular response rates were 50% (3/6), 71% (5/7), and 75% (9/12), respectively. Two cases of grade 2 cytokine release syndrome were observed, all of which resolved with steroids and tocilizumab. No cardiovascular adverse events were encountered. With a median follow-up of 8 months, the median survival was not reached; the 6-month and 1-year overall survival rates were 73%. The combination of blinatumomab with TKI is safe and effective in patients with relapsed/refractory Ph+ disease. Prospective studies are warranted.",Journal Article,886.0,42.0,The treatment of Philadelphia chromosome-positive Ph+ acute lymphoblastic has been revolutionized with the introduction of tyrosine kinase inhibitors TKIs and the combination of these agents with chemotherapy Blinatumomab is a bispecific anti-CD3/CD19 monoclonal antibody with clinical activity as single-agent in the relapsed setting and independent of BCR-ABL1 mutational status including T315I The combination of blinatumomab with a TKI may further improve outcomes for this high-risk population including higher eradication of minimal residual disease and minimize the use of chemotherapy We retrospectively studied 12 adults with relapsed/refractory Ph+ acute lymphoblastic n 9 and chronic myeloid in blast crisis n 3 treated with the combination blinatumomab and a TKI ponatinib n 8 dasatinib n 3 bosutinib n 1 All patients have previously failed at least 1 line of chemotherapy including allogeneic stem cell transplantation and 1 class of TKIs Patients were treated for either overt hematologic relapse n 6 or persistent minimal residual disease following other regimens n 6 The complete hematologic cytogenetic and molecular response rates were 50 3/6 71 5/7 and 75 9/12 respectively Two cases of grade 2 cytokine release syndrome were observed all of which resolved with steroids and tocilizumab No cardiovascular adverse events were encountered With a median follow-up of 8 months the median survival was not reached the 6-month and 1-year overall survival rates were 73 The combination of blinatumomab with TKI is safe and effective in patients with relapsed/refractory Ph+ disease Prospective studies are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 24, 1, 3006, 1170, 109, 2058, 286, 1275, 71, 85, 5746, 5, 3, 2456, 1, 564, 216, 222, 1671, 2, 3, 150, 1, 46, 183, 5, 56, 7182, 16, 8, 7408, 312, 3117, 3158, 848, 548, 5, 38, 128, 22, 226, 420, 4, 3, 591, 546, 2, 306, 1, 1062, 3557, 1619, 156, 141, 6184, 3, 150, 1, 7182, 5, 8, 1379, 68, 195, 401, 123, 9, 26, 64, 43, 266, 141, 142, 5173, 1, 1048, 753, 34, 2, 3241, 3, 119, 1, 56, 21, 894, 656, 133, 857, 5, 591, 430, 2058, 286, 1275, 78, 83, 2, 442, 533, 4, 3112, 6540, 78, 27, 73, 5, 3, 150, 7182, 2, 8, 1379, 5715, 78, 66, 1674, 78, 27, 5936, 78, 14, 62, 7, 47, 373, 1551, 28, 506, 14, 328, 1, 56, 141, 1063, 452, 31, 497, 2, 14, 1040, 1, 1671, 7, 11, 73, 9, 361, 7192, 813, 429, 78, 49, 15, 1882, 1048, 753, 34, 366, 127, 472, 78, 49, 3, 236, 813, 1266, 2, 219, 51, 151, 11, 212, 27, 49, 792, 33, 67, 2, 481, 83, 133, 106, 100, 140, 1, 88, 18, 1675, 2008, 681, 11, 164, 62, 1, 92, 3862, 5, 4580, 2, 29436, 77, 2179, 290, 281, 11, 3903, 5, 8, 52, 166, 126, 1, 66, 53, 3, 52, 25, 10, 44, 1300, 3, 49, 811, 2, 14, 111, 63, 25, 151, 11, 803, 3, 150, 1, 7182, 5, 1379, 16, 1165, 2, 323, 4, 7, 5, 591, 430, 2058, 34, 482, 94, 32, 1197]",1627.0,28927784,568
Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults.,American journal of hematology,Am. J. Hematol.,2017-10-31,"Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) is a biologically, clinically, and genetically distinct subtype of precursor-B ALL. The Ph chromosome, results from a reciprocal translocation of the ABL1 kinase gene on chromosome 9 to the breakpoint cluster region (BCR) gene on chromosome 22. Depending on the translocation breakpoint, typically a p210 BCR-ABL1 or a p190 BCR-ABL onc protein are generated; both are constitutively active tyrosine kinases that play a central role to alter signaling pathways of cell proliferation, survival, and self-renewal, leading to leukemogenesis. In Ph-positive ALL, the p190-BCR-ABL (minor [m]-bcr) subtype is more frequent than the p210-BCR-ABL (major [M]-bcr) subtype, commonly found in chronic myeloid leukemia. The Philadelphia chromosome is the most frequent recurrent cytogenetic abnormality in elderly patients with ALL. Its incidence increases with age, reaching 50% in patients with ALL aged 60 years and over. Patients traditionally had a very poor outcome with chemotherapy, particularly if they do not undergo allogeneic hematopoietic cell transplantation (allo-HCT) in first complete remission (CR1). With the availability of multiple tyrosine kinase inhibitors (TKI), the therapeutic armamentarium is expanding quickly. However, there is no consensus on how to best treat Ph-positive ALL. With modern therapy, improved outcomes have led to the emergence of a number of controversies, including the need for intensive chemotherapy, the ideal TKI, and whether all eligible patients should receive an allo-HSCT, and if so, what type. Here, we discuss these controversies in light of the available literature.",Journal Article,812.0,10.0,Philadelphia chromosome-positive Ph-positive acute lymphoblastic ALL is a biologically clinically and genetically distinct subtype of precursor-B ALL The Ph chromosome results from a reciprocal translocation of the ABL1 kinase gene on chromosome 9 to the breakpoint cluster region BCR gene on chromosome 22 Depending on the translocation breakpoint typically a p210 BCR-ABL1 or a p190 BCR-ABL onc protein are generated both are constitutively active tyrosine kinases that play a central role to alter signaling pathways of cell proliferation survival and self-renewal leading to leukemogenesis In Ph-positive ALL the p190-BCR-ABL minor m -bcr subtype is more frequent than the p210-BCR-ABL major M -bcr subtype commonly found in chronic myeloid The Philadelphia chromosome is the most frequent recurrent cytogenetic abnormality in elderly patients with ALL Its incidence increases with age reaching 50 in patients with ALL aged 60 years and over Patients traditionally had a very poor outcome with chemotherapy particularly if they do not undergo allogeneic hematopoietic cell transplantation allo-HCT in first complete remission CR1 With the availability of multiple tyrosine kinase inhibitors TKI the therapeutic armamentarium is expanding quickly However there is no consensus on how to best treat Ph-positive ALL With modern therapy improved outcomes have led to the emergence of a number of controversies including the need for intensive chemotherapy the ideal TKI and whether all eligible patients should receive an allo-HSCT and if so what type Here we discuss these controversies in light of the available literature,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 109, 2058, 109, 286, 1275, 62, 16, 8, 2665, 505, 2, 2301, 834, 875, 1, 2765, 132, 62, 3, 2058, 1170, 99, 29, 8, 8020, 2006, 1, 3, 3557, 216, 145, 23, 1170, 83, 6, 3, 8567, 3132, 1053, 1062, 145, 23, 1170, 350, 3221, 23, 3, 2006, 8567, 1969, 8, 11538, 1062, 3557, 15, 8, 18813, 1062, 1425, 71315, 178, 32, 1419, 110, 32, 2818, 544, 564, 1549, 17, 1343, 8, 854, 200, 6, 2688, 314, 460, 1, 31, 457, 25, 2, 1074, 4495, 1049, 6, 5661, 4, 2058, 109, 62, 3, 18813, 1062, 1425, 2278, 188, 1062, 875, 16, 80, 908, 76, 3, 11538, 1062, 1425, 458, 188, 1062, 875, 841, 204, 4, 442, 533, 3, 3006, 1170, 16, 3, 96, 908, 387, 1266, 3698, 4, 1216, 7, 5, 62, 211, 287, 1106, 5, 89, 6168, 23911, 4, 7, 5, 62, 1032, 335, 60, 2, 252, 7, 4206, 42, 8, 923, 334, 228, 5, 56, 823, 492, 491, 1022, 44, 1251, 1063, 1007, 31, 497, 2564, 1085, 4, 157, 236, 734, 4516, 5, 3, 2550, 1, 232, 564, 216, 222, 1379, 3, 189, 5543, 16, 4304, 7325, 137, 125, 16, 77, 1391, 23, 832, 6, 824, 943, 2058, 109, 62, 5, 2366, 36, 231, 123, 47, 836, 6, 3, 3397, 1, 8, 207, 1, 6613, 141, 3, 594, 9, 1686, 56, 3, 3662, 1379, 2, 317, 62, 625, 7, 257, 560, 35, 2564, 1703, 2, 492, 1743, 2067, 267, 467, 21, 1139, 46, 6613, 4, 1691, 1, 3, 390, 789]",1625.0,28971501,315
"TOX Regulates Growth, DNA Repair, and Genomic Instability in T-cell Acute Lymphoblastic Leukemia.",Cancer discovery,Cancer Discov,2017-10-03,"T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes. Using a transgenic screen in zebrafish, thymocyte selection-associated high mobility group box protein (TOX) was uncovered as a collaborating oncogenic driver that accelerated T-ALL onset by expanding the initiating pool of transformed clones and elevating genomic instability. TOX is highly expressed in a majority of human T-ALL and is required for proliferation and continued xenograft growth in mice. Using a wide array of functional analyses, we uncovered that TOX binds directly to KU70/80 and suppresses recruitment of this complex to DNA breaks to inhibit nonhomologous end joining (NHEJ) repair. Impaired NHEJ is well known to cause genomic instability, including development of T-cell malignancies in KU70- and KU80-deficient mice. Collectively, our work has uncovered important roles for TOX in regulating NHEJ by elevating genomic instability during leukemia initiation and sustaining leukemic cell proliferation following transformation.<b>Significance:</b> TOX is an HMG box-containing protein that has important roles in T-ALL initiation and maintenance. TOX inhibits the recruitment of KU70/KU80 to DNA breaks, thereby inhibiting NHEJ repair. Thus, TOX is likely a dominant oncogenic driver in a large fraction of human T-ALL and enhances genomic instability. <i>Cancer Discov; 7(11); 1336-53. 2017 AACR.</i><i>This article is highlighted in the In This Issue feature, p. 1201</i>.",Journal Article,840.0,14.0,T-cell acute lymphoblastic T-ALL is an aggressive malignancy of thymocytes Using a transgenic screen in zebrafish thymocyte selection-associated high mobility group box protein TOX was uncovered as a collaborating oncogenic driver that accelerated T-ALL onset by expanding the initiating pool of transformed clones and elevating genomic instability TOX is highly expressed in a majority of human T-ALL and is required for proliferation and continued xenograft growth in mice Using a wide array of functional analyses we uncovered that TOX binds directly to KU70/80 and suppresses recruitment of this complex to DNA breaks to inhibit nonhomologous end joining NHEJ repair Impaired NHEJ is well known to cause genomic instability including development of T-cell malignancies in KU70- and KU80-deficient mice Collectively our work has uncovered important roles for TOX in regulating NHEJ by elevating genomic instability during initiation and sustaining leukemic cell proliferation following transformation. b Significance /b TOX is an HMG box-containing protein that has important roles in T-ALL initiation and maintenance TOX inhibits the recruitment of KU70/KU80 to DNA breaks thereby inhibiting NHEJ repair Thus TOX is likely a dominant oncogenic driver in a large fraction of human T-ALL and enhances genomic instability i Cancer Discov 7 11 1336-53 2017 AACR. /i i This article is highlighted in the In This Issue feature p. 1201 /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[102, 31, 286, 1275, 102, 62, 16, 35, 571, 710, 1, 25586, 75, 8, 2862, 2413, 4, 10763, 16236, 881, 41, 64, 5717, 87, 4971, 178, 16429, 10, 5601, 22, 8, 14977, 1302, 2228, 17, 2241, 102, 62, 1707, 20, 4304, 3, 2637, 6545, 1, 2423, 2749, 2, 16877, 572, 1753, 16429, 16, 561, 570, 4, 8, 686, 1, 171, 102, 62, 2, 16, 616, 9, 457, 2, 1351, 1330, 129, 4, 399, 75, 8, 1019, 1926, 1, 583, 318, 21, 5601, 17, 16429, 3333, 1606, 6, 16360, 493, 2, 4079, 3202, 1, 26, 840, 6, 261, 4492, 6, 1433, 16858, 396, 10690, 12629, 972, 2364, 12629, 16, 149, 440, 6, 708, 572, 1753, 141, 193, 1, 102, 31, 441, 4, 16360, 2, 29257, 1971, 399, 2535, 114, 1357, 71, 5601, 305, 1790, 9, 16429, 4, 2681, 12629, 20, 16877, 572, 1753, 190, 1118, 2, 10100, 2015, 31, 457, 366, 1392, 132, 724, 132, 16429, 16, 35, 13559, 4971, 1101, 178, 17, 71, 305, 1790, 4, 102, 62, 1118, 2, 1146, 16429, 1576, 3, 3202, 1, 16360, 29257, 6, 261, 4492, 2267, 2062, 12629, 972, 631, 16429, 16, 322, 8, 2156, 1302, 2228, 4, 8, 375, 1509, 1, 171, 102, 62, 2, 2519, 572, 1753, 70, 12, 7183, 67, 175, 30358, 699, 3194, 1630, 70, 70, 26, 946, 16, 3681, 4, 3, 4, 26, 2537, 2705, 19, 19100, 70]",1436.0,28974511,250
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia.,Blood,Blood,2017-08-09,"Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic leukemia (ALL). Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin. A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose (MTCD) and evaluate safety, activity, pharmacokinetics, and immunogenicity of moxetumomab pasudotox in children, adolescents, and young adults with ALL (N = 55). Moxetumomab pasudotox was administered as a 30-minute IV infusion at doses of 5 to 50 g/kg every other day for 6 (cohorts A and B) or 10 (cohort C) doses in 21-day cycles. Cohorts B and C received dexamethasone prophylaxis against capillary leak syndrome (CLS). The most common treatment-related adverse events were reversible weight gain, hepatic transaminase elevation, and hypoalbuminemia. Dose-limiting CLS occurred in 2 of 4 patients receiving 30 g/kg of moxetumomab pasudotox every other day for 6 doses. Incorporation of dexamethasone prevented further dose-limiting CLS. Six of 14 patients receiving 50 g/kg of moxetumomab pasudotox for 10 doses developed hemolytic uremic syndrome (HUS), thrombotic microangiopathy (TMA), or HUS-like events, exceeding the MTCD. Treatment expansion at 40 g/kg for 10 doses (n = 11) exceeded the MTCD because of 2 HUS/TMA/HUS-like events. Dose level 6B (ie, 50 g/kg  6 doses) was the MTCD, selected as the recommended phase 2 dose. Among 47 evaluable patients, an objective response rate of 32% was observed, including 11 (23%) composite complete responses, 5 of which were minimal residual disease negative by flow cytometry. Moxetumomab pasudotox showed a manageable safety profile and evidence of activity in relapsed or refractory childhood ALL. This trial was registered at www.clinicaltrials.gov as #NCT00659425.","Clinical Trial, Phase I",895.0,24.0,Novel therapies are needed to overcome chemotherapy resistance for children with relapsed/refractory acute lymphoblastic ALL Moxetumomab pasudotox is a recombinant anti-CD22 immunotoxin A multicenter phase 1 study was conducted to determine the maximum-tolerated cumulative dose MTCD and evaluate safety activity pharmacokinetics and immunogenicity of moxetumomab pasudotox in children adolescents and young adults with ALL N 55 Moxetumomab pasudotox was administered as a 30-minute IV infusion at doses of 5 to 50 g/kg every other day for 6 cohorts A and B or 10 cohort C doses in 21-day cycles Cohorts B and C received dexamethasone prophylaxis against capillary leak syndrome CLS The most common treatment-related adverse events were reversible weight gain hepatic transaminase elevation and hypoalbuminemia Dose-limiting CLS occurred in 2 of 4 patients receiving 30 g/kg of moxetumomab pasudotox every other day for 6 doses Incorporation of dexamethasone prevented further dose-limiting CLS Six of 14 patients receiving 50 g/kg of moxetumomab pasudotox for 10 doses developed hemolytic uremic syndrome HUS thrombotic microangiopathy TMA or HUS-like events exceeding the MTCD Treatment expansion at 40 g/kg for 10 doses n 11 exceeded the MTCD because of 2 HUS/TMA/HUS-like events Dose level 6B ie 50 g/kg 6 doses was the MTCD selected as the recommended phase 2 dose Among 47 evaluable patients an objective response rate of 32 was observed including 11 23 composite complete responses 5 of which were minimal residual disease negative by flow cytometry Moxetumomab pasudotox showed a manageable safety profile and evidence of activity in relapsed or refractory childhood ALL This trial was registered at www.clinicaltrials.gov as NCT00659425,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[229, 235, 32, 575, 6, 1768, 56, 251, 9, 541, 5, 591, 430, 286, 1275, 62, 17017, 17018, 16, 8, 2835, 312, 7599, 14464, 8, 1570, 124, 14, 45, 10, 426, 6, 223, 3, 689, 421, 967, 61, 36490, 2, 376, 367, 128, 1159, 2, 4050, 1, 17017, 17018, 4, 541, 3101, 2, 1169, 857, 5, 62, 78, 614, 17017, 17018, 10, 468, 22, 8, 201, 3949, 478, 904, 28, 415, 1, 33, 6, 212, 7570, 503, 454, 127, 218, 9, 49, 736, 8, 2, 132, 15, 79, 180, 256, 415, 4, 239, 218, 410, 736, 132, 2, 256, 103, 1217, 2049, 480, 8943, 4238, 681, 9610, 3, 96, 186, 24, 139, 290, 281, 11, 2786, 924, 1803, 939, 6997, 3292, 2, 11667, 61, 817, 9610, 489, 4, 18, 1, 39, 7, 357, 201, 7570, 503, 1, 17017, 17018, 454, 127, 218, 9, 49, 415, 2838, 1, 1217, 3902, 195, 61, 817, 9610, 437, 1, 213, 7, 357, 212, 7570, 503, 1, 17017, 17018, 9, 79, 415, 276, 10425, 26034, 681, 25140, 6108, 13864, 5501, 15, 25140, 733, 281, 5178, 3, 36490, 24, 1422, 28, 327, 7570, 503, 9, 79, 415, 78, 175, 4726, 3, 36490, 408, 1, 18, 25140, 5501, 25140, 733, 281, 61, 301, 27840, 2523, 212, 7570, 503, 49, 415, 10, 3, 36490, 715, 22, 3, 793, 124, 18, 61, 107, 662, 859, 7, 35, 461, 51, 116, 1, 531, 10, 164, 141, 175, 382, 3308, 236, 253, 33, 1, 92, 11, 1048, 753, 34, 199, 20, 1412, 1914, 17017, 17018, 224, 8, 2808, 367, 800, 2, 241, 1, 128, 4, 591, 15, 430, 864, 62, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 71334]",1750.0,28983018,633
Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,Clin. Infect. Dis.,2017-11-01,"Infection is the most important cause of treatment-related morbidity and mortality in pediatric patients treated for acute lymphoblastic leukemia (ALL). Although routine in adults with leukemia, antibacterial prophylaxis is controversial in pediatrics because of insufficient evidence for its efficacy or antibiotic choice and concerns about promoting antibiotic resistance and Clostridium difficile infection. This was a single-center, observational cohort study of patients with newly diagnosed ALL, comparing prospectively collected infection-related outcomes in patients who received no prophylaxis, levofloxacin prophylaxis, or other prophylaxis during induction therapy on the total XVI study. A propensity score-weighted logistic regression model was used to adjust for confounders. Of 344 included patients, 173 received no prophylaxis, 69 received levofloxacin prophylaxis, and 102 received other prophylaxis regimens. Patients receiving prophylaxis had longer duration of neutropenia. Prophylaxis reduced the odds of febrile neutropenia, likely bacterial infection, and bloodstream infection by 70%. Levofloxacin prophylaxis alone reduced these infections, but it also reduced cephalosporin, aminoglycoside, and vancomycin exposure and reduced the odds of C. difficile infection by >95%. No increase in breakthrough infections with antibiotic-resistant organisms was seen, but this cannot be excluded. This is the largest study to date of antibacterial prophylaxis during induction therapy for pediatric ALL and the first to include a broad-spectrum fluoroquinolone. Prophylaxis prevented febrile neutropenia and systemic infection. Levofloxacin prophylaxis also minimized the use of treatment antibiotics and drastically reduced C. difficile infection. Although long-term antibiotic-resistance monitoring is needed, these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL. NCT00549848.",Clinical Trial,811.0,13.0,Infection is the most important cause of treatment-related morbidity and mortality in pediatric patients treated for acute lymphoblastic ALL Although routine in adults with antibacterial prophylaxis is controversial in pediatrics because of insufficient evidence for its efficacy or antibiotic choice and concerns about promoting antibiotic resistance and Clostridium difficile infection This was a single-center observational cohort study of patients with newly diagnosed ALL comparing prospectively collected infection-related outcomes in patients who received no prophylaxis levofloxacin prophylaxis or other prophylaxis during induction therapy on the total XVI study A propensity score-weighted logistic regression model was used to adjust for confounders Of 344 included patients 173 received no prophylaxis 69 received levofloxacin prophylaxis and 102 received other prophylaxis regimens Patients receiving prophylaxis had longer duration of neutropenia Prophylaxis reduced the odds of febrile neutropenia likely bacterial infection and bloodstream infection by 70 Levofloxacin prophylaxis alone reduced these infections but it also reduced cephalosporin aminoglycoside and vancomycin exposure and reduced the odds of C. difficile infection by 95 No increase in breakthrough infections with antibiotic-resistant organisms was seen but this can not be excluded This is the largest study to date of antibacterial prophylaxis during induction therapy for pediatric ALL and the first to include a broad-spectrum fluoroquinolone Prophylaxis prevented febrile neutropenia and systemic infection Levofloxacin prophylaxis also minimized the use of treatment antibiotics and drastically reduced C. difficile infection Although long-term antibiotic-resistance monitoring is needed these data support using targeted prophylaxis with levofloxacin in children undergoing induction chemotherapy for ALL NCT00549848,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[930, 16, 3, 96, 305, 708, 1, 24, 139, 787, 2, 282, 4, 815, 7, 73, 9, 286, 1275, 62, 242, 1311, 4, 857, 5, 15002, 2049, 16, 2010, 4, 12616, 408, 1, 3027, 241, 9, 211, 209, 15, 5210, 1866, 2, 2061, 545, 2388, 5210, 251, 2, 14864, 17781, 930, 26, 10, 8, 226, 574, 2495, 180, 45, 1, 7, 5, 732, 265, 62, 1430, 1143, 786, 930, 139, 123, 4, 7, 54, 103, 77, 2049, 18974, 2049, 15, 127, 2049, 190, 504, 36, 23, 3, 181, 25082, 45, 8, 1925, 368, 2337, 812, 320, 202, 10, 95, 6, 6611, 9, 4423, 1, 6993, 159, 7, 5785, 103, 77, 2049, 790, 103, 18974, 2049, 2, 2867, 103, 127, 2049, 472, 7, 357, 2049, 42, 589, 654, 1, 778, 2049, 405, 3, 610, 1, 2498, 778, 322, 5117, 930, 2, 10210, 930, 20, 6146, 18974, 2049, 279, 405, 46, 1875, 84, 192, 120, 405, 19153, 71365, 2, 9013, 645, 2, 405, 3, 610, 1, 256, 17781, 930, 20, 48, 77, 344, 4, 6022, 1875, 5, 5210, 436, 9694, 10, 527, 84, 26, 122, 44, 40, 1800, 26, 16, 3, 2166, 45, 6, 1244, 1, 15002, 2049, 190, 504, 36, 9, 815, 62, 2, 3, 157, 6, 643, 8, 2094, 1873, 41881, 2049, 3902, 2498, 778, 2, 403, 930, 18974, 2049, 120, 9243, 3, 119, 1, 24, 5214, 2, 11900, 405, 256, 17781, 930, 242, 319, 337, 5210, 251, 1315, 16, 575, 46, 74, 538, 75, 238, 2049, 5, 18974, 4, 541, 479, 504, 56, 9, 62, 40761]",1908.0,29020310,566
Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies.,"Stem cells (Dayton, Ohio)",Stem Cells,2017-10-25,"Gene-engineered T cell therapies are soon to be United States Food and Drug Administration (FDA) approved for at least two types of B cell malignancies in pediatric and adult patients, in the form of CD19 targeted chimeric antigen receptor T (CAR T) cell therapy. This represents a triumph of a true bench to bedside clinical translation of a therapy that was conceived of in the early 1990s. Clinical results have demonstrated efficacious responses in patients with the CD19 positive diseases B cell acute lymphoblastic leukemia and diffuse large B cell lymphoma. However, significant challenges have emerged, including worrisome immune-related toxicities, therapy resistance, and understanding how to administer CD19 CAR T cells in clinical practice. Although much remains to be learned, pioneering clinical trials have led to foundational insights about the clinical translation of this novel therapy. Here, we review the ""lessons learned"" from the pre-clinical and human experience with CAR T cell therapy. Stem Cells 2018;36:36-44.",Journal Article,818.0,15.0,Gene-engineered T cell therapies are soon to be United States Food and Drug Administration FDA approved for at least two types of B cell malignancies in pediatric and adult patients in the form of CD19 targeted chimeric antigen receptor T CAR T cell therapy This represents a triumph of a true bench to bedside clinical translation of a therapy that was conceived of in the early 1990s Clinical results have demonstrated efficacious responses in patients with the CD19 positive diseases B cell acute lymphoblastic and diffuse large B cell However significant challenges have emerged including worrisome immune-related toxicities therapy resistance and understanding how to administer CD19 CAR T cells in clinical practice Although much remains to be learned pioneering clinical trials have led to foundational insights about the clinical translation of this novel therapy Here we review the `` lessons learned '' from the pre-clinical and human experience with CAR T cell therapy Stem Cells 2018 36:36-44,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[145, 2794, 102, 31, 235, 32, 6176, 6, 40, 1088, 907, 1773, 2, 234, 634, 2078, 850, 9, 28, 506, 100, 630, 1, 132, 31, 441, 4, 815, 2, 780, 7, 4, 3, 1297, 1, 3158, 238, 2897, 448, 153, 102, 1881, 102, 31, 36, 26, 1449, 8, 47867, 1, 8, 2501, 11127, 6, 8516, 38, 2691, 1, 8, 36, 17, 10, 17168, 1, 4, 3, 191, 7524, 38, 99, 47, 264, 3289, 253, 4, 7, 5, 3, 3158, 109, 1342, 132, 31, 286, 1275, 2, 1388, 375, 132, 31, 137, 93, 1427, 47, 2054, 141, 13155, 250, 139, 385, 36, 251, 2, 612, 832, 6, 6888, 3158, 1881, 102, 37, 4, 38, 758, 242, 1802, 469, 6, 40, 6426, 25175, 38, 143, 47, 836, 6, 26942, 1957, 545, 3, 38, 2691, 1, 26, 229, 36, 467, 21, 206, 3, 8268, 6426, 522, 29, 3, 671, 38, 2, 171, 730, 5, 1881, 102, 31, 36, 452, 37, 2982, 511, 511, 584]",1004.0,29024301,17
"Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.",Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-10-13,"Therapeutic T cell engineering has recently garnered widespread interest because of the success of CD19 chimeric antigen receptor (CAR) therapy. CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced. CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia, and non-Hodgkin lymphoma. The toxicities of this treatment include B cell aplasia, cytokine release syndrome (CRS), and neurotoxicity. Although reversible in most instances, these toxicities may require specific medical interventions, including transfer to intensive care to treat severe CRS. Guidelines for managing these toxicities are emerging. The recent report of a nonhuman primate model for CRS is poised to help advance the management of this syndrome. Finally, new engineering modalities, based on the use of targeted nucleases like CRISPR, may further enhance the efficacy and safety of CAR T cells.",Journal Article,830.0,14.0,Therapeutic T cell engineering has recently garnered widespread interest because of the success of CD19 chimeric antigen receptor CAR therapy CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced CARs targeting CD19 a cell surface molecule found in most leukemias and lymphomas have yielded high remission rates in patients with chemorefractory relapsed disease including acute lymphoblastic chronic lymphocytic and The toxicities of this treatment include B cell aplasia cytokine release syndrome CRS and neurotoxicity Although reversible in most instances these toxicities may require specific medical interventions including transfer to intensive care to treat severe CRS Guidelines for managing these toxicities are emerging The recent report of a nonhuman primate model for CRS is poised to help advance the management of this syndrome Finally new engineering modalities based on the use of targeted nucleases like CRISPR may further enhance the efficacy and safety of CAR T cells,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[189, 102, 31, 6717, 71, 761, 21476, 3029, 1333, 408, 1, 3, 1825, 1, 3158, 2897, 448, 153, 1881, 36, 7441, 32, 3273, 1186, 9, 448, 17, 14744, 3, 1121, 2, 14947, 3, 343, 1, 3, 102, 37, 4, 92, 491, 32, 2301, 3955, 7441, 529, 3158, 8, 31, 1255, 1354, 204, 4, 96, 2792, 2, 1557, 47, 2178, 64, 734, 151, 4, 7, 5, 8923, 591, 34, 141, 286, 1275, 442, 1193, 2, 3, 385, 1, 26, 24, 643, 132, 31, 12307, 1675, 2008, 681, 3115, 2, 3561, 242, 2786, 4, 96, 5342, 46, 385, 68, 1353, 112, 484, 1151, 141, 2602, 6, 1686, 165, 6, 943, 905, 3115, 677, 9, 3969, 46, 385, 32, 1478, 3, 435, 414, 1, 8, 23273, 25233, 202, 9, 3115, 16, 13970, 6, 987, 3148, 3, 284, 1, 26, 681, 1368, 217, 6717, 1558, 90, 23, 3, 119, 1, 238, 36375, 733, 7736, 68, 195, 1304, 3, 209, 2, 367, 1, 1881, 102, 37]",1085.0,29032264,45
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.,American journal of hematology,Am. J. Hematol.,2017-11-03,"Nelarabine, a water soluble prodrug of 9--D-arabinofuranosylguanine (ara-G), is a T-cell specific purine nucleoside analogue. Given its activity in relapsed and refractory T acute lymphoblastic leukemia (T-ALL) and T lymphoblastic lymphoma (T-LBL), we sought to define its role in the frontline treatment of adult patients. Therefore, we conducted a single arm phase 2 study to determine the safety and efficacy of nelarabine in combination with hyper-CVAD in newly diagnosed patients. For induction/consolidation, patients received eight cycles of hyper-CVAD alternating with high-dose methotrexate and cytarabine plus two cycles of nelarabine given at a dose of 650 mg/m<sup>2</sup> intravenously daily for 5 days. This was followed by thirty months of POMP maintenance chemotherapy with two additional cycles of nelarabine given instead of cycles 6 and 7 of POMP maintenance. Sixty-seven patients, including 40 with T-ALL and 26 with T-LBL, were enrolled. Complete response rates in both T-ALL and T-LBL were 87% and 100% respectively. Grade 3 to 4 neurotoxic adverse events were reported in 5 patients. There were 21 relapses (31%) including 2 after allogeneic stem cell transplantation. Median duration of follow-up was 42.5 months. The 3-year complete remission duration (CRD) and overall survival (OS) rates were 66% and 65%, respectively. Compared to our historic hyper-CVAD data, there was no survival benefit with the addition of nelarabine. In conclusion, hyper-CVAD plus nelarabine was well tolerated and active in the frontline treatment of adult T-ALL/LBL patients.",Journal Article,809.0,15.0,Nelarabine a water soluble prodrug of 9--D-arabinofuranosylguanine ara-G is a T-cell specific purine nucleoside analogue Given its activity in relapsed and refractory T acute lymphoblastic T-ALL and T lymphoblastic T-LBL we sought to define its role in the frontline treatment of adult patients Therefore we conducted a single arm phase 2 study to determine the safety and efficacy of nelarabine in combination with hyper-CVAD in newly diagnosed patients For induction/consolidation patients received eight cycles of hyper-CVAD alternating with high-dose methotrexate and cytarabine plus two cycles of nelarabine given at a dose of 650 mg/m sup 2 /sup intravenously daily for 5 days This was followed by thirty months of POMP maintenance chemotherapy with two additional cycles of nelarabine given instead of cycles 6 and 7 of POMP maintenance Sixty-seven patients including 40 with T-ALL and 26 with T-LBL were enrolled Complete response rates in both T-ALL and T-LBL were 87 and 100 respectively Grade 3 to 4 neurotoxic adverse events were reported in 5 patients There were 21 relapses 31 including 2 after allogeneic stem cell transplantation Median duration of follow-up was 42.5 months The 3-year complete remission duration CRD and overall survival OS rates were 66 and 65 respectively Compared to our historic hyper-CVAD data there was no survival benefit with the addition of nelarabine In conclusion hyper-CVAD plus nelarabine was well tolerated and active in the frontline treatment of adult T-ALL/LBL patients,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[13149, 8, 4388, 2968, 5227, 1, 83, 1458, 427, 38235, 3899, 499, 16, 8, 102, 31, 112, 5006, 4032, 4696, 447, 211, 128, 4, 591, 2, 430, 102, 286, 1275, 102, 62, 2, 102, 1275, 102, 8315, 21, 990, 6, 1107, 211, 200, 4, 3, 3171, 24, 1, 780, 7, 673, 21, 426, 8, 226, 475, 124, 18, 45, 6, 223, 3, 367, 2, 209, 1, 13149, 4, 150, 5, 4855, 5574, 4, 732, 265, 7, 9, 504, 2173, 7, 103, 659, 410, 1, 4855, 5574, 5181, 5, 64, 61, 2116, 2, 1855, 349, 100, 410, 1, 13149, 447, 28, 8, 61, 1, 8642, 81, 188, 172, 18, 172, 1672, 391, 9, 33, 162, 26, 10, 370, 20, 977, 53, 1, 18675, 1146, 56, 5, 100, 402, 410, 1, 13149, 447, 3496, 1, 410, 49, 2, 67, 1, 18675, 1146, 1746, 648, 7, 141, 327, 5, 102, 62, 2, 432, 5, 102, 8315, 11, 346, 236, 51, 151, 4, 110, 102, 62, 2, 102, 8315, 11, 912, 2, 394, 106, 88, 27, 6, 39, 11148, 290, 281, 11, 210, 4, 33, 7, 125, 11, 239, 3713, 456, 141, 18, 50, 1063, 452, 31, 497, 52, 654, 1, 166, 126, 10, 595, 33, 53, 3, 27, 111, 236, 734, 654, 9366, 2, 63, 25, 118, 151, 11, 700, 2, 556, 106, 72, 6, 114, 6875, 4855, 5574, 74, 125, 10, 77, 25, 247, 5, 3, 352, 1, 13149, 4, 1221, 4855, 5574, 349, 13149, 10, 149, 421, 2, 544, 4, 3, 3171, 24, 1, 780, 102, 62, 8315, 7]",1521.0,29047158,688
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2017-06-15,"The incorporation of tyrosine kinase inhibitors (TKIs) into chemotherapy regimens has significantly improved the long-term survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Successive generations of TKIs with increased potency against BCR-ABL and broader spectrum of activity against ABL kinase domain mutations have led to incremental improvements in the outcomes of patients with this disease. In particular, ponatinib, a potent pan-BCR-ABL TKI capable of overcoming the T315I mutation, holds significant promise in the treatment of Ph+ALL, although the potential cardiovascular toxicity of this agent remains a concern. With the development of more potent TKIs that are capable of inducing deep and sustained remissions, future studies re-evaluating the need for intensive chemotherapy as well as the role for stem cell transplantation in first remission for patients with Ph+ALL are warranted.",Journal Article,950.0,6.0,The incorporation of tyrosine kinase inhibitors TKIs into chemotherapy regimens has significantly improved the long-term survival of patients with Philadelphia chromosome-positive acute lymphoblastic Ph+ ALL Successive generations of TKIs with increased potency against BCR-ABL and broader spectrum of activity against ABL kinase domain mutations have led to incremental improvements in the outcomes of patients with this disease In particular ponatinib a potent pan-BCR-ABL TKI capable of overcoming the T315I mutation holds significant promise in the treatment of Ph+ ALL although the potential cardiovascular toxicity of this agent remains a concern With the development of more potent TKIs that are capable of inducing deep and sustained remissions future studies re-evaluating the need for intensive chemotherapy as well as the role for stem cell transplantation in first remission for patients with Ph+ ALL are warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2838, 1, 564, 216, 222, 1671, 237, 56, 472, 71, 97, 231, 3, 319, 337, 25, 1, 7, 5, 3006, 1170, 109, 286, 1275, 2058, 62, 6808, 11083, 1, 1671, 5, 101, 3593, 480, 1062, 1425, 2, 5410, 1873, 1, 128, 480, 1425, 216, 1398, 138, 47, 836, 6, 3648, 1474, 4, 3, 123, 1, 7, 5, 26, 34, 4, 1454, 5715, 8, 1157, 3055, 1062, 1425, 1379, 2787, 1, 5344, 3, 6184, 258, 5253, 93, 1783, 4, 3, 24, 1, 2058, 62, 242, 3, 174, 2179, 155, 1, 26, 420, 469, 8, 2893, 5, 3, 193, 1, 80, 1157, 1671, 17, 32, 2787, 1, 1958, 2369, 2, 2275, 3166, 508, 94, 1491, 1435, 3, 594, 9, 1686, 56, 22, 149, 22, 3, 200, 9, 452, 31, 497, 4, 157, 734, 9, 7, 5, 2058, 62, 32, 1197]",926.0,29050692,503
High mTOR expression independently prognosticates poor clinical outcome to induction chemotherapy in acute lymphoblastic leukemia.,Clinical and experimental medicine,Clin. Exp. Med.,2017-10-26,"In acute lymphoblastic leukemia (ALL), limited data are available on mTOR gene expression in clinical samples and its role in predicting response to induction chemotherapy. mRNA expression of mTOR gene was determined quantitatively by real-time PCR in 50 ALL patients (30 B-ALL and 20 T-ALL) and correlated with clinical outcome after induction chemotherapy. Expression level of mTOR was upregulated in more than 50% of cases of ALL. In T-ALL, high expression of mTOR was commonly seen, more in adults than children (82 vs. 55% cases), while in B-ALL it was same (~63% cases) in both adults and children. Mean fold change of mTOR expression was significantly higher in non-responders compared to responders of both adult B-ALL (7.4 vs. 2.7, p=0.05) and T-ALL (13.9 vs. 2.4, p=0.001). Similar results were seen in pediatric non-responders when compared to responders of both B-ALL (14.5 vs. 2.5, p=0.006) and T-ALL (24.2 vs. 1.7, p=0.002). Interestingly, we have observed that mTOR expression was two times higher in non-responders of children compared to adults in both B-ALL (14.5 vs. 7.4, p=0.05) and T-ALL (24.2 vs. 13.9, p=0.01). Multivariate analysis with other known prognostic factors revealed that mTOR expression independently predicts clinical response to induction chemotherapy in ALL. This study demonstrates that high mTOR expression is associated with poor clinical outcome in ALL and can serve as a potential target for novel therapeutic strategies.",Journal Article,817.0,4.0,In acute lymphoblastic ALL limited data are available on mTOR gene expression in clinical samples and its role in predicting response to induction chemotherapy mRNA expression of mTOR gene was determined quantitatively by real-time PCR in 50 ALL patients 30 B-ALL and 20 T-ALL and correlated with clinical outcome after induction chemotherapy Expression level of mTOR was upregulated in more than 50 of cases of ALL In T-ALL high expression of mTOR was commonly seen more in adults than children 82 vs. 55 cases while in B-ALL it was same 63 cases in both adults and children Mean fold change of mTOR expression was significantly higher in non-responders compared to responders of both adult B-ALL 7.4 vs. 2.7 p 0.05 and T-ALL 13.9 vs. 2.4 p 0.001 Similar results were seen in pediatric non-responders when compared to responders of both B-ALL 14.5 vs. 2.5 p 0.006 and T-ALL 24.2 vs. 1.7 p 0.002 Interestingly we have observed that mTOR expression was two times higher in non-responders of children compared to adults in both B-ALL 14.5 vs. 7.4 p 0.05 and T-ALL 24.2 vs. 13.9 p 0.01 Multivariate analysis with other known prognostic factors revealed that mTOR expression independently predicts clinical response to induction chemotherapy in ALL This study demonstrates that high mTOR expression is associated with poor clinical outcome in ALL and can serve as a potential target for novel therapeutic strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 286, 1275, 62, 383, 74, 32, 390, 23, 873, 145, 55, 4, 38, 347, 2, 211, 200, 4, 1434, 51, 6, 504, 56, 956, 55, 1, 873, 145, 10, 509, 5889, 20, 1589, 98, 604, 4, 212, 62, 7, 201, 132, 62, 2, 179, 102, 62, 2, 438, 5, 38, 228, 50, 504, 56, 55, 301, 1, 873, 10, 2684, 4, 80, 76, 212, 1, 140, 1, 62, 4, 102, 62, 64, 55, 1, 873, 10, 841, 527, 80, 4, 857, 76, 541, 878, 105, 614, 140, 369, 4, 132, 62, 192, 10, 827, 676, 140, 4, 110, 857, 2, 541, 313, 1116, 707, 1, 873, 55, 10, 97, 142, 4, 220, 1983, 72, 6, 1983, 1, 110, 780, 132, 62, 67, 39, 105, 18, 67, 19, 13, 474, 2, 102, 62, 233, 83, 105, 18, 39, 19, 13, 144, 288, 99, 11, 527, 4, 815, 220, 1983, 198, 72, 6, 1983, 1, 110, 132, 62, 213, 33, 105, 18, 33, 19, 13, 1861, 2, 102, 62, 259, 18, 105, 14, 67, 19, 13, 1111, 2873, 21, 47, 164, 17, 873, 55, 10, 100, 1072, 142, 4, 220, 1983, 1, 541, 72, 6, 857, 4, 110, 132, 62, 213, 33, 105, 67, 39, 19, 13, 474, 2, 102, 62, 259, 18, 105, 233, 83, 19, 13, 355, 331, 65, 5, 127, 440, 177, 130, 553, 17, 873, 55, 1042, 2623, 38, 51, 6, 504, 56, 4, 62, 26, 45, 1902, 17, 64, 873, 55, 16, 41, 5, 334, 38, 228, 4, 62, 2, 122, 1833, 22, 8, 174, 283, 9, 229, 189, 422]",1411.0,29076004,522
An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001.,Pediatric blood & cancer,Pediatr Blood Cancer,2017-11-01,"This study compared the relative incidence of treatment-related toxicities and the event-free and overall survival between Hispanic and non-Hispanic children undergoing therapy for acute lymphoblastic leukemia (ALL) on Dana-Farber Cancer Institute ALL Consortium protocol 05-001. Secondary analysis of prospectively collected data from a phase III multicenter study in children and adolescents of 1-18 years with previously untreated ALL. Between 2005 and 2011, 794 eligible patients enrolled on DFCI 05-001, 730 of whom were included in this analysis (19% [N=150] Hispanic, 73% [N=580] non-Hispanic). Hispanic patients were more likely to be 10 years of age (32%vs. 24%, P=0.045) at diagnosis. Toxicity analyses revealed that Hispanic patients had significantly lower cumulative incidence of bone fracture (P<0.001) and osteonecrosis (ON; P=0.047). In multivariable risk regression, the risk of ON was significantly lower in Hispanic patients 10 years (HR 0.23; P=0.006). Hispanic patients had significantly lower 5-year event-free survival (EFS) (79.4%; 95% CI: 71.6-85.2) and overall survival (OS) (89.2%; 95% CI: 82.7-93.4) than non-Hispanic patients (EFS: 87.5%; 95% CI: 84.5-90.0, P=0.004; OS: 92.7%; 95% CI: 90.2-94.6, P=0.006). Exploratory analyses revealed differences between Hispanic and non-Hispanic patients in the frequency of common variants in genes related to toxicity or ALL outcome. Hispanic children treated for ALL on DFCI 05-001 had fewer bone-related toxicities and inferior survival than non-Hispanic patients. While disease biology is one explanatory variable for outcome disparities, these findings suggest that biologic and non-biologic mechanisms affecting drug delivery and exposure in this population may be important contributing factors as well.",Clinical Trial,811.0,4.0,This study compared the relative incidence of treatment-related toxicities and the event-free and overall survival between Hispanic and non-Hispanic children undergoing therapy for acute lymphoblastic ALL on Dana-Farber Cancer Institute ALL Consortium protocol 05-001 Secondary analysis of prospectively collected data from a phase III multicenter study in children and adolescents of 1-18 years with previously untreated ALL Between 2005 and 2011 794 eligible patients enrolled on DFCI 05-001 730 of whom were included in this analysis 19 N 150 Hispanic 73 N 580 non-Hispanic Hispanic patients were more likely to be 10 years of age 32 vs. 24 P 0.045 at diagnosis Toxicity analyses revealed that Hispanic patients had significantly lower cumulative incidence of fracture P 0.001 and osteonecrosis ON P 0.047 In multivariable risk regression the risk of ON was significantly lower in Hispanic patients 10 years HR 0.23 P 0.006 Hispanic patients had significantly lower 5-year event-free survival EFS 79.4 95 CI 71.6-85.2 and overall survival OS 89.2 95 CI 82.7-93.4 than non-Hispanic patients EFS 87.5 95 CI 84.5-90.0 P 0.004 OS 92.7 95 CI 90.2-94.6 P 0.006 Exploratory analyses revealed differences between Hispanic and non-Hispanic patients in the frequency of common variants in genes related to toxicity or ALL outcome Hispanic children treated for ALL on DFCI 05-001 had fewer bone-related toxicities and inferior survival than non-Hispanic patients While disease biology is one explanatory variable for outcome disparities these findings suggest that biologic and non-biologic mechanisms affecting drug delivery and exposure in this population may be important contributing factors as well,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[26, 45, 72, 3, 580, 287, 1, 24, 139, 385, 2, 3, 774, 115, 2, 63, 25, 59, 1776, 2, 220, 1776, 541, 479, 36, 9, 286, 1275, 62, 23, 4932, 4979, 12, 1377, 62, 2404, 1182, 474, 144, 568, 65, 1, 1143, 786, 74, 29, 8, 124, 316, 1570, 45, 4, 541, 2, 3101, 1, 14, 203, 60, 5, 373, 1278, 62, 59, 1242, 2, 1132, 13085, 625, 7, 346, 23, 11152, 474, 144, 13022, 1, 953, 11, 159, 4, 26, 65, 326, 78, 1577, 1776, 803, 78, 10624, 220, 1776, 1776, 7, 11, 80, 322, 6, 40, 4556, 60, 1, 89, 531, 105, 259, 19, 13, 4918, 28, 147, 155, 318, 553, 17, 1776, 7, 42, 97, 280, 967, 287, 1, 3956, 19, 13, 144, 2, 5404, 23, 19, 13, 5296, 4, 658, 43, 320, 3, 43, 1, 23, 10, 97, 280, 4, 1776, 7, 4556, 60, 168, 13, 382, 19, 13, 1861, 1776, 7, 42, 97, 280, 33, 111, 774, 115, 25, 1683, 842, 39, 48, 58, 792, 49, 772, 18, 2, 63, 25, 118, 887, 18, 48, 58, 878, 67, 966, 39, 76, 220, 1776, 7, 1683, 912, 33, 48, 58, 874, 33, 424, 13, 19, 13, 1520, 118, 937, 67, 48, 58, 424, 18, 960, 49, 19, 13, 1861, 2386, 318, 553, 362, 59, 1776, 2, 220, 1776, 7, 4, 3, 675, 1, 186, 839, 4, 214, 139, 6, 155, 15, 62, 228, 1776, 541, 73, 9, 62, 23, 11152, 474, 144, 42, 1497, 3417, 139, 385, 2, 1663, 25, 76, 220, 1776, 7, 369, 34, 891, 16, 104, 18277, 1347, 9, 228, 2227, 46, 272, 309, 17, 1283, 2, 220, 1283, 483, 2319, 234, 989, 2, 645, 4, 26, 266, 68, 40, 305, 3156, 130, 22, 149]",1697.0,29090520,139
CD38 antibodies in multiple myeloma: back to the future.,Blood,Blood,2017-11-08,"CD38 is highly and uniformly expressed on multiple myeloma (MM) cells, and at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of nonhematopoietic origin. CD38 is a transmembrane glycoprotein with ectoenzymatic activity, and also functions as a receptor and adhesion molecule. Altogether, this has triggered the development of several CD38 antibodies including daratumumab (fully human), isatuximab (chimeric), and MOR202 (fully human). CD38 antibodies have pleiotropic mechanisms of action including Fc-dependent immune-effector mechanisms, direct apoptotic activity, and immunomodulatory effects by the elimination of CD38<sup>+</sup> immune-suppressor cells. CD38-targeting antibodies are generally well tolerated and induce partial response or better in 30% of heavily pretreated MM patients as monotherapy. Based on their distinct mechanisms of action, favorable toxicity profile, and single-agent activity, CD38 antibodies are attractive partners in combination regimens. Indeed, deep responses and prolonged progression-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors. Infusion-related reactions, which typically occur during the first infusion, are the most frequent adverse events. Attention should also be paid to the interference of CD38 antibodies with certain laboratory assays, which may complicate response evaluation and blood compatibility testing. Several studies are currently examining the role of CD38-based therapies in newly diagnosed and high-risk smoldering MM. Furthermore, CD38 antibodies are currently also under investigation in other hematologic malignancies, including acute lymphoblastic leukemia, natural killer/T-cell lymphoma, and acute myeloid leukemia, as well as in solid tumors.",Journal Article,804.0,60.0,CD38 is highly and uniformly expressed on multiple MM cells and at relatively low levels on normal lymphoid and myeloid cells and in some tissues of nonhematopoietic origin CD38 is a transmembrane glycoprotein with ectoenzymatic activity and also functions as a receptor and adhesion molecule Altogether this has triggered the development of several CD38 antibodies including daratumumab fully human isatuximab chimeric and MOR202 fully human CD38 antibodies have pleiotropic mechanisms of action including Fc-dependent immune-effector mechanisms direct apoptotic activity and immunomodulatory effects by the elimination of CD38 sup /sup immune-suppressor cells CD38-targeting antibodies are generally well tolerated and induce partial response or better in 30 of heavily pretreated MM patients as monotherapy Based on their distinct mechanisms of action favorable toxicity profile and single-agent activity CD38 antibodies are attractive partners in combination regimens Indeed deep responses and prolonged progression-free survival can be achieved in relapsed/refractory MM patients when CD38 antibodies are combined with immunomodulatory agents or proteasome inhibitors Infusion-related reactions which typically occur during the first infusion are the most frequent adverse events Attention should also be paid to the interference of CD38 antibodies with certain laboratory assays which may complicate response evaluation and blood compatibility testing Several studies are currently examining the role of CD38-based therapies in newly diagnosed and high-risk smoldering MM Furthermore CD38 antibodies are currently also under investigation in other hematologic malignancies including acute lymphoblastic natural killer/T-cell and acute myeloid as well as in solid tumors,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4469, 16, 561, 2, 4254, 570, 23, 232, 321, 37, 2, 28, 1352, 154, 148, 23, 295, 2303, 2, 533, 37, 2, 4, 476, 742, 1, 19463, 1938, 4469, 16, 8, 5527, 4455, 5, 71506, 128, 2, 120, 1681, 22, 8, 153, 2, 2128, 1354, 6767, 26, 71, 4173, 3, 193, 1, 392, 4469, 890, 141, 6458, 1910, 171, 14054, 2897, 2, 71507, 1910, 171, 4469, 890, 47, 7872, 483, 1, 1578, 141, 4127, 470, 250, 2070, 483, 1196, 1631, 128, 2, 2555, 176, 20, 3, 3730, 1, 4469, 172, 172, 250, 1245, 37, 4469, 529, 890, 32, 1228, 149, 421, 2, 1290, 450, 51, 15, 380, 4, 19254, 1, 2447, 2193, 321, 7, 22, 1411, 90, 23, 136, 834, 483, 1, 1578, 913, 155, 800, 2, 226, 420, 128, 4469, 890, 32, 3059, 4005, 4, 150, 472, 4462, 2369, 253, 2, 1069, 91, 115, 25, 122, 40, 513, 4, 591, 430, 321, 7, 198, 4469, 890, 32, 397, 5, 2555, 183, 15, 1694, 222, 904, 139, 2428, 92, 1969, 1271, 190, 3, 157, 904, 32, 3, 96, 908, 290, 281, 2111, 257, 120, 40, 8328, 6, 3, 3182, 1, 4469, 890, 5, 1840, 1624, 1013, 92, 68, 11157, 51, 451, 2, 315, 22539, 471, 392, 94, 32, 694, 3282, 3, 200, 1, 4469, 90, 235, 4, 732, 265, 2, 64, 43, 7091, 321, 798, 4469, 890, 32, 694, 120, 669, 940, 4, 127, 813, 441, 141, 286, 1275, 1504, 3458, 102, 31, 2, 286, 533, 22, 149, 22, 4, 537, 57]",1776.0,29118010,311
Emerging Role of CAR T Cells in Non-Hodgkin's Lymphoma.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2017-11-01,"Adoptive T-cell therapy with chimeric antigen receptor T cells (CAR-Ts) has produced impressive clinical responses among patients with B-cell malignancies, and several groups have published positive results using anti-CD19 CAR-Ts for the treatment of B-cell acute lymphoblastic leukemia. Recently, new data from clinical trials have demonstrated the benefits of CAR-T therapy in the non-Hodgkin's lymphoma (NHL) setting. This review describes some of the most recent and promising advances in engineered T-cell therapy, with particular emphasis on the clinical benefits of NHL treatment.",Journal Article,811.0,6.0,Adoptive T-cell therapy with chimeric antigen receptor T cells CAR-Ts has produced impressive clinical responses among patients with B-cell malignancies and several groups have published positive results using anti-CD19 CAR-Ts for the treatment of B-cell acute lymphoblastic Recently new data from clinical trials have demonstrated the benefits of CAR-T therapy in the 's NHL setting This review describes some of the most recent and promising advances in engineered T-cell therapy with particular emphasis on the clinical benefits of NHL treatment,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3159, 102, 31, 36, 5, 2897, 448, 153, 102, 37, 1881, 3527, 71, 1687, 5790, 38, 253, 107, 7, 5, 132, 31, 441, 2, 392, 271, 47, 983, 109, 99, 75, 312, 3158, 1881, 3527, 9, 3, 24, 1, 132, 31, 286, 1275, 761, 217, 74, 29, 38, 143, 47, 264, 3, 1141, 1, 1881, 102, 36, 4, 3, 292, 1176, 546, 26, 206, 2677, 476, 1, 3, 96, 435, 2, 721, 954, 4, 2794, 102, 31, 36, 5, 1454, 3136, 23, 3, 38, 1141, 1, 1176, 24]",548.0,29118234,672
Agents in Development for Childhood Acute Lymphoblastic Leukemia.,Paediatric drugs,Paediatr Drugs,2018-04-01,"Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Standard chemotherapy has afforded outstanding outcomes for many patients; however, there remain some sub-groups with high-risk features, refractory disease, and patients that relapse who have a poor prognosis with conventional treatments. Over the past decade, there have been significant advances in newer treatment options, including improved monoclonal antibody therapies, T cell engagers, and chimeric antigen T-cell receptor products, all of which have changed the landscape for patients who relapse. These are now being introduced more frequently and at earlier stages of therapy. We present a brief overview of the biology and etiology of childhood ALL, treatment strategies currently in use, and discuss some newer strategies and their possible role in the future of ALL therapy for children.",Journal Article,660.0,2.0,Acute lymphoblastic ALL is the most common cancer in childhood Standard chemotherapy has afforded outstanding outcomes for many patients however there remain some sub-groups with high-risk features refractory disease and patients that relapse who have a poor prognosis with conventional treatments Over the past decade there have been significant advances in newer treatment options including improved monoclonal antibody therapies T cell engagers and chimeric antigen T-cell receptor products all of which have changed the landscape for patients who relapse These are now being introduced more frequently and at earlier stages of therapy We present a brief overview of the biology and etiology of childhood ALL treatment strategies currently in use and discuss some newer strategies and their possible role in the future of ALL therapy for children,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 3, 96, 186, 12, 4, 864, 260, 56, 71, 9150, 14565, 123, 9, 445, 7, 137, 125, 918, 476, 551, 271, 5, 64, 43, 404, 430, 34, 2, 7, 17, 429, 54, 47, 8, 334, 356, 5, 809, 640, 252, 3, 1219, 2025, 125, 47, 85, 93, 954, 4, 2246, 24, 838, 141, 231, 848, 548, 235, 102, 31, 50700, 2, 2897, 448, 102, 31, 153, 2766, 62, 1, 92, 47, 2368, 3, 2801, 9, 7, 54, 429, 46, 32, 1134, 486, 3955, 80, 746, 2, 28, 1677, 1153, 1, 36, 21, 364, 8, 3190, 2901, 1, 3, 891, 2, 2855, 1, 864, 62, 24, 422, 694, 4, 119, 2, 1139, 476, 2246, 422, 2, 136, 899, 200, 4, 3, 508, 1, 62, 36, 9, 541]",849.0,29143289,422
Disseminability of computerized cognitive training: Performance across coaches.,Applied neuropsychology. Child,Appl Neuropsychol Child,2017-11-21,"Cogmed is a computerized cognitive intervention utilizing coaches who receive standardized instruction in analyzing training indices and tailoring feedback to remotely monitor participant's performance. The goal of this study was to examine adherence, satisfaction, and efficacy of Cogmed across coaches. Survivors of pediatric brain tumors and acute lymphoblastic leukemia (N=68) were randomized to intervention (Cogmed) or waitlist control. The intervention group was matched with one of two coaches. Cognitive assessments were completed before and after intervention, and participants and caregivers in the intervention group completed satisfaction surveys. T-tests showed no differences in adherence across coaches (number of sessions completed p=.38; d=.32). Noninferiority statistics were not consistently equivalent for satisfaction, but equivalence was supported for caregiver perceptions of pragmatic utility and participant perceptions of logistical ease of Cogmed. Equivalence was not consistently suggested for cognitive outcomes, but was supported on measures tapping relevant cognitive domains (attention, working memory, processing speed, academic fluency). This study suggests adherence can be maintained across coaches. While aspects of satisfaction and cognitive outcomes were equivalent, the possible influence of coach-based variables cannot be ruled out. Findings highlight challenges in standardizing the coaching component of multicomponent computerized interventions and the need for ongoing research to establish dessiminability.",Journal Article,791.0,0.0,Cogmed is a computerized cognitive intervention utilizing coaches who receive standardized instruction in analyzing training indices and tailoring feedback to remotely monitor participant 's performance The goal of this study was to examine adherence satisfaction and efficacy of Cogmed across coaches Survivors of pediatric brain tumors and acute lymphoblastic N 68 were randomized to intervention Cogmed or waitlist control The intervention group was matched with one of two coaches Cognitive assessments were completed before and after intervention and participants and caregivers in the intervention group completed satisfaction surveys T-tests showed no differences in adherence across coaches number of sessions completed p .38 d .32 Noninferiority statistics were not consistently equivalent for satisfaction but equivalence was supported for caregiver perceptions of pragmatic utility and participant perceptions of logistical ease of Cogmed Equivalence was not consistently suggested for cognitive outcomes but was supported on measures tapping relevant cognitive domains attention working memory processing speed academic fluency This study suggests adherence can be maintained across coaches While aspects of satisfaction and cognitive outcomes were equivalent the possible influence of coach-based variables can not be ruled out Findings highlight challenges in standardizing the coaching component of multicomponent computerized interventions and the need for ongoing research to establish dessiminability,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[36506, 16, 8, 4912, 1863, 788, 2600, 27650, 54, 560, 1670, 19661, 4, 4449, 1741, 3824, 2, 7101, 3983, 6, 29924, 3334, 5705, 292, 528, 3, 1326, 1, 26, 45, 10, 6, 1004, 2149, 2885, 2, 209, 1, 36506, 716, 27650, 332, 1, 815, 342, 57, 2, 286, 1275, 78, 806, 11, 384, 6, 788, 36506, 15, 17391, 182, 3, 788, 87, 10, 655, 5, 104, 1, 100, 27650, 1863, 2182, 11, 781, 348, 2, 50, 788, 2, 776, 2, 2771, 4, 3, 788, 87, 781, 2885, 3666, 102, 895, 224, 77, 362, 4, 2149, 716, 27650, 207, 1, 4390, 781, 19, 519, 427, 531, 7386, 3065, 11, 44, 2433, 2017, 9, 2885, 84, 9779, 10, 2708, 9, 4828, 3746, 1, 14102, 1207, 2, 5705, 3746, 1, 9773, 7440, 1, 36506, 9779, 10, 44, 2433, 1148, 9, 1863, 123, 84, 10, 2708, 23, 1018, 39783, 867, 1863, 2703, 2111, 2644, 2407, 3325, 5051, 1916, 20475, 26, 45, 844, 2149, 122, 40, 1955, 716, 27650, 369, 2695, 1, 2885, 2, 1863, 123, 11, 2017, 3, 899, 1054, 1, 40766, 90, 682, 122, 44, 40, 11901, 1205, 272, 1817, 1427, 4, 15343, 3, 16681, 1249, 1, 24584, 4912, 1151, 2, 3, 594, 9, 942, 389, 6, 1811, 71618]",1518.0,29161113,156
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression.,American journal of hematology,Am. J. Hematol.,2017-12-23,"Blinatumomab, a bi-specific T-cell engaging CD3-CD19 antibody construct, has shown significant activity in patients with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL). Despite this improvement, most patients relapse. Here, we describe the outcome of 68 patients with R/R ALL after failure of blinatumomab therapy: 38 (56%) blinatumomab refractory; 30 (44%) relapsing after initial response. After a median follow-up of 49 months, 9 (13%) patients remained alive. The median overall survival after blinatumomab failure was 5.2 months. At the time of failure, among 61 patients evaluated for immunophenotype, 56 (92%) had CD19-positive blasts; only five (8%) had ALL recurrence with CD19-negative disease. Two patients progressed with lower CD19 expression. In summary, the outcome of patients with R/R ALL after blinatumomab failure is poor and treatment of these patients remains an unmet medical need. Our findings indicate that blinatumomab therapy would not exclude a significant number of patients from the potential benefit of subsequent CD19-directed therapies such as chimeric antigen receptor T-cell therapy.",Journal Article,759.0,13.0,Blinatumomab a bi-specific T-cell engaging CD3-CD19 antibody construct has shown significant activity in patients with relapsed/refractory R/R B-cell acute lymphoblastic ALL Despite this improvement most patients relapse Here we describe the outcome of 68 patients with R/R ALL after failure of blinatumomab therapy 38 56 blinatumomab refractory 30 44 relapsing after initial response After a median follow-up of 49 months 9 13 patients remained alive The median overall survival after blinatumomab failure was 5.2 months At the time of failure among 61 patients evaluated for immunophenotype 56 92 had CD19-positive blasts only five 8 had ALL recurrence with CD19-negative disease Two patients progressed with lower CD19 expression In summary the outcome of patients with R/R ALL after blinatumomab failure is poor and treatment of these patients remains an unmet medical need Our findings indicate that blinatumomab therapy would not exclude a significant number of patients from the potential benefit of subsequent CD19-directed therapies such as chimeric antigen receptor T-cell therapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7182, 8, 3984, 112, 102, 31, 8534, 3117, 3158, 548, 3883, 71, 443, 93, 128, 4, 7, 5, 591, 430, 668, 668, 132, 31, 286, 1275, 62, 550, 26, 767, 96, 7, 429, 467, 21, 897, 3, 228, 1, 806, 7, 5, 668, 668, 62, 50, 496, 1, 7182, 36, 519, 664, 7182, 430, 201, 584, 6758, 50, 388, 51, 50, 8, 52, 166, 126, 1, 739, 53, 83, 233, 7, 958, 1701, 3, 52, 63, 25, 50, 7182, 496, 10, 33, 18, 53, 28, 3, 98, 1, 496, 107, 713, 7, 194, 9, 5496, 664, 937, 42, 3158, 109, 2438, 158, 365, 66, 42, 62, 146, 5, 3158, 199, 34, 100, 7, 1839, 5, 280, 3158, 55, 4, 1962, 3, 228, 1, 7, 5, 668, 668, 62, 50, 7182, 496, 16, 334, 2, 24, 1, 46, 7, 469, 35, 3715, 484, 594, 114, 272, 1008, 17, 7182, 36, 688, 44, 6262, 8, 93, 207, 1, 7, 29, 3, 174, 247, 1, 706, 3158, 1166, 235, 225, 22, 2897, 448, 153, 102, 31, 36]",1090.0,29178361,9
Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-12-25,"Total body irradiation (TBI) has been included in standard conditioning for acute lymphoblastic leukemia (ALL) before hematopoietic cell transplantation (HCT). Non-TBI regimens have incorporated busulfan (Bu) to decrease toxicity. This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18-60 years old, in first or second complete remission (CR), undergoing HLA-compatible sibling, related, or unrelated donor HCT, who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014. TBI plus etoposide (25%) or cyclophosphamide (75%) was used in 819 patients, and intravenous Bu plus fludarabine (41%), clofarabine (30%), cyclophosphamide (15%), or melphalan (13%) was used in 299 patients. Bu-containing regimens were analyzed together, since no significant differences for patient outcomes were noted between them. Bu patients were older, with better performance status; took longer to achieve first CR and receive HCT; were treated more recently; and were more likely to receive peripheral blood grafts, antithymocyte globulin, or tyrosine kinase inhibitors. With median follow-up of 3.6 years for Bu and 5.3 years for TBI, adjusted 3-year outcomes showed treatment-related mortality Bu 19% versus TBI 25% (P=.04); relapse Bu 37% versus TBI 28% (P=.007); disease-free survival (DFS) Bu 45% versus TBI 48% (P=.35); and overall survival (OS) Bu 57% versus TBI 53% (P=.35). In multivariate analysis, Bu patients had higher risk of relapse (relative risk, 1.46; 95% confidence interval, 1.15 to 1.85; P=.002) compared with TBI patients. Despite the higher relapse, Bu-containing conditioning led to similar OS and DFS following HCT for ALL.",Comparative Study,757.0,10.0,Total body irradiation TBI has been included in standard conditioning for acute lymphoblastic ALL before hematopoietic cell transplantation HCT Non-TBI regimens have incorporated busulfan Bu to decrease toxicity This retrospective study analyzed TBI and Bu on outcomes of ALL patients 18-60 years old in first or second complete remission CR undergoing HLA-compatible sibling related or unrelated donor HCT who reported to the Center for International Blood and Marrow Transplant Research from 2005 to 2014 TBI plus etoposide 25 or cyclophosphamide 75 was used in 819 patients and intravenous Bu plus fludarabine 41 clofarabine 30 cyclophosphamide 15 or melphalan 13 was used in 299 patients Bu-containing regimens were analyzed together since no significant differences for patient outcomes were noted between them Bu patients were older with better performance status took longer to achieve first CR and receive HCT were treated more recently and were more likely to receive peripheral blood grafts antithymocyte globulin or tyrosine kinase inhibitors With median follow-up of 3.6 years for Bu and 5.3 years for TBI adjusted 3-year outcomes showed treatment-related mortality Bu 19 versus TBI 25 P .04 relapse Bu 37 versus TBI 28 P .007 disease-free survival DFS Bu 45 versus TBI 48 P .35 and overall survival OS Bu 57 versus TBI 53 P .35 In multivariate analysis Bu patients had higher risk of relapse relative risk 1.46 95 confidence interval 1.15 to 1.85 P .002 compared with TBI patients Despite the higher relapse Bu-containing conditioning led to similar OS and DFS following HCT for ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[181, 642, 1104, 4889, 71, 85, 159, 4, 260, 1933, 9, 286, 1275, 62, 348, 1007, 31, 497, 1085, 220, 4889, 472, 47, 2449, 3906, 3667, 6, 775, 155, 26, 459, 45, 311, 4889, 2, 3667, 23, 123, 1, 62, 7, 203, 335, 60, 1095, 4, 157, 15, 419, 236, 734, 684, 479, 1160, 7293, 3684, 139, 15, 2092, 1488, 1085, 54, 210, 6, 3, 574, 9, 944, 315, 2, 581, 941, 389, 29, 1242, 6, 1409, 4889, 349, 1934, 243, 15, 1112, 481, 10, 95, 4, 16447, 7, 2, 1262, 3667, 349, 2027, 605, 4149, 201, 1112, 167, 15, 2370, 233, 10, 95, 4, 8769, 7, 3667, 1101, 472, 11, 311, 1162, 1192, 77, 93, 362, 9, 69, 123, 11, 1051, 59, 1370, 3667, 7, 11, 434, 5, 380, 528, 156, 5060, 589, 6, 1359, 157, 684, 2, 560, 1085, 11, 73, 80, 761, 2, 11, 80, 322, 6, 560, 672, 315, 4713, 11016, 7819, 15, 564, 216, 222, 5, 52, 166, 126, 1, 27, 49, 60, 9, 3667, 2, 33, 27, 60, 9, 4889, 586, 27, 111, 123, 224, 24, 139, 282, 3667, 326, 185, 4889, 243, 19, 755, 429, 3667, 567, 185, 4889, 339, 19, 1999, 34, 115, 25, 1010, 3667, 512, 185, 4889, 576, 19, 465, 2, 63, 25, 118, 3667, 696, 185, 4889, 699, 19, 465, 4, 331, 65, 3667, 7, 42, 142, 43, 1, 429, 580, 43, 14, 641, 48, 307, 268, 14, 167, 6, 14, 772, 19, 1111, 72, 5, 4889, 7, 550, 3, 142, 429, 3667, 1101, 1933, 836, 6, 288, 118, 2, 1010, 366, 1085, 9, 62]",1595.0,29197676,447
Molecular genetic profile in BCR-ABL1 negative pediatric B-cell acute lymphoblastic leukemia can further refine outcome prediction in addition to that by end-induction minimal residual disease detection.,Leukemia & lymphoma,Leuk. Lymphoma,2017-12-03,"The recently proposed molecular genetic criteria promise improved risk-prediction in B-cell acute lymphoblastic leukemia (B-ALL). This study assesses their utility in BCR-ABL1 negative pediatric B-ALL, particularly with respect to end-induction minimal residual disease (MRD). The DNA was analyzed for copy number alterations in CDKN2A/B, PAX5, IKZF1, and other genes. Seventy-six cases with median age 7years (2months-18years) included MRD-positive (24; 32%), and MRD negative-standard(20; 26%), intermediate(20; 26%), & high risk (12;16%) cases. The risk classification was based on age, initial total leukocyte count, central nervous system involvement, cytogenetics, day 8 prednisolone response and MRD status after induction chemotherapy. The genetic profile based on Moorman's criteria identified two subgroups with different event free survival (EFS) (0.77 vs. 0.38;p=.045) and overall survival (OS) (0.90 vs. 0.30;p=.037) in the MRD-negative intermediate-risk group. The genetic profile also separated two subgroups with different EFS (0.75 vs. 0.41;p=.036) in the MRD-positive group, however the OS was not different (0.75 vs. 0.57;p=.293).",Journal Article,779.0,2.0,The recently proposed molecular genetic criteria promise improved risk-prediction in B-cell acute lymphoblastic B-ALL This study assesses their utility in BCR-ABL1 negative pediatric B-ALL particularly with respect to end-induction minimal residual disease MRD The DNA was analyzed for copy number alterations in CDKN2A/B PAX5 IKZF1 and other genes Seventy-six cases with median age 7 years 2 months-18 years included MRD-positive 24 32 and MRD negative-standard 20 26 intermediate 20 26 high risk 12 16 cases The risk classification was based on age initial total leukocyte count central nervous system involvement cytogenetics day 8 prednisolone response and MRD status after induction chemotherapy The genetic profile based on Moorman 's criteria identified two subgroups with different event free survival EFS 0.77 vs. 0.38 p .045 and overall survival OS 0.90 vs. 0.30 p .037 in the MRD-negative intermediate-risk group The genetic profile also separated two subgroups with different EFS 0.75 vs. 0.41 p .036 in the MRD-positive group however the OS was not different 0.75 vs. 0.57 p .293,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 761, 1587, 219, 336, 371, 1783, 231, 43, 1590, 4, 132, 31, 286, 1275, 132, 62, 26, 45, 7777, 136, 1207, 4, 1062, 3557, 199, 815, 132, 62, 823, 5, 2184, 6, 396, 504, 1048, 753, 34, 2029, 3, 261, 10, 311, 9, 1337, 207, 593, 4, 3175, 132, 6279, 8422, 2, 127, 214, 2073, 437, 140, 5, 52, 89, 67, 60, 18, 53, 203, 60, 159, 2029, 109, 259, 531, 2, 2029, 199, 260, 179, 432, 919, 179, 432, 64, 43, 133, 245, 140, 3, 43, 947, 10, 90, 23, 89, 388, 181, 3627, 1276, 854, 1880, 398, 799, 2510, 218, 66, 11253, 51, 2, 2029, 156, 50, 504, 56, 3, 336, 800, 90, 23, 71718, 292, 371, 108, 100, 1453, 5, 338, 774, 115, 25, 1683, 13, 849, 105, 13, 519, 19, 4918, 2, 63, 25, 118, 13, 424, 105, 13, 201, 19, 5171, 4, 3, 2029, 199, 919, 43, 87, 3, 336, 800, 120, 4910, 100, 1453, 5, 338, 1683, 13, 481, 105, 13, 605, 19, 5395, 4, 3, 2029, 109, 87, 137, 3, 118, 10, 44, 338, 13, 481, 105, 13, 696, 19, 7541]",1092.0,29199525,879
Clinical impact of sedentary behaviors in adult survivors of acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort study.,Cancer,Cancer,2017-12-04,"Sedentary behaviors are associated with poor health outcomes in the general population, but their clinical impact on adult survivors of childhood acute lymphoblastic leukemia (ALL) has not been characterized to date. In the current study, we described the prevalence of sedentary behaviors in survivors of ALL and examined associations between time spent sedentary and body composition and onset of cardiovascular disease (CVD) risk factors. Participants' self-reported screen time (eg, television, computer) and activity as measured by accelerometer were used to determine activity time (sedentary, light activity, and moderate or vigorous physical activity). The percentage of time spent in each activity was compared between 331 survivors of ALL and 330 controls. Associations between time sedentary and body composition were evaluated in survivors using linear regression models. Cox proportional hazard models were used to examine the association between time sedentary at baseline and CVD risk factor onset during follow-up. Survivors spent approximately 65% of their time sedentary, 32% in light activity, and 2% in moderate or vigorous physical activity compared with 67% (P=.04), 30% (P<.01), and 3% (P<.01), respectively, in controls. Among survivors, percentage lean body mass decreased by 1.0%0.4% (P=.01) per 10% increase in time sedentary. Survivors who were sedentary 60% per day were found to be at an increased risk of high total cholesterol (hazard ratio, 2.52; 95% confidence interval, 1.12-5.64) and any CVD risk factor (hazard ratio, 1.96; 95% confidence interval, 1.16-3.30). Sedentary behavior is associated with low lean mass and CVD risk factor development and should be limited in survivors of childhood ALL. Cancer 2018;124:1036-43.  2017 American Cancer Society.",Journal Article,778.0,4.0,Sedentary behaviors are associated with poor health outcomes in the general population but their clinical impact on adult survivors of childhood acute lymphoblastic ALL has not been characterized to date In the current study we described the prevalence of sedentary behaviors in survivors of ALL and examined associations between time spent sedentary and body composition and onset of cardiovascular disease CVD risk factors Participants self-reported screen time eg television computer and activity as measured by accelerometer were used to determine activity time sedentary light activity and moderate or vigorous physical activity The percentage of time spent in each activity was compared between 331 survivors of ALL and 330 controls Associations between time sedentary and body composition were evaluated in survivors using linear regression models Cox proportional hazard models were used to examine the association between time sedentary at baseline and CVD risk factor onset during follow-up Survivors spent approximately 65 of their time sedentary 32 in light activity and 2 in moderate or vigorous physical activity compared with 67 P .04 30 P .01 and 3 P .01 respectively in controls Among survivors percentage lean body mass decreased by 1.0  0.4 P .01 per 10 increase in time sedentary Survivors who were sedentary 60 per day were found to be at an increased risk of high total cholesterol hazard ratio 2.52 95 confidence interval 1.12-5.64 and any CVD risk factor hazard ratio 1.96 95 confidence interval 1.16-3.30 Sedentary behavior is associated with low lean mass and CVD risk factor development and should be limited in survivors of childhood ALL Cancer 2018 124:1036-43  2017 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9259, 3704, 32, 41, 5, 334, 341, 123, 4, 3, 1083, 266, 84, 136, 38, 345, 23, 780, 332, 1, 864, 286, 1275, 62, 71, 44, 85, 765, 6, 1244, 4, 3, 291, 45, 21, 1027, 3, 1078, 1, 9259, 3704, 4, 332, 1, 62, 2, 409, 685, 59, 98, 9509, 9259, 2, 642, 3761, 2, 1707, 1, 2179, 34, 5264, 43, 130, 776, 1074, 210, 2413, 98, 2887, 39056, 4236, 2, 128, 22, 644, 20, 25484, 11, 95, 6, 223, 128, 98, 9259, 1691, 128, 2, 1163, 15, 10309, 900, 128, 3, 1150, 1, 98, 9509, 4, 296, 128, 10, 72, 59, 7558, 332, 1, 62, 2, 7105, 535, 685, 59, 98, 9259, 2, 642, 3761, 11, 194, 4, 332, 75, 1646, 320, 274, 418, 831, 360, 274, 11, 95, 6, 1004, 3, 248, 59, 98, 9259, 28, 330, 2, 5264, 43, 161, 1707, 190, 166, 126, 332, 9509, 705, 556, 1, 136, 98, 9259, 531, 4, 1691, 128, 2, 18, 4, 1163, 15, 10309, 900, 128, 72, 5, 598, 19, 755, 201, 19, 355, 2, 27, 19, 355, 106, 4, 535, 107, 332, 1150, 6949, 642, 782, 340, 20, 14, 13, 810, 13, 39, 19, 355, 379, 79, 344, 4, 98, 9259, 332, 54, 11, 9259, 6690, 379, 218, 11, 204, 6, 40, 28, 35, 101, 43, 1, 64, 181, 5020, 360, 197, 18, 653, 48, 307, 268, 14, 133, 33, 660, 2, 500, 5264, 43, 161, 360, 197, 14, 921, 48, 307, 268, 14, 245, 27, 201, 9259, 1710, 16, 41, 5, 154, 6949, 782, 2, 5264, 43, 161, 193, 2, 257, 40, 383, 4, 332, 1, 864, 62, 12, 2982, 2834, 35404, 601, 2206, 1759, 597, 12, 1174]",1722.0,29205290,16
Current management of Philadelphia chromosome positive ALL and the role of stem cell transplantation.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2017-12-01,"Treatment of Philadelphia chromosome positive acute lymphoblastic leukemia exemplifies how the addition of potent targeted agents, directed at the molecular aberrations responsible for leukemic transformation, can overcome resistance mechanisms to traditional regimens and lead to improved outcomes. The introduction of <i>BCR-ABL1</i> targeted tyrosine kinase inhibitors (TKIs) has significantly improved the outcomes not only by allowing more patients to undergo allogeneic hematopoietic cell transplantation (alloHCT) but also by decreasing our reliance on this potentially toxic strategy, particularly in the less fit population. Long-term data using chemotherapy and TKI combinations demonstrate that a proportion of patients treated can achieve durable relapse-free survival without undergoing alloHCT. Furthermore, the availability of sensitive minimal residual disease monitoring assays may allow early detection of the patients who are more likely to relapse and who are likely candidates for early alloHCT. The emergence of more potent TKIs with significant activity against resistant mutations has allowed deintensification of chemotherapy regimens. Available data indicate that complete reliance on TKIs, alone or with minimal additional therapy, and elimination of more intensive chemotherapy or alloHCT is unlikely to achieve long term cure in most patients. However, introduction of other highly effective agents that can be combined with TKIs may allow further minimization of chemotherapy and alloHCT in the future, as we have witnessed in acute promyelocytic leukemia.",Journal Article,781.0,7.0,Treatment of Philadelphia chromosome positive acute lymphoblastic exemplifies how the addition of potent targeted agents directed at the molecular aberrations responsible for leukemic transformation can overcome resistance mechanisms to traditional regimens and lead to improved outcomes The introduction of i BCR-ABL1 /i targeted tyrosine kinase inhibitors TKIs has significantly improved the outcomes not only by allowing more patients to undergo allogeneic hematopoietic cell transplantation alloHCT but also by decreasing our reliance on this potentially toxic strategy particularly in the less fit population Long-term data using chemotherapy and TKI combinations demonstrate that a proportion of patients treated can achieve durable relapse-free survival without undergoing alloHCT Furthermore the availability of sensitive minimal residual disease monitoring assays may allow early detection of the patients who are more likely to relapse and who are likely candidates for early alloHCT The emergence of more potent TKIs with significant activity against resistant mutations has allowed deintensification of chemotherapy regimens Available data indicate that complete reliance on TKIs alone or with minimal additional therapy and elimination of more intensive chemotherapy or alloHCT is unlikely to achieve long term cure in most patients However introduction of other highly effective agents that can be combined with TKIs may allow further minimization of chemotherapy and alloHCT in the future as we have witnessed in acute promyelocytic,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 3006, 1170, 109, 286, 1275, 24934, 832, 3, 352, 1, 1157, 238, 183, 1166, 28, 3, 219, 2152, 2327, 9, 2015, 1392, 122, 1768, 251, 483, 6, 1847, 472, 2, 1122, 6, 231, 123, 3, 2456, 1, 70, 1062, 3557, 70, 238, 564, 216, 222, 1671, 71, 97, 231, 3, 123, 44, 158, 20, 2952, 80, 7, 6, 1251, 1063, 1007, 31, 497, 5514, 84, 120, 20, 2777, 114, 9007, 23, 26, 751, 1812, 692, 823, 4, 3, 299, 2975, 266, 319, 337, 74, 75, 56, 2, 1379, 1247, 608, 17, 8, 920, 1, 7, 73, 122, 1359, 1480, 429, 115, 25, 187, 479, 5514, 798, 3, 2550, 1, 745, 1048, 753, 34, 1315, 1013, 68, 1700, 191, 638, 1, 3, 7, 54, 32, 80, 322, 6, 429, 2, 54, 32, 322, 1931, 9, 191, 5514, 3, 3397, 1, 80, 1157, 1671, 5, 93, 128, 480, 436, 138, 71, 2313, 20038, 1, 56, 472, 390, 74, 1008, 17, 236, 9007, 23, 1671, 279, 15, 5, 1048, 402, 36, 2, 3730, 1, 80, 1686, 56, 15, 5514, 16, 3568, 6, 1359, 319, 337, 1722, 4, 96, 7, 137, 2456, 1, 127, 561, 323, 183, 17, 122, 40, 397, 5, 1671, 68, 1700, 195, 12807, 1, 56, 2, 5514, 4, 3, 508, 22, 21, 47, 10606, 4, 286, 4300]",1547.0,29222233,55
Progress in adult ALL: incorporation of new agents to frontline treatment.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2017-12-01,"Treatment of acute lymphoblastic leukemia (ALL) in adults remains a challenge, as the delivery of intensive chemotherapeutic regimens in this population is less feasible than it is in the pediatric population. This has led to higher rates of treatment-related toxicity as well as lower overall survival in the adult population. Over the past several years, a host of novel therapies (eg, immunotherapy and targeted therapies) with better tolerability than traditional chemotherapy are now being introduced into the relapsed/refractory population with very encouraging results. Additionally, insights into how to choose effective therapies for patients while minimizing drug toxicity through pharmacogenomics and the use of minimal residual disease (MRD) monitoring to escalate/de-escalate therapy have enhanced our ability to reduce treatment-related toxicity. This has led to the design of a number of clinical trials which incorporate both novel therapeutics as well as MRD-directed treatment pathways into the frontline setting. The use of increasingly personalized treatment strategies for specific disease subsets combined with standardized and rapid molecular diagnostic testing in the initial diagnosis and frontline treatment of ALL will hopefully lead to further improvements in survival for our adult patients.",Journal Article,781.0,5.0,Treatment of acute lymphoblastic ALL in adults remains a challenge as the delivery of intensive chemotherapeutic regimens in this population is less feasible than it is in the pediatric population This has led to higher rates of treatment-related toxicity as well as lower overall survival in the adult population Over the past several years a host of novel therapies eg immunotherapy and targeted therapies with better tolerability than traditional chemotherapy are now being introduced into the relapsed/refractory population with very encouraging results Additionally insights into how to choose effective therapies for patients while minimizing drug toxicity through pharmacogenomics and the use of minimal residual disease MRD monitoring to escalate/de-escalate therapy have enhanced our ability to reduce treatment-related toxicity This has led to the design of a number of clinical trials which incorporate both novel therapeutics as well as MRD-directed treatment pathways into the frontline setting The use of increasingly personalized treatment strategies for specific disease subsets combined with standardized and rapid molecular diagnostic testing in the initial diagnosis and frontline treatment of ALL will hopefully lead to further improvements in survival for our adult patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 286, 1275, 62, 4, 857, 469, 8, 1745, 22, 3, 989, 1, 1686, 1573, 472, 4, 26, 266, 16, 299, 1313, 76, 192, 16, 4, 3, 815, 266, 26, 71, 836, 6, 142, 151, 1, 24, 139, 155, 22, 149, 22, 280, 63, 25, 4, 3, 780, 266, 252, 3, 1219, 392, 60, 8, 1204, 1, 229, 235, 2887, 726, 2, 238, 235, 5, 380, 1543, 76, 1847, 56, 32, 1134, 486, 3955, 237, 3, 591, 430, 266, 5, 923, 2269, 99, 1724, 1957, 237, 832, 6, 6009, 323, 235, 9, 7, 369, 4501, 234, 155, 298, 7603, 2, 3, 119, 1, 1048, 753, 34, 2029, 1315, 6, 10400, 1566, 10400, 36, 47, 651, 114, 801, 6, 969, 24, 139, 155, 26, 71, 836, 6, 3, 771, 1, 8, 207, 1, 38, 143, 92, 3360, 110, 229, 1943, 22, 149, 22, 2029, 1166, 24, 460, 237, 3, 3171, 546, 3, 119, 1, 1635, 2175, 24, 422, 9, 112, 34, 1890, 397, 5, 1670, 2, 1321, 219, 752, 471, 4, 3, 388, 147, 2, 3171, 24, 1, 62, 303, 7464, 1122, 6, 195, 1474, 4, 25, 9, 114, 780, 7]",1295.0,29222234,552
Incorporation of nonchemotherapeutic agents in pediatric acute lymphoblastic leukemia.,Hematology. American Society of Hematology. Education Program,Hematology Am Soc Hematol Educ Program,2017-12-01,"With current available therapies, the prognosis for most children and adolescents with acute lymphoblastic leukemia (ALL) is favorable. However, the multiagent chemotherapy regimens used to treat newly diagnosed patients are associated with many acute and long-term complications, and therapy for relapsed disease is intensive and suboptimally effective. Over the last decade, several nonchemotherapeutic approaches have been evaluated, with the goal of identifying more effective, less toxic therapies that can be used in conjunction with, or even replace, current regimens. Novel nonchemotherapeutic therapies with activity in ALL include (1) tyrosine kinase inhibitors in high-risk patient subsets in whom potentially targetable alterations have been identified and (2) immunotherapeutic approaches, such as monoclonal antibodies, immunotoxins, bispecific T-cell-engaging antibodies, and chimeric antigen receptor T cells. This review summarizes promising results from recent clinical trials of these novel treatments.",Journal Article,781.0,1.0,With current available therapies the prognosis for most children and adolescents with acute lymphoblastic ALL is favorable However the multiagent chemotherapy regimens used to treat newly diagnosed patients are associated with many acute and long-term complications and therapy for relapsed disease is intensive and suboptimally effective Over the last decade several nonchemotherapeutic approaches have been evaluated with the goal of identifying more effective less toxic therapies that can be used in conjunction with or even replace current regimens Novel nonchemotherapeutic therapies with activity in ALL include 1 tyrosine kinase inhibitors in high-risk patient subsets in whom potentially targetable alterations have been identified and 2 immunotherapeutic approaches such as monoclonal antibodies immunotoxins bispecific T-cell-engaging antibodies and chimeric antigen receptor T cells This review summarizes promising results from recent clinical trials of these novel treatments,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5, 291, 390, 235, 3, 356, 9, 96, 541, 2, 3101, 5, 286, 1275, 62, 16, 913, 137, 3, 7148, 56, 472, 95, 6, 943, 732, 265, 7, 32, 41, 5, 445, 286, 2, 319, 337, 521, 2, 36, 9, 591, 34, 16, 1686, 2, 14800, 323, 252, 3, 1060, 2025, 392, 40438, 611, 47, 85, 194, 5, 3, 1326, 1, 1386, 80, 323, 299, 1812, 235, 17, 122, 40, 95, 4, 3357, 5, 15, 871, 7195, 291, 472, 229, 40438, 235, 5, 128, 4, 62, 643, 14, 564, 216, 222, 4, 64, 43, 69, 1890, 4, 953, 751, 3985, 593, 47, 85, 108, 2, 18, 3222, 611, 225, 22, 848, 890, 17170, 7408, 102, 31, 8534, 890, 2, 2897, 448, 153, 102, 37, 26, 206, 2869, 721, 99, 29, 435, 38, 143, 1, 46, 229, 640]",989.0,29222264,791
The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia.,Journal of thrombosis and thrombolysis,J. Thromb. Thrombolysis,2018-02-01,"Treatment for acute lymphoblastic leukemia (ALL) in adults confers a high risk of venous thromboembolic (VTE) complications. We describe the implementation and results of prophylactic anticoagulation guidelines in adults (18-50years) treated on a Dana-Farber Cancer Institute ALL pediatric inspired consortium protocol from 2007 to 2013. A high rate of asparaginase related toxicity events, including thrombosis, resulted in a protocol amendment adding guidelines for prophylactic anticoagulation and a modified asparaginase dose and schedule. After excluding patients with Philadelphia positive ALL, a cohort of 36 patients were treated after the protocol amendment with prophylactic anticoagulation and compared to 49 patients who received no prophylactic anticoagulation. Bleeding complications were not significantly different in those treated with prophylactic anticoagulation compared with those enrolled prior to the amendment (p=0.26). No patients on prophylactic anticoagulation had grade3 bleeding. Prior to the amendment, the 2year cumulative incidence of VTE post-induction was 41% compared to 28% while on prophylactic anticoagulation (p=0.32). The 2year cumulative incidence pulmonary embolus pre-amendment was 16% compared with 8% post-amendment (p=0.34). Prophylactic anticoagulation can be safely administered to adults with ALL without increasing the number or severity of bleeding events and, in addition to modifications in the asparaginase regimen, resulted in a reduction in the cumulative incidence of VTE.",Journal Article,719.0,6.0,Treatment for acute lymphoblastic ALL in adults confers a high risk of venous thromboembolic VTE complications We describe the implementation and results of prophylactic anticoagulation guidelines in adults 18-50 years treated on a Dana-Farber Cancer Institute ALL pediatric inspired consortium protocol from 2007 to 2013 A high rate of asparaginase related toxicity events including thrombosis resulted in a protocol amendment adding guidelines for prophylactic anticoagulation and a modified asparaginase dose and schedule After excluding patients with Philadelphia positive ALL a cohort of 36 patients were treated after the protocol amendment with prophylactic anticoagulation and compared to 49 patients who received no prophylactic anticoagulation Bleeding complications were not significantly different in those treated with prophylactic anticoagulation compared with those enrolled prior to the amendment p 0.26 No patients on prophylactic anticoagulation had grade  3 bleeding Prior to the amendment the 2 year cumulative incidence of VTE post-induction was 41 compared to 28 while on prophylactic anticoagulation p 0.32 The 2 year cumulative incidence pulmonary embolus pre-amendment was 16 compared with 8 post-amendment p 0.34 Prophylactic anticoagulation can be safely administered to adults with ALL without increasing the number or severity of bleeding events and in addition to modifications in the asparaginase regimen resulted in a reduction in the cumulative incidence of VTE,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 9, 286, 1275, 62, 4, 857, 4020, 8, 64, 43, 1, 2167, 4703, 1779, 521, 21, 897, 3, 2393, 2, 99, 1, 1862, 5361, 677, 4, 857, 203, 212, 60, 73, 23, 8, 4932, 4979, 12, 1377, 62, 815, 13161, 2404, 1182, 29, 1307, 6, 1346, 8, 64, 116, 1, 3709, 139, 155, 281, 141, 2839, 627, 4, 8, 1182, 11013, 2726, 677, 9, 1862, 5361, 2, 8, 1230, 3709, 61, 2, 1055, 50, 3207, 7, 5, 3006, 109, 62, 8, 180, 1, 511, 7, 11, 73, 50, 3, 1182, 11013, 5, 1862, 5361, 2, 72, 6, 739, 7, 54, 103, 77, 1862, 5361, 2294, 521, 11, 44, 97, 338, 4, 135, 73, 5, 1862, 5361, 72, 5, 135, 346, 324, 6, 3, 11013, 19, 13, 432, 77, 7, 23, 1862, 5361, 42, 88, 749, 27, 2294, 324, 6, 3, 11013, 3, 18, 111, 967, 287, 1, 1779, 539, 504, 10, 605, 72, 6, 339, 369, 23, 1862, 5361, 19, 13, 531, 3, 18, 111, 967, 287, 1087, 12738, 671, 11013, 10, 245, 72, 5, 66, 539, 11013, 19, 13, 562, 1862, 5361, 122, 40, 2268, 468, 6, 857, 5, 62, 187, 602, 3, 207, 15, 1702, 1, 2294, 281, 2, 4, 352, 6, 2916, 4, 3, 3709, 477, 627, 4, 8, 628, 4, 3, 967, 287, 1, 1779]",1495.0,29260426,240
Bone mineral density in children with acute lymphoblastic leukemia.,Cancer,Cancer,2017-12-19,"Children with acute lymphoblastic leukemia (ALL) can develop reduced bone mineral density (BMD). However, data from patients who received treatment on a frontline regimen without cranial irradiation are limited, and no genome-wide analysis has been reported. Lumbar BMD was evaluated by quantitative computed tomography at diagnosis, after 120 weeks of continuation therapy, and after 2 years off therapy in pediatric patients with ALL (ages 2-18 years at diagnosis) who were treated on the St. Jude Total XV Protocol. Clinical, pharmacokinetic, and genetic risk factors associated with decreased BMD Z-scores were evaluated. The median BMD Z-score in 363 patients was 0.06 at diagnosis, declined to -1.08 at week 120, but partly recovered to -0.72 after 2 years off therapy; BMD in patients with low BMD Z-scores at diagnosis remained low after therapy. Older age (10 years vs 2-9.9 years at diagnosis; P<.001), a higher BMD Z-score at diagnosis (P=.001), and a greater area under the plasma drug concentration-time curve for dexamethasone in weeks 7 and 8 of continuation therapy (P=.001) were associated with a greater decrease in BMD Z-score from diagnosis to week 120. Single-nucleotide polymorphisms in 2 genes important in osteogenesis and bone mineralization (COL11A1 [reference single-nucleotide polymorphism rs2622849]; P=2.3910<sup>-7</sup> ] and NELL1 [rs11025915]; P=4.0710<sup>-6</sup> ]) were associated with a decreased BMD Z-score. NELL1 (P=.003) also was associated with a greater dexamethasone area under the plasma drug concentration-time curve. BMD Z-scores decreased during therapy, especially in patients who had clinical, pharmacokinetic, and genetic risk factors. Early recognition of BMD changes and strategies to optimize bone health are essential. Cancer 2018;124:1025-35.  2017 American Cancer Society.",Journal Article,763.0,6.0,Children with acute lymphoblastic ALL can develop reduced mineral density BMD However data from patients who received treatment on a frontline regimen without cranial irradiation are limited and no genome-wide analysis has been reported Lumbar BMD was evaluated by quantitative computed tomography at diagnosis after 120 weeks of continuation therapy and after 2 years off therapy in pediatric patients with ALL ages 2-18 years at diagnosis who were treated on the St. Jude Total XV Protocol Clinical pharmacokinetic and genetic risk factors associated with decreased BMD Z-scores were evaluated The median BMD Z-score in 363 patients was 0.06 at diagnosis declined to -1.08 at week 120 but partly recovered to -0.72 after 2 years off therapy BMD in patients with low BMD Z-scores at diagnosis remained low after therapy Older age 10 years vs 2-9.9 years at diagnosis P .001 a higher BMD Z-score at diagnosis P .001 and a greater area under the plasma drug concentration-time curve for dexamethasone in weeks 7 and 8 of continuation therapy P .001 were associated with a greater decrease in BMD Z-score from diagnosis to week 120 Single-nucleotide polymorphisms in 2 genes important in osteogenesis and mineralization COL11A1 reference single-nucleotide polymorphism rs2622849 P 2.39 10 sup -7 /sup and NELL1 rs11025915 P 4.07 10 sup -6 /sup were associated with a decreased BMD Z-score NELL1 P .003 also was associated with a greater dexamethasone area under the plasma drug concentration-time curve BMD Z-scores decreased during therapy especially in patients who had clinical pharmacokinetic and genetic risk factors Early recognition of BMD changes and strategies to optimize health are essential Cancer 2018 124:1025-35  2017 American Cancer Society,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 286, 1275, 62, 122, 690, 405, 5033, 1263, 3503, 137, 74, 29, 7, 54, 103, 24, 23, 8, 3171, 477, 187, 2565, 1104, 32, 383, 2, 77, 898, 1019, 65, 71, 85, 210, 6187, 3503, 10, 194, 20, 1156, 1220, 872, 28, 147, 50, 2031, 244, 1, 6870, 36, 2, 50, 18, 60, 1889, 36, 4, 815, 7, 5, 62, 2165, 18, 203, 60, 28, 147, 54, 11, 73, 23, 3, 3062, 4841, 181, 16078, 1182, 38, 1456, 2, 336, 43, 130, 41, 5, 340, 3503, 3905, 703, 11, 194, 3, 52, 3503, 3905, 368, 4, 9517, 7, 10, 13, 1460, 28, 147, 3054, 6, 14, 1592, 28, 647, 2031, 84, 5180, 5784, 6, 13, 720, 50, 18, 60, 1889, 36, 3503, 4, 7, 5, 154, 3503, 3905, 703, 28, 147, 958, 154, 50, 36, 434, 89, 4556, 60, 105, 18, 83, 83, 60, 28, 147, 19, 144, 8, 142, 3503, 3905, 368, 28, 147, 19, 144, 2, 8, 378, 965, 669, 3, 554, 234, 1227, 98, 1496, 9, 1217, 4, 244, 67, 2, 66, 1, 6870, 36, 19, 144, 11, 41, 5, 8, 378, 775, 4, 3503, 3905, 368, 29, 147, 6, 647, 2031, 226, 1579, 1203, 4, 18, 214, 305, 4, 28317, 2, 21153, 71839, 2482, 226, 1579, 1907, 71840, 19, 18, 587, 79, 172, 67, 172, 2, 34471, 71841, 19, 39, 1615, 79, 172, 49, 172, 11, 41, 5, 8, 340, 3503, 3905, 368, 34471, 19, 1421, 120, 10, 41, 5, 8, 378, 1217, 965, 669, 3, 554, 234, 1227, 98, 1496, 3503, 3905, 703, 340, 190, 36, 1093, 4, 7, 54, 42, 38, 1456, 2, 336, 43, 130, 191, 2335, 1, 3503, 400, 2, 422, 6, 2465, 341, 32, 1452, 12, 2982, 2834, 24629, 465, 2206, 1759, 597, 12, 1174]",1756.0,29266176,147
Toxicity associated with intensive postinduction therapy incorporating clofarabine in the very high-risk stratum of patients with newly diagnosed high-risk B-lymphoblastic leukemia: A report from the Children's Oncology Group study AALL1131.,Cancer,Cancer,2017-12-19,"Children, adolescents, and young adults with very high-risk (VHR) B acute lymphoblastic leukemia (B-ALL) have poor outcomes, and novel therapies are needed for this subgroup. The AALL1131 study evaluated postinduction therapy using cyclophosphamide (CPM), etoposide (ETOP), and clofarabine (CLOF) for patients with VHR B-ALL. Patients who were 1 to 30 years old and had VHR B-ALL received modified Berlin-Frankfurt-Mnster therapy after induction and were randomized to 1) CPM, cytarabine, mercaptopurine, vincristine (VCR), and pegaspargase (control arm), 2) CPM, ETOP, VCR, and pegaspargase (experimental arm 1), or 3) CPM, ETOP, CLOF (30 mg/m<sup>2</sup> /d  5), VCR, and pegaspargase (experimental arm 2) during the second half of consolidation and delayed intensification. The rates of grade 4/5 infections and grade 3/4 pancreatitis were significantly increased in experimental arm 2. The dose of CLOF was, therefore, reduced to 20 mg/m<sup>2</sup> /d  5, and myeloid growth factor was required after CLOF administration. Despite these changes, 4 of 39 patients (10.3%) developed grade 4 infections, with 1 of these patients developing a grade 5 acute kidney injury attributed to CLOF, whereas only 1 of 46 patients (2.2%) in experimental arm 1 developed grade 4 infections, and there were no grade 4/5 infections in the control arm (n = 20). Four patients in experimental arm 2 had prolonged cytopenias for >60 days, whereas none did in the control arm or experimental arm 1. Counts failed to recover for 2 of these patients, one having a grade 5 acute kidney injury and the other removed from protocol therapy; both events occurred 92 days after the start of consolidation part 2. In AALL1131, CLOF, administered with CPM and ETOP, was associated with unacceptable toxicity. Cancer 2018;124:1150-9.  2017 American Cancer Society.","Clinical Trial, Phase III",763.0,6.0,Children adolescents and young adults with very high-risk VHR B acute lymphoblastic B-ALL have poor outcomes and novel therapies are needed for this subgroup The AALL1131 study evaluated postinduction therapy using cyclophosphamide CPM etoposide ETOP and clofarabine CLOF for patients with VHR B-ALL Patients who were 1 to 30 years old and had VHR B-ALL received modified Berlin-Frankfurt-Mnster therapy after induction and were randomized to 1 CPM cytarabine mercaptopurine vincristine VCR and pegaspargase control arm 2 CPM ETOP VCR and pegaspargase experimental arm 1 or 3 CPM ETOP CLOF 30 mg/m sup 2 /sup /d 5 VCR and pegaspargase experimental arm 2 during the second half of consolidation and delayed intensification The rates of grade 4/5 infections and grade 3/4 pancreatitis were significantly increased in experimental arm 2 The dose of CLOF was therefore reduced to 20 mg/m sup 2 /sup /d 5 and myeloid growth factor was required after CLOF administration Despite these changes 4 of 39 patients 10.3 developed grade 4 infections with 1 of these patients developing a grade 5 acute injury attributed to CLOF whereas only 1 of 46 patients 2.2 in experimental arm 1 developed grade 4 infections and there were no grade 4/5 infections in the control arm n 20 Four patients in experimental arm 2 had prolonged cytopenias for 60 days whereas none did in the control arm or experimental arm 1 Counts failed to recover for 2 of these patients one having a grade 5 acute injury and the other removed from protocol therapy both events occurred 92 days after the start of consolidation part 2 In AALL1131 CLOF administered with CPM and ETOP was associated with unacceptable toxicity Cancer 2018 124:1150-9  2017 American Cancer Society,0,0,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 3101, 2, 1169, 857, 5, 923, 64, 43, 12957, 132, 286, 1275, 132, 62, 47, 334, 123, 2, 229, 235, 32, 575, 9, 26, 1363, 3, 50780, 45, 194, 12543, 36, 75, 1112, 2900, 1934, 15995, 2, 4149, 29950, 9, 7, 5, 12957, 132, 62, 7, 54, 11, 14, 6, 201, 60, 1095, 2, 42, 12957, 132, 62, 103, 1230, 20405, 23389, 26350, 36, 50, 504, 2, 11, 384, 6, 14, 2900, 1855, 9223, 2132, 8886, 2, 12209, 182, 475, 18, 2900, 15995, 8886, 2, 12209, 1560, 475, 14, 15, 27, 2900, 15995, 29950, 201, 81, 188, 172, 18, 172, 427, 33, 8886, 2, 12209, 1560, 475, 18, 190, 3, 419, 1303, 1, 2173, 2, 1612, 5091, 3, 151, 1, 88, 39, 33, 1875, 2, 88, 27, 39, 4535, 11, 97, 101, 4, 1560, 475, 18, 3, 61, 1, 29950, 10, 673, 405, 6, 179, 81, 188, 172, 18, 172, 427, 33, 2, 533, 129, 161, 10, 616, 50, 29950, 634, 550, 46, 400, 39, 1, 587, 7, 79, 27, 276, 88, 39, 1875, 5, 14, 1, 46, 7, 931, 8, 88, 33, 286, 2730, 3073, 6, 29950, 547, 158, 14, 1, 641, 7, 18, 18, 4, 1560, 475, 14, 276, 88, 39, 1875, 2, 125, 11, 77, 88, 39, 33, 1875, 4, 3, 182, 475, 78, 179, 294, 7, 4, 1560, 475, 18, 42, 1069, 5635, 9, 335, 162, 547, 1292, 205, 4, 3, 182, 475, 15, 1560, 475, 14, 1911, 1551, 6, 9966, 9, 18, 1, 46, 7, 104, 1041, 8, 88, 33, 286, 2730, 2, 3, 127, 2264, 29, 1182, 36, 110, 281, 489, 937, 162, 50, 3, 2435, 1, 2173, 760, 18, 4, 50780, 29950, 468, 5, 2900, 2, 15995, 10, 41, 5, 3215, 155, 12, 2982, 2834, 31066, 83, 2206, 1759, 597, 12, 1174]",1735.0,29266189,489
Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2017-12-21,"Allogeneic hematopoietic cell transplantation (alloHCT) is curative for patients with acute lymphoblastic leukemia (ALL) who achieve complete remission (CR1) with chemotherapy. However, the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT. We compared clinical outcomes of 524 adult patients with ALL in CR1 who received 2 (n=109), 1 (n=93), or 0 cycles (n=322) of consolidation before myeloablative alloHCT from 2008 to 2012. As expected, time to alloHCT was longer with increasing cycles of consolidation. Patients receiving 2, 1, or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20%, 27%, and 22%; 1-year transplant-related mortality (TRM) of 16%, 18%, and 23%; adjusted 3-year leukemia-free survival (LFS) of 54%, 48%, and 47%; and 3-year overall survival (OS) of 63%, 59%, and 54% (all P values >.40). Multivariable analysis confirmed that consolidation was not prognostic for LFS (relative risk,1.20, 95% confidence interval, .86 to 1.67; P=.28 for no consolidation; RR,1.18, 95% confidence interval, .79 to 1.76; P=.41 for 1 cycle versus 2 cycles = reference). Similarly, consolidation was not associated with OS, relapse, TRM, or graft-versus-host disease. We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1.",Comparative Study,761.0,2.0,Allogeneic hematopoietic cell transplantation alloHCT is curative for patients with acute lymphoblastic ALL who achieve complete remission CR1 with chemotherapy However the benefit of consolidation chemotherapy remains uncertain in patients undergoing alloHCT We compared clinical outcomes of 524 adult patients with ALL in CR1 who received 2 n 109 1 n 93 or 0 cycles n 322 of consolidation before myeloablative alloHCT from 2008 to 2012 As expected time to alloHCT was longer with increasing cycles of consolidation Patients receiving 2 1 or 0 cycles of consolidation had an adjusted 3-year cumulative incidence of relapse of 20 27 and 22 1-year transplant-related mortality TRM of 16 18 and 23 adjusted 3-year leukemia-free survival LFS of 54 48 and 47 and 3-year overall survival OS of 63 59 and 54 all P values .40 Multivariable analysis confirmed that consolidation was not prognostic for LFS relative risk 1.20 95 confidence interval .86 to 1.67 P .28 for no consolidation RR 1.18 95 confidence interval .79 to 1.76 P .41 for 1 cycle versus 2 cycles reference Similarly consolidation was not associated with OS relapse TRM or graft-versus-host disease We conclude that consolidation chemotherapy does not appear to provide added benefit in adult ALL patients with available donors who undergo myeloablative alloHCT in CR1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1063, 1007, 31, 497, 5514, 16, 1075, 9, 7, 5, 286, 1275, 62, 54, 1359, 236, 734, 4516, 5, 56, 137, 3, 247, 1, 2173, 56, 469, 2717, 4, 7, 479, 5514, 21, 72, 38, 123, 1, 13927, 780, 7, 5, 62, 4, 4516, 54, 103, 3107, 78, 3486, 14, 78, 966, 15, 13, 410, 78, 8024, 1, 2173, 348, 3246, 5514, 29, 1375, 6, 1195, 22, 1336, 98, 6, 5514, 10, 589, 5, 602, 410, 1, 2173, 7, 357, 3107, 14, 15, 13, 410, 1, 2173, 42, 35, 586, 27, 111, 967, 287, 1, 429, 1, 179, 428, 2, 350, 14, 111, 941, 139, 282, 5064, 1, 245, 203, 2, 382, 586, 27, 111, 2647, 115, 25, 5674, 1, 667, 576, 2, 662, 2, 27, 111, 63, 25, 118, 1, 676, 728, 2, 667, 62, 19, 1030, 327, 658, 65, 557, 17, 2173, 10, 44, 177, 9, 5674, 580, 43, 14, 179, 48, 307, 268, 868, 6, 14, 598, 19, 339, 9, 77, 2173, 861, 14, 203, 48, 307, 268, 842, 6, 14, 846, 19, 605, 9, 14, 417, 185, 3107, 410, 2482, 1813, 2173, 10, 44, 41, 5, 118, 429, 5064, 15, 1599, 185, 1204, 34, 21, 2060, 17, 2173, 56, 1097, 44, 1322, 6, 377, 1953, 247, 4, 780, 62, 7, 5, 390, 2344, 54, 1251, 3246, 5514, 4, 4516]",1330.0,29275139,820
Influence of BCL2L11 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic leukemia.,The pharmacogenomics journal,Pharmacogenomics J.,2017-12-27,"Osteonecrosis (ON) is corticosteroid-related complication, reported in children with acute lymphoblastic leukemia (ALL). We have previously found that polymorphisms in BCL2L11 gene coding for pro-apoptotic Bim protein influence reduction of overall survival (OS) in a corticosteroid (CS) dose-dependent manner in childhood ALL patients. The same set of SNPs was here investigated for an association with CS-related ON assessed retrospectively in 304 children with ALL from Quebec (QcALL cohort) who received Dana-Farber Cancer Institute (DFCI) ALL treatment protocols. Two-year cumulative incidence of symptomatic ON was 10.6%. Two BCL2L11 polymorphisms, the 891T>G (rs2241843) in all QcALL patients and 29201C>T (rs724710) in high-risk group were significantly associated with ON, P=0.009 and P=0.003, respectively. The association remained significant in multivariate model (HR<sub>891TT</sub>=2.4, 95% CI 1.2-4.8, P=0.01 and HR<sub>29201CC</sub>=5.7, 95% CI 1.6-20.9, P=0.008). Both polymorphisms influenced viability of dexamethasone treated lymphoblastoid cell lines (P0.03). The 891T>G influenced Bim gamma isoform levels (0.03) and its association with ON was also confirmed in replication DFCI cohort (N=168, P=0.03). QcALL children had a high incidence of ON during therapy, which was highly associated with BCL2L11 polymorphisms.",Journal Article,755.0,1.0,Osteonecrosis ON is corticosteroid-related complication reported in children with acute lymphoblastic ALL We have previously found that polymorphisms in BCL2L11 gene coding for pro-apoptotic Bim protein influence reduction of overall survival OS in a corticosteroid CS dose-dependent manner in childhood ALL patients The same set of SNPs was here investigated for an association with CS-related ON assessed retrospectively in 304 children with ALL from Quebec QcALL cohort who received Dana-Farber Cancer Institute DFCI ALL treatment protocols Two-year cumulative incidence of symptomatic ON was 10.6 Two BCL2L11 polymorphisms the 891T G rs2241843 in all QcALL patients and 29201C T rs724710 in high-risk group were significantly associated with ON P 0.009 and P 0.003 respectively The association remained significant in multivariate model HR sub 891TT /sub 2.4 95 CI 1.2-4.8 P 0.01 and HR sub 29201CC /sub 5.7 95 CI 1.6-20.9 P 0.008 Both polymorphisms influenced viability of dexamethasone treated lymphoblastoid cell lines P  0.03 The 891T G influenced Bim gamma isoform levels 0.03 and its association with ON was also confirmed in replication DFCI cohort N 168 P 0.03 QcALL children had a high incidence of ON during therapy which was highly associated with BCL2L11 polymorphisms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 23, 16, 5654, 139, 1447, 210, 4, 541, 5, 286, 1275, 62, 21, 47, 373, 204, 17, 1203, 4, 16124, 145, 3097, 9, 1805, 1631, 3595, 178, 1054, 628, 1, 63, 25, 118, 4, 8, 5654, 2188, 61, 470, 1708, 4, 864, 62, 7, 3, 827, 916, 1, 1109, 10, 467, 565, 9, 35, 248, 5, 2188, 139, 23, 275, 894, 4, 8940, 541, 5, 62, 29, 19440, 41945, 180, 54, 103, 4932, 4979, 12, 1377, 11152, 62, 24, 2189, 100, 111, 967, 287, 1, 1704, 23, 10, 79, 49, 100, 16124, 1203, 3, 50791, 499, 71872, 4, 62, 41945, 7, 2, 71873, 102, 71874, 4, 64, 43, 87, 11, 97, 41, 5, 23, 19, 13, 2376, 2, 19, 13, 1421, 106, 3, 248, 958, 93, 4, 331, 202, 168, 551, 71875, 551, 18, 39, 48, 58, 14, 18, 39, 66, 19, 13, 355, 2, 168, 551, 71876, 551, 33, 67, 48, 58, 14, 49, 179, 83, 19, 13, 2155, 110, 1203, 2574, 2120, 1, 1217, 73, 10994, 31, 285, 19, 1552, 13, 680, 3, 50791, 499, 2574, 3595, 1705, 3995, 148, 13, 680, 2, 211, 248, 5, 23, 10, 120, 557, 4, 2079, 11152, 180, 78, 5359, 19, 13, 680, 41945, 541, 42, 8, 64, 287, 1, 23, 190, 36, 92, 10, 561, 41, 5, 16124, 1203]",1285.0,29282361,491
Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes.,Cancer medicine,Cancer Med,2017-12-28,"We conducted a surveillance epidemiology and end results (SEER)-based analysis to describe the incidence and characteristics of second primary acute lymphoblastic leukemia (sALL) among adults (18years) with a history of primary malignancies (1M). Standardized incidence ratios (SIRs) of sALL cases were calculated by site and 1M stage. We also evaluated the differences in 5-year sALL survival by age, site, and extent of 1M, latency of sALL after 1M, and evidence of underlying racial/ethnic disparity. We identified 10,956 patients with de-novo/primary acute lymphoblastic leukemia (1ALL) and 772 with sALL. Women (49.1% vs. 42.9%), white patients (72.0% vs. 59.5%), older patients (58.8% vs. 25.2%; age 65years), and patients diagnosed between 2003 and 2012 (66.8% vs. 53.9%) had a higher proportion of sALL compared with 1ALL. There was a significantly inferior median 5-year survival for sALL patients compared to 1ALL (6 vs. 15months; HR 1.20, 95% CI 1.10-1.31, P<0.001). The median latency period was 60.0months; the most common 1M among sALL patients were breast (17.9%) and prostate (17.4%). Patients with any 1M were at increased risk of developing sALL (SIR 1.76, 95% CI 1.58-1.95, P<0.001). Hematological-1M sites had significantly higher SIRs (hematological-SIR 7.35; solid-SIR 1.33; P<0.001). We observed a significant increase in sALL incidence after a 1M and a significantly worse 5-year survival with different demographic characteristics from 1ALL. There is a need to define appropriate screening methods for patients surviving their primary cancer.",Journal Article,754.0,10.0,"We conducted a surveillance epidemiology and end results SEER -based analysis to describe the incidence and characteristics of second primary acute lymphoblastic sALL among adults 18 years with a history of primary malignancies 1M Standardized incidence ratios SIRs of sALL cases were calculated by site and 1M stage We also evaluated the differences in 5-year sALL survival by age site and extent of 1M latency of sALL after 1M and evidence of underlying racial/ethnic disparity We identified 10,956 patients with de-novo/primary acute lymphoblastic 1ALL and 772 with sALL Women 49.1 vs. 42.9 white patients 72.0 vs. 59.5 older patients 58.8 vs. 25.2 age 65 years and patients diagnosed between 2003 and 2012 66.8 vs. 53.9 had a higher proportion of sALL compared with 1ALL There was a significantly inferior median 5-year survival for sALL patients compared to 1ALL 6 vs. 15 months HR 1.20 95 CI 1.10-1.31 P 0.001 The median latency period was 60.0 months the most common 1M among sALL patients were 17.9 and 17.4 Patients with any 1M were at increased risk of developing sALL SIR 1.76 95 CI 1.58-1.95 P 0.001 Hematological-1M sites had significantly higher SIRs hematological-SIR 7.35 solid-SIR 1.33 P 0.001 We observed a significant increase in sALL incidence after a 1M and a significantly worse 5-year survival with different demographic characteristics from 1ALL There is a need to define appropriate screening methods for patients surviving their primary cancer",1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 426, 8, 617, 1284, 2, 396, 99, 1605, 90, 65, 6, 897, 3, 287, 2, 374, 1, 419, 86, 286, 1275, 22996, 107, 857, 6624, 60, 5, 8, 532, 1, 86, 441, 19310, 1670, 287, 1137, 7120, 1, 22996, 140, 11, 981, 20, 606, 2, 19310, 82, 21, 120, 194, 3, 362, 4, 33, 111, 22996, 25, 20, 89, 606, 2, 1039, 1, 19310, 5301, 1, 22996, 50, 19310, 2, 241, 1, 1181, 2257, 2871, 4326, 21, 108, 79, 14137, 7, 5, 1566, 2018, 86, 286, 1275, 36521, 2, 15258, 5, 22996, 117, 739, 14, 105, 595, 83, 886, 7, 720, 13, 105, 728, 33, 434, 7, 717, 66, 105, 243, 18, 89, 5827, 60, 2, 7, 265, 59, 1522, 2, 1195, 700, 66, 105, 699, 83, 42, 8, 142, 920, 1, 22996, 72, 5, 36521, 125, 10, 8, 97, 1663, 52, 33, 111, 25, 9, 22996, 7, 72, 6, 36521, 49, 105, 167, 53, 168, 14, 179, 48, 58, 14, 79, 14, 456, 19, 13, 144, 3, 52, 5301, 727, 10, 335, 13, 53, 3, 96, 186, 19310, 107, 22996, 7, 11, 269, 83, 2, 269, 39, 7, 5, 500, 19310, 11, 28, 101, 43, 1, 931, 22996, 3636, 14, 846, 48, 58, 14, 717, 14, 48, 19, 13, 144, 2890, 19310, 633, 42, 97, 142, 7120, 2890, 3636, 67, 465, 537, 3636, 14, 466, 19, 13, 144, 21, 164, 8, 93, 344, 4, 22996, 287, 50, 8, 19310, 2, 8, 97, 639, 33, 111, 25, 5, 338, 1540, 374, 29, 36521, 125, 16, 8, 594, 6, 1107, 870, 453, 636, 9, 7, 3050, 136, 86, 12]",1471.0,29282894,692
TP53 Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-01-04,"Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome, a highly penetrant cancer predisposition condition. Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic leukemia (ALL) suggest that this type of leukemia is another manifestation of Li-Fraumeni syndrome; however, the pattern, prevalence, and clinical relevance of TP53 variants in childhood ALL remain unknown. Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children's Oncology Group frontline ALL clinical trials, AALL0232 and P9900. TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity, in silico prediction of damaging effects, and prevalence in non-ALL control populations. TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes. Results We identified 49 unique nonsilent rare TP53 coding variants in 77 (2.0%) of 3,801 patients sequenced, of which 22 variants were classified as pathogenic. TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls (odds ratio, 5.2; P < .001). Children with TP53 pathogenic variants were significantly older at ALL diagnosis (median age, 15.5 years v 7.3 years; P < .001) and were more likely to have hypodiploid ALL (65.4% v 1.2%; P < .001). Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival (hazard ratio, 4.2 and 3.9; P < .001 and .001, respectively). In particular, children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants, with 5-year cumulative incidence of 25.1% and 0.7% ( P < .001), respectively. Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy, particularly the risk of second malignant neoplasms.",Journal Article,747.0,34.0,"Purpose Germline TP53 variation is the genetic basis of Li-Fraumeni syndrome a highly penetrant cancer predisposition condition Recent reports of germline TP53 variants in childhood hypodiploid acute lymphoblastic ALL suggest that this type of is another manifestation of Li-Fraumeni syndrome however the pattern prevalence and clinical relevance of TP53 variants in childhood ALL remain unknown Patients and Methods Targeted sequencing of TP53 coding regions was performed in 3,801 children from the Children 's Oncology Group frontline ALL clinical trials AALL0232 and P9900 TP53 variant pathogenicity was evaluated according to experimentally determined transcriptional activity in silico prediction of damaging effects and prevalence in non-ALL control populations TP53 variants were analyzed for their association with ALL presenting features and treatment outcomes Results We identified 49 unique nonsilent rare TP53 coding variants in 77 2.0 of 3,801 patients sequenced of which 22 variants were classified as pathogenic TP53 pathogenic variants were significantly over-represented in ALL compared with non-ALL controls odds ratio 5.2 P .001 Children with TP53 pathogenic variants were significantly older at ALL diagnosis median age 15.5 years v 7.3 years P .001 and were more likely to have hypodiploid ALL 65.4 v 1.2 P .001 Carrying germline TP53 pathogenic variants was associated with inferior event-free survival and overall survival hazard ratio 4.2 and 3.9 P .001 and .001 respectively In particular children with TP53 pathogenic variants were at a dramatically higher risk of second cancers than those without pathogenic variants with 5-year cumulative incidence of 25.1 and 0.7 P .001 respectively Conclusion Loss-of-function germline TP53 variants predispose children to ALL and to adverse treatment outcomes with ALL therapy particularly the risk of second malignant neoplasms",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[743, 1009, 1206, 1380, 16, 3, 336, 877, 1, 5066, 9130, 681, 8, 561, 10301, 12, 2863, 2850, 435, 1198, 1, 1009, 1206, 839, 4, 864, 12135, 286, 1275, 62, 309, 17, 26, 267, 1, 16, 1809, 6746, 1, 5066, 9130, 681, 137, 3, 1177, 1078, 2, 38, 2088, 1, 1206, 839, 4, 864, 62, 918, 860, 7, 2, 636, 238, 615, 1, 1206, 3097, 1374, 10, 173, 4, 27, 14952, 541, 29, 3, 541, 292, 413, 87, 3171, 62, 38, 143, 32436, 2, 71903, 1206, 1142, 8349, 10, 194, 768, 6, 8593, 509, 1431, 128, 4, 6648, 1590, 1, 4904, 176, 2, 1078, 4, 220, 62, 182, 1184, 1206, 839, 11, 311, 9, 136, 248, 5, 62, 1656, 404, 2, 24, 123, 99, 21, 108, 739, 991, 32072, 622, 1206, 3097, 839, 4, 849, 18, 13, 1, 27, 14952, 7, 4040, 1, 92, 350, 839, 11, 1373, 22, 2806, 1206, 2806, 839, 11, 97, 252, 3324, 4, 62, 72, 5, 220, 62, 535, 610, 197, 33, 18, 19, 144, 541, 5, 1206, 2806, 839, 11, 97, 434, 28, 62, 147, 52, 89, 167, 33, 60, 603, 67, 27, 60, 19, 144, 2, 11, 80, 322, 6, 47, 12135, 62, 556, 39, 603, 14, 18, 19, 144, 2934, 1009, 1206, 2806, 839, 10, 41, 5, 1663, 774, 115, 25, 2, 63, 25, 360, 197, 39, 18, 2, 27, 83, 19, 144, 2, 144, 106, 4, 1454, 541, 5, 1206, 2806, 839, 11, 28, 8, 2729, 142, 43, 1, 419, 163, 76, 135, 187, 2806, 839, 5, 33, 111, 967, 287, 1, 243, 14, 2, 13, 67, 19, 144, 106, 1221, 407, 1, 343, 1009, 1206, 839, 6043, 541, 6, 62, 2, 6, 290, 24, 123, 5, 62, 36, 823, 3, 43, 1, 419, 393, 1179]",1895.0,29300620,862
MBD2 Ablation Impairs Lymphopoiesis and Impedes Progression and Maintenance of T-ALL.,Cancer research,Cancer Res.,2018-01-12,"Aberrant DNA methylation patterns in leukemia might be exploited for therapeutic targeting. In this study, we employed a genetically deficient mouse model to explore the role of the methylated DNA binding protein MBD2 in normal and malignant hematopoiesis. MBD2 ablation led to diminished lymphocytes. Functional defects of the lymphoid compartment were also observed after <i>in vivo</i> reconstitution of MBD2-deficient hematopoietic stem cells (HSC). In an established model of Notch1-driven T-cell acute lymphoblastic leukemia (T-ALL), MBD2 ablation impeded malignant progression and maintenance by attenuating the Wnt signaling pathway. In clinical specimens of human T-ALL, Wnt signaling pathway signatures were significantly enhanced and positively correlated with the expression and function of MBD2. Furthermore, a number of typical Wnt signaling inhibitory genes were abnormally hypermethylated in primary human T-ALL. Abnormal activation of Wnt signaling in T-ALL was switched off by MBD2 deletion, partially by reactivating epigenetically silenced Wnt signaling inhibitors. Taken together, our results define essential roles for MBD2 in lymphopoiesis and T-ALL and suggest MBD2 as a candidate therapeutic target in T-ALL.<b>Significance:</b> This study highlights a methylated DNA binding protein as a candidate therapeutic target to improve the treatment of T-cell acute lymphoblastic leukemias, as a new starting point for developing epigenetic therapy in this and other lymphoid malignancies. <i>Cancer Res; 78(7); 1632-42. 2018 AACR</i>.",Journal Article,739.0,1.0,Aberrant DNA methylation patterns in might be exploited for therapeutic targeting In this study we employed a genetically deficient mouse model to explore the role of the methylated DNA binding protein MBD2 in normal and malignant hematopoiesis MBD2 ablation led to diminished lymphocytes Functional defects of the lymphoid compartment were also observed after i in vivo /i reconstitution of MBD2-deficient hematopoietic stem cells HSC In an established model of Notch1-driven T-cell acute lymphoblastic T-ALL MBD2 ablation impeded malignant progression and maintenance by attenuating the Wnt signaling pathway In clinical specimens of human T-ALL Wnt signaling pathway signatures were significantly enhanced and positively correlated with the expression and function of MBD2 Furthermore a number of typical Wnt signaling inhibitory genes were abnormally hypermethylated in primary human T-ALL Abnormal activation of Wnt signaling in T-ALL was switched off by MBD2 deletion partially by reactivating epigenetically silenced Wnt signaling inhibitors Taken together our results define essential roles for MBD2 in lymphopoiesis and T-ALL and suggest MBD2 as a candidate therapeutic target in T-ALL. b Significance /b This study highlights a methylated DNA binding protein as a candidate therapeutic target to improve the treatment of T-cell acute lymphoblastic leukemias as a new starting point for developing epigenetic therapy in this and other lymphoid malignancies i Cancer Res 78 7 1632-42 2018 AACR /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1898, 261, 569, 764, 4, 822, 40, 5177, 9, 189, 529, 4, 26, 45, 21, 2516, 8, 2301, 1971, 830, 202, 6, 1645, 3, 200, 1, 3, 2963, 261, 791, 178, 20784, 4, 295, 2, 393, 5114, 20784, 1650, 836, 6, 2849, 1594, 583, 2945, 1, 3, 2303, 3616, 11, 120, 164, 50, 70, 4, 386, 70, 5616, 1, 20784, 1971, 1007, 452, 37, 5596, 4, 35, 635, 202, 1, 4607, 1621, 102, 31, 286, 1275, 102, 62, 20784, 1650, 15857, 393, 91, 2, 1146, 20, 12102, 3, 2112, 314, 308, 4, 38, 623, 1, 171, 102, 62, 2112, 314, 308, 2210, 11, 97, 651, 2, 2375, 438, 5, 3, 55, 2, 343, 1, 20784, 798, 8, 207, 1, 3476, 2112, 314, 1810, 214, 11, 11749, 6936, 4, 86, 171, 102, 62, 1668, 363, 1, 2112, 314, 4, 102, 62, 10, 7883, 1889, 20, 20784, 1528, 2995, 20, 21425, 8976, 5442, 2112, 314, 222, 1633, 1162, 114, 99, 1107, 1452, 1790, 9, 20784, 4, 30689, 2, 102, 62, 2, 309, 20784, 22, 8, 1609, 189, 283, 4, 102, 62, 132, 724, 132, 26, 45, 2527, 8, 2963, 261, 791, 178, 22, 8, 1609, 189, 283, 6, 401, 3, 24, 1, 102, 31, 286, 1275, 2792, 22, 8, 217, 1723, 741, 9, 931, 1418, 36, 4, 26, 2, 127, 2303, 441, 70, 12, 1936, 833, 67, 43829, 595, 4281, 1630, 70]",1505.0,29330145,93
Useful information provided by graphic displays of automated cell counter in hematological malignancies.,Journal of clinical laboratory analysis,J. Clin. Lab. Anal.,2018-01-21,"Automated cell counters have become more and more sophisticated with passing years. The numerical and graphic data both provide useful clues for suspecting a diagnosis especially when the workload is very high. We present our experience of useful information provided by graphic displays of an automated cell counter in hematological malignancies in a cancer hospital where a large number of complete blood count (CBC) requests are received either before or during chemotherapy. This study was conducted to assess the usefulness of hematology cell counter, viz. WBC-Diff (WBC differential), WBC/BASO (WBC basophil) and IMI (immature myeloid information) channel scatter plots, and the flaggings generated in various hematological malignancies. The graphic displays have been compiled over a period of 1 year (October 2015-September 2016) from blood samples of various solid and hematological malignancies (approximately 400 per day) received for routine CBC in the laboratory. Approximately 50000 scattergrams have been analyzed during the study period. The findings were confirmed by peripheral blood smear examination. The scattergram analysis on XE-2100 is very sensitive as well as specific for diagnosing acute leukemia, viz. acute myeloid leukemia, acute lymphoblastic leukemia; chronic myeloproliferative disorders, viz. chronic myeloid leukemia; and chronic lymphoproliferative disorder especially chronic lymphocytic leukemia. It is suggested that the laboratories using the hematology analyzers be aware of graphic display patterns in addition to flaggings generated which provide additional information and give clue toward the diagnosis even before peripheral smear examination.",Journal Article,730.0,0.0,Automated cell counters have become more and more sophisticated with passing years The numerical and graphic data both provide useful clues for suspecting a diagnosis especially when the workload is very high We present our experience of useful information provided by graphic displays of an automated cell counter in hematological malignancies in a cancer hospital where a large number of complete blood count CBC requests are received either before or during chemotherapy This study was conducted to assess the usefulness of hematology cell counter viz WBC-Diff WBC differential WBC/BASO WBC basophil and IMI immature myeloid information channel scatter plots and the flaggings generated in various hematological malignancies The graphic displays have been compiled over a period of 1 year October 2015-September 2016 from blood samples of various solid and hematological malignancies approximately 400 per day received for routine CBC in the laboratory Approximately 50 000 scattergrams have been analyzed during the study period The findings were confirmed by peripheral blood smear examination The scattergram analysis on XE-2100 is very sensitive as well as specific for diagnosing acute viz acute myeloid acute lymphoblastic chronic disorders viz chronic myeloid and chronic lymphoproliferative disorder especially chronic lymphocytic It is suggested that the laboratories using the hematology analyzers be aware of graphic display patterns in addition to flaggings generated which provide additional information and give clue toward the diagnosis even before peripheral smear examination,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[3235, 31, 33941, 47, 1417, 80, 2, 80, 8023, 5, 15589, 60, 3, 8736, 2, 25039, 74, 110, 377, 999, 10045, 9, 39945, 8, 147, 1093, 198, 3, 26852, 16, 923, 64, 21, 364, 114, 730, 1, 999, 487, 1052, 20, 25039, 7196, 1, 35, 3235, 31, 10259, 4, 2890, 441, 4, 8, 12, 702, 1257, 8, 375, 207, 1, 236, 315, 1276, 5711, 12948, 32, 103, 361, 348, 15, 190, 56, 26, 45, 10, 426, 6, 423, 3, 5235, 1, 6216, 31, 10259, 31121, 4685, 29104, 4685, 1777, 4685, 71992, 4685, 33203, 2, 15242, 5733, 533, 487, 8240, 9411, 8030, 2, 3, 50824, 1419, 4, 747, 2890, 441, 3, 25039, 7196, 47, 85, 8535, 252, 8, 727, 1, 14, 111, 2551, 1483, 2636, 1390, 29, 315, 347, 1, 747, 537, 2, 2890, 441, 705, 1524, 379, 218, 103, 9, 1311, 5711, 4, 3, 1624, 705, 212, 984, 71993, 47, 85, 311, 190, 3, 45, 727, 3, 272, 11, 557, 20, 672, 315, 8379, 1385, 3, 43987, 65, 23, 71994, 21341, 16, 923, 745, 22, 149, 22, 112, 9, 5798, 286, 31121, 286, 533, 286, 1275, 442, 1997, 31121, 442, 533, 2, 442, 4192, 2645, 1093, 442, 1193, 192, 16, 1148, 17, 3, 4884, 75, 3, 6216, 32835, 40, 4749, 1, 25039, 3640, 764, 4, 352, 6, 50824, 1419, 92, 377, 402, 487, 2, 4978, 12360, 1317, 3, 147, 871, 348, 672, 8379, 1385]",1595.0,29356090,123
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-01-30,"A MESSAGE FROM ASCO'S PRESIDENT I remember when ASCO first conceived of publishing an annual report on the most transformative research occurring in cancer care. Thirteen reports later, the progress we have chronicled is remarkable, and this year is no different. The research featured in ASCO's Clinical Cancer Advances 2018 report underscores the impressive gains in our understanding of cancer and in our ability to tailor treatments to tumors' genetic makeup. The ASCO 2018 Advance of the Year, adoptive cell immunotherapy, allows clinicians to genetically reprogram patients' own immune cells to find and attack cancer cells throughout the body. Chimeric antigen receptor (CAR) T-cell therapy-a type of adoptive cell immunotherapy-has led to remarkable results in young patients with acute lymphoblastic leukemia (ALL) and in adults with lymphoma and multiple myeloma. Researchers are also exploring this approach in other types of cancer. This advance would not be possible without robust federal investment in cancer research. The first clinical trial of CAR T-cell therapy in children with ALL was funded, in part, by grants from the National Cancer Institute (NCI), and researchers at the NCI Center for Cancer Research were the first to report on possible CAR T-cell therapy for multiple myeloma. These discoveries follow decades of prior research on immunology and cancer biology, much of which was supported by federal dollars. In fact, many advances that are highlighted in the 2018 Clinical Cancer Advances report were made possible thanks to our nation's support for biomedical research. Funding from the US National Institutes of Health and the NCI helps researchers pursue critical patient care questions and addresses vital, unmet needs that private industry has little incentive to take on. Federally supported cancer research generates the biomedical innovations that fuel the development and availability of new and improved treatments for patients. We need sustained federal research investment to accelerate the discovery of the next generation of cancer treatments. Another major trend in this year's report is progress in precision medicine approaches to treat cancer. Although precision medicine offers promise to people with cancer and their families, that promise is only as good as our ability to make these treatments available to all patients. My presidential theme, ""Delivering Discoveries: Expanding the Reach of Precision Medicine,"" focuses on tackling this formidable challenge so that new targeted therapies are accessible to anyone who faces a cancer diagnosis. By improving access to high-quality care, harnessing big data on patient outcomes from across the globe, and pursuing innovative clinical trials, I am optimistic that we will speed the delivery of these most promising treatments to more patients. Sincerely, Bruce E. Johnson, FASCO ASCO President, 2017 to 2018.",Address,721.0,46.0,A MESSAGE FROM ASCO 'S PRESIDENT I remember when ASCO first conceived of publishing an annual report on the most transformative research occurring in cancer care Thirteen reports later the progress we have chronicled is remarkable and this year is no different The research featured in ASCO 's Clinical Cancer Advances 2018 report underscores the impressive gains in our understanding of cancer and in our ability to tailor treatments to tumors genetic makeup The ASCO 2018 Advance of the Year adoptive cell immunotherapy allows clinicians to genetically reprogram patients own immune cells to find and attack cancer cells throughout the body Chimeric antigen receptor CAR T-cell therapy-a type of adoptive cell immunotherapy-has led to remarkable results in young patients with acute lymphoblastic ALL and in adults with and multiple Researchers are also exploring this approach in other types of cancer This advance would not be possible without robust federal investment in cancer research The first clinical trial of CAR T-cell therapy in children with ALL was funded in part by grants from the National Cancer Institute NCI and researchers at the NCI Center for Cancer Research were the first to report on possible CAR T-cell therapy for multiple These discoveries follow decades of prior research on immunology and cancer biology much of which was supported by federal dollars In fact many advances that are highlighted in the 2018 Clinical Cancer Advances report were made possible thanks to our nation 's support for biomedical research Funding from the US National Institutes of Health and the NCI helps researchers pursue critical patient care questions and addresses vital unmet needs that private industry has little incentive to take on Federally supported cancer research generates the biomedical innovations that fuel the development and availability of new and improved treatments for patients We need sustained federal research investment to accelerate the discovery of the next generation of cancer treatments Another major trend in this year 's report is progress in precision medicine approaches to treat cancer Although precision medicine offers promise to people with cancer and their families that promise is only as good as our ability to make these treatments available to all patients My presidential theme `` Delivering Discoveries Expanding the Reach of Precision Medicine '' focuses on tackling this formidable challenge so that new targeted therapies are accessible to anyone who faces a cancer diagnosis By improving access to high-quality care harnessing big data on patient outcomes from across the globe and pursuing innovative clinical trials I am optimistic that we will speed the delivery of these most promising treatments to more patients Sincerely Bruce E. Johnson FASCO ASCO President 2017 to 2018,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 10035, 29, 2697, 292, 15703, 70, 30523, 198, 2697, 157, 17168, 1, 31038, 35, 2114, 414, 23, 3, 96, 16947, 389, 1821, 4, 12, 165, 3170, 1198, 1559, 3, 1466, 21, 47, 72042, 16, 3813, 2, 26, 111, 16, 77, 338, 3, 389, 11857, 4, 2697, 292, 38, 12, 954, 2982, 414, 6926, 3, 5790, 3849, 4, 114, 612, 1, 12, 2, 4, 114, 801, 6, 6585, 640, 6, 57, 336, 14176, 3, 2697, 2982, 3148, 1, 3, 111, 3159, 31, 726, 2333, 1490, 6, 2301, 14947, 7, 4165, 250, 37, 6, 2469, 2, 8780, 12, 37, 2432, 3, 642, 2897, 448, 153, 1881, 102, 31, 36, 8, 267, 1, 3159, 31, 726, 71, 836, 6, 3813, 99, 4, 1169, 7, 5, 286, 1275, 62, 2, 4, 857, 5, 2, 232, 4211, 32, 120, 4378, 26, 353, 4, 127, 630, 1, 12, 26, 3148, 688, 44, 40, 899, 187, 1922, 8536, 12907, 4, 12, 389, 3, 157, 38, 160, 1, 1881, 102, 31, 36, 4, 541, 5, 62, 10, 3827, 4, 760, 20, 19836, 29, 3, 657, 12, 1377, 2580, 2, 4211, 28, 3, 2580, 574, 9, 12, 389, 11, 3, 157, 6, 414, 23, 899, 1881, 102, 31, 36, 9, 232, 46, 5012, 166, 1968, 1, 324, 389, 23, 6534, 2, 12, 891, 1802, 1, 92, 10, 2708, 20, 8536, 5521, 4, 1991, 445, 954, 17, 32, 3681, 4, 3, 2982, 38, 12, 954, 414, 11, 1229, 899, 22282, 6, 114, 16473, 292, 538, 9, 7829, 389, 5468, 29, 3, 843, 657, 5973, 1, 341, 2, 3, 2580, 6484, 4211, 7874, 740, 69, 165, 1937, 2, 5437, 3511, 3715, 1891, 17, 4745, 5764, 71, 1215, 32056, 6, 3585, 23, 22523, 2708, 12, 389, 7919, 3, 7829, 10081, 17, 16534, 3, 193, 2, 2550, 1, 217, 2, 231, 640, 9, 7, 21, 594, 2275, 8536, 389, 12907, 6, 5792, 3, 1574, 1, 3, 1305, 914, 1, 12, 640, 1809, 458, 853, 4, 26, 111, 292, 414, 16, 1466, 4, 2720, 1807, 611, 6, 943, 12, 242, 2720, 1807, 2339, 1783, 6, 3788, 5, 12, 2, 136, 1954, 17, 1783, 16, 158, 22, 1178, 22, 114, 801, 6, 2378, 46, 640, 390, 6, 62, 7, 11569, 33880, 10293, 4790, 5012, 4304, 3, 3690, 1, 2720, 1807, 522, 3026, 23, 50843, 26, 11940, 1745, 1743, 17, 217, 238, 235, 32, 5981, 6, 39612, 54, 19786, 8, 12, 147, 20, 1673, 1655, 6, 64, 372, 165, 12150, 10864, 74, 23, 69, 123, 29, 716, 3, 15194, 2, 10692, 4019, 38, 143, 70, 5886, 9566, 17, 21, 303, 5051, 3, 989, 1, 46, 96, 721, 640, 6, 80, 7, 38622, 41351, 563, 18915, 72043, 2697, 15703, 1759, 6, 2982]",2838.0,29380678,47
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.,Cancer,Cancer,2018-01-30,"Inotuzumab ozogamicin (InO) has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic leukemia (ALL) in the INO-VATE trial. This subset analysis compared the efficacy and safety of InO in younger and older patients. Intent-to-treat analyses of morphologic responses and overall survival (OS) included 326 randomized patients, and safety assessments included 307 patients receiving 1 or more doses of the study treatment. Of the 326 patients, 164 received InO at a starting dose of 1.8mg/m<sup>2</sup> /cycle (0.8mg/m<sup>2</sup> on day 1 and 0.5mg/m<sup>2</sup> on days 8 and 15 of a 21- to 28-day cycle [6 cycles]); 60 patients were aged 55 years, and 104 were aged <55 years. For older and younger patients, the median duration of InO therapy and the types and frequencies of adverse events of any grade were generally similar. Although the remission rates, median duration of remission (DOR), and progression-free survival were similar with InO for those aged <55 years and those aged 55 years, OS was longer for younger patients (median, 8.6 vs 5.6 months; hazard ratio, 0.610). Among patients proceeding to hematopoietic stem cell transplantation after InO treatment (28% of older patients and 58% of younger patients), the incidence of veno-occlusive disease was greater in older patients (41% vs 17%). The study database was not locked at the time of this analysis. InO was tolerable in older patients with relapsed/refractory ALL. Although OS was longer for younger patients versus older patients, InO demonstrated high response rates with similar DOR in the 2 age groups. Cancer 2018;124:1722-32.  2018 American Cancer Society.","Clinical Trial, Phase III",721.0,15.0,Inotuzumab ozogamicin InO has demonstrated efficacy and tolerability in patients aged 18 to 78 years with relapsed/refractory acute lymphoblastic ALL in the INO-VATE trial This subset analysis compared the efficacy and safety of InO in younger and older patients Intent-to-treat analyses of morphologic responses and overall survival OS included 326 randomized patients and safety assessments included 307 patients receiving 1 or more doses of the study treatment Of the 326 patients 164 received InO at a starting dose of 1.8 mg/m sup 2 /sup /cycle 0.8 mg/m sup 2 /sup on day 1 and 0.5 mg/m sup 2 /sup on days 8 and 15 of a 21- to 28-day cycle 6 cycles 60 patients were aged 55 years and 104 were aged 55 years For older and younger patients the median duration of InO therapy and the types and frequencies of adverse events of any grade were generally similar Although the remission rates median duration of remission DOR and progression-free survival were similar with InO for those aged 55 years and those aged 55 years OS was longer for younger patients median 8.6 vs 5.6 months hazard ratio 0.610 Among patients proceeding to hematopoietic stem cell transplantation after InO treatment 28 of older patients and 58 of younger patients the incidence of veno-occlusive disease was greater in older patients 41 vs 17 The study database was not locked at the time of this analysis InO was tolerable in older patients with relapsed/refractory ALL Although OS was longer for younger patients versus older patients InO demonstrated high response rates with similar DOR in the 2 age groups Cancer 2018 124:1722-32  2018 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6730, 5566, 8709, 71, 264, 209, 2, 1543, 4, 7, 1032, 203, 6, 833, 60, 5, 591, 430, 286, 1275, 62, 4, 3, 8709, 32612, 160, 26, 697, 65, 72, 3, 209, 2, 367, 1, 8709, 4, 773, 2, 434, 7, 1697, 6, 943, 318, 1, 2815, 253, 2, 63, 25, 118, 159, 9588, 384, 7, 2, 367, 2182, 159, 9682, 7, 357, 14, 15, 80, 415, 1, 3, 45, 24, 1, 3, 9588, 7, 5279, 103, 8709, 28, 8, 1723, 61, 1, 14, 66, 81, 188, 172, 18, 172, 417, 13, 66, 81, 188, 172, 18, 172, 23, 218, 14, 2, 13, 33, 81, 188, 172, 18, 172, 23, 162, 66, 2, 167, 1, 8, 239, 6, 339, 218, 417, 10020, 410, 335, 7, 11, 1032, 15425, 60, 2, 3407, 11, 1032, 614, 60, 9, 434, 2, 773, 7, 3, 52, 654, 1, 8709, 36, 2, 3, 630, 2, 2722, 1, 290, 281, 1, 500, 88, 11, 1228, 288, 242, 3, 734, 151, 52, 654, 1, 734, 8619, 2, 91, 115, 25, 11, 288, 5, 8709, 9, 135, 1032, 614, 60, 2, 135, 1032, 15425, 60, 118, 10, 589, 9, 773, 7, 52, 66, 49, 105, 33, 49, 53, 360, 197, 13, 11302, 107, 7, 13053, 6, 1007, 452, 31, 497, 50, 8709, 24, 339, 1, 434, 7, 2, 717, 1, 773, 7, 3, 287, 1, 10273, 8376, 34, 10, 378, 4, 434, 7, 605, 105, 269, 3, 45, 609, 10, 44, 15663, 28, 3, 98, 1, 26, 65, 8709, 10, 2668, 4, 434, 7, 5, 591, 430, 62, 242, 118, 10, 589, 9, 773, 7, 185, 434, 7, 8709, 264, 64, 51, 151, 5, 288, 8619, 4, 3, 18, 89, 271, 12, 2982, 2834, 26081, 531, 2206, 2982, 597, 12, 1174]",1644.0,29381191,236
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia.,The New England journal of medicine,N. Engl. J. Med.,2018-02-01,"CD19-specific chimeric antigen receptor (CAR) T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic leukemia (ALL) and long-term remissions in a subgroup of patients. We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center (MSKCC). Safety and long-term outcomes were assessed, as were their associations with demographic, clinical, and disease characteristics. A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC. After infusion, severe cytokine release syndrome occurred in 14 of 53 patients (26%; 95% confidence interval [CI], 15 to 40); 1 patient died. Complete remission was observed in 83% of the patients. At a median follow-up of 29 months (range, 1 to 65), the median event-free survival was 6.1 months (95% CI, 5.0 to 11.5), and the median overall survival was 12.9 months (95% CI, 8.7 to 23.4). Patients with a low disease burden (<5% bone marrow blasts) before treatment had markedly enhanced remission duration and survival, with a median event-free survival of 10.6 months (95% CI, 5.9 to not reached) and a median overall survival of 20.1 months (95% CI, 8.7 to not reached). Patients with a higher burden of disease (5% bone marrow blasts or extramedullary disease) had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden. In the entire cohort, the median overall survival was 12.9 months. Among patients with a low disease burden, the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden. (Funded by the Commonwealth Foundation for Cancer Research and others; ClinicalTrials.gov number, NCT01044069 .).","Clinical Trial, Phase I",719.0,354.0,CD19-specific chimeric antigen receptor CAR T cells induce high rates of initial response among patients with relapsed B-cell acute lymphoblastic ALL and long-term remissions in a subgroup of patients We conducted a phase 1 trial involving adults with relapsed B-cell ALL who received an infusion of autologous T cells expressing the 19-28z CAR at the Memorial Sloan Kettering Cancer Center MSKCC Safety and long-term outcomes were assessed as were their associations with demographic clinical and disease characteristics A total of 53 adults received 19-28z CAR T cells that were manufactured at MSKCC After infusion severe cytokine release syndrome occurred in 14 of 53 patients 26 95 confidence interval CI 15 to 40 1 patient died Complete remission was observed in 83 of the patients At a median follow-up of 29 months range 1 to 65 the median event-free survival was 6.1 months 95 CI 5.0 to 11.5 and the median overall survival was 12.9 months 95 CI 8.7 to 23.4 Patients with a low disease burden 5 marrow blasts before treatment had markedly enhanced remission duration and survival with a median event-free survival of 10.6 months 95 CI 5.9 to not reached and a median overall survival of 20.1 months 95 CI 8.7 to not reached Patients with a higher burden of disease 5 marrow blasts or extramedullary disease had a greater incidence of the cytokine release syndrome and neurotoxic events and shorter long-term survival than did patients with a low disease burden In the entire cohort the median overall survival was 12.9 months Among patients with a low disease burden the median overall survival was 20.1 months and was accompanied by a markedly lower incidence of the cytokine release syndrome and neurotoxic events after 19-28z CAR T-cell infusion than was observed among patients with a higher disease burden Funded by the Commonwealth Foundation for Cancer Research and others ClinicalTrials.gov number NCT01044069,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3158, 112, 2897, 448, 153, 1881, 102, 37, 1290, 64, 151, 1, 388, 51, 107, 7, 5, 591, 132, 31, 286, 1275, 62, 2, 319, 337, 3166, 4, 8, 1363, 1, 7, 21, 426, 8, 124, 14, 160, 1267, 857, 5, 591, 132, 31, 62, 54, 103, 35, 904, 1, 1028, 102, 37, 1046, 3, 326, 19130, 1881, 28, 3, 2563, 2783, 2784, 12, 574, 4191, 367, 2, 319, 337, 123, 11, 275, 22, 11, 136, 685, 5, 1540, 38, 2, 34, 374, 8, 181, 1, 699, 857, 103, 326, 19130, 1881, 102, 37, 17, 11, 16284, 28, 4191, 50, 904, 905, 1675, 2008, 681, 489, 4, 213, 1, 699, 7, 432, 48, 307, 268, 58, 167, 6, 327, 14, 69, 1016, 236, 734, 10, 164, 4, 852, 1, 3, 7, 28, 8, 52, 166, 126, 1, 462, 53, 184, 14, 6, 556, 3, 52, 774, 115, 25, 10, 49, 14, 53, 48, 58, 33, 13, 6, 175, 33, 2, 3, 52, 63, 25, 10, 133, 83, 53, 48, 58, 66, 67, 6, 382, 39, 7, 5, 8, 154, 34, 892, 33, 581, 2438, 348, 24, 42, 2195, 651, 734, 654, 2, 25, 5, 8, 52, 774, 115, 25, 1, 79, 49, 53, 48, 58, 33, 83, 6, 44, 1300, 2, 8, 52, 63, 25, 1, 179, 14, 53, 48, 58, 66, 67, 6, 44, 1300, 7, 5, 8, 142, 892, 1, 34, 4126, 581, 2438, 15, 5508, 34, 42, 8, 378, 287, 1, 3, 1675, 2008, 681, 2, 11148, 281, 2, 985, 319, 337, 25, 76, 205, 7, 5, 8, 154, 34, 892, 4, 3, 1797, 180, 3, 52, 63, 25, 10, 133, 83, 53, 107, 7, 5, 8, 154, 34, 892, 3, 52, 63, 25, 10, 179, 14, 53, 2, 10, 2756, 20, 8, 2195, 280, 287, 1, 3, 1675, 2008, 681, 2, 11148, 281, 50, 326, 19130, 1881, 102, 31, 904, 76, 10, 164, 107, 7, 5, 8, 142, 34, 892, 3827, 20, 3, 39785, 3247, 9, 12, 389, 2, 1749, 1252, 1239, 207, 35182]",1927.0,29385376,838
Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.,Leukemia research,Leuk. Res.,2018-01-03,"Pediatric acute lymphoblastic leukemia (ALL) regimens, including higher cumulative asparaginase doses, have been investigated in adult ALL to improve outcomes. Preliminary results are promising, but hepatotoxicity rates with long-acting pegaspargase are greater in adults than children. However, adult pegaspargase-related hepatotoxicity is not as clearly defined despite being the commonest adult toxicity. We studied the frequency and characteristics of high-grade pegaspargase-related hepatotoxicity in newly diagnosed adults on a pediatric-inspired regimen that included six planned pegaspargase doses, 2000 IU/m<sup>2</sup>/dose intravenously, with doses given at least four weeks apart and not discontinued or dose-reduced for previous hepatotoxicity. Pegaspargase-related toxicity was monitored weekly after 185 delivered doses and reported by NCI CTCAE v3.0. Fifty-one patients, aged 18-57, received 192 pegaspargase doses (3.8 doses/patient). High-grade hyperbilirubinemia occurred in 16 (31.4%) patients and 23 (12.4%) doses; high-grade transaminitis occurred in 33 (64.7%) patients and 62 (33.5%) doses. Of 11 patients with high-grade hyperbilirubinemia who received at least one subsequent pegaspargase dose, six (54.5%) experienced recurrent toxicity; of 24 patients with high-grade transaminitis who received at least one subsequent pegaspargase dose, 15 (62.5%) developed recurrent toxicity. Pegaspargase at this dose and interval is associated with high hepatotoxicity rates, but patients can be rechallenged despite earlier pegaspargase-related hepatotoxicity.","Clinical Trial, Phase II",748.0,4.0,Pediatric acute lymphoblastic ALL regimens including higher cumulative asparaginase doses have been investigated in adult ALL to improve outcomes Preliminary results are promising but hepatotoxicity rates with long-acting pegaspargase are greater in adults than children However adult pegaspargase-related hepatotoxicity is not as clearly defined despite being the commonest adult toxicity We studied the frequency and characteristics of high-grade pegaspargase-related hepatotoxicity in newly diagnosed adults on a pediatric-inspired regimen that included six planned pegaspargase doses 2000 IU/m sup 2 /sup /dose intravenously with doses given at least four weeks apart and not discontinued or dose-reduced for previous hepatotoxicity Pegaspargase-related toxicity was monitored weekly after 185 delivered doses and reported by NCI CTCAE v3.0 Fifty-one patients aged 18-57 received 192 pegaspargase doses 3.8 doses/patient High-grade hyperbilirubinemia occurred in 16 31.4 patients and 23 12.4 doses high-grade transaminitis occurred in 33 64.7 patients and 62 33.5 doses Of 11 patients with high-grade hyperbilirubinemia who received at least one subsequent pegaspargase dose six 54.5 experienced recurrent toxicity of 24 patients with high-grade transaminitis who received at least one subsequent pegaspargase dose 15 62.5 developed recurrent toxicity Pegaspargase at this dose and interval is associated with high hepatotoxicity rates but patients can be rechallenged despite earlier pegaspargase-related hepatotoxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[815, 286, 1275, 62, 472, 141, 142, 967, 3709, 415, 47, 85, 565, 4, 780, 62, 6, 401, 123, 1676, 99, 32, 721, 84, 6667, 151, 5, 319, 5375, 12209, 32, 378, 4, 857, 76, 541, 137, 780, 12209, 139, 6667, 16, 44, 22, 2536, 395, 550, 486, 3, 13637, 780, 155, 21, 656, 3, 675, 2, 374, 1, 64, 88, 12209, 139, 6667, 4, 732, 265, 857, 23, 8, 815, 13161, 477, 17, 159, 437, 1465, 12209, 415, 1081, 4588, 188, 172, 18, 172, 61, 1672, 5, 415, 447, 28, 506, 294, 244, 5461, 2, 44, 2402, 15, 61, 405, 9, 698, 6667, 12209, 139, 155, 10, 2909, 709, 50, 5805, 1623, 415, 2, 210, 20, 2580, 3898, 14296, 13, 1461, 104, 7, 1032, 203, 696, 103, 5016, 12209, 415, 27, 66, 415, 69, 64, 88, 7236, 489, 4, 245, 456, 39, 7, 2, 382, 133, 39, 415, 64, 88, 8181, 489, 4, 466, 660, 67, 7, 2, 744, 466, 33, 415, 1, 175, 7, 5, 64, 88, 7236, 54, 103, 28, 506, 104, 706, 12209, 61, 437, 667, 33, 592, 387, 155, 1, 259, 7, 5, 64, 88, 8181, 54, 103, 28, 506, 104, 706, 12209, 61, 167, 744, 33, 276, 387, 155, 12209, 28, 26, 61, 2, 268, 16, 41, 5, 64, 6667, 151, 84, 7, 122, 40, 16853, 550, 1677, 12209, 139, 6667]",1524.0,29407583,418
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2018-04-01,"Older adults with acute lymphoblastic leukemia (ALL) have worse survival compared to their younger counterparts. Here, we review the reasons for the poorer outcomes of older patients with ALL and also summarize the current and future therapeutic approaches to ALL in the elderly population. The poor outcomes of older adults with ALL are driven largely by lack of tolerance to standard-dose chemotherapy, which leads to unacceptably high rates of myelosuppression-related deaths. Recent studies have shown promising results with the use of low-intensity or chemotherapy-free regimens in older patients with ALL, which are able to retain efficacy without excess toxicity. Novel antibody constructs such as inotuzumab ozogamicin and blinatumomab as well as potent later-generation tyrosine kinase inhibitors such as ponatinib hold significant promise in the management of ALL in the older adult. Innovative combination strategies may further improve the outcomes of these patients.",Journal Article,660.0,2.0,Older adults with acute lymphoblastic ALL have worse survival compared to their younger counterparts Here we review the reasons for the poorer outcomes of older patients with ALL and also summarize the current and future therapeutic approaches to ALL in the elderly population The poor outcomes of older adults with ALL are driven largely by lack of tolerance to standard-dose chemotherapy which leads to unacceptably high rates of myelosuppression-related deaths Recent studies have shown promising results with the use of low-intensity or chemotherapy-free regimens in older patients with ALL which are able to retain efficacy without excess toxicity Novel antibody constructs such as inotuzumab ozogamicin and blinatumomab as well as potent later-generation tyrosine kinase inhibitors such as ponatinib hold significant promise in the management of ALL in the older adult Innovative combination strategies may further improve the outcomes of these patients,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[434, 857, 5, 286, 1275, 62, 47, 639, 25, 72, 6, 136, 773, 3953, 467, 21, 206, 3, 2325, 9, 3, 1769, 123, 1, 434, 7, 5, 62, 2, 120, 2479, 3, 291, 2, 508, 189, 611, 6, 62, 4, 3, 1216, 266, 3, 334, 123, 1, 434, 857, 5, 62, 32, 1621, 1733, 20, 926, 1, 2614, 6, 260, 61, 56, 92, 1940, 6, 11934, 64, 151, 1, 2858, 139, 1043, 435, 94, 47, 443, 721, 99, 5, 3, 119, 1, 154, 837, 15, 56, 115, 472, 4, 434, 7, 5, 62, 92, 32, 1665, 6, 6630, 209, 187, 2612, 155, 229, 548, 5500, 225, 22, 6730, 5566, 2, 7182, 22, 149, 22, 1157, 1559, 914, 564, 216, 222, 225, 22, 5715, 4164, 93, 1783, 4, 3, 284, 1, 62, 4, 3, 434, 780, 4019, 150, 422, 68, 195, 401, 3, 123, 1, 46, 7]",959.0,29423571,437
<i>PDGFRB</i> mutation and tyrosine kinase inhibitor resistance in Ph-like acute lymphoblastic leukemia.,Blood,Blood,2018-02-06,"Philadelphia chromosome (Ph)-like acute lymphoblastic leukemia (ALL) comprises 10% to 15% of childhood ALL cases, many of which respond exquisitely to tyrosine kinase inhibitors (TKIs), for example, imatinib in <i>PDGFRB</i>-rearranged ALL. However, some cases developed drug resistance to TKIs and the mechanisms are poorly understood. In this study, we identified a novel <i>PDGFRB</i> fusion gene, namely <i>AGGF1</i>-<i>PDGFRB</i>, and functionally characterized its oncogenic potential in vitro. Further genomic profiling of longitudinally collected samples during treatment revealed the emergence of a mutation, <i>PDGFRB</i><sup>
                        <i>C843G</i>
                    </sup> , which directly conferred resistance to all generations of ABL TKIs, including imatinib, dasatinib, nilotinib, and ponatinib. <i>PDGFRB</i>-mutant leukemia cells are highly sensitive to multitarget kinase inhibitor CHZ868, suggesting potential therapeutic options for some patients resistant to ABL TKIs. In summary, we describe a complex clonal evolution pattern in Ph-like ALL and identified a novel <i>PDGFRB</i> point mutation that drives leukemia relapse after ABL TKI treatment.",Case Reports,714.0,11.0,Philadelphia chromosome Ph -like acute lymphoblastic ALL comprises 10 to 15 of childhood ALL cases many of which respond exquisitely to tyrosine kinase inhibitors TKIs for example imatinib in i PDGFRB /i -rearranged ALL However some cases developed drug resistance to TKIs and the mechanisms are poorly understood In this study we identified a novel i PDGFRB /i fusion gene namely i AGGF1 /i i PDGFRB /i and functionally characterized its oncogenic potential in vitro Further genomic profiling of longitudinally collected samples during treatment revealed the emergence of a mutation i PDGFRB /i sup i C843G /i /sup which directly conferred resistance to all generations of ABL TKIs including imatinib dasatinib nilotinib and ponatinib i PDGFRB /i -mutant cells are highly sensitive to multitarget kinase inhibitor CHZ868 suggesting potential therapeutic options for some patients resistant to ABL TKIs In summary we describe a complex clonal evolution pattern in Ph-like ALL and identified a novel i PDGFRB /i point mutation that drives relapse after ABL TKI treatment,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 2058, 733, 286, 1275, 62, 6704, 19913, 6, 167, 1, 864, 62, 140, 445, 1, 92, 1892, 11936, 6, 564, 216, 222, 1671, 9, 2685, 577, 4, 70, 10231, 70, 3201, 62, 137, 476, 140, 276, 234, 251, 6, 1671, 2, 3, 483, 32, 1240, 1784, 4, 26, 45, 21, 108, 8, 229, 70, 10231, 70, 1212, 145, 5046, 70, 72151, 70, 70, 10231, 70, 2, 3772, 765, 211, 1302, 174, 4, 439, 195, 572, 1080, 1, 9278, 786, 347, 190, 24, 553, 3, 3397, 1, 8, 258, 70, 10231, 70, 172, 70, 72152, 70, 172, 92, 1606, 3851, 251, 6, 62, 11083, 1, 1425, 1671, 141, 577, 1674, 2638, 2, 5715, 70, 10231, 70, 620, 37, 32, 561, 745, 6, 19866, 216, 230, 32459, 802, 174, 189, 838, 9, 476, 7, 436, 6, 1425, 1671, 4, 1962, 21, 897, 8, 840, 1946, 2554, 1177, 4, 2058, 733, 62, 2, 108, 8, 229, 70, 10231, 70, 741, 258, 17, 5267, 429, 50, 1425, 1379, 24]",1070.0,29434033,266
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome.,"Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc",Mod. Pathol.,2018-02-14,"The Philadelphia chromosome resulting from t(9;22)(q34;q11.2) or its variants is a defining event in chronic myeloid leukemia. It is also observed in several types of de novo acute leukemia, commonly in B lymphoblastic leukemia, and rarely in acute myeloid leukemia, acute leukemia of ambiguous lineage, and T lymphoblastic leukemia. Acquisition of the Philadelphia chromosome during therapy of acute leukemia and myelodysplastic syndrome is rare. We reported 19 patients, including 11 men and 8 women with a median age of 53 years at initial diagnosis. The diagnoses at initial presentation were acute myeloid leukemia (n=11), myelodysplastic syndrome (n=5), B lymphoblastic leukemia (n=2), and T lymphoblastic leukemia (n=1); no cases carried the Philadelphia chromosome. The Philadelphia chromosome was detected subsequently at relapse, or at refractory stage of acute leukemia or myelodysplastic syndrome. Of 14 patients evaluated for the BCR-ABL1 transcript subtype, 12 had the e1a2 transcript. In 11 of 14 patients, the diseases before and after emergence of the Philadelphia chromosome were clonally related by karyotype or shared gene mutations. Of 15 patients with treatment information available, 7 received chemotherapy alone, 5 received chemotherapy plus tyrosine kinase inhibitors, 2 received tyrosine kinase inhibitors only, and 1 patient was not treated. Twelve patients had follow-up after acquisition of the Philadelphia chromosome; all had persistent/refractory acute leukemia. Thirteen of 15 patients died a median of 3 months after the emergence of the Philadelphia chromosome. In summary, secondary Philadelphia chromosome acquired during therapy is rare, and is associated with the e1a2 transcript subtype, terminal disease stage, and poor outcome.",Journal Article,706.0,6.0,The Philadelphia chromosome resulting from t 9 22 q34 q11.2 or its variants is a defining event in chronic myeloid It is also observed in several types of de novo acute commonly in B lymphoblastic and rarely in acute myeloid acute of ambiguous lineage and T lymphoblastic Acquisition of the Philadelphia chromosome during therapy of acute and syndrome is rare We reported 19 patients including 11 men and 8 women with a median age of 53 years at initial diagnosis The diagnoses at initial presentation were acute myeloid n 11 syndrome n 5 B lymphoblastic n 2 and T lymphoblastic n 1 no cases carried the Philadelphia chromosome The Philadelphia chromosome was detected subsequently at relapse or at refractory stage of acute or syndrome Of 14 patients evaluated for the BCR-ABL1 transcript subtype 12 had the e1a2 transcript In 11 of 14 patients the diseases before and after emergence of the Philadelphia chromosome were clonally related by karyotype or shared gene mutations Of 15 patients with treatment information available 7 received chemotherapy alone 5 received chemotherapy plus tyrosine kinase inhibitors 2 received tyrosine kinase inhibitors only and 1 patient was not treated Twelve patients had follow-up after acquisition of the Philadelphia chromosome all had persistent/refractory acute Thirteen of 15 patients died a median of 3 months after the emergence of the Philadelphia chromosome In summary secondary Philadelphia chromosome acquired during therapy is rare and is associated with the e1a2 transcript subtype terminal disease stage and poor outcome,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3006, 1170, 1113, 29, 102, 83, 350, 16609, 11532, 18, 15, 211, 839, 16, 8, 2847, 774, 4, 442, 533, 192, 16, 120, 164, 4, 392, 630, 1, 1566, 2018, 286, 841, 4, 132, 1275, 2, 2416, 4, 286, 533, 286, 1, 11286, 2542, 2, 102, 1275, 3405, 1, 3, 3006, 1170, 190, 36, 1, 286, 2, 681, 16, 622, 21, 210, 326, 7, 141, 175, 325, 2, 66, 117, 5, 8, 52, 89, 1, 699, 60, 28, 388, 147, 3, 2403, 28, 388, 1031, 11, 286, 533, 78, 175, 681, 78, 33, 132, 1275, 78, 18, 2, 102, 1275, 78, 14, 77, 140, 2629, 3, 3006, 1170, 3, 3006, 1170, 10, 530, 1611, 28, 429, 15, 28, 430, 82, 1, 286, 15, 681, 1, 213, 7, 194, 9, 3, 1062, 3557, 3268, 875, 133, 42, 3, 31351, 3268, 4, 175, 1, 213, 7, 3, 1342, 348, 2, 50, 3397, 1, 3, 3006, 1170, 11, 9157, 139, 20, 3385, 15, 2664, 145, 138, 1, 167, 7, 5, 24, 487, 390, 67, 103, 56, 279, 33, 103, 56, 349, 564, 216, 222, 18, 103, 564, 216, 222, 158, 2, 14, 69, 10, 44, 73, 2544, 7, 42, 166, 126, 50, 3405, 1, 3, 3006, 1170, 62, 42, 1882, 430, 286, 3170, 1, 167, 7, 1016, 8, 52, 1, 27, 53, 50, 3, 3397, 1, 3, 3006, 1170, 4, 1962, 568, 3006, 1170, 1294, 190, 36, 16, 622, 2, 16, 41, 5, 3, 31351, 3268, 875, 2158, 34, 82, 2, 334, 228]",1571.0,29449681,86
Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review.,JAMA oncology,JAMA Oncol,2018-05-01,"The incidence of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adolescent and young adult (AYA) patients (age range, 15-39 years) in the United States is increasing at a greater rate than in younger or older persons. Their optimal treatment has been increasingly debated as pediatric regimens have become more widely used in the age group. This review compares the basic features of pediatric and adult chemotherapy regimens for ALL and LBL, recognizes and describes the challenges of the pediatric regimen, and suggests strategies to facilitate its adoption for AYAs with ALL and LBL. All but 2 of 25 published comparisons of outcomes with pediatric and adult regimens for ALL and LBL in AYAs and 1 meta-analysis favor the pediatric regimen. After more than a half-century of clinical trials of the pediatric regimens, including at least 160 phase 3 trials in the United States, the pediatric regimens have become far more complex than most adult regimens. Asparaginase, a critical component of the pediatric regimens, is more difficult to administer to AYAs (and older patients) but nonetheless has a favorable benefit to toxicity ratio for AYAs. A dramatic reduction in outcome of ALL and LBL during the AYA years (the ""survival cliff"") is coincident with similar reductions in proportions of AYAs referred to academic centers and enrolled on clinical trials (the ""accrual cliff"" and ""referral cliff""). The accumulating data increasingly support treating AYAs with ALL and LBL with a pediatric-inspired regimen or an approved institutional or national clinical trial tailored for this patient group. A need to develop clinical trials specifically for AYAs and to encourage their participation is paramount, with a goal to improve both the quantity and quality of survival.",Journal Article,630.0,22.0,The incidence of acute lymphoblastic ALL and lymphoblastic LBL in adolescent and young adult AYA patients age range 15-39 years in the United States is increasing at a greater rate than in younger or older persons Their optimal treatment has been increasingly debated as pediatric regimens have become more widely used in the age group This review compares the basic features of pediatric and adult chemotherapy regimens for ALL and LBL recognizes and describes the challenges of the pediatric regimen and suggests strategies to facilitate its adoption for AYAs with ALL and LBL All but 2 of 25 published comparisons of outcomes with pediatric and adult regimens for ALL and LBL in AYAs and 1 meta-analysis favor the pediatric regimen After more than a half-century of clinical trials of the pediatric regimens including at least 160 phase 3 trials in the United States the pediatric regimens have become far more complex than most adult regimens Asparaginase a critical component of the pediatric regimens is more difficult to administer to AYAs and older patients but nonetheless has a favorable benefit to toxicity ratio for AYAs A dramatic reduction in outcome of ALL and LBL during the AYA years the `` survival cliff '' is coincident with similar reductions in proportions of AYAs referred to academic centers and enrolled on clinical trials the `` accrual cliff '' and `` referral cliff '' The accumulating data increasingly support treating AYAs with ALL and LBL with a pediatric-inspired regimen or an approved institutional or national clinical trial tailored for this patient group A need to develop clinical trials specifically for AYAs and to encourage their participation is paramount with a goal to improve both the quantity and quality of survival,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 287, 1, 286, 1275, 62, 2, 1275, 8315, 4, 3678, 2, 1169, 780, 4598, 7, 89, 184, 167, 587, 60, 4, 3, 1088, 907, 16, 602, 28, 8, 378, 116, 76, 4, 773, 15, 434, 4327, 136, 665, 24, 71, 85, 1635, 7755, 22, 815, 472, 47, 1417, 80, 1792, 95, 4, 3, 89, 87, 26, 206, 5815, 3, 2795, 404, 1, 815, 2, 780, 56, 472, 9, 62, 2, 8315, 10646, 2, 2677, 3, 1427, 1, 3, 815, 477, 2, 844, 422, 6, 1876, 211, 4350, 9, 6145, 5, 62, 2, 8315, 62, 84, 18, 1, 243, 983, 2213, 1, 123, 5, 815, 2, 780, 472, 9, 62, 2, 8315, 4, 6145, 2, 14, 1742, 65, 4283, 3, 815, 477, 50, 80, 76, 8, 1303, 7981, 1, 38, 143, 1, 3, 815, 472, 141, 28, 506, 3457, 124, 27, 143, 4, 3, 1088, 907, 3, 815, 472, 47, 1417, 3272, 80, 840, 76, 96, 780, 472, 3709, 8, 740, 1249, 1, 3, 815, 472, 16, 80, 1740, 6, 6888, 6, 6145, 2, 434, 7, 84, 4648, 71, 8, 913, 247, 6, 155, 197, 9, 6145, 8, 3079, 628, 4, 228, 1, 62, 2, 8315, 190, 3, 4598, 60, 3, 25, 41988, 522, 16, 9955, 5, 288, 2153, 4, 4117, 1, 6145, 1995, 6, 1916, 1168, 2, 346, 23, 38, 143, 3, 2262, 41988, 522, 2, 2096, 41988, 522, 3, 6233, 74, 1635, 538, 1367, 6145, 5, 62, 2, 8315, 5, 8, 815, 13161, 477, 15, 35, 850, 1115, 15, 657, 38, 160, 3632, 9, 26, 69, 87, 8, 594, 6, 690, 38, 143, 1225, 9, 6145, 2, 6, 7113, 136, 2599, 16, 7640, 5, 8, 1326, 6, 401, 110, 3, 7701, 2, 372, 1, 25]",1763.0,29450465,678
Flow-cytometric vs. -morphologic assessment of remission in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group (COG).,Leukemia,Leukemia,2018-02-23,"Minimal residual disease (MRD) after initial therapy is integral to risk stratification in B-precursor and T-precursor acute lymphoblastic leukemia (B-ALL, T-ALL). Although MRD determines depth of remission, remission remains defined by morphology. We determined the outcomes of children with discordant assessments of remission by morphology vs. flow cytometry using patients age 1-30.99 years enrolled on Children's Oncology Group ALL trials who underwent bone marrow assessment at the end of induction (N=9350). Morphologic response was assessed locally as M1 (<5% lymphoblasts; remission), M2 (5-25%), or M3 (>25%). MRD was centrally measured by flow cytometry. Overall, 19.8% of patients with M2/M3 morphology had MRD<5%. M1 with MRD5% was less common in B-ALL (0.9%) than T-ALL (6.9%; p<0.0001). In B-ALL, M1/MRD5% was associated with superior 5-year event-free survival (EFS) than M2/MRD5% (59.1%6.5% vs. 39.1%7.9%; p=0.009), but was inferior to M1/MRD<5% (87.1%0.4%; p<0.0001). MRD levels were higher in M2/MRD5% than M1/MRD5% patients. In T-ALL, EFS was not significantly different between M1/MRD5% and M2/MRD5%. Patients with morphologic remission but MRD5% have outcomes similar to those who fail to achieve morphological remission, and significantly inferior to those with M1 marrows and concordant MRD, suggesting that flow cytometry should augment the definition of remission in ALL.",Comparative Study,697.0,7.0,Minimal residual disease MRD after initial therapy is integral to risk stratification in B-precursor and T-precursor acute lymphoblastic B-ALL T-ALL Although MRD determines depth of remission remission remains defined by morphology We determined the outcomes of children with discordant assessments of remission by morphology vs. flow cytometry using patients age 1-30.99 years enrolled on Children 's Oncology Group ALL trials who underwent marrow assessment at the end of induction N 9350 Morphologic response was assessed locally as M1 5 lymphoblasts remission M2 5-25 or M3 25 MRD was centrally measured by flow cytometry Overall 19.8 of patients with M2/M3 morphology had MRD 5 M1 with MRD  5 was less common in B-ALL 0.9 than T-ALL 6.9 p 0.0001 In B-ALL M1/MRD  5 was associated with superior 5-year event-free survival EFS than M2/MRD  5 59.1  6.5 vs. 39.1  7.9 p 0.009 but was inferior to M1/MRD 5 87.1  0.4 p 0.0001 MRD levels were higher in M2/MRD  5 than M1/MRD  5 patients In T-ALL EFS was not significantly different between M1/MRD  5 and M2/MRD  5 Patients with morphologic remission but MRD  5 have outcomes similar to those who fail to achieve morphological remission and significantly inferior to those with M1 marrows and concordant MRD suggesting that flow cytometry should augment the definition of remission in ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1048, 753, 34, 2029, 50, 388, 36, 16, 4450, 6, 43, 1541, 4, 132, 2765, 2, 102, 2765, 286, 1275, 132, 62, 102, 62, 242, 2029, 9476, 2436, 1, 734, 734, 469, 395, 20, 2567, 21, 509, 3, 123, 1, 541, 5, 4570, 2182, 1, 734, 20, 2567, 105, 1412, 1914, 75, 7, 89, 14, 201, 1058, 60, 346, 23, 541, 292, 413, 87, 62, 143, 54, 208, 581, 455, 28, 3, 396, 1, 504, 78, 72241, 2815, 51, 10, 275, 795, 22, 4445, 33, 10521, 734, 821, 33, 243, 15, 9852, 243, 2029, 10, 4604, 644, 20, 1412, 1914, 63, 326, 66, 1, 7, 5, 821, 9852, 2567, 42, 2029, 33, 4445, 5, 2029, 749, 33, 10, 299, 186, 4, 132, 62, 13, 83, 76, 102, 62, 49, 83, 19, 13, 488, 4, 132, 62, 4445, 2029, 749, 33, 10, 41, 5, 1123, 33, 111, 774, 115, 25, 1683, 76, 821, 2029, 749, 33, 728, 14, 810, 49, 33, 105, 587, 14, 810, 67, 83, 19, 13, 2376, 84, 10, 1663, 6, 4445, 2029, 33, 912, 14, 810, 13, 39, 19, 13, 488, 2029, 148, 11, 142, 4, 821, 2029, 749, 33, 76, 4445, 2029, 749, 33, 7, 4, 102, 62, 1683, 10, 44, 97, 338, 59, 4445, 2029, 749, 33, 2, 821, 2029, 749, 33, 7, 5, 2815, 734, 84, 2029, 749, 33, 47, 123, 288, 6, 135, 54, 4373, 6, 1359, 4268, 734, 2, 97, 1663, 6, 135, 5, 4445, 13800, 2, 3610, 2029, 802, 17, 1412, 1914, 257, 4369, 3, 2470, 1, 734, 4, 62]",1346.0,29472723,0
Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells.,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,Clin. Infect. Dis.,2018-08-01,"Chimeric antigen receptor (CAR)-modified T cells that target the CD19 antigen present a novel promising therapy for the treatment of relapsed B-cell acute lymphoblastic leukemia (B-ALL). Although cytokine release syndrome (CRS) and neurotoxicity have emerged as predominant noninfectious complications of CD19 CAR T-cell therapy, infections associated with this treatment modality have not been well documented. We analyzed infectious complications that followed CD19 CAR T-cell therapy in 53 adult patients with relapsed B-ALL enrolled in a phase I clinical trial at Memorial Sloan Kettering Cancer Center (NCT01044069). Overall, 22 patients (42%) experienced 26 infections (17 bacterial, 4 fungal, and 5 viral) within the first 30 days of CAR T-cell infusion. In 10 of 32 (31%) patients in whom complete remission was achieved, 15 infections developed between days 31 and 180; the majority of these late infections were due to respiratory viruses. In general, bacterial, fungal, and viral infections were detected at a median of 18, 23, and 48 days, respectively, after CAR T-cell infusion. CRS grade 3 or higher was independently associated with increased risk of subsequent infection (adjusted hazard ratio [HR], 2.67; P = .05) and in particular with bloodstream infection (adjusted HR, 19.97; P < .001). Three of 53 patients (6%) died of an infection-related cause. Infections in adult patients with relapsed B-ALL are common after CD19 CAR T-cell therapy. Understanding the infectious complications that are temporally coincident with CD19 CAR T-cell therapy is critical for developing effective prophylactic and other supportive care measures to improve clinical outcomes. NCT01044069.","Clinical Trial, Phase I",538.0,21.0,Chimeric antigen receptor CAR -modified T cells that target the CD19 antigen present a novel promising therapy for the treatment of relapsed B-cell acute lymphoblastic B-ALL Although cytokine release syndrome CRS and neurotoxicity have emerged as predominant noninfectious complications of CD19 CAR T-cell therapy infections associated with this treatment modality have not been well documented We analyzed infectious complications that followed CD19 CAR T-cell therapy in 53 adult patients with relapsed B-ALL enrolled in a phase I clinical trial at Memorial Sloan Kettering Cancer Center NCT01044069 Overall 22 patients 42 experienced 26 infections 17 bacterial 4 fungal and 5 viral within the first 30 days of CAR T-cell infusion In 10 of 32 31 patients in whom complete remission was achieved 15 infections developed between days 31 and 180 the majority of these late infections were due to respiratory viruses In general bacterial fungal and viral infections were detected at a median of 18 23 and 48 days respectively after CAR T-cell infusion CRS grade 3 or higher was independently associated with increased risk of subsequent infection adjusted hazard ratio HR 2.67 P .05 and in particular with bloodstream infection adjusted HR 19.97 P .001 Three of 53 patients 6 died of an infection-related cause Infections in adult patients with relapsed B-ALL are common after CD19 CAR T-cell therapy Understanding the infectious complications that are temporally coincident with CD19 CAR T-cell therapy is critical for developing effective prophylactic and other supportive care measures to improve clinical outcomes NCT01044069,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2897, 448, 153, 1881, 1230, 102, 37, 17, 283, 3, 3158, 448, 364, 8, 229, 721, 36, 9, 3, 24, 1, 591, 132, 31, 286, 1275, 132, 62, 242, 1675, 2008, 681, 3115, 2, 3561, 47, 2054, 22, 2750, 13602, 521, 1, 3158, 1881, 102, 31, 36, 1875, 41, 5, 26, 24, 1396, 47, 44, 85, 149, 1405, 21, 311, 3398, 521, 17, 370, 3158, 1881, 102, 31, 36, 4, 699, 780, 7, 5, 591, 132, 62, 346, 4, 8, 124, 70, 38, 160, 28, 2563, 2783, 2784, 12, 574, 35182, 63, 350, 7, 595, 592, 432, 1875, 269, 5117, 39, 7800, 2, 33, 1667, 262, 3, 157, 201, 162, 1, 1881, 102, 31, 904, 4, 79, 1, 531, 456, 7, 4, 953, 236, 734, 10, 513, 167, 1875, 276, 59, 162, 456, 2, 3172, 3, 686, 1, 46, 807, 1875, 11, 520, 6, 2718, 4405, 4, 1083, 5117, 7800, 2, 1667, 1875, 11, 530, 28, 8, 52, 1, 203, 382, 2, 576, 162, 106, 50, 1881, 102, 31, 904, 3115, 88, 27, 15, 142, 10, 1042, 41, 5, 101, 43, 1, 706, 930, 586, 360, 197, 168, 18, 598, 19, 474, 2, 4, 1454, 5, 10210, 930, 586, 168, 326, 1015, 19, 144, 169, 1, 699, 7, 49, 1016, 1, 35, 930, 139, 708, 1875, 4, 780, 7, 5, 591, 132, 62, 32, 186, 50, 3158, 1881, 102, 31, 36, 612, 3, 3398, 521, 17, 32, 11114, 9955, 5, 3158, 1881, 102, 31, 36, 16, 740, 9, 931, 323, 1862, 2, 127, 1877, 165, 1018, 6, 401, 38, 123, 35182]",1627.0,29481659,334
Evolution of neurocognitive function in long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.,Journal of cancer survivorship : research and practice,J Cancer Surviv,2018-02-27,"The purpose of this study was to determine the evolution of neurocognitive problems from therapy completion to long-term follow-up in survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only. We evaluated whether attention problems observed at therapy completion evolve into long-term executive dysfunction in 158 survivors treated on a single institution protocol. Treatment data (high-dose intravenous methotrexate exposure [serum concentration] and triple intrathecal chemotherapy injections) were collected. Parent report of behavior and direct cognitive testing of survivors was conducted at end of therapy, and survivors completed neurocognitive testing when >5years post-diagnosis. At the end of chemotherapy, survivors (52% female; mean age 9.2years) demonstrated higher frequency of impairment in sustained attention (38%) and parent-reported inattention (20%) compared to population expectations (10%). At long-term follow-up, survivors (mean age 13.7years; 7.6years post-diagnosis) demonstrated higher impairment in executive function (flexibility 24%, fluency 21%), sustained attention (15%), and processing speed (15%). Sustained attention improved from end of therapy to long-term follow-up (p<0.001). Higher methotrexate AUC and greater number of intrathecal injections were associated with attention problems (p=0.009, p=0.002, respectively) at the end of chemotherapy and executive function (p<0.001, p=0.02, respectively) problems at long-term follow-up. Attention problems at the end of therapy were not associated with executive function problems at long-term follow-up (p's>0.05). The direct effect of chemotherapy exposure predicted outcomes at both time points. Survivors should be monitored for neurocognitive problems well into long-term survivorship, regardless of whether they show attention problems at the end of therapy. Treatment exposures are the best predictor of long-term complications.",Journal Article,693.0,2.0,The purpose of this study was to determine the evolution of neurocognitive problems from therapy completion to long-term follow-up in survivors of childhood acute lymphoblastic treated with chemotherapy only We evaluated whether attention problems observed at therapy completion evolve into long-term executive dysfunction in 158 survivors treated on a single institution protocol Treatment data high-dose intravenous methotrexate exposure serum concentration and triple intrathecal chemotherapy injections were collected Parent report of behavior and direct cognitive testing of survivors was conducted at end of therapy and survivors completed neurocognitive testing when 5 years post-diagnosis At the end of chemotherapy survivors 52 female mean age 9.2 years demonstrated higher frequency of impairment in sustained attention 38 and parent-reported inattention 20 compared to population expectations 10 At long-term follow-up survivors mean age 13.7 years 7.6 years post-diagnosis demonstrated higher impairment in executive function flexibility 24 fluency 21 sustained attention 15 and processing speed 15 Sustained attention improved from end of therapy to long-term follow-up p 0.001 Higher methotrexate AUC and greater number of intrathecal injections were associated with attention problems p 0.009 p 0.002 respectively at the end of chemotherapy and executive function p 0.001 p 0.02 respectively problems at long-term follow-up Attention problems at the end of therapy were not associated with executive function problems at long-term follow-up p's 0.05 The direct effect of chemotherapy exposure predicted outcomes at both time points Survivors should be monitored for neurocognitive problems well into long-term survivorship regardless of whether they show attention problems at the end of therapy Treatment exposures are the best predictor of long-term complications,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 743, 1, 26, 45, 10, 6, 223, 3, 2554, 1, 2958, 2408, 29, 36, 1438, 6, 319, 337, 166, 126, 4, 332, 1, 864, 286, 1275, 73, 5, 56, 158, 21, 194, 317, 2111, 2408, 164, 28, 36, 1438, 4800, 237, 319, 337, 6481, 1527, 4, 5162, 332, 73, 23, 8, 226, 731, 1182, 24, 74, 64, 61, 1262, 2116, 645, 524, 1227, 2, 1500, 5126, 56, 4344, 11, 786, 3841, 414, 1, 1710, 2, 1196, 1863, 471, 1, 332, 10, 426, 28, 396, 1, 36, 2, 332, 781, 2958, 471, 198, 33, 60, 539, 147, 28, 3, 396, 1, 56, 332, 653, 1061, 313, 89, 83, 18, 60, 264, 142, 675, 1, 2315, 4, 2275, 2111, 519, 2, 3841, 210, 23873, 179, 72, 6, 266, 5591, 79, 28, 319, 337, 166, 126, 332, 313, 89, 233, 67, 60, 67, 49, 60, 539, 147, 264, 142, 2315, 4, 6481, 343, 9794, 259, 20475, 239, 2275, 2111, 167, 2, 3325, 5051, 167, 2275, 2111, 231, 29, 396, 1, 36, 6, 319, 337, 166, 126, 19, 13, 144, 142, 2116, 1376, 2, 378, 207, 1, 5126, 4344, 11, 41, 5, 2111, 2408, 19, 13, 2376, 19, 13, 1111, 106, 28, 3, 396, 1, 56, 2, 6481, 343, 19, 13, 144, 19, 13, 588, 106, 2408, 28, 319, 337, 166, 126, 2111, 2408, 28, 3, 396, 1, 36, 11, 44, 41, 5, 6481, 343, 2408, 28, 319, 337, 166, 126, 20860, 13, 474, 3, 1196, 254, 1, 56, 645, 783, 123, 28, 110, 98, 862, 332, 257, 40, 2909, 9, 2958, 2408, 149, 237, 319, 337, 2560, 1583, 1, 317, 491, 514, 2111, 2408, 28, 3, 396, 1, 36, 24, 3401, 32, 3, 824, 980, 1, 319, 337, 521]",1880.0,29484542,104
Dasatinib in Pediatric Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Phase II Trial.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-03-02,"Purpose Safe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for children with Philadelphia chromosome-positive (Ph+) leukemias. Methods CA180-226/NCT00777036 is a phase II, open-label, nonrandomized prospective trial of patients < 18 years of age receiving dasatinib. There are three cohorts: (1) imatinib-resistant/intolerant CML-CP, (2) imatinib-resistant/intolerant CML in accelerated/blast phase or Ph+ acute lymphoblastic leukemia (n = 17), and (3) newly diagnosed CML-CP treated with tablets or powder for oral suspension. Major cytogenetic response > 30% for imatinib-resistant/intolerant patients and complete cytogenetic response (CCyR) > 55% for newly diagnosed patients were of clinical interest. Results Of 113 patients with CML-CP, 14 (48%) who were imatinib-resistant/intolerant and 61 (73%) who were newly diagnosed remained on treatment at time of analysis. Major cytogenetic response > 30% was reached by 3 months in the imatinib-resistant/intolerant group and CCyR > 55% was reached by 6 months in the newly diagnosed CML-CP group. CCyR and major molecular response by 12 months, respectively, were 76% and 41% in the imatinib-resistant/intolerant group and 92% and 52% in newly diagnosed CML-CP group. Progression-free survival by 48 months was 78% and 93% in the imatinib-resistant/intolerant and newly diagnosed CML-CP groups, respectively. No dasatinib-related pleural or pericardial effusion, pulmonary edema, or pulmonary arterial hypertension were reported. Bone growth and development events were reported in 4% of patients. Conclusion In the largest prospective trial to date in children with CML-CP, we demonstrate that dasatinib is a safe, effective treatment of pediatric CML-CP. Target responses to first- or second-line dasatinib were met early, and deep molecular responses were observed. Safety of dasatinib in pediatric patients was similar to that observed in adults; however, no cases of pleural or pericardial effusion or pulmonary arterial hypertension were reported.","Clinical Trial, Phase II",690.0,13.0,Purpose Safe effective treatments are needed for pediatric patients with chronic myeloid in chronic phase CML-CP Dasatinib is approved for treatment of adults and children with CML-CP A phase I study determined suitable dosing for children with Philadelphia chromosome-positive Ph+ leukemias Methods CA180-226/NCT00777036 is a phase II open-label nonrandomized prospective trial of patients 18 years of age receiving dasatinib There are three cohorts 1 imatinib-resistant/intolerant CML-CP 2 imatinib-resistant/intolerant CML in accelerated/blast phase or Ph+ acute lymphoblastic n 17 and 3 newly diagnosed CML-CP treated with tablets or powder for oral suspension Major cytogenetic response 30 for imatinib-resistant/intolerant patients and complete cytogenetic response CCyR 55 for newly diagnosed patients were of clinical interest Results Of 113 patients with CML-CP 14 48 who were imatinib-resistant/intolerant and 61 73 who were newly diagnosed remained on treatment at time of analysis Major cytogenetic response 30 was reached by 3 months in the imatinib-resistant/intolerant group and CCyR 55 was reached by 6 months in the newly diagnosed CML-CP group CCyR and major molecular response by 12 months respectively were 76 and 41 in the imatinib-resistant/intolerant group and 92 and 52 in newly diagnosed CML-CP group Progression-free survival by 48 months was 78 and 93 in the imatinib-resistant/intolerant and newly diagnosed CML-CP groups respectively No dasatinib-related pleural or pericardial effusion pulmonary edema or pulmonary arterial hypertension were reported growth and development events were reported in 4 of patients Conclusion In the largest prospective trial to date in children with CML-CP we demonstrate that dasatinib is a safe effective treatment of pediatric CML-CP Target responses to first- or second-line dasatinib were met early and deep molecular responses were observed Safety of dasatinib in pediatric patients was similar to that observed in adults however no cases of pleural or pericardial effusion or pulmonary arterial hypertension were reported,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[743, 1165, 323, 640, 32, 575, 9, 815, 7, 5, 442, 533, 4, 442, 124, 903, 2541, 1674, 16, 850, 9, 24, 1, 857, 2, 541, 5, 903, 2541, 8, 124, 70, 45, 509, 2884, 1280, 9, 541, 5, 3006, 1170, 109, 2058, 2792, 636, 31438, 7400, 72299, 16, 8, 124, 215, 1020, 1756, 5666, 482, 160, 1, 7, 203, 60, 1, 89, 357, 1674, 125, 32, 169, 736, 14, 577, 436, 4944, 903, 2541, 18, 577, 436, 4944, 903, 4, 2241, 3112, 124, 15, 2058, 286, 1275, 78, 269, 2, 27, 732, 265, 903, 2541, 73, 5, 6675, 15, 9984, 9, 518, 9348, 458, 1266, 51, 201, 9, 577, 436, 4944, 7, 2, 236, 1266, 51, 6412, 614, 9, 732, 265, 7, 11, 1, 38, 1333, 99, 1, 4259, 7, 5, 903, 2541, 213, 576, 54, 11, 577, 436, 4944, 2, 713, 803, 54, 11, 732, 265, 958, 23, 24, 28, 98, 1, 65, 458, 1266, 51, 201, 10, 1300, 20, 27, 53, 4, 3, 577, 436, 4944, 87, 2, 6412, 614, 10, 1300, 20, 49, 53, 4, 3, 732, 265, 903, 2541, 87, 6412, 2, 458, 219, 51, 20, 133, 53, 106, 11, 846, 2, 605, 4, 3, 577, 436, 4944, 87, 2, 937, 2, 653, 4, 732, 265, 903, 2541, 87, 91, 115, 25, 20, 576, 53, 10, 833, 2, 966, 4, 3, 577, 436, 4944, 2, 732, 265, 903, 2541, 271, 106, 77, 1674, 139, 2164, 15, 6657, 4433, 1087, 3306, 15, 1087, 3127, 1824, 11, 210, 129, 2, 193, 281, 11, 210, 4, 39, 1, 7, 1221, 4, 3, 2166, 482, 160, 6, 1244, 4, 541, 5, 903, 2541, 21, 608, 17, 1674, 16, 8, 1165, 323, 24, 1, 815, 903, 2541, 283, 253, 6, 157, 15, 419, 328, 1674, 11, 543, 191, 2, 2369, 219, 253, 11, 164, 367, 1, 1674, 4, 815, 7, 10, 288, 6, 17, 164, 4, 857, 137, 77, 140, 1, 2164, 15, 6657, 4433, 15, 1087, 3127, 1824, 11, 210]",2089.0,29498925,179
Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia.,Blood advances,Blood Adv,2018-03-01,"Recurrent chromosomal rearrangements carry prognostic significance in pediatric B-lineage acute lymphoblastic leukemia (B-ALL). Recent genome-wide analyses identified a high-risk B-ALL subtype characterized by a diverse spectrum of genetic alterations activating kinases and cytokine receptor genes. This subtype is associated with a poor prognosis when treated with conventional chemotherapy but has demonstrated sensitivity to the relevant tyrosine kinase inhibitors. We sought to determine the frequency of kinase-activating fusions among National Cancer Institute (NCI) high-risk, Ph-negative, B-ALL patients enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001 and to describe their associated clinical characteristics and outcomes. Among the 105 patients screened, 16 (15%) harbored an ABL-class fusion (<i>ETV6-ABL1</i>: n = 1; <i>FOXP1-ABL1</i>: n = 1; <i>SFPQ-ABL1</i>: n = 1; <i>ZC3HAV1-ABL2</i>: n = 1) or a fusion activating the JAK-STAT pathway (<i>P2RY8-CRLF2</i>: n = 8; <i>PAX5-JAK2</i>: n = 4). Sixty-nine percent of patients with an identified fusion had a concomitant <i>IKZF1</i> deletion (n = 11). In univariate analysis, fusion-positivity and <i>IKZF1</i> deletion were each associated with inferior event-free survival; <i>IKZF1</i> deletion retained statistical significance in multivariable analysis (hazard ratio, 2.64; <i>P</i> = .019). Our findings support therapy intensification for <i>IKZF1</i>-altered patients, irrespective of the presence of a kinase-activating fusion.",Journal Article,691.0,7.0,Recurrent chromosomal rearrangements carry prognostic significance in pediatric B-lineage acute lymphoblastic B-ALL Recent genome-wide analyses identified a high-risk B-ALL subtype characterized by a diverse spectrum of genetic alterations activating kinases and cytokine receptor genes This subtype is associated with a poor prognosis when treated with conventional chemotherapy but has demonstrated sensitivity to the relevant tyrosine kinase inhibitors We sought to determine the frequency of kinase-activating fusions among National Cancer Institute NCI high-risk Ph-negative B-ALL patients enrolled on Dana-Farber Cancer Institute ALL Consortium Protocol 05-001 and to describe their associated clinical characteristics and outcomes Among the 105 patients screened 16 15 harbored an ABL-class fusion i ETV6-ABL1 /i n 1 i FOXP1-ABL1 /i n 1 i SFPQ-ABL1 /i n 1 i ZC3HAV1-ABL2 /i n 1 or a fusion activating the JAK-STAT pathway i P2RY8-CRLF2 /i n 8 i PAX5-JAK2 /i n 4 Sixty-nine percent of patients with an identified fusion had a concomitant i IKZF1 /i deletion n 11 In univariate analysis fusion-positivity and i IKZF1 /i deletion were each associated with inferior event-free survival i IKZF1 /i deletion retained statistical significance in multivariable analysis hazard ratio 2.64 i P /i .019 Our findings support therapy intensification for i IKZF1 /i -altered patients irrespective of the presence of a kinase-activating fusion,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[387, 1860, 2072, 3542, 177, 724, 4, 815, 132, 2542, 286, 1275, 132, 62, 435, 898, 1019, 318, 108, 8, 64, 43, 132, 62, 875, 765, 20, 8, 1867, 1873, 1, 336, 593, 1616, 1549, 2, 1675, 153, 214, 26, 875, 16, 41, 5, 8, 334, 356, 198, 73, 5, 809, 56, 84, 71, 264, 485, 6, 3, 867, 564, 216, 222, 21, 990, 6, 223, 3, 675, 1, 216, 1616, 2530, 107, 657, 12, 1377, 2580, 64, 43, 2058, 199, 132, 62, 7, 346, 23, 4932, 4979, 12, 1377, 62, 2404, 1182, 474, 144, 2, 6, 897, 136, 41, 38, 374, 2, 123, 107, 3, 3263, 7, 2261, 245, 167, 3253, 35, 1425, 1040, 1212, 70, 7306, 3557, 70, 78, 14, 70, 19886, 3557, 70, 78, 14, 70, 35503, 3557, 70, 78, 14, 70, 72309, 18452, 70, 78, 14, 15, 8, 1212, 1616, 3, 4653, 4168, 308, 70, 25205, 8895, 70, 78, 66, 70, 6279, 2509, 70, 78, 39, 1746, 762, 714, 1, 7, 5, 35, 108, 1212, 42, 8, 1781, 70, 8422, 70, 1528, 78, 175, 4, 880, 65, 1212, 1887, 2, 70, 8422, 70, 1528, 11, 296, 41, 5, 1663, 774, 115, 25, 70, 8422, 70, 1528, 3532, 1050, 724, 4, 658, 65, 360, 197, 18, 660, 70, 19, 70, 4049, 114, 272, 538, 36, 5091, 9, 70, 8422, 70, 1495, 7, 3500, 1, 3, 463, 1, 8, 216, 1616, 1212]",1435.0,29507076,604
Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.,Cancer,Cancer,2018-03-06,"Inotuzumab ozogamicin (InO), an anti-CD22 antibody-calicheamicin conjugate, demonstrated superior clinical activity versus standard-of-care (SOC) chemotherapies for relapsed/refractory B-cell acute lymphoblastic leukemia in the phase 3 randomized controlled INO-VATE trial. The authors assessed patient-reported outcomes (PROs) from that study. Patients were randomized to receive either InO (1.8 mg/m<sup>2</sup> per cycle for 6 cycles) or SOC (fludarabine/cytarabine [ara-C]/granulocyte colony-stimulating factor, or ara-C plus mitoxantrone, or high-dose ara-C for 4 cycles) and completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the EuroQoL 5 Dimensions Questionnaires at baseline, on day 1 of each cycle, and at the end of treatment. Treatment differences in PROs were assessed using longitudinal mixed-effects models with random intercepts and slopes. Questionnaire completion rates in the InO (n = 164) and SOC (n = 162) arms were 85% and 65%, respectively. Baseline scores were similar between arms. Patients who received InO reported better quality of life (QoL), functioning, and symptom scores (except for constipation and emotional functioning). Least-squares mean (95% confidence interval [CI]) differences in physical, role, and social functioning and in appetite loss were significant (6.9 [95% CI, 1.4-12.3], 11.4 [95% CI, 3.2-19.5], 8.4 [95% CI, 0.7-16.1], and -8.7 [95% CI, -16.0 to -1.4], respectively; all P < .05) and had exceeded the minimally important difference of 5. Mean treatment differences in favor of InO on the EuroQoL visual analog scale and the global health status/QoL, dyspnea, and fatigue scales reached or approached the minimally important difference of 5, although without statistical significance. No dimensions were significantly worse with InO versus SOC. The current PRO data support the favorable benefit/risk ratio of InO for the treatment of relapsed/refractory acute lymphoblastic leukemia, with superior clinical efficacy and better QoL. Cancer 2018;124:2151-60.  2018 American Cancer Society.","Clinical Trial, Phase III",686.0,15.0,Inotuzumab ozogamicin InO an anti-CD22 antibody-calicheamicin conjugate demonstrated superior clinical activity versus standard-of-care SOC chemotherapies for relapsed/refractory B-cell acute lymphoblastic in the phase 3 randomized controlled INO-VATE trial The authors assessed patient-reported outcomes PROs from that study Patients were randomized to receive either InO 1.8 mg/m sup 2 /sup per cycle for 6 cycles or SOC fludarabine/cytarabine ara-C /granulocyte colony-stimulating factor or ara-C plus mitoxantrone or high-dose ara-C for 4 cycles and completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire and the EuroQoL 5 Dimensions Questionnaires at baseline on day 1 of each cycle and at the end of treatment Treatment differences in PROs were assessed using longitudinal mixed-effects models with random intercepts and slopes Questionnaire completion rates in the InO n 164 and SOC n 162 arms were 85 and 65 respectively Baseline scores were similar between arms Patients who received InO reported better quality of life QoL functioning and symptom scores except for constipation and emotional functioning Least-squares mean 95 confidence interval CI differences in physical role and social functioning and in appetite loss were significant 6.9 95 CI 1.4-12.3 11.4 95 CI 3.2-19.5 8.4 95 CI 0.7-16.1 and -8.7 95 CI -16.0 to -1.4 respectively all P .05 and had exceeded the minimally important difference of 5 Mean treatment differences in favor of InO on the EuroQoL visual analog scale and the global health status/QoL dyspnea and fatigue scales reached or approached the minimally important difference of 5 although without statistical significance No dimensions were significantly worse with InO versus SOC The current PRO data support the favorable benefit/risk ratio of InO for the treatment of relapsed/refractory acute lymphoblastic with superior clinical efficacy and better QoL Cancer 2018 124:2151-60  2018 American Cancer Society,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6730, 5566, 8709, 35, 312, 7599, 548, 13499, 3998, 264, 1123, 38, 128, 185, 260, 1, 165, 7615, 4203, 9, 591, 430, 132, 31, 286, 1275, 4, 3, 124, 27, 384, 1149, 8709, 32612, 160, 3, 738, 275, 69, 210, 123, 4660, 29, 17, 45, 7, 11, 384, 6, 560, 361, 8709, 14, 66, 81, 188, 172, 18, 172, 379, 417, 9, 10020, 410, 15, 7615, 2027, 1855, 3899, 256, 2764, 1975, 2122, 161, 15, 3899, 256, 349, 4419, 15, 64, 61, 3899, 256, 9, 11720, 410, 2, 781, 3, 1865, 2533, 9, 389, 2, 24, 1, 12, 372, 1, 358, 1770, 2, 3, 11850, 33, 6190, 2956, 28, 330, 23, 218, 14, 1, 296, 417, 2, 28, 3, 396, 1, 24, 24, 362, 4, 4660, 11, 275, 75, 2380, 1739, 176, 274, 5, 2324, 33670, 2, 19612, 1770, 1438, 151, 4, 3, 8709, 78, 5279, 2, 7615, 78, 5441, 1335, 11, 772, 2, 556, 106, 330, 703, 11, 288, 59, 1335, 7, 54, 103, 8709, 210, 380, 372, 1, 358, 1001, 2702, 2, 934, 703, 2187, 9, 4532, 2, 2671, 2702, 506, 11938, 313, 48, 307, 268, 58, 362, 4, 900, 200, 2, 2032, 2702, 2, 4, 4062, 407, 11, 93, 49, 83, 48, 58, 14, 39, 133, 27, 175, 39, 48, 58, 27, 18, 326, 33, 66, 39, 48, 58, 13, 67, 245, 14, 2, 66, 67, 48, 58, 245, 13, 6, 14, 39, 106, 62, 19, 474, 2, 42, 4726, 3, 2144, 305, 523, 1, 33, 313, 24, 362, 4, 4283, 1, 8709, 23, 3, 11850, 3046, 3497, 1124, 2, 3, 1648, 341, 156, 1001, 2923, 2, 613, 5083, 1300, 15, 5738, 3, 2144, 305, 523, 1, 33, 242, 187, 1050, 724, 77, 6190, 11, 97, 639, 5, 8709, 185, 7615, 3, 291, 1805, 74, 538, 3, 913, 247, 43, 197, 1, 8709, 9, 3, 24, 1, 591, 430, 286, 1275, 5, 1123, 38, 209, 2, 380, 1001, 12, 2982, 2834, 50912, 335, 2206, 2982, 597, 12, 1174]",1998.0,29508899,51
Gut Microbiome Composition Predicts Infection Risk During Chemotherapy in Children With Acute Lymphoblastic Leukemia.,Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,Clin. Infect. Dis.,2018-08-01,"Myelosuppression-related infections remain important causes of morbidity and mortality in children with acute lymphoblastic leukemia (ALL). By analyzing fecal samples collected at diagnosis and after each of the initial 3 phases of chemotherapy, we evaluated the role of gut microbiota in predicting infections in 199 children with newly diagnosed ALL. The bacterial 16S rRNA gene was analyzed by high-depth sequencing to determine the diversity and composition of the microbiome. After the induction and reinduction I phases of chemotherapy, microbial diversity decreased significantly relative to the prechemotherapy value. After chemotherapy, the relative abundance of certain bacterial taxa (eg, Bacteroidetes) decreased significantly, whereas that of other taxa (eg, Clostridiaceae and Streptococcaceae) increased. A baseline gut microbiome characterized by Proteobacteria predicted febrile neutropenia. Adjusting for the chemotherapy phase and ALL risk level, Enterococcaceae dominance (relative abundance 30%) predicted significantly greater risk of subsequent febrile neutropenia and diarrheal illness, whereas Streptococcaceae dominance predicted significantly greater risk of subsequent diarrheal illness. In children undergoing therapy for newly diagnosed ALL, the relative abundance of Proteobacteria before chemotherapy initiation predicts development of febrile neutropenia, and domination of the gut microbiota by Enterococcaceae or Streptococcaceae at any time during chemotherapy predicts infection in subsequent phases of chemotherapy. NCT00549848.",Clinical Trial,538.0,9.0,Myelosuppression-related infections remain important causes of morbidity and mortality in children with acute lymphoblastic ALL By analyzing fecal samples collected at diagnosis and after each of the initial 3 phases of chemotherapy we evaluated the role of gut microbiota in predicting infections in 199 children with newly diagnosed ALL The bacterial 16S rRNA gene was analyzed by high-depth sequencing to determine the diversity and composition of the microbiome After the induction and reinduction I phases of chemotherapy microbial diversity decreased significantly relative to the prechemotherapy value After chemotherapy the relative abundance of certain bacterial taxa eg Bacteroidetes decreased significantly whereas that of other taxa eg Clostridiaceae and Streptococcaceae increased A baseline gut microbiome characterized by Proteobacteria predicted febrile neutropenia Adjusting for the chemotherapy phase and ALL risk level Enterococcaceae dominance relative abundance 30 predicted significantly greater risk of subsequent febrile neutropenia and diarrheal illness whereas Streptococcaceae dominance predicted significantly greater risk of subsequent diarrheal illness In children undergoing therapy for newly diagnosed ALL the relative abundance of Proteobacteria before chemotherapy initiation predicts development of febrile neutropenia and domination of the gut microbiota by Enterococcaceae or Streptococcaceae at any time during chemotherapy predicts infection in subsequent phases of chemotherapy NCT00549848,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2858, 139, 1875, 918, 305, 1626, 1, 787, 2, 282, 4, 541, 5, 286, 1275, 62, 20, 4449, 6784, 347, 786, 28, 147, 2, 50, 296, 1, 3, 388, 27, 3523, 1, 56, 21, 194, 3, 200, 1, 7600, 7287, 4, 1434, 1875, 4, 5840, 541, 5, 732, 265, 62, 3, 5117, 17009, 19283, 145, 10, 311, 20, 64, 2436, 615, 6, 223, 3, 3653, 2, 3761, 1, 3, 7675, 50, 3, 504, 2, 10177, 70, 3523, 1, 56, 9138, 3653, 340, 97, 580, 6, 3, 10733, 549, 50, 56, 3, 580, 4778, 1, 1840, 5117, 21861, 2887, 31878, 340, 97, 547, 17, 1, 127, 21861, 2887, 72334, 2, 42003, 101, 8, 330, 7600, 7675, 765, 20, 29772, 783, 2498, 778, 1358, 9, 3, 56, 124, 2, 62, 43, 301, 50916, 16402, 580, 4778, 7783, 783, 97, 378, 43, 1, 706, 2498, 778, 2, 24780, 2973, 547, 42003, 16402, 783, 97, 378, 43, 1, 706, 24780, 2973, 4, 541, 479, 36, 9, 732, 265, 62, 3, 580, 4778, 1, 29772, 348, 56, 1118, 2623, 193, 1, 2498, 778, 2, 29773, 1, 3, 7600, 7287, 20, 50916, 15, 42003, 28, 500, 98, 190, 56, 2623, 930, 4, 706, 3523, 1, 56, 40761]",1530.0,29518185,184
Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2018-02-17,"Complete molecular response (CMR) and 2- and 3-year overall survival (OS) were compared for patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia (Ph<sup>+</sup> ALL) who had undergone front-line combination chemotherapy plus ponatinib versus combination therapy plus earlier generation tyrosine kinase inhibitors (TKIs; imatinib, dasatinib, and nilotinib). We identified 26 Ph<sup>+</sup> ALL studies: 25 of earlier generation TKIs and 1 of ponatinib. The outcomes from studies of combination chemotherapy plus earlier generation TKIs were summarized using pooled estimates with 95% confidence intervals (CIs) from a random-effects meta-analysis. A binomial distribution was assumed to calculate the 95% CIs for the results from the single-arm combination chemotherapy plus ponatinib trial. Adjusted logistic meta-regression analyses were used to compare the outcomes between the TKI groups. The percentage of patients achieving a CMR was greater with combination chemotherapy plus ponatinib (79%) than the pooled percentage of patients achieving a CMR with combination chemotherapy plus earlier generation TKIs (34%). Greater OS was observed with ponatinib compared with the pooled OS for earlier generation TKIs (2-year, 83% vs. 58%; 3-year, 79% vs. 50%). Odds ratios for ponatinib versus earlier generation TKIs were 6.09 (95% CI, 1.16-31.90; P= .034) for CMR, 3.70 (95% CI, 0.93-14.73; P= .062) for 2-year OS, and 4.49 (95% CI, 1.00-20.13; P= .050) for 3-year OS. Ponatinib plus chemotherapy might be associated with better outcomes than chemotherapy with earlier generation TKIs in patients with newly diagnosed Ph<sup>+</sup> ALL.",Journal Article,703.0,9.0,Complete molecular response CMR and 2- and 3-year overall survival OS were compared for patients with newly diagnosed Philadelphia-positive acute lymphoblastic Ph sup /sup ALL who had undergone front-line combination chemotherapy plus ponatinib versus combination therapy plus earlier generation tyrosine kinase inhibitors TKIs imatinib dasatinib and nilotinib We identified 26 Ph sup /sup ALL studies 25 of earlier generation TKIs and 1 of ponatinib The outcomes from studies of combination chemotherapy plus earlier generation TKIs were summarized using pooled estimates with 95 confidence intervals CIs from a random-effects meta-analysis A binomial distribution was assumed to calculate the 95 CIs for the results from the single-arm combination chemotherapy plus ponatinib trial Adjusted logistic meta-regression analyses were used to compare the outcomes between the TKI groups The percentage of patients achieving a CMR was greater with combination chemotherapy plus ponatinib 79 than the pooled percentage of patients achieving a CMR with combination chemotherapy plus earlier generation TKIs 34 Greater OS was observed with ponatinib compared with the pooled OS for earlier generation TKIs 2-year 83 vs. 58 3-year 79 vs. 50 Odds ratios for ponatinib versus earlier generation TKIs were 6.09 95 CI 1.16-31.90 P .034 for CMR 3.70 95 CI 0.93-14.73 P .062 for 2-year OS and 4.49 95 CI 1.00-20.13 P .050 for 3-year OS Ponatinib plus chemotherapy might be associated with better outcomes than chemotherapy with earlier generation TKIs in patients with newly diagnosed Ph sup /sup ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[236, 219, 51, 7334, 2, 18, 2, 27, 111, 63, 25, 118, 11, 72, 9, 7, 5, 732, 265, 3006, 109, 286, 1275, 2058, 172, 172, 62, 54, 42, 1989, 3007, 328, 150, 56, 349, 5715, 185, 150, 36, 349, 1677, 914, 564, 216, 222, 1671, 577, 1674, 2, 2638, 21, 108, 432, 2058, 172, 172, 62, 94, 243, 1, 1677, 914, 1671, 2, 14, 1, 5715, 3, 123, 29, 94, 1, 150, 56, 349, 1677, 914, 1671, 11, 3989, 75, 1830, 1423, 5, 48, 307, 1582, 1927, 29, 8, 2324, 176, 1742, 65, 8, 8538, 1395, 10, 6719, 6, 3232, 3, 48, 1927, 9, 3, 99, 29, 3, 226, 475, 150, 56, 349, 5715, 160, 586, 812, 1742, 320, 318, 11, 95, 6, 932, 3, 123, 59, 3, 1379, 271, 3, 1150, 1, 7, 1785, 8, 7334, 10, 378, 5, 150, 56, 349, 5715, 842, 76, 3, 1830, 1150, 1, 7, 1785, 8, 7334, 5, 150, 56, 349, 1677, 914, 1671, 562, 378, 118, 10, 164, 5, 5715, 72, 5, 3, 1830, 118, 9, 1677, 914, 1671, 18, 111, 852, 105, 717, 27, 111, 842, 105, 212, 610, 1137, 9, 5715, 185, 1677, 914, 1671, 11, 49, 1730, 48, 58, 14, 245, 456, 424, 19, 5337, 9, 7334, 27, 431, 48, 58, 13, 966, 213, 803, 19, 12139, 9, 18, 111, 118, 2, 39, 739, 48, 58, 14, 2038, 179, 233, 19, 10801, 9, 27, 111, 118, 5715, 349, 56, 822, 40, 41, 5, 380, 123, 76, 56, 5, 1677, 914, 1671, 4, 7, 5, 732, 265, 2058, 172, 172, 62]",1586.0,29519619,591
Behavioral symptoms and psychiatric disorders in child and adolescent long-term survivors of childhood acute lymphoblastic leukemia treated with chemotherapy only.,Psycho-oncology,Psychooncology,2018-03-30,"Prevalence of emotional, behavioral, and psychiatric outcomes in child and adolescent survivors of childhood acute lymphoblastic leukemia treated on a chemotherapy-only protocol were not well defined. Self- and parent-reported emotional and behavioral symptoms were assessed for 161 survivors of childhood acute lymphoblastic leukemia (51.0% female; mean [SD] age 12.1[2.6] years; 7.5[1.6] years post-diagnosis). Age- and sex-adjusted scores were calculated for standardized measures and compared with 90th percentile of norms. Frequencies of survivor psychiatric disorders from structured diagnostic interviews with parents were compared with the general population. Parent emotional distress and post-traumatic stress symptoms were assessed. Associations between child symptoms/disorders and parent distress were examined with log-binomial models, adjusting for highest parent education. Compared with population expectations (10%), more survivors self-reported symptoms of inattention (27.9; 95% CI, 21.0%-35.7%), hyperactivity/impulsivity (26.0%; CI, 19.2%-33.6%), and oppositional-defiant behavior (20.1%; CI, 14.1%-27.3%). Parents reported survivors with more symptoms of inattention (23.6%; CI, 17.2%-31.0%), higher frequencies of obsessive-compulsive disorder (10.3% vs 2%) and oppositional defiant disorder (16.0% vs 9.5%), but not attention-deficit/hyperactivity disorder (7.1% vs 7.8%) or generalized anxiety disorder (3.2% vs 4.1%), compared with national norms. Parent-report of child anxiety disorders was associated with parent self-reported emotional distress but not survivor self-report of anxiety. A significant minority of survivors have long-term psychiatric morbidity, multi-informant assessment is important to understand these symptom profiles and to inform selection of appropriate interventions. Interventions targeting inattention and oppositional behavior in children and emotional distress in parents are warranted in families with survivors who display behavioral problems.",Journal Article,662.0,0.0,Prevalence of emotional behavioral and psychiatric outcomes in child and adolescent survivors of childhood acute lymphoblastic treated on a chemotherapy-only protocol were not well defined Self- and parent-reported emotional and behavioral symptoms were assessed for 161 survivors of childhood acute lymphoblastic 51.0 female mean SD age 12.1 2.6 years 7.5 1.6 years post-diagnosis Age- and sex-adjusted scores were calculated for standardized measures and compared with 90th percentile of norms Frequencies of survivor psychiatric disorders from structured diagnostic interviews with parents were compared with the general population Parent emotional distress and post-traumatic stress symptoms were assessed Associations between child symptoms/disorders and parent distress were examined with log-binomial models adjusting for highest parent education Compared with population expectations 10 more survivors self-reported symptoms of inattention 27.9 95 CI 21.0 -35.7 hyperactivity/impulsivity 26.0 CI 19.2 -33.6 and oppositional-defiant behavior 20.1 CI 14.1 -27.3 Parents reported survivors with more symptoms of inattention 23.6 CI 17.2 -31.0 higher frequencies of obsessive-compulsive disorder 10.3 vs 2 and oppositional defiant disorder 16.0 vs 9.5 but not attention-deficit/hyperactivity disorder 7.1 vs 7.8 or generalized anxiety disorder 3.2 vs 4.1 compared with national norms Parent-report of child anxiety disorders was associated with parent self-reported emotional distress but not survivor self-report of anxiety A significant minority of survivors have long-term psychiatric morbidity multi-informant assessment is important to understand these symptom profiles and to inform selection of appropriate interventions Interventions targeting inattention and oppositional behavior in children and emotional distress in parents are warranted in families with survivors who display behavioral problems,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1078, 1, 2671, 4166, 2, 6563, 123, 4, 2566, 2, 3678, 332, 1, 864, 286, 1275, 73, 23, 8, 56, 158, 1182, 11, 44, 149, 395, 1074, 2, 3841, 210, 2671, 2, 4166, 507, 11, 275, 9, 5377, 332, 1, 864, 286, 1275, 725, 13, 1061, 313, 1270, 89, 133, 14, 18, 49, 60, 67, 33, 14, 49, 60, 539, 147, 89, 2, 1035, 586, 703, 11, 981, 9, 1670, 1018, 2, 72, 5, 15833, 6392, 1, 9875, 2722, 1, 2628, 6563, 1997, 29, 5198, 752, 4053, 5, 2418, 11, 72, 5, 3, 1083, 266, 3841, 2671, 1462, 2, 539, 11272, 1531, 507, 11, 275, 685, 59, 2566, 507, 1997, 2, 3841, 1462, 11, 409, 5, 1066, 8538, 274, 1358, 9, 1076, 3841, 1848, 72, 5, 266, 5591, 79, 80, 332, 1074, 210, 507, 1, 23873, 428, 83, 48, 58, 239, 13, 465, 67, 18391, 27932, 432, 13, 58, 326, 18, 466, 49, 2, 42004, 50917, 1710, 179, 14, 58, 213, 14, 428, 27, 2418, 210, 332, 5, 80, 507, 1, 23873, 382, 49, 58, 269, 18, 456, 13, 142, 2722, 1, 72336, 38602, 2645, 79, 27, 105, 18, 2, 42004, 50917, 2645, 245, 13, 105, 83, 33, 84, 44, 2111, 6819, 18391, 2645, 67, 14, 105, 67, 66, 15, 4169, 2021, 2645, 27, 18, 105, 39, 14, 72, 5, 657, 9875, 3841, 414, 1, 2566, 2021, 1997, 10, 41, 5, 3841, 1074, 210, 2671, 1462, 84, 44, 2628, 1074, 414, 1, 2021, 8, 93, 2652, 1, 332, 47, 319, 337, 6563, 787, 1414, 34517, 455, 16, 305, 6, 1640, 46, 934, 1241, 2, 6, 2295, 881, 1, 870, 1151, 1151, 529, 23873, 2, 42004, 1710, 4, 541, 2, 2671, 1462, 4, 2418, 32, 1197, 4, 1954, 5, 332, 54, 3640, 4166, 2408]",1912.0,29521470,38
Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-03-19,"For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions on post-transplantation outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. Using data from the Center for Blood and Marrow Transplant Research, we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013. Cox regression models were constructed using the following macroeconomic indicators as main effects: Gross national income per capita, health expenditure per capita, and Human Development Index (HDI). The outcome was overall survival at 100 days following transplantation. In each model, transplants performed within lower resourced environments were associated with inferior overall survival. In the model with the HDI as the main effect, transplants performed in the lowest HDI quartile (n=697) were associated with increased hazard for mortality (hazard ratio, 2.42; 95% confidence interval, 1.64 to 3.57; P<.001) in comparison with transplants performed in the countries with the highest HDI quartile. This translated into an 11% survival difference at 100 days (77% for lowest HDI quartile versus 88% for all other quartiles). Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL. The reasons for this disparity require further investigation.",Journal Article,673.0,1.0,"For patients with acute lymphoblastic ALL allogeneic hematopoietic cell transplantation alloHCT offers a potential cure Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery The impact of country-level economic conditions on post-transplantation outcomes is not known Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL Using data from the Center for Blood and Marrow Transplant Research we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013 Cox regression models were constructed using the following macroeconomic indicators as main effects Gross national income per capita health expenditure per capita and Human Development Index HDI The outcome was overall survival at 100 days following transplantation In each model transplants performed within lower resourced environments were associated with inferior overall survival In the model with the HDI as the main effect transplants performed in the lowest HDI quartile n 697 were associated with increased hazard for mortality hazard ratio 2.42 95 confidence interval 1.64 to 3.57 P .001 in comparison with transplants performed in the countries with the highest HDI quartile This translated into an 11 survival difference at 100 days 77 for lowest HDI quartile versus 88 for all other quartiles Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL The reasons for this disparity require further investigation",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9, 7, 5, 286, 1275, 62, 1063, 1007, 31, 497, 5514, 2339, 8, 174, 1722, 358, 3691, 521, 122, 3043, 29, 5514, 17, 1353, 3, 1581, 1, 8023, 341, 165, 989, 3, 345, 1, 5978, 301, 3875, 1298, 23, 539, 497, 123, 16, 44, 440, 114, 461, 10, 6, 423, 317, 46, 682, 11, 41, 5, 123, 9, 7, 4600, 9, 62, 75, 74, 29, 3, 574, 9, 315, 2, 581, 941, 389, 21, 159, 175, 7007, 7, 54, 103, 8, 157, 5514, 9, 62, 29, 9044, 1168, 716, 519, 2115, 59, 3, 60, 1, 1242, 2, 1346, 418, 320, 274, 11, 2776, 75, 3, 366, 38644, 3539, 22, 1895, 176, 1789, 657, 2306, 379, 17774, 341, 8699, 379, 17774, 2, 171, 193, 558, 6676, 3, 228, 10, 63, 25, 28, 394, 162, 366, 497, 4, 296, 202, 4016, 173, 262, 280, 41075, 10604, 11, 41, 5, 1663, 63, 25, 4, 3, 202, 5, 3, 6676, 22, 3, 1895, 254, 4016, 173, 4, 3, 2101, 6676, 3708, 78, 11989, 11, 41, 5, 101, 360, 9, 282, 360, 197, 18, 595, 48, 307, 268, 14, 660, 6, 27, 696, 19, 144, 4, 1155, 5, 4016, 173, 4, 3, 2115, 5, 3, 1076, 6676, 3708, 26, 5136, 237, 35, 175, 25, 523, 28, 394, 162, 849, 9, 2101, 6676, 3708, 185, 889, 9, 62, 127, 6028, 5978, 301, 38644, 3824, 11, 41, 5, 280, 25, 28, 394, 162, 50, 5514, 9, 62, 3, 2325, 9, 26, 4326, 1353, 195, 940]",1628.0,29567340,261
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.,Blood,Blood,2018-03-22,"Ponatinib has potent activity against native and mutant BCR-ABL1, including BCR-ABL1<sup>T315I</sup> The pivotal phase 2 Ponatinib Ph<sup>+</sup> ALL and CML Evaluation (PACE) trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) resistant/intolerant to dasatinib or nilotinib, or with BCR-ABL1<sup>T315I</sup> This analysis focuses on chronic-phase CML (CP-CML) patients (n = 270) with 56.8-month median follow-up. Among 267 evaluable patients, 60%, 40%, and 24% achieved major cytogenetic response (MCyR), major molecular response (MMR), and 4.5-log molecular response, respectively. The probability of maintaining MCyR for 5 years was 82% among responders. Dose reductions were implemented in October 2013 to decrease the risk of arterial occlusive events (AOEs); 90% of CP-CML patients who had achieved MCyR or MMR maintained response 40 months after elective dose reductions. Estimated 5-year overall survival was 73%. In CP-CML patients, the most common treatment-emergent adverse events were rash (47%), abdominal pain (46%), thrombocytopenia (46%), headache (43%), dry skin (42%), and constipation (41%). The cumulative incidence of AOEs in CP-CML patients increased over time to 31%, while the exposure-adjusted incidence of new AOEs (15.8 and 4.9 per 100 patient-years in years 1 and 5, respectively) did not increase over time. These final PACE results demonstrate ponatinib provides durable and clinically meaningful responses, irrespective of dose reductions, in this population of heavily pretreated CP-CML patients. This trial was registered at www.clinicaltrials.gov as #NCT01207440.","Clinical Trial, Phase II",670.0,56.0,Ponatinib has potent activity against native and mutant BCR-ABL1 including BCR-ABL1 sup T315I /sup The pivotal phase 2 Ponatinib Ph sup /sup ALL and CML Evaluation PACE trial evaluated efficacy and safety of ponatinib at a starting dose of 45 mg once daily in 449 patients with chronic myeloid CML or Philadelphia chromosome-positive acute lymphoblastic ALL resistant/intolerant to dasatinib or nilotinib or with BCR-ABL1 sup T315I /sup This analysis focuses on chronic-phase CML CP-CML patients n 270 with 56.8-month median follow-up Among 267 evaluable patients 60 40 and 24 achieved major cytogenetic response MCyR major molecular response MMR and 4.5-log molecular response respectively The probability of maintaining MCyR for 5 years was 82 among responders Dose reductions were implemented in October 2013 to decrease the risk of arterial occlusive events AOEs 90 of CP-CML patients who had achieved MCyR or MMR maintained response 40 months after elective dose reductions Estimated 5-year overall survival was 73 In CP-CML patients the most common treatment-emergent adverse events were rash 47 abdominal pain 46 thrombocytopenia 46 headache 43 dry 42 and constipation 41 The cumulative incidence of AOEs in CP-CML patients increased over time to 31 while the exposure-adjusted incidence of new AOEs 15.8 and 4.9 per 100 patient-years in years 1 and 5 respectively did not increase over time These final PACE results demonstrate ponatinib provides durable and clinically meaningful responses irrespective of dose reductions in this population of heavily pretreated CP-CML patients This trial was registered at www.clinicaltrials.gov as NCT01207440,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,"[5715, 71, 1157, 128, 480, 4646, 2, 620, 1062, 3557, 141, 1062, 3557, 172, 6184, 172, 3, 3754, 124, 18, 5715, 2058, 172, 172, 62, 2, 903, 451, 7265, 160, 194, 209, 2, 367, 1, 5715, 28, 8, 1723, 61, 1, 512, 81, 1059, 391, 4, 8865, 7, 5, 442, 533, 903, 15, 3006, 1170, 109, 286, 1275, 62, 436, 4944, 6, 1674, 15, 2638, 15, 5, 1062, 3557, 172, 6184, 172, 26, 65, 3026, 23, 442, 124, 903, 2541, 903, 7, 78, 6666, 5, 664, 66, 811, 52, 166, 126, 107, 7559, 859, 7, 335, 327, 2, 259, 513, 458, 1266, 51, 10240, 458, 219, 51, 2205, 2, 39, 33, 1066, 219, 51, 106, 3, 1320, 1, 3284, 10240, 9, 33, 60, 10, 878, 107, 1983, 61, 2153, 11, 3426, 4, 2551, 1346, 6, 775, 3, 43, 1, 3127, 8376, 281, 26550, 9613, 1, 2541, 903, 7, 54, 42, 513, 10240, 15, 2205, 1955, 51, 327, 53, 50, 4700, 61, 2153, 661, 33, 111, 63, 25, 10, 803, 4, 2541, 903, 7, 3, 96, 186, 24, 4348, 290, 281, 11, 1641, 662, 1467, 559, 641, 1340, 641, 4538, 601, 7922, 595, 2, 4532, 605, 3, 967, 287, 1, 26550, 4, 2541, 903, 7, 101, 252, 98, 6, 456, 369, 3, 645, 586, 287, 1, 217, 26550, 167, 66, 2, 39, 83, 379, 394, 69, 60, 4, 60, 14, 2, 33, 106, 205, 44, 344, 252, 98, 46, 1457, 7265, 99, 608, 5715, 777, 1480, 2, 505, 2538, 253, 3500, 1, 61, 2153, 4, 26, 266, 1, 2447, 2193, 2541, 903, 7, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 72418]",1655.0,29567798,630
Association of Cerebrospinal Fluid Biomarkers of Central Nervous System Injury With Neurocognitive and Brain Imaging Outcomes in Children Receiving Chemotherapy for Acute Lymphoblastic Leukemia.,JAMA oncology,JAMA Oncol,2018-07-12,"Little is known about treatment-related neurotoxic mechanisms in children with acute lymphoblastic leukemia (ALL) treated with chemotherapy only. To examine concentration of cerebrospinal fluid (CSF) biomarkers of brain injury at ALL diagnosis and during cancer therapy and to evaluate associations with long-term neurocognitive and neuroimaging outcomes and relevant genetic polymorphisms. This prospective cohort study included 235 patients with ALL who received a chemotherapy-only protocol. Patients provided CSF samples after diagnosis and throughout treatment. At 5 or more years after the diagnosis, 138 (69.7%) of 198 eligible survivors participated in long-term follow-up assessments. Children were treated from June 1, 2000, through October 31, 2010. Follow-up was completed on October 21, 2014, and data were analyzed from August 1, 2015, through September 30, 2016. Plasma concentration of high-dose intravenous methotrexate sodium and number of triple intrathecal chemotherapy injections. The CSF samples were assayed at 5 points from diagnosis to reinduction for biomarkers of myelin degradation (myelin basic protein [MBP]), neuronal damage (nerve growth factor [NGF] and total and phosphorylated tau protein), astrogliosis (glial fibrillary acidic protein [GFAP]), and neuroinflammation (chitotriosidase). DNA was genotyped for polymorphisms in drug metabolism, oxidative stress, and neurodevelopment. Leukoencephalopathy was evaluated by brain imaging. At 5 or more years after the diagnosis, survivors completed neurocognitive testing and brain imaging of white matter integrity. Among the 235 patients with CSF samples (120 boys [51.1%] and 115 girls [48.9%]; mean [SD] age at diagnosis, 6.8 [4.7] years), MBP and GFAP levels were elevated at baseline and through consolidation. The number of intrathecal injections was positively correlated with NGF level increase at consolidation (r=0.19; P=.005). Increases in GFAP (risk ratio [RR], 1.23; 95% CI, 1.09-1.40), MBP (RR, 1.06; 95% CI, 1.01-1.11), and total tau (RR, 1.76; 95% CI, 1.11-2.78) levels were associated with a higher risk for leukoencephalopathy and higher apparent diffusion coefficient in frontal lobe white matter 5 years after diagnosis (standardized estimate, 0.05; P<.001). Increase in total tau at consolidation was associated with worse attention (omissions z score estimate, -0.20; P=.04). Glial injury may be present at diagnosis of ALL. Neuronal injury was associated with intrathecal chemotherapy. The CSF biomarkers may be useful in identifying individuals at risk for worse neurologic outcomes, particularly those with genetic susceptibility to poor brain function.",Journal Article,558.0,8.0,Little is known about treatment-related neurotoxic mechanisms in children with acute lymphoblastic ALL treated with chemotherapy only To examine concentration of cerebrospinal fluid CSF biomarkers of brain injury at ALL diagnosis and during cancer therapy and to evaluate associations with long-term neurocognitive and neuroimaging outcomes and relevant genetic polymorphisms This prospective cohort study included 235 patients with ALL who received a chemotherapy-only protocol Patients provided CSF samples after diagnosis and throughout treatment At 5 or more years after the diagnosis 138 69.7 of 198 eligible survivors participated in long-term follow-up assessments Children were treated from June 1 2000 through October 31 2010 Follow-up was completed on October 21 2014 and data were analyzed from August 1 2015 through September 30 2016 Plasma concentration of high-dose intravenous methotrexate sodium and number of triple intrathecal chemotherapy injections The CSF samples were assayed at 5 points from diagnosis to reinduction for biomarkers of myelin degradation myelin basic protein MBP neuronal damage nerve growth factor NGF and total and phosphorylated tau protein astrogliosis glial fibrillary acidic protein GFAP and neuroinflammation chitotriosidase DNA was genotyped for polymorphisms in drug metabolism oxidative stress and neurodevelopment Leukoencephalopathy was evaluated by brain imaging At 5 or more years after the diagnosis survivors completed neurocognitive testing and brain imaging of white matter integrity Among the 235 patients with CSF samples 120 boys 51.1 and 115 girls 48.9 mean SD age at diagnosis 6.8 4.7 years MBP and GFAP levels were elevated at baseline and through consolidation The number of intrathecal injections was positively correlated with NGF level increase at consolidation r 0.19 P .005 Increases in GFAP risk ratio RR 1.23 95 CI 1.09-1.40 MBP RR 1.06 95 CI 1.01-1.11 and total tau RR 1.76 95 CI 1.11-2.78 levels were associated with a higher risk for leukoencephalopathy and higher apparent diffusion coefficient in frontal lobe white matter 5 years after diagnosis standardized estimate 0.05 P .001 Increase in total tau at consolidation was associated with worse attention omissions z score estimate -0.20 P .04 Glial injury may be present at diagnosis of ALL Neuronal injury was associated with intrathecal chemotherapy The CSF biomarkers may be useful in identifying individuals at risk for worse neurologic outcomes particularly those with genetic susceptibility to poor brain function,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1215, 16, 440, 545, 24, 139, 11148, 483, 4, 541, 5, 286, 1275, 62, 73, 5, 56, 158, 6, 1004, 1227, 1, 5156, 2357, 1211, 582, 1, 342, 2730, 28, 62, 147, 2, 190, 12, 36, 2, 6, 376, 685, 5, 319, 337, 2958, 2, 7468, 123, 2, 867, 336, 1203, 26, 482, 180, 45, 159, 6465, 7, 5, 62, 54, 103, 8, 56, 158, 1182, 7, 1052, 1211, 347, 50, 147, 2, 2432, 24, 28, 33, 15, 80, 60, 50, 3, 147, 4478, 790, 67, 1, 6189, 625, 332, 3025, 4, 319, 337, 166, 126, 2182, 541, 11, 73, 29, 1924, 14, 1081, 298, 2551, 456, 1120, 166, 126, 10, 781, 23, 2551, 239, 1409, 2, 74, 11, 311, 29, 2480, 14, 1483, 298, 2636, 201, 1390, 554, 1227, 1, 64, 61, 1262, 2116, 4682, 2, 207, 1, 1500, 5126, 56, 4344, 3, 1211, 347, 11, 4499, 28, 33, 862, 29, 147, 6, 10177, 9, 582, 1, 23428, 2373, 23428, 2795, 178, 22106, 7020, 1350, 2476, 129, 161, 21502, 2, 181, 2, 2365, 8127, 178, 31461, 6944, 19106, 8961, 178, 13154, 2, 24169, 72463, 261, 10, 3053, 9, 1203, 4, 234, 1600, 3495, 1531, 2, 34105, 8744, 10, 194, 20, 342, 270, 28, 33, 15, 80, 60, 50, 3, 147, 332, 781, 2958, 471, 2, 342, 270, 1, 886, 5090, 4797, 107, 3, 6465, 7, 5, 1211, 347, 2031, 12958, 725, 14, 2, 3670, 5989, 576, 83, 313, 1270, 89, 28, 147, 49, 66, 39, 67, 60, 22106, 2, 13154, 148, 11, 804, 28, 330, 2, 298, 2173, 3, 207, 1, 5126, 4344, 10, 2375, 438, 5, 21502, 301, 344, 28, 2173, 668, 13, 326, 19, 1614, 1106, 4, 13154, 43, 197, 861, 14, 382, 48, 58, 14, 1730, 14, 327, 22106, 861, 14, 1460, 48, 58, 14, 355, 14, 175, 2, 181, 8127, 861, 14, 846, 48, 58, 14, 175, 18, 833, 148, 11, 41, 5, 8, 142, 43, 9, 8744, 2, 142, 2235, 3438, 3200, 4, 8082, 4940, 886, 5090, 33, 60, 50, 147, 1670, 1191, 13, 474, 19, 144, 344, 4, 181, 8127, 28, 2173, 10, 41, 5, 639, 2111, 28390, 3905, 368, 1191, 13, 179, 19, 755, 6944, 2730, 68, 40, 364, 28, 147, 1, 62, 7020, 2730, 10, 41, 5, 5126, 56, 3, 1211, 582, 68, 40, 999, 4, 1386, 869, 28, 43, 9, 639, 2543, 123, 823, 135, 5, 336, 1432, 6, 334, 342, 343]",2547.0,29596541,575
Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia.,Pediatric blood & cancer,Pediatr Blood Cancer,2018-03-30,"We sought to determine the feasibility of co-administering everolimus with a four-drug reinduction in children and adolescents with acute lymphoblastic leukemia (ALL) experiencing a first marrow relapse. This phase I study tested everolimus with vincristine, prednisone, pegaspargase and doxorubicin in patients with marrow relapse occurring >18 months after first complete remission (CR). The primary aim was to identify the maximum tolerated dose of everolimus. Three dose levels (DLs) were tested during dose escalation (2, 3, and 5mg/m<sup>2</sup> /day). Additional patients were enrolled at the 3- and 5mg/m<sup>2</sup> /day DLs to further evaluate toxicity (dose expansion). Thirteen patients enrolled during dose escalation and nine during dose expansion. During dose escalation, one dose-limiting toxicity occurred (grade 4 hyperbilirubinemia) in six evaluable patients at DL3 (5mg/m<sup>2</sup> /day). The most common grade 3 adverse events were febrile neutropenia, infections, transaminitis, hyperbilirubinemia, and hypophosphatemia. Two of the 12 patients treated at DL3 developed Rothia mucilaginosa meningitis. Nineteen patients (86%) achieved a second CR (CR2). Of those, 13 (68%) had a low end-reinduction minimal residual disease (MRD) level (10<sup>-3</sup> by polymerase chain reaction-based assay). The CR2 rate for patients with B-cell ALL treated at DL3 (n=12) was 92%; 82% of these patients had low MRD. Everolimus combined with four-drug reinduction chemotherapy was generally well tolerated and associated with favorable rates of CR2 and low end-reinduction MRD. The recommended phase 2 dose of everolimus given in combination with a four-drug reinduction is 5mg/m<sup>2</sup> /day. This promising combination should be further evaluated in a larger patient cohort.","Clinical Trial, Phase I",662.0,7.0,We sought to determine the feasibility of co-administering everolimus with a four-drug reinduction in children and adolescents with acute lymphoblastic ALL experiencing a first marrow relapse This phase I study tested everolimus with vincristine prednisone pegaspargase and doxorubicin in patients with marrow relapse occurring 18 months after first complete remission CR The primary aim was to identify the maximum tolerated dose of everolimus Three dose levels DLs were tested during dose escalation 2 3 and 5 mg/m sup 2 /sup /day Additional patients were enrolled at the 3- and 5 mg/m sup 2 /sup /day DLs to further evaluate toxicity dose expansion Thirteen patients enrolled during dose escalation and nine during dose expansion During dose escalation one dose-limiting toxicity occurred grade 4 hyperbilirubinemia in six evaluable patients at DL3 5 mg/m sup 2 /sup /day The most common grade 3 adverse events were febrile neutropenia infections transaminitis hyperbilirubinemia and hypophosphatemia Two of the 12 patients treated at DL3 developed Rothia mucilaginosa meningitis Nineteen patients 86 achieved a second CR CR2 Of those 13 68 had a low end-reinduction minimal residual disease MRD level 10 sup -3 /sup by polymerase chain reaction-based assay The CR2 rate for patients with B-cell ALL treated at DL3 n 12 was 92 82 of these patients had low MRD Everolimus combined with four-drug reinduction chemotherapy was generally well tolerated and associated with favorable rates of CR2 and low end-reinduction MRD The recommended phase 2 dose of everolimus given in combination with a four-drug reinduction is 5 mg/m sup 2 /sup /day This promising combination should be further evaluated in a larger patient cohort,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 990, 6, 223, 3, 1437, 1, 1269, 5776, 1400, 5, 8, 294, 234, 10177, 4, 541, 2, 3101, 5, 286, 1275, 62, 2985, 8, 157, 581, 429, 26, 124, 70, 45, 650, 1400, 5, 2132, 1979, 12209, 2, 856, 4, 7, 5, 581, 429, 1821, 203, 53, 50, 157, 236, 734, 684, 3, 86, 1130, 10, 6, 255, 3, 689, 421, 61, 1, 1400, 169, 61, 148, 15038, 11, 650, 190, 61, 1125, 18, 27, 2, 33, 81, 188, 172, 18, 172, 218, 402, 7, 11, 346, 28, 3, 27, 2, 33, 81, 188, 172, 18, 172, 218, 15038, 6, 195, 376, 155, 61, 1422, 3170, 7, 346, 190, 61, 1125, 2, 762, 190, 61, 1422, 190, 61, 1125, 104, 61, 817, 155, 489, 88, 39, 7236, 4, 437, 859, 7, 28, 20544, 33, 81, 188, 172, 18, 172, 218, 3, 96, 186, 88, 2608, 290, 281, 11, 2498, 778, 1875, 8181, 7236, 2, 8021, 100, 1, 3, 133, 7, 73, 28, 20544, 276, 72472, 72473, 10792, 3498, 7, 868, 513, 8, 419, 684, 7865, 1, 135, 233, 806, 42, 8, 154, 396, 10177, 1048, 753, 34, 2029, 301, 11209, 172, 27, 172, 20, 1451, 1260, 1329, 90, 719, 3, 7865, 116, 9, 7, 5, 132, 31, 62, 73, 28, 20544, 78, 133, 10, 937, 878, 1, 46, 7, 42, 154, 2029, 1400, 397, 5, 294, 234, 10177, 56, 10, 1228, 149, 421, 2, 41, 5, 913, 151, 1, 7865, 2, 154, 396, 10177, 2029, 3, 793, 124, 18, 61, 1, 1400, 447, 4, 150, 5, 8, 294, 234, 10177, 16, 33, 81, 188, 172, 18, 172, 218, 26, 721, 150, 257, 40, 195, 194, 4, 8, 1077, 69, 180]",1725.0,29603593,135
Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation.,Blood,Blood,2018-04-02,"Although survival outcomes have significantly improved, up to 40% of patients die within 1 year of HLA-matched unrelated-donor blood and marrow transplantation (BMT). To identify non-HLA genetic contributors to mortality after BMT, we performed the first exome-wide association study in the DISCOVeRY-BMT cohorts using the Illumina HumanExome BeadChip. This study includes 2473 patients with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome and 2221 10/10 HLA-matched donors treated from 2000 to 2011. Single-variant and gene-level analyses were performed on overall survival (OS), transplantation-related mortality (TRM), and disease-related mortality (DRM). Genotype mismatches between recipients and donors in a rare nonsynonymous variant of testis-expressed gene <i>TEX38</i> significantly increased risk of TRM, which was more dramatic when either the recipient or donor was female. Using the SKAT-O test to evaluate gene-level effects, variant genotypes of <i>OR51D1</i> in recipients were significantly associated with OS and TRM. In donors, 4 (<i>ALPP</i>, <i>EMID1</i>, <i>SLC44A5</i>, <i>LRP1</i>), 1 (<i>HHAT</i>), and 2 genes (<i>LYZL4</i>, <i>NT5E</i>) were significantly associated with OS, TRM, and DRM, respectively. Inspection of NT5E crystal structures showed 4 of the associated variants affected the enzyme structure and likely decreased the catalytic efficiency of the enzyme. Further confirmation of these findings and additional functional studies may provide individualized risk prediction and prognosis, as well as alternative donor selection strategies.",Journal Article,659.0,4.0,Although survival outcomes have significantly improved up to 40 of patients die within 1 year of HLA-matched unrelated-donor blood and marrow transplantation BMT To identify non-HLA genetic contributors to mortality after BMT we performed the first exome-wide association study in the DISCOVeRY-BMT cohorts using the Illumina HumanExome BeadChip This study includes 2473 patients with acute myeloid acute lymphoblastic or syndrome and 2221 10/10 HLA-matched donors treated from 2000 to 2011 Single-variant and gene-level analyses were performed on overall survival OS transplantation-related mortality TRM and disease-related mortality DRM Genotype mismatches between recipients and donors in a rare nonsynonymous variant of testis-expressed gene i TEX38 /i significantly increased risk of TRM which was more dramatic when either the recipient or donor was female Using the SKAT-O test to evaluate gene-level effects variant genotypes of i OR51D1 /i in recipients were significantly associated with OS and TRM In donors 4 i ALPP /i i EMID1 /i i SLC44A5 /i i LRP1 /i 1 i HHAT /i and 2 genes i LYZL4 /i i NT5E /i were significantly associated with OS TRM and DRM respectively Inspection of NT5E crystal structures showed 4 of the associated variants affected the enzyme structure and likely decreased the catalytic efficiency of the enzyme Further confirmation of these findings and additional functional studies may provide individualized risk prediction and prognosis as well as alternative donor selection strategies,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 25, 123, 47, 97, 231, 126, 6, 327, 1, 7, 3384, 262, 14, 111, 1, 1160, 655, 2092, 1488, 315, 2, 581, 497, 4611, 6, 255, 220, 1160, 336, 9680, 6, 282, 50, 4611, 21, 173, 3, 157, 2865, 1019, 248, 45, 4, 3, 1574, 4611, 736, 75, 3, 7457, 72501, 16111, 26, 45, 1920, 39392, 7, 5, 286, 533, 286, 1275, 15, 681, 2, 72502, 79, 79, 1160, 655, 2344, 73, 29, 1081, 6, 1132, 226, 1142, 2, 145, 301, 318, 11, 173, 23, 63, 25, 118, 497, 139, 282, 5064, 2, 34, 139, 282, 26786, 1183, 11828, 59, 2190, 2, 2344, 4, 8, 622, 10233, 1142, 1, 7697, 570, 145, 70, 72503, 70, 97, 101, 43, 1, 5064, 92, 10, 80, 3079, 198, 361, 3, 5783, 15, 1488, 10, 1061, 75, 3, 36265, 1990, 412, 6, 376, 145, 301, 176, 1142, 2071, 1, 70, 72504, 70, 4, 2190, 11, 97, 41, 5, 118, 2, 5064, 4, 2344, 39, 70, 72505, 70, 70, 72506, 70, 70, 72507, 70, 70, 16997, 70, 14, 70, 72508, 70, 2, 18, 214, 70, 72509, 70, 70, 50975, 70, 11, 97, 41, 5, 118, 5064, 2, 26786, 106, 11746, 1, 50975, 9197, 2414, 224, 39, 1, 3, 41, 839, 1424, 3, 1644, 2772, 2, 322, 340, 3, 4784, 2904, 1, 3, 1644, 195, 3551, 1, 46, 272, 2, 402, 583, 94, 68, 377, 2596, 43, 1590, 2, 356, 22, 149, 22, 1091, 1488, 881, 422]",1517.0,29610366,577
"""Society of Hematologic Oncology (SOHO) State of the Art Updates and Next Questions""-Treatment of ALL.","Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2018-04-03,"The outcome of adult acute lymphoblastic leukemia (ALL) has substantially improved by adopting pediatric-inspired regimens, and approximately half of the patients are nowadays cured. The evaluation of minimal residual disease currently represents the most important prognostic indicator, which drives treatment algorithms, which include allogeneic stem cell transplantation (allo-SCT) allocation. Indeed, for high-risk patients, allo-SCT should be pursued as soon as possible, whereas in standard-risk patients this procedure should be avoided also in light of related toxicity and because there are no significant benefits. Furthermore, better characterization of the molecular genetic events can drive therapeutic decisions: a historical example in this respect is represented by the use of tyrosine kinase inhibitors (TKIs) in Philadelphia chromosome-positive ALL; in the upcoming future, TKIs might be used also in other subgroups, such as breakpoint cluster region/Abelson 1-like cases and others with deregulated tyrosine kinases. Finally, the greatest progress is currently achieved with new immunotherapies targeting frequently expressed surface antigens in ALL. It is also a new chance for elderly ALL patients, so far spared from intensive chemotherapy and allo-SCT. These targeted therapies will substantially change this treatment algorithm and the great challenge is to find optimal sequence of the extended therapy options in an individual patient.",Journal Article,658.0,3.0,The outcome of adult acute lymphoblastic ALL has substantially improved by adopting pediatric-inspired regimens and approximately half of the patients are nowadays cured The evaluation of minimal residual disease currently represents the most important prognostic indicator which drives treatment algorithms which include allogeneic stem cell transplantation allo-SCT allocation Indeed for high-risk patients allo-SCT should be pursued as soon as possible whereas in standard-risk patients this procedure should be avoided also in light of related toxicity and because there are no significant benefits Furthermore better characterization of the molecular genetic events can drive therapeutic decisions a historical example in this respect is represented by the use of tyrosine kinase inhibitors TKIs in Philadelphia chromosome-positive ALL in the upcoming future TKIs might be used also in other subgroups such as breakpoint cluster region/Abelson 1-like cases and others with deregulated tyrosine kinases Finally the greatest progress is currently achieved with new immunotherapies targeting frequently expressed surface antigens in ALL It is also a new chance for elderly ALL patients so far spared from intensive chemotherapy and allo-SCT These targeted therapies will substantially change this treatment algorithm and the great challenge is to find optimal sequence of the extended therapy options in an individual patient,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 228, 1, 780, 286, 1275, 62, 71, 2109, 231, 20, 10096, 815, 13161, 472, 2, 705, 1303, 1, 3, 7, 32, 26629, 3733, 3, 451, 1, 1048, 753, 34, 694, 1449, 3, 96, 305, 177, 3287, 92, 5267, 24, 3529, 92, 643, 1063, 452, 31, 497, 2564, 1988, 6834, 4462, 9, 64, 43, 7, 2564, 1988, 257, 40, 5299, 22, 6176, 22, 899, 547, 4, 260, 43, 7, 26, 1299, 257, 40, 5617, 120, 4, 1691, 1, 139, 155, 2, 408, 125, 32, 77, 93, 1141, 798, 380, 2136, 1, 3, 219, 336, 281, 122, 3279, 189, 1526, 8, 2252, 2685, 4, 26, 2184, 16, 3324, 20, 3, 119, 1, 564, 216, 222, 1671, 4, 3006, 1170, 109, 62, 4, 3, 11974, 508, 1671, 822, 40, 95, 120, 4, 127, 1453, 225, 22, 8567, 3132, 1053, 16881, 14, 733, 140, 2, 1749, 5, 5415, 564, 1549, 1368, 3, 2199, 1466, 16, 694, 513, 5, 217, 2811, 529, 746, 570, 1255, 1575, 4, 62, 192, 16, 120, 8, 217, 3477, 9, 1216, 62, 7, 1743, 3272, 6830, 29, 1686, 56, 2, 2564, 1988, 46, 238, 235, 303, 2109, 707, 26, 24, 2124, 2, 3, 2797, 1745, 16, 6, 2469, 665, 1532, 1, 3, 1747, 36, 838, 4, 35, 797, 69]",1427.0,29653823,175
Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia.,Cancer cell,Cancer Cell,2018-04-19,"Somatic genetic alterations of IKZF1, which encodes the lymphoid transcription factor IKAROS, are common in high-risk B-progenitor acute lymphoblastic leukemia (ALL) and are associated with poor prognosis. Such alterations result in the acquisition of stem cell-like features, overexpression of adhesion molecules causing aberrant cell-cell and cell-stroma interaction, and decreased sensitivity to tyrosine kinase inhibitors. Here we report coding germline IKZF1 variation in familial childhood ALL and 0.9% of presumed sporadic B-ALL, identifying 28 unique variants in 45 children. The majority of variants adversely affected IKZF1 function and drug responsiveness of leukemic cells. These results identify IKZF1 as a leukemia predisposition gene, and emphasize the importance of germline genetic variation in the development of both familial and sporadic ALL.",Journal Article,642.0,28.0,Somatic genetic alterations of IKZF1 which encodes the lymphoid transcription factor IKAROS are common in high-risk B-progenitor acute lymphoblastic ALL and are associated with poor prognosis Such alterations result in the acquisition of stem cell-like features overexpression of adhesion molecules causing aberrant cell-cell and cell-stroma interaction and decreased sensitivity to tyrosine kinase inhibitors Here we report coding germline IKZF1 variation in familial childhood ALL and 0.9 of presumed sporadic B-ALL identifying 28 unique variants in 45 children The majority of variants adversely affected IKZF1 function and drug responsiveness of leukemic cells These results identify IKZF1 as a predisposition gene and emphasize the importance of germline genetic variation in the development of both familial and sporadic ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1119, 336, 593, 1, 8422, 92, 4322, 3, 2303, 866, 161, 20613, 32, 186, 4, 64, 43, 132, 2520, 286, 1275, 62, 2, 32, 41, 5, 334, 356, 225, 593, 757, 4, 3, 3405, 1, 452, 31, 733, 404, 851, 1, 2128, 1598, 3440, 1898, 31, 31, 2, 31, 2477, 915, 2, 340, 485, 6, 564, 216, 222, 467, 21, 414, 3097, 1009, 8422, 1380, 4, 2200, 864, 62, 2, 13, 83, 1, 5472, 1928, 132, 62, 1386, 339, 991, 839, 4, 512, 541, 3, 686, 1, 839, 4311, 1424, 8422, 343, 2, 234, 3642, 1, 2015, 37, 46, 99, 255, 8422, 22, 8, 2863, 145, 2, 5560, 3, 1187, 1, 1009, 336, 1380, 4, 3, 193, 1, 110, 2200, 2, 1928, 62]",830.0,29681510,92
"First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.",Journal of hematology & oncology,J Hematol Oncol,2018-05-02,"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9-13months. Pediatric patients are exceedingly rare with an unclear clinical course. Currently, no standardized therapy has been established, although an acute lymphoblastic leukemia type of treatment appears to be more effective in those patients who are able to tolerate aggressive chemotherapy. SL-401 is a targeted therapy directed to CD123, a protein ubiquitously expressed at high level on the surface of BPDCN blasts. In adult phase 2 trials, it has demonstrated efficacy with 90% overall response rate. No pediatric patients with BPDCN using SL-401 have been reported. Here, we report the first pediatric experience of three children with BPDCN treated with SL-401 at our institution. All patients tolerated SL-401 without significant toxicities. One patient with multiply relapsed and refractory disease had no response. The other two cases had significant and rapid clinical improvement after the two courses of treatment. However, the response was transient, and growth of soft tissue mass was observed in-between cycles in both patients with large tumor burden. This is the first report of SL-401 in pediatric patients with BPDCN. Sl-401 was well tolerated and can produce a promising response. Further testing this agent in children is warranted.",Case Reports,629.0,10.0,Blastic plasmacytoid dendritic cell neoplasm BPDCN is a highly aggressive hematological malignancy with extremely poor outcome The median overall survival for adult patients is 9-13 months Pediatric patients are exceedingly rare with an unclear clinical course Currently no standardized therapy has been established although an acute lymphoblastic type of treatment appears to be more effective in those patients who are able to tolerate aggressive chemotherapy SL-401 is a targeted therapy directed to CD123 a protein ubiquitously expressed at high level on the surface of BPDCN blasts In adult phase 2 trials it has demonstrated efficacy with 90 overall response rate No pediatric patients with BPDCN using SL-401 have been reported Here we report the first pediatric experience of three children with BPDCN treated with SL-401 at our institution All patients tolerated SL-401 without significant toxicities One patient with multiply relapsed and refractory disease had no response The other two cases had significant and rapid clinical improvement after the two courses of treatment However the response was transient and growth of soft tissue mass was observed in-between cycles in both patients with large tumor burden This is the first report of SL-401 in pediatric patients with BPDCN Sl-401 was well tolerated and can produce a promising response Further testing this agent in children is warranted,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6529, 7978, 2464, 31, 2131, 8556, 16, 8, 561, 571, 2890, 710, 5, 2938, 334, 228, 3, 52, 63, 25, 9, 780, 7, 16, 83, 233, 53, 815, 7, 32, 10303, 622, 5, 35, 1200, 38, 906, 694, 77, 1670, 36, 71, 85, 635, 242, 35, 286, 1275, 267, 1, 24, 1233, 6, 40, 80, 323, 4, 135, 7, 54, 32, 1665, 6, 5010, 571, 56, 6570, 7191, 16, 8, 238, 36, 1166, 6, 8849, 8, 178, 11156, 570, 28, 64, 301, 23, 3, 1255, 1, 8556, 2438, 4, 780, 124, 18, 143, 192, 71, 264, 209, 5, 424, 63, 51, 116, 77, 815, 7, 5, 8556, 75, 6570, 7191, 47, 85, 210, 467, 21, 414, 3, 157, 815, 730, 1, 169, 541, 5, 8556, 73, 5, 6570, 7191, 28, 114, 731, 62, 7, 421, 6570, 7191, 187, 93, 385, 104, 69, 5, 14421, 591, 2, 430, 34, 42, 77, 51, 3, 127, 100, 140, 42, 93, 2, 1321, 38, 767, 50, 3, 100, 1993, 1, 24, 137, 3, 51, 10, 2473, 2, 129, 1, 1214, 246, 782, 10, 164, 4, 59, 410, 4, 110, 7, 5, 375, 30, 892, 26, 16, 3, 157, 414, 1, 6570, 7191, 4, 815, 7, 5, 8556, 6570, 7191, 10, 149, 421, 2, 122, 2410, 8, 721, 51, 195, 471, 26, 420, 4, 541, 16, 1197]",1406.0,29720227,265
Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study.,Leukemia,Leukemia,2018-03-15,"The survival of pediatric patients with multiply relapsed and/or refractory (R/R) B-cell acute lymphoblastic leukemia has historically been very poor; however, data are limited in the current era. We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013. Patient information, treatment, and response were collected. Prognostic factors influencing the complete remission (CR) rate and event-free survival (EFS) were analyzed. The analytic set included 578 salvage treatment attempts among 325 patients. CR rates (meanSE) were 514% for patients with bone marrow R/R B-ALL who underwent a second salvage attempt, 376% for a third attempt, and 316% for the fourth through eighth attempts combined. For patients achieving a CR after their second, third, and fourth through eighth attempts, the 2 year EFS was 416%, 137%, and 2713% respectively. Our results showed slight improvement when compared to previous studies. This is the largest and most recent study to date that evaluates the outcome of this patient population. Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL.",Journal Article,677.0,7.0,The survival of pediatric patients with multiply relapsed and/or refractory R/R B-cell acute lymphoblastic has historically been very poor however data are limited in the current era We conducted a retrospective study to determine the outcome of multiply R/R childhood B-ALL treated at 24 TACL institutions between 2005 and 2013 Patient information treatment and response were collected Prognostic factors influencing the complete remission CR rate and event-free survival EFS were analyzed The analytic set included 578 salvage treatment attempts among 325 patients CR rates mean  SE were 51  4 for patients with marrow R/R B-ALL who underwent a second salvage attempt 37  6 for a third attempt and 31  6 for the fourth through eighth attempts combined For patients achieving a CR after their second third and fourth through eighth attempts the 2 year EFS was 41  6 13  7 and 27  13 respectively Our results showed slight improvement when compared to previous studies This is the largest and most recent study to date that evaluates the outcome of this patient population Our data will provide detailed reference for the evaluation of new agents being developed for childhood B-ALL,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 25, 1, 815, 7, 5, 14421, 591, 2, 15, 430, 668, 668, 132, 31, 286, 1275, 71, 3578, 85, 923, 334, 137, 74, 32, 383, 4, 3, 291, 1713, 21, 426, 8, 459, 45, 6, 223, 3, 228, 1, 14421, 668, 668, 864, 132, 62, 73, 28, 259, 72710, 1764, 59, 1242, 2, 1346, 69, 487, 24, 2, 51, 11, 786, 177, 130, 4743, 3, 236, 734, 684, 116, 2, 774, 115, 25, 1683, 11, 311, 3, 5146, 916, 159, 10431, 992, 24, 4374, 107, 7139, 7, 684, 151, 313, 810, 3428, 11, 725, 810, 39, 9, 7, 5, 581, 668, 668, 132, 62, 54, 208, 8, 419, 992, 3448, 567, 810, 49, 9, 8, 1282, 3448, 2, 456, 810, 49, 9, 3, 3608, 298, 7732, 4374, 397, 9, 7, 1785, 8, 684, 50, 136, 419, 1282, 2, 3608, 298, 7732, 4374, 3, 18, 111, 1683, 10, 605, 810, 49, 233, 810, 67, 2, 428, 810, 233, 106, 114, 99, 224, 8041, 767, 198, 72, 6, 698, 94, 26, 16, 3, 2166, 2, 96, 435, 45, 6, 1244, 17, 4941, 3, 228, 1, 26, 69, 266, 114, 74, 303, 377, 2455, 2482, 9, 3, 451, 1, 217, 183, 486, 276, 9, 864, 132, 62]",1189.0,29728694,772
Graft-versus-host disease in recipients of male unrelated donor compared with parous female sibling donor transplants.,Blood advances,Blood Adv,2018-05-01,"Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation (HCT). Donor sex and parity are well-established risk factors for graft-versus-host disease (GVHD), with male donors typically associated with lower rates of GVHD. Well-matched unrelated donors (URDs) have also been associated with increased risks of GVHD as compared with matched sibling donors. These observations raise the question of whether male URDs would lead to more (or less) favorable transplant outcomes as compared with parous female sibling donors. We used the Center for International Blood and Marrow Transplant Research registry to complete a retrospective cohort study in adults with acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndrome, who underwent T-cell replete HCT from these 2 donor types (parous female sibling or male URD) between 2000 and 2012. Primary outcomes included grade 2 to 4 acute GVHD (aGVHD), chronic GVHD (cGVHD), and overall survival. Secondary outcomes included disease-free survival, transplant-related mortality, and relapse. In 2813 recipients, patients receiving male URD transplants (n = 1921) had 1.6 times higher risk of grade 2 to 4 aGVHD (<i>P</i> < .0001). For cGVHD, recipient sex was a significant factor, so donor/recipient pairs were evaluated. Female recipients of male URD grafts had a higher risk of cGVHD than those receiving parous female sibling grafts (relative risk [RR] = 1.43, <i>P</i> < .0001), whereas male recipients had similar rates of cGVHD regardless of donor type (RR = 1.09, <i>P</i> = .23). Donor type did not significantly affect any other end point. We conclude that when available, parous female siblings are preferred over male URDs.",Clinical Trial,630.0,2.0,Optimal donor selection is critical for successful allogeneic hematopoietic cell transplantation HCT Donor sex and parity are well-established risk factors for graft-versus-host disease GVHD with male donors typically associated with lower rates of GVHD Well-matched unrelated donors URDs have also been associated with increased risks of GVHD as compared with matched sibling donors These observations raise the question of whether male URDs would lead to more or less favorable transplant outcomes as compared with parous female sibling donors We used the Center for International Blood and Marrow Transplant Research registry to complete a retrospective cohort study in adults with acute myeloid acute lymphoblastic or syndrome who underwent T-cell replete HCT from these 2 donor types parous female sibling or male URD between 2000 and 2012 Primary outcomes included grade 2 to 4 acute GVHD aGVHD chronic GVHD cGVHD and overall survival Secondary outcomes included disease-free survival transplant-related mortality and relapse In 2813 recipients patients receiving male URD transplants n 1921 had 1.6 times higher risk of grade 2 to 4 aGVHD i P /i .0001 For cGVHD recipient sex was a significant factor so donor/recipient pairs were evaluated Female recipients of male URD grafts had a higher risk of cGVHD than those receiving parous female sibling grafts relative risk RR 1.43 i P /i .0001 whereas male recipients had similar rates of cGVHD regardless of donor type RR 1.09 i P /i .23 Donor type did not significantly affect any other end point We conclude that when available parous female siblings are preferred over male URDs,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[665, 1488, 881, 16, 740, 9, 1401, 1063, 1007, 31, 497, 1085, 1488, 1035, 2, 5754, 32, 149, 635, 43, 130, 9, 1599, 185, 1204, 34, 1562, 5, 1045, 2344, 1969, 41, 5, 280, 151, 1, 1562, 149, 655, 2092, 2344, 15979, 47, 120, 85, 41, 5, 101, 1098, 1, 1562, 22, 72, 5, 655, 3684, 2344, 46, 2172, 5008, 3, 2840, 1, 317, 1045, 15979, 688, 1122, 6, 80, 15, 299, 913, 941, 123, 22, 72, 5, 10191, 1061, 3684, 2344, 21, 95, 3, 574, 9, 944, 315, 2, 581, 941, 389, 1608, 6, 236, 8, 459, 180, 45, 4, 857, 5, 286, 533, 286, 1275, 15, 681, 54, 208, 102, 31, 11151, 1085, 29, 46, 18, 1488, 630, 10191, 1061, 3684, 15, 1045, 5847, 59, 1081, 2, 1195, 86, 123, 159, 88, 18, 6, 39, 286, 1562, 5873, 442, 1562, 6670, 2, 63, 25, 568, 123, 159, 34, 115, 25, 941, 139, 282, 2, 429, 4, 72725, 2190, 7, 357, 1045, 5847, 4016, 78, 49670, 42, 14, 49, 1072, 142, 43, 1, 88, 18, 6, 39, 5873, 70, 19, 70, 488, 9, 6670, 5783, 1035, 10, 8, 93, 161, 1743, 1488, 5783, 2773, 11, 194, 1061, 2190, 1, 1045, 5847, 4713, 42, 8, 142, 43, 1, 6670, 76, 135, 357, 10191, 1061, 3684, 4713, 580, 43, 861, 14, 601, 70, 19, 70, 488, 547, 1045, 2190, 42, 288, 151, 1, 6670, 1583, 1, 1488, 267, 861, 14, 1730, 70, 19, 70, 382, 1488, 267, 205, 44, 97, 1158, 500, 127, 396, 741, 21, 2060, 17, 198, 390, 10191, 1061, 2758, 32, 2514, 252, 1045, 15979]",1635.0,29739773,790
Management of acute lymphoblastic leukemia in young adults.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2018-02-01,"Substantial interest in acute lymphoblastic leukemia (ALL) in young adults (YAs) and investigations focused on this patient population have resulted in therapeutic advancements that are changing the management paradigm and improving outcomes. The pediatric ALL approach is feasible and effective when administered by medical oncologists. Advanced diagnostics and minimal residual disease measurements aid in prognostication and have resulted in shifting recommendations regarding allogeneic hematopoietic cell transplant in first remission. Blinatumomab, inotuzumab, and chimeric antigen receptor T-cell therapies are transforming the treatment of relapsed/refractory ALL. This comprehensive review of the current management of ALL in YAs summarizes recent scientific developments and clinical trial findings related to ALL biology, frontline management approaches, novel therapies, and supportive care specific to this patient population. Finally, a practical guide to modern YA management for practicing clinicians is provided.",Journal Article,719.0,3.0,Substantial interest in acute lymphoblastic ALL in young adults YAs and investigations focused on this patient population have resulted in therapeutic advancements that are changing the management paradigm and improving outcomes The pediatric ALL approach is feasible and effective when administered by medical oncologists Advanced diagnostics and minimal residual disease measurements aid in prognostication and have resulted in shifting recommendations regarding allogeneic hematopoietic cell transplant in first remission Blinatumomab inotuzumab and chimeric antigen receptor T-cell therapies are transforming the treatment of relapsed/refractory ALL This comprehensive review of the current management of ALL in YAs summarizes recent scientific developments and clinical trial findings related to ALL biology frontline management approaches novel therapies and supportive care specific to this patient population Finally a practical guide to modern YA management for practicing clinicians is provided,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1281, 1333, 4, 286, 1275, 62, 4, 1169, 857, 51053, 2, 2492, 1649, 23, 26, 69, 266, 47, 627, 4, 189, 6217, 17, 32, 3600, 3, 284, 2431, 2, 1673, 123, 3, 815, 62, 353, 16, 1313, 2, 323, 198, 468, 20, 484, 1339, 131, 5197, 2, 1048, 753, 34, 1685, 2427, 4, 4260, 2, 47, 627, 4, 8964, 883, 666, 1063, 1007, 31, 941, 4, 157, 734, 7182, 6730, 2, 2897, 448, 153, 102, 31, 235, 32, 3621, 3, 24, 1, 591, 430, 62, 26, 949, 206, 1, 3, 291, 284, 1, 62, 4, 51053, 2869, 435, 3138, 3703, 2, 38, 160, 272, 139, 6, 62, 891, 3171, 284, 611, 229, 235, 2, 1877, 165, 112, 6, 26, 69, 266, 1368, 8, 3320, 1597, 6, 2366, 38050, 284, 9, 6734, 1490, 16, 1052]",1004.0,29741514,483
Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2018-03-01,"Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) accounts for approximately one-fourth of cases of adult ALL. It typically presents with an aggressive clinical course, responds poorly to standard chemotherapy, and carries a high risk for relapse. The landscape of Ph+ ALL therapy has changed favorably since the development of tyrosine kinase inhibitors (TKIs). With the successful incorporation of TKIs into chemotherapy regimens, remissions occur more frequently and patients live longer. Imatinib was the first TKI that targeted the BCR-ABL1 oncoprotein in Ph+ ALL. Since then, nilotinib, dasatinib, bosutinib, and ponatinib have been developed. Despite the significant progress that has been made in inducing remission, frequent relapses remain a challenge, especially among those with resistant BCR-ABL1 mutations. Still, the therapeutic armamentarium of ALL therapy is expanding at a breathtaking pace today compared with a decade ago. Novel drugs, such as potent later-generation TKIs, antibody-drug conjugates, bispecific monoclonal antibodies, and chimeric antigen receptor T-cell therapies, are being developed and investigated in patients with Ph+ ALL. In this review, we summarize the current treatment options for Ph+ ALL and highlight the therapies that may become the standard of care in the near future.",Journal Article,691.0,7.0,Philadelphia chromosome-positive Ph+ acute lymphoblastic ALL accounts for approximately one-fourth of cases of adult ALL It typically presents with an aggressive clinical course responds poorly to standard chemotherapy and carries a high risk for relapse The landscape of Ph+ ALL therapy has changed favorably since the development of tyrosine kinase inhibitors TKIs With the successful incorporation of TKIs into chemotherapy regimens remissions occur more frequently and patients live longer Imatinib was the first TKI that targeted the BCR-ABL1 oncoprotein in Ph+ ALL Since then nilotinib dasatinib bosutinib and ponatinib have been developed Despite the significant progress that has been made in inducing remission frequent relapses remain a challenge especially among those with resistant BCR-ABL1 mutations Still the therapeutic armamentarium of ALL therapy is expanding at a breathtaking pace today compared with a decade ago Novel drugs such as potent later-generation TKIs antibody-drug conjugates bispecific monoclonal antibodies and chimeric antigen receptor T-cell therapies are being developed and investigated in patients with Ph+ ALL In this review we summarize the current treatment options for Ph+ ALL and highlight the therapies that may become the standard of care in the near future,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 109, 2058, 286, 1275, 62, 4162, 9, 705, 104, 3608, 1, 140, 1, 780, 62, 192, 1969, 2740, 5, 35, 571, 38, 906, 7920, 1240, 6, 260, 56, 2, 4942, 8, 64, 43, 9, 429, 3, 2801, 1, 2058, 62, 36, 71, 2368, 5001, 1192, 3, 193, 1, 564, 216, 222, 1671, 5, 3, 1401, 2838, 1, 1671, 237, 56, 472, 3166, 1271, 80, 746, 2, 7, 3812, 589, 577, 10, 3, 157, 1379, 17, 238, 3, 1062, 3557, 6159, 4, 2058, 62, 1192, 818, 2638, 1674, 5936, 2, 5715, 47, 85, 276, 550, 3, 93, 1466, 17, 71, 85, 1229, 4, 1958, 734, 908, 3713, 918, 8, 1745, 1093, 107, 135, 5, 436, 1062, 3557, 138, 1234, 3, 189, 5543, 1, 62, 36, 16, 4304, 28, 8, 72732, 7265, 5665, 72, 5, 8, 2025, 5028, 229, 600, 225, 22, 1157, 1559, 914, 1671, 548, 234, 5968, 7408, 848, 890, 2, 2897, 448, 153, 102, 31, 235, 32, 486, 276, 2, 565, 4, 7, 5, 2058, 62, 4, 26, 206, 21, 2479, 3, 291, 24, 838, 9, 2058, 62, 2, 1817, 3, 235, 17, 68, 1417, 3, 260, 1, 165, 4, 3, 1829, 508]",1303.0,29742077,615
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System.,Cell reports,Cell Rep,2018-05-01,"Chimeric antigen receptor (CAR) Tcell therapy has proven clinically beneficial against B cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma. However, suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR Tcells, antigen-negative relapses, and impairment by an immunosuppressive tumor microenvironment. Improvements in CAR Tcell design are required to enhance clinical efficacy, as well as broaden the applicability of this technology. Here, we demonstrate that interleukin-18 (IL-18)-secreting CAR Tcells exhibit enhanced invivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematological and solid malignancies. In addition, we demonstrate that IL-18-secreting CAR Tcells are capable of modulating the tumor microenvironment, as well as enhancing an effective endogenous anti-tumor immune response. IL-18-secreting CAR Tcells represent a promising strategy to enhance the clinical outcomes of adoptive Tcell therapy.",Journal Article,630.0,38.0,Chimeric antigen receptor CAR T cell therapy has proven clinically beneficial against B cell acute lymphoblastic and 's However suboptimal clinical outcomes have been associated with decreased expansion and persistence of adoptively transferred CAR T cells antigen-negative relapses and impairment by an immunosuppressive tumor microenvironment Improvements in CAR T cell design are required to enhance clinical efficacy as well as broaden the applicability of this technology Here we demonstrate that interleukin-18 IL-18 -secreting CAR T cells exhibit enhanced in vivo expansion and persistence and significantly increase long-term survival in syngeneic mouse models of both hematological and solid malignancies In addition we demonstrate that IL-18-secreting CAR T cells are capable of modulating the tumor microenvironment as well as enhancing an effective endogenous anti-tumor immune response IL-18-secreting CAR T cells represent a promising strategy to enhance the clinical outcomes of adoptive T cell therapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2897, 448, 153, 1881, 102, 31, 36, 71, 1930, 505, 2524, 480, 132, 31, 286, 1275, 2, 292, 137, 3291, 38, 123, 47, 85, 41, 5, 340, 1422, 2, 4108, 1, 8269, 4747, 1881, 102, 37, 448, 199, 3713, 2, 2315, 20, 35, 2989, 30, 995, 1474, 4, 1881, 102, 31, 771, 32, 616, 6, 1304, 38, 209, 22, 149, 22, 12338, 3, 5412, 1, 26, 2033, 467, 21, 608, 17, 1603, 203, 501, 203, 5052, 1881, 102, 37, 2239, 651, 4, 386, 1422, 2, 4108, 2, 97, 344, 319, 337, 25, 4, 5174, 830, 274, 1, 110, 2890, 2, 537, 441, 4, 352, 21, 608, 17, 501, 203, 5052, 1881, 102, 37, 32, 2787, 1, 3712, 3, 30, 995, 22, 149, 22, 2430, 35, 323, 2682, 312, 30, 250, 51, 501, 203, 5052, 1881, 102, 37, 1231, 8, 721, 692, 6, 1304, 3, 38, 123, 1, 3159, 102, 31, 36]",1017.0,29768210,591
"Child symptoms, parent behaviors, and family strain in long-term survivors of childhood acute lymphoblastic leukemia.",Psycho-oncology,Psychooncology,2018-06-29,"How family environment and parental factors affect health status and symptoms in childhood cancer survivors is understudied. We examined the influence of family cohesion, parent distress, and overprotection on child symptom burden and health-related quality of life (HRQOL) and family strain in survivors of childhood acute lymphoblastic leukemia. Parents of 213 children treated with chemotherapy only completed a survey when survivors were at least 5-year postdiagnosis. Family Environment Scale, Brief Symptom Inventory-18, Parent Protection Scale, Pediatric Quality of Life Inventory, and Impact on Family were used to assess family cohesion, parental distress, overprotection, child symptom burden and HRQOL, and family strain, respectively. Path analysis was conducted to quantify effects of family cohesion on family strain through parental distress, overprotection, child symptoms, and HRQOL. Lower family cohesion (=0.06, 95% CI, 0.01-0.13), higher parental distress (=0.35, 95% CI, 0.20-0.45), and overprotection (=0.17, 95% CI, 0.01-0.32) were associated with more child symptom burden. More symptom burden were associated with poorer child HRQOL (=0.66, 95% CI, 0.57-0.75), which in turn was associated with more family strain (=0.11, 95% CI, 0.01-0.22). Lower maternal education was associated with overprotection (=-0.23, 95% CI, -0.33 to -0.12), more child symptoms (=-0.30, 95% CI, -0.41 to -0.16), poorer child HRQOL (=-0.36, 95% CI, -0.46 to -0.21), and more family strain (=-0.15, 95% CI, -0.23 to -0.08). Family and parental factors contributed to health outcomes of childhood acute lymphoblastic leukemia survivors. Interventions to enhance family cohesion, decrease parental distress and overprotection, and ameliorate child symptoms may improve family functioning.",Journal Article,571.0,1.0,How family environment and parental factors affect health status and symptoms in childhood cancer survivors is understudied We examined the influence of family cohesion parent distress and overprotection on child symptom burden and health-related quality of life HRQOL and family strain in survivors of childhood acute lymphoblastic Parents of 213 children treated with chemotherapy only completed a survey when survivors were at least 5-year postdiagnosis Family Environment Scale Brief Symptom Inventory-18 Parent Protection Scale Pediatric Quality of Life Inventory and Impact on Family were used to assess family cohesion parental distress overprotection child symptom burden and HRQOL and family strain respectively Path analysis was conducted to quantify effects of family cohesion on family strain through parental distress overprotection child symptoms and HRQOL Lower family cohesion 0.06 95 CI 0.01-0.13 higher parental distress 0.35 95 CI 0.20-0.45 and overprotection 0.17 95 CI 0.01-0.32 were associated with more child symptom burden More symptom burden were associated with poorer child HRQOL 0.66 95 CI 0.57-0.75 which in turn was associated with more family strain 0.11 95 CI 0.01-0.22 Lower maternal education was associated with overprotection -0.23 95 CI -0.33 to -0.12 more child symptoms -0.30 95 CI -0.41 to -0.16 poorer child HRQOL -0.36 95 CI -0.46 to -0.21 and more family strain -0.15 95 CI -0.23 to -0.08 Family and parental factors contributed to health outcomes of childhood acute lymphoblastic survivors Interventions to enhance family cohesion decrease parental distress and overprotection and ameliorate child symptoms may improve family functioning,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[832, 607, 3087, 2, 3418, 130, 1158, 341, 156, 2, 507, 4, 864, 12, 332, 16, 8207, 21, 409, 3, 1054, 1, 607, 23891, 3841, 1462, 2, 23009, 23, 2566, 934, 892, 2, 341, 139, 372, 1, 358, 2534, 2, 607, 5041, 4, 332, 1, 864, 286, 1275, 2418, 1, 5833, 541, 73, 5, 56, 158, 781, 8, 1407, 198, 332, 11, 28, 506, 33, 111, 7163, 607, 3087, 1124, 3190, 934, 3818, 203, 3841, 3525, 1124, 815, 372, 1, 358, 3818, 2, 345, 23, 607, 11, 95, 6, 423, 607, 23891, 3418, 1462, 23009, 2566, 934, 892, 2, 2534, 2, 607, 5041, 106, 6361, 65, 10, 426, 6, 3091, 176, 1, 607, 23891, 23, 607, 5041, 298, 3418, 1462, 23009, 2566, 507, 2, 2534, 280, 607, 23891, 13, 1460, 48, 58, 13, 355, 13, 233, 142, 3418, 1462, 13, 465, 48, 58, 13, 179, 13, 512, 2, 23009, 13, 269, 48, 58, 13, 355, 13, 531, 11, 41, 5, 80, 2566, 934, 892, 80, 934, 892, 11, 41, 5, 1769, 2566, 2534, 13, 700, 48, 58, 13, 696, 13, 481, 92, 4, 3854, 10, 41, 5, 80, 607, 5041, 13, 175, 48, 58, 13, 355, 13, 350, 280, 6039, 1848, 10, 41, 5, 23009, 13, 382, 48, 58, 13, 466, 6, 13, 133, 80, 2566, 507, 13, 201, 48, 58, 13, 605, 6, 13, 245, 1769, 2566, 2534, 13, 511, 48, 58, 13, 641, 6, 13, 239, 2, 80, 607, 5041, 13, 167, 48, 58, 13, 382, 6, 13, 1592, 607, 2, 3418, 130, 3447, 6, 341, 123, 1, 864, 286, 1275, 332, 1151, 6, 1304, 607, 23891, 775, 3418, 1462, 2, 23009, 2, 9179, 2566, 507, 68, 401, 607, 2702]",1681.0,29772082,227
The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model.,The Journal of clinical investigation,J. Clin. Invest.,2018-05-21,"NOTCH1 is a prevalent signaling pathway in T cell acute lymphoblastic leukemia (T-ALL), but crucial NOTCH1 downstream signals and target genes contributing to T-ALL pathogenesis cannot be retrospectively analyzed in patients and thus remain ill defined. This information is clinically relevant, as initiating lesions that lead to cell transformation and leukemia-initiating cell (LIC) activity are promising therapeutic targets against the major hurdle of T-ALL relapse. Here, we describe the generation in vivo of a human T cell leukemia that recapitulates T-ALL in patients, which arises de novo in immunodeficient mice reconstituted with human hematopoietic progenitors ectopically expressing active NOTCH1. This T-ALL model allowed us to identify CD44 as a direct NOTCH1 transcriptional target and to recognize CD44 overexpression as an early hallmark of preleukemic cells that engraft the BM and finally develop a clonal transplantable T-ALL that infiltrates lymphoid organs and brain. Notably, CD44 is shown to support crucial BM niche interactions necessary for LIC activity of human T-ALL xenografts and disease progression, highlighting the importance of the NOTCH1/CD44 axis in T-ALL pathogenesis. The observed therapeutic benefit of anti-CD44 antibody administration in xenotransplanted mice holds great promise for therapeutic purposes against T-ALL relapse.",Journal Article,610.0,8.0,NOTCH1 is a prevalent signaling pathway in T cell acute lymphoblastic T-ALL but crucial NOTCH1 downstream signals and target genes contributing to T-ALL pathogenesis can not be retrospectively analyzed in patients and thus remain ill defined This information is clinically relevant as initiating lesions that lead to cell transformation and leukemia-initiating cell LIC activity are promising therapeutic targets against the major hurdle of T-ALL relapse Here we describe the generation in vivo of a human T cell that recapitulates T-ALL in patients which arises de novo in immunodeficient mice reconstituted with human hematopoietic progenitors ectopically expressing active NOTCH1 This T-ALL model allowed us to identify CD44 as a direct NOTCH1 transcriptional target and to recognize CD44 overexpression as an early hallmark of preleukemic cells that engraft the BM and finally develop a clonal transplantable T-ALL that infiltrates lymphoid organs and brain Notably CD44 is shown to support crucial BM niche interactions necessary for LIC activity of human T-ALL xenografts and disease progression highlighting the importance of the NOTCH1/CD44 axis in T-ALL pathogenesis The observed therapeutic benefit of anti-CD44 antibody administration in xenotransplanted mice holds great promise for therapeutic purposes against T-ALL relapse,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4607, 16, 8, 2485, 314, 308, 4, 102, 31, 286, 1275, 102, 62, 84, 2653, 4607, 1489, 2312, 2, 283, 214, 3156, 6, 102, 62, 1384, 122, 44, 40, 894, 311, 4, 7, 2, 631, 918, 4993, 395, 26, 487, 16, 505, 867, 22, 2637, 406, 17, 1122, 6, 31, 1392, 2, 2647, 2637, 31, 13960, 128, 32, 721, 189, 637, 480, 3, 458, 14232, 1, 102, 62, 429, 467, 21, 897, 3, 914, 4, 386, 1, 8, 171, 102, 31, 17, 11076, 102, 62, 4, 7, 92, 6053, 1566, 2018, 4, 5031, 399, 14787, 5, 171, 1007, 4321, 11744, 1046, 544, 4607, 26, 102, 62, 202, 2313, 843, 6, 255, 3035, 22, 8, 1196, 4607, 1431, 283, 2, 6, 4237, 3035, 851, 22, 35, 191, 4683, 1, 19788, 37, 17, 12343, 3, 1246, 2, 1368, 690, 8, 1946, 11459, 102, 62, 17, 5942, 2303, 2285, 2, 342, 2552, 3035, 16, 443, 6, 538, 2653, 1246, 4385, 1286, 1493, 9, 13960, 128, 1, 171, 102, 62, 1348, 2, 34, 91, 4051, 3, 1187, 1, 3, 4607, 3035, 2310, 4, 102, 62, 1384, 3, 164, 189, 247, 1, 312, 3035, 548, 634, 4, 31687, 399, 5253, 2797, 1783, 9, 189, 4624, 480, 102, 62, 429]",1337.0,29781813,449
Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?,Blood advances,Blood Adv,2018-06-01,"We sought to identify whether posttransplantation cyclophosphamide (PT-Cy) reduces or eliminates the detrimental impact of HLA mismatching on outcomes of HLA-haploidentical related donor transplantation for acute leukemia. Data from 2143 donor-recipient pairs (n = 218 haploidentical sibling; n = 218 offspring; n = 1707 HLA-matched sibling) with acute myeloid or lymphoblastic leukemia were studied. All received a calcineurin inhibitor for graft-versus-host disease (GVHD) prophylaxis while high-dose PT-Cy was also given to recipients of haploidentical transplant. Patient age correlated with donor-recipient relationship: haploidentical siblings donated to patients aged 18 to 54 years whereas offspring donated to patients aged 55 to 76 years. Therefore, transplant outcomes were examined separately in the 2 patient age groups. In patients aged 18 to 54 years, there were no significant differences in outcomes except chronic GVHD, which was lower after haploidentical sibling compared to HLA-matched sibling transplant (hazard ratio [HR], 0.63; <i>P</i> < .001). In patients aged 55 to 76 years, despite lower chronic GVHD (HR, 0.42; <i>P</i> < .001), graft failure (14% vs 6%; <i>P</i> = .003), nonrelapse mortality (HR, 1.48; <i>P</i> = .02), and overall mortality (HR, 1.32; <i>P</i> = .003) were higher after transplant from offspring compared with an HLA-matched sibling. These data demonstrate a superior outcome in older recipients when using an HLA-matched sibling instead of offspring, although there were differences in transplant platforms (GVHD prophylaxis and graft type) between the 2 groups. Validation of these findings requires a prospective randomized trial wherein the transplant platforms can be closely matched.",Clinical Trial,599.0,16.0,We sought to identify whether posttransplantation cyclophosphamide PT-Cy reduces or eliminates the detrimental impact of HLA mismatching on outcomes of HLA-haploidentical related donor transplantation for acute Data from 2143 donor-recipient pairs n 218 haploidentical sibling n 218 offspring n 1707 HLA-matched sibling with acute myeloid or lymphoblastic were studied All received a calcineurin inhibitor for graft-versus-host disease GVHD prophylaxis while high-dose PT-Cy was also given to recipients of haploidentical transplant Patient age correlated with donor-recipient relationship haploidentical siblings donated to patients aged 18 to 54 years whereas offspring donated to patients aged 55 to 76 years Therefore transplant outcomes were examined separately in the 2 patient age groups In patients aged 18 to 54 years there were no significant differences in outcomes except chronic GVHD which was lower after haploidentical sibling compared to HLA-matched sibling transplant hazard ratio HR 0.63 i P /i .001 In patients aged 55 to 76 years despite lower chronic GVHD HR 0.42 i P /i .001 graft failure 14 vs 6 i P /i .003 nonrelapse mortality HR 1.48 i P /i .02 and overall mortality HR 1.32 i P /i .003 were higher after transplant from offspring compared with an HLA-matched sibling These data demonstrate a superior outcome in older recipients when using an HLA-matched sibling instead of offspring although there were differences in transplant platforms GVHD prophylaxis and graft type between the 2 groups Validation of these findings requires a prospective randomized trial wherein the transplant platforms can be closely matched,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[21, 990, 6, 255, 317, 8046, 1112, 3395, 5757, 2389, 15, 10794, 3, 6227, 345, 1, 1160, 25074, 23, 123, 1, 1160, 5802, 139, 1488, 497, 9, 286, 74, 29, 50214, 1488, 5783, 2773, 78, 6070, 5802, 3684, 78, 6070, 8304, 78, 72833, 1160, 655, 3684, 5, 286, 533, 15, 1275, 11, 656, 62, 103, 8, 12028, 230, 9, 1599, 185, 1204, 34, 1562, 2049, 369, 64, 61, 3395, 5757, 10, 120, 447, 6, 2190, 1, 5802, 941, 69, 89, 438, 5, 1488, 5783, 858, 5802, 2758, 25982, 6, 7, 1032, 203, 6, 667, 60, 547, 8304, 25982, 6, 7, 1032, 614, 6, 846, 60, 673, 941, 123, 11, 409, 3582, 4, 3, 18, 69, 89, 271, 4, 7, 1032, 203, 6, 667, 60, 125, 11, 77, 93, 362, 4, 123, 2187, 442, 1562, 92, 10, 280, 50, 5802, 3684, 72, 6, 1160, 655, 3684, 941, 360, 197, 168, 13, 676, 70, 19, 70, 144, 4, 7, 1032, 614, 6, 846, 60, 550, 280, 442, 1562, 168, 13, 595, 70, 19, 70, 144, 1599, 496, 213, 105, 49, 70, 19, 70, 1421, 4640, 282, 168, 14, 576, 70, 19, 70, 588, 2, 63, 282, 168, 14, 531, 70, 19, 70, 1421, 11, 142, 50, 941, 29, 8304, 72, 5, 35, 1160, 655, 3684, 46, 74, 608, 8, 1123, 228, 4, 434, 2190, 198, 75, 35, 1160, 655, 3684, 3496, 1, 8304, 242, 125, 11, 362, 4, 941, 4364, 1562, 2049, 2, 1599, 267, 59, 3, 18, 271, 929, 1, 46, 272, 1706, 8, 482, 384, 160, 7893, 3, 941, 4364, 122, 40, 3210, 655]",1644.0,29794073,198
"Dasatinib Plus Intensive Chemotherapy in Children, Adolescents, and Young Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Results of Children's Oncology Group Trial AALL0622.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-05-29,"Purpose Addition of imatinib to intensive chemotherapy improved survival for children and young adults with Philadelphia chromosome-positive acute lymphoblastic leukemia. Compared with imatinib, dasatinib has increased potency, CNS penetration, and activity against imatinib-resistant clones. Patients and Methods Children's Oncology Group (COG) trial AALL0622 (Bristol Myers Squibb trial CA180-204) tested safety and feasibility of adding dasatinib to intensive chemotherapy starting at induction day 15 in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia age 1 to 30 years. Allogeneic hematopoietic stem-cell transplantation (HSCT) was recommended for patients at high risk based on slow response and for those with a matched family donor regardless of response after at least 11 weeks of therapy. Patients at standard risk based on rapid response received chemotherapy plus dasatinib for an additional 120 weeks. Patients with overt CNS leukemia received cranial irradiation. Results Sixty eligible patients were enrolled. Five-year overall (OS) and event-free survival rates ( standard deviations [SD]) were 86%  5% and 60%  7% overall, 87%  5% and 61%  7% for standard-risk patients (n = 48; 19% underwent HSCT), and 89%  13% and 67%  19% for high-risk patients (n = 9; 89% underwent HSCT), respectively. Five-year cumulative incidence ( SD) of CNS relapse was 15%  6%. Outcomes ( SDs) were similar to those in COG AALL0031, which used the same chemotherapy with continuous imatinib: 5-year OS of 81%  6% versus 86%  5% ( P = .63) and 5-year disease-free survival of 68%  7% versus 60%  7% ( P = 0.31) for AALL0031 versus AALL0622, respectively. IKZF1 deletions, present in 56% of tested patients, were associated with significantly inferior OS and event-free survival overall and in standard-risk patients. Conclusion Dasatinib was well tolerated with chemotherapy and provided outcomes similar to those with imatinib in COG AALL0031, where all patients received cranial irradiation. Our results support limiting HSCT to slow responders and suggest a potential role for transplantation in rapid responders with IKZF1 deletions.",Clinical Trial,602.0,21.0,Purpose Addition of imatinib to intensive chemotherapy improved survival for children and young adults with Philadelphia chromosome-positive acute lymphoblastic Compared with imatinib dasatinib has increased potency CNS penetration and activity against imatinib-resistant clones Patients and Methods Children 's Oncology Group COG trial AALL0622 Bristol Myers Squibb trial CA180-204 tested safety and feasibility of adding dasatinib to intensive chemotherapy starting at induction day 15 in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic age 1 to 30 years Allogeneic hematopoietic stem-cell transplantation HSCT was recommended for patients at high risk based on slow response and for those with a matched family donor regardless of response after at least 11 weeks of therapy Patients at standard risk based on rapid response received chemotherapy plus dasatinib for an additional 120 weeks Patients with overt CNS received cranial irradiation Results Sixty eligible patients were enrolled Five-year overall OS and event-free survival rates  standard deviations SD were 86  5 and 60  7 overall 87  5 and 61  7 for standard-risk patients n 48 19 underwent HSCT and 89  13 and 67  19 for high-risk patients n 9 89 underwent HSCT respectively Five-year cumulative incidence  SD of CNS relapse was 15  6 Outcomes  SDs were similar to those in COG AALL0031 which used the same chemotherapy with continuous imatinib 5-year OS of 81  6 versus 86  5 P .63 and 5-year disease-free survival of 68  7 versus 60  7 P 0.31 for AALL0031 versus AALL0622 respectively IKZF1 deletions present in 56 of tested patients were associated with significantly inferior OS and event-free survival overall and in standard-risk patients Conclusion Dasatinib was well tolerated with chemotherapy and provided outcomes similar to those with imatinib in COG AALL0031 where all patients received cranial irradiation Our results support limiting HSCT to slow responders and suggest a potential role for transplantation in rapid responders with IKZF1 deletions,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[743, 352, 1, 577, 6, 1686, 56, 231, 25, 9, 541, 2, 1169, 857, 5, 3006, 1170, 109, 286, 1275, 72, 5, 577, 1674, 71, 101, 3593, 1025, 4618, 2, 128, 480, 577, 436, 2749, 7, 2, 636, 541, 292, 413, 87, 6377, 160, 51086, 8116, 8117, 8118, 160, 31438, 5996, 650, 367, 2, 1437, 1, 2726, 1674, 6, 1686, 56, 1723, 28, 504, 218, 167, 4, 7, 5, 732, 265, 3006, 1170, 109, 286, 1275, 89, 14, 6, 201, 60, 1063, 1007, 452, 31, 497, 1703, 10, 793, 9, 7, 28, 64, 43, 90, 23, 3645, 51, 2, 9, 135, 5, 8, 655, 607, 1488, 1583, 1, 51, 50, 28, 506, 175, 244, 1, 36, 7, 28, 260, 43, 90, 23, 1321, 51, 103, 56, 349, 1674, 9, 35, 402, 2031, 244, 7, 5, 7192, 1025, 103, 2565, 1104, 99, 1746, 625, 7, 11, 346, 365, 111, 63, 118, 2, 774, 115, 25, 151, 810, 260, 7810, 1270, 11, 868, 810, 33, 2, 335, 810, 67, 63, 912, 810, 33, 2, 713, 810, 67, 9, 260, 43, 7, 78, 576, 326, 208, 1703, 2, 887, 810, 233, 2, 598, 810, 326, 9, 64, 43, 7, 78, 83, 887, 208, 1703, 106, 365, 111, 967, 287, 810, 1270, 1, 1025, 429, 10, 167, 810, 49, 123, 810, 8668, 11, 288, 6, 135, 4, 6377, 42072, 92, 95, 3, 827, 56, 5, 1314, 577, 33, 111, 118, 1, 865, 810, 49, 185, 868, 810, 33, 19, 676, 2, 33, 111, 34, 115, 25, 1, 806, 810, 67, 185, 335, 810, 67, 19, 13, 456, 9, 42072, 185, 51086, 106, 8422, 2439, 364, 4, 664, 1, 650, 7, 11, 41, 5, 97, 1663, 118, 2, 774, 115, 25, 63, 2, 4, 260, 43, 7, 1221, 1674, 10, 149, 421, 5, 56, 2, 1052, 123, 288, 6, 135, 5, 577, 4, 6377, 42072, 1257, 62, 7, 103, 2565, 1104, 114, 99, 538, 817, 1703, 6, 3645, 1983, 2, 309, 8, 174, 200, 9, 497, 4, 1321, 1983, 5, 8422, 2439]",2078.0,29812996,673
"Peripheral Neuropathy, Sensory Processing, and Balance in Survivors of Acute Lymphoblastic Leukemia.",Journal of clinical oncology : official journal of the American Society of Clinical Oncology,J. Clin. Oncol.,2018-05-29,"Purpose To compare peripheral nervous system function and balance between adult survivors of childhood acute lymphoblastic leukemia (ALL) and matched controls and to determine associations between peripheral neuropathy (PN) and limitations in static balance, mobility, walking endurance, and quality of life (QoL) among survivors. Patients and Methods Three hundred sixty-five adult survivors of childhood ALL and 365 controls with no cancer history completed assessments of PN (modified Total Neuropathy Score [mTNS]), static balance (Sensory Organization Test [SOT]), mobility (Timed Up and Go), walking endurance (6-minute walk test), QoL (Medical Outcomes Study 36-Item Short Form Survey), and visual-motor processing speed (Wechsler Adult Intelligence Scale). Results PN, but not impairments, in performance on SOT was more common in survivors than controls (41.4% v 9.5%, respectively; P < .001). In multivariable models, higher mTNS scores were associated with longer time to complete the Timed Up and Go ( = 0.15; 95% CI, 0.06 to 0.23; P < .001), shorter distance walked in 6 minutes ( = -4.39; 95% CI, -8.63 to -0.14; P = .04), and reduced QoL ( = -1.33; 95% CI, -1.79 to -0.87; P < .001 for physical functioning;  = -1.16; 95% CI, -1.64 to -0.67; P < .001 for role physical; and  = -0.88; 95% CI, -1.34 to -0.42; P < .001 for general health). Processing speed ( = 1.69; 95% CI, 0.98 to 2.40; P < .001), but not mTNS score, was associated with anterior-posterior sway on the SOT. Conclusion PN in long-term ALL survivors is associated with movement, including mobility and walking endurance, but not with static standing balance. The association between processing speed and sway suggests that static balance impairment in ALL survivors may be influenced by problems with CNS function, including the processing of sensory information.",Journal Article,602.0,2.0,Purpose To compare peripheral nervous system function and balance between adult survivors of childhood acute lymphoblastic ALL and matched controls and to determine associations between peripheral neuropathy PN and limitations in static balance mobility walking endurance and quality of life QoL among survivors Patients and Methods Three hundred sixty-five adult survivors of childhood ALL and 365 controls with no cancer history completed assessments of PN modified Total Neuropathy Score mTNS static balance Sensory Organization Test SOT mobility Timed Up and Go walking endurance 6-minute walk test QoL Medical Outcomes Study 36-Item Short Form Survey and visual-motor processing speed Wechsler Adult Intelligence Scale Results PN but not impairments in performance on SOT was more common in survivors than controls 41.4 v 9.5 respectively P .001 In multivariable models higher mTNS scores were associated with longer time to complete the Timed Up and Go 0.15 95 CI 0.06 to 0.23 P .001 shorter distance walked in 6 minutes -4.39 95 CI -8.63 to -0.14 P .04 and reduced QoL -1.33 95 CI -1.79 to -0.87 P .001 for physical functioning -1.16 95 CI -1.64 to -0.67 P .001 for role physical and -0.88 95 CI -1.34 to -0.42 P .001 for general health Processing speed 1.69 95 CI 0.98 to 2.40 P .001 but not mTNS score was associated with anterior-posterior sway on the SOT Conclusion PN in long-term ALL survivors is associated with movement including mobility and walking endurance but not with static standing balance The association between processing speed and sway suggests that static balance impairment in ALL survivors may be influenced by problems with CNS function including the processing of sensory information,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[743, 6, 932, 672, 1880, 398, 343, 2, 3459, 59, 780, 332, 1, 864, 286, 1275, 62, 2, 655, 535, 2, 6, 223, 685, 59, 672, 1751, 2700, 2, 1939, 4, 9708, 3459, 5717, 7467, 15794, 2, 372, 1, 358, 1001, 107, 332, 7, 2, 636, 169, 1128, 1746, 365, 780, 332, 1, 864, 62, 2, 7405, 535, 5, 77, 12, 532, 781, 2182, 1, 2700, 1230, 181, 1751, 368, 32888, 9708, 3459, 4148, 2533, 412, 22580, 5717, 12200, 126, 2, 3537, 7467, 15794, 49, 3949, 8200, 412, 1001, 484, 123, 45, 511, 3471, 978, 1297, 1407, 2, 3046, 3482, 3325, 5051, 17526, 780, 9125, 1124, 99, 2700, 84, 44, 6948, 4, 528, 23, 22580, 10, 80, 186, 4, 332, 76, 535, 605, 39, 603, 83, 33, 106, 19, 144, 4, 658, 274, 142, 32888, 703, 11, 41, 5, 589, 98, 6, 236, 3, 12200, 126, 2, 3537, 13, 167, 48, 58, 13, 1460, 6, 13, 382, 19, 144, 985, 3019, 23291, 4, 49, 2511, 39, 587, 48, 58, 66, 676, 6, 13, 213, 19, 755, 2, 405, 1001, 14, 466, 48, 58, 14, 842, 6, 13, 912, 19, 144, 9, 900, 2702, 14, 245, 48, 58, 14, 660, 6, 13, 598, 19, 144, 9, 200, 900, 2, 13, 889, 48, 58, 14, 562, 6, 13, 595, 19, 144, 9, 1083, 341, 3325, 5051, 14, 790, 48, 58, 13, 1096, 6, 18, 327, 19, 144, 84, 44, 32888, 368, 10, 41, 5, 2882, 3028, 51087, 23, 3, 22580, 1221, 2700, 4, 319, 337, 62, 332, 16, 41, 5, 7950, 141, 5717, 2, 7467, 15794, 84, 44, 5, 9708, 10909, 3459, 3, 248, 59, 3325, 5051, 2, 51087, 844, 17, 9708, 3459, 2315, 4, 62, 332, 68, 40, 2574, 20, 2408, 5, 1025, 343, 141, 3, 3325, 1, 4148, 487]",1715.0,29812998,375
SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.,"Clinical lymphoma, myeloma & leukemia",Clin Lymphoma Myeloma Leuk,2018-05-22,"The widespread adoption of Bcr-Abl-directed tyrosine kinase inhibitors (TKIs) into first-line regimens for patients with Philadelphia chromosome (Ph)-positive (Ph<sup>+</sup>) acute lymphoblastic leukemia (ALL) has revolutionized the outcomes of patients with this disease. Whereas Ph<sup>+</sup> ALL was historically associated with cure rates of<25% in the pre-TKI era, now long-term survival in more than 75% of patients has been reported. With the promising efficacy of later-generation TKIs (eg, ponatinib) and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual disease, the widespread use of allogeneic hematopoietic stem cell transplantation in first remission for patients with Ph<sup>+</sup> ALL has been increasingly questioned. Furthermore, with the development of more potent Bcr-Abl TKIs, several studies are evaluating novel strategies that reduce or eliminate chemotherapy. Herein, we review the major genomic and molecular prognostic factors in Ph<sup>+</sup> ALL and also discuss the current and future treatment paradigms for this disease.",Journal Article,609.0,5.0,The widespread adoption of Bcr-Abl-directed tyrosine kinase inhibitors TKIs into first-line regimens for patients with Philadelphia chromosome Ph -positive Ph sup /sup acute lymphoblastic ALL has revolutionized the outcomes of patients with this disease Whereas Ph sup /sup ALL was historically associated with cure rates of 25 in the pre-TKI era now long-term survival in more than 75 of patients has been reported With the promising efficacy of later-generation TKIs eg ponatinib and the emerging understanding of the prognostic significance of various cooperative genomic alterations and of minimal residual disease the widespread use of allogeneic hematopoietic stem cell transplantation in first remission for patients with Ph sup /sup ALL has been increasingly questioned Furthermore with the development of more potent Bcr-Abl TKIs several studies are evaluating novel strategies that reduce or eliminate chemotherapy Herein we review the major genomic and molecular prognostic factors in Ph sup /sup ALL and also discuss the current and future treatment paradigms for this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 3029, 4350, 1, 1062, 1425, 1166, 564, 216, 222, 1671, 237, 157, 328, 472, 9, 7, 5, 3006, 1170, 2058, 109, 2058, 172, 172, 286, 1275, 62, 71, 5746, 3, 123, 1, 7, 5, 26, 34, 547, 2058, 172, 172, 62, 10, 3578, 41, 5, 1722, 151, 1, 243, 4, 3, 671, 1379, 1713, 1134, 319, 337, 25, 4, 80, 76, 481, 1, 7, 71, 85, 210, 5, 3, 721, 209, 1, 1559, 914, 1671, 2887, 5715, 2, 3, 1478, 612, 1, 3, 177, 724, 1, 747, 1690, 572, 593, 2, 1, 1048, 753, 34, 3, 3029, 119, 1, 1063, 1007, 452, 31, 497, 4, 157, 734, 9, 7, 5, 2058, 172, 172, 62, 71, 85, 1635, 9089, 798, 5, 3, 193, 1, 80, 1157, 1062, 1425, 1671, 392, 94, 32, 1435, 229, 422, 17, 969, 15, 4964, 56, 1986, 21, 206, 3, 458, 572, 2, 219, 177, 130, 4, 2058, 172, 172, 62, 2, 120, 1139, 3, 291, 2, 508, 24, 4887, 9, 26, 34]",1088.0,29853276,77
Outcome of children and adolescents with Down syndrome treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001.,Pediatric blood & cancer,Pediatr Blood Cancer,2018-06-07,"Children and adolescents with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) are reported to have increased relapse rates and therapy-related mortality (TRM). Treatment regimens for DS-ALL patients often include therapy modifications. Dana-Farber Cancer Institute (DFCI) ALL Consortium protocols have used same risk-stratified treatment for patients with and without DS. We compared clinical and outcome data of DS (n=38) and non-DS (n=1,248) patients enrolled on two consecutive DFCI ALL trials 00-001 (2000-2004) and 05-001 (2005-2011) with similar risk adapted therapy regardless of DS status. There was no difference in demographic or presenting clinical features between two groups except absence of T-cell phenotype and lower frequency of hyperdiploidy in DS-ALL group. All DS-ALL patients achieved complete remission; four relapsed and one subsequently died. There was no TRM in DS-ALL patients. DS-ALL patients had significantly higher rates of mucositis (52%vs. 12%, p<0.001), non-CNS thrombosis (18%vs. 8%; p=0.036), and seizure (16%vs. 5%, p=0.010). Compared to non-DS-ALL patients, DS-ALL patients had a higher incidence of infections during all therapy phases. The 5-year event-free and overall survival rates of DS-ALL patients were similar to non-DS-ALL patients (91% [95% confidence interval (CI), 81-100] vs. 84% [95% CI, 82-86]; 97% [95% CI, 92-100] vs. 91% [95% CI, 90-93]). The low rates of relapse and TRM indicate that uniform risk-stratified therapy for DS-ALL and non-DS-ALL patients on DFCI ALL Consortium protocols was safe and effective, although the increased rate of toxicity in the DS-ALL patients highlights the importance of supportive care during therapy.",Clinical Trial,593.0,5.0,"Children and adolescents with Down syndrome DS and acute lymphoblastic ALL are reported to have increased relapse rates and therapy-related mortality TRM Treatment regimens for DS-ALL patients often include therapy modifications Dana-Farber Cancer Institute DFCI ALL Consortium protocols have used same risk-stratified treatment for patients with and without DS We compared clinical and outcome data of DS n 38 and non-DS n 1,248 patients enrolled on two consecutive DFCI ALL trials 00-001 2000-2004 and 05-001 2005-2011 with similar risk adapted therapy regardless of DS status There was no difference in demographic or presenting clinical features between two groups except absence of T-cell phenotype and lower frequency of hyperdiploidy in DS-ALL group All DS-ALL patients achieved complete remission four relapsed and one subsequently died There was no TRM in DS-ALL patients DS-ALL patients had significantly higher rates of mucositis 52 vs. 12 p 0.001 non-CNS thrombosis 18 vs. 8 p 0.036 and seizure 16 vs. 5 p 0.010 Compared to non-DS-ALL patients DS-ALL patients had a higher incidence of infections during all therapy phases The 5-year event-free and overall survival rates of DS-ALL patients were similar to non-DS-ALL patients 91 95 confidence interval CI 81-100 vs. 84 95 CI 82-86 97 95 CI 92-100 vs. 91 95 CI 90-93 The low rates of relapse and TRM indicate that uniform risk-stratified therapy for DS-ALL and non-DS-ALL patients on DFCI ALL Consortium protocols was safe and effective although the increased rate of toxicity in the DS-ALL patients highlights the importance of supportive care during therapy",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 2, 3101, 5, 1328, 681, 3602, 2, 286, 1275, 62, 32, 210, 6, 47, 101, 429, 151, 2, 36, 139, 282, 5064, 24, 472, 9, 3602, 62, 7, 629, 643, 36, 2916, 4932, 4979, 12, 1377, 11152, 62, 2404, 2189, 47, 95, 827, 43, 1173, 24, 9, 7, 5, 2, 187, 3602, 21, 72, 38, 2, 228, 74, 1, 3602, 78, 519, 2, 220, 3602, 78, 14, 7100, 7, 346, 23, 100, 935, 11152, 62, 143, 2038, 144, 1081, 1131, 2, 474, 144, 1242, 1132, 5, 288, 43, 3716, 36, 1583, 1, 3602, 156, 125, 10, 77, 523, 4, 1540, 15, 1656, 38, 404, 59, 100, 271, 2187, 1127, 1, 102, 31, 1005, 2, 280, 675, 1, 11299, 4, 3602, 62, 87, 62, 3602, 62, 7, 513, 236, 734, 294, 591, 2, 104, 1611, 1016, 125, 10, 77, 5064, 4, 3602, 62, 7, 3602, 62, 7, 42, 97, 142, 151, 1, 2606, 653, 105, 133, 19, 13, 144, 220, 1025, 2839, 203, 105, 66, 19, 13, 5395, 2, 5866, 245, 105, 33, 19, 13, 4873, 72, 6, 220, 3602, 62, 7, 3602, 62, 7, 42, 8, 142, 287, 1, 1875, 190, 62, 36, 3523, 3, 33, 111, 774, 115, 2, 63, 25, 151, 1, 3602, 62, 7, 11, 288, 6, 220, 3602, 62, 7, 970, 48, 307, 268, 58, 865, 394, 105, 874, 48, 58, 878, 868, 1015, 48, 58, 937, 394, 105, 970, 48, 58, 424, 966, 3, 154, 151, 1, 429, 2, 5064, 1008, 17, 3490, 43, 1173, 36, 9, 3602, 62, 2, 220, 3602, 62, 7, 23, 11152, 62, 2404, 2189, 10, 1165, 2, 323, 242, 3, 101, 116, 1, 155, 4, 3, 3602, 62, 7, 2527, 3, 1187, 1, 1877, 165, 190, 36]",1621.0,29878490,488
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.,Cancer discovery,Cancer Discov,2018-06-07,"CD19-specific chimeric antigen receptor (CAR) T-cell therapy is highly effective against relapsed or refractory acute lymphoblastic leukemia (ALL), but is hindered by neurotoxicity. In 53 adult patients with ALL, we found a significant association of severe neurotoxicity with high pretreatment disease burden, higher peak CAR T-cell expansion, and early and higher elevations of proinflammatory cytokines in blood. Patients with severe neurotoxicity had evidence of blood-cerebrospinal fluid (CSF) barrier disruption correlating with neurotoxicity grade without association with CSF white blood cell count or CAR T-cell quantity in CSF. Proinflammatory cytokines were enriched in CSF during severe neurotoxicity with disproportionately high levels of IL6, IL8, MCP1, and IP10, suggesting central nervous system-specific production. Seizures, seizure-like activity, myoclonus, and neuroimaging characteristics suggested excitatory neurotoxicity, and we found elevated levels of endogenous excitatory agonists in CSF during neurotoxicity.<b>Significance:</b> We detail the neurologic symptoms and blood, CSF, and neuroimaging correlates of neurotoxicity associated with CD19 CAR T cells and identify neurotoxicity risk factors. Our findings implicate cellular components other than T cells and suggest novel links between systemic inflammation and characteristic neurotoxicity symptoms. <i>Cancer Discov; 8(8); 958-71. 2018 AACR.</i><i>This article is highlighted in the In This Issue feature, p. 899</i>.","Clinical Trial, Phase I",593.0,64.0,CD19-specific chimeric antigen receptor CAR T-cell therapy is highly effective against relapsed or refractory acute lymphoblastic ALL but is hindered by neurotoxicity In 53 adult patients with ALL we found a significant association of severe neurotoxicity with high pretreatment disease burden higher peak CAR T-cell expansion and early and higher elevations of proinflammatory cytokines in blood Patients with severe neurotoxicity had evidence of blood-cerebrospinal fluid CSF barrier disruption correlating with neurotoxicity grade without association with CSF white blood cell count or CAR T-cell quantity in CSF Proinflammatory cytokines were enriched in CSF during severe neurotoxicity with disproportionately high levels of IL6 IL8 MCP1 and IP10 suggesting central nervous system-specific production Seizures seizure-like activity myoclonus and neuroimaging characteristics suggested excitatory neurotoxicity and we found elevated levels of endogenous excitatory agonists in CSF during neurotoxicity. b Significance /b We detail the neurologic symptoms and blood CSF and neuroimaging correlates of neurotoxicity associated with CD19 CAR T cells and identify neurotoxicity risk factors Our findings implicate cellular components other than T cells and suggest novel links between systemic inflammation and characteristic neurotoxicity symptoms i Cancer Discov 8 8 958-71 2018 AACR. /i i This article is highlighted in the In This Issue feature p. 899 /i,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3158, 112, 2897, 448, 153, 1881, 102, 31, 36, 16, 561, 323, 480, 591, 15, 430, 286, 1275, 62, 84, 16, 9981, 20, 3561, 4, 699, 780, 7, 5, 62, 21, 204, 8, 93, 248, 1, 905, 3561, 5, 64, 1194, 34, 892, 142, 2944, 1881, 102, 31, 1422, 2, 191, 2, 142, 4712, 1, 5767, 1886, 4, 315, 7, 5, 905, 3561, 42, 241, 1, 315, 5156, 2357, 1211, 3318, 3220, 5637, 5, 3561, 88, 187, 248, 5, 1211, 886, 315, 31, 1276, 15, 1881, 102, 31, 7701, 4, 1211, 5767, 1886, 11, 2220, 4, 1211, 190, 905, 3561, 5, 10094, 64, 148, 1, 6772, 9798, 22837, 2, 44975, 802, 854, 1880, 398, 112, 1529, 4448, 5866, 733, 128, 24582, 2, 7468, 374, 1148, 37866, 3561, 2, 21, 204, 804, 148, 1, 2682, 37866, 4774, 4, 1211, 190, 3561, 132, 724, 132, 21, 5000, 3, 2543, 507, 2, 315, 1211, 2, 7468, 1871, 1, 3561, 41, 5, 3158, 1881, 102, 37, 2, 255, 3561, 43, 130, 114, 272, 5545, 763, 1628, 127, 76, 102, 37, 2, 309, 229, 6491, 59, 403, 1815, 2, 2037, 3561, 507, 70, 12, 7183, 66, 66, 16493, 792, 4281, 1630, 70, 70, 26, 946, 16, 3681, 4, 3, 4, 26, 2537, 2705, 19, 16485, 70]",1459.0,29880584,378
"Therapy-related acute lymphoblastic leukemia has distinct clinical and cytogenetic features compared to <i>de novo</i> acute lymphoblastic leukemia, but outcomes are comparable in transplanted patients.",Haematologica,Haematologica,2018-06-14,"Therapy-related acute lymphoblastic leukemia remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity. We reviewed all consecutive cases of adult acute lymphoblastic leukemia treated at our institution between 2000 and 2017 and identified therapy-related cases - defined as acute lymphoblastic leukemia preceded by prior exposure to cytotoxic chemotherapy and/or radiation. Of 1022 patients with acute lymphoblastic leukemia, 93 (9.1%) were classified as therapy-related. The median latency for therapy-related acute lymphoblastic leukemia onset was 6.8 years from original diagnosis, and this was shorter for patients carrying the <i>MLL</i> gene rearrangement compared to those with other cytogenetics. When compared to <i>de novo</i> acute lymphoblastic leukemia, therapy-related patients were older (<i>P</i><0.01), more often female (<i>P</i><0.01), and had more <i>MLL</i> gene rearrangement (<i>P</i><0.0001) and chromosomes 5/7 aberrations (<i>P</i>=0.02). Although therapy-related acute lymphoblastic leukemia was associated with inferior 2-year overall survival compared to <i>de novo</i> cases (46.0% <i>vs</i> 68.1%, <i>P</i>=0.001), prior exposure to cytotoxic therapy (therapy-related) did not independently impact survival in multivariate analysis (HR=1.32; 95% CI: 0.97-1.80, <i>P</i>=0.08). There was no survival difference (2-year = 53.4% <i>vs</i> 58.9%, <i>P</i>=0.68) between the two groups in patients who received allogenic hematopoietic cell transplantation. In conclusion, therapy-related acute lymphoblastic leukemia represents a significant proportion of adult acute lymphoblastic leukemia diagnoses, and a subset of cases carry clinical and cytogenetic abnormalities similar to therapy-related myeloid neoplasms. Although survival of therapy-related acute lymphoblastic leukemia was inferior to <i>de novo</i> cases, allogeneic hematopoietic cell transplantation outcomes were comparable for the two entities.",Clinical Trial,586.0,6.0,Therapy-related acute lymphoblastic remains poorly defined due to a lack of large data sets recognizing the defining characteristics of this entity We reviewed all consecutive cases of adult acute lymphoblastic treated at our institution between 2000 and 2017 and identified therapy-related cases defined as acute lymphoblastic preceded by prior exposure to cytotoxic chemotherapy and/or radiation Of 1022 patients with acute lymphoblastic 93 9.1 were classified as therapy-related The median latency for therapy-related acute lymphoblastic onset was 6.8 years from original diagnosis and this was shorter for patients carrying the i MLL /i gene rearrangement compared to those with other cytogenetics When compared to i de novo /i acute lymphoblastic therapy-related patients were older i P /i 0.01 more often female i P /i 0.01 and had more i MLL /i gene rearrangement i P /i 0.0001 and chromosomes 5/7 aberrations i P /i =0.02 Although therapy-related acute lymphoblastic was associated with inferior 2-year overall survival compared to i de novo /i cases 46.0 i vs /i 68.1 i P /i =0.001 prior exposure to cytotoxic therapy therapy-related did not independently impact survival in multivariate analysis HR=1.32 95 CI 0.97-1.80 i P /i =0.08 There was no survival difference 2-year 53.4 i vs /i 58.9 i P /i =0.68 between the two groups in patients who received allogenic hematopoietic cell transplantation In conclusion therapy-related acute lymphoblastic represents a significant proportion of adult acute lymphoblastic diagnoses and a subset of cases carry clinical and cytogenetic abnormalities similar to therapy-related myeloid neoplasms Although survival of therapy-related acute lymphoblastic was inferior to i de novo /i cases allogeneic hematopoietic cell transplantation outcomes were comparable for the two entities,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[36, 139, 286, 1275, 469, 1240, 395, 520, 6, 8, 926, 1, 375, 74, 2270, 5842, 3, 2847, 374, 1, 26, 2983, 21, 446, 62, 935, 140, 1, 780, 286, 1275, 73, 28, 114, 731, 59, 1081, 2, 1759, 2, 108, 36, 139, 140, 395, 22, 286, 1275, 6083, 20, 324, 645, 6, 759, 56, 2, 15, 121, 1, 23971, 7, 5, 286, 1275, 966, 83, 14, 11, 1373, 22, 36, 139, 3, 52, 5301, 9, 36, 139, 286, 1275, 1707, 10, 49, 66, 60, 29, 2279, 147, 2, 26, 10, 985, 9, 7, 2934, 3, 70, 3049, 70, 145, 2675, 72, 6, 135, 5, 127, 2510, 198, 72, 6, 70, 1566, 2018, 70, 286, 1275, 36, 139, 7, 11, 434, 70, 19, 70, 13, 355, 80, 629, 1061, 70, 19, 70, 13, 355, 2, 42, 80, 70, 3049, 70, 145, 2675, 70, 19, 70, 13, 488, 2, 3560, 33, 67, 2152, 70, 19, 70, 13, 588, 242, 36, 139, 286, 1275, 10, 41, 5, 1663, 18, 111, 63, 25, 72, 6, 70, 1566, 2018, 70, 140, 641, 13, 70, 105, 70, 806, 14, 70, 19, 70, 13, 144, 324, 645, 6, 759, 36, 36, 139, 205, 44, 1042, 345, 25, 4, 331, 65, 168, 14, 531, 48, 58, 13, 1015, 14, 493, 70, 19, 70, 13, 1592, 125, 10, 77, 25, 523, 18, 111, 699, 39, 70, 105, 70, 717, 83, 70, 19, 70, 13, 806, 59, 3, 100, 271, 4, 7, 54, 103, 15122, 1007, 31, 497, 4, 1221, 36, 139, 286, 1275, 1449, 8, 93, 920, 1, 780, 286, 1275, 2403, 2, 8, 697, 1, 140, 3542, 38, 2, 1266, 1171, 288, 6, 36, 139, 533, 1179, 242, 25, 1, 36, 139, 286, 1275, 10, 1663, 6, 70, 1566, 2018, 70, 140, 1063, 1007, 31, 497, 123, 11, 1279, 9, 3, 100, 4613]",1827.0,29903756,399
Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy.,Molecular therapy : the journal of the American Society of Gene Therapy,Mol. Ther.,2018-06-15,"Patients with residual chronic lymphocytic leukemia (CLL) following initial purine analog-based chemoimmunotherapy exhibit a shorter duration of response and may benefit from novel therapeutic strategies. We and others have previously described the safety and efficacy of autologous Tcells modified to express anti-CD19 chimeric antigen receptors (CARs) in patients with relapsed or refractory B cell acute lymphoblastic leukemia and CLL. Here we report the use of CD19-targeted CAR Tcells incorporating the intracellular signaling domain of CD28 (19-28z) as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab. Outpatients received low-dose conditioning therapy with cyclophosphamide (600mg/m<sup>2</sup>), followed by escalating doses of 3 10<sup>6</sup>, 1 10<sup>7</sup>, or 3 10<sup>7</sup> 19-28z CAR Tcells/kg. An objective response was observed in 3 of 8 patients (38%), with a clinically complete response lasting more than 28months observed in two patients. Self-limited fevers were observed post-CAR Tcell infusion in 4 patients, contemporaneous with elevations in interleukin-6 (IL-6), IL-10, IL-2, and TGF-. None developed severe cytokine release syndrome or neurotoxicity. CAR Tcells were detectable post-infusion in 4 patients, with a longest observed persistence of 48days by qPCR. Further strategies to enhance CAR Tcell efficacy in CLL are under investigation.","Clinical Trial, Phase I",585.0,12.0,Patients with residual chronic lymphocytic CLL following initial purine analog-based chemoimmunotherapy exhibit a shorter duration of response and may benefit from novel therapeutic strategies We and others have previously described the safety and efficacy of autologous T cells modified to express anti-CD19 chimeric antigen receptors CARs in patients with relapsed or refractory B cell acute lymphoblastic and CLL Here we report the use of CD19-targeted CAR T cells incorporating the intracellular signaling domain of CD28 19-28z as a consolidative therapy in 8 patients with residual CLL following first-line chemoimmunotherapy with pentostatin cyclophosphamide and rituximab Outpatients received low-dose conditioning therapy with cyclophosphamide 600 mg/m sup 2 /sup followed by escalating doses of 3 10 sup 6 /sup 1 10 sup 7 /sup or 3 10 sup 7 /sup 19-28z CAR T cells/kg An objective response was observed in 3 of 8 patients 38 with a clinically complete response lasting more than 28 months observed in two patients Self-limited fevers were observed post-CAR T cell infusion in 4 patients contemporaneous with elevations in interleukin-6 IL-6 IL-10 IL-2 and TGF- None developed severe cytokine release syndrome or neurotoxicity CAR T cells were detectable post-infusion in 4 patients with a longest observed persistence of 48 days by qPCR Further strategies to enhance CAR T cell efficacy in CLL are under investigation,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,"[7, 5, 753, 442, 1193, 552, 366, 388, 5006, 3497, 90, 4438, 2239, 8, 985, 654, 1, 51, 2, 68, 247, 29, 229, 189, 422, 21, 2, 1749, 47, 373, 1027, 3, 367, 2, 209, 1, 1028, 102, 37, 1230, 6, 1669, 312, 3158, 2897, 448, 1186, 7441, 4, 7, 5, 591, 15, 430, 132, 31, 286, 1275, 2, 552, 467, 21, 414, 3, 119, 1, 3158, 238, 1881, 102, 37, 2570, 3, 2087, 314, 1398, 1, 5603, 326, 19130, 22, 8, 6618, 36, 4, 66, 7, 5, 753, 552, 366, 157, 328, 4438, 5, 7596, 1112, 2, 855, 5698, 103, 154, 61, 1933, 36, 5, 1112, 2383, 81, 188, 172, 18, 172, 370, 20, 2922, 415, 1, 27, 79, 172, 49, 172, 14, 79, 172, 67, 172, 15, 27, 79, 172, 67, 172, 326, 19130, 1881, 102, 37, 503, 35, 461, 51, 10, 164, 4, 27, 1, 66, 7, 519, 5, 8, 505, 236, 51, 3443, 80, 76, 339, 53, 164, 4, 100, 7, 1074, 383, 12488, 11, 164, 539, 1881, 102, 31, 904, 4, 39, 7, 11633, 5, 4712, 4, 1603, 49, 501, 49, 501, 79, 501, 18, 2, 2387, 2014, 1292, 276, 905, 1675, 2008, 681, 15, 3561, 1881, 102, 37, 11, 2083, 539, 904, 4, 39, 7, 5, 8, 5683, 164, 4108, 1, 576, 162, 20, 6162, 195, 422, 6, 1304, 1881, 102, 31, 209, 4, 552, 32, 669, 940]",1427.0,29910179,446
Oncogenic TRK fusions are amenable to inhibition in hematologic malignancies.,The Journal of clinical investigation,J. Clin. Invest.,2018-08-06,"Rearrangements involving the neurotrophic receptor kinase genes (NTRK1, NTRK2, and NTRK3; hereafter referred to as TRK) produce oncogenic fusions in a wide variety of cancers in adults and children. Although TRK fusions occur in fewer than 1% of all solid tumors, inhibition of TRK results in profound therapeutic responses, resulting in Breakthrough Therapy FDA approval of the TRK inhibitor larotrectinib for adult and pediatric patients with solid tumors, regardless of histology. In contrast to solid tumors, the frequency of TRK fusions and the clinical effects of targeting TRK in hematologic malignancies are unknown. Here, through an evaluation for TRK fusions across more than 7,000 patients with hematologic malignancies, we identified TRK fusions in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), histiocytosis, multiple myeloma, and dendritic cell neoplasms. Although TRK fusions occurred in only 0.1% of patients (8 of 7,311 patients), they conferred responsiveness to TRK inhibition in vitro and in vivo in a patient-derived xenograft and a corresponding AML patient with ETV6-NTRK2 fusion. These data identify that despite their individual rarity, collectively, TRK fusions are present in a wide variety of hematologic malignancies and predict clinically significant therapeutic responses to TRK inhibition.",Case Reports,533.0,10.0,"Rearrangements involving the neurotrophic receptor kinase genes NTRK1 NTRK2 and NTRK3 hereafter referred to as TRK produce oncogenic fusions in a wide variety of cancers in adults and children Although TRK fusions occur in fewer than 1 of all solid tumors inhibition of TRK results in profound therapeutic responses resulting in Breakthrough Therapy FDA approval of the TRK inhibitor larotrectinib for adult and pediatric patients with solid tumors regardless of histology In contrast to solid tumors the frequency of TRK fusions and the clinical effects of targeting TRK in hematologic malignancies are unknown Here through an evaluation for TRK fusions across more than 7,000 patients with hematologic malignancies we identified TRK fusions in acute lymphoblastic ALL acute myeloid AML histiocytosis multiple and dendritic cell neoplasms Although TRK fusions occurred in only 0.1 of patients 8 of 7,311 patients they conferred responsiveness to TRK inhibition in vitro and in vivo in a patient-derived xenograft and a corresponding AML patient with ETV6-NTRK2 fusion These data identify that despite their individual rarity collectively TRK fusions are present in a wide variety of hematologic malignancies and predict clinically significant therapeutic responses to TRK inhibition",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2072, 1267, 3, 12967, 153, 216, 214, 11220, 16151, 2, 11004, 12394, 1995, 6, 22, 6393, 2410, 1302, 2530, 4, 8, 1019, 1362, 1, 163, 4, 857, 2, 541, 242, 6393, 2530, 1271, 4, 1497, 76, 14, 1, 62, 537, 57, 297, 1, 6393, 99, 4, 4399, 189, 253, 1113, 4, 6022, 36, 2078, 1814, 1, 3, 6393, 230, 13463, 9, 780, 2, 815, 7, 5, 537, 57, 1583, 1, 784, 4, 748, 6, 537, 57, 3, 675, 1, 6393, 2530, 2, 3, 38, 176, 1, 529, 6393, 4, 813, 441, 32, 860, 467, 298, 35, 451, 9, 6393, 2530, 716, 80, 76, 67, 984, 7, 5, 813, 441, 21, 108, 6393, 2530, 4, 286, 1275, 62, 286, 533, 329, 13976, 232, 2, 2464, 31, 1179, 242, 6393, 2530, 489, 4, 158, 13, 14, 1, 7, 66, 1, 67, 9521, 7, 491, 3851, 3642, 6, 6393, 297, 4, 439, 2, 4, 386, 4, 8, 69, 526, 1330, 2, 8, 1734, 329, 69, 5, 7306, 16151, 1212, 46, 74, 255, 17, 550, 136, 797, 4989, 2535, 6393, 2530, 32, 364, 4, 8, 1019, 1362, 1, 813, 441, 2, 678, 505, 93, 189, 253, 6, 6393, 297]",1283.0,29920189,537
Progress and Innovations in the Management of Adult Acute Lymphoblastic Leukemia.,JAMA oncology,JAMA Oncol,2018-10-01,"Remarkable progress has occurred in understanding the pathophysiology and in developing improved personalized therapies in adult acute lymphoblastic leukemia (ALL). We searched MEDLINE (1990-2018), the American Society of Clinical Oncology, and American Society of Hematology websites (2010-2018). We used the search terms ""acute lymphoblastic or lymphocytic leukemia"" or ""ALL."" We largely selected publications in the past 5 years but did not exclude commonly referenced and highly regarded older publications. Target therapies toward specific transcripts (eg, BCR-ABL1 tyrosine kinase oncoprotein by tyrosine kinase inhibitors) and specific leukemic cell surface antigens (eg, CD20, CD22, and CD19 monoclonal antibodies) are major breakthroughs. Current treatments produce long-term survival in 50% of patients with precursor B-cell ALL including 50% to 70% with Philadelphia chromosome (Ph)-positive ALL, 50% to 60% with T-cell ALL, and 80% with mature B-cell ALL. Next-generation sequencing and genomic profiling in ALL have identified new prognostic markers, targets, and ALL subtypes (eg, Ph-like ALL). Monoclonal antibodies, bispecific antibody constructs, and chimeric antigen receptor T cellular therapies developed in the past 5 to 7 years have revolutionized the treatment of ALL and resulted in US Food and Drug Administration approvals of blinatumomab in 2014, as well as inotuzumab and tisagenlecleucel in 2017 as ALL salvage strategies. Their use in combined modalities as salvage and frontline therapies is currently under investigation. Therapies targeting specific transcripts or leukemic cell surface antigens are major breakthroughs in the treatment of adults with ALL. The incorporation of new monoclonal antibodies and other targeted approaches into frontline regimens is showing promising results. If confirmed, such strategies may increase the cure rates in adults to levels achieved in pediatric ALL and reduce the need for intensive and prolonged chemotherapy.",Journal Article,477.0,15.0,Remarkable progress has occurred in understanding the pathophysiology and in developing improved personalized therapies in adult acute lymphoblastic ALL We searched MEDLINE 1990-2018 the American Society of Clinical Oncology and American Society of Hematology websites 2010-2018 We used the search terms `` acute lymphoblastic or lymphocytic '' or `` ALL '' We largely selected publications in the past 5 years but did not exclude commonly referenced and highly regarded older publications Target therapies toward specific transcripts eg BCR-ABL1 tyrosine kinase oncoprotein by tyrosine kinase inhibitors and specific leukemic cell surface antigens eg CD20 CD22 and CD19 monoclonal antibodies are major breakthroughs Current treatments produce long-term survival in 50 of patients with precursor B-cell ALL including 50 to 70 with Philadelphia chromosome Ph -positive ALL 50 to 60 with T-cell ALL and 80 with mature B-cell ALL Next-generation sequencing and genomic profiling in ALL have identified new prognostic markers targets and ALL subtypes eg Ph-like ALL Monoclonal antibodies bispecific antibody constructs and chimeric antigen receptor T cellular therapies developed in the past 5 to 7 years have revolutionized the treatment of ALL and resulted in US Food and Drug Administration approvals of blinatumomab in 2014 as well as inotuzumab and tisagenlecleucel in 2017 as ALL salvage strategies Their use in combined modalities as salvage and frontline therapies is currently under investigation Therapies targeting specific transcripts or leukemic cell surface antigens are major breakthroughs in the treatment of adults with ALL The incorporation of new monoclonal antibodies and other targeted approaches into frontline regimens is showing promising results If confirmed such strategies may increase the cure rates in adults to levels achieved in pediatric ALL and reduce the need for intensive and prolonged chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3813, 1466, 71, 489, 4, 612, 3, 4320, 2, 4, 931, 231, 2175, 235, 4, 780, 286, 1275, 62, 21, 3080, 3388, 2289, 2982, 3, 597, 1174, 1, 38, 413, 2, 597, 1174, 1, 6216, 12706, 1120, 2982, 21, 95, 3, 1901, 1794, 286, 1275, 15, 1193, 522, 15, 62, 522, 21, 1733, 715, 4463, 4, 3, 1219, 33, 60, 84, 205, 44, 6262, 841, 13365, 2, 561, 7217, 434, 4463, 283, 235, 1317, 112, 2680, 2887, 1062, 3557, 564, 216, 6159, 20, 564, 216, 222, 2, 112, 2015, 31, 1255, 1575, 2887, 2198, 7599, 2, 3158, 848, 890, 32, 458, 9985, 291, 640, 2410, 319, 337, 25, 4, 212, 1, 7, 5, 2765, 132, 31, 62, 141, 212, 6, 431, 5, 3006, 1170, 2058, 109, 62, 212, 6, 335, 5, 102, 31, 62, 2, 493, 5, 2908, 132, 31, 62, 1305, 914, 615, 2, 572, 1080, 4, 62, 47, 108, 217, 177, 525, 637, 2, 62, 814, 2887, 2058, 733, 62, 848, 890, 7408, 548, 5500, 2, 2897, 448, 153, 102, 763, 235, 276, 4, 3, 1219, 33, 6, 67, 60, 47, 5746, 3, 24, 1, 62, 2, 627, 4, 843, 1773, 2, 234, 634, 6802, 1, 7182, 4, 1409, 22, 149, 22, 6730, 2, 51131, 4, 1759, 22, 62, 992, 422, 136, 119, 4, 397, 1558, 22, 992, 2, 3171, 235, 16, 694, 669, 940, 235, 529, 112, 2680, 15, 2015, 31, 1255, 1575, 32, 458, 9985, 4, 3, 24, 1, 857, 5, 62, 3, 2838, 1, 217, 848, 890, 2, 127, 238, 611, 237, 3171, 472, 16, 2069, 721, 99, 492, 557, 225, 422, 68, 344, 3, 1722, 151, 4, 857, 6, 148, 513, 4, 815, 62, 2, 969, 3, 594, 9, 1686, 2, 1069, 56]",1930.0,29931220,543
Brain Network Connectivity and Executive Function in Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia.,Brain connectivity,Brain Connect,2018-08-01,"Chemotherapeutic agents used to treat acute lymphoblastic leukemia (ALL), the most common cancer affecting young children, have been associated with long-term cognitive impairments that reduce quality of life. Executive dysfunction is one of the most consistently observed deficits and can have substantial and pervasive effects on academic success, occupational achievement, psychosocial function, and psychiatric status. We examined the neural mechanisms of executive dysfunction by measuring structural and functional connectomes in 161 long-term survivors of pediatric ALL, age 8-21 years, who were treated on a single contemporary chemotherapy-only protocol for standard/high- or low-risk disease. Lower global efficiency, a measure of information exchange and network integration, of both structural and functional connectomes was found in survivors with executive dysfunction compared with those without dysfunction (p<0.046). Patients with standard/high- versus low-risk disease and those who received greater number of intrathecal treatments containing methotrexate had the lowest network efficiencies. Patients with executive dysfunction also showed hyperconnectivity in sensorimotor, visual, and auditory-processing regions (p=0.037) and poor separation between sensorimotor, executive/attention, salience, and default mode networks (p<0.0001). Connectome disruption was consistent with a pattern of delayed neurodevelopment that may be associated with reduced resilience, adaptability, and flexibility of the brain network. These findings highlight the need for interventions that will prevent or manage cognitive impairment in survivors of pediatric acute lymphoblastic leukemia.",Journal Article,538.0,0.0,Chemotherapeutic agents used to treat acute lymphoblastic ALL the most common cancer affecting young children have been associated with long-term cognitive impairments that reduce quality of life Executive dysfunction is one of the most consistently observed deficits and can have substantial and pervasive effects on academic success occupational achievement psychosocial function and psychiatric status We examined the neural mechanisms of executive dysfunction by measuring structural and functional connectomes in 161 long-term survivors of pediatric ALL age 8-21 years who were treated on a single contemporary chemotherapy-only protocol for standard/high- or low-risk disease Lower global efficiency a measure of information exchange and network integration of both structural and functional connectomes was found in survivors with executive dysfunction compared with those without dysfunction p 0.046 Patients with standard/high- versus low-risk disease and those who received greater number of intrathecal treatments containing methotrexate had the lowest network efficiencies Patients with executive dysfunction also showed hyperconnectivity in sensorimotor visual and auditory-processing regions p 0.037 and poor separation between sensorimotor executive/attention salience and default mode networks p 0.0001 Connectome disruption was consistent with a pattern of delayed neurodevelopment that may be associated with reduced resilience adaptability and flexibility of the brain network These findings highlight the need for interventions that will prevent or manage cognitive impairment in survivors of pediatric acute lymphoblastic,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1573, 183, 95, 6, 943, 286, 1275, 62, 3, 96, 186, 12, 2319, 1169, 541, 47, 85, 41, 5, 319, 337, 1863, 6948, 17, 969, 372, 1, 358, 6481, 1527, 16, 104, 1, 3, 96, 2433, 164, 2752, 2, 122, 47, 1281, 2, 15130, 176, 23, 1916, 1825, 10318, 5088, 2322, 343, 2, 6563, 156, 21, 409, 3, 3922, 483, 1, 6481, 1527, 20, 2978, 3281, 2, 583, 51134, 4, 5377, 319, 337, 332, 1, 815, 62, 89, 66, 239, 60, 54, 11, 73, 23, 8, 226, 2667, 56, 158, 1182, 9, 260, 64, 15, 154, 43, 34, 280, 1648, 2904, 8, 1463, 1, 487, 6695, 2, 1801, 2676, 1, 110, 3281, 2, 583, 51134, 10, 204, 4, 332, 5, 6481, 1527, 72, 5, 135, 187, 1527, 19, 13, 4902, 7, 5, 260, 64, 185, 154, 43, 34, 2, 135, 54, 103, 378, 207, 1, 5126, 640, 1101, 2116, 42, 3, 2101, 1801, 19615, 7, 5, 6481, 1527, 120, 224, 73103, 4, 18270, 3046, 2, 11991, 3325, 1374, 19, 13, 5171, 2, 334, 5422, 59, 18270, 6481, 2111, 42094, 2, 22254, 4530, 3991, 19, 13, 488, 73104, 3220, 10, 925, 5, 8, 1177, 1, 1612, 34105, 17, 68, 40, 41, 5, 405, 9824, 19474, 2, 9794, 1, 3, 342, 1801, 46, 272, 1817, 3, 594, 9, 1151, 17, 303, 1682, 15, 4001, 1863, 2315, 4, 332, 1, 815, 286, 1275]",1642.0,29936880,165
Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001.,Blood advances,Blood Adv,2018-06-01,"Dana-Farber Cancer Institute (DFCI) ALL Consortium Protocol 05-001 tested a new risk stratification system in children and adolescents with newly diagnosed acute lymphoblastic leukemia (ALL). At study entry, B-ALL patients were classified as standard risk (SR) or high risk (HR) based on age, white blood cell (WBC) count, and central nervous system status. After achieving complete remission (CR), patients with high end-induction minimal residual disease (MRD) (10<sup>-3</sup> by polymerase chain reaction analysis of patient-specific antigen receptor rearrangements) and/or adverse cytogenetics (<i>KMT2A</i> rearrangement or hypodiploidy) were reclassified as very high risk (VHR) and received intensified therapy. <i>IKZF1</i> deletion status was retrospectively evaluated by multiplex ligation-dependent probe amplification. Between 2005 and 2011, 678 Philadelphia chromosome-negative B-ALL patients aged 1 to 18 years enrolled; 651 achieved CR and 648 received a final risk group. Among all 678 patients, 5-year event-free survival (EFS) was 87% (95% confidence interval [CI], 84-89) and overall survival 93% (95% CI, 90-94). Five-year disease-free survival of SR patients (N = 407) was 94% (95% CI, 91-96), HR (N = 176) was 84% (95% CI, 77-88), and VHR (N = 65) was 79% (95% CI, 67-87). <i>IKZF1</i> deletion was present in 62 of 385 (16%) assessed patients and was associated with inferior 5-year EFS (63%; 95% CI, 49%-74% vs 88%; 95% CI, 84%-91%; <i>P</i> < .001), and higher 5-year cumulative incidence of relapse, including among those with low MRD (24% vs 8%, <i>P</i> = .001). In multivariable analysis, age 15 years, WBC 50 10<sup>9</sup>/L, <i>IKZF1</i> deletion, and MRD 10<sup>-4</sup> was each associated with inferior outcome. In conclusion, risk-stratified therapy on DFCI 05-001 resulted in favorable outcomes for B-ALL patients, including those with VHR features. <i>IKZF1</i> deletion was an independent predictor of inferior outcome. This trial was registered at www.clinicaltrials.gov as #NCT00400946.",Clinical Trial Protocol,599.0,2.0,Dana-Farber Cancer Institute DFCI ALL Consortium Protocol 05-001 tested a new risk stratification system in children and adolescents with newly diagnosed acute lymphoblastic ALL At study entry B-ALL patients were classified as standard risk SR or high risk HR based on age white blood cell WBC count and central nervous system status After achieving complete remission CR patients with high end-induction minimal residual disease MRD 10 sup -3 /sup by polymerase chain reaction analysis of patient-specific antigen receptor rearrangements and/or adverse cytogenetics i KMT2A /i rearrangement or hypodiploidy were reclassified as very high risk VHR and received intensified therapy i IKZF1 /i deletion status was retrospectively evaluated by multiplex ligation-dependent probe amplification Between 2005 and 2011 678 Philadelphia chromosome-negative B-ALL patients aged 1 to 18 years enrolled 651 achieved CR and 648 received a final risk group Among all 678 patients 5-year event-free survival EFS was 87 95 confidence interval CI 84-89 and overall survival 93 95 CI 90-94 Five-year disease-free survival of SR patients N 407 was 94 95 CI 91-96 HR N 176 was 84 95 CI 77-88 and VHR N 65 was 79 95 CI 67-87 i IKZF1 /i deletion was present in 62 of 385 16 assessed patients and was associated with inferior 5-year EFS 63 95 CI 49 -74 vs 88 95 CI 84 -91 i P /i .001 and higher 5-year cumulative incidence of relapse including among those with low MRD 24 vs 8 i P /i .001 In multivariable analysis age 15 years WBC 50 10 sup 9 /sup /L i IKZF1 /i deletion and MRD 10 sup -4 /sup was each associated with inferior outcome In conclusion risk-stratified therapy on DFCI 05-001 resulted in favorable outcomes for B-ALL patients including those with VHR features i IKZF1 /i deletion was an independent predictor of inferior outcome This trial was registered at www.clinicaltrials.gov as NCT00400946,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4932, 4979, 12, 1377, 11152, 62, 2404, 1182, 474, 144, 650, 8, 217, 43, 1541, 398, 4, 541, 2, 3101, 5, 732, 265, 286, 1275, 62, 28, 45, 3001, 132, 62, 7, 11, 1373, 22, 260, 43, 7460, 15, 64, 43, 168, 90, 23, 89, 886, 315, 31, 4685, 1276, 2, 854, 1880, 398, 156, 50, 1785, 236, 734, 684, 7, 5, 64, 396, 504, 1048, 753, 34, 2029, 4556, 172, 27, 172, 20, 1451, 1260, 1329, 65, 1, 69, 112, 448, 153, 2072, 2, 15, 290, 2510, 70, 13454, 70, 2675, 15, 14828, 11, 7864, 22, 923, 64, 43, 12957, 2, 103, 7311, 36, 70, 8422, 70, 1528, 156, 10, 894, 194, 20, 4908, 5307, 470, 2888, 1073, 59, 1242, 2, 1132, 14892, 3006, 1170, 199, 132, 62, 7, 1032, 14, 6, 203, 60, 346, 13114, 513, 684, 2, 15201, 103, 8, 1457, 43, 87, 107, 62, 14892, 7, 33, 111, 774, 115, 25, 1683, 10, 912, 48, 307, 268, 58, 874, 887, 2, 63, 25, 966, 48, 58, 424, 960, 365, 111, 34, 115, 25, 1, 7460, 7, 78, 11595, 10, 960, 48, 58, 970, 921, 168, 78, 5800, 10, 874, 48, 58, 849, 889, 2, 12957, 78, 556, 10, 842, 48, 58, 598, 912, 70, 8422, 70, 1528, 10, 364, 4, 744, 1, 11297, 245, 275, 7, 2, 10, 41, 5, 1663, 33, 111, 1683, 676, 48, 58, 739, 794, 105, 889, 48, 58, 874, 970, 70, 19, 70, 144, 2, 142, 33, 111, 967, 287, 1, 429, 141, 107, 135, 5, 154, 2029, 259, 105, 66, 70, 19, 70, 144, 4, 658, 65, 89, 10249, 60, 4685, 5660, 79, 172, 83, 172, 805, 70, 8422, 70, 1528, 2, 2029, 4556, 172, 39, 172, 10, 296, 41, 5, 1663, 228, 4, 1221, 43, 1173, 36, 23, 11152, 474, 144, 627, 4, 913, 123, 9, 132, 62, 7, 141, 135, 5, 12957, 404, 70, 8422, 70, 1528, 10, 35, 306, 980, 1, 1663, 228, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 34806]",1891.0,29941458,853
Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia.,Blood advances,Blood Adv,2018-07-01,"In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed or refractory (r/r) Philadelphia chromosome-negative (Ph<sup>-</sup>) B-precursor acute lymphoblastic leukemia (ALL). Nearly all patients in both treatment arms experienced an adverse event (AE), and the incidence rate of serious AEs was higher for blinatumomab. However, as treatment exposure differed between the 2 arms, we conducted an exploratory safety analysis comparing exposure-adjusted event rates (EAERs) of blinatumomab vs SOC. Analyses were conducted for all patients who received therapy (safety population). Patients received a median (range) of 2 cycles (1-9) of blinatumomab (N = 267) vs 1 cycle (1-4) of SOC (N = 109). Grade 3 AE rates were generally higher in cycle 1 of blinatumomab than in cycle 2 (76% vs 37%). After adjusting for time on treatment, EAERs of grade 3 were significantly lower for blinatumomab vs SOC overall (10.73 vs 45.27 events per patient-year; <i>P</i> < .001) and for events of clinical interest, including infections (1.63 vs 6.49 events per patient-year; <i>P</i> < .001), cytopenias (3.64 vs 20.07 events per patient-year; <i>P</i> < .001), and neurologic events (0.38 vs 0.95 events per patient-year; <i>P</i> = .008). The EAER of grade 3 cytokine-release syndrome was higher for blinatumomab than for SOC (0.16 vs 0 events per patient-year; <i>P</i> = .038). These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for patients with r/r Ph<sup>-</sup> ALL. This trial was registered at www.clinicaltrials.gov as #NCT02013167.","Clinical Trial, Phase III",569.0,8.0,In the phase 3 TOWER study blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy SOC in adults with relapsed or refractory r/r Philadelphia chromosome-negative Ph sup /sup B-precursor acute lymphoblastic ALL Nearly all patients in both treatment arms experienced an adverse event AE and the incidence rate of serious AEs was higher for blinatumomab However as treatment exposure differed between the 2 arms we conducted an exploratory safety analysis comparing exposure-adjusted event rates EAERs of blinatumomab vs SOC Analyses were conducted for all patients who received therapy safety population Patients received a median range of 2 cycles 1-9 of blinatumomab N 267 vs 1 cycle 1-4 of SOC N 109 Grade 3 AE rates were generally higher in cycle 1 of blinatumomab than in cycle 2 76 vs 37 After adjusting for time on treatment EAERs of grade 3 were significantly lower for blinatumomab vs SOC overall 10.73 vs 45.27 events per patient-year i P /i .001 and for events of clinical interest including infections 1.63 vs 6.49 events per patient-year i P /i .001 cytopenias 3.64 vs 20.07 events per patient-year i P /i .001 and neurologic events 0.38 vs 0.95 events per patient-year i P /i .008 The EAER of grade 3 cytokine-release syndrome was higher for blinatumomab than for SOC 0.16 vs 0 events per patient-year i P /i .038 These data further support the role of blinatumomab as an efficacious and well-tolerated treatment option for patients with r/r Ph sup /sup ALL This trial was registered at www.clinicaltrials.gov as NCT02013167,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4, 3, 124, 27, 73129, 45, 7182, 264, 35, 63, 25, 247, 252, 260, 1, 165, 56, 7615, 4, 857, 5, 591, 15, 430, 668, 668, 3006, 1170, 199, 2058, 172, 172, 132, 2765, 286, 1275, 62, 1857, 62, 7, 4, 110, 24, 1335, 592, 35, 290, 774, 3633, 2, 3, 287, 116, 1, 1762, 1477, 10, 142, 9, 7182, 137, 22, 24, 645, 2512, 59, 3, 18, 1335, 21, 426, 35, 2386, 367, 65, 1430, 645, 586, 774, 151, 51139, 1, 7182, 105, 7615, 318, 11, 426, 9, 62, 7, 54, 103, 36, 367, 266, 7, 103, 8, 52, 184, 1, 18, 410, 14, 83, 1, 7182, 78, 7559, 105, 14, 417, 14, 39, 1, 7615, 78, 3486, 88, 2608, 3633, 151, 11, 1228, 142, 4, 417, 14, 1, 7182, 76, 4, 417, 18, 846, 105, 567, 50, 1358, 9, 98, 23, 24, 51139, 1, 88, 2608, 11, 97, 280, 9, 7182, 105, 7615, 63, 79, 803, 105, 512, 428, 281, 379, 69, 111, 70, 19, 70, 144, 2, 9, 281, 1, 38, 1333, 141, 1875, 14, 676, 105, 49, 739, 281, 379, 69, 111, 70, 19, 70, 144, 5635, 27, 660, 105, 179, 1615, 281, 379, 69, 111, 70, 19, 70, 144, 2, 2543, 281, 13, 519, 105, 13, 48, 281, 379, 69, 111, 70, 19, 70, 2155, 3, 73130, 1, 88, 2608, 1675, 2008, 681, 10, 142, 9, 7182, 76, 9, 7615, 13, 245, 105, 13, 281, 379, 69, 111, 70, 19, 70, 5215, 46, 74, 195, 538, 3, 200, 1, 7182, 22, 35, 3289, 2, 149, 421, 24, 1501, 9, 7, 5, 668, 668, 2058, 172, 172, 62, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 73131]",1572.0,29954814,44
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes.,Nature communications,Nat Commun,2018-07-10,"Mixed phenotype acute leukemia (MPAL) is a rare subtype of acute leukemia characterized by leukemic blasts presenting myeloid and lymphoid markers. Here we report data from integrated genomic analysis on 31 MPAL samples and compare molecular profiling with that from acute myeloid leukemia (AML), B cell acute lymphoblastic leukemia (B-ALL), and T cell acute lymphoblastic leukemia (T-ALL). Consistent with the mixed immunophenotype, both AML-type and ALL-type mutations are detected in MPAL. Myeloid-B and myeloid-T MPAL show distinct mutation and methylation signatures that are associated with differences in lineage-commitment gene expressions. Genome-wide methylation comparison among MPAL, AML, B-ALL, and T-ALL sub-classifies MPAL into AML-type and ALL-type MPAL, which is associated with better clinical response when lineage-matched therapy is given. These results elucidate the genetic and epigenetic heterogeneity of MPAL and its genetic distinction from AML, B-ALL, and T-ALL and further provide proof of concept for a molecularly guided precision therapy approach in MPAL.",Journal Article,560.0,9.0,Mixed phenotype acute MPAL is a rare subtype of acute characterized by leukemic blasts presenting myeloid and lymphoid markers Here we report data from integrated genomic analysis on 31 MPAL samples and compare molecular profiling with that from acute myeloid AML B cell acute lymphoblastic B-ALL and T cell acute lymphoblastic T-ALL Consistent with the mixed immunophenotype both AML-type and ALL-type mutations are detected in MPAL Myeloid-B and myeloid-T MPAL show distinct mutation and methylation signatures that are associated with differences in lineage-commitment gene expressions Genome-wide methylation comparison among MPAL AML B-ALL and T-ALL sub-classifies MPAL into AML-type and ALL-type MPAL which is associated with better clinical response when lineage-matched therapy is given These results elucidate the genetic and epigenetic heterogeneity of MPAL and its genetic distinction from AML B-ALL and T-ALL and further provide proof of concept for a molecularly guided precision therapy approach in MPAL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1739, 1005, 286, 9407, 16, 8, 622, 875, 1, 286, 765, 20, 2015, 2438, 1656, 533, 2, 2303, 525, 467, 21, 414, 74, 29, 2102, 572, 65, 23, 456, 9407, 347, 2, 932, 219, 1080, 5, 17, 29, 286, 533, 329, 132, 31, 286, 1275, 132, 62, 2, 102, 31, 286, 1275, 102, 62, 925, 5, 3, 1739, 5496, 110, 329, 267, 2, 62, 267, 138, 32, 530, 4, 9407, 533, 132, 2, 533, 102, 9407, 514, 834, 258, 2, 569, 2210, 17, 32, 41, 5, 362, 4, 2542, 11082, 145, 4249, 898, 1019, 569, 1155, 107, 9407, 329, 132, 62, 2, 102, 62, 551, 15295, 9407, 237, 329, 267, 2, 62, 267, 9407, 92, 16, 41, 5, 380, 38, 51, 198, 2542, 655, 36, 16, 447, 46, 99, 3061, 3, 336, 2, 1418, 1144, 1, 9407, 2, 211, 336, 6628, 29, 329, 132, 62, 2, 102, 62, 2, 195, 377, 3840, 1, 2545, 9, 8, 2372, 1808, 2720, 36, 353, 4, 9407]",1017.0,29991687,741
Acute lymphoblastic leukemia as a clonally unrelated second primary malignancy after multiple myeloma.,Leukemia,Leukemia,2018-07-19,"Multiple myeloma (MM) patients have an 11-fold increased risk of developing myeloid neoplasms compared to the general population; however, acute lymphoblastic leukemia (ALL) is rarely observed. Given that both MM and the majority of ALL are of B cell origin, this raises the question of whether ALL in patients with MM arises from the same clone. We report 13 cases of B-cell ALL following therapy for MM. The interval from MM diagnosis to ALL onset was 5.4 years (range 3.3-10). The median age at the time of ALL diagnosis was 60 years (range 43-67). MM therapy included immunomodulatory agents in all patients and autologous hematopoietic cell transplantation in 10 (77%) patients preceding ALL diagnosis. ALL genetics showed a normal karyotype, TP53 mutation/deletion, and monosomy 7 or 7q deletion in 5, 3, and 2 cases, respectively. Analysis of paired samples of MM and ALL using whole exome sequencing demonstrated that the malignancies arose from different clones. Thus, ALL as a second primary malignancy following MM is not clonally related but could potentially represent a therapy-related leukemia.",Journal Article,551.0,1.0,Multiple MM patients have an 11-fold increased risk of developing myeloid neoplasms compared to the general population however acute lymphoblastic ALL is rarely observed Given that both MM and the majority of ALL are of B cell origin this raises the question of whether ALL in patients with MM arises from the same clone We report 13 cases of B-cell ALL following therapy for MM The interval from MM diagnosis to ALL onset was 5.4 years range 3.3-10 The median age at the time of ALL diagnosis was 60 years range 43-67 MM therapy included immunomodulatory agents in all patients and autologous hematopoietic cell transplantation in 10 77 patients preceding ALL diagnosis ALL genetics showed a normal karyotype TP53 mutation/deletion and monosomy 7 or 7q deletion in 5 3 and 2 cases respectively Analysis of paired samples of MM and ALL using whole exome sequencing demonstrated that the malignancies arose from different clones Thus ALL as a second primary malignancy following MM is not clonally related but could potentially represent a therapy-related,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,"[232, 321, 7, 47, 35, 175, 1116, 101, 43, 1, 931, 533, 1179, 72, 6, 3, 1083, 266, 137, 286, 1275, 62, 16, 2416, 164, 447, 17, 110, 321, 2, 3, 686, 1, 62, 32, 1, 132, 31, 1938, 26, 5789, 3, 2840, 1, 317, 62, 4, 7, 5, 321, 6053, 29, 3, 827, 3910, 21, 414, 233, 140, 1, 132, 31, 62, 366, 36, 9, 321, 3, 268, 29, 321, 147, 6, 62, 1707, 10, 33, 39, 60, 184, 27, 27, 79, 3, 52, 89, 28, 3, 98, 1, 62, 147, 10, 335, 60, 184, 601, 598, 321, 36, 159, 2555, 183, 4, 62, 7, 2, 1028, 1007, 31, 497, 4, 79, 849, 7, 5892, 62, 147, 62, 2894, 224, 8, 295, 3385, 1206, 258, 1528, 2, 7521, 67, 15, 9723, 1528, 4, 33, 27, 2, 18, 140, 106, 65, 1, 2355, 347, 1, 321, 2, 62, 75, 902, 2865, 615, 264, 17, 3, 441, 7268, 29, 338, 2749, 631, 62, 22, 8, 419, 86, 710, 366, 321, 16, 44, 9157, 139, 84, 359, 751, 1231, 8, 36, 139]",1054.0,30026571,36
Treatment of young adults with Philadelphia-negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper-CVAD vs. pediatric-inspired regimens.,American journal of hematology,Am. J. Hematol.,2018-09-03,"For young adults with acute lymphoblastic leukemia, pediatric-based regimens are likely to provide the following when compared to hyper-CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality-adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper-CVAD regimens for the treatment of Philadelphia-negative B-precursor or T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.",Journal Article,505.0,5.0,For young adults with acute lymphoblastic pediatric-based regimens are likely to provide the following when compared to hyper-CVAD regimens better disease control less hospitalization time diminished acute toxicities decreased financial cost more quality-adjusted life years and fewer adverse late effects such as infertility myelodysplasia and second malignant neoplasms There are also reasons to expect less and cognitive dysfunction after pediatric regimens The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper-CVAD regimens for the treatment of Philadelphia-negative B-precursor or T-cell acute lymphoblastic and lymphoblastic in young adults,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,"[9, 1169, 857, 5, 286, 1275, 815, 90, 472, 32, 322, 6, 377, 3, 366, 198, 72, 6, 4855, 5574, 472, 380, 34, 182, 299, 2826, 98, 2849, 286, 385, 340, 3021, 835, 80, 372, 586, 358, 60, 2, 1497, 290, 807, 176, 225, 22, 5901, 6128, 2, 419, 393, 1179, 125, 32, 120, 2325, 6, 8439, 299, 2, 1863, 1527, 50, 815, 472, 3, 231, 372, 2, 7701, 1, 358, 41, 5, 815, 472, 8080, 1370, 7474, 6, 4855, 5574, 472, 9, 3, 24, 1, 3006, 199, 132, 2765, 15, 102, 31, 286, 1275, 2, 1275, 4, 1169, 857]",703.0,30058716,510
Novel Therapies in Acute Lymphoblastic Leukemia.,Current hematologic malignancy reports,Curr Hematol Malig Rep,2018-08-01,"Treatment options for patients with acute lymphoblastic leukemia (ALL) beyond standard chemotherapy have grown significantly in recent years. In this review, we highlight new targeted therapies in ALL, with an emphasis on immunotherapy. Major advances include antibody-based therapies, such as naked monoclonal antibodies, antibody-drug conjugates and bispecific T cell engaging (BiTE) antibodies, as well as adoptive cellular therapies such as chimeric antigen receptor (CAR) T cells. Apart from the above immunotherapeutic approaches, other targeted therapies are being employed in Philadelphia chromosome-positive (Ph+) ALL, Philadelphia-like (Ph-like) ALL, and T cell ALL. These new treatment strategies are changing the treatment landscape of ALL and challenging the current standard of care. Clinical trials will hopefully help determine how to best incorporate these novel therapies into existing treatment algorithms.",Journal Article,538.0,3.0,Treatment options for patients with acute lymphoblastic ALL beyond standard chemotherapy have grown significantly in recent years In this review we highlight new targeted therapies in ALL with an emphasis on immunotherapy Major advances include antibody-based therapies such as naked monoclonal antibodies antibody-drug conjugates and bispecific T cell engaging BiTE antibodies as well as adoptive cellular therapies such as chimeric antigen receptor CAR T cells Apart from the above immunotherapeutic approaches other targeted therapies are being employed in Philadelphia chromosome-positive Ph+ ALL Philadelphia-like Ph-like ALL and T cell ALL These new treatment strategies are changing the treatment landscape of ALL and challenging the current standard of care Clinical trials will hopefully help determine how to best incorporate these novel therapies into existing treatment algorithms,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 838, 9, 7, 5, 286, 1275, 62, 1654, 260, 56, 47, 5473, 97, 4, 435, 60, 4, 26, 206, 21, 1817, 217, 238, 235, 4, 62, 5, 35, 3136, 23, 726, 458, 954, 643, 548, 90, 235, 225, 22, 11975, 848, 890, 548, 234, 5968, 2, 7408, 102, 31, 8534, 15382, 890, 22, 149, 22, 3159, 763, 235, 225, 22, 2897, 448, 153, 1881, 102, 37, 5461, 29, 3, 2090, 3222, 611, 127, 238, 235, 32, 486, 2516, 4, 3006, 1170, 109, 2058, 62, 3006, 733, 2058, 733, 62, 2, 102, 31, 62, 46, 217, 24, 422, 32, 3600, 3, 24, 2801, 1, 62, 2, 1950, 3, 291, 260, 1, 165, 38, 143, 303, 7464, 987, 223, 832, 6, 824, 3360, 46, 229, 235, 237, 1692, 24, 3529]",892.0,30078158,634
Baseline characteristics and outcomes of children with cancer in the English-speaking Caribbean: A multinational retrospective cohort.,Pediatric blood & cancer,Pediatr Blood Cancer,2018-08-09,"English-speaking Caribbean (ESC) childhood cancer outcomes are unknown. Through the SickKids-Caribbean Initiative (SCI), we established a multicenter childhood cancer database across seven centers in six ESC countries. Data managers entered patient demographics, disease, treatment, and outcome data. Data collection commenced in 2013, with retrospective collection to 2011 and subsequent prospective collection. A total of 367 children were diagnosed between 2011 and 2015 with a median age of 5.7 years (interquartile range 2.9-10.6 years). One hundred thirty (35.4%) patients were diagnosed with leukemia, 30 (8.2%) with lymphoma, and 149 (40.6%) with solid tumors. A relative paucity of children with brain tumors was seen (N=58, 15.8%). Two-year event-free survival (EFS) for the cohort was 48.5%  3.2%; 2-year overall survival (OS) was 55.1%  3.1%. Children with acute lymphoblastic leukemia (ALL) and Wilms tumor (WT) experienced better 2-year EFS (62.1%  6.4% and 66.7%  10.1%), while dismal outcomes were seen in children with acute myeloid leukemia (AML; 22.7  9.6%), rhabdomyosarcoma (21.0%  17.0%), and medulloblastoma (21.4%  17.8%). Of 108 deaths with known cause, 58 (53.7%) were attributed to disease and 50 (46.3%) to treatment complications. Death within 60 days of diagnosis was relatively common in acute leukemia [13/98 (13.3%) ALL, 8/26 (30.8%) AML]. Despite this, traditional prognosticators adversely impacted outcome in ALL, including higher age, higher white blood cell count, and T-cell lineage. ESC childhood cancer outcomes are significantly inferior to high-income country outcomes. Based on these data, interventions for improving supportive care and modifying treatment protocols are under way. Continued data collection will allow evaluation of interventions and ensure maximal outcome improvements.",Journal Article,530.0,1.0,English-speaking Caribbean ESC childhood cancer outcomes are unknown Through the SickKids-Caribbean Initiative SCI we established a multicenter childhood cancer database across seven centers in six ESC countries Data managers entered patient demographics disease treatment and outcome data Data collection commenced in 2013 with retrospective collection to 2011 and subsequent prospective collection A total of 367 children were diagnosed between 2011 and 2015 with a median age of 5.7 years interquartile range 2.9-10.6 years One hundred thirty 35.4 patients were diagnosed with 30 8.2 with and 149 40.6 with solid tumors A relative paucity of children with brain tumors was seen N 58 15.8 Two-year event-free survival EFS for the cohort was 48.5  3.2 2-year overall survival OS was 55.1  3.1 Children with acute lymphoblastic ALL and tumor WT experienced better 2-year EFS 62.1  6.4 and 66.7  10.1 while dismal outcomes were seen in children with acute myeloid AML 22.7  9.6 21.0  17.0 and medulloblastoma 21.4  17.8 Of 108 deaths with known cause 58 53.7 were attributed to disease and 50 46.3 to treatment complications Death within 60 days of diagnosis was relatively common in acute 13/98 13.3 ALL 8/26 30.8 AML Despite this traditional prognosticators adversely impacted outcome in ALL including higher age higher white blood cell count and T-cell lineage ESC childhood cancer outcomes are significantly inferior to high-income country outcomes Based on these data interventions for improving supportive care and modifying treatment protocols are under way Continued data collection will allow evaluation of interventions and ensure maximal outcome improvements,0,0,1,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4201, 8519, 15140, 16538, 864, 12, 123, 32, 860, 298, 3, 73396, 15140, 4439, 20157, 21, 635, 8, 1570, 864, 12, 609, 716, 648, 1168, 4, 437, 16538, 2115, 74, 23540, 2836, 69, 2221, 34, 24, 2, 228, 74, 74, 2442, 14843, 4, 1346, 5, 459, 2442, 6, 1132, 2, 706, 482, 2442, 8, 181, 1, 10720, 541, 11, 265, 59, 1132, 2, 1483, 5, 8, 52, 89, 1, 33, 67, 60, 2899, 184, 18, 83, 79, 49, 60, 104, 1128, 977, 465, 39, 7, 11, 265, 5, 201, 66, 18, 5, 2, 4928, 327, 49, 5, 537, 57, 8, 580, 4832, 1, 541, 5, 342, 57, 10, 527, 78, 717, 167, 66, 100, 111, 774, 115, 25, 1683, 9, 3, 180, 10, 576, 33, 810, 27, 18, 18, 111, 63, 25, 118, 10, 614, 14, 810, 27, 14, 541, 5, 286, 1275, 62, 2, 30, 1820, 592, 380, 18, 111, 1683, 744, 14, 810, 49, 39, 2, 700, 67, 810, 79, 14, 369, 3929, 123, 11, 527, 4, 541, 5, 286, 533, 329, 350, 67, 810, 83, 49, 239, 13, 810, 269, 13, 2, 2714, 239, 39, 810, 269, 66, 1, 3590, 1043, 5, 440, 708, 717, 699, 67, 11, 3073, 6, 34, 2, 212, 641, 27, 6, 24, 521, 273, 262, 335, 162, 1, 147, 10, 1352, 186, 4, 286, 233, 1096, 233, 27, 62, 66, 432, 201, 66, 329, 550, 26, 1847, 9996, 4311, 4619, 228, 4, 62, 141, 142, 89, 142, 886, 315, 31, 1276, 2, 102, 31, 2542, 16538, 864, 12, 123, 32, 97, 1663, 6, 64, 2306, 5978, 123, 90, 23, 46, 74, 1151, 9, 1673, 1877, 165, 2, 4898, 24, 2189, 32, 669, 2255, 1351, 74, 2442, 303, 1700, 451, 1, 1151, 2, 3478, 2725, 228, 1474]",1675.0,30094928,420
The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.,Expert opinion on investigational drugs,Expert Opin Investig Drugs,2018-08-27,"Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive myeloid malignancy that contributes to <1% of all hematologic neoplasms. Before the introduction of various targeted agents, the therapeutic approach was based on regimens used for acute lymphoblastic or myeloid leukemia and non-Hodgkin's lymphoma (e.g. hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone alternating with high dose methotrexate and cytarabine) and CHOP(cyclophosphamide, doxorubicin, vincristine, prednisone) -based regimens) followed by allogeneic stem cell transplantation for eligible patients. Given that this disease primarily affects older patients, there is a significant barrier to using these highly toxic regimens, even though these regimens are usually associated with the most durable response. In this review, we briefly discuss outcomes with the use of leukemia-based induction regimens as well as the use of stem cell transplant. We also review low-intensity chemotherapeutic regimens. Finally, we will describe both preclinical and early clinical data regarding novel targeted strategies for treating BPDCN without the use of cytotoxic chemotherapy, with a focus on the use of CD123 directed therapy. While the current standard treatment for BPDCN is acute leukemia-based regimen followed by hematopoietic stem cell transplantation for transplant-eligible patients, there are very promising results for CD123 directed therapies. The future of BPDCN treatment may include targeted therapies without the need for cytotoxic chemotherapy.",Journal Article,512.0,3.0,Blastic plasmacytoid dendritic cell neoplasm BPDCN is a rare and aggressive myeloid malignancy that contributes to 1 of all hematologic neoplasms Before the introduction of various targeted agents the therapeutic approach was based on regimens used for acute lymphoblastic or myeloid and 's e.g hyperCVAD hyperfractionated cyclophosphamide vincristine doxorubicin and dexamethasone alternating with high dose methotrexate and cytarabine and CHOP cyclophosphamide doxorubicin vincristine prednisone -based regimens followed by allogeneic stem cell transplantation for eligible patients Given that this disease primarily affects older patients there is a significant barrier to using these highly toxic regimens even though these regimens are usually associated with the most durable response In this review we briefly discuss outcomes with the use of leukemia-based induction regimens as well as the use of stem cell transplant We also review low-intensity chemotherapeutic regimens Finally we will describe both preclinical and early clinical data regarding novel targeted strategies for treating BPDCN without the use of cytotoxic chemotherapy with a focus on the use of CD123 directed therapy While the current standard treatment for BPDCN is acute leukemia-based regimen followed by hematopoietic stem cell transplantation for transplant-eligible patients there are very promising results for CD123 directed therapies The future of BPDCN treatment may include targeted therapies without the need for cytotoxic chemotherapy,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6529, 7978, 2464, 31, 2131, 8556, 16, 8, 622, 2, 571, 533, 710, 17, 2444, 6, 14, 1, 62, 813, 1179, 348, 3, 2456, 1, 747, 238, 183, 3, 189, 353, 10, 90, 23, 472, 95, 9, 286, 1275, 15, 533, 2, 292, 563, 499, 13792, 6201, 1112, 2132, 856, 2, 1217, 5181, 5, 64, 61, 2116, 2, 1855, 2, 2907, 1112, 856, 2132, 1979, 90, 472, 370, 20, 1063, 452, 31, 497, 9, 625, 7, 447, 17, 26, 34, 1561, 2561, 434, 7, 125, 16, 8, 93, 3318, 6, 75, 46, 561, 1812, 472, 871, 2471, 46, 472, 32, 2082, 41, 5, 3, 96, 1480, 51, 4, 26, 206, 21, 6277, 1139, 123, 5, 3, 119, 1, 2647, 90, 504, 472, 22, 149, 22, 3, 119, 1, 452, 31, 941, 21, 120, 206, 154, 837, 1573, 472, 1368, 21, 303, 897, 110, 693, 2, 191, 38, 74, 666, 229, 238, 422, 9, 1367, 8556, 187, 3, 119, 1, 759, 56, 5, 8, 1222, 23, 3, 119, 1, 8849, 1166, 36, 369, 3, 291, 260, 24, 9, 8556, 16, 286, 2647, 90, 477, 370, 20, 1007, 452, 31, 497, 9, 941, 625, 7, 125, 32, 923, 721, 99, 9, 8849, 1166, 235, 3, 508, 1, 8556, 24, 68, 643, 238, 235, 187, 3, 594, 9, 759, 56]",1525.0,30118336,733
Comparative Analysis of Calcineurin Inhibitor-Based Methotrexate and Mycophenolate Mofetil-Containing Regimens for Prevention of Graft-versus-Host Disease after Reduced-Intensity Conditioning Allogeneic Transplantation.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-08-25,"The combination of a calcineurin inhibitor (CNI) such as tacrolimus (TAC) or cyclosporine (CYSP) with methotrexate (MTX) or with mycophenolate mofetil (MMF) has been commonly used for graft-versus-host disease (GVHD) prophylaxis after reduced-intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (alloHCT), but there are limited data comparing efficacy of the 2 regimens. We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL), chronic myelogenous leukemia (CML), and myelodysplastic syndrome (MDS) from 2000 to 2013 using HLA-identical sibling (matched related donor [MRD]) or unrelated donor (URD) peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis. Primary outcomes of the study were acute and chronic GVHD and overall survival (OS). The study divided the patient population into 4 cohorts based on regimen: MMF-TAC, MMF-CYSP, MTX-TAC, and MTX-CYSP. In the URD group, MMF-CYSP was associated with increased risk of grade II to IV acute GVHD (relative risk [RR], 1.78; P < .001) and grade III to IV acute GVHD (RR, 1.93; P = .006) compared with MTX-TAC. In the URD group, use of MMF-TAC (versus MTX-TAC) lead to higher nonrelapse mortality. (hazard ratio, 1.48; P = .008). In either group, no there was no difference in chronic GVHD, disease-free survival, and OS among the GVHD prophylaxis regimens. For RIC alloHCT using MRD, there are no differences in outcomes based on GVHD prophylaxis. However, with URD RIC alloHCT, MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention, but all the regimens were equivalent in terms of chronic GVHD and OS. Prospective studies, targeting URD recipients are needed to confirm these results.",Clinical Trial,514.0,2.0,The combination of a calcineurin inhibitor CNI such as tacrolimus TAC or cyclosporine CYSP with methotrexate MTX or with mycophenolate mofetil MMF has been commonly used for graft-versus-host disease GVHD prophylaxis after reduced-intensity conditioning RIC allogeneic hematopoietic cell transplantation alloHCT but there are limited data comparing efficacy of the 2 regimens We evaluated 1564 adult patients who underwent RIC alloHCT for acute myelogenous AML and acute lymphoblastic ALL chronic myelogenous CML and syndrome MDS from 2000 to 2013 using HLA-identical sibling matched related donor MRD or unrelated donor URD peripheral blood graft and received CYSP or TAC with MTX or MMF for GVHD prophylaxis Primary outcomes of the study were acute and chronic GVHD and overall survival OS The study divided the patient population into 4 cohorts based on regimen MMF-TAC MMF-CYSP MTX-TAC and MTX-CYSP In the URD group MMF-CYSP was associated with increased risk of grade II to IV acute GVHD relative risk RR 1.78 P .001 and grade III to IV acute GVHD RR 1.93 P .006 compared with MTX-TAC In the URD group use of MMF-TAC versus MTX-TAC lead to higher nonrelapse mortality hazard ratio 1.48 P .008 In either group no there was no difference in chronic GVHD disease-free survival and OS among the GVHD prophylaxis regimens For RIC alloHCT using MRD there are no differences in outcomes based on GVHD prophylaxis However with URD RIC alloHCT MMF-CYSP was inferior to MTX-based regimens for acute GVHD prevention but all the regimens were equivalent in terms of chronic GVHD and OS Prospective studies targeting URD recipients are needed to confirm these results,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 150, 1, 8, 12028, 230, 16942, 225, 22, 5643, 7364, 15, 9112, 29992, 5, 2116, 3453, 15, 5, 11902, 13246, 9889, 71, 85, 841, 95, 9, 1599, 185, 1204, 34, 1562, 2049, 50, 405, 837, 1933, 3365, 1063, 1007, 31, 497, 5514, 84, 125, 32, 383, 74, 1430, 209, 1, 3, 18, 472, 21, 194, 73484, 780, 7, 54, 208, 3365, 5514, 9, 286, 2194, 329, 2, 286, 1275, 62, 442, 2194, 903, 2, 681, 1223, 29, 1081, 6, 1346, 75, 1160, 3038, 3684, 655, 139, 1488, 2029, 15, 2092, 1488, 5847, 672, 315, 1599, 2, 103, 29992, 15, 7364, 5, 3453, 15, 9889, 9, 1562, 2049, 86, 123, 1, 3, 45, 11, 286, 2, 442, 1562, 2, 63, 25, 118, 3, 45, 2176, 3, 69, 266, 237, 39, 736, 90, 23, 477, 9889, 7364, 9889, 29992, 3453, 7364, 2, 3453, 29992, 4, 3, 5847, 87, 9889, 29992, 10, 41, 5, 101, 43, 1, 88, 215, 6, 478, 286, 1562, 580, 43, 861, 14, 833, 19, 144, 2, 88, 316, 6, 478, 286, 1562, 861, 14, 966, 19, 1861, 72, 5, 3453, 7364, 4, 3, 5847, 87, 119, 1, 9889, 7364, 185, 3453, 7364, 1122, 6, 142, 4640, 282, 360, 197, 14, 576, 19, 2155, 4, 361, 87, 77, 125, 10, 77, 523, 4, 442, 1562, 34, 115, 25, 2, 118, 107, 3, 1562, 2049, 472, 9, 3365, 5514, 75, 2029, 125, 32, 77, 362, 4, 123, 90, 23, 1562, 2049, 137, 5, 5847, 3365, 5514, 9889, 29992, 10, 1663, 6, 3453, 90, 472, 9, 286, 1562, 1070, 84, 62, 3, 472, 11, 2017, 4, 1794, 1, 442, 1562, 2, 118, 482, 94, 529, 5847, 2190, 32, 575, 6, 1843, 46, 99]",1659.0,30153491,373
Chimeric Antigen Receptor T-Cell Therapy.,Journal of the National Comprehensive Cancer Network : JNCCN,J Natl Compr Canc Netw,2018-09-01,"Patients with relapsed or refractory (R/R) cancers have a poor prognosis and limited treatment options. The recent approval of 2 chimeric antigen receptor (CAR) autologous T-cell products for R/R B-cell acute lymphoblastic leukemia and non-Hodgkin's lymphoma treatment is setting the stage for what is possible in other diseases. However, there are important factors that must be considered, including patient selection, toxicity management, and costs associated with CAR T-cell therapy. To begin to address these issues, NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology, cancer center administration, and health policy, which met for the first time in March 2018. This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves.",Journal Article,507.0,4.0,Patients with relapsed or refractory R/R cancers have a poor prognosis and limited treatment options The recent approval of 2 chimeric antigen receptor CAR autologous T-cell products for R/R B-cell acute lymphoblastic and 's treatment is setting the stage for what is possible in other diseases However there are important factors that must be considered including patient selection toxicity management and costs associated with CAR T-cell therapy To begin to address these issues NCCN organized a task force consisting of a multidisciplinary panel of experts in oncology cancer center administration and health policy which met for the first time in March 2018 This report describes the current state of CAR T-cell therapy and future strategies that should be considered as the application of this novel immunotherapy expands and evolves,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7, 5, 591, 15, 430, 668, 668, 163, 47, 8, 334, 356, 2, 383, 24, 838, 3, 435, 1814, 1, 18, 2897, 448, 153, 1881, 1028, 102, 31, 2766, 9, 668, 668, 132, 31, 286, 1275, 2, 292, 24, 16, 546, 3, 82, 9, 2067, 16, 899, 4, 127, 1342, 137, 125, 32, 305, 130, 17, 1642, 40, 515, 141, 69, 881, 155, 284, 2, 1201, 41, 5, 1881, 102, 31, 36, 6, 6886, 6, 1539, 46, 1553, 1944, 7511, 8, 3488, 4380, 2273, 1, 8, 1643, 993, 1, 3186, 4, 413, 12, 574, 634, 2, 341, 4196, 92, 543, 9, 3, 157, 98, 4, 2363, 2982, 26, 414, 2677, 3, 291, 1309, 1, 1881, 102, 31, 36, 2, 508, 422, 17, 257, 40, 515, 22, 3, 1581, 1, 26, 229, 726, 9365, 2, 10413]",838.0,30181421,132
Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations.,PLoS genetics,PLoS Genet.,2018-09-14,"PAX5, one of nine members of the mammalian paired box (PAX) family of transcription factors, plays an important role in B cell development. Approximately one-third of individuals with pre-B acute lymphoblastic leukemia (ALL) acquire heterozygous inactivating mutations of PAX5 in malignant cells, and heterozygous germline loss-of-function PAX5 mutations cause autosomal dominant predisposition to ALL. At least in mice, Pax5 is required for pre-B cell maturation, and leukemic remission occurs when Pax5 expression is restored in a Pax5-deficient mouse model of ALL. Together, these observations indicate that PAX5 deficiency reversibly drives leukemogenesis. PAX5 and its two most closely related paralogs, PAX2 and PAX8, which are not mutated in ALL, exhibit overlapping expression and function redundantly during embryonic development. However, PAX5 alone is expressed in lymphocytes, while PAX2 and PAX8 are predominantly specific to kidney and thyroid, respectively. We show that forced expression of PAX2 or PAX8 complements PAX5 loss-of-function mutation in ALL cells as determined by modulation of PAX5 target genes, restoration of immunophenotypic and morphological differentiation, and, ultimately, reduction of replicative potential. Activation of PAX5 paralogs, PAX2 or PAX8, ordinarily silenced in lymphocytes, may therefore represent a novel approach for treating PAX5-deficient ALL. In pursuit of this strategy, we took advantage of the fact that, in kidney, PAX2 is upregulated by extracellular hyperosmolarity. We found that hyperosmolarity, at potentially clinically achievable levels, transcriptionally activates endogenous PAX2 in ALL cells via a mechanism dependent on NFAT5, a transcription factor coordinating response to hyperosmolarity. We also found that hyperosmolarity upregulates residual wild type PAX5 expression in ALL cells and modulates gene expression, including in PAX5-mutant primary ALL cells. These findings specifically demonstrate that osmosensing pathways may represent a new therapeutic target for ALL and more broadly point toward the possibility of using gene paralogs to rescue mutations driving cancer and other diseases.",Journal Article,494.0,1.0,PAX5 one of nine members of the mammalian paired box PAX family of transcription factors plays an important role in B cell development Approximately one-third of individuals with pre-B acute lymphoblastic ALL acquire heterozygous inactivating mutations of PAX5 in malignant cells and heterozygous germline loss-of-function PAX5 mutations cause autosomal dominant predisposition to ALL At least in mice Pax5 is required for pre-B cell maturation and leukemic remission occurs when Pax5 expression is restored in a Pax5-deficient mouse model of ALL Together these observations indicate that PAX5 deficiency reversibly drives leukemogenesis PAX5 and its two most closely related paralogs PAX2 and PAX8 which are not mutated in ALL exhibit overlapping expression and function redundantly during embryonic development However PAX5 alone is expressed in lymphocytes while PAX2 and PAX8 are predominantly specific to and respectively We show that forced expression of PAX2 or PAX8 complements PAX5 loss-of-function mutation in ALL cells as determined by modulation of PAX5 target genes restoration of immunophenotypic and morphological differentiation and ultimately reduction of replicative potential Activation of PAX5 paralogs PAX2 or PAX8 ordinarily silenced in lymphocytes may therefore represent a novel approach for treating PAX5-deficient ALL In pursuit of this strategy we took advantage of the fact that in PAX2 is upregulated by extracellular hyperosmolarity We found that hyperosmolarity at potentially clinically achievable levels transcriptionally activates endogenous PAX2 in ALL cells via a mechanism dependent on NFAT5 a transcription factor coordinating response to hyperosmolarity We also found that hyperosmolarity upregulates residual wild type PAX5 expression in ALL cells and modulates gene expression including in PAX5-mutant primary ALL cells These findings specifically demonstrate that osmosensing pathways may represent a new therapeutic target for ALL and more broadly point toward the possibility of using gene paralogs to rescue mutations driving cancer and other diseases,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,"[6279, 104, 1, 762, 1684, 1, 3, 2359, 2355, 4971, 12691, 607, 1, 866, 130, 1698, 35, 305, 200, 4, 132, 31, 193, 705, 104, 1282, 1, 869, 5, 671, 132, 286, 1275, 62, 6206, 4167, 6096, 138, 1, 6279, 4, 393, 37, 2, 4167, 1009, 407, 1, 343, 6279, 138, 708, 6084, 2156, 2863, 6, 62, 28, 506, 4, 399, 6279, 16, 616, 9, 671, 132, 31, 4537, 2, 2015, 734, 1780, 198, 6279, 55, 16, 4138, 4, 8, 6279, 1971, 830, 202, 1, 62, 1162, 46, 2172, 1008, 17, 6279, 2299, 15837, 5267, 5661, 6279, 2, 211, 100, 96, 3210, 139, 22624, 15730, 2, 8958, 92, 32, 44, 1185, 4, 62, 2239, 4551, 55, 2, 343, 38702, 190, 5390, 193, 137, 6279, 279, 16, 570, 4, 1594, 369, 15730, 2, 8958, 32, 2117, 112, 6, 2, 106, 21, 514, 17, 5216, 55, 1, 15730, 15, 8958, 20576, 6279, 407, 1, 343, 258, 4, 62, 37, 22, 509, 20, 2356, 1, 6279, 283, 214, 5194, 1, 6599, 2, 4268, 910, 2, 2050, 628, 1, 14529, 174, 363, 1, 6279, 22624, 15730, 15, 8958, 49573, 5442, 4, 1594, 68, 673, 1231, 8, 229, 353, 9, 1367, 6279, 1971, 62, 4, 13649, 1, 26, 692, 21, 5060, 1874, 1, 3, 1991, 17, 4, 15730, 16, 2684, 20, 1976, 30383, 21, 204, 17, 30383, 28, 751, 505, 6171, 148, 6851, 3932, 2682, 15730, 4, 62, 37, 847, 8, 670, 470, 23, 73566, 8, 866, 161, 17428, 51, 6, 30383, 21, 120, 204, 17, 30383, 9641, 753, 955, 267, 6279, 55, 4, 62, 37, 2, 5259, 145, 55, 141, 4, 6279, 620, 86, 62, 37, 46, 272, 1225, 608, 17, 73567, 460, 68, 1231, 8, 217, 189, 283, 9, 62, 2, 80, 5482, 741, 1317, 3, 2526, 1, 75, 145, 22624, 6, 4256, 138, 4057, 12, 2, 127, 1342]",2096.0,30216339,616
Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin.,American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting,Am Soc Clin Oncol Educ Book,2018-05-01,"Monoclonal antibodies and bispecific antibody constructs hold considerable promise in improving the outcomes of patients with acute lymphoblastic leukemia (ALL). Antibody-drug conjugates such as inotuzumab ozogamicin and the bispecific T-cell engager blinatumomab represent novel antibody constructs that have shown substantial clinical activity in ALL. Although most studies have focused on the use of these agents in the salvage setting, incorporation of these antibodies into the frontline regimens is imperative to improve long-term survival for patients with ALL and to increase the cure rates of adult ALL to the levels achieved in the pediatric population.",Journal Article,630.0,6.0,Monoclonal antibodies and bispecific antibody constructs hold considerable promise in improving the outcomes of patients with acute lymphoblastic ALL Antibody-drug conjugates such as inotuzumab ozogamicin and the bispecific T-cell engager blinatumomab represent novel antibody constructs that have shown substantial clinical activity in ALL Although most studies have focused on the use of these agents in the salvage setting incorporation of these antibodies into the frontline regimens is imperative to improve long-term survival for patients with ALL and to increase the cure rates of adult ALL to the levels achieved in the pediatric population,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[848, 890, 2, 7408, 548, 5500, 4164, 2658, 1783, 4, 1673, 3, 123, 1, 7, 5, 286, 1275, 62, 548, 234, 5968, 225, 22, 6730, 5566, 2, 3, 7408, 102, 31, 19374, 7182, 1231, 229, 548, 5500, 17, 47, 443, 1281, 38, 128, 4, 62, 242, 96, 94, 47, 1649, 23, 3, 119, 1, 46, 183, 4, 3, 992, 546, 2838, 1, 46, 890, 237, 3, 3171, 472, 16, 6305, 6, 401, 319, 337, 25, 9, 7, 5, 62, 2, 6, 344, 3, 1722, 151, 1, 780, 62, 6, 3, 148, 513, 4, 3, 815, 266]",648.0,30231308,867
Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.,Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation,Biol. Blood Marrow Transplant.,2018-10-05,"Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL) is a subset of high-risk B cell ALLs. A large proportion of Ph-like ALL cases carry activating kinase mutations that could potentially allow them to be targeted by tyrosine kinase inhibitors. Ph-like ALL is not an uncommon entity, especially among adults, with a frequency exceeding 20%, including in older patients (>60 years old) with ALL. Ph-like ALL is associated with inferior outcomes across all ages, and studies have consistently shown a higher incidence of persistent postinduction minimal residual disease in patients carrying Ph-like ALL compared with other subgroups of ALL, and this translates into inferior leukemia-related outcomes. The inferior outcome of conventional chemotherapy for Ph-like ALL in adults raises the fundamental question of whether all adults with Ph-like ALL require an allogeneic hematopoietic cell transplantation (HCT) in first complete remission (CR1) regardless of other presenting features and treatment response parameters. Here we present and discuss several scenarios in which adults with Ph-like ALL underwent or were considered for HCT in CR1 for various reasons. Although the decision to proceed with HCT was clear and indisputable in some of these situations, in others we struggled with the decision to transplant in CR1 because of the lack of published data regarding the efficacy of allogeneic HCT as consolidation for Ph-like ALL. We emphasize the urgent need for developing well-designed studies to address this important question.",Case Reports,473.0,2.0,Philadelphia chromosome-like Ph-like acute lymphoblastic ALL is a subset of high-risk B cell ALLs A large proportion of Ph-like ALL cases carry activating kinase mutations that could potentially allow them to be targeted by tyrosine kinase inhibitors Ph-like ALL is not an uncommon entity especially among adults with a frequency exceeding 20 including in older patients 60 years old with ALL Ph-like ALL is associated with inferior outcomes across all ages and studies have consistently shown a higher incidence of persistent postinduction minimal residual disease in patients carrying Ph-like ALL compared with other subgroups of ALL and this translates into inferior leukemia-related outcomes The inferior outcome of conventional chemotherapy for Ph-like ALL in adults raises the fundamental question of whether all adults with Ph-like ALL require an allogeneic hematopoietic cell transplantation HCT in first complete remission CR1 regardless of other presenting features and treatment response parameters Here we present and discuss several scenarios in which adults with Ph-like ALL underwent or were considered for HCT in CR1 for various reasons Although the decision to proceed with HCT was clear and indisputable in some of these situations in others we struggled with the decision to transplant in CR1 because of the lack of published data regarding the efficacy of allogeneic HCT as consolidation for Ph-like ALL We emphasize the urgent need for developing well-designed studies to address this important question,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 1170, 733, 2058, 733, 286, 1275, 62, 16, 8, 697, 1, 64, 43, 132, 31, 10706, 8, 375, 920, 1, 2058, 733, 62, 140, 3542, 1616, 216, 138, 17, 359, 751, 1700, 1370, 6, 40, 238, 20, 564, 216, 222, 2058, 733, 62, 16, 44, 35, 2052, 2983, 1093, 107, 857, 5, 8, 675, 5178, 179, 141, 4, 434, 7, 335, 60, 1095, 5, 62, 2058, 733, 62, 16, 41, 5, 1663, 123, 716, 62, 2165, 2, 94, 47, 2433, 443, 8, 142, 287, 1, 1882, 12543, 1048, 753, 34, 4, 7, 2934, 2058, 733, 62, 72, 5, 127, 1453, 1, 62, 2, 26, 10328, 237, 1663, 2647, 139, 123, 3, 1663, 228, 1, 809, 56, 9, 2058, 733, 62, 4, 857, 5789, 3, 4595, 2840, 1, 317, 62, 857, 5, 2058, 733, 62, 1353, 35, 1063, 1007, 31, 497, 1085, 4, 157, 236, 734, 4516, 1583, 1, 127, 1656, 404, 2, 24, 51, 1038, 467, 21, 364, 2, 1139, 392, 3964, 4, 92, 857, 5, 2058, 733, 62, 208, 15, 11, 515, 9, 1085, 4, 4516, 9, 747, 2325, 242, 3, 948, 6, 6174, 5, 1085, 10, 885, 2, 39214, 4, 476, 1, 46, 5990, 4, 1749, 21, 42167, 5, 3, 948, 6, 941, 4, 4516, 408, 1, 3, 926, 1, 983, 74, 666, 3, 209, 1, 1063, 1085, 22, 2173, 9, 2058, 733, 62, 21, 5560, 3, 5013, 594, 9, 931, 149, 1114, 94, 6, 1539, 26, 305, 2840]",1524.0,30292743,41
"Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.",Cancer,Cancer,2018-10-11,"The outcomes of patients with relapsed or refractory (R-R) acute lymphoblastic leukemia (ALL) are poor. Inotuzumab ozogamicin and blinatumomab have single-agent activity in R-R ALL. Their addition to low-intensity chemotherapy may further improve the outcomes of patients with ALL in their first relapse. The chemotherapy was lower in intensity than conventional hyperfractionated cyclophosphamide, vincristine, adriamycin, and dexamethasone and was called mini-hyperfractionated cyclophosphamide, vincristine, and dexamethasone (or mini-HCVD). Inotuzumab was given on day 3 of each of the first 4 cycles at 1.8 to 1.3 mg/m<sup>2</sup> for cycle 1, and this was followed by 1.3 to 1.0 mg/m<sup>2</sup> for subsequent cycles. From patient 39 onward, the inotuzumab dose was reduced and fractionated into weekly doses (0.6 and 0.3 mg/m<sup>2</sup> during cycle 1 and 0.3 and 0.3 mg/m<sup>2</sup> during subsequent cycles), and blinatumomab was administered for up to 4 cycles after inotuzumab therapy. Forty-eight patients with Philadelphia chromosome-negative ALL with a median age of 39 years were treated during their first relapse. Overall, 44 patients (92%) responded, with 35 of them (73%) achieving a complete response. The overall minimal residual disease negativity rate among the responders was 93%. Twenty-four patients (50%) underwent allogeneic stem cell transplantation (ASCT). Veno-occlusive disease of any grade occurred in 5 patients (10%). With a median follow-up of 31 months, the median progression-free survival (PFS) and the median overall survival (OS) were 11 and 25 months, respectively. The 2-year PFS and OS rates were 42% and 54%, respectively. Of the 24 patients (50%) who underwent ASCT, 14 patients were alive at the last follow-up (13 [54%] in remission). Of the remaining 20 responding patients who did not undergo subsequent ASCT, 6 (30%) remained in remission at the last follow-up. According to propensity score matching, the combination of mini-HCVD and inotuzumab with or without blinatumomab conferred better outcomes than intensive salvage chemotherapy or inotuzumab alone. The combination of inotuzumab and low-intensity mini-HCVD chemotherapy with or without blinatumomab shows encouraging results in patients with ALL in first salvage.","Clinical Trial, Phase II",467.0,21.0,The outcomes of patients with relapsed or refractory R-R acute lymphoblastic ALL are poor Inotuzumab ozogamicin and blinatumomab have single-agent activity in R-R ALL Their addition to low-intensity chemotherapy may further improve the outcomes of patients with ALL in their first relapse The chemotherapy was lower in intensity than conventional hyperfractionated cyclophosphamide vincristine adriamycin and dexamethasone and was called mini-hyperfractionated cyclophosphamide vincristine and dexamethasone or mini-HCVD Inotuzumab was given on day 3 of each of the first 4 cycles at 1.8 to 1.3 mg/m sup 2 /sup for cycle 1 and this was followed by 1.3 to 1.0 mg/m sup 2 /sup for subsequent cycles From patient 39 onward the inotuzumab dose was reduced and fractionated into weekly doses 0.6 and 0.3 mg/m sup 2 /sup during cycle 1 and 0.3 and 0.3 mg/m sup 2 /sup during subsequent cycles and blinatumomab was administered for up to 4 cycles after inotuzumab therapy Forty-eight patients with Philadelphia chromosome-negative ALL with a median age of 39 years were treated during their first relapse Overall 44 patients 92 responded with 35 of them 73 achieving a complete response The overall minimal residual disease negativity rate among the responders was 93 Twenty-four patients 50 underwent allogeneic stem cell transplantation ASCT Veno-occlusive disease of any grade occurred in 5 patients 10 With a median follow-up of 31 months the median progression-free survival PFS and the median overall survival OS were 11 and 25 months respectively The 2-year PFS and OS rates were 42 and 54 respectively Of the 24 patients 50 who underwent ASCT 14 patients were alive at the last follow-up 13 54 in remission Of the remaining 20 responding patients who did not undergo subsequent ASCT 6 30 remained in remission at the last follow-up According to propensity score matching the combination of mini-HCVD and inotuzumab with or without blinatumomab conferred better outcomes than intensive salvage chemotherapy or inotuzumab alone The combination of inotuzumab and low-intensity mini-HCVD chemotherapy with or without blinatumomab shows encouraging results in patients with ALL in first salvage,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 123, 1, 7, 5, 591, 15, 430, 668, 668, 286, 1275, 62, 32, 334, 6730, 5566, 2, 7182, 47, 226, 420, 128, 4, 668, 668, 62, 136, 352, 6, 154, 837, 56, 68, 195, 401, 3, 123, 1, 7, 5, 62, 4, 136, 157, 429, 3, 56, 10, 280, 4, 837, 76, 809, 6201, 1112, 2132, 7700, 2, 1217, 2, 10, 3472, 7313, 6201, 1112, 2132, 2, 1217, 15, 7313, 32786, 6730, 10, 447, 23, 218, 27, 1, 296, 1, 3, 157, 39, 410, 28, 14, 66, 6, 14, 27, 81, 188, 172, 18, 172, 9, 417, 14, 2, 26, 10, 370, 20, 14, 27, 6, 14, 13, 81, 188, 172, 18, 172, 9, 706, 410, 29, 69, 587, 15088, 3, 6730, 61, 10, 405, 2, 3950, 237, 709, 415, 13, 49, 2, 13, 27, 81, 188, 172, 18, 172, 190, 417, 14, 2, 13, 27, 2, 13, 27, 81, 188, 172, 18, 172, 190, 706, 410, 2, 7182, 10, 468, 9, 126, 6, 39, 410, 50, 6730, 36, 1213, 659, 7, 5, 3006, 1170, 199, 62, 5, 8, 52, 89, 1, 587, 60, 11, 73, 190, 136, 157, 429, 63, 584, 7, 937, 2211, 5, 465, 1, 1370, 803, 1785, 8, 236, 51, 3, 63, 1048, 753, 34, 6014, 116, 107, 3, 1983, 10, 966, 737, 294, 7, 212, 208, 1063, 452, 31, 497, 1584, 10273, 8376, 34, 1, 500, 88, 489, 4, 33, 7, 79, 5, 8, 52, 166, 126, 1, 456, 53, 3, 52, 91, 115, 25, 300, 2, 3, 52, 63, 25, 118, 11, 175, 2, 243, 53, 106, 3, 18, 111, 300, 2, 118, 151, 11, 595, 2, 667, 106, 1, 3, 259, 7, 212, 54, 208, 1584, 213, 7, 11, 1701, 28, 3, 1060, 166, 126, 233, 667, 4, 734, 1, 3, 1844, 179, 3261, 7, 54, 205, 44, 1251, 706, 1584, 49, 201, 958, 4, 734, 28, 3, 1060, 166, 126, 768, 6, 1925, 368, 2616, 3, 150, 1, 7313, 32786, 2, 6730, 5, 15, 187, 7182, 3851, 380, 123, 76, 1686, 992, 56, 15, 6730, 279, 3, 150, 1, 6730, 2, 154, 837, 7313, 32786, 56, 5, 15, 187, 7182, 1949, 2269, 99, 4, 7, 5, 62, 4, 157, 992]",2190.0,30307611,197
"Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia.",Cancer,Cancer,2018-10-25,"Children with acute lymphoblastic leukemia (ALL) have an increased risk of obesity and short stature. To the authors' knowledge, data regarding patients treated on contemporary protocols without cranial irradiation are limited. Changes in z scores for body mass index (BMI), height, and weight from the time of diagnosis to 5 years off therapy were evaluated using multivariable analysis in 372 children with ALL who were aged 2 to 18 years at the time of diagnosis and were enrolled on the St. Jude Children's Research Hospital Total XV protocol from 2000 through 2007. The percentage of overweight/obese patients increased from 25.5% at the time of diagnosis to approximately 50% during the off-therapy period. Median BMI z scores increased significantly during glucocorticoid therapy (induction: 0.56; 95% confidence interval [95% CI], 0.29-0.64 [P<.001]; and reinduction II: 0.22; 95% CI, 0.13-0.49 [P=.001]) and during the first year after therapy (0.18; 95% CI, 0.08-0.46 [P=.006]). Among patients who were of healthy weight/underweight at the time of diagnosis, those aged 2 to <10 years at diagnosis had a significantly higher risk of becoming overweight/obese during or after therapy compared with those aged 10 years (P=.001). Height z scores declined during treatment and improved after therapy. Being aged 2 to <10 years at the time of diagnosis, being of low-risk status, having a white blood cell count<5010<sup>9</sup> /L at the time of diagnosis, and having negative central nervous system disease were associated with significantly better improvements in z scores for height during the off-therapy period compared with being aged 10 years, being of standard-risk/high-risk status, having a white blood cell count 5010<sup>9</sup> /L, and having positive central nervous system disease, respectively. The results of the current study demonstrate that obesity is prevalent, and height growth, especially in patients with identified risk factors, appears compromised. Multidisciplinary intervention should begin during induction therapy and continue during the off-therapy period.",Clinical Trial,453.0,3.0,Children with acute lymphoblastic ALL have an increased risk of obesity and short stature To the authors knowledge data regarding patients treated on contemporary protocols without cranial irradiation are limited Changes in z scores for body mass index BMI height and weight from the time of diagnosis to 5 years off therapy were evaluated using multivariable analysis in 372 children with ALL who were aged 2 to 18 years at the time of diagnosis and were enrolled on the St. Jude Children 's Research Hospital Total XV protocol from 2000 through 2007 The percentage of overweight/obese patients increased from 25.5 at the time of diagnosis to approximately 50 during the off-therapy period Median BMI z scores increased significantly during glucocorticoid therapy induction 0.56 95 confidence interval 95 CI 0.29-0.64 P .001 and reinduction II 0.22 95 CI 0.13-0.49 P=.001 and during the first year after therapy 0.18 95 CI 0.08-0.46 P=.006 Among patients who were of healthy weight/underweight at the time of diagnosis those aged 2 to 10 years at diagnosis had a significantly higher risk of becoming overweight/obese during or after therapy compared with those aged 10 years P=.001 Height z scores declined during treatment and improved after therapy Being aged 2 to 10 years at the time of diagnosis being of low-risk status having a white blood cell count 5010 sup 9 /sup /L at the time of diagnosis and having negative central nervous system disease were associated with significantly better improvements in z scores for height during the off-therapy period compared with being aged 10 years being of standard-risk/high-risk status having a white blood cell count  5010 sup 9 /sup /L and having positive central nervous system disease respectively The results of the current study demonstrate that obesity is prevalent and height growth especially in patients with identified risk factors appears compromised Multidisciplinary intervention should begin during induction therapy and continue during the off-therapy period,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[541, 5, 286, 1275, 62, 47, 35, 101, 43, 1, 1661, 2, 978, 13576, 6, 3, 738, 922, 74, 666, 7, 73, 23, 2667, 2189, 187, 2565, 1104, 32, 383, 400, 4, 3905, 703, 9, 642, 782, 558, 1140, 4594, 2, 924, 29, 3, 98, 1, 147, 6, 33, 60, 1889, 36, 11, 194, 75, 658, 65, 4, 10659, 541, 5, 62, 54, 11, 1032, 18, 6, 203, 60, 28, 3, 98, 1, 147, 2, 11, 346, 23, 3, 3062, 4841, 541, 292, 389, 702, 181, 16078, 1182, 29, 1081, 298, 1307, 3, 1150, 1, 3566, 2209, 7, 101, 29, 243, 33, 28, 3, 98, 1, 147, 6, 705, 212, 190, 3, 1889, 36, 727, 52, 1140, 3905, 703, 101, 97, 190, 5399, 36, 504, 42183, 664, 48, 307, 268, 48, 58, 13, 462, 13, 660, 19, 144, 2, 10177, 215, 42183, 350, 48, 58, 13, 233, 13, 739, 19, 144, 2, 190, 3, 157, 111, 50, 36, 42183, 203, 48, 58, 13, 1592, 13, 641, 19, 1861, 107, 7, 54, 11, 1, 1331, 924, 8094, 28, 3, 98, 1, 147, 135, 1032, 18, 6, 79, 60, 28, 147, 42, 8, 97, 142, 43, 1, 4009, 3566, 2209, 190, 15, 50, 36, 72, 5, 135, 1032, 4556, 60, 19, 144, 4594, 3905, 703, 3054, 190, 24, 2, 231, 50, 36, 486, 1032, 18, 6, 79, 60, 28, 3, 98, 1, 147, 486, 1, 154, 43, 156, 1041, 8, 886, 315, 31, 1276, 40393, 172, 83, 172, 805, 28, 3, 98, 1, 147, 2, 1041, 199, 854, 1880, 398, 34, 11, 41, 5, 97, 380, 1474, 4, 3905, 703, 9, 4594, 190, 3, 1889, 36, 727, 72, 5, 486, 1032, 4556, 60, 486, 1, 260, 43, 64, 43, 156, 1041, 8, 886, 315, 31, 1276, 749, 40393, 172, 83, 172, 805, 2, 1041, 109, 854, 1880, 398, 34, 106, 3, 99, 1, 3, 291, 45, 608, 17, 1661, 16, 2485, 2, 4594, 129, 1093, 4, 7, 5, 108, 43, 130, 1233, 4867, 1643, 788, 257, 6886, 190, 504, 36, 2, 1906, 190, 3, 1889, 36, 727]",2033.0,30358906,496
DNA methylation and obesity in survivors of pediatric acute lymphoblastic leukemia: A report from the Childhood Cancer Survivor Study.,"Genes, chromosomes & cancer",Genes Chromosomes Cancer,2018-12-04,"Because survivors of pediatric acute lymphoblastic leukemia (ALL) are more likely to be obese than unaffected contemporaries, we compared DNA methylation profiles between normal-weight and obese survivors at adiposity-associated CpG sites previously-reported by epigenome-wide association studies (EWAS) of body mass index (BMI) in the general population. We selected 96 ALL survivors from the Childhood Cancer Survivor Study: 48 obese and 48 normal weight. The Illumina HumanMethylation450 BeadChip was used to compare DNA methylation at 211 loci identified in EWAS of BMI in the general population. Thirty-nine loci were associated (false discovery rate <0.05) with obesity among survivors who only received chemotherapy (n=49). No loci were significantly associated with obesity among CRT-exposed survivors (n=47). Our results suggest that previously identified BMI-DNA methylation loci are associated with obesity in ALL survivors who were spared CRT, while no loci were significantly associated with obesity in survivors who received CRT.",Journal Article,413.0,0.0,Because survivors of pediatric acute lymphoblastic ALL are more likely to be obese than unaffected contemporaries we compared DNA methylation profiles between normal-weight and obese survivors at adiposity-associated CpG sites previously-reported by epigenome-wide association studies EWAS of body mass index BMI in the general population We selected 96 ALL survivors from the Childhood Cancer Survivor Study 48 obese and 48 normal weight The Illumina HumanMethylation450 BeadChip was used to compare DNA methylation at 211 loci identified in EWAS of BMI in the general population Thirty-nine loci were associated false discovery rate 0.05 with obesity among survivors who only received chemotherapy n 49 No loci were significantly associated with obesity among CRT-exposed survivors n 47 Our results suggest that previously identified BMI-DNA methylation loci are associated with obesity in ALL survivors who were spared CRT while no loci were significantly associated with obesity in survivors who received CRT,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[408, 332, 1, 815, 286, 1275, 62, 32, 80, 322, 6, 40, 2209, 76, 4585, 73898, 21, 72, 261, 569, 1241, 59, 295, 924, 2, 2209, 332, 28, 8462, 41, 2075, 633, 373, 210, 20, 10206, 1019, 248, 94, 51319, 1, 642, 782, 558, 1140, 4, 3, 1083, 266, 21, 715, 921, 62, 332, 29, 3, 864, 12, 2628, 45, 576, 2209, 2, 576, 295, 924, 3, 7457, 40441, 16111, 10, 95, 6, 932, 261, 569, 28, 5905, 2012, 108, 4, 51319, 1, 1140, 4, 3, 1083, 266, 977, 762, 2012, 11, 41, 2133, 1574, 116, 13, 474, 5, 1661, 107, 332, 54, 158, 103, 56, 78, 739, 77, 2012, 11, 97, 41, 5, 1661, 107, 1089, 2234, 332, 78, 662, 114, 99, 309, 17, 373, 108, 1140, 261, 569, 2012, 32, 41, 5, 1661, 4, 62, 332, 54, 11, 6830, 1089, 369, 77, 2012, 11, 97, 41, 5, 1661, 4, 332, 54, 103, 1089]",1012.0,30382603,29
Recommendations for the assessment and management of measurable residual disease in adults with acute lymphoblastic leukemia: A consensus of North American experts.,American journal of hematology,Am. J. Hematol.,2018-11-26,"Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL.",Journal Article,421.0,10.0,Measurable residual disease MRD that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic ALL However the optimal use of this information to influence therapeutic decisions is controversial Herein we comprehensively review the role of MRD assessment in adults with ALL including methods to quantify residual cells during remission prognostic impact of MRD across ALL subtypes and available therapeutic approaches to eradicate MRD This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1884, 753, 34, 2029, 17, 8936, 50, 388, 36, 16, 8, 3757, 980, 1, 429, 2, 25, 4, 286, 1275, 62, 137, 3, 665, 119, 1, 26, 487, 6, 1054, 189, 1526, 16, 2010, 1986, 21, 5627, 206, 3, 200, 1, 2029, 455, 4, 857, 5, 62, 141, 636, 6, 3091, 753, 37, 190, 734, 177, 345, 1, 2029, 716, 62, 814, 2, 390, 189, 611, 6, 5650, 2029, 26, 206, 2740, 1391, 7072, 2, 777, 35, 241, 90, 2586, 9, 6734, 11474, 2, 1339, 6, 119, 2029, 487, 6, 2378, 2696, 24, 1526, 4, 780, 7, 5, 62]",693.0,30394566,583
PRC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia.,The Journal of experimental medicine,J. Exp. Med.,2018-11-07,"The tendency of mitochondria to undergo or resist BCL2-controlled apoptosis (so-called mitochondrial priming) is a powerful predictor of response to cytotoxic chemotherapy. Fully exploiting this finding will require unraveling the molecular genetics underlying phenotypic variability in mitochondrial priming. Here, we report that mitochondrial apoptosis resistance in T cell acute lymphoblastic leukemia (T-ALL) is mediated by inactivation of polycomb repressive complex 2 (PRC2). In T-ALL clinical specimens, loss-of-function mutations of PRC2 core components (<i>EZH2</i>, <i>EED</i>, or <i>SUZ12</i>) were associated with mitochondrial apoptosis resistance. In T-ALL cells, PRC2 depletion induced resistance to apoptosis induction by multiple chemotherapeutics with distinct mechanisms of action. PRC2 loss induced apoptosis resistance via transcriptional up-regulation of the LIM domain transcription factor <i>CRIP2</i> and downstream up-regulation of the mitochondrial chaperone <i>TRAP1</i> These findings demonstrate the importance of mitochondrial apoptotic priming as a prognostic factor in T-ALL and implicate mitochondrial chaperone function as a molecular determinant of chemotherapy response.",Journal Article,440.0,3.0,The tendency of mitochondria to undergo or resist BCL2-controlled apoptosis so-called mitochondrial priming is a powerful predictor of response to cytotoxic chemotherapy Fully exploiting this finding will require unraveling the molecular genetics underlying phenotypic variability in mitochondrial priming Here we report that mitochondrial apoptosis resistance in T cell acute lymphoblastic T-ALL is mediated by inactivation of polycomb repressive complex 2 PRC2 In T-ALL clinical specimens loss-of-function mutations of PRC2 core components i EZH2 /i i EED /i or i SUZ12 /i were associated with mitochondrial apoptosis resistance In T-ALL cells PRC2 depletion induced resistance to apoptosis induction by multiple chemotherapeutics with distinct mechanisms of action PRC2 loss induced apoptosis resistance via transcriptional up-regulation of the LIM domain transcription factor i CRIP2 /i and downstream up-regulation of the mitochondrial chaperone i TRAP1 /i These findings demonstrate the importance of mitochondrial apoptotic priming as a prognostic factor in T-ALL and implicate mitochondrial chaperone function as a molecular determinant of chemotherapy response,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 7135, 1, 5443, 6, 1251, 15, 13010, 3214, 1149, 351, 1743, 3472, 2019, 4903, 16, 8, 3757, 980, 1, 51, 6, 759, 56, 1910, 10060, 26, 1567, 303, 1353, 21376, 3, 219, 2894, 1181, 3290, 1982, 4, 2019, 4903, 467, 21, 414, 17, 2019, 351, 251, 4, 102, 31, 286, 1275, 102, 62, 16, 517, 20, 2297, 1, 8666, 9851, 840, 18, 9321, 4, 102, 62, 38, 623, 407, 1, 343, 138, 1, 9321, 1793, 1628, 70, 3755, 70, 70, 14690, 70, 15, 70, 20862, 70, 11, 41, 5, 2019, 351, 251, 4, 102, 62, 37, 9321, 2286, 277, 251, 6, 351, 504, 20, 232, 6097, 5, 834, 483, 1, 1578, 9321, 407, 277, 351, 251, 847, 1431, 126, 863, 1, 3, 19837, 1398, 866, 161, 70, 73940, 70, 2, 1489, 126, 863, 1, 3, 2019, 7255, 70, 25296, 70, 46, 272, 608, 3, 1187, 1, 2019, 1631, 4903, 22, 8, 177, 161, 4, 102, 62, 2, 5545, 2019, 7255, 343, 22, 8, 219, 4372, 1, 56, 51]",1169.0,30404791,27
How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia.,Blood,Blood,2018-11-15,"The introduction of agents targeted at specific molecular events is changing the treatment paradigms in a number of malignancies. Historically, we have relied entirely on DNA-interactive, cytotoxic drugs for treating patients with leukemia. Increased understanding of the leukemic cell biology and pathogenesis, and the ways they evade the immune surveillance mechanisms, will likely lead to the development of more effective agents, and regimens less reliant on chemotherapy, able to achieve deep levels of disease eradication. In Philadelphia chromosome-positive acute lymphoblastic leukemia, the introduction of increasingly potent tyrosine kinas inhibitors (TKIs) has revolutionized therapy. These drugs have been established as the cornerstone of any therapeutic strategy in this disease, and a number of trials have better defined the best ways to incorporate them into the established paradigms. Despite using TKIs, we have continued to remain reliant on cytotoxic chemotherapy regimens and allogeneic hematopoietic cell transplant to achieve the best long-term outcomes. However, with the introduction of more potent TKIs and other novel agents, as well as better methods for monitoring minimal/measurable residual disease, we are entering an era where we hope to diminish our reliance on transplantation and cytotoxic chemotherapy in this disease.",Case Reports,432.0,3.0,The introduction of agents targeted at specific molecular events is changing the treatment paradigms in a number of malignancies Historically we have relied entirely on DNA-interactive cytotoxic drugs for treating patients with Increased understanding of the leukemic cell biology and pathogenesis and the ways they evade the immune surveillance mechanisms will likely lead to the development of more effective agents and regimens less reliant on chemotherapy able to achieve deep levels of disease eradication In Philadelphia chromosome-positive acute lymphoblastic the introduction of increasingly potent tyrosine kinas inhibitors TKIs has revolutionized therapy These drugs have been established as the cornerstone of any therapeutic strategy in this disease and a number of trials have better defined the best ways to incorporate them into the established paradigms Despite using TKIs we have continued to remain reliant on cytotoxic chemotherapy regimens and allogeneic hematopoietic cell transplant to achieve the best long-term outcomes However with the introduction of more potent TKIs and other novel agents as well as better methods for monitoring minimal/measurable residual disease we are entering an era where we hope to diminish our reliance on transplantation and cytotoxic chemotherapy in this disease,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 2456, 1, 183, 238, 28, 112, 219, 281, 16, 3600, 3, 24, 4887, 4, 8, 207, 1, 441, 3578, 21, 47, 9896, 6848, 23, 261, 4750, 759, 600, 9, 1367, 7, 5, 101, 612, 1, 3, 2015, 31, 891, 2, 1384, 2, 3, 4245, 491, 6636, 3, 250, 617, 483, 303, 322, 1122, 6, 3, 193, 1, 80, 323, 183, 2, 472, 299, 14803, 23, 56, 1665, 6, 1359, 2369, 148, 1, 34, 5173, 4, 3006, 1170, 109, 286, 1275, 3, 2456, 1, 1635, 1157, 564, 74025, 222, 1671, 71, 5746, 36, 46, 600, 47, 85, 635, 22, 3, 7019, 1, 500, 189, 692, 4, 26, 34, 2, 8, 207, 1, 143, 47, 380, 395, 3, 824, 4245, 6, 3360, 1370, 237, 3, 635, 4887, 550, 75, 1671, 21, 47, 1351, 6, 918, 14803, 23, 759, 56, 472, 2, 1063, 1007, 31, 941, 6, 1359, 3, 824, 319, 337, 123, 137, 5, 3, 2456, 1, 80, 1157, 1671, 2, 127, 229, 183, 22, 149, 22, 380, 636, 9, 1315, 1048, 1884, 753, 34, 21, 32, 7653, 35, 1713, 1257, 21, 3045, 6, 8440, 114, 9007, 23, 497, 2, 759, 56, 4, 26, 34]",1317.0,30442680,167
Should immunologic strategies be incorporated into frontline ALL therapy?,Best practice & research. Clinical haematology,Best Pract Res Clin Haematol,2018-09-25,"Survival rates in adult patients with acute lymphoblastic leukemia (ALL) have markedly improved during the past decade. The one-size-fits-all-ages approach has been replaced with adaptation of pediatric-inspired treatment protocols for younger adults. Yet different treatment strategies for older patients are needed due to chemotherapy-related toxicities. A new era of immunotherapy has arrived, offering opportunities for targeted treatments for ALL subtypes. While CD20 targeting with rituximab has been demonstrated to improve survival when combined with chemotherapy, it has little activity as a single agent in ALL. In contrast, antibody targeting of CD19 and CD22 with blinatumomab and inotuzumab ozogamicin, respectively, has had remarkable single-agent activity in the relapsed setting. Studies are now underway to test these agents in combination with chemotherapy in the frontline setting. The goal of these studies is to improve event-free survival and overall survival by using these approaches in the frontline to eradicate minimal residual disease and, particularly in older adults with ALL, to reduce treatment-related toxicity by limiting the exposure to traditional multi-agent chemotherapy with its attendant toxicities. This review focuses on new immunotherapeutic treatment options and strategies for frontline treatment, including a brief discussion of the use of true immunotherapy, chimeric antigen receptor T-cells, for relapsed B-cell ALL, the potential for targeting CD38 in T-cell ALL, and how these approaches are facilitating the next steps to improve survival for adult patients with ALL.",Journal Article,483.0,0.0,Survival rates in adult patients with acute lymphoblastic ALL have markedly improved during the past decade The one-size-fits-all-ages approach has been replaced with adaptation of pediatric-inspired treatment protocols for younger adults Yet different treatment strategies for older patients are needed due to chemotherapy-related toxicities A new era of immunotherapy has arrived offering opportunities for targeted treatments for ALL subtypes While CD20 targeting with rituximab has been demonstrated to improve survival when combined with chemotherapy it has little activity as a single agent in ALL In contrast antibody targeting of CD19 and CD22 with blinatumomab and inotuzumab ozogamicin respectively has had remarkable single-agent activity in the relapsed setting Studies are now underway to test these agents in combination with chemotherapy in the frontline setting The goal of these studies is to improve event-free survival and overall survival by using these approaches in the frontline to eradicate minimal residual disease and particularly in older adults with ALL to reduce treatment-related toxicity by limiting the exposure to traditional multi-agent chemotherapy with its attendant toxicities This review focuses on new immunotherapeutic treatment options and strategies for frontline treatment including a brief discussion of the use of true immunotherapy chimeric antigen receptor T-cells for relapsed B-cell ALL the potential for targeting CD38 in T-cell ALL and how these approaches are facilitating the next steps to improve survival for adult patients with ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[25, 151, 4, 780, 7, 5, 286, 1275, 62, 47, 2195, 231, 190, 3, 1219, 2025, 3, 104, 444, 11688, 62, 2165, 353, 71, 85, 6928, 5, 7275, 1, 815, 13161, 24, 2189, 9, 773, 857, 1145, 338, 24, 422, 9, 434, 7, 32, 575, 520, 6, 56, 139, 385, 8, 217, 1713, 1, 726, 71, 17855, 5846, 2605, 9, 238, 640, 9, 62, 814, 369, 2198, 529, 5, 855, 71, 85, 264, 6, 401, 25, 198, 397, 5, 56, 192, 71, 1215, 128, 22, 8, 226, 420, 4, 62, 4, 748, 548, 529, 1, 3158, 2, 7599, 5, 7182, 2, 6730, 5566, 106, 71, 42, 3813, 226, 420, 128, 4, 3, 591, 546, 94, 32, 1134, 3948, 6, 412, 46, 183, 4, 150, 5, 56, 4, 3, 3171, 546, 3, 1326, 1, 46, 94, 16, 6, 401, 774, 115, 25, 2, 63, 25, 20, 75, 46, 611, 4, 3, 3171, 6, 5650, 1048, 753, 34, 2, 823, 4, 434, 857, 5, 62, 6, 969, 24, 139, 155, 20, 817, 3, 645, 6, 1847, 1414, 420, 56, 5, 211, 18307, 385, 26, 206, 3026, 23, 217, 3222, 24, 838, 2, 422, 9, 3171, 24, 141, 8, 3190, 2488, 1, 3, 119, 1, 2501, 726, 2897, 448, 153, 102, 37, 9, 591, 132, 31, 62, 3, 174, 9, 529, 4469, 4, 102, 31, 62, 2, 832, 46, 611, 32, 5379, 3, 1305, 4022, 6, 401, 25, 9, 780, 7, 5, 62]",1587.0,30466749,720
"Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases.",Proceedings of the National Academy of Sciences of the United States of America,Proc. Natl. Acad. Sci. U.S.A.,2018-11-28,"Most B cell precursor acute lymphoblastic leukemia (BCP ALL) can be classified into known major genetic subtypes, while a substantial proportion of BCP ALL remains poorly characterized in relation to its underlying genomic abnormalities. We therefore initiated a large-scale international study to reanalyze and delineate the transcriptome landscape of 1,223 BCP ALL cases using RNA sequencing. Fourteen BCP ALL gene expression subgroups (G1 to G14) were identified. Apart from extending eight previously described subgroups (G1 to G8 associated with <i>MEF2D</i> fusions, <i>TCF3-PBX1</i> fusions, <i>ETV6-RUNX1</i>-positive/<i>ETV6-RUNX1</i>-like, <i>DUX4</i> fusions, <i>ZNF384</i> fusions, <i>BCR-ABL1</i>/Ph-like, high hyperdiploidy, and <i>KMT2A</i> fusions), we defined six additional gene expression subgroups: G9 was associated with both <i>PAX5</i> and <i>CRLF2</i> fusions; G10 and G11 with mutations in <i>PAX5</i> (p.P80R) and <i>IKZF1</i> (p.N159Y), respectively; G12 with <i>IGH-CEBPE</i> fusion and mutations in <i>ZEB2</i> (p.H1038R); and G13 and G14 with <i>TCF3/4-HLF</i> and <i>NUTM1</i> fusions, respectively. In pediatric BCP ALL, subgroups G2 to G5 and G7 (51 to 65/67 chromosomes) were associated with low-risk, G7 (with 50 chromosomes) and G9 were intermediate-risk, whereas G1, G6, and G8 were defined as high-risk subgroups. In adult BCP ALL, G1, G2, G6, and G8 were associated with high risk, while G4, G5, and G7 had relatively favorable outcomes. This large-scale transcriptome sequence analysis of BCP ALL revealed distinct molecular subgroups that reflect discrete pathways of BCP ALL, informing disease classification and prognostic stratification. The combined results strongly advocate that RNA sequencing be introduced into the clinical diagnostic workup of BCP ALL.",Journal Article,419.0,15.0,"Most B cell precursor acute lymphoblastic BCP ALL can be classified into known major genetic subtypes while a substantial proportion of BCP ALL remains poorly characterized in relation to its underlying genomic abnormalities We therefore initiated a large-scale international study to reanalyze and delineate the transcriptome landscape of 1,223 BCP ALL cases using RNA sequencing Fourteen BCP ALL gene expression subgroups G1 to G14 were identified Apart from extending eight previously described subgroups G1 to G8 associated with i MEF2D /i fusions i TCF3-PBX1 /i fusions i ETV6-RUNX1 /i -positive/ i ETV6-RUNX1 /i -like i DUX4 /i fusions i ZNF384 /i fusions i BCR-ABL1 /i /Ph-like high hyperdiploidy and i KMT2A /i fusions we defined six additional gene expression subgroups G9 was associated with both i PAX5 /i and i CRLF2 /i fusions G10 and G11 with mutations in i PAX5 /i p.P80R and i IKZF1 /i p.N159Y respectively G12 with i IGH-CEBPE /i fusion and mutations in i ZEB2 /i p.H1038R and G13 and G14 with i TCF3/4-HLF /i and i NUTM1 /i fusions respectively In pediatric BCP ALL subgroups G2 to G5 and G7 51 to 65/67 chromosomes were associated with low-risk G7 with 50 chromosomes and G9 were intermediate-risk whereas G1 G6 and G8 were defined as high-risk subgroups In adult BCP ALL G1 G2 G6 and G8 were associated with high risk while G4 G5 and G7 had relatively favorable outcomes This large-scale transcriptome sequence analysis of BCP ALL revealed distinct molecular subgroups that reflect discrete pathways of BCP ALL informing disease classification and prognostic stratification The combined results strongly advocate that RNA sequencing be introduced into the clinical diagnostic workup of BCP ALL",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[96, 132, 31, 2765, 286, 1275, 13168, 62, 122, 40, 1373, 237, 440, 458, 336, 814, 369, 8, 1281, 920, 1, 13168, 62, 469, 1240, 765, 4, 2191, 6, 211, 1181, 572, 1171, 21, 673, 1917, 8, 375, 1124, 944, 45, 6, 51352, 2, 5092, 3, 3917, 2801, 1, 14, 3907, 13168, 62, 140, 75, 893, 615, 3225, 13168, 62, 145, 55, 1453, 3344, 6, 51353, 11, 108, 5461, 29, 4782, 659, 373, 1027, 1453, 3344, 6, 20126, 41, 5, 70, 21835, 70, 2530, 70, 25178, 14434, 70, 2530, 70, 7306, 6092, 70, 109, 70, 7306, 6092, 70, 733, 70, 18043, 70, 2530, 70, 20919, 70, 2530, 70, 1062, 3557, 70, 2058, 733, 64, 11299, 2, 70, 13454, 70, 2530, 21, 395, 437, 402, 145, 55, 1453, 51354, 10, 41, 5, 110, 70, 6279, 70, 2, 70, 8895, 70, 2530, 74089, 2, 34065, 5, 138, 4, 70, 6279, 70, 19, 74090, 2, 70, 8422, 70, 19, 74091, 106, 24013, 5, 70, 5221, 40308, 70, 1212, 2, 138, 4, 70, 21570, 70, 19, 74092, 2, 24014, 2, 51353, 5, 70, 25178, 39, 49197, 70, 2, 70, 21900, 70, 2530, 106, 4, 815, 13168, 62, 1453, 3774, 6, 27663, 2, 21973, 725, 6, 556, 598, 3560, 11, 41, 5, 154, 43, 21973, 5, 10773, 3560, 2, 51354, 11, 919, 43, 547, 3344, 41011, 2, 20126, 11, 395, 22, 64, 43, 1453, 4, 780, 13168, 62, 3344, 3774, 41011, 2, 20126, 11, 41, 5, 64, 43, 369, 10102, 27663, 2, 21973, 42, 1352, 913, 123, 26, 375, 1124, 3917, 1532, 65, 1, 13168, 62, 553, 834, 219, 1453, 17, 2694, 5447, 460, 1, 13168, 62, 10603, 34, 947, 2, 177, 1541, 3, 397, 99, 1327, 8912, 17, 893, 615, 40, 3955, 237, 3, 38, 752, 4755, 1, 13168, 62]",1714.0,30487223,143
Novel susceptibility variants at the <i>ERG</i> locus for childhood acute lymphoblastic leukemia in Hispanics.,Blood,Blood,2018-12-03,"Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Characterized by high levels of Native American ancestry, Hispanics are disproportionally affected by this cancer with high incidence and inferior survival. However, the genetic basis for this disparity remains poorly understood because of a paucity of genome-wide investigation of ALL in Hispanics. Performing a genome-wide association study (GWAS) in 940 Hispanic children with ALL and 681 ancestry-matched non-ALL controls, we identified a novel susceptibility locus in the <i>ERG</i> gene (rs2836365; <i>P</i> = 3.76  10<sup>-8</sup>; odds ratio [OR] = 1.56), with independent validation (<i>P</i> = .01; OR = 1.43). Imputation analyses pointed to a single causal variant driving the association signal at this locus overlapping with putative regulatory DNA elements. The effect size of the <i>ERG</i> risk variant rose with increasing Native American genetic ancestry. The <i>ERG</i> risk genotype was underrepresented in ALL with the <i>ETV6-RUNX1</i> fusion (<i>P</i> < .0005) but enriched in the <i>TCF3-PBX1</i> subtype (<i>P</i> < .05). Interestingly, ALL cases with germline <i>ERG</i> risk alleles were significantly less likely to have somatic <i>ERG</i> deletion (<i>P</i> < .05). Our results provide novel insights into genetic predisposition to ALL and its contribution to racial disparity in this cancer.",Journal Article,414.0,7.0,Acute lymphoblastic ALL is the most common malignancy in children Characterized by high levels of Native American ancestry Hispanics are disproportionally affected by this cancer with high incidence and inferior survival However the genetic basis for this disparity remains poorly understood because of a paucity of genome-wide investigation of ALL in Hispanics Performing a genome-wide association study GWAS in 940 Hispanic children with ALL and 681 ancestry-matched non-ALL controls we identified a novel susceptibility locus in the i ERG /i gene rs2836365 i P /i 3.76 10 sup -8 /sup odds ratio OR 1.56 with independent validation i P /i .01 OR 1.43 Imputation analyses pointed to a single causal variant driving the association signal at this locus overlapping with putative regulatory DNA elements The effect size of the i ERG /i risk variant rose with increasing Native American genetic ancestry The i ERG /i risk genotype was underrepresented in ALL with the i ETV6-RUNX1 /i fusion i P /i .0005 but enriched in the i TCF3-PBX1 /i subtype i P /i .05 Interestingly ALL cases with germline i ERG /i risk alleles were significantly less likely to have somatic i ERG /i deletion i P /i .05 Our results provide novel insights into genetic predisposition to ALL and its contribution to racial disparity in this cancer,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[286, 1275, 62, 16, 3, 96, 186, 710, 4, 541, 765, 20, 64, 148, 1, 4646, 597, 3535, 3850, 32, 20708, 1424, 20, 26, 12, 5, 64, 287, 2, 1663, 25, 137, 3, 336, 877, 9, 26, 4326, 469, 1240, 1784, 408, 1, 8, 4832, 1, 898, 1019, 940, 1, 62, 4, 3850, 3620, 8, 898, 1019, 248, 45, 3297, 4, 11733, 1776, 541, 5, 62, 2, 14442, 3535, 655, 220, 62, 535, 21, 108, 8, 229, 1432, 2474, 4, 3, 70, 3032, 70, 145, 74114, 70, 19, 70, 27, 846, 79, 172, 66, 172, 610, 197, 15, 14, 664, 5, 306, 929, 70, 19, 70, 355, 15, 14, 601, 8266, 318, 15342, 6, 8, 226, 5163, 1142, 4057, 3, 248, 1235, 28, 26, 2474, 4551, 5, 2743, 1253, 261, 2531, 3, 254, 444, 1, 3, 70, 3032, 70, 43, 1142, 7370, 5, 602, 4646, 597, 336, 3535, 3, 70, 3032, 70, 43, 1183, 10, 9900, 4, 62, 5, 3, 70, 7306, 6092, 70, 1212, 70, 19, 70, 4252, 84, 2220, 4, 3, 70, 25178, 14434, 70, 875, 70, 19, 70, 474, 2873, 62, 140, 5, 1009, 70, 3032, 70, 43, 2558, 11, 97, 299, 322, 6, 47, 1119, 70, 3032, 70, 1528, 70, 19, 70, 474, 114, 99, 377, 229, 1957, 237, 336, 2863, 6, 62, 2, 211, 2925, 6, 2257, 4326, 4, 26, 12]",1317.0,30510082,156
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.,Pediatric blood & cancer,Pediatr Blood Cancer,2018-12-11,"Bacillus species are known to cause severe infection in immunocompromised hosts. The incidence of Bacillus bloodstream infections and characteristics of infection among children with cancer or indication for hematopoietic cell transplant (HCT) is unknown. We performed a retrospective medical record review of all cases of Bacillus bacteremia between January 1, 2005, and December 31, 2014, at Boston Children's Hospital. We report average incidences from 2012 to 2014. We performed a detailed review of infections among children with cancer or undergoing HCT and a case-control study to evaluate whether neutropenia at diagnosis caries higher risk of Bacillus infection for children with acute lymphoblastic leukemia (ALL). One hundred fourteen children developed Bacillus bacteremia during the study period, with an estimated incidence of 0.27/1,000 patients. Among children treated for cancer or undergoing HCT, there were 37 bloodstream infections (2.0/1,000 patients). Of the 37 oncology/HCT patients, oncologic diagnoses included ALL (18), acute myeloid leukemia (3), myelodysplastic syndrome (1), solid tumors (8), and 7 children were undergoing HCT. The incidence of infection among children with ALL was 34/1,000 patients and all central nervous system (CNS) infections (6) and deaths (3) occurred in this population. Neutropenia at time of diagnosis in children with ALL was not associated with risk of infection (P=0.17). We report the first hospital-wide analysis of Bacillus infection and found that immunocompromised children experience a significant proportion of Bacillus infections. Children with ALL have a high incidence of infection and are at higher risk of CNS involvement and death.",Journal Article,406.0,0.0,"Bacillus species are known to cause severe infection in immunocompromised hosts The incidence of Bacillus bloodstream infections and characteristics of infection among children with cancer or indication for hematopoietic cell transplant HCT is unknown We performed a retrospective medical record review of all cases of Bacillus bacteremia between January 1 2005 and December 31 2014 at Boston Children 's Hospital We report average incidences from 2012 to 2014 We performed a detailed review of infections among children with cancer or undergoing HCT and a case-control study to evaluate whether neutropenia at diagnosis caries higher risk of Bacillus infection for children with acute lymphoblastic ALL One hundred fourteen children developed Bacillus bacteremia during the study period with an estimated incidence of 0.27/1,000 patients Among children treated for cancer or undergoing HCT there were 37 bloodstream infections 2.0/1,000 patients Of the 37 oncology/HCT patients oncologic diagnoses included ALL 18 acute myeloid 3 syndrome 1 solid tumors 8 and 7 children were undergoing HCT The incidence of infection among children with ALL was 34/1,000 patients and all central nervous system CNS infections 6 and deaths 3 occurred in this population Neutropenia at time of diagnosis in children with ALL was not associated with risk of infection P 0.17 We report the first hospital-wide analysis of Bacillus infection and found that immunocompromised children experience a significant proportion of Bacillus infections Children with ALL have a high incidence of infection and are at higher risk of CNS involvement and death",0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[4947, 2915, 32, 440, 6, 708, 905, 930, 4, 7796, 9867, 3, 287, 1, 4947, 10210, 1875, 2, 374, 1, 930, 107, 541, 5, 12, 15, 3607, 9, 1007, 31, 941, 1085, 16, 860, 21, 173, 8, 459, 484, 3237, 206, 1, 62, 140, 1, 4947, 7085, 59, 1024, 14, 1242, 2, 1397, 456, 1409, 28, 7026, 541, 292, 702, 21, 414, 1011, 3981, 29, 1195, 6, 1409, 21, 173, 8, 2455, 206, 1, 1875, 107, 541, 5, 12, 15, 479, 1085, 2, 8, 473, 182, 45, 6, 376, 317, 778, 28, 147, 29155, 142, 43, 1, 4947, 930, 9, 541, 5, 286, 1275, 62, 104, 1128, 3225, 541, 276, 4947, 7085, 190, 3, 45, 727, 5, 35, 661, 287, 1, 13, 428, 14, 984, 7, 107, 541, 73, 9, 12, 15, 479, 1085, 125, 11, 567, 10210, 1875, 18, 13, 14, 984, 7, 1, 3, 567, 413, 1085, 7, 1998, 2403, 159, 62, 203, 286, 533, 27, 681, 14, 537, 57, 66, 2, 67, 541, 11, 479, 1085, 3, 287, 1, 930, 107, 541, 5, 62, 10, 562, 14, 984, 7, 2, 62, 854, 1880, 398, 1025, 1875, 49, 2, 1043, 27, 489, 4, 26, 266, 778, 28, 98, 1, 147, 4, 541, 5, 62, 10, 44, 41, 5, 43, 1, 930, 19, 13, 269, 21, 414, 3, 157, 702, 1019, 65, 1, 4947, 930, 2, 204, 17, 7796, 541, 730, 8, 93, 920, 1, 4947, 1875, 541, 5, 62, 47, 8, 64, 287, 1, 930, 2, 32, 28, 142, 43, 1, 1025, 799, 2, 273]",1627.0,30537106,52
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease.,Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners,J Oncol Pharm Pract,2018-12-11,"A 26-year-old male with a history of pre-B cell acute lymphoblastic leukemia and seizures presented with second relapse of acute lymphoblastic leukemia and central nervous system involvement, 19 years after the initial diagnosis. Over the next two months, the patient received six doses of triple intrathecal chemotherapy (cytarabine, methotrexate, and hydrocortisone), three concurrently with continuous blinatumomab in the second month. Approximately 12 days after blinatumomab initiation, he developed central nervous system toxicity manifesting as speech impairment, altered mental status, incontinence, and diffuse weakness. Blinatumomab was discontinued, and he was started on dexamethasone. Within the next couple of months, his neurologic status recovered, and he was able to perform all of his baseline activities without limitation. Unfortunately, the patient eventually expired after further relapse approximately one year later. To our knowledge, this is the first published case report of severe neurotoxicity in a patient who was given blinatumomab concurrently with intrathecal chemotherapy.",Case Reports,406.0,0.0,A 26-year-old male with a history of pre-B cell acute lymphoblastic and seizures presented with second relapse of acute lymphoblastic and central nervous system involvement 19 years after the initial diagnosis Over the next two months the patient received six doses of triple intrathecal chemotherapy cytarabine methotrexate and hydrocortisone three concurrently with continuous blinatumomab in the second month Approximately 12 days after blinatumomab initiation he developed central nervous system toxicity manifesting as speech impairment altered mental status incontinence and diffuse weakness Blinatumomab was discontinued and he was started on dexamethasone Within the next couple of months his neurologic status recovered and he was able to perform all of his baseline activities without limitation Unfortunately the patient eventually expired after further relapse approximately one year later To our knowledge this is the first published case report of severe neurotoxicity in a patient who was given blinatumomab concurrently with intrathecal chemotherapy,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[8, 432, 111, 1095, 1045, 5, 8, 532, 1, 671, 132, 31, 286, 1275, 2, 4448, 917, 5, 419, 429, 1, 286, 1275, 2, 854, 1880, 398, 799, 326, 60, 50, 3, 388, 147, 252, 3, 1305, 100, 53, 3, 69, 103, 437, 415, 1, 1500, 5126, 56, 1855, 2116, 2, 17127, 169, 3294, 5, 1314, 7182, 4, 3, 419, 811, 705, 133, 162, 50, 7182, 1118, 3174, 276, 854, 1880, 398, 155, 14163, 22, 9637, 2315, 1495, 3031, 156, 6152, 2, 1388, 6408, 7182, 10, 2402, 2, 3174, 10, 3461, 23, 1217, 262, 3, 1305, 12581, 1, 53, 3224, 2543, 156, 5784, 2, 3174, 10, 1665, 6, 2715, 62, 1, 3224, 330, 2042, 187, 5039, 3869, 3, 69, 3124, 13758, 50, 195, 429, 705, 104, 111, 1559, 6, 114, 922, 26, 16, 3, 157, 983, 473, 414, 1, 905, 3561, 4, 8, 69, 54, 10, 447, 7182, 3294, 5, 5126, 56]",1065.0,30537919,446
The Impact of Low-Dose Cranial Boost on the Long-Term Outcomes of Adult Patients with High-Risk Acute Lymphoblastic Leukemia Undergoing Total Body Irradiation and Allogeneic Hematopoietic Stem Cell Transplantation.,Practical radiation oncology,Pract Radiat Oncol,2018-12-20,"Total body irradiation (TBI) is an integral part of the conditioning regimen for patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic, hematopoietic, cell transplantation (allo-HCT). There are conflicting data in the literature regarding the utility of a cranial irradiation boost in high-risk adult ALL without evidence of preexisting central nervous system (CNS) involvement. This study investigates the posttransplant clinical outcomes of patients with high-risk adult ALL undergoing TBI conditioning for allo-HCT with or without a whole-brain boost, without overt CNS involvement at the time of diagnosis. A retrospective cohort study was conducted using a medical record analysis. We identified 58 patients who were treated between January 1998 and December 2016, and met our preset inclusion criteria of adults (age >18years old) who carried a pathologically confirmed diagnosis of CNS-negative, high-risk ALL, who underwent hematopoietic stem cell transplantation with TBI conditioning. A multivariate analysis of correlation between patient outcomes and collected categorical variables was assessed with stepwise Cox logistic regression. Survival analyses were assessed using the Kaplan-Meier technique with a log-rank test. With a median follow-up time of 5.3years, there was a statistically significant improvement in actuarial 7-year CNS relapse-free survival (100% vs 76.4%; P=.043) in favor of patients undergoing a cranial boost. There was no statistically significant improvement in 7-year progression-free survival (78.3% vs 62.5%; P=.076) or overall survival (49.4% vs 43.5%; P=.921) with versus without a cranial boost. On multivariate analysis, the presence of a cranial boost was the only identified variable with an independent relationship to CNS relapse-free survival. Adult patients with high-risk, CNS-negative ALL were found to have a statistically significant improvement in CNS relapse-free survival and a trend toward improved progression-free survival with the inclusion of a cranial boost with TBI pretransplant conditioning. Our data indicate that further investigation into the use of cranial boost in this patient population is warranted.",Clinical Trial,397.0,0.0,Total body irradiation TBI is an integral part of the conditioning regimen for patients with acute lymphoblastic ALL undergoing allogeneic hematopoietic cell transplantation allo-HCT There are conflicting data in the literature regarding the utility of a cranial irradiation boost in high-risk adult ALL without evidence of preexisting central nervous system CNS involvement This study investigates the posttransplant clinical outcomes of patients with high-risk adult ALL undergoing TBI conditioning for allo-HCT with or without a whole-brain boost without overt CNS involvement at the time of diagnosis A retrospective cohort study was conducted using a medical record analysis We identified 58 patients who were treated between January 1998 and December 2016 and met our preset inclusion criteria of adults age 18 years old who carried a pathologically confirmed diagnosis of CNS-negative high-risk ALL who underwent hematopoietic stem cell transplantation with TBI conditioning A multivariate analysis of correlation between patient outcomes and collected categorical variables was assessed with stepwise Cox logistic regression Survival analyses were assessed using the Kaplan-Meier technique with a log-rank test With a median follow-up time of 5.3 years there was a statistically significant improvement in actuarial 7-year CNS relapse-free survival 100 vs 76.4 P .043 in favor of patients undergoing a cranial boost There was no statistically significant improvement in 7-year progression-free survival 78.3 vs 62.5 P .076 or overall survival 49.4 vs 43.5 P .921 with versus without a cranial boost On multivariate analysis the presence of a cranial boost was the only identified variable with an independent relationship to CNS relapse-free survival Adult patients with high-risk CNS-negative ALL were found to have a statistically significant improvement in CNS relapse-free survival and a trend toward improved progression-free survival with the inclusion of a cranial boost with TBI pretransplant conditioning Our data indicate that further investigation into the use of cranial boost in this patient population is warranted,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[181, 642, 1104, 4889, 16, 35, 4450, 760, 1, 3, 1933, 477, 9, 7, 5, 286, 1275, 62, 479, 1063, 1007, 31, 497, 2564, 1085, 125, 32, 4274, 74, 4, 3, 789, 666, 3, 1207, 1, 8, 2565, 1104, 2569, 4, 64, 43, 780, 62, 187, 241, 1, 5004, 854, 1880, 398, 1025, 799, 26, 45, 7259, 3, 7346, 38, 123, 1, 7, 5, 64, 43, 780, 62, 479, 4889, 1933, 9, 2564, 1085, 5, 15, 187, 8, 902, 342, 2569, 187, 7192, 1025, 799, 28, 3, 98, 1, 147, 8, 459, 180, 45, 10, 426, 75, 8, 484, 3237, 65, 21, 108, 717, 7, 54, 11, 73, 59, 1024, 1850, 2, 1397, 1390, 2, 543, 114, 35804, 1680, 371, 1, 857, 89, 203, 60, 1095, 54, 2629, 8, 2998, 557, 147, 1, 1025, 199, 64, 43, 62, 54, 208, 1007, 452, 31, 497, 5, 4889, 1933, 8, 331, 65, 1, 816, 59, 69, 123, 2, 786, 5982, 682, 10, 275, 5, 5497, 418, 812, 320, 25, 318, 11, 275, 75, 3, 876, 882, 1312, 5, 8, 1066, 1026, 412, 5, 8, 52, 166, 126, 98, 1, 33, 27, 60, 125, 10, 8, 712, 93, 767, 4, 2361, 67, 111, 1025, 429, 115, 25, 394, 105, 846, 39, 19, 5653, 4, 4283, 1, 7, 479, 8, 2565, 2569, 125, 10, 77, 712, 93, 767, 4, 67, 111, 91, 115, 25, 833, 27, 105, 744, 33, 19, 13973, 15, 63, 25, 739, 39, 105, 601, 33, 19, 15223, 5, 185, 187, 8, 2565, 2569, 23, 331, 65, 3, 463, 1, 8, 2565, 2569, 10, 3, 158, 108, 1347, 5, 35, 306, 858, 6, 1025, 429, 115, 25, 780, 7, 5, 64, 43, 1025, 199, 62, 11, 204, 6, 47, 8, 712, 93, 767, 4, 1025, 429, 115, 25, 2, 8, 853, 1317, 231, 91, 115, 25, 5, 3, 1680, 1, 8, 2565, 2569, 5, 4889, 7763, 1933, 114, 74, 1008, 17, 195, 940, 237, 3, 119, 1, 2565, 2569, 4, 26, 69, 266, 16, 1197]",2136.0,30578956,888
Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.,EBioMedicine,EBioMedicine,2018-12-20,"Adoptive immunotherapy using T cells expressing chimeric antigen receptors (CARs) targeting CD19 has produced remarkable clinical outcomes. However, much of the mechanisms of action, such as the development of memory responses and sources of immune cytokines, remain elusive largely due to the challenge of characterizing human CAR T cell function in vivo. The lack of a suitable in vivo model also hinders the development of new CAR T cell therapies. We established a humanized mouse (hu-mouse) model with a functional human immune system and genetically-matched (autologous) primary acute B-lymphoblastic leukemia (B-ALL) that permits modeling of CD19-targeted CAR T cell therapy in immunocompetent hosts without allogeneic or xenogeneic immune responses. Anti-CD19 CAR T cells were detected in blood of leukemic hu-mice with kinetics and levels similar to those seen in patients receiving CAR T cell therapy. The levels of CAR T cells were correlated inversely with the burden of leukemia cells and positively with the survival times in anti-CD19 CAR T cell-treated leukemic hu-mice. Infusion of anti-CD19 CAR T cells also resulted in rapid production of T cell- and monocyte/macrophage-derived cytokines and an increase in frequency of regulatory T cells as reported in clinical studies. These results provide a proof-of-principle that this novel preclinical model has the potential to be used to model human CAR T cell therapy and facilitate the design of new CARs with improved antitumor activity.",Journal Article,397.0,5.0,Adoptive immunotherapy using T cells expressing chimeric antigen receptors CARs targeting CD19 has produced remarkable clinical outcomes However much of the mechanisms of action such as the development of memory responses and sources of immune cytokines remain elusive largely due to the challenge of characterizing human CAR T cell function in vivo The lack of a suitable in vivo model also hinders the development of new CAR T cell therapies We established a humanized mouse hu-mouse model with a functional human immune system and genetically-matched autologous primary acute B-lymphoblastic B-ALL that permits modeling of CD19-targeted CAR T cell therapy in immunocompetent hosts without allogeneic or xenogeneic immune responses Anti-CD19 CAR T cells were detected in blood of leukemic hu-mice with kinetics and levels similar to those seen in patients receiving CAR T cell therapy The levels of CAR T cells were correlated inversely with the burden of cells and positively with the survival times in anti-CD19 CAR T cell-treated leukemic hu-mice Infusion of anti-CD19 CAR T cells also resulted in rapid production of T cell- and monocyte/macrophage-derived cytokines and an increase in frequency of regulatory T cells as reported in clinical studies These results provide a proof-of-principle that this novel preclinical model has the potential to be used to model human CAR T cell therapy and facilitate the design of new CARs with improved antitumor activity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3159, 726, 75, 102, 37, 1046, 2897, 448, 1186, 7441, 529, 3158, 71, 1687, 3813, 38, 123, 137, 1802, 1, 3, 483, 1, 1578, 225, 22, 3, 193, 1, 2407, 253, 2, 3375, 1, 250, 1886, 918, 5327, 1733, 520, 6, 3, 1745, 1, 5723, 171, 1881, 102, 31, 343, 4, 386, 3, 926, 1, 8, 2884, 4, 386, 202, 120, 21066, 3, 193, 1, 217, 1881, 102, 31, 235, 21, 635, 8, 3619, 830, 5948, 830, 202, 5, 8, 583, 171, 250, 398, 2, 2301, 655, 1028, 86, 286, 132, 1275, 132, 62, 17, 8504, 2057, 1, 3158, 238, 1881, 102, 31, 36, 4, 6749, 9867, 187, 1063, 15, 11240, 250, 253, 312, 3158, 1881, 102, 37, 11, 530, 4, 315, 1, 2015, 5948, 399, 5, 3839, 2, 148, 288, 6, 135, 527, 4, 7, 357, 1881, 102, 31, 36, 3, 148, 1, 1881, 102, 37, 11, 438, 2659, 5, 3, 892, 1, 37, 2, 2375, 5, 3, 25, 1072, 4, 312, 3158, 1881, 102, 31, 73, 2015, 5948, 399, 904, 1, 312, 3158, 1881, 102, 37, 120, 627, 4, 1321, 1529, 1, 102, 31, 2, 5231, 2674, 526, 1886, 2, 35, 344, 4, 675, 1, 1253, 102, 37, 22, 210, 4, 38, 94, 46, 99, 377, 8, 3840, 1, 4968, 17, 26, 229, 693, 202, 71, 3, 174, 6, 40, 95, 6, 202, 171, 1881, 102, 31, 36, 2, 1876, 3, 771, 1, 217, 7441, 5, 231, 579, 128]",1466.0,30579863,646
Inotuzumab: from preclinical development to success in B-cell acute lymphoblastic leukemia.,Blood advances,Blood Adv,2019-01-01,"Inotuzumab ozogamicin (InO) is a recently US Food and Drug Administration-approved antibody-drug conjugate for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (ALL). InO consists of a CD22-targeting immunoglobulin G4 humanized monoclonal antibody conjugated to calicheamicin. Although initially developed for the treatment of non-Hodgkin lymphoma (NHL) because of activity in preclinical models and high response rates in indolent lymphomas, a phase 3 trial was negative and further development focused on CD22<sup>+</sup> ALL. Although results in NHL were disappointing, parallel testing in early-phase trials of CD22<sup>+</sup> ALL demonstrated feasibility and efficacy. Subsequently, the randomized phase 3 Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia trial showed that InO was superior to standard of care regimens with a significantly improved complete remission (CR) rate in patients with relapsed/refractory disease (80.7% vs 29.4%, <i>P</i> < .001). Patients achieving CR with InO also had a significantly higher rate of undetectable minimal residual disease compared with chemotherapy (78.4% vs 28.1%, <i>P</i> < .001). InO-specific side effects, including veno-occlusive disease, have been an ongoing area of concern, and consensus guidelines for minimizing toxicities are now available. Ongoing trials are investigating the combination of InO with other agents in the relapse setting and the addition of InO to frontline therapy. This review details the preclinical and clinical development of InO, focusing on how best to use it and future directions for further development.",Journal Article,385.0,4.0,Inotuzumab ozogamicin InO is a recently US Food and Drug Administration-approved antibody-drug conjugate for the treatment of relapsed/refractory B-cell acute lymphoblastic ALL InO consists of a CD22-targeting immunoglobulin G4 humanized monoclonal antibody conjugated to calicheamicin Although initially developed for the treatment of NHL because of activity in preclinical models and high response rates in indolent lymphomas a phase 3 trial was negative and further development focused on CD22 sup /sup ALL Although results in NHL were disappointing parallel testing in early-phase trials of CD22 sup /sup ALL demonstrated feasibility and efficacy Subsequently the randomized phase 3 Study Of Inotuzumab Ozogamicin Versus Investigator 's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic trial showed that InO was superior to standard of care regimens with a significantly improved complete remission CR rate in patients with relapsed/refractory disease 80.7 vs 29.4 i P /i .001 Patients achieving CR with InO also had a significantly higher rate of undetectable minimal residual disease compared with chemotherapy 78.4 vs 28.1 i P /i .001 InO-specific side effects including veno-occlusive disease have been an ongoing area of concern and consensus guidelines for minimizing toxicities are now available Ongoing trials are investigating the combination of InO with other agents in the relapse setting and the addition of InO to frontline therapy This review details the preclinical and clinical development of InO focusing on how best to use it and future directions for further development,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6730, 5566, 8709, 16, 8, 761, 843, 1773, 2, 234, 634, 850, 548, 234, 3998, 9, 3, 24, 1, 591, 430, 132, 31, 286, 1275, 62, 8709, 5132, 1, 8, 7599, 529, 2593, 10102, 3619, 848, 548, 3868, 6, 13499, 242, 1625, 276, 9, 3, 24, 1, 1176, 408, 1, 128, 4, 693, 274, 2, 64, 51, 151, 4, 2316, 1557, 8, 124, 27, 160, 10, 199, 2, 195, 193, 1649, 23, 7599, 172, 172, 62, 242, 99, 4, 1176, 11, 5964, 2755, 471, 4, 191, 124, 143, 1, 7599, 172, 172, 62, 264, 1437, 2, 209, 1611, 3, 384, 124, 27, 45, 1, 6730, 5566, 185, 3464, 292, 1866, 1, 56, 4, 7, 5, 591, 15, 430, 286, 1275, 160, 224, 17, 8709, 10, 1123, 6, 260, 1, 165, 472, 5, 8, 97, 231, 236, 734, 684, 116, 4, 7, 5, 591, 430, 34, 493, 67, 105, 462, 39, 70, 19, 70, 144, 7, 1785, 684, 5, 8709, 120, 42, 8, 97, 142, 116, 1, 3920, 1048, 753, 34, 72, 5, 56, 833, 39, 105, 339, 14, 70, 19, 70, 144, 8709, 112, 1152, 176, 141, 10273, 8376, 34, 47, 85, 35, 942, 965, 1, 2893, 2, 1391, 677, 9, 4501, 385, 32, 1134, 390, 942, 143, 32, 3103, 3, 150, 1, 8709, 5, 127, 183, 4, 3, 429, 546, 2, 3, 352, 1, 8709, 6, 3171, 36, 26, 206, 3791, 3, 693, 2, 38, 193, 1, 8709, 3312, 23, 832, 824, 6, 119, 192, 2, 508, 3540, 9, 195, 193]",1627.0,30622147,145
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin.,American journal of hematology,Am. J. Hematol.,2019-01-17,"Karyotype is frequently used to predict response and outcome in leukemia. This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) treated with inotuzumab ozogamicin (InO), a humanized CD22 antibody conjugated to calicheamicin, in the phase 3, open-label, randomized INO-VATE trial. Data as of March 8, 2016, are presented in this analysis. Of the 326 patients randomized, 284 had screening karyotyping data (144 in the InO arm and 140 in the standard care [SC] arm). With InO, complete remission or complete remission with incomplete hematologic recovery (CR/CRi), minimal residual disease negativity rates, and overall survival (OS) were not significantly different between cytogenetic subgroups. CR/CRi rates favored InO over SC in the diploid with 20 metaphases, complex, and ""other"" cytogenetic subgroups. The OS hazard ratio favored InO over SC in the diploid with 20 metaphases, complex, and other cytogenetic subgroups. Generally, InO is effective and provides substantial clinical benefit in patients with R/R ALL who have specific baseline karyotypes.","Clinical Trial, Phase III",369.0,0.0,Karyotype is frequently used to predict response and outcome in This post hoc exploratory analysis evaluated the relationship between baseline cytogenetics and outcome in patients with relapsed/refractory acute lymphoblastic R/R ALL treated with inotuzumab ozogamicin InO a humanized CD22 antibody conjugated to calicheamicin in the phase 3 open-label randomized INO-VATE trial Data as of March 8 2016 are presented in this analysis Of the 326 patients randomized 284 had screening karyotyping data 144 in the InO arm and 140 in the standard care SC arm With InO complete remission or complete remission with incomplete hematologic recovery CR/CRi minimal residual disease negativity rates and overall survival OS were not significantly different between cytogenetic subgroups CR/CRi rates favored InO over SC in the diploid with 20 metaphases complex and `` other '' cytogenetic subgroups The OS hazard ratio favored InO over SC in the diploid with 20 metaphases complex and other cytogenetic subgroups Generally InO is effective and provides substantial clinical benefit in patients with R/R ALL who have specific baseline karyotypes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3385, 16, 746, 95, 6, 678, 51, 2, 228, 4, 26, 539, 5428, 2386, 65, 194, 3, 858, 59, 330, 2510, 2, 228, 4, 7, 5, 591, 430, 286, 1275, 668, 668, 62, 73, 5, 6730, 5566, 8709, 8, 3619, 7599, 548, 3868, 6, 13499, 4, 3, 124, 27, 1020, 1756, 384, 8709, 32612, 160, 74, 22, 1, 2363, 66, 1390, 32, 917, 4, 26, 65, 1, 3, 9588, 7, 384, 8843, 42, 453, 10406, 74, 4415, 4, 3, 8709, 475, 2, 3304, 4, 3, 260, 165, 2969, 475, 5, 8709, 236, 734, 15, 236, 734, 5, 2610, 813, 1602, 684, 6341, 1048, 753, 34, 6014, 151, 2, 63, 25, 118, 11, 44, 97, 338, 59, 1266, 1453, 684, 6341, 151, 5269, 8709, 252, 2969, 4, 3, 6815, 5, 8076, 10653, 840, 2, 127, 522, 1266, 1453, 3, 118, 360, 197, 5269, 8709, 252, 2969, 4, 3, 6815, 5, 8076, 10653, 840, 2, 127, 1266, 1453, 1228, 8709, 16, 323, 2, 777, 1281, 38, 247, 4, 7, 5, 668, 668, 62, 54, 47, 112, 330, 6809]",1137.0,30623490,585
Effect of Neutropenic Diet on Infection Rates in Cancer Patients With Neutropenia: A Meta-analysis of Randomized Controlled Trials.,American journal of clinical oncology,Am. J. Clin. Oncol.,2019-03-01,"Neutropenic diets are commonly prescribed to cancer patients with neutropenia with the intention of reducing rates of infection. These diets are restrictive and are associated with lower patient satisfaction and possibly malnutrition. Further, it is unclear if these restrictive diets are effective in reducing infection. We performed a meta-analysis on the rates of infection reported in trials comparing the neutropenic diet to unrestricted diets in cancer patients with neutropenia. A comprehensive database search for all published randomized controlled trials comparing infection rates in cancer patients receiving a neutropenic diet versus an unrestricted diet was performed for all publications in English language from database's inception until September 12, 2017. The search strategy, study selection, and subsequent analysis adhered to PRISMA guidelines. Random effects modeling was used to obtain pooled relative risks. The primary outcome measure was the rate of infection. Five randomized controlled trials with a total of 388 patients were included in the final analysis. Patients mostly had acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or sarcoma. Infection was noted in 53.7% patients in the neutropenic diet group, as compared with 50% in the unrestricted diet group. No significant difference in infection rate was observed between the neutropenic diet versus unrestricted diet groups, pooled risk ratio (RR) 1.13 (95% CI, 0.98-1.30; P=0.10). This meta-analysis of randomized controlled trials suggests that the use of neutropenic diet was not associated with decreased risk of infection in neutropenic cancer patients. The continued use of neutropenic diets should be questioned.",Journal Article,326.0,3.0,Neutropenic diets are commonly prescribed to cancer patients with neutropenia with the intention of reducing rates of infection These diets are restrictive and are associated with lower patient satisfaction and possibly malnutrition Further it is unclear if these restrictive diets are effective in reducing infection We performed a meta-analysis on the rates of infection reported in trials comparing the neutropenic diet to unrestricted diets in cancer patients with neutropenia A comprehensive database search for all published randomized controlled trials comparing infection rates in cancer patients receiving a neutropenic diet versus an unrestricted diet was performed for all publications in English language from database 's inception until September 12 2017 The search strategy study selection and subsequent analysis adhered to PRISMA guidelines Random effects modeling was used to obtain pooled relative risks The primary outcome measure was the rate of infection Five randomized controlled trials with a total of 388 patients were included in the final analysis Patients mostly had acute myeloid AML acute lymphoblastic ALL or Infection was noted in 53.7 patients in the neutropenic diet group as compared with 50 in the unrestricted diet group No significant difference in infection rate was observed between the neutropenic diet versus unrestricted diet groups pooled risk ratio RR 1.13 95 CI 0.98-1.30 P=0.10 This meta-analysis of randomized controlled trials suggests that the use of neutropenic diet was not associated with decreased risk of infection in neutropenic cancer patients The continued use of neutropenic diets should be questioned,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,"[3659, 6906, 32, 841, 2746, 6, 12, 7, 5, 778, 5, 3, 3205, 1, 1818, 151, 1, 930, 46, 6906, 32, 11465, 2, 32, 41, 5, 280, 69, 2885, 2, 2150, 12860, 195, 192, 16, 1200, 492, 46, 11465, 6906, 32, 323, 4, 1818, 930, 21, 173, 8, 1742, 65, 23, 3, 151, 1, 930, 210, 4, 143, 1430, 3, 3659, 2453, 6, 16806, 6906, 4, 12, 7, 5, 778, 8, 949, 609, 1901, 9, 62, 983, 384, 1149, 143, 1430, 930, 151, 4, 12, 7, 357, 8, 3659, 2453, 185, 35, 16806, 2453, 10, 173, 9, 62, 4463, 4, 4201, 4794, 29, 609, 292, 11000, 1100, 2636, 133, 1759, 3, 1901, 692, 45, 881, 2, 706, 65, 18139, 6, 13714, 677, 2324, 176, 2057, 10, 95, 6, 3140, 1830, 580, 1098, 3, 86, 228, 1463, 10, 3, 116, 1, 930, 365, 384, 1149, 143, 5, 8, 181, 1, 11641, 7, 11, 159, 4, 3, 1457, 65, 7, 2754, 42, 286, 533, 329, 286, 1275, 62, 15, 930, 10, 1051, 4, 699, 67, 7, 4, 3, 3659, 2453, 87, 22, 72, 5, 212, 4, 3, 16806, 2453, 87, 77, 93, 523, 4, 930, 116, 10, 164, 59, 3, 3659, 2453, 185, 16806, 2453, 271, 1830, 43, 197, 861, 14, 233, 48, 58, 13, 1096, 14, 201, 19, 13, 79, 26, 1742, 65, 1, 384, 1149, 143, 844, 17, 3, 119, 1, 3659, 2453, 10, 44, 41, 5, 340, 43, 1, 930, 4, 3659, 12, 7, 3, 1351, 119, 1, 3659, 6906, 257, 40, 9089]",1660.0,30628912,74
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.,Nature genetics,Nat. Genet.,2019-01-14,"Recent genomic studies have identified chromosomal rearrangements defining new subtypes of B-progenitor acute lymphoblastic leukemia (B-ALL), however many cases lack a known initiating genetic alteration. Using integrated genomic analysis of 1,988 childhood and adult cases, we describe a revised taxonomy of B-ALL incorporating 23 subtypes defined by chromosomal rearrangements, sequence mutations or heterogeneous genomic alterations, many of which show marked variation in prevalence according to age. Two subtypes have frequent alterations of the B lymphoid transcription-factor gene PAX5. One, PAX5alt (7.4%), has diverse PAX5 alterations (rearrangements, intragenic amplifications or mutations); a second subtype is defined by PAX5 p.Pro80Arg and biallelic PAX5 alterations. We show that p.Pro80Arg impairs B lymphoid development and promotes the development of B-ALL with biallelic Pax5 alteration in vivo. These results demonstrate the utility of transcriptome sequencing to classify B-ALL and reinforce the central role of PAX5 as a checkpoint in B lymphoid maturation and leukemogenesis.",Journal Article,372.0,18.0,"Recent genomic studies have identified chromosomal rearrangements defining new subtypes of B-progenitor acute lymphoblastic B-ALL however many cases lack a known initiating genetic alteration Using integrated genomic analysis of 1,988 childhood and adult cases we describe a revised taxonomy of B-ALL incorporating 23 subtypes defined by chromosomal rearrangements sequence mutations or heterogeneous genomic alterations many of which show marked variation in prevalence according to age Two subtypes have frequent alterations of the B lymphoid transcription-factor gene PAX5 One PAX5alt 7.4 has diverse PAX5 alterations rearrangements intragenic amplifications or mutations a second subtype is defined by PAX5 p.Pro80Arg and biallelic PAX5 alterations We show that p.Pro80Arg impairs B lymphoid development and promotes the development of B-ALL with biallelic Pax5 alteration in vivo These results demonstrate the utility of transcriptome sequencing to classify B-ALL and reinforce the central role of PAX5 as a checkpoint in B lymphoid maturation and leukemogenesis",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[435, 572, 94, 47, 108, 1860, 2072, 2847, 217, 814, 1, 132, 2520, 286, 1275, 132, 62, 137, 445, 140, 926, 8, 440, 2637, 336, 2611, 75, 2102, 572, 65, 1, 14, 17991, 864, 2, 780, 140, 21, 897, 8, 4218, 15210, 1, 132, 62, 2570, 382, 814, 395, 20, 1860, 2072, 1532, 138, 15, 1564, 572, 593, 445, 1, 92, 514, 2003, 1380, 4, 1078, 768, 6, 89, 100, 814, 47, 908, 593, 1, 3, 132, 2303, 866, 161, 145, 6279, 104, 74311, 67, 39, 71, 1867, 6279, 593, 2072, 10285, 4877, 15, 138, 8, 419, 875, 16, 395, 20, 6279, 19, 51405, 2, 6435, 6279, 593, 21, 514, 17, 19, 51405, 8312, 132, 2303, 193, 2, 2148, 3, 193, 1, 132, 62, 5, 6435, 6279, 2611, 4, 386, 46, 99, 608, 3, 1207, 1, 3917, 615, 6, 4896, 132, 62, 2, 14238, 3, 854, 200, 1, 6279, 22, 8, 986, 4, 132, 2303, 4537, 2, 5661]",1067.0,30643249,470
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.,Blood,Blood,2019-01-18,"Retrospective studies have suggested that older adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL) have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams. To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams, we performed a prospective study, CALGB 10403, with doses and schedule identical to those in the Children's Oncology Group study AALL0232. From 2007 to 2012, 318 patients were enrolled; 295 were eligible and evaluable for response. Median age was 24 years (range, 17-39 years). Use of the pediatric regimen was safe; overall treatment-related mortality was 3%, and there were only 2 postremission deaths. Median event-free survival (EFS) was 78.1 months (95% confidence interval [CI], 41.8 to not reached), more than double the historical control of 30 months (95% CI, 22-38 months); 3-year EFS was 59% (95% CI, 54%-65%). Median overall survival (OS) was not reached. Estimated 3-year OS was 73% (95% CI, 68%-78%). Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature. Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective, resulting in improved survival rates compared with historical controls. CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL. This trial was registered at www.clinicaltrials.gov as #NCT00558519.",Clinical Trial,368.0,26.0,Retrospective studies have suggested that older adolescents and young adults AYAs with acute lymphoblastic ALL have better survival rates when treated using a pediatric ALL regimen administered by pediatric treatment teams To address the feasibility and efficacy of using a pediatric treatment regimen for AYA patients with newly diagnosed ALL administered by adult treatment teams we performed a prospective study CALGB 10403 with doses and schedule identical to those in the Children 's Oncology Group study AALL0232 From 2007 to 2012 318 patients were enrolled 295 were eligible and evaluable for response Median age was 24 years range 17-39 years Use of the pediatric regimen was safe overall treatment-related mortality was 3 and there were only 2 postremission deaths Median event-free survival EFS was 78.1 months 95 confidence interval CI 41.8 to not reached more than double the historical control of 30 months 95 CI 22-38 months 3-year EFS was 59 95 CI 54 -65 Median overall survival OS was not reached Estimated 3-year OS was 73 95 CI 68 -78 Pretreatment risk factors associated with worse treatment outcomes included obesity and presence of the Philadelphia-like gene expression signature Use of a pediatric regimen for AYAs with ALL up to age 40 years was feasible and effective resulting in improved survival rates compared with historical controls CALGB 10403 can be considered a new treatment standard upon which to build for improving survival for AYAs with ALL This trial was registered at www.clinicaltrials.gov as NCT00558519,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[459, 94, 47, 1148, 17, 434, 3101, 2, 1169, 857, 6145, 5, 286, 1275, 62, 47, 380, 25, 151, 198, 73, 75, 8, 815, 62, 477, 468, 20, 815, 24, 6127, 6, 1539, 3, 1437, 2, 209, 1, 75, 8, 815, 24, 477, 9, 4598, 7, 5, 732, 265, 62, 468, 20, 780, 24, 6127, 21, 173, 8, 482, 45, 4077, 42246, 5, 415, 2, 1055, 3038, 6, 135, 4, 3, 541, 292, 413, 87, 45, 32436, 29, 1307, 6, 1195, 8797, 7, 11, 346, 7051, 11, 625, 2, 859, 9, 51, 52, 89, 10, 259, 60, 184, 269, 587, 60, 119, 1, 3, 815, 477, 10, 1165, 63, 24, 139, 282, 10, 27, 2, 125, 11, 158, 18, 8635, 1043, 52, 774, 115, 25, 1683, 10, 833, 14, 53, 48, 307, 268, 58, 605, 66, 6, 44, 1300, 80, 76, 1627, 3, 2252, 182, 1, 201, 53, 48, 58, 350, 519, 53, 27, 111, 1683, 10, 728, 48, 58, 667, 556, 52, 63, 25, 118, 10, 44, 1300, 661, 27, 111, 118, 10, 803, 48, 58, 806, 833, 1194, 43, 130, 41, 5, 639, 24, 123, 159, 1661, 2, 463, 1, 3, 3006, 733, 145, 55, 1651, 119, 1, 8, 815, 477, 9, 6145, 5, 62, 126, 6, 89, 327, 60, 10, 1313, 2, 323, 1113, 4, 231, 25, 151, 72, 5, 2252, 535, 4077, 42246, 122, 40, 515, 8, 217, 24, 260, 1548, 92, 6, 5867, 9, 1673, 25, 9, 6145, 5, 62, 26, 160, 10, 1653, 28, 3064, 1252, 1239, 22, 74331]",1545.0,30658992,790
Bloodstream infections exacerbate incidence and severity of symptomatic glucocorticoid-induced osteonecrosis.,Pediatric blood & cancer,Pediatr Blood Cancer,2019-02-13,"Osteonecrosis is a common toxicity associated with glucocorticoid (e.g., dexamethasone and prednisone) treatment of children with acute lymphoblastic leukemia (ALL), but risk factors are incompletely defined. Infections are also a common complication of ALL therapy. Lipopolysaccharide (LPS) is used experimentally to mimic infection-related systemic effects. To our knowledge, the contribution of systemic infections to the risk of glucocorticoid-induced osteonecrosis has not been investigated. Patients with ALL on St. Jude Total Therapy XV (n=365) were assessed for documented bacteremia prior to development of osteonecrosis, which was confirmed by MRI, and graded using the National Cancer Institute's Common Terminology for Adverse Events (version 3.0). In a preclinical model, Balb/cJ mice treated with dexamethasone plus or minus LPS were assessed for frequency and severity of osteonecrosis and arteriopathy. We found that patients with ALL who experienced bacteremia had a higher frequency of symptomatic osteonecrosis (grade 2) than those who did not (OR: 1.88; 95% CI, 1.03-3.41, P=0.038). LPS exacerbated experimental dexamethasone-induced osteonecrosis. Mice treated with dexamethasone plus LPS had a higher incidence of osteonecrosis (P=0.00086) and arteriopathy (P=0.0047) than did those treated with dexamethasone alone, and the severity of osteonecrosis (P=0.00045) and arteriopathy (P=0.0048) was also more pronounced with the addition of LPS treatment. The increase in osteonecrosis was not explained by any alteration of dexamethasone pharmacokinetics by LPS. These data identify systemic infection during ALL therapy as a novel risk factor in the development of glucocorticoid-induced osteonecrosis.",Journal Article,342.0,1.0,Osteonecrosis is a common toxicity associated with glucocorticoid e.g. dexamethasone and prednisone treatment of children with acute lymphoblastic ALL but risk factors are incompletely defined Infections are also a common complication of ALL therapy Lipopolysaccharide LPS is used experimentally to mimic infection-related systemic effects To our knowledge the contribution of systemic infections to the risk of glucocorticoid-induced osteonecrosis has not been investigated Patients with ALL on St. Jude Total Therapy XV n 365 were assessed for documented bacteremia prior to development of osteonecrosis which was confirmed by MRI and graded using the National Cancer Institute 's Common Terminology for Adverse Events version 3.0 In a preclinical model Balb/cJ mice treated with dexamethasone plus or minus LPS were assessed for frequency and severity of osteonecrosis and arteriopathy We found that patients with ALL who experienced bacteremia had a higher frequency of symptomatic osteonecrosis grade 2 than those who did not OR 1.88 95 CI 1.03-3.41 P 0.038 LPS exacerbated experimental dexamethasone-induced osteonecrosis Mice treated with dexamethasone plus LPS had a higher incidence of osteonecrosis P 0.00086 and arteriopathy P 0.0047 than did those treated with dexamethasone alone and the severity of osteonecrosis P 0.00045 and arteriopathy P 0.0048 was also more pronounced with the addition of LPS treatment The increase in osteonecrosis was not explained by any alteration of dexamethasone pharmacokinetics by LPS These data identify systemic infection during ALL therapy as a novel risk factor in the development of glucocorticoid-induced osteonecrosis,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[5404, 16, 8, 186, 155, 41, 5, 5399, 563, 499, 1217, 2, 1979, 24, 1, 541, 5, 286, 1275, 62, 84, 43, 130, 32, 5252, 395, 1875, 32, 120, 8, 186, 1447, 1, 62, 36, 15082, 6310, 16, 95, 8593, 6, 5356, 930, 139, 403, 176, 6, 114, 922, 3, 2925, 1, 403, 1875, 6, 3, 43, 1, 5399, 277, 5404, 71, 44, 85, 565, 7, 5, 62, 23, 3062, 4841, 181, 36, 16078, 78, 7405, 11, 275, 9, 1405, 7085, 324, 6, 193, 1, 5404, 92, 10, 557, 20, 704, 2, 3468, 75, 3, 657, 12, 1377, 292, 186, 3462, 9, 290, 281, 2256, 27, 13, 4, 8, 693, 202, 8166, 74411, 399, 73, 5, 1217, 349, 15, 12297, 6310, 11, 275, 9, 675, 2, 1702, 1, 5404, 2, 25853, 21, 204, 17, 7, 5, 62, 54, 592, 7085, 42, 8, 142, 675, 1, 1704, 5404, 9140, 18, 76, 135, 54, 205, 44, 15, 14, 889, 48, 58, 14, 680, 27, 605, 19, 13, 5215, 6310, 10545, 1560, 1217, 277, 5404, 399, 73, 5, 1217, 349, 6310, 42, 8, 142, 287, 1, 5404, 19, 13, 74412, 2, 25853, 19, 13, 22518, 76, 205, 135, 73, 5, 1217, 279, 2, 3, 1702, 1, 5404, 19, 13, 74413, 2, 25853, 19, 13, 16612, 10, 120, 80, 3517, 5, 3, 352, 1, 6310, 24, 3, 344, 4, 5404, 10, 44, 3672, 20, 500, 2611, 1, 1217, 1159, 20, 6310, 46, 74, 255, 403, 930, 190, 62, 36, 22, 8, 229, 43, 161, 4, 3, 193, 1, 5399, 277, 5404]",1670.0,30758124,288
"Taking a ""BiTE out of ALL"": blinatumomab approval for MRD-positive ALL.",Blood,Blood,2019-02-22,"Blinatumomab, a bispecific T-cell engager (BiTE) associated with improved survival in relapsed or refractory acute lymphoblastic leukemia (ALL), was recently approved for treatment of minimal residual disease (MRD). MRD is an important predictor of survival in ALL, and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL. However, further research is needed to determine how to optimally incorporate blinatumomab, and other novel therapies, into current therapies for ALL.",Journal Article,333.0,4.0,Blinatumomab a bispecific T-cell engager BiTE associated with improved survival in relapsed or refractory acute lymphoblastic ALL was recently approved for treatment of minimal residual disease MRD MRD is an important predictor of survival in ALL and recent studies suggest that achievement of MRD-negativity with blinatumomab improves outcomes in patients with ALL However further research is needed to determine how to optimally incorporate blinatumomab and other novel therapies into current therapies for ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7182, 8, 7408, 102, 31, 19374, 15382, 41, 5, 231, 25, 4, 591, 15, 430, 286, 1275, 62, 10, 761, 850, 9, 24, 1, 1048, 753, 34, 2029, 2029, 16, 35, 305, 980, 1, 25, 4, 62, 2, 435, 94, 309, 17, 5088, 1, 2029, 6014, 5, 7182, 1804, 123, 4, 7, 5, 62, 137, 195, 389, 16, 575, 6, 223, 832, 6, 5074, 3360, 7182, 2, 127, 229, 235, 237, 291, 235, 9, 62]",512.0,30796026,26
Stage at diagnosis for children with blood cancers in Australia: Application of the Toronto Paediatric Cancer Stage Guidelines in a population-based national childhood cancer registry.,Pediatric blood & cancer,Pediatr Blood Cancer,2019-02-25,"Information on stage at diagnosis for childhood blood cancers is essential for surveillance but is not available on a population basis in most countries. Our aim was to apply the internationally endorsed Toronto Paediatric Cancer Stage Guidelines to children (<15 years) with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), Hodgkin lymphoma (HL), or non-Hodgkin lymphoma (NHL) and to assess differences in survival by stage at diagnosis. Stage was defined by extent of involvement of the central nervous system (CNS) for ALL and AML and using the Ann Arbor and St Jude-Murphy systems for HL and NHL, respectively. The study cohort was drawn from the population-based Australian Childhood Cancer Registry, consisting of children diagnosed with one of these four blood cancers between 2006 and 2014 with follow-up to 2015. Five-year observed survival was estimated from the Kaplan-Meier method. Stage was assigned to 2201 of 2351 eligible patients (94%), ranging from 85% for AML to 95% for ALL, HL, and NHL. Survival following ALL varied from 94% (95% CI=93%-95%) for CNS1 disease to 89% (95% CI=79%-94%) for CNS2 (P=0.07), whereas for AML there was essentially no difference in survival between CNS<sup>-</sup> (77%) and CNS<sup>+</sup> disease (78%; P=0.94). Nearly all children with HL survived for five years. There was a trend (P=0.04) toward worsening survival with higher stage for NHL. These results provide the first population-wide picture of the distribution and outcomes for childhood blood cancers in Australia by extent of disease at diagnosis and provide a baseline for future comparisons.",Journal Article,330.0,2.0,Information on stage at diagnosis for childhood blood cancers is essential for surveillance but is not available on a population basis in most countries Our aim was to apply the internationally endorsed Toronto Paediatric Cancer Stage Guidelines to children 15 years with acute lymphoblastic ALL acute myeloid AML HL or NHL and to assess differences in survival by stage at diagnosis Stage was defined by extent of involvement of the central nervous system CNS for ALL and AML and using the Ann Arbor and St Jude-Murphy systems for HL and NHL respectively The study cohort was drawn from the population-based Australian Childhood Cancer Registry consisting of children diagnosed with one of these four blood cancers between 2006 and 2014 with follow-up to 2015 Five-year observed survival was estimated from the Kaplan-Meier method Stage was assigned to 2201 of 2351 eligible patients 94 ranging from 85 for AML to 95 for ALL HL and NHL Survival following ALL varied from 94 95 CI 93 -95 for CNS1 disease to 89 95 CI 79 -94 for CNS2 P 0.07 whereas for AML there was essentially no difference in survival between CNS sup /sup 77 and CNS sup /sup disease 78 P 0.94 Nearly all children with HL survived for five years There was a trend P 0.04 toward worsening survival with higher stage for NHL These results provide the first population-wide picture of the distribution and outcomes for childhood blood cancers in Australia by extent of disease at diagnosis and provide a baseline for future comparisons,0,0,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[487, 23, 82, 28, 147, 9, 864, 315, 163, 16, 1452, 9, 617, 84, 16, 44, 390, 23, 8, 266, 877, 4, 96, 2115, 114, 1130, 10, 6, 4930, 3, 12828, 6864, 13368, 6138, 12, 82, 677, 6, 541, 167, 60, 5, 286, 1275, 62, 286, 533, 329, 1718, 15, 1176, 2, 6, 423, 362, 4, 25, 20, 82, 28, 147, 82, 10, 395, 20, 1039, 1, 799, 1, 3, 854, 1880, 398, 1025, 9, 62, 2, 329, 2, 75, 3, 7977, 10799, 2, 3062, 4841, 37572, 1530, 9, 1718, 2, 1176, 106, 3, 45, 180, 10, 5694, 29, 3, 266, 90, 13839, 864, 12, 1608, 2273, 1, 541, 265, 5, 104, 1, 46, 294, 315, 163, 59, 1324, 2, 1409, 5, 166, 126, 6, 1483, 365, 111, 164, 25, 10, 661, 29, 3, 876, 882, 596, 82, 10, 896, 6, 34163, 1, 41290, 625, 7, 960, 2223, 29, 772, 9, 329, 6, 48, 9, 62, 1718, 2, 1176, 25, 366, 62, 2051, 29, 960, 48, 58, 966, 48, 9, 74481, 34, 6, 887, 48, 58, 842, 960, 9, 74482, 19, 13, 1615, 547, 9, 329, 125, 10, 7257, 77, 523, 4, 25, 59, 1025, 172, 172, 849, 2, 1025, 172, 172, 34, 833, 19, 13, 960, 1857, 62, 541, 5, 1718, 2996, 9, 365, 60, 125, 10, 8, 853, 19, 13, 755, 1317, 4323, 25, 5, 142, 82, 9, 1176, 46, 99, 377, 3, 157, 266, 1019, 8951, 1, 3, 1395, 2, 123, 9, 864, 315, 163, 4, 6978, 20, 1039, 1, 34, 28, 147, 2, 377, 8, 330, 9, 508, 2213]",1501.0,30803139,785
Higher Reported Lung Dose Received During Total Body Irradiation for Allogeneic Hematopoietic Stem Cell Transplantation in Children With Acute Lymphoblastic Leukemia Is Associated With Inferior Survival: A Report from the Children's Oncology Group.,"International journal of radiation oncology, biology, physics",Int. J. Radiat. Oncol. Biol. Phys.,2019-02-23,"To examine the relationship between lung radiation dose and survival outcomes in children undergoing total body irradiation (TBI)-based hematopoietic stem cell transplantation (HSCT) for acute lymphoblastic leukemia on the Children's Oncology Group trial. TBI (1200 or 1320cGy given twice daily in 6 or 8 fractions) was used as part of 3 HSCT preparative regimens, allowing institutional flexibility regarding TBI techniques, including lung shielding. Lung doses as reported by each participating institution were calculated for different patient setups, with and without shielding, with a variety of dose calculation techniques. The association between lung dose and transplant-related mortality, relapse-free survival, and overall survival (OS) was examined using the Cox proportional hazards regression model controlling for the following variables: TBI dose rate, TBI fields, patient position during TBI, donor type, and pre-HSCT minimal residual disease level. Of a total of 143 eligible patients, 127 had lung doses available for this analysis. The TBI techniques were heterogeneous. The mean lung dose was reported as 904.5cGy (standard deviation, 232.3). Patients treated with lateral fields were more likely to receive lung doses 800cGy(P<.001). The influence of lung dose 800cGy on transplant-related mortality was not significant (hazard ratio [HR], 1.78; P=.21). On univariate analysis, lung dose 800cGy was associated with inferior relapse-free survival (HR, 1.76; P=.04) and OS (HR, 1.85; P=.03). In the multivariate analysis, OS maintained statistical significance (HR, 1.85; P=.04). The variability in TBI techniques resulted in uncertainty with reported lung doses. Lateral fields were associated with higher lung dose, and thus they should be avoided. Patients treated with lung dose <800cGy in this study had better outcomes. This approach is currently being investigated in the Children's Oncology Group AALL1331 study. Additionally, the Imaging and Radiation Oncology Core Group is evaluating effects of TBI techniques on lung doses using a phantom.","Clinical Trial, Phase III",332.0,2.0,To examine the relationship between radiation dose and survival outcomes in children undergoing total body irradiation TBI -based hematopoietic stem cell transplantation HSCT for acute lymphoblastic on the Children 's Oncology Group trial TBI 1200 or 1320 cGy given twice daily in 6 or 8 fractions was used as part of 3 HSCT preparative regimens allowing institutional flexibility regarding TBI techniques including shielding doses as reported by each participating institution were calculated for different patient setups with and without shielding with a variety of dose calculation techniques The association between dose and transplant-related mortality relapse-free survival and overall survival OS was examined using the Cox proportional hazards regression model controlling for the following variables TBI dose rate TBI fields patient position during TBI donor type and pre-HSCT minimal residual disease level Of a total of 143 eligible patients 127 had doses available for this analysis The TBI techniques were heterogeneous The mean dose was reported as 904.5 cGy standard deviation 232.3 Patients treated with lateral fields were more likely to receive doses 800 cGy P .001 The influence of dose 800 cGy on transplant-related mortality was not significant hazard ratio HR 1.78 P .21 On univariate analysis dose 800 cGy was associated with inferior relapse-free survival HR 1.76 P .04 and OS HR 1.85 P .03 In the multivariate analysis OS maintained statistical significance HR 1.85 P .04 The variability in TBI techniques resulted in uncertainty with reported doses Lateral fields were associated with higher dose and thus they should be avoided Patients treated with dose 800 cGy in this study had better outcomes This approach is currently being investigated in the Children 's Oncology Group AALL1331 study Additionally the Imaging and Radiation Oncology Core Group is evaluating effects of TBI techniques on doses using a phantom,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6, 1004, 3, 858, 59, 121, 61, 2, 25, 123, 4, 541, 479, 181, 642, 1104, 4889, 90, 1007, 452, 31, 497, 1703, 9, 286, 1275, 23, 3, 541, 292, 413, 87, 160, 4889, 6847, 15, 74491, 3071, 447, 936, 391, 4, 49, 15, 66, 1550, 10, 95, 22, 760, 1, 27, 1703, 6085, 472, 2952, 1115, 9794, 666, 4889, 1092, 141, 16362, 415, 22, 210, 20, 296, 3052, 731, 11, 981, 9, 338, 69, 23549, 5, 2, 187, 16362, 5, 8, 1362, 1, 61, 6333, 1092, 3, 248, 59, 61, 2, 941, 139, 282, 429, 115, 25, 2, 63, 25, 118, 10, 409, 75, 3, 418, 831, 1017, 320, 202, 1893, 9, 3, 366, 682, 4889, 61, 116, 4889, 3130, 69, 3559, 190, 4889, 1488, 267, 2, 671, 1703, 1048, 753, 34, 301, 1, 8, 181, 1, 4400, 625, 7, 4080, 42, 415, 390, 9, 26, 65, 3, 4889, 1092, 11, 1564, 3, 313, 61, 10, 210, 22, 13145, 33, 3071, 260, 3348, 74492, 27, 7, 73, 5, 3855, 3130, 11, 80, 322, 6, 560, 415, 31738, 3071, 19, 144, 3, 1054, 1, 61, 31738, 3071, 23, 941, 139, 282, 10, 44, 93, 360, 197, 168, 14, 833, 19, 239, 23, 880, 65, 61, 31738, 3071, 10, 41, 5, 1663, 429, 115, 25, 168, 14, 846, 19, 755, 2, 118, 168, 14, 772, 19, 680, 4, 3, 331, 65, 118, 1955, 1050, 724, 168, 14, 772, 19, 755, 3, 1982, 4, 4889, 1092, 627, 4, 4004, 5, 210, 415, 3855, 3130, 11, 41, 5, 142, 61, 2, 631, 491, 257, 40, 5617, 7, 73, 5, 61, 2796, 3071, 4, 26, 45, 42, 380, 123, 26, 353, 16, 694, 486, 565, 4, 3, 541, 292, 413, 87, 74493, 45, 1724, 3, 270, 2, 121, 413, 1793, 87, 16, 1435, 176, 1, 4889, 1092, 23, 415, 75, 8, 6755]",1946.0,30807822,19
"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells.",Blood,Blood,2019-02-26,"Chimeric antigen receptor (CAR) T cells have emerged as a promising class of cell-based immunotherapy in refractory malignancies. Neurotoxicity represents a common and potentially life-threatening adverse effect of CAR T cells, and clinical experience is limited. Here, we describe the clinical presentation and management of 25 adult patients who presented with neurotoxic syndromes after CAR T-cell therapy at the Massachusetts General Hospital. This cohort includes 24 patients treated with CD19-directed CAR T cells for non-Hodgkin lymphoma (n = 23) and acute lymphoblastic leukemia (n = 1), and 1 patient treated with -fetoprotein-directed CAR T cells for hepatocellular carcinoma (n = 1). Twelve of the 25 patients (48%) developed grade 1-2 neurotoxicity and 13 patients (52%) presented with grade 3-4 neurotoxicity. We found that lower platelet counts at time of CAR T-cell infusion were associated with more severe neurotoxicity (<i>P</i> = .030). Cytokine release syndrome occurred in 24 of 25 patients (96%). Serum levels of ferritin peaked with onset of neurologic symptoms, and higher ferritin levels were associated with higher neurotoxicity grade. Grade 3-4 neurotoxicity correlated negatively with overall survival (OS) (<i>P</i> = .013). Median OS of the entire cohort was 54.7 weeks. Eight patients (32%) with grade 3-4 neurotoxicity were deceased at database closure, whereas none died with neurotoxicity grade 1-2. High pretreatment lactate dehydrogenase was frequently encountered in lymphoma patients with grade 3-4 neurotoxicity and correlated negatively with progression-free survival (<i>P</i> = .048). We did not find evidence that steroid use 7 days altered the patient's outcome when compared with <7 days of steroids. Management of CAR T cell-mediated neurotoxicity warrants evaluation in prospective clinical trials.",Journal Article,329.0,7.0,Chimeric antigen receptor CAR T cells have emerged as a promising class of cell-based immunotherapy in refractory malignancies Neurotoxicity represents a common and potentially life-threatening adverse effect of CAR T cells and clinical experience is limited Here we describe the clinical presentation and management of 25 adult patients who presented with neurotoxic syndromes after CAR T-cell therapy at the Massachusetts General Hospital This cohort includes 24 patients treated with CD19-directed CAR T cells for n 23 and acute lymphoblastic n 1 and 1 patient treated with -fetoprotein-directed CAR T cells for carcinoma n 1 Twelve of the 25 patients 48 developed grade 1-2 neurotoxicity and 13 patients 52 presented with grade 3-4 neurotoxicity We found that lower platelet counts at time of CAR T-cell infusion were associated with more severe neurotoxicity i P /i .030 Cytokine release syndrome occurred in 24 of 25 patients 96 Serum levels of ferritin peaked with onset of neurologic symptoms and higher ferritin levels were associated with higher neurotoxicity grade Grade 3-4 neurotoxicity correlated negatively with overall survival OS i P /i .013 Median OS of the entire cohort was 54.7 weeks Eight patients 32 with grade 3-4 neurotoxicity were deceased at database closure whereas none died with neurotoxicity grade 1-2 High pretreatment lactate dehydrogenase was frequently encountered in patients with grade 3-4 neurotoxicity and correlated negatively with progression-free survival i P /i .048 We did not find evidence that steroid use 7 days altered the patient 's outcome when compared with 7 days of steroids Management of CAR T cell-mediated neurotoxicity warrants evaluation in prospective clinical trials,0,0,1,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2897, 448, 153, 1881, 102, 37, 47, 2054, 22, 8, 721, 1040, 1, 31, 90, 726, 4, 430, 441, 3561, 1449, 8, 186, 2, 751, 358, 3691, 290, 254, 1, 1881, 102, 37, 2, 38, 730, 16, 383, 467, 21, 897, 3, 38, 1031, 2, 284, 1, 243, 780, 7, 54, 917, 5, 11148, 2040, 50, 1881, 102, 31, 36, 28, 3, 5459, 1083, 702, 26, 180, 1920, 259, 7, 73, 5, 3158, 1166, 1881, 102, 37, 9, 78, 382, 2, 286, 1275, 78, 14, 2, 14, 69, 73, 5, 2014, 6607, 1166, 1881, 102, 37, 9, 134, 78, 14, 2544, 1, 3, 243, 7, 576, 276, 88, 14, 18, 3561, 2, 233, 7, 653, 917, 5, 88, 27, 39, 3561, 21, 204, 17, 280, 1596, 1911, 28, 98, 1, 1881, 102, 31, 904, 11, 41, 5, 80, 905, 3561, 70, 19, 70, 6542, 1675, 2008, 681, 489, 4, 259, 1, 243, 7, 921, 524, 148, 1, 9101, 11095, 5, 1707, 1, 2543, 507, 2, 142, 9101, 148, 11, 41, 5, 142, 3561, 88, 88, 27, 39, 3561, 438, 2723, 5, 63, 25, 118, 70, 19, 70, 3612, 52, 118, 1, 3, 1797, 180, 10, 667, 67, 244, 659, 7, 531, 5, 88, 27, 39, 3561, 11, 11956, 28, 609, 4830, 547, 1292, 1016, 5, 3561, 88, 14, 18, 64, 1194, 3330, 2374, 10, 746, 3903, 4, 7, 5, 88, 27, 39, 3561, 2, 438, 2723, 5, 91, 115, 25, 70, 19, 70, 4969, 21, 205, 44, 2469, 241, 17, 3853, 119, 10131, 162, 1495, 3, 69, 292, 228, 198, 72, 5, 67, 162, 1, 4580, 284, 1, 1881, 102, 31, 517, 3561, 2782, 451, 4, 482, 38, 143]",1728.0,30808634,431
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.,Leukemia research,Leuk. Res.,2019-02-23,"Incorporation of ABL-targeted oral tyrosine kinase inhibitors (TKIs) into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). However, patients with persistent minimal residual disease (MRD) exhibit increased risk of relapse. Combining consolidative chemotherapy with TKIs may increase rates of infectious complications, organ toxicity, hospitalization, and non-relapse mortality. Blinatumomab has demonstrated single-agent activity in patients with relapsed B-ALL or persistent MRD, including Ph+B-ALL. We have used blinatumomab concomitantly with commercially available TKIs as consolidative therapy to spare toxicities of conventional chemotherapy. We evaluated 11 adults with previously treated Ph+B-ALL who received blinatumomab concurrent with TKI (ponatinib, n=5; dasatinib, n=4; nilotinib, n=1; imatinib, n=1) to eradicate MRD or sustain MRD-negativity. Eight of 9 patients with MRD achieved BCR-ABL1 negativity (complete molecular response, CMR) after a median of one cycle; 2/2 patients without measurable disease durably maintained CMR. Cytokine release syndrome (all grade 1-2) was observed in 3/11 patients; one patient experienced transient grade 1 neurologic toxicity. Transient grade 2 transaminitis was observed in 6/11 patients, including 4/5 recipients of blinatumomab+ponatinib. This small series suggests blinatumomab+TKI is a safe and effective consolidation strategy for patients with Ph+ALL to achieve or maintain CMR.",Journal Article,332.0,3.0,Incorporation of ABL-targeted oral tyrosine kinase inhibitors TKIs into frontline therapeutic regimens has improved outcomes for adults with Philadelphia chromosome-positive acute lymphoblastic Ph ALL However patients with persistent minimal residual disease MRD exhibit increased risk of relapse Combining consolidative chemotherapy with TKIs may increase rates of infectious complications organ toxicity hospitalization and non-relapse mortality Blinatumomab has demonstrated single-agent activity in patients with relapsed B-ALL or persistent MRD including Ph B-ALL We have used blinatumomab concomitantly with commercially available TKIs as consolidative therapy to spare toxicities of conventional chemotherapy We evaluated 11 adults with previously treated Ph B-ALL who received blinatumomab concurrent with TKI ponatinib n 5 dasatinib n 4 nilotinib n 1 imatinib n 1 to eradicate MRD or sustain MRD-negativity Eight of 9 patients with MRD achieved BCR-ABL1 negativity complete molecular response CMR after a median of one cycle 2/2 patients without measurable disease durably maintained CMR Cytokine release syndrome all grade 1-2 was observed in 3/11 patients one patient experienced transient grade 1 neurologic toxicity Transient grade 2 transaminitis was observed in 6/11 patients including 4/5 recipients of blinatumomab ponatinib This small series suggests blinatumomab TKI is a safe and effective consolidation strategy for patients with Ph ALL to achieve or maintain CMR,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2838, 1, 1425, 238, 518, 564, 216, 222, 1671, 237, 3171, 189, 472, 71, 231, 123, 9, 857, 5, 3006, 1170, 109, 286, 1275, 2058, 62, 137, 7, 5, 1882, 1048, 753, 34, 2029, 2239, 101, 43, 1, 429, 1525, 6618, 56, 5, 1671, 68, 344, 151, 1, 3398, 521, 1259, 155, 2826, 2, 220, 429, 282, 7182, 71, 264, 226, 420, 128, 4, 7, 5, 591, 132, 62, 15, 1882, 2029, 141, 2058, 132, 62, 21, 47, 95, 7182, 6485, 5, 5262, 390, 1671, 22, 6618, 36, 6, 8539, 385, 1, 809, 56, 21, 194, 175, 857, 5, 373, 73, 2058, 132, 62, 54, 103, 7182, 750, 5, 1379, 5715, 78, 33, 1674, 78, 39, 2638, 78, 14, 577, 78, 14, 6, 5650, 2029, 15, 8844, 2029, 6014, 659, 1, 83, 7, 5, 2029, 513, 1062, 3557, 6014, 236, 219, 51, 7334, 50, 8, 52, 1, 104, 417, 18, 18, 7, 187, 1884, 34, 19104, 1955, 7334, 1675, 2008, 681, 62, 88, 14, 18, 10, 164, 4, 27, 175, 7, 104, 69, 592, 2473, 88, 14, 2543, 155, 2473, 88, 18, 8181, 10, 164, 4, 49, 175, 7, 141, 39, 33, 2190, 1, 7182, 5715, 26, 302, 988, 844, 7182, 1379, 16, 8, 1165, 2, 323, 2173, 692, 9, 7, 5, 2058, 62, 6, 1359, 15, 3040, 7334]",1484.0,30831480,600
No evidence that G6PD deficiency affects the efficacy or safety of daunorubicin in acute lymphoblastic leukemia induction therapy.,Pediatric blood & cancer,Pediatr Blood Cancer,2019-03-07,"Anthracyclines are used in induction therapy of pediatric acute lymphoblastic leukemia (ALL) and are known to generate oxidative stress; whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency is unknown. Among 726 pediatric patients with newly diagnosed ALL treated at St. Jude Children's Research Hospital, 22 had deficient G6PD activity. We compared the prevalence of positive minimal residual disease (MRD) 1% at Day 15/Day 19 of induction or 0.01% at Day 42/Day 46 (end of induction) and the number of red blood cell (RBC) transfusions after daunorubicin in induction between patients with or without G6PD deficiency, adjusting for ALL risk group, treatment protocol, age, and gender. There was no difference in Day 15/19 (P=1) or end of induction MRD (P=0.76) nor in the number of RBC transfusions (P=0.73); the lack of association with MRD was confirmed in a dataset of 1192 newly diagnosed male patients enrolled in a Children's Oncology Group trial (P=0.78). We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL.",Journal Article,320.0,0.0,Anthracyclines are used in induction therapy of pediatric acute lymphoblastic ALL and are known to generate oxidative stress whether this translates into enhanced antileukemic activity or hemolytic effects in patients with glucose-6-phosphate dehydrogenase G6PD deficiency is unknown Among 726 pediatric patients with newly diagnosed ALL treated at St. Jude Children 's Research Hospital 22 had deficient G6PD activity We compared the prevalence of positive minimal residual disease MRD 1 at Day 15/Day 19 of induction or 0.01 at Day 42/Day 46 end of induction and the number of red blood cell RBC transfusions after daunorubicin in induction between patients with or without G6PD deficiency adjusting for ALL risk group treatment protocol age and gender There was no difference in Day 15/19 P 1 or end of induction MRD P 0.76 nor in the number of RBC transfusions P 0.73 the lack of association with MRD was confirmed in a dataset of 1192 newly diagnosed male patients enrolled in a Children 's Oncology Group trial P 0.78 We found no evidence that G6PD deficiency affects daunorubicin activity during induction treatment for ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3597, 32, 95, 4, 504, 36, 1, 815, 286, 1275, 62, 2, 32, 440, 6, 2562, 3495, 1531, 317, 26, 10328, 237, 651, 4512, 128, 15, 10425, 176, 4, 7, 5, 2522, 49, 4849, 2374, 16146, 2299, 16, 860, 107, 13578, 815, 7, 5, 732, 265, 62, 73, 28, 3062, 4841, 541, 292, 389, 702, 350, 42, 1971, 16146, 128, 21, 72, 3, 1078, 1, 109, 1048, 753, 34, 2029, 3567, 28, 218, 167, 218, 326, 1, 504, 15, 8898, 355, 28, 218, 595, 218, 641, 396, 1, 504, 2, 3, 207, 1, 3422, 315, 31, 7256, 4987, 50, 5247, 4, 504, 59, 7, 5, 15, 187, 16146, 2299, 1358, 9, 62, 43, 87, 24, 1182, 89, 2, 1632, 125, 10, 77, 523, 4, 218, 167, 326, 19, 14, 15, 396, 1, 504, 2029, 19, 13, 846, 2110, 4, 3, 207, 1, 7256, 4987, 19, 13, 803, 3, 926, 1, 248, 5, 2029, 10, 557, 4, 8, 3014, 1, 35421, 732, 265, 1045, 7, 346, 4, 8, 541, 292, 413, 87, 160, 19, 13, 833, 21, 204, 77, 241, 17, 16146, 2299, 2561, 5247, 128, 190, 504, 24, 9, 62]",1132.0,30848065,665
Treatment of relapsed/refractory acute lymphoblastic leukemia.,Clinical advances in hematology & oncology : H&O,Clin Adv Hematol Oncol,2019-03-01,"Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6 months, and treatment options in the salvage setting have been limited to conventional cytotoxic chemotherapy with minimal activity. Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL. Blinatumomab, inotuzumab ozogamicin, and chimeric antigen receptor (CAR) T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL.",Journal Article,326.0,2.0,Patients with relapsed or refractory acute lymphoblastic R/R ALL have dismal outcomes with survival of less than 6 months and treatment options in the salvage setting have been limited to conventional cytotoxic chemotherapy with minimal activity Advances in the development of novel targeted therapies have significantly improved outcomes in R/R ALL Blinatumomab inotuzumab ozogamicin and chimeric antigen receptor CAR T-cell therapy constitute new treatment modalities that are challenging the historical regimens and paving a new path for treating patients with R/R ALL,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[7, 5, 591, 15, 430, 286, 1275, 668, 668, 62, 47, 3929, 123, 5, 25, 1, 299, 76, 49, 53, 2, 24, 838, 4, 3, 992, 546, 47, 85, 383, 6, 809, 759, 56, 5, 1048, 128, 954, 4, 3, 193, 1, 229, 238, 235, 47, 97, 231, 123, 4, 668, 668, 62, 7182, 6730, 5566, 2, 2897, 448, 153, 1881, 102, 31, 36, 4999, 217, 24, 1558, 17, 32, 1950, 3, 2252, 472, 2, 14246, 8, 217, 6361, 9, 1367, 7, 5, 668, 668, 62]",571.0,30969955,896
The relationship of child executive functions to parenting capacities in childhood acute lymphoblastic leukemia survivors.,Pediatric blood & cancer,Pediatr Blood Cancer,2019-04-29,"The current study examined associations between child executive functions and parenting capacities in long-term survivors of childhood acute lymphoblastic leukemia (ALL). Participants included 188 parent-child dyads; children were at least 8 years of age, 5 years postdiagnosis of ALL, and previously treated with chemotherapy only. Parents completed the Parental Protection Scale (PPS), Child Vulnerability Scale (CVS), and Decision-Making Questionnaire (DMQ). Children completed measures of executive functioning and general cognitive abilities. Multivariate multiple regression examined associations between child executive functioning and parenting, while controlling for child age, treatment risk, maternal education, and child intelligence quotient. An exploratory aim identified latent profiles of parenting capacities. Higher child cognitive flexibility ( = -0.16, P = .02) and planning abilities ( = -0.16, P = .049) were related to less parental overprotection. No other neurocognitive measures were related to child autonomy in decision making or perceived child vulnerability. For the exploratory aim, we found (a) a large class defined by normative parenting (94.3%) and (b) a small class characterized by higher levels of child vulnerability and overprotection. Class membership was unrelated to executive functioning, but higher maternal education was related to higher odds of class 2 membership (OR = 0.58, P = .04). Results suggest that parents respond to child executive function difficulties with greater overprotection, which may be adaptive but not conducive to the development of independence. Although most parents report normative levels of child vulnerability and overprotection, a small subset demonstrate parenting practices that may place some survivors at risk for adverse outcomes.",Journal Article,267.0,0.0,The current study examined associations between child executive functions and parenting capacities in long-term survivors of childhood acute lymphoblastic ALL Participants included 188 parent-child dyads children were at least 8 years of age 5 years postdiagnosis of ALL and previously treated with chemotherapy only Parents completed the Parental Protection Scale PPS Child Vulnerability Scale CVS and Decision-Making Questionnaire DMQ Children completed measures of executive functioning and general cognitive abilities Multivariate multiple regression examined associations between child executive functioning and parenting while controlling for child age treatment risk maternal education and child intelligence quotient An exploratory aim identified latent profiles of parenting capacities Higher child cognitive flexibility -0.16 P .02 and planning abilities -0.16 P .049 were related to less parental overprotection No other neurocognitive measures were related to child autonomy in decision making or perceived child vulnerability For the exploratory aim we found a a large class defined by normative parenting 94.3 and b a small class characterized by higher levels of child vulnerability and overprotection Class membership was unrelated to executive functioning but higher maternal education was related to higher odds of class 2 membership OR 0.58 P .04 Results suggest that parents respond to child executive function difficulties with greater overprotection which may be adaptive but not conducive to the development of independence Although most parents report normative levels of child vulnerability and overprotection a small subset demonstrate parenting practices that may place some survivors at risk for adverse outcomes,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 291, 45, 409, 685, 59, 2566, 6481, 1681, 2, 30040, 14866, 4, 319, 337, 332, 1, 864, 286, 1275, 62, 776, 159, 5664, 3841, 2566, 10003, 541, 11, 28, 506, 66, 60, 1, 89, 33, 60, 7163, 1, 62, 2, 373, 73, 5, 56, 158, 2418, 781, 3, 3418, 3525, 1124, 10513, 2566, 7665, 1124, 14723, 2, 948, 1079, 1770, 74735, 541, 781, 1018, 1, 6481, 2702, 2, 1083, 1863, 7965, 331, 232, 320, 409, 685, 59, 2566, 6481, 2702, 2, 30040, 369, 1893, 9, 2566, 89, 24, 43, 6039, 1848, 2, 2566, 9125, 15164, 35, 2386, 1130, 108, 6011, 1241, 1, 30040, 14866, 142, 2566, 1863, 9794, 13, 245, 19, 588, 2, 1349, 7965, 13, 245, 19, 5121, 11, 139, 6, 299, 3418, 23009, 77, 127, 2958, 1018, 11, 139, 6, 2566, 14086, 4, 948, 1079, 15, 2588, 2566, 7665, 9, 3, 2386, 1130, 21, 204, 8, 8, 375, 1040, 395, 20, 9658, 30040, 960, 27, 2, 132, 8, 302, 1040, 765, 20, 142, 148, 1, 2566, 7665, 2, 23009, 1040, 9592, 10, 2092, 6, 6481, 2702, 84, 142, 6039, 1848, 10, 139, 6, 142, 610, 1, 1040, 18, 9592, 15, 13, 717, 19, 755, 99, 309, 17, 2418, 1892, 6, 2566, 6481, 343, 4679, 5, 378, 23009, 92, 68, 40, 2454, 84, 44, 16774, 6, 3, 193, 1, 5773, 242, 96, 2418, 414, 9658, 148, 1, 2566, 7665, 2, 23009, 8, 302, 697, 608, 30040, 2634, 17, 68, 3536, 476, 332, 28, 43, 9, 290, 123]",1740.0,31033172,51
Demographics and Outcome of Philadelphia-positive ALL in a Pediatric Population in North India: a Single-center Experience.,Journal of pediatric hematology/oncology,J. Pediatr. Hematol. Oncol.,2019-07-01,"Philadelphia-positive (Ph+) acute lymphoblastic leukemia (ALL) in children had a worse outcome before the use of tyrosine kinase inhibitors. We have evaluated the demographics and outcome of Ph+ ALL patients treated with imatinib without blood marrow transplantation. Of the 206 children with ALL registered for treatment, the demographic data of 15 Ph+ ALL patients were compared with the remaining Ph- patients. Imatinib (340mg/m) was started on day 5 (D5) of induction in Ph+ patients, and their overall survival was compared with Ph- high-risk patients treated on similar protocols. Statistical analysis was carried out by the Fisher exact test and the t test. The Kaplan-Meier test was used for survival analysis. Philadelphia positivity noted in 15/206 (7.28%) ALL patients was higher than reported earlier. Median initial total leukocyte count and central nervous system positivity were significantly higher in Ph+ patients. Myeloid markers, CD13 and CD33, were also positive in 33.3% Ph+ patients. D15 and D35 marrow showed remissions in a larger proportion of Ph+ ALL, as compared with Ph- patients, but chemotherapy interruptions and neutropenic deaths were significantly higher after starting imatinib, as compared with Philadelphia high-risk patients. Overall survival was similar in Ph+ and Ph- high-risk ALL patients. Ph+ ALL, noted in 7.28%, presented with high initial white blood cell counts, high central nervous system positivity, poor steroid response, and higher induction deaths, as compared with high-risk Ph- ALL, and raised the question about the appropriate dose and time of introduction of imatinib to prevent toxicity.",Journal Article,204.0,0.0,Philadelphia-positive Ph+ acute lymphoblastic ALL in children had a worse outcome before the use of tyrosine kinase inhibitors We have evaluated the demographics and outcome of Ph+ ALL patients treated with imatinib without blood marrow transplantation Of the 206 children with ALL registered for treatment the demographic data of 15 Ph+ ALL patients were compared with the remaining Ph- patients Imatinib 340 mg/m was started on day 5 D5 of induction in Ph+ patients and their overall survival was compared with Ph- high-risk patients treated on similar protocols Statistical analysis was carried out by the Fisher exact test and the t test The Kaplan-Meier test was used for survival analysis Philadelphia positivity noted in 15/206 7.28 ALL patients was higher than reported earlier Median initial total leukocyte count and central nervous system positivity were significantly higher in Ph+ patients Myeloid markers CD13 and CD33 were also positive in 33.3 Ph+ patients D15 and D35 marrow showed remissions in a larger proportion of Ph+ ALL as compared with Ph- patients but chemotherapy interruptions and neutropenic deaths were significantly higher after starting imatinib as compared with Philadelphia high-risk patients Overall survival was similar in Ph+ and Ph- high-risk ALL patients Ph+ ALL noted in 7.28 presented with high initial white blood cell counts high central nervous system positivity poor steroid response and higher induction deaths as compared with high-risk Ph- ALL and raised the question about the appropriate dose and time of introduction of imatinib to prevent toxicity,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3006, 109, 2058, 286, 1275, 62, 4, 541, 42, 8, 639, 228, 348, 3, 119, 1, 564, 216, 222, 21, 47, 194, 3, 2221, 2, 228, 1, 2058, 62, 7, 73, 5, 577, 187, 315, 581, 497, 1, 3, 5956, 541, 5, 62, 1653, 9, 24, 3, 1540, 74, 1, 167, 2058, 62, 7, 11, 72, 5, 3, 1844, 2058, 7, 577, 7264, 81, 188, 10, 3461, 23, 218, 33, 19576, 1, 504, 4, 2058, 7, 2, 136, 63, 25, 10, 72, 5, 2058, 64, 43, 7, 73, 23, 288, 2189, 1050, 65, 10, 2629, 1205, 20, 3, 3135, 2472, 412, 2, 3, 102, 412, 3, 876, 882, 412, 10, 95, 9, 25, 65, 3006, 1887, 1051, 4, 167, 5956, 67, 339, 62, 7, 10, 142, 76, 210, 1677, 52, 388, 181, 3627, 1276, 2, 854, 1880, 398, 1887, 11, 97, 142, 4, 2058, 7, 533, 525, 13518, 2, 6353, 11, 120, 109, 4, 466, 27, 2058, 7, 25318, 2, 74736, 581, 224, 3166, 4, 8, 1077, 920, 1, 2058, 62, 22, 72, 5, 2058, 7, 84, 56, 7406, 2, 3659, 1043, 11, 97, 142, 50, 1723, 577, 22, 72, 5, 3006, 64, 43, 7, 63, 25, 10, 288, 4, 2058, 2, 2058, 64, 43, 62, 7, 2058, 62, 1051, 4, 67, 339, 917, 5, 64, 388, 886, 315, 31, 1911, 64, 854, 1880, 398, 1887, 334, 3853, 51, 2, 142, 504, 1043, 22, 72, 5, 64, 43, 2058, 62, 2, 5673, 3, 2840, 545, 3, 870, 61, 2, 98, 1, 2456, 1, 577, 6, 1682, 155]",1599.0,31033785,350
Severe hyperlipidemia in a case of acute lymphoblastic leukemia.,Indian journal of cancer,Indian J Cancer,,"Severe hyperlipidemia (>1000 mg/dL) at initial presentation of acute lymphoblastic leukemia (ALL) is rare. Cases of hyperlipidemia during therapy for childhood ALL where they were secondary to L-asparaginase or steroids have been described. This is a case report of a one-and-half-year-old boy who presented to us with fever, abdominal distension, severe pallor, and hepatosplenomegaly. Although his investigations were suggestive of ALL, the initial blood samples were found to be grossly lipemic. The lipid profile was abnormal, showing severe hypertriglyceridemia (serum triglycerides 1552 mg/dL). High-density lipoprotein and low-density lipoprotein levels were low, but there were raised very low-density lipoprotein level and serum lactate dehydrogenase (18117 U/L). The patient was started on induction of remission with careful monitoring of biochemical parameters. Abnormal lipid levels declined gradually with normalization of the levels at the end of one week of chemotherapy. No further complications were encountered during the course of induction of remission.",Case Reports,,0.0,Severe hyperlipidemia 1000 mg/dL at initial presentation of acute lymphoblastic ALL is rare Cases of hyperlipidemia during therapy for childhood ALL where they were secondary to L-asparaginase or steroids have been described This is a case report of a one-and-half-year-old boy who presented to us with fever abdominal distension severe pallor and hepatosplenomegaly Although his investigations were suggestive of ALL the initial blood samples were found to be grossly lipemic The lipid profile was abnormal showing severe hypertriglyceridemia serum triglycerides 1552 mg/dL High-density lipoprotein and low-density lipoprotein levels were low but there were raised very low-density lipoprotein level and serum lactate dehydrogenase 18117 U/L The patient was started on induction of remission with careful monitoring of biochemical parameters Abnormal lipid levels declined gradually with normalization of the levels at the end of one week of chemotherapy No further complications were encountered during the course of induction of remission,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[905, 12386, 2345, 81, 1826, 28, 388, 1031, 1, 286, 1275, 62, 16, 622, 140, 1, 12386, 190, 36, 9, 864, 62, 1257, 491, 11, 568, 6, 805, 3709, 15, 4580, 47, 85, 1027, 26, 16, 8, 473, 414, 1, 8, 104, 2, 1303, 111, 1095, 10802, 54, 917, 6, 843, 5, 2775, 1467, 18495, 905, 40747, 2, 15144, 242, 3224, 2492, 11, 3832, 1, 62, 3, 388, 315, 347, 11, 204, 6, 40, 7185, 74767, 3, 3121, 800, 10, 1668, 2069, 905, 10427, 524, 15000, 32536, 81, 1826, 64, 1263, 8984, 2, 154, 1263, 8984, 148, 11, 154, 84, 125, 11, 5673, 923, 154, 1263, 8984, 301, 2, 524, 3330, 2374, 74768, 1767, 805, 3, 69, 10, 3461, 23, 504, 1, 734, 5, 3465, 1315, 1, 1487, 1038, 1668, 3121, 148, 3054, 8092, 5, 5924, 1, 3, 148, 28, 3, 396, 1, 104, 647, 1, 56, 77, 195, 521, 11, 3903, 190, 3, 906, 1, 504, 1, 734]",1041.0,31062741,427
The changing burden of long-term health outcomes in survivors of childhood acute lymphoblastic leukaemia: a retrospective analysis of the St Jude Lifetime Cohort Study.,The Lancet. Haematology,Lancet Haematol,2019-05-08,"Treatment for childhood acute lymphoblastic leukemia has evolved over the past five decades, with moderation of traditional chemotherapy and radiotherapy and the introduction of targeted immune-based and cellular-based therapies. The affect of these changes on late health outcomes has not been assessed. Using data from the The St Jude Lifetime (SJLIFE) Cohort, we aimed to characterise the magnitude of morbidity and patterns of late health outcomes among survivors of childhood acute lymphoblastic leukaemia treated over time. The St Jude Lifetime (SJLIFE) Cohort is a retrospective cohort study with prospective follow-up and ongoing data accrual designed to facilitate longitudinal, clinically-based assessment of health outcomes among survivors of paediatric malignancies. 980 survivors included in this analysis were diagnosed with paediatric acute lymphoblastic leukaemia at St Jude Children's Research Hospital (SJCRH) between Aug 28, 1963, and July 19, 2003, were aged 18 years old and older at enrolment, had a minimum follow-up of 10 years after diagnosis, and completed an initial on-campus SJLIFE assessment as of data cutoff (June 30, 2015). 272 community control participants, matched to survivors on 5-year age blocks in each sex, were recruited for comparison. Cumulative chemotherapy and radiation dose exposures and major medical events during and after therapy were retrieved from the medical records of the survivors. History or physical examination, laboratory analysis, physical fitness, and neurocognitive testing were done. Health conditions were graded according to a modified version of the Common Terminology Criteria for Adverse Events. Neurocognitive domains of attention (Trial Making Test Part A and Conner's Continuous Performance Test-II) and executive function (Trail Making Test Part B, Controlled Oral Word Association Test, and Wechsler Adult Intelligence Scale-III Digit Span Test Backward) were measured and age-adjusted Z scores were calculated. Mean cumulative count was used to calculate the age-standardised cumulative burden of health conditions over time. This cohort study is registered at ClinicalTrials.gov, number NCT00760656. 980 survivors of acute lymphoblastic leukaemia (50% women, median age at diagnosis 5 years [IQR 31-91 years], and median time from diagnosis of 300 years [227-363]) had a median age of 358 years (294-429) at assessment compared with 351 years (287-426) for 272 controls. Survivors had significantly more growth hormone deficiency, hypogonadism, and neuropathy than controls. By age 30 years, survivors of acute lymphoblastic leukaemia had, on average, 54 (95% CI 51-58) grade 1-4 health conditions, including 32 (29-34) grade 2-4 health conditions, compared with 20 (CI 17-22) grade 1-4 and 12 (103-14) grade 2-4 health conditions among controls. The cumulative burden of grade 2-4 health conditions involved multiple organ systems for survivors treated on protocols between 1962-91, but after elimination of cranial radiotherapy for children with acute lymphoblastic leukaemia, conditions now predominately include musculoskeletal and endocrine disorders for survivors on protocols between 1991-2007. Although changes in paediatric acute lymphoblastic leukaemia treatment protocols have improved overall survival, the burden of late morbidity remains high for these patients. We show that the pattern of late toxic effects has markedly changed over time, with survivors having a reduction in health conditions that are immediately life-threatening, however, maintaining health status and quality of life for survivors of paediatric acute lymphoblastic leukaemia requires continued medical surveillance, counselling, and lifestyle modifications. US National Cancer Institute and the American Lebanese Syrian Associated Charities.",Journal Article,258.0,2.0,Treatment for childhood acute lymphoblastic has evolved over the past five decades with moderation of traditional chemotherapy and radiotherapy and the introduction of targeted immune-based and cellular-based therapies The affect of these changes on late health outcomes has not been assessed Using data from the The St Jude Lifetime SJLIFE Cohort we aimed to characterise the magnitude of morbidity and patterns of late health outcomes among survivors of childhood acute lymphoblastic leukaemia treated over time The St Jude Lifetime SJLIFE Cohort is a retrospective cohort study with prospective follow-up and ongoing data accrual designed to facilitate longitudinal clinically-based assessment of health outcomes among survivors of paediatric malignancies 980 survivors included in this analysis were diagnosed with paediatric acute lymphoblastic leukaemia at St Jude Children 's Research Hospital SJCRH between Aug 28 1963 and July 19 2003 were aged 18 years old and older at enrolment had a minimum follow-up of 10 years after diagnosis and completed an initial on-campus SJLIFE assessment as of data cutoff June 30 2015 272 community control participants matched to survivors on 5-year age blocks in each sex were recruited for comparison Cumulative chemotherapy and radiation dose exposures and major medical events during and after therapy were retrieved from the medical records of the survivors History or physical examination laboratory analysis physical fitness and neurocognitive testing were done Health conditions were graded according to a modified version of the Common Terminology Criteria for Adverse Events Neurocognitive domains of attention Trial Making Test Part A and Conner 's Continuous Performance Test-II and executive function Trail Making Test Part B Controlled Oral Word Association Test and Wechsler Adult Intelligence Scale-III Digit Span Test Backward were measured and age-adjusted Z scores were calculated Mean cumulative count was used to calculate the age-standardised cumulative burden of health conditions over time This cohort study is registered at ClinicalTrials.gov number NCT00760656 980 survivors of acute lymphoblastic leukaemia 50 women median age at diagnosis 5 years IQR 31-91 years and median time from diagnosis of 300 years 227-363 had a median age of 358 years 294-429 at assessment compared with 351 years 287-426 for 272 controls Survivors had significantly more growth hormone deficiency hypogonadism and neuropathy than controls By age 30 years survivors of acute lymphoblastic leukaemia had on average 54 95 CI 51-58 grade 1-4 health conditions including 32 29-34 grade 2-4 health conditions compared with 20 CI 17-22 grade 1-4 and 12 103-14 grade 2-4 health conditions among controls The cumulative burden of grade 2-4 health conditions involved multiple organ systems for survivors treated on protocols between 1962-91 but after elimination of cranial radiotherapy for children with acute lymphoblastic leukaemia conditions now predominately include musculoskeletal and endocrine disorders for survivors on protocols between 1991-2007 Although changes in paediatric acute lymphoblastic leukaemia treatment protocols have improved overall survival the burden of late morbidity remains high for these patients We show that the pattern of late toxic effects has markedly changed over time with survivors having a reduction in health conditions that are immediately life-threatening however maintaining health status and quality of life for survivors of paediatric acute lymphoblastic leukaemia requires continued medical surveillance counselling and lifestyle modifications US National Cancer Institute and the American Lebanese Syrian Associated Charities,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 9, 864, 286, 1275, 71, 3937, 252, 3, 1219, 365, 1968, 5, 47029, 1, 1847, 56, 2, 310, 2, 3, 2456, 1, 238, 250, 90, 2, 763, 90, 235, 3, 1158, 1, 46, 400, 23, 807, 341, 123, 71, 44, 85, 275, 75, 74, 29, 3, 3, 3062, 4841, 2898, 13437, 180, 21, 1295, 6, 16885, 3, 3131, 1, 787, 2, 764, 1, 807, 341, 123, 107, 332, 1, 864, 286, 1275, 2001, 73, 252, 98, 3, 3062, 4841, 2898, 13437, 180, 16, 8, 459, 180, 45, 5, 482, 166, 126, 2, 942, 74, 2262, 1114, 6, 1876, 2380, 505, 90, 455, 1, 341, 123, 107, 332, 1, 6138, 441, 15561, 332, 159, 4, 26, 65, 11, 265, 5, 6138, 286, 1275, 2001, 28, 3062, 4841, 541, 292, 389, 702, 19696, 59, 10497, 339, 23169, 2, 2066, 326, 1522, 11, 1032, 203, 60, 1095, 2, 434, 28, 8206, 42, 8, 2499, 166, 126, 1, 79, 60, 50, 147, 2, 781, 35, 388, 23, 18619, 13437, 455, 22, 1, 74, 2779, 1924, 201, 1483, 6905, 1714, 182, 776, 655, 6, 332, 23, 33, 111, 89, 2860, 4, 296, 1035, 11, 2619, 9, 1155, 967, 56, 2, 121, 61, 3401, 2, 458, 484, 281, 190, 2, 50, 36, 11, 4539, 29, 3, 484, 1064, 1, 3, 332, 532, 15, 900, 1385, 1624, 65, 900, 5959, 2, 2958, 471, 11, 1822, 341, 1298, 11, 3468, 768, 6, 8, 1230, 2256, 1, 3, 186, 3462, 371, 9, 290, 281, 2958, 2703, 1, 2111, 160, 1079, 412, 760, 8, 2, 74778, 292, 1314, 528, 412, 215, 2, 6481, 343, 2585, 1079, 412, 760, 132, 1149, 518, 15952, 248, 412, 2, 17526, 780, 9125, 1124, 316, 9553, 7165, 412, 10877, 11, 644, 2, 89, 586, 3905, 703, 11, 981, 313, 967, 1276, 10, 95, 6, 3232, 3, 89, 14041, 967, 892, 1, 341, 1298, 252, 98, 26, 180, 45, 16, 1653, 28, 1252, 1239, 207, 47774, 15561, 332, 1, 286, 1275, 2001, 212, 117, 52, 89, 28, 147, 33, 60, 2245, 17503, 29242, 60, 2, 52, 98, 29, 147, 1, 32220, 60, 41772, 51529, 42, 8, 52, 89, 1, 41576, 60, 41458, 25455, 28, 455, 72, 5, 41283, 60, 51530, 74779, 9, 6905, 535, 332, 42, 97, 80, 129, 785, 2299, 10616, 2, 1751, 76, 535, 20, 89, 201, 60, 332, 1, 286, 1275, 2001, 42, 23, 1011, 17493, 48, 58, 22748, 19336, 88, 14, 39, 341, 1298, 141, 23938, 14036, 22672, 88, 18, 39, 341, 1298, 72, 5, 14033, 58, 15768, 25562, 88, 14, 39, 2, 14363, 19351, 16552, 88, 18, 39, 341, 1298, 107, 535, 3, 967, 892, 1, 88, 18, 39, 341, 1298, 646, 232, 1259, 1530, 9, 332, 73, 23, 2189, 59, 14754, 970, 84, 50, 3730, 1, 2565, 310, 9, 541, 5, 286, 1275, 2001, 1298, 1134, 11583, 643, 5701, 2, 1293, 1997, 9, 332, 23, 2189, 59, 3372, 1307, 242, 400, 4, 6138, 286, 1275, 2001, 24, 2189, 47, 231, 63, 25, 3, 892, 1, 807, 787, 469, 64, 9, 46, 7, 21, 514, 17, 3, 1177, 1, 807, 1812, 176, 71, 2195, 2368, 252, 98, 5, 332, 1041, 8, 628, 4, 341, 1298, 17, 32, 3467, 358, 3691, 137, 3284, 341, 156, 2, 372, 1, 358, 9, 332, 1, 6138, 286, 1275, 2001, 1706, 1351, 484, 617, 13398, 2, 3487, 2916, 843, 657, 12, 1377, 2, 3, 597, 14666, 13671, 41, 14667]",3737.0,31078468,91
Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias.,PLoS genetics,PLoS Genet.,2019-06-14,"The lack of predictive preclinical models is a fundamental barrier to translating knowledge about the molecular pathogenesis of cancer into improved therapies. Insertional mutagenesis (IM) in mice is a robust strategy for generating malignancies that recapitulate the extensive inter- and intra-tumoral genetic heterogeneity found in advanced human cancers. While the central role of ""driver"" viral insertions in IM models that aberrantly increase the expression of proto-oncogenes or disrupt tumor suppressors has been appreciated for many years, the contributions of cooperating somatic mutations and large chromosomal alterations to tumorigenesis are largely unknown. Integrated genomic studies of T lineage acute lymphoblastic leukemias (T-ALLs) generated by IM in wild-type (WT) and Kras mutant mice reveal frequent point mutations and other recurrent non-insertional genetic alterations that also occur in human T-ALL. These somatic mutations are sensitive and specific markers for defining clonal dynamics and identifying candidate resistance mechanisms in leukemias that relapse after an initial therapeutic response. Primary cancers initiated by IM and resistant clones that emerge during in vivo treatment close key gaps in existing preclinical models, and are robust platforms for investigating the efficacy of new therapies and for elucidating how drug exposure shapes tumor evolution and patterns of resistance.",Journal Article,221.0,0.0,The lack of predictive preclinical models is a fundamental barrier to translating knowledge about the molecular pathogenesis of cancer into improved therapies Insertional mutagenesis IM in mice is a robust strategy for generating malignancies that recapitulate the extensive inter- and intra-tumoral genetic heterogeneity found in advanced human cancers While the central role of `` driver '' viral insertions in IM models that aberrantly increase the expression of proto-oncogenes or disrupt tumor suppressors has been appreciated for many years the contributions of cooperating somatic mutations and large chromosomal alterations to tumorigenesis are largely unknown Integrated genomic studies of T lineage acute lymphoblastic leukemias T-ALLs generated by IM in wild-type WT and Kras mutant mice reveal frequent point mutations and other recurrent non-insertional genetic alterations that also occur in human T-ALL These somatic mutations are sensitive and specific markers for defining clonal dynamics and identifying candidate resistance mechanisms in leukemias that relapse after an initial therapeutic response Primary cancers initiated by IM and resistant clones that emerge during in vivo treatment close key gaps in existing preclinical models and are robust platforms for investigating the efficacy of new therapies and for elucidating how drug exposure shapes tumor evolution and patterns of resistance,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 926, 1, 464, 693, 274, 16, 8, 4595, 3318, 6, 8446, 922, 545, 3, 219, 1384, 1, 12, 237, 231, 235, 23271, 8595, 2820, 4, 399, 16, 8, 1922, 692, 9, 3997, 441, 17, 7746, 3, 1344, 3606, 2, 2392, 4204, 336, 1144, 204, 4, 131, 171, 163, 369, 3, 854, 200, 1, 2228, 522, 1667, 6315, 4, 2820, 274, 17, 5619, 344, 3, 55, 1, 4976, 3326, 15, 6619, 30, 5704, 71, 85, 7292, 9, 445, 60, 3, 5621, 1, 11413, 1119, 138, 2, 375, 1860, 593, 6, 1565, 32, 1733, 860, 2102, 572, 94, 1, 102, 2542, 286, 1275, 2792, 102, 10706, 1419, 20, 2820, 4, 955, 267, 1820, 2, 723, 620, 399, 2396, 908, 741, 138, 2, 127, 387, 220, 23271, 336, 593, 17, 120, 1271, 4, 171, 102, 62, 46, 1119, 138, 32, 745, 2, 112, 525, 9, 2847, 1946, 5193, 2, 1386, 1609, 251, 483, 4, 2792, 17, 429, 50, 35, 388, 189, 51, 86, 163, 1917, 20, 2820, 2, 436, 2749, 17, 6371, 190, 4, 386, 24, 2336, 825, 5287, 4, 1692, 693, 274, 2, 32, 1922, 4364, 9, 3103, 3, 209, 1, 217, 235, 2, 9, 7980, 832, 234, 645, 14475, 30, 2554, 2, 764, 1, 251]",1414.0,31199785,389
The magnitude and predictors of abandonment of therapy in paediatric acute leukaemia in middle-income countries: a systematic review and meta-analysis.,"European journal of cancer (Oxford, England : 1990)",Eur. J. Cancer,2013-04-15,"Abandonment of therapy is a significant cause of paediatric cancer treatment failure in low- to middle-income countries (LMIC), but its impact has been underestimated. We performed a meta-analysis to determine the magnitude of abandonment in paediatric leukaemia in LMIC and sought to identify patient-, centre- and country-specific predictors of abandonment. We searched seven databases to identify paediatric oncology cohorts followed up from diagnosis and treated in LMIC. All languages were included. Two reviewers independently selected articles and extracted data. Authors were contacted for additional information. Subgroup analyses were planned a priori. Of 22,384 publications, 318 in eight languages met criteria for full text review. 157 studies met analysis inclusion criteria. Abandonment rates (ARs), obtained for 83 of the 157 studies (52.9%), ranged from 0% to 74.5%. ARs were frequently unreported and available only directly from authors. Forty studies (10,494 children in 20 countries) were quantitatively analysed. ARs for acute lymphoblastic laeukemia in lower-middle-income countries (lower-MICs) were higher than in upper-middle-income countries (29%, 95% confidence interval (CI) 23-36% versus 2%, 95% CI 1-3%; p<0.0001) but were heterogeneous (I(2)=98%; p<0.0001). This heterogeneity was not explained by centre-specific (free versus paid treatment) or country-specific (government health expenditure, per-capital income) subgroups. In LMICs, ARs are highest in lower-MICs. However, their broad range suggests that low ARs are possible in resource-constrained settings. Analysis of outliers may suggest interventions for use at other centres. Methodologically appropriate reporting of ARs should be adopted. Future research should evaluate interventions targeting abandonment.",Journal Article,2472.0,,"Abandonment of therapy is a significant cause of paediatric cancer treatment failure in low- to middle-income countries LMIC but its impact has been underestimated We performed a meta-analysis to determine the magnitude of abandonment in paediatric leukaemia in LMIC and sought to identify patient- centre- and country-specific predictors of abandonment We searched seven databases to identify paediatric oncology cohorts followed up from diagnosis and treated in LMIC All languages were included Two reviewers independently selected articles and extracted data Authors were contacted for additional information Subgroup analyses were planned a priori Of 22,384 publications 318 in eight languages met criteria for full text review 157 studies met analysis inclusion criteria Abandonment rates ARs obtained for 83 of the 157 studies 52.9 ranged from 0 to 74.5 ARs were frequently unreported and available only directly from authors Forty studies 10,494 children in 20 countries were quantitatively analysed ARs for acute lymphoblastic laeukemia in lower-middle-income countries lower-MICs were higher than in upper-middle-income countries 29 95 confidence interval CI 23-36 versus 2 95 CI 1-3 p 0.0001 but were heterogeneous I 2 =98 p 0.0001 This heterogeneity was not explained by centre-specific free versus paid treatment or country-specific government health expenditure per-capital income subgroups In LMICs ARs are highest in lower-MICs However their broad range suggests that low ARs are possible in resource-constrained settings Analysis of outliers may suggest interventions for use at other centres Methodologically appropriate reporting of ARs should be adopted Future research should evaluate interventions targeting abandonment",0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[9839, 1, 36, 16, 8, 93, 708, 1, 6138, 12, 24, 496, 4, 154, 6, 3897, 2306, 2115, 12950, 84, 211, 345, 71, 85, 10585, 21, 173, 8, 1742, 65, 6, 223, 3, 3131, 1, 9839, 4, 6138, 2001, 4, 12950, 2, 990, 6, 255, 69, 5931, 2, 5978, 112, 674, 1, 9839, 21, 3080, 648, 2348, 6, 255, 6138, 413, 736, 370, 126, 29, 147, 2, 73, 4, 12950, 62, 24312, 11, 159, 100, 7171, 1042, 715, 2384, 2, 2484, 74, 738, 11, 8590, 9, 402, 487, 1363, 318, 11, 1465, 8, 7499, 1, 350, 12612, 4463, 8797, 4, 659, 24312, 543, 371, 9, 1647, 6153, 206, 5311, 94, 543, 65, 1680, 371, 9839, 151, 9381, 683, 9, 852, 1, 3, 5311, 94, 653, 83, 1869, 29, 13, 6, 794, 33, 9381, 11, 746, 10046, 2, 390, 158, 1606, 29, 738, 1213, 94, 79, 10919, 541, 4, 179, 2115, 11, 5889, 3141, 9381, 9, 286, 1275, 77257, 4, 280, 3897, 2306, 2115, 280, 32278, 11, 142, 76, 4, 1726, 3897, 2306, 2115, 462, 48, 307, 268, 58, 382, 511, 185, 18, 48, 58, 14, 27, 19, 13, 488, 84, 11, 1564, 70, 18, 1096, 19, 13, 488, 26, 1144, 10, 44, 3672, 20, 5931, 112, 115, 185, 8328, 24, 15, 5978, 112, 7608, 341, 8699, 379, 17386, 2306, 1453, 4, 13457, 9381, 32, 1076, 4, 280, 32278, 137, 136, 2094, 184, 844, 17, 154, 9381, 32, 899, 4, 3069, 9133, 1947, 65, 1, 13137, 68, 309, 1151, 9, 119, 28, 127, 4496, 31554, 870, 1760, 1, 9381, 257, 40, 4457, 508, 389, 257, 376, 1151, 529, 9839]",,23597721,233
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.,British journal of haematology,Br. J. Haematol.,2014-03-03,"Precursor B-acute lymphoblastic leukaemias (pre-B ALLs) comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface. In the present study (Southwestern Oncology Group S0910), we evaluated the addition of epratuzumab, a humanized monoclonal antibody against CD22, to the combination of clofarabine and cytarabine in adults with relapsed/refractory pre-B ALL. The response rate [complete remission and complete remission with incomplete count recovery] was 52%, significantly higher than our previous trial with clofarabine/cytarabine alone, where the response rate was 17%. This result is encouraging and suggests a potential benefit to adding epratuzumab to chemotherapy for ALL; however, a randomized trial will be needed to answer this question. ","Clinical Trial, Phase II",2150.0,48.0,Precursor B-acute lymphoblastic leukaemias pre-B ALLs comprise the majority of ALLs and virtually all blasts express CD22 in the cytoplasm and on the cell surface In the present study Southwestern Oncology Group S0910 we evaluated the addition of epratuzumab a humanized monoclonal antibody against CD22 to the combination of clofarabine and cytarabine in adults with relapsed/refractory pre-B ALL The response rate complete remission and complete remission with incomplete count recovery was 52 significantly higher than our previous trial with clofarabine/cytarabine alone where the response rate was 17 This result is encouraging and suggests a potential benefit to adding epratuzumab to chemotherapy for ALL however a randomized trial will be needed to answer this question,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[2765, 132, 286, 1275, 12160, 671, 132, 10706, 5238, 3, 686, 1, 10706, 2, 5860, 62, 2438, 1669, 7599, 4, 3, 4558, 2, 23, 3, 31, 1255, 4, 3, 364, 45, 16288, 413, 87, 77528, 21, 194, 3, 352, 1, 14801, 8, 3619, 848, 548, 480, 7599, 6, 3, 150, 1, 4149, 2, 1855, 4, 857, 5, 591, 430, 671, 132, 62, 3, 51, 116, 236, 734, 2, 236, 734, 5, 2610, 1276, 1602, 10, 653, 97, 142, 76, 114, 698, 160, 5, 4149, 1855, 279, 1257, 3, 51, 116, 10, 269, 26, 757, 16, 2269, 2, 844, 8, 174, 247, 6, 2726, 14801, 6, 56, 9, 62, 137, 8, 384, 160, 303, 40, 575, 6, 6634, 26, 2840]",,24579885,119
Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.,The Lancet. Oncology,Lancet Oncol.,2014-06-19,"Treatment of patients with paediatric acute lymphoblastic leukaemia has evolved such that the risk of late effects in survivors treated in accordance with contemporary protocols could be different from that noted in those treated decades ago. We aimed to estimate the risk of late effects in children with standard-risk acute lymphoblastic leukaemia treated with contemporary protocols. We used data from similarly treated members of the Childhood Cancer Survivor Study cohort. The Childhood Cancer Survivor Study is a multicentre, North American study of 5-year survivors of childhood cancer diagnosed between 1970 and 1986. We included cohort members if they were aged 10-99 years at the time of diagnosis of acute lymphoblastic leukaemia and had received treatment consistent with contemporary standard-risk protocols for acute lymphoblastic leukaemia. We calculated mortality rates and standardised mortality ratios, stratified by sex and survival time, after diagnosis of acute lymphoblastic leukaemia. We calculated standardised incidence ratios and absolute excess risk for subsequent neoplasms with age-specific, sex-specific, and calendar-year-specific rates from the Surveillance, Epidemiology and End Results Program. Outcomes were compared with a sibling cohort and the general US population. We included 556 (13%) of 4329 cohort members treated for acute lymphoblastic leukaemia. Median follow-up of the survivors from 5 years after diagnosis was 184 years (range 00-330). 28 (5%) of 556 participants had died (standardised mortality ratio 35, 95% CI 23-50). 16 (57%) deaths were due to causes other than recurrence of acute lymphoblastic leukaemia. Six (1%) survivors developed a subsequent malignant neoplasm (standardised incidence ratio 26, 95% CI 10-57). 107 participants (95% CI 81-193) in each group would need to be followed-up for 1 year to observe one extra chronic health disorder in the survivor group compared with the sibling group. 415 participants (376-939) in each group would need to be followed-up for 1 year to observe one extra severe, life-threatening, or fatal disorder in the group of survivors. Survivors did not differ from siblings in their educational attainment, rate of marriage, or independent living. The prevalence of adverse long-term outcomes in children treated for standard risk acute lymphoblastic leukaemia according to contemporary protocols is low, but regular care from a knowledgeable primary-care practitioner is warranted. National Cancer Institute, American Lebanese-Syrian Associated Charities, Swiss Cancer Research.",Journal Article,2042.0,58.0,Treatment of patients with paediatric acute lymphoblastic leukaemia has evolved such that the risk of late effects in survivors treated in accordance with contemporary protocols could be different from that noted in those treated decades ago We aimed to estimate the risk of late effects in children with standard-risk acute lymphoblastic leukaemia treated with contemporary protocols We used data from similarly treated members of the Childhood Cancer Survivor Study cohort The Childhood Cancer Survivor Study is a multicentre North American study of 5-year survivors of childhood cancer diagnosed between 1970 and 1986 We included cohort members if they were aged 10-99 years at the time of diagnosis of acute lymphoblastic leukaemia and had received treatment consistent with contemporary standard-risk protocols for acute lymphoblastic leukaemia We calculated mortality rates and standardised mortality ratios stratified by sex and survival time after diagnosis of acute lymphoblastic leukaemia We calculated standardised incidence ratios and absolute excess risk for subsequent neoplasms with age-specific sex-specific and calendar-year-specific rates from the Surveillance Epidemiology and End Results Program Outcomes were compared with a sibling cohort and the general US population We included 556 13 of 4329 cohort members treated for acute lymphoblastic leukaemia Median follow-up of the survivors from 5 years after diagnosis was 184 years range 00-330 28 5 of 556 participants had died standardised mortality ratio 35 95 CI 23-50 16 57 deaths were due to causes other than recurrence of acute lymphoblastic leukaemia Six 1 survivors developed a subsequent malignant neoplasm standardised incidence ratio 26 95 CI 10-57 107 participants 95 CI 81-193 in each group would need to be followed-up for 1 year to observe one extra chronic health disorder in the survivor group compared with the sibling group 415 participants 376-939 in each group would need to be followed-up for 1 year to observe one extra severe life-threatening or fatal disorder in the group of survivors Survivors did not differ from siblings in their educational attainment rate of marriage or independent living The prevalence of adverse long-term outcomes in children treated for standard risk acute lymphoblastic leukaemia according to contemporary protocols is low but regular care from a knowledgeable primary-care practitioner is warranted National Cancer Institute American Lebanese-Syrian Associated Charities Swiss Cancer Research,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[24, 1, 7, 5, 6138, 286, 1275, 2001, 71, 3937, 225, 17, 3, 43, 1, 807, 176, 4, 332, 73, 4, 8934, 5, 2667, 2189, 359, 40, 338, 29, 17, 1051, 4, 135, 73, 1968, 5028, 21, 1295, 6, 1191, 3, 43, 1, 807, 176, 4, 541, 5, 260, 43, 286, 1275, 2001, 73, 5, 2667, 2189, 21, 95, 74, 29, 1813, 73, 1684, 1, 3, 864, 12, 2628, 45, 180, 3, 864, 12, 2628, 45, 16, 8, 5761, 2669, 597, 45, 1, 33, 111, 332, 1, 864, 12, 265, 59, 4868, 2, 3751, 21, 159, 180, 1684, 492, 491, 11, 1032, 19294, 25410, 60, 28, 3, 98, 1, 147, 1, 286, 1275, 2001, 2, 42, 103, 24, 925, 5, 2667, 260, 43, 2189, 9, 286, 1275, 2001, 21, 981, 282, 151, 2, 14041, 282, 1137, 1173, 20, 1035, 2, 25, 98, 50, 147, 1, 286, 1275, 2001, 21, 981, 14041, 287, 1137, 2, 1766, 2612, 43, 9, 706, 1179, 5, 89, 112, 1035, 112, 2, 11236, 111, 112, 151, 29, 3, 617, 1284, 2, 396, 99, 1243, 123, 11, 72, 5, 8, 3684, 180, 2, 3, 1083, 843, 266, 21, 159, 12341, 233, 1, 46260, 180, 1684, 73, 9, 286, 1275, 2001, 52, 166, 126, 1, 3, 332, 29, 33, 60, 50, 147, 10, 24010, 60, 184, 32239, 77651, 339, 33, 1, 12341, 776, 42, 1016, 14041, 282, 197, 19259, 48, 58, 19961, 21705, 245, 696, 1043, 11, 520, 6, 1626, 127, 76, 146, 1, 286, 1275, 2001, 437, 14, 332, 276, 8, 706, 393, 2131, 14041, 287, 197, 21770, 48, 58, 19294, 17502, 3650, 776, 48, 58, 865, 5744, 4, 296, 87, 688, 594, 6, 40, 370, 126, 9, 14, 111, 6, 4635, 104, 3420, 442, 341, 2645, 4, 3, 2628, 87, 72, 5, 3, 3684, 87, 10069, 776, 9534, 14457, 4, 296, 87, 688, 594, 6, 40, 370, 126, 9, 14, 111, 6, 4635, 104, 3420, 905, 358, 3691, 15, 3034, 2645, 4, 3, 87, 1, 332, 332, 205, 44, 1505, 29, 2758, 4, 136, 3624, 7108, 116, 1, 14822, 15, 306, 2798, 3, 1078, 1, 290, 319, 337, 123, 4, 541, 73, 9, 260, 43, 286, 1275, 2001, 768, 6, 2667, 2189, 16, 154, 84, 3316, 165, 29, 8, 19870, 86, 165, 11929, 16, 1197, 657, 12, 1377, 597, 14666, 13671, 41, 14667, 19196, 12, 389]",,24954778,77
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia.,Nature,Nature,2014-07-20,"Mutations that deregulate Notch1 and Ras/phosphoinositide 3 kinase (PI3K)/Akt signalling are prevalent in T-cell acute lymphoblastic leukaemia (T-ALL), and often coexist. Here we show that the PI3K inhibitor GDC-0941 is active against primary T-ALLs from wild-type and Kras(G12D) mice, and addition of the MEK inhibitor PD0325901 increases its efficacy. Mice invariably relapsed after treatment with drug-resistant clones, most of which unexpectedly had reduced levels of activated Notch1 protein, downregulated many Notch1 target genes, and exhibited cross-resistance to -secretase inhibitors. Multiple resistant primary T-ALLs that emerged in vivo did not contain somatic Notch1 mutations present in the parental leukaemia. Importantly, resistant clones upregulated PI3K signalling. Consistent with these data, inhibiting Notch1 activated the PI3K pathway, providing a likely mechanism for selection against oncogenic Notch1 signalling. These studies validate PI3K as a therapeutic target in T-ALL and raise the unexpected possibility that dual inhibition of PI3K and Notch1 signalling could promote drug resistance in T-ALL. ",Journal Article,2011.0,41.0,Mutations that deregulate Notch1 and Ras/phosphoinositide 3 kinase PI3K /Akt signalling are prevalent in T-cell acute lymphoblastic leukaemia T-ALL and often coexist Here we show that the PI3K inhibitor GDC-0941 is active against primary T-ALLs from wild-type and Kras G12D mice and addition of the MEK inhibitor PD0325901 increases its efficacy Mice invariably relapsed after treatment with drug-resistant clones most of which unexpectedly had reduced levels of activated Notch1 protein downregulated many Notch1 target genes and exhibited cross-resistance to -secretase inhibitors Multiple resistant primary T-ALLs that emerged in vivo did not contain somatic Notch1 mutations present in the parental leukaemia Importantly resistant clones upregulated PI3K signalling Consistent with these data inhibiting Notch1 activated the PI3K pathway providing a likely mechanism for selection against oncogenic Notch1 signalling These studies validate PI3K as a therapeutic target in T-ALL and raise the unexpected possibility that dual inhibition of PI3K and Notch1 signalling could promote drug resistance in T-ALL,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[138, 17, 21087, 4607, 2, 1102, 4497, 27, 216, 974, 649, 3128, 32, 2485, 4, 102, 31, 286, 1275, 2001, 102, 62, 2, 629, 15707, 467, 21, 514, 17, 3, 974, 230, 6165, 22694, 16, 544, 480, 86, 102, 10706, 29, 955, 267, 2, 723, 5727, 399, 2, 352, 1, 3, 1693, 230, 17885, 1106, 211, 209, 399, 6912, 591, 50, 24, 5, 234, 436, 2749, 96, 1, 92, 6016, 42, 405, 148, 1, 735, 4607, 178, 3315, 445, 4607, 283, 214, 2, 1416, 1383, 251, 6, 2655, 10014, 222, 232, 436, 86, 102, 10706, 17, 2054, 4, 386, 205, 44, 3725, 1119, 4607, 138, 364, 4, 3, 3418, 2001, 1859, 436, 2749, 2684, 974, 3128, 925, 5, 46, 74, 2062, 4607, 735, 3, 974, 308, 1736, 8, 322, 670, 9, 881, 480, 1302, 4607, 3128, 46, 94, 2183, 974, 22, 8, 189, 283, 4, 102, 62, 2, 5008, 3, 3792, 2526, 17, 1828, 297, 1, 974, 2, 4607, 3128, 359, 1617, 234, 251, 4, 102, 62]",,25043004,395
Targeting transcription regulation in cancer with a covalent CDK7 inhibitor.,Nature,Nature,2014-06-22,"Tumour oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state, but direct pharmacological inhibition of transcription factors has so far proven difficult. However, the transcriptional machinery contains various enzymatic cofactors that can be targeted for the development of new therapeutic candidates, including cyclin-dependent kinases (CDKs). Here we present the discovery and characterization of a covalent CDK7 inhibitor, THZ1, which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7. Cancer cell-line profiling indicates that a subset of cancer cell lines, including human T-cell acute lymphoblastic leukaemia (T-ALL), have exceptional sensitivity to THZ1. Genome-wide analysis in Jurkat T-ALL cells shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and the key role of RUNX1 in the core transcriptional regulatory circuitry of these tumour cells. Pharmacological modulation of CDK7 kinase activity may thus provide an approach to identify and treat tumour types that are dependent on transcription for maintenance of the oncogenic state. ",Journal Article,2039.0,285.0,Tumour oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state but direct pharmacological inhibition of transcription factors has so far proven difficult However the transcriptional machinery contains various enzymatic cofactors that can be targeted for the development of new therapeutic candidates including cyclin-dependent kinases CDKs Here we present the discovery and characterization of a covalent CDK7 inhibitor THZ1 which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain providing an unanticipated means of achieving selectivity for CDK7 Cancer cell-line profiling indicates that a subset of cancer cell lines including human T-cell acute lymphoblastic leukaemia T-ALL have exceptional sensitivity to THZ1 Genome-wide analysis in Jurkat T-ALL cells shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and the key role of RUNX1 in the core transcriptional regulatory circuitry of these tumour cells Pharmacological modulation of CDK7 kinase activity may thus provide an approach to identify and treat tumour types that are dependent on transcription for maintenance of the oncogenic state,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[770, 3326, 643, 866, 130, 17, 1269, 8966, 3, 1083, 1431, 6415, 6, 8844, 3, 1302, 1309, 84, 1196, 3419, 297, 1, 866, 130, 71, 1743, 3272, 1930, 1740, 137, 3, 1431, 6415, 4862, 747, 5226, 14937, 17, 122, 40, 238, 9, 3, 193, 1, 217, 189, 1931, 141, 1226, 470, 1549, 9336, 467, 21, 364, 3, 1574, 2, 2136, 1, 8, 10747, 19055, 230, 23023, 92, 71, 3, 5934, 801, 6, 283, 8, 9879, 6943, 7840, 2308, 2513, 1, 3, 4471, 216, 1398, 1736, 35, 12580, 2263, 1, 1785, 6072, 9, 19055, 12, 31, 328, 1080, 2640, 17, 8, 697, 1, 12, 31, 285, 141, 171, 102, 31, 286, 1275, 2001, 102, 62, 47, 9357, 485, 6, 23023, 898, 1019, 65, 4, 8433, 102, 62, 37, 1949, 17, 23023, 20708, 2561, 866, 1, 6092, 2, 844, 17, 485, 6, 23023, 68, 40, 520, 6, 7665, 3851, 20, 3, 6092, 10582, 4239, 2, 3, 825, 200, 1, 6092, 4, 3, 1793, 1431, 1253, 19902, 1, 46, 770, 37, 3419, 2356, 1, 19055, 216, 128, 68, 631, 377, 35, 353, 6, 255, 2, 943, 770, 630, 17, 32, 470, 23, 866, 9, 1146, 1, 3, 1302, 1309]",,25043025,193
Targeting oncogenic interleukin-7 receptor signalling with N-acetylcysteine in T cell acute lymphoblastic leukaemia.,British journal of haematology,Br. J. Haematol.,2014-09-26,"Activating mutations of the interleukin-7 receptor (IL7R) occur in approximately 10% of patients with T cell acute lymphoblastic leukaemia (T-ALL). Most mutations generate a cysteine at the transmembrane domain leading to receptor homodimerization through disulfide bond formation and ligand-independent activation of STAT5. We hypothesized that the reducing agent N-acetylcysteine (NAC), a well-tolerated drug used widely in clinical practice to treat acetaminophen overdose, would reduce disulfide bond formation, and inhibit mutant IL7R-mediated oncogenic signalling. We found that treatment with NAC disrupted IL7R homodimerization in IL7R-mutant DND-41 cells as assessed by non-reducing Western blot, as well as in a luciferase complementation assay. NAC led to STAT5 dephosphorylation and cell apoptosis at clinically achievable concentrations in DND-41 cells, and Ba/F3 cells transformed by an IL7R-mutant construct containing a cysteine insertion. The apoptotic effects of NAC could be rescued in part by a constitutively active allele of STAT5. Despite using doses lower than those tolerated in humans, NAC treatment significantly inhibited the progression of human DND-41 cells engrafted in immunodeficient mice. Thus, targeting leukaemogenic IL7R homodimerization with NAC offers a potentially effective and feasible therapeutic strategy that warrants testing in patients with T-ALL. ",Journal Article,1943.0,11.0,Activating mutations of the interleukin-7 receptor IL7R occur in approximately 10 of patients with T cell acute lymphoblastic leukaemia T-ALL Most mutations generate a cysteine at the transmembrane domain leading to receptor homodimerization through disulfide bond formation and ligand-independent activation of STAT5 We hypothesized that the reducing agent N-acetylcysteine NAC a well-tolerated drug used widely in clinical practice to treat acetaminophen overdose would reduce disulfide bond formation and inhibit mutant IL7R-mediated oncogenic signalling We found that treatment with NAC disrupted IL7R homodimerization in IL7R-mutant DND-41 cells as assessed by non-reducing Western blot as well as in a luciferase complementation assay NAC led to STAT5 dephosphorylation and cell apoptosis at clinically achievable concentrations in DND-41 cells and Ba/F3 cells transformed by an IL7R-mutant construct containing a cysteine insertion The apoptotic effects of NAC could be rescued in part by a constitutively active allele of STAT5 Despite using doses lower than those tolerated in humans NAC treatment significantly inhibited the progression of human DND-41 cells engrafted in immunodeficient mice Thus targeting leukaemogenic IL7R homodimerization with NAC offers a potentially effective and feasible therapeutic strategy that warrants testing in patients with T-ALL,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[1616, 138, 1, 3, 1603, 67, 153, 22756, 1271, 4, 705, 79, 1, 7, 5, 102, 31, 286, 1275, 2001, 102, 62, 96, 138, 2562, 8, 6943, 28, 3, 5527, 1398, 1049, 6, 153, 27291, 298, 14454, 14845, 1264, 2, 1232, 306, 363, 1, 5517, 21, 1237, 17, 3, 1818, 420, 78, 11729, 2103, 8, 149, 421, 234, 95, 1792, 4, 38, 758, 6, 943, 13239, 19809, 688, 969, 14454, 14845, 1264, 2, 1433, 620, 22756, 517, 1302, 3128, 21, 204, 17, 24, 5, 2103, 5576, 22756, 27291, 4, 22756, 620, 42593, 605, 37, 22, 275, 20, 220, 1818, 1521, 2639, 22, 149, 22, 4, 8, 3864, 11135, 719, 2103, 836, 6, 5517, 7849, 2, 31, 351, 28, 505, 6171, 1003, 4, 42593, 605, 37, 2, 6669, 6904, 37, 2423, 20, 35, 22756, 620, 3883, 1101, 8, 6943, 5099, 3, 1631, 176, 1, 2103, 359, 40, 7008, 4, 760, 20, 8, 2818, 544, 1254, 1, 5517, 550, 75, 415, 280, 76, 135, 421, 4, 3218, 2103, 24, 97, 879, 3, 91, 1, 171, 42593, 605, 37, 6914, 4, 5031, 399, 631, 529, 77762, 22756, 27291, 5, 2103, 2339, 8, 751, 323, 2, 1313, 189, 692, 17, 2782, 471, 4, 7, 5, 102, 62]",,25256574,59
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.,Nature communications,Nat Commun,2015-03-19,"There is incomplete understanding of genetic heterogeneity and clonal evolution during cancer progression. Here we use deep whole-exome sequencing to describe the clonal architecture and evolution of 20 pediatric B-acute lymphoblastic leukaemias from diagnosis to relapse. We show that clonal diversity is comparable at diagnosis and relapse and clonal survival from diagnosis to relapse is not associated with mutation burden. Six pathways were frequently mutated, with NT5C2, CREBBP, WHSC1, TP53, USH2A, NRAS and IKZF1 mutations enriched at relapse. Half of the leukaemias had multiple subclonal mutations in a pathway or gene at diagnosis, but mostly with only one, usually minor clone, surviving therapy to acquire additional mutations and become the relapse founder clone. Relapse-specific mutations in NT5C2 were found in nine cases, with mutations in four cases being in descendants of the relapse founder clone. These results provide important insights into the genetic basis of treatment failure in ALL and have implications for the early detection of mutations driving relapse. ",Journal Article,1769.0,137.0,There is incomplete understanding of genetic heterogeneity and clonal evolution during cancer progression Here we use deep whole-exome sequencing to describe the clonal architecture and evolution of 20 pediatric B-acute lymphoblastic leukaemias from diagnosis to relapse We show that clonal diversity is comparable at diagnosis and relapse and clonal survival from diagnosis to relapse is not associated with mutation burden Six pathways were frequently mutated with NT5C2 CREBBP WHSC1 TP53 USH2A NRAS and IKZF1 mutations enriched at relapse Half of the leukaemias had multiple subclonal mutations in a pathway or gene at diagnosis but mostly with only one usually minor clone surviving therapy to acquire additional mutations and become the relapse founder clone Relapse-specific mutations in NT5C2 were found in nine cases with mutations in four cases being in descendants of the relapse founder clone These results provide important insights into the genetic basis of treatment failure in ALL and have implications for the early detection of mutations driving relapse,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[125, 16, 2610, 612, 1, 336, 1144, 2, 1946, 2554, 190, 12, 91, 467, 21, 119, 2369, 902, 2865, 615, 6, 897, 3, 1946, 4447, 2, 2554, 1, 179, 815, 132, 286, 1275, 12160, 29, 147, 6, 429, 21, 514, 17, 1946, 3653, 16, 1279, 28, 147, 2, 429, 2, 1946, 25, 29, 147, 6, 429, 16, 44, 41, 5, 258, 892, 437, 460, 11, 746, 1185, 5, 17003, 13439, 35593, 1206, 77943, 2845, 2, 8422, 138, 2220, 28, 429, 1303, 1, 3, 12160, 42, 232, 9210, 138, 4, 8, 308, 15, 145, 28, 147, 84, 2754, 5, 158, 104, 2082, 2278, 3910, 3050, 36, 6, 6206, 402, 138, 2, 1417, 3, 429, 7243, 3910, 429, 112, 138, 4, 17003, 11, 204, 4, 762, 140, 5, 138, 4, 294, 140, 486, 4, 23718, 1, 3, 429, 7243, 3910, 46, 99, 377, 305, 1957, 237, 3, 336, 877, 1, 24, 496, 4, 62, 2, 47, 1268, 9, 3, 191, 638, 1, 138, 4057, 429]",,25790293,326
A variant at 9p21.3 functionally implicates CDKN2B in paediatric B-cell precursor acute lymphoblastic leukaemia aetiology.,Nature communications,Nat Commun,2016-02-12,"Paediatric B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) is the most common cancer of childhood, yet little is known about BCP-ALL predisposition. In this study, in 2,187 cases of European ancestry and 5,543 controls, we discover and replicate a locus indexed by rs77728904 at 9p21.3 associated with BCP-ALL susceptibility (Pcombined=3.32  10(-15), OR=1.72) and independent from rs3731217, the previously reported ALL-associated variant in this region. Of correlated SNPs tagged by this locus, only rs662463 is significant in African Americans, suggesting it is a plausible causative variant. Functional analysis shows that rs662463 is a cis-eQTL for CDKN2B, with the risk allele associated with lower expression, and suggests that rs662463 influences BCP-ALL risk by regulating CDKN2B expression through CEBPB signalling. Functional analysis of rs3731217 suggests it is associated with BCP-ALL by acting within a splicing regulatory element determining CDKN2A exon 3 usage (P=0.01). These findings provide new insights into the critical role of the CDKN2 locus in BCP-ALL aetiology. ",Journal Article,1439.0,22.0,"Paediatric B-cell precursor acute lymphoblastic leukaemia BCP-ALL is the most common cancer of childhood yet little is known about BCP-ALL predisposition In this study in 2,187 cases of European ancestry and 5,543 controls we discover and replicate a locus indexed by rs77728904 at 9p21.3 associated with BCP-ALL susceptibility Pcombined=3.32 10 -15 OR=1.72 and independent from rs3731217 the previously reported ALL-associated variant in this region Of correlated SNPs tagged by this locus only rs662463 is significant in African Americans suggesting it is a plausible causative variant Functional analysis shows that rs662463 is a cis-eQTL for CDKN2B with the risk allele associated with lower expression and suggests that rs662463 influences BCP-ALL risk by regulating CDKN2B expression through CEBPB signalling Functional analysis of rs3731217 suggests it is associated with BCP-ALL by acting within a splicing regulatory element determining CDKN2A exon 3 usage P=0.01 These findings provide new insights into the critical role of the CDKN2 locus in BCP-ALL aetiology",0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[6138, 132, 31, 2765, 286, 1275, 2001, 13168, 62, 16, 3, 96, 186, 12, 1, 864, 1145, 1215, 16, 440, 545, 13168, 62, 2863, 4, 26, 45, 4, 18, 5568, 140, 1, 1865, 3535, 2, 33, 11943, 535, 21, 6134, 2, 6423, 8, 2474, 20500, 20, 78317, 28, 9016, 27, 41, 5, 13168, 62, 1432, 78318, 27, 531, 79, 167, 15, 14, 720, 2, 306, 29, 52346, 3, 373, 210, 62, 41, 1142, 4, 26, 1053, 1, 438, 1109, 9874, 20, 26, 2474, 158, 42655, 16, 93, 4, 1410, 2731, 802, 192, 16, 8, 7761, 8088, 1142, 583, 65, 1949, 17, 42655, 16, 8, 1927, 10770, 9, 12634, 5, 3, 43, 1254, 41, 5, 280, 55, 2, 844, 17, 42655, 3859, 13168, 62, 43, 20, 2681, 12634, 55, 298, 28797, 3128, 583, 65, 1, 52346, 844, 192, 16, 41, 5, 13168, 62, 20, 5375, 262, 8, 3895, 1253, 4467, 2196, 3175, 1725, 27, 5015, 19, 13, 355, 46, 272, 377, 217, 1957, 237, 3, 740, 200, 1, 3, 78319, 2474, 4, 13168, 62, 13681]",,26868379,745
Consensus definitions of 14 severe acute toxic effects for childhood lymphoblastic leukaemia treatment: a Delphi consensus.,The Lancet. Oncology,Lancet Oncol.,2016-06-01,"Although there are high survival rates for children with acute lymphoblastic leukaemia, their outcome is often counterbalanced by the burden of toxic effects. This is because reported frequencies vary widely across studies, partly because of diverse definitions of toxic effects. Using the Delphi method, 15 international childhood acute lymphoblastic leukaemia study groups assessed acute lymphoblastic leukaemia protocols to address toxic effects that were to be considered by the Ponte di Legno working group. 14 acute toxic effects (hypersensitivity to asparaginase, hyperlipidaemia, osteonecrosis, asparaginase-associated pancreatitis, arterial hypertension, posterior reversible encephalopathy syndrome, seizures, depressed level of consciousness, methotrexate-related stroke-like syndrome, peripheral neuropathy, high-dose methotrexate-related nephrotoxicity, sinusoidal obstructive syndrome, thromboembolism, and Pneumocystis jirovecii pneumonia) that are serious but too rare to be addressed comprehensively within any single group, or are deemed to need consensus definitions for reliable incidence comparisons, were selected for assessment. Our results showed that none of the protocols addressed all 14 toxic effects, that no two protocols shared identical definitions of all toxic effects, and that no toxic effect definition was shared by all protocols. Using the Delphi method over three face-to-face plenary meetings, consensus definitions were obtained for all 14 toxic effects. In the overall assessment of outcome of acute lymphoblastic leukaemia treatment, these expert opinion-based definitions will allow reliable comparisons of frequencies and severities of acute toxic effects across treatment protocols, and facilitate international research on cause, guidelines for treatment adaptation, preventive strategies, and development of consensus algorithms for reporting on acute lymphoblastic leukaemia treatment.",Journal Article,1329.0,62.0,Although there are high survival rates for children with acute lymphoblastic leukaemia their outcome is often counterbalanced by the burden of toxic effects This is because reported frequencies vary widely across studies partly because of diverse definitions of toxic effects Using the Delphi method 15 international childhood acute lymphoblastic leukaemia study groups assessed acute lymphoblastic leukaemia protocols to address toxic effects that were to be considered by the Ponte di Legno working group 14 acute toxic effects hypersensitivity to asparaginase hyperlipidaemia osteonecrosis asparaginase-associated pancreatitis arterial hypertension posterior reversible encephalopathy syndrome seizures depressed level of consciousness methotrexate-related stroke-like syndrome peripheral neuropathy high-dose methotrexate-related nephrotoxicity sinusoidal obstructive syndrome thromboembolism and Pneumocystis jirovecii pneumonia that are serious but too rare to be addressed comprehensively within any single group or are deemed to need consensus definitions for reliable incidence comparisons were selected for assessment Our results showed that none of the protocols addressed all 14 toxic effects that no two protocols shared identical definitions of all toxic effects and that no toxic effect definition was shared by all protocols Using the Delphi method over three face-to-face plenary meetings consensus definitions were obtained for all 14 toxic effects In the overall assessment of outcome of acute lymphoblastic leukaemia treatment these expert opinion-based definitions will allow reliable comparisons of frequencies and severities of acute toxic effects across treatment protocols and facilitate international research on cause guidelines for treatment adaptation preventive strategies and development of consensus algorithms for reporting on acute lymphoblastic leukaemia treatment,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[242, 125, 32, 64, 25, 151, 9, 541, 5, 286, 1275, 2001, 136, 228, 16, 629, 22111, 20, 3, 892, 1, 1812, 176, 26, 16, 408, 210, 2722, 2825, 1792, 716, 94, 5180, 408, 1, 1867, 3833, 1, 1812, 176, 75, 3, 6803, 596, 167, 944, 864, 286, 1275, 2001, 45, 271, 275, 286, 1275, 2001, 2189, 6, 1539, 1812, 176, 17, 11, 6, 40, 515, 20, 3, 78485, 6641, 78486, 2644, 87, 213, 286, 1812, 176, 4034, 6, 3709, 78487, 5404, 3709, 41, 4535, 3127, 1824, 3028, 2786, 9954, 681, 4448, 9233, 301, 1, 15471, 2116, 139, 4408, 733, 681, 672, 1751, 64, 61, 2116, 139, 10682, 9820, 6937, 681, 3501, 2, 13243, 36277, 3485, 17, 32, 1762, 84, 5044, 622, 6, 40, 2814, 5627, 262, 500, 226, 87, 15, 32, 3779, 6, 594, 1391, 3833, 9, 2450, 287, 2213, 11, 715, 9, 455, 114, 99, 224, 17, 1292, 1, 3, 2189, 2814, 62, 213, 1812, 176, 17, 77, 100, 2189, 2664, 3038, 3833, 1, 62, 1812, 176, 2, 17, 77, 1812, 254, 2470, 10, 2664, 20, 62, 2189, 75, 3, 6803, 596, 252, 169, 3376, 6, 3376, 21469, 6941, 1391, 3833, 11, 683, 9, 62, 213, 1812, 176, 4, 3, 63, 455, 1, 228, 1, 286, 1275, 2001, 24, 46, 2005, 3564, 90, 3833, 303, 1700, 2450, 2213, 1, 2722, 2, 37703, 1, 286, 1812, 176, 716, 24, 2189, 2, 1876, 944, 389, 23, 708, 677, 9, 24, 7275, 3494, 422, 2, 193, 1, 1391, 3529, 9, 1760, 23, 286, 1275, 2001, 24]",,27299279,59
"Cognitive, behaviour, and academic functioning in adolescent and young adult survivors of childhood acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study.",The lancet. Psychiatry,Lancet Psychiatry,2016-09-14,"Survivors of childhood acute lymphoblastic leukaemia (ALL) are at risk for neurocognitive deficits that affect development in adolescence and young adulthood, and influence educational attainment and future independence. We examined a large and diverse cohort of survivors to identify risk predictors and modifiers of these outcomes. In this cohort study, cognitive and behaviour symptoms were assessed via a standardised parent questionnaire for 1560 adolescent survivors of ALL diagnosed between 1970 and 1999. Clinically significant symptoms (90th percentile) and learning problems were compared between survivors and a sibling cohort. Multivariable regression models were used to examine associations with demographic and treatment characteristics. Models were adjusted for inverse probability of sampling weights to reflect undersampling of ALL survivors in the expansion cohort. In a subset of survivors with longitudinal data (n=925), we examined associations between adolescent symptoms or problems and adult educational attainment. Compared with siblings, survivors treated with chemotherapy only were more likely to demonstrate headstrong behaviour (155 [19%] of 752 survivors vs 88 [14%] of 610 siblings, p=0010), inattention-hyperactivity (15 [19%] vs 86 [14%], p<00001), social withdrawal (142 [18%] vs 75 [12%], p=0002), and had higher rates of learning problems (191 [28%] vs 76 [14%], p<00001). In multivariable models among survivors, increased cumulative dose of intravenous methotrexate (ie, >43 g/m<sup>2</sup>) conferred increased risk of inattention-hyperactivity (relative risk [RR] 153, 95% CI 113-208). Adolescent survivors with cognitive or behaviour problems and those with learning problems were less likely to graduate from college as young adults than adolescent survivors without cognitive or behaviour problems. Although modern therapy for childhood ALL has eliminated the use of cranial radiation therapy, adolescent survivors treated with chemotherapy only remain at increased risk for cognitive, behaviour, and academic problems that adversely affect adult education outcomes. National Cancer Institute, American Lebanese-Syrian Associated Charities.",Journal Article,1224.0,21.0,Survivors of childhood acute lymphoblastic leukaemia ALL are at risk for neurocognitive deficits that affect development in adolescence and young adulthood and influence educational attainment and future independence We examined a large and diverse cohort of survivors to identify risk predictors and modifiers of these outcomes In this cohort study cognitive and behaviour symptoms were assessed via a standardised parent questionnaire for 1560 adolescent survivors of ALL diagnosed between 1970 and 1999 Clinically significant symptoms 90th percentile and learning problems were compared between survivors and a sibling cohort Multivariable regression models were used to examine associations with demographic and treatment characteristics Models were adjusted for inverse probability of sampling weights to reflect undersampling of ALL survivors in the expansion cohort In a subset of survivors with longitudinal data n=925 we examined associations between adolescent symptoms or problems and adult educational attainment Compared with siblings survivors treated with chemotherapy only were more likely to demonstrate headstrong behaviour 155 19 of 752 survivors vs 88 14 of 610 siblings p=0010 inattention-hyperactivity 15 19 vs 86 14 p 00001 social withdrawal 142 18 vs 75 12 p=0002 and had higher rates of learning problems 191 28 vs 76 14 p 00001 In multivariable models among survivors increased cumulative dose of intravenous methotrexate ie 43 g/m sup 2 /sup conferred increased risk of inattention-hyperactivity relative risk RR 153 95 CI 113-208 Adolescent survivors with cognitive or behaviour problems and those with learning problems were less likely to graduate from college as young adults than adolescent survivors without cognitive or behaviour problems Although modern therapy for childhood ALL has eliminated the use of cranial radiation therapy adolescent survivors treated with chemotherapy only remain at increased risk for cognitive behaviour and academic problems that adversely affect adult education outcomes National Cancer Institute American Lebanese-Syrian Associated Charities,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[332, 1, 864, 286, 1275, 2001, 62, 32, 28, 43, 9, 2958, 2752, 17, 1158, 193, 4, 6964, 2, 1169, 6002, 2, 1054, 3624, 7108, 2, 508, 5773, 21, 409, 8, 375, 2, 1867, 180, 1, 332, 6, 255, 43, 674, 2, 5663, 1, 46, 123, 4, 26, 180, 45, 1863, 2, 8173, 507, 11, 275, 847, 8, 14041, 3841, 1770, 9, 31569, 3678, 332, 1, 62, 265, 59, 4868, 2, 2043, 505, 93, 507, 78584, 6392, 2, 3434, 2408, 11, 72, 59, 332, 2, 8, 3684, 180, 658, 320, 274, 11, 95, 6, 1004, 685, 5, 1540, 2, 24, 374, 274, 11, 586, 9, 2931, 1320, 1, 2874, 7966, 6, 2694, 78585, 1, 62, 332, 4, 3, 1422, 180, 4, 8, 697, 1, 332, 5, 2380, 74, 78, 14838, 21, 409, 685, 59, 3678, 507, 15, 2408, 2, 780, 3624, 7108, 72, 5, 2758, 332, 73, 5, 56, 158, 11, 80, 322, 6, 608, 34319, 8173, 3735, 326, 1, 11611, 332, 105, 889, 213, 1, 11302, 2758, 19, 31997, 23873, 18391, 167, 326, 105, 868, 213, 19, 4599, 2032, 3683, 4785, 203, 105, 481, 133, 19, 22657, 2, 42, 142, 151, 1, 3434, 2408, 6130, 339, 105, 846, 213, 19, 4599, 4, 658, 274, 107, 332, 101, 967, 61, 1, 1262, 2116, 2523, 21704, 499, 188, 172, 18, 172, 3851, 101, 43, 1, 23873, 18391, 580, 43, 861, 49622, 48, 58, 22728, 47571, 3678, 332, 5, 1863, 15, 8173, 2408, 2, 135, 5, 3434, 2408, 11, 299, 322, 6, 19225, 29, 2979, 22, 1169, 857, 76, 3678, 332, 187, 1863, 15, 8173, 2408, 242, 2366, 36, 9, 864, 62, 71, 6173, 3, 119, 1, 2565, 121, 36, 3678, 332, 73, 5, 56, 158, 918, 28, 101, 43, 9, 1863, 8173, 2, 1916, 2408, 17, 4311, 1158, 780, 1848, 123, 657, 12, 1377, 597, 14666, 13671, 41, 14667]",,27639661,10
NT5C2 germline variants alter thiopurine metabolism and are associated with acquired NT5C2 relapse mutations in childhood acute lymphoblastic leukaemia.,Leukemia,Leukemia,2018-09-10,"The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides (TGN) and incorporated into DNA (DNA-TG), the active end metabolite. In a series of genome-wide association studies, we analysed time-weighted means (<sub>wm</sub>) of erythrocyte concentrations of TGN (Ery-TGN) and DNA-TG in 1009 patients undergoing maintenance therapy for acute lymphoblastic leukaemia (ALL). In discovery analyses (454 patients), the propensity for DNA-TG incorporation (<sub>wm</sub>DNA-TG/<sub>wm</sub>Ery-TGN ratio) was significantly associated with three intronic SNPs in NT5C2 (top hit: rs72846714; P=2.0910<sup>-10</sup>, minor allele frequency 15%). In validation analyses (555 patients), this association remained significant during both early and late maintenance therapy (P=8.410<sup>-6</sup> and 1.310<sup>-3</sup>, respectively). The association was mostly driven by differences in <sub>wm</sub>Ery-TGN, but in regression analyses adjusted for <sub>wm</sub>Ery-TGN (P<0.0001), rs72846714-A genotype was also associated with a higher <sub>wm</sub>DNA-TG (P=0.029). Targeted sequencing of NT5C2 did not identify any missense variants associated with rs72846714 or <sub>wm</sub>Ery-TGN/<sub>wm</sub>DNA-TG. rs72846714 was not associated with relapse risk, but in a separate cohort of 180 children with relapsed ALL, rs72846714-A genotype was associated with increased occurrence of relapse-specific NT5C2 gain-of-function mutations that reduce cytosol TGN levels (P=0.03). These observations highlight the impact of both germline and acquired mutations in drug metabolism and disease trajectory.",Journal Article,498.0,2.0,The antileukaemic drug 6-mercaptopurine is converted into thioguanine nucleotides TGN and incorporated into DNA DNA-TG the active end metabolite In a series of genome-wide association studies we analysed time-weighted means sub wm /sub of erythrocyte concentrations of TGN Ery-TGN and DNA-TG in 1009 patients undergoing maintenance therapy for acute lymphoblastic leukaemia ALL In discovery analyses 454 patients the propensity for DNA-TG incorporation sub wm /sub DNA-TG/ sub wm /sub Ery-TGN ratio was significantly associated with three intronic SNPs in NT5C2 top hit rs72846714 P 2.09 10 sup -10 /sup minor allele frequency 15 In validation analyses 555 patients this association remained significant during both early and late maintenance therapy P 8.4 10 sup -6 /sup and 1.3 10 sup -3 /sup respectively The association was mostly driven by differences in sub wm /sub Ery-TGN but in regression analyses adjusted for sub wm /sub Ery-TGN P 0.0001 rs72846714-A genotype was also associated with a higher sub wm /sub DNA-TG P 0.029 Targeted sequencing of NT5C2 did not identify any missense variants associated with rs72846714 or sub wm /sub Ery-TGN/ sub wm /sub DNA-TG rs72846714 was not associated with relapse risk but in a separate cohort of 180 children with relapsed ALL rs72846714-A genotype was associated with increased occurrence of relapse-specific NT5C2 gain-of-function mutations that reduce cytosol TGN levels P 0.03 These observations highlight the impact of both germline and acquired mutations in drug metabolism and disease trajectory,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3, 20016, 234, 49, 9223, 16, 4764, 237, 17598, 11381, 17846, 2, 2449, 237, 261, 261, 5107, 3, 544, 396, 3379, 4, 8, 988, 1, 898, 1019, 248, 94, 21, 3141, 98, 2337, 2263, 551, 1518, 551, 1, 16470, 1003, 1, 17846, 33141, 17846, 2, 261, 5107, 4, 24687, 7, 479, 1146, 36, 9, 286, 1275, 2001, 62, 4, 1574, 318, 11026, 7, 3, 1925, 9, 261, 5107, 2838, 551, 1518, 551, 261, 5107, 551, 1518, 551, 33141, 17846, 197, 10, 97, 41, 5, 169, 7998, 1109, 4, 17003, 3150, 6519, 33142, 19, 18, 1730, 79, 172, 79, 172, 2278, 1254, 675, 167, 4, 929, 318, 10823, 7, 26, 248, 958, 93, 190, 110, 191, 2, 807, 1146, 36, 19, 66, 39, 79, 172, 49, 172, 2, 14, 27, 79, 172, 27, 172, 106, 3, 248, 10, 2754, 1621, 20, 362, 4, 551, 1518, 551, 33141, 17846, 84, 4, 320, 318, 586, 9, 551, 1518, 551, 33141, 17846, 19, 13, 488, 33142, 8, 1183, 10, 120, 41, 5, 8, 142, 551, 1518, 551, 261, 5107, 19, 13, 4770, 238, 615, 1, 17003, 205, 44, 255, 500, 4007, 839, 41, 5, 33142, 15, 551, 1518, 551, 33141, 17846, 551, 1518, 551, 261, 5107, 33142, 10, 44, 41, 5, 429, 43, 84, 4, 8, 2282, 180, 1, 3172, 541, 5, 591, 62, 33142, 8, 1183, 10, 41, 5, 101, 2291, 1, 429, 112, 17003, 1803, 1, 343, 138, 17, 969, 11107, 17846, 148, 19, 13, 680, 46, 2172, 1817, 3, 345, 1, 110, 1009, 2, 1294, 138, 4, 234, 1600, 2, 34, 6118]",,30201983,249
Genetic predisposition to PEG-asparaginase hypersensitivity in children treated according to NOPHO ALL2008.,British journal of haematology,Br. J. Haematol.,2018-11-18,"Asparaginase is essential in childhood acute lymphoblastic leukaemia (ALL) treatment, however hypersensitivity reactions to pegylated asparaginase (PEG-asparaginase) hampers anti-neoplastic efficacy. Patients with PEG-asparaginase hypersensitivity have been shown to possess zero asparaginase enzyme activity. Using this measurement to define the phenotype, we investigated genetic predisposition to PEG-asparaginase hypersensitivity in a genome-wide association study (GWAS). From July 2008 to March 2016, 1494 children were treated on the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol. Cases were defined by clinical hypersensitivity and no enzyme activity, controls had enzyme activity  100 iu/l and no hypersensitivity symptoms. PEG-asparaginase hypersensitivity was reported in 138% (206/1494) of patients. Fifty-nine cases and 772 controls fulfilled GWAS inclusion criteria. The CNOT3 variant rs73062673 on 19q13.42, was associated with PEG-asparaginase allergy (P=46810<sup>-8</sup> ). We further identified two signals on chromosome 6 in relation to HLA-DQA1 (P=93710<sup>-6</sup> ) and TAP2 (P=15910<sup>-5</sup> ). This study associated variants in CNOT3 and in the human leucocyte antigen (HLA) region with PEG-asparaginase hypersensitivity, suggesting that not only genetic variations in the HLA region, but also regulation of these genes are of importance in the biology of this toxicity. Furthermore, our study emphasizes the importance of using asparaginase enzyme activity measurements to identify PEG-asparaginase hypersensitivity.",Clinical Trial,429.0,2.0,Asparaginase is essential in childhood acute lymphoblastic leukaemia ALL treatment however hypersensitivity reactions to pegylated asparaginase PEG-asparaginase hampers anti-neoplastic efficacy Patients with PEG-asparaginase hypersensitivity have been shown to possess zero asparaginase enzyme activity Using this measurement to define the phenotype we investigated genetic predisposition to PEG-asparaginase hypersensitivity in a genome-wide association study GWAS From July 2008 to March 2016 1494 children were treated on the Nordic Society of Paediatric Haematology and Oncology ALL2008 protocol Cases were defined by clinical hypersensitivity and no enzyme activity controls had enzyme activity  100 iu/l and no hypersensitivity symptoms PEG-asparaginase hypersensitivity was reported in 138 206/1494 of patients Fifty-nine cases and 772 controls fulfilled GWAS inclusion criteria The CNOT3 variant rs73062673 on 19q13.42 was associated with PEG-asparaginase allergy P 468 10 sup -8 /sup We further identified two signals on chromosome 6 in relation to HLA-DQA1 P 937 10 sup -6 /sup and TAP2 P 159 10 sup -5 /sup This study associated variants in CNOT3 and in the human leucocyte antigen HLA region with PEG-asparaginase hypersensitivity suggesting that not only genetic variations in the HLA region but also regulation of these genes are of importance in the biology of this toxicity Furthermore our study emphasizes the importance of using asparaginase enzyme activity measurements to identify PEG-asparaginase hypersensitivity,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,"[3709, 16, 1452, 4, 864, 286, 1275, 2001, 62, 24, 137, 4034, 2428, 6, 4424, 3709, 3145, 3709, 20513, 312, 2000, 209, 7, 5, 3145, 3709, 4034, 47, 85, 443, 6, 5766, 5115, 3709, 1644, 128, 75, 26, 2204, 6, 1107, 3, 1005, 21, 565, 336, 2863, 6, 3145, 3709, 4034, 4, 8, 898, 1019, 248, 45, 3297, 29, 2066, 1375, 6, 2363, 1390, 17794, 541, 11, 73, 23, 3, 20680, 1174, 1, 6138, 32502, 2, 413, 79815, 1182, 140, 11, 395, 20, 38, 4034, 2, 77, 1644, 128, 535, 42, 1644, 128, 749, 394, 4588, 805, 2, 77, 4034, 507, 3145, 3709, 4034, 10, 210, 4, 18674, 5956, 17794, 1, 7, 1461, 762, 140, 2, 15258, 535, 9091, 3297, 1680, 371, 3, 20101, 1142, 79816, 23, 14746, 595, 10, 41, 5, 3145, 3709, 9842, 19, 79817, 79, 172, 66, 172, 21, 195, 108, 100, 2312, 23, 1170, 49, 4, 2191, 6, 1160, 35017, 19, 79818, 79, 172, 49, 172, 2, 29336, 19, 27309, 79, 172, 33, 172, 26, 45, 41, 839, 4, 20101, 2, 4, 3, 171, 15541, 448, 1160, 1053, 5, 3145, 3709, 4034, 802, 17, 44, 158, 336, 2293, 4, 3, 1160, 1053, 84, 120, 863, 1, 46, 214, 32, 1, 1187, 4, 3, 891, 1, 26, 155, 798, 114, 45, 7519, 3, 1187, 1, 75, 3709, 1644, 128, 1685, 6, 255, 3145, 3709, 4034]",,30450575,79
